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MINUTES OF THE 45th GENERAL ASSEMBLY OF THE EUROPE-
AN ASSOCIATION FOR THE STUDY OF DIABETES
held in Messe Wien, Vienna, Austria on 1 October 2009
Present: Dr. U. Smith (President)
 Dr. G. Spinas (Honorary Treasurer)
 Dr. M. Stumvoll (Honorary Secretary)
 Dr. E. Gale (Editor-in-Chief, Diabetologia)
 Dr. J. Nolan (Chair, PGESC)
 Dr.V. Jörgens (Executive Director)
 Dr. M. Grüsser (Vice Director)
 and 51 members
c) Honorary Auditors
The President asked the Honorary Auditors, Drs. Pater-
son and Tack, to formally discharge the accounts. Dr. 
Tack confirmed that the accounts had been checked 
carefully and were in perfect order. Dr. Smith asked for 
the vote to accept the accounts. 
The accounts were unanimously discharged (four ab-
stentions).
d) Honorary Secretary
Dr. Stumvoll reported that more than 50% of those 
questioned in Rome scored the Meeting above average 
or outstanding. There had been a minor improvement in 
the ratings of the oral presentations.
For the Vienna Meeting, 2062 abstracts had been sub-
mitted and 1367 had been accepted. The highest number 
of submissions came from USA, UK and Germany. Re-
garding Travel Grants,146 had been awarded for the 
amount of €74,100.
Regarding the Stockholm Meeting, the Programme 
Committee had been put together and had had its first 
meeting. There are 16 in the Programme Committee, 
with one from USA. Dr. Stumvoll said he had received 
roughly 80 suggestions for symposia in Stockholm.
Dr. Stumvoll closed his report by thanking all members 
of the EASD staff, in particular Ms. H. Goliberzuch and 
The President welcomed everyone to the 45th General 
Assembly. 
1. MINUTES 44th GENERAL ASSEMBLY 2008
Since there were no comments, the minutes were approved 
unanimously and officially signed as a correct record.
2. REPORTS
a) President
The President said he had given his report during the 
Presidential Address on Wednesday 30 September 2009.
b) Honorary Treasurer
Dr. Spinas reported that the accounts were in a healthy 
state. He said the main income came from the member-
ship and registration fees. A transfer of 4 million Euros 
had been made to the Foundation.
Dr. Spinas expressed his thanks to Drs. Grüsser and Jörgens 
for their support and advice and to the team in Düsseldorf 
in general and to Mrs. Klee, Ms. Deparade and Ms. Weiss 
in particular for the precise handling of the accounts.
The President thanked the Honorary Treasurer for his 
diligence and asked if there were any questions. There 
were none. 
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Mrs. M. Toledo, for their outstanding help and support 
with the organisation of the EASD Annual Meetings.
Dr. Smith thanked Dr. Stumvoll for his diligence and 
asked if there were any questions. There were none.
e) Editor-in-Chief, Diabetologia
Dr. Gale reported that the impact factor had improved, 
reaching the highest ever for Diabetologia, and the gap 
was closing on Diabetes Care. In 2008, 1694 articles 
had been submitted to Diabetologia; 51% went through 
full peer-review. The acceptance rate of 20.2% had in-
creased slightly over 2007.
He expressed his thanks to the referees and associates 
and said their work was much appreciated. He also 
thanked his team in Bristol.
Dr. Smith thanked Dr. Gale for the excellent work he 
had done. 
f) Chair, Postgraduate Education Sub-committee
Dr. Nolan reported that the postgraduate course in 
Kiev in April 2009 had been very successful and it was 
planned to return to the Ukraine in 2010. He thanked 
Dr. Boulton for the organisation of the extra-European 
courses in Vietnam, India and China.
Dr. Nolan reported that the web-based educational lectures 
were developing well and CME accreditation had been 
granted for these. He thanked Mr. Carey for his assistance.
Dr. Nolan thanked Dr. Czupryniak for his support as Secre-
tary of the PGESC and the team in Düsseldorf, especially 
Mrs. Hata and Ms. Sommer, for their friendly assistance.
Dr. Smith thanked Dr. Nolan for his valuable work. 
There were no questions.
3. ELECTIONS
a) Vice President 2009-2012
The Council’s election of Dr. F. Bosch was unanimously 
approved with one abstention.
b) Editor-in-Chief 2010-2013
The election of Dr. J. Zierath was unanimously ap-
proved with one abstention.
c) Honorary Treasurer Extension 2009-2010
The General Assembly unanimously approved Dr. 
Spinas’ extension until 2010, with 1 abstention.
d) Chair PGESC, Extension 2009 -2010
The General Assembly unanimously approved Dr. No-
lan’s extension until 2010, with 1 abstention.
e) Council Members 2010-2013
The following Council Members were elected by the 
General Assembly:
Dr. Beguinot, F. (I) - unanimously; 
Dr. Dekker, J. (NL) - 1 abstention; 
Dr. Karpe, F. (UK) – unanimously;
Dr. Urbanavicius, V. (Li) - 1 abstention;
4. STUDY GROUPS
It was reported that two Study Groups had been dis-
banded:
Hypertension in Diabetes Study Group (HID)
Diabetes Optimization through Information Technology 
Study Group (DOIT)
5. HONORARY MEMBERSHIP
Drs. O. Crofford, J. Nerup and W. Waldhäusl were 
unanimously elected by the General Assembly.
6. ANY OTHER BUSINESS
There was no other business.
Dr. Smith thanked the out-going Vice President, Dr. C. 
Boitard, for his dedication and expressed his thanks for the 
confidence that Dr. Boitard had shown him as President.
Dr. Smith thanked the industry for their support. He 
also expressed his sincere gratitude to the Local Or-
ganising Committee for their outstanding contribution 
to the organisation of the 45th EASD Annual Meeting. 
He again thanked Dr. Stumvoll and the members of the 
Programme Committee for their hard work with regard 
to the scientific programme. The President warmly 
thanked the EASD team in Düsseldorf for their kind and 
efficient help.
Dr. Smith brought the General Assembly to a close at 
19:00.
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Agenda for the 46th General Assembly
of the European Association for the Study of Diabetes
to be held in the Sutherland Hall at the Stockholmsmässan 18:00 on Thursday 23 September 2010
1. Minutes of the 45th General Assembly, Vienna, Austria 2009
2. Reports
a) President Dr. U. Smith
b) Honorary Treasurer Dr. G. Spinas
c) Honorary Auditors Dr. K. Paterson 
  Dr. C. Tack
d) Honorary Secretary Dr. M. Stumvoll
e) Editor-in-Chief, Diabetologia Dr. E. Gale
f) Chair, Postgraduate Education Dr. J. Nolan
 Subcommittee
g) Chair, Extra-European Postgraduate Dr. A. J. M. Boulton
 Activities
3. Elections
a) Extension, Honorary Treasurer (2010 - 2011) G. Spinas
b) Honorary Secretary (2010 – 2013) in place of M. Stumvoll
c) Chair, PGESC (2010 – 2013) in place of J. Nolan
d) Council Members (2011 - 2014) in place of 
  T. BattelD. Matthews 
  J. Philippe 
  J. Zierath 
e)  Honorary Auditor (2010 - 2013) in place of C. Tack
4. Study Groups
5. Honorary Membership 
6. Any other business
 
Diabetologia (2010) 53:[Suppl1]S1–S556 S 5
1 C
46th EASD Annual Meeting of the European Association for the 
Study of Diabetes
Stockholm, Sweden, 20 – 24 September 2010
OP  42 Inflammation and metabolism
OP  43 New oral agents
OP  44 Impact of education on glycaemic outcome
OP  45 Brain effects on weight regulation and metabolism
OP  46  Prediction of type 2 diabetes: Can we do better 
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OP  48 Biomarkers of type 1 diabetes 
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OP 1 Novel formulations and 
delivery of insulin
1
Gene therapy for diabetic hyperglycaemia by expressing insulin and 
glucokinase in skeletal muscle: pre-clinical studies in diabetic dogs
D. Callejas1,2, C.J. Mann1, J. Montane1, E. Ayuso1,2, X. Leon1,2, A. Andaluz3,  
F. Mingozzi4, K.A. High4, F. Bosch1,2;
1CBATEG and Department of Biochemistry and Molecular Biology, School 
of Veterinary Medicine, Universitat Autonoma de Barcelona, Bellaterra, 
Spain, 2CIBER of Diabetes and Associated Metabolic Disorders, Barcelona, 
Spain, 3Department of Medicine and Animal Surgery, School of Veterinary 
Medicine, Universitat Autonoma de Barcelona, Bellaterra, Spain, 4Children’s 
Hospital of Philadelphia, Abramson Research Center, Philadelphia, USA.
Background and aims: We previously demonstrated the feasibility of a 
potential gene therapy strategy for type 1 diabetes based upon engineering 
mouse skeletal muscle to co-express human insulin (hIns) and glucokinase 
(Gck). Both genes act synergistically such that local production of hIns im-
proves glucose uptake, whereas Gck acts as a glucose sensor in a concentra-
tion-dependent manner to facilitate glucose disposal. We wished to perform 
a pre-clinical study in diabetic dogs to demonstrate the feasibility, efficiency, 
duration of effects as well as any biochemical and safety issues.
Materials and methods: Five dogs were made diabetic with streptozotocin 
and alloxan. Dog 1 was treated subsequently after diabetes induction with 
2.5E12 vg/kg of AAV1-CMV-hIns. Dog 2 was given AAV1-CMV-hIns 
(1.0E12 vg/kg) only, whereas dogs 3 and 4 received AAV1-CMV-hIns and 
AAV1-CMV-Gck simultaneously (1.0E12 vg/kg each vector). In addition, 
Dog 5 was left as an untreated diabetic control for 8 months before receiving 
the same treatment as Dog 3.
Results: In Dog 1 human C-peptide was successfully detected in serum 
and associated with improved glucose disposal after oral glucose tolerance 
test (GTT) and a reduced fasting glycaemia in the absence of any negative 
response to the vector. Dog 1 was sacrificed at 3 weeks after the treatment 
and insulin expression was confirmed by qPCR and Northern Blot in skel-
etal muscle, but not in other tissues. In the other four additional dogs that 
were treated with lower doses we wanted to find the minimum effective dose 
of AAV1-CMV-hIns able to produce normoglycaemia in fasting conditions. 
Circulating levels of human C-peptide were detected for >3 years after injec-
tion in Dogs 2, 3 and 4 and for >2 years in Dog 4. Dog 2 showed a nearly 
normalized fasting glycaemia whereas Dog 3, 4 and 5 achieved completely 
normalized fasting glycaemia and a vastly improved ability to dispose of glu-
cose compared to Dog 2 or Dog 4 when diabetic, by GTT, suggesting the 
concerted action of hINS and Gck. Dog 5 demonstrated a continuous deteri-
oration in weight and biochemical parameters (AST and ALT) while diabetic 
which was immediately rectified upon treatment.
Conclusion: Taken together, these results suggest that engineering skeletal 
muscle to produce insulin and glucokinase may be a potential therapy for the 
treatment of type 1 diabetes, because it shows long term efficacy and safety.
Supported by: SAF 2008-00962 and the EC (FP6 CLINIGENE)
2
Improved glycaemic variability in type 1 diabetes mellitus and type 2 
diabetes mellitus patients by coinjection of prandial insulin analogue 
with human hyaluronidase
M. Hompesch1, D. Muchmore2, L. Morrow1, E. Ludington2, D. Vaughn2;
1Profil Institute for Clinical Research, Chula Vista, 2Halozyme Therapeutics, 
Inc., San Diego, USA.
Background and aims: Studies in T1DM and T2DM patients to compare 
the postprandial glucose (PPG) response to a liquid meal for insulin lispro 
injected ± human hyaluronidase (PH20).
Materials and methods: Two standardized liquid meal studies were conduct-
ed; one in 22 T1DM patients [15 male, 9 female; mean age 40.7 (±10.7); mean 
BMI 24.2 (± 2.9)] and the other in 23 T2DM patients [14 male, 9 female; 
mean age 52 (37-69); mean BMI 33.5 kg/m2 (23.7-45.0)] on high insulin dos-
es, mean daily dose 105U (60-230). Patients fasted (10h) and refrained from 
SC insulin (>9h) before dosing. 2h before a liquid meal (60g CHO for T1DM 
or 80g CHO for T2DM), patients were titrated to 110±20mg/dL glucose tar-
get with IV glucose and/or IV insulin followed by a 30min intervention-free 
period. For the T1DM study, an optimum dose was found for lispro+PH20 
during up to 3 dose-finding visits (targeting a postprandial range of 60-160 
mg/dL) and the same dose was studied for lispro alone, while for the T2DM 
study the optimum dose (targeting a postprandial range of 70-140mg/dL) 
was separately optimized for lispro±PH20 (from 3 dose-escalating test meal 
visits each). Lispro±PH20 was injected SC immediately pre-meal, and plasma 
insulin and glucose concentrations were monitored for 8h.
Results: PH20 coinjection reduced hyperglycemic excursions in both studies 
with the same (T1DM) or reduced (T2DM) hypoglycemic risk. In the T1DM 
study, peak PPG was reduced from 174 to 148 mg/dL (p=.002) and the total 
hyperglycemic excursions (AUC > 140 mg/dL) were reduced 79%, allowing 
more patients to reach PPG goal (91% +PH20 v. 55% for lispro alone met the 
ADA goal of ≤180mg/dL). In the T2DM study, peak PPG was reduced from 
178 to 165 mg/dL (p=.095) and the total hyperglycemic excursions (AUC > 
140 mg/dL) were reduced 44%, allowing more patients to reach PPG goal 
(71% +PH20 v. 48% for lispro alone met the ADA goal of ≤180mg/dL). Hy-
poglycemic risk was similar in the T1DM study with equal lispro doses, and 
reduced in the T2DM study where the optimum dose was reduced by 8% for 
lispro+PH20. All injections were well tolerated.
Conclusion: Lispro+PH20 provided superior control of postprandial blood 
glucose compared to lispro alone in patients with both T1DM and T2DM in 
these test meal settings. 
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30 month post trial follow up of HbA1c with continuous intraperitoneal 
insulin infusion in type 1 diabetes
S.J.J. Logtenberg1, N. Kleefstra1,2, S.T. Houweling2, K.H. Groenier3,  
H.J.G. Bilo1,4;
1Diabetes Centre, Isala Clinics, Zwolle, 2Langerhans Medical Research 
Group, Zwolle, 3General Practice, UMCG, Groningen, 4Internal medicine, 
UMCG, Groningen, Netherlands.
Background and aims: Results from our randomized controlled trial (RCT) 
showed that with continuous intraperitoneal (IP) insulin infusion with an 
implantable pump (see Figure 1) it is possible to achieve better glycemic con-
trol and quality of life compared to subcutaneous insulin administration in 
patients with type 1 diabetes (T1DM). The aim of this analysis was to inves-
tigate patients therapy choice and glycemic control 30 months after the end 
of the trial.
Materials and methods: The 23 patients that ended the RCT in 2007/2008 all 
continued to use the IP pump. Last known HbA1c values were collected in 
the first quarter of 2010. Status regarding therapy mode were extracted from 
hospital records. Paired t-tests were used to compare HbA1c at the end of the 
IP study phase with mean HbA1c at follow up.
Results: In March 2010, 22 (12 female, 10 male) patients were still treated 
with CIPII, 1 patient (female) was back on subcutaneous insulin due to neu-
ropathic pains, for which the patient blamed the IP pump. Mean age at follow 
up was 46.6 (12.0) years; mean diabetes duration at the start of the study 
was 22.6 (10.6) years; mean baseline HbA1c 8.6 (1.1) %; HbA1c>7.5% in 20 
subjects; hypoglycemic events ≥5/week in 14 subjects. HbA1c was collected 
after 2.3 (0.6) years after the end of the study. Mean HbA1c was 7.7% (1.1). 
Compared to prestudy HbA1c values, this is a significant reduction of 0.83% 
(CI; -1.3, -0.4). Compared to the end of the IP phase of the trial, the results 
are comparable (0.2% (CI; -0.3, 0.7).
Conclusion: Our analysis shows that with CIPII it is possible not only to 
improve glycemic control in the short term, but also to achieve sustained 
improvement in glycemic control in patients with T1DM who were insuf-
ficiently controlled previously despite intensified subcutaneous insulin regi-
mens. Furthermore, there is a low drop out rate with CIPII (1 out of 23 of 
patients).
Figure 1: Schematic representation of the position of the insulin pump and 
catheter in situ.
Supported by: Medtronic
4
Insulin degludec, a new generation ultra-long acting insulin, used once 
daily or 3-times weekly in people with type 2 diabetes: comparison to 
insulin glargine
C. Mathieu1, G. Fulcher2, P.V. Rao3, N. Thomas4, L. Endahl5, T. Johansen5,  
A.J. Lewin6, J. Rosenstock7, M. Pinget8, B. Zinman9;
1UZ Gasthuisberg K.U.Leuven, Belgium, 2Royal North Shore Hospital, 
University of Sydney, Australia, 3Nizam’s Institute of Medical Sciences 
University, Hyderabad, India, 4Christian Medical College, Vellore, India, 
5Novo Nordisk A/S, Soeborg, Denmark, 6National Research Institute, Los 
Angeles, 7Dallas Diabetes and Endocrine Center at Medical City, Dallas, 
USA, 8University Hospital Strasbourg, France, 9Samuel Lunenfeld Research 
Institute, Mount Sinai Hospital, University of Toronto, Canada.
Background and aims: Insulin degludec (IDeg) is a novel insulin analog that 
forms soluble multi-hexamer assemblies after s. c. injection, resulting in ul-
tra-long duration of action. The aim of this phase 2 trial was to investigate 
the efficacy and safety of IDeg formulations administered once daily (OD) 
or 3-times weekly (3TW) in insulin-naïve people with type 2 diabetes inad-
equately controlled on OADs.
Materials and methods: This was a 16-week, open-label, randomized, 4-arm, 
parallel-group, treat-to-target trial. Participants (mean: 54.2 years, HbA1c 
8.7%, fasting plasma glucose (FPG) 10.2 mmol/l, BMI 29.5 kg/m2) received 
an OD formulation of IDeg (IDeg OD, n=60), a 3TW formulation of IDeg 
(IDeg 3TW, n=62), an alternative IDeg OD formulation (development dis-
continued, results not shown, n=61) or insulin glargine OD (IGlar, n=62), 
all in combination with metformin. All insulins were injected s. c. in the 
evening and titrated to achieve FPG 4.0-6.0 mmol/l. www.clinicaltrials.gov 
ID: NCT00611884.
Results: HbA1c after 16 weeks of treatment was similar across treatment arms 
with regard to mean reduction from baseline (IDeg OD: -1.3%; IDeg 3TW: 
-1.5%; IGlar: -1.5%; p=NS for all pairwise comparisons) and final mean value 
(IDeg OD: 7.4%; IDeg 3TW: 7.3%; IGlar: 7.2%). Treatments were also com-
parable with respect to final mean FPG (IDeg OD: 6.3 mmol/l; IDeg 3TW: 
6.5 mmol/l; IGlar: 6.4 mmol/l) and mean reductions from baseline (IDeg OD: 
-3.6 mmol/l; IDeg 3TW: -4.2 mmol/l; IGlar: -3.4 mmol/l). At end-of-trial, 
mean weekly insulin dose was similar for IDeg OD (3.1 U/kg/week=0.45 
U/kg/day), IDeg 3TW (3.4 U/kg/week=0.49 U/kg/day) and IGlar (3.3 U/kg/
week=0.48 U/kg/day). Body weight remained stable throughout the trial in 
all treatment arms. Rates of confirmed hypoglycemia (PG <3.1 mmol/l or 
requiring assistance) were low and only one severe event was reported (for 
IDeg 3TW). The rate of confirmed hypoglycemia appeared lower for IDeg 
OD than IDeg 3TW and IGlar (0.6, 2.3, 1.1 events/patient year, respectively; 
p=NS for both comparisons). The proportion of subjects with adverse events 
(AEs) was similar across treatment arms (IDeg OD: 47%; IDeg 3TW: 50%; 
IGlar: 66%) with no specific patterns or clustering. The majority of AEs were 
mild or moderate in severity.
Conclusion: This proof-of-concept trial demonstrated that IDeg used 3-
times weekly or once daily was safe, well tolerated and provided similar gly-
cemic control to IGlar.
Supported by: Novo Nordisk
5
Glycosylated hemoglobin and hypoglycaemia in patients with type 2 
diabetes mellitus: Technosphere insulin and usual antihyperglycaemic 
regimen vs usual antihyperglycaemic regimen
A.H. Boss1, P. Raskin2, M. Phillips1, A. Rossiter1, P.C. Richardson1;
1MannKind Corporation, Valencia, 2University of Texas Southwestern 
Medical Center at Dallas, USA.
Background and aims: Technosphere Insulin (TI) is an ultra-rapid-acting 
inhaled insulin with a pharmacokinetic profile well suited for earlier control 
of postprandial plasma glucose. One objective of this trial was to compare the 
efficacy and safety of prandial TI with usual diabetes care (UC) in patients 
with type 2 diabetes mellitus (T2DM) with inadequate glycemic control (glo-
cosylated hemoglobin [A1C] >6.6%, ≤12.0%).
Materials and methods: Patients either incorporated TI into their usual an-
tihyperglycemic regimen (TI group; n=656), or continued their usual antihy-
perglycemic regimen, which could include insulin, oral hypoglycemic drugs, 
and/or diet and exercise (UC group; n=678) over 2 years.
Results: Mean baseline characteristics were similar between groups. The av-
erage TI daily dose was 141.7±62.9 U. At 2 years, there was comparable re-
duction between groups in A1C (0.70% [TI], 0.59% [UC], p=0.30; see Figure). 
Total hypoglycemic event rates were 0.15 per patient-month in the TI group 
compared with 0.24 per patient-month for UC patients on insulin (p=0.03); 
mild/moderate (M/M), 0.15 per patient-month in the TI group compared 
with 0.24 per patient-month for UC patients on insulin (p=0.04); and severe, 
0.53 per 100 patient-months in the TI group compared with 1.17 per 100 
patient-months for UC patients on insulin (p=0.08). Weight gain in the TI 
group was +1.56 kg compared with 1.75 kg in the UC group (p=0.67).
Conclusion: In patients with T2DM, antihyperglycemic regimens containing 
prandial TI resulted in comparable A1C reductions, significant reductions in 
overall and M/M events, and a numerical reduction in severe hypoglycemic 
event rates.
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A novel pH-neutral formulation of the monomeric insulin VIAject® has a 
faster onset of action than insulin lispro
L. Nosek1, T. Heise1, F. Flacke2, A. Krasner2, P. Pichotta2, L. Heinemann1,  
S.S. Steiner2;
1Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany, 2Biodel 
Inc, Danbury, USA.
Background and aims: VIAject® is a monomeric insulin with a very fast on-
set of action. Previous studies used a formulation of VIAject with a concen-
tration of 25 U/ml and a pH of about 4 (VJ25). In this double-blind, cross-
over glucose clamp study we compared the pharmacodynamic (PD) and 
pharmacokinetic (PK) properties of a novel formulation of VIAject with a 
concentration of 100 U/ml and a neutral pH (VJ7) with those of VJ25 and 
insulin lispro (LIS).
Materials and methods: Fourty-three people with type 1 diabetes (21 fe-
male, age 43 (21-65) years, BMI 24.1 (20-28) kg/m², HbA1c 7.5 (5.7-9.5)%) 
received 12 U of either insulin under euglycemic glucose clamp conditions 
(Biostator-clamp, duration 8h postdose).
Results: VJ7 was bioequivalent to VJ25 (90% confidence interval of the ratios 
for total insulin (INS) AUCs and INSmax within 0.80-1.25). Compared with 
LIS, VJ7 showed a significantly faster absorption (t- INSmax 23 vs. 60 min, dif-
ference -30 [90% Confidence Interval (CI) -35;-23] min; t-INS50%early 8 vs. 22 
min, difference -16 [CI -17;-14] min; p<0.05 respectively) and faster onset of 
action (time to early half-maximal glucose infusion rate (GIR) 25 vs. 44, dif-
ference -18 [CI -26;-10] min, p<0.05), a higher GIR-AUC in the first 60 min 
post-dose (176 vs 107, ratio 1.65 [CI 1.27;2.14] mg/kg, p<0.05) and a slightly 
higher value for AUC-GIRtotal (1263 vs. 1095, ratio 1.15 [CI 1.06;1.26] mg/kg; 
p<0.05). GIRmax was similar between VJ7 and LIS (6.1 vs. 6.6, ratio 0.93 [CI 
0.86;1.01] mg/kg/min) as was t-INS50%late (136 vs. 129, difference 7 [CI -15;27] 
min) whereas the duration of action was longer with VJ7 (t-GIR50%late 274 vs. 
228, difference 50 [CI 25;73] min; p<0.05).
Conclusion: The novel, pH-neutral formulation of VIAject is bioequivalent 
to the previously used formulation and has a significantly faster absorption 
and onset of action than insulin lispro.
Supported by: Biodel Inc.
OP 2 Screening and prevention of 
gestational diabetes
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Hyperglycaemia and Adverse Pregnancy Outcome (HAPO) Study: 
Frequency of gestational diabetes mellitus (GDM) at collaborating 
centers based on IADPSG consensus panel recommended criteria
D.R. Hadden1, B.E. Metzger2, L.P. Lowe3, A.R. Dyer3, D.R. Coustan4,  
M. Hod5, J.J.N. Oats6, B. Persson7, E.R. Trimble8, HAPO Study Cooperative 
Research Group;
1Endocrinology, Royal Victoria Hospital, Belfast, United Kingdom, 
2Medicine, Northwestern University, Chicago, 3Preventive Medicine, 
Northwestern University, Chicago, 4Obstetrics & Gynecology, Women 
and Infants Hospital, Providence, USA, 5Obstetrics & Gynecology, Helen 
Schneider Hospital for Women, Rabin Medical Center, Tel Aviv, Israel, 
6Obstetrics & Gynecology, Royal Women’s Hospital, Melbourne, Australia, 
7Pediatrics, Karolinska Institute, Stockholm, Sweden, 8Endocrinology, 
Queen’s University Belfast, United Kingdom.
Background and aims: New criteria for GDM were recommended by the 
International Association of Diabetes in Pregnancy Study Groups (IADPSG). 
The aim is to apply the criteria to determine frequency of GDM at HAPO 
Study field centers.
Materials and methods: The IADPSG thresholds are one or more OGTT 
plasma glucose values => 5.1, 10.0, 8.5 mmol/l for fasting, 1-hr and 2-hr glu-
cose respectively. These were applied to the blinded participants at the 15 field 
centers that collaborated in the HAPO Study.
Results: GDM was diagnosed in 16.1% of the blinded study population. An 
additional 1.7% was unblinded with an OGTT glucose value above pre-de-
fined levels bringing the overall figure to 17.8%. However, there was consider-
able center-to-center variation of the study participants in maternal age, body 
mass index, frequencies of family history of diabetes and hypertension. Ad-
justing for these variables and for field center reduced, but did not eliminate 
center-center differences which in all likelihood reflect racial/ethnic group 
differences in the potential risk of disorders of glucose metabolism in these 
populations.
Conclusion: Using the diagnostic thresholds recommended by the IADPSG 
Consensus Panel, the frequencies of GDM show substantial variability be-
tween and within regions of the world. These variations may influence the 
future development of optimal, cost- effective strategies for detection and 
treatment of GDM.
Unadjusted Frequency of GDM at HAPO Field Centers
Field Center Frequency  
(%)
Field Center Frequency  
(%)
Bellflower, USA 22.9 Petah Tiqva, Israel 9.2
Chicago, USA 16.5 Beersheba, Israel 8.7
Providence, USA 14.2 Bangkok, Thailand 21.2
Cleveland, USA 23.7 Brisbane, Australia 12.1
Toronto, Canada 14.6 Newcastle, Australia 13.6
Belfast, UK 15.5 Singapore, Singapore 22.4
Manchester, UK 21.0 Hong Kong, China 13.4
Barbados, West Indies 9.9 HAPO Overall 16.1
Supported by: NIH, ADA
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Analysis of pregnancies after new IADPSG recommendation
A. Lapolla1, M. Dalfrà1, E. Ragazzi2, A. De Cata1, M. Masin1, B. 
Bonsembiante1, D. Fedele1;
1Medical and Surgical Sciences, 2Pharmacology and Anaesthesiology, 
University of Padova, Italy.
Background and aims: The IADPSG Consensus Panel recently has suggested 
new diagnostic criteria for gestational diabetes (GDM) diagnosis. Aim of our 
study was to evaluate clinical and metabolic characteristics and pregnancy 
outcome in women prior classified normal by Carpenter and Coustan criteria 
and now GDM according to the new recommendations.
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Materials and methods: We retrospectively analyzed 3953 pregnancies: 2138 
GDM and 1815 NGT by the new criteria: in the GDM group 112 women 
(2.8%) (GDM-NGT) were NGT with the old classification. We evaluated this 
group compared with GDM and NGT ones.
Results: As for clinical and metabolic parameter GDM-NGT women were 
younger (32.4 ± 4.5 yrs vs 33.4 ± 4.4 yrs, p=0.0039) and had a lower pre-
pregnancy BMI (23.7 ± 4.3 kg/m2 vs 24.7 ± 5.1 kg/m2, p=0.005) than GDM 
ones, while gestational week at diagnosis and HbA1c levels at diagnosis and 
at the 3rd trimester were not different. The analysis of OGTT showed that ,at 
all point of curve, glucose levels were significant higher in GDM-NGT with 
respect to NGT ones (basal 90.5 ± 7.8 mg/dl vs 79.2 ± 6.8 mg/dl, p<0.0001; 
60’: 153.7 ± 18.8 vs 140.6 ± 23.7, p<0.0001, 120’: 129.3 ± 20.6 vs 116.3 ± 20, 
p<0.0001). As for pregnancy outcome, caesarean section was 43.6% in GDM-
NGT group, 41% in GDM (n.s.) and 31.1% in NGT (p=0.008); gestational age 
at delivery and birthweight were not different. Ponderal index (g/cm3)was 
significant higher in GDM-NGT with respect to GDM and NGT (2.95 ± 0.61 
vs 2.8 ± 0.41 and vs 2.77 ± 0.34, p<0.0001 respectively). A correlation analysis 
showed that pre-pregnancy BMI and basal glucose level were significant re-
lated with newborn ponderal index (p<0.0001, p<0.05 respectively).
Conclusion: So the new GDM diagnostic criteria recommended by IADPSG 
identified a new group of GDM women that, classified normal with Carpen-
ter and Coustan criteria, show metabolic characteristics and pregnancy out-
come similar to those of GDM women.
9
New criteria for the diagnosis of gestational diabetes mellitus in 
comparison to former diagnostic criteria concerning maternal 
postpartum glucose levels and neonatal complications
T. Prikoszovich1, D. Bancher-Todesca2, R. Weitgasser3, H. Steiner4,  
G. Schernthaner5, B. Schneider6, C. Marth7, M. Lechleitner8,  
A. Kautzky-Willer9;
1Department of Internal Medicine III, Division of Nephrology and Dialysis, 
Medical University of Vienna, 2Obstetrics and Gynecology, Medical 
University of Vienna, 3First Department of Medicine, Paracelsus Private 
Medical University Salzburg, 4Obstetrics and Gynecology, Paracelsus 
Private Medical University Salzburg, 5Department of Internal Medicine 
I, Rudolfstiftung Vienna, 6Department of Medical Statistics, Medical 
University of Vienna, 7Obstetrics and Gynecology, Medical University 
of Innsbruck, 8Department of Internal Medicine, Medical University of 
Innsbruck, 9Department of Internal Medicine III, Division of Endocrinology 
and Metabolism, Medical University of Vienna, Austria.
Background and aims: New criteria for the diagnosis of gestational diabetes 
(GDM) were recently proposed by the Consensus Panel of the International 
Association of Diabetes Pregnancy Study Groups (ICP). We aimed to exam-
ine whether these new criteria (GDM-ICP) select women and children at risk 
better than criteria of the Forth International Workshop Conference of GDM 
(GDM-WC4) using the 2-hour 75g oral glucose tolerance test (OGTT).
Materials and methods: This was a prospective longitudinal open study in 
five tertiary care centers in Austria. 1466 women underwent an 2-hour 75g-
OGTT between the 24th and 28th gestational week and were treated if at least 
one value according to the GDM-WC4 was met or exceeded (GDM-WC4/1) 
in keeping with the recommendations of the Austrian and German Diabetes 
Association at that time. We evaluated the impact of risk factors, different 
thresholds (GDM-ICP vs. GDM-WC4/1) on fetal/neonatal complications 
and maternal postpartum glucose tolerance in pregnant women.
Results: Forty-nine percent of all women were diagnosed according to GDM-
ICP, whereas forty-six percent according to GDM-WC4/1. GDM-ICP identi-
fied a higher rate of obstetrical complications. We found 6.1 % more large for 
gestational age neonates (p=0.0047), 3.26% more cesarean sections (p=0.0001) 
and 4.5% more neonates with birth weight >4000g (p=0.0047) than with the 
former criteria. The rate of women with risk factors (history of GDM or pre-
diabetes, intrauterine fetal death, birth weight over 4000g, malformation, pre-
vious recurrent abortus, ethnic group at risk, adiposity, hypertension, dyslipi-
demia, preterm delivery, age, family history for DM2, glucosuria and macro-
somia) detected by the GDM-ICP was increased by 2.6% (p<0.0001). However 
concerning impaired postpartum glucose tolerance we found no differences.
Conclusion: These results support the use of the new, more stringent crite-
ria proposed by ICP for the diagnosis of GDM (GDM-ICP), because they 
can detect more obstetrical complications than the former diagnostic criteria 
(GDM-WC4/1) in a Central European population.
Supported by: Clinical research project award of the Austrian Diabetes Associa-
tion
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ATLANTIC DIP: Prevalence and implications of abnormal glucose 
tolerance in pregnancy in Ireland
E.P. O’Sullivan1, G. Avalos2, M.W. O’Reilly1, C. Dennedy1, F. Dunne1;
1Diabetes, Galway University Hospital, 2Medicine, National University of 
Ireland Galway, Ireland.
Background and aims: While many authorities now recommend universal 
screening for gestational diabetes mellitus (GDM), this is not available in the 
Irish Health Service. Consequently, the true prevalence of abnormal glucose 
tolerance (and its implications) in pregnancy is unknown.
Materials and methods: ATLANTIC DIP (Diabetes In Pregnancy) is a mul-
ticentre study on the west coast of Ireland which offers universal screening for 
gestational diabetes mellitus (GDM) using a 75g oral glucose tolerance test at 
24-28 weeks. Normal glucose tolerance (NGT), impaired glucose tolerance 
(IGT) and GDM were defined according to standard WHO criteria. Maternal 
and foetal outcomes were recorded. Statistical analysis was performed using 
SPSS, and all results were adjusted for maternal age and body mass index 
(BMI).
Results: Between 2006 and 2008, 5,670 women (mean age 1.5±5.4yrs, mean 
BMI 26.9±5.1kg/m2, 93.4% Caucasian) were screened. 5,100 (89.9%) women 
had a NGT, 431 (7.6%) had IGT, and 139 (2.5%) had GDM. The table below 
shows the Odds ratios [95% confidence intervals] of adverse maternal and 
foetal outcomes for IGT and GDM compared to NGT.
Conclusion: One in ten women screened had IGT or GDM. Given this prev-
alence and the associated significant adverse maternal and foetal outcomes, 
consideration should be given to universal screening for GDM throughout 
Ireland.
Adverse maternal and foetal outcomes
IGT GDM IGT/GDM
Hypertensive disorder of 
pregnancy
1.4[0.9-2.1] 1.9[1.0-3.6] 1.5[1.0-2.2]
Polyhydramnios 3.9[1.4-10.6] 2.9[0.4-22.9] 3.7[1.4-9.5]
Instrumental delivery/ 
Caesarean Section(CS)
0.8[0.6-1.1] 3.0[1.6-5.6] 1.1[0.8-1.4]
CS 0.8[0.6-1.2] 3.8[2.1-6.9] 1.2[0.9-1.6]
Emergency CS 0.6[0.4-1.0] 4.5[2.3-8.6] 1.2[0.8-1.7]
Elective CS 1.1[0.7-1.6] 3.1[1.5-6.5] 1.5[1.1-2.1]
Congenital Malformations 2.4[1.0-5.6] 1.1[0.1-8.5] 2.1[1.0-4.7]
Small for gestational age 1.4[0.7-2.8] 3.8[1.5-9.4] 1.8[1.1-3.1]
Neonatal ICU admission 3.4[2.4-4.9] 9.5[5.3-16.9] 4.3[3.2-6.0]
Supported by: HRB
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Is maternal educational level a risk factor for gestational diabetes in 
caucasian women?
A. Bertolotto1, M. Corfini1, A. Ghio1, V. Resi1, C. Lencioni1, L. Battini2,  
L. Volpe1, G. Di Cianni1;
1Department of Endocrinology and Metabolism, Section of Diabetes and 
Metabolic Diseases, University Hospital, 2Department Maternal-Childish, 
University Hospital, Pisa, Italy.
Background and aims: Gestational Diabetes (GDM) is associated with fea-
tures of Metabolic Syndrome (MS) and Cardiovascular Disease (CVD); low 
socio-economic status is a well known risk factor for these conditions. So, we 
performed this study to evaluate if maternal educational level (MEL) may be 
associated with the development of GDM as well as impaired glucose toler-
ance (IGT).
Materials and methods: From 2006 to 2009 we examined a cohort of Cau-
casian pregnant women attending 3-h 100-g OGTT in our Department of 
Diabetes. According to ADA criteria, GDM and IGT were diagnosed when 
almost 2 or 1 plasma glucose concentrations exceeded the cut-off levels, re-
spectively. At the enrolment, upon collection of anthropometric and clini-
cal parameters, we assessed the MEL on the basis of the level of attended 
school, evaluated by a questionnaire. So the women were categorized into 
three levels: low (primary school; L), intermediate (high school; I) and high 
(university; H) level.
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Results: We studied 1012 Caucasian pregnant women (mean age 33.8±4.4 
yrs;) at 27.4±4 wks of gestation: 20% L, 48.6% I and 31.4% H. L women were 
younger (33.4±6.2 vs 33.2 ± 4.3 and 34.9±3.7 yrs, p<0.0002) heavier (BMI 
25.7±5.6 vs 24.2±5 and 23±3.9 kg/m2, p<0.0001) with an higher rate of obes-
ity (22.4% vs 12% and 6.9%, p<0.0001) and an higher weight gain during 
pregnancy(10.9±4.9 vs 10.4±5.8 and 9.7±3.6 kg, p<0.01) while H women 
were older than others (L 33.4±6.1 and I 33.2±4.3 vs H 34.9±3.7; p< 0.002).
No differences were observed in family history for type 2 diabetes (27% L, 
26% I and 21.5% H) and parity (primiparous: 45% L, 44% I and 40% H). 
IGT and/or GDM was diagnosed in 58(29%) L, 124(25%) I and 80(25 %) H 
women, without difference among the three groups. IGT and GDM diagnosis 
were not related to MEL, while after multivariate logistic regression analysis 
including all clinical and metabolic parameters, only prepregnancy BMI (F 
test value 12.148 p< 0.005) and age ( F test value 9.318 p< 0.001) were inde-
pendently associated with IGT or GDM diagnosis.
Conclusion: We failed to find any relationship between abnormal OGTT and 
maternal education levels. Probably in our population, differently than others, 
low education level is not a condition of deprivation and low health knowl-
edge. Prepregnancy BMI and old age remain the best predictors of abnormal 
glucose tolerance during pregnancy. Obese and older women, independently 
of their education levels, have to be addressed to programs for preventing the 
development of glucose abnormalities during pregnancy.
12
Metformin does not prevent gestational diabetes mellitus in women with 
polycystic ovarian syndrome
S.M. Carlsen1, E. Vanky2;
1Department of Cancer Research and Molecular Medicine, 2Department 
of Laboratory Medicine, Children`s and Women`s Health, Norwegian 
University of Science and Technology, Trondheim, Norway.
Background: It is held that gestational diabetes mellitus (GDM) increases 
pregnancy complications and adverse pregnancy outcome. Metformin is also 
suggested to prevent pregnancy complications in women with polycystic 
ovary syndrome (PCOS). And some propose that metformin should be used 
to treat GDM.
Material and methods: In the first trimester of pregnancy, 273 PCOS women 
were randomized to metformin or placebo. At inclusion, gestational week 
19 and 32, an OGTT were performed and pregnancy complications were re-
corded.
Results: At inclusion, 13 women in the placebo group and 10 in the met-
formin group had GDM. During the rest of the pregnancy 21/125 (16.9%) 
in the placebo group and 22/125 (17.6%) in the metformin group developed 
GDM (p=0.87). Insulin was required in four patients in the placebo group 
and none in the metformin group. We found no differences in mean birth 
weight (3524 ± 559 vs 3543 ± 601, p=0.82), in the incidence of preterm de-
livery (2/64 (3.1%) vs. 14/206 (6.8%), p=0.83) and preeclampsia (3/64 (4.7%) 
vs. 12/206 (5.8%), p= 0.69) between those who developed GDM and those 
who did not.
Conclusion: Our findings do not support the view that metformin prevents 
GDM in women with PCOS. This is rather surprising, given the effect of met-
formin in non-pregnant patients with diabetes mellitus type 2. In pregnant 
women insulin resistance increases. However, the pathogenetic mechanisms 
involved in the development of GDM may be different from the mechanism 
responsible for increased insulin resistance in non-pregnant women. Met-
formin may lack effect on the mechanism responsible in increasing gestation-
al insulin resistance. The incidence of preterm delivery and preeclampsia were 
equal in PCOS women with and without GDM. This observation contradicts 
the view that GDM or blood glucose levels per se are directly involved in the 
development of preeclampsia and preterm delivery. If our observations are 
confirmed by future studies, other endocrine or metabolic aberrations associ-
ated with decreased glucose sensitivity must be responsible for the increased 
incidence of preeclampsia and preterm delivery seen in women with GDM. 
The observation that birth weight was not increased in offspring of PCOS 
women with GDM compared to those with normal glucose homeostasis is 
surprising. Our observations indicate that future studies on GDM should dif-
ferentiate between PCOS women and non-PCOS women. In conclusion the 
present study does not support that metformin prevents the development of 
GDM in PCOS pregnancies. GDM in PCOS women is not associated with 
increased pregnancy complications or increased birth weight.
Supported by: Weifa AS
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Higher plasma advanced glycation endproducts levels are associated 
with incident cardiovascular disease and all-cause mortality in type 1 
diabetes: a 12-year follow-up study
J.W.M. Nin1, A. Jorsal2, I. Ferreira1, C.G. Schalkwijk1, M.H. Prins3,  
H.-H. Parving4, L. Tarnow2, P. Rossing2, C.D.A. Stehouwer1;
1Internal Medicine, Maastricht University Medical Centre, Netherlands, 
2Steno Diabetes Center, Gentofte, Denmark, 3Clinical Epidemiology and 
Medical Technology Assessment, Maastricht University Medical Centre, 
Netherlands, 4Medical Endocrinology, Rigshospitalet, Copenhagen, 
Denmark.
Background and aims: Advanced glycation endproducts (AGEs) may con-
stitute a pathophysiologic mechanism linking hyperglycaemia to the devel-
opment of vascular complications. Therefore, we investigated the associations 
of plasma levels of AGEs with incident cardiovascular disease (CVD) and all-
cause mortality in individuals with type 1 diabetes, and the extent to which 
any such associations could be explained by endothelial and renal dysfunc-
tion, low-grade inflammation and arterial stiffness.
Materials and methods: We prospectively followed 169 individuals with 
diabetic nephropathy and 170 individuals with persistent normoalbuminuria 
(205 men, mean age at baseline of 41±10 yrs) who were free of CVD at study 
entry and in whom levels of AGEs (expressed as the average of the z-scores 
of Nε-(carboxymethyl)lysine, Nε-(carboxyethyl)lysine and pentosidine) and 
other biomarkers were measured at baseline. The median follow-up duration 
was 12.3 (inter-quartile range: 7.6-12.5) years. Data were analysed with Cox 
regression analyses.
Results: During the course of follow-up, 82 individuals (24.2%) died; 85 
(25.1%) suffered a fatal (n=48) and/or non-fatal (n=53) CVD event. The in-
cidence of cardiovascular morbidity and mortality (Fig. 1A) and of all-cause 
mortality (Fig. 1B) increased with higher baseline levels of AGEs independ-
ently of traditional CVD risk factors (as detailed in footnote to figure): hazard 
ratio (HR)=1.30 (95%CI=1.02 to 1.65) and HR=1.29 (1.01 to 1.65) per 1 SD 
increase in AGEs score, respectively. Adjustment for estimated glomerular 
filtration rate (eGFR), but not for markers of endothelial dysfunction, low-
grade inflammation and arterial stiffness, attenuated these associations to 
HR=1.16 (0.89 to 1.51) and HR=1.19 (0.90 to 1.57), respectively. Higher 
levels of AGEs were inversely associated with baseline eGFR: standardised 
regression coefficient=-0.29 (-0.38 to -0.20).
Conclusion: Higher levels of AGEs are associated with incident cardiovascu-
lar morbidity and mortality as well as all-cause mortality in individuals with 
type 1 diabetes. AGEs-associated renal dysfunction may partially explain 
these associations.
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Figure 1. Cumulative hazard for CVD morbidity and mortality (A) as well as 
all-cause mortality (B) across tertiles of plasma AGEs score. Data are adjusted 
for age, sex, case-control status, duration of diabetes and HbA1c, mean arte-
rial pressure, smoking status, total cholesterol, renin-angiotensin-aldosterone 
system, other antihypertensive agents, and continuation ofmedication at base-
line examination.
Dr. I.F. is supported by a Netherlands Heart Foundation grant 
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Repeated episodes of hypoglycaemia aggravate preclinical atherosclerosis 
in a group of young adult subjects with type 1 diabetes
M. Giménez1,2, R. Gilabert3, J. Monteagudo4, A. Alonso1, R. Casamitjana5,  
C. Paré6, I. Conget1,2;
1Endocrinology and Diabetes Unit, 2CIBERDEM, 3Radiology Unit, 
4Haemostasia Unit, 5Hormonal Unit, 6Echocardiology Unit, Hospital Clínic, 
Barcelona, Spain.
Background and aims: Type 1 Diabetes (T1D) is associated with an in-
creased age-adjusted relative risk for atherosclerosis even though many of 
the classical cardiovascular risk factors (CVRF) are absent. While intensive 
insulin therapy reduces the risk of complications, it is associated with an in-
crease in hypoglycaemia. Hypoglycaemia acutely provokes intense changes in 
haemodinamics and several haemorreological parameters. However, its role 
when chronically repeated as an accelerating factor for CV disease in diabetes 
is still far from proven.
Aims: To evaluate whether repeated episodes of hypoglycaemia represent an 
aggravating factor for vascular disease in subjects with T1D.
Materials and methods: Twenty-five T1D patients (34.6±7.8 years, 14 wom-
en, T1D duration 16.1±6.3 years, HbA1c 6.6+1.0) with >4 non-severe-hy-
poglycaemia (NSH)/week and >2 severe hypoglycaemia (SH)/previous year 
and without additional CVRF, micro/macrovascular complications (includ-
ing normal stress echocardiography) and no autonomic dysfunction were 
included (H-Group). In addition, 20 T1D subjects were selected as an age-
sex matched control group presenting <2 NSH/week, no previous SH and 
without micro/macro/autonomic complications (C-Group). Previous to the 
CV evaluation, an acute induction of hypoglycaemia was performed to as-
sess hypoglycaemia awareness. Inflammation/endothelial markers including 
leukocytes, Von Willebrand factor (VW), fibrinogen and ICAM-1 were also 
measured. B-mode-ultrasound was used to evaluate flow-mediated-dilata-
tion in braquial artery (FMD) and intima-media-thickness (IMT) at both 
carotid/femoral sites. A 72-h blinded CGMS was recorded.
Results: As expected, H-Group subjects had significantly higher number of 
NSH/week and SH than C-Group (NSH/week 5.2±1.9 vs. 0.3±0.5 p<0.01). 
In addition, they displayed hypoglycaemia unawareness by Clarke’s test and 
by symptomatic response to hypoglycaemia (Edinburgh’s scale). Unsurpris-
ingly, higher percentage of values and AUC <70mg/dl were observed in H-
Group (14.2±8.9 vs. 6.3±7.1%, p<0.02 and 2.4±1.8 vs. 0.6±1.0 AUC, p<0.01). 
The percentage of maximal FMD was lower in H-Group than in C-Group 
(6.52+2.92 vs. 8.62+3.13%; p<0.05). A significantly higher IMT was observed 
at both carotid/femoral sites in H-Group in comparison to C-Group (carotid, 
0.53±0.09 vs. 0.47±0.08mm; p<0.05 and femoral, 0.51±0.17 vs. 0.39±0.09mm; 
p<0.05). While in 10/25 subjects from the H-Group atherosclerotic plaques 
were detected this was not the case in any of the subjects from C-Group. 
Inflammation/endothelial dysfunction markers were higher in H-Group 
(leukocytes 7.0±1.8 vs. 5.6±1.4 x103/ul; VW 119±29 vs. 93±26 %; fibrinogen 
2.82±0.64 vs. 2.29±0.44 g/L; ICAM-1 408±224 vs. 296±95 ng/ml; p<0.05 for 
all).
Conclusion: In addition to the induction of hypoglycaemia unawareness and 
an increased risk for severe hypoglycaemia, repeated hypoglycaemia in T1D 
is associated with a worse prognosis in terms of preclinical atherosclerosis 
profile. The precise mechanisms explaining this association remains to be 
clarified.
Supported by: FIS 06250, Ajut “Josep Font” 2006-2009
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Pulse pressure predicts all - cause and cardiovascular mortality but not 
deterioration in kidney function in type 1 diabetic patients
S. Theilade1, M. Lajer1, A. Jorsal1, L. Tarnow1, H.-H. Parving2,3, P. Rossing1;
1Steno Diabetes Center, Gentofte, 2Department of Medical Endocrinology, 
Copenhagen University Hospital, Rigshospitalet, 3Faculty of Health Science, 
Aarhus University, Denmark.
Background and aims: Patients with type 1 diabetes have an elevated risk 
of early death due to cardiovascular disease (CVD) and development of end 
stage renal disease (ESRD). The aim of this analysis is to evaluate if pulse 
pressure (PP) (as an estimate of arterial stiffness) based on office arterial 
blood pressure predicts mortality, cardiovascular events and progression of 
diabetic nephropathy in patients with type 1 diabetes.
Materials and methods: A prospective observational follow-up study. The 
patients were followed for a median (range) of 8.2 (0.0-12.9) years. The cohort 
consisted of 898 type 1 diabetic patients. Of these, 456 patients had overt 
diabetic nephropathy (277 men; age (mean ± SD) 42.1 ± 10.5 years, duration 
of diabetes (mean ± SD) 28.3 ± 8.8 years, glomerular filtration rate (GFR) 76 
± 34 ml/min/1.73 m2) and were followed with yearly measurement of GFR. 
The remaining 442 patients had longstanding type 1 diabetes and persistent 
normoalbuminuria (234 men; age 45.4 ± 11.5 years, duration of diabetes 27.8 
± 10.1 years).
Results: During follow-up 178 (19.8 %) patients died; 109 (12.1%) patients 
died from CVD causes and 99 (11.0%) patients developed ESRD. Individuals 
with elevated PP had significantly higher all-cause mortality (hazard ratio 
per 10 mmHg increase), (HR [95% CI] 1.18 (1.07 to 1.30); p=0.001, adjusted 
for sex, age, duration of diabetes, smoking, diastolic blood pressure, HbA1c, 
eGFR, cholesterol, and history of CVD). For patients with diabetic nephropa-
thy the adjusted HR for all-cause mortality was 1.16 (1.04 to 1.30) p=<0.001. 
Elevated PP also predicted CVD mortality (adjusted HR 1.27 (1.13 to 1.43) 
p<0.001), and non fatal CVD events (adjusted HR 1.12 (1.01 to 1.25) p=0.04). 
For fatal and non-fatal CVD combined, the adjusted HR was 1.13 (1.04 to 
1.24) p=0.005). In patients with diabetic nephropathy, elevated PP was associ-
ated with higher risk of progression to ESRD (HR (per 10 mmHg increase) 
1.27 (1.12 to 1.43) p<0.001) but this was not significant after adjustment (HR 
1.03 (0.89 to 1.203) and elevated PP was not related to decline in GFR in 
patients with diabetic nephropathy.
Conclusion: Elevated office pulse pressure (arterial stiffness), predicts all-
cause and CV mortality in type 1 diabetic patients. In contrast, office pulse 
pressure was not associated with progression of diabetic nephropathy.
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Decreased endothelial progenitor cells associated with poor glycaemic 
control predict both morphological microvascular and macrovascular 
impairment in type 1 diabetic children within three years
K. Nagl1, T. Hoertenhuber1, M. Fritsch2, E. Schober2, O. Schlager1,  
M. Gschwandtner1, A. Willfort-Ehringer1, C. Margeta1, R. Koppensteiner1, 
G. Schernthaner3, B. Rami2, G.-H. Schernthaner1;
1Angiology, Medical University of Vienna, 2Pediatrics, Medical University of 
Vienna, 3Angiology, Rudolfstiftung, Vienna, Austria.
Background and aims: The risk of cardiovascular death before the age of 40 
is 20-fold increased in patients with type 1 diabetes mellitus (T1DM) com-
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pared to those without. Vascular damage, which might be responsible for the 
increased risk, can be estimated by bone marrow derived Endothelial Pro-
genitor Cells (EPC). EPC predict cardiovascular morbidity and mortality in 
patients without diabetes. Recently we have demonstrated that improvement 
or worsening of glycemic control resulted in indirect proportional changes 
in EPC in Type 1 diabetic children within one year. So, we asked whether 
a longer follow-up of these T1DM children would result in morphological 
changes of the macro- and microvasculature.
Materials and methods: We present data of 74 T1DM children: Gender: 
51.4% female; Age: 12.7±0.3 years; Body Mass Index: 20.8±0.4; Glycated 
Haemoglobin A1c (HbA1c): 7.0-9.1 (range); diabetes duration 4.8±0.4 years 
(all at time of inclusion). Study visits were inclusion, after 1.0±0.1 and 2.7±0.2 
years. EPC (flow cytometry) were measured at all visits.
For estimation of micro- and macrovascular damage two techniques were ap-
plied. For macrovascular damage - driven by plaque formation - Carotid In-
tima Media Thickness (IMT) was assessed by the average of 24 measurements 
of the vessel walls via high-resolution B-mode ultrasound. For microvascular 
damage - driven by vessel reactivity - tissue perfusion was investigated by 
Laser Doppler perfusion imaging (LDPI) and a post-occlusive reactive hyper-
emia provocation test. For statistical analysis a p-value < 0.05 was considered 
significant. Results are given in mean±STD or median (25;75 percentile).
Results: EPC at inclusion: 3410/106WBC (2515;4237), EPC at one year: 
3334/106WBC (2929;3898). LDPI parameters after 2.7 years: time to absolute 
peak 9.5s (6.0;21.3), time to baseline: 80.5s (63.0;108.3), Total Time (LDPI-
TT): 95.5s (78.0;118.3), Perfusion at absolute peak 1.435 (1.020;2.050), Per-
fusion at baseline: 0.390 (0.258;0.598), Difference of perfusion at peak and 
baseline: 1.055 (0.610;1.513). IMT at latest follow-up was 0.285 (0.258;0.350). 
EPC at earlier time points were significantly predictive for LDPI-TT (R=-
0.259; p=0.042) and IMT (R=-0.344; p=0.003). Cross-sectional the follow-
ing parameters were associated with LDPI-TT: HbA1c (R=0.255; p=0.045); 
mean-blood-glucose (R=0.331; p=0.013) and aspartate aminotransferase 
(ASAT) (R=0.315; p=0.015). Associations with IMT were systolic blood pres-
sure (R=0.248; p=0.035); ASAT (R=0.332; p=0.005); alanine aminotrans-
ferase (R=0.280; p=0.019); duration of diabetes (R=0.0255; p=0.028).
Conclusion: This is the first study demonstrating an association of EPC with 
disturbed micro- and macrovascular function in children with Type 1 Dia-
betes mellitus after a short observation period. Thus, it is most likely that 
glucose fluctuation with high HbA1c lead from depression of bone-marrow 
derived EPC to microvascular changes (LDPI), to plaque formation (IMT) 
and finally to premature cardiovascular disease and death.
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Early signs of atherosclerosis in diabetic children on intensive insulin 
treatment: a population based study 
H.D. Margeirsdottir1,2, K.H. Stensaeth3, J.R. Larsen4, C. Brunborg5,  
K. Dahl-Jorgensen2,4;
1Pediatric department Ullevaal, Oslo University Hospital, Oslo, 2Faculty 
of Medicine, University of Oslo, 3Radiology Department Ullevaal, Oslo 
University Hospital, 4Oslo Diabetes Research centre, 5Centre for Clinical 
Research Ullevaal, Oslo University Hospital, Norway.
Objective: Young adults with type 1 diabetes are at increased risk of early 
asymptomatic atherosclerosis and cardiovascular morbidity and mortality 
are substantially increased in this group of patients. The aim of this study was 
to evaluate early stages of atherosclerosis and predisposing factors in child-
hood diabetes compared to age- and sex matched healthy control subjects.
Research design and methods: All children and adolescents with type 1 dia-
betes, aged 8-18 years in Health Region South-East in Norway were invited to 
participate in the study (n=800). 40% (n=314) agreed to participate and were 
compared to118 age-matched healthy controls. Carotid artery Intima Media 
Thickness (cIMT) and elasticity was measured using standardized methods.
Results: Mean age of the diabetic patients was 13.7 years, diabetes duration 
5.5 years and HbA1c 8.4%. 97% were using intensive insulin treatment, 60% 
insulin pumps. Diabetic patients had more frequently elevated cIMT than 
healthy controls: 19.5% were above 90th centile of normal healthy controls 
and 13.1% above 95th centile (p<0.001). Mean cIMT was higher in diabetic 
boys compared to healthy controls (0.46mm /SD 0.06mm vs. 0.44mm/SD 
0.05mm, p=0.04) but not significantly so in girls. There was no significant 
difference between the groups regarding carotid distensibility, compliance 
and wall stress. None of the subjects had atherosclerotic plaque formation. 
Although within the normal range the mean values of systolic blood pressure 
(SBP), total cholesterol, LDL-cholesterol and ApoB were significantly higher 
in the diabetic patients than in healthy controls.
Conclusion: Despite short disease duration, intensive insulin treatment, fair 
glycemic control and no signs of microvascular complications, children and 
adolescents with type 1 diabetes had slightly increased cIMT compared to 
healthy controls, the differences being more prominent in the boys.
Supported by: The Norwegian Foundation for Health and Rehabilitation.
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Colesevelam effects on LDL-C, HbA1c, and GLP-1 in type 1 diabetes 
mellitus (T1DM)
S.K. Garg, P.J. Ritchie, E.G. Moser, R.S. Gutin, L.B. Crew, J.K. Snell-Bergeon;
Barbara Davis Center, University of Colorado Denver, Aurora, USA.
Background and aims: Colesevelam is indicated to lower LDL-C in hyperli-
pidemia and improve glycemic control in type 2 diabetes (T2DM). The clini-
cal effects in subjects with T1DM have not previously been evaluated.
Materials and methods: This was a double-blind, randomized, investigator-
initiated, single center, 12-week pilot study that evaluated 40 adults (36.4±9.4 
yr) with T1DM and hyperlipidemia. The study was powered to demonstrate 
a treatment difference of >10% LDL-C reduction from screening. Subjects 
were randomized to receive either 3.75 g/day colesevelam (n=20) or placebo 
(n=20) for 12 weeks. LDL-C and A1c levels were assessed at screening (week 
-2), baseline (week 0) and every 4 weeks for the duration of the study. All sub-
jects had a 4-hour Boost Plus® meal-challenge test (MCT) at baseline (week 
0) and at the end of study (week 12). Study drug was administered at time 0 
of the MCT. Incretin levels including GIP and GLP-1 were assessed during 
the MCT at the following time points (-30, 0, 30, 60, 120, 180 and 240 min). 
Screening demographics were similar in both treatment groups. Thirty-six 
subjects (n=18 in each group) completed the study. Compliance for both 
treatment groups was >88%.
Results: All data presented are from the intent-to-treat population with 
last observation carried forward. Colesevelam treatment resulted in a sig-
nificant difference in the least squared mean percent change in LDL-C at 4 
weeks (1.7% vs. -12.1%, difference between means 13.84 [95%CI: 2.2, 25.5], 
p=0.02), and this difference was marginally significant at 8 (p=0.05) and 12 
weeks (p=0.08) (Figure 1a). Treatment also resulted in a statistically signifi-
cant change in A1c from screening at week 4 (-0.19, p=0.04), however this did 
not remain significant for the study duration (Figure 1b).
Colesevelam resulted in significant median increases in GLP-1 levels during 
the first 2 hours of the baseline MCT compared to placebo following the first 
dose of study drug. There was no difference in GLP-1 levels between groups 
at the week 12 MCT. The GIP levels were similar between the two groups at 
baseline and 12 week MCTs.
There were no significant differences between or within groups for fasting 
glucagon, fasting and postprandial glucose, insulin dose, weight or BMI.
Conclusion: Results from this small pilot study suggest that Colesevelam 
treatment lowers LDL-C in patients with TIDM. While improvements in A1c 
were observed at week 4, significance was not maintained for the study dura-
tion. This effect might be explained by sample size, study duration, and/or 
chance. The treatment group showed an increase in GLP-1 levels at baseline, 
which may explain their improvements in A1c at week 4 of this study. How-
ever, the effect of Colesevelam on glycemic control in subjects with T1DM 
requires further clinical study involving a larger number of subjects over a 
longer duration.
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Obestatin and ghrelin bind to human pancreatic islet endothelial cells 
and inhibit apoptosis in high glucose condition
E. Favaro, I. Miceli, F. Settanni, A. Baragli, R. Granata, G. Camussi, E. 
Ghigo, P. Cavallo Perin, M.M. Zanone;
Department of Internal Medicine, University of Turin, Italy.
Background and aims: Pancreatic islet microendothelium exhibits unique 
structural and functional features, in an interdependent physical and functional 
relationship with the beta cells. Glucose toxicity is not solely restricted to beta 
cells, but affects also survival of pancreatic islet endothelial cells, thus contribut-
ing to beta cell function impairment and cell loss. Studies indicate that gastroin-
testinal products of the ghrelin gene, obestatin (Ob), acylated ghrelin (AG) and 
its major circulating form, unacylated ghrelin (UAG) stimulate proliferation and 
prevent apoptosis of pancreatic β cells and human islets. We aimed to investigate 
whether these peptides would display survival effects also in human pancreatic 
islet microendothelial cells (MECs) cultured in high glucose conditions.
Materials and methods: Islet MECs were cultured in 28 mmol/L glucose 
concentration and, in parallel cultures, stimulated with AG, UAG or Ob (10 
nM). Apoptosis was assessed by photometric enzyme immunoassay meas-
uring mono- and oligonucleosomes as an index of DNA fragmentation, by 
Hoechst staining of apoptotic cells, and by Caspase 3 activity. Western-blot 
analyses for P-Akt/Akt, P-ERK/ERK pathways and for Bcl-2 (anti-apoptotic 
gene) and Bax (pro-apoptotic gene) were performed. Blockade of PI3K/ade-
nylyl cyclase/cAMP/protein kinase A signalling was also performed.
Results: Islet MECs express the AG receptor (GRLN-receptor), assessed by 
RT-PCR analysis, and bind Ob, as assessed by immunofluorescence. In high 
glucose condition, AG, UAG and Ob inhibited islet MEC apoptosis, activat-
ing PI3K/Akt and ERK1/2 phosphorylation and upregulating intracellular 
cAMP. Further, Bcl-2 expression increased and Bax expression decreased. 
Blockade experiments counteracted the anti-apoptotic effects.
Conclusions: These data provide evidence that the ghrelin gene-derived pep-
tides bind to, and promote survival of, islet microendothelial cells. The anti-
apoptotic effects involve the PI3K/Akt, ERK1/2 and cAMP/PKA pathways. 
These peptides could therefore represent a potential tool to improve islet vas-
cularization and, indirectly, islet function.
Supported by: Ricerca Sanitaria Finalizzata Regione Piemonte
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Improved glucose-lowering, insulin-releasing and anorexigenic actions 
of a novel chemically modified analogue of oxyntomodulin,  
(D-Ser2)Oxm[mPEG-PAL]
V.A. Gault, B.D. Kerr, P.R. Flatt;
School of Biomedical Sciences, University of Ulster, Coleraine, United 
Kingdom.
Background and aims: Oxyntomodulin (Oxm) is a 37 amino acid peptide 
hormone released from intestinal L-cells in response to feeding. Oxm has 
been shown to exhibit a range of potentially beneficial actions for the alle-
viation of obesity-diabetes. However, possible exploitation of Oxm-based 
therapies has been severely restricted due to proteolytic degradation of the 
peptide by the ubiquitous enzyme dipeptidylpeptidase-IV (DPP-IV). There-
fore, the aim of this study was to assess the glucose-lowering, insulin-releas-
ing and anorexigenic actions of novel chemically modified, enzyme resistant 
analogues of Oxm.
Materials and methods: Oxm, (D-Ser2)Oxm and (D-Ser2)Oxm[mPEG-PAL] 
(all >97% purity) were incubated (0, 2, 4, 8 and 24 h) with DPP-IV (5 mU; 
n=3) to assess enzyme stability and with clonal pancreatic BRIN-BD11 cells 
to evaluate acute (20 min; n=8) insulin secretion. Cyclic AMP production 
(n=4) was examined using GLP-1 and glucagon receptor transfected cells. In 
vivo effect of Oxm analogues on glucose homeostasis, insulin secretion, food 
intake and body weight were examined in obese diabetic (ob/ob) mice.
Results: (D-Ser2)Oxm[mPEG-PAL] displayed enhanced DPP-IV resist-
ance compared to (D-Ser2)Oxm and Oxm (13.4 and 1.6-fold, respectively; 
P<0.001). Oxm, (D-Ser2)Oxm and (D-Ser2)Oxm[mPEG-PAL] stimulated 
cyclic AMP production in a concentration-dependent manner with similar 
potency in BRIN-BD11 cells with EC50 values of 1.84 ± 0.09 nmol/l; 1.81 ± 
0.37 nmol/l; and 1.97 ± 1.21 nmol/l, respectively. This was associated with 
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dual action at GLP-1 and glucagon receptors, although EC50 values were 15 
to 200-fold greater than respective natural ligands. All peptides significantly 
stimulated insulin secretion (1.6 to 2.5-fold; P<0.001) in a concentration-de-
pendent and equipotent manner. Acute administration (25 nmol/kg body-
weight) of (D-Ser2)Oxm[mPEG-PAL] and (D-Ser2)Oxm reduced plasma 
glucose (40-50% reduction; P<0.01) and food intake (1.1 to 1.4-fold; P<0.05 
to P<0.01), while plasma insulin levels were elevated (1.5 to 1.8-fold; P<0.01 
to P<0.001) in ob/ob mice. Animals treated with (D-Ser2)Oxm[mPEG-PAL] 
and (D-Ser2)Oxm four or eight hours prior to a glucose load (18 mmol/kg 
bodyweight) had significantly decreased plasma glucose concentrations (1.2 
to 2.0-fold reduction; P<0.05 to P<0.001) compared to Oxm-treated ani-
mals. Once-daily administration of (D-Ser2)Oxm[mPEG-PAL] for 14 days to 
ob/ob mice decreased food intake (1.2 to 1.5-fold; P<0.05 to P<0.001), body 
weight (1.1 to 1.5-fold; P<0.05 to P<0.01), plasma glucose (30-50%; P<0.05 to 
P<0.01) and increased plasma insulin (1.4 to 1.5-fold; P<0.01). Furthermore, 
daily (D-Ser2)Oxm[mPEG-PAL] administration improved glucose tolerance 
(1.2 to 1.6-fold; P<0.05 to P<0.001), increased glucose-mediated insulin se-
cretion (1.5 to 1.8-fold; P< 0.05 to P<0.01), pancreatic insulin content (1.5-
fold; P<0.001), circulating adiponectin (1.4-fold; P<0.01) and decreased both 
visfatin (1.3-fold; P<0.01) and triglyceride levels (1.4-fold; P<0.01).
Conclusion: The ability of enzyme resistant (D-Ser2)Oxm[mPEG-PAL] to 
improve glucose homeostasis, insulin secretion, satiety, body weight and 
markers of fat metabolism suggests significant promise for Oxm-based thera-
pies for obesity-diabetes.
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Synaptotagmin-7 is a positive regulator of glucose-induced GLP-1 
secretion
N. Gustavsson, Y. Wang, Y. Kang, W. Han;
Laboratory of Metabolic Medicine, Singapore Bioimaging Consortium, 
A*STAR, Singapore.
Background and aims: Glucagon-like peptide 1 (GLP-1) is produced by 
highly specialized gut endocrine L-cells. Despite the demonstrated medical 
benefits of targeting GLP-1 in the treatment of diabetes, very little is known 
about the molecular control of GLP-1 secretion. Similar to other endocrine 
cells, such as islet β-cells, L-cells are electrically excitable, and express ATP-
sensitive K-channels and calcium channels. Furthermore, GLP-1 is stored in 
secretory granules, and GLP-1 granule exocytosis is triggered by increased 
intracellular calcium levels resulting from stimulation by nutrient, neural 
and paracrine factors. Although the calcium dependence of GLP-1 granule 
exocytosis is well established, the identities of calcium-sensing proteins in 
GLP-1 exocytosis remain elusive. Several members of the synaptotagmin 
family have been identified as calcium sensors in neurotransmitter and hor-
mone release. In particular, synaptotagmin-7 regulates insulin and glucagon 
secretion in pancreatic islets, and catecholamine release in chromaffin cells. 
Considering the functional importance of synaptotagmin-7 in endocrine and 
neuroendocrine cells, we tested the involvement of synaptotagmin-7 in the 
regulation of GLP-1 secretion.
Materials and methods: Synaptotagmin-7 expression in intestinal L-cells 
was tested by immunohistostaining of frozen mouse intestinal sections for 
synaptotagmin-7 and GLP-1. GLP-1 levels were measured in synaptotagmin-
7 knockout mice challenged by glucose ingestion. Glucose-stimulated GLP-1 
release was also tested in lentiviral-mediated synaptotagmin-7 knockdown 
GLUTag cells using cell secretion assay and membrane capacitance measure-
ments. Data are presented as mean ± SEM.
Results: Synaptotagmin-7 was present in L-cells, as demonstrated by its co-
localization with GLP-1. Synaptotagmin-7 deletion in vivo resulted in a re-
duction of GLP-1 secretion (683 ± 48 and 360 ± 40 pmol/l/h, control and 
synaptotagmin-7 knockout, respectively, p < 0.001). Synaptotagmin-7 knock-
down GLUTag cells showed a ~50% decrease in glucose-stimulated GLP-1 
secretion as determined by cell secretion assay and by membrane capacitance 
measurements (24 ± 4 and 12 ± 3 fF s-1, control and synaptotagmin-7 KD, re-
spectively, p < 0.05). Synaptotagmin-7 knockdown cells exhibited normal cal-
cium responses, indicating the secretion defects occurred at or downstream 
of the calcium sensing step.
Conclusion: Taken together, our results demonstrate the importance of syn-
aptotagmin-7 in the regulation of GLP-1 secretion, consistent with its pro-
posed role as a calcium sensor in endocrine and neuroendocrine secretion.
Supported by: B.R.C. of A*STAR
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Assessment of the metabolic effects of the gut peptide xenin on insulin 
secretion, glycaemic control and satiety
N. Irwin, A.I. Taylor, P.R. Flatt, V.A. Gault;
School of Biomedical Sciences, University of Ulster, Coleraine, United 
Kingdom.
Background and aims: Recently significant focus has been directed towards 
the role of glucose-dependent insulinotropic polypeptide (GIP) and gluca-
gon-like peptide-1 (GLP-1) in the aetiology and treatment of type 2 diabetes. 
However, peptides co-secreted from the same enteroendocrine cells are less 
well studied. The present study examines the in vitro and in vivo metabolic 
effects of xenin, a peptide co-secreted with GIP from intestinal K-cells.
Materials and methods: Cyclic-AMP production (n=4) and insulin releasing 
activity (n=8) of xenin was measured in acute (20 min) studies with clonal 
pancreatic BRIN-BD11 cells. Effects of xenin on membrane potential and 
intracellular Ca2+ were also examined in BRIN-BD11 cells. The glucagon-se-
creting alpha cell-line, αTC1.9 was used to assess glucagon releasing activity 
of xenin (n=8). Effects of xenin on plasma glucose and insulin concentrations 
were examined in overnight fasted normal mice (n=8; 16-20 weeks of age) 
following subcutaneous (s.c.) injection (25 nmol/kg bodyweight) in combi-
nation with glucose (18 nmol/kg bodyweight). To assess duration of biologi-
cal action, groups of mice were injected with xenin (25 nmol/kg) 30 or 60 min 
prior to glucose load. For food intake studies, mice were fasted for 12 hours 
prior to s.c. injection of 50, 100 or 500 nmol/kg xenin. Mice were then al-
lowed free access to normal chow and cumulative food intake monitored.
Results: In clonal BRIN-BD11 cells xenin (10-6 M) stimulated insulin secre-
tion at 5.6 (P<0.05) and 16.7 (P<0.01) mmol/l glucose levels compared to 
respective controls. Xenin also exerted an additive effect (P<0.05 to P<0.01) 
on GIP and GLP-1 mediated insulin secretion. Xenin did not stimulate cellu-
lar cyclic AMP production, alter membrane potential or elevate intracellular 
Ca2+ concentrations. Similarly, in vitro glucagon release was not affected by 
xenin. In normal mice, administration of xenin together with glucose sig-
nificantly (P<0.05 to P<0.001) reduced individual glucose levels compared 
to glucose control. Moreover, the area under the curve (AUC) for glucose 
was significantly lower after administration of xenin compared with glu-
cose administered alone (2.3-fold; P<0.001). This was associated with a sig-
nificantly enhanced overall glucose-mediated insulin secretory response for 
xenin compared to glucose alone (1.4-fold; P<0.05). Administration of xenin 
30 min previously significantly (P<0.05) decreased individual glucose levels 
60 minutes post s.c. glucose injection in normal mice. This was associated 
with substantially enhanced (2.1-fold; P<0.05) overall insulin release com-
pared to respective controls. Administration 60 min prior to glucose chal-
lenge annulled the glucose lowering and insulin releasing effects of xenin. 
Assessment of effects of xenin on feeding revealed that xenin did not induce 
a significant change in cumulative food intake in overnight fasted mice when 
administered at a dose of 50 or 100 nmol/kg. However, when mice received a 
dose of 500 nmol/kg, xenin induced a 60% decrease (P<0.01) in food intake 
30 minutes post injection.
Conclusion: These data indicate that xenin is a short acting peptide with po-
tentially important metabolic effects on blood glucose control. Generation of 
specific xenin antagonists or longer acting xenin mimetics may be useful in 
assessing the overall biological consequence of xenin-mediated actions.
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The effects of brain glucagon-like peptide-1 on peripheral glucose 
homeostasis
L. Jessen, T.M. Greer, M.E. Iacono, K.S. Ellis, B.M. Paxton, D.A. Sandoval, 
R.J. Seeley, D.A. D’Alessio;
Department of Medicine, University of Cincinnati, USA.
Background and aims: Glucagon-like peptide-1 (GLP-1) is a gut peptide 
that promotes glucose homeostasis through regulation of islet-cell hormone 
secretion, gastric emptying, and hepatic function. GLP-1 is also synthesized 
in the brain, and recent findings indicate that central GLP-1 plays a role in 
the regulation of peripheral glucose homeostasis through effects on insulin 
secretion, hepatic glucose production, and insulin sensitivity. To gain further 
insights into those processes, we investigated the effects of central GLP-1 re-
ceptor (GLP-1r) activation and antagonism on insulin and glucagon release 
before and during experimental hyperglycemia in rats (study I). In addition, 
we studied the effects of central GLP-1r antagonism on glucose tolerance af-
ter meal ingestion in rats (study II).
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Methods and materials: In study I, 30 male Long Evans rats were equipped 
with third cerebral ventricular (i.c.v.) cannulae and catheters in the carotid 
artery and jugular vein. After an overnight fast freely-moving animals had 
continuous i.c.v. infusion with GLP-1 (18 µg/hr), the GLP-1r antagonist Ex-
endin 9-39 (Ex-9) (100 µg/hr), or saline for 125 min; all rats received 8 µl/
hr of infusate. Sixty min after the start of i.c.v. infusion, blood glucose was 
raised to 230 mg/dl with a primed i.v. infusion of 25% glucose. For 65 min 
the glucose infusion rate was varied to maintain hyperglycemia (230 mg/dl). 
Arterial blood was sampled during the infusion period every 5-15 min for 
measurements of blood glucose and plasma levels of insulin, glucagon, and 
corticosterone. In study II, 22 overnight fasted and freely-moving rats with 
i.c.v. cannulae and i.a. catheters were infused i.c.v. with Ex-9 (100 µg/hr), or 
saline for 150 min. Thirty min after the start of i.c.v. infusion bottles of Ensure 
liquid diet (5.5 ml) were made available for 10 min. Because the rats were 
trained to eat Ensure, they voluntarily consumed the meal within 5 min. After 
meal ingestion, arterial blood was sampled every 15 min for up to 120 min for 
measurements of blood glucose.
Results: In study I, infusion of i.c.v. GLP-1 increased fasting blood glucose 
levels (105.5 ± 3.8 vs 91.5 ± 2.9 mg/dl), reduced the average glucose infusion 
rate required to maintain the glucose clamp (40.0 ± 1.5 vs 54.3 ± 2.8 mg/kg/
min), and significantly reduced plasma insulin levels (AUC 14667 ± 1210 
vs 20168 ± 1883 pM∙min) compared to the saline group (p < 0.05 for each). 
GLP-1-treated rats also had significantly higher glucagon and corticosterone 
levels (p < 0.05 for each) than Ex-9- and saline-treated rats. Surprisingly, 
there were trends for i.c.v. Ex-9 to reduce insulin levels (p = 0.0641) and raise 
plasma glucagon (p = 0.1009). In study II, i.c.v. Ex-9 increased blood glucose 
levels after meal ingestion relative to the saline group, and the area under the 
curves (4844 ± 233 vs 4150 ± 188 (mg/dl)∙min) were significantly higher (p < 
0.05) in the Ex-9-treated rats compared to the saline group.
Conclusion: These results show that central GLP-1r activation has multiple 
effects on glucose homeostasis in rats. In the doses used in this study GLP-1 
activated the stress response, likely via autonomic-induced suppression and 
stimulation of insulin and glucagon secretion, respectively. Central GLP-1r 
blockade using Ex-9 was associated with lower insulin secretion, higher glu-
cagon levels, and higher glucose levels after meal ingestion, supporting a role 
for brain GLP-1 in the regulation of islet function and peripheral glucose 
homeostasis.
Supported by: NIHDK
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TGR5-mediated GLP-1 secretion
H.E. Parker, A. Habib, F. Reimann, F.M. Gribble;
Clinical Biochemistry, Cambridge Institute of Medical Research, United 
Kingdom.
Background and aims: The incretin hormone, GLP-1, is secreted from intes-
tinal L-cells in response to food ingestion, however little is known about how 
L-cells detect luminal nutrients. Bile acids are also released into the gut lumen 
in response to nutrients and have been associated with glucose homeostasis 
and GLP-1 secretion. The aim of this study was to investigate the expression 
of the bile acid sensitive G-protein coupled TGR5 receptor in primary L-cells 
and its role in GLP-1 secretion.
Materials and methods: mRNA expression was analyzed by qRT-PCR in L-
cells purified from transgenic mice with fluorescently labeled proglucagon-
expressing cells. GLP-1 secretion was assayed in primary colonic cultures and 
GLUTag cells. FRET based [cAMP]i and ratiometric [Ca
2+]i imaging experi-
ments were performed on GLUTag cells.
Results: TGR5 mRNA expression is highly enriched in L-cells compared to 
control intestinal epithelial cells. The bile acids deoxycholic acid, lithocholic 
acid and taurolithocholic acid (TLCA) and a TGR5 agonist increased GLP-1 
secretion and enhanced the glucose-triggered response. The GLP-1 response 
to TLCA and the TGR5 agonist from GLUTag cells was attenuated with 
TGR5 siRNA treatment. Consistent with signaling via Gs coupled pathways, 
the TGR5 agonist and TLCA elevated [cAMP]i in GLUTag cells. The TGR5 
agonist triggered [Ca2+]i and enhanced glucose-triggered [Ca
2+]i responses, 
consistent with previously observed responses of GLUTag cells to elevated 
cAMP.
Conclusion: Primary L-cells express the bile acid sensitive TGR5 receptor, 
which may contribute to the incretin response via the elevation of [cAMP]i 
and [Ca2+]i. The synergistic stimulation of GLP-1 release may be possible by 
combined activation of GPCRs and glucose-sensing pathways.
Supported by: MRC, WT
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Near-normoglycaemia prevents the development of polyneuropathy, a 
24-year prospective study from the diagnosis of type 1 diabetes
D. Ziegler1,2, M. Roden1,2;
1Institute for Clinical Diabetology, German Diabetes Center, 2Department of 
Metabolic Diseases, University Hospital, Düsseldorf, Germany.
Background and aims: Whether near-normoglycaemia instituted from the 
diagnosis of type 1 diabetes onward may completely or partially prevent the 
development of polyneuropathy and autonomic neuropathy has not been 
previously determined. To address this issue we conducted a long-term pro-
spective study.
Materials and methods: We examined 32 newly diagnosed Type 1 diabetic 
patients (21 male, 11 female) aged 12-36 (mean±SEM: 20.3±1.0) years who 
were followed over 24 years. Motor and sensory nerve conduction velocity 
(MNCV, SNCV), vibration perception threshold (VPT), thermal detection 
thresholds (TDT), coefficient of R-R interval variation at rest (CV), and 
clinical assessment were performed at the time of diagnosis, after 3 and 12 
months, and thereafter biennially for up to 24 years.
Results: During the 24-year period, 11 patients had mean HbA1c levels 
<7.0% according to the current guidelines (6.5±0.1%; Group 1), whereas 21 
patients had mean HbAc levels ≥7.0% (8.3±0.2%; Group 2). Within the first 
4 years, reduced sensory NCV and cardiac autonomic function, rather than 
elevated VPT and TDT were observed as markers indicating initial nerve 
dysfunction in Group 2 as compared with Group 1. After 24 years, MNCV 
was significantly faster in Group 1 than in Group 2 in the median (55.5±1.6 vs 
48.9±1.6 m/s), ulnar (56.5±1.5 vs 49.3±1.7 m/s), and peroneal nerve (44.7±1.6 
vs 36.8±2.5 m/s) and SNCV was faster in the median (53.6±1.6 vs 45.5±2.8 
m/s), ulnar (54.7±1.8 vs 43.0±3.9 m/s), and sural nerve (44.5±1.8 vs 35.5±2.6 
m/s) (all p<0.05). In Group 1 the decline in peroneal MNCV and sural SNCV 
was -0.1 and -0.2 m/s/year, respectively, comparable to a non-diabetic control 
group (n=15). In contrast, Group 2 showed corresponding losses of -0.4 and 
-0.5 m/s/year, respectively. Impairment in VPT, TDT, and CV also developed 
at a significantly faster rate in Group 2 than in Group 1 (all p<0.05). After 24 
years, none of the patients in Group 1, but 12 (57%) of those in Group 2 de-
veloped clinical polyneuropathy confirmed by NCV. Two patients in Group 2 
died during the period studied.
Conclusion: Near-normoglycaemia maintained from the diagnosis of type 
1 diabetes over the next 24 years effectively prevented the development of 
clinical polyneuropathy, a 3-fold faster annual hyperglycaemia-induced de-
cline in NCV, and deterioration in sensory and cardiac autonomic function, 
whereas poor glycemic control constituted the paramount permissive factor 
contributing to the evolution and progression of neuropathy in the majority 
of type 1 diabetic subjects.
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A double-blind randomised study comparing the effects of pregabalin, 
duloxetine and amitryptiline on aspects of neuropathic pain, mood and 
sleep in diabetic subjects with painful neuropathy
L. Gribble1, R. Gouni2, M. Eriksson1, J. Boyle1, D. Kerr2, D. Coppini3;
1Clinical Research Center, Surrey University, Guildford, 2Royal 
Bournemouth Hospital, 3Poole Hospital NHS Trust, United Kingdom.
Background and aims: The mechanisms of painful diabetic neuropathy are 
poorly understood and drug treatment if often unpredictable, with both an 
overall disappointing response rate, and generally poor patient tolerance to 
long term use. The main aim of the study was to try and identify which com-
monly used agent may have most beneficial effect on both pain and quality 
of life.
Materials and methods: Subjects with neuropathic pain (Leeds Assessment 
of Neuropathic Symptoms and Signs (LANSS)>12) were recruited from 2 
hospital diabetes clinics. Subjects were required to have a score >25 on the 
Mini Mental State Exam (MMSE). The 36 day study (placebo day 1-8) had a 
double blind, parallel groups design with three treatment arms consisting of 
either amitriptyline (50mg followed by 75mg), pregabalin (300mg followed 
by 600mg) or duloxetine (60mg followed by 120mg). Subjects previously on 
any of neuropathic medications had an appropriate wash out period prior 
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to study entry, and all other analgesic medications were withdrawn where 
possible. Subjects were studied on days 6-8, 20-22, and 34-36. 65 of 83 (78%) 
randomised subjects (mean age 65 (38-83) years, 69% male), completed the 
study. Subjects completed daily diaries for pain (brief pain inventory (BPI) 
and the Short-form McGill visual analogue scale (VAS).
Results: In all three groups there was a significant decrease (p <0.05) in pain 
severity (BPI severity and VAS) over time but there was no difference between 
the three treatments in reducing pain severity. Decrease in pain severity was 
significant in all treatment arms from placebo to low dose (p<0.05 for prega-
balin and amitriptyline, p<0.01 for duloxetine), but no significant additional 
treatment benefit was seen in any group with increased drug dosage. Patients 
on duloxetine showed a significant decrease in pain interference over time, 
both from placebo to low dose, and from low dose to high dose (p <0.05), and 
an improvement in BPI mood (<0.05). All three study drugs doses improved 
pain interference on sleep as assessed by the BPI (p<0.05) with no significant 
difference between any of the treatments.
Conclusion: Deciding on the ideal treatment drug for painful diabetic neu-
ropathy remains an enigma, with seemingly little difference between conven-
tional drugs on pain outcomes. Duloxetine, amitryptiline and pregabalin all 
improved subjective pain as assessed by the BPI and VAS and pain interfer-
ence on sleep with no significant difference between any of the treatments. 
With duloxetine there was also a reduction in pain interference and mood.
Supported by: PF
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New insights into central pain processing in painful diabetic neuropathy: 
a functional magnetic resonance imaging study
D. Selvarajah1, I.D. Wilkinson2, M.D. Hunter3, A. Shankar4, E. Cachia2,  
I. Tracey5, S. Tesfaye1;
1Diabetes and Endocrinology, Royal Hallamshire Hospital, Sheffield, 
2Academic Unit of Magnetic Resonance Imaging, University of Sheffield, 
3Department of Psychiary & Neuroimaging, University of Sheffield, 
4Diabetes and Endocrinology, University of Sheffield, 5Department of 
Clinical Neurology, Oxford University, Oxford Centre for Functional MRI 
of the Brain, United Kingdom.
The exact pathophysiology underlying painful-diabetic peripheral neuropa-
thy (DPN) remains unknown although several peripheral and central mecha-
nisms have been postulated. An investigation of the brain’s responses to acute 
painful stimuli may provide insights into the impact of the neuropathic proc-
ess on nociceptive processing, thereby identifying key areas possibly affected 
by DPN.
Methods: 6 subjects with Painful-DPN underwent detailed neurophysiologi-
cal assessments and functional magnetic resonance imaging (fMRI). All sub-
jects had severe neuropathic pain below the knees. Before fMRI, heat pain 
was applied to the anterior thigh (control region) and dorsum of the foot 
to establish the level of noxious thermal stimulus which elicited a response 
of >7/11 point Likert scale. This was repeated inside the scanner alternating 
between pain-free baseline and noxious stimulus in a box-car design. Im-
ages were analysed using statistical parametric mapping SPM5. Following 
spatial preprocessing, first-level functional images were produced comparing 
baseline and heat pain states. Images were combined at the group level in a 
random effects model.
Results: Painful stimuli delivered to the neuropathic foot site were associ-
ated with significantly reduced activation in the left posterior insular cortex 
compared with painful stimuli administered to the thigh (stereotactic co-
ordinates: x=-38, y=-20, z=16; peak t[5]=12.57; 55 voxels exceeded height 
threshold p<0.01, uncorrected). Conversely, compared with painful stimuli 
delivered to the thigh, painful stimuli administered to the neuropathic foot 
site evoked significantly greater brain activation in the right medial prefrontal 
cortex (x=12, y=36, z=34; t[5]=9.11; 42 supra-threshold voxels).
Discussion: The posterior insular cortex serves as an interface between af-
ferent processing mechanisms and more cognitively orientated mechanisms. 
Relative lack of activation in this region during acute noxious thermal stim-
ulation of the foot suggests a complex alteration of the pain experience in 
Painful-DPN. Prefrontal cortex is associated with high-order cognitive and 
emotional functions. Increased activation in this region during noxious stim-
ulation of the foot suggests greater emotional/cognitive involvement of acute 
pain processing in Painful-DPN. These preliminary results suggest that pain-
ful stimuli delivered to neuropathic and symptom-free sites in DPN evoke 
differential activation of distinct cortical regions, which could reflect abnor-
mal central pain processing.
Supported by: JDRF
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Obstructive sleep apnoea is independently associated with peripheral 
neuropathy in patients with type 2 diabetes
A.A. Tahrani1, A. Ali2, S. Begum2, K. Dubb1, S. Mughal2, B. Jose2, M. Piya1, 
D. Banerjee2, A.H. Barnett1, M.J. Stevens1, S. Taheri1,2;
1University of Birmingham, 2The Biomedical Unit, United Kingdom.
Background: Obstructive sleep apnoea (OSA) is prevalent in patients with 
type 2 diabetes (T2D). Since OSA and diabetes complications share common 
oxidative stress and inflammatory mechanisms, we hypothesized that there is 
a relationship between OSA and diabetic peripheral neuropathy (DPN).
Methods: T2D patients were recruited randomly from the outpatients of a 
tertiary diabetes centre in the UK. Patients with known respiratory disor-
der (including OSA) were excluded. DPN was diagnosed using the Michigan 
Neuropathy Screening Instrument (MNSI) (a score ≥7 on the questionnaire 
(MNSIq) or > 3 on the examination (MNSIe) was considered consistent with 
DPN). OSA was assessed using home-based portable multi-channel respira-
tory monitoring (Alice PDX, Philips Respironics, USA). An apnoea-hypop-
nea index (AHI) ≥ 5 events/hour was diagnostic of OSA (OSA+). Data are 
presented as median (IQR).
Table 1: Participants’ characteristics in relation to OSA status. P value calcu-
lated using the Mann-Whitney U in scale variables and the Chi-square test.
OSA+ OSA- P value
Age (years) 61 (54-66) 54 (44-61) 0.006
Diabetes duration (years)12.5 (6.0 -17.0) 10.5 (6.0-16.0) 0.42
BMI (kg/m2) 33.4 (30.9-37.2) 30.3 (27.4-35.8) 0.005
Waist circumference 
(cm)
112.8 (106.8-123.0) 106.0 (94.8-117.4) 0.005
Neck circumference (cm)42.3 (39.0-45.1) 38.5 (36.8-41.8) <0.001
HbA1c (%) 7.8 (6.8-9.5) 7.8 (6.9-8.8) 0.81
Total cholesterol  
(mmol/l)
3.7 (3.2-4.2) 3.7 (3.4-4.5) 0.26
Triglycerides (mmol/l) 1.8 (1.2-2.5) 1.6 (1.1-2.8) 0.87
BP-systolic (mmHg) 130 (124-137) 126 (114-137) 0.04
BP-diastolic (mmHg) 78 (71-84) 79 (71-83) 0.74
Male (%) 68.5 50.7 0.04
Smoker (%) 5.5 19.7 0.012
Alcohol (%) 30.1 9.9 0.005
Insulin (%) 59.7 43.7 0.066
GLP-1 analogue (%) 14% 7% 0.28
Statins (%) 87.5 85.9 0.81
Fibrates (%) 2.7% 5.6% 0.21
ACE inhibitors (%) 47.2 43.7 0.74
Diuretics (%) 43.1 22.5 0.012
Anti-platelet (%) 79.2 63.4 0.043
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Results: 143 patients were included; 50% had OSA and 46% had DPN. Partici-
pants’ characteristics in relation to OSA status are summarised in Table 1. The 
prevalence of DPN was significantly higher in OSA+ (compared to OSA-) patients 
(58% vs. 32%, p=0.003). In logistic regression model (goodness to fit test p=0.002, 
R2=0.34-0.46), OSA+ remained a significant predictor of DPN (OR: 3.08, 95%CI 
1.01-9.38, p=0.048) after adjusting for BP, HbA1c, total cholesterol, triglycerides, 
diabetes duration, smoking status, alcohol intake, gender, renal function, BMI, 
age and the use of GLP-1 analogues, insulin, oral anti-diabetes therapy, lipid 
lowering therapy, anti-hypertensives and anti-platelets. Other significant predic-
tors in the model included age (OR: 1.08, 95%CI 1.004-1.15,p=0.039), BMI (OR: 
1.15, 95%CI 1.05-1.26, p=0.003), not taking a statin (OR:4.71, 95%CI 1.12-19.86, 
p=0.035) and total cholesterol (OR: 2.43, 95%CI 1.25-4.71, p=0.009). Log (AHI) 
correlated significantly with the MNSIe score (r=0.22, p=0.012). This remained 
the case (r=0.23, p=0.015) after adjusting for age, diabetes duration, BP, HbA1c, 
triglycerides, total cholesterol and renal function.
Conclusion: We describe a novel association between OSA and DPN in pa-
tients with T2D. The severity of OSA correlated significantly with the severity 
of DPN based on MNSIe. Planned studies aim to confirm our findings and 
overcome the limitations of the current study.
Supported by: NIHR
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Effects of genetic versus environmental factors on cardiovascular 
autonomic function and baroreflex sensitivity: a twin study
J. Osztovits1, T. Horváth2, R. Steinbach3, Á. Jermendy3, L. Littvay4,  
Á. Tárnoki3, D. Tárnoki3, J. Métneki5, M. Kollai2, G. Jermendy1;
13rd. Department of Internal Medicine, Bajcsy Zsilinszky Teaching Hospital, 
2Institute of Human of Human Physiology and Clinical Experimental 
Research, Semmelweis University, 3Semmelweis University, 4Central 
European University, 5National Centre for Healthcare Audit and Inspection, 
Budapest, Hungary.
Background and aims: Cardiovascular autonomic neuropathy (CAN) and 
impaired baroreflex sensitivity (BRS) can often be detected in patients with 
diabetes mellitus. CAN and BRS are independent predictors of cardiovas-
cular morbidity and mortality. The heritability of cardiovascular autonomic 
function is not fully understood. The aim of the current study was to de-
termine the effects of genetic and environmental factors on cardiovascular 
autonomic function and BRS.
Material and methods: Healthy adult twin pairs (n=101; 63 monozygotic 
[MZ] and 38 dizygotic [DZ] pairs; 72.5% women, 27.5% men; age: 44.3±15.5 
years) were investigated. Anthropometric variables (weight, height, waist cir-
cumference) were registered, body mass index (BMI) was calculated, serum 
metabolic markers were measured; furthermore lifestyle and environmental 
background characteristics were evaluated by using questionnaires. Linear 
and spectral indices of heart rate variability (HRV) and BRS were determined 
by non-invasive methods. In resting supine position, RR interval was derived 
from ECG recordings, and continuous radial artery pressure was monitored 
simultaneously by applanation tonometry for 10 minutes. All parameters 
were adjusted for age and gender. Pearson correlation coefficients were calcu-
lated per zygosity (intraclass correlations) in order to determine the extent to 
which MZ twin pairs are more similar than DZ pairs. In addition, heritability 
model analyses were used for characterizing additive genetic, shared (com-
mon) and unshared (individual) environmental influences.
Results: There was no difference between BMI and waist circumference in 
MZ versus DZ pairs (25.9±4.9 vs. 25.8±5.9 kg/m2, p=0.642; and 88.2±14.6 
vs. 88.4±16.0 cm, p=0.986, respectively). The intraclass coefficients of cor-
relation (r values) were low for HRV and BRS indices, in both MZ and DZ 
twins (LF [HRV power in low frequency range) MZ=0.140 vs. DZ=0.401; 
HF [HRV power in high frequency range): MZ=0.299 vs. DZ=0.225) and the 
heritability model analysis showed high percents of unshared environmental 
contribution (LF=0.816; HF=0.701). The intraclass coefficients of correla-
tion (r values) for BRS were low in both MZ and DZ twins (BRSseq+ index: 
MZ=0.281 vs. DZ=0.279; BRSseq- index: MZ=0.456 vs. DZ=0.064) and the 
heritability model analysis showed high percents of unshared environmental 
contribution (BRSseq+ index=0.719; BRSseq- index=0.554). No significant 
changes were found after adjusting parameters for BMI values.
Conclusion: Unshared (individual) environmental but not inheritable fac-
tors have substantial influence on cardiovascular autonomic function and 
BRS. Accordingly, all modifiable environmental factors should appropriately 
be treated in order to prevent or decrease cardiovascular autonomic dysfunc-
tion and impaired BRS in patients with diabetes mellitus.
Supported by: Hungarian Diabetes Association, sanofi-aventis
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Role of depressed cardiac autonomic activity in the impairment of heart 
rate recovery after exercise in diabetic patients
M. Vivier, M. Nguyen, P. Weinmann, E. Cosson, P. Valensi;
Endocrinology-Diabetology-Nutrition, Jean Verdier Hospital, Bondy, 
France.
Background and aims: The heart rate (HR) profile during exercise and re-
covery is a powerful predictor of sudden death in coronary patients and in 
subjects without clinically detectable cardiovascular disease. A defect of HR 
recovery after the termination of an exercise has been suggested to result 
from an impairment of the ability to increase vagal and sympathetic activity 
rapidly. Alterations of vago-sympathetic activity might contribute to impair 
HR profile during exercise and recovery in diabetic patients. The aim of this 
study was to examine the role of depressed cardiac autonomic activity in the 
impairment of HR profile during exercise and recovery in diabetic patients.
Materials and methods: We included 165 type 2 diabetic patients, 98 men 
and 67 women, mean age 58 yrs and diabetes duration 12.5 yrs. All of them 
had at least one additional risk factor (including 132 patients with hyperten-
sion) and were prospectively screened for silent myocardial ischemia (SMI), 
defined as an abnormal stress myocardial scintigraphy. The stress exercise test 
was performed on a cycle ergometer, and HR was measured at rest, at exercise 
peak (HRmax) and after 2 minutes of recovery. Cardiac autonomic neuropa-
thy (CAN) was assessed using standard tests (deep-breathing, lying-to-stand-
ing and Valsalva) and was defined by at least one abnormal test.
Results: SMI, peripheral vascular disease, peripheral neuropathy and CAN 
were detected in 28%, 5%, 33% and 77% of the patients, respectively. HR at 
rest, HRmax and HR at recovery did not differ significantly in patients with 
or without CAN, peripheral neuropathy or vascular disease or SMI. In the 
total population HR decrease at recovery (% decrease from HRmax) cor-
related significantly with HR acceleration (% increase from rest) (r=0.532, 
p<0.0001). HR acceleration correlated significantly with age and HR at rest 
(p<0.001), and there was a trend to lower values in patients with peripheral 
neuropathy but HR acceleration did not differ significantly in patients with 
or without hypertension, peripheral vascular disease, SMI or CAN. In mul-
tivariate analysis HR acceleration was significantly associated (p=0.03) with 
peripheral neuropathy independently of age and HR at rest. HR decrease 
at recovery was slightly higher in women than in men (32±9% vs 29±10%, 
p=0.08), and slightly lower in patients with than in patients without CAN 
(30±11 vs 34±8%, p=0.143) and in those with 2 or 3 abnormal CAN function 
tests than in those with no or one abnormal test (29±11 vs 32±10%, p=0.148) 
but did not differ significantly in patients with or without hypertension, pe-
ripheral neuropathy or vascular disease or SMI. In multivariate analysis the 
association of HR decrease at recovery with CAN was significant (p<0.001), 
independently of age, gender and HR at rest. In the patients free of SMI for 
whom exercise was not stopped prematurely, HR decrease at recovery was 
significantly lower in those with CAN (p=0.02), in particular in those with 2 
or 3 abnormal CAN function tests (p=0.02).
Conclusion: In high-risk but asymptomatic type 2 diabetic patients, periph-
eral neuropathy and CAN are major determinants of HR acceleration during 
exercise and HR recovery, respectively.
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Glycaemia management of minority participants in ACCORD
J. Calles-Escandon1, L. Light1, L. Lovato1, A. Getaneh2, D. Simmons3,  
J. Kirk1, D. Bonds4, M.A. Banerji5, J.B. Green6, L. Menon1, A. Moogali1,  
R.M. Bergenstal7;
1Wake Forest Univ, Winston-Salem, 2Columbia Univ, New York City, 3Univ 
of Arkansas, Little Rock, 4NHLBI, Washington, 5State Univ, New York, 
Brooklyn, 6Duke Univ, Durham, 7ADA, Alexandria, USA.
Background: Epidemiologically, African Americans (AA) and Hispanic-
Americans (H) with type 2 diabetes (T2DM) have higher A1C levels than 
Whites (W). This difference might be due to socioeconomic factors, differ-
ences in health care access, and/or biological differences. Clinical trials may 
reduce the influence of some of these factors by provision of free medical 
care, education and medications. ACCORD trial tested the hypothesis that a 
therapeutic strategy targeting an A1C <6% (INT) compared to one targeting 
7 to 7.9% (STD) would reduce cardiovascular events in patients with T2DM. 
In this post-hoc analysis of ACCORD we use A1C values to evaluate if equali-
zation of access to health care reduces the variation in A1C across W, AA 
and H.
Methods: Baseline characteristics for each intervention arm were compared 
using ANOVA (continuous variables) and Chi-square (dichotomous vari-
ables). The proportion of participants who ever reached A1C <=6.5%, for the 
INT and <=7.9% for STD, and among those reaching these levels, the pro-
portion whose A1C increased to >6.5% / >7.9% at any subsequent visit, was 
calculated by race/ethnicity. Since most of the change in A1C in ACCORD 
was achieved during the first year, repeated measures models were created 
for A1C levels at 4-, 8-, and 12-month visits, stratified by glycaemia interven-
tion arm. A sequential modelling approach tested the significance of effect of 
race/ethnicity on A1C in these models.
Results: Of 10, 251 participants, 6,393 were W, 1953 AA, and 737 H. Base-
line A1C was higher for H (8.4% INT, 8.6% STD) and AA (8.5% both arms) 
compared with W (8.2% both arms, P <0.001 for both arms.). In the INT arm 
81% of W achieved A1C <6.5% compared with 68% AA and 70% H. In the 
STD arm 96% W compared with 91% AA and 90% H achieved A1C <7.9%. 
W in INT were less likely to ↑ A1C once target was achieved (63%) than 
AA(74%) or H (76%); rates were similar in the STD (W 71%, AA 73%, H 
67%). Mean A1C was higher at the 12 month visit in AA and H vs. W (7.8%, 
7.8%, and 7.6% respectively for STD; 6.8%, 6.7%, and 6.5% respectively for 
INT). However, mean insulin use (units/day or units/kg/day), as well as the 
mean number of oral hypoglycemic agents (OHA), was similar for all groups 
in both arms. When baseline characteristics were accounted for in regression 
models, race/ethnicity remained as a significant predictor of differences in 
A1C for both INT (p<0.001) and STD (p=0.001).
Discussion: With similar access to diabetes care and equal use of insulin and 
OHA, a large percent of AA and H achieved similar A1C compared with W. 
However, mean A1C remained different. In regression models baseline differ-
ences in A1C, BMI, duration of diabetes, and socio-demographic differences 
did not alter the observation nor did on-study insulin quantity or OHA. The 
major strengths of the study are the large number of H and AA participants 
with T2DM with equal access to diabetes care as W. Weaknesses of this study 
include the “secondary” nature of this analysis and the lack of pre-specified 
culturally sensitive patient education and management. It remains to be de-
termined whether the remaining mild differences in A1C between these eth-
nic groups are due to cultural or biological factors or both.
Supported by: NIH
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Screening for type 2 diabetes mellitus identifies a major burden of 
modifiable cardiovascular risk
B. Thiagarajan Srinivasan1, D.R. Webb1, M.J. Davies1, S.G. Griffin2, B.J. 
Echouffo-Tcheugui2, N.J. Wareham2, S. Campbell3, L.G. Gray1, K. Khunti3;
1Cardiovascular Sciences, University of Leicester, 2MRC Epidemiology Unit, 
Institute of Metabolic Science, Cambridge, 3Department of Health Sciences, 
University of Leicester, United Kingdom.
Background and aims: Population screening for Type 2 Diabetes (T2D) 
enables diagnosis earlier in the disease trajectory than existing approaches. If 
followed by sustained multifactorial intervention, vascular outcomes should 
theoretically improve. It is largely unknown whether population-based 
screening for T2D identifies cases at increased yet modifiable cardiovascular 
disease (CVD) risk. We aimed to compare baseline characteristics, modelled 
10 year risk and estimated CVD risk reduction of two newly diagnosed T2D 
populations: one-screen-detected and the other clinically diagnosed.
Materials and methods: The screen detected cohort (LEADER) is an amalga-
mation of two population-based programmes of screening for T2D by OGTT 
(n=309): (i) STAR which used targeted screening of those with at least one 
risk factor for T2D, (ii) ADDITION-Leicester a universal screening study and 
RCT of CVD risk intervention in screen-detected T2D.The clinically diag-
nosed group, representative of T2D cases in UK clinical practice was derived 
from an RCT of structured education (DESMOND) (n=824). In those with-
out prior CVD, an ethnicity adjusted Framingham equation (Ethrisk) was 
used to estimate 10-year CVD risk. The absolute risk reduction achievable 
and its plausible range were predicted using relative risk reductions for indi-
vidual therapies from published trials and sensitivity analysis.
Results: Screen-detected people had statistically significant higher levels of 
systolic and diastolic blood pressure and total cholesterol with lower levels of 
BMI and HbA1c compared to those who were clinically diagnosed. Medica-
tion use was significantly higher in those who were conventially diagnosed: 
anti-hypertensives 60% vs. 44%, lipid lowering 41% vs. 21%, aspirin 27% vs. 
16%, all p<0.0001. Mean 10 year CVD risk was significantly higher in the 
screen detected group (21.1% vs. 16.8%, p<0.0001). By commencing mul-
tifactorial therapy in this high risk screen-detected group the absolute risk 
reductions (ARR) achievable range from 4% to 10% (related to numbers 
needed to treat (NNT) of 10 to 25), with higher risk reductions being seen in 
those from a white European background compared to South Asians.
Conclusion: T2D cases identified through population screening are at high 
risk of CVD. At detection, this adverse CVD risk profile is often untreated, 
but appears potentially modifiable with existing preventative treatments. 
Lower estimated CVD risk reduction in south Asians suggests alternative 
factors may be important in determining risk within this group.
Estimation of absolute CVD risk reduction in screen detected T2D using 
Ethrisk
ARR (Range) NNT
No added effect treatment 
(Lipid Lowering therapy)
4.0 (2.7-5.2) 25
Additive effect: 
glucose, lipid and bp lowering therapies
8.5 (7.3-9.5) 12
Additive effect: 
glucose, lipid bp lowering therapies and aspirin
10 (9.3-11) 10
White Europeans n=154
No additive effect 4.6 (3.1-6.1) 21
Additive effect 9.7 (8.4-11) 10
Additive effect and aspirin 11.6 (11-12) 9
South Asians n=95
No additive effect 3.3 (2.2-4.3) 30
Additive effect 6.9 (6.0-7.7) 14
Additive effect and aspirin 8.2 (7.6-8.8) 12
Supported by: Diabetes UK & NHS
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Dispelling myths about social disparities in diabetes-related 
complications and mortality: Diabetes Study of Northern California 
(DISTANCE) 
A.J. Karter1, D. Schillinger2, A.S. Adams1, H.H. Moffet1, J. Liu1, N. Adler3;
1Division of Research, Kaiser Permanente, Bainbridge Island, 2School 
of Medicine, University of California, San Francisco, 3Department of 
Psychiatry, University of California, San Francisco, USA.
Background and aims: In contrast to studies of health disparities in the UK 
and Europe which focus primarily on social class, US studies have focused 
much more attention on disparities associated with race/ethnicity and “vul-
nerable minorities”. Few studies have considered how race/ethnicity and so-
cial class each relate to specific health problems. In diabetes, educational dis-
parities in related outcomes (complications and mortality) are under-studied. 
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We evaluated the size and direction of educational and race/ethnic disparities 
in diabetes-related complications and mortality.
Material and methods: We followed a cohort of 64,419 fully-insured, pa-
tients with diabetes (19 years or older) with uniform access to integrated care 
(Kaiser Permanente) for 10 years (1996-2005; ~463,800 person-years). Haz-
ard ratios (HR) were estimated from age and sex-adjusted Cox proportional 
hazard models (time to incident event), specified separately for all-cause 
mortality (MORT) and incident nonfatal and fatal complications (myocar-
dial infarction (MI), congestive heart failure (CHF), stroke, end stage renal 
disease (ESRD), lower extremity amputation (AMP), after excluding those 
with prevalent history for each complication model.
Results: There was a significant, stepwise relationship between education and 
diabetes endpoints, with a 20-60% greater comorbidity and mortality (e.g., 
HRs for amputation: 1.6, 1.4, 1.3, 1.0 and HR for mortality: 1.3, 1.2, 1.1, 1.0 
for less than high school (HS), HS graduate, some college and college grad re-
spectively) burden for those with less than a high school education compared 
to college graduates. Asians had markedly lower rates of amputation (HR: 
0.4 relative to Whites) than the other groups and together with Latinos, had 
the lowest overall morbidity and mortality rates. African Americans had the 
highest CHF, stroke, ESRD and amputation rates, although not significantly 
different than whites. Whites had the highest incidence of MI and mortality, 
but the lowest incidence of ESRD. Estimates were essentially unaltered after 
further adjustment for type of diabetes, duration of diabetes, diabetes medi-
cations, hypertension, dyslipidemia, CKD category based on GFR, albuminu-
ria, hemoglobin A1c, prevalent MI, stroke, CHF, ESRD, and amputation.
Conclusion: Contrary to convention wisdom, there are no race/ethnic 
groups that are consistently at highest (or lowest) risk for diabetes compli-
cations. In contrast, low educational attainment was consistently associated 
with poorer health across all outcomes, independent of race/ethnicity, and 
may be explained by risk factors held in common for all complications (e.g., 
smoking, inadequate health literacy, poor medication adherence and cost 
barriers), thus suggesting potential candidates for interventions that could 
reduce disparities for combined endpoints. Future efforts to reduce social 
disparities among patients with diabetes should pay greater attention to so-
cioeconomic/social class disparities, while maintaining existing attention to 
ethnic disparities.
Supported by: NIH (NIDDK and NICHD)
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Educational disparities and the risk for mortality in patients with type 2 
diabetes
N. Kleefstra1,2, G.W.D. Landman1, I. Drion1, K.J.J. van Hateren1,3, H.J.G. Bilo1;
1Diabetes Centre, Isala Clinics, Zwolle, 2Medical Research Group, 
Langerhans, Zwolle, 3Internal Medicine, University Medical Center 
Groningen, Netherlands.
Background and aims: The relationship between socioeconomic status and 
mortality is clear and has also been established in studies in type 2 diabetes 
(T2DM). The relationship between educational level and mortality in T2DM 
has recently received attention in a study from the United States (US). We 
studied this relationship in a Dutch cohort of T2DM patients.
Materials and methods: This study is part of the Zwolle Outpatient Diabetes 
project Integrating Available Care (ZODIAC) study, in which patients with 
T2DM, treated in primary care, were enrolled. The ZODIAC study started 
in January 1998. Data on educational level were first collected on 19 May 
1998, however. From this date on 858 patient were included in 1998, and 
educational level was known for 648 (76%) patients. The survival status (dead 
or alive) for each patient was recorded in January 2009. The relation between 
mortality and educational levels were studied with a Cox proportional hazard 
model. Educational level was divided in 3 categories: no education beyond 
primary school, high school, and college. Potential confounders for which 
was corrected were: age, sex, body mass index, smoking status (yes/no), mac-
rovascular complications (yes/no), diabetes duration and working status.
Results: After a median follow-up time of 9.7 years, 367 out of 858 patients 
had died, the cause of death was known for 350 patients: 40% died from car-
diovascular disease and 23% died from malignancies. Compared to patients 
who finished primary school, patients who had gone to college, had a Hazard 
Ratio (HR) of 0.42 (95% CI 0.19-0.91) for total mortality, and patients who 
had gone to secondary school had a HR of 0.75 (95% CI 0.51-1.11) for total 
mortality (see figure 1). No significant relationship between educational level 
and cardiovascular and cancer mortality was found.
Conclusion: Educational level was associated with total mortality even after 
adjustment for working status. Patients with no education beyond primary 
school had an increased risk for total mortality compared to those who had 
gone to college. The risk of mortality differs substantially according to educa-
tional level among persons with T2DM in the Netherlands and confirms the 
results recently found in the US.
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Socio-economic impact on the quality of diabetes mellitus type 2 care: 
can we improve the outcomes?
M. Bernas, J. Tatoń, Z. Szczeklik-Kumala;
Department of Internal Diseases and Diabetology, Medical University of 
Warsaw, Poland.
Background and aims: According to the European Commission, the execu-
tive body of the European Union, “social and economic deprivation involves 
persons, families or populations whose economic, cultural and social condi-
tions are limited to a level below the minimal life standard accepted in their 
country of domicile.” This definition embraces large populations with dia-
betes mellitus type 2. In order to counteract the impact of deprivation and 
poverty on treatment of diabetes mellitus in those populations, the specific 
patterns and mechanisms of poor socio-economic status existing in the real 
world of diabetes mellitus care should be objectively delineated. Therefore, 
the study presented below was conducted.
Materials and methods: Using standardized socio-medical and economic 
questionnaires, the study was conducted on a cohort of 1,050 persons with 
diabetes mellitus type 2 hospitalized in 2005-2008 in the public diabetologi-
cal centre (Department of Diabetology, Bródnowski Hospital, Warsaw). Their 
socio-economical and health status characteristics were diagnosed in a stand-
ardized way using appropriate questionnaires and a grading system contain-
ing four categories: 1, economic; 2, psychological and social; 3, educational, 
and 4, medical.
Results: In the cohort of 1,050 hospitalized diabetic type 2 persons under 
study, 282, or 29%, were found to have social, economical or psychologi-
cal and educational deprivation and poverty not meeting local minimal life 
standards as defined by the Central State Statistical Office. The specific com-
ponents of the deprivation and poverty standards that were analyzed were: 
1, character of family and social support; 2, profession and employment; 3, 
level of formal education; 4, monthly income, help of social organizations; 5, 
fear and depression; 6, practice of self-control, and 7, frequency of planned 
medical outpatient visits. Using these parameters, the existence or non-exist-
ence of deprivation and poverty was diagnosed and produced two groups of 
patients: 1, those afflicted by deprivation and poverty (282 out of 1,050 cases, 
or 27.9%), and 2. those not afflicted (768 out of 1,050 cases, or 72.1 %). The 
medical diagnoses in both subgbroups are presented below.
Conclusion: The social, economical, psychological and educational dep-
rivation and poverty acts as a separate risk factor for the level of diabetes 
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mellitus type 2 control. It is reflected by the differences in morbidity, due 
to the chronic complications of diabetes mellitus, and also by the existence 
of additional chronic diseases associated with diabetes mellitus. The defini-
tion and diagnosis of the deprivation and poverty in diabetes type 2 based 
on four components of this life status: social, economic, psychological and 
educational is very practical for counteraction plans. Each component may 
have individual expression and may require a separate counteractive plan, 
both clinical and administrative.
Medical parameters,  
percentage in both groups
Deprivation/ 
Poverty present
Deprivation/ 
Poverty not 
present
p<0.05
Level of HbA1c
X (SD) 10.6 (2.8) 8.2 (1.6) *
Lack of self-control practice 86 40 *
Retinopathy - all stages 52 40 *
Nephropathy - all stages 26 5 *
Ischemic diseases
Heart 72 64 -
Brain 62 46 *
Lower extremities 54 38 *
Neuropathy 60 36 *
Existence of additional chronic 
disease
89 72 *
Emotional disorders, depression 40 39 -
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Ethnic differences in the prevalence and recognition of depression in a 
primary care population with and without type 2 diabetes
S. Ali1, N.A. Taub2, M.A. Stone2, M.J. Davies3, T.C. Skinner4, K. Khunti2;
1Health Sciences Research Institute, Warwick Medical School, University of 
Warwick, Coventry, 2Department of Health Sciences, University of Leicester, 
3Department of Cardiovascular Sciences, University of Leicester, United 
Kingdom, 4Combined Universities Centre for Rural Health, The University 
of Western Australia, Geraldton, Australia.
Background and aims: Results from meta-analyses suggest that the preva-
lence of depression is higher in people with type 2 diabetes compared to those 
without. However a number of methodological limitations in the literature 
remain including the use of inadequate control groups and a failure to control 
for potentially confounding factors. The present study aimed to determine 
the prevalence of screen detected and prevalent (currently managed) depres-
sion in a multiethnic primary care population with and without type 2 dia-
betes in the UK. In addition the study aimed to examine ethnic differences in 
the prevalence of depression between South Asian (SA) and White European 
(WE) people with type 2 diabetes and to assess the recognition of depression 
in primary care.
Materials and methods: Consecutive primary care attendees were screened 
for depression using the depression subscale of the Hospital Anxiety and De-
pression Scale (HADS-D) during routine appointments in primary care. De-
mographic and medical data were also extracted from participants’ primary 
care records.
Results: Complete data were available for 860 adults with type 2 diabetes (560 
SA and 300 WE) and 643 without diabetes. No significant differences in the 
prevalence of depressive symptoms were observed between people with and 
without type 2 diabetes (HADS-D> 8= 28% vs.29%, P>0.05; HADS-D>11= 
17% vs. 17%, P>0.05). Higher rates of probable and/ or major depression 
were observed in SA people with type 2 diabetes compared to WEs: 32% vs. 
22%, P= 0.006 (HADS-D>8) and 13% vs. 10%, P= 0.166 (HADS-D >11). Us-
ing a cut-off of >8 on the HADS-D, the ethnic difference also persisted when 
controlling for age, gender, deprivation and the presence of one or more 
co-morbidity or diabetes-related complication. In those scoring >11 on the 
HADS-D, rates of unrecognised depression were higher in those with diabe-
tes compared to those without (83% vs. 70%, P=0.004), and were significantly 
higher in SA in comparison to WE both in those with type 2 diabetes (90% 
vs. 63% P=0.018) and those without (77% vs. 50%, P=0.002).
Conclusion: In contrast to previous research, the findings showed no sig-
nificant difference in risk for depression in those with diabetes compared to 
those without, suggesting that the association between depression and diabe-
tes may be less robust than previously acknowledged. However in people with 
type 2 diabetes, higher rates of depression were observed in SAs in compari-
son to WEs. Furthermore our results also indicate that depression is seriously 
under-diagnosed in people with type 2 diabetes, most acutely in SAs, suggest-
ing a need to improve methods of identifying depression in these patients.
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OP 7 The effects of insulin beyond 
glycaemia
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Insulin in patients with acute myocardial infarction and diabetes - friend 
or foe? A report from the DIGAMI 2 study
L.G. Mellbin1, K. Malmberg1, A. Norhammar1, H. Wedel2, L. Rydén1;
1Department of Cardiology, Karolinska Institutet, Stockholm, 2Nordic 
School of Public Health, Göteborg, Sweden.
Background and aims: The aim of the present report, a substudy to DIGAMI 
2, is to analyze long-term mortality and morbidity in relation to different 
glucose lowering agents in patients with myocardial infarction and type 2 
diabetes.
Materials and methods: In DIGAMI 2 patients with type 2 diabetes and 
suspect myocardial infarction were randomised to Group1) insulin based 
treatment; Group 2) insulin in-hospital followed by conventional glucose 
control; Group 3) conventional treatment. They were treated according to 
the protocol for 2.1 years and in an extended part of the trial followed up 
to 8.3 years (median =4.1). Long-term follow-up data was available in 1145 
patients, 91.3% of the original DIGAMI 2 cohort.
Results: The total mortality was 34%, (72 % cardiovascular). Cox regression 
analysis did not show any difference in total or cardiovascular mortality be-
tween treatment groups. The total number of fatal malignancies was 37 with 
the highest risk in group 1. Hazard Ratio compared with group 2:1.83 (95%CI 
0.90-3.71; p=0.096) and to group 3: 3.57 (95%CI 1.22-10.39; p=0.02). Patients 
on insulin treatment had a higher risk of non-fatal events (OR 1.90 (95%CI 
1.38- 2.6; p=<0.0001) but not increased mortality (OR 1.30, 95%CI 0.94-1.80; 
p=0.11). Metformin was associated with a lower mortality (HR 0.65, 95%CI 
0.47-0.90) and a lower risk of death of malignancies (HR 0.25, 95%CI 0.08-
0.83; figure).
Conclusion: Patients with diabetes and myocardial infarction have a very 
poor prognosis. The drug used for glucose control appears to have a prognos-
tic impact. Insulin was associated with an increased risk of non-fatal cardiac 
events and death due to malignancies while metformin seemed to be protec-
tive.
Supported by: the Swedish Heart-Lung Foundation, AFA Insurance
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Safety analysis of basal insulins: mitogenic potency and receptor binding
B.F. Hansen1, C.E. Stidsen1, T. Glendorf2, A. Lundby3, A.C. Hegelund3,  
C. Bonnesen1;
1Department of Insulin Biology, 2Department of Protein Chemistry, 
3Department of Cell Antibody Analysis, Novo Nordisk A/S, Måløv, 
Denmark.
Background and aims: The receptor binding profile of exogenous insulin 
may provide important information regarding mitogenicity; for example, 
higher affinity to the insulin-like growth factor-1 receptor (IGF-1R) has been 
linked to increased cellular proliferation. Furthermore, sustained signalling 
from the receptor might also increase cellular proliferation. Preclinical analy-
sis has demonstrated a comparable mitogenic profile between insulin detemir 
(IDet) and neutral protamine Hagedorn insulin. This analysis of insulin re-
ceptor (IR) and IGF-1R binding was undertaken to evaluate the mitogenic 
characteristics of basal insulin analogues.
Materials and methods: Three insulin analogues were compared with hu-
man insulin: IDet, insulin glargine (IGlar) and an experimental insulin, X10. 
Two experiments were performed: first mitogenic potency relative to human 
insulin was established through proliferation of two different cell lines - hu-
man mammary epithelial cells (HMEC), and L6 myoblasts modified to over-
express human insulin receptors (L6-hIR). Then, receptor binding for IDet 
and IGlar was measured using both cell membranes and solubilised recep-
tors, with binding curves generated to calculate the ratio of IGF-1R binding:
IR binding profile relative to human insulin. Both isoforms of insulin recep-
tor (A and B) were used.
Results: The mitogenic potency of IDet relative to human insulin was com-
paratively low for both cell lines (see Table). Data for IGlar were varied, with 
the HMEC cell line showing a high potency, and the L6-hIR line a relatively 
low potency. For X10, a consistently high potency in both cell lines was ob-
served. When the ratio of IGF-1R:IR binding was calculated for IDet, both 
IR isoforms, and both techniques showed a similar ratio relative to human 
insulin: 0.7 (IR-A) and 1.3 (IR-B) for membrane experiments and 0.4 (both 
IR-A and B) for solubilised receptors. For IGlar, ratios were increased relative 
to human insulin: 16.2 (IR-A) and 20.5 (IR- B) for membrane preparations, 
and 10.7 (both IR-A and B) for solubilised receptors.
Conclusion: Compared with human insulin, IDet has a lower mitogenic 
potency, although further parameters of molecular safety (for example, sus-
tained signalling from the IR or IGF-1R) may also be of note when evaluating 
the mitogenic potential. Our data show a similar balance between IGF-1R 
and IR binding for IDet and human insulin without evidence of significant 
differences in proliferation, supported by previous studies.
Table. Mitogenic potencies of study insulins relative to human insulin
Cell line Functional 
receptor 
Human 
insulin 
Insulin 
detemir 
Insulin 
glargine 
X10 
HMEC IGF-1 and 
insulin
100% 16.9% 650% 812%
L6-hIR Insulin 100% 9.2% 49% 744%
Supported by: Novo Nordisk
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Changes in the concentration of serum C-peptide in type 2 diabetes 
during long-term continuous subcutaneous insulin infusion therapy
Y.H. Noh1, J.H. Lee1, J.H. Park1, S.B. Choi2;
1Biochemistry, Konkuk University, Seoul, 2Internal Medicine, Konkuk 
University Hospital, Chungju, Republic of Korea.
Background and aims: Type 2 diabetes is characterized with impaired beta 
cell function and reduced beta cell mass which deteriorate over time. To see if 
beta cell function can be improved in type 2 diabetic patients through long-
term continuous insulin infusion (CSII) therapy, we examined changes in 
serum C-peptide levels during the treatment.
Materials and methods: We discontinued oral antidiabetic drugs (OADs) 
and applied CSII therapy to subjects with type 2 diabetes who had failed to 
control hyperglycaemia with OADs and/or insulin injections (number, 34 
with 59% of male; age, 56.8 ± 10.8 years; duration, 9.3 ± 7.3 years; HbA1c 
7.4 ± 1.8%). Blood samplings were performed yearly for 4 years at 12 hour-
overnight fasting and 30 and 120 minutes after ingestion of a standard mixed 
meal (500 kcal; carbohydrate 52.9%, lipid 30.4%, protein 16.7%) with at least 
9 hours cessation of CSII.
Results: During the 4 year-CSII treatment, the mean HbA1c significantly de-
creased from 7.4 ± 1.8% to 5.6 ± 0.4% (p < 0.01, Fig.1) and the mean serum C-
peptide level at 120 minutes after meal ingestion significantly increased from 
5.97 ± 2.71 to 7.46 ± 2.68 ng/ml (p < 0.05, Fig.1). The C-peptide increment 
from fasting to 120 minutes after meal also increased by 1.06 ± 1.97 ng/ml 
after 1 year-CSII therapy, 0.79 ± 1.91 ng/ml after 2 years, 1.61 ± 2.62 ng/ml 
after 3 years, and 4.27 ± 2.17 ng/ml after 4 years, respectively.
Conclusion: The resolution of glucotoxicity and maintenance of euglycaemia 
through long-term CSII therapy may contribute to the restoration of β-cell 
function in terms of serum C-peptide level after meal in type 2 diabetic pa-
tients.
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Fig.1. Changes in the mean HbA1c and the mean serum C-peptide concen-
tration at 120 minutes after ingestion of a standard mixed meal (500 kcal) 
during 4 year-continuous subcutaneous insulin infusion therapy in patients 
with type 2 diabetes.
Supported by: Novo Nordisk
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Body weight increase during the first year of insulin treatment in 
patients with type 2 diabetes mellitus; a systematic review and meta-
analysis of different insulin regimens
L. Miele1,2, A.E. Pontiroli2, A. Morabito2;
1Ospedale San Paolo, 2Medicina, Chirurgia e Odontoiatria, Università degli 
studi di Milano, Italy.
Background and aims: Insulin treatment increases body weight in type 2 
diabetes mellitus. Aim of this study was to define body weight increases dur-
ing the first year of insulin treatment as a function of treatment modalities.
Materials and methods: We considered 51 randomized, parallel group stud-
ies with 15202 patients, lasting 12 - 52 weeks, published as full papers during 
years 1991 - 2009. Of each study we analyzed number of patients, duration of 
treatment, co-treatment with oral agents, insulin regimen (basal, bis in die, 
prandial), glycemic target, daily insulin doses, HbA1c and its changes, pro-
portion of patients with hypoglycemia, body weight and its changes. Pooled-
random effects of estimates of insulin regimen on body weight increase, 
compared with other regimens, were calculated using the Der Simonian and 
Laird models.
Results: Body weight increased 2.1±0.16 kg (range -0.85 - +7.5 kg, 95% C.I. 
1.812-2.468), with no influence of basal body weight, lower with basal than 
with bis in die regimen (OR 0.42, 95% C.I. 0.25-0.59), and with no differ-
ence basal vs prandial, nor bis in die vs prandial regimen. Body weight in-
crease was directly related (weighted regressions) to duration of treatment 
(r = .514,p = 0.0001), insulin dose (r = .313, p = 0.0012), HbA1c (r = .331, p 
= 0.0005), HbA1c change (r = .402, p = 0.0001), glycemic target (r = .203, p 
= 0.0462), hypoglycemia (r = .453, p = 0.0001), and nocturnal hypoglycemia 
(r = .281, p = 0.0434). At stepwise regression analysis (model 1: r = .783, F 
= 36.865; model 2: r = .735, F = 41.597), independent variables duration of 
treatment, HbA1c (or HbA1c change), and frequency of hypoglycemia, were 
significantly correlated to body weight increase (dependent variable).
Conclusion: These data indicate a slight and progressive increase of body 
weight in patients with type 2 diabetes during the first year of insulin treat-
ment, related to insulin regimen, basal HbA1c, its changes, and to frequency 
of hypoglycemia.
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Effects of insulin detemir and NPH insulin on renal handling of sodium, 
fluid retention and weight in type 2 diabetic patients
K.V. Hendriksen1, T.J. Jensen2, B. Feldt-Rasmussen3, P. Oturai4;
1Endocrinology and Nephrology, 2Endocrinology, 3Nephrology, 4Clinical 
Physiology, Rigshospitalet, Copenhagen, Denmark.
Background and aim: In insulin treated type 2 diabetic patients, insulin 
Detemir (DET) seems to induce less weight gain compared to NPH insulin 
(NPH). The mechanism behind this weight-reducing effect of DET is un-
known, but it has been proposed that the cause is reduced fat accumulation 
or reduced sodium/water retention. Due to the albumin binding and reduced 
glomerular filtration, and thereby reduced tubular action of DET, we tested 
the hypothesis that type 2 diabetic patients should increase their urinary 
sodium excretion (UNaE) and thereby reduce extracellular volume (ECV) 
and body weight (weight) when insulin treatment was changed from NPH 
to DET.
Material and methods: In a randomised, open-labelled, two-way cross-over 
study, 24 patients with type 2 diabetes and normal urinary albumin excretion 
(mean age: 62 yr, mean diabetes duration: 15 yr, gender 17/7 (M/F), mean 
HbA1c: 7.6%) were included. They were first treated with either NPH or DET 
for 8 weeks. In the second period, they were changed to the other insulin for 
8 weeks. In a third 1-week period, they were changed back to the first insulin. 
At the end of each 8-week period ECV, weight and body composition (DEXA 
scan) was measured. In the last week of each 8 week period and on day 1, 3, 
and 5 in the first week after therapy change UNaE was determined. Weight 
was measured after 1 week. Twenty-four hour blood pressure was measured 
6 times in the course of the study.
Results: At the end of 8 weeks weight was reduced by 0.8(±0.2 kg)(mean±SEM) 
after DET treatment compared with NPH (paired t-test: p<0.01) A non sig-
nificant reduction in ECV of 0.8(±0.5 L/1.73m²)(paired t-test: p= 0.14) was 
found. The weight loss occurred already after 1 week 0.8(±0.2kg)(paired t-
test: p<0.001) and simultaneously a transient increase in UNaE was observed 
(Kruskal-Wallis test: p=0.07). HbA1c increased by 0.6%(±0.1) after 8 weeks 
of treatment with DET (paired t-test: p<0.001) in spite of a slightly increased 
insulin dose, but average blood glucose measured during the first week was 
similar during the two treatments. In addition, 24 h blood pressure and body 
composition remained similar during the two treatment periods.
Conclusion: DET induces a significant and sustained weight loss, first ob-
served within the first week after changing therapy from NPH. It was simul-
taneous with a trend towards a transient increase in UNaE and a reduction in 
ECV. The weight loss thus seems to be related to changes in fluid volume and 
may reflect changed insulin action in the kidneys.
Supported by: Novo Nordisk
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Basal insulin therapy improves indexes of endothelial damage and 
regeneration in type 2 diabetes. A randomised cross-over trial comparing 
detemir vs glargine
G. Fadini, S.V. de Kreutzenberg, V. Mariano, E. Boscaro, M.C. Marescotti, 
C. Agostini, A. Tiengo, A. Avogaro;
Department of Clinical and Experimental Medicine, University of Padova, 
Italy.
Background and aims: Endothelial damage is the leading mechanism of dia-
betic macroangiopathy. In diabetes, endothelial regeneration is also impaired 
owing to reduced levels of endothelial progenitor cells (EPCs). We tested the 
hypothesis that therapy with basal insulin analogues influences endothelial 
damage and regeneration in type 2 diabetes. Since the two basal analogues 
have different pharmacological properties, detemir and glargine were directly 
compared.
Materials and methods: This was a 3-month randomized cross-over trial 
comparing insulin detemir once daily versus glargine once daily added to 
oral agents in poorly controlled (HbA1c>7.0%) type 2 diabetic patients 
with cardiovascular disease (ClinicalTrial.gov NCT00699686). Insulin titra-
tion was aimed at achieving fasting plasma glucose between 5.0 mmol/l (90 
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mg/dL) and 6.1 mmol/l (110 mg/dL) as soon as possible after enrollment. At 
baseline, at cross-over (3 months) and at study end (6 months), we measured 
HbA1c, EPC levels (as an indicator of endothelial regenerative capacity) and 
serum concentrations of VCAM-1, ICAM-1 and E-selectin (as indicators of 
endothelial damage). EPCs were defined as CD34+KDR+ or CD133+KDR+ 
or CD34+CD133+KDR+ cells and measured by flow cytometry. We also re-
corded body weight and hypoglycemic episodes.
Results: Forty-two patients completed the study: 21 followed the glargine-
detemir (GD) schedule and 21 the detemir-glargine (DG) schedule. Patients 
were on average 66.1±1.2 year old and 74% were males. Baseline data did 
not differ between the two groups in terms of demographic and anthropo-
metric parameters, HbA1c, complications and concomitant treatment. At 
cross-over, patients in the GD schedule had a lower HbA1c as compared to 
patients in the DG schedule (p=0.040). Even if this difference in HbA1c was 
lost at study end, the overall HbA1c effect was in favor of glargine (p=0.016). 
Incidence of hypoglycemia (mild and severe together) and weight gain were 
lower during detemir than during glargine therapy. ICAM-1, VCAM-1 and 
E-selectine were all significantly reduced at crossover as compared to baseline 
and further decreased at study end, irrespectively of the treatment schedule. 
At cross-over, the levels of all EPC phenotypes did not change as compared to 
baseline, while CD133+KDR+ and CD34+CD133+KDR+ cells significantly 
increased (by 68% and 139%, respectively) at study end in both groups.
Conclusion: Basal insulin therapy improves indexes of endothelial dam-
age and regeneration in type 2 diabetic patients with cardiovascular disease. 
Glargine and detemir do not differ in their endothelial effects, but detemir 
achieved a similar endothelial protection with lower weight gain and hy-
poglycemic episodes, albeit at the expenses of a slightly higher HbA1c. These 
results might have implications for therapy of aging type 2 diabetic patients 
with cardiovascular disease.
Supported by: LIBRA project, Novo Nordisk
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Glucose control in adults during a 1-year randomised controlled trial 
comparing sensor-augmented pump therapy and multiple daily injection 
therapy: STAR 3 study
J.B. Green1, A. Ahmann2, R.M. Bergenstal3, G. Dailey4, R. Tanenberg5, J.B. 
Buse6, for the STAR 3 Study Group;
1Division of Endocrinology, Metabolism, and Nutrition, Duke University 
Medical Center, Durham, 2Oregon Health and Science University, Portland, 
3International Diabetes Center at Park Nicollet, Minneapolis, 4Scripps Insti-
tute, La Jolla, 5East Carolina University, Brody School of Medicine, Green-
ville, 6University of North Carolina School of Medicine, Chapel Hill, USA.
Background and aims: Recent studies have demonstrated overall improve-
ment in glucose control with use of CGM. Sensor augmented pump (SAP) 
therapy combines an insulin pump with real-time integrated continuous glu-
cose monitoring. We hypothesized SAP would improve glucose control (A1C 
and AUC >180 mg/dL) without increasing hypoglycemia.
Materials and methods: STAR 3 is a 1-year multicenter randomized con-
trolled trial which compared SAP therapy using insulin aspart to multiple 
daily injection (MDI) therapy using insulin glargine and insulin aspart in 329 
adult (age 19-70 years) and 156 pediatric (age 7-18 years) subjects with type 
1 diabetes. All subjects wore a “blinded” sensor for 6 days at baseline, and 
the MDI subjects wore subsequent blinded sensors for 6 days at 6 months 
and one year. Preliminary results for the adult cohort (age 19-70 years) are 
given for: A1C, mean sensor glucose, area under the curve (AUC), and severe 
hypoglycemia.
Results: The primary endpoint of change in A1C from baseline to 1 year 
showed the decline in mean A1C levels was significantly greater in the SAP 
group compared to MDI group (SAP: from 8.3±0.5% to 7.3±0.7%; MDI: from 
8.3±0.5% to 7.9±0.9%; treatment difference -0.6%; 95% CI, -0.77 to -0.45; 
p<0.001). The Table demonstrates that mean sensor glucose was statistically 
similar at baseline but significantly lower in the SAP group compared to the 
MDI group at 6 months (p<0.01) and 1 year (p<0.01). The improvement in 
glycemia with SAP was not associated with an increase in severe hypoglyc-
emia (p=0.58) or AUC <70 mg/dL at 1 year (p=0.82). There were no between 
group differences in incidence of DKA (p=0.38) or weight gain (p=0.20). A 
greater proportion of adult subjects in the SAP group (57/166, 34.3%) reached 
ADA targets for A1C compared to the MDI group (19/163, 11.7%; p<0.001). 
AUC for sensor glucose values >180 mg/dL at 6 months and 1 year were sig-
nificantly reduced in the SAP group compared to the MDI group (p<0.001).
Conclusion: SAP achieved a greater reduction in A1C and AUC>180 com-
pared to the MDI group without an increase in hypoglycemia over a period 
of a year.
Table. Mean Sensor Glucose, Hyperglycemia, and Hypoglycemia, SAP and 
MDI Treatment Groups 
Baseline 6 Months 1 Year
SAP MDI SAP MDI SAP MDI
Mean sensor 
glucose (SD), 
mg/dL
179.9 
(28.9)
178.7 
(27.6)
157.5* 
(25.4)
171.1 
(31.5)
158.6* 
(25.7)
174.2 
(31.7)
AUC>180 (SD) 28.9 
(17.8)
28.0 
(17.3)
16.0* 
(12.6)
24.7 
(18.5)
16.1* 
(12.8)
26.0 
(19.5)
ΔAUC>180 NA NA -12.9 -3.3 -12.8 -2.0
AUC<70 (SD) 0.3 (0.5) 0.3 (0.5) 0.3 (0.5) 0.4 (0.6) 0.3 (0.4) 0.3 (0.6)
ΔAUC<70 NA NA 0 0.1 0 0
*, p<0.01 compared to MDI group; SAP, sensor-augmented pump; MDI, mul-
tiple daily injection; AUC, area under the glucose concentration-time curve; 
Δ, change from baseline; NA, not applicable
Supported by: Medtronic, Inc.
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Effects of continuous glucose monitoring on glycaemic control in 
subjects with type 1 diabetes delivering insulin via pump or multiple 
daily injections: a prospective study
P.A. Gottlieb, L.B. Crew, E.G. Moser, M.K. Voelmle, C.R. Beatson,  
R.S. Gutin, S.K. Garg;
Barbara Davis Center, University of Colorado Denver, Aurora, USA.
Background and aims: There are no long-term prospective data describ-
ing the differential effects (if any) of continuous glucose monitoring (CGM) 
when used by patients with type 1 diabetes (T1D) who deliver insulin via 
multiple daily injections (MDI) as compared to those on continuous subcu-
taneous insulin infusion (CSII) pump therapy. This study assesses the long 
term effectiveness of CGM (DexCom SEVEN®PLUS) in subjects with T1D 
and compares the changes in glycemic control by CSII vs. MDI cohorts.
Materials and methods: Sixty adults with T1D were enrolled in this 6-month 
study; 30 subjects were on CSII, and 30 delivered insulin via MDI. For the 
first 4 weeks, all subjects were blinded from CGM values/trends/alarms; 
thereafter all subjects were unblinded for the remaining 20 weeks (real-time 
CGM data provided). A1C was measured during screening and at 4-week 
intervals throughout the study. Per the results of the JDRF CGM trials and 
the pre-specified analysis, population for this study included subjects who 
utilized CGM at least 6 days per week (86% of the time).
Results: Mean (±SD) age was 36 (±11) and 39 (±8) years; duration of diabetes 
was 22 (±11) and 23 (±10) years; and screening A1C was 7.61% (±0.76) and 
7.63% (±0.68) for CSII and MDI groups, respectively (p>0.05). Seventeen pa-
tients (57%) in each group utilized CGM for at least 6 days each week. Both 
groups similarly improved A1C values (Figure 1a) and time spent in target 
range glycemia (Figure 1b). Both groups reduced time spent in hypoglycemia 
(180 mg/dL) was reduced by one and two hours per day in the MDI and CSII 
groups, respectively.
Conclusion: Similar improvements in glucose control can be achieved with 
real-time CGM in compliant T1D patients using either CSII or MDI.
Supported by: A research grant through the University of Colorado Denver from 
Dexcom, Inc
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Closed-loop insulin delivery using subcutaneous infusion and glucose 
sensing, and equipped with a dedicated safety supervision algorithm, 
improves safety of glucose control in type 1 diabetes
E.M. Renard1, A. Farret1, J. Place1, S. Patek2, C. Cobelli3, B.P. Kovatchev2, 
M.D. Breton2;
1Department of Endocrinology, Diabetes and Nutrition, CHU Montpellier 
& University of Montpellier I, France, 2Department of Psychiatry and 
Neurobehavioral Sciences, University of Virginia, Charlottesville, USA, 
3Department of Information Engineering, University of Padova, Italy.
Background and aims: The reduction of blood glucose excursions outside 
a near-normal range is a main goal for the improvement of control of type 1 
diabetes. The modulation of insulin delivery according to blood glucose lev-
els and variations can be achieved by using closed-loop (CL) insulin delivery 
systems based on continuous interstitial glucose monitoring (CGM), subcu-
taneous insulin infusion (CSII), and control algorithms. We investigated the 
new concept of modular model-based safety supervision aiming the preven-
tion of hypoglycaemia while keeping blood glucose level in a safe range.
Materials and methods: Six type 1 diabetic patients (5 M/1F), duration of 
diabetes 31+/- 7 years, age 43 +/- 7, A1c 7.5 +/- 0.9 %, and BMI 25 +/- 3, 
treated by CSII for 7.6 +/- 3.9 years, were enrolled in a trial performed at the 
CHU Montpellier Clinical Research Center using Navigator CGM and Om-
niPod insulin pump infusing lispro to compare fully-automated CL control 
equipped with a dedicated safety supervision algorithm to physician-super-
vised CSII. The trial was composed of two periods during which each insulin 
delivery mode was tested in a randomised order from 2 pm to 8 am the next 
day. The patients performed a 30-min exercise bout on a cyclo-ergometer at 
50% VO2 max from 4 pm, took a 70g CHO-meal dinner at 7 pm as well as a 
20g CHO-snack at 10:30 pm, and slept from 11 pm to 8 am. Reference blood 
glucose was measured using YSI every 30 min from 2 to 11 pm and every 
hour from 12 to 8 am. Primary endpoint was the number of hypoglycaemic 
events according to symptoms and YSI glucose value below 70 mg/dl. Sec-
ondary study endpoints included % time spent outside a safe glucose range 
of 70-180 mg/dl, mean blood glucose level and maximal blood glucose dif-
ference during the entire trial periods and during exercise and following 2.5 
hours, 2 hour-post dinner period, and night-time from 9pm to 8 am.
Results: Compared to CSII, CL control reduced the incidence of hypoglycae-
mia two-fold: from 13 to 6 events. While mean blood glucose levels (mg/dl) 
were similar for both periods: 155 +/- 14 (CSII) vs. 145 +/- 14 (CL), percent 
time spent < 70 mg/dl and > 180 mg/dl were both lower during CL vs. CSII: 
2.4 +/- 0.9 vs. 4.7 +/-1.2 and 18.0 +/- 6.5 vs. 30.1 +/- 5.7, respectively. Maxi-
mal blood glucose difference (mg/dl) was significantly tighter at exercise and 
recovery time during CL: 84 +/- 16 vs. 123 +/- 21 (p=0.046).
Conclusion: Our preliminary data based on the first 6 patients enrolled in 
this pilot study show that a modular model-based safety supervision system 
results in fewer hypoglycaemic events and reduces the duration of blood glu-
cose excursions outside the target range 70-180 mg/dl, as well as the ampli-
tude of glucose variations associated with exercise in type 1 diabetes. Upcom-
ing larger clinical trials will confirm the benefits of added safety provided by 
this algorithm.
Supported by: JDRF
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Overnight closed-loop glucose control following consumption of alcohol 
in adults with type 1 diabetes
K. Kumareswaran1, J. Harris1, D. Elleri1, J.M. Allen1, M. Nodale1, M.E. 
Wilinska1, D.B. Dunger1, S.A. Amiel2, S.R. Heller3, M.L. Evans1, R. Hovorka1;
1Institute of Metabolic Science, University of Cambridge, 2King’s College 
London, 3University of Sheffield, United Kingdom.
Background and aims: Modern management of insulin in type 1 diabetes 
(T1D) uses flexible insulin therapy to minimise restrictions on daily life. By 
reducing the capacity for hepatic gluconeogenesis, alcohol consumption in-
creases the risk of delayed hypoglycaemia. Even for those patients who reduce 
overnight insulin after drinking, hypo- or hyperglycaemia can follow, espe-
cially where alcohol is consumed with larger meals in social settings. We have 
tested a closed-loop (CL) or artificial pancreas system linking off-the-shelf 
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continuous glucose monitoring (CGM) and continuous subcutaneous insu-
lin infusion (CSII) using a purpose-built model predictive control (MPC) al-
gorithm. We recently demonstrated that overnight CL in adults significantly 
increased time spent in euglycaemia and reduced time in hypoglycaemia. We 
have now examined the efficacy and safety of CL compared with standard 
CSII on overnight glycaemic control, after evening alcohol intake accompa-
nying a large dinner.
Materials and methods: Twelve adults with T1D treated by CSII (F 7, age 
37.2±9.9yrs, BMI 26.8±4.2 kg/m2, T1D duration 19.7±9.7yrs, duration on 
pump 1.9±2.5yrs, HbA1c 7.8±0.7%; mean±SD) were studied on 2 separate 
nights in random order, receiving either overnight CL (used from 2200 until 
1200 the next day) or usual CSII therapy (using a similar Deltec Cozmo in-
sulin pump on both nights). On CL nights, subcutaneous CGM values from 
the Freestyle Navigator were fed into an MPC algorithm every 15min, which 
calculated the infusion rate of Aspart (adjusted manually). On CSII nights, 
subjects used the Cozmo pump to deliver their usual insulin rates. On both 
occasions, between 2030 and 2200, a mixed meal (100g-carbohydrate) was 
ingested accompanied by 0.75g/kg ethanol as 13% white wine (mean volume 
consumed 564±133ml), with a pre-prandial insulin bolus using the subject’s 
usual bolus calculator. Plasma glucose was measured every 15min to assess 
CL performance.
Results: As shown in the table, CL significantly increased the time spent in 
target glucose range and reduced glucose variability (plasma glucose SD). CL 
reduced the high blood glucose index, a composite measure of duration and 
severity of hyperglycaemia. One episode of severe hypoglycaemia occurred 
with CSII and none during CL. Notably, improved glycaemic control with CL 
was achieved without a difference in the average insulin dose infused.
Conclusion: CL can provide significantly better overnight glucose control 
than conventional CSII after alcohol and large meal consumption. CL has the 
potential to improve efficacy and safety of flexible insulin regimens.
Comparison of overnight plasma glucose control during CL and CSII
CL CSII P
Time in target 3.9-8.0mmol/l (% of total time) 72±15 50±23 0.002
Time > 8.0mmol/l (% of total time) 23±16 37±26 0.042
Time < 3.9mmol/l (% of total time) 5±7 13±13 NS
Mean overnight glucose (mmol/l) 6.8±0.8 7.0±1.5 NS
SD overnight glucose (mmol/l) 1.8±0.5 2.3±0.7 0.031
High blood glucose index 1.8±1.6 3.2±2.6 0.016
Low blood glucose index 1.4±1.2 2.9±2.6 NS
Mean overnight insulin infusion (U/h) 0.9±0.4 0.9±0.4 NS
Supported by: Diabetes UK, NIHR, JDRF
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Comparison of total annual direct costs among Swedish residents 
with poorly controlled type 1 diabetes: standard care versus real-time 
continuous glucose monitoring 
C. Graham1, D.-C. Agardh2, P. Gerhardsson1, C.S. Hankin3;
1DexCom, Inc., San Diego, USA, 2Lund University, Malmö, Sweden, 
3BioMedEcon, Moss Beach, USA.
Background and aims: Among the 40,000 Swedish residents diagnosed with 
type 1 diabetes (T1DM), 18% (7,200) have poorly-controlled disease (defined 
as HbA1c ≥9%) and are at high risk for developing diabetes-related complica-
tions. Randomized clinical trials (RCTs) have shown that real-time continu-
ous glucose monitoring (RT-CGM) significantly improves HbA1c (A1c) levels 
among those with T1DM. We developed a decision-tree model to compare 
anticipated rates and costs of diabetes-related complications among a hypo-
thetical group of 7,200 Swedish subjects with poorly-controlled T1DM who 
received RT-CGM or standard therapy (ST).
Materials and methods: T1DM prevalence was obtained from the National 
Board of Health and Welfare and A1c levels from the Swedish Diabetes Regis-
try; A1c improvement among those with poorly-controlled T1DM who used 
RT-CGM was obtained from a RCT; rates of microvascular complications in 
Swedish subjects with T1DM were derived from the Stockholm Diabetes In-
tervention Study and the Diabetes Complications and Control Trial. Rates of 
severe hypoglycemia in T1DM were based on observational studies of Swedes 
and a RCT of RT-CGM. Annual direct medical costs of were obtained from 
published Swiss (serious retinopathy) and Swedish (nephropathy, peripheral 
neuropathy, severe hypoglycemia) economic analyses and reported as 2009 
USD. Costs for 7-day, continuous, RT-CGM were provided by a manufac-
turer of RT-CGM devices.
Results: Among the 7,200 who received RT-CGM, 26% achieved a 2-point 
A1c reduction, 50% a 1-point reduction, and 24% no improvement at 1 year; 
among a comparable group of 7,200 Swedish subjects who received ST, A1c 
did not change from baseline. Among those who received RT-CGM versus 
ST, 3,949 and 5,832, respectively, experienced microvascular complications, 
and 720 and 1,440-2,520, respectively, severe hypoglycemia. The total annual 
reduced direct costs associated with diabetes-related complications for those 
who received RT-CGM versus ST ranged from $43.3 to $45.9 million. The 
cost of receiving RT-CGM was $43.5 million ($6,038 per person). Thus, RT-
CGM reduced 2,603-3,683 diabetes-related complications over 1 year rang-
ing from a net break-even to a cost savings of $2.4 million.
Conclusion: In this decision-tree model, use of RT-CGM by 7,200 Swedes 
resulted in 2,603-3,683 (36-44%) fewer diabetes-related complications per 
year compared with ST at an estimated reduction in the direct cost of dia-
betes-related complications ranging from $43.3 to $45.9 million. The model 
demonstrates that this technology is a cost-effective means of reducing dia-
betes-related complications among Swedish persons with poorly-controlled 
T1DM. Because not all direct costs for diabetes-related complications (e.g., 
macrovascular events) were included in the model, RT-CGM may be associ-
ated with even greater cost savings relative to ST.
Supported by: DexCom, Inc.
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Accuracy of a continuous glucose monitoring system (CGMS): still room 
for improvement
S. Heckermann, L. Nosek, E. Zijlstra, T. Heise;
Profil Institut fuer Stoffwechselforschung GmbH, Neuss, Germany.
Background and aims: Clinical trials have shown improvements in glycemic 
control through CGMS in people with type 1 diabetes (T1D), but systematic 
investigations of the accuracy of CGMS are scarce. We studied the perform-
ance of the Guardian Real Time CGMS in 17 T1D (6 females, mean age 43 
(26-61) years, HbA1c 8.3 (7.6-8.9)%, all on basal-bolus insulin therapy).
Materials and methods: During two in-house stays of 7 days each with 
standard meals (identical for both periods) patients were connected to CGMS 
(hypoalarm setting 70 mg/dl with a predictive alarm 10 min earlier). Refer-
ence measurements using a laboratory device (Super GL glucose analyzer, 
Hitado, Möhnesee, Germany) were done at least every 4 hours and in case of 
hypoglycemic symptoms or a CGMS hypoalarm. All reference measurements 
were used for CGMS calibration.
Results: In total, 2328 paired data points were obtained covering a glucose 
range of 40 - 400 mg/dl. Mean absolute deviation was 24.5±24.0 mg/dl, mean 
relative absolute deviation was 18.3±18.7%. Frequent calibration did not seem 
to improve accuracy, relative absolute deviations for values obtained within 
1h after calibration was 18.8±18,6%. A Clarke Error Grid analysis showed 
93% of paired values to be in zones A (67.4%) and B (25.6%), but also 6.4% in 
zone D (figure). Reference measurements indicated 145 episodes of hypogly-
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cemia (blood glucose (BG) < 70 mg/dl) of which only 43 were detected with 
CGMS. Sixty additional CGMS hypoglycemic alarms were not confirmed, i.e. 
reference measurements showed BG values > 90 mg/dl. Thus, while CGMS 
had high specificity (97%) and good negative predictive value (95%) for hy-
poglycemia, positive predictive value (42%) and sensitivity (30%) were poor.
Conclusion: In conclusion, further improvements in the accuracy of CGMS 
measurements seem to be necessary in particular for a more reliable detec-
tion of hypoglycemic episodes.
OP 9 GWAS and their follow-up: 
analytical, technological and 
experimental developments
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Genome-wide association analysis in over 187,000 individuals identifies 
14 loci contributing to variation in fat-distribution
C.M. Lindgren, on behalf of the GIANT (Genetic Investigation of 
ANthropmetric Traits) Consortium.; Wellcome Trust Centre for Human 
Genetics, University of Oxford, United Kingdom.
Background and aims: Obesity is an increasing public health issue, but not 
all forms of obesity carry the same risk. Individuals with high waist-to-hip 
ratio (WHR) have an increased risk of Type 2 Diabetes (T2D), hypertension, 
heart disease, stroke and certain cancers. WHR is one of the primary meas-
ures of fat distribution and has a substantial heritability (~50%), independent 
of overall adiposity. Hitherto, the genetic variants that contribute to variation 
in WHR have not been well characterized.
Materials and methods: To detect common variants, we performed a meta-
analysis of 32 genome-wide association studies comprising >77,000 individu-
als of European ancestry as part of the GIANT consortium. We tested ~2.8 
million imputed and genotyped SNPs for association with WHR using an 
additive model, adjusted for age and BMI and sex.
Results: Our discovery analysis identified 16 independent loci associated 
with WHR with >110,000 individuals). In our analysis combining discovery 
and follow-up studies 14 loci reached genome-wide significance (p<5x10-
8). We confirmed the known locus near LYPLAL1 (1q41; p=4.9x10-19) and 
identified 13 novel associations, including four loci that suggest an overlap 
with developmental processes and T2D risk: RSPO3 (6q22; p=1.8x10-40), 
near VEGFA (6p12; p=5.9x10-25), TBX15 (1p11; p=8.7x10-25), and near 
ADAMTS9 (3p14; p=9.8x10-14). RSPO3 may regulate embryonic angiogen-
esis via the Wnt signaling pathway. TBX15 is differentially expressed between 
subcutaneous and visceral fat and the expression is correlated with WHR. 
VEGFA is a growth factor that has been suggested to play a role in diabetic 
nephropathy and retinopathy. ADAMTS9 is significantly associated with 
T2D, possibly mediating an effect through decreased insulin sensitivity of 
peripheral tissues. We find a directionally consistent enrichment of associa-
tions (above what would be expected by chance) for each single trait (P nomi-
nal <0.05) with increased triglycerides, LDL-cholesterol, fasting insulin, and 
HOMA-IR. We also observed a marked gender difference in our results; 7 of 
the 14 loci showed a stronger association in women than in men.
Conclusion: Taken together, these results promise to enhance our knowledge 
of underlying biological pathways involved in fat-distribution and propose a 
genetic overlap with metabolic risk and T2D. Hopefully these advancements 
will support functional and translational advances in the management of 
obesity through development of novel diagnostic and therapeutic options.
Supported by: The Wellcome Trust
50
Genetic susceptibility for obesity increases the risk of type 2 diabetes and 
is modified by macronutrient intakes
G. Rukh, E. Sonestedt, V. Lyssenko, A. Sharma, O. Melander,  
M. Orho-Melander;
Clinical Sciences in Malmö, Lund University, Malmoe, Sweden.
Background and aims: Genome-wide association studies (GWAS) have 
identified at least 16 novel single nucleotide polymorphisms (SNPs) associ-
ated with BMI or obesity. The aims of this study were to examine whether 
these SNPs associate with obesity, type 2 diabetes or cardiovascular disease 
(CVD) in Swedish population and to investigate if dietary intake (relative in-
takes of fat, carbohydrate, protein and fiber) or physical activity level modify 
the genetic effect, measured as a genetic risk score (GRS), on BMI and body 
composition.
Materials and methods: In total 17037 individuals from the Malmö Preven-
tive Project (MPP) were genotyped and a weighted GRS was created. Associa-
tion between SNPs and GRS and BMI, obesity, type 2 diabetes and CVD were 
studied cross-sectionally and prospectively after a mean of 23 years follow-
up. A total of 9023 non-diabetic subjects participated in the population-based 
Malmö Diet and Cancer Study (MDCS) with dietary data from a modified 
diet history method and with leisure time physical activity determined and 
S 28 Diabetologia (2010) 53:[Suppl1]S1–S556
1 C
were included to GRS x diet interaction analyses. Bioelectric impedance anal-
ysis was used to estimate body composition.
Results: 14 SNPs associated with BMI or related traits and were included in 
GRS. A 13% (10-17%) increased risk of obesity for each increased quintile 
of GRS was observed (p=3x10-16). Individuals in the highest vs. lowest GRS 
had a 29% (14-46%) increased risk of type 2 diabetes (P= 5x10-5 and P=0.006 
after adjustment for BMI). GRS was not significantly associated with CVD 
(p=0.12). The effect sizes of GRS quintiles on BMI were 2.2, 1.9 and 1.7 times 
higher comparing low carbohydrate-, low fiber and high fat intake tertiles to 
high carbohydrate, high fiber and low fat intake tertiles (p=0.016, p=0.022 
and p=0.084 for interaction, respectively). Interactions were strongest on lean 
mass (p=0.002, p=0.001 and p=0.049). Effect sizes of GRS on BMI, fat mass or 
lean mass did not significantly differ between tertiles of leisure time physical 
activity (p=0.44, p=0.88 and p=0.26, respectively).
Conclusion: GRS of 14 BMI/obesity SNPs associates with obesity and type 2 
diabetes. Diets low in carbohydrates and fiber and/or high in fat may accen-
tuate genetic susceptibility for obesity, particularly accumulation of fat-free 
mass in males. The fairly modest combined effect size on BMI by the so far 
identified BMI/obesity SNPs can partially be explained by the effect sizes be-
ing modified by dietary intakes.
Supported by: Swedish Medical Research Council, Påhlsson Foundation, an 
EFSD Clinical Research Grant, LUDC
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A genome-wide association analysis of over 75,000 individuals identifies 
gender-specific effects for fasting glycaemic traits
R. Mägi1, J.J. Hottenga2, I. Prokopenko1,3, MAGIC Investigators;
1WTCHG, University of Oxford, United Kingdom, 2Department of 
Biological Psychology, VU University Amsterdam, Netherlands, 3OCDEM, 
University of Oxford, United Kingdom.
Background and aims: Meta-analyses of genome-wide association (GWA) 
studies for glycaemic traits up to date have described 16 loci influencing fast-
ing glucose (FG) and two loci - fasting insulin (FI) levels. FG levels are tightly 
regulated, but may differ between genders. Gender differences in prevalence 
of IFG (impaired fasting glucose) and IGT (impaired glucose tolerance) are 
well known: IFG is more common in men and IGT in women but the mecha-
nisms for these differences are unknown. Within the Meta-Analyses of Glu-
cose and Insulin-related traits Consortium (MAGIC) we aimed to investigate 
gender-specific differences in genetic regulation of FG/FI levels, since such 
effort in a large enough sample was lacking.
Materials and methods: To identify gender-specific genetic effects we per-
formed gender-stratified meta-analyses of 36 genome-wide association 
(GWA) studies informative for FG and FI within MAGIC in up to 32,993 
and 27,870 non-diabetic men and 42,149 and 34,940 non-diabetic women, 
respectively. Age information was provided for ~69,600 individuals from 
32 cohorts. Mean age in males was 53.5(SD=10.2) and in females was 
51.1(SD=10.8) years.
Results: Among previously described loci DGKB-TMEM195I demonstrated 
the largest differential effect estimates (heterogeneity Q P=0.026, I2=80%) 
stronger in men (β=0.031 [SE=0.004], P=9.1x10-14) than in women (β=0.019 
[SE=0.004], P=1.1x10-7). Gender-specific heterogeneity for MTNR1B was 
also high (Q P<0.05, I2=75%) with higher effect estimates for men (β=0.080 
[SE=0.005], P=3.7x10-56) than for women (β=0.067 [SE=0.004], P=3.3x10-
51). Effects estimates in women were higher for C2CD4B and GCKR, where 
the gender heterogeneity was close to high, but not significant (I2~60%, Q 
P>0.05). G6PC2 and ADCY5 showed moderate and GCK, PROX1, SLC30A8 
low between-gender heterogeneity for FG (I2≤50% and I2<25%, respectively). 
We couldn’t detect gender-specific differences in the FG effect estimates for 
MADD, FADS1, CRY2, ADRA2A, GLIS3, SLC2A2 TCF7L2 and at GCKR for 
FI (heterogeneity I2=0%). In FG meta-analysis we uncovered a novel locus 
showing strong heterogeneity (Q P=0.055, I2=73%) near PCSK1 with women 
showing β=0.023 [SE=0.003], (P=3.0x10-9) and men β=0.012 [SE=0.004], 
(P=0.008); overall β=0.018 [SE=0.003], (P=9.0x10-10). Meta-analysis of FI 
has revealed higher effect estimates in men (β=0.034 [SE=0.006], P=3.3x10-
8) compared to women (β=0.018 [SE=0.006], P=0.001) at rs860598 (overall 
β=0.024 [SE=0.004], P=3.6x10-9, heterogeneity Q P=0.042, I2=76%) in IGF1 
locus, showing a stronger association than the previously described variant 
rs35767 (overall P=4.7x10-8, linkage disequilibrium r2=0.77).
Conclusion: We showed that some genetic loci have greater contribution to 
the fasting glycaemic traits variability in men (DGKB, MTNR1B, IGF1) than 
in women and vice versa (PCSK1) owing to differential gender-specific phys-
iological mechanisms of regulation of glycaemic traits. We also unveiled a 
novel FG locus near PCSK1. This analysis showed the importance of deep in-
vestigation of between-gender differences for quantitative phenotypes related 
to type 2 diabetes. Well powered GWA analyses should investigate the gender 
contribution to the quantitative traits variability in a systematic manner.
Supported by: European Commission under the Marie Curie Intra-European 
Fellowship
52
Identification of additional type 2 diabetes susceptibility loci through 
large-scale replication using “Metabochip”: early result
I. Prokopenko1,2, A. Mahajan3, V. Lagou1,2, N. Robertson1,2, W. Rayner1,2,  
A. Kumar1, C.J. Groves2, D. Buck1, A. Doney4, C.N.A. Palmer5, A.D. Morris5, 
A.P. Morris1, C.M. Lindgren1,2, M.I. McCarthy1,2, for the DIAGRAM 
consortium;
1WTCHG, University of Oxford, 2OCDEM, University of Oxford, United 
Kingdom, 3Institute of Genomics and Integrative Biology, CSIR, Delhi, 
India, 4Department of Medicine & Therapeutics, Ninewells Hospital & 
Medical School, Dundee, United Kingdom, 5Biomedical Research Institute, 
University of Dundee, Ninewells Hospital & Medical School, Dundee, 
United Kingdom.
Background and aims: Over 30 common variant signals influencing type 2 
diabetes (T2D)-susceptibility have been identified so far. However, replica-
tion efforts to date have focused on limited numbers of the most strongly-as-
sociated signals and have failed to exploit fully the information provided by 
the well-powered genome wide association (GWA) meta-analyses available 
for stage 1 discovery. The Metabochip - a custom iSELECT array containing 
~195,000 SNPs - has been designed to support large-scale follow-up of puta-
tive associations for T2D and other metabolic and cardiovascular traits, and 
to enable the fine-mapping of known loci.
Materials and methods: This analysis is based on Metabochip data from 
3,185 T2D cases and 3,569 controls (from the UK T2D Genetics Consortium 
sample recruited in Tayside, Scotland) that were successfully called (Gencall 
v1.1) and passed quality control (QC). Of 185,802 Metabochip SNPs passing 
QC, 4,821 were included in this analysis because they capture the top ~5,000 
independent autosomal signals from the DIAGRAM (v3) GWA meta-analy-
sis (12,057 T2D cases, 56,071 controls, all of European-descent). Association 
analysis was performed under an additive model with adjustment for 3 prin-
cipal components to account for sample substructure.
Results: We observed directional consistency for all published T2D-loci (and 
for 11 novel autosomal loci derived from the most recent DIAGRAM+ con-
sortium effort) including variants at TCF7L2 (P<10-14); SLC30A8, KCNQ1, 
FTO (P<10-4 ); KCNJ11 and IRS1 (P<5x10-3). We compared overall patterns 
of replication between the DIAGRAM stage 1 discovery data and the UK-
T2DGC follow-up results for 4,333 independent SNPs represented in both 
samples. Of these, 2,468 SNPs showed directionally consistent effects (bi-
nomial p<10-19) with 217 of the 2,468 also showing nominal replication (i.e. 
p<0.05, same effect direction). Only 79 of 4,333 SNPs had p<0.05 in the op-
posite direction (binomial p<10-18). Despite the modest size of this first fol-
low-up sample (compared to the discovery set), joint analysis of DIAGRAM+ 
Stage 1 and UKT2DGC Stage 2 data revealed several signals near to or ex-
ceeding genome-significance, including a locus near ARL15 (ADP-ribosyla-
tion factor-like 15) on chromosome 5p15 (UKT2DGC P=10-4, meta-analysis 
P=3.2×10-8, OR=1.11[95%CI 1.07-1.16]).
Conclusion: These preliminary data obtained from the Metabochip are con-
sistent with a long tail of common variant association signals of modest ef-
fect contributing to T2D-susceptibility. Metabochip-genotyping is currently 
underway in over 30,000 T2D cases and 50,000 controls of European descent. 
Follow-up on this scale should add considerably to the tally of proven T2D-
susceptibility loci. Even in this modestly scaled initial follow-up effort, we 
have identified one novel T2D-susceptibility signal mapping to chromosome 
5p15.
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Fine-scale mapping of type 2 diabetes susceptibility loci by imputation 
and conditional analysis
S. Wiltshire1,2, C.M. Lindgren1, A.P. Morris1, I. Prokopenko1,2,  
M.I. McCarthy1,2;
1Wellcome Trust Centre for Human Genetics, Oxford, 2Oxford Centre for 
Diabetes, Endocrinology and Metabolism, United Kingdom.
Background and aims: Up to 30 T2D susceptibility genes have been identi-
fied in the past few years from genome-wide association scans (GWAS). In 
this study, we focus on three regions implicated by GWAS in European popu-
lations - CDKAL1, CDKN2A/B, and FTO. To facilitate identification of the 
causative variants within these genes, we have undertaken fine-scale mapping 
at greater marker density, and explore the possibility of multiple causative 
signals in each gene.
Materials and methods: We used 1924 T2D cases and 2938 controls previ-
ously studied in a 500K GWAS by the Wellcome Trust Case Control Con-
sortium (WTCCC). We used imputation (with IMPUTEv2) to estimate the 
genotypes of an additional 3157 SNPs (frequency>1%) across these regions. 
This method uses a single, hierarchical, approach to combine a primary refer-
ence set of 112 phased CEU chromosomes from the 1000 Genomes project 
(August 2009 release) with a secondary panel of an additional 298 phased 
CEU and Tuscan chromosomes from the HapMap Phase 3 project (release 
2). We analysed each SNP under an additive genetic model using SNPTEST 
v1.1.4. We performed conditional analyses, adjusting for the most significant 
SNP at each stage using a forward selection strategy.
Results: At CDKAL1 we identified a cluster of imputed SNPs (the best being 
rs10440833, risk-allele frequency (RAF) =0.32, allelic OR=1.28, P=7.3x10-
8), with stronger T2D association than the previously reported lead SNPs 
(rs9465871 and rs10946398) from the WTCCC GWAS. This cluster is fo-
cussed on a 27kb haplotype block flanked by rs9465871 and rs10946398. We 
found a second independent signal at imputed SNP rs6930283 (P=0.0005, 
RAF =0.32) 100kb 5’ to the primary signal. In CDKN2A/B, the most signifi-
cant signal from our imputed data was seen at rs7018475 (RAF=0.30, allelic 
OR=1.37, P=1.2x10-9), at the 3’ end of the 9kb haplotype block containing 
rs10811661, the previously reported lead SNP. Rs10811661 remains associ-
ated (with P=0.004) after accounting for rs7018475, suggesting it represents 
a largely independent effect. At FTO, our imputed genotypes provide further 
evidence for association with BMI (in T2D cases, age & sex-adjusted) across 
the 50Kb haplotype block implicated in the WTCCC GWAS. The best signal 
in our study comes from imputed SNP rs11646715 (P=3.5x10-6). Condition-
ing the analysis on rs11646715 completely abolishes the evidence for asso-
ciation (P>0.2 at all SNPs) across the region. The strongest association with 
T2D from our imputed data in FTO comes from rs1421086 (allelic OR=1.27, 
P=1.8x10-8), comparable with previously identified lead SNPs rs7193144, 
rs8050136 and rs9939609. Conditioning association analysis on imputed 
SNP rs1421086, or these three lead SNPs, largely ablates the evidence for T2D 
association across the 50Kb haplotype, with the best residual signal being 
imputed SNP rs1861867 (P=0.001-0.005) in each case.
Conclusion: Imputation using data from the 1000 Genomes and HapMap3 
projects is a valuable tool for fine-mapping loci, identified from GWAS, with 
near complete coverage of common variants. Using this approach, we have 
more precisely localised the causative variants in CDKAL1, CDKN2A/B and 
FTO. These newly identified imputed variants are candidates for further gen-
otyping and functional assessment.
Supported by: The Wellcome Trust and the European Union (ENGAGE)
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Insights into glucokinase regulatory protein regulation from the cellular 
and kinetic characterisation of rare coding variants
M.G. Rees1,2, C. Turner2, F.M. Facio2, N.L. Beer1, NISC Comparative 
Sequencing Program, M.I. McCarthy1, L.G. Biesecker2, A.L. Gloyn1,  
F.S. Collins2;
1Oxford Centre for Diabetes Endocrinology & Metabolism, United 
Kingdom, 2National Institutes of Health, Bethesda, USA.
Background and aims: Genes containing common variants of significant 
phenotypic effect may also harbour rare variants (Minor Allele Frequency 
[MAF] <5%) of large effect. The common P446L glucokinase regulatory pro-
tein (GCKR; protein name GKRP) variant is associated with decreased risk of 
type 2 diabetes, lower fasting glucose and insulin, and increased triglyceride 
levels. GKRP binds and inhibits glucokinase (GCK) in the liver, sequestering 
GCK in the nucleus in the fasting state. Increased glucose levels trigger GCK 
dissociation from GKRP, nuclear GCK export, and GCK activation. Func-
tional analysis suggests the P446L variant acts through decreasing F6P-medi-
ated inhibition of GCK, increasing liver glucose uptake and disposal. The aim 
of this study was to identify and functionally characterise rare GCKR variants 
for cellular localization and GCK inhibition to provide insight into mutation 
severity and direct both clinical and genetic follow-up.
Materials and methods: Exonic GCKR sequencing was performed in 664 
individuals from the multi-ethnic NIH ClinSeq project using standard meth-
odology. Nonsynonymous variants (published and novel) were introduced 
into a YFP-tagged GKRP expression plasmid. Wild-type (WT) and variant 
YFP-GKRP were transiently transfected into HeLa cells and cellular localisa-
tion assessed microscopically 24 hours post-transfection. CFP-tagged GCK 
was co-transfected with YFP-GKRP to assess GCK interaction and nuclear 
sequestration. Recombinant human GCK and both WT and Q234P GKRP 
were generated. Q234P-GKRP and WT-GKRP inhibition of GCK activity 
and regulation by F1P and F6P were determined spectrophotometrically us-
ing an NADP+ coupled assay.
Results: Twelve (nine novel) nonsynonymous variants were identified. Seven 
variants were observed in only one individual. Excluding P446L, variants had 
MAFs ranging from 0.2-1% in the ClinSeq cohort. Of novel variants, only one 
(Q234P) was identified in the 1000 Genomes project. WT YFP-GKRP local-
ized primarily to the nucleus and was necessary and sufficient to sequester 
CFP-GCK to the nucleus. Of 18 variants tested, 12 (including P446L) had 
increased cytoplasmic: nuclear fluorescence compared to WT. Of the 12 vari-
ants with increased cytoplasmic fluorescence, six (including Q234P) did not 
sequester CFP-GCK to the nucleus. Kinetic analysis showed no difference in 
inhibition of GCK activity by WT- or Q234P-GKRP over a glucose concen-
tration range of 0-100mM. However, response to 20-500µM F1P (n=38; 5x10-
9<p<0.02) and 10-500µM F6P (n=41; 1x10-6<p<0.02) were both significantly 
diminished with Q234P-GKRP.
Conclusion: A large proportion (67%) of nonsynonymous GCKR vari-
ants disrupt nuclear localization and/or interaction with GCK in a cellular 
context. Since there is no apparent variant clustering it suggests that many 
changes in GKRP primary structure can affect global folding and three-di-
mensional structure. Prioritisation of variants for additional genetic analysis 
and targeted phenotyping may be aided not only by determining the MAF in 
appropriate ethnic groups but also by selecting variants such as Q234P that 
show both altered GCK sequestration and kinetic parameters.
Supported by: NIH GPP; MRC
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Exercise-induced reduction in liver fat is accompanied by improvements 
in vascular function in non-alcoholic fatty liver disease
C.J. Pugh1, H. Jones1, V.S. Sprung1, G.J. Kemp2, A. Irwin3, V.L. Adams2,  
W.E. Bimson2, N.T. Cable1, D.J. Green1, P. Richardson4, D.J. Cuthbertson3;
1Research Institute for Sport and Exercise Science, Liverpool John Moores 
University, 2Magnetic Resonance and Image Analysis Research Centre 
(MARIARC), University of Liverpool, 3Department of Diabetes and 
Endocrinology, University Hospital Aintree, Liverpool, 4Departement of 
Haemotology, Royal Liverpool University Hospital, United Kingdom.
Background and aims: Non-Alcoholic Fatty Liver Disease (NAFLD), the he-
patic manifestation of the metabolic syndrome is characterised by the accu-
mulation of triglycerides in the liver and is associated with liver-related mor-
bidity and mortality as well as increased cardiovascular risk. Exercise training 
is recommended as a therapeutic technique to reduce hepatic fat in NAFLD 
patients, yet the efficacy of exercise training remains equivocal. Flow medi-
ated dilation (FMD), the increase in conduit artery diameter in response to 
increases in flow, provides information regarding endothelial cell health and 
is an early barometer of cardiovascular disease. Endothelial function has been 
shown to improve with exercise training in young healthy, older sedentary 
and obese individuals but has not been investigated in the NAFLD popula-
tion. Therefore, the aim of this study was to examine the effect of regular 
exercise on intrahepatocellular lipid (IHCL) content and endothelial function 
in NAFLD patients.
Materials and methods: 6 sedentary NAFLD patients aged 56±9 yrs under-
went a 16-week supervised exercise training program (30-45mins, 3-5 times 
per week). Whole body magnetic resonance imaging with proton magnetic 
resonance spectroscopy was used to determine IHCL levels prior to and fol-
lowing training (n=5). Fasting glucose, lipids, AST and ALT, brachial artery 
FMD, responses to glyceryl trinitrate (GTN) and cardiorespiratory fitness 
(VO2peak) were also assessed before and after training. Differences between 
baseline and post-training data were analysed using paired t-tests. Data are 
described as mean±SD.
Results: IHCL significantly reduced by 28.7% following exercise training 
compared to baseline (21.4±13.7 vs 17.2±13.8%; P=0.01), this was accompa-
nied by a significant improvement in FMD (7.3±3.8% vs 3.8±1.6%, P=0.02). 
Liver enzymes also significantly improved following exercise training; ALT 
was reduced to 28±6U/l from 39±9U/l at baseline (P=0.008). Fitness im-
proved by 20.2% (23.50±4.56 vs 28.52±8.82ml/min/kg; P=0.06) and body 
mass (79.6±10.9 vs 77.2±12.0kg; P=0.04) and AST (P=0.01) were significantly 
reduced following exercise training. No significant changes in GTN or lipid 
profiles were evident after exercise training.
Conclusion: This is the first study to demonstrate that both IHCL and en-
dothelial function significantly improve following exercise training in 
NAFLD patients. This indicates that regular exercise has concomitant thera-
peutic effects on both excess hepatic fat and cardiovascular disease in these 
high risk patients. The exercise-mediated improvement in IHCL and FMD 
was accompanied by clinically significant reductions in liver enzymes and 
body mass. These data strongly support the efficacy of exercise training as a 
non-pharmacological management strategy in NAFLD and suggest as well as 
improving liver function, exercise may decrease the risk of heart disease and 
stroke in these patients.
Supported by: an EFSD Clinical Research Grant
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Study of GPIHBP1 expression in human adipose tissue, correlation with 
lipid parameters and regulation by rosiglitazone
S. Charriere1,2, A. Tchernof3, C. Debard1, M. Laville4, P. Moulin2, H. Vidal1;
1INSERM unité 870, Oullins, 2Fédération d’endocrinologie du pôle est, 
Hospices Civils de Lyon, France, 3Centre de recherche en endocrinologie 
moléculaire et oncologique, Québec, Canada, 4Centre de recherche en 
nutrition humaine, Lyon, France.
Background and aims: Glycosyl phosphatidyl inositol HDL binding 1 (GPI-
HBP1) gene encodes for a new endothelial surface binding site for lipoprotein 
lipase (LPL), the key enzyme for intravascular lipolysis of triglyceride-rich 
lipoproteins. Mice lacking GPIHBP1 manifest severe hyperchylomicronemia 
with lipolysis defect. Similarly to LPL, GPIHBP1 is expressed in adipose tis-
sue, skeletal muscle and heart. GPIHBP1 expression is stimulated by rosigli-
tazone (PPARγ agonist) in mice. GPIHBP1 involvement in triglyceride (TG) 
metabolism is not clearly established in Humans. The aim of this study is to 
investigate GPIHBP1 expression levels in human adipose tissue of healthy 
and type 2 diabetic subjects, its correlation with lipid parameters, and its po-
tential regulation by rosiglitazone.
Materials and methods: We studied GPIHBP1 expression by quantitative 
RT-PCR in sub-cutaneous adipose tissue (SCAT) and/or visceral adipose tis-
sue (VAT) biopsies of 20 healthy subjects and of 17 type 2 diabetic subjects 
after 12 weeks of placebo or rosiglitazone (4 mg/day).
Results: In healthy subjects, GPIHBP1 is expressed in both SCAT and VAT, 
with a significant correlation between the 2 tissues (R2=0.49, p=0.001). We 
find an inverse significant correlation between TG and GPIHBP1 expres-
sion in SCAT (R2=0.31, p=0.011) (Figure) and in VAT (R2=0.26, p=0.021). 
Conversely, HDLc is positively correlated with GPIHBP1 expression only 
in SCAT (R2=0.25, p=0.026) (Figure) (VAT: R2=0.11, p=0.144). Other lipid 
parameters, age and body mass index are not significantly associated with 
GPIHBP1 expression neither in SCAT or VAT. Additionally, GPIHBP1 ex-
pression is correlated with TG in type 2 diabetic subjects in SCAT (R2 =0.41, 
p=0.034). Moreover, its expression is significantly increased by rosiglitazone 
compared to placebo (+ 32.6 %, p=0.022).
Conclusion: We show for the first time in Humans that GPIHBP1 is ex-
pressed in both SCAT and VAT and that its expression is inversely correlated 
with TG in healthy and type 2 diabetic subjects and regulated by a PPARγ 
agonist. These results suggest an important role for GPIHBP1 in TG metabo-
lism in Humans.
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Cardiac lipid content increases upon exercise-induced elevation of 
plasma fatty acid concentrations
L. Bilet1, T. van de Weijer1, M.K.C. Hesselink2, J. Glatz3, H. Lamb4, M. Schär5,  
J. Wildberger6, M.E. Kooi6, P. Schrauwen1, V. Schrauwen-Hinderling1,6;
1Human Biology, MUMC, Maastricht, 2Human Movement Sciences, 
MUMC, Maastricht, 3Molecular Genetics, MUMC, Maastricht, 4Radiology, 
Leiden University Medical Center, Maastricht, Netherlands, 5Philips
Healthcare, Cleveland, USA, 6Radiology, MUMC, Maastricht, Netherlands.
Background and aims: Increasing evidence suggests that excessive lipid ac-
cumulation in cardiac tissue hampers cardiac function, predisposing to car-
diomyopathy and heart failure. Cardiac energy status (PCr/ATP) has strong 
prognostic value in heart failure patients and might be an early marker of dis-
turbed cardiac metabolism, and it has been suggested that cardiac lipid accu-
mulation reduces the energy status. We have previously shown that elevated 
levels of circulating FA, induced by exercise in the fasted state, lead to in-
creased levels of lipids in non-active skeletal muscle. However, it is unknown 
if the heart responds similarly. Here, we aimed to investigate if elevating 
plasma FA by exercise results in an increased IntraCardiomyoCellular Lipid 
(ICCL) content, and if this influences cardiac function and energy status.
Materials and methods: Nine male subjects (age: 25 ± 1.2 y, BMI: 23.0 ± 1.0 
kg/m2) underwent proton cardiac Magnetic Resonance Spectroscopy (1H-
MRS) (Intera, 1.5T, Philips Healthcare) in the morning in the fasted state 
to determine ICCL. Subsequently, subjects cycled for two hours at 50% of 
maximal performance. ICCL was measured directly after exercise and again 
four hours post-recovery, together with systolic function (by multi-slice cine-
MRI) and cardiac energy status (by 31P-MRS). All subjects underwent this 
procedure twice, once while fasted, and once while ingesting glucose during 
both exercise and recovery (bolus: 1.4g/kg, 8 x 0.35 g/kg), which has previ-
ously been shown to prevent elevation of plasma FA levels. For cardiac 1H-
MRS, a 6 cm3 VOI was placed in the septum of the heart (PRESS, TR = 4s, TE 
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= 26ms, n = 128). Signal acquisition was ECG-triggered to end-systole and 
respiratory-gated using a pencil beam navigator. Lipid content is expressed 
as percentage of the CH2 peak, relative to the unsuppressed water signal. For 
cardiac 31P-MRS, ISIS was used for localization to the left ventricle (TR = 
3.6 s, n = 192).
Results: Plasma FA concentrations were increased three-fold during exer-
cise and nine-fold during recovery in the fasted condition compared with 
the glucose condition (p<0.01). Fat oxidation was significantly higher in the 
fasted condition compared with the glucose-supplemented condition. ICCL 
was elevated at the end of the fasted test day (from 0.26 ± 0.04 to 0.44 ± 0.04 
%, p<0.01), while it did not change when glucose supplementation was given 
(from 0.32 ± 0.03 % to 0.26 ± 0.05%, p=0.3). There were no changes in ICCL 
directly after acute exercise. Furthermore, PCr/ATP was decreased by 32% 
in the high plasma FA condition compared with the low FA condition (n=6, 
P=0.014). However, in the high FA condition, the ejection fraction post-re-
covery was higher compared with the low FA condition (63 ± 2 % vs 59 ± 2 
%, p=0.018).
Conclusion: The increase in ICCL in the fasted condition suggests that plas-
ma FA concentrations play an important role in determining ICCL. Further-
more, increased ICCL was associated with a decreased cardiac energy status 
(lower PCr/ATP), which is in line with the “lipotoxic” action of cardiac lipids. 
However, ICCL seems not to be the main determinant of cardiac function.
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Ectopic lipid accumulation in the heart of severe obese patients: 
relationship to cardiac function and visceral fat 
B. Gaborit1,2, F. Kober3, A. Jacquier4, T. Cuisset2, S. Boullu1, M.-C. Alessi2,  
K. Clement5, M. Bernard3, A. Dutour1,2;
1Department of Endocrinology, Metabolic Diseases, and Nutrition, CHU 
Nord, Marseille, 2Inserm U626, Marseille, 313005, Centre de Résonance 
Magnétique Biologique et Médicale (CRMBM) UMR CNRS, Marseille, 
4Centre de Résonance Magnétique Biologique et Médicale (CRMBM) UMR 
CNRS Marseille, 5Institut national de la santé et de la recherche médicale, 
Paris, France.
Background and aims: Epicardial fat is an ectopic fat depot which develop-
ment is associated with coronaropathy. Its closed anatomic situation to the 
adjacent myocardium allows local paracrine interaction, suggesting that EF 
could have a functional role in obesity related cardiomyopathy. Myocardial 
lipid deposition is also a marker of ectopic fat accumulation, that could lead 
to impaired myocardial function, as suggested by preliminary results lim-
ited to midly obese patients. In this study, we quantified with a 70 cm bore 3 
teslas MRI, EF volume (EFV) and myocardial triglyceride content (MTGC) 
in morbid obese patients, in order to determine whether these ectopic fat de-
pots accumulate similarly, are linked to metabolic disorders or to myocardial 
function.
Materials and methods: 57 subjects with normal LV function and no coro-
nary artery disease, (33 lean, and 24 obese patients (9 with type 2 diabetes) 
(BMI= 21.4 ± 2 and 42.3 ± 6 kg/m2)) were studied by MRI, and underwent 
anthropometric, biological and visceral abdominal fat (VAT) assessment. 
EFV was assessed volumetrically, and MTGC using H1 spectroscopy.
Results and conclusions: EFV and MTGC were positively correlated 
(r=0.47, p<0.0001) even after VAT was accounted for (p=0.005), and were 
both strongly correlated with age, BMI, waist circumference (WC), and VAT. 
EFV was the only ectopic depot negatively correlated with thigh circumfer-
ence/BMI ratio (r=-0.68, p=0.0002), suggesting that the development of EF 
is related to the lack of increase of subcutaneous fat with weight gain. We 
observed that the two cardiac depots did not accumulate similarly, as the ra-
tio EFV/MTGC increased with diabetes and decreased with physical activity. 
Moreover, EFV and MTGC statistically increased between lean and obese 
patients (p=0.002, p=0.006), and there was a more twofold increase in EFV 
between obese and diabetics (123 ± 11 vs 240 ± 46 mL, p=0.003). EFV and 
MTGC were both strongly associated with metabolic syndrome (p<0.0001), 
and with metabolic risk markers (triglycerides r=0.59, p<0.0001; r= 0.35, 
p=0.01, HOMA-IR r=0.44, p<0.003; r= 0.38, p=0.02, and CRP r=0.39, p<0.03 
and r= 0.49, p=0.005, respectively). However, when including VAT and EFV 
or MTGC together, only VAT remained statistically associated with metabol-
ic parameters (p<0.01). Furthermore, EFV and MTGC were associated with 
parameters of cardiac function. Interestingly, MTGC was the only independ-
ent parameter associated with normalized end-diastolic and systolic volumes 
(r=-0.37, p=0.02 and r= -0.42, p=0.01), cardiac index (r=-0.34, p=0.04), and 
normalized stroke volume (r=-0.34, p= 0.03). To conclude, the developement 
of EFV and MTGC is not similar. EFV and MTGC are linked to metabolic 
disorders, but VAT remains the best predictor of metabolic risk. Lastly, our 
work reinforces the importance of cardiac steatosis, in that MTGC is associ-
ated with early myocardial dysfunction. It suggests that in an earlier stage of 
non ischemic cardiomyoapthy lipid oversupply to cardiomyocytes may lead 
to lipotoxic injury on myocardium.
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Role of pancreatic fat in beta cell dysfunction and diabetes
I. Lingvay1, J.L. Legendre1, B. Adams-Huet2, S. Zhang2, L.S. Szczepaniak3;
1Endocrinology, University of Texas Southwestern Medical Center, Dallas, 
2Clinical Sciences, UT Southwestern, Dallas, 3Cardiology, Cedar-Sinai 
Medical Center, Los Angeles, USA.
Background and aims: Fat accumulation in the beta-cells is thought to con-
tribute to the pathogenesis of beta-cell dysfunction and the development of 
diabetes, at least in animal models. We explored the relevance of this hypoth-
esis in the pathogenesis of diabetes in humans by evaluating the relationship 
between total pancreatic fat content (panTG) and insulin secretion in vivo in 
human volunteers.
Materials and methods: We enrolled 91 volunteers, with and without dia-
betes, with an average age of 41.2 years, and body mass index (BMI) of 32.9 
kg/m2. PanTG and visceral fat area were measured in vivo by magnetic 
resonance spectroscopy and imaging, respectively; beta-cell function was 
measured using a frequently sampled glucose tolerance test. Acute insulin 
response (AIR) is a measure of first phase insulin secretion, while the disposi-
tion index (DI) is a measure of insulin secretion adjusted for the prevailing 
insulin sensitivity. DI is a good indicator of disease progression, as it decreas-
es from normal (>1000) in patients with normal glycemia, to very low (<400) 
in those who have progressed to diabetes. Non-normally distributed variables 
were transformed. To compare panTG across DI groups while adjusting for 
age and BMI we used ANCOVA analysis. Multivariate regression analysis was 
performed for the dependent variable AIR, most representative models are 
shown in the figure.
Results: PanTG increased significantly across groups as DI worsened, even 
after adjusting for age and BMI (p=0.01). PanTG was highest in the group 
with the lowest DI, at 7.37 (+/-5.9) f/w% (panel A). PanTG, along with age, 
hip/waist ratio, and BMI were significant independent predictors of AIR 
(panel B - model 2). Visceral fat area was not a significant predictor of AIR 
when analyzed along with the same variables (panel B - model 3).
Conclusion: PanTG content is a significant contributor to beta-cell dysfunc-
tion, and ultimately development of diabetes, independent of visceral fat.
Supported by: K23 RR 024470 (IL), UL1 RR 024982 (IL, BAH, SZ), R01 DK 
081524 (LSS)
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Altered microRNAs expression is associated with insulin resistance 
status in high fat diet fed mice
S. Calderari1, M. Diawara1, S. Dubois1, J.F. Fearnside2, P.J. Kaisaki2,  
C.M. Lindgren2, D. Gauguier1,2;
1Centre de Recherche des Cordeliers - UMRS 872, Paris, France, 2The 
Wellcome Trust Centre for Human Genetics, Oxford, United Kingdom.
Background and aims: Disturbances of microRNAs (miRs) expression or 
function play a role in several aspects of metabolism and glucose homeos-
tasis. We have previously shown alterations in expression of miRs in insulin 
target tissues in the GK rat model of spontaneous type 2 diabetes, when com-
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pared to normoglycaemic control strains. Investigations in our group in con-
trol mouse strains have demonstrated that high fat diet (HFD) feeding pro-
motes the development of insulin resistance, obesity and fatty liver in 129S6 
and C57BL6/J mice, whereas BALB/c are resistant to these experimentally 
induced phenotypes. The objective of the present work is to further study the 
implication of miRs in insulin resistance in two insulin target tissues (liver 
and adipose tissue) in these mouse strains.
Materials and methods: At five weeks, male mice of C57BL6/J, BALB/c and 
129S6 were fed a normal carbohydrate diet (CHD) containing 5% fat, 19% 
protein, and 3.5% fibre or 40% HFD containing 32% lard oil and 8% corn 
oil ad libitum. At five months, liver and white adipose tissue were dissected 
(n=3-5), total RNA extracted and the expression of miR-125a, miR-27a, miR-
222 and miR-29a were determined using ABI’s taqman microRNA assays.
Results: 1/ When fed CHD, the expression of the four miRs was significantly 
higher in adipose tissue than in liver in the three mouse strains. Only miR-
29a showed lower expression (p<0.05) in adipose tissue than in liver in 129S6 
mice. 2/ When fed CHD, expression of miRs were highly variable between 
the 3 strains in both liver and adipose tissue. 3/ In HFD-fed 129S6 mice, ex-
pression of both miR-125a and miR-27a was upregulated in both liver (x4.6, 
p<0.05 and x2.1) and adipose tissue (x2.5, p<0.05 and x1.3). Tissue-specific 
miR over-expression was observed in liver for MiR-222 (x3.4, p<0.05) and in 
adipose tissue for miR-29a (x1.5). 4/ In HFD-fed C57BL6/J mice, miR-125a 
expression was not altered neither in liver nor adipose tissue. In response to 
HFD, expression of miR-27a was increased in liver (x2.4) and decreased in 
adipose tissue (-2.3). MiR-222 was over-expressed in liver (x3.4, p<0.05) and 
not altered in adipose tissue. Expression of miR-29a was unaffected in liver 
and decreased in adipose tissue (-1.6). 5/ In HFD-fed BALB/c mice, expres-
sion of miR-125a and miR-222 was not altered neither in liver nor adipose tis-
sue. Expression of miR-29a was unchanged in liver and increased in adipose 
tissue (x1.4). Expression of miR-27a was unchanged in liver, but decreased in 
adipose tissue (-1.6).
Conclusion: Our results demonstrate the complex tissue- and strain-specific 
regulation of miRNA expression in experimentally induced insulin resist-
ance, obesity and fatty liver disease. We observed a distinct correlation be-
tween miR altered expression and the metabolic status of HFD-fed mice. The 
129S6 strain, very sensitive to HFD-induced glucose intolerance and obesity, 
exhibited miR over-expression in 75% of cases, whereas BALB/c, which is 
relatively resistant to HFD, showed miR altered expression in only 25% of 
cases. Our results provide strong evidence supporting a role of miR on im-
paired glucose homeostasis in models of spontaneous (GK) and experimen-
tally induced (129S6) insulin resistance.
Supported by: Wellcome Trust and FGENTCARD
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Adeno-associated-mediated nerve growth factor gene transfer prevents 
the development of heart microangiopathy and cardiomyopathy in mice
C. Emanueli1, A. Caporali1, L. Zentilin2, P. Madeddu1, M. Giacca2,  
M. Meloni1;
1Experimental Cardiovascular Medicine, University of Bristol, United 
Kingdom, 2Molecular Medicine Laboratory, International Centre for 
Genetic Engineering and Biotechnology, Trieste, Italy.
Background and aims: Diabetes mellitus (DM) can cause cardiac dysfunc-
tion and heart failure independently of other risk factors like hypertension 
and myocardial infarction. The neurotrophin nerve growth factor (NGF) ex-
erts cardioprotective effects but it is downregulated in the diabetic heart. The 
present study challenged the hypothesis that NGF gene transfer (GT) could 
prevent diabetes-induced cardiac dysfunction.
Materials and methods: Type-1 DM was induced in CD1 mice by strepto-
zotocin injection (40 mg/Kg/day IP for five days). Two weeks later, GT with 
an adeno-associated vector serotype 2 carrying human NGF in the expres-
sion cassette (AAV-2-hNGF) or with an empty vector (AAV-2-βGal) was per-
formed. Constructs were delivered into the left ventricle (LV) by 4 injections 
(total dose of 1x1011 pfu). Age-matched normoglycemic mice injected with 
AAV-2-βGal were used as controls.
Results: X-Gal staining confirmed successful GT of LV. Moreover, hNGF 
transgene expression was detected in plasma by ELISA at 12 weeks. Echocar-
diography (Visual Sonics) at 12 weeks after GT showed a deterioration of 
systolic function in diabetic mice (LV ejection fraction: 64.6±3.8 vs 73.1±6.9% 
in healthy controls; LV fractional shortening: 35.3±2.8 vs 42.5±6.3%; P<0.05 
for both comparisons). In contrast, AAV-2-hNGF improved both LVEF and 
LVFS (113% and 121% respectively) as compared to diabetic controls (P<0.05 
for both comparisons; N.S. vs healthy). Moreover, AAV-2-hNGF improved LV 
systolic pressure (LVSP) and contractility (expressed as dP/dtmax and dP/dtmin) 
measured by Millar catheter (LVSP: 76±4 vs 61±5 mmHg in diabetic con-
trols; dP/dtmax and dP/dtmin: 141% and 149% of diabetic controls, respectively; 
P<0.01 for all comparisons). In addition, AAV-2-hNGF prevented enlarge-
ment of end-diastolic LV chamber volume (74±11 vs 89.1±13 µl in diabetic 
controls; P<0.05) and maintained the end-diastolic LV internal diameter 
(4.1±0.3 vs 4.4±0.3 µl in diabetic controls; P<0.05). Analyses in histological 
heart sections at 12 weeks indicated that diabetes induced microvessel rar-
efaction in the myocardium. By contrast, AAV-2-hNGF preserved capillary 
(measured as isolectin-B4 positive vessels) and small (diameter <50μm) ar-
teriole (measured as isolectin-B4 and α-smooth muscle actin double posi-
tive vessels) densities in the hearts of diabetic mice (4255±222 vs 3440±155 
capillaries/mm2 in diabetic controls; P=0.05; 50±15.8 vs 37±13.9 arterioles/
mm2 in diabetic controls; P=0.05). Finally, as measured by fluorescent micro-
spheres, DM reduced LV blood flow (0.39±0.1 vs 0.59±0.1 mL/min/g of tissue 
in healthy controls; P=NS), which was prevented by AAV-2-hNGF (0.69±0.1 
mL/min/g of tissue; P=0.05 vs diabetic controls).
Conclusion: These results provide evidence that prolonged NGF overexpres-
sion prevents LV dysfunction and heart failure in the mouse diabetic heart 
and it also preserves cardiac microvasculature in the settings of diabetic car-
diomyopathy.
Supported by: an EFSD/JDRF/Novo Nordisk grant
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VEGF and CD36 are potential players in the crosstalk between 
perivascular fat and human smooth muscle cells
R. Schlich, D. Lamers, H. Sell, J. Eckel;
Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes 
Center, Düsseldorf, Germany.
Background and aims: The increase of fat mass in obesity is an important 
risk factor for the development of atherosclerosis. Specifically, perivascular 
fat in connection with obesity and the metabolic syndrome might be an acti-
vator of inflammation and dysfunction of the vessel wall. In previous studies 
we could show that adipocyte-conditioned media (CM) induced prolifera-
tion and migration of human smooth muscle cells with a concomitant in-
crease in ICAM-1 expression. The combination (CMOA) of CM and oleic 
acid (OA) enhanced the proliferation in a synergistic way. CMOA induced 
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iNOS Expression, NO production and variable pro-inflammatory and pro-
liferative signalling pathways. The aim of this study is to identify factors and 
mechanism, which are responsible for the effect of CM and the synergism 
with OA on the proliferation of smooth muscle cells.
Materials and methods: CM was generated from human in vitro differen-
tiated human adipocytes and analysed for its content in adiponectin, IL-6 
and VEGF. Proliferation of human coronary artery smooth muscle cells was 
measured via BrdU incorporation into DNA.
Results: The content of VEGF correlated significantly with the proliferative 
effect of CM (n=17, r=0.79, p=0.002) while adiponectin correlated negatively 
with CM-induced proliferation (n=22, r=-0.465, p=0.029). VEGF alone 
showed a 2.5-fold augmentation of proliferation and the combination of 
VEGF and OA (VEGFOA) act additive (5-fold). Incubation with CMOA in-
duced a 2-fold increase of VEGF concentration compared with CM or OA 
alone, indicating that smooth muscle cells significantly contribute to prolif-
eration by releasing VEGF for an autocrine/paracrine stimulation. Blocking 
VEGF with a specific antibody reduced the proliferative impact of CM, VEGF, 
OA, and VEGFOA significantly to control levels (CM=97 ±5 %, VEGF=106 
±5 %, OA=90±9 %, VEGFOA= 125±12 %). In contrast, VEGF-blocking was 
not sufficient to reduce CMOA-induced proliferation to control levels (from 
569±40 % to 262±30 %). As CM and VEGF both significantly increase the 
expression of CD36 and as CM -treatment predisposes for increased lipid 
accumulation after OA addition, we propose that CD36 might be an addi-
tional player in CMOA-induced proliferation in smooth muscle cells. CD36 
belongs to the family of scavenger receptors and is also identified as a fatty 
acid transporter. Moreover it has been speculated, that CD36 might play a 
pro-atherogenic role as CD36 interacts with VEGF and its receptor. Silencing 
of CD36 reduced the proliferative effect of OA and VEGF to control levels 
(OA= 118±19 %, VEGF= 80±6 %) while CM- and CMAO-induced prolif-
eration remained significantly higher compared to control (CM=164±18 %, 
CMOA=257±30 %). Combining the silencing of CD36 with VEGF block-
ing, CMOA-induced proliferation could be reduced to only 150±7 % of the 
control level.
Conclusion: In this study we identified VEGF as an important factor for the 
proliferative effect of CM. The increase of CD36 expression by treatment with 
CM and VEGF could represent a key mechanism, how CM and OA synergis-
tically increase proliferation and inflammatory signalling in smooth muscle 
cells. Further work is intended to elaborate how increased CD36 and lipid 
accumulation in smooth muscle cells are involved in the crosstalk between 
perivascular adipose tissue and the vessel wall.
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Increased expression of TIMP3 protects against diabetes and 
atherosclerosis
M. Federici1, V. Casagrande1, R. Menghini1, A. Marino1, M. Cavalera1,  
S. Menini2, G. Pugliese2, D. Lauro1, P. Sbraccia1, R. Lauro1;
1Dept. of Internal Medicine, University of Tor Vergata, 2University La 
Sapienza Rome, Italy.
Background and aims: Tissue inhibitor of Metalloproteinase 3 (TIMP3), an 
inhibitor of TNF-alpha Convertase (ADAM17) and other metalloproteinases 
is decreased in atherosclerotic plaque from patients with Type 2 diabetes and 
in tissues of humans and mice affected by obesity.
Materials and methods: Because obesity and atherosclerosis are associ-
ated with increased macrophage accumulation in different tissues, we used a 
transgenic approach under control of CD68 promoter to reconstitute TIMP3 
levels to analyze the effects on metabolic and vascular homeostasis, using 
Diet Induced Obesity (DIO) to analyze the effect on insulin resistance and 
LDLR-/- background combined with atherogenic diet to analyze the effect on 
atherosclerosis. Transgenic (Tg) mice were identified by RT-PCR and con-
firmed by Southern blot. In Tg mice, TIMP3 overexpression was confirmed 
by RT-PCR, Western blot and Reverse Zymography in spleen, liver, periph-
eral blood monocytes and bone marrow derived macrophages, treated or not 
with LPS.
Results: In the DIO model, after 20 weeks of High Fat Diet (HFD), we ob-
served that Tg mice compared with WT littermates showed a significant 
improved glucose tolerance and insulin sensitivity, measured by IPGTT 
and IPITT (p<0.01 for all, n=8 per group); a study of Fluoro-Deoxy-Glu-
cose (FDG) uptake in combination with insulin infusion through Positron 
Emission Tomography scan (FDG-PET scan) revealed increased insulin in-
duced glucose uptake in forelimbs of Tg mice compared with WT littermates 
(p<0.05, n=6 per group). Insulin, leptin, AST and ALT were lower and adi-
ponectin increased in Tg mice compared with WT littermates (p<0.01 for all, 
n=8 per group). CT scan revealed significant reduction of visceral adipose 
tissue in Tg compared with WT littermates (p<0.05; n=3 per group). Histol-
ogy of white adipose tissue (WAT), liver, kidney and aorta showed accumula-
tion of lipids, intense fibrosis and increased inflammatory markers in WT 
compared with Tg mice. Tg revealed also significant reduction in adipose tis-
sue vascularization (CD31 staining, p<0.05); however, mean adipocyte area 
was reduced in Tg compared with WT mice (p<0.01). Expression profiling 
for metabolic and inflammatory genes revealed that Tg compared with WT 
have significant higher levels for Adiponectin/CEBPalpha/PPARgamma/be-
taKLOTHO/FABP4/SOD1 (p<0.01 for all) and lower levels for MCP1/F4/80/
SOCS3/Pref1/GP47/GP67 in WAT. In the liver TG showed increased Il-10 
with decreased G6Pase/Socs3/GP47/GP67/Il-6 in liver (p<0.01 for all, n=5). 
Next we analyzed the effect of Timp3 overexpression in the LDLR-Tg and 
LDLR knockout mice fed Western Diet for 12 weeks. Histology of aortic roots 
from LDLR-Tg mice revealed 60% reduction in plaque surface (p<0.001), re-
duced F4/80, CD3 and nitrotyrosine staining (p<0.01 for all), increased col-
lagen content and no necrotic cores, when compared to LDLR littermates 
(n=5 per group). Gene expression profiles in liver and aorta suggest reduced 
oxidative stress and less activation of inflammatory pathways in LDLR-Tg 
compared to LDLR mice.
Conclusion: Our data indicate that macrophage specific overexpression of 
TIMP3 protects from metabolic inflammation and related metabolic disor-
ders such as insulin resistance, glucose intoleramce and atherosclerosis.
Supported by: Fondazione Roma, Telethon, JDRF, FP7 EU FLORINASH
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Glucagon-like peptide-1 inhibits H2O2-dependent JNK phosphorylation 
and apoptosis in human cardiac progenitor cells
A. Leonardini, L. Laviola, V. Galleggiante, M. Melchiorre, M.R. Orlando,  
A. Natalicchio, S. Perrini, F. Giorgino;
Endocrinology & Metabolic Diseases, D.E.T.O., University of Bari, Italy.
Background and aims: The heart possesses a compartment of multipotent 
cardiac progenitor cells (CPCs), which provides a constant tissue renewal. 
Increased CPC apoptosis has been proposed as a mechanism of myocardial 
dysfunction, leading to heart failure. Glucagon-like peptide-1 (GLP-1) is an 
incretin hormone secreted by the small intestine in response to nutrient in-
gestion. There is growing evidence suggesting that GLP-1 may regulate car-
diac function and promote survival of cardiac cells in environmental stress 
conditions. The aim of this study was to investigate the protective effects of 
GLP-1 on H2O2-induced apoptosis in CPCs isolated from adult human heart 
biopsies, obtained from the auricle in the course of open heart surgery.
Materials and methods: Biopsy-obtained cells showed typical features of 
mesenchymal multipotent cells, including the ability to proliferate up to the 
15th passage, and the differentiation potential toward the osteogenic and 
chondrogenic lineages. Analysis of CD105, c-kit, CD34, CD31, CD133, and 
CD45 by flow cytometry, and lineage-specific intracellular markers by quan-
titative real-time PCR, including GATA-4 and MEF-2C, confirmed that the 
isolated cells represent resident cardiac progenitors. Alpha-MHC transcripts, 
which characterize differentiated cardiac cells, were undetectable. Expression 
and activation levels of the proteins under investigation were evaluated by 
immunoblotting techniques.
Results: Exposure of CPCs to 0.5 mM H2O2 for 20-120 min induced a 2-fold 
increase in cell apoptosis, measured by evaluation of cytosolic oligosomes 
(p<0.05) and cleaved caspase-3 (p<0.05). Exposure to H2O2 induced a 3-fold 
increase in the phosphorylation of Erk1/2 (p<0.05), a 1.5-fold increase in the 
phosphorylation of JNK1/2 (p<0.05) and a 6-fold increase in the phosphor-
ylation of Akt (p<0.05). When JNK activation was inhibited using the specific 
inhibitor SP600125 (10 µM), H2O2-dependent JNK phosphorylation ap-
peared to be prevented, and H2O2-induced apoptosis was decreased by 40% 
(P<0.05). SP600125 also inhibited the phosphorylation of the JNK substrate 
c-jun, but had no effects on the JNK upstream kinases MKK-4 and MKK-7. 
Preincubation of CPCs with 20 nM GLP-1 for 16 h inhibited both H2O2-in-
duced activation of JNK 1/2 (p<0.05 vs. H2O2-treated CPCs) and apoptosis 
(p<0.05 vs. H2O2-treated CPCs). GLP-1 incubation had no evident effect on 
Akt and Erk1/2 phosphorylation in response to H2O2. However, exposure of 
CPCs to GLP-1 (10-20 nM) was associated with a significant increase in the 
phosphorylation of the PKA-dependent transcription factor CREB.
Conclusion: Thus, GLP-1 prevents H2O2-mediated apoptosis in human 
CPCs, at least in part by interfering with the activation of JNK. A direct pro-
survival mechanism in myocardial progenitor cells may contribute to the ob-
served protective effects of GLP-1 on the heart.
Supported by: Eli Lilly & Co.
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Octyl-D-carnosine attenuates atherosclerosis and renal disease in ApoE 
null mice fed a western diet
S. Menini1, C. Iacobini1, C. Ricci1, A. Scipioni1, C. Blasetti-Fantauzzi1,  
A. Giaccari2, E. Salomone2, A. Lapolla3, M. Orioli4, G. Aldini4, G. Pugliese1;
1Department of Clinical Sciences, La Sapienza University, Rome, 
2Department of Endocrinology, Catholic University, Rome, 3Department 
of Medical and Surgical Sciences, University of Padua, 4Institute of 
Pharmaceutical and Toxicological Chemistry, University of Milan, Italy.
Background and aims: Reactive carbonyl species generated by oxidation of 
endoperoxides in lipoproteins react with proteins to form advanced lipoxida-
tion endproducts (ALEs), which have been implicated in both atherosclerosis 
and renal disease. L-carnosine was shown to act as a quencher of reactive 
carbonyl species, but, in humans, it is rapidly inactivated by carnosinase. This 
study evaluated the effect of carnosinase-resistant octyl D-carnosine (ODC) 
on the development of atherosclerosis and renal disease in the apoE null 
mouse model.
Materials and methods: Adult female ApoE null mice, fed either a western, 
pro-atherogenic, high fat diet (HFD, 42% fat, 0.2% cholesterol) or a stand-
ard, normal fat diet (NFD), were treated with ODC (Flamma SpA, Chignolo 
d’Isola, BG, Italy; 60 mg/kg body weight in the drinking water) or vehicle for 
12 weeks. Aortic and kidney lesions were evaluated, together with expression 
of inflammatory and disease progression markers.
Results: ODC-treated HFD-fed mice showed significantly reduced lesion 
area at the level of the aortic sinus (434.9±49.9 vs. 527.9±49.6 μm x 10-3, 
P<0.01) and, particularly, of the brachiocephalic artery (22.3±4.4 vs. 43.3±6.5 
% of luminal occlusion, P<0.01), as compared with untreated animals. Treat-
ment also produced a more stable plaque phenotype, with less foam cell accu-
mulation, inflammation and apoptosis and increased clearance of apoptotic 
bodies, resulting in reduced necrotic core formation (11.8±3.8 vs. 25.3±5.4%, 
P<0.001). Fibrosis was increased (42.6±5.8 vs. 28.7±7.8 % of lesion area, 
P<0.01) and disruption of vessel wall architecture was reduced, with less elas-
tin degradation and pseudo-microaneurysm formation. Oil red O staining 
of en-face aorta preparations showed a significantly reduced lipid accumula-
tion in ODC-treated vs. untreated HFD-fed ApoE null mice (13.2±2.5 vs. 
19.2±2.0%, P<0.001). Increases of protein content of F4/80, and CXCR3 as 
well as of mRNA expression of F4/80, CXCR3, VCAM-1, MCP-1, TNF-α, 
IFN-γ, MMP-9, and CHOP were significantly lower (or even normalized) 
and those of anti-inflammatory IL-4 and Il-10 significantly increased in 
ODC-treated versus untreated HFD-fed mice. This was associated with re-
duced tissue content of HNE adducts, oxLDLs, and nitrotyrosine and mRNA 
expression of the ALE-receptors CD36, TLR-2 and 4, RAGE and galectin-
3 in HFD-fed ODC-treated versus untreated ApoE null mice. Likewise, re-
nal lesions were significantly attenuated in ODC-treated versus untreated 
HFD-fed mice on HFD, with lower foam cell accumulation, inflammation, 
apoptosis, glomerular and tubulo-interstitial fibrosis, content of HNE ad-
ducts, oxLDLs, and nitrotyrosine and expression of pro-inflammatory and 
pro-fibrotic mediators. Serum ALE, pentosidine, carbonylated proteins, and 
isoprostane-8-epi-PGF2α levels were also lower in ODC-treated vs. untreated 
HFD-fed ApoE null mice.
Conclusion: These data support a central role for lipoxidation in atheroscle-
rosis and renal disease and indicate that quenching of carbonyl adducts with 
a D-carnosine ester may represent a promising approach to the prevention 
and treatment of these disorders.
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Methylglyoxal-mediated cardiovascular cell dysfunction: role of poly 
(ADP-ribose) polymerase
O.J. Bates1, J.G. Mabley2;
1Brighton and Sussex Medical School, 2School of Pharmacy & Biomolecular 
Sciences, University of Brighton, United Kingdom.
Background and aims: Methylglyoxal (MGO), a glycolysis derived reactive 
dicarbonyl compound, has been implicated in cardiovascular complications 
of diabetes. MGO reacts with many short and long-lived cellular proteins dis-
rupting their synthesis and function which may lead to increased cellular oxi-
dative stress. Overactivation of the DNA repair enzyme poly (ADP-ribose) 
polymerase (PARP) following oxidative stress-induced DNA damage with 
subsequent depletion of cellular high energy phosphate and NAD levels has 
been implicated in endothelial cell dysfunction in diabetes. The aims of this 
study were twofold, firstly to determine whether MGO-mediated activation 
of PARP was responsible for the observed cardiovascular cell dysfunction and 
hence the link between hyperglycaemia and PARP activation already reported 
in cardiovascular cells. Secondly, to determine whether the cardioprotective 
agent, resveratrol could protect against MGO-mediated dysfunction.
Materials and methods: The effects of MGO on acetylcholine-mediated NO 
dependent vasorelaxation were tested using ex vivo rat aortic rings exposed 
to 0.1, 0.3 and 1 mM MGO for 1, 2 and 4h. The role of PARP activation in 
MGO-mediated dysfunction was evaluated by the co-administration of the 
specific PARP inhibitor PJ34 (10 µM) with MGO (0.3 mM). The effect of the 
cardiovascular protective agent resveratrol (3 µM) on MGO-mediated car-
diovascular cell dysfunction was also determined. MGO effects on cardiac 
H9c2 myocyte cell viability was measured by MTT assay and oxidative stress 
was measured using the NBT assay.
Results: MGO dose and time dependently caused endothelial cell dysfunc-
tion, 0.1 mM MGO had no effect on endothelial cell-mediated vascular relax-
ation following 1, 2 or 4h exposure, whereas 0.3 and 1 mM though having no 
effect at 1h exposure, caused significant endothelial cell dysfunction at both 2 
and 4h. Exposure of aortic rings for 2h to MGO (0.3 mM) increased the IC50 
for acetylcholine-mediated relaxation from 15±3 nM to 82±4nM (p<0.01), 
no further damage was seen either with 1 mM MGO or an increased ex-
posure time (4h). Simultaneous exposure of aortic rings to MGO (0.3 mM) 
and the PARP inhibitor PJ34 (10 µM) for 2h protected against the MGO-me-
diated dysfunction significantly reducing the acetylcholine IC50 from 81±5 
nM to 18±4 nM (p<0.01 vs. MGO alone), also simultaneous application of 
resveratrol (3 µM) also protected endothelial cell function reducing the IC50 
to 19±6 nM (p<0.01 vs. MGO alone). MGO dose dependently reduced H9c2 
myocyte cell viability following 24h exposure. Simultaneous addition of res-
veratrol increased H9c2 cell viability from 28±0.5% with 0.8 mM MGO alone 
to 36±2%, 51±2% and 54±1% with 1, 3 and 10 µM respectively (p<0.05 vs. 
MGO alone). Exposure of H9c2 cells to MGO for either 4 or 6h significantly 
increased cellular oxidative stress. MGO at 1 mM increased oxidative stress 
by 25±11% and 46±12% above untreated cells following 4 and 6h exposure 
respectively (p<0.05 vs. untreated cells).
Conclusion: MGO exposure causes both endothelial and myocyte cellular 
dysfuction, effects which appear to be mediated by increased cellular oxida-
tive stress and activation of PARP. Resveratrol also appears to confer a protec-
tive effect against MGO-mediated endothelial and myocyte cellular dysfunc-
tion.
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Is G6PC2/IGRP a component of the beta cell glucose sensor?
L.D. Pound, Y. Wang, J. Oeser, O.P. McGuinness, R.M. O’Brien;
Molecular Physiology and Biophysics, Vanderbilt University, Nashville, 
USA.
Background and aims: Glucose-6-phosphatase catalyzes the hydrolysis of 
glucose-6-phosphate (G6P) to glucose and inorganic phosphate. The glucose-
6-phosphatase catalytic subunit (G6PC) gene family comprises three mem-
bers, G6PC, G6PC2 and G6PC3. G6PC, also known as G6Pase, is predomi-
nantly expressed in liver and kidney where it catalyses the terminal step in 
the gluconeogenic and glycogenolytic pathways. G6PC2, previously known 
as the islet-specific glucose-6-phosphatase catalytic subunit related protein 
(IGRP), is selectively expressed in insulin producing beta cells. In vitro, 
G6PC2 hydrolyzes G6P at a much lower rate than G6PC raising the question 
as to whether G6P is a physiologically important substrate for this protein.
Materials and methods: To assess the physiological importance of G6pc2, we 
have generated G6pc2-null mice, backcrossed onto a C57BL/6J background, 
and performed a phenotypic analysis focusing primarily on energy metabo-
lism and pancreatic hormone secretion.
Results: 16 week old G6pc2 KO mice on a chow fed diet exhibit no differ-
ences in body weight and no gross anatomical or behavioral changes. How-
ever, following a 6 hour fast, a decrease in blood glucose was observed in 
both male (WT: 130.7+/-3.6; KO: 109.2+/-3.5; p<0.001) and female (WT: 
121.9+/-4.3; KO: 104.3+/-4.4; p<0.01) G6pc2 KO mice relative to wild type 
(WT) littermates, while plasma insulin and glucagon concentrations were 
unchanged. Because glycolytic flux has been shown to determine the S0.5 of 
glucose-stimulated insulin secretion (GSIS) these observations are consistent 
with a model in which the glucose-6-phosphatase activity of G6PC2 opposes 
the action of glucokinase and thereby modulates the S0.5 of GSIS. Deletion 
of the G6pc2 gene is therefore predicted to abolish glucose cycling, increase 
glycolytic flux and lower the S0.5 of GSIS. Additional studies were performed 
to explore this concept. Pancreas perfusion experiments in which islets were 
challenged with variable glucose concentrations demonstrated that deletion 
of G6pc2 results in a leftward shift in the S0.5 of GSIS. A similar shift was 
observed in islet perifusion experiments. In addition, following static incuba-
tion of islets in a sub-maximal 11 mM stimulatory glucose concentration, 
islets isolated from G6pc2 KO mice displayed enhanced GSIS relative to 
islets isolated from WT mice (WT: 0.899 (%content/30 min)+/-0.142; KO: 
2.116+/-0.204; p<0.01). Finally, intraperitoneal glucose tolerance tests, again 
using a submaximal stimulatory glucose concentration, demonstrate that 
G6pc2 KO mice do not have enhanced glucose tolerance but rather lower 
blood glucose at all time points, a result that is again consistent with G6pc2 
regulating the S0.5 of GSIS.
Conclusion: The existing dogma in the islet field proposes that glucokinase 
is the beta cell glucose sensor. The significance of our observations is that 
they challenge this dogma and suggest that G6PC2 is a fundamental inhibi-
tory component of that sensor. Instead we propose that a glucokinase/G6PC2 
futile cycle acts as the beta cell glucose sensor determining glycolytic flux 
and hence the S0.5 of GSIS. This conclusion is consistent with genome wide 
association studies that have recently shown that single nucleotide polymor-
phisms in the G6PC2 gene are associated with variations in fasting plasma 
glucose levels in humans.
Supported by: NIH DK 76027
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Identification of an intracellular metabolic signature impairing beta cell 
function
N. Sauter1, I. Goehring2, G. Catchpole3, A. Assmann2, K. Suessbauer4,  
M. Moehlig2, A.F.H. Pfeiffer2, J. Oberholzer5, L. Willmitzer3, J. Spranger2,  
K. Maedler4;
1University Hospital Zurich, Switzerland, 2Charite, Department of 
Endocrinology, Diabetes and Nutrition, Berlin, 3Max Planck Institute 
of Molecular Plant Physiology, Potsdam, 4Centre for Biomolecular 
Interactions, University of Bremen, Germany, 5University of Illinois, 
Chicago, USA.
Background and aims: Chronic hyperglycaemia promotes the progressive 
failure of pancreatic β-cells in patients with diabetes mellitus, a clinically 
highly relevant phenomenon known as glucotoxicity. Assuming that changes 
of the intracellular metabolism contribute to this progressive β-cell failure, an 
unbiased metabolite profiling analysis was carried out to identify the meta-
bolic signature of β-cells during high glucose exposure.
Material and methods: Isolated human islets and INS-1E cells were cultured 
at 5.5 to 33.3 mM glucose from 1 to 96 h with or without 6-aminonicotina-
mide (6-AN), a potent inhibitor of 6-phosphogluconic acid dehydrogenase. 
After the glucose pre-treatment, islets underwent an additional glucose chal-
lenge at 5.5 and 22.2 mM glucose and of p-ERK, glucose stimulated insulin 
secretion (GSIS), insulin mRNA were analysed. Metabolites were analysed 
in islet lysates on a Leco Pegasus 3 time-of-flight mass spectrometer (Leco). 
PCA was performed with MATLAB 7.0 (Mathworks).
Results: To identify potential novel mediators of insulin gene suppression by 
chronic high glucose treatment, an unbiased time course analysis of metabo-
lites was performed in the β-cells INS-1E and in human islets, during which 
73 metabolites were uniquely identified. Principal component analysis (PCA) 
revealed that prolonged exposure to high glucose caused clear differentiation 
compared to early time points thus demonstrating the differential impact of 
acute and chronic glucose exposure on the β-cell. The most important me-
tabolites driving the separation from acute to chronic glucose were gluconic 
acid, glucono-delta-lactone and 6-phosphogluconic acid from the pentose 
phosphate pathway. The addition of 6-AN at low glucose, promoted the ac-
cumulation of the pentose phosphate metabolites thus partially reflecting the 
metabolic state of the β-cells under high glucose. Analysis of insulin mRNA 
revealed that 6-AN and the accompanied rise in pentose phosphate metabo-
lites lead to a 3.5-fold decrease of insulin gene expression compared to low 
glucose alone, similarly as exposure to chronic high glucose for 3 days (3.3-
fold decrease). Glucose-dependent regulation of insulin transcription is de-
pendent on extracellular signal-regulated protein kinases (ERK1/2). ERK1/2 
kinase is activated by acute glucose exposure. In contracts, we show here that 
pre-incubation of elevated glucose completely abolished a further glucose 
mediated ERK induction, which correlated with the loss of GSIS, suggesting 
that ERK stimulation, is essential for GSIS. Accumulation of pentose phos-
phate pathway metabolites in islets by 6-AN at low glucose concentrations, 
was able to promote ERK1/2 phosphorylation to a similar extent as long-term 
high glucose treatment, but also failed to maintain GSIS.
Conclusions: Based on unbiased metabolite analyses, the here presented 
insights provide novel perspectives in the therapeutic goal to preserve and 
potentially improve beta-cell function in patients with diabetes mellitus.
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miR-29a, miR-29b and miR-124 contribute to pancreatic beta cell specific 
silencing of monocarboxylate transporter 1 (Mct1/Slc16a1)
G.A. Rutter, T.J. Pullen;
Dept. Cell Biology / Div. Diabetes, Endocrinology & Metabolism, Imperial 
College, London, United Kingdom.
Background and aims: Glucose metabolism in pancreatic beta cells is spe-
cialised to efficiently couple glucose oxidation to ATP production, critical 
for stimulating insulin secretion. Alternative metabolic pathways that could 
interfere with glucose sensing are suppressed by specifically “disallowing” 
expression of certain genes in beta cells. For example, MCT1 (SLC16A1) en-
codes a plasma membrane monocarboxylate (pyruvate/lactate) transporter 
which is widely expressed in other tissues but not in beta cells. The effects of 
inappropriate expression of MCT1 are shown in the rare genetic disorder, Ex-
ercise Induced HyperInsulinism, linked to mutations in the MCT1 promoter. 
During strenuous physical exercise, the presence of the transporter in affect-
ed individuals is presumed to allow circulating pyruvate to enter beta cells, 
resulting in inappropriate insulin release and consequent hypoglycaemia. 
We aimed here to identify the mechanisms by which expression of MCT1 
is specifically disallowed in beta cells. The MCT1 promoter drives low but 
significant reporter gene expression in the MIN6 beta cell line suggesting that 
additional post-transcriptional mechanisms may be responsible for silencing 
this gene. We therefore investigated whether microRNAs (miRNA) expressed 
in beta cells contribute to the tissue specific silencing of this gene.
Materials and methods: Publicly available high throughput sequencing data 
from beta cells and thirteen other mouse tissues were interrogated to deter-
mine the abundance and specificity of microRNA expression. Potential miR-
NA binding sites within the MCT1 3´ UTR were identified using miRanda 
and PicTar algorithms. Hits were validated by luciferase assay on both hu-
man and mouse MCT1 3´ UTRs, and precise locations of binding sites con-
firmed by site-directed mutagenesis. Effects on endogenous Mct1 expression 
were determined by stable expression of miRNAs in the hepatocyte-derived 
mhAT3-F cell line where Mct1 mRNA is abundant.
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Results: Bioinformatic analysis of miRNA expression in beta cells ranked all 
detected miRNAs by a combined abundance and specificity score, success-
fully identifying known beta cell specific miR-375 and miR-7 within the top 
three. Eight miRNAs were predicted to target the Mct1 3´ UTR, of which 
miR-29a, miR-29b and miR-124 produced large and significant decreases in 
expression by luciferase assay in HEK293 cells. All three miRNAs fall within 
the top third of miRNAs ranked by combined beta cell abundance and specif-
icity score. Mutating the identified binding sites abolished the effect of miR-
124 and miR-29b and significantly reduced the effect of miR29a by luciferase 
assay. Stable expression of miR-29a and miR-124 in mhAT3-F cells virtually 
abolished, and miR-29b considerably reduced expression of Mct1 protein. 
Mutating either binding site significantly increased expression of luciferase 
bearing the Mct1 3´ UTR in MIN6 beta cells, confirming these miRNAs are 
expressed at sufficient levels to downregulate Mct1.
Conclusion: Our interrogation of publicly available miRNA expression 
data provides a novel prediction of miRNAs important for beta cell func-
tion. Among these we identify miR-29a, miR-29b and miR-124 as capable 
of downregulating Mct1 through a direct interaction with cognate binding 
sites in the 3´ UTR. We propose that the coordinated action of these miRNAs 
contributes to the beta cell specific silencing of Mct1 required for efficient 
glucose sensing.
Supported by: Wellcome Trust
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Inducible expression of Monocarboxylate Transporter 1 (Mct1/Slc16a1) 
in the beta cell of transgenic mice: a model of exercise induced 
hyperinsulinism
T.J. Pullen, G.A. Rutter;
Dept. Cell Biology / Div. Diabetes, Endocrinology & Metabolism, Imperial 
College, London, United Kingdom.
Background and aims: The plasma membrane monocarboxylate (pyruvate/
lactate) transporter MCT1/SLC16A1 is expressed at vanishingly low levels in 
pancreatic beta cells but at high levels in other tissues. The absence of this 
transporter may serve a dual function. Firstly, it may prevent circulating pyru-
vate from entering the beta cell and inappropriately stimulating insulin secre-
tion. In the rare dominant genetic disorder Exercise Induced HyperInsulinism 
(EIHI), linked to mutations in the MCT1 promoter, pyruvate produced by 
muscle during vigorous physical exercise stimulates insulin secretion, result-
ing in hypoglycaemia. Secondly, by preventing loss of pyruvate generated by 
glycolysis, it may ensure that glucose is efficiently oxidised by mitochondria, 
generating ATP to trigger insulin secretion. While the mutations associated 
with EIHI increase expression of reporter genes in beta cell lines and patients 
exhibit increased MCT1 expression in fibroblasts, there is no direct evidence 
that MCT1 is over-expressed in patient beta cells. Here we have created a 
transgenic mouse model in which MCT1 is expressed in pancreatic beta cells 
and examine the impact on pyruvate or glucose tolerance in vivo.
Materials and methods: We established a transgenic mouse line in which 
a tetracycline-regulatable promoter controls expression of human MCT1, 
then crossed this with mice expressing the reverse-tetracycline transactivator 
(rtTA) under control of the rat insulin promoter. This permits beta cell-spe-
cific expression of MCT1 upon addition of doxycycline only in mice bearing 
both transgenes. Littermates containing no transgenes were used as controls. 
MCT1 expression was induced by administering doxycycline (1 g/l) in drink-
ing water for at least 7 days. Glucose (1 g/kg body weight) or pyruvate (0.5 
g/kg) were administered intraperitonealy following 16 hour fast, and blood 
glucose levels were measured.
Results: Following induction of MCT1 expression, double transgenic (DT) 
mice showed a non-significant trend to lower fasting blood glucose relative 
to wildtype littermate controls (WT). Fasting blood glucose ± SEM: DT = 
5.17 ± 0.34 mmol/l, n=13; WT = 6.24 ± 0.33 mmol/l, n=5; p= 0.091. In the 
absence of doxycycline there was no difference in the effect of pyruvate on 
blood glucose in DT v WT. Blood glucose 30 min after pyruvate challenge 
± SEM: DT = 10.37 ± 0.45 mmol/l, n=13; WT = 9.90 ± 0.58, n=5; p=0.573). 
However, following doxycycline induction DT mice had significantly lower 
blood glucose: DT = 7.18 ± 0.40 mmol/l, n=13; WT = 8.78 ± 0.51 mmol/l, 
n=5; p=0.039. Thus, insulin secretion from beta cells appears to become sen-
sitive to pyruvate in DT mice, lowering blood glucose. Interestingly, these 
mice also showed decreased glucose tolerance. Blood glucose 30 min after 
glucose challenge ± SEM: DT = 18.01 ± 0.87 mmol/l, n=11; WT = 13.16 ± 
0.48 mmol/l, n=5; p=0.003). This is consistent with loss of pyruvate from beta 
cells lowering the yield of ATP from glucose metabolism hence reducing in-
sulin secretion.
Conclusion: Expression of MCT1 in beta cells is sufficient to replicate the key 
feature of EIHI, as pyruvate challenge lowers blood glucose relative to con-
trols. The demonstration that DT mice are also glucose intolerant reveals the 
importance of suppressed MCT1 expression in beta cells for normal glucose 
stimulated insulin secretion. Activating mutations in the MCT1/SLC16A1 
gene might also, therefore, increase susceptibility to type 2 diabetes.
Supported by: Wellcome Trust
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Regulation of pyruvate dehydrogenase by phosphorylation in the 
pancreatic beta cell
D.A. Akhmedov, C.B. Wollheim, A.C. Wiederkehr;
Department of Cell Physiology and Metabolism, University of Geneva, 
Switzerland.
Background and aims: In the pancreatic beta-cell, glycolysis-derived pyru-
vate is taken up into the mitochondria where it is oxidized by pyruvate dehy-
drogenase (PDH; oxidative pathway) or carboxylated by pyruvate carboxyla-
se, providing carbons to the TCA cycle (anaplerotic pathway). Recent studies 
suggest an important role of the anaplerotic pathway in glucose-stimulated 
insulin secretion. The relative flux through the two pathways in beta-cells 
may in part be determined by the PDH activity, which is regulated by phos-
phorylation/dephosphorylation of the E1 alpha subunit. Phosphorylation by 
PDH-kinases (PDK) leads to inactivation of PDH, while removal of phos-
phate by the calcium activated PDH-phosphatases (PDP) stimulates PDH 
activity. Here we have studied regulation of PDH by phosphorylation during 
glucose stimulation of the pancreatic beta-cell.
Materials and methods: INS-1E cells and rat islets were exposed to glucose 
or alternative secretagogues in the presence or absence of calcium signals. 
PDH phosphorylation was followed by Western-blotting, using an antibody 
specifically recognizing the phosphorylated (Serine-293) PDH E1 alpha sub-
unit. The blots were then re-probed with an antibody for detection of total 
PDH E1 alpha protein. Expression of PDK isoforms (PDK1, PDK2, PDK3 
and PDK4) in INS-1E cells was analyzed by RT-qPCR.
Results: Glucose stimulation leads to increase in mitochondrial calcium and 
thus would be expected to stimulate PDP resulting in dephosphorylation of 
PDH. Surprisingly, high glucose (16.7mM) or leucine (20mM) caused PDH 
E1 alpha phosphorylation in INS-1E cells and rat islets. A significant increase 
in phosphorylation was already observed after 5 minutes of glucose stimula-
tion. This effect was also seen under conditions of blocked insulin secretion, 
ruling out the possibility that increase in PDH E1 alpha phosphorylation is a 
consequence of insulin receptor signaling. Preventing calcium signals during 
glucose stimulation further increased PDH E1 alpha phosphorylation while 
raising calcium by KCl (30mM) decreased phosphorylation. These findings 
are consistent with the known regulation of PDP activity by calcium. Under 
resting glucose (2.5mM) augmenting or depleting calcium did not affect PDH 
E1 alpha phosphorylation. This shows that nutrient stimulation and not calci-
um per se is the principal signal for PDH phosphorylation. We hypothesized 
that during glucose stimulation total PDK activity is more activated than the 
PDP activity leading to an enhanced PDH phosphorylation despite the glu-
cose-stimulated mitochondrial calcium rise. We proceeded to determine the 
kinase (or kinases) responsible for the observed PDH E1 alpha phosphoryla-
tion. Expression of PDK1, PDK2 and PDK3 was detected in INS-1E cells. 
PDK4 was not detectable in this cell type. Remarkably, PDK3 transcript level 
was significantly higher than in any of the tested tissues, suggesting that this 
isoform may be particularly important in insulin-secreting cells.
Conclusion: PDH is rapidly phosphorylated following glucose stimulation in 
INS-1E cells and rat islets. Nutrient secretagogues regulate PDH phosphor-
ylation and thereby determine to what extent the oxidative and anaplerotic 
pathways are utilized. Inactivation of PDH by phosphorylation should favor 
anaplerosis, which is required for the export of mitochondrial metabolites and 
may thereby affect the formation of mitochondria-derived coupling factors.
Supported by: Swiss National Science Foundation
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Glucose induces oscillations of the ATP/ADP ratio in individual beta 
cells
J. Li, E. Gylfe, A. Tengholm;
Department of Medical Cell Biology, Uppsala University, Sweden.
Background and aims: The ATP/ADP ratio has a central messenger func-
tion in β-cells, linking changes in glucose metabolism to electrical activity, 
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Ca2+ signaling and insulin secretion. Biochemical and electrophysiological 
analyses as well as single-cell and islet recordings of e.g. oxygen consumption, 
NAD(P)H fluorescence and mitochondrial membrane potential have provid-
ed evidence for metabolic oscillations in β-cells, but it has been difficult to 
directly demonstrate fluctuations of the ATP/ADP ratio. Application of the 
firefly luciferase bioluminescence assay in single β-cells is very challenging 
and has provided limited information about ATP rather than the ATP/ADP 
ratio. Using a novel fluorescence protein-based ATP/ADP ratio sensor, the 
aim of the present study was to monitor changes in ATP/ADP ratio in single 
glucose-stimulated β-cells.
Materials and methods: Circularly permuted fluorescent protein cpmVenus 
inserted into the T-loop of the ATP-binding bacterial protein GlnK1 (Per-
ceval) was used as a cytoplasmic biosensor for ATP/ADP ratio in individual 
MIN6 β-cells. In some experiments the red fluorescent protein tdimer2 was 
used as a reference. Changes of cytoplasmic fluorescence were recorded with 
confocal microscopy.
Results: MIN6 β-cells expressed Perceval with essentially even distribution 
in the cytoplasm. The ATP-sensitivity of the probe was investigated after per-
meabilization of the plasma membrane with α-toxin. Changes of the medium 
concentration of ATP from 0 to 1, 3 and 10 mM resulted in concentration-de-
pendent increase of Perceval fluorescence with half-maximal effect at about 3 
mM ATP (n=9). Most intact cells showed stable fluorescence in the presence 
of 3 mM glucose. Application of 5 µM of the mitochondrial uncoupler FCCP 
dramatically diminished the Perceval fluorescence. Elevation of the glucose 
concentration from 3 to 20 mM induced oscillations of Perceval fluorescence 
with a frequency of 0.24±0.01 min-1 in >95% of the cells (n=107). In most 
cells (71%) the oscillations originated from an elevated level and the ampli-
tude averaged 15±1% of the fluorescence in 3 mM glucose. The increase in 
ATP/ADP ratio was counteracted by rise of cytoplasmic Ca2+, since hyper-
polarization with the KATP channel activator diazoxide (250 μM) increased 
the Perceval fluorescence with maintenance of the glucose-induced oscilla-
tions (50%) or stable elevation. Moreover, membrane depolarization with 
30 mM K+ in the presence of 3 mM glucose caused pronounced decrease in 
Perceval fluorescence.
Conclusions: Glucose stimulation of MIN6 β-cells triggers oscillations of the 
cytoplasmic ATP/ADP ratio. Cytoplasmic Ca2+ negatively regulates the ATP/
ADP ratio, but metabolic oscillations are maintained the absence of stimu-
lated entry of Ca2+.
OP 13 Incretin based therapies: new 
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Exenatide added to insulin glargine-treated patients with type 2 diabetes 
provided excellent fasting and postprandial control with weight loss and 
no increased risk of hypoglycaemia
R.M. Bergenstal1, J.B. Buse2, L.C. Glass3, C.R. Heilmann3, M.S. Lewis3,  
A.Y.M. Kwan4, B.J. Hoogwerf4, J. Rosenstock5;
1International Diabetes Center, Minneapolis, 2UNC School of Medicine, 
Chapel Hill, 3Eli Lilly and Company, Indianapolis, 4Lilly USA, LLC, 
Indianapolis, 5Dallas Diabetes and Endocrine Center, USA.
Background and aims: This is the first double-blind, placebo-controlled study 
adding exenatide (EXE) treatment in patients with type 2 diabetes subopti-
mally controlled (A1C ≥7.1 ≤10.5%) with basal insulin glargine therapy ± oral 
agents. The primary efficacy variable was change in A1C from baseline to 30 
weeks. Prandial glycemic control measures included 7-point self-monitored 
blood glucose (SMBG) values, continuous glucose monitoring (CGM) data, 
and 1,5-anhydroglucitol (1,5-AG), a marker that is inversely proportional to 
average glycemia with greater sensitivity to postprandial (PP) excursion.
Materials and methods: A total of 259 patients (mean age 59 years, weight 
94.4 kg, A1C 8.41%, diabetes duration 12.3 years, and insulin dose 48 U [0.51 
U/kg]) were randomized to add either exenatide (10µg BID, n=137) or pla-
cebo (n=122) to insulin glargine therapy. Groups were generally comparable 
at baseline. At randomization, insulin dose was maintained (A1C >8.0%) or 
decreased by 20% (A1C ≤8.0%) for 5 weeks and then titrated to achieve a 
target fasting glucose of <5.6 mmol/L.
Results: At 30 weeks, A1C decreased by -1.71% to 6.70% with EXE treatment, 
and by -1.00% to 7.41% with placebo (PBO [p<0.001]). Endpoint fasting glu-
cose values were not different between treatment groups (EXE 6.5±0.1, PBO 
6.6±0.1 mmol/L, p=0.633). All non-fasting SMBG values were significantly 
lower for EXE (Figure). The 24-hour average glucose measurement from 
CGM (n=23) decreased in EXE by -3.2 to 6.6±0.4 mmol/L, and in PBO by -
1.9 to 8.0±0.4 mmol/L (p=0.039). While baseline values of 1,5-AG were com-
parable between EXE and PBO (7.0±0.42 and 5.8±0.44 µmol/L, p=0.056), 
endpoint values were significantly higher for EXE than for PBO (12.7±0.5 vs 
10.6±0.6 µmol/L, p=0.003). Weight decreased in EXE (-1.8±0.3kg, p<0.001) 
and increased in PBO (+1.0±0.3kg, p=0.011). Insulin dose increased more in 
PBO (20±2 U, p<0.001) than in EXE (13±2 U, p<0.001), (p=0.026 between 
groups). Minor hypoglycemia was similar for EXE and PBO (rate: 1.43±0.31 
and 1.24±0.30 episodes/patient/year, p=0.666); major hypoglycemia (noc-
turnal) occurred twice in one PBO-treated patient. Adverse events were sig-
nificantly greater for EXE vs PBO : nausea (41 vs 8%), diarrhea (18 vs 8%), 
vomiting (18 vs 4%), headache (14 vs 4%), and constipation (10 vs 2%).
Conclusion: To our knowledge, this is the first report of a controlled trial us-
ing a GLP-1-receptor agonist with basal insulin. Addition of EXE therapy in 
patients treated with insulin glargine improved A1C by contributing a pran-
dial effect with no increased risk of hypoglycemia.
Supported by: Eli Lilly and Company and Amylin Pharmaceuticals
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Response at 3 months to insulin dose decisions made at exenatide 
initiation in the Association of British Clinical Diabetologists (ABCD) 
nationwide exenatide audit
K.Y. Thong1, R.E.J. Ryder1, B. Jose1, T. Sathyapalan2, W. Shafiq2, A. Rigby2,  
C. Walton2, ABCD Nationwide Exenatide Audit Contributors;
1City Hospital, Birmingham, 2Hull Royal Infirmary, United Kingdom.
Background and aims: To learn from experience of exenatide in real clinical 
use in the UK, ABCD began a nationwide audit in December 2008. Though 
exenatide is not licensed for use with insulin many contributors to the audit 
used the combination. There is uncertainty about what should be done with 
insulin dose when exenatide is added. We therefore studied the response at 3 
months after exenatide initiation in relation to insulin dose decisions made 
when exenatide was started.
Materials and methods: Patients were analysed according to three groups 
at initiation: non-insulin users (Group 1), insulin users in whom insulin 
was stopped (Group 2), and insulin users with insulin continued (Group 3). 
Group 3 was divided further into groups who had insulin doses unchanged, 
reduced by 1-40% (mean dose reduction 25.3%), 41-60% (mean 49.7%) and 
61-99% (mean 67.4%) for further analyses. HbA1c and weight changes were 
compared within and across groups at baseline and 3 months. Correlation be-
tween insulin dose reduction and HbA1c and weight changes were assessed. 
Differences in group characteristics were examined.
Results: Amongst 6717 patients in the audit, exact data on diabetes treatment 
at baseline and initiation as well as suitable HbA1c and weight data were avail-
able for 2575 and 2454 patients respectively. The distribution in each group 
(HbA1c data, weight data) was: Group 1 (1626, 1545), Group 2 (275, 271) and 
Group 3 (674, 638). Mean age (54.1, 54.8, 55.0yrs), BMI (40.0, 39.3, 40.3kg/
m2), and initial HbA1c (9.5, 9.7, 9.6%) were not statistically different between 
groups. Group 2 had lower baseline weight than Group 1 (110.8 v 114.6kg, 
p=0.009). Group 2 had longer diabetes duration than Group 1 (10.8 v 8.3yrs, 
p<0.001), but lesser duration (10.8 v 12.3yrs, p<0.001) and total insulin dose 
(92 v 121U, p<0.001) compared with Group 3. Group 1 and 3 achieved sig-
nificant HbA1c reductions (-0.95%, -0.53%, both p<0.001), but not Group 2 
(-0.01%, p=0.948). 48% in Group 2 had HbA1c increases, with 15% > 2.0%. 
All 3 groups achieved weight reductions (-3.7, -6.6 and -4.3kg, all p<0.001). 
Across groups, Group 2 achieved no HbA1c benefit compared with Group 1 
and 3 (both p<0.001) but the most weight benefit (both p<0.001). Group 3 had 
intermediate results showing less HbA1c reduction but more weight loss than 
Group 1 (p<0.001, p=0.007 respectively). Among Group 3, weight reduction, 
but not HbA1c change, correlated with total insulin dose reduction (p=0.003, 
p=0.158 respectively). Subgroup analyses revealed the group with average in-
sulin dose reduction of around half, and two-thirds, achieved more weight loss 
than the group with no dose changes (p=0.010, and p=0.037) or average dose 
reduction of a quarter (p=0.018, and p=0.035 respectively). Analyses on HbA1c 
changes among different insulin dose reduction groups did not reveal any sig-
nificant differences. No severe hypoglycaemia was recorded in Group 3.
Conclusion: Our analysis shows that continuing insulin at exenatide initia-
tion was safe and yielded HbA1c and weight reductions. Progressive insulin 
dose reductions yielded increasing weight loss but at the expense of HbA1c 
reduction, although there was no clear threshold when glycaemic reduction 
was negatively affected. When insulin was substituted, rather than combined 
with exenatide, almost half of patients had worsened glycaemic control.
Independent audit supported by an unrestricted grant from Eli Lilly Ltd
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Superior glycaemic control with taspoglutide, a once-weekly human 
GLP-1 analogue, compared with twice daily exenatide in type 2 diabetes: 
the T-emerge 2 Trial
G.B. Bolli1, J. Rosenstock2, B. Balas3, B. Charbonnel4, M. Boldrin5,  
R. Ratner6, R. Balena3;
1University of Perugia, Italy, 2Dallas Diabetes and Endocrine Center at 
Medical City, Dallas, USA, 3F. Hoffmann-La Roche, Basel, Switzerland, 
4Universite de Nantes, France, 5Roche Pharmaceuticals, Nutley, 6MedStar 
Research Institute, Hyattsville, USA.
Background and aims: Taspoglutide is a once-weekly (QW) human GLP-1 
analog in Phase 3 development. T-emerge 2 compared the safety and efficacy 
of QW taspoglutide (Taspo) with twice-daily (BID) exenatide (Exe) in adult 
patients with type 2 diabetes (T2DM) inadequately controlled with metform-
in+/-thiazolidinedione.
Materials and methods: In this multinational, open-label study, 1149 sub-
jects were randomized (1:1:1) to subcutaneous Taspo 10 mg QW (Taspo10), 
Taspo 10 mg QW for 4 wks titrated to 20 mg QW (Taspo20), or Exe 5 mcg 
BID for 4 wks titrated to 10 mcg BID. Primary outcome was HbA1c change 
at wk 24, testing for non-inferiority (NI) vs Exe (using 2-sided 95% CI for 
HbA1c difference and noninferiority margin of 0.4%) in the intent-to-treat 
(ITT) population. If NI was demonstrated, then statistical superiority was 
tested under closed test procedure.
Results: Baseline characteristics (56 yrs, 6.5 yrs T2DM, HbA1c 8.1%, BMI 33 
kg/m2) were similar across groups. At 24 wks in the ITT population, reduc-
tions in HbA1c and FPG with Taspo10 and Taspo20 were superior to Exe (Ta-
ble). More patients on Taspo10 or Taspo20 achieved target HbA1c ≤7% than 
Exe: 64.8% (95% confidence interval [CI], 59.8-69.6), 67.9% (95% CI, 63.0-
72.5), and 51.5% (95% CI, 46.3-56.7); respectively. Dose-dependent weight 
loss was seen with Taspo and weight loss with Taspo20 was similar to Exe 
(Table). Gastrointestinal (GI) complaints were the most frequently reported 
adverse events across all arms. Although they occurred with a higher inci-
dence in the Taspo groups, discontinuation rate due to GI events was similar 
in the 3 arms.
Conclusion: Once-weekly Taspo provided superior glycemic control to Exe, 
with similar body weight reduction at the higher dose and comparable toler-
ability. (NCT00717457)
LSMean ± SE Taspo10 
(n=384)
Taspo20 
(n=392)
Exe (n=373)
Baseline HbA1c (%) 8.08±0.05 8.08±0.05 8.05±0.05
Change from baseline HbA1c 
(95% CI)
-1.24±0.09 
(-1.41, -1.08)
-1.31±0.08 
(-1.48, -1.15)
-0.98±0.08 
(-1.14, -0.82)
Diff from Exe -0.26±0.06** -0.33±0.06** _
24 Week HbA1c% 6.91±0.05 6.84±0.04 7.15±0.05
Baseline FPG (mmol/l)
Change from baseline
FPG (95% CI)
9.91±0.13 
-2.18±0.20 
(-2.57, -1.79)
9.83±0.13 
-2.48±0.20 
(-2.87, -2.10)
9.87±0.13 
-1.81±0.19 
(-2.19, -1.43)
Diff from Exe -0.37±0.14 -0.67±0.13 _
Baseline body weight (kg) 95.46±0.98 93.18±0.97 94.48±0.99
Change from baseline body 
weight (95% CI)
-1.60±0.37 
(-2.33, -0.88)
-2.33±0.37 
(-3.05, -1.60)
-2.27±0.36 
(-2.98, -1.56)
Diff from Exe 0.67±0.25* -0.05±0.25 _
*P<0.05; **P<0.0001
Supported by: Roche
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Retrospective cohort studies of the risk of acute pancreatitis: initiators 
of exenatide compared to other antidiabetic drugs in two commercial US 
health insurance claims databases
G. Bloomgren1, M. Wenten1, D. Dore2, J. Seeger2;
1Amylin Pharmaceuticals, Inc., San Diego, 2i3 Drug Safety, Waltham, USA.
Background and aims: Cases of acute pancreatitis (AP) in patients treated 
with exenatide BID (Ex BID) have been reported.
Objective: To estimate the risk of AP in Ex BID initiators compared to initia-
tors of other antidiabetic drugs (AD).
Materials and methods: Two retrospective studies were conducted to 
compare the rates of AP between patients without prior claims for pancre-
atic disease who initiated Ex BID or other AD (from 6/2005 to 12/2008) 
within 2 US commercial healthcare claims databases (Normative Health 
Information Database [NHI], Lifelink). The study protocols were similar 
to evaluate reproducibility of results. Both studies compared the risk of AP 
during periods of current, recent, or past exposure to Ex BID relative to 
other AD. AP cases were defined as patients with medical chart-confirmed 
acute pancreatitis (NHI) or claims for a hospitalisation associated with a 
primary diagnosis of AP (Lifelink). The NHI study used a multivariable 
Poisson regression model to estimate the AP propensity score adjusted rate 
ratios (RRs), and 95% confidence intervals (CIs) for current, recent, or past 
exposure. It included a blinded-medical record adjudication of claims-
identified AP cases and a nested case-control study (NCCS) that involved 
conditional logistic regression modeling to obtain odds ratios (ORs) and 
95% CIs adjusted for differences in the prevalence of risk factors between 
patients who persisted or discontinued the study drugs. The LifeLink study 
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analysis used discrete-time survival models to account for time-dependent 
exposure and inverse probability of treatment weighting to estimate ORs 
and 95% CIs for current, recent, or past Ex BID exposure accounting for 
measured risk factors.
Results: In both studies, Ex BID-treated patients were more likely to be 
female, obese, and had more evidence of diabetes complications than 
initiators of other AD. In the NHI database, there were 40 confirmed-AP 
cases in the Ex BID cohort (N=25,719), compared to 254 cases in the 
other AD cohort (N=234,536). In the LifeLink database, there were 46 AP 
cases in the Ex BID initiation cohort (N= 24,437) and 802 AP cases in the 
other AD cohort (N=457,797). In both analyses, current and recent Ex 
use periods were not associated with an increased risk of AP (Figure). For 
the past Ex BID use group in the NHI study, an increased risk of AP was 
observed, which was attenuated following NCCS adjustments for chole-
lithiasis, past AP, and obesity identified from the medical record review. 
However, in the LifeLink study, past Ex BID use was not associated with 
an increased risk.
Conclusion: Two studies using distinct analytic methods and data sets found 
Ex use was not associated with an increased risk of AP.
Supported by: Amylin Pharmaceuticals, Inc. and Eli Lilly & Co.
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Effect of sitagliptin on glucose control in patients with type 1 diabetes - a 
pilot study
S.L. Ellis, E.G. Moser, J.K. Snell-Bergeon, R.S. Gutin, A.S. Rodionova,  
S.K. Garg;
Barbara Davis Center for Diabetes, University of Colorado Denver, Aurora, 
USA.
Background: Despite new therapies and technology, the average A1c in pa-
tients with type 1 diabetes (T1DM) remains well above ADA recommended 
targets. This investigator-initiated pilot study was designed to evaluate the ef-
fects of sitagliptin in poorly controlled (A1c 8.5-12%) patients with T1DM.
Methods: The study outcomes included area-under-the-curve for glucose 
excursions, A1c, and mean glucose values and other glycemic indices from 
CGM. Twenty patients were enrolled in this pilot randomized, double-blind, 
cross-over study to receive sitagliptin 100 mg daily or placebo for 1 month 
and then crossed over for 1 month. All patients used a blinded DexCom con-
tinuous glucose monitor (CGM) throughout the study period.
Results: There were no differences in baseline demographics between the 
two groups. Mean ± SD age and duration of diabetes were 32.5 ± 12.3 and 
17.3 ± 7.5 years respectively. One patient was discontinued while on placebo 
for severe hypoglycemia. There was a significant reduction in insulin dose 
in subjects while on sitagliptin (p=0.02). Sitagliptin use reduced A1c values 
during both periods within groups. After controlling for period, treatment 
and insulin dose, there was a significant reduction in A1c in patients receiv-
ing sitagliptin (LSM = -0.27±0.11%; p=0.025; Figure). The CGM downloads 
showed a decrease in mean (± SE) blood glucose (-10.9 ± 3.8, p=0.012), J 
Index (-9.0 ± 3.1, p=0.010), High Blood Glucose Index (2.2 ± 0.70, p=0.007), 
M100 (-8.1 ± 2.7, p=0.009) and GRADE (-1.1 ± 0.4, p=0.023) when patients 
were receiving sitagliptin. Time spent in euglycemic range (80-140 mg/dl) 
was also significantly increased during sitagliptin use (0.46±0.20, p=0.046), 
while subjects trended to spending less time (hrs) in hyperglycemic range 
>240mg/dl (-0.55± 0.38, p=0.17).
Conclusions: We conclude that sitagliptin reduced total daily insulin dose, 
A1c and mean blood glucose values in patients with T1DM. Further research 
involving larger sample size for a longer period is needed to determine ef-
ficacy and safety of sitagliptin in patients with type 1 diabetes.
Supported by: Merck & Co., Inc.
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Comparing ITCA 650, continuous subcutaneous delivery of exenatide 
via DUROS® device, vs. twice daily exenatide injections in metformin-
treated type 2 diabetes
R.R. Henry1, R. Cuddihy2, J. Rosenstock3, T. Alessi4, K. Luskey4;
1University of California, San Diego, La Jolla, 2International Diabetes Center, 
Minneapolis, 3Dallas Diabetes and Endocrine Center, Dallas, 4Intarcia 
Therapeutics Inc., Hayward, USA.
Background and aims: ITCA 650 provides for the continuous and consistent 
delivery of exenatide using the DUROS technology, a subcutaneous osmotic 
delivery system that can deliver exenatide for up to 12 months with a single 
administration. This provides the opportunity to escalate to optimal doses of 
exenatide with good tolerability and ensure 100% patient compliance.
Materials and methods: A phase 2 study to evaluate the efficacy, safety and 
tolerability of ITCA 650 treatment with an introductory treatment dose dur-
ing the initial 12 weeks and subsequent dose escalation is being conducted 
in subjects with inadequately controlled, metformin-treated type 2 diabetes 
(T2DM). In this study, subjects (n=50 /group) were initially randomized to 
receive either 20 or 40 mcg/day of exenatide delivered by ITCA 650 for 12 
weeks or twice daily exenatide injections at 5 mcg BID for 4 weeks followed 
by 10 mcg BID for 8 weeks. Subsequently, subjects were randomized to re-
ceive ITCA 650 at 20, 40, 60 or 80 mcg/day for an additional 12 weeks.
Results: Treatment with ITCA 650 was well tolerated with less reported nau-
sea at 20 mcg/day relative to exenatide injections. HbA1c was significantly 
lower after 12 weeks in all treatment groups (p<0.001 at week 12 relative to 
baseline). Weight was also reduced in all treatment groups. Dose escalation to 
ITCA 650 at the higher doses of 60-80 mcg/day resulted in further reductions 
in HbA1c at week 16 with a change of -1.3% (n=36) relative to baseline and 
continued weight loss.
Conclusion: ITCA 650 represents a novel and attractive treatment to deliver 
exenatide in a well-tolerated fashion that ensures 100% compliance for the 
long-term treatment of T2DM, resulting in substantial changes in HbA1c 
and weight without the need for repeated self injections. Escalation to higher 
doses leads to further reductions in HbA1c and weight in the long-term treat-
ment of T2DM.
S 40 Diabetologia (2010) 53:[Suppl1]S1–S556
1 C
HbA1c and Weight Loss at Week 12
Dose Group n Baseline 
HbA1c
HbA1c at 
Week 12
Change in 
HbA1c at 
Week 12
HbA1c 
≤7% at 
Week 12
n Change in 
weight at 
Week 12
ITCA 650
20 mcg/day
36 7.9% 
±0.8%
7.1% 
±0.8%
-0.8% 
±0.9%
58% 33 -0.5% 
±2.5%
ITCA 650
40 mcg/day
38 8.1% 
±0.8%
7.1% 
±0.8%
-1.0% 
±0.7%
63% 38 -2.1%
±3.3%
Exenatide 
injections
38 8.0% 
±0.9%
7.2% 
±0.8%
-0.8% 
±0.8%
53% 34 -1.9% 
±2.3%
OP 14 Biomarkers and coronary 
heart disease risk
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Fluctuation of haemoglobin A1c is associated with higher incidence of 
cardiovascular disease in patients with type 2 diabetes
R. Bouchi, T. Babazono, M. Mugishima, N. Yoshida, I. Nyumura, K. Toya,  
T. Hayashi, K. Hanai, N. Tanaka, A. Ishii, Y. Iwamoto;
Division of Nephrology and Hypertension, Diabetes Center, Tokyo Women’s 
Medical University, Japan.
Background and aims: Recent studies demonstrated that variability of he-
moglobin A1C (HbA1C) may be associated with the risk of diabetic micro- 
and macrovascular complications in patients with type 1 diabetes; however, 
whether the similar association may exist in patients with type 2 diabetes is 
unclear. We, therefore, conducted this cohort study to highlight the relation-
ship between the fluctuation of HbA1C and incident cardiovascular disease 
(CVD) in patients with type 2 diabetes.
Materials and methods: We studied 689 Japanese type 2 diabetic patients 
with an estimated glomerular filtration rate (eGFR) ≥ 15 mL/min/1.73 m2, 
including 295 women and 394 men (mean [± SD] age: 65 ± 11 years). Patients 
were observed at least 12 months. Variability of HbA1C was defined as the in-
trapersonal SD of serially measured HbA1C during the whole follow-up peri-
od. Patients were divided into quartiles of SD HbA1C. The primary endpoint 
was defined as incident CVD including cerebral infarction and hemorrhage, 
myocardial infarction, and angina pectoris requiring coronary revasculariza-
tion. Cox proportional hazard model was used to calculate hazard ratio and 
95% confidence interval (95% CI). In the multivariate Cox regression analy-
sis, the following variables were incorporated and selected by the stepwise 
procedure; age, sex, duration of diabetes, presence of proliferative diabetic 
retinopathy, smoking status, use of renin-angiotensin system inhibitors, an-
tiplatelet agents and statins, hemoglobin, uric acid, eGFR, urinary albumin-
to-creatinine ratio (ACR) at baseline, the mean of body mass index, systolic 
and diastolic blood pressures, triglycerides, high-density lipoprotein (HDL) 
and low-density lipoprotein (LDL) cholesterol levels during the follow-up pe-
riod, and the mean, SD and number of measured HbA1C.
Results: During a median follow-up period of 3.3 years (range: 1.0 - 6.3 years, 
2,279 patient-years), 26 ± 14 measurements of HbA1C were obtained per pa-
tient, and incident CVD episodes were observed in 61 patients (26.8 episodes 
per 1,000 patient-years). Patients with higher quartiles of SD HbA1C had a 
higher incidence of CVD; five-year cumulative incidence of CVD in patients 
with the first, second, third, and fourth quartile in order of increasing were 
4.9, 8.7, 17.1, and 26.2%, respectively (p < 0.001 by the log-rank test). In the 
multivariate Cox analysis, the fourth quartile of SD HbA1C was associated 
with significantly higher incidence of CVD (hazard ratio 3.38, 95% CI 1.07 
- 10.63) versus the first quartile, independently of the mean of HbA1C and 
traditional cardiovascular risk factors. Other significant covariates remained 
in the Cox model were age (hazard ratio 1.03, 95% CI 1.00 - 1.07), logarith-
mically transformed urinary ACR (hazard ratio 2.24, 95% CI 1.58 - 3.17, p 
< 0.001), and history of CVD (hazard ratio 2.34, 95% CI 1.32 - 4.16, p = 
0.004).
Conclusion: Visit-to-visit variability of HbA1C may be a potent predictor of 
incident CVD, independent of mean HbA1C in Japanese patients with type 
2 diabetes.
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Significant association of TCF7L2 variant rs7903146 with 
angiographically characterised coronary artery disease in women
A. Muendlein1,2, C.H. Saely1,2, S. Geller-Rhomberg1, G. Sonderegger1,  
P. Rein1,2, T. Winder1,2, S. Beer1,2, A. Vonbank1,2, H. Drexel1,2;
1Vorarlberg Institute for Vascular Investigation and Treatment, Feldkirch, 
Austria, 2Private University of the Principality of Liechtenstein, Triesen, 
Liechtenstein.
Background and aims: Type 2 diabetes mellitus (T2DM) confers a particu-
larly high risk of coronary artery disease (CAD) in women. Variations in the 
transcription factor 7-like 2 (TCF7L2) gene, particularly rs7903146, increase 
T2DM risk; their association with CAD is uncertain, no data are available for 
women. We therefore aimed at investigating potential links between TCF7L2 
variant rs7903146 and CAD in women.
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Materials and methods: We therefore investigated the association between 
rs7903146 and angiographically determined CAD in a cohort of 554 female 
Caucasian patients undergoing coronary angiography for the evaluation of 
established or suspected CAD. At angiography, significant CAD was diag-
nosed in the presence of significant coronary stenoses with lumen narrow-
ing of ≥50%. The severity of CAD was calculated as the sum of all stenosis 
percentages of a given patient divided by the number of coronary stenoses 
in this patient and the extent as the number of significant coronary stenoses. 
The association between rs7903146 and CAD was evaluated in an additive 
genetic model.
Results: Variant rs7903146 was significantly associated with angiographically 
characterized CAD (additive odds ratio (OR)=1.37 [1.07-1.76]; p=0.011). 
Adjustment for age, smoking, BMI, total- and HDL-cholesterol did not sig-
nificantly change this finding (OR)=1.37 [1.06-1.78]; p=0.016). Also, after 
further adjustment for T2DM, the association between rs7903146 and CAD 
remained significant (OR=1.31 [1.00-1.70]; p=0.047). Further, the extent of 
CAD significantly increased from subjects who were homozygous for the 
C allele over heterozygous subjects to those who carried the TT genotype 
(0.79±1.45, vs. 0.95±1.40 and 0.98±1.50, respectively; p=0.022). Similarly, a 
significant association between SNP rs7903146 and the severity of coronary 
lesions was observed (severity scores of 26.1±36.7, 35.7±39.9, and 36.7±39.4 
for the CC, CT, and TT genotype, respectively; p=0.004).
Conclusion: We conclude that TCF7L2 variant rs7903146 is significantly as-
sociated with angiographically diagnosed CAD in women.
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Trajectories of adiponectin before coronary heart disease (CHD): the 
Whitehall II prospective cohort study
M. Carstensen1, C. Herder1, M. Kivimäki2, M. Jokela2, M. Roden1,3,  
M.J. Shipley2, D.R. Witte2,4, E.J. Brunner2, A.G. Tabák2,5;
1German Diabetes Center, Düsseldorf, Germany, 2University College 
London, United Kingdom, 3University Hospital Düsseldorf, Germany, 
4Steno Diabetes Center, Gentofte, Denmark, 5Semmelweis University, 
Budapest, Hungary.
Background and aims: Adiponectin, an adipocyte-specific cytokine, is as-
sociated with reduced risk of type 2 diabetes, and it has anti-inflammatory, 
anti-thrombotic and anti-atherogenic properties. Although coronary heart 
disease (CHD) is a major complication of type 2 diabetes, high adiponectin 
levels have not been consistently linked to reduced CHD risk. One hypothesis 
is that the association between adiponectin and CHD varies as a function of 
the disease process over time. Thus, we took advantage of data from repeated 
measurements of adiponectin (i) to examine how serum adiponectin concen-
trations change during years preceding the manifestation of CHD and (ii) to 
compare these trajectories with those from individuals who did not develop 
CHD.
Materials and methods: This is a case-cohort analysis within the Whitehall 
II cohort with a total of 2778 participants without CHD at baseline, 26.9% 
women, mean age at baseline 49.3 (SD 5.9) years and average BMI 25.2 (SD 
3.5) kg/m2. There were 284 incident cases of CHD (myocardial infarction, 
angina) during follow-up and 2494 non-cases who remained CHD-free. Se-
rum adiponectin was measured at up to three time points for each participant 
(phase 3, the baseline: 1991-94; phase 5: 1997-99; phase 7: 2003-04). Year 
0 of the observation period was the year of CHD diagnosis for cases and a 
randomly selected time point during follow-up for non-cases to approximate 
the follow-up time distribution of cases. Adiponectin levels were traced back-
wards up to participants’ first adiponectin measurement. Multilevel models 
adjusted for age, sex and ethnicity were fitted to assess changes in adiponectin 
during the preceding 13 years based on 398 and 3871 serum samples in cases 
and non-cases, respectively.
Results: Serum adiponectin levels were 6% lower in cases [mean (95% CI), 
8457 (8021; 8916) ng/ml] than in non-cases [8989 (8837; 9151) ng/ml] at 
study baseline. This difference remained constant during the follow-up in a 
model adjusted for age, sex and ethnicity (p=0.03) which means that it was 
independent of time until CHD diagnosis. The addition of nonlinear time 
terms for CHD cases did not improve the fit of the multilevel models, nor did 
these terms reach statistical significance. After adjustment for BMI or waist 
circumference as time-varying covariates, the slope of the linear upward 
adiponectin trajectories remained similar both among cases and non-cases, 
however the difference between the two groups was no longer statistically 
significant.
Conclusion: Adiponectin is mildly, but significantly lower in individuals who 
develop CHD throughout the 13 years preceding disease onset compared to 
those who remained CHD-free. BMI or waist circumference accounted for a 
substantial part of this difference, suggesting that adiponectin does not pre-
dict CHD independently of obesity. We found no support for the hypothesis 
that the association between adiponectin and CHD varies as a function of the 
disease process.
Supported by: Medical Research Council (UK) New Investigator Award
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Vitamin D levels and asymptomatic coronary artery disease in type 2 
diabetic patients with elevated urinary albumin excretion rate
C. Joergensen1, H. Reinhard1, A. Schmedes2, P.R. Hansen3, N. Wiinberg4, 
C.L. Petersen4, K. Winther5, H.-H. Parving6,7, P.K. Jacobsen8,1, P. Rossing1;
1Steno Diabetes Center, Gentofte, 2Dept. of Clinical Biochemistry, Lillebaelt 
Hospital, Vejle, 3Dept. of Cardiology, Gentofte University Hospital, 4Dept. 
of Clinical Physiology and Nuclear Medicine, Frederiksberg University 
Hospital, 5Dept. of Clinical Biochemistry, Frederiksberg University Hospital, 
Gentofte, 6Dept. of Medical Endocrinology, Copenhagen University 
Hospital, Rigshospitalet, 7Faculty of Health Science, Aarhus University, 
8Copenhagen University Hospital, Rigshospitalet, Denmark.
Background and aims: Coronary artery disease (CAD) is the major cause of 
morbidity and mortality in type 2 diabetic patients. Severe vitamin D defi-
ciency has been shown to predict cardiovascular mortality in type 2 diabetic 
patients. We investigated the association between severe vitamin D deficiency 
and asymptomatic CAD in type 2 diabetic patients with elevated urinary al-
bumin excretion rate (UAER) > 30mg/24h. Furthermore, we evaluated the 
association between severe vitamin D deficiency and coronary calcium score 
(CCS).
Materials and methods: A cross sectional study including 200 type 2 dia-
betic patients without clinical signs of CAD. Plasma 25-hydroxy-vitamin D 
levels were determined by high performance liquid chromatography/tandem 
mass spectrometry. Severe vitamin D deficiency was defined as plasma 25-
hydroxy-vitamin D < 12.5 nmol/l. Patients with plasma NT-proBNP > 45.2 
ng/L and/or CCS > 400 were arbitrarily stratified as high risk patients for 
CAD (n = 129). High risk patients were examined by myocardial perfusion 
imaging (MPI; n = 109), and/or CT-angiography (CTA; n = 20), and/or coro-
nary angiography (CAG; n = 86).
Results: Patients received mulitifactorial treatment, yielding mean (SD) 
HbA1c 7.9 (1.3) %, plasma total cholesterol 3.9 (0.9) mmol/l and arterial blood 
pressure 130 (17)/75 (11) mmHg.
Median (range) vitamin D level was 36.9 (3.8-118.6) nmol/l. Vitamin D was 
not associated with sex, blood pressure, HbA1c and UAER but a weak positive 
association was found with age (R = 0.159, p = 0.025). The prevalence of se-
vere vitamin D deficiency was 9.5% (19/200). In 70 (35%) patients significant 
CAD was demonstrated by MPI and/or CAG. In a logistic regression model, 
severe vitamin D deficiency was associated with asymptomatic CAD, unad-
justed odds ratio (OR [95% CI] 2.24 [0.87-5.81]; p = 0.097). After adjusting 
for additional risk factors (sex, age, plasma total cholesterol, plasma creati-
nine, distal systolic blood pressure at toe level, vibratory perception threshold, 
heart rate variability and plasma NT-proBNP), the OR was 5.00 [1.28-19.49]; 
p = 0.020. The prevalence of CCS > 400 was 34% (68/200). Severe vitamin 
D deficiency was significantly associated with CCS > 400 (unadjusted OR 
4.32 [1.54-12.10]; p = 0.005). The association persisted after adjusting for all 
additional risk factors, (OR 3.98 [1.20-13.113]; p = 0.023). Moderate vitamin 
D deficiency, plasma 25-hydroxy-vitamin D: 12.5-25 nmol/l, and vitamin D 
insufficiency plasma 25-hydroxy-vitamin D: 25-50 nmol/l, were not signifi-
cantly associated with increased presence of CAD or CCS > 400.
Conclusion: In high risk type 2 diabetes patients with elevated urinary albu-
min excretion rate, low levels of vitamin D are strongly and independently 
associated with asymptomatic coronary artery disease.
Supported by: an EFSD Clinical Research Grant
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Prevalence and risk factors accounting for true silent myocardial 
ischaemia (clandestine ischaemia) in type 2 diabetic patients: a pilot 
case-control study
C. Hernández1, J. Candell-Riera2, A. Ciudin3, S. Aguadé-Bruix4, R. Simó1;
1Diabetes and Metabolism Research Unit , CIBERDEM and RECAVA, 
Institut de Recerca Hospital Universitari Vall d’Hebron, 2Cardiology 
Department and RECAVA, Hospital Universitari Vall d’Hebron, 3Diabetes 
and Metabolism Research Unit, Institut de Recerca Hospital Universitari 
Vall d’Hebron, 4Nuclear Medicine Department and RECAVA, Hospital 
Universitari Vall d’Hebron, Barcelona, Spain.
Background and aims: Given the elevated risk of cardiovascular events and 
the higher prevalence of silent coronary artery disease (CAD) in diabetic ver-
sus non-diabetic patients, the need to screen asymptomatic diabetic patients 
for CAD assumes increasing importance. The term of silent ischemia includes 
an entity named true silent myocardial ischemia or clandestine myocardial 
ischemia, which is characterized by myocardial perfusion defects in the ab-
sence of both angina and ST-segment depression > 1 mm during the exercise 
test. To the best of our knowledge there have been no studies addressed to 
determining its prevalence and the risk factors associated with its develop-
ment. The aims of the study were to assess prospectively the prevalence and 
clinical predictors of true silent myocardial ischemia or clandestine ischemia 
in asymptomatic type 2 diabetic patients.
Material and methods: Stress myocardial perfusion gated-SPECT (Single 
Photon Emission Computed Tomography) was carried out in 41 type 2 dia-
betic patients without history of cardiovascular disease and 41 nondiabetic 
patients matched by age and gender. Left ventricular end-diastolic and end-
systolic volumes, and ejection fraction were also measured in gated-SPECT. 
Exclusion criteria were: 1) history of cardiovascular disease (CVD); 2) elec-
trocardiographic evidence of Q-wave myocardial infarction, ischemic ST 
depression, T-wave changes, or complete left bundle branch block; 3) flat or 
downsloping ST segment depression > 1 mm at 80 ms after the J-point during 
an exercise test on a bicycle ergometer.
Results: Apart from diabetes there were no significant differences between 
the two groups regarding either the classic CVD risk factors (age, gender, 
smoking habit, dyslipemia, hypertension, and family history of CAD) or left 
ventricular function. Clandestine ischemia was detected in 21.9% of type 2 
diabetic patients but only in 2.4% of controls (p<0.01). The presence of myo-
cardial perfusion defects did not correlate with the number of risk factors but 
was independently associated with male gender and the presence of diabetic 
retinopathy (DR). The probability of having myocardial perfusion defects in 
an asymptomatic diabetic patient with DR was 11.7 [IC95%: 3.7-37].
Conclusion: We conclude that clandestine ischemia is frequent in asymp-
tomatic type 2 diabetic patients. In addition, DR is a high risk condition for 
true silent myocardial ischemia in asymptomatic type 2 diabetic patients, and 
point to these patients as a target to be screened for cardiovascular disease. 
Further prospective studies evaluating the prognostic value of these findings 
and their impact in economical terms are warranted.
Supported by: grants from CIBERDEM and RECAVA (ISCIII).
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Type 2 diabetes is not a coronary heart disease risk equivalent: 
results from an 8-year prospective cohort study on angiographically 
characterised coronary patients
T. Gansch1, C.H. Saely1,2, A. Vonbank1,2, P. Rein1,2, S. Beer1,2, S. Greber1,  
H. Drexel1,2;
1Vorarlberg Institute for Vascular Investigation and Treatment, Feldkirch, 
Austria, 2Private University of the Principality of Liechtenstein, Triesen, 
Liechtenstein.
Background and aims: Current guidelines consider diabetes as a coronary 
artery disease (CAD) risk equivalent, but cardiovascular risk in patients with 
diabetes may vary substantially depending on the presence of subclinical 
CAD at baseline. In the present study we therefore aimed at investigating the 
contribution of baseline coronary atherosclerosis to the risk of future vascu-
lar events in patients with diabetes.
Materials and methods: Vascular events were recorded over 8 years in 750 
consecutive patients undergoing coronary angiography for the evaluation of 
established or suspected stable CAD.
Results: From our patients, 244 had neither type 2 diabetes (T2DM) nor sig-
nificant CAD (i.e. coronary stenoses ≥50%) at the baseline angiography, 50 
had T2DM but not significant CAD, 342 did not have T2DM but had sig-
nificant CAD, and 114 had both T2DM and significant CAD. Non-diabetic 
subjects without significant CAD had an event rate of 20.5%. The event rate 
was similar in T2DM patients without significant CAD (22.0%; p = 0.811), 
but higher in non-diabetic patients with significant CAD (39.5%, p <0.001). 
Patients with T2DM plus significant CAD had the highest event rate (53.5%; 
p <0.001). Importantly, T2DM patients without significant CAD had a sig-
nificantly lower event rate than non-diabetic patients with significant CAD 
(p = 0.017).
Conclusion: T2DM per se is not a CAD risk equivalent. Moderate risk dia-
betic patients without significant CAD and very high-risk diabetic patients 
with significant CAD add up to a grand total of high risk diabetic patients: 
this is why diabetes appears as a CAD risk equivalent in many epidemiologi-
cal studies.
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Long-term prevention of mortality in morbid obesity through bariatric 
surgery. A systematic review and meta-analysis of trials performed with 
gastric banding and gastric bypass
A. Morabito1, A.E. Pontiroli1,2;
1Dipartimento di Medicina, Chirurgia e Odontoiatria, Università degli studi 
di Milano, 2Dipartimento di Medicina, Ospedale San Paolo, Milano, Italy.
Background: Bariatric surgery has been reported to reduce long-term mor-
tality in comparison with non-operated subjects, but there are no studies 
comparing gastric banding and gastric by-pass.
Methods: We performed a systematic review and meta-analysis of clinical 
trials published as full papers dealing with all-cause mortality, cardiovascular 
mortality, and global mortality (sum of all-cause and cardiovascular mortal-
ity). Pooled-random effects of estimates of the risk of mortality in subjects 
undergoing surgery, compared with controls, were calculated using the Der 
Simonian and Laird models.
Results: Of 44,022 participants from eight trials, death occurred in 3,317 sub-
jects (400 in surgery, 2,917 in controls); when the kind of death was specified, 
321 cardiovascular deaths (118 in surgery, 203 in controls), and 523 all-cause 
deaths (218 in surgery, 305 in controls) occurred. Compared with controls, 
surgery was associated with a reduced risk of global mortality (OR = 0.27, 
95% C.I. 0.16-0.45), of cardiovascular mortality (OR = 0.43, C.I. 0.24-0.77), 
and of all-cause mortality (OR = 0.60, C.I. 0.37-0.97). Data of all-cause mor-
tality were not heterogeneous; heterogeneity of data of cardiovascular mor-
tality and of global mortality disappeared when studies were grouped accord-
ing to size (larger vs smaller studies). At meta-regression analysis, decrease of 
global mortality (Log OR) was significantly associated with increasing BMI 
(p = 0.036). The effect of gastric banding and gastric by-pass (3,797 vs 10,255 
interventions) was not significantly different for the any kind of mortality.
Conclusion: This meta-analysis indicates that: 1) bariatric surgery reduces 
all-cause, cardiovascular, and global mortality; 2) there are no significant dif-
ferences between gastric banding and gastric by-pass; 3) the effect is more 
evident for greater BMI.
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Weight loss modulates DNA methylation of peroxisome proliferator-
activated receptor gamma coactivator-1 and pyruvate dehydrogenase 
kinase, isozyme 4 promoters
J. Yan1, R. Barrès1, A. Krook1, E. Näslund2, J.R. Zierath1;
1Karolinska Institutet, 2Department of Clinical Sciences, Danderyd Hospital, 
Karolinska Institutet, Stockholm, Sweden.
Background and aims: Obesity is associated with reduced insulin sensitiv-
ity and extensive changes in skeletal muscle. When diet and drugs no longer 
work, many morbidly obese individuals opt to undergo bariatric surgery as 
a means to reduce body mass. DNA methylation is believed to be modulated 
by the environment and can act as a reversible switch of gene expression that 
can lock genes in an active or repressed state. We determined whether DNA 
methylation of select proteins is altered in obesity and after weight loss.
Materials and methods: DNA methylation level of the Peroxisome Prolifera-
tor-Activated Receptor γ Coactivator-1 α (PGC-1α) and Pyruvate Dehydro-
genase Kinase, isozyme 4 (PDK4) promoters was investigated in vastus lat-
eralis skeletal muscle from eight non-diabetic obese people (41.8 ± 3.7 years) 
before (BMI 42.1 ± 1.5 kg/m2) and six months after gastric bypass surgery 
(BMI 31.2 ± 1.6 kg/m2).
Results: Plasma concentrations of glucose and insulin were reduced 6 months 
after weight loss surgery (5.6 ± 0.3 vs 4.8 ± 0.2 mmol/L and 99.9 ± 19.8 vs 
56.6 ± 8.4 pmol/L, glucose and insulin, respectively). Levels of inflammatory 
cytokines such as C-reaction protein (CRP) and monocyte chemoattract-
ant protein-1 (MCP-1) were markedly decreased after weight loss surgery. 
Weight loss induced hypomethylation of the PGC-1α promoter and hyper-
methylation of the PDK4 promoter as examined by bisulfite DNA methyla-
tion analysis. These changes in DNA methylation levels were inversely cor-
related with mRNA expression of PGC-1α and PDK4. To determine whether 
systemic factors associated with insulin resistance and obesity influence pro-
moter methylation, we incubated primary human skeletal muscle cultures for 
48 hours with tumor necrosis factor-α (TNF- α). In vitro exposure of muscle 
cells triggered hypermethylation of the PGC-1α promoter and hypomethyla-
tion of the PDK4 promoter.
Conclusion: The dynamic regulation of PGC-1α and PDK4 promoter methyla-
tion with obesity and after weight loss surgery appears to contribute to the reg-
ulation of mRNA expression and metabolism. Our results further suggest that 
environmental factors acutely alter the methylation status of promoters regu-
lating glucose and lipid metabolism in skeletal muscle. DNA methylation in 
somatic cells appears to be a more dynamic process than previously thought.
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Assessment of insulin secretion and insulin sensitivity with the 
hyperglycaemic clamp in type 2 diabetic patients with BMI below 35 
Kg/m2 submitted to ileal interposition associated to sleeve gastrectomy
S.A.C. Vencio1, A.R. Stival2, A.L. De Paula2;
1Endocrinology, Hospital de Especialidades, 2Metabolic Surgery, Hospital de 
Especialidades, Goiania, Brazil.
Background and aims: Type 2 diabetes is a progressive disease. Beta cell failure 
is related to the reduction in insulin secretion and associated with some com-
plications of the disease. Laparoscopic ileal interposition associated with sleeve 
gastrectomy (II-SG) had demonstrated a positive effect in insulin resistance. 
We used the hyperglycemic clamp, the gold standard method for measurement 
of insulin secretion to assess the impact of this operation on beta cell function.
Materials and methods: A 3-hour hyperglycemic clamp was performed in 35 
patients preoperatively and in 33 patients postoperatively. To calculate the first 
phase insulin secretion (1st phase), an intravenous glucose load was made at 
the beginning. In the 170 minutes remaining, glucose was kept 125 mg / dl 
above basal glucose, in order to calculate the second phase insulin secretion (2nd 
phase). Mean age was 55 years (range 34-69 years). Mean diabetes duration was 
12.3 years (5-24 years). Mean follow-up was 20 months (range 8-38 months).
Results: Postoperatively, BMI decreased from 29.5 +-5.2 Kg/m2 to 22.1 +- 2.4 
Kg/m2. Mean plasma glucose was 259 mg/dl in preoperative and 239 mg/dl 
in postoperative period. Insulin sensitivity increased from 69.4 mmol.min-
1.nmol-1 to 95.5 mmol.min-1.nmol-1. In the 1st phase, the acute C-peptide re-
sponse was 2219 +- 2268 pmol.l-1 .10min and increased to 2617 +- 2164 pmol.
l-1 .10min. The relation of incremental C-peptide area under the curve and 
incremental glucose area under the curve, increased from 30 +- 24 pmol.
mmol-1 to 46 +- 30 pmol.mmol-1. The evaluation of the 2nd phase by the 
insulin incremental area and insulin sensitivity was 688 x 104 pmol.mmol.
nmol-1 and increased to 811 x 104 pmol.mmol.nmol-1 postoperatively.
Conclusion: In non morbidly obese type 2 diabetic patients ileal interposi-
tion associated with sleeve gastrectomy showed an important improvement 
in insulin secretion after a mean follow-up of 20 months as demonstrated by 
the hyperglycemic clamp.
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The role of apolipoprotein A5 in non-alcoholic fatty liver disease
C. Ress1, A. Moschen2, A. Tschoner1, C. Ciardi1, C.F. Ebenbichler1,  
J.R. Patsch1, H. Tilg2, S. Kaser1;
1Department of Medicine 1, 2Department of Medicine 2, Medical University 
Innsbruck, Austria.
Background and aims: The term non-alcoholic fatty liver disease (NAFLD) 
comprises a wide spectrum of clinical entities ranging from simple steato-
sis, steatohepatitis to fibrosis and cirrhosis. NAFLD is strongly associated 
with obesity and is found in up to 91% of severe obese patients undergoing 
bariatric surgery. Apolipoprotein (apo) A5 is a recently discovered protein 
synthesized by the liver that plays a major role in triglyceride metabolism. In 
mice, overexpression of apoA5 leads to dramatically decreased plasma trig-
lyceride levels. Mechanistically, extracellular effects by activating lipoprotein 
lipase and intracellular effects have been proposed. In this study we aimed to 
investigate a possible role of apoA5 in NAFLD.
Materials and methods: Hepatic apoA5 mRNA expression was determined 
in 15 severely obese subjects with histologically proven NAFLD before and 
after pronounced weight loss due to bariatric surgery. Hepatic apoA5 mRNA 
expression was estimated by fluorescence-based real time polymerase chain 
reaction. Effects of apoA5 on hepatic triglyceride accumulation were investi-
gated in apoA5 deficient HepG2 cells due to transfection with apoA5 siRNA.
Results: Mean weight loss of 18 kg was accompanied by improved insulin 
sensitivity as estimated by the HOMA index and improvements in hepatic 
steatosis. In parallel, hepatic apoA5 mRNA expression was decreased by 41 % 
(p=0.017). Transfection of apoA5 siRNA in HepG2 led to a mean reduction 
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of 83 % in apoA5 mRNA expression (p=0.001), as determined by fluores-
cence-based real time PCR. Suppression of apoA5 in HepG2 cells resulted 
in a reduction of intracellular triglyceride content by 31 % (p<0.001), when 
compared to controls transfected with nonsilencing siRNA.
Conclusion: In summary, we found that pronounced weight loss in obese 
subjects with NAFLD results in a significant improvement of hepatic steatosis 
which is associated with a decline of hepatic apoA5 mRNA levels. Our in vit-
ro data suggest that weight loss induced reduction in hepatic apoA5 mRNA 
expression is not an epiphenomenon but has a causal role in improvement of 
NAFLD in morbid obesity.
Supported by: ÖDG
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Can diabetes and obesity be treated through the rectum?
T.E. Adrian1, S. Gariballa2, K.A. Parekh1, S.A. Thomas1, H. Saadi2,  
J. Al Kaabi2, N. Nagelkerke3, B.R. Gedulin4, A.A. Young4;
1Physiology, UAE University, 2Internal Medicine, UAE University, 
3Community Medicine, UAE University, Al Ain, United Arab Emirates, 
4Satiogen Pharmaceuticals Inc, San Diego, USA.
Background and aims: The enteroendocrine L cells produce glucagon gene 
products including GLP-1 and oxyntomodulin which are satiety factors and 
the former is an insulin secretagogue. The L-cells also produce PYY, the ma-
jor molecular form of which is also a satiety factor. The number of L-cells 
and hormonal contents increase distally through the gut with highest con-
centrations in the rectum. We have previously shown that intracolonic infu-
sion of bile salts in humans causes secretion of L-cell hormones, triggered via 
TGR5 membrane receptors. The present study was designed to investigate 
the dose-responsive effects of intrarectal taurocholic acid (TA) on circulat-
ing concentrations of GLP-1, PYY, insulin, glucose and on food intake of a 
subsequent meal.
Materials and methods: Ten obese type 2 diabetic subjects were each studied 
on five separate occasions after an overnight fast and administration of 100 
mg oral sitagliptin10 hours before the study. They then received an intrarectal 
infusion of either one of four amounts of TA (0.66, 2, 6.66, or 20 mmoles) or 
vehicle placebo in a random blinded fashion. Bile salts were administered in 
20 ml of a 1% carboxymethyl cellulose emulsion over 1 min. Hormone and 
glucose measurement was made in plasma samples were collected for one 
hour following the infusion. 75 mins after the infusion, the subjects were pre-
sented with an unlimited amount of a previously selected favorite meal and 
invited to eat until satisfied.
Results: TA caused a dose-responsive increase of GLP-1, PYY and insulin, 
with peak concentrations ~ 7-fold, 4-fold and 3-fold increased, respectively 
with 20 moles TA (all P<.0001). There was a corresponding decrease in cir-
culating glucose concentrations (P< 0.0001), with a decrease in glucose of 
~2.8 mmol/L with 20 moles TA. The TA infusions were also associated with 
a decrease in caloric consumption of the subsequent meal (P<0.0001), with a 
maximal inhibition of 45±6 % with 20 mmoles TA.
Conclusion: Intrarectal TA increased L cell secretion which markedly de-
creased food intake and, since the subjects had fasting hyperglycemia, this 
resulted in an incretin effect. These findings probably explain the glucose-
lowering effects of bile salt sequestrants. Intrarectal TGR5 agonists are likely 
to be valuable in the treatment of type 2 diabetes and obesity.
Supported by: Satiogen Pharmaceuticals
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Metabolic effects of transplanting gut microbiota from lean donors to 
subjects with metabolic syndrome
A. Vrieze1, F. Holleman1, M.J. Serlie2, M.T. Ackermans2, G.M. Dallinga-
Thie1, A.K. Groen3, E. van Nood1, J.F.W. Bartelsman4, R. Oozeer5, E. 
Zoetendal6, W.M. de Vos6,7, J.B.L. Hoekstra1, M. Nieuwdorp1;
1Department of Internal and Vascular Medicine, 2Department of 
Endocrinology and Metabolism, Academic Medical Centre, Amsterdam, 
3Center for Liver, Digestive, and Metabolic Diseases, University Medical 
Center Groningen, 4Department of Gastroenterology, Academic Medical 
Centre, Amsterdam, Netherlands, 5Danone Research Center, Paris, France, 
6Laboratory of Microbiology, Wageningen University, Netherlands, 
7Department of Veterinary Biosciences, University of Helsinki, Finland.
Background: Recent data in animal models revealed that obesity is associ-
ated with substantial changes in composition and metabolic function of gut 
microbiota. Moreover, colonization of germ-free mice with faeces harvested 
from obese mice resulted in a significantly greater increase in total body fat 
than colonization with a ‘lean microbiota’. However, data on the role of gut-
microbiota in human obesity are scarce. Thus, our aim was to examine the 
effect of faecal infusions derived from lean healthy donors on gut microbiota 
composition, glucose and lipids in metabolic syndrome.
Methods: This study was a double-blind, randomised controlled trial. A total 
of 18 male subjects with newly diagnosed metabolic syndrome (BMI≥30 kg/
m2, FPG>5.6mmol/L, TG>1,6 mmol/L with no medication use) underwent 
jejunum biopsies and subsequent polyethylene-glycol bowel lavage through 
duodenal tube followed by random assignment to either allogenic (from lean 
male donors with BMI<23 kg/m2, n=9) or autologous faecal transplantation 
(reinfusion of own collected faeces, n=9). We studied changes in sigmoidal 
microbiota composition and fasting lipidprofiles at 0.5, 2, 6 and 12 weeks after 
faecal transplantation. Weight, jejunal gut microbiota (epithelial biopsy) and 
glucose metabolism (peripheral and hepatic insulin sensitivity as assessed by 
hyperinsulinemic euglycemic clamp with stable isotopes) were studied before 
and 6 weeks after transplantation.
Results: Lean subjects were characterized by different sigmoidal gutmicrobi-
ota compared to obese subjects (by HITChip phylogenetic microarray analy-
sis). Fasting levels of TG-rich lipoproteins (TG/ApoB ratio) were significantly 
reduced following donor faeces (1.43 ± 0.21 to 1.11 ± 0.18, p<0.01) with no 
effect after autologous faeces infusion. REE and basal endogenous glucose 
production (EGP) did not change in both groups after faecal infusion. Al-
though weight remained stable, an improvement in both peripheral (Rd) and 
hepatic insulin sensitivity (suppression of EGP) was found 6 weeks after al-
logenic faeces (median Rd: from 26.2 to 45.3 μmol/kg.min, p=0.02 and EGP 
suppression: from 51.5 to 61.6 %, p=0.08) while no significant changes were 
observed in the autologous treatment group (Rd: from 21.0 to 19.5 μmol/
kg.min and EGP suppression:from 53.8 to 52.4 %, ns). Changes in jejunal 
microbiota are currently analyzed.
Conclusion: Lean donor faecal infusion improves hepatic and peripheral 
insulin resistance as well as fasting lipid levels in obese individuals with the 
metabolic syndrome underscoring the potential role of gut microbiota in the 
disturbances of glucose and lipid metabolism in obesity. Our data could pro-
vide pathophysiological insight in the metabolic deviations in obese subjects 
and a rationale for therapeutic intervention.
Supported by: VENI grant (NWO ZonMW) to M. Nieuwdorp
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The role of wnt antagonists in impaired beta cell exocytosis
T. Hamed, A. Salehi, E. Renström, A.H. Rosengren;
Lund University Diabetes Centre, Malmo, Sweden.
Background and aims: We have recently found that genetically encoded 
overexpression of ADRA2A (the alpha2A-adrenergic receptor) contributes 
to impaired insulin secretion in type 2 diabetes (T2D). The aim here is to get 
a more overall view of the adrenergic signaling system and linked molecular 
pathways in defective insulin release. Network methods have proven valuable 
for studying how cellular pathways cause disease and have been successfully 
applied to e.g. obesity. However, in the case of T2D little is known about the 
networks that drive the pathogenesis.
Materials and methods: We have used linear algebraic methods to analyze 
the topological overlap in microarray data from human islets and performed 
subsequent cluster analysis. Highly connected hub genes play an important 
role in networks, and hub gene validation has been conducted by insulin se-
cretion assays and patch-clamp recordings of exocytosis.
Results: We have characterized the gene expression networks in human is-
lets and identified a subnetwork with 120 genes connected to ADRA2A. The 
expression of this subnetwork was associated with reduced insulin secretion 
(p=0.008), elevated HbA1c (p=0.0002) and T2D (p=0.00006) in the islet do-
nors. Of the top 100 genes for which the expression was correlated with T2D 
in the microarray, as many as 53 belonged to the identified ADRA2A-related 
network (enrichment p value is 8e-189). One of the most highly connected 
hub genes of the ADRA2A subnetwork is a secreted frizzled-related protein 
(sfrp), which is an extracellular antagonist of the wnt system. Interestingly, 
TCF7L2, the strongest T2D gene known, is regulated by the wnt system. The 
role of sfrp in T2D has not been studied previously. Our data show that acti-
vation of the wnt system by wnt7a stimulated insulin secretion both during 
a 21 hour incubation at low glucose (5 mM) and when glucose thereafter 
was elevated to 16.7 mM (see Figure). Interestingly, sfrp has previously been 
shown to co-precipitate with wnt7a in neuron studies, and the addition of 
sfrp completely antagonized the stimulatory effect of wnt7a in islets (p<0.05). 
These findings were paralleled on the single-cell level. Beta-cell exocytosis 
increased from 12.5±2.2 fF/pF to 20.6±3.3 fF/pF (p=0.045) by pre-treatment 
with 400 ng/ml wnt7a. The stimulatory effect of wnt7a was abolished by the 
addition of 100 nM sfrp (10.2±4.1 fF/pF). Sfrp also had an inhibitory effect 
on its own and reduced exocytosis to 5.9±1.4 fF/pF (p=0.013 vs. control, and 
p=0.0002 vs. wnt7a).
Conclusion: We have characterized the gene expression networks in human 
islets and identified an ADRA2A-related subnetwork that is associated with 
T2D. One of the subnetwork hub genes, sfrp, reduced insulin secretion and 
beta-cell exocytosis when applied alone or in combination with wnt activa-
tors. This validates the importance of the identified subnetwork in T2D and 
illuminates an extracellular player that could affect insulin secretion through 
the TCF7L2 pathway.
Supported by: Novo Nordisk Foundation and the Albert Pahlsson Foundation
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Resveratrol potentiates glucose-stimulated insulin secretion in INS-1E 
cells and human islets through SIRT1 dependent mechanism
L. Vetterli1, J. Rodgers2, D. Bosco3, P. Puigserver2, P. Maechler1;
1Department of Cell Physiology and Metabolism, University of Geneva, 
Switzerland, 2Department of Cancer Biology, Harvard Medical School, 
Boston, USA, 3Department of Surgery, University of Geneva, Switzerland.
Background and aims: Sirtuins are energy sensors which mediate effects of 
calorie restriction-induced lifespan extension. SIRT1, one of the mammalian 
Sirtuin homolog, is a transcription factor that deacetylates specific substrates. 
Previous studies have shown that SIRT1 is implicated in glucose metabolism 
and beta-cell function. Here, we investigated the role of SIRT1 through the 
activating action of resveratrol on insulin secretion. Resveratrol is a polyphe-
nol found in red grapes and wine that has been demonstrated to increase 
lifespan and to protect mice against high-fat diet induced obesity and insulin 
resistance.
Materials and methods: Chronic (24h) treatment with 25 µM resveratrol 
was tested on insulinoma INS-1E cells and effects on insulin secretion, gene 
expression (qRT-PCR), and metabolic parameters were measured (ATP pro-
duction, glucose oxidation and utilization, oxygen consumption). We then 
tested resveratrol treatment in cells over-expressing SIRT1 or expressing in-
active mutant SIRT1 after adenoviral transduction, as well as pharmacologi-
cal SIRT1 inhibitor (1 µM EX-527). Chronic effects of resveratrol on insulin 
secretion and gene expression were also studied in human islets.
Results: Chronic treatment of INS-1E cells with 25 µM resveratrol resulted in 
marked potentiation of insulin secretion at 15 mM glucose (+114%, p<0.01). 
This effect was associated with enhanced metabolism since glucose utiliza-
tion was increased by +32% (p<0.01), resulting in elevated glucose oxidation, 
ATP generation, and mitochondrial oxygen consumption. Such changes cor-
related with up-regulation of key genes for beta-cell function and differen-
tiation, i.e. glucose transporter GLUT2 (+59%), glucokinase (+89%), Pdx-1 
(+70%), and TFAM (+232%). In human islets, chronic resveratrol treatment 
also significantly increased glucose-stimulated insulin secretion and induced 
expression of the same set of genes. Over-expression of SIRT1 in INS-1E cells 
potentiated resveratrol effects on insulin secretion. Conversely, inhibition of 
SIRT1 achieved either by expression of a mutant that lacks deacetylase activ-
ity or alternatively by using the EX-527 inhibitor, both abolished resveratrol 
effects on glucose-stimulated insulin secretion. Chronic treatment of INS-1E 
cells with EX-527 also prevented up-regulation of GLUT2, glucokinase, Pdx-
1, and TFAM, normally induced by resveratrol.
Conclusion: Treatment of beta-cells with resveratrol markedly enhanced glu-
cose-induced insulin secretion in INS-1E cells and human islets, even after 
removal of the compound from the medium. Data show that resveratrol ef-
fects were mediated by SIRT1 activation, defining a new role for SIRT1 in the 
regulation of insulin secretion.
Supported by: Swiss National Science Foundation
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Melatonin effects on insulin secretion and clock genes expression
J.A. Stamenkovic1, C.L.F. Nagorny1, C. Ling2, A. Salehi3, V.V. Sharoyko1,  
H. Mulder1;
1Clinical Sciences Malmö; Molecular Metabolism, Lund University, 
Malmoe, 2Clinical Sciences Malmö; Diabetes and Endocrinology, Lund 
University, Malmoe, 3Clinical Sciences Malmö; Islet Cell Physiology, Lund 
University, Malmoe, Sweden.
Background and aims: Melatonin is rhythmically released by the pineal 
gland and thus represents an important regulator of seasonal and circadian 
rhythms. Both melatonin receptors MTNR1A and MTNR1B are expressed in 
INS-1 cells and in rat and human islets (primarily in alpha cells). Genome-
wide association studies have identified a SNP, rs10830963, in MTNR1B that 
is associated with elevated fasting plasma glucose levels, impaired insulin 
secretion and T2D. Previously, peripheral circadian rhythms in heart, liver 
and pancreas have been shown and that these rhythms are independent from 
the central clock located in the suprachiasmatic nucleus (SCN). Given the 
association of MTNR1B with T2D and insulin secretion, we aimed to resolve 
whether the effects of melatonin on β-cells could be mediated by entrainment 
of circadian rhythm.
Materials and methods: Expression of mRNA for Clock genes in human is-
lets and clonal β-cells (INS-1 832/13 cells) was determined by microarray 
(Affymetrix) or RT-PCR, respectively. To determine the effects of melatonin 
on insulin secretion, we incubated human islets and clonal β-cells at 2.8 and 
16.7 mM glucose with or without 0.1 µM melatonin for 1 h. Released insulin 
was determined by radioimmunoassay.
Results: Microarray analysis of human islets showed that Clock, Per1-3, and 
Cry 1-2 were expressed. Moreover, while MTNR1A expression correlated 
positively with Per1 (rho=0.037; p=0.04), MTNR1B expression correlated 
negatively with Cry1 (rho=-0.41; p=0.02) in the human islets. RT-PCR con-
firmed mRNA expression of the melatonin receptors MTNR1A and MT-
NR1B in INS-1 832/13 cells. In addition, mRNA expression of the clock genes 
CLOCK and PER1 were detected in INS-1 832/13 cells. Insulin from 832/13 
cells increased 6.92-fold in response to16.7 mM glucose (69.65 ± 9.11 insulin 
ng/mg protein/h) compared to secretion at 2.8 mM glucose (10.07 ± 2.35 
insulin ng/mg protein/h). The stimulation of the INS-1 832/13 cells with glu-
cose + melatonin resulted in decreased GSIS (4.57 fold; p=0.02) at 16.7 mM 
glucose (36.54 ± 8.72 insulin ng/mg protein/h). Insulin from human islets, 
from 4 different donors, decreased 2-fold ( p=0.06) in response to 16.7 mM 
glucose + melatonin ( 0.79 ± 0.17 insulin ng /islet /h) compared to secretion 
at 16.7 mM glucose (1.34 ± 0.18 insulin ng /islet /h).
Conclusion: Our data demonstrate the existence of components of the mo-
lecular clock in human islets and clonal β-cells. In addition, melatonin exerted 
an inhibitory effect on insulin secretion provoked by high glucose. Given that 
islets and β-cells express CLOCK genes and are sensitive to melatonin, there 
is a possibility that melatonin may entrain circadian rhythm. This agrees with 
previous suggestions that insulin displays a diurnal pattern.
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Quantitative analysis of t-SNARE and Ca2+-channel clusters near 
secretory granules
S. Barg, N. Gandasi;
Medical Cell Biology, Uppsala University, Sweden.
Background and aims: For insulin to be secreted from pancreatic -cells, se-
cretory granules must translocate to and then dock at the plasma membrane. 
Secretagogues can then trigger exocytosis of these granules, resulting in re-
lease of insulin. Only a limited number of granules can dock at any time, 
suggesting the existence of specialized docking sites where the exocytosis 
machinery is assembled. This is supported by the finding that the t-SNARE 
syntaxin 1a (syx), an integral plasma membrane protein which is required for 
docking and exocytosis, clusters in raft-like nanodomains near docked gran-
ules. The function of these clusters is unknown, but it seems likely that they 
contain other t-SNARE and regulatory proteins, which together act as ac-
ceptor complex for the docking granule. Moreover, there is indirect evidence 
suggesting that clusters of L-type Ca2+-channels (CaV1.2) are required near 
the granule for rapid exocytosis; ablation of the gene encoding Cav1.2 abol-
ishes 1st phase insulin secretion and results in systemic glucose intolerance. 
The channel associates in biochemical assays with t-SNAREs. Here we have 
quantified the dynamic interaction of syx and CaV1.2 clusters with secretory 
granules during docking and exocytosis.
Materials and methods: Dual-color TIRF microscopy and novel quantita-
tive image analysis was used to study the association of GFP-labeled syx and 
Cav1.2 with granules at the plasma membrane of live Ins1- and PC12 cells. 
Granules were labeled with NPY-cherry as spatial reference. Single molecule 
imaging and PALM super-resolution microscopy were done on the same in-
strument to measure protein diffusion and cluster size.
Results: Syx and CaV1.2 formed small clusters (<100 nm) in the plasma 
membrane that contained about 70 molecules of syntaxin and associated with 
a subset of the docked granules (30-50%). Granules near such a cluster were 
more likely to undergo exocytosis during stimulation. Clusters were stable 
on a minute scale and moved no faster than docked granules. In contrast, the 
number of syx molecules fluctuated on a second scale and individual mol-
ecules of both proteins diffused rapidly in the plasma membrane. When ob-
served at the single molecule level, individual copies of syx and Cav1.2 were 
captured beneath docked granules, for a short time (<1s). Syx was recruited 
to the granule site during docking, and lost during undocking and exocyto-
sis. A syx mutant lacking the N-terminus formed clusters that were excluded 
from granules, while a mutation in the SNARE domain had little effect.
Conclusion: In summary, the protein composition of individual granule-as-
sociated nanodomains is remarkably dynamic and correlates with the gran-
ules’ ability to exocytose. This organization is established during or just af-
ter granule docking, which suggests that granules approaching the plasma 
membrane might induce the formation of their own docking site. Dynamic 
association of exocytosis proteins with individual granules occurs on a times-
cale consistent with rapid cellular signaling, and may be important for the 
short-term regulation of insulin secretion.
Supported by: an EFSD/MSD grant, G Gustafssons, NovoNordisk, Zetterlings, 
Ernfors
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CART is upregulated in islets of type 2 diabetic patients, stimulates 
insulin secretion, inhibits glucagon secretion and protects against beta 
cell death
R. Sathanoori1, U. Voss1, M. Riva1, M.S. Winzell1, B. Ahrén1, O. Korsgren2, 
N. Wierup1;
1Lund University Diabetes Centre, Lund University, 2Department of Clinical 
Immunology, Uppsala University, Sweden.
Background and aims: Cocaine- and amphetamine-regulated transcript 
(CART) is a regulatory peptide expressed in the islets of many laboratory 
animal species. CART KO mice exhibit impaired glucose tolerance due to is-
let dysfunction, and CART has been shown to regulate insulin secretion from 
rat islets and clonal beta cells. Furthermore, CART is upregulated in rodent 
models of type 2 diabetes (T2D). We examined CART expression in human 
islets from T2D patients and control subjects. Furthermore, we studied the 
effect of CART on beta cell survival, as well as the effect of CART on insu-
lin and glucagon secretion in vivo and in vitro in mice. We have previously 
shown that CART exerts its effect on insulin secretion in part via increased 
cAMP and PKA-dependent pathways. In this study we investigated potential 
effects of CART on Ca2+ signaling.
Materials and methods: CART expression was examined using immunocy-
tochemistry, in situ hybridization. IVGTT with i.v. administration of CART 
was performed in anesthetized C57Bl6 mice. Insulin and glucagon secretion 
after 1h static incubations of isolated mouse islets was analyzed with RIA or 
ELISA. Ca2+ fluorescence and glucotoxicity was assessed in INS-1 (832/13) 
cells.
Results: CART mRNA and protein expression was evident in human alpha 
and beta cells as well as in intra-pancreatic nerve fibers innervating the islets. 
T2D islets displayed 3-fold higher CART mRNA levels than controls. In addi-
tion, the number of CART-expressing alpha and beta cells was 2.5-fold high-
er in type 2 diabetic patients, as compared to control subjects. Intravenous 
CART administration improved glucose-elimination and increased glucose 
stimulated insulin secretion (GSIS) after an IVGTT in mice. CART increased 
insulin secretion from isolated mouse islets stimulated with glucose, GLP-1, 
and palmitate. On the other hand, CART had no effect on insulin secretion 
in the presence of KCl, alpha-KIC or carbachol. CART increased cytoplasmic 
Ca2+ concentration in INS-1 (832/13) cells in a dose-dependent fashion at 
both high and low glucose concentrations. The effect was still evident when 
Ca2+ was absent in the assay buffer, suggesting that Ca2+ is mobilized from 
internal stores. The effect of CART was sustained after prior exposure to per-
tussis toxin, suggesting that CART does not act via Gi/o coupled receptors. 
In addition, CART reduced secretion of glucagon from isolated mouse islets 
at both low and high glucose concentrations. Furthermore, addition of ex-
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ogenous CART resulted in a 50% decrease in glucose-induced cell death in 
INS-1 (832/13) cells.
Conclusion: We conclude that CART 1) is expressed in human islet cells and 
nerve fibers. 2) is upregulated in the islets of type 2 diabetic subjects. 3) im-
proves glucose elimination and stimulates insulin secretion in vivo and in 
vitro. 4) inhibits glucagon secretion. 5) exerts a cytoprotective effect on beta 
cells. Together these data suggest that CART is upregulated in human T2D 
islets to protect the islets against glucotoxicity and to lower plasma glucose.
Supported by: Novo Nordisk Foundation, Swedish Medical Research Council
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Dysfunctions of neuronal NO synthase in pancreatic beta cells from 
human islets issued from obese subjects
A. Chalançon, F. Castex, K. Mezghenna, P. Petit, R. Gross, A.-D. Lajoix;
Faculte de Pharmacie, CNRS UMR 5232, Montpellier, France.
Background and aims: We have previously shown that rat pancreatic β-cells 
express an isoform of neuronal NO synthase (nNOS), that controls insulin 
secretion through two catalytic activities: NO production and cytochrome c 
reduction. We also found functional and molecular abnormalities of nNOS, 
involved in pancreatic β-cell hyperactivity in an animal model of prediabetic 
state, the Zucker fa/fa rat. In the present study, we investigate whether, as 
observed in rats, nNOS dysfunctions could also occur in islets from obese 
subjects.
Materials and methods: Human islets from normal-weight or obese subjects 
were obtained from brain dead donors in the frame of a transplantation pro-
tocol of Gragil network. nNOS expression was studied by RT-PCR and West-
ern Blot, its subcellular localization by confocal microscopy. Insulin secretion 
in response to glucose (2.8, 8.3, and 16.7 mM) was evaluated on pools of 10 
islets during 90 minutes in the presence or not of a pharmacological inhibitor 
of nNOS, Nω-nitro-L-arginine methyl ester (L-NAME).
Results: We found that nNOS is expressed in human β-cells and, as previ-
ously observed in rats, co-locates with insulin secretory granules. In islets 
from obese subjects, nNOS is overexpressed and co-locates more strongly 
with insulin granules as compared to islets from normal-weight subjects. 
Moreover, islets from obese subjects were found more sensitive to glucose, 
as previously observed in fa/fat rats: at 2.8 mM glucose, insulin secretion 
reached 19.4 ± 2.05 (n = 2), versus 10.09 ± 0.8 ng/ml/10 islets/90 min (p < 
0.001) for islets from lean subjects (n = 3), 31.25 ± 2.8 versus 15.3 ± 1.3 ng/
ml/10 islets/90 min (p < 0.001) at 8.3 mM glucose and 31.2 ± 3.2 versus 21.35 
± 1.9 ng/ml/10 islets/90 min (p < 0.01) at 16.7 mM glucose. Finally, in islets 
issued from lean subjects, pharmacological blockade of nNOS with 10 mM 
L-NAME stimulated insulin secretion from 15.3 ± 1.3 to 22.4 ± 2.4 ng/ml/10 
islets/90 min (p < 0.01) at 8.3 mM glucose and from 21.35 ± 1.9 to 27.7 ± 2.8 
ng/ml/10 islets/90 min (p < 0.05) at 16.7 mM glucose, confirming that nNOS 
exerts an inhibitory tone on insulin secretion. In contrast, islets from obese 
subjects were found insensitive to L-NAME, whatever the glucose concentra-
tion studied, suggesting a constitutive defect of nNOS.
Conclusion: Islets from obese subjects display molecular and functional ab-
normalities of nNOS that could be involved in early dysfunctions observed in 
these islets, as previously observed in an animal model of prediabetic state.
OP 17 Role of mitochondria in 
muscle insulin action
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High oxidative capacity protects against lipid-induced insulin resistance
E. Phielix1, R.C.R. Meex2, J. Hoeks1, L. Sparks1, E. Moonen-Kornips1, 
M.K.C. Hesselink2, P. Schrauwen1;
1Human Biology, 2Human Movement Sciences, Maastricht University 
Medical Centre, Netherlands.
Introduction: Fat accumulation in skeletal muscle combined with low mito-
chondrial oxidative capacity, is associated with muscular insulin resistance. 
Endurance trained athletes, characterized by high oxidative capacity, have 
elevated amounts of intramyocellular lipid, yet are highly insulin sensitive. 
This suggests that a high oxidative capacity may prevent lipid-induced insulin 
resistance. We examined whether athletes are protected against lipid-induced 
insulin resistance. In addition, we examined whether ex vivo mitochondri-
al function deteriorates upon elevation of circulating fatty acids in healthy 
young men.
Methods: Nine endurance-trained athletes and 10 control subjects with a 
sedentary lifestyle were included and matched for age (23.4 ± 0.9 and 21.9 
± 0.9 y). Subjects underwent a 6h hyperinsulinemic-euglycemic clamp with 
simultaneous infusion of a triglyceride emulsion (intralipid) or glycerol. The 
rate of insulin-stimulated glucose disposal (Rd), oxidative (CHOox) and 
non-oxidative glucose (NOGD) disposal were computed as the difference 
between insulin stimulated conditions minus non-insulin stimulated con-
ditions. Muscle biopsies from the m. vastus lateralis were taken before and 
after the clamp to measure ex vivo mitochondrial function in the addition 
of several substrate combinations. Mitochondrial function was determined 
as ADP-stimulated respiration, uncoupled respiration and maximal oxidative 
capacity, all expressed as pmol/(s*mg)/ mtDNA copy number.
Results: Endurance trained subjects had higher VO2max values compared 
to control subjects (61.5 ± 1.2 vs 43.0 ± 1.1 ml kg-1 min-1, p<0.01). Inter-
estingly, although mitochondrial content was higher in trained subjects, ex 
vivo mitochondrial function normalized to mtDNA copy number was simi-
lar between trained and control subjects. Rd was 63% lower after intralipid 
compared to glycerol in control subjects (from 35.7 ± 2.7 to 12.0 ± 3.1 μmol 
kg-1 min-1, p<0.05). In contrast, Rd reduced only 29% upon lipid in trained 
subject (from 45.9 ± 3.6 to 31.6 ± 3.9 μmol kg-1 min-1, p<0.05), which was 
different from untrained subjects (p<0.05). The stimulation of CHO-ox by in-
sulin as seen in the glycerol condition was completely blunted after intralipid 
in both groups. Interestingly, in trained subjects insulin-stimulated NOGD 
was unaffected upon intralipid, but reduced by 52% in control subjects (from 
29.1 ± 2.7 to 14.0 ± 3.4 μmol kg-1 min-1, p<0.05). Finally, in both groups 
respiration values upon intralipid were not different from after glycerol and 
were unaffected by training status.
Discussion: We show that lipid-induced insulin resistance is blunted in ath-
letes. Interestingly, lipid infusion reduced the insulin-stimulated increase in 
carbohydrate oxidation rates to a similar extend in trained and untrained 
subjects, but the non-oxidative glucose disposal was completely unaffected 
in athletes. These results suggest that a high oxidative capacity prevents li-
pid-induced reduction of non-oxidative glucose storage and thereby blunts 
lipid-induced insulin resistance. Higher oxidative capacity in athletes was 
due to higher mitochondrial density and not intrinsic mitochondrial func-
tion, suggesting that the latter may be of less importance in lipid-induced 
insulin resistance. Finally, mitochondrial function does not deteriorate upon 
the infusion of lipids.
Supported by: Dutch Diabetes Research Foundation
98
Adiponectin and AdipoR1 regulate PGC-1alpha and mitochondria by 
Ca2+ signalling and AMPK/SIRT1 like exercise
T. Yamauchi, M. Iwabu, M. Okada-Iwabu, K. Ueki, T. Kadowaki;
Department of Metabolic Diseases, University of Tokyo, Japan.
Background and aims: Adiponectin is an anti-diabetic adipokine. Its recep-
tors AdipoRs possess a seven-transmembrane topology with the amino termi-
nus located intracellularly, which is opposite to G-protein coupled receptors. 
Intracellular signal transduction mechanisms of AdipoRs have yet to be well 
clarified. Insulin resistance has been reported to be associated with impaired 
skeletal muscle oxidation capacity and mitochondrial dysfunction. However, 
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the exact cause of mitochondrial dysfunction has yet to be ascertained. We at-
tempted to clarify whether decreased adiponectin/AdipoR1 signalling could 
be associated with mitochondrial dysfunction, and attempted to elucidate 
the signalling mechanisms by which adiponectin/AdipoR1 would exert their 
biological effects.
Materials and methods: We analyzed muscle-specific AdipoR1-knockout 
mice.
Results: Adiponectin induces extracellular Ca2+ influx via AdipoR1, which 
was necessary for subsequent activation of Ca2+ /calmodulin-dependent 
protein kinase kinase β (CaMKKβ) and AMPK/SIRT1, increased expression 
and decreased acetylation of peroxisome proliferator-activated receptor gam-
ma coactivator-1 alpha (PGC-1α), and increased mitochondria in myocytes.
Next we showed that muscle-specific disruption of AdipoR1 resulted in 
decreased elevation of the intracellular Ca2+ concentration and decreased 
activation of CaMKK/AMPK/SIRT1 by adiponectin as well as decreased ex-
pression and increased acetylation of PGC-1 alpha, decreased mitochondrial 
content and enzymes such as cytochrome c (CytC), decreased oxidative type 
I myofibers, decreased oxidative stress-detoxifying enzymes such as catalase 
and manganese superoxide dismutase (SOD2), and decreased molecules in-
volved in fatty-acid oxidation such as medium-chain acyl-CoA dehydroge-
nase (MCAD), thereby leading to increased oxidative stress and increased 
tissue triglyceride content in skeletal muscle. Furthermore, muscle-specific 
AdipoR1 knockout mice exhibited increased phosphorylation of p70 S6 ki-
nase and JNK and also increased serine phosphorylation of IRS-1 as well as 
decreased glucose transporter (GLUT)4 expression and decreased Akt acti-
vation by insulin, which were associated with decreased rates of glucose dis-
posal (Rd). Importantly, these alterations could result in insulin resistance 
and decreased exercise endurance. Moreover, AdipoR1 and AdipoR2 double 
knockout mice as well as obese diabetic db/db mice exhibited almost all the 
same phenotypes in skeletal muscle observed in muscle-specific AdipoR1 
knockout mice. Interestingly, AMPK activator AICAR could only partially 
rescue the phenotypes of muscle-specific AdipoR1 knockout mice such as in-
sulin resistance and decreased mitochondrial content and function, whereas 
exercise almost completely rescue their phenotypes.
Conclusion: AdipoR1 appears to 1) regulate mitochondrial function and 
oxidative stress in muscle as well as insulin sensitivity and exercise endur-
ance, and 2) be required for adiponectin-induced PGC-1α expression and 
activation via extracellular Ca2+ influx and AMPK/SIRT1, respectively, and 
subsequent mitochondrial bioenergetics stimulated with adiponectin in mus-
cle cells. Decreased levels of adiponectin/AdipoR1 in obesity may play causal 
roles in mitochondrial dysfunction and insulin resistance seen in diabetes. 
Agonism of AdipoR1 as well as strategies to increase AdipoR1 in muscle 
could be exercise-mimetics.
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Acute overexpression of PGC-1β in rat skeletal muscle increases 
mitochondrial substrate oxidation and ameliorates lipid-induced insulin 
resistance
L.E. Wright1, A.E. Brandon1, A.J. Hoy1, C.J. Lelliott2, G.J. Cooney1,  
N. Turner1;
1Garvan Institute of Medical Research, Darlinghurst, Australia, 
2AstraZeneca R&D, Mölndal, Sweden.
Background and aims: Lipid accumulation in skeletal muscle is strongly as-
sociated with the development of insulin resistance. In particular, reactive 
lipid species, such as diacylgycerols (DAG), ceramides, and long-chain acyl-
CoAs (LCACoA) are thought to antagonize numerous intracellular pathways, 
which ultimately leads to reductions in insulin sensitivity. Recent data has 
also implicated oxidative stress as a key determinant in this process. Upregu-
lation of mitochondrial capacity has been suggested as a potential approach 
to combat lipid overload and insulin resistance in skeletal muscle, however 
there is relatively little direct data to support this concept. In the current 
study we aimed to acutely overexpress PGC-1β in hindlimb skeletal muscle 
from chow and high-fat fed rats, and investigate the effect on mitochondrial 
function and insulin sensitivity.
Materials and methods: Rats were fed either a low-fat or high-fat diet for 
4wk, and in vivo electroporation was used to overexpress PGC-1β in the tibia-
lis cranialis and extensor digitorum longus muscles. Downstream effects of 
PGC-1β on markers of mitochondrial oxidative capacity and muscle lipid lev-
els were characterized, and insulin action was examined ex vivo using intact 
muscle strips and in vivo via a hyperinsulinemic-euglycemic clamp.
Results: PGC-1β expression was increased >100% over basal levels. This 
upregulated the expression of many metabolic proteins, including those in-
volved in mitochondrial function (ETC complexes I and II), lipid metabo-
lism (CD36, CPT-1) and antioxidant defences (SOD-1, SOD-2). Addition-
ally, the activity of oxidative enzymes and substrate oxidation (pyruvate and 
palmitate) was increased in muscles overexpressing PGC-1β. LCACoA was 
increased 2.3 fold in control muscles of high-fat fed rats, but remained simi-
lar to chow levels in muscles overexpressing PGC-1β (p<0.05, n=7). Under 
hyperinsulinemic-euglycemic clamp conditions, insulin-stimulated glucose 
uptake was decreased in tibialis cranialis (-20%, p<0.05) and extensor digi-
torum longus (EDL; -28%, p<0.01) muscles of high-fat fed rats, and was par-
tially restored towards control levels with PGC-1β overexpression (p<0.01). 
Furthermore in isolated EDL strips, PGC-1β overexpression ameliorated the 
reduced insulin-stimulated glucose uptake observed with high-fat feeding 
(p<0.01). Finally, in PGC-1β overexpressing muscles we observed a signifi-
cant decrease in two measures of oxidative stress; lipid peroxidation (-14% 
in chow fed, -19% in high-fat fed, p<0.05) and protein carbonylation (-15% 
in chow fed p<0.05).
Conclusion: These studies demonstrate that physiological overexpression of 
the transcriptional coactivator PGC-1β in rat skeletal muscle in vivo activates 
a coordinated subset of genes involved in mitochondrial function and sub-
strate oxidation. This prevents diet-induced LCACoA accumulation, amel-
iorates oxidative damage, and significantly improves insulin action in the 
skeletal muscle.
Supported by: AstraZeneca
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Knockdown of hypoxia-inducible factor-1 alpha ameliorates insulin-
stimulated glucose uptake in the skeletal muscle cells
H. Sakagami, Y. Makino, K. Mizumoto, T. Isoe, Y. Takeda, J. Watanabe,  
Y. Fujita, Y. Takiyama, A. Abiko, M. Haneda;
Division of Metabolism and Biosystemic Science, Department of Medicine, 
Asahikawa Medical College, Asahikawa, Japan.
Background and aim: Impaired insulin sensitivity in peripheral tissues com-
prises a major cause of hyperglycemia in type 2 diabetes mellitus. Skeletal 
muscle is the largest organ responsible for insulin-dependent glucose dis-
posal thus plays important part in the regulation of blood glucose homeosta-
sis. Molecular mechanism determining glucose uptake by skeletal muscle in 
response to insulin, however, remains largely unknown. The hypoxia-induc-
ible factor-1alpha (HIF-1alpha) is a transcription factor operating in the cel-
lular homeostatic regulation under hypoxic conditions. Recent studies have 
uncovered pleiotropic actions of HIF-1alpha in response to various cellular 
stimuli including insulin under normoxic condition. Physiological relevance 
of HIF-1alpha in regulation of insulin action in the target organs, however, 
has not been well documented. In the present study, we examined the role of 
HIF-1α in regulation of glucose uptake by the skeletal muscle cells.
Materials and Methods: C2C12 myoblast in which HIF-1alpha is knocked-
down (C2C12-deltaHIF) was generated by a stable transfection with HIF-1al-
pha shRNA expression plasmids. C2C12-deltaHIF myoblasts were differenti-
ated into myotubes then the glucose uptake rate of the cells treated with insulin 
was determined by monitoring the influx of [3H]-2-deoxy glucose (2-DG).
Results: Upon the treatment with 100nM insulin for 30 minutes, wild type 
C2C12 myotube increased uptake of 2-DG by 2-fold compared to the ba-
sal level. Knockdown of HIF-1alpha in the myotubes (C2C12-deltaHIF) 
resulted in abrogation of insulin-dependent glucose uptake. Accordingly, 
in C2C12-deltaHIF myotubes GLUT4 translocation to plasma membrane 
by treatment with insulin was severely inhibited. The Akt substrate of 160 
kDa (AS160), a Rab-GTPase activating protein is known to be responsible for 
GLUT4 vesicle transport. Immunoprecipitation assays demonstrated insulin-
dependent phosphorylation of AS160 in wild type C2C12 myoutubes. Con-
trary, in C2C12-deltaHIF myotube phosphorylation of AS160 by insulin was 
significantly reduced. On the other hand, adiponectin, an adipose-derived 
cytokines, induced GLUT4 translocation and glucose uptake in an additive 
manner to insulin to demonstrate its insulin-sensitizing action in wild type 
C2C12 myoutubes. Of interest, both insulin and adiponectin enhanced HIF-
1alpha expression in the wild type myotubes. On the other hand, in C2C12-
deltaHIF myotubes adiponectin did not demonstrate any additive enhancing 
effect on glucose uptake by insulin. Finally, we determined glucose uptake 
by the skeletal muscles of heterozygote of HIF-1alpha gene knock-out mice 
(HIF-1alpha+/-). Extensor digitorum longus (EDL) muscles were isolated 
from the wild type mice and HIF-1alpha+/- mice to carryout ex vivo culture. 
Insulin stimulated 2-DG uptake was increased up to 3-fold above basal levels 
in wild type mice. In contrast, HIF-1alpha +/- mice demonstrated significantly 
reduced uptake of 2-DG either in basal or in insulin-stimulated condition.
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Conclusion: HIF-1alpha is a critical determinant for insulin sensitivity and 
glucose disposal in the skeletal muscle thus as a possible target to alleviate 
insulin resistance in type 2 diabetes.
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Deletion of the Rab-GAP protein TBC1D1 protects from lipid-induced 
insulin resistance in skeletal muscle
A. Chadt1, F. Carlotti2, R.C. Hoeben2, H.-G. Joost1, H. Al-Hasani1;
1Pharmacology, German Institute of Human Nutrition, Nuthetal, Germany, 
2Molecular Cell Biology, Leiden University Medical Center, Netherlands.
Background and aims: The Rab-GTPase-activating (GAP) protein TBC1D1 
is highly expressed in skeletal muscle and was recently linked to severe human 
obesity. We previously described its role as susceptibility gene for high-fat 
diet-induced obesity and diabetes in mice. TBC1D1-deficient recombinant 
congenic mice displayed reduced adiposity and a lowered respiratory quo-
tient (RQ), indicating enhanced whole body lipid use. Consequently, intact 
isolated skeletal muscles from these animals showed increased fatty acid (FA) 
oxidation with concomitant decrease of insulin-stimulated glucose uptake, 
indicating that TBC1D1 regulates substrate preference in skeletal muscle. An 
impaired adaptation of skeletal muscle fuel preference to the availability of 
glucose and FA as energy substrates has been associated with the develop-
ment of insulin resistance and diabetes. We therefore sought to investigate 
the role of TBC1D1 in glucose and lipid metabolism and the mediation of 
lipid-induced insulin resistance in skeletal muscle.
Materials and methods: C2C12 myotubes were electroporated with siRNA 
oligonucleotides to achieve Tbc1d1 knockdown and subsequently exposed 
to different concentrations (0 - 750 µM) of palmitic acid for 16 h. In addi-
tion, intact skeletal muscles (EDL and soleus) from TBC1D1-deficient mice 
and wildtype controls were isolated and preincubated with increasing con-
centrations of palmitate. Insulin-stimulated 2-deoxyglucose (DOG) uptake 
and palmitate oxidation was determined using radioactive tracer techniques. 
Expression analysis was performed by quantitative real-time PCR and West-
ern Blot.
Results: In cultured C2C12 myotubes, siRNA-mediated knockdown of 
Tbc1d1 increased palmitate oxidation by approx. 30%. Likewise, isolated 
muscles from TBC1D1-deficient mice showed increased palmitate oxida-
tion compared to muscles from wildtype littermates. In both cultured cells 
and isolated muscles, the enhanced FA combustion was accompanied by 
increased levels of mRNA for genes involved in lipid metabolism including 
Acadl, Cd36, Ppargc1, and Fabp3. Importantly, additional knockdown of Cd36 
in Tbc1d1-depleted C2C12 myotubes completely abrogated the increase in 
palmitate uptake. Exposure of C2C12 myotubes and isolated skeletal muscles 
to palmitic acid led to a substantial and dose-dependent reduction in insulin-
stimulated AKT phosphorylation, and expression of Ppargc1 mRNA, respec-
tively. As a result, in the presence of 1 mM palmitate, the insulin-stimulated 
DOG uptake in isolated skeletal muscles was reduced by >50%. In contrast, 
depletion of TBC1D1 almost completely prevented the detrimental effect of 
palmitate on insulin-stimulated AKT phosphorylation, Ppargc1 expression 
and insulin-stimulated DOG uptake, and thus restored insulin sensitivity in 
muscle cells.
Conclusion: Our data demonstrate that TBC1D1 deficiency protects skel-
etal muscle from lipid-induced insulin resistance, presumably by enhancing 
FA oxidation. In cultured myotubes, the fatty acid translocase FAT/CD36 
is essential for TBC1D1-mediated FA uptake. Furthermore, we show that 
TBC1D1 exerts control on fuel selection and energy metabolism in skeletal 
muscle at least in part through the coordinated regulation of gene expression 
of key enzymes for lipid uptake and oxidation.
Supported by: DFG, an EFSD/Lilly grant, EUGENE2, SysProt
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Electrical pulse stimulation of human skeletal muscle cells mimics 
exercise and prevents insulin resistance induced by adipocyte-
conditioned medium
S. Lambernd, K. Eckardt, A. Schober, B. Platzbecker, J. Eckel;
Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes 
Center, Düsseldorf, Germany.
Background and aims: Skeletal muscle is one of the major insulin sensitive 
tissues and is responsible for about 80 % of the postprandial insulin-stimulat-
ed glucose uptake. Obesity is closely associated with muscle insulin resistance 
and a major risk factor for the pathogenesis of type II diabetes. Regular physi-
cal activity does not only prevent obesity, but also considerably improves in-
sulin sensitivity and skeletal muscle metabolism. Exercise leads to activation 
of AMPK, enhances insulin signalling and improves glucose uptake. The aim 
of our project is to establish and characterise an in vitro model of human 
skeletal muscle contraction to study signalling pathways and mechanisms, 
which are involved in beneficial effects of muscle activity.
Materials and methods: Differentiated primary human skeletal muscle cells 
(hSKM cells) were stimulated with a C-pace pulse generator for up to 24 h (1 
Hz, 11.5 V, 2 ms pulse duration), and immunofluorescence staining of sacro-
meric alpha-actinin was used to visualise the cytoskeleton. To induce insulin 
resistance, hSKM cells were incubated with adipocyte-derived conditioned 
media (CM) for 8 h. Afterwards, the cells were stimulated with 100 nM insu-
lin for 10 min and lysed. Protein expression and phosphorylation of Akt and 
AMPK were analysed by SDS-PAGE and western blotting.
Results: After 2-3 h few myotubes started to contract and after 24 h most of 
the myotubes showed noticable contractile activity. While the protein expres-
sion level of sarcomeric alpha-actinin did not change, immunofluorescence 
staining showed de novo formation of sarcomeres with typical striated pat-
tern. During contraction, AMPK phosphorylation increased over time and 
was significantly elevated after 8 h of contraction (5fold, n = 6). In addition, 
electric pulse stimulation of hSKM cells for 24 h led to increased secretion 
of IL-6 which was 2fold elevated compared to unstimulated controls (114 ± 
40 pg/ml to 221 ± 68 pg/ml, n = 6). The incubation of hSKM cells with CM 
significantly reduced the insulin-stimulated phosphorylation of Akt (Ser473) 
by 35 % compared to non-treated controls. However, when the cells were 
pulse-stimulated during the incubation with CM the effect of CM on insulin-
stimulated Akt phosphorylation was abrogated.
Conclusion: Our data show that the effects of electric pulse stimulation on 
hSKM cells were similar to the effect of exercise on skeletal muscle in terms of 
enhanced AMPK activation and IL-6 secretion. Furthermore, we observed de 
novo formation of functional active sarcomeric structures. The CM-induced 
impairment of insulin signalling could be prevented by contractile activity of 
hSKM cells. This result provides a direct evidence for the beneficial effect of 
muscle contraction activity in order to improve insulin sensitivity in condi-
tions of insulin resistance. In summary, our model provides a unique tool to 
investigate mechanisms and underlying signalling pathways which mediate 
the beneficial effects of muscle contraction, and will help to further clarify the 
potential of exercise to combat insulin resistance.
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OP 18 Diabetic nephropathy - 
experimental
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Effect of CB2 receptor activation in experimental diabetic nephropathy
F. Barutta, R. Gambino, S. Pinach, P. Cavallo Perin, G. Gruden;
Department of Internal Medicine, University of Turin, Italy.
Objective: Diabetic nephropathy (DN) is characterised by increased glomer-
ular permeability to proteins and excessive extracellular matrix accumulation 
in the mesangium, resulting eventually in glomerulosclerosis and progressive 
renal impairment. Endogenous cannabinoids (EC), anandamide and 2-ara-
chidonoylglycerol, bind to two endocannabinoid receptors, named CB1 and 
CB2. We have recently reported that the CB1 receptor is overexpressed by 
podocytes in experimental diabetes and that CB1 blockade prevents podo-
cyte protein downregulation and reduces albuminuria, indicating a deleteri-
ous effect of EC signalling through the CB1 receptor. Coexpression of both 
the CB1 and the CB2 receptors has been reported in several cell types. In 
addition, recent studies have shown that activation of the CB2 receptor has 
protective effects in experimental models of atherosclerosis, liver fibrosis, and 
cardiac ischemia/reperfusion injury through prevention of inflammatory and 
profibrotic processes. Therefore, our aim was to study if the CB2 receptor is 
expressed within the glomeruli and the effect of CB2 activation in experi-
mental diabetic nephropathy.
Methods: Male C57Bl6 mice were made diabetic by intraperitoneal (IP) in-
jection of streptozotocin at a dose of 55 mg/kg in citrate buffer delivered in 5 
consecutive days. Control mice were injected with citrate buffer alone. After 
the onset of diabetes both control (ND n=13) and diabetic mice (DM n=21) 
were further randomised to receive treatment with either AM1241, a selec-
tive CB2-receptor agonist (3 mg/kg IP daily), or vehicle. 14 weeks after the 
induction of diabetes, mice were individually placed in metabolic cages for 
urine collections and blood samples taken for blood glucose and glycated 
haemoglobin measurements. Then, mice were sacrificed, kidneys removed, 
weighed, and analysed. Urinary albumin excretion was measured by enzyme-
linked immunosorbent assay. CB2 receptor protein expression was studied by 
immunohistochemistry. Nephrin, synaptopodin, zonula occludens-1 (ZO-1) 
mRNA and protein expression were assessed by immunofluorescence and 
real-time PCR, respectively. Fibronectin, CTGF, and TGF-β1 mRNA levels 
were quantitated by real-time PCR on total renal cortex.
Results: The CB2 receptor was expressed within the glomeruli in a pre-
dominant podocyte distribution. Diabetes was associated with reduced body 
weight and elevations in both plasma glucose and glycated haemoglobin 
levels, but no differences were seen between treated and untreated mice. 
Albuminuria was significantly (p<0.001) increased in the diabetic animals 
[DM:296.86 (252.8-356.2) µg/18hrs, geometric mean (25th-75th percentile)] as 
compared to the controls [ND:78.87 (73.8-86.6)] and ameliorated by treat-
ment with AM1241 [ND+AM1241:67.75 (59.9-77.3); DM+AM1241:183.59 
(144.8-243.5); p<0.01 DM vs DM+AM1241]. In the diabetic mice the increase 
in albuminuria was paralleled a significant three-fold reduction in both ne-
phrin and ZO-1 protein expression and this effect was completely prevented 
in mice treated with AM1241. Similarly, diabetes-induced downregulation of 
both nephrin and ZO-1 mRNA levels was abolished by AM1241. By contrast 
in diabetic mice AM1241 administration did not affect fibronectin, TGF-β1, 
and CTGF overexpression.
Conclusion: These findings demonstrate that the CB2 receptor is expressed 
within the glomeruli and that CB2 activation ameliorates the diabetic pro-
teinuria, possibly via prevention of podocyte slit diaphragm protein loss.
Supported by: SID
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Poly(ADP-ribose) polymerase-1 (PARP-1) gene deficiency alleviates 
diabetic kidney disease
H. Shevalye, Y. Maksimchyk, P. Watcho, I.G. Obrosova;
Mechanisms of Diabetes Complications, Pennington Biomedical Research 
Center, Baton Rouge, USA.
Background and aims: Evidence for the important role of poly(ADP-
ribose)polymerase-1 (PARP-1) in chronic diabetic complications is emerging. 
Several structurally unrelated PARP-1 inhibitors have been reported to pre-
vent or alleviate diabetic nephropathy. This study evaluated further the role 
for PARP-1 in diabetic kidney disease using the PARP-1-deficient mouse.
Materials and methods: PARP-1-/- and the wild-type (129S1/SvImJ) mice 
were made diabetic with streptozotocin, 40 mg kg-1d-1, i.p., for, at least, 7 con-
secutive days, and were maintained for 12 weeks. PARP-1 and poly(ADP-
ribosyl)ated protein levels were evaluated by Western blot analyses, and 
urinary albumin excretion and renal cortex nitrotyrosine and transforming 
growth factor-β1 (TGF-β1) concentrations by ELISA. Glomerular collagen 
deposition and mesangial expansion (PAS-positive staining) were evaluated 
by histochemistry, followed by quantitation with the Threshold Colour plug-
in of ImageJ 1.43q and ImageJ 1.43q programs, respectively. Podocyte nuclei 
were detected with an anti-WT1 antibody, by immunohistochemistry. Po-
docyte numbers were counted per glomerular section, and 20-25 glomeruli 
were examined for each animal.
Results: Final blood glucose concentrations were ~3.7-fold higher in both 
diabetic groups than in controls. PARP-1 and poly(ADP-ribosyl)ated protein 
levels in the renal cortex were similar in non-diabetic and diabetic wild-
type mice (100% and 107%) whereas all knockouts were PARP-1-negative. 
Poly(ADP-ribosyl)ated proteins, however, have been identified in all groups, 
and their levels were increased by 18% and 14% in diabetic wild-type and 
diabetic PARP-1-/- mice, compared with the corresponding controls. Dia-
betes was associated with ~21-fold and ~13-fold increases in albuminuria 
in wild-type and PARP-1-/- mice, respectively. PARP-1 gene deficiency pre-
vented diabetes-induced kidney hypertrophy and alleviated mesangial ex-
pansion and collagen deposition. Renal podocyte loss, and nitrotyrosine and 
transforming growth factor-β1 accumulations were slightly lower in diabetic 
PARP-1-/- mice, but the differences with the diabetic wild-type group did not 
achieve statistical significance.
Conclusion: PARP-/- gene deficiency alleviates although does not com-
pletely prevent diabetic kidney disease. The lack of a complete prevention 
could be related to the presence of other PARPs responsible for poly(ADP-
ribosyl)ation in the renal cortex in PARP-1-deficient mouse and its increase 
in diabetes, and/or streptozotocin nephrotoxicity in mice.
Supported by: NIH
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TIMP3 deficiency accelerates diabetic nephropathy
M. Cavalera1, L. Fiorentino1, M. Fabrizi1, M. Mavilio1, S. Menini2,  
G. Pugliese2, D. Lauro1, A. Urbani1, R. Lauro1, M. Federici1;
1Dept. of Internal Medicine, University of Tor Vergata, 2Dept. of Clinical 
Sciences, University La Sapienza, Rome, Italy.
Background and aims: Some experimental models of nephropathy have 
recently shown that activation of TACE/ADAM17 is a key step in the pro-
gression of glomerulopathy, even though the exact role of ADAM17 and its 
inhibitor TIMP3in a hyperglycemic environment is still unclear.
Materials and methods: To test this hypothesis we treated WT mice with 
streptozocin to induce hyperglycemia, and then measured TACE activity in 
kidney; we found a significant activation of the enzyme in hyperglycemic 
(STZ, streptozocin-treated) mice compared to untreated controls (p<0.001). 
Next, we analyzed STZ-WT and STZ-Timp-3-/- kidneys by IHC, real time 
PCR and WB.
Results: STZ-Timp-3-/- mice showed significantly increased mean glomeru-
lar area and fractional mesangial area (p<0.05 and p<0.001, respectively). 
STZ-Timp-3-/- mice showed also a thicker glomerular basement membrane, 
due to an increased amount of type IV collagen deposition (p<0.01), that is 
one of the early feature of diabetic nephropathy. Moreover, they also showed 
increased macrophage infiltration, measured by F4/80 staining (p<0.01), 
resulting in inflammation. Oxidative stress markers staining revealed that 
STZ-Timp-3-/- mice are characterized by an increased expression of NOX4, 
RAGE and N-Carboxymethyl-lysine, a major product of oxidative modifica-
tion of glycated proteins (p<0.01 for all). To further analyze the role of TIMP3 
in diabetic nephropathy at a molecular level we performed real time PCR 
on RNA samples derived from kidneys of STZ-Timp-3-/- and WT mice. We 
found that the expression of MCP-1, a marker of inflammation, was signifi-
cantly increased in STZ-Timp-3-/- mice, while the expression of nephrin and 
WT1, two markers of podocyte functions, is reduced in STZ-Timp-3-/- mice 
compared to the WT littermates (p<0.01 for all). We also performed gene 
profiling experiments on kidneys of the same animals, and we could observe 
up-regulation of different classes of genes involved in inflammation (Cxcl9, 
Ccr5, Mcp-1, Mcp-5, Aif-1, Cd36, Mgl-1, Mgl-2), renal cells proliferation and 
fibrosis (Pdgf-d, Tgfβ3, Fgf, Ghr), lipid metabolism (Fabp5, Fasn, Ldlr, Acaca, 
Acms3) and transport (Slc13a1, Slc7a13, Slc7a6, Slco4c1, Slc12a3, Glut8) in 
STZ-Timp-3-/- mice compared to WT ones. We also found a significant reduc-
tion in the expression of genes connected to control of oxidative stress such 
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as Foxo1 and Foxo3a in the kidney of STZ-Timp-3-/- mice. Finally, we used a 
proteomic approach to identify proteins differentially expressed in kidneys 
of STZ- Timp-3-/- and WT mice. Proteomic analysis of total homogenates re-
vealed the presence of the 78 kDa glucose-regulated protein (GRP78) and 
protein disulfide-isomerase A3 only in kidneys from STZ-treated Timp-3-/- 
mice, indicating an increased levels of endoplasmic reticulum stress in these 
mice compared to WT ones.
Conclusion: In conclusion, our preliminary results show that Timp3 plays a 
protective role in preventing inflammation and oxidative stress accumulation 
in kidney and, doing so, it can interfere with the development and progres-
sion of diabetic renal nephropathy.
Supported by: JDRF
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D-carnosine prevents diabetic nephropathy in db/db mice
C. Iacobini1, S. Menini1, C. Ricci1, A. Scipioni1, C. Blasetti-Fantauzzi1,  
A. Giaccari2, E. Salomone2, A. Lapolla3, M. Orioli4, G. Aldini4, F. Pugliese1, 
G. Pugliese1;
1Department of Clinical Sciences, La Sapienza University, Rome, 
2Department of Endocrinology, Catholic University, Rome, 3Department 
of Medical and Surgical Sciences, University of Padua, Padua, 4Institute of 
Pharmaceutical and Toxicological Chemistry, University of Milan, Italy.
Background and aims: The advanced glycation end products (AGEs) are be-
lieved to participate in the pathogenesis of diabetic nephropathy by causing 
both direct modification of enzymatic activity, ligand binding, half-life and 
immunogenicity of proteins and receptor-mediated pro-inflammatory and 
pro-fibrotic effects. The endogenous dipeptide L-carnosine was shown to act 
as a quencher of reactive carbonyl AGE precursors. However, in humans, it 
is rapidly inactivated by carnosinase. The carnosinase-resistant compound 
D-carnosine (DC) have shown high activity, selectivity and plasma stability. 
Preliminary studies from our group have demonstrated that DC is effective 
in attenuating high fat diet-induced atherosclerosis in ApoE null mice. This 
study was aimed at evaluating the efficacy of DC in preventing diabetic ne-
phropathy in db/db mice.
Materials and methods: Adults (aged 6 weeks) male db/db mice and the 
corresponding db/m controls were treated with a DC derivative (60 mg/kg 
body weight in the drinking water; Flamma S.p.A.) or vehicle for 14 weeks. 
At the end of this period, urines were collected for assessment of proteinuria, 
then mice were killed and both kidneys were sampled. Glomerular sclero-
sis index (GSI) was assessed semiquantitatively, then mean glomerular area 
(mGA) and fractional mesangial area (fMA) were measured by computer-
assisted morphometry, with estimation of mean glomerular volume (mGV) 
from mGA and calculation of mean mesangial area (mMA) by the formula: 
(fMA x mGA)/100. Renal expression of inflammatory and disease progres-
sion markers as well as kidney content of HNE adducts and AGE receptors 
were assessed by immunohistochemistry and/or RT-PCR. Serum AGEs and 
isoprostane-8-epi-PGF2α were measured by ELISA, pentosidine by HPLC and 
total carbonylated proteins (PCOs) by slot blot immunoassay.
Results: DC treatment induced a significant attenuation of renal disease in 
db/db mice, whereas it did not influence renal structure in db/m control mice. 
Proteinuria (-35%), GSI (-31%), mGA (3.22 ± 0.27 vs. 3.52 ± 0.21 µm 2x103), 
mGV (137.5 ± 10.1 vs. 157.2 ± 13.7 µm 3x103), mMA (428.0 ± 82.5 vs. 588.5 
± 48.7 µm2) and fMA (13.2 ± 1.8 vs. 16.8 ± 1.7%) decreased significantly 
(P<0.001) in DC-treated db/db mice, as compared with untreated animals. 
Glomerular staining for HNE adducts (5.6 ± 2.7 vs. 13.5 ± 2.8 % of glomeru-
lar area) as well as for the extracellular matrix proteins fibronectin (11.7 ± 2.6 
vs. 19.7 ± 1.8 % of glomerular area) and collagen IV (13.2 ± 3.4 vs. 24.6 ± 3.1 
% of glomerular area) were also significantly reduced (P<0.001) in DC-treat-
ed vs. untreated db/db mice. The mRNA expression levels of F4/80, CXCR3, 
MCP-1, TNF-α, CHOP, and the AGE receptors RAGE, galectin-3 and CD36 
were also significantly lower in db/db mice treated with DC. Finally, serum 
AGE, pentosidine, PCOs, and isoprostane-8-epi-PGF2α levels were lower in 
DC-treated vs. untreated db/db mice.
Conclusion: These data show that DC is effective in reducing carbonyl reac-
tive species and preventing renal injury in db/db mice, thus suggesting that 
carbonyl stress plays a major role in diabetic nephropathy and that DC de-
rivatives might be useful for treatment of this complication.
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Glucagon like peptide-1 agonist, exendin-4, exerts anti-inflammatory 
effect on macrophage and glomerular endothelial cell through inhibition 
of NF-κB
R. Kodera, K. Shikata, K. Hitomi, T. Takatsuka, S. Miyamoto, M. Sasaki,  
N. Kajitani, S. Nishishita, K. Sarai, D. Hirota, C. Sato, D. Ogawa, H. Makino;
Department of Medicine and Clinical Science, Okayama University 
Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Japan.
Background and aims: Glucagon like peptide-1 (GLP-1) is known to have 
various extrapancreatic effects in addition to enhancement of insulin secre-
tion. We have recently shown the renoprotective effects of exendin-4 through 
anti-inflammatory effects.Exendin-4 suppressed macrophage infiltration, ex-
pression of ICAM-1 and type IV collagen and oxidative stress independent of 
blood glucose lowering actions in diabetic rats. In addition, we have demon-
strated that GLP-1 receptor is expressed on glomerular endothelial cells and 
monocytes/macrophages. The aim of this study is to clarify the mechanism 
for the protective effects of exendin-4 against diabetic nephropathy.
Materials and methods: Five-week old male Sprague-Dawley rats were di-
vided into four groups: non-diabetic: ND, non-diabetic rats treated with ex-
endin-4: ND+EX, diabetic rats without treatment: DM, diabetic rats treated 
with exendin-4: DM+EX. Rats were administered intraperitoneally with ex-
endin-4 (10μg/kg/day, ND+EX and DM+EX) or vehicle (ND and DM) every 
day for 8 weeks. To investigate the mechanisms of anti-inflammatory effects 
of exendin-4, we evaluated the nuclear factor-κB, p65DNA binding activity 
in the kidney, which is one of the most important transcription factors regu-
lating both inflammation and oxidative stress. In addition to direct effects of 
exendin-4 on macrophages and endothelial cells, we examined pro-inflam-
matory cytokine expressions (TNF-α and IL-1β mRNA) in THP-1 cells by 
15mM high glucose for 72 hours and ICAM-1 mRNA expression in human 
glomerular endothelial cells by 100pg/ml TNF-α for six hours. Furthermore, 
to confirm whether the effects of GLP-1 directly acted on GLP-1 receptor, we 
used the GLP-1 receptor antagonist.
Results: The activation of NF-κB p65DNA binding activity in the renal cor-
tex was significantly enhanced in DM group compared with non-diabetic 
groups. Exendin-4 treatment significantly inhibited the NF-κB p65 DNA 
binding activity. Stimulation with high glucose enhanced gene expression of 
TNF-α and IL-1β inTHP-1 cells. Exendin-4 significantly attenuated TNF-α 
and IL-1β gene expression with dose-dependent manner. The effects of ex-
endin-4 on TNF-α and IL-1β were blocked by GLP-1R antagonist. TNF-α 
enhanced ICAM-1 gene expression on human glomerular endothelial cells. 
Exendin-4 dose-dependently attenuated ICAM-1 gene expression. The effect 
of exendin-4 was blocked by GLP-1R antagonist.
Conclusion: The current results indicate that exendin-4 suppresses the activa-
tion of NF-κB in diabetic kidney. Exendin-4 directly acts on GLP-1 receptors 
and down-regulates the expression of cytokines and ICAM-1 on macrophage 
and glomerular endothelial cell. Exendin-4 may exert protective effects against 
diabetic nephropathy by inhibition of the interaction between macrophages 
and glomerular endothelial cells which promotes inflammatory process.
Supported by: Scientific Research from the Ministry of Education, Science, Cul-
ture, Sport
108
Altered expression profiles of microRNA in the glomeruli of diabetic 
mice
T. Takatsuka, K. Shikata, R. Kodera, H. Kataoka, S. Miyamoto, D. Hirota,  
N. Kajitani, C. Sato, H. Makino;
Okayama University Graduate School of Medicine, Dentistry and 
Pharmaceutical Science, Japan.
Background and aims: The postulated mechanism in the development of 
diabetic nephropathy involves several factors including protein kinase C ac-
tivation, TGF-β, AGE, oxidative stress and microinflammation which were 
induced by long-term exposure to high glucose. However, the therapeutic 
strategy for diabetic nephropathy has not fully developed, thus, more detail 
molecular mechanism in the pathogenesis of diabetic nephropathy and new 
treatment are still desired. The microRNAs, short non-coding RNAs of 21 
to 23 nucleotides, have recently been shown to play an important role on 
biological process, including development, differentiation and proliferation, 
in various types of cells. We examined microRNA expression profile in renal 
glomeruli of diabetic mice to clarify the pathogenesis and find a novel thera-
peutic target of diabetic nephropathy.
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Materials and methods: Eight-week-old male C57BL/6J mice were used. 
Diabetes were induced by intraperitoneal injection with streptozotocin at 
200 mg/kg in citrate buffer (DM, n=6). Non-diabetic control mice were in-
jected with citrate buffer (ND, n=5). Blood pressure, blood glucose, HbA1c 
and urinary excretion of albumin were measured every month. Kidneys were 
harvested at 6 months after induction of diabetes. Renal glomeruli were iso-
lated magnetically after intra-arterial injection of iron oxide. MicroRNAs 
were extracted by miRNeasy Mini Kit. Agilent microRNA array (567 mouse 
microRNAs) was used to analyze the microRNA expression profile.
Results: We identified the total 21 microRNAs that showed a specific expres-
sion pattern in DM mice compared with ND mice. Up-regulated microRNAs 
(1.5 > DM/ND) in DM renal glomeruli were 8 genes (mmu-miR-705, mmu-
miR-714, mmu-miR-34a, mmu-miR-21, mmu-miR-221, mmu-miR-141, 
mmu-miR-689, mmu-miR-671-5p). Down-regulated microRNAs (0.75 < 
DM/ND) in DM renal glomeruli were 13 genes (mmu-miR-1, mmu-miR-
219b-5p, mmu-miR-503, mmu-miR-574-5p, mmu-miR-133b, mmu-miR-
197, mmu-miR-466i, mmu-miR-467d, mmu-miR-466f-3p, mmu-miR-574-
3p, mmu-miR-335-5p, mmu-miR-322*, mmu-miR-1187).
Conclusion: We identified the microRNAs which showed a specific expres-
sion pattern in renal glomeruli of diabetic mice compared with non-diabetic 
mice. Some of these microRNAs are known to be related to inflammatory 
process and cell proliferation. Altered expression of these microRNAs may be 
associated with pathogenesis of diabetic nephropathy.
Supported by: Scientific Research from the Ministry of Education, Science, Cul-
ture, Sport
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Estimating the quality of life impact of diabetes related complications: 
new results from the UKPDS
M.L. Alva1, A. Gray1, B. Mihaylova1, P. Clarke2;
1Department of Public Health, Health Economic Research Centre, Oxford, 
United Kingdom, 2Department of Public Heath, University of Sydney, 
Australia.
Background and aims: Reliable estimates of the quality of life impact of dia-
betes related complications are important for researchers conducting trial-
based and model-based evaluations of the cost-effectiveness of interventions. 
Previous estimates based on a cross-sectional study of patients enrolled in the 
UKPDS have been widely used. Here we report updated results drawing on 
the UKPDS Post Trial Monitoring Study, which allows us to greatly extend 
follow-up, examine a larger number and wider range of complications, and 
compare cross-sectional results with those from repeated measures of quality 
of life over time.
Materials and methods: Quality of life was measured using the EuroQol EQ-
5D instrument, which was administered in 1996/7 and again annually over 
the period 2002-8 to all remaining participants in the study. We estimated the 
immediate and long term impact on quality of life of myocardial infarction, 
ischaemic heart disease, stroke, heart failure, amputation, renal failure, blind-
ness in one eye, retinal photocoagulation, cataract extraction and vitreous 
haemorrhage, controlling for age, sex and diabetes duration. We also com-
pared different methods of estimating these effects.
Results: A total of 4267 UKPDS patients were administered one or more 
EQ-5D questionnaires. The average number of questionnaires completed 
was 3.4 and the maximum was 7. Approximately 49% of respondents only 
answered the questionnaire once. 1425 patients died between 1997 and 2008. 
The response rate of fully completed questionnaires varied from 68% to 74%. 
Compared with our original study, many more complications were available 
for analysis: for example, in our data set the total number of myocardial inf-
arctions increased from 203 in the first questionnaire to 371 across all rounds, 
the number of amputations from 21 to 89, blindness to one eye from 93 to 
197 and stroke from 60 to 171. Mean quality of life was seen to decline from 
0.77 at the first questionnaire in 1996/7 to 0.64 in the last questionnaire in 
2007/8. This was related to the increasing age of patients over time (62 at first 
quality of life questionnaire compared with 72 at final questionnaire), and an 
increasing proportion of patients with a history of complications (27% at first 
questionnaire compared with 55% at last questionnaire). For those without 
complications of any sort the average utility across questionnaires was 0.74, 
compared with 0.66 for those with a history of myocardial infarction, 0.46 
with amputation, 0.60 with blindness to 1 eye and 0.53 with stroke.
Conclusion: This paper reports new results from the UKPDS on the quality 
of life impact of a range of diabetes related complications. These suggest that 
complications have substantial and long-lasting effects on patient quality of 
life. The results are based on well-validated patient history and adjudicated 
complications data from a landmark diabetes study, and should be useful in 
estimating more accurately the outcome of interventions that reduce these 
complications.
Supported by: UK MRC project grant on Disease Modelling
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The majority of type 2 diabetic patients with renal impairment have 
non-albuminuric renal disease - the Swedish National Diabetes register 
(NDR)
H. Afghahi1, H. Hadimeri1, J. Cederholm2, B. Eliasson3, B. Zethelius4,  
S. Gudbjörnsdottir3, M.K. Svensson3;
1Department of Nephrology, Kärnsjukhuset, Skövde, 2Department of Public 
Health and Caring Sciences, Family Medicine and Clinical Epidemiology, 
Uppsala University, 3Department of Medicine, Sahlgrenska Academy at 
the University of Gothenburg, 4Department of Public Health and Caring 
Sciences/Geriatrics, University of Uppsala, Sweden.
Background and aims: Albuminuria and renal impairment are two main 
manifestations of renal disease which are not entirely linked in patients with 
type 2 diabetes (T2D). The aim of this cross-sectional study was to identify 
the prevalence of non-albuminuric renal impairment in type 2 diabetic pa-
tients and to examine the clinical characteristics associated with non-albu-
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minuric renal impairment in a large nation-wide population-based diabetes 
register.
Materials and methods: 62 661 patients with T2D aged 30-80 years with 
complete datasets on albumin excretion, renal function (serum creatinine) 
and clinical characteristics reported to the Swedish National Diabetes Regis-
ter in 2008 were included. Albuminuria was defined as urinary albumin ex-
cretion rate > 20 µg/min and renal impairment as estimated glomerular filtra-
tion rate; eGFR< 60 ml/min/1.73 m2 according to MDRD. Logistic regression 
analyses for clinical and biochemical variables with renal impairment with or 
without albuminuria as dependent variable were performed. Adjusted odds 
ratios were calculated and continuous variables were increased per one stand-
ard deviation. 95% confidence intervals are given.
Results: 15% of all patients had renal impairment (n=9 308). Among patients 
with renal impairment 56% were non-albuminuric and 42% were albuminu-
ric. In a multivariate analyses patients with non-albuminuric renal impair-
ment had significantly and independently shorter diabetes duration (adj OR 
0.73; 95% CI 0.70-0.76), higher total cholesterol (1.05; 1.01-1.10), lower levels 
of triglycerides (0.83; 0.80-0.87), lower systolic blood pressure (0.81; 0.78-
0.84), better glycemic control (HbA1c%) (0.86; 0.82-0.91), lower BMI (0.88; 
0.84-0.93) and were more often female and non-smoking as compared with 
patients with albuminuric renal impairment.
Conclusion: The majority of patients with type 2 diabetes and renal impair-
ment have non-albuminuric renal disease. Distinct sets of risk factors were 
associated with the presence or absence of albuminuria, patients with non-
albuminuric renal impairment exhibiting less features of the “metabolic syn-
drome”. Non-albuminuric renal impairment could partly be explained by the 
use of renin angiotensin system inhibitors but our results also support the 
concept of different underlying pathophysiology mechanisms. Development 
of markers and methods for a more accurate estimation of renal function in 
T2D patients without albuminuria is important for screening, follow-up and 
treatment of these patients.
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Risk of progression of nephropathy in a population-based sample with 
type 2 diabetes
S. Vupputuri1, G.A. Nichols2, H. Lau3, P. Joski1, M.L. Thorp2;
1The Center for Health Research, Kaiser Permanente Georgia, Atlanta, 
2The Center for Health Research, Kaiser Permanente Northwest, Portland, 
3Evidence Based Medicine, Novartis Pharmaceuticals Inc., East Hanover, 
USA.
Background and aims: Progression through stages of nephropathy has not 
been well described in a large, well-characterized, population-based study. 
Estimates of the public health burden of nephropathy may be different in 
such a population. Our aims were to describe the progression of nephropathy 
and identify demographic and clinical characteristics associated with pro-
gression in a U.S. population-based sample.
Materials and methods: We identified 11,562 members of a managed care 
organization who had hypertension and type 2 diabetes, a urine albumin-
to-creatinine ratio (UACR) measurement in 2001-2003, and at least 1 fol-
low-up UACR. Baseline nephropathy stage was defined as normal albumin 
(UACR<3.4 mg/mmol), microalbuminuria (3.4-33.9 mg/mmol), and mac-
roalbuminuria (>33.9 mg/mmol). We searched records through 2008 for 
progression from baseline to a higher stage of nephropathy including ESRD.
Results: Mean age was 59.4+11.3 years; 49.8% were male, 17.5% African-
American, and mean A1C was 8.1%. At baseline, 59% had normal albumin, 
30% had microalbuminuria, and 11% had macroalbuminuria. The incidence 
of nephropathy progression (per 1000 person-yrs) was 94.6, 44.1, and 6.7 for 
normal albumin, micro-, and macro- albuminuria, respectively. The high 
rates of progression of nephropathy among those with normal albumin dem-
onstrate that 68% of all patients had developed micro- or macro- albuminu-
ria by the end of follow-up. Most patients received antihypertensive therapy; 
ACEi/ARB use ranged from 61-67%, except among patients with macroalbu-
minuria at follow-up. Age, diabetes duration, and A1C were significant pre-
dictors of progression.
Conclusion: Our study, one of the first to examine the progression of neph-
ropathy in a U.S population-based sample, showed that among adults with di-
abetes and hypertension, the lifetime risk of nephropathy and it’s progression 
may be greater than previously reported. Further, the use of ACEi/ARBs to 
slow and/or prevent the progression of nephropathy may be underutilized. 
Supported by: Novartis Pharmaceuticals Inc.
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Prospective association of B-type natriuretic peptide with left ventricular 
systolic and diastolic function in individuals with and without type 2 
diabetes - the Hoorn Study
M.H. Kroon1, K. van den Hurk1, M. Alssema1, O. Kamp2, C.D.A. 
Stehouwer3, R.M.A. Henry3, M. Diamant4, F. Boomsma5, G. Nijpels1,  
W.J. Paulus6, J.M. Dekker1;
1EMGO Institute for Health and Care research, VU Medical Center, 
Amsterdam, 2Department of Cardiology, VU Medical Center, Amsterdam, 
3Department of Internal Medicine, AZM, Maastricht, 4Department 
of Endocrinology, Diabetes Center, VU Medical Center, Amsterdam, 
5Department of Internal Medicine, Erasmus Medical Center, Rotterdam, 
6Department of Physiology, VU Medical Center, Amsterdam, Netherlands.
Background and aims: Individuals with type 2 diabetes mellitus (T2DM) 
have an increased risk of developing heart failure (HF). Higher plasma B-type 
natriuretic peptide (BNP) in a non-heart failure range predicts HF and CVD 
mortality and is associated with T2DM. We aimed to investigate prospec-
tively in a population based cohort the association of BNP levels in a non 
heart failure range with left ventricular (LV) mass, LV systolic function, and 
LV diastolic function in individuals with and without T2DM.
Materials and methods: In the Hoorn Study, a population-based prospec-
tive cohort study, plasma BNP (pmol/l) was determined at baseline. A 2D 
echocardiogram was made at baseline and after 8 years of follow-up to meas-
ure LV mass index (LVMI, g/m2), ejection fraction (EF, %, systolic function) 
and left atrial volume index (LAVI, ml/m2, diastolic function). Participants 
with atrial fibrillation, wall movement abnormalities and moderate or severe 
aortic or mitral valve disease were excluded. Linear regression analyses, ad-
justed for gender, age, baseline heart function, use of antihypertensive medi-
cation, BMI and heart rate were performed to investigate the association of 
BNP with LVMI, and LV systolic and diastolic function. In case of significant 
effect modification (p<0.10), we reported the regression coefficients for indi-
viduals with and without T2DM separately.
Results: Of the 796 individuals of whom echocardiograms at baseline were 
present, 441 (55%) attended the follow-up examination (baseline age 66 
years, 34% T2DM). Increase in LVMI was greater in those with higher base-
line BNP (Table 1). The association was stronger in patients with T2DM, and 
in non-T2DM the association was explained by baseline LVMI, BMI and use 
of antihypertensives, in T2DM the association was independent. Regardless 
of T2DM, a 10 pmol/l higher baseline BNP was associated with a 2.7% lower 
EF and a 5.0 ml/m2 higher LAVI at follow-up.
Conclusion: This study shows that BNP levels are prospectively associated 
with LV diastolic and systolic function and that there is a strong association 
between BNP levels in a non-heart failure range and LVMI for individuals 
with T2DM and not for those without.
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Table 1: Coefficients (95% CI) per 10 pmol increase of baseline BNP for 
LVMI, EF and LAVI (follow-up)
LVMI (g/m2) non-T2DM 
n = 161
T2DM 
n = 86
Crude model 5.7 (-0.03 - 11.5) 25.1 (11.0 - 39.3)*
adjusted for gender and age 6.5 (1.0 - 11.9)* 26.3 (11.4 - 41.2)*
+ adjusted for baseline 
LVMI, antihypertensives, 
BMI and heart rate
1.1 (-4.6 - 6.8) 29.1 (13.6 - 44.6)*
EF (%, LV systolic function) Total population 
n = 235
Crude model -2.3 (-4.4 - - 0.1)*
adjusted for gender and age -2.3 (-4.5 - - 0.1)*
+ adjusted for baseline 
EF, antihypertensives, 
BMI and heart rate
-2.7 (-4.9 - - 0.4)*
LAVI (ml/m2, LV diastolic  
function)
n = 268
Crude model 7.3 (5.3 - 9.2)*
adjusted for gender and age 7.0 (5.1 - 9.0)*
+ adjusted for baseline 
LAVI, antihypertensives, 
BMI and heart rate
5.0 (2.9 - 7.1)*
Supported by: The Dutch Diabetes Research Foundation and Novartis Pharma 
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Arterial stiffness is prospectively associated with left ventricular diastolic 
function in individuals with and without type 2 diabetes - The Hoorn 
Study
K. van den Hurk1, M. Alssema1, O. Kamp2, R.M.A. Henry3, C.D.A. 
Stehouwer3, Y.M. Smulders4, G. Nijpels5, W.J. Paulus6, J.M. Dekker1;
1Department of Epidemiology and Biostatistics, EMGO Institute for 
Health and Care Research, VU University Medical Center, Amsterdam, 
2Department of Cardiology, VU University Medical Center, Amsterdam, 
3Department of Internal Medicine, Maastricht University Medical Centre, 
Maastricht, 4Department of Internal Medicine, VU University Medical 
Center, Amsterdam, 5Department of General Practice, EMGO Institute for 
Health and Care Research, VU University Medical Center, Amsterdam, 
6Department of Physiology, VU University Medical Center, Amsterdam, 
Netherlands.
Background and aims: Left-sided heart failure (HF), especially with a nor-
mal ejection fraction, is common with type 2 diabetes (T2DM), but the un-
derlying mechanisms remain controversial. Arterial stiffness is suggested as a 
potential cause of HF. We investigated whether arterial stiffness was prospec-
tively associated with a higher left ventricular (LV) mass and worse LV diasto-
lic function and whether this differed in individuals with or without T2DM.
Materials and methods: In the Hoorn Study, a population-based cohort study 
of diabetes, echocardiography and arterial ultrasonography was performed in 
2000 and 2008. Linear regression analyses were performed to investigate as-
sociations of carotid, brachial and femoral artery distensibility coefficients 
(DC, arterial stiffness) with LV mass index (LVMI, g/m2) and left atrial vol-
ume index (LAVI, ml/m2, LV diastolic function). Individuals with moderate 
or severe mitral or aortic valve disease, or tachycardia (heart rate>90bpm) 
were excluded. Analyses were adjusted for age, sex, BMI, and baseline value 
of the outcome. Influence of T2DM or medication use was investigated by 
stratified analyses.
Results: Of the 796 individuals of whom echocardiograms at baseline were 
present, 441 (baseline age 66 years, 34% T2DM of whom 80% were newly 
diagnosed) attended the follow-up. Non-attendees were older, had lower DCs 
and higher LVMI and LAVI as compared to attendees. In crude analyses, 
femoral and carotid DC were significantly associated with LVMI, however 
this was explained by age and sex differences. Associations between DCs 
and LAVI were not different for individuals with or without T2DM (p for 
interaction >0.10). Individuals with T2DM had at baseline already lower DCs 
and higher LAVI compared to those without T2DM. In individuals who did 
not use lipid or glucose lowering medication, every 10-3 kPa-1 lower baseline 
brachial and femoral DC was independently associated with a 0.41 (95% CI: 
0.14-0.67) or 0.68 (0.12-1.23) ml/m2 higher LAVI, respectively. Associations 
adjusted for mean arterial pressure were 0.36 (0.09-0.63) and 0.57 (-0.01-
1.14, NS) ml/m2 higher LAVI per 10-3 kPa-1 lower DCs. The associations were 
absent in those who used glucose and/or lipid lowering medication. Further 
adjustments for HbA1c, heart rate, LVMI, systolic BP or use of antihyperten-
sive medication did not change our results.
Conclusion: Arterial stiffness was prospectively associated with a worse LV 
diastolic function, regardless of T2DM. These associations were only partly 
explained by mean arterial pressure. Because individuals with T2DM com-
monly have stiffer arteries than those without T2DM, our finding indicates 
that arterial stiffening might be one of the causes of a worse LV diastolic func-
tion in individuals with T2DM.
Supported by: the Dutch Diabetes Research Foundation 
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Natural course of glucose effectiveness in nondiabetic and diabetic 
individuals: the Insulin Resistance Atherosclerosis Study
C. Lorenzo1, L.E. Wagenknecht2, A.J. Karter3, A.J.G. Hanley4, J.M. Norris5, 
S.M. Haffner6;
1Medicine, University of Texas Health Science Center, San Antonio, 2Wake 
Forest University School of Medicine, Winston-Salem, 3Kaiser Permanente, 
Northern California Region, Oakland, USA, 4Nutritional Sciences and 
Medicine and Leadership Sinai Centre for Diabetes, Mt. Sinai Hospital and 
University of Toronto, Canada, 5Department of Epidemiology, Colorado 
School of Public Health. University of Colorado Denver, Aurora, 6Medicine, 
Baylor College of Medicine, Houston, USA.
Background and aims: Disposition index (DI), the product of insulin sen-
sitivity and secretion, decreases as glucose tolerance status deteriorates. Glu-
cose effectiveness (SG), the ability of glucose to enhance its own cellular up-
take and to suppress endogenous glucose production, is also a risk factor for 
type 2 diabetes, but the natural course of SG is not well characterized. Thus, 
we examined the natural course of SG relative to that of DI in participants in 
the Insulin Resistance Atherosclerosis Study (IRAS).
Materials and methods: DI and SG were measured in 923 IRAS participants 
aged 40 - 69 years (Hispanics, non-Hispanic whites, and African Americans) 
by the frequently sampled intravenous glucose tolerance test. DI and SG were 
also measured using the same protocol at the 5-year follow-up examination. 
DI was expressed as the product of insulin sensitivity index and acute insu-
lin response. Normal glucose tolerance (NGT), impaired glucose tolerance 
(IGT), and diabetes were defined by the 1999 World Health Organization cri-
teria. Individuals treated with glucose-lowering medications were excluded.
Results: At baseline, SG was 1.97 ± 0.03 in individuals with NGT, 1.53 ± 0.05 
in those with IGT, and 1.48 ± 0.03 x 10-2 min-1 in diabetic participants (ptrend 
<0.001). Corresponding values of DI were 103.6 ± 5.4, 27.8 ± 2.4, and 5.2 ± 
0.6 x 10-4 min-1. μU-1. ml-1 per μU/ml (ptrend <0.001). SG was directly related to 
DI (r = 0.40, p <0.001) by the Spearman’s rank test after controlling for age, 
sex, race/ethnicity, and center. During the follow-up period, DI decreased in 
all glucose tolerance categories except in individuals who had IGT at baseline 
and NGT at follow-up (Figure). In individuals with NGT at baseline, the de-
crease in DI (adjusted for baseline DI) was directly related to worsening of 
glucose tolerance status during the follow-up period (ptrend <0.001). Similar 
results were observed in individuals with IGT at baseline (ptrend <0.001). SG 
also decreased with time in all categories but in participants with NGT who 
had no change of status and in those with IGT whose status improved. In 
individuals with NGT at baseline, the decrease of SG (adjusted for baseline SG) 
was directly related to worsening of glucose tolerance status during the fol-
low-up period (ptrend <0.001); however, results were not statistically significant 
in those with IGT at baseline (ptrend = 0.075).
Conclusion: Failure to maintain DI and SG results in worsening of glucose 
tolerance status.
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RANKL/OPG signalling pathway mediates medial arterial calcification 
in diabetic Charcot neuroarthropathy
A. Ndip1,2, Y.M. Alexander2, A. Williams2, E.B. Jude3,2, A.J.M. Boulton1,2;
1Department of Medicine and Diabetes, Manchester Diabetes Centre, 
2Cardiovascular Research Group, The University of Manchester, 3Diabetes 
Centre, Tameside General Hospital, Ashton-Under-Lyne, United Kingdom.
Background and aims: Patients with Charcot neuroarthropathy (CN), dis-
play a paradoxical coexistence of medial arterial calcification (MAC) and 
osteolysis, with the suggestion of a key role for RANKL/OPG signal modula-
tion. We aimed to study the potential mechanisms of RANKL/OPG-medi-
ated vascular calcification in CN.
Materials and methods: Serum was obtained from 12 patients with acute 
CN, 10 patients with diabetes and 5 non-diabetic controls. Arterial segments 
were obtained from patients undergoing lower limb amputation and were 
fixed, sectioned and stained with Alizarin red and primary human RANK-
L antibody. Human vascular smooth muscle cells (VSMCs) were explanted 
from the same arterial segments for subsequent cell culture experiments.
Results: Using Bioplex multi-array technology and ELISA bioassays, we dem-
onstrated: i), higher serum OPG (8.2±2.7 vs 7.7±3.3 vs 4.2±0.4pM, p=0.031); 
ii), higher RANKL/OPG ratio (36.8±43.1 vs 5.2±4.9 vs 4.6±3.1 pM/pM, 
p= 0.033); iii), higher inflammatory cytokines IL-8 (p<0.0001) and G-CSF 
(p=0.002); and iv), a trend towards higher RANKL (0.32±0.42 vs 0.04±0.05 
vs 0.02±0.01pM, p=0.054) in CN compared to diabetic and non-diabetic 
controls respectively. Cultured VSMCs displayed accelerated osteoblastic dif-
ferentiation confirmed by Alkaline phosphatase activity (µM phosphate/mg 
protein/min) in the presence of serum from CN patients(49.9±7.3µM) com-
pared to diabetic serum (29.8±3.7µM, p=0.012), control serum (17.6±10.1, 
p=0.011) or osteogenic medium (OM) controls (15.3±5.4µM, p=0.003). 
Cultured VSMCs also displayed increased mineralisation after Alizarin red 
staining and dye elution in Charcot serum (OD units, 0.16±0.01, p=0.0003); 
diabetes serum (0.15±0.01, p=0.0004); and marginally higher in ‘Healthy’ 
serum (0.14±0.03, p=0.04) compared to OM controls (0.09±0.003). Miner-
alisation and differentiation of VSMCs induced by Charcot serum were sig-
nificantly attenuated (p=0.018 and p=0.004 respectively) when co-incubated 
with OPG, the decoy receptor for RANKL signalling. Immunohistochemical 
analysis of arterial sections showed positive RANKL expression within the 
vicinity of MAC compared to control non-calcified sections.
Conclusion: These data demonstrate that in humans, RANKL/OPG signal-
ling is modulated and implicated in MAC and in CN, thus suggesting that 
anti-RANKL therapy may be therapeutic in acute CN or could have potential 
preventative value in recurrent CN.
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Role of osteoprotegerin (OPG) in predicting development of foot ulcer 
and loss of foot pulse in type 1 diabetic patients with and without 
diabetic nephropathy 
M. Lajer1, A. Jorsal1, L. Tarnow1, L.M. Rasmussen2, H.-H. Parving3,4,  
P. Rossing1;
1Steno Diabetes Center, Gentofte, 2Dep. of Biochemistry, Pharmacology 
and Genetics, University Hospital of Odense, 3Dep. of Biochemical 
Endocrinology, Rigshospitalet, University Hospital of Copenhagen, 4Faculty 
of Health Science, University of Aarhus, Denmark.
Background and aims: The bone-related peptide osteoprotegerin is produced 
by vascular cells and is involved in the process of vascular calcification previ-
ously shown to predict mortality and cardiovascular events. We investigated 
the predictive value of plasma OPG in relation to foot complications in pa-
tients with type 1 diabetes (T1DM) with and without diabetic nephropathy.
Materials and methods: Prospective observational follow-up study of 397 
type 1 diabetic patients with overt diabetic nephropathy (243 men; age [mean 
± SD] 42.1 ± 10.6 years, duration of diabetes 28.3 ± 9.9 years, GFR 67 ± 28 
ml/min/1.73 m2) and a control group of 176 patients with longstanding type 
1 diabetes and persistent normoalbuminuria (105 men; age 42.6 ± 9.7 years, 
duration of diabetes 27.6 ± 8.3 years). p-OPG was measured by ELISA.
Results: During the 12 (0-15) years (median (range)) of follow-up, 107 (40%) 
with OPG levels above the median vs. 76 (27%) below developed a foot ulcer, 
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p=0.001. This corresponds to a hazard ratio (HR) of 1.7 [1.3-2.3] and co-
variate adjusted (sex, age, nephropathy status, smoking, HbA1c, systolic BP, 
eGFR, and CRP) HR 1.5 [1.0-2.1], p=0.04. Furthermore, 42 (16%) patients 
with higher OPG vs. 15 (5%) with lower lost foot pulse, adj. HR 2.2 [1.0-4.6], 
p=0.04. Similarly, 51 (18%) with higher OPG levels vs. 21 (7%) with lower 
had vascular surgery or amputation performed, HR 2.9 [1.7-5.0], p<0.001, 
however after adjustment this was no longer significant (p=0.53). In contrast, 
OPG levels were not related to loss of vibration perception or development of 
a Charcot foot, (p=0.11 and 0.27, respectively).
Conclusion: OPG is elevated in T1DM patients who developed a foot ulcer, 
lost foot pulse or had vascular surgery or amputation performed during fol-
low-up. Furthermore, higher OPG levels remained an independent predictor 
of development of foot ulcer and lost foot pulse when adjusting for covari-
ates.
Supported by: the European Commission 
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The diabetic foot in Germany: analysis of quality in specialised diabetic 
footcare centres
R. Lobmann1, E. Müller2, C. Gröne3, J. Kersken3;
1Endocrinology, Diabetes and Geriatrics, Stuttgart General Hospital and 
Medical School, 2General Practitioner and Diabetologist, Bernkastel-Kues, 
3Mathias-Spital und Jakobi-Hospital, Rheine, Germany.
Background and aims: The German Working Group on the Diabetic Foot 
developed certification requirements for diabetic foot centres. These certifi-
cation requirements established procedures by which specialised centres for 
the treatment of the diabetic foot syndrome could verify their management 
quality. In addition, this certification fulfils the demands of the 2006 IDF 
Global Guideline for Type 2 Diabetes. The aim was to establish comparable 
diabetic foot centers with clearly defined treatment structures.
Materials and methods: Conditions for the certification are quality param-
eters of the facility’s structure, treatment procedures and patient outcomes. 
Structural quality was based on the qualifications of staff, the facility’s spatial 
conditions and a minimum provision of equipment. Staff members of certi-
fied centres must visit each other. Also assessed are the application of availa-
ble guidelines and documentation systems, the establishment of a multidisci-
plinary team approach between the facility’s staff and other experts involved. 
For the evaluation, each centre documented 30 consecutively seen individu-
als with diabetic foot lesions. An evaluation of the outcomes was performed 
6 months after the initial presentation. All parameters are checked, presented 
and benchmarked in an open session of the working group.
Results: Data from 428 certified and re-certified centres are presented and a 
total of 12606 individuals were evaluated. At the 6-month follow-up assess-
ment more than half of the lesions were completely healed (58%). The results 
of the evaluation indicate a low level of major (above-ankle) amputations 
compared with the expected amputation rates in Germany (nearly 10-15%).
Data given in % Major-Amputation Minor-Amputation died
2005 3,9 19 4,6
2006 3,9 24 5,4
2007 3,6 20,1 5,1
2008 2,9 18,8 4,7
2009 2,7 16,7 2,9
Conclusion: These data represent the first analyses of the treatment outcomes 
of diabetic foot lesions in specialised centers in Germany over a time period 
of 5 Years. The data reflect a lower rate of major and minor amputations in 
specialist centres compared with the available epidemiological data for Ger-
many as a whole. This analysis presents the first German data collected using 
defined standards that include amputation rate and mortality in the treat-
ment of the diabetic foot in specialist centres. The established structures are 
appropriate to show consistent low rates of amputations over several years.
Supported by: Working Group of the Diabetic foot of the German Diabetes As-
sociation
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Acute antimicrobial effect of maggot therapy on diabetic foot ulcer 
infection as a basis for identification of antimicrobial peptides from 
maggots
R. Bem1, A. Jirkovská1, V. Fejfarová1, M. Dubský1, J. Skibová1, V. Čeřovský2;
1Diabetes Centre, Institute for Clinical and Experimental Medicine, 
2Institute of Organic Chemistry and Biochemistry, Academy of Sciences, 
Prague, Czech Republic.
Background and aims: The treatment of infected diabetic foot ulcers (DFU) 
is often complicated by emergence of antibiotic resistance; maggot debride-
ment therapy (MDT) may be helpful in overcoming this problem. Antimi-
crobial effect of MDT and stimulation of immune response were proven in 
vitro. The aim of our study was to assess the antimicrobial effect of MDT on 
different strains of bacteria in a 5-year cohort of patients with infected DFU 
as a basis for identification of antimicrobial peptides from maggots.
Materials and methods: 91 patients with infected DFU treated in our dia-
betic foot clinic were enrolled in the present study between January 2005 and 
February 2010. Sterile free-range larvae of the green bottle fly Lucilia sericata 
were applied to the ulcers for 3-5 days (5-10 larvae per cm2). Swabs or tissue 
samples were taken from deep structures of the wound after debridement. 
Specimens for culture were obtained immediately before and after MDT; con-
trol specimens were taken 10 (±3) days after the end of MDT. The individual 
bacterial species in positive swabs were determined by standard microbio-
logical methods and microorganisms were categorized by Gram staining. 
MRSA was identified according to positive test for mec gene. High-perform-
ance liquid chromatography, mass spectrometry and Edman degradation 
were used for identification and isolation of antimicrobial peptides.
Results: The mean duration of MDT was 3.6±0.4 days. There was a significant 
elimination of majority of bacteria immediately after MDT: MRSA (21/91 
vs. 5/91; p<0.001], Enterococcus sp. (36/91 vs. 15/91; p<0.001), Staphylococ-
cus coagulase negative (21/91 vs. 7/91; p<0.001), Streptococcus sp. (6/91 vs. 
0/91; p<0.001), Escherichia coli (13/91 vs. 5/91; p<0.02), Proteus sp. (13/91 
vs. 5/91; p<0.01) and Klebsiella sp. (12/91 vs. 5/91; p<0.01). Antimicrobial ef-
fect persisted 10±3 days after cessation of MDT for all these strains of bacteria 
(all p<0.02). MDT was ineffective against Pseudomonas sp. (12/91 vs. 9/91; 
NS) and Acinetobacter sp. (6/91 vs. 4/91; NS). Antimicrobial peptide named 
lucifensin was identified from maggots after MDT of infected DFU and the 
primary sequence of this peptide was determined. In vitro, lucifensin was 
effective against Staphylococcus aureus PS 3A, PS 77, methicilin-resistant 
Staphylococcus aureus, Baccilus subtilis, Rhodococcus sp., but was ineffec-
tive against Esherichia colli and Pseudomonas aeruginosa. There was some 
correspondence between in vitro assessed antimicrobial effect of lucifensin 
and clinical effect of MDT.
Conclusion: Our study demonstrated that MDT acutely eliminated most of 
the Gram-positive including MRSA and Gram-negative strains in patients 
with infected DFU, but was ineffective against Pseudomonas sp. and Acineto-
bacter sp. The insect defensin designated lucifensin was isolated from mag-
gots as a promising antimicrobial peptide.
Supported by: MZO 00023001
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A double blind randomised controlled trial of the efficacy of soluble 
beta-1,3/1,6-glucan in the management of chronic foot ulcers in diabetes
W.J. Jeffcoate1, P.E. Price2, L. Mudge2, B. Olaussen3, F.L. Game1;
1Diabetes and Endocrinology, Nottingham University Hospitals Trust, 
2School of Health Care Studies, Cardiff University, United Kingdom, 
3Clinical Development, Biotec Pharmacon ASA, Tromso, Norway.
Background and aims: Beta-glucans from a variety of non-animal sources 
have been shown to have immuno-modulatory effects in animals and hu-
mans, partly by being recognised by the Dectin-1 receptor and partly by a 
specific interaction with complement receptor 3 - both of which are present 
on mammalian phagocytic cells, including neutrophils and macrophages. It 
is therefore possible that the administration of a beta-glucan such as soluble 
beta-1,3/1,6-glucan (SBG) might improve the healing of chronic wounds in 
diabetes through such an action. Since an earlier small open label pilot study 
and a double blind phase II study of SBG had suggested benefit, this trial was 
designed as a Phase III study.
Materials and methods: Patients with diabetes and full-thickness foot ulcers 
present for >4 weeks but less than 2 years, and of area between 25mm2 and 
500 mm2, were randomised 1:1 to have either 2% aqueous SBG applied or 
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matching methyl cellulose placebo applied to their wounds on two or more 
occasions each week for 8 weeks. Those with active infection, without pal-
pable foot pulses or with ABPI <0.7 were excluded. The primary outcome 
measure was healing within 8 weeks. Secondary outcomes included time to 
healing, breakdown of healed ulcers within 12 weeks, change in ulcer area, 
safety, patient well-being and satisfaction (EQ-5D, Cardiff Wound Impact 
Schedule).
Results: 122 patients (mean age 58.5y; 76.2% male) in 10 UK centres were 
randomised with 67 (54.9%) in the SBG group; the demographic and base-
line characteristics of the two groups were comparable. Eight (3 SBG, 5 pla-
cebo) withdrew because of adverse event (5), death (1) or protocol violation 
(2). There was no difference in numbers healing within 8 weeks in the two 
groups (31.3% SBG versus 32.7% placebo; ITT p=0.87 CMH test). There was 
similarly no difference in time to healing in those that healed (ITT p=0.84, 
stratified log rank), or in change in ulcer area (ANCOVA p=0.45). There was 
no difference in change in local pain, or in EQ-5D and CWIS scores. 17.9% 
ulcers recurred within 12 weeks of complete healing, but there was no differ-
ence between groups (p=0.062 CMH). The majority of adverse events were 
mild or moderate in severity and unrelated to treatment.
Conclusion: We were unable to confirm the superiority of SBG versus pla-
cebo in terms of both primary and secondary endpoints in this study.
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Comparison of healing of ischaemic diabetic foot ulcers after stem cell 
therapy or percutaneous transluminal angioplasty
M. Dubský1, A. Jirkovská1, R. Bem1, L. Pagacova1, V. Fejfarová1, J. Skibova1, 
M. Varga1, E. Sykova2;
1Institute for Clinical and Experimental Medicine, 2Institute for 
Experimental Medicine, Prague, Czech Republic.
Background and aims: Critical limb ischaemia (CLI) is an important prog-
nostic factor for ulcer healing in patients with diabetic foot ulcers (DFU) and 
often leads to amputations. Treatment of CLI in diabetic patients is gener-
ally difficult. Autologous stem cell therapy is a new therapeutic method for 
patients with CLI while the standard therapy remains percutaneous translu-
minal angioplasty (PTA) or peripheral vascular by-pass. The aim of our study 
was to compare healing of DFU in patients treated by stem cell therapy and 
PTA.
Materials and methods: Ten patients treated by stem cells at our foot clinic 
between January 2008 and October 2009 were included into the study (SCT 
group). All patients were diagnosed of CLI (defined by transcutaneous oxy-
gen tension [TcPO2] < 30 mm Hg), ulcer size was between 0.5 and 7 cm
2 
with Texas classification 1C and 2C and no signs of acute infection. Stem 
cell therapy was indicated in patients with persisting ischaemia after standard 
revascularization. Autologous stem cells were obtained from bone marrow or 
peripheral blood after stimulation by growth factor and applied into muscles 
of affected lower limb. Ten patients from our foot clinic with the same inclu-
sion criteria treated by angioplasty (PTA group) during the same period were 
included into the control group. They did not significantly differ from SCT 
group in mean age (62 ± 10 vs. 64 ± 8.5 years), gender (80 % vs. 70 % men), 
glycated hemoglobin (7.4 ± 0.8 vs. 7.6 ± 1.2 %) and mean diabetes duration 
(25 ± 11 vs. 20 ± 7.1 years). All patients were treated by standard podiatric 
methods. Area defect reduction was assessed after 3 and 6 months and time 
to full healing was evaluated 6 months after stem cell therapy or PTA.
Results: There was no significant difference in defect area (2.6 ± 1.5 vs. 2.7 
± 2.5 cm2) and TcPO2 (16.3 vs. 14.3 mm Hg) between both groups before 
the treatment. Area defect reduction was significantly faster in SCT group in 
comparison with PTA group after 3 months (20 ± 89.8 vs. 84.1 ± 30.3 %, p = 
0.05); reduction after 6 months was not significantly different (38.1 ± 109.4 
vs. 93.2 ± 13.3 %, NS). Six months after the therapy were healed 6/10 patients 
in both groups, but time to full healing was significantly shorter in SCT group 
(65.8 ± 20.1 vs. 126 ± 39 days, p = 0.016).
Conclusion: Our study showed faster healing of DFU after stem cell therapy 
than after PTA in patients with CLI and the same effect on healed patients 
after 6 months. Autologous stem cell therapy is a promising alternative for 
treatment of severe ischemia and DFU, but randomized controlled studies are 
required to confirm these results.
Supported by: grant MZO 00023001
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Selective elevation of insulin in the head suppresses hepatic 
glucoregulatory gene expression and net hepatic glycogenolysis in the 
conscious dog
C. Ramnanan1, P.E. Williams2, B. Farmer1, D. Neal1, W. Snead1,  
A.D. Cherrington1, D. Edgerton1;
1Molecular Physiology and Biophysics, 2Surgical Research, Vanderbilt 
University Medical Center, Nashville, USA.
Background and aims: Studies in the rodent have demonstrated that hy-
pothalamic insulin signaling can play a role in controlling hepatic glucose 
production (HGP). However, we previously found in the dog that blockade of 
insulin signaling in the brain did not impair the suppression of HGP during 
a physiological elevation of insulin throughout the body. Thus, brain insulin 
signaling may not regulate HGP in non-rodent species with lower basal HGP, 
or alternatively, the effect of hepatic hyperinsulinemia may mask the subtle 
effects of brain insulin action. To determine the degree to which insulin ac-
tion in the brain might contribute to inhibition of HGP in the presence of 
basal insulin and glucagon levels in the dog, insulin was selectively elevated 
in the blood perfusing the brain.
Materials and methods: Dogs underwent head (carotid and vertebral artery; 
jugular vein) and liver (femoral artery; portal and hepatic vein) catheteriza-
tion and a cannula was inserted into the 3rd ventricle (ICV). On the day of 
the study, at -150 min [3-3H]glucose and somatostatin (to inhibit pancreatic 
hormone secretion) were infused into a peripheral vein and glucagon and 
insulin were infused intraportally at basal rates. Following a basal sampling 
period (-30 to 0 min), artificial cerebrospinal fluid (aCSF; n=7) or the PI3K 
inhibitor LY29004 (to block brain insulin action; LY; n=8) was infused ICV 
(0 to 300 min). From 60 to 300 min, the liver insulin level remained clamped 
at basal while plasma insulin was selectively increased (10-fold) in the head 
by infusion of the hormone into the carotid and vertebral arteries, coincident 
with a cessation of portal insulin infusion. Intralipid, heparin and glucose 
were infused as required to clamp NEFA and glucose at basal.
Results: In both groups head insulin (jugular) increased 10-fold, arterial in-
sulin increased 2-fold, and insulin at the liver remained basal. Glucose, glu-
cagon and NEFA remained at basal levels. The change in net hepatic glucose 
balance between basal and the last hour in the LY and aCSF groups, respec-
tively, was -0.09±0.12 and -0.58±0.27 mg/kg/min (P=0.05). The change in 
endogenous glucose Ra was -0.17±0.12 and -0.35±0.12 mg/kg/min, respec-
tively. Net hepatic glycogenolytic (NHGLY) and gluconeogenic flux (GNG) 
were estimated using net liver balance. Delta NHGLY was -0.15±0.07 and 
-0.63±0.23 mg/kg/min (P<0.05) in the two groups, respectively, while delta 
GNG was 0.06±0.11 and 0.00±0.08 mg/kg/min. Liver P-Akt was basal in both 
groups at the end of the study, while hypothalamic P-Akt was basal in LY but 
had increased 2-fold in aCSF (P<0.05). Likewise, hepatic P-STAT3, reported 
to be increased by brain insulin signaling, was basal in LY but had increased 
40% in aCSF (P<0.05). Liver PEPCK gene expression was reduced by 50% 
when insulin was selectively elevated in the head.
Conclusion: In the absence of an increase in insulin’s direct hepatic effects, 
insulin signaling in the brain affected gene expression in the liver in a large 
animal model. HGP tended to be reduced although the effect was small, did 
not become significant until 2.5 h, and was due to inhibition of net hepatic 
glycogenolysis. It would appear that the rapid decrease in HGP which nor-
mally occurs in response to an increase in insulin secretion in vivo is unre-
lated to brain insulin signaling.
Supported by: DK18243
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MCP-1 and chemerin are involved in the regulation of anandamide secre-
tion by human skeletal muscle cells
K. Eckardt1, M. Lehtonen2, B. Platzbecker1, A. Schober1, J. Eckel1;
1Inst. of Clin. Biochemistry and Pathobiochemistry, German Diabetes 
Center, Duesseldorf, Germany, 2Dep. of Pharm. Chemistry, University of 
Kuopio, Finland.
Background and aims: Obesity is one of the major components of the meta-
bolic syndrome and associated with increased adipose tissue mass, which 
is characterised by an altered secretion profile. It has been shown that be-
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sides other factors the levels of proinflammatory cytokines like MCP-1 and 
chemerin are elevated, and their implication in the induction of insulin resist-
ance in skeletal muscle could be demonstrated. In addition, obesity is associ-
ated with a dysregulation of the endocannabinoid system leading to elevated 
plasma levels of anandamide (AEA) and 2-arachidonoylglycerol (2-AG) as 
well as decreased expression and activity of the AEA-degrading enzyme fatty 
acid amide hydrolase (FAAH). Previously, we could show that AEA is in-
volved in the induction of skeletal muscle insulin resistance via enhanced 
IRS-1(Ser307) phosphorylation. Aim of the present study was to investigate 
whether skeletal muscle cells themselves are able to produce endocannabi-
noids and whether their secretion is regulated by selected cytokines.
Materials and methods: Differentiated primary human skeletal muscle cells 
(SkM) were incubated with 0.5 µg/ml chemerin and 2 ng/ml MCP-1, respec-
tively. Medium was collected after 24 h, endocannabinoids were extracted 
and analysed by liquid chromatography/mass spectrometry. Additionally, 
RNA was prepared after 8 h or 24 h incubation and used for qRT-PCR to 
study the expression of FAAH and the AEA-synthesizing enzyme N-acyl-
phosphatidylethanolamine-specific phospholipase D (NAPE-PLD).
Results: In media obtained from 3 different SkM donors we were able to 
detect AEA and 2-AG as well as palmitoyl ethanolamide (PEA) and oleoyl 
ethanolamide (OEA). The concentration in media from untreated cells was 
1.75±0.08 pmol/l for AEA, 260.06±35.99 pmol/l for 2-AG, 6.38±2.58 pmol/l 
for PEA and 3.09±0.32 pmol/l for OEA. Stimulation of SkM with MCP-1 and 
chemerin for 24 h led to a significant increase of AEA, while for 2-AG, PEA, 
and OEA no significant changes were observed. MCP-1 treatment resulted in 
a 1.3-fold and chemerin treatment in a 1.8-fold increase of AEA concentra-
tion (n=3). The analysis of NAPE-PLD and FAAH expression showed that 
after 8 h incubation with MCP-1 the expression of NAPE-PLD was increased 
by ~15% and with chemerin by ~20%, while no change in FAAH expres-
sion was observed. However, after 24 h the expression of FAAH was down-
regulated by MCP-1 (~16%) and chemerin (~26%), while the expression of 
NAPE-PLD was at the level of untreated controls (n=3).
Conclusion: To the best of our knowledge, these results demonstrate for the 
first time the ability of human skeletal muscle cells to produce and secrete en-
docannabinoids such as AEA and 2-AG. In addition, we could prove that the 
proinflammatory cytokines MCP-1 and chemerin are involved in the regula-
tion of AEA synthesis by causing an increase of AEA level. Part of this regula-
tion includes changes of NAPE-PLD and FAAH expression. In summary, our 
data link MCP-1 and chemerin, which are known to induce skeletal muscle 
insulin resistance by themselves, to the endocannabinoid system and AEA, 
which also has been shown to play a role in the induction of skeletal muscle 
insulin resistance. In states of obesity, which are characterised by elevated 
levels of proinflammatory cytokines and AEA, the influence of MCP-1 and 
chemerin on AEA synthesis in muscle tissue may thus lead to further impair-
ment of insulin sensitivity.
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Secreted adipocyte fatty acid binding protein (FABP4) forms the 
molecular basis of the adipo-insular axis
L.E. Wu, D.E. James, J. Cantley;
Diabetes and Obesity Program, Garvan Institute of Medical Research, 
Darlinghurst, Australia.
Background and aims: Obesity is closely linked with increased insulin lev-
els and β-cell mass. Obesity may be accompanied by adipose tissue hypoxia, 
which occurs when the rate of adipose tissue expansion exceeds the rate of 
required angiogenesis, leading to areas that are insufficiently vascularised and 
consequently hypoxic. We hypothesised the link between obesity and insulin 
levels to be a result of an inter-organ communication between hypoxic adi-
pose tissue and the β cell, which may involve a secretory component.
Materials and methods: To assess the effects of adipocyte conditioned media 
on β-cell function, 3T3-L1 adipocytes were incubated in serum free culture 
media (RPMI1640) under atmospheric or 1% O2 concentrations. Condi-
tioned media was dialysed and concentrated against a 10 kDa filter to remove 
small non-protein molecules. Dialysed conditioned media was diluted with 
10% foetal calf serum and used to treat islets isolated from mouse pancreas 
for 24 hr. Glucose stimulated insulin secretion from islets was subsequently 
assayed. A stable isotope labelling of amino acids in cell culture (SILAC) 
quantitative mass spectrometry screen was performed to identify hypoxia 
regulated adipocyte secretory proteins.
Results: Conditioned media from hypoxic, but not normoxic control 3T3-L1 
adipocytes led to an increase in glucose stimulated insulin secretion of 70% 
(412.7 ± 83.03 vs. 753.5 ± 108.6 pg insulin / islet / hr, p<0.05). A quantita-
tive mass spectrometry screen led to identification of the adipocyte fatty acid 
binding protein FABP4 as a hypoxia responsive adipocyte secretory protein. 
Western blotting and ELISA data confirmed increased secretion of FABP4 
from adipocytes into conditioned media during hypoxia (146.9 ± 16.64 vs. 
1166 ± 61.18 ng / ml FABP4, p<0.0001). Serum concentrations of FABP4 
were raised in high fat fed mice, along with circulating insulin concentra-
tions (chow fed 259.9 ± 67.05 vs. high fat fed 804.8 ± 173.7 ng / ml serum 
FABP4, p<0.05; 1.397±0.470 vs. 3.205±0.549 ng / ml serum insulin, p<0.05). 
In vitro treatment of islets with physiologically relevant concentrations of re-
combinant FABP4 pre-incubated with linoleate but not palmitate enhanced 
glucose stimulated insulin secretion to a degree similar to hypoxic adipocyte 
conditioned media (535.4 ± 32.32 vs. 947.0 ± 134.5 pg insulin / hr, p<0.05). 
Hypoxia inhibits mitochondrial function, and treatment of adipocytes with 
the mitochondrial poisons DNP and oligomycin also stimulated FABP4 se-
cretion. Treatment of adipocytes with insulin during hypoxia reduces FABP4 
secretion. Removal of glucose from media and substitution with pyruvate re-
verses the inhibition of secretion during hypoxia by insulin, indicating that 
the primary role of FABP4 secretion is to alleviate energy crisis by increasing 
glucose uptake into fat through increased insulin secretion.
Conclusion: Taken together, these data are indicative of an adipo-insular axis 
mediated by FABP4, which functions to coordinate insulin secretion and glu-
cose uptake in response to the prevailing needs of adipose tissue.
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Interleukin-6 as a key mediator of metabolic adaptation to fasting
S. Wueest1,2, H. Ellingsgaard3,2, E.J. Schoenle1, D. Konrad1,2;
1Endocrinology/Diabetology University Children’s Hospital Zurich, 2Zurich 
Center for Integrative Human Physiology, University of Zurich, 3Division 
of Endocrinology, Diabetes & Nutrition, University Hospital Zurich, 
Switzerland.
Background and aims: Fasting leads to increased production of ketone bod-
ies from non-esterified fatty acids (NEFA) liberated from white adipose tis-
sue. However, it is not known whether interleukin-6 (IL-6) contributes to this 
fasting-induced lipolysis. Thus, the aim of the present study was to analyze 
whether IL-6 contributes to the metabolic switch from carbohydrate to fat 
oxidation (metabolic flexibility) provoked by food deprivation (fasting) in 
lean mice, and if yes, whether this metabolic switch is maintained in obesity 
and insulin resistance.
Materials and methods: Experiments were performed in C57BL/6J mice fed 
regular chow or high fat diet (HFD) for 8 weeks and in IL-6 KO mice. Mice 
were fed ad libitum or fasted for 24 hours and blood was sampled after 0, 6, 
12 and 24 hours. Body weight as well as blood glucose and ketone levels were 
determined. In addition, plasma IL-6, leptin, insulin and NEFA levels were 
measured and IL-6 mRNA levels were analysed.
Results: The transcription of IL-6 was significantly induced in skeletal mus-
cle but not in white adipose tissue in chow-fed C57BL/6J mice after 6 hours 
of food withdrawal. Concomitantly, circulating IL-6 levels increased by 3-fold 
(p<0.05) without changes in plasma insulin levels. Moreover, increased circu-
lating IL-6 levels upon 6 hours of fasting were accompanied by elevated ketone 
levels (0.50±0.04 mmol/l in fasted vs 0.25±0.04 mmol/l fed mice; p<0.01), an 
effect that was blunted in IL-6 KO mice (0.48±0.09 mmol/l in WT vs 0.24±0.01 
mmol/l in IL-6 KO mice; p<0.05) and chow-fed mice injected with neutralizing 
IL-6 antibody (0.65±0.03 mmol/l in IgG vs 0.38±0.05 mmol/l in IL-6 nAB in-
jected mice; p<0.001). In addition, HFD-fed mice showed no increased circu-
lating IL-6 levels upon fasting, paralleled by a blunted increase in ketone bodies 
in the first 6 hours of food withdrawal compared to chow-fed mice (0.37±0.04 
mmol/l in chow-fed vs 0.15±0.04 mmol/l in HFD-fed mice; p<0.01).
Conclusion: IL-6 contributes to fasting-induced lipolysis and metabolic flex-
ibility.
Supported by: Swiss National Science Foundation
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New adipokines identified as downstream targets for adiponectin: 
lessons from adiponectin-overexpressing or deficient-mice
Q. Ge, L. Rycken, L. Noël, S.M. Brichard;
Unité d’Endocrinologie et Métabolisme, l’Université Catholique de Louvain, 
Bruxelles, Belgium.
Background and aims: Adipokines play a central role in the pathogenesis of 
the metabolic syndrome. Adiponectin (ApN) is a master regulator of immune 
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and fuel homeostasis. Identifying downstream adipokines targeted by ApN 
may help in understanding its action. We have generated transgenic mice al-
lowing persistent and moderate overexpression of ApN (ApN-Overex) spe-
cifically in white adipose tissue (AT)(by using the aP2 promoter). We took 
advantage of this model to unravel the adipokine secretion profile triggered 
by ApN in AT. We also examine whether a reverse profile occurred in ApN-
knockout (ApN-KO) mice.
Materials and methods: To investigate the early and specific effects of ApN, 
mice were studied at 10 wks of age (before any changes in adiposity or in 
circulating glucose/lipids). AT was fractionated into adipocytes and stromal-
vascular cells (SVC), which were cultured for 8 h. Medium was screened by 
cytokine antibody arrays allowing the detection of 144 cytokines. Secretion 
of relevant adipokines was quantified by ELISA and gene expression by RTQ-
PCR. NF-κB activity was measured by ELISA and Jun N-terminal kinase 
(JNK) phosphorylation by western blot.
Results: Profiling of secretory products by antibody arrays showed that 
~10 cytokines from each cellular fraction roughly differed between ApN-
Overex mice and wild type (WT) mice. These adipokines were quantified 
by ELISA. When compared to WT mice, the secretion of 3 pro-inflamma-
tory factors (IL-17B, IL-21, TNF-α) and 3 hematopoietic growth factors 
(GF)(Thrombopoietin, TPO; Granulocyte-, GCSF and granulocyte macro-
phage-stimulating GF, GMCSF) was reduced in adipocytes of ApN-Overex 
mice. In SVC of these mice, besides the hematopoietic GFs, the secretion of 
another GF (vascular endothelial GF receptor 1, VEGFR1), 2 chemokines 
(RANTES, ICAM-1) and 2 pro-inflammatory factors (IL-6, IL-12p70) was 
reduced as well. Only one cytokine was oversecreted by SVC of ApN-Overex 
mice: interleukin-1 receptor 4 (IL-1R4) that exhibits anti-inflammatory prop-
erties. Most of these changes in secretion were due to corresponding changes 
in mRNAs. To investigate whether these changes were specifically induced 
by ApN, we searched for a reverse profile of adipokine expression in mice 
lacking ApN. TPO gene expression was increased in adipocytes of ApN-KO 
mice, and the expression of VEGFR1, IL-12p70 and ICAM-1 was augmented 
in SVC of these mice. Concomitantly, IL-1R4 expression was reduced in SVC 
of ApN-KO mice. We next investigated the molecular pathways underlying 
these inflammatory changes. NF-κB activity was remarkably reduced in AT 
of ApN-Overex mice, while JNK phosphorylation was unaffected.
Conclusion: ApN regulates in vivo the secretion of downstream adipokines, 
thereby inducing a shift of the immune balance in both adipocytes and SVC 
toward a less inflammatory phenotype. These downstream adipokines may 
be new therapeutic targets for the management of the metabolic syndrome.
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Bradykinin 1 receptor inhibition improves glucose tolerance and reduces 
adipose tissue inflammation in high-fat diet fed mice 
M. Sörhede Winzell, A. Ahnmark, K. Lundmark, L. William-Olsson,  
J. Oscarsson, M. Strömstedt, D. Lindén;
Diabetes & Obesity, AstraZeneca R&D, Mölndal, Sweden.
Background and aims: Kinins are proinflammatory peptides which are in-
volved in the control of blood pressure, inflammation and pain. Recently, it 
was demonstrated that bradykinin 1 receptor (B1R) deficient mice had re-
duced fasting plasma glucose and insulin levels and were protected against 
high-fat diet (HFD) induced obesity. It is however not shown whether phar-
macological inhibition of B1R affects glucose tolerance and insulin sensitiv-
ity. The aim of this study was to establish whether B1R antagonism could 
improve glycemia and glucose tolerance in obese, insulin resistant mice. Fur-
thermore, the effect of B1R antagonism on inflammatory markers in adipose 
tissue was investigated.
Materials and methods: Female C57BL/6J mice were fed a HFD (60%fat) 
for up to 20 weeks. Thereafter, the mice were administered subcutaneously, 
twice daily for 12 days with a B1R antagonist (SSR240612, Sanofi-Avensis 
R&D, 10mg/kg/day). Control mice received vehicle only (5% mannitol). 
Body weight and food intake were registered every second day. After 7 days 
treatment, glucose tolerance was estimated in an oral glucose tolerance test 
(OGTT; 2 g/kg). At termination, adipose tissue samples were collected and 
the expression of inflammatory markers was analyzed using real time PCR.
Results: After feeding the mice with HFD, basal glucose was elevated (9.1±0.1 
vs. 7.8±0.1 mM, p<0.01) as well as insulin (1.8±0.3 vs. 0.37±0.06 ng/ml, p< 
0.001) compared to lean, normal diet (ND) fed mice, demonstrating signifi-
cantly impaired insulin sensitivity in the HFD fed mice. One week treatment 
of HFD fed mice with the B1R antagonist restored basal glucose levels to 
7.9±0.2 mM (p<0.01) and reduced insulin levels to 0.91±0.1 ng/ml (p<0.001) 
compared to HFD fed control mice, suggesting improved insulin sensitivity 
in the B1R antagonist treated mice. Body weight was significantly reduced 
during B1R antagonism (p<0.001), where treated mice lost 11% of their body 
weight compared to HFD fed control mice during the 12 days treatment pe-
riod. Food intake was slightly reduced during the second week of treatment, 
although the body weight loss was apparent earlier than any effects on food 
intake was observed, suggesting other mechanisms than reduced food intake 
to be responsible for the weight loss. The OGTT demonstrated improved 
glucose tolerance with reduced glucose and insulin excursions after B1R 
inhibition. In the HFD fed mice the expression levels of several markers of 
inflammation were increased in perigaonadal adipose tissue compared to ND 
fed mice. B1R antagonism resulted in reduced mRNA expression of MCP-1, 
TNFα, IL-6 and IL-1β in adipose tissue.
Conclusion: B1R antagonism in obese, insulin resistant mice resulted in 
improved glycemia, reduced basal insulin levels and improved glucose tol-
erance. These findings, in association with reduced expression of adipocy-
tokines, demonstrate that inhibition of B1R may be a novel treatment strategy 
for type 2 diabetes.
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Effective revascularisation and enhancement of islet engraftment by 
cotransplantation of islets with endothelial progenitor cells
S. Kang, H.S. Park, H.S. Jung, K.S. Park;
Snuh, Seoul, Republic of Korea.
Background and aims: Islet transplantation is an emerging therapeutic op-
tion for type 1 diabetic patients. However, it has many obstacles, one of which 
is impaired revascularization in transplanted islets leading to islet loss. In 
contrast to solid organ transplantation where the organ is nourished by large 
vessel anastomosis, avascular islets suffer from hypoxia and malnutrition for 
a long time as a consequence of absence of effective blood supply, which re-
sults in continuous islet loss and ultimately, only a short period of effective 
graft function. Endothelial progenitor cells (EPCs) are well known to induce 
neovascularization in diverse ischemic tissues. Here we aimed to increase is-
let engraftment by cotransplantation of islets with EPCs.
Materials and methods: Porcine islets were transplanted beneath the kidney 
capsule of athymic nude mice with or without human cord blood-derived 
EPCs (EPC group or islet only group, respectively). The transplanted β-cells, 
EPCs, and blood vessels from islets or host mouse were evaluated by insulin, 
UEA-1 lectin, and BS-1 lectin immunostaining, respectively. The islet func-
tion was followed for 4 weeks post-transplantation with random blood sugar 
level.
Results: The EPC group mice reached euglycemia (random blood 
sugar<200mg/dL) at 17 days after transplantation, whereas islet only group 
mice did not even though they showed improvement of glycemic control 
compared to diabetic sham control mice. The EPC group mice showed sig-
nificant increase of body weight compared to the islet only group mice, while 
sham control diabetic mice continuously lost their weight, which finally lead 
to death around 28 days post-transplantation. In addition, compared to sham 
control group, both the islet only and EPC group showed detectable porcine 
insulin level with the fact that EPC group showed higher level of insulin at 
both fasting and at glucose challenge compared to the islet only group. At 
28 days after transplantation, the kidney bearing transplanted islets were re-
moved to evaluate whether euglycemia induction was by transplanted por-
cine islets themselves or by regeneration of remnant pancreatic islets in the 
host. After 7 days of nephrectomy, blood glucose levels of the EPC group 
reached approximately 500 mg/dL, suggesting that the transplanted islets 
contributed mainly to glycemic control. Immunostaining of the transplant-
ed islets 5 weeks post-transplantation demonstrated that the islets from the 
EPC group were highly revascularized compared to those of the islet only 
group, which coincided with the higher β-cell mass in the EPC group. We 
also tracked the vasculature of transplanted islets at 3, 14, and 35 days post-
transplantation to see the time course of vessel ingrowth into the transplanted 
islets. Compared to the islet only group, the EPC group showed much more 
blood vessel organization and branching at 3 days and a significant increase 
in the number and length of vessel ingrowth at 14 days post-transplantation. 
Importantly, this was associated with a time-dependent increase of insulin(+) 
areas in the transplanted islets and also, proliferating, Ki-67-insulin double-
positive, regenerating β-cells, all of which were significantly increased in the 
EPC group than the islet only group.
Conclusion: Collectively, we concluded that cotransplantation of EPCs with 
islets induce better islet engraftment by enhancing graft revascularization and 
survival/regeneration of islets.
Supported by: IRICT
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Pancreatic islets transplanted intraportally into the liver in mice have a 
substantially lower blood flow than native islets 
J. Lau Börjesson1, J. Henriksnäs1, P.-O. Berggren2, M. Köhler2, 
P.-O. Carlsson1;
1Department of Medical Cell Biology, Uppsala University, 2The Rolf Luft 
Reserach Center for Diabetes and Endocrinology, Karolinska Institutet, 
Stockholm, Sweden.
Background and aims: Pancreatic islets are in the clinical setting trans-
planted intraportally into the liver, but with low long-term success rate. En-
graftment of pancreatic islets in the liver has been difficult to study, since the 
islets virtually disappear out of sight and imaging techniques have too poor 
resolution for their study. However, experimental studies have indicated a low 
revascularization of islets at the intrahepatic site, and that ingrowing blood 
vessels are derived solely from the hepatic artery and not the portal vein. 
The aim of the present study was to establish a model and quantify the blood 
perfusion of intrahepatically transplanted islets. Islet vascular density and the 
contribution of donor blood vessels in the islet revascularization process were 
also determined.
Materials and methods: Pancreatic islets were isolated from transgenic YC-
3.0 mice, which express the yellow chameleon protein 3.0 under the regula-
tion of the β-actin and cytomegalovirus promoters. Islets from these mice 
have previously been shown to express enhanced yellow fluorescent protein, 
one part of the hybrid YC-3.0 protein, in all cells. The islets were transplanted 
intraportally selectively into the right liver lobe of recipient nude mice by 
temporary occlusion of the other tributaries of the portal vein at the time 
of islet infusion (200 islets). One month later, blood perfusion of the trans-
planted islets was determined by a fluorescent microsphere technique and 
compared to the blood perfusion of native YC-3.0 islets. The vascular density 
and relative contribution of recipient and donor blood vessels in islet revas-
cularization was evaluated one month post-transplantation using islets ex-
pressing green fluorescent protein behind the Tie2 promoter (Tie2-GFP) for 
intraportal transplantation to nude mice.
Results: The blood flow in the YC-3.0 islets transplanted to the liver was 0.20 
± 0.1 ml/min/mg islet (n=10), which was markedly lower than the blood per-
fusion of native YC-3.0 islets (3.86 ± 0.54 ml/min/mg islet; n=6). The blood 
flow in the native islets of the transplanted nude mice was 3.54 ± 0.62 ml/
min/mg islet (n=10). Vascular density in the intraportally transplanted islets 
was decreased, and very few donor endothelial cells could be observed incor-
porated in the new islet vascular system.
Conclusion: The blood perfusion of intrahepatically transplanted islets is less 
than 10% of that in native islets when investigated one month post-trans-
plantation. Low numbers of donor blood vessels contribute to the revascu-
larization at the intrahepatic site, which may at least partially explain their 
insufficient vascular engraftment.
Supported by: JDRF, SRC, SDF, NNF and SSMF
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Clinical and experimental pancreatic islet transplantation to striated 
muscle: Establishment of a vascular system similar to that in native islets
G. Christoffersson1, J. Henriksnäs1, L. Johansson2, C. Rolny3, H. Ahlström2, 
J. Caballero-Corbalan2, R. Segersvärd4, J. Permert4, O. Korsgren2, P.-O. 
Carlsson1,5, M. Phillipson1;
1Department of Medical Cell Biology, Uppsala University, 2Department 
of Oncology, Radiology and Clinical Immunology, Uppsala University, 
3Department of Genetics and Pathology, Uppsala University, 4Department 
for Clinical Science, Intervention and Technology, Karolinska Institute, 
Stockholm, 5Department of Medical Sciences, Uppsala University, Sweden.
Background and aims: Curing type 1 diabetes by transplanting pancreatic 
islets into the liver is associated with poor long-term outcome and graft fail-
ure at least partly due to inadequate graft revascularization. The aim of the 
current study was to evaluate striated muscle as a potential angiogenic site 
for islet transplantation.
Materials and methods: The current study presents a new experimental 
model which is found applicable to clinical islet transplantation. Islets were 
implanted into striated muscle where after intra-islet vascular density and 
blood flow were visualized with intravital and confocal microscopy in mice, 
and by magnetic resonance imaging in three auto-transplanted pancreatect-
omized patients. Mice were rendered neutropenic by repeated injections of 
Gr-1 antibody and diabetes was induced by alloxan treatment.
Results: Contrary to liver engrafted islets, islets transplanted to mouse mus-
cle were revascularized with vessel densities and blood flow entirely compa-
rable to islets within intact pancreas. Initiation of islet revascularization at the 
muscular site was dependent on neutrophils, and the function of islets trans-
planted to muscle was proven by curing diabetic mice. The experimental data 
were confirmed in auto-transplanted patients where higher plasma volumes 
were measured in islets engrafted in forearm muscle compared to adjacent 
muscle tissue through high-resolution magnetic resonance imaging.
Conclusion: This study presents a novel paradigm in islet transplantation 
whereby recruited neutrophils are crucial for the functionally restored in-
tra-islet blood perfusion following transplantation to striated muscle under 
experimental and clinical situations.
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Tracking mouse islet isografts and allografts using a novel magnetic 
resonance contrast agent, chitosan-coated superparamagnetic iron oxide 
nanoparticles
J.-H. Juang1, C.-R. Shen2, J.-J. Wang3, C.-H. Kuo4, Z.-T. Tsai5, T.-C. Yen5;
1Division of Endocrinology and Metabolism, Chang Gung University 
and Memorial Hospital, 2Department and Graduate Institute of Medical 
Biotechnology and Laboratory Science, Chang Gung University, 
3Department of Medical Imaging and Radiological Sciences, Chang Gung 
University, 4Department of Biological Science and Technology, National 
Chiao Tung University, 5Molecular Imaging Center, Chang Gung Memorial 
Hospital, Taoyuan, Taiwan.
Background and aims: Although only 10% of islet recipients maintain insulin in-
dependence, 80% of them are C-peptide positive at 5 years after transplantation. To 
better understand the fate of transplanted islets, a magnetic resonance (MR) imag-
ing technique has been used to detect superparamagnetic iron oxide (SPIO)-labeled 
islet grafts. In this study, we utilized a novel MR contrast agent, chitosan-coated 
SPIO (CSPIO) nanoparticles, to monitor mouse islet isografts and allografts.
Materials and methods: Male C57BL/6 mice were used as donors and male in-
bred C57BL/6 (syngeneic) and Balb/c (allogenic) mice were used as recipients 
of islet transplantation. Mouse pancreas was digested by collagenase and islets 
were purified by density gradient. After being incubated with and without CS-
PIO (10 mg/ml), islets were examined under transmission electron microscope 
(TEM) and their insulin secretion was measured by static incubation and peri-
fusion studies. Cytotoxicity was evaluated by fluorescein diacetate and propid-
ium iodide staining for NIT-1, βTC and αTC1 cells. Three hundred islets were 
transplanted under left kidney capsule of each mouse. After transplantation, 3.0 
Tesla MR imaging of the recipients was performed. At the end of study, the islet 
graft was removed for insulin and Prussian blue staining and TEM studies.
Results: At 8 hours after incubation of isolated islets with CSPIO, TEM 
showed CSPIO particles located in endocytotic vesicles of both α- and β-cells. 
The islets incubated overnight with and without CSPIO had comparable insu-
lin responses to high glucose challenges. There was no increased death rates 
in NIT-1, βTC and αTC1 cells with increasing CSPIO iron concentrations up 
to 80 μg or incubation time up to 72 hours. At week 0, 1, 2, 3, 4, 5, 6, 8 after 
syngeneic transplantation, the grafts of CSPIO-labeled islets were visualized 
on MR scans as distinct hypointense spots homogeneously located at the up-
per pole of left kidney. Using the contralateral kidney as a reference, the MR 
signal intensity of CSPIO-labeled and control islet grafts was 81.9 ± 14.0% and 
103.8 ± 15.4%, respectively (P=3.68297E-05). At 8 weeks after transplantation, 
the CSPIO-labeled islet graft was positive for insulin and iron staining. Under 
TEM, there were several electron dense clumps distributed in the cytoplasm of 
islets with intact ultrastructure. The electron energy-loss spectroscopy further 
demonstrated these clumps contained elementary iron. At day 3, 10, 17, 24, 31, 
38 and 45 after allotransplantation, MR scans showed hypointense spots at the 
upper pole of left kidney gradually decreased in size. The histology of CSPIO-
labeled islet grafts at day 10, 17, 24, 31, 38 and 45 showed insulin- and iron-
staining co-localized in the same areas but the graft size decreased with time.
Conclusion: Our results indicate, after syngeneic and allo-transplantation, 
isolated mouse islets labeled with CSPIO nanoparticles can be effectively and 
safely imaged by using MR scanning.
Supported by: Chang Gung Memorial Hospital
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Generation of pancreatic endocrine cells from human adult fibroblast-
like limbal stem cells
C. Giordano1, A. Criscimanna1, G. Zito1, A. Taddeo1, P. Richiusa1, M. Pitrone1, 
D. Morreale2, G. Lodato2, G. Pizzolanti1, R. Citarrella1, A. Galluzzo1;
1Section of Endocrinology, DOSAC, Endocrinology, 2Dipartimento di 
Oculistica, Ophtalmology, Palermo, Italy.
Background and aims: Stem cells might provide unlimited supply of transplant-
able cells for β-cell replacement therapy in diabetes. The human limbus hosts 
epithelial stem cells - which sustain the continuous renewal of the cornea - and 
fibroblast-like stem cells (f-LSCs) - with apparent broader plasticity. The aim of 
this study was to isolate and characterize f-LSCs from human donors and to test 
their differentiation potential towards the pancreatic endocrine phenotype.
Materials and methods: f-LSCs were isolated from 14 limbal biopsies. f-
LSCs were characterized by flow cytometry and qRT-PCR for the expression 
of pluripotent markers and self-renewal ability. We then developed a 4-step 
pancreatic differentiation protocol, lasting 14-16 days, by adding in a step-by-
step way factors and supplements which are known to direct/support pancre-
atic differentiation, such as activin A, bFGF, B27, N2, nicotinamide and exen-
din-4. The expression of endodermal, pancreatic, islet and β-cell markers was 
assessed during differentiation by immunofluorescence, flow cytometry and 
western blot analysis. Presence of secretory granules was assessed by confocal 
and electron microscopy. f-LSC-derived cells were also investigated for the 
ability to secrete C-peptide in response to multiple secretory stimuli.
Results: FACS analysis of freshly digested limbal specimens showed signifi-
cant expression of the pluripotent stem cell marker SSEA4 (mean ± SD: 65.2 
± 7.6%). After 24-48 hrs, the single cell suspension formed floating spherical 
aggregates (‘limbospheres’), which eventually attached to the plastic surface, 
giving rise to highly proliferating f-LSCs. Adherent epithelial cells were also 
observed but f-LSCs progressively prevailed. Positivity for SSEA4 was higher 
in cultures obtained by re-plating limbospheres, which were devoid of epithe-
lial cells (mean ± SD: 90.8 ± 9.6%). SSEA4+ f-LSCs co-expressed Oct4, Sox2, 
c-Kit, TRA 1-60, TRA 1-81, ABCG2, Thy-1 and CD105. f-LSCs were negative 
for CD34, CD45, HLA-DR and for the limbal epithelial marker ΔNp63. Stain-
ing of CFSE-labelled SSEA4+ f-LSCs showed that cells are characterized by 
asymmetrical division. f-LSCs treated with pancreatic differentiation protocol 
transitioned through a series of intermediates similar to those occurring dur-
ing pancreatic development, as showed by sequential detection of endoder-
mal, pancreatic, islet and β-cell markers (Sox17, FOXA2, Ngn3, PDX1, MafA, 
ISL-1, β2NeuroD, NKX6.1, Pax4, GLUT2 and glucokinase). From stage 3 cells 
progressively gathered in clusters resembling human islets. qRT-PCR, immun-
ofluorescence and western blot analysis at the end of differentiation confirmed 
expression of islet hormones (c-peptide/proinsulin, insulin, glucagon, soma-
tostatin, ghrelin and PP). Quantification of endocrine cells by flow cytometry 
showed 72.1 ± 5.3% positive cells for C-peptide/proinsulin, 10.6 ± 2.4% for 
glucagon and 8.2 ± 2.6% for somatostatin. Confocal and electron microscopy 
indicated presence of secretory granules. Differentiated cells also possessed 
the ability to secrete C-peptide in response to glucose, KCl and Tolbutamide.
Conclusion: f-LSCs might represent a novel source of autologous, trans-
plantable, insulin-producing cells which could be tested for the reversal of 
diabetes.
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Metabolic control in patients with type 1 diabetes after autologous 
peripheral stem cell transplantation (apbsct)
A. Milczarczyk1, E. Snarski2, W. Jędrzejczak2, E. Franek1;
1CSK MSWiA, 2Medical University of Warsaw, Poland.
Background and aims: Type 1 diabetes mellitus is caused by autoimmunological 
process destroying pancreatic ß cells. APBSCT leads to modulation of immuno-
logical system (in terms of elimination of aggression against ß cells), what subse-
quently leads to alleviation of autoagressive process and to insulin independency.
Materials and methods: In 8 patients (4 female, 4 male, age 26.0±5.0) with new-
ly diagnosed type 1 diabetes APBSCT was performed. Treatment consisted of 2-
3 plasmaphereses, hematopoietic stem cell mobilization with cyclophosphamide 
(2g/m², on day -16) and G-CSF (10ug/kg from day -15), collection of at least 3 
x 106/ kg CD34+ cells, conditioning with cyclophosphamide (50 mg/kg/day on 
days -5,-4,-3,-2 prior to transplant) and antithymocyte globulin (0,5mg/kg/day 
on day -5, 1,0 mg/kg/day on days -4,-3,-2,-1) followed by stem cells infusion.
In all patients FPG, HbA1c, C-peptide fasting and after mixed meal, continuous 
glucose monitoring (CGM) and intravenous glucose tolerance test (IVGTT) 6 
months after transplantation were performed. Control group comprised 6 patients 
(2 female, 4 male, age 26.2±3.1) in whom after diagnosis an intensive insulin thera-
py was initiated. In the control group CGM and IVGTT were not performed.
Results: Parameters of metabolic control were shown in table 1. All patients 
6 months after APBSCT were insulin-free. HbA1c and FPG were comparable 
to the control group, but higher C-peptide values were noted. Insulin concen-
trations in IVGTT were as follows: 8.1; 9.2; 9.0; 8.7; 9.2; 9.1; 9.0; 8.9; 8.6; 7.6; 
7.3 uIU/l (basal 5.4uIU/l).
Conclusion: APBSCT seems to be a promising method of treatment of newly 
diagnosed type 1 diabetes.
Table 1
Insulin 
dosage 
(IU/kg)
FPG 
(mg/dl)
Fasting CP 
(ng/ml)
CP after 
mixed meal 
(ng/nl)
HbA1c 
(%)
Patients after 
APBSCT n= 8
0 111.8±23.9 1.25±0.57 2.62±1.04 6.01±0.63
Control group 
n= 6
0.4±0,13 112±30.2 0.77±0.2 1.87±0.7 6.1±0.9
p <0.001 NS NS (0.06) NS (0.18) NS
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Ctnnb1 gene expression is associated with impaired beta cell function of 
type 2 diabetic donors
V. D’Aleo1, S. Del Guerra1, G. Gualtierotti1, F. Vistoli2, U. Boggi2,  
F. Filipponi3, P. Marchetti1, S. Del Prato1, R. Lupi4;
1Endocrinology and Metabolism, Metabolic Unit, University of Pisa, 
2Department of Oncology, Transplantation and Advanced Technologies 
in Medicine, University of Pisa, 3Department of Liver Transplantation, 
Hepatology and Infectious Diseases, Azienda Ospedaliero-Universitaria 
Pisana, 4Endocrinology and Kidney, Metabolic Unit, Azienda Ospedaliero-
Universitaria Pisana, Pisa, Italy.
Background and aims: Common TCF7L2 genetic variants are associated 
with increased risk for development of type 2 diabetes (T2DM). Beta-catenin/
TCF7L2-dependent Wnt signaling is involved in pancreas development, islet 
function, and insulin production and secretion. Nonetheless, no study has yet 
assessed Wnt signaling in human islets of T2DM patients. We have, therefore, 
examined the expression of Wnt pathway component beta-catenin (CTNNB1) 
in islets isolated from the pancreases of non-diabetic and T2DM individuals.
Materials and methods: Islets were prepared from the pancreas of 9 non-diabet-
ic (CTRL) (5M/4F; age 60.25±13.7 yrs; 25.68±3.68 kg/m2) and 6 T2DM (2M/4F; 
64.4±7.2 yrs; 27.20±2.65 kg/m2) multiorgan donors. Glucose-stimulated insulin 
release (static incubation), mRNA expression of beta-catenin, TCF7L2, and in-
sulin (Real-time RT-PCR) were determined. In order to establish a cause-effect 
relationship, CTNNB1 and TCF7L2 gene expression were suppressed by siRNA 
in Ctrl and TCF7L2 overexpressed the by plasmid DNA in Ctrl islets.
Results: Glucose-stimulated insulin release was impaired in T2DM islets as 
compared to Ctrl (Stimulation Index: 1.34±0.32 vs. 3.59±1.72; p<0.05). Both 
CTNNB1 (0.03±0.01 vs. 0.09±0.03, p<0.001), and TCF7L2 mRNA expression 
(0.42±0.41 vs. 7.35±3.40, p<0.001) were higher in T2DM than in Ctrl islets. 
The two gene expressions were positively correlated (R2=0.508; p=0.0028) 
while they were negatively correlated with Stimulation Index (CTNNB1: 
R2=0.267, p=0.052; TCF7L2: R2=0.338, p=0.0231). CTNNB1 and TCF7L2 
siRNA transfection of Ctrl islets transfected resulted in a significant reduc-
tion of respective gene expression (-72.1±6.9% and -32.8±6.1%, respectively), 
whereas the Stimulation Index increased (+43.7±14.1% and +37.2±17.3% for 
CTNNB1 and TCF7L2 silencing, respectively; both p<0.05 or less vs. Ctrl). 
Insulin gene expression was marked increased in siRNA CTNNB1 transfected 
islets (+36.46±13.3%), compared to the controls (p<0.001). Finally, TCF7L2 
overexpression in non-diabetic islets (+55.7±16.3%) was associated with a 
significant increase of CTNNB1 gene expression (+67.5±17.9%, p<0.001).
Conclusion: CTNNB1 and TCF7L2 gene expression are increased in islets 
from T2DM isolated islets, and the expression is negatively correlated with im-
paired glucose-mediated insulin response. Moreover, modulation of TCF7L2 
expression is associated with simultaneous changes in CTNNB1 expression 
and glucose-mediated insulin release. Our results support the hypothesis that 
1) alterations of Wnt signaling occur in pancreatic islets of T2DM patients, and 
2) TCF7L2 effects may be mediated via consensual changes in beta-catenin.
134
Risk genotypes, allele-specific expression and methylation status in 
human islets at the KCNQ1 type 2 diabetes-susceptibility locus
M.E. Travers1, M. Dekker Nitert2, D.J.G. Mackay3, C.M. Lindgren4, 
L. Groop2, A.L. Gloyn1, M.I. McCarthy1;
1OCDEM, University of Oxford, United Kingdom, 2Lund University 
Diabetes Centre, Malmo, Sweden, 3Southampton University School of 
Medicine, 4WTCHG, University of Oxford, United Kingdom.
Background and aims: Though the number of Type 2 Diabetes (T2D) as-
sociated loci has increased rapidly, in relatively few cases have the mutational 
mechanisms through which they operate been enumerated. The KCNQ1 lo-
cus harbours 2 independent clusters of variants associated with T2D risk and 
impaired insulin secretion, the SNPs with strongest association in European 
populations in each peak being rs231362 and rs163184. Whilst both signals 
are intronic, one maps directly over a non-coding RNA (KCNQ1OT1), whose 
transcription is regulated by parent-of-origin specific methylation, and which 
is known to regulate transcription of several local cell-cycle repressors, in-
cluding CDKN1C, itself implicated in islet-specific growth phenotypes. As-
sociated SNPs at both signals confer T2D risk only when maternally inher-
ited, implicating aberrant regulation of imprinted expression as the probable 
mutational mechanism. The aim of this study was to determine whether, in 
human islets, risk genotype status at KCNQ1 has effects on DNA methyla-
tion, total gene expression and allele-specific expression consistent with this 
proposed mutational mechanism.
Materials and methods: DNA and RNA were extracted from 42 human islet sam-
ples of European origin. Associated SNPs in both signals (e.g. rs231362, rs163184) 
were genotyped (TaqMan), and methylation quantified (Bisulfite pyrosequenc-
ing). Total expression of KCNQ1, KCNQ1OT1, KCNQ1DN, CDKN1C, PHLDA2, 
SLC22A18 and SLC22A18AS was determined by qRT-PCR. Allele-specific gene 
expression was assessed by qRT-PCR, differentiating alleles via coding variants, or 
(for CDKN1C) fragment size analysis using a 12bp exonic indel (del171APVA).
Results: All genotypes were in accordance with expected (HapMap CEPH) 
frequencies, and displayed no departure from Hardy-Weinberg equilibrium. 
We found no effective tagging SNP for del171APVA, its strongest LD rela-
tionship being with rs2237901 (r2=0.59). With the exception of KCNQ1DN, 
all tested genes were quantifiably expressed in human islets. The clearest 
evidence of monoallelic expression was found for CDKN1C: without excep-
tion, samples heterozygous for del171APVA at the DNA level appeared ho-
mozygous at the cDNA level. However, we found no relationship between 
risk genotype and gene expression for any of the tested genes (p>0.05 in all 
cases). Risk genotype was correlated with methylation status at 2 sites located 
on the borders of KCNQ1OT1’s differentially methylated promoter region. At 
both CTCF and putative ZAC binding sites, methylation level increased with 
risk allele number. The effect was small (increases of 5.5% and 7.5% on top of 
40% and 36% respectively) but significant (p=0.0004 for each).
Conclusion: We have performed the first assessment of the association be-
tween risk genotypes at the KCNQ1 locus and regional effects on DNA meth-
ylation and gene expression (total and allele-specific) in human islets. We 
have shown monoallelic expression of CDKN1C in human islets and evidence 
that risk genotypes effect DNA methylation, but further work is required to 
demonstrate that these have consequences for regional gene expression. Our 
study demonstrates the complexity of translating association signals into mu-
tational mechanisms.
Supported by: MRC, an EFSD Albert Renold Fellowship
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Rare variants of the glucagon gene (GCG) associate with serum insulin 
and plasma glucagon release, type 2 diabetes, and measures of obesity
S.S. Torekov1,2, L. Ma3, I. Hainerova4, J. Lebl4, D.R. Witte5, A. Linneberg6,  
T. Jørgensen6, A. Sandbaek7, T. Lauritzen7, O. Madsen2, J. Wang3,  
S. Madsbad8, J.J. Holst1, T. Hansen2, O. Pedersen2;
1Department of Biomedical Sciences, University of Copenhagen, 2Hagedorn 
Research Institute, Gentofte, Denmark, 3Beijing Genomics Institute at 
Shenzhen, China, 4Charles University, Prague, Czech Republic, 5Steno 
Diabetes Center, Gentofte, 6Glostrup University Hospital, 7University of 
Aarhus, 8Hvidovre University Hospital, Denmark.
Background and aims: The glucagon gene (GCG) encodes several hormones 
crucial for energy metabolism: glucagon, oxyntomodulin, glucagon-like-pep-
tide (GLP) -1 and -2. We hypothesized that variants in GCG associate with 
type 2 diabetes (T2D), obesity, and/or related metabolic traits.
Materials and methods: GCG was sequenced in 481 whites with adult or early-
onset obesity or non-autoimmune diabetes and in 384 randomly chosen Danes. 
Twenty-nine different variants were identified and variants, which had minor 
allele frequency (MAF) ≥2% (rs4664447 and rs7581952) or were likely to be 
functional (Ile158Val and Trp169Ter) were genotyped in a total of 17,167 Danes 
(8,662 subjects from the ADDITTION study, 6,164 subjects from the INTER99 
study along with 1,820 T2D patients and 521 glucose tolerant subjects.
Results: In a population-based study of treatment-naïve subjects we found 
that homozygous carriers of the rare A-allele of rs4664447, which is predicted 
to disrupt an essential splice enhancer binding site, had lower levels of fast-
ing plasma glucose (mean±SD: 4.8±1.2 vs 5.5±0.8mmol/l, P=0.004), fast-
ing insulin (22±14 vs 42±27 pmol/l, P=0.04) and glucose-stimulated serum 
insulin (159±83 vs 290±183 pmol/l, P=0.01), insulinogenic index (15±9 vs 
29±19, P=0.04), and adult-height (165±10 vs 172±9cm, P=0.0009) compared 
to G-allele carriers. Following a hyperglycemic arginine stimulation test ho-
mozygous carriers of this variant had 40-50% decreased basal and stimulated 
levels of serum insulin, as well as plasma glucagon and fully processed GLP-2 
compared to matched controls (P = <0.0001-0.0008). In studies of T2D pa-
tients and glucose tolerant individuals, the rare Val-allele of Ile158Val was as-
sociated with a higher prevalence of T2D, OR 1.83 (1.05-3.6), P=0.04. Finally, 
G-carriers compared with T-carriers of rs7581952, had lower BMI (26.4±5.8 
vs 27.5±5.0 kg/m2, P=0.009) and body weight (76±16 vs 82±17kg, P=0.004 ). 
Trp169Ter did not co-segregate with obesity or diabetes.
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Conclusion: In the present biological candidate gene study in whites we demon-
strate that GCG harbors rare variants, rs4664447, rs7581952 and Ile158Val with 
relatively higher impact on glucose metabolism, measures of obesity and T2D 
prevalence, respectively, than the impact of most common variants shown to 
influence metabolic traits identified through genome-wide association studies.
Supported by: The Danish Research Council
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Influence of novel genetic loci affecting glucose and insulin levels during 
OGTT on islet function in man
T.S. Ahluwalia1, C. Ladenvall1, A. Jonsson1, J. Kravic1, E. Laurila1,  
B. Isomaa2, T. Tuomi3, L. Groop1, V. Lyssenko1;
1Clinical Sciences: Diabetes and Endocrinology and Lund University 
Diabetes Centre, Malmö, Sweden, 2Folkhalsan Research Centre, 3Medicine, 
Helsinki University Central Hospital and Research Program of Molecular 
Medicine, Helsinki, Finland.
Background and aims: Type 2 diabetes (T2D) is characterized by chronically 
elevated glucose levels. Impaired insulin secretion and action are hallmarks 
of T2D. The Meta-Analyses of Glucose and Insulin-related traits Consortium 
(MAGIC) identified 16 loci associated with fasting and postprandial glucose 
levels involved in glucose-sensing, signaling, insulin processing and cell 
proliferation. Only few of them, ADCY5, DGKB, PROX1, GCK and GCKR 
seem to influence risk of T2D. We investigated whether these genetic variants 
would also influence change in insulin secretion and/or action over time or 
proinsulin, glucagon, GIP, and adiponectin concentrations.
Materials and methods: In the Botnia prospective study (BPS), 2,444 non-dia-
betic subjects followed for a period of 8 years with OGTT and insulin measure-
ments were genotyped for common variants in 16 loci (PROX1, GCK, GCKR, 
G6PC2, ADCY5, SLC2A2, DGKB, GLIS3, ADRA2A, CRY2, MADD, FADS1, 
IGF1, VPS13C, C2CD4B and GIPR). In the Botnia Prevalence Prevention and 
Prediction study (PPP) (N=5,200) in addition to glucose and insulin, fasting/
postprandial glucagon and GIP levels, and adiponectin were measured.
Results: We could replicate previously observed associations of variants 
in MTNR1B (DIPPP, beta=-0.237, P=6×10
-29), GIPR (CIRPPP, beta=-0.057, 
P=0.008), FADS1 (CIRPPP, beta=-0.060, P=0.002), GCK (DIPPP, beta=-0.092, 
P=0.003) influencing decreased insulin secretion and MTNR1B (ISIPPP, 
beta=-0.066, P=2×10-6) in decreased insulin sensitivity. In longitudinal BPS, 
we observed CRY2 variant (CIR, beta= 0.008, Pinteraction=0.01) associated with 
increased insulin secretion and PROX1 (ISI, beta=-0.005, Pinteraction=0.03) with 
decreased insulin sensitivity over time. The glucose raising allele of MADD 
variant was associated with increased fasting and 2hr (beta=0.166, P=2×10-
8, beta=0.138, P=3×10-11), and MTNR1B with elevated 2hr (beta=0.062, 
P=0.0005) proinsulin levels, whereas FADS1 with decreased (beta=-0.079, 
P=0.0006, beta=-0.051, P=0.002) fasting and 2 hr proinsulin levels. The 2hr 
glucagon levels were increased in GLIS3 (beta=0.024, P=0.04), while de-
creased in DUSP9 (beta=-0.049, P=0.01) variant carriers. Fasting GIP lev-
els were elevated in carriers of CRY2 (beta=0.078, P=0.03), and 2hr GIP in 
PROX1 (beta=0.041, P=0.03). On contrary, fasting GIP was decreased in GCK 
(beta=-0.158, P=0.006), and (fasting and 2hr) in GIPR (beta=-0.087, P=0.03 
and beta=-0.091, P=2×10-5) variant carriers. MTNR1B variant was associated 
with lower (beta=-0.073, P=0.0002) adiponectin concentrations.
Conclusion: These results demonstrate that genetic variants influencing 
glucose and/or insulin levels also show effects on other metabolic traits like, 
proinsulin (MADD, FADS1), glucagon (GLIS3, DUSP9), GIP (GIPR, CRY2, 
GCK), and adiponectin (MTNR1B). Low GIP levels in carriers of a loss-of-
function variant in the GIPR gene in islets suggest the importance of non-
receptor mediated mechanisms in determining GIP levels.
Supported by: Swedish Research Council Linne grant
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Extending criteria for genetic testing increases diagnosis of maturity-
onset diabetes of the young 
G. Thanabalasingham1, A. Pal1, A.J. Farmer2, S. Ellard3, M.I. McCarthy1, 
K.R. Owen1;
1OCDEM, University of Oxford, 2Public Health, University of Oxford, 
3Molecular Genetics, Peninsula College of Medicine & Dentistry, Exeter, 
United Kingdom.
Background and aims: Increasing diagnosis rate of monogenic diabetes is 
essential to enable patients to benefit from optimal treatment and early di-
agnosis of family members. Current testing for Maturity Onset Diabetes of 
the Young (MODY) is largely restricted to individuals whose clinical features 
match the original descriptions of MODY families. This selection method 
has good specificity (94%) but low sensitivity (58%) in our dataset. Extended 
MODY testing criteria were defined to select subjects with atypical features 
of clinically diagnosed type 1 (T1DM) or type 2 (T2DM) diabetes (recruited 
from primary and secondary care), who then underwent re-sequencing of the 
Hepatocyte nuclear factor 1-alpha (HNF1A) and 4-alpha (HNF4A) genes.
Materials and methods: In those with apparent T1DM (n=247), HNF1A/4A 
re-sequencing was performed in individuals with residual β-cell function 
≥3y from diagnosis defined as random or glucagon-stimulated c-peptide 
≥0.2nmol/l (n=20). In those with apparent T2DM (n=291), HNF1A/4A re-
sequencing was performed in those with diabetes diagnosed ≤30y (n=35) or 
diabetes diagnosed ≤45y with absence of metabolic syndrome (MS-, n= 53). 
Diagnosis rates were compared to those meeting standard diagnostic criteria 
for MODY; diabetes diagnosed ≤25y with parental diabetes (n=14).
Results: In the T1DM group, 2 HNF1A mutations were found. Both indi-
viduals had random c-peptide ≥0.2nmol/l and positive GAD antibody titres. 
In those with apparent T2DM, 10 HNF1A and 2 HNF4A mutations were 
identified. Mutations were found in 22% diagnosed ≤30y and 16% of MS-. 
Only 43% of the MODY cases found met current diagnostic testing guide-
lines. Family investigations have identified a further 11 mutation carriers in-
cluding 2 with previously undiagnosed diabetes. Overall 24% of subjects have 
changed treatment following molecular testing.
Conclusion: We found a prevalence of transcription factor-MODY of 0.8% 
in apparent T1DM and 4.1% in apparent T2DM. Widened genetic testing cri-
teria based on simple pathophysiological features more than doubled MODY 
diagnosis rates. Subjects with β-cell antibodies should not be excluded from 
testing.
Supported by: NIHR Oxford Biomedical Research Centre
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The influence of carbohydrate content of diet on glycaemia in GCK-
MODY patients
T. Klupa1, I. Solecka1, N. Nowak1, M. Szopa1, M. Borowiec2, W. Młynarski2, 
M.T. Malecki1;
1Department of Metabolic Diseases, Jagiellonian University, Krakow, 
2Department of Pediatrics, Medical University of Lodz, Poland.
Background and aims: Heterozygous inactivating mutations in GCK 
gene encoding glucokinase result in maturity-onset diabetes of the young 
(MODY). Nutritional intervention remains the treatment of choice for this 
form of diabetes. An optimal diet formula for GCK-MODY patients remains, 
however, to be established. This clinical experiment was designed to evaluate 
the effect of diet carbohydrate (CH) quantity on glycaemia level in GCK-
MODY patients.
Materials and methods: We exposed 8 GCK mutation carriers (6 with diabe-
tes and 2 with impaired fasting glucose-IFG) to diet rich in CH (60% of daily 
calorie intake) for two days, then patients were switched to low CH diet (25% 
of daily calorie intake) for another two days. The caloric content was equal 
throughout the whole 4-day period. All patients were supposed to avoid high 
glycemic index products. Glucose levels were evaluated with continuous glu-
cose monitoring (CGMS, MiniMed, USA).
Results: In 6 GCK-MODY patients glucose levels were significantly higher 
during exposure to diet rich in CH vs. low CH diet: the mean glycemia was 
8.5 mmol/l (range 8.2-8.9 mmol/l) vs. 7.26 mmol/l (range 7.0-8.1 mmol/l), 
the mean time spent above the target level of 140 mg/dL was 41.4% (range 
23%-55%) and 27.6% (range 13%-46%) (p<0.02 for both comparisons), re-
spectively. In addition, 4 out of 5 patients experienced episodes of postpran-
dial hyperglycemia above 200 mg/dL lasting for at least 15 min (on average 
1.7 episodes/patient/day) when on high CH diet with no such episodes when 
on low CH diet. Interestingly, the carbohydrate content of meals had no ma-
jor impact on glucose levels among GCK mutation carriers with IFG.
Conclusion: Postprandial hyperglycemia is observed on high CH diet in 
GCK-MODY patients. Diet with modestly limited carbohydrate intake may 
be effective in optimizing metabolic control in GCK-MODY. Carbohydrate 
restriction seems to have no major impact on glycemias in GCK mutation 
carriers not meeting formal criteria of diagnosis of diabetes.
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Is the distinction between immunologic type 1A and idiopathic type 1B-
diabetes clinically relevant? A real-life study with 5 years of follow-up in 
3302 paediatric patients with diabetes onset prior to age 12
R.W. Holl1, S. Hofer2, A. Thon3, J. Rosenbauer4, T. Kapellen5, A. Icks4,  
K. Warncke6, B.O. Böhm7, E. Schober8, German-Austrian-DPV Initiative 
and German BMBF-Competence Network Diabetes;
1Epidemiology, University of Ulm, Germany, 2Pediatrics, University 
of Innsbruck, Austria, 3Pediatrics, Medical University Hannover, 
4Epidemiology, University of Düsseldorf, 5Pediatrics, University of Leipzig, 
6Pediatrics, Technical University of Munich, 7Internal Medicine, University 
of Ulm, Germany, 8Pediatrics, University of Vienna, Austria.
Background and aims: The current diabetes classification distinguishes pa-
tients with immunologic type-1A and idipathic type-1B. However, few stud-
ies so far addressed the relevance of B-cell-autoimmunity at onset for the 
subsequent course of diabetes under real-life conditions.
Materials and methods: The DPV register was started in 1995 on a nation-
wide basis: In order to monitor and improve the quality of care, relevant data 
are documented prospectively at 327 specialized diabetes centers in Germa-
ny / Austria. By March 2010, 200722 patients are included in the database 
(63578 patients type-1). 16921 patients had a pediatric onset of type-1 diabe-
tes prior to age 12, in 4254 of them at least two B-cell-antibodies (ICA, IA2, 
GAD or IAA at diagnosis) were measured. In 3302 patients, a continuous 
follow-up from diagnosis for 5 years was available (age at onset: 7.1±3.1 years, 
50.4% male). Data were analyzed using non-parametrical comparisons for 
unadjusted and a hierarchical mixed linear model for adjusted comparisons. 
Mean daily insulin doses per kg and DCCT-equivalent HbA1c were adjusted 
for age at onset, gender, BMI and insulin regimen using observed marginal 
frequencies.
Results: No B-cell-antibody was present in 263 patients, 1 antibody only 
in 790 (AB1+) and 2 or more positive ABs were present in 2249 patients 
(AB2+). These groups did not differ by gender, age at onset, initial BMI, rate 
of DKA or HbA1c at onset, while the reported duration of symptoms was 
slightly longer in AB- (2.84 weeks) compared to AB1+ (2.39) or AB2+ (2.17 
weeks, p < 0.005). Concomitant thyroid autoimmunity was present in 24.1 % 
of AB2+-patients compared to 17.6 % in AB1+ and 16.7 % in AB- patients 
(p<0.001, X²-test). Based on adjusted means, daily insulin requirement was 
slightly, but significantly higher in double-antibody-positive compared to an-
tibody-negative patients during the first 3 years of diabetes, but not thereafter 
(1st year: AB-: 0.52 U/kg versus AB2+ 0.55 U/kg, p<0.05). After 5 years of 
diabetes, insulin requirement was 0.83 U/kg in AB-, 0.85 U/kg in AB1+ and 
0.85 U/kg in AB2+ patients (n.s.). Throughout the 5-year period, adjusted 
HbA1c-values did not differ between the 3 groups: 5th year of diabetes: AB-: 
7.6 %, AB1+: 7.5 %, AB2+: 7.5 % (n.s.).
Conclusion: In this large cohort of prospectively followed children with 
type-1 diabetes, the presence of B-cell-autoimmunity at onset had only a 
small, clinically irrelevant and transient effect on daily insulin requirement, 
and no effect on metabolic control achieved. Based on antibody assays cur-
rently available in routine care, the presence of B-cell-AB at diagnosis is not 
predictive for disease severity after 5 years.
Supported by: German Federal Ministry for Education and Research
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Early introduction of roots in infancy associated with advanced beta cell 
autoimmunity in young children with HLA-conferred susceptibility to 
type 1 diabetes
S.M. Virtanen1,2, H.-M. Takkinen2, J. Nevalainen2,3, C. Kronberg-Kippilä1, 
M. Salmenhaara1,2, L. Uusitalo1,2, M.G. Kenward4, M. Erkkola5, R. Veijola6, 
O. Simell7, J. Ilonen8,9, M. Knip10,11;
1Department of Lifestyle and Participation, National Institute for Health and 
Welfare, Helsinki, 2Tampere School of Public Health, University of Tampere, 
3Department of Statistics, University of Turku, Finland, 4Department 
of Epidemiology and Population Health, London School of Hygiene & 
Tropical Medicine, United Kingdom, 5Department of Nutrition, University 
of Helsinki, 6Department of Paediatrics, University of Oulu, 7Department 
of Paediatrics, University of Turku, 8Department of Virology, University 
of Turku, 9Department of Virology, University of Eastern Finland, Kuopio, 
10Department of Paediatrics, Tampere University Hospital, 11Hospital for 
Children and Adolescents, University of Helsinki, Finland.
Background and aims: Early introduction of supplementary foods has been 
implicated to play a role in the development of β-cell autoimmunity. We set 
out to study the effects of breastfeeding and age at introduction of supple-
mentary foods on the development of β-cell autoimmunity.
Materials and methods: A prospective birth cohort of 6,069 infants with 
HLA-DQB1-conferred susceptibility to type 1 diabetes was recruited be-
tween 1996-2004. Antibodies against islet cells (ICA), insulin, glutamate 
dehydroxylase and islet antigen 2 were measured at 3 to 12- month inter-
vals. The families recorded at home the age at introduction of new foods and 
completed for each visit a structured dietary questionnaire. The endpoint was 
repeated positivity for ICA plus at least one other antibody and/or clinical 
type 1 diabetes (n=265).
Results: Early introduction of roots (by the age of 4 months) was related to 
increased risk of developing positivity for the endpoint [hazard ratio (95% 
CI) for earliest third 1.75 (1.11-2.75) and for middle third 1.79 (1.22-2.62) 
compared to last third (>4 months), likelihood ratio test p= 0.006], independ-
ently of introduction of other foods and of several putative sociodemographic 
and perinatal confounding factors. Introducing wheat, rye, oats and/or barley 
cereals (p=0.013) and egg (p=0.031) early was related to an increased risk of 
the endpoint but only during the first 3 years of life.
Conclusion: Early introduction of roots during infancy is independently as-
sociated with increased risk of β-cell autoimmunity among Finnish children 
with increased genetic susceptibility to type 1 diabetes.
Supported by: an EFSD/JDRF/Novo Nordisk grant, Academy of Finland, Medi-
cal Research Funds of Turku, Oulu and Tampere
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Effects of physical activity on insulin pump therapy in children and 
adolescents with type 1 diabetes: A randomised controlled trial
A.E. Gazzarri, M. Macedoni, S. Mazzantini, E. Giani, D. Spiri, A. De Palma, 
F. Redaelli, C. Mameli, L. Santoro, G. Zuccotti, A. Scaramuzza;
Paediatrics, University of Milano - Luigi Sacco Hospital, Italy.
Background and aims: Few papers have been evaluated the effects of physi-
cal activity on insulin pump therapy in children with type 1 diabetes. We 
evaluated the most effective strategy with insulin pump therapy in children 
with type 1 diabetes undergoing 2 hours of aerobic-anaerobic exercise.
Materials and methods: We enrolled 15 children and adolescents, aged 10-
18 yrs (mean±SD 13.1±2.7 yrs), with type 1 diabetes for 7.2±3.3 yrs, (BMI of 
20.05±3.05 m/kg2, insulin requirement 0.85±0.15 U/kg/day, HbA1c 7.66 ± 
0.81 %), who were using an insulin pump. Exercise (2 h of anaerobic-alactac-
id, anaerobic-lactacid and aerobic training prepared and supervised by a 
qualified trainer) has been maintained at the same level during each session 
(reliability has been evaluated by means of an arm band), and replicated by 
each patient for four consecutive days, with a different insulin pump scheme 
randomly assigned. The four schemes were as follow: the first day the pump 
has been kept active during exercise; the second day the pump has been sus-
pended during exercise; the third day the pump has been suspended after 
a ‘correction’ bolus (the amount of the insulin bolus was equal to the basal 
insulin the patient would have injected during the 2h-exercise, reduced by 
30%); the fourth day was as the third day, plus a temporary basal scheme 20% 
reduced applied 2 h prior and 4 h after exercise.
Results: Keeping the pump active, glycemic profiles were excellent during 
exercise, but we observed a significant lowering of blood sugar readings 3 h 
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after exercise (4/15 patients had had mild hypoglycemia), with a subsequent 
glycemic increase during the night. The suspension of the pump has shown 
good glycemic profiles, even if with a significant increase 90 minutes after ex-
ercise. The ‘correction’ bolus determined a significant lowering of glycaemia 
after 90 minutes from the beginning of exercise. The use of temporary basal 
scheme showed the highest glycemic variability (table).
Conclusion: We conclude that keeping pump active during exercise seems 
the best option to properly manage exercise in children with type 1 diabetes, 
with the recommendation to reduce basal rate by 20% for the 2-4 h after ex-
ercise, in order to avoid late-onset hypoglycaemia. However, for those sports 
that do not allow the use insulin pump, suspending the pump might be a good 
option, if followed by a +20-30% temporary basal for 2-4 h after exercise.
Glycaemic values during and after exercise according to different insulin pump patterns
During During During During After After After Night Night
T 0 min T 60 min T 90 min T 120 min T 60 min T 120 min T 180 min Midnight 3 o’clock
Insulin pump 
active
117±51 139±64 134±79 130±98 121±75 126±45 98±44 175±101 182±84
Insulin pump 
suspended
141±83 130±73 133±74 132±70 156±73 164±77 131±69 165±115 169±82
Insulin pump 
suspended + 
‘correction’ 
bolus
192±131 133±71 100±39 
0.005
108±43 
0.031
152±69 185±74 144±103 189±109 156±86
Insulin pump 
suspended 
+ correction 
bolus + tempo-
rary basal
188±124 103±62
0.043
134±62 251±101 236±117 157±100 155±108 184±149 200±113
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How common is common hypoglycaemia? Frequency of hypoglycaemia 
in insulin treated children <7years. A one year prospective study of self 
measured blood glucose
F. Sundberg, G. Forsander;
The Queen Silvia Childrens Hospital/ Sahlgrenska University Hospital, 
Gothenburg, Sweden.
Background and aims: Hypoglycemia is often regarded as the limiting fac-
tor when striving for good glycemic control. ISPAD has defined the HbA1c 
goal as <7, 5 % in children. Preschool children with insulin treated T1DM are 
prone to have fluctuating p-glucose and frequent hypoglycemias. The cogni-
tive consequences of hyper- and hypoglycemia during early childhood are 
under debate. Acute hypoglycemia causes discomfort and interrupts playing 
and other important activities of the child. Fear of hypoglycemia might affect 
the parents. The aim of this study was to describe the frequency of hypoglyc-
emia in children < 7 years of age with insulin treated T1DM and the number 
of nights with hypoglycemia during one year.
Materials and methods: Our hospital serves all patients with Diabetes Mel-
litus younger than 18 years living in the city of Gothenburg, Sweden and sur-
rounding area. All 36 patients who met the inclusion criteria (age<7 years, 
T1DM with duration > 3 months, patient at our diabetes unit) were invited 
to participate in a one year prospective multidimensional study (“DU7”). As 
a part of this study all SMBG was collected prospectively from autumn 2008 
until autumn 2009.The parents of 17 children gave informed consent to par-
ticipate and 14 of them managed to upload >300 days of p-glucose values 
from their child’s glucometer. Data was collected with the software Diasend. 
HbA1c was measured with DCA Vantage TM Analyzer, which was cali-
brated in accordance with Equalis standard, and the values were translated 
into DCCT standard. HbA1c was measured at the study start and at least 
four times during the year and the mean value of the year was used for every 
child. Night was defined as 22-06. Hypoglycemia was defined as p-glucose< 
4mmol/l. Severe hypoglycemia was defined as seizures or unconsciousness. 
14 children (8 boys) aged 4.8 (1.8-6.9) years with a diabetes duration of 2.4 
(0.6-4.7) years participated. 11 were on CSII and 3 on MDI when the study 
started, one shifted to CSII during the year.
Results: The average mean HbA1c was 7.8 (7.1-8.7) %. 7/14 (50%) had mean 
HbA1c <7.5 %. The mean p-glucose testing frequency was 2849 (1157-5209) 
per patient year with mean 7.8 (3.2-14.2) values per day. The mean frequency 
of hypoglycemia detected by SMBG was 241 (150-385) per patient year. The 
mean number of nights with detected hypoglycemia was 21 (4-42) per pa-
tient year. The mean number of night time SMBG was 452 (73-906) values 
per patient year. One child reported two and one child reported one severe 
hypoglycemia (21 events per 100 patient years).
Conclusion: The mean frequency of hypoglycemia was 0.66 events per day 
(or 4.6 events per week). The children were hypoglycemic 6 (1-12) % of the 
nights. We need to identify age-specific strategies to improve insulin treat-
ment for preschool children. Further data on how to balance nutrition, in-
sulin and physical activity in order to achieve good glycemic control and 
thereby preserve health and quality of life in the short and long perspective 
are needed.
Supported by: Barndiabetesfonden
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Suboptimal vitamin D status as a risk factor for CF-related diabetes in 
the Scandinavian Cystic Fibrosis Nutritional Study
T. Pincikova1, K. Nilsson1, I. Moen2, G. Fluge3, A. Hollsing4, P. Knudsen2,  
A. Lindblad5, L. Mared6, T. Pressler7, L. Hjelte1;
1Stockholm CF Center, B 59, Karolinska Institutet, Karolinska University 
Hospital Huddinge, Stockholm, Sweden, 2National Center for Cystic 
Fibrosis, Oslo University Hospital Ullevaal, 3Cystic Fibrosis Center, 
Department of Pediatrics, Haukeland University Hospital, Bergen, Norway, 
4Uppsala Cystic Fibrosis Center, KBH, Uppsala University Hospital, 5The 
West Swedish CF Center, Sahlgrenska University Hospital, Gothenburg, 
6Heart and Lung Center, Lund University Hospital, Sweden, 7Cystic Fibrosis 
Center, Department of Pediatrics, Copenhagen University Hospital, 
Denmark.
Background and aims: Cystic fibrosis (CF) is the most common life-short-
ening autosomal recessive disorder in Caucasians. The two main clinical 
characteristics of CF are progressive pulmonary disease and pancreatic in-
sufficiency. CF-related diabetes (CFRD) is a major complication of CF. With 
better medical care and longevity, prevalence of CFRD in adult CF popula-
tion is increasing and reaches up to 30%. CF patients worldwide are vitamin 
D insufficient. Recent literature suggests that vitamin D might possess certain 
antidiabetic properties. We aimed to assess the relationship between vitamin 
D and CFRD, glucose tolerance and HbA1C using cross-sectional data gath-
ered in the Scandinavian CF Nutritional Study.
Materials and methods: 898 CF patients were included (0.25 - 65 years) from 
7 centers in Denmark, Norway and Sweden. Serum 25-hydroxyvitamin D 
(25(OH)D) and HbA1C were measured, oral glucose tolerance test (OGTT) 
was carried out and vitamin D intake data were gathered using a seven-day 
dietary food record. Multiple linear regression analyses were performed for 
CFRD diagnosis, OGTT result and HbA1C as dependent variables, and se-
rum 25(OH)D, vitamin D insufficiency degree, daily food and supplemented 
vitamin D sources of intake as independent variables. The model was con-
trolled for country and centre, as well as for known CFRD risk factors: age, 
gender, genotype, liver dysfunction, long-term oral corticosteroid treatment, 
lung function and pancreatic insufficient vs. sufficient phenotype.
Results: In the group of all patients included in the study, CFRD diagnosis 
was positively associated with serum 25(OH)D < 30 nmol/L (N=718; ad-
justed R2=10,7%; beta=0,06; p=0,031) and vitamin D insufficiency degree 
(beta=0,025; p=0,033), and negatively associated with supplemented vitamin 
D per kg bodyweight (beta=-0,035; p=0,045). HbA1C value was positively as-
sociated with 25(OH)D < 30 nmol/L (N=698; adjusted R2=40,0%; beta=0,207; 
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p=0,009), 25(OH)D<50 nmol/L (beta= 0,147; p= 0,024) and vitamin D insuf-
ficiency degree (beta=0,081; p=0,016). In the subgroup of CF patients with-
out CFRD diagnosis, 25(OH)D<30 nmol/L was a significant determinant of 
the HbA1C value (beta= 0,15; p=0,035). In non-diabetic CF patients younger 
than 18 years, 25(OH)D<30 nmol/L determined the HbA1C value even more 
strongly (beta= 0,24; p=0,006). In non-diabetic CF patients, 18 years old or 
older, 25(OH)D<30 nmol/L did not determine the HbA1C value. Instead, 
total vitamin D intake per kg bodyweight was negatively associated with 
HbA1C in this patient group (beta=-0,95; p=0,045).
Conclusion: Increasing vitamin D intake may have some antidiabetic effect. 
The study supports the proposed role of vitamin D insufficiency in the patho-
physiology of diabetes mellitus and substantiates prospective studies.
Supported by: Heart Lung Foundation, Frimurare-Barnhuset, ALF, KI, Solvay 
Pharma,CF Assoc
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Exenatide lowers postprandial glycaemia and increases satiety without 
side effects in Prader-Willi syndrome
A. Viardot1, L. Sze2, L. Purtell3, G. Loughnan4, E. Smith5, H. Herzog6,  
K. Steinbeck4, L.V. Campbell3;
1Investigative Medicine, Imperial College, London, United Kingdom, 
2Clinics for Endocrinology, Diabetes and Clinical Nutrition, University 
Hospital Zurich, Switzerland, 3Diabetes & Obesity Research Program, 
Garvan Institute of Medical Research, Sydney, 4Prader-Willi Syndrome 
Clinic, Metabolism & Obesity Services, Department of Endocrinology, 
Royal Prince Alfred Hospital, Sydney, 5Department of Cytogenetics, The 
Children’s Hospital, Westmead Clinical School, Westmead, 6Neuroscience 
Research Program, Garvan Institute of Medical Research, Sydney, Australia.
Background and aims: Prader-Willi syndrome (PWS) is associated with hy-
perphagia and obesity, the major burdens in management of this complex 
disease. Pharmacological interventions have been disappointing so far, and 
behavioural constraints are still the only effective option today. Exenatide has 
demonstrated to have beneficial effects on appetite suppression and weight 
loss, in addition to its glucose lowering effects, but it also has significant side 
effects. To our knowledge, exenatide has not been tested as a suitable inter-
vention against hyperphagia and obesity in PWS. Therefore, we conducted a 
single dose pilot study to investigate the safety and effectiveness of exenatide 
on appetite regulation, glucose homeostasis and appetite hormones in PWS 
and obese control subjects.
Materials and methods: We recruited 8 subjects with PWS and 11 obese 
controls (OB) matched for age, sex and body fatness, assessed by DXA. Two 
standardised meal studies were performed, where subjects received either a 
single dose of 10 ug exenatide or normal saline injected sc 15 min before meal 
initiation in a single blinded cross-over design. Glucose, insulin, PYY, GLP-1 
and ghrelin were measured for 4 hours postprandially. Appetite and satiety 
were assessed by visual analogue scale (VAS). Resting energy expenditure 
(REE) was assessed by indirect calorimetry.
Results: PWS and OB were well matched for central and total body fat mass. 
Fasting glucose, insulin and degree of insulin resistance (HOMA-IR) were 
similar in both groups. Exenatide was well tolerated in PWS with no side 
effects recorded, in contrast to marked side effects observed in OB (bloating 
55%, nausea 45%, vomiting 18%). Exenatide significantly increased satiety 
120 min after meal initiation (PWS, VAS 1.9±0.4 to 5.3±1.1, p<0.05; OB, VAS 
3.5±0.7 to 5.4±0.8, p<0.05), but did not reduce appetite in both groups. Glu-
cose and insulin levels were lowered similarly in both groups. Furthermore, 
GLP-1 and PYY levels were suppressed to a similar degree. However, ghrelin 
levels were not affected by exenatide in both groups. Fasting REE was not 
different between groups when corrected for lean body mass. However, the 
postprandial increase in REE was only observed in obese but not in PWS 
subjects (121±31 vs. 0±49 kcal/24h, p=0.048).
Conclusion: This is the first report on the use of exenatide in PWS, dem-
onstrating that it is particularly well tolerated and also similarly effective in 
increasing satiety and lowering glucose as in simple obesity. Our observation 
of suppressed insulin and unchanged ghrelin levels challenges previous hy-
potheses on the cause of hyperghrelinemia in PWS, and it also suggests that 
delayed gastric emptying might be an important mode of action of exenatide. 
Longer and larger prospective studies should follow to investigate whether 
chronic administration of exenatide will lead to decreased food intake and 
weight loss in PWS.
Supported by: Supporters and families with children with Prader-Willi syn-
drome, SNSF
OP 25 Diabetes morbidity and 
mortality
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Significant excess mortality in middle-aged men with diabetes
C. Törn1, S. Ingemansson1, U. Lindblad2, S. Gudbjörnsdottir3, The DISS 
Study Group;
1Department of Clinical Sciences, Unit for diabetes and celiac disease, 
Malmö, 2Department of Public Health and Community Medicine, 
University of Gothenburg, 3The Nordic Research Academy for Global 
Health, The Nordic Research Academy for Global Health, Gothenburg, 
Sweden.
Background and aims: Several studies indicate that diabetes confers an in-
creased risk for early death. The aim of this study was to explore all cause 
mortality, site of death and certainty of day of death in a national cohort of 
patients with diabetes followed for 15 years from diagnosis and compare with 
healthy controls.
Materials and methods: Patients aged 15-34 years at diagnosis were regis-
tered in the national register Diabetes Incidence Study in Sweden (DISS) dur-
ing 1992 and 1993 (n=879). A healthy control matched for day of birth and 
sex was selected for each patient (n=837) at diagnosis of diabetes. Vital status 
of both patients (n=879) and controls (n=837) was ascertained through 2nd 
March 2009 by linking records to the Swedish Cause of Death Registry. The 
follow-up period represented a median of 15.9 years (range 1-17 years) and a 
total of 27173 person years.
Results: During 15 years of follow-up, 3.3% (29/879; 24 men and 5 women) 
of patients and 1.1% (9/837; 7 men and 2 women) of controls died. The risk 
for a patient with diabetes to die was almost three-fold increased HR=2.9; 
95% CI 1.4-6.2. This risk was confined to men HR=2.8; 95% CI 1.2-6.5. Dia-
betes was the dominating cause of death among patients, identified as the 
underlying cause of death in 34% (10/29), and as a contributory cause of 
death in an additional five cases. The second most common cause of death 
in patients was circulatory diseases in 17% (5/29). Most patients 55% (16/29) 
died at home, remaining patients in hospital 28% (8/29) or elsewhere 17% 
(5/29) compared to controls of whom 33% (3/9; p=0.45) died at home, 33% 
(3/9; p=1.0) in hospital and 33% (3/9; p=36) elsewhere. Only 55% (16/29) of 
patients had a specified day of death on death certificates compared to 100% 
(9/9; p=0.016) of controls.
Conclusion: Adult men with diabetes had an almost three-fold increased risk 
to die within the first 15 years after onset of diabetes compared with healthy 
men. Most middle aged patients with diabetes died at home and often with-
out a specified date of death recorded. The care of young and middle aged 
people with diabetes should consider the life situation.
Supported by: Crafoord Foundation, Lund, Sweden
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Association of tight glycaemic control with nine-year mortality in type 2 
diabetes patients
I. Strele1, S. Rozite2, G. Brigis1, V. Pirags3;
1Riga Stradins University, 2Centre of Health Economics, 3University of 
Latvia, Riga, Latvia.
Background and aims: Results of some clinical trials have recently suggested 
that intensive glycaemic control in type 2 diabetes patients, even if reducing 
the risk of cardiovascular events, does not show a benefit in terms of mor-
tality. The aim of this analysis was to assess the pattern of the relationship 
between glycaemic control and mortality in type 2 diabetes patients, based 
on observational data.
Materials and methods: The study population consisted of 3665 type 2 dia-
betes patients (1060 men and 2605 women) participating in the Latvian dia-
betes survey in 2000. All deaths (n=1429) that occurred within a subsequent 
nine-year period and causes of death were identified through the Latvian 
Diabetes Register and the Causes of Death Data Base of Latvia. The Cox pro-
portional hazard model was used to test associations between the baseline 
HbA1c, broken down in quintiles (Q1-Q5), and mortality after adjusting for 
sex, age, diabetes duration, and, subsequently, for frequency of blood glucose 
testing and education.
Results: Lower HbA1c was associated with a lower risk of death in patients 
without insulin therapy, e.g. the lowest HbA1c quintile (HbA1c<6.76%), com-
pared to the highest (HbA1c>10.14%), was associated with a 40% reduction 
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of both all-cause (HR 0.57 (95%CI 0.47-0.70)) and cardiovascular (HR 0.57 
(95%CI 0.44-0.74)) mortality, adjusted for sex, age and duration of diabe-
tes. However, among insulin treated patients the lowest risk of death was for 
the second HbA1c quintile (HR for death from any cause was 0.58 (95%CI 
0.42-0.81) and from cardiovascular disease - 0.59 (95%CI 0.38-0.90)), but 
not for the first quintile (corresponding HRs were 0.80 (95%CI 0.56-1.12) 
and 0.88 (95%CI 0.57-1.35)). Adding the frequency of blood glucose testing 
and education into the model, albeit both of them were inversely associated 
with mortality, did not affect the above mentioned relationship (Table). The 
observed associations did not change substantially after the deaths, which oc-
curred within the first three years, were excluded from analysis: e.g., among 
insulin treated patients HR for death from any cause was 0.95 (95%CI 0.63-
1.42) for the first quintile of HbA1c and 0.55 (95%CI 0.36-0.83) for the second, 
but HR for death from cardiovascular disease was 0.99 (95%CI 0.59-1.66) for 
the first and 0.53 (95%CI 0.30-0.91) for the second quintile of HbA1c, com-
pared to the highest quintile.
Conclusion: In insulin treated type 2 diabetes patients moderate (HbA1c be-
tween 6.76 and 7.73%), but not tight glycaemic control (HbA1c<6.76%), was 
associated with better long-term survival. However, tight glycaemic control 
predicted better survival in patients not treated with insulin.
Association between baseline HbA1c and mortality in 3665 type 2 diabetes pa-
tients, 2000 to 2009
HbA1c(%) All-cause mortality
(1429 cases)
Cardiovascular mortality
(881 case)
Insulin therapy: Insulin therapy:
Yes No Yes No
quintiles HR* (95%CI) HR* (95%CI) HR* (95%CI) HR* (95%CI)
Q1 0.84 (0.59-1.19) 0.58 (0.47-0.71) 0.90 (0.58-1.40) 0.57 (0.43-0.74)
Q2 0.64 (0.46-0.89) 0.64 (0.52-0.79) 0.64 (0.42-0.98) 0.59 (0.45-0.77)
Q3 0.73 (0.56-0.93) 0.61 (0.49-0.76) 0.74 (0.53-1.03) 0.66 (0.51-0.87)
Q4 0.72 (0.56-0.92) 0.80 (0.65-0.98) 0.85 (0.62-1.15) 0.78 (0.59-1.02)
Q5 1 (referent) 1 (referent) 1 (referent) 1 (referent)
* adjusted for age, sex, duration of diabetes, frequency of blood glucose test-
ing and education
Supported by: EU PHARE-LIEN
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Diabetes and insulin duration and cancer incidence: a register linkage 
study in Denmark
B. Carstensen1, D.R. Witte1, S. Friis2;
1Steno Diabetes Center, Gentofte, 2Department of Cancer Epidemiology, 
Danish Cancer Society, Copenhagen, Denmark.
Background and aims: Studies of cancer occurrence among diabetes patients 
in the past decades have shown elevated rates of cancer of the liver, kidney, 
female breast and corpus uteri in studies based on up to 8800 cancer cases 
or 30,000 deaths. Our aim was to extend these studies to assess the effect of 
diabetes duration and duration of insulin treatment on cancer incidence in 
the entire Danish population.
Material and methods: We linked the Danish National Diabetes Register and 
the Danish Cancer Register and followed diabetes patients for the occurrence 
of cancer and compared with the cancer occurrence in the non-diabetic part 
of the population. For those diagnosed with diabetes after 1995 we have re-
liable data on DM duration and the time since first insulin use. For these 
patients we modelled the effect of DM duration and duration of insulin use 
on the cancer occurrence rates. We used Poisson models for data in 1-year 
intervals by age and date of follow-up, date of birth, and in 6-month intervals 
by duration of disease and insulin treatment.
Results: We had 1.9 mio. years of follow-up, and observed a total of 30,000 
cancer cases among the diabetes patients. We found a rate-ratio (RR) of 1.15 for 
all cancers combined. RRs over 1 were seen for cancers of the digestive tract, 
with a tendency of decreasing RR from oesophagus to rectum. The RR for liver 
cancer was elevated (M: 3.7, F:1.8) as well as for pancreas cancers (M and F: 
3.0). Other cancer types with a substantially elevated RR were corpus uteri, 
kidney and lymphomas. Significant but small RRs were seen for lung cancer 
and female breast cancer. Testis cancer had a RR of 0.8, non-significant. For all 
cancer types combined, we found the effect of insulin use was highest just after 
start of treatment, starting at an RR of 2 and decreasing to a stable level of 1.5 
after 3 to 4 years after first insulin prescription (based on analyses restricted to 
DM diagnoses after 1995; 1.1 mio. PY, 18,000 cancers). This pattern was also 
seen for duration of diabetes, with the risk being highest in the period just after 
diagnosis at RR 1.5 decreasing to 1 (no excess risk) after 3 years.
Conclusion: Besides the well known elevated cancer risk among diabetes pa-
tients, we found that patients on insulin carry an extra risk of cancer, in the 
order of magnitude of 50% relative to the general population. The effect of 
diabetes duration and insulin is highest immediately after disease/treatment 
onset, indicating that it may not be duration or insulin per se that carries 
the risk, but partly causes common to cancer and diabetes/insulin treatment, 
such as obesity. This study is the largest of diabetes and cancer incidence so 
far, and the only one to model the duration effects of both diabetes and insu-
lin treatment. We have however no detailed phenotypic information on the 
entire Danish population allowing us to control for obesity and other known 
risk factors for diabetes.
The thick line shows the RR for patients not on insulin, and the thin lines the 
RR for patients starting insulin 0, 2 and 5 years after disease onset.
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Diabetes and pancreatitis: A population based study to determine the 
prevalence and incidence of pancreatitis in people with and without 
diabetes
H. Mani1,2, B. Thakrar3, M.J. Davies1,2, K. Khunti4;
1Diabetes and Endocrinology, University Hospitals of Leicester, 
2Cardiovascular Sciences, University of Leicester, United Kingdom, 3Roche 
AG, Bern, Switzerland, 4Health Sciences, University of Leicester, United 
Kingdom.
Background and aims: Acute Pancreatitis is one of the most common gastro-
enterological diseases. Incidence of acute pancreatitis has been increasing in 
the past 40 years. The most common causes of acute pancreatitis are gallstones 
and alcohol followed by idiopathic aetiology. There has been recent interest in 
concomitant increase of acute pancreatitis, type 2 diabetes (T2DM), and obesity 
with their associative risk factors for pancreatitis. The increasing use of incretin 
based therapies and their possible association with pancreatitis has also added 
to the debate. With limited published epidemiological data on pancreatitis in 
people with diabetes, we used the UK General Practice Research Database to 
investigate if there is an association between diabetes and pancreatitis.
Materials and methods: We identified all patients, ≥ 18 years, who were alive 
on 1st January 2004 and had at least one year previous history in the database. 
From these patients a cohort with a diagnosis of T2DM prior to index date 
was identified. The remaining patients formed the comparator cohort. From 
both cohorts those with a diagnosis of pancreatitis prior to index date were 
excluded. The two cohorts were followed forward from index date until the 
patients’ last date to determine the incidence rate of pancreatitis. Relative risk 
of acute pancreatitis, comparing the two cohorts, was estimated after adjust-
ing for gender and age using Poisson regression.
Results: Of 2.34 million patients aged 18 and over in the database, 75322 
(3.2%) had a history of T2DM. Overall 574 people with diabetes (0.76%) had 
a previous history of pancreatitis (vs. 0.17% in those without diabetes). After 
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adjusting for age and gender, odds ratio for history of pancreatitis in people 
with diabetes compared to those without was 3.05 (95%CI: 2.79-3.35). In the 
incident cohort, we included 74748 people with diabetes and 2,263,766 con-
trols with a mean age of 66 and 48 respectively. The mean follow up was 3.1 
years for people with T2DM and 3.2 years for control group. There were 134 
incident cases of acute pancreatitis in the people with diabetes and 1975 in 
the controls. The crude incident rate was 57.5 and 27.4 per 100,000 person 
years respectively, equal to a ratio of 2.09. After adjusting for age and gen-
der, the relative risk of acute pancreatitis associated with diabetes was 1.47 
(95%CI: 1.23-1.76). The relative incidence rate of pancreatitis in different age 
and sex groups are shown in table.
Conclusion: There is both an increased prevalence and incidence of pancrea-
titis in people with diabetes compared to those without diabetes. Incidence 
of pancreatitis in UK general population has increased compared to previous 
report of 10/100000 per year. The increasing incidence of T2DM might be a 
contributory factor in increasing incidence of pancreatitis.
Table. Relative risk of acute pancreatitis associated with gender, age, and diabetes
Gender Age in 
Years
People with T2 Diabetes 
(N=74810)
People without Diabetes 
(N=2,825,782)
Relative Incidence 
rate Diabetes/No 
DiabetesN cases Person  
years
incidence  
rate
N cases Person  
years
incidence 
rate
Females 18-39
40-49
50-59
60-69
70-79
80-
All ages
1075
2603
5203
8625
10095
6522
34123
4
2
4
18
15
16
59
3431
8668
17062
27900
31597
17774
106431
116.6
23.1
23.4
64.5
47.5
90.0
55.4
601850
213151
192829
144650
112157
89191
1153828
243
134
172
177
162
153
1041
1238321
701512
638809
477894
362284
248257
3667076
19.6
19.1
26.9
37.0
44.7
61.6
28.4
5.94
1.20
0.86
1.74
1.06
1.46
1.95
Males 18-39
40-49
50-59
60-69
70-79
80-
All ages
1077
3565
8190
11935
11172
4686
40625
1
8
20
17
24
5
75
3332
11578
26681
38336
34422
12394
126744
30.1
69.1
75.0
44.3
69.7
40.3
59.1
420244
220086
194050
138404
90418
46736
1109938
189
186
166
154
144
95
934
1311322
717250
638239
450689
284501
126602
3528603
14.4
25.9
26.0
34.2
50.6
75.0
26.5
2.09
2.66
2.88
1.29
1.37
0.53
2.23
Females  
and Males
All ages 74748 134 233175 57.5 2263766 1975 7195680 27.4 2.09
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Risk prediction of cardiovascular disease in type 2 diabetes - a new risk 
equation from the Swedish NDR
B. Zethelius1, S. Gudbjörnsdottir2, B. Eliasson2, K. Eeg-Olofsson2,  
A.-M. Svensson3, J. Cederholm1;
1Uppsala University, 2Gothenburgh University, 3Center of Registers Västra 
Götaland, Gothenburgh, Sweden.
Background and aims: Risk prediction models obtained in samples from the 
general population do not perform well in type 2 diabetes (T2DM) patients, 
and 5-year risk estimates are proposed more accurate than 10-year risk esti-
mates. We assessed the association of risk factors with cardiovascular disease 
(CVD), in order to elaborate a risk model for the absolute 5-year risk of CVD 
in patients with T2DM from the Swedish National Diabetes Register (NDR).
Materials and methods: Investigational sample consisted of 20,571 female 
and male patients aged 18-70 years, 14% with a history of CVD before baseline 
in 2002-03, with 1,776 fatal/nonfatal CVD events when followed for 5 years 
from 2003 to 2007. A separate sample of 2,898 female and male patients aged 
18-70 years, was used for application of the risk model, 14% with previous 
CVD, with 223 CVD events when followed for 4 years from 2004 to 2007.
Results: Adjusted hazard ratios at Cox regression for fatal/nonfatal CVD for 
a 1 standard deviation increase in continuous variables were: 1.55 for T2DM 
onset age; 1.53 for T2DM duration; 1.19 for Total-/HDL-Cholesterol ratio; 
1.13 for HbA1c; 1.12 for systolic BP; 1.07 for BMI; and dichotomous vari-
ables, 1.51 for male gender; 1.44 for smoking; 1.29 for microalbuminuria; 
1.49 for macroalbuminuria (>200 µg/min); 1.67 for atrial fibrillation and 1.73 
for previous CVD. All 12 variables were used to elaborate the risk equation 
for 5-year CVD risk. Calibration was excellent when assessed by comparing 
predicted 5-year risk, mean 10.34+7.1%, and observed 5-year failure rate at 
survival analysis, 9.94 (95% CI 9.48-10.43) %, with a ratio of 1.04. Figure 1 
shows the association between predicted and observed survival rate for CVD. 
Discrimination was sufficient, with a receiver operator curve (ROC) statistic 
of 0.70 at logistic regression, and with sensitivity for predicted risk >5%; 95% 
and specificity for risk <10%; 63%. Application of the 4-year CVD risk esti-
mated with use of the presented risk model in another 2,898 separate T2DM 
patients followed for 4 years still showed a good calibration when comparing 
predicted 4-year risk, mean 8.80+6.2%, and observed 4-year failure rate at 
survival analysis, 7.81 (95% CI 6.89-8.86) %, with a ratio of 1.13. Discrimi-
nation was sufficient, with a ROC-statistic of 0.73, and with sensitivity for 
predicted risk >5%; 96% and specificity for risk <10%; 72%.
Conclusion: This risk model for the 5-year CVD risk based on 12 predic-
tors, elaborated in a large observational study from the normal population 
of T2DM, showed adequate calibration and discrimination, and should be 
useful for clinical practice. However, the risk model also needs to be tested in 
samples including patients with T2DM from other countries or regions.
Supported by: The Swedish Association of Local Authorities and Regions funds 
the NDR
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A new risk model for cardiovascular disease in type 1 diabetes
K. Eeg-Olofsson1, B. Zethelius2, A.-M. Svensson3, S. Gudbjörnsdottir1, B. 
Eliasson1, J. Cederholm2;
1Institute of Medicine, Göteborg, Sweden, 2Department of Public Health and 
Caring Sciences, Uppsala, Sweden, 3Center of Registers in Region Västra 
Götaland, Göteborg, Sweden.
Background and aims: Risk prediction models are lacking in patients with 
type 1 diabetes. We assessed the association of risk factors with cardiovascu-
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lar disease (CVD), in order to elaborate a risk model for the absolute 5-year 
risk of CVD in patients with type 1 diabetes from the Swedish national dia-
betes register (NDR).
Materials and methods: 4601 female and male patients aged 20-70 years, 
5.4% with a history of CVD before baseline in 2002, with 206 fatal/non-fatal 
CVD events when followed for 5 years from 2003 to 2007. Another sample of 
5501 patients aged 20-70 years used for application of the risk model, 5.5% 
with previous CVD, with 219 CVD events when followed for 4 years from 
2004 to 2007.
Results: Adjusted hazard ratios at Cox regression for fatal/nonfatal CVD 
with 1 standard deviation increase in continuous variables were 3.42 for dia-
betes duration, 1.62 for onset age, 1.26 for HbA1c, 1.23 for the ratio total-
cholesterol : HDL-cholesterol, 1.14 for BMI, and 1.08 for systolic BP, and with 
the dichotomous variables smoking 1.94, macroalbuminuria (>200 µg/min) 
1.49, a history of CVD 2.53, adjusted also for sex. All nine variables were 
used to elaborate the risk equation for 5-year CVD risk. Calibration was ex-
cellent when assessed by comparing predicted 5-year risk, mean 4.4±7.4%, 
and observed 5-year failure rate at survival analysis, 4.5 (95% CI 3.9-5.1) %, 
with a ratio of 0.98. Discrimination was sufficient, with a receiver operator 
curve statistic of 0.87 at logistic regression, and with sensitivity and specificity 
for the highest quartile of predicted risk (≥5%), 80% and 78% respectively. 
The presented risk model was applied in a separate sample of 5501 patients 
followed for 4 years and still showed good calibration when comparing pre-
dicted 4-year risk, mean 3.6±6.2%, and observed 4-year failure rate at sur-
vival analysis, 4.0 (95% CI 3.5-4.6) %, with a ratio of 0.90. Discrimination 
was sufficient, with a receiver operator curve statistic of 0.83, and with sen-
sitivity and specificity for the highest tertile of predicted risk 83% and 69%. 
Figure 1 shows the association between predicted and observed survival rate 
for CVD.
Conclusion: This risk model for the 5-year CVD risk based on nine predic-
tors, elaborated in a large observational study from the normal adult popula-
tion of type 1 diabetes, showed adequate calibration and discrimination, and 
should be useful for clinical practice. However, the risk model also needs to 
be tested in patients with type 1 diabetes from other countries.
OP 26 Hypertension and retinopathy
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Risk of hypertension in people with IGT: effect of postprandial glucose 
control
M. Hanefeld1, C. Köhler1, T. Westermeier2, G. Saunders3, J.-L. Chiasson4;
1Center for Clinical Studies, GWT-TUD GmbH, Dresden, 2Center for 
Clinical Studies, Bayer Vital GmbH, Leverkusen, Germany, 3Enterprises 
Inc., Drayton Valley, 4Center for Clinical Studies, Universite de Montral, 
Montreal, Canada.
Background and aims: Already prediabetes is associated with a high preva-
lence of hypertension. There exists now evidence from prospective clinical 
trials that people with impaired glucose tolerance (IGT) represent a high risk 
group for development of hypertension. So far, little is known on risk factors 
and impact of glucose control in the prediabetic stage on development of hy-
pertension. This report analyses (1) risk factors for hypertension (2) effect of 
glucose control by acarbose on incidence of newly diagnosed hypertension in 
the data pool of the randomized placebo-controlled STOP-NIDDM trial.
Materials and methods: In this multinational trial 14, 742 subjects (age 40-
70 years, BMI 25-40 kg/m², > 95 % Caucasians) were screened with a 75 g 
oGTT, 1,429 eligible patients with IGT were randomised, 1,368 were valid for 
ITT analysis, mean follow-up time 3.3 years.
Results: At baseline 666 (48.7%) (341 placebo, 325 acarbose) patients were 
normotensive and 702 (51.3%) had a hypertension (BP>=140/90 mmHg 
and/or antihypertensive drugs), 96 (14.4%) developed hypertension, an-
nual progression rate of 4.4%. In the intervention group 10.5% developed 
hypertension vs. 18.2% in the placebo arm. Patients with subsequent devel-
opment of hypertension had significantly higher levels of blood pressure at 
baseline. In univariate analysis of time to development of hypertension large 
waist circumference, metabolic syndrome and treatment group were the only 
significant predictors. Multivariate analysis confirmed only treatment group 
as significant variable with a hazard ratio in favour of acarbose of 0.59 (C.I 
0.35-0.90).
Conclusion: In about any second subject IGT was associated with hyperten-
sion before glucose lowering treatment. At follow-up IGT was accompanied 
by a high incidence of hypertension (annual rate 4.4%). Control of postpran-
dial hyperglycemia by acarbose reduced significantly rate of newly diagnosed 
hypertension.
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Cardiorespiratory fitness and reduction in blood pressure and insulin 
resistance during lifestyle intervention
N. Stefan1, C. Totsikas1, J. Röhm1, K. Kantartzis1, C. Thamer1, K. Rittig1,  
J. Machann2, F. Schick2, J. Hansel1, A. Niess1, A. Fritsche1, H.-U. Häring1;
1Department of Internal Medicine, 2Section of Experimental Radiology, 
University of Tübingen, Germany.
Background and aims: Lifestyle intervention, in general, is effective for im-
proving arterial hypertension and other cardiovascular risk factors. However, 
there is a large variability in these responses. Because high cardiorespiratory 
fitness (CRF) protects from cardiovascular disease and mortality, we deter-
mined whether CRF at baseline predicts the improvement of blood pressure, 
insulin resistance and other cardiovascular risk factors during a lifestyle in-
tervention.
Materials and methods: A total of 219 subjects at risk for type 2 diabetes, 
who underwent a 9 months lifestyle intervention with diet modification and 
increase in physical activity, and had measurement of CRF, were studied. In-
sulin sensitivity was estimated during a 75g oral glucose tolerance test. Total 
body-, visceral- and liver fat were measured by magnetic resonance (MR) 
tomography and 1H-MR spectroscopy. CRF was estimated during incremen-
tal cycle exercise (maximal aerobic capacity-VO2max) and motorized treadmill 
(individual anaerobic threshold-IAT) tests.
Results: During the intervention adiposity, glycemia, CRF and insulin sen-
sitivity largely improved (all p<0.0003), however, blood pressure and serum 
lipids only moderately decreased (all p<0.06). High CRF at baseline predicted 
a larger decrease in systolic (p<0.0002) and diastolic (p<0.004) blood pres-
sure, and a larger increase in insulin sensitivity (p<0.04), but not change in 
serum lipids (all p>0.06).While weight loss was similar among quartiles of 
CRF (p>0.17), systolic (p<0.0009) and diastolic (p<0.01) blood pressure only 
decreased in the higher two quartiles. For 1 SD increase in CRF at baseline 
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the odds ratio for resolution of hypertension or prehypertension was 2.26 
(95% CI, 1.40-3.80) for IAT and 1.75 (95% CI, 1.08-2.89) for VO2max.
Conclusion: We provide novel data that measurement of CRF at baseline 
helps to predict the effectiveness of a lifestyle intervention in improving 
blood pressure and insulin sensitivity in humans.
Supported by: DFG (KFO 114) / DFG (Heisenberg Stipend to NS)
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Static and dynamic retinal vessel analysis in normo- and hypertensive 
type 1 diabetic patients 
A. Mandecka1, W. Vilser2, J. Dawczynski3, M. Schwefer4, M. Blum5, N. 
Müller1, C. Kloos1, G. Wolf1, U.A. Müller1;
1Internal Medicine III, Friedrich Schiller University, Jena, 2IMEDOS Systems 
UG, Jena, 3Department of Ophthalmology, Friedrich Schiller University, 
Jena, 4Department of Cardiology, Helios Clinic, Erfurt, 5Department of 
Ophthalmology, Helios Clinic, Erfurt, Germany.
Background and aims: There is evidence that retinal vessel dilation results in 
disturbed autoregulation of retinal microcirculation in diabetic retinopathy 
(DR). On the other hand, stimulation of the retina with flicker light increases 
retinal vessel diameters in humans. The reduction of flicker light-induced va-
sodilation is considered endothelial dysfunction. We investigated the static 
calibre of retinal vessels and retinal vasodilation after stimulation with flick-
ering light in type 1 diabetic patients with and without hypertension.
Materials and methods: Participants consisted of 76 control participants, 58 
normotensive type 1 diabetic patients and 57 hypertensive type 1 diabetic 
patients. DR was classified according to the Early Treatment Diabetic Retin-
opathy Study criteria (no DR, mild- moderate and severe nonproliferative 
NPDR). The arteriolar retinal calibre (CRAE, µm) and flicker light-induced 
retinal vasodilatation (percentage increase over baseline diameter) was meas-
ured using Dynamic Vessel Analyzer.
Results: In normotensive diabetic patients, after adjustment for age, sex and 
glycated hemoglobin, patients without retinopathy (209.7 µm) and with mild 
NPDR (217.6 µm) had significantly wider arteriolar caliber compared to 
controls (183.2 µm). Patients with severe NPDR (190.9 µm) had significantly 
reduced CRAE in comparison to patients without DR or with mild NPDR. 
After adjustment for age, sex, glycated hemoglobin and CRAE the flicker-
induced arteriolar dilation decreased with increasing stages of retinopathy 
(p-trend <0.014). In diabetic patients with hypertension, after adjustment for 
age, sex and glycated hemoglobin, patients without retinopathy (202.4 µm) 
and with mild NPDR (198.6 µm) had significantly wider arteriolar caliber 
compared to controls. Patients with severe NPDR (181.0 µm) had significant-
ly reduced CRAE in comparison to patients without DR. After adjustment 
for age, sex, glycated hemoglobin and CRAE the flicker-induced arteriolar 
dilation decreased with increasing stages of retinopathy (p-trend <0.001). 
Normotensive patients with mild NPDR had, after adjustment for age, sex, 
glycated hemoglobin and diabetes duration, wider arteriolar caliber in com-
parison to hypertensive diabetic patients (p<0.007). Normotensive diabetic 
patients without retinopathy had wider arteriolar caliber compared to hyper-
tensive patients (p<0.058).
Conclusion: In normotensive type 1 diabetic patients the initial stages of 
retinopathy are associated with wider arteriolar caliber in comparison to hy-
pertensive patients. The arteriolar vasodilation results in disturbed autoregu-
lation of retinal vessels. The distinct arteriolar vasodilation in normotensive 
type 1 diabetic patients may contribute to increased vulnerability of retinal 
microcirculation. Additionally, the flicker-induced arterial vasodilatation 
decreased significantly with increasing stages of retinopathy independent of 
CRAE. The decreased flicker-induced dilation of retinal vessels of diabetic 
patients implies the reduced capacity to autoregulate the blood flow in dia-
betic retinopathy.
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The role of the vascular endothelial growth factor A in the progression of 
diabetic retinopathy
A.G. Kuzmin, D.V. Lipatov, T.A. Tchystyakov, O.M. Smirnova,  
M.I. Arbuzova, A.V. Ilyin, M.V. Shestakova;
Endocrinology Research Centre, Moscow, Russian Federation.
Background and aims: The diabetic retinopathy (DR) remains the main 
cause leading to the blindness among young people. There are many patho-
logical mechanisms of DR progression. Vascular endothelial growth factor A 
(VEGF-A) is known to be a factor of the neovascularisation of the retina and 
development of the neovascular glaucoma (NG). The aim of this study was to 
investigate the level of VEGF-A in the aqueous humor (AH) in diabetic pa-
tients undergone to the cataract and glaucoma surgery, to estimate the grade 
of DR after the cataract operation and to analyze any correlations between the 
level of VEGF and DR stage.
Materials and methods: The study included 164 diabetic eyes (110 patients, 
among them 93 had type 2 diabetes mellitus (DM) and 17 - type 1 DM) and 
24 nondiabetic eyes (20 patients) as a control group (CG). Glaucoma group 
consisted of 15 diabetic patients. All patients were operated due to the cata-
ract or glaucoma; the phacoemulsification of the cataract, extracapsular cata-
ract extraction or Ahmed glaucoma valve implantation were carried out. For 
assessment of VEGF-A the samples of AH were obtained during operation, 
were prepared by prompt centrifugation (15,000 g*min) and stored at -80°C. 
The VEGF-A value was analyzed by ELISA. The patient’s examination in-
cluded standard ophthalmological end endocrinological tests before and after 
operation. The grade of DR was measured using recommendation of WHO 
(1999). The grading of DR in diabetic patients was performed in 2 week after 
operation. The follow up period was from 1 till 24 month. Results of data were 
expressed as Mediana (95% CI). Relationship between the parameters was 
analyzed using nonparametric criteria.
Results: The VEGF-A value in patients without diabetes (CG) was 78,85 pg/
ml (95% CI, 55,72-120,51). Among diabetic patients the DR grade estimated 
after cataract operation was the following: 10% eyes didn’t have sings of DR, 
33% had nonproliferative DR, 39% had preproliferative DR and 18% had 
proliferative DR. The VEGF-A value in diabetic patients without DR sings 
was 18,3 pg/ml (95% CI, 10,05-57,65), in patients with nonproliferative DR 
was 51,12 pg/ml (95% CI, 41,6-88,21), in patients with preproliferative DR 
was 74,5 pg/ml (95% CI, 66,61-113,03), in patients with proliferative DR was 
337,56 pg/ml (95% CI, 234,58-422,79), (p<0,05) (fig.1). The patients with the 
NG had the VEGF-A value of 1634,01 pg/ml (95% CI, 610,69-2657,33), that 
was 20 times more than in CG.
Conclusion: Our data confirm the possible role of VEGF-A in the progres-
sion of neovascularisation of the retina and development of the NG.
Figure 1: CG - control group; no DR - diabetic patients without DR; NP DR 
- patients with nonproliferative DR; PP DR - patients with preproliferative 
DR; PDR - patients with proliferative DR.
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Immunologic markers at the clinical onset of type 1 diabetes mellitus 
and the risk of retinopathy 15 years later
R.A. Jensen1, E. Agardh2, Å. Lernmark3,4, N.L. Smith5,6, D.S. Siscovick7, C. 
Törn4;
1General Internal Medicine, University of Washington, Seattle, USA, 
2Department of Clinical Sciences, Ophthalmology, University Hospital 
MAS, Malmö, Sweden, 3Department of Medicine, University of Washington, 
Seattle, USA, 4Department of Clinical Sciences, Clinical Research Center, 
Lund University, Malmö, Sweden, 5Department of Epidemiology, University 
of Washington, Seattle, 6Seattle Epidemiologic Research and Information 
Center, Department of Veterans Affairs, Seattle, 7Departments of Medicine 
and Epidemiology, University of Washington, Seattle, USA.
Background and aims: Previous studies have examined the associations of 
human leukocyte antigen (HLA) genes, islet autoantibodies and residual C-
peptide with diabetic retinopathy (DR). In this study we examine the asso-
ciation of these factors, measured at the time of the clinical onset of type 1 
diabetes mellitus (T1DM), with DR 15 years later using models to assess the 
independent effects each of these factors.
Materials and methods: The cohort was first identified in 1992 and 1993 by 
the Diabetes Incidence Study in Sweden (DISS) which attempts to enroll all 
incident cases of diabetes for patients between 15 and 34 years of age. Blood 
samples at diagnosis were analyzed for HLA genotype, islet autoantibodies 
and serum C-peptide. In 2008, copies of the most recent fundus photographs 
were obtained from existing patient records. Poisson regression was used to 
model the relative risk (RR) and 95% confidence interval (95% CI) of DR.
Results: Subjects with HLA DQ6 had a 70% reduced risk of any retinopathy 
15 years after the clinical onset of diabetes compared to subjects without any 
DQ6, DQ8 or DQ2 haplotypes, RR = 0.29, (95% CI: 0.10 - 0.89). In addition, 
each unit increase in autoantibodies against the 65kD isoform of glutamate 
decarboxylase (GAD65, GADA) increased the risk of moderate or more se-
vere DR by 45%, compared to subjects with mild or no DR, RR = 1.45 (95% 
CI: 1.01 - 2.07). C-peptide was not associated with DR.
Conclusion: We have shown that two immunologic factors capable of being 
determined at the clinical onset of T1DM may be useful to determine the risk 
of DR 15 years later. Not only does HLA DQ6 provide protection from devel-
oping T1DM it may also protect subjects from developing DR. In addition, 
increased levels of GADA at the time of diabetes onset were associated with 
the presence of moderate or more severe levels of DR.
Supported by: NHLBI, NIH, KAWF, JF, FVI, LUSCC
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Pericyte-endothelial cell interactions in co-culture models mimicking the 
physiological and diabetic retinal microenvironment, protective role of 
thiamine and benfotiamine
S. Tarallo, E. Beltramo, E. Berrone, M. Porta;
Dept Internal Medicine, University of Turin, Italy.
Background and aims: Pericytes regulate vascular tone and perfusion pres-
sure in capillaries, and endothelial cell (EC) proliferation. Their selective loss 
in the early phases of diabetic retinopathy may cause angiogenesis, due to the 
failure of their control on endothelium proliferation. We standardized two 
human retinal pericyte (HRP)/EC co-culture models, to mimick the physi-
ological and diabetic retinal microenvironment. Our aim in this work was to 
evaluate the interactions between co-cultured HRP/EC in terms of prolifera-
tion and apoptosis and the possible protective role of thiamine (T) and its li-
pophilic analogue benfotiamine (BT) against high glucose-induced damage.
Materials and methods: EC and HRP were co-cultured for 8 days in physi-
ological glucose (NG, 5.6 mmol/l), stable high glucose (HG, 28 mmol/l) and 
intermittent HG (HGint, 48h HG/48h NG twice), with or without 50 µmol/l 
T or BT. No-contact model: EC were plated on the inner surface of a mem-
brane suspended into the medium and HRP on the bottom of the same well, 
without physical cell-to-cell contact. Cell-to-cell contact model: EC and HRP 
were plated on the opposite sides of the same membrane, HRP being able 
to directly contact the abluminal surface of the EC through the pores of the 
membrane. In control experiments HRP and EC were plated on the relevant 
surfaces alone. Proliferation (cell counts and DNA synthesis, ELISA) and ap-
optosis (DNA fragmentation, ELISA) were measured.
Results: In the no-contact model, HG reduced proliferation of co-cultured 
EC (counts: -23.6%, DNA:-18.7%, p<0.005 vs NG), co-cultured HRP (counts: 
-24.6%, DNA: -12.9%, p=0.001 vs NG) and EC alone (counts: -22.5%, DNA: -
20.3%, p<0.05) and increased apoptosis in co-cultured EC (+21.5%, p<0.05 vs 
NG) and HRP (+45%, p<0.05). In the contact model, both HG and HGint re-
duced co-cultured EC and HRP number (EC: -24.2 and -18.8%, respectively, 
p<0.05; HRP: -29.6 and -38.7%, p=0.005) and DNA synthesis (EC:-28.2 and 
-26.0%, respectively, p<0.05; HRP: -25.7 and -26.2%, p<0.05), while increas-
ing co-cultured HRP apoptosis (HRP: +75.7 and +150%, p<0.005). Stable HG 
had no effects on HRP in separate cultures. Both EC and HRP proliferated 
more in co-culture than when cultured alone (p<0.05). T and BT countered 
HG and HGint induced-damage in all cases.
Conclusion: Retinal pericytes may be sensitive to soluble factors, whose na-
ture remains to be clarified, released by the endothelium, cultured in high 
glucose conditions. Thiamine and benfotiamine are able to counteract this 
damage, confirming once again their possible role in the prevention/treat-
ment of diabetic microvascular complications.
Supported by: Compagnia di SanPaolo, Regione Piemonte (Torino, Italy)
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Incretins directly suppress the development of macrophage-driven 
atherosclerosis in apolipoprotein E-null mice
T. Hirano1, M. Nagashima1, T. Watanabe2, K. Nohtomi1, M. Terasaki1,  
A. Miyazaki2;
1Diabetes, Metabolism, and Endocrinology, 2Biochemistry, Showa 
University School of Medicine, Tokyo, Japan.
Background and aims: Several lines of evidence suggest that the incretin-
based therapies suppress the development of cardiovascular disease in type 2 
diabetes. We investigated the possibility that glucagon-like peptide (GLP)-1 
and glucose-dependent insulinotropic polypeptide (GIP) can prevent the de-
velopment of atheroscrelosis in apolipoprotein E-null (ApoE-/-) mice.
Materials and methods: GLP-1 (1.5 pmol/kg/min) or GIP (17 pmol/kg/min) 
was continuously infused for 4 weeks into 17-week-old ApoE-/-mice fed on 
atherogenic diet. Alternatively, DPP-4 inhibitor (PKF275-055, Vildagliptin 
analogue, Novartis) was administrated as drinking water for 4 weeks. Aortic 
atherosclerosis, oxidized LDL-induced cholesterol ester accumulation (foam 
cell formation), and its related gene expression in exudate peritoneal macro-
phages were determined.
Results: Administration of GLP-1, GIP, or DPP-4 inhibitor did not affect 
food intake, body weight, blood pressure, and plasma levels of lipids, glucose 
and insulin. Remarkable atherosclerotic lesions in the aorta were observed in 
21-week-old ApoE-/- mice. Administration of GLP-1, GIP, or DPP-4 inhibi-
tor significantly reduced the surface areas of atherosclerotic lesions and sup-
pressed atheromatous plaque size and macrophage accumulation in the aor-
tic root as compared with vehicle controls. The suppressive effects of incretins 
and DPP-4 inhibitor on atherosclerosis were associated with significant de-
creases in foam cell formation and down-regulation of acyl-CoA:cholesterol 
acyltransferase 1 (ACAT1) and CD36 in exudate peritoneal macrophages. 
Incubation with active GLP-1 or GIP but not inactive forms for 48 h resulted 
in significant suppression of foam cell formation in peritoneal macrophages 
obtained from non-treated ApoE-/- mice. The suppression of foam cell forma-
tion by incretins was totally cancelled by the pretreatment with the receptor 
antagonists, exendin9-39 or (Pro3)GIP. Both GLP-1 and GIP receptors were 
detected in the peritoneal macrophages of ApoE-/- mice.
Conclusion: Our study provided the first evidence that both GLP-1 and GIP 
directly and vildagliptin analogue seen at physiological levels of incretins by 
DPP-4 inhibition suppress the development of macrophage-driven athero-
sclerotic lesions associated with down-regulation of essential molecules of 
foam cell formation such as ACAT-1 and CD36.
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Liraglutide inhibits endothelial cell dysfunction and expression of 
vascular adhesion molecules in an ApoE mouse model of atherogenesis
A.E. Dear1, H. Liu1, T. Gaspari2, I. Welungoda2, R.E. Widdop2, L.B. 
Knudsen3, R.W. Simpson4;
1Medicine, Monash University, Melbourne, 2Pharmacology, Monash 
University, Melbourne, Australia, 3Research and Development, Novo 
Nordisk A/S, Bagsvaerd, Denmark, 4Endocrinology, Box Hill Hospital, 
Melbourne, Australia.
Background and aims: Glucagon-like peptide-1 (GLP-1) is a hormone known 
to potentiate insulin and lower glucagon secretion. Recently, the once daily 
GLP-1 analogue, liraglutide, has been approved as a new treatment for type 2 
diabetes. Most importantly liraglutide improves glycaemic control and lowers 
body weight. We have previously shown that liraglutide attenuates TNFα and 
mild hyperglycemia (10mmol/l)-mediated induction of plasminogen activa-
tor inhibitor-1 (PAI-1) and vascular cell adhesion molecule expression in hu-
man vascular endothelial cells (hVEC’s). Endothelial cell dysfunction (ECD), 
an early abnormality in atherosclerosis and pre-diabetes, is associated with 
increased expression of vascular adhesion molecules. The aim of the current 
study was to determine whether liraglutide was vaso-protective in the non-
diabetic ApoE-/- mouse model of ECD and atherosclerosis and establish the 
dependence of this effect on the GLP-1 receptor (GLP-1R).
Materials and methods: In vitro studies: ICAM-1 and VCAM-1 protein lev-
els were determined in conditioned medium from C11-STH hVEC’s treated 
with TNFα (10ng/ml) alone or TNFα + liraglutide (100nM) or TNFα + li-
raglutide +exendin (9-39)(100nM) for 16hrs using ELISA kits. Semi-quan-
titative RT-PCR was used to determine mRNA expression of ICAM-1 and 
VCAM-1. In vivo studies: ApoE-/ - mice were fed a high fat diet for 16 weeks. 
Chronic liraglutide treatment was administered in the final 4 weeks via sub-
cutaneous twice daily injection (total of 300μg/kg/day). Treatments included: 
saline (vehicle; s.c. injection twice daily), liraglutide (s.c. injection of 150μg/
kg, twice daily), liraglutide + exendin (9-39) a GLP-1R antagonist (150pmol/
kg/min via osmotic mini-pump). Post-treatment the abdominal aorta was di-
vided into four aortic rings per mouse (~3mm long). Concentration response 
curves to the endothelium-dependent vasodilator acetylcholine (ACh) were 
constructed in preconstricted aortic rings.
Results: In vitro TNFα induced ICAM-1 and VCAM-1 mRNA and protein 
expression in C11-STH hVEC’s at 16 hrs. This effect was significantly in-
hibited by the addition of liraglutide. The inhibitory effect of liraglutide on 
TNFα induction of ICAM-1 and VCAM-1 was attenuated by concomitant 
addition of exendin (9-39). Following these experiments ex vivo organ bath 
studies using isolated aortic rings taken from ApoE-/- mice on a high fat diet 
treated with liraglutide for 4 weeks demonstrated a significant improvement 
in endothelial function with liraglutide compared with vehicle treated mice 
(max relaxation: liraglutide Rmax = 78.45±2.5% vs 55.36±6.89%; P<0.01; 2-way 
ANOVA). The improvement in endothelial function was completely abol-
ished in mice co-treated with exendin (9-39) (Rmax= 53.95±6.54%).
Conclusion: These observations suggest liraglutide significantly inhibits 
TNFα induction of ICAM-1 and VCAM-1 protein and mRNA expression 
in vitro in a GLP-1R dependent manner. In vivo liraglutide treatment signifi-
cantly inhibited ECD also in a GLP-1R dependent manner. Based on these 
observations liraglutide may have the potential to attenuate atherogenesis.
Supported by: Novo Nordisk
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Liraglutide regulates key hypothalamic appetite-related signals in diet-
induced obese rats
N. Vrang1, J. Jelsing1, K. Raun2, L. Bjerre Knudsen2;
1Gubra, Frederiksberg C, 2Novo Nordisk, Maløv, Denmark.
Background and aims: Glucagon-Like Peptide-1 (GLP-1) analogues are 
emerging as an important drug class for the treatment of diabetes and pos-
sibly also obesity. While the physiological basis of the anti-diabetic properties 
of GLP-1 analogues is well understood, less is known about the mechanisms 
underlying the weight loss effect.
Materials and methods: In the current study we examined the effects of 28 
days of daily administration with the GLP-1 analogue liraglutide (0.2 mg/kg) 
on food intake, body-weight and energy expenditure in male diet-induced 
obese (DIO) rats compared to vehicle and food-restricted rats (weight-
matched to the liraglutide group). Liraglutide reduced food intake (vehicle 
530±12 g, liraglutide 439±6.7 g; p<0.0001 vehicle vs liraglutide) and body-
weight (vehicle 685±6.0 g, liraglutide 626±5.6 g, p<0.001 vehicle vs liraglu-
tide).
Results: Interestingly, weight-matched animals consumed less food than the 
liraglutide group (weight-matched 321±0 g; p<0.0001 liraglutide vs weight-
matched). In line with these observations, 12-hour energy expenditure 
measurements at day 14 revealed a near significant increase in oxygen con-
sumption in liraglutide-treated rats (ml/h/kg; vehicle 2051±112, liraglutide 
2535±242, weight-matched 2037±200; p=0.12 vehicle vs liraglutide, p=0.089 
liraglutide vs weight-matched). Semi-quantitative in situ hybridisations 
(ISH) on hypothalamic brain sections from liraglutide-treated rats revealed 
a marked and significant increase in mean cocaine and amphetamine-regu-
lated-transcript (CART) mRNA levels in the arcuate (vehicle 100±15%; li-
raglutide 161±15%; weight-matched 109±11%; p<0.001 vehicle vs liraglu-
tide) and paraventricular nuclei (vehicle 100±11%, liraglutide 190±30%, 
weight-matched 116±15%; p<0.01 vehicle vs liraglutide). Arcuate POMC 
mRNA levels were unchanged (vehicle 100±8.9%, liraglutide 91±0.11%, 
weight-matched 97±10%), whereas mean NPY (vehicle 100±10%; liraglutide 
104±14%, weight-matched 141±10%; p=0.039 vehicle vs weight-matched) 
and AgRP (vehicle 100±10%, liraglutide 92±14%, weight-matched 174±17%; 
p<0.001 vehicle vs weight-matched) mRNA levels were significantly elevated 
in food-restricted rats only.
Conclusion: Our data demonstrate that the GLP-1 analogue liraglutide po-
tently lowers food intake and body-weight possibly by: (1) an increase in ar-
cuate CART mRNA; and (2) by blocking weight-loss-induced increases in 
arcuate NPY and AgRP mRNA levels.
Supported by: Novo Nordisk
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Role of lysophosphatidylcholine in GIP secretion by primary K-cells
E. Diakogiannaki, F.M. Gribble, F. Reimann;
Clinical Biochemistry, University of Cambridge, United Kingdom.
Background and aims: Glucose-dependent insulinotropic polypeptide (GIP) 
is a hormone secreted by enteroendocrine K-cells found in highest density in 
duodenal and jejunal epithelium. Apart from being a critical regulator of in-
sulin secretion, GIP modulates pancreatic beta-cell proliferation and surviv-
al, and controls dietary fat metabolism. GIP has also been postulated to link 
over nutrition to the development of obesity as pharmacological and genetic 
interference with GIP signaling proved protective in several rodent obesity 
models. Although it is known to be secreted in response to the presence of 
nutrients in the gut lumen, and particularly ingested lipids, the molecular 
mechanisms involved in the nutrient sensing by K-cells and subsequent se-
cretion of GIP are still unclear. Therefore, understanding these pathways is 
necessary for the elucidation of the role of the hormone in the development 
of obesity and type 2 diabetes. The aim of this study was to investigate the 
effects of lipid micelles on GIP secretion by K-cells.
Materials and methods: GIP secretion was assayed in primary duodenal cul-
tures and STC-1 cells. Ratiometric [Ca2+]i imaging experiments and FRET 
based [cAMP]i and were performed on STC-1 cells.
Results: Experiments were performed on primary cultures of murine duo-
denal epithelium and the enteroendocrine model cell line STC-1. To simu-
late the conditions epithelial cells experience after a lipid rich meal, “post-
prandial micelles”, comprised of oleic acid (200µM), 2-monooleoyl glycerol 
(70µM), L-α-lysophosphatidylcholine (LPC) (70µM), cholesterol (17µM) and 
taurocholic acid (TC) (700µM), were applied. Both primary and STC-1 cells 
responded to lipid micelles by secreting enhanced amounts of GIP (9.2 fold 
and 3.1 fold stimulation, respectively compared to baseline, p<0.001 for both). 
The stimulation of GIP secretion by lipid micelles was not attributable to cell 
lysis, as monitored by lactate dehydrogenase activity released into the super-
natant. Fluorescence calcium imaging measurements in STC-1 cells, follow-
ing loading with Fura-2AM, demonstrated elevations in intracellular calcium 
in response to lipid micelles (R340/380 increased 1.8 fold compared to baseline 
p<0.001 n=104). To investigate the relative importance of the different micel-
lar lipids for the secretory response a series of experiments was performed 
omitting individual components. Exclusion of LPC significantly reduced se-
cretory responses in both primary and STC-1 cells (46% in primary cells n=7 
p<0.05; 22% in STC-1 n=12, compared to stimulation by micelles containing 
LPC). Replacement of LPC with phosphatidylcholine (PC) could not compen-
sate (1.14-fold stimulation by micelles containing PC in primary cells; n=4). 
LPC (in the presence of 700µM TC) promoted the release of GIP in a dose de-
pendent manner over the range of concentrations between 1-100µM. Both in 
the presence and absence of TC, 70 μM LPC stimulated reversible rises in the 
cytosolic Ca2+ and cAMP concentration monitored in STC-1 cells preloaded 
with Fura2 or transfected with a Epac2-based FRET-sensor respectively.
Conclusion: Lipid micelles stimulate GIP secretion from primary murine 
cultures and STC-1 cells. One of the components, LPC, enhanced intracel-
lular concentrations of calcium and augmented levels of intracellular cAMP 
suggesting the involvement of Gs protein- mediated signaling.
Supported by: Wellcome Trust
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Exendin-4 inhibits apoptosis of human pancreatic islet endothelial cells 
in high glucose condition: effects on the AKT/cAMP/PKA signalling 
pathways
I. Miceli, E. Favaro, F. Settanni, A. Baragli, R. Granata, G. Camussi,  
E. Ghigo, P. Cavallo Perin, M.M. Zanone;
Internal medicine, University of Turin, Italy.
Introduction: Increased understanding of the glucoregulatory action of incre-
tin hormones has yielded greater insight into the pathophysiology of diabetes 
and has led to the development of new treatments for type 2 diabetes. Specifi-
cally, it has been demonstrated that the endogenous human incretin hormone 
glucagon-like peptide-1 (GLP-1), the major product from intestinal proglu-
cagon processing, decreases blood glucose by several pathways and that the 
normal physiologic response to GLP-1 is impaired in type 2 diabetes. Not only 
does it stimulate beta cell proliferation, but also enhances the differentiation 
of new beta cells from progenitor cells in the pancreatic duct epithelium and 
inhibits beta cell apoptosis. The GLP-1 receptor agonists, exendin-4, exhibits 
actions similar to those of GLP-1, promoting beta-cell growth, survival, insu-
lin secretion and enhancing proinsulin biosyntheses. However, it is established 
that glucose toxicity is not solely restricted to beta cells, but affects also sur-
vival, proliferation and function of pancreatic islet endothelial cells, possibly 
contributing to beta cell function impairment and beta cell loss. We analyzed 
the effects of exendin-4 and the pathways involved on cultured human pancre-
atic islet microendothelial cells (MECs) in hyperglycemic conditions,.
Materials and methods: MECs were cultured in 28 mmol/L glucose concen-
tration up to seven days and, in parallel, stimulated with exendin-4 (10 nM). 
Apoptosis was evaluated by a photometric enzyme immunoassay measuring 
mono- and oligonucleosomes in the cytoplasmic fraction of cell lysates as an 
index of DNA fragmentation, with Hoechst staining of apoptotic cells, and 
with assay of Caspase 3 activity. Western-blot analysis for P-Akt/Akt, P-Erk/
Erk. Bcl-2, Bax were also performed. To evaluate the role of the PI3K/Akt, 
adenylyl cyclase and PKA pathways, treatments with the inhibitors wortman-
nin and LY294002, MDL12330A and KT5720 were also performed.
Results: In high glucose condition, proliferation of MECs progressively de-
creased and apoptosis increased, accompanied by a reduced activation of the 
survival signaling pathway PI3K/Akt. Incubation with exendin-4 (10 nM) in-
hibited apoptosis, increasing Akt and Erk phosphorylation and Bcl-2 expres-
sion and decreaseing Bax expression. The antiapoptotic effect of the peptides 
was blocked by inhibition of adenylyl cyclase (AC)/cAMP/protein Kinase A 
(PKA) and PI3k/Akt signaling pathways.
Conclusion: These results suggest that exendin-4, in addition to its effects 
on endocrine cells, also promote islet microendothelium survival. The sur-
vival effect involves the PI3K/Akt and (AC)/cAMP/protein Kinase A (PKA) 
signaling pathway. Exendin-4 could therefore represent a potential tool to 
improve islet vascularization and, indirectly, islet function.
Supported by: Ricerca Sanitaria Finalizzata Regione Piemonte, I
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Chronic treatment with taspoglutide, a once-weekly human GLP-1 analogue, 
prevents beta cell apoptosis, islet inflammation and fibrosis in ZDF rats
S. Uhles1, J. Funk2, M. Brecheisen1, A. Benardeau1, L. Tobalina3,  
C.B. Wollheim4, S. Sewing1, C. Migliorini1, E. Sebokova1;
1Metabolic and Vascular Diseases, F. Hoffmann-La Roche AG, Basel, 2Pharma 
Research Non-Clinical Safety, F. Hoffmann-La Roche AG, Basel, Switzerland, 
3Ipsen Pharma, San Feliu de Llobregat, Spain, 4Department of Cell Physiology 
and Metabolism, University Medical Center, Geneva, Switzerland.
Background and aims: Our previous data have demonstrated that taspoglu-
tide, a novel once-weekly human glucagon-like peptide (GLP)-1 analog, pre-
serves islet integrity and β-cell function in ZDF rats, a rodent model of insu-
lin resistance and Type 2 diabetes. To further explore the protective effect of 
taspoglutide on pancreatic islets, its effect on β-cell apoptosis, islet inflamma-
tion and fibrosis in vivo was investigated in ZDF rats after chronic treatment.
Materials and methods: Semi-quantitative immunohistochemistry analysis 
was performed to assess β-cell apoptosis, infiltration of inflammatory cells 
into the islet core and islet fibrosis on pancreatic sections of 9-week-old male 
ZDF rats 3 weeks after single application of taspoglutide (1 mg, s.c., formulat-
ed to mimic human exposure) or vehicle to 6-week-old ZDF rats (ZDF 6w).
Results: Disease progression in ZDF rats lead to a pronounced decrease in 
β-cell survival. In particular, the proportion of apoptotic β-cells increased 
significantly in vehicle-treated rats at the age of 9 weeks when compared to 
ZDF 6w (p<0.001). Conspicuously, the number of apoptotic β-cells correlated 
with the total number of β-cells per islet cross-section in the 9-week-old dia-
betic animals. In addition, a significant higher number of apoptotic β-cells 
was present in the islets located in the pancreatic head (near the duodenum) 
than in islets located in the pancreatic tail (near the spleen). Taspoglutide-
treatment improved β-cell survival as demonstrated by a significantly re-
duced number of apoptotic β-cells per islet cross-section (taspoglutide: 0.06 
vs vehicle: 0.19, p <0.001 and n.s. vs. ZDF 6w). This protective effect was even 
superior in the pancreatic tail. In addition, vehicle-treated ZDF rats at the age 
of 9 weeks demonstrated a significant increase in infiltration of inflammatory 
cells into the islet center and the progression of fibrosis within and in close 
distance to the islets when compared to ZDF 6w and this effect was more pro-
nounced in the pancreatic head. Taspoglutide prevented this inflammatory 
process as demonstrated by significantly less infiltration of inflammatory cells 
into the islet center and prevented islet fibrosis. In analogy with the apoptosis 
results, prevention of fibrosis was more effective in the pancreatic tail.
Conclusion: In summary, these results demonstrate for the first time new 
aspects of β-cell protective effects of incretins in vivo. In particular, in ZDF 
rats after chronic treatment protective effects of taspoglutide, a novel once-
weekly human GLP-1 analogue, on 1) β-cell apoptosis 2) islet inflammation 
and 3) islet fibrosis were shown.
Supported by: Roche
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Beta cell proliferation is impaired in the absence of survivin in the 
pancreas of duct-ligated adult mouse
X. Wu1, Q. Zhang1, C. Liu1, K. Xu1, X. Mao1, T. Yang1, H. Okada2, M. Woo3;
1Department of Endocrinology, First Affiliated Hospital of Nanjing Medical 
University, China, 2Division of Signaling Biology, Ontario Cancer Institute, 
Toronto, 3Institute of Medical Science, Ontario Cancer Institute, University 
of Toronto, Canada.
Background and aims: As type 1 and type 2 diabetes result from absolute 
or relative deficiencies in beta cell mass, respectively, understanding how 
beta cell mass is determined and can be manipulated may lead to new thera-
peutic options. We previously showed that transient perinatal expression of 
survivin,the inhibitor of apoptosis protein,is essential for pancreatic beta cell 
mass establishment by regulation of cell cycle progression. This study was 
designed to determine whether survivin was required for regeneration of beta 
cell mass in the pancreas of duct-ligated adult mouse.
Materials and methods: Using the Cre-loxP recombination system, we 
generated a rat insulin promoter (RIP)-driven survivin (also known as 
Birc5) knockout mouse with a specific deletion of survivin in pancreatic 
beta cells. Adult RIPCre+survivinflox/flox mice and their control littermates 
(RIPCre+survivin+/+) were subjected to partial pancreatic duct ligation (PDL) 
or a sham operation, after which islet expression of survivin, beta cell func-
tion, beta cell mass, proliferation, beta cell size and apoptosis were analyzed.
Results: In control mice, PDL stimulated beta cell mass regeneration and 
beta cell proliferation and activated survivin reexpression in beta cells in 
the ligated tail of pancreas within 2-week. At day 7 post-PDL, control mice 
underwent significant regeneration of beta cell mass, increase of beta cell 
proliferation and beta cell numbers in the ligated tail of pancreas. However, 
targeted deletion of survivin in beta cells exhibited glucose intolerance at day 
7 after PDL, with specific impairments in beta cell mass regeneration, beta 
cell proliferation and pAkt expression, and with larger average beta cell size 
and nucleus size. Although the number of beta cell clusters was markedly 
decreased, the mutant mice specifically exhibited an increased proportion of 
small beta cell clusters (one to ten beta cells) within the ligated tail of pancre-
as. Additionally, islet architecture, beta cell development and apoptosis were 
not affected by absence of survivin after PDL.
Conclusion: Our results indicate that survivin reexpression in the pancreatic 
beta cells after PDL is essential for beta cell mass regeneration through beta 
cell proliferation. The preexisting beta cells seemingly exhibit a stronger re-
quirement for survivin than new beta cells formed by neogenesis. This study 
highlights the importance of preexisting beta cell proliferation as a mecha-
nism of beta cell mass regeneration. Beta cell neogenesis, without adequate 
proliferation, is not sufficient to regenerate a significant amount of beta cell 
mass after PDL.
Supported by: NSFC
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Id1 may play an important role in beta cell dysfunction in type 2 diabetes
M.C. Åkerfeldt, D.R. Laybutt;
Diabetes and Obesity, Garvan Institute of Medical Research, Sydney, 
Australia.
Background and aims: Pancreatic β-cell dysfunction is central to the de-
velopment of type 2 diabetes (T2D). Chronically elevated glucose and lipid 
levels may contribute to β-cell dysfunction in T2D, although the molecular 
mechanisms remain unknown. In islets of diabetic db/db mice, we found that 
β-cell dysfunction was associated with upregulation of a transcriptional regu-
lator, inhibitor of differentiation 1 (Id1). Id proteins are negative regulators of 
helix-loop-helix (HLH) transcription factors. HLH proteins are critical for 
β-cell development and function and therefore we investigated the role of Id1 
in insulin secretion and glucose homeostasis in MIN6 cells and Id1 knockout 
mice.
Materials and methods: Id1 knockout (Id1-/-) and Wildtype (Wt) mice were 
fed ad libitum for 6 or 18 weeks with standard chow (8% calories from fat) or 
high-fat diet (45% calories from fat [lard]) followed by intraperitoneal glu-
cose tolerance test (ipGTT), insulin tolerance test (ipITT) or insulin secretion 
assay (batch incubations of isolated islets). To examine effects of increased 
Id1 expression on insulin secretion, Id1 was overexpressed in MIN6 cells fol-
lowed by insulin secretion assay. Statistical analysis was performed by stu-
dent’s t-test or two-way ANOVA.
Results: Id1-/- mice were completely protected from high-fat diet-induced 
glucose intolerance (ipGTT, P<0.001). This was not associated with altered 
food intake, body weight or epididymal fat pad weight, which were similar 
in fat-fed Wt and Id1-/- mice. However, insulin levels during the ipGTT 
(P<0.01) and insulin release from isolated islets (P<0.001) were significantly 
increased in fat-fed Id1-/- mice compared to fat-fed Wt mice. This protection 
from diet-induced glucose intolerance in association with augmented insulin 
secretion was observed at 6 and 18 weeks of high-fat feeding. No differences 
in insulin action were observed during ipITT of fat-fed Wt and Id1-/- mice, 
suggesting that the protection from diet-induced glucose intolerance is due to 
improved β-cell function rather than by changes in insulin sensitivity. No dif-
ferences in glucose tolerance or insulin secretion were observed in chow-fed 
Wt and Id1-/- mice, indicating that deletion of Id1 enhances insulin secretion 
only under conditions of fat oversupply and insulin resistance. In MIN6 cells, 
overexpression of Id1 led to reduced glucose-stimulated insulin secretion 
(P<0.05), indicating that increased expression of Id1 is sufficient to inhibit 
insulin secretion.
Conclusion: An important role of Id1 in β-cell dysfunction is supported by 
evidence that deletion of Id1 in mice protects against diet-induced glucose in-
tolerance and enhances insulin secretion under conditions of fat oversupply, 
and that increasing Id1 expression in β-cells inhibits insulin secretion. Thus, 
Id1 expression may contribute to β-cell dysfunction in T2D.
Supported by: JDRF and NHMRC of Australia
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Sodium glucose co-transporter type 2 knockout reduces hyperglycaemia 
and preserves islet function in db/db mice
R.G. Kibbey1, M.J. Jurczak1, A.L. Birkenfeld1, F.R. Jornayvaz1, H.-Y. Lee1, 
R.L. Pongratz1, X. Zhao1, V.T. Samuel1, J.M. Whaley2, G.I. Shulman1;
1Internal Medicine/Endocrinology, Yale University School of Medicine, New 
Haven, 2Metabolic Diseases Biology, Bristol-Meyers Squibb Research and 
Development, Princeton, USA.
Background and aims: Defective glucose-stimulated insulin secretion by 
pancreatic beta-cells due to glucose-toxicity has been implicated in the patho-
genesis of type-2 diabetes. Therapies that reduce hyperglycemia could there-
fore not only prevent complications, but could potentially preserve beta-cell 
function. Inhibition of the sodium-glucose co-transporter type 2 (SGLT2) is 
a novel insulin-independent approach to lowering plasma glucose. SGLT2 is 
responsible for reabsorbing the majority of filtered glucose in the kidney. Thus, 
reducing SGLT2 activity leads to significant loss of glucose in the urine.
Materials and methods: To determine the effects of SGLT2 knockout on 
glucose homeostasis, insulin action and islet function against a background 
of extreme insulin resistance (db/db), we characterized wild type (db/db-
SGLT2+/+), SGLT2 heterozygote (db/db-SGLT2+/-) and SGLT2 homozygote 
(db/db-SGLT2-/-) null mice by hyperinsulinemic euglycemic studies as well 
as with hyperglycemic clamps. Isolated islets from the mice were perifused to 
assess insulin secretion.
Diabetologia (2010) 53:[Suppl1]S1–S556 S 75
1 C
Results: Fasting plasma glucose and insulin were reduced in db/db-SGLT-
/- mice relative to db/db-SGLT+/+ mice (P<0.001), while there was no differ-
ence in db/db-SGLT+/- mice (glucose: 124 ± 8, 199 ± 15, 202 ± 20 mg/dl; 
insulin: 92 ± 6, 163 ± 22, 176 ± 22 µU/ml). There was no difference in body 
weight between genotypes, despite a 1.5-3 fold greater daily urine output and 
glucosuria in db/db-SGLT-/- compared to db/db-SGLT+/+ mice. Nevertheless, 
adiposity was 5% less (P<0.01) in db/db-SGLT-/- mice compared to db/db-
SGLT+/+. During hyperinsulinemic euglycemic clamp studies, the glucose 
infusion (GINF) required to maintain euglycemia in db/db-SGLT-/- mice was 
100% higher than db/db-SGLT+/- and 170% higher than db/db-SGLT+/+ mice 
(P<0.01). There were no differences in muscle or fat glucose uptake suggesting 
that reduced hepatic glucose output and/or glucose loss in urine accounted 
for changes in GINF. Interestingly, in vivo islet function as assessed by hyper-
glycemic clamp studies suggested that SGLT2 inhibition may preserve islet 
function: AUC insulin secretion was approximately 190% greater in db/db-
SGLT-/- mice compared to db/db-SGLT+/+ mice (P<0.05). Lastly, perifusion 
studies with isolated islets demonstrated no difference in glucose stimulated 
insulin secretion in db/db-SGLT-/- compared to db/db-SGLT+/+ mice on a per 
islet basis, suggesting that changes in beta-cell mass and/or islet number ac-
counted for the increased insulin secretion during hyperglycemic clamps.
Conclusion: SGLT2 knockout reduced adiposity and prevented hyperglyc-
emia in db/db mice. Furthermore, reduced hyperglycemia appeared to pre-
serve overall beta-cell function in vivo, resulting in greater insulin secretion 
during the hyperglycemic clamp. Taken together, these data suggest that 
SGLT2 inhibition is an attractive therapeutic target for type 2 diabetes.
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Deletion of beta cell Raf-1 kinase results in glucose intolerance
E.U. Alejandro, G.E. Lim, X. Hu, R. Liang, F. Taghizadeh, T. Kalynyak,  
J.D. Johnson;
Department of Cellular and Physiological Sciences, University of British 
Columbia, Vancouver, Canada.
Background and aims: Regulation of glucose homeostasis by insulin de-
pends on pancreatic beta-cell survival, growth, and function. Raf-1 kinase is 
a major downstream target of many growth factors that promote growth and 
survival of many cell types including the pancreatic beta-cells. We have previ-
ously reported that insulin protects beta-cells from apoptosis and promotes 
proliferation by activating Raf-1 signalling in dispersed primary mouse islets 
and in the mouse-insulinoma MIN6 cell line. As Raf-1 activity also regulates 
basal apoptosis and insulin secretion in vitro, we hypothesized that Raf-1 may 
play an important role in beta-cell function in vivo.
Materials and methods: To test this hypothesis, we utilized the Cre-loxP recom-
bination system to obtain a pancreatic beta-cell specific ablation of Raf-1 kinase 
gene (RIPCre+/-:Raf-1flox/flox) and their littermate controls (RIPCre+/-:Raf-
1wt/wt). Immunofluorescense imaging was performed on paraffin-embedded 
mouse pancreas sections to analyze Raf-1 localization. Quantitative PCR was 
performed on isolated islet RNA from RIPCre+/-:Raf-1wt/wt and RIPCre+/-:
Raf-1flox/flox. Protein expression of Raf-1, B-Raf, ERK1/2, and SNARE proteins 
were examined by western blotting. Glucose and insulin tolerance tests were 
performed on RIPCre+/-:Raf-1flox/flox mice and their littermate controls.
Results: Raf-1 is expressed in various cell types in the pancreas including 
insulin positive cells. Of the Raf isoforms, A-Raf message levels were the 
highest, followed by B-Raf and Raf-1 in control mice. Beta-cell specific dele-
tion of Raf-1 did not alter the expression of A-Raf or B-Raf message levels 
in RIPCre+/-:Raf-1flox/flox mice. B-Raf and Erk1/2 protein expression lev-
els did not change in RIPCre+/-:Raf-1flox/flox mice compared to controls. 
RIPCre+/-:Raf-1flox/flox mice are viable, and no effects on weight gain were 
observed. RIPCre+/-:Raf-1flox/flox mice have increased fasting basal blood 
glucose levels, impaired glucose tolerance, but normal insulin tolerance com-
pared to littermates control. Islet perifusion studies demonstrated that islets 
isolated from RIPCre+/-:Raf-1flox/flox mice have impaired response to both 
glucose and KCl, consistent with the concept that Raf-1 plays an important 
role in beta-cell function. To ascertain if Raf-1 function regulates the expres-
sion of the exocytotic machinery, SNARE proteins were examined by western 
blot. In preliminary studies with MIN6 cells, Raf-1 inhibition was associated 
with an impairment of glucose-stimulated insulin secretion. Furthermore, 
phosphorylation of synapsin-1, which is required for liberating insulin gran-
ules from the actin cytoskeleton, was also completely abrogated.
Conclusion: Together with our previous work demonstrating that Raf-1 pro-
motes survival and proliferation, these new results suggest that Raf-1 posi-
tively regulates beta-cell function in vivo.
Supported by: JDRF and NIH
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Function of Insm1 in mature pancreatic beta cells
S. Jia, M. Poy, C. Birchmeier;
Developmental Biology / Signal Transduction, Max Delbrück Centrum Für 
Molekula, Berlin, Germany.
Background and aims: Insm1 was originally isolated from a human insuli-
noma subtraction library and was subsequently found to be expressed in a 
large numbers of tumors of neuroendocrine origin as well as in mouse de-
veloping nervous systems, many developing and adult endocrine cell types, 
among them adult pancreatic β-cells. Mouse Insm1 is an intron-less gene, 
which encodes a protein of 521 amino acids that contains three proline-rich 
regions, five C2H2 zinc finger motifs, a SNAG motif and a nuclear location 
signal (NSL). Insm1 is predicted to act as a transcription factor. Our previ-
ous work showed that Insm1 is essential for differentiation of pancreatic and 
intestinal endocrine cells. In the pancreas of Insm1 null mutant mice, endo-
crine precursors are formed, but only very few insulin-positive β-cells are 
generated. Instead, endocrine precursor cells accumulate that express none 
of the pancreatic hormones. However, the function of Insm1 in mature pan-
creatic β-cells is still unknown
Materials and methods: To define Insm1 function in mature pancreatic β-
cells, we introduced a conditional mutation into the Insm1 gene in mature 
β-cells. For this, we used a floxed Insm1 allele and a tamoxifen-inducible 
variant of cre, creER, which is expressed under the control of the insulin pro-
moter (RIP-creER).
Results: Conditional mutation of Insm1 in mature pancreatic β-cell blocks 
glucose induced insulin secretion and causes hyperglycemia. However, 
Insm1 mutation did not ablate amino acid (e.g. Arginine) stimulated insu-
lin secretion, and the secretory machinery appears therefore not to be de-
fected. Whole pancreatic insulin contains are comparable between wild type 
and conditional mutant mice, which is consistent with β-cell mass and β-cell 
number. Microarray analysis shown expression of numerous genes that are 
important for pancreatic β-cell function is abnormal.
Conclusion: Insm1 is important for maintaining of mature pancreatic β-cell 
function. Deletion of Insm1 in mature pancreatic β-cells causes diabetic phe-
notype.
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Deletion of the mitochondrial chaperone prohibitin-2 in beta cells 
results in beta cell apoptosis and promotes diabetes in transgenic Bet-
Phb2-/- mice
S.M. Supale1, T. Brun1, I. Avril1, A. Gjinovci1, C. Merkwirth2, P.L. Herrera1, 
T. Langer2, P. Maechler1;
1Department of Cell Physiology and Metabolism, University of Geneva, 
Switzerland, 2Institute for Genetics, University of Cologne, Germany.
Background and aims: Prohibitins are evolutionary well conserved and 
ubiquitously expressed proteins having two interdependent homologues, 
prohibitin-1 and -2 (PHB2). They are implicated in cell cycle regulation, ROS 
production, cancer, obesity, and inflammation. Prohibitins form ring com-
plexes in the inner mitochondrial membrane, thereby controlling mitochon-
drial dynamics, cristae remodeling and apoptosis. In pancreatic beta-cells, 
mitochondria are essential players in the control of metabolism-secretion 
coupling. Nevertheless, we lack information regarding importance of mito-
chondrial dynamics in general and putative role of prohibitins in particular. 
Here, we generated beta-cell specific Phb-2 knockout mice (Bet-Phb2-/-) to 
study prohibitins and mitochondrial integrity in the regulation of glucose 
homeostasis, islet physiology, and beta-cell mass.
Materials and methods: Bet-Phb2-/- mice were generated by crossing mice 
with Phb2 allele flanked by lox-P sites (Phb2fl/fl) with animals carrying the 
Cre recombinase driven by an insulin promoter (Rip-Cre). Mice thus gener-
ated (Bet-Phb2-/-) were assessed by genomic PCR and immunoblotting on 
isolated tissues. Glucose homeostasis was characterized by glucose tolerance 
tests and plasma insulin levels. In-situ pancreatic perfusions were carried out 
to study effects of Phb2 deletion on glucose-stimulated insulin secretion. Islet 
morphology, beta-cell mass, proliferation and apoptosis were studied using 
immuno-histochemistry. The study has been carried out along the principles 
of laboratory animal care.
Results: Non-fasting blood glucose showed that Bet-Phb2-/- mice were nor-
moglycaemic up to the age of 4 weeks and then became hyperglycemic (14.6 
mM, p<0.05) at 6 weeks, further developing diabetes with age and eventually 
causing death at the age 12-15 weeks. Bet-Phb2-/- mice grew normally until 6 
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weeks of age before progressive decline and weight loss. At 6 weeks, ipGTT 
revealed that Bet-Phb2-/- mice were glucose intolerant (AUC +133%, p<0.001) 
compared with littermate control (Phb2fl/fl) mice. Plasma insulin levels were 
lower by 66% (p<0.01) during fasting and 93% (p<0.001) after glucose injec-
tion in 6-week old Bet-Phb2-/- mice. In-situ pancreatic perfusions revealed 
that both first and second phases of glucose-stimulated insulin secretion were 
markedly reduced (-76%, p<0.001 and -78%, p<0.001, respectively) in 6-week 
old Bet-Phb2-/- mice. Up to the age of 4 weeks, beta-cell proliferation was 3 
times higher in Bet-Phb2-/- versus controls. Bet-Phb2-/- islets were disorgan-
ized at the age of 4 weeks onwards and beta-cell mass progressively declined 
with age.
Conclusion: These results demonstrate that prohibitin-2 is essential for beta-
cell function and survival. Loss of this mitochondrial chaperone protein led 
to beta-cell death and diabetes. Interestingly, beta-cell proliferation could 
compensate apoptosis and postponed diabetes during the first 4 weeks of life 
of the Bet-Phb2-/- mice.
Supported by: Swiss National Science Foundation
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Investigation of the expressional profiles in human pancreatic islets for 
candidate genes located in 40 type 1 diabetes associated regions
C.A. Brorsson, R. Bergholdt, T. Fløyel, L.A. Berchtold, A. Mellerup,  
J. Størling, F. Pociot;
Hagedorn Research Institute, Gentofte, Denmark.
Background and aims: Today more than 40 non-HLA regions have been 
demonstrated to be robustly associated with the risk of type 1 diabetes (T1D). 
However, the causal variants have not yet been identified for any of the genes 
located within these regions. For most of the genes their function in relation 
to the disease pathogenesis is also unknown. One way of dissecting possible 
roles for these genes in the pathogenesis is to investigate their expression, 
under cytokine stimulation in human pancreatic islets, to mimic the inflam-
matory process that precedes the clinical onset of T1D. Genes that change 
their expression can be presumed to have a functional relevance and further 
investigations can then be focused on these.
Materials and methods: Candidate genes were chosen from the 40 risk loci 
that were identified in the genome wide association scan published by the 
Type 1 Diabetes Genetics Consortium (T1DGC). The genes that were located 
closest to the association signal within each associated region were chosen for 
evaluation. The gene expression of 47 candidates was evaluated using custom 
designed Low Density Arrays (Applied Biosystems). Expression levels were 
measured in eight individual human pancreatic islet preparations before and 
after cytokine stimulation (mix of TNF-α, IFN-γ and IL-1β). Gene expression 
levels were normalized against the geometric mean of three different house-
keeping genes and compared using the paired t-test.
Results: We detected expression in human pancreatic islets for 30 of the 49 
investigated genes, of which 13 were significantly and four borderline regu-
lated by cytokine treatment. Already well known candidate genes, such as 
INS and IFIH1 were among the significantly regulated genes. Furthermore, 
among genes located in recently associated regions IL10 (1q32), IL7R (5p13), 
MMP19 (12q13) and TNFAIP3 (6q23) were up-regulated whereas CTSH 
(15q25), COBL (7p12), CTRB2 (16q23) and SKAP2 (7p15) were down-regu-
lated by cytokines.
Conclusion: Expression profiling of genes located in T1D associated regions 
has pin-pointed genes that are affected by cytokine stimulation in human is-
lets, thus guiding the investigation towards their functional implication in the 
pathogenesis. In addition, the results demonstrate that despite that many of 
the investigated genes have been classified as “immune genes” they are in fact 
also expressed in human islets, and moreover they are affected by cytokines. 
Future studies involve the investigation of risk genotype-specific effects on gene 
expression in human lymphocytes to find out how genetic variation associated 
with the risk genes can affect their function and lead to a pathogenic state.
Supported by: JDRF
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Type 1 diabetes protein network analyses combined with gene expression 
profiling in human islets
R. Bergholdt1, C.A. Brorsson1, T. Fløyel1, L.A. Berchtold1, A. Palleja2, L. 
Jensen2, J. Størling1, F. Pociot1,3;
1Dept of Genome Biology, Hagedorn Research Institute, Gentofte, 
2Novo Nordisk Foundation Center for Protein Research, University of 
Copenhagen, Denmark, 3Institute for Clinical Science, University of Lund, 
Sweden.
Background: In type 1 diabetes (T1D) 40 non-HLA regions have been dem-
onstrated to be robustly associated. For none of the regions the causal variant 
is known and most contain many genes. Even with the genetic contribution 
from these 40 regions and the HLA region we have still not explained the 
total genetic heritability for T1D. Novel approaches are needed to identify 
the causal T1D genes and to explain this missing heritability. We have identi-
fied all positional candidate genes in the 40 non-HLA T1D associated regions 
identified in genome-wide association studies (GWAS) and used these as in-
put for network-based data mining analyses. For all input genes and interac-
tion partners we performed expression profiling in human pancreatic islets.
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Methods: 350 positional candidate genes were identified from non-HLA 
T1D associated LD regions from GWAS using NCBI databases. These genes 
were used as input into STRING data mining software extracting human 
protein-protein interaction networks enriched for input proteins. We used 
custom designed Low Density Arrays (Applied Biosystems) to evaluate gene 
expression levels of all genes identified as nodes in the networks. Expression 
levels were measured in eight individual human pancreatic islet preparations 
+/- cytokine stimulation. Gene expression levels were normalized against the 
geometric mean of three different housekeeping genes and compared using 
paired t-test.
Results: We identified 17 interaction networks containing 247 nodes, of 
which ~40 were input proteins from T1D associated regions. Three net-
works contained a significant amount of differentially regulated genes upon 
cytokine stimulation, whereas others contained none or only a few signifi-
cantly regulated genes. These three networks highlight interesting pathways 
and shed light on the effect of cytokines on network level The data suggest 
that both classical inflammatory, but also non-inflammatory, pathways are 
important disease pathways.
Conclusion: We have used a novel approach to identify networks and genes 
of importance in T1D. Only few of the significantly regulated genes were lo-
cated in T1D genetic regions identified in GWAS, so we extracted informa-
tion not directly obtainable from genetic studies, i.e. GWAS. We believe this 
approach of combining genetic knowledge with bioinformatics and function-
al genomics unravels knowledge of relevance for disease pathogenesis from 
GWAS, which can be used to point at potential novel pathways or targets for 
new prevention or treatment strategies.
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Identification of type 1 diabetes candidate genes by in silico phenome-
interactome analysis
J. Størling1, L.A. Berchtold1, Z.M. Størling2, F. Ortis3, J. Hald4, T. Galbo4,  
K. Lage2, C.B. Berthelsen1, D.L. Eizirik3, S. Brunak2, F. Pociot1;
1Dept. of Diabetes Inflammation, Hagedorn Research Institute, Gentofte, 
2Center for Biological Sequence Analysis, Lyngby, Denmark, 3Universite 
Libre de Bruxelles, Brussels, Belgium, 4Hagedorn Research Institute, 
Gentofte, Denmark.
Background: Type 1 diabetes (T1D) has a strong genetic background, but 
except for a few, the specific genes that contribute to disease remain to be 
discovered.
Methods: A systems biology/bioinformatics method for predicting genes in-
volved in disease was recently developed. The method is based on in silico 
generation of protein networks and disease phenotype association. We used 
this “phenome-interactome protein network analysis” to identify novel T1D 
candidate genes. Follow-up studies involved experiments to address the func-
tional role of predicted genes in pancreatic beta-cells.
Results: Using T1D genome-wide linkage results as input data, we performed 
a phenome-interactome protein network analysis. The analysis revealed 11 
candidate genes including two HLA genes and the INS gene. A top-scoring 
candidate gene was Huntingtin-interacting protein (HIP)-14. No previous 
reports have linked HIP14 to T1D. To explore the potential functional role 
of HIP14 in pancreatic beta-cells, we performed a series of experiments on 
different beta-cell model systems. Immuno-histochemical staining and West-
ern blotting indicated that HIP14 is expressed in both primary and clonal 
beta-cells. Comparison of HIP14 expression in a beta-cell line and an alfa-cell 
line demonstrated that HIP14 is 2-fold higher expressed in beta-cells ver-
sus alfa-cells. Knock-down experiments with either siRNA or short-hairpin 
RNA against HIP14 in purified primary rat beta-cells or INS-1 cells induced 
apoptotic cell death suggesting that HIP14 is required for beta-cell survival. 
Further, knock-down of HIP14 caused a reduction in beta-cell insulin re-
lease. Consistent with a pro-survival role of HIP14 in beta-cells, inflamma-
tory cytokines (IL-1 + IFN) known to contribute to beta-cell dysfunction and 
apoptosis in T1D reduced the expression of HIP14 in rat islets and INS-1 
cells. In human islets, cytokines decreased HIP14 expression in 6 out of 8 
donor islet preparations.
Conclusion: Using a bioinformatics/systems biology approach to predict dis-
ease candidate genes, we, among several other genes, identified HIP14 as a 
gene being involved in T1D. Functional studies demonstrated that expression 
of HIP14 is suppressed under inflammatory conditions resembling those of 
T1D, and that HIP14 is needed for beta-cell survival and insulin secretion.
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Factors associated with early/childhood onset of the disease in 
families with type 1 diabetes. Results from the type 1 diabetes genetics 
consortium (T1DGC)
A.M. Wägner1,2, A. Santana3, J.C. Wiebe1, M. Hernández4, J. Nóvoa1,2,  
D. Mauricio4, T1DGC;
1Endocrinology, Complejo Hospitalario Universitario Insular Materno-
Infantil, Las Palmas de Gran Canaria, 2Ciencias Médicas y Quirúrgicas, 
Universidad de Las Palmas de Gran Canaria, 3Matemáticas, Universidad de 
Las Palmas de Gran Canaria, 4Endocrinology, Hospital Universitari Arnau 
de Vilanova, Lleida, Spain.
Background and aims: Families with at least 2 affected siblings have been 
included by the T1DGC in order to find genes associated with risk/protection 
for type 1 diabetes (T1D). The aim of our study was to find factors associated 
with early and childhood onset of the disease.
Materials and methods: Clinical information was obtained with question-
naires, serum anti-GAD and anti-IA2 antibodies were measured (RBA) in 
the affected siblings and HLA was genotyped (PCR-based, sequence-spe-
cific oligonucleotide probe system). Early onset of the disease was defined as 
onset in the lowest tertile (<6 years), whereas childhood-onset diabetes was 
defined as that diagnosed before the age of 15. Differences between groups 
were analysed with Wilcoxon-Mann-Whitney’s test and chi-square. The first 
two siblings per family diagnosed with T1D were included in the analysis. 
To identify the factors independently associated with early and childhood 
onset, multivariate regression analysis was performed, including time since 
diagnosis, antibody positivity, presence of associated autoimmune diseases 
(AAID) and number of risk and protective HLA haplotypes as independ-
ent variables. High-risk and protective haplotypes were defined as the 4 most 
susceptible and protective, respectively, according to a previous report from 
the T1DGC.
Results: Data including unequivocal HLA haplotypes was available from 
2663 families (4817 participants). Median (range) age of onset of the disease 
was 9 (0-49) years, time since diagnosis, 7 (0-57) years, 49.3% were female, 
47.3% were positive for GADA and 47.2% for IA2A. Subjects with early onset 
of T1D were less frequently GADA and IA2A positive, had longer disease 
duration and had more high-risk HLA haplotypes. In the multiple regression 
analysis, male gender (OR 1.15 (1.02-1.31), p=0.019), negativity to GADA 
(OR 0.48 (0.42-0.54), p=2*10-16 for positivity) and IA2A (OR 0.68 (0.60-
0.78), p=4.25*10-9) and time since diagnosis (non-lineal, p=2.45*10-13) were 
independently associated with early onset. Participants with childhood onset 
T1D (84%) were more frequently male, had less frequent AAID, less GADA 
and more IA2A positivity, less protective and more high-risk HLA haplotypes 
and longer time since diagnosis than participants with adult-onset T1D. In 
the multiple regression analysis, the following were independently associated 
with childhood-onset disease: male gender (OR 1.49 (1.28-1.74), p=2.35*10-
7, AAID (OR 0.75 (0.60-0.92), p=0.007), GADA negativity (OR 0.35 (0.30-
0.41) for positivity, p=2*10-16) and IA2A positivity (OR 1.30 (1.11-1.52), 
p=0.001), number of protective HLA haplotypes (OR 0.27 (0.11-0.70) per 
haplotype, p=0.007) and time since diagnosis (non-linear, p=0.001).
Conclusion: Early onset of T1D was independently associated with male pre-
dominance and antibody negativity at examination, whereas childhood onset 
disease was associated with male predominance, IA2A positivity and GADA 
negativity, less frequent AAID and fewer protective HLA haplotypes.
Supported by: NIDDK (DK-62418), JDRF, and EFSD/JDRF/Novo Nordisk 
grant, ISCIII
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HLA and insulin genes: Bayesian networks confirm interaction between 
the two most important susceptibility genes in type 1 diabetes in a 
French caucasian population
R. Portuesi1, B.O. Böhm2, C. Julier3, P. Pozzilli1;
1University Campus Bio-Medico, Rome, Italy, 2University Hospital Ulm, 
Internal Medicine I, Ulm, Germany, 3Centre National de Genotypage, Evry, 
France.
Background and aims: Type 1 diabetes (T1D) is an autoimmune chronic 
disease resulting from the interaction between more or less favouring en-
vironmental factors with multiple susceptibility genes. HLA, Insulin (INS), 
CTLA4 and PTPN22 are considered the main T1D susceptibility genes. As 
many epidemiological studies have demonstrated, T1D incidence is increas-
ing worldwide by 3.9% per year, particularly in Caucasian population of 
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Northern Europe. Unlike in single gene disorders, in multifactorial diseases, 
such as T1D, identifying the combination of causative genes is still difficult. 
Genetic profiles of individuals who are affected by T1D appear to change 
among different countries shifting from mainly high-risk genotypes towards 
higher percentages of median and low-risk genotypes. In a previous study 
we demonstrated the interaction between HLA and INS genes in an Italian 
population from Lazio region using the Bayesian Network approach. To con-
firm our previous findings, the aim of the present study was to investigate and 
verify in T1D the dependency and interaction between HLA and INS genes 
by investigating another Caucasian population.
Materials and methods: We have analyzed a database of genetic data from 
a French Caucasian population, the case-control cohort consisted of 868 
French T1D patients (M/F 1.13, 19.63 ±14.40 yrs mean age of T1D onset) 
and 93 French control subjects (M/F 0.7). Diagnosis of T1D was based on 
the ADA classification criteria. We divided HLA alleles in high, moderate 
and low risk for T1D, PTPN22 alleles in susceptibility/non susceptibility al-
leles and INS gene alleles in susceptibility/protection. We created a Bayesian 
Network model trained on genetic variables and group status (T1D/control). 
Bayesian networks, also called belief networks, are probabilistic graphical 
models that represent a set of variables and their probabilistic dependencies. 
To gain insights into the dependency/interaction between susceptibility genes 
involved in T1D, we have assessed more than one gene at the time (namely 
HLA, INS and PTPN22 genes).
Results: We implemented a Bayesian Networks model learning the structure 
of the specified database, with a fixed level of significance equal to 0.05 to find 
out the interaction. The model showed that group status was directly influ-
enced by HLA (p = 1.0*10^(-26)) and that there was a dependency of INS on 
HLA (p = 4*10^(-4)). In addition to our previous data, having separated the 
data group wise, the analysis of T1D patients group also highlighted the gene 
interaction between HLA and INS (p = 3.7*10^(-4)). No significant relation 
between HLA and PTPN22 (p = NS) and PTPN22 and “status group” (p = 
NS) was found.
Conclusion: The presence of interactions between susceptibility genes can 
explain why the study of a single susceptibility gene in a polygenic disease 
such as T1D offers limited information. Bayesian network type of analysis 
represents a step forward in understanding gene interactions and may offer 
novel clues for T1D pathogenesis. Further studies are needed to clarify the 
true nature of the biological interaction between HLA and INS gene alleles.
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Functional genomics of the type 1 diabetes gene interferon-induced 
helicase 1-linked downstream signal mechanisms in humans
I. Szatmari1, A. Jermendy1, Z. Almassy2, R. Hermann3, and the 
HUNT1DGENES Study Group;
1CellScreen Applied Biomedical Research Center, Semmelweis 
University, Budapest, 2Heim Pal Childrens Hospital, Budapest, Hungary, 
3Immunogenetics Laboratory, University of Turku, Finland.
Background and aims: In type 1 diabetes (T1D) beta cell injury develops as 
a consequence of interaction between a complex polygenic background and 
environment. More than 40 T1D loci have been identified to date, however, 
their functional characterization, and their assignment to specific disease 
endophenotypes is lacking. Recently, a non-synonymous SNP (rs1990760) 
in the gene encoding interferon induced helicase C containing domain 1 
(IFIH1) showed an association with type 1 diabetes. IFIH1 is a cytosolic viral 
recognition receptor, and may provide a link between viral infections and 
T1D. In the present study we evaluated the variation in the gene expression 
profile of IFIH1, and related global gene expression profiles in response to 
type I interferon and a viral infection model.
Materials and methods: We compared downstream signal mechanisms in 
T1D children with the wild type AA and the T1D predisposing GG geno-
types. Jurkat (T lymphocytic) and MonoMac (monocytic) cells were stimu-
lated with interferon-β or/and polyinosinic acid-polycytidylic acid complex 
(polyI:C). Global expression profiling was carried out using high density gene 
expression arrays. Bioinformatics analysis was performed using HT associa-
tion pattern mining, FDR significance estimation, GO and KEGG pathway 
annotation.
Results: Treatment of both cell lines with interferon-β resulted in a biphasic 
induction of IFIH1. The maximum level of IFIH1 mRNA was apparent at 8 h 
in Jurkat cells and 4 h in MonoMac cells, then decreased before a subsequent 
increase observed at 24 h postinduction in both cell lines. The expression of 
IFIH1 mRNA increased in a interferon-β dose-dependent manner. The tem-
poral kinetics of IFIH1 expression after polyI:C induction differed in the two 
studied cell lines. In a 24 hour time frame, Jurkat cells presented a biphasic in-
duction profile, in the monocytic cells IFIH1 mRNA levels presented a single 
peak. The combined treatment with IFNβ followed by polyI:C had a distinct 
effect. Gene network analysis results will be presented on the event.
Conclusion: In the mononuclear cell lines Jurkat and MonoMac, as a result 
of interferon-β/polyI:C treatment the IFIH1 mRNA level’s temporal kinetic 
presented distinct characteristics in the first phase, but similar in long term 
effect. The results serve as take-off data for further studies carried out in hu-
man peripheral blood mononuclear cells, presenting basis for the analysis 
of the role of IFIH1 in T1D pathomechanism. The global expression profil-
ing data, and their relation to disease pathways will be released during the 
presentation.
Supported by: an EFSD New Horizons grant, Academy of Finland
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OP 30 Insulin action and glucose 
uptake in vitro
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Insulin stimulates human brown adipose tissue glucose uptake effectively
K.A. Virtanen1, J. Orava1, V. Oikonen1, T. Noponen1, P. Nuutila1,2;
1Turku PET Centre, 2Department of Medicine, Turku University Hospital, 
Finland.
Background and aims: Brown adipose tissue (BAT) has been acknowledged 
to be noteworthy in adults but its role in metabolism is still poorly 
understood. The aim of this study was to investigate the effects of insulin 
on glucose uptake (GU) and perfusion in BAT depots confirmed by cold 
activation in healthy adults.
Materials and methods: We measured BAT, subcutaneous adipose tissue 
(WAT) and skeletal muscle perfusion and GU using 15O-H2O- and 
18F-FDG-
PET/CT in 26 healthy normal-weighted subjects during cold exposure and 
either with or without insulin stimulation using euglycemic clamp in nor-
mal environment. Energy expenditure with indirect calorimetry was assessed 
during PET/CT studies.
Results: During cold exposure, 70% of the subjects showed BAT activa-
tion. In those cases, GU in BAT was 10-fold increased (9.1±5.1 vs. 0.9±0.4 
umol/100g/min, P=0.002). Perfusion in BAT correlated with GU rates in cold 
(r=0.82, P<0.001) but was only doubled (from 7.5±3.7 to 15.9±4.9 vs. ml/
100g/min, P<0.001) and did not explain the activation. Insulin-stimulated 
GU in BAT was 5-fold higher than when measured at fast in normal room 
temperature (4.7±2.4 umol/100g/min, P<0.001). No association was found 
between insulin-stimulated BAT GU and perfusion. The effect of insulin on 
BAT metabolic rate was close to that in skeletal muscle (6.0±2.5 umol/100g/
min) while GU in WAT was increased only by 50% by insulin. Plasma nore-
pinephrine concentrations were increased substantially during cold exposure 
and energy expenditure tended to be higher among the subjects with active 
BAT.
Conclusions: Glucose uptake in BAT is under hormonal control and can be 
activated by insulin close to the same extent as in skeletal muscle in healthy 
adult humans. This increment of metabolism is independent on perfusion. 
Whether dietary and hormonal activation is altered in obesity is under evalu-
ation.
Supported by: Academy of Finland and The Diabetes Research Foundation
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Effects of AMPK activation on glucose and energy homeostasis in leptin 
deficient ob/ob mice
R.Z. Tom, P.M. Garcia-Roves, M. Gilbert, L.Q. Jiang, A.S. Deshmukh,  
E. Vieira, M. Björnholm, J.R. Zierath;
Karolinska Institutet, Stockholm, Sweden.
Background and aim: AMPK is a heterotrimeric complex, composed of a 
catalytic subunit (α) and two regulatory subunits (β and γ), which acts as 
a metabolic sensor to regulate glucose and lipid metabolism. A point mu-
tation in the γ3 subunit (R225Q) increases basal AMPK phosphorylation, 
while concomitantly reducing sensitivity to AMP. AMPKγ3R225Q transgenic 
mice have increased glycogen content, enhanced mitochondrial biogenesis 
and are protected against dietary-induced triglyceride accumulation and in-
sulin resistance in glycolytic skeletal muscle. We determined whether skeletal 
muscle-specific expression of the AMPKγ3R225Q isoform prevents metabolic 
abnormalities in leptin-deficient ob/ob mice (ob/ob-γ3R225Q mice).
Materials and methods: Glucose tolerance and tissue-specific in vivo glucose 
uptake were determined in lean-wild-type (WT), lean-γ3R225Q, ob/ob-WT and 
ob/ob-γ3R225Q mice. Skeletal muscle glycogen and triglyceride content, as well 
as lipid oxidation was biochemically assessed.
Results: Glycogen content was increased in gastrocnemius muscle from lean-
γ3R225Q mice (lean-γ3R225Q 5.3±0.4 mg/g vs. lean-WT 3.9±0.2 mg/g; p<0.05), 
as well as ob/ob-γ3R225Q mice (ob/ob-γ3R225Q 6.2+0.6 mg/g vs. ob/ob-WT 
3.8+0.2 mg/g; p<0.05). Glucose tolerance was unaltered in either lean-γ3R225Q 
or ob/ob-γ3R225Q mice versus respective WT controls. Insulin-stimulated glu-
cose uptake in EDL muscle during the euglycemic-hyperinsulinemic clamp 
was increased in lean-γ3R225Q mice (p<0.05), but not in ob/ob-γ3R225Q mice. 
In contrast, insulin-stimulated glucose uptake in soleus, brown adipose tis-
sue (BAT) and heart was unaltered in lean γ3R225Q and decreased (p<0,05) in 
ob/ob-γ3R225Q mice. Basal lipid oxidation was increased in EDL muscle from 
lean-γ3R225Q and ob/ob-γ3R225Q mice (p<0.05). Pharmacological AMPK activa-
tion increased lipid oxidation in EDL, but not soleus muscle from lean-γ3R225Q 
and ob/ob-γ3R225Q mice. Elevations in gastrocnemius muscle triglyceride con-
tent were slightly prevented in ob/ob-γ3R225Q mice. Whole body respiratory 
exchange ratio was unaltered between γ3R225Q mutant and WT mice.
Conclusion: The AMPKγ3R225Q mutation increases skeletal muscle glycogen 
content and enhances basal lipid oxidation in lean and ob/ob mice. Howev-
er these improvements are insufficient to ameliorate insulin resistance and 
obesity in leptin deficient ob/ob mice. Thus, central defects due to leptin de-
ficiency override any positive benefit conferred by peripheral overexpression 
of the AMPKγ3R225Q mutation to improve glucose and energy homeostasis.
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Pancreatic roles for GLUT2 in human neonates evaluated by GLUT2 
mutants
A. Michau1, S. L’Hoste2, T. Grand2, J. Teulon2, E. Brot-Laroche1,  
P. de Lonlay3, A. Leturque1, M. Le Gall1;
1Team 9, UMRS 872, 2Team 3, UMRS 872, 3Reference Center for Inherited 
Metabolic Disorders, Necker-Enfants Malades Hospital, University Paris 
Descartes, Paris, France.
Background and aims: GLUT2 is a facilitative sugar transporter; its low affin-
ity and high capacity allow large fluxes of sugar in the liver, intestine, kidney 
and brain. GLUT2 is also a glucose receptor, detecting extracellular sugar and 
transducing a signal independent of glucose metabolism. The implication of 
GLUT2 in insulin secretion by beta pancreatic cells is well characterized in 
rodents but remains to be clarified in human. Mutations in human GLUT2 
give a Fanconi-Bickel syndrome (FBS), patients suffer from glycogenosis and 
glucose homeostasis disorders but not from overt diabetes. A study showed 
that after oral glucose, young FBS patients displayed hyperglycemia and 
relative hypoinsulinemia, improving with age. Accordingly, GLUT2 expres-
sion in pancreatic beta cells, controversial in adults, was reported in human 
neonates. Neonates suffering from Congenital Hyperinsulinism syndrome 
(CHI) showed sever hypoglycemia due to high insulin secretion. Mutations 
in the pancreatic ATP-sensitive potassium channel are responsible for most 
characterized CHI, however 50% of cases remain unexplained and mutation 
in others genes are explored. Our hypothesis is that constitutive activation of 
GLUT2 functions could be consistent with CHI syndrome. The aim of this 
study was thus to evaluate the role of GLUT2 in human neonate pancreatic 
function investigating hGLUT2 mutants and their impact on insulin secre-
tion.
Materials and methods: We generated by side-directed mutagenesis a panel 
of 6 hGLUT2 mutants. 3 single point homozygous mutations identified in 
FBS patients were generated to test their biological activity, they are sus-
pected to abolish sugar transport. 3 other mutations were generated as pos-
sibly activating GLUT2 mutations (E,H,D). GLUT2 kinetic parameters were 
calculated by measuring the uptake of radio-labeled 2-deoxy-D-glucose in 
Xenopus oocytes. Insulin secretion was assayed using the insulin-secreting 
cell line Min6.
Results: As expected, the 3 FBS-associated mutations abolished GLUT2 trans-
port function. Conversely, E and H mutations induced an increase in kinetic 
parameters of GLUT2 (lower Km, higher Vmax respectively) and D mutation 
decreased Vmax. Expression of these 3 mutants in Min6 cells stimulated in-
sulin secretion at glucose concentrations inefficient in cells transfected with 
wild-type hGLUT2. For E mutant, insulin secretion occurred even in absence 
of glucose. This disqualified increased sugar transport as the single signaling 
event, and suggested that activation of receptor function of hGLUT2 may be 
in part responsible for the increased insulin secretion. Finally, we found in a 
pancreas sample of a CHI neonate that hGLUT2 was present in insulin posi-
tive cells, likely to play a crucial role on neonate human pancreas function.
Conclusion: With this work, we involve human GLUT2 as a direct actor in 
insulin secretion process not only through its transporter- but also through 
its receptor-function in neonates. Since activating mutations of GLUT2 can 
increase insulin secretion even in absence of glucose, we propose GLUT2 as 
a candidate gene to be sequenced in CHI patients. Modulating the receptor 
function of GLUT2 without affecting its transporter function that provides 
vital sugar may be a strategy to improve or decrease insulin production in 
patients suffering from metabolic diseases.
Supported by: MREST, INSERM, CNRS, UPMC, PNRD
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OP 30 Insulin action and glucose 
uptake in vitro
178
The effect of Astaxanthin, a strong antioxidant, on reactive oxygen 
species or insulin signaling in vitro
M. Ishiki, H. Ishibashi, I. Usui, M. Urakaze, K. Tobe;
First Department of Internal Medicine, Toyama University, Toyama-shi, 
Japan.
Background and aims: Astaxanthin, a strong antioxidant, has been reported 
that it has a various effects on glucose or lipid metabolism, although precise 
mechanism(s) of its effect on signaling pathway in the cell remains to be elu-
cidated. Here we examined its effects on reactive oxygen species (ROS) or 
insulin action in vitro.
Materials and methods: We stimulated L6 muscle cell or 3T3-L1 adipocyte 
with 50 mU/ml glucose oxidase (GO) or 7.5 mM Menadione, strong ROS 
generators widely used in research, or 10 nM insulin respectively, along with 
or without 30 μM Astaxanthin. The effect of Astaxaxnthin on signaling path-
way in distinct conditions was conducted by western blotting, kinase assay or 
RT-PCR analysis.
Results: Astaxanthin enhances insulin-induced Akt phosphorylation but 
does not change IRS-1 phosphorylation. Intriguingly, it enhances GO or Me-
nadione induced Akt phosphorylation as well although both generators do 
not phosphorylate IRS-1. We next explored which factor(s) involves in regu-
lating further Akt phosphorylation by Astaxanthin. We found that PP2A ac-
tivity, a serine/threonine-protein phosphatase, which dephosphorylates Akt, 
is subtly decreased by Astaxanthin itself and slightly decreased by insulin. On 
the other hand, Astaxanthin significantly lowered PP2A activity decreased 
by insulin. We speculate that Astaxanthin regulates Akt phosphorylation in-
duced by insulin via regulation of PP2A activity and this effect requires insu-
lin signal input. Similarly, we also observed that GO or Menadione decreased 
PP2A activity, again which is lowered by Astaxanthin. Although it has been 
reported that PP2A activity is regulated through src by insulin, src inhibi-
tor does not have effect on enhanced Akt phosphorylation by Astaxanthin. 
These results suggest Astaxanthin regulates Akt phosphorylation induced by 
insulin or ROS generators through the same mechanism involving PP2A ac-
tivity. Next, we explored the effect of Astaxanthin on cell apoptosis in various 
conditions. We found that Astaxanthin strongly decreased induction of Didt3 
mRNA level or JNK phosphorylation by GO or Menadione. Furthermore, 
Astaxanthin decreased insulin induced JNK phosphorylation. Of particular 
interests to other molecules involved by insulin, shc phosphorylation is de-
creased with Astaxanthin. Finally we examined the effect of Astaxanthin on 
mitochondrial function since mitochondria plays an important role for oxi-
dative stress response in the cell. We observed that Astaxanthin induced HO 
-1, PGC-1α or PPARα mRNA level significantly respectively.
Conclusion: These results in vitro suggest Astaxanthin appears to play a 
role as `insulin enhancer` and prevent cell from apoptosis induced by ROS 
presumably by eliminating ROS with regulating of mitochondrial function. 
Regarding intriguing Astaxanthin`s impact on insulin signaling, it seems to 
promote only good effect of insulin since shc phosphorylation leading to cell 
proliferation, which could cause some diabetic complication, induced by in-
sulin is rather decreased by Astaxanthin. Similar results of the effect of Astax-
anthin on insulin or ROS generators signaling pathway could be due to the 
ROS generation by insulin as reported. Astaxanthin would be a very effective 
tool which improves not only abnormal glucose metabolism or cell apoptosis 
caused by oxidative stress but also insulin sensitivity in vivo as well.
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Endothelin-1 acutely affects glucose metabolism in human skeletal 
muscle
A. Shemyakin, F. Salehzadeh, D. Duque Guimaraes, F. Böhm, E. Rullman,  
T. Gustafsson, J. Pernow, A. Krook;
Karolinska Institute, Stockholm, Sweden.
Background and aims: Endothelin (ET)-1 is a vasoconstrictor and pro-in-
flammatory peptide that may interfere with glucose uptake. The objective of 
the study was to investigate if exogenous ET-1 affects basal forearm glucose 
uptake in patients with insulin resistance (IR) and in cultured human skeletal 
muscle cells.
Materials and methods: Nine male subjects (age 61±3) with IR (total body 
glucose uptake <5.5 mg/kg/min or HOMA index >3) participated in a pro-
tocol using saline infusion followed by ET-1 infusion (20 pmol/min) for 2 h 
into the brachial artery. Forearm blood flow was assessed with venous-oc-
clusion plethysmography. Endothelium-dependent (EDV) and -independent 
vasodilatation (EIDV) were determined. Forearm glucose uptake (FGU) was 
calculated from the arterio-venous plasma glucose concentration difference 
and plasma flow. Molecular signaling and glucose metabolism were deter-
mined in cultured skeletal muscle cells by western blot in the absence and 
presence of ET-1. Localization of ET receptors was characterized in human 
skeletal muscle tissue and cultured cells.
Results: Thirty min saline infusion did not change FGU. Infusion of ET-1 
decreased FGU by 39% (P<0.05) from 5.8±2.0 to 3.4±0.8 μmol/min x 1000ml 
after 2 hour infusion. ET-1 administration decreased basal forearm blood 
flow by 36% (28.3±2.5 at baseline vs. 18.0±3.2 ml/min x 1000ml at 2 h of ET-
1 infusion; P<0.05) and impaired both EDV (P<0.01) and EIDV (P<0.05). 
Incubation of cultured human muscle with ET-1 for 1 h increased glucose 
uptake in cells from subjects with normal glucose tolerance (NGT), but im-
paired insulin-stimulated glucose uptake in cells from IR subjects. ET-1 de-
creased insulin-stimulated Akt phosphorylation by 73% in NGT cells. ETA 
receptor expression was detected in Western blots of cell cultures and in re-
gions corresponding to the skeletal muscle cell membrane of skeletal muscle 
biopsies.
Conclusion: The study demonstrates that ET-1, in addition to attenuating en-
dothelium-dependent vasodilatation, acutely impairs forearm glucose uptake 
in subjects with IR, as well as in skeletal muscle cells from IR subjects via a 
mechanism that seems to involve reduced Akt phosphorylation. This finding 
suggests that ET-1 may contribute to the development of IR.
Supported by: HLF, NNF
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Enhanced lipid -but not carbohydrate- supported mitochondrial 
respiration in PGC-1α overexpressing mice
J. Hoeks1, Z. Arany2, E. Phielix1, M.K.C. Hesselink3, P. Schrauwen1;
1Human Biology, Maastricht University Medical Centre, Netherlands, 
2Cardiovascular Institute, Beth Israel Deaconess Medical Center, Boston, 
USA, 3Human Movement Sciences, Maastricht University Medical Centre, 
Netherlands.
Background and aims: A reduced functional capacity of skeletal muscle mi-
tochondria has been associated with type 2 diabetes mellitus. Both reduc-
tions in mitochondrial density and lower intrinsic mitochondrial function 
- i.e. respiration per mitochondria - have been reported in type 2 diabetic pa-
tients. Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha 
(PGC-1α), a master regulator of mitochondrial metabolism, has also been 
shown to be reduced in type 2 diabetes and muscle-specific overexpression of 
PGC-1α results in pronounced increase in mitochondrial density. Whether 
PGC-1α overexpression also results in intrinsic mitochondrial adaptations is 
currently unknown and subject of the present study.
Material and methods: To this purpose, we isolated skeletal muscle mito-
chondria from 10 male, ±10 week-old muscle-specific PGC-1α overexpress-
ing mice (PGC-1αTG) and 8 wild-type (WT) mice. Equal mitochondrial 
quantities were then analyzed for their oxidative capacity by high-resolution 
respirometry, fuelled by a carbohydrate (pyruvate) and lipid (palmitoyl-CoA 
plus carnitine) substrate. Additionally, we assessed mitochondrial ROS pro-
duction in isolated mitochondria by electron spin resonance (ESR) spectros-
copy and UCP3 protein levels by western blotting.
Results: As anticipated, the mitochondrial yield was ~4.6-fold higher in 
PGC-1αTG mice as compared to WT mice (40.8 ± 3.4 vs. 8.9 ± 1.6 mg/g 
muscle, respectively; p<0.001). ADP-stimulated respiration fuelled by pyru-
vate tended to be reduced in mitochondria from PGC-1αTG (229.8 ± 11.9 vs. 
260.1 ± 9.9 nmol O2/min/mg mitochondrial protein in PGC-1αTG vs. WT, 
respectively; p=0.08). Maximal uncoupled respiration, reflecting the maxi-
mal capacity of the electron transport chain was similar in both genotypes 
(396.5 ± 18.7 vs. 382.4 ± 17.0 nmol O2/min/mg mitochondrial protein in 
PGC-1αTG vs. WT, respectively; p=0.60). PGC-1αTG mice displayed a pro-
nounced augmentation of mitochondrial fat oxidative capacity, evidenced by 
an increased ADP-stimulated respiration (136.9 ± 4.3 vs. 77.4 ± 2.6 nmol 
O2/min/mg mitochondrial protein in PGC-1αTG vs. WT, respectively; 
p<0.001). Also maximal uncoupled respiration was significantly enhanced in 
PGC-1αTG upon palmitoyl-CoA plus carnitine (159.4 ± 6.2 vs. 103.8 ± 3.6 
nmol O2/min/mg mitochondrial protein in PGC-1αTG vs. WT, respectively; 
p<0.001). Mitochondrial ROS production was similar in PGC1αTG and WT 
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mice, and averaged 6705 ± 441 vs. 5933 ± 393 AU in PGC1αTG and WT, 
respectively (p=0.33). Mitochondrial UCP3 protein levels were markedly re-
duced in PGC1αTG mice as compared to WT (85.9 ± 14.2 vs. 24.8 ± 6.1 AU, 
respectively; p<0.001).
Conclusion: Besides stimulating mitochondrial proliferation in skeletal 
muscle, overexpression of PGC-1α also leads to clear intrinsic mitochondrial 
adaptations, i.e. an enhanced capacity upon fatty acids as substrates and a 
decreased UCP3 content. The low levels of UCP3 are in line with previous 
observations in endurance-trained athletes, who are also characterized by a 
high fat oxidative capacity.
Supported by: Dutch Diabetes Research Foundation
OP 31 Prevention of type 2 diabetes 
mellitus
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Vitamin D is associated with progression from impaired glucose 
regulation to type 2 diabetes in a UK multiethnic population 
D.R. Webb1, B.T. Srinivasan1, L.G. Gray2, S.A. Mostafa1, D. Talbot3,  
K. Khunti2, M.J. Davies1;
1Department of Cardiovascular Sciences, University of Leicester, 
2Department of Health Sciences, University of Leicester, 3Unilever 
Corporation, Colworth, United Kingdom.
Background: Vitamin D is implicated in the aetiology of Type 2 Diabetes 
(T2D). Cross-sectional analyses have consistently associated plasma 25-hy-
droxyVitamin D concentration (VD) with measures of insulin resistance and 
beta-cell dysfunction but prospective data relating to progression in groups 
at risk of T2D are scarce. Mixed ethnicity populations with a significant south 
Asian representation are an excellent study group as their rates of VD defi-
ciency and T2DM are particularly high. Our aim was to determine if Vitamin 
D independently predicts progression to T2D within a UK multiethnic popu-
lation with Impaired Glucose Regulation (IGR).
Materials and methods: In a population based screening study (ADDI-
TION-Leicester), people with IGR, defined as a composite of WHO catego-
rised Impaired Fasting Glycaemia (IFG) and/or Impaired Glucose Tolerance 
(IGT) are offered an annual 75g-Oral Glucose Tolerance Test and cardiovas-
cular risk assessment. Baseline and one year measurements include standard 
anthropometrics, fasting and 2-hour glucose estimates, VD (IDS 25(OH) 
D2/D3 enzyme immunoassay), together with self-reported ethnicity, physi-
cal activity (via IPAQ questionnaire) and medication use (including non-pro-
priety preparations). Those taking vitamin D or calcium supplements were 
excluded from this analysis. Baseline VD was adjusted for age, sex, waist cir-
cumference, physical activity and ethnicity. Logistic regression adjusting for 
confounders was used to identify if VD was independently associated with 
progression to T2D.
Results: 1,080 people with IGR were diagnosed from a total screened popula-
tion of 6,749 (16% prevalence). 624 randomly selected subjects (75.6% White 
European, 23.9% South Asian,) with IGR but not taking VD supplements 
had VD analysed at baseline, of which 583 (93.4%) attended for follow up 
(Median duration 425 days, inter quartile range: 393 - 462). There were no 
significant differences amongst attendees and non attendees in terms of age, 
body mass index, blood pressure or glycaemic markers. 39 (6.7%) progressed 
to T2D, 225 (38.6%) continued to have IGR and 319 (54.7%) reverted to nor-
mal glycaemic status. Mean unadjusted baseline VD concentration for South 
Asians was 21.29±12.29 ng/l vs White Europeans 58±23.88 ng/l (p<0.001). 
Waist circumference (P<0.05), sex (p<0.05), physical activity (p<0.05) and 
ethnicity (P<0.001) influenced baseline VD concentration. Subjects progress-
ing to T2D had a significantly lower adjusted baseline VD compared to those 
who continued to have IGR and who reverted to normal (T2D: 50.8±20.7 
vs. IGR: 60.5±19.6 vs. Normal: 62.8±18.9 P=0.001). Lower adjusted VD sig-
nificantly predicted progression to T2D at 12 months (Odds Ratios: 0.98, 
0.96- 0.99, P=0.001). Significantly higher progression rates were seen in the 
lowest tertile of Vitamin D compared to higher levels (11.1% vs. 5.1% vs. 4.1% 
respectively, P=0.013), this difference remained statistically significant after 
adjustment for confounders.
Conclusion: Vitamin D may play an influential role in the progression of 
metabolic disease. Our preliminary data would support the need for a ran-
domised intervention trial exploring the glucose lowering potential of VD 
replacement in multiethnic Northern latitude populations at risk of T2D.
Supported by: NovoNordisk Research Foundation
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Long-term outcomes from the PREPARE (Pre-diabetes Risk Education 
and Physical Activity Recommendation and Encouragement) 
randomised controlled trial
T. Yates1, M.J. Davies1, J. Henson2, S. Sehmi2, K. Khunti3;
1Cardiovascular Sciences, University of Leicester, 2University Hospitals 
of Leicester, NHS Trust, 3Health Sciences, University of Leicester, United 
Kingdom.
Background and aims: The PREPARE programme, a theory-driven group-
based structured education programme aimed at promoting increased am-
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bulatory activity through pedometer use, has been shown to be effective at 
promoting physical activity and improving glucose regulation in people with 
impaired glucose regulation (IGT) at 12-months. The present study aims to 
assess whether the improvements in glucose regulation were sustained at 24 
months.
Materials and methods: Overweight or obese individuals with IGT were 
recruited from population-based diabetes screening programmes, October 
2006 to April 2007, Leicester, UK. Participants were randomized to receive 
either an advice leaflet, n = 34; a standard 3-hour group-based structured 
education programme aimed at promoting physical activity (E group), n = 
31; or a 3-hour structured education programme that included enhanced 
self-regulation through personalized steps/day goals and pedometer use (EP 
group), n = 33. Both intervention conditions also received brief counselling 
at 3 and 6 months. The original study was designed to detect a 1 mmol/l dif-
ference in 2-h glucose; follow-up was conducted at 3, 6 and 12 months. As 
part of a local diabetes screening programme, participants were offered an 
additional appointment to assess their glycaemic status at 24 months. Out-
comes included fasting and 2-hour glucose, progression to type 2 diabetes 
(WHO criteria) and body weight; all clinical measurements and blood assays 
were conducted blind to allocation using standardized criteria. Differences in 
change from baseline were analyzed using ANCOVA modelling.
Results: 24-month follow-up data was available for 74 (76%) participants; 
female = 38%, South Asian ethnicity = 20%. There was no difference in demo-
graphic or biochemical measures at baseline between those who did and did 
not attend. Those in the EP group maintained a significant reduction in 2-h 
glucose (baseline = 8.7 ± 2.3 mmol/l, follow-up = 7.3 ± 2.2 mmol/l; change 
compared to the control group adjusted for baseline value = -1.5 mmol/l; 95% 
CI = -2.8 to -0.3; p = 0.01). There was a trend towards a significant reduction 
in fasting glucose in the EP group (baseline value = 5.6 ± 0.6 mmol/l, fol-
low-up = 5.4 ± 0.7 mmol/l, change compared to the control group adjusted 
for baseline value = - 0.3 mmol/l; 95% CI = - 0.7 to 0.0; p = 0.07). There was 
no difference between the control and E group in glucose levels. There was 
no difference in body weight in either intervention group compared to the 
control group. The accumulative incidence of type 2 diabetes over 24 months, 
diagnosed at any follow-up time-point, were: control = 18%, E = 16%, EP = 
6%.
Conclusion: This study suggests that a 3-hour structured education pro-
gramme aimed at promoting increased physical activity through personal-
ized pedometer use leads to sustained improvements in glucose regulation in 
overweight or obese individuals with IGT, despite no change in body weight. 
This finding highlights the importance of promoting physical activity for its 
own sake rather than the end-point of weight loss. As the PREPARE pro-
gramme is suitable for implementation within primary care, these findings 
are likely to have important implications for usual health care practice.
Supported by: Diabetes UK
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An individual lifestyle intervention program is not more effective in 
changing diabetes risk and lifestyle behaviors than providing health 
brochures: the Hoorn Prevention Study
J. Lakerveld1, S.D.M. Bot1, M.J.M. Chinapaw2, P.J. Kostense3, G. Nijpels1;
1Department of General Practice, 2Department of Public and Occupational 
Health, 3Department of Epidemiology and Biostatistics, EMGO Institute for 
Health and Care Research, Amsterdam, Netherlands.
Background and aims: Diabetes mellitus type 2 (T2DM) is associated with 
lifestyle dependent risk factors. In this study we examined the effects of a 
lifestyle intervention targeting the lifestyle behaviors physical activity, diet 
and smoking in adults at high risk of T2DM, compared to providing written 
information only.
Materials and methods: Adults (n= 622) with an increased risk of devel-
oping T2DM based on the ARIC risk score were randomly assigned to the 
intervention or control group. The intervention group received a lifestyle in-
tervention consisting of a cognitive behavioral program provided by trained 
practice nurses. In a maximum of six individual counseling sessions, followed 
by 3-monthly booster sessions by phone, motivational interviewing and prob-
lem solving treatment were used. The program focused in particular on in-
trinsic motivation to change and on self-management of problems. Primary 
outcome measure was the T2DM risk score with age standardized at 60 years. 
Secondary outcome measurements were physical activity, dietary behavior 
and smoking behavior. Results of the baseline and 6 and 12 months follow-up 
measurements are reported.
Results: 536 of the 622 participants (86.2%) completed the 6 months follow-
up measurements and 504 completed the 12 months follow-up (81.0%). The 
mean age at baseline was 43.5 years (SD 5.3) and 363 participants were female 
(58.4%). The mean baseline risk score of the total sample was 18.9% (SD 8.2) 
on the ARIC risk formula. Participants in the intervention group received 2.5 
counseling sessions on average. Regression analysis based on the intention 
to treat principle showed no significant differences in outcomes between the 
intervention and the control group at both follow-up measurements, adjusted 
for baseline (see Table 1).
Conclusion: The lifestyle intervention was not more effective at 6 and 12 
months than providing written information, in improving T2DM risk score 
or lifestyle behaviors in an at risk population.
Supported by: the Netherlands Organization for Health Research and Develop-
ment
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Effect of a diabetes prevention programme (PREDIAS) on metabolic risk 
factors and quality of life: results of a randomised controlled trial
B. Kulzer1, N. Hermanns1, D. Gorges1, P. Schwarz2, T. Haak1;
1Research Institute of Diabetes Academy Mergentheim (FIDAM), Bad 
Mergentheim, 2Department of Medicine, Gustav Carus University Dresden, 
Germany.
Background and aims: The objective of this randomized, prospective trial 
was to evaluate the efficacy of a group program (PREDIAS) aiming at lifestyle 
changes and weight reduction for diabetes prevention with regard to weight 
reduction, glycaemic parameters and quality of life.
Materials and methods: The PREDIAS program consisted of 12 lessons based 
on the Diabetes Prevention Program. All lessons were delivered in group ses-
sions. Topics of PREDIAS were: assessment of own diabetes risk, motivation for 
weight loss, behavioural strategies for weight reduction, physical exercise and 
stress management. The control group (CG) received written information about 
diabetes prevention. Risk factors like weight, fasting glucose and lipids as well as 
quality of life were assessed at baseline and at a 12 month follow-up. Quality of 
life was measured by using the Health Survey (SF12) consisting of 12 items.
Results: A total of 182 participants were randomised (age 56.3 ±10.1 yrs; 43% 
female; education 13.2 ±4.1 years; BMI 31.5 ±5.3 kg/m²; fasting glucose 105.7 
±12.8 mg/dl). At follow-up 17 participants (9.3%) were lost to follow-up. At 
12 month follow-up members of PREDIAS lost significant more weight than 
control group members (-3.8 ±5.2 vs. -1.4 ±4.0 p=.002). Fasting glucose de-
creased in PREDIAS by -4.3 ±11.3 mg/dl whereas it increased by 1.8 ±13.1 
mg/dl in the control group (p=.001). There was no significant effect of the 
prevention program with regard to lipids (Cholesterol -10.3 ±35.9 vs. -2.0 
±35.1 mg/dl p=.144; Triglycerides -35.6 ±137 vs. -2.5 ±100.3 mg/dl p=.087, 
HDL -1.3 ±6.9 vs. -2.2±9.4 mg/dl p.479) and blood pressure (systolic RR -4.6 
±19.1 vs. -1.0 ±16.7 mm Hg; diastolic RR -4.4 ±11.7 vs. 2.1 ±12.6 mm Hg). At 
baseline all study participants reported a similar quality of life score in the SF 
12 than the general population (Mental Component Summary Score (MCS) 
50.3 ±5.3 vs. 51.1 ±8.1 p=.13: Physical Component Summary Score (PCS) 
48.2 ±6.6 vs. 47.9 ±9.7 p=.36). However at 12 month follow-up members of 
PREDIAS reported a significant higher MCS than the control group (51.5 
± 3.9 vs. 49.9 ±5.4 p=.04). There was no significant effect of the prevention 
programme with regard to the PCS (50.7 ±5.6 vs. 48.3 ±5.7 p=.19).
Conclusion: The PREDIAS prevention program was able to reduce weight and 
fasting glucose significantly in a 12 month follow-up. The lifestyle change with 
regard to weight reduction was not achieved at the expense of quality of life 
aspects. Although other metabolic risk factors were considerable improved, the 
difference between members of PREDIAS and the control group failed to reach 
significance. The observed improvements with regard to metabolic risk factors 
after 12 month are comparable to meta-analytic findings about the efficacy of 
diabetes prevention programs. Since PREDIAS is a group intervention it can be 
expected that PREDIAS has the potential to provide lifestyle interventions ef-
fectively in a less expensive way than many hitherto evaluated diabetes preven-
tion programs, which were mainly conducted in individual settings.
Supported by: Roche Diagnostics
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Effect of pioglitazone on beta cell function and adipocyte insulin 
resistance in impaired glucose tolerance: results form ACTNOW 
D. Tripathy, M.-A. Baneri, G. Bray, T. Buchanan, S. Clemment, M. Nicolas, P. 
Reaven, D. Schwenke, F. Stenz, S. Mudaliar, R.R. Henry, A. Kitabchi, R. DeFronzo;
Diabetes, Medicine, University of Texas Health Science Center, San Antonio, 
USA.
Background and aims: Individuals with impaired glucose tolerance (IGT) are 
maximally insulin resistant and have lost 70-80% of their beta cell function. 
Thiazolidinediones have been shown to delay/prevent onset of diabetes. ACT 
NOW is a randomized double-blind, placebo-controlled study to examine 
whether pioglitazone (PIO) can prevent/delay development of type 2 diabetes 
mellitus (T2DM). The aim of this study was to examine whether pioglitazone 
prevents/delays onset of diabetes by improving beta cell function.
Materials and methods: 602 IGT subjects (FPG =105, 2-h PG [OGTT]=168 
mg%;) were randomized to PIO (45 mg/day) or placebo (PLAC) and followed 
for 2.8 years; 427 subjects returned for final study visit. Indices of insulin secre-
tion and insulin sensitivity were derived from the plasma glucose, insulin, and 
C peptide concentrations during the OGTT. The acute insulin response (AIR0-
10 min) and insulin sensitivity (SI) also were measured with frequently sampled 
intravenous glucose tolerance test (FSIVGTT) in a subset. Adipocyte insulin 
resistance was calculated as the fasting plasma FFA x fasting plasma insulin.
Results: 50 PLAC-treated subjects developed diabetes versus 15 PIO-treated 
subjects (hazard ratio=0.30, 95% CI=0.11- 0.54, p<0.00001). Pioglitazone 
therapy significantly reduced fasting and 2-h plasma glucose. Pioglitazone 
improved Matsuda insulin sensitivity index (MI) (4.3 ± 0.3 to 7.7 ± 0.3, 
p<0.0005). The insulin secretion insulin resistance index ΔI0-120/ΔG0-120 x MI 
(3.4 ± 0.3 vs 5.4± 0.3, p<0.0005) improved in PIO treated subjects. In contrast 
no significant changes in Matsuda Index (4.3 ± 0.3 to 5.2 ± 0.3, p=ns) or ΔI0-
120/ΔG0-120 x MI (3.8 ± 0.3 vs 4.2 ± 0.2, p=ns) were observed in subjects treated 
with PLAC. Subjects treated with PIO also had significantly greater insulin 
secretion/insulin resistance index from FSIVGTT (Si x AIR) than PLAC 
(1186 ± 113 vs 832 ± 57, p=0.005). Pioglitazone reduced basal adipocyte in-
sulin resistance index (5.96 ± 0.4 to 3.49 ± 0.4 p < 0.005) while no change in 
was noted in IGT patients on PLAC (5.97 ± 0.4 to 5.57 ± 0.4, p =ns).
Conclusion: Pioglitazone (1) improved β-cell function, and insulin sensitiv-
ity in IGT subjects, and (2) improved adipocyte insulin resistance. The im-
provement in beta cell function and adipocyte insulin sensitivity could repre-
sent fundamental mechanisms by which pioglitazone reduces the conversion 
of IGT to T2DM.
Supported by: Takeda Pharmaceuticals
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Lifetime health economic benefits of type 2 diabetes prevention in high 
risk subjects in an Australian setting: an updated analysis based on the 
results of the Diabetes Prevention Program and Diabetes Prevention 
Program Outcomes Study
A.J. Palmer, D.M.D. Tucker;
Department of Health Economics, Menzies Research Institute, Hobart, 
Tasmania, Australia.
Background and aims: Metformin and intensive lifestyle interventions (ILI) 
were shown to reduce incidence of type 2 diabetes (T2D) versus standard 
care in overweight or obese subjects with impaired glucose tolerance (IGT) in 
the Diabetes Prevention Program (DPP) trial and Diabetes Prevention Pro-
gram Outcomes Study (DPPOS), a total follow-up of 10 years. Our aim was 
to project the lifetime clinical and health economic outcomes to be expected 
from T2D prevention in high-risk subjects managed with standard care, met-
formin or ILI, based on the latest published results from the DPP+DPPOS.
Materials and methods: A semi-Markov, 2nd-order Monte Carlo computer 
simulation model was developed to project the 10-year clinical and resource 
utilization results of the DPP+DPPOS to patient lifetimes. Four health states 
were modelled: normoglycaemia (NG); IGT; T2D and dead. Subjects started 
in IGT and progressed to T2D or NG, at rates dependent on the treatment 
received. State-specific mortality rates for NG, IGT or T2D were used. We 
incorporated direct medical costs (from official Australian published sources 
and the reimbursement perspective) and Australian health utility and prob-
ability data. For each treatment arm, we calculated years free of T2D, cumu-
lative incidences of T2D, non-discounted life expectancies, quality-adjusted 
life years (QALY), total lifetime costs and incremental costs per QALY gained 
versus standard care. Costs and QALYs were discounted at 5% annually. Uni-
variate and probabilistic sensitivity analyses were performed.
Results: For standard care, metformin or ILI, mean (standard deviation) 
number of years free of T2D were 9.47 (0.08), 11.98 (0.09), 15.17 (0.11) years 
respectively. Cumulative incidences of T2D were 89.7% (0.2), 83.7% (0.2) and 
73.4% (0.3%) for standard care, metformin or ILI respectively. Mean life ex-
pectancies from baseline age of 50 years were 27.64 (0.14), 27.95 (0.12), 28.33 
(0.11) years for standard care, metformin or ILI respectively. Delayed onset of 
T2D led to QALY-gained of 0.12 (0.04) and 0.38 (0.05) years for metformin 
or ILI versus standard care, respectively. Total lifetime cost increases of $1,116 
(4,338) per patient were projected for metformin versus standard care, and cost 
savings of $282 (4,222) for ILI versus standard care. ILI was therefore dominant 
to standard care, with both improvements in clinical outcomes and overall cost 
savings. Incremental costs per QALY gained for metformin versus standard 
care were $8,757. Probability of acceptance at a typical Australian willingness to 
pay threshold of $50,000 were 85% and 100% for metformin or ILI respectively. 
Results were most sensitive to probabilities of developing T2D, relative risks of 
mortality in each health state, and costs of implementing the interventions.
Conclusion: Based in the latest published data from the DPP+DPPOS, sub-
stantial improvements in lifetime clinical outcomes can be expected in high 
risk subjects treated with metformin or ILI to delay or prevent the onset of 
T2D. Prevention of T2D in this group of subjects is good value for money, 
and may even lead to long term cost savings in an Australian setting.
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The effect of combining angiotensin receptor blocker and direct renin 
inhibitor on albuminuria in type 2 diabetic patients with nephropathy
V.I. Pankiv1, N.V. Pasiechko2, I.V. Pankiv2;
1Preventive Endocrinology, Centre of Endocrinology, Kyiv, 2Endocrinology, 
Gorbachevsky State Medical University, Ternopil, Ukraine.
Background and aims: Angiotensin receptor blocker (ARB) and direct renin 
inhibitor (DRI) have been shown to reduce albuminuria and preserve renal 
function in patients with diabetic nephropathy. Both agents are thought to 
confer renal protection via blockade of renin-angiotensin-aldosterone system 
(RAS). Simultaneous blockade of RAS at different levels with ARB and DRI 
may have synergistic anti-albuminuric effect compared to monotherapy. The 
study aims to compare the effect of combining Losartan and Aliskiren with 
that of administering either drug alone on 24-hour urine albumin excretion 
(UAE) in patients with type 2 diabetes mellitus (DM) with nephropathy.
Materials and methods: Forty-eight patients (mean age 58±9.2 years, 16 fe-
males) were prospectively studied. After a 4-week washout period, 23 patients 
received Losartan 100 mg once daily and 25 received Aliskiren 150 mg for 8 
weeks. Following this, all 48 patients received a combination of Aliskiren 150 
mg and Losartan 100 mg for 8 weeks, followed by a double dose of both drugs 
for another 8 weeks. Blood pressure (BP), glycosylated hemoglobin (HbA1c) 
and UAE were monitored.
Results: Baseline characteristics (age, BMI, duration of DM, HbAlc, BP, cre-
atinine clearance and UAE) were similar in both groups. There was a sig-
nificant reduction in mean (95% CI) UAE after 8 weeks of monotherapy 
[17.0% (4.2% to 31.8%) p=0.002]. The reduction in UAE was significant in 
patients treated with Losartan [23.8% (2.4% to 45.6%) p=0.01] but failed to 
reach statistical significance for patients treated with Aliskiren [11% (-7% to 
29.1%) p= 0.076]. Mean BP reduction was not significantly different between 
these 2 groups (p= 0.66). After 16 weeks of combination therapy, there was 
further 11.4% reduction in UAE [(-8% to 31%), p = 0.018] while mean BP 
and HbA1c were not statistically different at the beginning (week 8) and end 
(week 24) of the combination therapy.
Conclusion: The study showed superior effect of Losartan (100 mg) over Al-
iskiren (150 mg) in reducing albuminuria in patients with diabetic nephropa-
thy. The combination of both drugs showed further benefit in albuminuria 
reduction independent of BP control.
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Glycaemic and blood pressure variability correlates with cardiovascular 
factors in type 2 diabetic patients
A. Di Flaviani1, F. Picconi1, I. Malandrucco1, I. Giordani1, P. Di Stefano2,  
P. Maggio3, F. Passarelli3, F. Farina3, G. Frajese1, S. Frontoni1;
1University of Rome Tor Vergata, 2Medtronic Italia spa, 3S. Giovanni Calibita 
Fatebenefratelli Hospital, Rome, Italy.
Background and aims: The correlation between Glycemic and Blood Pres-
sure variability (GV and BPV) and cardiovascular risk has not been fully ad-
dressed.
Materials and methods: Therefore, the relationships between GV and BPV 
on one side and intima-media thickness (IMT), left ventricular mass index 
(LVMI), flow-mediated dilation (FMD) on the other side were evaluated in 
26 DM2 patients (age 59±10 years; diabetes duration 53±58 months; HbA1c 
6.7±1.3%) on diet and/or metformin, no hypotensive treatment or complica-
tions. All subjects underwent 24-h continuous glucose monitoring: GV was 
calculated as Mean Amplitude Glucose Excursion (MAGE), Coefficient of 
Variation (CV), CONGA-1 and 2. From 24-h BP monitoring, CV systolic and 
diastolic BP (CV SBP and DBP) and the delta between nocturnal and diurnal 
BP [>10%: Dippers (D); <10%: Non-Dippers (ND)] were also calculated.
Results: IMT and LVMI were significantly increased in ND vs. D (0.77 ± 0.08 
vs. 0.68 ± 0.13; p= 0.04 and 62 ± 23 vs. 50 ± 19 p= 0.047). All patients displayed 
a negative correlation between LVMI and delta SBP (r=-0.48 p= 0.02); while a 
positive correlation was observed with CONGA 1 and 2 (r= 0.54 p=0.005 and 
r= 0.65 p=0.0005, respectively). A negative correlation was observed between 
IMT and delta SBP and DBP (r= -0.42 p= 0.036 and r= - 0.54 p= 0.005, respec-
tively) while such correlation was absent with GV indexes. Finally a negative 
correlation was found between CONGA 1 and FMD (r= -0.42 p= 0.032).
Conclusion: Our data show that glucose excursions and BP variability signif-
icantly impact on endothelial function and cardiovascular damage in patients 
with short duration of disease and optimal metabolic control.
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Different impact of type 2 diabetes mellitus and essential hypertension 
on aortic, carotid and peripheral vascular stiffness
G.A. Daniele1, L. Pucci1, D. Lucchesi1, R.M. Bruno2, L. Ghiadoni2, E. Storti1, 
E. Russo1, C. Bianchi1, S. Taddei2, R. Miccoli1, S. Del Prato1, G. Penno1;
1Endocrinology and Metabolism, 2Internal Medicine, University of Pisa and 
Azienda Universitaria Ospedaliera Pisana, Pisa, Italy.
Background and aims: Diabetes and hypertension both accelerate vascular 
aging. Arterial stiffness an emergent biomarkers of cardiovascular disease, in-
creases with age and in the presence of main cardiovascular disease risk fac-
tors, such as hypertension, diabetes and lipid disorders. Pathologic stiffening 
of large arteries with advancing age and risk factor exposure predominantly 
involves the elastic aorta and carotid arteries. Aim of this study was to evalu-
ate the impact of type 2 diabetes, hypertension, and their combination on 
aortic, carotid and peripheral arteries stiffening.
Materials and methods: A total of 114 subjects were enrolled: 18 normoten-
sive subjects (NT), 37 hypertensive individuals (HT), 20 diabetic normoten-
sive (DMNT), and 39 diabetic hypertensive (DMHT). Applanation tonom-
etry was used to measure aortic (carotid to femoral) and peripheral (carotid 
to radial) pulse wave velocity (aPWV and pPWV, respectively). Common 
carotid intima-media thickness (IMT) and carotid diameter were obtained 
by B-mode ultrasound image sequences, using the real-time computerized 
contour-tracking system “Carotid Studio”. Common carotid stiffness (CCS) 
was determined from stroke change in lumen area and local pulse pressure 
obtained by applanation tonometry.
Results: Hypertensive groups (HT and DMHT) have similar systolic and di-
astolic blood pressure values and lipid parameters; diabetic subjects (DMNT 
and DMHT) have similar HbA1c levels and lipid profile. Peripheral pulse wave 
velocity (pPWV) was superimposable in all groups. On the contrary, aPWV 
significantly increased from NT (7.2±1.0 m/s) to HT (8.1±1.4 m/s) and DMNT 
(8.2±0.8 m/s), reaching the highest values in the DMHT group (10.6±1.9 m/s; 
Kruskal-Wallis, p<0.001). Common carotid stiffness (CCS) behaved similarly 
(NT 6.0±0.7 m/s, DMNT 6.5±1.2 m/s, HT 6.6±1.2 m/s, DMHT 7.3±1.2 m/s; 
Kruskal-Wallis, p<0.01). The presence of hypertension carried a higher risk of 
having increased (above the median value) aPWV (OR: 6.9; 5-95% confidence 
interval: 1.9-24.8), common carotid stiffness (OR: 2.8; 5-95%CI: 1.-1-7.4), and 
carotid diameter (OR: 3.9; 5-95%: 1.4-10.6), regardless of age and diabetes, 
while the differences were not significant for pPWV and IMT. The presence of 
diabetes carried a higher risk of having increased (above the median) aPWV 
(OR: 9.6; 5-95%CI: 3.3-27.2), and IMT (OR:2.7; 5-95%CI: 1.1-6.6), , regardless 
of age and hypertension, while the differences were not significant for pPWV, 
carotid diameter and common carotid stiffness.
Conclusion: Both type 2 diabetes and hypertension are associated with in-
creased aortic PWV, and their combination induces an even greater aortic 
stiffening. Hypertension is characterized by vascular stiffening at both the 
aortic and carotid level. In contrast, type 2 diabetes is associated only with 
increased aortic PWV. The two conditions also differ for carotid remodeling 
characteristics, since hypertension determines carotid dilation while type 2 
diabetes is associated with carotid wall thickening.
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Risk factor control in patients with type 2 diabetes and coronary heart 
disease
A.-M. Svensson1, S. Gudbjörnsdottir2, B. Eliasson2, K. Eeg-Olofsson2,  
B. Zethelius3, J. Cederholm3;
1Center of Registers Västra Götaland, Göteborg, 2University of Gothenburg, 
3Uppsala University, Sweden.
Background and aims: Patients with type 2 diabetes have a markedly in-
creased risk of coronary heart disease (CHD), and the long-term prognosis 
after a CHD event is worse in diabetic than in non-diabetic patients. We as-
sessed risk factor control in patients with type 2 diabetes and CHD from the 
Swedish National Diabetes Register (NDR).
Materials and methods: Cross-sectional study of patients with first incidence 
of CHD (myocardial infarction, unstable angina, percutaneous coronary in-
tervention and/or coronary artery bypass graft) 1-2 years before examination, 
aged 18-79 years: 666 examined in 2002, 1414 examined in 2005, and 2557 
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examined in 2008. HbA1c analyses were quality assured nationwide by regu-
lar calibration. Patients with LDL-cholesterol (LDL-C) data available were 
around 70% of all due to missing data. Significance was analysed by GLM 
regression, adjusting for age and sex.
Results: As shown in Table 1, mean HbA1c, blood pressure (BP) and LDL-C 
decreased across the 6-year period from 2002 to 2008, while mean BMI was 
unchanged and as high as 30 kg/m2. Achievement of the treatment targets 
HbA1c <7%, BP <130/80 mmHg and LDL-C <2.5% improved considerably 
across the 6-year period, and were 56%, 48% and 79% in 2008. Patients ex-
amined in 2008 within intervals of HbA1c <7%, 7.0-7.9% and >8% were 56%, 
27% and 17%, and those within intervals of systolic BP (SBP) <130, 130-139 
and >140 mmHg were 36%, 26% and 38%. Use of antihypertensive drugs, as-
pirin (ASA), and especially lipid-lowering drugs increased across the 6-year 
period, and were as high as 96%, 87% and 90% in 2008. A high prevalence 
of adverse lifestyle characteristics prevailed during the 6-year period, and in 
2008 the frequency of obesity (BMI >30 kg/m2) was 44%, while 45% per-
formed physical activity <3 times/week, and 20% of patients with age <65 
years were smokers.
Conclusion: Control of HbA1c, BP and LDL-C improved significantly across 
the 6-year period from 2002 to 2008. Although fewer patients available in 
2002, significant improvement was also seen for BP and LDL-C from 2005 
to 2008. In 2008, treatment targets were achieved by more than half of pa-
tients for HbA1c, and by 70% for LDL-C. Although barely half achieved BP 
<130/80 mmHg, only one-third had systolic BP >140 mmHg. However, a 
high prevalence of adverse lifestyle characteristics prevailed. Evidence-based 
therapy with professional lifestyle intervention seems necessary for further 
improvement in secondary prevention. 
Table 1. Risk factors in patients with type 2 diabetes and CHD
Examination year P trend P 2005
2002 2005 2008 2002-08 vs. 2008
Numbers 666 1414 2557
Men, % 70 68 72 <0.01 <0.01
Age (mean), years 68 (8) 67 (8) 68 (8) n.s. n.s.
Duration (mean), years 10 (7) 9 (8) 9 (7) <0.01 n.s.
HbA1c (mean), % 7.4 (1.3) 7.1 (1.1) 7.1 (1.1) <0.001 n.s.
HbA1c <7.0, % 41.9 54.4 55.8 <0.001 n.s.
HbA1c 7.0-7.9 / >8.0, % 33 / 25 27 / 18 27 / 17 <0.001 n.s.
BP (mean), mmHg 139 / 76 138 / 75 134 / 74 <0.001 <0.001
BP <130/80, % 33.3 39.6 48.1 <0.001 <0.001
SBP <130 / 130-139 / >140 24/18/58 29/22/49 36/26/38 <0.001 <0.001
LDL-C (mean), mmol/l 2.6 (0.9) 2.3 (0.8) 2.2 (0.8) <0.001 n.s.
LDL-C <2.5, % 48.5 65.4 69.6 <0.001 <0.05
BMI (mean), kg/m2 29.6 (4.8) 29.6 (4.8) 29.7 (4.6) n.s. n.s.
Obesity (BMI >30), % 41.1 42.0 43.6 n.s. n.s.
Phys. activity <3 per w, % - 53.5 44.5 - <0.001
Smoker + age <65 yrs, % 16.7 18.9 20.2 n.s. n.s.
Antihypertensive drugs, % 88.5 94.4 95.7 <0.001 n.s.
Lipid lowering drugs, % 73.9 85.9 90.2 <0.001 <0.001
ASA, % 82.7 89.3 87.0 <0.001 n.s.
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Type 2 diabetes significantly modulates the impact of low left ventricular 
ejection fraction on the risk of cardiovascular events
S. Greber1, C.H. Saely1,2, P. Rein1,2, A. Vonbank1,2, T. Gansch1, C. Boehnel1,2, 
V. Jankovic1,2, H. Drexel1,2;
1Vorarlberg Institute for Vascular Investigation and Treatment, Feldkirch, 
Austria, 2Private University of the Prinicpality of Liechtenstein, Triesen, 
Liechtenstein.
Background and aims: The prevalence of coronary artery disease and of con-
gestive heart failure is high in patients with diabetes. In the present study we 
aimed at prospectively investigating the impact of the left ventricular ejec-
tion fraction (LVEF) and of angiographically verified coronary artery disease 
(CAD) on the risk of cardiovascular events in patients with type 2 diabetes 
(T2DM) and in non-diabetic subjects.
Materials and methods: Cardiovascular events were recorded over 8 years 
in 629 consecutive patients undergoing coronary angiography for the evalu-
ation of established or suspected stable CAD. At the baseline angiography, 
significant CAD was diagnosed in the presence of significant coronary sten-
oses with lumen narrowing ≥50%, and the baseline LVEF was determined 
invasively by ventriculography.
Results: The baseline prevalence of significant CAD was higher (68.6% vs. 
55.5%; p = 0.006) in patients with T2DM (n = 137) than in non-diabetic sub-
jects (n = 492); the baseline LVEF was similar in these two patient subgroups 
(65±15% vs. 67±15%; p = 0.253). Prospectively, significant CAD (HR = 2.07 
[1.50-2.88]; p <0.001) and the LVEF (standardised HR = 0.79 [0.71-0.88]; p 
<0.001) after multivariable adjustment both proved significantly predictive 
of caridiovascular events in a mutually independent manner. The incidence 
of vascular events was significantly higher in patients with T2DM than in 
non-diabetic subjects (43.8% vs. 30.1%; p = 0.003). In analyses with respect 
to the diabetes status, the LVEF strongly and significantly predicted cardio-
vascular events in non-diabetic subjects (HR = 0.72 [0.62-0.82]; p <0.001) but 
not in patients with T2DM (1.00 [0.75-1.22]; p = 0.711). An interaction term 
LVEF*T2DM was significant (p = 0.047), indicating that the cardiovascular 
risk conferred by a low LVEF was significantly higher in non-diabetic sub-
jects than in patients with T2DM. The presence of significant CAD proved 
significantly and independently predictive of vascular events both in non-
diabetic subjects and in patients with T2DM (HRs 1.84 [1.26-2.67]; p = 0.001 
and 2.45 [1.18-5.06]; p = 0.016, respectively).
Conclusion: From the results of this 8-year prospective cohort study we con-
clude that T2DM significantly modulates the cardiovascular risk conferred by 
a low left ventricular ejection fraction.
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Predictors of incident heart failure in community-dwelling older adults 
with diabetes mellitus
S. Akter1,2, K. Karatzidou3, C. Adamopoulos3, M. Mujib4, Z. Hassan5,  
L. Ali1,2, A. Ahmed6;
1Department of Biochemistry and Cell Biology, BIRDEM, Dhaka, 2Dept of 
Biochemistry, Bangladesh Institute of Health Sciences, Dhaka, Bangladesh, 
3Papageorgiou General Hospital, Thessaloniki, Greece, 4University of 
Alabama at Birmingham, Birmingham, USA, 5Department of Physiology & 
Molecular Biology, BIRDEM, Dhaka, Bangladesh, 6Medicine, University of 
Alabama at Birmingham and VA Medical Center, Birmingham, USA.
Background and aims: Type-II diabetes mellitus (DM) is a major risk factor 
for heart failure (HF). However, little is known about the risk factors for HF 
in those with DM. We used public-use copies of the Cardiovascular Health 
Study (CHS) datasets, obtained from the United States National Institutes of 
Health, to examine the predictors of HF in older adults with DM.
Materials and methods: Of the 5795 CHS participants, ≥65 years, 5461were 
free of baseline HF. Of these, 862 had baseline DM (based on past history and 
baseline fasting blood glucose ≥126 mg/dL) and 963 had baseline coronary 
artery disease (CAD). Multivariable-adjusted Cox regression models were 
used to determine predictors of centrally-adjudicated incident HF among 
those with DM during over 12 years of median follow-up. Considering that 
DM is considered CAD-equivalent, we repeated our analysis in a cohort with 
baseline CAD.
Results: Participants with DM had a mean (±SD) age of 73 (±5) years, 50% 
were women, and 24% were African American. Those with CAD had a mean 
(±SD) age of 74 (±6) years, 45% were women, and 15% were African Ameri-
can. Incident HF occurred in 272 (32%) and 324 (34%) of participants with 
DM and CAD respectively. Significant predictors of incident HF among those 
with DM and in those with CAD are presented in Table. 
Conclusion: Community-dwelling older adults with DM had similar inci-
dence and risk factors for new-onset HF as those with baseline CAD. Man-
agement of modifiable risk factors such as smoking and systolic blood pres-
sure may provide opportunities for reducing risk of incident HF among both 
high-risk populations.
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Table. Predictors of incident heart failure in older adults with diabetes mel-
litus (DM) and without DM but with coronary artery disease (CAD)
Variable With baseline DM With baseline CAD
Adjusted HR 
(95% CI)
P value Adjusted HR 
(95% CI)
P value
Age 75 year and older 1.53 (1.8-2.00) 0.001 1.77 (1.41-2.23) <0.001
Female 0.89 (0.69-1.15) 0.383 0.71 (0.55-.91) 0.008
Current smoking 1.55 (1.02-2.36) 0.038 1.77 (1.24-2.51) 0.001
Systolic blood pressure, 
mm Hg
1.02 (1.02-1.03) <0.001 1.01 (1.00-1.01) 0.005
Baseline coronary 
artery disease
2.20 (1.68-2.88) <0.001 --- ---
Baseline diabetes mel-
litus
--- --- 1.71 (1.22-2.39) 0.002
Serum creatinine, 
mg/dL
1.25 (1.06-1.48) <0.001 --- ---
Serum uric acid,  
mg/dL
1.13 (1.04-1.23) 0.003 1.14 (1.06-1.23) 0.001
Left ventricular systolic 
dysfunction
2.13 (1.50-3.04) <0.001 1.54 (1.17-2.02) 0.002
Supported by: US NIH/NHLBI
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A comparison of performance from using two HbA1c cut-points (a ‘rule-
in, rule-out’ spectrum) and one HbA1c cut-point to detect type 2 diabetes 
in a multi-ethnic cohort
S.A. Mostafa1, K. Khunti2, D.R. Webb1, B. Srinivasan1, L.G. Gray2, M.J. Davies1;
1Diabetes Research Unit, 2Health Sciences, University of Leicester, United 
Kingdom.
Background and aims: HbA1c≥ 6.5% has been recommended as a diagnos-
tic tool to detect people with Type 2 Diabetes Mellitus (T2DM). However, us-
ing HbA1c≥ 6.5% leads to discordance in people detected with T2DM from 
using an oral glucose tolerance test (OGTT). Therefore, using two HbA1c 
cut-points has been suggested to reduce the number of false positives/nega-
tives: the first to ‘rule out’ T2DM (HbA1c ≤5.5%) and the second to ‘rule 
in’ T2DM (HbA1c≥ 7.0%). Those with HbA1c 5.6-6.9% could have T2DM, 
especially if 6.5-6.9%, and may need a further glucose test for diagnosis. The 
aim of this study was to compare detection rates for T2DM using (a) HbA1c≥ 
6.5% or (b) the ‘rule-out, rule in spectrum’ and to determine the optimal cut-
points in our multi-ethnic cohort.
Materials and methods: Analysis of 8696 previously undiagnosed primary 
care adults aged 40-75 years from the LEADER cohort, a combination of two 
systematic screening programmes. Participants underwent an OGTT and 
had HbA1c measured from 2002-2008 in Leicestershire, UK. T2DM was di-
agnosed according to WHO 1999 criteria.
Results: Use of an OGTT detected 291 (3.3%) people with previously 
undiagnosed T2DM. Using HbA1c≥6.5% to detect T2DM produced a 
sensitivity/specificity/positive predictive value (PPV)/negative predic-
tive value (NPV) of 62.1%/97.7%/44.8%/98.9% in white Europeans and 
78.9%/92.8%/36.2%/98.8% in south Asians. Using ROC curve analysis, the 
single optimal HbA1c cut-point for detecting T2DM was ≥ 6.1%, (sensi-
tivity/specificity: 83.0%/87.8%) in white Europeans and ≥ 6.3% (sensi-
tivity/specificity: 87.9%/85.5%) in south Asians. ‘Rule-out, rule-in’ spec-
trum: HbA1c ≤5.5% produced a high sensitivity/negative predictive value 
(NPV) of 98.4%/99.9% in white Europeans and 98.9%/99.7 in south Asians. 
HbA1c≥ 7.0% produced high specificity of 99.6% and 98.8% in white Euro-
peans and south Asians respectively, however produced lower PPV of 76.0% 
and 68.1% respectively. Furthermore, 5115 (58.8%) people in the total co-
hort had HbA1c 5.6-6.9%, and 4793 (55.1%) people with HbA1c 5.6-6.4%. 
Using an alternate higher ‘rule-out’ cut-point of HbA1c ≤5.8% maintains a 
high sensitivity/NPV of 91.8%/99.6% in white Europeans and 97.9%/99.8% 
in south Asians; a lower ‘rule-in’ cut-point of HbA1c≥ 6.8% has a specifi-
city/PPV of 99.4%/69.8% and 97.2%/53.6% in white Europeans and south 
Asians. The remaining spectrum of HbA1c 5.9-6.7% detects fewer people, 
n=2505 (28.2%).
Conclusion: The optimal HbA1c cut-point to detect T2DM studied was low-
er than HbA1c of 6.5% in both ethnic groups. Using a two cut-point ‘rule-in, 
rule out’ spectrum to detect T2DM appears to have better performance than 
using HbA1c≥ 6.5% in isolation in our multi-ethnic cohort. However, as over 
50% of this cohort had HbA1c values between 5.6-6.9%, many people may 
require a subsequent glucose test on a second visit, involving fasting, which 
could be impractical to implement. Within our cohort, a better two cut-point 
spectrum of HbA1c ≤5.8% and HbA1c≥ 6.8% maintains high sensitivity/spe-
cificity/NPV and a reasonable PPV. Furthermore, using these cut-points, ap-
proximately one-quarter of the cohort would require a subsequent glucose 
test, which is more feasible to implement in clinical practice. 
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Moving to the new HbA1c diagnostic criteria has a deep impact on 
prevalence of gluco-metabolic abnormalities among high-risk Spanish 
population
J.J. Cabre1, B. Costa1, F.X. Cos1, F. Barrio1, J.L. Piñol1, C. Castell2, J. 
Lindström3, N. Barengo4, J. Tuomilehto4, DE-PLAN-CAT Research Group;
1Primary Health Care Division, Jordi Gol Primary Care Research Institute, 
Reus & Barcelona, 2Department of Public Health, Barcelona, Spain, 3Diabetes 
Prevention Unit, Helsinki, 4Department of Public Health, Helsinki, Finland.
Background and aims: Diabetes screening in risk individuals is usually based 
on the detection of hyperglycemia through an increase in fasting plasma glu-
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cose (FPG) or 2-hour post-load glucose (2hPG) in the oral glucose tolerance 
test (OGTT). The American Diabetes Association (ADA) has recently au-
thorized the use of A1C as a diagnostic criteria for diabetes and other glucose 
abnormalities. To investigate the concordance between conventional 2hPG 
and/or FPG diagnostic criteria and the proposed new A1C criteria for dia-
betes, results from an active public health program (DE-PLAN) in Catalonia 
(Spain) were used.
Materials and methods: Non-diabetic individuals aged 45-75 y. were evalu-
ated by general practitioners in 18 primary health care centres. They have 
been first screened using the FINDRISC questionnaire. A 2-hour oral glu-
cose tolerance test plus A1C test (NGSP/DCCT rules) were simultaneously 
performed yearly.
Results: By January 2010 a total of 2287 blood test results have been recorded 
corresponding to 1144 subjects: 65% women; age=61.4 years; BMI=29.9 kg/
m²; 68% with a FINDRISC score >12 points (moderate, high or very high 
risk). Diagnoses by 2hPG were: 1482 (64.8%) normal glucose tolerance (95% 
CI: 62.8-66.7), 609 (26.6%) prediabetes (20.7-25.6) and 196 (8.6%) diabe-
tes (7.7-11.2). FPG-based findings were: 1572 (68.7%) normal FPG (66.8-
70.6), 652 (28.5%) prediabetes (26.7-30.4) and 63 (2.8%) diabetes (2.2-3.5). 
Findings by A1C were: 1906 (83.4%) normal A1C [<5.7%] (81.7-84.8), 350 
(15.3%) prediabetes [5.7-6.4%] (13.9-16.8) and 31 (1.3%) diabetes [>6.5%] 
(0.9-1.9). Among the 201 diabetic diagnoses according to either the 2hPG 
or the A1C criteria, only 26 (12.9%) were classified as diabetic with both 
criteria (2hPG and A1C, k value=0.29). Likewise, only 19 out of 75 diabetic 
diagnoses according to either the FPG or the A1C criteria (25.3%) were clas-
sified as diabetic with both FPG and A1C (k=0.39). No differences in main 
phenotypes (age, sex, BMI, WC and risk score) were found between subjects 
who remained and did not remain diabetic by both criteria glucose and A1C. 
The overlap index between prediabetes diagnoses (2hPG / FPG vs. A1C) was 
20.3%/27.2% (k=0.16/0.28, respectively).
Conclusion: To apply the new A1C diagnostic criteria evidenced a dramatic 
decrease in diabetes prevalence among this high-risk population by the FIN-
DRISC. Overall, prediabetes and diabetes-specific concordances were very 
poor. A1C alone seems to be not advisable to screen for gluco-metabolic ab-
normalities among the high-risk Spanish population.
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Comparison of HbA1c and OGTT in the diagnosis of diabetes in a high-
risk population. The HUNT-DE-PLAN Study, Norway
K. Midthjell1, C.M.Y. Lee2, C. Platou1, S. Colagiuri2;
1Institute of Community Medicine and General Practice, HUNT Research 
Centre, Levanger, Norway, 2Boden Institute of Obesity, Nutrition and 
Exercise, Sydney, Australia.
Background and aims: Due to more standardized methods of measuring 
HbA1c and reports showing an association between diabetes complications 
and HbA1c in persons without manifest diabetes, an HbA1c of 6.5% has been 
introduced as a diagnostic criterion for diabetes. Those with HbA1c 6.0-6.4% 
are recommended preventive measures. We wanted to compare the OGTT 
and HbA1c diagnostic criteria in persons defined at increased risk of dia-
betes.
Materials and methods: The third HUNT Survey was performed in 2006-
2008, examining 50406 persons >20 years of age (54% of those invited). The 
population is almost exclusively Caucasian. All participants were asked to 
complete the FINDRISC questionnaire. In all 9.9% had a FINDRISC score of 
15 or more corresponding to at least a 30% risk for diabetes in the next ten 
years. All defined in risk were invited to a follow-up study including an OGTT 
and HbA1c measurement. Glucose was measured in serum and HbA1c by a 
standard and continuously validated method, both at Levanger Hospital.
Results: In total 2645 persons participated in this follow-up study. The OGTT 
identified 254 (9.6%) with diabetes, 446 (16.9%) with impaired glucose toler-
ance (IGT) and 217 (8.2%) with impaired fasting glucose (IFG). Mean HbA1c 
(SD) was 6.4 (0.7) for those with diabetes, 5.8 (0.5) for IGT and 5.8 (0.4) for 
IFG. The proposed new HbA1c diagnostic criterion defined 170 (6.5%) with 
diabetes and 17% (450) in the 6.0-6.4% zone. Of the 170 with HbA1c defined 
diabetes, 100 had OGTT defined diabetes and 167 of the 450 in the HbA1c 
risk zone had IGT/IFG.70 people had diabetes and 283 persons were at in-
creased risk only by the HbA1c criterion, compared with to 154 with diabetes 
and 496 with IGT or IFG by the OGTT. Among those with diabetes according 
to WHO criteria 60.7% had an HbA1c below 6.5%.
Conclusion: The overlap between the 1999 WHO criteria and the proposed 
new HbA1c criterion for diabetes was poor in this geographically defined 
Caucasian population. The new criteria do not strictly define a risk zone, but 
the overlap between those with HbA1c 6.0-6.4% and those with IGT/IFG 
was also poor.
Supported by: Norw. Health Directorate, DE-PLAN/EU, Health and Rehabil., 
GSK Norway
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Diagnosis of abnormal glucose levels in patients at high risk for the 
development of diabetes: A comparison of the oral glucose tolerance test 
and measurement of HbA1c following the American Diabetes Association 
recommendations 2010
E. Cosson1,2, M. Nguyen1,2, E. Hamo Tchatchouang1,3, I. Banu1,3, S. Chiheb1,3, 
P. Valensi1,3;
1Jean Verdier Hospital, Bondy, 2UMR U557 INSERM U1125 INRA, 
Bobigny, 3IMAGE Center, Bondy, France.
Background and aims: American Diabetes Association have published in 
2010 precise recommendations (ADA 2010) about (i) the population to be 
screened for dysglycemia, (ii) the diagnostic criteria for intermediate hyper-
glycemia (IH) and diabetes which include glucose values during oral glucose 
tolerance test (OGTT) and A1c and (iii) the patients to be considered for 
metformin treatment (those with both impaired fasting glucose and impaired 
glucose tolerance, or those with A1c ≥6%). The aim of the study was to evalu-
ate diagnostic strategy with OGTT and/or A1C criteria.
Materials and methods: A total of 1157 patients (962 women; body mass 
index 37.0±7.2 kg/m²; 41.2±13 years old) fulfilling the ADA 2010 criteria to 
be screened and who had not been diagnosed for diabetes previously under-
went an oral glucose tolerance test (OGTT) and measurement of A1c. They 
were assessed for diabetes risk score (Findrisc and DESIR score) and UKPDS 
coronary risk score.
Results: Based on OGTT and A1c respectively, 76 and 113 patients had dia-
betes; 307 and 299 patients had IH; and 130 and 255 patients would have 
been eligible for treatment with metformin. The sensitivity/specificity of A1c 
≥6.5% for the diagnosis of diabetes according to OGTT were 45.9/92.0%. In 
patients with A1c <6.5%, the sensitivity/specificity of A1c 5.7-6.4% for the 
diagnosis of IH were 59.9/56.2%. Diabetes risk scores and UKPDS risk score 
were the highest in the 130 patients with both an abnormal OGTT and an 
A1c ≥5.7%.
Conclusion: OGTT and A1c are both considered as relevant diagnostic crite-
ria for dysglycemia as they correlate with retinopathy and the risk for devel-
oping diabetes. We show in a population who should be screened that choos-
ing the A1c strategy rather than the OGTT strategy leads to diagnose more 
diabetes and to treat more patients with metformin, although the consistency 
of both diagnostic criteria is low (for example, 1/3 of the patients with A1c 
≥6.5% have a normal OGTT). The patients who have the highest a priori risk 
of diabetes and cardiovascular disease are those with an abnormal OGTT 
associated with an A1c≥5.7%.
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Hemoglobin A1c in a population with pre-diabetes, diagnosed and 
previously undiagnosed diabetes
J.M. Boavida1,2, L. Gardete-Correia3, S. Massano-Cardoso4, C. Mesquita3, 
J.F. Raposo3;
1Portuguese Society of Diabetology, Lisbon, 2Portuguese Diabetes 
Programme, Directorate General Health, Lisbon, 3Portuguese Diabetes 
Association, Lisbon, 4Hygiene and Social Medicine Intitute, Coimbra, 
Portugal.
Background and aims: Diabetes is a serious public health problem with 
epidemic characteristics. Diabetes diagnosis is based on the values of fasting 
plasma glucose and on the Oral Glucose Tolerance Test (OGTT). Recently, 
determination of A1c has been proposed for the diagnosis of “pre-diabetes” 
and diabetes. To analyze the reliability of screening for “pre diabetes” and 
undiagnosed type 2 diabetes using A1c values. To obtain information regard-
ing A1c distribution in a representative population sample including subjects 
without diabetes, with diagnosed and previously undiagnosed diabetes, and 
with “pre diabetes”.
Materials and methods: A randomized study was performed to determine 
the prevalence of diabetes in Portugal (PREVADIAB) covering 5,167 people 
randomly selected across the country, according to the population distribu-
tion. Diabetes prevalence was 11.7% between 20 and 79 years (previously 
diagnosed and undiagnosed). A1c was determined in all subjects. A1c data 
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were analyzed according to the recommendations of the “International Ex-
pert Committee Report on the Role of the A1c Assay in the Diagnosis of 
Diabetes” ADA/EASD/IDF (diabetes >= 6.5% and “pre-diabetes” > 5.7% and 
<6.4%).
Results: Excluding people who had a previous diagnosis of diabetes, 96.8% 
(CI 95%: 96.5% to 97.5%) of the population had A1c <6.5%. When the re-
maining 3.2% with A1c >= 6.5 were tested with an OGTT, 65% had undi-
agnosed diabetes, 29% had “Pre-Diabetes” and 6% had no diabetes criteria. 
30,0% of previously undiagnosed people had A1c levels <6.5% (CI 95%: 
23.6% to 36.4%). Thus, this method would not have allowed the diagnosis of 
30,0% of cases of diabetes. Looking at metabolic control in people with pre-
viously diagnosed diabetes, we found that 34% had A1c values under 6.5%, 
69.7% had values <7% and 15.4% had values > 8%. Analyzing A1c values 
in people with Impaired Fasting Glucose (IFG), 29.9% had values >= 6.5% 
and 98% values <7%, while in people with Impaired Glucose Tolerance (IGT) 
29.7% had values >= 6.5% and 99.2% <7%. According to the criteria proposed 
by the ADA/EASD/IDF and analyzing the total population of PREVADIAB 
we verified that in the group of people with A1c values, <5.7%, 2.9% of people 
had diabetes. With A1c between 5.7% and 6.4%, 13.9% of people had diabetes 
and A1c values >= 6.4%, 86.5% of people had diabetes. “Pre-diabetes” was 
present in the three levels, mainly in the group with A1c values between 5.7% 
and 6.4% (30.0% of the group).
Conclusions: Using A1c > 6.4% as a means of diagnosis, a large number of 
people without previous diagnosis of diabetes (30,0%) would not be diag-
nosed. In the population with A1c values between 5.7% and 6.4% we found 
that 13.9% had diabetes, 30.0% had “pre-diabetes” and 56.1% had normal 
glycoregulation. Thus we should be cautious using A1c for diagnosis. In our 
opinion, the use of fasting glucose and OGTT remains pertinent.
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Discordance between fasting glucose-based and hemoglobin A1c-based 
diagnosis of diabetes mellitus in Koreans
C.-H. Kim1, H.-K. Kim2, S.J. Bae2, J.Y. Park3, K.-U. Lee3;
1Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, 
Kyeonggi-do, 2Health Promotion Center, Asan Medical Center, Seoul, 
3Internal Medicine, University of Ulsan College of Medicine, Seoul, Republic 
of Korea.
Background and aims: Recently, the International Expert Committee recom-
mended that hemoglobin A1c (HbA1c) ≥ 6.5% to be included as a diagnostic 
criterion for diabetes mellitus. However, the degree of diagnostic agreement 
with the fasting glucose-based criteria may be different across ethnic groups 
and populations. The aim of this study was to examine the difference between 
using fasting plasma glucose (FPG) and HbA1c criteria in screening for dia-
betes in Korean asymptomatic health check-up recipients.
Materials and methods: We retrospectively analyzed clinical and laboratory 
data of 37,754 Korean adults (age 20-89 years, 41% women) which were re-
corded during regular health check-ups. After excluding subjects with previ-
ously diagnosed diabetes mellitus (n = 1,812) and significant anemia or he-
moglobinopathies (n = 318), 35,624 subjects (21,201 men and 14,423 women) 
were categorized by FPG (126 mg/dL) and HbA1c (6.5%) cutoff values.
Results: Among the 35,624 subjects without known diabetes, 1143 (3.2%) pa-
tients were newly diagnosed as having diabetes using FPG criteria and 1019 
(2.9%) patients by HbA1c criteria (Table 1). Thus, using HbA1c alone could 
detect slightly less (-9%) diabetic patients compared with using FPG alone. 
By combining both FPG and HbA1c criteria, 1493 (4.2%) patients previously 
unknown to have diabetes could be newly diagnosed. Therefore, about 30% 
more diabetic patients could be detected by including new HbA1c criteria in 
addition to FPG criteria. Among the 1493 newly diagnosed diabetic subjects, 
473 (31.6%) met FPG criteria only (DM-FPG group), 350 (23.5%) met HbA1c 
criteria only (DM-A1c group), and 668 (44.9%) were diagnosed as diabetes 
by both criteria. When we compared the DM-FPG and DM-A1c group, DM-
A1c group were significantly older (55.1 ± 9.4 vs. 53.4 ± 9.2 years, P = 0.032), 
and had lower blood hemoglobin concentration (14.6 ± 1.5 vs. 15.2 ± 1.3 mg/
dL, P < 0.001). In contrast, DM-IFG group had higher systolic (123 ± 15 vs. 
119 ± 13 mmHg, P = 0.006) and diastolic (78 ± 9 vs. 74 ± 9 mmHg, P < 0.001) 
blood pressure, fasting serum insulin level (11.5 ± 8.7 vs. 8.8 ± 5.5 mIU/L, P < 
0.001) and HOMA-IR (3.81 ± 2.95 vs. 2.47 ± 1.57, P < 0.001).
Conclusion: There was significant discordance in diagnosing diabetes mel-
litus between the FPG- and HbA1c-based criteria. Our results support the 
notion that fasting glucose criteria may be better in detecting patients with 
hepatic insulin resistance, while HbA1c criteria may be more useful in pa-
tients with predominant impairment of postprandial glucose metabolism. 
Further studies are needed to know which criterion is better in predicting the 
risk of long-term vascular complications of diabetes.
Table 1. Prevalences (%) of newly diagnosed diabetes mellitus in health 
check-up recipients according to age groups by fasting plasma glucose (FPG) 
and HbA1c criteria 
20-29 30-39 40-49 50-59 60-69 70-89 Total
FPG
HbA1c
Combined
0.4
0.3
0.5
1.5
1.4
1.8
2.8
2.3
3.4
3.9
3.5
5.1
4.7
4.8
6.9
7.7
6.4
10.7
3.2
2.9
4.2
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Effect of IL-1beta and TNFalpha inhibition on insulin secretion and 
metabolic control of type 2 diabetes patients with overweight or obesity
M. González-Ortiz1,2, M.G. Ramos-Zavala1, E. Martínez-Abundis1,2,  
J.A. Robles-Cervantes1, R. González-López1, N.J. Santiago-Hernández1;
1Medical Research Unit in Clinical Epidemiology, Mexican Institute of 
Social Security, 2Physiology Department, University of Guadalajara, Jalisco, 
Mexico.
Background and aims: To compare the effect of IL-1β and TNFα inhibition 
on insulin secretion and metabolic control of type 2 diabetes patients with 
overweight or obesity.
Materials and methods: A randomized, double-blind, placebo-controlled 
clinical trial was carried out in 40 type 2 diabetes patients, aged between 
40 to 60 years, BMI between 25 to 34.9 Kg/m², glucose between 126 to 200 
mg/dl, A1C >7%, without pharmacological treatment. At beginning and at 
end of the study, BMI, blood pressures, a metabolic profile (fasting glucose, 
A1C and lipids), IL-1β and TNFα concentrations were measured, as well as, 
insulin secretion assessment using the hyperglycemic - hyperinsulinemic 
clamp technique. The patients were randomly assigned to receive diacerein 
(50 mg twice/day), an inhibitor of IL-1β and TNFα, or placebo for a period 
of 60 days. Statistical analyses were calculated with Mann-Whitney U and 
Wilcoxon tests. The study protocol was reviewed and approved by the hospi-
tal-based Ethic Committee and written informed consent was obtained from 
all volunteers.
Results: In both groups decreased the BMI (30.9 ± 2.5 vs. 29.8 ± 2.5 kg/m², p 
= 0.002 and 30.6 ± 2.6 vs. 29.8 ± 2.8 kg/m², p = 0.001; respectively placebo and 
diacerein groups) in the same magnitude, p = 0.756. Diastolic blood pressure 
(77 ± 8 vs. 75 ± 6 mmHg, p = 0.040), fasting glucose (145 ± 28 vs. 124 ± 19 
mg/dl, p = 0.001), A1C (8.3 ± 1.0 vs. 7.0 ± 0.8%, p <0.001), IL-1β (26.4 ± 6.6 
vs. 17.9 ± 2.7 pg/ml, p=0.005), and TNFα concentrations (18.2 ± 3.9 vs. 13.8 
± 2.7 pg/ml, p=0.003) decreased significantly with diacerin administration, as 
well as increasing in first (17.0 ± 10.6 vs. 21.8 ± 12.7 μU/ml, p = 0.002), late 
(36.6 ± 18.6 vs. 46.9 ± 22.5 μU/ml, p = 0.002) and total (29.9 ± 15.4 vs. 36.1 ± 
16.6, p = 0.002) phases of insulin secretion were observed.
Conclusion: Inhibition of IL-1β and TNFα by means of diacerein adminis-
tration improved insulin secretion and the metabolic control of type 2 diabe-
tes patients with overweight or obesity.
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CCR5 promotes adipose tissue inflammation and insulin resistance in 
obesity
T. Ota, H. Kitade, K. Sawamoto, H. Inoue, S. Kaneko;
Frontier Science Organization, Kanazawa University, Japan.
Background and aims: Adipose tissue macrophages (ATMs) play a criti-
cal role in obesity-induced inflammation and insulin resistance. Monocyte 
chemoattractant protein-1 (MCP-1) and its receptor CCR2 are important for 
ATM recruitment and the development of insulin resistance. However, defi-
ciency of CCR2 or MCP-1 does not normalize obesity-induced ATM recruit-
ment and insulin resistance. Therefore, other chemokine systems could also 
play a role in these processes. Recent reports have also shown that CCR5, a 
different CC chemokine receptor, and its ligands are upregulated in adipose 
tissue of human obesity. However, it is not known if CCR5 is involved in 
ATM recruitment and insulin resistance. Here, we investigated the role of 
CCR5 in obesity-induced adipose tissue inflammation and systemic insulin 
resistance by high fat (HF) feeding or leptin deficiency.
Materials and methods: We analyzed gene expression levels of several chem-
okines and their receptors in white adipose tissue (WAT) of genetically (ob/
ob) and HF diet-induced obese (DIO) mice. To determine whether CCR5 
is required for obesity-induced ATM recruitment and insulin resistance, we 
examined metabolic phenotype of CCR5-/- mice. In addition, we performed 
bone marrow transplantation (BMT) of CCR5-/- mice or wild type (WT) 
C57Bl/6J mice donor cells into irradiated WT recipient mice to generate my-
eloid cell specific chimeric mice.
Results: Expression of mRNA for CCR5 and its all ligands was markedly 
increased in WAT in both DIO mice (CCR5,11.1-; MIP-1α, 5.2-; MIP-1β, 
5.2-; RANTES, 4.0-; MCP-2, 2.1-fold; all p<0.05 vs WT) and ob/ob mice 
(CCR5, 5.3-; MIP-1α,17.5-; MIP-1β, 19.9-; RANTES,4.9-; MCP-2,15.9-fold; 
all p<0.05 vs WT) at 15 weeks of age. Interestingly, upregulation of CCR5 and 
its ligands preceded ATM recruitment in DIO mice, and their expression lev-
els were higher than MCP-1/CCR2 in ob/ob mice. CCR5-/- mice fed normal 
chow showed slightly better glucose tolerance. On a HF diet, CCR5-/- mice 
had decreased macrophage infiltration and crown-like structure formation 
in adipose tissue compared with WT mice at 20 weeks, even though weight 
and adipocyte size (191.5±9.3 vs 186.3±6.4 μm p=0.4) were similar. HF diet-
induced insulin resistance and glucose intolerance were also significantly 
improved in CCR5-/- mice. These findings were associated with decreased 
inflammatory cytokine expression (TNFα and iNOS), reduction of endo-
plasmic reticulum stress evaluated by XBP-1 splicing, attenuation of MAPK 
(p38-MAPK, JNK) and NF-κB activation in adipose tissue, and improvement 
of hepatic steatosis. We next introduced CCR5 deficiency into ob/ob mice to 
generate double-knockout (DKO) mice. DKO mice were strikingly resistant 
to the development of both insulin resistance and fatty liver. DKO mice also 
had decreased ATM recruitment compared to ob/ob littermates. Importantly, 
mRNA expression for CCR5 and its ligands in adipose tissue was higher in 
stromal vascular fraction than adipocyte fraction from DIO mice at 15 weeks. 
Furthermore, BMT study revealed that chimeric mice lacking CCR5 in my-
eloid cells were protected from HF diet-induced hyperinsulinemia (CCR5-/-
BMT 2.6±0.3 vs WT-BMT 5.1±1.1 ng/ml, p<0.05) and glucose intolerance.
Conclusion: Expression of CCR5 and its ligands is markedly increased in 
WAT of obese mouse models. Deficiency of CCR5 prevents insulin resistance 
induced by HF feeding or leptin deficiency. Therefore, CCR5 plays a crucial 
role in ATM recruitment and subsequent development of insulin resistance 
independently of MCP-1/CCR2.
Supported by: MEXT, Japan
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Heat shock protein 60 stimulates the secretion of pro-inflammatory 
adipokines from human adipocytes and induces insulin resistance in 
human skeletal muscle cells
H. Sell1, T. Märker2, S. Famulla1, A. Glöde2, P. Zilleßen2, C. Habich2,  
J. Eckel1;
1Institute for Clinical Biochemistry and Pathobiochemistry, 2Institute for 
Clinical Diabetology, German Diabetes Center, Düsseldorf, Germany.
Background and aims: Adipose tissue is an endocrine active organ produc-
ing a variety of bioactive proteins. In the obese state expanded adipose tissue 
releases increased amounts of pro-inflammatory adipokines which mediate 
adipose tissue inflammation. It is well-known that obesity is a strong risk fac-
tor for the development of insulin resistance and a component of the metabol-
ic syndrome which involves the crosstalk between adipose tissue and skeletal 
muscle. Adipokines released from enlarged fat cells are important mediators 
of this crosstalk by autocrine/paracrine and endocrine effects. The autologous 
stress protein heat shock protein 60 (Hsp60) is released from adipocytes and 
increased in serum of diabetic patients. This study is aimed to analyze the 
effects of Hsp60 on the release of adipokines from human adipocytes and to 
assess if Hsp60 affects insulin sensitivity of human skeletal muscle cells.
Materials and methods: Preadipocytes were isolated from subcutaneous adi-
pose tissue of lean or overweight healthy women and differentiated in vitro. 
The release of pro-inflammatory adipokines after LPS and Hsp60 treatment 
was measured by a multiplex beads analyses. The specificity of Hsp60-bind-
ing to human adipocyte receptor structures was analyzed. In vitro differenti-
ated skeletal muscle cells were incubated with Hsp60 concentrations ranging 
from 1 to 20 µg/ml. Insulin signaling and the induction of pro-inflammatory 
and stress pathways were analyzed by Western blotting.
Results: Unstimulated human preadipocytes and adipocytes secrete measur-
able amounts of TNFα, IL-6, IL-8, MCP-1 and RANTES. Hsp60 treatment 
leads to significantly increased secretion of TNFα (up to 168-fold), IL-8 (up 
to 7-fold) and RANTES (up to 9-fold) from preadipocytes as compared to 
untreated preadipocytes. As for mature adipocytes, Hsp60 stimulated the se-
cretion of TNFα (up to 21-fold), IL-6 (up to 32-fold), IL-8 ( up to 3-fold), 
MCP-1 (up to 6-fold) and RANTES (up to 8-fold) compared to unstimulated 
adipocytes. The specificity of Hsp60-Binding on human adipocytes could be 
demonstrated by binding assays. Binding of labeled Hsp60 could be inhibited 
by up to 69 % using unlabeled Hsp60, whereas ovalbumin was without effect. 
As human adipocytes express and release Hsp60, we tested the effect of this 
adipokine on skeletal muscle cells. Hsp60 activates pro-inflammatory and 
stress signaling in skeletal muscle cells in a dose-dependent way. Hsp60 sig-
nificantly increases the phosphorylation of NF-κB, JNK and ERK1/2 up to 2- 
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to 3-fold over the control level. Hsp60 also induces insulin resistance on the 
level of insulin-stimulated Akt and GSK3 phosphorylation in a dose-depend-
ent manner with significant inhibition being observed at concentrations from 
5 to 20 µg/ml of Hsp60 which reflects pathophysiological concentrations.
Conclusion: We demonstrate for the first time that treatment of human 
preadipocytes and adipocytes with Hsp60 results in increased release of vari-
ous pro-inflammatory adipokines in a dose- and differentiation-dependent 
way. In skeletal muscle cells Hsp60 activates pro-inflammatory signaling 
pathways and leads to impaired insulin signaling. Therefore, Hsp60 might be 
a factor contributing to adipose tissue inflammation and obesity-associated 
insulin resistance.
Supported by: DFG
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Communication between insulin-resistant skeletal muscle and beta cells
K. Bouzakri1, P. Ribaux1, T. Berney2, M.Y. Donath3, P.A. Halban1;
1Department of Genetic Medicine and Development, CMU, Geneva, 
2Cell Isolation and Transplantation Center, Division of Surgical Research, 
Department of Surgery, University Hospital, Geneva, 3Division of 
Endocrinology and Diabetes, Department of Internal Medicine, University 
Hospital, Zurich, Switzerland.
Background and aims: Obesity and type 2 diabetes mellitus are characterized 
by an overlapping phenotype of insulin resistance with a relative deficiency 
in insulin secretion underlying hyperglycemia in type 2 diabetes. Systemic 
inflammation is another common feature, raising the hypothesis that elevated 
cytokine levels may contribute to peripheral insulin resistance and decreased 
beta cell functional mass. In healthy humans, TNF-α infusion induces skel-
etal muscle insulin resistance. We now explore the potential communication 
between insulin-resistant skeletal muscle and beta-cells.
Materials and methods: Human skeletal muscle cells were cultured for up to 
24h with or without (control) 20 ng/ml TNF-α to induce insulin resistance. 
mRNA expression for cytokines was analysed after 8h by hybridising cDNA 
to low-density oligo-nucleotide arrays. Conditioned media (test: TNF-α-CM; 
control: C-CM) were collected and candidate cytokines were measured by 
antibody array. Human and rat primary beta-cells were used to explore the 
impact of exposure to conditioned media for 24h on apoptosis (TUNEL as-
say), proliferation (BrdU incorporation), short-term insulin secretion, and 
key signalling protein phosphorylation and expression. Data are mean+/-SE.
Results: Muscle cells (n=4) treated for 8h showed an increase in expression 
of 19 cytokine and chemokine genes (confirmed and quantified by RT-qPCR) 
with increased amounts of 13 cytokines after 24h in TNF-α-CM vs. C-CM. 
Both TNF-α-CM and TNF-α alone added to C-CM at the start of the beta-
cell culture decreased glucose-stimulated insulin secretion to a similar extent. 
However, only TNF-α-CM also increased human and rat beta-cell apopto-
sis by 6.22+/- 2.1 and 6.14+/- 0.9 -fold respectively (p< 0.05) and decreased 
proliferation of rat beta-cells (1.08 +/- 0.15 vs. 8.2 +/- 1.7 % BrdU positive 
cells, TNF-α-CM vs. C-CM, p<0.01). In rat beta-cells, 1h of glucose stimula-
tion (16.7 mM) induced phosphorylation of proteins from the insulin signal-
ling pathway including Akt, AS160, other Akt substrates, and ERK, an effect 
prevented by prior culture for 24h with TNF-α-CM. Both TNF-α-CM and 
TNF-α added to C-CM decreased IRS-2 protein by approx. 60% but only 
TNF-α-CM also decreased IRS-2 mRNA by 42 +/- 5 % vs. C-CM (p<0.05). 
Interestingly, both CM and TNF-α-CM increased IRS-1 protein and mRNA 
expression. In order to identify which mechanism was involved in the specific 
effects of TNF-α-CM and potentially attributable to insulin-resistant muscle 
cytokines, rat beta-cells were pre-treated with GLP-1, IL1-Ra or IL6 blocker 
(AF-227-NA and Sant 7). Both GLP-1 and IL1-Ra partially protected against 
the TNF-α-CM evoked increased in apoptosis but not the decreased prolif-
eration.
Conclusion: Taken together these results show that induction of insulin-re-
sistance in human skeletal muscle by TNF-α leads to secretion of myokines 
which impact negatively on beta-cell proliferation and survival. The identi-
fication of these myokines and their molecular targets on beta-cells opens 
the possibility for new therapeutic strategies for preservation of functional 
beta-cell mass in type 2 diabetes.
Supported by: Investigator initiated grant from MSD
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IL-6 stimulated TLR-4 gene expression via mTOR and STAT3 in human 
skeletal muscles myotube and human skeletal muscle of IGT subject 
S.-E. Choi1, T.H. Kim1, E.S. Ha1, S.Y. An1, Y.J. Jung1, E.K. Kim1, M.S. Lee1, 
S.J. Han1, H.J. Kim1, D.J. Kim1, Y. Kang2, K.-W. Lee1;
1Endocrinology and Metabolism, 2Institute for Medical Science, Ajou 
University School of Medicine, Suwon, Republic of Korea.
Insulin resistance is associated with chronic inflammation, and many inflam-
matory cytokines and signaling pathways are involved. In this study we in-
vestigated the cytokines and mechanisms involved in the induction of insulin 
resistance in human skeletal muscle. We recruited 10 IGT subjects and 10 
control subjects. Whole-body insulin-mediated glucose uptake was deter-
mined using a euglycemic hyperinsulinemic clamp test. Muscle biopsies were 
obtained from the vastus lateralis muscle. We determined levels of inflam-
matory cytokine, TLR gene expression, and insulin signaling using immuno-
blotting. We examined the mechanisms underlying TLR-4 gene expression 
using a human myotube culture system. Fasting blood glucose was signifi-
cantly higher in IGT subjects than the controls. HbA1c showed a tendency 
to be higher in IGT subjects (p=0.059). Although there was no difference in 
HOMA beta cell function between the two groups, glucose utilization rates 
were significantly lower in the IGT group. Levels of IL-6, TNF-α, and TLR-4 
was significantly increased in the IGT group, but TLR-2 was not. We stud-
ied which inflammatory cytokines induce TLR-4 gene expression using IL-6, 
TNF-α, free fatty acid, and high glucose. TLR-4 gene expression increased 
significantly in human skeletal muscle myoblasts treated with IL-6. To deter-
mine the main signaling pathway for IL-6-induced TLR-4 gene expression, 
we examined several signaling factors associated with IL-6 signaling path-
ways. We found that the active forms of signal transducer and activator of 
transcription3 (STAT3) was increased in the IGT group as compared with 
controls (mTOR: 183.22 ± 13.01 vs. 100 ± 12.63, p < 0.05; STAT3: 170.3949 ± 
18.11 vs. 14.64, p < 0.05). Stattic (STAT3 inhibitor) markedly inhibited TLR-
4 gene expression. We suggest IL-6 induction of TLR-4 gene expression via 
STAT3 is one of the main mechanisms underlying insulin resistance in hu-
man skeletal muscle.
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Toll-like receptor 2 knockout mice present iNOS-dependent insulin 
resistance
A.M. Caricilli1, P.K. Picardi1, L.L.F. de Abreu1, M. Ueno1, P.O. Prada1,  
S.M. Hirabara2, R. Curi3, J. Carvalheira1, L.A. Velloso1, M.J.A. Saad1;
1UNICAMP, Campinas, 2UNICSUL, São Paulo, 3USP, São Paulo, Brazil.
Background and aims: There are evidences that the activation of JNK, IKK 
and iNOS pathways are associated with the reduction of the insulin sensitivity, 
but only recently it has been shown that those pathways can be integrated in 
the insulin resistance by membrane receptors, such as the Toll-like Receptors 
(TLRs). Studies in our laboratory show that mice with an inactivating muta-
tion of TLR4 are protected from diet-induced obesity and activation of IKKβ 
and JNK. It is possible that other TLRs participate in this phenomenon. TLR2 
is a good candidate, because it is activated by saturated fatty acids. However, 
no study has characterized the role of TLR2 in the insulin resistance of animal 
models. Therefore, the goal of the present study is to investigate the role of 
TLR2 on insulin resistance of mice.
Materials and methods: We investigated weight gain, insulin sensitivity and 
signaling in liver, muscle and white adipose tissue in TLR2 knockout (KO) 
mice and their controls, both fed with a standard chow. The glucose utili-
zation was studied through euglicemic-hyperinsulinemic clamp, the protein 
signaling through Western Blotting, serum insulin, IL-6 and TNF-α through 
ELISA, oxygen consumption through an indirect open circuit calorimeter 
and glucose uptake by the soleus muscle was determined in vitro using 2-de-
oxy-D-[2,6-3H] glucose. In order to inhibit the expression of JNK and iNOS, 
we used SP600125 (30mg/kg body weight) and l-N6-(l-iminoethyl) lysine 
(l-NIL; 80 mg/kg body weight). All procedures were approved by the ethics 
committee at the Sytate University of Campinas.
Results: The animals were similar in concern to the weight gain, however 
TLR2 KO mice had a decreased oxygen consumption and a decreased UCP1 
expression comparing with their controls. Moreover, TLR2 KO mice pre-
sented decreased glucose tolerance and decreased insulin sensitivity. The in-
sulin signaling was also alterated in these animals, because the activation of 
the insulin receptor and of AKT was reduced. IKK activation was reduced in 
TLR2 KO mice, which was accompanied by the decreased serum concentra-
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tion of IL-6 and TNF-α comparing with the controls, while the phosphoryla-
tion of JNK was increased in muscle and liver, suggesting that other proteins 
might be involved in the modulation of the insulin signaling, leading to an 
increased activation of JNK. In order to elucidate this question, we studied 
proteins associated with the endoplasmic reticulum (ER) stress, since they 
activate JNK, and observed an increased phosphorylation of PERK and an in-
creased expression of IRE-1α, which are associated with the ER stress. How-
ever, when inhibiting the expression of JNK and iNOS, we observed that only 
the inhibition of iNOS was able to improve the insulin sensitivy, suggesting 
that the insulin resistance in these animals is iNOS-dependent.
Conclusion: Although we have found many activated mechanisms that have 
the potential of inducing insulin resistance in TLR2 KO mice, only one was 
capable of reversing this state - the iNOS pathway. Therefore, TLR2 KO mice 
present iNOS-dependent insulin resistance.
Supported by: FAPESP
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Fork-head box transcription factor, FoxO1 inhibits glucose-regulated 
insulin gene expression in pancreatic beta cells by direct binding to the 
promoter region
G. Meur1, Q. Qian2, G. Da Silva Xavier1, T. Tsuboi2, C. McKinnon2,  
L.M. Fletcher2, J.M. Tavaré2, G.A. Rutter1;
1Division of Diabetes, Endocrinology and Metabolism, Imperial College, 
London, 2Department of Biochemistry, University of Bristol, United 
Kingdom.
Background and aims: Glucose and insulin stimulate preproinsulin (PPI) 
gene expression in pancreatic beta cells through mechanisms which are only 
partly defined. Pancreatic duodenum homeobox-1 (Pdx1) is a major trans-
activator of PPI whose action is antagonised by the fork-head box member 
protein, FoxO1. The effect of FoxO1 is thought to be largely due to inhibition 
of Pdx1 expression. However, we have also noted that a potential binding 
site also exists in the 5’ flanking region of the rodent, and intron 2 of the hu-
man, PPI genes. Here we explore whether FoxO1 directly binds to this site 
to regulate insulin gene expression and examine the intracellular signalling 
pathways involved.
Materials and methods: Adenoviruses expressing wild type and a consti-
tutively active (S256A) FoxO1-GFP and wild type Pdx1 were generated by 
standard techniques. Silencing of FoxO1 was achieved after 48 h of transfec-
tion of SiRNAs (10nM, Smart Pool) with Lipofectamine RNAiMAX in MIN6 
beta cell lines. Chromatin immunoprecipitation was carried out after 24 h of 
CA-FoxO1 viral transduction, using a monoclonal anti-GFP antibody and 
CHIP grade protein G agarose. Real-time FoxO1 translocation was studied 
using a Nipkow spinning disc confocal microscope. The mRNA level was 
measured by qRT PCR using an ABI Fast Real-time PCR system normalised 
to endogenous cyclopholin. Insulin promoter-luciferase assays were carried 
out using a Stop and Glo, dual-luciferase kit. Statistical analyses of signifi-
cance were done by Student’s t test or ANOVA.
Results: Culturing of MIN6 beta cells at low (3mM versus 30mM) glucose 
led to a 2-3 fold decrease in PPI and Pdx1 mRNA levels. Constitutively active 
FoxO1-GFP over-expression led to a decrease in insulin and Pdx1 gene ex-
pression even at high glucose while silencing (~75%) of FoxO1 abolished the 
effects of low glucose. The effects of FoxO1 over-expression on PPI mRNA 
levels were still observed in the presence of over-expressed Pdx1 though both 
were present in the nucleus, and consistent with the direct action of FoxO1 
on the insulin gene promoter. Chromatin immunoprecipitation using an 
anti-GFP antibody revealed direct binding of FoxO1 to a region located -768 
to -141bp upstream of the transcriptional start site. FoxO1 over-expression 
inhibited the activity of an insulin promoter-reporter (luciferase) construct 
bearing this region and the latter inhibition was retained after co-expression 
of Pdx1, but lost in a truncated construct lacking the putative FoxO1 bind-
ing site. Confocal imaging revealed that wild type FoxO1-GFP translocated 
from the nucleus after 30-60 min of exposure to high glucose and this shift 
was blocked by a pharmacological inhibitor of phosphatidyl inositol 3’ kinase 
(PI 3-kinase, LY294002) but not by inhibitors of glycogen synthase kinase 3 
(GSK3 beta, SB216763 and SB415286).
Conclusion: We show here that FoxO1, which is regulated through a PI 3-ki-
nase dependent signalling pathway, has a direct binding site on rodent insulin 
gene promoter. This newly identified mechanism may contribute to the regula-
tion of endogenous Insulin and Pdx1 gene complimenting an effect on Pdx1 
promoter described previously. Further dissection of this pathway may provide 
new therapeutic approaches to regulating the insulin gene in type 2 diabetes.
Supported by: Wellcome Trust, MRC, JDRF
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Carbohydrate-Responsive Element-Binding Protein (ChREBP) activity 
is regulated by Ca2+ ions in pancreatic beta cells via soluble resistant-
related calcium binding protein (Sorcin)
N.A. Noordeen, G. Meur, P. Patel, G.A. Rutter, I. Leclerc;
Dept. Cell Biology / Div. Diabetes, Endocrinology & Metabolism, Imperial 
College, London, United Kingdom.
Background and aims: We have recently shown that ChREBP is an impor-
tant mediator of pancreatic beta cell glucolipotoxicity. ChREBP activation by 
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high glucose increases the expression of the lipogenic genes liver-type pyru-
vate kinase (L-PK) and fatty acid synthase (FAS) and inhibits the expression 
of ARNT/HIF1-β . We have also shown previously that Ca2+ influx is neces-
sary for ChREBP activation in these cells. However, the precise molecular 
mechanism(s) through which ChREBP activity may be regulated by Ca2+ is 
unknown.
Materials and methods: A yeast two-hybrid screen was performed using 
ChREBP as a bait and the Matchmaker Gal4 Two-Hybrid System 3 (Clon-
tech) with an in-house MIN6 pancreatic β cell library. Mammalian cell 
transfection was carried out using Lipofectamine 2000, and cells were im-
aged using a Zeiss Axiovert 200M microscope fitted with a PlanApo x63 oil-
immersion objective. Confocalilty was achieved using a Nipkow spinning 
disc under the control of VolocityTM 4.0 (Improvision) software. An EGFP-
ChREBP chimaera was generated by in-frame fusion of the corresponding 
cDNAs. Sorcin-specific siRNAs were purchased from Dharmacon. Chroma-
tin immunoprecipitation was carried out using an in-house rabbit polyclonal 
anti-ChREBP antibody.
Results: Sorcin, a penta EF hand Ca2+ binding protein, was identified as a 
ChREBP interacting partner by yeast two-hybrid analysis. We confirmed that 
sorcin and ChREBP interacted in INS-1(832/13) and MIN6 β cells by co-im-
munoprecipitation and that they also co-localised in the cytosol in a punc-
tiform pattern in cells maintained in 3 mM glucose, as revealed by confocal 
microscopy. However, the extent of ChREBP and sorcin colocalisation was 
markedly reduced when cells were maintained at elevated (30 mM) glucose 
concentrations, where ChREBP staining became apparent in the nucleus. 
Moreover, ChREBP binding to the L-PK promoter, assessed by chromatin im-
munoprecipitation, was increased at low glucose concentrations following sor-
cin inactivation by RNA interference. As the apparent physical interaction of 
sorcin with ChREBP implied that ChREBP may be regulated by intracellular 
Ca2+, we tested the ability of ChREBP to respond to elevated intracellular lev-
els of these ions. Using live cell imaging of a GFP-tagged ChREBP construct, 
we found that ChREBP translocated into the nucleus within 5 - 7 min. of cell 
depolarization with 50 mM K+ and activated Ca2+ influx. Finally, demonstrat-
ing the likely importance of sorcin in retaining ChREBP in the cytosol, sorcin 
silencing significantly inhibited insulin secretion from MIN6 β cells.
Conclusion: These results demonstrate that sorcin is a physiologically rel-
evant molecular binding partner from ChREBP, and define a role for sorcin 
in β cell function and insulin secretion. We propose a model wherein, at low 
glucose concentrations, sorcin sequesters ChREBP in the cytosol. Elevated 
glucose concentrations, which trigger Ca2+ influx, lead to conformational 
changes in sorcin which release ChREBP and allow it to translocate into the 
nucleus to regulate the transcription of genes involved in lipid synthesis. The 
up-regulation of these target genes may then contribute to gluco-lipotoxicity, 
and hence diminished beta cell function and survival, in the context of type 
2 diabetes.
Supported by: DUK, Wellcome Trust
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Beta cell specific c-Kit receptor over-expression improves beta cell 
growth and function
R. Wang1, S.-P. Yee2, J. Li1;
1Physiology & Pahrmacology, Children’s Health Research Institute, 
the University of Western Ontario, London, Canada, 2Genetics and 
Developmental Biology, University of Connecticut Health Center, 
Farmington, USA.
Background and aims: One of the major defects in diabetes is the loss of 
insulin producing cells in the pancreas. The reasons for beta-cell loss are not 
well understood. We previously focused on determining factors responsible 
for the maintenance of beta-cell mass and function and have demonstrated 
that the c-Kit receptor and its ligand, stem cell factor (SCF), are important for 
both rodent and human pancreatic islets. These results show that c-Kit is not 
only a marker of beta-cell precursors but is also critical for beta-cell prolifera-
tion, maturation, function and survival in vitro. Study on the c-KitWv/+ mice 
further showed that the mutant male mice displayed early onset of diabetes. 
However, a better understanding of the underlying mechanisms is necessary 
prior to the development of novel physiologically relevant cell-based ap-
proaches to treat and manage diabetes. The aim of the present study is to 
examine whether a beta-cell specific c-Kit overexpression would have physi-
ological and functional implications in beta-cell development and function.
Materials and methods: A beta-cells specific over-expression c-Kit [RIP-c-
Kit(h)] transgenic mouse model in C57BL/6J background was generated fol-
lowed by the characterization of beta-cell proliferation and function.
Results: We found that the beta-cell specific c-Kit transgenic mice display 
relatively large body mass and normal fasting blood glucose level compared 
to the control littermates. However, a significant improved glucose tolerance 
in the beta-cell c-Kit transgenic mice at both 4 and 8 weeks of age was ob-
served (p<0.05). Morphometric analysis revealed a significant increase in the 
islet number and size (p<0.01) at 4 weeks of age. Increase beta-cell mass in 
beta-cell c-Kit transgenic mice along with an increase in beta-cell prolifera-
tion, Pdx-1 and Nkx6.1 expression compared with controls (p<0.05).
Conclusion: Our results demonstrate that c-Kit receptor tyrosine kinase 
is involved in the regulation of glucose metabolism and contributes to the 
maintenance of beta-cell function.
Supported by: Canadian Institute of Health Research
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Mitochondria distinguish between fast and slow cytosolic Ca2+ 
oscillations in pancreatic beta cells
A.I. Tarasov1, M.A. Ravier1,2, E.A. Bellomo1, G.A. Rutter1;
1Department of Medicine, Imperial College London, United Kingdom, 
2INSERM, Montpellier, France.
Background and aims: The normal pulsatility of insulin secretion from pan-
creatic beta cells, critical for maintenance of glucose homeostasis, is lost in 
type 2 diabetic patients. Mitochondrial Ca2+ uptake has been suggested to be 
involved in the control of oxidative metabolism and ATP generation which, 
via the closure of ATP-sensitive K+ channels, may underlie fluctuations in the 
electrical activity of the beta cell plasma membrane. Whether Ca2+ influx into 
mitochondria can occur rapidly enough to contribute to the polarisation of 
the plasma membrane during glucose-induced bursts of electrical activity, 
or to slower oscillations in plasma membrane potential (Vm), is unknown. 
Here, we have combined optical imaging of targeted probes and patch clamp 
electrophysiology to monitor cytoplasmic [Ca2+] ([Ca2+]c), intramitochon-
drial [Ca2+] ([Ca2+]m), and Vm simultaneously in single living beta cells. The 
relationship between these parameters was studied in response to glucose or 
other stimuli.
Materials and methods: Mouse beta cells were infected with an adenovirus 
encoding the ratiometric GFP-based mitochondrial Ca2+ sensor, pericam. 
Vm was manipulated using the perforated-patch patch-clamp technique. The 
dynamics of Ca2+ changes in the cytosol (Fura-Red) and mitochondria (peri-
cam) were imaged simultaneously using appropriate excitation wavelengths 
(490 and 410 nm respectively) and emission filters.
Results: Glucose (17 vs 3 mM) induced slow (2-5 min period) oscillations in 
[Ca2+]c. The onset of each oscillation was tracked by changes in [Ca
2+]m, with 
the changes delayed by ~10s. Each glucose-induced increase of [Ca2+]c was 
preceded by depolarization of the plasma membrane. The imposition of depo-
larizations by extracellular K+ was able to mimic the glucose-induced oscilla-
tions of Ca2+ in both compartments, indicating that mitochondrial Ca2+ uptake 
occurred as a result of the [Ca2+]c increase. Likewise, acetylcholine-mediated 
Ca2+ mobilization from intracellular stores prompted increases in [Ca2+]m and 
these were also delayed compared to the [Ca2+]c increases. For a given [Ca
2+]c 
rise, peak [Ca2+]m values were larger after cell membrane depolarization than 
after Ca2+ mobilization. To explore whether [Ca2+]c changes elicited by rapid 
membrane depolarizations could be sensed by mitochondria we next imposed 
trains of action potentials, mimicking those provoked by glucose, by voltage 
clamping the cell membrane. Such trains (23 pulses to 0 mV in 6 s imposed 
in 15 s intervals) led to increases in [Ca2+]c, which were maximal after the first 
burst, and partially recovered between bursts. By contrast, [Ca2+]m did not in-
crease detectably until the third burst in this protocol, and did not increase at 
all when the interburst interval was increased to >30 s.
Conclusion: We show that Ca2+ accumulation by beta cell mitochondria is 
dependent upon the duration and frequency of [Ca2+]c pulses. These results 
suggest that: (a) the filtering out by mitochondria of [Ca2+]c oscillations with 
sub-threshold frequency may contribute to the steep dependency of insulin 
secretion upon glucose concentration; (b) mitochondrial Ca2+ uptake and 
release are not a prerequisite for plasma membrane bursting electrical activ-
ity; (c) deranged uptake of Ca2+ by mitochondria may contribute to defective 
insulin secretion in some forms of type 2 diabetes.
Supported by: Wellcome Trust, JDRF
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Impaired pancreatic beta cell Ca2+ dynamics and function in premature 
ageing
L. Li1, A. Trifunovic2,3, M. Köhler1, J. Petrovic-Berglund1,4, N.-G. Larsson2,5, 
P.-O. Berggren1;
1The Rolf Luft Research Center for Diabetes and Endocrinology, Karolinska 
Institutet, Stockholm, 2Department of Laboratory Medicine, Karolinska 
Institutet, Stockholm, Sweden, 3CECAD Cologne - Excellent in Aging 
Research at the Institute for Genetics, University of Cologne, Germany, 
4Department of Cell Biology, Duke University Medical Center, Durham, 
USA, 5Max Planck Institute for Biology of Ageing, Cologne, Germany.
Background and aims: People over age 65 have a significantly increased 
risk for type 2 diabetes. In ageing humans, only those whose beta-cells fail 
to compensate for insulin resistance develop diabetes. However, the ageing 
of beta-cells is poorly understood. Here we, for the first time, demonstrates 
a clear coupling between ageing and impaired pancreatic beta-cell function 
and thereby glucose homeostasis in mice with premature ageing induced by 
accumulation of mitochondrial DNA (mtDNA) mutations.
Materials and methods: We used homozygous knock-in mice expressing a 
proofreading-deficient form of the catalytic subunit of mtDNA polymerase 
γαμμα. This mutant polymerase γαμμα induces error-prone mtDNA synthe-
sis, which, in turn, leads to accumulation of somatic mtDNA mutations with 
increasing age and a reduced lifespan and premature onset of ageing-related 
phenotypes. We performed glucose and insulin tolerance tests in animals. 
Cytochrome c oxidase and succinate dehydrogenase activities were measured 
by enzyme histochemical double staining of cryostat sections from pancreas. 
In isolated islets, measurements of glucose-stimulated changes in insulin re-
lease, mitochondrial membrane potential and cytoplasmic free Ca2+ concen-
tration ([Ca2+]i) were performed.
Results: Compared to wild-type littermate control mice, the mtDNA mu-
tator mice develop impaired glucose tolerance (p<0.05) due to progressive 
mitochondrial respiratory chain dysfunction in pancreatic islets and subse-
quent deficiency in glucose-stimulated insulin secretion (p<0.01). Both δελτα 
rhodamine 123 fluorescence, a probe to measure mitochondrial membrane 
potential, and δελτα peak [Ca2+]i values were decreased in islets obtained 
from mtDNA mutator mice after stimulation by 11 mM glucose (p<0.001 and 
p<0.01). We further demonstrate that the progressive decline in pancreatic 
beta-cell function in mice with premature-ageing phenotypes is associated 
with a slower frequency (p<0.05) and decreased amplitude (p<0.001) of glu-
cose-stimulated oscillations in [Ca2+]i. The latter findings are likely to be 
accounted for by down-regulated PLC/InsP3-mediated Ca2+ mobilization 
from intracellular stores and decreased beta-cell Ca2+ influx over the plasma 
membrane.
Conclusion: This study demonstrates that an age-related deterioration in 
[Ca2+]i signaling serves as a link between impaired beta-cell function and 
premature ageing in mtDNA mutator mice. It also suggests that enhancement 
in beta-cell Ca2+ signaling can be a potential target for the development of 
novel pharmacological regimens in the treatment of diabetes in the ageing 
population.
Supported by: the Swedish Research Council and the Novo Nordisk Founda-
tion
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Loss of anti-apoptotic Bcl-xL or Bcl-2 enhances beta cell glucose 
signalling
D.S. Luciani, S.B. Widenmaier, F. Taghizadeh, X. Hu, J.D. Johnson;
Department of Cellular and Physiological Sciences, University of British 
Columbia, Vancouver, Canada.
Background and aims: In many cell types, including pancreatic beta-cells, 
Bcl-2 and Bcl-xL have been demonstrated to preserve mitochondrial integrity 
and suppress apoptosis under a variety of cellular stress conditions. Whether 
these important pro-survival proteins also regulate beta-cell physiology in 
vivo or in vitro under normal conditions is not known. In this study we used 
a combination of genetic and pharmacological loss-of function approaches to 
test the hypothesis that Bcl-2 and Bcl-xL impact beta-cell energy metabolism, 
calcium homeostasis and insulin secretion.
Materials and methods: Beta-cell function and glucose homeostasis were 
studied in vivo and following conditional deletion of Bcl-x in adult beta-cells 
by tamoxifen-injection of Bcl-xflox/flox;Pdx1-CreER (Bcl-x KO) and littermate 
Bcl-xflox/flox (Bcl-x WT) control mice. Glucose signalling was assessed in islets 
and dispersed beta-cells from Bcl-2 knockout, heterozygous and wild-type 
littermate mice. Small molecule antagonists were used to assess the impact 
of acute Bcl-2/Bcl-xL inhibition on mitochondrial physiology, cellular ATP/
ADP, calcium signalling and insulin secretion of beta-cells in vitro.
Results: Quantitative real-time PCR and western blot confirmed the near 
complete loss of Bcl-xL expression and protein in islets from inducible Bcl-x 
KO mice. Loss of islet Bcl-x resulted in a moderate improvement of glucose 
tolerance in 10-12 week old mice within days of tamoxifen administration. 
The cellular ATP-to-ADP ratio of Bcl-x KO islet cells was markedly increased 
in the presence of both basal and stimulatory glucose. Moreover, cytosolic 
calcium responses were significantly enhanced in glucose-stimulated islets 
and dispersed beta-cells from both Bcl-xL and Bcl-2 deficient animals relative 
to their respective controls. In accordance with these findings, acute treat-
ment of normal mouse and human islet cells with Bcl-2/Bcl-xL antagonists in 
the presence of 3 mM glucose enhanced basal glucose-dependent respiration 
and induced mitochondrial calcium fluctuations within minutes. This raised 
ATP/ADP and triggered KATP channel- and voltage-dependent calcium influx 
and insulin secretion. Sustained Bcl-2/Bcl-xL inhibition resulted in beta-cell 
death but detailed time-course analyses demonstrated the induction of ap-
optosis to be temporally and causally disconnected from the observed physi-
ological responses.
Conclusion: Our findings demonstrate that anti-apoptotic Bcl proteins exert 
a tonic suppression of beta-cell metabolic signalling and thus work at the 
interface of beta-cell survival and physiology. Further study of these sur-
vival-regulating proteins and the molecular mechanisms of their metabolic 
functions may help identify factors to preserve the functional beta-cell mass 
required to maintain glucose homeostasis.
Supported by: D.S.L is supported by CDA and MSFHR. J.D.J. by JDRF, CIHR, 
MSFHR and CDA
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The endocannabinoid system links gut microbiota to adipogenesis
P.D. Cani1, D. Naslain1, F. Bäckhed2, C.S. Reigstad2, D.M. Lambert1,  
N.M. Delzenne1, G.G. Muccioli1;
1LDRI, Univeristé Catholique de Louvain, Brussels, Belgium, 2University of 
Gothenburg, Sweden.
Background and aims: Obesity is characterized by a massive expansion of 
the adipose tissue associated with a low-grade inflammation. Recently, we 
and others have proposed that gut microbiota would favour the occurrence 
of inflammation, insulin resistance and metabolic diseases associated with 
obesity. We have demonstrated a connection between the gut microbiota, fat 
mass, gut permeability and inflammation associated with higher plasma LPS 
levels (metabolic endotoxaemia). The endocannabinoid-system (eCB) plays a 
major role in the development of the inflammation and metabolic disorders 
associated with obesity via mechanisms not fully understood. Interestingly, 
LPS is known to stimulate eCB system tone. Therefore, we postulate that the 
higher plasma LPS levels and eCB system-tone found in obesity could act as 
key mechanisms leading to gut barrier disruption and altered adipogenesis.
Materials and methods: To determine the contribution of gut microbiota 
on the regulation of the intestinal and adipose tissue eCB-system tone (CB1 
mRNA, FAAH mRNA, AEA) in both physiological and obese conditions, 
we investigated selective (prebiotics, high-fat), drastic (antibiotics, germ-
free mice) modulation of the gut microbiota and bacteria-host interaction 
(Myd88-/-) models. To investigate the role of the eCB-system tone, we blocked 
the CB1 receptor with a specific and selective antagonist (SR141716A) in 
obese ob/ob mice, or we mimicked the higher eCB-system tone observed 
during obesity by chronic (4-weeks) infusion of a CB receptor agonist (HU-
210). We investigated in-vivo and in-vitro intestinal permeability, adipocyte 
differentiation (PPAR-γ, aP2, C/EBP-α) and lipogenesis (SREBP-1c, ACC, 
FAS) and the occurrence of inflammation (plasma LPS, cytokines) in the dif-
ferent models.
Results: Obese mice (genetic and nutritional models) are characterized by 
a higher intestinal and adipose tissue eCB system tone (higher AEA content 
and CB1 mRNA expression, lower FAAH mRNA). We found that the gut 
microbiota directly controls the intestinal eCB system-tone in all five models 
of gut microbiota modulation. We found in-vitro and in-vivo that the activa-
tion of the intestinal eCB-system increases gut permeability (higher plasma 
LPS and plasma Dextran-FITC, alteration of tight junctions proteins ZO-1 
and Occludin). We demonstrated that the blockade of the CB1 receptor re-
duced plasma LPS levels by a mechanism linked to the improvement of these 
markers. At the adipose tissue level, we show both in-vitro and ex-vivo that 
both eCB system and gut microbiota regulates adipogenesis, by increasing 
markers of differentiation (PPAR-γ, aP2, C/EBP-α) and lipogenesis (SREBP-
1c, ACC, FAS). In addition, we found that LPS acts as a key regulator on the 
endocannabinoid and PPARγ-driven adipogenesis.
Conclusion: First, we demonstrate that the peripheral (intestine and adipose 
tissue) eCB-system tone is under the control of the gut microbiota. Second, 
we demonstrate that eCB-system controls gut barrier function and therefore 
endotoxaemia. Third, we provide evidence that adipogenesis is under the 
control of the gut microbiota, through the modulation of the gut and adipose 
tissue endocannabinoid systems. These data indicate that gut microbiota de-
termines adipose tissue physiology through LPS-eCB system regulatory loops 
and may play a critical role in the adipose tissue plasticity during obesity.
Supported by: FRS-FNRS (Fonds de la recherche Scientifique, Belgium)
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Depot-specific induction of transdifferentiation, inflammation and 
apoptosis via cannabinoid type 1 receptor blockade
I. Wagner, N. Perwitz, M. Drenckhan, H. Lehnert, J. Klein;
Internal Medicine, Universität zu Lübeck, Germany.
Background and aims: The endocannabinoid system is a major component 
in the control of energy metabolism. CB1-receptor blockage induces weight 
loss and reduces the risk to develop the metabolic syndrome with its associ-
ated cardiovascular complications. These effects are mediated by central and 
peripheral pathways. Interestingly weight loss is mainly achieved by a reduc-
tion of visceral fat mass. Therefore we investigated fat depot-specific differ-
ences on adipocyte differentiation, inflammation, and oxidative metabolism 
in CB1-receptor knockout cells.
Materials and methods: We used newly generated inguinal and epididymal 
adipose cell lines from CB1-R knockout mice. Differences in differentiation 
were measured by fat specific oil red o staining and quantitative RT-PCR-
based mRNA expression analysis of key differentiation markers. Induction of 
apoptosis was evaluated by using a cell death detection ELISA and perform-
ing protein analysis of p53 phosphorylation. Inflammation markers were 
quantified on RNA level. For analyzing the process of transdifferentiation we 
measured oxygen consumption and mitochondrial biogenesis.
Results: Differentiation was reduced in visceral adipocytes from CB1-re-
ceptor knockout mice as compared to wildtype controls. All markers of late 
differentiation, including AP2, GLUT 4 and PPAR gamma were decreased 
in these CB1-R-KO cells. Moreover, the inhibitory preadipocyte factor, Pref-
1, was elevated. Furthermore, we found a significant induction of apoptosis 
(increased by 51%) in these cells from the visceral fat depots. In contrast, 
subcutaneous cells from CB1-R knockout mice showed an accelerated dif-
ferentiation as well as a reduced induction of apoptosis (decreased by 41%). 
Inflammation was increased in visceral fat cells, as analyzed by the expres-
sion pattern of IL-6 (+357%), MCP-1 (+326%), TNF α (+371%), whereas in 
subcutanous adipocytes these markers were declined by -60%, -26%, -32% 
respectively. In addition, subcutaneous CB1-R knockout cells were more sen-
stitive towards a conversion into a brown fat phenotype. UCP-1 expression 
in these cells was significantly elevated by 176% in preadipocytes and 285% 
in fully differentiated adipocytes. Moreover, PGC-1 α expression was aug-
mented by 152% and by 140%, respectively. Finally, we found an increase in 
mitochondrial biogenesis demonstrated by mitochondrial fluorescence stain-
ing and RNA expression pattern of TFAM and NRF-1 in these cells. In line 
with these data, there was also an increase in oxygen consumption by 83% in 
subcutaneous preadipocytes as well as an 92% enhancement in fully differen-
tiated cells compared to wildtyp controls.
Conclusion: In conclusion, we found depot-specific effects on differen-
tiation, apoptosis, inflammation and oxidative metabolism in CB1-receptor 
knockout cells. Visceral adipocytes showed a lack of differentiation and an 
enhancement of apoptosis. In contrast to visceral fat cells, subcutaneous cells 
expressed an antiinflammatory cytokine profile and were more sensitive to-
wards a conversion into a brown fat cell phenotype. Thus, CB1 receptor-me-
diated pathways differentially target adipose tissue depots to a dual effect that 
minimizes cardiometabolic risk, on the one hand, by diminishing fat, and 
that enhances thermogenesis in subcutaneous adipocytes, on the other.
Supported by: sanofi aventis
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Portal IL-6 determines the effect of fat tissue transplantation on glucose 
homeostasis
J.M. Rytka1,2, S. Wueest1,2, E.J. Schoenle1, D. Konrad1,2;
1Division of Diabetology und Endocrinology, University Children’s Hospital 
Zurich, 2Zurich Center for Integrative Human Physiology, University of 
Zurich, Switzerland.
Background and aims: Visceral obesity has been associated with insulin re-
sistance, however the molecular mechanisms relating visceral fat accumula-
tion and hepatic insulin resistance (portal theory) are still not well known. 
The portal theory implicates increased drainage of pro-inflammatory cy-
tokines and lipids from portal drained adipose tissue directly to the liver. We 
applied herein a novel adipose tissue transplantation approach to investigate 
a potential effect of adipose tissue localization and in particular of venous 
drainage (caval versus portal) on glucose metabolism. Moreover, we hypoth-
esized that IL-6 is a major contributor to hepatic insulin resistance associated 
with visceral fat accumulation.
Materials and methods: Epididymal fat pads of six weeks old C57Bl6J donor 
mice were transplanted either to the mesenterium (portal venous drainage) 
or to the peritoneum (caval venous drainage) of healthy littermates. Sham-
operated mice were used as control. After five weeks of transplantation glu-
cose metabolism was assessed by glucose tolerance test (2g/kg body weight) 
and by hyperinsulinemic-euglycemic clamp.
Results: Mice receiving a portal-drained fat transplant developed impaired 
glucose tolerance compared to mice receiving a caval-drained transplant (p< 
0.001) and to sham-operated (p<0.01) mice. In portal transplanted mice, glu-
cose infusion rate (GIR) and insulin-mediated inhibition of hepatic glucose 
production (HGP) during hyperinsulinemic-euglycemic clamp was reduced 
compared to sham-operated mice (p< 0.05) demonstrating the development 
of hepatic insulin resistance in portal transplanted mice. This was also con-
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firmed by reduced insulin-stimulated Akt phosphorylation (p< 0.01) in livers 
of portal transplanted mice. In contrast, hepatic lipid content and Kupffer 
cell activation was not different. Interestingly, Fas-ligand and interleukin-6 
mRNA expression was increased in portal transplanted fat pads. Moreover, 
IL-6 levels of portal transplanted mice were elevated in portal compared to 
systemic plasma samples whereas no difference was found in sham-operated 
mice. Intriguingly, mice receiving a portal drained IL-6-deficient fat trans-
plant showed normal glucose tolerance and hepatic insulin sensitivity. In ad-
dition, expression of pro-inflammatory cytokines was significantly reduced 
in IL-6-deficient transplants.
Conclusion: These results demonstrate an important role for venous drain-
age of adipose tissue on glucose homeostasis. In addition, IL-6 seems to play 
a major role in the development of hepatic insulin resistance associated with 
visceral fat accumulation.
Supported by: SNF,ZIHP
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Hyperactivation of inflammasome-mediated caspase-1: a new 
mechanism underlying increased inflammatory activity in visceral 
adipose tissue 
T.B. Koenen, R. Stienstra, B. van Tits, M.G. Netea, C.J. Tack, 
A.F.H. Stalenhoef, J. de Graaf;
General Internal Medicine, Radboud University Nijmegen Medical Centre, 
Netherlands.
Background and aims: Abdominal adipose tissue, stored viscerally (VAT) or 
subcutaneously (SAT), is metabolically active and secretes a wide variety of 
adipokines and cytokines. It has been suggested that VAT possesses more pro-
inflammatory properties characterized by an enhanced release of cytokines as 
compared to SAT. The pro-inflammatory trait of VAT may account for its 
stronger correlation with insulin resistance, relative to SAT. The inflamma-
tory IL-1 family members IL-1β and IL-18 are increased in obese subjects and 
negatively affect insulin signaling. The inactive pro-forms of both cytokines 
are processed into active IL-1β and IL-18 by a cysteine protease called cas-
pase-1. Activation of this enzyme is mediated by the inflammasome, which 
involves formation of a complex between NOD like receptors and the adapter 
protein ASC. In this study, we assessed the presence of the inflammasome in 
human adipose tissue and tested whether inflammasome-dependent caspase-
1 activation is more dominant in abdominal VAT compared to SAT.
Materials and methods: Paired abdominal SAT and VAT biopsies were ob-
tained from ten mildly obese subjects (BMI: 25-28 kg/m2; aged 40-60 years). 
Intact adipose tissue fragments were immediately cultured for 24 hours from 
both depots after which medium, RNA, and protein lysates were collected to 
determine the expression of the inflammasome components and the secre-
tion levels of pro-inflammatory cytokines.
Results: Ex-vivo experiments using adipose tissue explants cultures revealed 
a higher release of bioactive IL-1β (10-fold; P < 0.05) and IL-18 (4-fold; P < 
0.05) from VAT compared to SAT. The increased secretion of both cytokines 
was significantly reduced when caspase-1 activity was blocked by the spe-
cific inhibitor pralnacasan. Although caspase-1 protein was expressed in both 
adipose tissue depots, western blot analyses and caspase-1 activity assays re-
vealed a 3-fold (P <0.05) up-regulation of active caspase-1 protein in VAT 
in line with the enhanced production of IL-1β and IL-18. In addition to the 
augmented caspase-1 activity, protein levels of the inflammasome complex 
members ASC and the Nod like receptor NLRP3 were significantly higher in 
VAT. Fractioning of VAT into mature adipocytes and stromal vascular cells 
revealed that caspase-1 gene expression mainly originates from adipocytes, 
while ASC was found to be more expressed in the stromal vascular cells. Con-
current with the enhanced bioactive IL-1β secretion, IL-6 and IL-8 release 
was also induced (3-fold; P < 0.05 and 4-fold; P < 0.05, respectively) in the 
VAT explants while adiponectin secretion was two times lower (P < 0.05).
Conclusion: Our results show that NLRP3 inflammasome components and 
caspase-1 are present in human abdominal adipose tissue and are highly acti-
vated in VAT compared to SAT, resulting in an enhancement of IL-1β and IL-
18 secretion. These findings imply that inflammasome-dependent caspase-1 
activation contributes to the pro-inflammatory status of VAT.
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The role of TGF-beta/Smad3 signalling in the pathogenesis of obese fat 
tissue
Y. Tsurutani, M. Fujimoto, M. Takemoto, K. Yokote;
Department of Diabetes, Metabolism, and Endocrinology, Chiba University 
Graduate School of Medicine, Chiba, Japan.
Background and aims: Obesity is serious problem because it causes many 
kind of life-style related illness, such as type2 diabetes, hypertension, and 
dyslipidemia. In recent years, obesity is recognized to closely associate with 
inflammation, because hypertrophic visceral adipose tissue secretes a variety 
of inflammatory cytokines that lead to insulin resistance. TGF-β has a wide 
range biological effect, differentiation, proliferation, immunomodulation, and 
so on. We have previously reported the role of TGF-β on atherosclerosis and 
diabetic nephropathy, using mice lacking Smad3, a major mediator of TGF-β 
signaling. TGF-β is known to have inhibitory effect for adipocytogenesis, but 
the detail molecular mechanism is not fully understood. On the other hand, 
several studies have shown that cross-talk between TGF-β/Smad3 and Wnt-
β-catenin signaling, also known to have inhibitory effect for adipocytogene-
sis, plays important roles in the regulation of cell differentiation. In this study, 
we aimed to clarify the role of TGF-β/Smad3 signaling in the pathogenesis of 
obese fat tissue, and investigate the role of cross-talk between TGF-β/Smad3 
and Wnt/β-catenin signaling in adipocytogenesis.
Materials and methods: (1) In order to clarify the expression of TGF-β/
Smad3 signaling in obese fat tissue, we isolated epididymal white adipose 
tissue of 12-week old obese ob/ob mice and wild type (WT) mice, and ana-
lyzed the expression of mRNA and protein related to TGF-β/Smad3 signal-
ing. (2) To clarify whether TGF-β inhibits adipocytogenesis dependent on 
Smad3, WT and Smad3 KO (KO) mouse embryonic fibroblasts (MEFs) were 
induced to differentiate into adipocyte with or without 1 ng/ml TGF-β. (3) 
To clarify the role of cross-talk between TGF-β/Smad3 signaling and Wnt-
β-catenin signaling in adipocytogenesis, WT and KO MEFs were stimulated 
with 1 ng/ml TGF-β, and then evaluated the translocation of β-catenin into 
nucleus. Moreover, HW preadipocytes were infected with retrovirus carrying 
empty vector or cby, an antagonist of β-catenin, and then differentiated into 
adipocytes with or without 1 ng/ml TGF-β. (4) To clarify the role of TGF-
β/Smad3 signaling in vivo, eight-week-old WT and KO mice were fed high 
fat diets for 8 weeks. The food intake and body weight were recorded. After 8 
weeks, we performed insulin tolerance test and isolated epididymal WAT for 
histological and genetic analyses.
Results: (1) mRNA and protein expression of TGF-β, and phosphorylation of 
Smad3 were increased in the epididymal WAT of ob/ob mice. (2) TGF-β sup-
pressed adipocyte differentiation on WT MEF, but this inhibitory effect was 
attenuated on KO MEF. (3) TGF-β promoted translocation of β-catenin into 
nucleus on WT MEF, but this effect was attenuated on KO MEF. On the other 
hand, TGF-β suppressed adipocyte differentiation almost completely not 
only on empty vector infected HW cells but also on cby-infected HW cells. 
(4) Despite the amount of food intake was similar between two groups, the 
percent increase in the body weight was significantly larger in KO mice. KO 
mice were more insulin-sensitive than WT mice. WAT from KO displayed a 
larger number of adipocytes with a smaller cell diameter.
Conclusion: TGF-β is highly expressed in obese fat tissue, and it inhibits adi-
pocytogenesis via Smad3 and contributes to development of insulin-resist-
ance. TGF-β emphasizes Wnt-β-catenin signaling, but its inhibitory effect on 
adipocytogenesis may be not dependent on Wnt-β-catenin signaling.
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PI3Kγ in non-hematopoietic cells plays a major role in the promotion of 
obesity, inflammation and glucose intolerance
G. Solinas1, R. Marone2, B. Becattini1, F. Zani1, A. Dulloo1, J.-P. Montani1, 
F. Preitner3, M.P. Wymann2;
1Department of Medicine, Physiology, University of Fribourg, 2University 
of Basel, 3Center for Integrative Genomics, University of Lausanne, 
Switzerland.
Background and aims: Obesity is associated with a state of chronic low-
grade inflammation (metabolic inflammation), which is believed to play an 
important role in the pathogenesis of obesity and type-2 diabetes. Metabolic 
inflammation is characterized by leukocyte infiltration into obese adipose 
tissue, and polarization of T-cells and macrophages toward a more pro-in-
flammatory cellular population. The lipid kinase phosphoinositide 3-kinase 
γ (PI3Kγ) has previously been shown to be central in leukocyte chemotaxis 
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in different models. Furthermore PI3Kγ was shown to play a major role in β-
adrenergic receptors signaling within cardiomyocytes, and in angiotensin II 
signaling in vascular cells. Therefore PI3Kγ is a likely candidate signal trans-
ducer at the interface between inflammation and metabolism. In this study 
we investigated the role of PI3Kγ in diet-induced obesity, metabolic inflam-
mation, and insulin resistance.
Materials and methods: C57BL/6J mice (wt) and mice with a targeted Pi3kγ 
locus (Pi3kγ-/-) were exposed to a high-fat diet (60% of calories from fat) for 
16 weeks. Body weight was measured weekly to determine growth curves. 
Analysis of body composition, energy balance, in-vivo and ex-vivo calorim-
etry were performed. To test the role of PI3Kγ in glucose homeostasis and 
insulin sensitivity we performed glucose tolerance test, insulin tolerance test, 
and hyperinsulinemic-euglycemic clamp. To learn about the cell-type impli-
cated in the metabolic action of PI3Kγ we have generated mice lacking PI3Kγ 
either in hematopoietic or non-hematopoietic cells by adoptive transfer. To 
test the role of the kinase dependent and independent functions of PI3Kγ we 
have investigated mice expressing a mutated form of PI3Kγ where its kinase 
function is selectively blocked (Pi3kγKD/KD). Gene expression profiling was 
performed by DNA microarrays, and by real-time PCR.
Results: When placed on chow diet, wt and Pi3kγ-/- mice display a similar 
phenotype. However, when fed with high-fat diet Pi3Kγ-/- mice are resist-
ant to diet-induced obesity, mainly because of increased energy expenditure. 
Insulin and glucose tolerance were markedly improved in Pi3kγ-/- animals 
versus wt mice, and hyperinsulinemic-euglycemic clamp revealed a four-fold 
increase in insulin sensitivity in Pi3kγ-/- mice compared to controls. Meta-
bolic inflammation was also markedly decreased in Pi3kγ-/- mice compared 
to wt mice. Bone marrow transplantation experiments mapped the role of 
PI3Kγ in diet-induced obesity,-inflammation, and -glucose intolerance in the 
non-hematopoietic compartment. When placed on high-fat diet Pi3kγKD/
KD mice also showed a leaner phenotype, improved glucose homeostasis, 
and decreased inflammation compared to wt mice.
Conclusion: We demonstrate here for the first time that the PI3Kγ activity 
in non-hematopoietic cells plays a major role in the promotion of diet-in-
duced obesity, metabolic inflammation, and insulin resistance by a molecular 
mechanism involving its kinase activity.
Supported by: the Swiss National Science Foundation grant SNF31
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Thirty years of prospective nationwide incidence of childhood type 1 
diabetes: the accelerating increase by time tends to level off in Sweden
Y.T. Berhan1, I. Waernbaum2, T. Lind1, A. Möllsten1, G.G. Dahlquist1;
1Clinical Sciences, Pediatrics, 2Statistics, Umea University, Sweden.
Background and aims: A rising incidence in childhood type-1 diabetes 
(T1D) has been reported from many countries during the last 20 years. Sec-
ond to Finland, Sweden has the highest reported nationwide incidence of 
T1D in the world (>40/100.000). Over a 20 year period (1978 - 1997) the in-
cidence of T1D among ages <15 yrs was almost doubled in Sweden, with the 
largest increase among children aged 0-5 yrs. The change over time has been 
partly explained by changes in lifestyle causing rapid early growth and weight 
development. In the present 30 yr follow up (1978 - 2007) of the Swedish 
Childhood Diabetes Register we describe the current time trend by age, sex 
and birth cohort, and analyze the changes in incidence using statistical mod-
els. We also aim to discuss the possibility to predict numbers of new cases of 
childhood onset T1D using generalised models over long periods of time. For 
discussion we also examine possible correlations between time trend in T1D 
incidence and indicators that mirror calorie-intake.
Materials and methods: The Swedish Childhood Diabetes Registry has re-
corded cases of childhood onset T1D (0-14yrs) since 1 July 1977 with a high 
level of coverage (96-99% of cases). This study is based on 14 721 incident 
cases of childhood onset T1D occurring 1 Jan 1978-31 Dec 2007. Incidence 
numbers were calculated after extracting population data from Statistics Swe-
den. Official population projections were used to predict numbers of new 
cases in Sweden in 2017, 2027 and 2037. Generalized additive models were 
fitted for Poisson distributions and the impact of calendar year at onset in five 
years age groups, sex and interaction terms were tested. Model coefficients 
with significant goodness of fit were used for the prognosis of the trends in 
incidence. Finally a coefficient of determination was calculated to determine 
the extent to which incidence of child hood onset T1D and yearly soft drink 
consumption could be related.
Results: Age and sex specific incidence rates varied from 21·6 (95 % CI 19·4 
- 23·9) during 1978-1980 to 43·9 (95 % CI 40·7 - 47·3) during 2005-2007. Cu-
mulative incidence shifted to younger age at onset over the first 22 years, but 
from the birth year 2000 a reversed trend was seen. Using a model including 
all calendar years, age and sex the predicted number of incident cases may 
more than triple the next 30 years period (648 in 2007 and 2294 in 2037). 
An ecological analysis using soft drink consumption as a marker for eating 
habits and high energy intake showed a strong correlation with incidence rate 
in Sweden (R2= 0·84).
Conclusions: Childhood T1D increased dramatically and shifted to younger 
age at onset the first 22 years of the study period, but since year 2000 for the 
first time we report a reversed trend. The predicted almost tripling of incident 
cases over the next 30 years is thus probably an overestimation. No distinct 
conclusions can be made from the ecological analysis, but the strong correla-
tion between increasing soft drink consumption and increasing trend of T1D 
add an interesting contribution to the discussion.
Supported by: VR and VLL
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The changing natural history of type 1 diabetes: contrasts between those 
diagnosed in the 1960s and 1970s
T.J. Orchard, R.G. Miller, T. Costacou;
Epidemiology, University of Pittsburgh, USA.
Background and aims: Individuals with type 1 diabetes (T1D) face a number 
of different complications, or outcomes, and thus it is important to view, from 
a management perspective, a broad combination of major outcomes of dia-
betes (MOD). Little is known concerning the cumulative risk of MOD for 
childhood onset T1D and to what extent this may have declined with im-
proved care.
Materials and methods: To examine these changes, data from the 22 year 
historical prospective Pittsburgh Epidemiology of Diabetes Complications 
study of childhood onset (<17 years) T1D diabetes were used. Participants, 
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diagnosed between 1960 and 1980 at Children’s Hospital of Pittsburgh, were 
grouped by year of diabetes diagnosis (1960-1969, n=321 and 1970-1980, 
n=368). MOD was defined as diabetes-related death, CAD (MI, revasculari-
zation), stroke, end-stage renal disease, amputation or blindness. Cumula-
tive incidence estimates (figure) were calculated using Weibull accelerated 
failure-time modeling.
Results: By 25 years of diabetes duration, 34% (110) of individuals from the 
1960s cohort had experienced such events (5% had died, 6% had CAD, 2% 
stroke,12% ESRD, 8% blindness, 1% amputation) while for the 1970s cohort 
only 18% had suffered a MOD (3% had died, 2% had CAD, <1% stroke, 2% 
ESRD, 9% blindness, 2% amputation). These observed cumulative incidences 
were close to those predicted using Weibull models, which estimated that 
31% (95% CI 27.4, 35.8) of the 1960s cohort and 20% (95% CI 16.7, 23.9) 
of the 1970s cohort would have an MOD event by 25 years of T1D duration 
(p=0.0001). The majority of the care for the 1960s cohort was before the ad-
vent of self-monitoring of blood glucose and HbA1c testing, while the reverse 
is true of the 1970s cohort.
Conclusion: While these results suggest encouraging falls in many compo-
nents of MOD, it is striking that no reduction is seen for blindness or amputa-
tion, which together now account for 60% of MOD events in the first 25 years 
of T1D in the 1970s cohort as opposed to only 27% in the 1960s. Further 
attention should be paid to the total morbidity burden of those with T1D 
and to understanding why blindness and amputation are not being delayed 
or prevented.
Supported by: NIH
219
HbA1c levels and hospital admission in people with type 1 diabetes
L. Govan, The Scottish Diabetes Research Network Epidemiology Group;
Public Health and Health Policy, University of Glasgow, United Kingdom.
Background and aims: There has been recent concern that very tight glycae-
mic control might be associated with an increase in morbidity in people with 
diabetes. We assessed the relationship between deciles of HbA1c and hospital 
admissions in patients with type 1 diabetes.
Materials and methods: The Scottish Care Information - Diabetes Collabo-
ration (SCI-DC) is a dynamic national register of diagnosed cases of diabetes 
in Scotland. These data were linked to centralised data on hospital admissions 
from Information Services Division (ISD) of NHS National Services. We 
identified 24,760 people with type 1 diabetes during January 2005 to Decem-
ber 2007 and include 19,777 patients with complete recording of covariates. 
Patients were divided into deciles according to levels of HbA1c. All-cause 
admission to hospital was the primary outcome. Logistic regression models 
were used to estimate the association between HbA1c and all cause admis-
sions expressed with decile 3 (mean HbA1c 7.8%, range 7.6%-8.0%) as refer-
ent and adjusted for potential confounding factors including age, sex, previ-
ous vascular disease, creatinine, body mass index and diabetes duration.
Results: 8.1 % of people had HbA1c <7.0% and 16.2% under 7.5%. There was 
a J-shaped relationship of HbA1c to all hospital admissions with highest like-
lihood of admission (adjusted odds ratio 3.54, 95%CI 3.04-4.12) in the high-
est HbA1c decile (12.1%; 10.8-18.4%) but also increased admissions (adjusted 
OR 1.36, 95%CI 1.13-1.64) in the lowest HbA1c decile (6.5%; 4.4-7.1%). Can-
cer admissions showed a broadly inverse relationship with HbA1c (adjusted 
OR 2.38, 95%CI 1.33-6.03) in the lowest decile of HbA1c, see Figure. Vascu-
lar admissions showed a positive relationship with HbA1c with significantly 
higher likelihood of admission in HbA1c deciles 7 through 10 (9.03-18.4%). 
Likelihood of vascular admission was not significantly increased in the low-
est decile of HbA1c (adjusted OR 1.10, 95%CI 0.65-1.87) and an increase in 
all cause admissions remained even after excluding admissions due to cancer 
and hypoglycaemia (adjusted OR 1.26, 95%CI 1.07-1.49).
Conclusion: Low and high mean HbA1c values were associated with in-
creased admission to hospital with lowest rates of admission for any cause in 
deciles 2 through 5 (HbA1c 7.1-8.7%) People with the lowest levels of HbA1c 
had an increase in cancer admissions and this likely reflects reverse causal-
ity in this observational dataset. However, an increase in admissions remains 
even after exclusion of cancer and hypoglycaemic admissions. Overall the 
likelihood of admissions increases markedly with HbA1c and the highest 
levels of HbA1c marks out a group with high likelihood of admission and 
attendant hospital costs.
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Time trends of mortality in patients diagnosed with type 1 diabetes 
below 30 years between 1970-1999 in Finland 
V. Harjutsalo1,2, C. Forsblom1,3, P.-H. Groop1,3;
1Folkhälsan Institute of Genetics, Folkhälsan Research Centre, Biomedicum 
Helsinki, 2National Institute of Health and Welfare, Diabetes Prevention 
Unit, Helsinki, 3Division of Nephrology, Department of Medicine, Helsinki 
University Central Hospital, Finland.
Background and aims: Despite of great advances in the diabetes care, type 
1 diabetes (T1D) is still associated with a premature mortality due to both 
acute and long-term diabetic complications. The aim of this study was to as-
sess long-term time trends in mortality among patients diagnosed with early-
onset (0-14 years) and late-onset (15-29 years) T1D in Finland. In addition, 
we aimed to study causes of deaths addressing the changes in the mortality 
over time.
Materials and methods: Individuals diagnosed with T1D during 1970-1999 
(n=17,306) were identified from the Finnish nationwide population-based 
registers. Vital status and causes of deaths were obtained from the Finnish 
Cause of Death Register until the end of 2007. Patients were stratified into 
subcohorts by the year of diagnosis: 1970-74, 1975-79, 1980-84, 1985-89, 
1990-94 and 1995-99. Cumulative mortalities were evaluated using Kaplan-
Meier method. Crude mortality (per 100,000 person-years) and standardized 
mortality rates (SMR) were calculated. Time trend evaluation in the SMRs 
was performed by means of Poisson regression modeling.
Results: A total of 1,338 deaths were observed during 370,733 person-years of 
follow-up giving an all-cause mortality rate of 361 (342-382). The crude mor-
tality was higher in the late-onset than in the early-onset cohort; 531 vs 245. 
However, the SMR was similar, 2.9 (2.6-3.1) in the early-onset and 2.7 (2.6-
2.9) in the late-onset cohort. Women had higher SMR in both cohorts, 3.8 
(3.4-4.1) and 3.5 (3.0-4.0), compared to men, 2.5 (2.3-2.6) and 2.4 (2.2-4.7). 
Overall cumulative mortality at 35 years of duration of diabetes was 17.9% 
(17.0-18.8). There was no beneficial development in the long-term progno-
sis by diagnosis years. However, a decreasing trend was seen in the 20-year 
cumulative mortality in the early-onset cohort from 4.7% (3.7-5.8) to 4.3% 
(3.3-5.2), 3.6% (2.8-4.5) and 2.7% (1.9-3.4) in the subcohorts 1970-74, 1975-
79, 1980-84 and 1985-89. The SMR at 20 years duration of diabetes decreased 
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from 2.6 (2.0-3.2) to 1.5 (0.8-2.2) from 1970-74 subcohort to 1985-89 (p for 
trend 0.07). There was, however, an inverse trend in the late-onset cohort with 
corresponding rates 4.4% (3.3-5.6), 5.9% (4.6-7.1), 6.5% (5.1-7.8) and 7.9% 
(6.4-9.4). The SMR increased from 1.3 (1.0-1.7) to 2.7 (2.0-3.3) from 1970-74 
to 1985-89 (p for trend 0<0.001). At 20-years of duration of diabetes chronic 
diabetic complications explained 38% of the deaths in the 1970-74 subcohort 
decreasing to 17% in the 1985-89 subcohort among those with early-onset 
diabetes. In the late-onset cohort mortality decreased from 58% to 26%. The 
proportion of alcohol and drug related deaths was high in the early-onset 
diabetes, appr. 25%, while it increased to 39% in the late-onset cohort. SMR 
for alcohol-related deaths was 4.4 (3.1-5.7) and 2.7 (2.2-3.3) in the early and 
late-onset cohorts and was equal for men and women. SMR for suicides was 
significant only in women with early-onset diabetes, 3.3 (1.9-4.7).
Conclusion: We found improvement in survival of people with early-onset 
T1D. On the contrary, individuals with late- onset T1D showed worse surviv-
al after the 1980s compared to the 1970s. Reduction in chronic diabetic com-
plications was, however, replaced by alcohol- and drug-related mortality.
OP 38 Diabetic nephropathy - 
clinical trials
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Intensive glucose control is renoprotective in type 2 diabetes: New 
analyses from ADVANCE
S. Zoungas1, J. Chalmers1, A. Patel1, M. Marre2, C.E. Mogensen3, L. Billot1, 
Q. Li1, M.E. Cooper4, on behalf of the ADVANCE Collaborative Group;
1The George Institute for International Health, The University of Sydney, 
Australia, 2Hôpital Bichat-Claude Bernard and Université Paris 7, France, 
3Aarhus Sygehus, Denmark, 4Baker IDI Heart and Diabetes Institute, 
Melbourne, Australia.
Background: Blood glucose is an important determinant of kidney disease 
among patients with type 2 diabetes. In these analyses we determine the ef-
fects of intensive glucose lowering, targeting an HbA1c of less than or equal 
to 6.5%, a level below the currently recommended targets, on a range of renal 
outcomes among 11,140 patients who had type 2 diabetes and participated in 
the Action in Diabetes and Vascular disease: preterAx and diamicroN-MR 
Controlled Evaluation (ADVANCE) study.
Methods: Patients were randomly assigned to intensive glucose control based 
on the use of gliclazide MR and other therapy as required to achieve an HbA1c 
level less than or equal to 6.5%, or standard glucose control. Treatment effects 
on total renal events, new or worsening nephropathy, new-onset microalbu-
minuria (UACR 30 to 300 g/mg), new-onset macroalbuminuria (UACR >300 
g/mg), progression of albuminuria by at least 1 stage (from normoalbuminu-
ria to either micro- or macroalbuminuria or from micro- to macroalbuminu-
ria) and regression of albuminuria by at least 1 stage, were assessed.
Results: After a median follow-up of 5.0 years, the mean HbA1c level 
achieved in the intensive control group was 6.5% as compared with 7.3% in 
the standard control group. As compared to standard glucose control, inten-
sive glucose control reduced the risk for total renal events by 11% (95% CI 
=(5%-17%), P<0.001), new or worsening nephropathy by 21% (95% CI, 7-
34%,p=0.006), new-onset microalbuminuria by 9% (95% CI, 2-5%, p=0.018), 
new-onset macroalbuminuria by 30% (95% CI, 15-43%, P<0.001) and pro-
gression of albuminuria by 10% (95% CI, 2-16%, p=0.028). In patients with 
albuminuria at baseline, regression by at least one stage occurred in 62% of 
intensively treated patients, with the majority achieving normoalbuminuria. 
Compared to standard glucose control, intensive glucose control increased 
regression of albuminuria by 15% (95% CI, 5-26%, P<0.002). Effects of active 
treatment on total renal events were consistent across subgroups defined by 
median HbA1c level at baseline (p for interaction>0.1).
Conclusion: The gliclazide MR-based intensive glucose control regimen, 
aiming for an HbA1c level less than or equal to 6.5% in patients with estab-
lished type 2 diabetes, provided renal benefits including regression or nor-
malisation of albuminuria. This renoprotection, is evident even among those 
with initial HbA1c levels < 7% and we could not identify an HbA1c threshold 
below which renal benefit was lost.
Supported by: Servier and NHMRC of Australia
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Prevention of microalbuminuria in type 2 diabetes (ROADMAP Trial)
H. Haller1, E. Ritz2, L. Ruilope3, T. Rabelink4, G. Viberti5, for the 
ROADMAP Steering Committee;
1Medical School Hannover, 2University of Heidelberg, Germany, 3Hospital 
12 de Octubre, Madrid, Spain, 4Leiden University Medical Center, 
Netherlands, 5King’s College London School of Medicine, United Kingdom.
Background and aims: Microalbuminuria is an early sign of diabetic ne-
phropathy and increased cardiovascular risk. We investigated whether early 
treatment with an angiotensin receptor blocker (ARB) in diabetic subjects 
with normal albumin excretion delays the occurrence of microalbuminuria 
and concomitantly recorded cardiovascular and renal events.
Materials and methods: We studied 4,447 patients with type 2 diabetes and 
at least one additional cardiovascular risk factor in a randomized, double-
blind, multicentre, controlled, and event-driven (onset of microalbuminu-
ria) trial. They received either 40 mg olmesartan or placebo once daily for 
a median duration of 3.2 years. In both groups, additional antihypertensive 
drug treatment (except ACE inhibitors or ARBs) was used to reach the target 
blood pressure of <130/80 mmHg.
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Results: Baseline eGFR, blood pressure and cardiovascular disease (CVD) 
risk profiles were comparable in both groups. Nearly 80% of the subjects in 
the olmesartan group and 71% in the placebo group achieved target blood 
pressure at month 48. Kaplan-Meier analysis showed a cumulative incidence 
of microalbuminuria of 8.2% (n=178) with olmesartan and 9.8% (n=210) with 
placebo which represents a risk reduction of 23% (HR: 0.77; 95.1% CI: 0.63 to 
0.94; p= 0.01) in favour of subjects receiving olmesartan. At study end eGFR 
was lower in the olmesartan-treated subjects (80.1 vs. 83.7 mL/min/1.73 m2, 
p<0.001). In both groups 23 subjects had a doubling of the baseline serum 
creatinine. Overall cardiovascular morbidity and mortality rate was low and 
similar between groups with cardiovascular morbidity events in 81 (3.6%) 
and 91 (4.1%) patients, and total mortality in 26 (1.2%) and 15 (1.7%) on 
olmesartan and placebo, respectively (p> 0.1). Cardiovascular mortality how-
ever was higher (15 (0.7%) vs. 3 (0.1%); p= 0.01) in the olmesartan group, 
possibly due to hypotensive episodes in subjects with pre-existing CVD.
Conclusion: In subjects with type 2 diabetes and excellent blood pressure 
control early treatment with the ARB olmesartan showed a significant risk 
reduction regarding the ‘time to onset of microalbuminuria’. ClinicalTrials.
gov ID no.: NCT00185159.
Supported by: Daiichi Sankyo
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Renin angiotensin system blockade is effective in preventing 
microalbuminuria in hypertensive but not normotensive people with 
type 2 diabetes; further analysis of the DIRECT Programme
R.W. Bilous1, H.-H. Parving2, T.J. Orchard3, R. Klein4, M. Porta5, J. Fuller6, 
A.-K. Sjolie7, N. Chaturvedi8;
1Academic Centre, James Cook University Hospital, Middlesbrough, 
United Kingdom, Rigshospitalet, Copenhagen, Denmark, 3Epidemiology, 
University of Pittsburgh, 4Ophthalmology, University of Wisconsin School 
of Medicine, Madison, USA, 5Internal Medicine 1, University of Turin, 
Italy, 6Epidemiology, University College, London, United Kingdom, 
7Ophthalmology, Odense University Hospital, Denmark, 8International 
Centre for Circulatory Health, Imperial College, London, United Kingdom.
Background and aims: Renin angiotensin system (RAS) blockade prevents 
microalbuminuria in people with type 2 diabetes (T2DM) at high cardio-
vascular risk. However, most of these studies measured albumin:creatinine 
ratio on a single spot urine to define microalbuminuria. Using multiple timed 
overnight collections the DIRECT Programme could not demonstrate a ben-
efit of RAS blockade on the development of persistent (3 of 4 consecutive 
samples > 20 μg/min) microalbuminuria. We re-analysed our data using the 
less stringent microalbuminuria definition of a single value >20μg/min to be 
more consistent with previous studies.
Materials and methods: 1905 people with T2DM and mild/moderate retin-
opathy were randomised to Candesartan (titrated to 32mg/d) or placebo. At 
baseline all were normoalbuminuric (median albuminuria 5.5 (IQR 3.5,8.5) 
μg/min. 62% were hypertensive (mean BP at entry 139/79 mmHg) and 38% 
normotensive (BP < 130/85, mean 123/75 mmHg). Subjects collected 2 timed 
overnight urine collections annually for at least 4 years.
Results: The adjusted risk (Hazard Ratio - HR) and (95% CI) for micro-
albuminuria for Candesartan versus placebo was 0.80 (0.67,0.96) p = 0.016. 
This beneficial effect was similar in normotensive (HR 0.81 (0.61,1.09) p = 
0.166) and hypertensive (0.79 (0.63,0.99) p = 0.037) individuals at baseline 
although remaining statistically significant only in the latter. In contrast, no 
beneficial effect of Candesartan was seen using our more stringent definition 
of persistent microalbuminuria (HR 0.80(0.58,1.11); 0.66(0.40,1.09) ; and 
0.91 (0.60,1.40) for the entire group, normotensive and hypertensive subjects 
respectively; p = NS for all.
Conclusion: Candesartan is effective at preventing microalbuminuria in 
people with T2DM and hypertension using the looser definition of a single 
positive sample. No effect was seen in people with T2DM and normal blood 
pressure. These results highlight the need for careful and standardized defini-
tions of early nephropathy in intervention trials.
Supported by: Astra Zeneca and Takeda
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Aldosterone reduction during 24 weeks of treatment with aliskiren 
or placebo added to losartan in patients with type 2 diabetes and 
nephropathy, an AVOID substudy
F. Persson1, H.-H. Parving2,3, J.B. Lewis4, E.J. Lewis5, N.K. Hollenberg6;
1Steno Diabetes Center, Gentofte, 2Medical Endocrinology, Rigshopitalet, 
Copenhagen, 3Faculty of Health Sciences, Aarhus University, Denmark, 
4School of Medicine, Vanderbilt University, Nashville, 5Medical Center, Rush 
University, Chicago, 6Brigham and Women’s Hospital, Harvard Medical 
School, Boston, USA.
Background and aims: Aldosterone suppression reduces albuminuria in 
diabetic and non-diabetic patients, and is known to improve cardiorenal 
prognosis. This study assessed the effects on urinary aldosterone, plasma 
renin activity (PRA) and plasma renin concentration (PRC) of direct renin 
inhibition with aliskiren (ALI) in combination with the ARB losartan (LOS) 
and optimal antihypertensive therapy in the Aliskiren in the EValuation of 
PrOteinuria In Diabetes (AVOID) study.
Materials and methods: In the AVOID study, 599 patients aged 18-85 years 
with hypertension and diabetic nephropathy received 6 months’ ALI (150 mg 
force titrated to 300 mg after 3 months) or PBO added to LOS 100 mg and 
optimal antihypertensive therapy. Study exclusion criteria comprised non-
diabetic kidney disease, urinary albumin:creatinine ratio (UACR) >3500 mg/
g, eGFR <30 ml/min/1.73 m2 and serum potassium >5.1 mmol/l. Urinary 
aldosterone, PRA and PRC were measured at baseline of the double-blind 
period and after 24 weeks in a subset of 133 patients.
Results: ALI added to LOS provided large reductions from baseline in urinary 
aldosterone compared with adding PBO (−24% vs. −4%, p=0.017) at week 24. 
There was no significant difference between the aliskiren and placebo groups 
in the proportion of patients with aldosterone breakthrough (ALI 35%, PBO 
46%, p=0.199). There was no correlation between change in urinary aldoster-
one levels and change in UACR or change in systolic blood pressure (SBP). 
ALI treatment reduced PRA by 90% at 24 weeks (p<0.001); PBO treatment 
had no significant effect. PRC increased by 228% from baseline with ALI and 
decreased by 17% with PBO (p<0.001).
Conclusion: Adding ALI to LOS and optimal antihypertensive therapy pro-
vided significant, long-term reductions in urinary aldosterone beyond those 
provided by ARB and optimal antihypertensive therapy. Reduction in PRA 
by ALI treatment may be a potential mechanism behind the reduction in uri-
nary aldosterone levels.
Supported by: Novartis
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Acute administration of the GLP-1 receptor agonist, Exenatide, restores 
impaired central responses to food ingestion in type 2 diabetes
Y. Nathan1, S. Lee2, T. Evans3, S. Coates3, L.J. Reed4, M.J. Brammer2, F.O. 
Zelaya2, S.A. Amiel1;
1Diabetes Research Group, King’s College London, 2Brain Image Analysis 
Unit, Institute of Psychiatry, 3Paxton Green Health Centre, 4Institute of 
Psychiatry, London, United Kingdom.
Background and aims: An appetite control system that allowed continued 
eating when food is available would be of evolutionary advantage in a hunter-
gatherer lifestyle but would predispose to obesity in the modern world. In-
cretins, such as GLP-1, are secreted by the gastrointestinal tract in response 
to food ingestion and are involved in the satiety response that terminates eat-
ing. Incretin responses to food ingestion are abnormal in obesity and Type 
2 diabetes (T2DM) and incretin-based therapies can deliver weight loss and 
improved diabetic control. The aim of our study was to use the GLP-1 recep-
tor agonist Exenatide to explore the central control of appetite and satiety 
in people with T2DM, using functional magnetic resonance imaging (fMRI) 
and the food cue of food image viewing.
Materials and methods: 12 subjects with lifestyle ± metformin treated dia-
betes (age 55.0 ± 1.8 yrs, BMI 31 ± 1.7, HbA1c 7.1 ± 0.2%) underwent 4 
fMRI brain scans, while observing images of food and non-food shown in a 
block design paradigm, after overnight fast. Satiety and hunger were assessed 
by visual analogue scales before and after both ingestion and image viewing. 
On two occasions, subjects consumed a mixed meal (554kcals) as 200 mls 
chocolate ice cream (FED studies); on two they took 50 mls water to mimic 
the physical actions of ingestion (FASTED), prior to image viewing. A single 
subcutaneous injection of either an active GLP-1 receptor agonist (10 mcg 
Exenatide), or placebo was given immediately prior to each scan. Scans were 
done in random order with subject and investigator blinded to the nature of 
the injection. Changes in blood oxygenation level dependent (BOLD) signal 
collected during image viewing were analysed with XBAM software. Brain 
regions with changes in activation in response to food image viewing, shown 
by changes in BOLD signal, were compared using sum of squares (SSQ). Data 
from 12 healthy volunteers, age 25± 1.2 yrs, BMI 22±0.8 were available for 
comparison.
Results: Subjects felt more hungry after water in the fasted state (p=0.01), 
an effect reduced by Exenatide (p<0.01). Visual cortical activation occurred 
in all subjects and conditions, with BOLD signal change in response to food 
and non-food images (p=0.9). In contrast, distinctive BOLD signal changes 
showed activation in the ventral tegmental area (VTA) in T2DM patients ob-
serving food images when FED, which were not present FASTED (p=0.036). 
The activation was reduced in FED by Exenatide (p<0.02 vs FASTED pla-
cebo), to a degree not different from the FED non-diabetic data (p=0.70). 
The T2DM FED response to food image viewing was not different from the 
non-diabetic FASTED state (p=0.13).
Conclusion: The VTA is central to perception of the reward value of food 
and in animal studies its responses are affected by insulin. Its activation pat-
tern in T2DM after eating is different from in health, resembling the healthy 
response to food cues in the fasted state. Acute elevation of incretin action, 
by Exenatide, restores the reward circuitry response of the early T2DM in the 
fed state towards normal. The T2DM activation pattern indicates a failure of 
satiety and would be expected to encourage prolonged eating. Such a mecha-
nism may contribute to obesity in people with insulin resistant diabetes.
Supported by: Eli Lilly UK
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Abnormal reward processing towards appetizing food in obesity
L. Nummenmaa1, J. Hirvonen2, J. Hannukainen2, A. Karmi2, P. Nuutila2;
1Department of Biomedical Engineering and Computational Science, Aalto 
University, Espoo, 2Turku PET Centre, Finland.
Background and aims: Comparative studies have identified an interconnect-
ed network comprising of subcortical and frontocortical regions in various 
aspects of reward processing. This reward circuit plays a key role in guiding 
appetitive behaviours, and its dysfunctions have been associated with obes-
ity. The aim was to study brain metabolism of glucose and the processing of 
anticipatory food reward in obesity.
Materials and methods: The brains of 19 morbidly obese (age 46±10 years, 
BMI 43.9±3.7 kg/m2) and 16 lean individuals (age 48±10 years, BMI 24.1±2.1 
kg/m2) were studied with 2-[18F]fluoro-2-deoxyglucose positron emission to-
mography (PET) during euglycemic hyperinsulinemia, and with functional 
magnetic resonance imaging (fMRI) while anticipatory food reward was in-
duced by repeated presentations of appetizing and bland food pictures.
Results: We found that in obese individuals glucose metabolic rate (GMR) of 
the caudate nucleus was elevated when compared to controls (4, 8, 4, T = 3.97, 
p = .03 SVC), but not in any other a priori region of interest. Responses to all 
foods (appetizing and bland) were higher in obese patients than in controls 
in the left inferior occipital gyrus (-39, 59, -8, T = 3.76, p < .005, unc.), left 
amygdala (-30, -10, -27, T = 3.89, p < .005, unc.), right posterior cingulate 
cortex (8, -38, 19, T = 3.84, p < .005, unc.), and right postcentral gyrus (56, 
-16, 30, T = 3.81, p < .005, unc.). However, responses were lower in obese 
than in lean subjects in the left superior frontal gyrus (-24, 49, 4, T = 3.95, p < 
.005, unc.). Obese patients showed elevated functional responses to appetiz-
ing vs. bland food viewing compared with controls specifically in the right 
caudate nucleus, whereas they had lowered functional responses in the left 
insula, lateral frontal cortex, superior parietal lobule, right orbitofrontal cor-
tex and superior temporal gyrus. The evaluation of functional connectivity of 
the caudate nucleus revealed that obese patients showed significantly larger 
coupling between right caudate nucleus and right basolateral amygdala (33 -5 
-16, T = 3.92, p < .005, unc.), primary somatosensory cortex (39, -13, 32, T = 
3.63, p < .005) and posterior insula (30, 14, 18, T = 3.47, p < .005) than lean 
control subjects. This abnormal connectivity was specific to obesity, since no 
task-dependent changes in connectivity while viewing appetizing vs. bland 
foods were observed in the whole study group.
Conclusion: We found that obese individuals had increased hemodynamic 
responses in the caudate while viewing appetizing vs. bland foods, and in-
creased amygdala responses to both appetizing and bland foods. Moreover, 
while viewing appetizing vs. bland foods the functional connectivity of the 
caudate nucleus and amygdala was increased in the obese vs. lean individu-
als. Conversely, insular cortex showed elevated responses to appetizing vs. 
bland foods in lean vs. obese individuals. These data show that adiposity is 
associated with caudate nucleus’s elevated baseline activity, responses to ap-
petizing foods as well as functional connectivity with amygdala and insula 
while viewing appetizing and bland foods. The elevated amygdala responses 
to foods and increased amygdalo-striatal connectivity and high tonic GMR in 
obese patients could be the critical mechanism which would explain overeat-
ing in obesity.
Supported by: EU FP6 (18734, HEPADIP), Academy of Finland grant, 
AivoAALTO Grant
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MRI-measured cerebral microbleeds and their relation to cognitive 
functioning and cerebral activity in patients with longstanding type 1 
diabetes mellitus
E. van Duinkerken1,2, M.P. Wattjes3, F.J. Snoek2, E.H. Serné4, M. Klein2,  
C.J. Stam5, R.G. IJzerman1, F. Barkhof3, M. Diamant1;
1Diabetes Centre / Department of Internal Medicine, 2Department of 
Medical Psychology, 3Department of Radiology, 4Department of Internal 
Medicine, 5Department of Clinical Neurophysiology / MEG Centre, VU 
University Medical Centre, Amsterdam, Netherlands.
Background and aims: Only recently an increased occurrence of cerebral 
microbleeds (CMB), a magnetic resonance imaging (MRI) marker of vas-
cular fragility, was reported in type 2 diabetic patients, in particular in those 
with proliferative diabetic retinopathy (DRP), relative to non-diabetic sub-
jects. Here, we explored the relationship of CMBs, cognitive functions and 
functional brain connectivity, using MRI, neuropsychological assessment and 
magnetoencephalography (MEG), respectively, in a sample of patients with 
type 1 diabetes (T1DM) with and without microangiopathy and controls.
Materials and methods: Forty-eight T1DM patients with microangiopathy, 
43 T1DM patients without microangiopathy and 42 healthy controls under-
went MRI imaging using susceptibility-weighted imaging (SWI) to detect 
CMBs and neuropsychological assessment to measure cognitive perform-
ance. Blood was drawn and cortical communication was recorded by MEG.
Results: Nineteen participants (14.3%) showed one or more CMBs on SWI, 
of whom 11 had T1DM with microangiopathy (9.0%), 3 were T1DM patients 
without microangiopathy (2.3%) and 4 were controls (3.0%). Those with 
CMBs were older (45.8 vs 39.3 P = 0.007). CMBs were mainly located in the 
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temporal and frontal areas. There were no statistically significant more CBMs 
in the whole diabetes group compared to controls (P > 0.05), however, a sig-
nificant linear trend across the 3 groups was observed (P = 0.035). Adjust-
ment for age, gender, hypertension and depressive symptoms yielded signifi-
cantly more CMBs in T1DM participants with microangiopathy as compared 
to T1DM patients without microangiopathy and healthy controls (both P > 
0.05). Adjusting for either diabetes duration or diabetes age-of-onset, did not 
change the results. Interestingly, individuals with CMBs did not show cogni-
tive impairments (P > 0.05), but demonstrated lower cortical communica-
tion in the lower alpha-band (8 - 10 Hz) compared to all individuals without 
CMBs (P < 0.05). Per group analyses yielded the same pattern of changes in 
cerebral communication, albeit in different frequency bands, with preserved 
cognitive functions. In T1DM patients the presence of CMBs was significant-
ly correlated with later-onset of diabetes (P < 0.05).
Conclusion: Taking into account the relatively small number of patients af-
fected, the results indicate that CMBs are more prevalent in T1DM patients 
with microangiopathy and are related with changes in cerebral communica-
tion. CMB presence was not associated with impaired cognitive functioning, 
but related to older age at diabetes onset. We hypothesize that the observed 
changes in cortical communication may reflect a restructuring of neural net-
works in order to compensate for structural damage, thus allowing cognitive 
functions to be temporarily spared. Whether CMBs are a marker of future 
cognitive decline, and whether these abnormalities are diabetes-specific, re-
mains to be determined in large-scaled longitudinal studies.
Supported by: Dutch Diabetes Research Foundation
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Comparison of neuropsychological testing and 99mTc-HMPAO brain 
SPET findings in patients with diabetes mellitus type 1 and type 2
M. Migra1, M. Kutlák1, A. Lacko2, P. Galajda1, M. Mokan1;
11. Internal Clinic, Faculty Hospital in Martin, 2Internal Clinic, Central 
Military Hospital, Ružomberok, Slovakia.
Background and aims: Diabetes mellitus is a chronic metabolic disease char-
acterised by macrovascular and microvascular complication. Although the 
evidence of cognitive deterioration in diabetic individuals is well known, the 
neuroanatomical substrate of subscribed changes remains uncertain. Evalu-
ate and localise the resting alterations in brain microcirculation and compare 
them with affected cognitive domains.
Materials and methods: We examined 47 patients, 20 individuals with 
T1DM (13 men, 7 women), average age 37 ± 12,7 years, 27 individuals with 
T2DM (14 women, 13 men), average age 60 ± 9,2 years. Diabetic patients 
were compared with control group composed of 40 non-diabetic age-related 
individuals. Written consent was obtained from all patients prior the study. 
Patients performed battery of neuropsychological testing including 9 tasks 
covering 5 cognitive domains. Individuals underwent 99mTc-HMPAO brain 
SPET. Vascular and metabolic determinants were recorded. Collected data 
were analysed using nonparametric statistic methods.
Results: Compared to control group we found in type 1 diabetics changes in 
working memory, mental flexibility, mental recording, vigilance and infor-
mation processing (p = 0,01) without significant correlation to gender, age, 
metabolic compensation or duration of diabetes (p > 0,05). In type 2 dia-
betes we discovered deterioration of short time memory, mental flexibility, 
information processing (p < 0,01) correlated with duration of diabetic disease 
more than 10 years (p = 0,01). Brain SPET revealed hypoperfusion on micro-
circulatory level in 65 % of T1DM group (thalamus and basal ganglia 30 %, 
temporal lobe 20 %, parietal lobe 40 %, cerebellum 25 %, occipital lobe 10 
%, frontal lobe 10 %). In T2DM cohort was hypoperfusion in 81 % patients 
(parietal lobe 64 %, temporal lobe 36 %, occipital lobe 27 %, cerebellum 18 
%, thalamus and basal ganglia 9 %. In frontal lobe we have seen both hypop-
erfusion and hyperperfusion in 32%) related to age and duration of diabetes. 
Comparing the results of neuropsychological testing to brain SPET findings 
in both diabetic groups we found anatomically equivalent correlation only in 
verbal memory test, digit span test backwards and Stroop test C.
Conclusion: We confirmed expected cognitive changes in diabetic individu-
als, which did not correlate with brain SPET findings in all cognitive domains. 
Therefore we suggest multidimensional patomechanism including changes in 
perfusion, neurotransmitters and neuronal metabolism.
OP 40 The diabetic patient in the 
hospital
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Mean glucose during ICU admission is related to mortality by a U-
shaped curve; implications for clinical care
J.H. DeVries1, S.E. Siegelaar1, J. Hermanides1, H.M. Oudemans-van 
Straaten2, P.H.J. van der Voort2, R.J. Bosman2, D.F. Zandstra2;
1Internal Medicine, Academic Medical Centre, 2Intensive Care Medicine, 
Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands.
Background and aims: Reducing hyperglycaemia at the ICU reduces mortal-
ity but recently the optimal glucose target range has become unclear. We in-
vestigated in which way glucose regulation, defined as mean achieved glucose 
concentration during admission, is associated with ICU mortality, thereby 
trying to reconcile the conflicting data from the Leuven and NICE-SUGAR 
trials.
Materials and methods: We performed a retrospective database cohort study 
including patients admitted to a 20-bed medical/surgical ICU in a teaching 
hospital between January 2004 and December 2007. 5983 patients were eli-
gible for analysis after excluding readmissions, patients with a withholding 
care policy and patients with only one glucose value measured. From this 
population we randomly selected 2435 patients with a surgical/medical ICU 
admission ratio of 55/45%, to enable comparison with the Leuven and NICE-
SUGAR populations. All patients were treated for hyperglycaemia using a 
fully computerized tight glucose algorithm targeting for glucose values be-
tween 4.0 and 7.0 mmol/l. The cohort was subdivided in deciles and logistic 
regression analysis was performed adjusted for age, sex, severity of disease 
and admission duration to assess the odds ratio of ICU mortality per glucose 
stratum.
Results: A median (IQR) of 12 (8-14) glucose values per admission day per 
patient was collected. The total population and the random sample were 
comparable regarding all baseline characteristics. We observed a U-shaped 
relation between mean glucose and mortality, with high mortality in the low-
est and highest glucose-stratum, 21.3% and 27.6% respectively. Mean glucose 
values <7.0 mmol/l and >9.0 mmol/l were associated with significantly in-
creased ICU mortality compared with the stratum with the lowest mortality 
(OR 2.06-4.24 and 2.33-6.70 respectively; Figure). Limitations of the study 
were its retrospective design and possible incomplete correction for severity 
of disease.
Conclusion: Mean glucose during ICU admission is related to mortality by a 
U-shaped curve. A ‘safe range’ of mean glucose regulation might be defined 
between 7.0 and 9.0 mmol/l. The U-shaped curve may help to explain the in-
creased mortality in the intensively treated group of the NICE-SUGAR study 
but not the low mortality in the intensively treated groups of the Leuven stud-
ies. According to these findings and awaiting further studies we recommend 
treating hyperglycaemia at the ICU in a moderately intensive way, targeting 
for mean glucose values between 7.0 and 9.0 mmol/l and avoiding hypogly-
caemia.
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Accuracy and reliability of continuous glucose monitoring at the ICU; a 
head to head comparison of two subcutaneous glucose sensors in cardiac 
surgery patients
S.E. Siegelaar1, T. Barwari1, J. Hermanides1, W. Stooker2,  
P.H.J. van der Voort3, J.H. DeVries1;
1Internal Medicine, Academic Medical Centre, 2Cardiothoracic Surgery, 
Onze Lieve Vrouwe Gasthuis, 3Intensive Care Medicine, Onze Lieve Vrouwe 
Gasthuis, Amsterdam, Netherlands.
Background and aims: Both hyperglycaemia and hypoglycaemia are com-
mon during intensive care unit (ICU) stay and are associated with increased 
mortality. Continuous glucose monitoring (CGM) is a promising tool to assist 
glucose control but the accuracy and reliability of these devices in critically ill 
patients is uncertain. We studied two different CGM devices post-operatively 
in cardiac surgery patients in an investigator initiated trial.
Materials and methods: Two CGM devices (Guardian RT, Medtronic Min-
imed; FreeStyle Navigator, Abbott Diabetes Care) were placed subcutaneous-
ly in the abdominal area in 60 patients before surgery. Both devices were cali-
brated simultaneously upon arrival at the ICU after surgery. Further calibra-
tions were performed according to manufacturers’ instructions. An arterial 
blood glucose value was measured with an AccuChek device as a reference 
value every two hours. Mean absolute difference (MAD) between reference 
and sensor glucose values was calculated in six 5 minute intervals after the 
time of the reference glucose, to assess a possible delay for the CGM devices.
Results: In total, 1017 reference glucose values were measured. Of those, 
77.8% could be paired with a Guardian and 91.8% with a Navigator glucose 
value. Missing values indicate technical problems with the device. Median 
(IQR) MAD was significantly smaller for Navigator compared to Guardian 
glucose measurements at the first and second interval (0.11 [0.08-0.16] and 
0.10 [0.08-0.16] compared to 0.14 [0.11-0.18] and 0.14 [0.11-0.17], p=0.05 
and p=0.001, Wilcoxon signed ranks test; figure). The lowest MAD of the 
Navigator was observed in the second interval, 5-9 minutes after reference 
glucose. The MAD of the Guardian was lowest after 15-19 minutes. Only for 
the Guardian there was a significant decrease over time indicating a delay 
(p=0.01, repeated measures ANOVA). For glucose values ≤6 mmol/l median 
(IQR) MAD was lower for the Navigator in all intervals, however not sig-
nificantly (interval 1: Navigator 0.13 [0.10-0.33], Guardian 0.26 [0.17-0.41], 
p=0.24). The limited number of values ≤6 mmol/l (n=121) could have limited 
the power of this sub-analysis.
Conclusion: We report that the FreeStyle Navigator CGM system performed 
better than the Guardian RT in accuracy as well as reliability in post-opera-
tive cardiac surgery patients during ICU stay. Remarkably, the MAD of both 
sensors was quite good as compared to reported data for outpatients. Based 
on our results we conclude that this device can be used in this group of ICU 
patients characterized by relatively low disease severity scores and low mor-
tality rates. Whether or not the use of CGM improves glycemic control and 
mortality has needs further research.
Supported by: an EFSD/LifeScan grant
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Intensive care unit (ICU) glucose monitoring measured in plasma using 
mid-infrared spectroscopy
G. Lim1, C. Calentine1, J. Gable1, L. Nosek2, T. Heise2;
1Optiscan Biomedical Corporation, Hayward, USA, 2Profil Institut für 
Stoffwechselforschung GmbH, Neuss, Germany.
Background and aims: There are increasing calls for a highly accurate, au-
tomated system to enable tight glycemic control and avoid hypoglycemia in 
an ICU setting. The OptiScanner (model 5000) is a glucose monitor based on 
mid-infrared spectroscopy that draws blood samples (120 µl) and measures 
plasma glucose concentration approximately every 15 min. The goal of this 
study was to validate the performance of the OptiScanner at different glyc-
emic levels in a healthy diabetic patient population.
Materials and methods: Sixty people (50 males, age 49 (18-65) years, BMI 
29.7 (21.4-40.1 kg/m²)) with type 1 (n=18) or type 2 (n=42) diabetes were 
connected to an OptiScanner. Their blood glucose concentrations were kept 
in a euglycemic (75-180 mg/dl), hypoglycemic (180 mg/dl) range by iv ad-
ministrations of insulin and glucose. Each OptiScanner blood sample was 
automatically withdrawn from a forearm vein. Blood samples for reference 
measurements using the YSI 2300 were withdrawn from the same arm within 
60 seconds of the OptiScanner draw and analyzed immediately.
Results: The aggregate data points (1155 paired readings between the OptiScan-
ner and the YSI 2300) were within ISO standard, with 98.6% of the glucose val-
ues within +/-20% above 75 mg/dL and +/- 15 mg/dl below this value. A Clark 
Error Grid analysis showed a total of 1139 points (98.6%) in Zone A. Points out-
side of A exceeded the A zone boundary by an average of 4.3% and a maximum 
of 26.4%. The total coefficient for variance was 6.4%. The total r² was 0.99.
Conclusion: These preliminary results show that the OptiScanner is highly 
accurate in a healthy diabetic population.
Supported by: Optiscan Biomedical Corporation
232
Randomised study of basal bolus insulin therapy in the inpatient 
management of patients with type 2 diabetes undergoing general surgery 
(RABBIT 2 Surgery)
G.E. Umpierrez1, D. Smiley1, S. Jacobs1, L. Peng2, A. Temponi1, C. Newton1, 
D. Umpierrez1, P. Mulligan1, D. Olson1, M. Rizzo3;
1Medicine-Division of Endocrinology, Emory University, 2Department 
of Biostatistics, Emory University Rollins School of Public Health, 
3Department of Surgery, Emory University, Atlanta, USA.
Background and aims: This randomized multicenter trial compared the ef-
ficacy and safety of a basal/bolus regimen to sliding scale regular insulin (SSI) 
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in non-ICU patients undergoing general surgery. Study outcomes included 
differences in daily BG levels and a composite of hospital complications in-
cluding postoperative wound infection, pneumonia, respiratory failure, acute 
renal failure, and bacteremia.
Materials and methods: A total of 211 patients (age: 58±11 yr, admission 
BG: 190±92 mg/dl, A1C: 7.72±2.2%, ±SD) with a BG between 140-400 mg/dl 
and a history of T2DM >3 months were randomized to glargine + glulisine 
(Gla+Glu, n=104) or SSI (n=107). Total daily dose of Gla+Glu was started at 
0.5 U/kg, given half as glargine once daily and half as glulisine before meals. 
SSI was given 4 times/day for BG >140 mg/dl.
Results: The mean daily BG level after the 1st day of Gla+Glu vs. SSI was 
145±32 mg/dl and 172±47 mg/dl, respectively, p<0.01. The percentages of BG 
readings <140 mg/dl were higher in Gla+Glu than SSI (53±30% vs 31±28%, 
p<0.001). We observed significant difference between groups in the frequency 
of the composite outcome (24.3% and 8.6% in the SSI and Gla+Glu, respec-
tively; P=0.003). There were no differences in mortality (1% vs 1%); however, 
there were reductions with Gla+Glu as compared with SSI in wound infec-
tion (2.9% vs 10.3%), pneumonia (0% vs 2.8%), and acute renal failure (3.8% 
vs 10.3%), p=0.05, 0.24, 0.10. Compared to SSRI group, Gla+Glu reduced the 
number of post-surgical ICU admissions (19.6% vs 12.5%, p=0.159) and ICU 
length of stay (3.2±2 vs 1.2±0.6 days, p=0.003). A BG <70 mg/dl was reported 
in 23.1% of patients (1.9 % of BG readings) in the Gla+Glu and in 4.7% (0.3% 
of BG readings) in the SSI group, p<0.001; but only 3.8% of patients in the 
Gla+Glu and 0% in SSI had a BG <40 mg/dl (p=0.057).
Conclusion: In summary, treatment with glargine once daily plus glulisine 
before meals improved glycemic control and reduced hospital complications 
compared to SSI in general surgery patients with T2DM. Our study indicates 
that basal/bolus insulin regimen is preferable to SSI in the hospital manage-
ment of general surgery patients with T2DM. NCT00596687.
Supported by: Investigator-initiated grant from Sanofi-Aventis
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Effect of different dietary fat quantity and quality on skeletal muscle fatty 
acid handling in subjects with the metabolic syndrome
A. Jans1, A.M.J. van Hees1, I.M.F. Gjelstad2, A.C. Tierney3, U. Risérus4,  
C.A. Drevon2, H.M. Roche3, E.E. Blaak1;
1Human Biology, Maastricht University, Netherlands, 2Department of 
Nutrition, University of Oslo, Norway, 3Nutrigenomics Research Group, 
University College Dublin, Ireland, 4Department of Public Health and 
Caring Sciences, Uppsala University, Sweden.
Background and aims: Insulin resistance is characterized by disturbances in 
lipid metabolism and increased fat storage in ‘non-adipose tissues’ like skel-
etal muscle (SM). The aim of this study was to investigate whether SM gene 
expression and the lipid content and the fatty acid (FA) profile of the SM 
lipids are affected by diets with different fat quantity and quality in subjects 
with the metabolic syndrome (MetS, NCEP criteria).
Materials and methods: 84 subjects (age 57.3±0.9y, BMI 30.9±0.4kg/m2, 42men/
42women) were randomly assigned to one of four isoenergetic diets: high-SFA 
(HSFA); high-MUFA (HMUFA) and two low-fat, high-complex carbohydrate 
(LFHCC) diets, supplemented with 1.24 g/day of long chain n-3 PUFA (LCn-
3) or control for 12 weeks. Insulin sensitivity (SI) was determined by a insulin 
modified intravenous glucose tolerance test. SM biopsies were taken before and 
after the intervention to determine expression of genes involved in lipid metabo-
lism. In a subgroup (n=25, all men) muscle TAG, DAG, free FA (FFA), and phos-
pholipid content, their fractional synthetic rate (FSR) as well as lipid composition 
were determined. The people in the subgroup consumed (before and after dietary 
intervention) a high-fat mixed meal (2.6MJ, 61E% fat) with 200 mg [U-13C]-
palmitate added. Muscle biopsies were taken before and four hours after the meal. 
The FSR per lipid fraction was calculated by dividing the change in 13C-enrich-
ment (at 4h postprandial minus baseline) in each fraction by the change in 13C-
enrichment in the precursor pool (FFA). The study protocol was approved by the 
local Medical Ethical Committee of the Maastricht University.
Results: Expression of genes involved in lipogenesis (SREBP1c, SREBP2, 
ChREBP and ACC2) were downregulated after 12-weeks on HMUFA (mean 
fold change (FC) of -1.3) and on LFHCC LCn-3 (mean FC -1.7) in insulin 
resistant (IR) subjects (below the median of SI), whereas insulin sensitive (IS) 
subjects showed the opposite effect (mean FC +1.6 at both diets). HMUFA 
diet caused reduced DAG content (paired t-test p=0.027) and tended to de-
crease the FSR in TAG (p=0.055) and DAG (p=0.066). LFHCC LCn-3 diet 
reduced the muscle TAG content (p=0.032) and tended to increase percent-
age saturation of DAG (p=0.064).
Conclusion: Both HMUFA and LFHCC LCn-3 promoted a reduction of 
lipogenic genes in IR subjects with the MetS. In a subgroup HMUFA and 
LFHCC LCn-3 reduced DAG or TAG content, respectively, suggesting that 
these diets may reduce muscle fat accumulation by affecting the balance be-
tween fat storage and oxidation.
Supported by: DFN
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Adipokines promote lipotoxic effects of low levels of palmitic acid 
but not oleic acid by reducing fatty acid oxidation and increasing 
diacylglycerol
A. Taube1, B. Platzbecker1, A. Schober1, G. van Echten-Deckert2, M. Bosma3, 
J. Weiss1, K. Jeruschke1, K. Eckardt1, J. Eckel1;
1Institute of Clinical Biochemistry and Pathobiochemistry, German Diabetes 
Center, Duesseldorf, 2Kekulé-Institute LIMES Membrane Biology and 
Lipid Biochemistry, University of Bonn, Germany, 3Department of Human 
Biology, Maastricht University, Netherlands.
Background and aims: Skeletal muscle insulin resistance is an early defect in 
the pathogenesis of type 2 diabetes mellitus. Numerous studies have shown 
that elevated plasma free fatty acid (FA) levels as well as intramyocellular lipid 
accumulation are positively correlated with the incidence of insulin resist-
ance. Furthermore, it is accepted that adipose tissue functions as a secre-
tory organ releasing various adipokines. Aim of this study was to investigate 
combined effects of adipokines with physiological concentrations of free FA 
on human skeletal muscle metabolism. Furthermore, possible differences of 
saturated and unsaturated FA were to be analysed.
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Materials and methods: Differentiated primary human skeletal muscle cells 
(SkMC) were incubated with adipocyte-conditioned media (CM) for 24 h, 
while oleic acid (OA, 100 µmol/l) or palmitic acid (PA) were added for the 
final 18 h of incubation. Subsequently, SkMC were lysed for Western Blot 
analysis, incubated with 14C-FA for FA oxidation, fixed for microscopic ex-
amination, or analysed using thin layer chromatography (TLC).
Results: Incubation of SkMC with CM increased the expression of FA trans-
port protein CD36 (2-fold, n=3), while isolated adipokines failed to produce 
the same effect. Electron microscopic examination showed profound accu-
mulation of lipid droplets after incubation with OA and CM, while there were 
no lipid droplets observed after treatment with PA alone or combined with 
CM. However, mitochondrial morphology was noticeably altered after treat-
ment with PA. Analysis of the lipid droplet coating protein ADRP revealed a 
significantly increased expression after incubation with OA and CM (2-fold, 
n=6). FA oxidation was found to be reduced after incubation with PA and 
CM (by 72%), while incubation with CM (34%), OA (23%), and OA in com-
bination with CM (33%, n≥5) caused a more moderate effect. Additionally, 
treatment of SkMC with a higher FA concentration (300 µmol/l) yielded a 
more severe reduction of FA oxidation by ~90% after treatment with PA and 
CM. TLC analysis revealed a significantly increased diacylglycerol (DAG) 
content (3-fold, n≥3) after incubation with PA and CM.
Conclusion: The results of this study indicate that physiological levels of FA, 
which are described to not affect SkMC metabolism, have deleterious effects 
in combination with adipokines. Hence, it may be speculated that adipokines 
rather than FA may play a more crucial role in mediating insulin resistance, 
since they not only increase FA uptake but also seem to interfere with FA 
metabolism. Furthermore, these results support the notion that saturated FA 
like PA are more detrimental than unsaturated FA like OA. While OA seems 
to increase the potential of the cell to store excess lipids in lipid droplets by 
increasing the expression of ADRP, PA seems to impair mitochondrial integ-
rity and in combination with adipokines leads to incomplete FA oxidation 
and concurrent accumulation of DAG. Thus it may be assumed that already 
at an early stage of weight gain, when lipolysis has not yet contributed to 
increased plasma free FA levels, there might be lipotoxic damage to skeletal 
muscle cells.
235
Splanchnic balance of free fatty acids, endocannabinoids and lipids in 
subjects with NAFLD
A. Kotronen1, J. Westerbacka1, B.A. Fielding2, J. Wahren3, L. Hodson2,  
T. Seppänen-Laakso4, T. Suortti4, J. Arola1, R. Hultcrantz3, S. Castillo4,  
K.N. Frayn2, M. Oresic4, H. Yki-Järvinen1;
1University of Helsinki, Finland, 2University of Oxford, United Kingdom, 
3Karolinska Hospital, Stockholm, Sweden, 4VTT Technical Research Centre 
of Finland, Espoo, Finland.
Background and aims: Animal studies suggest that endocannabinoids could 
contribute to the development of non-alcoholic fatty liver disease (NAFLD). 
In addition, NAFLD has shown to be associated with multiple changes in 
lipid concentrations in liver biopsies. There are no data on splanchnic free 
fatty acid, glycerol, ketone body, endocannabinoid and lipid fluxes in vivo in 
subjects with NAFLD.
Materials and methods: We performed hepatic venous catheterization stud-
ies in combination with [2H2]palmitate infusion in the fasting state and dur-
ing a low-dose insulin infusion (0.5 mU/kg min) in nine subjects with vari-
ous degrees of hepatic steatosis as determined using liver biopsy. Splanchnic 
balance of endocannabinoids and individual lipids was determined using Ul-
tra Performance Liquid Chromatography coupled to mass spectrometry.
Results: Splanchnic free fatty acid (FFA) extraction during the euglycemic 
hyperinsulinemia correlated with liver fat content (r=0.75, p=0.05). Con-
centrations of the endocannabinoid anandamide were higher in arterialized 
(91±33 μmol/l basally) than in hepatic venous (51±19 μmol/l, p<0.05) plas-
ma. Fasting arterial (r=0.72, p=0.031) and hepatic venous (r=0.70, p=0.037) 
concentrations of anandamide were positively related to liver fat content. 
Analysis of fluxes of 85 different triglycerides showed that the fatty liver over-
produces saturated triglycerides. In the plasma FFA fraction in the basal state, 
the relative amounts of palmitoleate and linoleate were lower and those of 
stearate and oleate higher in the hepatic vein than in the artery. Absolute 
concentrations of all non-triglyceride lipids were comparable in arterialized 
venous plasma and the hepatic vein both in the basal and insulin-stimulated 
states.
Conclusion: FFA extraction during hyperinsulinemia correlates with liver fat 
content, consistent with data showing defects in insulin action on lipolysis to 
contribute to liver fat. The human fatty liver takes up anandamide and over-
produces triacylglycerols containing saturated fatty acids, which might reflect 
increased de novo lipogenesis.
Supported by: Academy of Finland, Sigrid Juselius Foundation, HEPADIP,FDRA, 
OF, RAF, HBRF
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Fatty acid class influences spillover from chylomicrons into plasma 
nonesterified fatty acids
R.H. Nelson, A. Smailovic, D. Vlazny, J.M. Miles;
Endocrinology, Mayo Clinic, Rochester, USA.
Background and aims: The mechanism by which diets high in polyunsatu-
rated fatty acids (PUFA) reduce cardiovascular risk is not known. Lipopro-
tein lipase (LPL) mediates dietary fat storage in adipose tissue via its action 
on chylomicron triglycerides, but a portion of LPL-generated fatty acids are 
released directly into the plasma nonesterified fatty acid (NEFA) pool via a 
process known as spillover. The present study was undertaken to determine 
whether there are differences in spillover among different classes of fatty ac-
ids.
Materials and methods: Twelve lean, healthy adults were studied after a 5 
day controlled diet and an overnight fast. Volunteers consumed ~15 mL of a 
liquid meal, consisting of a commercial dietary supplement and [1-13C] tri-
palmitin, [1-13C] triolein and [9,10-3H] trilinolein, every 15 minutes for 6 
hours. [1-14C] palmitate, [U-13C] oleate and [U-13C] linoleate were infused 
intravenously for 2 h. Blood samples were taken for NEFA concentrations, 
tracer enrichment and specific activity, as well as chylomicron and total trig-
lyceride concentration. Systemic rate of appearance (Ra) and spillover were 
calculated for each fatty acid using steady state assumptions.
Results: Total NEFA concentrations were 114±11 μmol/L during meal ab-
sorption. Plasma oleate concentration was significantly higher than palmitate 
or linoleate concentrations (41±5 vs 23±3 and 29±3 μmol/L, respectively; 
p<0.05 for both). The Ra of palmitate was significantly lower than the Ra of 
either linoleate or oleate (0.4±0.03 vs 0.8±0.07 and 0.8±0.06 μmol/kg/min, 
respectively, both p < 0.001). Clearance of linoleate was higher than that of 
either palmitate or oleate (32±3 vs 21±3 and 22±2 mL/kg/min, respectively; p 
< 0.03 for both). Fractional spillover among the 3 groups was 40±4% v 38±3% 
v 23±2% for palmitate, oleate and linoleate respectively. The difference be-
tween linoleate compared to palmitate and oleate was significant (p<0.01 for 
both comparisons). There was no difference between palmitate and oleate 
spillover.
Conclusion: These data show a significant difference in spillover of chylomi-
cron linoleate during meal absorption in normal subjects compared to the 
other two most abundant dietary fatty acids. The low spillover of linoleate 
indicates comparatively efficient storage of this fatty acid and thus less availa-
bility for ectopic fat accumulation in tissues such as liver and skeletal muscle. 
The relationship between this finding and the apparent reduction in cardio-
vascular risk associated with PUFA-enriched diets will require further study.
Supported by: NIH: K23DK082473 & NCRR 1 UL1 RR024150
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Resistin and adipocyte fatty acid binding protein are linked in type 2 
diabetes mellitus and atherosclerosis
C. Höbaus1, M. Grujicic1, M. Ursli1, T. Hoertenhuber1, N. Reinprecht1,  
F. Höllerl1,2, G. Schernthaner2, R. Koppensteiner1, G.-H. Schernthaner1;
1Angiology, Medical University of Vienna, 2Medicine I, Rudolfstiftung, 
Vienna, Austria.
Background and aims: Systemic atherosclerosis is the co-morbidity of type 
2 diabetes mellitus (T2D). Patients with T2D have increased body weight 
and adipokine production. The adipokines resistin and adipocyte fatty acid 
binding protein (AFABP) have each been linked to T2D and atherosclerosis. 
Recently, a direct influence of resistin on AFABP has been demonstrated in 
cell culture of human endothelial cells, whereas respective experiments in 
knockout mice failed. We investigated the interrelationship of resistin and 
AFAB in a cohort study of human individuals.
Materials and methods: Resistin and AFABP serum levels were investigated 
in 168 patients (61 female, 107 male) with systemic atherosclerosis. All pa-
tients suffered from peripheral arterial disease (PAD); 76 patients showed 
additional coronary or cerebral artery disease. Oral glucose tolerance tests 
(oGTT) were performed in all patients. Resistin and AFABP were obtained 
by commercially available ELISA (BioVendor, Modrice, Czech Republic). 
Inter-assay coefficient of variation (CV) and intra-assay CV were 7.8% and 
4.8% for resistin and 6.5%, and 2.9% for AFABP. Students’ unpaired t-test, 
univariate and multivariate regression modeling were applied as appropri-
ate. Skewed data were lg10 transformed to render the distribution normal for 
parametric tests. Normal data are given as mean±STD, non-parametric data 
as median (25%;75%). In multivariate analysis, change of beta (D-beta) over 
10%, were considered as confounding.
Results: According to oGTT, we had 51 subjects with normal glucose me-
tabolism (NGM), 35 subjects with pre-diabetes (PRED, impaired fasting glu-
cose/glucose tolerance), and 82 subjects with overt T2D. Resistin levels did 
not differ (NGM vs PRED vs T2D 6.5±1.7 vs 7.02±2.9 vs 7.26±2.5 ng/ml; 
p=0.195). AFABP levels were significantly higher in diabetes (NGM vs PRED 
vs T2D 29 (16;39) vs 30 (20;41) vs 33 (23;45) ng/ml; p=0.035). By univariate 
regression resistin was associated with AFABP in all patients (beta=0.308; 
p<0.001). Subgroup analysis revealed that the association was based on T2D 
(beta=0.392; p<0.001). Since recent papers have suggested an association be-
tween diabetes, hypertension and resistin in mouse models, data of the T2D 
subgroup were tested for confounding by multivariate modeling. Linear re-
gression revealed that the effect of resistin on AFABP is not affected by the 
subjects’ blood pressure (systolic D-beta=1%; diastolic D-beta=2%), but is 
attenuated with increasing number of anti-hypertensive medication taken by 
the patient (D-beta=11%). Vice versa, alternative linear regression models 
showed that the association of AFABP on resistin is not affected by the sub-
jects’ blood pressure (systolic D-beta=1%; diastolic D-beta=0%) or hyper-
tension medication (D-beta=1%). Furthermore, this association of resistin 
on AFABP or AFABP on resistin was not attenuated by body mass index in 
multivariate models (D-beta=1% and D-beta=4%). The severity of athero-
sclerosis showed no effect on resistin and AFABP levels.
Conclusion: This is the first study to demonstrate an association of the adi-
pokines resistin and AFABP in patients with systemic atherosclerosis. This 
association was due to the existence of diabetes, but not pre-diabetes. Wheth-
er hypertension is interrelated with resistin and AFAB in patients with or 
without diabetes needs to be investigated.
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Asymmetric dimethylarginine does not contribute to endothelial 
dysfunction in subjects with abnormalities of glucose regulation
D. Lucchesi1, L. Pucci1, R.M. Bruno2, L. Ghiadoni2, E. Storti1, E. Russo1, 
C. Bianchi1, G.A. Daniele1, S. Taddei2, G. Penno1, S. Del Prato1, M.C. 
Stuhlinger3, R. Miccoli1;
1Endocrinology and Metabolism, 2Internal Medicine, University of Pisa 
and Azienda Universitaria Ospedaliera Pisana, Pisa, Italy, 3Division of 
Cardiology, University of Innsbruck, Austria.
Background and aims: Asymmetric dimethylarginine (ADMA), an endog-
enous inhibitor of endothelial nitric oxide synthase (eNOS), has been asso-
ciated with endothelial dysfunction and atherosclerosis. Increased plasma 
levels of ADMA have been described in diabetic subjects with nephropathy 
or cardiovascular disease. Studies assessing ADMA levels in people with un-
complicated type 1 or type 2 diabetes report conflicting results.
Materials and methods: Circulating levels of ADMA, SDMA (symmetrical 
dimethylarginine) and L-arginine (L-arg) together with brachial artery en-
dothelium-dependent flow-mediated dilation (FMD) and endothelium-inde-
pendent dilation by 25 µg sublingual glyceryl trinitrate (GTN) were evaluated 
in 26 subjects with normal glucose tolerance (NGT), 34 with pre-diabetes 
(IFG or IGT, pre-DM) and 18 newly diagnosed type 2 diabetics (newT2DM) 
identified through OGTT. Plasma concentrations of ADMA, SDMA and L-
arg were determined simultaneously by high-performance liquid chroma-
tography. FMD and GTN were assessed by high-resolution ultrasound and 
computerized edge detection system.
Results: Groups showed similar distribution for gender, smoking habits, 
BMI, waist circumference, dBP, total and LDL cholesterol, apoA1 and apoB, 
fibrinogen, and fasting insulin. Namely, there were no differences in eGFR 
and cystatin C. Age (55±5, 53±8 vs 48±9 years, p=0.01), fasting and post-
load OGTT glucose, glucose area under the OGTT curve (AUCgluc), HbA1c 
(6.0±0.4, 6.5±0.6 vs 5.5±0.4%, p<0.0001) and triglycerides were higher in 
pre-DM and newT2DM than in NGT; HDL cholesterol was lower. In pre-
DM, sBP (127±13) was in between NGT (118±15) and newT2DM (137±15 
mmHg, p=0.0005). GTN decreased (Δ% 9.9±3.4, 8.8±3.3 and 7.4±3.9, 
m±sd; p=0.081) with significant differences between NGT and newT2DM 
(p=0.025). FMD was lower in newT2DM (Δ% 4.4±3.3, m±sd) and in pre-
DM (Δ% 6.0±2.8) compared with NGT (Δ% 7.9±3.6, p=0.0017). L-arg 
levels were similar in NGT (97.5±20.0) and pre-DM (97.1±20.6), lower in 
newT2DM (81.2±18.9 µmol/l, p=0.015). ADMA progressively reduced from 
NGT (1.33±0.96 µmol/l) to pre-DM (1.02±0.79 µmol/l, p=0.14 vs NGT) 
and newT2DM (0.72±0.53 µmol/l, p=0.017 vs NGT; ANOVA, p=0.05). 
SDMA was similar in NGT (1.78±0.74) and pre-DM (1.56±1.02, p=0.31), 
reduced in newT2DM (0.97±0.35 µmol/l, p=0.002 vs NGT, p=0.02 vs pre-
DM; ANOVA, p=0.006). No association was observed between ADMA (or 
SDMA) and eGFR or cystatin C. No correlation emerged between ADMA 
and FMD (r=0.14, p=0.23) with a weak one between ADMA e GTN (r=0.29, 
p=0.014). By multiple regression, AUCgluc (p=0.002) and sBP (p=0.047), but 
not ADMA were inversely related with FMD. AUCgluc, inversely, (p=0.024) 
and ADMA (0.044) correlated with GTN.
Conclusion: We suggest that uncomplicated newT2DM and subjects with 
pre-DM have lower circulating ADMA than nondiabetic control subjects, 
in presence of impaired endothelium-dependent flow-mediated dilation. 
ADMA levels are not related to endothelial function. In these subjects with 
early abnormalities of glucose regulation, endothelial dysfunction seems not 
a result of eNOS inhibition by ADMA.
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Vascular inflammation stratified by C-reactive protein and LDL-
cholesterol levels: analysis with 18F-Fluorodeoxyglucose positron 
emission tomography
H.Y. Choi, J.H. Kim, M.J. Cho, Y.J. Kim, C.R. Eun, S.Y. Yang, H.J. Yoo,  
H.Y. Kim, J.A. Seo, S.G. Kim, N. Kim, S.H. Baik, D.S. Choi, K.M. Choi;
Endocrinology and Metabolism, Korea University College of Medicine, 
Seoul, Republic of Korea.
Background and aims: 18F-fluorodeoxyglucose (FDG) positron emission 
tomography (PET) is a promising imaging technique for the assessment of 
vascular inflammation within atherosclerotic plaques. Inflammatory biomar-
kers, such as high sensitivity C-reactive protein (hsCRP), have been suggest-
ed as independent predictors of cardiovascular events that add prognostic 
information beyond conventional risk factors. Recently, the justification for 
the use of statins in primary prevention: an intervention trial evaluating ro-
suvastatin (JUPITER) study has demonstrated that rosuvastatin significantly 
reduces the incidence of major cardiovascular events in asymptomatic indi-
viduals with low LDL-C levels, but increased hsCRP levels, a population that 
is currently not recommended to receive statin therapy.
Materials and methods: We examined vascular inflammation, represented 
as the target-to-background ratio (TBR) measured using FDG-PET scans 
in 120 healthy subjects without history of cardiovascular diseases, who had 
been stratified into four groups according to hsCRP (cut-point, 2mg/L) and 
low-density lipoprotein cholesterol (LDL-C) levels (cut-point, 130mg/dL). We 
also determined the correlation between circulating levels of other emerg-
ing inflammatory markers, such as lipoprotein-associated phospholipase 
A2 (Lp-PLA2), monocyte chemoattractant protein-1 (MCP-1), and vascular 
inflammation assessed by FDG-PET. Lastly, we compared the factors which 
determine TBR and carotid intima-media thickness (IMT).
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Results: Maximum TBR levels of the high hsCRP, low LDL-C group were 
significantly higher than those of the low hsCRP, low LDL-C or low hsCRP, 
high LDL-C group, even though there were no significant differences in IMT. 
TBR values were associated with various cardiovascular risk factors, includ-
ing hsCRP, which had the strongest positive correlation with TBR. However, 
Lp-PLA2 or MCP-1 levels were not independently associated with TBR val-
ues. Multiple stepwise regression analyses showed that hsCRP and diastolic 
blood pressure were independent decisive factors for maximum TBR, where-
as age, diastolic blood pressure, and LDL-C were factors which determined 
the maximum IMT.
Conclusion: Vascular inflammation measured using FDG-PET was increased 
in healthy individuals without hyperlipidemia, but with elevated hsCRP.
Figure 1. Maximum intima-media thickness (IMT) (A) and maximum tar-
get-to-background ratios (TBR) (B) by stratified groups according to high 
sensitivity C-reactive protein (hsCRP) and low-density lipoprotein choles-
terol (LDL-C) levels. P-value represents pair-wise comparison based on Bon-
ferroni’s multiple comparison procedure under analysis of covariance (AN-
COVA) adjusted for age, gender and BMI. N.S, non-significant.
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High serum LPS-activity is associated with features of the metabolic 
syndrome in patients with type 1 diabetes
M. Nymark1,2, C. Forsblom1,2, P.-H. Groop1,2, M. Lehto1,2, on behalf of the 
FinnDiane Study Group;
1FinnDiane, Folkhälsan Insitute of Genetics, 2Department of Medicine, 
Division of Nephrology, Helsinki, Finland.
Background and aims: Long duration of diabetes, poor glycemic control and 
the metabolic syndrome (MetS) increase the risk for diabetic complications 
(retinopathy, neuropathy and nephropathy). We have recently shown that 
elevated serum levels of bacterial endotoxins are associated with the develop-
ment of diabetic kidney disease in Finnish Type 1 diabetic (T1D) patients. 
In addition to kidney failure, lipopolysaccharide (LPS) infusion in human or 
in mice induces also insulin resistance, fasting hyperglycemia, and obesity, 
which all are features of the MetS. In the present study, we wanted to investi-
gate whether serum LPS-activity is associated with MetS in T1D patients with 
normal albumin excretion.
Materials and methods: Serum LPS activity was analysed in 624 T1D pa-
tients and 220 nondiabetic control subjects (Limulus amoebocyte lysate chro-
mogenic end point assay, Hycult Biotechnology). T1D patients were divided 
into quartiles according to their LPS activity. MetS was assessed according 
to National Cholesterol Education Program (NCEP) criteria which included 
waist circumference, triglycerides, HDL-cholesterol, and blood pressure or 
antihypertensive medication. All patients fulfilled the criteria for hypergly-
cemia. Three out of five criteria were required for the diagnosis of MetS. A 
metabolic score (1-5) was calculated based on the number of criteria each 
patient fulfilled. Data is presented as mean (standard deviation) or median 
[inter quartile range] as appropriate.
Results: LPS was significantly higher in patients with T1D than healthy con-
trols [57 (50-69) vs. 53 (39-68), p≤0.001]. In T1D patients, comparison was 
made between the highest (q4) and lowest (q1) LPS quartiles. Patients in q4 
had a higher HbA1c, BMI, waist, triglycerides, cholesterol, diastolic blood 
pressure and lower HDL-cholesterol and insulin sensitivity (eGDR) com-
pared to patients in q1. The overall frequency of MetS was 28% among all 
T1D patients. Patients belonging to the highest LPS quartile q4 had signifi-
cantly higher frequency of MetS compared to patients in q1 (Table 1).
Conclusion: In the present study, we show that about one third of T1D pa-
tients with normal albumin excretion fullfill the criteria for MetS. Features of 
the MetS are more often found in T1D patients with high serum LPS-activity. 
These results indicate that Gram-negative bacterial infections could also play 
a significant role in the development of MetS. We believe that MetS patients 
with elevated levels of bacterial endotoxins may carry the highest risk for the 
development of not only micro- but also macrovascular complications.
Supported by: Stockmann foundation, von Frenckell foundation, Liv och Hälsa
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Dapagliflozin vs glipizide in patients with type 2 diabetes mellitus 
inadequately controlled on metformin: 52-week results of a double-blind, 
randomised, controlled trial
M. Nauck1, S. Del Prato2, K. Rohwedder3, M. Elze4, S. Parikh5;
1Diabetes Centre, Bad Lauterberg, Germany, 2University of Pisa, Italy, 
3AstraZeneca, Wedel, Germany, 4ClinResearch, Koeln, Germany, 
5AstraZeneca, Wilmington, USA.
Background and aims: Glipizide (GLIP) is commonly used as an add-on to 
metformin (MET), but is associated with weight gain and hypoglycaemia. 
Dapagliflozin (DAPA) is a selective inhibitor of sodium-glucose cotransport-
er 2 that inhibits renal glucose reabsorption in an insulin-independent man-
ner. DAPA is a potential therapy to reduce hyperglycaemia in T2DM, and has 
been associated with weight loss. We tested the efficacy, safety and tolerability 
of DAPA vs GLIP as add-on to MET in patients with T2DM.
Materials and methods: This randomized, double-blind, active-control-
led, parallel-group, multicentre trial (D1690C00004) included patients with 
T2DM inadequately controlled with oral antidiabetic drugs (OADs) includ-
ing MET (HbA1c 6.5-10.0%). Prior to randomization, as needed, OADs other 
than MET were discontinued and MET dose was up-titrated to the nearest 
of 1500, 2000, or 2500 mg/day, before an 8-week (wk) stabilization period. 
After a 2-wk placebo lead-in, patients (≥18 years) were randomized to DAPA 
(n=406, starting 2.5 mg/d) or GLIP (n=408, starting 5 mg/d) added to open-
label MET for 52 wk. For the first 18-wk study drugs were up-titrated (GLIP 
to ≤20 mg/d; DAPA to ≤10 mg/d) until fasting plasma glucose <6.1 mmol/L 
or to the max tolerated dose. The dose at the end of titration was maintained 
for a further 34 wk. Down-titration was allowed at any point in cases of recur-
rent hypoglycaemia. Primary endpoint was change from baseline in HbA1c at 
52 wk, tested for non-inferiority of DAPA vs GLIP with a predefined margin 
of 0.35%. Secondary endpoints included change in body weight and number 
of subjects reporting hypoglycaemic episodes. There was no preplanned sta-
tistical analysis for other adverse events (AEs).
Results: Mean baseline HbA1c was 7.72%. At the end of the titration period, 
86.9% of DAPA and 72.5% of GLIP patients were taking max doses. Adjusted 
mean changes from baseline in HbA1c at 52 wk were -0.52% (95% CI -0.60, 
-0.44) for DAPA and -0.52% (95% CI -0.60, -0.44) for GLIP (difference [95% 
CI] = 0.00 [-0.11, 0.11]), confirming non-inferiority. DAPA led to weight loss 
(change from baseline at 52 wk -3.2 kg) vs weight gain (1.4 kg) with GLIP 
(difference [95% CI] = -4.7 kg [-5.1, -4.2]; p<0.0001). Significantly more pa-
tients experienced weight loss of ≥5% from baseline with DAPA (33.3%) vs 
GLIP (2.5%) (p<0.0001). There were reductions in systolic and diastolic blood 
pressure (nominal p<0.0001) and improvement in HDL (nominal p<0.0001) 
in DAPA vs GLIP. More patients had hypoglycaemic episodes with GLIP 
(40.8%) vs DAPA (3.5%) (p<0.0001). Overall AEs were similar across groups. 
Serious AEs were 8.6% in DAPA and 11.3% in GLIP. Actively solicited events 
suggestive of urinary tract infection (UTI) were 10.8% and 6.4% for DAPA vs 
GLIP. Actively solicited events suggestive of genital infection (GI) were 12.3% 
(5.3% male, 21.1% female) and 2.7% (0.4% male, 5.4% female) for DAPA vs 
GLIP. One UTI led to discontinuation in each of the DAPA and GLIP arms. 
Three cases of GI led to discontinuation in the DAPA arm.
Conclusion: In T2DM inadequately controlled with OADs including MET, 
the addition of DAPA was non-inferior to GLIP in improving HbA1c at 52 
wk, resulted in significant weight loss and significantly fewer hypoglycaemic 
episodes vs GLIP, and was generally well tolerated, with a tendency to more 
UTIs and GIs.
Supported by: AstraZeneca and Bristol-Myers Squibb
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MK-0941, a novel glucokinase activator (GKA), lowers HbA1c in type 2 
diabetes (T2DM) but lacks glycaemic durability
G.E. Meininger, Y. Shentu, Y. Chen, Q. Yu, D. Sheng, B.J. Musser, M. Alba, 
B.B. Zhang, E.M. Migoya, J. Ehrhart, K.D. Kaufman, B.J. Goldstein;
Merck, Rahway, USA.
Background and aims: GKAs are allosteric activators of the GK enzyme that 
bind to the same region as naturally-occurring GK activating mutations in 
humans. GKAs are being developed as novel potential treatments for patients 
(pts) with T2DM. Preclinical studies with the GKA MK-0941 showed robust 
glucose-lowering effects both acutely and chronically (up to 9 mo) in associa-
tion with hypoglycaemia (Hypo) in fasted and fed non-diabetic animals. MK-
0941 was evaluated in Phase (Ph) I studies, including those up to 4 wks in 
pts with T2DM, as monotherapy, add-on to metformin (MET), and add-on 
to insulin glargine (IG). In these studies, MK-0941 was generally well-toler-
ated, with no significant treatment-related effects on ECGs, vital signs, or lab 
measures, and was shown to have a duration of action of ~4 hrs. On the back-
ground of IG, MK-0941 showed robust glucose-lowering, with a reduction 
in 24-hr weighted mean glucose (WMG) of ~2.7 mmol/L relative to placebo 
(pbo). These data supported continuing development of MK-0941 with Ph II 
studies in pts with T2DM.
Materials and methods: MK-0941 was evaluated in 3 randomized, double-
blind Ph II trials:
• 007, a 54-wk, pbo-controlled study in 587 pts on ongoing IG therapy (± 
MET ≥1500 mg/d), comprising an initial 14-wk, dose-ranging (10 - 40 mg 
TID) period followed by an additional 40-wk period during which all pts 
were to be up-titrated as tolerated to 40 mg or pbo TID;
• 017, a 6-wk, active-controlled study in 143 pts on going MET (≥1500 mg/
d), with patients randomized to MK-0941 (up to 40 mg TID) or glimepiride 
(GLIM; up to 8 mg QD);
• 018, a 20-wk, pbo-controlled, MK-0941 dose-titration (up to 40 mg TID) 
study in 68 pts on ongoing IG therapy.
The primary endpoint was change from baseline in HbA1c (007 and 018) or 
24-hr WMG (017).
Results: In 007, at Wk 14, all MK-0941 doses studied significantly improved 
HbA1c and 2-hr postmeal glucose (PMG) vs. pbo, with maximal pbo-sub-
tracted changes from baseline in HbA1c (baseline HbA1c ~9.0%) and 2-hr 
PMG of -0.8% and -2.1 mmol/L, respectively. No significant effect on FPG 
was observed at any dose vs. pbo. Unexpectedly, efficacy results up to 30 wks 
demonstrated a lack of durability in glycaemic control (despite dose up-titra-
tion of MK-0941 after Wk 14), a phenomenon not predicted based on earlier 
studies. MK-0941 was associated with an increased incidence of Hypo rela-
tive to pbo that was, in part, managed with down-titration of MK-0941. In 
017, 6-wk treatment with MK-0941 or GLIM added to ongoing MET resulted 
in similar changes in 24-hr WMG from baseline and incidences of Hypo. In 
007 and 017, statistically significant increases in serum triglycerides (~15% 
median percent increase from baseline) and the proportion of pts meeting 
criteria for predefined limits of change for BP measures were observed. These 
safety findings were not seen in preclinical or Ph I studies. In 018, change in 
HbA1c from baseline at Wk 20 was not significantly different between MK-
0941 and pbo when added to IG. The incidence of Hypo was numerically 
higher with MK-0941.
Conclusion: In Ph I studies, MK-0941 showed promise as an investigational 
agent for T2DM. This expectation was not borne out in 3 longer-term, Ph II 
studies. It is unknown if the efficacy and safety profiles observed with MK-
0941 were compound-specific or mechanism-based. In light of the above, a 
better understanding of the GK mechanism and its downstream metabolic 
effects are needed to determine whether GK activation is a viable treatment 
target.
Supported by: Merck
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A selective GPR40 agonist, TAK-875, augments glucose-dependent 
insulin secretion without affecting glucagon secretion in isolated rat and 
human islets
H. Yashiro1, Y. Tsujihata1, K. Takeuchi1, M. Hazama1, P. Rorsman2;
1Pharmaceutical Research Division, Takeda Pharmaceutical Company 
Limited, Osaka, Japan, 2The Oxford Centre for Diabetes, Endocrinology and 
Metabolism, United Kingdom.
Background and aims: GPR40 is a G protein-coupled receptor dominantly 
expressed in pancreatic β cells, and is involved in free fatty acid-induced in-
sulin secretion. TAK-875 is a GPR40-selective agonist that improves glucose 
control in type-2 diabetic animal models by stimulation of glucose-depend-
ent insulin secretion. We examined the effects of TAK-875 on insulin and 
glucagon secretion, and on intracellular Ca2+ ([Ca2+]i) in pancreatic β- and 
α-cells using both human and rat intact islets.
Materials and methods: Rat and human islets were isolated by collagenase 
digestion. Secreted insulin and glucagon were measured using radioimmu-
noassay. Gene expression levels were quantified by TaqMan PCR. For [Ca2+]i 
measurement, isolated islets were loaded with fluorescent indicator fluo-4-
AM and monitored by confocal microscopy during perifusion experiments.
Results: In static incubation, TAK-875 augmented insulin secretion from rat 
islets at high (16 mmol/l) but not at low (1 mmol/l) glucose. The glucose-de-
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pendent insulinotropic action of TAK-875 was also shown in islet perifusion 
experiment: TAK-875 enhanced both 1st and 2nd phase insulin secretion at 
high glucose but was without effect at low glucose. In human islets, expres-
sion of GPR40 was comparable to that of GLP-1R or ABCC8 (SUR1), and 
TAK-875 enhanced glucose-dependent insulin secretion to the same extent 
as GLP-1 in static incubation experiment. In both rat and human islets TAK-
875 was without effect on glucagon secretion at both low and high glucose. 
Measurements of [Ca2+]i in intact rat and human islets showed that TAK-
875 enhanced glucose-induced [Ca2+]i in β cells. In contrast to β cells, α cells 
showed oscillatory [Ca2+]i response at low glucose which was suppressed by 
high glucose concentration. The addition of TAK-875 at high glucose did not 
affect α-cell oscillatory [Ca2+]i in rat islets, whereas it augmented the inhibi-
tory effect of glucose in human islets.
Conclusion: These data indicate that TAK-875 potentiates glucose-depend-
ent insulin secretion via direct stimulation of [Ca2+]i in β cells of both rat 
and human islets. TAK-875 does not increase glucagon secretion or [Ca2+]i 
in both rat and human α-cells. We conclude that the glucose-lowering action 
of TAK-875 principally results from its capacity to stimulate insulin secre-
tion. The fact that it only stimulates insulin secretion at elevated glucose lev-
els without affecting glucagon secretion may offer additional advantages by 
minimizing the risk of hypoglycaemia.
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ZGN-201 (ZGN), a methionine aminopeptidase 2 (MetAP2) inhibitor, 
durably eliminates excess body fat in obese mice through regulation of 
fat metabolism and food intake
T.E. Hughes, A.J. Nichols, J.E. Vath;
Zafgen, Incorporated, Cambridge, USA.
Background and aims: MetAP2 inhibitor treatment reduces body weight 
(BW), reduces food intake, and increases fat oxidation in obese mice; how-
ever the mechanism(s) leading to weight loss have not been elaborated. We 
evaluated the effects of a 9 month treatment with ZGN on body weight and 
metabolic parameters in obese mice.
Materials and methods: Age-matched male C57BL/6J mice were maintained 
on standard chow or a 60% high fat diet for 12 weeks to induce obesity (DIO; 
mean BW 39.9 g) prior to treatment for 9 months. After matching on the 
basis of body weight, animals were assigned to either HFD (DIO; n=15 mice) 
or HFD supplemented with ZGN-201 to provide a daily dose of ~1 mg/kg 
(ZGN; n=15 mice). A group of lean age-matched chow-fed mice were studied 
for comparison (CHOW; n=15 mice). Food consumption was assessed every 
two days for groups of three animals per cage. Body weights were assessed 
for each animal every other day. Plasma glucose and beta-hydroxybutyrate 
concentrations were measured by standard colorimetric assays. Insulin was 
measured by ELISA. Gene expression analysis was performed in liver using 
quantitative RQ-PCR, and levels were corrected for expression of 18S rRNA.
Results: During the first 4 weeks of treatment with 1 mg/kg ZGN p.o., mice 
lost all excess BW (loss of 9.4±0.7g vs a gain of 5.0±0.4g for control (DIO) 
mice, p<0.01), driven by a 30% reduction in food intake during days 3 - 12 
of treatment (p< 0.01). Once a BW nadir was reached on day 28 (23% BW 
loss, p<0.01), food intake returned to a level 13 percent below DIO (0.81g vs. 
0.94g/mouse-day, p<0.01) and was stable for the following 8 months, during 
which time the ZGN treated animals remained weight stable. Following 9 
months, BW of ZGN mice were 43% lower than DIO (32.5±0.8 vs 57.1±1.7g, 
p<0.01). Fasting plasma glucose (6.8±0.4 vs 11.2±0.8 mmol/L, p<0.01) and 
insulin (34±17 vs 380±34 pmol/L, p<0.01) were reduced by ZGN and plasma 
β-hydroxybutyrate was increased (1.5±0.1 vs 1.0±0.1 mEq/L, p<0.05) relative 
to DIO, a consistent feature of MetAP2 treatment. Gene expression analysis 
revealed a down-regulation of key lipid synthesis genes in liver for ZGN vs 
DIO or age-matched CHOW mice. The insulin- and carbohydrate-responsive 
genes acetyl CoA carboxylase 1 and 2, fatty acid synthase, stearoyl CoA de-
saturase 1, and SREBP1c all were down-regulated by 58, 77, 80, 99, and 74%, 
respectively vs. DIO (all p<0.005), and by 31, 71, 74, 98, and 43%, respectively 
vs. CHOW (ZGN vs. CHOW, all p<0.05).
Conclusion: Hyperinsulinemia in the setting of diet-induced obesity acti-
vates fatty acid biosynthesis and transport pathways, reduces adipose lipoly-
sis, and suppresses ketone body synthesis leading to enhanced triglyceride 
storage. MetAP2 inhibition appears to be well-tolerated and shows promise 
as a strategy to reverse hyperinsulinemia and other obesity-associated meta-
bolic adaptations while driving rapid weight loss.
OP 44 Impact of education on 
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Patient education: impact on care outcomes, resources consumption 
and absenteeism. International Diabetes Management Practices Study 
(IDMPS) data 
J.J. Gagliardino1, P. Aschner2, S.-H. Baik3, J. Chan4, H. Ilkova5,  
A. Ramachandran6;
1CENEXA (UNLP-CONICET), La Plata, Argentina, 2Endocrinology 
Unit, Bogota, Colombia, 3Division of Endocrinology, Seoul, Republic of 
Korea, 4Department of Medicine and Therapeutics, Shatin, Hong Kong, 
5Department of Internal Medicine, Istanbul, Turkey, 6India Diabetes 
Research Foundation, Chennai, India.
Background and aims: Achievement of diabetes treatment goals greatly de-
pends on the patient´s active and efficient participation in the control and 
treatment of the disease. Even when evidence has demonstrated the value of 
education to obtain such participation, in many places education is consid-
ered an additional cost rather than an important component of diabetes care. 
This study measures diabetes care indicators and resources consumption in a 
population of educated and non educated persons with type 2 diabetes.
Materials and methods: The IDMPS is an international, multicenter, obser-
vational study performed in 27 countries within Africa, Asia, Eastern Europe, 
Middle East and Latin America. Data were collected from people with type 
1 and 2 diabetes (≥18 years) seen in current medical practice in yearly cycles 
(2-week cross-sectional recruitment period followed by a 9-month longitudi-
nal period for type 2 patients) for 5 years. IDMPS was performed in compli-
ance with the Helsinki Declaration and Good Clinical Practice Standards. We 
currently report and compare results from 11384 people with type 2 diabetes 
(educated vs. non educated, 5692 in each group, paired by age, gender and 
diabetes duration) recruited during the second cross-sectional period (No-
vember and December 2006). Data were analyzed using the Wilcoxon and 
the chi2 tests for continuous and categorical variables, respectively.
Results: The mean age ± SD for both groups was 57.7 ± 11.1 (53.1% female), 
with an average BMI of 28 ± 5.2 and 8 ± 7 years of diabetes duration. Edu-
cated patients had significantly (p< 0.001) higher figures of people with nor-
mal BMI (28.3 vs. 24.4%), diastolic BP <80 mm Hg (36.5 vs. 32.3%), HbA1c 
< 7.0% (38.1 vs. 35.8%), LDL-c < 100 mg/dL (39.5 vs. 33%) and triglyceride < 
150 mg/dL (52.7 vs. 49%). The percentage of complications was low in both 
groups (<20%), but the educated group had significantly lower values of peo-
ple with proteinuria (16.6 vs. 18%) and foot ulcer (2.4 vs. 3.5%). Visits of 
educated patients to specialists increased by 21%, as well as insulin treatment 
(40%), fasting (10%) and postprandial (52%) SMBG performance. Absentee-
ism was 15% lower in educated patients.
Conclusion: These data, one of the largest reported on education of people 
with type 2 diabetes, demonstrate that education can significantly improve 
treatment outcomes, with a low increase in resources consumption and a de-
crease in absenteeism. They also show that education is an efficient tool to 
improve diabetes care quality with low impact on resources consumption and 
additional positive impact on productivity, particularly important for devel-
oping countries that bear the heaviest part of the global diabetes epidemic.
Supported by: an unrestricted grant from sanofi-aventis
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The effects of a structured educational programme (DAFNE) for 
individuals with type 1 diabetes on DKA admissions
H. Kahal1, J.D. Ng1, D.M. Mellor1, V. Bansiya1, A. Rigby2, S.L. Atkin3, J. Patmore1;
1Department of Diabetes and Endocrinology, Hull Royal Infirmary, 
2University of Hull, 3Academic Diabetes, Endocrinology and Metabolism, 
Hull York Medical School, United Kingdom.
Background and aims: In the UK national diabetes audit 2007/2008, around 
10% of people with type 1 diabetes had an episode of Diabetic Ketoacido-
sis (DKA) within 5 years. Structured education programmes for individuals 
with Type 1 diabetes are acknowledged as an effective means of delivering 
skills based training to improve knowledge of diabetes. They aim to influence 
behaviour and to optimise self management and reduce negative outcomes. 
Locally we deliver DAFNE, Dose Adjustment for Normal Eating, as a 5 day 
programme for individuals with type 1 diabetes. DAFNE was introduced in 
our centre in 2005. The aim of our study was to assess the effects of attend-
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ing DAFNE on DKA admissions to an acute University Teaching Hospital 
in the UK.
Materials and methods: A retrospective review of all individuals with type 
1 diabetes who attended a DAFNE course between Oct 2005 and July 2008. 
Only patients who lived locally and subsequently would have been admitted 
acutely to our hospital in a case of DKA were selected. We used the hospital 
coding system to detect all DKA admissions for the same group between Oct 
2002 and July 2009.
Results: A total of 236 patients attended the DAFNE course. DKA admis-
sions are summarized in table 1. DKA admission rate in the first year before 
DAFNE was 0.113 admissions/person/year (95% CI=0.073, 0.165) compared 
to 0.069 admissions/person/year (95% CI= 0.039, 0.112) in the first year af-
ter DAFNE. Relative risk reduction 39% (95% CI= 0, 78%); P= 0.05. For the 
group of patients with any DKA admission (n= 24), median duration of fol-
low up of 24 months (range 15 - 44) before and after attending DAFNE, DKA 
admission rate was 2.375 admissions/person/year (95% CI= 1.789, 3.0777) 
before Vs 1.166 admissions/person/year (95% CI= 0.775, 1.686) after DAF-
NE. 212 patients had no DKA admissions before or after DAFNE within the 
same period of follow up.
Conclusion: Attending structured education (DAFNE) resulted in significant 
reduction in hospital DKA admission rate for individuals with type 1 diabe-
tes. This suggests that offering a structured education might be a productive 
strategy in reducing DKA admissions in type 1 diabetes.
Table 1. DKA admissions in relation to DAFNE
Time in relation to DAFNE course 2
nd year 
before
1st year 
before
1st yr 
after
2nd yr 
after
No. of DKA admissions 31 26 16 11
No. of patients with data available 217 230 236 163
DKA admissions per group per year 14.2% 11.3% 6.7% 6.7%
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PRODIACOR: Educative interventions improve clinical and metabolic 
outcomes and optimise treatment costs in an Argentinean population 
with type 2 diabetes 
G. Pfirter1, S. Lapertosa2, M. Villagra2, J.E. Caporale1, C. Gonzalez3,  
C. Clark Jr.4, J.J. Gagliardino1, on behalf of the PRODIACOR Group;
1CENEXA (UNLP-CONICET), La Plata, 2Hospital Vidal, Corrientes, 
3UBA, Buenos Aires, Argentina, 4Indiana University School of Medicine, 
Indianapolis, USA.
Background and aims: PRODIACOR is a randomized controlled clinical tri-
al implemented in a primary care setting (Corrientes city, Argentina) aimed 
at measuring the impact of educative interventions upon quality of care of 
people with type 2 diabetes (T2DM) and to measure the cost-effectiveness of 
such interventions.
Materials and methods: 36 primary care physicians and 468 persons with 
T2DM were randomized at physician level and allocated to 4 groups: 1) pa-
tients but not physicians received an education programme, 2) physicians 
but not patients received an education programme, 3) both physicians and 
patients received an education programme, and 4) control group (physicians/
patients received no education but education material and data feedback). 
Patients from all groups received complete coverage of drugs and supplies; 
clinical, metabolic and therapeutic indicators were recorded. Educated phy-
sicians attended 4 interactive theoretical-practical modules and received a 
manual with all the algorithms for diagnosis, control and treatment of T2DM. 
Educated patient attended 4 weekly teaching units and a reinforcing session 
after 6 weeks, with a focus at improving health behaviour. Educational ma-
terial included an individual log-booklet to record the self-monitored data 
(blood glucose and body weight) and a book with the main contents of the 
programme. Every patient - irrespective of his group allocation - received 
a check-book which served 2 purposes: a) as a reminder system for medi-
cal visits and laboratory test performance, and b) as a data collection system 
(record of laboratory tests, consultations or prescriptions for drugs or de-
vices). Physicians monitored and recorded clinical data and data collection 
was monitored twice a year. We currently report baseline and 3-year follow-
up data.
Results: The population age was (Mean±SD) 63±9 years (66% female) and 
diabetes duration was 10±8 years. After the 3-year follow up we recorded 
no significant changes in BMI but significant improvements (p<0.001) in all 
groups in systolic (142±17 vs. 134±15 mmHg) and diastolic (87±11 vs. 80± 9 
mmHg) blood pressure, FBG (8.0±2.5 vs. 7.2±2.2 mmol/L), HbA1c (7.8±1.5 
vs. 7.1±0.8%) and total cholesterol (4.7±0.9 vs. 4.4±0.7. mmol/L). All these 
changes were significantly larger in the intervention groups. The percentage 
of patients at target for all these parameters was significantly (p<0.01) larger 
in these groups. In the educated groups, we also recorded a significant in-
crement in combined against oral monotheraphy (42 vs. 30%) and insulin 
use (15 vs. 9%). Drug consumption and strips for blood glucose represented 
64 and 83% of the total care cost at baseline and 3-year follow up, respec-
tively. This cost increased (113%) in the control group while it significantly 
decreased (11 to 20%) in the intervention groups, particularly in the patient/
physician educated group.
Conclusion: Educative interventions implemented at a primary care level to 
people with T2DM improved the clinical and metabolic outcomes and op-
timized the use of drugs for DM and other associated cardiovascular risks 
factors, decreasing the total costs.
Supported by: NovoNordisk International Affairs.
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An integrated hospital-community diabetes education network based on 
self-management school and Telecom
Z.L. Sun1, L.L. Liu1, B. Xie2, C.P. Ju1, H. Jin1, Q.S. Lu1;
1Department of Endocrinology, Zhongda Hospital, Southeast University, 
2Medical School, Southeast University, Nanjing, China.
Background and aims: It was shown from new data that China became the 
global epicentre of the diabetes epidemic with 92.4 million patients. The chal-
lenge for China is to find proper ways to deal with the big problem and help 
diabetic patients to control the disorder. In the present study, we established 
an integrated hospital-community diabetes education network based on a 
self-management school and telecommunication system, and evaluated the 
efficacy of this network on the metabolic control of diabetic patients in com-
munity.
Materials and methods: A total of 524 new diagnosed diabetic patients 
screened in community were recruited and assigned to intensive group 
(n=266) or control group (n=258). The patients in intensive group were en-
rolled in diabetes self-management school located in university hospital first 
to receive a five sequential days diabetes education course which including 
diabetes knowledge and diabetes self-management skills delivered by multi-
disciplinary teacher such as physicians, nurse, dietitian and podiatrist. After 
graduated from this one week duration school patients were back to com-
munity and followed up by community doctor and got subsequent regular 
advice based on educational focus (information, lifestyle behaviors, glucose 
monitoring and self-management skills) with telephone, short messages or 
internet. In the control group, subjects received common education lecturer 
once a week for up to five weeks followed by regular advice. Outcomes were 
classified as knowledge, self-management skills and glycemic control in one 
year using questionnaires and laboratory data.
Results: All patients aged from 9 to 79 years, and average age was 55.19±12.67 
years (male 274, female 250), there were no significant difference between two 
groups in age, gender, diabetes duration, education level, work status, type of 
insurance, HbA1c, blood pressure, BMI and lipid profile at baseline. After 
intervention with the integrated diabetes education network, the scores for 
diabetes knowledge and self-management skills were significantly increased 
from baseline and higher than control group (P<0.05). Mean HbA1c level 
was reduced from baseline by 2.43% in intensive group but 1.61% in control 
group. The percentage of patients with HbA1c<6.5% was significantly higher 
than control group (68.82% vs 18.53%, P<0.01). The rate of patients’ BMI 
meeting criterion (Male 25kg/m2,Female 24kg/m2) was elevated from 54.52% 
to 61.24% in intensive group(P<0.05). However, there were no significant 
changes in control group.
Conclusion: Evidence supports the positive effectiveness of the integrated 
hospital-community diabetes education network on knowledge and self-
management skills, finally the better glycemic control was demonstrated.
Supported by: Jiangsu Health Science and Technique Foundation
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Nesfatin-1-regulated oxytocinergic signalling in the paraventricular 
nucleus causes anorexia via melanocortin pathway
Y. Maejima1, U. Sedbazar1, S. Suyama1, D. Kohno1, T. Onaka1, M. Koike2,  
Y. Uchiyama2, T.L. Horvath3, M.O. Dietrich3, M. Mori4, T. Yada1;
1Physiology, Jichi Medical University, Shimotsuke, 2Cell Biology and 
Neuroscience, Juntendo University School of Medicine, Tokyo, Japan, 3Yale 
University School of Medicine, New Haven, USA, 4Gunma University, 
Maebashi, Japan.
Background and aims: Nesfatin-1 is a recently discovered anorectic peptide 
derived from nucleobindin2. Nesfatin-1 is localized in several brain areas 
including the hypothalamic paraventricular nucleus (PVN). Starvation de-
creases NUCB2 mRNA specifically in the PVN. However, the mechanism 
underlying anorectic action of nesfatin-1 remains unknown. The aim of this 
study is to clarify the neural pathway through which nesfatin-1 regulates 
feeding.
Materials and methods: Cytosolic Ca2+ concentration ([Ca2+]i) in single neu-
rons were measured with fura-2 combined with immunocytochemical cell 
identification. The guide cannula was placed stereotaxically into the third 
ventricle (3V) in Wistar rats or Zucker fatty Rats. Oxytocin (Oxt) releases 
from PVN slices were measured by radioimmunoassay.
Results: After 3V injection of nesfatin-1, c-FOS was induced in several hy-
pothalamus nuclei including the PVN and in the brain stem nucleus tractus 
solitarius (NTS). Intra-PVN injection of nesfatin-1 decreased food intake, 
suggesting that PVN was one of the target sites for nesfatin-1-induced ano-
rexia. 3V nesfatin-1 injection induced c-FOS substantially in the PVN Oxt 
neurons. In the PVN, nesfatin-1 increased [Ca2+]i in single neurons immuno-
reactive to Oxt, nesfatin-1 and both. In the PVN slices, nesfatin-1 stimulated 
Oxt release. Immunoelectron micrographs revealed nesfatin-1 specifically in 
the secretory granules of PVN neurons, and immuno-neutralization against 
endogenous nesfatin-1 suppressed Oxt release in the PVN slices. These re-
sults suggested the paracrine and/or autocrine action of nesfatin-1 in the 
PVN. Nesfatin-1-induced anorexia was suppressed by an Oxt receptor an-
tagonist. Furthermore, Oxt-induced anorexia was abolished by SHU9119, a 
melanocortin 3/4 receptor (MC3/4R) antagonist, suggesting that MC3/4R is 
involved in the downstream of nesfatin-1-regulated Oxt neurons. Moreover, 
Oxt terminals were closely associated with proopiomelanocortin (POMC) 
neurons in the NTS, and Oxt increased [Ca2+]i in single POMC neurons in 
the NTS. In Zucker fatty rats whose leptin receptors are mutated, 3V injec-
tion of Oxt induced anorexia that was blocked by SHU9119. The incidence of 
[Ca2+]i responses to leptin in NTS POMC neurons was markedly reduced in 
Zucker fatty rats compared with lean rats. In contrast, the incidence of [Ca2+]i 
responses to Oxt in NTS POMC neurons was the same between Zucker fatty 
and lean rats. This result indicates that Oxt can activate the NTS POMC neu-
rons under leptin-resistant conditions.
Conclusion: Nesfatin-1 activates the activity and secretion of Oxt neurons 
in the PVN, and Oxt activates POMC neurons in the NTS. This pathway can 
function independently of leptin signaling and may provide a therapeutic tar-
get for treatment of leptin-resistant obese humans showing hyperphagia.
Supported by: JSPS 
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Role of brain insulin signalling on tissue-specific glucose disposal
C.P. Coomans1, N.R. Biermasz1, L.M. Havekes2, J.A. Romijn1;
1Endocrinology, Leiden University Medical Center, 2The Netherlands 
Organization for Applied Scientific Research - BioSciences, Gaubius 
Laboratory, Leiden, Netherlands.
Background and aims: Circulating insulin inhibits hepatic glucose produc-
tion and stimulates glucose uptake in peripheral tissues. Hypothalamic insu-
lin signaling is required for the inhibitory effects of circulating insulin on en-
dogenous glucose production. In this study, we examined the central effects 
of circulating insulin on tissue-specific glucose uptake.
Materials and methods: Tolbutamide, an inhibitor of ATP-sensitive potas-
sium channels, was infused in the lateral ventricle (i.c.v.) in hyperinsulinemic 
euglycemic clamp conditions in chow-fed and in diet-induced obese C57Bl6/
J mice. Whole body glucose uptake was measured by D-[14C]glucose kinetics 
and tissue-specific glucose uptake by 2-deoxy-D-[3H]glucose uptake.
Results: I.c.v. administration of tolbutamide impaired the ability of circu-
lating insulin to inhibit endogenous glucose production by ~20% (P<0.01). 
Surprisingly, i.c.v. tolbutamide infusion also diminished insulin-stimulated 
glucose uptake by muscle (-59%; P<0.05), but not by heart or adipose tissue. 
In contrast, in diet-induced obese mice, high fat feeding abolished the inhibi-
tory effect of i.c.v. tolbutamide on insulin-stimulated glucose production or 
muscle glucose uptake.
Conclusion: Circulating insulin stimulates glucose uptake in muscle in part 
through effects via ATP-sensitive potassium channels in the central nervous 
system, similarly to the effects on hepatic glucose production. In diet-in-
duced obese mice, these effects of circulating insulin via the central nervous 
system are absent. These observations stress the role of the central effects of 
circulating insulin in normal physiological conditions and in diet-induced 
insulin resistance.
Supported by: TI Pharma
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Lipoprotein lipase inhibition in rat hippocampus leads to increase in 
body weight, fat mass, and basal insulinaemia without change in food 
intake
A. Picard, C. Rouch, C. Magnan, C. Cruciani-Guglielmacci;
Université Paris 7, France.
Background and aims: Regulation of energy balance implies peripheral 
signals (hormones, nutrients) conveying to specialized brain areas. Among 
them, the hypothalamus and the hindbrain contain both glucose and free 
fatty acids (FFA) sensitive neurons, which have been demonstrated to be part 
the central integration of circulating signals of hunger and satiety. However 
other brain structures associated with the higher-order behavioral response, 
such as hippocampus, may also participate on the processing of these signals. 
Hippocampus is densely populated with both ghrelin, leptin and insulin re-
ceptors as well as with lipoprotein lipase (Lpl). Thus we postulated that trig-
lycerides hydrolysis by lipoprotein lipase within the hippocampus may play a 
role in the control of energy homeostasis through local FFA delivery.
Materials and methods: Osmotic minipumps were stereotactically inserted 
in the hippocampus of male Wistar rats. They received a chronic infusion of 
tyloxapol (an inhibitor of Lpl activity, 10 µg/day, TYL), or saline (SAL) dur-
ing 28 days. Food consumption and body weight were measured daily and 
body composition was analyzed weekly. Between day 20 and day 24, rats were 
placed in metabolic cages to study metabolic parameters. On day 23, ghrelin 
orexigenic response (10 nmol IP) was evaluated. On day 27, feeding response 
to mild hypoglycemia induced by insulin (1 UI/rat) was also analyzed. In 
another series of experiment, rats were imposed a 24 hour fast. Hippocampus 
and cortex were collected for the measurement of Lpl activity.
Results: 28 days after minipump implantation, the Lpl activity in hippocam-
pus of TYL rats was decreased by 26% (TYL: 0.91 ± 0.03 U/mg vs. SAL: 1.24 ± 
0.08 U/mg, p<0.005) ; TYL rats have gained significantly more weight (TYL: 
141.7 ±1.1% vs SAL: 134.6 ±2.8% , p<0.005) than SAL rats while the cumula-
tive food intake stayed unchanged. Increase in fat mass (TYL:+ 20.6 ± 2.4% 
vs SAL: +9.5 ± 1.5%, p<0.05) accounted for most of body weight gain. This 
increased fat storage was neither due to a decreased energy expenditure as 
measured by indirect calorimetry nor to a decrease in total activity. Glycemia, 
circulating FFA and TG were similar between the two groups, whereas TYL 
rats displayed basal hyperinsulinemia (TYL: 694.1 ± 42.7pM vs SAL: 485.6 
± 40.6 pM, p<0.05). Food intake measurements after a 24 hour fast or after 
an insulin challenge were the same in SAL and TYL rats, whereas TYL rats 
displayed a decreased response to ghrelin (TYL: 5.6 ± 4.6 g/kg vs SAL: 13.9 ± 
5.8 g/kg after 4 hours, p<0.05), indicating a potential adaptive mechanism to 
surfeit food intake and further weight gain.
Conclusion: The inhibition of hippocampal LPL activity by a chronic tyloxa-
pol infusion led to a gain in body weight without any modification of food 
intake, plasma TG and FFA, and antagonized the orexigenic action of ghre-
lin. Moreover, tyloxapol-infused rats displayed a hyperinsulinemia without 
any change in blood glucose, suggesting an autonomic adaptation leading to 
mild peripheral insulin resistance. Taken together these results support the 
idea that hippocampal TG hydrolysis might directly influence energy balance 
regulation at both the metabolic and behavioral levels.
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Hypothalamic leptin improves mitochondrial function in soleus muscle: 
The role of PI3K signalling
E.A. Roman1, A.P.S. Arruda1, T. Romanatto2, C. Solon1, J. Morari1,  
C.E.C. Nuñez1, L.A. Velloso1, M.A. Torsoni3;
1University of Campinas, 2University of São Paulo, 3University of Braz 
Cubas, Mogi das Cruzes, Brazil.
Background and aims: Complex metabolic diseases such as obesity and 
type 2 diabetes mellitus (DM2), result from multiple interactions between 
genetic and environmental factors. DM2 is characterized by insulin resist-
ance in skeletal muscle and other insulin-sensitive tissues, which is accom-
panied by defective insulin secretion. Muscle insulin resistance is manifested 
by a reduced capacity of insulin to stimulate glucose uptake due to impaired 
intracellular signaling. Additionally, insulin-resistant subjects present a re-
duced capacity to oxidize glucose and lipids in muscle which, at least in part, 
is due to impaired mitochondrial activity as evidenced by reduction of mito-
chondrial oxidative and phosphorylative activities. Acting in the hypothala-
mus, anorexigenic hormones such as leptin and insulin, as well as nutrients 
can modulate peripheral glucose homeostasis. Some of these effects depend 
on neural control of hepatic gluconeogenesis. However, the mechanisms by 
which hypothalamic leptin leads to improved glucose homeostasis in skeletal 
muscle are incompletely known. The aim of this study was to investigate the 
molecular mechanism by which ICV leptin improves glucose homeostasis in 
skeletal muscle.
Materials and methods: Rats were divided in three groups: i) Control (Sa-
line-ICV); ii) Leptin (Leptin-ICV); and, iii) LYL (Ly 294002 + Leptin-ICV). 
The expressions of PGC1α, Cytochrome c and UCP3 expression was per-
formed by Western Blotting; Citrate synthase activity was analyzed by an 
espectrophotometric assay and mitochondrial respiration was measured 
in soleus muscle fibers, permeabilized with saponine, by a high-resolution 
respirometry assay (OROBORUS). All procedures were approved by the Eth-
ics Committee at the University of Campinas.
Results: The central administration of leptin increased PGC1α expression 
(>100 %) in skeletal muscle and the ICV administration of Ly 294002 (inhibi-
tor of PI3K) prior to leptin inhibited this effect. Similar effect was observed 
in Cytochrome c and UCP3 expressions, which increased 480 % and 43 %, 
respectively, after ICV leptin injection if compared to control group and the 
previous administration of Ly (ICV) reduced these effects. In addition, leptin 
injection (ICV) increased the activity of Citrate synthase (80 %) and mito-
chondrial respiration (18 %) compared to control group.
Conclusion: Leptin injection (ICV) is able to modulate the expression of pro-
teins and mitochondrial function in the skeletal muscle in a hypothalamic 
PI3K-dependent manner.
Supported by: CNPq / FAPESP
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Low-cost screening model with standard cardiometabolic risk factors for 
prediction of incident type 2 diabetes: the Whitehall II study
A. Heraclides1, D. Vistisen1, E.J. Brunner2, A.G. Tabák2,3, M. Kivimäki2,  
J. Ferrie2, D.R. Witte1,2;
1Epidemiological Research, Steno Diabetes Center, Gentofte, Denmark, 
2Department of Epidemiology and Public Health, UCL, London, United 
Kingdom, 31st Department of Internal Medicine, Semmelweis University 
Faculty of Medicine, Budapest, Hungary.
Background and aims: Accurate prediction of incident type 2 diabetes 
(T2DM) is pivotal in enhancing strategies for diabetes prevention and car-
diovascular risk management. Current strategies generally include a blood 
sample in a first or second stage, but few studies have systematically com-
pared the accuracy of multiple alternative predictive models. We examined 
the predictive capability of 5 screening models for incident T2DM in incre-
mental stages of accessibility and cost.
Materials and methods: We tested the following models in a cohort of 4352 
men and women aged 39-64 years, free from diabetes (the Whitehall II study): 
(A) questionnaire only (age; gender; BMI; family history of diabetes; use of 
antihypertensive/lipid lowering medication); (B) clinical (previous model + 
blood pressure + waist circumference); (C) low-cost biomarker (previous + 
fasting glucose + fasting triglycerides + total cholesterol + HDL-cholesterol); 
(D) medium-cost biomarker (previous + fasting insulin); and (E) high-cost 
biomarker (previous + ApoA1/B + lipoprotein(a)+ CRP + IL-6 + fibrinogen 
+ von Willebrand factor + factor VII).
Results: Multivariate Cox regression analysis was used to estimate predic-
tive models for 20-year incident T2DM (574 cases). We used a 2-step ap-
proach: (i) Receiver Operating Characteristics (ROC) analysis for assessing 
the improvement in prediction of each subsequent model; and (ii) Based on 
the results from ROC analysis, backwards elimination analysis for deriving a 
parsimonious model without reducing predictive performance. The Area Un-
der the ROC Curve (AUC) was higher in all 3 screening models requiring a 
blood sample (Models C-E) compared to the questionnaire/clinical screening 
models (Models A and B) (table 1). Compared to model A, the ‘clinical mod-
el’ (B) was not better in predicting incident T2DM (AUC difference=0.001). 
The ‘low-cost biomarker model’ (C), improved significantly Model B (AUC 
difference=0.054). Only marginal improvement was found beyond Model C 
(addition of fasting insulin and detailed lipid/inflammatory markers) (AUC 
difference=0.008 and 0.007 respectively). In backwards elimination, we esti-
mated a parsimonious model, which did not reduce the prediction of Model 
C, containing age, gender, BMI, family history of diabetes, use of antihyper-
tensive/lipid lowering medication, fasting glucose, fasting triglycerides and 
HDL-cholesterol.
Conclusions: A questionnaire/clinical screening model for predicting inci-
dent T2DM is substantially improved by a low-cost blood sample test con-
taining fasting glucose, triglycerides and HDL-cholesterol. Improvements 
to this model by addition of higher cost biomarkers are not of a clinically 
relevant magnitude.
Table 1 Area under the ROC curve for additive screening models
Predictive models for incident type 2 diabetes Area under curve (95% CI)
p for model 
improvement
Questionnaire only - model A (sex + age + family history of diabetes + use of 
antihypertensive or lipid lowering medication + BMI)
0.72 (0.69; 0.75) n/a
Clinical - model B (questionnaire + blood pressure + waist circumference) 0.72 (0.69; 0.75) 0.72
Low-cost biomarker - model C (clinical model + fasting glucose + triglycerides + 
total cholesterol + HDL-cholesterol)
0.78 (0.75; 0.81) <0.001
Medium-cost biomarker - model D (low-cost biomarker + fasting insulin) 0.79 (0.76; 0.82) 0.001
High-cost biomarker - model E (medium-cost biomarker + ApoA1/B + Lp(a) + 
CRP + IL-6 + fibrinogen + vWf + factor VII)
0.79 (0.76; 0.82) 0.015
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The risk of incident diabetes for all possible combinations of metabolic 
syndrome components
G.A. Nichols1, E.J. Moler2;
1Kaiser Permanente Center for Health Research, Portland, 2Tethys 
Bioscience, Inc, Emeryville, USA.
Background and aims: Because metabolic syndrome (MetS) is defined as 
any three of five criteria, not all persons with MetS have the same cluster of 
risk factors. Whether the various combinations of criteria confer equal dia-
betes risk is not known. Our aim was to estimate the risk of incident diabetes 
simultaneously for all possible combinations of MetS components.
Materials and methods: Using electronic medical record data from a group 
model HMO, we identified an observational cohort of 58,056 non-pregnant 
adults age > 30 with no evidence of diabetes and all MetS components meas-
ured in 2003-2004. Subjects were followed for up to 5 years for onset of type 
2 diabetes. We estimated age and sex-adjusted diabetes incidence for all pos-
sible combinations of MetS components.
Results: The overall incidence rate of diabetes was 12.5/1,000 person-years (95% 
CI 12.1-12.9). The presence of each individual MetS component was associated 
with significantly greater diabetes incidence than absence of the component. 
The greatest relative difference was found among those with impaired fasting 
glucose, with an age and sex-adjusted incidence of 37.4/1000 person years (36.0-
38.9) compared to 3.8 (3.6-4.1) among those with normal glucose. Although 
persons with 1 or 2 MetS factors comprised about 50% of the sample, diabetes 
occurred in fewer than 5% of these individuals. While the proportion of the 
sample declined with each additional factor, the proportion developing diabetes 
increased precipitously with the number of factors present, reaching 28% among 
those with all 5 components. However, there was wide variation within each 
count of factors. Depending on which factors were present, incidence varied by 
>9-fold in patients with 3 risk factors, >5-fold in patients with 4 factors, and >54-
fold in patients with <3 factors. Specifically, there was a clear separation between 
combinations that did and did not include hyperglycemia. In fact, all two-fac-
tor combinations that included hyperglycemia had higher incidence rates than 
three- or four-factor combinations that did not. For example, incidence in pa-
tients with only hyperglycemia and obesity was 21.7/1000 person-years (95% CI 
17.4-27.1), compared to 11.4 (9.8-13.4) among those with the four component 
combination of obesity, hypertension, low HDL and elevated triglycerides.
Conclusion: Diabetes risk increases exponentially with MetS factor count, 
but varies substantially depending upon which factors are present. Hyperg-
lycemia, regardless of the presence of MetS, is a much stronger predictor of 
incident diabetes than MetS without hyperglycemia.
Supported by: Tethys Bioscience, Inc
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Physiological predictors of changes in glucose tolerance in a non-diabetic 
population: the RISC Study
A. Natali1, E. Muscelli1, B.D. Astiarraga1, A. Mari2, E. Ferrannini1, on behalf 
of the RISC Study Investigators;
1Department of Internal Medicine, University of Pisa, 2Institute of 
Biomedical Engineering, National Research Council, Padova, Italy.
Background and aims: Previous studies using the euglycaemic insulin clamp 
technique have reported that both insulin resistance and a reduced acute 
insulin response to intravenous glucose (AIR) predict incident diabetes in 
isolates (the Pima Indians). We undertook to systematically analyse the re-
lationship between insulin sensitivity/secretion and spontaneous changes in 
glucose tolerance in non-diabetic subjects.
Materials and methods: In 1,048 subjects from the RISC cohort (561 wom-
en and 467 men, mean age 44 years) followed up for 3 years, we measured 
baseline insulin sensitivity (by a 240 pmol.min.m-2 insulin clamp) and ß-cell 
function (i.e., fasting insulin secretion rate, total insulin output and ß-cell 
glucose sensitivity, by mathematical modelling of the C-peptide response to 
a standard OGTT). Subjects were categorised as NGT, IFG, IGT or T2D and 
then grouped into stable NGT (if they were NGT both at baseline and follow 
up, n=809), stable non-NGT (if they were IFG or IGT on both occasions, 
n=49), progressors (if their glucose tolerance deteriorated, n=129) or regres-
sors (if their glucose tolerance improved, n=61).
Results: In comparison with stable NGTs, progressors, regressors and stable 
non-NGTs presented a similar clinical (higher prevalence of familial diabetes, 
older age and higher WHR, fasting and 2-hour plasma glucose, fasting and 
2-hour plasma insulin concentrations) and metabolic phenotype (lower in-
sulin sensitivity and reduced ß-cell glucose sensitivity with increased fasting 
secretion rate and total insulin output). In a multivariate logistic model, both 
insulin sensitivity and glucose sensitivity were independent negative predic-
tors of progression (odds ratios [95% CI] of 0.70 [0.52-0.93] and 0.42 [0.28-
0.65], respectively), while WHR and fasting glucose le-vels were positively 
associated with progression. The same set of baseline variables also predic-ted 
regression. At follow up, insulin sensitivity and ß-cell glucose sensitivity were 
unchanged in the stable NGTs and non-NGTs, declined in the progressors 
and improved in the regressors.
Conclusion: Among non-diabetic Caucasians, non-NGTs, progressors and 
regressors appear to derive from a common pool of at-risk subjects, in whom 
reduced insulin sensitivity and impaired ß-cell glucose sensitivity predict de-
terioration of glucose tolerance. Changes in both insulin sensitivity and ß-cell 
glucose sensitivity mark progression as well regression of dysglycaemia.
Supported by: EU grant QLG1/CT-2001-01252; AstraZeneca; MERCKSERO-
NO
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Serum fibroblast growth factor 21 and triglycerides independently 
predict the development of type 2 diabetes
B. Angelin1, A. Hilding1, C.-G. Östenson1, H.A. Bina2, A. Kharitonenkov2, 
M. Rudling1;
1Department of Endocrinology, Metabolism & Diabetes, Karolinska 
Institutet and University Hospital, Stockholm, Sweden, 2Lilly Research 
Laboratories, Indianapolis, USA.
Background and aims: There is a need to identify novel factors that more 
accurate predict the risk of developing type 2 diabetes (T2D. Circulating lev-
els of both fibroblast growth factors 19 and 21 (FGF19 and FGF21) show a 
large interindividual variation in normal humans. Case-control studies have 
reported correlations between FGF21 and impaired glucose tolerance, insulin 
resistance, hypertriglyceridemia, obesity and/or T2D. We tested the hypoth-
esis that fasting levels of FGF19, FGF21 or triglycerides could predict the sub-
sequent development of prediabetes (IFG, IGT) or T2D in a healthy cohort 
followed for a ten-year period.
Materials and methods: In the Stockholm Diabetes Prevention Program 
(SDPP), a total of 2227 men and 3205 women with normal glucose tolerance 
were followed-up after ten years. We identified 461 subjects with abnormal 
glucose regulation (163 with T2DM, 97 of which were newly diagnosed) and 
compared them with 479 matched controls that remained normal at follow-
up. Serum levels of FGF19 and FGF21 were analyzed by ELISA.
Results: At baseline in all subjects (n=940; 396 F and 544 M), mean age was 
48.2 yr, BMI 26.3, fasting glucose 4.73 mM, cholesterol 6.23 mM, triglycer-
ides 1.45 mM, FGF19 139 pg/mL, and FGF21 193 pg/mL. At follow-up, sub-
jects with prediabetes or T2D had significantly higher levels of FGF21, 262 
and 328, respectively, compared to controls,179; P<0.001 and of triglycerides 
(1.83 and 2.07 versus 1.33; P<0.001); FGF19 and cholesterol levels were simi-
lar, and there were no gender differences. When baseline levels were analyzed 
in the groups, FGF21 levels were higher in both women and men who later 
developed prediabetes (213; 228) or T2DM (241; 286) compared to controls 
(150; 165). This was also seen for triglycerides (prediabetes, F/M, 1.45; 1.86; 
T2DM, 1.69; 1.89 versus controls 1.11; 1.32); all differences were highly sig-
nificant (P<0.001). FGF19 or cholesterol did not show any relation to de-
velopment of glucose intolerance or T2DM. Adjusted for age, BMI, physical 
activity, smoking, and socioeconomic position, FGF21 and triglyceride level 
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still predicted an increased risk for glucose intolerance or T2DM (OR for 
women, 1.91 and 3.63, for men, 2.36 and 4.04, for highest quartile of FGF21; 
OR for women, 3.33 and 6.82, for men, 3.17 and 2.26 for highest quartile of 
triglycerides). BMI, FGF21, and triglycerides were shown to be independent 
as risk predictors when combining women and men in the logistic regression 
analysis.
Conclusion: Elevated fasting levels of circulating triglycerides and FGF21, 
but not of FGF19, are associated with a substantially increased risk to develop 
prediabetes or T2DM in humans. Both elevated FGF21 and triglycerides are 
independent of each other and of BMI, and point to the presence of an early 
state of metabolic abnormality predisposing to glucose intolerance. High 
levels of circulating FGF21 may reflect a state of “resistance” to this newly 
described metabolic regulator.
Supported by: Swedish Diabetes Association, Research Council, Heart-Lung 
Foundation
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Gene-metabolite networks for signature of insulin action in humans
N.N. Rudovich1,2, V.J. Nikiforova3, O. Pivovarova1, A. Erban3,  
Ö. Gögebakan1, A.F.H. Pfeiffer1;
1Clinical Nutrition, DIFE Potsdam-Rehbrücke, Nuthetal, 2Endocrinology, 
Diabetes and Nutrition, Charité University Medicine Berlin, 3Max Planck 
Institute of Molecular Plant Physiology, Potsdam, Germany.
Background and aims: Insulin is a key metabolic hormone in the body. Few 
studies describe insulin-dependent transcriptome changes and no data ex-
ist for insulin-related plasma metabolome. We investigated the regulation 
of subcutaneous adipose tissue (SAT) gene expression during different glu-
cose/insulin concentrations and its relation with insulin-induced changes of 
plasma metabolome.
Materials and methods: Healthy subjects (n=14) underwent a saline-infu-
sion test (INF) and/or a hyperinsulinemic-euglycemic clamp (EC), and/or 
a hyperinsulinemic-hyperglycemic clamp (HC). SAT biopsy and plasma 
samples were taken before and at 240 min of the tests. Full human genome 
Agilent chips were used for transcript profiling, and GC-TOF/MS analysis 
was applied to get the metabolome of plasma. We created a gene-metabolite 
network for each experiment and extracted the insulin effects in respect to 
blood glucose concentrations by alternative network subtraction analysis.
Results: Insulin down regulates about 16% of plasma metabolome under eug-
lycemia, while simultaneous expressional changes are only minor. In the HC 
experiments, more metabolites were up-regulated. In the subtracted network 
of EC, insulin was directly connected only with two genes and two metabo-
lites (tetradecanoate and octadecanoate). Moreover, a clock-gene NR1D2 was 
a major “hub” in this network and was negatively correlated with insulin. 
The resting network structure included the six hubs of predominantly fatty 
asides and their derivates. In the network of HC, the major “hub” was fruc-
tose. From the six genes, included in this network, five were genes encoding 
transcriptional factors.
Conclusion: “Gen-metabolite signatures” of insulin action allow us to visual-
ize insulin-dependent patterns of gene-metabolite interactions and help to 
further understand the mechanisms involved in the pathogenesis of obesity 
and T2DM.
Supported by: German Science Foundation (DFG Grant No.Pf164/021002 )
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Urinary proteome analysis for diagnosis of diabetic nephropathy
P. Zürbig1, P. Rossing2, G.J. Navis3, I. Rychlík4, B.M. Winklhofer-Roob5,  
H. Mischak1,6;
1Mosaiques Diagnstics GmbH, Hannover, Germany, 2Steno Diabetes 
Centre, Gentofte, Denmark, 3University Medical Centre Groningen, 
Netherlands, 4Second Department of Internal Medicine, Third Faculty of 
Medicine, Charles University, Prague, Czech Republic, 5Human Nutrition 
& Metabolism Research and Training Center, Institute of Molecular 
Biosciences, Karl Franzens University of Graz, Austria, 6BHF Glasgow 
Cardiovascular Research Centre, University of Glasgow, United Kingdom.
Background and aims: Diabetic nephropathy (DN) is a leading cause of 
morbidity and mortality in people with diabetes mellitus. Current clinical 
methods to predict development of diabetic kidney disease are subject to 
measurement variability and lack predictive power. In several recent stud-
ies, it has been shown that urinary proteome analysis enables the definition 
of biomarkers specific for chronic kidney disease (CKD) in general and for 
DN; both models includes in the majority different collagen fragments. These 
might prove valuable in clinical practice, but confirmation of their diagnostic 
value in independent patient population not included in the original samples 
used in discovery is required to support their validity and robustness. There-
fore, we aimed to validate these biomarkers and biomarker-based models in 
an independent blinded set of 148 samples, collected prospectively in multi-
ple centers not involved in the original identification of biomarkers to rule 
out any center-based bias.
Materials and methods: Cases of diabetic nephropathy were defined as albu-
minuria >300 mg/d and diabetic retinopathy (n=66). Controls were matched 
for gender and diabetes duration (n=82). High-resolution capillary-electro-
phoresis coupled to time-of-flight mass-spectrometry (CE-MS) was used to 
profile the low-molecular-weight proteome in urine of these type 2 diabetic 
S 114 Diabetologia (2010) 53:[Suppl1]S1–S556
1 C
patients. CE-MS spectra were evaluated employing the previously developed 
biomarker models for all case and control patients in a blinded setting.
Results: Urinary profiling using CE-MS was successfully applied to urine 
samples of diabetic patients with or without existing DN. Models for the di-
agnosis of CKD in general and for the identification of patients with DN in 
particular, were validated with this multicentre blinded test set and allowed 
diagnosis of DN with high accuracy (AUC>0.94) (see figure). Furthermore, 
61 of the 65 previously identified peptides (94%) were significantly different 
between these cases and controls.
Conclusion: These data provide the first independent confirmation that pro-
filing of the urinary proteome by CE-MS can adequately identify subjects 
with DN, supporting the generalizability of this approach. The data further 
establish urinary collagen fragments as biomarkers for diabetes-induced re-
nal damage that may serve as earlier and more specific biomarkers than the 
currently used urinary albumin.
Supported by: PREDICTIONS 
259
Quantitative proteomic analysis of the adipocyte plasma membrane 
proteome identifies the Sodium/Hydrogen exchanger NHE6 as a novel 
insulin-responsive protein
M.J. Prior1, M. Larance1, J. Soul1, J. Burchfield1, H. Kanazawa2, M. Raftery3, 
D.E. James1;
1Diabetes and Obesity Program, Garvan Institute of Medical Research, 
Sydney, Australia, 2Department of Biological Science, Osaka University, 
Machikaneyama, Japan, 3Bioanalytical Mass Spectrometry Facility, 
University of New South Wales, Sydney, Australia.
Background and aims: In mammals the maintenance of glucose homeosta-
sis is achieved via insulin-stimulated translocation of the glucose transporter 
GLUT4 to the plasma membrane (PM) of adipocytes and myotubes. After 
insulin stimulation the PM is the target membrane for intracellular vesicles 
containing GLUT4 and so the proteins present there both before and after in-
sulin stimulation along with their phosphorylation status are of great interest. 
In order to identify novel regulators of insulin-stimulated GLUT4 transloca-
tion to the PM, we conducted a quantitative and comprehensive proteomic 
screen of this organelle, before and after insulin stimulation. We have also 
taken advantage of the high binding affinity between many of the substrates 
of Akt, a key regulator of insulin stimulated GSV translocation, and 14-3-3, 
by using 14-3-3 affinity chromatography to identify novel insulin-regulated 
phospho-proteins acting downstream of this kinase at the PM.
Materials and methods: Stable isotopes were incorporated into mouse 3T3-
L1 adipocytes and protein abundance and 14-3-3 binding in the PM from 
unstimulated cells, cells treated with 100 nM insulin for 20 minutes and cells 
treated with insulin plus the PI3Kinase inhibitor wortmannin was quanti-
tated by LC-MS/MS and immunoblotting. PM fractions were isolated using 
cationic colloidal silica and these were further fractionated by a high salt, 
high pH wash. 14-3-3 binding proteins were identified using human 14-3-3-
beta coupled to cyanogen bromide activated Sepharose 4B and all LC-MS/MS 
data were processed, searched and quantified using the Maxquant software 
version 1.0.13.13 package.
Results: These studies revealed 35 proteins that underwent insulin-depend-
ent translocation to the PM and included both known (GLUT4, IRAP, Trans-
ferrin receptor protein-1, Cation-dependent mannose-6-phosphate receptor 
and Syntaxins -6 and -12) and previously unknown insulin-responsive pro-
teins. An additional 9 insulin-responsive proteins, including cGMP-inhibited 
3’,5’-cyclic phosphodiesterase B were identified by 14-3-3 pull-down. More 
detailed studies using a Sodium/hydrogen exchanger memeber 6 (NHE6) 
specific antibody showed that this protein underwent a 2-3 fold increase at 
the PM and is expressed predominantly in brain and adipose tissue. Further-
more, in 3T3-L1 fibroblasts, NHE6 protein expression is up-regulated during 
the differentiation process and is partially co-localised with GLUT4.
Conclusion: The approach demonstrated here has led to the most extensive 
characterisation of a mammalian PM proteome and its constituent insulin-
responsive compartments. Differential analysis identified 27 novel insulin-
responsive proteins, including the sodium/hydrogen exchanger NHE6. In-
sulin-stimulated NHE6 translocation may explain the observed elevation 
in intracellular pH induced by this hormone and thus NHE6 may play an 
important role in insulin action.
Supported by: NHMRC and DART
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Urinary collagen fragments are significantly altered in diabetes: a link to 
pathophysiology
J. Siwy1, D.M. Maahs2, H. Mischak1,3, P. Rossing4, E. Schiffer1,  
J.K. Snell-Bergeon2, P. Zürbig1;
1Mosaiques Diagnostics Inc., Hannover, Germany, 2Barbara Davis Center 
for Childhood Diabetes, University of Colorado Denver, Aurora, USA, 3BHF 
Glasgow Cardiovascular Research Centre, Glasgow, United Kingdom, 4Steno 
Diabetes Center, Gentofte, Denmark.
Background and aims: Although all forms of diabetes mellitus (DM) are 
characterized by hyperglycemia and β-cell dysfunction, the pathogenesis of 
DM is variable, comprising different degrees of β-cell dysfunction, apoptosis, 
inflammation and immune responses. Proteome analysis holds the promise 
of delivering substantial insight into the pathophysiological changes associ-
ated with different types of diabetes. Recently, we identified and validated uri-
nary proteomics biomarkers for diabetes, and diabetes-associated micro- and 
macrovascular complications. Based on these initial findings, we aimed to 
further validate urinary proteomics biomarkers specific for diabetes in gen-
eral, and specifically associated with either type 1 (T1D) or type 2 diabetes 
(T2D).
Materials and methods: The low-molecular-weight urinary proteome of 902 
subjects from 9 different clinical centres, 315 controls and 587 patients with 
T1D (n=299) or T2D (n=288), was analyzed using capillary-electrophoresis 
mass-spectrometry.
Results: A previously discovered panel of 261 urinary biomarkers (102 were 
sequenced) based on 205 subjects distinguished DM subjects from control 
subjects with 94% (95% CI: 92-95) accuracy in 697 independent subjects. To 
identify biomarkers that differentiate T1D from T2D, a subset of normoalbu-
minuric patients with T1D (n=68) and T2D (n=42) was employed, enabling 
tentative identification of 204 biomarker candidates (68 were sequenced) dif-
ferentially regulated between T1D and T2D. These biomarkers distinguished 
T1D from T2D in an independent validation set of normoalbuminuric pa-
tients (n=108) with 93% (95% CI: 86-97%) accuracy. When applied to patients 
with impaired renal function (n=369) accuracy was 91% (95% CI: 88-94%). 
Most of the biomarkers significantly associated with diabetes, and those that 
are apparently diabetes-type specific, were specific collagen fragments, indi-
cating highly significant changes in collagen turnover and extracellular ma-
trix as one hallmark of the molecular pathophysiology of diabetes. Additional 
indications for chronically sustained renal injury mediated by inflammatory 
processes and pro-thrombotic alterations were observed.
Conclusion: These findings, based on the largest proteomic study ever per-
formed on subjects with DM, pinpoint potential differences in the patho-
physiology of T1D and T2D that may improve understanding of diabetes 
and diabetes-associated complications and result in improved therapeutic 
strategies.
Supported by: PREDICTIONS, InGeniousHyperCare 
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Age-related and islet autoimmunity associated differences in metabolites 
of the amino acid and lipid metabolism in children at high risk for type 
1 diabetes
M. Pflueger1, A.-G. Ziegler1, P. Achenbach1, M. Orešič2;
1Institut fuer Diabetesforschung Helmholtz Zentrum Munich, Germany, 
2VTT Technical Research Centre of Finland, Espoo, Finland.
Background and aims: Data from the BABYDIAB study demonstrate that 
islet autoimmunity in children of mothers or fathers with type 1 diabetes 
(T1D) is initiated early in life with two phenotypically distinct peaks of anti-
body incidence before age 4 and after age 7 years. Changes in lipid and amino 
acid metabolism are suggested to precede the development of T1D. The aim 
of this study was to examine whether there are changes in serum metabo-
lite profiles (metabolomics) which are characteristic for early (< age 4 years) 
compared to late (> age 7 years) initiation of islet autoimmunity.
Material and methods: Metabolites of the amino acid and lipid metabolism 
were measured in samples from 70 BABYDIAB children, including 13 who 
developed islet autoantibodies (AA) early (< age 4 years) and 22 who de-
veloped islet AA late (> age 7 years), and 35 age, date of birth, and HLA-
matched children who remained islet AA negative (‘controls’). Metabolites 
and lipids were measured quantitatively in the first antibody positive serum 
sample or in aged-matched samples of ‘controls’ using UPLC coupled with 
UV detection and UPLC-MS, respectively. The 511 detected molecular lipids 
were clustered into 12 groups (LC). Concentrations were compared using the 
Mann-Whitney-U-Test.
Results: Specific changes in metabolite and lipid profiles were identified 
in BABYDIAB children. These included both age-related and antibody ap-
pearance related. Regardless of antibody status, children aged >7years had 
higher concentrations of glutamine (p=0.004), arginine (p=0.008), glycine 
(p<0.0001), and citric acid (p=0.006) as compared to children <4years of 
age. Similarly, older children had higher concentrations of LC 2 and 4 which 
represent proinflammatory lysophosphatidylcholines and sphingomyelins 
compared to younger children (p<0.0001 and p=0.002), respectively, whereas 
younger children had higher concentrations of lipids in LC10, containing 
saturated triglycerides, as compared to older children (p<0.0001). Related 
to the appearance of islet AA we found lower concentrations of methionine 
(p<0.0001), ethanolamine (p=0.02) and glutamic acid (p=0.03) in children 
who developed islet AA early, and lower concentrations of hydroxyproline 
in children who developed islet AA late as compared to islet antibody-nega-
tive children of the respective age-group (p=0.03). Furthermore for both age 
groups (early and late) we found higher concentrations of LC8, a functionally 
diverse lipid cluster of specific phospholipids and triglycerides, in children 
developing islet AA compared to children who remained islet antibody-nega-
tive (p=0.0001).
Conclusion: These data demonstrate that there are changes in metabolomic 
profiles that appear specifically associated with the appearance of islet au-
toantibodies and with the age of antibody seroconversion. These changes may 
reveal important novel pathways related to the pathogenesis of autoimmune 
diabetes. Additional marked age related changes of metabolomic profile 
which are independent of autoimmunity indicate that age is an important 
confounder for any future studies using metabolomics technology.
Supported by: EU(EP7-HEALTH-2007,DIAPREPP),KKNDm funded by BMBF 
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A distinct metabolic profile at birth identifies children developing type 1 
diabetes before 20 years of age
D. La Torre1, Å. Lernmark1, P. Spégel1, H. Elding Larsson1, S.A. Ivarsson1, 
M. Orešič2;
1Clinical Sciences, Lund University, Malmö, Sweden, 2VTT Technical 
Research Centre of Finland, Espoo, Finland.
Background and aims: Islet autoantibodies are early markers of developing 
type 1 diabetes and are useful for disease prediction. Recent data suggests 
that metabolomics analysis may uncover metabolic disturbances prior to se-
roconversion and clinical diabetes, and that specific alterations may already 
be detectable at birth. The aim of this study was to confirm evidence of altered 
metabolic pattern at birth in children who developed type 1 diabetes before 
20 years of age.
Materials and methods: Unbiased metabolomics analysis was applied in a 
case-control analysis of paired cord blood samples from 24 children diag-
nosed with type 1 diabetes at a median age of 17 years (range 3.2-18.8) and 
an equal number of healthy controls matched for age (year/month/day) and 
gender. Cord blood serum from the cases and controls was collected in 1970-
1991. All samples were stored frozen at -20°C and had been subjected to an 
equal number of freeze-thaw cycles. Children born to diabetes mothers were 
excluded. The analysis of coded samples was performed randomly by Gas 
Chromatography/Time-of-Flight Mass Spectrometer (Pegasus 4D; Leco). The 
potential effect of long-term storage on metabolites was investigated through 
Spearman´s rho correlation between metabolite concentrations and sample 
age. Paired case-control differences were calculated with nonparametric Wil-
coxon rank-sum test (p<0.05 considered significant).
Results: The type 1 diabetes progression related changes were detected in 
specific groups of metabolites. The cord blood serum metabolome from the 
children who develop type 1 diabetes showed 1.2-1.4 -fold higher concentra-
tions of several fatty acids compared to the controls: linoleic acid p<0.008, 
myristic acid p<0.002, lauric acid p<0.002, stearic acid p<0.017, palmitoleic 
acids p<0.02 . Oleic and palmitic acid did not differ between cases and con-
trols. Fatty acids did not correlate with the years of storage except for lauric 
acid that increased up to 2-fold in the oldest samples (p<0.001) in cases as 
well as in controls. There was no significant correlation between metabolite 
concentrations and age at diagnosis or maternal age in the case group.
Conclusion: Although storage time and conditions are critical in metabo-
lomics studies for the potential confounding effects of lipolysis and proteoly-
sis on the metabolites, our samples from carefully matched cases and controls 
enabled the use of older samples. In our study the metabolite pattern at birth 
distinguished children who developed type 1 diabetes from the matched con-
trol children who remained healthy. The evidence of these early metabolic 
alterations may give new insights into type 1 diabetes early pathogenesis and 
identify potential triggering factor of islet autoimmunity possibly involving 
gestational events. The identification and validation of key metabolites mark-
ing the progression to islet autoimmunity and clinical onset may also provide 
new markers for disease prediction.
Supported by: DIAPREPP
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GAD65- and (pro)insulin-specific CD4+ T cells detected by MHC class II 
tetramers in diabetes-associated autoimmunity
V. Öling1, H. Reijonen2, O. Simell3, M. Knip4,5, J. Ilonen1,6;
1Immunogenetics Laboratory, University of Turku, Finland, 2Benaroya 
Research Institute at Virginia Mason, Seattle, USA, 3Department of 
Paediatrics, University of Turku, 4Hospital for Children and Adolescents 
and Folkhälsan Research Center, University of Helsinki, 5Department 
of Paediatrics, Tampere University Hospital, 6Department of Clinical 
Microbiology, University of Eastern Finland, Kuopio, Finland.
Background and aims: Autoreactive CD4+ T cells contribute to the destruc-
tion of insulin producing beta-cells in type 1 diabetes (T1D). The aim of this 
study was to investigate the frequency of circulating GAD65-, proinsulin- 
and insulin-specific CD4+ T cells during the pre-clinical phase of T1D and to 
evaluate the naïve/memory phenotype of these autoreactive T cells.
Materials and methods: Using MHC class II tetramers, we have analysed the 
frequency of GAD65- (274-286 and 555-567 557I), proinsulin- (B24-36) and 
insulin- (A1-15 and A6-21) specific CD4+ T cells in 26 children with recently 
diagnosed T1D, 48 multiple autoantibody-positive children and 70 HLA- and 
age-matched control children. In a smaller group of children memory and 
naïve T-cell responses to the same autoantigens were investigated as well.
Results: We observed that the children with multiple autoantibodies recog-
nize the GAD65 555-567 (557I) peptide more frequently (52.4%) than the 
children with T1D (22.2%) or controls (30.5%) (P=0.027). Furthermore, mul-
tiple autoantibody-positive children had more often memory (CD45RO+) T 
cells specific for GAD65 555-567 compared to controls (P=0.028), in whom 
none (n=27) displayed a positive memory T-cell response to this peptide. In-
terestingly, in children with T1D GAD65 555-567 specific T cells were both 
memory and naïve, (P=0.029 and 0.044, in comparison to controls, respec-
tively). The other investigated peptides were frequently recognized in the 
study population, but no statistically significant differences were observed.
Conclusion: These results indicate a higher CD4+ T-cell reactivity to the 
GAD65 555-567 epitope in children with recently diagnosed T1D and in 
multiple autoantibody-positive children compared to unaffected controls 
testing negative for autoantibodies.
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Novel triples mix radio binding assay for the ZnT8 (ZnT8RWQ) 
autoantibody variants in children with newly diagnosed diabetes
F. Vaziri-Sani1, A.J. Delli1, H.E. Larsson1, B. Lindblad2, A. Carlsson3,  
G. Forsander2, S.A. Ivarsson1, J. Ludvigsson4, C. Marcus5, Å. Lernmark1;
1Department of Clinical Sciences, Lund University, Malmö, 2Department of 
Pediatrics, The Queen Silvia Children’s Hospital, Göteborg, 3Department of 
Pediatrics, Lund University, 4Linköping University Hospital, Department of 
Clinical and Experimental Medicine, 5Department of Pediatrics, Karolinska 
University Hospital, Huddinge, Sweden.
Background and aims: Autoantibodies (A) against the ZnT8 transporter are 
common in type 1 diabetes. The ZnT8A analyses are complicated by the fact 
that it is not only one but three autoantigens representing ZnT8R (arginine), 
ZnT8W (tryptophan) and ZnT8Q (glutamin) at amino acid position 325. It is 
important to detect all ZnT8A variants not only to predict type 1 diabetes but 
also to select subjects for prevention and intervention clinical trials. The aims 
were: 1) to develop an autoantigen triple mix Radio-Binding Assay (RBA) to 
screen for ZnT8A; 2) to identify the individual ZnT8-RWQA reactivity and 
3) to validate the triple mix ZnT8Ab RBA in children with newly diagnosed 
type 1 diabetes.
Materials and methods: Serum or plasma samples were obtained from 1868 
patients in the on-going Better Diabetes Diagnosis (BDD) study. BDD is a 
nationwide prospective cohort study that involves newly diagnosed diabe-
tes children who are <18 years from 40 (95%) pediatric clinics in Sweden. 
The cDNA coding for the C-terminal end of each variant was subcloned into 
the high efficiency in vitro transcription translation pTNT vector (Promega, 
Madison, WI, USA) following site-directed mutagenesis. The ZnT8 variants 
were labelled with 35S-methionine and used at 425 cpm/µL in standard RBA 
separating free from autoantibody-bound autoantigen with Protein A-Sepha-
rose. All samples were first analyzed for autoantibodies to each individual 
variant of ZnT8. Bound radioactivity was converted into in-house units using 
a standard curve generated negative controls and by a type 1 diabetes serum 
standard with high reactivity for each of the ZnT8R, ZnT8W and ZnT8Q an-
tigens. All samples were also analyzed in a triple mix RBA to detect all three 
variants (ZnT8-RWQA) simultaneously. The ZnT8-RWQA RBA was per-
formed after the three variants were mixed at a final concentration of 425±25 
cpm/µL. The bound radioactivity were converted into in-house units using 
negative controls and a type 1 diabetes serum standard with high reactivity 
for all three ZnT8A variants.
Results: We examined sera from 1868 (53% males) newly diagnosed incident 
type 1 diabetes patients <18 years who were registered in the BDD study. 
ZnT8-RA was detected in 964 (52%) patients, ZnT8-WA in 895 (48%) and 
ZnT8-QA in 609 (33%). Autoantibodies to all three variants were found in 
527 (28%) patients. ZnT8-RWQA was detected in 1267 (68%) patients repre-
senting only 5.6% false positive samples. None of the new-onset patients was 
false negative for ZnT8-RWQA. The highest ZnT8A frequencies were found 
among the 5-9 (67%) and 10-14 (72%) year old patients. Neither the ZnT8-
RWQA nor the three individual variants showed gender variation.
Conclusion: The major finding in this study was that the ZnT8A triple mix 
assay had a low false positive rate and a negligible false negative rate. The 
ZnT8A triple mix assay would therefore be highly suitable for screening the 
general population, as it is likely not to miss individuals who have anyone of 
the three variants.
Supported by: DIAPREPP, NIH, SCDF, SRC, SDARF, SCCFRD and SKL
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Differences in thrombotic and inflammatory markers comparing 
subjects with maturity onset diabetes of the young and type 2 diabetes
M.J. Bottomley1, G. Thanabalasingham2, K. Hess1, K.R. Owen2, R.A. Ajjan1; 
1Leeds Institute of Genetics, Health and Therapeutics, Leeds, 2Oxford Centre 
for Diabetes, Endocrinology and Metabolism, University of Oxford, United 
Kingdom.
Background and aims: Mutations in the Hepatocyte Nuclear Factor 1α (HN-
F1A) gene are the commonest cause of Maturity onset diabetes of the young 
(MODY) in the UK, characterised by β-cell dysfunction without insulin re-
sistance. Cardiovascular disease is the main cause of mortality in individuals 
with diabetes and it has been demonstrated that fibrin network structure and 
its resistance to lysis determines predisposition to atherothrombotic disease. 
The aim of this work was to investigate clot structure/fibrinolysis and cardio-
vascular inflammatory markers in subjects with HNF1A-MODY and type 2 
diabetes (T2DM).
Materials and methods: Subjects with HNF1A-MODY (n=18, mean age 35.3 
years, 11 female) and T2DM (n=12, mean age 43.3 years, 8 female) were re-
cruited. Fibrin clot structure was measured using a validated turbidimetric 
assay; clot final turbidity, a measure of clot density and time from full clot 
formation to 50% lysis, an indicator of lysis potential, were recorded. Plasma 
fibrinogen, plasminogen activator inhibitor-1 (PAI-1) and the cardiovascu-
lar inflammatory proteins complement-3 (C3) and C-reactive protein (CRP) 
were also measured by ELISA. All values are given mean±SEM.
Results: The groups did not significantly differ in age, gender, insulin use, 
blood pressure, HbA1c or BMI. The HNF1A-MODY group recorded lower 
final turbidity compared with T2DM (0.33±0.13 vs 0.44±0.12 au respectively, 
p=0.03). Time from full clot formation to 50% lysis was shorter in the HNF1A-
MODY group than T2DM (473±159 vs 588±199s, p=0.048). Despite differ-
ences in final turbidity and lysis time, fibrinogen levels were similar (2.8±0.7 
vs 2.9±0.5g/L, p=0.6), as were PAI-1 levels (1.99±1.27 vs 1.65±0.82ng/ml, 
p=0.47). C3 levels were significantly lower in HNF1A-MODY subjects than 
T2DM (0.58±0.20 vs 0.80±0.21mg/ml, p=0.006), whereas CRP was not dif-
ferent (1.16±2.07 vs 1.85±1.09 mg/L, p=0.3). C3, a protein known to be in-
corporated into the fibrin network, correlated strongly with final turbidity (r= 
0.66, <0.001) and time to 50% lysis (r=0.7, p<0.001).
Conclusion: Our data suggest that, despite phenotypic similarities between 
the groups, those with T2DM have tighter clot structure, which is more re-
sistant to fibrinolysis compared with HNF1A-MODY. The similar plasma 
levels of fibrinogen and PAI-1 suggests this is due to post-translational modi-
fications in the fibrinogen molecule or other, yet unidentified, plasma factors. 
One possible explanation may be related to higher C3 plasma levels in T2DM 
patients, directly affecting clot structure and lysis time. Taken together, our 
data suggest that patients with HNF1A-MODY are at lower risk of macrovas-
cular diabetic complications than matched T2DM patients.
Supported by: Oxford NIHR
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A large part of the MODY patients in Slovakia do not have any mutation 
in GCK, HNF1A, HNF4A, HNF1B, KCNJ11 or insulin genes
D. Gasperikova1, J. Stanik1,2, M. Huckova1, L. Valentinova1, I. Masindova1, 
D. Lesayova1,3, L. Barak2, M. Kusekova4, V. Sandrikova5, J. Javorkova6,  
J. Michalek7, Slovak MODY Collaborative Study Group, I. Klimes1; 
1DIABGENE, Institute of Experimental Endocrinology, Bratislava, 2Children 
Diabetes Center, 1st Dept. of Pediactrics, Comenius University, Bratislava, 
31st Dept. of Pediatrics, Children University Hospital, Bratislava, 41st 
Dept. of Pediatrics, P.J Safarik University, Kosice, 5Outpatient Children 
Endocrinology Clinic, Prievidza, 6Dept. of Pediatrics, Jessenius Medical 
School, Comenius University, Martin, 7National Inst. of Diabetes and 
Endocrinology, Lubochna, Slovakia.
Introduction: Maturity Onset Diabetes of the Young (MODY) is a heterog-
enous group of monogenic diabetes with early onset, familiar appearance, 
and autosomal dominant inheritance. MODY could be caused by a muta-
tion in one of the nine MODY genes, or genes causing predominantly neo-
natal diabetes. Nevertheless, large number of MODY families does not have 
any mutation in the genes so far identified. Patients with clear phenotype 
of MODY diabetes without one of the known mutation, are thus labelled as 
MODY-X subjects.
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Aim: Of this study was to identify the genetic background of families, fulfill-
ing the MODY clinical criteria, and to calculate the frequency of selected 
MODY subtypes and MODY-X in Slovakia.
Methods: 239 patients from 97 families fulfilling the MODY clinical diagnos-
tic criteria (Ellard et al, 2008), were actively identified in the diabetes outpa-
tient clinics throughout Slovakia. The relevant genes responsible for MODY 
(GCK, HNF1A, HNF1B, HNF4A, KCNJ11 and insulin) were analyzed using 
the direct sequencing technique and MLPA.
Results: 152 patients from 57 families had 35 different mutations in one of 
the target genes: 33 probands and 65 family relatives had a mutation in GCK 
gene; 22 probands and 29 their family relatives had a mutation in HNF1A 
gene; one family (2 pts) had a mutation in the HNF4A gene, and one proband 
had a HNF1B whole gene deletion. No KCNJ11 and insulin gene mutation 
carriers were found.
Conclusion: Out of 97 families, 40 families had no mutation in the genes 
analyzed. Among the MODY subtypes, the most prevalent are the GCK 
mutations (34% of MODY), followed by HNF1A (23%), HNF4A (1%) and 
HNF1B (1%) mutations. Despite of DNA analysis of the six MODY genes, the 
MODY-X families account up to 41% of all cases. The latter is a great chal-
lenge for identification of further genes leading to MODY diabetes.
Supported by: MZ.2005/15-NEDU-01, APVV-51-014205, CENDO and Slovak 
Diabetes Association
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Liver adenomatosis in MODY 3 diabetes mellitus families: screening 174 
patients
A. Rod1, C. Bellanne-Chantelot2, PHRC MODY 3 and Liver Adenomatosis 
Study Group, L. Chiche3, Y. Reznik1; 
1Service d’endocrinologie - diabétologie, CHU Côte de nacre, Caen, 
2Laboratoire de génétique des maladies métaboliques, CH La Pitié 
Salpetrière, Paris, 3Service de chirurgie digestive et hépato-biliaire, CHU 
Côte de nacre, Caen, France.
Background and aims: Liver adenomatosis is a rare disorder susceptible to 
hemorrhagic complication and rarely malignant transformation. Liver ad-
enomatosis results from the biallelic inactivation of the HNF1A gene which 
encodes a transcriptional factor.The epidemiology of the disease is poorly 
documented. The aim of this study was to evaluate the frequency of liver ad-
enomatosis in a population of MODY 3 patients carrying a HNF1A germinal 
mutation, and to describe the clinical course of the disease in the patients 
affected by the liver disease.
Materials and methods: 174 patients from 74 families MODY 3 were includ-
ed in 13 French centres. Screening for liver adenomatosis was performed by 
systematic liver ultrasonography. When the disease was suspected, liver CT 
or MRI was performed for confirmation of the diagnosis. Histopathological 
analysis was performed when a surgery was mandatory.
Results: Among 137 patients carrying an HNF1A mutation, 9 cases of liver 
adenomatosis were identified in 7 different families. Mutations were spread 
all over the coding region of the HNF1A gene. Patients mean age was 32,8 
years (11-56), the M/F sex ratio was 2/7, 7/9 patients had diabetes mellitus, 
the two remaining patien ts were children presently normoglycemic. Liver 
imaging showed adenomas of various sizes from less than ten mm (1/9), to 
larger lesions (8/9) up to 120 mm. Liver biology was near normal in all pa-
tients. One case of adenomatosis was revealed by two episodes of internal 
hemorrhage. Five women had ten pregnancies without any complication nor 
progression of the adenoma size. Histopathological confirmation of liver ad-
enomatosis was available in five patients, and all adenomas were steatotic at 
variable degree.
Conclusion: The frequency of liver adenomatosis in this cohort of MODY 
3 diabetic patients (6,5%) and the risk for hemorrhagic complication of the 
disease favours the systematic screening for liver adenomatosis in MODY 3 
families.
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Hypomagnesaemia revealing Maturity Onset Diabetes of the Young 
(MODY) type 5 linked to TCF2 mutation
D. Quintin1, A.-S. Balavoine1, C. Hober2, L. Heidet3, C. Antignac3, R. 
Vargas-Poussou4, M.-C. Vantyghem1; 
1Endocrinology and Metabolism, Lille University Hospital, 2Endocrinology 
and Metabolism, Henin-Beaumont Hospital, 3Genetic Departments, 
Necker-Enfant Malades Hospital, Paris, 4Genetic Departments, European 
Hospital G Pompidou, Paris, France.
Two to 5% of non insulin dependent diabetes (NIDD) are related to ß cell 
genetic anomalies among which six types of Maturity Onset Diabetes of the 
Young (MODY), linked respectively to mutations of genes encoding 1) HNF-
4alpha, 2) GCK, 3) HNF-1alpha, 4) IPF-1, 5) the transcription factor HNF-1ß 
(encoded by TCF2) and 6) NeuroD1/ß2. A 34 year-old woman was referred 
for uneasiness with tremor and paresthesia. Hypertension was present in her 
two parents. Her own medical history was marked by 4 episodes of seizures 
at 8 months one of them related to hypocalcemia (60mg/l; Normal range (N): 
95-105) with otherwise negative etiological investigations except fever in an-
other episode. She developed mild mental retardation without dysmorphic 
features, and was regularly menstruated. NIDD was discovered at 18 years 
old. At 34 years old, her BMI was 25 and her blood pressure 130/80 mmHg 
with normal clinical examination. Biological investigations without treat-
ment showed severe hypomagnesemia (12 mg/l; N: 18-20) by renal wasting 
(152 mg/24h; N: 80-180), with calciuria between 72 and 130 mg/24h; N:100-
250) with normal blood creatinine (10mg/l), potassium (4.1mmol/l), calcium 
(96 mg/l), HCO3- (28 mmol/l), PTH (34 pg/ml), 25 OH vitamin D (50 nmol/
l; N:25-150), renin and aldosterone levels. There was nor proteinuria, micro-
albuminuria, neither sediment anomalies. The NIDD was characterized by 
normal blood C-peptide level (2.2 ng/ml (N: 0.5-2, neutral HLAdq suscepti-
bility for type 1 diabetes and undetectable islet auto-antibodies. HbA1c was 
7.2% (N<6.5). Intravenous glucose tolerance test performed with and with-
out intravenous magnesium repletion, showed high insulinemia when blood 
magnesium levels were low, arguing for severe insulin resistance (insulinemia 
200 to 250 mU/l), corrected by magnesium repletion (insulinemia 10 to 15 
mUI/l) for similar blood glucose levels (reaching 3,5g/l). Kidney cysts, hy-
pertension and increased liver enzyme levels (TGO 109, TGP 218; n<40 UI/l) 
occurred with time. Genetic investigation showed a heterozygous deletion 
of the 9 exons of TCF2 gene, which was identified nor in 2 of her 3 living 
brothers and sisters (one was dead). To conclude, mild low magnesium level 
has been reported in NIDD. Nevertheless the severity of hypomagnesemia 
linked to renal wasting suggested a tubulopathy. Early occurrence of hy-
pomagnesemia with hypocalcemia was compatible with TRPM6 mutations, 
whereas isolated hypomagnesemia are associated with mutations of pro-EGF 
(with often mental retardation) or gamma sub-unit of Na-K ATPase. Finally, 
genetically determined diabetes with hypomagnesemia can be linked to mi-
tochondrial cytopathy or TCF2 mutations. The presence of renal cysts sug-
gested this last diagnosis, even if in MODY 5, hypomagnesemia is rarely so 
severe. In this situation low magnesium levels are probably explained by the 
regulation of FXYD2 transcription, which participates to magnesium tubular 
reabsorption, by HNF 1ß.
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Genetic counselling for MODY, MIDD and other type of diabetes 
mellitus
N. Iwasaki1,2, M. Takizawa1, R. Fujimaki1, M. Ogata1, K. Saito2, Y. Iwamoto1; 
1Diabetes Center, 2Institute of Medical Genetics, Tokyo Women’s Medical 
University, Tokyo, Japan.
Background and aims: Recently, genetic testing is provided in the clinical 
practice of diabetes mellitus. We have started the genetic counseling for dia-
betes since May 2006, however, such medical service is still few and no report 
has been published in Japan. The aim of this study is to clarify the current 
status of genetic testing for diabetes and evaluate the quality of genetic coun-
seling by a hospital based setting.
Materials and methods: We reviewed the medical records of the cases who 
received genetic counseling for diabetes in the Institute of Medical Genetics 
at Tokyo Women’s Medical University from May 2006 to March 2010. The 
number of such proband was 22. After informed consent was obtained from 
the patients, the screening for mutations in the candidate genes had done at 
the Diabetes Center and other academic institute according to the disease.
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Results: Two patients were self referral and 20 were referred by other physi-
cians. Ten patients had been diagnosed with mitochondrial diabetes (MIDD) 
including mitochondrial myopathy, encephalopathy, lactic acidosis, and 
stroke (MELAS) syndrome, 8 patients with maturity-onset diabetes of the 
young (MODY), one with early onset type 2 diabetes having renal hypopla-
sia, one with diabetes insipidus, diabetes mellitus, optic atrophy and deafness 
(DIDMOAD) or Wolfram syndrome, one with type 2 diabetes and cardiac 
myopathy, and one with just type 2 diabetes. We found 4 cases with mutations 
in the HNF-1a/MODY3 gene among 7 cases of MODY (57%) who received 
the genetic testing; two cases with P291fsinsC, one with R200W and one 
with P379S (CCT>TCT). A subject with renal hypoplasia but lacking family 
history of diabetes showed a large deletion at chromosome 17q12 including 
HNF-1b/MODY5 gene. Among 8 cases with MIDD, 6 cases were positive for 
3243 A>G mutation in the mitochondrial gene. Subjects with DIDMOAD 
had found to have compound heterozygous mutation in the exon 8 of wolf-
ram 1 gene (L468X, del509VYLLY). Genetic testing for three patients with 
MIDD/MELAS and one with MODY had been carried out at other institu-
tions. They had not received appropriate counseling regarding the nature of 
their condition and visited our clinic to obtain more information regarding 
the results of the genetic testing.
Conclusion: Our study indicates that 1) a need of the genetic counseling for 
diabetes exists in Japan, 2) MODY3 is prevalent among MODY in our insti-
tute, 3) patients should receive genetic counseling and psychological evalua-
tion before any genetic testing are carried out.
Supported by: Ministry of Education, Science, Culture and Sports
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Insulin sensitivity in children with permanent neonatal diabetes mellitus 
treated with sulfonylurea
A. Szadkowska, I. Pietrzak, A. Gach, B. Mianowska, W. Fendler,  
W. Młynarski; 
Department of Pediatrics, Oncology, Hematology and Diabetology, Medical 
University of Lodz, Poland.
Background and aims: Adults with permanent neonatal diabetes mellitus 
(PNDM), carriers of a Kir6.2 mutation were characterized by decreased insu-
lin sensitivity. The transfer to sulphonylurea therapy improved insulin sensi-
tivity in them. Aim of the study was to estimate insulin sensitivity in PNDM 
children with Kir6.2 mutation during insulin therapy and after their transfer 
to sulfonylurea.
Materials and methods: Three children aged 9, 11, 14 years with diabetes 
mellitus recognized in the first 6 months of life with confirmed Kir6.2-acti-
vating mutations were included into the study. Euglycemic-hyperinsulinemic 
clamp was performed to estimate insulin sensitivity. Glucose disposal rate 
(M value) determined during the last 30 min of the test was calculated as a 
surrogate of insulin resistance. The height, weight were measured and body 
mass index (BMI) was calculated. HbA1c was measured by HPLC. All ex-
aminations were performed on insulin therapy and 6 months after transfer 
to sulphonylurea.
Results: Baseline M values in children were: 15,0; 7,25 and 13,33 mg · kg−1 · 
min−1, (mean 11,86±4,08). The mean BMI was 15,27±1,10 kg· m−2 and HbA1c 
was 6,93±0,38%. Six months after the initiation of sulfonylurea therapy we 
did not observe significant reduction of body weight (Δ BMI = - 0,46±0,54; 
p=0,28). The improvement in metabolic control was noted (Δ HbA1c = 
- 1,03±0,25%; p=0,02). A substantial improvement in insulin sensitivity 
was found in all examined patients. Mean decrease in M value (Δ M) was 
2,92±1,88 mg · kg−1 · min−1 (p=0,11). After adjusting to BMI and HbA1c Δ M 
value was -1,21±1,52 mg · kg−1 · min−1 (p=0,33).
Conclusion: In PNDM children insulin resistance was not observed during 
insulin therapy. A slight improvement of insulin sensitivity was noted after 
initiation of sulphonylurea therapy, but it was influenced by improvement of 
metabolic control.
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The first case report of sulphonylurea use in a woman with PNDM due to 
KCNJ11 mutation during a high risk pregnancy
E. Kozek1, T. Klupa1, N. Nowak1, K. Cyganek1, A. Gach2, T. Milewicz3,  
K. Czajkowski4, J. Tolloczko5, W. Mlynarski6, M.T. Malecki1; 
1Department of Metabolic Diseases, Jagiellonian University, Krakow, 
2Department of Genetics, Polish Mother’s Memorial Hospital, Lodz, 
3Department of Gynecological Endocrinology, Jagiellonian University 
Medical College, 42nd Department of Obstetrics and Gynecology, Warsaw 
Medical University, 5Department of Neonatology and Neonatal Intensive 
Care, Warsaw Medical University, 6Department of Genetics, Polish Mother’s 
Memorial Hospital, Poland.
Background and aims: Sulphonylureas (SU) were proven to be more effec-
tive than insulin in most KCNJ11 gene (encoding Kir6.2) related Permanent 
Neonatal Diabetes Mellitus (PNDM) patients. So far, there was no data on SU 
use in pregnancy in a KCNJ11 mutation carrier. Here, for the first time, we 
report SU use in a woman with PNDM due to the KCNJ11 mutation during 
a high-risk pregnancy.
Materials and methods: A woman with the R201H Kir6.2 mutation became 
pregnant at the age of 37. The patient had been on glipizide 30 mg for 3 years; 
her HbA1c level was 5.8%. She was diagnosed with chronic diabetes com-
plications and a congenital defect of urogenitary tract- a bicornuate uterus 
with septum. As the effect of SU on fetal development is uncertain, she was 
switched to insulin after the pregnancy diagnosis, however, the subsequent 
glycemic control was unsatisfactory, with episodes of hyper- and hypoglyc-
emia. Thus, in the 2nd trimester, the patient was transferred to SU (gliben-
clamide 40 mg).
Results: Transfer to glibenclamide resulted in stabilization of glycemic con-
trol; HbA1c in the 3rd trimester was 5.8%. The prenatal genetic testing ex-
cluded the Kir6.2 R201H mutation in the fetus. The preterm Cesarian deliv-
ery was carried out in the 35th week due to cardiotocography abnormalities. 
The Apgar score of the newborn boy (weight 3010g, 75th percentile) was 8 at 
1 min. He presented with hypoglycemia, transient tachypnea of the newborn 
(TTN), and hyperbilirubinemia. The recovery was uneventful. No birth de-
fects were recorded. His development at the 9th month of life was normal.
Conclusion: We show a high-risk pregnancy in long-term PNDM that in 
spite of perinatal complications ended with the birth of a healthy child. SU, 
that seem to constitute an alternative to insulin during pregnancy in Kir6.2 
related PNDM, were used during the conception period and most of the 2nd 
and 3rd trimester. Prenatal molecular testing should be considered in preg-
nant women with PNDM especially when other medical indications for am-
niocentesis, like older age of the mother, are present.
Supported by: Polish Ministry of Education and Science
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Diabetes onset among carriers of the WFS1 gene mutation in the families 
with Wolfram syndrome
A. Zmyslowska, M. Borowiec, K. Wyka, K. Antosik, A. Szadkowska,  
I. Pietrzak, W. Mlynarski; 
Department of Pediatrics, Oncology, Hematology and Diabetology, Medical 
University of Lodz, Poland.
Background and aims: Wolfram syndrome is a rare form of diabetes mel-
litus associated with an optic atrophy and disorders of different organs e.g. 
deafness, endocrinologic, neurologic and hematologic abnormalities. This 
syndrome is caused by the mutations in wolframin gene localized on chro-
mosome 4p16.1 (WFS1). Wolfram syndrome is inherited as an autosomal 
recessive trait. The aim of the study was an evaluation of the clinical course of 
this syndrome and the mutations in the WFS1 gene in the Polish patients.
Materials and methods: 9 patients with the clinical symptoms suggesting 
Wolfram syndrome (at least diabetes mellitus and optic atrophy) aged: 10-24, 
mean 15.4±4.9 years and 22 first-degree relatives aged: 3-50, mean 27.8±15.7 
years were examined. The genetic analysis was carried out by direct DNA 
sequencing of WFS1 gene. Additionally, a cosanquinity evaluation using the 
multiplex-PCR method at16 polymorphic loci was performed.
Results: In 9 patients with Wolfram syndrome nine mutations in WFS1 gene 
were identified. In the patients the mean age of diagnosis of diabetes mellitus 
was 5.6±1.8 years. Six patients were homozygous for the following mutations: 
V412fs, S443R, W539X, V659fs. They developed diabetes at the age of 5, 5, 
4, 4, 5 and 8 years, respectively. Three patients were complex heterozygous 
for the following mutations: S167fs, Q392X, Y513fs, W648X, V779G. They 
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developed diabetes at age of 8.8, 7 and 3.8 years, respectively. Among dif-
ferent nine mutations five - S167del, S443R, Q392X, Y513fs, W539X were 
novel. Among first-degree relatives 17 individuals were heterozygotic carriers 
of the mutation. In this group no clinical symptoms characteristic for Wolf-
ram syndrome were noticed and none of these carriers had diabetes (age at 
examination: 34.2±16.1 yrs).
Conclusion: Mean age of diagnosis of diabetes among the Polish patients 
was typical for Wolfram syndrome, however, complex heterozygous patients 
were slightly older at diabetes onset. Interestingly, none of the heterozygotic 
carriers of WFS1 mutation suffered from diabetes, which is in contrary with 
the results from the whole genome association studies suggesting that some 
common SNPs in WFS1 may predispose to type 2 diabetes.
Supported by: Polish Ministry of Science and Higher Education
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Clinical and genetical characterisation of a series of patients with type 1 
diabetes induced by interferon therapy
K. Nakanishi1,2; 
1Dept. of Endocrinology and Metabolism, Okinaka Memorial Institute for 
Medical Research, Tokyo, 2Dept. of Internal Medicine, Fuji-Toranomon 
Hospital, Gotemba, Japan.
Background and aims: Interferon alpha is widely used for treatment of sev-
eral diseases including chronic hepatitis C, and rarely causes type 1 diabetes. 
The aim of this study is to clarify clinical and genetical characteristics of in-
terferon-induced type 1 diabetes.
Materials and methods: Subjects were consecutive 12 patients in whom type 
1 diabetes occurred after interferon therapy due to chronic hepatitis C during 
1998-2009. To compare clinical pictures, 128 patients with type 1A diabe-
tes who had at least one data about anti-GAD65 antibodies or serum fasting 
C-peptide levels during first 4 years were enrolled. As genetic controls, 10 
patients in whom diabetes did not develop after interferon therapy due to 
chronic hepatitis C were enrolled. In addition, 136 normal control subjects 
were enrolled. GAD antibodies were assayed by radioligand binding assay, 
and C-peptide was measured by sensitive radioimmunoassay. HLA-A, -DRB, 
-DQA and -DQB alleles were typed by PCR-RFLP methods.
Results: Ten of 12 (83.3%) patients with interferon-induced type 1 diabetes 
showed ketosis at the onset and 11 of 12 (91.7%) needed insulin therapy with-
in 3 months after the onset of diabetes. Titer of GAD antibodies were higher 
in the patients with interferon-induced type 1 diabetes than those with type 
1A diabetes at the onset [median (range): 3,309 (15-110,000) vs. 7.7 (<1.2-
38,000) U/ml, p<0.0001], at 1year [347 (31-10,000) vs. 1.6 (<1.2-3,194) U/ml, 
p=0.0041], and at 2-4 years [1,248 (37.6-6,379) vs. 3.5 (<1.2-6,514) U/ml, 
p=0.0002] after the onset of diabetes. Levels of fasting serum C-peptide were 
higher in the patients with interferon-induced type 1 diabetes than those with 
type 1A diabetes at the onset (0.42 ± 0.27 vs. 0.25 ± 0.24 nmol/l, mean ± SD, 
p=0.016), at 1year (0.49 ± 0.24 vs. 0.23 ± 0.23 nmol/l, p=0.0015) and at 2-4 
years (0.37 ± 0.32 vs. 0.13 ± 0.15 nmol/l, p=0.018) after the onset of diabe-
tes. Insulin dose was not different at the onset (0.37 ± 0.21 vs. 0.47 ± 0.20 
U/kg/day, p=0.12), but lower at 1year (0.30 ± 0.19 vs. 0.59 ± 0.14 U/kg/day, 
p=0.0007) and at 2-4 years (0.41 ± 0.25 vs. 0.59 ± 0.21 U/kg/day, p=0.029) 
after the onset of diabetes in the patients with interferon-induced type 1 dia-
betes than those with type 1A diabetes, while mean HbA1c levels during first 
5 years were not different between 2 groups (7.07 ± 0.97 vs. 7.48 ± 1.38%, 
p=0.51). Allele frequency of HLA-A*2402 was increased in patients with in-
terferon-induced type 1 diabetes compared with those who did not develop 
diabetes despite interferon therapy [50.0% (12/24) vs. 20.0 % (4/20), odds ratio 
(OR) (95% confidence interval (CI)): 4.00 (1.09-17.26)]. Although frequency 
of other HLA-A alleles and DR-DQ haplotypes did not differ between these 
two groups, phenotypic frequency of DRB1*1302-DQA1*0102-DQB1*0604 
was increased in these two groups combined [59.9% (13/22)] compared with 
normal controls [16.2% (22/136), OR (95%CI): 7.48 (2.89-20.27)], and those 
with type 1A diabetes [9.7% (10/103), OR (95%CI): 13.4 (4.72-40.96)].
Conclusion: Despite acute-onset form, interferon-induced type 1 diabetes 
was characterized by prolonged high titers of GAD antibodies, relatively 
preserved residual beta cell function, and subsequently lesser dose of insu-
lin required. Addition of HLA-A*2402 to specific HLA class II background 
(DRB1*1302-DQA1*0102-DQB1*0604) may confer susceptibility to type 1 
diabetes induced by interferon therapy.
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The frequency of ZnT8 autoantibodies and their HLA associations differ 
between Swedish and immigrant children with newly diagnosed type 1 
diabetes in the Better Diabetes Diagnosis Study
A.J. Delli1, F. Vaziri-Sani1, A. Carlsson2, G. Forsander3, S.A. Ivarsson1,  
B. Lindblad3, J. Ludvigsson4, C. Marcus5, Å. Lernmark1; 
1Department of Clinical Sciences, Lund University, Malmö, 2Department 
of Pediatrics, Lund University Hospital, 3Department of Pediatrics, The 
Queen Silvia Children’s Hospital, Göteborg, 4Department of Clinical and 
Experimental Medicine, Linköping University Hospital, 5Department of 
Pediatrics, Karolinska University Hospital, Huddinge, Stockholm, Sweden.
Background and aims: The ZnT8 autoantibodies (ZnT8A) are assuming an 
increasing importance in the prediction and diagnosis of childhood type 1 di-
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abetes (T1D). The fact that single amino acid polymorphism at position 325 
of ZnT8 identifies three antigenic variants: Argenine (ZnT8-R), Tryptophan 
(ZnT8-W) or Glutamine (ZnT8-Q); highlights the importance of ZnT8A in 
T1D. The type and frequency of autoantibodies against ZnT8 variants and 
their associations with the HLA class II DQ genes among different ethnic 
entities were not previously investigated. Our aim was to determine the rela-
tion between ethnic origin of the patient and the detection of ZnT8A in rela-
tion to high-risk HLA DQ genotypes and conventional islet autoantibodies 
(GAD65A, IA-2A and IAA) in Sweden.
Materials and methods: A total of 1868 (53% males) newly diagnosed T1D 
children <18 years at onset were recruited from the Better Diabetes Diagnosis 
(BDD) study during the period from May 2005 to September 2008. This cohort 
was grouped into three subgroups based on the origin of patients defined by 
country of birth of their parents and grandparents into Swedes (67%), non-
Swedes (8%) and mixed-origin (16%) with 9% were of uncertain origins. Chi 
square test of independence was used to detect significant differences among 
ethnic groups in relation to ZnT8A variants and HLA and other islet autoan-
tibodies. Logistic regression models were used to assess a possible association 
between nine high-risk HLA DQ genotypes and ZnT8A among ethnic groups.
Results: A total of 964 (52%) tested positive for ZnT8RA, 895 (48%) for 
ZnT8WA and only 609 (33%) for ZnT8QA. Among the same cohort, 1338 
(72%) patients were positive for IA-2A, 1052 (56%) for GAD65A and 587 
(31%) for IAA. In total only 126 (7%) patients were negative for all six au-
toantibodies. Nine HLA DQ genotypes were identified as high risk genotypes 
among the BDD patients compared to the Swedish general population. Only 
the ZnT8WA variant was significantly higher among Swedes (49%) compared 
to non-Swedes (39%) (p<0.02). Among Swedes ZnT8WA was associated with 
DQ8/8 (p<0.009) and DQ8/6.4 (p<0.001) genotypes while ZnT8RA and 
ZnT8QA were associated only with DQ8/6.4 genotype (p<0.009 and p<0.007 
respectively). However, the DQ2 haplotype but not the DQ2/2 genotype was 
negatively associated with ZnT8RA and ZnT8QA variants among Swedes 
(p<0.008 and p<0.005 respectively) but not the ZnT8WA variant. Among 
non-Swedes none of these genotypes showed an association with any of the 
three ZnT8A variants. On the other hand, among Swedes both IA-2A and 
GAD65A were associated with all the three variants of ZnT8A. However, 
among non-Swedes only IA-2A showed associations with ZnT8RA and ZnT-
8WA but not ZnT8QA (p values are not shown).
Conclusion: The DQ8/6.4 genotype and specifically the DQ6.4 haplotype are 
associated with ZnT8A among Swedish patients with T1D. Immigrant pa-
tients; however, develop ZnT8A in association with IA-2A but they may have 
different genetic associations from Swedish patients.
Supported by: NIH, SCDF, SRC, SDARF, SCCFRD and SKL Sweden
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Novel type 1 and type 2 diabetes susceptibility genes influence 
development of islet autoimmunity and type 1 diabetes in children of 
parents with type 1 diabetes
C. Winkler1, E. Bonifacio2, H. Grallert3, C. Lauber1, E. Trovesi2, T. Illig3, 
A.-G. Ziegler1,4; 
1Institut fuer Diabetesforschung der Forschergruppe Diabetes e.V. at 
Helmholtz Center Munich, Neuherberg, 2Center for Regenerative Therapies 
- Dresden University of Technology, 3Institute of Epidemiology, Helmholtz 
Center Munich, Neuherberg, 4Forschergruppe Diabetes der Technischen 
Universitaet Muenchen, Germany.
Background and aims: Type 1 Diabetes (T1D) is an autoimmune disease 
with multiple susceptibility genes. It has been suggested that T1D and type 
2 diabetes (T2D) may share some pathophysiological and genetic aetiology. 
The aim was to investigate whether novel T1D and T2D suceptibility genes 
influence development of islet autoimmunity and/or progression from islet 
autoimmunity to T1D.
Materials and methods: The single nucleotide polymorphisms (SNPs) in 6 
T1D associated gene regions (PTPN22, ERBB3, PTPN2, KIAA0350, CD25, 
IFIH1) and 9 T2D associated gene regions (KCNJ11, PPARG, TCF7L2, 
SLC30A8, CDKAL1, CDKN2A2/2B, HHEX-IDE, IGF2BP2, FTO) were ana-
lyzed in 1350 children from the German BABYDIAB study, a prospective 
observational study that follows offspring of mothers or fathers with T1D 
from birth to adulthood. A total of 137 children developed at least one per-
sistent islet autoantibody [median age at first islet autoantibody appearance 
4.9 (IQR 2.0-8.1)]; and 43 of these children progressed to T1D [median age at 
diagnosis 11.9 (IQR 9.4-14.9)].
Results: The T2D protective TCF7L2 TT genotype was associated with a sig-
nificantly higher incidence of islet autoimmunity than the CT and CC geno-
type (12% vs. 7% by age of 10 years, p=0.012). After stratification of the HLA 
genotype the TCF7L2 TT genotype was associated with a significantly higher 
incidence of islet autoimmunity than the CT and CC genotype in children 
carrying the moderate/neutrale/protective HLA genotypes (10% vs. 5% by 
age 10 years p=0.006) but not in children carrying the high risk HLA geno-
types (DR3/4 or DR4/4) (p=0.483). None of the other T1D and T2D suscep-
tibility genes were associated with the development of islet autoimmunity in 
our cohort. Amongst the islet autoantibody positive children, progression to 
T1D was increased in children with the T1D susceptible IFIH1 GG geno-
type (47% within 10 years after seroconversion vs. 32% in children with the 
GA and AA genotypes; OR: 1.9, p=0.01), children with the T1D susceptible 
PTPN22 AA genotype (OR: 15.9, 95%CI: 1.6-160.4; p=0.001 vs CA and CC 
genotypes), children with the T2D susceptible SLC30A8 CC genotype (OR: 
2.4, 95%CI: 1.2-4.8; p=0.015 vs CT and TT genotypes), and children with the 
T2D susceptible FTO AA genotype (OR: 2.4, 95%CI: 1.1-5.4; p=0.031 vs CA 
and CC genotypes).
Conclusion: These data suggest that T2D susceptibility genotypes are un-
likely to predispose to the development of islet autoimmunity, but that both 
T1D and T2D susceptibility genes may increase the rate of progression from 
islet autoantibody positive to diabetes.
Supported by: BMBF (Kompetenznetz Diabetes mellitus), DFG Center CRTD, 
NGFN
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Genetic predisposition score for obesity is associated with BMI in 
individuals with type 1 diabetes
E. Fagerholm1,2, C. Forsblom1,2, N. Sandholm1,3, J. Söderlund1,2,  
V. Harjutsalo1, J. Wadén1,2, N. Tolonen1,2, M. Saraheimo1,2, D. Gordin1,2,  
L. Thorn1,2, P.-H. Groop1,2, on behalf of the FinnDiane Study Group; 
1Folkhälsan Institute of Genetics, Folkhälsan Research Center, Biomedicum, 
Helsinki, 2Department of Medicine, Division of Nephrology, Helsinki 
University Central Hospital, Helsinki, 3Department of Biomedical 
Engineering and Computational Science, Helsinki University of Technology, 
Espoo, Finland.
Background and aims: With the help of large genome-wide association stud-
ies (GWAS) several obesity-predisposing variants have been identified. At-
tempts to replicate and further evaluate the association of these variants with 
different measures of obesity have also been carried out. The replications have 
been performed in different populations using both individual SNPs and ge-
netic scores of identified SNPs. Whether the same obesity-predisposing SNPs 
that affect obesity in the general population affect obesity in individuals with 
type 1 diabetes (T1D) is not known. Therefore our aim was to study the as-
sociation of obesity-predisposing SNPs with obesity in T1D using both indi-
vidual SNPs and a genetic predisposition score based on the identified SNPs.
Materials and methods: All patients were part of a nationwide study of adult 
patients with T1D. Body mass index (BMI) and genotype data were available 
for 3232 individuals. 12 single nucleotide polymorphisms (SNP) in or near the 
following genes: FTO, MC4R, SH2B1, MTCH2, KCTD15, NEGR1, TMEM18, 
GNPDA2, BDNF, FAIM2, SEC16B, ETV5 were used to create a genetic predis-
position score for BMI. The SNPs had previously been associated with BMI 
in two large GWAS with BMI. The genetic predisposition score was created 
by calculating the number of risk alleles of the 12 SNPs for each patient. The 
genetic predisposition score for BMI among the patients ranged from 6 to 
20. BMI was divided into three obesity categories: normal weight (BMI < 25, 
N=1609), overweight (BMI 25-29, N=1245) and obesity (BMI > 29, N=336).
Results: In the single SNP analyses only the SNPs located in FTO and near 
TMEM18 were significantly associated with BMI (P=0.0008 for FTO and 
P=0.01 for TMEM18) in directions consistent with prior reports. The sig-
nificance persisted after adjustment for age, HbA1c and eGFR, factors known 
to affect BMI in T1D. While the FTO SNP was significant in both males 
(P=0.02) and females (P=0.02), the SNP near TMEM18 was significant in 
males (P=0.02) but not in females (P=0.3). Although none of the other SNPs 
were associated with BMI, the genetic predisposition score differed signifi-
cantly between the three obesity categories. Obese individuals had a genetic 
predisposition score of 13.1±2.0 (mean ± SD) compared to 12.8±2.0 for over-
weight and 12.7±1.9 for normal weight individuals (P=0.006). The score was 
independently associated with BMI when adjusted for factors affecting BMI 
in T1D (OR=1.11 [95%CI 1.04-1.19], P=0.002).
Conclusion: The obesity-predisposing SNPs in FTO and near TMEM18, 
originally identified in the general population, are also associated with BMI 
in individuals with T1D. Similarly, a genetic predisposition score of 12 obes-
ity-predisposing SNPs was associated with BMI and obesity in T1D.
Diabetologia (2010) 53:[Suppl1]S1–S556 S 121
1 C
Supported by: Folkhälsan Research Foundation, Stockmann Foundation, Liv 
och Hälsa
277
Association of type 2 diabetes genes WFS and HHEX-IDE with disease 
progression in children with new onset type 1 diabetes 
L.B. Nielsen1, M.-L.M. Andersen1, J. Svensson1, S. Pörksen1, P. Hougaard2,  
P. Swift3, H. Hoey4, H.B. Mortensen1, L. Hansen1; 
1Pediatrics, Glostrup University Hospital, 2Statistics, University of Southern 
Denmark, Odense, Denmark, 3Leicester Royal Infirmary Children’s 
Hospital, United Kingdom, 4University of Dublin, Ireland.
Background and aims: Recently, several T2D related SNPs were investigated 
in a large T1D case-control study and PPARG and HHEX-IDE showed as-
sociation with T1D. Previously we reported association of PPARG with re-
sidual beta-cell function and glycemic control during disease progression in 
T1D patients. The objective of this study was to investigate the impact of 11 
newly identified T2D-related SNPs on disease progression in children with 
new onset T1D.
Materials and methods: The study is a multicenter longitudinal investiga-
tion with 18 participating paediatric centres from 15 countries in Europe 
(84% Caucasians). Clinical information and blood samples were collected 
from 275 children at diagnosis and at 1, 6, 12 months after onset. Genotyp-
ing of common SNPs in CDKAL1, WFS1, SLC30A8, CDKN2A-2B, IGFBP2, 
TCF7L2, FTO, HHEX-IDE, THADA was done by KBioscience using an in-
house KASPar assay system. Statistics: C-peptide, HbA1c, IDAA1c and proin-
sulin were analysed by multiple regression using age at onset, gender, DKA 
at onset, HLA class II risk groups, and genotypes as explanatory factors in a 
compound symmetric repeated measurement model.
Results: In a dominant model the G allele carriers (the wildtype allele) of the 
rs10010131 variant of the wolframin gene, WFS1, was significantly positively 
associated with stimulated C-peptide (est.: 1.73, p<0.0001), negatively with 
HbA1c (est.: -0.49, p=0.005), negatively with IDAA1c (est.: -0.67, p=0.017) and 
positively with proinsulin (est.: 1.55, p=0.0045) the first 12 month after dis-
ease onset compared to the AA genotype carriers. In a co-dominant model 
the G allele carriers of the rs1111875 variant of the HHEX-IDE locus was 
significantly associated with stimulated C-peptide 12 months after disease 
onset compared to the AA genotype carriers in a allele dose-dependent man-
ner (est.: 1.76 (GG), 1.30 (AG); p=0.0031).
Conclusion: The wildtype allele of the rs10010131 variant of the WFS1 gene 
is highly associated with a better residual beta-cell function and a correspond-
ing better metabolic control during disease progression in new onset T1D 
compared to AA carriers. In addition the rs1111875 variant of the HHEX-
IDE locus is significantly associated with a better residual beta-function with 
an allele-dose effect the first 12 month after diagnosis. This longitudinal study 
shows that genetic variants related to T2D might have an impact on disease 
progression in new onset T1D patients even if these same variants are found 
not to be predisposing to the onset of T1D. Thus, there might be some mecha-
nistic overlap between T1D and T2D, which potentially can have therapeutic 
benefits for children with new onset T1D.
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The PTPN22 1858T allele enhances the emergence of clinical type 1 
diabetes after the initiation of beta cell autoimmunity
J. Lempainen1, R. Hermann1, R. Veijola2, O. Simell3, M. Knip4,5, J. Ilonen1,6; 
1Immunogenetics Laboratory, University of Turku, 2Department of 
Pediatrics, University of Oulu, 3Department of Pediatrics, University of 
Turku, 4Department of Pediatrics, Tampere University Hospital, 5Hospital 
for Children and Adolescents, University of Helsinki, 6Department of 
Clinical Microbiology, University of Kuopio, Finland.
Background and aims: Data on genetic factors enhancing beta-cell destruc-
tion and emergence of type 1 diabetes (T1D) after the initiation of autoim-
munity is limited. We set out to analyze the role of two polymorphisms as-
sociated with T1D, PTPN22 1858C/T and insulin gene (INS) -23HphI A/T in 
progression to T1D after the appearance of beta-cell autoimmunity.
Materials and methods: The study population comprised 285 children from 
the Finnish DIPP cohort with HLA-confirmed T1D risk. All subjects had 
developed positivity for at least one of the T1D-associated biochemically de-
fined autoantibodies and 136 subjects presented with T1D. Two hundred-
eight subjects developed at least two biochemically defined autoantibodies, 
and among these 124 presented with T1D.
Results: After the appearance of the first biochemically defined beta-cell au-
toantibody the PTPN22 1858T allele was strongly associated with progres-
sion to T1D. Fifty-eight (60%) subjects with the TT or CT genotype presented 
with T1D compared to 71 (40%) subjects with the CC genotype (P<0.001, HR 
2.044, 95% CI 1.425-2.931, Cox regression analysis, multivariate test for the 
effect of PTPN22, INS and HLA DR3/DR4 genotypes). The effect remained 
significant also when analyzed after the appearance of the second biochemi-
cally defined autoantibody (P=0.001). INS -23HphI AA genotype was simi-
larly associated with progression to clinical disease after the appearance of the 
first autoantibody (P=0.03), but the association disappeared when analyzed 
after the emergence of the second autoantibody (P=0.14).
Conclusion: The PTPN22 1858T allele is strongly associated with beta-cell 
destruction and progression to clinical disease after the initiation of beta-
cell autoimmunity. The effect of the INS genotype predisposing to beta-cell 
autoimmunity remained weaker and disappeared after autoantibody spread-
ing.
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Mutation in SIRT1 in familial type 1 diabetes
M. Böni-Schnetzler1, A. Biason-Lauber2, B.P. Hubbard3, K. Bouzakri4,  
M. Meyer-Böni2, D. Meier1, F. Pociot5, G. Leibowitz6, B. Glaser6,  
H. Zulewski7, C. Westphal8, D.A. Sinclair3, M.Y. Donath1; 
1University Hospital of Zürich, 2University Children’s Hospital, Zürich, 
Switzerland, 3Harvard Medical School, Boston, USA, 4University of 
Geneva, Switzerland, 5Hagedorn Research Institute and Steno Diabetes 
Center, Gentofte, Denmark, 6Hadassah Hebrew University Medical Center, 
Jerusalem, Israel, 7University Hospital of Basel, Switzerland, 8Sirtris, Boston, 
USA.
Background and aims: Type 1 diabetes was diagnosed in a 26-year-old 
Ashkenazi Jewish male on the basis of hyperglycaemia, a lean body mass in-
dex of 21.5 Kg/m2 and β-cell auto-antibodies. The patients’ sister, father, and 
a paternal cousin were also diagnosed with type 1 diabetes at the ages of 7, 12, 
and 15 years, respectively. The aims were to further characterise the patient, 
to identify the mutation and its pattern of inheritance and to characterise the 
molecular phenotype of the mutated protein.
Materials and methods: To characterise the index patient an OGTT, a eug-
lycemic-hyperinsulinemic clamp and a muscle biopsy were performed. The 
mutation was identified with a candidate gene approach and exonic sequenc-
ing and introduced by site directed mutagenesis into a retroviral vector 
(MSCV) containing the wild type gene. Mutated and wt protein were stably 
expressed in 293T cells and insulin producing MIN6 cells.
Results: The index patient presented with signs of beta-cell autoimmunity 
(auto-antibodies to glutamic acid decarboxylase 1150 U/L and islet-cell au-
toantibody-2 3.0 U/L), insulin dependence and impaired beta-cell function. 
Further, there was an unexpected insulin resistance as revealed by a euglyc-
emic-hyperinsulinemic clamp study (M value 34.1 10-3 mM / min / Kg BW) 
and a muscle biopsy. The affected family members lacked measurable C-pep-
tide and were also islet auto-antibody positive. The pattern of inheritance was 
indicative of an autosomal dominant mutation. Analysis of SIRT1, a protein 
deacetylase implicated in ageing, beta-cell function and insulin resistance, 
revealed the presence of a T to C exchange in exon 1 of a single allele, corre-
sponding to a Leucine-Proline mutation at residue 107 in the protein. A com-
mon polymorphism of the T to C substitution, mutations in the MODY genes 
and HLA associations were ruled out. Analysis of the structure of the SIRT1 
protein revealed that L107P lies outside of the conserved Sirtuin enzymatic 
core, in a densely-charged region of the protein involved in protein-protein 
interactions. Isolated SIRT1-L107P protein showed only a slight decrease 
in deacetylase activity relative to the wild-type protein, and there were no 
changes in protein stability and the subcellular localization of SIRT1. Sta-
ble overexpression of L107P sirt1 protein in the beta-cell line MIN6 did not 
change insulin mRNA expression and insulin secretion relative to an equal 
expression of the wild-type protein. NF-kappaB is a known deacetylation tar-
get of SIRT1 and SIRT1 L107P MIN6 cells displayed elevated expression of 
NF-kappaB regulated genes iNOS, chemokine KC and cytokine TNF-alpha 
together with overproduction of nitric oxide.
Conclusion: Here we describe the first human mutation in the SIRT1 gene in 
a family with clusters of type1 diabetes. The study implicates that SIRT1 plays 
a role in auto-immunity and glucose homeostasis in humans and it may serve 
as a paradigm to initiate further screening of SIRT1 mutations in families 
with clusters of type 1 diabetes.
Supported by: Swiss National Science Foundation
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Genetic regulation of 25(OH)D3 and 1,25(OH)2D3 serum concentrations 
in type 1 diabetes patients
K. Badenhoop, H. Kahles, C. Greissl, M. Penna-Martinez, F. Shoghi,  
E. Ramos-Lopez; 
Endocrinology, Diabetes & Metabolism, University of Frankfurt am Main, 
Germany.
Background and aims: Growing evidence suggests an important role for the 
vitamin D system in the pathogenesis of type 1 diabetes. In humans, low se-
rum levels of 25(OH)D3 and its active form 1, 25(OH)2D3 correlate with a 
higher risk for this disease. In order to become biologically active, vitamin 
D3 needs to be hydroxylated first into 25(OH)D3 in the liver by the enzyme 
CYP2R1. After this hydroxylation, 25(OH)D3 binds to the vitamin D bind-
ing protein (DBP) and circulates. In the kidney 25(OH)D3 is hydroxylated to 
1,25(OH)2D3 by CYP27B1. Then 1,25(OH)2D3 binds to the vitamin D recep-
tor (VDR) to exert its immunmodulator effects via vitamin D response ele-
ments (VDRRE). Catabolism of both the 25(OH)D3 and 1,25(OH)2D3 occur 
via the 24-hydoxylase (CYP24). Therefore we investigated whether genetic 
variation in vitamin D synthesis, metabolism, transport and catabolism influ-
ence 25(OH)D3 and 1,25(OH)2D3 serum levels in type 1 diabetes patients.
Material and methods: 223 type 1 diabetes patients were genotyped for 
polymorphisms (n= 13) within the VDR- (rs7975232, rs731236, rs1544410, 
rs10735810), the CYP2R1- (rs10741657, rs12794714), the DBP-(rs4588, 
rs7041), the CYP27B1- (rs10877012) and the CYP24- (rs229641, rs2248137, 
rs2585426, rs927650) genes by using restriction fragment length polymor-
phism or real time PCR. The 25(OH)D3 and 1,25(OH)2D3 serum levels were 
measured by radioimmunoassay (DIASORIN). Concentrations of 25(OH)2D3 
< 20 ng/ml were defined as vitamin D insufficiency, while a range of 19.9-67 
pmol/ml of 1,25(OH)2D3 was considered normal. The non-parametric Wil-
coxon-Mann-Whitney -test was used for the statistic analysis. A p value < 
0.05 was considered as significant.
Results: Deficiency of 25(OH)D3 or 1,25(OH)2D3 was found in 54% and 9.4% 
respectively. Of the 13 analyzed polymorphisms the rs10877012, rs10741657 
and the rs7041 within the CYP27B1, CYP2R1 and the DBP genes, respec-
tively, had a statistically significant influence on the serum concentrations 
of 25(OH)D3 or 1,25(OH)2D3. Thus patients carrying the allele C of the 
CYP27B1, which has been reported to be a risk factor to develop type 1 dia-
betes, had lower 1,25(OH)2D3 serum levels (34 pmol/L) than those patients 
carrying the alleles A (42 pmol/L) or AC (38 pmol/L; p<0.05). Also patients 
carrying the allele T of the rs7041 within the DBP gene showed lower levels of 
25(OH)D3 (p<0.02), whereas patients with the genotype A of the rs10741657 
within the CYP2R1 had higher levels of 25(OH)D3 in comparison to those 
patients without these genotypes (p<0.03).
Conclusion: This study demonstrates that vitamin D serum levels, both 
25(OH)D3 and 1,25(OH)2D3, are regulated by genetic variations at least within 
the genes coding for CYP27B1, CYP2R1 and DBP altering 25(OH)D3 and 
1,25(OH)2D3 concentrations. Therefore these genetic variants are function-
ally relevant and may thereby predispose to impaired function of the immune 
system in type 1 diabetes through systemic and/or tissue specific differences 
in vitamin D action.
Supported by: EU-FP7(NAIMIT), Else-Kröner-Fresenius-Stiftung
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Meta-analysis of sex-specific genome-wide association studies of type 2 
diabetes
A.P. Morris1, S. Cauchi2, M. Ganser3, H. Grallert4, G. Thorleifsson5,  
B.F. Voight6, The DIAGRAM Consortium; 
1Wellcome Trust Centre for Human Genetics, University of Oxford, United 
Kingdom, 2Institute of Biology, Pasteur Institute, Lille, France, 3Department 
of Biostatistics, University of Michigan, Ann Arbor, USA, 4Institute of 
Epidemiology, Helmholtz Zentrum Muenchen, Neuherberg, Germany, 
5deCODE Genetics, Reykjavik, Iceland, 6The Broad Institute of Harvard and 
Massachusetts Institute of Technology, Cambridge, USA.
Background and aims: Genome-wide association studies (GWAS) of type 2 
diabetes (T2D) have identified more than thirty confirmed loci contributing 
effects to the disease. However, despite this success, much of the genetic com-
ponent of T2D susceptibility remains unexplained. One potential source of 
genetic variation contributing to this “missing heritability” is that with effects 
that differ in magnitude and/or direction in males and females. Sex-specific 
effects have been observed in a variety of traits, including lipid levels and 
schizophrenia, but may not be readily identified through traditional analy-
sis of GWAS of males and females, combined, because of a lack of statistical 
power. We have therefore undertaken the first large-scale meta-analysis of 
sex-specific T2D GWAS to address the following aims: (i) assess the hetero-
geneity of effects between the sexes at confirmed disease loci; and (ii) identify 
novel male- and female-specific associations with the disease for follow-up.
Materials and methods: We performed GWAS of T2D in six cohorts of 
northern European ancestry (total effective sample size of 9332 males and 
7744 females). Genotype data were imputed in each cohort for up to 2.5 mil-
lion SNPs, genome-wide, including the X chromosome. SNPs were subse-
quently tested, in males and females separately, for association with disease 
under an allelic-dose model, adjusting for cohort specific covariates. For each 
sex, allelic odds ratios (OR) were then combined across cohorts through 
fixed-effects inverse-variance weighted meta-analysis. Heterogeneity of com-
bined allelic OR between males and females was assessed by means of Co-
chran’s Q-statistic.
Results: Among confirmed T2D loci, allelic effects between males and fe-
males were generally homogeneous. However, there was nominal evidence 
of heterogeneity at two loci, both demonstrating stronger effects on T2D in 
males: BCL11A (p = 0.023, male OR = 1.16 [1.10-1.24], female OR = 1.05 
[0.99-1.12]); and KCNQ1 (p = 0.036, male OR = 1.15 [1.08-1.22], female 
OR = 1.04 [0.98-1.12]). The strongest novel signals of association with T2D 
in sex-specific meta-analyses were observed in males, with SNPs at two 
loci achieving genome-wide significance (p<5x10-8): proximal to SLC35D3 
(p=1.7x10-8, OR = 1.19 [1.12-1.26]); and proximal to DGKB (p=2.5x10-8, OR 
= 1.26 [1.16-1.37]). The male-specific signal at DGKB is independent of the 
overall T2D association previously reported at this locus (r2=0.023). Novel 
signals with suggestive evidence of association (p<10-5) were observed at 7 
additional loci in males, and at 14 loci in females, both sets incorporating 
genes with plausible biological candidacy for T2D.
Conclusion: Sex-specific GWAS of T2D did not highlight strong evidence 
of heterogeneity of allelic effects between males and females at already con-
firmed loci. SNPs from 23 regions with at least suggestive evidence of associa-
tion, identified using male- and female-specific meta-analyses, are currently 
being followed up in additional cohorts through in silico replication and de 
novo genotyping.
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Age-dependent genetic effects on post-load glucose during 18 years of 
follow-up of the Whitehall II Cohort
C. Langenberg1, A.C. Jensen2, A. Barker1, E.J. Brunner3, A.D. Hingorani3, 
M. Kumari3, M. Kivimäki3, N.J. Wareham1, A.G. Tabák3, D.R. Witte2; 
1MRC Epidemiology Unit, Cambridge, United Kingdom, 2Steno Diabetes 
Center, Gentofte, Denmark, 3Department of Epidemiology & Public Health, 
London, United Kingdom.
Background and aims: Cross-sectional, genome-wide association studies 
have recently identified common, single nucleotide polymorphisms (SNPs) 
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associated with fasting and/or 2-hour post-load glucose levels in non-dia-
betic individuals. It is unknown whether effects of these variants are constant 
over time or change with advancing age, as most genetic studies rely on glu-
cose measurements at a single time point.
Material and methods: A total of 4,519 non-diabetic British civil servants 
(aged 40-78 years) participating in the Whitehall II study and attending up 
to four 5-yearly clinic visits including repeated oral glucose tolerance tests 
were studied. A weighted genetic score of glucose raising alleles was calcu-
lated separately for fasting and 2-hour glucose levels, including 16 and 5 SNPs 
respectively (mean score (SD) 17.0 (3.0) for fasting and 4.0 (1.4) for 2-hour 
glucose). Multilevel models accounting for the dependence of measurements 
within individuals and adjusted for sex and BMI were used to study the main 
effects of each genotype score on fasting and 2-hour glucose levels and their 
interactions with age.
Results: Over a mean follow-up of 10 years (range 0-18 years), 2-hour but not 
fasting glucose levels showed a significant increase with age (0.048 (95%CI: 
0.037-0.058) mmol/l per year in participants without any risk alleles). The 
fasting glucose score significantly predicted glucose levels at 55 years (0.030 
(95%CI: 0.026-0.034) mmol/l difference per genetic score point), an effect 
that remained constant over time (figure 1, left). At age 55 years, 2-hour glu-
cose levels differed by 0.070 (95%CI: 0.044-0.096) mmol/l per genetic score 
point; notably, this effect became stronger with increasing age (0.004 (95%CI: 
0.001-0.006) mmol/l per genetic score point per year), resulting in diverging 
age trajectories by genetic score (figure 1, right).
Conclusion: Genetic effects on 2-hour glucose appear to depend on age, such 
that the difference in 2-hour glucose levels per additional risk allele increases 
with advancing age. Our findings suggest that the effects of age or related 
environmental factors need to be taken into account when studying genetic 
influences on 2-hour glucose levels.
 
Supported by: MRC
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Genetic predisposition to long-term deterioration in glucose 
homeostasis: 10-yr follow-up of the GLACIER Study
D. Shungin1,2, F. Renström1,3, I. Johansson2, MAGIC investigators,  
J.C. Florez4, G. Hallmans5, F.B. Hu4, P.W. Franks1; 
1GECRG, Department of Public Health & Clinical Medicine, Umeå, 
2Department of Odontology, Umeå University, Sweden, 3Department of 
Nutrition, Harvard School of Public Health, Boston, 4Massachusetts General 
Hospital and Harvard Medical School, Boston, USA, 5Department of Public 
Health & Clinical Medicine, Section for Nutritional Research, Umeå, 
Sweden.
Background: Major advances have recently been made in discovering genetic 
loci for hyperglycemia. These findings emerged primarily through genome-
wide scans of cross-sectional data. Little is known of how these loci affect 
changes in glycaemia over time.
Methods: Sixteen recently discovered fasting glucose-raising loci were geno-
typed in middle-aged non-diabetic participants in the GLACIER Study, a 
population-based prospective cohort from Northern Sweden. Genotypes 
were tested for association with baseline fasting and 2-hr glucose concentra-
tions (N=16,048), and with change in glucose concentrations and the devel-
opment of impaired fasting glucose (IFG) over 10-yrs follow-up (N=4,109). 
Results: Cross-sectional directionally consistent replication with fasting glu-
cose levels was achieved for 12/16 variants. After adjusting for fasting glucose 
levels, the fasting glucose risk alleles for 4 loci were positively and 3 loci were 
negatively associated with 2-hr glucose concentrations. In a genetic risk score 
(GRS) derived by adding unweighted risk alleles, those in the 80th GRS percen-
tile had fasting glucose levels 0.17 mmol/l higher than those in the 20th GRS 
percentile (P=5.3x10-35). In prospective analyses (Table 1), fasting glucose-
raising alleles at 5 loci were nominally associated with worsening fasting gly-
caemia, 3 also predicted the development of IFG. After adjustment for base-
line and follow-up fasting glucose, 2 variants were nominally associated with 
change in 2-hr glucose levels, (ADCY5 rs11708067, MTNRB1 rs10830963). 
Surprisingly the MTNRB1 variant, which was predictive of worsening fasting 
glycaemia, was protective of deterioration in 2-hr glycaemia. The GRS (80th 
vs. 20th percentiles) was associated with 0.13 mmol/l (P=4.3x10-5) greater ele-
vations in fasting glucose and 1.34-fold (95% CI: 1.07-1.70) greater risk of de-
veloping IFG during 10-yrs follow-up. Adjusting the fasting glucose models 
for 2-hr glucose, or vice versa, or weighting the GRS by previously published 
effect estimates did not materially affect these results.
Conclusion: Multiple genetic loci predict deteriorations in fasting glucose 
concentrations during 10-yrs follow-up of a Northern Swedish cohort. Stud-
ies testing prospective relationships with the development of diabetes com-
plications will be required to determine the clinical value of these genetic 
prediction models.
Supported by: Novo Nordisk, the Swedish Research Council, and NHLBI
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Glycaemia determines the effect of type 2 diabetes risk genes on insulin 
secretion
M. Heni, C. Ketterer, C. Thamer, S.A. Schäfer, M. Guthoff, K. Kirchhoff,  
F. Machicao, H. Staiger, A. Fritsche, H.-U. Häring; 
Department of Internal Medicine IV, Tübingen, Germany.
Background and aims: Several polymorphisms in genes associated with 
diabetes risk reduce glucose- and/or incretin-induced insulin secretion. In 
this study, we investigated whether there are interactions between glycemia 
and such diabetes-risk polymorphisms. We hypothesized that diabetes risk 
genes specifically associated with impaired incretin-induced insulin secre-
tion would show a glycemia dependent effect on insulin secretion.
Materials and methods: Insulin secretion was assessed by insulinogenic in-
dex and AUCC-pep/AUCGlc in 1576 subjects with various glucose tolerance 
statuses using an oral glucose tolerance test. Participants were genotyped for 
SNPs which were previously shown to be associated with type 2 diabetes and 
impaired insulin secretion and specifically impaired incretin-induced insu-
lin secretion (rs7903146 [TCF7L2], rs10010131 [WFS1]). Furthermore, the 
impact of the interaction between genetic variation in TCF7L2 and glycemia 
on changes in insulin secretion was tested in 315 individuals taking part in a 
lifestyle intervention study for 9 months.
Results: For two SNPs (TCF7L2, WFS1) we found a significant interaction 
with glucose control on insulin secretion (all p less of equal 0.0018 for glucose 
x genotype). When plotting insulin secretion against glucose at 120 minutes 
during the OGTT, the compromising effect of the risk alleles on insulin se-
cretion is most apparent under high glucose conditions for both SNPs. In 
the longitudinal study, rs7903146 in TCF7L2 showed a significant interaction 
with baseline glucose tolerance on change in insulin secretion during lifestyle 
intervention (p=0.0008). Increased glucose levels at baseline predicted an in-
crease in insulin secretion in carriers of the risk alleles, whereas the change 
in insulin secretion during lifestyle intervention was not influenced by blood 
glucose levels in carriers of the non-risk alleles. None such interaction was 
found for the WFS1 SNP.
Conclusion: For the diabetes risk genes TCF7L2 and WFS1 which are as-
sociated with impaired incretin signaling, glycemia determines SNP effects 
on insulin secretion. This implicates the relevance of these SNPs in different 
stages of the pathogenesis towards type 2 diabetes mellitus.
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The risk allele score for type 2 diabetes mellitus were associated with age 
of diagnosis and basal insulin secretion in Japanese population
M. Iwata1, Y. Kamura1, C. Kobashi1, M. Ishiki1, I. Usui1, K. Yamazaki1,  
M. Urakaze1, K. Tobe1, A. Takano2, R. Temaru3, H. Kato4, S. Murakami2,  
N. Akagawa5, Y. Fukushima5, K. Higuchi6; 
1Toyama University, 2Saiseikai Takaoka Hospital, 3Nanto City Hospital, 
4Shakaihoken Takaoka Hospital, 5Asahi General Hospital, Shimoniikawa, 
6Itoigawa General Hospital, Japan.
Background and aims: T2DM is a multifactorial disease whose onset de-
pends not only on the genetic predisposition, but also environmental factors, 
and it remains unclear to what extent genetic predisposition affects the clini-
cal presentation. Large-scale studies in Europe have reported that the odds 
ratio of each polymorphism for the onset of diabetes is low, ranging from 1.1 
to 1.5. Consequently, it is considered that the onset of diabetes mellitus may 
be related to the accumulation of several polymorphisms. We counted the 
number of risk alleles of the SNPs in Japanese participants and defined the 
total number of risk alleles as a risk allele score. In this study, the effect of the 
risk allele score on the clinical presentation of T2DM was investigated.
Materials and methods: The subjects were 720 T2DM outpatients of our hos-
pital and associated hospitals, and 760 non-diabetic controls. Ten SNPs out 
of 10 candidate T2DM-susceptibility genes, namely, HHEX , CDKAL1 ,CD-
KN2A/B, SLC30A8 KCNJ11 , IGF2BP2, PPARG, TCF7L2, FTO and KCNQ1 
were genotyped by TaqMan PCR assay. Clinical information, including the cur-
rent BMI, age at diagnosis of diabetes, age at the maximum body weight, family 
history, disease duration, FPG, HbA1c, F-CPR(= fasting serum CPR), CPI (=F-
CPR*100/FPG), UCPR (=urinary C-peptide)/Cr and treatment was collected.
Results: Of the 10 genes, a significant difference between the T2DM group 
and control group was found for 5 genes, namely, CDKAL1, CDKN2A/B, 
SLC30A8, IGF2BP2 and KCNQ1. Based upon the frequency distribution of 
the risk alleles of the 5 SNPs, which were significantly associated with type 2 
diabetes, we classified the participants into low-(a total of four or fewer risk 
alleles), intermediate-(a total of five or six risk alleles) and high-(a total of 
seven or more risk alleles)risk genetic groups. In the comparison of the clini-
cal presentation between the low-risk group and high-risk group, although 
the maximum BMI of the latter group (27.0) was significantly lower than that 
of the former group (28.3) (p<0.01), the age at diagnosis of diabetes in the lat-
ter group (49.4 years) was significantly younger than that of the former group 
(52.1 years) (p<0.05). However, there was no significant correlation between 
the total number of risk alleles (0-2) for each gene and the age at diagnosis of 
diabetes mellitus. Regarding the indices of the basal linsulin secretary capac-
ity, the F-CPR, CPI and UCPR/Cr were all significantly lower in the high-risk 
group than in the low-risk group, after adjustments for age, sex, FPG, BMI, 
and duration of diabetes (p<0.01). The ratio of insulin therapy in the high-
risk group (37%) was greater than that in the low-risk group (25%) (p<0.05).
Conclusion: It was demonstrated that while the risk alleles for each individu-
al polymorphism had little effect on the onset of diabetes, the high risk allele 
score of 5 SNPs, which were associated with significantly associated with type 
2 diabetes in this study, was related with earlier age at onset of diabetes, de-
creased insulin secretion and increment of the ratio of insulin therapy.
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Replication of European GWAS-derived type 2 diabetes susceptibility 
SNPs in Pakistani populations
S. Rees1, S. Bellary2, M.Z.I. Hydrie3, J.P. O’Hare4, S. Kumar4, A.S. Shera5, 
A. Basit3, A.H. Barnett2,1, M.A. Kelly1; 
1College of Medical and Dental Sciences, University of Birmingham, 2Heart 
of England NHS Foundation Trust, Birmingham, United Kingdom, 3Baqai 
Institute of Diabetology and Endocrinology, Karachi, Pakistan, 4Warwick 
Medical School, University of Warwick, Coventry, United Kingdom, 
5Diabetic Association of Pakistan, Karachi, Pakistan.
Background and aims: Type 2 diabetes (T2D) is a major public health is-
sue in the Indian subcontinent (India, Pakistan and Bangladesh), where it is 
predicted that the disease will affect approximately 76 million adults by 2025. 
A high prevalence of the disease is also observed in populations of South 
Asian ancestry living in other areas of the world. Although lifestyle factors, 
such as diet and exercise, undoubtedly contribute to the development of T2D, 
these factors cannot fully explain the high prevalence of the disease in South 
Asian populations. This excess risk has been partly attributed to the genetic 
background of the population. Recently the advent of genome-wide asso-
ciation studies (GWAS) has led to the discovery of a number of novel SNPs 
(single nucleotide polymorphisms) that confer risk of T2D development. The 
majority of these large scale studies, however, have investigated cohorts of 
white European origin, and South Asian populations have been considerably 
understudied. In this study we investigated 16 SNPs that have been robustly 
associated with T2D in Europeans to determine whether they have a similar 
effect on disease risk in two Pakistani populations of Punjabi ancestry, one 
UK-resident and one indigenous to Pakistan.
Materials and methods: We genotyped 2992 subjects (1609 with T2D and 
1383 normoglycaemic controls) for 16 SNPs using either TaqMan (Ap-
pliedBiosystems, Warrington, UK) or KASPar (KBiosciences, Hoddesdon, 
UK) methods. One SNP was chosen from each of the following loci: TC-
F7L2, CDKN2A/2B, CDKAL1, HHEX/IDE, IGF2BP2, CDC123/CAMK1D, 
SLC30A8, PPARG, KCNJ11, WFS1, TCF2, ADAMTS9, THADA, NOTCH2, 
TSPAN8/LGR5, JAZF1. Logistic regression was used to investigate the asso-
ciation between each SNP and T2D, using an additive model and including 
sex, age and population as covariates. An allelic risk score variable was con-
structed using those SNPs that showed some evidence (p<0.1) for association 
with T2D, by combining the total number of risk alleles for each subject.
Results: Significant associations with T2D were observed for TCF7L2 
(OR=1.25 [1.12, 1.40] p=0.00008), CDKN2A/2B (OR=0.79 [0.67, 0.93] 
p=0.005), HHEX/IDE (OR=1.14 [1.03, 1.26] p=0.013), IGF2BP2 (OR=1.18 
[1.06, 1.31] p=0.002) and TCF2 (OR=0.90 [0.80, 1.00] p=0.041). Trends to-
wards association with T2D were also observed for SLC30A8 (OR=0.89 [0.79, 
1.01] p=0.064) and PPARG (OR=0.88 [0.75, 1.02] p=0.089). These variants 
appear to have an additive effect on T2D risk, the allelic risk score showing 
that each risk allele contributes a 1.15-fold increase in disease risk (OR=1.15 
[1.10, 1.21] p=2.04 x 10-9).
Conclusion: We have demonstrated that a number of genetic variants that 
predispose to T2D in European populations have a similar effect in popu-
lations of Pakistani origin. Furthermore, to our knowledge this is the first 
time that a disease association with variants in CDKN2A/2B, HHEX/IDE and 
TCF2 has been demonstrated in any South Asian population.
Supported by: Diabetes UK
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Evaluation of the phenotypic effects of common FTO and MC4R genetic 
polymorphisms in a general population from South India
S.K. Vasan1, P. Samuel2, B. Antonisamy2, N. Thomas3, M.J. Neville4,  
F. Karpe4, H.F. Gu1, K. Brismar1; 
1Molecular Medicine & Surgery, Karolinska Institutet, Stockholm, Sweden, 
2Biostatistics, Christian Medical College, Vellore, India, 3Endocrinology, 
Diabetes & Metabolism, Christian Medical College, Vellore, India, 4Oxford 
Centre for Diabetes, Endocrinology and Metabolism (OCDEM), University 
of Oxford, United Kingdom.
Background and aims: Obesity is a multi-factorial trait that results from a 
complex interplay between genes and environment. Genome wide associa-
tion (GWA) studies have shown that common variants in the FTO (Fat mass 
and Obesity associated) and MC4R (Melanocortin 4 receptor) genes are asso-
ciated with increased risk of Obesity and type 2 diabetes in Caucasians. These 
associations, however, were not consistent and the effect was independent of 
body mass index (BMI) in the subjects with type 2 diabetes among Asians. In 
the present study, we aimed to evaluate the phenotypic effects of the common 
FTO and MC4R genetic polymorphisms in a young adult population from 
South India.
Materials and methods: We examined the common variants of the FTO 
(rs9939609) and MC4R (rs17782313) genes in two independent cohorts 
(n=3241) stratified based on the area of residence to rural (n=1221) semiur-
ban (n=1023) and urban (n=997)from South India. Anthropometric meas-
urements of adiposity including BMI, waist circumference (WC), waist-hip 
ratio (WHR), body fat % and skin fold thickness were performed. Serum 
glucose, lipids were measured in non fasting venous blood samples. The 
data were summarized by comparing means across groups by ANOVA and 
Kruskall Wallis tests respectively for normal distributed and skewed vari-
ables. Comparative analyses of genotype frequencies between study groups 
were performed using chi-square test. Phenotypic effects in each genotypes 
were deduced based on dominant/recessive models using multivariate logis-
tic regression analyses.
Results: The rural group comprised of lean phenotypes with low mean BMI 
(19.8 ± 3.4) and WHR (0.83 ±0.07) while the urban population had a sig-
nificantly higher mean BMI (21.8 ± 3.9, p<0.001), higher WC (77.1 ± 10.9, 
p<0.001) and higher fasting blood glucose (5.6 ± 1.0) compared to the ru-
ral and semi-urban groups. Despite a lean phenotype, the homozygous AA 
genotype of the FTO gene, was significantly associated with higher body fat 
% (23.2 ± 9.6, p=0.03), Skin fold measurements at triceps ( median 9.55 in-
terquartile range 6.53-14, p=0.004), biceps ( median 4.53, range 3.13-7.22, 
p=0.03), subscapular (14.73, range 10.35-25.88, p=0.01) and abdomen (me-
dian 16.13, range 8.63-30.55, p=0.002) in the rural group. Significant associa-
tion with anthropometric measurements was not seen among the urban and 
the semi urban group though they had a significantly higher BMI and subcu-
taneous fat. A similar trend was also observed amongst the rural population 
in the homozygous CC genotype of MC4R with modest significance.
Conclusion: Data from the present study suggests that the common variants 
of the FTO and MC4R genes have significant genetic influence on subcuta-
neous fat and body fat percentage, but not BMI in the South Indian popula-
tion.
Supported by: Svenska Institutet, Sweden
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Common variant of MTNR1B is associated with difficulties maintaining 
sleep but fails to influence the association between sleep disturbances 
and type 2 diabetes: the HUNT study
L. Olsson1, E. Pettersen2, A. Ahlbom1, S. Carlsson1, K. Midthjell3, V. Grill2,4; 
1Department of Epidemiology, Karolinska Institutet, Stockholm, Sweden, 
2Department of Cancer Research and Molecular Medicine, The Norwegian 
University of Science and Technology, Trondheim, 3Department of 
Community Medicine and General Practice, HUNT Research Centre, The 
Norwegian University of Science and Technology, Levanger, 4Department of 
Endocrinology, St. Olav University Hospital, Trondheim, Norway.
Background and aims: Recent studies have demonstrated that genetic varia-
tion in the melatonin receptor 1B (MTNR1B) is associated with type 2 diabe-
tes. Melatonin contributes to the regulation of sleep, and sleep problems are a 
documented risk factor for type 2 diabetes. Whether the MTNR1B gene vari-
ant, which confers risk of diabetes, induces sleep problems is not known, nor 
whether a putative effect on sleep impacts on the link between sleep problems 
and type 2 diabetes. We tested 1) whether the risk variant SNP rs10830963 
in the MTNR1B gene is associated with self reported sleep problems, and 2) 
whether presence of the risk variant influences the association between sleep 
disturbances and type 2 diabetes.
Materials and methods: We used information from a case-control study 
nested within the population-based Nord-Trøndelag Health Study, includ-
ing 1,074 cases of type 2 diabetes and 1,447 controls (matched by age and 
sex). Information on different aspects of sleep disturbances was obtained by 
questionnaire. Genotyping was performed using the Tacman discrimination 
assay (Applied biosystems). Odds ratios (OR) and 95% confidence intervals 
(CI), adjusted for age, sex and BMI, were calculated using logistic regression 
models.
Results: Reported difficulties maintaining sleep were more frequent in sub-
jects with the G allele of the rs10830963 (OR 1.49, 95% CI 1.04-2.14). In con-
firmation of previous studies, this allele also conferred increased risk of type 
2 diabetes (OR 1.19, 95% CI 1.01-1.41). However, the previously documented 
association between sleep problems and type 2 diabetes was not influenced by 
the MTNR1B G allele. Hence, the OR for the association between sleep dis-
turbances and type 2 diabetes was 1.46 (95% CI 1.01-2.10) for subjects with 
the G allele of rs10830963, and 1.53 (95% CI 1.08-2.16) for subjects without 
the G allele.
Conclusion: The common variant rs10830963 in the MTNR1B gene is asso-
ciated with difficulties maintaining sleep and also with type 2 diabetes. How-
ever, presence of the risk allele does not influence the association between 
sleep disturbances and type 2 diabetes.
Supported by: Liason Committee, St Olav´s Hospital Trust/Medical Faculty 
NTNU and FAS
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Expression of ARL15, a type 2 diabetes risk variant, is increased in 
cultured human skeletal muscle cells from insulin-resistant type 2 
diabetes patients
A.E. Brown1, C.J. Williams1, N. Rocha2, J.B. Richards3,4, R. Semple2,  
M. Walker1; 
1Institute of Cellular Medicine, Newcastle University, 2University of 
Cambridge Metabolic Research Laboratories, Institute of Metabolic Science, 
University of Cambridge, United Kingdom, 3Departments of Medicine, 
Human Genetics and Epidemiology and Biostatistics, McGill University, 
Montreal, Canada, 4Twin Research and Genetic Epidemiology, King’s 
College London, United Kingdom.
Background and aims: A recent genome wide association (GWAS) meta-
analysis identified a new variant in the ARL15 gene associated with decreased 
circulating adiponectin levels, and increased risk of coronary heart disease 
and type 2 diabetes. ARL15 (ADP-ribosylation factor-like 15) encodes a 
GTP-binding protein of unknown function that is highly expressed in skel-
etal muscle. The aim of this study was to investigate ARL15 expression in cul-
tured human skeletal muscle cells, and to determine (1) whether expression 
changed with differentiation from myoblasts to myotubes, and (2) whether 
expression was altered in cultured muscle cells from insulin resistant type 2 
diabetic patients.
Materials and methods: Cultured skeletal muscle cells derived from type 2 
diabetic patients with a family history of diabetes and clinical evidence of 
insulin resistance and healthy non-diabetic control subjects with no family 
history of diabetes were studied. We have previously shown that defects of in-
sulin action are retained in the cultured myotubes from the diabetic patients. 
ARL15 expression was measured in cultured myoblasts and day 7 differentiat-
ed myotubes. Quantitative real-time PCR (QPCR) was used to measure gene 
expression relative to GAPDH as the reference gene, while protein expression 
was determined by Western blotting. Statistical analyses were performed us-
ing the Wilcoxon signed rank and Mann Whitney U tests.
Results: In cultures from healthy control subjects, ARL15 was expressed in 
both myoblasts and myotubes and increased with differentiation. After nor-
malisation to GAPDH, expression increased from 0.24±0.06 (mean±SEM) 
units in myoblasts to 0.68±0.25 in myotubes (n=9; p=0.03). Western blot-
ting confirmed ARL15 protein expression in both myoblasts and myotubes, 
and was 1.6-fold higher following differentiation to myotubes (n=3; p=0.04). 
ARL15 expression was compared between cultured muscle cells obtained 
from 6 insulin-resistant type 2 diabetic patients and 6 age- and BMI-matched 
controls. ARL15 expression tended to be higher in diabetic vs control myob-
lasts (0.44±0.24 vs 0.12±0.04 units; p=0.06). ARL15 expression increased with 
differentiation in both groups, and was significantly higher in the diabetic vs 
control myotube cultures (0.94±0.27 vs 0.25±0.05 units, p=0.004).
S 126 Diabetologia (2010) 53:[Suppl1]S1–S556
1 C
Conclusion: These data show that ARL15 and the encoded protein are well 
expressed in cultured human skeletal muscle cells, and expression increases 
with differentiation. ARL15 expression was increased in differentiated myo-
tubes from insulin resistant type 2 diabetic patients. Further work is needed 
to explore whether the increased ARL15 expression in the diabetic myotubes 
is directly related to the previously observed impairment of insulin action in 
these muscle cell cultures.
Supported by: Diabetes UK
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Whole genome sequencing identifies naturally-occurring 
polymorphisms in a polygenic model of spontaneous type 2 diabetes
P.J. Kaisaki, M. Ria, A. Rimmer, K. Argoud, A. Authier, R. Yahia, G. Lunter, 
D. Gauguier; 
Wellcome Trust Centre for Human Genetics, Oxford, United Kingdom.
Background and aims: The GK rat is a well-established inbred model of type 
2 diabetes (T2D), spontaneously exhibiting the main features of T2D, as the 
consequence of naturally-occurring diabetes-causative DNA variants isolated 
from an outbred Wistar stock By making use of massively parallel next-gen-
eration sequencing technologies, our aim was to sequence the entire genome 
of the GK rat at sufficient coverage for accurate identification of nucleotide 
and possibly structural variants. More particularly we will examine GK ge-
nomic regions linked to phenotypes related to T2D and other metabolic traits 
as well as genes found to be differentially expressed between GK and control 
strains through genome-wide gene expression (eQTL) studies.
Materials and methods: Genomic DNA is extracted from GK rat liver using 
Qiagen DNeasy blood and tissue kit. The DNA is fragmented, and adaptors 
are ligated to the fragments to make a library for 51-bp paired-end sequenc-
ing on an Illumina Solexa Genome Analyzer II next-generation sequencer. 
Solexa software is used for base calling (Bustard) and initial alignment (GER-
ALD) with the ELAND algorithm. Further alignments are carried out using 
STAMPY, and SNP detection by an in-house algorithm at the Wellcome Trust 
Centre for Human Genetics.
Results: In total, 29 lanes of sequencing were run, giving a total of about 
330 million 51-bp reads, and resulting in approximately 9x average coverage 
across the genome. Currently 80% of the sequence maps back to the BN rat 
RGSC 3.4 assembly. Looking specifically in a 6.32Mb region carried by a con-
genic rat strain bred to capture a GK diabetes QTL, we find 14,453 candidate 
SNPs, some in genes that have emerged from monogenic family studies and 
genome wide association studies in humans, including Glis3, as well as in 
Dmrt3, a novel candidate which is an expression QTL in GK. Gene expres-
sion and physiological QTLs are now annotated with a more complete set of 
SNPs and other variants.
Conclusion: We have generated whole genome sequence for the GK rat, 
aligned it to the BN reference sequence, and have identified sequence vari-
ants in candidate genes for T2D. Integration of whole genome polymorphism 
data with physiological and genome-wide gene expression quantitative trait 
loci in F2 crosses and congenic strains, provides a powerful novel resource 
for understanding the full genomic landscape of spontaneous polygenic T2D 
and for identifying new candidate genes and pathways contributing to T2D 
and the metabolic syndrome.
Supported by: Wellcome Trust, FGENTCARD, EC
PS 4 Genes and islets
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What can a meal test tell us about the heritability of the beta cell 
function?
A.M.C. Simonis-Bik1, D.I. Boomsma2, J.M. Dekker3, M. Diamant1,  
E.J.C. de Geus2, L.M. ‘t Hart4, R.J. Heine1, M.H.H. Kramer5, A.J. Maassen1, 
A. Mari6, A. Tura6, G. Willemsen2, E.M.W. Eekhoff1; 
1Diabetes Centre, VU University Medical Centre, Amsterdam, 2Biological 
Psychology, VU University Amsterdam, 3Epidemiology and Biostatistics 
and EMGO institute for Health and Care Research, VU University Medical 
Centre, Amsterdam, 4Molecular Cell Biology and Medical Statistics, 
Leiden University Medical Centre, 5Internal Medicine, VU University 
Medical Centre, Amsterdam, Netherlands, 6CNR Institute of Biomedical 
Engineering, Padova, Italy.
Background and aims: Type 2 diabetes is a multi-factorial disease in which 
deterioration of the beta cell function plays a crucial part. This same-sex twin 
family study is the first to assess the heritability of beta cell function param-
eters derived from the most physiological challenge test, the mixed-meal tol-
erance test.
Materials and methods: We recruited 77 same-sex twin families from the 
Netherlands Twin Register, including 51 MZ twin pairs, 21 DZ twin pairs, 5 
twins without a co-twin and 34 same-sex siblings of the twins. All 183 healthy 
participants (77 male) were of European origin and aged 20-49 years. After 
anthropometric measurements were performed, a standardized mixed-meal 
was given and blood was sampled repeatedly. Glucose, insulin and C-peptide 
levels were determined to calculate the insulin sensitivity, the insulinogenic 
index, insulin levels at different time periods, 4 parameters of postprandial 
glycaemia and 9 model derived (Mari) parameters of beta-cell function, 
namely beta-cell glucoses sensitivity, rate sensitivity, potentiation factor 
ratios and insulin secretion rate in 5 different periods. All genetic analyses 
were carried out in Mx, a structural equation modeling program. In the uni-
variate analyses the heritability of each variable was estimated individually. 
Subsequent multivariate analyses were performed to test overlap in the ge-
netic factors influencing beta cell function, waist circumference and insulin 
sensitivity.
Results: The highest heritability was found for the insulinogenic index (63%), 
of which one third was shared with waist and insulin sensitivity. Beta cell 
glucose sensitivity had a heritability of 50% with a negligible overlap with 
genetic factors for waist and insulin sensitivity. Insulin secretion rate was only 
heritable before and during the first 2 postprandial hours (range 40-45%). 
Genetic factors determine half of the variability of the insulin sensitivity and 
of the postprandial glycaemic responses during mixed-meal tolerance tests. 
The fasting insulin but not postprandial insulin levels showed significant her-
itability (38%). In 7 beta cell function parameters, of which 5 were model-
derived, genetic influence did not reach significance.
Conclusion: Classical and model derived beta cell function parameters of the 
first two hours of a meal test show a significant heritability. These parameters 
provide important physiological data that can be used to follow up results of 
gene finding studies.
Supported by: DFN and NWO-MagW
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Genetic variability of G6PC2 influences beta cell function and insulin 
sensitivity in patients with newly diagnosed type 2 diabetes
F. Turrini1, S. Bonetti1, M. Trombetta1, L. Boselli1, E. Trabetti2, G. Malerba2, 
P.F. Pignatti2, M. Muggeo1, I. Pichiri1, E. Bonora1, R.C. Bonadonna1; 
1Department of Medicine, 2Department of Life and Reproduction Sciences, 
University of Verona, Italy.
Background and aims: G6PC2 (glucose-6-phosphatase catalytic subunit 2) 
is the catalytic subunit of glucose-6-phosphatase and it has specific expres-
sion in the beta cell. The rs560887 G allele of G6PC2 is associated with higher 
levels of fasting plasma glucose (G) and increased first phase of insulin se-
cretion during IVGTT. We evaluated the role of genetic variation at G6PC2 
in determining clinical and pathophysiological traits in patients with newly 
diagnosed type 2 diabetes (T2D).
Methods: 494 GAD-negative and drug-naïve patients (age 57.7±10.3 years, 
BMI 29.9±5.1 kg/m2, HbA1c 7.0±1.4 %) with newly diagnosed T2D under-
went standard clinical characterization. Furthermore, beta cell function (BF) 
and insulin sensitivity (SI) were assessed by mathematical modeling of G/C-
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peptide curves during a 240’ frequently sampled OGTT and by euglycemic 
insulin clamp, respectively. The beta-cell responses to the rate of increase of G 
(derivative or dynamic control: DC; median[IQ range]: 430[0.6-904] [pmol.
m-2 BSA]/[mM.min-1]) and to G concentration (proportional or static con-
trol, PC, presented as the insulin secretion rate at G concentrations of 5.5, 8.0, 
11.0, 15.0 and 20.0 mM, respectively; 160±68, 222±121, 358±219, 569±378, 
839±594 pmol.min-1.m-2 BSA) are herein reported as measures of BF. SI is 
presented as the M value in the last 60’ of the clamp (561[355-796] µmol.min-
1.m-2 BSA). We genotyped the following tag SNPs which reportedly capture 
~95% of genetic variability of G6PC2 locus: rs853770 , rs483109, rs12475700 
(a), rs13387347 (b) and rs560887 (c). We report the results of variants a, b and 
c, because of their relevance to BF and SI.
Results: Both in our patients and in HapMap, a higher LD value (r2= 0.54) 
was found between the proximal (a) and the distal (c) variant than between 
adjacent SNPs (a/b r2= 0.10; b/c r2= 0.29). Consistently with this observation, 
both major alleles of rs12475700 (A allele, frequency: 0.56) and rs560887 (G 
allele, frequency: 0.70) were associated with increased DC (A allele: +90±46, 
p<0.05; G allele: +95±49, p<0.03). In turn, the rs13387347 A allele (frequency: 
0.43) was associated with reduced SI (-44±22, p<0.03), and increased levels 
of fasting C-peptide (+0.086±0.024 nmol/L, p=0.002) and insulin (+8.4±3.1 
pmol/L, p<0.002). The increases in C-peptide/insulin were statistically sig-
nificant also after adjustment for SI (p=0.006 and p<0.05 respectively).
Conclusion: In patients with newly diagnosed type 2 diabetes the G6PC2 lo-
cus is associated with changes in BF and in SI of opposite sign, only partially 
explained with reciprocal compensation. These data could be of etiopatho-
genic and pathophysiological relevance and lead to clinical and therapeutic 
applications.
Supported by: an EFSD/Novartis grant
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Potential role of MTNR1B locus in regulating beta cell function and 
glucose levels in patients with newly diagnosed type 2 diabetes
S. Bonetti1, M. Trombetta1, F. Turrini1, L. Boselli1, E. Trabetti2, G. Malerba2, 
P.F. Pignatti2, M. Muggeo1, E. Bonora1, R.C. Bonadonna1; 
1Department of Medicine, 2Department of Life and Reproduction Sciences, 
University of Verona, Italy.
Background and aims: The high affinity melatonin receptor, MTNR1B, is 
expressed in brain, retina and endocrine pancreas. In non-diabetic subjects, 
the MTNR1B variant rs10830963 is associated with increased levels of fasting 
glucose (G), reduced beta cell function (BF) and increased risk of developing 
type 2 diabetes (T2D). We investigated the role of MTNR1B in determining 
clinical and pathophysiological traits in patients with newly diagnosed T2D.
Materials and methods: 494 GAD-negative and drug-naïve patients (age 
57.7±10.3 years, BMI 29.9±5.1 kg/m2, HbA1c 7.0±1.4 %) with newly diag-
nosed T2D underwent standard clinical characterization. Furthermore, beta 
cell function (BF) and insulin sensitivity (SI) were assessed by mathematical 
modeling of G/C-peptide curves during a 240’ frequently sampled OGTT 
and by euglycemic insulin clamp, respectively. The beta-cell responses to the 
rate of increase of G (derivative or dynamic control: DC; median[IQ range]: 
430[0.6-904] [pmol · m-2 BSA]/[mM · min-1]) and to G concentration (pro-
portional or static control, PC, presented as the insulin secretion rate at G 
concentrations of 5.5, 8.0, 11.0, 15.0 and 20.0 mM, respectively; 160±68, 
222±121, 358±219, 569±378, 839±594 pmol · min-1 · m-2 BSA) are herein re-
ported as measures of BF. SI is presented as the M value in the last 60’ of the 
clamp (561[355-796] µmol · min-1 · m-2 BSA). We genotyped the following tag 
SNPs which reportedly capture ~94% of genetic variability of MTNR1B lo-
cus:: rs7102746 e rs11523890 upstream to, rs10830963 within and rs9666752 
downstream to MTNR1B.
Results: The LD of these SNPs was found to be consistent with HapMap 
(CEU popolation). The rs11523890 G allele (frequency: 0.65) was associated 
with reduced DC (-136±55, p=0.002). The diabetes risk allele G of rs10830963 
(frequency: 0.26) was significantly associated to reduced DC in a dominant 
model (GG+AG:-101±45, p<0.03), and also in multivariate analysis with 
rs11523890 as a covariate. In the combinatory rs11523890-rs10830963 geno-
type, no patient was homozygous for both risk alleles (GG-GG), but a tiny 
group (n=6, age:49±12; BMI:29.4±4.3) was homozygous for both non risk 
alleleles (CC-AA) and had the best DC (1982±642; p<0.01) and the worst SI 
(362±101; p<0.01). Finally, the rs9666752 A allele (frequency: 0.52) was as-
sociated with increased HbA1c (+0.22±0.09%, p<0.02).
Conclusion: MTNR1B may play a relevant role in the regulation of G lev-
els and BF in patients with newly diagnosed T2D. These data, if confirmed. 
could lead to clinical and therapeutic application, including, but not limited 
to, identification of specific subgroups of patients for diagnostic-therapeutic 
purposes.
Supported by: an EFSD/Novartis grant
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Pancreatic islets of melatonin receptor knock-out mice
C.L.F. Nagorny1, U. Voss2, H. Bennet3, J.A. Stamenkovic1, R. Sathanoori2,  
M. Fex3, N. Wierup2, H. Mulder1; 
1Clinical Sciences Malmö; Molecular Metabolism, Lund University, Malmö, 
2Experimental Medical Science; Neuroendocrine Cell Biology, Lund 
University, Lund, 3Clinical Sciences Malmö; Diabetes and Celiac Disease, 
Lund University, Malmö, Sweden.
Background and aims: Genome-wide-association studies (GWAS) have re-
cently suggested that a receptor (MTNR1B) for the pineal hormone mela-
tonin is involved in the pathogenesis of Type 2 Diabetes Mellitus (T2DM). 
Melatonin binds predominantly to its receptors MTNR1A (MT1) and MT-
NR1B (MT2), which are G-protein coupled receptors and are proposed to 
exert an inhibitory effect on insulin secretion. Here, we investigate whether 
a metabolic phenotype evolves in mice when melatonin receptor signalling 
is disrupted. Also, we examined whether a knock-out of melatonin receptors 
affects islet morphology and function.
Materials and methods: Knock out mice for MT1, MT2 and both recep-
tors were kindly provided by Professor David Weaver. Every second week 
blood samples were taken from the Saphenous vein in awake male mice. We 
measured glucose and insulin concentrations in plasma. We also performed 
immunohistochemistry to calculate β-cell mass and area and to determine 
cellular location of the receptors in islets. Standard errors are given as stand-
ard deviations.
Results: Plasma glucose (8.61 ±1.43 mM) and insulin levels (1.58 ±0.98 ng/
ml) did not differ between the mouse lines and did not change over time (10-
22 weeks). MT2 knock-out mice were significantly heavier than WT, MT1 
and MT1/2 knock-out mice (MT2: 39.7 ±1.0g; WT: 34.0 ±0.9g; MT1: 31.0 
±0.7g; MT1/2: 30.45g ±0,7). Mean β-cell mass did not vary between mouse 
lines, but there was a trend towards increased islet area in MT2 and MT1/2 
double knock-out mice (MT2: 2.42 x 10-5 ±2.0 x 10-5 AU (Arbitrary Units); 
MT1/2: 2.44 x 10-5 ±1.7 x 10-5 AU; WT: 1.52 x 10-5 ±1.1 x 10-5 AU; MT1 1.39 
x 10-5 ±1.0 x 10-5 AU).
Conclusion: Our data indicate differences in whole body metabolic regula-
tion in MT2 receptor knock-out mice, since they are significantly heavier 
than WT, MT1 and MT1/2 knock-out mice. The trend towards increased 
islet area in MT2 and MT1/2 double knock-out mice suggests that MT2 and 
MT1/2 knock-out mice tend to have more islets than MT1 and WT mice, 
which could be explained by increased demands for insulin in the heavier 
mice.
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Effects of KCNQ1 on glucose-induced insulin secretion in rat pancreatic 
beta cells or on glucagon-like peptide-1 secretion in cultured NCI-H716 
cells
S. Maeda, S. Tsukada; 
Laboratory for Endocrinology and Metabolism, RIKEN Center for Genomic 
Medicine, Yokohama, Japan.
Background and aims: Two genome-wide association studies conducted in 
Japanese populations have identified a gene encoding KCNQ1 (potassium 
voltage-gated channel, KQT-like subfamily, member 1) as a strong suscep-
tibility gene to type 2 diabetes, and the polymorphisms in the KCNQ1 have 
been also shown to be associated with ß cell functions, or with secretion of 
glucagons-like peptide-1 (GLP-1). The aim of the present study is to know 
the role of the KCNQ1 in insulin secretion using isolated rat pancreatic ß 
cells, or in GLP-1 secretion using cultured human GLP-1 secreting cell lines 
(NCI-H716).
Materials and methods: We examined the expression of KCNQ1 mRNA 
by real-time PCR. The rat isolated ß cells were incubated with or without 
choromanol 293 (specific KCNQ1 inhibitor), and insulin secretion from the 
cells were measured by enzyme linked immunosorbent assay (ELISA). We 
also measured GLP-1 secretion from the NCI-H716 cells with or without the 
treatment of chromanol 293 by ELISA.
Results: We found clear expressions of the KCNQ1 as well as KCNE2, a ß 
subunit of the potassium channel, in isolated rat pancreatic islets by RT-PCR. 
Treatment of isolated rat ß cells with chromanol 293B (100 µM) could signifi-
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cantly increase the glucose (16.7mM)-induced insulin secretion. A similar ef-
fect could be observed in isolated pancreatic ß cells under the presence of 300 
µM of tolbutamide, although the difference was not statistically significant. 
The KCNQ1 inhibitor did not affect insulin secretion from the ß cells under 
low glucose conditions or under the presence of 30 mM KCl. In NCI-H716 
cells, the expressions of KCNQ1 and KCNE1 - 5 were detected. The treatment 
with chromanol 293 increased bethanechol (1000 µM)-induced GLP-1 secre-
tion, but did not affect GLP-1 secretion under a basal condition or under the 
presence of 10 µM ionomycine.
Conclusion: These results suggest that KCNQ1 can regulate secretion of in-
sulin and GLP-1, and may contribute to the susceptibility to type 2 diabetes 
by decreasing glucose-induced insulin secretion in the pancreatic β cells or 
diet-induced GLP-1 secretion in the L cells.
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Polymorphisms in CACNA1D affect insulin release and channel 
expression and associate with type 2 diabetes
T.M. Reinbothe, V. Lyssenko, S. Lang, E. Renström; 
Lund University Diabetes Centre, Lund University, Malmö, Sweden.
Background and aims: Voltage-gated Ca2+ channels of the L-type are essen-
tial triggers for insulin secretion in rodents but little is known about their 
role in human type 2-diabetes. We here set out to determine the contribution 
of the human L-type channel subtype Cav1.3 (encoded by CACNA1D) for 
inherited capacity of insulin secretion.
Materials and methods: Gene expression in human islets: Total RNA was iso-
lated from pancreatic islet donors including 45 non-diabetics / 6 diabetics 
(24/4 males, 21/2 females, age=56±10/58±15, BMI=26±3/28±4) using the 
AllPrep DNA/RNA Mini Kit (Qiagen) and analyzed using Gene 1.0 ST whole 
transcript based assays (Affymetrix). Genetic studies: DNA from the Diabetic 
Genetics Initiative was analysed with the Affymetrix Human Mapping 500K 
GeneChip® in order to identify single nucleotide polymorphisms. Three 
candidate SNPs were tested in 766 non-diabetics (358 males, 408 females, 
age=49±13, BMI=25±4) from the Botnia study by genotyping using Taqman 
allelic discrimination assays and common variants were detected by ABI 
PRISM 7900. Phenotypes were assessed with oral (OGTT) or intravenous 
(IVGTT) glucose tolerance tests with insulin measured using a radioimmu-
noassay. Insulin phenotypes were corrected for age, gender and BMI.
Results: In non-diabetics, the marker rs312480 associated significantly with 
inappropriate fasting insulin release (IVGTT, corrected insulin response 
(CIR), p=0.027, additive model) and in individuals younger than 41 years 
significantly affected the acute insulin (AI) release (OGTT, p=0.009) as well 
as altered levels at time points 60 and 120 minutes (p=0.006 and 0.032 respec-
tively). This marker also evoke our interest as it is located within the 5’UTR 
region of the gene, contains putative methylation sites and significantly af-
fects expression of the gene (p=0.014) in our microarray study. The marker 
rs312486 was found to correlate with increases in 1- and 2-h glucose levels 
(OGTT, p=0.017 and 0.046 resp.). In a larger material (Botnia-PPP, 5210 
individuals) this polymorphism showed significant association with type-2 
diabetes status (p=0.016, OR=1.317). Interestingly, the minor allele of this 
marker links significantly with raised blood pressure in younger individu-
als (<41 years). The third SNP of interest, rs9841978, was found to relate to 
reductions in first phase insulin secretion (p=0.001). In addition, our micro-
array data suggests an association between the expression of CACNA1D and 
the diabetes status (p=0.025).
Conclusion: Single nucleotide polymorphisms in the Cav1.3 encoding gene 
CACNA1D affect mRNA expression of the channel in human pancreatic is-
lets and associate with impaired insulin secretion as well as type-2 diabetes.
Supported by: Cavnet MRTN-CT-2006-035367, Linnaeus grant (Swedish Re-
search Council)
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A common variant in the PAX6 gene influences islet function in man
E. Ahlqvist1, F. Turrini1, S. Lang1, T. Elgzyri1, Y. Zhou1, B. Isomaa2,3,  
T. Tuomi2,4, V. Lyssenko1, L. Groop1; 
1Department of Clinical Sciences, Lund University, Malmö, Sweden, 
2Folkhälsan Research Centre, Helsinki, 3Malmska Municipal Health Care 
Center and Hospital, Jakobstad, 4Department of Medicine, University of 
Helsinki, Finland.
Background and aims: PAX6 is an important regulator of pancreas develop-
ment and a key transcription factor for genes involved in glucose homeosta-
sis, including insulin, incretins and prohormone convertase genes. Impaired 
glucose tolerance and insulin secretion has been reported in families with 
protein disrupting PAX6 mutations and suggested to result from defective 
proinsulin processing due to lack of PCSK1. In this study we investigated 
the effect of a common PAX6 variant on glucose homeostasis and insulin 
processing as well as expression of target genes.
Materials and methods: A candidate SNP was identified in a genome-wide 
association study. Association with glucose tolerance, insulin processing and 
secretion was assessed in four Scandinavian cohorts. Insulin secretion and 
expression of PAX6 and transcriptional targets was studied in human pan-
creatic islets.
Results: We identified a SNP that was associated with fasting proinsulin/in-
sulin ratio in the Diabetes Genetics Initiative (DGI) genome-wide associa-
tion scan. The G allele of rs685438 was associated with lower fasting proin-
sulin/insulin ratio as well as with increased fasting insulin (p=0.001) and 
HOMA-IR (p=0.0008). Expression of PAX6 (p=0.01) and PCSK1 (p=0.001) 
was lower in pancreatic islets from human donors carrying the G-allele. The 
effect on fasting proinsulin/insulin ratio was also seen in the Helsinki birth 
cohort study (P=0.07), as was higher fasting insulin (p=0.04) and HOMA-IR 
(p=0.03). In the Botnia Prospective study G allele carriers had higher 2 hour 
insulin levels (p=0.03) and higher 2 hour glucose levels (p=0.0001). Acute 
arginine-stimulated insulin secretion in a cohort of 167 diabetic and non-dia-
betic individuals was reduced (p=0.02). Glucose stimulated insulin secretion 
was also significantly lower in human pancreatic islets (p=0.002). Further, 
G allele carriers had lower fasting plasma levels of both GIP (p=0.03) and 
glucagon (p=0.03).
Conclusion: A common variant in PAX6 affects PAX6 and PCSK1 expression 
and islet function. In spite of increased insulin resistance individuals with low 
expression have lower proinsulin/insulin ratio rather than higher, which was 
previously reported for carriers of PAX6 mutations. In contrast, they have re-
duced acute arginine-stimulated insulin secretion, a measure of total insulin 
secretion capacity, and reduced incretin levels, which is in accordance with 
the expected effect of PAX6 on expression of insulin and incretin mRNA.
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TCF7L2-conferred apoptosis in pancreatic beta cells involves the p53 
pathway
Y. Zhou1, E. Zhang2, E. Renström2, L. Groop1, O. Hansson1,2; 
1Clinical Sciences, Endocrinology and Diabetes, 2Clinical Sciences, Islet 
Pathophysiology, Lund University, Malmö, Sweden.
Background: The SNP rs7903146 of the TCF7L2 gene increases risk for type 
2 diabetes through a perturbed insulin secretion, an impaired incretin effect 
and impaired cell survival (increased apoptosis and/or decreased prolifera-
tion). The mechanisms by which TCF7L2 would influence beta cell apoptosis 
and/or proliferation are not known.
Aim: To identify the molecular mechanism/s by which TCF7L2 confers the 
apoptotic effect in pancreatic beta cells.
Material and methods: Chromatin immunoprecipitation on microarray 
(ChIP-on-chip) was used to identify potential TCF7L2 target genes in INS-1 
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832/13 cells. The expression level of Tcf7l2 and Tp53inp1 in INS-1 832/13 
cells was manipulated using siRNA and measured using qPCR. Apoptosis 
was measured using antibodies against Annexin V, and 7-AAD and visual-
ized using confocal microscopy.
Results: The p53 pathway was identified as a key TCF7L2 target using ChIP-
on-chip technology. SiRNA of Tcf7l2 was subsequently used to verify the 
ChIP-on-chip results and a knock down of Tcf7l2 (69.5 ± 0.04%) in INS-1 
832/13 cells results in elevated Tp53 (19.2 ± 0.05%) and Tp53inp1 (52.6 ± 
0.23%) mRNA levels. Interestingly, TP53INP1 has recently been associated 
with increased risk of T2D. Upregulation of Tp53 and Tp53inp1 was associat-
ed with increased apoptosis in the beta cell line (3.92 ± 1.68 fold). Tp53inp1 is 
a co-activater of Homeodomain interacting protein kinase 2 (HIPK2), which 
can specifically phosphorylate p53 on serine 46 and thereby induce apopto-
sis. A rescue experiment restoring (decreasing) the Tp53inp1 expression level 
prevented the increase in apoptosis seen after Tcf7l2 knock down, suggesting 
that the Tcf7l2 effect required the p53 pathway and Tp53inp1.
Conclusion: The p53 pathway, particularly TP53INP1 seems to be central for 
mediating effects of TCF7L2 on apoptosis in beta cells. We thereby provide 
a link between two genes shown to increase risk of T2D, i.e. TCF7L2 and 
TP53INP1.
Supported by: Swedish Research Council and Swedish Diabetes Fund
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Progression of beta cell dysfunction in Japanese type 2 diabetic patients 
in comparison with those who carry S20G mutation of islet amyloid 
polypeptide gene: a long-term follow-up study
S. Morita1, S. Sakagashira2, Y. Shimajiri1, M. Furuta1, T. Sanke1; 
1Department of Clinical Laboratory Medicine, 2The First Department of 
Medicine, Wakayama Medical University, Japan.
Background and aims: Type 2 diabetic patients have islet amyloid deposi-
tion with considerably high frequency. Islet amyloid polypeptide (IAPP) was 
identified as a main constituent of the islet amyloid, and has been consid-
ered to be associated with pathophysiology or development of human type 
2 diabetes due to its amyloidgenicity. We found S20G (AGCSer to GGCGly) 
mutation of IAPP gene, and have investigated that the G20-IAPP variant 
had stronger amyloidogenicity and cytotoxicity than wild type IAPP in vitro. 
However, there is little clinical data how impairments of insulin secretion 
progress in patients carrying S20G mutation. The long time course of the 
beta-cell function in type 2 diabetic patients also remains unknown. In this 
study, we first estimated the decline of insulin secretion in non-obese (BMI 
< 30 kg/m2) Japanese type 2 diabetic patients without S20G mutation (T2D-
patients), and then compared it with that of type 2 diabetic patients carrying 
S20G mutation (S20G-patients).
Materials and methods: We studied 70 T2D-patients and 6 S20G-patients. 
Patients with renal dysfunction (serum creatinine > 1.1 mg/dl) or those car-
rying anti-insulin antibodies were excluded. Serum C-peptide (CP) was em-
ployed as the indices for evaluation of endogenous insulin secretion, fasting 
level (F-CP), 5 min value after intravenous 1 mg glucagon injection (5’-CP), 
and 5 min increment from the basal after glucagon injection (d-CP). CP was 
measured by immunoenzymometric assay. The individual annual decline of 
endogenous insulin secretion (IAD) was calculated from the individual re-
gression line between CP and duration (years after diagnosis). The estimated 
annual decline of endogenous insulin secretion (EAD) was calculated from 
regression line between total points of CP and duration (n=527 for F-CP, 
n=165 for 5’-CP and d-CP) in all T2D-patients (n=70), although it was a 
cross-sectional analysis. In T2D-patients, we used EAD of both 5’-CP and 
d-CP instead of IAD, because IAD of both 5’-CP and d-CP could not be cal-
culated due to small number of the plots of each patient.
Results: IAD of F-CP was greater in S20G-patinets than T2D-patients 
(0.140±0.076 Vs 0.034±0.110 ng/ml/year, p=0.025). In T2D-patients, EAD 
was 0.031 ng/ml/year and it was almost same as IAD. IAD of both 5’-CP 
(n=4) and d-CP (n=4) in S20G-patients were high compared with those of 
EAD in T2D-patients (5’-CP: 0.202±0.096 Vs 0.101 ng/ml/year and d-CP: 
0.118±0.056 Vs 0.062 ng/ml/year, respectively).
Conclusion: We showed the long-termed decline of the endogenous insulin 
secretion in non-obese Japanese T2D-patients. The results suggested that the 
decline of the endogenous insulin secretion is more rapid in S20G-patients 
than T2D-patients.
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A common polymorphism in the ccl2 gene regulatory region affects 
mcp-1 gene expression and function of isolated non-diabetic and type 2 
diabetic islets
S. Del Guerra1, V. D’Aleo1, G. Gualtierotti1, F. Vistoli2, F. Filipponi3,  
U. Boggi2, S. Del Prato1, P. Marchetti4, R. Lupi5; 
1Endocrinology and Metabolism, Metabolic Unit, 2Oncology, Transplants 
and Advanced Technologies in Medicine, Division of Surgery in Uremic 
Patients, 3Oncology, Transplants and Advanced Technologies in Medicine, 
Liver Transplant Unit, 4Endocrinology and Metabolism, Division of Organ 
Transplantation and Cellular, University of Pisa, 5Endocrinology and 
Kidney, Metabolic Unit, Azienda Ospedaliero-Universitaria Pisana, Pisa, 
Italy.
Background and aims: It has been shown that human islets release monocyte 
chemoattractant protein-1 (MCP-1), a macrophage chemokine which may 
impair the fate of the islets in vivo and after a transplant. In this study we 
evaluated presence and role of monocyte chemoattractant protein-1 (MCP-1) 
and its receptor CC -chemokine receptor-2 (CCR2) in isolated non-diabetic 
(Ctrl) and type 2 diabetic (T2DM) islets, including genotyping for a common 
polymorphism.
Materials and methods: Pancreatic islets were obtained from 47 Ctrl and 18 
T2DM multiorgan donors. We evaluated glucose-stimulated insulin release 
(IR, µU/islet/min, expressed as Stimulation Index: SI), measured MCP-1, 
CCR2 and insulin mRNA expression, and analyzed the MCP-1 (-2518 G/
A, rs1024611 in the promoter region) and the CCR2 (G46295A Val64Ile, 
rs1799864 in exon2) Single Nucleotide Polymorphisms (SNP).
Results: As expected, in T2DM islets SI (1.44±0.17) and insulin gene expres-
sion (7.15±1.5) were significantly reduced respect to Ctrl (2.34±0.20 and 
26.47±6.64, respectively) islets (all p<0.001). MCP-1 and CCR2 expression 
was significantly higher in T2DM (3.80±0.62 and 0.31±0.05, respectively), 
respect to Ctrl (1.60±0.18 and 0.062±0.02, respectively) islets (all p<0.001). 
We observed a positive significant correlation between MCP-1 and CCR2 
gene expression (R2=0.235, p=0.0032), a negative significant correlation be-
tween MCP-1 mRNA expression and both SI (R2=0.116, p=0.0095) and IR at 
16.7 mmol/l glucose (R2=0.077, p=0.037), and a positive significant correla-
tion between MCP-1 gene expression and BMI (R2=0.076, p=0.039). Both in 
Ctrl and in T2DM, we found that MCP-1 mRNA expression was significantly 
higher in CC and CT respect to TT genotype groups, with a SI significant 
lower in CC respect to TT genotype group. Intriguingly, islets presenting 
both SNPs studied (rs1799864 and rs1024611), showed a high MCP-1 and 
CCR2 gene expression and a reduced beta-cell function.
Conclusion: These data show that MCP-1 gene is present in human pancre-
atic islets, it’s more expressed in T2DM respect to Ctrl islets, is regulated by 
the -2518 G/A polymorphism, and correlates with glucose-stimulated insulin 
release. The study of MCP-1 expression and genotype could be useful also 
in understanding the inflammatory response in vivo against pancreatic islets 
after transplantation.
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Relationship between adiponectin and insulin-like growth factor-
binding protein 1 and their combined effects in type 2 diabetes
T. Gu1, L. Kärvestedt1,2, K. Brismar1, H.F. Gu1; 
1Department of Molecular Medicine and Surgery, Karolinska Institutet, 
Stockholm, 2Stockholm Sjukhem, Sweden.
Background and aims: Evidence has demonstrated that serum levels of adi-
ponectin (AdipoQ) and insulin-like growth factor-binding protein 1 (IGFBP-
1) are decreased in type 2 diabetes (T2D) patients compared to non-diabetic 
control subjects. AdipoQ genetic polymorphisms are found to be associated 
with T2D. IGFBP-1 genetic polymorphisms are associated with impaired re-
nal function in T2D. However, whether adiponectin and IGFBP-1 have gene-
gene and protein-protein interactions in T2D is unknown. In the present 
study, we attempted to explore possible relationship between these two mol-
ecules and their effects in T2D.
Materials and methods: We genotyped five SNPs (-11426A/G, -11391G/A, 
-11377C/G, +45T/G Gly15Gly and +276A/C) in the AdipoQ gene and two 
SNPs (-575G/A and +4403A/G Ile253Met) in the IGFBP-1 gene in 163 Swed-
ish T2D patients. Of the patients, 85 had family history of diabetes (FHD). 
We also measured serum levels of adiponectin and IGFBP-1 in all patients 
by using radio-immunoassays. We further employed generalized multifac-
tor dimensionality reduction (GMDR) to assess the impact of gene-gene 
interactions (the patients without FHD as controls). Linear regression and 
logistic regression models were used for correlation analyses of adiponec-
tin and IGFBP-1 serum levels and for confirmation of the data from GMDR 
analyses.
Results: We found that serum adiponectin levels in T2D-FHD(+) (4.47 mg/
l, geometrical means 4.07-4.90) was significantly lower compared to T2D-
FHD(-) (5.50 mg/l, 4.90-6.17) (P=0.006). GMDR analyses of all studied SNPs 
between the AdipoQ and IGFBP-1 genes implicated that two promoter poly-
morphisms -11377C/G in the AdipoQ gene and -575G/A in IGFBP-1 had an 
impact of gene-gene interaction (P=0.054, cross-validation consistency 10/10 
and testing accuracy 59.9%). Further analyses indicated that there was a sig-
nificant correlation between adiponectin and IGFBP-1 at protein levels in 
T2D-FHD(-) (R=0.268, P=0.023) but not in T2D-FHD(+) (P=0.167). Among 
T2D-FHD(-) carrying with GG and CG genotypes of AdipoQ -11377C/G 
polymorphism, this correlation between adiponectin and IGF-BP1 was re-
mained (R=0.414, P=0.023) but not presented in T2D-FHD(-) with CC gen-
otype (P=0.295). Similarly, serum levels of adiponectin and IGFBP-1 were 
significantly correlated (R=0.303, P=0.047) in T2D-FHD(-) carrying with 
AA and GA genotypes of IGFBP1 -575G/A polymorphism, but not in T2D-
FHD(-) with GG genotype (P=0.374).
Conclusion: Data from the present study implicate that promoter polymor-
phisms of the AdipoQ and IGFBP-1 genes may have an impact of gene-gene 
interaction in T2D. These two promoter polymorphisms may influence the 
correlation between adiponectin and IGFBP-1 at protein levels. Replication 
study with additional T2D patients and non-diabetic control subjects will be 
conducted to further understand genetic and functional effects of adiponec-
tin and IGFBP-1 in the development of T2D.
Supported by: Family Erling-Persson foundation
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Circulating HMW adiponectin is positively correlated and shares a 
common genetic background with urinary albumin excretion in non 
diabetic white caucasians from Italy
C. Menzaghi1, L. Salvemini1, C. De Bonis1, D. Mangiacotti1, G. Fini1,  
V. Trischitta1,2, S. De Cosmo3; 
1Research Unit of Diabetes and Endocrine Diseases, IRCCS, San Giovanni 
Rotondo, 2University “Sapienza”, Rome, 3Unit of Endocrinology, IRCCS, San 
Giovanni Rotondo, Italy.
Background and aims: Circulating levels of adiponectin, an insulin sensitiz-
ing hormone, have been reported to be paradoxically increased in patients 
with higher urine albumin excretion (UAE), a condition characterized by 
insulin resistance. In order to avoid the possible confounding effects exerted 
in these previous studies by the presence of diabetes - and related treatments 
- and that of reduced kidney function, we investigated the relationship be-
tween adiponectin and UAE levels in a large (n = 640, 246M/394F), family-
based sample of relatively young (age 40.3 ± 14.5 yrs) non diabetic, White 
Caucasians from Italy without known kidney impairment who were not on 
any pharmaceutical treatment.
Materials and methods: UAE was measured by nephelometric method and 
reported as urinary albumin-creatinine ratio (ACR). Serum adiponectin 
(high, medium and low molecular weight isoforms; HMW, MMW, LMW) 
levels were measured by ELISA. Glomerular filtration rate was estimated by 
the reciprocal of serum cystatin C (CC) expressed in mg/L multiplied by 100 
(CC-GFR; mean: 125.4 ± 35.9). Five SNPs in the ADIPOQ gene, previously 
reported to be associated to adiponectin levels and/or diabetic nephropathy 
(rs182052, rs17300539, rs2241766, rs1501299 and rs677395) were genotyped. 
A linear mixed effects model was used to assess both phenotypic correlations 
and to test associations. Bivariate analyses were conducted to study genetic 
correlations between adiponectin isoforms and UAE.
Results: ACR levels (median: 0.53 mg/mmol; range 0.06 - 12.4) were directly 
associated with HMW adiponectin (β ± SE = 0.058 ± 0.02, p = 3.7x10-3). 
Further adjustment for CC-GFR, did not significantly change this associa-
tion (β = 0.06 ± 0.02, p=2.7x10-3). A significant genetic correlation (rhog = 
0.38 ± 0.20; p=0.04) was observed between ACR and HMW adiponectin. 
Among the ADIPOQ SNPs tested, rs17300539, which was associated with 
both HMW (p = 4.4x10-5) and ACR (p=2.7 x 10-3), partially accounted for this 
genetic correlation (2.5%).
Conclusion: In conclusion, circulating HMW adiponectin and UAE levels 
are directly correlated and share, at least partly, a common genetic back-
ground, involving the ADIPOQ locus for a small proportion of it.
Supported by: Accordo Programma Quadro Regione Puglia-PST 2006
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Associations of common variants of ADIPOQ, ADIPOR1 and ADIPOR2 
with adiponectin concentration and diabetes incidence in the Diabetes 
Prevention Program
K.J. Mather1, C.A. Christophi2, K.A. Jablonski2, W.C. Knowler3,  
R.B. Goldberg4, S.E. Kahn5, F.X. Pi-Sunyer6, T.I. Pollin7, J.C. Florez8,  
P.W. Franks9, for the Diabetes Prevention Program Research Group; 
1Indiana University School of Medicine, Indianapolis, 2The George 
Washington University Biostatistics Center, Rockville, 3National Institute 
of Diabetes and Digestive and Kidney Diseases, Phoenix, 4The University 
of Miami Miller School of Medicine, Miami, 5Veterans Affairs Puget Sound 
Health Care System, Seattle, 6St. Luke’s-Roosevelt Hospital, New York City, 
7University of Maryland School of Medicine, Baltimore, 8Center for Human 
Genetic Research, Massachusetts General Hospital, Boston, USA, 9Umea 
University Hospital, Umea, Sweden.
In the Diabetes Prevention Program, a trial enrolling people from multiple 
ethnic backgrounds who were overweight and had impaired glucose regula-
tion, baseline concentrations of adiponectin were independently predictive of 
incident type 2 diabetes. We examined the association of genetic variation in 
the genes encoding adiponectin (ADIPOQ) and the two known adiponectin 
receptors (ADIPOR1, ADIPOR2) with circulating adiponectin concentra-
tions and with diabetes incidence. Fourteen of 24 ADIPOQ SNPs were nomi-
nally associated with adiponectin concentrations; 9 exceeded experiment-
wide significance and 4 exceeded genome-wide significance in the entire 
study population (rs1648707 p=10-15; rs17366568 p=10-14; rs6810075 p=10-11; 
rs182052 p=10-12). For these 4 SNPs, minor allele homozygotes had 11-25% 
lower mean circulating concentration of adiponectin than major allele ho-
mozygotes. Among white subjects only (n=1622) these SNPs showed similar 
patterns of association (rs1648707 p=10-11; rs17366568 p=10-14; rs6810075 
p=10-9; rs182052 p=10-10), indicating that these signals are not confounded 
by population stratification. One ADIPOR1 SNP (rs10800890) was also as-
sociated with adiponectin concentrations (p=10-4); no ADIPOR2 SNPs were 
associated with adiponectin concentrations. Three of 22 ADIPOR1 SNPs and 
2 of 31 ADIPOR2 SNPs were associated with diabetes incidence in the whole 
population (p=10-2 to 10-3). None of the ADIPOQ variants, and specifically 
none of those associated with adiponectin concentrations, was associated 
with diabetes incidence in the whole study population. Two of the 77 evalu-
ated SNPs interacted with treatment to influence diabetes incidence in the 
whole study population (ADIPOQ rs17373414 p=0.04, hazard ratio higher 
in lifestyle than placebo; ADIPOR2 rs758027 p=0.01, hazard ratio higher in 
metformin than placebo). A parallel rs758027 interaction was evident among 
whites, again arguing against confounding by population stratification. ADI-
POQ SNPs are significantly associated with adiponectin concentrations in 
the DPP cohort, confirming the results published from cohorts with lower 
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diabetes risk and expanding them to a multi-ethnic population with impaired 
glucose regulation. Despite associations with circulating adiponectin concen-
trations and the known robust relationship between adiponectin concentra-
tions and diabetes risk in this cohort, loci influencing diabetes risk did not 
overlap with those influencing adiponectin concentrations in the DPP. This 
highlights the complex relationships of genetic and non-genetic determinants 
of adiponectin concentrations with type 2 diabetes risk.
Supported by: NIH Grant
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Effect of variants in the RORA gene on risk of type 2 diabetes
A. Jonsson1, S. Alkayyali1, B. Isomaa2,3, T. Tuomi2,4, L. Groop1, V. Lyssenko1; 
1Clinical Sciences, Diabetes & Endocrinology, Lund University, Malmö, 
Sweden, 2Folkhälsan Research Centre, Helsinki, 3Malmska Municipal Health 
Care Center and Hospital, Jakobstad, 4Medicine, Helsinki University Central 
Hospital and University of Helsinki, Finland.
Background and aims: A genetic variation in the RAR-related orphan recep-
tor alpha (ROR-α) gene (RORA) was found to be associated with reduced 
insulin secretion in the DGI genome wide association study for early insulin 
secretion. ROR-α has been previously implicated in glucose and lipid me-
tabolism. The aim of the study is to validate the effect of genetic variants in 
RORA on insulin secretion, and to explore its effects on risk for type 2 diabe-
tes (T2D) and related phenotypes.
Materials and methods: Six RORA variants (rs10519116, rs11071557, 
rs17204545, rs2414689, rs4774389 and rs4775292) were genotyped in three 
cohorts, totaling 13,560 Scandinavian individuals (Malmö Case Control 
[MCC], n=6,380; Prevalence, prediction and prevention of diabetes in Botnia 
[PPP], n=4,852, and Botnia Prospective Study [BPS], n=2,328 with a median 
follow-up period of 7.6 years).
Results: In the DGI, the T-allele of rs4775292 was associated with reduced 
insulin secretion (N=1,018, beta (sem) -0.214 (0.041), P=0.0024). Further-
more, in the independent follow-up PPP study the same allele showed in-
creased insulin secretion in young (N=1,499, 0.103 (0.031), P=0.00079), 
but decreased in elderly (N=1,245, -0.081 (0.030), P=0.0073, median age 50 
yrs as cut-off). Combined analysis confirmed association of the T-allele of 
rs4775292 with reduced insulin secretion in elderly individuals (N=2,698, 
-0.075 (0.023), P=0.0011). In the MCC, in line with increased insulin se-
cretion, the T-allele of rs4775292 was associated with protection from T2D 
(OR [95%CI]: 0.78 [0.61-0.99], P=0.039) in young, but no effect was seen 
(1.00 [0.91-1.11], P=0.94) in elderly. Of note, in the MCC, the C-allele of 
another SNP, rs10519116, was more frequent in cases than in controls (26.5% 
vs. 24.2%, P=0.015). This difference was more pronounced in elderly indi-
viduals (27.0% vs. 24.0%, P=0.0027), which translated into an age, sex and 
BMI adjusted OR for T2D of 1.16 [1.03-1.29], P=0.011. The same C-allele of 
rs10519116 and also the T-allele of rs4775292 were associated with increased 
2hr proinsulin and GIP levels during OGTT (rs10519116: 0.081 (0.036), 
P=0.024 and 0.119 (0.037), P=0.0014; rs4775292: 0.080 (0.030), P=0.0079 and 
0.105 (0.031), P=0.00091) in male PPP participants. Furthermore, the same 
T-allele of rs4775292 and the GT/TT-genotype of rs11071557 were associated 
with decreased HDL and APOA1 both at baseline (rs4775292: -0.037 (0.014), 
P=0.0087 and -2.77 (1.00), P=0.0059; rs11071557: -0.183 (0.057), P=0.0015 
and -14.43 (4.08), P=0.00042) and at follow-up (rs11071557: -0.203 (0.075), 
P=0.0071 and -11.17 (4.98), P=0.025) in male BPS participants. Finally, two 
SNPs were associated with decreased insulin sensitivity (rs17204545: PPP 
-0.053 (0.020), P=0.0079 and rs2414689: BPS -0.077 (0.026), P=0.0026) in 
male participants. Interestingly, RORA shows a rich methylation pattern 
where rs4775292 is a candidate for a CpG site. Methylation studies are on-
going to provide insights whether they can explain the age effect on insulin 
secretion and risk of T2D.
Conclusion: These results suggest that genetic variants in the RORA gene 
are associated with increased risk of T2D, and influence glucose and lipid 
metabolism.
Supported by: Swedish Research Council, an EFSD Clinical Research Grant, 
Påhlsson and Novo Nordisk foundations
305
Vaspin is involved in the pathophysiology of type 2 diabetes by regulating 
insulin sensitivity
J. Breitfeld1, N. Klöting2, J.T. Heiker3, U. Enigk1, M. Kern2, Y. Böttcher2,  
D. Schleinitz1, K.E. Dietrich1, N. Wiele2, A. Tönjes2, A.G. Beck-Sickinger3, 
M. Stumvoll2, M. Blüher2, P. Kovacs1; 
1Interdisciplinary Centre for Clinical Research, 2Department of Medicine, 
3Institute of Biochemistry, University of Leipzig, Germany.
Background and aims: Visceral adipose tissue derived serine protease in-
hibitor (vaspin) is a novel adipokine that may link obesity, insulin resistance 
(IR) and type 2 diabetes (T2D), but so far its pathophysiological role remains 
largely unknown. The first aim was to study the effects of recombinant vaspin 
treatment on insulin sensitivity in db/db mice. In addition, we investigated 
the role of genetic variation in the human vaspin gene in the pathogenesis 
of T2D.
Materials and methods: Animal studies: After recombinant vaspin admin-
istration (1mg/kg body weight i.p.; at 6 pm and at 6 am prior to the tests), 
we performed glucose tolerance tests (2g/kg body weight i.p.) and hyper-
insulinemic-euglycemic clamps in db/db mice (N=5 for each test). Human 
genetic studies: Vaspin (exons, exon-intron boundaries, 5´ and 3´ UTRs) 
was sequenced in DNA samples from 48 unrelated Caucasian subjects (ABI 
PRISM 3100 Avant; Applied Biosystems Inc.). Six single nucleotide poly-
morphisms (SNPs) identified by sequencing and 22 haplotype tagging SNPs 
representative for their linkage disequilibrium groups (r2>0.8 and minor al-
lele frequencies >0.05) were genotyped in 1046 clinically well-characterized 
Sorbs from Germany for subsequent association studies on metabolic traits 
including insulin resistance and secretion indices (e.g. fasting Belfiore, Stum-
voll index, HOMA-IR) based on glucose tolerance test in non diabetic sub-
jects. P values <0.05 were considered to be of nominal statistical significance. 
For in vitro analyses of the effects of the stop codon mutation (p.R211X), 
full-length (wild type) and short-length (carrying the mutation) vaspin was 
cloned into p3xFLAG-myc-CMV™ expression vector (Sigma-Aldrich) and 
transfected into HEK-cells (Fugene® HD Transfection Kit; Roche). Proteins 
were detected by western blot.
Results: Animal studies: Vaspin administration in db/db mice resulted in im-
proved glucose tolerance (P<0.05). Consistently, glucose infusion rate (GIR) 
during the steady state of the clamp significantly increased after vaspin treat-
ment (P<0.05). Human genetic studies: Sequencing of the vaspin gene re-
vealed one SNP (rs61757459) in exon 3 resulting in a STOP-codon (p.R211X). 
Western blot experiments showed that full-length and short-length vaspin 
were expressed in eukaryotic cells. Short-length vaspin yielded in a promi-
nent ~25-kDa band. Several SNPs were nominally associated with WHR 
(waist-to-hip-ratio), 30min glucose levels or 2-hr-insulin levels (adj. for age, 
sex and BMI). Furthermore one SNP (rs2236242) showed additional associa-
tions with AUCGlucose, insulin sensitivity and insulin resistance indices.
Conclusion: In conclusion, our data demonstrate the substantial insulin sen-
sitizing effect of vaspin and suggest a role of vaspin genetic variants in the 
pathophysiology of insulin resistance and T2D.
Supported by: DFG
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ABO blood groups and incidence of type 2 diabetes in men and women
L. Qi1, Y. Song2, J. Manson2, F.B. Hu1; 
1Nutrition and Epidemiology, Harvard School of Public Health, Boston, 
2Department of Medicine, Harvard Medical School, Boston, USA.
Background and aims: Previous small studies associated ABO blood types 
with the prevalence of diabetes. Recent genome-wide scans identified ABO 
locus might determine various risk factors for type 2 diabetes.
Materials and methods: We prospective examined the relationship between 
ABO blood types and the risk of incident type 2 diabetes in men and women 
from two cohorts: the Health Professionals Follow-up Study (HPFS) and the 
Nurses’ Health Study (NHS). 
Results: In the HPFS, during 452,404 person-years of follow-up, 1,764 par-
ticipants developed type 2 diabetes. Compared with participants with blood 
group O, the relative risk (RR) associated with blood group A, B, and AB 
were 1.08 (95% confidence interval [CI] 0.97-1.20), 1.15 (1.00-1.34), and 1.31 
(1.10-1.57). In the NHS, during 111,7247 person-years of follow-up, 4,376 
participants developed type 2 diabetes. Compared with participants with 
blood group O, the RRs (95% CI) of type 2 diabetes associated with blood 
groups A, B, and AB were 1.10 (1.03-1.18), 1.03 (0.94-1.13), and 1.02 (0.91-
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1.15), adjusting for traditional risk factors. The association of blood group A 
with diabetes risk was more evident in postmenopausal than premenopausal 
women. Overall, as compared with O blood group, the non-O blood group 
(blood group A, B, or AB) was associated with 12% (2-24%) and 7% (1-14%) 
increased diabetes risk in men and women; respectively; and was associated 
with 9% (4-15%) increased diabetes risk in the combined samples. The popu-
lation attributable risk (PAR) for type 2 diabetes due to non-O blood group 
was 4.7%.
Conclusion: ABO blood types were significantly associated with the risk of 
type 2 diabetes. Non-O blood groups were associated with an increased risk 
of diabetes in both genders. The associations of specific blood groups with 
diabetes risk showed a gender difference. 
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Contribution of mother and father in the familiar transmission of type 2 
diabetes mellitus according to the proband’s gender
F.L. Cavalot, P. Poy, A. Pomero, A. Pagliarino, P. Massucco, M. Trovati; 
Dept of Clinical and Biological Sciences, Faculty of Medicine San Luigi 
Gonzaga, University of Turin, Orbassano, Italy.
Background and aims: Type 2 diabetes mellitus (T2DM) shows strong fa-
miliar aggregation: the relative role of maternal and paternal familiarity, how-
ever, needs to be further investigated. In this study, we evaluated the distinct 
contribution of the mother and the father in T2DM transmission according 
to proband’s gender.
Materials and methods: We evaluated through a structured interview the 
familial transmission in 1076 T2DM patients aged <70 years attending our 
Diabetes Clinic, divided into two groups according to the age at diagnosis: 
30-49 years (Group A: 540 consecutive patients, M/F: 366/174) and 50-69 
years (Group B: 536 consecutive patients, M/F: 312/224).
Results: Group A showed the following parental transmission: only mother: 
34.6%; only father: 19.8%; both parents: 10.7%. Thus, mother was affected in 
45.3%, father in 30.5% (p<0.0001). When proband’s gender was considered, 
parental transmission was: a) in men (n=366): only mother: 34.2%; only fa-
ther: 22.4%; both parents: 7.7%. Thus, mother was affected in 41.9%, father 
in 30.1% (p<0.018); b) in women (n=174): only mother: 35.6%; only father: 
14.4%; both parents: 17.2%. Thus, mother was affected in 52.8%, father in 
31.6% (p<0.004). Thus, the excess of maternal transmission was present in 
both genders, but women probands showed an increased probability to have 
both parents affected (p=0.026); furthermore, in the presence of father af-
fected, the conditional probability to have also mother affected was greater 
in women than in men (55% vs 25%, p=0.007). Familiarity was not modified 
by proband’s body mass index. In Group B, parental transmission was less 
frequent than in Group A, mother being affected in 35.7% vs 45.3% in Group 
A (p=0.023), father in 14.8% vs 30.5% in Group A (p<0.0001). Also in Group 
B, however, mother was more frequently affected than father (p<0.0001). By 
considering the two groups together, multivariate linear regression showed 
that, in comparison to the absence of familiarity in parents: a) in men 
probands, familiarity in the mother anticipated diabetes diagnosis 2.6±0.7 
yrs (p<0.0001), in the father 5.1±0.9 yrs (p<0.0001) and in both parents 
9.1±1.4 years (p<0.0001); b) in women probands, familiarity in the mother 
anticipated diabetes diagnosis 2.2±1.0 yrs (p=0.023), in the father 2.5±1.3 yrs 
(p=0.065) and in both parents 7.2±1.5 yrs (p<0.0001). Thus, familiarity in 
the father anticipated the diagnosis of T2DM more strongly in men than in 
women. Men excess in both Group A and Group B induced us to compare 
our data with the percentage of men in T2DM patients aged < 70 years living 
in the District in which our Hospital is located, obtained from the Health 
Service data of our Region: this percentage was 65% (vs 68% in Group A) 
in patients with diabetes diagnosis at age 30-49 years and 57% in those with 
diabetes diagnosis at age 50-69 years (vs 58% in Group B). Thus, an excess of 
diabetic men vs women was present in our District, independently from at-
tendance at our Diabetes Clinic.
Conclusion: In Type 2 diabetes: i) familiarity predicts early diagnosis; ii) 
maternal transmission is stronger than the paternal-one in both proband 
genders independently of age at diagnosis; iii) if father is affected, maternal 
co-transmission is more frequent in women.
Supported by: Regione Piemonte Research Grant
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TCF7L2 and therapeutic response to sulfonylureas in patients with type 
2 diabetes
M. Hahn1, A. Körner2, M. Stumvoll3, P. Kovacs4, A. Holstein1; 
11st Department of Medicine, Klinikum-Lippe, Detmold, 2University 
Hospital for Children and Adolescents, University of Leipzig, 3Department 
of Medicine, University of Leipzig, 4Interdisciplinary Centre for Clinical 
Research, University of Leipzig, Germany.
Background and aims: Variants in the TCF7L2 have been shown to be asso-
ciated with an increased risk for type 2 diabetes (T2D). Since the association 
with diabetes could be explained by effects on insulin secretion, we investi-
gated whether patients with diabetes risk alleles at rs7903146 might have an 
altered hypoglycaemic response to sulfonylureas (SUs).
Materials and methods: We recruited 189 patients with T2D being treated 
with SUs and determined the rs7903146 diabetes risk genotype. We used a lo-
gistic regression with secondary SU failure defined as the addition of insulin 
after at least 6 months of SU therapy and corresponding A1C measurement 
of ≥7.0%.
Results: In univariate regression analyses, TCF7L2 genotype and diabetes 
duration were the main predictors of SU treatment failure. The rs7903146 
T-allele was significantly more frequent in the group of patients additionally 
treated with insulin (40%) than in the control group treated only with SUs (28 
%) [P=0.03; odds ratio: 1.73 (1.06-2.84) in an additive mode of inheritance]. 
The genotype effect was independent of diabetes duration.
Conclusion: Our data suggest that patients with diabetes risk alleles in TC-
F7L2 have an altered hypoglycaemic response to SUs resulting in early sec-
ondary failure, thus supporting previously reported findings and indicating 
the potential of pharmacogenomics in the therapy of T2D.
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The role of genetic variation in the sodium-glucose cotransporter 2 gene 
(SGLT2) in the pathophysiology of type 2 diabetes
D. Schleinitz1, U. Enigk1, J. Breitfeld1, B. Enigk1, K. Dietrich1, I. Müller2,  
J. Halbritter2, A. Fischer-Rosinsky3,4, A.H. Pfeiffer3,4, J. Spranger3,4,  
M. Stumvoll2, P. Kovacs1, A. Tönjes2; 
1IZKF Leipzig, University of Leipzig, 2Department of Medicine, University 
of Leipzig, 3Department of Endocrinology, Diabetes and Nutrition, Charité-
Universitätsmedizin Berlin, 4Department of Clinical Nutrition, German 
Institute of Human Nutrition Potsdam-Rehbrücke, Nuthetal, Germany.
Background and aims: The sodium-glucose cotransporter 2 (SGLT2) is the 
major cotransporter involved in glucose reabsorption in the kidney. Muta-
tions in the SGLT2 gene cause renal glucosuria and are associated with re-
duced circulating glucose levels. Treatment with SGLT2-inhibitors results 
in decreased fasting glucose levels, reduction of HbA1c and lower BMI. We 
therefore investigated the effects of common genetic variation in SGLT2 on 
glucose traits and BMI in non-diabetic subjects as well as the association with 
type 2 diabetes (T2D).
Materials and methods: Four HapMap tagging single nucleotide polymor-
phisms (SNPs) (www.hapmap.org) were genotyped (TaqMan, Applied Bio-
systems, Inc.) for subsequent association studies on BMI, T2D and related 
metabolic traits in 1046 Sorbs from Germany who had undergone a detailed 
phenotyping. The SNPs were representative of their linkage disequilibrium 
groups and were selected according to r2>0.8 and minor allele frequency 
>0.01. An independent cohort from Berlin, Germany (N=2046, including 
359 subjects with T2D) was taken for replication.
Results: In a case control study including 106 patients with T2D and 786 
controls with normal glucose tolerance, none of the SNPs showed association 
with T2D. However, rs9934336 was nominally associated with 30 min plasma 
glucose, 2 hr insulin concentrations and incremental AUC120glucose during oral 
glucose tolerance test in 892 non-diabetic subjects (P<0.05 in additive model 
adjusted for age, sex and BMI). Carriers of the rs9934336 G-allele had higher 
30 min plasma glucose and 2 hr insulin concentrations. The SNP showed no 
association with T2D in the Berlin cohort, but was, however, nominally asso-
ciated with 60 min plasma glucose (adjusted P<0.05) and showed consistent 
effect on AUC120glucose in a subgroup of subjects with impaired fasting glucose 
and impaired glucose tolerance (N=485).
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Conclusion: In conclusion, our data suggest a role of SGLT2 genetic variation 
in the regulation of insulin and glucose levels in non-diabetic individuals. 
SGLT2 polymorphisms might therefore be potential candidates in pharma-
cogenomic studies investigating the interaction between these genetic vari-
ants and the efficacy of antidiabetic treatment based on inhibition of SGLT2.
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ENPP1 expression and metformin efficacy in type 2 diabetes
O. Ludovico1, M.G. Farina2, S. Prudente3, A.P. Palena1, V. Proto3,  
V. Marotta2, L. Frittitta2, V. Trischitta1,3; 
1Endocrinology, IRCCS “CSS”, San Giov. Rotondo, 2Intern Med, Univ.of 
Catania, 3IRCCS “CSS”-Mendel, Roma, Italy.
Background: ENPP1 is an inhibitor of insulin signalling whose overexpres-
sion plays a role on insulin-resistance. Also the ENPP1 K121Q polymorphism 
has been associated with insulin resistance, with the Q121 variant being a 
gain of function substitution which increases the protein inhibitory activity 
on insulin signalling. Metformin (Met) is an insulin-sensitizer, established as 
“first choice” oral hypoglycemic agent (OHA) in type 2 diabetes (T2D). In the 
Diabetes Prevention Program (DPP) study, the efficacy of Met in preventing 
future T2D was significantly greater in Q121 carriers (individuals carrying 
KQ or QQ genotypes) as compared to those carrying the KK genotype, thus 
suggesting that higher ENPP1 inhibitory activity predicts higher metformin 
efficacy.
Aims: to investigate i) whether ENPP1 expression predicts the efficacy of 
3-month metformin monotherapy on fasting glucose (FG) in patients with 
T2D; ii) whether Met modulates ENPP1 expression in peripheral blood 
mononuclear cells (PBMC).
Methods: 55 patients (31 M/24 F; age: 40-70 yrs; disease duration: 2-25 yrs; 
HbA1c: 6.5-9%; no need of insulin therapy) were recruited. Contraindications 
to Met treatment were considered as exclusion criteria. Previous OHA were 
discontinued for 5 days and then Met (2550 mg/daily) was given. Body mass 
index (BMI), HbA1c, glucose, insulin, insulin-resistance HOMA index, trig-
lycerides and HDL-cholesterol were measured at baseline and 12 weeks after 
Met treatment. ENPP1 expression levels were measured by quantitative RT-
PCR in PBMC before and after treatment.
Results: ENPP1 baseline expression was significantly and directly correlated 
with Met efficacy as indicated by change in FG after treatment (i.e. baseline 
FG minus 3-month FG) (adjusted R2=0.09, p=0.015). Of all other measured 
variables, only baseline FG was able to predict Met efficacy (adjusted R2=0.33, 
p<0.0001). Of note, ENPP1 maintained a significant prediction ability also 
when adjusted for baseline FG (p=0.045) as well as when also sex, BMI and 
duration of T2D were added into the model (p=0.04). Average ENPP1 ex-
pression levels didn’t change after Met treatment (6.94+6.14 arbitrary units 
and 7.66+5.78, before and after, respectively; p=0.173).
Conclusion: Our data indicate that Met efficacy is higher in individuals with 
higher ENPP1 expression and then, presumably characterized by higher 
ENPP1 inhibitory effect on insulin signalling. These data are very much along 
the same line of those from the DPP study showing increased metformin 
efficacy in carriers of ENPP1 Q121 variant. A better understanding of these 
phenomena could help setting up strategies aimed at predicting Met efficacy.
Supported by: Società Italiana di Diabetologia (SID) 2007
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Cyp2c8 variant reduce the therapeutic response to thiazolidinediones - a 
godarts study
K. Zhou, L. Burch, S. Vella, C.N.A. Palmer, E.R. Pearson; 
Biomedical Research Institute, Dundee, United Kingdom.
Background and aims: The reason for highly variable glycaemic response 
to thiazolidinediones (TZDs) is poorly understood. TZDs are mainly me-
tabolized by the cytochrome p450 2C8 enzyme encoded by CYP2C8. Two 
common CYP2C8 variants *3 and *4 are associated with greater clearance 
and lower plasma concentrations of TZDs. We hypothesised that patients 
carrying these variants would have reduced glycaemic response to thiazo-
lidinediones.
Materials and methods: Linear and logistic regressions were used to model 
HbA1c reduction and achieving a treatment target of HbA1c <7% in 374 pa-
tients from the GoDARTS cohort in Tayside, Scotland. Parameters included 
are age, gender, BMI, baseline HbA1c, adherence and CYP2C8 genotype.
Results: Compared to the wild-type carriers, model adjusted HbA1c reduc-
tion was 0.8% lower in those patients who carry two functional variant alleles 
(p=0.001). These patients were also 3.8 times more likely to fail achieving 
treatment target (p=0.06).
Conclusion: In keeping with the pharmacokinetic role of this gene, our data 
suggest CYP2C8 variants have a marked impact on glycaemic response.
Supported by: DUK 07/0003525
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Resistance to exercise-induced changes in the global DNA methylation 
pattern of skeletal muscle in individuals with a family history of type 2 
diabetes
M. Dekker Nitert, T. Dayeh, S. Lang, T. Elgzyri, B. Yang, O. Hansson,  
T. Rönn, K.-F. Eriksson, L. Groop, C. Ling; 
Lund University Diabetes Centre, Malmö, Sweden.
Background and aims: First degree relatives of individuals with type 2 diabe-
tes (T2D) have an increased risk of developing the disease. This is conferred 
by genetic and shared environmental factors, not least physical inactivity, 
as physical activity is known to improve glucose homeostasis. However, it 
is unknown if epigenetic changes contribute to the increased risk of T2D. 
Whether physical exercise can affect methylation of genes of importance for 
the abnormal glucose metabolism characteristic of individuals with a genetic 
predisposition to T2D is not known. This study examines the global changes 
in DNA methylation in skeletal muscle in humans with or without a family 
history of T2D before and after a six-month exercise intervention.
Materials and methods: 16 men with (FH+) and 13 men without (FH-) a 
first-degree family history of T2D, matched for age, BMI and VO2max, par-
ticipated in a supervised six-month exercise intervention study. Biopsies 
from the vastus lateralis muscle were obtained before and after the exercise 
intervention. DNA was isolated and MeDIP-Chip was performed e.g. 1 μg 
DNA was immunoprepitated with a monoclonal antibody against methyl-
ated cytosine and hybridized to the NimbleGen 2.1 DeLuxe Array containing 
2.1 million probes covering a 10 kB region of all genes, with 7.5 kB upstream 
and 2.5 kB downstream of the transcription start site in addition to all known 
CpG islands.
Results: Before exercise, 1891 genes displayed lower methylation and 1237 
genes showed higher methylation in skeletal muscle from FH+ vs FH- indi-
viduals. Exercise increased methylation of 1402 and decreased methylation 
of 2136 genes in the whole chohort. Notably, exercise changed methylation of 
fewer genes in FH+ than in FH- subjects (1085 vs 2355 genes increased, and 
2035 vs 3281 decreased methylation) with little overlap between the top 100 
genes of the two groups.
Conclusion: Human skeletal muscle of individuals with a family history of 
T2D is partially resistant to epigenetic changes induced by exercise in indi-
viduals with no T2D heredity.
Supported by: The Swedish Research Council, an EFSD/Lilly grant, Påhlsson 
Novo Nordisk Foundation
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Does macronutrient intake or physical activity level interact with genetic 
risk for increased fasting glucose?
G. Hindy1, E. Sonestedt1,2, A. Sharma1, M. Orho-Melander1; 
1Department of Clinical Sciences, Diabetes and Cardiovascular Disease, 
Genetic Epidemiology, Sweden, 2Nutrition Epidemiology, Lund University 
Diabetes Centre, Lund University, Malmö, Sweden.
Background and aims: The prevalence of type 2 diabetes (T2D) is drasti-
cally increasing around the globe and is believed to be linked to the adoption 
of a western lifestyle mainly in terms of dietary habits and physical inactiv-
ity. Genome-wide association studies (GWAS) have identified several single 
nucleotide polymorphisms (SNPs) associated with fasting glucose (fGLU) 
levels and T2D. The aim of this study was to investigate if a combined effect 
of 15 SNPs previously shown to associate with fGLU levels in GWAS inter-
acts with dietary intakes or physical activity level on fasting glucose levels in 
the population based Malmö Diet and Cancer Study- Cardiovascular cohort 
(MDC-CV).
Materials and methods: The 15 SNPs identified in or near G6PC2, MTNR1B, 
GCK, DGKB-TMEM195, GCKR, ADCY5, MADD, CRY2, ADRA2A, PROX1, 
SLC2A2, GLIS3, SLC30A8, FAM148B, and TCF7L2 were genotyped by taq-
man in MDC-CV. After excluding all patients with diabetes, individuals 
without diet-data and those with incomplete genotype information we in-
cluded 4615 individuals in the study (41% males, age 57±6 years, BMI 26±4 
kg/m2, fGLU 5.7±0.8 mmol/l). A fGLU genetic risk score (fGLU-GRS) was 
S 134 Diabetologia (2010) 53:[Suppl1]S1–S556
1 C
created summing the number of fGLU increasing alleles of the 15 SNPs. As-
suming additive model and adjusting for age and sex we analysed association 
between fGLU-GRS and fGLU. Association between GRS and fGLU was eval-
uated in strata of gender-specific tertiles according to percentage of energy 
from macronutrients as well as physical activity score. Interaction between 
dietary factors or physical activity and fGLU-GRS was assessed by introduc-
ing a multiplicative factor with continuous variables adjusting for age, sex, 
season and total energy intake.
Results: The fGLU-GRS was strongly associated with fGLU (p=5.8e-15) with 
a mean effect size of 0.04 mmol/l per each glucose increasing allele. Similar 
associations were found in males (p=1.7e-6) and females (p=2.4e-10). Indi-
viduals in the highest fGLU-GRS quintile had 0.26 mmol/l higher fGLU com-
pared to those in the lowest quintile. The effect sizes of each fGLU increasing 
alleles were 0.04, 0.06 and 0.02 mmol/l within low, medium and high carbo-
hydrate intake tertiles (p=0.11, p=0.09 and p=0.71 for interaction in all, males 
and females, respectively); 0.05, 0.04 and 0.04 mmol/l within low, medium 
and high fiber intake tertiles (p=0.27, p=0.50 and p=0.43) and 0.02, 0.05 and 
0.04 mmol/l in low, medium and high fat intake tertiles (p= 0.23, p=0.16 and 
p=0.89). The mean effect size of each fGLU increasing allele was 0.4 mmol/l 
in all physical activity tertiles (p=0.84, p=0.50 and p=0.65 for interaction in 
all, males and females, respectively).
Conclusion: GRS of 15 fGLU SNPs associated strongly with fGLU in a popu-
lation based Swedish sample. Our study did not reveal significant interac-
tions between such genetic susceptibility and macronutrient intakes or physi-
cal activity level. We believe that larger sample sizes and taking into account 
the quality of dietary carbohydrates and fat need to be taken into account in 
future studies to exclude such interactions.
Supported by: Swedish Medical Research Council, Swedish Diabetes Founda-
tion and LUDC
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Body mass index is a potential modifier of the influence on beta cell 
function exerted by SLC30A8 and KCNJ11 diabetes risk variants in 
patients with newly diagnosed type 2 diabetes
M. Trombetta1, S. Bonetti1, F. Turrini1, L. Boselli1, E. Trabetti2, G. Malerba2, 
P.F. Pignatti2, M. Muggeo1, E. Bonora1, R.C. Bonadonna1; 
1Department of Medicine, 2Department of Life and Reproduction Sciences, 
University of Verona, Italy.
Background and aims: The zinc transporter, SLC30A8, and the potassium 
channel, KCNJ11, are both expressed in the beta cell and are involved in insulin 
transport and secretion. The rs13266634 G allele in SLC30A8 and the rs5219 
A allele in KCNJ11 are associated with type 2 diabetes (T2D) risk and with re-
duced beta cell function (BF) in non-diabetic subjects. We evaluated the role of 
these two non-synonymous polymorphisms in determining clinical and patho-
physiological traits in patients with newly diagnosed type 2 diabetes.
Materials and methods: 456 GAD-negative and drug-naive patients (age 
57.8±10.3 years, BMI 29.9±5.1 kg/m2, HbA1c 7.0±1.4 %) with newly diag-
nosed type 2 diabetes underwent standard clinical characterization. BF and 
insulin sensitivity (SI) were assessed by mathematical modeling of glucose/C-
peptide curves during a 240’ frequently sampled OGTT and by euglycemic 
insulin clamp, respectively. The beta-cell responses to the rate of increase of 
glucose (G) (derivative or dynamic control: DC; median[IQ range]: 421[0.6-
907] [pmol · m-2 BSA]/[mM · min-1]) and to G concentration (proportional or 
static control, PC, presented as the insulin secretion rate at G concentrations 
of 5.5, 8.0, 11.0, 15.0 and 20.0 mM, respectively; 160±69, 223±122, 359±218, 
572±376, 843±591 pmol · min-1 · m-2 BSA) are herein reported as measures of 
BF. SI is presented as the M value in the last 60’ of the clamp (561[355-796] 
µmol · min-1 · m-2 BSA). Rs13266634 in SLC30A8 and rs5219 in KCNJ11 were 
genotyped in all patients.
Results: In obese patients (n=202 with BMI>=30), but not in the nonobese 
(p=0.40), the rs13266634 G allele of SLC30A8 (frequency: 0.74) was associat-
ed with reduced PC (-8.5±7.7, -27.3±13.8, -60.3±24.4, -93.9±45.8, -136±74.3 
at G concentrations of 5.5, 8.0, 11.0, 15.0 e 20 mM; p<0.04) and with increased 
levels of glucose at 2 hours during OGTT (+0.80±0.33 mmol/l, p<0.02). In 
nonobese patients (n=254 with BMI<30), but not in the obese (p=0.64), the 
rs5219 A allele of KCNJ11 (frequency: 0.39) was associated with reduced DC 
(-157±58; p<0.01) according to an additive model, and to both reduced PC 
(-6.9±10.8, -38.7±21.1, -86.8±38.3, -135±63.4, -167±97.2 at G concentrations 
of 5.5, 8.0, 11.0, 15.0 e 20 mM; p<0.05) and increased fasting plasma G (AA: 
+0.81±0.33 mmol/l; p<0.02) according to a recessive model.
Conclusion: In patients with newly diagnosed type 2 diabetes the non-syno-
nymic variants of SLC30A8 and KCNJ11 herein investigated are associated 
with worse BF, with BMI (obesity) apparently playing a modifying role on 
this relationship. These data, if confirmed, could be useful for diagnostic, 
therapeutic and clinical purposes.
Supported by: an EFSD/Novartis grant
315
The presence of CAD significantly modulates the diabetes risk conferred 
by the TCF7L2 rs7903146 variant
S. Geller-Rhomberg1, A. Muendlein1,2, C.H. Saely1,2, G. Sonderegger1,  
P. Rein1,2, T. Winder1,2, S. Beer1,2, A. Vonbank1,2, H. Drexel1,2; 
1Vorarlberg Institute for Vascular Investigation and Treatment, Feldkirch, 
Austria, 2Private University of the Principality of Liechtenstein, Triesen, 
Liechtenstein.
Background and aims: Genetic variant rs7903146 in the transcription factor 
7-like 2 (TCF7L2) gene has been consistently associated with type 2 diabetes 
(T2DM) in several studies. It is unknown whether it confers the same amount 
of diabetes risk in patients with CAD as in patients who do not have CAD. We 
therefore aimed at investigating whether the presence of CAD modulates the 
association of TCF7L2 variant rs7903146 with T2DM.
Materials and methods: We therefore performed genotyping of variant 
rs7903146 in a large cohort of 1650 consecutive Caucasian patients undergo-
ing coronary angiography for the evaluation of established or suspected CAD. 
At angiography, significant CAD was diagnosed in the presence of significant 
coronary stenoses with lumen narrowing of ≥50%. The association between 
rs7903146 and T2DM was evaluated in an additive genetic model.
Results: Variant rs7903146 was significantly associated with the presence of 
T2DM in the total study cohort (adjusted odds ratio (OR)=1.38 [1.15-1.65]; 
p<0.001). Also, diabetes duration significantly (p=0.024) increased from the 
CC over the CT to the TT genotype (7.7±8.6, 8.1±7.3 and 9.2±6.8 years). 
When patients with CAD (n=950) were analyzed separately from those with-
out significant CAD, the association between variant rs7903146 and T2DM 
was strongly significant in patients with significant CAD (adjusted OR=1.59 
[1.26-2.00]; p<0.001), but not in subjects who did not have significant CAD 
(OR=1.04 [0.77-1.40]; p=0.807). Variant rs7903146 was also significantly as-
sociated with diabetes duration in individuals with CAD (7.9±8.8 8.9±7.4 
and 9.3±6.8 years for the CC, CT, and TT genotype, respectively, p=0.018), 
but not in patients without significant CAD (p=0.718). An interaction term 
CAD x rs7903146 was significant (p=0.018), indicating a significantly strong-
er impact of the polymorphism on T2DM risk in patients with significant 
CAD than in subjects without significant CAD.
Conclusion: We conclude that the presence of CAD significantly modulates 
the diabetes risk conferred by the TCF7L2 rs7903146 variant.
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Allelic variations in the catalase gene are associated with development 
and progression of diabetic nephropathy in subjects with type 1 diabetes
K. Mohammedi1,2, S. Maimaitiming1, N. Bellili1, N. Emery3, K. Billariki2,3,  
R. Roussel1,2, S. Hadjadj4, F. Fumeron1,3, M. Marre1,2, G. Velho1; 
1INSERM, Unité 695, Paris, 2Service d’Endocrinologie-Diabétologie, AP-
HP. Hôpital Bichat Claude Bernard, Paris, 3Université Paris Diderot, Paris, 
4Service de Médecine Interne, Hôpital Universitaire de Poitiers, France.
Background and aims: Oxidative stress is involved in the pathophysiology of 
diabetic nephropathy (DN). The antioxidant enzyme Catalase plays a major 
role in the detoxification of reactive oxygen species and thus could have a 
protective role against DN. In this study, we tested the impact of allelic varia-
tion in the Catalase gene (CAT) on the development and progression of DN 
in subjects with Type 1 Diabetes Mellitus (T1DM).
Materials and methods: Twelve SNPs (table 1), giving information on ~90% 
of the allelic variation of the haplotypic block containing CAT gene were 
analyzed in 1463 subjects from three independent T1DM cohorts: the SUR-
GENE prospective study (follow-up of 10 ± 3 years, mean ± SD), GENEDIAB 
and GENESIS studies. Genotypes were determined by an Assay by Design kit 
from Applied Biosystems. Genotype associations with DN were assessed by 
logistic regression analyses. Associations with DN severity were assessed by 
ordinal logistic regression analyses, with stages of DN coded as ordinal poly-
tomic dependent variables: absence (1), microalbuminuria (2), macroalbu-
minuria (3), reduced renal function (4) and end stage renal failure (5).
Results: In the SURGENE cohort, the rs7947841 variant was associated with 
DN both at baseline (Odds Ratio 8.60, 95% C.I. 1.83 - 40.32, p=0.005) and 
at follow-(Odds Ratio 4.34, 95% C.I. 1.29 - 14.78, p=0.01). The variant was 
also associated with the severity of DN, both at baseline (p=0.005) and at 
follow-up (p=0.001). In GENEDIAB cohort, five SNPs were associated with 
DN (Table 1). These SNPs were also associated with the severity of DN sever-
ity (p=0.009, p=0.06, p=0.02, p=0.006 and p=0.006, respectively) and with 
microalbuminuria (p=0.03, p=0.05, p=0.04, p=0.01 and p=0.003, respec-
tively). We have also observed associations of these variants with arterial 
hypertension.
Conclusion: We have observed associations of CAT allelic variations with di-
abetic nephropathy, its severity and with intermediate phenotypes in subjects 
with T1DM. We are currently performing haplotypic studies in the 3 cohorts 
and analysis of 6 years follow-up data of GENESIS and GENEDIAB cohorts.
Table 1: GENEDIAB study: Association of CAT polymorphisms with diabetic 
nephropathy
SNP
Diabetic nephropathy at baseline
Odds ratio (95% IC) p*
rs2266630 1.17 (0.41 - 3.66) 0.76
rs1001179 2.84 (1.24 - 6.79) 0.01
rs11032699 1.23 (0.63 - 2.42) 0.54
rs12272630 0.18 (0.04 - 0.77) 0.02
rs2300182 0.77 (0.33 - 1.84) 0.56
rs11032703 1.22 (0.40 - 3.87) 0.73
rs2300181 0.65 (0.32 - 1.33) 0.24
rs10488736 0.44 (0.22 - 0.88) 0.02
rs2420388 1.00 (0.49 - 2.08) 0.99
rs566979 0.44 (0.23- 0.86) 0.01
rs7947841 1.87 (0.55 - 6.73) 0.32
rs499406 2.14 (1.07 - 4.32) 0.03
*Adjusted for sex, age, duration of diabetes, HbA1c and ACE inhibitors
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Does genetic variability in the fructosamine-3-kinase play a role in 
the progression of diabetic nephropathy, morbidity and mortality of 
diabetics?
L. Pácal1, V. Tanhäuserová1, J. Svojanovský2, D. Krusová2, S. Štěpánková3,  
J. Olšovský2, J. Bělobrádková3, J. Řehořová3, J. Smržová3, K. Kaňková1; 
1Department of Pathophysiology, Faculty of Medicine, Masaryk University, 
2Department of Internal Medicine, St. Anne’s Faculty Hospital, 3Department 
of Gastroenterology, Faculty Hospital Brno-Bohunice, Brno, Czech 
Republic.
Background and aims: Fructosamines are products of non-enzymatic gly-
cation formed in accelerated rate during hyperglycemia. As precursors of 
advanced glycation end-products (AGEs) fructosamines supposedly contrib-
ute to the development of glucotoxic injury. Mechanism of enzymatic degly-
cation of proteins in vivo by fructosamine-3-kinase (FN3K) was described 
recently. FN3K is a ubiquitous intracellular enzyme that phosphorylates 
fructosamines resulting in unstable fructosamine-3-phosphate, which sub-
sequently spontaneously decomposes to inorganic phosphate, 3-deoxyglu-
cosone and the unmodified amine. Recently, the -385A/G (rs3859206) and 
900C/G (rs1056534) single nucleotide polymorphisms (SNPs) in the FN3K 
gene were found to have potential functional impact - association with FN3K 
enzyme activity in erythrocytes (genotypes -385AA and 900GG associated 
with lowest enzymatic activity). Fructosamine pathway may therefore rep-
resent either potentially protective metabolic process in hyperglycemia since 
degradation of fructosamines prevents formation of Lys-based AGEs or quite 
the reverse - harmful process - by formation of 3-deoxyglucosone as a potent 
mobile Arg-directed glycating agent. The aim was to study relationship be-
tween polymorphisms in FN3K gene, progression of diabetic nephropathy 
(DN) and cardiovascular morbidity and mortality of diabetics.
Materials and methods: Study comprised a total of 420 T1DM or T2DM 
subject with variable stage of DN (i.e. normoalbuminuria, microalbuminuria, 
proteinuria or ESRD) prospectively followed for 45 [21 - 63] months (median 
[IQR]). Following end-points were considered: [1] renal (progression of DN 
by stage or reaching the ESRD), [2] major cardiovascular event (MCVE: non-
fatal myocardial infarction or stroke, limb amputation), [3] cardiovascular 
mortality (CVM: fatal myocardial infarction, stroke or sudden death) and 
[4] all-cause mortality (AM). SNPs were genotyped by PCR with subsequent 
RFLP.
Results: Progression of DN was reached in 16.5% of subjects, MCVE in 
15.6%, CVM in 9.9% and ACM in 19.3%. Allele and genotype frequencies did 
not differ between DN stage groups (chi-square test). Using Kaplan-Meier 
time-to-event analysis significant effects were ascertained for the carrier state 
of the -385AA and 900GG genotype combinations and progression of DN, 
MCVE and CVM (all P<0.05, log-rank test). In all cases, group defined by the 
presence of at least one “low-activity” allele in both positions (i. e. -385AA or 
AG combined with 900GG or GC) were associated with significantly longer 
median of time to DN progression, MCVE and CVM.
Conclusion: Interindividual variability in FN3K enzyme activity represents 
potentially significant genetic risk factor for the progression of DN and car-
diovascular morbidity and mortality of diabetics. Based on our results, we 
can’t identify high FN3K deglycating activity as a protective factor, on the 
contrary higher rate of 3-deoxyglucosone formation may counterbalance pu-
tative protection by providing substrate for Arg-directed glycation and AGE 
formation.
Supported by: NR 9443-3/2007 and Research grant from DANONE
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PPAR-γ2 P12A polymorphism and albuminuria in patients with type 2 
diabetes
S. De Cosmo1, S. Prudente2, O. Lamacchia3, D. Camarchio3, M. Cignarelli3, 
M. Copetti4, V. Trischitta5; 
1Unit of Endocrinology, Scientific Institute “Casa Sollievo della Sofferenza”, 
SGR, Foggia, 2CSS-Mendel Institute, Rome, 3Department of Medical 
Sciences, Unit of Endocrinology, Foggia, 4Scientific Institute “Casa Sollievo 
della Sofferenza”, SGR, Foggia, 5Scientific Institute Casa Sollievo della 
Sofferenza and University of Rome, SGR, Foggia and Rome, Italy.
Background and aims: Insulin resistance (IR) is believed to be pathogenic 
for albuminuria in patients with T2D. The PPAR-γ2 P12A polymorphism has 
been consistently associated with IR and T2D with the A12 variant playing 
a protective role. The association of this variant with a reduced risk of albu-
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minuria in T2D has been controversial. The aim of this study was to investi-
gate the relationship between PPAR-γ2 P12A polymorphism and albuminu-
ria in patients with T2D.
Materials and methods: To get deeper insights about this issue, we first test-
ed the association between the A12 variant and albuminuria in two new case-
control studies in patients with T2D from Italy, and then performed a meta-
analysis of all studies available to date. The first study comprised 261 cases 
(162 male/99 female; age, 63.2±10.0 yrs) and 580 controls (264 male/316 
female; age, 61.6±9.5 yrs) recruited at Scientific Institute CSS in San Gio-
vanni Rotondo. The second study comprised 254 cases (131male/123 female; 
age, 63.9±12.2 yrs) and 369 controls (170 male/199 female; age, 62.2±12 yrs) 
recruited at University Hospital of Foggia. In these 2 studies, albuminuria 
was defined if ACR was >2.5 in men and 3.5 mg/mmol in women. Pro12Ala 
polymorphism was genotyped by TaqMan-based assay in genomic DNA. The 
8 studies we meta-analyzed comprised 2144 cases and 3706 controls. In four 
studies albuminuria was determined by albumin excretion rate (AER) and in 
four by albumin concentration in a single spot (i.e. urine albumin/creatinine 
ratio in 3 studies and urinary albumin concentration in one study).
Results: The overall OR (95% CI) for association between A12 and albu-
minuria was 0.67 (0.49-0.91), with values of individual studies ranging from 
0.29 to 1.13. A significant heterogeneity of the genetic effect was observed 
(Cochran’s Q test p=0.017). Approximately one third of it (36.4%) was ex-
plained by the different method of urine collection and albuminuria defini-
tion utilized across the studies. Most of the protective effect of the A12 variant 
was observed in the 4 studies using AER rather than in those using albumin 
concentration in a single spot (OR, 95% CI: 0.52, 0.34-0.79, p=0.0024 and 
0.84, 0.58-1.21, p=0.35, respectively).
Conclusion: The present meta-analysis shows that the PPARγ2 Ala12 variant 
is significantly associated with a reduced risk of albuminuria among patients 
with T2D. This association is particularly evident among studies where the 
ascertainment of case-control status was obtained by measurement of albu-
min excretion rate.
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INPPL1 gene is associated with the metabolic syndrome but not with 
diabetic nephropathy in patients with type 1 diabetes
M.E. Hyvönen1,2, C. Forsblom3,4, P. Ihalmo3, J. Söderlund3, N. Sandholm3, 
M. Parkkonen3, L. Thorn3,4, S. Lehtonen1, P.-H. Groop3,4, FinnDiane Study 
Group; 
1Department of Pathology, University of Helsinki, 2Hospital for Children 
and Adolescents, 3Folkhälsan Institute of Genetics, University of Helsinki, 
4Department of Medicine, Helsinki University Central Hospital, Finland.
Background and aims: The metabolic syndrome has been shown to be a fre-
quent phenomenon in patients with type 1 diabetes and to associate with dia-
betic nephropathy. INPPL1 gene encodes lipid phosphatase SHIP2, a negative 
regulator of PI3-kinase mediated insulin signaling. Polymorphisms in INPPL1 
gene have been found to associate with components of the metabolic syndrome 
in British and Japanese cohorts. The aim of this study was to investigate if single 
nucleotide polymorphisms (SNPs) in INPPL1 are associated with the metabolic 
syndrome or diabetic nephropathy in Finnish patients with type 1 diabetes.
Materials and methods: We selected 2520 patients participating in the 
FinnDiane study for this cross-sectional study. The metabolic syndrome was 
defined according to the most recent criteria (joint statement 2009), and pa-
tients were divided into controls without the metabolic syndrome (n=1010) 
and cases with the metabolic syndrome (n=1475), as well as into four groups 
based upon their albumin excretion rate: normoalbuminuria (n=1256), 
microalbuminuria (n=442), macroalbuminuria (n=553) and end stage renal 
disease (n=266). Nine SNPs were selected for genotyping from the HapMap 
database (CEPH, r2>0.8) for INPPL1 gene plus/minus 20 kbs. Genotyping 
was performed with ABI Prism 7900 Sequence Detection System based on 
TaqMan chemistry. The associations between the SNPs and outcome vari-
ables were analysed with the Chi-squared test.
Results: Two INPPL1 SNPs, rs2276047 (in an intron) and rs2276048 (silent 
mutation), were found to associate with the metabolic syndrome in males, 
with p-values 0.018 and 0.001, respectively. When both genders were includ-
ed, the association was not significant. No association between the genotyped 
SNPs and various degrees of nephropathy was observed.
Conclusion: INPPL1 gene variants may contribute to susceptibility to the 
metabolic syndrome, however, not to diabetic nephropathy in patients with 
type 1 diabetes.
Supported by: CLIGS, Found. for Paed. Res., Diab. Res. Found., Folkhälsan Res. 
Found.
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CNDP1 gene polymorphism predicts cardiovascular mortality in female 
patients with type 2 diabetes (ZODIAC 22)
A. Alkhalaf1,2, K.J.J. van Hateren2, G.W.D. Landman2,3, S.J.L. Bakker1,  
G.J. Navis1, N. Kleefstra2,4, H.J.G. Bilo1,2; 
1Internal Medicine, University Medical Center Groningen, 2Diabetes Centre, 
Isala Clinics, Zwolle, 3Internal Medicine, Isala Clinics, Zwolle, 4Langerhans 
Medical Research Group, Zwolle, Netherlands.
Background and aims: Carnosine has been shown to be protective against 
oxidative stress and endothelial damage. Homozygosity for 5-leucine re-
peat (5L-5L) in the carnosinase gene (CNDP1) has recently been found to 
be associated with diabetic nephropathy in cross-sectional studies, mainly 
in women with type 2 diabetes. Longitudinal data on survival are, however, 
not yet available. We prospectively investigated whether allelic variation in 
CNDP1 predicts (cardiovascular) mortality in patients with type 2 diabetes 
and to what extent this is modified by sex.
Materials and methods: This study is part of the ZODIAC study, a prospec-
tive observational study in primary care patients with type 2 diabetes. Leu-
cine repeats in CNDP1 were assessed by fluorescent DNA analysis. In 2009, 
data on mortality were collected. A Cox proportional hazard model was used 
to compare 5L-5L with other allelic variations, after adjustment for potential 
confounders, including age, body mass index, duration of diabetes, macrov-
ascular complications, systolic blood pressure, HbA1c, total cholesterol to 
HDL-cholesterol ratio, plasma creatinine, and urine albumin excretion. Fur-
thermore, CNDP1 and sex were entered as an interaction term.
Results: 872 patients [age 68.1 ± 11.2 years, 366 (42%) males] were included. 
At baseline, median diabetes duration was 5 (interquartile range (IQ) 2-11) 
years, mean HbA1c 56 ± 12 mmol/mol, plasma creatinine 91 (IQ 82-104) 
µmol/L, and urinary albumin creatinine ratio 1.94 (IQ 0.95-6.18) mg/mmol. 
5L-5L was found in 331 patients (38%; this was for men 39% and for women 
37%). After 9.5 (IQ 5.9-10.3) years of follow-up, 136 (41%) patients with 
5L-5L had died, with 55 deaths (17%) attributable to cardiovascular causes. 
In patients with other allelic variants, these numbers were 205 (38%) and 
81 (15%), respectively. Adjusted hazards ratios (HR) for all-cause mortal-
ity and cardiovascular mortality in 5L-5L versus other allelic variants were 
1.08 (95%CI 0.87-1.35) and 1.12 (95%CI 0.79-1.60), respectively. There was 
a significant interaction between allelic variation in CNDP1 and sex for pre-
diction of cardiovascular mortality (P=0.02), but not for all-cause mortality 
(P=0.69). After stratification for sex, adjusted HRs of 5L-5L for cardiovascu-
lar mortality were 0.74 (95%CI 0.42-1.32, P=0.31) in males and 1.61 (95%CI 
1.02-2.55, P=0.04) in females.
Conclusion: In this prospective study on allelic variation in CNDP1 in pa-
tients with type 2 diabetes, 5L-5L was gender-dependently associated with 
the risk for cardiovascular mortality, with a higher risk in women.
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Two common variants on 9p21 affect mortality risk in type 2 diabetes 
patients (ZODIAC-15) 
G.W.D. Landman1, J.V. van Vliet-Ostaptchouk2, N. Kleefstra1,3,  
K.J.J. van Hateren1, I. Drion1, K.H. Groenier4, R.O.B. Gans5, C. Wijmenga6, 
M.H. Hofker2, H.J.G. Bilo7,5; 
1Diabetes Centre, Isala Clinics, Zwolle, 2Molecular Genetics, Department 
of Pathology and Medical Biology, University Medical Centre Groningen 
and University of Groningen, 3Langerhans, Medical Research Group, 
Zwolle, 4General Practice, University Medical Centre Groningen, 5Internal 
Medicine, University Medical Centre Groningen, 6Department of Genetics, 
University Medical Centre Groningen and University of Groningen, 
7Diabetes Centre, Internal Medicine, Isala Clinics, Zwolle, Netherlands.
Background and aims: Recent genome wide association (GWA) studies 
identified two single nucleotide polymorphisms (SNP), rs10811661 and 
rs10757278 in the same region on the 9p21 chromosome to be consistently 
and independently associated with the risk of developing type 2 diabetes 
(T2DM) and cardiovascular disease, respectively.
We examined the SNPs in relation to the risk of total and cardiovascular mor-
tality in a population based cohort of T2DM patients.
Materials and methods: The ZODIAC study is a prospective cohort study 
of T2DM patients treated in primary care in the Netherlands. Rs10811661 
and rs10757278 were genotyped in 914 subjects from the ZODIAC study and 
920 healthy Dutch controls. Associations of the SNPs with mortality were 
assessed by use of Cox proportional hazard analyses.
Results: After a median follow-up of 9.5 years 358 out of 914 patients had died. 
The adjusted Hazard Ratio’s (HR) for total mortality for patients homozygote and 
heterozygote for the wild type allele of rs10811661 was 1.34 (95% CI 1.06-1.69, 
p=0.01) compared to individuals homozygous for the risk allele. For rs10757278 
total mortality was lower among patients heterozygous and homozygous for the 
wild-type allele than in homozygous carriers for the risk allele (HR 0.64 (95%CI 
0.43-0.95), p=0.03, and HR 0.73 (95%CI 0.48-1.11), p=0.14, respectively). This 
effect was more pronounced in the lower tertile of HbA1c: the adjusted HR for 
patients heterozygous and homozygous for wild-type allele of rs10757278 was 
0.48 (95%CI 0.28-0.83, p=0.01) and 0.48 (95%CI 0.27-0.85, p=0.01), respective-
ly, compared with the patients homozygous for the risk allele.
Conclusion: This prospective study shows a significant association between 
two common SNPs on 9p21 and mortality in type 2 diabetes patients.
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Genome wide association analysis for free fatty acid levels in DGI
I.A. Stojkovic1, C. Saloranta2, P. Almgren3, V. Lyssenko3, E. Laurila3,  
M. Svensson1, A. Sharma1, B. Isomaa4, L. Groop3, M.O. Melander1; 
1Diabetes, Cardiovascular Disease and Genetic Epidemiology, Lund 
University, Malmö, Sweden, 2Department of Medicine, Helsinki University 
Hospital, Finland, 3Diabetes and Endocrinology, Lund University, Malmö, 
Sweden, 4Department of Medicine, Folkhälsan Research Center, Helsinki, 
Finland.
Background and aims: Recent genome-wide association studies (GWAS) 
have identified a number of common single nucleotide polymorphisms 
(SNPs) that contribute to multifactorial human phenotypes. Free fatty acids 
(FFAs) serve as physiologically important energy substrates and their release 
from adipose tissue is regulated by the energy demands of the body. FFAs are 
increased in obese patients and T2D and cause insulin resistance in all major 
insulin target organs. Although FFA levels have a heritability of 50-60%, very 
little is known about contributing genetic factors. The aim of this study is to 
identify genetic factors regulating FFA levels using a GWAS approach.
Materials and methods: In total 1094 non-diabetic unrelated individuals 
(49% males, age 59±11 years, BMI 27±4 kg/m2) from the Diabetes Genetics 
Initiative (DGI) GWAS of 500K were included in the analyses. FFA-levels were 
determined using Half-micro and Micro 96-plate methods with two differ-
ent kits NEFA HR (2) and NEFA C (Waco), after an overnight fast (FFA0) 
and after an OGTT (FFA120) and a dFFA was calculated reflecting insulin 
suppression (FFA0-FFA120). FFA-levels of the 1094 individuals were FFA0 
655±235 μmol/l, FFA120 221±114 μmol/l and dFFA 432±221. Linear regres-
sion analyses were performed in plink with age, sex, fasting insulin, BMI and 
region or age, sex and region as covariates. Replication analyses are performed 
among 2845 participants of the Botnia Prevalence, Prediction and Prevention 
of Diabetes study (Botnia-PPP: 47% males, age 48±15 years, BMI 27±4 kg/m2, 
FFA0 593±246 μmol/l, FFA120 159±80 μmol/l and dFFA 431±229).
Results: In DGI, the lowest p-values for FFA0, FFA120 and dFFA were found 
in or near TUB, UBE2NL/SPANXN2 and c4orf32/TIFA loci on chromosomes 
11, 23 and 4 (p= 1x10-6, p=1x10-5 and p=4x10-6, respectively). In total 24, 
15 and 29 SNPs provided p-values of less than 1x10-4 for FFA0, FFA120 and 
dFFA, respectively. 14 loci associated with both FFA120 and dFFA with 
p<1x10-4. All SNPs with p<1x10-4 in DGI were chosen for replication in Bot-
nia-PPP. Similar to DGI, the TUB SNP associated with significantly lower 
dFFA in PPP (p=0.0005) while association with FFA0 did not reach statistical 
significance (p=0.065). These results were similar with and without adjust-
ment for fasting insulin and BMI.
Conclusion: A GWAS for FFA identified 64 loci with p<1x10-4 and replica-
tion genotyping of these loci is ongoing. Our results so far provide evidence 
for involvement of TUB gene in regulation of FFA levels in man. TUB codes 
for the human homolog of a gene that causes maturity onset obesity and in-
sulin resistance in tubby mice.
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Interpretation of genome wide association data for lipoprotein traits 
using systems biology approach
A. Sharma1, N. Gulbahce2, S. Lang1, C. Ladenvall1, S. Kathiresan3,  
M. Orho-Melander1, A.-L. Barabasi2; 
1Diabetes and Cardiovascular Diseases, Genetic Epidemiology unit, Lund 
University, University Hospital Malmö, Sweden, 2Department of Physics, 
Center for Complex Network Research, Boston, 3Center for Human Genetic 
Research and Cardiovascular Research Center, General Hospital, Harvard 
Medical School, Boston, USA.
Background and aims: Genome wide association studies (GWAS) with large 
meta-analyses have identified a number of new loci contributing to multifac-
torial diseases. Hereby we assumed that by analysis of interaction networks 
of GWAS genes with SNPs providing P <5x10-8 (seed genes) in meta-analysis 
data of Global Lipids Genetics Consortium (GLGC) including > 100,000 in-
dividuals it could be possible to reveal novel candidate genes and pinpoint 
important pathways for lipid and lipoprotein traits. By integrating GLGC 
meta-analysis data with Molecular networks (expression, transcriptional, 
proteomic and metabolic interaction networks) as well as with phenotypic 
disease network (comorbidity network), we wish to gain new biological in-
sights for better understanding of lipoprotein metabolism.
Materials and methods: GLGC meta-analysis data of ~ 2.6 million geno-
typed or imputed SNPs for four lipid/lipoprotein traits i.e. total cholesterol 
(TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein 
cholesterol (HDL-C), and triglycerides (TG) was analyzed. After correcting 
for linkage disequilibrium, SNPs were assigned to genes on the basis of being 
located within 20kb region of first and last exon. We defined a seed genes data 
set (association p-value <5x10-8) of 112 genes for HDL-C, 117 for LDL-C, 158 
for TC and 115 for TG. Interaction information gleaned from the first order 
neighbours and second order neighbours were used in further analysis. We 
then approached to identify additional candidate genes by studying clusters 
of seed genes using Molecular Triangulation (MT) algorithm. In the next step 
we only selected genes that were co-expressed with the seed genes using 79 
human tissues expression data. Further, the GLGC meta-analysis p-values 
of seed genes were superimposed on the interaction networks to identify the 
sub-networks and additional 100 random control networks were generated. 
For weighing the identified sub-networks for comorbidity we utilized the large 
scale US Medicare database of comorbidity patterns of 13 millions patients.
Results: By MT algorithm we identified 223, 172, 140 and 243 additional can-
didate genes for HDL-C, LDL-C, TG and TC with significance of real scores 
of P=5.4x10-5, P=4.7x10-5, P=4.4x10-5 and P=6.5x10-5, respectively. Receiver 
operating characteristic (ROC) curve showed accuracy of 93% and sensitivity 
of 64% for MT algorithm with the seed genes. After priorization of those ad-
ditional candidate genes that co-expressed with seed genes and were present 
in the sub-networks having highest comorbidity values we were left with 39, 
19, 27 and 20 genes for HDL-C, LDL-C, TG and TC. Of these genes, lowest 
p-values in GLGC meta-analysis data were for HDL-C in INSR (P=2x10-5) 
and ASCC2 (P=0.0005), for LDL-C in SH3GL2 (P=0.0001) and NDUFA4L2 
(P=0.0003), for TG in GCK (P=3.7x10-5) and RAF1 (P=8.6x10-5) and for TC 
in SH3GL2 (P=0.0002) and GOLM1 (P=0.004).
Conclusion: Combining large GWAS meta-analysis data with systems bi-
ology approaches and comorbidity data identified new candidate genes for 
lipoprotein traits and addresses the importance of network based genetic 
analyses in the future.
Supported by: SMRC and Heart & Lung Foundation
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Association of FTO gene variation with fat oxidation in women with 
polycystic ovary syndrome
I. Kowalska1, A. Adamska1, M.T. Malecki2, M. Karczewska-Kupczewska1,  
A. Nikolajuk1, M. Szopa2, A. Lebkowska1, M. Górska1, M. Straczkowski1; 
1Endocrinology, Diabetology and Internal Medicine, Medical University, 
Bialystok, 2Department of Metabolic Diseases, Jagiellonian University, 
Medical College, Krakow, Poland.
Background and aims: Polycystic ovary syndrome (PCOS) is heterogeneous 
disorder, where insulin resistance might be involved in the development of 
endocrine and metabolic abnormalities. It was recently shown that the FTO 
gene modifies weight, fat mass and insulin sensitivity in women with poly-
cystic ovary syndrome, where its role might be larger than in other pheno-
types. The aim of the present study was to estimate the effect of FTO variation 
on glucose and lipid oxidation in PCOS women.
Materials and methods: The study group consisted of 68 women with PCOS 
and 25 healthy, normally menstruating women. Clinical examination, an-
thropometric measurements, euglycemic hyperinsulinemic clamp and the 
measurements of serum sex hormones were performed. Glucose and lipid 
oxidation was evaluated with indirect calorimetry in the baseline state and 
during the last 30 minutes of the clamp. The FTO rs9939609 polymorphism 
was genotyped using the restriction fragment length polymorphism meth-
od.
Results: There was no difference in glucose and lipid oxidation between 
PCOS and control women. TT homozygotes had higher baseline fat oxida-
tion in comparison to the carriers of A allele (p=0.019) in the entire study 
population. We found similar differences when PCOS women were analyzed 
separately (p=0.018). We did not observe the effect of FTO gene variation on 
insulin-stimulated lipid oxidation and either baseline or insulin-stimulated 
glucose oxidation.
Conclusion: Our data show that FTO gene variation might influence baseline 
lipid oxidation in PCOS patients. This might be one of potential mechanism 
explaining the impact of the FTO gene on body weight.
Supported by: Medical University of Bialystok
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Impact of the I148M mutation in PNPLA3 (adiponutrin) on weight loss-
induced decrease in liver fat
K. Sevastianova1, A. Kotronen1, A. Gastaldelli2, A. Hakkarainen3,  
N. Lundbom3, E. Ferrannini2, A. Rissanen4, H. Yki-Järvinen1; 
1Department of Internal Medicine, Helsinki University Central Hospital, 
Finland, 2Department of Internal Medicine, University of Pisa School of 
Medicine, Italy, 3Department of Radiology, Helsinki University Central 
Hospital, 4Department of Psychiatry, Obesity Research Unit, Helsinki 
University Central Hospital, Finland.
Background and aims: The rs738409 C>G single nucleotide polymorphism 
(SNP) in the patatin-like phospholipase domain-containing 3 (PNPLA3; adi-
ponutrin) gene leads to a missense mutation (I148M) in PNPLA3. Carriers of 
the GG genotype (prevalence ~5%) have a marked 60% increase in liver fat. 
In vitro, adiponutrin has been associated with both transacylase and lipase 
activities. We explored whether the I148M variant in the adiponutrin gene 
influences weight loss -induced decrease in liver fat in humans.
Materials and methods: We recruited 17 subjects of whom 8 had the GG 
genotype and 9 the CC genotype. We matched the groups with respect to age 
(48 ± 4 vs. 53 ± 4 yrs, GG vs. CC, NS), BMI (29.2 ± 2.1 vs. 31.5 ± 1.9 kg/m2, 
NS) and liver fat (10.2 ± 1.8 vs. 13.2 ± 1.8 %, NS). The subjects were placed on 
a hypocaloric (1000 kcal deficit/ day) low-carbohydrate (<20 g/ day) diet for 
six days. Liver fat was measured by proton magnetic resonance spectroscopy 
before and after the intervention. Whole-body insulin sensitivity was meas-
ured by the euglycemic insulin (0.4 mU * kg-1 * min-1) clamp technique.
Results: Weight loss was similar in both groups (-3.7 ± 3.5 vs. -3.3 ± 0.3 kg, 
GG vs. CC, NS). Liver fat decreased by 45 % in the GG and by 20 % in the 
CC group (p=0.046). Whole-body insulin sensitivity increased significantly 
in the GG group from 0.90 ± 0.18 to 1.33 ± 0.25 mg * kg-1 * min-1 (p=0.04) 
and remained unchanged in the CC group (0.62 ± 0.10 vs. 0.68 ± 0.11 mg * 
kg-1 * min-1, p=0.58). No significant differences between changes in fasting 
concentrations of triglycerides, glucose or insulin were observed.
Conclusion: These data suggest that the I148M mutation facilitates weight 
loss -induced mobilization of intrahepatocellular triglyceride in vivo in hu-
mans.
PS 8 Epidemiology and genetics of 
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Three year-follow-up incidence of cardio-metabolic alterations in a 
metabolically normal population
Z. Pataky, E. Bobbioni-Harsch, V. Makoundou, A. Golay; 
WHO Collaborating Centre, University Hospitals of Geneva, Switzerland.
Background and aims: It has been claimed that obese subjects with normal 
metabolic profile are not at increased risk for cardio-metabolic diseases, as 
compared to normal body weight. The aim was to compare the 3-year evo-
lution of cardio-metabolic parameters in normal body weight (NBW) and 
obese (OB) healthy subjects, free from MS and with a normal glucose toler-
ance at baseline.
Materials and methods: We investigated a sub-group of the RISC study (Rela-
tionship between Insulin Sensitivity and Cardiovascular Disease) participants 
(NBW=288 and OB=141) free from metabolic syndrome (MS, according to 
IDF criteria) and with a normal glucose tolerance at baseline. In these subjects, 
fasting insulin was measured and insulin sensitivity was assessed by euglycae-
mic hyperinsulinaemic clamp. Based on quartiles established in NBW, both 
NBW and OB subjects were classified as normo-insulinaemic or hyper-in-
sulinemic and insulin sensitive or insulin resistant. Metabolic normality was 
defined as the presence of normal levels of both fasting insulin and insulin 
sensitivity. Three years later, the cardio-metabolic parameters suggested by the 
IDF to define MS as well as glucose tolerance were re-measured.
Results: At 3 years, the incidence of MS was 6.6% in NBW and 21.3% in 
OB (p<0.0001), the incidence of impaired fasting glucose was 7.6% vs 20.6% 
(p<0.0001) and of impaired glucose tolerance 3.8% vs 10.6% (p=0.005), in 
NBW and in OB respectively. Hypertension occurred in 6.3% of NBW vs 
14.9% in OB (p=0.003). In the overall population, both BMI at baseline and 
BMI modifications along the 3-year period were predictors for MS (OR=1.12, 
p=0.04 and OR=1.44, p=0.01, respectively), whereas BMI at baseline was 
predictor of impaired fasting glucose (OR=1.20, p=0.001). BMI evolution 
predicted impaired glucose tolerance (OR=1.44, p=0.02) and hypertension 
(OR=1.47, p=0.04).
Conclusion: Even when metabolically normal, OB subjects show an in-
creased risk for MS, pre-diabetes and hypertension. Therefore, they need a 
closer surveillance.
Supported by: EU
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Gestational diabetes is not associated with adiposity measurements in 18 
months offspring: the mother child rhea cohort in Crete, Greece
L. Chatzi1, E. Papadopoulou1, M. Vafeiadi1, K. Mathianaki1, A. Pappas2,  
A. Koutis1, M. Kogevinas3,4; 
1Department of Social Medicine, Heraklion, 2Diabetic Clinic, Venizelio 
Hospital, Heraklion, Greece, 3Centre for Research in Environmental 
Epidemiology (CREAL), Barcelona, Spain, 4National School of Public 
Health, Athens, Greece.
Background and aims: Studies of developmental origins of health and dis-
ease have put focus on the possible role of intrauterine exposure to hypergly-
cemia in the pathogenesis of obesity and cardiovascular disease in offspring. 
Although gestational diabetes is a strong risk factor for obesity in the off-
spring, the age at which this association becomes apparent is unknown. The 
purpose of this study was to examine the relation of gestational diabetes with 
measures of adiposity in early childhood.
Materials and methods: The mother-child “Rhea”study in Crete is a prospec-
tive cohort examining pregnant women (Greek and immigrants) residents at 
the prefecture of Heraklion that became pregnant during one year starting in 
February 2007 and initiated prenatal care before 15 weeks of gestation (mean: 
12 weeks). Six hundred and thirty five pregnant women and their children, 
were included in the analysis. Pregnant women were screened for gestational 
diabetes (GDM) between 24 and 28 weeks of gestation, and GDM was defined 
by the criteria proposed by Carpenter and Coustan. Weight, height, abdominal 
circumference, and thickness of triceps, subscapular, suprailiac, and subscapu-
lar were measured in 635 children at 18 months of age (59 offspring of mothers 
with gestational diabetes). Multivariable linear and logistic regression models 
were used to estimate the effect of GDM on the risk of adiposity in early child-
hood after adjusting for offspring sex, age, maternal education, and parity.
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Results: Offspring of mothers with gestational diabetes did not differ signifi-
cantly in BMI (beta coefficient: -0.20, 95% Confidence Intervals: -0.83-0.44), 
abdominal circumference (beta coefficient: 0.30, 95% Confidence Intervals: 
-0.65-1.25), or body fat percentage (beta coefficient: -0.27, 95% Confidence 
Intervals: -1.59-1.05) compared with offspring of non-diabetic mothers after 
adjustment for offspring sex, age, maternal education, and parity. Similarly, 
adiposity rates (BMI≥85th percentile-Odds ratio: 0.96; 95% Confidence In-
tervals:0.44-1.55 , abdominal circumference≥85th percentile-Odds ratio: 1.29; 
95% Confidence Intervals: 0.59-2.84, sum of skin folds >85th percentile-
Odds ratio: 1.14; 95% Confidence Intervals: 0.20-1.26, and percent body fat 
>85th percentile-Odds ratio: 0.95; 95% Confidence Intervals: 0.36-2.55) did 
not differ significantly between the two groups.
Conclusion: The study found no association between gestational diabetes 
and obesity in early childhood. These findings are consistent with the few 
other studies with adiposity measurements in early childhood. Further follow 
up of this cohort will allow determining if gestational diabetes has, an effect 
on obesity and cardiovascular risk in later childhood.
Supported by: the EU Integrated Project Chicos
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Body mass index and fasting glucose levels in a large cohort of patients 
assigned to age decades between <20 and >80 years - relationship with 
cardiovascular events and medication
A. Dzien1, C. Dzien-Bischinger1, E. Theurl2, H. Winner3, M. Lechleitner4; 
1Internal Medicine, Medical Center Hentschelhof, Innsbruck,  2Public 
Economics, University of Innsbruck, 3Economics and Social Sciences, 
University of Salzburg, 4Internal Medicine, Hospital Hochzirl, Zirl, Austria.
Background and aims: There is an ongoing debate about the relationship 
between obesity and morbidity in the elderly and the clinical relevance of 
overweight in older patients. The main purpose of our study was to investi-
gate whether a higher BMI is associated with an increase in fasting glucose 
levels and cardiovascular morbidity in all age groups.
Subjects and methods: We performed a retrospective evaluation of clinical 
data from 5374 patients who visited a medical outdoor center for diagnostic 
and/or therapeutic interventions in the period from January 1995 to Septem-
ber 2009. Patients were assigned to eight age groups of one decade from <20 
years to ≥80 years and results were analyzed with respect to the presence or 
absence of cardiovascular events and need for medication.
Results: The Body Mass Index (BMI) revealed a hump-shaped pattern, with a 
peak in the age group 60-69. In all age groups, there was a significant difference 
in the BMI in patients with and without a cardiovascular event. BMI and the 
percentage of body fat were higher in all patients with cardiovascular events. 
The fasting glucose values increased continuously in the patients without events 
from 85.7±15.9 mg/dL in the age group <20 to 115.6±40.4 mg/dL in patients ≥80 
years. In patients with events fasting glucose values increased up to 134.8±61.6 
mg/dL in the age group 40-49, and, probably because therapeutical interven-
tions were begun at that point, no further increase could be observed with in-
creasing age. The analysis of patients with and without a need for medication 
demonstrated that patients with a need for medication revealed higher fasting 
glucose levels in the age groups between <20 and 60-69 years. Fasting glucose 
values showed a continuous increase with increasing age with the highest values 
in the age group 70-79 in patients without medication (112.2±30.4 mg/dL) and 
in the age group ≥80 in patients with medication (115.1±41.6 mg/dL).
Conclusion: Our study supports the hypothesis that overweight is a risk fac-
tor not only for younger and middle-aged, but also for active elderly patients. 
Fasting glucose levels revealed a continuous increase up to the oldest age 
groups. Preventive strategies for type 2 diabetes should thus be offered for 
all age groups.
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Comparison of visceral adiposity and liver fat in 4277 individuals from 
an international cohort of patients classified according to their glucose 
tolerance status: the INSPIRE ME IAA Study 
J.-P. Després1, S.M. Haffner2, B.J. Balkau3, R. Ross4, N. Alméras1, INSPIRE 
ME IAA investigators; 
1Quebec Heart and Lung Institute, Quebec, Canada, 2Baylor College of 
Medicine, Houston, USA, 3INSERM Unit 1018, Villejuif, France, 4Queen’s 
University, Kingston, Canada.
Background and aims: Excess visceral adiposity and liver fat are well known 
correlates of metabolic abnormalities increasing the risk of type 2 diabetes 
(T2D) and cardiovascular disease. The first aim of the INSPIRE ME IAA 
study was to determine the relationships between visceral adiposity and liver 
fat measured by computed tomography (CT), related cardiometabolic risk 
markers and history of ischemic cardiovascular events and T2D.
Materials and methods: The INSPIRE ME IAA study (INternational Study 
of Prediction of Intra-abdominal adiposity and its RElationships with car-
dioMEtabolic risk/Intra-Abdominal Adiposity) is an international obser-
vational prospective study with a planned 3-yr follow up conducted in 29 
countries and involving 297 physicians. Physicians were either 1- hospital 
based primary care physicians and internists, 2- cardiologists or 3- endo-
crinologists/diabetologists with approximately 1/3 of each clinical practice 
group represented. Of the 4505 patients included in the study, 4277 had data 
available for the present analyses. Male outpatients were aged 40-70 years 
whereas female outpatients were aged 45-70 years. At baseline, demographic 
and clinical data were obtained as well as a cardiometabolic profile which in-
cluded a 75 g oral glucose tolerance test. Visceral adiposity and liver fat were 
measured by CT and all images were read centrally by a core imaging labora-
tory. The present analyses focus on the comparison of visceral adiposity/liver 
fat across subgroups of patients defined according to their glucose tolerance 
status: 1- normal (NGT), 2- impaired fasting glucose (IFG) or impaired glu-
cose tolerance (IGT), 3- controlled T2D (HbA1c<7%), 4- poorly controlled 
T2D (HbA1c≥7%). All comparisons across the 4 groups were adjusted for 
age, region and clinical practice group.
Results: Across the 4 groups with differing glucose control, there was a clear 
gradient for waist circumference with the lowest values found in NGT sub-
jects and the highest in poorly controlled T2D patients (p<0.001). Accord-
ingly, there was also a positive gradient for fasting triglyceride levels and a 
negative gradient for HDL-cholesterol, the lowest values being found in pa-
tients with poorly controlled T2D (p<0.005). There was also a progressive 
increase in visceral adiposity measured by CT from the NGT subjects to the 
poorly controlled patients with T2D (p<0.001). Mean attenuation value of 
the liver (used as an index of liver fat) also showed significant group differ-
ences (p<0.001). In men and women, significant correlations were observed 
between visceral adiposity and the CT-derived index of liver fat (r=-0.39 in 
men and r=-0.47 women, p<0.001).
Conclusion: INSPIRE ME IAA is the largest international study on visceral 
adiposity/liver fat and cardiometabolic risk profile. Analyses of the baseline 
data revealed marked differences in visceral adiposity/liver fat associated 
with glucose tolerance status. In both men and women, T2D diabetes is char-
acterized by high levels of visceral adipose tissue/liver fat. A strong associa-
tion between visceral adipose tissue and liver fat is found in both men and 
women. Excess visceral adiposity/liver fat is associated with a deteriorated 
cardiometabolic risk profile in patients with T2D.
Supported by: sanofi-aventis
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Variants in vitamin D genes are associated with liver density and 
non-alcoholic fatty liver disease (NAFLD) in Hispanics and African 
Americans: the IRAS Family Study
K.A. Young1, T.E. Fingerlin2, L.E. Wagenknecht3, C.D. Engelman4,  
S.M. Haffner5, C. Lorenzo5, Y.-D. Chen6, S.P. Sibbel2, J.M. Norris2; 
1Colorado School of Public Health, Aurora, 2Colorado School of Public 
School, Aurora, 3School of Medicine, Wake Forest Univesity, Winston-
Salem, 4School of Medicine and Public Health, University of Wisconsin, 
Madison, 5University of Texas Health Sciences Center, San Antonio, 6Cedars 
Sinai Medical Center, Los Angeles, USA.
Background and aims: NAFLD is a condition that may be involved in the 
pathogenesis of type 2 diabetes, obesity, and the metabolic syndrome. Given 
the association between these factors and vitamin D status, we examined 
whether vitamin D pathway genes are associated with NAFLD in Hispanic- 
(HA) and African-Americans (AA), two ethnicities at increased risk for obes-
ity, type 2 diabetes, and vitamin D deficiency.
Materials and methods: After eliminating 120 subjects with excessive alcohol 
intake, the IRAS Family Study examined 830 HA and 350 AA individuals from 
families in San Antonio, San Luis Valley and Los Angeles who had a computed 
tomography (CT) measure of the liver and visceral fat (VAT), and single-nucle-
otide polymorphism (SNP) data on VDR (15 SNPs), DBP (11 SNPs), CYP27B1 
(5 SNPs), CYP24A1 (22 SNPs), and CYP2R1 (3 SNPs) genes. The continuous 
outcome liver density was examined using a variance components approach, 
while the dichotomous outcome of NAFLD (liver:spleen density ratio < 1) 
was examined using generalized estimating equations (GEE); both analytic 
approaches account for the relatedness of the subjects. Additive models were 
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assumed for the SNPs. Models were adjusted for age, gender, admixture, and 
VAT. HA analyses were also adjusted for clinic site.
Results: In HA, mean age was 48.2 years, 63.4% were female, and mean VAT 
was 116.9 cm2. In AA, mean age was 49.8 years, 60.2% were female, and mean 
VAT was 103.3 cm2. 236 subjects were classified as having NAFLD (203 HA 
and 33 AA). CYP27B1 and CYP2R1 were not associated with liver density 
nor NAFLD in HA and AA. In HA, DBP and VDR were not associated with 
NAFLD, however, rs4334089 in VDR in was associated with liver density 
(p=0.027). In AA, while DBP and VDR were not associated with liver density, 
3 SNPs in DBP and 1 SNP in VDR were associated with NAFLD. In AA, each 
copy of the A allele at rs10783219 in VDR resulted in 3.70 greater odds of 
having NAFLD (95% CI: 1.03-14.29); and for DBP, each copy of the T allele at 
rs4752 resulted in 3.09 greater odds of NAFLD (95% CI:1.51-6.34); each copy 
of the C allele at rs222020 resulted in 1.89 greater odds of NAFLD (95%CI: 
1.08-3.33); and each copy of the G allele at rs10011000 resulted in1.96 greater 
odds of NAFLD (95% CI: 1.13-3.40). Several SNPs in CYP24A1were asso-
ciated with liver density in AA [rs2248359 (p=0.036), rs3787554 (p=0.023), 
rs4809960 (p=0.044), rs6022999 (p=0.016)] and in HA [rs3787555 (p=0.013), 
rs6068816 (p=0.002), rs6097809 (p=0.029), rs6127119 (p=0.039)]. In addi-
tion, SNPs rs3787557 in AA and rs6068816 in HA were significantly associ-
ated with NAFLD. In AA individuals, each copy of the C allele at rs3787557 
resulted in 2.60 greater odds of having NAFLD (95% CI: 1.33-5.07). In HA 
individuals, each copy of the C allele at rs6068816 resulted in 1.59 greater 
odds of having NAFLD (95% CI: 1.05-2.38).
Conclusion: In a two minority populations at increased risk for obesity and 
type 2 diabetes, variants in vitamin D pathway genes, particularly CYP24A1, 
are associated with liver density and NAFLD.
Supported by: American Heart Association 
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Using imputation to investigate association of low-frequency variants 
with adiposity in the 1966 Northern Finnish birth cohort
J.M. O’Connell1, S. Ripatti2, E. Zeggini3, L. Peltonen4, M.-R. Jarvelin5,  
M.I. McCarthy1, A.P. Morris1, C.M. Lindgren1; 
1Wellcome Trust Centre for Human Genetics, Oxford, United Kingdom, 
2University of Helsinki, FIMM Institute for Molecular Medicine, Helsinki, 
Finland, 3Wellcome Trust Sanger Institute, Cambridge, 4Deceased, 
Cambridge, 5Division of Epidemiology, Public Health and Primary Care, 
Imperial College London, United Kingdom.
Background and aims: Adiposity measures are known to be substantially 
heritable. While genome-wide association studies (GWAS) have identified 
over 20 common variants associatied with adiposity measures, less than 3% of 
the total heritability of adipose traits has been explained. One possible source 
of this missing heritablity is in low-frequency causal variants, say with minor 
allele frequency (MAF) <5%. Such variants pose several analytical challenges, 
due to a lack of statistical power for detecting association and their sparse 
availibility on current GWAS genotyping chips (by design). Here, we utilise 
genotype imputation and a novel statistical test of association to try and over-
come these challenges.
Materials and methods: Given a set of SNPs for some individuals, imputa-
tion allows us to estimate genotypes at untyped variants in each individual 
by utilising a combination of population reference panels and a fine-scale re-
combination map. The recent release of 1000 Genomes pilot data (and already 
available HapMap3 data) allows us to impute the majority of low-frequency 
variants with MAF as low as 1%, as well as many much rarer variants. Using 
this newly available data, we test for association of gene regions with adiposity 
measures by considering the proportion of low-frequency and rare variants 
per genomic region at which individuals carry minor alleles in a linear regres-
sion framework. This method offers improved power over the traditional tests 
of association typically applied to common variants. Using this framework, 
four different adiposity phenotypes were investigated in the 1966 Northern 
Finnish Birth Cohort (genotyped using the Illumina HumanCNV-370DUO 
chip). We examined variants with MAF of <5% for association with BMI, hip 
circumference (HC), waist circumference (WC) and waist to hip ratio (WHR). 
Additional covariates were included in the model to adjust for population 
structure as well as sex. Models were also fitted separately for each sex.
Results: Imputation allowed us to investigate 89 514 and 1 121 653 variants 
with MAF <1% and <5% respectively, as opposed to the original GWAS data 
which contained 14 119 and 28 470 variants. The strongest signal of associa-
tion over all genes and phenotypes was with WHR adjusted for BMI in males 
on a region of chromosome 7 (p=2.1x10-8, allelic effect β=-0.23 [-0.31, -0.15]). 
In addition to this, a total of nine genes demonstrated strong evidence of 
association (p<10-5) with the adiposity measures investigated. A further ten 
genes with nominal evidence of association (p<10-4), but with plausible bio-
logical roles in adiposity have been highlighted for further investigation. For 
example, three genes on chromosome 11; PNPLA2, RPLP2 and TSPN4, had 
p<10-4 and are all reported to be preferentially expressed in adipose tissue.
Conclusion: A number of novel possible adiposity associated genomic re-
gions have been identified for follow up. Many of the identified regions have 
previously been identified as having plausible biological roles in adiposity and 
these regions are currently being sequenced in individuals at the extremes of 
the phenotypes.
Supported by: WT
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MC4R gene variant rs17782313 (C/T) is associated with increased muscle 
mass in lean women
O. Bradnova1,2, M. Vankova1, P. Lukasova1, J. Vcelak1, H. Kvasnickova1,  
K. Vondra1, J. Vrbikova1, B. Bendlova1; 
1Molecular Endocrinology, Institute of Endocrinology, 2Dep. of 
Anthropology and Human Genetics, Charles University, Prague, Czech 
Republic.
Background and aims: Melanocortin-4 receptor (MC4R) plays a critical 
role in regulating food intake and energy balance. MC4R activation in brain 
reduces food intake and increases energy expenditure via leptin signaling. 
MC4R deficiency is the most common form of monogenic obesity. Recently, 
the meta-analysis of 15 genome-wide association studies strongly confirmed 
the association of the common polymorphism rs17782313 lying 188 kb 
downstream of the MC4R gene with body mass index (BMI) and obesity risk 
in adults and children. We examined the impact of the rs17782313 (C/T) on 
obesity in cohort of Czech women and studied its possible metabolic effects.
Materials and methods: Polymorphism was assesed by ABI TaqMan SNP 
Genotyping Assay in 951 non-diabetic normoglycaemic women: 128 
lean (age 26.4±5.86 years; BMI 18.9±0.92 kg/m²), 409 normal weight (age 
30.4±9.84 years; BMI 22.3±1.38 kg/m²), 208 overweight (age 37.8±13.65 
years; BMI 27.3±1.39 kg/m²) and 206 obese women (age 38.6±13.86 years; 
BMI 34.9±4.11 kg/m²). All women were detailed anthropometrically and bi-
ochemically characterized including oGTT and ITT tests. For statistical anal-
yses the Mann-Whitney test and Chi-square test were used (NCSS 2004).
Results: Genotypes were in Hardy-Weinberg equilibrium. The allelic fre-
quencies did not differ among groups (risk minor C allele: lean 33.2%; nor-
mal 27.3%; overweight 26.9%; obese 29.1%). The frequency of the minor al-
lele corresponds to the other European populations. In the whole group of 
pooled women (age 30.5±9.28 years; BMI 24.9±5.54 kg/m²), the carriers of 
the minor C allele (CC+CT) did not differ in BMI in comparison with non-
carriers (TT) and surprisingly, they had significantly lower WHR (0.82 vs. 
0.84, p=0.046) and waist circumference (73.8 vs. 75.9 cm, p=0.035) and high-
er serum creatinine level (69.9 vs. 66.9 umol/L, p=0.005). These effects were 
most apparent in the subgroup of lean women with BMI<20 kg/m2 where the 
C allele carriers had significantly lower WHR (0.78 vs 0.82, p=0,001), waist 
(65.6 vs. 66.9 cm, p=0.02) and abdominal circumference (69.5 vs. 74.9 cm, 
p=0.008), higher % of muscle mass (41.3 vs. 39.1, p=0.0001) and higher cre-
atinine levels (73.4 vs. 64.2 umol/L, p=0.02). In the sugroup of obese women 
with BMI > 30 kg/m2, the association of the C allele with anthropometric 
parameters was not found, but the C allele carriers tend to be more obese and 
had also increased creatinine levels compared to non-carriers (69.8 vs. 61.9 
umol/L, p=0.01).
Conclusion: We did not confirm the association of rs17782313 with obesity 
in our cohort of women. However, the C allele carriership was associated 
with increased creatinine levels and increased % of muscle mass, especially 
in lean women.
Supported by: IGA MHCR NS/9839-4, NS 10209-3/2009
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The effect of birth weight on obesity is not modified by FTO rs9939609
K. Færch1, K. Pilgaard1, E.A. Andersson2, M.N. Harder2, D.R. Witte1, C. 
Pisinger3, T. Jørgensen3,4, O. Pedersen2, T. Hansen2, A.A. Vaag1; 
1Steno Diabetes Center, Gentofte, 2Hagedorn Research Institute, Gentofte, 
3Research Centre for Prevention and Health, Glostrup, 4Faculty of Health 
Sciences, University of Copenhagen, Denmark.
Background and aims: Increased birth weight and the A allele of FTO 
rs9939609 are both associated with adult obesity. However, it is unknown 
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whether the effects of birth weight and FTO variation are additive or whether 
the FTO risk variant modifies the effect of birth weight on adult obesity. Thus, 
the aim of this study was to examine whether there is an interaction between 
birth weight and the FTO rs9939609 on the development of adult obesity.
Materials and methods: Baseline data from the Danish population-based In-
ter99 study were used. Birth weight data on 4,584 participants (all singletons) 
were collected through midwife journals from the Danish State Archives. The 
FTO rs9939609 was genotyped using KASPar® technology (n=4,371). Obesity 
was assessed by body mass index (BMI). Age- and sex-adjusted linear regres-
sion analyses with BMI as outcome were performed. Model 1 allowed for 
interaction between birth weight and FTO rs9939609, whereas model 2 only 
included main effects of birth weight and FTO rs9939609.
Results: Mean BMI in the population was 26.11 kg/m2 (SD: 4.5), mean age 
was 46.3 years (SD: 7.9), and 46.5% were men. There was no interaction be-
tween birth weight and the FTO rs9939609 variant on adult BMI (P=0.23, 
model 1), but both birth weight and FTO rs9939609 were independently as-
sociated with adult BMI in model 2. One kg increase in birth weight was 
associated with an increase in adult BMI of 0.46 kg/m2 (95% CI: 0.20-0.71, 
P<0.001). Likewise, the A allele of FTO rs9939609 was associated with an 
increase in BMI of 0.49 kg/m2 (95% CI: 0.30-0.68) per risk allele (P<0.001) 
assuming an additive genetic model.
Conclusion: The effect of birth weight on obesity in adult life is not modified 
by the FTO rs9939609 variant in the Danish population. Thus, FTO variation 
and birth weight contribute independently to adult obesity.
Supported by: Danish Medical Research Council, Danish Centre for Health 
Tech. Ass. etc.
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GIP receptor polymorphism rs10423928 affects body mass index and 
insulin and glucagon response after ingestion of glucose or mixed meals 
in Japanese
D. Yabe, K. Watanabe, Y. Kitamoto, K. Sugizaki, K. Sugawara, M. Hishizawa, 
T. Hyo, T. Kurose, Y. Seino; 
Division of Diabetes, Clinical Nutrition and Endocrinology, Kansai Electric 
Power Hospital, Osaka, Japan.
Background and aims: GIP enhances insulin and glucagon secretion, and 
regulates fat deposition and bone formation through binding to GIP receptor 
(GIPR). Recent study showed an association of a single nucleotide polymor-
phism (SNP) in the human GIPR gene, rs10423928 with elevated post-chal-
lenge plasma glucose levels. To evaluate effects of this SNP, as well as SNPs 
in KCNQ1 and TCF7L2, on secretion of insulin and glucagon, we measured 
levels of insulin, glucagon and glucose in response to ingestion of glucose or 
mixed meal in Japanese untreated type 2 diabetes (T2DM), impaired glucose 
tolerance (IGT) and healthy controls.
Materials and methods: Japanese healthy controls (n=33, age 46±;2, HbA1c 
5.2 ±;0.0%, BMI 21.6±;0.5), IGT (n=24, age 56±;2, HbA1c 5.9±;0.3%, BMI 
23.7±;0.5) and untreated T2DM (n=22, age 58±;2, HbA1c 6.3±;0.1%, BMI 
23.3±;0.4; duration 1.9±;0.4 years) were subjected to 75-g oral glucose and 
480-kcal meal tolerance tests (OGTT and MTT, respectively) and their glu-
cose, insulin and glucagon levels were measured. SNPs were genotyped by an 
allele-specific primer PCR method using peripheral leukocyte DNA of each 
subject.
Results: Allele frequencies of SNPs in each group were as follows: GIPR 
rs10423928 Controls, AA 0.2/AT0.3/TT0.5; IGT, AA0/AT0.3/TT0.7; T2DM, 
AA0/AT0.4/TT0.6; KCNQ1 rs2237892 Controls, CC0.4/CT0.4/TT0.1; IGT, 
CC0.4/CT0.4/TT0.2; T2DM, CC0.4/CT0.4/TT0.2; TCF7L2 rs7903146 Con-
trols, CC0.9/CT0.1/TT0; IGT, CC0.9/CT0.1/TT0; T2DM, CC0.9/CT0.1/TT0. 
Parameters that are significantly different (unpaired t-test, p<0.05) between 
GIPR rs10423928 AA- and TT-carriers are as follows (Figure 1): BMI, glu-
cose-AUC(0-120) in OGTT and MTT, and glucagon-AUC(0-120)in OGTT 
and MTT. Parameters related to insulin secretion (i.e. insulinogenic index, 
insulin-AUC(0-120), HOMA-beta) and insulin resistance (i.e. HOMA-IR) 
show no significant difference between AA- and TT-carriers, although insu-
lin-AUC(0-120) in OGTT and MTT showed significance difference between 
AT- and TT-carriers. No parameter related to insulin and glucagon secretion 
shows significant difference among KCNQ1 rs2237892 CC-, CT- and TT-car-
riers. No parameter shows significant difference between TCF7L2 rs7903146 
CC- and CT-carriers.
Conclusion: GIPR rs10423928 AA-carriers have significantly lower BMI, re-
duced glucagon secretion, and lower plasma glucose levels after ingestion of 
glucose or meal. In addition, GIPR rs10423928 also affects insulin secretion 
after ingestion of glucose or meal. Notably, no GIPR rs10423928 AA-car-
rier was found in IGT and T2DM of the current study. Although the subject 
number in the current study is limited, our results are consistent with roles of 
GIP in secretion of glucagon and insulin and fat accumulation, and strongly 
suggests that GIP dysfunction could play a role in pathogenesis of T2DM.
Supported by: Japan Diabetes Foundation, Diabetes Masters Conference
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Replication initiator 1 gene (Repin1) is involved in the pathophysiology 
of human obesity
K. Dietrich1, M. Kern2, D. Schleinitz1, J. Breitfeld1, I. Mueller1,2, B. Enigk1,  
J. Kosacka2, A. Toenjes2, M. Stumvoll2, M. Blueher2, P. Kovacs1, N. Kloeting2; 
1Interdisciplinary Centre for Clinical Research, 2Department of Medicine, 
University of Leipzig, Germany.
Background and aims: The replication initiator 1 gene (Repin1) maps within 
a quantitative trait locus for obesity and is related to dyslipidemia in subcon-
genic rat strains. Here, we investigated the role of Repin1 in the pathophysiol-
ogy of human obesity.
Materials and methods: Repin1 mRNA expression was measured in intraab-
dominal visceral (Vis) and abdominal subcutaneous (Sc) adipose tissue in 
196 individuals with a wide range of metabolic phenotypes using RT-PCR 
(TaqMan, Applied Biosystems, Inc.). The Repin1 was sequenced (exons, exon-
intron boundaries, 5´and 3´ UTRs) in DNA samples from 48 non-related 
Caucasian subjects to identify genetic variants. 18 variants were identified, 
including a 12 bp deletion in exon four resulting in a final protein missing 
four amino acids (rs3832490; P356_A359del). The deletion and nine single 
nucleotide polymorphisms (SNPs) including six HapMap (www.hapmap.org) 
tagging SNPs representing their linkage disequilibrium groups were geno-
typed for subsequent association studies in two independent cohorts with 
detailed metabolic testing: German Caucasians from Leipzig (N=2194; mean 
age 56±15 years) and a self-contained population of Sorbs from Germany 
(N=1046; 48±16 years), totalling 3240 subjects. TaqMan assays were used for 
SNP genotyping and restriction fragment length polymorphism (RFLP) tech-
nique for the deletion.
Results: We found significant correlations between Repin1 mRNA expres-
sion in human Vis and Sc adipose tissue and total body fat mass as well as 
adipocyte size, suggesting Repin1 as novel candidate gene for human obesity 
and related traits. In a case control study including 1018 subjects with type 2 
diabetes (T2D) vs. 616 subjects with normal glucose tolerance (NGT), three 
SNPs (rs3735170, rs10278590, rs1051760) were significantly associated with 
T2D (P<0.05 after adjusting for age, sex and BMI) in the Leipzig cohort. In 
subjects with NGT, rs4725336 was significantly associated with cholesterol, 
rs9640161 with HbA1c, and rs3832490 (P356_A359del) with % body fat and 
2 hr glucose (adjusted P<0.05). In the self-contained population of the Sorbs, 
rs4725336 showed association with obesity in a case control study including 
397 obese (BMI>30 kg/m2) vs. 234 lean (BMI<25 kg/m2) subjects (adjusted 
P<0.05). Consistent with results from the Leipzig cohort, rs3832490 (P356_
A359del) was moderately associated with % body fat in Sorbian subjects with 
NGT (N=835) and rs6971465 correlated with cholesterol and LDL-choles-
terol (adjusted P<0.05).
Conclusion: Correlation of mRNA expression in adipose tissue with obesity 
as well as the association of Repin1 genetic variants with T2D, obesity and 
relevant metabolic traits suggest a potential role of Repin1 in the pathophysi-
ology of human obesity.
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Estimate of incidence and prevalence of type 1 diabetes using electronic 
drug prescription archives
M. Maggini1, R. Da Cas1, C. Lunghi2, F. Pricci3; 
1Epidemiology, National Institute of Health, Roma, 2ProtEra, Sesto 
Fiorentino, 3Cell Biology, National Institute of Health, Roma, Italy.
Background and aims: A very wide range of childhood diabetes incidence 
rates within Europe has been shown, but no recent data are available in Italy. 
Type 1 diabetes features are that is usually diagnosed in children and young 
adults, and causes dependence on insulin treatment for life. On the other 
hand, diabetes is the only indication for insulin therapy. Aim of this study was 
to estimate incidence and prevalence of type 1 diabetes among people 0-15 
years old in the Lazio Region in the period 2005-2008, and to describe the in-
sulin prescription pattern, using a record linkage between drug prescription 
and National Health Service (NHS) enrollee electronic archives.
Materials and methods: The Italian NHS provides antidiabetic drugs free of 
charge to all citizens. Data on outpatient antidiabetic drug use were obtained 
from the Regional drug prescription monitoring database for the period 
2005-2008. Data on characteristics of population exposed to the study drugs 
were derived from Lazio (about 6 millions inhabitants) database of NHS en-
rollees, which contains demographic data of residents. The two databases can 
be linked by a unique individual code allowing to trace back an hystorical 
patient drug profile. Patients were considered as “prevalent” cases if they re-
ceived insulin (ATC A10A - insulins and analogs) prescriptions during the 
study period. “Incident” case was defined as a patient who received the first 
insulin prescription in the period 2006-2008, without any antidiabetic pre-
scription in the previous 12 months. The date of the first insulin prescription 
was used as date of diagnosis.
Results: An annual mean of 692 type 1 diabetes cases were identified in 
the four-year study period. The prevalence of diagnosed type 1 diabetes in-
creased from 81 (CI 95% 74-87) per 100,000 inhabitants in 2005 to 91 (CI 
95% 84-97) in 2008 with no evidence of a difference between boys and girls. 
The prevalence rates increase with age, in 2008 they were 20 per 100,000 (CI 
95% 11-28) for children aged 1-3 years, and 173 (CI 95% 156-191) for 12-15 
years. A total of 469 incident cases were identified from 2006 through 2008. 
The cumulative incidence varied from 21 (CI 95% 17-24) per 100,000 in 2006 
to 17 (CI 95% 14-19) in 2008. At the first prescription, the majority of chil-
dren received rapid-acting human insulin and analogs. Overall, with respect 
to 2005 there was a shifting of prescriptions to long-acting insulin.
Conclusion: The estimated incidence is quite higher from that previously re-
ported for Lazio: 8.1 per 100,000 in the period 1993-94. Our study shows a 
limited increase in the prevalence rates of diagnosed type 1 diabetes among 
children 0-15 years from 2005 through 2008. However, the study period was 
too short to investigate a time trend in incidence and prevalence. Complete-
ness of ascertainment is being evaluated through a validation procedure with 
the data of one of the most important diabetic centre of the Region. The use of 
routinely collected data to estimate incidence and prevalence of type 1 diabe-
tes, and to identify cohorts of patients, may represent an alternative to other 
costly and time consuming methods.
337
Increasing incidence of childhood onset type 1 diabetes in Norway 
T. Skrivarhaug1, L.C.M. Stene2, H. Strøm2, A.K. Drivvoll1, P.R. Njølstad3,  
G. Joner1, The Norwegian Childhood Diabetes Study Group; 
1Dept of Pediatrics, Oslo University Hospital, Ulleval, 2Division of 
Epidemiology, Norwegian Institute of Public Health, Oslo, 3Dept of 
Pediatrics, Haukeland University Hospital, Bergen, Norway.
Background and aims: There is a worldwide increase of type 1 diabetes 
(T1DM). In 1989, the Norwegian population-based childhood diabetes reg-
ister was initiated including all newly diagnosed children aged 0-14 years 
with diabetes. All 26 paediatric departments in Norway reports new cases of 
childhood diabetes to The Norwegian Childhood Diabetes Register based on 
informed consent from the child and/or parents. Since 2004 the Prescription 
Database (NorPD) at the National Institute of Public Health has registered 
all drug prescription in Norway, including insulin. Data published by the 
authors previously showed a clear increasing trend during the period 1973 - 
2003 with IR moving from 19.1/105 in 1973 to 28.9/105 in 2001-2003. The aim 
of the study was to determine the incidence of T1DM in children 0-14 years 
in Norway during 2005-2008, and to calculate the ascertainment in the na-
tionwide Norwegian Childhood Diabetes Register during the same period.
Materials and methods: During the study period 2005-2008,1232 new cases 
of childhood onset diabetes were registered by The Norwegian Childhood 
Diabetes Register. Of these, 1144 were classified as T1DM and were below 15 
years at onset. Information on individual insulin prescriptions was obtained 
from The Prescription Database, and the first prescription of insulin 2004-
2008 was registered and assumed to be at a date close to onset of T1DM. 
Consequently, “new cases” in the NorPD could only be defined for the years 
2005-2008. The assumption of source independence and equal probability of 
capture of each case by these two sources is verifiable. This is the first time 
these two registries are linked with the purpose to give information about 
incidence of childhood T1DM and completeness of The Norwegian Child-
hood Diabetes Register.
Results: In the period 2005-2008, the uncorrected incidence rate of T1DM 
0-14 years was 32.4 /105/year for both sexes, for boys 34.1*105 and for girls 
30.9*105, which indicates an steadily increasing trend compared to previously 
published incidence rates. The Prescription Database contained data on first 
time insulin prescriptions in 115 subjects, not reported to the diabetes reg-
ister and the completeness is calculated to 92 % for the whole study period 
which is appropriate according to the criteria for entering national data into 
the EURODIAB study.
Conclusion: The incidence of type 1 diabetes has further increased in Nor-
way as in many other European countries. The incidence has been studied na-
tionwide since 1989 and the completeness of registration of new cases can be 
documented to be 90-95% % in all periods with obligatory signed informed 
consent forms from all patients.
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The influence of birth cohort on the incidence of childhood type 1 
diabetes in Wales
J.N. Harvey1, R. Hibbs1, H. O’Connell2, J.W. Gregory2, on behalf of the 
Brecon Group; 
1Centre for Endocrinology & Diabetes, Wales College of Medicine, 
Wrexham, 2Paediatrics, Wales College of Medicine, Cardiff, United 
Kingdom.
Background: It is suggested that type 1 diabetes (T1DM) occurs when ge-
netically susceptible individuals experience a viral infection in the period 
preceding diagnosis: a period effect. There is also evidence that perinatal 
factors influence the incidence of T1DM in childhood. Systematic change in 
these would produce a birth cohort effect meaning an effect from being born 
at a particular time or having shared experience with those born at the same 
time.
Aims: To examine the influence of period and birth cohort on the incidence 
of T1DM in children aged <15y in Wales from 1995-2008.
Materials and methods: Information on 2046 cases diagnosed with T1DM 
from 1995-2008 was obtained prospectively from all paediatric units in 
Wales. Ascertainment was >95% in each calendar year to 2006.
Results: The overall increase in incidence (poisson regression modelling) as-
suming continuous linear growth was 1.9% per annum (residual deviance 
0.84, p<0.001) but best fit was obtained with a model showing no further 
increase in incidence rate since 2000 (residual deviance <0.7, p<0.001) with 
no further increase in cases before age 5. The current annual incidence rate 
is 28 cases per 100,000 children. Modelling the influence of birth cohort sug-
gests an effect of approx 1.5 on incidence rate when birth cohorts since 1985 
are compared with 1980-84 and that this effect has not increased since 1985. 
Adding period effect produces a less good model (residual deviance 1.27, 
p<0.001) but indicates that an increasing period effect is counterbalanced by 
a reducing birth cohort effect.
Conclusion: The incidence rate of T1DM has not increased in Wales since 
2000. Birth cohort effects have more influence than period effects and the 
absence of any continuing increase in birth cohort effect in Wales is a major 
influence on the incidence rate. Perinatal factors therefore require further 
investigation. Differences in the relative contribution of birth cohort and pe-
riod effects on incidence compared to other nations may explain the current 
plateau in incidence in Wales.
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Incidence of childhood and youth type 1 diabetes in La Palma Island 
1993-2009
B.M. Belinchón1, J.A. Hdez.-Bayo2, S. Vázquez Dieguez3; 
1Family Care, S/C La Palma, 2Endocrinology, General Hospital of La Palma, 
Breña Alta, 3Pediatrics, General Hospital of La Palma, Breña Alta, Spain.
Background and aims: The incidence of type 1 diabetes shows wide geo-
graphical variability and heterogeneity. The aim of this study was to deter-
mine the incidence of type 1 diabetes in children and young people younger 
than 30 yr in La Palma Island (the most northwest of Canary Islands, Spain: 
730 Km2, 85000 habitants and subtropical climate).
Materials and methods: All subjects with type 1 diabetes (according WHO 
and/or ADA criteria) diagnosed between January 1993 and December 2009 
(prospectively 1995-2009) were included. The population at risk (0-29 yr) 
fluctuated between 36419 habitants (15711 habitants younger than 15 yr) 
-1991 General Census- and 29620 (11899 habitants younger than 15 yr) -
2001 General Census-. All the reported cases were on insulin treatment. All 
subjects were living in La Palma Island at least six months before diagnosis 
of type 1 diabetes. Using the capture-recapture method (primary source was 
hospital records, while secondary sources were membership files of La Palma 
Diabetic Association and Primary Care Physicians), the ascertainment was 
100 %. The incidence rates were expressed as number of cases per 105 habit-
ants per year. The 95% Confidence Intervals were estimated assuming the 
Poisson distribution of the cases. The age adjustment for the rates was done 
using the direct method with a World and European Standard Population.
Results: 113 subjects younger than 30 yr had presented type 1 diabetes at the 
last 17 yr (64 boys, 49 girls; medium age: 13±7.6 yr). The annual incidence 
fluctuates between 5.8 and 33.7/105, being the average annual incidence 
20.8/105 (95% CI: 18.6-23; 34/105 in the 0-14 yr group, CI 95%: 31.2-36.8; 
11.6/105 in the 15-29 yr group, CI 95%: 10-13.2) without sex differences 
(21.4/105 per yr in boys versus 17.3/105 per yr in girls). The incidence was 
higher in the 5-9 yr age-group (39.6/105 per yr), followed by the 10-14 yr 
age-group (38.4/105 per yr), the 0-4 yr age-group (21.9/105 per yr), the 25-29 
yr age-group (13/105 per yr), the 15-19 yr age-group (12.8/105 per yr) and 
the 20-24 yr age-group (9/105 per yr). The age-adjusted incidence to World 
Standard Population was 23.1/105 per yr (95% CI: 20.8-25.4; 32.4/105 in the 
0-14 yr group, 11.6/105 in the 15-29 yr group]. The age-adjusted incidence 
to European Standard Population was 22.4/105 per yr (95% CI: 20.2-24.6; 
32.8/105.in the 0-14 yr group, 11.6/105 in the 15-25 yr group).
Conclusion: The incidence of type 1 diabetes in La Palma Island is the high-
est reported up to date in a Spanish community, and is close to the highest 
of the world. It is inconsistent with the hypothesis of a north-south gradient 
in diabetes risk. The knowledge of the incidence rates in La Palma Island can 
contribute to study the role that genetics and environmental factors may play 
in these differences.
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Prospective nation wide registration of type 1 diabetes incidence in 0-34 
years old during 25 years - a shift to younger age at diagnosis
G.G. Dahlquist1, L. Nyström2, C.C. Patterson3, Swedish Childhood Diabetes 
Study Group and Diabetes Incidence in Sweden Study Group; 
1Clinical Science, Pediatrics, Umeå university, 2Public Health and Clinical 
Medicine, Epidemiology, Umeå University, Sweden, 3Department of 
Epidemiology and Public Health, Queen’s University, Belfast, United 
Kingdom.
Background and aims: To clarify if the increase in childhood type1 diabetes 
is mirrored by a decrease in older age groups on a birth cohort basis and to 
test the hypothesis that autoimmune diabetes shifted to younger age at onset. 
To test if cohort effects dominated over calendar period effects.
Materials and methods: The data base included 20 249 individuals with 
diabetes onset 1983 to 2007 combining data from two prospective research 
registers, the Swedish Childhood Diabetes Register including cases 0-14.9 
years at onset and the Diabetes in Sweden Study including cases 15-34.9 years 
at onset. Incidence rates over time were analyzed using Poisson regression 
models.
Results: The overall yearly incidence rose to a peak of 42.3 per 100000 in 
males10-14 years and of 37.1 in females 5-9 years age group and decreased 
thereafter with increasing age. There was a significant increase by calendar 
year in both sexes in the three under 15 years’ age groups but decreases in the 
older age groups with significant decreases in the two age groups over 25.A 
cohort effect dominated over the time period effect.
Conclusion: Twenty-five years of prospective nationwide incidence registra-
tion demonstrates a clear shift to younger age at onset rather than a uniform 
increase in incidence rate across all age-groups. Exposures that affect young 
children more than older children and adults and accelerates disease onset 
may be responsible.
Supported by: Swedish Research Council
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Ethnic differences in incidence rates of childhood type 1 diabetes in 
Yorkshire 1978-2007
K. Harron1, P.A. McKinney1, R.G. Feltbower1, C.R. Stephenson1,  
P.D. Norman2, H.J. Bodansky3, G. Chhokar4, R.C. Parslow1; 
1Paediatric Epidemiology Group, University of Leeds, 2School of Geography, 
University of Leeds, 3Leeds General Infirmary, 4St. James University Hospital, 
Leeds, United Kingdom.
Aims: To examine incidence rates and trends of childhood Type 1 diabetes in 
Yorkshire from 1978-2007.
Materials and methods: Data from the population-based Yorkshire Register 
of Diabetes in Children and Young People was used to analyse the incidence 
of Type 1 diabetes in children aged <15 years diagnosed in the former York-
shire Regional Health Authority. Incidence rates (per 100,000 per year) were 
estimated using mid-year population estimates stratified by sex, age and eth-
nicity: south Asian (Indian, Pakistani, Bangladeshi) or non-south Asian (all 
other ethnicities). Ethnicity was assigned using two name recognition pro-
grams (Nam Pehchan and SANGRA) and a local expert. Age-sex standard-
ised rates were calculated between 1978-2007 and by ethnic-group between 
1990-2007. Poisson regression was used to assess incidence trends and esti-
mate predicted rates up to 2020. Goodness-of-fit, AIC and likelihood-ratio 
tests were used to assess model fit.
Results: 3911 children were diagnosed in Yorkshire between 1978-2007. 
Overall incidence was 18.1 (17.6-18.7) and lowest among 0-4 year-olds com-
pared to 5-9 and 10-14 year-olds: 11.7 (95% CI 10.9-12.5), 18.6 (17.6-19.6) and 
23.7 (22.6-24.8) respectively. Incidence increased significantly over time with 
an average annual percentage change (AAPC) of 2.9% (2.5-3.2). The AAPC 
differed slightly between age-groups - 0-4: 2.6% (1.7-3.4), 5-9: 3.2% (2.6-3.8) 
and 10-14 years: 2.8% (2.2-3.3). The inclusion of an age-sex interaction term 
provided evidence for differences in trends between sexes depending on age, 
with females having higher incidence and AAPC than males for those aged 5-
9. Incidence for non-south Asians (21.6 (20.7-22.4)) was significantly higher 
than that of south Asians (14.7 (12.4-17.1)) over the entire study period. A 
significant increasing trend in incidence was observed for non-south Asians 
of 3.4% (2.7-4.2) compared to a non-significant trend seen in south Asians 
(1.5% (-1.5, 4.5)). Overall forecasted incidence for 2020 is 38.8.
Conclusion: Type 1 diabetes incidence rates have continually risen over the 
last three decades for non-south Asians of all ages but not for south Asians, 
whose families come from a low incidence area. This is contrary to findings 
in the Bradford area of Yorkshire between 1978-1998. Overall incidence in-
creased most quickly in the 5-9 age-group. Incidence doubled from 12.5 to 
25.6 between 1978-2007. If current trends continue, rates will rise by 52% to 
38.8 between 2007-2020.
Supported by: NHS Diabetes, HCQIP
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Long-term mortality and causes of death among patients with type 1 
diabetes in Japan
A. Morimoto, R. Nishimura, H. Sano, T. Matsudaira, N. Tajima,  
K. Utsunomiya; 
Division of Diabetes, Metabolism and Endocrinology, Department of 
Internal Medicine, Jikei University School of Medicine, Tokyo, Japan.
Aims: To investigate long-term prognosis including causes of death among 
patients with type 1 diabetes in Japan.
Methods: A total of 1,387 patients (556 males and 831 females) were reg-
istered from two nationwide type 1 diabetes surveys in Japan. They were 
diagnosed as type 1 diabetes at less than 18 years of age between 1965 and 
1979. All patients were tracked for survival status until January 1, 2005, with 
this status determined based on the questionnaires sent to their attending 
physicians or the residents’ records. Causes of death were identified through 
questionnaires or death certificates. Their survival status as of January 1, 2005 
was expressed in terms of standardized mortality ratio (SMR) and crude 
mortality rate (CMR). Mortality was compared between the male and female 
patients by using the Cox proportional-hazards model. The causes of death 
for deceased cases were divided into 9 groups (1. diabetic renal disease; 2. 
acute diabetic complications; 3. accident/suicide; 4. cardiovascular disease; 5. 
infections; 6. malignant neoplasms; 7. other non-diabetic causes; 8. other dia-
betic causes; 9. unknown) and were also compared by duration of diabetes. 
Statistical analyses were performed by using SAS 9.1.
Results: The mean age at diagnosis was 8.8 ± 4.1 (SD) years, with a duration 
of diabetes of 27.9 ± 6.4 years. One thousand one hundred and three patients 
were confirmed as alive as of January 1, 2005, and 223 deaths (16.1%) were 
observed (confirmation rate: 95.6%). The SMR was 10.6 (males, 9.6; females 
14.3), and the CMR was 658/100,000 person-years (males, 778; females, 
579). The male patients were shown to be at 1.37-fold higher mortality risk 
compared to the female patients (95% CI, 1.02-1.85). The causes of death 
identified included diabetic renal disease (51 patients; 22.9%), cardiovascu-
lar disease (40; 17.9%), acute diabetic complications (38; 17.0%), infections 
(34; 15.3%), accidents and suicides (21; 9.4%), unknown cause (18; 8.1%), 
other non-diabetic causes (13; 5.8%), other diabetic causes (6; 2.7%), and 
malignant neoplasms (2; 0.9%). Leading causes of death included acute dia-
betic complications among those with less than 10 years’ duration of disease, 
diabetic renal disease among those with 10 to 20 years’ duration, infections 
among those with 20 to 30 years’ duration, and cardiovascular disease among 
those with 30 to 40 years’ duration. Thus, the longer the duration of disease, 
the less the mortality from acute diabetic complications, and the greater the 
mortality from cardiovascular disease. The time from the initiation of dialysis 
to death was shown to be 5.5 ± 4.8 years in 89 patients who were confirmed to 
have been dead after initiation of dialysis.
Conclusion: The mortality risk of patients diagnosed as type 1 diabetes be-
tween 1965 and 1979 in Japan was shown to be 10.6-fold higher than that 
of the general population. The males were found to be at 1.37-fold higher 
mortality risk than the females. Diabetic renal disease, cardiovascular dis-
ease and acute diabetic complications were found to be the leading causes 
of death. However, as the duration of disease became longer, acute diabetic 
complications contributed less and cardiovascular disease contributed more 
to mortality.
Supported by: NIH, Health Science Research Grant (Japan), Ministry of Educa-
tion
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First trimester cytokine levels in mothers to children diagnosed with islet 
autoimmunity or type 1 diabetes before eight years of age
S.R. Resic Lindehammer1, M. Fex1, K. Marsal2, Å. Lernmark1; 
1Diabetes and Celiac Disease, Clinical Sciences, Malmoe, 2Department of 
Obstetrics and Gynecology, Clinical Sciences, Lund, Sweden.
Background and aims: Gestational infections and/or stress have with con-
flicting results been associated with an increased type 1 diabetes risk in off-
spring. Using multi-array analysis of cytokines, we tested whether Th1/Th2 
cytokines during the first trimester were different between mothers who gave 
birth to children who developed islet autoimmunity at 1-8 years of age and 
matched control mothers.
Materials and methods: First trimester serum samples were analyzed for 
IFNγ, IL-10, IL-12, IL-13, IL-1β, IL-2, IL-4, IL-5, IL-8 and TNFα using the 
Meso-Scale Multi-Array system (MesoScale, Gaithersburg, Maryland). We 
compared 53 non-diabetic mothers who gave birth to a child who developed 
at least two islet autoantibodies against either GAD65, IA-2 or insulin with 
increasing levels at the second, third, fourth or fifth year of follow-up (a to-
tal of 40 children developed type 1 diabetes before 8 years of age) with 106 
non-diabetic control mothers which were matched by age, HLA genotype as 
well as first trimester sampling date. The mothers included in this study are 
participating in the Skåne Diabetes Prediction Study (DiPiS). In 2000-2004, 
DiPiS recorded 48 058 live births with the aim to determine etiology indica-
tors of type 1 diabetes. Blood samples (both mothers serum and cord blood) 
were obtained at the time of delivery in 75% of the 48 058 recorded live births, 
and first trimester samples (10-16 gestational weeks) were available from the 
Southern Sweden Microbiological biobank for the non-diabetic mothers in-
cluded in this part of the study.
Results: The median of IFNγ (p=0.02) and IL-1β (p=0.04) levels were signifi-
cantly higher in the index mothers compared to the matched controls. The 
mean length of gestation in the index mothers was 275 days compared to 280 
days in control mothers (p=0.04). The shortened gestational length was not 
related to the IFNγ or IL-1β levels. However, the gestational length in index 
but not control mothers was significantly correlated to IL-10 (p=0.03), IL-12 
(p=0.01), IL-13 (p=0.04), IL-2 (p=0.04) and IL-5 (p=0.008).
Conclusion: This study revealed that 1) index mothers had elevated Th1 me-
diated cytokines (IFNγ and IL-1β) during the first trimester; 2) gestational 
length was significantly shortened in the index mothers; and that 3) several 
Th2 mediated cytokines were inversely related to the gestational length in the 
index but not in the control mothers, in first trimester samples. We therefore 
conclude that an increase in Th1 cytokine levels during the first trimester 
may signify gestational infection or stress. Furthermore, we conclude that 
Th2 cytokines may affect gestational length. In summary, these aberrations 
may contribute to an increased risk for islet autoimmunity and subsequent 
development of type 1 diabetes in the offspring.
Supported by: an EFSD Clinical Research Grant
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First trimester serum cytokine levels and the development of 
autoimmune disease in offspring
M. Fex1, S. Björck1, K. Lynch1, C. Brundin1, K. Marsal2, D. Agardh1,  
S.R. Resic Lindehammer1; 
1Diabetes and Celiac Disease, Lund University, Malmö, 2Department of 
Obstetrics and Gynecology, Lund University Hospital, Lund, Sweden.
Background and aims: Pregnancy involves local and systemic changes in the 
balance between the Th1 and Th2 immunological response. It is generally 
accepted that pregnancy is mediated by a Th2 response inducing tolerance in 
the mother towards the fetal allograft. Several studies suggest that a shift in 
the Th1/Th2 balance during pregnancy caused by underlying environmen-
tal factors could be associated with post-partum autoimmune disease in the 
offspring. In this study we used Celiac disease as a model to investigate if 
autoimmunity is triggered already in utero during early pregnancy, observed 
as changes in the mother’s cytokine profile.
Material and methods: Ten cytokines were measured by electro chemi-lu-
miniscent multiplex ELISA in serum samples obtained from mothers dur-
ing the first trimester. Cases included women with children who before the 
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age of 5 developed verified Celiac disease. Matched controls were selected 
based on age, Celiac Disease associated HLA genotype and serum sampling 
date. Mann-Whitney U tests first tested for a significant overall shift in cy-
tokine levels in cases compared to controls. Chi-square tests further exam-
ined whether the cases were distributed evenly across quartiles ranges of the 
control distribution.
Results: We observed that seven out of ten cytokines were significantly in-
creased in the cases when compared to matched controls. Five of the cytokines 
were Th1 mediated (TNFα, IFNγ, IL-2, IL-1β, IL-12), and two were Th2 me-
diated cytokines (IL-13 and IL-10). In the matched case-control analysis, the 
three top cytokines were shown to be: TNFα (p=0.002), IL-13 (p=0.002) and 
IFNγ (p=0.005) which all were all elevated in the case group.
Conclusion: A delicate balance between Th1/and Th2 mediated cytokines is 
required to ensure a successful pregnancy. However, changes in this balance 
could predispose the fetus to future disease. In this study we show that au-
toimmunity in children is triggered already during early pregnancy and can 
be observed as quantitative changes in the serum cytokine levels of pregnant 
mothers.
Supported by: an EFSD Clinical research Grant and the Novo Nordisk founda-
tion
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Maternal serum 25-hydroxy-vitamin D during late pregnancy and risk of 
type 1 diabetes in the offspring
L.C.M. Stene1, I.M. Sørensen2, P.A. Torjesen3, P.A. Jenum4, A. Eskild5,  
G. Joner2,6; 
1Division of Epidemiology, Norwegian Institute of Public Health, Oslo, 
2Department of Paediatrics, Oslo University Hospital Ullevål, Oslo, 
3Hormone Laboratory, Oslo University Hospital Aker, Oslo, 4Department 
of Microbiology, Asker and Bærum Hospital, Bærum, 5Department of 
Obstetrics and Gynaecology and Medical Faculty Division, Akershus 
University Hospital, University of Oslo, 6Institute of Health and Society, 
University of Oslo, Norway.
Background and aims: A few case-control studies and one cohort study have 
suggested that use of vitamin D supplement in childhood or by the mother 
during pregnancy may be associated with lower risk of type 1 diabetes in 
children. However, vitamin D status is influenced not only by dietary intake 
(from food and supplements) but also skin exposure to ultraviolet light. No 
published study has yet reported the possible relation between the serum 
level of 25-hydroxy-vitamin D, which is a good marker of the integrated ef-
fects of dietary and endogenous sources of vitamin D, and the risk of type 1 
diabetes. We aimed to test whether higher maternal serum concentration of 
25-hydroxy-vitamin D during late pregnancy predicts a lower risk of child-
hood onset type 1 diabetes in the offspring.
Materials and methods: Based on a prospective cohort of nearly 30 000 
pregnant women who gave birth in Norway during 1992-94, we analysed 
serum samples from 99 pregnant women whose child developed type 1 dia-
betes before 15 years of age and 155 randomly selected control women whose 
child did not develop type 1 diabetes during follow-up. The sera were col-
lected around week 37 of pregnancy and stored at -20°C until analysed in 
2008/9. Cases were identified by record linkage to The Norwegian Childhood 
Diabetes Registry. Serum 25-hydroxy-vitamin D was analysed using a radio 
immunoassay (DiaSorin). Power calculations showed 88% power to detect a 
significant association with a test for trend over quartiles with 100 cases and 
150 controls, assuming an odds ratio of 0.33 comparing the upper vs. lower 
quartile of 25-hydroxy-vitamin D and a logit-linear dose-response relation.
Results: There were no significant differences between cases and controls 
in demographic data. The mean level of 25-hydroxy-vitamin D in cases was 
66.4 nmol/l and in controls 71.5 nmol/l, odds ratio (per nmol/l): 0.9 (95% CI 
0.9-1.0, p=0.1). Comparing the 4th vs. 1st quartile of maternal serum 25-hy-
droxy-vitamin D, the odds ratio was 0.6 (95% CI 0.3-1.3). Test for trend over 
quartiles: p=0.2. Adjustment for season of blood collection, maternal diabe-
tes or other potential confounding variables did not influence these results.
Conclusion: In this first study to test the hypothesis that high serum 25-
hydroxy-vitamin D status during pregnancy predicts a lower risk of type 1 
diabetes in children we found no statistically significant association despite 
a suggestive trend.
Supported by: South–Eastern Norway Regional Health Authority
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No association of human enterovirus RNA in monthly faecal samples 
and islet autoimmuinity in the Norwegian MIDIA study
G. Tapia1,2, O. Cinek2, T. Rasmussen1, E. Witsø1, B. Grinde3, L.C.M. Stene1,  
K.S. Rønningen1; 
1Department of Epidemiology, Norwegian Institute of Public Health, Oslo, 
Norway, 2Second Faculty of Medicine, Charles University, Prague, Czech 
Republic, 3Department of Virology, Norwegian Institute of Public Health, 
Oslo, Norway.
Background and aims: To test whether the frequency of human enterovirus 
RNA in faecal samples collected monthly from early infancy was associated 
with development of multiple islet autoantibodies in children with the high-
est risk HLA genotype.
Materials and methods: Individuals carrying the HLA-DRB1*0401-
DQA1*03-DQB1*0302/DRB1*03-DQA1*05-DQB1*02 genotype were iden-
tified at birth and followed with monthly stool samples from 3 to 35 months. 
Blood samples taken at age 3, 6, 9, 12 months, and then annually, were tested 
for autoantibodies to insulin, glutamic acid decarboxylase 65 and protein ty-
rosine phosphatase IA-2. Twenty seven children developed positivity for at 
least 2 islet autoantibodies in 2 or more consecutive samples (cases). Two 
matched controls per case were selected. Stool samples from these children 
were analyzed for enterovirus with a semiquantitative real-time reverse tran-
scriptase PCR. The frequency of enterovirus was modelled as the dependent 
variable and took account of the intra-individual correlation in enterovirus 
infection using a random intercept for the enterovirus infection. The data 
was also analysed using conditional logistic regression modelling with islet 
autoimmunity as the outcome.
Results: The frequency of enterovirus RNA in stool samples from cases 
prior to seroconversion (43/339, 12.7%) did not differ from the frequency 
in matched controls (94/692, 13.6%); odds ratio=1.01 (95% CI: 0.59 - 1.72), 
P=0.97. Results remained essentially unchanged after adjustment for poten-
tial confounders, restriction to various time windows before seroconversion, 
infections in the first year of life, or after including samples collected after se-
roconversion. There was no difference in the average quantity of enterovirus 
RNA, or the frequency of repeatedly positive samples. In the conditional lo-
gistic regression analysis, the “odds ratio” per enterovirus infection was 1.12, 
with corresponding 95% confidence interval 0.66-1.91.
Conclusion: The data strongly suggest that faecal shedding of enteroviral 
RNA does not predict islet autoimmunity, as human enterovirus infections 
are not more frequent before or after autoantibodies appear.
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Identification of type 1 diabetes-associated methylation variable 
positions that precede disease diagnosis
H. Beyan1, V.K. Rakyan1, T.A. Down2, M.I. Hawa1, S. Maslau2, C. Wallace3, 
D. Aden1, C.A. Mein4, B. Manfras5, A. Curtotti4, C.G. Bell6, J.A. Todd3,  
B.O. Böhm5, S. Beck6, R.D. Leslie1; 
1Centre for Diabetes, Blizard Institute of Cell and Molecular Science, 
London, 2Department of Genetics,, University of Cambridge, 3Department 
of Medical Genetics, Department of Medical Genetics, Cambridge Institute 
for Medical Research, University of Cambridge, Addenbrooke’s Hospital, 
London, 4The Genome Centre, Queen Mary University of London, Barts 
and The London School of Medicine and Dent, London, United Kingdom, 
5Department of Internal Medicine I, University Medical Center Ulm and 
Center, University Medical Center Ulm, Germany, 6UCL Cancer Institute, 
University College London, United Kingdom.
Background and aims: Type 1 diabetes (T1DM) is a complex multifacto-
rial autoimmune disease caused by a combination of genetic and non-genetic 
factors. A role for the latter is suggested by studies of migrant populations, 
twin-cohorts, and the recent rise in T1DM prevalence. To assess whether epi-
genetic factors could contribute to these non-genetically determined effects 
we performed a genome-wide, promoter-specific DNA methylation analysis.
Materials and methods: We studied CD14+ monocytes from 15 childhood-
onset T1DM-discordant monozygotic (MZ) twin pairs, 9 control MZ twin 
pairs, plus 7 non-diabetic antibody-positive children studied prospectively 
before and after they developed T1DM. Methylation profiling was done using 
Illumina HumanMethylation27 BeadChips which allow for DNA methylation 
analysis of >27,000 CpG sites associated with >14,000 promoters per sample.
Results: We identified 132 T1D-associated methylation variable positions 
(T1D-MVPs) (P=0.02). Importantly, T1D-MVPs displayed statistically sig-
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nificant trends for methylation differences in the expected direction in an 
independent set of T1DM singletons and controls, both before (P=0.001) and 
after (P=0.015) disease-onset, indicating epigenetic variation before T1DM 
clinical onset.
Conclusion: The identified T1DM-MVPs are associated with genes involved 
in pathways strongly implicated in the aetiopathogenesis of T1DM including 
major antigen expression, proinflammation, regulation of immunoglobulin 
secretion and apoptosis, with only a small over-representation of T1D-MVPs 
within known T1DM genetic susceptibility regions. Changes in DNA meth-
ylation in critical immune-response pathways probably contribute to the 
pathogenesis of T1DM.
Supported by: JDRFI
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A lipotoxicity model in the INS-1 832/13 beta cell line and the epigenetic 
alterations induced by it
S. Malmgren, V.V. Sharoyko, D.G. Nicholls, C.L.F. Nagorny, P. Spégel,  
M. Dekker Nitert, H. Mulder, C. Ling; 
Department of Clinical Sciences in Malmö, Lund University, Malmö, 
Sweden.
Background and aims: The hallmarks of Type 2 Diabetes Mellitus (T2D) are 
peripheral insulin resistance that in combination with impaired insulin secre-
tion results in hyperglucemia. While T2D has a strong genetic component, 
the disease can be triggered by obesity and a sedimentary lifestyle. Plasma 
free fatty acids (FFA) are elevated in obese subjects and this is believed to 
be an important pathogenic factor in T2D. Histone proteins and the nucleo-
somes they form with DNA are the fundamental building blocks of chro-
matin. Histone acetylation is a chromatin modification associated with an 
open chromatin structure and increased gene transcription. Histone acetyl 
transferases (HATs) and histone deacetyltransferases (HDACs) are enzymes 
which regulate histone acetylation. It has previously been demonstrated that 
the regulation of insulin expression by glucose is under the control of histone 
acetylation. The aim of our study is to examine whether a lipotoxic challenge 
of clonal 832/13 beta-cells induces epigenetic alterations and impaired me-
tabolism.
Materials and methods: Insulin secretion for one hour in static incubation 
was measured by RIA. Differences in glucose metabolism were assessed by 
Extracellular flux analyzer XF24 (Seahorse Bioscience, Billerica, MA). HAT 
and HDAC activity was measured using a Nuclear/Cytosol Fractionation Kit 
(BioVision, Mountain View, CA) and HAT/HDAC colorometric assays (Bio-
Vision, Mountain View, CA).
Results: Lipotoxic conditions, assessed as 0,5 mM palmitate for 48 h, signifi-
cantly increased basal secretion at 2,8 mM of glucose from 9 ±3 ng/mg/h to 
29 ±6 ng/mg/h (p<0,001) and significantly decreased glucose-stimulated in-
sulin secretion at 16,7 mM of glucose in beta-cells from 172 ±60 ng/mg/h to 
52 ±15 ng/mg/h (p<0,05). In extracellular flux (XF) measurements lipotoxic 
beta-cells failed to increase oxygen consumption rates (OCR) in response to 
elevated glucose to the same extent as control cells. While 16,7 mM of Glu-
cose increased OCR expressed as area under curve (AUC) with 32 ±0,02 % 
the same increase was only 12 ±0,03 % under lipotoxic conditions (p<0,05). 
This suggests that the lipotoxic beta-cells have a diminished ability to increase 
ATP production in response to increases in glucose concentration. HAT ac-
tivity was elevated more than 4-fold in lipotoxic cells versus control cells 
(p<0.05), which suggests that elevated levels of FFA may induce epigenetic 
changes and gene transcription in the clonal 832/13 beta-cells. HDAC activ-
ity was not affected by lipotoxicity.
Conclusion: The lipotoxicity model we established affected glucose-stimu-
lated insulin secretion in a way which mimics that seen in T2D patients. We 
can also conclude that part of this is due to metabolic effects such as lack of 
increased OCR, probably reflecting a decrease in ATP production. Finally, el-
evations in HAT activity indicate that lipotoxicity induces activation of genes 
in the clonal 832/13 beta-cells.
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Smoking impairs glucose control in patients with type 1 diabetes 
mellitus: a prospective, longitudinal single-center study
P.A. Gerber, R.E. Locher, G.A. Spinas, R. Lehmann; 
Endocrinology and Diabetes, University Hospital Zurich, Switzerland.
Background and aims: Smoking is known to negatively influence meta-
bolic control in patients with type 1 diabetes mellitus. However, previous 
multicenter cross-sectional studies lack information on possible differences 
in diabetes therapy and consultation adherence between smokers and non-
smokers. The aim of this prospective single-center study was to determine 
the effect of smoking on metabolic control during a longitudinal observation 
period.
Materials and methods: Patients with type 1 diabetes mellitus who were re-
ferred to our institution were included if written informed consent was given. 
Data on smoking habits and metabolic control (HbA1c) were taken at baseline 
and during follow-up, as well as on insulin dosage, weight, blood pressure 
and serum lipids. All patients were seen every 3 to 4 month and treated with 
intensive insulin therapy or continuous subcutaneous insulin infusion.
Results: 763 patients were included, 160 (17.1%) were smokers. HbA1c levels 
differed significantly between current smokers and non-smokers at baseline 
and during follow-up (mean 6.6 years, mean HbA1c 7.9±1.3 vs 7.3±1.1%, 
p=0.001) (figure 1, **p<0.001, *p<0.05). There was no difference between 
smokers and non-smokers in terms of age (35.1±12.8 vs 36.1±14.2y), diabe-
tes duration (11.5±10.8 vs 13.4±12.5y) and BMI (23.6±4.5 vs 23.9±5.8kg/m2). 
However, there was a significant difference in gender between the two groups 
(71.3% male in smokers, 52.1% in non smokers). Therefore, every analysis 
comparing the two groups was adjusted for gender. At the end of follow-
up, weight, blood pressure and serum lipids were not different between the 
two groups when adjusted for gender. The proportion of patients with two 
or more diabetes related complications was higher in smokers at the end of 
follow-up (p=0.04). Insulin requirement at the end of follow-up was higher 
in smokers than in non-smokers (0.71±0.30 vs 0.65±0.31IU/kg/d, p=0.04), 
whereas there was no difference in the occurrence of severe hypoglycemias 
(16 events per 100 patient years in smokers, 17 in non-smokers).
Conclusion: In conclusion, this study demonstrates that patients with type 
1 diabetes mellitus who smoke have a significantly worse metabolic control 
than non-smokers despite the same quality and intensity of diabetes treat-
ment.
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PS 11 Ethnic differences in metabolic 
traits
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A comparison of diabetes incidence in Whites, South Asians, Chinese and 
Blacks: a population-based cohort study in Ontario, Canada
M. Chiu, P. Austin, D.G. Manuel, B.R. Shah, J. Tu; 
Institute for Clinical Evaluative Sciences, Toronto, Canada.
Background and aims: Diabetes is a growing epidemic in many countries 
worldwide. While ethnic differences in the prevalence of diabetes is well 
documented, little is known about the relative incidence of diabetes across the 
world’s four major racial-ethnic groups; Whites, Chinese, South Asians, and 
Blacks. We therefore conducted a population-based comparison of incidence 
rates of diabetes across Whites, Chinese, South Asians, and Blacks living in 
Ontario, Canada. We also derived ethnic-specific body-mass index (BMI) 
cutoff values to define obesity based on clinically-ascertained diabetes.
Materials and methods: We conducted a cohort study of 59824 non-dia-
betic adults (57210 Whites, 866 Chinese, 1001 South Asians, and 747 Blacks) 
aged 30 years or older, who were derived from Statistics Canada’s population 
health surveys (1996-2005). Subjects were followed up for up to 12 years for 
diabetes incidence using record linkages to the Ontario Diabetes Database, 
an administrative-based algorithm shown to identify diabetes with 86% sen-
sitivity and 97% specificity.
Findings: Diabetes incidence (per 1000 person-years) was highest among 
South Asians (20.8), followed by Blacks (16.3), Whites (9.5), and Chinese 
(9.3). Cox proportional hazards regression models adjusted for age, sex, 
BMI, and sociodemographic characteristics revealed hazard ratios (HR) that 
were significantly higher in South Asians (HR: 3.40), Blacks (HR: 1.99), and 
Chinese (HR: 1.87) than Whites (all p<0.0001). The median age at diagnosis 
was 9 years younger in South Asians and 3 years younger in Chinese than in 
Whites. Ethnic-specific BMI cutoff points for diabetes risk were identified 
using Poisson regression and restricted cubic splines. For the equivalent inci-
dence rate of diabetes at BMI 30 kg/m2 in Whites, the candidate BMI cut-off 
points were 23 kg/m2, 25 kg/m2, and 26 kg/m2 for South Asians, Chinese, and 
Blacks, respectively (see Figure).
Interpretation: Current screening and prevention strategies for diabetes are 
informed mainly by studies of White populations; however, our study sug-
gests that the risk of new diabetes is significantly greater in South Asians, 
Chinese, and Blacks; that these groups present with diabetes at younger ages; 
and that the current definition of obesity is inadequate for assessing diabetes 
risk in these non-White groups. Ethnic-specific prevention programs and eq-
uitable health services are needed to reduce the burden of diabetes in these 
high-risk populations.
Supported by: Heart and Stroke Foundation of Ontario; CIHR Canada Gradu-
ate Scholarship
351
The association between physical activity and type 2 diabetes according 
to weight status among different ethnic groups
W.M. Admiraal1,2, I.G.M. van Valkengoed2, J.S.L. de Munter2,  
J.B.L. Hoekstra1, K. Stronks2, F. Holleman1; 
1Department of Internal Medicine, 2Department of Social Medicine, 
Academic Medical Centre, Amsterdam, Netherlands.
Background and aims: Physical inactivity and adiposity are both independently 
related to type 2 diabetes (DM). Some studies have suggested that a high level of 
physical activity can counterbalance the negative health effects of obesity. This im-
plies a differential effect of physical activity according to weight status. Moreover, 
effects of physical activity may potentially differ between ethnic groups. Therefore, 
we studied differences in the association between physical inactivity and DM ac-
cording to weight status among individuals from different ethnic groups.
Materials and methods: We analysed data on 508 White Dutch, 596 African-
Surinamese and 339 Hindustani Surinamese participants, aged 35-60 years, 
in the population-based, cross-sectional SUNSET study. Physical activity was 
measured using the Short Questionnaire to Assess Health-enhancing Physical 
Activity, which covers similar topics as the long-format International Physical 
Activity Questionnaire and has been validated for the Dutch population. Physi-
cal inactivity was defined as the lowest quartile of reported activity (min/week). 
Overweight was primarily defined as a BMI > 25 kg/m2, and in a second analysis 
as a waist circumference ≥ 94 cm in men and ≥ 80 cm in women. DM was de-
fined based on fasting plasma glucose levels and self-reported diagnosis of DM.
Results: Physical inactivity was independently associated with DM; after adjust-
ment for sex, age, ethnicity and BMI, the odds of having diabetes was 1.69 (95% 
CI: 1.08-2.63) higher in individuals in the lowest quartile of physical activity, 
compared to those in the highest quartile. This association was present in both 
overweight individuals and those with a normal BMI, although this was only 
significant in overweight individuals (normal BMI: OR 1.51, 95% CI 0.60-3.75, 
overweight: OR 1.79, 95% CI 1.07-2.98). The association between physical inac-
tivity and diabetes was stronger in ethnic Dutch, (OR 4.81, 95% CI 1.32-17.61) 
than in Hindustani Surinamese (OR 1.50, 95% CI 0.76-2.98) and African Suri-
namese (OR 1.40, 95% CI 0.70-2.81), after adjustment for sex, age and BMI. As 
also observed in the total population, weight status did not alter the association 
between physical activity and DM within the ethnic groups. Similar results were 
obtained when using waist circumference as an indicator of overweight.
Conclusion: Physical inactivity was independently associated with type 2 di-
abetes among both individuals with overweight and individuals with normal 
weight. This confirms the importance of regular exercise for all. However, the 
results suggest that potential health gain may differ between ethnic groups.
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Risk factors associated with age at diagnosis of type 2 diabetes mellitus in 
a bi-ethnic population
A. Chetrit1, K. Abu-Saad1, H. Murad2, F. Lubin1, A. Ziv3, G. Alpert4,  
A. Atamna4, O. Kalter-Leibovici1,5; 
1Cardiovascular Epidemiology, Gertner Institute, Ramat-Gan, 2Biostatistics, 
Gertner Institute, Ramat-Gan, 3Information and Computer, Gertner 
Institute, Ramat-Gan, 4Shomron Administration, Clalit Health Services, 
Hadera, 5Sackler Faculty of Medicine, Tel-Aviv University, Israel.
Background and aims: Ethnic minorities have higher prevalence of type-
2 diabetes mellitus (T2DM) as compared to majority population groups. 
Younger age at diagnosis may further increase the burden of disease in eth-
nic minority groups. We explored factors associated with age at diagnosis of 
T2DM in the Arab minority and the Jewish majority groups in Israel.
Materials and methods: Participants (1,100; age: 25-74 years) were selected 
at random from the urban general population in the Hadera district in Israel. 
Information collected by interviews included socioeconomic status (SES) pa-
rameters, diabetes status, lifestyle habits (including dietary intake till T2DM 
diagnosis or interview), height, body weight during most of adult life, and 
history of diabetes in first degree relatives. Family history score of diabetes 
(T2DM FHScore) and dietary energy density (DED) in calories/grams were 
calculated. Factors associated with age at diagnosis of T2DM were tested us-
ing a multivariate Cox proportional hazard model.
Results: Of 1,093 participants with information on diabetes status, 180 had 
T2DM (16.5%). Arabs had higher prevalence of T2DM than Jews (21.0% vs. 
12.0%; HR: 1.99 [95%CI: 1.47-2.71], P<0.01). The mean (SD) age at T2DM 
diagnosis was 52.2 (10.2) years in Arabs vs. 56.1 (10.8) in Jews; p=0.02. By the 
age of 57 years, 25% of the Arab participants had T2DM. The corresponding 
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age in the Jewish participants was 68 years (p<0.0001). In multivariate analy-
sis, Arabs had 1.70 times greater risk for T2DM compared to Jews (95%CI: 
1.19-2.43), adjusted for gender, BMI during most of adult life, T2DM FH-
Score and DED. Other factors associated with risk of T2DM included: higher 
BMI during most of adult life, higher T2DM FHScore, and higher DED (see 
table). SES parameters, cigarette smoking, gender, and current physical activ-
ity were not significantly associated with the risk for T2DM.
Conclusion: Compared to the Jewish majority group, people of the Arab mi-
nority group in Israel are at higher risk for having T2DM at a younger age, 
and greater loss of healthy life-years. Efforts to prevent or delay the onset of 
T2DM should be directed towards ethnic minority groups at high risk, in 
order to reduce diabetes-related health disparities.
Table: Factors associated with the risk for T2DM
Risk Factor* Hazard Ratio (HR);  
95% confidence interval (CI)
Ethnic group (Arabs vs. Jews) 1.70; 1.19-2.43
BMI during most of adult life  
(highest vs. tertile)
2.07; 1.34-3.21
T2DM FHScore (highest vs. lowest) 5.78; 3.99-8.36
DED (highest vs. lowest quartile) 1.67; 1.08-2.61
*-adjusted for gender
Supported by: The Israel National Institute for Health Policy & Health Services 
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Ethnic-specific cut-points for central obesity measures for predicting 
insulin resistance in South African women
J. Evans1, L. Micklesfield1,2, C. Jennings1, Y. Joffe1, N.S. Levitt1,  
E.V. Lambert1, T. Olsson3, J.H. Goedecke1; 
1University of Cape Town, 2University of the Witwatersrand, Johannesburg, 
South Africa, 3Umea University, Sweden.
Background and aims: The relationship between waist circumference (WC), 
visceral adipose tissue (VAT) and insulin resistance (IR) differs by ethnicity. 
The aim of the present study was to explore ethnic-specific cut-points for 
measures of central obesity for predicting IR as estimated by the homeostasis 
model (HOMA-IR) in black and white women, and to determine the optimal 
measure of central obesity i.e. WC vs. waist-height-ratio (WHtR) vs. VAT that 
best predicts IR in each ethnic group.
Materials and methods: Anthropometry (weight, height, WC, hip circum-
ference), VAT (computed tomography) and HOMA-IR were measured in 241 
black and 188 white premenopausal non-diabetic South African women, free 
from known disease and not on medication. IR was defined as the upper ter-
tile of HOMA-IR for the whole group. The Youden index was calculated to 
determine the ‘optimal’ cut-point for WC, WHtR and VAT that best predicted 
IR. The accuracy of each measure to predict IR was assessed using receiver 
operator characteristic (ROC) curves.
Results: Ethnic-specific cut-points for central obesity measures for predict-
ing IR are presented in Table 1.
Conclusion: In our population of apparently healthy black and white South 
African women, we show that measures of central obesity better predict IR 
in white than black women, but there is little difference between WC, WHtR 
and VAT in their ability to predict IR in both ethnicities. As we show that VAT 
adds no advantage in the prediction of risk, WC or WHtR, basic cost-effec-
tive anthropometrical measures, should be used to identify risk. Long-term 
prospective studies are required to examine whether individuals from these 
ethnic groups who exceed these cut-points develop cardiovascular disease 
and diabetes and/or whether these relationships are similar in groups with 
known disease or pathophysiology.
Table 1: Optimal WC, WHtR and VAT cut-points which best predict IR de-
fined as HOMA-IR >2.09
Black Women White Women
ROC AUC 
± SE
Cut-
point
J value ROC AUC 
± SE
Cut-
point
J value
WC (cm) 0.76 ± 0.03 >94 0.42 0.85 ± 0.03 >96 0.60
WHtR 0.77 ± 0.03 >0.62 0.44 0.84 ± 0.03 >0.59 0.55
VAT (cm2) 0.72 ± 0.04 >78 0.36 0.81 ± 0.04 >100 0.47
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The impact of migration on metabolic outcomes and coronary heart 
disease risk: a comparison of migrant South Asians, Asian Indians and 
white Europeans
J.J. Henson1, L.J. Gray2, K. Khunti2, A. Guru3, A. Misra3, M.J. Davies4; 
1Diabetes Research, Leicester Royal Infirmary, 2Health Sciences, University of 
Leicester, United Kingdom, 3Department of Diabetes and Metabolic Diseases, 
Fortis Hospitals (Vasant Kunj and NOIDA), New Delhi, India, 4Department 
of Cardiovascular Sciences, Leicester Royal Infirmary, United Kingdom.
Background and aims: Given the consistent findings of increased preva-
lence, premature onset and increased mortality from CHD in South Asian 
(SA) individuals, there is a need to determine the underlying causes in order 
to develop effective prevention and treatment strategies. One fifth of the de-
veloping world is represented by individuals of a SA origin and migration has 
resulted in large numbers of SAs settling in many developed countries. We 
investigated the impact of migration upon metabolic and CHD risk factors.
Materials and methods: This cohort consisted of 2287 White Europeans 
(WEs), 1007 SAs living in India (ISA) and 927 Migrant SAs (MSA) residing 
in the United Kingdom (UK). All subjects were aged 40-75 years. The WE 
and MSA cohort were recruited from a cross-sectional diabetes screening 
study conducted in Leicestershire, UK. ISA participants were recruited from 
a community-based epidemiological study, undertaken in Punjab, India. All 
participants underwent metabolic and anthropometric measurements. All 
those with established or newly diagnosed diabetes and CHD were excluded 
from analysis. Data is presented as mean ± SD or number (%). The MSA 
group were used as reference. P values were calculated using between groups 
ANOVA (*p<0.05, **p<0.001; see table 1). Non-parametric data were ana-
lysed using the Kruskal-Wallis test. χ² test was used for categorical data.
Results: MSAs had a significantly higher mean BMI and waist circumference for 
both males and females (p< 0.001) compared to ISAs; however, WEs had a sig-
nificantly larger waist circumference than both Asian groups (see table 1). These 
relationships remained statistically significant after adjustment for age. MSAs 
had a significantly higher fasting plasma glucose compared to ISAs (p<0.05); 
furthermore, the prevalence of the metabolic syndrome (International Diabetes 
Federation criteria) was greater in MSAs compared to both ISAs (p<0.001) and 
WEs (p<0.05). MSA males had significantly higher cholesterol compared to ISAs 
(5.1mmol/L vs. 4.8mmol/L, p<0.05). In addition, MSA males had a significantly 
higher 10-year CHD risk (Framingham) compared to WEs (p<0.05); however, 
WE and ISA females had a significantly higher risk than MSAs (p<0.05).
Conclusion: This large dataset demonstrates that factors associated with migration 
serve to exacerbate some important indicators of cardiovascular and diabetes risk 
such as BMI, fasting glucose, serum cholesterol and waist circumference; however, 
certain modifiable risk factors, such as smoking were higher in ISAs females com-
pared to MSAs, which contributed to a higher CHD risk in this group.
Table 1. Comparison of lifestyle and anthropometric variables by ethnicity and sex
Females Males
Migrant South Asian Asian Indian White European Migrant South Asian Asian Indian White European
BMI (kg/m2) 27.9 ± 5.1 23.5 ± 5.9** 28.3 ± 5.8 26.1 ± 3.4 23.4 ± 5.2** 27.9 ± 4.4**
Waist circumference (cm) 90.4 ± 11.3 82.4 ± 13.8** 92.0 ± 13.7* 95.5 ± 9.9 90.8 ± 15.3** 99.3 ± 12.0**
Fasting plasma glucose (mmol/L) 5.1 ± 1.1 4.9 ± 2.0* 5.0 ± 0.8 5.3 ± 0.6 4.9 ± 0.8** 5.2 ± 1.1
Hypertension 89 (21) 213 (55.5)** 460 (37.7)** 162 (36.7) 136 (49.1)* 434 (45.1)*
Smoker 3 (0.7) 107 (22.7)** 152 (28.7)** 70 (15.8) 101 (36.1)** 280 (28.9)**
Total cholesterol (mmol/L) 5.2 ± 0.9 5.2 ± 1.2 5.6 ± 1.0** 5.1 ± 0.9 4.8 ± 1.0* 5.4 ± 1.0*
Metabolic syndrome (International Diabetes  
Federation criteria)
355 (83.9) 291 (58.9)** 994 (81.2)* 315 (71.4) 169 (52.5)** 663 (68.6)*
Framingham Coronary Heart Disease risk (10 year) 4.8 ± 3.9% 6.5 ± 6.2%* 7.5 ± 4.7%* 18.3 ± 12.2% 18.5 ±13.6% 15.6 ± 7.6%*
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Levels of 25-OH-vitamin D in early pregnancy in women from five ethnic 
groups with and without gestational diabetes
L. Sletner1,2, K. Mørkrid1, B. Nakstad2, K.I. Birkeland1, A.K. Jenum1; 
1Dep. of Endocrinology, Oslo University Hospital, Aker, 2Dep. of Pediatrics, 
Akershus University Hospital, Lørenskog, Norway.
Background: The STORK Groruddalen Research Program was set up to 
identify predictors for gestational diabetes (GDM) and foetal growth in a 
multiethnic population in Oslo. Inclusion will finish in May 2010. Poor vita-
min D status has been linked to insulin resistance and in some studies it has 
been associated with GDM.
Aims: To assess levels of 25-OH-vit. D in early pregnancy in women from 
five ethnic groups who later developed GDM compared to women without 
GDM.
Methods: This is a population-based cohort study of pregnant women at-
tending the Child Health Clinics in Groruddalen and their offspring. In-
formation and questionnaires were translated to eight languages, covering 
the largest ethnic groups. Women were eligible if 1) living in the districts, 2) 
planned giving birth at the study hospitals, 3) in gestational week (GW) ≤20, 
4) not suffering from diseases necessitating intensive hospital follow-up dur-
ing pregnancy, 5) could communicate in Norwegian or any of the translated 
languages and 6) able to give informed consent. Ethnic origin in the present 
study: Europe (including North America), South Asia, East Asia, Middle 
East (including North Africa/Central Asia) and Somalia. Questionnaire data, 
blood pressure, anthropometric measurements, fasting blood and urine sam-
ples collected by midwifes were obtained at GW 10-20, 28 and 12 weeks post-
partum. A 75 g OGTT was performed at GW 28 (24-32), glucose analyzed 
on site in venous EDTA blood samples (HemoCue, Angelholm, calibrated for 
plasma). The diagnosis of GDM was based on the WHO-criteria: fasting ≥7.0 
or 2-hour value ≥7.8 mmol/l. 25-OH-vitamin D was measured by a radioim-
munoassay method (DiaSorin, Stillwater, MN, USA). Descriptive analyses, 
ANOVA for continuous variables, chi-square tests for categorical variables 
and logistic regression analyses were performed.
Results: By March 1st 2010, 744 women were included (From Europe: 81.2% 
of the invited, Asia: 66.0%, Middle East: 64.5%, Africa: 60.3%). OGTT data 
were available from 539 women and 78 GDM cases (14.5%) were identified 
The crude prevalence of GDM was high in all groups (Europe: 12.7%, South 
Asia 13.4%, East Asia 24,0%, Middle East 22.4%, Somalia 18.5%)(Table 1). 
East Asian GDM women had a lower mean BMI than European GDM wom-
en (p<0.05). In women without GDM mean BMI was higher in the Middle 
East group than in Europeans (p<0.05). Odds ratio for GDM adjusted for age, 
parity, BMI and GW for minority groups from Asia and Africa compared to 
Europeans was 1.5-2.7, borderline significant for women from Middle East 
(p=0.057) and East Asia (p=0.054). 25-OH-vit. D was significantly lower in 
both GDM and non-GDM women from ethnic minorities compared to Nor-
wegians, but no significant differences between GDM and non-GDM women 
were found.
Conclusion: The crude prevalence of GDM was high in all groups, but high-
est in groups from Asia and Africa. Low levels of 25-OH-vit.D was signifi-
cantly associated with ethnicity, but not with GDM. 
Supported by: NRC
356
Trends in the prevalence of diabetes based on the level of education 
among Korean women: Korea National Health and Nutrition 
Examination Survey 1998-2007
J. Park1, S.G. Kim2, S.J. Yang3; 
1Inju University Sanggye Paik Hospital, Seoul, 2Korea University Anam 
Hospital, Seoul, 3Korea Univsersity Guro Hospital, Seoul, Republic of Korea.
Objective: This study was designed to determine the differences in the preva-
lence of diabetes based on the level of education in Korean women.
Research design and methods: A total of 3,842, 2,894, 3,020, and 1,647 
women were included from The Korea National Health and Nutrition Ex-
amination Survey 1998, 2001, 2005, and 2007 surveys, respectively. Diabetes 
was defined as a self-reported history or a fasting plasma glucose ≥126 mg/dl. 
Education was classified into the following three categories: low (less than 
high school graduate), medium (less than college graduate), and high (college 
graduate or more). A linear model was used to test a trend of diabetes preva-
lence according to educational health inequality. A multiple logistic regres-
sion analysis was performed to estimate odds ratios for diabetes prevalence 
according to education levels.
Results: The prevalence of diabetes among Korean women was decreased 
from 8.1% in 1998 to 6.6% in 2007. Between these periods, there was a sig-
nificant decreasing trend of the prevalence from 2.8% to 0.7% among women 
with a high education level, but no significant change was observed, such as 
from 12.2% to 15.3% among those with a low level of education (p=0.002 
and p=0.15, respectively). A difference of diabetes prevalence between the 
high and low levels of education increased significantly across survey periods 
(p=0.0007). The odds ratio for the prevalence of diabetes in women with a 
low level of education compared to women with a high level of education 
increased from 1.6 in 1998 to 2.2 in 2001, 3.4 in 2005, and 4.8 in 2005 after 
adjusting for age, BMI, smoking, and exercise.
Conclusion: The prevalence of diabetes had an inverse relationship with the 
level of education in Korean women during last decade. More than the nega-
tive relationship, an educational health inequality for the prevalence of diabe-
tes was widened during Korea’s rapid economic development. Further stud-
ies on the causes of educational inequalities in the prevalence of diabetes, as 
well as the development of an effective intervention program, are imperative 
to reduce the prevalence of diabetes and a gap of the prevalence in Korean 
women.
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Dairy consumption and insulin resistance syndrome: results from a 
French prospective study, D.E.S.I.R., data from the Epidemiological 
Study on the Insulin Resistance syndrome
F. Fumeron1, A. Lamri1, I. Porchay-Baldérelli1, R. Jaziri1, O. Lantieri2,  
S. Vol2, B.J. Balkau3, M. Marre1; 
1INSERM U695, Paris, 2IRSA, La Riche, 3INSERM U1018, Villejuif, France.
Background and aims: In the French population from the D.E.S.I.R. cohort, 
cross-sectional analyses have shown that a higher consumption of dairy prod-
ucts or calcium is associated with a lower prevalence of the insulin resistance 
syndrome (IRS). The aim of our study was to assess the influence of dairy prod-
ucts on the nine year cumulative incidence of the IRS or associated diseases in 
this population-based prospective study with a 9-year follow-up, D.E.S.I.R..
Materials and methods: In total, 5212 volunteers from the western central part 
of France were included in the cohort. A questionnaire was completed by each 
participant at baseline, to determine the frequency and level of consumption of 
different foods. Two items concerned dairy products (cheese, milk and other 
dairy products). There were 4 groups according to the intake of dairy products 
(except cheese) and 3 groups for cheese intake. Calcium intake was calculated 
from the questionnaire. Calcium density of the diet was defined as the amount 
of calcium ingested per 1000kCal. Sex-specific calcium density quartiles were 
calculated. The associations between these dairy variables at inclusion and the 
incidence of metabolic diseases were tested using logistic regression models 
adjusted 1) for sex, age, alcohol, smoking, physical activity, fat intake and 2) 
the same covariates plus BMI. The odds ratios were determined by the logistic 
regression, indicating the risk for a change from one group to the next, e.g. from 
one quartile of calcium density to the next quartile. The association of dairy 
products with continuous variables was tested by analysis of covariance for re-
peated measures, using the same covariates as for the logistic regression.
Results: The consumption of dairy products other than cheese and calcium 
density of the diet were inversely associated with the incidence of the IRS and 
with the incidence of impaired fasting glycaemia (IFG) or type 2 diabetes 
(T2D) during the 9-year follow-up. The consumption of cheese was negative-
ly associated with the incidence of the IRS, in particular after adjustment for 
BMI. (Table). These 3 parameters were associated with lower 9-year means 
of diastolic blood pressure, plasma triglycerides and insulin levels and with 
lower BMI gain in this period. Higher cheese intake and calcium density were 
associated with lower increase in waist circumference and plasma triglyceride 
levels. Dairy products and cheese intake were associated with a lower increase 
in blood pressure during the follow-up.
Conclusion: A higher consumption of dairy products and calcium reduces 
the incidence of the IRS during a 9-year period in a large cohort drawn from 
the French general population. This inverse association is observed with 
most of the traits of the metabolic syndrome. These results indicate that dairy 
product consumption could improve the cardiovascular risk.
Odds ratios (95% CI) of developping a metabolic disease during the 9-year 
follow-up
IRS (IDF definition) IRS (NCEP definition) IFG + T2D
Dairy products (except cheese)
Model 1
Model 2
0.89  
(0.80-0.99)
0.91  
(0.81-1.00)
p=0.03
p=0.07
0.87  
(0.78-0.98)
0.91  
(0.81-1.03)
p=0.02
p=0.13
0.85  
(0.76-0.95)
0.86  
(0.77-0.97)
p=0.005
p=0.01
Cheese
Model 1
Model 2
0.88  
(0.75-1.03)
0.82  
(0.69-0.97)
p=0.11
p=0.02
0.78  
(0.65-0.93)
0.70  
(0.58-0.86)
p=0.01
p=0.004
0.87  
(0.73-1.04)
0.84  
(0.70-1.00)
p=0.14
p=0.06
Calcium density
Model 1
Model 2
0.96  
(0.89-1.03)
0.91  
(0.84-0.99)
p=0.28
p=0.03
0.92  
(0.85-1.00)
0.88  
(0.81-0.97)
p=0.06
p=0.008
0.93  
(0.85-1.01)
0.91  
(0.84-0.99)
p=0.08
p=0.03
Supported by: CERIN/CNIEL
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High intake of fermented milk is associated with decreased risk of type 2 
diabetes and better insulin sensitivity
E. Sonestedt, M. Orho-Melander; 
Department of Clinical Sciences, Lund University, Malmö, Sweden.
Background and aims: Several observational studies have shown an in-
verse association between intake of dairy products and risk of type 2 dia-
betes (T2D). Fermented dairy products contain probiotic bacteria that may 
influence the composition of the gut microbiota, which are suggested to play 
a crucial role in the development of metabolic disorders; however, studies 
examining the association with fermented milk are lacking. We therefore ex-
plored the association between intake of specific dairy products (fermented 
milk, non-fermented milk, cheese (>10% fat), cream and butter) and incident 
T2D using the large Swedish Malmö Diet and Cancer study (MDCS) with 
comprehensive and detailed data on dairy food intakes. A genetic variant 
near the insulin receptor substrate 1 gene (IRS1) has been shown to associate 
with insulin resistance and T2D and we therefore wanted to examine if the 
associations between dairy intake and T2D differentiate depending on IRS1 
genotype.
Materials and methods: Among participants in the MDCS without a his-
tory of cardiovascular disease and diabetes (n=26,369; 44-74 y of age; 62% 
females), 1,616 individuals with incident T2D were identified from national 
and regional registers during a mean period of 12 y follow-up. Fasting blood 
glucose and plasma insulin were measured in 4,628 of the subjects at base-
line, and HOMA index was used as a measure of insulin resistance. A total 
of 24,132 of the individuals were genotyped for the genetic variant in IRS1 
(rs2943641). Dietary data was collected using a modified diet history method. 
Cox proportional hazard regression was used to calculate hazard ratios (HR) 
for each energy-adjusted food group adjusted for several potential confound-
ers (i.e. age, sex, energy intake, BMI, smoking habits, alcohol consumption, 
leisure-time physical activity, and education). In sensitivity analyses we ex-
cluded individuals reporting dietary change in the past as they are suspected 
to have unstable food habits. The interaction between IRS1 genotype and 
food variables on incident T2D was assessed by introducing a multiplicative 
factor with continuous variables in the multivariate analyses.
Results: After adjusting for potential confounders, high intake of ferment-
ed milk was associated with lower HOMA index (P-trend=0.002), whereas 
high intakes of non-fermented milk and butter were associated with higher 
HOMA index (P-trend=0.0002 and 0.006, respectively). Without taking 
dietary change in the past into account, high intakes of cream, cheese and 
butter were associated with decreased risk of T2D (P-trend<0.05 for all). 
However, after excluding those 22% individuals reporting dietary change in 
the past, only high intake of fermented milk was significantly associated with 
decreased incidence of T2D (HR, 0.76; 95% CI, 0.64-0.91 for highest tertile 
of consumers vs. zero-consumers; P-trend=0.008). The C allele of rs2943641 
was associated with insulin resistance assessed by the HOMA index (P=0.04) 
and T2D risk (OR, 1.13; 95% CI, 1.04-1.21). However, we observed no signifi-
cant interaction between IRS1 genotype and food variables on incident T2D.
Conclusion: This study indicates that intake of fermented milk is associated 
with better insulin sensitivity and that a high intake may reduce the risk of 
T2D. Our observation suggests that it is crucial to separate the effect of fer-
mented and non-fermented milk products when investigating the health ef-
fect of dairy foods.
Supported by: Lund University Diabetes Center
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Alcohol consumption and the risk of developing prediabetes and type 2 
diabetes in Swedish middle-aged men and women
M. Cullmann, A. Hilding, C.-G. Östenson; 
Department of Molecular Medicine and Surgery, Karolinska Institutet, 
Stockholm, Sweden.
Background and aims: Type 2 diabetes (T2D) has become a major health 
problem in many industrialized countries. Alcohol consumption represents a 
common and increasing habit in Sweden. It has been suggested as a potential, 
modifiable risk factor of T2D. However, more detailed information on effects 
of different types of alcoholic beverages as well as the effects on early phases 
of T2D development seems warranted. The aim of the present study was to 
investigate the influence of alcohol consumption and specific alcoholic bever-
ages on the risk of developing prediabetes and T2D in Swedish middle-aged 
men and women.
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Materials and methods: The data of 2004 men and 2961 women, aged 35-
56 yrs at baseline, from the Stockholm Diabetes Prevention Program was 
evaluated in this cohort study. All subjects had normal glucose tolerance at 
baseline. Logistic regression analysis was performed to estimate the risk (ex-
pressed as odds ratio (OR) and 95% CI) to develop prediabetes and T2D at 
follow up, 8-10 yrs later, in relation to self reported, baseline alcohol intake 
(converted to g/day) derived from wine, beer, dessert wine and hard liquor. 
Adjustment was preformed for several life style factors.
Results: When adjusted for confounders, no significant association was 
found with total alcohol consumption and prediabetes or T2D in both men 
and women. However, men showed a higher risk for T2D when having a 
high liquor consumption (OR: 2.01 (95% CI: 1.10-3.65)) and a higher risk 
for prediabetes when drinking high amounts of beer (OR: 1.72 (1.06-2.81)) 
compared to occasional drinkers. Women showed a reduced risk for T2D in 
the medium liquor group (OR: 0.39 (0.17-0.91)) and a 2-fold higher risk for 
prediabetes in the high liquor group (OR: 2.37 (1.44-3.89)) but a reduced risk 
for prediabetes in the high wine intake group (OR: 0.65 (0.43-0.99)) com-
pared to occasional drinkers.
Conclusion: This is the first study to investigate the possible risk of different 
alcoholic beverages on the development of prediabetes in women. Although 
no significant associations were found to total alcohol consumption in men 
and women, high consumption of hard liquor and beer increased the risk of 
T2D development. Since alcohol in some instances reduced the risk, it is pos-
sible that other factors than ethanol might play a role.
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The inverse association between alcohol intake and complement C3 can 
be attributed to wine consumption and is explained by inflammation, 
HDL and insulin resistance, the CODAM study
M.M.J. van Greevenbroek1, C.J.H. van der Kallen1, I. Ferreira2, E.E. Blaak3, 
C.G. Schalkwijk1, E.J.M. Feskens4, C.D.A. Stehouwer1; 
1Internal Medicine (UNS 50 box 14), Maastricht University, 2Internal 
Medicine / KEMTA, Maastricht University, 3Human Biology, Maastricht 
University, 4Wageningen University, Netherlands.
Background and aims: Moderate alcohol consumption has beneficial effects 
on CVD risk. Complement C3 is an early marker of insulin resistance and a 
risk factor for CVD and a negative association between alcohol consump-
tion and circulating C3 has been reported. However, whether all sources of 
alcohol (e.g. wine, beer or other) are equally associated with C3 is not known. 
Also, the mechanisms that can explain any such inverse associations are not 
known. Beneficial effects of (moderate) alcohol consumption on inflamma-
tion, HDL and insulin resistance are likely candidates in this regard. The aim 
of this study was therefore to determine whether an inverse association be-
tween alcohol consumption and C3 is present and to investigate the extent 
to which this is (1) due to a specific source of alcohol and (2) explained by 
inflammation, HDL and/or insulin resistance.
Materials and methods: We investigated the Cohort on Diabetes and Athero-
sclerosis Maastricht (n=574, 61.3% men, 59.1 ± 7.0 yrs of age). Alcohol intake 
from different sources (beer, wine and others) was estimated by means of a 
validated food frequency questionnaire (FFQ). Subjects with unreliable FFQ 
(n=56) or who had missing data on the other variables (n=22) were excluded. 
First, we determined the association between alcohol consumption (total 
amount or from different sources, main determinant) and C3 (main outcome, 
standardized value) using linear regression (adjusted for age, sex, total energy 
intake, physical activity, waist, smoking, total cholesterol, ALAT, prior CVD, 
glucose tolerance status, use of medication). Next, we investigated whether 
this association could be attributed to a specific dietary source of alcohol. 
Lastly we investigated whether this association was (statistically) explained 
by inflammation (expressed as the average Z-score of CRP, IL6, SAA, sICAM, 
ceruloplasmin and haptoglobin), HDL-cholesterol and/or insulin resistance 
(as HOMA2ir).
Results: After adjustment for the above-mentioned covariates, alcohol con-
sumption (in 10 g/d) was inversely associated with circulating C3; β [95% CI]; 
-0.057 [-0.100; -0.014] (p=0.010). When each source of alcohol was adjusted 
for each other and the covariates, only wine was independently associated 
with C3 (βs [95% CI] were -0.087 [-0.140; -0.033], p=0.002; -0.042 [-0.107; 
0.023], p=0.222; -0.004 [-0.080; 0.072], p=0.908 for wine, beer and others, 
respectively). In the final analyses, we therefore focused on alcohol consump-
tion from wine (in 10 g/d). The strength of the association between alcohol 
from wine and C3 was attenuated after further adjustments for inflammation 
(by 24.1%), HDL (by 33.3%), or HOMA2IR (by 36.8%), and was attenuated 
by 73.6% when these three mediators were added together.
Conclusion: The negative association between alcohol intake and circulating 
C3 can be mainly attributed to wine consumption and is largely explained 
by the favorable impact of alcohol consumption on inflammation, HDL and 
insulin resistance. This suggests that this association is more likely related to 
non-alcohol components of wine, than to the alcohol component itself.
Supported by: NWO/DFN. IF is supported by NHS
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Steatosis of donor’s liver and its relationship to post-transplant diabetes 
mellitus in liver transplantation
M.X. Yu, X. Chen, J. Zhou, J. Gao, X. Gao; 
Endocrinology, Zhongshan Hospital Affiliated to Fudan University, 
Shanghai, China.
Background and aims: Previous study indicated that HCV infection, im-
munosuppressant including steroid and calcineurin inhibitor, age over 
45yrs, family history of DM, overweight, impaired glucose regulation be-
fore transplant, MCV infection, acute rejection(AR), cirrhosis especially 
decompensation cirrhosis et al were risk factors to post-transplant diabetes 
mellitus(PTDM). The relation between steatosis of donor’s liver and PTDM 
was rarely reported. The aim of our study was to discuss steatosis of donor’s 
liver and its relationship to post-transplant diabetes mellitus in liver trans-
plantation.
Materials and methods: We retrospectively analyzed 438 patients who per-
formed orthotopic liver transplantation (OLT) in our center between April, 
2001 and December, 2008. Patients with history of using steroids, or data in-
complete or died within 3 months after OLT were excluded. The grade of liver 
steatosis was taken pathological grading of non-alcoholic fatty liver disease 
(NAFLD), and fatty content less than 5% was considered without steatosis, 
otherwise was steatosis. Liver function was graded to A, B and C level accord-
ing to Child-Pugh grade system. Patients were divided into PTDM and non-
PTDM group according to fasting plasma glucose(FPG) after operation. Uni-
variate analysis was used to analyze the possible risk factors, such as age, gen-
der, family history of DM, HBV or HCV infection, FPG, BMI, liver function 
pre-operation, cirrhosis, steatosis of donor’s liver, AR, immunosuppressive 
drugs, metabolite related risk factors, interleukin 2 receptor antagonist(IL-
2RA). Multivariate logistic regression was used to analyze factors including 
age, FPG, HBV infection, cirrhosis, liver function pre-operation, steatosis 
of donor’s liver, basic diseases before operation, IL-2RA, immunosuppres-
sive drugs and AR. Student’s t test (One-Way ANOVA) was used to compare 
quantitative variables and Chi-square test was used to compare qualitative 
variables. P value less then 0.05 was considered statistically significant. Statis-
tic analysis was done by SAS 8.2 and SPSS 16.0.
Results: Among 438 patients, there were 298 non-PTDM and 140 PTDM 
patients. Among 298 non-PTDM patients, there were 103 steatosis of do-
nor’s liver, taking 34.6%, and 62 steatosis of donor’s liver among 140 PTDM 
patients, taking 44.3%. Univariate analysis indicated that liver function and 
fasting plasma glucose pre-operation, the use of IL-2RA and calcineurin in-
hibitor were significantly related with PTDM (All P< 0.05), but steatosis of 
donor’s liver was at the critical level (P=0.050). While multivariate logistic 
regression indicated that FPG pre-operation and steatosis of donor’s liver 
had positive relationship with PTDM, their OR value was 1.853 (P<0.01) and 
1.803 (P<0.05) respectively. And the use of IL-2RA was negatively related 
with PTDM with OR value of 0.427 (P<0.01).
Conclusion: We found that steatosis of donor’s liver, abnormal fasting plasma 
glucose, liver function pre-operation and calcineurin inhibitor were risk fac-
tors of PTDM.
362
B12 deficiency is more common than folate deficiency in early 
pregnancy: do we need to consider B12 fortification?
P. Saravanan1, C. Wood2, N. Anderson2; 
1CSRI, Warwick Univ. & George Eliot Hospital, Coventry, 2Biochemistry, 
George Eliot Hospital, Nuneaton, United Kingdom.
Background and aims: Foetal programming due to gene-diet interactions 
during the periconceptional period has been linked to increased risk of 
Type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD) in the 
offspring during their adult life. In addition, children who are born small 
but gain weight rapidly during the early years and become obese in adult life 
are particularly at risk of T2DM and CVD. A large prospective observational 
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study showed that offspring born to mothers with high folate and low B12 
levels during mid-pregnancy, had the highest adiposity and greatest insulin 
resistance. In presence of such imbalance, it is plausible biochemically, excess 
energy is converted to adipogenesis as opposed to myogenesis. Though such 
imbalance is likely to be common in a mainly vegetarian population such as 
in India, recent evidence suggests that such phenomenon may not be uncom-
mon in the UK adult population too. In animal studies, epigenetic alterations 
of DNA methylation by B12 and folate during the periconceptional period 
result in increased adiposity and metabolic risk in the offspring. In addition, 
methyl donor deficiency leads to dysfunction of the ghrelin system with dra-
matic effects on intrauterine growth. Because of fortification of various foods 
and the recommendation for periconceptional folic acid supplementation, 
folate deficiency has become rare. B12 deficiency has thus become a poten-
tially major modifiable risk factor for metabolic disease as well as neural tube 
defects (NTDs). Indeed, in the presence of adequate folate, NTDs due to B12 
deficiency have tripled. Thus, reducing the incidence of B12 deficiency by for-
tification / supplementation has the potential to reduce the risk of metabolic 
disease in adult life and the overall burden of metabolic disease world-wide.
To investigate the incidence of B12 deficiency in a Caucasian population dur-
ing early pregnancy.
Materials and methods: 200 Maternal serum samples (mean age 27y) at 16-
18 weeks gestation were analysed for B12 and folate levels using an electro-
chemiluminescence immunoassay. 200 samples from non-pregnant women 
of child-bearing age (mean 28y) were analysed as controls.
Results: B12 deficiency (<191ng/L) was common during pregnancy com-
pared to age-matched control non-pregnant women (20% vs 4%, p=<0.0001). 
Folate deficiency was 6% and 13% in the pregnant and non-pregnant women 
respectively (<4.6μg/L). Significantly more pregnant women had folate levels 
above the reference range (>18.7μg/L), compared to the non-pregnant group 
(8% vs 3%, p=0.0283). This is likely due to increased folic acid intake dur-
ing pregnancy. Median B12 levels are significantly lower (median: 262ng/L 
vs 363ng/L, p=<0.0001) at 16-18 weeks of pregnancy. This may be due to 
increased utilization during pregnancy, especially in the presence of higher 
folate levels.
Conclusion: These data indicate that B12 deficiency is common in early preg-
nancy even in a non-vegetarian UK population. If untreated, such deficiency 
may get worse in later pregnancy, potentially increasing the risk of metabolic 
disorders such as T2D and CVD. Given recent evidence linking B12 deficien-
cy to NTDs, our findings suggest in addition to folic acid, B12 fortification 
should be considered. Intervention studies of B12 supplementation in early 
pregnancy and their effects on offspring are urgently needed. In addition, 
further studies designed to identify the potential mechanisms are warranted.
PS 13 Screening and prediction of 
type 2 diabetes mellitus
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Comparison of American Diabetes Association and World Health 
Organisation indications for performing oral glucose tolerance test
P. Tzoulis1, E. Denver1, N. James2, M. Barnard1; 
1Department of Diabetes, 2Department of Biochemistry, The Whittington 
Hospital NHS Trust, London, United Kingdom.
Background and aims: There is a discrepancy between American Diabetes 
Association (ADA) and World Health Organisation (WHO) cut-off values 
of fasting plasma glucose (FPG) for diagnosing Impaired Fasting Glycaemia 
(IFG). ADA recommends an FPG cut-point for IFG of 100 mg/dl (5.6 mmol/
l). WHO and the European Diabetes Epidemiology Group recommend the 
cut-point of 110 mg/dl (6.1 mmol/l). The aim of this study is to determine 
which FPG cut-point should be used when deciding whether to perform an 
Oral Glucose Tolerance Test (OGTT). It also aims to assess the impact of age, 
gender and ethnic origin on the relationship between FPG and 2-h plasma 
glucose (2-h PG).
Materials and methods: Our hospital serves an inner city area in London 
with a multiethnic population of over 250,000 people. We conducted a ret-
rospective analysis of OGTTs performed in our institution over a 24-month 
period from 1st May 2006 to 30th April 2008.
Results: Data was collected on 1598 patients (mean age 58.7 years ± 13.5 
years, 54.2% males and 45.8% females). Amongst the subjects there were 
44.7% White, 9.9% Black, 6.2% Asian and 39.2% cases of ‘other ethnic origin’ 
or ‘not stated’. Among participants with FPG of 100-109 mg/dl (normal ac-
cording to WHO, but IFG according to ADA) 34.1% had impaired glucose 
tolerance (IGT) and 11.8% had diabetes based on 2-h PG (overall 45.9% im-
paired glucose regulation). In those with FPG of 110-125 mg/dl (IFG accord-
ing to both ADA and WHO), 39.0% had IGT and 29.0% diabetes based on 
2-h PG (overall 68.0% impaired glucose regulation). In those with FPG of 
<100 mg/dl (normal according to ADA and WHO), 19.3% had IGT and 4.6% 
diabetes based on 2-h PG (23.9% impaired glucose regulation). A statistically 
significant association was found between FPG and 2-h PG (p<0.001) and a 
positive linear relationship between FPG and 2-h PG was observed (correla-
tion coefficient 0.436). For participants with FPG of 100-109 mg/dl, a statisti-
cally significant relationship between different age groups and 2-h PG was 
demonstrated (p=0.012). The proportion of participants with FPG of 100-109 
mg/dl who had IGT showed a steady increase: 26.7% among <50 years of 
age, 29.6% among 50-60 years , 38.7% among 60-70 years , 42.4% among >70 
years of age. A similar trend was noted in the proportion of individuals who 
were diagnosed with diabetes based on 2-h PG. For subjects with FPG of 100-
109 mg/dl, no statistically significant association was noted between gender 
or ethnic origin and 2-h PG.
Conclusion: In this study, by applying a WHO cut-point for FPG of 110 
mg/dl (6.1 mmol/l) we would have missed the diagnosis of impaired glucose 
regulation in a large proportion of subjects. A significant proportion of our 
population with FPG of 100-109 mg/dl had IGT (34.1%) or diabetes (11.8%) 
based on 2-h PG. This may reflect the characteristics of our local population 
and further studies should guide whether OGTT is indicated in individuals 
with FPG of 100-109 mg/dl.
Distribution of subjects by fasting and 2-h plasma glucose
FPG <140 mg/
dl(normal)
140-199 mg/dl 
(IGT)
≥ 200 mg/dl
(diabetes)
<100 mg/dl 347 (76.1%) 88 (19.3%) 21 (4.6%)
100-109 mg/dl 219 (54.1%) 138 (34.1%) 48 (11.8%)
110-125 mg/dl 148 (32.0%) 180 (39.0%) 134 (29.0%)
≥ 126 mg/dl 24 (8.7%) 56 (20.4%) 195 (70.9%)
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Elevated one-hour post-load plasma glucose levels identifies subjects 
with normal glucose tolerance and impaired beta cell function, insulin-
resistance and worse cardiovascular risk profile, the GENFIEV study
C. Bianchi1, R. Miccoli1, R.C. Bonadonna2, G. Penno1, G.A. Daniele1,  
S. Politi1, A. Agostini1, S. Del Prato1, on behalf of the GENFIEV Study Group;
1Endocrinology and Metabolism, University of Pisa and Azienda 
Universitaria Ospedaliera Pisana, 2Biomedical and Surgical Sciences, 
University of Verona, Italy.
Background and aims: Recent evidence suggests that in subjects with nor-
mal glucose tolerance (NGT) one-hour post-load plasma glucose (1h-OGTT 
glucose) >155 mg/dl may predict type 2 diabetes (T2DM) and is associated 
with subclinical atherosclerosis. This study evaluates beta-cell function, insu-
lin-sensitivity and cardiovascular risk profile of NGT subjects with 1h-OGTT 
glucose >155 mg/dl.
Materials and methods: In 929 subjects, participating in to the GENFIEV 
(Genetic and Pathophysiology of Type 2 Diabetes Evolution) study, we per-
formed an OGTT with measurement of C-peptide and fasting insulin. Insulin 
resistance was assessed by HOMA-IR, while beta-cell function was estimated 
by the Insulinogenic Index and minimal model analysis of plasma glucose 
and C-peptide response to a 2-hr 75-g OGTT.
Results: Based on the OGTT results, 51% had NGT, 4% IFG, 24% IGT, 7% 
both IFG and IGT, and 14% were diagnosed with new T2DM. Thirty-nine 
percent among NGT, 76% of IFG, 90% of IGT, 99% of IFG+IGT and 98% 
of newly diagnosed T2DM had 1h-OGTT glucose >155 mg/dl. This cutoff 
point has an high specificity (89%), a good sensibility (69%) and an high 
positive predictive power (92%) in identifying subjects with IGR or newly 
diagnosed T2DM. Among subjects with NGT (n. 474, 37% men and 63% 
women; age: 46±12 years, BMI: 28.4±5.3 kg/m2), those with 1h-OGTT glu-
cose >155 mg/dl, were more insulin-resistant (HOMA-IR 2.7±1.9 vs 2.1±1.2 
mmol/L x µU/ml; p<0.01) and had impaired first phase insulin secretion 
(Insulinogenic Index: 0.052±0.030 vs 0.092±0.17; p<0.01; C-CD: 1381±865 
vs 1721±1384 Pmol/m2BSA/mM/min; p<0.005) and beta-cell performance 
(Disposition Index: 0.055±0.097 vs 0.026±0.025; p<0.001) compared to those 
with 1h-OGTT glucose ≤155 mg/dl. Moreover, HbA1c (5.6±0.4 vs 5.3±0.4%; 
p<0.0001), blood pressure (systolic: 128±13 vs 122±14 mmHg; p<0.0001 and 
diastolic: 81±10 vs 77±11 mmHg; p<0.0001), LDL-cholesterol (136±41 vs 
127±37 mg/dl; p<0.05) and triglycerides (136±96 vs 117±75 mg/dl; p155 mg/
dl, while HDL-cholesterol was lower (52±14 vs 56±16 mg/dl; p155 mg/dl had 
a similar cardiovascular risk profile, a comparable insulin-sensitivity impair-
ment and a slightly better beta-cell function.
Conclusion: 1h-OGTT glucose >155 mg/dl shows a good performance in 
discriminating subjects with IGR/newly diagnosed T2DM and may iden-
tify, among NGT individuals, those with lower insulin-sensitivity, impaired 
beta-cell function and worse cardiovascular risk profile, i.e. those subjects at 
higher risk of developing T2DM and cardiovascular disease.
Supported by: FoRiSID with an unconditioned grant from Eli Lilly, Italy
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New and old criteria for the diagnosis of diabetes mellitus in patients 
with coronary artery disease
P. Rein1,2, C.H. Saely1,2, A. Vonbank1,2, C. Boehnel1,2, V. Jankovic1,2,  
J. Breuss1,2, S. Beer1,2, H. Drexel1,2; 
1Vorarlberg Institute for Vascular Investigation and Treatment, Feldkirch, 
Austria, 2Private University of the Principality of Liechtenstein, Triesen, 
Liechtenstein.
Background and aims: Recently, an International Expert Committee con-
cluded that haemoglobin A1c (hba1c) may be a better means of diagnosing 
diabetes than glucose levels. A diagnosis of diabetes was recommended with 
hba1c ≥6.5%. Data on the concordance of new and old criteria for the di-
agnosis of diabetes are very scarce; no data at all are available for patients 
with coronary artery disease (CAD). We therefore aimed at investigating the 
concordance of new and old diabetes criteria in a large cohort of patients with 
angiographically proven CAD.
Materials and methods: We consecutively enrolled 1124 Caucasian patients 
with angiographically proven CAD who did not have previously known dia-
betes. An oral glucose tolerance test (oGTT) was performed in all patients.
Results: From the patients with diabetes according to the new diagnostic cri-
terion hba1c ≥6.5% (n=110), 58 (53%) fulfilled the WHO glucose criteria for 
diabetes, 13 (12%) had impaired glucose tolerance (IGT), 26 (24%) impaired 
fasting glucose (IFG), and 13 (12%) normal fasting glucose (NFG). Converse-
ly, the hba1c ≥6.5% criterion was fulfilled in 58 patients (63%) with diabetes 
according to WHO criteria, in 13 patients (11%) with IGT, in 26 patients (8%) 
with IFG, and in 13 patients (2%) with NFG. Compared to the standard of 
WHO criteria, the proposed hba1c ≥6.5% for the diagnosis of diabetes had a 
sensitivity of 63% and a positive predictive value of 53% for detecting previ-
ously undiagnosed diabetes, whereas specificity and negative predictive value 
were 95% and 97%, respectively.
Conclusion: The recently recommended hba1c criterion for the diagnosis of 
diabetes among CAD patients is highly specific but not sensitive. This might 
strongly limit its use as a screening tool for identifying individuals with dia-
betes.
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Prevalence of diabetes mellitus after pregnancy with gestational diabetes 
mellitus using different cut-off criteria for abnormal glucose tolerance
E. Anderberg1, M. Landin-Olsson2, J. Kalén3, A. Frid4, D. Ursing2, K. 
Berntorp4; 
1Obstetrics and gynecology, University of Lund,  Lund, 2Endocrinology and 
Diabetoplogy, University of Lund, Lund, 3Internal Medicine, University of 
Lund, Lund, 4Endocrinology Malmö, University of Lund,  Lund, Sweden.
Background and aims: Gestational diabetes mellitus (GDM) is diagnosed 
using an oral glucose tolerance test (OGTT) but there is no consensus on di-
agnostic criteria. GDM is a reliably predictor for subsequent diabetes mellitus 
but more knowledge on the relationship between the OGTT result and future 
diabetes is needed. The aim was to determine the incidence of diabetes after 
GDM as defined by WHO 1999 using different cut-off levels for abnormal 
glucose tolerance during pregnancy.
Materials and methods: Women undergoing a 75 g oral OGTT during preg-
nancy and delivering during 2003-2005 were invited to a 5-year follow-up 
program postpartum. At first check-up, 1-2 years after delivery, 160 women 
with GDM, 309 with gestational impaired glucose tolerance (GIGT) and 167 
controls with gestational normal glucose tolerance underwent an OGTT. 
Cut-off levels defining GDM and GIGT were 2-h capillary blood glucose lev-
els of 9.0 and 7.8 mmol/l or plasma glucose 10.0 and 8.6 mmol/l.
Results: In addition to 15 women with GDM and 2 with GIGT diagnosed 
with diabetes before follow-up, 11% of women with GDM and 4% of women 
with GIGT were diagnosed as having diabetes, implying diabetes in 6% in the 
combined group. The corresponding figures for impaired glucose tolerance 
(IGT) were 23% and 24%. No one in the control group had diabetes whereas 
10 % had IGT. Due to the low reproducibility of the OGTT women with 
GIGT were retested within one week, following which 24% were reclassified 
as having GDM, 43% with GIGT and 33% with GNGT with corresponding 
diabetes prevalence at follow-up of 13%, 4% and 0%.
Conclusion: Lowering the cut-off level for GDM to that proposed by WHO 
1999 would substantially increase the number of women identified during 
pregnancy and thereby committed to special care during pregnancy and to 
follow-up postpartum. Lowering the threshold would dilute the diabetes 
prevalence and does not seem optimal to identify those at the highest risk of 
diabetes development. Retesting the GIGT group might offer a possible way 
to identify those in most need of medical attendance.
Supported by: foundations of the County of Skåne, Sweden
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Usual delay in sample processing can underestimate detection of 
prediabetes and diabetes in Korea
J. Kang1, C. Kim1, S. Lee1, S.-H. Ihm1, M. Choi2, H.-J. Yoo3, C.-Y. Park4,  
S. Park4; 
1Hallym University Sacred Heart Hospital, Gyeonggi-do, 2Chuncheon 
Sacred Heart Hospital, Gangwon-do, 3Hangang Sacred Heart Hospital, 
Seoul, 4Endocrinology and Metabolism, Kangbuk Samsung Hospital, Seoul, 
Republic of Korea.
Background and aims: Diabetes has emerged as a public health issue world-
wide, particularly in East Asia including Korea and consensus statements rec-
ommended early detection and preventive treatment in high-risk individu-
als. For detection of prediabetes and diabetes(hyperglycemic state), fasting 
plasma glucose (FPG) alone is commonly used as a screening test but serum 
should not be used, because the glucose concentration decreases 5~7% per 
hour as a result of erythrocyte glycolysis or slow serum/plasma separation. 
However, since serum glucose is commonly used as screening test in Korea. 
The purpose of this study was to assess whether ordinary delay in sample 
processing influences screening results of hyperglycemic state.
Materials and methods: Between 2007 and 2009, study subjects were recruit-
ed in 2028 Korean who visited the division of endocrinology for the evalu-
ation of the IFG previously diagnosed with the serum glucose in the health 
examination. We make a comparison of difference between fasting serum 
glucose and fasting plasma glucose, measured at the same times, and evalu-
ated the classification of glucose tolerance determined by a 75g oral glucose 
tolerance test (OGTT). We also make a comparison of laboratory findings 
between normoglycemia and diabetes, diagnosed with plasma glucose in 
study populations with normoglycemia in routine chemistry. We conducted a 
cross-sectional study, which was approved by the Institutional Review Board 
of the University Hospital.
Results: We firstly obtained blood samples from another 30 adults and serum 
glucose concentrations were measured immediately and after 0.5, 1, 1.5, 2, 
2.5and 3 hr. All the specimens were kept at room temperature during this 
preliminary test. The concentration of glucose declined with time (118.9mg/
dL, 114.4mg/dL, 111.9mg/dL, 109.7mg/dL, 107.1mg/dL, 105.8mg/dL and 
102.6mg/dL at each times) and the main decrease occurred during the first 
30 min. Among 1428 persons, we recruited 1254 subjects who were diag-
nosed with normal fasting glucose or IFG using FPG. Mean glucose con-
centrations were 117.4 ± 11.3 mg/dL in plasma and 106.8 ± 8.1mg/dL using 
routine chemistry (mean difference: 10.6 ± 2.5 mg/dL). Of 1061 subjects di-
agnosed with IFG using serum glucose, 235 (22.1%) were newly diagnosed 
with diabetes in fasting plasma glucose and 306 (28.8%) in 75g OGTT. Age, 
c-peptide and insulin level at 30minutes for 75g OGTT, AST and metabolic 
syndrome (%) showed significant differences between normoglycemia and 
diabetes diagnosed with plasma glucose in 169 subjects with normoglycemia 
in routine chemistry.
Conclusion: This study evaluated that the ordinary delay in sample process-
ing influences diagnosis of hyperglycemic state and our results showed that 
this delay can underestimate detection of hyperglycemic state, in Korea. For 
the screening of prediabetes and diabetes, glucose level should be measured 
in plasma or within 30 minutes from venous sampling.
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Increasing the flexibility of a screening model for incident diabetes only 
increases the predictive power marginally
D. Vistisen, A. Heraclides, K. Borch-Johnsen, D.R. Witte; 
Steno Diabetes Center A/S, Gentofte, Denmark.
Background and aims: Risk scores for predicting diabetes tend to be simple 
and highly dependent on age. As such, they have limited use as a first step in a 
screening programme. The aim of this study was to derive a screening model 
based on established risk factor information obtainable through a mailed 
questionnaire but with a more flexible structure which accommodates the 
fact that some risk factors for diabetes may have different impacts in different 
sub-groups of people.
Materials and methods: The analysis is based on a Danish population-based 
primary prevention study, the Inter99 study. A total of 4,363 participants, 
free of diabetes at baseline and with 5-year follow-up data on diabetes status 
were analysed. All participants had complete information on age, sex, BMI, 
waist circumference, the use of antihypertensive- or lipid lowering treatment, 
family disposition to diabetes, smoking and physical activity. Glucose toler-
ance status at baseline was based on OGTTs. Incident diabetes was based on 
self-reported diabetes or OGTTs at follow-up examination. Two alternative 
screening models for incident diabetes were derived. A standard risk score 
assessed by Poisson regression analysis (risk score) and a more flexible model 
identified through tree-structured regression analysis (decision tree). The 
performance of the models was compared by ROC analysis.
Results: The standard risk score included information on age, sex, BMI, the 
use of antihypertensive- and lipid lowering treatment, parents with diabe-
tes, smoking and leisure-time physical activity. The AUC of the standard risk 
score was 0.78 (95%-CI: 0.74-0.82). The decision tree included the same in-
formation as the standard model with the additional inclusion of waist cir-
cumference and had an AUC of 0.79 (95%-CI: 0.75-0.82).
Conclusion: A screening model allowing for a more flexible structure only 
increased the performance marginally.
Supported by: DMRC, DCHTA, Novo Nordisk
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Value of the FINDRISC questionnaire to identify prediabetes in a middle 
sized town in Sweden
M.I. Hellgren1, P. Friberg1, M. Petzold2, C. Björkelund1, H. Wedel2,  
P.-A. Jansson3, U. Lindblad1; 
1Department of Public Health and Community Medicine/Primary Health 
Care, University of Gothenburg, 2Nordiska Högskolan för Hälsovetenskap, 
3Dep of Molecular and Clinical Medicin, University of Gothenburg, 
Göteborg, Sweden.
Background: Diabetes is a common disease in the western world today, par-
ticularly in Sweden and in Finland where the prevalence of the population 
between 45-75 years is about 5% and 5-10%, respectively. Type 2 diabetes 
(T2D) is preceded by a pre-diabetic state with either impaired fasting glucose 
(IFG) or impaired glucose tolerance (IGT). In this state, which may last for 
many years, several studies have shown that diabetes can be prevented. A 
combination of improved diet and increased physical activity is recognized as 
an efficient means to prevent development of overt T2D in subjects with IGT, 
but is not proved to be efficient in subjects with prediabetes/IFG. Identifica-
tion of subjects with IGT is therefore of utmost importance in the strategy to 
prevent T2D. A questionnaire, FINDRISC, the Finnish Diabetes Risk Score, 
is developed and validated in Finland to identify subjects with increased risk 
of abnormal glucose tolerance (AGT =IFG/IGT/T2D). FINDRISC has never 
been evaluated in a Swedish population and is not validated to identify indi-
viduals with IGT.
Aim: To evaluate the FINDRISC questionnaire as a screening tool for diabe-
tes and prediabetes (AGT) in an ordinary Swedish middle-aged and elderly 
population. In particular we wanted to identify individuals with IGT.
Materials and methods: The FINDRISC questionnaire was sent to a complete 
population of 5157 people, 35 to 75 years old, in a defined area in Skövde, a 
middle sized town of 50,000 inhabitants in the Western part of Sweden. All 
recipients were asked to return the completed questionnaire to the Primary 
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Health Care Centre at Hentorp. Maximum score was 26 and all with a self-
calculated score ≥15 were encouraged to report to the clinic to have their 
fasting blood glucose tested. Those without diabetes were then tested with 
oral glucose tolerance test (OGTT) twice and participants were categorized 
as normal glucose tolerance (NGT), IFG, IGT, or T2D, respectively. Those 
with a mean 2h glucose showing IGT were invited to a diabetes prevention 
program.
Results: Research is ongoing and till now 2,618 questionnaires have been 
returned (50,7%). Mean age was 56±11 years in women and 58±12 years in 
men and mean score was 8.5±5.1 in men and 8.4±4.5 in women. Of these, 
260 individuals (9.9%) had a risk score ≥15 and altogether 153 have, so far, 
had a fasting blood glucose test taken at the health care unit. We detected 16 
subjects with new T2D (10.4%), 15 with IGT (9.8%) and 47 with IFG (30.7%). 
A FINDRISK score ≥15 was associated with a positive predictive value (PPV) 
of 51% for AGT, and a PPV of 9.8% for IGT.
Conclusion: In this first Swedish study the FINDRISC questionnaire was 
found to have a relatively high PPV of 51% when screening for AGT, but for 
IGT a PPV of only 9.8% was found. IFG was by far the most common form of 
abnormal glucose metabolism and preventive measures for these individuals 
should be better defined.
Supported by: GU, Sahlgrenska Academy, VGR, Skaraborg Institute
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A Chinese diabetes risk score for opportunistic screening of undiagnosed 
diabetes and abnormal glucose tolerance
M. Liu1, M. Jin2, C. Pan3; 
1Endocrinology, The First Hospital Affiliated to Chinese PLA General 
Hospital, 2Endocrinology, Peking University First Hospital, 3Endocrinology, 
Chinese PLA General Hospital, Beijing, China.
Background and aims: To develop a diabetes risk score (DRS) to predict in-
cident diabetes and evaluate its efficiency on screening for individuals at high 
risk for undiagnosed diabetes and abnormal glucose tolerance in Chinese 
population.
Materials and methods: Three DRSs were developed based on a 10-year 
follow-up cohort of 1,457 individuals aged 48-87 years without diabetes at 
baseline and validated on another cohort of 394 non-diabetes individuals age 
43-88 years, followed up after 10 years. DRS1 contained simple clinical infor-
mation, while DRS2 added fasting plasma glucose based on DRS1, and DRS3 
added serum lipids based on DRS2. The DRS with the largest area under the 
ROC curve (AUC) was chose as the final DRS and was evaluated on screening 
of glucose abnormality in a cross-sectional sample of 699 individuals without 
known diabetes.
Results: DRS3 was considered as the final DRS because it had the best pre-
diction property. AUC was 0.734 (95% CI 0.702-0.766) predicting diabetes 
within 10 years, and also had adequate performance in validation cohort 
(AUC=0.759 (0.686-0.831). The DRS3 had sensitivity of 64.5% and 72.9%, 
specificity of 71.6% and 63.9% with an optimal cutoff of 4 of 12. In the cross-
sectional sample, AUCs were respectively 0.828 (0.797-0.860) and 0.909 
(0.884-0.933) detecting abnormal glucose tolerance and diabetes. A two-step 
strategy, identifying individual at increased risk for diabetes using DRS3 as a 
first step, followed by OGTT performance led to the identification of 76.2% of 
case of abnormal glucose tolerance and 100% of cases of unknown diabetes, 
whereas only requiring an OGTT in 47.2% study group.
Conclusion: The diabetes risk score, including clinical information and bio-
chemical indexes has good predictive ability for incident diabetes and is prac-
tical to screen subjects with abnormal glucose tolerance and diabetes in the 
general Chinese population.
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Low self rated health is associated with impaired glucose tolerance in 
men
B. Daka1, C.A. Larsson2, L. Bennet2, L. Råstam2, U. Lindblad1; 
1Department of Public Health and Community Medicine, The Sahlgrenska 
Academy, University of Gothenburg, 2Lund University, Department of 
Clinical Sciences, Malmö, Sweden.
Background and aims: Self-rated health (SRH) is an independent predictor 
of future mortality. Recently, the weight gain in women seems to be influ-
enced by previous poor SRH. Poor SRH in diabetics has been related with 
increased mortality according to McEwen et al. We attempt to see how poor 
SRH is related to IGT in subjects who are not aware of having it, in a Swedish 
population.
Materials and methods: This investigation is based on data from a popu-
lation-based study in Vara(1811) and Skövde(1005) including subjects aged 
30-74 years (1416 women and 1400 men) in two small communities in a ru-
ral area of south-western Sweden, as part of the Skaraborg Project. SRH was 
investigated by the question: “How do you rate your current health status in 
general?” with reply alternatives very good, good, reasonable, bad and very 
bad (called SRH-5 in the following text). Only a few participants rated their 
own health bad and very bad (fig 1). The variable SRH-5 was dichotomised 
in 2 values: High-SRH if the answer was “very good” and “good” and Low-
SRH if the answer was “reasonable”, “bad” and “very bad”. A standard 75g 
oral glucose tolerance test (OGTT) was performed in each participant with-
out known diabetes. Blood samples at fasting, 10, 30, 60 and 120 minutes 
after glucose administration were collected and analysed for p-glucose and 
s-insulin. IFG, IGT and diabetes was defined concordant with WHO criteria. 
HOMA-IR was calculated by formula HOMA-IR= FPG X FP insulin/22.5. 
Subjects with diabetes (108) were excluded from our analysis. Average weekly 
alcohol consumption, physical activities (PA) and sleeping disorders were es-
timated in a structured questionnaire. Logistic regression analysis has been 
used on estimating dichotomised variables and Univariate Analysis of Vari-
ance was used to estimate mean differences for continuous variables in sub-
jects with low respective high SRH. Results were calculated separately in men 
and women.
Results: According to criteria described on methods 72.6 % rated high his 
own health and 26.3 % low (in 30/2816=1.1% missing). An evaluation av 
mean differences between subjects with low respective high SRH showed that 
low SRH is associated with higher BMI, fasting glucose, fasting insulin and 
HOMA-IR. Low SRH was also associated with higher incidence of IGT(M: 
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5.2% resp 13.4% Or 2,83 CI 1.8-4.4 p<0,001; F 8.5% resp 12.4% Or 1.52 CI 
1,0-2.2 p=0.033). Adjusting for possible confounders age, BMI, PA, alcohol 
consumption and sleeping disorders we found a remaining strong association 
between SRH and IGT in males but not in females (Tab.1).
Conclusion: These results confirm IGT to influence independently the per-
ception of health even when it is an unknown state. Nevertheless there are 
some gender differences suggesting ulterior confounders in men, in addition 
to those we reported. On the other hand SRH is confirmed an independ-
ent risk factor to disease which confirm the importance of using it on daily 
practice. 
Tab 1. Logistic regression analysis adjusted for possible confounders in 
males.
Males High 
SRH
Low 
SRH
OR/Δ 
mean
CI P-value P-value
IGT 5.2% 13.4% 2,83 1.8-4.4 0.000 0.000
Adj. for age 2.83 1.8-4.5 0.000 0.000
Adj. for age and BMI 2.51 1.6-4.1 0.000 0.000
Adj. for age and PA 2.36 1.4-3.9 0.001 0.001
Adj. for age and sleep 2.76 1.7-4.6 0.000 0.000
Adj. for age and alcoh 2.88 1.8-4.7 0.000 0.000
Adj. for all conf together 1.95 1.1-3.4 0.017 0.017
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Predictors of normalisation of prediabetes and of persistence of normal 
glucose tolerance: KORA S4/F4 cohort study
B. Kowall1, W. Rathmann1, M. Heier2, R. Holle2, A. Peters2, B. Thorand2,  
C. Herder1, K. Strassburger1, G. Giani1, C. Meisinger2; 
1German Diabetes Center, Düsseldorf, 2Helmholtz Zentrum München, 
Germany.
Background and aims: Reversion from prediabetes to normal glucose toler-
ance (NGT) without specific interventions has been rarely studied. We in-
vestigated in a cohort study which factors beyond blood glucose (lifestyle, 
clinical parameters) are associated with normalization of glucose tolerance. 
In addition, we investigated which factors contribute to long-term persist-
ence of NGT.
Materials and methods: Oral glucose tolerance tests were conducted at 
baseline and at follow-up in a population-based study in Southern Germa-
ny (KORA S4/F4; 1,223 non-diabetic subjects aged 55-74 years at baseline 
(1999-2001); 887 subjects (73%), 436 of whom had prediabetes at baseline, 
participated in the 7-year follow-up). Prediabetes comprised impaired fast-
ing glucose (IFG) and impaired glucose tolerance (IGT) (ADA diagnostic 
criteria). Subjects who were prediabetic at baseline and normoglycaemic at 
follow-up were only classified as “return to NGT” when their fasting plasma 
glucose decreased by > 5 mg/dl or when their 2 h glucose decreased by > 10 
mg/dl (clinically relevant differences).
Results: 66 of 436 (15%) subjects who had been prediabetic at baseline re-
turned to NGT after 7 years. In a logistic regression model with age, sex, BMI, 
change of BMI, glucose values, diabetes family history, and lifestyle factors as 
independent variables, fasting and 2h glucose were strong predictors of nor-
malization of prediabetes (p<0.001 both). Women were more likely to return 
to NGT (OR=2.6, 95%-confidence interval (CI)=1.3-5.0). A decrease in BMI 
significantly improved the chance of returning to NGT (OR, 95%CI: 7.7, 3.0-
20.1 for BMI change <= -1kg/m2, and 3.6, 1.6-8.2 for -1kg/m2 < BMI change 
<= 1kg/m2, compared to BMI change > 1kg/m2) whereas baseline BMI was 
not independently associated with return to NGT (p=0.57). Physical activity, 
smoking and alcohol intake were not significantly associated with return to 
NGT. After replacing BMI by waist circumference (WC), an increase in WC 
turned out to diminish chances of return to NGT (OR: 0.7, 0.5-0.9 per 5 cm). 
Moreover, subjects with hypertriglyceridaemia (triglycerides >= 2.0 mmol/l) 
and subjects with low HDL-cholesterol (men: <= 1.03 mmol/l, women: <= 
1.29 mmol/l) were less likely to become normoglycaemic (p<0.05). Among 
451 subjects with NGT (baseline) 321 (71%) remained normoglycaemic 
in the 7-year follow-up. In a logistic regression model with age, sex, BMI, 
glucose values, family history, and lifestyle factors as independent variables, 
higher levels of 2h glucose (p<0.001), higher BMI at baseline (OR: 0.93, 0.88-
0.99 per BMI unit), high alcohol consumption (OR: 0.5, 0.3-0.97 compared to 
moderate consumption), and parental diabetes (OR: 0.5, 0.3-0.9) significantly 
decreased the likelihood of NGT persistence. For BMI change, a borderline 
significance was found (OR, 95%CI: 1.9, 0.99-3.8 for BMI change <= -1kg/m2 
compared to BMI change > 1kg/m2).
Conclusion: Reversion to NGT without specific interventions is not a rare 
event in older prediabetic subjects. Several factors modifiable by lifestyle (in 
particular weight change) have an influence on normalization of prediabetes 
as well as on persistence of NGT.
Supported by: German Research Foundation (DFG)
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Assessment of glycated haemoglobin A1c as a potential diagnostic tool in 
prediabetes and diabetes 
T. Tankova, N. Chakarova, L. Dakovska, I. Atanassova; 
Department of Diabetology, Clinical Center of Endocrinology, Sofia, 
Bulgaria.
Background and aims: During recent years there is an increasingly recog-
nized need to develop strategies and criteria for diabetes screening and diag-
nosis that will allow effective early disease detection and will find out the pos-
sible utility of glycated hemoglobin A1c (HbA1c). The aim of the present study 
is to measure the level of HbA1c in subjects with different glucose tolerance 
- normal glucose tolerance (NGT), impaired fasting glucose (IFG), impaired 
glucose tolerance (IGT) and newly-diagnosed diabetes (NDD) and to evalu-
ate the potential role of HbA1c as a diagnostic tool for undetected diabetes 
and prediabetes (IFG and IGT).
Materials and methods: A total of 2134 subjects (899 males and 1235 females), 
of mean age 50.3±13.9 years and mean BMI 29.5±6.2 kg/m2 were included in 
the study. According to their glucose tolerance they were divided into 4 groups 
- 1198 with NGT, 313 with IFG, 241 with IGT and 382 with newly-diagnosed 
screening-detected type 2 diabetes. All participants underwent a standard oral 
glucose tolerance test (OGTT) with 75g glucose and the categories of glucose 
tolerance were defined according to 2006 WHO criteria. Plasma glucose during 
OGTT - fasting and 2-hour level, was measured by a hexokinase enzyme meth-
od. HbA1c was measured by an immunoturbidimetric method (COBAS INTE-
GRA 400, Roche Diagnostics GmbH, Mannheim, Germany). Statistical analysis 
of the data was performed by SPSS 16.0 for Windows (SPSS, Chicago, USA). 
Receiver operating characteristic (ROC) curve analysis was used to examine the 
sensitivity and specificity of HbA1c for detecting diabetes and prediabetes.
Results: HbA1c levels were significantly higher in all groups with altered glu-
cose tolerance - 5.72±0.61% in IFG, 5.84±0.63% in IGT and 7.5±1.69% in 
NDD as compared to the group with NGT - 5.23±0.65% (p<0.0001 for all 
groups). There was significant difference in HbA1c between the two prediabet-
ic states (p=0.02), the level of HbA1c of both groups being significantly lower 
as compared to NDD (p<0.0001). Significant positive correlation was estab-
lished between the level of HbA1c and both fasting plasma glucose (r=0.78, 
p<0.001) and 2-hour plasma glucose (r=0.76, p<0.001). The ROC analysis 
demonstrated that HbA1c had strong correlation with undiagnosed diabetes, 
with an area under the receiver operating characteristic curve (AUC-ROC) of 
0.958 (95% CI: 0.946-0.970), as well as with undiagnosed prediabetes - AUC-
ROC of 0.729 (95% CI: 0.702-0.755). The AUC-ROC for undiagnosed DM 
was similar between HbA1c and fasting plasma glucose - 0.99 (95% CI: 0.983-
0.997) and 2-hour plasma glucose - 0.982 (95% CI: 0.973-0.992). Analysis 
with ROC curves showed that the optimal cut-off level of HbA1c for diagnosis 
of diabetes was 6.1% with a sensitivity of 86% and specificity of 92%. The 
optimal cut-off level of HbA1c for undiagnosed prediabetes (IFG and IGT) 
appeared to be 5.5% with a sensitivity of 71% and specificity of 64%.
Conclusion: HbA1c appears to be a sensitive and useful tool for identifying 
subjects with impairment in glucose tolerance (prediabetes and diabetes) and 
it should be considered in the development of diagnostic strategies.
Supported by: Ministry of Education and Science, Bulgaria
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The role of haemoglobin A1c testing in diagnosing diabetes in Korean 
adults
H.-J. Lee1, J.-Y. Oh1, Y.-A. Sung1, D.-J. Kim2, S.-H. Kim3, S.G. Kim4,  
S. Moon5, I. Park6, E.-J. Rhee7, C. Chung8; 
1Internal Medicine, Ewha Womans University, Seoul, 2Internal Medicine, 
Inje University, Seoul, 3Internal Medicine, Kwandong University, Seoul, 
4Internal Medicine, Korea University, Seoul, 5Internal Medicine, Catholic 
University, Incheon, 6Internal Medicine, Gachon University, Incheon, 
7Internal Medicine, Sungkyunkwan University, Seoul, 8Internal Medicine, 
Yonsei University, Gangwon, Republic of Korea.
Background and aims: The international expert committee has recently rec-
ommended the use of HbA1C assay to diagnose diabetes, with a threshold of 
≥ 6.5%. We aimed to characterize the cut off value of HbA1C in diagnosing 
diabetes based on 75-g oral glucose tolerance test (OGTT) in Korean adults.
Materials and methods: We recruited 902 adults (mean age 40±13(21~80) 
yrs, mean BMI 22.9±3.5 kg/m2) without a self-reported history of diabetes 
from 8 university hospitals in 2009. A 75-g OGTT and HbA1C sampling 
were performed in all examinees. Glucose concentrations were measured by 
colorimetry method (ADVIA2400 autoanalyzer, Siemens, USA), and HbA1C 
was measured by immunoturbidimetric method (Cobas integra800, Roche, 
Switzerland) at the central laboratory. Receiver operating characteristic curve 
analysis was used to examine the sensitivity and specificity of HbA1C for 
diagnosing diabetes.
Results: The HbA1C threshold of 6.0% proved to be the optimal limit for 
diagnosing diabetes, with a 88.2% sensitivity and a 79.9% specificity. The cut 
off values increased with age (6.0% at ages 21~40, 6.2% at 41~60, and 6.4% at 
> 61 years) and were similar in both men and women (6.2 vs. 6.1%). HbA1C 
of ≥6.5% had a 53.8% sensitivity and a 98.3% specificity in detecting diabetes. 
This relatively low sensitivity may limit its use as a screening method for dia-
betes. Using the HbA1C ≥ 6.5% criteria, the positive predictive value (PPV) 
of OGTT based diabetes was 74.6%, with a negative predictive value (NPV) 
of 95.2%. And using the HbA1C ≥ 6.0% criteria, the PPV of OGTT based 
diabetes was 74.6%, with a NPV of 95.2%.
Conclusion: From our study, the cut-off value of HbA1C for diagnosing dia-
betes based on 75-g OGTT was 6.0%, and adjustment of this value by age 
would be needed. Further studies will be carried out to determine whether 
age-specific diagnostic criteria should be needed.
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Screening for diabetes; inappropriate classification of “low risk”?
A.J. Dawson1, J.M. Ng1, K.A. Smith2, D.D. Mellor1, M.M. Aye1, S.L. Atkin1, 
E.S. Kilpatrick2; 
1Department of Diabetes and Endocrinology, University of Hull, 
2Department of Clinical Biochemistry, Hull and East Yorkshire NHS Trust, 
Hull, United Kingdom.
Background and aims: Recently there has been debate regarding screening 
strategies for type 2 diabetes (T2DM). Latest guidelines from the American 
Diabetes Association (ADA) and from the UK Department of Health in the 
United Kingdom (DoH) recommend the use of glycolysated haemoglobin 
(HbA1c) as a method of diagnosing T2DM in patients and also identifying 
patients at risk of developing the condition in the future. The threshold of 
6.5% has been agreed upon by both parties as the diagnostic threshold for the 
diagnosis of T2DM. In the identification of patients at high risk of T2DM, the 
ADA has proposed an HbA1c of equal to or more than 5.7% as compared to 
DoH of 6.0%. Patients considered at high risk of developing DM should be 
offered diet/lifestyle interventions and recommended for regular screening in 
the future. This study sought to study the patients who had an HbA1c and a 
concurrent glucose tolerance test (OGTT) and to study the relationship be-
tween the two results with regard to these new proposed thresholds.
Materials and methods: During the period Jan 2007 to Nov 2009 inclusive, 
all patients who had an OGTT and HbA1c performed concurrently within 
our primary care trust were included in the analysis. Data was obtained from 
the laboratories services serving the area. All HbA1c results were calibrated 
through harmonisation to the DCCT (NGSP) assay. All patients tested for 
gestational diabetes or were pregnant were excluded from the analysis. The 
results were then stratified into groups with HbA1c of less than 5.7%, be-
tween 5.7 and 5.9% and more than 6.0% and OGTT result of either a fasting 
glucose of ≥7 mmol/L or a 2 hour reading of ≥ 11.1 mmol/L.
Results: There were a total of 835 patients who fit the criterion for analysis. 
(444M, 391F, median age 64 years (interquartile range 56-73). Using the ADA 
cut off of an HbA1c of less than 5.7%, 4.0% of all patients screened had an 
OGTT consistent with diabetes. Increasing the cut off to less than 6.0% (DoH 
guidelines) results in a further 58 patients (6.9% of all patients screened), i.e. 
in total 91 patients (10.9% of all screened) who would have been stratified as 
low risk despite their abnormal OGTT.
Discussion: In summary using a current ADA cut off of HbA1c 5.7% in the 
identification of patients at risk of developing DM fails to identify approxi-
mately 1 in 25 patients who may have overt diabetes mellitus. The DoH cut 
off of 6.0% results in a further 1 in 15 of patients who were classified as low 
risk. This results highlight a clinical concern as these patients may not receive 
another screening appointment for a prolonged period despite results which 
previously would have resulted them receiving appropriate intervention.
Table 1
HbA1c < 5.7% HbA1c 5.7-5.9% HbA1c ≥ 6.0%
Normal OGTT 88 (10.5%) 98 (11.7%) 119 (14.3%)
Abnormal OGTT 33 (4.0%) 58 (6.9%) 439 (52.5%)
Total 121 156 558
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Screening diabetes with HbA1c and fasting plasma glucose
T. Yang, D. Yu, H. Zhou, G. Zhu; 
Dept. Endocrinology, First Affiliated Hospital of Nanjing Medical 
University, China.
Background and aims: To examine the validity of glycated Haemoglobin Alc 
and fasting plasma glucose (FPG) as a screening test for type 2 diabetes.
Materials and methods: A total of 1330 Chinese subjects (433 male and 
897 female) at an average age of 58.23±12.75 were enrolled. All subjects un-
derwent a 75g oral glucose tolerance test (OGTT) and AlC measurement. 
Receiver operating characteristic curve (ROC curve) analysis was used to 
examine the sensitivity and specificity of FPG and Alc for detecting diabetes.
Results: Based on 1999 WHO criteria,944 had normal glucose 
tolerance(NGT),22 had impaired fasting glucose(IFG),236 had impaired 
glucose tolerance(IGT),37 had both of IGT and IFG,91 had diabetes. The 
prevalence of newly diagnosed diabetes was 6.84%. Based on the ROC curve, 
the optimal cut-point of FPG related to diabetes diagnosed by OGTT was 
5.77 mmol/L which was associated with a sensitivity and specificity of 85.7% 
and 91.2% respectively. The area under the curve (AUC) is 0.923 (95%CI 
0.881~0.964). The positive likelihood ratio is 9.74 while the negative likeli-
hood ratio is 0.16. The optimal cut-point of Alc related to diabetes diagnosed 
by OGTT was 6.1%,which was associated with a sensitivity and specificity 
of 83.5% and 88.88% respectively. The area under the curve (AUC) is 0.905 
(95% CI0.861~0.950). The positive likelihood ratio is 7.46 while the nega-
tive likelihood ratio is 0.19. The optimal cut-point of FPG related to IGT was 
4.98mmol/L which was associated with a sensitivity and specificity of 65.2% 
and 65.2% respectively. The area under the curve (AUC) is 0.718(95%CI 
0.684~0.752). The positive likelihood ratio is 1.87 while the negative likeli-
hood ratio is 0.53. The optimal cut-point of HbAlc related to IGT was 5.7% 
which was associated with a sensitivity and specificity of 65.6% and 63.1% re-
spectively. The area under the curve (AUC) is 0.680(95%CI 0.643~0.717). The 
positive likelihood ratio is 1.77 while the negative likelihood ratio is 0.55.
Conclusion: Compared with A1c, FPG has a greater value in diabetes screen-
ing, they have relativity in sensitivity, specificity, positive likelihood ratio 
and negative likelihood ratio. The subjects with HbA1c ≥ 6.1% or FPG ≥ 
5.77mmol/L should be tested by OGTT to identify if they have diabetes or 
not.
Comparisons of the sensitivity and specificity with different diagnosis values 
for diabetes
Standard Sensitivity (%)
Specificity 
(%)
Positive like-
lihood ratio
Negative like- 
lihood ratio
FPG≥5.60mmol/L 85.7 88.5 7.45 0.16
FPG≥7.00mmol/L 62.6 100 ∞ 0.37
FPG≥5.77mmol/L 85.7 91.2 9.74 0.16
bA1c≥6.1% 83.5 88.8 7.46 0.19
FPG≥5.77mmol/L 
and HbA1c≥6.1%
78.0 95.2 16.25 0.23
FPG≥5.77mmol/L  
or HbA1c≥6.1%
93.4 78.6 4.36 0.08
Supported by: Jiangsu Province’s Key Medical Center Program of China
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Limitations of HbA1c as a diagnostic test
A. Peter, E. Schleicher, H.-U. Häring, A. Fritsche; 
Universität Tübingen, Germany.
Background and aims: Recent ADA recommendations have included gly-
cated hemoglobin as a new diagnostic criteria for diabetes mellitus. However, 
glycation of hemoglobin is a complex process influenced by hereditary, racial 
and environmental factors as well as the hemoglobin turnover. Together, only 
about 50% of the variation in glycated hemoglobin levels is expected to be 
explained by blood glucose profiles. In this study, we have therefore com-
pared the diagnostic value for diabetes of glycated hemoglobin and fasting 
and stimulated blood glucose concentrations after an oral glucose tolerance 
test according to the new ADA recommendations in a risk cohort.
Materials and methods: 2036 previously non-diabetic Caucasians at risk to 
develop type 2 diabetes consecutively underwent a 75g oral glucose tolerance 
test. Glycated hemoglobin was determined with the HPLC method (Tosoh 
A1c 2.2), external and internal quality controls were well within the allowed 
ranges.
Results: The oral glucose tolerance test classified 1523 individuals as normal 
glucose tolerant (NGT), 387 as impaired glucose tolerant (IGT) or impaired 
fasting glycemia (IFG) and 126 as diabetic. Using the newly recommended 
glycated hemoglobin cut-off for diabetes of 6.5%, 53 % of the diabetic indi-
viduals were not detected. In our cohort, 2-h plasma glucose but not fast-
ing glucose identifies 65% of all diabetic patients with glycated hemoglobin 
<6.5%. 39% of the diabetic patients’ glycated hemoglobin was in the inter-
mediate range of 5.7-6.5% . To diagnose these patients, one third of the total 
cohort with a glycated hemoglobin in the intermediate range would need to 
undergo a re-screening by an OGTT. Still, one in seven diabetic subjects had 
a glycated hemoglobin below 5.7% and would remain undiagnosed.
Conclusion: Aiming to prevent glucotoxic beta-cell destruction at an early 
stage of the disease, increased postprandial blood glucose values need to be 
diagnosed and treated. Therefore, despite the intriguing simplicity, glycated 
hemoglobin has obvious limitations to diagnose diabetes and prevent its 
complications.
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The HbA1c cut points for detecting type 2 diabetes and prediabetes in a 
risk population - is this the right way?
C. Koehler, E. Henkel, F. Schaper, M. Hanefeld; 
Center for Clinical Studies, GWT-TUD GmbH, Dresden, Germany.
Background and aims: The study’s aim was to evaluate the adequacy of a 
HbA1C cut point as screening tool to detect type 2 diabetes (T2DM) and 
prediabetic stages in a risk population for diabetes.
Materials and methods: A total of 1,028 middle aged (40-70 years) German 
participants of the Risk factors in IGT for Atherosclerosis and Diabetes study 
(RIAD) without known diabetes were included. A standardized 75g OGTT 
was performed after an overnight fasting period. As the basis for the clas-
sification of diabetes and its prediabetes stages it was applied the definition 
by WHO. Plasma glucose was measured by hexokinase method and HbA1C 
by HPLC. Based on the method of the receiver operating characteristic curve 
(ROC) the optimal cut point for T2DM, impaired glucose tolerance (IGT) 
and impaired fasting glucose (IFG) with sensitivity and specificity was cal-
culated.
Results: The prevalence of newly detected T2DM was 13.8%, of IGT 25.7% 
and IFG 10.6%. The cut points with the corresponding values for sensitivity 
and 1-specificity were prepared in the table.
Conclusion: The results of the HbA1C measurement (as screening tool 
for newly diagnosed T2DM and the prediabetic stages) suggest in this risk 
population a sensitivity of approx. 65% but a high rate of false positive tests 
between 21 and 48%. This indicates that HbA1C could not appropriate to de-
tect T2DM and prediabetes in a risk population. The physicians should assess 
the individual risk of the patient and in case of high risk should perform an 
OGTT to evaluate the glycemic state.
HbA1C cut points for the hyperglycemic stages
HbA1C cut point value (%) AUC Sensitivity 1-specificity
T2DM 6.0 0.80 0.66 0.21
IGT 5.6 0.62 0.67 0.48
IFG 5.6 0.65 0.63 0.44
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The HbA1c assays in population diabetes screening in Eastern Poland
G. Mardarowicz, T.A. Nicer; 
Family Medicine Department, Lublin, Poland.
Background and aims: The glycosylated haemoglobin (HbA1c) assay is the 
test of choice for the metabolic control of diabetes (DM). In recent time it 
is recommended also for its diagnosis. The aim of the study was to evaluate 
the diagnostic utility and limitations of HbA1c in screening for DM in adult 
population of Eastern Poland.
Materials and methods: In the representative sample of adult population of 
the Lublin region chosen from the general population by two layer drowning, 
the oral glucose tolerance test (OGTT) , estimation of blood lipids , evalua-
tion of blood pressure , body mass index (BMI) at baseline (1999-2001), and 
at 5th yr follow-up (2004-2005) were performed. DM was diagnosed accord-
ing to WHO criteria. HbA1c was determined in 2170 of 3781 survey par-
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ticipants (mean age 55,9±12,3) at baseline screen and it was repeated in 386 
subjects in follow-up. HbA1c assay was performed by LPLC chromatography 
standardized by NGSP. The diagnostic usefulness of HbA1c was evaluated 
using ROC (Receiver or operating characteristic) curve analysis.
Results: The mean value of HbA1c in 1294 subjects with normal OGTT was 
5,4± 0.54% ,in 617 subjects with impaired glucose tolerance- 5,55 ±0.6%, 
in 214 subjects with newly detected DM - 5,96 ±1.13%, and in 40 - with 
known DM- 7,1 ±1.64% .The HbA1c didn’t change significantly in a group 
of 253 subjects during 5 year long prospective observation (5,51±0,48 vs 
5,49±0,51%). In follow-up study 240 newly detected diabetics were recog-
nised. The baseline cut- off point of HbA1c in ROC curve for future diabetes 
was estimated at 5,3% (75,2% sensitivity, 50,1% specificity). The HbA1c value 
≥6.5% was found in 154 subjects (14,1% of studied cases). Among them 65 
subjects were diagnosed by WHO criteria as diabetic and 52 subjects had 
DM diagnosis by ADA criteria. As the cut-off point of 6.5% is related more to 
the risk of diabetic complications than single measures of glucose concentra-
tions, the ADA criteria didn’t captured 66%, and WHO criteria -58% of high 
risk individuals. The sensitivity/specificity of A1c cut-off point of 6,5% was in 
our population 16/97%.
Conclusion: Our results are consistent with data from US population study 
with comparable sample size and similar age. The diagnostic utility of HbA1c 
with recommended cut-off point of 6,5% is limited by low sensitivity of test 
assessed in polish population on 16%.
Supported by: Polish Ministry of Health
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Detection of diabetes in coronary artery disease: oral glucose tolerance 
test or glycated haemoglobin and fasting plasma glucose?
E. Delgado1, J.M. De la Hera2, I. Lozano2, E. Hernandez2, J.M. Vegas3,  
C. Fernandez-Cimadevilla2, F. Torres2, A. Carro2, J. Bayon2, J.M. Garcia-
Ruiz2, P. Avanzas2; 
1Endocrinology, Hospital Universitario Central de Asturias, Oviedo, 
2Cardiology, Hospital Universitario Central de Asturias, Oviedo, 
3Cardiology, Hospital Clínico Universitario, Valladolid, Spain.
Background and aims: The proposal of the ADA of incorporating the glycat-
ed hemoglobin (A1C) in the diagnosis of the newly detected diabetes (NDD) 
may interfere with the recommendation of the EASD about performing the 
oral glucose tolerance test (OGTT) in patients with coronary artery disease 
without known diabetes. We sought to determine the impact of both test, 
A1C and OGTT, in the diagnosis of diabetes in our series.
Methods: We analysed 338 patients with coronary artery disease without 
known diabetes treated with percutaneous intervention. Two weeks after dis-
charge an analysis including fasting plasma glucose (FPG), OGTT and A1C 
was performed. Newly detected diabetes was diagnosed by FPG if glucose 
>126 mg/dl; by A1C if FPG< 126 mg/dl and A1C>6.5% and by OGTT if 
FPG< 126 mg/dl and A1C< 6.5% and glucose post-challenge >200 mg/dl.
Results: Age 66.5 (56-74), males 80.1%, hypertension 49.7%, obesity 35.5%, 
previous myocardial infarction 37.3%. After the analysis the metabolic pro-
file of the series was: NDD 77 patients (22.8%), prediabetes 146 (43.2%) and 
normoglycemic 115 (34%). Of the totality of patients diagnosed of NDD, in 
19 (24.6%) the diagnosis was by FPG, 5 (6.4%) with the A1C and 53 (69%) 
by OGTT.
Conclusion: In our series a screening of diabetes in patients with coronary 
artery disease based in the FPG and A1C only diagnoses 31% of the real 
NDD. The OGTT is still absolutely necessary to rule out the NDD in this 
population.
Supported by: Spanish Society of Cardiology
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Proposal to rule out the unknown diabetes in patients with coronary 
disease
J.M. De la Hera1, J.M. Vegas2, I. Lozano1, E. Hernandez1, J.M. Garcia-Ruiz1, 
J. Bayon1, C. Fernandez-Cimadevilla1, F. Torres1, S. Secades1, T. Menendez3, 
P. Avanzas1, E. Delgado3; 
1Cardiology, Hospital Universitario Central de Asturias, Oviedo, 
2Cardiology, Hospital Clinico Universitario, Valladolid, 3Endocrinology, 
Hospital Universitario Central de Asturias, Oviedo, Spain.
Background and aims: The EASD recommends to perform an oral glu-
cose tolerance test (OGTT) to all the patients with coronary disease with-
out known diabetes. This proposal needs to be balanced with three facts: the 
OGTT is not usually performed in daily practice, the key in this population 
is the diagnosis of unknown diabetes (UDM) because the presence of predia-
betes would not substantially modify its secondary prevention and lastly the 
inclusion of the glycated hemoglobin (A1C) in the diagnosis of diabetes. We 
sought to validate a new score to rule out the presence of UDM in patients 
with coronary disease, selecting the indication of the OGTT.
Materials and methods: In a cohort of 338 patients without known DM, we 
perfectly characterized the glycometabolic profile with fasting plasma glu-
cose (FPG), OGTT, A1C and insulinemia, the coronary risk factors and the 
extension of the coronary disease. With a logistic regression analysis the pre-
dictors of UDM by the OGTT (defined as glucose postchallenge>200 mg/dl) 
were determined and a score was assigned to each patient.
Results: Seventy-seven of the 338 patients presented UDM, 146 prediabetes 
and 115 were normoglycemics. Thirty-one percent of the UDM could be di-
agnosed only with the FPG and A1C. The predictors of UDM in OGTT were: 
Age> 65 years (OR 2.8 (1.2-5.2), p=0.015, 3 points), non-coronary vascular 
disease (OR 2.6 (1.2-5.9) p=0.018, 3 points), ejection fraction<45% (OR 2.7 
(1.03-7) p=0.044, 3 points), FPG> 100 mg/dl (OR 4.74 (2.4-9.5) p<0.001, 5 
points) and A1C>6.1% (OR 5.8 (1.5-21.7) p=0.009, 6 points). The best cut-off 
point was established in >6 points (AUC 0.80, CI 95% (0.74-0.87) p<0.001). 
Thus, performing the OGTT to 31% of the population and together with the 
diagnosis by FPG and A1C it is possible to localize 83% of the real cases of 
UDM.The score was validated in another series of 115 patients with very 
close reproductability (AUC 0.84, CI 95% (0.74-0.95) p<0.001).
Conclusions: A systematic screening with FPG and A1C and performing the 
OGTT only depending on the risk assessed by our score (31% of the popula-
tion) allows the diagnosis of 83% of the UDM.
Supported by: Spanish Society of Cardiology
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Differences in cardiovascular risk profile of diabetic subjects 
discordantly classified by diagnostic criteria based on glycated 
haemoglobin and the oral glucose tolerance test
L. Lopez Rios1, M. Boronat Cortés2,1, P. Saavedra3, M. Riaño4,  
A.M. Wägner2,1, F.J. Nóvoa2,1; 
1Dtpo. Ciencias Médicas y Quirúrgicas, Universidad de Las Palmas de GC, 
2Sección de Endocrinología, Complejo Hospitalario Universitario Insular 
Materno Infantil de Gran Canarias, 3Dtpo. Matemáticas, Universidad 
de Las Palmas de GC, 4Servicio de Bioquímica, Complejo Hospitalario 
Universitario Insular Materno-Infantil, Las Palmas de GC, Spain.
Background and aims: Last year, an International Expert Committee advo-
cated the use of glycated haemoglobin A1C testing for diagnosis of diabetes. 
Based on the correlation between A1C levels and risk of retinopathy in sev-
eral epidemiological studies, the committee determined that an A1C value 
of 6.5% or greater should be used as the diagnostic threshold. Guided by this 
report, several leading organizations, including the American Diabetes As-
sociation (ADA), have approved the use of A1C as an additional criterion 
for diagnosing type 2 diabetes. The present study assesses the differences in 
the cardiovascular risk profiles of subjects differently categorized as having 
or not having diabetes with diagnostic criteria based on plasma glucose and 
A1C proposed by the 2010 American Diabetes Association clinical practice 
recommendations.
Materials and methods: A standard oral glucose tolerance test (OGTT), 
A1C, and a set of cardiovascular risk factors and indirect measures of insu-
lin resistance and insulin secretion were assessed in 964 individuals without 
previously known diabetes participating in the Telde Study, a cross-sectional 
epidemiological survey in Gran Canaria, Canary Islands, Spain.
Results: Taking the OGTT as the golden standard, the sensitivity and spe-
cificity of an A1C value ≥ 6.5% were 38.7% and 99.6%, respectively. Only 
four subjects diagnosed with diabetes by A1C did not also fulfil OGTT-based 
diagnosis. Those who met both diagnostic criteria presented greater meas-
ures of BMI and waist circumference, and higher values for fasting and 2-h 
plasma glucose, HOMA-IR, plasminogen activator inhibitor-1 and fibrino-
gen than subjects with diabetic OGTT but A1C < 6.5%. Abdominal obesity 
and 2 hours plasma glucose were the only variables independently associated 
with an A1C value ≥ 6.5% in a multivariate regression analysis.
Conclusion: Newly diagnosed diabetic individuals who fulfill both glucose 
and A1C-based diagnostic criteria for the disease seem to display a more un-
favorable cardiovascular risk profile than individuals who meet the glucose-
based but not A1C-based criteria.
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Prediction of incident type 2 diabetes in Norwegians using simple 
anthropometric measures - the HUNT study
C.M.Y. Lee1, S. Colagiuri1, M. Woodward2, K. Midthjell3; 
1Boden Institute of Obesity, Nutrition and Exercise, The University of 
Sydney, 2The George Institute for International Health, Sydney, Australia, 
3HUNT Research Centre, Norwegian University of Science and Technology, 
Levanger, Norway.
Background and aims: Waist circumference cut-points have been used to 
indicate increased risk of diabetes and cardiovascular disease. The cut-points 
for Caucasians have been recommended, however, based on limited data. 
Moreover, it is still uncertain if measures of abdominal obesity such as waist 
circumference and waist-to-hip ratio are superior at predicting diabetes risk 
over body mass index. The aims were, therefore, to establish which simple 
anthropometric measure best predicts incident type 2 diabetes, and to deter-
mine the optimal cut-points of each anthropometric measure for the predic-
tion of incident type 2 diabetes in Caucasians.
Materials and methods: Participants without known diabetes at the Nor-
wegian HUNT second survey (HUNT 2) who also participated in the third 
survey (HUNT 3), with height, weight, waist and hip circumferences meas-
ured at HUNT 2, and diabetes outcome at HUNT 3 were included. Receiver 
operating characteristic curves were used to assess discrimination of type 2 
diabetes, separately, for men and women.
Results: A total of 34293 participants (55% female) with 1176 new cases of 
type 2 diabetes were included in the analyses. The area under the curves for 
waist-to-height ratio (0.783 for men; 0.821 for women) and waist circumfer-
ence (0.768 for men; 0.810 for women) were larger than for body mass index 
(0.760 for men; 0.797 for women). The optimal cut-points for men were 27.8 
kg/m2 for body mass index (sensitivity 67%; specificity 71%), 95 cm for waist 
circumference (sensitivity 70%; specificity 70%), 0.90 for waist-to-hip ratio 
(sensitivity 76%; specificity 62%), and 0.53 for waist-to-height ratio (sensi-
tivity 71%; specificity 71%). For women, the respective cut-points were 26.8 
kg/m2 (sensitivity 81%; specificity 66%), 85 cm (sensitivity 76%; specificity 
71%), 0.81 (sensitivity 76%; specificity 66%), and 0.51 (sensitivity 81%; spe-
cificity 68%).
Conclusion: Measures of abdominal obesity were superior to body mass in-
dex in the prediction of type 2 diabetes. There was, however, no statistical dif-
ference to suggest clinical advantage of one measure over another. The opti-
mal cut-points for body mass index in both sexes and for waist circumference 
in women were higher than those currently applied to Caucasians. Hence, the 
current anthropometric cut-points for Caucasians, or at least for Norwegians, 
may be inappropriate. These results should inform risk prediction algorithm 
in Caucasians.
Supported by: Nord-Trøndelag County Council, NTNU, GlaxoSmithKline
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Waist circumference and body mass index as predictors of prediabetes 
and type 2 diabetes in middle-aged Swedish women and men
A. Hilding, C.-G. Östenson; 
Dept. of Molecular Medicine and Surgery, The Endocrine and Diabetes 
Unit, Karolinska Institutet, Stockholm, Sweden.
Background and aims: Obesity is an important risk factor for type 2 diabetes 
(T2D). Waist circumference (WC) and body mass index (BMI), measure-
ments of central fat distribution and general obesity, respectively, are used 
to predict T2D. Recently, in a 7-yrs follow-up study of older subjects (mean 
age 69 yrs at baseline) it was shown that WC and BMI yielded similar predic-
tion in men, whereas WC was a superior predictor of T2D in women. The 
aim of the present population-based study was to evaluate WC and BMI as 
predictors of T2D, as well as of prediabetes (IFG, IGT), in a cohort of younger 
Caucasian subjects and in separate analysis for men and women.
Materials and methods: Subjects having normal glucose tolerance (NGT) 
at baseline, 3190 women (48±5 yrs, mean±SD) and 2215 men (47±5 yrs), 
participants of Stockholm Diabetes Prevention Program, were again at fol-
low-up, 8-10 years later, investigated with an oral glucose tolerance test 
(OGTT). T2D, including also those who were diagnosed with T2D during 
the time period between baseline and follow-up, IFG and IGT was detected 
in 59 (1.8%), 41 (1.3%) and 120 (3.8%) women and in 107 (5.0%), 81 (3.7%) 
and 126 (5.7%) men, respectively. Logistic regression analysis was performed 
and receiver operating characteristic (ROC) curves, with corresponding area 
under curve (AUC), evaluated the predictive power of WC and BMI, meas-
ured at baseline.
Results: In univariate analysis, both WC and BMI were strongly associated 
with the development of IFG, IGT and T2D in women and men, p<0.001. In 
women, WC and BMI predicted IFG similarly, ROC-AUC was 0.73 (0.67-
0.81, 95% CI) for WC and 0.75 (0.69-0.81) for BMI. However, for IGT and 
T2D WC was a stronger predictor in women; ROC-AUC was 0.70 (0.65-0.75) 
as compared to 0.67 (0.62-0.72), p=0.034, for IGT, and corresponding values 
for T2D were 0.80 (0.74-0.86) vs. 0.76 (0.69-0.83), p=0.010. In men, BMI was 
superior to WC in the prediction of IFG, ROC-AUC was 0.65 (0.59-0.70) vs. 
0.59 (0.53-0.65), p=0.005, whereas the two measurements predicted similarly 
for IGT and T2D. The BMI ROC-AUCs were 0.67 (0.62-0.72) and 0.68 (0.63-
0.73) and the WC ROC-AUCs were 0.65 (0.59-0.70) and 0.67 (0.61-0.72) for 
IGT and T2D, respectively. The optimal cut-off point for WC in the predic-
tion of T2D, using optimal sensitivity and specificity, was 83 cm in women 
and 96 cm in men.
Conclusion: In middle-aged men BMI is equal or better than WC in the pre-
diction of prediabetes and T2D. In contrast, in women WC is the equal or 
stronger predictor. The cut-off points for WC in the prediction of T2D are 
close to the values of the metabolic syndrome definition according to the In-
ternational Diabetes Federation.
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Optimal waist circumference cutoff value predicting the incident type 
2 diabetes as a diagnostic criterion of metabolic syndrome in Korean 
population aged 40 years and over: the Chungju Metabolic Disease 
Cohort study (CMC study)
Y.-M. Park1, H.-S. Kwon2, H.-S. Ha1, S.-H. Lee2, J.-H. Lee3, H.-W. Yim1,  
K.-H. Yoon2, M.-I. Kang2, H.-Y. Son2, W.-C. Lee1; 
1Department of Preventive Medicine, 2Division of Endocrinology and 
Metabolism, Department of Internal Medicine, 3The Catholic Institute of 
Ubiquitous Healthcare, The Catholic University of Korea, Seoul, Republic 
of Korea.
Background and aims: In 2009, a joint statement of the International Diabe-
tes Federation (IDF); the National Heart, Lung, and Blood Institute (NHLBI); 
the American Heart Association (AHA); the World Heart Federation; the In-
ternational Atherosclerosis Society; and the International Association for the 
Study of Obesity proposed a harmonized definition of metabolic syndrome 
(MetS) in which the presence of any three of five risk factors comprises a 
diagnosis of MetS. This new definition of MetS recommends that the IDF 
cutoff points of waist circumference (WC) be used for non-Europeans until 
more data are available. Several WC cutoffs for Korean population have been 
proposed, however, their results have limitation of cross-sectional studies. We 
aimed at determining the cutoff value of waist circumference as a diagnostic 
criterion of metabolic syndrome with respect to its ability to predict the inci-
dent type 2 diabetes in a Korean population.
Materials and methods: The Chungju Metabolic Disease Cohort (CMC) 
study that began in 2003 is an ongoing community-based cohort study of 
metabolic disease including type 2 diabetes and metabolic syndrome in 
a population aged 40 years and over. We conducted a baseline study using 
stratified random cluster sampling between 2003 and 2006. A total of 3,815 
non-diabetic subjects (1,474 men and 2,341women) without a history of 
ischemic heart disease and cerebrovascular disease were followed up for an 
average of 4.5 years. Receiver operating characteristic (ROC) curve analysis 
using Youden index and the area under curve (AUC) was applied. In addi-
tion, we performed a multivariate Cox proportional hazard model adjusting 
age, BMI, smoking, and smoking, drinking alcohol, exercise, and dietary hab-
its to evaluate the relative risk of development of type 2 diabetes according to 
the WC category for men and women.
Results: In the ROC curve analysis for the different WC cutoffs including 
80 cm, 85 cm, and 90 cm, the highest value of Youden index was obtained 
at a WC cutoff point of 85 cm for both sexes. Sensitivity and specificity were 
55.7% and 66.4% in men and 60.0% and 54.7% in women, respectively. After 
being controlled for other covariates, the relative risks for the development 
of type 2 diabetes tended to increase significantly, especially in women, as 
WC incremented. In addition, the relative risk for the development of type 
2 diabetes using <75 cm of waist circumference as a reference increased sig-
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nificantly in the category of 85-89.9 cm for women. Statistically significant 
associations also were consistently observed over the category of 85-89.9 cm 
for women.
Conclusion: The optimal cutoff value for waist circumference predicting the 
incident type 2 diabetes is considered to be 85 cm, especially in women, sug-
gesting that the Asian criterion of abdominal obesity (90 cm for men and 80 
cm for women) as a component of metabolic syndrome might not be applica-
ble for middle-aged to older population in Korea.
Supported by: Seoul R&D project, Ministry for health, welfare and family af-
fairs
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Association of body height with diabetes, blood pressure and metabolic 
syndrome among Sri Lankan adults
P. Ranasinghe1, M.A.R. Jayawaradena1, G.R. Constantine1, R. Sheriff1, D.R. 
Matthews2, P. Katulanda1; 
1Department of Clinical Medicine, Diabetes Research Unit, Colombo, Sri 
Lanka, 2Oxford Center for Diabetes Endocrinology and Metabolism, United 
Kingdom.
Background and aims: Being tall has been suggested to be associated with 
better cardio-vascular health and longevity. Height, a marker of childhood 
growth, is associated with lower mortality and morbidity from diabetes mel-
litus and from associated risk factors. It is thought that better childhood con-
ditions, such as improved nutrition and fewer respiratory infections, result 
in both greater adult height and lower rates of chronic non-communicable 
diseases. We aimed to report the relationship of height with diabetes mellitus, 
blood pressure (BP) and metabolic syndrome (MS) among Sri Lankan adults
Materials and methods: Data were available for height and socio-demo-
graphic factors from a nationally representative cross-sectional sample of 
4477 subjects above 18 years. Recruitment was preformed between 2005-
2006. Height was measured using Harpenden pocket stadiometers to the 
nearest 0.1 cm according to the standard methods. Subjects were considered 
to have ‘diagnosed diabetes’ if they had been previously diagnosed at a gov-
ernment hospital or by a registered medical practitioner. New cases (‘undi-
agnosed diabetes’) and metabolic syndrome were diagnosed according to 
World Health Organization criteria Seated blood pressure was recorded on 
two occasions after at least a 10-min rest using an Omron IA2 digital blood 
pressure monitor. Data were analysed using SPSS.
Results: Males were 39.5% and mean age of all subjects was 46.1 (SD±15.1) 
years. The mean height of all adults, males and females were 156.2±8.9cm, 
163.6±6.9cm and 151.4±6.4cm respectively (p<0.001, males vs. females). 
In all adults Height showed a significant negative correlation with fasting 
blood glucose (p<0.05, r= -0.052), 2-hour post-glucose blood glucose levels 
(p<0.001, r = - 0.089) and diabetes (p<0.001, r = -0.069). There was a sig-
nificant negative correlation between mean systolic BP and height (p<0.05, 
r = -0.032), this was not observed for the mean diastolic BP. Height demon-
strated significant correlations with total cholesterol (p<0.001, r = -0.106), 
HDL cholesterol (p<0.001, r = -0.142), LDL cholesterol (p<0.001, r = -0.104) 
and triglyceride (p<0.001, r =0.064) levels. Similar changes were observed in 
both genders (Table 1). The mean heights of patients with MS and without 
MS were 154.8 ± 8.8 cm and 156.6 ± 8.9 cm respectively (p<0.001).
Conclusion: Our data showed a negative correlation between height and 
blood glucose levels, serum cholesterol levels and mean systolic BP. Also pa-
tients with MS were significantly shorter than those without MS. These data 
suggest that being tall reduces diabetes and cardiovascular risks and the un-
derlying mechanisms needs further study.
Table:1 Relationship between height and metabolic parameters (*p<0.05)
Metabolic parameter Correlation coefficient (r)
All Male Female
Fasting blood sugar -0.052* -0.068* -0.052*
2 hour post glucose blood sugar -0.089* -0.062* -0.089*
Presence of diabetes -0.069* -0.105* -0.069*
Mean systolic blood pressure -0.032* -0.097* -0.123*
Mean diastolic blood pressure -0.028 -0.010 -0.029
Total cholesterol -0.106* -0.117* -0.103*
LDL cholesterol -0.104* -0.102* -0.083*
HDL cholesterol -0.142* -0.083* -0.018*
Triglycerides 0.064* 0.079 -0.097*
Supported by: The NSF, Sri Lanka and OCDEM, UK
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Neck circumference positively related with central obesity, overweight 
and metabolic syndrome in Chinese people with type 2 diabetes
G. Yang, S. Yuan, H. Fu; 
Endocrinology, Tongren Hospital, Beijing, China.
Background and aims: To investigate the association between neck circum-
ference and central obesity, overweight as well as metabolic syndrome in Chi-
nese individuals with type 2 diabetes.
Materials and methods: Subjects with type 2 diabetes (age 20-80 years) were 
recruited from 15 community health centers in Beijing using a multi-stage 
random sampling approach. Anthropometrics, including neck and waist cir-
cumference measurement was conducted. Metabolic syndrome was identi-
fied based on criteria of WHO. Central obesity was diagnosed according to 
criteria of IDF.
Results: 3182 diabetics (1294 men and 1888 women) without thyroid swell-
ing, were enrolled with mean (±SD) age of 64.0±10.1 years. The diabetic du-
ration was 9.37±6.56 years. The mean neck circumference was 36.6±3.7 cm, 
38.4 ±3.6 cm for men, and 35.4±3.3 for women (p<0.001). Receiver operating 
characteristics (ROC) analysis showed that the area under the neck-circum-
ference-and-central-obesity curve was 0.74 (95% C.I. (0.72, 0.77)) for men, 
and 0.75 (95% C.I. (0.72, 0.78)) for women (p<0.001). Furthermore, neck 
circumferences of ≥39 cm (with sensitivity of 56.3% and specificity of 79.2%) 
for men and ≥36cm (with sensitivity of 61.1% and specificity of 73.1%) for 
women were best cutoff levels for determining people with BMI ≥25.0 kg/
m2.Neck circumferences of ≥ 38 cm for men ,and ≥ 36 cm for women were 
best cutoff levels for determining people with metabolic syndrome. After ad-
justing with gender and age, neck circumference was associated significantly 
with metabolic syndrome (OR, 1.13 [95% C.I. (1.10-1.17)).
Conclusion: In the present study, neck circumference is positively related 
with body mass index, waist circumference and metabolic syndrome in Chi-
nese people with type 2 diabetes. The neck circumference might be used in 
clinical convenient index as a predictor for central obesity and metabolic syn-
drome. Further studies are needed for closer identification of this association 
in general population.
Supported by: Capital Medical Developing Foundation of China
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Impaired insulin sensitivity and beta cell function predict the onset of 
diabetes in non-diabetic women with former gestational diabetes
A. Grassi1,2, A. Tura1, G. Pacini1, A. Mari1, Y. Winhofer3,  
A. Kautzky-Willer3; 
1Metabolic Unit, ISIB-CNR, Padova, 2Department of Information 
Engineering, University of Padova, Italy, 3Department of Internal Medicine 
III, Medical University of Vienna, Austria.
Background and aims: Gestational diabetes mellitus (GDM) is the specific 
type of diabetes that may develop during pregnancy. After delivery, women 
with previous GDM (pGDM) often normalize their glucose levels, but they 
are at increased risk of developing type 2 diabetes, especially if they have 
other risk factors (i.e. obesity, hypertension, family history of type 2 diabe-
tes). In this context, it is important to see whether there are indications in 
pGDM immediately after delivery about their possible development of overt 
diabetes. Aim of this study was the analysis of possible differences in insulin 
sensitivity and beta cell function between non-diabetic pGDM developing 
diabetes within 3-5 years from delivery and those who instead remained non-
diabetic.
Materials and methods: A total of 77 pGDM were studied with a 75-g 3h oral 
glucose tolerance test (OGTT) at baseline (i.e., immediately after partum) 
and during the 5 year study period. Insulin sensitivity was evaluated with 
the oral glucose sensitivity index (OGIS), while beta cell function through 
mathematical modelling of C-peptide, that yields B-cell sensitivity to glucose 
stimulus (BGS) and early insulin response (rate sensitivity, BRS). After the 
baseline examination, at a following visit the OGTT of 17 women matched 
the ADA/WHO criteria for diabetes (progressors, PROG), while in the re-
maining 60 women no sign of diabetes was found (NON-PROG).
Results: In Table 1, subjects’ characteristics and metabolic parameters at 
baseline are shown. PROG were slightly older and with higher BMI. Glucose, 
both fasting and during OGTT, was more elevated in PROG, while insulin 
was not significantly different, yielding lower insulin sensitivity (OGIS). Beta 
cell response was markedly impaired in PROG, especially the beta cell sensi-
tivity to glucose (BGS) which was 40% lower.
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Conclusion: Non-diabetic women with previous GDM developing diabetes 
within 3-5 years exhibit lower insulin sensitivity and B-cell function than 
pGDM who remain non-diabetic. The assessment of these metabolic param-
eters immediately after delivery could therefore be very useful to characterize 
the subjects at particularly high risk in order to start early prevention against 
the development of diabetes.
Table 1
NON-PROG PROG p-value
Age (years) 33.4 ± 0.5 36.2 ± 1.2 0.0337
BMI (kg m-2) 25.6 ± 0.5 31.8 ± 1.7 <0.0001
Fasting plasma glucose (pmol l-1) 4.80 ± 0.06 5.45 ± 0.16 <0.0001
Plasma glucose at 2h (pmol l-1) 6.06 ± 0.17 8.30 ± 0.41 <0.0001
Mean plasma glucose (pmol l-1) 6.37 ± 0.13 8.41 ± 0.22 <0.0001
Mean plasma insulin (pmol l-1) 280 ± 21 336 ± 50 0.133
OGIS (ml min-1m-2) 456 ± 9 379 ± 13 <0.0001
BGS (pmol min-1m-2mM-2) 106 ± 6 64 ± 7 0.0005
BRS (pmol m-2mM-1) 649 ± 66 324 ± 98 0.0321
Characteristics and metabolic parameters of the subjects at the baseline 
(mean ± SE).
Supported by: Austrian Nationalbank Jubiläumsfonds, grant 11198 to AKW
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Contribution of different biomarkers to risk of type 2 diabetes
J. Montonen1, D. Drogan1, H.-G. Joost1, H. Boeing1, A. Fritsche2,  
E. Schleicher2, M.B. Schulze3, T. Pischon1; 
1German Institute for Human Nutrition Potsdam-Rehbruecke, Nuthetal, 
2University of Tuebingen, 3Technische Universität München, Freising, 
Germany.
Background and aims: Over the past years, a number of circulating blood 
biomarkers have been identified and proposed as predictors of type 2 diabe-
tes. In the present study we quantified to what extent biomarkers of different 
metabolic pathways contribute to the risk of type 2 diabetes.
Materials and methods: The contribution of different biological pathways 
to the development of type 2 diabetes was estimated in a case-cohort design 
based on circulating blood biomarkers from participants aged 35 - 65 years in 
the EPIC-Potsdam Study. The analytic sample included 613 participants with 
incident diabetes and 1965 participants without diabetes. We constructed a 
biomarker score based on plasma values of glycated haemoglobin (HbA1c), 
gamma-glutamyltransferase (GGT), HDL-cholesterol, hs-CRP, and adi-
ponectin. Cox proportional hazard regression was used to estimate relative 
risks adjusted for age, sex, body mass index, waist-circumference, education, 
sport activity, cycling, occupational activity, and smoking and alcohol intake. 
The proportion of the association between the score and diabetes risk ex-
plained by each biomarker was estimated using effect decomposition method 
by entering quintiles of glycated haemoglobin (HbA1c), gamma-glutamyl-
transferase (GGT), HDL-cholesterol, CRP, and adiponectin simultaneously 
in the model.
Results: The relative risk of type 2 diabetes between extreme quintiles of the 
overall biomarker index score was 14.6 (95% confidence interval (CI): 6.81, 
31.2; P<0.001). A total of 27.7% (CI: 22.0, 34.1) of the risk was explained by 
HbA1c. For the other biomarkers the corresponding proportions were 11.5% 
(CI: 5.53, 17.7) by GGT, 14.4% (CI: 8.67, 20.3) by HDL-cholesterol, 6.45% 
(CI: -0.38, 13.4) by hs-CRP, and 13.5% (CI: 6.98, 20.3) by adiponectin.
Conclusion: The results support the hypothesis that different biological 
pathways reflected by markers such as HbA1c, GGT, HDL-cholesterol, and 
adiponectin play a role in the development of type 2 diabetes independently 
from each other.
Supported by: Bundesministerium für Bildung und Forschung
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Association between liver markers and insulin sensitivity, insulin 
secretion and endogenous glucose production in non-diabetic 
individuals
F. Bonnet1, M. Laville2, B.J. Balkau3, on behalf of the RISC Study investigators;
1Dept of Endocrinology-Diabetology, University hospital; Inserm U625, 
Rennes, 2Inserm U870-Inra 1235, Centre de Recherche en Nutrition 
humaine Rhône-Alpes, Lyon, 3INSERM CESP U1018, Villejuif, France.
Background and aims: An association between elevated concentrations of 
gammaglutamyl transferase (GGT) and alanine aminotransferase (ALT) with 
the risk of type 2 diabetes has been shown. However, the underlying patho-
physiological mechanisms remain poorly determined. The aim of our study 
was therefore to explore whether a modest elevation of liver markers is asso-
ciated with insulin resistance and/or altered insulin secretion.
Materials and methods: We studied 1310 healthy individuals from the RISC 
study (Relationship between Insulin Sensitivity and Cardiovascular disease). 
All participants had a euglycemic-hyperinsulinemic clamp and an OGTT 
with determination of indices of insulin secretion. A subgroup of 409 also 
had an assessment of endogenous glucose production (EGP) with a tracer.
Results: Both fasting and 2 h glycaemia progressively increased over GGT 
and ALT quartiles. Insulin sensitivity (as assessed by the M/I value) was 
inversely correlated to the plasma concentration of GGT or ALT (r=-0.30, 
p<0.0001 for each). Modest elevations in liver markers were significantly as-
sociated with an increase risk of insulin-resistance (defined as the M/I value 
in the first quartile) after adjustment for age, sex, physical activity and waist: 
GGT>20 UI/l, OR :1.80 (1.3-2.5), p=0.0007; ALT>20 UI/l, OR :1.59 (1.2-2.2), 
p=0.004. There was no association between aspartate aminotransferase levels 
and insulin sensitivity. The hepatic insulin resistance index (EGP x fasting in-
sulinaemia) was more strongly correlated with GGT (r=0.29, p=0.0001) than 
with ALT levels (r=0.16, p=0.02). These significant associations persisted in 
multivariate models. GGT and ALT levels were positively correlated with 
fasting glucagon and inversely to adiponectin concentrations. Insulin secre-
tion, as assessed by the disposition index, was not significantly associated 
with liver markers. In multivariate models, GGT and ALT were independent 
determinant of 2h glycaemia during the OGTT.
Conclusion: GGT and ALT, even at moderately elevated levels, are closely 
linked to both peripheral and hepatic insulin resistance but not with insulin 
secretion, in healthy non-diabetic individuals. This confirms the pertinence 
of these markers to identify insulin resistant individuals at high risk of type 
2 diabetes.
Supported by: EU 
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Urinary myo-inositol is a useful and cost-effective marker to detect 
glucose intolerance: a community-based “Tottori-Kofu” study
H. Shiochi1, H. Shimohiro2, S.-I. Taniguchi1, N. Yamamoto1, Y. Fujioka1,  
K. Sumi1, K. Matsuzawa1, S. Izawa1, H. Kinoshita1, T. Ohkura1, H. Ohkura1, 
K. Inoue3, M. Takechi4, C. Shigemasa1; 
1Division of Molecular Medicine and Therapeutics, Department of 
Mutidisciplinary Internal Medicine, Tottori University Faculty of Medicine, 
Yonago, 2Department of Pathobiological Science and Technology, School 
of Health Science, Tottori University, Yonago, 3Hino Hospital, 4Ebi Clinic, 
Kofu, Japan.
Background and aims: Myo-inositol is one of 9 inositol stereoisomers with 
cyclic sugar alcohol and its composition is like D-glucose. Myo-inositol ex-
ists in human tissues. The urinary excretion of myo-inositol is augmented in 
diabetes patients, since the ascent of plasma glucose obstructs the re-absorp-
tion of myo-inositol in renal uriniferous tubule. Consequently, urinary myo-
inositol excretion indirectly reflects plasma glucose level. Therefore, urinary 
myo-inositol could be a useful marker of glucose intolerance. We performed 
Tottori-Kofu study, which was designed to pick up patients with impaired 
glucose tolerance(IGT). We applied 75gOGTT as the most effective strategy 
to detect IGT. However, OGTT requires much time and cost. We presumed 
urinary myo-inositol could be a good candidate marker to detect IGT. In this 
study, we aimed to estimate urinary myo-inositol value in OGTT.
Materials and methods: We performed 75gOGTT in 110 people (male 35, 
female 75, average age 68.3 years old). In OGTT, we collected blood samples 
before, 30, 60 and 120 min. after glucose loading. Urine samples were also 
taken before and 120 min. after glucose loading. According to OGTT results, 
we segmented the group “normal glucose tolerance (NGT)” (plasma glucose 
<110mg/dl before glucose loading and <140 mg/dl after 120 min.), “IGT” 
(plasma glucose ≥140mg/dl and <200 mg/dl after 120 min.) and “diabetes 
mellitus(DM)” (plasma glucose ≥200mg/dl after 120 min.). We defined the 
subjects as pre-IGT if their plasma glucose is ≥180 mg/dl after 60 min. The 
OGTT results were follows: NGT 67(male15 / female52), pre-IGT 9 (m3 
/ f6), IGT 27 (m12 / f15) and DM 7(m5 / f2). Urinary myo-inositol(UMI) 
was calibrated by urinary creatinine(Ucre). We calculated ΔUMI as follows: 
ΔUMI(mg/gCre) =UMI/Ucre of 120min. - UMI/Ucre of 0min.
Results: ΔUMI was significantly associated with the plasma glucose re-
sponse in OGTT. Estimated ΔUMI(mg/gCre) was follows; NGT(8.6±13.4), 
pre-IGT(26.7±18.9), IGT(27.6±30.0) and DM(97.0±48.4). The worse glucose 
intolerance, the higher ΔUMI would be expected. Based on the ROC curve, 
we set ΔUMI cut-off value as 10mg/gCre and compared the detecting abil-
ity of glucose intolerance among ΔUMI, A1C(≥6.2%) and urinary glucose 
excretion (≥100mg/dl after 120 min in OGTT). Within these three candi-
dates, ΔUMI(≥10 mg/gCre) was the most powerful marker to isolate IGT. 
The positive rate of detecting glucose intolerance was follows; ΔUMI 69.8%, 
A1C 18.6% and urinary glucose excretion 55.8%.
Conclusion: We confirmed that ΔUMI derived from OGTT protocol is an 
effective marker to isolate glucose intolerance. We presume ΔUMI measure-
ment could be an easy and cost-effective way in a community-based screen-
ing of glucose intolerance, since we need only urine samples, not blood, after 
oral glucose loading to calculate ΔUMI.
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The association between IGFBP-1 and type 2 diabetes is modified by 
degrees of insulin sensitivity and early insulin response
C. Berne1, A. Flyvbjerg2, H. Grønbæk3, K. Jensevik4, L. Berglund4,  
B. Zethelius5; 
1Department of Medical Sciences, Uppsala University, Sweden, 2Department 
of Endocrinology and Internal Medicine, Clinical Institute, Aarhus 
University Hospital, 3Medical Department V, Clinical Institute, Aarhus 
University Hospital, Denmark, 4Uppsala Clinical Research Center, Uppsala 
University, 5Department of Public Health and Caring Sciences /Geriatrics, 
Uppsala University, Sweden.
Background and aims: Clinical studies suggest that insulin-like growth fac-
tor binding protein 1 (IGFBP-1) may be an important determinant of glucose 
tolerance. Further, defects in insulin secretion and action are major abnor-
malities in type 2 diabetes (T2DM). Accordingly, we studied the relationship 
between serum IGF-I, IGF-II, IGFBP-1, IGFBP-3 and T2DM, taking into ac-
count insulin sensitivity (M/I) and the early insulin response (EIR).
Materials and methods: The participants were from a population-based co-
hort of 71-year-old men (n=1219) from which patients taking anti-diabetic 
oral medication or insulin were excluded. The cohort then underwent a 7-
year follow-up (n=667). At baseline a euglycaemic insulin clamp and a 75-
gram OGTT were performed. The concentrations of IGF-I, IGF-II, IGFBP-1 
and IGFBP-3 were measured and their respective relationship with T2DM 
was assessed using logistic regression, presenting odds ratios (ORs) with 95% 
confidence intervals (CIs) for 1 SD increase in the predictor variable, adjusted 
for BMI and heredity for diabetes.
Results: The cross sectional associations with T2DM are presented in Table 1. 
The odds ratio for the association between IGFBP-1 and a low risk of T2DM 
was altered after adjustment for insulin sensitivity. IGF-I, IGF-II, IGFBP-1 
or IGFBP-3 were not significantly associated with the risk for T2DM over 7 
years of follow-up (p=0.14-0.90).
Conclusion: The association between IGFBP-1 and risk of T2DM is modified 
by EIR and insulin sensitivity implying confounding effects of insulin secre-
tion and insulin resistance on the association, whereas it was not observed for 
IGF-II and the carrier proteins. The IGFs and their carrier proteins did not 
predict T2DM but were associated with the diabetic state.
Table 1. Cross sectional associations between IGF-I, IGF-II, IGFBP-1 or 
IGFBP-3 and T2DM
Variable OR, 95 %CI, crude OR,adjusted for EIR OR,adjusted for M/I
IGF-I 1,36, 1,07-1,73 1,53, 1,18-1,99 1,28, 0.99-1,65
IGF-II 1,33, 1,05-1,70 1,42, 1,09-1,86 1,29, 1,02-1,64
IGFBP-1 0,71, 0,56-0,90 0,52, 0,40-0,68 1,23, 0.90-1,66
IGFBP-3 1,38, 1,07-1,77 1,52, 1,15-2,01 1,34, 1,03-1,74
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The association between soluble urokinase plasminogen activator 
receptor (suPAR) levels and incident diabetes is modified by body weight 
status in high-risk people with impaired glucose regulation
T.M. Jensen1, A. Heraclides1, S.S.S. Rasmussen2, J. Eugen-Olsen3,4,  
S.B. Haugaard3,2, K. Borch-Johnsen1, A. Sandbaek5, T. Lauritzen5,  
D.R. Witte1; 
1Steno Diabetes Center, Gentofte, 2Department of Endocrinology, 
Copenhagen University Hospital, Hvidovre, 3Clinical Research Center, 
Copenhagen University Hospital, Hvidovre, 4ViroGates A/S, Birkerød, 
5Department of General Medicine, University of Aarhus, Denmark.
Background and aims: An association between the inflammatory marker 
soluble urokinase plasminogen activator receptor (suPAR) and incident type 
2 diabetes mellitus (T2DM) has been documented in healthy individuals. 
We aimed to assess whether this association exists among high-risk people 
with impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) and 
whether it is affected by other risk factors for progression to diabetes.
Materials and methods: suPAR levels were measured in plasma samples 
from 1933 participants of the ADDITION study (aged 37-73 years) who had 
isolated IFG, isolated IGT or combined IFG/IGT at baseline (2001-2006) us-
ing the suPARnostic® ELISA kit (ViroGates, Denmark). Incidence of T2DM 
was ascertained by OGTT at 3 years of follow-up in combination with regu-
lar reports on glucose measurements in GP practice up to December 2008. 
The association between suPAR levels at baseline and incident T2DM was 
analyzed using logistic regression. Analyses were stratified by glucose regula-
tion status (IFG, IGT, IFG/IGT) and BMI (lean, overweight, obese - WHO 
definition).
Results: Adjusting for sex and age, there was a 48% overall increase in risk 
of developing T2DM per 2-fold increase in baseline level of fasting suPAR 
(Table 1). The association was modified by body weight status, being limited 
to overweight participants. Additional adjustment for waist, blood pressure, 
lipids and smoking attenuated the association between suPAR levels and 
T2DM in the population as a whole; however, the association in the over-
weight group remained robust. Glucose regulation status did not modify the 
association.
Conclusion: suPAR levels are associated with incident T2DM in overweight 
individuals with impaired glucose regulation. Our finding of an absence of 
association among the obese may be due to the exclusion by design of those 
with diabetes at baseline, or may be caused by a difference in phenotype of 
obese subjects compared to overweight participants. This effect needs to be 
examined in greater detail in future studies.
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Table 1. Odds Ratios for incident type 2 diabetes per each 2-fold increase in 
baseline suPAR level among 1933 participants of the ADDITION study.
sex+age adjusted sex+age+BMI*+ 
waist+ bp+ 
triglycerides+ 
HDL+ smoking
No of cases/
total
OR (95% CI) OR (95% CI)
Whole sample 599/1933 1.48. (1.12; 1.96) 1.24. (0.91; 1.69)
By glucose regulation status**
i-IFG 186/800 1.36 (0.84; 2.21) 1.08 (0.63; 1.84)
i-IGT 175/652 1.56 (0.95; 2.56) 1.48 (0.85; 2.58)
IFG/IGT 238/481 1.28 (0.75; 2.16) 1.12 (0.63; 2.01)
By body weight status**
Lean (BMI<25kg/m2) 70/341 0.65 (0.31; 1.37) 0.61 (0.26; 1.41)
Overweight  
(BMI ≥25 <30kg/m2)
231/806 2.36 (1.48; 3.76) 2.14 (1.31; 2.51)
Obese (BMI≥30kg/m2) 298/786 1.12 (0.73; 1.73) 1.00 (0.63; 1.60)
*BMI included both as linear and quadratic term; Only waist circumference 
was used in the models stratifying by BMI
**p for interaction = 0.93 for glucose regulation status; 0.003 for body weight 
status
Supported by: Funding of the ADDITION study: http://www.addition.au.dk/
Funding.htm
394
Leptin independently predicts diabetes in Swedish men
M. Lilja1,2, O. Rolandsson2, M. Norberg2, P.W. Franks2, S. Söderberg2; 
1The Research and Development Unit, Jämtland County Council, 
Östersund, 2Departement of Public Health and Clinical Medicine, Umeå 
University, Sweden.
Background and aims: Leptin may have detrimental effects on the beta-cell 
function, and may decrease insulin sensitivity. Previous studies have shown 
an independent association between leptin levels and future diabetes in men, 
but not in women, whereas other studies have opposed these findings. The 
aim of this study was to evaluate leptin as an independent predictor of future 
diabetes in a northern Sweden setting.
Materials and methods: Within the Västerbotten Intervention Program 
(VIP), all inhabitants were invited to a health survey the year they turned 40, 
50 and 60 years old. Questionnaires, blood sampling, measurements of an-
thropometry and blood pressure, and an oral glucose tolerance test (OGTT) 
were included. Through registries covering Västerbotten County, 638 subjects 
with type 2 diabetes were identified, who had participated in VIP prior (more 
than one year, mean 6.4 years) to diagnosis. A control group of 1564 non-dia-
betics, group matched for age, sex, region of residence and survey date within 
VIP was identified. Leptin was analysed with a RIA in stored samples. Logis-
tic regression analysis was performed, and Odds Ratios (OR) and their 95 % 
Confidence Interval (95% CI) calculated. Leptin data are presented as quar-
tiles with sex-specific cut offs based on the distribution amongst controls.
Results: In the univariate analysis, high leptin (Quartile 4 vs. Quartile 1) 
predicted diabetes in both men (OR 8.2 95% CI 5.2-13.0) and women (OR 
6.4 95% CI 3.8-10.6, ptrend <0.0005). After adjustments for BMI, cholesterol, 
smoking habits, physical activity, education level and hypertension, leptin re-
mained associated with diabetes in men OR 2.2 95% CI 1.2-3.9, ptrend 0.05). 
In separate models adjusting for BMI and adiponectin, diabetes heredity and 
fasting and 2-hour glucose levels from OGTT, or for a homeostasis model 
assessment (HOMA 2), leptin remained associated to future diabetes in men 
(ptrend <0.0005 for all).
Conclusion: Leptin independently predicts future diabetes in Swedish men, 
but not in women.
Supported by: Visare Norr
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A novel method for the assessment of insulin physiology: urinary C-
peptide creatinine ratio can be used to assess insulin sensitivity and beta 
cell function in non-diabetic subjects
A. Rawlingson, B.A. Knight, R. Oram, T.J. McDonald, B.M. Shields,  
A.T. Hattersley; 
Peninsula NIHR Clinical Research Facility, Exeter, United Kingdom.
Background: Urinary C-peptide creatinine ratio (UCPCR) is a convenient, 
non-invasive measure of insulin secretion that is stable at room temperature 
for 3 days. It has been validated as a test of beta-cell function in type 1 and 
type 2 diabetes. The aim of our study was to test if UCPCR can be used to 
assess insulin sensitivity and insulin secretion in non-diabetic subjects under 
laboratory conditions and in the home setting.
Methods: We performed an oral glucose tolerance test (OGTT) using a 
standardised 75 g glucose load on 30 healthy volunteers (median age = 46 
years; median BMI = 24.47). Serum insulin and C-peptide were measured on 
fasting blood samples and those taken at 30 min intervals for 120 min follow-
ing glucose load and used to calculate insulin secretion and insulin resistance. 
UCPCR was measured on fasting urine samples and 120 min following glu-
cose load. On a separate day, volunteers were asked to collect urine samples 
at home, 120 min following their largest meal of the day and post them to 
the laboratory.
Results: Fasting UCPCR correlated with HOMA-S (R=0.55; P<0.001). 120 
min OGTT UCPCR correlated with serum insulin area under the curve 
(AUC) (R=0.69; P<0.001), serum C-peptide AUC (R=0.60; P<0.001) and ear-
ly insulin secretion (R=0.41; P<0.05). Post-meal UCPCR correlated with 120 
min OGTT UCPCR (R=0.55; P=0.01), serum insulin AUC (R=0.55; P<0.01), 
serum C-peptide AUC (R=0.53; P<0.05) and early insulin secretion (R=0.42; 
P=0.05).
Conclusion: In non-diabetic subjects, UCPCR measured in fasting urine 
samples and those collected following a glucose load or large meal are cor-
related with physiological measures of insulin sensitivity and insulin secre-
tion. As urine samples are stable for 3 days at room temperature and can 
be collected by individuals at home, UCPCR is a convenient method for the 
assessment of insulin physiology that could be used in large scale epidemio-
logical studies.
Supported by: Research & Development Directorate, Royal Devon & Exeter 
Hospital
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Sialic acid predicts incident cases of hospital-treated diabetes during 40 
years of follow-up in a defined population: the Värmland Health Survey, 
Sweden
P. Khalili1, F. Lundin2, J. Jendle1, I. Jungner3, P. Nilsson4; 
1Faculty of Health Sciences, Örebro, 2Värmland County Research Council, 
Karlstad, 3Department of Medicine, Karolinska Institutet, Stockholm, 
4Department of Clinical Sciences, Malmö, Sweden.
Background and aims: Elevated inflammatory markers correlate with fea-
tures of the metabolic syndrome and predict the development of type 2 dia-
betes. Sialic acid (SA) is related to glycoproteins and a marker of inflamma-
tion that has previously been associated with risk of coronary heart disease 
(CHD) events. We examined the role of SA in predicting incident hospital-
treated cases of diabetes during 40 years of follow-up.
Materials and methods: A population-based health survey was carried out 
between 1962 and 1965 in the county of Värmland, Sweden. In total, 47,527 
men and 48,124 women participated (mean age 48.9 and 48.6 years; range 
25-80 years). The screening consisted of measurement of height, weight and 
blood pressure, as well as blood sampling including the determination of 
serum SA concentration. All subjects have been followed in national regis-
ters until end of 2005 for incident cases of hospital-treated diabetes mellitus 
(DM) as primary or secondary diagnosis. The material was sub-divided into 
quintiles (Q1-Q5) from lowest (Q1) to highest SA-levels (Q5). The risk of 
incident DM in relation to SA was analyzed by logistic regression separately 
for each sex. The association between baseline SA and risk of incident hos-
pital-treated diabetes was analyzed by Cox proportional hazards regression 
before and after stepwise adjustment for baseline characteristics (age, BMI, 
hepatic transaminase GOT).
Results: During 40 years of follow-up, in all 4591 cases of diabetes treated in 
hospitals was recorded for men (9.7% of all men), and 5184 cases for wom-
en (10.8% of all women). The risk (OR) of incident DM in relation to SA-
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quintiles for men was 1.0 in Q1 (reference), 1.19 (95% CI 1.08-1.30) in Q2, 
1.20 (1.09-1.32) in Q3, 1.13 (1.02-1.25) in Q4 and 1.12 (1.02-1.24) in Q5. In 
women the corresponding OR was 1.0 in Q1, 1.24 (CI 1.12-1.36) in Q2, 1.31 
(1.19-1.43) in Q3, 1.56 (1.42-1.71) in Q4 and 1.56 (1.45-1.74) in Q5. After full 
adjustment in the Cox-regressions, Exp (B) for one standard deviation of SA 
was 1.11 (95% CI 1.08-1.14) in men. The corresponding risk for women was 
1.14 (1.11-1.17). P-values for all analyses were <0.0001.
Conclusion: The risk of incident diabetes mellitus in relation to high levels of 
sialic acid as an inflammatory marker is stronger in women than in men. The 
increased risk was independent of the other baseline characteristics.
Supported by: The Värmland County Research Council, Sweden
PS 17 Epidemiology of type 
2 diabetes mellitus and its 
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Cardiovascular risk factors and micro- and macrovascular complications 
in patients with type 2 diabetes in Italy
G. Pugliese1, A. Solini2, E. Bonora3, E. Orsi4, G. Zerbini5, C. Fondelli6,  
S. Morano1, M. Cignarelli7, L. Laviola8, F.L. Cavalot9, G. Gruden9,  
R. Trevisan10, M. Vedovato11, A. Nicolucci12, G. Penno2; 
1La Sapienza University, Rome, 2University of Pisa, 3University of Verona, 
4Fondazione IRCCS Cà Granda – Ospedale Maggiore Policlinico, Milan, 
5San Raffaele Scientific Institute, Milan, 6University of Siena, 7University 
of Foggia, 8University of Bari, 9University of Turin, 10Ospedali Riuniti, 
Bergamo, 11University of Padua, 12Consorzio Mario Negri Sud, S.Maria 
Imbaro, Italy.
Background and aims: Type 2 diabetes mellitus (T2DM) is associated with 
increased morbidity and mortality for cardiovascular disease (CVD) and mi-
crovascular complications. This study aimed at assessing the prevalence of 
CVD risk factors and micro and macrovacular complications in patients with 
T2DM in Italy.
Materials and methods: We used baseline data from the Renal Insufficiency 
And Cardiovascular Events (RIACE) Italian Multicenter Study, a prospective 
cohort study on reduced estimated GFR as an independent predictor of CVD 
morbidity and mortality in T2DM subjects. The RIACE cohort consists of 
15,773 T2DM patients consecutively visiting 19 Diabetes Clinics throughout 
Italy in years 2007-2008. Exclusion criteria were dialysis or renal transplan-
tation. The following information was collected by a structured interview: 
age, gender, smoking status, diabetes duration, current therapy, and previous 
major acute CVD events. Height, weight, blood pressure (BP), HbA1c, trig-
lycerides (TG), total- and HDL- cholesterol (C), creatinine and albuminuria 
were measured, GFR was estimated using the 4-variable MDRD equation, 
and retinopathy was assessed with ophtalmoscopy or retinography
Results: Age was 66.0± 10.3 years, diabetes duration 13.2± 10.2 years, and 
male (M)/female (F) ratio 57/43. HbA1c was 7.55±1.51%, with 24.2% and 
40.9% below 6.5% and 7%, respectively; 61.4%% were on oral agents, 15.5% 
on insulin, and 9.6% on combined therapy. BMI was 28.96±5.14, with 41.9% 
overweight, and 24.4%. 8.4% and 3.3%, respectively, with grade I, II and III 
obesity. Waist was 103.7±12.7 cm, with 51.8% M below 102 and only 12.4% 
F below 88. TG, HDL-, LDL- and non-HDL-C levels were 139.2±88.2, 
49.8±13.6, 107.7±32.6 e 134.9±36.8 mg/dl, respectively, with 68.3% on-target 
for TG, 50.7% of M and 56.8% of F for HDL-C, 42.1% for LDL-C and 48.3% 
for non-HDL-C; 46.2% were on lipid-lowering drugs and 42.5% on a statin. 
BP levels were 138.1±18.0 and 78.8±9.4 mmHg, with 43.5% and 73.1% with 
systolic and diastolic values <130 and 80 mmHg, respectively; 70.7% were on 
anti-hypertensive agents and 58.1% on RAS blockers. Current, former and 
never smokers were 15.3%, 28.1% and 55.6%, respectively. History of any 
CVD event was detected in 23.2%, myocardial infarction in 11.1%, stroke 
in 3.3%, foot ulcer/gangrene in 3.4%, and coronary, carotid and lower limb 
revascularization in 10.0%, 4.9% and 2.9%, respectively. Background and ad-
vanced retinopathy were detected in 12.5% and 9.6%, and micro and mac-
roalbuminuria in 22.2% and 4.7%, respectively. Prevalence of GFR classes 1, 
2, 3 and 4-5 as estimated by the MDRD formula was 29.6%, 51.7%, 17.1% and 
1.6%, respectively. Of the 2,960 patients with chronic kidney disease, 56.6% 
were normo, 30.8% micro and 12.6% macroalbuminuric.
Conclusion: Results of this large-cohort study indicate a relatively good con-
trol of CDV risk factors and low prevalence of complications in Italian T2DM 
patients.
Supported by: Fo.Ri.SID, DEM Foundation, Eli-Lilly Italia, Takeda, Chiesi and 
Boehringer
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Diabetes duration: a crucial factor when determining individual target 
levels of glycaemic control in old age? (ZODIAC-20)
K.J.J. van Hateren1, G.W.D. Landman1, N. Kleefstra1,2, I. Drion1,  
K.H. Groenier3, S.T. Houweling2,4, H.J.G. Bilo1,5; 
1Diabetes Centre, Zwolle, 2Langerhans Medical Research Group, Zwolle, 
3Department of General Practice, University Medical Center Groningen, 
4General Practice Sleeuwijk, 5Department of Internal Medicine, University 
Medical Center Groningen, Netherlands.
Background and aims: Studies regarding macrovascular consequences of 
glucose control in elderly patients (>75 years) with type 2 diabetes mellitus 
(T2DM) are lacking. This study aimed to investigate the relationship between 
HbA1c and (cardiovascular) mortality, and the role of diabetes duration in 
this relationship, in an elderly population.
Materials and methods: Between 1998 en 1999, 374 primary care patients 
older than 75 years with T2DM participated in the ZODIAC study, a prospec-
tive observational study. Data on mortality were collected in 2009. A Cox 
proportional hazard model was used to investigate the relationship between 
HbA1c as a continuous variable, as well as dichotomous variables (HbA1c 
<53 mmol/mol vs. HbA1c ≥53 mmol/mol, and HbA1c <48 mmol/mol vs. 
HbA1c ≥48 mmol/mol) and mortality. Analyses were performed in strata ac-
cording to diabetes duration (<5 years, 5-11 years, and ≥11 years). Age, gen-
der, smoking (yes or no), BMI, duration of diabetes, serum creatinine level, 
macrovascular complications (yes or no), albuminuria (yes or no), systolic 
blood pressure, total cholesterol-HDL ratio, and use of insulin (yes or no) 
were selected as possible confounders.
Results: In the group with a diabetes duration <5 years, the hazard ratios 
for HbA1c as a continuous variable were 1.40 (95%CI 1.14-1.73) and 1.66 
(95%CI 1.25-2.21) for all-cause and cardiovascular mortality respectively. 
Within this patient group, a HbA1c level of <53 mmol/mol at baseline was as-
sociated with a reduced all-cause and cardiovascular mortality risk compared 
to patients with worse glycemic control. The hazard ratios were 0.56 (95%CI 
0.33-0.95) and 0.28 (95%CI 0.11-0.69) respectively. Figure 1 illustrates the 
increased cardiovascular mortality rates for patients with a HbA1c level ≥53 
mmol/mol. Glycemic control was not related to mortality for patients with a 
diabetes duration ≥5 years.
Conclusion: Worse glycemic control is related to increased mortality in 
elderly diabetic patients, but only in those with T2DM of short duration. 
Randomised controlled trials are necessary to answer the question whether 
improving glycemic control is beneficial in elderly patients. Perhaps different 
optimum target levels should be used for T2DM of short and long duration.
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The role of cardiovascular risk factors in postmenopausal 
hypercholesterolemic women with abnormal fasting glucose: a post hoc 
analysis of the MEGA Study
T. Nakagami1, R. Nishimura2, H. Sone3, N. Tajima2; 
1Diabetes Centre, Tokyo Women’s Medical University School of Medicine, 
2Division of Diabetes, Metabolism and Endocrinology, Department of 
Internal Medicine, Jikei University School of Medicine, Tokyo, 3University 
of Tsukuba, Mito Medical Centre, Department of Endocrinology and 
Metabolism, Ibaraki, Japan.
Background and aims: The incidence of cardiovascular disease (CVD) is 
increased in postmenopausal women, and the presence of CVD risk factors 
diminishes the favorable profile of women against CVD. Thus, understanding 
the role of CVD risk factors for CVD events and identifying effective inter-
ventions is important in postmenopausal women. The aim of this study is to 
assess the combined effect of CVD risk factors including abnormal fasting 
glucose (AFG) on the development of CVD in hypercholesterolemic post-
menopausal women, and to evaluate the effect of low-dose pravastatin treat-
ment, using the data from a large-scale clinical trial (MEGA Study).
Material and methods: The MEGA Study examined the effect of low-dose 
pravastatin (10-20 mg/day, approved dose in Japan) on primary prevention of 
CVD in 7,832 Japanese patients (5,356 women, post-menopause to 70 years; 
2,476 men, 40 to 70 years) with mild to moderate hypercholesterolemia. Pa-
tients were randomized to diet alone (3,966 patients) or diet + pravastatin 
(3,866 patients) and followed for an average 5 years. AFG was defined as fast-
ing plasma glucose (FPG) ≥6.1 mmol/L or anti-hyperglycemic agent users. 
Patients not having FPG value were excluded from this analysis (n=1,661). 
Normal fasting glucose (NFG) was defined as FPG <6.1mmol/L. Hyperten-
sion was defined by the attending physician as ≥140/90 mmHg, using the 
Japan Society of Hypertension guideline. The incidence of CVD in relation 
to age, hypertension, and AFG were compared between sexes. Hazard ratios 
(HRs) for incident CVD were calculated by using Cox’s multivariable pro-
portional hazards model, with the combinations of age, hypertension, and 
AFG, adjusted for treatment arm, high density lipoprotein cholesterol, and 
smoking.
Results: The incidence of CVD events was 2.3% (125/5,356) in women and 
5.3% (130/2,476) in men. Table shows HRs for incident CVD for the eight 
possible combinations of the analyzed risk factors (age, hypertension, AFG). 
In women, compared to men, the risk for CVD was higher for each possi-
ble combination of age, hypertension and AFG, although no sex interaction 
was found for any risk factor combination due to small number of events. A 
similar risk reduction for coronary heart disease and cerebral infarction was 
found in the diet + pravastatin group compared to diet alone group (23% for 
women, p=0.39; 43% for men; p=0.03; interaction p=0.81).
Conclusion: The combining the older age and hypertension in AFG marked-
ly increased the CVD risk in postmenopausal hypercholesterolemic women 
than men. Women with AFG may achieve a similar risk reduction for coro-
nary heart disease and cerebral infarction with low-dose pravastatin as did 
men with AFG.
HRs for incident CVD for the combinations of age, hypertension, and AFG
Age ≥60y HT AFG Men Women
n.
(Events/
Patients)
HRs P-values n.
(Events/
Patients)
HRs P-values
- - - 9/536 1.0 4/955 1.0
+ - - 8/191 2.6 0.0142 12/857 3.3 0.0391
- + - 12/258 3.0 0.0496 12/512 4.9 0.0059
- - + 14/299 2.7 0.0207 4/291 3.0 0.1241
- + + 17/183 5.4 <0.0001 9/207 8.8 0.0003
+ + - 13/190 4.6 0.0005 27/723 8.3 0.0001
+ - + 17/177 5.9 <0.0001 18/303 13.5 <0.0001
+ + + 22/152 9.4 <0.0001 21/337 12.7 <0.0001
Supported by: MEGA Study Group, Daiichi Sankyo, Tokyo, Japan.
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Peptic ulcers and inflammatory diseases of the upper digestive tract 
increase the risk of incident diabetes independently of obesity. The 
Whitehall II study
D.R. Witte1, B. Carstensen1, A.G. Tabák2,3, C. Herder4, M. Kivimäki2; 
1Steno Diabetes Center, Gentofte, Denmark, 2Epidemiology and Public 
Health, University College London, United Kingdom, 3Semmelweis 
University, Budapest, Hungary, 4Institute for Clinical Diabetology, 
Düsseldorf, Germany.
Background and aims: Recent interest in the effect of intestinal microflora 
and gastric bypass surgery on diabetes risk has highlighted the close connec-
tion between the gastro-intestinal (GI) system and glucose metabolism. We 
studied whether a diagnosis of upper GI peptic/inflammatory or ulcerative 
disease increased the risk of subsequent diabetes during up to 20 years of 
follow up.
Materials and methods: We studied 6766 participants of the Whitehall II 
study [69.7% men, mean age: 49.9 years (SD:6.0), BMI: 25.3 (3.7)] free of 
diabetes and GI diagnoses at baseline in 1991-1993. Participants were fol-
lowed for incident diabetes with repeated OGTTs at 5-year intervals and self 
reports at 2.5-year intervals until December 2009. Hospital diagnoses were 
obtained from Hospital Episode Statistics data, covering all admissions to 
National Health Service hospitals in England. Participants with oesophagitis, 
gastritis, duodenitis, dyspepsia, gastro-oesophageal reflux or peptic ulcers of 
the oesophagus, stomach or duodenum (ICD-10 codes K20-K22, K25-K27, 
K29-K31) prior to diagnosis of diabetes or end of follow up were considered 
exposed. Their risk of incident diabetes was compared to the risk in those 
not exposed to an upper GI diagnosis using multivariate Poisson regression 
adjusting for relevant confounders.
Results: During a mean follow up of 16.9 years (total: 114,442 py), we ob-
served 772 cases of incident diabetes (incidence rate: 8.0 per 1000 py) and 363 
upper GI diagnoses. Mean time between GI diagnosis and DM was 5.5 years 
(SD: 3.3). The risk of diabetes increased after an upper GI diagnosis (Table 
1). Adjustment for BMI, waist circumference, HDL cholesterol, triglycerides, 
fasting glucose and hs-CRP did not attenuate the effect. Models assuming 
that exposure starts with a 1-year lag after an upper GI diagnosis showed very 
similar results. The proportion of diabetes cases diagnosed through a study 
visit OGTT did not differ significantly between those with and without a GI 
diagnosis, indicating that detection bias is unlikely. Results were also consist-
ent when examining oesophageal or gastric/duodenal diagnoses separately.
Conclusion: We found that peptic/inflammatory or ulcerative conditions in 
the upper GI tract increase the risk of diabetes by 10% per year in subsequent 
years independently of central and over-all obesity as well as other major risk 
factors for diabetes. Although baseline low grade inflammation did not ex-
plain our results, a later inflammatory response may play a role, in conjunc-
tion with alterations of the internal environment in the upper GI tract. Our 
results indicate that clinicians should be alert to the elevated risk of diabetes 
in patients with upper GI peptic/ulcerative diseases.
Table 1. Incidence rate ratio’s (IRR) for the risk of diabetes after an upper GI 
diagnosis
Per year after diagnosis
IRR (95% Confidence Interval)
Model A 1.08 (1.02;1.15)*
Model B 1.09 (1.03;1.16)*
Model C 1.10 (1.04;1.17)*
‘Ever diagnosed’
IRR (95% Confidence Interval)
Model A 1.69 (1.23;2.32)*
Model B 1.74 (1.27;2.40)*
Model C 1.85 (1.35;2.55)*
Adjustments: Model A: age and sex, Model B: A + BMI
and waist, Model C: B + HDL-cholesterol, triglycerides,
fasting glucose and hs-CRP. *: p-value <0.01.
Supported by: Funding structure: http://www.ucl.ac.uk/whitehallII/index.htm
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Increased risk of acute renal failure in patients with type 2 diabetes 
compared to those without diabetes
K.G. Brodovicz1, C.J. Girman1, T.D. Kou1, S.S. Engel2, L. Katz2,  
C.M. Alexander3, D.E. Williams-Herman2; 
1Epidemiology, Merck, North Wales, 2Metabolism, Merck, Rahway, 3Global 
Medical Affairs, Merck, North Wales, USA.
Background and aims: Acute renal failure (ARF) is characterized by a rapid 
decline in glomerular filtration rate and can occur in patients with normal re-
nal function as well as patients with pre-existing renal disease. ARF is a broad 
condition encompassing a spectrum of clinical renal dysfunction. While the 
natural history of a progressive decline in renal function from diabetic ne-
phropathy has been well-described in patients with type 2 diabetes mellitus 
(T2DM), few studies have assessed the risk of ARF in a large population of 
T2DM patients. This study quantified the risk of ARF associated with T2DM 
in a large general practice database from the United Kingdom. In addition, 
the risk of ARF in T2DM patients with multiple comorbidities was assessed.
Materials and methods: Patients with T2DM (n=148,963) based on diag-
nosis, prescriptions or laboratory glucose and patients without diabetes 
(n=2,834,927) were identified from the General Practice Research Database. 
Patients with end-stage renal disease were excluded from the study. Crude 
incidence and age/gender-adjusted hazard ratios (HR) of ARF were estimat-
ed for T2DM and non-DM. Multivariate Cox regression models adjusted for 
risk factors including prior ARF, chronic kidney disease (CKD - including 
diabetic nephropathy), congestive heart failure (CHF), hypertension (HT), 
alcohol use, obesity, smoking, and Charlson comorbidity index. To assess po-
tential additive effects, ARF risk was also assessed in patients with T2DM plus 
CHF and/or HT relative to patients without T2DM.
Results: Between 2003 and 2007, ARF incidence was 192 per 100,000 per-
son-years (p-y) in patients with T2DM compared to 24/100,000 p-y among 
patients without T2DM (crude HR 8.3, 95% CI 7.7, 8.9). Age, obesity, prior 
ARF, CHF, CKD, HT, and comorbidity index were also higher in patients with 
T2DM. The risk of ARF for T2DM patients remained significant but attenu-
ated in multivariate analyses adjusting for these factors (adjusted HR 2.4, 95% 
CI 2.2, 2.5). Adjusted ARF risk was also increased for patients with CHF (ad-
justed HR 2.2, 95% CI 2.0, 2.4), HT (adjusted HR 2.0, 95% CI 1.8, 2.2), and all 
of the above factors except CKD. Interestingly, the presence of CKD was not 
associated with an increased risk of ARF diagnosis (adjusted HR 1.25, 95% 
CI: 0.97 - 1.59). Adjusted ARF risk increased in T2DM patients with CHF 
and/or HT- T2DM with no HT/CHF: HR 2.3 (95% CI 2.1, 2.5), T2DM+HT 
(no CHF): HR 2.0 (95% CI 1.8, 2.3), T2DM+CHF (no HT): HR 4.5 (95% CI 
3.7, 5.5), T2DM+HT+CHF: HR 3.5 (95% CI 2.7, 4.5).
Conclusion: Patients with T2DM have increased risk for ARF compared to 
patients without diabetes, even after adjustment for known risk factors in-
cluding CKD. The finding that CKD alone is not associated with an increased 
risk of ARF diagnosis needs to be confirmed in other studies. The combina-
tion of T2DM, CHF, and HT further increased the risk for ARF relative to 
patients without T2DM. Physicians should be aware of this increased risk of 
ARF in T2DM patients, and the additional risk associated with the presence 
of other comorbidities such as CHF and HT.
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Oral contraceptive use and abnormal glucose regulation in Swedish 
middle aged women
A. Deleskog, A. Hilding, C.-G. Östenson; 
Molecular Medicine and Surgery, Stockholm, Sweden.
Background and aims: Use of oral contraception has been suggested to 
increase the risk of type 2 diabetes. Results of previous studies are however 
conflicting. The aim of this study was to investigate the association between 
oral contraceptives (OCs) use and abnormal glucose regulation in Swedish 
middle aged women.
Materials and methods: The present study includes 4794 women, aged 36-
56 at baseline (1996-98), residing in five municipalities in Stockholm Coun-
ty Council and participating in the cross-sectional and follow-up study of 
Stockholm Diabetes Prevention Programme, which is a prospective popula-
tion-based study. At both baseline and follow up 8 years later, the women 
were examined by oral glucose tolerance test (OGTT) classifying the subjects 
as having normal glucose tolerance, prediabetes (impaired fasting glucose 
(IFG), impaired glucose tolerance (IGT) or IFG+IGT) or type 2 diabetes. In 
addition, anthropometric measurements were collected and a questionnaire 
S 168 Diabetologia (2010) 53:[Suppl1]S1–S556
1 C
was answered, including questions on lifestyle factors and use of OCs in dif-
ferent doses of estradiol and progesterone.
Results: In the cross sectional study, current use of OCs was associated with 
prediabetes, odds ratio (OR)=4.1 (95%CI: 2.2-7.8) but not with type 2 diabe-
tes. The association to prediabetes was entirely linked to IGT, OR=7.1 (3.3-
15.8) in current users of OCs and in former users, OR=2.1 (1.1-3.9). Women 
who used OC at baseline had a better cardiovascular risk profile with lower 
BMI, were more physically active and smoking was less common. At the fol-
low up, the increased risk for prediabetes did not persist.
Conclusion: Current use of OC was associated with a four times increased 
risk of having prediabetes and seven times increased risk of having impaired 
glucose tolerance. No increased risk persisted at the follow-up, suggesting 
that the risk of prediabetes due to prior use of OC is decreasing with time. 
The healthier lifestyle in women who used OCs may have contributed to re-
duce the long-term risk of prediabetes.
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Diabetic patient or patients with diabetes: an approach from comorbidity 
in primary health care
G. Mora Navarro1, Á. Alberquilla Menéndez-Asenjo1, P. Magán Tapia2,3,  
M. Gil de Pareja Palmero1, V. Del Saz Moreno1, C. González Rodríguez-
Salinas2, M. Pilas Pérez2, M. Ugalde Díez2, P. Vallejo Sánchez-Monge1,  
L. Rodríguez García1, G. García Álvarez1; 
111th Primary Health Care Area, Madrid, 2Hospital Universitario 12 de 
Octubre, Madrid, 3CIBER Epidemiología y Salud Pública, Barcelona, Spain.
Background and aims: To describe differences in burden of illness and vari-
ability in the Family Physicians management of patients with diabetes de-
pending on their co-morbidity.
Materials and methods: Cross-sectional observational and descriptive study. 
Participans and settings: 129 family physicians selected by quality clini-
cal records, attending 149417 patients during 2007. Computerized clinical 
record and pharmaceutical billing database: after grouping all patients with 
an episode of diabetes through case-mix ACGs System, the following indica-
tors were built: chronic co-morbidities, consumption of visits, pharmaceuti-
cal consumption and referrals and standardized morbidity rate (SMR, using 
standard prevalence observed in all patients). To analyse variability of family 
physicians management of diabetes, two indicators were calculated for each 
family physician: Risk Index (RI) that relates the complexity of patients with 
the standard (if > 1, more complexity) and Efficiency Index (EI) that reports 
on the management of patients relating the consumption observed with ex-
pected, based on attended case-mix (if > 1, more consumption than expect-
ed). Variability indicators: coefficient of variation (CV), Extremal Quotient 
(EQ), excluding the outliers beyond of the 5-95 percentiles (EQ5-95) and of 
the 25-75 percentiles (EQ25-75)
Results: 10058 (6.7%) patients suffering from diabetes with an mean age 
of 66.7 years (SD 15.1), 52.6% were female. 9.7% of those with diabetes has 
no associates chronic co-morbidities and 41% had 3 or 4 and 34% 5 and 
more chronic co-morbidities. Most frequent pathologies were hypertension 
(61.2%), dyslipidaemia (44.5%), obesity (33,05%) and depression (21.5%). 
The correlation between the burden of illness and the number of visits, phar-
macy and the number of referrals was R=0.99 (R2=0.99), R=0, 99 (R2=0.99) 
and R=0.97(R2=0,94) respectively. SMR was higher than 1 for most of chronic 
diseases , especially hepatic chronic disease, skin ulcer, kidney chronic dis-
ease, chronic heart failure and coronary heart disease; and was lower than 1 
for osteoporosis. Variability indicators using visits criterion was RI range: 0.7-
1.2 (CV = 9% EQ5-95=1.4; EQ25-75=1.1) and EI range: 0.3-1.8 (CV=21% 
RV5-95=1.8; RV25-75=1.3) and using pharmaceutical consumption criterion 
RI range: 0.5-1.3 (CV=18%; EQ5-95=1.9; EQ25-75=1.3) and EI range: 0.9-
3.3 (CV= 3% RV5-95=1.9; RV25-75=1.3).The correlation between RI and EI 
concerning visits consumption is R=-0.21 (R2=-0.05) and pharmaceutical 
consumption R=-0.36 (R2=0.13)
Conclusion: Most of diabetic patients has high associated co-morbidity, es-
pecially hypertension, dyslipidaemia, obesity and depression. Burden of ill-
ness seems to highly determine the impact of diabetic patients consumption 
on the National Health System. There is important variability in the family 
physician management of diabetic patients no related with complexity of 
case-mix.
Supported by: Fondo de Investigación Sanitaria, Instituto de Salud Carlos III
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Prevalence of diabetes mellitus and pre-diabetes in an Irish cohort age 
45-75 years
M. Sinnott1, B. Carr1, C. Walsh2, P. O’Grady1, G. Boran3, B.T. Kinsley4,  
J.J. Nolan5; 
1Vhi Healthcare, 2Dept of Statistics, Trinity College Dublin, 3Dept of Clinical 
Chemistry, Tallaght Hospital, 4Dept of Endocrinology, Mater Hospital, 
5Dept of Endocrinology, St James’s Hospital, Dublin, Ireland.
Backgrounds and aims: Type 2 diabetes (T2DM) and pre diabetes are pre-
ventable if known risk factors are identified and modified. To date there have 
been no large-scale studies of the prevalence of T2DM or pre-diabetes in 
Ireland. To address this issue the largest Irish health insurer, (covering over 
62% of individuals with Private Medical insurance; 1.4 million members), 
has undertaken a study of the prevalence of undiagnosed T2DM and pre dia-
betes by screening 30,000 members. We report results from the first year of 
screening. To identify the prevalence of undiagnosed T2DM, impaired fast-
ing glucose (IFG), impaired glucose intolerance (IGT) and diabetes risk in an 
Irish population.
Materials and methods: Members without a diagnosis of T2DM, aged 45 to 
75 years living within 5 km of two major University Teaching Hospitals in 
Dublin, were chosen randomly and invited to participate. Participants com-
pleted a detailed medical questionnaire. Fasting plasma glucose (FPG), lipid 
profiles, blood pressure, weight, height, BMI, waist circumference, and waist:
hip ratio were measured. Those subjects with initial FPG results of greater 
than or equal to 5.6 less than or equal to 6.9mmol/L had an Oral Glucose 
Tolerance Test (OGTT) performed. Those with an FPG greater than or equal 
to 7.0mmol/L had a repeat FPG performed. The Diabetes Risk Score was cal-
culated based on FINRISK.
Results: 3771 participants (2125 female / 1646 male), were screened. Mean 
Age 60 ± 8.3 years (59.8 years ±8.2 for women; 60.2 years ± 8.3 for men). In 
the total screened group: T2DM = 1.8%, IFG = 6.5%, IGT = 3.8%. However 
among those subjects with an FPG between 5.6-6.9 mmol/L: T2DM = 5%, 
IFG = 26%, IGT =15 %. Glucose and OGTT results are summarised in the Ta-
ble 1. Diabetes Risk Score results indicated that over 25 % of participants had 
a moderate or greater risk of developing T2DM (15 % women; 10 % men).
Conclusion: The prevalence of undiagnosed T2DM in the population 
screened to date is low, however over 10% of participants have pre-diabetes. 
Performing an OGTT as follow up on FPG 5.6-6.9 mmol/ identified either 
T2DM or pre diabetes in 46% of those tested. In conclusion screening for 
T2DM or pre diabetes is achievable in this setting, identifies unrecognised 
vascular and diabetes risk and could lead to disease prevention if the identi-
fied risk factors are modified.
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Health-related quality of life: a marker of increased mortality in elderly 
type 2 diabetic patients (ZODIAC-18)
S.T. Houweling1,2, K.J.J. van Hateren3, G.W.D. Landman3, K.H. Groenier4, 
N. Kleefstra2,3, H.J.G. Bilo3,5; 
1General Practice Sleeuwijk, 2Langerhans Medical Research Group, Zwolle, 
3Diabetes Centre, Zwolle, 4Department of General Practice, University 
Medical Center Groningen, 5Department of Internal Medicine, University 
Medical Center Groningen, Netherlands.
Background and aims: Diabetes-related complications and physical impair-
ment are more prevalent in old age, and are likely to have detrimental effects 
on health-related quality of life (HRQOL). The aim of the present study was 
to assess the relationship between HRQOL and (cardiovascular) mortality, 
and the role of age in this relationship.
Materials and methods: Between 1998 en 1999, 1353 primary care patients 
with type 2 diabetes mellitus (T2DM) participated in the ZODIAC study, a 
prospective observational study. Early 2009, data on mortality were collected. 
HRQOL at baseline was assessed using the RAND-36 questionnaire. A Cox 
proportional hazard model was used to investigate the relationship between 
HRQOL and mortality. Analyses were performed in strata according to age: ≤ 
75 years (n=979) and >75 years (n=374). The following variables were select-
ed as possible confounders: age, gender, smoking (yes or no), systolic blood 
pressure, BMI, duration of diabetes, macrovascular complications (yes or 
no), albumin-creatinine ratio, serum creatinine level, total cholesterol-HDL 
ratio, and HbA1c.
Results: After a follow-up time of 10 years, 570 out of 1353 patients (42%) 
had died, of whom 280 deaths (41%) were attributable to cardiovascular 
causes. The Physical Component Summary (PCS) in both age groups was 
inversely related to all-cause and cardiovascular mortality (table 1; the hazard 
ratios refer to an increase of 10 points in the HRQOL scores). For the Mental 
Component Summary (MCS) an inverse relationship was observed only for 
patients aged 75 years of younger. Two separate RAND-36 dimensions were 
inversely related to all-cause and cardiovascular mortality in both age groups: 
physical functioning and general health perception.
Conclusion: Decreased HRQOL was related to increased all-cause and car-
diovascular mortality in both younger and older patients with T2DM. These 
results are of special interest for elderly patients, since traditional risk factors 
become less predictive of mortality at higher age. HRQOL may be a useful 
tool to identify elderly patients at high-risk of mortality.
Hazard ratios of all-cause and cardiovascular mortality for PCS and MCS
RAND-36 All-cause mortality Cardiovasular mortality
Physical Component Summary
≤ 75 years 0.86 (0.80-0.93) 0.83 (0.73-0.93)
> 75 years 0.89 (0.81-0.96) 0.87 (0.76-0.98)
Mental Component Summary
≤ 75 years 0.88 (0.81-0.95) 0.84 (0.74-0.95)
> 75 years 0.92 (0.85-1.00) 0.96 (0.84-1.08)
PS 18 Diabetes comorbidities: 
hospitalisation and cancer
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Analysis of hospital admission causes in diabetic patients
P. Magán Tapia1,2, Á. Alberquilla Menéndez-Asenjo3, G. Mora Navarro3,  
C. González Rodríguez-Salinas1, V. Del Saz Moreno3, M. Ugalde Díez1,  
M. Gil de Pareja Palmero3, M. Pilas Pérez1; 
1Hospital Universitario 12 de Octubre, Madrid, 2CIBER Epidemiología y 
Salud Pública, Barcelona,  311th Primary Health Care Area, Madrid, Spain.
Background and aims: To describe the clinical features of diabetic patients 
who require hospital admission and the main reasons.
Materials and methods: Descriptive cross-sectional, observational study. 
Participants and settings: 584896 persons assigned to one of the Primary 
Health Care Centres attached to a reference hospital. From Primary Health 
Centres and hospital medical records, clinical data, number of admission 
and diagnostics that motivated during 2007 were registered. Hospitalization 
episodes were pooled using the patients DRGs (diagnostic related groups) 
classification system.
Results: 26845 patients were diabetics (4.6%), of which 10.6% (2840) had at 
least one admission. 51.6% of admitted were women and 52.2% of those who 
never was admitted during 2007, p = 0. 56. Admitted diabetic patients gener-
ated 4032 episodes of hospitalization, 1.4 admissions/patient (range 1-14). 
61% was an emergency admission and the reason for discharge was recov-
ery in 98.4%. Hospital death rate was 1.2%. The most common ICD-9 codes 
were coronary atherosclerosis 2.5%, congestive heart failure 2.0%, leg degen-
erative osteoarthritis 1.8% and intermediate coronary syndrome 1.6%. The 
admissions obtained by major diagnosis categories (MDC) distribution was 
23.6% circulatory, 9.9% musculoskeletal, 9.6% respiratory and 9.2% digestive 
pathology. Episodes concerning endocrine, nutritional and metabolic were 
4.6% of the cases. DRGs associated to diabetes appear only in 2.6% of hospi-
talisations. More frequent DRGs were respiratory disorders (3.4%) excluding 
infections, bronchitis and asthma complications or major co-morbidity, fol-
lowed by two related heart failure DRGs (4.7%) Avoidable hospitalizations ac-
cording to list of validated Ambulatory Care Sensitive Conditions (ACSC) for 
Spain diabetes codes were only 39 cases (0.97%) of this admissions group.
Conclusion: Cardiovascular pathology is the most usual cause of hospitaliza-
tion in diabetic patients. Other complications of diabetes do not appear to be 
frequent admission reasons for patients with diabetes. A limited number of 
hospital admissions of diabetics are avoidable, which may reflect an appropri-
ate management of diabetics in Primary Health Care.
Supported by: Fondo de Investigación Sanitaria, Instituto de Salud Carlos III
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The impact of diabetes mellitus in a tertiary hospital
P. Sousa1, T. Brito1, S. Pedro2, S. Pereira1, A. Lopes1, E. Pina1, V. Gomes1; 
1Hospital of Faro, 2CEAUL & ESGHT, UAlg, Faro, Portugal.
Background and aims: The number of people with diabetes worldwide is set 
to double in the next 20 years. The impact of diabetes mellitus and associated 
co-morbidities on a tertiary Hospital is not completely understood. The aim 
of this study is to characterize the diabetic population admitted to our Hospi-
tal and analyze its evolution in the years 2000, 2005 and 2009.
Materials and methods: A retrospective, descriptive and correlational study, 
encompassing patients with diabetes (as primary or secondary diagnoses) ad-
mitted to a tertiary Hospital in the years 2000, 2005 and 2009 was performed. 
We evaluated age, gender, type of diabetes, cause of admission, length of stay, 
macrovascular complications, such as acute myocardial infarction and stroke 
and in-hospital mortality. Our results were compared with a national dia-
betes database. We used the International Classification of Diseases-9-Clini-
cal Modification and the information provided by the local Medical Support 
System database. Statistical analysis of the data was performed using Statisti-
cal Package for Social Sciences 18. Inferential statistics (t test, ANOVA and 
X2)was used to conduct an analysis of age, length of stay and in-hospital mor-
tality predictors.
Results: The total patients admitted to our Hospital in these three years was 
85588, 24635 in the year 2000, 30261 in the year 2005 and 30692 in the year 
2009. In these years, 872 patients (4%), 1874 patients (6%) and 2205 patients 
(7%) had the diagnosis of diabetes, as primary or secondary, diagnoses in a 
total of 4951 diabetic patients (6%), 2624 (53%) male. The rate of diabetes as 
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a primary diagnosis was 14,3% and among these 30,6% were type 1 diabe-
tes. We included patients of all ages (9 months - 100 years) with a mean of 
69±16 years (2000: 68±16 years; 2005: 69±16 years; 2009: 70±16 years). In 
patients with type 1 diabetes the average age was 39±28 years and in patients 
with type 2 diabetes 69±15 years (p<0,001). Acute myocardial infarction was 
the primary diagnosis in 353 diabetic patients (7,1%) and stroke in 91 pa-
tients (1,8%). The average length of in-hospital stay of diabetic patients in 
the three years was 10±12 days. The average length of stay of type 1 diabetic 
patients was lower comparing with patients with type 2 diabetes (p=0,019). 
Age (p<0,001) and macrovascular complications (p<0,001) were also predic-
tors of increased length of stay. Comparing the average hospitalization time 
between diabetic and non-diabetic patients, there was no significant differ-
ence (p=0,202) in year 2000. Inversely, there were significant differences in 
the years 2005 (p<0,001) and 2009 (p<0,001). The in-hospital mortality rate 
in diabetic patients was three times higher than that of non-diabetic patients 
(12% versus 4%, p<0,001). Age (p<0,001), diabetes as secondary diagnosis 
(p=0,013) and macrovascular complications (p=0,004), were predictors of 
higher mortality.
Conclusion:
1- The number of hospitalizations and the average age of diabetic patients, as 
primary or secondary diagnosis, have increased over a ten year period.
2- Patients with type 2 diabetes have a longer length of stay than patients with 
type 1 diabetes, probably related to their advanced age.
3- The average length of stay and in-hospital mortality in diabetic patients 
were higher comparing with national diabetes database.
4- This study suggests the need for a more aggressive intervention in the pre-
vention, diagnosis and treatment of diabetes mellitus, reinforcing the need for 
optimal metabolic control for prevention of macrovascular complications.
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Gender effect on the relation between diabetes and hospitalisation for 
heart failure
C. Seghieri1, S. Nuti1, G. Seghieri2, F. Bardelli2, F. Franconi3; 
1Scuola Superiore S.Anna, University of Pisa, 2Dpt of Internal Medicine, 
Spedali Riuniti, Pistoia, 3Dpt. of Pharmacology, University of Sassari, Italy.
Background and aims: Heart failure (HF) is a major cause for hospitaliza-
tion especially in the elderly, and, at the same time, is mainly due to ischemic 
heart disease which, as well known, is strongly related to diabetes mellitus. It 
is likewise known that women are more protected than men toward the risk 
of cardiovascular diseases at least during the premenopausal period, while 
diabetes fully reverses such advantage, conferring to postmenopausal females 
a higher risk for cardiovascular complications and consequently HF. With 
such premises one can expect that gender difference is able to modify the as-
sociation between diabetes and HF hospitalization, but no clear information 
so far exists about this point. More details on this point might be obtained by 
the availability of a wide centralized database containing all discharges across 
a given period of time from hospitals of a homogeneous region.
Materials and methods: To achieve this purpose we used a database concern-
ing all hospital discharges from the wards of internal medicine (n=362,352M 
and n=385,806F) and of cardiology (n=91,411M and 49,212F) in Tuscany, 
Italy (3,686,377inhabitants) during the period 2002-2007 with a DRG de-
rived from the corresponding ICD-9-CM codes of diabetes (250.xx) and/or 
of HF (DRG 127, containing ICD-9-CM codes 401.91, 402.01, 402.11, 402.91, 
404.01, 404.3, 404.13, 404.93, 428.0, 428.1, 428.9) as main or secondary di-
agnosis. We considered discharges above age of 30 years due to the very low 
prevalence of HF below this age and calculated the relative risk and 95% CIs 
of being diagnosed diabetic in patients hospitalized for HF, stratified for age 
and sex.
Results: HF related hospitalization rate increased with age from 2.3% in the 
age group 30-39yr to 27.3% in the age group ≥90yr in men and from 1.1% to 
30% in females, while diagnosis of diabetes progressively increased from the 
first decade to a maximum in age class 70-79yr (16.4% in men and 18.1% in 
females) and then decreased with further ageing in both sexes. The relative 
risk (95% CI) of HF hospitalization was about two-fold higher in diabetic 
than in non diabetic individuals across the entire observation period [1.97 
(1.34-3.41) in males and 2.16 (1.60-3.53) in females]. The association diabe-
tes-HF had a ‘horse-shoe’ pattern significantly raising in decade 30-39yr [2.27 
(1.56-4.03)] (only in males), then reaching a maximum in class 40-49yr for 
males [3.24 (2.64-3.53)] and in decade 50-59yr for women [3.75 (1.94-4.03)], 
and afterwards progressively decreased, remaining more elevated in females 
during the entire period 40-69yr, and becoming equal in both genders during 
the following decades.
Conclusion: Hospitalization risk for HF was about two-fold higher in pa-
tients of both sexes with diabetes, being more elevated in females than in 
males in the life period ranging between 40 and 60 years, thus disclosing a 
risk peak linked to the existence of a ‘perimenopausal effect’.
Supported by: Fondazione Cassa di Risparmio di Pistoia e Pescia, Italy
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Glucose status in emergency medical admissions to one of the five busiest 
emergency hospitals in the Republic of Ireland
G.A. Roberts1, D.B. Moore1, K.T. O’Brien1, S.E. Manley2; 
1Waterford Institute of Technology, Ireland, 2Clinical Biochemistry, 
University Hospital Birmingham NHS Foundation Trust, United Kingdom.
Background and aims: Decreasing physical activity and increasing obesity 
of ageing populations in Western Europe contribute to increased incidence 
of impaired glucose tolerance (IGT) and diabetes mellitus (DM). Stress hy-
perglycaemia is common in acutely ill patients. Dysregulation of glucose 
is associated with increased morbidity / mortality and has major financial 
implications for healthcare. In this study, glycaemic status was determined 
in emergency medical admissions to the one of the five busiest emergency 
hospitals in the Republic of Ireland.
Materials and methods: During an 18 month time frame, an unselected 1237 
(14%) of all 8659 emergency medical admissions were enrolled in the study. 
Patients with prior diagnosis of diabetes, impaired fasting glucose (IFG) or 
IGT were recorded. In the remaining patients, a 75g OGTT was performed 
on patients (18 years or older) who displayed symptoms of diabetes or a his-
tory suggestive of diabetes complications. OGTT glycaemic status was re-
corded according to WHO 2006 definitions.
Results: 270 of the sample admissions had previously diagnosed type 1, type 
2 diabetes, or IGT. 6 new cases of type 1 diabetes were diagnosed at the time 
of admission without the need for OGTT. 719 sample admissions (58%) did 
not meet the inclusion criteria for performing the OGTT. 20 of the sample 
admissions were excluded from the OGTT due to age <18 years or known en-
docrine disease. OGTT was performed in the remaining 222 (18%) of sample 
admissions. All 222 were Caucasian with median age 71 years, IQ range 58 
years to 81 years, 122 (55%) male. 55% were admitted due to cardiological ill-
ness, 12% due to neurological illness (including stroke or transient ischaemic 
attack) and 12% due to respiratory illness. 78 (35%) of OGTT screened pa-
tients were demonstrated to be normoglycaemic. 84 (38%) of OGTT screened 
patients demonstrated IGT and 53 (24%) demonstrated FPG or 2h-PG in the 
diabetic range. 144 (65%) of OGTT screened patients had abnormal glucose 
states that were previously undiagnosed representing 12% of the admissions 
sample. Adding to the 270 (22%) of admissions who had previously known 
abnormal glucose states, we demonstrated a minimum of 33.5% of emergen-
cy medical admissions that had abnormal glucose states.
Conclusion: This study indicates that 65% of patients admitted to one of 
the five busiest emergency admissions hospital of Ireland with symptoms of 
diabetes or its complications but not previously diagnosed with glucose dys-
regulation had impaired glucose tolerance or diabetes diagnosed by a OGTT 
during their stay. Whether this persists after their recovery needs to be as-
certained, however there is still a considerable burden on diabetes services 
during their acute admission stay.
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Elevated basal insulin increases the risk for total mortality in cancer 
incident subjects: The Israel Glucose Intolerance, Obesity and 
Hypertension 25-year Follow-Up Study 
R. Dankner1,2, A. Chetrit1, C. Cohen1, P. Segal3; 
1Unit for Cardiovascular Epidemiology, Gertner Institute for Epidemiology 
and Health Policy Research, Ramat Gan, 2Epidemiology and Preventive 
Medicine, School of Public Health, Sackler School of Medicine, Tel Aviv, 
3Endocrinology, Sackler School of Medicine, Tel Aviv, Israel.
Background and aims: Type 2 diabetes has been associated with increased 
incidence, in the range of 1.2-2.5, for cancers of the liver, pancreas, en-
dometrium, breast, colon, and bladder, and non-Hodgkin’s lymphoma. Pos-
sible upstream factors, i.e. shared risk factors of diabetes and cancer, such as 
obesity, hyperlipidemia, and baseline hyperinsulinemia, have been suggested 
as explanations. The aim of this study was to investigate endogenous insulin 
as a risk factor in 25-year cumulative cancer incidence and as a prognostic 
factor among subjects who developed cancer.
Materials and methods: We followed cancer incidence and mortality in a 
sample of 1770 non-diabetic men and women, with mean age at baseline of 
52.1+8.0, from 1980 until 2005. Baseline fasting, 1 and 2-hour post-load plas-
ma glucose and insulin levels were recorded. All subjects were free of cancer 
at baseline. Cancer incidents occurring within the first 2 years of follow-up 
were excluded.
Results: During the follow-up period 327 individuals (18.5%) developed can-
cer (3.0%, 2.2%, and 2.7% developed breast, prostate, and colon/rectum can-
cers, respectively). Fasting insulin was not found to be significantly associ-
ated with overall cancer incidence, or with incidence of specific sites (breast, 
prostate, colon/rectum, or bladder). Median survival time for cancer patients 
in the upper fasting insulin quartile at baseline (>18.9 mU/L) was half that 
of those in the lower three quartiles: 4 years, 95%CI = 2-13 years, compared 
to 8 years, 95%CI = 6-15 years; p=0.1. In a Cox Proportional Hazard model, 
adjusting for age, sex, and ethnic origin, fasting insulin in the upper quar-
tile conferred a 53% increased risk for total mortality (95%CI = 1.04 - 2.23) 
compared to the lower quartiles. Male sex, age, and ethnic origin were also 
found to be associated with a greater risk for mortality (p = 0.003, < 0.001, 
0.03 respectively).
Conclusion: This long term cohort study suggests a role for elevated insulin 
levels in adulthood, not as a carcinogen, but as a factor adversely affecting 
cancer prognosis.
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Diabetes is associated with an increased risk of cancer in the Canarian 
population
A. Arin Martínez1, A. Cabrera de León2, M.C. Rodríguez Pérez2,  
D. Almeida González2, B. Brito Díaz2, J. Nóvoa1,3, A. González Hernández2, 
A.M. Wägner1,4; 
1Endocrinology Department, Complejo Hospitalario Universitario Insular 
Materno-Infantil de Gran Canaria, Las Palmas de Gran Canaria, 2Research 
Unit, Hospital Universitario Nuestra Señora de Candelaria. Universidad de 
La Laguna., Santa Cruz de Tenerife, 3Departamento de Ciencias Médicas y 
Quirúrgicas., Universidad de Las Palmas de Gran Canaria, 4Departamento 
de Ciencias Médicas y Quirúrgicas, Universidad de Las Palmas de Gran 
Canaria, Spain.
Background and aims: While obesity has shown an association with most 
types of cancer, the association of diabetes with the disease is still controver-
sial. The Canary Islands (Spain) have a high prevalence of obesity (32% of 
the adult population), diabetes (13%) and the metabolic syndrome (25.3%, 
according to the criteria of the International Diabetes Federation). Further-
more, some types of cancer are also increased in our population, especially 
breast cancer. The aim of this study was to assess the relationship between 
diabetes and the risk of cancer in the Canarian population.
Methods: A cross-sectional study was performed on the subjects enrolled 
in the “CDC (cancer, diabetes and cardiovascular disease) of the Canary Is-
lands”, a population-based cohort of 6729 individuals, aged 18-75 years, cho-
sen randomly from the census of health care system affiliates (covering 99% 
of the population). Recruitment took place between 2000 and 2005. Clinical 
information was obtained using a questionnaire, anthropometric measure-
ments were taken and blood samples were drawn. Diabetes was defined if the 
patient had a known diagnosis and/or received glucose-lowering treatment. 
In the absence of information confirming the diagnosis, diabetes was defined 
by fasting glucose concentrations above 125 mg/dl on two separate occasions. 
Cancer was self-referred and confirmed with data obtained about hospital 
admissions and treatment prescriptions. The risk of cancer was compared 
between 6721 subjects (8 were lost due to absence of reply) with and with-
out diabetes (chi-squared, Yates’ continuity correction). In order to adjust for 
possible confounders, a multiple logistic regression analysis was performed, 
including the overall risk of cancer as the dependent variable and age, gender, 
body mass index, years of smoking and parental history of cancer as inde-
pendent variables. A p value below 0.05 was considered significant.
Results: Information was available for analysis from 6721 subjects of the co-
hort. The overall prevalence of cancer was 1.8%: 3.9% among the diabetic 
and 1.5% among the non-diabetic subjects (OR 2.604 [95% CI 1.694-4.002], 
p<0.0005). After adjustment for possible confounders, the association be-
tween diabetes and cancer remained significant (OR 1.633 [1.034-2.579], 
p=0.036). Gender (OR 0.511 [0.327-0.797], p=0.004 for males), age (OR 
1.067 [1.048-1.086] per year, p<0.0005) and maternal history of cancer (OR 
2.391 [1.598-3.579], p<0.0005) were also associated with cancer in this mod-
el, whereas years of smoking, body mass index and paternal history of cancer 
were not.
Conclusions: Diabetes is associated with an increased risk of cancer in the 
Canarian population, independently of age, gender, body mass index, smok-
ing and parental history of cancer.
Supported by: an EFSD/JDRF/Novo Nordisk grant, Instituto de Salud Carlos III 
(MICIIN), FUNCIS and ACIISI
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Diabetes and cancer in Mauritius
D.J. Magliano1, S. Söderberg1,2, P. Zimmet1, S. Kowlessur3, V. Pauvaday3,  
J.E. Shaw1; 
1Population and profiling, Baker IDI Heart and Diabetes Institute, 
Melbourne, Australia, 2Department of Public Health and Clinical Medicine, 
Cardiology, Umeå University Hospital, Sweden, 3Ministry of Health and 
Quality of Life, Port Louis, Mauritius.
Background and aims: Although evidence supporting the association of dia-
betes with cancer risk is growing, there are no data on diabetes and cancer in 
South Asian and Africans populations. The aim of this work was to explore 
the relationship between diabetes, impaired glucose tolerance (IGT) and im-
paired fasting glycaemia (IFG) and all-cause and site-specific cancer mortal-
ity adjusted for conventional risk factors in a large multi-ethnic cohort living 
in the developing nation of Mauritius.
Materials and methods: Population-based surveys were undertaken in Mau-
ritius in 1987, 1992 and 1998 (n= 9559). Participants were aged 18 years or 
greater and 66%, 27%, and 7% were of South Asian (Indian), African (Cre-
ole), and Chinese descent, respectively. Response rates for all surveys were 
greater than 85%. Questionnaires, anthropometric measurements, and a 2 
hour 75-g oral glucose tolerance test were undertaken at each survey. Glu-
cose tolerance was classified according to World Health Organisation 1999 
criteria. In 2007, a mortality follow-up was undertaken. Cox’s proportional 
hazards model with age as the time scale was used to obtain hazard ratios 
(HRs) for risk of all-cause cancer and site-specific cancer mortality, adjusted 
for sex, smoking, prior CVD, ethnicity, hypertension, education, waist and 
hip circumference, and leisure time physical activity.
Results: Over a median follow-up of 15.1 years, there were 1559 deaths (199 
due to cancer), 7168 survivors and 832 participants were lost to follow-up. 
After exclusion of deaths in the first year after baseline, compared with those 
with normal glucose tolerance (NGT), the all-cancer mortality HRs (95% 
confidence intervals (CIs)) for known diabetes mellitus (KDM), newly di-
agnosed diabetes mellitus (NDM), impaired glucose tolerance and impaired 
fasting glycaemia were 2.34 (1.19 to 4.59), 1.80 (1.00 to 3.26), 1.34 (0.73 to 
2.46) and 0.80 (0.28 to 2.25) in men and 1.19 (0.63 to 2.22), 0.58 (0.26 to 
1.33), 1.34 (0.80 to 2.27) and 0.53 (0.13 to 2.22) in women, respectively. In 
men, but not women, total cancer mortality risk increased with rising plasma 
levels of postload glucose - HR for the top versus bottom quintile was 2.52 
(1.34 to 5.59), Ptrend <0.025 in fully adjusted models. There was no relation-
ship between fasting plasma glucose and total cancer mortality in either sex. 
The HRs for breast and reproductive tract cancer mortality for women with 
diabetes (KDM and NDM) compared to women without diabetes were 2.67 
(0.95 to 7.67) and 1.09 (0.28 to 4.26) in South Asians and Africans, respec-
tively after adjustment for age, smoking and waist circumference.
Conclusion: This is the first study in a developing country of the impact of 
glucose intolerance on cancer mortality in an African or South Asian popula-
tion. The independent association of diabetes (KDM and NDM) and post-
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load glucose with total cancer mortality risk in men in this study provides 
first time evidence of such a relationship in Africans and South Asians. These 
results are important in a global context for future health policy in the light 
of the impact of the rapid increase in prevalence of diabetes and cancer, espe-
cially in developing nations.
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Chronic hepatitis B infection increased risk of all site cancer in type 2 
diabetic patients with suboptimal glycaemic control
R.C.W. Ma, W.-Y. So, A. Luk, L.W.L. Yu, A.P.S. Kong, C.C. Chow,  
P.C.Y. Tong, X. Yang, J.C.N. Chan; 
Dept of Medicine and Therapeutics, Chinese University of Hong Kong, 
China.
Background and aims: Over 10% of people in China have chronic HBV in-
fection and type 2 diabetes (T2DM). Both of these chronic conditions have 
been implicated in carcinogenesis. We hypothesized that chronic HBV infec-
tion may interact with poor glycaemic control to increase risk of cancer in 
type 2 diabetes.
Materials and methods: In a prospective cohort from the Hong Kong Dia-
betes Registry (HKDR) consisting of 4205 T2D patients with known HBV 
status and detailed documentation for risk factors, complications, treatments 
and clinical outcomes followed up for a mean period of 6 years, we examined 
the incidence of cancer in patients stratified by A1c and explored their in-
teractions with HBV carrier status. Cox proportional hazard regression was 
used to obtain hazard ratios (HRs) of HBV infection for cancer in univari-
able models and multivariable models. To test possible interactions between 
HBV infection and hyperglycaemia for cancer, we separately performed ini-
tial checking of the HRs of HBV infection for the risk of cancer among pa-
tients with A1c<7.4% and among those patients with A1c≥7.4% in univariate 
and multivariate models. We further examined biological interaction of HBV 
infection and hyperglycaemia (i.e., A1c≥7.4%) using: 1) Relative excess risk 
due to interaction (RERI); 2) Attributable proportion due to interaction (AP); 
and 3) Synergy index (S).
Results: HBV carriers have increased risk of cancer (HR 1.70; CI: 1.28-2.25, 
p<0.0001). When divided according to HbA1c, the hazard ratios of all-site 
cancer was 2.23 (CI: 1.57-3.16; p<0.0001), after adjustment of other clinical 
attributes. Interactive models suggest the increased risk of cancer in HBV 
carriers is present among subjects with HbA1c ≥7.4%. Analysis using the 
RERI, AP or S index revealed there was statistically significant biological in-
teraction between HBV carrier status and HbA1c ≥ 7.4 mmol/L for the risk 
of cancer in Type 2 diabetes.
Conclusion: In type 2 diabetic patients with suboptimal glycemic control, the 
coexistence of chronic HBV infection substantially increased the risk of can-
cer. The rapid transition from communicable to noncommunicable diseases 
in China will have major implications on morbidity and mortality including 
cancer.
Supported by: HKFRDD, LWY Diabetes Research Fund
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Risk factors for pancreatic cancer aetiology of glucose intolerance
L. Czupryniak1, A. Gasiorowska2, R. Talar-Wojnarowska2, E. Szymanska-
Garbacz1, M. Pawlowski1, M. Saryusz-Wolska1, A. Borkowska1, E. Malecka-
Panas2, J. Loba1; 
1Internal Medicine and Diabetology Department, Medical University of 
Lodz, 2Digestive Tract Diseases Department, Medical University of Lodz, 
Poland.
Background and aims: Relationship between the incidence of pancreatic 
cancer and the development of diabetes is unclear. Diabetes has been sug-
gested to be a risk factor for pancreatic cancer. On the other hand, glucose 
intolerance or frank diabetes is often the first sign of a pancreatic cancer, a 
fatal disease unless diagnosed at a very early stage. However, at present with 
diabetes being so prevalent, cancer etiology of glucose intolerance might be 
easily missed, bringing fatal consequences upon a patient. We studied glu-
cose tolerance in patients with newly diagnosed pancreatic cancer aiming at 
identifying factors suggestive of cancer etiology of glucose metabolism dis-
turbances. The additional aim of the study was to assess endothelial dysfunc-
tion and subclinical inflammation as markers of cardiovascular risk, often 
neglected in this group of patients.
Materials and methods: The study group was 18 non-diabetes individuals 
with newly diagnosed pancreatic cancer (PC group) (mean age 69.6±8.9 
years, BMI 23.0±4.7 kg/m2); 13 age- and body weight-matched healthy 
subjects served as controls. All subjects underwent oral glucose tolerance 
test (OGTT) according to WHO protocol with plasma glucose and insulin 
measurements. HOMA index and fasting plasma adiponectin, TNF-alfa, in-
terleukin-6 (IL-6), interleukin-1beta (IL-1b), sE-selectin, thrombomodulin, 
soluble adhesion molecules sICAM and sVCAM, and high-sensitive CRP 
were assessed.
Results: PC and control subjects plasma glucose values in OGTT were at 
0 min 98±21 and 90±17, 60 min - 166±43 and 103±36 (p<0.01), 120 min - 
173±39 and 90±28 (p<0.001) mg/dl, and plasma insulin at 0 min 3.6±1.8 and 
10.2±7.9 (p<0.01), 60 min - 22.3±17.4 and 33.1±21.4, 120 min - 31.9±19.3 
and 34.1±44.7 mIU/l. PC patients presented also with significantly greater 
insulin sensitivity as measured with HOMA than the controls (0.83±0.39 vs 
2.34±1.87; p<0.01). Moreover, PC subjects as compared with the controls had 
significantly greater plasma adiponectin (16132±8165 vs 6681±4329 ng/ml; 
p<0.001), IL-6 (8.6±4.9 vs 3.9±1.4 pg/ml; p<0.01), thrombomodulin (2.0±0.8 
vs 1.1±0.5 ng/ml; p<0.01), sICAM (929±417 vs 318±85 ng/ml; p<0.001) and 
sVCAM (1669±489 vs 857±312 ng/ml; p<0.001).
Conclusion: Individuals with newly diagnosed pancreatic cancer present 
with elevated post-challenge plasma glucose associated with significant insu-
lin sensitivity. Diagnosing glucose metabolism disturbances in lean subjects 
with high insulin sensitivity should point at the possibility of pancreatic can-
cer as an underlying condition. Moreover, despite absence of insulin resist-
ance, newly diagnosed PC subjects present with clinical markers of subclini-
cal inflammation and endothelial dysfunction.
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PS 19 Early mechanisms in 
autoimmune diabetes - animal 
models
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An experimental study showing dietary gluten as triggers of type 1 
diabetes
J.T.J. Visser1, K. Lammers2, A. Fasano2, H. Harmsen3, G. Welling3,  
F. Stellaard4, N. Bos4, J. Rozing1; 
1Cell Biology, Section Immunology, University Medical Center Groningen, 
Netherlands, 2Mucosal Biology Research Center, Baltimore, USA, 3Medical 
Microbiology, University Medical Center Groningen, 4University Medical 
Center Groningen, Netherlands.
Background and aims: Type 1 diabetes (T1D) is a multifactorial autoim-
mune disease and besides genetic susceptibility several environmental fac-
tors such as diets and gut microbiota contribute to the onset of the disease. 
Recent epidemiological data indicate that T1D incidence in Europe might 
double around the year 2020. Genetic factors cannot explain this dramatic 
increase, which indicate that changes in environmental factors are mainly 
responsible. There is accumulating evidence that dietary gluten might be im-
portant dietary triggers of T1D. Epidemiological data show that early intro-
duction of dietary gluten increases the chance to develop T1D. Also aberrant 
immune responses against wheat gluten have been found in T1D patients. 
In this study we investigated in the diabetes prone (DP)BB rat animal model 
for T1D whether dietary gluten can modulate diabetes development and po-
tential mechanisms involved such as changes in gut microbiota composition, 
intestinal barrier function and (innate/mucosal) immune status.
Materials and methods: BBDP rats were fed specific diets with different 
amounts of gluten. One group received the hydrolysed casein (HC) diet. The 
HC-diet is gluten free and the proteins are degraded to small fragments lead-
ing to the loss of diabetogenic epitopes. The other groups received the HC-
diet with 2%, 4% and 10% gluten respectively. The control group received the 
standard diet with ±4% gluten. Rats were followed for T1D development and 
feces, gut tissue, lymph-nodes and blood were collected. Because gluten can 
affect intestinal permeability, BBDP rats were subjected to a Lactulose Man-
nitol (LA/MA) test to measure intestinal permeability in vivo. Composition 
of gut microbiota was established in the feces by qPCR.
Results: Addition of 10% gluten to the HC-diet completely abrogated the dia-
betes protective effect of the HC-diet. HC-fed rats (n=21), 50% diabetic me-
dian age 85 days vs HC+gluten fed rats (n=14), 90% diabetic median age 76 
days (p<0.05, log rank test). Moreover, addition of 10% gluten also completely 
reversed the HC-diet induced improved intestinal barrier function as shown 
by a 2-fold increased urinary LA/MA levels (p<0.05, MWU test) and a trend 
for a reduced ileal expression of claudin-1 mRNA (p<0.1, MWU test). We 
have shown previously that the HC-diet lowers intestinal bacteroides levels of 
BBDP rats. Yet, the gut microbiota composition of HC fed rats did not differ 
from HC+gluten fed rats. High levels of anti gliadin antibodies were found in 
sera of HC+gluten fed rats, indicating systemic immune activation. Effects of 
gluten on (innate/mucosal) immune status are now under investigation.
Conclusion: Gluten are potent dietary triggers of T1D. Manipulating intes-
tinal barrier function and (innate/mucosal) immune activation might be im-
portant mechanisms for this effect. Better insight in how dietary gluten can 
induce T1D development will lead to dietary intervention strategies in order 
to reduce the chance to develop T1D in people at risk.
Supported by: Dutch Diabetes Foundation
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Rapid influx of macrophages into peritoneal cavity of NOD mice after 
weaning suggests increased permeability to gut bacteria
A.L.M. Hänninen, C. Alam, S. Valkonen; 
Medical Microbiology and Immunology, University of Turku, Finland.
Background and aims: Increased gut permeability has been proposed as an 
important mechanism of sensitization against T1D-related autoantigens in 
gut immune system. The distal part of gut also contains a large ecosystem of 
microbes, which are important in creating the right balance of helper-T-cell 
subsets for gut immune responses. Our recent findings indicate an excess of 
Th17 cells and other inflammatory cells in colons of young NOD mice. The 
aims of this study were to investigate if this inflammation leads to extra-intes-
tinal manifestations such as increased peritoneal cell numbers, and any signs 
of bacterial leakage from the gut.
Materials and methods: Peritoneal leukocytes in NOD and BALB/c mice 
were counted and phenotyped using trypan blue, flow cytometry and real-
time PCR. Presence of bacteria was investigated with PCR using primers for 
bacterial 16S-RNA. IL-1β, IL-6 and IL-12 were analyzed using qt-PCR.
Results: In peritoneum of 4,5 week-old NOD mice total number of macro-
phages was 3.0(±0.43)x10E6 compared to 0.76(±0.23)x10E6 in BALB/c mice 
and 0.68(±0.51)x10E6 in NOD mice fed antidiabetogenic Prosobee-diet (p < 
0,001, one-way ANOVA). At the same age, bacterial 16S-RNA PCR revealed 
the presence of bacterial DNA in peritoneum of 3/20 NOD mice compared 
to 0/20 BALB/c mice (N.S.). In all 3 cases, sequencing identified the presence 
of the same bacterial species in NOD peritoneum. The excess of macrophages 
did not associate with increased production of proinflammatory cytokines in 
the peritoneum compared to BALB/c mice.
Conclusion: Shortly after weaning, there is a rapid “influx” of macrophages 
into peritoneum of NOD mice which is prevented by antidiabetogenic diet. 
Simultaneously, bacteria may gain access to extra-intestinal locations. This 
may stimulate the innate arm of systemic immune responses and break toler-
ance to autoantigens.
Supported by: Finnish Academy and Päivikki and Sakari Sohlberg Foundation
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Daintain/AIF-1 plays important role in the initiation and progress of 
type 1 diabetes 
Z.-W. Chen1,2, X.-Y. Huang1, W. Wang1, Y.-Y. Zhao1; 
1College of Life Science and Technology, Wuhan, China, 2Department of 
Molecular Medicine, Karolinska Hospital, Stockholm, Sweden.
Background and aims: Type 1 diabetes (T1D) is characterised by progressive de-
struction of pancreatic beta cells as a consequence of infiltration by mononuclear 
cells and lymphocytes. The early stage of the disease process is termed insulitis. 
The beta cell death in the course of insulitis is suggested to be caused by direct 
contact with activated macrophages and T-cells, and/or exposure to soluble me-
diators secreted by these cells, including cytokines, nitric oxide (NO), and oxygen 
free radicals. The molecular mechanisms for the pathogenesis of T1D are still in-
completely understood. Daintain/AIF-1, as an inflammatory factor, is secreted by 
macrophages and T cells. We have previously demonstrated a densely accumula-
tive daintain/AIF-1 immunostaining in the pancreas of BB rats, an animal model 
of T1D, when they were suffering from insulitis. The aim of the present study was 
to further investigate the roles of daintain/AIF-1 in the pathogenesis of T1D.
Materials and methods: Studies were performed in NOD mice, an animal 
model of T1D, using immunoprecipitation, Western blots, immunohisto-
chemistry, Total Internal Reflection Fluorescence Microscope (TIRFM), flow 
cytometry, and affinity chromatography.
Results: Using immunoprecipitation followed by Western blot, we found that 
daintain/AIF-1, as a circulating protein, exists in the blood of non-diabetic 
Balb/c and diabetic NOD mice, but the plasma concentration in NOD mice 
was distinctly higher than in age-matched Balb/c mice (40 ug/L vs 10 ug/L, 
p < 0.001), which suggests that daintain/AIF-1 associates with T1D. We also 
found that daintain/AIF-1 immunostaining appeared in the pancreas of NOD 
mice when they already suffered with T1D, and no insulin was detected in the 
pancreas of those animals, indicating that daintain/AIF-1 may be involved 
in beta cell death in T1D. When daintain/AIF-1 was intravenously injected 
into NOD mice (100ug/25 g body weight, 3 times in other 10 days), the white 
blood cell proliferation in the mice was largely increased (4.5 x 109/L vs 1.7x 
109/L, p < 0.001), indicating that daintain/AIF-1 is able to promote inflamma-
tion in the mice. In parallel, the plasma concentration of insulin was gradu-
ally decreased and the plasma glucose concomitantly increased. Finally, using 
immunocytochemistry it was also found that the beta cells were undetected, 
but the alpha cells existed in the pancreas, which suggests that daintain/AIF-
1 selectively damage beta cells. Using TIRFM and flow cytometry, we found 
Daintain/AIF-1 is able to infiltrate into the primary pancreas beta cells and 
damage the cells in vitro. With affinity chromatography and followed by pep-
tide mass fingerprinting, a kind of Daintain/AIF-1-interacting proteins was 
identified as cystathionine beta-synthase (CBS) from the mice pancreas. CBS 
is involved in the metabolism of homocysteine, the later is a risk factor for 
damaging tissues, and beta cells are very sensitive to homocysteine.
Conclusion: Taken together, these results indicate that daintain/AIF-1 plays 
important roles in the initiation and progress of T1D. Daintain/AIF-1 will be 
a novel target molecule for prevention and treatment of T1D.
Supported by: Foundation, the Swedish Diabetes Association; Grants of Chinese 
863 Program
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Previous Coxsackievirus B3 infection in mothers protect offspring from 
virus-induced type 1 diabetes
P.G. Larsson, M. Flodström-Tullberg; 
Center for Infectious Medicine, Dept. of Medicine, HS, Karolinska Institutet, 
Stockholm, Sweden. 
Background and aims: Type 1 diabetes (T1D) results from the destruction 
of the pancreatic insulin-producing beta cells. It is a complex autoimmune 
disease involving both genetic and environmental risk factors. Epidemio-
logical studies and clinical observations point to an association between T1D 
and enterovirus infections, in particular those with Coxsackie B virus sero-
types (CVBs); Enteroviruses have been identified in and isolated from the 
pancreas of newly diagnosed T1D patients. Moreover, enterovirus RNA has 
been more frequently found in serum from recent-onset T1D patients than 
in serum from healthy controls. Despite the strong association between en-
terovirus infections and T1D, recent studies in different human populations 
(countries) have suggested that the presence of enterovirus infections in the 
background population shows an inverse relationship with the population in-
cidence of T1D. This counterintuitive finding has lead to the suggestion that 
enterovirus infections may have a more severe impact in populations where 
infections occurr less frequently (a.k.a. the poliovirus hypothesis). Indeed, 
low background herd immunity to a pathogen may lead to more severe dis-
ease in infected individuals. This may in part be due to a reduced transfer of 
maternal antibodies to offspring (passive immunity). To date there has been 
no attempts to experimentally test this hypothesis. Thus, the aim of this study 
was to establish a model in which we could determine whether maternally 
transferred antibodies protect genetically susceptible offspring from entero-
virus-induced T1D.
Materials and methods: The present study used the SOCS-1 transgenic 
NOD model (SOCS-1 Tg NOD) that develops T1D rapidly after infection 
with CVB3 and CVB4, and non-tg NOD mice that do not develop T1D upon 
infection with these viruses. NOD females were infected intra-peritoneally 
(i.p.) with an immunizing dose of CVB3 (10^2 pfu). After the acute infec-
tion was cleared, infected and uninfected females were bred with SOCS-1-Tg 
NOD males, progeny was challenged i.p. with a diabetogenic dose of CVB3 
(10^3 pfu). Diabetes development was monitored by daily blood glucose 
measurements. Neutralizing antibodies were quantified by a serum neutrali-
zation assay.
Results: Immunized NOD females (n=3) had CVB3-neutralizing antibodies 
in the serum (p<0,001, vs. uninfected controls, n=4). The majority of SOCS-
1-transgenic offspring from uninfected mothers developed T1D after infec-
tion (83%, n=10/12). In contrast, only approximately half (54%, n=13/24) of 
the transgenic offspring from immunized mothers developed T1D (p=0,14).
Conclusion: Preliminary observations suggest that passive immunization 
via the transfer of antibodies from the mother protects offspring from vi-
rus-induced T1D. These results support the extended poliovirus hypothesis 
as an explanation for the reported inverse correlation between the observed 
number of enterovirus infections and the incidence of T1D in a population. 
These studies may also have important implications for the development of 
an effective therapy to protect neonates from enterovirus infections. Our 
findings indicate that vaccination of women before childbirth could be an 
efficient therapy to prevent enterovirus infections in progeny, and thereby 
possibly also virus-induced T1D.
Supported by: the Swedish Diabetes Research Association and the Swedish 
Child Diabetes Foundations
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Apoptosis resistance of non-obese diabetic mouse thymocytes is 
mediated by a defective p53 expression and altered microRNA network 
controlling cell death and proliferation
N. Tormo-Badia, C. Bolmeson, M. Carlsén, A. Makowska, S. Ahmad,  
C.M. Cilio; 
Clinical Sciences, Lund University, Malmö, Sweden.
Clonal deletion during negative selection in the thymus is fundamental in 
order to establish central tolerance and to avoid the development of autoim-
mune disorders such as type 1 diabetes (T1D). It has been previously shown 
that NOD thymocytes display a defect in the establishment of central toler-
ance as well as and resistance to cell death when exposed to apoptosis induc-
ing agents. However, the underlying mechanisms contributing to these traits 
are still elusive. The tumour suppressor gene p53 has been demonstrated to 
be involved in thymocyte apoptosis and is up-regulated in response to DNA 
damage and during thymocyte selection. Our aim was to study the molecular 
basis of apoptosis resistance of NOD thymocytes and to understand whether 
this process could be involved in diabetes pathogenesis in NOD mice. Here 
we were able to show that NOD mice are unable to up-regulate p53 and cas-
pases 1 and 11 after γ-irradiation compared to wild type C57BL/6 mice. Re-
cently, it has been shown that p53 is regulated by the microRNA (miRNA) 
family miR-34. We found a decreased expression of mir-34a and mir-34b/c 
in NOD thymocytes in response to DNA damage. Sequencing of the miR-
34 gene family revealed 3 significant polymorphisms in the miR-34a gene 
in NOD mice. Interestingly, one of the nucleotide variant in NOD miR-34a 
gene is located in close proximity to a p53 binding site. The miR-34a gene 
is located in the mouse Idd-9.2 diabetes susceptibility locus, and the miR-
34b/c genes are clustered in the Idd2-locus. Thus, the miR-34 genes represent 
potential candidate genes for diabetes development in NOD mice. In con-
clusion, our results highlight the molecular basis for thymocytes apoptosis 
resistance observed in NOD mice, which might ultimately predispose to the 
development of autoimmune diabetes.
Supported by: VR
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MafA is a key regulator of insulin expression in the thymus
S. Noso1, K. Kataoka2, Y. Kawabata1, N. Babaya1, Y. Hiromine1, K. Yamaji3,  
T. Fujisawa3, H. Ikegami1; 
1Department of Endocrinology, Metabolism and Diabetes, Kinki 
University School of Medicine, Osaka-sayama, 2Laoratory of Melecular and 
Developmental Biology, Nara Institute of Science and Technology, Ikoma, 
Nara, 3Department of Geriatric Medicine, Osaka University Graduate 
School of Medicine, Suita, Japan.
Background and aims: Tissue-specific self-antigens are ectopically expressed 
within the thymus and play an important role in the induction of central tol-
erance. Abnormal regulation of the intra-thymic expression of a certain self-
antigen is therefore expected to cause organ-specific autoimmune disease. 
Insulin is expressed in both pancreatic islets and the thymus, and is consid-
ered to be the primary antigen for type 1 diabetes. Here, we report the role 
of insulin transactivator MafA in the expression of insulin in the thymus and 
susceptibility to type 1 diabetes.
Materials and methods: The expression profiles of transcriptional factors 
(Pdx1, NeuroD, Mafa and Aire) in pancreatic islets and the thymus were 
examined in NOD (non obese diabetic) and control mice(C3H mice). The 
nucleotide sequence of Mafa was identified by direct sequencing in NOD, 
C3H, Balb/c, CTS and NSY mice. Luciferase reporter assay was performed 
for newly identified promoter polymorphisms of NOD Mafa sequences .
Results: Mafa, Ins2 and Aire expression was detected in the thymus. Mafa 
expression was significantly lower in NOD thymus than control, and was 
correlated with Ins2 expression(R2=0.809). When the data were stratified by 
strain, the correlation was stronger in control (R2=0.863) than in NOD mice 
(R2=0.393). No correlation was found between Ins2 and Aire in either control 
C3H (R2=0.145) or NOD mice (R2=0.135). The entire nucleotide sequence 
of mouse Mafa was identical among the control strains (Balb/c, C3H and 
CTS mice) and an animal model of type 2 diabetes (NSY mice). Only NOD 
mice showed variation in the nucleotide sequence of Mafa compared to other 
strains. NOD Mafa promoter activity was significantly lower than that of wild 
type by 27% (p<0.0001).
Conclusion: These data suggest that MafA is a key regulator of insulin ex-
pression in the thymus, and functional polymorphisms of Mafa are newly 
identified in the NOD mouse.
Supported by: Grants-in-Aid for Scientific Research (C) and Japan Diabetes 
Foundation
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Altered leukocyte recruitment during inflammation in type 1 and type 2 
diabetes models
U.S. Pettersson, S.M. Santos, G. Christoffersson, L. Jansson, J. Henriksnäs, 
M. Phillipson; 
Dept. of Medical Cell Biology, Uppsala University, Sweden.
Background and aims: Diabetes is often associated with a systemic low-grade 
inflammation, the origin of which is uncertain. Despite the low-grade inflam-
mation, diabetic patients are known to have an impaired bacterial clearance. 
To fight an infection, leukocytes need to leave the circulation at the afflicted 
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site, which occurs through regulated steps of activation and interactions of 
endothelium and leukocytes. The effect of hyperglycemia on leukocyte func-
tion is a matter of debate. The aim of this study was to evaluate leukocyte 
recruitment in established models of inflammation during high- and moder-
ate hyperglycemia.
Materials and methods: The experimental models of diabetes used in the 
current study were induced either by i.v. administration of alloxan, causing 
a severe hyperglycemia, or by a high fat diet, causing a moderate hyperglyc-
emia. In anaesthetized diabetic or control C57Bl/6 mice, the number of ad-
herent and emigrated leukocytes was studied using intravital microscopy of 
the exposed cremaster muscle before and during exposure to the chemokine 
MIP-2. Bacterial clearance in alloxan- or untreated mice was studied after a 
subcutaneous injection of luminescent S. aureus using a non-invasive IVIS 
camera system, and the fraction of recruited leukocyte subtypes was analyzed 
at different time points post infection.
Results: During basal conditions, prior addition of chemokines, both severe 
and moderate hyperglycemia resulted in increased numbers of adherent 
and emigrated leukocytes compared to normoglycemic mice. In response to 
MIP-2 addition, the number of emigrated cells was significantly increased in 
severely hyperglycemic mice compared to control mice. However, alloxan-
treated mice demonstrated decreased number of recruited leukocytes after 5 
and 10 days post infection and an impaired ability to clear bacterial infections 
compared to control mice.
Conclusion: In conclusion, in both alloxan-, and high fat diet-induced dia-
betes, leukocyte recruitment was increased in untreated as well as chemokine 
exposed cremaster muscles, indicating that acute hyperglycemia activated 
leukocytes and/or endothelial cells. However, the ability to clear bacterial 
infections was reduced in alloxan-treated mice due to fewer amounts of re-
cruited leukocytes later in the recruitment process.
Supported by: Thurings stiftelse
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Metabolic phenotypes in preclinical autoimmune diabetes in man and 
mouse: pathways behind progression to overt disease
M. Oresic1, M. Sysi-Aho1, A. Ermolov2, P. Gopalacharyulu1,  
T. Seppänen-Laakso1, O. Simell3, M. Knip4, S. Kaski2, E. Savontaus3; 
1VTT Technical Research Centre of Finland, Espoo, 2Aalto University 
School of Science and Technology, Espoo, 3University of Turku, 4University 
of Helsinki, Finland.
Background and aims: The incidence of type 1 diabetes among children and 
adolescents has increased markedly in the Western countries during the re-
cent decades and is presently, for unknown reasons, increasing at a faster rate 
than ever before. Recent evidence from serum metabolomics indicates that 
specific characteristic metabolic disturbances precede β-cell autoimmunity 
markers and accurately identify those children who subsequently progress 
to diabetes. The causes and tissue-specific mechanisms leading to these early 
metabolic disturbances are unknown.
Materials and methods: A total of 70 mice (26 female) were monitored week-
ly with serum collection from age 3 weeks until either (a) the development of 
diabetes and then followed by treatment with insulin for 4 weeks (progressor 
group), or (b) followed until 36 weeks of age in females and 40 weeks in males 
in the absence of a diabetic phenoptype (non-progressor group). Global lipi-
domics using UPLC/MS was applied on all 1172 samples, and a biomarker for 
diabetes prediction in 8 week old female mice was developed based on insulin 
autoantibody (IAA) level and the lipidomic profile. Computational statistical 
modeling was applied to compare and align the longitudinal lipidomic pro-
files of NOD mice with the profiles of children who later developed diabetes. 
In an independent experiment normoglycemic female NOD mice were sac-
rificed at 8 (n=57) or 19 (n=14) weeks of age and blood, liver and pancreas 
samples were collected. The mice were stratified according to high or low risk 
of developing diabetes based on lipidomics-derived serum marker. Addition-
ally, lipidomics, metabolomics (GCxGC-TOFMS) and transcriptomics were 
applied to isolated islets and liver.
Results: The specificity of the pre-autoimmune metabolic changes identified 
in serum lipidomes of human type 1 diabetes progressors, as indicated by 
their conservation in murine model of type 1 diabetes. We show that young 
female non-obese prediabetic mice who later progress to autoimmune dia-
betes exhibit the same lipidomic pattern than prediabetic children, and that 
these changes are accompanied by dysregulation of specific metabolic and 
immunoregulatory pathways in pancreatic islets and liver. Specifically, plas-
ma insulin, insulinotropic amino acids in islets, and pathways of liver insulin 
signaling were already significantly upregulated in those prediabetic mice at 
high risk of developing diabetes. The pathogenic relevance of these metabolic 
pathways is further suggested by the observation that insulin autoantibody 
positive mice, that were protected from diabetes, had reduced mitochondrial 
pathways including OXPHOS in the islets.
Conclusion: The findings indicate that autoimmune diabetes is preceded by a 
state of islet increased metabolic demands resulting in elevated insulin secre-
tion and suggest alternative metabolic related pathways as potential thera-
peutic candidate targets.
Supported by: EU FP7 project DIAPREPP
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Depletion of IL-2/15 receptor beta-positive cells protects from diabetes 
in non-obese diabetic mice: role of natural killer cells and a subset of 
CD8+ T cells
H. Brauner1, S. Johansson1, H. Hall1, M. Flodström-Tullberg2, K. Kärre1,  
P. Höglund1; 
1Microbiology, Tumor and Cellbiology, 2Center for Infectious Medicine, 
Dept. of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.
Background and aims: A role for natural killer (NK) cells in type 1 diabetes 
has been suggested, but the literature is conflicting. We have recently shown 
NK cells with unique phenotypic and functional properties in the pancreas 
of NOD mice. This project aims at elucidating a possible role of NK cells in 
type 1 diabetes (T1D) by applying in vivo depletion of NK cells in non-obese 
diabetic (NOD) mice using the monoclonal antibody TMβ1.
Materials and methods: TMβ1 is a monoclonal antibody directed against the 
beta chain of the murine IL-2/15 receptor (CD122). CD122 is highly expressed 
on all NK cells and on a small subpopulation of CD8+ T cells in the spleen. 
200ug of the antibody to CD122 (TMβ1) was given i.p. once weekly to NOD 
mice and urine glucose measured. The effect on NK cells and T cell subsets 
were investigated in the pancreas, spleen and draining pancreatic lymph nodes 
(PLN). In order to investigate the presence and phenotype of pancreatic lym-
phocytes without contamination of lymphocytes from blood or lymph nodes 
the mice were flushed with PBS via the heart and lymph nodes removed under 
microscopy. The effect of TMβ1 treatment on lymphocyte infiltration into the 
pancreas was also explored using immunohistochemistry. NK cell function 
after TMβ1 treatment was assessed in vivo as the elimination of fluorescently 
labelled MHC class I-deficient spleen cells. The influence of TMβ1 treatment 
on primary CD8+ T cell responses was studied as IFNg production following 
immunization with the non diabetogenic antigen GP33. The TMβ1 effect on 
priming in the draining lymph nodes was investigated in an adoptive transfer 
model where BDC2.4 transgenic CD4+ T cells bearing a diabetogenic TCR 
were labelled with cells labelled with the fluorescent dye CFSE and transferred 
to NOD mice treated with TMβ1 or PBS. CFSE distributes equally in divided 
cells, and was used to measure proliferation after 3 days.
Results: In vivo administration of the TMβ1 antibody to non-obese diabetic 
(NOD) mice protected against diabetes development when administered just 
before disease onset. Depletion removed all NK cells and most CD122-express-
ing CD8+ T cells in the spleen. Some CD8+ T cells in the pancreas also disap-
peared despite lack of CD122 expression, suggesting either an indirect effect of 
NK cells, or reduced trafficking of CD122+ peripheral T cells to the pancreas. 
NK cell function is totally abolished after TMβ1 treatment whereas specific 
CD8+ T cell responses remain unaltered and the levels of the activation marker 
CD69 is unchanged on T cells both in the pancreas, spleen and PLN. Prelimi-
nary results suggest that TMβ1 treatment does also not affect the proliferation 
of T cells in the PLN. The possibility that the cytokine production may be al-
tered in these proliferating T cells is being investigated. A detailed immunohis-
tochemical analysis of the infiltrating lymphocytes is also currently ongoing.
Conclusion: We propose that targeting of CD122+ cells may represent a novel 
treatment strategy against late events in type 1 diabetes. With only minor effects 
on the immune system this treatment could prolong the disease free period, or 
even prevent disease onset, in patients at risk of developing type 1 diabetes.
Supported by: the Swedish Diabetes Association
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Efficient gene transfer to the pancreas using adeno-associated viral 
vectors for prevention of type 1 diabetes in mice
A. Casellas1,2, V. Jimenez1,2, E. Ayuso1,2, J. Agudo1,2, M. Obach1,2,  
A. Salavert1,2, S. Muñoz1,2, M. Moya1,2, X. Leon1,2, M. Molas1,2, D. Ramos3,2,  
J. Ruberte3,2, F. Bosch1,2; 
1CBATEG and Department of Biochemistry and Molecular Biology, School 
of Veterinary Medicine, Universitat Autonoma de Barcelona, Bellaterra, 
2CIBER of Diabetes and Associated Metabolic Disorders, Barcelona, 
3CBATEG and Department of Animal Health and Anatomy, School of 
Veterinary Medicine, Universitat Autonoma de Barcelona, Bellaterra, Spain.
Background and aims: Gene therapy may provide new treatments for se-
vere pancreatic disorders. However, gene transfer to the pancreas is difficult 
because its anatomic location and structure, and pancreatitis is a serious con-
cern. We have previously shown that pancreatic beta cells can be transduced 
to express marker genes after systemic injection of first generation adenovi-
rus (FGAd) in mice with clamped hepatic circulation. However, FGAd are 
not suitable for long term effects because the immune system recognizes and 
eliminates transduced cells due to the expression of viral genes. Here we in-
vestigated whether adeno-associated viral vectors (AAV), which lack all viral 
genes, are low immunogenic and capable of long-term expression, were able 
to mediate efficient gene transfer to the pancreas.
Materials and methods: AAV serotypes 6, 8 and 9 carrying GFP as a marker 
gene or murine hepatocyte growth factor (mHGF) were generated by triple 
transfection in 293 cells and were purified by double cesium chloride gra-
dient. AAV vectors were administered into the pancreatic duct through the 
sphincter of Oddi while the choledoc was clamped close to the liver edge.
Results: The intraductal injection of several doses of AAV6, AAV8 and AAV9 
vectors coding GFP resulted in an efficient transduction of the exocrine and 
endocrine pancreas. The number of transduced acinar cells increased in a 
dose dependent manner and AAV9 was the most efficient serotype trans-
ducing these cells. Transduction of ductal cells was only observed when 
AAV6 was administered intraductally. AAV6, AAV8 and AAV9 vectors ad-
ministered via the pancreatic duct transduced beta cells in the periphery of 
the islets. Moreover, beta cells in the periphery and in the core of the islets 
showed high expression of the marker gene when high doses of AAV6, AAV8 
and AAV9 were administered to the pancreas. However low percentage of 
alpha cells were transduced by AAV serotypes 6, 8 and 9. Furthermore, the 
intraductal administration of AAV9 vectors coding mHGF resulted in partial 
prevention of T1D in a transgenic animal model of diabetes.
Conclusion: These results show that AAV administration via the pancreatic 
duct is an efficient approach for genetic manipulation of the pancreas. This 
approach could be used to study islet and pancreas physiology and also to as-
say new gene therapy approaches for Diabetes Mellitus and other pancreatic 
disorders.
Supported by: SAF2008-00962 and the EC (FP6 CLINIGENE)
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Administration of an IL-1 trap counteracts type 1 diabetes in NOD mice
T. Rydgren, A. Börjesson, S. Sandler; 
Medical Cell Biology, Uppsala, Sweden.
Background and aims: We previously reported that the addition of IL-1 traps 
(hybrid molecules consisting of the extracellular domain of IL-1 receptor ac-
cessory protein and IL-1 receptor type 1 arranged inline and fused to the Fc-
portion of IgG1) to rat pancreatic islets in vitro can protect against noxious 
effects induced by IL-1β as well as a cytokine combination. In this study we 
tested the effect of administration of a murine IL-1 trap on the recurrence of 
disease (ROD) model in non obese diabetic (NOD) mice.
Materials and methods: Spontaneously diabetic female NOD mice received 
implantation of a curative number (600) of syngeneic pancreatic islets, from 
young healthy NOD mouse donors, beneath their left kidney capsule. Once 
a day, the mice were injected subcutaneously with IL-1 trap (30 mg/kg body-
weight), or an equimolar dose Fc-control protein (8.4 mg/kg bodyweight) or 
saline. The treatments were maintained until ROD (i.e. a blood glucose value 
>11.1 mM for 2 consecutive days) or until 5 days after transplantation. Data 
are presented as means ± SEM.
Results: Analysis of cumulative islet graft survival revealed that mice treated 
with IL-1 trap had an increased graft survival (14.1 ± 3.2 days) compared to 
mice treated with Fc-control protein (5.6 ± 1.0 days) (p<0.05), when com-
pared with the Kaplan-Meier survival curve and Logrank test, and a trend 
for prolonged graft survival compared to saline treated mice (7.6 ± 0.9 days) 
(p=0.076). Analysis of relative cytokine mRNA levels in isolated spleen cells, 
retrieved after both endpoints, showed elevated IL-4 mRNA levels in cells 
from mice treated with IL-1 trap, compared to both control groups (endpoint 
ROD: Saline 0.0072 ± 0.0008, Fc-protein 0.0101 ± 0.0019, IL-1 trap 0.0239 ± 
0.0063*, endpoint 5 days post tx: Saline 0.0059 ± 0.0009, Fc-protein 0.0042 
± 0.0004, IL-1 trap 0.0142 ± 0.0041* (2-ΔCT), n=5-7, *=p<0.05 vs. both Saline 
and Fc-protein treated animals using one way ANOVA with subsequent all 
pair-wise comparison procedures by Student-Newman-Keuls method). This 
suggests a shift toward Th2 cytokine production in the IL-1 trap treated ani-
mals, which may contribute to its protective effect.
Conclusion: Administration of an IL-1 trap counteracts islet cell destruction 
in this recurrence of disease NOD mouse model of type 1 diabetes.
Supported by: Swedish Research Council, Swedish Diabetes Association
Diabetologia (2010) 53:[Suppl1]S1–S556 S 177
1 C
426
Ciliary neurotrophic factor prevents, delays and ameliorates type 1 
diabetes in Swiss, C57Bl6 and iNOS-/- mice
L.F. Rezende, G.J. Santos, E.M. Carneiro, A.C. Boschero; 
Anatomy, Celular Biology and Physiology and Biophysics, Institute of 
Biology, State University of Campinas, Brazil.
Background and aims: CNTF is a cytokine known for its survival effects 
in many cell types, including rat pancreatic islets. Type 1 Diabetes (DM1) is 
characterized by a selective loss of pancreatic islet beta-cell mass and sub-
sequent hyperglycaemia, a condition that can be induced by Multiple Low 
Doses of Streptozotocin (STZ), a model (MLDS) that resembles human Type 
1 Diabetes. The Nitric Oxide (NO) production and Inducible Nitric Oxide 
Sintase (INOS) expression role on the DM1 onset and progression have been 
controversial. Given CNTF beta-cell protection against apoptosis, we decided 
to evaluate the effects of CNTF in a Type 1 Diabetes model that resemble the 
human disease (MLDS), and since CNTF was described to increase INOS ex-
pression and NO production, we assessed whether or not its effects on DM1 
would be hampered in a INOS Knockout mice.
Materials and methods: For MLDS, 4-6 weeks-old Swiss, C57Bl6 or INOS-
/- mice were administered by intra-peritoneal injection once daily for 5 con-
secutive days using saline injection as control (C), 40mg/Kg of STZ for MLDS 
group (S) 40mg/Kg of STZ plus 0.1 mg/Kg of CNTF for CNTF group (N). 
We assessed mice fed glycaemia in days -3, 0, 1, 3, 7, 14, 21, 28 and 35 after 
the first injection. Type 1 diabetes considered as blood glycaemia >250 mg/dl 
for 2 days. We evaluated mice overall glycaemia, Type 1 diabetes incidence, 
severity and time until occurrence. Furthermore, we evaluate INOS mRNA 
expression in MIN6 cells cultured for 3 days in the absence (CTL) or pres-
ence 0.1nM, 1nM or 5nM of CNTF by RT-PCR (n=16). Data=Mean +-SEM. 
P<0.05.
Results: In all strains (Swiss, C57Bl6 and iNOS-/-), CNTF-treated mice had 
an overall lower glycaemia than STZ-group and a lower Type 1 diabetes in-
cidence, although it was more pronounced in the C57Bl6 one. Even among 
those that developed diabetes in CNTF group, it took them longer to occur 
and was less severe than the STZ group. CNTF increased INOS expression 
in MIN6 cells in a dose-dependent manner, but even so, its protective effects 
against DM1 in INOS-/- strain were similar to those observed in the wild-
type C57BL6.
Conclusion: The results indicate that CNTF protects against STZ-induced 
Type 1 Diabetes, even in INOS-/- mice strain. Given that CNTF increased 
MIN6 cells INOS expression in a dose-dependent manner, the CNTF protec-
tive effects were not mediated trough or hampered by the increased INOS 
expression, and the functional importance of this increase in INOS expres-
sion by CNTF in mice beta-cells is yet to explained. Lastly, we can conclude 
CNTF could be a potential therapeutic tool in the prevention or even early 
treatment of DM1 patients.
Supported by: FAPESP/CNPq
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Induction of regulatory CD8 T cells after diabetes manifestation by 
treatment with a rat specific CD3 antibody in the IDDM rat as a tool for 
protection of pancreatic beta cell function
T. Arndt, S. Lenzen, A. Jörns; 
Institute of Clinical Biochemistry, Hannover Medical School, Germany.
Background and aims: In human type 1 diabetic patients the residual func-
tion of the beta cells, measured by C-peptide, can be restored by treatment 
with CD3-antibody (AB) for up to one year. Interestingly, in humans it was 
found that the number of regulatory CD8 T-cells in the blood was increased 
after therapy with CD3-AB. In this study we treated IDDM (LEW.1AR1-
iddm) rats, an animal model of type 1 diabetes mellitus (T1DM), immediately 
after diabetes manifestation with CD3-AB in analogy to the human therapy. 
The aim of the study was to analyse changes of the immune cell subpopu-
lations in the blood and pancreas draining lymph nodes of animals treated 
with CD3-AB in comparison to acutely diabetic animals without therapy and 
normoglycaemic rats.
Materials and methods: To secure beta cell function after diabetes manifes-
tation, acutely diabetic IDDM rats were treated with CD3-AB (Clon R73 0.5 
mg/kg b. wt.) consecutively over 5 days. The effect of the CD3-AB therapy 
and changes in the immune cell subpopulations were analysed by flow cyto-
metric analysis in the blood and by real time PCR analysis of isolated T-cells 
from pancreas draining lymph nodes. The infiltration stages of the pancre-
atic islets in CD3-AB treated IDDM rats were compared to normoglycaemic 
IDDM rats and diabetic rats without treatment.
Results: In prevention therapy with CD3-AB, initiated directly after diabetes 
manifestation, the reduction of all T-cells can be monitored by flow cytomet-
ric analysis. FoxP3 positive T-cells, especially CD8 T-cells, increased within 
one week of therapy. The increased number of regulatory CD8 T-cells in-
duced by CD3-AB therapy was observed in all treated IDDM rats in compari-
son to acutely diabetic rats even though the efficacy of the prevention therapy 
with CD3-AB was dependent of the metabolic state of the diabetic IDDM rats 
before start of treatment. Only animals with a blood glucose concentration 
up to 13 mmol/l at the start of the therapy could be completely cured. After 
therapy the number of pancreatic beta cells increased in the islets of these 
animals whereas the signs of immune cell infiltration were less reduced in 
comparison to the diabetic animals without treatment. Even after a complete 
clinical remission of diabetes, a certain immune cell infiltration remained in 
the islets.
Conclusion: Interestingly, analogues to the findings in type 1 diabetic pa-
tients under CD3-AB therapy, the IDDM rats showed also an increased 
number of regulatory CD8 T-cells in the blood. This indicates that the IDDM 
rat is a very good model to analyse the function of regulatory T-cells in the 
context of CD3-AB treatment to modulate the imbalance of the immune cells 
during diabetes development by an increase of regulatory T-cells.
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Comparison of two type 1 diabetes prevention therapies of a CD3 
antibody in combination with FTY720 or a TNF-α antibody on beta cell 
function in the IDDM rat, an animal model of type 1 diabetes 
A. Jörns1, M. Akin1, G. Ertekin1, A. Meyer zu Vilsendorf2, T. Taivankhuu1, 
S. Lenzen1; 
1Institute of Clinical Biochemistry, 2Department of Visceral- and 
Transplantation Surgery, Hannover Medical School, Germany.
Background and aims: The IDDM (LEW.1AR1-iddm) rat is an animal model 
of type 1 diabetes mellitus without lymphopenia and therefore very suitable 
for evaluation of combined immunomodulatory therapies. The aim of the 
CD3-antibody (AB) treatment in combination with the immunomodulatory 
agent FTY720 or the TNF-α-AB was to protect the remaining pancreatic beta 
cells from autoimmune destruction after onset of the disease. The CD3-AB 
interacts with the T-cell receptor to inhibit cytokine production and release 
from T-lymphocytes, while the sphingosin-1-phosphate receptor antagonist 
FTY720 retains the lymphocytes in the organ draining lymph nodes and the 
TNF-α-AB blocks the released TNF-α.
Materials and methods: Animals were treated with CD3-AB (0.5 mg/kg body 
weight) in combination with either TNF-α-AB (1 mg/kg b. wt.) consecutively 
over 5 days or over 40 days with FTY720 (1 mg/kg b. wt.). Besides the meta-
bolic changes, pancreatic biopsies at the time point of diabetes manifestation, 
at the end of therapy, and 60 days after the end of therapy were analysed for 
beta cell survival and immune cell infiltration by ultrastructure as well as on 
the gene and protein expression level.
Results: Prevention therapy with both combinations starting immediately af-
ter disease manifestation with blood glucose concentration values between 10 
- 15 mmol/l reversed clinical diabetes leading to normoglycaemia during and 
after therapy. Morphologically, beta cells in the islets during and after therapy 
showed a fivefold reduced apoptosis rate and a threefold increased islet beta 
cell area. Both CD8 T-cells and CD68 macrophages were markedly decreased 
in the islets at the end of therapy and nearly completely lost 60 days later. The 
small amount of immune cells surrounding the islets and in the capillary sys-
tem of the islets lost the pro-inflammatory cytokine expression after therapy. 
In both combined therapies with the immunomodulatory agents the remain-
ing beta cells in the islets were ultrastructurally well preserved without signs 
of destruction. The only difference between both combination therapies was 
the higher amount of macrophages in and around the islets after CD3- and 
TNF-α-ABs-therapy.
Conclusion: Combined therapy of CD3-AB with FTY720 or with TNF-α-AB 
showed a great benefit with respect to the survival of pancreatic beta cells 
with a normalized apoptosis rate in islets without immune cell infiltration in 
comparison to the initial small number of beta cells and the high apoptosis 
rate in the severely infiltrated islets before the start of the therapy. The ben-
eficial effects of both strategies could be maintained also after the end of the 
therapy.
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Combined measurement of autoantibodies against GAD, IA-2, insulin 
and ZnT8 in the Diabetes Autoantibody Standardization Program 2009 
Workshop
M. Schlosser1, P.W. Mueller2, V. Lampasona3, A.J.K. Williams4,  
P. Achenbach5; 
1Department of Medical Biochemistry and Molecular Biology, Ernst-Moritz-
Arndt University Greifswald, Karlsburg, Germany, 2Centers for Disease 
Control and Prevention, Atlanta, USA, 3Center of Genomics, Bioinformatics 
and Biostatistics, Milano, Italy, 4Clinical Science at North Bristol, University 
of Bristol, United Kingdom, 5Diabetes Research Group of the TU Munich, 
Germany.
Background and aims: The Diabetes Autoantibody Standardization Program 
(DASP) is a collaboration between the Immunology of Diabetes Society and 
US Centers for Disease Control and Prevention, set up to evaluate and im-
prove assays for type 1 diabetes (T1D)-associated autoantibodies (AAb). The 
DASP 2009 workshop aimed to assess the sensitivity/specificity and concord-
ance of assays measuring AAb to GAD (GADA), IA-2 (IA-2A), insulin (IAA), 
and zinc transporter 8 (ZnT8A) in laboratories throughout the world. We 
assessed the combined detection of these four AAb in DASP serum samples 
considering differences in assay performance.
Materials and methods: Coded sera from 50 patients with newly diagnosed 
T1D and 100 healthy controls were analyzed in laboratories from 19 coun-
tries by 53 GADA assays, 52 IA-2A assays, 31 IAA assays and 19 ZnT8A as-
says. Six control sera that were found positive for multiple AAb or with very 
high titre GADA in >90% of laboratories were excluded from this analysis. 
Sera were categorized according to the number of laboratories calling them 
positive using local assay thresholds, and further stratified between patients 
and controls by the number of positive AAb. Category 1 (C1) included sera 
that were found AAb positive by at least 90% of assays. Category 2 (C2) in-
cluded C1-sera plus additional sera that were found AAb positive by at least 
50% of assays. Category 3 (C3) included C2-sera plus sera that were found 
AAb positive by at least 25% of assays.
Results: Of 50 patient sera, 41(82%) were included in C1, 45 (90%) in C2 and 
46 (92%) in C3. None of the 94 control sera were included in C1 (0%), while 
7 (7%) and 13 (14%) control sera were included in C2 and C3 respectively. 
The number of multiple AAb positive patient sera increased from 24 (59%) 
in C1, to 34 (76%) in C2, and 41 (89%) in C3 (p=0.001). One control serum 
in C3 was positive for multiple AAb. For all AAb specificities, C1-sera had 
significantly higher antibody titres than C2-sera (p<0.0001). Among the 46 
AAb positive patient sera in C3, 18 (39%) had all four AAb, and another 15 
(33%) had three positive AAb, most frequently as the combination of GADA 
plus IA-2A plus ZnT8A. Among single AAb positive sera, GADA were most 
frequently detected in both, patients (n=4) and controls (n=6).
Conclusion: We conclude that laboratories with sensitive assays for GADA, 
IA-2A, IAA, and ZnT8A could detect AAb in almost all sera from newly 
diagnosed T1D patients in the DASP 2009 workshop, and multiple AAb in 
up to 90% of AAb positive patient sera. AAb assays may infrequently detect 
positive signals against single but usually not multiple antigens in sera from 
controls. Discrepancies in autoantibody measurement were found to occur 
most commonly for low titre GADA samples and identify a subset worthy 
of further study.
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Identification of autoantibody to Zinc Transporter 8 in Japanese diabetic 
patients
T. Nakagawa1, A. Kasuga2, T. Moriki3, S. Oguchi4, H. Hirose3, I. Saito3,  
M. Murata1, T. Maruyama5; 
1Laboratory Medicine, Keio University School of Medicine, Tokyo, 2Internal 
Medicine, Tokyo Electric Power Company’s Hospital, Tokyo, 3Health Center, 
Keio University, Tokyo, 4Laboratory Medicine, Keio University Hospital, 
Tokyo, 5Internal Medicine, Saitama Social Insurance Hospital, Japan.
Background and aims: Zinc transporter 8 (ZnT8) is expressed specifically 
on the membrane of insulin secretary granules in pancreatic β-cells. Recently, 
autoantibody to ZnT8 (ZnT8Ab) was reported to be implicated in type 1 dia-
betes especially in Caucasian. This study aimed to evaluate the clinical signifi-
cance of ZnT8Ab in Japanese patients with diabetes.
Materials and methods: Sera from 1316 diabetic patients (258 from type 1 
diabetes (T1D), 848 from type 2 diabetes (T2D), 210 from latent autoimmune 
diabetes in adults (LADA)) were collected in Saitama Social Insurance Hos-
pital, and control sera were collected from 177 healthy subjects without any 
histories of diabetes or autoimmune diseases. ZnT8Ab titer was measured 
by radioimmunoprecipitation assay using a recombinant ZnT8 C-terminal 
peptide (aa268-369, Arg325; CR) or a chimeric construct of CR and CW 
(Trp325) (CR-CW) as antigens (kindly provided by Prof. Hutton, Colorado 
Univ.).
Results: Sera from healthy subjects were 1.1% positive to CR and 1.7% to CR-
CW. The positive rate of ZnT8Ab was 2%, 19% and 38% in T2D, LADA and 
T1D, respectively. In case of T1D, the positive rate decreased markedly after 2 
years from the onset; therefore, we selected and analyzed samples within one 
year from the onset. In this instance, the positive rate of T1D was 51% (n=94). 
Moreover, the positive rate was higher in age group from 13 to 19 years old 
(82%) than that over 20 years old (44%) (p = 0.004). We then examined the 
association between ZnT8Ab and other autoantibodies (GADAb, IA-2Ab) in 
T1D. Among sera positive to ZnT8Ab, GAD antibody (GADAb) and IA-2 
antibody (IA-2Ab) was detected in 88% and 68%, respectively. Alternatively, 
sera negative to ZnT8Ab exhibited 67% and 36% positive to GADAb and IA-
2Ab, respectively. In T1D, the prevalence of GADAb as a single autoantibody 
was 77%, and double positive rate with IA-2Ab was 80%. Further addition of 
ZnT8Ab increased the rate up to 85%. In clinical respects, serum C-peptide 
demonstrated a significant difference between ZnT8 positive patients and 
negative patients (0.75±0.57 vs. 0.96±0.66; p=0.024). And body mass index 
of ZnT8Ab positive patients was lower than that of negative patients (19±2.1 
vs. 21±3.4; p=0.005).
Conclusion: In Japanese patients with diabetes, ZnT8Ab was positive in 51% 
of T1D and 2% of T2D. In T1D, patients in the age from 13 to 19 demon-
strated higher positive rate than elder groups. ZnT8Ab seemed to be asso-
ciated with other autoantibodies, especially such as IA-2Ab, suggesting its 
similar feature. Combination of ZnT8Ab in addition to GADAb and IA-2Ab 
increased the positive rate of autoantibodies in T1D by 5%. We supposed that 
ZnT8Ab might become a useful marker in Japanese diabetic patients.
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The catalytic cysteine of islet antigen 2 is crucial to autoantibody binding 
in type 1 diabetes
K.T. Elvers1, J.W. Broadhurst1, P.R. Easton2, V. Lampasona3, P.J. Bingley1, 
A.J.K. Williams1; 
1Clinical Science at North Bristol, University of Bristol, 2Cellular and 
Molecular Medicine, University of Bristol, United Kingdom, 3Center of 
Genomics, Bioinformatics and Biostatistics, Milano, Italy.
Background and aims: Autoantibodies to islet antigen 2 (IA-2A) are impor-
tant for characterising the prodrome of type 1 diabetes (T1D) and underpin 
current methods of disease prediction. IA-2A show selective binding to dom-
inant epitopes in the juxtamemebrane (JM) and protein tyrosine phosphatase 
(PTP) regions of IA-2. We have shown that azide and high concentrations of 
Tween-20 cause large reductions in binding to PTP epitopes of IA-2, possibly 
by modification of cysteine residues. This could disrupt disulphide bonds or 
modify the catalytic cysteine of the PTP active site. Our aim was to identify 
which cysteine residues are critical to autoantibody binding in patients with 
T1D.
Materials and methods: Candidate cysteine residues within a major epitope 
region (position 846) and the catalytic cysteine (position 909) of IA-2ic (606-
979) were substituted with serine by site-directed mutagenesis. The effects 
of these changes on autoantibody binding were investigated by radiobind-
ing assay using in vitro transcribed and translated 35-S labelled antigens 
(20,000cpm) with; (1) A panel of 22 well-characterised samples which in-
cluded 19 IA-2A positive sera from 15 patients with T1D, 3 T1D relatives and 
1 T1D standard pool, as well as IA-2 negative sera from 3 healthy controls (2) 
sera from 35 IA-2A positive patients (19 male) with newly diagnosed T1D 
(median age 11, range 2 to 19 years).
Results: (1) Mutation of the catalytic cysteine at position 909 caused a large 
reduction in IA-2A binding by the 19 well-characterised IA-2A positive sera 
(Figure); median 73%, range 7 to 90%, (p<0.001, Wilcoxon signed rank test), 
affecting sera positive for antibodies to both PTP and JM regions. In con-
trast, cysteine substitution at position 846 had no effect; median 3%, range 
-31 to 12% (p=0.167). (2) In IA-2A positive patients with T1D, mutation of 
cysteine 909 caused a median reduction in binding of 60%, range 21 to 79%, 
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(p<0.001). Mutation of cysteine at 846 again had no significant effect; median 
3%, range -4 to 16% (p=0.091).
Conclusion: Mutation of the catalytic cysteine causes profound reduction in 
IA-2A binding by sera from patients with T1D and identifies a novel site that 
is critical to epitope integrity in the cytoplasmic region of IA-2. These find-
ings indicate that the catalytic cysteine is a crucial residue in determining the 
conformation of IA-2.
Supported by: Diabetes UK
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Characterisation of IA-2 antibody epitopes by proteolysis of antibody-
antigen complexes and mass spectrometry
K.A. McLaughlin1, C.C. Richardson1, K.A. Homer2, M.R. Christie1; 
1Diabetes Research Group, 2Department of Microbiology, Dental Institute, 
King’s College London, United Kingdom.
Background and aims: Destruction of pancreatic beta cells in Type 1 dia-
betes is T-cell-mediated but circulating autoantibodies are also strongly as-
sociated with disease progression. Autoantibody-secreting B-cells participate 
in diabetes pathogenesis by facilitating antigen processing and presentation 
and are potential targets for diabetes therapy. Knowledge of autoantibody 
epitopes will aid the development of antigen-specific, B-cell targeted immune 
intervention. We have two monoclonal autoantibodies from diabetic patients 
that recognise dominant epitopes on IA-2, a major target of autoimmunity 
in the disease. Limited information on these epitopes has been obtained by 
amino acid substitution experiments. The aim of this study was to further 
define the antibody binding region by mass spectrometric identification of 
peptides remaining bound to antibody after proteolysis of antibody-antigen 
complexes.
Materials and methods: Recombinant protein representing the tyrosine 
phosphatase (PTP) domain of IA-2, either free or complexed with the Sepha-
rose-bound monoclonal antibodies, were digested with chymotrypsin and 
antibody-bound peptides eluted at pH 11.7. Peptides were analysed by ma-
trix assisted laser desorption/ionisation time of flight (MALDI-TOF) mass 
spectrometry and identified by mass comparison against a database of IA-2 
chymotryptic products. Peptide identity was confirmed by liquid chromatog-
raphy-tandem mass spectrometry. Acceptance criteria included a mass toler-
ance of less than 1.5 Da and X-correlation score of greater than 2 for doubly 
charged ions and greater than 2.5 for triply charged ions.
Results: Mass spectrometry of chymotryptic digestion products of free IA-2 
PTP domain identified peptides with broad coverage (78%) of the molecule, 
whereas peptides eluted from the two monoclonal antibodies were restricted 
to four regions spanning positions 765-795, 813-832, 833-854 and 855-873. 
The latter 3 regions are adjacent on the surface of a model of the IA-2 PTP do-
main and encompass residues previously shown to be important in antibody 
binding using site directed mutagenesis. The 765-795 region is largely buried 
within the protein and lies directly beneath the regions previously mentioned. 
Six cleavage sites (at positions 794, 823, 839, 850, 856 and 872) detected with 
free IA-2 were never cleaved in peptides eluted from the antibodies, suggest-
ing that antibody protects these sites from protease digestion.
Conclusion: Using antibody footprinting followed by mass spectrometry, we 
have mapped regions on IA-2 that represent major epitopes for diabetes-asso-
ciated autoantibodies in Type 1 diabetes, confirming and extending previous 
studies using site-directed mutagenesis. Peptides remaining antibody-bound 
after proteolytic digestion closely overlap with areas of known T-cell reactiv-
ity in Type 1 diabetes, supporting the concept that B-cells influence the T-cell 
response through modulation of antigen processing.
Supported by: JDRF
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Formation of insoluble immune complexes impairs detection of type 1 
diabetes-associated autoantibodies in radioligand binding assays
C.C. Richardson, K.A. McLaughlin, M.R. Christie; 
Diabetes Research Group, King’s College London, United Kingdom.
Background and aims: Detection of autoantibodies associated with Type 1 
diabetes is commonly achieved using radioligand binding assays. In these 
assays, complexes of serum autoantibodies with radiolabelled autoantigens 
are captured on protein A-Sepharose prior to quantification by scintillation 
counting. We have observed that a proportion of Type 1 diabetic patients 
show up to 5-fold higher recoveries of immunoprecipitated IA-2 or glutamic 
acid decarboxylase when serum antibodies are pre-bound to protein A Sepha-
rose prior to incubation with antigen (solid phase assay) than when immune 
complexes are formed in solution and subsequently captured on protein A 
Sepharose (liquid phase assay). These observations suggested either the pres-
ence of a serum factor inhibiting autoantibody-antigen interactions, or poor 
binding to protein A Sepharose of immune complexes with autoantibodies of 
some diabetic patients. The aim of this study was to investigate the cause of 
these differences using IA-2 as the target antigen.
Materials and methods: Sera were selected from Type 1 diabetic patients 
showing higher antibody reactivity to IA-2 in the solid phase compared to liq-
uid phase assay. IgG fractions were isolated from sera by protein A-Sepharose 
affinity chromatography and IA-2-specific autoantibodies affinity purified 
on IA-2-conjugated Sepharose and eluted at pH 11.7. Fab fragments of IgG 
were generated by papain cleavage. Antibody binding to radiolabelled IA-2 
was analysed in two assay formats: i) where antibodies were pre-bound to 
protein A Sepharose and washed before addition of in vitro transcribed and 
translated IA-2 (40,000 cpm per reaction) for 4 h or ii) where antibodies were 
incubated for 4h in liquid phase with the radiolabelled IA-2 before protein 
A Sepharose addition. Protein A Sepharose-bound complexes were washed 
by centrifugation (5,000 cpm for 30 secs on microfuge) before scintillation 
counting. Insoluble immune complexes were isolated by centrifugation at 
13,000 rpm for 20 mins and washed with 5% polyethylene glycol. All incuba-
tions were performed at 4C.
Results: Increased IA-2 antibody binding in solid phase assay was observed 
with both serum and protein A sepharose-purified antibodies from diabetic 
patients, indicating that any factor that may inhibit antibody binding was 
present in IgG fraction. Inhibitory effects of anti-idiotypic antibodies were 
shown to be unlikely because Fab fragments of IA-2 antibody-depleted IgG 
failed to block binding of affinity-purified antibodies to IA-2 in liquid phase 
assays. However, we were able to demonstrate the presence of radiolabelled 
IA-2 within insoluble immune complexes isolated from supernatants from 
the liquid phase assays. These insoluble immune complexes failed to bind 
protein A Sepharose. Radiolabelled IA-2 was not detected in insoluble im-
mune complexes isolated from solid phase assays.
Conclusion: This study demonstrates that a proportion of Type 1 diabetic 
patients possess circulating IA-2 autoantibodies that form insoluble immune 
complexes with antigen with poor binding to protein A. Assays dependent 
on protein A capture of immune complexes may underestimate autoantibody 
levels in those patients and these observations need to be considered when 
designing new protocols for autoantibody detection. The ability to form in-
soluble immune complexes in vivo may have implications for tissue damage 
and the regulation of autoimmune responses in the diabetic patient.
Supported by: an EFSD/JDRF/Novo Nordisk grant
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Seroconversion to persistent antibody-positivity occurs frequently after 
age 10 and is best predicted by GAD antibodies
I. Vermeulen, I. Weets, O. Costa, M. Asanghanwa, K. Decochez, J. Ruige,  
K. Casteels, D. Pipeleers, F. Gorus, Belgian Diabetes Registry; 
Belgian Diabetes Registry, Brussels, Belgium.
Background and aims: The appearance of autoantibodies (Ab+) before clini-
cal diabetes onset has mainly been studied in children. However, most pa-
tients develop type 1 diabetes in adulthood. We studied seroconversion to 
Ab+ in first-degree relatives aged 0-39 years to determine 1) age distribution 
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at seroconversion; 2) predictors of Ab-persistence and prediabetes; 3) order 
of appearance of different Ab-types.
Materials and methods: Seroconverters (n=221) were identified by measur-
ing Abs against insulin (IAA), islet cell cytoplasm (ICA), GAD (GADA), IA-2 
(IA-2A) and zinc transporter 8 (ZnT8A-CRCW) during follow-up of 6125 
first-degree relatives.
Results: One hundred and five (48%) relatives seroconverted to persistent 
Ab+. Most seroconversions (63%) occurred after age 10. Persistently Ab+ rela-
tives were more frequently GADA+ (61% vs 23%) and multiple Ab+ (26% vs 
2%) (resp. p<0.001 and p<0.008 by logistic regression) at seroconversion than 
transiently Ab+ relatives. The prevalence of IA-2A and ZnT8A was initially 
the lowest (resp. 12% and 7%) but increased most thereafter (resp. +100% 
and +214% vs +24% for IAA and +11% for GADA). Progression to diabetes 
occurred almost exclusively (20/22) in persistently Ab+ relatives (p<0.001 by 
logrank vs transiently Ab+) and preferentially in case of seroconversion under 
age 10 (p<0.021). Still, 9 (41%) prediabetics, had seroconverted after age 10.
Conclusion: 1) Seroconversion after age 10 is not a rare event; 2) GADA is 
the best predictor of Ab-persistence which is in turn associated with progres-
sion to diabetes; 3) in case of Ab-persistence, IA-2A and ZnT8A preferentially 
mark later disease stages, compatible with their known association with rapid 
progression to diabetes.
Supported by: JDRF and FWO
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Frequency of development of type 1 diabetes mellitus and immunity 
indices in prediabetic children of Ukraine who are positive to 
autoantibodies to Langerhans islet antigens
V.V. Popova, K.P. Zak, B.M. Mankovsky, M.D. Tronko; 
Dept. of Preventive Diabetology, Institute of Endocrinology and 
Metabolism, Kiev, Ukraine.
Background and aims: The discovery of human diabetes-associated au-
toantibodies (DAAb) contributed to an early prediction of development of 
type 1 diabetes mellitus (T1DM) and to investigations of the immunological 
mechanisms of its progression to a latent stage. In 1998, for the first time in 
Ukraine a Programme “Immunity at preclinical stage of T1DM progression” 
has been developed by the Institute, whose purpose was a prospective study 
of the frequency of T1DM development and dynamics of changes in several 
immunity indices in prediabetic period among children of a number of re-
gions of Ukraine, who have a family history of diabetes and are positive or 
negative to the presence of DAAb.
Materials and methods: 450 children aged 13.62+2.34 years were followed 
up. Out of 366 practically healthy normoglycemic children with first degree 
relatives having T1DM, 94 were positive (group A) and 272 (group B) nega-
tive to DAAb (GADA and IA-2A). A control group C comprised 84 normo-
glycemic children without a family history of diabetes and being DAAb-nega-
tive. The measurements of IAA, GADA, and IA-2A titers were carried out by 
radioimmunoassay, the immunophenotype of lymphocytes (CD3+, CD4+, 
CD8+, CD20+, and CD56+ cells) by FACS-analysis, the content of cytokines 
(IL-1, IL-4, IL-6, IL-8, IL-10, IL-16, TNFα, and IFN-γ) by ELISA.
Results: T1DM has appeared in different periods of follow-up (from 6 months 
to 9 years: 30.9+3.2 months) in 48.9% of children from group A and in one 
child (0.8%) from group B. Among relatives of group A subjects, in 55.3% 
of children the sibs, in 36.1% the father, and in 9.6% the mother, had diabe-
tes. Group A, unlike groups B and C, was characterized by a lower absolute 
number of content of CD3+ (0.79+0.05x109/L), CD4+ (0.52+0.03x109/L), 
and CD56+ (0.18+0.02x109/L) cells in peripheral blood compared to group 
C (1.39+0.09x109/L; p<0.01; 0.98+0.04 x109/L; p<0.001; 0.29+0.02 x109/L; 
p<0.01, respectively), and group B (1.02+0.06 x109/L; p<0.05; 0.67+0.04 x109/
L; 0.24+0.03 x109/L; p<0.01, respectively), and by a higher concentration of 
circulating IL-1α, IL-6, IL-8, IL-16, TNFα and a decreased IL-4, with a higher 
degree of changes of these indices at preclinical stage in a number of patients 
than after disease manifestation. In children from group A, whose father had 
T1DM and in which a higher simultaneous increase in GADA and IA-2A tit-
ers correlated with the most pronounced decrease in the content of IL-4 and 
CD3+ cells (0.59+0.05 x109/L; p<0.01) and of CD4+ cells (0.38+0.03 x109/L; 
p<0.01), CD56+ cells (0.15+0.03 x 109/L; p<0.01), and with elevated levels 
of IL-16, IL-8, TNFα and IFN-γ, a faster progression of T1DM (16.32+4.45 
months vs 30.9+3.2 months, p<0.01) was reported, along with a more aggres-
sive character of disease course.
Conclusion: The frequency of development of T1DM in DAAb+ normoglyc-
emic children of Ukraine is near the upper limits of this index for other coun-
tries. The velocity of T1DM progression and aggressiveness of disease course 
depend not only on the presence of a higher DAAb titer and the degree of 
changes in T- and NK-immunity indices, but on the presence of a history of 
diabetes in one of the parents as well.
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Role of diabetic family history in the prediabetic autoimmune process in 
children recruited from the general population based on HLA-associated 
disease risk
H.T.A. Siljander1,2, R.-T. Salonsaari2, A. Hekkala3, S. Simell4, R. Veijola3,  
J. Ilonen5,6, O. Simell4, M. Knip1,2; 
1Research Laboratory, Hospital for Children and Adolescence, Helsinki, 
2Department of Pediatrics, Tampere University Hospital, 3Department 
of Pediatrics, University of Oulu, 4Department of Pediatrics, University 
of Turku, 5Department of Clinical Microbiology, University of Kuopio, 
6Immunogenetics Laboratory, University of Turku, Finland.
Background and aims: To assess differences in the in the appearance and 
progression of beta-cell autoimmunity between children with and without 
first-degree relatives (FDRs) affected by type 1 diabetes (T1D) in a study co-
hort recruited from the general population based on HLA-conferred disease 
risk.
Materials and methods: 7410 children with HLA-conferred disease risk were 
recruited at birth from the general population and observed for 9.2 years 
(median) for beta-cell autoimmunity and T1D. At birth 177 (2.4%) of the 
children had affected FDRs. ICA were used for autoantibody screening. After 
ICA-positivity or T1D was confirmed, all samples available from that individ-
ual were analyzed for ICA, IAA, GADA, and IA-2A. Children with advanced 
autoimmunity (persistent positivity for ≥2 diabetes-associated autoantibod-
ies, DAAs) were eligible for an intervention trial with nasally administrated 
insulin/placebo that proved to have no effect on progression to T1D.
Results: Children with affected FDRs seroconverted to autoantibody positiv-
ity and developed persistent multipositivity more frequently, and serocon-
verted at a younger age than children without FDRs with T1D (Table 1). They 
had also higher autoantibody levels throughout the follow-up. However, in 
children with advanced multipositivity autoantibody levels were similar re-
gardless of family history. In children with affected FDRs, paternal T1D was 
associated with higher risk of seroconversion (paternal vs. maternal/sib: OR 
2.0 [CI95% 1.0-3.9], P=0.04), persistent multipositivity (OR 2.2 [CI95% 1.0-5.0], 
P=0.048), and T1D (OR 4.5 [CI95% 1.7-11.7], P=0.002) than maternal T1D or 
T1D in siblings. For comparison, OR for T1D in children with paternal T1D 
vs. children without affected FDRs was 13.4 (CI95% 7.8-23.1).
Conclusion: The most conspicuous effect of familial T1D is seen in the initia-
tion of the preclinical disease process. Children with paternal T1D are at the 
highest risk of developing beta-cell autoimmunity and T1D. After the dia-
betic autoimmune process is established, the FDR status plays a minor role in 
terms of disease progression.
Table 1. Beta-cell autoimmunity in children with HLA-conferred disease risk 
in relation to family history of type 1 diabetes (T1D). 
*P≤0.001, †P=0.02. ICA, islet cell antibodies; IAA, GADA, and IA-2A: au-
toantibodies against insulin, glutamate decarboxylase, and islet antigen 2, 
respectively.
Supported by: Academy of Finland, JDRF, the Novo Nordisk Foundation
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Effect of family history of type 1 diabetes on the phenotype of type 2 
diabetes
V.M. Lundgren1,2, M.K. Andersen3,4, B. Isomaa5, L. Groop1,6, T. Tuomi1, 
Botnia Study Group; 
1Department of Medicine, Helsinki University Central Hospital, 2Folkhälsan 
Research Centre, Helsinki, 3Research Program of Molecular Medicine, 
Helsinki, 4Research Program of Molecular Medicine, University of Helsinki, 
5Folhälsan Östanlid and Malmska Municipal Health Care, Jacobstad, 
Finland, 6Department of Clinical Sciences-Diabetes & Endocrinology, 
Malmö, Sweden.
Background and aims: Type 2 diabetes (T2D) is a heterogeneous disease 
and 10- 20 % of patients develop marked insulin deficiency. Some have GAD 
antibodies (LADA, latent autoimmune diabetes in adults) and share suscepti-
bility genotypes with type 1 diabetes. In Finland, Type 1 and Type 2 diabetes 
cluster in same families. We evaluated the impact of family history of diabetes 
and susceptibility genotypes on the phenotype of type 2 diabetic patients.
Materials and methods: We recruited 197 T2D patients with family his-
tory of T1D and 139 matched (age, age of onset, BMI, sex) T2D controls 
with family history of T2D only. Phenotypical data included an oral glucose 
tolerance test (OGTT) and i.v. glucagon test followed by i.v. insulin toler-
ance test (GITT) and GAD antibodies (GADA). Patients were genotyped for 
T1D (HLA-DQA1-DQB1, PTPN22, INS) and T2D (TCF7L2,FTO, PPARG, 
KCNQ1, SLC30A8) susceptibility genes. Patients were stratified according to 
T1D family history and GADA positivity.
Results: There were altogether 58 GADA+ T2D patients; 43 with T1D family 
history (LADAMIX ; 30 had 1
st degree relatives with T1D) and 17 with family 
history for T2D only (LADAT2), p=0.024. The LADAMIX patients had higher 
HbA1c and glucose values during OGTT than both LADAT2 and GADA- T2D 
patients with mixed family history (T2DMIX) (table 1). They were less obese 
and they had lower measures of insulin secretion (fasting and glucagon-
stimulated C-peptide, corrected insulin response during 30 min of OGTT, 
CIR) even when adjusted for the degree of insulin resistance (Disposition 
index). 37.2% of the LADAMIX patients had markedly decreased stimulated 
C-peptide (< 0.7 nmol/l) compared to 10.4% of T2DMIX and 4.9% of T2DT2 
patients(p<0.001). Surprisingly the LADAMIX patients also seemed to be more 
insulin resistant (higher HOMA and lower KITT during the insulin toler-
ance test), but this could be due to worse diabetes control. LADAMIX patients 
had significantly more often HLA-DQ T1D risk genotypes 19/43 (44.2%) 
compared with T2DMIX 39/154 (25.3%; p=0.05) and T2DT2 17/121 (14.0%; 
p=0.0003).
Conclusion: TID family history together with GADA positivity is associated 
with insulin deficiency in type 2 diabetic patients.
Table: Data are means ± SD or median (IQR). In statistical analyses (An-
cova) the data were adjusted for sex. *p<0.05, **p<0.001 LADAMIX vs T2DMIX,
 
†
 p<0.05, 
††
 p<0.001 LADAMIX vs LADAT2 
Clinical characteristics
LADAT2 
(n=17)
LADAMIX 
(n=43) 
T2DMIX 
(n=156)
T2DT2 
(n=122)
BMI (kg/m) 29.3±2.3 28.2±4.2 29.8±5.7 30.4±4.8
GADA (IU/ml) 42[58] †† †† 89.0[2136]** 12.0[9.25]** 16.0[12.0]
Diabetes duration (years) 6.0[9.5] 7.0[11.0] 6.0[8.3] 8.0[8.0]
Diabetes onset (years) 50.0[16.0] 49.0[13.0] 52.0[12.3] 52.0[10.3]
HbA1c (%) 6.9 ± 1.) † † 7.7 ± 1.5** 6.9 ± 1.1** 6.8 ± 1.0
FPG (mmol/l) 8.2 ± 2.7 8.4 ± 2.6 7.9 ± 2.0 7.5 ± 1.8
C-peptide GITT 6 min 
(nmol/l)
1.5[0.8] † † 1.0[1.4]** 1.4[0.9]** 1.4[0.8]
HOMAOGTT 2.3[4.2] 2.5[2.0]* 3.3[3.2]* 3.0[2.8]
CIR 21.9[20.0] 18.0[24.1]* 22.7[22.2]* 22.0[23.5]
Disposition indexITT 2.7[1.8]
†† ††1.6[2.2]** 2.6{2.3]** 2.7[2.3]
KITT 2.0[1.1] 1.5[1.4]* 1.9[1.3]* 2.0[1.3]
PS 22 T regulatory cells and Th17 
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IL-17 immunity in human type 1 diabetes
J. Honkanen1, J.K. Nieminen1, R. Gao2, K. Luopajärvi1, H.M. Salo1,  
J. Ilonen3,4, M. Knip5,6, T. Otonkoski2, O. Vaarala1; 
1Department of Vaccination and Immune Protection, National Institute for 
Health and Welfare, Helsinki, 2Biomedicum Stem Cell Center, University of 
Helsinki, 3Immunogenetics Laboratory, University of Turku, 4Department 
of Clinical Microbiology, University of Eastern Finland, Kuopio, 5Hospital 
for Children and Adolescents, University of Helsinki, 6Department of 
Pediatrics, Tampere University Hospital, Finland.
Background and aims: T1D is considered as an autoimmune disease caused 
by T-cell mediated destruction of the insulin-producing pancreatic beta-cells. 
Th17 immunity has been demonstrated in the development of autoimmune 
diabetes in animal models. IL-17 neutralization prevented development of 
diabetes in NOD mice. Moreover, islet-cell antigen specific Th17 cells con-
verted into IFN-γ secreting Th1-like cells and caused diabetes in mice recipi-
ents. Our aim was to address the role of Th17 cells in human T1D.
Materials and methods: We studied 15 children with T1D and 12 non-dia-
betic children for the comparison of IL-17 immunity in PBMCs stimulated 
with plate-bound anti-CD3 and soluble anti-CD28 for 40h. Culture super-
natants were collected for cytokine analysis and stimulated cells were col-
lected for gene expression analysis of IL-17, ROR-C2, IL-22, IFN-γ, T-bet 
and FOXP3 with qRT-PCR. Th17 immunity associated genes in freshly puri-
fied CD4+ memory T-cells were also compared between nine T1D patients 
and eight healthy children. CCR6, TCR-αβ, TCR-γδ and intracellular IFN-γ 
expression of IL-17 producing cells were analysed by flow cytometry. The ap-
optotic and inflammatory effects of IL-17 alone or in combination with IL-1β 
and IFN-γ on human islets from five different donors were studied in vitro 
with qRT-PCR. The proportion of apoptotic islets cells were determined by 
nuclear double staining with Hoechst 33342 and propidium iodide.
Results: We observed increased IL-17 secretion (p=0.018, median 173 pg/ml 
vs. 0 pg/ml), and mRNA expression (p=0.012, median 42 RU vs. 3 RU) in ac-
tivated PBMC from patients with T1D. Also ROR-C2 (p=0.02, median 70 RU 
vs 19 RU), IL-22 (p=0.005, median 3.6 RU vs. 0.9 RU), and FOXP3 (p=0.03, 
median 40 RU vs. 25 RU) showed increased expression in diabetic children. 
No difference was observed in the expression level of IFN-γ or T-bet. IL-17A 
and IL-22 mRNA was expressed in the population of CD4+ memory T-cells 
from children with T1D, whereas minimal or undetectable expression levels 
were seen in healthy children (6/8 vs 0/8; p=0.007 for IL-17 and 5/8 vs 0/7; p= 
0.026 for IL-22). Higher expression level of FOXP3 in CD4+ memory T cells 
were seen in children with T1D than in healthy children (5/9 vs 0/8; p=0.009). 
IL-17 positive T cells of T1D patients appeared to be CD4+ cells expressing 
TCR-αβ and CCR6, and a subpopulation showed co-production of IFN-γ. In 
combination with IL-1β and IFN-γ, IL-17 enhanced up-regulation of iNOS, 
COX-2, SOD-2 and down-regulation of anti-apoptotic gene BCL-2.
Conclusion: The activation of IL-17/IL-22 immunity is a major immune 
alteration in children with T1D. Simultaneous up-regulation of IL-17 with 
FOXP3 or IFN-γ suggests aberrant immune regulation in T1D. IL-17 was 
shown to be detrimental for human islet cells, and IL-17 together with IL-1β 
and IFN-γ enhanced the stress response of islet cells. We conclude that the 
activation of IL-17 producing cells may be involved in the pathogenesis of 
human T1D.
Supported by: Sigrid Juselius Foundation and Academy of Finland
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The role of regulatory CD4+CD25+ T lymphocytes and FoxP3 expression 
in evolution and progression of type 1 diabetes
T.V. Nikonova1, E.V. Pekareva1, V.A. Gorelysheva1, P.V. Apanovich2,  
S.A. Prokofyev1, I.I. Dedov1; 
1Endocrinology Research Center, 2Medical Genetics Research Center, 
Moscow, Russian Federation.
Background and aims: CD4+25+ T-lymphocytes (Treg) play a crucial role 
in the regulation of immune response. Lack of amount and/or activity may 
cause loss of self-tolerance to beta-cell autoantigens and the development of 
autoimmune process. The aim was to evaluate changes in terms of number or 
function of Tregs in high-risk diabetes subjects who are positive for diabetes-
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specific autoantibodies and have a genetic susceptibility and type 1 diabetes 
mellitus (T1DM) patients at different stages of the disease.
Materials and methods: We examined 85 patients with T1DM at different 
stages of the disease: 36 patients with recent-onset T1DM, 12 - with the dura-
tion of diabetes from 1 to 5 years, 11 - from 5 to 10 years, 26 - over 10 years. 
14 subjects at high-risk diabetes and 8 healthy subjects (control group) also 
included in the study. The HLA-DR and DQ alleles were detected by using 
PCR method. CD3+, CD4+, CD8+, CD38+, HLA-DR+, CD25+, CD4+25+ cells 
were analyzed by flow cytometry. FoxP3 expression was determined by Real 
Time PCR. All subjects were tested for islet cell antibodies, autoantibodies 
to glutamic acid decarboxylase, insulin and tyrosine phosphatase, C-peptide, 
HbA1c.
Results: An increasing tendency of CD 25+ and CD4+25+ T-lymphocytes and 
decreasing tendency of FoxP3 expression between control and high-risk sub-
jects was observed (p<0.1). Significant differences were found in content of 
activation molecules CD38 and HLA-DR (p<0.05) in those groups, indicat-
ing the tension of the immune system. There was no significant difference 
in the percentage of Tregs in patients with recent-onset T1DM (0.8% [0.6; 
0.8]) and control subjects (0.8% [0.3; 2.1]). However FoxP3 expression was 
significantly lower in patients with recent-onset T1DM than in the control 
group (0.39 [0.18; 0.71] vs. 1.11 [0.66; 2.26], Z = 5.26, p<0.001). Reduced 
FoxP3 expression was observed at any stage of the disease compared with 
control subjects. FoxP3 expression was 0.37 [0.18; 0.89] (Z = 2.62, p<0.01) 
in patients with duration of diabetes from 1 to 5 years; 0.14 [0.11; 0.31] (Z = 
3.33, p<0.01) in patients with duration of diabetes from 6 to 10 years and 0.47 
[0.17; 0.86] (Z = 3.15, p<0.01) over 10 years of the disease.
Conclusion: A rising tendency of Tregs in high-risk subjects may appoint 
for suppression of autoimmune process. Despite the fact that there was no 
significant difference in the content of Tregs in patients with T1DM com-
pared with control subjects, their functional activity - FoxP3 expression was 
significantly lower at any stage of the disease, which may indicate the reduced 
ability to suppress T cell proliferation.
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The deficiencies of T regulatory lymphocytes (Tregs) in cell amount, 
expression and coordination of suppresion-related proteins at type 1 
diabetes onset are only partially remedied in long term patients
S.A. Paschou1, G. Vartholomatos2, A. Petsiou2, N. Kolaitis3, E. Giotaki4,  
A. Tsatsoulis1, G.K. Papadopoulos5; 
1Department of Endocrinology, University of Ioannina Regional Hospital, 
2Molecular Biology Unit, Haematology Laboratory, University of Ioannina 
Regional Hospital, 3Haematology Laboratory, University of Ioannina 
Regional Hospital, 4Department of Nursing, Epirus Institute of Technology, 
Ioannina, 5Laboratory of Biochemistry and Biophysics, Epirus Institute of 
Technology, Arta, Greece.
Background and aims: T regulatory lymphocytes (Tregs) play an important 
role in tolerance and autoimmunity. Tregs, defined as CD4+CD25high T lym-
phocytes, and are thought to regulate the immune response in mammals. We 
previously showed a deficiency of Tregs in cell amount, expression and coor-
dination of suppression-related proteins in newly-diagnosed type 1 diabetics 
(t1d) compared to controls. The aim of our study was to investigate the vari-
ous features of Tregs in long standing t1d patients and to identify differences 
between them and newly diagnosed t1d patients.
Materials and methods: Peripheral blood from 13 newly-diagnosed patients 
(9M/4F, ages 12.5 ± 9.4 years), 26 long-standing patients (12 M/14 F, ages 26.7 
± 9.2 years) with mean disease duration of 11.6 ± 7.4 years (range 2-25 years) 
and 32 healthy controls with no first or second degree relatives suffering from 
any autoimmune disease (13 M/19 F, ages 25.3 ± 11 years) was analysed by 
flow cytometry for various phenotypic markers of Tregs. We included as such, 
molecules that had been linked to Treg function (FoxP3, CD28, CD45RO, 
CD127, CD152, TGFβ and TGFβRII), gene products or their receptors linked 
to heredity in type 1 diabetes (HLA-DR/DQ, CD25, InsR, CD152) and pro-
teins linked to apoptosis (CD95) and cell proliferation (CD27). The statistical 
analysis was performed using SPSS for Windows, Version 16.0.
Results: Newly-diagnosed t1d patients have a significantly lower percent of 
Tregs (as percent of total CD4+ T cells) compared to controls: 1.259 ± 0.264 
% vs 3.047 ± 0.264 % respectively, p < 0.001. Long standing t1d patients have 
an intermediate value of Tregs, 1.748 ± 0.308 %, that is significantly differ-
ent from that of both controls (p < 0.001) and long standing patients (p < 
0.001), suggesting a “rebound phenomenon”. Tregs of controls exhibit highly 
coordinated control of the frequency of expression of markers such as IL-
2Rβ, CTLA-4, InsR, TGFβ, TGFβRII, HLA-DQ, and HLA-DR, several of 
these being products of t1d susceptibility genes. In newly-diagnosed patients 
there is a near total absence of coordinated expression of these markers, and 
a decreased level of expression of TGFβ and TGFβRII. In long-term patients 
there is a deficiency of expression of TGFβ, while there is an increase in the 
level of TGFβRII and the frequency of Tregs expressing HLA-DR and CD95; 
here the coordinated expression involves mostly CD45RO, CD95, IL-2Rβ, 
and HLA-DQ.
Conclusion: Our data are consistent with a pathogenesis mechanism that ac-
tively disrupts the amount, functioning and coordinated expression of effec-
tor molecules in Tregs at disease onset, while at long term these deficiencies 
are only partially remedied.
Supported by: ARCHIMEDES I of the 3rd CSF to GKP
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The effect of Vitamin D supplementation on peripheral regulatory T cells 
in healthy humans, a randomised controlled trial
B. Prietl1, G. Bock1, J.K. Mader1, E. Höller1, M. Wolf1, S. Pilz1,  
W.B. Graninger2, B.M. Obermayer-Pietsch1, T.R. Pieber1; 
1Department of Endocrinology and Nuclear Medicine, 2Department of 
Clinical Rheumatology and Immunology, Medical University of Graz, 
Austria.
Background and aims: Regulatory T cells (Tregs) play a central role in the 
maintenance of self tolerance and immune homeostasis. Thus an imbalance 
between different types of T cells, such as effector T cells and Tregs, has been 
reported to play a major role in the pathogenesis in autoimmune diseases 
like type 1 diabetes. Growing bodies of evidence from animal and in vitro 
studies suggest a role for vitamin D in modulating the function of CD4+ T 
cells, including Tregs. In the present study, we aimed to elucidate, whether 
supplementation with vitamin D has the potential to increase the number or 
function of peripheral Tregs in apparently healthy human individuals. Fur-
thermore we investigated the pleiotropic in vivo effects of Vitamin D sup-
plementation on other important circulating cells of the human innate and 
adaptive immune system.
Materials and methods: A double-blinded and placebo controlled trial was 
performed among 35 healthy subjects (46% females, mean age: 35 ± 11 years). 
Subjects were randomized to oral vitamin D (140 000 IU monthly) or pla-
cebo treatment for 3 months. Peripheral blood was drawn at baseline and 
monthly visits and the percentage of Tregs within 20000 CD4+ T cells as well 
as the percentage of other circulating cells of the human innate and adaptive 
immune system were determined by using a multi-parametric FACS-analy-
sis. Functional tests for FACS-sorted Tregs were assessed in a 3H-Thymidin 
based suppression co-culture, including stimulation of effector cells with anti 
CD3/CD28 beads.
Results: 25-hydroxyvitamin D levels were significant higher in the vitamin 
D treated group than in the placebo group (mean level at 3 months: 60.2 ± 
21.1 ng/ml vs 18.8 ± 7.2 ng/ml). Accordingly, the median percentage of Tregs 
increased significantly from a median baseline level of 4.8% (interquartile 
range: 4.3-5.8%) to a level of 6.4% (5.9-7.2%) at month 3 (p<0.001 for general 
linear model with repeated measurements) in the vitamin D group whereas 
there was no statistically significant change in the placebo group (p=0.956). 
Between group comparison at month 3 revealed a significant difference in 
the median levels of %Tregs (p=0.017). Suppressive function of regulatory T 
cells remained unchanged in both groups. Furthermore, analysing the other 
peripheral immune cells showed no statistically significant chances in the fre-
quency of naive CD4+ and CD8+ T cells, memory CD4+ and CD8+ T cells, 
CD25++CD8+ cells, NK cells, NKT cells, B cells, monocytes, granulocytes, 
stem cells and blood dendritic cells (myeloid and plasmacytoid DC) in both 
groups. C-reactive protein was within the normal range before and after the 
treatment and did not change significantly between the study visits. In both 
groups no clinically relevant adverse events have been reported.
Conclusion: High dose of vitamin D supplementation increased the frequen-
cy of peripheral Tregs significantly in healthy subjects. This finding supports 
previously described associations of vitamin D deficiency and autoimmune 
diabetes and provides a rationale for further studies to investigate the im-
munemodulatory effects of vitamin D in diabetic subjects.
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Insulin treatment during pregnancy induces insulin-reactive 
CD4+CD25+FOXP3+ regulatory T cells in the infant
K. Luopajärvi1, J.K. Nieminen1, J. Ilonen2,3, H.K. Åkerblom4, M. Knip4,5,  
O. Vaarala1; 
1Immune Response Unit, National Institute for Health and Welfare, 
Helsinki, 2Department of Clinical Microbiology, University of Eastern 
Finland, Kuopio, 3Immunogenetics Laboratory, University of Turku, 
4Hospital for Children and Adolescents, University of Helsinki, 5Department 
of Pediatrics, Tampere University Hospital, Finland.
Background and aims: Reduced risk for type 1 diabetes (T1D) has been 
reported in the offspring of mothers with T1D when compared to children 
of affected fathers. To evaluate the hypothesis that exposure of the offspring 
to maternal diabetes and insulin therapy results in tolerization to insulin in 
utero and thereby decreases the risk for T1D, we compared the FOXP3 ex-
pressing regulatory T cells in cord blood of infants born to mothers with or 
without T1D.
Subjects and methods: Cord blood mononuclear cells from 20 infants with 
maternal T1D and from 20 infants with an unaffected mother were analysed 
for the expression of CD4+CD25+ cells and FOXP3 ex vivo and after 72h 
stimulation with human insulin by flow cytometry. The mRNA expression of 
FOXP3, TGF-β and IL-10 was measured by real-time RT-PCR.
Results: The percentage of CD4+CD25highFOXP3+ cells in cord blood was 
higher in the infants of mothers with T1D than in the infants of unaffected 
mothers (p = 0.023; median values 31.5% [range 6.1-63.1%] and 16.4% [range 
2.0-36.3%], respectively). The numbers of FOXP3 positive CD4+CD25high cells 
were higher after in vitro stimulation of cord blood cells with human insulin 
than in unstimulated cord blood cells in the infants with maternal T1D (p 
< 0.001; Wilcoxon test; median values 17.2% [range 2.4-56.9%] and 28.1% 
[range 8.4-60.8%]). In infants of non-diabetic mothers there was no difference 
in FOXP3 expression in CD4+CD25 high T cells stimulated with insulin com-
pared to non-stimulated CB mononuclear cells (p = 0.21, Wilcoxon test; medi-
an values 10.9% [range 1.0-35.3] and 15% [range 0.7-31.4%]. Furthermore, an 
increased intensity of FOXP3 in CD4+CD25high cells was observed in response 
to insulin stimulation in infants of T1D mothers (p < 0.05). Only in infants 
with maternal diabetes FOXP3-, IL-10- and TGF-β specific mRNA increased 
in cord blood cells in response to insulin (Wilcoxon- test p <0.001, p = 0.003, p 
= 0.013, respectively). The HLA genotype did not modulate the results.
Conclusion: We suggest that maternal insulin treatment induces expansion 
of insulin-specific FOXP3 expressing regulatory T cells in the fetus, likely due 
to tolerization to insulin through transplacental transfer of insulin bound to 
insulin antibody complexes. 
Supported by: Diabetes Research Foundation, Sigrid Juselius Foundation
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Otelixizumab differentially modulates human regulatory and non-
regulatory T cells
I. Apostolou, J. Guild, L. Vaickus, M. Rosenzweig; 
Tolerx, Inc., Cambridge, USA.
Background and aims: Otelixizumab is an Fc-disabled monoclonal antibody 
(mAb) with specificity for CD3ε that has been shown to preserve β cell func-
tion in subjects with new onset type 1 diabetes mellitus (NOT1DM). Ote-
lixizumab is being evaluated in placebo-controlled Phase 3 clinical studies 
in NOT1DM patients. The cellular and molecular mechanisms by which 
otelixizumab and other anti-CD3 mAbs turn off the autoimmune attack in 
humans are not well understood. Although otelixizumab binds to all T cells, 
treated subjects do not exhibit signs of chronic immunomodulation other 
than arrest of the pathogenesis mediated by pancreas-specific T cells. This 
suggests that this apparently non-antigen-specific therapy selectively signals 
antigen-activated T cells. Furthermore, peripheral blood Foxp3+ CD4+ regu-
latory T cells (Tregs) increase after otelixizumab administration, suggesting 
that it promotes Treg expansion/migration as well as function. This prompted 
us to investigate whether otelixizumab has a differential effect on distinct T 
cell subsets and whether it preferentially regulates activated T cells in an in 
vitro model of antigen reactivity.
Materials and methods: Mixed lymphocyte reactions (MLRs), using HLA-
A2 mismatched donors to distinguish responders from stimulator cells, were 
conducted without or with otelixizumab. Proliferation and survival of CFSE-
labeled responder Tregs, activated effector T cells (Teffs), and naïve T cells 
were examined by flow cytometry.
Results: Otelixizumab markedly inhibited the proliferation of alloantigen-
specific Teffs in primary MLRs as well as secondary MLRs, where the mAb 
was added to primed alloantigen-specific Teffs. Inhibition of T cell prolifera-
tion was dose-dependent and peaked at the highest saturating concentration 
of otelixizumab. Subsaturating concentrations of mAb resulted in the prolif-
eration of a subset of T cells with an activated but not a naïve phenotype, and 
the number of naïve T cells did not decrease in the presence of mAb. Addition 
of otelixizumab to primary MLRs was accompanied by the appearance of and 
an increase in the number of dividing Tregs, irrespective of the dose. Ote-
lixizumab-induction of Treg proliferation was optimal at subsaturating con-
centrations. The dose-dependent inhibition of T cell proliferation was more 
pronounced among Teffs than Tregs, resulting in a ~5-fold decrease in the 
ratio of dividing Teff:Tregs at saturating concentrations of mAb as compared 
to controls. Furthermore, addition of otelixizumab to primary MLRs was as-
sociated with increases in non-dividing Tregs, suggesting that otelixizumab 
can induce Treg-commitment in activated T cells. Lastly, no mAb-induced 
cell death was observed.
Conclusion: These studies indicate that Tregs, activated Teffs, and naïve T 
cells respond differently to otelixizumab and to different concentrations of 
otelixizumab. Naïve T cells were minimally affected by otelixizumab. In con-
trast, otelixizumab induced a significant increase in Tregs that exhibited a 
lower susceptibility to otelixizimab-mediated inhibition of proliferation than 
activated Teffs. This suggests that otelixizumab’s immunoregulatory effects 
are principally confined to activated Teffs and Tregs, and are markedly affect-
ed by dose. Further experiments comparing otelixizumab-induced signaling 
cascades in the various T cell subsets and the antigen specificity and potency 
of otelixizumab-expanded Tregs are being conducted.
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Dynamic changes of CD95 and CD95L expression on lymphocytes in 
patient with new-onset type 1 diabetes mellitus
E.V. Pekareva, T.V. Nikonova, V.A. Gorelysheva, S.M. Stepanova,  
S.A. Prokofyev, O.M. Smirnova, I.I. Dedov; 
Endocrinology Research Centre, Moscow, Russian Federation.
Background and aims: The CD95 molecule triggers cell apoptosis. It is ex-
pressed by activated lymphocytes and involved in switching-off the immune 
response. Impaired CD95 expression may play a role in type 1 diabetes mel-
litus (T1DM) initiation. Expression of apoptosis molecules is impaired in 
T1DM. Aims were: (i) To determine expression of apoptosis molecules on 
lymphocytes in patients with T1DM at onset of disease. (ii) To compare these 
parameters during the first year of the disease.
Materials and methods: 29 patients (12 women and 17 men) T1DM includ-
ed. Age of onset diabetes (median) was 29 years old. Expression of surface 
CD95 and CD95L molecules on peripheral blood lymphocytes was meas-
ured in onset, remission period, and 12 months after diagnosis. CD95 and 
CD95L expression was detected by flow cytometry, using monoclonal anti-
bodies. Samples for HbA1c analysis were collected at onset and after 3, 6 and 
12 months. The patients were also examined for C-peptide, HLA-typing and 
tested for islet cell antibodies, antibodies to glutamic acid decarboxylase, in-
sulin autoantibodies and tyrosine phosphatase-like IA-2.
Results: 17 (59%) patients entered partial remission and 3 (10%) patients 
had complete remission. The susceptible genetic haplotypes, in particular 
DR3/DR4, were prevalent. HbA1c level was 11.5% [10.8; 12.9] at onset, 6.9% 
[6.5; 8.1] after 6 months and 6.5% [5.3; 7.9] after 12 months. CD95 expres-
sion on lymphocytes was significantly lower at onset T1DM than at remission 
of the disease (p=0.02) and than after 12 months (p=0.05). The amount of 
CD95-positive cells was 29% [27.1; 32.5] at onset; 33.5% [31.5; 38.8] at remis-
sion phase and 33% [29.5; 39.1] after 12 months. No significant differences 
were found in CD 95L expression on lymphocytes between onset and after 12 
months (p=0,21). Expression CD95L was similar during first year of disease. 
The amount of CD95L-positive cells were 1.4% [1.0; 3.0] at onset; 2.5% [1.6; 
5.2] 12 months later. Autoantibodies titers decreased in the remission phase 
of the disease.
Conclusion: There are a lower level of CD95 expression on lymphocytes in 
new-onset T1DM patient and increase of it during the first year of the disease. 
This low CD95 expression on lymphocytes could be a contributing factor to 
markedly decreased suppressive potential of these cells in the initial phase of 
disease. We suggest that suppression of activated lymphocytes apoptosis may 
contribute to prolongation of autoimmune response in new-onset T1DM.
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Analysis of expression of Th1 and Th2-associated chemokine receptors 
on CD4+ T lymphocytes: comparison between recent onset type 1 
diabetics and nondiabetic first degree relatives 
T. Milicic1, N. Lalic1, A. Jotic1, I. Markovic2, M. Zamaklar1, K. Lalic1,  
L. Lukic1, N. Rajkovic1, M. Macesic1, J. Seferovic1, S. Aleksic1; 
1Clinical Center of Serbia, Institute for Endocrinology, 2University of 
Belgrade, Institute for Biochemistry, Belgrade, Serbia.
Background and aims: Previous studies have reported an important role of 
the chemokine receptors CXCR3 and CCR4, which are associated with Th1 
and Th2 CD4+ cell subsets respectively and involved in their extravasations 
into inflamed pancreatic islets, in the initial phase of Type 1 diabetes (T1D). 
However, the changes in CXCR3+ and CCR4+ subsets of the memory CD4+ 
CD45RO+ T cells in recent onset type 1 diabetics and their nondiabetic first-
degree relatives (FDRs), have not yet been clarified. Therefore, the aim of this 
study was to analyze the percentage of the (a) CXCR3+ (Th1 associated) and 
(b) CCR4+ (Th2 associated) subsets of T memory cells, in peripheral blood 
in 24 recent-onset T1D patients in insulin-requiring state (IRS) at the onset 
(group A), 10 T1D patients in the state of clinical remission (CR) (group B), 
41 nondiabetic FDRs (group C), as well as in 18 healthy, age-matched control 
subjects (group D).
Materials and methods: T1D was diagnosed in accordance to WHO criteria. 
The CR was defined as optimal metabolic control without insulin lasting >30 
days. The percentages of CXCR3+ and CCR4+ T memory CD4+ CD45RO+ 
cell subsets were analyzed in peripheral blood by using four-color immun-
ofluorescence staining and flow cytometry.
Results: We found that there was no difference among the groups concern-
ing the percentage of CD4+CD45RO+ T lymphocytes (A: 27.23±8.54 vs B: 
24.19±6.50 vs C: 25.73±6.78 vs D:27.67±6.59 %, A vs B vs C vs D, p=NS). 
However, when the percentage of CXCR3+ T memory lymphocytes was ana-
lyzed, we found that in groups A and B it was significantly lower than in groups 
C and D (A: 40.19±11.52; B: 42.16±11.13; C: 53.92±8.19; D: 53.09±6.29 %; A 
vs C, D: p<0.001; B, vs C, D: p<0.01), while there was no difference between 
groups C and D. Simultaneously, the percentage of CCR4+T memory cells 
was also found to be significantly lower in groups A and B than in groups C 
and D (A: 31.53±9.67; B: 31.40±8.14; C: 39.88±9.10; D:40.90±7.24%; A vs C, 
D and B vs C,D p<0.01) also without difference between goups C and D.
Conclusion: Our results have shown that the onset of T1D was associated 
with the decreases in the CXCR3+ and CCR4+ subsets of T memory lym-
phocytes, presumably reflecting their extravasation into pancreatic tissue. 
However, these changes could not be detected in the nondiabetic FDRs, thus 
implying that the onset of the disease could be modified on the level of these 
subsets of T memory cells.
PS 23 Inflammatory mediator 
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Systemic cytokines and chemokines in prediction of type 1 diabetes in 
high risk antibody positive subjects
M.-C. Simon1, S. Schimmack1, K. Strassburger1, M. Roden1,2, E.A.M. Gale3, 
P.J. Bingley3, T. Mandrup-Poulsen4,5, H. Kolb6, N.C. Schloot1,2, ENDIT 
Group; 
1Institute for Clinical Diabetology, German Diabetes Center, Duesseldorf, 
2Clinic for Metabolic Diseases, University Hospital Duesseldorf, Germany, 
3Department of Clinical Science at North Bristol, University of Bristol, 
United Kingdom, 4Steno Diabetes Center, Gentofte, 5Hagedorn Research 
Institute, Gentofte, Denmark, 6Medical Faculty, Heinrich-Heine University 
Düsseldorf, Germany.
Background and aims: Type 1 diabetes is the result of a chronic immune me-
diated destruction of ß-cells lasting several months to years before manifesta-
tion of overt hyperglycemia. Cytokines and chemokines have been shown 
to orchestrate the immune response and can also directly harm ß-cells and 
associate with the disease process after diabetes manifestation. This study 
therefore aimed to evaluate whether systemic concentrations of cytokines 
and chemokines predict type 1 diabetes.
Materials and methods: Serum samples from baseline visits of 291 first-de-
gree ICA-positive relatives, (55% males / 45% females, age 20±6.1years) of 
the European Nicotinamide Diabetes Intervention Trial (ENDIT) were ana-
lysed for chemokines (IL-8, MIP1-α) and cytokines (MIF, TNF-α, interleukin 
(IL)-13, IL-1ß, IL-1receptor antagonist [IL-1ra]). The clinical endpoint (overt 
diabetes mellitus) was monitored during the observational period of 5 years. 
Subjects were grouped into two age groups, below and above 16 years of age, 
as disease progression is thought to be faster in younger versus older subjects. 
Immune-mediators were measured by ELISA based technology. Regression 
analysis was adjusted for potential confounders sex, age, body mass index 
(BMI) and nicotinamide treatment.
Results: 73 (25%) subjects were diagnosed with type 1 diabetes during the 
follow up, with the earliest diabetes manifestation observed after one year 
and the latest after 5 years. 218 (75%) subjects remained non-diabetic. As 
known from previous ENDIT analyses, diabetes developed more frequently 
in pediatric (56 of 138, 41%) than in adults (16 of 153, 10%; p=0.001). Sub-
jects above age 16 showed higher IL1ra concentrations compared to children 
(239 pg/ml versus 183 pg/ml, p=0.0197). All other immune parameters did 
not differ between pediatric versus adult subjects. Within the age groups, nei-
ther IL1ra, nor IL-8, MIP1-α, MIF, TNF-α, IL-13 or IL-1ß were predictive for 
later diabetes development.
Conclusion: In our study systemic chemokines, cytokines or cytokine recep-
tor antagonist concentrations obtained one to five years before diabetes onset 
did not serve as predicitive markers for disease manifestation. The age-associ-
ated increase of IL1ra in adult subjects may contribute to the overall reduced 
rate of diabetes development compared to younger subjects.
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Proinflammatory and regulatory cytokines are similar in type 1 diabetes 
(T1D) and LADA and lower compared to type 2 diabetes (T2D) patients: 
results from Action LADA Study
M.N. Pham1, M.I. Hawa2, C. Pfleger3, M. Roden1,4, G. Schernthaner5,  
P. Pozzilli6, R. Buzzetti7, J. Seissler8, S. Hunter9, R.D. Leslie2, N.C. Schloot1,4, 
the Action LADA Study Group; 
1German Diabetes Center, Duesseldorf, Germany, 2Institute of Cell 
and Molecular Science, London, United Kingdom, 3Benaroya Research 
Institute, Seattle, USA, 4Clinic for Metabolic Diseases, University Hospital, 
Duesseldorf, Germany, 5Rudolfstiftung Hospital, Vienna, Austria, 
6University Campus Bio-Medico, Rome, 7Dipartimento Scienze Cliniche, 
Rome, Italy, 8Ludwig-Maximillians-University, Munich, Germany, 9Centre 
for Endocrinology and Diabetes, Belfast, United Kingdom.
Background and aims: LADA (latent autoimmune diabetes in adults) is clin-
ically almost indistinguishable from T2D but has T1D like islet antibodies 
(GADA). Previous studies showed that cytokines are involved in the patho-
genesis of T1D and T2D. As cytokines play an important role in pathogenesis 
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of T1D and T2D we aimed to search for differences of LADA compared to 
T1D and T2D.
Material and methods: We investigated systemic cytokines of 90 patients 
with T1D (F/M= 28/62, age 45±10yrs), 61 LADA patients (35/26, 52±10yrs) 
positive for GADA who had not required insulin for at least 6 months after 
diagnosis, 465 T2D patients who were GADA negative (202/263, 55±9yrs) 
and 41 control subjects (C) (25/16, 47±9yrs). All patients were recruited 
from the Action LADA cohort with diabetes duration <5yrs. Anti-inflam-
matory IL-1ra and pro-inflammatory TNF-a and IL-6 from serum samples 
were measured by multiplex technology. Differences of circulating cytokine 
concentrations between all groups were assessed using Kruskal-Wallis test 
followed by Mann-Whitney test. With multiple linear regression models we 
compared log-transformed systemic cytokine concentrations of different 
groups as dependent variables using age, sex, BMI, blood pressure (BP) and 
diabetes duration as covariates.
Results: For all three cytokines significant differences were detected between 
different groups (all p<0.0001). Group by group comparison revealed similar 
cytokine concentrations in T1D and LADA patients. Compared with con-
trols, T1D and LADA had significantly up-regulated IL-1ra, IL-6 and TNF-a 
(p<0.05). When comparing T1D and LADA versus T2D, all three cytokines 
were significantly higher in T2D (IL-6 p<0.001, TNF-a and IL-1ra p<0.05). 
As groups differed by BMI, age, sex, BP and disease duration we performed 
stepwise regression analysis with adjustment for these potential confounders. 
As expected, systemic concentrations of IL-1ra and IL-6 were positively as-
sociated with BMI (p<0.0001). TNF-a did not show an association with BMI. 
The significant increase of cytokines in T2D versus T1D/ LADA and C found 
in unadjusted comparisons persisted upon adjustment for sex, age, BMI, BP 
and diabetes duration in multiple linear regression models (all p<0.05).
Conclusion: We conclude that proinflammatory as well as anti-inflamma-
tory cytokines are elevated in T2D compared to T1D, LADA and C. IL-1ra, 
IL-6 and TNF-a of LADA were lower compared to T2D but were similar 
compared to T1D. As cytokines cannot distinguish T1D from LADA, other 
factors are likely to determine clinical outcome that is characterized in im-
mediate insulin need in T1D and preserved endogenous insulin secretion in 
LADA. Further studies should investigate which other factors might influ-
ence the pathogenic process leading to slower deterioration of ß-cell function 
in LADA and faster deterioration of ß-cell function in T1D.
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Serum CXCL1 levels are elevated in subjects with type 1 diabetes mellitus 
and possibly reflect the rate of c-peptide loss.
K. Takahashi, M. Masaya, T. Takahashi, K. Nagasawa, H. Homma,  
M. Yamashina, M. Ishii, F. Fujiwara, T. Kajiwara, H. Taneichi, N. Takebe,  
J. Satoh; 
Division of Diabetes and Metabolism, Department of Internal Medicine, 
Iwate Medical University, Morioka, Japan.
Background and aims: Identification of unique inflammatory biomarkers may 
improve prediction of type 1 diabetes (T1D), and be used as clinical measures 
in trials aimed at preventing this disease. We previously compared transcript 
profiles of bone marrow (BM)-derived dendritic cells (DC) from NOD mice, 
a model of T1D, with those from a sister strain, NON mice, to characterise 
molecular changes in BMDC, and then found that BMDC from 4-week-old 
female NOD displayed 3-5 times stronger expression of inflammatory media-
tors, including CCL7, CXCL1, CXCL5, and S100A8/100A9, than those from 
NON. Intriguingly, in the human, these chemokines (Wang X, 2008) and S100 
proteins (Collins CD, 2006) have been noted as possible biomarkers reflective 
of active anti-islet autoimmunity by microarray analyses. In the present study, 
we investigated weather serum levels of these molecules serve as effective bi-
omarkers for T1DM, and those reflecting active autoimmune process.
Materials and methods: CCL7, CXCL1, CXCL5, and S100A8/100A were 
quantified by ELISA in sera from Japanese subjects with T1D and T2D as a 
matched disease control. Serum fasting C-peptide (CPR) levels were meas-
ured by CLEIA at the beginning of the study, and followed up after a year. The 
study groups consisted of: (i) 26 subjects (11 females, 15 males; median age 43 
years, range 16-75 years; duration of diabetes 10 years, range 1-40 years ) with 
acute-onset T1D; (ii) 20 subjects (10 female, 10 males; age 69 years, range 
38-79 years; duration of diabetes age 10 years, range 3-26 years) with slowly 
progressive T1D; and (iii) 20 subjects (8 females, 12 males; mean age 10 years, 
range 21-83 years; duration of diabetes age 10 years, range 1-32 years) with 
T2D. All T1D subjects were positive for autoantibodies.
Results: It was noted that serum CXCL1 levels were significantly higher in 
subjects with acute-onset (median 113.2 ng/ml, range 41.75-457.2 ng/ml), 
and slowly progressive (median 100.8 ng/ml, range 32.87-225.0 ng/ml) 
T1D than in those with T2D (median 71.58 ng/ml, range 32.45-152.6 ng/
ml, p=0.01 and 0.03, respectively, Mann-Whitney U test). Decreases in fast-
ing CPR levels per year were significantly correlated with the CXCL1 levels 
(n=10, r=-0.01, p=0.02) in the subpopulation of slowly progressive T1D sub-
jects displaying preserved beta-cell function, whereas cross-sectional fasting 
CPR levels were not. Serum CCL7, CXCL5, and S100A8/100A9 concentra-
tions showed no difference between T1D and T2D subjects.
Conclusion: To our knowledge, this is the first report that reveals T1D sub-
jects display elevated serum CXCL1 levels, irrespective of the subtypes, com-
pared to control T2D subjects. CXCL1 is produced by monocytes and den-
dritic cells, as well as by beta cells, and reportedly involved in activating Th17 
cells which play a pivotal role in developing T1D. The serum concentrations 
of this chemokine were able to predict the loss of CPR in slowly progressive 
T1D subjects, possibly reflecting activity of the anti-islet autoimmune proc-
ess, however, failed to distinguish subtypes of T1D. The predictive value of 
CXCL1 in the development of acute-onset T1D should be further investi-
gated in the first-degree relatives at risk or the recent onset subjects. In con-
clusion, we propose that the elevated serum CXCL1 levels are good markers 
for T1D, predisposing to anti-islet autoimmunity.
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High risk vs low risk nondiabetic first degree relatives of type 1 diabetics: 
differences in expression of Th1 and Th2 associated chemokine receptors 
and chemokine levels 
A. Jotic1, N.M. Lalic1, T. Milicic1, I. Markovic2, M. Zamaklar1, K. Lalic1,  
L. Lukic1, N. Rajkovic1, M. Macesic1, J. Seferovic1, S. Aleksic1; 
1Institute for Endocrinology, Clinical Center of Serbia, 2Institute for 
Biochemistry, Belgrade, Serbia.
Background and aims: It has been previously suggested that expression of 
Th1 and Th2 associated chemokine receptors determine the recruitment of 
CD4+T cells into sites of inflammation during the onset of Type 1 diabetes 
(T1D). However, the relevance of the changes in expression of chemokine re-
ceptors, CXCR3+ (Th1 associated) and CCR4+ (Th2 associated), on T mem-
ory CD4+CD45RO+ cells and in respective chemokine levels, interferon-γ 
inducible chemokine (IP-10) (Th1 associated), and thymus-and activation-
regulated chemokine (TARC) (Th1 associated), for the development of T1D 
has not yet been elucidated. Therefore, the aim of this study was to compare 
the changes in (a) percentage of CXCR3+ and CCR4+ subsets of CD4+ T 
memory cells (b) the level of chemokines IP-10 and TARC, in peripheral 
blood between two groups, the high-risk and the low-risk group, of nondia-
betic first-degree relatives (FDRs) of patients with T1D as well as in the group 
of healthy controls. The difference between the two groups of FDRs was based 
on presence or absence of glutamic acid decarboxylase (GADA) and tyrosine 
phosphatase insulinoma antigen-2 (IA-2) antibodies. Thus, in the study we 
included 10 high-risk nondiabetic FDRs (GADA+, IA-2+) (group A) and 34 
low-risk nondiabetic FDRs (GADA-, IA-2-) (group B) and 18 healthy unre-
lated control subjects (GADA-, IA-2-) (group C).
Materials and methods: T1D and glucose intolerance were excluded in the 
study by using WHO criteria. IP-10, TARC, GADA and IA-2 levels were de-
termined by ELISA. The percentages of CD4+CXCR3+ and CD4+CCR4+ T 
memory cell subsets were analyzed in peripheral blood by using four-color 
immunofluorescence staining and flow cytometry.
Results: When the percentage of CXCR3+ T memory cells was analyzed, it 
was found to be higher in group A vs groups B and C (A: 64.27±6.53 vs B: 
51.79±6.79; C: 53.09±6.29%, p<0.05). Simultaneously, the level of IP-10 was 
higher in group A vs groups B and C (A: 154.56±112.99 vs B: 109.73±79.52; 
C: 85.24±19.82 pg/ml, p<0.05). In contrast, the percentage of CCR4+ T mem-
ory cells was significantly lower in group A vs groups B and C (A: 30.04±3.26 
vs B 41.90±8.59; C: 40.90±7.24 %, p<0.05). However, when TARC level was 
tested, it was similar in group A in comparison to group B and did not differ 
significantly compared to group C (A: 406.66±171.44 vs B: 336.01±166.26; C: 
236.88±89.19 pg/ml, p=NS).
Conclusion: Our results have demonstrated that high risk FDRs showed 
higher levels of CXCR3+ T cell subset and IP-10 chemokine, both associated 
with increased Th1 response, together with lower levels of CCR4+ Th2 cell 
subset. The results imply that in FDRs the risk for developing T1D might be 
strongly influenced by enhanced activity of Th1 and diminished activity of 
Th2 autoimmune response.
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The association between vitamin D levels and biomarkers in newly 
diagnosed children with diabetes and their siblings
J. Svensson1, H.B. Mortensen1, J. Johannesen1,2, M. Fenger3, A. Linneberg2,3; 
1Dept. of Paediatrics, Glostrup University Hospital, 2Glostrup University 
Hospital, 3Hvidovre University Hospital, Denmark.
Background and aims: Vitamin D insufficiency has been suspected as a con-
tributing factor to the development of type 1 diabetes. Different cells in the 
immune system are capable of converting 25-OH to its active form 1,25 OH 
and vitamin D has been shown to suppress Th1 cytokines and enhance Th2 
cytokines. The aim of the present study was to investigate the association be-
tween levels of vitamin D and different cytokines and chemokines.
Materials and methods: Data is derived from The Danish Diabetes Registry 
(DIA-REG B&U) initiated in 1996 with an attached bio bank. All serum sam-
ples were analysed using high-capacity Luminex xMAP technology. Vitamin 
D is determined by HPLC and divided in quartiles. Data was analysed using 
multiple regression with biomarkers as outcome and vitamin D in quartiles 
and CYP27B1 genotype as explanatory variables together with age and gen-
der. All children were genotyped for the CYP27B1 variant rs4646536.
Results: There were 466 newly diagnosed children with diabetes and 466 
healthy siblings. 509 were males and 423 females. We found no difference 
in vitamin D level between patients and siblings. CXCL8 (0.34 +/- 0.12; 
p<0.001), IL-4 (0.12 +/- 0.04; p=0.01), IL-18 (0.03 +/- 0.028; p=0.03) and IL-
1b (0.20 +/- 0.11; p<0.001) significantly increased with increasing vitamin D 
level in the joined analysis of patients and siblings, when only patients were 
analysed CXCL8 (0.20 +/- 0.17; p=0.02), IL-18 (0.07 +/- 0.04; p<0.001) and 
IL-1b (0.16 +/- 0.15; p=0.04) were still positively associated with vitamin D. 
No association was found with IL-10, IL-12, IFN-g and TGF-b. Only for IL-
1b and IL-18 there was a significant association with CYP27B1 genotype
Conclusion: We found no indication of suppressed Th1 and enhanced Th2 
in either patients or healthy siblings with high levels of vitamin D but on the 
contrary increasing levels of Th1 oriented cytokines/chemokine IL-1b, IL-8, 
CXCL8 and Th2 oriented cytokine IL-4 with each quartile in vitamin D. The 
effect of vitamin D in relation to onset may be questioned.
Supported by: Copenhagen Region
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MicroRNA profiling from peripheral blood of diabetic patients
C.M. Khoo, A. Armugam, P. Swaminathan, P. Lim, K. Jeyaseelan; 
National University Health System, Singapore.
Background and aims: MicroRNAs (miRNAs) play important roles in post-
transcriptional control of gene expression. While specific miRNAs are impli-
cated in several disease processes including type 2 diabetes (DM), few have 
been evaluated and validated in humans. We therefore profiled the miRNA 
expression from the peripheral blood of type 2 DM patients.
Materials and methods: We compared 12 DM male subjects with 12 healthy 
male controls. They were well matched in age [mean(SD) 37.3 (7.1) yrs] and 
body mass index [mean(SD) 26.1 (5.6) kg/m2]. Blood pressure (BP) and 
fasting blood for glucose, lipids and HbA1c were measured. Total RNA was 
extracted from peripheral blood for miRNA profiling and real-time PCR 
analysis. The signal log ratio and p-values were calculated. T-test was used to 
compare DM subjects with controls.
Results: Systolic BP, fasting glucose, HbA1c, total cholesterol and LDL-
cholesterol levels were significantly higher in DM subjects compared with 
controls (all P<0.05). Compared with controls, we identified 37 differentially 
regulated miRNAs in DM subjects. Among them, 21 miRNAs were upregu-
lated (two to five-fold change, P<0.01) and 16 miRNAs were downregulated 
(1.5 to two-fold change, P<0.01). These miRNAs are primarily involved in 
regulating pancreatic development and functions, adipocyte differentiation, 
insulin signaling and glucose-dependent insulin secretion.
Conclusion: We have found several differentially expressed miRNAs from 
the peripheral blood of DM patients that are involved in glucose homeostasis 
and related functions. These miRNAs can be used as markers of disease pro-
gression and may be developed for therapeutic applications in DM.
Supported by: NUHS Cross Department Collaborative Grant
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Virus-induced beta cell death depends on CXCL10 and the AKT-JNK-
PKR crosstalk
E. Domsgen1, F. Paroni1, J. Kerr-Conte2, A. Dotzauer1, K. Maedler1; 
1Centre for Biomolecular Interactions, University of Bremen, Germany, 
2INSERM /Université de Lille, Thérapie Cellulaire du Diabète, France.
Background and aims: Both, type 1 (T1DM) and type 2 diabetes (T2DM) re-
sult from β-cell destruction and decreased β-cell mass. Virus infection seems 
to be an important environmental factor for the development and progres-
sion of the disease. Group B coxsackievirus (CVB) infection of β-cells has 
been associated with the development of diabetes. Intra-islet viral particles 
have been detected in pancreata from patients with T1DM and T2DM, but 
the mechanisms of a correlation between virus infection and diabetes pro-
gression are poorly understood. In this study we asked the question whether 
virus induced cytokines and chemokines correlate with β-cell destruction 
and which intracellular signals are involved.
Materials and methods: Isolated human islets and the CM human β-cell line 
were infected with two different CVB serotypes B3 and B4. Replication of 
CVB was confirmed by immunostaining of viral protein 1 (VP1) and titration 
of islet lysates. CXCL10 secretion from the islets was measured by ELISA, 
CXCL10, IFNβ, IFNγ, IL-1β, TNFα, IL-6, MCP1 and IL-8 mRNA produc-
tion by quantitative RT-PCR and β-cell apoptosis by double-staining for the 
TUNEL assay and insulin. Islet protein expression and phosphorylation were 
analyzed by western blot.
Results: CVB3 and CVB4 infection of isolated human islets and β-cells in-
duced a high virus replication, VP1 positive staining in up to 70% of the β-
cells and resulted in a 7-fold increase in β-cell apoptosis in both the CVB3 
and -4 infected islets together with an abolished glucose stimulated insulin 
secretion. This correlated with the increase in CXCL10, IFNβ, IL-1β, TNFα, 
IL-6, MCP1 and IL-8 mRNA levels in the infected islets. CXCL10 was the 
highest induced factor (~35-fold increase in secretion, 15-fold increase in 
mRNA, p<0.001), compared to uninfected islets. In contrast, IFNγ remained 
unchanged, suggesting that CXCL10 upregulation was independent of the 
known induction pathway. To determine the host cell pathways involved in 
CVB infection, we analyzed the kinetics of pro- and anti-apoptotic signals. 
We have previously shown, that CXCL10 induces transient Akt phosphoryla-
tion despite massive induction of β-cell apoptosis. In line with this data, Akt 
was also activated during CVB infection within 30 minutes p.i. and lasted for 
up to 24 h. After 24 h, Akt was downregulated together with an up-regula-
tion of phospho c-Jun NH2-terminal kinase (pJNK), activation of Caspase-3, 
strong induction of CXCL10 and the appearance of VP1, switching survival 
signals into apoptosis. A link of such pro-inflammatory signals and viral in-
fections is provided by double-stranded RNA-dependent protein kinase R 
(pPKR). Both virus strains lead to phosphorylation of PKR as well as its sub-
strate eIF2α in islets. Blocking PKR phosphorylation by 2-aminopurine lead 
to a decreased VP1 expression.
Conclusion: Our data show that CBV infections have a direct deleterious 
effect on β-cell survival, resulting from virus-induced activation of pro-in-
flammatory cytokines and chemokines. During the early phase of infection, 
the virus triggers the Akt pathway, possibly to initially maintain host sur-
vival and its own replication. Antagonism by JNK and PKR phosphorylation 
would switch β-cell pro-survival paths into death. Further understanding of 
the pathways involved in viral infection of β-cells will be of particular interest 
in order to develop new therapies to rescue the β-cell.
Supported by: JDRF
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Coxsackievirus B3 induces the mRNA expression of IFNbeta and viral 
recognition receptors in human pancreatic islets
K. Lind1, P.G. Larsson1, M. Hühn1, O. Korsgren2, M. Flodström-Tullberg1; 
1Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, 
2Department of Clinical Immunology, Uppsala University, Sweden.
Background and aims: Many observations have suggested a role for en-
terovirus infections, especially those with Coxsackieviruses (CV), in the 
etiopathogenesis of type 1 diabetes (T1D). Enteroviruses may contribute to 
T1D development by inducing functional impairment of beta cell functions, 
and/or beta cell destruction. An important immune response upon infection 
is the rapid production of type 1 interferons (IFNs) that inhibit viral spread 
and facilitate viral clearance. Interferon production is initiated via viral rec-
ognition by pattern recognition receptors. Cellular detection of RNA viruses 
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is mainly dependent on two receptor families, the toll-like receptors (TLRs) 
including TLR3, 7 and 8, and the cytoplasmic retinoic acid-inducible gene I 
-like helicases (RLHs) including melanoma differentiation associated gene 5 
(MDA5) and retinoic-acid-inducible protein I (RIG-I). Stimulation of these 
sensors trigger the production of pro-inflammatory cytokines and type I 
IFNs. The aim of this study was to investigate the expression of intracellular 
viral sensors and IFNβ in human pancreatic islet cells infected with CV.
Material and method: Human islets from 20 donors were obtained from the 
Nordic Network for Clinical Islet Transplantation. The mRNA expressions 
of IFNβ, MDA5, RIG-I, TLR3, 7 and 8 were measured in human islets 48 h 
after infection with CV serotype B3 (CVB3) using quantitative Real-Time 
PCR analysis.
Results: Human islets responded to a CVB3 infection by upregulating the 
mRNA expression of IFNβ (p<0.0005 vs. uninfected control). Moreover, 
there was a significant upregulation of the mRNA expression for the intra-
cellular viral sensors MDA5, RIG-I and TLR3 (p<0.01, 0.005, 0.005, vs. un-
infected control, respectively). A small, but not significant, upregulation of 
TLR7 and TLR8 mRNAs was also observed (p=0.16 and 0.21, vs. uninfected 
controls, respectively).
Conclusion: Our results show that human pancreatic islet cells express low 
basal levels of intracellular viral sensors and IFNβ, which are robustly in-
duced upon CVB3 infection. Mounting an antiviral response rapidly upon 
infection might be important for beta cell survival and protection against vi-
rus induced type 1 diabetes.
Supported by: an EFSD/JDRF/Novo Nordisk grant, Swedish Research Council, 
Swedish Diabetes Fund, Swedish Child Diabetes Fund
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Role of STAT-1 and IRF-1 in cytokine-mediated dysfunction and 
apoptosis in mouse islets of Langerhans
L. Overbergh1, W. D’Hertog1, C. Gysemans1, D.L. Eizirik2, E. Waelkens3,  
C. Mathieu1; 
1LEGENDO, Catholic University of Leuven, 2Laboratory for Experimental 
Medicine, Université Libre de Bruxelles, 3Laboratory of Protein 
Phosphorylation and Proteomics, Catholic University of Leuven, Belgium.
Background and aims: Type 1 diabetes (T1D) is an autoimmune disease 
characterized by a T-cell mediated destruction of the pancreatic beta cells. 
Cytokines, such as IL-1β and IFN-γ, play a crucial role in beta cell destruc-
tion, by activating two different pathways, NF-κB and JAK/STAT, among oth-
ers. Previous work from our group discovered a dual role for the IFN-γ sign-
aling pathway. If the pathway was interrupted at the level of STAT-1, islets and 
purified beta cells were fully protected against cytokine-induced apoptosis; 
however, deletion of the direct downstream effector gene of STAT-1, IRF-1, 
showed a dual response. Thus, whole mouse islets were partially protected 
in vitro, while purified beta cells demonstrated no difference in protection 
against cytokine-induced apoptosis, suggesting a role for non-beta cells in 
the islets in this destruction. In vivo, IRF-1 deletion in islets was associated 
with a higher prevalence of primary non-function and shorter functioning 
graft survival. In the present study, we aimed to study the protein profiles in 
islets with a disruption of either transcription factor exposed to inflammatory 
cytokines.
Materials and methods: Alterations in protein profile upon cytokine-treat-
ment were investigated in islets from C57BL/6, STAT-1-/- or IRF-1-/- mice after 
24h incubation with/without a combination of IFN-γ (1000 U/ml) and IL-1β 
(50 U/ml). Differential protein expression was analyzed using 2-dimensional 
difference gel electrophoresis (2D-DIGE) and differentially expressed spots 
were identified by MALDI-TOF/TOF. In parallel, susceptibility to apoptosis 
was measured by microscopic counting (Hoechst/PI staining).
Results: While the combined treatment of IL-1β + IFN-γ clearly caused 
apoptosis in C57BL/6 islets (40.6±3.7%, similar to 5.6±1.1% apoptosis for 
non-treated islets, p<0.001, n=12), STAT-1-/- islets were completely protected 
against cytokine-induced apoptosis (4.6±0.3% compared to 5.0±0.7% for non-
treated islets (n=10)) and IRF-1-/- islets were partially protected (25.1±4.4% 
compared to 5.1±0.7% for non-treated islets (p<0.001, n=9)). 2D-DIGE anal-
ysis, revealed a total of 1853 spots, of which 301 were differentially expressed 
(p<0.05, n=4). Of these, we identified by now 144 spots. 60% of these were 
exclusively regulated in the C57BL/6 islets, with identified proteins belonging 
to different functional groups such as mRNA processing, insulin signaling, 
metabolism and folding of proteins. Treatment with cytokines generated far 
less response in the proteome of STAT-1-/- and IRF-1-/- islets. Moreover, the 
proteomic response generated in the knock-out mouse islets was indicative 
for unique effects of Stat1 or Irf1 gene disruption. An example is heat shock 
70 kDa protein 9 (GRP75), which had markedly lower levels in IRF-1-/- islets 
and higher levels in STAT-1-/- islets, as compared to control C57BL/6 islets 
(p<0.05).
Conclusion: We identified proteins whose regulation was not only dependent 
on STAT-1 and/or IRF-1, but whose functionality can explain the difference 
in sensitivity of these islets to cytokine-induced cell death. These proteins 
could be important targets for clinical intervention in T1D, as disruption of 
the JAK/STAT pathway is not a feasible option for treatment or prevention 
of T1D.
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T cell function is released from the anti-inflammatory effects of 
adiponectin in type 1 diabetes (T1D): a potential link between insulin 
resistance (IR) and T1D
T.T.L. Pang, M. Chimem, E. Goble, S.A. Eldershaw, P. Narendran; 
School of Clinical and Experimental Medicine, University of Birmingham, 
United Kingdom.
Background and aims: IR is independently associated with the development 
of T1D, though the mechanism for this is not clear. Adiponectin is an insulin 
sensitising and anti-inflammatory adipokine whose serum levels are reduced 
with IR. We hypothesised that changes in adiponectin and its receptors may 
mediate the link between IR and T1D. We have previously shown that recep-
tors for adiponectin, AdipoR1 & AdipoR2, are expressed by peripheral blood 
mononuclear cells (PBMC), and in particular by monocytes and CD11c+ 
CD1a+ dendritic cells (DC). We also found the monocytic expression of Adi-
poR1 & AdipoR2 is reduced by 45% (p<0.01) in patients with T1D, compared 
to matched healthy controls as well as subjects with insulin treated type 2 
diabetes. In this present study, we determined the effect of adiponectin on 
DC-mediated T cell proliferation, as well as the functional significance of the 
reduced AdipoR expression in T1D.
Materials and methods: 10 subjects with T1D were compared against 10 
age and BMI-matched healthy controls. AdipoR1 & AdipoR2 expression was 
measured by flow cytometry and qPCR. In serum-free conditions, we studied 
changes in the expression of CD80, CD86, HLA-DR, CD1a, DC-SIGN on 
monocyte-derived DC, following exposure to adiponectin. The stimulatory 
capacity of DC on T cells and whole PBMC proliferation was assessed by 
CFSE dilution.
Results: The addition of adiponectin to CD14+ monocytes decreased the 
expression of CD86 on DC at both RNA and protein level by 39-64%. This 
inhibitory effect on CD86 was dose dependent (IC50 = 1.3-1.9 ug/ml). This 
pronounced effect was not observed when adponectin was added at >24 
hours of DC culture and was overcome by LPS added on day 5. The expres-
sion of CD1a, DC-SIGN, HLA-DR & CD80 did not alter. DC generated in the 
presence of adiponectin showed reduced stimulatory capacity when tested on 
CFSE+CD4+CD25- effector T cells. In T1D, adiponectin induced suppres-
sion of CD86 expression at the fixed dose of 10ug/ml was significantly de-
creased in T1D by up to 31% (IC50 = 1.55-2.08 ug/ml p<0.05). The degree of 
inhibition correlated with AdipoR1 protein expression of the monocyte pre-
cursors (r =-0.69 p <0.05). Furthermore, adiponectin treated DC from T1D 
subjects retained greater T cell stimulatory capacity, in the presence of OKT3. 
In corroboration, the suppression of PBMC proliferation by adiponectin to 
the common antigen tetanus toxoid was also significantly reduced in T1D 
(Healthy controls 48% vs 25% in T1D p<0.05).
Conclusion: T cells are released from the anti-inflammatory effects of adi-
ponectin in patients with T1D. This mechanism may contribute to the as-
sociation between IR and the development of T1D.
Supported by: NN
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Preservation of beta cell function by treatment with DiaPep277® - a 
retrospective analysis of phase II data in adult type 1 diabetes patients
S. Dagan1, D. Elias1, M. Tamir1, A. Avron1, G. Harari2, I. Raz3, 352 Study 
Group, 520 Study Group; 
1Andromeda Biotech Ltd., Yavne, 2MediStat Ltd., Tel Aviv, 3Hadassah Center 
for the Prevention of Diabetes, Hadassah University Hospital, Jerusalem, 
Israel.
Background and aims: DiaPep277®, a peptide derived from the human 
Hsp60, modulates the immunological destruction of β cells that lead to au-
toimmune diabetes. Several phase II studies (352, 420, 441/451, 520) were 
conducted to evaluate the ability of DiaPep277® to preserve insulin secretion 
in adult type 1 diabetes (T1D) patients. Due to the small number of patients 
and the diversity in β cell function among T1D patients, a statistically signifi-
cant difference could be demonstrated only for one study (420) despite the 
similarity in trend analysis in all 4 studies analyzed. To evaluate the efficacy 
of DiaPep277® in a larger number of patients, we performed a retrospective 
combined data meta analysis of the efficacy parameters.
Materials and methods: To compensate for the small group size in the in-
dividual studies, the efficacy data of studies 352, 420, 441/451, and 520 were 
pooled and analyzed. This is justifiable in view of the comparable demo-
graphic data. Patients were treated for 12 months and C-peptide levels were 
measured at month 13 and at month 18 (6 months after end of treatment, 
excluding study 441/451). Preservation of β cell function was evaluated as 
the change in total secreted C-peptide (AUC) following glucagon stimulation 
from Baseline to 13 and 18 months.
Results: A significant preservation of β cell function in patients treated with 
1.0 mg DiaPep277® was demonstrated. At the end of treatment, the change in 
glucagon stimulated C-peptide AUC in the DiaPep277® treated group (n=58) 
was -0.36 nmol/l/min as compared to -2.79 nmol/l/min in the placebo group 
(n=46) (p=0.028). At the end of follow-up, although C-peptide values had 
declined in both arms, the decrease in the DiaPep277® arm was significantly 
smaller than that in the placebo arm, -2.28 ± 5.4 nmol/l/min versus -5.56 ± 
7.0 nmol/l/min, respectively (p=0.04). This decrease may indicate that the 
treatment of adult patients should be longer than 1 year to maintain treat-
ment effect. In addition, DiaPep277® treatment improved the ability to main-
tain the ADA-recommended HbA1c target of <7%. At the end of follow-up, 
64% of DiaPep277® treated subjects reached the target glycemic level com-
pared to only 47% in the placebo group.
Conclusion: The combined data analysis of the phase II studies in adult T1D 
patients showed a statistically significant treatment effect of preservation of 
β cell function and clinical benefit of improved glycemic control. This clearly 
indicates that the lack of conclusive difference in the individual studies stems 
from the small number of patients per arm and not from a limited treatment 
effect. Based on these results, 2 phase III studies are being conducted world-
wide in newly diagnosed adult T1D patients to obtain regulatory approval 
for registration.
Phase II clinical studies in T1D subjects - Baseline demographic data (aver-
age ± SD)
Study 352 Study 420 Study 441/451 Study 520
Gender 32 males16 females 35 males
46 males
18 females
32 males
18 females
BMI 23.1±3.6 21.2±2.8 22.7±3.0 23.5±3.5
Age (years) 31±6.9 25.7±9.7 26±8.3 27.8±8.1
Basal C-peptide
(nmol/l) 0.29±0.24 0.48±0.44 0.25±0.2 0.53±0.48
% HbA1c 5.93±0.92 6.83±1.27 7.61±1.57 7.02±1.36
Insulin Dose U/kg/day 0.44±0.17 0.34±0.18 0.34±0.23 0.37±0.20
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CoQ10 affects peripheral natural killer cells in patients with type 1 
diabetes mellitus
J. Grünler1, G. Dallner1, K. Brismar1, A. Brauner2, H. Brauner2; 
1Department of Molecular Medicine and Surgery, 2Department of 
Microbiology, Tumor and Cell Biology, Karolinska Institute, Stockholm, 
Sweden.
Background and aims: Natural killer (NK) cells have been implied in the 
pathogenesis of type 1 diabetes (T1D), although their exact role in the dis-
ease is still not known. T1D leads to long term complications, including in-
creased mortality mainly due to cardiovascular disease (CVD). The antioxi-
dant CoenzymeQ10 (CoQ10) has been suggested to decrease CVD risk by 
a mainly unknown mechanism. We here, for the first time, investigate the 
impact of CoQ10 treatment on the NK cells in T1D.
Materials and methods: Patient data and peripheral blood samples were col-
lected immediately before and after 12 weeks of oral CoQ10 treatment (100 
mg twice daily). Peripheral blood mononuclear cells (PBMC) were analysed 
using flow cytometry after staining with monoclonal antibodies. The NK cells 
were defined as CD56+CD3- lymphocytes. NK cell frequency, subset distribu-
tion and phenotype in patients with T1D was compared with patients with 
type 2 (T2D) diabetes as controls since they too exhibit chronic hyperglycae-
mia, which by itself could influence lymphocyte phenotype and function, but 
lack the autoimmune pathology of particular interest to this study. 13 T1D 
and 10 T2D patients (mean age 58.1 ± 9.8 vs 62.8 ± 8.9 yrs, females 54 vs 30%, 
fasting plasma glucose 7.2±1.3 vs 6.9±3.3 mM p=0.27, HbA1c 6.7±1.3 vs 5.6 
±1.1, none significantly different) were treated 12 weeks with CoQ10. Retin-
opathy was more common in T1D (92 vs 40%, p= 0.02) while nephropathy 
was more common, although not significantly, in T2D patients (30 vs 8%). 
No difference was observed regarding neuropathy.
Results: Treatment with CoQ10 did not affect the overall frequency of NK 
cells in PBMC, in T1D or T2D patients. However, several phenotypic altera-
tions of the peripheral pool of NK cells were observed after CoQ10 treatment. 
The NK cell activating receptor NKG2D has previously been shown to be 
downregulated in NK cells from T1D patients. Here we show that CoQ10 
leads to a small but highly significant (p<0.001) upregulation of NKG2D on 
NK cells in T1D, hence potentially normalizing the NKG2D levels. Some 
NKG2D ligands are upregulated in response to stress and NKG2D has been 
implicated in several pathological conditions. We also observed an increased 
subset of CD11c expressing NK cells, both among the T1D and T2D (p<0.01 
and p<0.05 respectively) after treatment. CD11c positive NK cells have been 
demonstrated to be potent cytokine producers and might interact in long 
term complications. NK cells are divided into two phenotypically and func-
tionally distinct subsets on the basis of their expression level of the surface 
marker CD56. While NK cells with a bright expression of CD56 have a higher 
capacity to produce cytokines, the CD56 dim NK cells are more cytotoxic. In 
patient with T1D, we found a significant increase of CD56 bright NK cells 
after CoQ10 treatment. A similar trend was observed also in T2D. This find-
ing further supports the idea that cytokine producing NK cells are increased 
in peripheral blood following CoQ10.
Conclusion: Our results demonstrate that CoQ10 treatment increased NK 
cells expressing CD11c in both T1D and T2D, as well as the percentage of 
CD56 bright NK cells and the activating receptor NKG2D in T1D. Collec-
tively our results opens up for a possible role of NK cells in a CoQ10 mediated 
beneficial effect in patients with T1D.
Supported by: Erling Perssson Foundation
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Does immune tolerance with Alum-GAD prevent or delay onset of type 1 
diabetes in non-diabetic children with multiple islet autoantibodies?
H. Elding Larsson1, C. Andersson1, A. Carlsson2, E. Cedervall3,  
G. Hansson1, S.A. Ivarsson1, B. Jönsson4, K. Larsson5, Å. Lernmark1,  
J. Neiderud6, C. Nilsson1, for the DiAPREV-IT Study Group; 
1Department of Clinical Sciences, Malmö, 2Pediatrics, Lund, 3Pediatrics, 
Ängelholm, 4Pediatrics, Ystad, 5Pediatrics, Kristianstad, 6Pediatrics, 
Helsingborg, Sweden.
Background and aims: Type 1-diabetes (T1D) is predictable by HLA-risk 
genotypes and islet autoantibodies. The subclinical phase, lasting months to 
years, is defined by islet autoantibodies (A) against GAD65 (GADA), insuli-
noma-associated protein 2 (IA-2A), insulin (IAA) or the ZnT8 transporter 
(ZnT8A). A gradually deteriorating glucose metabolism precede clinical 
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onset. Children with genetic risk of T1D are followed prospectively by us 
in the Diabetes Prediction in Skåne (DiPiS) and The Environmental Deter-
minants of Diabetes in the Young (TEDDY) studies. Immune tolerance with 
human recombinant GAD65 formulated with alum (Alum-GAD) has shown 
promising results to preserve residual beta-cell function in newly diagnosed 
T1D children. As only a fraction of the residual beta-cell function remains 
at onset, we initiated Diabetes Prevention -Immune Tolerance (DiAPREV-
IT) as a first prevention study with Alum-GAD. The aim is to evaluate safety 
and efficacy of Alum-GAD in non-diabetic children from 4 years of age with 
multiple islet autoantibodies.
Materials and methods: DiAPREV-IT is an investigator-initiated, placebo-
controlled, double-blinded study of Alum-GAD (donated by Diamyd Medi-
cal AB, Sweden) in children with GADA and at least one additional islet au-
toantibody. Children from 4 years of age (n=50) recruited from DiPiS and 
TEDDY will be treated with placebo (n=25) or Alum-GAD (n=25) in two 
doses of 20 microgram. The children are followed every 3rd month during 
the 5 year follow-up with alternating IVGTT and OGTT to evaluate beta-cell 
function. Placebo children developing T1D during the study period will be 
treated with Alum-GAD at clinical onset. GADA, IA-2A, IAA and ZnT8A 
(both ZnT8RA and ZnT8WA) are measured by standardised radioimmu-
noassays.
Results: As of April 1, 2010, a total of 26 islet autoantibody-positive children 
have been screened for participation. Of those, three children had lost GADA 
or the additional islet autoantibody at screening. One family withdrew their 
consent and another child was excluded due to illness. The included 21 chil-
dren were 4-9.8 (mean 6.0) years old. All but one child (20/21) were positive 
for one or two of ZnT8R/WA and 17/21 were positive for IA-2A. While 2/21 
children were positive for GADA and only one additional autoantibody, the 
remaining 19 children were positive for 3, 4 or 5 autoantibodies. A total of 17 
children have received both injections, and an additional two children have 
received the first injection. The first visit after the second injection has been 
completed by 14 children. No serious adverse events were reported and none 
of the children have developed T1D. Mild to moderate injection site reactions 
were reported by all participants.
Conclusion: DIAPREV-IT is the first prevention study with Alum-GAD in 
non-diabetic children with multiple islet autoantibodies. In including analy-
sis of the ZnT8RWA the number of T1D-risk children is increased. As no 
serious adverse events have been reported so far, DIAPREV-IT will continue 
to recruit children.
Supported by: Swedish Research Council, Swedish Childhood Diabetes Fund, 
ALF
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Prediction of remission after 6 months and residual beta cell function 12 
months after diagnosis in Danish children using multivariate statistical 
methods
M.-L.M. Andersen1, M.A. Rasmussen2, S. Pörksen1, L.B. Nielsen1,  
J. Svensson1, J.V. Jørgensen3, J. Thomsen4, N.T. Hertel5, J.S. Petersen6,  
A.E. Karlsen6, L. Hansen1, H.B. Mortensen1; 
1Pediatrics, Herlev University Hospital, 2Quality and Technology, Dep. of 
Food Science, Copenhagen, 3Pediatrics, Skejby University Hospital, Aarhus, 
4Pediatrics, Kolding Hospital, 5Pediatrics, Odense University Hospital, 
6Department of Diabetes Research Unit, Novo Nordisk A/S, Maaloev, 
Denmark.
Background and aims: Children and adolescents with newly diagnosed type 
1 diabetes (T1D) experience a remission period, where the requirement for 
exogenous insulin treatment declines or even becomes non-existent. The 
purpose of this prospective study, conducted in a Danish cohort of children 
with new onset T1D, is to identify patterns of early clinical and laboratory 
characteristics and to explore the metabolic disturbance and genetic back-
ground as predictors of the residual beta-cell function and remission the first 
12 months after diagnosis.
Materials and methods: 129 children and adolescents aged < 17 years from 4 
centres in Denmark with newly diagnosed T1D were followed for 12 months. 
HbA1c, autoantibodies, HLA typing and mixed meal stimulated C-peptide, 
proinsulin, Glp-1, GIP and Glucagon 1, 3, 6, 12 months after diagnosis were 
analyzed centrally. pH and standard bicarbonate were determined locally. In 
addition 40 SNPs in either T1D or T2D related genes have been genotyped. 
Regression models for prediction of log (C-peptide), and insulin dose ad-
justed HbA1c (IDAA1c) at 12 months was done by 10 fold cross validated 
Lasso for variable selection followed by Multiple Linear Regression (MLR) 
analysis on these relatively few selected variables. Covariates for age, gender 
and the clinical- and laboratory data were included in the analysis. Data is 
initially split randomly into 70% training data and 30% test data in order to 
estimate model performance from independent data. Statistical inference is 
reported for the test set.
Results: The best predictors for stimulated C-peptide concentration at 12 
months were HbA1c at diagnosis (positive association (PA)), C-peptide at 1, 
3, and 6 months (PA), IDAA1c at 3 months (negative association (NA)) and 
proinsulin at 6 months (PA). The selected variables are consistent over time, 
the model performance slightly improves when data are included over the 
different time points (r=0.74 0, 1 month data; r=0.79 0, 1, 3 months data and 
r=0.84 0, 1, 3, 6 months data) and all models are significant (p<0.001). Geno-
types of common variants in the PTPN22 and TCF2 genes refine the C-pep-
tide models, but they do not have a significant quantitative impact. HLA risk 
groups and autoantibodies were not selected by the models. The best predic-
tors for remission after 6 months are C-peptide at 1 month (NA), stimulated 
blood glucose at 1 month (PA) and height at 1 month (NA), probably a sur-
rogate marker for beta-cell mass. This model is significant (p=0.007, r=0.42) 
both when we use IDAA1c ≤ 9, to define partial remission (stimulated C-pep-
tide > 300 pmol/l) and IDAA1c as a continuous variable (p=0.013, r=0.41).
Conclusion: This study illustrates the strength of multivariate statistical 
analysis when applied to observational data, in predicting the course of the 
residual beta-cell function and remission in children with new-onset T1D. 
The results suggest that disease progression and proportion of patients in 
remission can be predicted by objective factors present soon or later after 
diagnosis.
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Fasting and stimulated C-peptide at aseline in DEFEND-1, a phase 3 
study of otelixizumab in new onset type 1 diabetes
P. Pozzilli1, G. Ghirlanda2, A.M. Brennan3, B. Belanger3, C.M. McKee3; 
1Endocrinology and Diabetes, Università Campus Biomedico, Rome, 
2Endocrinology and Diabetes, Universita Cattolica del Sacro Cuore, Rome, 
Italy, 3Tolerx, Cambridge, USA.
Background and aims: Stimulated C-peptide is frequently used to determine 
residual beta cell function. We compared mixed meal-stimulated and fasting 
C-peptide levels using baseline data from the DEFEND-1 Phase 3 study, and 
investigated the optimal single time point post-meal for determining maxi-
mum C-peptide in adults and adolescents with new onset type 1 diabetes 
mellitus (NOT1DM).
Materials and methods: DEFEND-1 is a multinational, placebo-controlled 
Phase 3 study of the safety and efficacy of otelixizumab, an investigational 
Fc-disabled anti-CD3 monoclonal antibody with T cell immunomodulatory 
activity, in subjects with NOT1DM (clinical trials identifier NCT00678886). 
Subjects were 12-45 years old, enrolled within 90 days of diagnosis, had BMI < 
32, had at least 1 T1DM-associated autoantibody, and were otherwise healthy. 
Adult subjects had a mixed meal tolerance test (MMTT) with BOOST® at 
screening and another MMTT at predose (≤ 14 days before the first dose of 
study drug); subjects < 18 years had a single C-peptide assessment at 120 min 
post-meal at screening and a full MMTT at predose. To be eligible for DE-
FEND-1, subjects had to have a maximum stimulated C-peptide > 0.20 nmol/
L at screening or predose. The current analysis includes data from one MMTT 
per subject: the predose MMTT if available, otherwise the screening MMTT.
Results: Data were available from 243 adult and 29 adolescent subjects who 
went on to receive either otelixizumab or placebo and 101 adults and 8 ado-
lescents who failed screening. Baseline characteristics are shown in Table 1. 
Fasting and stimulated C-peptide values were available for 339 subjects. Fast-
ing C-peptide was highly correlated with maximum stimulated C-peptide 
(r=0.76, p=<0.0001) and age group had no significant effect on this associa-
tion. In adults, a fasting C-peptide > 0.1 nmol/L had a sensitivity of 88% and a 
specificity of 75% to identify subjects with a maximum stimulated C-peptide 
> 0.2 nmol/L. In adolescents, the same cutoff value had a sensitivity of 78% to 
identify subjects with a maximum stimulated C-peptide > 0.2 nmol/L; spe-
cificity could not be determined, as no adolescents had a maximum stimu-
lated C-peptide < 0.2 nmol/L. Maximum stimulated C-peptide occurred at 
120 min in most subjects (42%); maximum values occurred at 30, 60, and 90 
min in 5%, 16%, and 35% of subjects, respectively. Of the 334 subjects with a 
recorded C-peptide at 120 min, 326 had a maximum stimulated C-peptide > 
0.2 nmol/L; of these, only 2 (0.6%) had C-peptide < 0.2 nmol/L at 120 min.
Conclusion: In these subjects with NOT1DM, a fasting C-peptide level of 
> 0.1 nmol/L was a reasonable determinant of residual beta cell function 
and, when combined with a single 120 minute post-meal sample for subjects 
who fall below this threshold, captured 99% of subjects compared with a full 
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MMTT. These data are of relevance for future trials and interventions in this 
population.
Baseline characteristics of study population (data presented are means and 
SD unless specified)
Enrolled 
adults, 
n=243
Screen  
ailed adults, 
n=101
Enrolled 
Adolescents, 
n=29
Screen 
failed ado-
lescents, 
n=8
Age, Years 26.2 (5.85) 27.0 (6.59) 13.9 (1.78) 12.4 (5.21)
Female, n (%) 84 (34.6%) 28 (30.1%) 11 (37.9%) 2 (28.6%)
Caucasian, n (%) 231 (95.1%) 84 (83.2%) 24 (82.8%) 7 (87.5%)
Time since diagnosis, 
days
59.3 (19.34) N/A 62.9 (18.5) N/A
BMI 23.7 (3.12) N/A 20.5 (2.58) N/A
Insulin dose, U/kg/day 0.35 (0.19) N/A 0.36 (0.16) N/A
HbA1c, % 7.18 (1.35) 9.17 (2.43) 7.80 (1.49) 8.51 (1.82)
Max stimulated  
C-peptide, nmol/L
1.27 (0.77) 1.42 (1.27) 1.12 (0.68) 0.68 (0.35)
C-peptide AUC,  
nmol/L/min
0.90 (0.56) 1.06 (0.99) 0.85 (0.54) 0.47 (0.26)
Fasting C-peptide, 
nmol/L
0.31 (0.26) 0.47 (0.53) 0.31 (0.23) 0.17 (0.12)
461
DIA-AID 1 - An international phase III clinical study to evaluate the 
biological effect of DiaPep277® in preservation of beta cell function in 
newly diagnosed T1D patients
A.-G. Ziegler1, D. Elias2, S. Dagan2, I. Raz3, DIA-AID 1 Study Group; 
1Institut für Diabetesforschung an der Klinik und Hochschulambulanz für 
Kinder, Munchen, Germany, 2Andromeda Biotech Ltd., Yavne, 3Hadassah 
Center for the Prevention of Diabetes, Hadassah University Hospital, 
Jerusalem, Israel.
Background and aims: DiaPep277®, a peptide derived from the human 
Hsp60, modulates the immunological destruction of β cells that lead to au-
toimmune diabetes. Following phase II studies which demonstrated good 
safety and tolerability and preservation of β cell function after treatment with 
DiaPep277®, a phase III study was initiated and is currently being conducted 
in 40 medical centers in Europe, South Africa and Israel. The goal is to evalu-
ate safety and therapeutic effect of DiaPep277® in preserving insulin secreting 
β cells in newly diagnosed type 1 diabetes (T1D) patients.
Materials and methods: The study is randomized, double blinded, placebo 
controlled. Major inclusion criteria: Age 16 - 45, diagnosed within 3 months, 
fasting C-peptide > 0.2 nmol/L and positive islet autoantibodies. Subjects re-
ceived 1 mg DiaPep277® or placebo at 0, 1, 3, 6, 9, 12, 15, 18, and 21 months. 
Co-primary endpoints were defined as the change in total secreted C-peptide 
(AUC) measured by the glucagon stimulation test and by the mixed meal 
tolerance test. Secondary endpoints included glycemic control, daily dose 
insulin requirement and number of hypoglycemic events as determined by 
continuous glucose monitoring system. Clinical safety was monitored by 
electrocardiogram, blood chemistry and haematology. Immune monitoring 
included peptide-specific dermal sensitivity, antibody titers, cytokine and 
chemokine profiles and cell surface markers in a population sub-group.
Results: Out of 688 patients screened, 457 were randomized to the study. 221 
patients have completed 2 years of therapy and 163 patients are still under treat-
ment protocol. Screening failures were mostly due to fasting C-peptide levels 
being below the limit (18%) and to an absence of autoantibodies (14%). 16% of 
the randomized patients dropped out of the study, mostly because withdrawal 
of consent. Glycemic control was maintained during the treatment period. The 
mean value of HbA1c at baseline was 7.38% (n=457), at 12 months 7.2% (n=347) 
and at 24 months 7.46% (n=221). An independent committee that reviews the 
safety data every six months reported no drug-related safety concerns. Long 
term safety and treatment effect of DiaPep277® is being followed in an extension 
study in which patients are divided into a treatment arm and a follow-up arm.
Conclusion: Based on the efficacy and safety data from phase II studies, we 
designed a phase III clinical study in newly diagnosed T1D patients who are 
treated with 1 mg DiaPep277® for 2 years. Currently, 51% of the patients have 
completed 2 years of therapy. Safety evaluation indicates a very favorable 
safety profile. Results of the study are expected at the end of 2011. A second, 
confirmatory phase III clinical study is being initiated worldwide in newly 
diagnosed adult T1D patients. 
Clinical and metabolic parameters of patients with T1D randomized into 
the study at baseline. Data is shown as average + SD and interquartile range 
(in brackets)
Age 27.15 ± 7.93 (20 - 32)
Gender 302 Males / 155 Females
BMI 24.08 ± 3.42 (21.6 - 26.09)
Fasting C-peptide 0.47 ± 0.25 (0.3 - 0.55)
%HbA1c 7.38 ± 1.7 (6.2 - 8.1)
Insulin U/kg/day 0.4 ± 0.24 (0.25 - 0.52)
Autoantibodies IA2A+ve 60%, IAA+ve 74%, GADA+ve 86%
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Effect of sirolimus versus mycophenolate mofetil on glucose metabolism 
in pancreas and kidney transplantation: final results of a prospective 
randomised study
T. Havrdova1, F. Saudek1, K. Lipar2, T. Jedinakova1, J. Skibova3; 
1Diabetes Center, 2Transplant Center, 3Statistical Department, Inst. Clinical 
Exp. Medicine, Prague, Czech Republic.
Objectives: Metabolic effects of immunosuppressive agents are important 
in pancreas or islet transplantation. The aim of our study was to compare 
glucose metabolism in Type 1 diabetic pancreas and kidney recipients on tac-
rolimus-based immunosuppression in conjunction with sirolimus (RAPA) or 
mycophenolate mofetil (MMF) in a prospective randomised study.
Methods: The investigation was performed in 40 insulin-independent re-
jection-free patients after simultaneous pancreas and kidney transplanta-
tion (with systemic venous drainage of pancreatic graft) on discharge from 
the hospital (0.60±3 [mean±SD] month post-transplant; with steroid dose 
11±4.3 mg/day) and subsequently at 21.2±9.9 months (steroid-free). All re-
cipients had a good function of the kidney graft. Fasting glycemia, insulin 
and C-peptide levels, HbA1c, IVGTT with KG-calculation were assessed in 
both groups. Insulin sensitivity was evaluated by HOMA-IR. Areas under the 
insulin/C-peptide curves during the IVGTT (AUC-IRI, AUC-CP) were used 
as the parameters of insulin/C-peptide secretion.
Results: The RAPA and MMF groups did not differ in age, BMI, post-trans-
plant period and steroid daily dose. Trough levels of tacrolimus had no signif-
icant impact on any of examined parameters. KG and HOMA-IR of the whole 
study group significantly improved between the exams (1.0±0.4 vs. 1.43±0.44 
%/min., p<0.001 and 4.1±4.1 vs. 2.73±1.98, p<0.05, respectively). We found 
only a significant difference between the groups in stimulated AUC-CP after 
steroid withdrawal. 
RAPA group (n=20) MMF group (n=20)
Examination 
1 (a)
Examination 
2 (b)
Examination 
1 (c)
Examination 
2 (d)
HbA1c
(%)
6.3±0.9 5.6±0.5
(p<0.01 vs. a)
5.9±0.6 5.4±0.6
(p<0.05 vs. c)
Fasting glycemia 
(mmol/L)
5.2±0.6 4.8±0.5
(p<0.05 vs. a)
5.4±0.8 4.7±0.7
(p<0.01 vs. c)
KG
(%/min.)
1.0±0.5 1.35±0.36
(p<0.01 vs. a)
1.0±0.3 1.51±0.5
(p<0.001 vs. c)
AUC-IRI (mIU/
L/60min.)
2056±1321 2062±1229 3148±2270
(p<0.01 vs. a)
2601±1368
AUC-CP
(pmol/mL/60min.)
138.7±57.3 96,6±29.8
(p=0.001 vs. a)
180±85,1 114,7±33,7
(p<0.01 vs. c)
Stimulated AUC-
CP (pmol/mL/
60min.)
47.9±24.7 47.6±18.8 73.8±29
(p<0.01 vs. a)
63.8±22.6
(p<0.05 vs. b)
HOMA-IR 3.4±2.7 2.6±1.7 4.7±5.0 2.8±2.2
Conclusion: Glucose tolerance measured by IVGTT significantly improved in 
whole study group probably due to better insulin sensitivity after steroid with-
drawal. The higher stimulated C-peptide secretion in the MMF was not associ-
ated with a significant difference in IVGTT results between the groups. In ster-
oid-free tacrolimus based immunosuppression the choice of RAPA or MMF did 
not lead to clinically relevant differences in parameters of glucose metabolism.
Supported by: MZO 00023001
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Long-term ( 4 years) efficacy and safety of pancreas transplantation alone 
in type 1 diabetic patients
M. Occhipinti, U. Boggi, R. Giannarelli, A. Coppelli, R. Mariotti,  
A. Piaggesi, L. Rondinini, A. Tedeschi, M. Sartini, G. Amorese,  
M. Del Chiaro, C. Croce, F. Vistoli, P. Marchetti; 
Dept. Endocrinology and Metabolism, University of Pisa, Italy.
Background and aims: The role of pancreas transplantion alone (PTA) in 
type 1 diabetic patients (T1DM) is still debated. This study describes the ef-
fects of pancreas transplant alone (single centre experience) on metabolic 
parameters, cardiovascular risk factors, diabetic complications and kidney 
function in type 1 diabetic patients followed up to 4 years post-transplant.
Materials and methods: We report our single centre experience on PTA in 
71 T1DM (age: 38.4±8.5 yrs; gender: 37 males/34 females; body mass index, 
BMI: 23.5±3.0 kg/m2; duration of diabetes: 23.7±9.9 yrs), with a follow-up of 
up to 4 yrs. Patients were transplanted according to the portal (73.2%) or sys-
temic (26.8%) drainage technique, with enteric diversion of exocrine secre-
tion. Immunosuppression consisted of induction with basiliximab (76.1%) or 
thymoglobulin (23.9%) and high-dose steroid, followed by mycophenolate 
mophetil, tacrolimus and low-dose steroid for maintenance.
Results: Patient and pancreas (insulin independence) survival at 4 yrs from 
transplant were respectively 98.4% and 76.7% with graft losses mainly due 
to immunological reasons. Relaparatomy was needed in 18.3% of cases, and 
15.5% of recipients developed infections. Fasting plasma C-peptide levels 
rose from 0.15±0.33 ng/ml pre-transplant to 3.00±1.92, 2.78±1.40, 2.36±1.19 
and 2.74±1.26 ng/ml at 1, 2, 3 and 4 yrs post-transplant. This was associated 
with sustained normalization of fasting plasma glucose concentrations and 
HbA1c levels. In addition, several cardiovascular risk factors (blood pres-
sure, total and LDL-cholesterol and fibrinogen) decreased significantly after 
PTA and so remained up to 4 yrs of follow-up, with no apparent changes 
in anti-hypertensive or anti-dyslipidemic pharmacological treatment. Left 
ventricular ejection fraction, as assessed by ecography, rose from 54.4±4.3 
to 57.4±3.2% ( p<0.01) . PTA had also beneficial effects on diabetic retin-
opahy. Pre-transplant 7.5% patients had no retinopathy, and these remained 
lesion-free at 4-yrs-post operation. Of the 29.5% patients who had non-pro-
liferative retinopathy, 75% improved and 25% remained unchanged, whereas 
in the gropu with proliferative and/ore laser treated retinopathy, the lesion 
were stable at 4 yrs post PTA in 82% of subjects and progressed to a more 
serious grade in the remaining 18%. Protenuria decreased from 1.36±2.72 
to 0.29±0.51 g/24h ( p<0.01) , which was associated with increased creati-
nine levels and reduced glomerular filtration rate; however, kidney function 
changes mainly depended on the pre-transplant status. Finally neuropathy 
assessment showed a significant improvement of several index of peripheral 
and autonomic responses after PTA.
Conclusion: We conclude that PTA was effective and reasonably safe in se-
lected type 1 diabetic patients.
PS 25 Differentiation and expansion 
of beta cells
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In vivo GSK3β knockdown hastens endocrine and exocrine pancreatic 
regeneration in 90 % pancreatectomised rats
J. Movassat, F. Figeac, A. Ilias, M. Faro, B. Portha; 
University Paris Diderot, Paris, France.
Background and aims: The Wnt signaling pathway has been recently im-
plicated in pancreas development as well as in beta cell biology. Glycogen 
synthase kinase 3 β (GSK3β), a pivotal partner of the Wnt signaling is a mul-
tifunctional enzyme that negatively regulates the growth and function of the 
beta cells. The aim of our study was to assess the impact of GSK3β down-
regulation on the stimulation of exocrine and endocrine regeneration after 
subtotal pancreatectomy in rat.
Materials and methods: Adult Wistar rats underwent 90% pancreatectomy. 
In groups of pancreatectomized rats, either antisense oligonucleotides di-
rected against GSK3β (AS-GSK3β) or LiCl were injected directly within the 
remnant pancreatic tissue immediately after pancreatectomy. Two additional 
groups were administered with non specific standard oligonucleotides (Std 
group) or with saline and were used as control for the AS-GSK3β and LiCl 
treated groups respectively. Beta cell mass was assessed by morphometry 7 
days and 4 weeks after pancreatectomy. Beta cell, ductal cells and acinar cell 
proliferation was measured by BrdU incorporation method 8h and 48h after 
surgery. Apoptosis was assessed in beta cells, ductal cells and acinar cells by 
the TUNEL method
Results: GSK3β down regulation via administration of LiCl or AS-GSK3β 
greatly improved the beta cell regeneration 7 days after surgery (p<0.01). 
Moreover the use of AS-GSK3β had sustained effect on the beta cell mass, 
since 4 weeks after surgery the beta cell mass in the remnant pancreas was 
found to be higher (p<0.05) in AS-GSK3β treated group compared to the Std 
treated group. The effect of GSK3β inactivation on the beta cell mass seemed 
to be mediated by the stimulation of beta cell proliferation. Regarding the 
exocrine pancreas, GSK3β knockdown significantly stimulated acinar cell 
proliferation. Interestingly, GSK3β inactivation reduced the number of apop-
totic acinar cells compared to that found in the control Std group.
Conclusion: Here we show that intra pancreatic knockdown of GSK3β in 
vivo, promotes both endocrine and exocrine regeneration within the rem-
nant pancreas and could have potential application in the treatment of diabe-
tes and other pancreatic diseases such as pancreatitis.
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Effects of gastrin-treatment on pancreatic metaplasia in 
pancreatectomised rats
N. Tellez1,2, M. Vilaseca1, E. Montanya1,2; 
1Lab. Diabetes and Experimental Endocrinology, IDIBELL-University of 
Barcelona, L’Hospitalet de Llobregat, 2CIBERDEM, Barcelona, Spain.
Background and aim: We have recently found that gastrin treatment im-
proved glucose tolerance and increased beta cell regeneration in pancreate-
ctomized rats. Gastrin stimulated the expression of the crucial transcription 
factors ngn3, neuroD1, pdx-1 and nkx6.1, required for beta cell differentia-
tion, in the early phase of regeneration after pancreatectomy (Px). In these 
initial days pancreatic tissue undergoes remodeling with increased prolifera-
tion in the ductal epithelium. The mitogenic activity of the epithelial ductal 
cells is first seen in the common pancreatic duct and later on in smaller ducts 
and in metaplastic tissue with tubular complexes (TC), previously identified 
as “focal areas of regeneration”. These regions of regeneration are composed 
of tubular structures surrounded by mesenchymal cells with high prolifera-
tive rate. The aim of this study was to investigate the effects of gastrin on the 
phenotype of these focal areas of regeneration.
Material and Methods: Sprague-Dawley rats underwent 90%-Px and were 
treated with [15leu] gastrin-17 (Px+G, n=19) or with vehicle (Px+V; n=20). 
Pancreatic remnants were harvested on days 1 and 3 after Px and processed 
for total RNA extraction or paraffin embedding. Gene expression was deter-
mined by quantitative real time PCR and protein identification by immun-
ofluorescence.
Results: 3 days after Px, beta cell relative volume was higher in the pancre-
atic remnants of gastrin-treated rats than in vehicle-treated group (Px+G: 
0,57±0,10% vs Px+V: 0,26±0,07%, p=0.03). Beta cell proliferation was similar 
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in Px+G (2.99±0.32%) and Px+V (3.98±0.35%, p NS) groups, suggesting that 
the higher beta cell relative volume in Px+G group was not due to increased 
beta cell proliferation. Twenty-four hours after Px, the areas of regeneration 
accounted for 6.81±1.11% and 5.95±2.16% of the total pancreatic tissue in 
Px+V and Px+G groups respectively. On day 3, the areas of regeneration had 
expanded to 38±7.05% and 35.1±5.68% of the total pancreatic tissue (Px+V 
and Px+G respectively). Two types of TC were identified, TC consisting of 
many small duct-like cells with strong immunoreactivity for CK20 antibody, 
and TC formed by few larger cells which exhibit lower levels of immun-
ofluorescence for CK20. TC with small duct-like cells were predominant in 
Px+V rats, whereas TC with larger cells were more frequent in the gastrin-
treated group. Concordantly, gene expression of ductal cell markers (ck20, 
ca2, hnf1β, hnf6) was higher in pancreatic remnants of Px+V rats than Px+G 
group (p<0.05).
Summary and Conclusion: Pancreatic remnants of gastrin-treated rats 
showed increased beta cell relative volume but similar beta cell proliferation 
than vehicle-treated rats. In pancreatic remnants from Px+G group, gene ex-
pression of ductal cell markers was lower than in Px+V group, and the focal 
areas of regeneration showed TCs with predominantly larger cells with weak 
CK20 immunofluorescence. These results suggest that gastrin-induced beta 
cell regeneration after pancreatectomy may involve phenotypic changes in 
the metaplastic tissue. Further analysis of these areas of regeneration will pro-
vide valuable information to understand the mechanisms of gastrin-induced 
beta cell regeneration.
Supported by: CIBERDEM-ISCIII
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MafA promotes maturation of mouse embryonic progenitor-derived 
insulin-producing cells
Y. Gao1, S. Shao1, B. Xie1, W. Nishimura2, A. Sharma2, G. Li1; 
1National University Medical Institutes, National University of Singapore, 
2Joslin Diabetes Center, Harvard Medical School, Boston, USA.
Background and aims: Shortage of cadervic pancreata has restricted the 
transplantation therapy of curing insulin-dependent type 1 diabetes. Genera-
tion of functional insulin-producing cells from stem cells may circumvent 
this obstacle. We established a dozen of expansible and glucose-responsive 
insulin-producing cell lines (e.g. MEPI and ERoSHK) from differentiation of 
mouse embryonic stem and progenitor cells. Transplantation of these cells in 
diabetic animals could correct hyperglycemia, but they also revealed features 
of immaturation as reflected by higher un-regulated insulin release and slow 
continuous proliferation in vivo. Consistent with the role of MafA (v-maf 
musculoaponeurotic fibrosarcoma oncogene homolog A) as a master tran-
scription factor implicated in regulating islet β-cell development and glucose 
responsiveness, its expression was significantly lower in our insulin-produc-
ing cells. This study tests the hypothesis that the restoration of MafA levels 
will improve the function of progenitor-derived insulin-producing cells.
Materials and methods: Mouse embryonic progenitor-derived insulin-pro-
ducing (MEPI)-1 cells were transfected with lentivirus expressing MafA, fol-
lowed by assessments of various cell functions. MafA was determined by real 
time RT-PCR, immunofluorescence staining and immunoblotting.
Results: MafA levels in MEPI-1 cells could be restored to that present in iso-
lated adult islets after 72-h transfection with the virus. Insulin expression and 
its content were enhanced by about 20% whereas the cell proliferation rate was 
reduced after restoration of MafA. MafA overexpression significantly enhanced 
expression of several molecules important for β-cell functions, including glu-
cagon-like peptide-1 (GLP-1) receptor, Glut2, glucokinase, Nkx6.1 and Kir6.2 
in MEPI-1 cells. These cells exhibited better signaling responses to glucose 
stimulation, i.e. higher glucose metabolic rate and ATP generation, enhanced 
membrane potential depolarization and larger rise of intracellular Ca2+ concen-
trations. Notably, restoration of MafA markedly improved glucose-stimulated 
insulin secretion (GSIS) profile, revealing a suppressed basal insulin release and 
shifting the dose-response curve of insulin secretion upon glucose stimulation 
similarly to that observed in isolated islets. In addition, insulin secretion in-
duced by high K+, glibenclamide and GLP-1 was also augmented.
Conclusion: Our data demonstrate that normalization of MafA levels in 
MEPI-1 cells enhances expression of the β-cell relevant gene profile, reduces 
cell proliferation, elevates insulin biosynthesis and substantially improves 
GSIS via augmenting multiple signaling cascades. Therefore, we suggest that 
MafA can promote maturation of embryonic stem cell-derived insulin-pro-
ducing cells, making them suitable for cell replacement therapy of type 1 
diabetes.
Supported by: grants from NMRC and BMRC of Singapore
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Role of Maf transcription factors in the endocrine cell differentiation in 
the developing pancreas
M.A. Mazur, I. Artner; 
Stem Cell and Pancreas Developmental Biology, Lund University, Lund, 
Sweden.
Background and aims: Pancreatic endocrine cell differentiation is depend-
ent on the interactions of several transcription factors. MafA and MafB are 
essential activators of insulin and glucagon expression. However, MafA and 
MafB are distinct from others in regards to temporal and islet cell expres-
sion pattern, with beta cells only affected by MafB during development and 
exclusively by MafA in the adult. To elucidate the function of MafA and MafB 
in β cell differentiation, E18.5 mutant pancreata were analyzed for changes in 
gene expression. From these gene profiling studies several genes regulated by 
MafA and MafB factors were identified.
Materials and methods: To identify genes regulated by MafB, expression 
profiling was performed on wild type and MafB-/- pancreata at embryonic 
day 18.5. Samples of embryonic and adult tissue were evaluated for candidate 
genes by qRT-PCR, immunohistochemistry and in situ hybridization.
Results: The microarray studies showed that expression levels of several 
genes are altered in MafB deficient mice. Gene ontology analysis revealed 
that the differentially expressed genes were mainly associated with mature 
beta cell function, such as ion binding and transport, signal transduction, 
and hormone secretion. This suggests that MafB is involved in beta cell matu-
ration and function. My experiments have shown that Neuronatin (Nnat) 
and islet-specific zinc transporter (Slc30a8), Endothelin receptor B (Ednrb), 
Melanocortin 3 receptor (Mc3R), and Microphthalmia associated transcrip-
tion factor (Mitf) are downregulated in mutant embryonic pancreata. In con-
trast, the mRNA level of Retinol Binding Protein-4 (Rbp4) was upregulated 
in mutant tissue. Immunohistochemical analysis shows that Mitf, Ednrb and 
Mc3r are expressed in the adult pancreas. Endothelin and melanocortin sig-
nalling pathways are coupled in the modulation and expression of Mitf gene.
Conclusion: These novel findings indicate a possible involvement of Mitf, 
Ednrb and Mc3r in the differentiation of pancreatic endocrine cells and adult 
beta cell function.
Supported by: JDRF, Jeanssons Stiftelser
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Glucagon-like peptide 1 protein and receptor are present during 
embryonic life. Biological effects and gene targets
C. Sanz1, P. Vázquez1,2, E. Blázquez1; 
1CIBERDEM-University Complutense of Madrid, 2Centro de 
Investigaciones Biológicas (CSIC), Madrid, Spain.
Background and aims: Glucagon-like peptide 1 (GLP-1) functions during 
adult life as an incretin hormone with antidiabetogenic properties. However, 
the role of GLP-1 if any, in early stages of development or in undifferenti-
ated cells, such as human bone marrow mesenchymal stem cells (hMSCs) or 
mouse embryonic stem cells (mES), remains unknown and it was the aim of 
this study.
Materials and methods: The presence of GLP-1 and GLP-1 receptor were 
tested by immunostain of mES and hMSC, as well as in mouse embryos (E 
8.5, E10.5 and E13.5). Furthermore, the effects of GLP-1 were tested in hMSC 
under proliferative, cytoprotective and adipogenic conditions and signalling 
pathways involved in these processes were also analyzed. Additionally, GLP-1 
genes target were studied by quantitative gene expression in a TaqMan Low 
Density Array.
Results: The isolated hMSCs expressed mRNA and GLP-1 receptor protein. 
One-day treatment with 10 nM GLP-1 did not modify the stem cell mark-
ers SCF, nestin, c-kit and Thy-1, but produced a transcriptional induction 
of the pancreatic transcription factors neurogenin-3, isl-1 and ipf-1. GLP-1 
increased the proliferation of hMSCs, which decreased when they were in-
duced to differentiate into adipocytes. Differentiation produced biochemi-
cal and cell morphologic changes with the expression of PPARγ, c/EBPβ, 
AP2 and LPL in a time-dependent pattern. Interestingly, GLP-1 significantly 
reduced the expression of PPARγ, c/EBPβ and LPL (inhibition of 30%±4, 
33%±2 and 90%±5 respectively). These effects were, at least, exerted through 
MEK and PKC signalling pathways. In addition, GLP-1 significantly reduced 
cell apoptosis. In other way, both, peptide and GLP-1receptor were present 
in mouse embryonic stem cells derived from the inner cell mass where were 
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found new genes target for GLP-1. Likewise, they were mainly present in cells 
derived from ectodermal and endodermal linages, in early development of 
the mouse.
Conclusion: Our data indicate that GLP-1 promotes proliferation and cy-
toprotection of hMSC, at the same time as it prevents its differentiation into 
adipocytes, which suggests that this peptide may play a role in the renewal 
of tissues. Furthermore, both peptide and receptor are present in embryonic 
life before GLP-1 may play a role as an incretin and modulates the expression 
of new target genes in mouse embryonic stem cells. These results open new 
views about the role of this peptide during different periods of life.
Supported by: CIBERDEM and MINISTERIO DE CIENCIA E INNOVACION
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Ablation of FGFR2b in a subset of pdx1+ pancreatic progenitor cells 
Z.M. Löf-Öhlin, P. Nyeng, I. Artner, H. Semb; 
Stem Cell & Pancreas Developmental Biology, Lund University, Lund, 
Sweden.
Background and aims: Mesenchymal-epithelial interactions mediated by Fi-
broblast growth factor receptor 2b, FGFR2b, and its ligand FGF10 have been 
shown to play an important role in early pancreatic development by regulat-
ing proliferation and differentiation. However, it is not know if these effects 
are direct or indirect due to interactions between the pancreatic epithelium 
and mesenchyme. 
Materials and methods: To address the functional role of FGFR2b in pan-
creatic development in a cell-autonomous fashion, we generated mice with 
a conditional mosaic deletion of FGFR2b under regulation of the pdx1 pro-
moter. All statistical analyses were performed using GraphPad Prism version 
4.03 and t-tests.
Results: This study confirms that FGFR2b deletion in a subset of pancre-
atic progenitors results in a smaller pancreas due to reduced proliferation 
of pdx1+ cells. We have also successfully narrowed this lack of proliferation 
down to between embryonic day e13.5 and e14.5. Surprisingly, the cells still 
retained their ability to differentiate into all lineages of the pancreas, although 
the ductal development was favored at the expense of the exocrine.
Conclusion: We conclude that proliferation mediated by FGFR2b is cell 
autonomous while differentiation defects are rescued in the mosaic mouse 
model, suggesting that there is signaling crosstalk between mutant and wild 
type cells. Which these secondary signals are and how the differentiated cells 
behave in terms of migration capacity, maturation status and functionality 
are still to be determined.
Supported by: JDRF, NIH, EU, VR
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Gene therapy of diabetic rats by hepatic insulin expression after lentiviral 
gene transfer
M. Elsner1, T. Terbish1, A. Jörns2, S. Lenzen1; 
1Institute of Clinical Biochemistry, 2Center of Anatomy, Hannover Medical 
School, Germany.
Background and aims: The release of insulin from non-endocrine cells is an 
interesting therapeutic concept for the treatment of insulin dependent dia-
betes mellitus. Modern lentiviral vector systems are able to transduce non-
dividing cells and are therefore a valuable tool for gene therapy approaches. 
The aim of the present study was to normalise the blood glucose concentra-
tions by lentiviral gene transfer of the human insulin gene into hepatocytes 
of diabetic rats.
Materials and methods: The cDNA of furin-cleavable human insulin was 
subcloned into a lentiviral vector system. The ubiquitous protease furin al-
lows a processing of proinsulin into mature biological-active insulin in non-
endocrine cells. Lentiviruses were isolated by ultrafiltration with a titer of 
7x109 infectious particles per ml. Virus solutions were injected into the portal 
vein of immune-diabetic IDDM and STZ-diabetic rats. Diabetic controls were 
treated with GFP lentivirus. The blood glucose concentrations and the body 
weight of the treated animals were measured over one year. 30 and 270 days 
after virus injection oral glucose tolerance test (OGTT; 2 g/kg body weight) 
were performed. The serum insulin and c-peptide concentrations were meas-
ured by an EILSA. The insulin expression in the liver and the pancreas was 
analysed by PCR and immunostaining.
Results: 10 days after injection of insulin lentivirus into the portal vein of im-
mune-diabetic IDDM or STZ-diabetic rats the blood glucose concentrations 
were lowered from 21.6 mmol/l ± 4.6 to 5.9 mmol/l ± 1.1 or from 19.6 mmol/l 
± 3.5 to 5.5 mmol/l ± 0.7, respectively. In control rats treated with GFP virus 
was no significant reduction of the blood glucose concentration detectable. 
The blood glucose concentration after OGTT of rats injected with insulin 
virus increased up to 19.7 mmol/l after 30 min and were normalised after 3 
h. The serum insulin concentrations increased from <0.1 ng/ml to 2.1 ng/ml 
after treatment with insulin lentivirus. The rat c-peptide concentrations were 
below the detection limit. Insulin expression in the liver was detected by PCR 
and immunostaining. Around 20 % of the hepatocytes were insulin positive. 
The hepatocytes showed no signs of transdifferentiation into beta cells.
Conclusion: The lentiviral gene transfer of furin-cleavable human insulin 
into hepatocytes of immune-diabetic IDDM and STZ-diabetic rats leads to 
a blood glucose normalisation for more than one year. The insulin was proc-
essed in the hepatocytes and released constitutively from the cells. This study 
shows that the diabetic state can be improved by insulin release from non-
endocrine cells in a somatic gene therapy approach.
471
Modulation of components of Hedgehog signalling pathway in response 
to beta cell injury
F.A. Grieco1,2, M. Moretti3, G. Sebastiani1,2, I. Spagnuolo1,2, E. De Smaele3,  
A. Gulino3, M. Maroder3, F. Dotta1; 
1University of Siena, 2Fondazione Umberto Di Mario, Siena, 3University of 
Rome “La Sapienza”, Rome, Italy.
Background and aims: Pancreatic beta cell mass undergoes major remod-
eling during neonatal growth and adult life. It has been established that both 
in Type 1 and Type 2 diabetes there is a significant loss of insulin-producing 
beta cells and consequently decreased functional beta cell mass. The molecu-
lar mechanisms that regulates beta cell mass are still not fully characterized. 
Since Hedgehog (Hh) pathway plays an important role both in endocrine 
pancreas development and in the regulation of insulin secretion, we have fo-
cused our attention on the contribution of Hh pathway in the regulation of 
beta cell mass after beta cell injury. To this end, we have studied the expres-
sion of Hh signaling key molecules (transcription factors Gli1, Gli2, Gli3) 
and of Hh receptor Ptch, in C57/BL6 mice in which diabetes was induced by 
streptozotocin (STZ).
Materials and methods: Six-week old C57/BL6 male mice (n=12) were intra-
peritoneally injected with a single dose of STZ (200mg/kg b.w.) and then sac-
rificed and pancreas was collected after 1, 3, 7 and 10 days post STZ admin-
istration. In addition, a group of 6-week old C57/BL6 male mice (n=10) not 
treated with STZ was used as control. The expression of Gli-1, -2, -3, and of 
the inhibitory receptor Ptch was analyzed on pancreatic sections by indirect 
immunofluorescence with confocal microscopy analysis. In order to establish 
the endocrine cell type expressing the Hh molecules of interest, double im-
munostaining for each of the Hh component and for insulin, glucagon and 
somatostatin was performed as well.
Results: In untreated mice, Gli1 was expressed both in alpha and beta cells, 
while Gli2 and Gli3 expression was beta-cell specific. Following STZ ad-
ministration, Gli1 was not detected in the residual beta cells (1 and 3 days 
post-STZ) in which it reappeared after 7 days; Gli1 expression remained un-
changed in alpha cells after STZ. In contrast, expression of Gli2 and Gli3 did 
not change in beta cells. Of note, Gli2 and Gli3, which showed a beta-cell 
specific expression in untreated mice, were detected in alpha cells in a time 
window between 1 and 3 days post STZ. As for the inhibitory receptor Ptch, 
this was detected only in somatostatin-positive cells (i.e. delta cells) and its 
expression was not affected by STZ treatment.
Conclusion: These data show a differential expression, among pancreatic 
endocrine cell subsets, of Gli transcription factors family members and that 
such expression is modulated in response to beta cell injury, thus confirming 
the involvement of Hh pathway in the regulation of beta cell mass. Moreover, 
the expression of the inhibitory receptor Ptch only in delta cells indicates 
that in these cells the Hh pathway is inactive and indirectly supports the hy-
pothesis that Hedgehog signaling is indeed involved in the development and 
regulation of both alpha and beta cells.
Supported by: FORISID- Italian Diabetes Research Foundation, Italian Minis-
try of Research
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Adaptive response of pancreatic alpha cells and hepatic carbohydrate me-
tabolism during chronic nutritional deprivation
E. Fernández-Millán1, J. De Toro-Martín2, E. Lizárraga-Mollinedo1, F. Es-
crivá1,2, C. Álvarez1,2; 
1Ciber de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM). 
ISCIII, 2Bioquímica y Biología Molecular II, Facultad de Farmacia Universi-
dad Complutense, Madrid, Spain.
Background and aims: Type 2 diabetes is mainly characterized by β-cell se-
cretory dysfunction and decreased β-cell mass but inappropriate levels of cir-
culating glucagon and increase in the α-cell/β-cell mass ratio are also impor-
tant determinants of the hyperglycemia seen in type 2 diabetes patients. In 
rats, pancreatic β-cell development is particularly sensitive to an altered intra-
uterine environment what contributes to increase the incidence of adult onset 
type 2 diabetes. However, little is known about the contribution of α-cells in 
this context. We previously showed that food-restriction applied during the 
last third of gestation caused in fetuses at term, an increase of β-cell mass, 
hyperinsulinemia and enhanced insulin secretion while prolonged malnutri-
tion until adulthood impaired β-cell growth and functionality. Therefore, our 
first aim was to determine whether maternal food-restriction would affect 
α-cell growth and functionality in offspring. Since pancreatic hormones play 
a crucial role in the regulation of hepatic glucose metabolism, our second aim 
was to examine the adaptive changes of carbohydrate metabolism in response 
to chronic food deprivation.
Materials and methods: Wistar rats were 65% food-restricted from the last 
week of gestation until adult age. The experiments were carried out in fetuses 
at term, in suckling and adult rats. α-cell mass, neogenesis and apoptosis were 
evaluated by immunocytochemistry and morphometry. For the study of α-
cell function fetal and adult islets were isolated. Serum hormone levels, islet 
glucagon secretion and content were measured by radioimmunoassay. Basal 
glycogen storage, PEPCK activity and phospho- and total GSK3β protein lev-
els were determined in homogenized livers after fasting.
Results: Undernourished (U) suckling rats were hypoglycaemic. Serum in-
sulin/glucagon ratio was higher in U fetuses and neonates on postnatal day 
4 (PN4) as compared to controls (C) but, from PN14 onwards this ratio was 
lower in U rats. Moreover, glucagon secretion was damaged in U fetuses and 
adults. α-cell mass increased from fetal period to PN14 then, it remained 
stable until PN23 and finally, it decreased at adult age in both populations. 
However, U rats showed defective α-cell mass comparing with C at all the 
ages studied. The impaired α-cell growth was neither due to increased α-cell 
apoptosis nor decreased neogenesis but to the presence of islets of smaller 
size. Liver glycogen content was enhanced in U rats at all the ages studied and 
this was associated with a higher inhibition of GSK3β. In contrast, PEPCK 
activity was found impaired from PN14 to adulthood in U rats.
Conclusion: 1) Intra-uterine growth restriction due to maternal malnutri-
tion induces a defective metabolic adaptation of neonates to extrauterine life; 
2) The factors involved include morphological and functional alterations of 
pancreatic α- and β-cells, improved efficiency to store glycogen in the liver 
but impaired glyconeogenesis; 3) This adaptive process could be crucial to 
survival during periods of nutritional scarce but detrimental in case of nor-
mal diet or overfeeding.
Supported by: CIBERDEM (ISCIII) and MEC, Spain
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Live in vivo imaging of Langerhans islets in normal and diabetic mice by 
extended focus optical coherence microscopy
J. Goulley1, M. Villiger2, C. Berclaz1, P. Meda3, A. Grapin-Botton1, T. Lasser1; 
1UPGRA, EPFL-SV, Lausanne, 2LOB, EPFL, Lausanne, 3Department of Cell 
Physiology and Metabolism, University of Geneva, Switzerland.
Background and aims: Structural and functional imaging of the islets of 
Langerhans and the insulin-secreting beta cells during diabetes progression 
represents a significant challenge and a long lasting objective. We have de-
veloped extended focus optical coherence microscopy (xfOCM) to image 
murine islets of Langerhans in- vivo. No labeling is required, since the native, 
intrinsic scattering properties of pancreatic tissues allow for a direct visu-
alization of endocrine islets of various sizes, blood vessels and ductal tree. 
Moreover, streptozotocin-induced destruction of beta-cells was detected and 
quantification of this depletion was determined in-vitro to evaluate the sensi-
tivity of xfOCM. A longitudinal study performed on NOD mice, a model of 
type I diabetes, unraveled new perspectives for xfOCM to image onset and 
progression of diabetes.
Materials and methods: A very same group of NOD mice was repeatedly 
monitored using xfOCM prior to the development of diabetes, at the early 
onset of the disease, weeks later and just before sacrifice. Imaging was fol-
lowed by automated quantification of islet mass. The same animals were regu-
larly sampled for basal glucose measurement tests, intraperitoneal glucose 
tolerance tests, and body weight measurements. Histological analysis of the 
pancreata after immunohistochemistry allowed us to characterize the nature 
of the detected structures.
Results: We show that xfOCM can detect islets of Langerhans in the absence 
of labeling in mice, and that the islet mass in the sample can be quantified. 
The longitudinal in vivo imaging study performed on NOD mice shows that 
(1) we can detect infiltrated islets (2) a decrease in beta cell mass measured by 
xfOCM is detected prior to detection of impaired glucose tolerance and overt 
diabetes. The presence of infiltrated islets and beta cell mass disappearance 
were confirmed by immunohistochemistry.
Conclusion: Our results demonstrate that xfOCM is a suitable tool to assess 
insulitis and beta cell mass loss prior to impaired glucose homeostasis and 
diabetes. Therefore, xfOCM will be useful to anticipate a diabetes outcome, 
since it non-invasively captures islet alterations that cannot be appreciated in 
vivo by other methods.
Supported by: an EFSD/MSD grant, Betaimage
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Bioluminescence quantifies alterations of beta cells mass in living Ins-
DTR mice
L. Vinet1, J. Virotsko2, D. Caille1, O. Fazio1, A. Powers2, P.L. Herrera1, P. 
Meda1; 
1Université de Genève, Switzerland, 2Vanderbilt University, Nashville, USA.
Background and aims: Studies of β cell loss in the pre-diabetic and diabetic 
state are impeded by the inability to non-invasively assess pancreatic β cell 
mass. Non-invasive imaging may also aid the development of therapeutic in-
terventions aimed at mitigating the diabetes-related β cell loss or to regener-
ating islets. Current methods for quantifying β cell mass and regeneration re-
quire the sacrifice of mice and the analysis of pancreatic sections, and do not 
allow for a sequential evaluation of β cell loss and regeneration in individual 
mice over time. To assess whether bioluminescence may help to address this 
problem, we generated MIP-Luc/Ins-DTR double transgenic mice which ex-
press the diphtheria toxin receptor (DTR) and luciferase (Luc) under the con-
trol of the insulin promoter, i.e. specifically in β cells. In these mice, injection 
of luciferin permits the emission of photons from β cells, whereas injection of 
diphtheria toxin (DT) causes a loss of the cells expressing DTR.
Materials and methods: Two-3 month old MIP-Luc/Ins-DTR double trans-
genic mice, both on a C57BL/6 genetic background, were injected 3 times 
i.p. with DT at 3 day intervals. When blood glucose was > 450 mg/dl, mice 
received a s.c. insulin implant. At weekly intervals, bioluminescence imaging 
(BLI) was recorded from a pancreatic region of interest, 5, 10, 15 and 25 min 
after the luciferin injection.
Results: In control MIP-Luc mice, the BLI recorded over the pancreas re-
mained stable for the 4 month duration of the experiment. Prior to DT injec-
tion, males and females MIP-Luc/Ins-DTR mice had similar values of BLI. 
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After DT injection, this BLI signal sharply decreased in males (n=5) to about 
5-10% its initial value, as the animals developed hyperglycaemia, consistent 
with a major loss of β-cells. BLI, then, remained at this low level through-
out the rest of the experiment. In age-matched females (n=4), DT decreased 
pancreas BLI by 40-70%, but did not cause hyperglycemia, consistent with 
the loss of only a fraction of the β-cells. The BLI, then, remained stable for 
the first 2 months. Thereafter, it increased, suggesting a change in β-cell mass 
and/or in the efficiency of the photon emission. In this model, the BLI and 
blood glucose changes differed in males and females, due to the targeted in-
sertion of the DTR transgene to the X chromosome.
Conclusion: The data show that bioluminescence provides for a non-invasive 
monitoring of graded, and sequential changes in β-cells mass within indi-
vidual mice.
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Islets transplanted into the anterior chamber of the eye serve as a mirror 
of in situ pancreatic islets
E. Ilegems1, A. Bahow1, A. Sharma1, A. Dicker1, S. Speier2, P. Karlsson 
Edlund1, M. Köhler1, I.B. Leibiger1, P.-O. Berggren1; 
1Department of Molecular Medicine and Surgery, Karolinska Institutet, 
Stockholm, Sweden, 2Technical University Dresden, Germany.
Background and aims: Since insulin-secreting beta-cells are located in the 
endocrine pancreas, deeply embedded in the exocrine pancreas, imaging of 
beta-cells in living organisms is difficult. The anterior chamber of the eye was 
recently proposed as a transplantation site for non-invasive in vivo imaging 
of pancreatic islets. This location can be used as a natural “body-window” 
allowing for a repetitive assessment of islet mass and function. The aim of 
the present study is to demonstrate that islets transplanted into the anterior 
chamber of the eye are representative of the islets status in the endogenous 
pancreas.
Materials and methods: We performed syngeneic transplantations into 
control and obese-hyperglycemic ob/ob mice - a model for type 2 diabetes. 
Animals were transplanted into the anterior chamber of the eye at 4 weeks of 
age with islets isolated from age-matched donors. Pancreas and transplanted 
eyes were collected 3 months later and processed for immunohistochemical 
studies.
Results: Immunohistochemical staining for insulin showed an altered expres-
sion pattern in both ob/ob pancreatic and transplanted islets as compared to 
control mice. Islets in ob/ob mice showed a strong proliferation rate (1.0 ± 0.2 
%) as well as an increased size of beta cells (+30 %), both at the transplanta-
tion site and in the endogenous pancreas. The typical increase in intra-islet 
vessel diameter in the ob/ob mouse was also observed and found to be identi-
cal in transplanted islets. We next aimed at demonstrating islet plasticity in 
the anterior chamber of the eye. Ob/ob mice were treated with daily injec-
tions of leptin 2 months after transplantation. After 1 month of treatment, 
their blood glucose levels normalized and their body weight diminished to 
reach a similar value as in control mice. Immunostaining at this time point 
showed that the typical islet properties of ob/ob mice were reversed: quantifi-
cation of beta cell size, proliferation, and vessel diameters gave similar values 
as observed in control non-obese mice.
Conclusion: Islets transplanted into the anterior chamber of the eye reflect 
endogenous pancreatic islets properties. This transplantation site thus serves 
as a perfect imaging platform allowing for a non-invasive and repetitive as-
sessment of islet function and beta-cell mass regulation at single-cell resolu-
tion under normal and diabetic conditions.
Supported by: Wenner-Gren Foundation & Swedish Research Council
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High resolution magnetic resonance imaging detects individual 
pancreatic islets in whole pancreas
S. Lamprianou1, R. Immonen2, A. Gjinovci1, L. Vinet1, R. Gruetter2,  
P. Meda1; 
1PHYME, Université de Genève, 2Laboratory for Functional and Metabolic 
Imaging, EPFL, Lausanne, Switzerland.
Background and aims: In type 1 and type 2 diabetes the gradual loss of 
pancreatic β-cell function and mass leads to impaired regulation of blood 
glucose with severe secondary peripheral effects. Currently, we lack non in-
vasive methods for monitoring the evolution of the disease. β-cells make-up 
80% of the islets of Langerhans which, in the adult, represent 1% of the total 
pancreatic volume, have a diameter of 30-600 μm and are scattered within the 
pancreas. Imaging these islets in vivo is the ultimate challenge. To approach 
this goal, we tested whether the ultra high field of 14.1T MRI, in combination 
with manganese infusion, can image individual pancreatic islets.
Materials and methods: Mice were untreated (3 mice) or subjected to a 
MnCl2 i.v. infusion together with a glucose i.p. stimulus (6 mice). MnCl2 
and glucose infused mice were further injected i.p. with either streptozotocin 
(STZ) (4 mice) or citrate buffer (5 mice). In all cases, the pancreata were ex-
cised, fixed in 4% PFA for 6h and placed into Fomblin. Samples were then 
imaged in a 14.1T 26 cm horizontal bore scanner using quadrature half-vol-
ume coil 20 mm in diameter. High resolution images were acquired using 
gradient echo multi slice sequence with fourteen 0.3 mm-thick slices, FOV 
26*25 mm, data matrix 512*512 (51*49 μm in plane resolution) to cover the 
whole mouse pancreas. Two sets of combined T1 and T2* weighted images 
(TR=282 ms, TE=7 ms, flip=60°, 30 averages and TR=500 ms, TE=14 ms, flip 
60°, 20 averages) were acquired for optimal tissue contrast.
Results: The ultra high field of 14.1 T allows for the visualization of different 
pancreas tissues (lymphatic ganglia, ducts and vessels), whose identity was 
ascertained by histology. Structures that featured the size, shape and distribu-
tion of pancreatic islets were also revealed. The MRI signal of the later struc-
tures was enhanced by MnCl2 and glucose infusion, and their islet nature was 
demonstrated by histological analysis. The distribution of islet areas observed 
in MRI images was consistent with that evaluated in the histological sections 
of the very same samples. However, the two distributions were not identical, 
due to the shrinking of the pancreas during the histological treatment, and 
to the partial volume effects ascribed to the finite slice thickness of MRI. Pre-
liminary experiments indicate that the approach can detect the loss of islets 
induced by injection of a diabetogenic dosis of STZ.
Conclusion: We conclude that, when using high resolution MRI together 
with manganese and glucose infusion, individual pancreatic islets can be vis-
ualized within the whole pancreas in the absence of β-cells targeted labeling. 
The study provides the first proof of concept that a clinically relevant imaging 
method could be applied for visualizing individual islets in vivo and holds 
promise for the evaluation of the β-cell changes induced in diabetes.
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Vesicular monoamine transporter 2 gene expression in beta cells of 
primates but not of rodents: implications for developing radioligands for 
imaging of beta cell mass in animal models
M.K. Schafer1, L.E. Eiden2, E. Weihe1; 
1Molecular Neuroscience, Institute of Anatomy and Cell Biology, University 
of Marburg, Germany, 2Section on Molecular Neuroscience, NIMH, 
Bethesda, USA.
Background and aims: Imaging of pancreatic islets and in particular of beta 
cell mass is a major challenge in diabetes research. Our original observation 
that the vesicular monoamine transporter 2 (VMAT2) is expressed in the vast 
majority of human and non-human primate beta cells has led to the sugges-
tion that VMAT2 is a promising biomarker of beta cell mass independent 
of mechanisms of insulin production. Consequently, radiolabeled analogs of 
tetrabenazine, a low molecular weight VMAT2 selective ligand, have been 
employed for pancreatic islet imaging in humans and rats. However, contro-
versial results and limited success in discrimination from background and 
avoiding overestimation of beta cell mass were obtained. Here we investigated 
VMAT2 expression patterns in mouse and rat pancreas in order to determine 
whether these rodents qualify as suitable models to optimize tetrabenazine 
based beta cell mass imaging.
Materials and methods: Pancreatic tissue was obtained from Wistar, Sprague 
Dawley and Lewis rats as well as from C57/BL.6 and Balb-C mice. Depar-
affinized sections or cryosections from formaldehyde or Bouin Hollande 
fixed tissues were processed for immunocytochemistry with a panel of spe-
cies-specific VMAT2 antisera and in situ hybridization in combination with 
immunostaining for insulin and RT-PCR analysis from laser-microdissected 
beta cells.
Results: We demonstrated lack of specific VMAT2 expression in beta cells of 
both mice and rats throughout development. Our antisera revealed an abun-
dant network of VMAT2 positive catecholaminergic innervation costained 
for tyrosine hydroxylase, the rate limiting enzyme of catecholamine biosyn-
thesis. Absence of VMAT2 transcripts from beta cells was confirmed by RT-
PCR analysis from laser-micodissected beta cells. In contrast, beta cells from 
primates exhibited abundant VMAT2 expression on the mRNA and protein 
level as previously reported. Thus, it is clearly shown that primate but not 
rodent species qualify as animal models for beta cell mass imaging with radi-
olabeled VMAT2 ligands such as 11-C-dihydrotetrabenazine or newly devel-
oped VMAT2 biomarkers.
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Conclusion: The choice of species is crucial for developing optimal animal 
models for beta cell mass imaging and requires proof of principle experi-
ments including species-specific gene expression analysis that the biomar-
ker in question is truly valid for both humans and the animal model used. 
Tetrabenazine remains one of the ligands of choice for imaging of VMAT2 in 
human pancreas, however existing animal models must be adjusted and/or 
chosen carefully. Transgenic VMAT2 mice under the insulin promoter may 
be a way to provide a rodent model for pancreatic beta cell imaging.
Supported by: EU FP7/2007-2013 
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In vivo visualisation of transplanted islets in rat by SPECT imaging with 
111In-Exendin-3
K.M. Andralojc, M. Brom, L. Joosten, W. Oyen, O. Boerman, M. Gotthardt; 
Department of Nuclear Medicine, Radboud University Nijmegen Medical 
Center, Netherlands.
Background and aims: At this moment, there is no reliable non-invasive 
method to determine beta-cell mass in vivo. Such a method would not only 
allow longitudinal studies on the engrafted islets survival in case of human 
islet transplantation, but might also enable improved treatment of patients 
with immune-suppressive drugs to prevent rejection of transplanted islets. 
We have developed a non-invasive imaging technique that specifically visu-
alizes beta-cells in vivo. This method is based on the targeting of the gluca-
gon-like peptide 1 receptor (GLP-1R). The GLP-1R is expressed at high levels 
on pancreatic beta-cells. We have developed an In-111-labeled tracer that 
specifically binds to the GLP-1R: In-111-labeled Exendin-3. Previous stud-
ies showed a linear correlation between the beta-cell mass and Exendin-3 
uptake. We examined whether intramuscularly transplanted beta-cells in rats 
could be visualized by SPECT (Single Photon Emission Computed Tomogra-
phy) imaging after i.v. injection with radiolabeled Exendin-3.
Materials and methods: Langerhans islets were isolated from Wag/Rij rats 
and cultured overnight in RPMI medium prior to transplantation. One 
thousand islets were transplanted in the left hind limb muscle of Wag/Rij 
rats, while vehicle was injected in the right muscle as a control (n=3). Two, 
7 and 14 days after transplantation 111In-labeled Exendin-3 was injected in-
travenously and SPECT images were acquired 1 hour post injection using 
a U-SPECT II microSPECT scanner. After acquiring the SPECT images at 
the day 14 the rats were euthanized and the radioactivity in the transplant 
and other relevant tissues was measured. The muscle with engrafted islets 
was fixed and embedded in paraffin for autoradiography and immunohisto-
chemical analysis. 
Results: The transplanted islets were clearly visualized with SPECT at 7 and 
14 days after transplantation. Ex vivo autoradiography of the engrafted islets 
showed high uptake of In-111-Exendin-3 in the islets. Immunohistochemis-
try confirmed that those islets were viable and produced insulin. In-111-Ex-
endin-3 uptake in the muscle with the engrafted islets was higher than uptake 
in the control muscle (0.27+0.06 %ID vs 0.07+0.02 %ID).
Conclusion: 111In-Exendin-3 accumulated efficiently in transplanted islets. 
Transplanted islets could be clearly delineated by microSPECT imaging after 
injection of 111In-Exendin-3. 111In-Exendin-3 could potentially be used for 
non-invasive beta-cell mass determination of transplanted islets.
Supported by: NIH and the FP7/2007-2013 
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Quantitative determination of the beta cell mass by SPECT imaging with 
111In-DTPA-Exendin-3 in rats
M. Brom1, P. Baumeister2, S. Verwijnen3, L. Joosten1, P. Laverman1,  
M. Béhé4, M. de Jong3, W. Oyen1, O. Boerman1, M. Gotthardt1; 
1Department of Nuclear Medicine, Radboud University Nijmegen Medical 
Centre, Netherlands, 2Department of Nuclear Medicine, University Hospital 
Giessen and Marburg, Marburg, Germany, 3Department of Nuclear 
Medicine, Erasmus Medical Center, Rotterdam, Netherlands, 4Department 
of Nuclear Medicine, University Hospital of Freiburg, Germany.
Background and aims: A reliable, non-invasive method that could quanti-
tatively determine the pancreatic beta-cell mass in vivo would give further 
insight in the pathophysiology of type 1 and 2 diabetes. Such a test would 
allow monitoring effects of diabetes treatments on beta-cell mass, enable 
individually-tailored therapy and could be used to monitor islet transplan-
tation. The GLP-1 receptor (GLP-1R) is expressed on pancreatic beta-cells. 
GLP-1, the natural ligand of the GLP-1R, cannot be used for in vivo GLP-1R 
targeting due to its low stability in plasma. Exendin-3 is a more stable analog 
of GLP-1 and therefore suitable for targeting of the GLP-1R. Exendin-3 was 
conjugated with DTPA, allowing radiolabelling with 111In. We investigated 
the potential of SPECT imaging with 111In-DTPA-Exendin-3 to determine 
the beta-cell mass in vivo.
Materials and methods: Diabetes was induced in Brown Norway rats by 
injecting different doses of alloxan (0, 15, 30, 45, 60 mg/kg) intravenously. 
Alloxan specifically destroys beta-cells in a dose-dependent manner. One 
week after alloxan injection, 111In-labeled Exendin-3 was injected intrave-
nously and SPECT images were acquired 1 hour post injection. After SPECT 
scanning the rats were euthanized and the radioactivity in the pancreas and 
relevant organs was measured and specific uptake in the Langerhans islets 
was determined by autoradiography. The beta-cell mass was determined by 
quantitative analysis of pancreatic sections that were stained immunohisto-
chemically.
Results: In untreated rats, the pancreatic uptake of 111In-DTPA-Exendin-3 was 
0.15 ± 0.02 %ID/g. Treatment with 60 mg/kg alloxan resulted in a 80% reduc-
tion of pancreatic uptake of 111In-DTPA-Exendin-3 (0.03 ± 0.02 %ID/g). Ex 
vivo autoradiography showed that 111In-DTPA-Exendin-3 specifically accumu-
lated in the endocrine pancreas. The pancreata of untreated rats were clearly 
visualized on the SPECT images acquired 1 h after injection of 111In-DTPA-Ex-
endin-3. After treatment with 60 mg/kg alloxan the pancreata were non-detect-
able by SPECT. There was a significant correlation between Exendin uptake and 
beta-cell mass (r=0.83). The uptake of Exendin as determined by quantitative 
analysis of the SPECT images correlated with the beta-cell mass (r=0.64).
Conclusion: 111In-DTPA-Exendin-3 can be used to determine the pancreatic 
beta-cell mass non-invasively by SPECT. The uptake of the tracer is beta-cell 
specific. The uptake correlated linearly with beta-cell mass and disappeared 
in diabetic animals without remaining beta-cells. 111In-DTPA-Exendin-3 is a 
promising tracer for the determination of the beta-cell mass. Clinical trials in 
healthy volunteers and type 1 diabetic patients are planned.
Supported by: NIH and European Community’s FP7/2007-2013
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Autografting of BMSCs into miniature porcine pancreas for early phase 
of type 1 diabetes mellitus and tracing it by MRI in vivo
K. Tang1, D. Liu2, Y. Chen3, Y. Wang4, X. Yang5, Y. Shen5, H. Duan5,  
H. Liang5, M. Cai5, J. Yan5, Y. Zhu5, J. Weng5; 
1Department of Geriatrics, Department of Endocrinology, Qilu Hospital of 
Shandong University, the 3rd Affiliated Hospital of Sun Yat-sen University, 
2Department of Vascular Surgery, the 1st Affiliated Hospital of Sun Yat-sen 
University, 3Department of Radiology, the 1st Affiliated Hospital of Sun 
Yat-sen University, 4Interventional Department, the 1st Affiliated Hospital 
of Sun Yat-sen University, 5Department of Endocrinology, the 3rd Affiliated 
Hospital of Sun Yat-sen University, Guangzhou, China.
Background and aims: Recently, several researches in rodent animals and 
T1DM patients indicated that T1DM in the early stage might be reversed by 
autografting BMSCs (ABMSCs). However, the potential mechanisms re-
mained unknown. The aims of the research are to disclose the efficiency and 
security of autografting BMSCs labeled by super-paramagnetic iron oxide 
(SPIO) quantitatively into the pancreas of minipig with T1DM in early stage.
Materials and methods: Nine normal, healthy, 3-month old male Tibetan 
miniature pigs were randomized into 3 groups, including normal controls 
(NC), diabetic conventional therapy (DMC) and diabetic autografting BM-
SCs (DMAB) group. T1DM pig model were induced by streptozotocin (STZ). 
T1DM pigs were administrated with protamine zinc INS via subcutaneous 
injection to control fasting plasma glucose (FBG) level less than 10.0 Mm/L. 
In 4-6th wks after successful modeling, DMAB pigs accepted ABMSCs labeled 
by SPIO into the pancreas under the guidance of digital subtraction angiogra-
phy. Blood routine biochemical parameters were determined to evaluate the 
security of ABMSCs at 4 timepoints. At the 3rd and 6th week after ABMSCs, 
the pancreases of DMAB animals were scanned by 3.0T MR. IVGTT and 
OGTT were used to evaluate pancreatic beta-cell function and glucose tol-
erance. Immunohistochemical examination were performed to estimate the 
regeneration of islets.
Results: After successful modeling, the diabetic animals’ FBG were control-
led at 5.1-12.5 Mm/L. DMAB group were treated with ABMSCs labeled with 
SPIO (7.4×107,6.8×107,7.0×107 cells, respectively) through dorsal pancre-
atic artery. The biochemical parameters of DMAB group had no significant 
change after ABMSCs. Comparing with pre-ABMSC, the MRI showed scat-
tered low-signal area in the pancreases at the 3rd and 6th wk after ABMSCs. 
Before ABMSC, the INS dosage and FBG had no significant difference be-
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tween DMC and DMAB group. At about 17 to 28 days after ABMSCs, FBG 
of DMAB group decreased progressively and waved between 2.3-7.5 Mm/L 
with INS free. IVGTT showed increased INS levels with a delayed peak at 10 
min, and improved blood glucose tolerance gradually that had no significant 
difference comparing with baseline. Pathologic research showed that BMSCs 
labeled with SPIO differentiated into islet cells or pancreatic ductal epithe-
lial cells in islets which showed positive response in brussian blue staining, 
and many small neogenetic intact islets in DMAB group and caritive ones 
in DMC group.
Conclusion: Our data suggested the security and efficiency of quantitative 
ABMSC through the femoral artery intervention for early stage T1DM mini-
pigs. ABMSCs could improve islet function effectively and maintain nearly 
normal FBG free from INS for a period of time. Autografting BMSCs could 
differentiate into islet cells or improve local microcirculation, and then re-
verse new-onset T1DM.
Supported by: the grant 20070410251 of CPDSF, 7001536 of GDPNSF, 
Y2007C036 of SDPNSF
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Rapamycin impairs proliferation of transplanted islet beta cells
G. Parnaud, D. Bosco, T. Berney; 
Cell Isolation and Transplantation Center, Department of Surgery, Geneva 
University Hospital and University of Geneva, Switzerland.
Background and aims: Five years after islet transplantation, only 10 % of pa-
tients remain insulin independent revealing a progressive islet dysfunction. 
The cause of this event is undefined to date but may be the result of adverse 
effects of immunosuppressive agents. In this study, we examined the effect of 
rapamycin, a key component of the immunosuppressive regimen in clinical 
islet transplantation, on islet cell replication in vivo. 
Materials and methods: Streptozotocin (200 mg/kg i.p.) was used to induce 
diabetes in NOD/Scid mice at least 5 days before islet transplantation. Five 
hundred rat islets were transplanted under the left kidney capsule of nor-
moglycemic or diabetic mice. Three days after transplantation, animals were 
randomly allocated into the experimental groups (control or rapamycin) and 
BrdU (5 mg/ml) was added to drinking water for 7 days. Mice were treated 
with rapamycin (0.3mg/kg/every day, i.p.) and control animals received ap-
propriate vehicle treatment. An i.p. glucose tolerance test was performed on 
all animals at 10 days. Beta cell replication was determined by double im-
munofluorescence staining for insulin and BrdU. Data are expressed as % 
positive BrdU beta cells and as mean ± SEM for 3 or more independent ex-
periments.
Results: Although control and rapamycin-treated mice had similar blood 
glucose levels before and 2h after i.p. glucose injection, both the peak glucose 
levels and duration of the glucose excursion (AUC in mM of glucose over 120 
min) were increased in rapamycin-treated mice when compared to control 
mice (830±95 vs. 284±42; rapamycin vs. control, P=0.0004). In non strep-
tozotocin-treated mice, rapamycin decreased the % of BrdU positive beta 
cells within endogenous islets (0.66±0.16 vs. 1.71±0.41; rapamycin vs. con-
trol, P=0.029). Furthermore, rapamycin reduced the % of BrdU positive beta 
cell in transplanted islets (0.71±0.16 vs. 4.60±0.42; rapamycin vs. control, 
P<0.0001). Similar results were obtained with Ki67 staining as an alternative 
mean of identifying proliferating cells (0.08±0.04 vs. 0.80±0.17; rapamycin 
vs. control, P=0.002). When streptozotocin-treated mice were treated with 
rapamycin, the % of BrdU positive beta cell in the graft was also significantly 
decreased (1.39±0.26 vs. 3.96±0.71; rapamycin vs. control, P=0.004). Finally, 
the apoptotic rate in transplanted islets was very low and no significant differ-
ence was observed between control and rapamycin-treated mice.
Conclusion: Our results indicate that rapamycin reduces the rate of pancre-
atic beta cell proliferation in transplanted rat islets but also in native pancre-
atic murine islets. It is therefore suggested that progressive graft islet dysfunc-
tion may result in part from an impairment of beta cell regeneration induced 
by rapamycin in transplanted patients.
Supported by: an EFSD/Novartis grant
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Differences in blood perfusion correlates to pancreatic islet function in 
vitro
J.E. Svensson, J. Lau, P.-O. Carlsson; 
Medical Cell Biology, Uppsala University, Sweden.
Background and aims: The blood perfusion between different pancreatic is-
lets varies considerably. In recent experiments we observe that this result in a 
markedly heterogenous oxygenation of the islets. The present study tested the 
hypothesis that heterogeneity between islets with regard to vascular support 
is also reflected in differences in islet beta-cell function. 
Materials and methods: Fluorescent microspheres (10 µm in size) were used 
to measure the blood perfusion of individual pancreatic islets in adult Wistar-
Furth rats. Based on the microsphere distribution islets were separated into 
two groups, with blood flow below or above 0,4 µl/min. Functional studies of 
glucose-stimulated insulin release, insulin content and glucose oxidation rate 
were performed in vitro on freshly isolated islets. Gene expression studies 
were performed by RT-PCR. Vascular density quantification using two-pho-
ton confocal microscopy was performed separately for each group of islets 
after intravascular visualization of blood vessels by IB4 isolectin.
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Results: Functional studies on freshly isolated islets of the two groups re-
vealed that islets with better blood perfusion had much higher basal and glu-
cose-stimulated insulin release when compared to less perfused islets. No dif-
ferences were observed between groups with regard to total insulin content, 
mitochondrial function, as assessed by studies of glucose oxidation rate, or in 
islet size. Vascular density quantification showed that approximately 10% of 
islets were composed of blood vessels in both groups, but that the vasculature 
in islets with lower blood perfusion had less tortuous architecture. Moreo-
ver, preliminary studies suggest that islets with better blood perfusion have 
higher gene expression of glucose transporter 2.
Conclusion: Our results indicate that pancreatic islets with higher blood per-
fusion also have better function that remains after isolation of the islets. This 
may partially be explained by differences in vascular structure, but need to be 
further investigated. 
Supported by: JDRF, SRC, SDF, NNF
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Hypoxia-protective effects of preconditioning in beta cells are exerted 
at the level of insulin biosynthesis and are mediated by inhibition of 
calcium inflow
A. Björklund1, Z. Ma1, V. Grill2; 
1Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden, 
2Cancer Research and Molecular Medicine, Norwegian University of Science 
and Technology, Trondheim, Norway.
Background and aims: Pharmacological preconditioning alleviates the im-
pact of hypoxia in heart and brain; therefore similar procedures may also 
adapt beta cells to hypoxia prior to transplantation and this could be thera-
peutically useful. We have found that preconditioning in vitro by the K-ATP-
channel opener diazoxide alleviates the diminution of cellular insulin con-
tents brought about by experimental hypoxia on rat pancreatic islets. Here we 
report on possible mechanisms behind these beneficial effects.
Materials and methods: Rat or human islets were maintained in tissue cul-
ture (RPMI, 11mM glucose). They were subjected to 5.5 h of hypoxia with or 
without a 22h period of preconditioning with diazoxide and/or other agents.
Results: Rat islet insulin contents were reduced by 23 % after hypoxia and 
by 61% after a further 22 h re-oxygenation period. Preconditioning with dia-
zoxide (325 µmol/l) alleviated the hypoxia effect (2.7 fold increase, p <0.001 
vs. hypoxia alone). Hypoxia reduced proinsulin biosynthesis (3H-leucine 
incorporation into proinsulin) by 35 ± 6 % and this decrease was partially 
corrected by preconditioning (by 91 %, p < 0.03). Beneficial effects of dia-
zoxide were abolished by including tolbutamide or elevated potassium (i.e. 
conditions which increase calcium inflow) during preconditioning. Precon-
ditioning with 10 µmol/l of nifedipine, a calcium channel blocker, reproduced 
the beneficial effects of diazoxide. We employed cooling, i.e. culture at 28 C 
before hypoxia, to dissociate effects on insulin secretion (inhibited by cool-
ing) from effects on calcium inflow (marginally affected by cooling). Cooling 
inhibited glucose induced insulin secretion by 64 ± 2 % but did not induce 
any positive preconditioning effect, instead a negative one was recorded (-40 
± 6 %). Both diazoxide and nifedipine moderately but significantly inhibited 
glucose oxidation before the period of hypoxia.
Conclusion: 1) hypoxia-induced functional deficits are alleviated by prior 
blocking of calcium inflow, probably acting through attendant effects on 
mitochondrial metabolism, 2) both agents which block calcium inflow indi-
rectly and those which block directly have therapeutic potentials.
Supported by: an EFSD/MSD grant
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Composite pig islet-human endothelial progenitor cell grafts can reduce 
the instant blood-mediated inflammatory reaction
H.S. Jung1, H.I. Kim1, M.J. Kim1, S.H. Hong1, Y.Y. Lee1, H.C. Jang2,  
S.Y. Kim2, K.S. Park2; 
1Seoul National University Hospital, 2Seoul National University, Republic of 
Korea.
Background and aims: One of obstacles in clinical islet transplantation is 
the islet loss in the early post-transplant period, which is as much as 50-60% 
of the grafts. This mainly results from intravascular islet-induced nonspe-
cific inflammatory and coagulation pathways promoting a so-called instant 
blood-mediated inflammatory reaction (IBMIR). Endothelial cells are known 
to protect against complement-mediated lysis and activation of coagulation. 
Endothelial progenitor cells (EPC) seem to have lower profile of procoagula-
tion in some environment compared to mature endothelial cells. EPC can be 
isolated from peripheral blood, and be expanded ex vivo, which is important 
as for clinical application. In addition, EPC display a unique ability to pro-
mote angiogenesis although the underlying molecular mechanism remains 
poorly understood. These suggest that EPC might be a better source to pro-
tect IBMIR. Therefore, we tested effects of composite pig islet- human EPC 
grafts in vivo.
Materials and methods: Porcine islets were cocultured with human EPC 
overnight to obtain about 50% coverage. The cells were transplanted to STZ-
diabetic athymic (nu/nu) nude mice through portal vein. Daily body weight 
and fed blood glucose were monitored, and serial harvest of liver tissues was 
performed for morphologic analysis.
Results: Composite pig islet-human endothelial progenitor cell grafts signifi-
cantly improved blood glucose levels compared to islet grafts immediately af-
ter transplantation and then for 1 week, which suggested better graft survival 
from IBMIR. On morphologic examination, transplanted composite grafts 
showed a reduction in leukocyte infiltration and coagulation, and stained 
positive for insulin and human lectin demonstrating presence of both islets 
and EPC.
Conclusion: If optimal EPC-islet coculture method can be identified, EPC-
coating has potential as a candidate that can control the strong innate im-
mune response induced by islet grafts transplanted through the portal vein, 
and clinical islet transplantation would be more available and feasible strat-
egy for the cure of diabetes.
Supported by: IRICT, the ministry of health and welfare, Republic of Korea
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Co-transplantation with mesenchymal stem cells improves islet 
transplantation outcome in mice
A.J.F. King, C. Rackham, P. Chagastelles, P.M. Jones; 
Diabetes Research Group, King’s College London, United Kingdom.
Background and aims: Islet transplantation is a potential cure for Type 1 
diabetes, but despite recent advances most patients revert to hyperglycaemia 
within five years. It is thought lack of success may be partially due to beta cell 
death in the immediate post transplantation period and poor revascularisa-
tion. Mesenchymal stem cells (MSCs) are adult progenitor cells which play a 
major role in tissue repair. The aim of the study was to investigate whether 
co-transplantation of MSCs with islets could improve transplantation out-
comes in mice.
Materials and methods: Mesenchymal stem cells were isolated from the kid-
neys of C57Bl/6 mice and were expanded in vitro. Islets were isolated from 
the pancreases of donor C57Bl/6 mice. Streptozotocin-diabetic C57Bl/6 mice 
were transplanted with a suboptimal graft of either 150 islets alone or 150 is-
lets + 250,000 MSCs under the kidney capsule. Blood glucose concentrations 
were monitored for 28 days after which the graft-bearing kidneys of cured 
mice were nephrectomised. The islet grafts and endogenous pancreases were 
analysed histologically for insulin, glucagon and CD34 as markers for beta, 
alpha and endothelial cells, respectively.
Results: Prior to transplantation, blood glucose concentrations were 27.6 ± 
1.8 mM and 28.2 ± 1.3 mM in the islet alone and islets + MSC groups, respec-
tively. After transplantation, the mice that were implanted with islets + MSCs 
had lower blood glucose concentrations than mice implanted with islets 
alone (day 7: 11.6 ± 2.2 mM vs 27.5 ± 2.1 mM, day 14: 11.1 ± 2.1 mM vs 26.9 
± 2.0 mM, day 28: 8.6 ± 1.0 mM vs 19.0 ± 3.6 mM, n=9, p<0.01, 2 way RM 
ANOVA with Bonferroni Post-Hoc test). After 28 days, in cured mice (non-
fasting blood glucose<11.1 mM: 8 of 9 mice in islets + MSC group, 3 of 9 mice 
in islet alone group) the graft bearing kidney was removed, after which all 
mice reverted to hyperglycaemia (>20 mM). The density of endothelial cells 
was increased in the islet + MSC grafts (978 ± 92 endothelial cells/mm2) com-
pared to the islet alone grafts (702 ± 23 endothelial cells/mm2, n=4-6, p<0.01, 
t-test). No differences were seen in the endogenous pancreases between the 
two groups with regard to size of islets and frequency of insulin and glucagon 
staining, with most cells in the islet remnants consisting of alpha cells.
Conclusion: Co-transplantation with MSCs improves syngeneic islet trans-
plantation outcome in mice. This is associated with increased numbers of 
endothelial cells in the graft and altered islet graft morphology. There is no 
difference in insulin positivity in the endogenous pancreases between the 
groups, indicating that the positive effects of MSCs are indeed a direct effect 
on the graft.
Supported by: RCUK
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Gene transfer of glucagon-like peptide-1 to mouse islets improves 
transplantation outcome
S.-H. Ihm1, M.-G. Choi1, H.-J. Yoo1, H.-S. Jun2, J. Ihm3; 
1Internal Medicine, Hallym University, Chuncheon, 2Lee Gil Ya Cancer and 
Diabetes Institute, Gachon University of Medicine and Science, Incheon, 
3Biochemistry, Kyonggi University, Suwon, Republic of Korea.
Background and aims: Pancreatic islet transplantation (TPL) is a promising 
therapeutic intervention for T1DM. One of the significant obstacles to suc-
cessful islet TPL is a high number of cell deaths in islet grafts during the early 
days after TPL, mostly from inflammatory and hypoxic damage. To overcome 
these obstacles and improve the outcome of islet TPL, the transfer of cyto-
protective genes to isolated islets has been attempted. Because glucagon-like 
peptide-1 (GLP-1) was shown to stimulate beta-cell proliferation and have 
anti-apoptotic effects on beta cells, we examined whether adenovirus-medi-
ated gene transfer of GLP-1 would result in cytoprotection of islets in vitro 
and in vivo TPL setting.
Materials and methods: Isolated mouse islets were transduced with an ad-
enoviral vector coding for GLP-1 (rAd-GLP-1) or green fluorescent protein/
beta-galactosidase (rAd-GFP/LacZ). After transfection, GLP-1 expression 
was assessed by RT-PCR of islet mRNA and RIA of culture media. To assess 
the in vitro cytoprotective effect, transduced islets were treated with H2O2 
(200 microM for 30 min) and cell death and MMP were measured using AO/
PI and JC-1. To assess the effect of GLP-1 expression on islet survival in vivo, 
suboptimal mass of transduced islets was transplanted into renal subcapsular 
space of syngeneic diabetic mice.
Results: Adenoviral delivery of GLP-1 to islets resulted in dose (m.o.i.)-de-
pendent increase in synthesis and secretion of GLP-1. Islets transduced with 
rAd-GLP-1 were protected from H2O2-induced cell damage in vitro. Two 
weeks after TPL, diabetes cure rate with islets transduced with rAd-GLP-1 
(81%) was significantly higher than that with islets transduced with rAd-
GFP/LacZ (25%).
Conclusion: Theses results indicate that the overexpression of GLP-1 in islets 
enhances islet survival in vitro and preserves islet function in transplants. 
Our results suggest that GLP-1 expression in islets is one of plausible and use-
ful strategies for ex vivo cytoprotective gene therapy in islet TPL.
Supported by: IRICT, Republic of Korea
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The thyroid hormone T3 improves function and survival of rat 
pancreatic islets during in vitro culture
C. Mangialardo, C. Verga Falzacappa, A. Stigliano, V. Toscano, S. Misiti; 
II Faculty of Medicine, Sapienza, Università di Roma, Italy.
Background and aims: Islet cell transplantation is an alternative therapy to 
conventional ones for type 1 diabetic patients. However, this strategy is se-
verely limited by the shortage of organ donors. Ex vivo islet cell culture prior 
to transplantation is a good alternative, but the maintenance of islets in cul-
ture is at the moment a difficult task. Therefore, stimulation of islet prolifera-
tion and differentiation in vitro remains the major scientific and clinical goal. 
Many growth factors have been studied, and related to intracellular signalling 
molecules and cell cycle regulators playing key roles in pancreatic beta cells. 
Among these, the kinase Akt has been indicated as a crucial intracellular 
mediator of beta cell growth and survival both in vitro and in vivo studies. 
We previously demonstrated that thyroid hormone T3 can increase beta cell 
function via specific activation of Akt, therefore we suggest that the addition 
of T3 to primary rat islets culture could preserve islets features from their 
physiological degradation, improving their status prior to transplantation.
Materials and methods: Rat pancreatic islets, isolated by collagenase diges-
tion, have been cultured in the presence or not of T3 10-7M. Immunofluo-
rescence analysis has been performed to evaluate the expression of thyroid 
receptor beta1 in rat islets. The islets viability has been studied by the use of 
two different dyes, one cell permeable green fluorescent dye and propidium 
iodide, and by the analysis of core cell damage upcoming. Beta cell prolifera-
tion within islets was analyzed by BrdU incorporation. Moreover, islet func-
tion has been evaluated by measuring insulin secretion. The ability of beta 
cells to counteract apoptosis induced by streptozotocin has been analyzed by 
TUNEL assay, and the Akt activation by Western blotting analysis.
Results: We demonstrated that treatment of primary cultures of rat pancreat-
ic islets with T3 results in increased beta cell vitality with an augment of their 
functional properties. Contemporary a sensible reduction of the core damage 
has been observed in T3 treated islets, showing a preservation of the beta cells 
integrity during the culture period. Furthermore, when BrdU incorporation 
was performed, a much higher number of positive nuclei in T3 treated islets 
indicates that T3 not only improves islet status, but also that induces beta 
cell proliferation. Nonetheless, the insulin secretion is sensibly augmented 
after T3 stimulation. All the observed effects were associated with a strong 
increment in Akt activation, suggesting the involvement of this kinase in T3-
mediated phenomena in pancreatic islets.
Conclusion: Our observations indicate the thyroid hormone T3 as a suitable 
factor to optimize and stimulate recovery and subsequent function of islets 
during in vitro culture suggesting that thyroid hormone could play an impor-
tant role in physiological function of pancreatic islets.
Supported by: IRICT, Republic of Korea
S 200 Diabetologia (2010) 53:[Suppl1]S1–S556
1 C
PS 28 Mitochondria in beta cells
488
Transcriptome analysis of type 2 diabetic islets: evidence of 
mitochondrial dysfunction
M. Bugliani1, R. Liechti2, L. Marselli1, U. Boggi1, F. Filipponi1, I. Xenarios2, 
P. Marchetti1; 
1University of Pisa, Italy, 2Swiss Institute of Biostatistics, Vital-IT group, 
Lausanne, Switzerland.
Background and aims: Type 2 diabetes (T2D) is a multifactoral syndrome, 
with genetic and environmental factors causing a progressive beta cell dys-
function. The molecular alterations affecting T2D islets are not fully under-
stood.
Materials and methods: We performed microarray analysis, followed by 
quantitative PCR of a few selected genes, of isolated islets from 6 T2D (age: 
71±9 yrs; gender: 3M/3F; BMI: 26.0±2.2 Kg/m2) and 7 non-diabetic (ND, 
age: 58±17 yrs; gender: 4M/3F; BMI: 24.8±2.5 Kg/m2) subjects. RNA was 
hybridized on Affymetrix chips (HG U133A). After quality control by affy 
and affyPLM, gene expression intensity values were normalized by Robust 
Multi-array Average (RMA), whereas differential expression was assessed by 
limma. Functional studies were also performed with isolated islets.
Results: When T2D islets were compared to ND, the expression of 1345 
probe sets resulted (p<0.01 and fold change of <0.5 and >2.0) different; of 
these, 59 were up-regulated and 1286 down-regulated. Overall, they identi-
fied 1230 genes, related to several beta-cell features. By using Gene Ontology 
and KEGG databases, we observed that those genes influenced 21 processes 
and 13 pathways, respectively. All the differences were confirmed by Gene 
Set Enrichment Analysis, which showed that, of the 1419 gene sets analyzed, 
195 were positively and 42 negatively enriched in T2D samples. In all the 
analyses a reduction of the expression for genes involved in oxidative phos-
phorylation and citric acid cycle was observed. Accordingly, by qPCR a sig-
nificant (p<0.02) decrease (-42%) of succinate dehydrogenase (SDH) subunit 
B expression was detected. When ND islets were exposed to methyl malonic 
acid, an inhibitor of SDH activity, a reduction (-33%) of glucose-stimulated 
insulin release was observed, that was accompanied by an alteration of the 
ADP/ATP ratio.
Conclusions: In conclusion, type 2 diabetic islets show many alterations of 
transcriptome, including changes of genes involved in mitochondrial ATP 
production; it remains to understand which alterations are cause or conse-
quence of the diabetic condition.
Supported by: EURODIA
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Mitochondrial proteome analysis reveals changes in expression of 
multiple proteins in pancreatic beta cells exposed to high glucose
S. Muhammed1, M. Ahmed1, B. Kessler2, A. Salehi1; 
1Clinical Science, Lund University, Malmö, Sweden, 2Clinical Science, 
Oxford University, United Kingdom.
Aims: Chronic hyperglycemia leads to deterioration of insulin release from 
pancreatic β-cells as well as insulin action on peripheral tissues. However, 
the mechanism underlying β-cell dysfunction resulting from glucose toxicity 
has not been fully elucidated. The aim of present study was to define a set of 
alterations in mitochondrial profiles of pancreatic β-cell lines using two-di-
mension gel electrophoresis (2-DGE) and mass spectrometry.
Material and methods: INS1E cells were incubated in the presence of 5.5 
and 20 mM glucose for 72 hrs. An aligate of media was removed for meas-
urement of insulin release (RIA) and the cells were subjected then either for 
isolation of mitochondria or were frozen for western blot analysis , protein 
profile determined by two-dimension gel electrophoresis (2-DGE) and mass 
spectrometry.
Results: More than 400 spots were detected on the colloidal coomassie stained 
2-D gels; of these protein spots, 75 displayed two fold or more significant 
change (p>0.05) in relative abundance in the presence of 20mM glucose com-
pared to the control. Thirty-three protein spots appear only on the control 
mitochondrial map. Mitochondrial proteins down regulated in glucotoxic 
conditions includes ATPsynthase α chain and δ chain, malate dehydrogenase, 
aconitase, trifunctional enzyme β subunit, NADH-cytochrome b5 reductase 
and VDAC2.There was up regulation of VDAC1, GPR75, HSP60 and HSP10.
Protein identification revealed contamination of the mitochondrial fraction 
with proteins from other organelles. These differentially expressed proteins 
includes proinsulin, calreticulin, PD1A6, PKCsubstrate60.1kDa protein 
ORP150, endopalsmin, HSC70, heterogeneous nuclear rib nucleoproteins 
D0 and A2/B1, lamin B1, histones H2B, H3.3 and H4 and elongation factor 
1-α-1. In conclusion, orchestrated changes in expression of VDAC and multi-
ple proteins involved in nutrient metabolism, ATP synthesis, cellular defence, 
glycoprotein folding, apoptosis signaling and mDNA stability may explain 
cellular dysfunction in glucotoxicity resulting in altered insulin secretion.
Supported by: Swedish Research Council
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Novel islet respirometry assay reveals high levels of uncoupled 
respiration in rodent and human islets
J.D. Wikstrom1, A. Elorza2, E.M. Allister3, L. Stiles4, S.B. Sereda1, G. Las1, 
M.B. Wheeler5, D.A. Ferrick6, O.S. Shirihai1; 
1Medicine, Boston University, Boston, USA, 2Departamento de Biologia, 
Universidad Andres Bello, Santiago, Chile, 3Departments of Physiology and 
Medicine, University of Toronto, Canada, 4Medicine/Pharmacology, Boston 
University/Tufts University, Boston, USA, 5Departments of Physiology and 
Medicine, University of Toronto, Canada, 6Seahorse Bioscience, Billerica, 
USA.
Background and aims: Mitochondrial metabolism is essential for proper 
insulin secretion as oxidative phosphorylation produces the majority of the 
cells ATP required for insulin granule exocytosis. However, mitochondrial 
substrate oxidation is not fully coupled to ATP synthesis as part of the pro-
ton gradient across the inner mitochondrial membrane reenters the matrix 
through other ways than ATPsynthase; this is termed uncoupled respiration 
or proton leak. In this study we sought to characterize the basal proton leak of 
intact islets, it’s regulation as well as its profile in diseased islets.
Materials and methods: To enable this study we developed a high-through-
put islet respirometry approach based on the XF24 platform, originally de-
signed to study monolayers of cells. By applying drugs that act on the respira-
tory chain we can estimate the level of fuel-stimulated, uncoupled, maximal 
as well as non-mitochondrial respiration under various conditions. Islets 
were derived from wildtype and high fat diet fed C57Bl6/J mice as well as 
from human donors.
Results: When stimulated with fuels mouse islets displayed a marked increase 
in respiration. The basal level of islet uncoupled respiration was measured to 
55%, strikingly higher than other cell types. We found that cellular fuels such 
as amino acids, free fatty acids and glucose significantly uncouple islet mito-
chondria and that this is prevented by antioxidants. Further we found that 
the adenine nucleotide transporter, but not the permeability transition pore, 
makes a significant contribution to the proton leak. In vitro incubation with 
palmitate did not affect the level of uncoupled respiration under low glucose, 
but had a significant effect when the islets were stimulated with high glucose. 
Further, islets from high-fat diet-fed mice exhibited higher levels of uncou-
pled respiration compared to islets from chow fed control animals. Islets with 
beta-cell specific deletion of uncoupling protein 2 (UCP2) were found to ex-
hibit normal levels of uncoupled respiration pointing to UCP2 not being a 
major contributor to the measured uncoupled respiration. In addition to the 
studies on mouse islets, human islets from healthy as well as diabetic donors 
were tested. Human islets also display high levels of uncoupled respiration 
that is increased by high glucose.
Conclusion: Islets have relative high levels of uncoupled respiration, which 
is regulated by cellular fuels and reactive oxygen species. Adenine nucleotide 
transporter but not UCP2 or permeability transition pore appears to contrib-
ute to the observed uncoupled respiration. Interestingly levels of uncoupled 
respiration increase in a diabetes animal model. In principle, tuning islet mi-
tochondrial efficiency may represent a therapeutic target.
Supported by: NIH
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Oxidative phosphorylation-dependent insulin secretion in pancreatic 
beta cells: new insights by disrupting TFB1M
T. Köck, P. Spégel, V.S. Sharoyko, C. Ling, H. Mulder; 
Clinical Sciences in Malmö, University Malmö Hospital, Sweden.
Background and aims: Oxidative phosphorylation (OXPHOS) is a mito-
chondrial metabolic pathway that uses energy released by the oxidation of 
nutrients to produce ATP. It depends on the functional status of the mito-
chondrial electron transport system (ETS). Disrupting the mitochondrial 
transcription factor B1 (TFB1M) impairs the function of the ETS complexes 
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as TFB1M regulates the translation of mitochondria encoded subunits. The 
fact that these subunits are of different importance for the individual ETS 
complexes allows us to investigate the metabolic regulation of the ETS activ-
ity, OXPHOS, and therefore insulin secretion in glucose-responsive INS-1 
832/13 clonal beta-cells in detail.
Materials and methods: Knock down (KD) of TFB1M was achieved by RNA 
interference. Oxygen consumption rates were measured using the Seahorse 
Extracellular Flux Analyzer XF24. Stable isotope-labeling with amino acids 
in cell culture (SILAC) and immunoprecipitation were used for proteomic 
analysis of the ETS complexes. ATP levels were detected by luciferase assay. 
Insulin secretion was determined by RIA.
Results: SILAC analysis and detection of TFB1M by immunoblotting con-
firmed its knock down by more than 50% in INS-1 cells. In intact cells, as pre-
dicted, TFB1M knock down significantly decreased the glucose-stimulated 
ADP-activated coupled OXPHOS capacity P (10.9 +/- 0.3 nmol O2/min/mg 
protein vs. 9.0 +/- 0.5 nmol O2/min/mg protein; P<0.01) and electron trans-
port capacity E of the ETS (15.5 +/- 0.5 nmol O2/min/mg protein vs. 12.1 +/- 
0.9 nmol O2/min/mg protein; P<0.05) as well as mitochondrial ATP genera-
tion and triggering pathway-dependent insulin secretion. Immunoblotting 
and SILAC analysis showed a decreased expression level of nucleus and mi-
tochondria encoded ETS subunits, foremost of complex I, which also showed 
the most extensive decrease in activity to 40.7 +/- 2.8 % of the activity in 
control cells. Consistently, measurements with defined metabolic substrates 
supporting ETS complex I activity in permeabilized cells demonstrated that 
P (47.9 +/- 0.8 nmol O2/min/mg protein in control vs. 33.9 +/- 1.3 nmol O2/
min/mg protein in TFB1M KD; P<0.01) and E (75.3 +/- 5.9 nmol O2/min/
mg protein in control vs. 50.4 +/- 3.5 nmol O2/min/mg protein in TFB1M 
KD; P<0.01) were affected significantly. However, measurements with sub-
strates employing complex II showed no significant differences in P and E, 
despite pronounced TFB1M knock down-dependent decreases in complex 
III and IV activity to 60.1 +/- 4.7 % and 74.5 +/- 3.5 % of the activity in con-
trol cells, respectively.
Conclusion: (1) ETS complex I activity is rate-limiting for the metabolite-
stimulated electron transport of the ETS and therefore OXPHOS and ATP 
generation in beta-cells. (2) 832/13 clonal beta-cells employ significant excess 
capacity of complex III and IV activity (3) Mitochondrial OXPHOS is cru-
cial for the fuel stimulation of insulin secretion. (4) In INS-1 832/13 clonal 
beta-cells, disruption of mitochondrial translation profoundly affects mito-
chondrial function, predominantly by diminished complex I stability. Thus, 
based on these novel findings, further studies concerning the mechanisms of 
metabolic regulation of ETS activity and OXPHOS and therefore mitochon-
dria-based metabolic coupling of insulin secretion open a new avenue for 
research in pancreatic islet cell biology.
Supported by: VR
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The Atp8 mutation of complex V impairs secretory function of beta cells 
- role of mitochondrial ROS and ATP in response to glucose challenge
H. Weiss1, C. Koch1, L. Wester-Rosenloef1, S. Ibrahim2, M. Tiedge1; 
1Institute of Medical Biochemistry and Molecular Biology, University 
of Rostock, 2Department of Dermatology, Allergology and Venereolgy, 
University of Lübeck, Germany.
Background and aims: The conplastic mouse strain B6mtFVB carries a stable 
mtDNA mutation of the Atp8 gene affecting the assembly of the Fo subunit 
of the ATP-synthase complex. It was the aim of the study to correlate secre-
tory responsiveness to glucose with ATP/ADP levels and mitochondiral ROS 
generation in comparison to the B6mtAKR control strain.
Materials and methods: B6mtFVB and B6mtAKR were regularly monitored for 
blood glucose and tested for glucose tolerance feeding standard diet. Pan-
creatic islets were isolated from normoglycaemic mice (age 12 - 16 weeks) 
and cultured at 5 or 30 mmol/l glucose for 24 h and 48 h. Production of 
mitochondrial superoxides was measured by the MitosoxTM indicator using 
fluorescence microscopy. Cellular ATP and ADP levels in isolated islets were 
measured by a luminometric assay. Glucose stimulated insulin secretion of 
isolated islets was measured by ELISA.
Results: B6mtFVB as well as B6mtAKR mice showed normal blood glucose lev-
els (5.8 ± 0.4 vs. 6.8 ± 0.6 mmol/l). Both strains showed a normal glucose 
tolerance when challenged with 1 g glucose/kg b. wt. Exposure of isolated 
B6mtFVB islets to 30 mmol/l glucose for 24 h or 48 h resulted in a significant 
decrease of glucose-stimulated insulin secretion by 80 % (p < 0.001) and 50 
% (p < 0.05) in comparison to B6mtAKR islets. Basal as well as glucose-stimu-
lated (2.8 vs. 20 mmol/l) insulin secretion were not different between the two 
mouse strains when the islets were pre-cultured at 5 mmol/l glucose for 24 
h or 48 h. Islets from B6mtAKR mice showed a 4-fold increase of ATP levels 
when glucose concentrations were increased from 2.8 to 20 mmol/l. ATP lev-
els in islets from B6mtFVB mice were insensitive to changes of glucose. The 
ATP/ADP ratio was 2.5-fold higher in islets from B6mtAKR mice in compari-
son to the B6mtFVB strain after 24 h preculture at 30 mmol/l glucose. In islets 
from B6mtFVB mice mitochondrial ROS generation increased significantly at 
30 mmol/l glucose while there were only slight increases in islets from B6m-
tAKR mice. However, mitochondrial ROS generation at 5 mmol/l glucose was 
higher in islet cells from B6mtAKR mice than in islets from the B6mtFVB strain. 
Preculture of islet cells at 30 mmol/l glucose for 24 h or 48 h did not signifi-
cantly affect cell viability in the B6mtFVB and B6mtAKR strain.
Conclusion: The beta cell dysfunction in islets with the Atp8 gene mutation 
is plausibly explained by reduced ATP production through complex V of the 
respiratory chain. In line with metabolic stimulus-secretion coupling this re-
sulted in reduced glucose-responsiveness of insulin secretion. Mitochondrial 
ROS generation in B6mtFVB islets is more sensitive to high glucose than in 
B6mtAKR islets. Our data provide evidence that in islets with Atp8 gene muta-
tions adaptive changes of mitochondrial ROS generation rather than absolute 
levels are important to induce beta cell dysfunction under conditions of nu-
trient stress.
Supported by: German Diabetes Association (DDG)
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Marked, but not moderate induction of uncoupling protein 2 enhances 
selected aspects of beta cell mitochondrial metabolism and decreases 
susceptibility to toxicity
I. Hals1, Z. Ma2, H. Ogata1, A. Björklund2, V. Grill1,2; 
1Department of Cancer Research and Molecular Medicine, Norwegian 
University of Science and Technology, Trondheim, Norway, 2Department of 
Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Background and aims: The effects of uncoupling protein 2 (UCP-2) for mi-
tochondrial metabolism, for beta cell function and for propensity of diabetes 
have been intensely studied. However, because of conflicting results no agree-
ment on the role(s) of UCP-2 has been reached. Different degrees of induc-
tion or inhibition of UCP-2 between studies could be an important but unex-
plored reason for conflicting results. Here we investigated effects of a fourfold 
induction on mitochondrial, insulin and toxicity parameters and tested for 
replication of positive findings at a lower level of induction.
Materials and methods: We transfected INS-1 cells to obtain a tet-on induc-
ible cell line. A 48 h exposure to 1 μg/ml of dox induced UCP approximately 
fourfold (424 ± 113 %, mean ± SEM) and 0.1 μg/ml twofold (178 ± 29%, n 
= 3).
Results: Fourfold induced cells displayed normal mitochondrial membrane 
potential (by Rhodamine 123), normal mitochondrial mass (Mitotracker 
Green) and normal ATP levels. By immunoblotting subunits of complex 1 
(ND6) and 2 (FeS) and 4 (COX I) were not changed. However, core2 for com-
plex III was up-regulated 17 %, and α subunit for complex V by 20%. Glucose 
oxidation (at 11 mM glucose) was not significantly affected (+5 ± 9 %, n = 6), 
however, oxidation of fatty acids (14C-oleate) was increased by 35 ± 15 % (p < 
0.05, n = 12). Cellular insulin contents (-4 ± 7 %, n = 3) and glucose-induced 
insulin secretion were not affected (+27 ± 11 %, n = 5), nor insulin responses 
to oleate. A fourfold induction protected against H2O2-induced toxicity by 
22 ± 5 % (p < 0,01, n = 8, MTT assay and flow cytometry). However, the 
lower (approximately two-fold) induction of UCP-2 did not reproduce mi-
tochondrial and metabolic effects, nor protection against toxicity effects (and 
susceptibility towards the latter was not aggravated by UCP-2 down-regula-
tion by siRNA).
Conclusion: A fourfold induction of UCP-2 induces subtle but definite en-
hancing effects on mitochondrial metabolism and also toxicity protection. 
However, lack of reproducibility at lower levels of induction as well as lack 
of a negative effect on insulin parameters argues against an important role of 
UCP-2 in beta cells in diabetes.
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Cytosolic phosphate, a regulator of mitochondrial function in insulin-
secreting cells
K.-S. Park1,2, X. Quan1, R. Das1, S. Xu1, A.C. Wiederkehr2, C.B. Wollheim2; 
1Physiology, Yonsei University, Wonju College of Medicine, Wonju, 
Republic of Korea,, 2Cell Physiology and Metabolism, University of Geneva, 
Switzerland.
Background and aims: Mitochondrial energy metabolism depends on the 
continued uptake of ADP and inorganic phosphate as substrates of the ATP 
synthase and the export of the product ATP from the organelle. The exchange 
of ATP against ADP is mediated by the adenine nucleotide translocase 
(ANT). Uptake of inorganic phosphate by mitochondria is linked to the net 
uptake of one proton per phosphate anion. Here we tested whether inorganic 
phosphate regulates mitochondrial energy metabolism in INS-1E cells in ad-
dition to its role as a substrate for the ATP synthase.
Materials and methods: Mitochondrial ATP synthesis was studied in staphy-
lococcal alpha-hemolytic toxin permeabilized INS-1E cells. This treatment 
leaves the membranes of intracellular organelles such as mitochondria intact 
and allows us to distinguish between intraorganellar ATP and the ATP pool 
released from mitochondria. ATP was measured with a bioluminescence as-
say. A fluorescence microscopic imaging system was used to study the mi-
tochondrial matrix pH and a microplate reader to record the mitochondrial 
membrane potential with JC-1.
Results: Permeabilised INS-1E cells showed mitochondrial membrane hyper-
polarisation and matrix alkalinization in response to substrates such as suc-
cinate or glycerolphosphate. We find that the hyperpolarisation was strongly 
dependent on the extramitochondrial phosphate concentration. Phosphate 
addition alone induced mitochondrial matrix acidification in permeabilised 
cells. Matrix alkalinization induced by succinate was less dependent on the 
extramitochondrial phosphate concentration than mitochondrial hyperpo-
larisation. ATP release from mitochondria induced by substrate but not the 
increase of the organellar pool of ATP was completely blocked by atractylo-
side, an inhibitor of the ANT. ATP release was also strictly dependent on the 
presence of extramitochondrial ADP, implying that ATP release from mito-
chondria is exclusively dependent on ANT activity. Upon stimulation with 
mitochondrial substrates, the amount of ATP exported from mitochondria 
was markedly accelerated by increased phosphate concentrations contrasting 
with the modest elevation of ATP inside the mitochondria.
Conclusion: We demonstrate that the cytosolic phosphate concentration has 
a strong impact on the mitochondrial electrochemical gradient, ATP synthe-
sis and ATP export from the organelle. Our results suggest that inorganic 
phosphate affects mitochondrial energy metabolism beyond its role as a sub-
strate for ATP synthesis. As large changes in phosphate transport across the 
plasma membrane have been reported in islets, our results emphasize the 
importance of cytosolic inorganic phosphate concentrations in metabolism-
secretion coupling.
PS 29 Glucose and mitochondrial 
metabolism
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Naturally occurring glucokinase mutations at the same amino acid 
residue cause opposite clinical phenotypes of hypo- and hyperglycaemia
N.L. Beer1, N.D. Tribble1, K. Colclough2, P. Arundel3, J. Grimsby4, C. Chik5, 
S. Ellard2, A.L. Gloyn1; 
1OCDEM, University of Oxford, 2Royal Devon & Exeter NHS Trust, Exeter, 
3Sheffield Children’s NHS Foundation Trust, Sheffield, United Kingdom, 
4Department of Metabolic Disease, Hoffman-La Roche Inc., Nutley, 
USA, 5Division of Endocrinology & Metabolism, University of Alberta, 
Edmonton, Canada.
Background and aims: Glucokinase (GCK) mutations cause disorders of glu-
cose homeostasis. Heterozygous activating and inactivating mutations cause 
hyperinsulinaemia of infancy (HI) and maturity-onset diabetes of the young 
(MODY) respectively. Activating mutations cluster at the allosteric activator 
site, a target for pharmacological GCK activators (GKAs) which are currently 
in development. This study reports 2 novel activating mutations (V389L & 
T103S), at residues where GCK-MODY mutations (V389D & T103N) have 
also been reported. We hypothesised that the physiochemical properties and 
position of the substituted residue could result in opposite phenotypes. We 
structurally and functionally characterised these mutations in the presence 
and absence of GCK regulators, providing further insight into critical resi-
dues within this important drug target.
Materials and methods: Recombinant human wild-type (WT) GCK and 
all 4 mutants were generated. Enzyme kinetic activity was determined spec-
trophotometrically using an NADP+-coupled assay. Kinetic characteristics 
and responses to the physiological inhibitor glucokinase regulatory protein 
(GKRP) and pharmacological GKA RO0281675 were calculated. Structural 
modelling and bioinformatic analysis were performed using PyMOL.
Results: Both HI mutations were kinetically activating with relative activity 
indices (RAI) of 6.0 and 8.4 for V389L and T103S respectively (vs 1.0 for 
WT). This higher activity was driven by an increased affinity for glucose (glu-
cose S0.5 3.5 ± 0.1 for V389L, 3.3 ± 0.1 for T103S, 7.5 ± 0.1mM for WT). The 
MODY mutation V389D had dramatically decreased enzyme activity (RAI 
<0.1). Paradoxically the T103N MODY mutation was mildly kinetically acti-
vating (S0.5 5.8 ± 0.1mM, Kcat 51.5 ± 1.1S
-1, RAI 1.5). Inhibition assays showed 
a similar response to GKRP for WT and V389L (IC50 both 1.1 ± 0.1 GKRP 
units), whilst T103S and -N had decreased affinity (1.5 ± 0.1 and 1.9 ± 0.1 
respectively). All mutations responded to the GKA; T103N had a similar fold 
increase in Kcat/S0.5 to WT (18.0 ± 1.5 vs 14.4 ± 0.3 respectively), whilst that 
for T103S & V389L was lower (5.7 ± 0.5 and 7.4 ± 1.3 respectively). V389D 
Kcat/S0.5 increased considerably (33.9 ± 2.1). V389 lies within an α-helix, with 
both mutations causing extra intra-helical bonds. T103 is in a β-sheet close to 
the allosteric activator site, both mutations losing an intra-strand bond whilst 
forming new polar interactions.
Conclusion: Different physiochemical properties of substituted residues 
within GCK can determine clinical phenotype. V389 (or its α-helix) is inte-
gral to protein activity, with its mutation affecting glucose turnover. T103 lies 
in a β-sheet close to the allosteric activator site. Both T103S/N have increased 
GCK activity, suggesting the pathogenesis for T103N may be due to catalytic 
instability (reflected by decreased GKRP affinity). Our study has implications 
for drug development, as it demonstrates a fine balance between catalytic and 
structural stability upon intervention at certain GCK residues/areas of GCK 
secondary structure.
Supported by: Medical Research Council
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Identification of an ubiquitin-like domain as a potential new interaction 
partner of glucokinase in pancreatic beta cells
A. Brix1, K. Kollmann1, S. Langer1, S. Lenzen1, S. Baltrusch2; 
1Institute of Clinical Biochemistry, Hannover Medical School, 2Institute 
of Medical Biochemistry and Molecular Biology, University of Rostock, 
Germany.
Background and aims: In pancreatic beta cells, glucokinase (GK) acts as a 
glucose sensor and catalyzes the rate-limiting step for initiation of glucose-in-
duced insulin secretion. GK is mainly regulated on the posttranslational level 
by protein-protein interactions. The bifunctional enzyme 6-phosphofructo-
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2-kinase/fructose-2,6-bisphosphatase serves as an activating GK interaction 
partner in both, beta cells and liver. In contrast an inhibiting GK protein, the 
GK regulatory protein is only expressed in liver, but not in beta cells. This 
raised the question whether unidentified beta cell specific GK interaction 
partners exist. Therefore the aim of this study was to identify beta cell specific 
GK interaction partners through a yeast two hybrid (YTHS) screening of a 
rat islet library.
Materials and methods: RNA isolated from rat pancreatic islets was used to 
generate a cDNA library by SMART technology (Clontech). Recombination 
of the cDNA library with the pGADT7-R vector was performed in S. cer-
evisiae AH109. Mating with the pGBKT7-GK containing S. cerevisiae Y187 
yeast strain was established resulting in analysis of 5.5 x 105 clones in three 
independent runs. Initially positive clones were characterized by histidine 
(His) and adenine (Ade) reporter gene assays in yeast. Thereafter binding to 
GK was determined in MIN6 beta cells using a recently established fluores-
cence based mammalian two-hybrid system (MMTHS) in a high-throughput 
scanR (Olympus) microscopy setup.
Results: 73 positive clones were selected by His reporter gene expression in 
yeast, whereas four clones showed also significant Ade reporter gene expres-
sion. In YTHS experiments with the control plasmid lamin only one clone 
exhibited specific interaction with GK. Sequence and protein database analy-
ses revealed a 180 amino acid containing protein fragment with homology 
to the N-terminal part of midnolin 2 of mus musculus. Thus, no full-length 
protein was discovered. However, a complete sequence of an ubiquitin-like 
domain (UbD) consisting of 72 amino acids was identified inside of the pro-
tein fragment by NCBI-BLAST data base analyses and further analyzed in 
the MMTHS. For this the UbD was subcloned in frame with the binding 
domain (pBIND-ECFP-UbD), and interaction with GK subcloned in frame 
with the activation domain (pACT-GK) in comparison to control (pACT) 
was elucidated in single MIN6 beta cells. Interestingly, a specific interaction 
between the UbD and GK determined as an increase of the EYFP reporter 
gene expression in relation to the constitutively expressed ECFP fluorescence 
over time was elucidated.
Conclusion: We have identified an ubiquitin-like domain as a potential new 
GK binding partner. Recently an ubiquitin interacting motif has been discov-
ered in GK. As the ubiquitin-proteasome pathway plays an important role in 
pancreatic beta cells our study supports the hypothesis of GK regulation by 
ubiquitination.
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The novel naturally occurring activating glucokinase gene mutation 
E442K maintains INS-1E cell proliferation and protects against glucose-
induced apoptosis
A.L. Cuesta-Muñoz1, N. Cobo-Vuilleumier1, R. Araujo2, P. Rodriguez-
Bada1, A. Gavito1, E. Baixeras1, F. Martin2, F. Bedoya3, A. Bernad4,  
B. Gauthier5; 
1Centre for the Study of Pancreatic Beta-cell Diseases, IMABIS Foundation, 
Málaga, 2Pancreatic Islets and Stem Cells, CABIMER, Sevilla, 3Celular 
Therapy and Regenerative Medicine, CABIMER, Sevilla, 4Regenerative 
Cardiology, CNIC, Madrid, 5Pancreatic Islet Development and 
Regeneration, CABIMER, Sevilla, Spain.
Background and aims: In addition to its glucose sensor function in islet beta 
cells, glucokinase (GK) has recently been proposed to participate in cell pro-
liferation and survival. These GK-mediated effects appear to require IRS-2 
and BAD, respectively. We have previously described in humans two novel 
mutations located almost contiguously in the same domain of GK yet hav-
ing opposite clinical phenotypes: a naturally inactivating (GCK-E440G) and 
activating (GCK-E442K) GK mutations which cause monogenic diabetes and 
congenital hypoglycaemia, respectively. In order to establish a potential link 
between GK activity and beta cell survival as well as expansion, we constitu-
tively expressed these mutant variants in the insulinoma INS-1E cell line.
Materials and methods: Using lentiviral technology, we created stable clones 
of INS-1E cells constitutively expressing GK (INS-1E-cmv.GCK-WT.ires.
GFP), the two mutant variants (INS-1E-cmv.GCK-E440G.ires.GFP, INS-1E-
cmv.GCK-E442K.ires.GFP) or the control GFP lentiviral vector (INS-1E-
cmv.ires.GFP). Transcript levels for GK, E442K, E440G, GFP, BAD and IRS2 
were determined by quantitative real time RT-PCR (QT-PCR). Acute insulin 
secretion in response to glucose (3 and 15 mM) was also measured. In addi-
tion, the impact of increasing concentration of glucose (3, 11 and 20 mM) on 
proliferation and survival was estimated at 72 hours.
Results: Overexpression of GK or E442K in INS-1E did not alter glucose-in-
duced insulin secretion (GSIS) as compared to control GFP cells. In contrast, 
overexpression of the inactivating mutation E440G resulted in impaired GSIS. 
QT-PCR revealed that both the GK and E442K transcript were expressed at 
similar levels whereas E440G was at least 5-fold higher, explaining the poten-
tial altered GSIS. Similar results were found with GFP transcript levels. In-
terestingly, BAD and IRS2 expression levels remained unaltered in all clones 
as compared to control GFP cells. More importantly, our results showed that 
after 72 hours at either 3 mM or 20 mM glucose, the clone expressing the 
E442K variant displayed significantly reduced apoptosis (12- and 6-fold, re-
spectively) whereas the E440G only protected cells at low (2-fold) but not at 
high glucose as compare to GFP expressing cells. GK had no protective effect. 
In contrast all clones exhibited protection at 11 mM glucose (6-fold as com-
pared to GFP), corresponding to normal culture conditions. Proliferation at 
11 or 20 mM glucose was identical for all clones. Astonishingly, the E442K 
clone was also able to sustain proliferation even at 3 mM glucose.
Conclusion: Taken together, our results indicate that the naturally occur-
ring activating mutation GK-E442K may convey protection and maintain 
proliferation of β-cells under altered glycaemic conditions. Yet, the fact that 
the inactivating mutation GK-E440G, located in the vicinity of the E442K, 
also protects at low glucose suggests an insulin independent effect. We are 
currently investigating a potential link between the BAD protein and these 
mutant variants in β-cell survival.
Supported by: FPYS to BRG; SAF2006-12863; SAS/PI-0236/2009 to AC-M
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Activation of PPARδ promotes mitochondrial energy metabolism and 
decreases basal insulin secretion in palmitate-treated beta cells
L. Jiang, J. Wan, L.-Q. Ke, Q.-G. Lü, N.-W. Tong; 
Sichuan University, Chengdu, China.
Background and aims: The peroxisome proliferator-activated receptor 
δ(PPARδ)regulates the expression of genes involved in cellular lipid and cell 
energy metabolism in many metabolically active tissues, such as liver, muscle 
and fat and plays a role in the cellular response to stress and environmental 
stimuli. The particular role of PPARδ in insulin-secreting beta-cells, however, 
is not as well understood; therefore, our aim was to investigate the cell-spe-
cific role of PPARδ on mitochondrial energy metabolism and insulin secre-
tion in beta-cells.
Materials and methods: After exposing a Syrian hamster pancreatic beta-cell 
line, HIT-T15, to high-concentrations of palmitate and/or the specific PPARδ 
agonist GW501516, we detected the gene expression changes for transcripts 
associated with mitochondrial biogenesis, such as peroxisome proliferator-
activated receptor gamma co-activator 1 (PGC-1α), nuclear respiratory factor 
1 (NRF-1), mitochondrial transcription factor A (mtTFA), using real-time 
quantitative polymerase chain reaction (RTQ-PCR). The protein levels of the 
mitochondria uncoupling protein 2 (UCP2) were measured by western blot 
analysis; the insulin secretion capacity and ATP/ADP ratio were analyzed 
using enzyme linked immunosorbent assay (ELISA) and high performance 
liquid chromatography, respectively.
Results: Activation of PPARδ promoted generation of mitochondrial ATP, as 
well as expression levels of PGC-1α, NRF-1 and mtTFA in palmitate-treated 
HIT-T15 cells. Activated PPARδ also decreased basal insulin secretion, but 
had no effect on glucose-stimulated insulin secretion (GSIS) via increased 
amounts of UCP2.
Conclusion: GW501516 treatment enhanced mitochondrial energy metabo-
lism, but it also promoted a concomitant mitochondrial uncoupling and re-
sulted in decreased basal insulin secretion and restricted GSIS. Activation of 
PPARδ induced a reduction of basal insulin secretion, but did not appear to 
improve GSIS; this observation indicated the possible action of a protective 
mechanism responding to the alleviation of basal insulin load in lipotoxic 
beta-cells.
499
Role if tissue specific alterations of mitochondrial dynamics in 
development of type 2 diabetes
J. Schultz, S. Baltrusch; 
Institut of Medical Biochemistry and Molecular Biology, Rostock, Germany.
Background and aims: Mitochondrial dysfunction has been proposed to 
play an important role in the development of type 2 diabetes. Mitochondrial 
function is regulated in a tissue specific manner and in recent studies mito-
chondrial dynamics have been elucidated to be important to maintain cellu-
lar metabolism. Mitochondria constitute a mobile network that continuously 
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cycle through fusion and fission events. By this process dysfunctional mito-
chondria are segregated and their removal by autophagy is initiated. Mito-
fusin 1 and 2 (Mfn1 and Mfn2) and the optic atrophy 1 (Opa1) are essential 
for mitochondrial fusion, whereas the fission protein 1 (Fis1) and the dy-
namin related protein 1 (Drp1) control fission. Alterations in mitochondrial 
function may be evoked by obesity, and thus, crucial to explain both insulin 
resistance in peripheral tissue and pancreatic beta cell dysfunction resulting 
in impaired insulin secretion in type 2 diabetes. Therefore the aim of this 
study was to investigate tissue specific alterations in mitochondrial dynamics 
in obese ob/ob mice compared to normal weight control mice.
Materials and methods: Islets from obese ob/ob mice (B6.V-lebob) and con-
trol mice (C57BL/6J) were isolated by collagenase digestion. Furthermore 
liver, muscle, adipose tissue and brain were taken from ob/ob and control 
mice. RNA and protein were isolated and quantitative Real-Time PCR anal-
yses and western blot analyses of Fis1, Drp1, Opa1, Mfn1 and Mfn2 were 
carried out, respectively. Additionally frozen sections were made for immun-
ofluorescence analyses.
Results: Gen expression of Fis1, Drp1, Opa1, Mfn1 and Mfn2 in islets of 
obese ob/ob mice was significantly reduced compared to control mice and 
the resulting expression pattern indicated an imbalance of mitochondrial fu-
sion and fission processes. In liver Fis1 was down regulated in ob/ob mice 
compared to control, while Drp1 was up regulated. As both proteins cannot 
replace each other, fission was disturbed in liver of ob/ob mice. Furthermore 
immunofluorescence analyses revealed an inhomogeneous expression pat-
tern of fission proteins in liver of ob/ob mice. Additionally Mfn1 and Mfn2 
were significantly reduced on the gene as well as protein level in liver of ob/
ob mice. Interestingly Mfn2 a protein which plays a role in mitochondrial 
substrate oxidation was significantly down regulated in islets, liver, muscle 
and adipose tissue, but not in the brain of ob/ob mice compared to control. 
Gene and protein expression of Fis1, Drp1, Mfn1 and Mfn2 was reduced in 
adipose tissue and muscle of ob/ob mice compared to control, but in muscle 
to a much higher extent. Solely in muscle a significant down regulation of the 
Opa 1 protein was determined.
Conclusion: We have observed tissue specific changes in mitochondrial dy-
namic in obese mice compared to normal weight control mice. In future ex-
periments we will elucidate whether these alterations are a reversible adaptive 
process maintaining cell function or represent mitochondrial dysfunction. In 
conclusion, our study provides further evidence that obesity induced mito-
chondrial alterations contribute to the development of type 2 diabetes.
500
Implication of mitochondria in IAPP induced-beta cell toxicity
M. Soty, M. Visa, L. Cadavez, M. Carmona, A. Novials; 
Laboratori de Diabetis i Obesitat, IDIBAPS, Hospital Clínic, CIBER de 
Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Barcelona, 
Spain.
Background and aims: Type 2 diabetes is characterised by islet dysfunctions 
that lead to the impairment of insulin secretion. The presence of islet amyloid 
deposition is a recognised hallmark in islets of type 2 diabetes patients. Amy-
loid fibrils are formed by human islet amyloid polypeptide (hIAPP). There 
is now very strong evidence supporting the key role of amyloidogenesis in 
the progressive loss of pancreatic beta-cell mass and function. Mitochondria 
have a central role in the regulation of insulin secretion since the latter is 
largely controlled by ATP production through oxidative phosphorylation 
(OXPHOS) taking place in the mitochondrial respiratory chain. The main 
objective of this project is to investigate whether mitochondria may play a 
role in the mechanisms by which human IAPP induces beta-cell cytotoxic-
ity.
Materials and methods: The rat pancreatic beta-cell line INS1E was stably 
transfected with a hIAPP plasmid (hIAPP cells) or pcDNA3 (control cells). 
In order to characterise the impact of hIAPP on beta-cell function, we meas-
ured insulin and IAPP secretion and intracellular calcium mobilisation in 
response to glucose. Calcium levels were measured using Fura-2 labelling. 
Mitochondrial function was explored by monitoring cellular respiration, 
mitochondrial membrane potential and reactive oxygen species (ROS) pro-
duction. Rhodamine 123 and CM-H2DHCFA probes were used to monitor 
membrane potential and ROS levels, respectively.
Results: In response to 16,7 mM glucose, insulin and IAPP secretion was 
strongly decreased in hIAPP compared with control cells (3.5 ± 0.7 vs 15.6 
± 2.9 % insulin release expressed as a percentage of cellular insulin content 
and 2.6 ± 0.9 vs 8.7 ± 1.4 % IAPP release expressed as a percentage of cellular 
IAPP content, p<0.01). Consistent with these results, the study of calcium sig-
nals demonstrated an absence of response to glucose in hIAPP cells. Whereas 
76,61% of control cells (194/201) exhibited a normal response to 16.7mM glu-
cose, none of the hIAPP cells tested were able to respond to glucose (0/192). 
hIAPP cells showed an oxygen consumption higher than control cells which 
is likely due to an increase in uncoupled respiration (25.8 ± 2.2 vs 15.6 ± 2.5 
pmol/s/million of cells, p<0.05). Moreover, hIAPP cells exhibited a signifi-
cantly increased mitochondrial membrane potential relative to control cells 
which is represented by a greater decrease of probe fluorescence in response 
to glucose stimulation (64.02 ±1.45 vs 79.57 ± 1.73 % leftover fluorescence 
relative to 2.2 mM glucose, p<0.05). In addition, hIAPP cells cultured in 16.7 
mM glucose for 24h had significantly elevated ROS levels compared to con-
trol cells cultured in the same conditions (1.37 ± 0.1 vs. 1.01 ± 0.02 fold over 
2.2 mM glucose, p<0.01).
Conclusion: Our preliminary results show that hIAPP overexpression de-
creased glucose stimulated insulin and IAPP secretion. Those results could be 
explained by an inhibition of intracellular calcium mobilisation, an increased 
ROS generation in response to glucose, and an altered mitochondrial func-
tion.
Supported by: FIS(PI08/0088)
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PS 30 Cytokines and beta cell 
survival
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Mimitin overexpression protects insulin-producing INS1E cells against 
cytokine-induced apoptosis via prevention of MAP1S action
K. Hanzelka, S. Lenzen, E. Gurgul-Convey; 
Institute of Clinical Biochemistry, Hannover Medical School, Germany.
Background and aims: Mimitin is a mitochondrial protein, which was 
shown to be induced by cytokines in insulin-producing cells. It has been re-
ported that in some cell types it can interact with a partner protein called 
MAP1S. MAP1S is a microtubule associated protein, which triggers a cyto-
plasmic signal for apoptosis, mainly via induction of ER stress. The aim of 
this study was to investigate the possible interaction of these two proteins 
in insulin-producing cells and the influence of mimitin overexpression on 
cytokine-stimulated apoptotic pathways.
Materials and methods: Insulin-producing INS1E cells and INS1E-hMim 
cells (overexpressing mimitin) were used. The cells were treated with IL-1 
beta 600 U/ml or with a cytokine mixture (60 U/ml IL-1 beta, 175 U/ml 
TNF-alpha and 14 U/ml IFN-gamma) for 24 h. Cell viability was estimated 
by MTT assay, cell proliferation by BrdU incorporation, NF-kappa B by an 
SEAP reporter gene assay, nitrite accumulation was determined by the Griess 
method and caspase activation was quantified by flow cytometry. Fluorescent 
microscopy was used to analyze mimitin and MAP1S expression.
Results: The analysis of mimitin and MAP1S expression using specific fluo-
rescent probes revealed that mimitin resided in the mitochondria, while 
MAP1S was in the cytoplasm. Upon exposure to cytokines mimitin partially 
moved from mitochondria into the cytoplasm and interacted there with 
MAP1S. Overexpression of mimitin protected INS1E cells against cytokine 
toxicity and prevented deleterious effects of cytokines towards cell prolifera-
tion (MTT 24h: INS1E IL-1 beta 58%, cytokine mix 37% vs. INS1E-hMimitin 
IL-1 beta 84 %, cytokine mix 57%; proliferation rate after 24h: INS1E IL-1 
beta 58%, cytokine mix 28% vs. INS1E-hMimitin IL-1 beta 85%, cytokine 
mix 54%). The cytokine-induced caspase-3 activation was completely abol-
ished in INS1E-hMim cells (24 h, INS1E: IL-1 beta 156 ± 16, cytokine mix 
165 ± 19; INS1E-hMim: IL-1 beta 110 ± 11, cytokine mix 88 ± 10). The mi-
tochondrial caspase-9 activation induced by cytokines was not affected by 
mimitin overexpression (24 h, INS1E: IL-1 beta 188 ± 16, cytokine mix 181 
± 16; INS1E-hMim: IL-1 beta 129 ± 5, cytokine mix 150 ± 11). Interestingly, 
caspase-8, triggering the extrinsic apoptotic pathway and caspase-12, associ-
ated with the ER stress response, were both downregulated by mimitin over-
expression (caspase 8 after 24 h, INS1E: IL-1 beta 187 ± 14, cytokine mix 
138 ± 8; INS1E-hMim IL-1 beta 110 ± 8, cytokine mix 108 ± 8; caspase-12, 
INS1E: IL-1 beta 151 ± 11, cytokine mix 198 ± 17; INS1E-hMim: IL-1 beta 
105 ± 10, cytokine mix 116 ± 15). No significant effect of mimitin overexpres-
sion on the NF-kappa B-iNOS pathway was observed.
Conclusion: Mimitin prevents cytokine-induced death of insulin-producing 
cells and stimulates cell proliferation. We hypothesize that the protective ef-
fect of mimitin against cytokine-induced apoptosis occurs via prevention of 
cytotoxic action of the proapoptotic protein MAP1S.
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Expression of iNOS in pancreatic islets of human type 2 diabetic patients
A. Balhuizen, S. Muhammed, R. Kumar, A. Salehi; 
Department of Clinical Sciences, Lund University, Malmö, Sweden.
Background and aims: Accumulating data suggest that nitric oxid (NO) 
produced by inducible NOS (iNOS) play an essential role in the β-cell dys-
function and apoptosis. The main purpose of this investigation was to clarify 
whether the iNOS derived NO is involved in secretory defect and β-cell dys-
function of pancreatic islets isolated from human type 2 diabetic patients is 
associated with exaggerated NO production through the induction of iNOS 
expression.
Materials and methods: iNOS expression was analyzed by confocal micros-
copy, Western blot and qPCR in islets from both human type 2 diabetic and 
non-diabetic donors. Hormone secretion was determined with RIA.
Results: Confocal microscopy revealed that iNOS is expressed in pancreatic 
islet cells (insulin, glucagon and somatostatin) of type 2 diabetic subjects 
and that no iNOS was detected in islets from normal human donors. iNOS 
mRNA and protein expression was markedly higher in diabetic vs normal 
human islets (p<0.001). The hormone secretory pattern of type 2 diabetic 
pancreatic islets incubated at different glucose concentrations showed a re-
duced insulin and somatostatin response to glucose. The suppressing effect 
of glucose on glucagon secretion was not observed in the incubated islets of 
type 2 diabetic subjects.
Conclusion: Our data shows that long term hyperglycemia seen in human 
type 2 diabetic patients, based on their HbA1c, might result in the expression 
of iNOS in the pancreatic islets which consequently might disrupt he normal 
β-cell function.
Supported by: Swedish Science Council
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Mcl-1 degradation by pro-inflammatory cytokines and palmitate is an 
early and major event for beta cell apoptosis
A.K. Cardozo1, D. Cunha1, F. Moore1, J. Vanderwinden2, D.L. Eizirik1,  
F. Allagnat1; 
1Laboratory of Experimental Medicine, 2Laboratory of Neurophysiology, 
Université Libre de Bruxelles, Belgium.
Background and aims: Apoptosis of the insulin-secreting pancreatic beta 
cell is a key feature of diabetes mellitus and the mitochondrial pathway of 
apoptosis is a major mediator of beta cell death. The myeloid cell leukemia 
sequence 1 (Mcl-1) is an important anti-apoptotic protein of the Bcl-2 family, 
a group of proteins involved in the mitochondrial pathway of apoptosis. The 
aim of this study was to evaluate the role of Mcl-1 in beta cell apoptosis.
Materials and methods: We studied the effect of pro-inflammatory cy-
tokines (IL-1β or TNF-α, in combination or not with IFN-γ), free fatty acids 
(palmitate or oleate), and chemical ER stressors (CPA, thapsigargin, tuni-
camycin) on Mcl-1 mRNA and protein expression in INS-1E cells, and, in 
selected experiments, in FACS-purified rat beta cells. Using mRNA silencing 
and recombinant adenoviruses, we studied the effect of Mcl-1 knockdown 
and overexpression on beta cell function and apoptosis. Expression of Mcl-1 
and key downstream genes and proteins were measured by real time RT-PCR 
and/or Western blot. Localisations of Bax and cytochrome c were studied 
by immunofluorescence in cells overexpressing Mcl-1 and treated with cy-
tokines, palmitate or thapsigargin. Cell viability was evaluated by HO 342 
and propidium iodide.
Results: All cytotoxic stresses described above increased Mcl-1 mRNA ex-
pression by 2 fold, but rapidly and preferentially decreased Mcl-1 protein 
expression by 30 to 60% (p< 0.05). ER stress-induced Mcl-1 down-regula-
tion was prevented upon PERK knock down and resulting inhibition of 
eIF2α phosphorylation, indicating that translation arrest contributes to Mcl-1 
downregulation. Additionally, the effect of cytokines on Mcl-1 expression was 
also partially prevented in presence of a JNK inhibitory peptide. Knocking-
down Mcl-1 using siRNAs increased by 40% apoptosis and caspase 3 cleavage 
induced by cytokines, palmitate or thapsigargin (p<0.01). On the other hand, 
Mcl-1 overexpression reduced by 50% Bax translocation to the mitochondria, 
cytochrome c release, caspase 3 cleavage and apoptosis induced by the beta 
cell death effectors (P< 0.01). Neither Mcl-1 knockdown nor overexpression 
modified basal or glucose-stimulated insulin secretion.
Conclusion: The present data suggest that Mcl-1 downregulation is a crucial 
event leading to beta cell apoptosis and provide new insights in the mecha-
nisms linking ER stress and the mitochondrial intrinsic pathway of apoptosis. 
Mcl-1 is therefore an attractive target for the design of new strategies in the 
treatment of diabetes.
Supported by: JDRF, FNRS Belgium
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Effects of proinflammatory cytokines on the pancreatic alpha cells 
response to glucose, Zn2+ and insulin
M. Farrelly1,2, C. Murphy1, P. Newsholme2; 
1Department of Biology, I.T. Tallaght, Belgard Road, Dublin, 2School of 
Biomedical and Biomolecular Science, University College Dublin, Belfield, 
Dublin, Ireland.
Background and aims: The study of the effects of diabetogenic factors on 
the pancreatic α-cell are relatively limited when compared to its neighbour, 
the pancreatic β-cell. In recent years the regulation of glucagon secretion has 
attracted considerable attention from molecular bioscientists. The dysregula-
tion of glucagon secretion in both type 1 and type 2 diabetes mellitus is of 
physiologic and pathologic importance as little has been achieved in relation 
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to counteracting the dysregulation of glucagon secretion in diabetes. The ef-
fects of proinflammatory cytokines on the β-cell are well documented but lit-
tle has been reported on the mechanisms of cytokine induced α-cell dysregu-
lation. IL-1β, TNF-α and IFN-γ are commonly used for initiation of dysfunc-
tion and death in the pancreatic β-cell. This investigation has determined the 
effects of these cytokines on the pancreatic α-cell under various incubation 
conditions relating to the availability of islet cell secretory products.
Materials and methods: The clonal cell line α-TC1-9 were seeded in 6 well 
plates under various conditions in relation to proinflammatory cytokine lev-
els, Zn2+ levels, Insulin Levels and glucose levels for various time points. Me-
tabolite consumption, Glutathione ratio and ATP levels were assessed using 
enzymatic methods, glucagon levels were assessed using HTRF techniques 
and Ca2+ fluctuations were assessed using flow cytometry.
Results: Addition of various concentrations of the cocktail of proinflamma-
tory cytokines to the αTC1-9 cell line (various dilutions of the following: 5U/
ml IL-1β, 1000U/ml TNF-α and 500U/ml IFN-γ) resulted in a dose depend-
ent increase in glucagon secretion, up 327% compared to basal levels (n=6). 
Intracellular levels of reduced glutathione were increased by 1.2 fold, while 
intracellular levels of oxidised glutathione were not increased significantly in 
any condition. Glucose and Glutamine consumption was also increased, dose 
dependently, with increases in proinflammatory cytokine cocktail concentra-
tion. Glucagon secretion was reduced by addition of Zn 2+ and/or insulin an 
effect partly attenuated (34.3-69.4%) by addition of various concentrations of 
glucose (0-25mM). This inhibitory effect was lost in a dose dependent fashion 
with the addition of the proinflammatory cytokine cocktail.
Conclusion: Proinflammatory cytokines had a dose dependent effect on me-
tabolite consumption including glucose, glutamine etc. and glucagon secre-
tion from α-TC1-9 cells. Glucose was able to partly attenuate the negative 
effect of the cytokines.
Supported by: TSR, An tÚdarás um Ard-Oideachas, An Roinn Oideachais agus 
Eolaíocht,
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Toll-like receptor 4 in islets of Langerhans - a potential role in beta cell 
death in type 2 diabetes
M. Ladefoged, A.M. Hansen; 
Novo Nordisk A/S, Måløv, Denmark.
Background and aims: Type 2 diabetes is a characterised by insulin resistance, 
beta-cell dysfunction and increased systemic levels of free fatty acids (FFA). 
Furthermore, it is recently becoming clear that activation of the innate immune 
system via toll-like receptors (TLRs), in particular TLR2 and TLR4, is impli-
cated in the pathogenesis of insulin resistance and type 2 diabetes. Activation 
of TLR4 by ligands of both exogenous and endogenous origin (e.g. LPS, FFA) 
causes an initiation of intracellular pro-inflammatory signalling pathways and 
a subsequent release of pro-inflammatory mediators such as TNFα, IL-1 and 
IL-6. Most cells in the body, including immune and insulin-sensitive cells, have 
a low basic expression of TLR4 under normal conditions. In obese and type 2 
diabetic patients the level of the TLR4 ligands LPS and FFA are elevated, and 
recent studies demonstrate a resulting increase in TLR4 expression in macro-
phages, adipocytes and muscle cells suggesting a link between TLR4 expression 
and development of insulin resistance. In addition to insulin resistance, type 
2 diabetes is characterised by beta-cell dysfunction. Recent studies report in-
creased infiltration of macrophages in islets of Langerhans from patients with 
type 2 diabetes and in a variety of type 2 diabetic animal models, raising the 
possibility that TLR4 expression and a resulting cytokine release might be in-
creased in islets under diabetic conditions. TLR4 expression has been described 
in pancreatic islets under normal conditions; however changes in the expres-
sion pattern have not yet been investigated with respect to diabetes develop-
ment. Our hypothesis is that TLR4 expression and signalling is increased in is-
lets of Langerhans in obesity and the resulting increase in secretion of cytokines 
causes beta-cell dysfunction and manifestation of diabetes. We investigate the 
hypothesis in the db/db mouse - an animal model of type 2 diabetes.
Materials and methods: Islets of Langerhans from male db/db (4, 8 and 15 
weeks old, representing diabetes progression with age) as well as control db/+ 
(15 weeks old) mice were isolated using collagenase digestion. RNA was ex-
tracted and changes in gene expression of Toll-like pathway products (TLR4, 
TLR2, MyD88, NFκB) and selected cytokines (TNFα, IL-1α, IL-1β, IL-6, IP-
10, IFNγ) during development of diabetes examined using real-time PCR. 
Additionally, secretion over a 24h period of the above mentioned cytokines 
from islets was quantified (Milliplex).
Results: TLR4 mRNA was found in islets from both lean and obese mice with 
a 7.4 ± 1.6 fold higher level in islets from obese diabetic 15 weeks old db/db 
compared to 15 weeks old db/+ mice (p<0.01) (n≥3). TLR4 gene expression 
increased with progression of diabetes in db/db mice showing a 5.6 fold high-
er level of TLR4 mRNA in islets from 15 weeks old db/db compared to islets 
from 4 weeks old db/db mice (p<0.01) (n≥3). Furthermore, both protein and 
gene levels of all cytokines examined, except IFNγ, increased significantly in 
islets during development of type 2 diabetes in db/db mice. No significant 
differences were observed for IFNγ.
Conclusion: Expression of TLR4 and its intracellular signalling molecules 
in db/db mouse islets were increased in parallel with diabetes development. 
Also, expression and secretion of cytokines and chemokines were found 
significantly increased in diabetic vs. non-diabetic mouse islets. Our results 
support the hypothesis that, in addition to its contribution to insulin resist-
ance, TLR4 may also be a causative factor in beta-cell death leading to type 
2 diabetes.
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Regulation of beta cell survival and function by 14-3-3 proteins
G.E. Lim, J.D. Johnson; 
Cellular and Physiological Sciences, University of British Columbia, 
Vancouver, Canada.
Background and aims: Diabetes is associated with increases and decreases in 
pancreatic beta cell death and function. Numerous factors promote cell sur-
vival through the activation of survival kinases and deactivation of pro-apop-
totic proteins. Previously, we have demonstrated that insulin promotes beta 
cell survival and proliferation via Raf-1 kinase. The importance of Raf-1 as a 
regulator of survival was further elucidated by pharmacological inhibition of 
Raf-1, which induced cell death. In other cell types, scaffold proteins of the 
14-3-3 family regulate Raf-1 and other growth factor signaling cascades, but 
their function in beta cells is unknown. We, therefore, hypothesize that 14-3-
3 proteins regulate beta cell function and survival.
Materials and methods: The MIN6 beta cell line and primary mouse islets 
were used to assess the role of 14-3-3 proteins on cell function and survival 
by overexpression of proteins and shRNA. Quantitative PCR (qPCR) was 
performed to measure mRNA levels. Fluorescent microscopy was used to 
visualize protein localization as well to quantify cell death. Western blots and 
co-immunoprecipitation were used to detect protein interactions, phosphor-
ylation, and expression. Insulin was measured by ELISA.
Results: Of the 7 isoforms, 14-3-3 ζ, η, θ transcripts levels were expressed 
at the highest levels, followed by γ, β, ε, and σ in MIN6 cells and mouse is-
lets. Fluorescent microscopy showed that 14-3-3 ζ was localized to beta cells, 
endothelial cells, but not exocrine tissue in the mouse pancreas. In isolated 
primary beta cells, 14-3-3 ζ was predominantly cytoplasmic, and co-locali-
zation with insulin granules was also observed. To analyze the function of 
14-3-3 proteins, difopein-EYFP, a pan 14-3-3 inhibitor, was expressed in 
MIN6 cells. Inhibition caused a 3.8-fold increase (p<0.05) in propidium io-
dide-positive cells, a marker of cell death and a 1.5-fold increase (p<0.05) 
in cleaved caspase-3, a marker of apoptosis. Moreover, there was a 1.3-fold 
increase (p<0.05) in basal insulin release. As several studies have shown that 
14-3-3 ζ regulates cell survival, MIN6 cells were transfected with wild-type 
(WT) 14-3-3 ζ or control plasmids. Treatment with cytokines (25ng/ml TNF-
α, 10ng/ml IL-1β, and 10mg/ml IFN-γ) induced a 2.5-fold increase in cell 
death (p<0.05), which was completely prevented by WT-14-3-3 ζ over-ex-
pression. Similarly, cell death stimulated by 1μM thapsigargin was reduced 
by 43% (p<0.05). Transfection of MIN6 cells with shRNAs against 14-3-3 ζ 
led to a 1.4-fold increase (p<0.05) in cleaved caspase-3 levels. Dissociation 
of Raf-1 from 14-3-3 ζ is required for its activation, and treatment of MIN6 
cells with a picomolar concentration of insulin decreased by 63% (p<0.05) 
the amount of Raf-1 that complexed with 14-3-3 ζ. The decrease in 14-3-3 ζ:
Raf-1 association was mirrored by an increase in 14-3-3 ζ association with 
Bad, a proapoptotic protein. Static cultures on MIN6 cells were used to assess 
the effect of WT-14-3-3 ζ or shRNAs on insulin secretion. Overexpression 
of WT-14-3-3 ζ induced an 8.5-fold increase in basal insulin secretion from 
MIN6 cells. Conversely, shRNA-mediated knockdown of 14-3-3 ζ decreased 
basal and glucose-induced insulin secretion.
Conclusion: The present study demonstrates for the first time that 14-3-3 
proteins regulate beta cell survival and function. Alterations in the expression 
of 14-3-3 proteins may represent a novel therapeutic approach to modulate 
insulin signaling and promote beta cell survival and function.
Supported by: CIHR, JDRF, MSFHR
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Expression of salivary type amylase in human pancreatic beta cells and 
its induction by pro-inflammatory cytokines in MIN6 beta cells
S. Arai-Yamashita1, H. Shimura2, K. Aida2, S. Takizawa2, M. Takahashi2,  
M. Aoyagi2, S. Tanaka2, T. Endo2, T. Kobayashi2; 
1Department of Clinical Science, Lund University/CRC, Malmö, Sweden, 
2Third Department of Internal Medicine, University of Yamanashi, Japan.
Background and aims: Autoantibodies against amylase (AMY) were detect-
ed at a high frequency in sera from patients with diabetes associated with au-
toimmune pancreatitis (DAIP) or with fulminant type 1 diabetes (FT1DM). 
The possible relationship between beta-cell destruction and autoimmunity 
against AMY is not clear. The aim of this study was to examine AMY expres-
sion in 1) the pancreatic islet-cells of autopsied patients with FT1DM and 2) 
mouse MIN6 beta cells exposed to Th1 cytokines.
Materials and methods: AMY expression in islet beta cells from three 
FT1DM patients dead 2-5 days after the onset and three non-diabetic con-
trol pancreas were analyzed by immunohistochemical staining with AMY1 
(salivary type) -specific monoclonal and AMY2 (pancreatic) -specific mono-
clonal antibodies. Quantitative RT PCR was used to detect the expression of 
both AMY1 and AMY2 (pancreatic type) in MIN6 beta cells incubated with 
Th1 cytokines. The MIN6 cells were also subjected to immunohistochemical 
staining using monoclonal AMY1 antibodies.
Results: Severe mononuclear cells infiltration (insulitis) was observed in is-
lets of FT1DM patients but not the islets of control non-diabetic subjects. An 
AMY1, but not AMY2, monoclonal antibody identified immunoreactivity of 
AMY in beta cells, but not alpha or exocrine acinar cells, of non-diabetic 
human. The AMY1 staining was also observed in the islets from FT1DM pa-
tients. Western blotting revealed that serum from patients with autoimmune 
pancreatitis had IgG detecting AMY1. AMY1 mRNA levels in MIN6 beta 
cells were 108-fold higher than AMY2. MIN6 beta cells cultured with either 
IFN-γ or TNF-α alone did not affect AMY1 expression. In contrast, simulta-
neous addition of IFN-γ and TNF-α induced a synergistic 5-fold increase of 
AMY1 but not AMY2 levels. The MIN6 beta cells cultured simultaneously 
with IFN-γ and TNF-α showed an increased AMY immunoreactivity com-
pared to the cells treated with IFN-γ or TNF-α alone.
Conclusion: We conclude that human pancreatic islet beta-cells express 
AMY1 and its expression was also observed in islets from FT1DM patients. 
Infiltrating mononuclear cells in FT1DM or DAIP are known to produce Th1 
cytokines. It was of interest that the expression of AMY1 gene in pancreatic 
MIN6 beta-cells was enhanced synergistically by Th1 cytokines. This obser-
vation suggests that islet beta-cells hyper-expressing AMYI may be the target 
for beta-cell autoimmunity in DAIP and FT1DM.
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Siglecs are differentially expressed in pancreatic islets and regulate beta 
cell function and survival
G. Dharmadhikari1, F. Paroni1, J. Kerr-Conte2, S. Kelm1, K. Maedler1; 
1Centre for Biomolecular Interactions, University of Bremen, Germany, 
2Thérapie Cellulaire du Diabète, INSERM /Université de Lille, France.
Background and aims: In both type 1 diabetes mellitus (T1DM) and type 2 
diabetes mellitus (T2DM), local inflammation and cytokine and chemokine 
production within pancreatic islets has been observed and is detrimental for 
the β-cell. Siglecs (Sialic-acid binding immunoglobulin like lectins) are cell sur-
face receptors expressed on haematopoietic cells which participate in immune 
responses. Their prominent position, negative charge and widespread distribu-
tion make sialic acids an important component in cell-cell interactions as well 
as pathogen and toxin binding. Our investigations revealed a cell-type specific 
expression of Siglecs in pancreatic islets, which is altered in diabetic conditions, 
hinting towards their role in survival and function of these pancreatic cells.
Materials and methods: The expression of Siglecs 3, 5, 6, 7, 8 and 10 in pan-
creatic sections was analyzed by immunofluorescence in pancreatic sections 
from autopsy from patients with T2DM and controls as well as in isolated hu-
man islets exposed to a diabetic milieu (increasing glucose (11.1-33.3 mM), 
2 ng/ml IL-1β alone or in combination with 1,000 U/ml IFN-γ, 100 ng/ml 
LPS, 0.5 mM palmitate, 50 μg/ml synthetic ds RNA analogue Poly:IC or 50 
μM H2O2). The siglecs cellular localization was confirmed by Confocal Laser 
scanning microscopy. Siglec expression was evaluated by quantitative real 
time PCR of cDNA from human pancreases from autopsy. To investigate its 
role in β-cell function, Siglec 7 over-expression by plasmid transfection was 
carried out followed by glucose stimulated insulin secretion (GSIS).
Results: Triple staining for Siglecs 3, 5, 6, 7, 8 and 10; glucagon and insulin 
in pancreatic sections of healthy controls and patients with T2DM showed 
cell type specific siglec expression in the human pancreas: Siglecs 3, 5 and 
8 were expressed in the glucagon producing α-cells, Siglecs 7 and 10 were 
expressed in the insulin producing β-cells and Siglec 6 was expressed in the 
exocrine pancreas. Siglec expression was not uniform in the cells but was ag-
gregated at certain locations; this was observed independently from diabetes. 
This expression pattern hints towards a cell-cell interaction junction which is 
facilitated by these siglecs. A diabetic milieu had an inductive effect on siglec 
expression in those cells in human islets in vitro and in vivo. Real time PCR 
analysis revealed that siglecs expressed in α-cells Siglec-3,-5 and -8 showed 
a 5.9-fold, 7.9-fold and 6.1-fold increase in its expression in patients with 
T2DM as compared to the non diabetic controls. In contrast, in the siglecs 
expressed in the β-cells, there was an 85% decreased expression in siglec 7 
and a 47% decrease in siglec 10 expression in patients with T2DM. Since Si-
glec 7 was markedly downregulated in T2DM in poorly functional β-cells, 
we wanted to know if over-expression of siglec 7 has an opposite effect on 
β-cell function. Indeed, plasmid over-expression of Siglec 7 increased GSIS 
1.5-fold in human islets and prevented glucose and palmitate induced apop-
tosis, when compared to the lacZ transfected control islets.
Conclusion: Our data suggest that Siglecs are differentially expressed in 
pancreatic islets, are regulated in T2DM and influence β-cell function and 
survival. Siglecs could play an important role not only in the crosstalk of β-, 
α- and immune cells but also in maintaining glucose homeostasis.
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MST1 mediates beta cell apoptosis and impaired function
A. Ardestani1, F. Paroni1, J. Kerr-Conte2, K. Maedler1; 
1Centre for Biomolecular Interactions, University of Bremen, Germany, 
2Thérapie Cellulaire du Diabète, INSERM /Université de Lille, France.
Background and aims: Pancreatic β-cell death is the fundamental cause 
of type 1 and type 2 diabetes (T2DM). Mammalian sterile 20-like kinase 1 
(MST1) is a serine threonine kinase, which mediates apoptosis in response 
to cytotoxic stress. MST1 is both, cleaved and activated by caspases, and also 
serves as an activator of caspases to amplify the apoptotic signaling pathways. 
In the present study, we investigated the possible patho-physiological activa-
tion of MST1 in β-cells under diabetic conditions, which may be a major 
common pathway of β-cell death in diabetes.
Materials and methods: Isolated human islets and the human β-cell line 
CM9 were exposed to a diabetic milieu (cytokine mixture IL-1β/IFNγ, oxida-
tive stress (H2O2) or increasing glucose concentrations). Phospho-MST1 and 
MST1 cleavage, Phospho-JNK, Phospho-Histone2B (direct cellular substrate 
of MST1) and β-cell apoptosis (cleaved Caspase 3 & PARP) were analyzed by 
western blotting. MST1 or dominant-negative MST1 were overexpressed by 
plasmid transfection into human islets and CM9 cells and its direct effect on 
β-cell apoptosis (TUNEL assay & caspase 3 activation) and function (GSIS, 
PDX1 localization) analyzed. MST1 activation was investigated in isolated 
islets from a patient with T2DM and from an animal model of T2DM, the 
high fat/ high sucrose diet fed mouse (HFD).
Results: MST1 cleavage & phosphorylation was increased in human islets 
and CM9 cells exposed to IL-1β/IFNγ mixture, H2O2 or increasing glucose 
concentrations (11.1-33.3 mM). This correlated with increased P-H2B, P-JNK 
and apoptosis. We found the JNK pathway as a mediator of MST1-induced 
apoptosis, because JNK inhibition (by JNK inhibitor SP600125) diminished 
caspase-mediated MST1 cleavage and apoptosis. In isolated islets from pa-
tients with T2DM as well as from HFD mice, MST1 activation was increased 
and correlated with JNK activation and apoptosis. Inhibition of endogenous 
MST1 activity by overexpression of dominant negative MST1 inhibited ap-
optosis induced by a diabetic milieu. In contrast, overexpression of MST1 
increased β-cell apoptosis 4-fold (P>0,05) and reduced glucose stimulated 
insulin secretion 1.6-fold (p>0,05), indicating that MST1 alone is sufficient to 
promotes β-cell failure. By an in vitro kinase assay using recombinant MST1 
and PDX-1 as substrate we found that MST1 phosphorylates PDX-1. In line 
with this MST1 overexpression induced PDX-1 shuttling from the nucleus to 
the cytosol, providing an explanation for the impaired insulin secretion.
Conclusion: Our results suggest that MST1 is a critical mediator of impaired 
β-cell function and apoptosis. Inhibiting the MST1-pathway could be an im-
portant strategy to prevent β-cell apoptosis.
Keywords: Mammalian sterile 20-like kinase 1 (MST1), apoptosis, diabetes, 
β-cell, c-Jun N-terminal kinase (JNK) and Pancreatic Duodenal Homeobox-1 
(PDX-1).
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Islet human amylin oligomer formation is differentially correlated with 
beta cell death and diabetes onset between homozygous and hemizygous 
human amylin transgenic mice
S. Zhang, H. Liu, X. Li, M. Au, C.-L. Chuang, G.J.S. Cooper; 
School of Biological Sciences, University of Auckland, New Zealand.
Background and aims: One of the pathological features of type-2 diabetes 
mellitus (T2DM) is the presence of islet amyloid deposits comprising mainly 
human amylin (hA)/hIAPP. Recent studies suggested that soluble oligomers 
of human amylin may be the primary cause of β-cell damage and thus con-
tribute to the onset/development of T2DM. However, the molecular basis of 
this process remains to be fully elucidated. We aimed to investigate the con-
nection between soluble oligomers and hA cytotoxicity, and their correlation 
with diabetes development using a rodent model of diabetes. 
Materials and methods: We performed a comparative phenotypic analysis of 
homozygous and hemizygous hA transgenic mice for hA in their islet β-cells. 
Oligomer formation was studied by detection of amylin oligomer-like immu-
noreactive material (AOLIM) with specific anti-oligomer antibodies using 
immunofluorescence techniques. A co-localization study of oligomerization 
was carried out wherein islet cell hormones were detected by multi-labelled 
immunofluorescence. Apoptosis was assessed by active-caspase-3 staining.
Results: Both homozygous and hemizygous hA transgenic mice developed 
spontaneous diabetes associated with different elevations in hA levels and 
with different time frames of disease onset and death. Abnormal β-cell 
function and apoptosis were detected before early onset of hyperglycaemia 
in homozygous animals, while β-cell function (insulin secretion) remained 
normal till late diabetes onset in hemizygous mice. Interestingly, intracellular 
and extracellular AOLIM was clearly detectable before onset of diabetes in all 
transgenic animals with strong correlation with β-cell death in homozygous 
mice. However, there was no correlation between the appearance of AOLIM 
and the time of cell death occurring in hemizygous mice, implying a differ-
ence in the size and/or the extent of cytotoxic oligomerization in these ani-
mals. We also found that rapid β-cell depletion occurs soon after appearance 
of cytotoxic oligomers and onset of diabetes in homozygous animals whereas 
apoptosis developed slowly after the later onset of diabetes in hemizygous 
animals, which exhibited significant β-cell loss in a much later time frame.
Conclusion: The difference in time at which oligomerization occurs in rela-
tion to cell death and diabetes onset between homozygous and hemizygous 
hA-transgenic mice may suggest a dose-dependent cytotoxic effect of hA oli-
gomers. The findings from this study will provide new insights on the cellular 
fate of oligomers and further enhance our understanding of amyloidosis and 
T2DM.
Supported by: FRST & HRC NZ
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Dual effect of advanced glycation end products in pancreatic islet 
apoptosis and the protective role of benfotiamine and MitoQ
M. Correa-Giannella1, F.L. Costal1, E.R. Oliveira1, A.R. Amaral1,  
A.M.S. Lima2, M. Passarelli2, D. Giannella-Neto3; 
1Endocrinology - LIM25, 2Endocrinology - LIM10, 3Gastroenterology - 
LIM07, University of Sao Paulo Medical School, Brazil.
Background and aims: Loss of beta cell function hastens the deterioration 
of metabolic control in people with type 2 diabetes. Besides lipo- and glu-
cotoxicity, advanced glycation end products (AGEs) seem to contribute to 
this process by promoting islet apoptosis. In other tissues, AGEs interact with 
their specific receptors (RAGEs) and elicit reactive oxygen species (ROS) 
generation and NF-kB activation. In order to investigate the temporal effect 
of AGEs on islet apoptosis as well as the potential of antioxidant compounds 
to decrease islet damage caused by AGEs,
Materials and methods: Rat pancreatic islets were treated for 24, 48, 72 
and 96 h with either AGEs generated from co-incubation of bovine serum 
albumin (BSA) with D-glyceraldhyde (GAD, 5 mg/mL) or BSA (5 mg/mL, 
control). Apoptosis was evaluated by quantification of DNA fragmentation 
(ELISA), caspase-3 enzyme activity and detection of mitochondrial perme-
ability transition (MitoProbe JC-1). The expression of the genes Bax, Bcl2 
and Nfkb1 was evaluated by RT-qPCR. In the time points at which increased 
apoptosis was detected, the effect of two antioxidant compounds was evalu-
ated: benfotiamine (350 μM), a liposoluble vitamin B1, and Mito Q (1 µM), a 
derivative of ubiquinone targeted to mitochondria
Results: In 24 and 48 h, AGEs elicited a significant decrease in the apoptosis 
rate in comparison to the control condition concomitantly with a significant 
increase in the RNA expression of the antiapoptotic gene Bcl2 and a signifi-
cant decrease in the Nfkb1 RNA expression. In contrast, after 72 and 96 h, 
AGEs promoted a significant increase in the apoptosis rate in comparison to 
the control condition concomitantly with a significant decrease in Bcl2 RNA 
expression and a significant increase in Nfkb1 RNA expression. Benfotiamine 
and Mito Q were able to decrease the apoptosis rate of islets exposed to AGEs 
for 72 and 96 h.
Conclusion: AGEs exerted a dual effect in cultured pancreatic islets, being 
protective against apoptosis after short exposition but proapoptotic after 
prolonged exposition. Mito Q and benfotiamine deserve further evaluation 
as drugs that could offer islet protection in conditions of chronic hypergly-
cemia.
Supported by: FAPESP
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Galectin-3 deficiency reduces immune-mediated beta cell destruction in 
vitro
S. Stošić-Grujičić1, T. Cvjetićanin1, G. Timotijevic2, N. Zdravkovic3,  
M. Lukic3; 
1Immunology, Institute for Biological Research “Sinisa Stankovic”, 
University of Belgrade, 2Institute for Molecular Genetics and Genetic 
Engineering, University of Belgrade, 3Center for Molecular Medicine, 
Faculty of Medicine, University of Kragujevac, Serbia.
Background and aims: Galectin-3 (Gal-3), a multifunctional beta-galacto-
side binding lectin, affects numerous biological processes and is implicated 
in the pathogenesis of several inflammatory/autoimmune disorders. It has 
been shown that Gal-3 may increase inflammatory responses through its 
function in cell activation, cell migration, or inhibition of apoptosis. We have 
recently reported that Gal-3-deficient (Gal-3-/-) mice are relatively resistant 
to diabetogenesis induced by multiple low doses of streptozotocin. Little is 
known however, about the relevance and influence of the endogenous Gal-3 
at the level of target tissue (pancreatic islets). It is established that, in Type 1 
as well as in Type 2 diabetes, beta-cell function and viability are progressively 
disturbed through a complex process of inflammation. In addition, hyperli-
pidemia and inflammation, when acting in concert, may carry out a powerful 
attack upon pancreatic beta cells. In this context, our aim was to analyze the 
possible role of endogenous Gal-3 in beta cell survival and death pathways 
following in vitro treatment with cytokines and one of the most common free 
fatty acid -palimitic acid.
Materials and methods: Pancreatic islets isolated from C57BL/6 mice or 
Gal-3-null mice were incubated with palmitate and/or concanavalin A-stim-
ulated spleen-cell culture supernatant containing soluble immune cell prod-
ucts. Alternatively, the cooperative effect of culture supernatant components 
was mimicked with the combination of recombinant cytokines (IL-1β+TNF-
α+IFN-γ). After incubation, beta cell apoptosis was determined by MTT test, 
or histone-DNA ELISA. Expression profiles of various related genes were de-
termined at mRNA and protein levels by real time PCR, and Western blot, 
respectively.
Results: Targeted disruption of Gal-3 gene attenuated palmitate-induced 
beta cell lipotoxicity. Moreover, Gal-3-/- pancreatic islets were more resistant 
than wild type counterparts to cytokine induced apoptosis. The transcription 
of anti-apoptotic Bcl-2 was up-regulated in Gal-3-/- islets only, whereas in wild 
type islets it was down-regulated. Although Bcl-xL mRNA was up-regulated 
in both groups of islets, the increase was more pronounced in Gal-3-/- islets. In 
contrast, the transcription of pro-apoptotic Bid was down-regulated in Gal-
3-/- islets only. Interestingly, basal levels of anti-apoptotic proteins were higher 
in Gal-3-/- islets than in wild type islets, further suggesting favouring of cell 
protective over pro-apoptotic molecules in molecular regulation of Gal-3-/- 
beta cell survival.
Conclusion: Our findings clearly show that the absence of Gal-3 confers beta 
cell protection from the lethal insult of different agents, namely cytokines and 
saturated free fatty acids. This protection is probably mediated by differen-
tial regulation of pro- and anti-apoptotic molecules within the beta cells. The 
study thus provides in vitro evidence for a critical role of Gal-3 in destruction 
at the level of pancreatic islets and suggests a new therapeutic strategy for the 
treatment of diabetes based on the selective inhibition of Gal-3 activity.
Supported by: Serbian Ministry of Science 
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Ectopic overexpression of acute stress protein p8 reduces streptozotocin 
(STZ)-induced apoptosis in INS-1E (STZ) beta cells
G. Päth, E. Tsaroucha, I. Pilz, P.J. Feilen, S. Ehler, M. Alt, B. Dufner,  
J. Seufert; 
Endocrinology / Diabetology - Labor B9, University Hospital Freiburg, 
Germany.
Background and aims: Protein p8 is associated with proliferation and tis-
sue protection. p8 knock out animals display enhanced lethality after LPS 
treatment and enhanced pancreatitis-induced tissue damage in the exocrine 
pancreas. Within the endocrine pancreas own previous work characterised 
p8 as a glucose-dependent mediator of beta cell proliferation. Here we in-
vestigate the cell protective properties of p8 in response to STZ treatment in 
INS-1E beta cells.
Methods and results: Exposure of native INS-1E to STZ strongly upregulates 
activity of the apoptosis effector molecules caspases 3 and 7 (Chemilumines-
cence assay) resulting in cell death with a 24 h LD50 of 0.66 mM STZ (MTS). 
In parallel, 0.66 mM STZ acutely induces endogenous p8 gene expression 
(qPCR), which peaks after 6 h and fastly declines to vehicle control levels 
after 12 h. STZ-induced p8 gene expression (6 h) was further strictly dose-
dependent up to 1 mM STZ and gets saturated at 3.3 mM. To investigate 
effects of high p8 levels on viability and apoptosis, we generated INS-1E beta 
cells with stable p8 overexpression under the control of a CMV promoter 
(p8-INS1) and empty plasmid control cells (mock-INS1). Under basal condi-
tions, p8-INS1 cells as compared to mock controls demonstrate substantially 
enhanced viability resulting in significantly increased cell numbers after 5 
days in culture. Also under tissue stress conditions, viability of p8-INS1 was 
substantially enhanced if exposed to 0.33 to 3.3 mM STZ for 24 h. These 
findings correspond to significantly lowered (about 60%) 0.33 to 1 mM STZ-
induced activation of caspases 3 and 7 after 8 h.
Conclusion: These results demonstrate that, in beta cells, p8 is acutely in-
duced by tissue stress and mediates enhanced viability and proliferation and 
reduces STZ-induced apoptotic cell death.
Supported by: DFG and BMBF, Germany
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Paracrine signaling loops in adult pancreatic islets: Netrins modulate 
beta cell apoptosis via Neogenin and Unc5a
Y.H.C. Yang1, B.G. Hoffman2, M. Szabat1, C. Bragagnini1, K. Kott1,  
C.D. Helgason3, J.D. Johnson1; 
1Department of Cellular and Physiological Sciences, Department of 
Surgery, University of British Columbia, Vancouver, 2Child & Family 
Research Institute, Department of Surgery, University of British Columbia, 
Vancouver, 3Department of Cancer Endocrinology, BC Cancer Research 
Center, Vancouver, Canada.
Background and aims: Adult pancreatic islets contain multiple cell types that 
produce and secrete well characterized hormones including insulin, glucagon 
and somatostatin. Although it is becoming increasingly apparent that islets 
release and respond to more secreted factors than previously thought, sys-
tematic analyses are lacking. The aims of the present study were to identify 
potential autocrine/paracrine islet growth factor loops and to characterize 
the function of a family of previously unreported islet secreted factors and 
their receptors.
Materials and methods: Gene expression databases, islet specific SAGE and 
Tag-Seq libraries, and microarray datasets of FACS purified human beta-cells 
were used to compile a list of secreted factors and secreted factor receptors 
present in mouse or human islets. The presence of Netrins and their cognate 
receptors were assessed using RT-PCR, western blot analysis, and immnoflu-
orescence staining. The roles of Netrin-1 and Netrin-4 in beta-cell function, 
apoptosis, and proliferation were also examined.
Results: A list of 230 secreted factors and 238 secreted factor receptors (189 
factor-receptor pairs) were found in islets. This genome-wide analysis led us 
to characterize the role of netrins in adult pancreatic beta-cell apoptosis. The 
presence of netrins and their cognate receptors (Neogenin, DCC, and Un-
c5A-D) were confirmed using RT-PCR, western blot analysis, and immnoflu-
orescence staining. Down-regulation of caspase-3 activation was observed 
when MIN6 cells were exposed to exogenous Netrin-1 and Netrin-4 under 
hyperglycaemic conditions, and the observed effects were not dependent on 
induction of insulin secretion. Reduction in caspase-3 cleavage was linked to 
the decrease in dependence receptors, Neogenin and Unc5A.
Conclusion: Together, our results highlight the large number of potential islet 
growth factors and point to a context-dependent pro-survival role for netrins 
in the adult pancreatic beta-cells. Since diabetes results from a deficiency in 
functional beta-cell mass, these studies are an important step towards devel-
oping novel therapies to improve beta-cell survival.
Supported by: JDRF, SCN, MSFHR, CIHR, NSERC
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The fibrosis in pancreatic islets at an early stage of life involves in 
diabetes development in obese diabetic db/db mice 
Y. Kanda, S. Hamamoto, M. Shimoda, K. Tawaramoto, M. Hashiramoto,  
K. Kaku; 
Diabetes and Endocrine Division, Kawasaki Medical School, Kurashiki-shi, 
Japan.
Background and aims: The db/db mice develop diabetes with severe insulin 
resistance and limited capacity of insulin secretion. On the other hand, the 
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ob/ob mice with a similar genetic background do not present diabetic mani-
festation because of a compensatory hypersecretion of insulin. We previously 
reported that the ob gene, but not db gene, homozygote acquires a compensa-
tory mechanism of beta cell protection probably through anti-oxidative stress 
mechanism at 12 weeks of age. In this study, to further investigate the molec-
ular mechanism of diabetes development in db/db mice, the beta cell function 
and gene expression profiles specific for pancreatic islets in db/db mice were 
compared with those in ob/ob mice at an early stage of life, when metabolic 
parameters were not different between two strains of mice.
Materials and methods: Body weight (BW), fasted blood glucose (FBG), 
fasted insulin (FIRI), TG and FFA in db/db, ob/ob and lean littermates m/m 
mice were measured at 6 weeks of age. The beta cell mass and cell ratio were 
assessed by histological analysis of the islet tissue. In the first step of mo-
lecular analysis, we examined comprehensive gene expression profiles of iso-
lated islets by the cDNA microarray analysis. Furthermore, gene expressions 
specific for the core area of pancreatic islet were analyzed by Laser Capture 
Microdissection (LCM) method and real time RT-PCR. Primer pairs encod-
ing genes associated with pancreatic hormones, cell proliferation, apoptosis, 
cell cycle, and oxidative stress were prepared, and real-time RT-PCR with 
Sybr Green was applied at 6 week old mice.
Results: BW in db/db mice was significantly greater than that in m/m mice, 
but was lower than ob/ob mice. FBG and FIRI in db/db and ob/ob mice were 
significantly higher than those in m/m mice, but no difference was observed 
between db/db and ob/ob mice (FBG: 93.1±6.0 in db/db, 89.9±5.8 in ob/ob, 
53.6±3.6 mg/dl in m/m, FIRI: 1.84±0.10, 1.58±0.12, 0.12±0.01 ng/ml at 6 
weeks of age, p<0.05, respectively). TG and FFA levels in db/db and ob/ob 
mice were significantly higher than those in m/m mice. The beta cell mass 
and cell ratio in db/db was significantly less than those in ob/ob and m/m mice 
at 6 weeks of age (cell mass: 1.03±0.04 in db/db, 1.16±0.02 in ob/ob, 1.12±0.06 
mg in m/m, and cell ratio: 81.1±0.1, 83.0±0.5, 82.9±0.4%, respectively). The 
cDNA microarray analysis at 6 weeks of age demonstrated no significant dif-
ference in the islet gene expressions related with cell differentiation/prolif-
eration and ER/oxidative stress among three groups. On the other hand, the 
tissue fibrosis and inflammation related genes were highly expressed in db/db 
mice than in ob/ob mice. The LCM and real-time PCR analysis revealed a 
significant increase in insulinIIgene expression in both db/db and ob/ob mice. 
Nkx6.1 gene related with cell differentiation was significantly increased in ob/
ob compared with db/db and m/m mice. The cell proliferation, cell apoptosis 
and ER/oxidative related gene expressions were not different among three 
groups of mice. On the other hand, fibronectin and collagen type 1 gene ex-
pressions were significantly up-regulated in db/db mice compared with ob/ob 
and m/m mice.
Conclusion: The present results suggest that the preceding tissue fibrosis in 
pancreatic islets at an early stage of life may be involved in diabetes develop-
ment in db/db mice. 
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A lipidomic screen of lipotoxic pancreatic beta cells reveals links between 
ceramide accumulation in the endoplasmic reticulum (ER), impaired 
protein trafficking, ER stress and apoptosis
E. Boslem1, A.M. Preston1, M. Fuller2, D.R. Laybutt1, P.J. Meikle3, T.J. Biden1; 
1Diabetes and Obesity, Garvan Institute of Medical Research, Sydney, 
2Children, Youth and Women’s Health Service, Adelaide, 3Baker IDI Heart 
Research Institute, Melbourne, Australia.
Background and aims: An intrinsic effect of saturated fatty acids (FAs) on 
the pancreatic β-cell contributes to the β-cell death that occurs in Type 2 dia-
betes. The exact mechanism by which saturated FAs bring this about remains 
elusive, but is mediated, in part, by endoplasmic reticulum (ER) stress. This 
study attempts to pinpoint the toxic lipid metabolite responsible for ER stress 
and apoptosis and offer mechanistic insight into its action.
Materials and methods: Pancreatic β-cell line, MIN6, and their palmitate-
resistant (PR) negative controls, were treated chronically (48 h) with 0.4mM 
palmitate:0.92% BSA, as a model of lipid oversupply. A comprehensive lipi-
domic screen of β-cells, was undertaken via mass spectrometry. The level of 
apoptosis (DNA fragmentation ELISA) was determined following palmitate 
treatment and in combination with genetic intervention via overexpression 
of glucosylceramide synthase. Western blotting to measure ER stress-induced 
protein, CHOP, was performed and ER-to-golgi trafficking using a VSV-Gt045-
GFP reporter assay were measured. Subcellular fractionation was undertaken 
using density gradient centrifugation.
Results: Palmitate pretreatment caused only very modest increases in mass 
of some major neutral phospholipids (triglyceride and phosphatidylcholine). 
There was also a 70% increase in glycosylceramide that was manifest in most 
side-chain species and cellular locations. Although total ceramide levels 
where unchanged, there were specific increases in the ER (56%) and lyso-
somal compartments (23%). A selective decrease in sphingomyelin species 
with side chain lengths greater than 20 carbons in length was also observed, 
consistent with a defective vesicular trafficking of longer chain ceramide spe-
cies that impacts on corresponding sphingomyelin forms. Protein traffick-
ing was also reduced by palmitate pretreatment, and this was overcome by 
overexpression of glucosylceramide synthase which metabolises ceramide. 
ER stress and apoptosis was also reduced under these conditions. The protein 
chaperone, phenyl-butryric acid did not rescue the sphingolipid alterations 
due to palmitate, nor were they reproduced by thapsigargin or tunicamycin, 
showing that the alterations are upstream, not downstream, of ER stress.
Conclusion: Our data provides a mechanistic link between ceramide accu-
mulation and ER stress in lipotoxic β-cells and thereby reconciles two previ-
ously disparate areas of prior investigation. Specifically, we demonstrate that 
increases in ER ceramide underlie apoptosis in even mild models of lipo-
toxicity. Our results also lend support to the idea that protein overload, sec-
ondary to reductions in ER-to-golgi protein trafficking caused by ceramide, 
contributes to the induction of ER stress.
Supported by: NHMRC
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The decrease in insulin secretion by prednisolone involves activation of 
the endoplasmic reticulum stress pathway in INS-1E cells
M.L. Linssen1, D.H. van Raalte2, G.C.M. van der Zon1, J. Kriek1,  
J.A. Maassen1,2, M. Diamant2, B. Guigas1, D.M. Ouwens1,3; 
1Molecular Cell Biology, Leiden University Medical Center, 2Department 
of Internal Medicine/Diabetes Center, VU University Medical Center, 
Amsterdam, Netherlands, 3Institute of Clinical Biochemistry and 
Pathobiochemistry, German Diabetes Center, Duesseldorf, Germany.
Background and aims: The glucocorticoid prednisolone (PRED) impairs 
multiple aspects of beta cell function in man, resulting in a decreased insu-
lin secretory potential. One of the possible underlying mechanisms could be 
induction of endoplasmic reticulum (ER) stress, which leads to inhibition 
of gene transcription and protein synthesis. Here, we investigated whether 
PRED-induced ER stress contributes to beta cell dysfunction in INS-1E 
cells.
Materials and methods: INS-1E cells were treated with 700nM PRED, and 
insulin secretion in response to glucose and KCl was determined at differ-
ent time points. mRNA and protein expression of various ER stress markers 
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(PERK, eIF2α, IRE1α, and XBP1s) were determined by real-time PCR and 
western blot, respectively.
Results: Exposure of INS-1E cells to PRED caused a time-dependent reduc-
tion in glucose-stimulated insulin secretion (GSIS). Inhibition of GSIS was 
already present 1 h after the addition of PRED, and occurred without affect-
ing insulin content. This short-term treatment had no inhibitory effect on 
KCl-stimulated insulin secretion (KSIS). By contrast, prolonged incubation 
with PRED (20 h) abrogated both GSIS and KSIS, lowered insulin and PDX1 
mRNA and protein expression, and increased the expression of the apoptosis 
marker cleaved caspase 3. These effects of PRED were preceded by a decrease 
in the phosphorylation of PERK and its substrate eIF2α, and an increase in 
the expression of the endonuclease IRE1α, and its target spliced XBP1s. Fi-
nally, all PRED-induced effects were reversed by the glucocorticoid receptor 
antagonist RU486.
Conclusion: PRED acutely inhibits insulin secretion by a mechanism which 
does not involve alteration of insulin content. By contrast, inhibition of insu-
lin secretion by chronic PRED exposure can be ascribed to reduced insulin 
content resulting from ER-stress. We propose that PRED-induced dephos-
phorylation of the PERK/eIF2α-pathway lowers PDX1- and insulin- mRNA 
and protein levels through activation of IRE1α/XBP1s-pathway.
Supported by: TIPharma T1-106, EU-COST BM602
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Losartan protect human pancreatic islets from glucotoxic ER and 
oxidative stress
Y. Pan1, S. Dubois1, R. Cassel1, A. Mesnier1, D. Bosco2, C. Thivolet1,  
A.-M. Madec1; 
1Faculte de Medecine Lyon-Sud, INSERM U.870, Oullins, France, 
2Departement of Surgery, Cell Isolation and Transplantation Center, 
Geneva, Switzerland.
Background and aims: In animal models and humans, chronic hyperglyc-
emia is associated with alterations in beta-cell mass and function. Chronic 
high glucose concentrations increased glucose metabolism through oxida-
tive phosphorylation. This causes mitochondrial dysfunction and excess 
production of reactive oxygen species (ROS) in beta-cells due to their low 
levels of ROS-detoxifying enzymes. Beta-cells present a developed ER in or-
der to answer to high demand for synthesis of insulin. Recent data suggest 
that ER stress is present in human beta-cells and that this could be a common 
mechanism for the two major pathophysiological events in type 2 diabetes, 
insulin resistance and beta-cell failure. Data from prospective studies suggest 
a significant reduction in the risk of type 2 diabetes after blockade of the 
renin angiotensin system (RAS). Since RAS has been found in pancreatic is-
lets, we hypothesized that these beneficial effects could be attributed to direct 
actions on islets. Our present study evaluates the effects of the Angiotensin 
II receptor blocker Losartan on stress induced by glucose in isolated human 
beta cells.
Material and methods: Human islets from 6 distinct donors were studied 
following 96 hrs in culture in presence of 5.5 mmol/l or 16.7 mmol/l glucose 
concentrations with or without 5 µmol/l Losartan during the last 48 hrs. ER 
stress-related mRNA, INS and VEGF mRNA expressions were detected by 
real-time RT-PCR, GRP78 protein expression and eIF2 α phosphorylation 
by Western-blot. Angiogenesis-related protein expression was measured by 
protein arrays. ROS levels were determined by measuring DCF oxidation and 
insulin secretion by IRMA.
Results: Insulin gene expression and protein secretion were significantly in-
creased by 6.5 times at 16.7 mmol/l glucose compared to 5.5 mmol/l glucose 
(p=0.03; p=0.006, respectively). This increase was not modified by Losartan. 
Chronic high glucose exposure decreases VEGF mRNA and protein expres-
sion levels (20% and 64%, p=0.05 and p=3.10-6, respectively). Protein arrays 
showed that high glucose reduced expression of additional factors such as 
IGFBP2 by 53% (p=5.10-7) and IL8 by 24% (p=0.008). Losartan was able 
to reverse effects observed on protein expression of VEGF by 25%, p=0.05, 
IGFBP-2 by 100%, p=0.002 and IL8 by 100%, p=0.02. Chronic high glucose 
up regulates ROS levels by 60% (p=0.02). This effect was half abrogated by 
Losartan. GRP78, spliced XBP-1 mRNA expressions increased with glucose 
concentration, (x2.2;p<0.012, x1.5 ;p<0.009, respectively). The expression of 
CHOP, an ER stress marker of apoptosis, remained the same, suggesting that 
this chronic glucose treatment caused mild ER stress but not cell death. Mod-
erate increase of GRP78 protein expression (x1.4) and eIF2α phosphorylation 
(x1.3) was observed with high glucose concentration. Addition of Losartan to 
16.5mmol/l glucose medium reduced significantly ER stress markers’ expres-
sion, GRP78 mRNA by 55% (p< 0.01), XBP1-s mRNA by 51% ;p<0.02) as 
compared to high glucose condition alone.
Conclusion: Chronic high glucose exposure of human islets reduces ang-
iogenesis and parallely increases oxidative and ER stress. Blockade of islet 
RAS by Losartan modulates angiogenesis and protects islet cells against ER 
and oxydative stress. These findings may have important therapeutic conse-
quences both for prevention of type 2 diabetes and islet transplantation.
Supported by: Centaure Foundation
519
New players in the beta cell ER stress response: UFM1 and UFBP1
K. Lemaire1, R.F. Moura2, M. Granvik1, H.E. Hohmeier3, N. Hendrickx1,  
E. Waelkens1, C.B. Newgard3, M. Cnop2, F. Schuit1; 
1Molecular Cell Biology, KU Leuven, 2Laboratory of Experimental Medicine, 
Université Libre de Bruxelles, Belgium, 3Sarah W. Stedman Nutrition and 
Metabolism Center and Departments of Pharmacology and Cancer Biology, 
Duke University Medical Center, Durham, USA.
Background and aims: To fulfil their demanding metabolic task - the regu-
lated synthesis, storage and secretion of insulin - pancreatic beta cells possess 
a highly developed endoplasmic reticulum (ER). This may explain why beta 
cells are vulnerable for ER overload as was illustrated by heterozygous eIF2al-
phaser51ala mutant mice fed a high fat diet. Therefore, optimal functioning of 
the ER is essential for proper insulin folding and beta cell survival. Chronic 
imbalance between protein synthetic demands and ER folding capacity leads 
to ER stress and activation of the ER stress response to restore ER homeosta-
sis. The aim of the present study was to identify new players in the ER stress 
response, starting from genome wide mRNA expression analysis and genes 
with unknown function which are highly expressed in islets. Ubiquitin-fold 
modifier 1 (UFM1), the most recently identified ubiquitin-like protein with 
unknown function, is proposed as being a new player in the beta cell ER 
stress response.
Materials and methods: mRNA expression analysis was performed by Af-
fymetrix microarrays and confirmed by RT-PCR. Using STrEP-tag affinity 
purification and mass spectrometry we identified a new target of UFM1. 
The cellular localisation of UFM1 and its target was identified via cellular 
fractionation and immunocytochemistry. The effect of free fatty acids and of 
cyclopiazonic acid on ER stress and on apoptosis was analysed in INS1 cells 
treated with Ufm1 specific siRNA. The influence of UFM1 and its target on 
ER associated protein degradation was analysed by overexpression of CD3δ, 
a known target of ERAD, in siRNA treated INS1 cells.
Results: Among a panel of 20 investigated organs and tissues, UFM1 is highly 
expressed in pancreatic islets of Langerhans and in other protein-secreting 
exocrine cell types (pancreatic acini, salivary glands, and seminal vesicles), 
both at the mRNA and protein level. We identified a highly conserved, un-
known protein as a target of UFM1 and named it UFBP1 for UFM1-bind-
ing protein 1 containing a PCI domain. Both UFM1 and UFBP1 co-localised 
in the ER. Pharmacological induction of ER stress by cyclopiazonic acid (25 
µM) enhanced expression of both Ufm1 and Ufbp1 (respectively 3.7-fold and 
5.3-fold) in INS1 cells. This pharmacolocial effect was partially mimicked by 
addition of the free fatty acids oleate and palmitate which enhanced Ufbp1 
expression (respectively 1.7-fold and 2.4-fold). siRNA-mediated reduction of 
Ufm1 or Ufbp1 expression enhanced apoptosis upon ER stress stimulation 
and diminished ERAD as evidenced by less degradation of CD3δ.
Conclusion: Our data show for the first time that UFM1 via its target protein 
UFBP1 is a new molecular player in ERAD and ER stress-induced beta cell 
apoptosis.
Supported by: IAP, JDRF
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Cell type-specific transcriptional regulation of 4E-BP1 under ER stress in 
MIN6 beta cells
H. Ishihara1, C. Satake2, R. Tominaga2, S. Yamguchi2, Y. Oka2; 
1Division of Diabetes and Metabolism, Nihon University, Tokyo, 2Division 
of Molecular Metabolism and Diabetes, Tohoku University, Sendai, Japan.
Background and aims: Recent studies reveal that translational control of pro-
tein expression is activated in cells under stress conditions. We have recently 
identified translational control involving a transcriptional suppressor 4E-BP1 
is important for beta-cell survival under ER stress and oxidative stress condi-
tions. The Eif4ebp1 gene, encoding 4E-BP1, is also shown to be a direct target 
of a transcription factor ATF4, a master regulator of gene expression in stress 
responses, in MIN6 insulinoma cells. In the current study, we investigated 
4E-BP1 expression under ER stress in various cell lines.
Materials and methods: MIN6 cells and other cell lines were treated with 
thapsigargin and subjected to Western blot analysis. Luciferase reporter 
constructs containing varying lengths of the Eif4ebp1 gene were generated 
and introduced into MIN6 cells and mouse embryonic fibroblasts (MEFs). 
Transcriptional activity of the Eif4ebp1 gene fragments were analyzed in these 
cells.
Results: Although ER stress increased mRNA and protein levels of 4E-BP1 in 
MIN6 cells, little increases in 4E-BP1 protein levels were observed in response 
to thapsigargin in MEFs, COS7 and NIH3T3 cells as well as eight other cell 
lines tested, despite marked increases in stress marker proteins, ATF4 and 
CHOP. Expression of 4E-BP1 mRNA levels were not significantly increased 
in MEFs treated with thapsigargin neither, suggesting that lack of 4E-BP1 in-
duction occurred at the transcriptional level. In order to gain insight into the 
difference in 4E-BP1 expression between MIN6 cells and MEFs, we examined 
different portions of the Eif4ebp1 promoter and enhancer. An approximately 
1 kbp region of the Eif4ebp1 gene was found to be attributable to the differ-
ent expression in response to thapsigargin treatment. Furthermore, we found 
that Smad signaling pathway are different between MIN6 cells and MEFs, 
and that lack of expression of a transcriptional coactivator of Smad might be 
involved in different expression of 4E-BP1 under ER stress.
Conclusion: Our results provide the evidence for cell type-specific transcrip-
tional regulation of 4E-BP1 in MIN6 cells under stress conditions.
Supported by: Grants-in-Aid for Scientific Research from Japanese Govern-
ment
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Metallothioneins and beta cell function during glucose or palmitate 
stress
N.S. Lund1, K. Smidt1, M.G. Jensen1, T. Maxel1, B. Brock1, M. Penkowa2,  
J. Rungby1; 
1Department of Pharmachology, University of Aarhus, 2Department of 
Neuroscience and Pharmacology, University of Copenhagen, Denmark.
Background and aims: Metallothioneins (MT) are metalloregulatory pro-
teins partly controlling intracellular and extracellular zinc metabolism. MT I 
and II are low molecular weight (6-7 kDa) nonenzymatic cysteine-rich pro-
teins. Both are important for the regulation of pathophysiological processes 
that depend on zinc and the processes during which oxidative stress mobi-
lizes zinc. MTs may influence survival of cells in several organs and affect 
transmitter systems depending on zinc ions for optimal function. MTs are 
highly inducible by e.g. endotoxins and glucocorticoids as well as by heavy 
metals such as zinc or copper. Beta cells depend on zinc ions for storage and 
secretion of insulin. Zinc metabolism in beta cells is regulated by a number of 
proteins transporting zinc across membranes, notably ZnT8 and ZnT3. Fur-
thermore, cell survival may be influenced by zinc levels and thus by MTs. The 
aim of this study was to investigate the effects of MTs on insulin secretion, 
gene expression of the apoptosis-regulating genes BAX and BCL2 as well as 
the expression of ZnT3 and ZnT8.
Materials and methods: Glucose sensitive INS-1E cells were examined after 
exposure to varying doses of glucose or palmitate for 24 hours. 1. Beta-cells 
were exposed to 3.3mM, 6.6mM or 21mM glucose with or without Zn7Met-
allothionein-2A (rabbit). 2. Beta-cells were exposed to palmitate 0 mM, 0.4 
mM or 1.0 mM with or without Zn7Metallothionein-2A (rabbit). All experi-
ments were performed in replicas of 6. Gene expressions of BAX, BCL-2, 
Insulin, Zinc-transporters (ZnT3, ZnT5, ZnT8) and Metallothioneins (1A 
and 3) were investigated by RT-PCR and insulin secretion and content were 
determined by ELISA.
Results: Zn7Metallothionein-2A did not change insulin gene expression. 
During basal conditions MT decreased insulin secretion (6.6 mM glucose) 
but MT increased the insulin secretion during stress (high glucose or high 
palmitate). The ZnT8 gene expression was decreased by Zn7Metallothionein-
2A at high palmitate and glucose concentrations. The ZnT3 gene expression 
was increased by Zn7Metallothionein-2A after palmitate but decreased by MT 
at basal conditions. BAX/BCL ratio was decreased by Zn7Metallothionein-2A 
during glucose stress, but showed no change with palmitate stress.
Conclusion: Manipulating intracellular zinc metabolism by exogenous MTs 
influence insulin secretion, the expression of zinc transporting proteins and 
genes related to apoptosis in a complex manner. Exogenous MTs seem to fa-
vour an enhanced insulin secretion during glucose or lipid stress and may 
affect the expression of apoptotic genes in a favourable direction. Induction 
of MTs may favourably influence beta cell function and survival, a complex 
mechanism of action involving also ZnTs needs clarification.
Supported by: Danish Agency for Science Technology and Innovation
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Dysfunction and proliferation of pancreatic beta cells by cyclic 
intermittent hypoxia
H. Ota, S. Tamaki, A. Itaya-Hironaka, A. Yamauchi,  
S. Sakuramoto-Tsuchida, T. Morioka, S. Takasawa, H. Kimura; 
Nara Medical University, Kashihara, Japan.
Background and aims: Sleep apnea syndrome (SAS) is a highly prevalent 
sleep disorder characterized by cyclic intermittent hypoxia (IH). Accumu-
lating evidence suggests that SAS is associated with glucose intolerance and 
insulin resistance independent of age, gender, smoking status, body mass 
index, and waist circumference. In addition to the development of glucose 
intolerance and insulin resistance, the progression to type 2 diabetes is de-
pendent on the impairment of glucose-induced insulin secretion (GIS) from 
pancreatic beta cells and the compensatory replication of pancreatic beta cells 
to combat the presence of insulin resistance. However the direct effects of IH 
on GIS and beta cell replication have been obscured.
Materials and methods: Hamster insulinoma HIT-T15 cells, rat insulinoma 
RINm5Fcells, and isolated rat islets were exposed either to sustained hypoxia 
(SH) (1% O2), 64 cycles/24 hours of intermittent hypoxia (IH) (5 min hypox-
ia/10 min normoxia (21%O2)), or normoxia for 24 hours. After the treatment, 
HIT-T15 cells and rat islets were incubated in RPMI1640 medium containing 
5.5 mM glucose (LG), or 22 mM glucose (HG) for 1h in normoxia. Insulin 
in the medium was measured by an ELISA kit. Real-time RT-PCR of insulin, 
CD38, glucose transporter 2, glucokinase, sulfonylurea receptor1, and L-type 
Ca channel1.2 was performed using normoxia- or IH-treated islet RNA as 
template. Cellular proliferation and apoptosis were measured by WST-8 assay 
and TUNEL method, respectively.
Results: The GIS of IH-treated HIT-T15 cells was attenuated, whereas GIS 
of the cells treated with normoxia was increased by HG (p<0.01). GIS from 
the isolated rat islets was also abolished by the treatment of IH. Real-time 
RT-PCR revealed that the level of insulin mRNA was unchanged by IH treat-
ment. We then examined the mRNA levels of several genes involved in GIS 
in the islets. The mRNA levels of glucose transporter 2, glucokinase, sulfony-
lurea receptor1, and L-type Ca channel1.2 in IH-treated-islets were similar to 
those in normoxia-treated islets. In contrast, the mRNA level of CD38 in IH-
treated islets was significantly lower than that in normoxia-treated islets (39% 
of the control), indicating possible dysfunction of the CD38-cyclic ADP-ri-
bose signal system for insulin secretion in IH-treated beta cells. By WST-8 as-
say, the HIT-T15 cell proliferation was significantly increased by IH (p<0.01) 
and decreased by SH (p<0.01) compared to that of normoxia-trated cells. The 
cellular proliferation of RINm5F cells was also increase by IH, whereas apop-
tosis in RINm5F cells and HIT-T15 cells were unchanged by IH treatment. 
The mRNA level of Reg I, an autocrine/paracrine beta cell growth factor, was 
significantly increased by IH-treated RINm5F cells.
Conclusion: These results indicate that IH stress attenuates GIS and stimu-
lates beta cell proliferation as compensatory response. It is quite possible that 
the cyclic change of hypoxia-reoxygenation, which occurs in SAS patients, 
induces beta cell dysfunction and proliferation, resulting in glucose intoler-
ance and type 2 diabetes.
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Pancreatic beta cell Uchl1 regulates glucose homeostasis in high-fat fed 
mice
K. Chu1, H. Li1, K. Wada2, J.D. Johnson1; 
1Cellular and Physiological Sciences, University of British Columbia, 
Vancouver, Canada, 2Degenerative Neurological Diseases, National Institute 
of Neuroscience, Tokyo, Japan.
Pancreatic beta-cells are professional secretory cells with substantial protein 
production and degradation demands. Defects in the production or secre-
tion of insulin contribute to the pathogenesis of diabetes. Pancreatic beta-
cells express ubiquitin C-terminal hydrolase L1 (Uchl1) is a component of the 
ubiquitination pathway, which deubiquitinizes polyubiquitin into monomers 
after proteasomal degradation, but its functional role has not been studied. 
Our previous proteomic screen suggested that Uchl1 protein was increased 
by the fatty acid palmitate at 5 mM glucose. Here, western blot analysis con-
firmed that Uchl1 protein was increased by 24-hour palmitate treatment at 5 
mM, but surprisingly not 25 mM, glucose. Ubiquitin levels were reduced at 
high glucose condition independent of palmitate treatment. Mice harbouring 
the gracile axonal dystrophy (gad) mutation in the Uchl1 gene were used to 
study the role of Uchl1 in lipid-induced pancreatic beta-cell dysfunction. Gad 
mice exhibited normal body weight, glucose tolerance, and insulin tolerance, 
beta-cell mass and islet architecture on a normal chow diet. However, after 
4 weeks of high fat feeding, male gad mice became glucose intolerant and 
without changes in insulin sensitivity. In these gad mice, the first phase of in-
sulin secretion was impaired in both in vivo and in vitro studies. Intracellular 
calcium level was not affected, suggesting a specific defect in the exocytosis of 
insulin. Islets from Uchl1 mutant mice also exhibited an increase in ER-stress 
and apoptosis. Together, these data suggest that beta-cell UCHL1/gad may 
play a previously unappreciated role in glucose homeostasis.
Supported by: CDA
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Rapid alternations in DNA methylation patterns in insulin-producing 
beta cells correlate with changes in ambient glucose levels
E. Wallin Öhman1, J. Staaf1, R. Nilsson1, M. Fraga2, P. Bergsten1; 
1Department of Medical Cell Biology, Uppsala University, Sweden, 
2Department of Immunology and Oncology, National Center for 
Biotechnology, Madrid, Spain.
Background and aims: Elevated levels of glucose are characteristic of indi-
viduals with type 2 diabetes mellitus. Prolonged hyperglycemia is detrimen-
tal for insulin-producing beta-cells and leads to impaired glucose-stimulated 
insulin secretion and apoptosis. The harmful effects have been connected 
with changes in transcript levels of several genes. The aim was to determine 
whether extended episodes of hyperglycemia and the following alternations 
in gene expression are connected with changes in epigenetic patterns and, if 
so, such patterns can be reversed following a period of normoglycemia.
Materials and methods: Insulin-secreting INS-1E cells were cultured at 16.7 
mM glucose for 1, 3, 5 or 7 days. For cells cultured for 7 days, the glucose con-
centration was reduced from 16.7 to 11 mM glucose during the last 2 days. 
Cells cultured at 11 mM glucose were used as controls. Cells were harvested 
after 1, 3, 5 and 7 days and total DNA extracted for analysis of DNA meth-
ylation. After sodium bisulfite treatment, DNA was amplified by PCR and 
subsequently sequenced. DNA methylation patterns were measured at four 
different sites in the repetitive DNA segment Long Interspersed Nucleotide 
Element (LINE) 1. The methylation status of this segment is known to be 
representative of global DNA methylation patterns.
Results: INS-1E cells cultured at 16.7 mM glucose for 24 hours showed no 
changes in methylation of the CpG sites within LINE1. In contrast, after 3 days 
a significant change in the methylation patterns was observed in cells exposed 
to 16.7 mM glucose. No further change was observed after 5 days of exposure 
to the hyperglycemic milieu. Interestingly, methylation patterns were reversed 
back to those observed in control cells when cells cultured at 16.7 mM glucose 
for 5 days were exposed to 11 mM glucose for an additional 2 days.
Conclusion: Exposure to elevated glucose levels induces global epigenetic 
changes in the beta-cell within only a few days. These changes can be reversed 
by normalization of the glucose levels. Glucose-induced epigenetic changes 
may thus contribute to altered transcription levels associated with hyperglyc-
emia. These findings call for experimentation addressing epigenetic changes 
of specific genes. The results illustrate how environmental factors affect gene 
regulation and may give insight into mechanisms connected with develop-
ment and reversal of hyperglycemia and thus serve as a model for disease 
progression and recovery in type 2 diabetes mellitus.
Supported by: Swedish Medical Research Council and Swedish Diabetes Asso-
ciation
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A novel bioinformatics approach combining array profiling and 
independent component analysis identifying microRNAs with potential 
roles in beta cell maturation and dysfunction
T. Fløyel1, C.H. Bang-Berthelsen1, L. Pedersen2, P.H. Hagedorn3, F. Pociot1,4; 
1Hagedorn Research Institute, Gentofte, Denmark, 2Niels Bohr Institute, 
University of Copenhagen, Denmark, 3AstraZeneca, Lund, 4Institute for 
Clinical Science, University of Lund, Lund, Sweden.
Background and aims: The selective β-cell destruction taking place in type 1 
diabetes (T1D) is believed to involve a sensitivity to interleukin-1β (IL-1β) that is 
acquired during β-cell maturation and has been associated with the transcription 
factor Pancreatic and duodenal homeobox 1 (Pdx1). microRNA (miRNA) repress 
gene expression posttranscriptionally through mRNA degradation or translation-
al inhibition. Several miRNAs have been associated with β-cell differentiation or 
dysfunction. The aim of the study was to identify candidate miRNAs by using a 
cellular model of acquired IL-1β sensitivity and a novel bioinformatics approach.
Materials and methods: Array profiling was performed on miRNA and 
mRNA expression levels in a β-cell line with inducible Pdx1 expression 
(INSrαβ) in response to Pdx1 induction alone or in combination with IL-1β 
exposure. Independent component analysis (ICA) was applied to decompose 
the mRNA profiling data into independent components (ICs), thus identify-
ing biologically coherent groups of genes. For identification of inverse cor-
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related miRNA and mRNA expressions Pearson correlation coefficients were 
calculated. Predicted miRNA targets were defined as mRNAs with a given 
miRNA 6mer seed match in their 3’UTR. INS-1 cells were used to verify the 
expression of the identified miRNAs.
Results: Array profiling identified eight miRNAs (miR-124, miR-128, miR-
192, miR-194, miR-204, miR-375, miR-672 and miR-708) with differential 
expression in response to Pdx1 induction and/or IL-1β exposure (Bonferroni 
corrected p<0.1). Four of the eight miRNAs show a significant enrichment 
of predicted targets among highly inverse correlated mRNAs (q<0.01), in-
dicating miRNA-mediated repression of these mRNAs. Performing ICA on 
the mRNA data revealed five highly significant ICs (Bonferroni corrected 
p<0.0001) correlating to the experimental conditions, as shown by a signifi-
cant enrichment of known Pdx1 and IL-1β regulated genes in the respective 
ICs (p<0.05). Interestingly, all eight miRNAs can be represented (percent var-
iance explained >97%) by a superposition of the five ICs. Further, testing for 
enrichment of ICA-identified genes in KEGG-annotated pathways identified 
25 pathways e.g. Type 1 Diabetes Mellitus, Maturity Onset Diabetes of the 
Young and Type 2 Diabetes Mellitus (q<0.05). Except for miR-124, there was 
a good resemblance between the IL-1β-induced miRNA expression changes 
in the INS-1 cells and the Pdx1-induced INSrαβ cells.
Conclusion: The mRNA expression is influenced by a number of factors such 
as accessibility, transcription factor binding and miRNA repression, thus few 
mRNAs have a clear inverse correlation with their targeting miRNAs. Here, ICA 
was applied as an attempt to filter all the various contributions from each other. 
The result was an identification of eight miRNAs with potential involvement in 
β-cell maturation and dysfunction. Interestingly, the miRNAs appear to directly 
or indirectly affect pathways of relevance to disease mechanisms in T1D.
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MicroRNA miR-187 is reduced in human pancreatic islets from type 
2 diabetic donors and in glucagon-secreting cells following palmitate 
treatment
G. Sebastiani1,2, F.A. Grieco1,2, E.T. Maniscalchi3, S. Piro3, P. Marchetti4,  
F. Purrello3, F. Dotta1,2; 
1University of Siena, 2Fondazione Umberto Di Mario, Siena, 3University of 
Catania, 4University of Pisa, Italy.
Background and aims: The pancreatic islet damage during type 2 diabetes 
(DM2) is mediated by lipotoxicity phenomena with consequent beta cell dys-
function and increase in glucagon secretion. In vitro treatment with palmitate 
is sufficient to mimic a functional damage in pancreatic islets similarly to what 
observed in DM2. MicroRNAs are small endogenous RNAs, whose function 
is to pair mRNAs 3’UTRs regions of protein-coding genes, negatively affect-
ing their translation or stability. MicroRNAs are involved in cellular differ-
entiation and proliferation as well as in endocrine pancreas development, in 
regulation of insulin secretion and of insulin signalling. We have previously 
shown a differential miRNAs expression profiling in DM2 vs control human 
pancreatic islets characterized by a major downregulation of miR-187 expres-
sion, which resulted virtually undetectable in DM2 islets. Consequently, the 
aim of the present study was to analyze the effects of palmitate treatment on 
the alpha cell component of the pancreatic islets in terms of miR-187 expres-
sion, in order to establish whether such treatment could mimic in vitro the 
scenario present in the type 2 diabetic islet.
Materials and methods: Experiments were performed employing the al-
phaTC1-6 cell line, which was treated with palmitate 0.5 mM for 48h. Quanti-
tative analysis of miR-187 and of islet specific miR-375 and miR-7 expression 
was performed using stem loop specific primers for reverse transcription fol-
lowed by real time PCR. All values were normalized to U6 endogenous RNA.
Results: A 49±22% reduction of miR-187 (p<0.05) was observed in al-
phaTC1-6 cells following palmitate treatment, while islet-specific miR-375 
and miR-7, whose expression was not found altered in DM2 islets, resulted 
unaffected. Of note, the computational analysis of miR-187 mRNAs targets 
with TARGETSCAN and MIRANDA algorithms revealed genes of potential 
interest such as glucagon, the alpha-cell transcription factor Pax6 and the 
insulin receptor.
Conclusion: This study demonstrates that in vitro treatment with palmi-
tate of alphaTC1-6 cells determines a reduction in miR-187 expression that 
is similar to that observed in pancreatic islets from type 2 diabetic patients, 
thus suggesting that an altered expression of miR-187 could be involved in 
the islet dysfunction in DM2 and therefore may represents a potential thera-
peutic target.
Supported by: FORISID- Italian Diabetes Research Foundation, Italian Minis-
tery of Research
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MicroRNA differences in human islets and glucose-sensitive tissues
C. Bolmeson, J.L.S. Esguerra, D. Speidel, L. Eliasson, C.M. Cilio; 
Dep of Clinical Sciences, Lund University, Malmo, Sweden.
Background and aims: We aim to identify microRNAs (miRNAs) that are 
expressed in the human pancreatic islets compared to other glucose-sensitive 
tissue such as liver and skeletal muscle. The hypothesis is that specific miR-
NAs expression affects the translation of messenger RNAs that are involved 
in glucose-stimulated insulin secretion (GSIS).
Materials and methods: We profiled 322 miRNAs in the islets of a human 
donor, as well as commercial liver and skeletal muscle RNA using locked nu-
cleic acid (LNA)-based microarray. The eight most highly expressed miRNAs 
in islets compared to liver and skeletal muscle were selected, and expression 
in 16 additional human islet donors were validated using quantitative PCR. 
The effects of GSIS on miRNAs expression were investigated by incubating 
the islets for 1 hour at different glucose concentrations. Insulin release from 
intact islets was determined by radioimmunoassay. Bioinformatics predic-
tions of miRNAs targets were filtered by available mRNA expression data, 
and enriched for gene ontology terms.
Results: We found a correlation between mir-375, mir-127 and mir-184 and in-
sulin biosynthesis (Spearman R = 0,8022, p = 0,0005). Surprisingly, all three miR-
NAs were negatively correlated to insulin secretion. Hierarchical clustering of the 
global islet miRNAs profile allowed to separate islet-specific miRNAs from liver 
and muscle-specific miRNAs. Ten qPCR-validated miRNAs displayed expression 
differences in all tissues. Bioinformatic analysis revealed that the predicted miR-
NAs targets were enriched for genes with known role in insulin secretion.
Conclusion: In conclusion, high levels of islet mir-375, mir-127 and mir-184 
may directly or indirectly affect insulin-secretion negatively. Our results also 
depict a role of islet-specific miRNAs in pathways of importance for type 2 
diabetes and maturity onset diabetes of the young (MODY).
Supported by: Swedish Research Council
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Glucagon stimulates glucagon gene transcription in mouse and human 
islets by an autocrine feedback loop
T. Moede, I.B. Leibiger, P. Vaca-Sanchez, P.-O. Berggren, B. Leibiger; 
Dept. Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Background and aims: The glucagon gene is expressed in pancreatic alpha-cells, 
intestinal L-cells and specific neurons, but only the alpha-cell produces and se-
cretes glucagon due to different posttranslational processing. We have demonstrat-
ed that secreted glucagon positively regulates the transcription of its own gene in 
the pancreatic alpha-cell line alphaTC1-9. The molecular mechanism underlying 
this positive autocrine feedback involves the glucagon receptor, protein kinase A 
and C and the transcription factor CREB. Because these observations were made 
utilizing a cell line system, the aim of this study was to verify whether this positive 
feedback mechanism also exists in mouse and human pancreatic islets.
Materials and methods: Mouse islets were isolated from 4 month old BALB/
C mice and cultured for 72 h in RPMI 1640 medium containing 10% fetal calf 
serum (FCS). Human islets were cultured in RPMI 1640 medium containing 
10% FCS for 72 h after arrival prior to experiments. Islets were stimulated 
by either 2 mM glucose for 15 min or 200 nM glucagon for 5 min at 11 mM 
glucose in RPMI 1640 medium containing 10% FCS. After stimulation the 
islets were returned to fully supplemented RPMI 1640 medium. For inhibitor 
experiments the islets were incubated with the pharmacological inhibitors for 
30 min prior to and during the stimulation. 60 min after the start of stimula-
tion RNA was isolated from the islets. Changes in glucagon mRNA levels 
were then determined by QPCR normalized to cyclophilinA mRNA levels. 
Results: Stimulation of islets with low glucose (2mM) led to a 1.4±0.1 fold in-
crease in glucagon mRNA levels. Addition of exogenous glucagon for 5 min re-
sulted in a 3.0±0,1 (mouse) or 2.5±0.2 (human) fold increase of glucagon mRNA. 
This increase was abolished in both mouse and human islets by treatment with 
20 nM glucagon receptor antagonist II (Merck), a specific pharmacological in-
hibitor of the glucagon receptor, demonstrating the critical importance of glu-
cagon receptor signalling. To verify the involvement of protein kinase C and 
protein kinase A in the stimulation of glucagon gene transcription by glucagon, 
we incubated islets with either a protein kinase A inhibitor (100 µM RPCAMPS) 
or a protein kinase C inhibitor (150 nM bisindolylamide II). Either treatment 
abolished the stimulatory effect of glucagon in human and mouse islets.
Conclusion: Our findings demonstrate that secreted glucagon up-regulates 
glucagon gene transcription in both mouse and human islets through an au-
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tocrine feedback loop involving the glucagon receptor and protein kinases 
A and C.
Supporteed by: EuroDia, Novo Nordisk Fonden, Family Erling-Persson Founda-
tion, KI Fonder
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Impact of a stabilized human reg3a protein on islet neogenesis and 
glycaemic control
C.S. Levetan1, A.J. Peters2, K.J. Novelli3, B.E. Marks4, A.E. Katz4,  
R.G. Peterson5, L.V. Upham6; 
1Chestnut Hill Hospital, Philadelphia, 2Unit on Cognitive Neurophysiology and 
Imaging, National Institutes of Health, Bethesda, 3Cabrini College, Rosemont, 
4Thomas Jefferson University School of Medicine, Philadelphia, 5The University 
of Notre Dame, South Bend, 6CureDM, Inc., Wynnewood, USA.
Background and aims: We set forth to compare the impact of a 14 amino acid 
bioactive region within the human Reg3a gene protein known as Human pr-
oIslet Protein (HIP2) on islet neogenesis and glucose-lowering ability to a sta-
bilized form of this protein. The Reg gene is upregulated during new onset in 
type 1 diabetes and among many mammalian species following acute pancre-
atic injury and may be a potential agent to reverse type 1 and 2 diabetes. Reg3a 
is hypothesized as an initiating trigger for islet neogenesis and has been shown 
in animal models to result in formation of new functional islets containing al-
pha, beta gamma and delta cells. HIP was previously shown to significantly 1) 
increase insulin levels in human pancreatic ductal tissue and 2) lower glucose 
levels and increase islet numbers in STZ-rendered diabetic mice.
Materials and methods: The half-life of native HIP2 is 1.2 minutes. We sta-
bilized HIP2 to enhance its potential efficacy as a human drug candidate. 
HIP was modified by blocking the ends, PEGylation and dimerization with 
in vitro trials conducted in a PANC1 cell line. A candidate was selected based 
upon improved half-life (20.4 minutes) without evidence of cell damage. In-
vivo trials were conducted among STZ-rendered diabetic mice. At the end of 
the 39 day study, mice were fasted for 12 hours.
Results: Placebo-treated mice had significantly higher fasting glucose levels 
of 258.00 ± 84.5 mg/dL compared to stabilized HIP2B-treated animals with 
106.7 ± 0.58 mg/dL (p=0.046). HIP2B treated mice had significantly lower 
daily random glucose levels compared to controls (Figure 1). The stabilized 
HIP2B group had a three-fold higher number of islets staining for insulin, 
glucagon and somatostatin compared to the placebo group (94.00 ± 32.74 
and 31.67 ± 15.28 p=0.040). Total islet area was significantly greater in the 
stabilized HIP2B group compared to placebo (416,714.67 µm2± 121,389.01 
and 127,410.67 µm2± 96930.78 p=0.032). There were no differences between 
islet size between the stabilized HIP2B group and placebo (p= 0.518).
Conclusion: HIP2B may address key pathological issues to reverse diabetes. 
For humans to maintain the success seen in mice may require lifestyle modi-
fications among type 2 patients and concomitant usage of immune therapy 
among type 1 patients. Human trials with stabilized HIP2B among type 1 and 
2 patients will commence in the coming year.
Supported by: CureDM, Inc.
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Growth arrest specific protein 6 (gas6) and its receptors expression and 
signalling in beta cells
V.V. Sharoyko1, T. Koeck1, C. Ekman2, N. Wierup3, F. Sundler3,  
B. Dahlbäck2, H. Mulder1; 
1Clinical Sciences, 2Laboratory Medicine, Lund University, Malmo, 
3Experimental Medical Science, Lund University, Lund, Sweden.
Background and aims: The growth arrest-specific protein 6 (GAS6) belongs 
to the family of plasma vitamin K-dependent proteins. It shows homology 
(~40%) to the plasma anticoagulant protein S, another gamma-carboxylated 
protein. GAS6 exhibits growth factor-like effects, as it interacts with receptor 
tyrosine kinase, such as Axl, Tyro3 and Mer. GAS6 and Axl, Tyro3 and Mer 
have further been implicated in inflammation, cytokine production, immune 
responses, hemostasis, and cancer. It was therefore of major interest to study 
GAS6 signalling in islets and clonal beta-cells.
Materials and methods: Glucose-responsive INS-1 832/13 insulinoma beta-
cells and human pancreatic islets were used. TaqMan qRT-PCR analysis was 
applied to measure cytokine mRNA expressions. Immunoblotting and im-
munocytochemistry were used to detect GAS6 and its receptors in human 
pancreatic islets and INS-1 832/13 beta-cells as well as GAS6-induced phos-
phorylation of Axl [pY779] and Akt/PKB [pS473]. To asses further GAS6-
stimulated global post-translational protein modifications, especially tyrosin 
phosphorylation, in INS-1 832/13 beta-cells 2D-PAGE and immunoblotting 
were combined with stable isotope labeling with aminoacids (13C615N1Leu) 
in cell culture (SILAC) to quantify the effect of GAS6 by mass spectrometry. 
To do so, protein samples extracted from 2D-gels were analyzed by MALDI-
Trap and LC-MS/MS.
Results: Immunoblotting and immunocytochemistry showed expression of 
GAS6 and its receptors Axl and Tyro3 but not Mer in human pancreatic is-
lets. Immunoblotting for Axl [pY779] and Akt/PKB [pS473] detected phos-
phorylation of Axl-receptor and Akt/PKB induced by 400 ng/ml GAS6 in 
INS-1 832/13 cells. Thus, treatment of INS-1 832/13 beta-cells with GAS6 
leads to Axl-receptor mediated PI3-kinase/Akt signalling. Furthermore, the 
comparison of untreated and GAS6-stimulated INS-1 832/13 beta-cells by 
2D-immunoblotting for phospho-tyrosine showed 23 modified proteins. Up 
to now, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and glucose 
regulated protein 78 (GRP78/BiP) were identified by mass spectrometric 
peptide sequencing and changes in GAS6-induced protein expression and 
tyrosine phosphorylation quantified based on SILAC. These GAS6-induced 
protein modifications are associated with preventive effect of GAS6 on high 
glucose-induced increase in TNF-alpha mRNA expression in INS-1 832/13 
beta-cells.
Conclusion: We show for the first time that GAS6 and its receptors are present 
in pancreatic islets and beta-cells and alter TNF-alpha production. The em-
ployed proteomic methods revealed that (i) activation Axl/PI3-kinase/Akt 
signalling and (ii) tyrosine phosphorylation of GAPDH and GRP78, as part 
of the cellular response to GAS6-stimulation downstream of PI3-kinase and 
Akt, might be involved in the GAS6 effects on cytokine production. These ef-
fects of GAS6 on pancreatic beta-cells demand further investigations.
Supported by: Swedish Research Council, Novo Nordisk
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Complement receptor C5aR is expressed in pancreatic islets and affects 
glucose-induced insulin and glucagon secretion
V. Nagaraj1, U. Krus1, A. Blom2, E. Renström1; 
1Department of Clinical Sciences, 2Department of Laboratory Medicine, 
Lund University, Malmö, Sweden.
Background and aims: Complement factors form an important part of the 
humoral innate immune system and have been implicated in the pathogen-
esis of autoimmune diseases, including type 1-diabetes. There is however ac-
cumulating evidence that the complement system can modulate pancreatic 
islet function and may also be an important player in the development of 
type 2-diabetes. For example, patients with type 2-diabetes exhibit increased 
neutrophil levels of C5a. C5a is produced as a result of complement activation 
from complement factor C5 and exerts its effect by binding to its receptor 
C5aR. In this study we have detailed the expression of human complement 
system in normal islets, and investigated the role of the C5a and C5a receptor 
antagonist (C5aRant) in human islet function.
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Materials and methods: Expression in human islets: Total RNA was isolated 
from pancreatic islets from 34 non-diabetic donors using the AllPrep RNA 
Mini Kit and analyzed using Gene 1.0 ST whole transcript based assays. Se-
cretion assay: Insulin and Glucagon secretion was measured by RIA using 
donor human islets obtained from the Nordic Network of Clincial Islet Trans-
plantation (Prof. Olle Korsgren, Uppsala University) in collaboration with 
the Lund University Diabetes Center Human Tissue Lab (Dr. Jalal Taneera).
Results: Microarray analysis demonstrated the presence of transcripts of 
nearly all the complement genes in human pancreatic islets. Next, the effect 
of C5a on insulin and glucagon secretion was investigated using normal and 
diabetic human islets. In normal human islets, C5a failed to affect glucose-
stimulated insulin secretion (16.7mM). However, addition of C5a together 
with the C5a receptor antagonist (C5aRant), significantly increased insulin 
release by (32%; P=0.003; n=38). It was ascertained that the C5aR antagonist 
alone did not stimulate insulin release. Interestingly, in diabetic human islets 
C5a and C5aR antagonist did not produce any significant effects on insulin 
secretion. Similar observations were made for glucagon measurements. In 
the normal human islets, C5a had no significant effect, whereas in the simul-
taneous presence of C5a and C5aRant an increase in the amount of glucagon 
released was observed (37%; P=0.003; n=37). In diabetic islets, the effects on 
glucagon secretion by C5a and the C5a receptor antagonist were essentially 
similar to normal islets; C5a alone had no clear effect, whereas addition of the 
C5a receptor antagonist C5aRant produced a clear increase (57%; P<0.0001; 
n=12) in glucagon release.
Conclusion: Human islets express all complement factors. The C5a signalling 
system affects both insulin and glucagon secretion. In addition, C5a signal-
ling in the beta-cell may be altered in type 2-diabetes.
Supported by: Linnaeus grant to Lund Univ Diabetes Center from Swedish Re-
search Council
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p140Cas-associated protein (Cap), expressed in beta cell, suppresses 
insulin secretion
M. Yamauchi1, H. Okada1, K. Fujioka1, I. Mori1, T. Hanamoto1, T. Ikeda1,  
Y. Uno1, H. Morita1, K.-I. Nagata2, K. Kajita1, T. Ishizuka1; 
1General Internal Medicine, Gifu University Graduate School of Medicine, 
Gifu City, Japan, 2Molecular Neurobiology, Developmental Research, Aichi 
Hyman Service Center, Kasugai, Japan.
Background and aims: p140Cap is a multidomain adaptor protein that was 
first found as an interactive partner of p130Cas (Crk-associated substrates), a 
protein highly tyrosine phosphorylated in fibroblasts transformed with v-Src 
or v-Crk oncogene. In non-transformed cells, p130Cas is tyrosine phospho-
rylated upon ligation of integrins. p140Cap is also tyrosine phosphorylated 
upon integrin-dependent adhesion or epidermal growth factor signaling, 
indicating a possible role in cell matrix and in growth factor signaling. In 
addition, p140Cap was also identified as a synaptosome-associated protein of 
25 kDa (SNAP-25)-interacting protein. SNAP-25 plays a major role in mem-
brane docking of synaptic vesicles during neurotransmitter release. Subcel-
lular fractionation analysis suggested that p140Cap interacts with cortical 
cytoskeleton as well as SNAP-25, it may contribute to neuronal secretion in 
brain. We had identified a multidomain adaptor protein, vinexine, of which 
third Src-homology domain interacts with the C-terminal Pro-rich motif of 
p140Cap with screening study of p140Cap-binding proteins in rat brain. In 
this study, we examined the possibility whether p140Cap and vinexine might 
be expressed in the pancreas islet, since proteins involved signal transduc-
tions in neurons are often shared with endocrine cells.
Materials and methods: Immunohistological studies using anti-p140Cap 
antibody and anti-vinexine antibody were performed in rat pancreas. Next, 
to evaluate the role of p140Cap, the effect of gene silencing using the complex 
of Lipofectamine 2000 and shRNA on glucose-stimulated insulin secretion 
was examined in Ins-1 cells and cultured rat insulinoma cells. We studied 
effect of progression of diabetes mellitus on the expression of p140Cap in 
Otsuka Long Evans Tokushima Fatty (OLETF) rats, a model of obese type 
2 diabetes.
Results: Although p140Cap is associated with vinexine in neurons, p140Cap 
was detected in beta cells, whereas vinexine in alpha cells in islet. Insulin se-
cretion was elevated in the presence of glucose with time and dose depending 
manner in Ins-1 cells. Knockdown of p140Cap with shRNA enhanced glu-
cose-stimulated insulin secretion to 260% without increasing in basal insulin 
level. Silencing of p140Cap resulted in an increase of high potassium-stimu-
lated insulin secretion, but no increase in glucose-stimulated one in MIN6 
cells. Our results strongly suggested that p140Cap might negatively regulate 
insulin secretion in beta cells. Moreover, both immunoreactive insulin and 
p140Cap were detected in the same cells of pancreas islets in control rat, while 
poor concordance was observed in OLETF rats. In conclusion, p140Cap and 
vinexine were recognized in beta cells and alpha cells, respectively.
Conclusion: p140 Cap was expressed in beta cell, which may negatively regu-
late insulin secretion.
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Expression and function of equilibrative nucleoside transporter 3 in beta 
cells
B. Liu1, K. Hussain2, C.C. Richardson1, P.M. Jones1, S.J. Persaud1; 
1Diabetes Research Group, King’s College London, 2Institute of Child 
Health, University College London, United Kingdom.
Background and aims: Loss of function recessive mutations in the SLC29A3 
gene encoding ENT3 have been identified in a novel diabetes syndrome 
called “pigmented hypertrichotic dermatosis with insulin-dependent diabe-
tes” (PHID). ENT3 is a member of the equilibrative nucleoside transporter 
family that function primarily as cellular mediators of nucleoside uptake. It 
is distinct from other ENTs due to its predominant intracellular localisation. 
Recently, it was reported that in human hepatocytes and placental tissues, 
ENT3 is expressed mainly in the mitochondria, to which it transports native 
nucleosides. This study aimed to investigate the expression and function of 
ENT3 in pancreatic beta cells.
Materials and methods: ENT3 expression was examined by RT-PCR, West-
ern blotting and immunohistochemistry. The subcellular localisation of 
ENT3 was determined by exposure of MIN6 beta cells to MitoTracker red 
CMXRos before subsequent immunostaining with an ENT3 antibody. Cy-
tokine-induced apoptosis was quantified by caspase 3/7 assays in MIN6 cells 
that had been either exposed to the ENT inhibitor dipyridamole or trans-
fected with ENT3 siRNAs.
Results: PCR amplifications using human and mouse ENT3 primers pro-
duced single products of the appropriate sizes from human islet, MIN6 beta 
cell, mouse islet, and exocrine pancreas cDNAs. Western blotting using an 
ENT3 antibody detected a 52kDa protein in human islets, mouse islets and 
exocrine pancreas. A 65kDa protein was detected in MIN6 cells, mouse islets 
and exocrine pancreas, which most likely represents a post-translationally 
modified form of ENT3. Immunohistochemistry using archived human pan-
creas sections demonstrated extensive ENT3 immunostaining of beta cells, 
which was confirmed by co-staining with an anti-insulin antibody. Further-
more, immunostaining of MIN6 cells that had been exposed to MitoTracker 
with an ENT3 antibody showed co-localisation of ENT3 to beta cell mito-
chondria. Inhibition of MIN6 cell ENTs with 10 µM dypridamole resulted 
in significant increases in basal apoptosis (caspase 3/7 assay luminescence 
units; dypiridamole-treated vs. control: 47,741 ±2,249 vs. 42,550 ±840; n=8; 
P <0.05) and in cytokine-induced apoptosis (725,136 ±28,919 vs. 624,147 
±24,279; n=8; P <0.05). More specifically, MIN6 cells transfected with siR-
NAs directed against mouse ENT3 showed significantly enhanced levels of 
cytokine-induced beta cell apoptosis compared to control cells transfected 
with scrambled siRNAs (139,634 ±4,613 vs. 106,426 ±3,001; n=8; P <0.001).
Conclusion: These observations demonstrate that ENT3 is predominantly 
expressed by islet beta cells, with lower expression levels detected in the exo-
crine pancreas. Our results also indicate that ENT3 co-localises with mito-
chondria in MIN6 cells, suggesting a functional role in beta cell physiology. 
Finally, reduced ENT3 activity or expression is associated with enhanced beta 
cell apoptosis, which might account for the occurrence of autoantibody-neg-
ative insulin-dependent diabetes in individuals with non-functional ENT3 
mutations.
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The role of neurexins in the exocytosis of insulin granules from beta cells
M. Mosedale, A.T. Suckow, S. Egodage, R.C. Calma, S.D. Chessler; 
Medicine, University of California, San Diego, La Jolla, USA.
Background and aims: Pancreatic β cells express many protein constituents 
of the neurotransmitter exocytotic machinery including a family of trans-
membrane, synaptic adhesion molecules called neurexins (NRXNs). In the 
brain, α-NRXNs help organize the neuronal exocytotic machinery via extra-
cellular interactions with other synaptic proteins and via intracellular interac-
tions with the exocytotic proteins CASK, Mint, Munc18, and Syntaxin. We 
hypothesized that α-NRXNs play a comparable role in β cells, participating 
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in insulin secretory granule docking and exocytosis. The aims of this study 
were:
1) to characterize NRXN expression in β cells.
2) to determine if NRXN contributes to insulin granule exocytosis.
Materials and methods: Plasma membrane purification, western blot analy-
sis, immunostaining, and absolute RT-qPCR were used to examine NRXN 
expression and localization in β cells. Immunoprecipitation was used to 
identify NRXN binding partners in the INS-1E β-cell line. To test whether 
NRXNs are involved in insulin secretion, we examined the effect on glu-
cose-stimulated insulin secretion of NRXN1 knockdown using siRNA and 
of NRXN1 overexpression in INS-1E β cells. Knockdown and overexpression 
experiments were also conducted by measuring glucose-stimulated human 
growth hormone (hGH) secretion from cells cotransfected with hGH. Con-
stitutive secretion in knockdown experiments was evaluated by cotransfect-
ing NRXN1 siRNA with secreted alkaline phosphatase (SEAP) and measur-
ing SEAP secretion at basal (2.5mM) and high (15mM) glucose. Western blot 
analysis was used to examine NRXN protein levels in INS-1E β cells after 
high glucose stimulation.
Results: We determined that NRXN protein is expressed on the β-cell surface 
and is not present in other islet cell types. NRXN1α and 2β are the most abun-
dant NRXN isoforms in the β cell, with transcript levels comparable to those 
in brain. CASK, Syntaxin1 and Munc18 coimmunoprecipitated with NRXN1 
from INS-1E β cells. Decreased NRXN1 expression after siRNA treatment of 
INS-1E cells resulted in a 54% increase (p<0.05) in insulin secretion at high 
glucose but had no effect on basal insulin secretion. This result was confirmed 
by measuring secretion of transfected hGH, which is packaged and secreted 
in insulin-containing secretory granules. NRXN1 knockdown did not affect 
constitutive secretion. Increased levels of NRXN1 had no effect on secretion 
at high glucose but resulted in a slight (24%) but consistent increase in basal 
secretion. After 1h of glucose stimulation, NRXN1 protein levels decreased 
by 33% in non-transfected and 40% in NRXN1-overexpressing INS-1E β cells 
(p<0.05).
Conclusion: We conclude that NRXN1 is an integral component of the β-cell 
submembrane secretory machinery. NRXNs are involved in the exocytosis of 
insulin granules from β cells, possibly by organizing the exocytotic machin-
ery and/or by contributing to the granuphilin-mediated docking of granules 
at the β-cell surface. Increased insulin secretion after NRXN1 gene silencing 
and the decrease in NRXN1 levels observed during glucose stimulation sug-
gest that NRXN1, like granuphilin, contributes to the negative regulation of 
insulin release. Future work will determine the role of NRXNs in the docking, 
priming and fusion steps of insulin granule exocytosis.
Supported by: US NIH (NIGMS and NIDDK)
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Neuroligin-2 increases insulin expression and secretion in pancreatic 
beta cells via extracellular binding interactions
S.D. Chessler1, I.R. Sweet2, S. Egodage1, D. Comoletti3, P. Taylor3,  
A.T. Suckow1; 
1Department of Medicine, University of California, San Diego, La Jolla, 
2Department of Medicine, University of Washington School of Medicine, 
Seattle, 3UCSD Skaggs School of Pharmacy and Pharmaceutical Sciences, La 
Jolla, USA.
Background and aims: The pancreatic β-cell secretory apparatus is similar 
to that used by neurons for synaptic exocytosis. Many of the scaffolding and 
vesicular proteins important for neurotransmitter secretion are key compo-
nents of the β-cell insulin secretory machinery. In neurons, extracellular in-
teractions of neuroligin proteins with either neurexins or other synaptic pro-
teins help to drive the recruitment of the exocytotic machinery to the axonal 
membrane. These transmembrane, synaptogenic adhesion molecules are of 
particular interest because a specific subset is expressed by β cells and because 
neuroligin-2 (NL-2) has been implicated by our group in the regulation of 
insulin secretion. These results along with previous studies demonstrating 
a role for neuroligins in the maintenance and differentiation of the neuro-
transmitter release machinery in the brain and the importance of cell-cell 
contacts in the regulation of insulin secretion led us to test the hypothesis that 
NL-2 helps to drive the assembly of the β cell secretory apparatus through 
extracellular interactions that facilitate β cell maturation and regulated in-
sulin secretion.
Materials and methods: Antibodies targeted to the NL-2 extracellular do-
main and recombinant soluble NL-2 were utilized to test for the presence 
of NL-2 protein and NL-2 binding partners on the β cell surface. The role of 
extracellular interactions involving NL-2 in contact-enhanced stimulus-se-
cretion coupling and β-cell insulin expression was tested by assessing insulin 
secretion and content after co-culturing MIN-6 and INS-1E β cells with other 
cells (HEK293) transfected with NL-2 or control expression constructs. Solu-
ble NL-2 protein was utilized to disrupt extracellular protein interactions in 
rat islets and MIN6 cell cultures. The binding of radioiodinated, recombinant 
NL-2 to the surface of intact β cells was analyzed by determination of com-
petitive binding curves.
Results: Fluorescence flow cytometry reveals that NL-2 is expressed on the 
surface of INS-1E and MIN-6 β cells. Binding of NL-2 to the β cell surface 
was also detected, with INS-1E and MIN6 β cells each yielding two distinct 
populations with different binding properties. The dissociation constant (Kd) 
of NL-2 with its binding partner on the β-cell surface is 15 nM, lower than 
would be expected if the binding partner were neurexin. Addition of solu-
ble NL-2 to the culture media of isolated rat islet or INS-1E β cells reduces 
insulin secretion by up to 70% in a concentration-dependent manner. Half-
maximal inhibition of insulin secretion is achieved with 9 nM soluble NL-2, 
a concentration approximately the same as the Kd of the binding interaction. 
Coculture of β cells with cells expressing neuroligin-2 increased stimulated 
insulin secretion by 37% (p<0.01) and cellular insulin content by up to 40% 
(p<0.05).
Conclusion: NL-2 is expressed on the β cell surface and binds with high af-
finity to another β-cell surface protein. Extracellular interactions involving 
NL-2 increase insulin expression and secretion by β cells. These results are 
consistent with the hypothesis that NL-2 promotes the development and 
maintenance of the insulin secretory machinery in β cells through trans-cel-
lular interactions.
Supported by: U.S. NIH (NIDDK) and NSF
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Inhibition of beta-secretase activity affects pancreatic beta cell function
P. Casini, S. Piquer, S. Casas, J. Altirriba, R. Gomis, A. Novials; 
Laboratori de Diabetis i Obesitat. IDIBAPS. Hospital Clínic. CIBER de 
Diabetes y Enfermedades Metabolica Asociadas (CIBERDEM), Barcelona, 
Spain.
Background and aims: BACE1 and BACE2 (ß-site APP-cleaving enzyme 1 
and 2) are proteases sharing typical structural features with type I membrane 
associated aspartyl proteases. Both enzymes have been found to be differ-
ently expressed in various human tissues and, in particular, BACE1 appears 
to be more abundant in the brain, where it is involved in the pathogenesis 
of Alzheimer’s disease as the ß-secretase generating the ß-amyloid peptide. 
In all amyloidogenic diseases, including Alzheimer’s Disease and Diabetes, 
abnormally folded and insoluble proteins accumulate within or around cells 
and interfere with their function. Although the ß-secretases BACE1 and 
BACE2 have also been found in the pancreas, their functional role in this 
tissue still remains unknown. This report is aims to characterize the localiza-
tion of BACE proteins in the human pancreas and to determine their role on 
pancreatic function.
Materials and methods: The enzymatic activity of BACE was detected in 
protein extracts of the human pancreas with a fluorometric ß-secretase pro-
teolytic activity assay. Immunoblot and immunohistochemistry with specific 
antibodies in paraffined sections were used to determine the human pancre-
atic cell types expressing BACEs. The intracellular localization of BACE1 and 
BACE2 was assessed by the immunocolocalization with specific intracellular 
markers (Na+/K+-ATPase, clathrin, insulin, Gm130, Tfrc) in MIN-6 cell line. 
To study the role of BACE on MIN-6 cells, we used a selective and fast cell-
permeable substrate-based inhibitor designed from the ß-secretase cleavage 
sites (BI-II). Real time-PCR was used for insulin transcript quantification.
Results: High levels of BACE enzymatic activity were detected in protein 
extracts of human pancreatic islets and exocrine tissue. In human, BACE1 
is expressed by both a and ß pancreatic cells population as well as in the 
exocrine tissue, while BACE2 is restricted to islet ß-cells. The intracellular lo-
calization of BACEs in MIN-6 cells showed BACE1 colocalization with insu-
lin and BACE2 expression in clatrin-coated endocytic vesicles of the plasma 
membrane. When BACE pharmacological inhibition (BI-II) was performed 
for 24h in MIN-6 cells, BACE2 content in plasma membrane and clathrin-
coated vesicles was significantly increased compared to control (from 4.8±0.8 
to 9.7±2.6%, p<0.05 and from 14.0±2.6 to 26.2±1.9%, p<0.001 respectively), 
suggesting a BACE2 involvement in the processes of receptor-mediated en-
docytosis and recycling by clathrin-coated vesicles. The analysis of insulin 
internalization rate after glucose stimuli is reduced in BI-II treated MIN-6 
cells compared to control (0.23±0.02 to 0.30±0.02%, p<0.05) despite of sig-
nificantly increased levels of IRß protein extracts. The immunofluorescence 
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analysis showed a significant decrease in receptor expression at the plasma 
membrane (Na+/K+-ATPase) of treated cells compared to control (from 
4.9±1.9 to 0.3±0.01%, p<0.05), with the receptor pool being retained in the 
Golgi apparatus (Gm130). Coherently with the impaired IRß trafficking to 
the plasma membrane, we also observed a 1,4 fold reduction in the transcrip-
tional activity of the insulin promoter.
Conclusion: Our data suggest that the ß-secretes activity is needed for insu-
lin expression in ß-cells and that the BACE2 is the enzyme involved. Thus, 
BACE2 is here presented as a potentially essential enzyme for ß-cell func-
tion.
Supported by: FIS 
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Transgenic mice expressing an intestine-specific secretory protein, 
IBCAP, demonstrates pancreatic beta cell augmenting activity
T. Yokoo1,2, K. Watanabe3, K. Tada-Iida3, H. Suzuki3, H. Shimano3,  
S.-E. Ishikawa1, M. Kawakami1, Y. Okazaki2, N. Yamada3, H. Toyoshima1; 
1Division of Endocrinology and Metabolism, Department of Medicine, 
Saitama Medical Center, Jichi Medical University, Saitama, 2Division 
of Functional Genomics & Systems Medicine, Research Center for 
Genomic Medicine, Saitama Medical University, Hidaka, 3Department of 
Internal Medicine, Metabolism and Endocrinology, Graduate School of 
Comprehensive Human Sciences, University of Tsukuba, Japan.
Background and aims: Recent success with GLP-1 analogs and DPP IV in-
hibitory drugs in the clinical application for diabetic patients has highlighted 
the role of intestine as a hormone producing organ. Crucial roles of these 
hormones, including GLP-1, GIP and Ghrelin, in the control of energy me-
tabolism and food intake, and their relation with the metabolic syndrome 
have been brought to worldwide attention. In the current studies, we aimed 
to search for secretory proteins expressed in the intestine.
Materials and methods: We have constructed and screened a mouse intes-
tinal cDNA library to search for genes encoding secretory and membrane 
proteins, using the Oligo-cap Signal Sequence Trap (Oligo-cap SST) method 
developed in our laboratory. For CF266 functional analysis in vivo, we pre-
pared the recombinant CF266 expressing adenovirus and we analyzed the 
phenotype of CF266 over-expression mice model.
Results: We have identified CF266 as a novel intestine-specific secretory pro-
tein using the Oligo-cap SST strategy. We demonstrated that CF266 had in-
sulin secretion promoting effect, and furthermore, that adenovirus-mediated 
expression of CF266 in STZ-treated type 1 diabetes model mice improved 
the blood glucose level of the animal, and showed the increased pancreatic β-
cells detected by the histological analysis. Here, we have developed transgenic 
(Tg) mice expressing CF266 under the control of CAG-promoter. Analyses 
of the Tg mice have shown marked increase of pancreatic islets, confirming 
our former findings with the STZ-induced diabetic mice treated with CF266 
expressing adenovirus. Thus, we renamed CF266 as IBCAP; intestine-derived 
beta-cell augmenting promoter. Further analyses have shown that blood glu-
cose concentration and OGTT of IBCAP Tg mice are relatively normal com-
pared with the control mice. Therefore, IBCAP seems to have promoted the 
augmentation of islets which are functionally normal. We are now testing 
whether augmentation of the β-cell islets is due to inhibition of apoptosis or 
stimulation of proliferation.
Conclusion: Our findings will provide IBCAP as another potential therapeu-
tic target for diabetes and pancreatic β-cell regeneration.
Supported by: Ministry of Education, Culture, Sports, Science and Technol-
ogy of Japan
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Increased phosphorylation of FOXO1 during glucocorticoid excess is not 
mediated by SGK1 (Serum glucocorticoid inducible kinase 1) in insulin 
secreting cells
G. Schulz-Raffelt1, S. Berchtold2, D. Michael1, F. Ranta1, H.-U. Häring1,  
S. Ullrich1; 
1Internal Medicine IV and Clinical Chemistry, 2Internal Medicine I, 
University of Tübingen, Germany.
Background and aims: The essential role of insulin receptor signalling 
including PI3K and PKB activation for sufficient insulin disposal is well 
documented. Previously, we demonstrated that glucocorticoids induce the 
expression of serum- and glucocorticoid-inducible kinase 1 (SGK1), an en-
zyme with 54 % identity in the catalytic domain with PKB and stimulated by 
insulin. SGK1 in parallel to PKB exerts anti-apoptotic effects in a variety of 
cells. Indeed, unlike glucocorticoids, transfection with SGK1 did not aug-
ment apoptotic cell death of insulin secreting INS-1E cells. The aim of the 
present study was to examine whether FOXO1, a PKB substrate, is regulated 
by SGK1 in cells under glucocorticoid excess.
Materials and methods: Insulin secreting INS-1E cells were treated with dex-
amethasone (dexa, 100 nM) to induce the endogenous expression of SGK1. 
SGK1 activity was selectively inhibited with a specific inhibitor (GSK650394) 
or by transient transfection with siRNA against SGK1. Alternatively, cells 
were transiently transfected with constitutive active or dominant negative 
hSGK1. Expression and phosphorylation of proteins were analyzed by West-
ern blotting. Cellular distribution of immunostained proteins was examined 
using confocal microscopy.
Results: Treatment of the cells with dexa reduced phosphorylation of PKB, 
but paradoxically increased phoshorylation of FOXO1. The inhibition of PKB 
by Akti-1/2 abolished phosphorylation of FOXO1 in control cells. In dexa-
treated cells FOXO1 phosphorylation was inhibited by Akti-1/2 but not by 
SGK1 inhibitor (up to 10 µM). In parallel, Akti-1/2 promoted nuclear trans-
location of FOXO1 while SGK1 inhibitor did not. Pretreatment of cells with 
siRNA against SGK1 inhibited the induction of SGK1 by dexa by 66 % at 
the mRNA level and by 80 % at the protein level. Although SGK1 protein 
level was reduced dexa treatment still increased FOXO1 phosphorylation. 
Furthermore, in cells transfected with either constitutive active or dominant 
negative hSGK1 phosphorylation of FOXO1 was unchanged.
Conclusion: These data suggest that the increased phosphorylation of 
FOXO1 observed after dexa-treatment is sensitive to PKB inhibition but does 
not depend on SGK1 in INS-1E cells.
Supported by: DFG and GRK1302
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PLCζ expressing in islet beta cells: does it express in sperm specifically?
H. Zheng1, W. Wu2; 
1Endocrinology, Xinqiao Hospital, 2Cardiothoracic Surgery, Southwest 
Hospital, Third Military Medical University, Chongqing, China.
Background and aims: Phospholipase C (PLC) is considered to modulate 
insulin secretion stimulated by diverse factors such as nutrients, hormone, 
neurotransmitter and ions. There are six established families of PLC termed 
β, γ, δ, ε, ζ andη, however, the role of each isoform in stimulated insulin se-
cretion remains obscure. In this study, several isoforms of PLC which could 
express in pancreatic beta cell were identified. And the expression level of 
each isoform after stimulated by different factors was quantified in order to 
reveal the function of each isoform in insulin secretion.
Materials and methods: The expression levels of the isoforms of PLC in 
INS-1 cells (a rat insulinoma cell line ) were semi-quantified by RT-PCR. In 
order to study on the role of each isoform in different factor-stimulated insu-
lin secretion, glucose, L-aminoglutaminic acid (L-GLU), chloratum kalium 
(KCL), cholecystokinin-octopeptide (CCK8), and acetylcholine chloride 
were chosen as stimulating factors. INS-1cells were stimulated by the factors 
mentioned above respectively, and the mRNA level of each PLC isoform was 
semi-quantified by RT-PCR.
Results: Surprisingly, PLCζ, an isoform of PLC which was thought to express 
specifically in sperms was detected in INS-1 cell line and rat pancreatic tissue 
in our study. The expression of PLCδ, PLCβ, PLCγ and PLCη could also be 
detected in INS-1 cells except for PLCε. Many isoforms were induced when 
INS-1 cell line stimulated by different factors. PLCδ (1.97 folds), PLCβ and 
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PLCγ expressions on INS-1 cells were significantly up-regulated after stimu-
lation with glucose (P<0.05); PLCβ (1.98 folds), PLCδ and PLCζ expressions 
on INS-1 cells were significantly up-regulated after stimulation with L-GLU 
(P<0.05); PLCη(1.89 folds), PLCδ, PLCγ and PLCζ expressions on INS-1 cells 
were significantly up-regulated after stimulation with KCL (P<0.05); PLCδ 
(2.54 folds), PLCγ and PLCη expressions on INS-1 cells were significantly up 
regulated (P<0.05) after stimulation with CCK8; And the expression of PLCδ 
was increased 1.84 folds when INS-1 cells were stimulated by acetylcholine 
chloride(P<0.05).
Conclusion: This is the first study to demonstrate that PLCζ expresses in islet 
beta cells. The expression of PLCδ was significantly increased while INS-1 
cells were stimulated by glucose, CCK8 and acetylcholine chloride; The ex-
pression of PLCβ was significantly increased while INS-1 cells were stimu-
lated by L-GLU; and the expression of PLCη was significantly increased while 
INS-1 cells were stimulated by KCL. Different isoforms of PLC were differ-
entially expressed while INS-1 cells under different pressures, indicating that 
different stimulation factor stimulate INS-1 cell to secrete insulin through 
different isoforms of PLC.
Supported by: National Natural Science Foundation of China 
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PKCdelta modulates cell cycle progression and survival through the 
regulation of cytosolic-nuclear trafficking of p21 in insulin secreting 
INS-1E cells
F. Ranta, T. Theilig, J. Leveringhaus, H.-U. Häring, S. Ullrich; 
Internal Medicine IV and Clinical Chemistry, University Hospital Tübingen, 
Germany.
Background and aims: The main cause for overt type 2 diabetes mellitus 
is decreased beta-cell mass due to increased apoptosis and reduced prolif-
eration. Accumulating evidences suggest the involvement of PKCdelta in 
apoptotic signalling of beta-cells but little is known about the role of this ki-
nase for proliferation. Regulation of cell cycle through PKCdelta-dependent 
modulation of p21 protein was described in several cell systems. p21WAF1/CIP1 
is an inhibitor of several cyclin-dependent kinases in the nucleus. It has been 
described that PKCdelta- and PKB-dependent phosphorylation of p21 affects 
its cytosolic-nuclear trafficking. In pancreatic beta-cells the role of p21 is still 
under debate. While the p21 KO mice have normal beta-cell mass and repli-
cation rate, the over-expression of p21 in beta-cells led to increased apoptosis 
but surprisingly conferred improved recovery from streptozotocin-induced 
diabetes. This study was undertaken to elucidate the role of PKCdelta and p21 
for cell cycle progression and survival of beta-cell.
Materials and methods: INS-1E cells were stably infected with wild type 
(PKCdeltaWT) or kinase dead (PKCdeltaKN) PKCdelta using a retroviral 
system. Cell cycle was analysed after staining nuclear DNA with propidium 
iodide using fluorescence activated cell sorting (FACS). Proteins expression 
was assessed by Western blotting and their subcellular distribution by West-
ern blotting after nuclear and cytosolic fractionation of cells or by confocal 
microscopy after immunostaining for the respective proteins. Apoptosis was 
quantified by TUNEL staining.
Results: PKCdeltaKN cells displayed reduced growth and increased ap-
optosis (7.8 %), while growth and apoptosis (4.5 %) of PKCdeltaWT cells 
were similar to those of control INS-1E cells (3.7 %). The analysis of cell cy-
cle phases revealed that PKCdeltaKN cells have a strongly impaired G2/M 
transition accumulating in G2, whereas the cell cycle distribution pattern of 
PKCdeltaWT cells did not differ from control INS-1E cells. Further, 17.4 % 
of the PKCdeltaKN cells stained positive for the G2/M marker p-ser10-his-
tone H3 but only 5.8 % of PKCdeltaWT and 8.3 % of control INS-1E cells 
were histone H3-positive. The G2 cell cycle regulatory protein cdc2 and the 
inhibitor p27 were expressed at similar levels in control, PKCdeltaWT and 
PKCdeltaKN cells, whereas p21 protein was reduced in PKCdeltaWT cells. 
The analysis of subcellular distribution showed extrusion of p21 from the 
nucleus in PKCdeltaWT cells. In control cells 8.1 % of nuclei and in PKCdel-
taKN cells 24.2 % of nuclei stained positive for p21. Inhibition of the nuclear 
export machinery with leptomycin B neither induced nuclear accumulation 
of p21 in PKCdeltaWT cells nor augmented the accumulation of p21 in PK-
CdeltaKN nuclei.
Conclusion: These observations suggest that PKCdelta inhibits nuclear en-
trance of p21 and the cytosolic trapping of p21 sustains cell cycle progression. 
On the other hand, in PKCdeltaKN cells increased nuclear accumulation of 
p21 may lead to prolonged G2 phase and impaired cell cycle progression af-
fecting cell growth and survival.
Supported by: DFG 
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Knock-down of PI3K-C2α leads to increased proliferation of pancreatic 
beta cells
B. Leibiger, T. Moede, P.-O. Berggren, I.B. Leibiger; 
Department of Molecular Medicine and Surgery, Karolinska Institutet, 
Stockholm, Sweden.
Background and aims: PI3K-C2α plays an important role in controlling cell 
survival via the intrinsic cell death pathway. Knock-down of PI3K-C2α pro-
tein levels led to a reduction in cell proliferation and viability in a number 
of cancer-derived cell lines. We have recently shown that PI3K-C2α gener-
ates PI(3,4)P2 in beta cells and is involved in glucose-stimulated insulin re-
lease. Knock-down of PI3K-C2α levels leads to reduced PKBα activity, AS160 
phosphorylation and glucokinase protein levels. The aim of this study was to 
evaluate the role of PI3K-C2α in beta cell proliferation and survival.
Materials and methods: MIN6 cells and primary mouse beta cells were 
treated with control siRNA or siRNA against PI3K-C2α. Knock-down of pro-
tein levels of PI3K-C2α was verified by Western blotting (80% knock-down). 
Proliferation in MIN6 cells was measured directly by counting the number 
of cells and by BrdU-incorporation. Apoptosis rate of MIN6 cells after treat-
ment with either H2O2 or staurosporine was determined by triple staining 
with Hoechst 33342, propidium iodide (PI) and AlexaFluor488-annexinV, 
where AlexaFluor488-annexinV positive PI-negative stained cells were con-
sidered apoptotic. Cell proliferation of primary mouse beta cells was deter-
mined by BrdU-incorporation. Phosphorylation of PKB target proteins and 
Raf-1 in MIN6 cells was evaluated by Western blotting.
Results: To our surprise knock-down of PI3K-C2α did not lead to an inhibi-
tion of cell growth like in other cell lines, but to an increased cell proliferation. 
Cell count 120 h after siRNA transfection gave a 3.2 ± 0.12fold increase in cell 
number in PI3K-C2α siRNA-treated cells compared to control siRNA-treated 
MIN6 cells. BrdU incorporation was increased to 21.75 ± 2.54% in PI3K-C2α 
siRNA-treated MIN6 cells (9.38 ± 1.06% in control siRNA-treated cells) and 
to 1.67 ± 0.22% in primary mouse beta cells treated with PI3K-C2α siRNA 
(0.71 ± 0.067% in control siRNA-treated cells). Knock-down of PI3K-C2α led 
to a significant (p<0.05) protection against apoptosis induced by 20µM H2O2 
(11.95 ± 1.86 % apoptotic cells in PI3K-C2α siRNA-treated MIN6 cells ver-
sus 24.19 ± 0.89 % in control siRNA-treated cells) or by 6µM staurosporine 
(24.89 ± 1.37 % apoptotic cells in PI3K-C2α siRNA-treated MIN6 cells ver-
sus 34.61% ± 2.42 % in control siRNA-treated cells). Since insulin-stimulated 
PKBα activity was diminished in PI3K-C2α siRNA-treated cells, we evalu-
ated the phosphorylation of PKB target proteins (TSC2, GSK3β, FoxO1) in 
MIN6 cells after insulin stimulation. GSK3β Ser9-phosphorylation was not 
altered by PI3K-C2α-siRNA treatment. The increase of TSC2-Thr1462- and 
FoxO1-Ser256-phosphorylation after insulin stimulation was abolished by 
PI3K-C2α siRNA-treatment. Ser338-phosphorylation of Raf-1 was increased 
in PI3K-C2α siRNA-treated MIN6 cells after insulin stimulation (1.54 ± 
0.12fold compared to control siRNA-treated cells). The observed changes in 
the phosphorylation status of TSC2 and FoxO1 are in line with diminished 
PKBα activation in response to insulin stimulation, but would lead to inhibi-
tion of cell growth, rather than to its stimulation. The increased phosphoryla-
tion of Raf-1, a kinase of the Ras/Raf-1/ERK cascade known to be involved 
in beta cell proliferation and protection against apoptosis, could explain the 
increased proliferation in PI3K-C2α siRNA-treated cells.
Conclusion: Knock-down of PI3K-C2α in pancreatic beta cells leads to in-
creased cell proliferation by a pathway involving Raf-1 activation.
Supported by: EuroDia, Novo Nordisk Foundation, Family Erling-Persson 
Foundation
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Focal adhesion remodelling is crucial for glucose-stimulated insulin 
secretion and involves activation of focal adhesion kinase and paxillin 
D. Rondas, A. Tomas, P. Halban; 
Genetic Medicine and Development, University of Geneva, Switzerland.
Background and aims: Despite the numerous studies on the mechanism of 
pancreatic beta cell insulin secretion, many aspects of the molecular machin-
ery remain to be elucidated. Actin cytoskeleton remodelling is well known to 
be positively involved in glucose-stimulated insulin secretion (GSIS). We have 
observed glucose-stimulated changes at the beta cell surface that are similar to 
focal adhesion remodelling in cell migration. This led us to study the role of 
two key focal adhesion proteins, Focal Adhesion Kinase (FAK) and paxillin, in 
glucose-stimulated beta cell focal adhesion remodelling and insulin secretion.
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Materials and methods: FACS-sorted rat primary beta cells were used unless 
stated otherwise. For immunofluorescence staining and protein phosphor-
ylation, beta cells were incubated for 2h at 2.8 mM glucose followed by 16.7 
mM glucose for up to 1h. siRNA was used to knockdown paxillin expression: 
cells were transfected (Lipofectamine 2000; 100nM siRNA) 3 days prior to 
testing GSIS [2h pre-incubation at 2.8 mM glucose; 1h 2.8 mM glucose (ba-
sal); 1h 16.7mM glucose (stimulated)]. Data are mean±SEM, n=3 independ-
ent experiments.
Results: In the basal state, FAK (Tyr-397) and paxillin (Tyr-118) were mod-
estly phosphorylated and localised in few long filopodia at the basal cell 
surface. Stimulation for 20 min at high glucose resulted in increased phos-
phorylation of FAK and paxillin and cell spreading, with a 59±8% (p<0.001) 
increase in cell surface area vs. basal after 1h at high glucose. Within 20 min 
at 16.7 mM glucose there was appearance at the basal surface of numerous 
newly formed, shorter actin filopodial extensions, containing phosphor-
ylated paxillin. Co-incubation with the L-type Ca2+ channel blocker, SR-7037 
(10µM), completely inhibited this sequence of events, indicating requirement 
of increased cytosolic Ca2+. Furthermore, knockdown of paxillin (45±2% 
decrease by western blot) decreased GSIS by an average of 61±4% (p<0.05) 
vs. control transfected with scramble RNAi. A 43±1% (p<0.05) decrease in 
GSIS was observed following pharmacological inhibition of glucose-induced 
phosphorylation of FAK Tyr-397 by compound Y15 in the MIN6B1 beta cell 
line; this was confirmed in a single preliminary experiment on primary rat 
beta cells.
Conclusions: We show here that glucose-stimulated spreading of beta cells 
coincides with the remodelling of filopodial extensions and phosphorylation 
of the two main focal adhesion proteins, FAK and paxillin. Additionally, GSIS 
was significantly decreased by paxillin knockdown and inhibition of FAK ac-
tivation, showing for the first time that focal adhesion remodelling is a critical 
event in pancreatic beta cell function.
Supported by: Swiss National Foundation for Scientifique Research 
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Novel aspects of female sex hormone estrogen in diabetes
R. Kumar1, A. Balhuizen1, A. Salehi1, I. Lundquist1, S. Amisten2; 
1Clinical Science, Lund University Malmo, Sweden, 2Clinical Science, 
Oxford University, United Kingdom.
Background and aims: The lower prevalence of diabetes in females suggests 
that female sex steroids protect from β-cell injury. Consistent with this hy-
pothesis, 17β-estradiol manifests antidiabetic actions in humans and rodents. 
Our recent findings show that the stimulatory action of 17β-estradiol on in-
sulin secretion is mediated by the G protein coupled receptor 30 (GPR30), 
raising the prospect that antidiabetic action of 17β-estradiol might be due, 
in part, by an antiapoptotic effect on β-cells exerted through activation of 
GPR30.Therefore,the objective of this study was to identify expression of 
GPR30 in human pancreatic islets and to further clarify the role of GPR30 in 
pancreatic hormone secretion and beta cell survival.
Materials and methods: GPR30 expression was analyzed by confocal micro-
scopy, Western blot and qRT-PCR in human pancreatic islets from female 
and male donors. Hormone secretion and cAMP content in islets were deter-
mined with RIA and apoptosis with the Annexin-V method.
Results: Confocal microscopy revealed GPR30 expression in alpha, beta and 
delta cells of pancreas. GPR30 mRNA and protein expression was markedly 
higher in female vs male islets (p<0.01). Dose-response studies of G-1 (a se-
lective agonist of GPR30) vs 17β-estradiol in isolated islets at 12 mM glucose 
showed an almost similar pattern in potentiating insulin and suppressing 
glucagon and somatostatin secretion. The 17β-estradiol genomic receptor 
(ERα and ERβ) antagonist ICI-182,780 (Fulvestrant) or Acolbifene (EM-
652) did neither influence the amplifying effects of G-1 or 17β-estradiol on 
cAMP content (p<0.001) nor insulin secretion from islets. Cytokine-induced 
(IL1β+TNFα+INFγ) apoptosis in islets, cultured for 24 h at 5 mmol/l glucose, 
was almost abolished by G-1 or 17β-estradiol treatment (p<0.001).These ben-
eficial effects of G-1 or 17β-estradiol on pancreatic islets were not affected by 
either Fulvestrant or Acolbifene.
Conclusion: In view of these novel finding we suggest that drugs that could 
selectively modulate the activity of GPR30, represent a promising frontier in 
diabetes mellitus co-adjuvant therapy.
Supported by: Swedish Research Council
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Polyamines and human pancreatic beta cells
L. Marselli1, J. Thorne2, M. Bugliani1, A. Lena1, M. Tancredi1, K. Fujiwara3, 
V. Gremigni1, A. Sharma2, G.C. Weir2, P. Marchetti1; 
1University of Pisa, Italy, 2Harvard University, Boston, USA, 3Sojo University, 
Kumamoto, Japan.
Background and aims: Polyamines (PA, in particular putrescine, spermidine 
and spermine) are ubiquitous chemical entities that play an important role in 
cell function and turnover, as well as in the synthesis of proteins and nucleic 
acids. Aim of the study was to assess whether PA may be of importance in af-
fecting beta-cells in non-diabetic subjects and type 2 diabetic individuals.
Materials and methods: Pancreatic tissue obtained from 17 type 2 diabetic 
subjects (T2DM; age: 67±9 years; M/F:11/6; BMI: 29±5 kg/m2) and 15 non-
diabetic controls (ND; age: 62±15 years; M/F:11/4; BMI: 26±2 kg/m2) was 
studied. The presence of PA in beta-cells was assessed on electron microscopy 
by immunogold technique. Gene expression studies were performed with iso-
lated islets or beta-cell enriched samples prepared by laser capture microdis-
section. Islets insulin secretion was determined in response to acute glucose 
stimulation after 24 h incubation with or without 2-difluoromethylornithine 
(DFMO, an inhibitor of ornithine decarboxylase I, 5 mM), putrescine (50 
μM) and spermidine (50 μM), alone or in combination.
Results: Putrescine and spermine were detected in beta-cells from ND and 
T2DM by electron microscopy. Localization was mainly in the cytoplasm for 
putrescine and in both the cytoplasm and the nucleus for spermine. Micro-
array analyses showed that ornithine decarboxylase I (key enzyme in PA 
synthesis) was lower in beta-cells (p<0.001) and islets (p=0.03) from T2DM. 
Data were confirmed by qPCR studies, which detected also a lower expres-
sion of arginase II in diabetic samples. DFMO caused a decrease (p<0.05) of 
glucose-stimulated insulin release (-32 ± 9.5%); the same was observed in 
presence of spermidine (-48 ± 32%, p=0.05). Putrescine prevented the inhibi-
tory effect of spermidine.
Conclusion: This study shows that 1) PA are present in human beta-cells; 2) 
PA biosynthesis pathway may be different in type 2 diabetic beta-cells; and 3) 
PA may have a role in insulin secretion.
Supported by: Italian Society of Diabetes
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Insulin secretion is affected by disruption of mini-P-glycoprotein
D.-Q. Li, Y.-Z. Tang, S.-Y. Meng, Q. Ding, D.-M. Yu; 
Key Lab of Hormones and Development (Health Ministry of China), 
Tianjin Metabolic Diseases Hospital, China.
Background and aims: A 65-kDa mdr1-like protein, which exhibited bio-
logical functions similar to the sulfonylurea receptor, had been preliminary 
identified as a mini-P-glycoprotein in rat islets. In this study, the mini-P-
glycoprotein was down-regulated by siRNA technique and effects on biphasic 
insulin secretion were determined.
Materials and methods: Stealth TM / siRNA duplex oligoribonucleotides (In-
vitrogen) was designed to silence the abcb1b gene (mdr1, encoding P-glyco-
protein). Stealth RNAi Negative Control Duplexes was severed as negative 
control. The silencing effects were determined by fluorescence microscopy, 
quantitative PCR and Western blot. Biphasic insulin secretion was investi-
gated in rat islet batch incubations in three different groups: silencing, nega-
tive control and blank (without oligoribonuccleotides). In parallel, apoptosis 
in the rat islets in the respective groups was also evaluated.
Results: After 48 hours incubation, more than 95% of the islets were visibly 
transected. The expression of the abcb1b mRNA was decreased significantly 
by the siRNA but not the abcb1a mRNA, which were used as technique con-
trol (P<0.001 and P=0.815, respectively). Mini-P-glycoprotein expression was 
detected using the specific antibody C219 and was reduced by more than 80%. 
Biphasic insulin release was dramatically reduced by the silencer, both in the 
first and second phase, when compared with the negative control or the blank 
groups (P<0.05 and 0.001; n=10 for all the groups, Fig.1). Apoptosis was in-
duced when islets were cultured in high glucose (16.7mmol/L) culture medi-
um for 48 hours compared to those in normal culture medium. Up-regulated 
expression of casp3 and bax were detected in the silencing group (P<0.01 and 
0.001 vs the negative control group or blank group), while Bcl-2 expression 
was down-regulated (P<0.001). However, the expressions of casp3, bax and 
bcl-2 were not influenced by the silencing of the mini-P-glycoprotein.
Conclusion: The mini-P-glycoprotein may contribute to biphasic insulin se-
cretion. Apoptosis of rat islets is not induced by the disruption of the mini-
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P-glycoprotein. It has been suggested that the mini-P-glycoprotein might 
function as one of the regulatory proteins to the chloride transport protein 3 
to mediate insulin granules acidification and priming. Further investigation 
need to be done to evaluate the underlying mechanisms.
Supported by: an EFSD research grant supported by BMS
PS 36 Receptors, secretagogues and 
modelling in islets
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CART is overexpressed in beta cells of diabetic mice to improve insulin 
secretion
M. Riva, N. Wierup; 
Lund University Diabetes Centre, Lund University, Sweden.
Background and aims: Cocaine- and amphetamine-regulated transcript 
(CART) is a novel islet regulatory peptide. CART null mutant mice exhibit 
impaired glucose tolerance due to islet dysfunction, and diminished expres-
sion of PDX-1. CART regulates islet hormone secretion, including augment-
ing GLP-1-enhanced glucose-stimulated insulin secretion (GSIS) in vitro. 
Moreover, CART is upregulated in the beta cells of Type-2 diabetic (T2D) 
rats. Although the effects of exogenously added CART on the beta cell are es-
tablished, the role of endogenous beta cell CART is unknown. Furthermore, 
CART expression in islets of T2D mouse models has not been studied. We 
studied islet expression of CART in diabetic db/db and ob/ob mice using 
immunocytochemistry and in situ hybridization. To mimic the situation in 
beta cells of T2D models we overexpressed CART in clonal INS-1 (832/13) 
beta cells using adenovirus and measured: 1) Insulin secretion stimulated 
with glucose (GSIS) and an array of secretagogues. 2) Gene expression of 
key genes related to insulin secretion and beta cell function. 3) Regulation 
of CART gene and protein levels after culture in different glucose concentra-
tions.
Materials and methods: Male db/db, ob/ob, and C57BL/6 mice were used. 
CART expression was examined with immunocytochemistry, in situ hybridi-
zation, immunogold labeling and transmission electron microscopy (TEM), 
real-time PCR and Western blot. preproCART was overexpressed in INS-1 
(832/13) cells and insulin secretion after 1h static incubations was analyzed 
using RIA. GFP-adenovirus was used as negative control.
Results: CART was robustly upregulated in beta cells of both db/db and 
ob/ob mice, compared to control mice. Immunogold labeling for CART re-
vealed that CART was located to the beta cell granules. CART overexpres-
sion in INS-1 (832/13) cells was verified using real-time PCR and western 
blot. Overexpression of CART resulted in a moderate and dose-dependent 
augmentation of GSIS. Furthermore, overexpression of CART resulted in 
increased forskolin-enhanced GSIS. On the other hand, overexpression of 
CART was without effect on GSIS in the presence of 35mM KCl. Moreover, 
overexpression of CART elevated mRNA expression levels of insulin, PDX-
1 and syntaxin 1A. On the other hand, CART had no effect on the mRNA 
expression levels of GLUT2, Kir6.2, or Munc-18-1. Culturing CART-over-
expressing cells for 24 h in 16.7 mM glucose provoked a decrease in CART 
mRNA expression and an upregulation of CART protein levels, compared to 
culture in 3 mM and 11.1 mM glucose.
Conclusion: We conclude that CART is upregulated in the beta cells of di-
abetic mice and that beta cell CART is regulated by glucose. Furthermore 
CART stimulates the triggering pathway of insulin secretion, as well as ex-
pression of insulin and genes important for beta cell function and insulin 
exocytosis. Together these data suggest that CART is upregulated in beta cells 
of T2D animals to improve insulin secretion and gene expression. The po-
tential for CART-based substances for future treatment of T2D remains to 
be established.
Supported by: The Novo Nordisk Foundation, Swedish Medical Research Coun-
cil
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Stimulation of 5-HT1a receptor decreased insulin secretion in islets of 
Langerhans from mice and humans
H. Bennet1, C.L.F. Nagorny2, N. Wierup3,4, M. Dekker-Nitert2,  
Å. Lernmark1, M. Fex1; 
1The unit of diabetes and celiac disease, Clinical Science, Malmö, 2Clinical 
science, Malmö, 3Experimental Medical Science, Lund, 4Clinical Science, 
Malmö, Sweden.
Background and aims: 5-Hydroxytryptamine, also known as serotonin 
activates the receptors 5-HT1a (5-hydroxy-tryptophane receptor 1a) and 5-
HT1a (5-hydroxy-tryptophane receptor 2b). 5-HT1a and 5-HT2b are both 
G-protein coupled receptors, 5-HT1a couples negatively to adenylate cyclase 
while 5-HT2b activates Gq and activates the phospholipase C pathway. The 
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G-protein activation result in different cellular events by two distinct intracel-
lular pathways, affecting the levels of calcium in the cell. Both receptors have 
previously been found in islets of Langerhans from rodents. In addition, sero-
tonin has been shown to be present in islet cells from several different animal 
species. As both receptors and amines are present, serotonin may potentially 
regulate hormone secretion from islets of Langerhans. In the previous stud-
ies we have shown that a selective 5-HT2b agonist alpha-Methyl serotonin 
potentiates glucose stimulated insulin secretion from INS-1 cells, mouse, 
and human islets of Langerhans from healthy individuals. This has now been 
further investigated in human islets of Langerhans from type 2 diabetic indi-
viduals. We have also investigated the effect of a 5-HT1a receptor agonist on 
insulin secretion in islets of Langerhans from both mouse and humans.
Material and methods: We used RT PCR and sequence specific primers to 
detected expression of the receptors in the beta-cell line (INS 832/13) and 
in islets of Langerhans. Immuno-histochemical analysis was used to detect 
the receptors at the protein level in rodent islet and human islets. Islets from 
mouse were isolated by standard collagenase digestion. Human and mice is-
lets were incubated with glucose and Buspirone or alpha-methyl serotonin 
at 37 oC for 1h and assayed for insulin secretion. Insulin was measured with 
insulin ELISA specialized for mice and human islets.
Results: 5-HT2b mRNA was found in the 832/13 cells. We also found both 5-
HT1a and 5-HT2b to be expressed in rodent and human islets, at both mRNA 
and protein level. Interestingly, 5-HT receptors in islets were localized in two 
different cell types in the islets. In rodent islets, 5-HT2b was predominantly 
expressed in beta-cells while 5-HT1a was more abundant in the alpha-cells. 
In human, islets the situation was reversed. While stimulation with alpha-
methyl serotonin potentiated glucose stimulated insulin secretion in human 
islets of Langerhans from type 2 diabetic individuals. Buspirone showed a 
significant decrease of insulin secretion at stimulatory glucose concentrations 
in mouse and human islets.
Conclusion: Our results strongly suggest that serotonin and the 5-HT1a and 
2b receptors regulate insulin secretion. As both 5-HT1a and 5-HT2b are ex-
pressed in rodent and human islets and activate two very distinct cellular 
pathways, these receptors may in fact modulate secretion from both alpha 
and beta-cells. In conclusion, pathways of serotonin and its receptors may 
provide exciting new insight in the regulation of islet hormone secretion.
Supported by: Novo Nordisk Foundation, Krapperup Foundation
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Nesfatin-1 stimulates insulin secretion, inhibits glucagon secretion and 
is expressed in human and rodent beta cells
U. Voss, M. Riva, M.N. Dekker Nitert, C. Ling, A. Lindqvist, N. Wierup; 
Lund University Diabetes Centre, Lund University, Sweden.
Background and aims: Nesfatin-1 is a recently discovered regulatory peptide 
with anorexigenic properties. The peptide is the N-terminal part of nucleob-
indin 2 (NUCB2) and is highly expressed in brain areas known to regulate 
feeding behaviour. Outside the brain, nesfatin-1 expression has been reported 
in gastric endocrine cells. We studied the possibility of nesfatin-1 expression 
in human, rat, and mouse islets of Langerhans using immunocytochemistry 
and in situ hybridization. Furthermore, we investigated potential influence of 
nesfatin-1 on secretion of insulin and glucagon. Effects of nesfatin-1 on Ca2+ 
and cAMP levels was studied in INS-1 (832/32) cells, and nesfatin-1 gene 
expression in human islets under glucolipotoxic conditions was examined 
using affymetrix.
Materials and methods: Nesfatin-1 expression was examined using immu-
nocytochemistry, in situ hybridization. Insulin and glucagon secretion after 
1h static incubations of isolated mouse islets was analyzed with RIA or ELI-
SA. Ca2+ fluorescence and cAMP was studied in INS-1 (832/13) cells.
Results: Nesfatin-1 was found to be highly expressed in human islets. Double 
staining for nesfatin-1 and the main islet hormones revealed that nesfatin-1 
was exclusively expressed in human beta cells. Nesfatin-1 was also highly ex-
pressed in rat and mouse islets. The majority of all nesfatin-1 expressing cells 
were beta cells in rat and mouse. In the rat a minor subpopulation of the alpha 
cells harbored also nesfatin-1. Importantly, in situ hybridization and micro-
array for NUCB2 mRNA confirmed the immunocytochemical data. Studies 
in isolated mouse islets revealed that nesfatin-1 stimulates insulin secretion 
at both low (2.8 mM and 5.5mM, p<0.001) and high glucose concentrations 
(11.1. mM, p<0.001). Nesfatin-1 also augmented forskolin-enhanced glu-
cose-stimulated insulin secretion (GSIS) (p<0.01), but not GSIS potentiated 
by carbachol or KCl. In addition, nesfatin-1 lowered secretion of glucagon at 
low (2.8 and 5.5 mM) glucose (p<0.001), but not at high (11.1 mM) glucose. 
Further, nesfatin-1 caused an increase in Ca2+ influx, but decreased cAMP 
in INS-1 (832/13) cells. Moreover, affymetric analysis revealed that NUCB2 
mRNA was moderately upregulated under glucolipotoxic conditions in hu-
man islets.
Conclusion: Together our data suggest that nesfatin-1 is a novel glucose-low-
ering peptide in human and rodent islets. In view of these data, stimulation 
of the nesfatin-1 pathway could be a new treatment strategy for Type 2 dia-
betes.
Supported by: Swedish Medical Research Council
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Expression of Bombesin Receptor Subtype-3 (BRS-3) in islets from 
different species and its role in the regulation of insulin secretion and 
glucose homeostasis 
Y.-P. Zhou, Y. Feng, J. Xiao, J. Gorski, J.M. Metzger, X. Guan, L. Lin,  
A.D. Howard, M. Reitman, N.A. Thornberry, B.B. Zhang; 
Metabolic Disorders, Merck Research Laboratories, Rahway, USA.
Background and aims: Bombesin-like peptides, such as bombesin and gas-
trin-releasing peptide, are known to promote insulin secretion and possibly 
β-cell proliferation. The biological functions of these peptides are mediated 
by a family of G-protein coupled receptors. The expression and roles of those 
receptors in pancreatic islets have not been fully investigated. Here we study 
the physiology of Bombesin Receptor Subtype-3 (BRS-3) in islets from vari-
ous species, as it has recently been shown to be involved in the regulation of 
energy homeostasis and BRS-3 knockout mice manifest age-dependent obes-
ity and reduced islet size.
Materials and methods: TaqMan analysis was used to measure mRNA lev-
els. siRNA-mediated BRS-3 silencing, whole body Brs-3 knockout and BRS-3 
specific agonist or antagonist were used to study the effects of BRS-3 on insu-
lin secretion in mouse and human islets, and glucose tolerance in mice.
Results: Utilizing quantitative PCR, we observed high levels of BRS-3 mRNA 
in human, dog, and mouse (but not rat) pancreatic islets. Silencing BRS-3 
with siRNA or pharmacological blockade with a BRS-3 antagonist, Bantag-1, 
reduced glucose stimulated insulin secretion (GSIS) in the rat INS-1 832/3 
cells. In contrast, activation of the receptor with Bag-1, a potent, selective 
BRS-3 agonist, increased GSIS in the rat insulinoma cell line. The acute effects 
of Bag-1 on GSIS in isolated islets and on blood glucose in vivo during oral 
glucose tolerance tests (OGTT) were examined. Bag-1 significantly enhanced 
GSIS in isolated islets and reduced OGTT glucose levels in wild-type, but 
not Brs3 knockout mice. BRS-3 agonists also promoted GSIS in human islets 
isolated from a non-diabetic subject and from a patient with type 2 diabetes. 
These results reveal a role for BRS-3 in islet physiology, with agonism directly 
promoting GSIS.
Conclusion: In addition to its potential role in the regulation of body weight 
and energy homeostasis, BRS-3 may also regulate glucose homeostasis. Mod-
ulation of BRS-3 represents a potential new mechanism for glycemic control 
in type 2 diabetic patients.
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p42/44 MAPK activation is required for receptor-operated stimulation of 
insulin release
J.E. Bowe, A. Chander, S.J. Persaud, P.M. Jones; 
King’s College London, United Kingdom.
Background and aims: We have previously shown that activation of the re-
ceptors GPR54 and CaR, by kisspeptin and the CaR agonist A568 respective-
ly, potentiates glucose-induced insulin release via a p42/44 MAPK depend-
ent pathway. The present study aimed to further examine the role of p42/44 
MAPKs in receptor-operated potentiation of insulin release.
Materials and methods: Mouse islets were incubated for 1hr in a physio-
logical salt solution and insulin release was measured by radioimmunoassay. 
Activation of p42/44 MAPK was measured by western blotting for phospho-
MAPK relative to total MAPK immunoreactivity.
Results: Both the CaR agonist A568 (10µM) and kisspeptin (1µM) caused 
a significant potentiation of insulin secretion (214±26% and 182±19% basal 
respectively, n=9, p<0.05) at 20mM glucose. The stimulatory effects of both 
A568 and kisspeptin on insulin secretion were significantly blocked by the 
presence of the p42/44 MAPK inhibitor PD098059 (50µM; 131±12% and 
109±8% basal respectively, p<0.05 versus absence of PD098059). However, 
whilst the acetyl choline analogue carbachol (500µM) also significantly po-
tentiated glucose-induced insulin release (287±21% basal, n=9, p<0.05), the 
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presence of PD098059 had no effect. Furthermore, whilst activation of p42/44 
MAPK was enhanced by incubation (5 min, 37ºC) in the presence of stimu-
latory glucose levels, kisspeptin (1µM) had no effect on MAPK activation. 
A568 caused an increase in p42/44 MAPK activation at 2mM glucose, but 
had no effect at 20mM glucose. Finally islets were incubated in the presence 
of okadaic acid and sodium pervanadate in order to inhibit the dephospho-
rylation of p42/44 MAPK. Whilst neither kisspeptin nor A568 significantly 
affect insulin release from islets at sub-stimulatory glucose concentrations 
under normal conditions, in the presence of okadaic acid and sodium per-
vanadate (10µM and 100µM respectively) both kisspeptin and A568 caused 
a significant increase in insulin release from islets incubated at 2mM glucose 
(381±52% and 456±39% basal respectively, n=9, p<0.05).
Conclusion: These observations suggest that p42/44 MAPK activation may 
play a permissive role in the potentiation of glucose-induced insulin secre-
tion by some receptor operated agonists such as kisspeptin and A568.
Supported by: DRWF
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In vitro functions of pancreatic pseudoislets
R.A. Zuellig, R.E. Locher, G.A. Spinas, R. Lehmann; 
Division of Endocrinology, Diabetes and Clinical Nutrition, University 
Hospital Zurich, Switzerland.
Background and aims: Recently it was shown, that transplantation of small 
islets results in a better outcome than transplantation of large islets. Small 
islets can be produced in vitro by dissociating islets of all sizes in single cells 
and reaggregating the dispersed islet cells into pseudoislets of defined small 
sizes by the hanging drop method. We describe an alternative method to 
produce pseudoislets of different sizes in micro-well plates and analyse their 
morphology and in vitro function.
Materials and methods: Islets were dissociated into single cells by trypsin/
EDTA treatment. The cells are seeded at defined densities into hanging-drops 
(HD) or especially designed micro-well plates. Plates of four different types of 
plastics were used: two types of polycarbonate (PC and NO), one polystyrene 
(PS) and one cyclic olefin copolymer (TO). Islets and seeded islet cells were 
cultivated for 7-14days and the resulting pseudoislets analysed in terms of 
morphology and glucose-stimulated-insulin-secretion (GSIS).
Results: Dissociated islet cells reaggregated to pseudoislets in micro-well 
plates. There was no significant difference in pseudoislet size between the dif-
ferent plastics. Pseudoislets originating from 300 seeded cells have an aver-
age diameter of (in micrometer) NO 60.9±15.4 n=15, PC 62.7±20.7 n=14, 
PS 70.7±17.7 n=9, TO 65.4±14.1 n=18; NO-PS p=0.19. The diameter of 
pseudoislets is approximately proportional to the numbers of cells seeded 
(to the power of 0.33), for NO with 600 cells 76.4±17.2 n=6. Pseudoislets 
from micro-well plates are smaller and have a larger variation in diameter 
as compared to HD-pseudoislets with 300 cells 93.1±6.1 n=4, HD with 750 
cells 135.5±4.9 n=4, with 1500 cells 180.6±5.0 n=4. GSIS was similar for islets 
from micro-well plates and HD (basal 0.1 - 0.2, stimulated 1.2 - 1.5 fmol 
insulin/IEQ/min). In contrast to HD-pseudoislets derived from rat islets, 
GSIS was not increased in human pseudoislets (HD or micro-well plates). 
Human pseudoislets however exhibited an improved first phase insulin secre-
tion (300cells per pseudoislet 1.94±0.5 fold steady state second phase, n=32; 
600 cells per pseudoislet 1.95±0.15 n=5) compared to intact islets (1.31±0.33 
n=57; p<0.005) whereas in rat pseudo- and intact islets there was no clear first 
phase insulin secretion.
Conclusion: The newly developed micro-well plates offer the possibility to 
produce large numbers of pseudoislets of similar quality as compared to the 
hanging-drop method. Small human pseudoislets exhibit an equal or im-
proved insulin secretion as compared to intact islets. The true advantage of 
small pseudoislets in transplantation due to smaller size and better diffusion 
properties has to be proven in a large animal model.
Supported by: Waelchli Stiftung
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Pharmacological effects on insulin release in a mathematical model of 
human beta cells
M.G. Pedersen; 
Islet cell exocytosis, Lund University Diabetes Centre, Malmoe, Sweden.
Background and aims: Beta-cells use electrical activity to transduce changes 
in plasma glucose to calcium-triggered exocytosis and insulin secretion. Us-
ing a mathematical model based on recent electrophysiological characteriza-
tions of human beta-cells, the effect of a range of pharmacological interven-
tions on patterns of electrical activity and exocytosis was investigated.
Materials and methods: A mathematical model based on high quality data 
from human beta-cells has been developed. The model is formulated as a set 
of ordinary differential equations, and describes voltage-gated K- and Na-
channels, as well as T-, P/Q- and L-type Ca-channels. In addition, a back-
ground leak current, and ATP-sensitive K(ATP) and Ca-activated BK-po-
tassium channels are also included. Exocytosis evoked by calcium currents 
through different types of Ca-channels is modeled. Numerical simulations 
corresponding to pharmacological interventions were performed.
Results: The model reproduces satisfactorily electrical patterns in response 
to blockage of various ion channels. The central role of K(ATP)-channels is 
shown, and electrical activity is a result of K(ATP)-channel closing by glu-
cose or tolbutamide. For K(ATP)-conductance larger than ~0.02 nS/pF the 
model is silent and hyperpolarized, while it shows spiking activity for smaller 
K(ATP)-conductances, which results in exocytosis. A role for sodium and 
calcium channel activation for the upstroke, and activation of potassium 
channels for the downstroke of action potentials is found by simulating ion 
channels blockage. In the presence of K-channel blockers such as TEA, inac-
tivation of Ca-channels is responsible for repolarization. It is shown that P/Q-
types calcium currents are crucial for evoked exocytosis, and that the result 
on insulin secretion of modification of other channels is transduced mainly 
by changes in electrical activity and P/Q-type Ca-currents. Modifying a leak 
current is shown to be a possible strategy for enhancing insulin secretion.
Conclusion: A mathematical model of electrical activity in human beta-cells 
is shown to predict the effects of ion channel modulating drugs. It is shown 
to be useful for hypothesis testing and prediction of the effect of ion channel 
modulation on electrical activity and insulin secretion.
Supported by: Lundbeck Foundation; EU
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Developing a mathematical model of the mechanism by which alanine 
enhances glucose-stimulated insulin secretion
M. Salvucci1, Z. Neufeld2, P. Newsholme1; 
1School of Biomolecular and Biomedical Science (SBBS), Ireland, 2Complex 
& Adaptive Systems Laboratory (CASL), University College Dublin (UCD), 
Dublin, Ireland.
Background and aims: Pancreatic beta-cells play a key role in the glucose 
homeostasis, secreting insulin in response to blood nutrient fluctuations. This 
is due to a complex relationship between metabolism and insulin secretion 
which comprises both triggering (ATP and Ca2+ dependent) and amplifying 
(mitochondrial metabolite dependent) pathways of insulin secretion. Specific 
amino acids can modulate beta-cells function and thus acutely and chronical-
ly regulate insulin secretion through different mechanisms of action. Alanine 
is known to acutely stimulate insulin secretion alone or synergistically en-
hance glucose-stimulated insulin secretion (GSIS) both in vivo and in vitro. 
This study has attempted to develop a mathematical model, validated against 
wet lab experimental results, of the role played by the amino acid alanine in 
enhancing glucose-stimulated insulin secretion in pancreatic beta-cells.
Materials and methods: A simplified kinetic model of the glucose-stimu-
lated insulin secretion in pancreatic beta-cells which takes into account gly-
colysis, Krebs cycle, NADH shuttles and glutamate and alanine transaminase 
was built. The model’s input is made up of two nutrient components: glucose 
and alanine, while the output is constituted by NADH, ATP and glutamate. 
Experimental work was carried out on a functional clonal insulin-secreting 
cell line (BRIN- BD11). BRIN-BD11 cells were cultured for 48h prior to ex-
periments, starved for 40 minutes at basal glucose level (1.1 mM) and then 
stimulated with different concentrations of only glucose (1.1, 5, 16.7, 30 mM), 
only alanine (10 mM) and their combinations. Samples were collected before 
and 10, 20, 60 minutes after administration of the stimulus. Samples were 
assayed for consumption and production of the key components of the math-
ematical model: glucose, lactate, ATP and insulin.
Results: Both glucose consumption and lactate production showed a dose-
dependent increase which was significantly enhanced by addition of 10 mM 
alanine (p<0.001 and p<0.05, respectively at both 16.7 mM and 30 mM glu-
cose). The kinetic of ATP production following stimulation over a 60 minutes 
period revealed that different stimulatory conditions can affect not only the 
magnitude of response, but also the kinetic mechanism of release. All stimu-
latory conditions showed an increase in ATP release over the first 20 minutes, 
subsequently ATP content reached a steady state and markedly decreased 
after 60 min incubation only in presence of alanine. Acute insulin secretion 
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was biphasic and concentration dependent with respect to glucose: increasing 
glucose concentration from 1.1 to 30 mM increased insulin secretion by 32% 
from 1.12 ng/mg protein/20 min to 1.48 ng/mg protein/20min. The addition 
of 10 mM alanine significantly increased (p<0.05) glucose stimulated insulin 
secretion by 1.8-2.3 fold after 20 minutes incubation. Administration of 10 
mM alanine exhibited a strong insulin release (1.39 ng/mg protein/ 20 min).
Conclusion: These results highlight the synergistic effect of Alanine in en-
hancing glucose metabolism. Alanine metabolism may increase ATP release 
increasing insulin secretion through the K+ ATP-dependent pathway. Alanine 
oxidation may also result in generation of glutamate, a putative messenger in 
insulin secretion, which may account for increased insulin release despite a 
lower ATP content.
Supported by: IRCSET funding
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The membrane potential response is altered in pancreatic beta cells 
chronically exposed to high glucose
I. Göhring1, T. Köck1, H. Mulder1, D. Nicholls2,1; 
1Unit of Molecular Metabolism, Lund University Diabetes Centre, Malmö, 
Sweden, 2Buck Institute for Age Research, Novato, USA.
Background and aims: Fuel-stimulated insulin secretion is coupled to in-
creased cellular metabolic activity and consequently an increase of the ATP/
ADP ratio, thereby leading to plasma membrane depolarisation and exocy-
tosis. Any disturbance of the metabolic processing of fuels, such as glucose, 
particularly in mitochondria, may consequently affect the secretory process. 
Frequent episodes of severe hyperglycaemia are observed during the onset 
of diabetes and characterise poorly- or un-controlled Type 2 Diabetes. These 
elevated glucose levels lead to beta-cell desensitisation, and ultimately im-
paired beta-cell function. It is therefore of great interest to detect potential 
disturbances of normal fuel-stimulated plasma membrane changes as a result 
of chronic exposure to elevated glucose levels.
Materials and methods: INS-1 832/13 cells were cultured in either 2.8 mM 
or 16.7 mM glucose for 48 h. All cells were then starved for 2 h in buffer 
containing 2.8 mM glucose, after which recordings of the plasma membrane 
potential of a monolayer of cells, using a proprietary fluorescent anion and 
confocal microscopy were performed at 16.7 mM glucose with subsequent 
additions of 1 µg/ml oligomycin and 25 mM KCl. Insulin secretion was de-
termined by radioimmunoassay.
Results: After 48 h culture in 16.7 mM glucose, glucose-stimulated insulin 
secretion was significantly (p<0.05) suppressed in INS-1 832/13 cells (15.32 ± 
1.6 ng/mg/h) in comparison to cells cultured at 2.8 mM glucose (41.43 ± 8.13 
ng/mg/h). Concurring, chronic high glucose levels altered the plasma mem-
brane depolarisation response. Recordings of membrane potential activities 
of cells cultured at 2.8 mM glucose for 48 h showed complete hyperpolarisa-
tion before glucose stimulation (-79.5 ± 1.6 mV). Following addition of 16.7 
mM glucose a mean depolarisation of all cells measured was recorded (-58.1 
± 0.4 mV) and individual cells produced rhythmic action potentials bursts, 
acquired in real time as oscillations in fluorescence intensity. By inhibiting 
the mitochondrial ATP synthase, oligomycin hyperpolarised the plasma 
membrane potential to basal values while high KCl produced a maximum 
membrane depolarisation of -41.6 ± 0.1 mV. In contrast, cells chronically 
cultured at 16.7 mM glucose produced rhythmic bursts of action potentials 
after the starvation period even before high glucose stimulation. The basal 
membrane potential recorded was higher (-72.1 ± 0.6 mV) than in cells cul-
tured at 2.8 mM glucose. In addition, the mean depolarisation response of the 
chronic high glucose-treated cells was suppressed (-62.7 ± 0.3 mV) after anew 
stimulation with high glucose.
Conclusion: While cells kept at low glucose responded to stimulatory glucose 
concentrations with elevated plasma membrane depolarisation and stimu-
lation-induced action potential bursts, in cells under chronic high glucose 
conditions this depolarisation response was greatly diminished. However, ac-
tion potential bursts were recorded independent of glucose stimulation due 
to the inability of glucose-desensitised cells to fully hyperpolarise. We suggest 
that, as a consequence of chronic fuel overload, multiple cellular alterations, 
including changed glucose metabolism, contribute to a disturbance in the 
fuel-dependent coordination and regulation of plasma membrane potential 
changes and therefore the failure of beta-cells to secrete insulin.
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Paradoxical membrane repolarisation during onset of insulin secretion
M. Willenborg1, S. Denicke2, H. Ghaly1, U. Panten1, I. Rustenbeck1; 
1Institute of Pharmacology and Toxicology, 2Institute of Physical Chemistry, 
University of Braunschweig, Germany.
Background and aims: Plasma membrane depolarization (typically by KATP 
channel closure), activation of voltage-dependent Ca2+ channels and Ca2+ 
influx are regarded as indispensable for the initiation of stimulated insulin 
secretion. In addition to this “triggering pathway” nutrient secretagogues like 
glucose or ketoisocaproic acid (KIC) activate an “amplifying pathway” not 
involving depolarization and Ca2+ influx. The metabolic amplification can be 
demonstrated by a pretreatment with a maximal sulfonylurea concentration, 
then adding a stimulatory concentration of a nutrient secretagogue. Surpris-
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ingly, we found the addition of nutrients to be related to a repolarization, 
thus abolishing the triggering signal which is believed to be necessary for the 
nutrient amplification to exert its effect.
Materials and methods: The plasma membrane potential of normal mouse 
beta cells was measured in the perforated patch mode of patch-clamp tech-
nique. The cytosolic Ca2+ concentration ([Ca2+]i) as indicated by Fura and 
the NAD(P)H autofluorescence was measured by microfluorimetry of single 
perifused islets. NAD(P)H autofluorescence lifetime was determined by 2 
photon excitation imaging. Insulin secretion was measured by batch perifu-
sion and ELISA of the fractionated effluate.
Results: In the absence of any nutrient 2.7 µM glipizide depolarized the 
plasma membrane to a plateau of -45.5 ± 3.0 mV with superimposed action 
potentials peaking at -24.4 ± 4.0 mV (n=5). After application of 30 mM glu-
cose or 10 mM KIC the membrane completely repolarized ($ -68.4 ± 2.1 mV) 
within 150 s (glucose) or 80 s (KIC). The repolarization phase lasted for 5.5 
± 2.0 minutes (glucose) and 6.8 ± 2.9 minutes (KIC) and then abruptly, the 
depolarization reappeared with the same characteristics. Concurrent with the 
depolarization by KATP channel closure, glipizide increased the [Ca
2+]i, which 
remained elevated until the addition of nutrients. Both with glucose and with 
KIC the repolarization coincided with a biphasic decrease of the [Ca2+]i down 
to values which existed before the exposure to glipizide (n = 4 each). While 
the elevated [Ca2+]i completely recovered within 10 minutes in the case of glu-
cose, there was only a partial recovery of [Ca2+]i in the presence of KIC. Under 
the same conditions 10 mM KIC induced a strong increase of the secretion 
rate (by more than 10fold within 10 min), which remained elevated for more 
than 30 min. In contrast, 30 mM glucose was unable to further elevate the 
secretion rate established by glipizide in the absence of nutrients. Both glu-
cose and KIC elevated the NAD(P)H autofluorescence of perifused islets, the 
relation between the increase by glucose and that by KIC was the same as in 
the absence of glipizide. Since both components of NAD(P)H fluorescence 
lifetime were left unchanged, both glucose and KIC induce a real increase of 
the mass of NAD(P)H and not a change in fluorescence properties.
Conclusion: Apparently glucose and KIC differ in their mechanisms of meta-
bolic amplification. The onset of a strong and lasting secretory response to 
KIC does not necessarily require the presence of a depolarized plasma mem-
brane and an increased [Ca2+]i.
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In situ electrophysiological examination of alpha cells in type 1 diabetes 
revealing the cellular basis of glucagon hypersecretion
Y.-C. Huang1, M. Rupnik2, P.L. Herrera3, P. Gilon4, H.Y. Gaisano5; 
1Medical Science, University of Toronto, Canada, 2University of Maribor, 
Slovenia, 3University of Geneva, Geneva, Switzerland, 4University of 
Louvain, Brussels, Belgium, 5University of Toronto, Canada.
Background and aims: The cellular properties of α cells in type 1 diabetes 
(T1D) are unknown. This is because T1D autoimmune destruction of β cells 
causes the islet mass to shrink in size rendering islet isolation and dispersion 
not technically feasible; and consequently electrophysiological characteri-
zation of islet cells to reveal the underling mechanisms explaining the dis-
torted glucagon secretion in T1D could not be done. We employed GluCre-
ROSA26-YFP (GYY) mice, which expresses YFP in pancreatic α cells. Along 
with our newly developed pancreas slice preparation whereby α cell and its 
precise secretory physiology within intact pancreatic tissue can be examined 
by patch clamp technique, unperturbed by conventional islet isolation and 
dispersion procedures, we are able to reliably localize and directly examine 
α cells electrophysiological properties in situ in health and T1D. We hypoth-
esize that T1D α cells possess perturbed ion channels properties which con-
tribute to hyperglucagonemia in early stage of T1D.
Materials and methods: GYY mice were treated with streptozotocin (STZ) 
to induce T1D. IPGTT and radioimmunoassay (RIA) were performed to con-
firm diabetes phenotype. Pancreas slices were prepared from these mice to 
directly examine α cells ion channel properties in healthy and diseased islets 
by patch clamp technique. The identities of patched-cells were further con-
firmed by infusing fluoresecent marker (biocytin) during patching, showing 
its co-localization with YFP by confocal microscopy.
Results: Normal GYY mice α cells in slices revealed identical electrophysi-
ological features to those of their background C57/BL6 mice we previously 
characterized. These α cells are equipped with readily-activated A-type IK, 
voltage-gated INa, small size, low resting conductance, and inducible H/LVA 
ICa at -80mV. ICa influx correlated with glucagon exocytosis as either train of 
depolarization or UV photo-release of intracellular-loaded caged-Ca2+ stimu-
lated Cm increase. 4 weeks after STZ treatment, GYY mice developed T1D, 
exhibiting higher fasting glucose, slower glucose clearance after a glucose 
challenge and higher fasting (control; 89 pg/ml vs. STZ group;122 pg/ml) 
and fed (control; 78 pg/ml vs. STZ group;112 pg/ml) serum glucagon levels. α 
cells in slices from these diabetic mice revealed augmentation of INa (control; 
368 ± 43 pA vs. STZ group; 480 ± 71pA) and LVA ICa amplitudes (control; 40 
± 5 vs. STZ group; 49 ± 6 pA). HVA ICa however remained unaltered by T1D 
(control; 44 ± 5 pA vs. STZ group; 46 ± 6 pA) . Voltage-gated K+ current was 
found to be increased (STZ group; 2.13 nA vs. control; 1.76 nA). α cell size 
was unchanged compared to control (control; 4.7 ± 0.20 pF vs. STZ group; 
4.8 ± 0.23 pF).
Conclusion: GYY mouse α cell ion channel properties examined in slices 
were largely consistent with our previous findings and others, validating the 
feasibility of using pancreas slice approach to investigate α cells in normal 
and diabetic subjects. We postulate that the observed upregulation of INa and 
LVA ICa in diabetic α cells potentially elevates membrane potential that would 
more readily to trigger HVA Ca2+ channels opening, with ensuing initiation 
of action potential firing leading to glucagon secretion. This explains in part 
the observed glucagon hypersecretion in early stage of T1D.
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Active CFTR channels are important for insulin- and glucagon secretion
A. Edlund1, M. Hühn2, M. Flodström-Tullberg2, L. Eliasson1; 
1Clinical Sciencies Malmö, CRC, Lund University Diabetes Centre, Malmö, 
2Karolinska Institute, Huddinge, Center for Infectious Medicine, Stockholm, 
Sweden.
Background and aims: Cystic fibrosis (CF) is a monogenic autosomal re-
cessive disease caused by mutation in the cystic fibrosis gene that encodes 
the chloride channel cystic fibrosis transmembrane conductance regulator 
(CFTR). One of the leading complications of CF is cystic fibrosis related dia-
betes (CFRD). The mechanism behind CFRD is unclear but the progressive 
inflammation in the exocrine pancreas has been suggested. Another possible 
mechanism is that CFTR is present in the islet cells and a mutation in CFTR 
interferes with hormonal secretion. The aim of this study was to investigate 
the presence of active CFTR channels in pancreatic alpha- and beta cells and 
if CFTR influence secretion and exocytosis.
Materials and methods: Patch-clamp recordings and capacitance measure-
ments were performed on single mouse beta-cells. Detection of CFTR in 
islet cells was investigated using rt-PCR and confocal immunocytochemis-
try. Insulin-and glucagon secretion was measured using radio immunoassay 
(RIA).
Results: Mouse islets express CFTR mRNA as confirmed by rt-PCR (n=5) 
and CFTR protein was specifically detected in alpha- and beta cells using 
immunocytochemistry. Electrophysiological investigation of CFTR was per-
formed using the standard whole-cell configuration and CFTR was activated 
by addition of forskolin (10 μM). In single mouse beta-cells, a cAMP-acti-
vated membrane conductance of 0.05 ± 0.03 nS/pF at negative potentials 
and 1.03 ± 0.18 nS/pF at positive potentials (n=12; P<0.001 vs in absence of 
forskolin) was measured. The conductance was significantly reduced (n=7; 
P<0.001) and the current almost totally inhibited in the presence of the 
CFTR-antagonist, CFTRinh-172 (10 μM). A similar CFTR current could be 
activated in pancreatic alpha-cells (n=5; P<0,017). In addition, cAMP-am-
plified glucagon secretion measured at 1 mM glucose was reduced by ~60% 
(n=8; P<0.001) in the presence of CFTRinh-172 (40 μM) and by ~40% (n=8; 
P<0.08) in the presence of another CFTR-antagonist, GlyH-101 (50 μM). Cy-
clic AMP- amplified insulin secretion at 16.7 mM glucose was reduced by 
~30% in the presence of CFTRinh-172 (n=10; P<0.05) and by ~30% in the 
presence of GlyH-101 (n=11; P<0.05). Moreover, exocytosis elicited by a train 
of 10 membrane depolarisations and measured as an increase in membrane 
capacitance on single beta-cells was significantly reduced by 70 ± 10% (n=9; 
P<0.05) in the presence of cAMP (100 μM) and CFTRinh-172 (10 μM).
Conclusion: Our data indicate the presence of active CFTR in pancreatic 
alpha- and beta cells and the importance of this channel for glucagon- and 
insulin secretion. Further, CFTR inhibition reduced exocytosis in pancreatic 
cells. Thus, we suggest a role for CFTR in the control of the exocytotic process 
important for release of glucagon and insulin.
Supported by: The Swedish Research Council, RFCF, Fredrik and Ingrid Thur-
ings Foundation
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Distinct roles of voltage-gated potassium channels Kv2.1 and Kv2.2 in 
governing the secretion islet hormones
X. Li1, J. Herrington1, K. Ratliff1, L. Ge1, Y. Feng1, A. Petrov1, G. Eiermann1, 
Y. Xiong1, M. Jensen2, H.E. Hohmeier2, C.B. Newgard2, N.A. Thornberry1, 
A.D. Howard1, B.B. Zhang1, Y.-P. Zhou1; 
1Metabolic Disorders, Merck Research Laboratories, Rahway, 2Biochemistry, 
Duke University, Durham, USA.
Background and aims: Voltage-gated potassium channel Kv2.1 has been 
suggested to regulate glucose stimulated insulin secretion (GSIS) in islets, yet 
little is known about the role of Kv2.2, the other member of the delayed recti-
fier K channel also expressed in islets.
Materials and methods: We studied the roles played by each of the two Kv 
channels individually in islets using siRNA mediated gene-silence, Kv2.1 
knockout (Kv2.1-/-) mice and highly selective peptide and small molecule 
Kv2 blockers newly discovery in our laboratories.
Results: siRNA directed against Kv2.1 in INS-1 cells remarkably reduced 
the Kv current and augmented GDIS, whereas Kv2.2 siRNA had no effect 
on GDIS. Pancreatic β-cells from Kv2.1 knockout mice manifested signifi-
cantly smaller Kv current and greater GDIS in vitro. GxTx-1E diminished 
Kv current completely and enhanced GDIS dramatically in isolated mouse 
islets. But surprisingly, GxTX-1E only had a minimal in vivo effect to lower 
blood glucose levels during IPGTT (intraperitoneal glucose tolerance test) in 
mice. We thus examined the effects of GxTx-1E and Kv2i-A, a small molecule 
blocker of Kv2.1 and Kv2.2 discovered in our laboratories, on the release of 
glucagon and somatostatin, the other two major islet hormones. Besides pro-
moting insulin secretion, both GxTX-1E and Kv2i-A enhanced somatostatin 
(SST) release from the cultured islets or in vivo animals. The effect of GxTX-
1E to promote SST secretion was still seen in islets from Kv2.1 knockout 
mice, and was further augmented when Kv2.2 expression was 65% ablated by 
adenoviral delivered siRNA, indicating that Kv2.2 but not Kv2.1 regulates SST 
secretion in the pancreatic islets. This was corroborated by high expression 
of Kv2.2 in SST secreting δ-cells of the islets revealed by in situ hybridization 
and immunohistochemistry.
Conclusion: Kv2.1 and Kv2.2 have distinct roles in regulating islet insulin 
and SST secretion. Development of selective Kv2.1 inhibitor and Kv2.2 ac-
tivator may provide new avenue for novel insulin secretagogues for diabetes 
therapy.
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Evidence of functional hemi-channels in beta cells: their opening by K+-
depolarisation and/or Ca2+-omission
J. Tamarit-Rodriguez1, J. Pizarro-Delgado1, R. Martín-del-Río2; 
1Biochemistry, Complutense University, 2Research Department, Hospital 
Ramón y Cajal, Madrid, Spain.
Background and aims: We have previously reported that islet depolarization 
(70 mM KCl + 0.25 mM diazoxide) induces release of GABA and taurine 
(Tau) and suppresses KIC-induced insulin secretion. The aim of this work 
is to characterize the responsible mechanism of this increased amino acid 
release.
Materials and methods: Insulin secretion of rat perifused islets was moni-
tored by RIA. Islet content and release of amino acids were measured by fluo-
rescent detection after pre-column derivatization with o-phtalaldialdehyde 
and their HPLC separation. Islet ATP and ADP contents were measured with 
the luciferin/luciferase system.
Results: At 5 mM glucose, Ca2+-omission (0 mM Ca2+ + 0.1 mM EGTA) stim-
ulated islet release of GABA (438.5 ± 35.4, n=4 vs.289.7 ± 41.2 pmol/30 islets 
x 60 min, n=4; p<0.03) and Tau (119.3 ± 11.5, n=4 vs. 66.7 ± 4.2 pmol/30 
islets x 60 min, n=4; p<0.005) and suppressed proportionately their contents. 
70 mM KCl depolarization potentiated the releasing effect of Ca2+-omission 
on both GABA (747.1 ± 98.7, n=4 vs. 438.5 ± 35.4 pmol/30 islets x 60 min, 
n=4; p<0.03) and Tau (194.1 ± 28.1, n=4 vs. 119.3 ± 11.5, n=4 pmol/30 islets 
x 60 min, n=4; p<0.05) and diminished proportionately their contents. Islet 
ATP release could not be measured due to the presence of a very efficient 
ecto-nucleotidase activity resistant to available inhibitors. However, at 3 mM 
glucose, ATP content was decreased by the combination of depolarization and 
Ca2+-omission (1.3 ± 0.14, n=12 vs. 2.8 ± 0.14 pmol/ islet, n=18; p<0.0001) 
without affecting the ATP/ADP ratio (p=0.05). At physiological [Ca2+]o, islet 
depolarization alone suppressed ATP content at 3 mM glucose (0.9 ± 0.1, n=6 
vs. 2.9 ± 0.3 pmol/islet, n=6; p<0.0001) and slightly decreased the ATP/ADP 
ratio (0.95 ± 0.05, n=5 vs. 1.26 ± 0.08 pmol/ islet, n=5; p<0.011). 20 mM 
glucose prevented the loss of islet ATP induced by the combination of depo-
larization and Ca2+-omission observed at 3 mM glucose (4.4 ± 0.16, n=8 vs. 
4.6 ± 0.09 pmol/islet, n= 12; N.S.) and preserved the elevated ATP/ADP ratio 
(1.8 ± 0.17, n=7 vs. 2.2 ± 0.22 pmol/islet, n=12; N.S.). Mefloquine (50 uM) 
did not modify islet ATP content at 3 mM glucose but counteracted the com-
bined effects of islet depolarization + Ca2+-omission (2.1 ± 0.27, n=8 vs. 1.3 ± 
0.14, n=12 pmol/islet; p<0.006); it also partially suppressed islet amino acid 
release under the same experimental conditions. 20 mM glucose stimulation 
of insulin secretion in perifused islets (100 ± 9.3%) was dose-dependently 
decreased by mefloquine to 84.8 ± 11.5% (10 uM; N.S.), 53.7 ± 7.3 % (25 uM; 
p<0.01) and 27.5 ± 5.2 % (50 uM; p<0.001). At concentrations above 100 uM, 
it stimulated a secretory response that was independent of the glucose and 
calcium concentration and it decreased islet insulin content.
Conclusion: Islet amino acids and ATP are released by procedures known 
to open hemi-channels/pannexins in other tissues. This is supported by the 
protective effect of mefloquine, a known connexin 36 inhibitor. Inhibition of 
insulin secretion by mefloquine highlights the importance of beta cell com-
munication for an optimal insulin response to glucose.
Supported by: MICINN(SAF2009-12671)
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Analysis of submembrane insulin granule behaviour by TIRF 
microscopy during moderate and strong K+ depolarization
K. Hatlapatka1, M. Matz2, K. Baumann2, I. Rustenbeck1; 
1Institute of Pharmacology and Toxicology, 2Institute of Medicinal 
Chemistry, University of Braunschweig, Germany.
Background and aims: The release of a pool of membrane-adjacent secretory 
granules which are in a primed and docked state and await one final trigger, 
a depolarization-induced influx of Ca2+, is held responsible for the first phase 
of glucose-induced insulin secretion. Recently, we observed that 15 mM K+ 
led to a 20 mV depolarization and to a lasting increase of the cytosolic Ca2+ 
concentration ([Ca2+]i), but only to a modest transient increase in secretion, 
suggesting that the effect of depolarization on insulin secretion is only in-
completely understood.
Materials and methods: Insulin secretion was measured by perifusion of 
mouse islets and MIN6 pseudoislets and ELISA of the fractionated effluate. 
The [Ca2+]i of islets and MIN6 cells was measured with the Fura technique. 
Submembrane granules were visualized by transient transfection of MIN6 
cells with an insulin-EGFP fusion protein and imaging by TIRF microscopy 
at 37°C. The images were evaluated by a purpose-made program written in 
MatLab to achieve a complete observer-independent quantitation.
Results: Islets perifused with 5 mM glucose showed only a transient increase 
in secretion when K+ was raised to 15 mM. A subsequent elevation to 40 mM 
K+ resulted in a prompt overshooting increase in secretion which remained 
increased as long as 40 mM K+ was present. In contrast, [Ca2+]i was continu-
ously elevated by 15 mM K+ and increased further when K+ was raised to 40 
mM. The same secretion and [Ca2+]i pattern could be observed with MIN6 
pseudoislets. MIN6 cells transfected with insulin-EGFP were therefore used 
to analyse the behavior of submembrane granules by TIRF microscopy at 5 
time points: beginning, prior to high K+, one each during 15 and 40 mM K+ 
and one after washout of high K+. At each time point a sequence of 100 im-
ages was acquired within 12 s. Referring to the first sequence as 100%, the 
numbers of submembrane granules at the next time points were 109%, 76%, 
50% and 56%. More than 50% of the granules were long-term resident (≥ 12 
s). The percentage of short-term resident granules (≤ 1 s) increased slightly 
during 15 mM K+, then significantly during 40 mM K+ and remained so after 
washout. This correlated with an increase of the percentage of newly arriving 
granules from 4% initially to 7% during 15 mM K+ and to 15% during 40 mM 
K+ and washout. Very similar percentages applied for departing granules (i.e. 
return or release). There were no such changes in control experiments. The 
total and the net distances covered by the submembrane granules were not 
affected by high K+.
Conclusion: 40 mM K+ affects arrival, departure and residence time of in-
sulin granules, but not movement parallel to the membrane. 15 mM K+ is 
moderately effective, which concurs with dynamic secretion measurements. 
Currently there is no indication that long-term resident granules are prefer-
entially departing during stimulation.
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Abnormal regulation of pancreatic beta cell Na,K-ATPase on glucose 
intolerant rats
A.R. Costa1,2, C.M. Antunes1,3, J. Cruz-Morais1,2; 
1Chemistry, University of Évora, 2ICAAM - Institute of Mediterranean 
Agricultural and Environmental Sciences, Évora, 3CNC - Centre for 
Neurosciences and Cell Biology, Coimbra, Portugal.
Background and aims: Glucose (G) is the most important physiological in-
sulin secretagogue. It is widely accepted that, in pancreatic -cell, G evoked 
early ionic events such as membrane depolarization and Ca2+ influx through 
voltage dependent Ca2+ channels triggers insulin exocytosis. However, the 
role of other electrogenic systems, namely ionic pumps, to these events re-
mains essentially uninvestigated. It is known that the activity of Na,K-ATPase 
is modified in type 2 diabetes (T2D). The pump is responsible for maintain-
ing Na+ and K+ gradients across the plasma membrane and generates a net 
outward current as a result of 3Na+/2K+ exchange. It remains elusive whether 
Na,K-ATPase activity is regulated by G in pancreatic β-cell and/or this cur-
rent contributes to the ionic events regulating insulin secretion. The aim of 
this work was to assess G evoked regulation of Na,K-ATPase activity in intact 
-cells of normal and G intolerant rats.
Materials and methods: Pancreatic -cells, from normal (controls) or glucose-
intolerant Wistar rats (GIR), were isolated and cultured (48h). Cell batches 
were pre-incubated (30min) with 2.1mM G to reach basal. Afterwards cells 
were challenged with [G] in the interval 0-11.1mM for 60min, for dose-de-
pendence evaluation, or with 8.4mM G for 5-120min, for time-dependence 
evaluation. ATPase activity was assessed in intact cells by colorimetric quan-
tification of Pi formed in 30min. Na,K-ATPase activity was calculated by the 
difference between the activities obtained in the absence and in presence the 
of 1mM ouabain.
Results: G evoked both time- and dose-dependent regulation of Na,K-AT-
Pase. In β-cells from controls, G induced a bimodal regulation of Na,K-AT-
Pase. In the absence of G, Na,K-ATPase activity was 0.056±0.015U/mg. Rais-
ing [G] to 2.1mM induced a ≈3 fold increase of Na,K-ATPase activity whereas 
a further increase in [G] in the interval of 5.6-11.1mM evoked a significant 
reduction of Na,K-ATPase activity to the levels observed in the absence of the 
secretagogue. Compared to 2mM G, the activity was reduced in 68%, 55% 
and 66% when [G] was increased to 5.6, 8.4 and 11.1mM, respectively (n=3-
12). GIR β-cells exhibit an altered profile of response to the secretagogue; 
In the absence of G, Na,K-ATPase activity was ≈4 fold the activity observed 
in the controls (0.202±0.036U/mg; n=3). The pump activity remained un-
changed for 2.1-5.6mM G and similar to maximal activity observed in the 
controls (0.188±0.035 U/mg, for 2.1mM G; n=4). A significant reduction of 
the pump activity in GIR β-cells was induced by 8.4mM G (0.118±0.018 U/
mg). G (8mM) induced a time-dependent inhibition of Na,K-ATPase with 
a biphasic profile. Pump activity decreased to a minimum value (32%) after 
20min exposure to G, showing a partial recovery to 45%, 46% and 47% for 
30, 60 and 120min, respectively (n=5-12). GIR β-cells showed an attenuated 
response to G (59% activity after 20min) without any recovery (n=5-11).
Conclusion: This work demonstrates that Na,K-ATPase is finely regulated 
by G in pancreatic β-cell from normal subjects. This regulation is impaired 
in GIR where desensitization and an attenuation of the inhibitory action of G 
were observed. In summary, Na,K-ATPase contribution to G-induced ionic 
events and insulin secretion might be relevant in T2D development.
Supported by: ICAAM, CNC and a PhD grant from FEA
PS 38 Ca2+ and cAMP in beta cells
562
Interplay between [Ca2+]c and [Ca2+]ER in mouse beta cells: role of 
SERCA2b and SERCA3
M.A. Ravier1,2, D. Daro1, R. Cheng-Xue1, P. Gilon1; 
1Endocrinology and Metabolism, University of Louvain, Brussels, Belgium, 
2Institut de Genomique Fonctionnelle, Inserm U661, Montpellier, France.
Background and aims: Pancreatic β-cells express 2 types of sarco-endoplas-
mic Ca2+-ATPases, SERCA2b and SERCA3, which take up Ca2+ from the 
cytosol to the endoplasmic reticulum (ER). Whereas the changes in the cy-
tosolic Ca2+ concentration ([Ca2+]c) have been well characterized in β-cells, 
the changes in the ER Ca2+ concentration ([Ca2+]ER) are still largely unknown. 
Here, we studied the correlation between [Ca2+]c and [Ca
2+]ER and the roles of 
SERCA2b and SERCA3 in [Ca2+]ER homeostasis.
Materials and methods: We generated an adenovirus encoding the Ca2+ in-
dicator D4 and addressed it to the endoplasmic reticulum (D4ER). D4ER was 
expressed under the control of the rat insulin promoter in clusters of β-cells 
from C57BL6 (WT) mice or SERCA3KO mice. In most experiments, [Ca2+]ER 
(D4ER) and [Ca2+]c (Fura PE3) were simultaneously recorded.
Results: Confocal microscopy and immunocytochemistry demonstrated that 
D4ER was specifically expressed in the ER of β-cells. We ascertained our abil-
ity to study the correlation between [Ca2+]c and [Ca
2+]ER. This was the case 
since 45mM KCl increased both [Ca2+]c and [Ca
2+]ER, whereas acetylcholine 
elicited the expected anti-parallel changes of both parameters in β-cells from 
WT mice. During spontaneous [Ca2+]c oscillations induced by 15mM glucose 
(G), [Ca2+]c and [Ca
2+]ER oscillated in phase. G-induced [Ca
2+]c oscillations 
were larger and much steeper, whereas [Ca2+]ER oscillations were smaller in 
SERCA3KO than in WT mice, suggesting that G-induced [Ca2+]ER oscilla-
tions partly involve SERCA3. We then evaluated the relative contribution of 
SERCA2b or SERCA3 to the refilling of the ER in Ca2+ elicited by an accelera-
tion of cell metabolism. In the continuous presence of diazoxide, i.e. when 
[Ca2+]c remained low, G dose-dependently increased [Ca
2+]ER (half-maximal 
and maximal effects at 5 and 8 mM, respectively) and to a similar extent in 
β-cells from WT and SERCA3KO mice, demonstrating that SERCA2b is the 
only isoform responsible for this replenishment. To evaluate the contribution 
of both SERCA isoforms to the refilling of the ER in Ca2+ triggered by a rise in 
[Ca2+]c, β-cells were submitted to depolarizations with various [KCl] (10, 15, 
25, 35, 45mM). As expected the rise in [Ca2+]ER increased dose-dependently 
with the depolarizations. In WT β-cells, the changes in [Ca2+]c and [Ca
2+]ER 
were parallel soon after the depolarization. Intriguingly, when [Ca2+]c was 
kept high for a prolonged period (> 2 min with [KCl] ≥ 25mM ), [Ca2+]c 
and [Ca2+]ER changes were antiparallel demonstrating that the ER started to 
release Ca2+ by a process that is referred to as atypical Ca2+-induced Ca2+ re-
lease (CICR). The rises in KCl-elicited [Ca2+]c and [Ca
2+]ER were, respectively, 
larger and smaller in SERCA3KO than in WT β-cells demonstrating that 
SERCA3 contributes to the refilling of the ER in Ca2+ when [Ca2+]c increases. 
No atypical CICR was observed in β-cells from SERCA3KO mice.
Conclusion: [Ca2+]c and [Ca
2+]ER oscillate in phase during spontaneous 
[Ca2+]c oscillations induced by G. SERCA2b is the only isoform responsible 
for the Ca2+ replenishment of the ER elicited by an acceleration of cell metab-
olism whereas SERCA3 also contributes to the Ca2+ refilling of the ER when 
[Ca2+]c increases. During prolonged and prominent [Ca
2+]c elevation, the ER 
releases Ca2+ possibly to avoid its overfilling by SERCA3.
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Spatial control of Epac2 by cAMP and Ca2+
O. Idevall Hagren, A. Tengholm; 
Medical Cell Biology, Uppsala University, Sweden.
Background and aims: Glucose-stimulated insulin release from β-cells is 
pulsatile and controlled by synchronized oscillations of the Ca2+ and cAMP 
concentrations beneath the plasma membrane ([Ca2+]pm and [cAMP]pm). Im-
portant effects of cAMP are mediated by the guanine nucleotide exchange 
factor Epac2, which promotes insulin secretion through activation of the 
small GTPase Rap1, as well as via interactions with the KATP-channel and 
components of the exocytosis machinery. Epac2 undergoes a conformational 
change upon cAMP binding allowing interaction with downstream effectors, 
but little is known about the subcellular localization of Epac2. The aim of 
the present study was to investigate the spatial control of Epac2 in β-cells by 
cAMP and Ca2+ signals.
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Materials and methods: Evanescent wave fluorescence imaging was used to 
record plasma membrane association of fluorescence-tagged Epac2 in sin-
gle MIN6 β-cells. [cAMP]pm and [Ca
2+]pm was measured in parallel using a 
fluorescent cAMP translocation biosensor and the Ca2+ indicator Fura Red, 
respectively.
Results: Rise of intracellular cAMP or direct activation of Epac by the se-
lective agonist 007-AM caused rapid translocation of GFP- Epac2 from the 
cytoplasm to the plasma membrane. Increase of the glucose concentration 
from 3 to 11 mM triggered oscillatory translocation of GFP-Epac2 that were 
preceded by elevations of [cAMP]pm and [Ca
2+]pm. The translocation was sup-
pressed by 43±20% (n=16, P<0.01) and 41±8% (n=23, P<0.01) after inhibi-
tion of adenylyl cyclases or removal of extracellular Ca2+, respectively. Rise 
of [Ca2+]pm evoked by KCl-depolarization caused GFP-Epac2 translocation, 
but this effect was suppressed by inhibition of adenylyl cyclases. Ca2+ nev-
ertheless contributed to cAMP-induced GFP-Epac2 translocation, since the 
response was reduced by 48±7% (n=43, P<0.01) after removal of extracellular 
Ca2+ and depletion of intracellular Ca2+ stores. However, the effect of Ca2+ was 
dual, and high [Ca2+]pm spikes evoked by tetraethylammonium caused tem-
porary dissociation of GFP-Epac2 from the membrane (40±7% reduction, 
n=32, P<0.01). Epac2 mutants lacking the cAMP-binding or Ras-association 
domains were unable to translocate and localized constitutively to the plasma 
membrane and cytoplasm, respectively.
Conclusion: Epac2 localization is dynamically controlled by both cAMP and 
Ca2+ signals. Epac2 recruitment to the plasma membrane should be impor-
tant for the activation of effectors involved in the regulation of insulin secre-
tion.
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Crosstalk between cAMP- and Zn2+-signalling in insulin secretion
O. Dyachok, O. Idevall, A. Tengholm, E. Gylfe; 
Department of Medical Cell Biology, Uppsala University, weden.
Background and aims: Glucose stimulation of β-cells evokes synchronized 
oscillations of the sub-membrane cytoplasmic Ca2+ ([Ca2+]pm) and cAMP 
([cAMP]pm) concentrations, which underlie pulsatile insulin secretion (IS). 
Whereas Ca2+ is the principal trigger, cAMP is an important amplifier of IS. 
Zn2+ is present in high concentrations in insulin secretory vesicles and Zn2+ 
co-released with insulin has been proposed to exert a negative feedback on 
IS by inhibiting Ca2+ influx after activation of hyperpolarizing K+ channels. 
cAMP turnover is also modulated by Zn2+. In the present study, we investi-
gated how glucose affects the sub-membrane Zn2+ concentration ([Zn2+]pm) 
and it’s influence on [Ca2+]pm, [cAMP]pm and insulin secretion kinetics in sin-
gle β-cells.
Materials and methods: Simultaneous measurements of [Ca2+]pm
 and [Zn2+]pm 
were performed in single MIN6 β-cells co-loaded with the fluorescent indica-
tors Fura Red and FluoZin-3. [cAMP]pm was detected by a fluorescent pro-
tein-based translocation biosensor. Another translocation biosensor reported 
phosphatidylinositol-3,4,5-trisphosphate formation in the plasma membrane 
([PIP3]pm) after autocrine insulin receptor activation, and this assay was used 
as readout for IS from single cells. Changes in [Zn2+]pm, [Ca
2+]pm, [cAMP]pm 
and [PIP3]pm were recorded with evanescent wave microscopy.
Results: Glucose stimulation of MIN6 cells induced pronounced [Ca2+]pm 
and [cAMP]pm oscillations resulting in pulsatile is detected as [PIP3]pm oscil-
lations. Glucose also elevated [Zn2+]pm and some cells showed synchronized 
oscillations of [Zn2+]pm and [Ca
2+]pm, which were particularly prominent after 
addition of the K+ channel blocker tetraethylammonium. Blocking of voltage-
dependent Ca2+ channels with methoxyverapamil or inhibition of Ca2+ influx 
by hyperpolarization with diazoxide prevented both [Ca2+]pm and [Zn
2+]pm 
oscillations. Addition of exogenous Zn2+ to glucose-stimulated MIN6 cells 
resulted in amplification of the [Zn2+]pm oscillations but marked inhibition 
of the [cAMP]pm and [PIP3]pm responses as well as suppressed insulin release 
detected by ELISA. The Zn2+-inhibited [PIP3]pm oscillations were rescued by 
8-Br-cAMP. In the absence of added Zn2+ the membrane permeable Zn2+ 
chelator TPEN abolished the Zn2+ signal and much amplified the [Ca2+]pm, 
[cAMP]pm and [PIP3]pm responses to glucose stimulation.
Conclusion: These data reinforce the idea that Zn2+ feedback-regulates pulsa-
tile insulin secretion by inhibiting cAMP signaling in β-cells.
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Adenylate cyclase 8 is required for glucose-induced calcium signalling in 
pancreatic beta cells
M. Raoux1, P. Vacher2, J. Papin1, B. Roger1, C. Magnan3, J. Lang1; 
1UMR CNRS 5248, Institut Européen de Chimie et Biologie, Université de 
Bordeaux, Pessac, 2Inserm U916, Institut Bergonié, Université de Bordeaux, 
3CNRS EAC 4413, Université Denis Diderot, Paris, France.
Background and aims: Glucose raises [Ca2+]i
 in β-cells, which is a pivotal ac-
tion of the sugar. Its metabolism leads to an increase in ATP/ADP ratios and 
the ensuing closure of KATP channels results in membrane depolarisation and 
Ca2+ influx. Glucose also stimulates cAMP generation, a second messenger 
considered as an amplifier of the cellular effects of Ca2+. We had previously 
observed that the Ca2+-activated adenylate cyclase 8 (ADCY8) mediates in-
cretin effect on [Ca2+]i and that glucotoxicity strongly down-regulates ADCY8 
in rat and human islets. In the present study, we addressed the role of cAMP 
and more specifically of ADCY8 in glucose-induced changes in [Ca2+]i.
Materials and methods: [Ca2+]i was measured using INDO-1 in clonal INS-
1E and primary mouse β-cells. In addition we used, for the first time, a novel 
electrophysiological approach in β-cells that is the extracellular recording of 
electrical signals with microelectrode arrays.
Results: In INS-1E cells, glucose-induced increases in [Ca2+]i were sig-
nificantly reduced from 330+43 (n=16) to 14+3 nM (n=20; 2p<0.001) by 
SQ22,536 (100 µM), a general inhibitor of adenylate cyclases. Similarly, the 
cAMP antagonist Rp-cAMPS (50 µM) reduced glucose effects to 47+12 nM 
(n=16; 2p<0.001) in INS-1E and from 258+64 to 34+9 nM in primary β-cells 
(n=21-25; 2p<0.005). In contrast, responses evoked by depolarization with 
KCl remained unchanged pointing towards a glucose-specific mechanism. 
The activation of kinases by cAMP, and particularly PKA, seems to be in-
volved as H-89 (40 µM) reduced glucose-evoked [Ca2+]i-increases to 5+2 nM 
in INS-1E cells (n=11; 2p<0.001). In the same vein, glucose-evoked firing 
rates recorded with microelectrode arrays were decreased by H-89 in a re-
versible manner from 1.36+0.18 to 0.10+0.02 Hz in INS-1E (n=33; p<0.001) 
and from 1.91+0.50 to 0.22+0.15 Hz in mouse β-cells (n=7; p<0.01). Among 
adenylate cyclases, ADCY8 appeared to play a key role as its overexpression 
increased the amplitude of glucose-induced increase in [Ca2+]i from 218+27 
to 1005+115 nM and its knockdown reduced the response to 72+10 nM in 
INS-1E cells (n=7-51; 2p<0.001). In contrast, responses to KCl or thapsi-
gargin remained unaltered. Similarly, knockdown reduced glucose-induced 
[Ca2+]i increases in islet cells from 209+36 to 32+5 nM (n=21 each; 2p<0.001) 
without altering responses to KCl. Finally, preliminary data using ADCY8-/- 
knockout mice suggest equally a defect in glucose-induced [Ca2+]i responses 
and impaired glucose tolerance under normal diet.
Conclusion: Taken together, these results indicate a permissive rather than 
only amplifying role of cAMP and specifically of ADCY8 in the sequence of 
events leading from glucose exposure to increases in [Ca2+]i in clonal and pri-
mary β-cells. In line with the down-regulation of this gene during glucotoxic-
ity in rat and human islets, our data underline the pivotal importance of this 
enzyme in normal β-cell function and potentially in type 2 diabetes.
Supported by: SFD and AFD
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Glucose and muscarinic stimulation trigger distinct diacylglycerol 
signals in pancreatic beta cells
A. Wuttke, H. Emanuelsson, A. Tengholm; 
Medical Cell Biology, Uppsala University, Sweden.
Background and aims: Diacylglycerol (DAG) is generated in the plasma 
membrane via phospholipase cleavage of phosphoinositides in response to 
nutrients and receptor stimuli. Several DAG-activated proteins like protein 
kinase C, protein kinase D and Munc13 have been implicated in the regula-
tion of insulin secretion. The aim of this study was to characterize the tem-
poral pattern of plasma membrane DAG signaling in insulin-secreting cells 
exposed to different stimuli.
Materials and methods: A biosensor based on the two adjacent DAG-bind-
ing C1 domains of rat protein kinase Cγ tagged to green fluorescent protein 
(C1aC1b-GFP) was used to monitor DAG in individual MIN6 β-cells. The 
probe translocates to the plasma membrane upon DAG formation, which was 
monitored with confocal and evanescent wave microscopy. The cytoplasmic 
Ca2+ concentration in the immediate sub-plasma membrane space was re-
corded with evanescent wave microscopy in cells loaded with the fluorescent 
indicator Fura Red.
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Results: Confocal imaging of MIN6 β-cells expressing C1aC1b-GFP showed 
diffuse cytoplasmic fluorescence and a slight accumulation of the probe 
in the nucleus under basal conditions. Addition of 1 μM of the functional 
DAG mimetic phorbol myristate acetate caused rapid redistribution of the 
fluorescence to the plasma membrane. This translocation was detected as a 
pronounced increase of fluorescence when imaging the plasma membrane 
with evanescent wave microscopy. Activation of muscarinic receptors with 
carbachol caused a dose-dependent and sustained, plasma membrane trans-
location of C1aC1b-GFP with threshold and maximal response at about 0.1 
and 100 μM (130±7 % fluorescence increase), respectively, and the half maxi-
mal effect at 7±0.7 μM (n=50). Depolarization with 30 mM K+ caused a rapid 
increase in the plasma membrane C1aC1b-GFP fluorescence followed by a 
decline and brief (3-13 s duration), irregular spikes, often originating from 
a slightly elevated level. This response required influx of Ca2+, since Ca2+-
deficient medium containing 2 mM EGTA reversibly removed all spiking. 
Elevation of the glucose concentration from 3 to 11 mM induced complex 
changes of the plasma membrane C1aC1b-GFP fluorescence. The majority of 
cells (55.5%) showed brief irregular high-amplitude (60±12 % fluorescence 
increase, n=25) spiking like during K+ depolarization. In 15.5% of the cells, 
glucose triggered slow (0.31±0.2 min-1), low-amplitude (28±6 % fluorescence 
increase, n=7) oscillations without spikes, and in 29% of the cells the high-
amplitude spikes were grouped into bursts with similar frequency as the slow 
oscillations. The glucose-induced DAG signaling was Ca2+-dependent and si-
multaneous measurements revealed that the initial increase of C1aC1b-GFP 
fluorescence was always preceded by an increase of the sub-plasma mem-
brane Ca2+ concentration.
Conclusion: The plasma membrane DAG concentration shows distinct and 
complex changes in insulin-secreting cells exposed to receptor, nutrient and 
depolarizing stimuli, probably reflecting different modes of phospholipase C 
activation. The DAG signaling patterns may differently affect downstream ef-
fector proteins involved in the regulation of insulin secretion.
PS 39 Incretins and beta cell mass in 
rodents
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Preservation of pancreatic beta cell mass in high fat-fed STZ treated mice 
by the Dipeptidyl peptidase-4 inhibitors Saxagliptin and Sitagliptin
S.M. Poucher1, J. Francis2, S. Vickers3, S. Cheetham3, G. Birmingham3,  
K. Dickinson3, B. Zinker4, A. Bellamine5, M. Kirby6; 
1Cardiovascular Discovery Department, AstraZeneca Pharmaceuticals, 
Macclesfield, United Kingdom, 2ASTL, AstraZeneca Pharmaceuticals, 
Charnwood, United Kingdom, 3RenaSci Consultancy, Nottingham, United 
Kingdom, 4Diabetes Drug Discovery, Bristol-Myers Squibb, Princeton, USA, 
5CV / Metabolism US Medical Strategies, Bristol-Myers Squibb, Princeton, 
USA, 6DIabetes Drug Discovery, Bristol-Myers Squibb, Princeton, USA.
Background and aims: Saxagliptin is a potent, selective DPP-4 inhibitor, 
specifically designed for extended inhibition of the DPP-4 enzyme. DPP-4 
inactivates incretins that stimulate glucose-dependent insulin secretion. A 
proposed mechanism of action involves protecting incretins from DPP-4 
degradation, thus improving β-cell preservation in conditions of β-cell stress. 
In this study we investigated the β-cell preservation effects of saxagliptin and 
sitagliptin at similar exposures in relation to their potencies as DPP-IV in-
hibitors.
Materials and methods: C57BL/6J mice (12 per group) were placed on a 
60% fat diet for 4 weeks prior to 50mg/kg streptozotocin (STZ, ip, daily for 
3 days). All animals were randomised based on bodyweight, glucose, insulin 
and HbA1c. They were dosed with Vehicle (V) Sitagliptin (Sita) or Saxaglip-
tin (Saxa) (10mg/kg/day, po) throughout the study commencing either one 
week prior to STZ treatment or 1 day after STZ treatment. Glycaemic control 
was determined by oral glucose tolerance tests (OGTT) 3 weeks post-STZ 
treatment and by fasting blood glucose 36 days post STZ. Automated imag-
ing and analysis systems were used to determine β-cell mass using terminal 
formalin-fixed, paraffin-embedded samples taken 36 days after induction of 
treatment.
Results: Plasma compound concentration measured 24 hours after the final 
dose gave calculated unbound concentrations 7.9 and 3.1 fold above the Ki 
value for Saxa and Sita, respectively. Glycaemic control and β-cell mass data 
are given in the table.
Glycaemic control and beta cell mass following compound treatment
Vehicle STZ Sita Pre STZ Sita Post STZ Saxa Pre STZ Saxa Post STZ
FBG (mM) 17.9±1.3 16.1±0.7 15.6±1.2 17.6±1.2 14.4±1.0*
HbA1c (%) 6.8±0.2 6.2±0.2* 6.3±0.2 6.5±0.2 6.1±0.2†
OGTT Glucose  
AUCBaseline (mM.min)
32.9±1.9 28.4±1.0† 28.4±0.8† 28.3±1.3† 28.3±1.8†
OGTT Insulin  
AUCBaseline (ng/ml.min)
-0.05±0.14 0.12±0.09 0.09±0.20 -0.05±0.17 0.19±0.17
Beta cell mass (mg) 0.13±0.03 0.16±0.02 0.42±0.06† 0.23±0.03* 0.28±0.05*
(Data are mean and sem calculated from the residuals of the SAS ROBUSTREG procedure and t-tests undertaken using 
two-sided tests. *, P<0.05 and †, P<0.01 compared to vehicle).
In animals treated post STZ, both saxa and Sita significantly reduced glucose 
AUCBaseline with no effect on insulin AUCBaseline during OGTT. Saxa induced 
a significant reduction in HbA1c and fasting glucose levels. Both treatments 
demonstrated a significant improvement in β-cell mass. Mice dosed pre STZ 
showed that both Saxa and Sita again reduced the glucose AUCBaseline. Saxa 
also demonstrated improvement in β-cell mass compared with vehicle.
Conclusion: Overall both Saxa and Sita showed similar improvements in gly-
caemic control and β-cell mass preservation in the high fat-fed, STZ mouse 
model of pancreatic β-cell degeneration. We have demonstrated for the first 
time that saxagliptin along with improving glycaemic control had a positive 
impact on β-cell preservation in a rodent model of type 2 diabetes.
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Protective effects of DPP-4 inhibitor against increased beta cell apoptosis 
with multiorgan glucolipotoxicity by a combination of dietary sugar and 
fatty acid
J. Shirakawa1, E. Takeda2, Y. Terauchi1; 
1Endocrinology and Metabolism, Yokohama City University, 2Clinical 
Nutrition, Tokushima University, Japan.
A composition of diet affects metabolic states in diabetes. We investigated 
diet-induced glucolipotoxicity and effects of des-fluoro-sitagliptin (DFS), a 
DPP-4 inhibitor, on it, in β cell-specific glucokinase haploinsufficient (Gck+/-) 
diabetic mice. We challenged the mice with diet containing a combination of 
sucrose and oleic acid (SO), or sucrose and linoleic acid (SL) for 25 weeks. 
In Gck+/- mice, but not in the wild-type mice, SL induced impaired insulin 
secretion in response to glucose. Histochemical analyses revealed that, in 
Gck+/- mice fed SL, β cell mass and proportion of β cells to islet cells were 
significantly decreased, α cell were dispersed into islet, and both CHOP- and 
TUNEL-positive β cells were significantly increased, compared to those fed 
SO. Analysis of mRNA expression showed that CHOP, Bip and SREBP-1c 
were significantly increased and E-cadherin was significantly decreased in 
islets of Gck+/- mice fed SL, compared to SO. These results indicated that the 
SL diet induced endoplasmic reticulum (ER) stress and apoptosis in β cells, 
which resulted in β cell loss and abnormal islet morphology by modifica-
tion of SREBP-1c and E-cadherin expression. Whereas histology and flow 
cytometry of epididymal fat indicated increased number of F4/80+ CD11c+ 
M1 macrophages and CD8+ T cell in SL, compared to SO. We next evaluated 
DFS monotherapy for increased beta cell apoptosis and glucolipotoxicity in 
Gck+/- mice fed SL diet with 1.1% DFS. Treatment with DFS improved glucose 
tolerance, protected against β cell apoptosis, restored β cell mass, and nor-
malized islet morphology in Gck+/- mice fed SL. DFS normalized the changes 
of islet mRNA expression of CHOP, Bip, SREBP-1c and E-cadherin by SL 
diet. DFS also reduced CD8+ T cell and M1 macrophage infiltration to epidi-
dymal fat. Furthermore, DFS prevented liver steatosis in SL-fed mice. Liver 
mRNA expression of SREBP-1c and SCD-1 were decreased, and PPARα was 
increased in DFS treated group. Taken together, DFS protected against meta-
bolic disorders in multiple organs induced by dietary sugar and fatty acid 
(multiorgan glucolipotoxicity).
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Enhanced proliferation of islet beta cells in spontaneously diabetic GK 
rats treated with DPP-IV inhibitor (Vildagliptin)
S. Yagihashi, H. Mizukami, W. Inaba, K. Takahashi; 
Pathology and Molecular Medicine, Hirosaki University, Japan.
Background and aims: Progressive decline of beta cell mass is a hallmark 
of either obese or lean type 2 diabetic patients. Currently, incretins are ex-
pected to not only exert insulin secretion but to protect beta cell depletion. It 
is not entirely clear, however, whether DPP-IV inhibitors have a potential to 
maintain beta cell survival or to prevent apoptotic processes of beta cells in 
lean type 2 diabetes. Spontaneously diabetic GK rats are non-obese, typical 
of lean type 2 diabetes model. In this study, we studied the effects of DPP-IV 
inhibitor on the islet pathology in GK rats to explore how it can protect the 
development of beta cell depletion.
Materials and methods: GK rats 4 weeks of age were orally given DPP-IV 
inhibitor (Vildagliptin 15mg/kg)(VG) twice a day for following 18 weeks. 
Untreated GK rats were given saline alone. Non-diabetic Wistar rats served 
controls. At end, all the animals were sacrificed after glucose tolerance test 
(GTT) (2g/kg) and insulin tolerance test (ITT) (0.5U/kg). Then, pancreases 
were subjected to evaluation of islet pathology and morphometric analysis 
of beta cells.
Results: VG treatment significantly suppressed postprandial hyperglycemia 
and food intake in GK rats, but did not affect blood glucose levels in normal 
Wistar rats. Gluose intolerance on GTT was also significantly improved in 
VG-treated GK rats. Lowered insulin secretion in GK rats after meals was sig-
nificantly improved by VG treatment while no effects on Wistar rats. Insulin 
resistance detected in GK rats on ITT was significantly improved at 30 min 
point in VG-treated GK rats, while there was no effect in Wistar rats. The is-
lets in GK rats were atrophic and irregular mixed with macrophage infiltration. 
VG-treated GK rats exhibited marked hyperplastic islets and less inflammatory 
changes. Islet morphometry disclosed significant decline of islet volume (48% 
of Wistar) and beta cell mass (41% of Wistar) in GK rats.VG-treated GK rats re-
covered the islet volume (120% of Wistar) and beta cell mass (103% of Wistar). 
Volume density of alpha cells was also decreased in GK rats and corrected by 
VG-treatment. Proliferation rate of beta cells as revealed by MIB-1 index was 
significantly reduced in GK rats (21% of Wistar) and VG-treated GK rats recov-
ered the index (5.6 times of untreated GK rats). Apoptotic cells in the islets were 
not detected in any group, either diabetic or non-diabetic groups. .
Conclusion: Our present study demonstrated that significant recovery of 
islet size and beta cell volume density was obtained in lean type 2 diabetic 
GK rats when treated with VG. The effects were mainly caused by enhanced 
proliferation of beta cells and associated with improved glucose intolerance 
and insulin secretion.
Supported by: Novartis Research Fund
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GLP-1 counteracts fatty acid inducing expression of PANDER, an 
apoptotic cytokine secreted from pancreatic islets, through activating 
Akt pathway
X. Cao, S. Chen, H. Xiao, S. Chen, X. Mo, Y. Li; 
Endocrinology, First Affiliated Hospital, Sun Yat-sen University, Guangzhou, 
China.
Background and aims: PANDER is a novel discovered cytokine that is se-
creted from pancreatic islet cells. It has been demonstrated that overexpres-
sion of PANDER induces pancreatic beta-cell apoptosis and dysfunction. To 
a better understanding of the pathophysiological role of PANDER in the islet 
beta-cells, we analyzed the effects of fatty acid and the counteracting effects of 
GLP-1 on PANDER expression and the possible mechanism.
Materials and methods: Beta-TC3 cells were cultured with or without Pal-
mitic acid (PA), and/or GLP-1, Akt inhibitor (Akti). Cell viability was meas-
ured with MTT. Annexin-V-FITC/PI FACS was used to analyze cell apop-
tosis. PANDER mRNA and protein expression were measured by real-time 
fluorescence quantitative PCR and western blot, respectively.
Results: PA decreases cell viability of pancreatic beta-TC3 cell in a dose de-
pendent manner as measured with MTT, Cell viability reduced one third 
when cells were treated with 0.8mmol/L PA, and a further decrease of 40% 
was observed when 1.0 mmol/L PA was used. Cell viability were increased 
significantly in PA + GLP-1 treated cells comparing to the PA treated cells 
(P<0.05). There were no significant differences between control group and PA 
+ GLP-1 group(P>0.05). Annexin-V-FITC/PI FACS analysis has showed that 
the apoptotic rate of beta-TC3 cells were (18.20 ± 2.14)%, (52.73 ± 3.29)% , 
and (34.49 ± 1.57)% in control, cells treated with PA, and cells treated with PA 
+ GLP-1, respectively. PA increased cell apoptosis significantly (vs control, P 
<0. 05), and GLP-1 rescued cells from PA inducing apoptosis. Comparing to 
the PA treated cells, the apoptotic cells was significantly lower in cells treated 
with PA + GLP-1 (P <0. 05). PANDER mRNA expression is presented by F 
value of real time-PCR. The lower of F value, the higher the mRNA expres-
sion level. The F values were (1.00 ± 0.00) %, (0.16 ± 0.16) %, and (2.01 ± 
0.46) % in control cells, cells treated with PA, and cells treated with PA + 
GLP-1 respectively. PA increased PANDER mRNA expression significantly 
(vs control, P <0. 05), while GLP-1 decreased PA inducing PANDER mRNA 
expression (vs PA, P <0. 05). Western blot has shown that PA induced 1.5 fold 
increase of PANDER protein expression, and there is no significant difference 
of PANDER protein expression between the control and PA+GLP-1 treated 
cells. GLP-1 reduced PA inducing PANDER protein expression significant 
(vs PA, P <0. 05). The p-Akt protein expression was increased in both of the 
GLP-1 and GLP-1+PA groups. When Akti was added, there are no signifi-
cant differences of PANDER protein expression between PA and PA+GLP-1 
treated cells were observed. The effect of GLP-1 on PA inducing PANDER 
expression was reduced.
Conclusion: GLP-1 counteracts PA inducing PANDER expression and res-
cues beta-cells from PA inducing apoptosis. This effect of GLP-1 on PA in-
ducing PANDER expression is partially through activating the Akt pathway.
Supported by: NSFC
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Exendin-4 inhibits palmitate-induced apoptosis in pancreatic beta cells
A. Natalicchio1, R. Labarbuta1, M.R. Orlando1, F. Tortosa1, A. Leonardini1, 
A. Cignarelli1, M. Melchiorre1, A. Peschechera1, P. Marchetti2, S. Perrini1,  
L. Laviola1, F. Giorgino1; 
1Endocrinology & Metabolic Diseases, D.E.T.O., University of Bari, 
2Endocrinology and Metabolism of Transplantation, AOU, University of 
Pisa, Italy.
Background and aims: Type 2 diabetes is characterized by a progressive de-
cline in the number of insulin-producing beta-cells, largely due to increased 
cellular apoptosis. Free fatty acids (FFA) are essential energy metabolites in 
the normal state, but induce beta-cell dysfunction and death when their levels 
are chronically increased, thus contributing to the pathogenesis of type 2 dia-
betes. GLP-1 and its long-acting receptor agonist exendin-4 (ex-4) increase 
the survival of beta-cells exposed to various pro-apoptotic stimuli, including 
FFA. The aim of this study was to investigate the mechanisms of FFA-induced 
beta-cell apoptosis and the potential protective effects of GLP-1 mimetics on 
this response in the rat insulin-secreting cell line INS-1 and in isolated hu-
man islets.
Materials and methods: INS-1 beta-cells and isolated human islets were ex-
posed to 0.5 mM palmitate for several h. The effects of ex-4 were evaluated 
by pre-incubating INS-1 cells with 10 nM ex-4 for 16 h. Protein content and 
phosphorylation of intracellular signaling intermediates were evaluated by 
immunoprecipitation and immunoblotting techniques. Gene expression was 
evaluated by qRT-PCR. Beta-cell apoptosis was quantified by an ELISA assay 
evaluating oligosome release into the cytosol.
Results: Exposure of both INS-1 cells and isolated human islets to 0.5 mM 
palmitate, a saturated fatty acid, up to 48 h induced a 2.5-fold increase in 
cell apoptosis, measured by evaluation of cytosolic oligosomes (p<0.05) and 
cleaved caspase-3 (p<0.05). Palmitate induced a 3.5-fold increase in the phos-
phorylation of JNK1/2, a class of mitogen-activated protein kinases largely 
involved in beta-cell apoptosis, evaluated by both immunoblotting and im-
munofluorescence (p<0.05), and a 3.8-fold increase in the mRNA levels of the 
JNK substrate c-jun (p<0.05), evaluated by qRT-PCR. Preincubation with 10 
μM SP600125, a specific JNK inhibitor, for 2 h prevented palmitate-induced 
apoptosis (p<0.05 vs. palmitate-treated cells). Treatment with 10 nM ex-4 
for 16 h inhibited both palmitate-induced activation of JNK1/2 (p<0.05 vs. 
palmitate-treated cells) and apoptosis (p<0.05 vs. palmitate-treated cells) in 
both rat insulin-secreting cells INS-1 and isolated human islets. Furthermore, 
ex-4 inhibited palmitate-induced phosphorylation of the upstream stress sig-
naling kinases MKK4 and MKK7, which are implicated in JNK activation 
(p<0.05 vs. palmitate-treated cells), and increased the protein content of Islet-
Brain 1 (IB1), a blocker of the stress-induced JNK pathway (p<0.05).
Conclusion: Palmitate induces apoptosis of human and rat beta-cells by ac-
tivating JNK1/2, and the GLP-1 analog ex-4 prevents palmitate-mediated 
apoptosis, at least in part by interfering with the JNK activation pathway. 
These results provide evidence that the ability of ex-4 to prevent FFA-induced 
apoptosis involves inhibition of the JNK pathway, identifying an important 
mechanism by which GLP-1 receptor agonists may halt beta-cell death trig-
gered by metabolic abnormalities.
Supported by: University of Bari
572
PEGylated PYY3-36 has beneficial effects on glucose handling and exhibits 
islet sparing effects in db / db mice
A. Konkar1, W. Danho2, I. Mikaelian3, R. Garrido3, L. Rumennik1,  
C. Spence1, T. Truitt4, H.A. Salari1, G. Ehrlich5, N. Brown1,  
K. Conde-Knape1, C. Rondinone1, H.L. Char6; 
1Metabolism Discovery, 2Discovery Chemistry, 3Non clinical Safety, 
4Discovery Technologies, 5Formulation Research, 6Pharmaceutical & 
Analytical R&D, Hoffmann-La Roche Inc., Nutley, USA
 Background and aims: NPY2-receptor peptide agonists suppress appetite in 
animal models of obesity, and therefore show great promise as treatment for 
obesity. However, their anti-diabetic potential has not been fully explored. In 
this study we investigated the anti-diabetic potential of long acting PEGylated 
PYY3-36 (PEG-PYY).
Materials and methods: Acute effect of PEG-PYY (3, 10, 20 and 30 mg/kg) 
on fasting glucose 26 h after a single subcutaneous (sc) administration was 
measured in diabetic 11-week old female db/db mice (Jackson Laboratories, 
Bar Harbor, ME). An oral glucose tolerance test was conducted to determine 
the effects on glucose disposal. We next examined the effects of PEG-PYY 
(sc, q2d) administration on glucose handling and islet morphology following 
sub-chronic dosing for 6 weeks in 9-week old db/db mice. The effects of 3-
week PEG-PYY treatment (q2d) on body weight and insulin sensitivity were 
measured in male C57Bl/6 DIO mice (Jackson laboratories).
Results: PEG-PYY exhibited high NPY2-receptor selectivity (>100-fold) 
against related NPY-receptors. In leptin receptor deficient diabetic db/db 
mice, a single sc dose of PEG-PYY produced a 61% reduction in fasting 
blood glucose levels at 26 h post-dose. In addition, there was a significant im-
provement in glucose handling observed following an oral glucose challenge. 
Similar benefits were observed following sub-chronic dosing with PEG-PYY. 
In 9-week old db/db mice, PEG-PYY (20 mg/kg) injected every other day 
for 6-weeks improved glucose handling and had an islet sparing effect. A 
substantial improvement in islet morphology and insulin immunoreactivity 
was observed in PEG-PYY treated mice. In addition to its anti-diabetic ben-
efits, PEG-PYY displayed robust anti-obesity effects as expected. Following 
sub-chronic dosing in DIO mice, a sustained reduction in body weight gain 
(12% @ 20 mg/kg) and an improvement in insulin sensitivity were observed. 
Significant improvements in levels of glucose, insulin, triglycerides and cho-
lesterol were also noted.
Conclusion: In summary, we have observed that PEG-PYY improves glucose 
handling following an acute dose diabetic db/db mice. Sub-chronic treatment 
with PEG-PYY delayed the onset of diabetes in mildly hyperglycemic db/db 
mice and maintained islet health. These benefits of PEG-PYY likely involve its 
effects on insulin sensitivity, food intake, weight gain and lipid metabolism. 
Thus long acting PYY analogs have the potential to be developed as treat-
ments for diabesity, with the added benefit of improved lipid parameters.
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A basal−bolus regimen of insulin glargine and insulin glulisine results 
in a lower rate of hypoglycaemia relative to endpoint HbA1c versus twice-
daily premixed insulin in type 2 diabetes patients
A. Fritsche1, M. Larbig2, H.-U. Häring1, The GINGER Study Group; 
1Fourth Medical Department and Policlinic, University Tübingen, Germany, 
2sanofi-aventis, Berlin, Germany.
Background and aims: We recently demonstrated, in the GINGER study, 
that an intensified basal−bolus regimen using insulin glargine (GLAR) and 
insulin glulisine (GLU) provides significantly superior glycaemic control 
compared with premixed insulin therapy (ΔHbA1c reduction 0.5%; Table) 
in a population with long-standing insulin-treated type 2 diabetes mellitus 
(T2DM). Although a difference in rates of hypoglycaemia favouring the 
basal−bolus arm was present, this was not statistically significant. It is well 
known that greater improvements in HbA1c are associated with higher rates 
of hypoglycaemia. The aim of this analysis was to investigate the rate of hy-
poglycaemia relative to the achieved glycaemic control in terms of HbA1c.
Materials and methods: In this 52-week, open, randomized, multinational, multi-
centre clinical trial, mealtime GLU and once-daily GLAR (n=153) was compared 
with an optimized conventional therapy of twice-daily premixed insulin (n=157) in 
T2DM patients inadequately controlled with their previous premixed insulins. In 
the premixed insulin group, 63 subjects received a combination of NPH/aspart. At 
baseline, the characteristics of the total study population (49% female) were (mean 
± standard deviation): age, 61 ± 8 years; body mass index, 30.1 ± 3.7 kg/m²; diabetes 
duration, 13 ± 6 years; and insulin use, 5 ± 4 years. We used negative binomial re-
gression analysis to model hypoglycaemia outcomes by endpoint HbA1c, adjusting 
for baseline HbA1c and diabetes duration, taking zero inflation into account.
Results: The subjects with GLAR/GLU therapy had a 24.5% lower rate of 
overall hypoglycaemia (1399.17 ± 2324.24 vs 1854.31 ± 3694.83 events per 
patient year for GLAR/GLU and premix, respectively; unadjusted rate; Ta-
ble) than the whole premix group (p=0.1211 from the adjusted model) and a 
43.3% (p=0.0196) lower rate of overall hypoglycaemia than the NPH/aspart 
subgroup. When the analysis only included patients with at least one episode 
of hypoglycaemia during the study, the subjects with GLAR/GLU therapy 
had a 26.5% (p=0.0442) and 40.7% (p=0.0086) lower rate of overall hypogly-
caemia than the whole premix group and NPH/aspart subgroup, respectively. 
Analyses with confirmed hypoglycaemia yielded similar results.
Conclusions: In the GINGER study, basal−bolus treatment with GLAR/GLU dis-
played a lower rate of hypoglycaemia in relation to endpoint HbA1c compared with 
premixed insulin therapy. This was more pronounced in the analysis comparing the 
NPH/aspart-treated subgroup with basal−bolus treatment. Therefore, a basal−bolus 
regimen with insulin analogues is safer than premixed insulin therapy in T2DM pa-
tients with long-standing diabetes, when considering endpoint HbA1c.
Table: Hypoglycaemia and HbA1c
Insulin 
glargine/insu-
lin glulisine
Premix
Al NPH/aspart
Hypoglycaemia (events per 100 patient−years; safety population)
n=153 n=157 n=63
Overall hypoglycaemia 1399.17 ± 
2424.24
1854.31 ± 
3694.83
2468.39 ± 
4853.41
Confirmed hypoglycaemia* 1129.52 ± 
2286.84
1548.67 ± 
3630.64
2172.21 ± 
4868.58
HbA1c (mean ± standard deviation; full analysis set)
n=153 n=157 n=61
Baseline HbA1c, % 8.62 ± 0.83
† 8.51 ± 0.86 8.44 ± 0.90
Endpoint HbA1c, % 7.31 ± 1.16 7.71 ± 1.14 7.74 ± 1.31
Baseline to endpoint change, % −1.31 ± 1.19‡§ −0.80 ± 1.01 −0.70 ± 1.08
Adjusted mean difference in HbA1c 
change versus GLAR/GLU, % (95% 
confidence interval)
− −0.476
(−0.714, 
−0.238)
−0.589
(−0.933, 
−0.246)
*Confirmed hypoglycaemia was defined as an event with confirmed blood 
glucose level ≤60 mg/dL; †p=0.3315 compared with premix; ‡p=0.0001 
compared with premix; §p=0.0009 compared with NPH/aspart
Supported by: sanofi-aventis
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Detection of patient-specific intra-day patterns among hypoglycaemia 
episodes using continuous glucose monitoring
R. Cheng, T.C. Dunn; 
Abbott Diabetes Care, Alameda, USA.
Background and aims: Incidence of hypoglycemia can be affected by insulin 
dosing, exercise, meals and sleep. Patterns in lifestyle and treatment deci-
sions can result in consistent hypoglycemic patterns. Rapid computational 
screening of patient data can identify times of day with significant temporal 
patterns, which can then inform self-management adjustments that lead to 
improved glycemic control. A computational method for identifying patient-
specific patterns in hypoglycemic episodes is proposed and applied to CGM 
data from a 40-day Freestyle Navigator® System home-use study to evaluate 
the impact of unmasked CGM readings on hypoglycemic patterns.
Materials and methods: 64 (T1DM=46, T2DM=18, all insulin users) subjects 
were selected for analysis based on high data availability and presence of at 
least 2 hours of hypoglycemia (<3.89 mmol/L) over the 40 day study. Subjects 
had glucose data masked for the first 20 days and unmasked for the following 
20 days. During the masked phase, subjects were not able to see their CGM 
glucose values or trends and did not have glucose threshold or projected 
alarms available. CGM data from each subject’s 20-day phases are divided 
into 2,880 ten-minute segments and categorized as hypoglycemic or not. For 
each subject, the number of ten-minute hypoglycemic segments is counted 
in each of six periods of the day (Early Morning: 4:00-8:00, Late Morning: 
8:00-12:00, Early Afternoon: 12:00-16:00, Late Afternoon: 16:00-20:00, Early 
Night: 20:00- 0:00, Late Night: 0:00-4:00). Any period of the day with 30 or 
more hypoglycemic segments (corresponding to an average of 1.5 segments, 
or 15 minutes of hypoglycemia, in a given four hour period per day) is la-
beled as a persistent hypoglycemia pattern for that subject. The proportions 
of subjects with such patterns during the masked and unmasked phases were 
compared for each period of the day using pooled-proportion z-tests.
Results: The proportion of subjects with persistent hypoglycemia patterns differed 
significantly between the masked and unmasked phases in the Early Night (28%, 
5%, p=0.0003) and Late Night (38%, 6%, p < 0.0001) periods. In the Early Morn-
ing (28%, 16%, p=0.0872), Late Morning (8%, 6%, p=0.7296), Early Afternoon 
(8%, 8%, p=1.0000) and Late Afternoon (17%, 6%, p=0.0544) periods, the propor-
tion of subjects with persistent hypoglycemia patterns did not differ significantly.
Conclusion: The proposed computational method is useful for identifying 
periods of the day with hypoglycemic patterns on a per-subject basis. When 
used to compare masked and unmasked phases of a CGM home-use study, 
the incidence of persistent hypoglycemia was found to be significantly lower 
during the Early Night and Late Night periods of the unmasked phase relative 
to the masked phase. The method can be extended to identify other glycemic 
episodes of interest (such as hyperglycemia) over different time periods (e.g. 
days of the week). Prospective studies would be needed to evaluate the meth-
od’s ability to improve therapy decisions.
Supported by: Abbott Diabetes Care
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Relationship of hypoglycaemia with medication, discontinuation and 
costs in type 2 diabetes mellitus patients 
M. Bron1, A.P. Yu2, M. Marynchenko2, H. Yang2, O. Dabbous1, S.X. Sun1; 
1Takeda Pharmaceuticals International, Inc., Deerfield, 2Analysis Group, 
Inc., Boston, USA.
Background and aims: Hypoglycemia is a common and potentially severe 
adverse effect of antidiabetic treatment and poses significant barrier to main-
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taining tight blood glucose control. (Amiel, 2008; Cryer, 2009) This study 
investigates the clinical and economic effect of hypoglycemia in type 2 dia-
betes mellitus (T2DM) patients initiated on oral and/or insulin antidiabetic 
drugs (OADs). Risks of hypoglycemia, likelihood of discontinuation, medical 
costs and medication type are compared between patients diagnosed with 
hypoglycemia vs. no hypoglycemia.
Materials and methods: T2DM patients initiated on OADs were identified 
in the Ingenix IMPACT Database (1999-2008). Included patients were ≥18 
years old and had ≥1 year of continuous eligibility following the index date 
(first OAD prescription). Hypoglycemia risk factors in the subsequent 6-
month interval were examined with multivariate Cox PH models adjusting 
for demographic characteristics and time-varying covariates (diabetes treat-
ments and co-morbidities). The effect of hypoglycemia and other factors on 
antidiabetic treatment discontinuation was analyzed using GEE models with 
repeated measures. Annual cost outcomes for hypoglycemia were analyzed 
using GLM regressions.
Results: A total of 212,061 T2DM patients with ≥1 OAD treatment were 
identified, with 4,860 (2.3%) patients having a hypoglycemia diagnosis in the 
first year following the index date. Use of sulfonylureas (HR=1.58, p<.0001), 
insulins (HR=1.77, p<.0001), meglitinides or alpha-glucosidases (HR=1.27, 
p<.0001) was associated with a significant increase in hypoglycemia risk in 
the next 6-month interval. Use of DPP-4 inhibitors (HR=0.79, p=.0141), 
TZDs (HR=1.06, p=.0133) or metformin (HR=0.99, p=.8203) had minimal 
effect on hypoglycemia risk. Hypoglycemia diagnosis in a given 6-month 
interval significantly increased the likelihood of treatment discontinuation 
(OR=1.27, 95% CI=1.23, 1.32) within the same and the next 6-month interval 
(OR=1.14, 95% CI=1.09, 1.19). Moreover, for patients with a hypoglycemia 
diagnosis, average annual total costs (medical+drug costs, $18,273 vs. $8,908, 
p<.0001) and diabetes-related costs ($8,969 vs. $3,220, p<.0001) were signifi-
cantly higher than for those without a diagnosis.
Conclusions: Patients experiencing hypoglycemia are at a higher risk of ther-
apy discontinuation while hypoglycemia risk varies among treatments; insu-
lin and SUs are associated with the most risk within the short term. The cost 
impact is twice as high with hypoglycemia compared to no hypoglycemia due 
to significantly higher total medical and diabetes-related costs.
Supported by: TPNA, Inc.
576
Impact of HbA1c and sulfonylurea use on hypoglycaemia in type 2 
diabetes mellitus
K. Clements1, M. Bron2, D. Taylor1, N. Emptage1, S. Hudgens2, O. Dabbous2; 
1i3 Innovus, Medford, 2Takeda Pharmaceuticals International, Inc., 
Deerfield, USA.
Background and aims: This study examined the relationship between HbA1c 
level, oral antidiabetics, and hypoglycemia among type 2 diabetes mellitus 
(T2DM) patients receiving sulfonylureas (SU).
Materials and methods: A retrospective claims analysis of the I3 Innovus 
population from Jan 1, 2002-Dec 31, 2008 was conducted on T2DM patients 
with no history of diabetes-related complications or recent (3 months prior) 
T2DM medication changes (N=10,291). Patients receiving SU at baseline 
were included and classified as high or low dose based on the median SU dose 
(10 mg glyburide or glipizide, 4 mg glimepiride). Dose was classified as high 
dose if the average daily dose was above the median dose. In addition to SU, 
insulin use was also assessed. The outcome measure was incidence of diabe-
tes-related hypoglycemic events, derived from claims with an ICD-9 code for 
hypoglycemia. Cox proportional hazards models measured the association 
between HbA1c and hypoglycemia, adjusting for clinical and demographic 
characteristics.
Results: At baseline for all 10,291 SU patients (mean age 57; 57% male; 
mean HbA1c 7.8%), 35% (n=3,628) of patients received high-dose SU; 7.7% 
(n=788) received SU and insulin. Over the average 3 year follow-up period, 
7.2% (n=736) had a hypoglycemic event. The likelihood of a hypoglycemic 
event increased monotonically by HbA1c. Specifically, those with high base-
line index HbA1c (≥9.0) were 47.2% more likely to have a hypoglycemic 
event in the follow-up period (OR 1.472, CI=1.094, 1.982). Similarly, patients 
receiving high-dose SU were 35.7% more likely to have hypoglycemic events 
than low-dose patients, and those patients on insulin in addition to SU had an 
increase in likelihood of 72.1% (Table 1).
Conclusion: The results indicate that high-dose SU and increased HbA1c are 
associated with increased likelihood of hypoglycemic events.
Table 1. Predictors of Hypoglycemia in Patients Receiving SU
Variables OR 95% Wald Confidence Limits
HbA1c Level (6.5 - 6.9% as Ref)
<6.5% 1.238 0.924 1.659
7.0 - 7.9% 1.234 0.926 1.645
8.0 - 8.9% 1.242 0.913 1.689
≥ 9% 1.472* 1.094 1.982
High-Dose SU 1.357** 1.152 1.598
Age (yrs) 1.032** 1.025 1.040
Male Gender 0.906 0.777 1.056
Concomitant Diabetes Medications
Insulin (+ Any SU) 1.721** 1.351 2.192
Other (+ Any) 1.116 0.931 1.338
Charlson Index** 1.199** 1.119 1.284
* p <0.05 ** p <0.01
Supported by: TPNA, Inc.
577
Risk factors for symptomatic hypoglycaemia in people with type 
2 diabetes mellitus initiated on insulin therapy: evidence from the 
CREDIT study
G. Vespasiani1, N. Freemantle2, B.J. Balkau3, N. Danchin4, E. Genestin5,  
M. Marre6, M. Marre6, R. Kawamori7, P. Home8; 
1Diabetology and Metabolic Disorders Centre, San Benedetto Del Tronto, 
Italy, 2Department of Primary Care and General Practice, University 
of Birmingham, Edgbaston, United Kingdom, 3INSERM CESP U1018, 
Villejuif, France, 4Division of Coronary Artery Disease and Intensive 
Cardiac Care, Paris, France, 5sanofi-aventis, Paris, France, 6Université Paris, 
France, 7Department of Medicine, Juntendo University, Tokyo, Japan, 
8Institute of Cellular Medicine – Diabetes, Newcastle University, United 
Kingdom.
Background and aims: Hypoglycaemia has been suggested to be a potential 
causative factor in the development of diabetes-associated cardiovascular dis-
ease (CVD). We evaluated risk factors for symptomatic hypoglycaemia in the 
CREDIT study, a 314-centre, multinational, non-interventional, prospective 
study designed to investigate the effects of insulin initiation and long-term 
glycaemic control on CVD risk, with 3031 type 2 diabetes mellitus (T2DM) 
patients enrolled.
Materials and methods: Patients with at least one documented episode of 
symptomatic hypoglycaemia between 6 months and 1 year after initiating 
insulin were identified. Potential factors associated with hypoglycaemia (in-
cluding patient demographics, medical history, CVD risk factors, glycaemic 
control and diabetes treatment) were described and assessed in a multivari-
able stepwise logistic regression. To enter and retain each factor in the model 
a p value of 0.20 and 0.05, respectively, was required. Multivariable analysis 
was adjusted for country.
Results: Of 2510 patients included in this analysis, 504 (20.1%) experienced 
at least one documented episode of symptomatic hypoglycaemia over the 
analysis period. In the final multivariable model, body mass index (BMI) at 
insulin initiation and HbA1c level following 1 year of treatment were inversely 
correlated with symptomatic hypoglycaemia (Table). Each 1% increment 
in HbA1c levels at 1 year was associated with a 25% reduction in the risk of 
symptomatic hypoglycaemia over the course of the study. Each 1 kg/m2 incre-
ment in BMI at initiation was associated with a 3% reduction in symptomatic 
hypoglycaemia. Risk of hypoglycaemia was significantly lower with basal in-
sulin alone than with other insulin strategies including premixed insulin and 
short-acting insulin alone. Non-intensive versus intensive insulin therapy 
and physical inactivity versus activity were also associated with a lower rise of 
symptomatic hypoglycaemia.
Conclusion: In patients with T2DM recently initiated on insulin therapy, low 
BMI at insulin initiation, low HbA1c and insulin regimen at 1 year, physical 
activity and use of intensive insulin therapy were significant risk factors for 
symptomatic hypoglycaemia. The use of basal insulin alone was associated 
with a lower risk of symptomatic hypoglycaemia than other insulin regi-
mens. 
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Table: Multivariable model of risk factors for documented symptomatic 
hypoglycaemia
Variable Odds ratio* 95% CI p value
BMI (kg/m2) at insulin initiation 0.968 [0.948; 0.988] 0.0021
Physical activity: no vs yes 0.735 [0.589; 0.917] 0.0063
Normalized HbA1c (%) at 1 year 0.752 [0.687; 0.822] <0.0001
Insulin used at 1 year
Basal + short-acting vs basal alone
Premixed insulin vs basal alone
Short-acting alone vs basal alone
Other insulin† vs basal alone
1.972
1.730
1.766
2.381
[1.412; 2.755]
[1.298; 2.307]
[1.113; 2.802]
[1.336; 4.243]
<0.0001
0.0002
0.0158
0.0033
Intensified insulin therapy: yes vs no 1.424 [1.109; 1.830] 0.0057
*Odds ratios were adjusted for between-country differences; †Any insulin 
regimen not covered by the four other insulin categories; BMI=body mass 
index; CI=confidence interval
Supported by: sanofi-aventis
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The average length of hospital stay for a hypoglycaemic event in patients 
diagnosed with type 1 diabetes mellitus and type 2 diabetes mellitus
G.H. Chamberlain, P.H. McEwan; 
Cardiff Research Consortium L.t.d, Cardiff, United Kingdom.
Background and aims: Hypoglycemia, abnormally low blood glucose levels, 
can occur in patients diagnosed with both type 1 diabetes mellitus (T1DM) 
and type 2 diabetes mellitus (T2DM), and is often associated with intensive 
treatment strategies. The resulting outcomes range from hunger, dizziness 
and confusion, to seizure, unconsciousness and rarely, brain injury. Patients 
who experience a severe hypoglycemic event are commonly hospitalized and 
therefore contribute to the health service burden. The aim of this study was 
to determine and examine the comparative length of hospital stay associated 
with hypoglycemic events in patients with T1DM and T2DM.
Material and methods: Routine hospital data were obtained from the Hos-
pital Episode Statistics (HES) data warehouse, which contains anonymized, 
continuously collected data from all English hospitals. All patients with a pri-
mary diagnosis of hypoglycemia (ICD10 E162) between 1999 and 2006 were 
selected. Only a patient’s first hypoglycemic event was included in the study, 
subsequent events were removed. Patients were subsequently categorized ac-
cording to their type of diabetes using previous hospital admission defini-
tions within the time period; T1DM (ICD10 E10) or T2DM (ICD10 E11). 
Patients whose history included a diagnosis of both T1DM and T2DM were 
removed from the study. The single outcome measure was length of hospital 
stay in days.
Results: The number of patients experiencing a hypoglycemic event within 
the dataset was 15,995 for T1DM and 21,736 for T2DM. Patients with T2DM 
were associated with significantly (p<0.0001) longer mean length of hospital 
stay for hypoglycemic their events (6.0 days; SD 8.9), compared to those with 
T1DM (3.2 days; SD 11.1).
Conclusion: The mean length of hospital stay associated with hypoglycemic 
events was 88% greater for those patients diagnosed with T2DM when com-
pared to patients diagnosed with T1DM. Use of therapies for T2DM that are 
associated with a reduced risk of hypoglycemia can reduce the number of 
hypoglycemic events in these patients, and consequentially reduce length of 
hospital stay, and ultimately the burden to the health service.
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Severe sulphonylurea-induced hypoglycaemia - a problem of uncritical 
prescription and deficiencies of diabetes care in geriatric patients
A. Holstein1, C. Hammer1, M. Hahn1, N.-S. Kulamadayil1, P. Kovacs2; 
11st Department of Medicine, Klinikum-Lippe, Detmold, Germany, 
2Interdisciplinary Center of Clinical Research, University of Leipzig, 
Germany.
Background and aims: Severe sulphonylurea-induced hypoglycaemia (SH) 
remains a life-threatening and underreported condition. We investigated the 
incidence of SH and clinical characteristics of patients with type 2 diabetes 
mellitus (T2DM) to demonstrate typical risk constellations.
Materials and methods: In a population based observational study, all con-
secutive cases of SH in the period 2000-2009 in a German area with 200.000 
inhabitants were registered. Severe hypoglycaemia was defined as a sympto-
matic event requiring treatment with intravenous glucose and was confirmed 
by a blood glucose measurement of <50 mg/dl.
Results: A total of 1.419 cases of severe hypoglycaemia, 141 (10%) of them 
having been treated with sulphonylureas, were registered among the 103.256 
patients who attended the medical emergency department. A mean incidence 
of 7 episodes of SH per year and 100.000 inhabitants was registered. The 139 
hypoglycaemic individuals with T2DM ( mean plasma glucose level of 31±10 
mg/dl) had been treated with glimepiride (n=98), glibenclamide (n=40) or 
gliquidone (n=1). Neither preparation showed a constant dose-effect rela-
tionship, SH occurring within a wide dose range. The patients were charac-
terised as follows: age 77.5±9.4 years, duration of diabetes 11±7 years, BMI 
26.3±4.9 kg/m2, HbA1c 6.6±1.3%, creatinine clearance 46±24 ml/min. with 
renal insufficiency in 73%, comedication 7±3 drugs. 27% of patients with SH 
received additional drugs which were also main substrates of CYP2C9 the 
genetically polymorphic cytochrome P450 enzyme being responsible for the 
hepatic metabolism of SUs. In particular, they received torasemide, clopi-
dogrel, phenprocoumon, diclofenac, phenytoine or fluvastatine. Two third 
of all subjects lived independently at home whereas one third was cared for 
by a home nursing service or received care in nursing homes. 30% had par-
ticipated in diabetes education programs. In 31% systematic blood glucose 
monitoring was performed.
Conclusion: The tight glycaemic control (HbA1c 6.6%) in our patients can 
be regarded as highly predictive for recurrent antecedent hypoglycaemic epi-
sodes that were not perceived either by the patients themselves or by their 
relatives or care staff. Uncritical prescription of sulphonylureas neglecting 
crucial contraindications - particularly renal insufficiency - and deficiencies 
of diabetes care contributed substantially to the risk of SH in the mainly geri-
atric patients. There is a need for alternative therapeutic concepts that mini-
mize the risk of hypoglycaemia in geriatric patients with T2DM.
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The PANORAMA pan-European Survey: impact of severe and non-
severe hypoglycaemia on quality of life and other patient reported 
outcomes in patients with type 2 diabetes
C. Bradley1, E. Eschwège2, P. de Pablos-Velasco3, K.G. Parhofer4, D. Simon5,  
M. Tafalla6, E. Pascual6, L.A. Gönder-Frederick7; 
1Royal Holloway, University of London, United Kingdom, 2INSERM U-
1018, Paris, France, 3Dr Negrin Hospital, Las Palmas University, Spain, 
4Klinikum der Universität, München, Germany, 5Hôpital de la Pitié / 
INSERM U-1018, Paris, France, 6AstraZeneca, Madrid, Spain, 7University of 
Virginia, Health System, USA.
Background and aims: Hypoglycaemia is a side effect of glucose-lowering 
treatment that can cause distress and injury, and may damage quality of life 
(QoL) in patients with type 2 diabetes (T2D). PANORAMA is a large pan-
European cross-sectional survey (NCT00916513) aimed at assessing patient 
reported outcomes in patients with T2D treated with glucose-lowering thera-
pies. The present analysis compares data on QoL, treatment satisfaction and 
fear of hypoglycaemia in patients with T2D in relation to their experience of 
hypoglycaemia.
Materials and methods: Patients with T2D were randomly or consecutively 
selected from physician practices (mainly in primary care) in 8 countries 
(Belgium, Germany, Greece, Italy, the Netherlands, Spain, Turkey, and the 
UK). Eligible patients were ≥40 years of age, with a diagnosis of T2D for >1 
year prior to study entry and an available medical record at the clinic of >1 
year. All patients received dietary and exercise advice. Most patients were also 
being treated with either oral hypoglycaemic agents (OHAs) or injectables 
(insulin and GLP-1 receptor analogues) with or without OHAs. Treatment 
type was unchanged in the previous 3 months. Patients completed the Au-
dit of Diabetes-Dependent Quality of Life (ADDQoL), Diabetes Treatment 
Satisfaction Questionnaire (DTSQ) and the worry subscale of the Hypogly-
caemic Fear Survey-II (HFS-II). Data on history of severe and non-severe 
hypoglycaemic episodes were collected.
Results: 5,156 patients were included in the study between June and Novem-
ber 2009: 47.8% women; mean age 65.9 years (SD 10.3). Mean time since 
diagnosis was 9.0 years (SD 7.4). Patients who had experienced at least one 
episode of severe hypoglycaemia in the past 12 months showed significantly 
more negative impact of diabetes on QoL (ADDQoL, p<0.001), less satis-
faction with treatment (DTSQ, p=0.004) and greater fear of hypoglycaemia 
(HFS-II, p<0.001) than patients who had not experienced severe hypoglycae-
mia. Similar differences were found on all three measures for a comparison 
of patients who experienced more than one episode of non-severe hypogly-
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caemia per month with those who experienced one or fewer episodes per 
month (all p<0.001).
Conclusion: The occurrence of both severe and non-severe hypoglycaemia 
in T2D is associated with greater negative impact of diabetes on QoL, less 
treatment satisfaction, and greater fear of hypoglycaemia, and may be an im-
portant barrier to optimal glycaemic control in some patients.
Mean (SD) ADDQoL average weighted impact score, DTSQ treatment 
satisfaction score and HFS-II fear of hypoglycaemia score for patients who 
experienced ≥1 vs 0 episodes of severe hypoglycaemia, and patients who 
experienced >1 vs ≤1 episodes of non-severe hypoglycaemia in the last year
Episodes of hypoglycae-
mia in past 12 months n
Mean (SD) score
ADDQoL$ DTSQ^ HFS-II§
≥1 severe 313 -1.0 (0.6) 26.3 (7.0) 30.4 (18.1)
0 severe 4,831 -0.6 (0.5) 30.1 (6.0) 12.9 (15.3)
Difference1 -0.22** -1.14* 10.26**
>1 non-severe/month 889 -0.8 (0.6) 28.2 (6.8) 21.9 (17.7)
≤1 non-severe/month 4,258 -0.6 (0.5) 30.2 (5.9) 12.2 (15.1)
Difference2 -0.18** -1.07** 7.34**
$average weighted impact score: range -9 (most negative impact) to +3 
(most positive impact of diabetes on QoL); ^range 36 (very satisfied) to 0 
(very dissatisfied); §range 72 (most fearful) to 0 (least fearful)
1Patients with ≥1 episode of severe hypoglycaemia - patients with 0 episodes 
of severe hypoglycaemia.
2Patients with >1 non-severe hypoglycaemic episode/month - patients with 
≤1 non-severe hypoglycaemic episode/month.
Differences were calculated with mixed-effects regression models adjusting 
for centre.
*p=0.004; **p<0.001
Supported by: AZ & BMS
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Effect of erythropoietin on cognitive performance, symptoms and 
counter-regulation during hypoglycaemia in patients with type 1 
diabetes
P.L. Kristensen1, U. Pedersen-Bjergaard1, N.V. Olsen2, B. Thorsteinsson1,3; 
1Department of Cardiology and Endocrinology, Hillerød Hospital, 
2Department of Neuroanaesthesia, Copenhagen University Hospital 
(Rigshospitalet), 3University of Copenhagen, Denmark.
Background and aims: The incidence of severe hypoglycaemia in type 1 dia-
betes has not decreased over the past decades. New treatment modalities to 
minimise episodes of hypoglycaemia and attenuate hypoglycaemic cognitive 
dysfunction are needed. We studied if treatment with the potentially neuro-
protective hormone erythropoietin (EPO) enhances cognitive function dur-
ing hypoglycaemia.
Materials and methods: Eleven type 1 diabetic subjects with hypoglycaemia 
unawareness and at least two episodes of severe hypoglycaemia in the last 
year underwent a double-blind, randomised, balanced, cross-over study eval-
uating the effect of 40.000 IU of EPO on cognitive function, hypoglycaemic 
symptoms and counter-regulatory response during clamped hypoglycaemia. 
EPO or placebo were injected intravenously six days before the two experi-
ments which were separated by at least six weeks. Two reaction time tests 
(CalCAP), Stroop’s Colour and Word Test and a Trail Making Test (TMT) 
were used to evaluate cognitive function. The effects of EPO on cognitive 
function, hypoglycaemic symptoms and counter-regulatory hormones were 
assessed by analysis of covariance with baseline values and blood glucose 
during hypoglycaemia as co-variates.
Results: Mean (SD) plasma glucose concentration during hypoglycaemia 
was 2.2 (0.3) mmol/l on the EPO day and 2.0 (0.3) mmol/l on the placebo 
day (p=0.17). Compared with placebo, EPO treatment was associated with 
(parameter estimate (95% C.I.): a) reduction in the two reaction times during 
hypoglycaemia: 5 msec (-79 - 68; p=0.88) and 44 msec (-91 - 4; p=0.07); b) 
reduction in errors in the two reaction time tests: 0.3 (-1.4 - 2.1; p=0.68) and 
4.1 (-7.4 - -0.9; p=0.017); c) increase in completed items in Stroop’s Word, 
Colour and Word-Colour Test: 2 (-6 - 11; p=0.58), 1 (-6 - 8; p=0.71), and 2 
(-4 - 7; p=0.51), respectively; d) reduction in completion time in TMT: 3 sec 
(-45 - 40; p=0.88); and e) reduced neuroglycopenic and autonomic symp-
tom scores: -0.9 points (-3.8 - 2.0 points; p=0.46) and -0.6 points (-5.5 - 4.3; 
p=0.8), respectively. Peak values of adrenaline, cortisol, growth hormone and 
glucagon did not differ between EPO and placebo days.
Conclusion: In patients with type 1 diabetes and hypoglycaemia unaware-
ness, treatment with EPO is associated with a beneficial effect on cognitive 
function in only one of six tests of cognitive function. Hypoglycaemic and 
counter-regulatory hormonal responses were not changed by EPO treatment. 
However, it cannot be ruled out that alternative timing and dosage of EPO or 
new non-erythropoietic EPO analogues may be more efficient in enhancing 
cognitive function during hypoglycaemia.
Supported by: Research foundation of Hillerød Hospital (primary donor)
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The effect of diabetes and its control on susceptibility to learned 
helplessness in streptozotocin-induced diabetes rats
Y. Go1, H. Kitaoka2; 
1Internal medicine, Seikeikai Hospital, Sakai City Osaka, 2Internal medicine, 
Seikeikai Hospital, Sakai City, Japan.
Aims: In order to examine the mechanism linking diabetes to depression, 
specifically whether diabetic rats in good glycemic control versus those in hy-
perglycemic, or subject to exposed alternative periods of hyper and hypogly-
cemia, are different at risk of affective disorder. We induced learned helpless-
ness, as model of depression, is indicated the rate of cognitive processing.
Methods: Using the streptzotocin rats receiving insulin NPH or saline, to-
tally 37 rats, were divided into 4 types of glycemic control groups, Group 
A (good), B (hypo-hyper) ,C (untreated), D (controls). The bodyweight, the 
blood glucose concentration and HbA1c were measured. And all animals were 
placed in a learned helplessness paradigm, Forced swimming test (FST): the 
scorer would rate the rat’s behavior each 5 second period, as one of the follow-
ing four behaviors: immobility and another action. We examined the differ-
ences in the length of immobility ( a key marker of learned helplessness) with 
the analysis using Tukey-Kramer multiple comparison.
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Results: Glycemic control: Group A had nearly kept smaller change of blood 
glucose throughout the day. Group B of blood glucose showed a very steep 
fall from 475.8 ± 193.2 (mean ± SD) mg/dl to 42.8 ± 22.6 mg/dl within three 
hours after the insulin injection. Mean HbA1c of the diabetic group without 
insulin treatment significantly increased from 5.9 ± 1.3 to 8.7 ± 4.0 % (p < 
0.0001). In diabetic groups receiving insulin injection once a day or twice a 
day, the level of HbA1c significantly decreased from 5.6 ± 1.0 to 3.8 ± 0.6 % 
and 6.4 ± 1.7 to 3.7 ± 0.5 % respectively. There was no difference in the levels 
of HbA1c before treatment and after treatment between the groups with one 
daily injection and two daily injection of insulin. The bodyweight in A and 
B groups was not significantly different compared with that in non diabetic 
control group (P = 0.001, 0.001). Group C is significantly low compared with 
that in Group D (< 0.0001). FST: There were trends for counts of immobil-
ity to be higher in all 3 diabetic groups compared to Group D, especially in 
Group B, the mean count of immobility is significantly high compared with 
Group D (< 0.001). There is no significant difference between 4 groups in the 
mean counts of swimming. The climbing was significantly low in Group C 
compared to Group D (< 0.001).
Conclusion: The rats which had been exposed to hypoglycemia and hyper-
glycemia are more likely to develop learned helplessness than good glycemic 
control rats. These investigations are thought to be interesting to examine 
the relationship between diabetes and depression, and suggested that acute 
varieties in glycemic control could be the mechanism of susceptibility to af-
fective disorder.
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Physiological and performance differences between drivers with type 1 
diabetes with and without a history of recurrent hypoglycaemia driving 
mishaps
D.J. Cox1, B.P. Kovatchev1, H. Singh1, L.K. Campbell2,  
L.A. Gonder-Frederick1; 
1Psychiatry & Neurobehavioral Sciences, University of Virginia Health 
System, Charlottesville, 2Department of Psychiatry and Behavioral Sciences, 
Medical University of South Carolina, Charleston, USA.
Background and aims: In Europe and the U.S. collisions are more than twice 
as common among drivers with type 1 diabetes (T1DM) than spouses who do 
not have diabetes. This increased risk appears to be attributable to a subgroup 
of drivers with T1DM. The hypothesis tested is that this vulnerable subgroup 
is more at risk for hypoglycemia and its disruptive effects on driving ability.
Materials and methods: Thirty-eight drivers with Type 1 diabetes, 16 with 
(+History) and 22 without (-History) a recent history of recurrent hypogly-
cemia-related driving mishaps, drove a virtual reality driving simulator and 
watched a videotape of someone else driving a simulator for 30 minute peri-
ods. Driving and video testing occurred in a double-blind, randomized, cross-
over manner during euglycemia (5.5 mmol/L) and progressive hypoglycemia 
(3.9 down to 2.5 mmol/L). Subjects completed a brief neuropsychological test 
battery pre and post the euglycemia trial, and during the hypoglycemia trial 
they completed the battery at euglycemia immediately before and after and at 
hypoglycemic naidar. Examiners were blind to which subjects were +/-His-
tory, while subjects were blind to their blood glucose levels and targets.
Results: Groups did not differ on gender, driving history, HbA1c, insulin 
dose, BMI, hypoglycemia awareness or frequency of self-treatment during 
hypoglycemic driving in the laboratory study. +History subjects did report 
more episodes of severe hypoglycemia in the previous 12 months (p<.03). 
During euglycemia, +History participants reported more autonomic and 
neuroglycopenic symptoms (p<.01), performed worse on neuropsychologi-
cal tests (p<.01) and tended to require more dextrose infusion to maintain 
euglycemia with the same insulin infusion (p<.09). During progressive hy-
poglycemia, these subjects demonstrated less epinephrine release (p=.02), 
greater driving impairments (p=.03), and performed worse on neuropsycho-
logical tests (p<.01).
Conclusion: Current findings support the speculation that there is a sub-
group of type 1 diabetes drivers more vulnerable to experiencing hypogly-
cemia-related driving mishaps. This increased vulnerability may be due to 
possibly greater carbohydrate utilization, rendering them more vulnerable 
to experiencing hypoglycemia. During hypoglycemia they may release less 
hormonal counter-regulation, leading to more profound hypoglycemia, and 
more neuroglycopenia, rendering them more vulnerable to hypoglycemia-
impaired driving. Such individuals may be counseled to treat pending or 
actual hypoglycemia more aggressively and early immediately before and 
during driving.
Supported by: NIH/NIDDK
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PHUn - Psychopathology of Hypoglycaemia Unawareness
H. Rogers1, N. de Zoysa2, S.A. Amiel2; 
1Diabetes Dept, King’s College Hospital, London, 2Diabetes Research Group, 
King’s College London, United Kingdom.
Background and aims: A structured education programme teaching flexible 
insulin therapy to people with Type 1 diabetes (T1DM) demonstrated that 
hypoglycaemia awareness could be regained in 48% of hypoglycaemia-una-
ware patients who had attended a 5 day course. However neuroimaging data 
show abnormal reward responses in people with T1DM and hypoglycaemia 
unawareness (HU). And there remain 52% HU patients who do not regain 
awareness from education. Indeed, this group show less behaviour change 
with current educational strategies and are at high risk of severe hypoglycae-
mia. Our study was designed to examine the meanings people with HU as-
sign to their condition. The study aims to: 1. use clinical interviews to identify 
cognitive biases; 2. construct a theoretical account which explains why the 
cognitive abnormality does not self-correct; 3. develop specialised psycho-
logical interventions to address the cognitive bias; 4. test the efficacy of the in-
terventions in randomised controlled trials and 5. make the treatments more 
broadly available through dissemination studies. This abstract addresses the 
first 2 aims and further research is being carried out to address the latter.
Materials and methods: People with T1DM and HU underwent semi-struc-
tured interviews. Data were recorded and analysed using grounded theory 
principles and interviews continued until saturation (common themes recur-
ring).
Results: 17 people (10 female, mean age 53.1+7 yrs) were interviewed to 
reach saturation. The common themes were identified and categorised, this 
lead to the development of a theory which proposes that individuals with HU 
can be placed into 1 of 5 groups. Group 1: people with T1DM who may not 
have received adequate education about HU and do not realise that aware-
ness can be restored. Group 2: people with HU, but they are able to carry on 
life quite normally with no perceived clinical or quality of life disadvantage. 
They do not experience severe hypoglycaemia. Group 3: those who experi-
ence horrendous episodes of severe hypoglycaemia, which they perceive as 
frightening, disabling and/or deeply embarrassing socially, this group evalu-
ate and act to regain awareness. Group 4: This group all have a cognitive bias 
preventing them from hearing and acting upon the cues. The biases manifest 
in their not being able to recognise or act on the danger in which HU places 
them. They realise they have HU but are not ‘appropriately’ worried about it. 
The cognitive biases fall into the following categories: (a) because they do not 
feel any symptoms, they do not act; (b) because of fear of complications they 
act on any high blood glucose levels; (c) they believe ‘it won’t happen again’; 
(d) there is a strong desire to be ‘normal’ so may not disclose HU; (e) they 
believe that severe hypoglycaemia is normal, part of their lives, so nothing 
need be done. Group 5. those who derive some secondary gain from having 
severe hypoglycaemia.
Conclusion: Factors underlying the known persistence of HU in a propor-
tion of people with T1DM can be identified for individuals and fall into one 
of 5 categories. Identifying the factors operating in an individual will allow 
therapies to restore hypoglycaemia awareness to be tailored (eg Group 1 edu-
cation; Group 3 increased monitoring technology; Group 4 a psychological 
intervention) to their situation and help more people with T1 regain their 
endogenous defences against severe hypoglycaemia.
Supported by: NIHR
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Variable recovery from hypoglycaemic encephalopathy following 
massive insulin overdose in type 1 diabetes
C. Ballav, A. Cairns, J. Heritage, S. Kotnis, H. Brain; 
Diabetes and Endocrinology, Buckinghamshire Hospitals NHS Trust, High 
Wycombe, United Kingdom.
Background and aims: To describe and compare the clinical course of three 
male type 1 diabetes patients admitted to the Intensive Care Unit with hy-
poglycaemic encephalopathy following massive Insulin overdose, in light of 
available evidence.
Materials and methods: We compare outcome at 6 weeks following hypogly-
caemic encephalopathy from insulin overdose and make a retrospective anal-
ysis of clinical course in the first week of admission. A review of the literature 
looking at the incidence, pathogenesis of hypoglycaemic encephalopathy and 
predictors of outcome in massive insulin overdose.
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Results: Of 64 attendances for hypoglycaemia in 12 months, 3 patients 
(4.69%) had hypoglycaemic encephalopathy, from insulin overdose. In 2 pa-
tients the overdose was deliberate, with no previous history of depression. 
The patients had mean age of 37.6 years (range 32 - 41 years), with a mean 
capillary glucose of 2.26mmols/l (range 1.4 - 3mmol/l) at presentation. The 
mean interval between presentation following insulin overdose and initiation 
of treatment was 4.3 hours (range 1 - 8 hours). Glucagon was administered 
to all 3 patients and the mean glucose infused was 175g (range 50g - 425g). 
The mean duration of mechanical ventilation was 63 hours (range 0 - 120 
hours). The outcome at 6 weeks was persistent vegetative state and death in 
the patient requiring maximum duration of mechanical ventilation, loss of 
recent memory with partial recovery at 6 weeks in the second and loss of 
higher cortical functions with partial recovery at 6 weeks in the third patient. 
The most severe outcome was in the patient requiring maximum amount of 
glucose and mechanical ventilation. The clinical outcome was not related to 
the severity of hypoglycaemia at diagnosis.
Conclusion: Hypoglycaemic encephalopathy from insulin overdose is rare. 
The severity of clinical outcome correlated with the interval between over-
dose and start of treatment, amount of glucose infused and duration of me-
chanical ventilation. This is in keeping with existing evidence on prognostic 
indicators in patients with hypoglycaemic encephalopathy and may be used 
to predict outcomes in acute setting.
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Detection of hypoglycaemia associated EEG-changes during sleep in type 
1 diabetes
L. Folkestad1, R. Elsborg2, L. Remvig2, H. Beck-Nielsen3, B. Thorsteinsson4, 
P. Jennum5, M.D. Gjerstad5, C. Juhl2; 
1Sydvestjysk Sygehus Esbjerg, 2Hyposafe, Lyngby, 3Odense Universitets 
Hospital, 4Hillerød Hospital, Hillerød, Denmark, 5Glostrup Hospital, 
Denmark.
Background and aims: Nocturnal hypoglycemia is a feared complication to 
insulin treated diabetes and is often the limiting factor for further intensifica-
tion of treatment. Hypoglycemia unawareness, being increasingly common 
with tight metabolic control and long diabetes regulation, increases the risk of 
severe hypoglycemia. Slow wave electroencephalogram (EEG) patterns can be 
demonstrated during episodes of daytime hypoglycemia, and real-time detec-
tion of specific EEG changes may constitute a novel technique for a hypoglyc-
emia alarm. Sleep EEG diverges significantly from daytime EEG including ep-
isodic occurrence of slow wave patterns. The present study tests the hypothesis 
that specific hypoglycemia associated EEG changes also occur during sleep, 
and that these can be detected in time for the patient to take action.
Materials and methods: Ten type 1 diabetes patients (mean age 47 years, dia-
betes duration 23,7 years, HbA1c 7.5%) all suffering from hypoglycemia una-
wareness, were subjected to induced hypoglycemia by graded insulin infusion 
both during daytime and sleep. One patient dropped out after the first night 
experiment. EEG was recorded from a single electrode with three measuring 
points placed subcutaneously at the temporal region and was analyzed real-time 
by an automated multi-parameter algorithm based on EEG frequency, ampli-
tude and several other features derived from pilot experiments. The patients re-
ceived an auditory alarm when EEG-changes met a predefined threshold. The 
patients were instructed beforehand to consume a sandwich and a juice at the 
time of alarm. If blood glucose fell to 1.7mmol/l without alarm, hypoglycemia 
was ceased. To explore intraindividual variability, the subjects were exposed to 
an additional night with identical study procedures but no alarm was given.
Results: Seven out of nine patients developed hypoglycemia associated EEG-
changes during daytime (mean blood glucose (BG) 2.7mmol/l) of which six 
were able to revert hypoglycemia by carbohydrate ingestion. During sleep 
nine out of ten developed EEG-changes (mean BG 2,0mmol/l) and eight 
woke up due to the alarm. Four corrected hypoglycemia by ingestion (mean 
BG 2,2mmol/l) while the remaining four (mean BG 1,9mmol/l) was supple-
mented with glucose due to cognitive impairment. Only two events of false 
alarm were recorded. EEG was analyzed according to the American Academy 
of Sleep scoring manual to determine sleep stages. Hypoglycemia associated 
EEG changes occurred irrespective of the sleep stages and overruled physi-
ological sleep related patterns.
Conclusion: We conclude that automated real-time analysis of EEG is a pos-
sible method to warn diabetes patients of impending hypoglycemia both dur-
ing daytime and sleep. Post hoc improvement of the algorithm indicates that 
earlier detection of hypoglycemia may be possible, which will improve the 
sensitivity of the alarm.
Supported by: Hyposafe
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Management of hypoglycaemia in a tertiary inpatient centre: clinical 
audit
S.G. Wijetilleka, K.P. Lim, E. Chinnasamy, I. Malik, A. Flanagan,  
A. Panahloo, N.H. Patel; 
Diabetes & Endocrinology, St George’s Hospital, London, United Kingdom.
Background and aims: Treatment-induced hypoglycemia causes recurrent 
morbidity and mortality in patients with type 1 diabetes mellitus (T1DM) 
and advanced type 2 diabetes mellitus (T2DM). The ACCORD study showed 
that patients with cardiovascular disease over an average of 3.5 years of treat-
ment, 22% more patients from the intensively-controlled blood glucose 
group died. The rate of death in the intensive group, who experienced 3 times 
as many severe hypoglycaemic episodes compared to the standard-treatment 
group, is statistically significant. Profound hypoglycaemia causes neurologi-
cal damage and can be fatal. In June 2009, an audit examining the identifica-
tion and management of inpatient hypoglycaemic episodes was performed at 
St. George’s Hospital. The aim of this audit was to compare current practice 
against good practice guidelines. Management was shown to be sub-optimal 
so a trustwide Hypobox and ward-based teaching sessions were commenced. 
A re-audit was performed to demonstrate subsequent changes and improve-
ments in practice.
Materials and methods: 8 wards (5 medical, 1 cardiology, 2 surgical) were 
visited daily for one week. The diabetic charts of all patients on the ward were 
reviewed for episodes of hypoglycemia, how patients perceived them and 
how these were managed. We looked at whether efforts were made to identify 
the reason for the hypoglycaemic episode and whether steps were taken to-
wards preventing a recurrence.
Results: The average age was 74 years. Mean CBG at time of hypoglycaemic 
episode was 3.2 mmol/L. Majority of episodes (75.6%) of hypoglycemia were 
mild where 95.5% had a GCS of 15/15. The remaining 24.4% of episodes were 
moderate (1.5 - 2.5 mmol/l). 96% of hypoglycaemic episodes were detected on 
routine diabetic CBG monitoring, 72% of hypoglycaemic episodes occurred 
between 2200 and 0600 hours. 31% of episodes were corrected according to 
trust guidelines appropriate for the CBG and GCS, 87.5% had their CBG re-
checked. 11.1% of patients had reasons for their hypoglycaemia identified 
and steps were taken in 8.9 % of patients to prevent further episodes.
Comparison with the original audit: The original audit showed that only 
58.3% of patients had their capillary blood glucose checked within fifteen 
minutes of commencing treatment for hypoglycaemia. Only 20% of patients 
received fast-acting carbohydrate as a treatment measure. Attempts took 
place to identify the cause of hypoglycaemia in one sixth of hypoglycaemic 
episodes, with just 12.5% of patients having steps taken to prevent the recur-
rence of hypoglycaemia. With the re-audit, there has been some improve-
ment with 87% of CBGs checked post-treatment and the types of treatment 
used (31% from Hypobox).
Conclusion: Compared to the initial audit, improvements have been made 
with the products used to treat hypoglycaemia and the monitoring of pa-
tients post-treatment. Identifying and preventing the causes of hypoglycae-
mia remains problematic despite provision of the Hypobox and protocols. 
Staff awareness of hypoglycaemia guidelines is the crucial factor in ensuring 
patients receive optimal management and prevention of hypoglycaemic epi-
sodes. Further teaching with audit data is required.
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Fear of hypoglycaemia - how to identify patients at risk in a routine 
clinical practice?
K. Kanc1, A. Kastrin2, M. Kastrin1, L.A. Gonder-Frederick3; 
1Diabetes&Me (jazindiabetes), Private Diabetes Centre, Ljubljana, Slovenia, 
2Institute of Medical Genetics, University Medical Centre, Ljubljana, 
Slovenia, 3University of Virginia, Virginia, USA 
Background and aims: Hypoglycaemia is a frequent experience in people 
with insulin-treated diabetes mellitus and may lead to the development of 
fear of hypoglycaemia (FoH). This condition may be often overlooked, caus-
ing emotional and behavioral changes that can jeopardize daily life with dia-
betes as well as future development of diabetes complications. The aim of the 
study is to explore the relation of FoH to diabetes regulation, diabetes-related 
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problems and the awareness of hypoglycaemia in persons with type 1 (T1D) 
and type 2 diabetes (T2D).
Materials and methods: All insulin-treated patients (N = 140) registered with 
private diabetes centre at the time of study were contacted and 114 agreed to 
participate (56 males, 58 females). Age varied across sample from 15 to 88 
years with a mean age of 53 (±19) years; mean ages of T1D (30 CSII and 23 
MDI-treated) and T2D (61) patient subgroups were 39 years (±15) and 65 
years (±13), respectively. Patients completed the Hypoglycaemia Fear Survey 
(HFS) and the Problem Areas in Diabetes (PAID) questionnaires. Hypoglyc-
emia awareness status was assessed by Clarke’s questionnaire. We confirmed 
high internal consistency reliability of the translated questionnaires (Cron-
bach’s alphas were 0.93, 0.94, and 0.49 for HFS, PAID, and Clarke’s question-
naire, respectively). Wilcoxon test (W) was used to evaluate differences be-
tween independent groups as appropriate. Metabolic control was assessed by 
measuring glycated haemoglobin A1c (HbA1c).
Results: Statistically significant differences across gender were found for the 
HFS score (Total scale: W = 1179, p = 0.012; Worry subscale: W = 1122, p = 
0.004) and PAID score (W = 1106, p = 0.003), indicating greater FoH and 
inadequate emotional response to diabetes in females. HFS score was signifi-
cantly higher in T1D in comparison to T2D patients (Total scale: W = 2021, p 
= 0.022; Worry subscale: W = 2094, p = 0.007). Comparing therapy regimen 
for T1D patients, we found significant differences for the HFS Behavior sub-
scale score (W = 212, p = 0.014) in MDI, implying greater behavior-related 
FoH in MDI-treated patients. Significant correlation between HFS and PAID 
scores (r = 0.70, p < 0.001) indicate that FoH increases with more diabetic 
problems. In addition, significant correlation was found between HFS score 
and Clarke’s score in general (r = 0.20, p = 0.030), T2D (r = 0.27, p = 0.036), 
T1D (r = 0.17, p = 0.217), meaning that patients with T2D experience an 
increase in FoH as their awareness decreases. Bivariate correlations with 
questionnaire scores and HbA1c level found significant association of HbA1c 
with HFS score (r = 0.23, p = 0.015) and PAID score (r = 0.47, p < 0.001), 
indicating worse glucose control with increasing FoH and diabetes problems. 
On the contrary, four patients had very high PAID and HFS score and low 
HbA1c.
Conclusion: In particular MDI-treated women with T1D, bad glycaemic 
regulation and lower awareness of hypoglycaemia need clinical attention, 
focused on hypoglycaemia. Patients with excellent glycaemic control, com-
bined with great FoH and pronounced diabetes-related problems however, 
should not be overlooked.
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Nature of association between severe hypoglycaemia and risks of vascular 
events and death in ADVANCE
B.E. De Galan1,2, S. Zoungas2,3, A. Patel2, Q. Li2, L. Billot2, M. Woodward2,4, 
J. Chalmers2, B. Neal2, S. MacMahon2, D. Grobbee5,6, S.R. Heller7; 
1Medicine, Radboud University Nijmegen Medical Centre, Netherlands, 
2The George Institute for International Health, Sydney, Australia, 3Monash 
University, Melbourne, Australia, 4Mount Sinai School of Medicine, New 
York, USA, 5Julius Centre for Health Sciences and Primary Care, Utrecht, 
Netherlands, 6Sheffield Teaching Hospitals National Health Service 
Foundation Trust, United Kingdom, 7University of Sheffield, United 
Kingdom.
Background and aims: The present analyses were performed to explore the 
risk factors for severe hypoglycaemia associated with glucose control and to 
examine the relationship between severe hypoglycaemia and major clinical 
outcomes in patients with type 2 diabetes participating in the Action in Dia-
betes and Vascular disease: Preterax and Diamicron Modified Release Con-
trolled Evaluation (ADVANCE) trial.
Materials and methods: Baseline factors predicting severe hypoglycae-
mia were assessed. Associations between severe hypoglycaemia and major 
macrovascular or microvascular events and death were examined with Cox 
proportional hazards models, adjusting for baseline and post randomization 
covariates.
Results: Over a median of 5-years of follow-up, 231 patients (2.1%) experi-
enced severe hypoglycaemia, a considerably lower rate than reported in other 
large-scale trials of intensive glucose control. Baseline factors associated with 
severe hypoglycaemia were age, diabetes duration, history of microvascular 
disease, kidney dysfunction, smoking, BMI, HbA1c, education level, cogni-
tive dysfunction, combination anti-hyperglycaemic therapy and assignment 
to intensive glucose control (all p < 0.05). The median times from the first 
severe hypoglycaemia to first major macrovascular event, microvascular 
event or death were 1.56 years (IQR = 0.84, 2.41 years), 0.99 years (IQR = 
0.40, 2.17 years) and 1.05 years (IQR = 0.34, 2.41 years) respectively. During 
follow up, adjusted risks of major macrovascular events (HR 2.88, 95% CI 
2.01-4.12), major microvascular events (HR 1.81, 95% CI 1.19-2.74), cardio-
vascular death (HR 2.68, 95% CI 1.72-4.19) and all-cause death (HR 2.69, 
95% CI 1.97-3.67) were significantly increased among those experiencing 
prior severe hypoglycaemia compared to those who did not (all p < 0.0001). 
Similar associations were also apparent for a range of non-vascular outcomes 
including respiratory, digestive system and skin events (all p < 0.01). When 
the analyses were performed stratified by treatment allocation, the results re-
mained essentially unchanged.
Conclusion: Severe hypoglycaemia was strongly associated with increased 
risks of diverse major clinical outcomes, but not temporally related. Severe 
hypoglycaemia appears to be a marker of vulnerability for rather than a direct 
cause of adverse clinical outcomes. The complex interplay of confounding 
factors makes attribution of causation difficult.
Supported by: NHMRC and Servier
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The effect of modafinil on counterregulatory and cognitive responses 
to experimental hypoglycaemia in type 1 diabetic patients with 
hypoglycaemia unawareness
P. Thomakos, M.M. Teh, Y. Samarasighe, A. Pernet, B. Wilson,  
P. Choudhary, S.A. Amiel; 
Diabetes Research Group, King’s College School of Medicine, London, 
United Kingdom.
Background and aims: Patients with Type 1 diabetes rely on symptoms of 
hypoglycaemia to detect hypoglycaemia and take corrective action before 
blood glucose drops low enough to impair cognitive function or conscious-
ness. Repeated hypoglycaemia can impair hypoglycaemia awareness increas-
ing the risk of severe hypoglycaemia 3-6 fold. Modafinil reduces the release 
of the inhibitory brain neurotransmitter GABA and improves adrenergic sen-
sitivity and some aspects of cognitive function at hypoglycaemia in normal 
individuals. We aimed to assess the effect of modafinil on cognitive function 
as well as symptomatic and hormonal responses to hypoglycaemia.
Material and methods: Eight individuals with type 1 diabetes and hypogly-
caemia unawareness (mean age 47+10 years, BMI 24.3+2.5 kg/m2, HbA1c 
6.6+0.9, duration of diabetes 29+12.3 years) received, in random order, two 
100-mg doses of modafinil or placebo, followed by a paired hypoglycaemic 
clamp study in which plasma glucose was reduced stepwise to 5.0, 4.4, 3.8, 
3.4, 2.8 and 2.4mmol/l. Catecholamines, symptom scores and cognitive func-
tion were measured throughout. Subjects rated neuroglycopenic (difficulty 
speaking, confusion, dizziness, irritability, blurred vision and drowsiness) 
and autonomic symptoms (sweating, anxiety, tremor, palpitations, feeling hot 
and tingling) on a visual analogue scale on which patients graded the symp-
toms from 1 (absent) to 7 (very severe) at 20 minutes intervals. Four-choice 
reaction time, Digit Symbol Substitution Test, Stroop Black-White, Colour-X 
reading and Colour-Word interference test were administered at each step.
Results: Neuroglycopenic symptoms of hypoglycaemia were experienced 
at higher glucose level with modafinil [mean 2.7+0.6 vs 2.3+0.4 mmol/l; 
p=0.025], and to a greater degree [area under curve for neuroglycopenic 
symptoms corrected for baseline 322.5+121 vs 146.2+90; p=0.01] (see fig-
ure) with a higher peak score [peak-baseline neuroglycopenic symptom 
score 4.12+3.3 vs 2.62+2.5; p=0.009]. There were no differences in autonomic 
symptom responses. There were no differences in glucose thresholds, area 
under the curve or peak levels for catecholamine responses to hypoglycae-
mia. Despite higher neuroglycopenic scores there was no difference in glu-
cose thresholds or degree of deterioration in cognitive function tests.
Conclusion: The use of modafinil was associated with generation of warning 
symptoms of hypoglycaemia at higher glucose level and to a greater degree 
than placebo although there was no difference in hormonal responses or cog-
nitive dysfunction. The data support a role for disinhibition of GABAergic 
neurons in the generation of neuroglycopenic symptoms in hypoglycaemia 
which may be reversible, but imply a different sensitivity or involvement of 
other pathways in other aspects of the normal counterregulatory response.
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Risk of hypoglycaemias and hypoglycaemia prevention behaving in 
type 1 diabetic patients - results of continuous glucose monitoring and 
Gravelling´s questionaire - a pilot study
J. Broz1, J. Polak1, E. Silhova1, V. Donicova2; 
13rd medical Faculty, Charles University, Prague, Czech Republic, 2Private 
Department of Diabetology, Internal Medicine and Metabolism, Košice, 
Slovakia.
Background and aims: Hypoglycemic episode during driving could cause 
a fatal incident. Using a continuous glucose monitoring in type 1 diabetic 
patients we wanted to determine the glycemic excursions during periods of 
driving.
Materials and methods: We monitored 12 patients with type 1 diabetes mel-
litus treated with intensified insulin regimen (7 men, 5 woman), duration 
of disease 11,2 ± 5,2 year. Each patient wore a CGMS for 3-5 working days 
during his normal activity and was not alowed to see actual glycaemic values. 
Patients were asked to record all important events (such as insulin injection, 
exercise, meals, working periods) including periods of a car driving. After 
CMGS use, continuous glucose profiles were reviewed to identify glycaemic 
excursion during periods of car driving with a special interest in hypogly-
caemic episodes (values under 3,5 mmol/l) and periods of glycemias under 
4,5 mmol/l with considerable risk of hypoglycaemia. Each patient complete 
Gravelling´s questionnaire.
Results: We evaluated 2772 min ( 46 hours 12 min) of driving, an average 77 
± 27,3 per day and patient. Patients recorded 2 symptomatic episodes while 
driving. We found 7 episodes of asymptomatic hypoglyceamias, all in 2 pa-
tients. Total duration of period with glycaemia under 4,5 was 132 min (4,8% 
of total driving time).Total duration of period with glycemia under 3,5 was 
22 min ( 0,8% of total driving time). Selected results from questionaire: 2 pa-
tients almost never measure glycemia before or during driving, none of them 
stops after hypoglycemia for longer than 45 min.
Conclusion: Risk of hypoglycaemia even in well experienced patients with 
type 1 diabetes mellitus during driving is considerable and should be regu-
larly focused in education.
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Prevalence and risk factors of hypoglycaemia unawareness and severe 
hypoglycaemia in patients with type 1 diabetes
T. A’Campo1, B. Schouwenberg1, B. Veldman2, C.J. Tack3, P. Smits1,  
B.E. De Galan3; 
1Departments of Pharmacology -Toxicology, Radboud University Nijmegen 
Medical Centre, 2Department of Internal Medicine, Canisius Wilhelmina 
Hospital, 3Department of Internal Medicine, Radboud University Nijmegen 
Medical Centre, Netherlands.
Background and aims: Hypoglycaemia is the most frequent adverse effect of 
insulin therapy in patients with type 1 diabetes (T1DM). Repeated episodes 
of hypoglycaemia may lead to hypoglycaemia unawareness (HU), which in 
turn is a risk factor for severe hypoglycaemia (SH). Modern insulin ana-
logues and insulin pump therapy, which are associated with lower rates of 
hypoglycaemia, are being increasingly used. We therefore aimed to assess the 
prevalence of HU and SH in a contemporary cohort of T1DM patients and to 
identify potential risk factors.
Materials and methods: We performed a cross-sectional study of a cohort of 
486 T1DM patients (47% male), who visited the outpatient clinic of a Dutch 
University Hospital between 2006 and 2008. All patients were asked to com-
plete a Dutch translation of the Clarke questionnaire, where a score of 3 or 
more (out of 5) was assumed to indicate HU. SH was assessed on the basis of 
the same questionnaire. Clinical data on demographics, diabetes treatment, 
concurrent medication and vascular complications were retrieved from med-
ical records. Unadjusted and adjusted Odds ratio’s (OR) were calculated using 
binary logistic regression.
Results: The mean diabetes duration was 25 years, HbA1c averaged 7.9% and 
89% used insulin analogues. 144 patients (30%) used insulin pumps. A total 
of 158 patients (33%) had a score indicating HU and 103 patients (21%) re-
called SH in the year prior to the questionnaire. In unadjusted analyses, HU 
was associated with male sex, lower HbA1c, duration of diabetes, autonomic 
neuropathy and estimated GFR < 60ml/min/1.73m2 (all P < 0.05). After ad-
justments, duration of diabetes (OR per year 1.03; 95% CI: 1.01-1.05), esti-
mated GFR < 60ml/min/1.73m2 (3.30; 1.20-9.10) and lower HbA1c (per % 
1.49; 1.22-1.81) were still associated with HU. SH was independently associ-
ated with the presence of autonomic neuropathy (3.62; 1.65-7.94) and the 
use of benzodiazepines (4.59; 1.80-11.73), but not with HbA1c or diabetes 
duration. The use of insulin analogues, insulin pump therapy, ACE inhibitors 
or beta-blockers were not associated with either HU or SH.
Conclusion: HU is still highly prevalent in T1DM patients despite advances 
in insulin therapy. Diabetes duration, lower HbA1c level and kidney dysfunc-
tion were independent risk factors for HU. Autonomic neuropathy and use 
of benzodiazepines were risk factors for SH. Clinicians treating patients with 
T1DM should be aware of the still high prevalence of HU and its risk fac-
tors.
Odds ratio for hypoglycaemia unawareness and severe hypoglycemia
Hypoglycaemia 
unawareness (HU)
Hypoglycaemia 
unawareness (HU)
Severe hypoglycae-
mia (SH)
Severe hypoglycae-
mia (SH)
Unadjusted OR 
(95% CI)
Adjusted OR  
(95% CI)
Unadjusted OR  
(95% CI)
Adjusted OR (95% 
CI)
Sex (male vs. female) 1.47 (1.00-2.15) 1.38 (0.92-2.07) 1.05 (0.68-1.62)
Age (per year) 1.02 (1.01-1.04) 1.01 (0.99-1.03) 1.00 (0.98-1.01)
HbA1c (per 1% lower) 1.40 (1.16-1.68) 1.49 (1.22-1.81) 1.08 (0.89-1.30)
Diabetes duration (per year) 1.03 (1.02-1.05) 1.03 (1.01-1.05) 1.01 (0.99-1.02)
Autonomic Neuropathy
(yes vs. no)
2.34 (1.10-4.97) 1.66 (0.72-3.84) 3.27 (1.52-7.05) 3.62 (1.65-7.94)
eGFR
< 60ml/min/1.73m2)  
(yes vs. no)
3.70 (1.43-9.59) 3.30 (1.20-9.10) 2.22 (0.85-5.79)
Peripheral arterial disease  
(yes vs. no)
1.54 (0.69-3.43) 2.43 (1.07-5.54) 1.56 (0.63-3.84)
Benzodiazepine use  
(yes vs. no)
2.35 (0.94-5.91) 4.40 (1.74-11.13) 4.59 (1.80-11.73)
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Effects of short-term continuous subcutaneous insulin infusion on 
insulin sensitivity and plasma FGF-21 levels in patients with new-onset 
type 2 diabetes mellitus
D. Jing1, G. Yang1, L. Li2; 
1Department of Endocrinology, 2Department of Clinical Biochemistry, 
Chongqing Medical University, China.
Background and aims: FGF-21 is a recently described member of the FGF 
family that is highly expressed in adult mouse liver and thymus. Recent data 
have shown that FGF-21 is a potent regulator of glucose homeostasis. In the 
present study, we investigate the effects of short-term continuous subcutane-
ous insulin infusion(CSII) on insulin sensitivity and plasma FGF-21levels in 
patients with new-onset type 2 diabetes mellitus (T2DM). We also assessed 
the association between plasma FGF-21 body composition, and several meta-
bolic parameters in these subjects.
Materials and methods: 30 patients with new-onset T2DM were treated with 
CSII for 2 weeks. A hyperinsulinemic-Euglycemic clamp was performed for 
determining insulin sensitivity in T2DM patients. The body composition was 
assesses. Blood samples were drawn after an overnight fast and Plasma insu-
lin, FFA, HbA1c, TG, TC, LDL-C, HDL-C were measured. Plasma FGF-21 
levels were measured with a radioimmunoassay. The homeostasis model as-
sessment of insulin resistance (HOMAIR) and the homeostasis model assess-
ment of β-cell insulin secretion (HOMAIS) were calculated. Plasma FGF-21 
levels were measured by an ELISA.
Results: Fasting plasma FGF-21 levels were higher in T2DM than in con-
trols (1.6±0.1 vs.1.1±0.4μg/L, P<0.01). After treatment with CSII, fasting 
blood glucose (FBG), HbA1c, fasting plasma insulin(FIns)and HOMA-IR 
were decreased significantly in T2DM (14.5±1.4 vs. 5.8±0.5 mmol/L, 10.4±1
.2%vs.8.6±1.2%,16.79±2.75vs.12.87±5.71mU/L and 10.56±1.37 vs. 3.33±1.61 
respectively, P<0.05 and P<0.01), while glucose infusion rate (GIR)was in-
creased significantly (2.99±1.43 vs. 5.10±1.78 mg.kg-1.min-1, P<0.01). Fasting 
plasma FGF-21 levels were decreased significantly by CSII treatment (1.6±0.1 
vs.1.3±0.1μg/L, P < 0.05).
Conclusion: Short-term CSII therapy can remarkably ameliorate insulin sen-
sitivity and degrade plasma FGF-21 levels in T2DM patients. The change of 
plasma FGF-21 levels may be related to metabolic disturbance and insulin 
resistance.
Supported by: National Natural Science Foundation of China
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Comparison of fasting apelin and visfatin levels between subjects 
with type 1 diabetes mellitus and controls and response after insulin 
administration
K. Alexiadou1, A. Kokkinos1, D. Perrea2, C. Voulgari1, S. Liatis1,  
N. Katsilambros1, N. Tentolouris1; 
1Laiko General Hospital, 2Laboratory of Experimental Surgery and Surgical 
Research “N. S. Christeas”, Athens, Greece.
Background and aims: Apelin and visfatin are two recently described adi-
pokines. Experimental data have shown that apelin exerts important benefi-
cial cardiovascular effects and its synthesis is stimulated by insulin. Visfatin is 
involved in the regulation of glucose homeostasis by binding to and activat-
ing the insulin receptor in a manner distinct from insulin. No data exist on 
differences in plasma concentrations of apelin and visfatin between subjects 
with type 1 diabetes mellitus (T1DM), a condition characterized by insulin 
deficiency, and healthy controls and on the effect of exogenous insulin ad-
ministration on plasma concentrations of these adipokines. In the present 
study we examined differences in plasma apelin and visfatin concentrations 
between healthy controls and subjects with T1DM. Additionally, we studied 
the effect of a bolus insulin administration on plasma apelin and visfatin lev-
els during an oral glucose tolerance test (OGTT) in patients with T1DM.
Materials and methods: A total of 120 subjects (60 with T1DM and 60 age, 
gender and body mass index matched-controls) were studied. Plasma apelin, 
visfatin, glucose and lipids were measured in the fasting state. A total of 14 
subjects with T1DM and 14 controls volunteered to participate in a second 
phase of the study. They were studied on two occasions (phases A and B) 
with a time interval of about 1 week in between and in random order. In both 
phases an OGTT was performed. In phase A, before the OGTT 7 units of 
insulin lispro (approximately 1 unit for every 10 g of glucose consumed) was 
administered subcutaneously in the patients with T1DM, while an equal vol-
ume of water for injection (placebo) was administered in the control group. 
In phase B, no insulin or placebo was administered in either patients with 
T1DM or controls. Plasma levels of glucose, insulin, apelin and visfatin were 
measured at baseline, and 10, 20, 30, 60, 90, 120, 150, and 180 min after glu-
cose consumption.
Results: Fasting plasma apelin concentrations were significantly higher 
in subjects with T1DM than in controls (1.93±0.14 vs. 1.39±0.09 ng/ml, 
p<0.001). On the contrary fasting visfatin levels were significantly lower 
in subjects with T1DM than in controls (17.55±1.68 vs. 25.28±3.63 ng/ml, 
p<0.001). Plasma apelin and visfatin levels did not change significantly dur-
ing phase A of the experiment in either the group of patients with T1DM or 
the controls and there was no significant difference between the two groups. 
The same was valid for the phase B of the study. The overall apelin and vis-
fatin response during the experiment, expressed as the area under the curve 
(AUC), was not significantly different between patients with T1DM and con-
trols during either phase A or phase B of the study.
Conclusion: Apelin levels are higher and visfatin levels are lower in the fast-
ing state in patients with T1DM in comparison with healthy controls. Ad-
ditionally, they do not change during an OGTT with or without insulin ad-
ministration.
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Valsartan improves beta cell function and insulin sensitivity in 
normotensive subjects with impaired fasting glucose and/or impaired 
glucose tolerance
N.J. Van der Zijl1, C.C.M. Moors2, G.H. Goossens2, M.H. Hermans2,  
E.E. Blaak2, M. Diamant1; 
1Endocrinology / Diabetes Centre, VU University Medical Centre, 
Amsterdam, 2Human Biology, Maastricht University, Netherlands.
Background and aims: Recently, the NAVIGATOR trial, a long-term inter-
vention study performed in normotensive subjects with impaired glucose 
metabolism (IGM), showed that treatment with the angiotensin-receptor 
blocker valsartan (VAL) for 5 years, resulted in a relative reduction of 14% 
in the incidence of T2DM. The underlying mechanisms are incompletely un-
derstood and may, besides improvement in insulin sensitivity also include a 
delay in beta-cell function decline.
Materials and methods: In the present study, we assessed the effect of 26-
weeks VAL (320mg QD) vs. placebo (PLB) on various aspects of beta-cell 
function and insulin sensitivity in normotensive subjects with impaired 
fasting glucose (IFG) and/or impaired glucose tolerance (IGT). In this ran-
domized, controlled, double-blind, two-center study, 43 IFG (51% males; 
mean±SE age 58±1.1 yrs; BMI 28.8±0.7 kg/m2; BP 128/82±2/1 mmHg) and 
36 IFG/IGT (53% males; age 58±1.1 yrs; BMI 29.5±0.7 kg/m2; BP 131/82±2/1 
mmHg) Caucasian subjects, received VAL (n=40) or PLB (n=39). Beta-cell 
function and insulin sensitivity were assessed at baseline and after 26 weeks 
treatment using a combined euglycaemic-hyperinsulinaemic and hypergly-
caemic clamp with subsequent arginine-stimulation and a 2-hour 75-g oral 
glucose tolerance test (OGTT). Treatment effects were analyzed using AN-
COVA, adjusting for center, glucometabolic status and gender.
Results: At week 26, VAL vs PLB, increased 1st-phase (P=0.06), and 2nd-phase 
glucose-stimulated insulin secretion (P=0.026). However, the enhanced ar-
ginine-stimulated insulin secretion did not differ (P=0.25). VAL vs PLB im-
proved the disposition index (P=0.067) and insulin sensitivity (P=0.045). 
VAL but not PLB increased the OGTT derived insulinogenic index ((I30-I0)/
(G30-G0), representing 1
st-phase insulin secretion after an oral glucose load, 
P=0.035). At 26 weeks, VAL compared to PLB treatment resulted in a signifi-
cantly greater reduction in systolic and diastolic blood pressure (P<0.001). 
BMI remained unchanged in both treatment groups.
Conclusion: Twenty-six week VAL treatment showed a significant improve-
ment in glucose-stimulated insulin release and insulin sensitivity in normo-
tensive subjects with IGM. These findings may partly unveil the mechanisms 
underlying the observed effects of VAL in the prevention or delay of the onset 
of T2DM.
Supported by: An Investigator-Initiated Study Grant from Novartis Pharma
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Valsartan induced improvement of insulin sensitivity was not associated 
with improved microvascular function in subjects with impaired glucose 
metabolism 
C.C.M. Moors1, N.J. Van der Zijl2, G.H. Goossens1, R.G. IJzerman3,  
E.E. Blaak1, M. Diamant3, E.H. Serné3; 
1Human Biology, Maastricht University, 2Diabetes Centre, VU University 
Medical Centre, Amsterdam, 3Endocrinology / Diabetes Centre, VU 
University Medical Centre, Amsterdam, Netherlands.
Background and aims: Microvascular dysfunction, affecting both flow resist-
ance and perfusion, is not only important in the development of target-organ 
damage in the heart, kidney and eyes, but also in the development of insulin 
resistance. Capillary recruitment is an important mechanism by which insu-
lin promotes uptake of glucose. Capillary rarefaction and impaired recruit-
ment may therefore reduce glucose uptake and contribute to insulin resist-
ance. Recently, in the NAVIGATOR trial, a long-term intervention study per-
formed in normotensive subjects with impaired glucose metabolism (IGM), a 
relative risk reduction of 14% in the incidence of T2DM was reached with the 
angiotensin-receptor blocker valsartan (VAL). The underlying mechanisms 
are incompletely understood but may include enhanced peripheral insulin 
sensitivity and beneficial effects on microvascular function. In this study we 
investigated the relation between functional and structural capillary density 
and insulin sensitivity in subjects with impaired fasting glucose (IFG) and/
or impaired glucose tolerance (IGT). Furthermore, we examined whether 
26-weeks of VAL treatment improved insulin sensitivity and microvascular 
function.
Materials and methods: Caucasian subjects with IFG (n=29, 52% males; 
mean±SE age 57±1.4 yrs; BMI 29±1.1 kg/m2; BP 130/81±3/1 mmHg) and 
combined IFG/IGT (n=19, 63% males; mean±SE age 56±1.4 yrs; BMI 30±1.2 
kg/m2; BP 131/84±3/2 mmHg), were treated with VAL for 26 weeks. Glucose 
tolerance was assessed with a 2-hour oral glucose tolerance test (OGTT). At 
baseline and after 26-weeks subjects underwent a) an euglycaemic-hyperin-
sulinaemic clamp to assess insulin sensitivity and b) capillaroscopy to exam-
ine functional skin capillary density at baseline and after 4 minutes of arterial 
occlusion as well as structural capillary density during venous occlusion. 16 
normoglycaemic healthy subjects (NGT, 62% males; mean±SE age 54±1.8 
yrs; BMI 28±0.7 kg/m2; BP 122/78±2/2 mmHg) were the control group.
Results: Subjects with IFG and combined IFG/IGT were more insulin resist-
ant compared to NGT (M-value: 4.8 ±2.3 mg/min/kg, 4.6 ±1.2 mg/min/kg 
and 9.4 ±3.0 mg/min/kg, P<0.001, IFG/IGT, IFG and NGT, respectively). 
In subjects with IFG, IFG/IGT, capillary density was reduced in the basal 
state, during venous occlusion and after arterial occlusion compared to con-
trols (all P<0.001). Functional and structural capillary density was positively 
correlated with insulin sensitivity (all P=0.004). In multivariable regression 
analyses, the associations between capillary density and insulin sensitivity 
were independent of age, sex, blood pressure and BMI (P=0.04). 26-weeks 
of VAL treatment improved insulin sensitivity (P=0.038), without changes in 
microvascular function.
Conclusion: Subjects with IFG and IFG/IGT are characterized by impaired 
functional and structural capillary density. The microvascular dysfunction 
was associated with diminished insulin sensitivity. Treatment with VAL did 
improve insulin sensitivity, however there were no changes in microvascular 
function.
Supported by: an Investigator-Initiated Study Grant from Novartis Pharma
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Effect of the interleukin-1 receptor antagonist anakinra on insulin 
sensitivity in obese, insulin resistant individuals: results from a double-
blind placebo-controlled study
E.J.P. van Asseldonk, R. Stienstra, T.B. Koenen, M.G. Netea, C.J. Tack; 
General Internal Medicine, Radboud University Nijmegen Medical Centre, 
Netherlands.
Background and aims: The global prevalence of obesity is rapidly rising 
and paralleled by an increasing incidence of type 2 diabetes mellitus. Strong 
evidence has emerged that inflammatory changes link excess energy/fat to 
insulin resistance, one of the prime pathophysiological defects in type 2 dia-
betes. In vivo studies in mice and in vitro experiments have demonstrated 
that obesity activates Interleukin (IL)-1, which subsequently leads to insu-
lin resistance. Blocking IL-1 by recombinant IL-1Receptor antagonist (Ra) 
thus should diminish insulin resistance. Recent findings show that blocking 
IL-1 by recombinant human IL-1Ra, anakinra, improves glycemic control in 
patients with type 2 diabetes. In the present study we investigated whether 
anakinra was able to improve insulin sensitivity in obese, insulin resistant but 
non-diabetic subjects.
Materials and methods: Non-diabetic subjects were treated with anakinra 
150 mg s.c. once daily or matching placebo for 4 weeks in a double blind 
cross-over study. Between treatment periods there was a 4 weeks wash-out 
interval. Inclusion criteria: age ≥18 yrs, BMI ≥ 30 kg/m2 and ≥ 3 character-
istics of the metabolic syndrome (IDF definition). 19 Patients were included 
in the study and randomized. Power calculations revealed that 12 paired 
observations would provide sufficient power to detect a 20% difference in 
insulin sensitivity.Insulin sensitivity (primary endpoint) was evaluated using 
a euglycemic hyperinsulinemic clamp, beta-cell functions by oral glucose tol-
erance test (OGTT). After each treatment period, a subcutaneous fat biopsy 
was taken to evaluate effects at the level of the fat tissue.
Results: A total of 13 subjects (F:M = 9:4) completed all studies, 6 withdrew 
from the study. Most subjects experienced local injection site reactions. Av-
erage BMI at baseline was 33 ± 5 kg/m2 and this did not change during the 
study. Anakinra had no effect on insulin sensitivity (glucose disposal rate 19.8 
± 2.3 for anakinra vs 18.6 ± 2.5 μMol/kg/min for placebo P=0.44, nor on 
insulin sensitivity index 0.17 ± 0.03 vs 0.14 ± 0.02 μMol/kg/min/mE P=0.15). 
HbA1c, fasting glucose levels and C-Peptide during OGTT were not affected. 
The disposition index improved significantly after anakinra treatment (154 
± 26 vs,106 ± 20 pmol/mmol P=0.04). Markers of systemic inflammation 
HsCRP, IL-6 and IL-8 remained unchanged. IL-1Ra levels in serum and in 
fat were significantly higher during treatment with anakinra (serum 735 ± 
86 vs 0.66 ± 0.09 μg/l P<0.001, fat 217 ± 19 vs 47.7 ± 9.0 ng/mg fat tissue 
P<0.001).
Histochemical analysis of fatbiopsies showed higher numbers of CD68-posi-
tive cells, while expression of PPARγ, and FABP4 significantly decreased in 
adipose tissue after anakinra treatment (both P<0.05), adiponectin tended to 
decrease (P=0.07).No carry-over effects were found.
Conclusion: Treatment with anakinra does not result in improved insulin 
sensitivity in obese, insulin-resistant, non-diabetic subjects. While there was 
a hint towards an improved insulin secretion, no beneficial changes were 
found at the fat tissue level. Either the dose of anakinra is too low, the half 
life too short, or IL-1 plays a relatively minor role at the level of the human 
fat tissue.
Supported by: an EFSD/Novartis grant, NWO Vici grant for MGN
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Long-term effect of anti TNF-alpha therapy on insulin resistance, body 
composition and adipokines
M.-T. Arce-Franco1, I. Ferraz-Amaro2, V. Hernandez-Hernandez2,  
M.-J. Domínguez-Luis2, J.G. Oliva-Garcia3, A.M. Herrera2, J.R. Muñiz4,  
F. Diaz-Gonzalez2, J. Lopez-Fernandez1; 
1Endocrinology Department, Hospital Universitario de Canarias (HUC), 
2Rheumatology Department, HUC, 3Endocrinlogy and Nutrition 
Department, Hospital Universitario Nuestra Señora de la Candelaria, Santa 
Cruz de Tenerife, Spain, 4IMETISA, HUC, La Laguna, Spain.
Background and aims: Insulin resistance (IR) is a condition associated, 
among others to abdominal obesity, endothelial dysfunction, hypertension, 
atherogenic lipid profile, type2 diabetes mellitus and cardiovascular (CV) 
events. Remarkably, IR has been observed in inflammatory chronic diseases, 
like rheumatoid arthritis (RA), which suggests that IR and systemic inflam-
matory response are linked events. It has been suggested that tumour necro-
sis factor(TNF)-α, a proinflammatory cytokine that plays a key role in the 
pathogenesis of several human inflammatory disease, might be a connection 
between inflammation and CV disease apparently through its effects on en-
dothelial function, vascular homoeostasis, IR, as well as on production of 
adipokines. However, the clinical significance of this potential association has 
not been fully confirmed. The aim of this study was to determine whether or 
not chronic blockade of systemic TNF-α in humans has some influence on 
CV-associated risk factors, such as insulin sensitivity, body fat distribution, 
body composition, physical activity or levels of adipokines.
Material and methods: Sixteen patients with RA (mean age 50.8±14.6 years, 
mean duration of disease 6.3±2.7 years) in whom anti-TNFα agents were 
added to methotrexate because active disease were followed up during a year. 
At baseline and after 3 and 12 months of TNFα treatment, we assessed: dis-
ease activity by DAS28, physical activity by accelerometry, anthropometric 
measures, IR by Homeostatic Model Assessment (HOMA-2), body compo-
sition by multifrequency bioelectric impedance analysis, abdominal fat dis-
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tribution (subcutaneous and intraabdominal) by magnetic resonance (MR) 
imaging and serum level of several key adipokines by ELISA. None patient 
used steroids a month before the start or during the study.
Results: In spite of a significant improvement in DAS28, patients’ physical 
activity remains stable during the follow up. The body mass index showed a 
significant increase after one year (25.7±3.2 vs 28.06±4.5 kg/m2, p=0.02) of 
treatment with anti-TNFα. The body composition (impedance) in terms of 
fat and fat-free mass showed no difference between visits except for a signifi-
cant elevation of body cell mass (25.5±4.6 vs 26.6±3.1 kg, p=0.02). Values of 
visceral intraabdominal and subcutaneous abdominal adipose tissue by MR 
were not modified because of treatment. HOMA-2 values showed not chang-
es in β-cell function or IR index but a significant increase (110[94-138] vs 
118[107-156]%, p=0.045) in insulin sensitivity after 3 months was observed. 
Basal levels of adiponectin, visfatin, leptin, ghrelin, resistin, and apelin did 
not change in response to anti-TNF-α treatment; only retinol binding protein 
4 showed a significant change (51.7±32.7 vs 64.9±28.4 μg/mL, p=0.03) at the 
end of the study.
Conclusions: IR, adiposity, body composition and adipokines are not signifi-
cantly affected by 1 year blockade of TNFα in RA patients. More studies with 
longer period of follow-up must be done to further clarify the real beneficial 
role of chronic anti-TNFα treatments in cardiovascular risk factors.
Supported by: FUNCIS 31/2007
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In type 2 diabetic patients the improvement in insulin sensitivity 
is associated with a decrease in plasma C-peptide levels and an 
improvement in intima media thickness
C. Hohberg1, A. Pfützner1, I. Kleine2, M. Löbig1, W. Fuchs2, T. Forst1; 
1Institute for Clinical Research and Development, Mainz, Germany, 2Takeda 
Pharma, Aachen, Germany.
Background and aims: There is increasing evidence that in type 2 diabetic 
patients increased C-Peptide levels might predict vascular inflammation and 
the progression atherosclerotic plaques. The aim of this study was to investi-
gate a potential relationship between the decrease in plasma C-peptide levels 
and an improvement in intima media thickness (IMT) during treatment with 
Pioglitazone.
Materials and methods: The Pioneer Study investigated the change in IMT 
over 6 months in 89 type 2 diabetic patients treated with pioglitazone (PIO: 
age 62.2±8.4 years; duration of diabetes 89.8 months) and in 84 type 2 dia-
betic patients treated with glimepiride (GLIM: age: 63.0±7.4 years; duration 
of diabetes 82.5±77.5 months). At baseline and after 6 months the IMT was 
measured at the common carotid artery and fasting blood samples were taken 
for the measurement of glucose, insulin, C-peptide, and HbA1c. The HO-
MAIR Score was calculated as a measure of insulin resistance.
Results: Both treatments resulted in a comparable improvement in HbA1c 
levels (PIO: from 7.52±0.85 to 6.71±0.89; GLIM: from 7.44±0.89 to 6.83±0.85 
%, p<0.05). During treatment with pioglitazone the IMT declined from 
0.949±0.149 to 0.893±0.144 mm (p<0.05), while no significant change in 
IMT could be observed in the GLIM group (from 0.924±0.150 auf 0.911± 
0.158 mm (n.s.). Pioglitazone treatment declined the HOMAIR Score from 
6.2±4.1 to 3.9±1.9(p<0.05), and C-peptide levels from 2.03±0.94 to 1.69±0.75 
ng/ml (p<0.05) . During GLIM treatment, HOMAIR changed from 5.8±3.7 to 
6.0±4.7 (n.s.), and C-peptide changed from 1.95±0-85 to 1.94±0.96 ng/ml; 
(n.s.). A linear correlation could be observed in between the decrease in IMT 
and the HOMAIR Score (r=0.29; p<0.05), and a decrease in plasma C-peptide 
(r=0.28; p<0-05).
Conclusion: This study confirmed a linear association between the decrease 
in IMT and an improvement in insulin sensitivity, as well as a decline in plas-
ma C-peptide levels. The study further emphasizes the complex interrelation-
ship in between Insulin and C-peptide secretion and vascular pathology in 
patients with diabetes mellitus type 2.
Supported by: Takeda Pharma
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Long-term treatment with the angiotensin-receptor blocker valsartan 
improves adipose tissue function in normotensive subjects with impaired 
glucose metabolism
G.H. Goossens1, C.C.M. Moors1, N.J. van der Zijl2, J.P. Cleutjens3,  
M. Diamant2, E.E. Blaak1; 
1Department of Human Biology, NUTRIM School for Nutrition, Toxicology 
and Metabolism, Maastricht University Medical Centre, 2Department 
of Internal Medicine, VU University Medical Centre, Amsterdam, 
3Department of Pathology, Cardiovascular Research Institute Maastricht, 
Maastricht University Medical Centre, Netherlands.
Background and aims: Adipose tissue dysfunction may contribute to the 
development of obesity-related insulin resistance and type 2 diabetes (T2D). 
Increased activity of the renin-angiotensin system in obese insulin resist-
ant subjects may be implicated. The recently published prospective NAVI-
GATOR trial demonstrated that the angiotensin-receptor blocker valsartan 
(VAL), at median follow-up 5.0 years, reduced the incidence of T2D by 14% 
compared to placebo (PLB) in normotensive subjects with impaired glucose 
metabolism (IGM). However, no underlying mechanisms were reported. We 
hypothesized that VAL treatment in subjects with IGM improves adipose tis-
sue function, which in turn may contribute to increased insulin sensitivity.
Materials and methods: In this randomized, placebo-controlled, double-
blind, two-center study, the effect of VAL (320 mg daily) or PLB on insulin 
sensitivity (hyperinsulinaemic-euglycaemic clamp) was investigated before 
and at 26 weeks of therapy in 79 normotensive subjects with impaired fasting 
glucose (IFG) and/or impaired glucose tolerance (IGT) (52M/48F; age 58±7 
yrs; BMI 29.7±4.3 kg/m2; BP 130/82±11/6 mmHg). In a subgroup of 17 IFG 
(10M/7F; age 60±1 yrs; BMI 29.5±0.9kg/m2; BP 127/78±2/3 mmHg) and 14 
IFG/IGT (6M/8F; age 59±1 yrs; BMI 32.1±1.2kg/m2; BP 129/82±2/2 mmHg) 
subjects matched for age, BMI and blood pressure, the effects of VAL or PLB 
on adipose tissue function was examined. Adipose tissue blood flow (ATBF) 
was measured under fasting conditions and for 4h after intake of a high-fat 
mixed-meal using the 133Xe wash-out technique. In addition, abdominal sub-
cutaneous adipose tissue biopsies were obtained for measurement of mean 
adipocyte diameter and size distribution. In addition to treatment effects, 
baseline comparisons were made between men and women and between 
subjects with different glucometabolic status (mixed ANOVA).
Results: At baseline, fasting ATBF was lower (P=0.01) and mean abdominal 
adipocyte size higher (increase in fraction of large adipocytes and decrease 
in small adipocytes, P<0.01 for both) in women (7IFG / 8IFG/IGT) com-
pared to men (10IFG / 6IFG/IGT). No significant differences were found for 
baseline ATBF and adipocyte size between IFG and IFG/IGT subjects. VAL 
increased insulin sensitivity (P=0.045), fasting ATBF (P=0.02) and postpran-
dial ATBFAUC 0-4h (P=0.04) compared to PLB. In addition, mean adipocyte 
diameter was decreased by VAL compared to PLB (P<0.001), with a shift 
towards a higher proportion of small and less large adipocytes (P<0.001 for 
both), whereas no changes in body weight were noted.
Conclusion: 26-weeks VAL treatment increased insulin sensitivity, fasting 
and postprandial ATBF and decreased mean abdominal subcutaneous adi-
pocyte size, with a shift from large to small adipocytes, in subjects with IGM. 
The present data suggest that improved adipose tissue function may contrib-
ute to the reduced development of T2D in patients following long-term VAL 
treatment.
Supported by: Investigator-Initiated Study Grant from Novartis Pharma
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The relationship of serum A-FABP, retinol binding protein 4, and 
adiponectin levels to the development of metabolic syndrome in 
children: a 3-year prospective cohort study
S.J. Yang, M.J. Cho, H.Y. Choi, Y.J. Kim, J.H. Kim, C.R. Eun, H.J. Yoo,  
H.Y. Kim, J.A. Seo, N.H. Kim, S.G. Kim, S.H. Baik, D.S. Choi, K.M. Choi; 
Endocrinology and Metabolism, Korea University College of Medicine, 
Seoul, Republic of Korea.
Background and aims: Adipocyte-fatty acid binding protein (A-FABP) and 
retinol binding protein 4 (RBP4) has been reported to be associated with 
metabolic syndrome in adults. We evaluated the prospective association of A-
FABP, RBP4, and adiponectin with metabolic syndrome as defined by pediat-
ric adaption of the National Cholesterol Education Program criteria.
Materials and methods: In this prospective cohort study, 159 boys from the 
school-based Metabolic disorders & Obesity Study in Elementary School 
children (MOSES) study were followed up for 3 years.
Results: At baseline, A-FABP levels (12.8 ± 5.1 µg/L vs. 23.6 ± 8.2 µg/L, P 
<0.001) and RBP4 levels (59.7 ± 15.3 vs. 69.3 ± 17.1, P = 0.001) were sig-
nificantly higher, whereas adiponectin levels (18.1 ± 8.4 µg/mL vs. 11.5 ± 5.4 
µg/mL, P <0.001) were significantly lower in overweight children compared 
to normal control. During 3 year of follow-up, in addition to their association 
with change of weight, A-FABP levels were positively associated with change 
of waist circumference and adiponectin levels were negatively associated with 
change of triglyceride. Although both baseline A-FABP and adiponectin were 
associated with the development of metabolic syndrome, multiple logistic re-
gression analysis showed that only A-FABP was the independent predictor of 
the development of metabolic syndrome after adjustment for Tanner stage, 
insulin resistance, and BMI during 3 year of follow-up (odds ratio, 12.0; 95% 
CI, 1.3 to 107.4; highest versus lowest tertile).
Conclusion: A-FABP predicts the development of metabolic syndrome inde-
pendently of adiposity and insulin resistance in Korean boys.
Table 1. Logistic regression analysis of baseline adipokines in the prediction 
of the development of metabolic syndrome at 3 years later.
Q1 Q2 Q3
Adiponectin 2.42-11.04 11.19-18.47 18.66-41.08
Model 1 1.0 0.10 (0.01-1.04) 0.07 (0.01-0.73)
Model 2 1.0 0.03 (0.01-0.87) 0.09 (0.01-0.6)
Model 3 1.0 0.31 (0.03-3.47) 0.12 (0.01-1.51)
A-FABP 5.0-11.0 12.0-17.0 18.0-43.0
Model 1 1.0 1.09 (0.06-18.81) 10.82 (1.15-101.52)
Model 2 1.0 1.02 (0.06-16.79) 9.56 (1.15-79.64)
Model 3 1.0 1.29 (0.08-21.47) 12.00 (1.34-107.36)
Model 1: adjusted for Tanner stage
Model 2: adjusted for model 1 plus HOMA-IR at baseline
Model 3: adjusted for model 2 plus BMI at baseline
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The relationship between liver fat content and insulin resistance and beta 
cell function in individuals with different status of glucose metabolism
H. Bian1, H. Lin1, S. Rao2, X. Yao2, M. Zeng2, J. Zhou3, W. Jia3, X. Gao1; 
1Department of Endocrinology and Metabolism, Zhongshan Hospital, 
Fudan University, 2Department of Radiology, Zhong Shan Hospital, Fudan 
University, 3Department of Endocrinology and Metabolism, Shanghai Jiao 
Tong University Affiliated Sixth People’s Hospital, Shanghai, China.
Aims: Nonalcoholic fatty liver disease (NAFLD) is commonly associated 
with type 2 diabetes, dyslipidemia, and insulin resistance. Many studies have 
shown NAFLD was a predictor of type 2 diabetes and metabolic syndrome. 
Excess deposition of liver fat may be affect the glucose by deteriorating the 
β-cell function and increasing the insulin resistance. This study aims to study 
the relationship between liver fat content(LFC), insulin resistance and β-cell 
function in individuals with different status of glucose metabolism in China.
Materials and methods: 109 subjects including 31 impaired glucose regula-
tion (IGR), 31 newly diagnosed type 2 diabetes (NT2DM) and 47 normal 
control(NC) with normal metabolic parameters were involved in the study 
by measuring the LFC using Proton magnetic resonance spectroscopy, evalu-
ating the insulin resistance and β-cell function using C peptide and insulin 
from oral 75g glucose tolerance test.
Results: (1)LFC was 3.83%, (inter-quartile range, 2.35-7.59%),12.82%(inter-
quartile range, 8.10-21.37%),21.99%(inter-quartile range, 11.89-34.43%) in 
NC,IGR,NT2DM groups and was elevated in turn(P<0.01);(2) The subjects 
were divided into four subgroups by LFC Quartile named Quartile 1-4 as-
sociated with the increasing LFC.HOMA-IR were elevated from Quartile 2 
by turns(P<0.01);(3) Insulin from 0 to 30 min (ΔI30),the ratio of change in 
insulin from 0 to 30 min to that in glucose from 0 to 30 min (ΔI30/ΔBG30),and 
C peptide from 0 to 30 min (ΔCP30) increased in Quartile 2,then decrease in 
Quartile 3,but without statistical significance. In Quartile 4 ,ΔI30/ΔBG30 and 
ΔCP30 sharply decreased(P<0.05,and P<0.01). The ratio of C peptide from 0 
to 30 min to that in glucose from 0 to 30 min (ΔCP30/ΔBG30) begun to de-
crease from Quartile 3(P<0.05). The ratio of area under curve of C peptide 
to area under curve of glucose (CP AUC / BG AUC) were significantly decreased 
from Quartile 3(P<0.05). From Quartile 3,glucose level abnormally elevated 
to the diagnosis value of IGR(P<0.01)(Tab 1);(4) LFC was positively corre-
lated with HOMA-IR(rs =0.618)(P <0.01),but was negatively correlated with 
ΔCP30(rs=-0.282),ΔCP30/ΔBG30(rs=-0.404),CP AUC / BG AUC(rs=-0.308)(All P 
<0.01);(5)Stepwise regression analysis demonstrated LFC was the strongest 
predictor of HOMA-IR .But LFC failed to enter all models about β-cell func-
tion.
Conclusion: LFC was an independent risk factor of insulin resistance. When 
LFC moderate increased, the early phase of insulin secretion also compen-
satively increased, but as the LFC further deposition, both the early phase 
and whole β-cell function were deteriorated, and hyperglycemia developed. 
These suggest that deposition of LFC participates in the pathogenesis of type 
2 diabetes.
Supported by: 07JC1401107,SHDC12006101
603
Defects in glutaeal adipogenesis are associated with obesity-related 
insulin resistance in black South African women
J.H. Goedecke1,2, K. Adams3, P. Hayes3, J. Evans2, J. Dave3, N.S. Levitt3,  
E.V. Lambert2, S.E. Kahn4, T. Olsson5; 
1South African Medical Research Council, Cape Town, South Africa, 
2Department of Human Biology, University of Cape Town, South Africa, 
3Department of Medicine, University of Cape Town, South Africa, 4Division 
of Metabolism, Endocrinology, and Nutrition, Department of Medicine, 
VA Puget Sound Health Care System and University of Washington, Seattle, 
USA, 5Department of Medicine, Umeå University, Sweden.
Background and aims: It has been proposed that defects in the ability to 
store fat in subcutaneous adipose tissue (SAT) depots may be associated with 
increased visceral adipose tissue (VAT) accumulation and decreased insulin 
sensitivity (SI). The aims of the study were to measure the expression of genes 
involved in adipogenesis in abdominal SAT and gluteal depots, and deter-
mined their relationship with VAT and SI in black and white South African 
women who differed in body fat distribution and SI.
Materials and methods: VAT (computerised tomography scan), SI (frequent-
ly sampled intravenous glucose tolerance test), and abdominal and gluteal 
SAT gene expression were measured in 14 normal-weight (BMI <25 kg/m2) 
black, 14 normal-weight white, 15 obese (BMI >30 kg/m2) black and 13 obese 
white South African women.
Results: With increasing BMI, black women accumulated less VAT (P=0.03) 
and more abdominal SAT (P=0.017), but had lower SI (P<0.01) than white 
women. After adjusting for differences in VAT and SI, abdominal SAT adi-
pogenic gene expression did not differ by ethnicity. However, gluteal SAT 
expression of adipogenic transcription factors (CEBPβ and STAT5a) were 
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higher in black than white women (P<0.05). In contrast, gluteal expression 
of adipogenic (PPARγ), lipogenic (FASN, PEPCK) and lipolytic (HSL, FABP) 
genes were down-regulated in obese black women (P<0.05). Further, CEBPα 
(r=0.53, P=0.007), FASN (r=0.50, P=0.011), PEPCK (r=0.45, P=0.024), LPL 
(0.52, P=0.008), HSL (r=0.59, P=0.002) and FABP (r=0.61, P=0.001) mRNA 
levels in gluteal SAT, but not abdominal SAT, correlated with SI in black 
women, independent of % body fat. In white women, FASN expression in 
both gluteal and superficial SAT depots correlated equally with SI (r=0.47, 
P=0.025). VAT correlated negatively with mRNA levels of adipogenic tran-
scription factors (CEBPα (r=-0.47, P=0.025), CEBPβ (r=-0.44, P=0.037) and 
SREBPS (r=-0.46, P=0.028)) in white women, whereas in black women, no 
associations with VAT were found.
Conclusion: Obese black women have impaired expression of gluteal SAT 
adipogenic genes compared to white women, which associates with reduced 
SI. These findings therefore refute the hypothesis that black South African 
women display ‘healthy obesity’ due to their greater peripheral fat distribu-
tion, but rather suggests that obesity in black women impairs gluteal SAT 
adipogenesis and storage, potentially leading to insulin resistance, which in-
creases the risk for type 2 diabetes.
Supported by: South African NRF, MRC and UCT
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Adipose tissue dysregulation and reduced insulin sensitivity in non-
obese individuals with enlarged abdominal adipose cells
A. Hammarstedt, U. Smith; 
Molecular and Clinical Medicine, Medicine, Goteborg, Sweden.
Background and aims: Obesity promotes type 2 diabetes through induction 
of insulin resistance. Insulin resistance in the adipose tissue is, however, seen 
long before type 2 diabetes develops and this is associated with a dysfunc-
tional adipose tissue including an impaired ability to recruit pre-adipocytes 
and, thus, promoting adipocyte hypertrophy. Animal studies have shown that 
expansion of the adipose tissue does not necessarily affect the metabolic phe-
notype as long as the adipose tissue is not dysfunctional. In order to examine 
this in man, we here investigated GLUT4 expression and other markers of 
insulin resistance in the adipose tissue, including adipose cell size as a marker 
of impaired pre-adipocyte differentiation in non-obese, first-degree relatives 
to type 2 diabetic patients in relation to the whole-body phenotype.
Materials and methods: 34 non-obese, first-degree relatives to type 2 diabetic 
patients were recruited through advertisement in a local newspaper. Anthropo-
metric measures were recorded, blood samples collected for quantification of cir-
culating factors and insulin sensitivity measured by the hyperinsulinaemic-eug-
lycaemic clamp method. Abdominal subcutaneous adipose tissue biopsies were 
obtained, adipocyte cell size and gene and protein expression were measured.
Results: Our findings show that these individuals, although non-obese, exhib-
it clear signs of a dysfunctional adipose tissue, characterized by low expression 
of GLUT4, altered adipokine profile, and enlarged adipocyte cell size that cor-
relate with the clinical phenotype and insulin sensitivity. In summary, cell size, 
in these non-obese individuals, is correlated with WHR (R=0.42, p=0.014), 
f-glucose (R=0.30, p=0.085), fs-insulin (R=0.58, p<0.001), HbA1c (R=0.33, 
p=0.058), GIR (R=-0.41, p=0.016), TG (R=0.44, p=0.009), s-HDL cholesterol 
(R=-0.41, p=0.017), s-Adiponectin (R=-0.56, p=0.001), GLUT4 mRNA (R=-
0.45, p=0.007) and GLUT4 protein (R=-0.29, p=0.095). In addition, GLUT4 
expression in the adipose tissue and circulating adiponectin, which is secreted 
from the adipose tissue, was closely related (mRNA: R=0.42, p=0.013; protein: 
R=0.36, p=0.037) and show a similar association with clinical parameters.
Conclusion: In conclusion, these findings support the concept that it is not 
obesity per se, but rather the presence of a dysregulated adipose tissue which 
relates to whole-body insulin sensitivity and the associated phenotype.
Supported by: SRC Novo Nordisk SDF SSF Söderberg Wiberg Bergvall
605
Retinol binding protein-4, insulin sensitivity and intima media thickness 
in non diabetic subjects with normal glucose tolerance 
E. Muscelli, A. Solini, C. Morizzo, B.D. Astiarraga, C. Palombo, A. Casolaro, 
M. Kozakova; 
Department of Internal Medicine, University of Pisa, Italy.
Background and aims: Retinol binding protein-4 (RBP4) is a novel adipok-
ine able to modulate the action of insulin in several tissues; its role in humans 
is controversial. RBP4 has been associated to increase in carotid intima-media 
thickness (IMT) in hypertensive women but its association with early athero-
sclerotic changes in normortensive subjects was not studied. Thus, the aim of 
the present study was to evaluate the relationship between RBP4 and insulin 
sensitivity and IMT in lean and obese non-diabetic normotensive subjects.
Materials and methods: Insulin sensitivity (euglycemic hyperinsulinemic 
clamp), IMT in common carotid artery (high-resolution B-mode ultrasound) 
and serum RBP4 levels were assessed in 72 subjects (39 males, 43.9 ± 8.3 
years; BMI 27.1 ± 4.6 kg/m2 [range 19.1 to 30.3 kg/m2]). Study subjects were 
divided in lean (L, n=29), overweight (OW, n=17) and obese (OB, n=26).
Results: Insulin sensitivity (M value) ranged from 11.9 to 81.2 μmol/kg 
FFM/min (mean±SD = 50.0±14.0 μmol/kg FFM/min) and was lower in OB 
(L = 60.0±12.7; OW = 45.7±11.1 and OB = 42.3±12.4μmol/kg FFM/min, 
p<0.0001). IMT was higher in OB and OW, as compared to L (OW = 0.601 
± 0.081 and OB = 0.658 ± 0.092mm vs. L = 0.589 ± 0.074, p=0.01). RBP4 
levels were similar between genders, BMI subgroups and between the lowest 
and higher M quartile (56.2 ± 32 vs. 55.8 ± 28.3 μg/ml; p=ns). In the whole 
study no relationship was observed between RBP4 and BMI, blood pressure, 
M value, IMT, plasma adiponectin and glucose and insulin plasma levels dur-
ing the OGTT. IMT was independently correlated only with age and weight 
(r2=0.35; p<0.0001).
Conclusion: In non-diabetic normotensive subjects, RBP4 levels are neither 
related to the degree of obesity and of insulin sensitivity nor to blood pressure 
and to IMT. In this healthy population increase in IMT seems to reflect physi-
ologic aging and adaptation to body size.
606
Nonalcoholic steatohepatitis (NASH) is a prediabetic state frequently 
associated with abnormal glucose tolerance and severe hepatic and 
adipose tissue insulin resistance
K. Cusi, B. Orsak, C. Ortiz-Lopez, R. Lomonaco, J. Hardies, V. Kochunov,  
C. Darland, J. Finch; 
UTHSCSA, San Antonio, USA.
Background and aims: No previous study has systematically screened pa-
tients with nonalcoholic steatohepatitis (NASH) for type 2 diabetes mellitus 
(T2DM). In addition, the role of hyperglycemia and insulin resistance (IR) 
in relation to the severity of NASH is poorly understood. To better under-
stand this, we studied the prevalence of impaired fasting glucose (IFG), IGT 
and T2DM, and the impact of glucose tolerance status and IR on liver histol-
ogy, in biopsy-proven NASH pts from the University of Texas at San Antonio 
NASH Trial (NCT00994682). This large (n=120) study aims to understand 
the metabolic/molecular mechanisms associated with NASH and the effi-
cacy/safety of long-term treatment with pioglitazone.
Materials and methods: We report on 79 subjects. Clinical characteristics: 
age=51±1, gender=52/27 (M/F), BMI=35.8±0.9 kg/m2, FPG=123±4 mg/dl, 
A1c=6.4±0.2%, AST=48±3/ALT=73±3 IU/L). We measured: 1) glucose, insu-
lin and FFA during an OGTT; 2) liver fat by magnetic resonance spectroscopy 
(MRS); 3) ]liver/muscle (Rd) insulin sensitivity (euglycemic insulin clamp with 
3H glucose and indirect calorimetry); and 4) hepatic (Hep-IR index= EGP x 
fasting plasma insulin [FPI]) and adipose tissue (Adipo-IR index= fasting FFA 
x FPI) insulin resistance. Liver histology was assessed by Kleiner criteria.
Results: In a predominantly Hispanic population (~2/3) glucose metabo-
lism was abnormal in 90% of patients with 51% of these being unaware 
of this until testing. In those not known previously to have diabetes, 22% 
were newly diagnosed T2DM, 40% had both IFG and IGT, 20% IFG or IGT 
while only 18% had normal fasting/postprandial glucose metabolism. While 
T2DM and non-diabetics with NASH were well matched for age, ethnicity, 
percent body fat (DXA), lipids and liver steatosis (both by MRS [27±3%] 
and histology), T2DM patients had worse steatohepatitis (data available in 
69) (necroinflammation= 2.8±0.1 vs. 1.8±0.1) and ALT (83±9 vs. 64±5 IU/
L, both p<0.001). Diabetics were more insulin-resistant at the level of the 
liver (Hep-IR=36.1±9.0 vs. 23.9±4.6 mg/kg−1•min−1•μU/ml; suppression of 
EGP by low-dose insulin infusion: -59% vs. 83%, both p<0.001) and adipose 
tissue (Adipo-IR= 13.3±1.8 vs. 8.5±1.1 mmol/liter•U/ml, p<0.001). In con-
trast, Rd (muscle) was diminished but identical in both groups (2.3±0.4 mg/
kg−1•min−1). Hepatocyte necroinflammation correlated closely with A1c, 
Hep-IR and Adipo-IR (p<0.05-0.01).
Conclusion: The prevalence of IFG, IGT and T2DM in a predominantly 
Hispanic population with NASH is much higher than previously appreciated 
and such patients may benefit from early screening for T2DM. Patients with 
NASH and T2DM have worse steatohepatitis, which appears related at least 
in part, to their more severe hepatic and adipose tissue insulin resistance.
Supported by: The Burrough Wellcome Fund, American Diabetes Association, 
VAMC and NCRR
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Insulin resistance, rather than BMI, predicts metabolic severity in 
anorexia nervosa
A. Prioletta, G. Muscogiuri, C. Cipolla, E. Salomone, G. Sorice, T. Mezza,  
S. Della Casa, A. Giaccari; 
Endocrinology, Catholic University, Rome, Italy.
Introduction: Anorexia nervosa (AN) is a psychiatric eating disorder, char-
acterized by self-induced weight loss and body image distortion. The pro-
longed starvation causes changes in body composition as loss of fat and lean 
masses while nutritional recovery results in significant changes in body com-
position, especially in fat mass distribution as well as in FT3 normalization. 
It is well known that changes in body composition may modify insulin-sen-
sitivity (IS) nevertheless, the determination of insulin sensitivity in AN has 
provided conflicting results.
Aim: In our study we aimed to examine IS, measured by hyperinsulinemic 
euglycemic clamp (HEC), in patients affected by AN. The second aim was 
to evaluate the relationship between IS and the usual clinical parameters of 
recovery from AN, including FT3 and body fat mass.
Subjects and methods: 26 women with restrictive AN (age 24.4± 6.0 years; 
disease duration 66.4±7.8 months), were enrolled. We measured BMI, hor-
mones (FT3, FT4, TSH, serum and urinary free cortisol, GH and IGF-1), 
and performed OGTT and HEC. Body composition was determined by dual 
energy X-ray absorptiometry (DEXA). Fat body mass was calculated for the 
total body and for trunk and leg regions. We considered patients in partial 
recovery if FT3 was within normal range (≥ 2 pg/ml).
Results: All studied subjects were normo-tolerant. After dividing the cohort 
based on FT3 levels, the two groups were similar in age and disease dura-
tion although subjects with normal FT3 levels had higher BMI, total fat mass, 
trunk fat mass and ratio trunk fat mass/total fat mass (p<0.05). No differences 
in the levels of plasma and urinary cortisol, GH, TSH, FT4 were present. The 
group with low FT3 had lower IGF1 (p<0.05). A linear negative correlation 
was observed between glucose uptake during HEC and trunk fat mass (R=-
0.72; p=0.01), while no correlation between glucose uptake and BMI (R=-
0.08; p=0.82) was found. A linear negative correlation was shown between 
FT3 and glucose uptake (R=-0.75; p=0.01); and (positive) with abdominal fat 
(R=0.901; p=0.003).
Discussion: The inverse correlation found between body fat mass (trunk and 
total) and glucose uptake and the absence of any correlation between BMI 
and glucose uptake allow us to hypothesize that, in patients with anorexia 
nervosa, BMI is not a reliable index of metabolic status, in opposite to what 
was observed in patients with metabolic syndrome or diabetes. The measure-
ment of body fat by DEXA seems to be more reliable than BMI. Our study 
also showed that the metabolic alterations and the body composition were 
correlated with indices of disease that per se could constitute a marker of 
the metabolic state in these patients, offering a reliable prognostic indica-
tions. In perspective, although AN patients in partial recovery were still with 
an extremely reduced fat mass, we hypothesize that the reappearance of fat 
exclusively in the abdomen induces insulin resistance and may contribute to 
the usual difficulty to reach normal weight in these patients.
608
Does insulin resistance or insulin secretion predict weight changes in 
non-diabetic subjects?
E. Rebelou, E. Muscelli, M. Nannipieri, S. Camastra, E. Ferrannini, on 
behalf of the RISC Study investigators; 
Department of Internal Medicine, University of Pisa, Italy.
Background and aims: Previous studies using the euglycaemic insulin clamp 
technique have reported that a high degree of insulin sensitivity predicts 
weight gain. This association, however, has not been confirmed in other stud-
ies using different surrogate measures of insulin sensitivity. Likewise, both 
increased and decreased insulin secretion have been linked with weight gain. 
We therefore undertook to systematically analyse the relationship between 
insulin sensitivity/secretion and spontaneous weight changes in non-diabetic 
subjects.
Materials and methods: In 1,048 subjects from the RISC cohort (561 wom-
en and 467 men, mean age 44 years) followed up for 3 years, we measured 
baseline insulin sensitivity (by a 240 pmol.min.m-2 insulin clamp) and ß-cell 
function (i.e., fasting insulin secretion rate, total insulin output and ß-cell 
glucose sensitivity, by mathematical modelling of the C-peptide response to 
oral glucose).
Results: In the whole cohort, both men and women gained weight over 3 
years (0.9 [4.6] and 0.9 [4.6] kg, respectively, median [IQR], p<0.0001 vs 
zero). Baseline BMI was significantly higher in both weight gainers (top 20% 
of the distribution of BMI changes, +6 [3] kg) and weight losers (bottom 20%, 
-4 [3] kg) as compared to weight stable subjects (25.7 [5.0] and 26.3 [4.6] 
kg.m-2 , respectively, vs 24.3 [4.6] kg.m-2, p<0.0001 for both). In contrast, in-
sulin sensitivity (as the M or M/I index) was not associated with either weight 
gain or weight loss across quartiles of baseline BMI. By multiple logistic or 
linear regression analyses adjusting for centre, age and sex, baseline waist 
circumference (or BMI or body weight) was the only significant, independ-
ent predictor of both weight gain and weight loss. In none of these models 
did any parameter of ß-cell function show an independent association with 
weight changes; this was also the case for baseline glucose tolerance status 
(NGT, IFG or IGT).
Conclusion: In a large cohort of non-diabetic Caucasian subjects, neither 
insulin sensitivity nor insulin secretion predicts spontaneous weight changes. 
As compared to lean subjects, heavier individuals are prone to either gaining 
or losing weight regardless of their degree of insulin sensitivity.
Supported by: EU; AstraZeneca and Merck Serono
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A multi-marker risk score predicts insulin sensitivity and beta cell 
function-driven type 2 diabetes from a fasted sample
S.M. Watkins1, M.W. Rowe1, J.A. Kolberg1, R.N. Bergman2,  
L.E. Wagenknecht3; 
1Research, Tethys Bioscience, Emeryville, 2Keck School of Medicine, 
University of Southern California, Los Angeles, 3School of Medicine, Wake 
Forest University, Winston-Salem, USA.
Background and aims: The Insulin Resistance in Atherosclerosis (IRAS) 
Study demonstrated that insulin sensitivity (SI), acute insulin response (AIR) 
and the disposition index (DI) as measured by frequently-sampled intrave-
nous glucose tolerance tests (FSIGT) were each predictive of future diabetes 
in a multi-ethnic population. While such careful measurements of glucose 
homeostasis provide useful prognostic information, the FSIGT test itself is 
impractical for standard clinical practice. The PreDx™ Diabetes Risk Score 
(DRS) is a prognostic test that combines the fasting concentrations of glu-
cose, insulin, hemoglobin A1c, adiponectin, C-reactive protein, ferritin and 
interleukin-2 receptor alpha into an absolute risk for conversion to diabetes 
within five years (as defined by the WHO 1999 criteria).
Materials and methods: We measured the DRS in baseline IRAS samples 
from 722 subjects (including 127 that subsequently converted to diabetes) 
and evaluated the correlation of the DRS and its individual components with 
SI, AIR and DI. To further evaluate the relationship of the DRS to insulin sen-
sitivity, insulin secretion or beta cell function, we determined the incremental 
performance of logistic models combining SI, AIR or DI with the fixed DRS 
score in predicting incident diabetes.
Results: The DRS was strongly and significantly correlated with both SI (r = 
-0.52, p < 0.01) and DI (r = -0.54, p < 0.01), and weakly correlated with AIR 
(r = -0.20, p < 0.01). Additionally, each of the individual components of the 
DRS except IL-2 receptor alpha correlated significantly with SI and DI. The 
DRS, SI, AIR and DI were each significant predictors of the onset of diabetes 
(p < 0.01) with C-statistics of 0.75, 0.68, 0.69 and 0.79, respectively. Adding 
SI to DRS did not significantly improve the prediction of incident diabetes, 
indicating that the DRS captures the biological basis of SI-induced diabetes. 
Conversely, adding DRS increased the C-statistics of SI by 0.07 (p < 0.01) and 
AIR by 0.10 (p < 0.01), but did not improve the performance of the DI.
Conclusion: The DRS correlates strongly and significantly with SI and the 
DI. In addition to this correlation the DRS substitutes for, and exceeds, the 
capacity of SI to predict incident diabetes (p < 0.01), and it can be performed 
from a fasted sample. The DRS represents a simple and practical approach to 
identifying patients at risk for SI or DI-driven type 2 diabetes.
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Screening for insulin resistance in persons with increased diabetes risk 
by EZSCAN
P. Brunswick1, O. Luis-Dominguez2, J.-P. Deslypere3, J.-H. Calvet1,  
P. Schwarz2; 
1Impeto Medical, Paris, France, 2Medizinische Fakultät Carl-Gustav Carus, 
Dresden, Germany, 3Aesculape Pte Ltd, Singapore, Singapore.
Background and aims: Prevalence of type 2 diabetes and pre-diabetes are in-
creasing globally. Early identification and intervention even in persons with 
pre-diabetes will reduce/delay progression to diabetes and related complica-
tions. There is a lack of simple, fast, reproducible and cheap methods for early 
diagnosis and screening of people at risk for diabetes. EZSCAN was recently 
developed to measure sweat gland function through measurement of electro 
skin conductance (ESC) based on reverse iontophoresis. The aim of the study 
was to evaluate the ability of EZSCAN to predict insulin resistance in subjects 
at high risk of diabetes.
Materials and methods: 230 subjects with a family history of type 2 diabetes, 
obesity or dyslipoproteinaemia from the city of Dresden and adjoining area 
(37% male, mean age 56.4±13.9yrs, mean BMI 27.8±5.0kg/m2) were involved 
in the study and had an oral glucose tolerance test (OGTT) with measure-
ment of plasma glucose, pro-insulin, insulin and C-peptide at 0, 30, 60, 90 
and 120 minutes. EZSCAN results are given in colour codes based on the val-
ues of ESC on feet, hands and forehead: Green - Normal; Yellow - Borderline; 
Orange-Red - High risk.
Results: Based on ESC values measured by EZSCAN 56 subjects were clas-
sified as green, 115 as yellow and 54 as orange-red. Results of glucose, pro-
insulin, insulin and C-peptide for OGTT according to EZSCAN classifica-
tion are displayed on Figure. Patients classified as green on EZSCAN had 
significant lower values for glucose and insulin at 60, 90 and 120 min. and 
for C-peptide at 90 and 120 min. when compared to patients of yellow or 
orange-red groups.
Conclusion: EZSCAN is a new simple and non invasive method for identify-
ing subjects at high risk for diabetes.
611
Serum advanced glycation end products is associated with insulin 
resistance independent of adiponectin 
K.C.B. Tan, S.W.M. Shiu, Y. Wong, X. Tam; 
Department of Medicine, The University of Hong Kong, Hong Kong.
Background and aims: Recent in vitro experimental data have suggested that 
advanced glycation end products (AGEs) may play a significant role in the 
development of insulin resistance by interfering with the molecular pathways 
of insulin signaling. We have investigated whether the degree of insulin re-
sistance in human subjects is associated with circulating level of AGEs.
Materials and methods: 165 healthy non-diabetic subjects (77 male and 88 
female) were recruited from the community. Serum levels of AGEs and adi-
ponectin were measured by ELISA. Insulin resistance was determined by us-
ing the homeostasis model assessment index (HOMA-IR).
Results: Serum AGEs was higher in male than female subjects (3.91 ± 1.18 
unit/ml vs 3.49 ± 1.22, p=0.03). There was no significant difference in age 
between male and female subjects but male subjects had higher body mass 
index (25.5 ± 2.6 kg/m2 vs 23.6 ± 3.3, p<0.01) and waist circumference (86.4 
± 7.1 cm vs 76.4 ± 8.6, p<0.01). Male subjects were more insulin resistant, 
HOMA- IR [median 1.37 (interquartile range 0.81 - 2.19) vs 1.12 (0.64 - 1.78), 
p=0.04] and had lower serum adiponectin level [6.24 ug/ml (3.99 - 8.98) vs 
10.67 (7.92 - 15.12), p<0.01]. In both male and female subjects, serum AGEs 
correlated with HOMA-IR (r=0.37, p< 0.01; r=0.26, p=0.02 respectively). Se-
rum AGEs remained an independent determinant of HOAM-IR even after 
adjusting for age, gender, waist, smoking and adiponectin level on multiple 
linear regression analysis.
Conclusion: Formation and accumulation of AGEs progress during normal 
aging. We have demonstrated that circulating level of AGEs is associated with 
insulin resistance in non-diabetic subjects independent of adiponectin.
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Alzheimer’s disease in normoglycaemic patients: an association 
with decreased insulin sensitivity and atherogenic profile of lipid 
abnormalities
M. Macesic1, N.M. Lalic1,2, V.S. Kostic2, A. Jotic1, E. Stefanova2, K. Lalic1,  
T. Milicic1, L. Lukic1, N. Rajkovic1, J. Seferovic-Mitrovic1, S. Aleksic1; 
1Institute for endocrinology, 2Institution for neurology, Belgrade, Serbia.
Background and aims: Previous studies have suggested that insulin resist-
ance might play an important role in pathogenesis of Alzheimer’s disease 
(AD), but the relevant mechanisms of this influence have not yet been clari-
fied. The study was aimed to analyze in patients with AD the levels of (a) 
insulin sensitivity (IS), (b) plasma insulin (PI) and (c) lipid parameters com-
prising total cholesterol (Ch), low-density (LDL) and high density (HDL) 
Ch, triglycerides and apolipoproteins (apoAI, apoAII, apoB, Lp(a) and apoE) 
potentially involved the pathogenesis of the disease.
Materials and methods: In the study we included 57 normoglycemic patients 
with AD (group A; BMI: 23,95 +/- 0.81 kg/m2, mean age of 72,34+/-8,60 
years) and 25 matched controls (group B; BMI: 25,43 +/- 0,66 kg/m2, mean 
age of 61,33+/-6,75 years). IS was evaluated by using euglycemic hyperin-
sulinemic clamp technique with insulin infusion rate of 1 mU/kgbw/min 
during 120 min and glucose infusion adjusted manually, at 5 min intervals, 
to maintain target euglycemia. Total glucose uptake (M value) was calculated 
on the basis of the amount of glucose infused during steady state period (80-
120 min). PI levels were determined by radioimmunossay and PG levels by 
glucose oxidase method. Total cholesterol, HDL-Ch, and triglycerides levels 
were determined by using enzymatic method, and LDL-Ch was calculated 
using the formula of Friedewald. Apolipoproteins ApoAI, ApoAII, Lp(a), 
ApoB and ApoE were determined by using nephelometry method.
Results: We found that total glucose uptake was significantly lower in group 
A compared to group B (6,41 +/- 0,60 vs 8,13 +/- 0,33 mg/min/kg, p<0.01). In 
addition, basal PI levels were higher in group A compared to group B (15,57 
+/- 2,01 vs 7,34+/-0,98 mU/l, p<0.05), while basal PG levels did not differ 
between the groups. Moreover, the levels of total Ch and LDL-Ch were sig-
nificantly higher in group A in comparison to group B (6,47 +/- 0,23 vs 5,71 
+/- 0,19; 4,40 +/- 0,19 vs 3,58 +/- 0,17 mmol/l, respectively, p<0.01), while 
the HDL-Ch levels were significantly lower in group A than in group B (1,21 
+/- 0,04 vs 1,48 +/- 0,32 mmol/l, p<0.01). The levels of triglycerides did not 
differ significantly between the groups (1,58+/- 0,14 vs 1,58 +/- 0,13 mmol/l, 
p=NS. In addition, the levels of ApoAI were significantly lower in group A in 
comparison to group B (1,493+/-0,058 vs 2,02+/-0,37 g/l, p<0.01), while the 
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levels of other apolipoproteins, ApoAII, ApoB, Lp(a) and ApoE did not dif-
fer significantly between the groups (330,24+/-10,57 vs 330,37+/-12,07 mg/L; 
1,135 +/- 0,056 vs 1,06 +/- 0,28 g/l; 0,264+/-0,053 vs 0,24+/-0,07 g/l; 42,63+/-
1,89 vs 40,40+/-1,15 mg/L, respectively, p=NS).
Conclusion: Our results have demonstrated that the presence of AD in nor-
moglycemic patients was associated with decreased IS and increases in pe-
ripheral insulin levels. Our results imply that decreased IS levels might exert, 
at least partly, their pathogenic influence through the lipid abnormalities es-
pecially the decreases in HDL-Ch and ApoAI levels.
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Relationship between insulin resistance and puberty in obese children 
with increased cardiometabolic risk
B. Tobisch1, L. Blatniczky1, L. Barkai2; 
1St. John’s and North-Buda United Hospitals of Budapest Municipality, 
Budapest, 2Postgraduate Institute of Pediatrics, University of Debrecen 
Medical and Health Science Center, Miskolc, Hungary.
Background and aims: Epidemiolgy data provide evidences that the fre-
quency of obesity and cardiometabolic risk factors shows an increasing ten-
dency in childhood. Insulin resistance playa a central role in the pathogenesis 
of cardiovascular and metabolic consequences of obesity. Transient decrease 
in the insulin sensitivity during puberty is a well-known physiological proc-
ess, however the feature of this phenomenon is not clear in obese children 
with increased cardiometabolic risk. The aim of present study was to assess 
the effect of puberty on insulin resistance and metabolic parameters in obese 
children with and without increased cardiometabolic risk.
Materials and methods: Anthropometry data, insulin levels during OGTT 
and lipid status were analyzed of 161 obese children aged 10-18 years. 
Σinsulin/Σglucose ratio obtained during glucose load and HOMA index were 
used to assess insulin resistance. Children were sorted into prepubertal (T1), 
pubertal (T2-4) and postpubertal (T5) cohorts according to Tanner staging 
criteria and metabolic and insulin resistance parameters were evaluated. In-
creased cardiometabolic risk (CMR) was defined as the presence of any two 
risk factors (elevated FPG, BP, TG or decreased HDL-C) in addition to obes-
ity.
Results: Out of 161 obese subjects, 43 (26.7%) had CMR. Decreased HDL 
and/or elevated TG was observed in 92 (57.1%) cases. IGT and/or IFG was 
found in 25 (15.5%) cases. In subjects without CMR, the Σinsulin/Σglucose 
ratio in T1 stage was significantly lower than in T2-4 and T5 stages (p=0.01). 
In children with CMR, the Σinsulin/Σglucose ratio was similar in T1, T2-4 
and T5 stages, however it was significantly higher in T1 stage as compared to 
subjects without CMR (p=0.04). In T2-4 and T5 stages, the Σinsulin/Σglucose 
ratio did not differ between children with and without CMR. No difference 
was found in HOMA index between groups with and without CMR in T1 
stage, however significantly higher levels were observed in CMR subjects in 
T2-4 stages (p=0.01), indicating the presence of fasting hyperinsulinaemia 
in this cohort. Elevated HbA1c (>6.0%) was found in 13 (12.6%) out of 81 
children investigated, of whom only two cases had abnormal OGTT results. 
In cases having normal HbA1c, OGTT showed IGT in 2 cases, IFG in 2 cases 
IGF and IGT together in 2 cases and T2DM also in 2 cases, respectively.
Conclusion: Increased insulin resistance can be observed in obese children 
without CMR. In obese children with CMR, substantial insulin resistance oc-
curs in prepuberty and it is present in similar level throughout puberty. Fast-
ing insulin levels are elevated in obese CMR subjects as compared to those 
without CMR. To reveal T2DM cases, HbA1c and OGTT results should be 
assessed in parallel.
PS 46 At home with HOMA?
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In vivo glucose and amino acid sensitivity to insulin in subjects with 
impaired glucose regulation
L.F. Clark1, M.C. Thivierge1, S.C. McGeoch1, P. Abraham2, D.W.M. Pearson2, 
G.E. Lobley1; 
1Rowett Institute of Nutrition and Health, University of Aberdeen, 
2Department of Diabetes, Aberdeen Royal Infirmary, United Kingdom.
Background and aims: Insulin is central to control of glycaemia but also 
regulates tissue protein metabolism including skeletal muscle, a major con-
tributor to post-prandial glucose disposal.
Hypothesis: A dysregulation in insulin sensitivity to glucose will be accom-
panied by a comparable change in sensitivity of protein metabolism in sub-
jects with impaired glucose regulation (IGR) as has been shown in healthy 
volunteers by Chevalier et al. This change in insulin sensitivity may occur 
through suppression of endogenous glucose production (EGP) and protein 
breakdown and/or altered disposal of glucose and amino acids (AA).
Materials and methods: Twenty-four volunteers (16 men, 8 women; mean 
age 60.3 years (52-68 years)) with IGR had assessment of basal EGP and 
whole body protein breakdown determined with stable isotope tracers. This 
was followed immediately by a 3h hyperinsulinaemic-euglycaemic-euami-
noacidaemic clamp (40 mU/m2/min) to assess insulin sensitivity. During 
the clamp, suppression of EGP and whole body protein breakdown were de-
termined with the stable isotopes. The relationship between basal metabolic 
parameters and both glucose and AA disposal with other variables were in-
vestigated using regression analyses.
Results: Mean pre-clamp EGP was 2.80mg/kgFFM/min (2.08-4.40 mg/
kgFFM/min) with a mean suppression of 78.8% (63.6-98.2%) during the 
clamp and mean protein breakdown was 5.20 mg/kgFFM/min (4.20-8.06 
mg/kgFFM/min) with suppression of 30.1% (15.0-50.7%) during the clamp. 
Mean disposal of exogenous glucose was 5.63 mg/kgFFM/min (Range: 1.85-
13.30 mg/kgFFM/min) and mean disposal of total glucose (exogenous glu-
cose and residual EGP) was 6.12 mg/kgFFM/min (Range: 2.34-14.07 mg/
kgFFM/min). Mean disposal of exogenous AA was 1.13 mg/kgFFM/min 
(Range: 0.49-1.76 mg/kgFFM/min) and mean disposal of total AA (exog-
enous and non-suppressed protein breakdown) was 4.72mg/kgFFM/min 
(Range: 3.05-5.94 mg/kgFFM/min). Exogenous glucose disposal (EGD) did 
not show a strong relationship with exogenous AA disposal (R2=0.14, NS), 
nor was there a relationship between total glucose and AA disposal. EGD and 
total glucose disposal showed inverse relationships with HOMA-IR (R2=0.38, 
P=0.008; R2=0.35, P=0.01), weight (R2=0.37, P= 0.002; R2=0.34, P=0.003), 
2 hour venous glucose (75g OGTT) (R2=0.33, P=0.009; R2=0.32, P=0.004) 
and fasting insulin (R2=0.40, P=0.007; R2=0.37, P=0.009). A relationship was 
demonstrated between total AA disposal and HOMA-IR (R2=0.34, P=0.008). 
AA disposal (total or exogenous) was not related to other variables studied.
Conclusion: The hyperinsulinaemic-euglycaemic clamp is a well recognised 
tool in the assessment of insulin sensitivity; use of an AA clamp is less com-
mon. Pereira et al found that HOMA-IR predicted 44% of the variance in 
the AA clamp in men with type 2 diabetes. Whilst we found similar results 
between total AA disposal and HOMA-IR, on direct comparison during the 
insulin clamp no relationship was seen between AA disposal and glucose dis-
posal. These findings in subjects with IGR contrast with Chevalier et al who 
found a correlation between glucose and AA disposal during the hyperinsuli-
naemic-euglycaemic-euaminoacidaemic clamps in healthy volunteers.
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Mesenteric fat thickness explains the inconsistent relationships between 
central obesity and insulin resistance
G.T. Ko1, W.-Y. So1, E. Liu2, R.C.W. Ma1, R. Ozaki1, A.P.S. Kong1, W. Chu2,  
J.C.N. Chan1; 
1Department of Medicine and Therapeutics, 2Department of Diagnostic 
Radiology and Organ Imaging, the Chinese University of Hong Kong, Hong 
Kong, China.
Background and aims: Waist circumference is a screening tool to identify 
high risk individuals for insulin resistance. However, some obese subjects are 
insulin sensitive while some non-obese subjects exhibit features of insulin 
resistance. We previously reported that mesenteric fat thickness (MFT) meas-
ured by ultrasound scan explained most of the variance of cardiometabolic 
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risks. Here, we hypothesize that MFT may explain the inconsistent relation-
ships between central obesity (CO) and insulin resistance.
Materials and methods: This is a cross-sectional study of MFT by ultrasound 
on 68 healthy Chinese men (mean age [±SD]: 43.7 ± 7.7 years, median: 44.5 
years, range 26-68 years). High MFT was defined as MFT ≥ mean ±1 SD (8.7 
+ 2.9 = 11.6 mm) and CO as WC ≥85 cm.
Results: In these 68 men, 35 (51.5%) did not have CO (CO-) and 33 (48.5%) 
had CO (CO+). In the CO+ group, subjects in the top quartile of HOMA-IS 
had lower MFT, higher adiponectin level and were less likely to have fatty 
liver than the less insulin-sensitive subjects. In the CO- group, subjects in 
the top HOMA-IR quartile were more likely to have fatty liver, higher MFT 
and lower adiponectin level than the less insulin resistant subjects. Stratified 
by CO and MFT, 7 (21.2%) had (CO+MFT+), 26 (78.8%) had (CO+MFT-), 
5 (14.3%) had (CO-MTF+) and 30 (85.7%) had (CO-MTF-). The CO+MF+ 
(1.31 ± 0.51) and CO-MF+ (1.34 ± 1.55) groups had the highest HOMA-IR 
followed by the CO+MF- (1.17 ± 0.57) and CO-MFT- (0.79 ± 0.37) groups 
(p-value for trend = 0.036). On multivariate analysis, the independent predic-
tors for HOMA-IS were age, BMI and MFT.
Conclusion: The heterogeneous relationships between IR and CO are largely 
attributed to MFT which can be used to identify non-obese but insulin resist-
ant subjects as well as obese but insulin sensitive subjects.
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Prevalence, metabolic features and prognosis of metabolically healthy 
obese Italian individuals: the Cremona Study
G. Perseghin1,2, G. Lattuada1,2, G. Calori1, M. Garancini3, E. Bosi1,4, L. Luzi1,2, 
G. Ruotolo1,5, L. Piemonti1; 
1Internal Medicine, Instituto Scientifico H San Raffaele, Milano, Italy, 
2Università degli Studi di Milano, Milano, Italy, 3Instituto Scientifico H San 
Raffaele, Milano, Italy, 4Università Vita e Salute, Milano, Italy, 5Astra Zeneca, 
Molndal, Sweden.
Background and aims: Some obese individuals have normal insulin sensitiv-
ity and appear metabolically healthy. Whether this phenotype is associated 
with increased all-cause mortality risk is controversial.
Materials and methods: We established all-cause mortality through Re-
gional Health Registry files in 2,074 Caucasian middle-aged (57±11 years), 
individuals of the population survey carried out in 1990-1991 in Lombardy, 
Italy (Cremona Study) 15 years after the baseline assessment. Study subjects 
were divided in four categories based on BMI (non-obese: < 30 kg/m2; obese; 
≥ 30 kg/m2) and estimated insulin resistance (insulin-sensitive: HOMA-IR < 
2.5; insulin-resistant ≥ 2.5).
Results: Data for 2,011 individuals were available. 43 of the 380 obese indi-
viduals (11%; 95%CI: 8.1-14.5%) were insulin-sensitive based on HOMA-IR. 
Their BMI was not different when compared to obese insulin-resistant (32±4 
vs 33±3 kg/m2), but they had lower waist circumference (94±9 vs 104±11 
cm; p<0.05), blood pressure, fasting glucose, triglycerides and fibrinogen, 
and higher HDL-cholesterol. The total number of deaths after 15 years was 
495 (CVD: 221, cancer: 180). We found that age, and sex adjusted all-cause 
mortality was higher in the obese insulin-resistant (HR: 1.40; 95% CI: 1.08-
1.81; P=0.01) but not in the metabolically healthy obese (HR: 0.99; 95% CI: 
0.46-2.11; P=0.97) when compared to non-obese insulin-sensitive subjects. 
Also CVD and cancer mortalities were higher in the obese insulin-resistant 
(HR for CVD: 1.61; 95% CI: 1.10-2.36; P=0.015 and HR for cancer: 1.52; 95% 
CI: 1.02-2.26; P=0.04, respectively) but not in the metabolically healthy obese 
(HR for CVD: 0.73; 95% CI: 0.18-3.00; P=0.66 and HR for cancer: 1.04; 95% 
CI: 0.32-3.30; P=0.95, respectively) when compared to non-obese insulin-
sensitive subjects.
Conclusion: The metabolically healthy obese phenotype is less frequent than 
previously thought and in contrast with the obese insulin resistant subjects, 
did not show an increased all-cause mortality risk during the 15 years obser-
vational period.
Supported by: Italian Minister of Health MURST Cofin, an EFSD Clinical Re-
search Grant
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Insulin demand, beta cell response and glucose control among 
contemporary children - an eight-year longitudinal study
T.J. Wilkin, A.N. Jeffery, B.S. Metcalf, J. Hosking, A.E. Fremeaux, L.D. Voss; 
University Medicine, Derriford Hospital, Plymouth, United Kingdom.
Background and aims: Glucose control becomes impaired when insulin se-
cretion can no longer meet insulin demand. Little is known of their trends 
over time in contemporary children, for whom obesity, insulin demand and 
diabetes are rising progressively.
Materials and methods: We plotted the trajectories of fasting glucose and in-
sulin annually over eight years in a single cohort of 258 healthy children (144 
boys) and modelled the corresponding beta-cell response from the HOMA2 
programme. Analyses were conducted according to exposures at 5y (quartiles 
of insulin and quartiles of BMI) and outcome at 13y (quartiles of glucose). 
The children were of uniform age (SD±3m) and race (99% White Caucasian), 
and were randomly selected at 5y from 54 primary schools.
Results: Mean glucose rose linearly from 4.3 mmol/l at 5y to 5.1 mmol/l at 
13y (p<0.001).
Exposures: BMI had no impact on the behaviour of glucose. HOMA-B rose 
gently from 5-13y among children in the lowest quartile for insulin (panel 1), 
consistent with a progressive rise in demand, but fell steeply from 5-7y - despite 
rising glucose - among those in the highest quartile (consistent with a primary 
loss of beta cell function in those most beta cell stressed). Outcome: mean glu-
cose at 13y was considerably higher in Q4 (5.5 mmol/l) than Q1 (4.7 mmol/l, 
p<0.001), and had been higher throughout (panel 2). Fasting insulin levels, on 
the other hand, were similar (at 5y Q1 4.10, Q4 3.42 mu/l, p=0.13; at 13y, Q1 
6.11, Q4 7.22 mu/l, p=0.16). The difference between Q1 and Q4 children for 
glucose at 13y lay in HOMA-B (panel 3), which was substantially lower in Q4 
than Q1 (83.1% v 102.5% at 13y, p=0.005) Gender, physical activity (accelerom-
etry) and pubertal stage all influenced these trends, but only marginally.
Conclusion: HOMA-B should be interpreted in the context of insulin de-
mand, and the striking difference for children in the highest quartile for glu-
cose at 13y was not their insulin demand at 5y, but their lack of beta cell 
response to the subsequent rise in insulin demand - consistent with (and pos-
sibly explaining) their relatively poorer glucose control.
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Insulin resistance and increased PAI-1 as factors of non-alcoholic fat 
liver disease in children, adolescents and youth metabolic syndrome
V.S. Dimitrijevic-Sreckovic1, B.M. Sreckovic2, P.B. Djordjevic1,  
D.M. Gostiljac1, M. Civcic1, I. Soldatovic3, H.S. Petrovic1; 
1Diabetology, Institute of Endocrinology, Diabetes and Metabolic Diseases, 
Clinical Center of Serbia, 2Cardiology, Clinical Center Bezanijska Kosa, 
3Statistics, Institute for Medical Statistics and Informatics, Clinical Center of 
Serbia, Belgrade, Serbia.
Background and aims: In metabolic syndrome (MS) patients, abdominal 
obesity accompanied with hyperinsulinism and insulin resistance is related to 
hypertension and lipid status disturbance where thrombotic and inflamma-
tory factors and low antioxidant status and tendency to early atherosclerosis 
are present. Hepatic fat accumulation in childhood obesity is associated with 
increased visceral fat and insulin resistance (IR). IR results in fat deposition 
in the liver and occurrence of non-alcoholic fat liver disease (NAFLD). The 
study was aiming at determining NAFLD and its most important provoking 
factors in MS and pre-metabolic (pre-MS) syndrome patients.
Materials and methods: The study included 173 obese individuals aged 7 
to 30 classified into 3 groups: I-children (7-15), II-adolescents (16-20) and 
III-youth (20-30). Three of the following five criteria were used for meta-
bolic syndrome (MS) diagnosis in adolescents: waist circumference >90Pct; 
triglycerides >1.7mmol/l; HDL-cholesterol<1.0mmol/l; hypertension>90Pct, 
glycemia >6.0mmol/L. ATP III classification was applied for youth. Patients 
with less than three afore mentioned criteria were considered patients with 
pre-MS. OGTT was used to evaluate the extent of disorder. Insulin sensitivity 
was determined by HOMA IR. PAI-1 was determined by plasminogen sub-
strate assay. SGOT, SGPT and γ-GT were considered liver function param-
eters. Liver ultrasonography was used to diagnose NAFLD.
Results: NAFLD, increasing considerably with age, was found in 7.3% children, 
18.9% adolescents and 29.0% youth (p<0.05). NAFLD existed in 17.5% pre-MS 
and 29.0% MS patients. NAFLD found by groups: pre-MS patients - I-11.5%, 
II-17.7%, III-20.4%; MS patients - II-20.4%, III-40.0%. Logistic regression analy-
sis indicated the most important NAFLD factors: body weight - odds ratio (OR) 
1.039, p<0.001; LDL-cholesterol OR 1.55, p<0.05; creatinine clearance OR 1.01, 
p<0.05; uric acid OR 1.00, p<0.05; insulins - 0min OR 1.012, p<0.002, 120min 
OR 1.008, p<0.001; HOMA IR OR 1.059, p<0.001; PAI-l OR 2.79, p<0.001; SGPT 
OR 1.27, p<0.001. Patients with NAFLD had increased WC (110.7±11.9cm), 
LDL-cholesterol (3.3±1.0mmol/l), triglycerides (1.81±1.15mmol/l), uric acid 
(383.8±86.3), insulins 0min (61.1±81.3U/l) and 120min (93.1±108.4U/l), HOMA 
IR (14.7±4.4±19.3µmol/mU/ml), PAI-1 (7.3±0.6U/ml), SGPT (56.7±20.9U/l), γ-
GT (44.1±22.8U/l). Patients without NAFLD had normal SGPT, γ-GT, uric acid 
and increased WC (98.6±16.7cm), insulins 0min (21.6±31.3U/l) and 120 min 
(44.3±49.5U/l), HOMA IR (6.2±3.4µmol/mU/ml), triglycerides (1.74±1,63mmo/
l), PAI-1 (6.0±1.4U/ml) but lower than NAFLD patients.
Conclusion: Obesity, hyperinsulinemia with IR (characterized by increased 
uric acid and PAI-1), SGOT and LDL-cholesterol are the most frequent risk 
factors for NAFLD. NAFDL may be the liver sign of pre-MS and MS children, 
adolescents and youth associated with visceral obesity, IR, lipid status distur-
bance, thrombotic and inflammatory factors.
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Steatohepatitis is closely associated with insulin resistance and the 
metabolic syndrome from early stages of their development
Y. Mori1, K. Ura2, K. Matsuura1, Y. Itoh1, J. Yokoyama1, N. Tajima1; 
1Department of Internal Medicine, Jikei University School of Medicine, 
Tokyo, 2Department of Internal Medicine, Utsunomiya Memorial Hospital, 
Utsunomiya, Japan.
Background and aims: Non-alcoholic fatty liver disease (NFALD), insulin 
resistance, and the metabolic syndrome were examined for correlation in in-
dividuals undergoing elaborate health checkup programs with the influence 
of abdominal obesity being ruled out.
Materials and methods: Of the 909 subjects undergoing the health checkups, 
626 individuals who underwent a 75 g OGTT and were evaluated by abdomi-
nal ultrasound for fatty liver and the metabolic syndrome were enrolled in 
the study, and 130 individuals each with fatty liver (fatty liver group; FLG) 
and without fatty liver (non-fatty liver group; NFLG), who were matched 
for gender, age, BMI, and waist circumference, were compared for relevant 
biochemical parameters, insulin resistance, number of risk factors implicated 
per individual, and frequency of the metabolic syndrome detected.
Results: There was no significant difference between the FLG and the NFLG 
in the male to female ratio (%), age, BMI (24.8 ± 2.9 and 24.2 ± 1.8, respec-
tively), and waist circumference (85.8 ± 6.6 and 84.5 ± 5.8, respectively). In 
contrast, significantly higher values were noted in the FLG than in the NFLG 
with regard to the area under the glucose curve at 75 g OGTT (363.0 ± 81.3 
versus 319.0 ± 70.6; P < 0.001), area under the insulin curve (109.0 ± 80.4 ver-
sus 76.1 ± 45.1; P < 0.001), HOMA-R index (1.73 ± 1.24 versus 1.17 ± 0.56; P 
< 0.001), HbA1c, AST, ALT, TG, and LDL-C, while HDL-C was significantly 
lower in the FLG than in the NFLG. Additionally, significantly higher values 
were noted in the FLG than in the NFLG with regard to the number of risk 
factors implicated per individual (1.83 ± 1.15 versus 1.37 ± 1.09; P < 0.001), 
frequency of the metabolic syndrome detected (30/130, 23.1% versus 14/130, 
10.8%; P < 0.05).
Conclusion: Study results suggested that NAFLD is closely associated with 
insulin resistance and the metabolic syndrome even when the influence of 
abdominal obesity is excluded. It was further suggested that, given the BMI of 
< 25 kg/m2 and the waist circumference of no more than 85 cm in the subjects, 
NAFLD appears to be implicated in the pathogenesis of insulin resistance and 
the metabolic syndrome from quite early stages of their development.
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Distinctive metabolic signature in subjects with early onset type 2 
diabetes
K. Wanic1, A. Pazderska1, S. Shah1, D. O’Hanlon1, J.R. Bain2, R.D. Stevens2, 
C.B. Newgard2, J.J. Nolan1; 
1St. James’s Hospital, Trinity College Dublin, Metabolic Research Unit, 
Ireland, 2Duke University, Durham, USA.
Subjects with early onset type 2 diabetes have severe insulin resistance, re-
duced VO2 max response to exercise, and abnormal mitochondrial function 
relative to equally obese insulin resistant control subjects. Having previously 
used a metabolomics approach to demonstrate that obese insulin resistant 
subjects have a distinct metabolic profile compared to lean controls, we 
have now studied subjects with early-onset type 2 diabetes. We used tar-
geted MS/MS and GC/MS-based metabolomics to measure fasting plasma 
concentrations of amino acids and total and free fatty acids in 24 subjects 
with early onset type 2 diabetes (mean age 26.1, BMI 35.6 kg/m2), 17 obese 
controls (mean age 22.8, BMI 34.2 kg/m2) and 28 lean controls (mean age 
24.7, BMI 22.4 kg/m2). Confirming previous studies, the obese subjects had 
increased levels of branched-chain and other amino acids, total non-esteri-
fied fatty acids (NEFA), and several individual fatty acid species compared to 
lean controls. Interestingly, subjects with type 2 diabetes exhibited additional 
increases in levels of valine, leucine/isoleucine, glutamate/glutamine, and as-
partate/asparagine, as well as NEFA and individual fatty acids compared to 
obese controls. Insulin resistance, measured by HOMA-IR correlated with 
concentrations of valine, leucine, histidine and glutamate. 
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Parameter studied (μM) Early onset type 2 Obese controls Lean controls P value (1 vs. 2) P value (1 vs. 3)
L-valine 298 261 214 0.031 <0.001
L-leucine/isoleucine 206 170 151 0.004 <0.001
L-aspartic acid/aspargine 103 78 70 0.009 <0.001
L-glutamic acid/glutamine 101 87 71 0.04 <0.001
Histidine 80 92 72 0.02 0.01
Total fatty acids 15424 13004 9520 0.039 <0.001
Palmitic acid (C16:0) 2629 2125 1442 0.021 <0.001
Oleic acid (C18:1) 4881 3703 2385 0.025 <0.001
Stearic acid (C 18:0) 41 31 25 0.012 <0.001
We conclude that subjects with early-onset type 2 diabetes have a metabo-
lomic profile distinguishing them from BMI-matched insulin resistant indi-
viduals with normal glucose tolerance. Further studies are needed to assess 
whether these changes are a reflection of altered mitochondrial function in 
these subjects.
Supported by: an EFSD/Novo Nordisk grant
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Insulin resistance is associated with metabolic syndrome but not with 
angiographically determined coronary artery disease in female patients 
A. Vonbank1,2, C.H. Saely1,2, P. Rein1,2, S. Beer1,2, C. Boehnel1,2, V. Jankovic1,2, 
H. Drexel1,2; 
1Vorarlberg Institute for Vascular Investigation and Treatment, Feldkirch, 
Austria, 2Private University of the Principality of Liechtenstein, Triesen, 
Liechtenstein.
Background and aims: Insulin resistance (IR) is the key feature of the meta-
bolic syndrome (MetS) and in prospective studies predicts atherothrombotic 
events. Its association with directly visualised coronary atherosclerosis, es-
pecially in female patients, is unclear. We hypothesised that IR is associated 
with both angiographically determined coronary artery disease (CAD) and 
with the MetS.
Material and methods: We enrolled 354 consecutive female patients under-
going coronary angiography for the evaluation of suspected or established 
stable CAD; significant CAD was diagnosed in the presence of significant 
coronary stenoses with lumen narrowing ≥50%. IR was determined by the 
HOMA index; the MetS was defined according to ATPIII criteria.
Results: HOMA-IR scores were significantly higher in MetS female patients 
than in female subjects without the MetS (4.9 ± 4.7 vs. 1.9 ± 1.1; p <0.001). 
In contrast HOMA-IR did not differ significantly between patients with sig-
nificant CAD and those who did not have significant CAD 3.3 ± 3 vs. 3.1 ± 
3; p = 0.823). When both, the presence of MetS and of significant CAD were 
considered, HOMA-IR was significantly higher in patients with the MetS 
both among those who had significant CAD (4.9 ± 4.8 vs. 1.9 ± 1.1; p <0.001) 
and among those who did not have significant CAD (5.0 ± 4.7 vs. 1.9 ± 1.1; p 
<0.001) whereas it did not differ significantly between patients with signifi-
cant CAD and subjects without significant CAD in patients with the MetS 
(5.0 ± 4.7 vs. 4.9 ± 4.8; p = 0.383) nor in those without MetS (1.9 ± 1.1 vs. 1.9 
± 1.0; p = 0.860). Similar results were obtained with the IDF definition of the 
metabolic syndrome.
Conclusion: In female patients IR is significantly associated with the MetS 
but not with angiographically determined coronary atherosclerosis.
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Obstructive sleep apnoea and metabolic abnormalities in type 2 diabetes
S.K. Wangnoo1, M.A. Siddiqui1, M. Gupta1, M.S. Kanwar2; 
1Endocrinology, 2Pulmonary Medicine, Apollo Hospital, New Delhi, India.
Background and aims: The burgeoning load of type 2 diabetes is a major 
public health concern in our part of the world with high morbidity, mortal-
ity, and health-care costs. Recent reports have indicated that the majority of 
patients with type 2 diabetes also have obstructive sleep apnea (OSA). There 
is compelling evidence that OSA is a significant risk factor for cardiovascular 
disease and mortality. Because both diabetes and OSA are associated with 
increased cardiovascular morbidity and mortality, it is possible that the pres-
ence of both conditions results in additive or even synergistic health risks. 
The aim of this study was to evaluate the prevalence of OSA in the study 
population and its effect on the metabolic profile.
Materials and methods: After taking the informed consent of the subjects, 
we performed polysomnography studies in 30 consecutive patients with 
diabetes and obesity according to the Asian-Indian criteria recruited from 
outpatient clinics between July 2009 and January 2010. Apnoea- hypopnoea 
index (AHI) > or = 10/hour was considered relevant for OSA diagnosis. Sub-
jects with AHI< 10 were considered as controls. We assessed AHI, Epworth 
sleepiness scale (ESS), body mass index (BMI, kg/m2), glycosylated haemo-
globin (HbA1c, %), fasting serum total cholesterol (mg%), HDL-(mg%), 
LDL-cholesterol(mg%), triglycerides (TG) (mg%), HOMA index and highly 
sensitive C-reactive protein (hsCRP, mg/l).
Results: Data are presented as mean +/- SD or median (interquartile range) 
for parametric and nonparametric data respectively. 22 out of 30 subjects 
(73%) of with diabetes had OSA (AHI > or =10). AHI in the OSA group was 
21 (16-30) and 5 (3-8) in controls (p < 0.001). BMI was higher in OSA (33.8 
+/- 5.8) vs. controls (29.4 +/- 3.1) (p = NS). Patients with OSA had higher 
HbA1c (9.72 +/- 0.9) vs. (8.94 +/- 0.8)( p = 0.03), TG (210 +/- 55.2) vs. (140.2 
+/- 41.9) (p = 0.046), HOMA-IR (2.35 +/- 1.6) vs. (1.93 +/- 1.5)( p = 0.046) 
and hsCRP (4.2 +/- 0.9) vs. (2.89 +/- 1.4)( p = 0.01). HDL-cholesterol was 
lower in OSA group compared to control (30.8 +/- 6.1 vs. 40.3 +/- 11.4) (p = 
0.02). HbA1c correlated best with AHI(p < 0.001, r = 0.39).
Conclusion: Identifying the possibility of previously unrecognized OSA 
amongst patients with diabetes is important for treating physicians even in 
the absence of specific symptoms. The high prevalence of OSA in obese pa-
tients with type 2 diabetes is also associated with more severe metabolic de-
rangements and its treatment along with adjustment of antidiabetic therapy 
may ameliorate some of the associated morbidity and mortality.
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High dietary fat consumption decreases hepatic glucokinase activity and 
net hepatic glucose uptake in the absence of impaired insulin signalling 
in dogs
K.C. Coate, G. Kraft, B. Farmer, M. Smith, M. Shiota, A.D. Cherrington; 
Molecular Physiology and Biophysics, Vanderbilt University, Nashville, 
USA.
Background and aims: High dietary fat consumption has been associated 
with a reduction in insulin’s ability to suppress hepatic glucose production 
during euglycemia, but its impact on net hepatic glucose uptake (NHGU) 
and disposition during hyperglycemia (HG) has not been determined. The 
purpose of the present study was to elucidate the effect of high fat feeding on 
the ability of the liver to take up glucose in the presence of hyperinsulinemia 
(HI), HG and the portal glucose signal (PS).
Materials and methods: Adult male dogs were fed either a high fat diet 
(HFD, % kcal: 53% fat, 21% protein, 26% carbohydrate; n=4) or a chow con-
trol diet (CTR, % kcal: 26% fat, 31% protein, 43% carbohydrate; n=5) for 4 
weeks. Dogs underwent hepatic/portal vein catheterization at 2 weeks and 
an HIHG clamp 2 weeks later. Somatostatin was infused peripherally (Pe) to 
disable the endocrine pancreas while glucagon (basal) and insulin (4x basal) 
were replaced intraportally (Po). The glucose load to the liver was doubled 
first by infusing glucose Pe (Period 1; P1), then by infusing glucose Po (PS; 
22.2 µmol/kg/min) and Pe (Period 2; P2).
Results: When challenged with HI and HG (P1), NHGU (µmol/kg/min) was 
significantly lower in the HFD group (0.0±0.0.5) compared to the CTR group 
(9.4±1.1, P<0.01). Consistent with this finding, glycogen synthesis (µmol/kg/
min; HFD: -1.4±0.3 [breakdown], CTR: 4.0±1.7, P<0.01) and net hepatic lac-
tate output (µmol/kg/min; HFD: 2.9±0.4, CTR: 6.8±0.9, P<0.01) were also 
significantly lower in the HFD group compared to the CTR group. On the 
other hand, Po glucose delivery (PS; P2), elicited a comparable increase in 
NHGU (ΔP1-P2, µmol/kg/min; HFD: 8.2±1.7, CTR: 9.0±2.6, P=0.7) and 
glycogen synthesis (ΔP1-P2, µmol/kg/min; HFD: 9.0±2.7, CTR: 10.9±2.5, 
P=0.8) in both groups, suggesting that the portal glucose signal was still effec-
tive in the HFD group. Terminal liver biopsies revealed a reduction (≈20%) in 
glucokinase (GK) total protein content coincident with a significant decrease 
(≈48%, P<0.01) in GK activity (U/g liver) in the HFD group (2.3±0.4) com-
pared to the CTR group (4.4±0.5). Surprisingly, the decrease in GK protein 
was not the consequence of attenuation in insulin signal transduction given 
that phosphorylation of IRS1-Y1222 and Akt-S473 was similar between the 
HFD and CTR groups.
Conclusion: Four weeks of HFD consumption impaired the effect of hyper-
insulinemia and hyperglycemia on NHGU and glycogen synthesis; however, 
it did not alter the response of either to the portal glucose signal. Although 
the HFD was associated with a decrease in hepatic GK activity, this was not 
due to a reduction in the activation of either IRS1 or Akt. These data suggest 
that alternative control mechanisms are involved in the regulation of hepatic 
GK, and these may have a significant impact on the ability of the liver to take 
up glucose.
Supported by: NIH
624
Hepatic glycogen supercompensation reduces glycogen synthesis without 
altering net hepatic glucose uptake in dogs
J.J. Winnick, Z. An, M. Smith, W. Snead, A.D. Cherrington; 
Molecular Physiology & Biophysics, Vanderbilt University, Nashville, USA.
Background and aims: A hallmark characteristic of diabetes mellitus is glu-
cose intolerance, which is manifest by postprandial hyperglycemia. Because 
one-third of an oral glucose load is taken up and metabolized by the liver, 
efforts are underway by pharmaceutical companies to create medications that 
would increase liver glucose uptake and glycogen synthesis during the post-
prandial state. While both hyperinsulinemia and portal vein glucose infusion 
have been shown to stimulate hepatic glucose uptake, little is known about 
how an increase in the hepatic glycogen content could affect the responses 
of the liver to these stimuli. Thus, the purpose of this study was to determine 
how an acute increase in hepatic glycogen affects the liver’s ability to take up 
and metabolize glucose in response to hyperglycemic/hyperinsulinemia or 
portal glucose infusion.
Materials and methods: During the first 4h of each study, all dogs received 
somatostatin and basal amounts of intraportal insulin and glucagon. Blood 
glucose was doubled by glucose infusion into a peripheral vein and either 
saline (SAL; n=13) or fructose (5.5 µmol/kg/min; FRU; n=13) was infused in-
traportally; the latter to trigger liver glycogen loading. The glycogen loading 
period was followed by a 2h control period, during which basal replacement 
of hormones was continued but fructose was not infused. A 2h experimental 
period followed, during which hyperglycemia was maintained. One subset of 
animals from each group received 4x basal insulin (SAL-INS; n=7 and FRU-
INS; n=6) while another received an intraportal glucose infusion (22 µmol/
kg/min; SAL-PG; n=6 and FRU-PG; n=7) to assess the effect of the hepatic 
glycogen content on net hepatic glucose uptake (NHGU) and disposition.
Results: Fructose infusion led to marked differences in hepatic glycogen 
(345±17 and 538±24 µmol/g liver in SAL and FRU, respectively). The large 
difference in glycogen had no effect on NHGU (µmol/kg/min) seen in re-
sponse to hyperinsulinemia (16±4 and 15±4 in SAL-INS and FRU-INS, re-
spectively) or portal vein glucose infusion (19±2 and 17±2 in SAL-PG and 
FRU-PG, respectively). On the other hand, the percentage of NHGU that 
was directed to glycogen was reduced (p<0.04) by hepatic glycogen super-
compensation during hyperinsulinemia (70±3 and 58±10% in SAL-INS and 
FRU-INS, respectively) and during portal vein glucose infusion (70±6 and 
54±3% in SAL-PG and FRU-PG, respectively). Furthermore, these reduc-
tions in glycogen synthesis were accounted for primarily by an increase in 
liver lactate output (p<0.05) during both hyperinsulinemia (16±3 and 33±8% 
in SAL-INS and FRU-INS, respectively) and in response to portal vein glu-
cose infusion (27±6 and 38±4% in SAL-PG and FRU-PG, respectively).
Conclusion: Our data show that acutely increasing the glycogen level from 
~350 to ~540 µmol/g had no observable effect upon NHGU, although it caused 
a reduction in hepatic glycogen synthesis and a compensatory increase in 
lactate output. Since the reduction in glycogen synthesis seen in response to 
hyperinsulinemia vs. portal vein glucose infusion were similar, altered activ-
ity of glycogenic enzymes are likely responsible for the diminished glycogen 
synthesis associated with glycogen supercompensation. Thus, as medications 
are developed to increase postprandial hepatic glucose disposal it should be 
remembered that although high glycogen levels will not inhibit NHGU, they 
will increase carbon flux through non-glycogenic pathways.
Supported by: NIDDK
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Per2 plays a major role in the control of liver glycogen metabolism and 
fasting glycaemia
F. Zani1, B. Becattini1, A. Provenzani2, A. Stauffer3, J.-P. Montani1,  
U. Albrecht3, G. Solinas1; 
1physiology, university of Fribourg, Switzerland, 2University of Trento, Italy, 
3Biochemistry, University of Fribourg, Switzerland.
Background and aims: Recent evidence suggests that obesity-induced de-
rangements of the expression of molecular components of the circadian clock 
may be implicated in the development of glucose intolerance. The aim of this 
study was to investigate the role of the clock protein period 2 (Per2), a key 
component of the circadian clock whose expression is deranged during obes-
ity, in glucose homeostasis in lean and obese mice.
Materials and methods: To investigate the role of Per2 in glucose metabo-
lism in-vivo we used mice bearing a targeted gene mutation in the Per2 gene 
(Per2brdm) and thus unable to express a functional Per2 protein. Mice were 
hosted in our standard mouse facility in a 12-hour light and 12-hour dark 
cycle. Wt and Per2brdm mice were fed with either standard chow diet or 
high-fat diet for 24 weeks and analyzed for glucose homeostasis. Glucose tol-
erance test (GTT) and insulin tolerance test (ITT) were performed on mice 
food deprived for 7 hours. For pyruvate tolerance test (PTT) mice were fasted 
for 14 hours. Glucose levels were measured over 12 hours starvation time-
courses during the light and the dark phase. Fed and fasting blood glucose 
and hepatic glycogen content were measured over different circadian time-
points. To investigate the role of Per2 in the control of liver gene expression 
we performed DNA-microarray analysis of RNA preparations from liver of 
Per2brdm and WT mice. Results were validated by QPCR.
Results: Our results suggest that Per2 loss of function is not a basic require-
ment for the development of obesity-induced insulin resistance. Per2brdm 
mice show similar glucose tolerance compared to WT mice when placed on 
chow diet, and Per2 loss of function does not predispose to high-fat diet-
induced insulin resistance. However, we have identified an important role 
for Per2 in the control of fasting glycemia and hepatic glycogen metabolism. 
Per2brdm mice show a decreased fasting glycemia compared to WT controls 
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during the light phase. This difference is observed after 4 hours of food dep-
rivation, is maximal at 7-8 hours of starvation, and disappears after about 12 
hours of starvation. Gene expression-signature analysis from the microar-
ray data indicates decreased expression of genes involved in gluconeogenesis 
and glycogen metabolism in livers from Per2brdm mice compared to livers 
from WT mice. PTT was performed to evaluate whole body gluconeogen-
esis. The results show that WT and Per2brdm mice display similar gluco-
neogenic potential in a PTT test. To evaluate the role of Per2 in glycogen 
metabolism we measured hepatic glycogen content in fed or 8 hours fasted 
WT and Per2brdm mice. The results show that fed Per2brdm mice display 
lower liver glycogen content during the light phase compared to WT controls. 
This difference is more pronounced in mice that were starved for 8 hours with 
Per2brdm mice displaying less than a third of the hepatic glycogen content 
compared to control WT mice (p-value < 0.005).
Conclusion: Our data suggest that Per2 loss of function is not a major cause 
or a predisposition factor to impaired glucose tolerance. Nonetheless our re-
sults suggest that Per2 plays an important role in the control of fasting glyc-
emia and in hepatic glycogen metabolism.
Supported by: Swiss National Science Foundation
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Evidence for a key role of hepatic mitochondrial phosphoenolpyruvate 
carboxykinase in glucose homeostasis in vivo
R. Stark1, C.N. Feriod1, X. Zhao1, J. Dong1, S. Bhanot2, M. Roden3,  
G.I. Shulman1, R.G. Kibbey1; 
1Internal Medicine/Endocrinology, Yale University School of Medicine, 
New Haven, USA, 2Internal Medicine/Endocrinology, Isis Pharmaceuticals, 
Carlsbad, USA, 3German Diabetes Center, Dusseldorf, Germany.
Background and aims: The cytosolic isoform of phosphoenolpyruvate car-
boxykinase (PEPCK-C) is generally regarded as the primary enzyme that 
provides PEP for gluconeogenesis and glyceroneogenesis. The metabolic role 
of the mitochondrial isoform, PEPCK-M, however, has not been established. 
In contrast to PEPCK-C whose transcription is strongly inhibited by insulin, 
we hypothesized that the constitutively expressed PEPCK-M isoform, might 
instead be regulated in response to fuel supply by mitochondrial GTP- a 
known sensor of mitochondrial metabolic flux in the pancreatic beta-cells.
Materials and methods: To assess its role, PEPCK-M was silenced using 
siRNA in primary rat hepatocytes and in vivo with antisense oligonucleotides 
in young, weight-matched Sprague Dawley rats. Gluconeogenesis rates in he-
patocytes were assessed using 13C-labeled substrates with analysis by mass 
spectroscopy. Live awake rats were studied by euglycemic hyperinsulinemic 
clamps and a 36-hour fast.
Results: An 80% reduction of PEPCK-M mRNA in hepatocytes reduced glu-
coneogenesis by 60% (P<0.001). Similar reductions in gluconeogenesis with 
PEPCK-M silencing were observed regardless of the presence of glucose, 
glucagon, or insulin. PEPCK-M message was silenced 80% in liver and the 
plasma glucose was significantly reduced in fed rats (160±4 vs. 146±5 mg/dl, 
P<0.05) but was equivalent following a 36 hour fast (115±2 vs. 116±2 mg/dl, 
P=0.88). Similarly, fed insulin was reduced (57±6 vs. 35±6, P<0.02) but not 
with fasting (19±3 vs. 18±6 μU/ml, P=0.87). Euglycemic hyperinsulinemic 
clamps identified significantly increased insulin sensitivity when PEPCK-M 
was silenced (GINF: 20±1 vs. 26±1 mg/kg/min, P=0.003) that could not be 
accounted for by differences in endogenous glucose production nor uptake 
in the muscle or adipose. Interestingly, post-absorptive hepatic glycogen was 
82% lower and plasma triglycerides 42% lower along with a 25% reduction in 
WAT suggesting a constitutive defect in PEP production.
Conclusion: These data from silenced PEPCK-M both in primary hepato-
cytes and in vivo support an important role for PEPCK-M in glucose ho-
meostasis via gluconeogenesis and possibly glyceroneogenesis. Because of the 
beneficial effects of lowering glucose, insulin, triglycerides and fat mass with 
a concomitant increase in insulin sensitivity but without hypoglycemia fol-
lowing a prolonged fast, PEPCK-M may be an attractive target for the treat-
ment of type-2 diabetes.
Supported by: ADA, NIH
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Farnesoid X Receptor inhibits glucose-induced LPK gene expression 
by interfering with Carbohydrate Response Element Binding Protein 
(ChERBP) activity
C. Huaman, S. Caron, H. Dehondt, F. Lien, O. Briand, P. Lefebvre, B. Staels; 
Inserm u1011, Récepteurs Nucléaires, Maladies Cardiovasculaires et 
Diabète, Lille, France.
Background and aims: Carbohydrate response element binding protein 
(ChREBP) is a transcription factor which can be activated in response to glu-
cose to induce the expression of the glycolytic gene Liver Pyruvate Kinase 
(LPK) as well as some lipogenic genes such as Fatty Acid Synthase (FAS) and 
Acetyl CoA Carboxylase (ACC1). Previous works in our team have shown 
that the activation of nuclear receptor FXR (Farnesoid X Receptor) inhibits 
the glucose-mediated induction of these genes. Our aim is to unravel the mo-
lecular mechanisms undergoing the negative effect of FXR on the expression 
of glycolytic and lipogenic genes.
Materials and methods: Two human hepatocyte cell lines, IHH and Hepa-
RG, were treated with different glucose concentrations and with FXR agonist 
GW4064. Real-time PCR experiments were performed to analyse the expres-
sion of the LPK gene. Western blot analysis was used to study the nuclear 
localisation of ChREBP. Chromatine immunoprecipitation (ChIP) experi-
ments were performed to follow the binding of ChREBP and FXR to the LPK 
promoter under different experimental conditions.
Results: We show that FXR activation inhibits the glucose-mediated in-
duction of the LPK gene expression. Our hypothesis is that this inhibition 
could be due to an interference of FXR with ChREBP transcriptional activity. 
Our results show that the nuclear receptor FXR interacts physically with the 
transcription factor ChREBP but this interaction does not interfere with the 
nuclear translocation of ChREBP or its binding to the LPK promoter. Recent 
results suggest that the activation of FXR leads to a recruitment of Histone 
Deacetylases (HDAC) to the LPK promoter since a treatment with Tricho-
statin A blocks the FXR effect on the LPK gene expression.
Conclusion: These results demonstrate that FXR plays an important role in 
regulating the glucose-mediated induction of glycolysis and lipogenesis by 
interfering with ChREBP transcriptional activity.
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Comparison of direct and indirect pathways of hepatic glycogen 
synthesis using the [1-13C]glucose and deuterated water methods in fed 
and healthy subjects
C. Barosa1, A. Fagulha2, L. Barros2, M. Caldeira3, M. Carvalheiro2, J. Jones1; 
1Center for Neurosciences and Cell Biology, Coimbra, 2Department of 
Endocrinology, University Hospital of Coimbra, 3Department of Chemistry, 
University of Coimbra, Portugal.
Background and aims: Hepatic glycogen is synthesized by two distinct pro-
cesses: the classical direct pathway from intact glucose units, and the indirect 
pathway involving 3-carbon intermediates. It is now well established that the 
direct pathway is the major route of hepatic glycogen synthesis in healthy 
subjects but its contribution is significantly reduced in both Type 1 and Type 
2 diabetes. Direct and indirect pathway activities can be safely and noninva-
sively measured using stable isotope tracers to label the glycogen precursors 
and glucuronidation probes such as Paracetamol to sample the enrichment 
of UDP-glucose from these tracers. The analysis can be applied in a routine 
clinical setting and could potentially be a diagnostic tool for assessing hepatic 
glucose and glycogen metabolism. [1-13C]glucose is the most widely used 
tracer to quantify the contribution of the direct and the indirect pathways to 
the glycogen synthesis but it is relatively expensive. Moreover, both plasma 
and urine need to be collected and analyzed for 13C-enrichment analysis 
thus incurring a significant analytical burden. Deuterated water (2H2O) has 
advantages over [1-13C]glucose since it is less expensive and the analysis only 
requires a single urine sample. To date, the two tracers have not been veri-
fied against each other. Therefore, we administered both [1-13C] glucose and 
2H2O to healthy subjects and compared the direct/indirect pathway contri-
butions from both tracers for each subject.
Materials and methods: Six overnight-fasted healthy young subjects took a 
breakfast, were the CHO portion included 10 grams of [1-13C] glucose. A 
2H2O load was ingested to attain body water 2H-enrichment of 0.3%. This 
enrichment was maintained throughout the study by providing drinking wa-
ter enriched with 0.3% 2H2O. Paracetamol was taken for UDPG sampling 
as urinary Paracetamol glucuronide and a blood sample was also collected. 
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Paracetamol glucuronide and blood glucose were derivatized to MAG for 1H, 
2H and 13C NMR analysis. Body water 2H-enrichment was also quantified 
by 2H NMR. Direct pathway from [1-13C] glucose ingestion was calculated 
by the analysis of excess 13C enrichment of C1 and C6 of MAG obtained 
from both glucuronide and plasma. Direct pathway from 2H2O was obtained 
from the 2H5/body water ratio.
Results: Direct pathway measured by 13C and 2H was 59% ± 7.34 and 61% ± 
1.88 respectively while indirect pathway was 41% ± 7.34 and 39% ± 1.88. Data 
are presented as means ± standard errors.
Conclusion: In conclusion, direct and indirect pathway measured by 13C 
analysis after ingestion of [1-13C] glucose in the postprandial state, matches 
the data obtained by 2H NMR analysis of 2H enrichment from 2H2O under 
the same conditions.
Supported by: JDRF
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New aspects of hepatic glucose phosphorylation by intracellular 
glucokinase localisation
M.T. Kaminski1, S. Lenzen1, S. Baltrusch1,2; 
1Institute of Clinical Biochemistry, Hannover Medical School, 2Institute 
of Medical Biochemistry and Molecular Biology, University of Rostock, 
Germany.
Background and aims: Coupling of millimolar glucose concentrations to 
liver metabolism is mediated by the glucose phosphorylating enzyme glu-
cokinase (GK) and vital to maintain glucose homeostasis. Only in liver a spe-
cific glucokinase regulatory protein (GRP) inhibits GK activity and mediates 
the GK nuclear import at low glucose. It is poorly understood so far whether 
GRP affects GK nuclear export at high glucose concentrations. Therefore one 
aim of this study was to elucidate the role of the GRP in GK nuclear export. 
Furthermore, a function of GK in the nucleus has not yet been ascertained. 
Recently we could establish a fluorescence resonance energy transfer (FRET) 
based glucose specific nanosensor (FLIPglu) to monitor intracellular glucose 
flux. Thus a second aim of this study was to characterize glucose uptake and 
metabolism in hepatocytes with respect to the cytoplasmic and nuclear com-
partments.
Materials and methods: Localization and translocation of GK and GRP were 
analyzed in primary rat hepatocytes in comparison to MIN6 beta cells by 
ECFP and EYFP fluorescent fusion proteins and through fluorescence dis-
tribution after photoconversion of a Dendra2 or PA-GFP fusion protein, re-
spectively. Dynamic changes in the nuclear and cytoplasmic glucose concen-
tration were determined in perifusion experiments in primary hepatocytes, 
COS cells and MIN6 cells expressing either the cytoplasmic FLIPglu or the 
nuclear FLIPglu-nuc.
Results: In hepatocytes a higher portion of the GRP has been identified in 
the nucleus compared to the cytoplasm. The nuclear/cytoplasmic ratio of the 
GRP was only marginally affected by glucose. In contrast the nuclear/cyto-
plasmic ratio of glucokinase was significantly higher at low as compared to 
high glucose. In MIN6 cells endogenously expressing GK but not GRP, com-
parable results were observed after overexpression of an EYFP-GRP protein. 
By selective photoconversion it was demonstrated that one fraction of the 
GRP protein pool in hepatocytes continuously shuttled between the nucleus 
and the cytoplasm, both at high and low glucose. While the cytoplasmic frac-
tion of the GRP was completely mobile, in the nucleus an immobile fraction 
of the GRP was elucidated. Using compartment specific FLIPglu sensor ex-
pression it was shown that the cytoplasmic glucose uptake was accompanied 
by an only slightly time-delayed nuclear glucose uptake irrespective of the 
analyzed cell type. Interestingly, after removal of extracellular glucose the 
nuclear glucose concentration decreased twofold faster in hepatocytes com-
pared to MIN6 cells and COS cells, which indicates that glucose phosphor-
ylation takes place only in the nucleus of hepatocytes, where GK is present.
Conclusion: GK leaves the nucleus in a glucose dependent, but GRP inde-
pendent manner. For the first time we have shown that after dissociation 
from the GRP, GK is active in the nucleus of hepatocytes. Our results open 
new therapeutic perspectives for the development of liver specific GK activat-
ing compounds interfering with the GK-GRP interactions.
PS 48 Clinical insulin resistance - 
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Insulin resistance alters post-prandial haemodynamic parameters: an 
impedance cardiography approach 
S. Vigili de Kreutzenberg1, F. Boscari1, E. Rossi1, G. Fadini1, G. Ceolotto1, S. 
Guerra2, G. Sparacino2, M. Bottero3, A. Avogaro1; 
1Clinical and Experimental Medicine, Padova University, 2Information 
Engineering, Padova University, 3Cardiology Unit, SS Giovanni e Paolo 
Hospital, Venezia, Italy.
Background and aims: In postprandial state insulin regulates both metabolic 
and cardiovascular responses. In insulin resistance (IR) states, insulin action 
is impaired at both levels. However, the hemodynamic responses of postpran-
dial phase in IR patients are poorly characterized. Impedance Cardiography 
(ICG), a relatively easy-to-use technique, allows a reliable beat-to-beat non 
invasive haemodynamic evaluation. We investigated cardiac/vascular hemo-
dynamic response by ICG technique in fasting and postprandial state, in sub-
jects with and without IR.
Materials and methods: In 66 volunteers (50 male, 16 female, age 48±8 
years), without subclinical atherosclerosis, a mixed meal (10 kcal/kg; 55% 
carbohydrate, 15% proteins, 5% fats) was administered while basal and post-
meal (180 min) continuous ICG monitoring was performed. Insulin sensi-
tivity (Si) was determined by the minimal model analysis, and the follow-
ing haemodynamic parameters were recorded: systolic and diastolic arterial 
blood pressure (BP), heart rate (HR), stroke volume (SV), cardiac index (CI), 
systemic vascular resistance index (SVRI), left cardiac work index (LCWI).
Results: According to the median value of Si (7.27×10-4dl•kg-1•min-1 per μU/
ml) subjects were divided in insulin-resistant (IR; n 33) and insulin sensitive 
(IS; n 33). In fasting condition, IR showed higher values of systolic (p=0.003) 
and diastolic (p=0.002) BP and SVRI (p=0.011), compared to IS. In post-
prandial state vasodilatation was comparable and synchronous (at 30 min) 
in IR versus IS (SVRI respectively -12.7±2.5% and -3.6±2.5%; p M-ANOVA 
0.209), but the subsequent recovery (30-180min) was significantly impaired 
in IR (M-ANOVA 0.018). In post-prandial state haemodynamic parameters 
linked to cardiac function were not statistically different in IR vs IS.
Conclusion: IR subjects show a worse cardiovascular performance compared 
to IS in fasting condition. In post-prandial phase, IR associates with a shorter 
duration of vasodilatation in the absence of an altered cardiac performance. 
Hemodynamic alterations in both fasting and postprandial states are impor-
tant features of insulin resistance.
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Assessment of insulin signalling in isolated circulating leukocytes is 
feasible and parallels whole-body insulin resistance in prednisolone-
treated healthy men
D.H. van Raalte1, M.M.L. Linssen2, E.B.M. Nascimento2, M. Diamant1, 
D.M. Ouwens2,3; 
1Department of Internal Medicine / Diabetes Centre, VU University 
Medical Centre, Amsterdam, Netherlands, 2Department of Molecular 
Cell Biology, Leiden University Medical Centre, Netherlands, 3Institute of 
Clinical Biochemistry and Pathobiochemistry, German Diabetes Centre, 
Duesseldorf, Germany.
Background and aims: Impaired insulin-stimulated glucose disposal in skel-
etal muscle is a hallmark of type 2 diabetes mellitus (T2DM). Thus, several 
defects in the insulin-signalling cascade in skeletal muscle were reported in 
subjects with impaired glucose metabolism or T2DM. Assessment of these 
defects in vivo requires laborious and invasive skeletal muscle biopsies. The 
aim of this study was to investigate whether it would be feasible to measure 
insulin signalling in more easily accessible circulating leukocytes. To this end, 
healthy men were treated with low- or high dose prednisolone in order to 
induce various levels of insulin resistance.
Materials and methods: Healthy men (n=21; mean±SE: age: 21±2; BMI: 
22±2) underwent a hyperinsulinaemic-euglycaemic clamp at baseline and 
on day 14 of treatment with either prednisolone 30 mg daily (PRED30), 
prednisolone 7,5 mg daily (PRED7.5) or placebo (PLB). Blood samples were 
obtained at t=-5 min, t=5 min, t=10 min and t=20 min during insulin in-
fusion (at 40 mU/m2•min) for isolation of peripheral leukocytes using an 
erythrocyte lysis buffer. The expression and phosphorylation (at Thr246) of 
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proline-rich Akt substrate of 40 kDa (PRAS40), a marker of the insulin-sig-
nalling cascade, was assessed by immunoblotting and densitometry analysis. 
Insulin sensitivity was quantified as the M-value, obtained during 90-120 min 
of insulin infusion.
Results: Both PRED7.5 and PRED30 vs. PLB decreased insulin sensitivity 
(mean difference -2.8±1.0 mg/kg•min, P = 0.03 and -4.5±0.9 mg/kg•min, 
P = 0.001 respectively). Insulin infusion increased phosphorylated PRAS40 
(P-PRAS40)/total PRAS40 ratio at t=5 min, t=10 min and t =20 min as com-
pared to t=-5 min by 35% (P < 0.05 for all). During treatment, P-PRAS40/to-
tal PRAS ratio was decreased in the PRED30 group (P = 0.05), but not in the 
PRED7.5 arm. The change in P-PRAS40/total PRAS40 ratio during treatment 
correlated with the change in M-value (R=0.447, P = 0.042).
Conclusion: Molecular aspects of insulin signalling and changes thereof can 
be measured in peripheral leukocytes and correlate with whole-body insulin 
sensitivity. Although the physiological role of these assessments in leukocytes 
requires further study, this method may provide an alternative, less-invasive 
tool to monitor changes in insulin signalling in health and disease.
632
Meal-related increases in microvascular vasomotion are impaired in 
obese individuals
A.J.H. Houben1, A.M. Jonk1, N.C. Schaper1, P.W. de Leeuw1, E.H. Serné2, 
Y.M. Smulders2, C.D.A. Stehouwer1; 
1Dept of Internal Medicine, Maastricht University Medical Centre, 
Maastricht, 2Dept of Internal Medicine, VU Medical Center, Amsterdam, 
Netherlands.
Background and aims: Steady state hyperinsulinaemia during a hyperinsuli-
naemic euglycaemic clamp stimulates endothelium-dependent vasomotion 
as well as capillary recruitment, which contribute to increased glucose up-
take; these phenomena have been shown to be blunted in obesity. If insulin’s 
effects on microcirculatory function indeed play a physiological role in regu-
lating insulin-mediated glucose uptake, such effects should be demonstrable 
not only during steady-state hyperinsulinaemia, but also after meal ingestion. 
The aim of the present study was to investigate the effects of an oral glucose 
load and a liquid mixed meal on cutaneous microvascular vasomotion in lean 
and obese subjects.
Materials and methods: A randomised, placebo-controlled trial was per-
formed in 18 lean (BMI 22.5±1.7 kg/m2) and 13 obese (BMI 34.0±3.5 kg/m2) 
subjects, to examine the effects of a glucose drink (75 g glucose), a 495-kcal 
liquid mixed meal (60% carbohydrates, 25% proteins, 15% fat) or placebo 
(tap water) on microvascular function. Skin blood flow was measured by la-
ser Doppler flowmetry (LDF). Vasomotion was examined by Fourier analysis 
of the LDF signal.
Results: Both the glucose drink and the liquid mixed meal, but not the wa-
ter drink, induced hyperinsulinaemia. The levels of hyperinsulinaemia were 
higher in obese compared to healthy subjects (glucose drink: 98.1±82.5 vs. 
39.2±17.0 mU/l, P<0.05; mixed meal: 99.8±78.9 vs. 52.7±20.5 mU/l P=0.07). 
Water intake did not alter the energy density of any of the five frequency 
components in either the lean and obese group. Intake of the glucose drink 
increased the endothelial component of vasomotion (P<0.05) in lean sub-
jects. In lean subjects, intake of the mixed meal drink increased the energy 
density of all five frequency components (P<0.01, P<0.01, P<0.01, P<0.01, 
and P<0.05, respectively), and the total energy density of the entire spectrum 
(P<0.01). In obese individuals, neither the glucose nor the mixed meal drink 
had any effect on the energy density of the five frequency bands or the total 
energy density. The increase in the energy density of the endothelial, neuro-
genic, and respiratory frequency components and the total energy density in 
lean individuals in response to the mixed meal drink was significantly differ-
ent from the response to the mixed meal drink in obese individuals (P<0.01, 
P<0.05, P<0.05, and P<0.01, respectively).
Conclusion: Our data demonstrate that ingestion of a meal increases mi-
crovascular vasomotion in lean individuals. In addition, we found that the 
increase in microvascular vasomotion with meal ingestion was impaired in 
obese individuals and that this lack of meal-induced stimulation of micro-
vascular vasomotion paralleled blunted insulin-stimulated glucose disposal 
after meal feeding in these subjects. Thus, these data are consistent with a 
physiological role for insulin-stimulated microvascular vasomotion in insu-
lin-mediated glucose uptake in the postprandial state.
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Effects of starvation on insulin sensitivity and glucose metabolism in 
obese patients with type 1 diabetes mellitus
F. Musil, A. Smahelova, A. Ticha, R. Hyspler, J. Lesna, V. Blaha, L. Sobotka; 
Department of Metabolic Care and Gerontology, Charles University and 
University Hospital, Hradec Králové, Czech Republic.
Background and aims: At present time obesity is more frequently connected 
with type 1 diabetes mellitus (T1DM) in western population. The effect of 
reduced energy intake and several days of fasting is not fully known in this 
group of diabetic patients. The aim of our work was to study the influence 
of seven days of starvation on insulin sensitivity and glucose metabolism in 
obese patients with T1DM.
Materials and methods: We studied 14 obese patients with T1DM (42,6±9,4 
years, BMI 32,4±2,1 kg m-2) and 13 non-obese control patients with T1DM 
(36,9±13,9 years, BMI 22,6±2,1 kg m-2). The insulin sensitivity and glucose 
oxidation were measured in obese T1DM patients before starvation, imme-
diately after 7 days of starvation and 21 days thereafter. Control group was 
studied only after overnight starvation. Insulin sensitivity was measured us-
ing hyperinsulinemic euglycemic clamp (the 2-step hyperinsulinemic eug-
lycemic clamp lasting 6 hours, period 1: 0 to 120 minutes 1 IU/kg/min of 
insulin and period 2: 120 to 360 minutes 10 mU/kg/min of insulin - Humulin 
R, Elly-Lilly, USA). Glucose oxidation and non-oxidative glucose disposal 
were measured before and during the clamp by indirect calorimetry - ven-
tilated canopy system (VMAX, Sensormedics, Anaheim, USA). Evaluations 
of urinary urea nitrogen excretion was made to calculate protein oxidation. 
Mean±SD, T-test, ANOVA were used for statistical evaluation.
Results: All patients tolerated the period of starvation. Obese T1DM patients 
lost 6,1±1,1 kg. Glycaemia during starvation was maintained at 5 mmol/l by 
adjustment of basal insulin dose. Starvation reduced insulin-mediated glu-
cose disposal in both phases of clamp (P<0,001). This was caused mainly by 
reduced glucose oxidation after starvation period (P<0,001). Non-oxidative 
glucose disposal was not changed.
Conclusion: One week of starvation transiently decreased insulin mediated 
glucose disposal in obese T1DM patients. This was namely caused by reduced 
glucose oxidation. To our best knowledge we are the first who described this 
effect.
Insulin infusion rate 10mU/kg/min,*P<0,001 obese during the time, 
#P<0,05 obese vs controls
Obese T1DM
(n=14)
Before 
starvation
After star-
vation
21 days after 
starvation
Controls 
(n=13)
Glucose disposal  
(mg/min/kg)
9,69±1,48# 6,78±1,21* 9,31±1,16 12,02±2,16
Glucose oxidation 
(mg/min/kg)
2,81±0,52 0,88±0,98* 2,80±0,67 3,54±1,17
Non-oxidative glucose 
disposal (mg/min/kg)
6,88±1,44# 5,94±0,87 6,51±1,03 8,48±1,58
Supported by: Research projects MSM0021620820, MZO 00179906, IGA MZ 
CR No.NT/11351
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Adipocyte fatty acid binding protein in diabetes mellitus - effects of 
hyperinsulinaemia and acute angiotensin II type 1 receptor blockade
E. Švehlíková1, M. Klementová1, S. Kratochvílová1, J. Kopecký Jr.1, P. Wohl1, 
L. Kazdová1, P. Mlejnek2, M. Pravenec2, M. Hill3, T. Pelikánová1; 
1Diabetes Center, Institute for Clinical and Experimental Medicine, 
2Institute of Physiology, Academy of Sciences of the Czech Republic, 
3Institute of Endocrinology, Prague, Czech Republic.
Background and aims: Beside of its regulatory role in lipid metabolism, adi-
pocyte fatty acid binding protein (A-FABP) has been suggested to be involved 
in the development of insulin resistance. We investigated: a) plasma concen-
trations of A-FABP in parallel with its expressions in subcutaneous adipose 
tissue (SAT) and b) their response to acute hyperinsulinaemia and acute an-
giotensin II type 1 receptor blockade (ARB) in type 2 diabetes.
Materials and methods: 11 patients with type 2 diabetes (D) and 12 healthy 
age-matched control subjects (C) underwent: 1) hyperinsulinaemic-eugly-
caemic clamp (HEC); 2) HEC after acute ARB (losartan 200 mg) (AT-HEC) 
and 3) saline infusion (SAL) as a volume control examination. At 0 min and 
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240 min of the interventions blood sampling for assessment of plasma A-
FABP and needle biopsies of abdominal SAT were performed. Adipose tis-
sue samples were processed for real-time PCR method to quantify gene ex-
pressions of A-FABP, E-FABP (epidermal FABP, a minor FABP-isoform of 
adipose tissue) and PPAR-γ. For statistical analysis ANOVA with repeated 
measures was used (significances in Table: a Treatment effect p<0.05 - differ-
ence between interventions: HEC vs. AT-HEC vs. SAL; b Time effect p<0.05 
- changes between time points: 0 min vs. 240 min).
Results: Plasma A-FABP was 1.6-fold higher in D relative to C (p<0.001). 
In D, a comparable decrease in plasma A-FABP was detected during both 
clamps, whereas no changes were observed during SAL. In C, time profiles 
of A-FABP differed between the clamps, showing an increase in basal con-
centrations in AT-HEC. A-FABP expression in SAT was 3.0-fold higher in 
D (p<0.001) without any dynamic changes during all interventions. Plasma 
A-FABP correlated positively with its expression (r=+0.59; p<0.001). Both 
A-FABP plasma concentrations and mRNA expressions were independently 
associated with BMI, waist circumference, glycaemia, insulinaemia and glu-
cose disposal. E-FABP showed higher expressions in C (p<0.001). A-FABP/E-
FABP mRNA ratio was 3.0-fold higher in D compared to C (p<0.001) without 
any changes within and between clamps. PPAR-γ expressions were lower in D 
compared to C (p<0.01), no dynamic changes were shown.
Conclusion: A-FABP plasma concentrations as well as expressions are in-
creased in type 2 diabetes and they are closely associated with parameters of 
obesity, insulin resistance and hyperglycaemia. On the contrary, the expres-
sions of E-FABP and PPAR-γ are decreased in diabetes. Hyperinsulinaemia 
differentially regulates A-FABP in D compared to C. In C but not in D, losar-
tan stimulates basal A-FABP plasma concentrations without any effect on its 
expressions.
A-FABP plasma concentrations and expressions of selected genes in SAT. Data shown as mean (95% CI).
Variable D (n=11) C (n=12) Group effect
(p value)0 min 240 min 0 min 240 min
A-FABP
plasma concentrations 
(ng/ml)
HEC 21.31
(19.3-23.45)
18.85b
(17.15-20.74)
12.56a
(11.3-14.0)
12.64
(11.38-14.09)
<0.001
AT-HEC 23.4
(21.2-25.77)
20.02b
(18.08-22.18)
15.24a
(13.64-17.08)
12.73b
(11.45-14.19)
SAL 22.42
(20.23-24.86)
21.64
(19.53-23.99)
13.86a
(12.37-15.59)
15.20b
(13.61-17.03)
A-FABP mRNA /  
Cyclophilin mRNA
HEC 1937
(1686-2314)
1971
(1695-2401)
718.4
(647.6-808.6)
650.3
(592.8-721.8)
<0.001
AT-HEC 2004
(1732-2422)
1940
(1688-2318)
758.3
(679.2-860.9)
675.6
(610.0-758.9
E-FABP mRNA / Cyclophi-
lin mRNA
HEC 196.5
(181.0-214.3)
184.1
(170.2-200.0)
257.8 a
(210.7-322.7)
238.5
(196.3-295.9)
<0.001
AT-HEC 198.1
(182.4-216.1)
184.7
(169.8-201.8)
292.9 a
(232.5-380.1)
259.8
(212.2-325.6)
PPAR-γ mRNA / Cyclophi-
lin mRNA
HEC 139.6
(112.4-166.3)
158.9
(132.1-185.3)
169.8
(116.3-243.5)
168.1
(115.1-241.2)
<0.01
AT-HEC 137.0
(109.8-163.8)
158.9
(132.1-185.2)
167.5
(111.1-247.3)
202.5
(140.0-288.2)
Supported by: Grant IGA MH CZ 
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Fasting and postprandial hepatic glycogen content is not altered by 
systemic insulin delivery in type 1 diabetic patients after successful 
pancreas kidney transplantation
M. Stadler1, C. Anderwald2, D. Jankovic2, M. Krssak2, C. Göbl2,  
Y. Winhofer2, G. Pacini3, M. Bischof4, M. Haidinger2, M. Saemann2,  
F. Mühlbacher5, A. Luger2, R. Prager1, M. Krebs2; 
13rd Medical Department of Metabolic Diseases and Nephrology, Hietzing 
Hospital, Vienna, Austria, 2Endocrinology and Metabolism, Medical 
University Vienna, Austria, 3Metabolic Unit, ISIB-CNR, Padova, Italy, 
4Krankenhaus der Elisabethinen, Vienna, Austria, 5Department of Surgery, 
Medical University Vienna, Austria.
Background and aims: Insulin replacement in Type 1 diabetes mellitus 
(T1DM) is usually performed via a systemic (subcutaneous) instead of the 
physiologic portal route. So far it is unclear whether this systemic route of 
insulin delivery might contribute to metabolic defects in these patients. Suc-
cessful pancreas kidney transplantation (PKT) with systemic venous drain-
age is an ideal model of optimized systemic insulin therapy. Therefore, the 
aim of the present study was to investigate the effects of PKT on fasting and 
postprandial liver glycogen content.
Materials and methods: Using 13C-nuclear magnetic resonance spectros-
copy (13C-NMR), liver glycogen concentrations were assessed in 9 T1DM 
patients after successful PKT (24±1kg/m², 47±3yrs, 3f/6m, fasting glucose 
84±3mg/dl, HbA1c 5.1±0.2%) with systemic venous drainage and in 9 match-
ing nondiabetic controls (CON) (24±1 kg/m², 47±3yrs, 3f/6m, 89±3 mg/dl, 
5.4±0.1%) at fasting and after two standardized mixed meals.
Results: Liver glycogen concentrations at fasting (PKT:195±12, 
CON:209±10mM), after breakfast (PKT:216±12, CON:233±11mM) and 
after lunch (PKT:230±13 vs. CON:171±15mM), as well as the increment of 
liver glycogen content after the meals were comparable in PKT and CON. 
Mean and fasting concentrations of glucose, insulin, C-peptide and glucagon 
were similar in PKT vs. CON.
Conclusion: Despite systemic insulin secretion, T1DM after successful PKT 
exhibit unchanged fasting and postprandial liver glycogen stores in compari-
son with age-and BMI-matched non-diabetic controls. Thus, this study indi-
cates that systemic insulin substitution does not cause alterations of hepatic 
glycogen storage.
Supported by: Austrian Diabetes Association; Austrian National Bank to M.K.
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PS 49 GLP-1 effects in animal models 
and cells
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The effect of liraglutide on metabolism in ApoE-/- mice with RNAi-
mediated adiponectin gene inhibition
Z. Zhang1, G. Yang1, L. Li2; 
1Department of Endocrinology, the Second Affiliated Hospital, 2Department 
of Clinical Biochemistry, Chongqing Medical University, Chongqing, China.
Background and aims: Liraglutide is an analogue of Glucagon-like peptide-
1(GLP-1), researched and developed by Novonordisk. It can bind with the 
GLP-1 specific receptor, which belongs to the Islets of Langerhans β cells, 
promote the expression and biosynthesis of the pre-insulin gene, and facili-
tate the secretion of insulin in the genetic level. But its specific mechanism 
retains unknown. In our study, we have investigated the effects of Liraglu-
tide on insulin sensitivity and glucose-lipid metabolism in ApoE-/- mice with 
RNAi-mediated adiponectin gene inhibition.
Materials and methods: High-fat diet fed male apoE-/- mice were randomly 
divided into adiponectin shRNA adenovirus injection group (ADI group, 
n=8), Liraglutide co-injection of adiponectin shRNA adenovirus group 
(HEA group, n=8) and adenovirus control group (GF group, n=6). The hy-
perinsulinemic-euglycemic clamp combined with 3-[3H] glucose was used as 
a tracer to assess the insulin sensitivity. Plasma FFA, insulin concentrations 
(PIns), high density lipoprotein cholesterol (HDL-C), low density lipoprotein 
cholesterol (LDL-C), TG and TC concentrations were measured.
Results: In the IVGTT, the group with 1mg· kg-1 Liraglutide, Bid, at time 
points of 5, 15, 30 min after glucose challenge, presented lower significantly 
than other groups in the blood glucose(P<0.01), with a significant increase 
in the plasma insulin at the points of 5 and 15 min(P<0.01). Fasting blood 
glucose (FBG), body weight, Free fatty acids (FFA),TC,TG,LDL-C,HDL-C 
and fasting plasma insulins (PIns) in ApoE-/- mice with Liraglutide and adi-
ponectin shRNA adenovirus (HEA group) co-injection of were significantly 
lower than those with high-fat diet and adiponectin shRNA adenovirus injec-
tion (ADI group) ( P<0.01). However, HDL-C showed a significant elevation, 
compared HEA with ADI group ( P<0.05). During the steady-state of clamp, 
plasma insulin in ADI group was significantly higher than that in HEA group 
(P<0.01). Although FFA, TC and TG were suppressed in all groups, they were 
still higher in ADI group than those in HEA group( P<0.05). Glucose in-
fusion rate(GIR) in HEA group were significantly higher than ADI group 
(P<0.01). In the end of clamp, glucose disappearance rate (GRd) was signifi-
cantly lower, and HGP significantly higher in ADI group than HEA group 
(P<0.01). 
Conclusion: Liraglutide administration can improve insulin resistance by 
increasing plasma adiponectin level in ApoE-/- mice with RNAi-mediated 
adiponectin gene inhibition.
Supported by: National Natural Science Foundation of China
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Normalising effect of GLP-1 and Exendin-4 on the deleterious hepatic 
metabolism, of an obesity model
I. Gutiérrez-Rojas, P. Moreno, B. Nuche-Berenguer, I. Valverde,  
M.L. Villanueva-Peñacarrillo; 
IIS-Fundación Jiménez Díaz, Madrid, Spain.
Background and aims: Obesity is often related with several metabolic altera-
tions that can drive to insulin resistance and finally diabetes. GLP-1 and its 
structurally homologous peptide, exendin-4 (Ex-4), both have insulinotropic 
and antidiabetic actions and stimulatory effects on the glucose metabolism of 
extrapancreatics tissues such as liver and muscle. Here, we have studied the 
effect of GLP-1 and Ex-4 treatment, on Glut-2 expression and other param-
eters, in an obesity model (Ob) compared to normal (N).
Materials and methods: Ob model was obtained in adult Wistar rats by 
chronic feeding -5 weeks- with a “cafeteria diet”, consisting in standard chow 
supplemented with cookies, liver paste, bacon, and whole-milk containing 
sucrose (333 g/l) and 10 g/l of a mineral and vitamin complex (65% energy 
derived from lipids). The N group was fed with standard chow and water ad 
libitum (8% calories from fat). Although weight was not different between N 
and Ob, the Ob model showed fasting plasma glucose, triglycerides (159±14 
mg/dl, n=9) and cholesterol (94±4 mg/l, n=10) higher than N (overall mean: 
145±7% Δ N-rats, p<0.001); no significant differences with N were detected 
in plasma insulin or GLP-1 -RIA-. Ob (n=5-10 rats/group) and N (4-10 rats/
group) were treated (3 days), through an osmotic pump, with saline (control), 
GLP-1 (0.86 nmol/kg/h) or Ex-4 (0.1nmol/kg/h). Blood samples were taken 
before and by the end of treatment for plasma measurements. In liver, we 
analyzed Glut-2 expression -protein, by Western blot, and mRNA, by RT-
PCR- and also glycogen content -antrona method-.
Results: In Ob, liver Glut-2-mRNA was much lower than that in N animals 
(0.41±0.02 times N-control, n=10 rats, p<0.001), while Glut-2-protein was 
higher (123±10% N-control, n=14, p<0.05); GLP-1 treatment reduced the 
Glut-2-protein levels (64±4% Ob-control, n=7, p<0.001), without altering the 
mRNA value (0.96±0.04 times Ob-control, n=5); treatment with Ex-4 low-
ered the Glut-2-protein (60±4% Ob-control, n=7, p<0.001) to a value close 
to that in N (84±7% N-control), without modifying the mRNA expression 
(1.02±0.06 times Ob-control, n=5). The liver glycogen content in Ob rats 
(902±52 μg/mg protein, n=6), compared to than that in N animals (395±34 
μg/mg protein, n=6), was much higher (228±13% N-control, n=6, p<0.001); 
treatment with GLP-1 reduced the liver glycogen content in Ob, to a value 
(396±15 μg/mg protein, n=5, p<0.001) undistinguible from that in N rats; Ex-
4 also exerted a lowering effect on glycogen content in Ob rats (81±5% Δ Ob-
control, n=5, p<0,02), to a level though (726±45 μg/mg protein, n=5, p<0.05) 
still higher (p<0.001) than that shown in the N group. Plasma glucose and 
insulin were not apparently different in any group or condition; yet, in the Ob 
group, GLP-1 lowered the higher than N triglycerides (-50±4% Δ Ob-basal, 
p<0.04, n=5 rats) to a value even lower than that in N (76±7% N-control, 
p<0.02), without modifying that of cholesterol; Ex-4 induced a reduction in 
both parameters, the magnitude of its effect on cholesterol being small but 
clear (-12±3% Δ Ob-basal, p<0.01, n=6), and that on triglycerides (-57±6% Δ 
Ob-basal, p<0.01, n=5) as that exerted by GLP-1.
Conclusion: Both, GLP-1 and Ex-4 have a normalizing effect on the high 
hepatic glycogen accumulation in this obesity model, perhaps through their 
lowering action upon the higher than normal liver Glut-2 expression, mainly 
at the translational process, and by reducing the also higher than normal cir-
culating triglycerides levels.
Supported by: FIS and Ciberdem
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Enhanced GIP and attenuated GLP-1 incretin effects during IVGTT in 
Wistar rats under DPP-4 inhibition
E.-J. Freyse, S. Berg, P. Heinke, K.-D. Kohnert, E. Salzsieder; 
Institut für Diabetes, Karlsburg, Germany.
Background and aims: DPP-4 (dipeptidyl peptidase-4) inhibition has been 
reported to increase incretin effects of GIP as well as GLP-1 by prolonging 
their half life. DPP-4 cleaves GIP into dipeptide and the GIP metabolite GIP 
(3-42), whereas the GLP-1 (7-36) amide is cleaved to GLP-1 (9-36) amide. 
Based on studies in man, pig and rat, these peptides are involved in various 
glucoregulatory processes. We have recently developed a test to differentiate 
the insulinotropic effects of both peptides in rats. In the present study, we 
compared the incretin effects of the intact GIP and the GLP-1 (7-36) amide 
during IVGTT following DPP4 inhibitor administration.
Materials and methods: Groups of catheterized Wistar rats were tested: pla-
cebo (P; 0.1 % BSA), DPP4 inhibitor (INH; 30 µmol/kg P32/98, p.o.), incretin 
in the absence (+P) and presence of INH (+INH) three days apart in a random 
order. 4.0 nmol/kg GLP-1 ((7-36) amide; Neo MPS; Strasbourg, France) or 2.0 
nmol/kg GIP (Probiodrug AG, Halle/Saale, Germany) were injected. Samples 
for blood glucose (BG) and insulin (I) were taken (-5, 0 min and at 1, 2, 3, 5, 
7, 10, 15, 25, 40 and 60 min). INH was given at -20 min, the incretin at -5 min 
and the IVGTT (0.4 g glucose/kg) commenced at 0 min. G- and I- AUC0-25min, 
insulinogenic Index iI (I- and G-AUC area quotient (ng/mmol) was selected 
to measure incretin effects), glucose efflux KG (min
-1; Conard (1959)) was cal-
culated from IVGTT curves. Groups were compared with two-tailed t-test 
with Bonferroni-Holm correction, a *p<0.05 was considered significant.
Results: INH significantly increased the effects of GIP - G-AUC (P+P: 220±34, 
INH+P: 185±17, P+GIP: 157±14*, INH+GIP: 156±25* mmol·min/L), I-AUC 
(P+P: 77±33, INH+P: 60±19, P+GIP: 115±34, INH+GIP: 153±39* ng·min/
mL) and Ii (P+P: 0.35±0.17, INH+P: 0.33±0.11, P+GIP: 0.74±0.24*, INH+GIP: 
0.99±0.26* ng/mmol) and improved glucose efflux KG (P+P: 14.5±4.1, INH+P: 
14.2±2.4, P+GIP: 19.8±3.1*, INH+GIP: 20.5±5.0* min-1). In contrast, INH at-
tenuated GLP-1 effects - G-AUC (P+P: 226±33, INH+P: 182±20*, P+GLP-1: 
183±24, INH+GLP-1: 215±14 mmol·min/L), I-AUC (P+P: 63±28, INH+P: 
65±33, P+GLP-1: 125±19*, INH+GLP-1: 106±38 ng·min/mL) and Ii (P+P: 
0.27±0.10 , INH+P: 0.35±0.16 , P+GLP-1: 0.70±0.18*, INH+GLP-1: 0.50±0.19 
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ng/mmol) and declined glucose efflux KG (P+P: 12.6±5.1, INH+P: 14.5±3.0, 
P+GLP-1: 14.9±3.1, INH+GLP-1: 11.1±3.7 min-1).
Conclusion: DPP4 inhibition revealed that GLP-1 and GIP differ remarkably 
in their glucoregulatory actions in healthy rats. These previously unrecog-
nized actions of DPP4 inhibitors may have implications for the use of DPP-4 
inhibitors in humans.
Supported by: Forschungsprämie Zwei - 03FPZL0025
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GLP-1 and somatostatin are part of a paracrine feedback loop in the 
isolated perfused porcine ileum
K.R. Hjøllund, S. Pilgaard, J.J. Holst; 
Department of Biomedical Sciences, University of Copenhagen, Denmark.
Background and aims: When DPP-4 inhibitors are administrated, periph-
eral plasma concentrations of intact glucagon-like peptide-1 (GLP-1) and 
glucose-dependent insulinotropic polypeptide (GIP) increase; however, 
overall (total) incretin secretion appears to be inhibited. The mechanism is 
unknown, but it has been suggested that increased concentrations of intact 
GLP-1 may feedback on neighbouring somatostatin-releasing D-cells, which 
in turn increase their tonic, paracrine restraint on L-cell secretion.
Materials and methods: We examined whether somatostatin (SS) is involved 
in the local regulation of GLP-1 secretion using the isolated perfused porcine 
ileum (n=8). In an attempt to break the paracrine circuitry, we infused the 
GLP-1 receptor antagonist, exendin 9-39 (Ex 9-39)(0.1umol/l), a somatostatin 
receptor subtype 5 (SSTR5) antagonist (0.1umol/l), or GLP-1(7-36)(1nmol/
l), either alone, or in combination with SSTR5 antagonist. Glucagon-like pep-
tide-2 (GLP-2) is co-secreted with GLP-1 from the L-cells, and was therefore 
used as an index of L-cell secretion.
Results: GLP-1 infusion significantly increased SS secretion from a prestimu-
latory level of 3.68 ± 0.67 to stimulatory 6.70 ± 1.46 fmol/min (p=0.0195). 
Moreover, infusion of GLP-1 together with SSTR5 antagonist blocked the in-
hibitory effect of SS on endogenous L-cell secretion (GLP-2 output increased 
to 134.7 ± 11.6 % of basal; p=0.0391), resulting in augmented SS output from 
a prestimulatory level of 3.81 ± 0.64 to stimulatory 9.11 ± 2.34 fmol/min 
(p=0.0039). Infusion of either SSTR5 antagonist or Ex 9-39 alone resulted 
in a significant increases L-cell secretion (total GLP-2 output; p=0.0234 and 
p=0.0391, respectively).
Conclusion: These results indicate that SS regulates the L-cells via SSTR5, 
and that there is a negative feedback loop between GLP-1 and SS. Addition-
ally we found that GLP-2 secretion was increased by Ex 9-39 alone, indicating 
that GLP-1 has an indirect tonic inhibitory effect on the L-cells. This feedback 
mechanism may explain the decreased secretion from the L-cell during DPP-
4 inhibitor, even though the concentration of intact GLP-1 plasma concentra-
tion increases.
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Glucose-dependent insulinotropic polypeptide regulates cytokine 
expression and lipolysis in human adipocytes
K. Timper1, J. Grisouard1, T. Radimerski1, K. Dembinski1, R. Peterli2,  
H. Zulewski1, U. Keller1, M.Y. Donath3,4, B. Müller1,5, M. Christ-Crain1; 
1Department of Biomedicine, Division of Endocrinology, Diabetes and 
Clinical Nutrition, Basel, 2Department of Surgery, St. Claraspital Basel, 
3Clinic of Endocrinology and Diabetes, University Hospital of Zurich, 
4Zurich Center for Integrative Human Physiology, University of Zurich, 
5Internal Medicine, Kantonsspital Aarau, Switzerland.
Background and aims: Serum levels of IL-6, IL-1ß and IL-1 receptor antagonist 
(IL-1Ra) as well as of glucose-dependent insulinotropic polypeptide (GIP) are 
increased in obese individuals. The so-called low-inflammatory state in obesity 
is associated with adipose tissue dysfunction, leading to altered secretion of 
cytokines, lipolysis and insulin resistance. Inhibition of GIP signalling in ro-
dents protected against diet-induced obesity and insulin resistance. Since GIP 
is pro-lipolytic in adipocyte-cultures, we hypothesized, that GIP might also be 
involved in the induction of an inflammatory state in human adipocytes.
Materials and methods: Using a human in vitro model of preadipocyte-de-
rived adipocytes we analyzed the effect of GIP treatment on mRNA expression 
of IL-6, IL-1ß and IL-1Ra. Human adipocytes were exposed to recombinant 
human GIP(1-42), the beta subunit of IkappaB kinase (IKK-ß) inhibitor sc-
514 and to recombinant human IL-1Ra (rhIL-1Ra). mRNA expression was 
analyzed by real-time PCR. Glycerol content in the cell culture supernatant 
was determined as an index of lipolysis.
Results: Treatment of differentiated human adipocytes with GIP from 10pM to 
100nM for 1h induced IL-6, IL-1ß and IL-1Ra mRNA expression. Treatment 
with 1nM GIP maximally increased IL-6 to 4.21±0.28 fold (p<0.001 vs. con-
trol) and IL-1ß to 1.64±0.13 fold (p<0.05 vs. control). IL-1Ra mRNA expression 
was induced to a maximum of 23.5±3.94 fold (p<0.001 vs. control) with 100nM 
GIP. During time-course experiments with 1nM GIP, IL-6 mRNA expression 
was acutely increased to 2.55±0.5 fold (p<0.001 vs. control) after 1h. IL-1ß gene 
expression was constantly increased during 24h with a maximum expression 
of 1.64±0.13 fold (p<0.001 vs. control) after 4h of 1nM GIP treatment. IL-1RA 
mRNA expression was upregulated by 4.77±0.5 fold (p<0.001 vs. control) after 2h 
and reached a maximal increase by 5.2±0.53 fold (p<0.001 vs. control) at 4h. Pre-
incubation with sc-514 (100µM) for 1h inhibited GIP-induced IL-6 expression 
by 57% (p<0.05 vs. GIP 1nM 1h) and GIP induced IL-1Ra expression by 78% 
(p<0.01 vs. GIP 1nM 1h), while GIP-induced IL-1ß expression was not inhibited. 
Preincubation with rhIL-1RA 1µg/ml inhibited GIP-induced IL-6 expression by 
68% (p<0.01 vs. GIP 1nM 1h). Treatment with 1nM GIP for 6h in serum free 
conditions revealed a 1.64±1.37 fold (p<0.01 vs. control) increase of basal glycerol 
release. Pretreatment with sc-514 (100µM) fully blocked GIP-induced glycerol 
release (p<0.001 vs. GIP 1nM 6h) while 1µg/ml rhIL-1Ra 1h prior to 1nM GIP 
reduced GIP-induced lipolysis by 66% (p<0.05 vs. GIP 1nM 6h).
Conclusion: Our findings demonstrate the potential of GIP to induce a pro-
inflammatory state with a concomitant anti-inflammatory IL-1Ra response 
in human adipocytes, leading to lipolysis. The GIP effect on IL-6 and IL-1Ra 
mRNA expression and lipolysis seems to involve the classical NF-kB pathway 
and suggests the involvement of an autokrine IL-1ß effect.
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Effects of glucagon like Peptide-1 and metformin on the proliferation, 
apoptosis and function of glucagon like Peptide-1-secreting cells
C. Kappe1, J.J. Holst2, C. Patrone1, Q. Zhang1, Å. Sjöholm1; 
1Department of Clinical Research and Education, Stockholm, Sweden, 
2The Panum Institute, Department of Biomedical Science, Copenhagen, 
Denmark. 
Background and aims: Glucagon-like peptide-1 (GLP-1) is an incretin hor-
mone, secreted from gut L-cells upon nutrient intake, and forms the basis for 
novel drugs against type 2 diabetes. Secretion of GLP-1 is impaired in type 2 
diabetes. Little is known about the influence of antidiabetic drugs on L-cell 
function and regeneration. The aim of this study was to investigate the effects 
of GLP-1 and metformin on the proliferation, apoptosis and function of the 
GLP-1-secreting cells and the mechanisms underlying such effects.
Materials and methods: The GLP-1-secreting cell line GLUTag was cultured 
in DMEM media. Cell proliferation was evaluated by 3H-thymidine incorpo-
ration, MTT-assay and Ki67 staining after a 48 h-incubation with the anti-
diabetic agents in the presence or absence of the GLP-1 receptor antagonist 
exendin(9-39). Cellular cAMP production and secretion of GLP-1 from the 
cells was measured using specific ELISA kits. Apoptosis was evaluated using 
cell death detection ELISA and caspase-3 activity was measured using cas-
pase-3 activity ELISA kit. The expression of the GLP-1 receptor in GLUTag 
cells was assessed by Western blotting using anti-GLP-1 receptor antibody.
Results: GLP-1 stimulated proliferation of the GLP-1-secreting GLUTag cells 
to a similar extent as insulin at low (3 mM), but not high (11 mM), concentra-
tions of glucose. The DPP-IV inhibitor sitagliptin also promoted proliferation 
of GLUTag cells at high glucose. These cells expressed the GLP-1 receptor 
as demonstrated by Western blotting. The stimulatory effect of GLP-1 on 
GLUTag cell proliferation was blocked by pre-treatment with the receptor an-
tagonist Exendin(9-39). However, the cAMP agonist Sp-cAMP[S] suppressed 
cell proliferation under these conditions. Metformin significantly inhibited 
proliferation of GLUTag cells but dose-dependently protected the cells from 
palmitate-induced apoptosis. In contrast, GLP-1 did not influence palmitate-
induced apoptosis of the GLUTag cells. In addition, metformin significantly 
stimulated short-term secretion of GLP-1 from these cells.
Conclusion: The present study shows that GLP-1 stimulated proliferation 
of GLP-1-secreting cells, an effect that was blocked by a GLP-1 receptor an-
tagonist, indicating a requirement of the GLP-1 receptor for this event. The 
results suggest that a positive feedback mechanism by GLP-1 may stimulate 
these cells in an autocrine/paracrine manner. Since serum GLP-1 levels are 
decreased in type 2 diabetic patients, the mitogenic stimulation of GLP-1-
producing cells by GLP-1 and the protective effect of metformin against 
lipoapoptosis noted here suggests a novel beneficial long term effect of these 
antidiabetic drugs in clinical practice, i.e. by restoring GLP-1 deficiency 
through enhanced L-cell mass.
Supported by: an EFSD/Amylin grant
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GLP-1 inhibits glucagon secretion from human alpha cells by a direct 
effect
R.D. Ramracheya, C. Ward, F. Abdulkader, M. Shigeto, A. Clark,  
P. Johnson, M. Braun, P. Rorsman; 
OCDEM, University of Oxford, United Kingdom.
Background and aims: Glucagon is secreted from the alpha-cells of the pan-
creatic islets. Both intrinsic and paracrine mechanisms are involved in the 
metabolic regulation of glucagon release. Glucagon secretion is also under 
hormonal control, one of which is glucagon-like peptide 1 (GLP-1). GLP-1 
enhances insulin release but most importantly its hypoglycaemic action is 
amplified by a concomitant suppression of glucagon secretion. Oversecretion 
of glucagon occurs in type-2 diabetes, exacerbating the hyperglycaemia re-
sulting from the lack of insulin and this constitutes a valuable feature of GLP-
1 action. However, the mechanism by which GLP-1 modulates islet glucagon 
secretion remains unclear. Here we have examined the effects of GLP-1 on 
glucagon secretion in human pancreatic islets.
Materials and methods: Immunocytochemistry was used to examine expres-
sion of GLP-1 receptors in human islet cells. Islet hormone release was mea-
sured from intact islets by static incubation. Confocal microscopy was used 
to investigate the effects of GLP-1 on the spontaneous [Ca2+]i oscillations at 1 
mM glucose to reflect the activity of alpha-cells. Perforated patch whole-cell 
measurements were used for membrane potential recordings.
Results: Human pancreatic beta- and delta-cells exhibited clear GLP-1 re-
ceptor (GLP-1R) immunoreactivity but only ~1% of the alpha-cells showed 
detectable levels of the receptor. GLP-1 (10 nM) inhibited glucagon secre-
tion elicited by 1 mM glucose (1G; mean±sem as pg/islet/h: 1G: 20.27±4.06; 
1G+GLP-1: 10.83±1.96; p<0.05). This effect was not associated with any stimu-
lation of insulin secretion (as ng/islet/h; 1G: 0.15±0.02; 1G+GLP-1: 0.18±0.03) 
but correlated with a ~3-fold stimulation of somatostatin (SST) secretion (as 
fmol/islet/h: 1G: 0.35±0.08; 1G+GLP-1: 0.63±0.1; p<0.05). The inhibitory ac-
tion of GLP-1 on glucagon secretion was only partially antagonised by the SST 
receptor antagonist CYN154806 (100 nM) and GLP-1 retained a 35% inhibi-
tory effect (1G: 3.44±0.41; 1G+GLP-1: 1.58±0.15; p<0.001; 1G+CYN154806: 
3.74±0.76; 1G+CYN154806+GLP-1: 2.36±0.25; p<0.05). Effects of GLP-1 and 
glucose were next compared with forskolin (10 nM) which blocked glucagon 
secretion by 30% (1G: 15.76±2.99; 1G+forskolin: 11.06±2.16; p<0.05). GLP-1 
inhibition was mimicked by the P/Q-type Ca2+-channel blocker ω-agatoxin 
(AGA; 100 nM; 1G: 10.41±1.7; 1G+GLP-1: 3.85±0.86; 1G+AGA: 6.65±0.65). 
GLP-1 had no effect on the amplitude of the [Ca2+]i oscillations at 1G (20 al-
pha-cells in 10 islets; n=6 donors). They were also unaffected by 1 μM insulin 
(42 alpha-cells from 4 islets; n=2 donors) or 10 μM Zn2+ (41 alpha-cells in 5 is-
lets; n=2 donors). In an alpha-cell in an intact islet GLP-1 depolarized the cell 
by a few mV and reduced the peak voltage of the action potential by ~10 mV.
Conclusion: GLP-1 receptors are expressed at low levels in alpha cells. Block-
ade of insulin and SST signalling does not affect glucagon inhibition. GLP-1 
effects on glucagon secretion can be mimicked by nanomolar concentrations 
of forskolin. These data suggest that GLP-1 principally acts by a direct effect 
on human alpha cells
Supported by: Wellcome Trust
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Effects of glucose, GLP-1 and adrenaline on alpha cell electrical activity 
and glucagon secretion from mouse pancreatic islets
Q. Zhang1, Y.Z. De Marinis2, R.D. Ramracheya1, O. Braha1, M. Braun1,  
P. Rorsman1; 
1Oxford Centre for Diabetes, Endocrinology and Metabolism, United 
Kingdom, 2Department of Clinical Sciences, Malmo, Sweden.
Background and aims: Pancreatic islet α-cells secrete glucagon during hy-
poglycaemia. Glucagon secretion is suppressed by elevation of glucose con-
centration and by the incretin hormone GLP-1 but stimulated by the stress 
hormone adrenaline. Like beta cells, alpha cells generate action potentials to 
allow influx of Ca2+ which in turn triggers exocytosis of glucagon-containing 
granules. Several ion channels are involved in this process. Both voltage gated 
Na+ channels and Ca2+ channels contribute to the upstroke of the action 
potentials (AP) and K+ channels are involved in repolarisation. Here we have 
analyzed the mechanism by which glucose, GLP-1 and adrenaline modulate 
glucagon secretion.
Materials and methods: Static incubation experiments using intact mouse 
islets were performed to measure glucagon secretion under treatment of dif-
ferent glucose concentrations as well as various reagents. Electrical activity 
and exocytosis was measured by patch-clamp measurements in alpha cells 
within intact mouse islets. In membrane potential recordings, alpha cells 
were identified by its active electrical activity when islets were exposed to 1 
mmol/l glucose. In voltage clamp experiments, cells were infused with biocy-
tin and later indentified by immunocytochemistry.
Results: Glucagon secretion is suppressed by 6 mmol/l glucose by ~50%. GLP-1 
exerted similar effect while adrenaline stimulated the secretion of glucagon by ~2-
fold. Mouse alpha cells exposed to 1 mM glucose fire overshooting APs starting at 
-51 mV with a peak of +5 mV. Glucose (6 mmol/l) depolarises the interspike volt-
age by ~4 mV and reduced the peak voltage by 6 mV. GLP-1 (100 nmol/l) did not 
detectably affect the interspike voltage but reduced spike height by ~2 mV. GLP-1 
inhibited N-type Ca2+-channels by a PKA-dependent mechanism. Inhibition of 
N-type Ca2+-channels using ω-conotoxin mimicked the effects of glucose and 
GLP-1 on glucagon secretion. Inhibition of N-type Ca2+-channels by ω-cono-
toxin or GLP-1 inhibited α-cell exocytosis. Blockade of N-type Ca2+-channels 
reduced action potential amplitude by ~2 mV without affecting the interspike 
voltage. Adrenaline (10 μmol/l) depolarised the α-cell by ~10 mV and lowered 
the amplitude of APs by 20 mV. Glucagon secretion enhanced by adrenaline in-
volved L-type Ca2+-channels and the cyclic AMP sensor Epac2.
Conclusion: We propose that glucose and GLP-1-induced suppression of 
glucagon secretion by inhibition of N-type Ca2+-channel activity. In the case 
of glucose, this effect is secondary to membrane depolarisation and voltage-
dependent inactivation of the N-type Ca2+-channels. GLP-1 directly affects 
N-type Ca2+-channel gating by an effect not mediated by membrane depo-
larisation. In both cases, the resultant inhibition of N-type Ca2+-channel ac-
tivity results in suppression of depolarisation-evoked exocytosis. Adrenaline 
by-passes this inhibitory effect by activation of Epac2 and L-type Ca2+-chan-
nels.
Supported by: Wellcome Trust
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PPAR delta positively regulates GLP-1 production by intestinal 
endocrine L cells and improves the oral glucose-induced insulin 
secretion in diabetic obese mice
S. Lestavel1,2, M. Daoudi1,2, N. Hennuyer1,2, M.G. Borland3, J.M. Peters3,  
B. Staels1,2; 
1Inserm U1011, Lille, France, 2Université Lille Nord de France, France, 
3Department Veterinary and Biomedical Sciences, The Pennsylvania State 
University, USA.
Background and aims: GLP-1 (Glucagon-Like Peptide-1) is an incretin hor-
mone derived from the proglucagon gene transcription product and secreted 
by the intestinal L cells in response to dietary nutrients. GLP-1 stimulates 
glucose-dependent insulin secretion and insulin biosynthesis, inhibits glu-
cagon secretion and gastric emptying and reduces food intake. In this study, 
we examined the regulation of GLP-1 production by PPARdelta/beta (Peroxi-
some Proliferator-Activated Receptor delta/beta) which is a nuclear receptor 
reported to improve islet function and to prevent weight gain.
Materials and methods: We used the murine and human L cell lines (respec-
tively GLUtag and NCI-H716) activated or not with the synthetic PPARdelta 
ligands (GW501516 and GW0742). Wild type and diabetic ob/ob mice were 
also treated with these compounds.
Results: We show in the L cell lines that in vitro PPARdelta activation induces 
proglucagon gene expression in a dose and time dependant manner (up to 3 
fold with 1µM of GW501516 at 24h) and increases to the same extent glucose 
and bile acid-induced GLP-1 release. Interestingly, we show that a 15 day oral 
treatment of wild type and ob/ob mice with GW501516 (once per day at 10 
mg/kg) increases (3 fold increase compared to vehicle) GLP-1 secretion at 15 
min after orally glucose tolerance test (O-GTT) but not after IP-GTT and that 
is correlated with the up-regulation of proglucagon gene expression in the 
ileum (2 fold increase) and the up-regulation of GLP-1 receptor expression in 
pancreas. In addition, we also observed in vivo and in vitro the positive effect 
of PPARdelta activation by another agonist GW0742. Moreover, GW501516 
treatment in ob/ob mice decreases the basal insulin mRNA expression in the 
pancreas and basal insulin concentration in the plasma which could reflect 
the improvement of the glycemic control.
Conclusion: Altogether, these data suggest that the PPARdelta/beta activa-
tion potentiates the incretin system that is crucial in regulating postprandial 
glycemia and that pharmacological targeting of PPARdelta/beta may consti-
tute a promising incretin-based strategy for the treatment of insulin resist-
ance, diabetes and associated metabolic disorders.
Supported by: AMIDiab
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Effects of enterically coated, nutrient-containing pellets on glycaemia 
and incretin hormone release in patients with type 2 diabetes
C.K. Rayner1,2, J. Ma1,2, H.L. Checklin1,2, J.M. Wishart1,2, J.E. Stevens1,2, K.L. 
Jones1,2, M. Horowitz1,2, J.H. Meyer1,3; 
1Discipline of Medicine, University of Adelaide, Royal Adelaide Hospital, 
Australia, 2Centre of Clinical Research Excellence in Nutritional Physiol-
ogy, University of Adelaide, Australia, 3Meyer Nutriceuticals, Santa Monica, 
USA.
Background and aims: In principle, delivery of a small amount of nutrient 
to a long length of distal gut could be a potent stimulus for release of glu-
cagon-like peptide-1 (GLP-1), with consequent improvements in glycaemic 
responses to subsequent meals. We evaluated the effects of enteric coated 
pellets designed for continuing release of small amounts of lauric acid along 
ileum and colon, on GLP-1 secretion and the glycaemic response, after both 
breakfast and a subsequent lunch.
Materials and methods: Ten patients with well controlled type 2 diabetes 
(glycated haemoglobin 5.9 ± 0.2 %), managed by diet alone, were studied on 
two separate days. On each study day, they ingested either 10 g active pellets 
(47 % lauric acid by weight, or ~40 kcal) or placebo pellets at T = 0 min dur-
ing breakfast (71 g carbohydrate, 4.3 g protein, 12 g fat, 415 kcal). A second 
meal (lunch; 89 g carbohydrate, 29 g protein, 26 g fat, 708 kcal) was con-
sumed at T = 240 min. Blood was sampled for measurement of blood glucose, 
serum insulin, and plasma total GLP-1 and glucose-dependent insulinotropic 
polypeptide (GIP).
Results: Data are shown as mean ± standard error. After active pellets, blood 
glucose concentrations were lower, and plasma GLP-1 concentrations higher, 
than after placebo, following both breakfast and lunch (*P < 0.05 in the fig-
ure). In contrast, the rises in insulin and GIP after breakfast and lunch did not 
differ between active pellets and placebo.
Conclusion: Enteric coated pellets which sustain release of lauric acid along 
distal small intestine and colon diminish the glycaemic response to both 
breakfast and lunch in type 2 diabetes, associated with stimulation of GLP-1, 
establishing that exposure of the distal gut to a small quantity of nutrient can 
have substantial effects on GLP-1 release and hence glycaemic control. 
Supported by: NHMRC
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Degradation of GIP but not of GLP-1 is reduced after protein ingestion 
in obese subjects
O. Lindgren1, J. Vikman1, C.F. Deacon2, R.D. Carr3, J.J. Holst2, B. Ahrén1; 
1Department of clinical sciences, Lund University, Sweden, 2Department 
of Biomedical Sciences, Copenhagen University, Denmark, 3Novo Nordisk 
A/S, Bagsvaerd, Denmark.
Background and aims: The incretin hormones, glucagon-like peptide-1 
(GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are re-
leased after meal ingestion and potentiate glucose-stimulated insulin secre-
tion. Both hormones are rapidly degraded by the enzyme DPP-4 (dipeptidyl 
peptidase 4). This major site of degradation is thought to be the gut wall, 
where we previously showed in animal studies that DPP-4 activity varies de-
pending on macronutrient ingestion, being reduced by protein. We previ-
ously showed that secretion and metabolism of the incretin hormones after 
mixed meal and oral glucose is different in obese versus lean subjects. Thus, 
GLP-1 but not GIP secretion is lower in obesity after meal ingestion and oral 
glucose, whereas GIP but not GLP-1 metabolism is increased in obesity af-
ter meal ingestion. In this study, we have proceeded and examined GIP and 
GLP-1 secretion and metabolism after oral ingestion of pure protein in lean 
versus obese subjects.
Materials and methods: The study was undertaken in healthy male human 
volunteers that were either lean (BMI 20-25kg/m2; n=12) or obese (BMI 30-
35kg/m2; n=12). After an overnight fast, the subjects at three different oc-
casions consumed 2.22g protein mix (Promax protein 85R)/kg b wt. Blood 
samples were collected before and up to five hours after intake of each macro-
nutrient for measurements of total(t) and intact(i) GLP-1 and GIP. Hormone 
responses were assessed as suprabasal AUC300 over the entire 300 minutes 
study period.
Results: Both GIP and GLP-1 secretion increased following ingestion of pro-
tein, as reflected by increased concentrations of tGLP-1 and tGIP. Whereas 
the secretion of GIP was markedly lower in the obese subjects (AUCtGIP 
10.0±2.8 vs. 18.4±2.7 pmol/l; P=0.046), there was no difference between 
obese and lean subjects in AUCiGIP. This suggests that degradation of GIP is 
reduced after protein ingestion in obese subjects. In contrast, GLP-1 did not 
show any differences between lean and obese after protein ingestion for either 
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intact or total levels, suggesting that secretion and degradation of GLP-1 are 
not affected by obesity.
Conclusion: Our results show a reduced GIP but a normal GLP-1 secretion 
after protein ingestion in obese subjects in association with a reduced rate of 
GIP degradation but a normal degree of GLP-1 degradation. This resulted 
in normal concentrations of intact forms of the two incretins after protein 
ingestion in obesity. The reduced degradation of GIP after protein ingestion 
in obese subjects may be the result of decreased DPP-4 activity after protein 
in the proximal portion of the gut.
Supported by: The Swedish Research Council, Region Skåne, Faculty of Medi-
cine, Lund University
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Short-term intervention with steroid hormone, relative physical 
inactivity and high calorie diet in healthy subjects results in increased 
postprandial GIP and glucagon responses
F.K. Knop1, K.B. Hansen2,3, J.I. Bagger1, J.J. Holst3, T. Vilsbøll1; 
1Department of Internal Medicine F, Gentofte Hospital, University of 
Copenhagen, 2Department of Clinical Physiology, Glostrup Hospital, 
University of Copenhagen, 3Department of Biomedical Sciences, The Panum 
Institute, University of Copenhagen, Denmark.
Background and aims: The incretin hormone glucose-dependent insulino-
tropic polypeptide (GIP) has been proposed as a link between consumption 
of high fat diets and the development of obesity, insulin resistance, hyperin-
sulinaemia and type 2 diabetes mellitus (T2DM). In obese subjects the GIP 
response to a mixed meal is reported to be increased perhaps contributing to 
postprandial hyperinsulinaemia. Additionally GIP has been shown to stimu-
late glucagon secretion. Postprandial responses of the other incretin hormone 
glucagon-like peptide-1 (GLP-1) has been reported to be decreased in obese 
individuals as well as in patients with T2DM. In the present study we evalu-
ated the impact of disruption of insulin sensitivity on postprandial GIP, GLP-
1 and glucagon responses in healthy young male subjects without any risk 
factors for diabetes.
Materials and methods: Postprandial GIP, GLP-1 and glucagon responses 
were measured using a 520 kcal-liquid meal test (58 g carbohydrate, 28 g fat 
and 10 g protein) in 10 healthy Caucasian male subjects without family histo-
ry of diabetes (age: 23.9±3.1 years (mean±SD); BMI: 24.1±1.7 kg/m2; fasting 
plasma glucose: 4.9±0.3 mM, HbA1c: 5.4±0.1%) before and after induction 
of insulin resistance using high calorie diet, relative physical inactivity and 
administration of prednisolone (37.5 mg/day) for 10 days.
Results: The intervention had a significant impact on insulin resistance ac-
cording to the homeostatic model assessment (1.4±0.1 vs. 2.3±0.4, p=0.02) 
without affecting body weight. In line with this, fasting insulin levels (36±3 
vs. 61±6 pM, p=0.03) and insulin responses (as assessed by AUC) increased 
following the intervention (30±6 vs. 59±16 nM·4h, p=0.02). The impaired in-
sulin sensitivity had no impact on postprandial GLP-1 responses (1.5±1 vs. 
2.0±1 nM·4h, p=0.56), but postprandial GIP responses rose significantly fol-
lowing induction of insulin resistance (10.6±1.3 vs. 14.1±1.5 nM·4h, p=0.03) 
as well as postprandial glucagon responses (1.6±1.5 vs. 2.4±3.2 nM·4h, 
p=0.03).
Conclusion: Our data show that induction of insulin resistance using pred-
nisolone, high calorie diet and relative physical inactivity results in increased 
postprandial GIP responses suggesting that increased GIP secretion observed 
in conditions characterised by insulin resistance may occur as a consequence 
of insulin resistance rather than being a primary pathogenetic trait. Addition-
ally, our data suggest that hyperglucagonaemia (observed in obese individu-
als with type 2 diabetes) may be a consequence of insulin resistance, while 
insulin resistance not seems to be directly responsible for the reduced post-
prandial GLP-1 responses observed in individuals with type 2 diabetes.
Supported by: an EFSD/Novartis grant
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The incretin effect is apparent after lipid challenge in healthy humans
B. Ahrén1, O. Lindgren1, J. Vikman1, C.F. Deacon2, J.J. Holst2, G. Pacini3,  
A. Mari3; 
1Lund University, Sweden, 2Copenhagen University, Denmark, 3ISIB.CNR, 
Padua, Italy.
Background and aims: It is well known that oral glucose gives rise to a great-
er insulin response than an isoglycaemic intravenous (iv) glucose infusion, 
due to the incretin effect. We examined whether an incretin effect exists also 
after lipid ingestion.
Materials and methods: After an overnight fast, 12 healthy male volunteers 
(age 20-30 years; BMI 20-25 kg/m2) received lipids (intralipidR) orally (0.6 
g/kg) or iv (infusion rate min 0-30 0.15g/min, min 30-60 0.30g/min and min 
60-90 0.45g/min, designed to mimic plasma triglyceride (TG) responses to 
the oral load). Blood samples were taken over 300 min for analysis of TG, glu-
cose, insulin, C-peptide and intact and total concentrations of glucagon-like 
peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP).
Results: Plasma glucose did not rise during lipid administration, whereas 
plasma TG levels rose similarly during oral and iv lipid (peak at 180 min 
of 1.0±0.2 mmol/l for both). Plasma insulin and C-peptide were unchanged 
during iv lipid but rose after oral lipid, the difference being largest during the 
first 60 min. Suprabasal 0-60 min AUC for insulin was 0.46±0.10 nmol/lx60 
min after oral lipid vs. -0.11±0.14 after iv lipid (P=0.03); corresponding val-
ues for C-peptide were 2.45±0.45 vs. 0.43±0.32 nmol/lx60 min (P=0.001). 
Figure (left panel) shows the insulin secretory rate (ISR) during the 300 min 
tests and (right panel) the ratio of ISR after oral vs. iv lipid as estimated from 
C-peptide data, illustrating the larger insulin secretory response to oral vs iv 
lipid with matching TG levels. Plasma intact and total GLP-1 and GIP were 
unchanged during iv but rose after oral lipid. Suprabasal 0-60 min intact GLP-
1 was 243±53 pmol/lx60 min after oral lipid vs. -9±5 after iv lipid (P<0.001); 
corresponding values for intact GIP were 302±118 vs. 9±53 pmol/lx60 min; 
P=0.031). Suprabasal 60 min AUC for ISR correlated to corresponding AUC 
for both intact GLP-1 (r=0.42; P=0.043) and intact GIP (r=0.42; P=0.047).
Conclusion: Oral vs iv lipid administration to matching TG levels reveals 
that oral lipid elicits a clear incretin effect with a pronounced stimulation of 
insulin secretion during the first 60 min. Since oral lipid as well stimulates the 
release of the two incretins and the increase in intact (insulinotropic) GLP-1 
and GIP correlates with insulin secretion, we conclude that an incretin effect 
induced by the classical incretin hormones also exists after oral lipid inges-
tion in healthy humans.
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Effect of GLP-1 and exendin-4 treatment on glucose and fat metabolism, 
in obese state
P. Moreno, B. Nuche-Berenguer, I. Gutiérrez-Rojas, A. Acitores, I. Ramos-
Álvarez, N. González, I. Valverde, M.L. Villanueva-Peñacarrillo; 
Metabolism, Nutrition & Hormones, IIS-Fundación Jiménez Díaz, Madrid, 
Spain.
Background and aims: Obesity is often associated with hypertension, car-
diovascular disease and diabetes. GLP-1, incretin with insulin-independent 
antidiabetic actions, and its homologous exendine-4, both have shown posi-
tive effects upon the glucose metabolism of extrapancreatic tissues participat-
ing in the hexose homeostasis. Here we studied the effect of GLP-1 and Ex-4 
on GLUT-4 expression and other parameters, in fat and muscle of an obesity 
(Ob) rat model, compared to normal (N).
Materials and methods: Ob was developed in male Wistar rats by chronic 
feeding -5 weeks- with a daily intake of standard chow combined with a 
“cafeteria diet” (65 % energy from lipids). The N group was fed with stan-
dard chow and water ad libitum (8 % energy as fat). Although weight was 
not different between N and Ob, the Ob model showed fasting plasma glu-
cose, triglycerides (153±13 mg/dl, n=11) and cholesterol (92±4 mg/dl, n=12) 
higher than normal (overall mean: 37±5 % Δ N-rats, p<0.02); no significant 
differences with N were detected in insulin or GLP-1 -by RIA-. Ob and N 
were 3-days treated -through an osmotic pump- with saline (control), GLP-1 
(0.86 nmol/kg/h) or Ex-4 (0.1nmol/kg/h). Blood samples were taken before 
and by the end of the treatment for plasma measurements. In epididimal fat 
and soleous muscles, we studied: GLUT-4 expression -mRNA by RT-PCR, 
and protein by Western blot-, isolated adipocytes glucose transport (GT) -
2-deoxi-D-[1,2-3H]glucose uptake- and muscle glycogen synthase a activity 
(GSa) -UDP-glucose into glycogen-.
Results: In muscle of Ob (n=5-7 rats), GLUT-4-protein was lower than in N 
(71±4 % N-control, p<0.01) while mRNA was higher (1.81±0.04 times N-con-
trol, p<0.001); GLP-1 did not modify mRNA, but increased the protein, to a 
value (180±14 % Ob-control, p<0.01) even higher (128±7 % N-control, p<0.02) 
than that in N (100±13 % N-control, n=6); Ex-4, like GLP-1, failed to modify 
mRNA, but stimulated the GLUT-4-protein (129±6 % Ob-control, p<0.05) to 
N levels (92±4 % N-control). GSa in Ob (1.30±0.16 U/g protein) was lower 
(p<0.001) than in N; GLP-1 did not affect the GSa, while Ex-4 induced a clear 
increase (175±20 Ob-control, p<0.02) toward normalization; no apparent ef-
fect was detected in N after GLP-1 or Ex-4. In fat of Ob (n=5-9), GLUT-4-
mRNA was lower than normal (0.39±0.05 times N-control, p<0.001), without 
differences in the protein; either GLP-1 or Ex-4 reduced GLUT-4-mRNA even 
further (GLP-1: 0.29±0.05 times Ob-control; Ex-4: 0.65±0.15; both p<0.01), as 
previously observed in N rats; both GLP-1 and Ex-4 exerted a slight but clear 
increase in GLUT-4-protein (137±9 % Ob-control and 118±5 %, respectively, 
both p<0.02). GT in Ob (6.7±0.7 fmol/105 cells) was lower (p<0.001) than in N 
(15.1±1.6 fmol/105 cells); GLP-1 and Ex-4 increased the value (159±10 % Ob-
control and 178±18 %, respectively, both p<0.01) toward normalization (over-
all mean: 74±8 % N-control). In Ob, Ex-4 highly reduced to normalization 
the triglycerides (86±3 mg/dl, p<0.01 vs Ob-control) and cholesterol values 
(75±3 mg/dl, p<0.01 vs Ob-control), while GLP-1 only decreased triglycerides 
to normalization (103±9 mg/dl, p<0.05 vs Ob-control).
Conclusion: In obese state, both GLP-1 and Ex-4 could exert a beneficial ef-
fect on its deleterious glucose metabolism, perhaps by their increasing action 
upon the muscle and fat glucostransporter translation process, together with 
a normalizing effect on the impaired lipid metabolism.
Supported by: FIS, CIBERDEM
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The separate and combined impact of the intestinal hormones GIP, GLP-
1 and GLP-2 on glucagon secretion in type 2 diabetes
A. Lund1,2, T. Vilsbøll1, J.I. Bagger1, J.J. Holst2, F.K. Knop1; 
1Department of Internal Medicine F, Gentofte Hospital, University of 
Copenhagen, Hellerup, 2Department of Biomedical Sciences, The Panum 
Institute, University of Copenhagen, Denmark.
Background and aims: Type 2 diabetes mellitus (T2DM) is associated with re-
duced suppression of glucagon during oral glucose tolerance test (OGTT) where-
as isoglycaemic intravenous (iv) glucose infusion (IIGI) results in normal gluca-
gon suppression in these patients. We aimed to evaluate the role of the intestinal 
hormones glucose-dependent insulinotropic polypeptide (GIP), glucagon-like 
peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2) in this discrepancy.
Materials and methods: Glucagon responses were measured during a 3-hour 
50 g-OGTT (day a) and a corresponding IIGI (day b) in 10 patients with 
T2DM (age (mean±SEM): 51±3 years; BMI: 33±2 kg/m2; HbA1c: 6.5±0.2%). 
During four additional IIGIs, GIP (day c), GLP-1 (day d), GLP-2 (day e) and 
a combination of the three intestinal hormones (day f), respectively, were in-
fused intravenously to mimic postprandial responses.
Results: Isoglycaemia during all six study days was obtained. As expected, 
no suppression of glucagon occurred during the initial phase of the OGTT, 
whereas significant (p<0.05) suppression of glucagon during the first 30 min-
utes of the IIGI (day b) was observed. As illustrated in Fig. 1, the glucagon re-
sponse during the IIGI+GIP+GLP-1+GLP-2 (day f) equalled the inappropri-
ate glucagon response to OGTT (p=NS). The separate GIP infusion (day d) 
elicited significant hypersecretion of glucagon, whereas GLP-1 infusion (day 
d) resulted in potentiation of glucagon suppression during IIGI. IIGI+GLP-2 
infusion resulted in a glucagon response in the mid-range between the inap-
propriate glucagon response to OGTT and the preserved suppression during 
IIGI.
Conclusion: Our results indicate that the intestinal hormones, GIP, GLP-1 
and GLP-2, may play a role in the inappropriate glucagon response to orally 
ingested glucose in T2DM with GIP acting as a strong glucagonotropic sub-
stance.
Supported by: Danish Diabetes Association and The Novo Nordisk Foundation
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The contribution of GLP-1 to the enteroinsulinar axis in type 2 diabetes 
mellitus
J. Schirra, L. Carneiro, M. Nicolaus, A. Derani, B. Aulinger, B. Göke; 
Department of Internal Medicine II, Campus Großhadern, University of 
Munich, Germany.
Background: The gut born hormones GLP-1 and GIP augment glucose-de-
pendently the postprandial (PP) insulin release from the pancreatic B-cell, 
mediating the so-called incretin effect which constitutes the difference be-
tween the postprandial (PP) and the isoglycemic fasting insulin response. In 
addition, GLP-1 reduces glucagon. In T2DM, the incretin effect is reduced 
and plasma glucagon increased. A defect of the GIP action has been sug-
gested in T2DM. However, the contribution of either hormone in T2DM is 
not known.
Aim: To analyze the contribution of endogenous GLP-1, we examined the ef-
fect of a duodenally perfused meal on pancreatic insulin and glucagon secre-
tion using the specific GLP-1 receptor antagonist exendin(9-39) (Ex-9).
Methods: 12 patients with T2DM (age 60±2, BMI 28.1±1.2, HbA1c 6.4±0.3) 
and 12 healthy subjects (HS) participated in 3 study days in random order. 
Plasma insulin and glucagon concentrations were measured during a 3 hour 
hyperglycemic clamp at 180mg/dl using IV glucose. 30 min prior the clamps, 
a duodenal meal perfusion (2.03 kcal/min, 77% lipid, 23% glucose) was initi-
ated and continued throughout the study on 2 days. This was accompanied 
by IV infusion of Ex-9 (600 pmol/kg/min) or saline, respectively. A third day 
with duodenal perfusion of saline served as isoglycemic fasting control (IF) 
to calculate the incretin effect. The acute insulin response (AIR) to hyperg-
lycemia and the sustained responses of plasma insulin (SIR) and glucagon 
(SGR) were calculated during the first 10min and between 60 and 120min of 
the hyperglycemic clamp as incremental AUC (see table).
Results: In HS, AIR and SIR during the duodenal meal (PP) were markedly 
increased compared to isoglycemic fasting conditions (IF) corresponding to 
an incretin effect of 0.34±0.1 and 5.1±0.8 mU/ml*min, respectively. In T2DM, 
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both AIR and SIR were significantly lower compared to HS and the incretin 
effect was significantly reduced (0.13±0.04 and 1.9±0.7 mU/ml*min, p<0.05 
vs HS). Ex-9 reduced PP AIR and SIR both in HS and T2DM. Also with Ex-9, 
PP AIR and SIR remained significantly elevated compared to IF both in HS 
and T2DM corresponding to a GLP-1 independent incretin effect in T2DM 
of 0.08±0.03 (AIR) and 0.60±0.25 (SIR) mU/ml*min, thus representing 79% 
and 51% of PP insulin response, respectively. Plasma glucagon concentra-
tions were markedly elevated in T2DM. Ex-9 significantly increased SGR in 
both, HS and T2DM.
Conclusion: Both the acute and sustained postprandial response to hyper-
glycemia is largely mediated by gut hormones. This incretin effect is clearly 
reduced in T2DM compared to HS. However, GLP-1 and non-GLP-1 incre-
tins contribute equally to the incretin effect both in HS and T2DM. We sug-
gest GIP to account for the remaining incretin effect also in T2DM. As in 
HS endogenous GLP-1 contributes largely to the postprandial suppression 
of plasma glucagon. We conclude that although pancreatic islet cell secre-
tion is disturbed in T2DM, the enteroinsulinar axis seems to be intact also 
in T2DM.
HS T2DM
PP+SAL PP+Ex9 IF PP+SAL PP+Ex-9 IF
AIR
(mU/ml*min) 0.60±1.5 0.38±0.08*# 0.25±0.08 0.16±0.05 0.10±0.04*# 0.02±0.02
SIR
(mU/ml*min) 6.4±1.0 3.5±0.4*# 1.3±0.5 2.5±0.8 1.2±0.3*# 0.6±0.2
SGR
(ng/ml*min) -0.8±0.3 -0.3±0.26*# -1.1±0.2 0.05±0.2 0.9±0.2*# -0.9±0.2
AUC, Mean±SEM. ANOVA: *P<0.05 vs SAL, #P<0.05 vs IF
Supported by: DFG
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Insulin resistance and glucose intolerance independently reduce the 
incretin effect via a beta cell defect
D.H. Jensen1, K. Aaboe2, A. Voelund3, J.E. Henriksen4, J.J. Holst5,  
S. Madsbad6, T. Krarup1; 
1Endocrinology, Bispebjerg University Hospital, Copenhagen, 
2Endocrinology, Herlev University Hospital, 3Endocrinology, Bispebjerg 
Hospital, Copenhagen, 4Endocrinology, Odense University Hospital, 
5Department of Biomedical Sciences, Panum Institute, Copenhagen, 
6Endocrinology, Hvidovre University Hospital, Denmark.
Background and aims: The incretin effect is impaired in type 2 diabetes. We 
wanted to evaluate the separate impact of insulin resistance and glucose intol-
erance on the incretin effect and whether changes in the incretin effect were 
associated with β-cell defects.
Materials and methods: 21 healthy 1st degree relatives to type 2 diabetes 
patients with normal glucose tolerance underwent a 75g OGTT on day 1 and 
an isoglycemic i.v. glucose test on day 2. The two tests were performed before 
and after 5 days treatment with 2mg dexamethasone bid. Insulin, C-peptide, 
GIP and GLP-1 were measured during the 4 tests. The incretin effect was 
estimated by relating the incremental insulin response during the OGTT to 
the incremental insulin response during the i.v. glucose infusion. Further-
more, the insulin secretion rates during the i.v. glucose infusions were plotted 
against ambient P-glucose, and the slopes of these linear relations were used 
as an index of the β-cell glucose sensitivity, which is known to be impaired 
already in the early stages of type 2 diabetes. To relate the β-cell glucose sen-
sitivity to the ambient insulin resistance the disposition index was calculated 
by multiplying β-cell glucose sensitivity with 1/HOMAIR.
Results: The dexamethasone treatment increased insulin resistance in all 21 
subjects, and 11 subjects in addition to insulin resistance also developed glu-
cose intolerance (IGT) (10 subjects remained glucose tolerant (NGT)). The 
incretin effect was in the NGT and IGT group 71±3.2 and 67±4.6% before 
and 58±5.2 and 32±8.8% after treatment, respectively. There was no differ-
ence in the incretin effect between groups at baseline but a significant dif-
ference after treatment (P < 0.05). A multiple regression analysis of pooled 
data from the two groups related the changes in incretin effect (Δincretin 
effect) to changes in insulin resistance (ΔHOMAIR) and glucose tolerance 
(delta 2-hour P-glucose during OGTT, ΔPG120). ΔPG120 and ΔHOMAIR were 
negatively and independently correlated with Δincretin effect (P < 0.05), and 
accounted for 45% of the overall variation in Δincretin effect. The disposition 
index was 1.7±0.20 and 1.4±0.17 pmol kg-1 min-1 mM-1 in the NGT and IGT 
groups, respectively (P = NS). After the dexamethasone treatment this index 
was 1.3±0.19 in the NGT group and 0.9±0.12 pmol kg-1 min-1 mM-1 in the 
IGT group, respectively (P < 0.05). The reduction in the disposition index in 
the NGT group was not significant (P =NS). Responses of GLP-1 and GIP did 
not differ between groups before or after dexamethasone during the OGTT.
Conclusion: Insulin resistance and glucose intolerance contribute indepen-
dently to the reduced incretin effect seen in type 2 diabetes. In addition we 
find that the incretin effect is reduced very early in NGT insulin resistant 
people, before the β-cell sensitivity to i.v. glucose is affected, and deteriorates 
further when β-cell function declines in people with IGT. This points to an 
early, specific β-cell defect in the action of the incretin hormones before the 
development of overt type 2 diabetes.
Supported by: The Novo Nordisk Foundation
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GIP controls human core circadian genes indicating an integrative role 
in food-regulated metabolism
Ö. Gögebakan1, M.A. Osterhoff1, F. Isken1, N.N. Rudovich1, K.-N. Fernaz1,  
M. Nauck2, A.F.H. Pfeiffer1; 
1Clinical Nutrition, DIfE, Rehbrücke, 2Diabeteszentrum, Bad Lauterberg, 
Germany.
Background and aims: Adaptation of metabolism to circadian rhythms 
is critical for its proper function. Rhythmically expressed peripheral clock 
genes are regulated by food intake but detailed mechanisms are unknown. 
We investigated the role of the food induced hormones, GIP, insulin and glu-
cose on expression of core circadian genes in human adipose tissue.
Materials and methods: 17 overweight healthy humans (BMI: 28-40 kg/m2, 
age: 30-65 y) with normal glucose tolerance were infused with placebo or 
GIP in physiological doses for 4h i.v. either alone, or during euglycemic or 
hyperglycemic hyperinsulinemic clamps. Biopsies were taken from subcuta-
neous adipose tissue before and after treatment. Total RNA was isolated from 
all biopsies and transcribed into cDNA. Expression patterns of circadian 
genes were analysed by hybridisation to a total number 100 Agilent 60-mer 
Whole Human Genome (4x44K) single-color DNA microarrays and results 
confirmed by quantitative RT-PCR. Statistical analysis of microarray data was 
performed with Agilent GeneSpring GX software.
Results: The expression of REV ERBalpha (NR1D1) was regulted during 
the 4 h treatment even under placebo conditions and decreased significantly 
about 4 fold. The expression of other circadian genes like PER2, PER3, TEF 
and DBP did not change significantly. Neither insulin nor glucose affected 
clock gene expression in euglycemic or hyperglycemic hyperinsulinemic 
clamps. However, GIP either alone or combined with insulin and glucose, 
significantly enhanced the circadian decrease of the core clock genes REV 
ERBalpha 6.5 - 9 fold as well as PER2, PER3 and the clock output genes TEF 
and DBP between 1.5 - 2.5 fold. These genes were among the most signifi-
cantly GIP-regulated genes even after correction for multiple testing (Ben-
jamini Hochberg). Additional correlation analysis showed a disintegration of 
clock gene correlations among each other as a result to GIP administration. 
The decrease was not reproduced in a mouse model upon treatment with GIP 
at different circadian time points pointing to species specific differences.
Conclusion: We identify GIP as a powerful regulator of the core clock gene 
machinery in human adipose tissue in vivo which provides the missing link 
from food intake to peripheral clock gene regulation. Since i.e. REV ERBal-
pha is involved in regulation of glucose, lipid and cholesterol metabolism, fat 
cell differentiation and inflammatory processes, the disruption of circadian 
rhythms by GIP may explain its obesogenic and fatty liver inducing proper-
ties.
Supported by: DFG
Diabetologia (2010) 53:[Suppl1]S1–S556 S 263
1 C
PS 51 Clinical insulin secretion - 
methods and associations
654
Dynamic beta cell function in young type 2 diabetes patients (15-34 
years) in the Diabetes Incidence Study in Sweden register
M. Sjostrand1, H.J. Arnqvist2, J.W. Eriksson1, S. Gudbjörnsdottir3,  
S. Lindmark4, M. Landin-Olsson5, L. Nyström4, M.K. Svensson3,  
P. Adolfsson1, K. Arneklev1, J. Bolinder6; 
1Early Phase Development, R&D, AstraZeneca, Mölndal, 2Linköping 
University Hospital, 3Sahlgrenska University Hospital, Göteborg, 4Umeå 
University, 5Lund University Hospital, 6Karolinska University Hospital, 
Stockholm, Sweden.
Background and aims: Simple methods for evaluation of dynamic beta-cell 
function in epidemiological and clinical studies of type 2 diabetic patients 
(T2D) are needed. The first phase insulin response after intravenous (iv) glu-
cose is diminished whereas the insulin response after non-glucose stimulation, 
i.e. iv arginine is less dependent on prevailing glucose levels. The objective of 
this study was to compare these methods for assessment of dynamic beta-cell 
function in young T2D with different disease duration and treatments.
Materials and methods: 54 T2D patients from the Diabetes Incidence 
Study in Sweden (DISS) and 23 healthy controls; group-wise matched for 
age (35+5.4 vs 40+5.8 years), sex (M/F 33/21 vs. 12/11) and BMI (33+5.7 vs. 
33+4.5 kg/m2) were included in a cross-sectional study. Beta-cell function 
was assessed by iv pulses of arginine 5g followed after 30 min by iv glucose 
0.3g/kg. The acute insulin and c-peptide response to arginine (AIRarg and Ac-
pepRarg) and to glucose (AIRglu and Ac-pepRglu) was calculated as the mean of the 
three highest levels of insulin and c-peptide obtained during 5 minutes minus 
the plasma level of insulin and c-peptide at baseline.
Results: Fasting p-glucose at baseline was 7.5 mmol/L in T2D and 5.5 mmol/
L in healthy controls. AIRglu and Ac-pepRglu were reduced approx 90% in T2D 
and AIRarg and Ac-pepRarg were reduced approx 30% in T2D (7.6+24 vs.93+60, 
p<0.05; 0.5+1.3 vs. 4.2+2.4, p<0.05 and 51+45 vs.72+43, p= 0.07 and 2.4+1.6 
vs 3.2+1.4, p=0.06)(compared to the healthy controls). AIRglu and Ac-pepRglu 
but not AIRarg and Ac-pepRarg responses was negatively correlated with fasting 
p-glucose at baseline (r= -0.52, r=-0.48 p<0.05 and r=0.10 and r=0.15, ns). 
AIRarg and Ac-pepRarg disciminated patients with different disease duration 
better than AIRglu and Ac-pepRglu as displayed in Table. In addition, AIRglu and 
Ac-pepRglu was higher in the diet-treated group compared to other treatments, 
while AIRarg and Ac-pepRarg were decreased in insulin-treated patients com-
pared to other treatments groups (see Table).
Conclusion: AIRarg and Ac-pepRarg were less reduced than AIRglu and Ac-pepRglu 
in young type 2 diabetic patients and discriminated better between groups 
with different disease duration. AIRarg and Ac-pepRarg was also less dependent 
on baseline plasma glucose levels. AIRarg and Ac-pepRarg may be used epide-
miological and clinical studies to select patients suitable for drugs affecting 
dynamic beta-cell function.
Acute insulin (AIR, µU/ml) and c-peptide( Ac-pepR, nmol/L) responses after iv glucose and iv arginine
Diabetes duration <5 yrsn= 11
5-8 yrs
n=20
>8 yrs
n=23 p-value
AIRglu 8.6±38 10.4±26 4.6±8.4 ns
Ac-pepRglu 0.4±2.0 0.7±1.5 0.3±0.7 ns
AIRarg 83±52 57±51 31±20 p<0.05>8 years vs. 5-8 and <5 years
Ac-pepRarg 3.6±1.9 2.8±1.8 1.6±0.7 p<0.05>8 years vs. 5-8 years
Antidiabetic treatment Dietn=10
Tablets
n=22
Tablets+insulin
n=12
Insulins only
n=10 p-value
AIRglu 26.5±42 4.3±18 2.3±15 2.0±3.8 p<0.05diet vs. other treatments
Ac-pepRglu 1.4±2.4 0.22±1.0 0.44±0.9 0.16±0.37 p<0.05diet vs. other treatments
AIRarg 67±62 59±48 50±27 18±6.6 p<0.05insulin vs. other treatments
Ac-pepRarg 2.9±2.0 2.8±1.8 2.5±1.2 1.2±0.5 p<0.05insulin vs. other treatments
Supported by: AstraZeneca
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The graded glucose infusion is comparable to the hyperglycaemic clamp 
as a tool for measurement of glucose-dependent insulin secretion
D.E. Kelley1, R.R. Shankar2, B. Keymeulen3, L. Mixson4, D.L. Mixson5,  
C. Chung5, E. Vandemeulebroucke3, M. DeSmet6, C. Cilissen6,  
G.A. Herman7, C.R. Beals5, H.O. Steinberg2, S.S. Shankar5; 
1Diabetes and Obesity, Merck Research Laboratories, Rahway, USA, 
2Clinical Research-Metabolism, Merck Research Laboratories, Rahway, 
USA, 3Metabolism, UZ Brussels, Belgium, 4BARDS, Merck Research 
Laboratories, Rahway, USA, 5Experimental Medicine, Merck Research 
Laboratories, Rahway, USA 6Clinical Pharmacology, Merck Sharpe and 
Dohme, Brussels, Belgium, 7Early Stage Development, Merck Research 
Laboratories, Rahway, USA.
Background and aims: The hyperglycemic clamp (HGC), considered the 
gold standard method for measurement of glucose-dependent insulin secre-
tion (GDIS) is technically resource intensive. In contrast, the Graded Glucose 
Infusion (GGI) is a simpler, but less well-characterized method. We tested 
the hypothesis that the GGI is comparable to the HGC as a tool to measure 
changes in GDIS, by performing a randomized, double-blind, placebo-con-
trolled experiment that directly compared the GGI and the HGC, using ex-
enatide as a probe.
Materials and methods: Following an overnight fast, 18 non-obese healthy 
subjects (age 29 ± 8 yrs, BMI 23.5 ± 2.3 kg/m2, basal fasting glucose 4.50 ± 
0.24 mmol/L) received 5μg exenatide s/c or matched placebo, immediately 
prior to the procedures. Each subject underwent a GGI (glucose infusion 
rates (GIR) of 2, 4, 6 and 12mg/kg/min, 40 minute periods each) and a HGC 
(glycemia maintained at 11.1 mmol/L for 120 minutes; steady-state (SS) 90 to 
120 minutes) on separate days, in a randomized crossover design.
Results: Data are presented as Mean ± SEM, exenatide vs placebo. HGC: At 
matched SS plasma glucose (10.80 ± 0.11 vs 10.71 ± 0.13 mmol/L), signifi-
cant differences (p<0.001 for all comparisons) were observed in GIR (1.05 
± 0.09 vs 0.45 ± 0.07 mmol/kg/min), plasma insulin (4111.44 ± 303.50 vs 
322.94 ± 225.02 pmol/L), C-peptide (9.76 ± 0.59 vs 2.06 ± 0.47 nmol/L), and 
insulin secretion rates (ISR) (1398.6 ± 99.9 vs 333.0 ± 66.6 pmol/min). GGI: 
At matched GIR, significant (p<0.001 for all comparisons) differences were 
observed in ambient plasma glucose levels (G) (7.72 ± 0.59 vs 13.19 ± 0.59 
mmol/L), ISR (1465.2 ± 166.5 vs 699.3 ±166.5 pmol/min), and Φ (slope of 
ISR/G: 4.2 ± 0.17 vs 1.89 ± 0.15). Both methods were compared using the 
only common end-point, the ratio of ISR to G. The ISR/G for exenatide in the 
GGI was comparable to that in the HGC (2.95 ± 0.29 vs 2.14 ± 0.15 respec-
tively). The GGI was operationally simpler than the HGC.
Conclusion: This study demonstrates for the first time in a head to head set-
ting, that the GGI is comparable to the HGC in its ability to detect clinically 
relevant changes in GDIS, while being less resource intensive. Our data indi-
cate that the GGI is a sensitive, reliable and feasible tool for measurement of 
GDIS effects in healthy subjects.
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A novel tool to measure changes in glucose-dependent insulin secretion 
in healthy subjects
S.S. Shankar1, R.R. Shankar1, L. Mixson2, D.L. Miller1, N. Handa3,  
M. Cross4, G.A. Herman5, C.R. Beals1, H.O. Steinberg6, D.E. Kelley7; 
1Experimental Medicine, Merck Research Laboratories, Rahway, USA, 
2BARDS, Merck Research Laboratories, Rahway, USA, 3Merck Sharpe and 
Dohme, Gurgaon, India, 4Veeda Research Inc., Ahmedabad, India, 5Early 
Stage Development, Merck Research Laboratories, Rahway, USA, 6Clinical 
Research-Metabolism, Merck Research Laboratories, Rahway, USA, 
7Diabetes and Obesity, Merck Research Laboratories, Rahway, USA.
Background and aims: The Meal Tolerance Test (MTT) can detect changes 
in prandial glucose-dependent insulin secretion (GDIS) in Type 2 Diabetes 
Mellitus (T2DM) subjects; however, it is less suitable as a tool in healthy vol-
unteers (HV), where effect sizes are small, and variability high. We hypothe-
sized that changes in GDIS can be detected in HV, if the MTT is conducted in 
a milieu simulating the hyperglycemia of T2DM. We tested the hypothesis by 
performing a randomized, double-blind, placebo controlled, crossover study 
that measured GDIS effects of the DPP4 inhibitor sitagliptin, in the setting of 
a MTT superimposed on stable hyperglycemia achieved by a hyperglycemic 
clamp (HGC) (HGC-MTT).
Materials and methods: Following an overnight fast, and a single dose of 
sitagliptin 100mg or matched placebo, 12 healthy non-obese subjects (age 27 
± 6 yrs., BMI 20.5 ± 1.3 kg/m2) underwent a HGC at target glycemia of 8.9 
mmol/L for 370 minutes (mins.); a standardized liquid meal was adminis-
tered at 180 mins, and consumed over 10 mins.
Results: Data are presented as Mean ± SEM, sitagliptin vs placebo. Pre-
meal (120-180mins.): At matched plasma glucose (8.79 ± 0.05 vs 8.95 ± 0.06 
mmol/L), significant (p<0.001 for all between group comparisons) differ-
ences were observed in glucose infusion rates (GIR) (0.72 ± 0.03 vs 0.58 ± 
0.03 mmol/kg/min), active GLP-1 (1.7 ± 0.1 vs 1.2 ± 0.1 pmol/L), plasma 
insulin (1279.26 ± 228.49 vs 752.84 ± 231.96 pmol/L) and insulin secretion 
rates (ISR) (1598.4 ± 133.2 vs 1065.6 ± 133.2 pmol/min). Post-meal (190-
340mins.): At matched plasma glucose (9.34 ± 0.03 vs 9.26 ± 0.04 mmol/L), 
further significant (p<0.001 for all parameters) increments over pre-meal 
were seen in all parameters in both groups, and significant (p<0.001 for all 
between group comparisons) differences were observed in GIR (0.83 ± 0.02 
vs 0.76 ± 0.02 mmol/kg/min), active GLP-1 (6.4 ± 0.6 vs 3.1 ± 0.7 pmol/
L), plasma insulin (5809.49 ± 988.97 vs 3833.64 ± 993.13 pmol/L) and ISR 
(3230.1 ± 266.4 vs 2664.0 ± 266.4 pmol/min).
Conclusion: Our data demonstrate for the first time in HV that the GLP-1 
stabilizing property of sitagliptin has significant GDIS effects in the prepran-
dial state, with further significant augmentation in the prandial state. The 
HGC-MTT appears to be a novel reliable tool for measurement of prepran-
dial and prandial GDIS in a single experiment in a single dose setting in HV.
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Differences in insulin release between long term type 2 diabetes mellitus 
and NGT - a model of discovery of changes in proteins using liquid 
chromatography-mass spectrometry (LC-MS)
M. Pepaj, P.M. Thorsby; 
Oslo University Hospital, Aker, Hormone Laboratory, Norway.
Background and aims: Proteomics-based candidate biomarker discovery ef-
forts have gained significant attention due to the power of these technologies 
for analyzing complex protein mixtures and their potential for identifying 
novel markers indicative of disease. The aim of this project is to apply ad-
vanced quantitative proteomic methodology to quantify relative changes in 
protein levels in serum samples from individuals with normal glucose toler-
ance (NGT) and long term type 2 diabetes (T2DM) investigated with hyper-
glycaemic.
Materials and methods: 13 men 7 women were followed for 10 years, with 
these baseline characteristics: age 58,4 (6,1) (mean (SD)) years, diabetes du-
ration 7,0 (3,0) years, HbA1c 8,5 (1,6)%, BMI 25,8 (2,7) kg/m2, weight 76,6 
(10,3) kg and anti-GAD negative. Hyperglycaemic clamp was preformed in 
all with glucose increase of + 7.2 (1.10) mmol/l during two hours, followed 
by a bolus of 5 mg iv arginine stimulation. For comparison, the hyperglycae-
mic clamp with arginine was also performed in seven aged-matched healthy 
volunteers. Our approach uses an enzymatic 18O stable isotope labeling pro-
cedure followed by liquid chromatography- mass spectrometry (LC-MS) to 
directly detect and quantitatively compare proteins present in patients with 
T2DM to be compared with persons with NGT during the hyperglycaemic 
clamp. With this approach, we can rapidly identify and measure difference 
in expression levels for thousands of peptides in a single analysis. So far only 
insulin secretion data from the hyperglycemic clamp have been analyzed.
Results: Insulin secretion measured as the mean increase in C-peptide con-
centrations after one hour of hyperglycaemia were significantly lower in pa-
tients than in controls, 189 (99) pmol/l vs 1044 (433) pmol/l, p < 0.001. Also, 
the maximal C-peptide value after arginine stimulation was significantly 
lower in patients than in controls, 723 (583) pmol/l vs 4292 (2114) pmol/l, 
p< 0.001, This represents 38% increase in the mean C-peptide level during 
the first hour of hyperglycaemia in patients compared to a 97% increase in 
healthy volunteers, and 71% increase in patients after arginine compared to 
115% in controls. Fig 1
Conclusion: There are large differences in insulin secretion between T2DM 
and NGT after more than seventeen years of diabetes, but rapid insulin re-
lease is still present when stimulating the b-cells with arginine. The difference 
in insulin response may be due to undiscovered proteins.
Fig 1 Mean levels of C-peptide during hyperglyceamic clamp with arginine 
(5g) infusion after two hours of 8 mmol/l hyperglyceamia (• and black line) 
and 7 healthy volunteers (dotted line)
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The aging type 2 diabetes. Differential effects of aging and diabetes on 
insulin sensitivity, beta cell function and incretin production
B. Geloneze1,2, A.C.J. Vasques1, M.S. Oliveira1, F.S. Novaes1, J.C. Pareja1,2, 
M.J.A. Saad3,2, M.A. Tambascia1,2; 
1Laboratory of Investigation on Metabolism and Diabetes - LIMED, 
University of Campinas, 2National Institute of Science and Technology on 
Obesity and Diabetes, Campinas, 3Laboratory of Clinical Investigation on 
Insulin Resistance, University of Campinas, Brazil.
Background and aims: Diabetic physiopathology is a combination of insulin 
resistance, beta cell dysfunction, and impaired incretin action or production. 
Aging is related to increased prevalence of T2DM. The aim of the present 
study is to quantitate the separate impact of aging and diabetes on the dia-
betic physiopathology [i.e., insulin sensitivity (IS), beta cell function and in-
cretin production].
Materials and methods: Hyperglycemic clamp (HC) and meal tolerance test 
(515 Kcal) were performed in 48 subjects divided in 24 with normal glucose 
tolerance [NGT], and 24 with type 2 diabetes (DM) with less than 5 years 
of disease and taking OADs. Both NGT and DM groups were composed by 
12 middle-age (35 to 50 y) and 12 aging subjects (> 65 y), with a BMI below 
30 kg/m2. IS and insulin production were evaluated by HC. During the 180 
minutes MTT, both incretins: GLP-1 and GIP were evaluated.
Results: The IS (Clamp-derived insulin sensitivity index - ISI, and glucose in-
fusion rate - GIR) were reduced in DM compared with NGT (p < 0.01). These 
results were also affected by aging, but in a less intense manner when subjects 
were stratified by aging category (p < 0.05). Beta cell function (Clamp-derived 
derived first and second phase insulin secretion in relation to ISI - First and 
Second phase Disposition Indexes - DI) were reduced in DM compared to 
NGT (p<0.05). Aging did not affect DI in NGT, but exacerbates the difference 
between DM groups (p<0.01). The 180min total GIP production were similar 
among groups. GIP incremental area under the curve AUC(0-60 min) were 
greater in DM groups (p<0.05), but not affected by aging. The 180min GLP-1 
production were reduced in aging groups (p<0.05), but independent of the 
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presence of DM. In middle age group, total GLP-1 production was reduced 
in DM in comparison to NGT (p<0.05). GLP-1 incremental AUC(0-60 min) 
were reduced in aging groups independent of the presence of DM (p<0.05).
Conclusion: In non-obese subjects, diabetic state and aging impair insulin 
sensitivity and incretin production independently of one another. Insulin 
production is affected by the DM itself, and aging exacerbates this condition. 
Aging associated defects superimposed diabetic physiopathology, in special 
regarding incretin production. The knowledge of complex relationship of ag-
ing and glucose homeostasis in diabetic and non-diabetic subjects could sup-
port the development of physiopathological-based diabetic therapies.
Supported by: Merck Sharp & Dohme
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Risk factors for the development of diabetes after acute beta cell mass 
reduction
G. Muscogiuri1, G. Sorice1, L. Marselli2, A. Prioletta1, T. Mezza1, M. 
Tancredi2, A. Lassandro1, P. Marchetti2, A. Giaccari1; 
1Department of Endocrinology, Rome, 2Department of Endocrinology and 
Metabolism, Pisa, Italy.
Background and aims: Insulin secretion (IS) defects and insulin resistance 
(IR) contribute to the onset and progression of type 2 diabetes (T2D), though 
the relative contribution of each factor is still unknown. In our series we 
studied the role of β cell in the pathogenesis of type 2 diabetes by analyzing 
patients undergoing acute β-cells mass reduction after duodeno-pancreatec-
tomy (DP).
Methods: Eight patients were evaluated for glucose tolerance (OGTT), IS 
(hyperglycemic clamp), β-cell mass (arginine bolus) and insulin sensitivity 
(hyperinsulinemic euglycemic clamp; 40 mU/m2) before and after DP. Ab-
dominal-CT was performed to quantify visceral adipose tissue (VAT) and 
subcutaneous adipose tissue volumes (SAT). During surgery we collected 
pancreas specimens on which we performed positive insulin area measure-
ments (PIA) by a computer assisted system.
Results: there were 4 women and 4 men aged (mean ± SD) 58.7 ± 21.9 years, 
BMI (mean ± SD) 29.6 ± 6.1 kg/m2. At the enrollment no patient reported 
history of type 2 diabetes. Before surgery 5 patients resulted IGT. After DP, 
4/8 developed diabetes, 3/8 IGT and 1/8 preserved normal glucose tolerance. 
There were not significative changes in whole body glucose uptake (4.3±1.1 
vs. 3.8±1.1 mg/kg/min before and after surgery respectively; p=NS) follow-
ing DP. A significant reduction of β-cell mass calculated as AUC of insulin 
after arginine bolus (AUC Arg) was detected after surgery (before 7485.8 
± 363.5 vs. after surgery 2312.2 ± 239.5 μUI/ml/min; P=0.001) as well as 
the I and II phase of IS (AUC I: 186.5 ± 17.4 vs. 95.0 ± 10.9 μUI/ml/min, 
P=0.04; AUC II: 3124.1 ± 194.3 vs. 1409.7 ± 162.4 μUI/ml/min, P=0.001). 
PIA was 1.67±1.43%. When AUC I and II were adjusted for beta cell mass 
(AUC Arg), we found a significative increase in the AUCI/AUCArg after sur-
gery (0.05±0.03 vs. 0.14±0.12; p=0.03) but no changes in AUCII/AUCArg. 
We found a significant relationship of Δ(AUCI/AUCArg) with IR(r=-0,84; 
P=0.03) and VAT (r=0.82; P=0.03) but no with SAT, indicating that insulin 
resistant subjects better partially recovered the first phase of IS after surgery. 
In the same way PIA correlated with the degree of IR (r=-0.76;p<0.05) and 
VAT (r=0.9; p<0.01) but not with SAT.
Conclusion: We highlighted the unequal impact of acute β-cell mass reduction 
on glucose control. All patients experienced reduction in IS after DP although 
only half of them developed diabetes. We hypothesize that the VAT and the 
consequent IR may induce hypertrophy/hyperplasia of β cell mass, as docu-
mented by the strong relationship of PIA with IR and VAT. Although the IR 
subjects had a better partial recovery of first phase of IS, they developed diabe-
tes. Thus, they were not able to overcome IR, indicating that loss of β-cell mass 
rather than the first phase plays the major role in the pathogenesis of diabetes.
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Long-term recovery of beta cell function after partial pancreatectomy in 
humans
B.A. Menge1, T.G.K. Breuer1, H. Schrader1, W. Uhl2, W.E. Schmidt1, J.J. 
Meier1; 
1Department of Medicine I, 2Department of Surgery, St. Josef-Hospital, 
Bochum, Germany.
Background and aims: Glucose homeostasis and insulin secretion are sig-
nificantly altered after partial pancreatectomy in humans. The present study 
was designed to evaluate the long-term consequences of a hemipancreatec-
tomy in 20 patients (12 males, 8 females; age 57.4 ± 13.0 years) with chronic 
pancreatitis (CP; n = 10) or benign pancreatic and extra-pancreatic tumours 
(n = 10).
Materials and methods: In all patients, a 240 min oral glucose challenge was 
performed before and shortly (30.0 ± 33.9 days) after surgery, as well as after 
a follow-up of 3.1± 0.5 years. Plasma concentrations of glucose, insulin and 
C-peptide were determined, and indices of insulin sensitivity and insulin se-
cretion were determined.
Results: In CP patients, glucose concentrations immediately after surgery 
were higher at t = 180-240 min compared to pre-operative levels (p < 0.05). 
At the time of follow-up, the post-challenge glucose concentrations were 
intermediate in between the pre-operative assessment and the experiments 
immediately after surgery (p < 0.05). Insulin secretion was reduced by ~50% 
immediately after surgery in CP patients (p < 0.001). The patterns of insu-
lin and C-peptide concentrations determined at the time of follow-up were 
significantly shifted back towards pre-operative levels (p < 0.001), although 
complete normalization was still not achieved at this point in time. In the 
adenoma/tumour patients, fasting and post-challenge (from t = 150 - 240 
min) glucose concentrations were higher immediately after surgery, but were 
almost completely normalized at the time of follow-up (p < 0.001). Likewise, 
post-challenge insulin and C-peptide concentrations had increased signifi-
cantly compared to the early post-operative levels (p < 0.0001). The Matsuda 
index of insulin sensitivity was unchanged during the follow-up in both 
groups. However, the oral disposition index was restored to pre-operative 
levels at the time of follow-up both in CP patients (0.45 ± 0.1, 0.29 ± 0.07, and 
0.60 ± 0.1 mM-1 , before surgery, shortly after surgery and at the follow-up, 
respectively; p = 0.02) and in the tumour/adenoma patients (1.2 ± 0.3, 0.8 ± 
0.2, 1.4 ± 0.3 mM-1, respectively; p = 0.03).
Conclusion: These findings demonstrate a capacity for recovery of glucose 
control after partial pancreatectomy and suggest that beta-cell function can 
improve significantly over time even in adult humans. Whether this is due to 
increases in beta-cell mass or function cannot be clarified from this study, but 
given the limited capacity for beta-cell regeneration in adult humans, func-
tional improvements in insulin secretion are most likely.
Supported by: DFG
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Ghrelin suppresses insulin secretion and compromises beta cell function 
in healthy humans
J. Tong1, R.L. Prigeon2, H.W. Davis1, M.H. Tschöp1, D. D’Alessio1; 
1Internal Medicine, University of Cincinnati, 2School of Medicine, 
University of Maryland, Baltimore, USA.
Background and aims: The orexigenic gut hormone ghrelin and its recep-
tor, the growth hormone secretagogue receptor 1a, are present in pancreatic 
islets. While ghrelin reduces insulin secretion in rodents, its effect on insulin 
secretion in humans has not been established. Our objective was to test the 
hypothesis that circulating ghrelin suppresses glucose-stimulated insulin se-
cretion in healthy subjects.
Materials and methods: Acyl ghrelin (0.2 and 0.6 pmol/kg/h) or saline was 
infused in 10 healthy subjects (4M/6F; age 29.5 ± 5.2 y; BMI 22.8 ± 3.0 kg/m2, 
fasting plasma glucose 5.2 ± 0.1 pM, mean ± SEM) on 3 separate occasions in 
a counterbalanced fashion. The ghrelin was infused for 45 minutes to achieve 
steady-state levels and continued through a 180-minute frequently sampled 
intravenous (IV) glucose tolerance test (FSIGT). The acute (first phase) insu-
lin response to IV glucose (AIRg) was calculated from plasma insulin con-
centrations between 2 and 10 min after the glucose bolus. Insulin sensitivity 
index (SI) and glucose effectiveness at basal insulin (Sg) were quantified using 
the minimal model of glucose kinetics. Disposition index (DI), a measure of 
β-cell function, was a product of AIRg and SI. IV glucose tolerance was mea-
sured by the glucose disappearance constant (Kg) from 10 to 20 min.
Results: Ghrelin infusion did not alter fasting plasma insulin or glucose, but 
the 0.6 pmol/kg/h dose decreased AIRg (569.6 ± 187.0 vs. 861.2 ± 288.5 min.
mU/l-1) and Sg (0.015 ± 0.002 vs. 0.023 ± 0.002 min
-1) significantly compared 
to the saline control (p < 0.05 for ghrelin vs. control). Furthermore, both the 
0.2 and 0.6 pmol/kg/h ghrelin infusions decreased DI significantly (1940 ± 
570, 1669 ± 628 vs. 3825 ± 1283, respectively, p < 0.05 for both doses vs. con-
trol). Ghrelin administration did not alter IV glucose tolerance as measured 
by Kg.
Conclusion: Exogenous ghrelin reduces the first-phase insulin response to 
IV glucose and lowers β-cell function in healthy humans. These findings raise 
the possibility that endogenous ghrelin has a role in control of regulation 
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of insulin secretion, and that ghrelin antagonists could improve β-cell func-
tion. 
Supported by: NIH/NIDDK 
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NEFA kinetics during an OGTT after islet transplantation
G. Ward, Islet Tx Study Group; 
Endocrinology & Diabetes, St. Vincent’s Health Melbourne, Australia.
Background and aims: In addition to its effects on carbohydrate metabo-
lism, insulin inhibits lipolysis and promotes lipogenesis/fat storage. Abnor-
mal NEFA kinetics are a feature of both type 1 & 2 diabetes but have not 
been studied in type 1 diabetes patients after intra-portal allogeneic islet 
transplantation. The liver is an important site of NEFA synthesis and islet re-
cipients are known to develop periportal steatosis secondary to paracrine ef-
fects of high local concentrations of insulin. In view of the transplanted islets’ 
heterotopic location in close proximity to hepatocytes, we aimed to evaluate 
NEFA dynamics in response to an oral glucose challenge in islet recipients 
who achieved insulin-independence.
Materials and methods: A 4-hour 75g OGTT was performed in 2 insulin-
independent islet recipients, 3 patients with type 2 diabetes (T2DM) on oral 
medications (withheld 1 week pre-study) and 5 controls. Plasma glucose, in-
sulin and NEFA were assayed at 0,30,60,90,120,150,180 and 240min.
Results: Mean age of islet recipients, T2DM patients and controls was 56 + 
4, 55 + 1 and 49 + 5 SEM years respectively; mean BMI was 19.8 + 1.0, 37.5 
+ 4.2 and 25.1 + 1.4 SEM kg/m2 ; mean HbA1c was 5.7 + 0.3, 7.0 + 0.3 and 
5.5 + 0.1 SEM %. Although recipients had diabetic profiles (mean glucose: 
fasting 6.3 + 0.2, after 2 hours 13.0 + 1.4 SEM mmol/l ), they were insulin -
independent maintaining HbA1c < 6% without oral hypoglycaemics. Insulin 
secretion(AUCins corrected for glucose) during OGTT was lower in recipi-
ents and T2DM subjects when compared with controls(14.7%, 14.1%, 100% 
respectively). When corrected for prevailing insulin sensitivity, as measured 
by Kahn’s modification of Disposition Index for OGTT[Δins(0-30min)/
Δglu(0-30min)/fasting insulin], insulin secretion was 30.1% and 19.7% nor-
mal in recipients and T2DM subjects. The following table summarizes indices 
of NEFA kinetics in all 3 groups: 
Islet recipients 
(n=2)
Type 2 Diabetes 
(n=3)
Controls 
(n=5)
NEFA nadir (mmol/l) 0.014 + 0.007 0.063 + 0.025 0.035 + 0.006
2 hr NEFA (mmol/l) 0.019 + 0.010 0.130 + 0.036 0.056 + 0.010
Time to nadir 140 + 20min 157 + 19min 156 + 6min
Time to plateau 90 + 17min 137 + 38min 66 + 6min
NEFA suppression(area 
below basal)(0-120min)
(mmol/l.min)
42 + 11 29 + 4 38 + 6
% NEFA suppression to 
nadir †
97 + 1 90 + 4 93 + 1
% NEFA suppression to 
120min††
96 + 2 80 + 5 89 + 2
kNEFA(30-90min) * 
(min-1)
0.039 + 0.008 0.010 + 0.003 0.027 + 0.005
† (fasting NEFA - nadir NEFA)/fasting NEFA x 100%
††(fasting NEFA - 2hr NEFA)/fasting NEFA x 100%
*slope of the regression line relating the log of NEFA levels from time 30-
90min
**kNEFA(30-90min)/incremental AUCins from 30-90min
Conclusion: This is the first report of NEFA suppression in intra-portal islet 
recipients during an OGTT. We found NEFA dynamics in islet recipients are 
not impaired and may be even better than in controls despite reduced periph-
eral insulin secretion and immunosuppressants known to cause dyslipidemia. 
We also found that despite marginally better glycaemia and peripheral insu-
lin secretion when compared with T2DM subjects, recipients had dispropor-
tionately greater NEFA suppression. As the liver plays a central role in lipid 
metabolism/transport, high periportal insulin levels (secondary to proximity 
of transplanted β-cells to hepatocytes) in recipients could explain the nor-
mal and even improved NEFA dynamics. An alternative explanation would 
be that very little insulin is required for normal NEFA suppression. These 
preliminary findings echo those of Rickels et al, who found improved NEFA 
disposal in islet recipients compared with controls, during insulin-modified 
IVGTT. This data is of interest as improved NEFA dynamics post-transplant 
could contribute to enhanced glucose disposal by reducing glucolipotoxicity. 
Further studies, however, with larger numbers of subjects are required.
Supported by: JDRF
663
Effect of ameliorating glucotoxicity on incretin secretion in patients with 
type 2 diabetes
S.-H. Ko1, S.-H. Lee1, K.-H. Yoon2, Y.-B. Ahn1; 
1Internal Medicine, St. Vincent’s Hospital, Suwon, 2Internal Medicine, Seoul 
St. Mary’s Hospital, Republic of Korea.
Background and aims: The condition of type 2 diabetes and accompany-
ing hyperglycemia and insulin resistance leads to the impairment in secre-
tion or action of the incretin hormones. In this study, we aimed to determine 
whether reversal of hyperglycemia and insulin resistance can affect incretin 
secretion in patients with type 2 diabetes. The associated factors with incretin 
secretion were also investigated.
Materials and methods: Meal tolerance test (MTT) was performed in eigh-
teen poorly-controlled diabetic (pDM) patients and fifteen well-controlled 
diabetic (wDM) patients. Fourteen patients in pDM group underwent fol-
low-up MTT after mean 2.4 months of insulin treatment. Plasma concentra-
tions of glucose, insulin, C-peptide, glucagon, intact glucagon-like peptide 
1 (iGLP-1) and total glucose-dependent insulinotropic polypeptide (tGIP) 
were measured and their secretions during MTT were calculated by total and 
incremental area under the curve (TAUC and IAUC) values.
Results: Post-treatment HbA1c level was significantly improved in pDM 
group (from 11.2 ± 0.9 to 7.9 ± 0.9%). The relative secretion of incretin hor-
mones adjusted by glucose levels were mildly but significantly increased in 
pDM group after treatment (TAUCiGLP-1/TAUCglucose, from 0.07 ± 0.01 
to 0.08 ± 0.01; TAUCtGIP/TAUCglucose, from 0.19 ± 0.03 to 0.24 ± 0.03; 
IAUCtGIP/IAUCglucose, from 0.73 ± 0.14 to 0.91 ± 0.13), although they 
were still significantly lower when compared to wDM group. IAUCiGLP-1 
was negatively correlated with insulin resistance (r = -0.446, P = 0.011) while 
IAUCtGIP was positively correlated with β-cell function (r = 0.418, P = 0.016) 
assessed by homeostasis model assessment.
Conclusion: Intensive insulin treatment increased the relative secretory 
capacity of incretin hormones adjusted by glucose levels. GLP-1 secretion 
showed negative correlation with the index of insulin resistance. These find-
ings indicate the importance of ameliorating glucotoxicity and lowering the 
degree of insulin resistance to improve incretin secretion in patients with 
type 2 diabetes.
Supported by: Korean Diabetes Association
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Acute exposure to palmitate induces endoplasmic reticulum stress and 
impairs insulin action in isolated human skeletal muscle strips
P.A. Skrobuk1,2, J. Kärkkäinen1,2, H.A. Koistinen1,2; 
1Minerva Institute, Helsinki, 2Division of Cardiology, Department of 
Medicine, Helsinki University Central Hospital, Finland.
Background and aims: Obesity and high fat diet have been linked to insulin 
resistance, which may involve endoplasmic reticulum (ER) stress. Here, we 
studied the effect of acute palmitate exposure on insulin action on glucose 
transport (GT), glycogen synthesis, insulin signaling and ER stress.
Materials and methods: We studied 18 men (47±3 years, BMI 26.2±0.8 kg/
m2, fP-gluk 5.5±0.1 mM). Open muscle biopsy was obtained from m. vastus 
lateralis, and small muscle strips were incubated for 4 h with or without (w/o) 
palmitate (1mM), and with or w/o insulin (1.2 nM).
Results: Insulin increased GT (in nmol/mg/20 min) 1.9-fold (from 0.6±0.05 to 
1.2 ±0.1, p<0.001). With palmitate, basal GT tended to be increased (0.9±0.1, 
p=0.062), insulin-stimulated GT was unchanged (1.2±0.1), and insulin ac-
tion on GT (insulin-stimulated minus basal) reduced by 49 % (p=0.068). Pal-
mitate reduced insulin-stimulated glycogen synthesis 18 % (70±13, vs 85±15 
nmol/g/h, p<0.02), but did not affect AKT-Ser473 phosphorylation. When 
men were divided by BMI, insulin increased GT with palmitate in lean, but 
not in overweight men. Palmitate induced ER stress (1.3-fold increased phos-
phorylation of eIF2α) in overweight but not in lean men
Conclusion: Acute exposure to palmitate impairs insulin action in human 
muscle strips. This effect is more pronounced in men with overweight, and 
may involve activation of ER stress.
Supported by: NNF, SJF, HU, FAS
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ER Stress in adipocytes inhibits insulin signalling, represses lipolysis and 
alters the secretion of adipokines without inhibiting glucose transport
L. Xu, G.A. Spinas, M. Niessen; 
Endocrinology, Diabetology & Clinical Nutrition, University Hospital of 
Zurich, Switzerland.
Background and aims: ER stress and activation of the unfolded protein re-
sponse (UPR) contribute to insulin resistance and the development of dia-
betes in obesity. It was shown previously in hepatocytes that the UPR acti-
vates c-jun N-terminal kinase (JNK) which phosphorylates insulin receptor 
substrate (IRS) proteins on serine residues thereby inhibiting insulin signal 
transduction. Here we describe how ER stress affects insulin signalling and 
the biological function of adipocytes.
Materials and methods: ER stress was induced with either thapsigargin or 
tunicamycin. Activation of insulin signal transduction and of the unfolded 
protein response (UPR) were assessed by Western blotting. The function of 
3T3-L1 adipocytes and of primary mouse adipocytes was assessed by mea-
suring insulin-dependent 14C-2-deoxy-D-glucose uptake, glycerol to analyse 
lipolysis and by multiplex analysis of culture supernatants for various cyto-
kines.
Results: In addition to inhibition of IRS we found that ER stress downregu-
lates the expression of the insulin receptor. Concomitantly, insulin-induced 
activation of Akt/PKB and of ERK1/2 was strongly inhibited. Ectopic expres-
sion of IRS1 or IRS2 strongly counteracted the inhibitory effect of ER stress 
on insulin signalling while pharmacological inhibition of JNK with SP600125 
resulted only in a mild improvement. ER stress decreased the secretion of 
the adipokines adiponectin and leptin, but strongly increased secretion of 
IL-6. ER stress inhibited expression and insulin-induced phosphorylation 
of AS160, reduced lipolysis but did not inhibit glucose transport. Superna-
tants collected from 3T3-L1 adipocytes undergoing ER stress improved or 
impaired proliferation when used to condition the culture medium of INS-1E 
β-cells dependent on the degree of ER stress.
Conclusion: ER stress in adipocytes might initially lead to changes resem-
bling early pre-diabetic stages which at least in part support the regulation of 
systemic energy homeostasis.
Supported by: Velux Foundation, Swiss Government, COST Action BM0602
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Endoplasmic reticulum stress plays a role in both the adaptive and 
deleterious effects of lipid on insulin signalling in liver cells
C.S. Achard, D.R. Laybutt; 
Diabetes and Obesity Research Program, Garvan Institute of Medical 
Research, Sydney, Australia.
Background and aims: Insulin resistance (IR) in peripheral tissues including 
liver, combined with β-cell failure, leads to type 2 diabetes. Obesity and as-
sociated lipid oversupply is a likely cause of IR in liver but the mechanisms re-
sponsible remain unknown. The endoplasmic reticulum (ER) stress response 
has emerged as a potential signalling pathway involved in obesity-associated 
IR. Furthermore, high levels of fatty acids, particularly saturated forms such 
as palmitate, can induce ER stress in liver cells, but its necessary contribution 
to IR has not been elucidated. We therefore investigated whether ER stress 
was necessary for palmitate-induced hepatic IR. Moreover, as the ER stress 
response has also been described as a protective signalling pathway required 
for cell adaptation, we investigated the consequences of chronic mild ER 
stress on hepatic insulin signalling.
Materials and methods: To examine the role of ER stress in lipid-induced 
IR, human hepatoma HepG2 cells or mouse primary hepatocytes were ex-
posed for 1-24 h to BSA-coupled palmitate (100-750 µmol/l) in presence or 
not of chemical chaperones trimethylamine N-oxide (TMAO) or taurourso-
deoxycholic acid (TUDCA). To investigate the effects of prolonged mild ER 
stress activation on insulin signalling, HepG2 cells were exposed to low level 
of thapsigargin (2-2.5 nmol/l) or tunicamycin (0.1 µg/ml) for 3-6 days (two 
passages), or to palmitate (100-200 µmol/l) for 6-12 days (three passages). 
Activation of the ER stress response and insulin signalling pathway were ex-
amined using Western blot analysis and glycogen synthesis assay.
Results: In HepG2 cells, exposure to palmitate dose- (250-750 µmol/l) and 
time- (1-24 h) dependently led to activation of two arms of the ER stress re-
sponse as evidenced by increased EIF2α phosphorylation, XBP1 splicing and 
JNK activation. We confirmed in hepatocytes that elevated levels of palmi-
tate (500-750 µmol/l) induced an increase in PERK phosphorylation, XBP1 
splicing and CHOP expression. In HepG2 cells and primary hepatocytes, 
this is associated with defective insulin signalling (decreased insulin-stimu-
lated Akt phosphorylation) and reduced insulin action (insulin-stimulated 
glycogen synthesis). Treatment of HepG2 cells or primary hepatocytes with 
TMAO (100 mmol/l) or TUDCA (500 µg/ml), respectively, attenuated pal-
mitate-induced ER stress and partially reversed the defect in insulin signal-
ling, demonstrating that ER stress makes a necessary contribution to lipid-
induced IR in liver cells. However, strikingly distinct effects were observed 
following exposure to mild ER stress. Chronic exposure of HepG2 cells to 
low level thapsigargin, tunicamycin or palmitate led to enhanced insulin sig-
nalling (increased insulin-stimulated Akt phosphorylation), suggesting the 
establishment of an ER stress adaptive pathway. This was associated with an 
attenuated ER stress activation in response to subsequent high-level palmi-
tate or thapsigargin (10 nmol/l) exposure.
Conclusion: Our results suggest chronic exposure of liver cells to low-level 
palmitate induces mild ER stress and an adaptive response that enhances in-
sulin signalling and confers protection against acute palmitate-induced ER 
stress. However, more severe ER stress induced by chronically elevated pal-
mitate overwhelms the adaptive response leading to IR. Thus, ER stress could 
contribute to both the adaptive and deleterious effects of lipid on insulin sig-
nalling in liver cells.
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Endoplasmic reticulum stress induced by hyperglycaemia and saturated 
fatty acids is alleviated by salicylates in cultured primary human 
adipocytes
M. Langowska, S. Alhusaini, K.C. McGee, A.L. Harte, P.G. McTernan,  
S. Kumar, G. Tripathi; 
CSRI, University of Warwick, Coventry, United Kingdom.
Background and aims: Obesity and type 2 diabetes mellitus (T2DM) are 
closely associated with chronic inflammation. Adipose tissue may have a 
significant role in obesity associated inflammation but, the mechanisms un-
derlying the pathogenesis of obesity induced inflammation remains unclear. 
Recent findings indicate that endoplasmic reticulum (ER) stress is critical to 
the initiation and integration of pathways of inflammation and insulin ac-
tion. The ER stress occurs when there is an accumulation of unfolded/mis-
folded proteins, in addition to other factors. This results in activation of the 
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unfolded protein response (UPR) to restore functional integrity which, leads 
to upregulation of master regulators of ER, PKR-like ER-regulated kinase 
(PERK), inositol requiring enzyme1α (IRE1α) and activating transcription 
factor6 (ATF6) and protein chaperones. Factors acknowledged to elicit cel-
lular stresses are hyperglycaemia, hyperlipidaemia, viral infections and in-
creased protein synthesis; the majority of which are features of obesity and 
T2D. Therefore, our aims were to determine the existence and causes of ER 
stress in human adipocytes.
Methods: Human abdominal subcutaneous (AbSc) adipose tissue (AT) was 
obtained from a Caucasian non-diabetic population (BMI: 27.9±7.3 kg/m2: 
age 36-49 yrs; n=40; all female subjects) that underwent elective liposuction 
surgery, as part of the well established AT collection program. The human 
preadipocytes were isolated from stromal fraction, grown and fully differ-
entiated into human adipocytes (n=5). Well differentiated adipocytes were 
then treated with tunicamycin (750ng/ml), high glucose (HG) (25 mM) and 
saturated fatty acids (SFA) (2 mM) and in combination with 20mM salicylate, 
salicylate alone and controls. To characterise protein expression of the key 
markers relevant to ER stress, inflammation and insulin signalling pathway, 
total protein and RNA was extracted from adipose tissue and cultured adi-
pocytes using standard protocol. Western blots and Real-Time RT-PCR were 
performed to examine protein and RNA expression levels.
Results: The expression of ER stress proteins Calnexin1, glucose regulated 
protein (Grp78)/BiP1, Ero-1α, protein disulfide isomerise (PDI), IRE1α and 
Phospho-PERK were significantly increased in AbSc AT from obese com-
pared to lean subjects (n=4; p<0.05 to p<0.001). PERK activated phospho-
eIF2α (n=5; p<0.005) was significantly induced by tunicamycin, HG and SFA 
(p<0.001) proving the existence of ER stress in differentiated human adipo-
cytes. ATF6 mRNA expression was also significantly induced by tunicamycin 
and HG but not SFA. Grp78/Bip was also significantly induced by tunicamycin 
and SFA. Down-stream targets Calnexin, PDI, Ero1-Lα and Chop were also 
significantly induced by all three treatments (p<0.05 to p<0.001). In the same 
adipocytes ER stress was significantly reduced when treated with anti-inflam-
matory compound salicylate. Similarly, phospho-Akt (S473) (n=5; p<0.002), 
was also activated when ER stress was down-regulated by salicylate.
Conclusion: Our results demonstrate that hyperglycaemia (HG) and SFA 
induce ER stress in human adipocytes and therefore could cause increased 
inflammation and insulin resistance in human adipose tissue. We also dem-
onstrate that salicylate alleviates this stress and also activates Akt which could 
lead to increased insulin sensitivity.
Supported by: Research Councils UK
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Doubling of both insulin sensitivity and beta cell function explains 
remission of type 2 diabetes within one week after Roux-en-Y Gastric 
Bypass
N.B. Jorgensen1, S.H. Jacobsen1, D. Worm1, D.L. Hansen1, L. Naver2,  
L.E. Hvorlis2, J.J. Holst3, S. Madsbad1; 
1Dep. of Endocrinology, Hvidovre Hospital, 2Dep.of Surgery, Hvidovre 
Hospital, 3Dep. of Biomedical Sciences, University of Copenhagen, 
Denmark.
Background and aims: Roux-en-Y gastric bypass (RYGB) for morbid obes-
ity is known to cause remission of type 2 diabetes within days after surgery, 
but the mechanistic explanations of this phenomenon are poorly understood. 
Here we report the acute effects of RYGB on glucose metabolism within 4-6 
days after the operation.
Materials and methods: 8 patients referred with the diagnosis of type 2 dia-
betes (treated with oral antiglycaemic agents or diet) and a fasting P-glucose 
of more than 7 mM on the last weekday before the operation, were included 
in the study. Patients had a BMI of 45 ± 1,8 kg/m2, an HbA1c of 6.9 ± 0.3 and 
an average age of 53 ± 3 y. A mixed meal tolerance test was performed 1-3 
days before and 4-6 days after bypass surgery. 3 fasting blood samples were 
drawn, before patients were given a 200 mL liquid meal (Fresubin Energy, 
1260 kJ, protein E% 15, carbohydrate E% 50, fat E% 35), that was ingested 
over a 30 min period. Blood was sampled frequently over a 4 h-period after 
meal start for measurement of plasma glucose, insulin and c-peptide. To re-
late beta-cell function to the ambient insulin resistance, disposition index was 
calculated as the insulinogenic index (0-30 min C-peptide/0-30 min glucose) 
(IGI) multiplied by 1/HOMA-IR.
Results: A significant reduction in the fasting plasma glucose levels was ob-
served after RYGB compared to preoperative levels (9.2 ± 0.98 mmol/l vs. 7.2 
± 0.43 mmol/l, p<0.05), and an even greater reduction in mean 2 h postpran-
dial glucose levels (12.3 ± 1.2 mmol/l vs 9.2 ± 0.68 mmol/l, p<0.01) could be 
demonstrated. Fasting insulin levels were also reduced postoperatively (17.4 
± 3.27 µU/ml vs. 10.9 ± 2,09 µU/ml, p<0.01), as was the corresponding C-
peptide levels (1.68 ± 0.21 nmol/l vs. 1.36 ± 0.24 nmol/l, p < 0.01). Accord-
ingly, insulin resistance evaluated by HOMA-IR was reduced by almost 50% 
postoperatively (6.71 ± 1.12 mmol/l*µU/mL vs. 3.55 ± 0.71 mmol/l*µU/mL, 
p<0.01). In parallel the Matsuda Index increased from 2.6 ± 0.5 before to 
4.3 ± 0.8 after surgery (p<0.05). The incremental area under the curve for 
C-peptide (210 ± 27 vs. 272 ± 40 min*nmol/l, p=0,055) showed a clear trend 
towards being greater after surgery, but failed to reach statistical significance. 
The insulinogenic index (IGI) was not influenced by RYGB (0.57 ± 0.10 be-
fore and 0.54 ± 0.14 after), however, the disposition index was significantly 
increased after compared to before surgery (0.097 ± 0.02 before vs. 0.163 ± 
0.03 after, p<0,03).
Conclusion: Within one week after RYGB fasting P-glucose and 2 h post-
prandial glucose levels in type 2 diabetics are significantly reduced compared 
to pre surgical levels. These changes are associated with a near doubling of 
both insulin sensitivity and beta-cell function.
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Evaluation of insulin secretion and insulin sensitivity in diabetic and 
non-diabetic patients with morbid obesity before and after metabolic 
surgery
G. Schernthaner1, J.M. Brix1, H.-P. Kopp1, G. Pacini2; 
11 Med Department, Rudolfstiftung Hospital, Vienna, Austria, 2Metabolic 
Unit, ISIB-CNR, Padua, Italy.
Background and aims: In recent years metabolic surgery (MS) is widely used 
in patients with morbid obesity (MO) and a resolution of diabetes mellitus 
(DM) was seen in most patients presenting with DM before MS. The mecha-
nisms for the “cure” of DM are still widely unknown but seem to be rather 
complex. Information about the change of insulin secretion and insulin sen-
sitivity before and after MS is very limited in particular when MO obese pa-
tients with and without DM are compared.
Materials and methods: We investigated the insulin secretion and insulin 
sensitivity in 88 patients with MO (BMI 46.3±0.7 kg/m2; 40.7± 1.2 years) be-
fore and 2 years after MS. Before the intervention, 16 patients had DM and 72 
were nondiabetic (Non-DM). An oral glucose tolerance test (OGTT; 75 g glu-
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cose) was performed before and after MS, as well as in 30 nondiabetic control 
(CO) subjects (mean BMI 28.4±1.4kg/m2) with similar age and sex. Insulin 
sensitivity was evaluated at fasting with QUICKI and during the OGTT with 
dynamic OGIS; ß-cell function was assessed with the insulinogenic index 
(IGI) as the ratio of the area under the insulin to that of glucose, representing 
the ability of the beta cell to respond to the glucose stimulation.
Results: The characteristics of the subjects and metabolic parameters are 
shown in Table 1. In the pre-operative (pre-op) state MO patients, compared 
to CO, showed low insulin sensitivity, both QUICKI and OGIS, and high 
insulin secretion (IGI). DM and non-DM only differ for the glucose pattern 
(p<0.003), but no difference was found for OGIS (307±55 vs. 303±19) and 
IGI (75±6 vs. 88±19). After surgery, OGIS and QUICKI increased till nor-
malization (440±15 and 0.44±0.01, respectively), being similar to those of CO 
in all subjects (p>0.35). IGI (68±7), though markedly reduced was still higher 
than in CO (p=0.006). Out of the 16 MO who were diabetic pre-surgery, only 
4 remained diabetic after surgery. No specific parameter, assessed pre-sur-
gery, seems to predict the post-surgery status of the DM.
Conclusion: In conclusion, metabolic surgery, and the consequent loss of 
weight, is able to restore normal insulin sensitivity, even in those diabetic 
subjects who remain diabetic, implying that obesity per-se is more important 
than diabetes in modulating the metabolic parameters; i.e., when BMI is el-
evated, possible additional effects of diabetes are masked by those of obesity. 
Beta cell function remains elevated, indicating that the pancreas seems to 
remain up-regulated, despite the reduction of BMI and the increase in insulin 
sensitivity.
Table1-Patients characteristics
all patients before MS CO p-value
HbA1c (%) 5.9±0.1 5.3±0.1 <0.001
BMI (kg/m²) 46.3±0.7 28.4±1.3 <0.001
QUICKI 0.36±0.00 0.46±0.01 <0.001
OGIS (ml/min¹/m²) 318.2±7.6 459.2±16.2 <0.001
Insulinogenic Index 95.1±7.1 36.8±4.1 <0.001
AUC-Glucose (mol/L 2h) 0.86±0.02 0.67±0.03 <0.001
670
Improvement of first-phase insulin secretion and insulin sensitivity 72 
hours after sleeve gastrectomy
D. Capoccia, C. Maglio, M. De Luca, F. Coccia, G. Borgonuovo, R. Asprino, 
C. Tiberti, F. Abbatini, M. Rizzello, N. Basso, F. Leonetti; 
University of Rome Sapienza, Italy.
Background and aims: Obesity is a consequence of over-eating and seden-
tary life style. Type 2 Diabetes (T2D) is often associated and strongly related 
to obesity. Morbid obesity treatment actually provides medical therapy, life-
style changes and bariatric surgery. Bariatric surgery is now considered the 
most successfully therapy for obesity. The purpose of this study was to evalu-
ate the possible role of Laparoscopic Sleeve Gastrectomy (LSG) “per se” in the 
reversibility of type 2 diabetes immediately after surgery.
Materials and methods: We have studied insulin secretion and sensitivity in 
eighteen type 2 diabetic obese patients divided, by the statistical median of 
diabetes duration (10,5 years), in two groups: group A, patients with less than 
10,5 years of disease; group B, patients with more than 10,5 years of disease. 
Ten non diabetic obese patients, group C, were included as control group. In 
all patients an Intra Venous Glucose Tolerance Test (IVGTT) was performed 
before and after LSG, as the following protocol: preoperatively, all patients 
underwent IVGTT after three days of fasting with only non caloric liquids 
and without antidiabetic drugs. Then, they normally fed for other three days 
before LSG and were submitted again to IVGTT three days after surgery 
without receiving neither nutrients or caloric liquids nor antidiabetic drugs, 
in order to avoid weight changes and interference of intestinal mechanisms 
on insulin secretion and sensitivity. Patients with fasting plasma glucose over 
200 mg/dl before starting IVGTT were excluded.
Results: In group A, the first phase of insulin secretion promptly improved 
after bariatric surgery. In fact, the early insulin Area Under the Curve (AUC) 
significantly increased from 133.50 ± 86.70 µUI ml-1 . min to 254.10 ± 158.44 
µUI ml-1 · min; p 0.012, indicating an increased glucose induced insulin se-
cretion. The second phase of insulin secretion, expressed by the late insulin 
AUC, significantly decreased after SG in all groups: group A from 5275.00 ± 
4533.900 µUI · ml-1 · min to 3552.41 ± 3326.32 µUI · ml-1 · min, p 0.04; group 
B from 3891.66 ± 2115.98 µUI · ml-1 · min to 1825.33 ± 988.83 µUI · ml-1 · 
min, p 0.045; group C from 15906.20 ± 3297.91 µUI · ml-1 · min to 3156.40 ± 
2532.68 µUI · ml-1 · min, p 0.028. These findings suggest an improvement of 
insulin peripheral sensitivity.
Conclusion: Restoration of the first phase of insulin secretion, improved in-
sulin sensitivity in type 2 diabetic obese patients, immediately after LSG, be-
fore any food passage through the gastrointestinal tract and before any weight 
loss, might be related to changes due to the removal of gastric fundus.
671
Early and long-term effects of Roux-en-Y gastric bypass on tissue 
insulin-resistance in type 2 diabetic and non-diabetic morbidly obese 
subjects
S. Camastra1, A. Gastaldelli2, E. Muscelli1, S. Bonuccelli1, B.D. Astiarraga1,  
G. Scartabelli3, S. Frascerra1, E. Buzzigoli2, S. Baldi1, D. Ciociaro2, F. Santini3, 
M. Anselmino4, E. Ferrannini1; 
1Department of Internal Medicine, University of Pisa, 2Institute of Clinical 
Physiology, CNR, Pisa, 3Department of Endocrinology, University of Pisa, 
4Bariatric Division, IV Surgery, S.Chiara Hospital, Pisa, Italy.
Background and aims: Weight loss after bariatric surgery is associated with 
a marked improvement of insulin resistance (IR), but the tissues involved 
in this effect have not been determined. Roux-en-Y gastric bypass (RYGB, a 
predominantly restrictive procedure) has been shown to improve IR in pro-
portion to the weight loss in the long term; whether RYGB also has acute, 
weight-independent effects is controversial. Aim of our study was to measure 
the early and long-term effect of RYGB on IR at the level of muscle, liver and 
adipose tissue in morbidly obese non-diabetic and diabetic subjects.
Materials and methods: In 11 diabetic (T2D) (BMI=49±2 kg.m-2) and 8 
non-diabetic patients (OB) (BMI=55±2 kg.m-2) matched by sex and age, we 
performed a euglycaemic hyperinsulinaemic clamp combined with tracers 
infusion (6,6-2H2-glucose and 1-
2H-glycerol to measure hepatic glucose pro-
duction (HGP) and lipolysis (Ra-Gly), respectively) at baseline, 2 weeks and 
1 year following RYGB. Muscle insulin sensitivity (M-IR = M value/steady 
state plasma insulin), hepatic insulin sensitivity (H-IR = HGP xfasting insu-
lin) and adipose tissue insulin sensitivity (AT-IR = Ra-Gly x fasting insulin) 
were measured.
Results: Two weeks after RYGB, body weight was reduced minimally (7±1% 
in T2D and 4±1% in OB, p=0.01 for both); at 1 year, weight was reduced by 
35±1% in T2D and 34±4% in OB (p<0.0001). Baseline fasting plasma glucose 
was reduced at two weeks and 1 year in both groups (7.9±0.6 vs 6.8±0.4 vs 
5.2±0.2 mmol/l in T2D and 5.5±0.1 vs 5.3±0.1 vs 4.8±0.1 in OB, p<0.0001) 
as was fasting insulin (165±96 vs 92±11 vs 50±9 pmol/l in T2D and 125±22 
vs 103±19 vs 40±5 in OB, p=0.0001). At 2 weeks, M-IS was marginally im-
proved only in T2D (31±6 vs 43±6 µmol.min-1.kgFFM
-1.pM-1, p=0.05; in OB, 
38±10 vs 36±5, p=ns), while at 1 year M-IS was doubled in OB and tripled 
in T2D (79±6 and 86±10 µmol.min-1.kgFFM
-1.pM-1, respectively, p<0.0001). At 
both 2 weeks and 1 year, H-IR was significantly reduced (2.0±0.3 vs 1.1±0.1 
vs 0.7±0.1 mmol.min-1.kgFFM
-1.pM in T2D and 1.6±0.3 vs 1.2±0.3 vs 0.5±0.1 
in OB, p=0.0001). At 2 weeks, AT-IR was modestly decreased only in T2D 
(71±12 vs 35±5 µmol.min-1.pM-1, p=0.003; in OB 47±11 vs 39±6, p=ns), while 
at 1 year the improvement was statistically significant in both groups (11±13 
and 11±2 µmol.min-1.pM-1, respectively in OB and T2D, p<0.0001). One year 
after surgery, both H-IR and AT-IR were fully normalised as compared to a 
normal-weight control group (p=ns).
Conclusion: One year after RYGB and in concomitance with major weight 
loss, IR is improved in the principal target tissues (muscle, liver, adipose tis-
sue) both in type 2 diabetic and non-diabetic subjects. In T2D patients, some 
improvement of tissue IR is evident acutely after surgery, in particular for 
liver and adipose tissue, and is likely responsible for the early amelioration 
of glycaemic control.
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One year effect of gastric bypass and intensive lifestyle on insulin 
secretion in morbidly obese patients: a controlled clinical trial
D. Hofsø1, T. Jenssen2, K. Godang2, R. Sandbu1, J. Hjelmesæth1; 
1Morbid Obesity Centre, Vestfold Hospital Trust, Tønsberg, 2Department of 
Medicine, Oslo University Hospital Rikshospitalet, Norway.
Background and aims: The effect of bariatric surgery on insulin secretion 
has been incompletely explained. The objective of this study was to compare 
the effect of bariatric surgery and lifestyle intervention on various measures 
of beta-cell function.
S 270 Diabetologia (2010) 53:[Suppl1]S1–S556
1 C
Materials and methods: The study population included 119 morbidly obese 
patients (mean age 44 years, mean BMI 45.5 kg/m2, 84 women) without 
known diabetes classified into normal glucose tolerance (NGT, fasting glucose 
< 6.1 mmol/l and 2 hour glucose < 7.8 mmol/l) or abnormal glucose tolerance 
(AGT, fasting glucose ≥ 6.1 mmol/l and/or 2 hour glucose ≥ 7.8 mmol/l), and 
29 normal weight controls with NGT. The morbidly obese subjects participat-
ed in a one year non-randomised controlled clinical trial (The MOBIL study, 
ClinicalTrials.gov identifier: NCT00273104) and were treated with either 
Roux-en-Y gastric bypass (RYGB) surgery (n=64) or intensive lifestyle inter-
vention (ILI) at a rehabilitation centre (n=55). An oral glucose tolerance test 
(0, 30, and 120 min sampling) was conducted at baseline and after one year, 
and indices for insulin secretion (Stumvoll first phase) and insulin sensitivity 
(HOMA S) were calculated from glucose and insulin concentrations. Disposi-
tion index (DI), calculated as the product of Stumvoll first phase insulin secre-
tion index and HOMA S, provided a measure of insulin secretion adjusted for 
insulin sensitivity. Stimulated plasma proinsulin-to-insulin ratio represented 
an estimate of the efficiency of proinsulin processing in beta-cells.
Results: Mean (SD) weight reduction was 30 (8) % in the RYGB group and 9 
(10) % in the ILI group (p < 0.001). The figure shows: 1) the hyperbolic imag-
ing of the DI in the subjects with NGT at baseline [curved line; log(HOMA S) 
= constant + β x log(Stumvoll fist phase) with β (95% CI) = -0.869 (-0.971 to 
-0.766)]; 2) higher insulin sensitivity after RYGB (dashed line) compared to 
ILI (solid line) (both p ≤ 0.001) 3) a more substantial increase in the DI in the 
RYGB groups than in the ILI groups (both p < 0.001); and 4) that the DI in the 
RYGB NGT group was significantly higher than in the NGT control group (p 
< 0.001). The reduction in mean (SD) proinsulin-to-insulin ratio at 30 minutes 
was also more pronounced in the RYGB than in the ILI groups: NGT; -1.7 (1.9) 
% vs. 0.1 (2.1) % (p < 0.001); and AGT -4.3 (3.4) % vs. -1.7 (4.6) % (p = 0.024).
Conclusion: The improvement in beta-cell function was greater after RYGB 
than ILI. Post surgery, insulin secretion in the NGT group was when related 
to insulin sensitivity, even higher than in normal weight NGT controls.
Supported by: grants from Novo Nordisk A/S (to DH)
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Plasma FGF21 is increased in response to an oral glucose load post 
operative in obese subjects undergoing Roux-en-Y gastric bypass
B. Andersen1, S.H. Jacobsen2, S. Madsbad2, D. Worm2, L.E. Hvolris2,  
L. Naver2, T. Almdal2, J.J. Holst3, D.L. Hansen2, T.R. Clausen4; 
1Novo Nordisk A/S, Gentofte, 2Hvidovre Hospital, 3University of 
Copenhagen, 4Novo Nordisk A/S, Måløv, Denmark.
Background and aims: Fibroblast growth factor 21 (FGF21) is an endocrine 
hormone involved in regulation of energy homeostasis. Treatment of diabetic 
mice and diabetic rhesus monkeys with rFGF21 has been shown to lower 
blood glucose, correct dyslipidemia and increase energy expenditure. The 
physiological role of FGF21 in humans is not well understood, but FGF21 
seems to be increased in states where fat oxidation is required. FGF21 has also 
been shown to be increased in patients with type 2 Diabetes and in obese sub-
jects. FGF21 is highly expressed in the liver, and to a lower extent in skeletal 
muscle, pancreas and fat tissue. The basal level of FGF21 seems to be highly 
controlled by the liver, while FGF21 from the skeletal muscle is increased in 
response to insulin. In this study, we investigate the fasting levels of FGF21 
before and after bariatric surgery, as well as the effect of an oral glucose load 
(25g and 50g) on plasma FGF21 and insulin before and after the surgery.
Materials and methods: 9 obese, non-diabetics patients (2 males and 7 fe-
males, average BMI 46.4; age 26 to 56) underwent Roux-en-Y Gastric Bypass. 
Fasting plasma FGF21 was measured on three different days before and after 
surgery. Furthermore, on two different days before surgery and on two differ-
ent days after surgery, the subjects were given an oral glucose load (25g and 
50g glucose) and blood samples were taken starting 30 min before the glucose 
load followed by 15 min intervals until 180 min after the oral glucose load. 
Statistics: Student’s t-test (paired).
Results: FGF21 in plasma varied in the fasted state from 30 to 1118 pg/ml 
(258 ± 105 pg/ml) before surgery and from 38 to 1792 pg/ml (399 ± 170 
pg/ml) after surgery. In average there was no significant change in fasting 
plasma FGF21. However, three subjects had a significant (p=0.024, p = 0.013 
and p=0.035) increase in fasting plasma FGF21. Furthermore, after the sur-
gery there was a significant (p=0.0002) increase in the total plasma insulin 
concentration during the time course, determined as the area under the curve 
(AUC) in response to 25g glucose, while there was no change in insulin AUC 
when 50g glucose was orally administered. The AUC of FGF21 was also sig-
nificantly increased in response to 25g glucose (p=0.039), while the AUC of 
FGF21 in response to 50g glucose was only borderline significant (p=0.076). 
Plasma FGF21 level peaked at t=120 min and at this time point the plasma 
levels of FGF21 were significantly increased post surgery, in response to both 
25g and 50g glucose (p=0.015 and p=0.008, respectively).
Conclusion: As previously observed, large individually variations in plasma 
FGF21 were found. In the nine subjects undergoing Roux-en-Y Gastric sur-
gery, three subjects had a significant increase in fasting FGF21, while six sub-
jects had no change in fasting plasma FGF21. The increase in plasma FGF21 
in response to oral glucose post surgery is believed to arise from the stimula-
tory effect of insulin on the skeletal muscles and could be due to either an in-
crease in muscle insulin sensitivity or the increased insulin release observed 
in response to glucose (25g). In conclusion, the increase in plasma FGF21 in 
response to glucose post surgery could play an important role in the positive 
metabolic outcome of a Roux-en-Y Gastric Bypass.
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Mechanisms of early diabetes improvement after biliopancreatic 
diversion in non-morbidly obese diabetic subjects
B.D. Astiarraga1, E. Muscelli1, S. Camastra1, M. Nannipieri1, F. Papadia2,  
G. Adami2, N. Scopinaro2, E. Ferrannini1; 
1Department of Internal Medicine, University of Pisa, 2DISC - Department 
of surgical sciences and diagnostics, University of Genova, Italy.
Background and aims: A strong improvement or resolution of diabetes has 
been reported after biliopancreatic diversion (BPD) in diabetic obese pa-
tients. On long-term follow up, insulin sensitivity in morbidly obese subjects 
with or without type 2 diabetes is completely normalised after BPD despite 
persisting obesity. The early effect of BPD in less obese (BMI 27-35 kg/m2) 
diabetic subjects is not known. The aim of this study was to assess diabetes 
control and measure insulin sensitivity early after BPD in diabetic non-mor-
bidly obese patients.
Materials and methods: We studied 12 patients (6 men and 6 women; 56 ± 4 
years, BMI range 26.9-33.1 kg/m2) before and 59 ± 24 days after BPD (range 29-
101 days). At baseline and following surgery, insulin sensitivity was measured 
by a 3-hour euglycaemic hyperinsulinaemic (240 pmol.m-2.min-1) clamp.
Results: After surgery, BMI decreased by 13 ± 4% (mean± SD, from 28.8 ± 1.9 
to 25.0 ± 2.1 kg/m2, p = 0.002). Before BPD, all patients were on oral antidi-
abetic agents and/or insulin. After surgery, fasting plasma glucose dropped 
from 12.6 ± 3.1 to 8.3 ± 2.2 mmol/l (p=0.002) and HbA1c from 7.93 ± 1.10 
to 6.42 ± 0.86%; p=0.002. Six patients could be taken off pharmacological 
treatment. Insulin sensitivity (as the M value) increased from 19.5 ± 3.4 to 
34.8 ± 12.0 µmol.min-1.kgFFM-1, p=0.002. By simple regression analysis, the 
improvement in insulin sensitivity was not related to the decrease in BMI or 
to the time since surgery (p=ns for both).
Conclusion: In diabetic non-morbidly obese patients, biliopancreatic diver-
sion is followed by an early improvement in glycaemic control and insulin 
sensitivity at a time when weight loss is modest. These findings are compat-
ible with the notion that this type of bariatric surgery impacts on glucose 
homeostasis by mechanisms at least partly independent of weight loss.
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Triple tracer (TT) and double tracer (DT) techniques are reliable 
methods to estimate glucose appearance in type 1 diabetes
A. Haidar1, D. Elleri2, J.M. Allen1, J. Harris1, K. Kumareswaran1, M. Nodale1, 
C.L. Acerini2, M.E. Wilinska1, N. Jackson3, A.M. Umpleby3, M.L. Evans1,  
D.B. Dunger2, R. Hovorka1; 
1Institute of Metabolic Science, University of Cambridge, 2Department 
of Paediatrics, University of Cambridge, 3Postgraduate Medical School, 
University of Surrey, Guilford, United Kingdom.
Background and aims: Measurement of physiological postprandial glucose 
fluxes in type 1 diabetes could potentially facilitate improvements in modern 
insulin therapy regimens. TT technique has been proposed to be the gold 
standard technique to measure postprandial glucose appearance. We validat-
ed TT technique and compared it against DT technique in type 1 diabetes.
Materials and methods: Eight young subjects with type 1 diabetes (age 
20.8±3.3yrs, BMI 24.0±1.5kg/m2, HbA1c 8.7±1.5%, diabetes duration 
10.7±8.9yrs, total daily insulin 0.8±0.2U/kg/day; mean±SD) were studied. 
From 1800 to 0200 next day, intravenous (iv) 20%dextrose enriched with [U-
13C]glucose was infused at a variable rate mimicking meal-derived glucose 
appearance while iv insulin was administered to achieve basal and postpran-
dial insulin concentration. From 1530 to 0200, primed iv [6,6-2H2]glucose 
was infused in a manner that mimicked the expected endogenous glucose 
production. From 1800 to 0200, iv [U-13C; 1,2,3,4,5,6,7-2H7]glucose was in-
fused in a manner that mimicked the expected glucose appearance from a 
standard meal. The iv dextrose infusion was reconstructed using TT and DT 
techniques utilizing a modified stochastic Mari model. Plasma glucose was 
measured every 10-15min. Glucose enrichment was measured by gas chro-
matography - mass spectrometry every 10 - 30min.
Results: Figure shows actual and reconstructed dextrose infusion rates. The 
difference between individual actual and individual reconstructed dextrose 
infusion rates as assessed by the root mean square error (RMSE) was identi-
cal for the two methods (8.1± 2.1 vs. 10.6 ± 4.5 µmol/kg/min; TT vs. DT; P = 
NS, paired t-test). RMSE associated with mean dextrose infusion was 3.0 and 
4.2 µmol/kg/min. Overall, 98 ± 9% and 93 ± 16% (P = NS) of the dextrose 
infusion was recovered.
Conclusion: TT and DT techniques combined with advanced computational 
methods can measure reliably postprandial glucose appearance in type 1 
diabetes. TT tends to outperform slightly DT but the latter benefits from re-
duced experimental and analytical complexity.
Supported by: JDRF, NIHR and Diabetes UK
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Effects of impaired fasting glucose on the rate of transaldolase exchange 
R. Basu1, C. Barosa2, V. Pattan1, P. Reich1, A. Saad1, J. Jones2, A. Basu1,  
R. Rizza1; 
1Endocrinology, Mayo Clinic College of Medicine, Rochester, USA, 2Dept of 
Zoology, University of Coimbra, Portugal.
Background and aims: The deuterated water (2H2O) method is extensively 
used to measure gluconeogenesis in humans. One of the premises of this 
method is that there is negligible exchange of the lower three carbons of fruc-
tose-6-phosphate and glyceraldehyde-3-phosphate (GAP-3-P) via transaldo-
lase exchange. When this exchange is active, then glucose is labeled on the 
fifth carbon via simple exchange with labeled GAP-3-P without net gluco-
neogenic flux. We have recently shown that transaldolase exchange is active 
in healthy non-diabetic humans and ~30% of the 2H on the fifth carbon of 
glucose is derived by this mechanism resulting in an overestimation of glu-
coneogenesis.
Materials and methods: To eliminate possible isotope effects associated with 
2H, we assessed the extent of transaldolase exchange with a 13C-tracer where 
isotope effects are negligible. [1-13C] acetate was infused in 9 subjects with 
impaired fasting glucose (IFG) and 11 age and BMI matched normal fasting 
glucose (NFG) subjects. UDP-glucose enrichment was measured following 
an overnight fast and during a 0.35 mu/kgFFM/min insulin infusion. Soma-
tostatin, glucagon and growth hormone also were infused during the clamp 
to ensure comparable and equal portal concentrations in both groups. NMR 
spectroscopy was utilized to measure the ratio of [3-13C] UDP-glucose and 
[4-13C] UDP-glucose in plasma. In the absence of transaldolase exchange, 
carbon 4 and carbon-3 are equally labeled resulting in a C3/C4 ratio of 1.0. 
Transaldolase exchange selectively enriches labeling of carbon 4 resulting in 
a C3/C4 ratio of < 1.0.
Results: Glucose concentrations in IFG were significantly higher than NFG 
before (5.9 ± 0.1 vs. 5.4 ± 0.1mmol/L;p<0.005) but matched (6.3 ± 0.0 vs.6.1 ± 
0.0mmol/L;p=ns) during the clamp. Insulin concentrations followed a simi-
lar trend being higher in the IFG subjects before (49 ± 5.2 vs.34 ± 3.8 pmol/L; 
p<0.005) but not during (109 ± 6 vs.106 ± 4) the clamp. C-peptide concentra-
tions remained suppressed during the clamp and glucagon concentrations 
similar in both groups before and during clamp. The ratio of [3-13C] UDP-
glucose/[4-13C] UDP-glucose was <1.0 in all subjects but did not differ in the 
IFG and NFG subjects either in the fasting state (0.68 ± 0.03 vs.0.66 ± 0.04) or 
during the hyperinsulinemic clamp (0.62 ± 0.04 vs.0.59 ± 0.05).
Conclusions: Transaldolse exchange a) occurs in people with NFG and IFG; 
b) it is not altered by an insulin infusion; and c) does not differ in NFG and 
IFG. Thus transaldolase exchange can account for ~35-40% of the deuterium 
that is present on the carbon 5 following ingestion of 2H2O resulting in a pro-
portionate overestimation of gluconeogenesis. Future studies will be required 
to determine whether the impact of these processes on the measurement of 
gluconeogenesis differs in other disease states (e.g. diabetes or obesity) or 
changes with varying amounts of fast and/or insulin.
Supported by: NIDDK
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Protein and fat modify the glycaemic and insulinaemic responses of a 
mashed potato-based meal
K.A. Hätönen1, J. Virtamo2, J.G. Eriksson2,3, H.K. Sinkko1, J.E. Sundvall2, 
L.M. Valsta1; 
1Department of Lifestyle and Participation, 2Department of Chronic Disease 
Prevention, National Institute for Health and Welfare, 3Department of 
General Practise and Primary Health Care, University of Helsinki, Finland.
Background and aims: Potatoes, especially mashed potatoes, are known to 
result in high glycaemic and insulinaemic responses. In most meals, however, 
potatoes are accompanied by other foods. The objectives of the present study 
were to investigate how glycaemic and insulinaemic responses to mashed po-
tato meal changed when fat, protein or/and salad were added to the meal and 
to assess how precise the estimate of GI of the mixed meal by using individual 
GI values of the components of the meal.
Materials and methods: Eleven healthy subjects (age 36.2±14.1 yrs, BMI 
21.3±1.7 kg/m2) were served the six different mashed potato-based meals 
(mashed potato alone; with oil; with chicken breast; with salad; with oil, 
chicken breast and salad; and with oil, chicken breast, salad and rye bread) 
containing 50-54 g of available carbohydrates once and the reference food 
(glucose solution) twice in a random order at one-week intervals. Capillary 
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blood samples were then drawn for 2 h and the glucose and insulin were 
analysed. The incremental areas under the curve (IAUC), glycaemic index 
(GI) and insulinaemic index (II) were calculated to estimate glycaemic and 
insulinaemic responses.
Results: The 2-hour glycaemic responses to six mashed potato-containing 
meals varied more than two-fold. The glycaemic index (GI) of pure mashed 
potato was 108, whereas combined with protein, fat and salad, it was only 
54. The latter GI also differed considerably from its predicted value of 103, 
which was based on the individual GIs of the components of the meal. The in-
sulinaemic indices (II) of mashed potato-based meals varied between 94 and 
148. Protein in the meal increased the insulinaemic response and fat dimin-
ished it. However, the insulinaemic response to mashed potato with protein 
and fat was lower than for mashed potato alone.
Conclusion: The protein, fat and salad content of a meal exert considerable 
influence on the glycaemic and insulinaemic responses to the meal. The es-
timate of the GI of a mixed meal by the calculation of its components is im-
precise.
Supported by: Academy of Finland, Finnish Cultural Foundation, ABS Gradu-
ate School
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Glucose appearance of large slowly-absorbed evening meal containing 
complex carbohydrates (CHO) in type 1 diabetes (T1D)
D. Elleri1, J. Harris1, K. Kumareswaran1, J.M. Allen1, A. Haidar1, M. Nodale1, 
A. Swamy1, M.E. Wilinska1, J. Weston2, C.L. Acerini1, N. Jackson3,  
A.M. Umpleby3, M.L. Evans1, D.B. Dunger1, R. Hovorka1; 
1University of Cambridge, 2Addenbrooke’s Hospital, Cambridge, 3University 
of Surrey, Guildford, United Kingdom.
Background and aims: Many young patients with T1D report difficulty in 
adjusting the dose and timing of insulin when eating complex meals contain-
ing large CHO loads. Using novel methodology, we estimated appearance of 
complex and simple CHO in young people with T1D.
Material and methods: Eight subjects with T1D (age 20.8±3.3yrs, BMI 
24.0±1.5kg/m2, A1c 8.7±1.5%, diabetes duration 10.7±8.9yrs, total daily 
insulin 0.8±0.2U/kg/day; mean±SD) were studied on 2 separate visits at a 
clinical research facility. On both visits, from 1000 until 1730, variable in-
travenous (iv) insulin was infused to achieve normoglycaemia. On Visit 1 
the subjects fasted until 1800 when they consumed a slowly absorbed pasta 
meal (CHO:protein:fat 121:35:30g; sugars:starch 13:107g; glycaemic load 54) 
enriched with [U-13C]glucose and until 0200 next day iv insulin was infused 
to mimic prandial bolus of rapid-acting insulin (14±2U) and basal insulin 
delivery (0.9±0.3U/h). On Visit 2 identical iv insulin was given but, instead 
of the meal, variable iv 20%dextrose enriched with [U-13C] glucose was in-
fused to reproduce the plasma glucose profile observed on Visit 1. Iv infu-
sion of [6,6-2H2] glucose and [U-
13C;1,2,3,4,5,6,6-2H7] glucose were given on 
both visits in a fashion to mimic endogenous glucose production (EGP) and 
glucose appearance of simple and complex CHO from the meal (Ra_meal), 
respectively. Plasma glucose enrichment with the 3 tracers was measured by 
gas chromatography mass spectrometry. Total glucose appearance (Ra_total) 
on Visit 1 was estimated by double tracer approach. Ra_meal on Visit 1 was 
calculated as “Ra_total - EGP”, where EGP was obtained from Visit 2 and 
estimated by double tracer approach. Glucose appearance of simple CHO 
(Ra_meal_simple) on Visit 1 was estimated by triple tracer approach.
Results: Ra_meal extended over 8 hours with a sustained plateau of 30μmol/
kg/min over the first 3 hours, see Figure; 25% of the Ra_meal appeared 88±21 
min after meal consumption, 50% at 175±39 min, and 75% at 270±54 min. 
Ra_meal_simple was significantly faster with 25, 50 and 75% of the total ap-
pearance at 39±13, 84±30 and 159±42 min respectively (p<0.0001, paired t-
test). Bioavailability of simple CHO did not differ from that of complex and 
simple CHO (108±25 vs 101±14%, p=0.30).
Conclusions: Glucose appearance after consumption of a large slowly-ab-
sorbed evening meal is sustained over 1-3hours and may extend up to 8hours. 
This finding may have implications on prandial insulin dosing in T1D sug-
gesting a need for dual and/or delayed insulin doses.
Supported by: JDRF, NIHR BRC, MRC, Diabetes UK
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Can we identify typical glycaemic patterns around meals for individuals 
with or without diabetes? The ADAG Study
R. Borg1, A.C. Jensen1, B. Carstensen1, J. Kuenen2, R.J. Heine2, H. Zheng3, 
D.M. Nathan3, D.R. Witte1; 
1Steno Diabetes Center, Gentofte, Denmark, 2VU Medical Center, 
Amsterdam, Netherlands, 3Diabetes/Biostatistics Department, MGH/
Harvard Medical School, Boston, USA.
Background and aims: Postprandial glucose concentrations are determined 
by factors such as meal composition, physical activity, glucose tolerance, and 
glucose lowering therapy. Glucose profiles under real-life circumstances are 
not widely studied. The aim of this study was to describe the glucose profiles 
among persons with type 1 (T1DM), type 2 (T2DM) and in healthy con-
trol subjects (non-DM) based on intensive continuous glucose monitoring 
(CGM).
Materials and methods: In the A1c Derived Average Glucose (ADAG) study, 
participants underwent intensive glucose monitoring using CGM for approx-
imately 13 days over a 3 month period. The study included 264 participants 
with T1DM, 99 with T2DM without insulin treatment, 60 with T2DM with 
insulin treatment, and 80 healthy controls. Multi-level mixed models with 
5-point splines were fitted for 4-hour time windows around the 3 main meals 
of the day for each subgroup accounting for the variation between and within 
individuals. Mean and peak glucose levels were modelled as a linear function 
of age, BMI, HbA1c, and the glucose reference value one hour before each 
meal.
Results: Glucose levels following breakfast were higher than those following 
lunch and dinner. Glucose concentrations peaked earlier after breakfast than 
after either of the other meals. The time to glucose peak value for T1DM after 
breakfast was 80 minutes, after lunch 95 minutes, and after dinner 100 min-
utes. Times to peak for T2DM without insulin treatment were 70, 85 and 100 
minutes respectively. Non-DM individuals naturally presented much lower 
peak values, but also showed significantly shorter time to peak (50-85 min-
utes). The prandial glucose curves and the inter- and intra-individual varia-
tion are illustrated in the Figure.
Conclusion: Based on intensive continuous glucose monitoring in patients 
with T1DM, T2DM and healthy controls under real life circumstances, we 
found that glucose excursions after meals are largest in DM, compared to 
non-DM, both in terms of peak value and time to peak. The three diabetic 
subgroups presented similar patterns. We found considerable day to day vari-
ability in meal glucose excursions within individuals with a a stable treatment 
regime. This variability was larger than the variation between individuals 
within the same clinical subgroup. Overall, breakfast was followed by higher 
glucose levels than either lunch or dinner.
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Bottom: Glucose levels as a function of time, age, BMI and HbA1c around 
the main meals of the day for the 4 clinical patient groups. The dotted line 
illustrates meal time.
Top: The variability (SD) of the peak glucose level within and between per-
sons. 
Supported by: ADA, EFSD, Abbott, Merck&Co, Bayer, Lifescan, GSK, Medtron-
ic, sanofi-aventis
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Analysis of the control exerted by glucokinase and glucose-6-
phosphatase on glycerol metabolism of liver cells using different systems 
biology frameworks
S. Marin, A. Miranda, V.A. Selivanov, I. Marin, J.J. Guinovart, M. Cascante; 
Biochemistry and Molecular Biology, Universitat de Barcelona, Spain.
Background and aims: The metabolic flux profile of a cell is the result of the 
whole of cellular processes, and is characteristic of its phenotype. Stable iso-
tope tracer data is normally used to reveal the metabolic flux profile in cells 
under various conditions studied. Models of hepatic liver cells are very useful 
to understand the metabolic dysregulations associated to pathologies such as 
diabetes, due to its key role in glucose homeostasis. Glucokinase (GK) and glu-
cose-6-phosphatase (G6Pase), the enzymes that catalyze the first futile cycle in 
glycolysis, have been proven to have a key role in the development of MODY2 
and GSD-1 diseases. Our goal was to know if the GK-G6Pase futile cycle com-
promises the metabolism of glycerol, the main gluconeogenic substrate of liver 
cells in long fasting. The use of softwares capable of integrating all generated 
data allows a better extraction of relevant biological information. Thus, another 
aim of this study is to compare the metabolic flux profile obtained in these ex-
periments using Mass Isotopomer Distribution Analysis (MIDA) and Isodyn, a 
home-made software developed for the quantification of metabolic fluxes.
Materials and methods: Primary cultures of rat hepatocytes treated with in-
creasing doses of adenovirus encoding the rat liver GK or G6Pase, are incubated 
for 3h with 10mM glycerol 50% enriched in [U-13C]-glycerol. The biochemi-
cal concentrations and isotopomer patterns of glucose, lactate and glycogen are 
analyzed at the end of incubation. The obtained data are analyzed using MIDA 
and Isodyn. Using the framework of Metabolic Control Analysis, the control co-
efficients of GK and G6Pase over the different quantified fluxes are estimated.
Results: So far, overexpression of GK and G6Pase induced different bio-
chemical concentrations and isotopomer patterns, which correlate with the 
increase of enzyme activity. The MIDA analysis of the experimental data 
allowed us to calculate the fluxes of glucose, glycogen and lactate synthesis 
from glycerol at the different enzyme activities.
Conclusion: The analysis of functional organization of metabolism based on the iso-
topic isomer distribution allows us to estimate the changes associated with a pertur-
bation of the metabolic network in the central carbon metabolism. The results so far 
indicate that glycerol metabolism induces metabolic flux distributions that are de-
pendent on the activity of the futile GK-G6Pase cycle. The modifications performed 
in our software Isodyn will make it a model valid for modelling liver cell, extracting 
relevant biological information and being able to integrate all generated data.
Supported by: SAF2005-01627, DIAPREPP, ETHERPATHS
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Metabolic and anti-inflammatory benefits of eccentric endurance 
exercise
S. Beer1,2, P. Rein1,2, C.H. Saely1,2, A. Vonbank1,2, V. Kiene1, S. Aczel1,  
T. Bochdansky3, H. Drexel1,2; 
1Vorarlberg Institute for Vascular Investigation and Treatment, Feldkirch, 
Austria, 2Private University of the Prinicpality of Liechtenstein, Triesen, 
Liechtenstein, 3Academic Teaching Hospital Feldkirch,  Austria.
Background and aims: The interplay of muscle contraction with an external 
force can result in one of three types of muscle activity: shortening or “con-
centric” when muscle contraction is stronger than the external force; length-
ening or “eccentric” when the external force is stronger; and isometric when 
both forces are equal. Eccentric endurance exercise (e.g. hiking downwards) 
is less strenuous than concentric exercise (e.g. hiking upwards) but its meta-
bolic effects are largely unknown. In the present study we therefore aimed at 
elucidating the metabolic effects of this training modality.
Materials and methods: We allocated 93 healthy sedentary individuals to an 
exercise intervention program, consisting of hiking downwards a pre-defined 
route in the Austrian Alps over two months. For the opposite way, a cable 
car was used where compliance was recorded electronically. The difference in 
altitude was 540 metres; the distance was covered three to five times a week. 
A matched group of 25 individuals served as a control group. Fasting and 
postprandial metabolic profiles were obtained at baseline and after the two 
months period.
Results: Compared with baseline, eccentric exercise significantly lowered fast-
ing glucose (97±15 vs. 94±9mg/dl; p=0.025) and glucose tolerance (239±50 
vs. 217±47 mg*dl-1 h-1; p<0.001), whereas both were unchanged in the con-
trol group (p=0.265 and p=0.231, respectively). Body mass index (27.7±4.4 
vs. 27.4±4.3 kg/m2; p=0.003) and C-reactive protein (0.27±0.42 vs. 0.23±0.25 
mg/dl; p=0.031) also significantly declined in the eccentric exercise group but 
not in the control group (p=0.053 and p=0.864, respectively). Furthermore, 
eccentric exercise significantly lowered triglyceride tolerance (1959±1330 
vs. 1670±1085 mg*dl-1 h-1; p=0.003) and the postprandial leukocyte count 
(68.8±11.6 vs. 66.5±13.6 G*L-1 h-1; p=0.031), whereas both were unchanged 
in the control group (p=0.819 and p=0.600, respectively).
Conclusion: Eccentric exercise is a promising new exercise modality with fa-
vourable metabolic and anti-inflammatory effects. This moderately strenuous 
training option could become especially important in patients with diabetes, 
because a large proportion of these patients suffer from comorbidities confer-
ring a low tolerance for high-intensity training protocols.
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Comparison of Square-Wave Endurance Exercise Test (SWEET) training 
with endurance training targeted at the level of maximal lipid oxidation 
in type 2 diabetics
J.-F. Brun, J. Maurie, E. Jean, A.-J. Romain, J. Mercier; 
Metabolic Unit, INSERM ERI 25, Montpellier, France.
Background and aims: Both low and high intensity exercise have been dem-
onstrated to be useful in the management of type 2 diabetes. Their effects are 
likely to be different and complementary. We aimed at comparing in type 
2 diabetes a protocol of endurance training precisely targeted at the power 
intensity of maximal lipid oxidation (LIPOXmax) with a protocol combin-
ing resistance and endurance training (Square-Wave Endurance Exercise Test 
(SWEET) training).
Materials and methods: 63 type-2 diabetics (age 52.6±1.5 years; BMI 
32.7±0.7) were divided into 3 groups matched for age, BMI, and HbA1c and 
were compared over a period of 3 months, without nutritional intervention: 39 
were trained at the LIPOXmax determined with exercise calorimetry, 12 were 
submitted to a SWEET training, and 12 untrained patients served as controls.
Results: After 3 months, both procedures increased maximal aerobic capac-
ity (VO2max) (SWEET training +42±16.4% p=0.027 vs LIPOXmax training 
(+14±4.09% p=0.0011). The effect of SWEET training on VO2max was stron-
ger than that of LIPOXmax training (p=0.0016). SWEET training reduced 
resting systolic blood pressure (-12.08±5.17 mmHg p=0.040) and total choles-
terol (-0.74±0.33 mmol/l p=0.049), while LIPOXmax training did not. Both 
procedures decreased weight and BMI. By contrast, the LIPOXmax training 
improved the ability to oxidize lipids (maximum lipid oxidation rate +53 ± 
13.53 mg/min p=0.0005) shifted it to a higher power intensity (+20.9 ± 4.29 
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watts p=0.00002), decreased fat mass (- 1±0.37 %; p=0.012), increased fat-
free mass (+1 ±0.37 % p=0.012), decreased waist circumference (-3.76±0.99 
cm p=0.0007) and hip circumference (-2.18±0.78 cm p=0.009) while SWEET 
training did not significantly affect any of those parameters. Over this short 
period the effects of training on HbA1c were significant in the LIPOXmax 
group (-0.15±0.07% p=0.044) but not in the SWEET group.
Conclusion: This study shows that SWEET training improves aerobic work-
ing capacity, blood pressure and lipid profile, while low intensity endurance 
training (LIPOXmax training) improves the ability to oxidize lipids at exer-
cise, increases fat free mass, decreases fat mass and decreases HbA1c. The ben-
efits of these two procedures are thus quite different and both are probably 
interesting to associate in the management of type 2 diabetes.
683
Objectively measured sedentary behaviour and physical activity in 
relation to adiposity in a multi-ethnic population at risk of developing 
diabetes
V.E. Kumar1, T. Yates1, M.J. Davies1, E.G. Wilmot1, K. Khunti2; 
1Cardiovascular Sciences, University of Leicester, 2Health Sciences, 
University of Leicester, United Kingdom.
Background and aims: Sedentary behaviour (SB), typically measured indi-
rectly (e.g. through self-reported TV viewing), is increasingly reported to be 
an important factor in the obesity epidemic, independent of physical activity. 
However data using objective measures of sedentary behaviour are lacking 
in high-risk populations. We aim to test the hypotheses that in a population 
identified with a high risk of diabetes, SB and light-intensity physical activity 
(LPA) are more important determinants of obesity than moderate-vigorous 
physical activity (MVPA).
Methods and materials: Participants with a high risk of diabetes, identified with 
the validated Leicester risk score, were recruited from primary care, Leicester, 
UK. SB, LPA and MVPA were measured objectively using validated acceler-
ometers (GT3X, Actigraph), worn for 7 consecutive days. Freedson’s validated 
cut-off points were used to calculate SB (<100 counts/min), LPA (100-1,951 
counts/min) and MVPA (1,951 counts/min). Basic anthropometric measure-
ments were conducted using standardized methods. Following best practice, 
total (non-sleeping) sedentary time was calculated by deducting non-wear time 
estimated using standardized criteria. Linear regression analysis models exam-
ined the effects of SB, LPA and MVPA on waist circumference and BMI.
Results: 89 participants were used in the analysis; mean age = 62.7 years (S.D. 
9.3), Mean BMI = 33.5 kg/m2 (S.D. 5.6), mean waist circumference = 105.5cm 
(S.D. 11.8). Mean daily sedentary time = 550min (S.D. 115), mean daily LPA 
= 248min (S.D. 73) and mean MVPA = 19min (S.D 16). After adjusting for 
confounders, sedentary time had the greatest effect on both waist circumfer-
ence and BMI with standardised beta coefficients of 0.40 (SE = 0.18; p=0.03) 
and 0.31 (SE = 0.15; p=0.04) respectively (see Table 1).
Table 1 - association between different categories of activity and adiposity 
Waist circumference BMI
Sedentary time Standardised beta 
coefficient ± S.E.
P value Standardised beta 
coefficient ± S.E.
P value
Model 1a 0.57 ± 0.16 0.001 0.40 ± 0.13 0.003
Model 2b 0.40 ± 0.18 0.03 0.31 ± 0.15 0.038
Light intensity 
physical activity
P value P value
Model 1a -0.32 ± 0.12 0.008 -0.23 ± 0.09 0.019
Model 2b -0.24 ± 1.17 0.048 -0.18 ± 0.1 0.071
moderate-to vig-
orous-intensity 
physical activity 
(MVPA)
P value P value
Model 1a -0.33 ± 0.1 0.001 -0.20 ± 0.08 0.017
Model 2c -0.22 ± 0.11 0.051 -0.12 ± 0.09 0.215
aadjusted for wear time, gender, age, ethnic origin & smoking status
badjusted for wear time, gender, age, ethnic origin, smoking status & MVPA
cadjusted for wear time, gender, age, ethnic origin, smoking status & seden-
tary time
Conclusion: Our findings conclude that in a population with high risk of 
diabetes, identified through a validated risk score, adiposity is more strongly 
linked with time engaged in SB than MVPA. Hence, diabetes prevention pro-
grammes aimed at weight loss may be more effective if the emphasis is shifted 
from traditional MVPA goals to reducing SB, such as sitting. If these find-
ings are confirmed by appropriately designed intervention studies, they could 
have dramatic implications on future public health recommendations.
684
Situation of exercise therapy for patients with diabetes mellitus in Japan 
- a joint project with the Japan Medical Association
Y. Sato1, H. Sone2, M. Kobayashi3, R. Kawamori4, Y. Tamura4, Y. Atsumi5,  
Y. Oshida6, S. Tanaka7, S. Suzuki8, S. Makita9, I. Ohsawa1, Research 
Committee for the Establishment of Therapeutic Exercise for Diabetics of 
the Japan Diabetes, S. Imamura10, T. Watanabe1; 
1Aichi Gakuin Univ., Nisshin, 2Univ. of Tsukuba, Mito, 3Univ. of Toyama, 
4Juntendo Univ., Tokyo,  5Saiseikai Central Hosp., Tokyo, 6Nagoya Univ., 
7Osaka Sangyo Univ., Daito, 8Ohta General Hosp., Koriyama, 9Saitama 
Medical Univ., Hidaka, 10Japan Medical Association, Tokyo, Japan.
Background and aims: Regardless of the well-known health-promoting ben-
efits of exercise, it is actually less prescribed than diet and drug therapy in 
the clinical practice. In addition, up till now a national survey on the present 
situation of exercise therapy for patients with diabetes mellitus has not been 
conducted in Japan. Therefore, our committee in the Japan Diabetes Society 
joined the Japan Medical Association to conduct the first nationwide survey 
that aimed to investigate the actual situation of exercise therapy for diabetic 
patients in Japan.
Materials and methods: Questionnaires concerning the practice and adopt-
ed systems of exercise guidance for diabetic patients were mailed to randomly 
selected diabetologists (n = 600) and non-specialist physicians (n = 600). Re-
sponses were obtained from a total of 403 doctors (response rate of 33.6%), 
275 diabetologists (50.3 ± 10.6 years of age; mean ± SD) and 128 non-special-
ist physicians (52.4 ± 9.8 years of age). Collected data were analyzed using the 
chi-square test, the Fisher’s exact test, and the Student’s t-test.
Results: While only 18% of the non-specialist physicians were found to carry 
out special clinic for diabetic patients, this rate was 64% among diabetologists 
(p < 0.001). Diabetologists (78%) and non-specialist physicians (67%) were 
found to provide dietary guidance to almost all patients at the initial visit to 
the clinic; however, exercise guidance to the patients at their initial visit was 
performed by only about 40% of both categories of doctors. In addition, 10% 
of the diabetologists and 18% of the non-specialist physicians did not provide 
exercise guidance to their patients. On the other hand, while about 60% of the 
diabetologists provided exercise prescription and group or personal guidance 
to the patients, the rate among non-specialist physicians was about 30%. Less 
than 20% of the diabetologists answered to have physical exercise educators 
in their clinics. Another finding of this survey was that 46% of the diabetolo-
gists and 40% of the non-specialist physicians have no appropriate guidelines 
for exercise therapy of diabetic patients. Taking into consideration the main 
problems related with the implementation of exercise therapy by the doctors 
(i.e., no additional consultation fee for exercise guidance, lack of time to pro-
vide guidance, absence of specialized physical educator); it becomes clear that 
an early improvement of this situation is challenging.
Conclusion: The present nationwide survey on the situation of exercise ther-
apy for diabetic patients revealed that, in Japan, (1) the proportion of dietary 
guidance is markedly higher than the proportion of exercise guidance and (2) 
significant differences between diabetologists and non-specialist physicians 
do exist. These results suggest that, as exercise guidelines are more realistic 
and effective than other demands of doctors, preparation of proper exercise 
guidelines for exercise therapy of diabetic patients is necessary.
685
Associations between cardio-respiratory fitness and glycaemic indices in 
a Danish population at high diabetes risk 
A.-L.S. Hansen1, D. Vistisen1, J.W. Helge2, M. Aadahl3, A. Sandbaek4,  
D.R. Witte1; 
1Epidemiology Group, Steno Diabetes Center A/S, Gentofte, 2Department 
of Biomedical Sciences, University of Copenhagen, 3Research Centre for 
Prevention and Health, Glostrup, 4Department of General Practice, Institute 
of Public Health, Aarhus, Denmark.
Background and aims: High cardio-respiratory fitness is known to be associ-
ated with several health-outcomes such as low risk of cardiovascular diseases 
and all cause mortality. Furthermore, studies have shown that cardio-respira-
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tory fitness is positively related to insulin sensitivity. The aim of this study 
was, to compare the strength of the association between cardio-respiratory 
fitness and multiple glycaemic indices in a population at high diabetes risk, 
taking into account obesity.
Materials and methods: Data from participants of the ADDITION-PRO 
study (cross-sectional study, subjects at high diabetes risk identified by a 
stepwise screening programme) are included in the analysis. Associations 
between fitness level and glycaemic indices are examined using linear regres-
sion models. Fitness levels were derived from estimated maximal oxygen con-
sumption, VO2max (mlO2 x kg
-1 x min-1), based on the relationship between 
heart rate and physical activity intensity during an 8 minutes sub-maximal 
step test. Homeostatic model of assessment (HOMA2) was used to calculate 
insulin resistance (HOMA2-IR) and beta cell function (HOMA2-B). Insulin 
sensitivity was estimated by the Insulin Sensitivity Index (0,120). Pancreatic 
response was estimated by disposition index. The analyses were adjusted for 
sex, age, and waist circumference, WC.
Results: Data from the first 87 subjects, aged 52-77 years, 63% men, were 
included in the analyses. Mean VO2max was: 32 (men) and 27 (women) mlO2 
x kg-1 x min-1. The changes in standardized estimates of glycaemic markers 
per one standard deviation (SD) change in the estimated VO2 max (partial 
correlation coefficients) are presented in table 1.
Conclusion: In this high diabetes risk population with low fitness levels, 
higher cardio-respiratory fitness was associated with better insulin sensitiv-
ity. In an age- and sex-adjusted model estimated VO2max showed a positive 
association with Insulin Sensitivity Index and a negative association with 
HOMA2-IR reflecting the association of fitness and peripheral insulin sen-
sitivity and hepatic insulin resistance, respectively. WC abolished these 
associations. However, this may be due to over-adjustment. Pancreatic re-
sponse determined by disposition index and beta-cell function estimated by 
HOMA2-beta showed no associations with fitness level.
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Different responses of adipocytokine, free fatty acid, and insulin 
sensitivity to diet or exercise induced weight loss and maintenance in 
type 2 diabetes
K.A. Han, K. Pak, K.W. Min, H.K. Lee; 
Department of Internal Medicine, Eulji university, Seoul, Republic of Korea.
Background and aims: The aim of the study was to compare the effects of 
diet or exercise induced weight loss and maintenance trial on free fatty acid, 
adipokine, and inflammatory cytokines in type 2 diabetes.
Materials and methods: Total 39 women with type 2 diabetes were ran-
domly assigned to control (C, N=14), diet (D, N=11), exercise (E, N=14) 
and completed the 3 month weight loss program, and then followed by body 
weight(BW) maintenance for 3 months. The restriction of calorie intake (< 
1400 kcal/day) was done for D, walking for 60 minutes at moderate inten-
sity (3.6 to 5.2 METs) five times a week for E. Diet was monitored with 3 
day dietary record, and physical activity with accelerometer. We assessed 
anthropometric parameters, free fatty acid (FFA), high-sensitive C-reactive 
protein(hsCRP) and intrleukin 6(IL6) and adiponectin leptin ratio(ALr) and 
homeostasis model assessment of insulin resistance (HOMA- IR) at baseline, 
3 months, and 6 months.
Results: At baseline, the participants’ age was 54.9±7.4 years and BMI was 
27.2±3.4kg/m2 (BW: 66.8±8.7kg) without the differences across 3 groups. 
Body weight (BW) decreased from baseline by 4.9±1.5kg in D, and by 1.4 
±1.6 kg in E during weight loss program (p=0.001, p=0.008), and didn’t 
change significantly during following maintenance in both intervention 
groups period. Increased ALr and decreased HOMA-IR were found only in 
D at 3 months (p=0.004, p=0.06 respectively), which didn’t sustain until 6 
months. HOMA-IR decreased gradually and made significant difference only 
at 6 months in E(P=0.04). ALr changed with BW and HOMA-IR during first 
3 months(r=-0.748, p<0.001; r=-0.432, p=0.006, respectively). Within group 
analysis showed that FFA did not change from baseline at 3 months and de-
creased at 6 months in D, but decreased at 3 month and sustained until 6 
month in E. FFA changed with relation to hsCRP at 3 months, and to IL6 at 6 
months in all subjects((r=0.428, P=0.007: r=0.323, P=0.045, respectively).
Conclusion: These results suggest that diet induced weight loss resulted in 
favorable effects on insulin resistance and adipokines which were not promi-
nent during weight maintenance. Exercise induced the improvement of in-
sulin resistance slower than diet without relation to adipokines and body 
weight. On the other hand, FFA improved earlier in exercise than in diet. The 
lifestyle modification for 6 months was not sufficient to change the inflamma-
tory cytokines in type 2 diabetes.
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Pioglitazone increases the aerobic capacity with improved skeletal 
muscle energetics in patients with insulin resistance
T. Yokota1, S. Kinugawa1, K. Hirabayashi1, T. Suga1, S. Takada1, M. 
Takahashi1, S.A. Mochamad1, T. Ono1, N. Morita2, K. Okita3, H. Tsutsui1; 
1Cardiovasucular Medicine, Hokkaido University Graduate School of 
Medicine, Sapporo, 2Hokkaido University of Education, Iwamizawa, 
3Hokusho University, Ebetsu, Japan.
Background and aims: Low aerobic capacity is a strong predictor for cardio-
vascular morbidity and mortality in insulin resistance and type 2 diabetes. 
Recent study reported that pioglitazone, known as peroxisome proliferator-
activated receptors (PPARs)-γ agonist, enhances the expression of genes in-
volved in mitochondrial function and fatty acid oxidation in patients with 
type 2 diabetes. Skeletal muscle energy metabolism is an important deter-
minant of aerobic capacity. Therefore, the aim of the study was to investigate 
the effect of pioglitazone on aerobic body (whole-body oxidative capacity) in 
relation to alteration in skeletal muscle energy metabolism.
Materials and methods: Fourteen male insulin-resistant subjects with no 
habitual exercise participated in the study before and after 3 months of 15 
mg/day pioglitazone treatment. Blood was corrected in after 10 hrs fasting. 
To assess the aerobic capacity, peak oxygen uptake (peak VO2) and anaerobic 
threshold (AT) during incremental exercise testing with cycle ergometer were 
measured. Body composition was measured by BOD POD, an air displace-
ment plethysmograph and the aerobic capacity was normalized to lean body 
mass to eliminate the influence of altered body composition. Daily physical 
activity was monitored for a week before and after treatment by a pedometer 
with an accelerometry sensor. To assess the skeletal muscle energy metabo-
lism, high-energy phosphates metabolites at rest and during plantar flexion 
exercise with a constant load of 20% one-repetition-maximum for 4 minutes 
were measured using 31P-magnetic resonance spectroscopy (MRS). Intra-
myocellular lipid (IMCL) content was also measured using 1H-MRS. Data are 
expressed as mean ± SD.
Results: Pioglitazone significantly decreased fasting blood glucose (116 ± 18 
vs. 106 ± 13 mg/dL, P < 0.01), insulin (13.7 ± 9.8 vs. 6.7 ± 2.7 μIU/mL, P < 
0.05), and HOMA-IR (4.0 ± 3.3 vs. 1.8 ± 0.8, P < 0.05). Body weight and %Fat 
were comparable before and after treatment. Daily physical activity, assessed 
by daily steps and movement-related calorie consumption were not altered 
before and after treatment. Peak VO2 (35.1 ± 5.9 vs. 38.2 ± 5.2 mL/kg/min, P 
< 0.01) and AT (18.3 ± 3.0 vs. 20.2 ± 3.3 mL/kg/min, P < 0.05) normalized to 
lean body mass were significantly increased after treatment of pioglitazone. 
Phosphocreatine (PCr) loss during plantar flexion exercise was significantly 
decreased after treatment of pioglitazone (0.293 ± 0.112 vs. 0.256 ± 0.086, P < 
0.05), suggesting increased energy reserve. Moreover, IMCL content tended 
to be decreased after treatment of pioglitazone (4.5 ± 1.3 vs. 3.3 ± 2.1 mmol/
kg wet weight, P = 0.06).
Conclusion: Pioglitazone increased the aerobic capacity with improved skel-
etal muscle high-energy phosphates metabolism and decreased IMCL con-
tent in patients with insulin resistance without alteration in physical activ-
ity. These findings raise the possibility that pioglitazone might increase the 
aerobic capacity, at least in part, through improvement of fatty acid oxidation 
in skeletal muscle.
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Physical activity may offset pregnancy-related insulin resistance
A. Gradmark1, J. Pomeroy2, F. Renström1, S. Steiginga1, A. Wright3,  
S.E. Kahn4, I. Mogren5, M. Domellöf6, P.W. Franks1; 
1Medicine, GECRG, Public Health and Clinical Medicine, Umeå, Sweden, 
2NIDDK/NIH, Diabetes Epidemiology and Clinical Research Section, 
Phoenix, USA, 3MRC Human Nutrition Research, Cambridge, United 
Kingdom, 4Medicine, Division of Metabolism, Endocrinology and 
Nutrition, Seattle, USA, 5Department of Clinical Sciences, Obstetrics & 
Gynecology, Umeå, Sweden, 6Department of Pediatrics, Umeå, Sweden.
Background and aims: Insulin resistance increases in pregnancy, which is 
often compensated for by increase in insulin secretion in order to maintain 
normoglycemia. Physical activity improves insulin sensitivity outside preg-
nancy, but little is known of whether physical activity can offset pregnancy-
related insulin resistance, which was the focus of this study.
Materials and methods: Thirty-two women in gestational weeks 28-32 from 
Västerbotten, Sweden were recruited through advertisement. Glucose and 
insulin levels were measured fasting and at 30, 60, and 120 minutes during 
a 75g oral glucose tolerance test. Insulin resistance was estimated using the 
homeostasis model assessment of insulin resistance (HOMA-IR). Insulin se-
cretion was estimated via early insulin response (EIR) and the oral disposi-
tion index (DIO). Resting metabolic rate (RMR) and total energy expenditure 
(TEE) were directly measured using indirect calorimetry and doubly-labeled 
water, respectively, from which physical activity energy expenditure (PAEE) 
was calculated. Heart rate measured with the Actiheart (CNT Ltd, Papworth, 
UK) was used to calculate time spent in moderate-to-vigorous physical ac-
tivity and also to estimate sedentary time (min/day). Associations between 
gestational PAEE, sedentary time and insulin sensitivity or secretion were 
determined using generalized linear regression (SAS v9.1, Cary, NC).
Results: Total daily PAEE was positively associated with DIO after adjustment 
for maternal age, height, and weight. Time spent in moderate-to-vigorous 
activity was not associated with any of the estimates of insulin sensitivity or 
secretion, but sedentary time was negatively associated with EIR.
Conclusions: Insulin resistance typically increases during pregnancy and 
raises the risk of gestational diabetes mellitus. These data indicate that this 
may be ameliorated by maintaining high levels of physical activity. Specifi-
cally, our findings suggest that minimizing time spent in sedentary behaviors 
might be the focus of future interventions aimed at preventing gestational 
diabetes mellitus.
Table 1. Tests of association between physical activity and estimates of in-
sulinemia during pregnancy (28-32 weeks gestation) 
PAEE (kcal/day) Sedentary time (minutes/day)
Moderate - Vigorous 
time (minutes/day)
Women  
(n = 32) Partial r
2 β Partial r2 β Partial r2 β
HOMA-IRa 0.009 -0.14 0.03 0.13 0.04 -0.19
EIRa 0.002 -0.06 0.15* -0.35 0.0017 0.03
DIO
a 0.14* 0.38 0.008 0.19 0.03 0.13
Adjusted *p< 0.05. Multiple testing was adjusted for using the Holm proce-
dure; Partial r2 = variance in outcome explained by physical activity variable; 
β = standardized beta coefficient; PAEE = Physical activity energy expendi-
ture; HOMA-IR = Homeostasis model assessment of insulin resistance; EIR 
= Early Insulin Response; DIO = Oral disposition index; a. Corrected for ma-
ternal age, height, weight
Supported by: Foundation of: T, R Söderbergs, F, I Thurings, Västerbotten 
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Impact of exercise on continuously-monitored glucose levels in type 1 
diabetes patients >14 years of age on insulin pump therapy
A.M. Gomez, C.M. Gomez, A. Veloza, O. Muñoz, C.P. Rubio; 
Endocrinology, Hospital Universitario San Ignacio, Bogota, Colombia.
Background and aims: Exercise is a risk factor for hypoglycemia in type 1 
diabetes, but the relationship between exercise intensity and duration to the 
onset and severity of hypoglycemia is unclear. Here we compared the impact 
of standardized morning and afternoon exercise on glycemic control for 36 h 
post-exercise using a continuous glucose monitoring (CGM) system in type 
1 diabetes patients >14 years old.
Materials and Methods: Thirty-two subjects on CGM sensor-augmented pump 
therapy (Paradigm REAL-Time System, Medtronic Diabetes, Northridge, CA, 
USA) were evaluated at the Diabetes Clinic of Hospital San Ignacio, Bogotá, Co-
lombia. They participated in morning and afternoon exercise sessions maintaining 
a heart rate of 50-70% of maximum, for 4 15-min bouts of treadmill walking with 
5-min breaks between the bouts. Capillary blood glucose values were measured 4 
times during exercise and 8 times in the next 24 h; CGM readings were collected 
every 5 min in the 24 h before and 36 h after exercise. The primary outcomes was 
the incidence of hypoglycemia (<70 mg/dl) and hyperglycemia (>200 mg/dl) per 
100 patient-hours during and after exercise. Secondary outcomes were the per-
centage of time in goals (70-200 mg/dl) according to the time before and after 
exercise and the precision of the data obtained from CGMS during exercise.
Results: Among the 32 patients exercising in the morning, there were 180 events 
of hypoglycemia detected by CGMS (5.6 per patient) and 39 events detected by 
SMBG (incidence rate 15.2 per 100 patient-hours). The highest risk of hypogly-
cemia was between 15 and 24 h post-exercise (ie, between 10 pm and 7 am). Of 
the 30 patients exercising in the afternoon, 322 events were detected by CGMS 
(10.7 per patient) and 62 events were detected by SMBG (incidence rate 29.0 per 
100 patient-hours), and the highest risk of hypoglycemia was between 15 and 21 
hours post-exercise (ie, between 7 am and 2 pm). The rates of hypoglycemia fol-
lowing morning and afternoon exercise were significantly different (incidence 
rate ratio: 0.52, 95% CI (0.43-0.63) P <0.001), but there was no between-groups 
difference in the risk of hyperglycemia. On the day after exercise, subjects who 
exercised in the morning spent 20% more time with CGM readings between 70 
and 200 mg/dl (p=0.003); there was no such benefit in the afternoon exercise 
group, but there was an increase in percent of time with CGM readings <70 mg/
dl (p=0.011). The accuracy of the data of the CGMS was evaluated by the mean 
absolute difference between CGM and capillary blood measurements; this was 
found to be 18.5% and was not affected by exercise.
Conclusions: In type 1 diabetes, exercising in the morning carries a lower 
risk of subsequent hypoglycemia than does equivalent afternoon exercise. The 
highest risk of post-exercise hypoglycaemia is between 15 and 24 hours after 
cessation of exercise. Morning exercise improves metabolic control on day 
after exercising. The use of continuous glucose monitoring during and after 
exercise detects a higher number of glycemic excursions than does capillary 
glucose measurement. CGM precision is not influenced by physical exercise.
Supported by: Medtronic, Abbott
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Examination of timing of pre-exercise administration of low GI 
carbohydrates on blood glucose after running in type 1 diabetes mellitus
D.J. West, R.D. Morton, R. Davies, J.W. Stephens, S. Bain, R.M. Bracken; 
Sports and Exercise Science Research Centre, Swansea University, United 
Kingdom.
Background and aims: Current research recommends the use of high GI CHO 
immediately prior to exercise to prevent hypoglycaemia. In contrast, research 
examining the use of low GI (LGI) carbohydrates 2 hours before exercise dem-
onstrates more stable blood glucose concentrations after exercise. However, 
given the slower digestion rates of LGI carbohydrates it is unclear if the tim-
ing of consumption of LGI carbohydrates before exercise should differ from 
those carbohydrates with a HGI. This study examined the blood glucose and 
metabolic responses to alterations in the timing of isomaltulose, a LGI carbo-
hydrate (GI=32), before running in type 1 diabetes individuals (T1DM).
Materials and methods: Seven T1DM (31±2 years; BMI 26±0.3 kg/m2; 
HbA1c 8.3±0.1%) attended the laboratory on four occasions, each time con-
suming 75 g of isomaltulose and administering a 75% reduced insulin dose, 
in a randomised fashion. T1DM then remained at rest for 120 (120min), 90 
(90min), 60 (60min) or 30 (30min) min before completing 45 min of running 
at 71±1%VO2peak. Blood glucose concentrations (BG) were measured before 
and 3 hours after exercise. Substrate oxidation was calculated from respira-
tory data taken at rest and during exercise. Data (mean±SEM) were analysed 
using repeated measures ANOVA and expressed as changes from rest.
Results: Fasting BG was similar between conditions. Immediate pre-exer-
cise BG under 30min (+2.8±0.2 mmol.l-1) tended to be lower than 60min 
(+3.9±0.2 mmol.l-1), 90min (+4.3±0.2 mmol.l-1) and 120min (+4.1±0.6 mmol.
l-1), (P<0.1). BG dropped less with exercise under 30min compared to 120min 
(30min 4.6±0.3 vs. 120min 6.4±0.3 mmol.l-1, P<0.05). In the 60 min post-ex-
ercise period BGauc was different under 30min when compared to 60min and 
120min (30min 7.8±0.5 vs. 60min 10.1±0.7, 120min 5.9±0.5 mmol.l-1.hr-1, 
P<0.05). The greatest incidence of hypoglycaemia (BG ≤3.5 mmol.l-1) occurred 
under 120min from 60 min onwards following exercise (120min, n=5; 90min, 
n=2; 60min, n=1 and 30min n=0). Substrate oxidation rates during exercise 
displayed a strong tendency for greater lipid (30min 0.13±0.01 vs. 120min 
0.07±0.01 g.min-1) and lower CHO oxidation (30min 3.88±0.08 vs. 120min 
4.38±0.05 g.min-1) rates under 30min compared with 120min (P<0.10).
Conclusion: BG concentrations are best preserved after consumption of the 
low GI carbohydrate isomaltulose 30 minutes before exercise. Better preserva-
tion of post-exercise glycaemia in the 30 min ingestion trial led to a shorter di-
gestion time before and during exercise, altering fuel metabolism towards lipid 
combustion and reducing the incidence of post-exercise low blood glucose.
Supported by: The Welsh Office of Research and Development
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Heat flux is inversely associated with glucose concentrations in free 
living subjects with type 1 diabetes
J.J. Valletta1,2, A.J. Chipperfield2, G.F. Clough1, C.D. Byrne1; 
1Institute of Developmental Sciences, Endocrinology and Metabolism Unit, 
2Computational Engineering and Design Group, School of Engineering 
Sciences, University of Southampton, United Kingdom.
Background and aims: Good glycaemic control in people with type 1 dia-
betes is achieved by the right balance of calorie intake, exogenous insulin 
administration and physical activity energy expenditure (PAEE). Few trials 
have studied the continuous relationship between PAEE and glucose concen-
trations in free-living individuals during normal daily living. Most studies 
to date have studied fit adults in a controlled environment while following 
an exercise protocol. The aim of our study was to investigate the relationship 
between a continuous read out of glucose concentrations and daily physical 
activity energy expenditure in a free-living environment.
Patients and methods: 15 adults (9 female) with type 1 diabetes have been studied 
(age=37±10y, BMI=26.1±6kg.m-2, diabetes duration=17±11y, HbA1c=8.2±1.3%, 
mean±SD). Participants with clinical evidence of diabetic neuropathy were ex-
cluded. The participants wore a SenseWear Pro2 armband (BodyMedia Inc., USA) 
and a Guardian Real-Time Continuous Glucose Monitoring System (CGMS) 
(Medtronic MiniMed Inc., USA) continuously for up to 15 days. The armband 
is worn on the right triceps muscle and is only removed prior to water-based ac-
tivities. The SenseWear Pro2 utilises five sensors (two accelerometers, heat flux, 
galvanic skin response, skin and near-body temperature sensors) to provide an 
estimate of overall physical activity energy expenditure. The Guardian CGMS 
monitors interstitial glucose concentrations from which a blood glucose value is 
estimated every 5mins using a proprietary algorithm. The participants were asked 
to perform normal daily activities and not to change their usual behaviour.
Results: Both devices were worn for 9±3days (mean±SD) and a total of 139 
days of data were analysed. There was no association between mean daily 
PAEE, measured as area under curve for metabolic equivalent (AUCMETs) and 
mean daily glucose concentrations, measured as area under curve for blood 
glucose (AUCBG) (r=-0.10, p=0.26), although there was a correlation between 
the variance in blood glucose and the variance in METs (r=0.26, p=0.002). 
Interestingly, there was also an association between AUCBG and area under 
curve for heat flux (AUCHF) (r=-0.26, p=0.002), even though AUCMETs and 
AUCHF are strongly correlated (r=0.40, p<0.0001).
Conclusion: We show for the first time a strong inverse relationship between 
heat flux and a measure of glycaemic control and a positive relationship be-
tween variance in glucose concentrations and variance in physical activity lev-
els in free living people. The data shows that greater fluctuations in physical ac-
tivity are associated with greater variation in blood glucose levels throughout 
the day. Since heat energy (measured as heat flux) is a by-product of ATP gen-
eration in mitochondria, these data suggest that higher levels of mitochondrial 
activity are related to lower levels of glucose concentrations. We suggest that 
further work is needed to explore the relationship between ATP generation 
and glycaemic control and to determine whether heat flux could potentially be 
used as a novel non-invasive measure of glycaemic variability.
Supported by: Diabetes UK
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Glucose regulation of STIM1 translocation reflecting store-operated 
channel modulation in pancreatic islet cells
G. Tian1, A.V. Tepikin2, A. Tengholm1, E. Gylfe1; 
1Department of Medical Cell Biology, Uppsala University, Sweden, 2The 
Physiological Laboratory, University of Liverpool, United Kingdom.
Background and aims: Store-operated calcium channels (SOCs) are pro-
posed important both for the regulation of insulin and glucagon secretion. 
Recent studies have identified STIM1 as a Ca2+ sensor in the ER. This protein 
oligomerizes upon Ca2+ store depletion and translocates to plasma membrane 
(PM)-adjacent regions of the ER where it interacts with the channel-forming 
PM molecule Orai1 that participates in the formation of SOCs. The aim of the 
present study was to clarify the movements of STIM1 in pancreatic islet cells 
under conditions known to modulate insulin and glucagon secretion.
Materials and methods: Islets isolated from C57/Bl mice were infected with 
adenovirus expressing STIM1 protein fused with enhanced yellow fluorescent 
protein (EYFP). STIM1-EYFP translocation in peripherally located islet cells 
was studied with confocal and total internal reflection fluorescence (TIRF) 
microscopy. Glucagon-releasing α- and insulin-secreting β-cells were identi-
fied by immunostaining, cell size and their different responses to adrenaline.
Results: In 3 mM glucose there was diffuse STIM1-EYFP fluorescence in pe-
ripheral islet cells with confocal microscropy, but some PM-associated fluo-
rescence puncta were observed in TIRF microscopy. Depletion of the ER Ca2+ 
stores by inhibition of the ER Ca2+ ATPase with cyclopiazonic acid (CPA), 
which activates SOCs in α- and β-cells, induced after a delay of 118 ± 21 s 
pronounced formation of STIM1-EYFP puncta that preferentially associated 
with the PM. Less pronounced PM translocation was observed after islet ex-
posure to Ca2+-deficient medium containing EGTA. In the presence of 3 mM 
glucose about 70% of the islet cells reacted to 5 μM adrenaline with a loss of 
PM-associated STIM1-EYFP fluorescence indicating dissociation from the 
PM. These cells were larger than other cells and stained for insulin. In about 
10% of the cells, that were smaller and stained for glucagon, adrenaline in-
stead triggered pronounced translocation of STIM1-EYFP to the PM with 
formation of distinct puncta. When the glucose concentration was raised 
from 3 to 20 mM, there was a 248 ± 32 s delayed reduction of PM-associ-
ated STIM1-EYFP fluorescence in β-cells that only partially recovered after 
reintroduction of 3 mM glucose but the PM STIM1-EYFP fluorescence was 
rapidly restored in glucose-deficient medium. Stepwise increase of the glu-
cose concentration from 0 to 3, 7, 11 and 20 mM induced graded reduction 
of PM STIM1-EYFP fluorescence with maximal effects at 3 and 11 mM in 
adrenaline-identified α- and β-cells, respectively.
Conclusions: The effects of CPA, glucose, and adrenaline on STIM1 localiza-
tion are consistent with their stimulatory and inhibitory effects on SOCs in 
α- and β-cells. The glucose sensitivity of STIM1 translocation is considerably 
higher in α- than in β-cells, consistent with a proposed role of SOC inactiva-
tion in glucose inhibition of glucagon secretion.
Supported by: Swedish Reseach Council
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Glucose inhibits glucagon secretion from mouse pancreatic islets 
independently from Zn2+ or somatostatin, and from an action on KATP 
channels
R. Cheng-Xue1, L. Noel1, M.A. Ravier1, F. Chimienti2, F. Schuit3, P. Gilon1; 
1Université Catholique de Louvain, Brussels, Belgium, 2Mellitech, Grenoble, 
France, 3Katholieke Universiteit Leuven, Belgium.
Background and aims: The mechanisms by which glucose (G) inhibits glu-
cagon secretion are still unknown. The role of KATP channels in the G-induced 
suppression of glucagon secretion (GISG) is unclear and has been assessed 
here using NMRI mice and KATP channel modulators, or SUR1 knockout 
mice (SUR1-/-), contributed by the Bryan Lab. Several hypotheses suggest 
that a paracrine factor, i.e. zinc released from β-cells or somatostatin released 
from δ-cells, is responsible for GISG. Zinc is specifically accumulated within 
granules of insulin by the ZnT8 transporter since no zinc exocytosis is ob-
served in ZnT8 KO mice. In the present study, we have evaluated the role of 
zinc and somatostatin in GISG by using ZnT8 KO (ZnT8-/-) and C57BL/6J 
mice (ZnT8+/+, used as control), and somatostatin KO (SST-/-) and CBA/Ca x 
C57BL/10 F1 mice (SST+/+, used as control).
Materials and methods: Mouse islets were isolated by collagenase digestion 
of the pancreas and cultured overnight in RPMI 1640 medium containing 
7 mM G. Glucagon secretion from islets was measured either in perifusion 
experiments in the continuous presence of a 6 mM mixture of amino-acids (2 
mM alanine, 2 mM glutamine, 2 mM arginine) or in incubation experiments 
(only for the experiments with ZnT8-/- and ZnT8+/+ islets) in the continuous 
presence of 20 mM arginine.
Results: Increasing the [G] of the perifusion medium from 1 to 7 mM revers-
ibly inhibited glucagon secretion from NMRI islets. Addition of 500 µM of 
the KATP channel closer, tolbutamide, to a medium containing 1 mM G did 
not reproduce the inhibitory effect of 7 mM G, whereas the KATP channel 
opener diazoxide (250 µM) strongly inhibited glucagon secretion. These ef-
fects of tolbutamide or diazoxide were specific for KATP channels since they 
were not observed with SUR1-/- islets. Increasing the [G] of the perifusion 
medium from 1 to 7 mM in the continuous presence of 500 µM tolbutamide 
inhibited glucagon secretion from NMRI islets, but to a much lesser extent 
than in the absence of the sulfonylurea. 7 mM G also decreased glucagon 
secretion from SUR1-/- islets, but again to a lesser extent than from WT islets. 
In the continuous presence of 250 µM diazoxide, increasing [G] from 1 to 
7 mM reversibly suppressed the already low glucagon secretion. Perifusion 
experiments performed with SST+/+ and SST-/- islets showed that glucagon 
secretion elicited by 1 mM G was higher with SST-/- than SST+/+ islets, and that 
G inhibited glucagon secretion of both types of islets. Incubation experiments 
performed with ZnT8-/- and ZnT8+/+ islets demonstrated that G decreased 
glucagon secretion to the same extent in both types of islets.
Conclusion: The observations that tolbutamide did not reproduce the inhibi-
tory effect of G, and that G could inhibit glucagon secretion in the presence 
of tolbutamide or diazoxide and in SUR1-/- islets suggest that G can modulate 
glucagon secretion independently from KATP channels. However, an involve-
ment of these channels cannot entirely be ruled out because GISG was blunt-
ed by tolbutamide or in SUR1-/- mice. Somatostatin exerts a tonic inhibitory 
effect on glucagon secretion. However, neither somatostatin nor zinc are the 
paracrine factor responsible for GISG.
Supported by: JDRF
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Glucagon normalises disposition index by increasing acute insulin 
response to intravenous glucose: comparison with incretins
G. Pacini1, B. Ahrén2; 
1Metabolic Unit, ISIB-CNR, Padova, Italy, 2Department of Medicine, Lund 
University, Sweden.
Background and aims: Besides insulin resistance and defective insulin secre-
tion, impaired glucose tolerance and type 2 diabetes are also associated with 
hyperglucagonemia due to inadequate suppression of glucagon production. 
While it is known that insulin resistance is compensated by increased insulin 
secretion to maintain normoglycemia, the consequence of the hypergluca-
gonemia as an adaptive response is not known. The model of glucose intol-
erance in mice given high-fat feeding is associated with markedly reduced 
glucose elimination after intravenous glucose, because of insufficient hyper-
insulinemia. We examined whether the defective adaptations can be normal-
ized by glucagon, as previously was documented for the incretins GIP and 
GLP-1.
Materials and methods: C57BL/6J mice were fed a normal chow (ND, 11%) 
or a diet with 60% fat for 8 weeks (HF). After baseline blood sample, a bo-
lus injection of 35 g/kg glucose with or without addition of synthetic GIP 
or GLP-1 (at 3 nmol/kg) and glucagon (at 1 and 10 µg/kg) was given intra-
venously followed by six blood samples in 50 min with glucose and insu-
lin measurements. The insulin sensitivity index (SI) was estimated with the 
minimal model. Insulin secretion (early phase) was assessed as the increase 
in insulin levels within 5 min after injection (dAIR); glucose elimination (KG) 
was the percent reduction of log-transformed glucose during the first 20 min; 
B-cell adaptation was calculated as SI×dAIR (disposition index, DI) and total 
B-cell sensitivity as the ratio of the area under the curve of insulin to that of 
glucose.
Results: Metabolic parameters are shown in Table 1. KG was lower in HF fed 
mice (P<0.0002), normalized with incretins, but even worsened with gluca-
gon (P=0.008). SI was reduced in HF (P<0.00001) but neither incretins nor 
glucagon were able to restore a normal sensitivity. On the other hand, both 
incretins and glucagon yielded a marked increase of the first phase response 
(dAIR, P<0.00001): higher with glucagon, as also reflected by an elevated to-
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tal B-cell sensitivity vs. HF and HF+incretins (P<0.02). The resulting DI was 
completely normalized as it was with incretins.
Conclusion: Glucagon, as the incretins, acts on the adaptive mechanisms of 
the B-cell by eliciting an upregulation of the response to the glucose stimulus, 
thus restoring a normal disposition index. This is seen in spite of being un-
able, as the incretins, to ameliorate insulin sensitivity in severe HF induced 
insulin resistant mice.
Table 1. Metabolic Parameters (means±SE)
ND (n=89) HF (46) HF+incretins 
(28)
HF+glucagon 
(13)
BW (g) 22.3±0.2 35.3±1.0 38.6±1.3 30.5±0.9
KG (%min
-1) 1.96±0.10 1.37±0.11 2.09±0.17 0.75±0.13
SI (min
-1/(pmol/l)) 1.07±0.07 0.53±0.06 0.56±0.04 0.40±0.02
dAIR (pmol/l) 987±52 598±67 2207±151 2630±234
DI 11.0±0.9 3.0±0.4 12.7±1.2 10.5±0.9
B-cell sensitivity 22±1 37±3 38±3 59±5
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Preserved ability to slow gastric emptying in response to increasing 
concentrations of orally ingested glucose solutions in patients with type 
2 diabetes
T. Vilsbøll1, J.I. Bagger1, A. Lund1, J.J. Holst2, F.K. Knop1; 
1Diabetes Research Division, Department of Internal Medicine F, Gentofte 
Hospital, Copenhagen, 2Department of Biomedical Sciences, The Panum 
Institute, Copenhagen, Denmark.
Background and aims: The rate of gastric emptying (GE) of carbohydrate is a 
major determinant for postprandial plasma glucose (PG) excursions. It is well 
established that GE during OGTTs in healthy subjects decreases the greater 
the glucose amount applied. This mechanism contributes to keep postpran-
dial PG concentrations within a narrow range averting hyperglycaemia. It is 
unknown whether patients with type 2 diabetes mellitus (T2DM) are able to 
reduce their GE rate in response to increasing orally administered glucose 
loads. Therefore, we aimed to investigate the GE rates in patients with T2DM 
ingesting ‘isovolumic’ glucose solutions of increasing concentrations.
Materials and methods: GE rate was measured during three 4-hour OGTTs 
with increasing glucose loads (25 g, 75 g and 125 g) using the paracetamol 
method in 8 patients with T2DM (fasting plasma glucose (FPG): 7.7 (7.0-8.9) 
mmol/l (mean (range)); Haemoglobin A1c (HbA1c): 7.0 (6.2-8.4)%) and in 
8 healthy control subjects (CTRLs) matched for sex, age and BMI (FPG: 5.3 
(4.8-5.7) mmol/l; HbA1c: 5.4 (5.0-5.7)%).
Results: PG peak concentrations increased significantly among patients with 
T2DM with increasing glucose loads (12.8±0.5, 17.5±0.8 and 17.7±1.2 mmol/
l; p=0.001) whereas they remained constant in CTRLs (8.9±0.5, 10.4±0.9 and 
10.2±0.9 mmol/l; p=NS). Interestingly, equal slowing (p<0.05) of GE rate (as 
assessed by time-to-peak of plasma paracetamol) in response to increasing 
oral glucose loads occurred in both groups (25 g: 41±4 (T2DM) vs. 36±5 min 
(CTRL), p=NS; 75 g: 92±9 vs. 105±15 min, p=NS; 125 g: 131±11 vs. 150±16 
min, p=NS) (Figure 1).
Conclusion: Reduced slowing of GE rate in response to increased orally in-
gested glucose loads does not seem to be a determinant for the inability of 
patients with T2DM to keep peak PG concentrations constant independently 
of the amount of glucose ingested.
Supported by: Investigator-Initiated Studies Programme (IISP) from MSD
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Akt influences glycogen synthase in skeletal muscle through regulation 
of NH2-terminal phosphorylation
M. Friedrichsen1,2, J.F.P. Wojtaszewski3, E.A. Richter3, R. Ribel-Madsen1, 
B.F. Hansen4, H. Beck-Nielsen5, A.A. Vaag1,6, P. Poulsen1,7; 
1Steno Diabetes Center, Gentofte, Denmark, 2Department of Biomedical 
Sciences, University of Copenhagen, Denmark, 3Molecular Physiology 
Group, Department of Exercise and Sport Sciences, University of 
Copenhagen, Denmark, 4Novo Nordisk A/S, Måløv, Denmark, 5Diabetes 
Research Center, Odense University Hospital, Denmark, 6Department 
of Clinical Sciences, Lund University, University Hospital MAS, Malmö, 
Sweden, 7Novo Nordisk A/S, Søborg, Denmark.
Background and aims: Type 2 diabetes is characterized by reduced non-oxi-
dative glucose metabolism. Although studies have investigated the regulation 
of the key enzyme in this process, glycogen synthase (GS), the nature of the 
link between proximal insulin signaling and GS activation is still debated. 
We previously demonstrated that phosphorylation of residue threonine-308 
of Akt (Akt-308phos) and Akt2 activity as well as GS activity in muscle were 
associated with insulin sensitivity in the present study population. Now, we 
aimed to evaluate the significance of each step in proximal insulin signaling 
on GS activity.
Materials and methods: 184 non-diabetic twins were examined with gold-
standard techniques including the euglycemic-hyperinsulinemic clamp. 
Insulin signaling was evaluated at the levels of the insulin receptor, IRS-1-
associated phosphoinositide 3-kinase (PI3K), Akt and GS employing kinase 
assays and phospho-specific Western blotting. Multivariate analyses adjusted 
for age, sex, VO2max, total fat percentage and basal glycogen content were 
performed to evaluate the regulation of GS activity/phosphorylation status. 
A similar model was employed to evaluate the differences among groups in 
Figure 1.
Results: We demonstrated that the insulin-mediated increase (delta) of GS 
fractional activity was positively associated with Akt-308phos (P=0.002, Fig-
ure 1A) and Akt2 activity (P=0.008) but not Akt-473phos or insulin receptor 
tyrosine kinase or IRS-1-associated PI3K activity. Furthermore, Akt-308phos 
and Akt2 activity were negatively associated with phosphorylation of sites 
2+2a (P<0.001 and P=0.001, respectively, Figure 1B) on GS which in turn was 
negatively associated with delta GS fractional activity (P=0.002, Figure 1D). 
We found no association between Akt and GS phosphorylation of sites 3a+3b 
(Figure 1C) which in turn was also not associated with delta GS fractional 
activity (Figure 1E).
Conclusion: Our study suggests that the association between proximal insu-
lin signaling and GS activity in skeletal muscle primarily is mediated through 
Akt-dependent regulation of sites 2+2a phosphorylation of GS.
Figure 1. Delta GS fractional activity (A), pGS2+2a (B) and pGS3a+3b (C) 
in the lowest (open bars), middle (stripped bars) and highest (black bars) 
tertiles of Akt-308phos and delta GS fractional activity in the lowest (open 
bars), middle (stripped bars) and highest (black bars) tertiles of pGS2+2a (D) 
and pGS3a+3b (E). AU: Arbitrary units. Data are means±SEM.
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Coordinated myocyte expression of PPARdelta and adiponectin 
receptors reflects lipid metabolism, but not insulin sensitivity, of the 
myocyte donors
H. Staiger, F. Machicao, H.-U. Häring; 
Internal Medicine IV, Medical Clinic, Eberhard-Karls-University Tübingen, 
Germany.
Background and aims: Muscle lipid oxidation can be stimulated via peroxi-
some proliferator-activated receptor (PPAR) delta or adiponectin receptors. 
Both kinds of receptors sense different signals from adipose tissue: PPARdel-
ta senses insulin resistance-associated long-chain fatty acids, adiponectin re-
ceptors the insulin sensitivity-associated adipokine adiponectin. Therefore, 
we asked whether myocyte expression of PPARdelta and the adiponectin 
receptors AdipoR1, AdipoR2, and T-cadherin reflects these different insulin 
sensitivity states.
Materials and methods: Skeletal myoblasts from 39 non-diabetic human 
donors with a broad range of insulin sensitivity were differentiated into myo-
tubes. mRNA and 28S-rRNA contents were quantified by qPCR. Blood glu-
cose, insulin, free fatty acids, and triglycerides were measured using standard 
laboratory methods. Insulin sensitivity was calculated from hyperinsuline-
mic-euglycemic clamp.
Results: Myocyte mRNA contents of PPARdelta, AdipoR1, AdipoR2, and T-
cadherin markedly varied between the individual donors, but were not asso-
ciated with the donors’ insulin sensitivity (adjusted for sex, age, and BMI; all 
p>0.5). Unexpectedly, the expression levels of the four receptors were closely 
interrelated (all r>=0.75, p<0.0001). Furthermore, PPARdelta was, independ-
ently of the other genes, a significant determinant of T-cadherin (p=0.0002), 
but not of AdipoR1 or AdipoR2 (both p>0.05), suggesting T-cadherin as a 
PPARdelta target gene. However, GW501516 treatment did not increase T-
cadherin expression (p=0.8, n=16). After adjustment for sex, age, and BMI, 
fasting plasma triglycerides were inversely associated with myocyte AdipoR1 
and T-cadherin expression (both p<0.03) and tended to inversely associate 
with AdipopR2 and PPARdelta expression (both p<=0.1).
Conclusion: Human myocyte expression of PPARdelta or the adiponectin 
receptors AdipoR1, AdipoR2, and T-cadherin does not reflect the donors’ 
insulin sensitivity. This lack of association might be due to these receptors’ 
coordinated expression. Even though the physiological meaning of this in-
tegration of different pathways is currently unclear, the inverse association 
between myocyte receptor contents and the donors’ plasma triglyceride con-
centrations point to its relevance for human lipid metabolism.
698
TGF beta impairs muscle differentiation and induces autophagy by PED/
PEA-15-mediated pathway
S. Iovino, F. Oriente, G. Botta, S. Cabaro, C. Miele, G. Portella, F. Beguinot, 
P. Formisano; 
Cellular and Molecular Biology and Pathology, University of Napoli 
“Federico II”, Napoli, Italy.
Background and aims: Loss of muscle mass and de-differentiation occur in a 
variety of disease, including cancer, chronic heart failure, acquired immuno-
deficiency syndrome and diabetes. Preventing muscle wasting by promoting 
growth and differentiation has been proposed as a possible therapeutic ap-
proach. Tgf beta is an important negative modulator of myogenesis. However, 
its role in adulthood is not fully understood. Recently, it has been shown that 
TGF beta activates autophagy, which plays a critical role in protein break-
down, muscle atrophy and myofiber survival. Although autophagy has been 
found impaired in atrophying muscle, the exact mechanisms by which its de-
regulation might impair skeletal muscle differentiation are still unclear.
Results: Western blot and qRT-PCR analysis revealed that in L6 skeletal mus-
cle cells, TGF beta1 stimulation increased the expression of PED/PEA-15, a 
gene overexpressed in type 2 diabetic patients. Moreover, Tgfbeta1 led to LC3 
I/II conversion, increased expression of beclin-1 and enhanced the forma-
tion of autophagosomes in L6 cells, peculiar features of autophagy activa-
tion. These molecular events paralleled an impairment of L6 myotubes dif-
ferentiation, as revealed by morphological analysis and reduction of myoD1, 
myogenin and glut4 gene expression. Importantly, silencing of PED/PEA-15 
by specific shRNA restored the expression of myoD1, myogenin, and glut4 
and L6 differentiation upon TGF beta1 stimulation. Interestingly, silencing 
of PED/PEA-15 also partially reverted the LC3 I/II conversion, beclin-1 lev-
els and autophagosome formation. Furthermore, FACS analysis showed that 
the transfection of PED/PEA-15 cDNA in L6 cells, which we have previously 
described to induce insulin-resistance, activated autophagy and impaired the 
myotubes formation. The block of autophagy in L6PED by using 3-Methylad-
enine, restored myotubes formation and recovered the expression of differen-
tiation markers. These data indicate that Tgf beta may impair skeletal muscle 
differentiation by inducing autophagic process and PED/PEA-15 might be a 
key regulator to mediate this effect.
Conclusion: These results suggest the existence of a direct relationship be-
tween insulin-resistance, autophagy and muscle de-differentiation.
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Cyclin G2: a downstream cellular marker for the mitogenicity of insulin, 
insulin-like growth factors and insulin analogues?
P. De Meyts1, A.M. Svendsen1, C.B. Warzecha1, W. Sajid1, J. Hald2, J. Nøhr1; 
1Receptor Systems Biology Laboratory, 2Dept of Beta Cell Regeneration, 
Hagedorn Research Institute, Gentofte, Denmark.
Background and aims: The cellular and molecular mechanisms whereby 
some insulin analogues may cause enhanced stimulation of cell proliferation 
through either the insulin receptor (IR) or the IGF-I receptor (IGF-IR) are in-
completely understood. Previous research in our laboratory has demonstrat-
ed differential metabolic and mitogenic signalling with some ligands in L6 
rat myoblasts overexpressing the human IR (L6-hIR). While insulin was very 
potent in stimulating thymidine incorporation, the insulin mimetic peptide 
S597 had a poor mitogenic response and unlike insulin, caused a poor stimu-
lation of the ERK/MAPK pathway. Gene expression profiling showed that 
the gene most downregulated (30-fold) by insulin (but 10 times less by S597) 
Diabetologia (2010) 53:[Suppl1]S1–S556 S 281
1 C
was ccng2, the gene coding for cyclin G2, an atypical cyclin downstream of 
FOXO1 that blocks the cell cycle at the G1/S transition. Our hypothesis is that 
cyclin G2 may be a key downstream effector of the mitogenicity of insulin 
and IGFs, and therefore may be a useful cellular biomarker of mitogenicity.
Materials and methods: L6 myoblasts (WT and h-IR), were stimulated with 
insulin, Asp B10-insulin (X10), or insulin-like growth factor-I (IGF-I), in the 
absence or presence of the PI3-K inhibitors Wortmannin and LY294002 and 
the MAPK inhibitors PD98059 or UO126. Clinically relevant analogues were 
also tested. The human beta cell line INS-1 was stimulated with insulin, X10, 
IGF-I and GLP-1. The cells were lysed using TRI® Reagent and RNA was ex-
tracted. Gene expression was measured in a two-step qRT-PCR. The Ct values 
were normalized to 18S RNA and fold changes were calculated.
Results: In wild type L6 cells, expressing no IRs and 135.000 IGF-IRs, insulin 
was less potent than IGF-I in downregulating ccng2 (3-fold vs 10-fold at 10 
nM). Glargine, glulisine and aspart insulins had effects comparable to insulin 
while detemir had no significant effect on ccng2. In L6-hIR cells, expressing 
275.000 IRs and 230.000 IGF-IRs (or hybrids), insulin, IGF-I and X10 insulin 
were all very potent downregulators of ccng2. IGF-I had the highest response, 
downregulating the expression of ccng2 50-fold after 3 hours of stimulation 
with 10 nM. Both insulin and X10 insulin downregulated gene expression 25-
fold after 3 and 8 hours respectively. Inhibitors showed that both the MAPK 
and PI3-K pathways are involved in the regulation of ccng2. A 2 to 3-fold 
downregulation of ccng2 was seen in INS-1 cells with insulin, X10 and IGF-I, 
as well as with GLP-1, all at 10nM.
Conclusion: X10 and IGF-I, both having a higher mitogenic potency than 
insulin, have a higher effect on the expression of the cell cycle inhibitor ccng2 
than insulin has, making this gene a possible candidate as a cellular biomar-
ker for mitogenicity.
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Essential but not diabetogenic fatty acids of skeletal muscle structural 
and neutral lipids are associated
S.B. Haugaard1,2, S. Madsbad3, H. Mu4, A.A. Vaag5; 
1Clinical Research Centre, University Hospital of Copenhagen, Hvidovre, 
2Dept. of Internal Medicine, University Hospital of Copenhagen, 
Amager, 3Dept. of Endocrinology, University Hospital of Copenhagen, 
Hvidovre, 4Dept. of Pharmaceutics and Analytical Chemistry, Faculty 
of Pharmaceutical Sciences, University of Copenhagen, 5Steno Diabetes 
Center, Gentofte, Denmark.
Background and aims: Fatty acid (FA) composition of structural membrane 
phospholipids may reflect dietary FA sources in man. However, it is unknown 
the extent to which skeletal muscle phospholipid FA composition reflects 
and/or is associated with intramyocellular triglyceride FA composition. In 
particular, the association between structural and intramyocellular lipids for 
essential FA of marine origin facilitating insulin action and the saturated FA 
palmitic acid, respectively, is of interest to study due to their different effects 
on health including insulin action.
Materials and methods: Vastus lateralis skeletal muscle biopsies were ob-
tained from 59 weight-stable sedentary subjects, i.e. 27 obese women (7 dia-
betic), 20 obese men (6 diabetic), and 12 lean healthy normal-weight subjects 
(7 women). FA composition of neutral and structural fat was determined by 
thin-layer and gas-liquid chromatography.
Results: In structural versus intramyocellular lipids, the concentration of 
essential FA of dietary origin including linoleic (C18:2n-6) and linolenic 
(C18:3n-3) FA correlated significantly (r=0.34, P<0.01; r=0.62, P<0.001). 
Similarly, the concentration of polyunsaturated FA of marine origin (r=0.51, 
P<0.001) including the ratio of n-3/n-6 (r=0.56, p<0.001) polyunsaturated 
FA was also significantly correlated between structural and intramyocellu-
lar lipids. The correlations remained virtually unaffected after correction for 
gender, percentage of body fat mass and insulin resistance (partial correla-
tions, r=0.32; r=0.66; r=0.51; r=0.56, respectively). Total monounsaturated 
FA (r=0.43, P<0.001; r=0.36, P<0.01)) and trans FA (r=0.33, P=0.01; r=0.32, 
P<0.02) correlated between the two types of lipids using both univariate as 
well as corrected analyses. In contrast, total saturated fat (r=0.01, P=ns), in-
cluding the potentially “diabetogenic” palmitic acid (C16:0, r=0.10, P=ns), 
did not correlate between structural and intramyocellular FA composition.
Conclusion: Dietary essential FA ingestion may influence the intramyocel-
lular lipid composition. However, the levels of saturated FA including pal-
mitic acid may differ substantially between structural phospholipids versus 
intramyocellular lipids. Understanding the underlying differential mecha-
nisms regulating structural versus intramyocellular fat metabolism may have 
implications for health including insulin action.
Supported by: Danish Diabetes Association; Foundation of Oda and Hans 
Svenningsen
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Suppression of the 5´nucleotidase NT5C2 promotes AMPK 
phosphorylation and lipid oxidation in human skeletal muscle
S.S. Kulkarni, H.K.R. Karlsson, A. Krook, J.R. Zierath; 
Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden.
Objective: The 5’Nucleotidases (NT5) family of enzymes dephosphorylate 
non-cyclic nucleoside monophosphates to produce nucleosides and inor-
ganic phosphates. We hypothesized that gene silencing of 5’Nucleotidases to 
increase the intracellular availability of AMP would increase AMPK activity 
and metabolism.
Research design and methods: The present study was designed to determine 
the role of the cytosolic 5’ nucleotidases in the metabolic responses liked to 
the development of insulin resistance in obesity and type 2 diabetes.
Results: mRNA expression of NT5C1A and NT5C2 were elevated in exten-
sor digitorum longus (EDL) and soleus muscle of ob/ob mice compared to 
wild-type litter mates, respectively. NT5C1A mRNA was increased in vastus 
lateralis skeletal muscle obtained from type 2 diabetic patients, compared to 
normal glucose tolerant subjects. Using siRNA to silence NT5C2 expression 
in cultured human myotubes, we observed a 2-fold increase in AMPK phos-
phorylation (Thr172) and a 4-fold increase in phosphorylation of its down-
stream target ACC (Ser79) (p<0.05). siRNA silencing of NT5C2 expression 
increased palmitate oxidation 2-fold in the absence and 8-fold in the presence 
of AICAR. This response was paralleled by an increase in glucose transport 
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and a decrease in glucose oxidation and incorporation into glycogen and lac-
tate release from NT5C2 depleted myotubes.
Conclusion: Our results provide evidence to suggest that endogenous NT5C2 
inhibits basal lipid oxidation and glucose transport in skeletal muscle. Reduc-
tion of 5’Nucleotidase expression or activity may be one potential avenue to 
promote metabolic flexibility in type 2 diabetes.
Supported by: ERC-ICEBERG, EXGENESIS, Swedish Research Council
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Bombesin receptor subtype-3 signalling and its role on glucose transport 
in human myocytes
N. Gonzalez1, I. Ramos-Álvarez1, A. Martín-Duce2, P. Moreno1,  
B. Nuche-Berenguer1, R. Sanz1, S. Portal-Nuñez1, R.T. Jensen3,  
M.L. Villanueva-Peñacarrillo1; 
1IIS-Fundación Jiménez Díaz, Madrid, Spain, 2Universidad de Alcalá de 
Henares, Madrid, Spain, 3National Institutes of Health, Bethesda, USA.
Background and aims: Bombesin Receptor Subtype-3 (BRS-3) is one of the 
candidate genes of obesity; in fact, BRS-3-knock-out mice is characterized by 
hypertension, insulin resistance, mild obesity, impaired GLUT-4 transloca-
tion in adipocytes and unbalanced glucose metabolism, suggesting a role of 
BRS-3 in glucose homeostasis. Previously, it was shown not only that human 
skeletal muscle expresses functional BRS-3, but also a lower than normal lev-
els of its gene expression in muscle tissue from Type-1, Type-2 and obese 
patients. The aim of this study was to gain insight into the BRS-3 signalling 
pathways in normal human myocytes, by using the BRS-3 agonist peptide 
[D-Tyr(6),βAla(11),Phe(13),Nle(14)]Bn-(6-14)] (BRS-3-AP), and to explore 
the action of BRS-3-AP upon glucose transport (GT).
Materials and methods: Primary culture myocytes were established from 
skeletal muscle pieces (≈400 mg), obtained, previous informed consent given, 
from five normal subjects (5F; age: 49±9 yr; fasting plasma glucose: 96±6 mg/
dl) undergoing surgery. PKB and p42/44 MAPKs activity - phosphorylation 
degree- was measured by immunoblotting, in cells after 3 min incubation 
in the absence (control) and presence of BRS-3-AP (10-10-10-8 M); GT was 
examined as 3H-2-deoxy-D-glucose incorporation, in the absence and pres-
ence BRS-3-AP (10-12-10-7 M) and without and with 10-6 M wortmannin or 
2.5x10-5 M PD-98059, respective inhibitors of PI3K/PKB and MAPKs activ-
ity; insulin was also included in all assays as positive control.
Results: BRS-3-AP, at 10-9 M and 10-8 M, clearly increased (p<0.05) PKB 
phosphorylation (168±17% control and 192±42% control, respectively) to 
the same level as that reached by 10-9 M insulin (175±28%, p<0.05); however, 
while at 10-10 M and 10-9 M BRS-3-AP failed to modify the global MAP ki-
nases activity (overall mean value: 101±7% control), a clear increase (p<0.05) 
in the phosphorylation level of p42/44 MAPKs occurred when 10-8 M BRS-
3-AP was present (p-p42: 160±22% control; p-p44: 142±14%), values of the 
same of magnitude as those by 10-9 M insulin (p-p42: 131±2% control; p-p44: 
126±9%). BRS-3-AP caused a concentration-related stimulation of GT, which 
was already detected at 10-10 M of the peptide (133±11% control, p<0.05), 
maximal at 10-9 M (159±13%, p<0.01) and maintained thereafter up to 10-
7 M BRS-3-AP (10-8 M: 158±18% control, p<0.02; 10-7 M: 196±36, p<0.05), 
effect which was similar to that induced by insulin. Wortmannin abolished 
the stimulatory action of 10-8 M BRS-3-AP on GT (102±7% control), and the 
same blocking effect was observed in the additional presence of PD-98059 
(94±4%).
Conclusion: These results implicate human BRS-3 in the glucose homeo-
stasis process, and open the possibility that this receptor could be used as 
a molecular target, and/or its agonist peptide, in the therapy of diabetes and 
obesity.
Supported by: FIS and CIBERDEM
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The role of phospholemman in the regulation of glucose uptake in 
insulin sensitive tissues
B. Benziane, H. Boon, S. Pirkmajer, S. Jagtap, J.R. Zierath, A.V. Chibalin; 
Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Background and aims: Phospholemman (PLM, FXYD1) is a phosphoprotein 
expressed in the cell plasma membrane in different tissues including adipose 
tissue, liver, heart and skeletal muscle. Phosphorylation of PLM leads to an 
increase in Na+/K+ pump activity and thus regulates active ion transport. In 
adipocytes PLM is reported to be involved in insulin-induced GLUT4 trans-
location to the plasma membrane. The aim of this study was to determine 
the role of PLM in insulin-induced glucose uptake in skeletal muscle and 
adipocytes.
Materials and methods: L6 myoblasts, which have a intrinsically low PLM 
expression, were transfected with plasmids encoding either wild-type PLM, 
phosphorylation-mutant Ser68Ala-PLM or double-mutant Ser63Ala/Ser-
68Ala-PLM. Thereafter, insulin-stimulated glucose uptake was measured. 
Interaction of GLUT4 and PLM was assessed by co-immunoprecipitation. 
3T3-L1 fibroblasts were induced to differentiation into adipocytes. In differ-
entiated adipocytes, siRNA PLM silencing was performed and insulin-stimu-
lated glucose uptake was measured.
Results: PLM overexpression increased insulin-stimulated glucose uptake in 
comparison with mock transfected cells, whereas overexpression of mutant 
Ser63 and/or Ser68 had no effect on insulin-stimulated glucose uptake. Ba-
sal glucose uptake was unaltered by overexpression of PLM. PLM co-immu-
noprecipitates with GLUT4 in rat epitochlearis muscle and this interaction 
is increased after insulin stimulation. In 3T3-L1 cells the induction of PLM 
expression follows GLUT4 expression during differentiation into adipocytes. 
The silencing of PLM in 3T3-L1 adipocytes leads to decrease in insulin-stim-
ulated glucose uptake.
Conclusion: PLM over-expression enhances insulin-stimulated glucose up-
take in L6 myoblasts, and the effect is dependant upon PLM phosphorylation 
on Ser63 and/or Ser68 residues. Increased co-immunoprecipitation of PLM 
and GLUT4 after insulin stimulation provides evidence to suggest that an 
interaction between PLM and GLUT4 may be involved in regulation of the 
glucose uptake. Furthermore, the expression level and phosphorylation sta-
tus of PLM appears to be important for the regulation of insulin-stimulated 
glucose uptake in insulin sensitive tissues.
Supported by: Swedish Research Council, Novo-Nordisk Foundation
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The beneficial effect of electro-acupuncture on insulin resistance
D. Koya1, F. Liang2; 
1Endocrinology & Metabolism, Kanazawa Medical University, Kahokugun, 
Ishikawa, Japan, 2Department of Traditional Chinese Medicine, University 
of Science and Technology, Wuhan, China.
Background and aims: Electro-acupuncture (EA) improves insulin resis-
tance, although the biochemical mechanism underlying this effect remains 
unclear. This study investigated the effect of low-frequency EA on metabolic 
action in genetically insulin-resistant diabetic db/db mice.
Materials and methods: Nine-week-old db/m and db/db mice were ran-
domly divided into four groups: db/m, db/m+EA, db/db, and db/db+EA. 
Db/m+EA and db/db+EA mice received 3-Hz EA five times/wk for 8 weeks.
Results: The EA reduced fasting blood glucose and maintained insulin levels 
without significant alteration of food intake or body weight in db/db mice. 
Improved insulin sensitivity was established in EA-treated db/db mice by in-
traperitoneal insulin tolerance test. EA also decreased free fatty acid levels 
in the db/db mice and increased skeletal muscle sirtuin 1 (SIRT1) protein 
expression. These effects induced concurrent upregulation of the genes re-
lated to mitochondrial biogenesis such as peroxisome proliferator-activated 
receptorγ (PPARγ) coactivator 1alpha (PGC-1alpha) and nuclear respiratory 
factor 1 (NRF1). Furthermore, EA treatment activated AMP-activated pro-
tein kinase (AMPK) and increased Akt phosphorylation in skeletal muscle 
of the db/db mice.
Conclusion: These findings suggest that EA has a beneficial effect on insulin 
resistance, at least partly via stimulating SIRT1/PGC-1alpha and AMPK ac-
tivity, resulting in improved insulin signal defect.
705
A mRNA marker for glycolytic muscle fibres may be used to determine 
fibre type composition in human skeletal muscle
A.H. Olsson, T. Elgzyri, E. Laurila, L. Groop, O. Hansson, C. Ling; 
Department of Clinical Sciences, Diabetes and Endocrinology, Lund 
University Diabetes Center, Malmo, Sweden.
Background and aims: Human skeletal muscle contains three major fibre 
types distinguished by their myosin heavy chain (MHC) isoforms. The mi-
tochondria content and oxidative capacity is the highest in slow oxidative 
type I fibres, lower in fast oxidative type IIa fibres, and lowest in fast glyco-
lytic type IIx/d fibres. The amount of oxidative type I fibres is reduced and 
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glycolytic type IIx/d fibres is increased in muscle from patients with type 2 
diabetes. We have previously shown that mRNA expression level of mark-
ers for oxidative fibres were positively related to insulin-stimulated glucose 
uptake and VO2max, meanwhile mRNA expression level of markers for gly-
colytic fibres were negatively related to these metabolic factors. The aim of 
the present study was to investigate whether mRNA expression levels of fibre 
type markers can be used as a proxy to determine fibre type composition in 
human skeletal muscle.
Materials and methods: Human skeletal muscle biopsies were analysed from 
two different cohorts (cohort 1 n=36 and cohort 2 n=37). An ATPase stain-
ing method was used to determine the fibre types. The expression levels of 
three fibre type markers; MHC7 (slow oxidative), MHCIIa (fast oxidative) 
and MHCIIx/d (fast glycolytic), were measured using microarrays and the 
mRNA expression was correlated with muscle fibre type.
Results: By using bivariate non-parametric correlation tests, we found that 
MHCIIx/d mRNA expression was positively correlated to the level of type 
IIx/d muscle fibres in both cohorts (cohort 1: r=0.39 and p=0.020; cohort 2: 
r=0.59 and p=0.00023), meanwhile mRNA expression of MHC7 and MHCIIa 
did not significant correlate with levels of its respective fibre type in neither 
cohort. When using regression analysis corrected for BMI, age and diabe-
tes status, the same results were obtained. MHCIIx/d mRNA expression was 
positively related to type IIx/d fibres in both cohorts (cohort 1: beta = 0.04 
± 0.002 and p=0.016; cohort 2: beta= 7.99 ± 2.92 and p=0.020), meanwhile 
no significant relationship was found between MHC7 mRNA expression and 
amount of type I fibres or between MHCIIa mRNA expression and amount 
of type IIa fibres in neither cohort. Interestingly, mRNA expression of MH-
CIIx/d was negatively correlated to both amount of type I and type IIa fibres 
in cohort 2 (r= -0.41 and p=0.012, respectively, r= -0.38 and p=0.028).
Conclusion: Fibre type composition has been shown to be of importance in 
the pathogenesis of type 2 diabetes and a practical marker is needed. Here we 
show that the mRNA expression level of MHCIIx/d, may be used as such a 
marker for fast glycolytic muscle fibres in human skeletal muscle.
PS 59 Insulin action and metabolism 
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Microfluidic technology for multi-parametric studies on patient-derived 
three-dimensional human adipose tissue model
M. Flaibani, A. Zambon, E. Cimetta, E. Magrofuoco, N. Elvassore; 
Dep. Chemical Engineering Principle and Practice, University of Padova, Italy.
Background and aims: Type 2 Diabetes Mellitus is a complex disease affect-
ing many pathways in different tissues. The complexity of this disease led to 
the use of several classes of drugs acting with different mechanisms and tar-
gets and with effects which often change between patients. The screening of 
all these anti-diabetic drugs with animal models is not economically and tim-
ing sustainable and often not giving reliable results for human. On the other 
hand, specific study on human patients are possible but are tremendously ex-
pensive and require a huge effort in term of ethical approval and safety issues. 
Within this scenario we aim at developing a microfluidic platform allowing to 
perform in vitro highthroughput patient-specific tests of anti-diabetic drugs 
on patient-derived three-dimensional human adipose tissue. In particular, 
the first step is the realization of a microfluidic system for culturing human 
adipose tissue able to control the temporal evolution of culture conditions in 
terms of concentration of oxygen, metabolites, and insulin and able to per-
form multi-parametric analyses of the adipose tissue behaviour.
Materials and methods: Biopsies of subcutaneous and visceral adipose tissues 
were obtained from both patients affected by Type 2 Diabetes and insulin-sensi-
tive individuals. 1cm3 biopsy was minced right after surgery into 10-20mg tis-
sues. Each piece was placed in a 24well plate with 1ml medium for 24h. Then the 
tissue was either cultured for additional time in the 24well plate with fresh me-
dium or placed into the microfluidic system. A microfluidic platform including 
micro-valves, injectors, pumps, mixers was realized by soft-lithographic tech-
nique and its design, development, and application was assisted by mathemati-
cal modeling. In line measurements of tissue metabolic activity were performed 
using micro-biosensors placed downstream the culture chambers and able to 
detect glucose, lactate and oxygen concentration. The tissue responses to insulin 
were investigated also through analyses of free fatty acids and glycerol. Viability 
and histological analyses were performed at the end of the cultures.
Results: Microscale adipose tissues were cultured within the microfluidic 
platform for up to 4 days. MTT assay at the end of the culture showed high 
tissue viability and no significant differences with controls in 24well plates. 
On the other end, the microfluidic system allowed a two times higher glucose 
uptake then the controls by reducing the glucose diffusive resistance. We then 
investigated the effect of different insulin concentrations (20, 40 and 100nM). 
Preliminary results obtained with tissues of insulin-sensitive individuals 
showed an high variability between biopsies and between cultures from the 
same biopsy. However, we observed an enhancement of glucose uptake for 
increasing insulin concentration when using 25mM glucose medium. We 
also investigated the difference on glucose uptake between insulin-sensitive 
individuals and patients affected by Type 2 Diabetes.
Conclusion: We developed a microfluidic platform for culturing small-scale 
human adipose tissue and allowing to accurately control the temporal evo-
lution of the culture conditions in terms of concentration of metabolites, 
oxygen, and insulin concentration. This system with in line biosensors open 
important perspectives towards the realization of high-throughput dynamic 
screening of anti-diabetic drugs on human adipose tissue.
Supported by: an EFSD/Roche grant
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Effects of different commercial insulins on adipogenesis and adipocyte 
metabolism
E. Garcia-Escobar1, F. Rodriguez-Pacheco2, S. Garcia-Serrano1,  
J.M. Gomez-Zumaquero1, S. Morcillo1, E. Rubio-Martin1, G.M. Martin-Nuñez1, 
C. Gutierrez-Repiso1, J.J. Haro-Mora1, F. Soriguer1, G. Rojo-Martinez1; 
1Servicio de Endocrinologia y Nutricion. Hospital Civil de Malaga, 
CIBERDEM CB07/08/0019 of the Instituto de Salud Carlos III, Malaga, 
2Facultad de Medicina, Departamento de Fisiología, Santiago de Compostela, 
CIBER of the Pathophysiology of Obesity and Nutrition (CB06/03/0018) of 
the Instituto de Salud Carlos III, Santiago de Compostela, Spain.
Background and aims: Insulin has several roles in metabolism, so the use of 
exogens insulins could be modifying metabolic process related with adipo-
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cyte metabolism that might explain the secondary problems derivated of in-
sulin therapy. We investigate the effects of six different insulins on adipocyte 
cell differentiation, lipolytic activity, and expression levels of PPARg, SCD-1, 
HSL, InsR and SREBP-1c .
Materials and methods: 3T3-L1 cells were induced to differentiate with 6 
commercial insulins: Glargine, Lispro, Aspart, Detemir, NPH and regular 
recombinated human insulin (used as control). Cell differentiation, lipolysis 
and gene expression were measured at day 7 (D7) and at day 10 (D10) after 
differentiation induction.
Results: The highest values of cell differentiation and lipolisys were found 
at D10 for all the insulins tested (p<0.001). Preadipocyte differentiation was 
different according to the insulin used at both moments (p<0.0001), Detemir 
insulin being the least adipogenic. PPARg mRNA level variated according 
to the insulin and it was a good genetic marker of adipogenesis at D7, but 
at D10 PPARγ gene expression didn’t reflect the differences on the cell dif-
ferentiation between each insulin. Cells treated with Glargine insulin showed 
lower antilipolytic effects (p<0.0001) with the highest level of HSL expression 
at both days (p< 0.0001 at both days). Gene expression of InsR, SREBP-1c 
and SCD-1 were different regarding to the insulin investigated (p<0.0001, 
p<0.0001and p<0.001 respectively at D7; and p<0.001, p<0.003 and p<0.005 
respectively at D10)
Conclusion: Detemir insulin is less adipogenic than the other insulins tested, 
while Glargine insulin is the less anti-lipolitic. The modifications made on 
commercials insulins also affect the adipocyte differentiation, the lipolysis 
activity, and the expression of different genes which can modify metabolic 
pathways independent of glucose metabolism.
Supported by: PI021480; SAS02/03; SAS125/02; SAS115/02
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Orexin A stimulates lipogenesis and adiponectin expression via 
PPARgamma-dependent mechanism in isolated primary rat and mature 
3T3-L1 adipocytes
M. Skrzypski1,2, T.T. Le1, P. Kaczmarek2, P. Pietrzak3,  
E. Pruszynska-Oszmalek2, D. Szczepankiewicz2, A.M. Arafat4,  
B. Wiedenmann1, K.W. Nowak2, M.Z. Strowski1; 
1Hepatologie, Gastroenterologie & Interdisziplinäres Stoffwechsel-
Centrum/Endokrinologie und Diabetes, Charité - Universitätsmedizin 
Berlin, Germany, 2Animal Physiology and Biochemistry, Poznan University 
of Life Sciences, Poland, 3Department of Physiological Sciences, Faculty 
of Veterinary Medicine, Warsaw, Poland, 4Endocrinology, Diabetes, and 
Nutrition, Charité - Universitätsmedizin Berlin, Germany.
Background and aims: Orexin A (OXA) plays a role in the regulation of 
food intake and body metabolism. Dysfunction of the orexin system is as-
sociated with obesity and glucose intolerance. Recently, orexin receptors were 
identified in human adipocytes. Activation of orexin receptors in adipocytes 
increased PPARgamma2 expression and reduced lipolysis. Here, we charac-
terize the effects of OXA on glucose uptake, lipid accumulation, adiponectin 
gene expression, and secretion in adipocytes. We also describe the underlying 
mechanism.
Materials and methods: We used isolated primary rat adipocytes and dif-
ferentiated 3T3-L1 adipocytes. We studied the effects of OXA on lipogenesis, 
lipolysis, glucose uptake and ATP levels using biochemical assays, Western 
blots and immunofluorescence. The effects of OXA on adiponectin secretion 
and expression were measured by RIA and Western blots. Mechanisms of ac-
tion were studied using siRNA technique and pharmacological inhibitors of 
crucial signaling pathways.
Results: OXA stimulated active glucose uptake by translocating the glucose 
transporter type 4 from plasma into the plasma membrane via the PI3ki-
nase-/AKT-pathway. OXA increased cellular ATP content, as well as lipid ac-
cumulation. OXA enhanced the lipogenesis and reduced lipolysis. OXA in-
creased adiponectin secretion and expression. OXA increased the expression 
of PPARgamma. The effects of OXA on lipogenesis and adiponectin secretion 
were blocked by pharmacological inhibitors of PPARgamma activity and by 
specific PPARgamma siRNA.
Conclusion: In summary, our study demonstrates that OXA PI3kinase-/
AKT-dependently stimulates glucose uptake in adipocytes and that the evolv-
ing energy is stored as lipids. OXA increases the expression and secretion of 
adiponectin, as well as lipogenesis through PPARgamma-dependent mecha-
nism. The effects of OXA on the function of adipocytes may be of clinical rel-
evance in the pathophysiology of obesity and in peripheral insulin resistance, 
the hallmark of type 2 diabetes mellitus.
Supported by: DFG
709
Carrier-mediated trans-membrane delivery of PIP3 overcomes cellular 
insulin resistance induced by proximal, but not distal signaling defect
A. Rudich1, I. Kachko-Chernetsky2, T. Traitel2, N. Bashan1, R. Jelinek3,  
J. Kost2; 
1Department of Clinical Biochemistry, 2Department of Chemical 
Engineering, 3Department of Chemistry, Ben Gurion University of the 
Negev, Beer-Sheva, Israel.
Background and aims: Using bio-mimetic liposomes we have identified an 
efficient specific polyethyleneimine (PEI)-based carrier to efficiently deliver 
phosphoatidylinositol-3,4,5-trisphophate (PIP3) across the plasma mem-
branes of cultured muscle and fat cells in a manner that can activate insulin 
signaling (Diabetologia, 51: S276: 687). In the present study, we aimed at ob-
taining proof-of-concept for the possibility to utilize PIP3 to overcome some 
forms of insulin resistance.
Materials and methods: We utilized chronic exposure of L6 muscle cells to 
high glucose-high insulin to induce an insulin resistance state characterized 
by early signalling defect, and 3T3-L1 adipocytes treated with nelfinavir as 
a cellular model for insulin resistance emanating from signalling defect(s) 
downstream of endogenous PIP3 generation (Endocrinology 150: 2618, 
2009).
Results: 3T3-L1 adipocytes treated for 18h with the HIV protease inhibitor 
nelfinavir exhibited marked attenuation of insulin-stimulated translocation 
and plasma membrane fusion of a GFP-GLUT4-myc reporter. PEI-PIP3 com-
plexes induced in control cells a nearly full response of GLUT4 translocation 
compared to that observed with insulin. Yet, after pre-incubation with nelfi-
navir, the response to PEI-PIP3 was greatly blunted, suggesting that PEI-PIP3 
can not bypass the signaling defect induced by nelfinavir. In contrast, L6 cells 
exposed for 18h to high (25 mM) glucose high (100nM) insulin exhibited 
a 2-fold increase in basal Ser473 phosphorylation of Akt, along with 40% 
diminished insulin-stimulated Akt phosphorylation. In this system, control 
cells treated with PEI-PIP3 exhibited 70% of the 10-fold increase in pS-Akt 
induced by insulin, and after high-glucose - high insulin treatment the re-
sponse to PEI-PIP3 was fully intact. Moreover, pS-Akt was higher after high-
glucose - high insulin in response to PEI-PIP3 than in response to insulin.
Conclusion: We show that efficient carrier-mediated delivery of PIP3 can 
elicit biologically relevant insulin-like responses in adipocytes and muscle 
cells. Insulin resistance resulting from signaling defects downstream of en-
dogenous PIP3 generation can not be bypassed by introducing exogenous 
PIP3. However, PEI-PIP3 retains its ability to elicit insulin signaling events in 
muscle cells rendered resistant to the effects of the hormone when the signal-
ing defect is upstream of PIP3 generation, constituting a proof-of-concept for 
“second messenger therapeutics” for some forms of insulin resistance.
Supported by: Israel Science Foundation
710
Immunosuppressive agents alter insulin signalling and glucose and lipid 
metabolism in human subcutaneous adipocytes
M.J. Pereira1,2, J. Palming1, M.K. Svensson3, M. Aureliano4, E. Carvalho2, 
J.W. Eriksson1,5; 
1Department of Molecular and Clinical Medicine, The Lundberg Laboratory 
for Diabetes Research, Göteborg, Sweden, 2Center for Neuroscience and 
Cell Biology, University of Coimbra, Portugal, 3Department of Molecular 
and Clinical Medicine, Göteborg, Sweden, 4FCT- CCMAR, University of 
Algarve, Faro, Portugal, 5AstraZeneca R & D, Mölndal, Sweden.
Background and aims: The immunosuppressive agents (IAs), Cyclosporine 
(CsA) and Tacrolimus (FK) can cause new-onset diabetes in transplant re-
cipients (NODAT). This is one of the most serious long-term metabolic com-
plications of solid organ transplantation and it is associated with increased 
cardiovascular morbidity and mortality. Rapamycin (Rap), another potent IA 
and potential anti-tumoral agent, inhibits the mammalian target of rapamycin 
(mTOR). Although mTOR can mediate nutrient-induced insulin resistance 
by down-regulating insulin receptor substrate proteins, with subsequently 
reduced AKT phosphorylation, the effects of Rap on glucose metabolism are 
unclear. The aim of this study was to elucidate direct effects of IAs on insulin 
signaling, glucose and lipid metabolism in human subcutaneous adipocytes.
Materials and methods: Abdominal subcutaneous adipose tissue was ob-
tained from healthy volunteers (n=22, BMI: 21-36kg/m2). After adipocyte 
isolation, cells were incubated in medium containing 4% albumin with or 
without IAs: CsA (0.001-10 µM); FK (0.001-10 µM) and Rap (0.001-10 µM), 
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all ranges including therapeutic levels. Following adipocyte incubation with 
or without IAs, 14C-Glucose uptake was measured (75 minutes incubation, 
n=7) and western-blot analyses of insulin signaling protein (IRS1/2, PI3K, 
GLUT4, AKT and insulin-stimulated pSer473AKT and pThr308AKT) were 
performed (n=13; 15 minutes, 3 and 24 hours incubation). Basal and isopre-
naline-stimulated lipolysis rates were measured after adipocyte incubation 
with IAs for 2 hours (n=15).
Results: Insulin-stimulated glucose uptake was reduced in a dose-dependent 
manner after incubation with IAs: CsA by 23-28% (p<0.001), FK by 23-43% 
(p<0.001) and Rap by 12-42% (p<0.001). Treatment with Rap (≥3 h) caused 
a reduction in IRS2 protein level by 20% (p<0.01). FK and Rap caused a de-
crease in insulin-stimulated phosphorylation of AKT Ser473 (p<0.05), but 
did not change IRS1, PI3K, AKT and GLUT4 protein levels. Exposure of cells 
to CsA, FK and Rap increased isoprenaline-stimulated lipolysis (1.7, p<0.01; 
1.5, p<0.05 and 1.2 fold, p<0.05, respectively) but only Rap induced basal 
lipolysis (1.4 fold, p<0.05).
Conclusion: These results demonstrate that the investigated IAs, CsA, FK 
as well as the mTOR inhibitor Rap, impair insulin action on glucose uptake 
in subcutaneous human adipocytes, and this may be mediated via increased 
lipolysis and altered insulin signaling. These alterations can contribute to the 
development of NODAT and to dyslipidemia found in post-transplant pa-
tients. Moreover, it is suggested that mTOR is an important modulator of 
insulin-stimulated glucose uptake. Inhibition by Rap may contribute to the 
development of NODAT in organ transplanted patients, rather than having 
an insulin-sensitizing effect.
Supported by: FCT – The Portuguese Foundation
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Metabolic endotoxaemia as a mediator of mitochondrial dysfunction in 
human adipose tissue, alleviated by salicylate
K.C. McGee1, G. Tripathi1, S.J. Creely1, A.L. Harte1, M. Langowska1,  
N.F. Da Silva2, A. Brown2, J. Oscarsson2, J. Clapham2, S. Kumar1,  
P.G. McTernan1; 
1Unit for Diabetes and Metabolism, University of Warwick Medical School, 
Coventry, 2CVGI Bioscience, Astrazeneca R&D, Macclesfield, United 
Kingdom.
Background and aims: The pathogenesis of obesity and type 2 diabetes 
(T2DM) mediates mitochondrial dysfunction which, in part, may arise from 
a chronic low level inflammatory response due to gut derived endotoxaemia. 
Our previous studies have shown that changes in diabetic status increase cir-
culating endotoxin levels. Furthermore our current studies have shown that 
serum endotoxin levels correlate positively with BMI (r=0.281, p=0.016) as 
well as serum insulin levels (r=0.34, p=0.009) and HOMA index (r=0.331, 
p=0.021) suggesting a positive association between circulating endotoxin lev-
els and insulin resistance. As previous studies in muscle from patients with 
severe IR have highlighted decreased mitochondrial function, we undertook 
studies to investigate whether endotoxin may, in part, influence mitochon-
drial dysfunction in human adipose tissue (AT).
Materials and methods: Abdominal subcutaneous (Abd Sc), omental (Om) 
(BMI: 20.1-33.9kg/m2, age: 29-48yr; n=35) and Abd Sc T2DM (BMI: 52.4-
67.59kg/m2; age: 29-44yr; n=7) AT was taken from subjects undergoing elective 
surgery with ethical approval. Gene expression was assessed by qRT-PCR.
Results: In Abd Sc AT, increasing adiposity significantly reduced FAS 
(p<0.05), COX4 and UCP2 mRNA (p<0.001), whilst PGC1α mRNA was in-
creased (p<0.01). No significant difference in expression was observed in Abd 
Sc AT from T2DM subjects vs. Abd Sc AT from obese ND subjects. In Om AT, 
FAS, PGC1α, COX4 and UCP2 mRNA were reduced (p<0.001). No significant 
difference in expression was observed in Abd Sc AT from T2DM subjects vs. 
Abd Sc AT from obese ND subjects. Therefore we investigated the direct effect 
of endotoxin (lipopolysaccharide (LPS)) treatment on mitochondrial encoded 
genes and the therapeutic potential of Salicylate (Sal) in human differenti-
ated adipocytes. Differentiated pre-adipocytes were treated for 24 hr with LPS 
(100ng/ml) with or without Sal (20mM) and assessed by qRT-PCR. Treat-
ment with LPS+Sal led to a significant up-regulation of NRF1, FAS, UCP2 and 
UCP3 (p<0.05) compared with adipocytes treated with LPS alone.
Conclusion: In summary, these studies highlight significant changes in mi-
tochondrial properties in response to conditions of obesity and T2DM. Such 
dysregulation in mitochondrial gene expression may, in part, arise due to the 
effects of inflammation imposed by LPS which appears negated by Sal treat-
ment. Taken together, these data indicate therapeutics to reduce LPS may al-
leviate mitochondrial dysfunction and its pathogenic consequences.
Supported by: AstraZeneca
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The effect of ligand activated LXR-alpha on the PPAR-γ-target genes in 
mature adipocytes
F. Zheng, H. Li, W. Lu, F. Wu, J. Zhou; 
Endocrinology, Zhejiang University, Hangzhou, China.
Backgrouds and aims: A selective activation of peroxisome proliferator-ac-
tivated receptor gamma (PPAR-γ) in adipocytes plays an important role in 
insulin sensitivity and inflammation. Like PPAR-γ, Liver X receptor alpha 
(LXR-α), which is another ligand-activated transcription factor in adipocytes, 
also forms a heterodimer with retinoid X receptor alpha (RXR-α). Whether 
the activation of LXR-α interferes with the PPAR-γ signaling in adipocytes is 
unknown. To explore potential interactions between LXR-α and PPAR-γ in 
adipocytes and investigate the effect of LXR-α activation on the expressions 
of PPAR-γ target genes.
Methods: Differentiation of pre-adipocytes 3T3-L1 into mature adipocytes 
were induced by addition of differentiation cocktail for 12 days, and cells 
were harvested every 2 days for LXR-α mRNA analysis. T0901317 was used 
to activate LXR-α or Pioglitazone to activate PPAR-γ respectively. Differenti-
ated adipocytes (at day 8) were treated with (1) different concentrations of 
T0901317 (0, 0.3, 1, 3, 6 and 10uM) for 24 h; (2) different concentrations of 
T0901317 with 3uM Pioglitazone for 24 h; (3) LXR-α silence (or non-silenc-
ing control) for 48 h followed by different concentrations of T0901317 for 24 
h; (4) LXR-α silence (or non-silencing control) for 48 h followed by different 
concentrations of T0901317 with 3uM Pioglitazone for 24 h. Expressions of 
the PPAR-γ target genes in harvested adipocytes, including adiponectin, re-
sistin and TNF-α, were determined by Real-time PCR, and Western blot.
Results: (1) LXR-α mRNA level increased dramatically 4 days after the initia-
tion of the differentiation program, reached the peak at day 8 (16.3 times of 
that in pre-adipocytes 3T3-L1) and gradually declined at day 10 and day 12. 
(2) Adiponectin, a representative gene product positively regulated by PPAR-
γ, was suppressed dose dependently by T0901317 in both the mRNA and the 
protein levels. mRNA levels of TNF-α and resistin produced by genes nega-
tively regulated by PPAR-γ were increased dose dependently by T0901317. 
Addition of pioglitazone at a concentration of 3uM partly reversed the 
expressions of adiponectin, resistin and TNF-α at each concentration of 
T0901317. However, the dose dependent suppressions of adiponectin and 
up-regulations of TNF-α and resistin transcriptions by T0901317 were still 
observed in the presence of pioglitazone. (3) Treated with shRNA specific for 
LXR-α for 48 h, the differentiated adipocytes were down-regulated by 60-70% 
in LXR-α protein level. mRNA level of adiponectin was moderately increased, 
while TNF-α and resistin mRNA levels were decreased by LXR-α silencing at 
each concentration of T0901317. More significant increase in adiponectin, as 
well as decrease in TNF-α and resistin mRNA levels were found in presence 
of 3uM pioglitazone,as compared with those treated with non-silencing con-
trol shRNA and different concentrations of T0901317; However, the absolute 
increase in adiponectin mRNA and reduction in resistin and TNF-α mRNA 
levels by LXR-α silencing were decreased consistently with the increasing 
concentration of T0901317, regardless of the presence of 3uM Pioglitazone.
Conclusion: These observations suggest that LXR-α activation interferes with 
the expressions of PPAR-γ-target genes, indicating a possible role of LXR-α in 
insulin action by counteracting PPAR-γ signaling in adipocytes.
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PPARγ-sparing thiazolidinediones: stimulation of mitochondrial 
biogenesis by a PGC1α-independent pathway
W.G. McDonald1, S.L. Cole1, B.N. Finck2, D.D. Holewa1,  
A.S. Brightwell-Conrad1, R.R. Eversole3, J.R. Colca1, R.F. Kletzien1; 
1Metabolic Solutions Development Co, Kalamazoo, 2Washington University, 
St. Louis, 3Western Michigan University, Kalamazoo, USA.
Background and aims: It is well established that mitochondrial content and 
capacity are decreased in some tissues in insulin-resistant states and type 2 dia-
betes. Therapeutic agents such as the thiazolidinediones (TZDs) have shown 
promise in restoring mitochondrial capacity in both experimental models and 
clinical studies. However, the TZDs have well established side effects which can 
be traced back to activation of the PPARγ transcription factor. Therefore, we 
have sought to identify and develop experimental drugs of the TZD class that 
spare this receptor (PPARγ-sparing thiazolidinediones, PsTZDs) but retain the 
desirable pharmacology, including stimulation of mitochondrial biogenesis.
Materials and methods: We have used the PsTZD clinical candidate, MSDC-
0160, to examine mitochondrial biogenesis in cells derived from brown ad-
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ipose tissue (BAT). In this model system, BAT precursor cells are isolated 
from CD1 mice and maintained in tissue culture.
Results: Treatment of cells with MSDC-0160 elicited the differentiated BAT 
cellular phenotype after 96 hours of drug treatment. During this timeframe, 
a robust increase in mitochondrial content was observed as measured by 
fluorescent dye staining, light microscopy and confirmed by transmission 
electron microscopy. Expression of the mitochondrial uncoupling protein, 
UCP1 (mRNA, protein) was first detected following 96 hours of drug treat-
ment and maximum expression was observed after 168 hours. Citrate syn-
thase was monitored as an index of mitochondrial mass and a detailed time 
course of expression after drug treatment revealed progressive, dose-depen-
dent increases (4 to 5-fold). We assumed that the nuclear transcription factor, 
PGC1α (peroxisomal proliferator activator receptor γ coactivator 1α), was 
driving the increased mitochondrial content through expression of nuclear 
and mitochondrial genes involved in mitochondrial biogenesis. However, 
analysis of PGC1α mRNA expression as a function of time of drug treatment 
revealed that there was no detectable increase. We then examined the abil-
ity of the PsTZDs to elicit differentiation and mitochondrial biogenesis in 
BAT precursor cells isolated from mice in which the PGC1α gene had been 
ablated. We found that cellular differentiation, UCP1 protein expression and 
mitochondrial biogenesis as measured by citrate synthase activity were robust 
and similar to that seen in the control animals.
Conclusion: Therefore, we conclude that the PsTZDs are fully capable of 
stimulating mitochondrial biogenesis through a pathway that does not in-
clude PGC1α. This pathway may synergize with the epinephrine/PGC1α 
pathway. The definition of this PsTZD-stimulated, PGC1α -independent 
pathway may have important implications for understanding the mechanism 
of action of insulin sensitizing agents.
PS 60 Glucose and lipid metabolism 
in animal models
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Insights into the mechanism of FATP1 activating effect on pyruvate 
dehydrogenase
M. Guitart1, C. García-Martínez2, A.M. Gómez-Foix1; 
1Dep. Bioquímica i Biologia Molecular, CIBERDEM, Universitat de 
Barcelona, 2Dep. Patologia i Terapèutica Experimental, CIBERDEM, 
Universitat de Barcelona, Hospitalet de Llobregat, Spain.
Background and aims: FATP1 is a membrane-bound fatty acid (FA)-binding 
protein that has acyl-CoA synthetase activity. FATP1 gene expression is high-
est in skeletal muscle, heart and fat. FATP1 is a metabolic regulator. FATP1-
null mice are protected against diet-induced obesity and insulin resistance. 
In cultured skeletal muscle cells, FATP1 overexpression enhances FA uptake 
and storage as triacylglyceride, whereas FA oxidation is either not stimulated 
or only moderately enhanced. FATP1 strongly stimulates glucose oxidation 
and raises the activity of the pyruvate dehydrogenase (PDH) complex and 
pyruvate decarboxylase PDH-E1 catalytic subunit. FATP1 is immunolocal-
ized in internal membranes and mitochondria, although the suborganelle 
compartment is unknown. We examined the mechanism of effect of FATP1 
on PDH activity and submitochondrial localization of FATP1 in cultured 
skeletal muscle cells.
Materials and methods: FATP1 effects on PDH activity were analyzed af-
ter adenoviral-mediated transfer of the mouse FATP1 cDNA into cultured 
muscle cells. PDH complex and PDH-E1 subunit activities were determined 
by measuring the 14CO2 production from [1-
14C]-pyruvate. Western blotting 
was used to assess PDH complex protein content and phosphorylated PDH-
E1α at site 1 and site 2 using specific antibodies (kindly provided by Dr. H. 
Pilegaard). Subcellular and suborganelle immunolocalization was assessed in 
cells expressing FATP1 fused at the C terminus to EGFP using anti-GFP anti-
bodies and electron microscopy.
Results: Overexpression of FATP1 in cultured myotubes raised the levels 
of the active form of the PDH complex and the PDH-E1 catalytic subunit, 
whereas no differences in the phosphorylation of PDH-E1α at site 1 or site 
2 were observed. The levels of the active form of the PDH complex and the 
PDH-E1 catalytic subunit were not altered by incubation of myotubes with 
palmitate, oleate or their mixture. Palmitate partially counteracted the activa-
tion of the PDH complex and PDH-E1 catalytic subunit by FATP1, whereas 
oleate or the mixture of palmitate with oleate did not. Immuno-electron mi-
croscopy showed that FATP1-GFP was localized inside the mitochondria, 
within the inner membrane-matrix compartment, whereas GFP was local-
ized intracytoplasmatically and in the nucleus.
Conclusion: In cultured skeletal muscle cells FATP1 activates the PDH com-
plex and PDH-E1 catalytic subunit, without affecting the phosphorylation 
of PDH-E1α at site 1 or site 2. This activation is counteracted by palmitate. 
FATP1-GFP is localized in skeletal muscle cells inside the mitochondria, 
where the PDH complex lies. These data provide insight into how FATP1 
activates the PDH complex.
Supported by: SAF2009-07559 MCI, Spain
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Adipose tissue-specific cholesteryl ester transfer protein expression in 
mice: impact on glucose metabolism
H. Zhou1, Q. Cui1, X. Ju1, W. Wang1, J. Jiang1, T. Yang1, X.-C. Jiang2; 
1Endocrinology and Metabolism, the first affiliated hospital of Nanjing 
Medical University, China, 2Anatomy and Cell Biology, State University of 
New York Downstate Medical Center, Brooklyn, USA.
Background and aims: Cholesteryl ester transfer protein mediates HDL 
cholesteryl ester delivery to the liver cells. Adipose tissue is a highly conserved 
site of cholesteryl ester transfer protein (CETP) expression across species, 
adipose tissue CETP makes a major contribution to CETP in the circulation. 
To investigate the impact of adipose CETP expression on adipocyte function 
and metabolism of glucose and lipid, we set up adipose tissue-specific CETP 
transgenic (CETPTg) mice.
Materials and methods: We created adipose tissue-specific CETP transgenic 
(CETPTg) mice successfully, using the aP2 promoter. HE-stained sections 
of adipose tissue from CETPTg mice and WT mice, in order to know the 
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change of adipocyte size, the frequency distribution of adipocyte cell surface 
area of both groups were evaluated. Then we evaluated the body weight and 
food consumption after four month chow diet or high fat diet. The glucose 
tolerance test and insulin tolerance test were all applied in CETPTg mice and 
WT mice after chow or high fat diet.
Results: CETP mRNA was predominantly expressed in adipose tissue in CE-
TPTg mice. Plasma lipoprotein analysis showed marked reductions in HDL 
cholesterol ; and adipocytes were significantly smaller than those in control 
mice and stored less lipid than those of wild type mice. No differences were 
found between WT and CETPTg mice in body weight and food consumption 
after four month chow diet or high fat diet. Differences between the CETPTg 
and the WT littermates under chow diet were detected when a glucose toler-
ance test was administered. The blood glucose levels in the CETP Tg mice 
were higher than in WT mice after injection of a glucose solution. The differ-
ences were significant after 30 min and 60min of the test (P< 0.05), indicating 
that CETPTg mice displayed impaired glucose tolerance. In an insulin toler-
ance test, the CETPTg mice became significantly more hypoglycemic at 15, 
30min after insulin injection than the WT mice (P < 0.001, P < 0.05 respec-
tively), showed an increased sensitivity to insulin. The GTT and ITT were 
also investigated in the CETPTg and WT mice after high fat diet. The results 
indicated that the tendency was still there but without significance, high fat 
diet masked the effect of CETP overexpression.
Conclusion: GTT reflects both insulin sensitivity and insulin secretion, while 
ITT only reflects insulin sensitivity. Smaller adipocyte shows a higher insulin 
sensitivity. Adipose tissue-specific CETP overexpression reduced their adi-
pocyte size with an increased insulin sensitivity, however the glucose toler-
ance was impaired. We predict that maybe there is problem with the beta cell 
function, we need to do further investigation in the next study.
Supported by: National Natural Science Foundation of China
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Loss of pigment epithelium-derived factor deteriorates lipid and glucose 
metabolism
A.L. Birkenfeld1, C. Chung2, H.-Y. Lee3, M.J. Jurczak3, F.R. Jornayvaz3,  
S. Crawford4, G.I. Shulman3, V.T. Samuel3; 
1Endocrinology and Clinical Nutrition, Charite University School of 
Medicine, Berlin Nuthetal, Germany, 2Digestive Diseases, Yale University 
School of Medicine, New Haven, USA, 3Endocrinology, Yale University 
School of Medicine, New Haven, USA, 4Pathology, Northwestern University, 
Chicago, USA.
Background and aims: Pigment epithelium-derived factor (PEDF) is an 
endogenous protein with neuroprotective and anti-angiogenic effects. Ex-
perimental studies report that PEDF is a putative ligand for adipose triglyc-
eride lipase. Clinical reports indicate that elevated serum PEDF may be a 
compensatory protein in the metabolic syndrome. However, the physiologi-
cal significance of PEDF as a regulator of lipid metabolism is unknown. We 
hypothesized that deletion of PEDF promotes lipid accumulation and leads 
to insulin resistance
Materials and methods: PEDF deficient (PEDF ko) and age-matched control 
(WT) mice (n=8/group) were studied in metabolic cages on a regular chow 
diet, and an IPGTT (1 mg/g) was performed after an overnight fast.
Results: Compared to WT mice, energy expenditure was reduced 25% 
(p<0.001) in PEDF ko mice with a 50% decrease in food consumption 
(P<0.01) and total activity (P<0.001). Body weight was increased by 10% 
(P=0.01), and fat mass, as measured by 1H magnetic resonance spectroscopy, 
was more than two-fold higher (P<0.001) in PEDF deficient mice. PEDF ko 
mice had higher fasting glucose concentrations (156±8 vs 103±8 mg/dL, 
P<0.001), and marked hyperinsulinemia (58±2 vs 14±3 μU/ml, P=0.02), sug-
gesting severe insulin resistance. During the IPGTT, the glycemic excursion 
was higher in the PEDF ko mice with an 80% increase in the AUC glucose, 
but without additional glucose stimulated insulin secretion.
Conclusion: Loss of PEDF promotes obesity and insulin resistance in mice.
Supported by: DFG
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Effect of RNAi-mediated gluconeogenic gene depletion on the fasting 
blood glucose level in alloxan-diabetic mice
K. Jin Hwa1, B. HakYeon1, K. SangYong1, L. Byoung Rai2; 
1Department of Internal Medicine, 2Department of Biochemistry, College of 
Medicine, Chosun University, Kwangju, Republic of Korea.
Background and aims: Glucose 6-phosphatase(G6Pase) catalyses the final 
reaction in hepatic glucose production by gluconeogenesis, and has been pro-
posed as a potential target for antihyperglycaemic drugs for type 2 diabetes. 
PPAR gamma-coactivator 1(PGC-1) stimulatse this enzyme. To evaluate the 
potential of G6Pase and PGC-1 as a therapeutic target of type 2 diabetes, we 
investigated the response to dietary caloric restriction on the PGC-1 expres-
sion in liver of Otsuka Long-Evans Tokushima Fatty(OLETF) rats, and per-
fomed depletion of G6Pase and PGC-1 gene by siRNA-expressing plasmid 
DNA(siRNA-pDNA) injection in alloxan-diabetic mice.
Materials and methods: In OLETF rats and Long-Evans Tokushima 
Otsuka(LETO) rats, liver PGC-1 mRNA and blood glucose levels were inves-
tigated at 1, 2, and 3 weeks after the beginning of 30% caloric restriction(CR). 
siRNAs of G6Pase and PGC-1 were constructed to siRNA-pDNA. Each siR-
NA-pDNA was injected to alloxan-diabetic mice by tail vein and monitored 
blood glucose level. The levels of G6Pase and PGC-1 mRNA in liver of mice 
were measured by real time PCR.
Results: The liver PGC-1 mRNA expression were increased to 19% in LETO 
rats but significant change was not observed in OLETF rats by 30% CR. Post-
prandial blood glucose level was not changed between control and siRNA-
pDNA(G6Pase, PGC-1) treated alloxan-diabetic mice. After 12 hour fasting, 
the blood glucose levels of control were 235±27 mg/dL. Each glucose levels 
of G6Pase and PGC-1 siRNA-pDNA injected alloxan-diabetic mice were 
115±16 and 127±10 mg/dL at the same time. There were significant differ-
ences between control and experimental groups after 12 hour fasting. G6Pase 
and PGC-1 mRNA levels in liver of mice were decreased by injection of siR-
NA-pDNA.
Conclusion: Gluconeogenic gene such as G6Pase and PGC-1 depletion by 
siRNA-pDNA treatment leads to lowering fasting blood glucose levels in dia-
betic mice. This represents the potential of G6Pase and PGC-1 as a therapeu-
tic target of type 2 diabetes.
718
Effects of high-fat diet on lipid metabolism in ApoE-/- mice
S. Xu1, L. Li1, G. Yang2 
1The Key Laboratory of Laboratory Medical Diagnostics in the Ministry of 
Education, 2Department of Endocrinology, the Second Affiliated Hospital, 
Chongqing Medical University, China.
Background and aims: High-fat diet (HFD) is associated with insulin resis-
tance, hyperinsulinemia, elevated plasma free fatty acid (FFA), and increased 
risk for atherosclerotic vascular disease (ASVD). However, the mechanisms 
underlying the tissue-specific effects of HFD on the expression of genes in-
volved in glucose and lipid metabolism have not been fully clarified. In our 
study, we have studied the effects of HFD on key enzymes and transcription 
factors involved in glucose and lipid metabolism in ApoE-/- mice.
Materials and methods: Twenty male ApoE-/- mice aging 8 weeks old were 
housed in individual cages and subjected to an environmentally controlled 
room with a 12-h light/dark cycle. Mice were randomly assigned to one of 
two groups. One for a normal chow diet (NC, n=10). The other for a high-fat 
diet (HF, n=10). Hyperinsulinemic-euglycemic clamp study was carried out. 
Plasma FFA, insulin concentrations (PIns), high density lipoprotein choles-
terol (HDL-C), low density lipoprotein cholesterol (LDL-C), TG and TC con-
centrations were measured. The mRNA levels of insulin-induced gene (IN-
SIG), sterol regulatory element binding protein cleavage activating protein 
(SCAP), sterol regulatory element binding protein-2 (SREBP-2), 3-hydroxy-
3-methylglutaryl coenzyme A reductase (HMGCR) and low density lipopro-
tein receptor (LDLr) were determined by RT-QPCR; The concentrations of 
protein visfatin and FGF-21 were assay. The liver and adipose in mice ATGL, 
INSIG2, FGF-21 and visfatin protein were measured by western blot.
Results: Whole body insulin sensitivity were evaluated by hyperinsulinemic-
euglycemic clamp technique combined with [3-3H] glucose as a tracer. The 
GIR in the HF group was markedly lower than in the controls (P< 0.01).Com-
pared to controls, mice fed a high fat diet (HFD) had significantly increased 
body weight, fasting blood glucose (FBG) and plasma concentrations of in-
sulin, FFA, TG, TC, HDL-C, and LDL-C (P<0.01,). The mRNA expression 
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of INSIG2 and SCAP was significantly up-regulated (P<0.01,) and INSIG2 
protein level in liver was also increased in HF group (P<0.05). The mRNA ex-
pression of SREBP-2, HMGCR and LDLr was down-regulated in liver of HF 
group (P<0.05 and P<0.01). In adipose tissue, mRNA expression of INSIG1, 
INSIG2 and SCAP, and protein levels of INSIG2 were no differences between 
the two groups. The mRNA expression of SREBP-1, ATGL and PPARγ in 
liver and adipose tissues were significantly down- regulated in HF group than 
in NC group (P<0.05 and P<0.01). But FAS mRNA and HSL levels were no 
differences in two groups.
Conclusion: Hyperglycemia, dyslipidosis and hyperinsulinemia in this 
animal model might result from, at least in part, the changes of these key 
enzymes and transcription factors. Our findings might also account for the 
characteristics of glucose and lipid metabolism in diet-induced insulin re-
sistance.
Supported by: National Natural Science Foundation of China 
719
The lack of beta 2 adrenoceptors in mice results in glucose intolerance 
and impaired insulin secretion
A. Lombardi1, G. Santulli2, D. Sorriento2, A. Anastasio2, S. Iovino1, C. Del 
Giudice2, B. Trimarco2, F. Beguinot1, P. Formisano1, C. Miele1, G. Iaccarino2; 
1Dbpcm & ieos-cnr, “Federico II” University - Dpt. Cellular and Molecular 
Biology and Pathology, 2DMCSCI, “Federico II” University - Dpt. Clinical 
Medicine, Cardiovascular & Immunologic Sciences, Naples, Italy.
Background: The reciprocal regulation of Sympathetic Nervous System and 
Insulin relays on molecular mechanisms that are not fully understood. Beta 2 
adrenergic receptors (beta 2 ARs), in particular, are known to be involved in 
insulin production and in peripheral glucose uptake, but their role in devel-
opment of diabetes is not clear.
Methods and results: We characterized the metabolic phenotype of mice 
(age 6 months) with deletion of the beta 2 AR gene (KO, n=21), perform-
ing tolerance tests to glucose (GTT, 1mg/Kg), insulin (ITT, 0.75 IU/Kg) and 
sodium pyruvate (PTT 2g/Kg) and hyperinsulinemic euglicemic clamps. As 
control we used C57BL/6 mice (WT, n=18). KO mice exhibited decreased 
glucose tolerance compared to WT mice (AUC GTT KO: 40980±6890 vs 
AUC GTT WT 19290±2120, p<0.01, ANOVA). However, ITTs showed that 
KO mice did not feature peripheral insulin resistance compared to WT mice 
(AUC ITT KO: 8280±1250 vs AUC ITT WT 13950±1815, p<0.01, ANOVA). 
Clamp studies in KO mice revealed a lower Glucose Infusion Rate (KO vs 
WT: 14.6±8 vs 30±9 mg/Kg/min), an increased endogenous glucose produc-
tion: (79.8±4 vs 36.1±3 mg/Kg/min) and an increased rate of glucose disap-
pearance (96.6±5 vs 63.2±3.4 mg/Kg/min; p<0.05), suggesting that insulin 
resistance develops at the hepatic level in KO mice compared to WT mice. 
KO mice showed impaired insulin response to hyperglycemia compared to 
WT mice. Histological analysis of pancreatic tissues displayed a normal ar-
chitecture of the islets in both KO and WT mice. Also total insulin content 
(insulin KO: 4.93±0.87 ng/g of pancreas vs WT: 4.19±1.82 ng/g of pancreas) 
and glucagone content (glucagone KO: 577.8±106.5 pg/g of pancreas vs WT: 
636.17±112.8 pg/g of pancreas) were comparable in both KO and WT mice. 
However, whilst in islets isolated from WT mice glucose induced insulin se-
cretion by 3-fold, islets from the KO mice exhibited a blunted response to 
glucose. Glucagon secretion was not different in KO and WT mice. Increas-
ing beta 2 AR expression in KO mice isolated islets by the infection of an 
adenoviral construct bearing the beta 2 AR cDNA, restored the ability of KO 
islets to secrete insulin in response to glucose.
Conclusion: Our results suggest that beta 2 AR plays a critical role in the reg-
ulation of glucose metabolism and insulin secretion both in vivo and ex vivo. 
These findings open new fields of investigation for the development of strate-
gies to produce drugs with potential therapeutic applications in diabetes.
PS 61 Animal models insulin 
resistance
720
Folate deficiency increases adipose tissue and muscle insulin resistance 
in spontaneously hypertensive rats 
M. Maxová1, M. Pravenec2, L. Kazdová1; 
1Institute for Clinical and Experimental Medicine, 2Institute of Physiology, 
Czech Academy of Science, Prague, Czech Republic.
Background and aims: Controversial clinical data and a few studies in ani-
mal have been reported on the association between insulin resistance and 
plasma folate levels. The aim of this work was to compare the influence of the 
folate-deficient diet and high-fructose diet on insulin resistance parameters 
in spontaneously hypertensive rats (SHR), which are commonly used as a 
model of a metabolic syndrome.
Materials and methods: One group of adult male SHR rats (n=9) were fed 
a folate-deficient diet (Harlan Teklad, Netherlands) ad libitum for 4 weeks, 
the second group (n=9) were fed a high-fructose diet (70 cal.%). Triglycer-
ides, glucose and free fatty acids concentrations were determined with com-
mercially available kits (Pliva Lachema, Czech Republic; Roche Diagnostic 
GmbH, Germany, resp.). Serum folate levels were estimated by folate test 
AxSYM (Abbott Laboratories). Tissue insulin sensitivity was measured in 
vitro without or with insulin (250 µU/ml) according to basal and insulin-
stimulated 14C-U-glucose incorporation into muscle glycogen or adipose tis-
sue lipids.
Results: After 4 weeks, the rats fed the folate-deficient diet has lower se-
rum folate concentration in comparison with rats fed a high-fructose diet 
(11.07±0.47 nmol/l vs 75.96±3.46 nmol/l; p<0.00001). Animals fed with fo-
late-deficient diet showed increased body weight (381±4.9 g vs 351±6.1 g; 
p<0.001), whereas epididymal fat pads weight when related to body weight 
were not different between groups. Nonfasting serum glucose levels were in-
creased in the folate deficient rats (5.8±0.1 vs 4.99±0.2 mmol/l; p<0.0004). 
Surprisingly folate-deficient diet markedly decreased serum triglycerides 
concentrations (0.77±0.03 vs 2.14±0.17 mmol/l; p<0.000001) whereas free 
fatty acids were not different. There were found no significant differences 
in liver and muscles triglycerides concentrations between folate-deficient or 
fructose fed rats, however both groups showed hepatic steatosis as a results 
of increased triglycerides accumulation (17.69±1.30 vs 15.46±0.98 μmol/
l, N.S.). The rats fed on the folate-deficient diet exhibited significantly de-
creased glucose incorporation into adipose tissue lipids and into muscle gly-
cogen in comparison with fructose fed animals (Tab). The ability of insulin 
to stimulate glucose incorporation was lower in folate-deficient rats than in 
fructose fed rats.
Conclusion: Our results show that folate-deficiency impaired glucose sensi-
tivity of peripheral tissues and stimulated hepatic steatosis similarly as fruc-
tose feeding and support hypothesis that folate deficiency may contribute to 
the pathogenesis of metabolic syndrome.
Folate-deficiency 
diet
High-fructose 
diet
p<
Lipogenesis -insulin 338 ± 42 467 ± 46 0.05
(nmol glucose/g/2h) +insulin 738 ± 89 1427 ± 221 0.01
Glycogenesis -insulin 39 ± 5,7 299 ± 60 0.0005
(nmol glucose/g/2h) +insulin 68 ± 8,7 644 ± 62 0.0000001
Supported by: IGA Ministry of Health of the Czech Republic.
721
Enhanced neuronal NO Synthase breakdown through the ubiquitin-
proteasome pathway in skeletal muscle of insulin resistant Zucker fa/fa 
rats
K. Mezghenna, M. Manteghetti, M. Tournier, P. Petit, R. Gross,  
A.-D. Lajoix; 
CNRS UMR 5232, Montpellier, France.
Background and aims: In type 2 diabetes, due to a decrease in insulin sensi-
tivity, glucose uptake is impaired in skeletal muscle. The latter is well known 
to express a splice variant of the neuronal isoform of NO Synthase (nNOS), 
nNOSμ. Because nNOSμ exerts a physiological role in the control of skeletal 
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muscle contractility and glucose uptake, we were prompted to investigate 
whether alterations of muscle nNOSμ could occur in prediabetic states and 
in the early phases of type 2 diabetes.
Materials and methods: We performed our study using Zucker fa/fa rats, 
characterized by a strong insulin resistance and hyperinsulinemia, two im-
portant features of prediabetic states. Zucker fa/+ lean rats were used as con-
trols. nNOSμ catalytic activity was evaluated by measuring citrulline produc-
tion from labelled arginine. nNOSμ expression was measured by quantitative 
PCR and western blotting. MG132 was used as an inhibitor of proteasomal 
function. Subcellular localization of nNOSμ was determined in immunofluo-
rescence studies with specific antibodies.
Results: In skeletal muscle extracts from Zucker fa/fa rats, we found a 41% 
decrease in nNOSμ catalytic activity when compared to control fa/+ extracts 
(p<0.01). This decrease correlates with a significant 42% reduction in the en-
zyme proteic level (p<0.05) with no change in nNOSμ mRNA, which argues 
for the occurrence of an increased proteasomal breakdown. Use of the pro-
teasomal function inhibitor MG132 in isolated skeletal muscle enabled us to 
bring evidence for an increased level of nNOSμ ubiquitination in fa/fa rats. 
In addition, inhibition of the ubiquitin-proteasome pathway resulted into a 
significant recovery of both nNOSμ proteic expression and catalytic activity, 
to levels similar to those recorded in fa/+ controls. In immunofluorescence 
studies, we could confirm the decrease in the expression nNOSμ protein in 
skeletal muscle of fa/fa rats; interestingly this decrease was found associated 
to a disturbance of the enzyme sub-membrane distribution.
Conclusion: In Zucker fa/fa obese insulin resistant rats, skeletal muscle 
displays a decreased nNOSμ catalytic activity resulting from an increased 
breakdown of the enzyme through the ubiquitin-proteasome pathway. These 
abnormalities, associated to a disturbed nNOSμ sub-membrane distribution, 
could be involved in the impaired skeletal muscle glucose uptake in the early 
phases of type 2 diabetes.
722
Analysis of insulin sensitivity in p66shcA KO mice by hyperinsulinaemic 
euglycaemic clamp
G. Sorice1, S. Chiatamone Ranieri2, G. Muscogiuri1, A. Giaccari1, G. Pani2; 
1Endocrinology, 2General Pathology, Catholic University, Rome, Italy.
Introduction and aim: Emerging clinical and experimental evidence point 
to a major role of tissue oxidative stress in linking ageing and excess body 
weight with insulin resistance; molecular mechanism underlying this connec-
tion are however still elusive. The signaling adaptor protein p66shcA promotes 
mitochondrial generation of oxidant species in several models of age-related 
disease, and p66KO mice live 30% longer than their WT littermates; thus, this 
protein may represent a critical determinant of the intracellular redox-state 
imbalance associated with diabetes and metabolic syndrome. We have previ-
ously shown that genetically obese, hyperinsulinemic (LepOb/Ob) mice lacking 
p66shcA are partially protected from glucose intolerance observed in their 
p66shc proficient littermates (Chiatamone et al., submitted), demonstrating 
that p66shc promotes insulin resistance in this setting. However, no major ef-
fects of p66shc on glucose homeostasis were detected in normal, lean mice by 
standard Intraperitoneal glucose tolerance test (ipGTT, 1g glucose/Kg BW) 
and insulin tolerance test (ITT, 0.75 U/Kg BW).
Methods and Results: Prompted by this discrepancy we have set up and 
performed hyperinsulinemic euglycemic clamp (18 mUI∙kg-1∙min-1) on lean 
mice of the two genotypes. This more reliable assay clearly demonstrated an 
enhanced insulin sensitivity in p66shcA-/- mice in comparison to WT animals 
(M, as mg of glucose metabolized per kg of BW per minute, and SEM: re-
spectively 161 mg∙kg-1∙min-1,± 35; 66 mg∙kg-1∙min-1,± 4.4; p<0.02). In keeping 
with this finding, biochemical analysis of the insulin signalling pathway in 
the adipose tissue of p66shcA null mice demonstrated reduced serine phos-
phorylation (serine 307+serine 636-639) of the insulin substrate IRS-1, an 
hallmark of insulin desensitization.
Conclusions: These findings confirm and extend our observation that p66shcA 
participates in the regulation of insulin action in an hyperinsulinemic setting, 
as it occurs in ageing-associated metabolic disorders including obesity and 
metabolic syndrome. While the possible connection between p66-dependent 
oxidative stress and insulin resistance needs to be further investigated, our 
data strongly encourage pharmacological research aimed at blocking the 
deleterious effect of the p66shcA protein to improve glucose homeostasis and 
prevent type 2 diabetes.
723
Lack of inducible nitric oxide synthase prevents lipid infusion-induced 
insulin resistance in mice
S.-Y. Park1, H.-N. Cha1, Y.-W. Kim1, J.-Y. Kim1, K.-C. Won1, J.-M. Dan2; 
1College of Medicine, Yeungnam University, Daegu, 2School of Medicine, 
Cha university, Gumi, Republic of Korea.
Background and aims: The role of inducible nitric oxide synthase (iNOS) 
on lipid-induced insulin resistance was examined in iNOS knockout (KO) 
mice and wild-type litter mate using hyperinsulinemic-euglycemic clamp 
technique.
Materials and methods: Four days before clamp, chronic catheter was in-
serted into jugular vein and connected to three-way to infuse insulin (15 
pmol·kg-1·min-1) and 20% glucose on the day of clamp. After overnight fast-
ing, 20% of intralipid and 33 U/ml of heparin were infused for 2 hours before 
and during clamp in lipid group, and saline was infused in saline group.
Results: Body weight was not different between wild-type and iNOS KO mice 
but epididymal fat mass was significantly elevated in iNOS KO mice. Glu-
cose infusion rate (GIR) to maintain euglycemia was significantly reduced by 
lipid infusion in wild-type mice but GIR was not reduced by lipid infusion 
in iNOS KO mice. Lipid infusion produced whole body insulin resistance in 
wild-type mice but lack of iNOS prevented development of lipid infusion-
induced insulin resistance. Whole body insulin resistance was contributed by 
30% decrease in skeletal muscle glucose uptake in wild-type mice, whereas 
lipid infusion had no effect on glucose uptake of skeletal muscle in iNOS 
KO mice. Skeletal muscle insulin resistance was accompanied with decrease 
in glycolysis in lipid-infused wild-type mice. Plasma level of tumor necro-
sis factor-α was increased by lipid infusion in both iNOS KO and wild type 
mice. Proinflammatory cytokines in skeletal muscle and adipose tissue were 
also increased by lipid infusion in both groups. While nitrotyrosine level in 
skeletal muscle was increased by lipid infusion in wild-type mice, it was sig-
nificantly lower in lipid-infused iNOS KO mice compared with lipid-infused 
wild-type mice.
Conclusion: These results suggest that lack of iNOS prevents whole body and 
skeletal muscle insulin resistance induced by lipid infusion, which may be 
contributed by reduced nitrosative stress.
Supported by: KOSEF
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Inhibition of PSGL-1-selectin pathway ameliorates obesity-related 
insulin resistance in db/db mice
D. Hirota, K. Shikata, C. Sato, R. Kodera, S. Miyamoto, N. Kajitani,  
T. Takatsuka, H. Makino; 
Department of Medicine and Clinical Science, Okayama University  
Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Japan.
Background and aims: There have been accumulating evidences that inflam-
mation in adipose tissue is involved in the mechanism of obesity-related in-
sulin resistance. Macrophages and proinflammatory cytokines are increased 
in visceral adipose tissues of obese people and animal models. Infiltration of 
monocyte/macrophage is mediated by the interaction of cell adhesion mol-
ecules expressed on monocytes and endothelial cells. We previously screened 
the gene expression profiles in adipose tissues from obese mice using DNA 
microarray and found that P-selectin glycoprotein ligand-1 (PSGL-1) is up-
regulated in both db/db mice and high-fat diet (HFD) fed mice. PSGL-1 is 
expressed on both leukocytes and endothelial cells and binds to P-, L- and 
E-selectin. We found PSGL-1 is expressed on both endothelial cells and mac-
rophages in adipose tissues of obese mice. Furthermore, we demonstrated 
that PSGL-1 deficient mice fed with HFD revealed decreased macrophage 
infiltration into adipose tissues, improved adipocyte hypertrophy and insulin 
resistance as compared with wild type mice fed with HFD. The aim of this 
study is to identify the inhibitory effect of the PSGL-1-selectin pathway using 
anti-PSGL-1 monoclonal antibody.
Materials and methods: Anti-PSGL-1 monoclonal antibody or normal rat 
IgG was administered by intraperitoneal injection to six week-old male db/db 
mice. An intraperitoneal insulin tolerance test (IPITT) and an intraperitoneal 
glucose tolerance test (IPGTT) were performed at 7 weeks old. We measured 
serum lipids, insulin, HbA1c and adipocytokines. We also examined the gene 
expression of proinflammatory cytokines, chemokines, adhesion molecules, 
adipocytokines and infiltration of macrophages in epididymal white adipose 
tissues (WAT). The size of adipocytes was measured and analyzed by mor-
phometry.
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Results: There was no significant difference in body weight, weight of epidi-
dymal WAT, total cholesterol, free fatty acid and HbA1c. Significant reduc-
tions were observed in fasting blood glucose (104.5 vs 138.5 mg/dl) and LDL 
cholesterol (6.25 vs 10.5mg/dl) in treated group ( treated group vs control 
group, p<0.05). The average values of triglyceride and fasting IRI were de-
creased in treated group as compared with control group. The size of adi-
pocytes in epididymal WAT was also significantly decreased in treated group 
as compared with control group. Glucose tolerance and insulin sensitivity 
were significantly improved in treated group in IPITT and in IPGTT. The ex-
pressions of MCP-1 and CD68 were decreased in treated group as compared 
with control group.
Conclusion: The administration with anti-PSGL-1 antibody revealed de-
creased macrophage infiltration in adipose tissues, improved adipocyte 
hypertrophy and insulin resistance in db/db mice. These results provide the 
direct evidence that PSGL-1-selectin pathway promotes the recruitment of 
macrophages into adipose tissue. PSGL-1 might be a novel target for the pre-
vention of insulin resistance in obesity.
Supported by: Grant-in Aid for Scientific Research from the Ministry of Educa-
tion, Science
PS 62 Brain and cognitive function
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Decreased serum brain-derived neurotrophic factor concentration in 
young nonobese subjects with low insulin sensitivity
M. Karczewska-Kupczewska, A. Adamska, A. Nikolajuk, E. Otziomek,  
M. Górska, M. Straczkowski, I. Kowalska; 
Department of Endocrinology, Diabetology and Internal Medicine, Medical 
University of Bialystok, Poland.
Background and aims: Insulin resistance and type 2 diabetes are associated 
with an increased risk of neurodegenerative diseases. Brain-derived neuro-
trophic factor (BDNF) regulates neuronal diff0erentiation and synaptic plas-
ticity and its decreased levels are supposed to play a role in the pathogenesis 
of Alzheimer disease and other disorders. Decreased circulating BDNF levels 
in obesity and type 2 diabetes were reported, however, it is unclear, whether 
BDNF might be associated with insulin resistance in young, nonobese popu-
lation. The aim of the present study was to estimate serum BDNF concentra-
tion in apparently healthy, nonobese women divided into subgroups accord-
ing to their insulin sensitivity.
Materials and methods: We studied 46 young (age: 25.15±5.16 years), ap-
parently healthy, nonobese (BMI: 24.02±2.84 kg x m-2) women with normal 
glucose tolerance. Anthropometric and biochemical parameters and serum 
concentrations of BDNF and adiponectin were measured. Insulin sensitivity 
was estimated with the euglycemic hyperinsulinemic clamp technique. Then, 
participants were divided into subgroups of high insulin sensitivity (high IS, 
above median from the clamp study, n=23) and low insulin sensitivity (low 
IS, below median, n=23).
Results: The difference in BMI and waist circumference between the groups 
did not reach the level of significance, whereas the percent of body fat was 
higher in the low IS group (p=0.024). We observed decreased serum BDNF 
concentration in women with low IS (p=0.001), which remained significant 
after adjustment for the difference in the percent of body fat. In the entire 
study population, serum BDNF was positively related to insulin sensitivity 
(r=0.43, p=0.003). In multiple regression analysis, this correlation remained 
significant after adjustment for other estimated parameters. In the low IS 
group, relationship between serum BDNF and adiponectin was also observed 
(r=0.52, p=0.027).
Conclusions: Our data show that serum BDNF is decreased in young non-
obese women with low IS. Thus, early detection and prevention of insulin 
resistance might be useful in the prevention of neurodegenerative disorders.
Supported by: Poland’s Ministry of Science and Higher Education
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Hypothalamic dysfunction in obesity as evaluated by functional 
magnetic resonance image
S.S. Lee, F.R.S. Pereira, D.E. Cintra, L.M. Li, F. Cendes, L.A. Velloso; 
Unicamp, Campinas, Brazil.
Background and aims: Hypothalamic inflammation and dysfunction have 
emerged as important factors determining the loss of the coordinated control 
of caloric intake and energy expenditure in animal models of obesity. Here we 
use functional magnetic resonance image (fMRI) to explore the hypothesis 
that obese humans also present some degree of dysfunctional hypothalamic 
activity.
Materials and methods: Functional images were acquired during a resting 
state paradigm before and after an oral glucose load. The BOLD signal was 
recorded for five minutes before and 25 minutes after glucose ingestion, and 
the Kendall’s coefficient of concordance was estimated.
Results: Twelve obese patients undergoing bariatric surgery were submitted 
to fMRI before surgical procedure and approximately eight months after sur-
gery, when absolute body mass was reduced by 29±4%. Eight age-matched 
lean controls were evaluated by the same method. Nutritional evaluation at 
enrolment revealed a mean caloric intake of 5,600±3,400 kCal/day, with high 
consumption of saturated fat. After surgery, mean caloric intake dropped to 
805±350 kCal/day, with substantial reduction of the consumption of satu-
rated fat. Caloric intake of lean subjects was 2,380±850 kCal/day. Reduction 
of body mass was accompanied by significant reductions of blood insulin and 
leptin and by the increase of adiponectin. In addition inflammatory mark-
ers such as C-reactive protein and blood leukocyte counts were significantly 
reduced. The comparison of obese patients before surgery with lean controls 
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revealed a significantly reduced loss of local homogeneity (t-score -8.71, 
p<0.05) in the hypothalamus (a representative image showing areas with loss 
of homogeneity in color is depicted in the accompanying figure). After sur-
gery this loss of homogeneity was not so pronounced but still significant (t-
score -7.30, p<0.05). Finally, when comparing obese patients before and after 
surgery a significant change in the loss of homogeneity was detected with a 
higher score in the post-surgical acquisition (t-score -4.64, p<0.05).
Conclusion: Although the loss of homogeneity in the hypothalamus was still 
smaller in the post-surgical group than in lean subjects, it is clear that the 
reduction of body mass was somehow correlated with a modification in the 
functional pattern of the hypothalamus towards the lean subjects standard. 
Thus, hypothalamic function, as determined by fMRI differs obese and lean 
subjects, and massive body mass loss produced by bariatric surgery leads to 
significant change in this parameter. fMRI may become an attractive, non-
invasive method to study central nervous system function in metabolic dis-
eases.
Supported by: Fapesp
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Deep brain stimulation in patients with Parkinson’s disease: involvement 
of local brain regions in systemic glucose metabolism?
N.M. Lammers1, B.M. Sondermeijer2, T.B. Twickler3, R.M.A. de Bie4,  
M.T. Ackermans5, E. Fliers1, S.E. la Fleur5, M.J.M. Serlie1; 
1Endocrinology & Metabolism, 2Vascular Medicine, 3Vacular Medicine, 
4Neurology, 5Clinical Chemistry, Laboratory of Endocrinology, AMC, 
Amsterdam, Netherlands.
Background and aims: We have previously shown that schizophrenic drug-
naïve patients display hepatic insulin resistance, suggesting that central dopa-
mine signaling is involved in the regulation of endogenous glucose produc-
tion (EGP). As a first step to test this hypothesis in an experimental setting, 
we studied whether deep brain stimulation (DBS) in the subthalamic nucleus 
of patients with Parkinson’s disease results in a change in basal EGP or he-
patic insulin sensitivity.
Materials and methods: We studied 6 patients with Parkinson’s disease treat-
ed by DBS both in the basal state and during a low-insulinemic euglycemic 
clamp using stable isotopes with DBS switched on or off. Each subject served 
as his own control and studies were performed in random assignment. We 
measured EGP and hepatic insulin sensitivity as well as resting energy expen-
diture (REE), glucoregulatory hormones and the Unified Parkinson’s Disease 
Rating Scale (UPDRS).
Results: We included 6 men (age 60 [44-65] years and BMI 28.2 [22.6-33.1] 
kg/m2). REE was not significantly different between the on and the off-situa-
tion. UPDRS was significantly higher when DBS was switched off. There was 
no significant difference in glucoregulatory hormones in either state. Basal 
plasma glucose and EGP (after 15 hrs of fasting) did not differ when DBS 
was switched on or off (EGP on 8.32 ± 0.73 and off 8.22 ± 1.09 μmol/kg·min, 
p=0.68). Hepatic insulin sensitivity did not significantly change (EGP on 3.15 
± 1.07 and off 2.8 ± 0.91 μmol/kg·min, p=0.36). 
Conclusion: Deep brain stimulation of the subthalamic nucleus in patients 
with Parkinson’s disease does not influence basal endogenous glucose pro-
duction or hepatic insulin sensitivity.
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Reduced hypothalamic insulin receptor expression and insulin-
dependent Akt phosphorylation in a type 2 diabetes model associated 
with a defect in serotonergic system
K. Gerozissis1, F. Berthou1, C. Rouch2, N. Vicaire1, I. Papazoglou1,  
D. Bailbe3, B. Portha3, M. Taouis1; 
1Neuroendocrinologie Moléculaire de la Prise Alimentaire,University Paris 
11, CNRS CNPS UMR 8195, Orsay, 2Unité BFA - Université Paris 7, 3B2PE 
Unité BFA - Equipe 1, Université Paris 7, France.
Background and aims: Insulin resistance both in the periphery and the brain 
act synergistically in the induction of metabolic diseases (MD) and co-mor-
bidities. Previous own studies and literature suggest a cross-talk between in-
sulin and the neurotransmitter serotonin (5HT), a regulator of energy and 
glucose homeostasis, key element in depressive syndromes. In the present 
study, using a T2D model, the Goto Kakizaki (GK) rat, we focused on hy-
pothalamic and liver insulin signalling and on the impact of 5HT.
Materials and methods: Male Wistar (W) or GK , 8-12 weeks old rats. In-
sulin receptor (IR) and Phospho-Tyrosine Phosphatase 1B (PTP-1B) protein 
expression or phosphorylation of Akt (a downstream protein kinase in IR/
IRS/PI3K signalling pathway), following ip injection of either insulin (1 U/ 
kg) or dexfenfluramine (stimulator of 5HT, 5 mg/ Kg) 30 min before eutha-
nasia, was assessed by western blot. Endocrine and metabolic parameters 
were determined with appropriate methods. Statistical significance was set 
at p<0.05. N= 5-10.
Results: Compared to age matched W, glycemia, insulinemia and leptinemia 
was increased in GK rats. In W and GK rats, dexfenfluramine increased in-
sulinemia and glycemia but did not alter leptinemia. Glycemia was increased 
more in GK as compared to W. IR protein expression was lower in GK liver 
and hypothalamus. In the hypothalamus, insulin injection induced Akt phos-
phorylation only in W rats. In liver, GK exhibits higher expression of PTP-1B 
associated to a lower insulin-dependent Akt phosphorylation, as compared 
to W. Finally, dexfenfluramine stimulated Akt phosphorylation only in the 
hypothalamus of W rats.
Conclusion: In diabetes, tissue specific alterations in insulin signalling oc-
cur within peripheral tissues. Here, were observed important alterations in 
hypothalamic and hepatic insulin signalling. In spite of inefficient insulin- 
induced Akt phosphorylation in GK probably due to altered IR and higher 
expression level of PTP1B, insulin lowered glycaemia, confirming that insulin 
resistance is not yet totally established in young adult GK. The effect of sero-
tonin on central insulin signalling in W, reported for the first time, extends 
previous own work shown central insulin-serotonin interaction. The impact 
of the serotonergic system in GK was altered. In fact, it failed to phosphor-
ylate hypothalamic Akt and increased glycemia in diabetic rats in higher lev-
els than in Wistar, suggesting an exaggerated counter-regulatory effect. This 
study points out the complexity of insulin-serotonin cross-talk on molecular 
mechanisms potentially linking depressive disorders and diabetes.
KG and FB, participated equally.
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Sucrose-induced insulin resistance is accompanied by morphologic and 
functional changes in the adrenal cortex of the rat
C. Martinez Calejman1, F. Astort1, E.M. Repetto1, R. Sanchez1, J.M. Di 
Gruccio1, C.B. Cymeryng1, P. Arias2; 
1Human Biochemistry Department, University of Buenos Aires - School of 
Medicine - CEFYBO- CONICET, 2Physiology and Biophysics Department, 
University of Buenos Aires -School of Medicine, Argentina.
Background and aims: Hyperactivation of the hypothalamic-pituitary-adre-
nal (HPA) axis has been widely described in both human and animals show-
ing insulin resistance (IR). However, a direct effect of the biochemical abnor-
malities that characterize this syndrome (e.g. elevated plasma glucose, serum 
insulin and free fatty acid levels, hypertriglicerydemia and oxidative stress) 
on adrenal function has not been elucidated yet. In this study we assessed the 
effect of a sucrose-enriched diet (SED) on adrenocortical structure and func-
tion (corticosterone secretion) in rats.
Materials and methods: Male Wistar rats were fed a sucrose-enriched diet 
(SED, drinking water contaning 30% w/v sucrose) up to 12 weeks. Rosiglita-
zone (4mg/kg, orally and daily) was administered throughout the duration of 
the sucrose treatment to a group of animals. Protein levels of different isofor-
ms of nitric oxide synthase (NOS), phosphorylated Akt and cyclooxygenase 2 
(COX-2) were analyzed by immunoblot while mRNA levels of steroidogenic 
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acute regulatory protein (StAR) and the macrophage marker F4/80 were as-
sessed by semiquantitative RT-PCR. Steroid levels were determined by RIA. 
Sudan III staining was performed on adrenocortical slices previously fixed in 
4% formaldehyde.
Results: As compared to controls, rats under SED for 7 weeks showed higher 
fasting plasma glucose (74 ± 5 and 130 ± 6 mg/dl; p<0,001, Mann-Whitney 
test) and serum triacylglyceride (104 ± 52 vs.604 ± 60 mg/dl; p<0,001) and 
insulin concentrations (0.99 ± 0.14 vs. 1.97 ± 0.4 ng/ml; p<0,005). An im-
pairment in the insulin signalling pathway was detected at adrenal level as 
decreased p-Akt protein levels were measured by immunoblot analysis. The 
adrenal glands were lighter and showed a significant lipidic infiltration, as 
demonstrated by histochemistry. NOS activity and the expression levels of 
eNOS, iNOS and COX-2 were increased in the SED group. StAR and F4/80 
mRNAs were also elevated. These animals showed significantly elevated basal 
serum corticosterone levels (6,63 ± 1,14 vs. 9,62 ± 0,84 ng/ml p<0,001) but 
a lower response to an acute stimulation with 4 UI/kg ACTH i.v., (115,68 
± 34, 03 vs 40,59 ± 25,39 percentage stimulation, p<0,05). On another set 
of experiments, rosiglitazone, a selective PPARgamma agonist, reverted the 
nutritionally-induced changes in NOS activity and corticosterone levels and 
decreased lipid infiltration in the adrenal tissue.
Conclusions: A sucrose enriched diet seems to induce IR at adrenal level 
after 7 weeks of treatment, generating morphological and functional distur-
bances that finally could lead to the dysregulation of adrenal steroidogenesis. 
In this sense, the increase in NOS activity could trigger posttranscriptional 
modifications of several proteins (nitration, S-nitrosilation etc). Among 
them, those involved in steroid biosynthesis and its regulation. Both COX-2 
and F4/80 could also be related to the chronic inflammatory state linked to 
IR in several tissues. Finally, some of these effects were prevented by rosigli-
tazone treatment, suggesting a signal transduction pathway that could be a 
target for pharmacological interventions designed to ameliorate this adrenal 
disfunction.
Supported by: ANPCyT-PICT 2008-1034-CONICET-UBACyT
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Glucose metabolism and cognitive dysfunction
A. Backeström1, S. Eriksson2, L.-G. Nilsson3, L. Nyberg4, T. Olsson5,  
O. Rolandsson1; 
1Department of Public Health and Clinical Medicine, Family Medicine, 
Umeå, 2Department of Community Medicine and Rehabilitation, Geriatric 
Medicine, Umeå, 3Department of Psychology, Psychology, Stockholm, 
4Department of Radiation Sciences, Umeå University, Psychology, 
5Department of Public Health and Clinical Medicine, Medicine, Umeå, 
Sweden.
Background and aims: The association between type 2 diabetes and different 
forms of cognitive impairment is well established. The mechanism behind the 
association is however still unrevealed. We have recently reported that raised 
blood glucose levels were associated to impairment in episodic memory, the 
memory function first affected in the progress to dementia. However, patients 
with type 2 diabetes have not only elevated levels of blood glucose, but also 
increased levels of insulin because of insulin resistance. It has been suggest-
ed that insulin itself might have a negative effect on cognitive function and 
memory. Diabetes is associated with a long standing hyperglycaemia but also 
with hypertension and hyperlipideima, leading to micro and macro vascular 
disease. Thus, our aim was to study whether insulin affects episodic memory 
independently of glucose in a nondiabetic adult population.
Materials and methods: We linked and matched two large population based 
data sets in Sweden, the Betula study and the Västerbotten Intervention Pro-
gram. We identified 364 (F/M 207/157, mean age 50.5 ±8.0 years) nondia-
betic subjects, free from dementia, who had participated in the two surveys 
within six months. The memory test included testing of episodic memory. 
We transformed the results using the mean values and standard deviation 
from the youngest age group to compute a composite z-score (subjects’ value 
minus mean score in the 40-year-old group divided by SD). Fasting plasma 
insulin (FPI) and glucose (FPG) were analyzed with standard methods.
Results: Women had higher levels of episodic memory (mean z-score -0.06, 
SD 0.54) compared to men (mean z-score -0.36, SD 0.51, p<0.001). Given the 
sex difference in the outcome variable we stratified for sex. In a univariate lin-
ear regression both FPG (B -0.274, SE 0.068, Beta -0.271, p<0.001) and FPI (B 
-0.389, SE 0.131, Beta -0.204, p=0.003) were significantly associated with epi-
sodic memory in women but not in men. FPG, but not FPI, remained signifi-
cantly associated with episodic memory after adjustment for hypertension, 
total P-cholesterol, bodymass index, educational level, depression, smoking 
and cardiovascular disease ( FPG: B -0.218, SE 0.070, Beta -0.220, p=0.002; 
FPI: B -0.232, SE 0.149, Beta -0.127, p=n.s.), when FPG and FPI were ana-
lyzed separately. Entering both FPG and FPI into the regression model did 
not attenuate the association between FPG and episodic memory (FPG: B 
-0.204, SE 0.071, Beta -0.206, p=0.005).
Conclusion: We conclude that an increase in plasma glucose, but not plasma 
insulin, is associated with impairment in episodic memory in women. This 
could be explained by a negative effect on the hippocampus caused by raised 
plasma glucose levels.
Supported by: The Västerbotten County Council
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Cognitive function in older adults with type 2 diabetes
E. Lopez Gonzalez, A. Luongo, A. Garcia, S. Milrad, M. Varela, M. Ruiz 
Morosini, DECOyDI; 
Sociedad Argentina de Diabetes, Buenos Aires, Argentina.
Background and aims: Several studies have reported increased risk of 
Cognitive Dysfunction (CD) and dementia in people with Type 2 Diabetes 
(DM2). The outcome of these research efforts indicate that several causes may 
affect CD, include many pathophysiologic mechanisms and risk factors. We 
investigated DM2 as a risk factor for CD when compared with control group. 
Describe the frequency of DC in patients with DM2 and its relationship to 
education, income, physical activity, alcohol consumption, cardiovascular 
risk factors and depression.
Materials and methods: Cognitive function was assessed using the test Mini 
Mental State Examination (MMSE) and defined by scores (normal 28-30, 
mild cognitive dysfunction (MCD) between 27 to 24, and severe cognitive 
dysfunction (SCD) 9 points and pathological 65 years old and control group. 
The study was carried out by 17 Argentinean doctors specialized in Diabetes 
from the provinces of Buenos Aires, Salta and Buenos Aires City (Argen-
tina). The evaluation included the following items: anthropometric measures, 
laboratory, level of education, life style and income. Chi2, Wilcoxon test and 
Multiple Logistic Regression were the tools used for the statistical analysis.
Results: 748 patients were included: DM2 (DMG) n=433 and control group 
(CG) n=315. Mean age=71.83 ± 5.58 in DMG and 71.79 ± 5.51 years in CG 
(p>0.92). In DMG the duration of diabetes 11.78 ± 9.17 years, the average 
HbA1c was 7.15 ± 2.73. The alcohol consumption was 48.73% in the DMG 
and 46.98% in CG. Education under 7 years was 40.8% in DMG vs. 35.67% 
in CG (p=0.39). The monthly income < 300 euros was 27.48% in DMG and 
27.94% in CG (p=0.87). Depression was present in 18.2% of DMG and 12.4% 
of CG. SCD was present in 21.3% of DMG and 14.6% of CG and MCD in 
35.3% of DMG and 31.7% of CG (p<0.0018). In women, diabetes acted as 
a risk factor for cognitive dysfunction (crude OR=2.13, 95% CI=1.46-3.11, 
p<0.0001). In men the mentioned above relation was not statistically sig-
nificant (crude OR=1.14, 95% CI=0.71-1.85; p=0.57). In multivariate analy-
sis, cognitive dysfunction in women was related with the presence of DM2 
(adjusted OR=1.91; CI=1.26-2.90; p=0.002), low education level (OR=3.96; 
CI=2.55-6.13, p<0.0001 ), low-income (OR=2.06; CI=1.29-3.26; p=0.002), 
depression (OR=1.83; CI=1.08-3.04, p=0.026) and alcohol use (OR=1.57M; 
CI=1.01-1.45; p=0.04). In multivariate analysis, independent predictors 
of cognitive decline in men were low education (OR=4.9; CI=2.28-6.88; 
p<0.0001), low-income (OR=2.33; CI=1.14-4.58; p=0.01) and age (OR=2.25; 
CI=1.08-3.20; p=0.02).
Conclusion: The outcomes of our study indicate that DM2 in women in-
creased the risk of CD. The low education level, low income, presence of de-
pression and alcohol consumption were independent risk predictors. DM2 in 
men was not a predictor of CD in this sample. Low education, low income, 
and age were independent risk predictors of CD in men.
Supported by: Argentine Society of Diabetes
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Brain volume changes in type 1 diabetes mellitus patients with 
microangiopathy are related to poorer cognitive functioning
E.H. Serné1, I.C. Sluimer2, H. Vrenken2, E. van Duinkerken3,4,  
R.G. IJzerman3, M. Klein4, F.J. Snoek4, F. Barkhof2, M. Diamant3; 
1Department of Internal Medicine, 2Department of Radiology, 3Diabetes 
Centre / Department of Internal Medicine, 4Department of Medical 
Psychology, VU University Medical Centre, Amsterdam, Netherlands.
Background and aims: Type 1 diabetes (T1DM) has been associated with 
lower amounts of brain volume as compared to matched healthy controls. 
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Furthermore, T1DM is associated with cognitive impairment, most pro-
nounced in patients with microangiopathy. Here, we hypothesized that brain 
volume loss would be most marked in T1DM patients with microangiopathy 
and would be associated with impaired cognitive functions. Using magnetic-
resonance imaging (MRI), we quantified grey and white matter volume and 
total brain volume and performed a neuropsychological assessment in 155 
T1DM patients with and without microangiopathy and matched healthy con-
trols.
Materials and methods: Fifty-one T1DM patients with and 53 without 
microangiopathy, and 51 matched healthy controls underwent a detailed 
neuropsychological assessment including the domains of general cognitive 
ability, memory, information processing speed, executive functions, atten-
tion, motor and psychomotor speed and a MRI-scan. This MRI-scan con-
sisted of 10 different sequences to detect differences in cerebral structure and 
function among which was a T1 Magnetization Prepared Rapid Gradient 
Echo (MP-RAGE) for the estimation of both grey and white matter volume 
and total brain volume. Volumes were estimated using the Structural Image 
Evaluation, using Normalisation, of Atrophy (SIENAX) tool in the FMRIB 
Software Library (FSL4.1). This tool enables reliable estimation of brain vol-
ume by controlling for differences in brain size.
Results: Both grey matter volume and total brain volume were significantly 
decreased in T1DM patients with microangiopathy, compared to T1DM pa-
tients without microangiopathy and healthy controls (both P < 0.05). Howev-
er, these differences were lost when controlling for age. In T1DM patients with 
microangiopathy a moderate positive correlations between motor speed and 
both white matter volume and total brain volume was found. T1DM patients 
without microangiopathy demonstrated a small positive correlation between 
motor speed and white matter volume (P < 0.05). In controls no correlations 
were found between brain volumes and cognitive function domains.
Conclusion: After correction of age, no differences in brain volume could 
be detected between T1DM patients with and without microangiopathy and 
healthy controls. Nevertheless, in T1DM patients positive correlations of 
MRI-measured brain volumes and motor speed could be demonstrated. These 
data may suggest that loss of brain volume is associated with poorer cognitive 
performance in this domain, although no causal relationships can be estab-
lished. Longitudinal studies are warranted to confirm and expand these find-
ings, to further detail the underlying mechanisms and to define their impact 
on patients, in terms of clinical consequences and quality of life.
Supported by: Dutch Diabetes Research Foundation
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Cerebral functioning is associated with carotid intima media thickness 
in uncomplicated type 1 diabetes mellitus
R.G. Ijzerman1, E. van Duinkerken1,2, M. Klein2, E.H. Serné3,  
N.S.M. Schoonenboom4, J. Boerop1, F.J. Snoek2, C.J. Stam4, M. Diamant1; 
1Diabetes Centre / Department of Internal Medicine, 2Department of 
Medical Psychology, 3Department of Internal Medicine, 4Department of 
Clinical Neurophysiology / MEG Centre, VU University Medical Centre, 
Amsterdam, Netherlands.
Background and aims: Measures of subclinical atherosclerosis, including ca-
rotid intima media thickness (cIMT), have shown to negatively affect brain 
function and structure in the general population. In type 1 diabetes (T1DM), 
an increased cIMT has been reported, but it is unknown whether cIMT is 
associated with cerebral function and activity in these patients and whether 
this association is affected by the additional presence of microvascular com-
plications.
Materials and methods: We investigated 51 T1DM patients with prolifera-
tive diabetic retinopathy or other microvascular complications, as a marker 
of microangiopathy (DRP), 54 without microangiopathy (non-DRP), and 
51 gender-matched controls. We measured cIMT using ultrasound and 
neuropsychological functions like memory, information processing speed, 
executive functions, attention, motor and psychomotor speed and general 
cognitive ability. Functional brain connectivity, an estimate of cerebral com-
munication, was assessed using magnetoencephalography. Linear regression 
was used to determine the association between cIMT, cognitive functions and 
functional connectivity.
Results: In the non-DRP group, but not in DRP patients, cIMT was nega-
tively associated with general cognitive ability, information processing speed 
and attention (all P<0.05). Also, in non-DRP patients a positive association 
of cIMT and functional connectivity for the delta-band, representing com-
munication within both hemispheres and a negative association for the upper 
gamma-band, regarding interhemispheric communication were found (both 
P<0.05). Except for information processing speed all associations were inde-
pendent of age, gender, diabetes duration and onset age.
Conclusion: In uncomplicated T1DM patients, but not in patients with 
microangiopathy, cIMT was inversely associated with cognitive functioning 
and related to aspects of functional connectivity, previously linked to cerebral 
pathology and changes in cognitive functions. Taken together, these findings 
suggest that, in T1DM patients without microangiopathy, subclinical athero-
sclerosis may exert a negative effect on the brain, whereas in T1DM with 
microangiopathy the impact of cIMT seems subordinate to other factors.
Supported by: Dutch Diabetes Research Foundation
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Comprehensive neuropsychological assessment of patients with 
longstanding type 1 diabetes mellitus with and without microangiopathy
M. Klein1, E. van Duinkerken2,1, M. Diamant2, E.H. Serné3, R.G. IJzerman2, 
F.J. Snoek1; 
1Department of Medical Psychology, 2Diabetes Centre / Department of 
Internal Medicine, 3Department of Internal Medicine, VU University 
Medical Centre, Amsterdam, Netherlands.
Background and aims: Type 1 diabetes (T1DM) is associated with mild cog-
nitive decrements, and more so in the presence of proliferative retinopathy 
(DRP) as was shown in a small study comparing DRP patients with patients 
without DRP (non-DRP) and controls. In the present study, we hypothesized 
that T1DM patients with DRP would show cognitive decrements compared 
to T1DM patients without DRP and other microvascular complications and 
controls.
Materials and methods: Fifty-one DRP patients, 54 non-DRP patients and 
51 controls underwent a comprehensive neuropsychological assessment, cov-
ering the domains general cognitive ability, memory, information processing 
speed, executive functions, attention, motor and psychomotor speed. Prior to 
assessment, blood glucose level of T1DM patients had to be in the range of 
4-15 mmol/l and hypoglycaemic events 24 hours prior to assessment resulted 
in rescheduling the assessment. MANCOVA corrected for age, depressive 
symptoms and multiple comparisons was used to determine group differenc-
es and regression analysis to identify determinants of cognitive decrements.
Results: T1DM patients as one group compared to controls showed decre-
ments in general cognitive ability, memory, information processing speed, 
motor and psychomotor speed (all P¬<0.05). Effect sizes ranged from 0.3 
- 0.6. Gender, proliferative DRP, blood pressure and blood glucose level 
were independent predictors of these decrements. When separating both 
T1DM patient groups, DRP patients were found to be oldest, reported most 
depressive symptoms, had longest disease duration and earliest age of dia-
betes onset. Both non-DRP and DRP patients showed reduced information 
processing speed compared to controls, with DRP patients showing the larg-
est deterioration. DRP patients also showed decrements in memory, motor 
and psychomotor speed compared to controls and in attention and general 
cognitive ability compared to non-DRP and controls (all P¬<0.05).
Conclusion: In this large sample, we showed that T1DM patients as com-
pared to controls are susceptible to cognitive decrements. Furthermore, pa-
tients with DRP seem to be at the highest risk to develop cognitive decre-
ments. Interestingly, patients without microangiopathy appear also suscepti-
ble to loss of processing speed, suggesting that selective cognitive functions 
are affected before microangiopathy becomes manifest.
Supported by: Dutch Diabetes Research Foundation
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Apical sodium-dependent bile transport inhibitors is identified as 
potential antidiabetic agents: parallels with metformin
B.R. Gedulin, G. Gedulin, E.K. Austin, A.A. Young; 
Physiology, Satiogen Pharmaceuticals Inc., San Diego, USA. 
Background and aims: The presence of bile acids (BA’s) in the distal gut pow-
erfully stimulates secretion of GLP-1 and other peptides from enteroendo-
crine L-cells. An effect of metformin is the inhibition of bile acid reuptake, 
which is mediated via apical sodium-dependent bile transporters (ASBT) in 
the ileum. Especially in the presence of dipeptidyl peptidase-IV inhibition 
(DPP4i), metformin stimulates secretion of L-cell products, including GLP-
1.
Materials and methods: To probe the hypothesis that metformin’s therapeu-
tic effects are mediated via ASBT inhibition, we compared the dose-depend-
ence of secretion of active GLP-1 in fasted normal rats pre-treated with a 
DPP4i (sitagliptin) and orally administered metformin (0, 30, 100, 300 mg/
kg) or a non-absorbable ASBTi (SC-435; doses 0, 3, 30, 100 mg/kg). In db/db 
mice we tested the effects of orally administered metformin (0, 3, 30, 100, 300 
mg/kg; n=5-12/group) and SC-435 (0, 3, 30, 100 mg/kg; n=9-12/group) on 
glucose level and 48 hour body weight.
Results: SC-435 dose-dependently increased 5-hour integrated GLP-1 con-
centrations 2.5 to 3.2 fold (-/+ DPP4i, respectively) vs vehicle, and metformin 
evoked 3.3 to 4.3 fold increases. SC-435 was ~1.6 fold more potent than met-
formin. Peak [GLP-1] of 30-36 pM observed 4-5 hours after metformin or 
SC435 in the present studies may promote antidiabetic and weight-loss ef-
fects otherwise only attainable with injected GLP-1 agonists. In db/db mice, a 
7.9 mg/dL reduction in 24-hour plasma glucose invoked by 30 mg/kg valine-
pyrolidide (a DPP4i) was amplified up to 3.8 fold by the addition of SC-435 
This exceeded the antidiabetic effect of metformin in this model. Both SC-
435 and metformin (+DPP4i) dose-dependently reduced body weight (by up 
to 5.2%, 4.3% respectively) over 48 hours in db/db mice, SC 435 being 10.5 
fold more potent.
Conclusion: In summary, the parallel behavior of metformin and a non-re-
sorbable bile salt transport inhibitor to stimulate GLP-1 secretion, to lower 
plasma glucose, to lower body weight, and to elevate BA’s in the distal bowel, 
are consistent with their actions being via indirect L-cell stimulation with 
BA’s. These studies further identify ASBTi’s, including those without systemic 
exposure, as a potentially new class of oral antidiabetic antiobesity agent.
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Effects of angiotensin II on receptor mediated insulin transcytosis in 
bovine aortic endothelial cells
W.C. Ha1, S.J. Oh1, J.I. Lee1, J.H. Kim1, S.A. Chang1, O.K. Hong1, B.Y. Cha1, 
H.W. Lee2, H.S. Son1; 
1The Catholic University of Korea, Seoul, 2Yeungnam University Medical 
Center, Daegu-si, Republic of Korea. 
Background and aims: Angiotensin II(ATII) is involved in the pathogenesis 
of hypertension and increases insulin resistance. It is known that the main 
role of insulin receptor in endothelial cells is to deliver insulin to target tissue 
by a series of process - binding of insulin on insulin receptor, internalization 
of insulin-insulin receptor complex and releasing of insulin around target 
tissue - called receptor mediated transcytosis. We investigated the effects of 
ATII on receptor mediated insulin transcytosis in endothelial cell.
Materials and methods: After treating with {insulin alone}, {insulin and 
ATII}, {insulin, ATII and angiotensin receptor blocker(ARB)} on bovine aor-
tic endothelial cells, we observed the change of the total amount of insulin re-
ceptor, the amount of insulin receptor on membrane and in cytosol, binding 
of insulin on insulin receptor and internalization of insulin-insulin receptor 
complex, time dependently.
Results: 1) Insulin increased the total amounts of insulin receptor, binding 
of insulin on insulin receptor and internalization of insulin-insulin receptor 
complex. 2) ATII decreased the total amount of insulin receptor, and it de-
creased the binding of insulin on insulin receptor up to 70 %. 3) After treating 
with ATII, the amount of insulin receptor on cell membrane was decreased 
but the amount of insulin receptor in cytosol was increased, time depend-
ently. 4) ATII decreased the internalization of insulin-insulin receptor com-
plex, but the difference is imperceptible. 5) ARB improved the ATII- induced 
reduction of binding of insulin on insulin receptor up to 30 %.
Conclusion: It seems that ATII inhibits the receptor mediated insulin trans-
cytosis in endothelial cell by reducing the binding of insulin on insulin recep-
tor, and ARB improves this inhibitory effect. We think that this inhibitory 
effect is due to reduction of the amount of insulin receptor on cell membrane 
by reduction of the expression of insulin receptor and increase of the trans-
location of insulin receptor from cell membrane to cytosol. As a result, the 
delivery of insulin around target tissue is decreased, and this may explain 
partially insulin resistance by ATII.
737
Taurine improves hepatic insulin resistance induced by free fatty acid 
through inhibiting c-Jun NH2-terminal kinase 1(JNK1) pathway and 
improving insulin signalling
N. Wu, P. Han, S. Zhao, L.l. Zhou, Y. Li; 
Department of Endocrinology, Shengjing Hospital of China Medical 
University, China. 
Background and aims: It is well established that elevated circulating free 
fatty acids (FFA) can induce hepatic insulin resistance, which is the primary 
contributor to increased hepatic glucose production and overt hyperglycemia 
in type 2 diabetes. However, the exact mechanism by which FFAs cause insu-
lin resistance in the liver is not completely known, but may involve oxidative 
stress. Intralipid plus heparin (IH) infusion is a standard nontoxic method to 
elevate FFA levels in vivo. Therefore, we established an in vivo model of insu-
lin resistance by prolonged (48h) IH infusion in wistar rats. And co-infusion 
with taurine (an antioxidant) was designed to investigate the effects of taurine 
on hepatic insulin resistance, and to explore the potential mechanism of IH-
induced hepatic insulin resistance in prolonged lipid infusion model.
Materials and methods: Cannulated rats (n=12-14/group) were infused for 
48h intravenously with saline(SAL), or intralipid plus heparin (IH), or IH 
plus taurine (IHT), or taurine (TAU). Half of each group rats were randomly 
assigned to either the basal group or a clamp group. During the last 2h of 
the 48h infusion, hyperinsulinemic-euglycemic clamps with [6-3H] glucose 
infusion (20μCi bolus followed by constant infusion at 0.4 μCi/min) were 
performed to assess hepatic insulin sensitivity. Oxidative stress measured 
as the concentration of 8-Iso-Prostaglandin F2a (8-iso-PGF2α) in liver was 
analyzed using anenzyme-linked immunoassay (ELISA) commercial kit. We 
evaluated JNK1 activation, insulin-stimulated IRS-1 tyrosine phosphoryla-
tion and insulin-stimulated IRS-2 tyrosine phosphorylation in the liver by 
immunoprecipitation and immunoblotting.
Results: The results showed during hyperinsulinemic-euglycemic clamp, IH 
infusion induced hepatic insulin resistance as indicated by elevation of HGP 
compared with SAL. Taurine prevented the elevation of HGP induced by IH 
infusion (HGP in umol/kg.min, SAL: 25±4 , IH: 71±6 , IHT: 30±7 , TAU: 26± 
4 , p<0.05 IH vs. other treatment groups). This indicates that IH-induced 
hepatic insulin resistance was abolished with taurine co-infusion. Further-
more, taurine co-infusion reversed IH-induced 1) increase in 8-iso-PGF2α, 
2) increase in JNK1 activity, 3) decrease in insulin-stimulated tyrosine phos-
phorylation of IRS-2 in liver. Insulin-stimulated tyrosine phosphorylation of 
IRS-1 in liver did not differ among the four groups in this study.
Conclusion: In summary, prolonged IH-infusion induced the impairment of 
hepatic insulin sensitivity probably by activating JNK1 pathway and reducing 
the insulin-stimulated tyrosine phosphorylation of IRS-2 in liver. Taurine, 
as an antioxidant, prevented hepatic insulin resistance might also associated 
with inhibiting JNK1 and increasing insulin-stimulated tyrosine phosphory-
lation of IRS-2 in vivo.
Supported by: Education Bureau of Liaoning Province, China
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Probiotic Bifidobacterium lactis 420 reverses diabetic status in 
mice under high-fat diet by reducing plasma endotoxin and tissue 
inflammation
R. Burcelin1, S. Lahtinen2, A. Waget1, P. Klopp1, C. Vachoux1, K. Olli2, D. 
Carcano3, J. Amar4, N. Rautonen2; 
1Functional Genomics, Inserm U858, Toulouse, France, 2, Health & 
Nutrition, Danisco Bioactives, kantivik, Finland, 3Danisco Bioactives, Paris, 
France, 4Department of Therapeutics, Toulouse, France.
Background and aims: It has been proposed that alterations in the intestinal 
microbiota may be causally involved in high-fat diet (HFD)-induced meta-
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bolic diseases. Therefore, an efficient probiotic treatment should modifies the 
deleterious impact of the fat-enriched diet on the occurrence of diabetes.
Materials and methods: We here daily treated insulin resistant HFD mice 
with 10-8 to 10-10 Bifidobacterium lactis 420 daily for 6 weeks.
Results: The probiotic treatment dose dependently reduced glucose intoler-
ance. The treatment with 109cells daily reduced the impact of HFD on body 
fat mass, mesenteric adipose tissue mass, fasted hyperinsulinemia, and in-
sulin resistance as assessed by the euglycemic clamp technique. Conversely, 
fed insulin secretion was improved. This improved glucose metabolism was 
associated with a lowering of plasma LPS concentration i.e. metabolic endo-
toxemia. Similarly, liver and adipose tissue cytokine mRNA expression (Il6, 
TNFa, IL1, PAI-1) were reduced. Interestingly, we detected bacteria in the 
mesenteric adipose depot of HFD mice when compared with normal chow 
whereas the subcutaneous fat was mostly unaffected. Among these bacteria, 
the Enterobacteriaceae (LPS containing bacteria) were mainly increased. The 
probiotic treatment reduced this enrichment. We then explored that a change 
in intestinal epithelial cells permeability could be at the origin of the translo-
cation of intestinal bacteria towards the adipose tissue in response to a HFD. 
Our data show that the probiotic extract or supernatant regulates the trans-
epithelial electrical resistance in vitro on Caco2 cells.
Conclusion: Altogether our data suggest that Bifidobacterium lactis 420 
treatment improved glucose metabolism of HFD-induced diabetic mice by 
reducing intestinal bacterial translocation, metabolic endotoxemia, and adi-
pose tissue inflammation.
739
Discovery of a compound with potent efficacy on the activation of AMPK 
and treatment of type 2 diabetes
Y. Leng, S. Huang, Y. Feng, Y. Shen, Y. Hu; 
Shanghai Institute of Materia Medica, Chinese Academy of Sciences, China.
Background and aims: Glucose uptake in skeletal muscle plays a key role in 
the maintaining glucose homeostasis. YL01 was discovered from our com-
pound collections which could increase glucose uptake in L6 myotubes. In 
the present study, the in vivo anti-diabetic effect of YL01 was evaluated and 
its possible mechanisms were explored.
Materials and methods: D-2-[3H]deoxyglucose uptake and [3H] palmitate 
oxidation assay were performed to examine the effects of YL01 on the glucose 
uptake and free fatty acid oxidation in L6 myotubes. Activation of YL01 on 
the AMPK and insulin signaling pathway was investigated by western blot 
analysis. For in vivo study, YL01 was administered orally to ob/ob mice at the 
dose of 200mg/kg for 23 days. Metformin was used as positive control.
Results: YL01 dose dependently enhanced the glucose uptake and free fatty 
acid oxidation in L6 myotubes. Incubation of L6 myotubes with 3μM YL01 
resulted in a 1.8 and 1.5 fold increase in basal glucose uptake and free fatty 
acid oxidation, respectively. YL01 showed no effect on Akt phosphorylation, 
but significantly increased AMPK and ACC phosphorylation in L6 myo-
tubes. However, YL01 could not directly activate the recombinant AMPK 
kinase. The YL01 induced glucose uptake and fatty acid oxidation could be 
fully blocked by the pretreatment with compound C, an AMPK inhibitor. 
Oral administration of YL01 significantly reduced both of the non-fasting 
and fasting blood glucose levels and improved the impaired glucose toler-
ance of ob/ob mice. Moreover, the HbA1c levels in ob/ob mice also showed a 
decrease tendency after 23 days treatment with YL01 although it didn’t reach 
statistic significance.
Conclusion: YL01 exerts antidiabetic effect on ob/ob mice, which suggested 
that it might be a therapeutic candidate for the treatment of T2DM and meta-
bolic syndrome. Indirect activation of AMPK might be one of the possible 
mechanisms of this effect.
740
AT1-receptor blockade and insulin sensitivity in hypertensive subjects: 
the role of capillary recruitment
A.M. Jonk1, A.J.H. Houben1, N.C. Schaper1, P.W. de Leeuw1, E.H. Serné2, 
Y.M. Smulders2, C.D.A. Stehouwer1; 
1Dept of Internal Medicine, Maastricht University Medical Centre, 
Netherlands, 2Dept of Internal Medicine, VU Medical Center, Amsterdam, 
Netherlands.
Background and aims: Blocking the renin-angiotensin system (RAS) im-
proves insulin sensitivity in hypertensive subjects. However, the underlying 
mechanisms are undefined. An effect of insulin that is crucial for stimulating 
glucose uptake is the ability of insulin to regulate its own delivery, and that of 
glucose, to muscle cells via recruitment of the microvasculature. This study 
was designed to investigate the effect of acute angiotensin II AT1-receptor 
blockade (ARB) on insulin-mediated microvascular function and insulin-
mediated glucose uptake in hypertensive subjects.
Materials and methods: A randomised, double-blind placebo-controlled tri-
al was performed in 15 untreated mildly hypertensive subjects (BMI 26.9±2 
kg/m2; BP 150/92 mmHg), to examine the effects of acute ARB treatment 
(irbesartan, 600mg, oral single dose) or Ca2+-blockade (felodipine, 10mg 
idem) as a pressor control on insulin-induced microvascular function and on 
insulin-mediated whole body glucose uptake (WBGU, mg/kg/min) during 
a hyperinsulinaemic euglycaemic clamp (50mU/kg/h). Effects of irbesartan 
and felodipine were compared to placebo. Skin capillary density (n/mm2) and 
capillary recruitment (peak n/mm2 during post-occlusive reactive hyperae-
mia, PRH) were measured with capillaroscopy. All subjects were tested on a 
low sodium diet (100 mmol/day).
Results: Compared to the basal state, hyperinsulinaemia increased baseline 
capillary density (56.8±7.1 vs. 60.2±8.3 n/mm2, P<0.02). Relative to placebo, 
irbesartan, but not felodipine, increased insulin-induced capillary density (Δ 
cap density (median (interquartile range) +3.5 (-1.3 - +5.0) n/mm2, P<0.02). 
Insulin-induced capillary recruitment was not altered by either treatment. 
Neither irbesartan nor felodipine enhanced WBGU.
Conclusion: Our data demonstrate that acute AT1-receptor blockade aug-
ments insulin-induced capillary density in mildly hypertensive subjects. Al-
though glucose uptake did not increase significantly, the increased insulin-
induced microvascular function found with ARB might point to improved 
insulin and glucose delivery as the underlying mechanism for the improved 
insulin sensitivity with longterm ARB treatment.
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Ciliary neurotrophic factor increases plasmatic insulin half-life and 
improves metabolic profile in a non-insulin resistance type 2 diabetes 
mellitus model
G.J. Santos, C.A.M. Oliveira, E.M. Carneiro, A.C. Boschero, L.F. Rezende; 
Department of Anatomy, Cell Biology and Physiology and Biophysics, State 
University of Campinas, Brazil.
Background and aims: Type 2 diabetes mellitus (DM2) is characterized by 
impaired insulin sensitivity and secretion, leading to hyperglycaemia. CNTF 
is a cytokine that improves metabolic profile in obesity-induced and insulin 
resistant DM2 models, allegedly through an increase in insulin sensitivity. 
Besides that, CNTF promotes in vitro pancreatic islet survival. Given that, 
we decided to evaluate the role of functional beta cell mass maintenance by 
CNTF in a non-insulin resistant DM2 model. Insulin clearance is an impor-
tant process that plays a role in controlling insulin action, usually evaluated as 
plasmatic insulin half-life. Abnormalities in this process are involved in many 
metabolic disorders, particularly in DM2.
Materials and methods: Neonate Swiss mice received intra-peritoneal in-
jection of Citrate buffer (CTL), CNTF 0,1mg/Kg (CNTF), Alloxan 250mg/
Kg (ALOX) or a combination of both (CNTF+ALOX). We performed an 
intraperitonal glucose tolerance test (ipGTT) in p26 and an intraperitonal 
insulin tolerance test (ipITT) in p28. Plasma glycaemia was assessed by a 
Roche Accu-Chek II Glucometer. Plasma insulin was assessed by Radioim-
munoassay (RIA). Data are expressed as mean +/- SEM, and p<0,05.
Results: Alloxan-treated mice were hyperglycaemic and glucose intolerant, 
indicating that they are diabetic (DM2). Nevertheless glycaemia decrease 
after ipITT was similar to CTL, therefore they were not insulin resistance. 
CNTF+ALOX mice had lower fasting and similar fed glycaemia than CTL. 
Besides the glycaemia decreased after ipITT was similar to CTL. CNTF in-
creased plasmatic insulin half-life in both CNTF and CNTF+ALOX groups 
(Figs.3-4), despite the fact that its impairs pancreatic islet glucose-stimulated 
insulin secretion.
Conclusion: The results indicate that CNTF improved metabolic profile in 
non-insulin resistant DM2 model, similarly to other insulin resistant models, 
such as obesity, suggesting that CNTF protective effects might involve mech-
anisms other than just increased insulin sensitivity, specially by increased 
plasmatic insulin half-life, and supposedly also through functional beta cell 
mass maintenance.
Supported by: FAPESP/CNPq
742
Direct effects of FGF 21 on glucose uptake in human skeletal muscle: 
implications for type 2 diabetes and obesity
F.L. Mashili1, R.L. Austin2, A.S. Deshkmukh3, T. Fritz4, K. Caidahl2,  
K. Bergdahl2, Z.R. Juleen2, D.E. Moller5, A. Kharitonenkov5, A. Krook1; 
1Physiology and Pharmacology, Karolinska Institute, Stockholm, Sweden, 
2Molecular medicine and surgery, Karolinska institute, Stockholm, Sweden, 
3Molecular medicine and aurgery, Karolinska institute, Stockholm, Sweden, 
4Family medicine, Karolinska institute, Stockholm, Sweden, 5Lilly Research 
Laboratories, Indianapolis, USA.
Fibroblast growth factor (FGF)-21, a novel member of the FGF family, plays 
a role in a variety of endocrine functions, including the regulation of glucose 
and lipid metabolism. We assessed serum levels of FGF-21 and skeletal mus-
cle mRNA in normal glucose tolerant (NGT; n=40) type 2 diabetic patients 
(n=40). We also determined whether FGF-21 has a direct effect on glucose 
metabolism in cultured myotubes from NGT subjects (n=8) and adult exten-
sor digitorum longus (EDL) skeletal muscle. Serum FGF-21 levels were in-
creased 20% in type 2 diabetic versus NGT subjects, whereas skeletal muscle 
mRNA expression was unaltered. Fasting insulin, HOMA-IR, waist circum-
ference and BMI were significantly correlated with serum fasting FGF-21 lev-
els in type 2 diabetic, but not NGT subjects (p<0.01). Serum FGF-21 concen-
trations were significantly greater in the type 2 diabetic patients in the highest 
tertile of fasting insulin (p<0.05) and BMI (p<0.05). Stepwise regression anal-
ysis further identified BMI as the strongest independent variable that posi-
tively correlated with FGF-21 levels. FGF-21 exposure increased basal and 
insulin-stimulated glucose uptake in primary human myotubes, coincident 
with increased GLUT1 mRNA. In isolated EDL muscle, FGF-21 potentiated 
insulin-stimulated glucose transport, without altering phosphorylation of in-
sulin or AMPK signaling. In conclusion plasma FGF-21 is increased in type 
2 diabetic patients, and positively correlated with fasting insulin and BMI. 
Moreover, FGF-21 has a direct effect on skeletal muscle glucose uptake.
Supported by: SRC, ERC, SRF and The Novo-Nordisk Faundation
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Characterisation of FGF19, FGF21, and FGF23 stimulated FGFR1/4 
activation
M. Sommerfeld1, K. Klein1, C. Kleinmann1, K. Kleinschmidt1, S. Risch2,  
O. Boscheinen2, H.-L. Schäfer1; 
1BD Diabetes, Sanofi-Aventis, 2Protein Production, Sanofi-Aventis, 
Frankfurt am Main, Germany.
Background and aims: The members of the FGF19-family including FGF19, 
FGF21, and FGF23 play a distinct role from the other FGFs based on their en-
docrine action and the necessity of a co-receptor. These proteins exert a wide 
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variety of metabolic activities like the regulation of bile acid, carbohydrate 
and lipid metabolism as well as phosphate, calcium and vitamin D homeosta-
sis via binding to and activation of FGF receptors (FGFR) in presence of α-
Klotho (KL) or β-Klotho (KLB). Aim of the present study was to characterize 
the activation of FGFR1 and FGFR4 in presence or absence of KL or KLB by 
FGF19, FGF21, and FGF23.
Materials and methods: The FGF induced FGFR autophosphorylation was 
measured via in-cell western (ICW) in CHO cells overexpressing either hu-
man FGFR1c short or long form, or FGFR4 in presence or absence of KL or 
KLB. ERK phosphorylation as a downstream signalling readout for FGFR 
activation was analysed by ICW in human primary visceral adipocytes. Time 
dependent in vivo signalling of FGF21 in WAT and liver of C57bl6/J mice was 
analysed using ELISA after s.c. injection of 0.6 mg/kg FGF21.
Results: We established a specific and highly sensitive ICW assay for direct 
analysis of the FGF induced FGFR autophosphorylation in CHO cells over-
expressing different human FGFR ± KL/KLB. EC50 values were obtained 
from dose-response curves and are summarized in table 1. In these CHO 
cells FGF1 and FGF2 activated either FGFR1 or -4 independent of KL/KLB. 
FGF19 activated only FGFR4 in presence of KL or KLB. In contrast FGF21 
activated the long and short form of FGFR1c efficiently only in complex with 
KLB. FGF21 was also able to stimulate FGFR4-KLB but was 4 times less po-
tent than FGF19. FGF23 needed the co-receptor KL for an efficient activation 
of FGFR1 and -4. The analysis of ERK phosphorylation in human primary 
visceral adipocytes which express mainly FGFR1 and KLB demonstrated that 
in addition to FGF2 only FGF21 was able to activate FGFR signalling. After 
s.c. injection of FGF21 in mice a comparable ERK activation was found in 
fat tissue. No ERK activation was detectable in liver where predominantly 
FGFR4 is expressed. Contrary to this in WAT FGF21 stimulated a fast in-
crease, reaching a maximum after 30-60 minutes. The decreasing signal was 
detectable even up to 8 hours.
Conclusion: Using cell lines overexpressing FGFR and co-receptors we could 
demonstrate that all members of the FGF19-family require the presence of 
KL or KLB for an efficient signalling through a particular FGFR isoform, 
e.g. FGF21 only activates FGF signalling in adipocytes that primarily express 
FGFR1, but not FGF19 or FGF23. We conclude that the expression of KLB 
and KL, in combination with particular FGFR isoforms, determines the tis-
sue-specific metabolic activities of the FGF19-family.
Summarized in vitro data for FGF induced FGFR phosphorylation in CHO cells & in human adipocytes
Cell line CHO R1cS CHO R1cS+KL CHO R1cS+KLB CHO R1cL+KLB CHO R4 CHO R4+KL CHO R4+KLB human visceral 
Adipocytes
(nmol/L) (nmol/L) (nmol/L) (nmol/L) (nmol/L) (nmol/L) (nmol/L) (nmol/L)
FGF1 7.6±4.2 - 0.8±0.2 - 11.2±9.0 - 13.6±7.4 -
FGF2 1.4±0.2 2.2±0.8 0.9±0.2 1.6±0.5 15.6±10.4 8.0±3.0 19.0±11.2 0.04±0.007
FGF19 >250 >250 >250 >250 >250 63±14.1 54±5.9 >250
FGF21 >250 >250 3.1±0.3 12.8±5.9 >250 >250 213±60 0.81±0.19
FGF23 >250 1.7±0.4 >250 >250 >250 12.1±5.3 >250 >250
744
Effects of short-term continuous subcutaneous insulin infusion on 
fasting plasma Vaspin levels in patients with new-onset type 2 diabetes 
mellitus
L. Ling1,2, G. Yang3, K. Li3; 
1The Key Laboratory of Laboratory Medical Diagnostics in the Ministry 
of Education, 2Department of Clinical Biochemistry, 3Department of 
Endocrinology, the Second Affiliated Hospital, Chongqing Medical 
University, China.
Background and aims: Visceral adipose tissue-derived serine protease in-
hibitor (Vaspin) has recently been characterized as an insulin-sensitizing 
adopokine. However, the roles of this factor in humans remain unknown. 
This study was aimed to investigate the effects of short-term continuous sub-
cutaneous insulin infusion (CSII) on plasma vaspin levels in patients with 
severe newly diagnosed type 2 diabetes.
Materials and methods: Thirty patients with severe newly diagnosed type 
2 diabetes (T2DM), 37 subjects with impaired glucose regulation (IGT) and 
38 sex-, age- and BMI-matched normal controls (NGT) participated in the 
study. T2DM group was treated with CSII for 2 weeks. Euglycemic-hyper-
insulinemic clamps (EHC) were performed in 16 subjects of T2DM group. 
Plasma vaspin concentrations were measured with a commercial ELISA kit. 
The relationship between plasma vaspin levels and metabolic parameters was 
also analyzed.
Results: Fasting plasma vaspin levels were higher in T2DM than in and 
IGT and NGT groups (1.83+/-0.55 vs. 0.43+/-0.21 vs. 0.56 +/-0.26microg/L, 
P<0.05), but there was no difference between IGT and NGT groups. Fasting 
plasma vaspin concentrations were decreased significantly in T2DM group 
after two-week CSII treatment (1.83+/-0.55 vs. 1.19+/-0.57microg/L, P<0.05) 
accompany with significant amelioration of insulin sensitivity and glucose 
control. Changes in circulating vaspin concentrations were correlated posi-
tively with those of insulin sensitivity.
Conclusion: In T2DM patients, plasma vaspin levels are elevated, but sig-
nificantly decreased after CSII treatment. These data suggest that vaspin play 
may a role in insulin sensitivity of diabetic humans.
Supported by: National Natural Science Foundation of China (30370671, 
30771037, 30971388)
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Omentin, a novel visceral fat depot-specific secretory protein, enhances 
insulin-stimulated glucose uptake, in peripheral monocytes, in patients 
with type 2 diabetes
E. Maratou1, E. Boutati2, M. Peppa2, V. Lambadiari2, P. Mitrou1,  
F. Spanoudi2, G. Dimitriadis2, S.A. Raptis1,2; 
1Hellenic National Diabetes Center, 22nd Department of Internal Medicine, 
Research Institute and Diabetes Center, Athens University, “Attikon” 
University Hospital, Greece.
Background and aims: Omentin is an adipocytokine, selectively expressed 
and secreted from visceral adipose tissue. Its biological action is not clear, 
but it is speculated that it has a beneficial effect on insulin action, since it 
has been shown to increase insulin signal transduction and to enhance insu-
lin-stimulated glucose transport. Omentin plasma levels have been inversely 
correlated with indicators of metabolic risk, such as body mass index and 
HOMA. The present study investigates the effect of omentin on glucose up-
take in peripheral monocytes from patients with type 2 diabetes (DM) and 
normoglyceamic subjects (NG).
Materials and methods: Blood (20ml) was withdrawn from 10 treatment-
naive patients with type 2 diabetes (BMI 23±2kg/m2, age 52±5years), and 8 
healthy volunteers (BMI 22±2kg/m2, age 50±6years). Circulating monocytes 
were incubated for 1 hour with insulin (0, 25 and 100mU/l) or/and omentin 
(100, 300ng/ml) to determine the abundance of GLUT4 on the plasma mem-
brane. Cells were stained with antiGLUT4 antisera. Glucose uptake was assayed 
with the addition of insulin and/or omentin and the fluorescent analogue of 
glucose 6-NBDG and was monitored until plateau was reached. The abundance 
of surface GLUT4 and the glucose uptake were studied by flow cytometry. Sta-
tistical analysis of glucose uptake in response to omentin, insulin and their 
combination was performed by repeated-measures ANOVA. The comparison 
between the increments of surface GLUT4 from baseline (absence of insulin 
or omentin) to maximal hormonal challenge was carried out by paired t-test. 
Comparisons between DM and NG were performed using unpaired t-test.
Results: In monocytes from NG, insulin increased glucose uptake in a dose-
dependent manner (P<0.001), as well as the recruitment of GLUT4 (P<0.001). 
Omentin per se, had no significant effect on either glucose uptake or GLUT4 
and showed no additive effect with insulin. In DM, insulin increased glucose 
uptake, although to a lesser degree than in NG. In DM, omentin (300ng/ml), 
when added to 25 or 100uU/ml insulin, enhanced glucose uptake compared 
to 100uU/ml insulin (P<0.05 and P<0.01, respectively). This enhancement 
was supported by increments of GLUT4 (10.6±2.6% for 300ng/ml omentin 
+25uU/ml insulin, 15.9±4.4% for 300ng/ml omentin +100uU/ml insulin vs 
7.9±2.8% for 100uU/ml insulin, P<0.05).
Conclusions: Omentin had no additive effect to insulin in monocytes from 
NG. On the other hand in DM, where insulin’s action was defective, omentin 
enhanced insulin-stimulated glucose uptake in monocytes, partially compen-
sating insulin’s failure to produce a maximal effect. 
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NBDG uptake  
(%increment  
from blank)
w/o insulin, 
omentin
25uU/ml 
insulin
100 uU/ml 
insulin
100ng/ml 
omentin
100ng/ml 
omentin+
25uU/ml 
insulin
100ng/ml 
omentin+
100uU/ml 
insulin
300ng/ml 
omentin
300ng/ml  
mentin+
25uU/ml 
insulin
300ng/ml 
omentin+
100uU/ml 
insulin
Diabetics (DM) 28.97±3.1 35.84±2.1+ 37.52±2.4++ 34.67±1.42+ 38.22±3.41++ 44.48±2.92+++ 33.02±2.92 43.23±1.91*,++ 48.6±3.05**, +++
Normoglyceamic 
(NG) 32.91±2.9 51.3±5.1
++, a 62.96±6.5+++,aa 38±5.8 52±6.3++,a 62±5.36+++,aa 44.45±8.27 55.47±6.44++,a 65±5.96+++,a
*p<0.05, **p<0.01 vs 100 uU/ml Insulin
+p<0.05, ++p<0.01,+++p<0.001 vs 0 uU/ml Insulin
a p<0.05, aap<0.01 vs respective value of DM
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Acute effects of estrogen receptor agonists on vascular reactivity of 
diabetic ovariectomised rats
G. Ozansoy, T. Akhayeva, N. Arı; 
Department of Pharmacology, Ankara University, Faculty of Pharmacy, 
Turkey.
Background and aims: Estrogen protects against cardiovascular disease in 
premenopausal women. These cardioprotective effects are absent in diabetic 
and postmenopausal women. But the relative role of estrogen receptors (ER-
alpha; ER-beta) is not clear in estrogen-induced vasorelaxation of these situ-
ations. The aim of the study was to determine how individual estrogen recep-
tor isoforms modulate vascular reactivity in diabetic ovariectomized rats.
Materials and methods: 4 groups of Wistar rats have been used in this study. 
Control group (C;n=8), ovariectomized group (OVX; n=13), diabetic group 
(DIA;n=5), diabetic ovariectomized group (DIA+OVX; n=7). Bilateral ova-
riectomy had been performed to anesthetized (ketamine+xylasine) animals. 
Diabetes induced by a single i.v.injection of streptozotocin (45 mg/kg) a week 
after the operation. After 8 weeks, thorasic aortae were removed and mount-
ed in organ baths for measuring isometric relaxations. Experiments were car-
ried out on rings precontracted with phenylephrine (PE) to 60% of maximal 
contraction. Cumulative concentration-response curves for 17-beta estradiol 
(E2; nonselective agonist), 4,4’,4’’-(4-propyl-[1H]-pyrazole-1,5-triyl) tiphe-
nol (PPT;ER-alpha selective agonist) and diarylpropionitrile (DPN;ER-beta 
selective agonist) were obtained with (10-13 - 10-6 M) concentration range.
Results: An increase in body weight was observed in OVX group (p<0.001 vs 
C group) but not in the diabetic groups. Blood glucose levels were increased 
in the DIA and OVX+DIA group compared with the C group (p<0.001). 
Plasma estradiol levels and the ratio of uterine weight/body weight were re-
duced in OVX,DIA and OVX+DIA group compared C group respectively 
(p<0.01;p<0.001) The vasorelaxation responses to estrogenic agonists E2 and 
PPT were reduced in OVX, DIA and OVX+DIA however these responses to 
DPN were reduced both OVX groups (p<0.001).The ratios % of the maxi-
mum relaxations with E2, PPT and DPN of PE-precontracted aortic rings 
were shown in Table(***p<0.001 vs C).
Conclusion: These findings suggest that ER-alpha has still play a vital role in 
diabetes or ovariectomized vessels. This study also support that the estrogenic 
vasodilatation is abolished under diabetic ovariectomized condition which 
may be contribute to diabetic postmenopausal vascular dysfunction.
The % of the maximum relaxations with E2, PPT and DPN of PE-precon-
tracted aortic rings
Groups E2 PPT DPN
C 24.0 ± 0.1 29.6 ± 1.0 17.0 ± 0.4
OVX 16.6 ± 0.4*** 18.0 ± 6.3*** 6.9 ± 1.0***
DIA 16.1 ± 1.1*** 19.6 ± 1.2*** 12.0 ± 1.4
OVX+DIA 8.5 ± 0.5*** 9.0 ± 0.6*** 8.0 ± 1.3***
Supported by: Ankara University 20070803004 HP
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Differential role of testosterone and estradiol on glucose and lipid 
metabolism in human skeletal muscle cells
F. Salehzadeh, L. Al-Khalili; 
Molecular medicine and surgery, Karolinska Institutet, Stockholm, Sweden.
Background and aims: Testosterone and estradiol ratio differs between sexes, 
where changes in sex hormones homeostasis may cause different pathological 
response. We have previously shown that human skeletal muscle cell culture 
obtained from elderly female and male healthy subjects showed no intrinsic 
sex differences on glucose and lipid metabolism. Aim of the study is to deter-
mine whether testosterone or estradiol treatment have different role on lipid 
and glucose metabolism in human skeletal muscle cell culture.
Materials and methods: Myotubes obtained from women and men donors 
were treated with 10 nM testosterone or estradiol for 4 days. Insulin-stimu-
lated glycogen synthesis and palmitate oxidation were assessed and samples 
were collected for immunoblot analysis to assess AMPK, AKT, ERK1/2 and 
p38 MAPK phosphorylation and total protein. mRNA levels of different met-
abolic genes were also determined using real-time PCR analysis.
Results: Testosterone enhanced glucose incorporation to glycogen and insu-
lin-stimulated Akt phosphorylation specifically in myotubes from women, 
but not from men, donors, indicating sex specific role of testosterone on 
glycogen synthesis in skeletal muscle. Testosterone enhanced both AMPK 
phosphorylation and lipid oxidation in myotubes obtained from both sex-
es. mRNA expression showed a differential response to either sex hormone 
treatment with no sex differences. Testosterone increased the glycogen syn-
thase 1 (GYS1), while estradiol altered the mRNA expression of stearoyl-CoA 
desaturase (SCD) and Pyruvate dehydrogenase kinase 4 (PDK4).
Conclusion: Only testosterone treatment showed an effect on lipid metabo-
lism while, both sex hormones changed the mRNA expression of some genes 
involved in lipid oxidation. In this study, we are able to suggest an important 
role of testosterone on glucose and lipid metabolism in human skeletal mus-
cle cells, with no clear effect of estradiol on metabolism and there is a sexual 
difference on cellular metabolism with sex hormones treatment.
748
Circulating pigment epithelium-derived factor levels are associated with 
insulin resistance and decrease after weight loss
M. Sabater1, J.M. Moreno-Navarrete1, F.J. Ortega1, G. Pardo1, W. Ricart1,  
G. Frühbeck2, J.M. Fernández-Real1; 
1Department of Diabetes, Endocrinology and Nutrition, Institut 
d’Investigació Biomèdica de Girona, 2Department of Endocrinology and 
Metabolic Research Laboratory, Clínica Universitaria, University of Navarra, 
Pamplona, Spain.
Background and aims: Pigment Epithelium-Derived factor (PEDF) is a 50-
kDa protein with anti-inflammatory activity. We aimed to study PEDF in 
vivo in association with insulin resistance and in vitro in human adipocytes.
Materials and methods: Circulating PEDF (ELISA) and metabolic profile 
were assessed in 125 Caucasian men. PEDF levels were also assessed in an 
independent cohort of subjects (n=33) to study the effects of changing insulin 
action. PEDF gene expression and PEDF secretion were also measured dur-
ing differentiation of human preadipocytes.
Results: In all subjects, PEDF were positively associated with BMI (r=0.326, 
p<0.0001), waist-to-hip ratio (r=0.380, p<0.0001), glycated hemoglobin 
and fasting triglycerides; and negatively with insulin sensitivity (r=-0.320, 
p<0.0001). Circulating PEDF levels was significantly increased in subjects 
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with altered glucose tolerance and type 2 diabetes. Of the inflammatory 
markers measured, circulating PEDF levels were positively associated with 
serum sTNFR1 and IL-10 in obese subjects. Interestingly, weight loss led 
to significantly decreased of PEDF concentration from 34.8±19.3 µg/ml to 
22.5±14.2 µg/ml (p<0.0001). Multiple linear regression analyses revealed that 
insulin sensitivity contributed independently to explain 14% of the variance 
in circulating PEDF levels, after controlling for the effects of BMI, age, and 
log fasting triglycerides. Differences in circulating total PEDF observed after 
weight loss were strongly related to changes in obesity and insulin resistance 
measures. PEDF gene expression and PEDF secretion increased during dif-
ferentiation of human pre-adipocytes.
Conclusion: Circulating PEDF is strongly associated with insulin sensitiv-
ity. The findings show, for the first time in humans, that circulating PEDF 
concentrations decrease significantly after weight loss in association with im-
provement of insulin action. PEDF seems to be involved in human adipocyte 
biology.
Supported by: the Ministerio de Educación y Ciencia (SAF2008-0273)
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Osteocalcin and its effect on metabolic control in type 1 diabetes
N. Napoli1, C. Bizzarri2, D. Pitocco3, C. Suraci4, M. Altomare4, E. Sacchetti1, 
L. Valente1, P. Pozzilli1; 
1Campus Bio-Medico di Roma, 2Unit of Endocrinology and Diabetes, 
Bambino Gesù Children’s Hospital, 3Universita’ Cattolica del Sacro Cuore, 
4Ospedale Sandro Pertini, Roma, Italy.
Background and aims: Osteocalcin (OC), produced by osteoblasts, is con-
sidered a predictor of fractures and its elevated levels are associated with both 
high bone formation and turnover. Recent animal studies have shown that 
OC acts also as a hormone regulating glucose metabolism and fat mass. Few 
studies have explored this relationship in humans showing an inverse cor-
relation with fasting plasma glucose, HbA1c and fat mass in type 2 diabetic 
patients. However, no data are available in type 1 diabetes (T1D). Aim of 
this study was to investigate the relationship between OC, HbA1c and fasting 
serum C-peptide in patients with recent onset T1D. Moreover, we tested in 
T1D patients the effect of 1 year calcitriol administration on OC, residual β-
cell function and metabolic control (HbA1c and insulin requirement).
Material and methods: 34 subjects (mean age 22.2±1.7 SE) with recent-onset 
T1D and baseline C-peptide > 0.25 nM were enrolled in this study. Intensive 
insulin therapy was implemented with three daily injections of regular insu-
lin + bedtime insulin in these patients. Osteocalcin was analyzed at the time 
of diagnosis and one year after treatment with either 0.25 µg daily calcitriol 
or placebo. OC was evaluated by ECLIA method (modular E170, Roche Di-
agnostics, Mannheim, Germany) in relation to C-peptide.
Results: At T1D diagnosis, OC levels were significantly lower in female than 
in male patients (17.8±3.1 ng/mL vs 43.9±6.9 ng/mL; p<0.01) while no other 
metabolic parameters as HBA1c, C-peptide differed between gender. Analyz-
ing the whole group of patients, OC levels were positively associated with 
insulin requirement (r=0.48, P<0.01), while no significant correlation were 
found in relation to HbA1c and C-peptide. At 1 year follow-up, OC levels 
were increased (11%) in the placebo group while dropped by 25% in the 
calcitriol group, but their levels were not significantly different compared to 
diagnosis due to high variability. No significant differences were observed 
between calcitriol and placebo groups for OC (37.2±11.8 ng/mL vs 25.8±7.4 
ng/mL; p=NS), C-peptide(1.05±0.25 nM vs 25.8±7.4 nM; p=NS), HbA1c 
(6.8±1.13% vs 7.14±1.1%; p=NS) and insulin requirement (0.48±0.2 vs 
0.58±0.21; p=NS).
Conclusion: In contrast to what expected, OC was not associated with re-
sidual pancreatic β-cell function or metabolic control in recently diagnosed 
T1D patients. Calcitriol had no effect on residual β function, insulin dose or 
the overall metabolic control. Further studies with a larger group of patients 
are needed to confirm these data.
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The relationship between vitamin D status and markers of oxidation and 
inflammation in subjcets with the metabolic syndrome
K.I. Birkeland1, H.L. Gulseth1, I.M.F. Gjelstad1,2, J.A. Lovegrove3,  
C. Defoort4, E.E. Blaak5, J. Lopez-Miranda6, A. Dembinska-Kiec7,  
U. Risérus8, H.M. Roche9, C.A. Drevon2; 
1Department of Endocrinology, Oslo University Hospital Aker, Norway, 
2Department of Nutrition, University of Oslo, Norway, 3University of 
Reading, Reading, United Kingdom, 4Department of Endocrinology, 
INSERM, Marseille, France, 5NUTRIM, Maastricht University, Netherlands, 
6University of Cordoba, Spain, 7Jagiellonian Medical College, Krakow, 
Poland, 8Uppsala University, Sweden, 9University College Dublin, Ireland.
Background and aims: Low levels of vitamin D may increase the risk of 
developing type 2 diabetes, and inflammation and oxidative stress may par-
ticipate in the pathogenesis of diabetes. We have evaluated the relationship 
between serum 25-hydroxyvitamin D3 (25(OH)D3) and markers of inflam-
mation and oxidative stress in subjects with the metabolic syndrome (MetS).
Material and methods: 25(OH)D3 was measured with HPLC-MS in subjects 
with the MetS in the LIPGENE dietary intervention study. CRP was mea-
sured by ELISA and urinary 8-iso-prostaglandin F2α (8-iso-PGF2α) and 15-
keto-dihydro-prostaglandin F2α (15-keto PGF2α) were determined by RIA 
and adjusted for urinary creatinine. Subjects (n = 446, 45% males) were from 
eight European centres. Mean (SD) age was 54.7 (9.0) years and BMI 32.3 
(4.1) kg/m2. 
Results: The mean (SD) concentration of 25(OH)D3 was 57.1 (26.0) nmol/L. 
Subjects were grouped according to their vitamin D status; severely deficient 
(<25 nmol/L, n=20), deficient (25-49.9 nmol/L, n=189), insufficient (50-74.9 
nmol/L, n=146 ) and sufficient (> 75nmol/L, n=91). Markers of oxidative 
stress (8-iso-PGF2α, p=0.022) and inflammation (15-keto PGF2α, p=0.022 and 
CRP, p=0.05) differed significantly across categories of 25(OH)D3. Plasma 
concentrations of 25(OH)D3 were significantly negatively associated with 
BMI (r=-0.23, p<0.001), CRP (r=-0.11, p=0.02) and 15-keto PGF2α (r=-0.10, 
p=0.039), but not with 8-iso-PGF2α (r=-0.08, p=0.09).
Conclusion: In a large sample of subjects with the metabolic syndrome low 
plasma concentrations of 25(OH)D3 were associated with enhanced markers 
of inflammation and oxidative stress.
Supported by: EU 6.FP (FOOD- CT-2003-505944)
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Arab herbal medicine-based combination of four anti-diabetes plants 
stabilises a physiological blood glucose level
H. Zaid, O. Saed, B. Saad; 
Qasemi Research Center, Al-Qasemi Academic College, Baqa El-Gharbia, 
Israel.
Background and aims: Medicinal plant-based drug discovery provides im-
portant leads against various pharmacological targets including diabetes, 
which represents a worldwide predominant public health concern. Several 
drugs are used to treat this disease. Based on our traditional knowledge, Jug-
lans regia L., Olea europea L., Urtica dioica L., and Atriplex halimus. L. exhibit 
favorable effects on blood glucose levels. This study was aimed at investigat-
ing safety and efficacy of a fixed mixture of these plants.
Materials and methods: In the present study we assessed safety and anti-dia-
betic effects of the combination of the four plants leave extracts using in vivo 
(human type2 diabetic volunteers and Streptozotocin-induced diabetic rats) 
and in vitro test systems (human fibroblasts and skeletal muscle cells treated 
with increasing concentrations of Plant mixture).
Results: No sign of toxic effects were seen in cultured human fibroblasts and 
skeletal muscle cells treated with increasing concentrations of Plant mixture. 
Anti-diabetic effects were evidenced by inhibition of glucose intestinal ab-
sorption (~49%) in a rat gut-segment. Furthermore, treatment with these 
plant combined extracts of Streptozotocin-induced diabetic rats for 2-3 
weeks, showed a significant reduction in glucose levels [above 400±50 mg/dl 
to 210±22 mg/dl (P<0.001)] and significantly improved sugar uptake dur-
ing the glucose tolerance test, compared with positive control. In addition, 
glucose levels were tested in sixteen human volunteers, with the recent onset 
of type 2 diabetes mellitus, who received the plants mixture tablets 1X3 daily 
for a period of 4 weeks. Within the first week of the tablets consumption, 
baseline glucose levels were significantly reduced from 290±40 to 210±20 
mg/dl. At baseline, a subgroup of eleven of these subjects had glucose levels 
below 300mg/dl and the other subgroup had levels ≥300 mg/dl. Clinically ac-
ceptable glucose levels were achieved during the 2-3 weeks of therapy in the 
former subgroup and during the 4th week of therapy in the latter subgroup. 
No side effect was reported.
Conclusion: Results demonstrate safety, tolerability and efficacy of herbal 
combinations of four plants that seem to act differently but synergistically to 
regulate glucose-homeostasis.
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Effects of Mongolian traditional medicinal plant extract of Gentianaceae 
on in vivo insulin action in streptozotocin-induced diabetic rats
O. Khookhor, Y. Sato; 
Department of Health Science, Aichi Gakuin University, Nagoya, Japan.
Background and aims: Lomatogonuim rotatum (L) Fries ex Fern and Gen-
tiana acuta Michaux of the family Gentianaceae have been documented as 
traditional plant treatments for liver diseases.We firstly performed a prelimi-
nary investigated on the acute effect of Mongolian medicinal plant extracts 
Lomatogonuim rotatum and Gentiana acuta , Gentianaceae on the blood 
glucose tolerance in rats, evaluated by an oral glucose tolerance test (OGTT). 
Then, investigated the effects of the same extracts on in vivo insulin action 
in streptozotocin (50mg.kg-1BW,i.v.)-induced diabetic rats by means of the 
euglycemic clamp.
Materials and methods: Plant materials were provided by the Institute of 
Chemistry and Chemical-technology of MAS (Mongolia). Air-dried plant 
materials were extracted with 10 volumes of hot water (80C), filtered, lyophi-
lized, and stored at 40C. Male Wistar rats aged 8 weeks (220-240g bw).Oral 
glucose tolerance test (OGTT). Time-course blood glucose concentrations 
were determined 30, 60, and 120 min after glucose load. Whole blood and 
plasma assays. Blood glucose concentration was determined using an auto-
mated analyzer model 2300 STAT Plus. Plasma insulin concentration was 
measured by the Special Reference Laboratories Inc. using a chemilumines-
cence enzyme immunoassay method. Statistical analysis: Data were analyzed 
by one-way analysis of variance. When a significant difference was found (P 
< 0.05), values were further compared with the Student’s t test. The Stat View 
was used for statistical analyses. Data are expressed as means ± SE.
Results: 1.Effect of plant extract on blood glucose concentrations. Blood 
glucose concentrations and net incremental area under the curve (net AUC) 
for control and plant extracts before and after oral load of glucose are sum-
marized. Compared to the control group, plant extract groups (30min) had 
significantly lower peak blood glucose concentrations during the OGTT with 
Lomatogonium rotatum and Gentiana acuta, Gentianaceae. 2. Effect of 7 days 
administration of plant extracts on MCR Rats divided into control and 7-
days oral administration groups. At low-dose insulin infusion, the decreased 
metabolic clearance rates of glucose (MCR) in diabetic rats were improved by 
a 7 days administration of plant extracts ( 500mg.kg.BW, p.o.; 7 days effect: 
non-diabetic control: 15.2± 0.8 ml kg-1min-1, diabetic control: 7.6± 0.7ml 
kg-1min-1. versus plant extract 1: 14.1 ± 1.4 ml kg-1min-1, and versus plant 
extract 2: 13.2 ± 1.2 ml kg-1min-1, P<0.001, respectively).
Conclusion: These results suggest that a 7 days administration of the Mongo-
lian plant extracts Gentianaceae can improve glucose utilization and insulin 
resistance in diabetic rats.
Supported by: MEXT of Japan (16500402)
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Chronic caffeine intake reverses age induced-insulin resistance in the rat
S.V. Conde1, E.C. Monteiro1, M. Mota-Carmo2, M.P. Guarino2; 
1Pharmacology, 2Pathophysilogy, CEDOC, Faculty of Medical Sciences, 
Lisboa, Portugal.
Background and aims: Aging is known to be associated with increasing in-
sulin resistance and declining glucose tolerance. Insulin resistance is one of 
the core metabolic abnormalities in type 2 diabetes and metabolic syndrome. 
One of the lifestyle changes advised in these diseases is coffee withdrawal, 
based on several studies describing that caffeine can acutely lower insulin 
sensitivity. However the benefits of coffee withdrawal have been questioned 
by several studies that suggest no association between long-term coffee con-
sumption and diabetes which seems to indicate that acute and chronic in-
take have opposite effects. In the present work we tested the hypothesis that 
chronic caffeine intake reverses age induced-insulin resistance in the rat and 
investigated if the mechanism by which caffeine restores insulin sensitivity is 
due to a decrease in visceral fat or oxidative stress.
Materials and methods: Six groups of rats were used: 3 months old (con-
trol), 3 months caffeine-treated, 12 months old, 12 months caffeine-treated, 
24 months old and 24 months caffeine-treated. Caffeine was administered 
in drinking water (1g/l) during 15 days. Insulin sensitivity was assessed by 
means of an insulin tolerance test. Blood pressure, weight, visceral and total 
fat, basal glycemia, insulinemia and plasma total antioxidant capacity were 
also measured.
Results: Insulin sensitivity diminished in 12 and 24 months rats as the con-
stant of the insulin tolerance test (KITT) decreased significantly to 2.77±0.17 
and 2.47±0.18 compared to the control value 4.69±0.42 (3 months rats). 
Chronic caffeine intake restored insulin sensitivity to control values both in 
12 and 24 months rats. Basal glycemia was 100.53±4.32 mg/dL, 96.87±3.43 
mg/dL and 96.63±3.10 mg/dL in 3, 12 and 24 months rats. Caffeine did not 
modify basal glycemia in any of the groups tested. Both 12 and 24 months 
rats were hyperinsulinemic, as insulin levels increased significantly by 169 
and 160%, respectively from a control value of 2.05±0.4 µg/L. Chronic caf-
feine intake significantly decreased plasma insulin levels (p<0.5) both in 12 
and 24 months rats, although without restoring plasma insulin to control 
values. Visceral and total fat were significantly increased both in 12 and 24 
months rats when compared with 3 month rats, however no correlations were 
found between visceral fat and the KITT in both 12 and 24 months rats (p=0.06 
and r=0.88; p = 0.77 and r= 0.13, respectively). Caffeine intake significantly 
decreased visceral and total fat in 12 but not in 24 months rats. Also, no cor-
relations were found between visceral fat and the KITT in 12 and 24 months 
old caffeine treated rats (p=-0.35 and r=0.35; p = 0.57 and r= 0.24, respec-
tively). Additionally, chronic caffeine intake did not significantly modify the 
weight of the animals within the groups. Total antioxidant capacity (TAC) 
was decreased in 12 and 24 months rats. Caffeine intake did not modify sig-
nificantly TAC in any of the groups tested.
Conclusion: Chronic caffeine intake reverses age induced-insulin resistance 
in rats, an effect that were independent of weight loss, visceral fat and oxida-
tive stress.
Supported by: 2009 L’Oreal Medals and by Soc Portuguesa de Diabetologia/
Lilly Portugal
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Shikonin improves blood glucose levels in diabetic GK rats and increases 
glucose uptake in adipocyte and muscle cells, independent of its effect on 
NADPH oxidase 
K. Yassin1, A. Öberg2, R.I. Csikasz2, I.G. Shabalina2, M. Wilcke3,  
C.-G. Östenson1, T. Bengtsson2; 
1Department of Molecular Medicine and Surgery, Karolinska Institutet, 
2Department of Physiology, Arrhenius Laboratories, The Wenner-Gren 
Institute, Stockholm University, 3Glucox Biotech AB, Stockholm, Sweden.
Background and aims: Shikonin is a naphtoquinone derivative from the 
Chinese plant Lithospermum erythrorhizon. It has been reported to inhibit 
the formation of the NADPH oxidase, an enzyme complex that catalyses the 
formation of highly reactive superoxide anions. Shikonin has been shown to 
stimulate glucose-uptake, and potentiate insulin-induced glucose-uptake in 
3T3-L1 adipocytes. The diabetic state is associated with excess superoxide 
production that may contribute to failure of insulin to stimulate glucose up-
take in fat and muscle. Hence, our aim was to investigate the effect of shikon-
in, administered intraperitoneally (i.p.), on blood glucose levels and insulin 
sensitivity in the spontaneously diabetic Goto-Kakizaki (GK) rats. Having 
found that shikonin improved glucose homeostasis in GK rats, we further 
studied its mechanism of action in vitro.
Materials and methods: Shikonin was given i.p. to GK rats (n=6) once daily 
(10 mg/kg) for 4 days and compared with placebo (vehicle DMSO/oil (9:1)) 
injected i.p. during 4 days in the same animals. Plasma glucose (PG) lev-
els were measured daily before and 6h after i.p. injections. At the 4th day, an 
insulin sensitivity test was performed, where glucose responses were meas-
ured after s.c. injection of 0.5 U/kg insulin. L6 muscle cells and 3T3-L1 cells 
were used as model systems to study how shikonin regulates glucose uptake. 
Glucose uptake was measured using the 2-deoxy-[3H]-D-glucose method. 
AMPK and Akt phosphorylation were determined by Western blot. Oxygen 
consumption was monitored with a Clark-type oxygen electrode.
Results: Shikonin significantly lowered morning PG on 2nd, 3rd and 4th days 
compared to day 1 (p < 0.01 for all days compared to the first day); the total 
area under the glucose curve was lower in shikonin treated rats vs control 
rats (p= 0.014). In the insulin sensitivity test, PG levels were more reduced 
in the shikonin treated rats; 30-240 min after injection of insulin, the areas 
under the PG curves (AUCs) being 39.3±105.9 and 536.4 ±144.0 mM/210 
min, respectively (p<0.02). Shikonin increased basal and insulin-stimulated 
glucose uptake in L6 cells and 3T3-L1, which does not express all subunits 
of NADPH oxidase. Shikonin did not mimic the effect of AMPK activator 
AICAR on AMPK-phosphorylation, i.e. AMPK was not phosphorylated by 
shikonin. Furthermore, shikonin did not induce any change in AMP-to-ATP 
ratio and Akt phosphorylation in L6 cell lines, nor did it increase oxygen 
consumption in skeletal muscle mitochondria. However the cell-permeable 
calcium chelator, BAPTA-AM (5 µM), blocked shikonin-stimulated glucose 
uptake in L6 cell lines.
Conclusion: We conclude that shikonin treatment in GK rats decreases PG 
levels and improve insulin sensitivity. Since shikonin increased glucose up-
take in cell lines devoid of NADPH oxidase, this enzyme cannot be involved 
in shikonin-mediated effects on glucose metabolism. Our present findings 
suggest that shikonin exerts its effect on glucose uptake by a calcium related 
pathway.
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Effect of resveratrol on insulin sensitivity, oxidative stress and Akt 
pathway in humans
P. Brasnyó1, G.A. Molnár1, M. Mohás1, L. Markó1, B. Laczy1, J. Cseh1,  
E. Mikolás1, I.A. Szijártó1, Á. Mérei1, R. Halmai1, L.G. Mészáros2, B. Sümegi3, 
I. Wittmann1; 
1Second Department of Medicine and Nephrological Center, University 
of Pécs, Medical Faculty, Hungary, 2Life Sciences Foundation Theoretical 
Biochemistry Group, Augusta, USA, 3Department of Biochemistry and 
Medical Chemistry, University of Pécs, Medical Faculty, Hungary.
Background and aims: To examine whether the red wine polyphenol, res-
veratrol, improves insulin sensitivity in type 2 diabetic patients, and to gain 
insight into the mechanism of its action.
Materials and methods: After an initial general examination (including 
blood chemistry), 19 patients enrolled in the 4-week long study were ran-
domly assigned into two groups: a resveratrol group receiving oral 2 x 5 mg 
resveratrol and a respective control group receiving placebo. Before, after 
two weeks and at the end of the trial insulin resistance/sensitivity, creatinine-
normalized ortho-tyrosine level in urine samples (as a measure of oxidative 
stress), incretin levels and pAkt/Akt ratio in platelets were assessed and sta-
tistically analyzed.
Results: After 4 weeks, resveratrol significantly decreased insulin resistance 
(HOMAIR) and urinary ortho-tyrosine excretion, while it increased pAkt/
Akt levels in platelets. On the other hand, it had no effect on parameters char-
acterizing beta cell function.
Conclusion: This study shows the first time that resveratrol improves insulin 
sensitivity in humans, which might be due to a resveratrol-induced decrease 
in oxidative stress that leads to a more efficient insulin signaling via the Akt 
pathway.
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An analysis of liver enzymes in type 1 and type 2 diabetes and their 
associations with glycaemic status independent of total adiposity
N. Sattar, Scottish Diabetes Research Network Epidemiology Group, The 
Scottish-Southampton Diabetes and Liver Disease Collaboration; 
BHF Glasgow Cardiovascular Research Centre, University of Glasgow, 
United Kingdom.
Background and aims: Robust evidence indicates hepatic fat and related 
liver enzymes, alanine transaminase [ALT] and gamma glutamyl transferase 
[GGT], predict type 2 diabetes. However, the association of these enzymes 
with glycaemic control in people with diabetes is less well studied. We there-
fore investigated whether there is an association between liver enzymes and 
glycaemic control independently of age, sex, adiposity and smoking status in 
type 1 and type 2 diabetes
Materials and methods: We used population-based diabetes register data for 
2008 linked to laboratory data for 3862 people with type 1 and 25075 people 
with type 2 diabetes in south-east Scotland. Regression analyses were used to ex-
amine associations between ALT or GGT and HbA1c in people with type 1 and 
type 2 diabetes controlling for age, sex, current smoking status and body mass 
index (BMI); after excluding people with ALT and GGT values more than twice 
the upper limit of normal (>2ULN) and people with HbA1c>10% (associations 
were not linear beyond these values). Data on alcohol intake were not available.
Results: Data were available for ALT and GGT on 27258 (94%) and 25840 
(89%) people respectively. There were 1447 people (5.3%) whose ALT was 
>2ULN (>100U/l), 4662 people (18.0%) whose GGT was >2ULN (>110U/l) 
and 1972 (6.9%) people whose HbA1c was >10% leaving data available for 
analysis for 2416 people with type 1 and 19058 people with type 2 diabetes. 
ALT was 9.9 U/l higher (p<0.0001) and GGT was 10.5 U/l higher (p<0.0001) 
in people with type 2 compared to type 1 diabetes after adjustment as de-
scribed above. BMI>30kg/m2 was associated with higher levels of ALT (2.63 
U/l, p<0.001) and GGT (4.65U/l, p<0.001) when compared to BMI<30kg/m2. 
Current smoking compared to non-current smoking status was associated with 
lower ALT levels (by 1.84 U/l, p<0.001) and higher GGT levels (by 1.94 U/l, 
p<0.001). In fully adjusted analyses, each 1% increase in HbA1c was associated 
with: a) no significant change in ALT in type 1 diabetes but a 0.90 U/l increase 
in type 2 diabetes (p<0.0001); and b) a 0.73 U/l increase in GGT (p=0.04) in 
type 1 diabetes, and a 1.23U/l (p<0.0001) increase in type 2. There was a sig-
nificant (p<0.001) interaction between obesity (BMI>30kg/m2) and GGT with 
HbA1c as the outcome for people with type 2 diabetes in adjusted analyses
Conclusion: The relationship between glycaemic control and either ALT or 
GGT differs by diabetes type. The data provide strong, albeit indirect, evi-
dence for an influence of hepatic fat accumulation (independent of total adi-
posity) on glycaemic control in type 2 diabetes. Further work is required to 
establish the role of alcohol consumption and diabetes drugs on such patterns 
and to investigate whether improved glycaemic control results in reduction of 
liver enzymes and / or vice versa.
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Serum interleukin 1 receptor antagonist level is independently associated 
with nonalcoholic steatohepatitis in humans
J.A. Pihlajamäki1, M. Simonen1, T. Kuulasmaa1, V. Kärjä2, S. Gronlund3, P. 
Kakela3, M. Paakkonen3, K. Punnonen4, H. Gylling5, J. Kuusisto1,  
M. Laakso1; 
1Department of Medicine, 2Department of Pathology, 3Department of 
Surgery, 4ISLAB, 5Department of Clinical Nutrition, University of Eastern 
Finland, Kuopio, Finland.
Background and aims: Mechanisms leading to non-alcoholic steatohepatitis 
(NASH) have remained unclear, and noninvasive diagnosis of NASH is chal-
lenging. In this study we aimed to identify novel serum markers for NASH.
Materials and methods: In a cross-sectional population-based cohort of 6447 
men (58±7 years, BMI 27.0±3.9 kg/m2) the association of serum ALT levels 
with glucose tolerance, Matsuda insulin sensitivity index (ISI), serum lipids 
and lipoproteins, and serum levels of adiponectin and cytokines were inves-
tigated. Liver biopsies from 60 morbidly obese individuals (44.2±8.3 years, 
BMI 45.5±6.1 kg/m2) were used for histological assessment. Gene expression 
of IL1RN in liver, subcutaneous fat and visceral fat was investigated.
Results: The strongest determinants of ALT levels were Matsuda ISI and 
serum IL-1RA levels in the population study. IL-1RA levels associated sig-
nificantly with ALT levels even after adjusting for BMI, alcohol consumption 
and insulin sensitivity (general linear model, p=2x10-21). In morbidly obese 
subjects serum levels of IL-1RA also associated with the degree of lobular 
inflammation in liver histology (p=0.034). Furthermore, serum IL-1RA 
levels decreased after obesity surgery (r=0.443, p=0.024) and this decrease 
correlated with the change in histologically assessed lobular inflammation 
(r=0.662, p=0.027). Finally, expression of IL1RN in liver and visceral fat cor-
related positively with serum IL-1RA levels and liver steatosis (r=0.352 and 
0.462, respectively, p<0.05).
Conclusion: IL-1RA serum levels correlate with serum ALT independent of 
obesity, alcohol consumption and insulin resistance, most likely reflecting an 
association between serum IL-1RA and NASH.
Supported by: Academy of Finland, Finnish Diabetes Research Foundation
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Increased intramyocellular lipid but normal intrahepatocellular lipid 
content characterises polycystic ovary syndrome compared with age- and 
BMI-matched healthy controls
H. Jones1, V.S. Sprung1, C.J. Pugh1, A. Irwin2, N. Aziz3, G.J. Kemp4,  
V.L. Adams4, W.E. Bimson4, D.J. Cuthbertson2; 
1Research Institute for Sport and Exercise Sciences, Liverpool John Moores 
University, 2Department of Diabetes and Endocrinology, University Hospital 
Aintree, 3Department of Gynaecology, Liverpool Women’s Hospital, 
4Magnetic Resonance and Image Analysis Research Centre (MARIARC), 
University of Liverpool, United Kingdom.
Background and aims: It has been suggested that there is a high prevalence 
of non-alcoholic fatty liver disease (NAFLD) in women with Polycystic Ova-
ry Syndrome (PCOS) as both are associated with obesity and insulin resist-
ance (IR). Furthermore, the mechanism for the peripheral insulin resistance 
observed in PCOS remains unclear. The aim of this study was to determine 
whether PCOS women have higher liver fat (intrahepatocellular lipid, IHCL) 
or skeletal muscle fat (intramyocellular lipid, IMCL), compared with age- and 
body mass index-matched controls, and to determine whether higher tissue 
fat content may explain IR.
Materials and methods: 20 PCOS women and 9 healthy controls were re-
cruited. Fasting glucose, lipids, AST and ALT were measured and all subjects 
underwent whole body magnetic resonance imaging with proton magnetic 
resonance spectroscopy to determine IHCL and IMCL (soleus, SOL and 
tibialis anterior, TA) levels.
Results: PCOS women and healthy controls were similar with respect to BMI 
and age (32 ± 8 vs. 28 ± 5 kg/m2; 26 ± 4y vs. 28 ± 7y). PCOS women had 
higher fasting triglycerides but similar liver transaminases and similar IHCL 
(8 ± 13% vs. 3 ± 4%; p=0.09). IHCL was significantly correlated with BMI 
and waist:hip ratio (WHR) in PCOS and control women. At any given BMI 
or WHR, PCOS women and control women had similar IHCL. IHCL was re-
lated to serum triglycerides. There was also a close correlation between IMCL 
and BMI. IMCL content was greater in the TA muscle in PCOS vs. control (77 
± 56% vs. 41 ± 30%; p<0.05) but not in soleus (54 ± 38% vs. 34±24; p=0.1).
Conclusion: Despite the reported high prevalence of NAFLD in PCOS we 
found that IHCL was elevated similarly in proportion to the BMI in both 
PCOS and healthy controls unlike IMCL which was higher in women with 
PCOS and may potentially explain peripheral insulin resistance.
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Proteasome dysfunction contributes to endoplasmic reticulum stress and 
insulin resistance in type 2 diabetic liver
T. Otoda1, H. Misu1, S. Kurita1, M. Yamamoto2, T. Ota3, K.R. Shima1,  
S. Iseki2, S. Murata4, K. Tanaka5, S. Kaneko1, T. Takamura1; 
1Disease Control and Homeostasis, Kanazawa University Graduate School 
of Medical Science, 2Histology and Embryology, Kanazawa University 
Graduate School of Medical Science, 3Frontier Science Organization, 
Kanazawa University, 4Laboratory of Protein Metabolism, Department of 
Integrated Biology, Graduate School of Pharmaceutica, The University of 
Tokyo, 5Laboratory of Frontier Science, Tokyo Metropolitan Institute of 
Medical Science, Japan.
Background and aims: Insulin resistance is a key feature of people with 
type 2 diabetes (T2D). Growing evidence has suggested that accumulation 
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of endoplasmic reticulum (ER) stress in liver is a major contributor to in-
sulin resistance; however, the molecular mechanisms linking diabetes and 
ER stress are not fully understood. We have previously reported that the he-
patic expression of genes involved in proteasomal degradation pathway are 
coordinately up-regulated in people with obesity and T2D (Obesity 2008). 
Specifically, the expression levels of proteasome activator (PA) 28-α subunit 
gene was significantly higher in people with obesity than in non-obese indi-
viduals. The proteasome is an important multicatalytic enzyme complex that 
degrades misfolded and oxidized proteins, signal transduction factors, and 
antigenic peptides for presentation. Indeed, NEFA or oxidative stress have 
been reported to induce proteasome dysregulation in hepatocyte. The aim of 
this study is to clarify the role of proteasome function for insulin resistance in 
obesity and T2D using PA 28α, β, and γ triple knockout (KO) mice.
Materials and methods: We assessed the metabolic phenotype of PA28αβγ 
KO mice. After sacrifice, blood sample, liver and femoris muscle were collect-
ed and proteasome activity was measured by the chymotrypsin-like protease 
activity. Livers were observed by electron microscope. Gene and protein ex-
pression of markers associated with ER stress was analyzed by realtime-PCR 
and Western blot.
Results: 1) Proteasome activity was inhibited in livers of both genetically 
diabetic db/db mice and C57BL/6 mice fed a high-fat diet (HFD) (p<0.05; 
p=0.083, n=4), whereas gene expression levels involved in proteasomal degra-
dation pathway were up-regulated in livers of mice fed a HFD. 2) Proteasome 
activity in livers of PA28αβγ KO mice was inhibited by 35% compared with 
control mice (p=0.05, n=3). 3) PA28αβγ KO mice showed glucose intorelance 
in glucose loading test. 4) Insulin-stimulated phosphorylation of Akt was im-
paired in livers of PA28αβγ KO mice, but not in skeletal muscle. 5) Western 
blot analysis displayed an accumulation of polyubiquited proteins in the liver 
of PA28αβγ KO mice. 6) Electron microscopic examination detects a massive 
expansion of endoplasmic reticulum and double-membrane and multilamel-
lar structures of large autophagosomes in hepatocytes from PA28αβγ KO 
mice. 7) CHOP and spliced XBP-1 mRNA level were increased in livers from 
PA28αβγ KO mice (p<0.05; p=0.077, n=3-5). 8) GRP78, pPERK, peIF2α, 
pIRE-1, CHOP, and pJNK protein levels were up-regulated in livers obtained 
from PA28αβγ KO mice (p<0.05, n=5).
Conclusion: Proteasome dysfunction induces ER stress and subsequent in-
sulin resistance in the liver with obesity and T2D. Our study demonstrates a 
previously unrecognized role of ubiquitin-proteasome pathway for the devel-
opment of insulin resistance in the liver and suggests that this pathway is a 
novel target for the treatment of T2D.
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Berberine reduces hepatic fat content in SD rats with a high-fat diet by 
increasing hepatic MTTP function
X. Chang1, X. Gao1, M. Liu1, H. Yan1, Y. Liu2, Q. Wang2; 
1Endocrinology & Metabolism, Zhongshan Hospital, 2Laboratory of 
Inflammation, Cellular Stress and Metabolic Regulation, The Institute for 
nutritional science, Shanghai, China.
Background and aims: Nonalcoholic fatty liver disease (NAFLD) is closely 
associated with obesity, insulin resistance, and type 2 diabetes. Hepatic fat 
content plays a key role in these disorders, so reducing hepatic fat accumula-
tion can be an effective strategy to prevent type 2 diabetes. In our previous 
study, we found that berberine (BBR) can reduce hepatic triglyceride content 
and decline the DNA methylation level of hepatic microsomal triglyceride 
transfer protein (MTTP) promoter to upregulate MTTP expression. MTTP 
is necessary for the assembly and secretion of apoB-containing lipoproteins 
(e.g.VLDL, LDL), whereby lipids are normally exported from the liver. Hy-
permethylation of MTTP promoter reversed by BBR treatment, but it is un-
clear whether BBR improve hepatic MTTP function. So we further explored 
the mechanism of BBR reducing liver fat content by regulating MTTP.
Materials and methods: After Sprague- Dawley (SD) rats (n=16) were fed 
with 8 weeks of high-fat diet (HFD, 51% energy from fat, 4.64 kcal/g ), 
NAFLD model was successfully established. Then rats with NAFLD were ran-
domly divided into two groups, one of which were treated with BBR orally 
at 200mg/(kg d) (n=8, BBR+HFD group) and another group fed with vehicle 
(0.5% methylcellulose) as HFD control (n=8, HFD group), for sixteen weeks. 
Meanwhile, SD rats with normal diet (12.5% energy from fat, 3.2kcal/g) 
received the vehicle as normal control (n=8, ND group). At the end of the 
experiment, all rats were sacrificed and samples of liver tissue were taken 
for quantitative real-time PCR analysis and hepatic fat content measurement 
after overnight fasting. Total blood samples were also collected for serum li-
poprotein profiles.
Results: Liver triglyceride content is significantly lower in BBR treatment 
group than in HFD group (p<0.05, Fig A), although it was higher than in 
the normal control. The results of quantitative real-time PCR showed that 
treated with BBR for 16 weeks upregulated hepatic MTTP mRNA level ap-
proaching that of normal control (p<0.05, Fig B), and MTTP gene expres-
sion declined by 70%in livers from rats in the HFD group in contrast to ND 
group. Accordingly, the protein levels of MTTP were higher in BBR-treated 
group than in HFD group (Fig C). Serum lipoproteins were separated using 
fast protein liquid chromatography (FPLC) (Fig D). The contents of apoB100 
and apoB48, in the fractions were visualized by Western blotting. These re-
sults showed that TG-rich VLDL particles were significantly higher in BBR- 
treated group than HFD group according to area under the curve (AUC) 
(Fig E) and the levels of apolipoprotein B (apoB) -100 and -48 in isolated 
VLDL fractions were higher in BBR-treated group than HFD group (Fig F).
Conclusion: BBR can improve fatty liver by upregulating MTTP expression 
to increase hepatic VLDL-TG secretion in SD rats induced by a high-fat 
diet.
Supported by: STCSM(07JC1401107, 08dj1400601) and NNFSC(30900500)
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cAMP response element binding protein H, CREBH decreases hepatic 
lipogenesis
H.-S. Kim1, M.-K. Kim1, A.-K. Min2, N.-K. Kim1, G.-S. Jung1, Y. Seo1,  
I.-K. Lee2, K.-G. Park1; 
1Department of Internal Medicine, Keimyung University School of 
Medicine, 2Department of Internal Medicine, Kyungpook National 
University School of Medicine, Daegu, Republic of Korea.
Background and aims: Nonalcoholic fatty liver disease (NAFLD) is closely 
associated with insulin resistance state, such as obesity and type 2 diabe-
tes. Sterol regulatory element binding protein-1c (SREBP-1c) is one of the 
major regulators of the expression of genes involved in hepatic triglyceride 
synthesis. Hepatic expression of SREBP-1c is regulated by insulin-induced 
activation of liver X receptor (LXR) and specific protein 1 (Sp1). Endoplasmic 
reticulum-bound transcription factor families are shown to be involved in 
the control of various metabolic pathways. Here we show a novel function of 
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ER-bound transcription factor, cAMP response element binding protein H 
(CREBH), in the regulation of hepatic lipogenesis
Materials and methods: To demonstrate that CREBH expression is influ-
enced by insulin, we determined hepatic CREBH expression during fast-
ing and after the refeeding of control and streptozotocin-induced diabetic 
rats. We next examined whether CREBH decreased hepatic lipogenesis and 
SREBP-1c expression in high fat diet fed mice, using tail vein injection of ad-
enovirus encoding the active form CREBH. Finally, we examined the mecha-
nism by which CREBH inhibits hepatic SREBP-1c expression.
Results: We found that fasting induced but feeding suppressed CREBH ex-
pression. However, feeding did not suppress its expression when endogenous 
insulin was eliminated by treatment with streptozotocin. Insulin treatment 
decreased CREBH expression in cultured hepatocytes, suggesting that the 
refeeding-suppression of CREBH expression is mainly mediated by insulin. 
Adenovirus-mediated overexpression of CREBH inhibited insulin- and LXR 
agonist, TO901317-stimulated SREBP-1c mRNA expression in cultured he-
patocytes. Moreover, adenovirus-mediated overexpression of CREBH inhib-
ited hepatic steatosis in animal models through an inhibition of SREBP-1c 
expression. Transient transfection and gel shift assays showed that CREBH 
inhibited the activities of LXR and Sp1, known mediators of insulin-depen-
dent SREBP-1c expression.
Conclusion: Collectively, these data suggest that CREBH could be a novel 
negative regulator of hepatic lipogenesis. This raises the possibility that 
CREBH can be therapeutic target to prevent the development of fatty liver 
disease in patients with insulin resistance.
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The effect of metformin on liver mitochondria and lipid metabolism in 
NAFLD
M. Cahova1, Z. Drahota2, O. Oliarnyk1, Z. Cervinkova3, O. Kucera3,  
H. Dankova1, L. Kazdová1,2; 
1Department of Diabetes and Metabolism, Institute for Clinical and 
Experimental Medicine, Prague, 2Department of Bioenergetics, Institute of 
Physiology AV CR, Prague, 3Faculty of Medicine Charles University, Hradec 
Kralove, Czech Republic.
Background and aims: Metformin is a weak inhibitor of complex I of mito-
chondrial respiratory chain (MRC) what may negatively influence the cellular 
energy balance. Our study was designed to determine the effect of long-term 
high-fat diet administration in combination with metformin treatment on 
the lipid metabolism in liver, oxidative capacity of liver mitochondria and 
sensitivity of the liver to the ischemia reperfusion injury.
Material and methods: Male Wistar rats were fed standard (SD) or high-fat 
diet (HFD, 60% of calories derived from lard) for 10 weeks. Half of the HFD 
group was administered metformin in food (150 mg/kg b.wt.) for the last 5 
weeks of the feeding period. In a separate experiment, animals were subjected 
to the warm liver ischemia induced by 20 min clamping of portal vein 2 days 
prior decapitation.
Results: HFD resulted in TAG accumulation in liver (3±0.3 vs 38±4.6 umol/
g; p<0.001) and diminished liver glycogen content (219±18 vs 280±13 umol/
g p<0.05). The effect of the diet was further potentiated by metformin (TAG: 
73±2.5 umol/g, p<0.001; glycogen 169±6 umol/g, p<0.01). The increased ac-
tivity of liver lysosomal lipase (LAL) in HFD group suggests the enhanced 
breakdown of endogenous TAG. Concomitantly, an increased expression 
of diacylglycerolacyltransferase-1 (DGAT-1) was found what indicates the 
increased FA reesterification. Metformin in combination with HFD further 
increased both LAL activity and DGAT-1 expression compared with HFD 
alone. The stimulatory effect of metformin on endogenous TAG degradation 
is supported by the elevated ketogenesis in HFD+Met group. HFD decreased 
the oxidative capacity of liver mitochondria on all tested substrates (glutama-
te + malate p=0.045; glutamate + malate + ADP p= 0.05; palmitoylcarnitine 
p=0.043; succinate p=0.051). Metformin potentiated the deleterious effect 
of HFD on mitochondria but only in animals that underwent liver ischemia 
(HFD+Met vs HFD: glutamate + malate + ADP p=0.042; palmitylcarnitoin 
p=0.025). We proved 40% decrease of in vitro activity of NADH:cytochrome 
c oxidoreductase in HFD+Met vs HFD alone. Liver ischemia resulted in the 
increased formation of lipoperoxidation products (HFD > SD). Metformin 
had no additional effect. In animals subjected to the liver ischemia, the ac-
tivity of antioxidative enzymes (SOD, GSH-Px, catalase) were significantly 
lower in HFD vs SD group. Metformin treatment of HFD animals resulted in 
70-80% increase in the activity of all tested enzymes.
Conclusion: The administration of metformin in combination with HFD 
worsened hepatic steatosis but it was not associated with the impairment of 
TAG degradation. On the contrary, the activity of lypolitic enzyme (LAL) 
was elevated. Metformin also potentiated HFD-induced impairment of mito-
chondria what deteriorated their ability to utilize released FA by mitochon-
drial oxidation and re-directed them into ketogenesis. TAG accumulation in 
liver significantly worsened the oxidative stress in liver ischemia/reperfusion. 
Metformin stimulated the activity of antioxidant enzymes but this was NOT 
accompanied by concomitant decrease in lipoperoxide formation. This fact 
could be interpreted as the adaptive response of the cell to the increased reac-
tive oxygen species formation due to the impairment of MRC.
Supported by: grants No.: NS 10504-3 IGA MH CR, MSM 0021620820 and 
AV0Z50110
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Adiponutrin, a lipid droplet surface enzyme - evidence for regulation by 
ChREBP, SREBP1c and FXR in human hepatocytes
J. Perttilä1, S. Caron-Houde2, B. Staels2, H. Yki-Järvinen3, V.M. Olkkonen1; 
1Minerva Medical Research Institute, Helsinki, Finland, 2Institut Pasteur de 
Lille, INSERM UMR 545, Lille, France, 3Department of Medicine, Division 
of Diabetes, University of Helsinki and Minerva Medical Research Institute, 
Helsinki, Finland.
Background and aims: Adiponutrin, encoded by the PNPLA3 gene, belongs 
to the family of patatin-like domain containing enzymes. A non-synony-
mous sequence variation, encoding an isoleucine to methionine substitution 
at amino acid 148 (rs738409; I148M), has been consistently associated with 
a markedly increased hepatic fat content in humans with non-alcoholic fatty 
liver disease. Adiponutrin is reported to show in vitro triglyceride lipase 
and acyltransferase activities, but its physiologic function and regulation are 
poorly known. We aim to eludicate (i) transcriptional regulation of PNPLA3, 
(ii) its subcellular localization in human hepatocytes, and (iii) expression pat-
tern of adiponutrin in human tissues.
Materials and methods: PNPLA3 regulation was studied in a new cell line, 
immortalized human hepatocytes (IHH). The cells were treated for 24 h with 
agonists/antagonists of LXR, FXR, PXR, SREBP, PPARα, or PPARγ, followed 
by qPCR quantification of PNPLA3 mRNA. Human PNPLA3 cDNA was 
isolated, and the I148M variant was generated by site-directed mutagenesis. 
Wild-type and I148M cDNAs were expressed in IHH and visualized by con-
focal microscopy. Expression of adiponutrin protein in human subcutaneous 
adipose tissue and liver was studied by Western blotting.
Results: PNPLA3 mRNA was induced by high glucose, dependent on 
ChREBP. The oxysterols 25- and 22(R)-hydroxycholesterol suppressed the 
mRNA, in the absence of effect by the LXR agonist T0901317, suggesting 
regulation of PNPLA3 by SREBP1c. Furthermore, stimulation of FXR by 
chenodeoxycholic acid or GW4064 suppressed PNPLA3. Both wild-type adi-
ponutrin and the I148M variant were found to localize extensively on lipid 
droplets in IHH cells. Western analysis demonstrated abundant presence of 
adiponutrin protein in both human subcutaneous adipose tissue and liver.
Conclusion: The results are consistent with a function of adiponutrin as-
sociated with up-regulation of hepatic lipogenesis by carbohydrate feeding. 
PNPLA3 expression is positively controlled by central transcription factor 
systems responsive to glucose and insulin, ChREBP and SREBP1c, which en-
hance glycolysis and lipogenesis. PNPLA3 is suppressed by FXR, an effect 
possibly mediated via SREBP1c. Location of adiponutrin on lipid droplets 
suggests its intimate involvement in neutral lipid metabolism on the droplet 
surface.
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Discovery of a novel in vivo active heterocyclic inhibitor of stearoyl-CoA 
desaturase 
M.D. Voss, G. Zoller, A.W. Herling, G. Biemer-Daub, H. Matter,  
A. Pfenninger, M. Kohlmann; 
Research and Development, Sanofi-Aventis, Frankfurt am Main, Germany.
Background and aims: Stearoyl-CoA desaturase (SCD1) is linked to the 
pathogenesis of obesity, dyslipidemia and type 2 diabetes. SCD1 is rate-limit-
ing in the synthesis of monounsaturated 16:1 n-7 and 18:1 n-9 fatty acyl-
CoAs and catalyses an essential part of lipogenesis. Here, we describe the 
identification, in vitro properties and in vivo efficacy of a novel heterocyclic 
small molecule SCD1 inhibitor.
Materials and methods: SCD1, cytochrome b5 reductase, FADS1 and 
FADS2 activities were determined in rat liver microsomes. Cellular human 
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and rat enzyme activities were measured in HepG2 and H4IIE hepatoma cell 
lines, respectively. Metabolic stability was determined in liver microsomes, 
cell permeability in CaCo-2 cells. Male obese ZDF rats were used to assess in 
vivo effects on serum desaturation indices, body weight, blood glucose and 
triglycerides in a 4 weeks multiple dose study. All clinical blood parameters 
were determined by commercially available diagnostic kits on a Hitachi 912 
device, serum fatty acid desaturation indices were analysed by LCMS.
Results: Hexahydropyrrolopyrole SCD1 inhibitors were discovered and a 
compound representative of the series was optimised to an IC50 of 7nM in 
rat liver microsomes and a cellular IC50 of 56 nM in rat H4IIE hepatoma 
cells. The compound is highly selective towards fatty acid desaturases 1 and 
2 (D5 and 6 desaturases) and cytochrome b5 reductase (> 400-fold). Low 
metabolic lability in liver microsomal fractions (4%) and high cell permabil-
ity (401x107 cm/s) allowed an in vivo assessment in ZDF rats. After 5 days 
dosing at 20mg/kg per os serum Cmax levels reached 4520 ng/mL and a plasma 
half life of 14 hrs could be determined. After 28 days of treatment at 20mg/
kg, the compound significantly decreased body weight (-8.1±0.5%), serum 
triglycerides (-56.1±4.0%), blood glucose levels (-28.0±3.4%) and HbA1c (-
22.8±5.8 %) compared to vehicle in the obese animals. In parallel, serum fatty 
acid desaturation indices were decreased (-94.8±11.6%). However, fissures of 
the eye lid, alopecia and inflammation of the skin were observed from day 14 
on in all animals treated with the same metabolically active dose.
Conclusion: In summary, we described in vitro and in vivo properties of a 
novel, potent and selective SCD1 inhibitor that improved body weight, blood 
glucose and triglycerides in an animal model of obesity, type 2 diabetes and 
dyslipidemia. However, the favourable in vivo features of systemic SCD1 in-
hibition shown in this study were accompanied by adverse target-related ef-
fects observed in skin. Thus, systemic SCD1 inhibition by small molecules 
might therefore not represent a feasible approach for the treatment of chronic 
metabolic diseases.
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Expression of nonalcoholic fatty liver disease associated adiponutrin 
variant I148M causes triglyceride accumulation
H.A. Jones, C. Fernandez, S. Larsson, C. Holm; 
Experimental Medical Sciences, Lund University, Lund, Sweden.
Background and aims: The strong association between adiponutrin variant 
I148M and hepatic steatosis has recently highlighted adiponutrin as an im-
portant putative enzyme involved in lipid metabolism. Based on structural 
similarities to patatin domain-containing proteins, adiponutrin has been 
proposed to have both lipolytic and lipogenic capabilities, but its function 
and physiological relevance in lipid homeostasis are still unknown. Despite 
efforts, the biological role of adiponutrin and the mechanisms underlying the 
strong association between the I148M adiponutrin variant and elevated he-
patic triacylglycerol levels remain elusive. Here we examine the impact of the 
polymorphism encoding I148M in adiponutrin on lipid storage in HEK293 
cells.
Materials and methods: HEK293 cells were transfected with human wild 
type, I148M, C99G and K434G variants of adiponutrin. 36h post transfection 
the cells were analyzed with regard to lipid content, profile of extracted lipids 
and lipid accumulation by imaging of stained cells.
Results: Overexpression of wild type or the I148M variant of adiponutrin 
leads to significant increases in triglyceride content [30% (p<0.05) or 2-fold 
(p<0.001), respectively] compared to control transfected cells. Interestingly, 
the I148M variant caused a significantly greater [50% (p<0.001)] lipid ac-
cumulation compared to wild type adiponutrin. Thin layer chromatography 
of extracted lipids from parallel experiments confirmed that both wildtype 
and the I148M variant of adiponutrin cause accumulation of triacylglycerol 
in cells, leaving monoacylglycerol and diacylglycerol content unaffected, and 
that I148M more effectively promotes triglyceride formation compared to 
wild type. Imaging experiments of fixed cells revealed increased neutral lipids 
contained in visibly larger lipid droplets in wild type and I148M transfected 
cells compared to control. The control variants C99G and K434G behaved 
similarly to wild type adiponutrin in all experiments.
Conclusion: The presented data where expression of human recombinant 
adiponutrin promotes lipid storage suggests a primarily lipogenic rather than 
a lipolytic role for adiponutrin. Our data showing an increased lipogenic po-
tential of the I148M variant of adiponutrin, compared to wild type, corrobo-
rates the strong association between I148M and liver steatosis in patients.
Supported by: Lund University Diabetes Centre
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Adipocyte control of cancer cell growth
V. D’ Esposito1, F. Passaretti1, A. Hammarstedt2, R. Valentino1, G. Perruolo1, 
P. Mirra1, C. Miele1, U. Smith2, F. Beguinot1, P. Formisano1; 
1DBPCM e IEOS/CNR, Università degli studi di Napoli, Napoli, Italy, 
2Department of Molecular and Clinical Medicine/Diabetes, Institute of 
Medicine, Sahlgrenska Universitetssjukhuset, Göteborg, Sweden.
Obesity is one of the most challenging and growing health problems, world-
wide. Epidemiologic studies now provide compelling evidence that obesity 
is a risk factor for both cancer incidence and mortality. In particular, obesity 
increases rates of breast cancer in postmenopausal women and is associated 
with a more poor survival and increased recurrence of disease, regardless the 
menopausal status. It is now becoming clear that adipocytes, which represent 
very abundant cell types surrounding cancer cells, particularly in the mam-
mary gland, could influence several aspects of tumorigenesis, from promot-
ing local invasion to angiogenesis and metastasis. However, the molecular 
mechanisms involved in the adipocyte control of the malignant phenotype 
remain poorly understood. We have studied the mechanisms by which adi-
pocytes may affect breast cancer cell phenotypes. We have obtained evidence 
that conditioned medium (CM) of adipocytes derived from human mam-
mary adipose tissue and from subcutaneous abdominal fat biopsies was capa-
ble to elicit growth of MCF7 breast cancer cells. This was also observed when 
mature adipocytes were obtained from undifferentiated precursors isolated 
from the stromal-vascular fraction (SVF). Similarly, CM from 3T3-L1 cells 
induced growth of MCF7 cells, in a time-dependent manner. In particular, 
CM from fully differentiated adipocytes was 2-fold more effective than CM 
from pre-adipocytes in inducing MCF7 growth. Cell cycle analysis by flow 
cytometry revealed that these changes are due to reduced apoptosis instead 
of increased proliferation. Multiplex screening for growth factors in the CM 
revealed that VEGF, FGF and PDGF secretion is higher by SVF cells than by 
adipocytes, suggesting a major involvement of SVF in promoting angiogen-
esis. In contrast, the content of IGF-1 produced by adipocytes is two-fold 
higher than that released by pre-adipocytes. Thus, IGF-1 could be a good 
candidate in mediating survival effect of adipocyte CM. Moreover, treatment 
of MCF7 with the IGF-1R inhibitor AG1024 reverted the adipocyte CM ef-
fect on cell growth. In conclusion, adipocyte-derived factors promote breast 
cancer cell growth by inhibiting apoptosis. This effect is more evident for fac-
tors released by adipocytes than by pre-adipocytes and is, at least in part, 
mediated by IGF-1.
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High dose detemir inhibits proliferation of a human bladder cancer T24 
cell line independent of Akt and ERK pathway
S. Liu1, Y. Li2, Y. Liang2, T. Lin1; 
1Research Center of Medicine, 2Department of Endocrinology, The Second 
Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China.
Background and aims: Growing evidence indicated the involvement of mi-
togenicity of insulin and insulin analogues in the increased risk of carcino-
genesis in diabetes subjects. This study was aimed to investigate the effect 
of insulin detemir in comparison to regular human insulin on proliferation 
of a human bladder cancer T24 cell line and the role of Akt and ERK in the 
process.
Materials and methods: T24 cells were cultured and treated with detemir or 
insulin at the indicated concentrations for different time courses. A specific 
inhibitor for ERK1/2 (PD98059) or Akt (LY294002) was used either alone or 
in combination with detemir or insulin to test the involvement of Akt and 
ERK pathway in detemir or insulin-induced cell proliferation as evaluated 
using cell counting kit-8 reagents. Protein levels of Akt, pAkt, ERK, pERK 
were detected by Western blotting.
Results: Human insulin time- and dose-dependently enhanced proliferation 
of T24 cell at the concentrations of 10 and 100IU/L after treatment for 48, 72 
and 96 hours. However, detemir inhibited T24 cell growth at 100IU/L. Both 
insulin and detemir promoted phosphorylation of ERK and Akt at 15, 30, 
and 60 min of treatment. Although ERK inhibition significantly enhanced 
while Akt inhibition reduced T24 cell proliferation, insulin still promoted 
while detemir inhibited T24 cell growth in the presence of either Akt or ERK 
inhibitor.
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Conclusion: Insulin promotes proliferation of T24 cells. Detemir inhibits 
T24 cell proliferation at high dose independent of Akt or ERK activation.
Supported by: China NSFC grant 30671974, GDSF grants 04009408 and 
06021329
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Anti-apoptotic activities of insulin and insulin-like growth factor (IGF) 1 
in human osteosarcoma Saos-2/B10 cells 
C. Schmid, C. Ghirlanda, M. Niessen; 
University Hospital of Zurich, Switzerland.
Background and aims: Obesity, insulin resistance and hyperinsulinaemia are 
associated with an increased risk of growth progression of some cancer types 
and possibly also with enhanced survival of tumour cells. We studied anti-
apoptotic effects of insulin and IGF 1 in a cell line which is critically depen-
dent on IGF- or insulin- like signals for proliferation and survival in vitro.
Materials and methods: B10 cells were grown in serum-containing media 
and then exposed to serum-free test media. DNA synthesis was measured as 
3H-thymidine incorporation during a pulse given 18-21 h following expo-
sure to test media, and apoptosis was assessed after 4 h by an ELISA detecting 
cytosolic oligonucleosomes. Insulin/IGF 1 signalling was analysed by West-
ern blotting.
Results: Effects of insulin and IGF 1 were dose-dependent: 0.4 nM IGF 1 or 
20 nM insulin was required for half-maximal stimulation of DNA synthesis 
whereas 0.04 nM IGF 1 or 1 nM insulin resulted in half-maximal inhibition 
of apoptosis. Effects of insulin and IGF 1 were time-dependent: 1 nM IGF 1 
or 100 nM insulin prevented apoptosis half-maximally when added for the 
last 1-2 (of a total of 4) h whereas sequestering IGF 1 (but not of insulin) 
by adding IGF-binding protein (IGFBP)-3 led to a half-maximal loss of pro-
tection from apoptosis within the last 1-2 (of 4) h. Insulin and IGF 1 both 
activated Akt/PKB to similar levels, but activation of ERK1/2 was higher in 
the presence of insulin (after stimulation for 4 h). Insulin or IGF 1 did not 
protect against apoptosis in the continuous presence of 100 nM wortmannin 
(4 h) which was associated with reduced phosphorylation of PKB but more 
than half-maximal protection was still found when wortmannin was added 
only for the last 3 h.
Conclusion: Continuous exposure to IGF 1 (suppressible by IGFBP-3) or to 
insulin (not suppressible by IGFBP-3) prevents B10 cell apoptosis, possibly 
dependent on Akt/PKB. Apoptosis appears to be more sensitive to regulation 
by IGF 1 and insulin than mitogenesis.
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The role of juxtaposed with another zinc finger gene 1 on glucose-lipid 
metabolism and related genes in vitro
L. Du1,2, L. Li1,2, G. Yang3; 
1The Key Laboratory of Laboratory Medical Diagnostics in the Ministry 
of Education, 2Department of Clinical Biochemistry, 3Department of 
Endocrinology, the Second Affiliated Hospital, Chongqing Medical 
University, China.
Background and aims: Epidemiologic studies have shown the association of 
Diabetes Mellitus (DM) with either increased or decreased risk of develop-
ing malignant tumors. Recently, a genome-wide association studies have sug-
gested the association of JAZF1 (juxtaposed with another zinc finger gene 1) 
with DM and prostate cancer. JAZF1 encodes a 27 kDa nuclear protein con-
taining three putative zinc finger motifs, and is expressed in a variety of tis-
sues of mouse, with highest expression in adipose tissue and testis. however, 
little is known about the functions in regulating metabolism. In our study, we 
investigated the influence of an overexpression of JAZF1 on 3T3-L1 adipose 
cells and hepatoma carcinoma Hepa1-6 cells which represent target tissue for 
diabetes and insulin resistance.
Materials and methods: To survey the tissue distribution of JAZF1 in healthy 
C57BL/6J mice by real-time quantitative PCR(SYBR GreenI); Expression 
vector for JAZF1 gene was constructed and transient transfected into 3T3-
L1 preadipocytes and hepatoma carcinoma Hepa1-6 cells, respectively. Oil 
Red O staining for 3T3-L1 preadipocytes was carried out. The mRNA lev-
els of JAZF1, GLUT1,GLUT4, FAS(fatty acid synthetase), ACC(acetyl-CoA 
carboxylase), SREBP1(Sterol Regulatory Element Binding Protein1), and 
HSL(Hormone Sensitive lipase) implicated in glucose and lipid metabolism 
were determined by RT-QPCR; JAZF1 protein levels were measured by west-
ern blot.
Results: JAZF1 is expressed in all tissues examined, with highest levels de-
tected in testis and adipose tissues and lowest levels in muscle and kidney. 
In JAZF1-transfected adipocytes, JAZF1 mRNA expression and protein 
levels were significantly higher than control cells after transfected 48h. The 
mRNA levels of HSL was increased obviously(P<0.05)in JAZF1 transfection 
group compared with negative control and empty vector group, and the rela-
tive expression of FAS,ACC,SREBP1 mRNA were decreased significantly(all 
P<0.001). However, the mRNA levels of GLUT1,GLUT4 were not changed (all 
P>0.05). Intercelluar lipid accumulation was decreased obviously (P<0.05)by 
Oil Red O staining and colorimetric in JAZF1-transfected cells compared 
with negative control and empty vector group.
Conclusion: There were a widely expression of JAZF1 in various organiza-
tion of C57BL/6J mice, it indicated that JAZF1 might play a role in maintain-
ing normal physiological function. These results show that overexpression 
of JAZF1 in 3T3-L1 cells can reduce lipid synthesis, increase lipolysis and 
improve lipid accumulation. We speculate that JAZF1 might provide a new 
potential therapeutic target for obesity and diabetes.
Supported by: National Natural Science Foundation of China (30370671, 
30771037, 30971388)
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Induction of HSP72, a potential novel therapeutic approach for 
metabolic syndrome and type 2 diabetes
T. Kondo1, R. Matsuyama1, K. Sasaki1, S. Morino-Koga2, M.A. Suico2,  
J. Kawashima1, H. Motoshima1, N. Furukawa1, K. Tsuruzoe1, N. Miyamura1, 
H. Kai2, E. Araki1; 
1Metabolic Medicine, 2Molecular Medicine, Kumamoto University, 
Kumamoto, Japan.
Background and aims: Life-style related diseases, such as type 2 diabetes and 
metabolic syndrome (MS) are associated with reduction of heat shock protein 
(Hsp) 72 levels, and activation of Hsp72 expression may improve insulin re-
sistance and visceral adiposity. The present study investigated whether Hsp72 
induction using an apparatus which provides Mild Electrical stimulation with 
Thermotherapy (MET) could reduce visceral adiposity and improve glucose 
homeostasis in mice models of type 2 diabetes and in human with MS.
Materials and methods: C57/BL6 mice fed with high-fat feeding and db/db 
mice were treated with MET (12V, 55 pulses per second, 10 min at 42oC, 
twice a week for 8~10 weeks) or sham-treatment. High-fat fed mice were also 
treated with Hsp72 inducer geranylgeranylacetone (GGA), 200 mg/day for 4 
weeks. Forty eligible male MS subjects were randomly assigned to two groups, 
each containing 20 subjects. Group I was subjected to a 12-week intervention 
period of MET (12V, 55 pps, 60 min at 42oC, 4 times a week) followed by 12 
weeks with no treatment. The order was reversed in Group II.
Results: High-fat fed mice and db/db mice presented following favorable 
changes upon treatment with either MET or GGA administration. 1) Reduc-
tion of visceral (-34%) and subcutaneous (-44%) fat mass, 2) Reduction of 
fasting glucose (-20%) and insulin levels (-38%), 3) Improvement of glucose 
homeostasis and insulin resistance, 4) Upregulation of serum adiponectin 
levels (+94%), 5) Improvement of insulin signaling in liver. We observed fol-
lowing results upon MET treatment in male subjects with MS. 1) Reduction 
of visceral fat (-5.8%) and total abdominal fat (-3.3%) area, but not subcu-
taneous fat area, 2) Decrease of waist circumference (-0.7%), but not body 
weight, 3) Reduction of both systolic (-4.2%) and diastolic blood pressure (-
2.7%), 3) Improvement of fasting plasma glucose (-4.9%) and insulin levels (-
8.5%) as well as HOMA-IR (-11.7%), QUICKI (+2.4%) and composite WBISI 
(+17.2%), 4) Trend of reduction in HbA1c (-1.2%, p=0.065), 5) Decrease of 
insulinogenic index (-10.2%), 6) Amelioration of inflammatory cytokines or 
adpokines, such as hs-CRP (-27.4%), adiponectin (+9.3%), leptin (-8.3%) and 
TNF-α (-10.2%), 7) Decrease of WBC (-5.4%) and LDL-C (-5.3%) levels.
Conclusion: Hyperthermia with mild electrical stimulation improved glu-
cose homeostasis and insulin resistance in mice models of type 2 diabetes and 
human with MS. Therefore, this treatment could have beneficial impacts on 
body composition and metabolic abnormalities in life-style related diseases. 
Type 2 diabetes could be one of the other targets for the treatment.
Supported by: the Ministry of Economy, Trade and Industry of Japan
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Taurocholate delivered to the distal gut suppresses food intake and 
causes weight loss in rats
A.A. Young, G. Gedulin, M. Tryon, B.R. Gedulin; 
Physiology, Satiogen Pharmaceuticals Inc., San Diego, USA.
Background and aims: Bile acids (BA’s), the endogenous ligands for TGR5 
receptors located on enteroendocrine L-cells, stimulate the secretion of the 
anorexigenic hormones GLP-1, PYY and oxyntomodulin, as well as GLP 
2. Several orally administered TGR5 agonists do not evoke robust anorexic 
effects, perhaps by failing to reach colon and rectum, wherein the peptide 
content and secretory response of L cells can be over 2 orders of magnitude 
higher than in more accessible stomach and duodenum.
Materials and methods: Effects of rectal BA’s on food intake were studied 
in [male] Sprague Dawley rats fasted 12 hours. In a series of dose-response 
experiments, each of 12 rats received each of 4 taurocholate (TCA) doses 0 
(control), 0.15, 0.45 or 1.5 mmol in 3 replicates of a 4x4 Latin Square de-
sign. In separate study, taurocholate was delivered to the distal gut of [male] 
Sprague Dawley rats via an intraperitoneally implanted osmotic minipump 
(Alza) and intraluminal catheter at a rate of 6 µmol/hour (n=6) for 7days; 
control group minipump delivered saline only (n=6).
Results: Cumulative food intake measured up to 24 hours after rectal delivery 
of TCA was dose dependently decreased. Relative to controls, food intake 
in TCA treated rats was reduced by 32%, 43%, and 70% by 0.15, 0.45 and 
1.5 mmol doses, respectively (P<0.05, 1-way ANOVA). The ED50 for TCA-
induced reduction in cumulative food intake at 1 hour was 1.6 mmol. For 24 
hour intake, the value was 7.2 mmol. In the second study 10% weight loss 
induced by taurocholate delivered for 7days was greater than the 5% observed 
in surgical controls ( P<0.05).
Conclusion: In conclusion, we have demonstrated an effect of rectally ad-
ministered taurocholate to dose-dependently inhibit food intake in normal 
rats for up to 24 hours, and for sustained taurocholate delivery to the lower 
bowel to induce weight loss.
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Weight loss during a hypo-caloric diet induces an anti-inflammatory 
response in adipose tissue
M. van Eijk1, M. Brands2, N.M. Lammers2, H.P. Sauerwein2, E. Endert2,  
M.T. Ackermans2, M.J. Serlie2; 
1Medical Biochemistry, 2Endocrinology and Metabolism, Acadmic Medical 
Center, Amsterdam, Netherlands.
Adipose tissue of obese insulin resistant subjects is characterized by a low-grade 
inflammatory phenotype and reduced levels of adiponectin and GLUT4. The 
low-grade inflammation is associated with pro-inflammatory macrophages in 
adipose tissue. The aim of this study was to evaluate whether this inflammatory 
response is an early or late feature during the course of weight gain. Therefore, we 
studied the inflammatory changes in plasma and subcutaneous adipose tissue in 
healthy lean men before and after a positive energy balance resulting in modest 
weight gain, and a negative energy balance resulting in loss of the gained weight. 
We studied 9 healthy lean men (age 37 [27-43] years and BMI 23.6 [20.6-25.6] 
kg/m2). The hypercaloric diet was calculated as 1.4 x caloric need to maintain 
body weight. After a median of 35 [28-43] days participants gained 7 [5.1-7.6]% 
of their initial body weight. The hypocaloric diet was calculated as 1.00x resting 
energy expenditure. At the end of the hypo-caloric diet participants returned to 
their initial weight. The protein, fat and carbohydrate content of the diets were 
16%, 30% and 54% respectively. Participants were monitored weekly to assess 
body weight, body composition, and plasma leptin concentrations. Before the 
diet intervention and after the hypercaloric (HYPER) and hypocaloric (HYPO) 
diet, blood samples and abdominal subcutaneous adipose tissue (AT) biopsies 
were taken after an overnight fast to measure plasma concentrations and AT ex-
pression levels of inflammatory markers and adipokines. Plasma levels of leptin, 
adiponectin and MCP-1 were all increased in the HYPER state. In AT, inflam-
matory markers (TNF, IL10, MCP1, osteopontin) did not change significantly, 
but expression of the mannose receptor (MR) decreased significantly. Interest-
ingly, expression of GLUT 4 in AT was significantly increased during the posi-
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tive energy balance. During the period of the negative energy balance, plasma 
adiponectin, MCP-1 levels and resistin returned to baseline, while leptin levels 
decreased below baseline levels. In AT expression of adiponectin and a trend 
for decreased GLUT4 expression compared to baseline was observed. Interest-
ingly, the expression of CD68, CD163 and MR increased in the HYPO state, 
indicating that there was a higher content of alternatively activated macrophages 
after the negative energy balance. In conclusion, in the early phase of a posi-
tive energy balance resulting in modest weight gain, a limited pro-inflamma-
tory response in plasma is present. GLUT 4 expression is increased facilitating 
triglyceride formation. During a negative energy balance, alternatively activated 
macrophages are present in AT indicating an anti-inflammatory response which 
may be important in tissue remodelling.
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Phentermine/topiramate combination therapy significantly improves 
glucose impairment in overweight/obese patients
L.F. Van Gaal1, W.T. Garvey2, B. Troupin3, W.W. Day3; 
1Antwerp University Hospital, Antwerp, Belgium, 2University of Alabama; 
Birmingham VA Medical Center, Birmingham, 3VIVUS, Inc, Mountain 
View, USA.
Background and aims: Obesity, which is strongly linked to type 2 diabetes 
mellitus (T2DM), is on the rise. Impaired fasting glucose/impaired glucose 
tolerance (IFG/IGT) are prediabetic glycemic states associated with insulin re-
sistance and increased risk of cardiovascular disease. A 56-week Phase 3 study 
(CONQUER) was performed to confirm the efficacy and safety of once-daily, 
low-dose, controlled-release phentermine/topiramate (PHEN/TPM CR) in 
overweight/obese patients with at least 2 comorbidities such as prediabetes 
or T2DM. In addition, this study evaluated the effects of PHEN/TPM CR on 
various glycemic parameters in a subgroup of patients with IFG/IGT.
Materials and methods: All subjects underwent oral glucose tolerance test-
ing (OGTT) at baseline, Week 4, and Week 56. From this, a subgroup of sub-
jects with IFG/IGT at baseline was defined using fasting serum glucose >5.55 
mmol/L, or serum glucose >7.77 mmol/L 2 hours after a 75 g glucose load.
Results: Out of 2487 patients enrolled, 1635 (66%) were identified as having 
IFG/IGT. Patients were randomized to either placebo (n=655), PHEN/TPM 
CR 7.5/46 mg (7.5/46 [n=335]), or PHEN/TPM CR 15/92 mg (15/92 [n=645]); 
treatment with both doses of PHEN/TPM CR resulted in a significantly greater 
percent weight loss than placebo. For subjects with IGT/IFG, the mean percent 
weight loss at Week 56 with LOCF was 2.3% for placebo, 8.3% for 7.5/46, and 
10.5% for 15/92. The table presents the results for change in HbA1c and fasting 
serum glucose from baseline to Week 56 (ITT-LOCF). Both PHEN/TPM CR 
doses led to significantly greater improvement vs placebo in HbA1c and fast-
ing serum glucose. Further analysis showed that, among the subgroup of pa-
tients with IFG/IGT (per OGTT) who completed the study (n=562), achieve-
ment of normal OGTT was 44.2%, 63.1%, and 73.1% for placebo, 7.5/46, and 
15/92, respectively (P<0.0001 vs placebo) (Table). The percentage of IFG/IGT 
subjects progressing to T2DM during the study was 15.3%, 6.9%, and 4.5% for 
placebo, 7.5/46, and 15/92, respectively. PHEN/TPM CR was well tolerated.
Conclusion: In addition to achieving significant weight loss, patients with 
IFG/IGT who were treated with PHEN/TPM CR achieved significant im-
provements in glycemic parameters and decreased incidence of progression 
to worsening glycemic status, suggesting prevention of progression to diabe-
tes and/or reversion to normal glycemic status.
Change in Glycemic Parameters From Baseline to Week 56 in Subjects With 
Impaired Glucose (ITT-LOCF)
Parameter Placebo PHEN/TPM CR 
7.5/46
PHEN/TPM CR 
15/92
HbA1c (%)
n 539 309 594
LS Mean 0.0 -0.1* -0.2*
Fasting Serum Glucose (mmol/L)
n 628 328 623
LS Mean -0.16 -0.34* -0.42*
Achievement of normal OGTT
n 190 69 145
Percentage of patients 44.2 63.1** 73.1*
*P<0.0001 vs placebo **P=0.0005 vs placebo
Supported by: Vivus, Inc
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Once-daily, low-dose, controlled-release phentermine/topiramate results 
in significant clinical improvements in overweight/obese patients with 
type 2 diabetes
W.T. Garvey1, B. Troupin2, W.W. Day2; 
1University of Alabama; Birmingham VA Medical Center, Birmingham, 
2VIVUS, Inc, Mountain View, USA.
Background and aims: Weight loss can delay progression to type 2 diabetes 
mellitus (T2DM) and improve glycemic control in patients with T2DM. A 
56-week Phase 3 trial (CONQUER) was conducted to evaluate efficacy and 
safety of low-dose, controlled-release phentermine/topiramate (PHEN/TPM 
CR) for weight loss in overweight/obese patients with and without T2DM, 
and effects on glycemic control and medication load in T2DM patients.
Materials and methods: In this randomized, double-blind trial, 2487 obese 
subjects meeting at least 2 criteria for the metabolic syndrome received pla-
cebo (n=994), PHEN 7.5 mg/TPM CR 46 mg (7.5/46 [n=498]), or PHEN 
15 mg/TPM CR 92 mg (15/92 [n=995]). At baseline, T2DM subjects were 
treated with lifestyle intervention or metformin; they were managed to ADA 
standards of care. This T2DM subpopulation was further analyzed.
Results: At baseline, the mean weight of all randomized subjects was 103.1 
kg, mean BMI was 36.6 kg/m2, and mean HbA1c was 5.9%. In total, 338 
(15.8%) patients had a previous diagnosis of T2DM or an elevated fasting glu-
cose (FG) (>6.94 mmol/L) at baseline. Mean baseline HbA1c for the T2DM 
subpopulation was 6.8%; mean FG was 7.43 mmol/L. At Week 56, the least 
squares (LS) mean weight loss for placebo, 7.5/46, and 15/92, was 1.2%, 7.8%, 
and 9.8%, respectively, for the overall ITT-LOCF population (P<0.0001 for 
PHEN/TPM CR vs placebo). Those subjects completing 56 weeks of treat-
ment on drug also experienced significant weight loss vs placebo (P<0.001): 
1.6%, 9.6%, and 12.4% for placebo, 7.5/46, and 15/92, respectively. Among 
ITT-LOCF subjects with T2DM at baseline, LS mean weight loss was sig-
nificant vs placebo at Week 56 (P<0.0001): 1.9%, 6.8%, and 8.8% for placebo, 
7.5/46, and 15/92, respectively. During the study, a greater proportion of sub-
jects with T2DM in the placebo group required an increase in concomitant 
antidiabetic medications than those in the PHEN/TPM CR groups (Table). 
LS mean decrease in HbA1c from baseline to Week 56 in subjects with T2DM 
(ITT-LOCF) was significantly greater with both doses of PHEN/TPM CR vs 
placebo (0.4%, 0.4% vs 0.1%; P<0.05). LS mean decreases from baseline in 
FG (mmol/L) were also greater in the PHEN/TPM CR groups vs placebo: 
0.31, 0.54, and 0.66 for placebo, 7.5/46, and 15/92, respectively (P=0.0556 for 
15/92 versus placebo; P=0.3325 for 7.5/46 vs placebo). PHEN/TPM CR was 
well tolerated with the majority of adverse events (AEs) being mild in sever-
ity. The most common AEs were tingling, dry mouth, constipation, altered 
taste, and insomnia.
Conclusion: In this study, patients with T2DM experienced significant weight 
loss with PHEN/TPM CR therapy. These results were associated with clini-
cally meaningful improvements in glycemia through 56 weeks compared to 
placebo, despite increased use of diabetes medications in the placebo group. 
Thus, PHEN/TPM CR can enhance glycemic control in overweight/obese 
patients with T2DM.
Changes in Number of Antidiabetic Medications, Baseline to Week 56: 
Diabetic Population (ITT-LOCF)
Treatment n Subjects With 
Decrease
n (%)
Subjects With 
No Change
n (%)
Subjects With 
Increase
n (%)
Placebo 157 4(2.5) 130 (82.8) 23 (14.6)
PHEN/TPM CR 
7.5/46
67 2 (3.0) 62 (92.5) 3 (4.5)
PHEN/TPM CR 
15/92
164 6 (3.7) 151 (92.1) 7 (4.3)
Supported by: Vivus, Inc
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Restoration of beta cell function in severely obese type 2 diabetic patients 
after gastric bypass surgery 
B. Schultes1, B. Ernst1, B. Wilms1, M. Thurnheer1, E. Svehlikova2,  
B.M. Obermayer-Pietsch2, T.R. Pieber2; 
1Interdisciplinary Obesity Center, Kantonsspital St. Gallen, Rorschach, 
Switzerland, 2Division of Endocrinology and Nuclear Medicine, Department 
of Internal Medicine, Medical University of Graz, Austria.
Background and aims: Gastric bypass surgery has been shown to frequently 
resolve type 2 diabetes but the mechanism underlying are incompletely un-
derstood. Here we report preliminary results on a systematic assessment of 
beta-cell function along with insulin sensitivity before and shortly after gas-
tric bypass surgery in the first 6 type 2 diabetic patients of an ongoing study.
Materials and methods: Before and 8 to 21 days after the operation, patients 
were subjected to an OGTT as well as to a botnia clamp which combines an 
IVGTT with a subsequent hyperinsulinemic-euglycemic clamp. Established 
models were used to calculate varies indices of glucose metabolism. Known 
diabetes duration in our patients ranged from 1 to 14 years (mean ± SEM: 
8.2 ± 2.0 years).
Results: Body weight decreased from 121.4 ± 9.2 to 113.7 ± 8.4 kg and BMI 
from 43.3 ± 1.5 to 40.7 ± 1.6 kg/m2 (both P < 0.005) and diabetes medication 
was markedly reduced after the operation (before: 4 patients short- and long-
acting insulin, average dose 56.5 ± 12.1 U/day and 51.5 ± 10.0 U/day, respec-
tively, 6 patients metformin, one patients gliclazide; after: 4 patients long-act-
ing insulin, average dose 21.5 ± 5.9 U/day, no short-acting insulin, no oral 
antihyperglycemic agents). Concentrations of HbA1c, fasting glucose, and 2 
h glucose response to the OGTT were significantly reduced after surgery (all 
P < 0.05). None of the calculated indices of insulin secretion, e.g. acute insulin 
response (AIR), pointed to a significant improvement of beta-cell function 
(all P > 0.5) while indices of insulin sensitivity tended to increase (e.g. M-
value 1.65 ± 0.59 vs. 3.67 ± 0.52; P = 0.07).
Conclusion: In contrast to previous studies in type 2 diabetic patients not 
treated with insulin with disease duration less than 6 years, we did not find an 
improvement in beta-cell function shortly after gastric bypass surgery. Thus, 
improved glucose metabolism soon after the operation appears to rely prima-
rily on enhanced insulin sensitivity. However, these preliminary observations 
do not exclude a restoration of beta-cell function later after gastric bypass 
surgery.
Supported by: an EFSD/MSD grant
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Sleeve gastrectomy, only a restrictive surgical procedure?
D. Benaiges1, A. Goday1, J.M. Ramon2, E. Hernandez-Rivas1, M. Villatoro1,  
J. Flores1, M. Carrera1, L. Grande2, J.F. Cano1; 
1Endocrinology and Nutrition, 2Surgery, Hospital Universitari del Mar, 
Barcelona, Spain.
Background and aims: Bariatric Surgery (BS) offers new therapeutic pos-
sibilities for subjects with morbid obesity (MO) and type 2 diabetes mellitus 
(DM2). Several studies suggest that the malabsorptive surgical procedures 
are more effective than restrictive techniques (Gastric Banding and Vertical 
Banded Gastroplasty) for the treatment of DM2. The aim of this study is to as-
sess the efficiency of Laparoscopic Sleeve Gastrectomy (LSG) vs Laparoscopic 
Y de Roux Gastric By-pass (LYRGB) in the normalization of glucose metabo-
lism disorders, and to analyze subsequent changes in Insulin Resistance (IR) 
in patients with and without glucose metabolism abnormalities.
Materials and methods: Cohort study of MO patients consecutively ad-
mitted for BS (LYRLB or LSG). Patients were grouped according to glucose 
metabolism state categories defined by ADA: DM2, impaired fasting glucose 
(IFG) and normal glucose metabolism (nonDM). IR was defined as a Ho-
meostasis model assessment (HOMA-IR) ≥3.29 (Spanish population study). 
The following clinical and metabolic parameters were gathered at baseline, 3, 
6 and 12 months after the procedure: venous blood glucose, HbA1c, HOMA-
IR and estimated glucose disposal rate (EGDR). DM2 remission was defined 
as: 2 consecutive glucose measurements <126mg/dl, HbA1c <6.5% and no 
need for hypoglycemic drugs. IFG normalization was defined as: 2 consecu-
tive glucose values <100mg/dl and HbA1c <5.7%. And IR resolution was 
characterized by a HOMA <3.28. Multivariate analysis were used to identify 
predictive factors for remission of glucose metabolism disorders and IR.
Results: 140 patients were included with a mean age of 45.6 ± 7.9, 85.6 % 
women, and mean BMI of 45.7 ± 5.0 Kg/m2. 67.9 % underwent a LYRGB 
and 32.1 % a LSG. Baseline characteristics of DM2 patients in both surgical 
interventions were comparable in terms of age, sex, need of hypoglycemic 
drugs, DM2 duration, glucose levels and HbA1c. Clinical outcomes at three 
months follow-up in both surgical groups were as follows: 1) 80.6% DM2 
remission, 2) 89.5% IFG remission, 3) IR remission was achieved in 79.2 % 
of the DM2 patients, in 95.9 % of IFG subjects and in 97.7 % of the nonDM 
subjects. Independent predictors for a significant decrease in HOMA-IR at 12 
months were EGDR and BMI (R2=0.449) . No predictive factors for DM2 or 
IFG resolution were identified.
Conclusion: A restrictive surgical procedure like LSG is equally effective as 
malabsortive techniques in terms of weight loss, improvement of glucose me-
tabolism and IR. EGDR negatively correlates with IR improvement after the 
BS.
LSG LYRGB significance
Age (years) 44.4 ± 9.8 46.1 ± 8.2 p>0.05
BMI (Kg/m2) 44.5 ± 45.5 46.3 ± 4.7 p>0.05
EGDR (mg/kg-1 min-1) 8,9 ± 2.1 8,2±2.4 p>0.05
HOMA-IR 4.2 ± 2.4 4.6 ± 3.0 p>0.05
DM2/ IFG (%) 15.6 / 44.4 26.3 / 40.0 p>0.05
IR (%) 67.6 67.1 p>0.05
Percentage of excess weight loss  
12 months
82.9 ± 18.8 80.9 ± 16.6 p>0.05
HOMA-IR decrease 12 months 2.2 ± 1.5 3.6 ± 3.0 p>0.05
IR remission (%) 12 months 95.5 100 p>0.05
IFG remission (%) 12 months 85 94.6 p>0.05
DM2 remission (%) 12 months 100 92 p>0.05
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Respiratory function in massive obesity: effects of surgically induced 
weight loss
J. Aron-Wisnewsky1,2, C. Minville3,4, A. Basdevant1, J. Gonzalez5, P 
. Clement1,2, J.-L. Pepin3,4; 
1Nutrition and Endocrinology Department and CRNH-Ile de France, 
275006, UMR S 872, Centre de Recherche des Cordeliers, Université 
Pierre et Marie Curie-Paris6, 3INSERM ERI 17, HP2 laboratory (Hypoxia: 
Pathophysiology), Joseph Fourier University, Grenoble, 4Rehabilitation and 
Physiology Department, Grenoble University, 5Pulmonary Medicine and 
Intensive care unit, Paris, France.
Background and aims: In obese patients, adipose tissue around the rib cage 
and abdomen and in the visceral cavity loads respiratory system, increases 
work of breathing and reduces lung volumes particularly functional residual 
capacity (FRC) and expiratory reserve volume (ERV). Obesity also affects air-
way caliber with a slight reduction in expiratory flows. To date, limited data 
are available on the effects of bariatric surgery on respiratory function. We 
aimed to systematically investigate respiratory function of obese patients at 
baseline (T0) and 6 months (T6) after surgically induced weight loss.
Materials and methods: We conducted a retrospective analysis of a single 
center observational cohort of 77 obese patients (BMI = 47.8 ±6.7 kg/m²) 
who underwent laparoscopic bariatric surgery (63 Roux-en-Y-gastric bypass; 
14 gastroplasty). Arterial blood gazes and respiratory function tests including 
lung volume and flow measurements were assessed at T0 and T6.
Results: Patient’s characteristics at baseline were as follows: 74% women, 
mean age = 43 ± 11 years, mean PaO2 = 82.9 ± 9.2 mmHg, mean PaCO2= 40.2 
± 6.2 mmHg. Mean values of forced expiratory volume in 1 second (FEV1), 
vital capacity (VC), FEV1/VC and total lung capacity (TLC) as expressed in % 
of predicted values were in the normal range. FRC and ERV were significantly 
reduced (absolute values and % of predicted: 2.0 ± 0.6L; 65 ± 16% and 0.53 ± 
0.33L; 44 ± 25% respectively). On flow volume loops, expiratory flows at 25% 
of VC was also decreased (3.5 ± 0.9L/min; 52 ± 26%). After bariatric surgery 
(T6), we observed a significant weight loss (Δ-30.6 ± 13kg; -22.4 % of the 
initial BMI, p<0.0001) along with a significant improvement from baseline 
in VRE (absolute values and % of variation from baseline: Δ0.4 ± 0.3L; +44 
± 95%; p<0.0001), expiratory flows at 25% of VC (Δ0.13 ±0.39L/min; +9 ± 
33%; p=0.03), FRC (Δ0.4 ± 0.4L; +16 ± 18%; p<0.0001), FEV1 (Δ0.2 ±0.2L/
min; +7 ± 9%; p=0.004) and FVC (Δ0.2 ± 0.3L, +6 ± 8%, p=0.007). More-
over, we found an inverse association between BMI reduction and increases 
in ERV, expiratory flows at 25% and 50% of VC (p=0.0035; p=0.037; p=0.04, 
respectively). Changes in PaO2 and PaCO2 were close to a statistically sig-
nificant improvement (ΔPaO2= 7.3 ± 22 mmHg; p=0.06, ΔPaCO2= -3.9 ± 9 
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mmHg; p=0.07). Whereas 25/77 patients (32.5%) were hypoxemic at baseline 
(PaO2<80mmHg), 13 improved with weight loss at 6 months. All of the 4 
being hypercapnic at baseline normalized their PaCO2.
Conclusion: To our knowledge, this is the largest cohort evaluated in terms 
of respiratory function before and 6 months after surgically induced weight 
loss. Morbidly obese patients exhibited reduced expiratory reserve volume 
with increased risk of airway closure demonstrated by significant reduction 
of expiratory flows at 25% of VC. This is associated with underventilation of 
some lung regions explaining low PaO2 in more than 30% of our cohort. Im-
portantly, surgically induced weight loss allowed a significant improvement 
in pulmonary functions, volumes, flows and blood gazes.
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Massive body mass loss leads to reduced endoplasmic reticulum stress 
and activation of autophagy in adipose tissue
E.P. Araujo, C.E.C. Nuñez, B. Geloneze, J.C. Pareja, L.A. Velloso; 
University of Campinas, Brazil.
Background and aims: Endoplasmic reticulum stress (ER-stress) has 
emerged as an important link between nutritional overload and insulin re-
sistance. High consumption of nutrients, especially saturated fats, induces 
the activation of ER-stress, which promotes inflammatory gene transcription 
and eventually the activation of pro-apoptotic signaling. The inflammatory 
proteins induced by this process mediate the activation of serine/threonine 
kinases in insulin sensitive tissues, contributing for the impairment of the 
insulin signal transduction. Body mass loss is one of the most efficient means 
for correcting glucose intolerance. The reduction of the adipose tissue pro-
duction of inflammatory factors plays a central role in this process. How-
ever, the molecular and cellular mechanisms behind this outcome are poorly 
understood. Here, we explore the hypothesis that massive body mass loss is 
accompanied by reduced ER-stress in the adipose tissue.
Materials and methods: Ten obese patients were submitted to subcutane-
ous adipose tissue biopsy before and 6-8 months after bariatric surgery. Ten, 
age matched lean subjects were employed as controls. Samples were used for 
evaluation of protein and mRNA expression of markers of ER-stress, inflam-
mation and autophagy. Metabolic parameters were evaluated at the same 
time-points as biopsies.
Results: Body mass index dropped from 48±4 to 37±4 (controls, 24±2), 
which was accompanied by the reduction of blood insulin, leptin, TNF-α, 
IL-6 and C-reactive protein and by the increase in the blood levels of adi-
ponectin. Significant reductions in protein (amount/activity) and/or mRNA 
levels of the ER-markers, PERK, eIF2α, IRE1α, spliced XBP1 and JNK were 
observed. The inflammatory proteins TNFα, IL-1β, IL-6, IKK and SOCS-3 
were also negatively modulated by body mass loss. Interestingly, markers of 
autophagy, such as beclin, LC3 and CHOP increased after body mass loss.
Conclusion: The reduction of ER-stress may be an important molecular/
cellular mechanism linking the loss of body mass with reduced adipose-tis-
sue-driven inflammation. The induction of autophagy in this setting may 
contribute to prolonged adipocyte survival during catabolism and may play 
an important role in body mass regain, which is commonly seen in patients 
undergoing restrictive dieting programs.
Supported by: FAPESP
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Identification of determinants for weight reduction in children 
and adolescents with overweight and obesity with an standardised 
questionnaire and electronic health technology
A. Kaps1, G. Bieber2, R. Schiel1,3; 
1MEDIGREIF Inselklinik Heringsdorf, Ostseebad Heringsdorf, Germany, 
2Fraunhofer Institute, IGD Rostock, 3University of Applied Sciences, Faculty 
for Diabetes and Health Management, Rheine, Germany.
Background and aims: The prevalence of overweight/obesity increased 
markedly during the last decades. It is associated with a high risk for diabetes 
and death. Patients often fail to reach sufficient long-term weight reduction. 
The aim of the trial is the development of an research programme to identify 
the determinants of overweight/obesity.
Materials and methods: 97/117 children/adolescents with overweight/obesi-
ty admitted to our hospital to participate in a structured treatment and teach-
ing programme (STTP) due to overweight/obesity were included in the trial 
(age 13.4±2.6 years, BMI 31.2±5.0 kg/m², BMI-SDS 2.49±0.52). All children 
filled out a standardized questionnaire and participate in an intelligence test. 
To asses physical activity and eating habits electronic health technology was 
used (Fraunhofer-Institute, IGD, Germany). The system consists in a motion 
sensor integrated in a mobile phone (DiaTrace). The system analyses kind, 
intensity & duration of physical activity and eating habits.
Results: During participation in the STTP the children/adolescents had a 
weight reduction of 6.97±2.91 kg (p<0.001). BMI/BMI-SDS decreased from 
31.3±5.2 kg/m²/2.50±0.50 to 28.7±4.9 kg/m² (p<0.001)/2.15±0.57 (p<0.001). 
The IQ was 99.6±12.9 points for the vocabulary test & 96.4 ±15.3 points for 
the analytical test. There were significant correlations between weight reduc-
tion and body weight at onset of the trial (r=-0.564, p<0.001), family climate 
(r=0.265, p=0.046), stress management (r=0.273, p=0.04), eating behaviour 
(r=-0.272, p=0.001), intrinsic motivation (ß=0.732, p<0.001), intrafamilial 
conflicts (ß=0.461, p=0.04), introspection (r=-0.331, p=0.012) duration of 
physical activity measured with MoSeBo/DiaTrace (ß=-0.438, p=0.002) and 
body fat mass (ß=-0.393, p=0.005). Multivariate analysis shows associations 
with the motivation for weight reduction (ß= 0.388, p=0.021), conflicts at 
school (ß= -0.299, p=0.036), self-regulation of emotions (ß= 0.575, p<0,001), 
education of the father (ß= -0.246, p=0.039) and physical activity assessed 
with DiaTrace (ß=-0.181, p=0.044). Comparing self-reported physical activ-
ity with objective assessment by the diatrace system there were significant dif-
ferences (p<0.001). In general the duration of physical activity documented 
by children and adolescents was much higher than the objective assessment. 
Similarly, the real caloric intake was higher than recommended (p=0.085).
Conclusion: 1. There are important psychological parameters with a asso-
ciation with the weight reduction. On the background of the identified pa-
rameters a new questionnaire will be developed and used in a larger multi-
center cohort. In a 1 year follow-up examination all determinants for weight 
reduction will be evaluate. After that a systematic adaptation of the STTP 
should follow. 2. There are differences between patients´ self-assessment and 
objective perception of physical activity and eating habits. Discrepancies in 
perception is a important determinants of poor long-term outcome. Using 
modern electronic health technology allows the objective assessment of kind, 
intensity and quantity of physical activity and eating habits. This could be an 
important advanced method to improve the therapy of obesity and diabetes.
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Fatty acid oxidation rate is higher in obese women than obese men
F. Shojaee-Moradie1, K. Backhouse1, I. Sarac1, M. Stoliniski1, D. Robertson1, 
J.D. Bell2, E.L. Thomas2, D. Russell-Jones1, M. Umpleby1; 
1Diabetes and Endocrinology, University of Surrey, Guildford, 2Metabolic 
and Molecular Imaging Group, Imperial College London, United Kingdom.
Background and aims: Excess plasma fatty acids have been associated with 
insulin resistance, increased hepatic triglyceride production and cardiovas-
cular risk. Women have been shown to produce more fatty acids than men 
relative to their resting energy expenditure. This study investigated whether 
the oxidation rate of circulating fatty acids is also greater relative to resting 
energy expenditure in obese women compared to men matched for age and 
BMI.
Materials and methods: 12 obese men (58 ± 2y, BMI 31 ± 1 kg/m2)(mean 
± SEM) and 12 postmenopausal obese women (59 ± 1y, BMI 32 ± 1 kg/m2) 
were studied. Resting energy expenditure (REE) and total lipid oxidation 
was measured by indirect calorimetry. An iv infusion of [U-13C] palmitate 
was administered with measurements of plasma palmitate enrichment and 
13CO2 production rate to calculate palmitate production, metabolic clearance 
(MCR) and oxidation rate. On a separate day an iv infusion of [1,2-13C]acetate 
was given with measurements of 13CO2 production rate to correct palmitate 
oxidation for the loss of label in the Krebs cycle. Whole body fat mass was 
measured by MRI. Statistical analysis was by unpaired t test.
Results: Palmitate turnover rate (Ra), MCR and oxidation rate (Ox) ex-
pressed as kg fat free mass (FFM) were significantly higher in obese women 
than in obese men (Ra: 4.5 ± 0.3 v 2.8 ± 0.2 umol/min/kgFFM, p<0.001); 
MCR 31.2 ± 1.5 v 20.7 ± 1.4 ml/min/kgFFM, p<0.001; Ox 1.6 ± 0.1 v 1.2 ± 
0.1 umol/min/kgFFM, p<0.002). Palmitate Ra expressed as kg fat mass was 
not significantly different between genders. Plasma palmitate concentrations 
and total lipid oxidation expressed as kg FFM, measured by indirect calor-
imetry, were not different in the women and men. When corrected for REE 
both palmitate Ra, MCR and Ox remained significantly greater in women 
than men (p<0.003, p=0.006, p=0.03 respectively). When subset of subjects 
(7men, 7 women) were matched for adiposity (men: 38 ± 3 kg fat, women 
38 ± 1 kg fat), these measurements remained significantly greater in women 
than in men (p=0.003, p<0.01 and p=0.002 respectively).
Conclusion: This study shows that when adjusted for FFM and REE, palmi-
tate oxidation rate was higher in women than men suggesting that women 
oxidise more circulating fatty acids than men. Since total lipid oxidation ad-
justed for FFM did not differ between men and women this suggests that men 
oxidise more non-plasma lipids.
Supported by: an EFSD/sanofi-aventis grant
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Metabolomics reveals differential metabolic regulation at the catabolic-
anabolic switchpoint during oral glucose challenge testing in women 
after recent gestational diabetes
W. Peissner1, M. Wallner2, M. Bunk2, A.-G. Ziegler2, B. Koletzko1; 
1Div. Metabolism and Nutrition, LMU Munich University, Dr. von Hauner 
Children‘s Hospital, 2Research Group Diabetes at the Helmholtz Centre 
Munich, Diabetes Research Institute, Germany.
Background and aims: Insulin-mediated postprandial suppression of non-
esterified fatty acid release from adipose tissue is acknowledged as an im-
portant physiological function to protect non-adipose tissues from lipotoxic 
effects. Functional metabolic characterization of the catabolic-anabolic tran-
sition in the early postprandial state is supposed to provide valuable insight 
into. The PINGUIN trial is a randomized intervention trial assessing the 
protective potential of Vildagliptin medication for the prevention of diabetes 
type 2 in a high-risk population of women after recent gestational diabetes. 
Extensive follow-up and longitudinal monitoring by repeated oral glucose 
and food challenge testing provides a unique opportunity to systematically 
analyze changes in metabolic systems performance during diabetes progres-
sion.
Materials and methods: After overnight fasting, eligible women and volun-
teers completed oral glucose tolerance testing or consumed a standard break-
fast meal. Serum samples were drawn at 6-8 times between 20 min before and 
120 min after the oral food challenge. Direct infusion- and HPLC-tandem 
mass spectrometry were used to quantitate amino acids, acylcarnitines, hex-
oses, sphingomyelins, phosphocholines and lysophosphocholines (180 me-
tabolites in total) from serum sample time series.
Results: Targeted metabolomics analyses were able to show consistent re-
sponses of distinct metabolite groups rapidly following oral glucose or food 
uptake. Most notable changes occurred in short-chain acylcarnitines that rep-
resent the decreasing production and utilization of ketone bodies and organic 
acids. Similarly, levels of medium- and long-chain acylcarnitines and distinct 
long-chain sphingomyelins dropped rapidly, representing the suppression of 
fatty acid release from adipose tissue. Reaction profiles of amino acids were 
divided, prominent postprandial decrease was seen in all branched-chain and 
urea cycle-related amino acids, mirroring the halting of protein catabolism. 
Interestingly, fasting levels of several closely related acylcarnitines and amino 
acids were strikingly different in women with recent history of gestational di-
abetes as compared to healthy young volunteers. Some of the women showed 
differing metabolite pattern without significant changes over time, in contrast 
to the general decreasing trend. The significance of this finding has to be fur-
ther evaluated by extending the study to include more subjects.
Conclusion: Assessment of dynamic metabolite changes during oral chal-
lenge testing reveals consistent pattern of metabolic regulation. Functional 
phenotyping by metabolomics techniques may be able to improve stratifica-
tion of preventive intervention in populations at high risk for diabetes and 
metabolic syndrome.
Supported by: BMBF
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Serum concentrations and tissue expression of components of insulin-
like growth factor-axis in patients with type 2 diabetes mellitus and 
obesity: the influence of very low calorie diet
M. Haluzik, J. Krizova, M. Mraz, D. Haluzikova, M. Bartlova, P. Kavalkova, 
J. Drapalova, P. Trachta, V. Hanusova, M. Matoulek, Z. Lacinova, S. Svacina; 
3rd Department of Medicine, Charles University, Prague, Czech Republic.
Background and aims: Insulin-like growth factor (IGF)-axis plays a complex 
role in glucose homeostasis, insulin sensitivity and pathogenesis of diabetes 
mellitus. The aim of the present study was to measure serum levels and tissue 
expression of selected components of the IGF-axis in type 2 diabetic patients 
at baseline and after dietary intervention.
Materials and methods: 12 obese females with type 2 diabetes mellitus 
(T2DM) and 10 healthy lean, sex- and age-matched controls (C) were in-
cluded into the study. Serum concentrations of selected biochemical and 
hormonal parameters were measured by commercial ELISA and RIA kits. 
The expression analysis of genes for IGF-I and -II, insulin-like growth fac-
tor binding protein(IGFBP)-1 and -3 and insulin-like growth factor-recep-
tor (IGF-R) in subcutaneous adipose tissue (SCAT) and isolated peripheral 
monocytes was performed by RT PCR at baseline and after 2 weeks of very 
low calorie diet (VLCD, energy intake 2500 kJ/day). The study was approved 
by the Ethical Committee of General University Hospital in Prague.
Results: Compared to C group, T2DM group had significantly increased 
fasting glucose, insulin and leptin concentrations and mRNA expression 
of IGF-R and IGFBP-3 in peripheral monocytes. Serum levels of IGF-I and 
adiponectin and mRNA expression of IGF-I, IGFBP-3 and IGF-R in SCAT 
were significantly reduced in T2DM group. IGF-II expression did not dif-
fer between the groups. mRNA expression of IGFBP-1 was not detected in 
either SCAT or peripheral monocytes. mRNA expression of IGF-I and IGF-II 
was not detected in peripheral monocytes. In SCAT, the mRNA expression of 
IGF-I, IGFBP-3 and IGF-R negatively correlated with BMI, insulin, glucose 
and HOMA index. IGF-R mRNA expression in peripheral monocytes posi-
tively correlated with BMI, insulin and HOMA index, while IGFBP-3 mRNA 
expression positively correlated only with BMI. Two weeks of VLCD signifi-
cantly decreased body weight, and improved glycemia, insulin resistance and 
lipid profile. VLCD further significantly decreased serum IGF-I levels and 
increased IGF-I mRNA expression in SCAT. mRNA expression of other stud-
ied parameters was not influenced by VLCD.
Conclusion: Our results suggest that decreased mRNA expression of IGF-1 
in SCAT and increased expression of IGFBP-3 in peripheral monocytes may 
induce local metabolic disturbances in adipose tissue contributing to devel-
opment of insulin resistance and type 2 diabetes mellitus.
Supported by: MZOVFN2005 and IGA NS10024-4
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Visceral fat reduction is associated with increased IL-10 levels in obese 
subjects that underwent caloric restriction
G. Formoso1, M.P.A. Baldassarre1, M. Taraborrelli1, M. D’Adamo2,  
P. Di Fulvio1, N. Di Pietro3, A. Nicolucci4, A. Tartaro5, A. Pandolfi3,  
A. Consoli1; 
1Medicine and Aging Sciences, University of Chieti, Chieti Scalo, 
2Department of Internal Medicine, University of Rome, 3Biomedical 
Sciences, University of Chieti, Chieti Scalo, 4Department of Clinical 
Pharmacology and Epidemiology, Consorzio Mario Negri Sud, Santa Maria 
Imbaro, 5Department of Clinical Sciences and Bio-imaging, University of 
Chieti, Chieti Scalo, Italy.
Background and aims: Obese subjects are characterized by a low grade in-
flammatory state that may contribute in predisposing them to develop athero-
sclerosis. An excess of adipose tissue, particularly in intra-abdominal depots, 
is thought to play a role in the pathophysiology of the metabolic syndrome, 
closely linked to insulin resistance, and to increase the risk of cardiovascu-
lar disease. Although circulating levels of proinflammatory cytokines as well 
as other inflammation markers have been shown to be elevated in human 
obesity, little is known about the role of anti-inflammatory cytokines in this 
setting. IL-10 is a major inhibitor of cytokines synthesis; it suppresses mac-
rophage function and inhibits the production of proinflammatory cytokines. 
Recent studies have shown an increase in IL-10 levels after caloric restriction. 
However, scant data exist about the effects on plasma IL-10 levels of the loss 
of visceral and/or subcutaneous fat tissue (VF and SF respectively). Aim of 
the present study was to verify whether changes in insulin sensitivity and in 
plasma levels of IL-10 together with several adipokines such as TNFα, IL-6 
and Leptin specifically correlate with changes in VF or SF.
Materials and methods: We measured VF and SF by Magnetic Resonance 
(MRI), plasma levels of glucose, insulin, IL-10, TNFα, IL-6 and Leptin be-
fore and after a caloric restriction induced weight loss of at least 5% of the 
original body weight, in 14 (4 men, 10 women) obese subjects (BMI 34.4±6.5 
Kg/mq).
Results: As we expected, weight loss improved insulin sensitivity (Quicki 
index= 0.35+0.03 vs 0.37+0.04, p<0.05), increased IL-10 levels (3.41+1.98 
pg/ml vs 4.63+1,03pg/ml, p<0.05) and reduced TNFα , IL-6 e leptin levels 
(2.52+1.32 pg/ml vs 1.60+1.52 pg/ml; 2.32+0.42 pg/ml vs 1.64+0.64 pg/ml; 
56.1+30.2 ng/ml vs 37.2+29.3 ng/ml respectively, p<0.05 for all). Moreover 
we observed a significant correlation between the amount of VF loss and the 
improvement in insulin sensitivity (r=0.44, p<0.05) and between the percent 
reduction in VF and the percent reduction in both TNFα (r=0.56, p<0.05) 
and IL6 (r=0.19, P<0.05) plasma levels. On the contrary, no correlation was 
observed between the investigated parameters and either the amount or the 
percentage of SF lost. Furthermore, in a multiple regression analysis, the 
amount of VF loss independently correlated with the increase in IL-10 lev-
els.
Conclusion: These data suggest that the reduction in visceral but not in sub-
cutaneous adipose tissue is associated with an improvement in the inflamma-
tory pattern characterizing obesity and, specifically, that a loss in VF is associ-
ated with increased plasma levels of the anti-inflammatory adipokine IL-10.
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Weight loss in women is followed by a significant decrease of 11β 
hydroxysteroid dehydrogenase 1 in subcutaneous adipose tissue
K. Simonyte1, T. Olsson1, I. Näslund2, J.-E. Angelhed3, L. Lonn4,  
C. Mattsson1, E. Rask5; 
1Public Health and Clinical Medicine, Medicine, Umea, Sweden, 2Surgery, 
Orebro University Hospital, Sweden, 3Medicine, Sahlgrenska Academy, 
Gothenburg, Sweden, 4Radiology and Vascular Surgery, Rigshospitalet, 
Copenhagen, Denmark, 5Medicine, Orebro University Hospital, Sweden.
11ß hydroxysteroid dehydrogenase (11βHSD1) catalyzes the conversion of 
the inactive glucocorticoid compund cortisone into active cortisol, in a tis-
sue-specific manner. This enzyme may have a key role in the development 
of central obesity and obesity-related complications. In humans, positive as-
sociations between 11βHSD1 in subcutaneous (sc) adipose tissue and differ-
ent features of metabolic syndrome, including body mass index (BMI), blood 
pressure, and insulin sensitivity, have been reported. Furthermore, we have 
recently shown a positive correlation between 11βHSD1 and phosphoenol-
pyruvate carboxykinase C (PEPCK) - a key enzyme in gluconeogenesis. This 
supports a role for glucocorticoids in fatty acid (FA) metabolism in obesity, 
leading to increased rate of FA re-esterification in adipose tissue. In this study 
we evaluated peripheral glucocorticoid metabolism in the subcutaneous adi-
pose depot before and after stabilized weight loss and explored a putative link 
between 11βHSD1 and fatty acid recycling in women. Twenty-seven obese 
women underwent gastric bypass surgery with collection of sc fat biopsies 
and blood before and two years after surgery. Computed tomography (CT) 
was used to estimate regional fat distribution and the amount of liver fat. 
Adipose tissue expression of 11βHSD1, leptin, adiponectin, PEPCK, sterol 
regulatory element binding protein (SREBP), fatty acid synthase (FAS), per-
ilipin and hormone sensitive lipase (HSL) expression levels were analyzed 
with real-time PCR; serum leptin and adiponectin levels with ELISA. Two 
years after bypass surgery, there was a 69% mean decrease in BMI associated 
with a 2-fold reduction in the sc depot and 4-fold decrease in the intraab-
dominal depot. Liver attenuation decreased, reflecting decreased liver fat. 
11βHSD1 gene expression decreased 4-fold after weight loss. Leptin and adi-
ponectin expression decreased significantly, with concomitantly significantly 
decreased circulating leptin and increased adiponectin levels. There were no 
differences in the expression of genes involved in gluconeogenesis (PEPCK), 
lipolysis (perilipin, HSL), and lipogenesis (FAS, SREBP) after weight loss. Be-
fore surgery, sc 11βHSD1 gene expression correlated only to waist circumfer-
ence, whereas after the significant weight reduction, 11βHSD1 mRNA levels 
correlated with multiple measures of central fat accumulation, ie. BMI, L4 
total adipose tissue area and the intraabdominal fat area (p<0.01, p<0.05 
and p<0.001; respectively). A significant correlation between 11βHSD1 and 
PEPCK observed before surgery was lost after weight loss (r=0.57, P<0.05 vs 
r=-0.02) respectively). Weight loss links to metabolically favorable changes in 
11βHSD1 expression in fat and circulating levels of leptin and adiponectin. 
The reduction of 11βHSD1 in fat after weight loss suggests that up-regulation 
of this enzyme is a consequence, rather than a cause, of obesity. No significant 
differences in gene expression of the key enzymes involved in lipid metabo-
lism and lack of associations to anthropometric measurements suggest that 
weight loss per se does not directly affect transcription of these genes in sc 
adipose tissue.
Supported by: T.O. from Swedish Research Council and Swedish Heart and 
Lung Foundation
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11β- HSD1 in subcutaneous adipose tissue of SGA adults is dysregulated 
but not associated with metabolic disorders
E. Carreira1, T. Meas1,2, M. Rauh3, Y. Wang4, C. Poitou5, K. Clément5,  
J. Dotsch3, C. Lévy-Marchal1,2; 
1INSERM U690, 2Université Paris 7, France, 3Department of Pediatrics, 
University of Erlangen-Nueremberg, Germany, 4CIC Robert Debré, 
5INSERM U872, Paris, France.
Background and aims: The mechanisms relating being born small for ges-
tational age (SGA) and the later risk of metabolic disorders are not yet fully 
understood. Adipose 11β-HSD1 activity and expression has been positively 
associated with metabolic syndrome in animals and humans. In humans, no 
in vivo studies have explored 11β-HSD1 activity and gene expression in sub-
cutaneous adipose tissue of SGA subjects.
Materials and methods: 39 subjects SGA, birth weight< 10th percentile, were 
matched on gender and age with 36 subjects born Appropriate for Gestational 
age (AGA - 25th <birth weight<75th percentile); the two groups were stratified 
according to body fat content into “low fat mass” (20 SGA and 18 AGA) and 
“high fat mass” (19 SGA and 18 AGA) subjects. Basal and stimulated activi-
ties of the 11β-HSD1 enzyme were assessed in the effluent of microdialysis 
performed in the abdominal subcutaneous wall in vivo. mRNA expression 
was measured by real-time quantitative PCR in subcutaneous adipose tissue.
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Results: 
“low fat mass” 
AGA 
N= 18
“high fat 
mass”AGA 
N= 18
“low fat mass” 
SGA
N= 20
“high fat mass” 
SGA 
N= 19
P low/high 
fat mass
P
SGA/
AGA
Gender (M/F) 8/10 7/11 10/10 8/11
Age (yr) 29.6 (26.1;33.3) 31.6 (26.7;32.9) 30.1
(24.7; 34.2)
32.6
(28.3 ; 35.0)
Body fat (%) 21.8
(15; 28)
35.9
(29.5; 42)
22
(15; 27)
39
(28.7; 41)
M clamp
(mg/min/kg
lean body mass )
12.5
(10.8; 14.8)
6.4
(4.8 ; 8.3)
10.5
(8.6 ; 15.0)
5.5
(4.1 ; 8.2)
0.001 0.68
Microdialysis
Basal 11β-HSD1 activity 
(cortisol/
Cortisone)
1.7
(1.3; 1.9)
2.2
(0.9; 3.5)
1.9
(1.5 ; 2.5)
2.3
(1.5 ; 2.9)
0.83 0.69
Activation of 11β-HSD1 at 
nadir (%)
12.5
(5.7; 45.9)
18.8
(7.9; 95.7)
8.3
(5.3; 3.8)
7.3
(5.2; 15.1)
0.06 0.004
Fat Biopsy N= 18 N=14 N=16 N=16
Expression of 11β-HSD1
(arbitrary unit)
119
(90; 147)
249
(147; 407)
193
(112; 262)
341
(198; 421)
0.0001 0.18
Adipocyte diameter (µm) 84.5
(77.3; 89.8)
98.4
(90.3;110.3)
76.2
(56.4; 79.0)
99.3
(87.3;103.7)
<0.0001 0.003
Conclusion: The in vivo stimulated 11β-HSD1 activity was decreased in sub-
jects born SGA as compared to adults born AGA. 11β-HSD1 gene expression 
was associated with body fat but not with birth weight. We also found an 
independent effect of both birth weight and body fat on adipocyte diameter. 
Moreover, expression and activation of 11β-HSD1 were strongly associated 
with the adipocyte diameter in SGA group, suggesting a “protective” role of 
the decreased size of adipocytes on the development of metabolic complica-
tions. It is therefore unlikely that local glucocorticoid metabolism in subcu-
taneous fat plays a major role in the development of the metabolic complica-
tions associated with being born SGA.
Supported by: ALFEDIAM Novo Nordisk 2008 and INSERM
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Labisia pumila var alata extract down-regulates 11-beta hydroxysteroid 
dehydrogenase type-1 and corticosterone levels in overweight 
ovariectomized rats
M. Fazliana1,2, W. Wan Nazaimoon2, H.F. Gu1, C.-G. Östenson1; 
1Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden, 
2Diabetes and Endocrine Unit, CDNRC, Institute for Medical Research, 
Kuala Lumpur, Malaysia.
Background and aims: The enzyme 11-beta hydroxysteroid dehydrogenase 
type-1 (Hsd11b1) is highly expressed in key metabolic tissues including adi-
pose and liver. In rats, it converts inactive 11-dehydrocorticosterone to active 
corticosterone (CORT). Activation of Hsd11b1 and glucocorticoid receptor 
could result in the production of excess tissue glucocorticoids which affects 
glucose homeostasis, insulin action and adiposity, all of which are associated 
with the development of type-2 diabetes and visceral obesity. Ovariectomy 
(OVX) rats have increased body weight and decreased insulin sensitivity 
in relation to estrogen deficiency. Our microarray analysis of liver of OVX 
rats has shown increased expression of Hsd11b1. Therefore, we examined 
Hsd11b1 expression and CORT levels on OVX rats after treatment with Labi-
sia pumila var alata (LP), a Malaysian plant with phytoestrogen effects.
Materials and methods: Thirty-six Sprague-Dawley rats were ovariect-
omized (OVX) at 6-weeks of age and one group (N=7) undergone sham 
operation (SHAM). After two weeks, the rats were treated with oral gavage 
of LPva10, LPva20 and LPva50 extract (10, 20 and 50 mg/kg/day respective-
ly), estrogen replacement (ERT) (0.625 mg/kg/day) for 30 days (n=7) or as 
controls (SHAM and OVX). Microarray analysis was done with liver tissue, 
followed by real-time RT-PCR of liver and adipose tissues. CORT levels in 
plasma were analyzed using ELISA and protein expressions were detected by 
Western blotting.
Results: OVX rats gained more body weight than SHAM rats (74.5 ± 3.7 g 
vs. 56.9 ± 3.6 g, p < 0.05). Treatment of OVX with LP50 or ERT significantly 
reduced the weight gain by 16.8% and 25.5%, respectively (p < 0.05 for both). 
CORT levels in OVX group increased significantly (135 ± 25 ng/ml, p<0.05) 
in comparison to SHAM (53 ± 22 ng/ml, p<0.05). The levels decreased in 
all LP10, LP20 and LP50 (85 ± 19 ng/ml, 95 ± 14 ng/ml and 92 ± 25 ng/ml 
respectively, p < 0.05 for all) and ERT (88 ± 16 ng/ml, p < 0.05). In adipose 
tissues, the Hsd11b1 mRNA level of OVX group increased by 55 % (p<0.05) 
in comparison to Sham, normalized in LPva10, LPva20 and LPva50 and but 
not significantly decreased in ERT treated rats. The Hsd11b1 mRNA levels in 
liver of OVX was increased by 75 % (p < 0.05) when compared to Sham and 
restored to normal level when given LPva extracts and ERT. Protein levels 
of Hsd11b1 were down-regulated in both adipose tissues and liver of LPva-
treated rats, in comparison to Ovx rats (significant difference in all LPva 
groups and ERT, p<0.05).
Conclusion: OVX had increased body weight, increased adipose and liver 
expression of Hsd11b1 and elevated CORT levels. Treatment with LPva ex-
tracts, similar to ERT, normalized Hsd11b1 mRNA and protein levels in OVX 
rats, in parallel with decreased CORT levels. Based on our results, we hypoth-
esize that anti-obesity effects of LPva are attributed, at least in part, to the 
inhibition of Hsd11b1 expressions in adipose tissue and liver. These changes 
suggest the use of LPva for a postmenopausal treatment and possibly, in other 
conditions related to metabolic syndrome.
Supported by: MOSTI, Swedish Research Council and Swedish Diabetes As-
sociation
787
Transgenerational non-genomic inheritance of glucose intolerance by 
neonatal overfeeding in mice
J.C. Jimenez-Chillaron1, T. Pentinat1, J. Cebria1, M. Ramon-Krauel2,  
R. Diaz2; 
1Endocrinology, Fundacio per la Recerca Sant Joan de Deu, 2Endocrinology, 
Hospital Pediatric Sant Joan de Deu, Esplgues, Barcelona, Spain.
Background and aims: Epidemiologic evidence suggests that sub-optimal 
nutrition during foetal and/or postnatal development influences diabetes risk 
later in life. In addition, such environmentally-induced phenotypes may man-
ifest in subsequent generations, even when the environmental triggers are not 
present anymore (transgenerational effects). We have previously generated a 
mouse model of neonatal over-nutrition (ON-F0) by culling offspring to 4 
pups per dam during lactation. Neonatal overfeeding led to rapid early weight 
gain and later development of metabolic syndrome in adult mice, by age 6 
months: i.e. obesity, dislipidemia, hyperglycaemia, hyperinsulinemia, insulin 
resistance and glucose intolerance.
Here we aimed to explore whether neonatal over-nutrition may influence 
metabolism of successive generations, F1 and F2.
Materials and methods: Control and ON males from the F0 generation were 
mated with non-sibling control females to generate the first generation-off-
spring, F1. At birth, all litters are adjusted to 8 pups per dam. Thus, contrary 
to the parental generation, ON-F1 pups are not neonatally overfed as com-
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pared to their matched controls. We next repeated the breeding protocol, by 
using C-F1 and ON-F1 males, to obtain the second-generation offspring, F2. 
Likewise, all litters are equalized to 8 pups per dam to match normal nutri-
tion during the neonatal period. Thus, an important consideration for the 
experimental design is that ON-F1 and ON-F2 male mice are not themselves 
overfed during lactation.
Results: We show that ON-F1 and ON-F2 male mice also develop several 
features of the metabolic syndrome, including fasting hyperinsulinemia (C= 
0.22± 0.01 ng/ml; ON-F1= 0.44± 0.06**; ON-F2= 0.31± 0.05*; *p< 0.05, 
**p< 0.01), mild insulin resistance (HOMA-IR, C= 0.5± 0.04; ON-F1= 1.4± 
0.21**; ON-F2= 0.7± 0.23, p= 0.1; **p< 0.01) and glucose intolerance by age 
4 months. Impaired glucose tolerance in ON-F1 and ON-F2 mice appears be 
accounted for primarily by peripheral insulin resistance, since beta-cell func-
tion remains normal in these cohorts. Thus, here we show, for the first time, 
that neonatal overfeeding programs adult diabetes-related phenotypes not 
only to exposed individuals, but also to their offspring and grand-offspring. 
To note, transgenerational inheritance of insulin resistance occurs through 
the paternal lineage. Thus, transgenerational inheritance of the diabetic phe-
notypes must occur through, nutritionally-induced, modifications in cells of 
the germ line. It has been proposed that trans-paternal inheritance of such 
environmentally-acquired phenotypes might be mediated, in part, by epige-
netic mechanisms.
Conclusion: In summary, nutritional challenges occurring during sensitive 
periods of development may have adverse metabolic consequences well be-
yond the lifespan of affected individuals and manifest in subsequent genera-
tions. Transgenerational progression of metabolic phenotypes through the 
male lineage supports a potential role for epigenetic mechanisms in mediat-
ing these effects.
Supported by: MICINN to JCJ-CH and Fundacion2000 to RD
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Paradoxical response in feeding in short-time fasted rAAV-leptin treated 
mice
N. Ueno1, A. Inui2; 
1Department of Internal Medicine, Kobe Seaside Hospital, 2Department of 
Behavioral Medicine, Kagoshima University, Graduate School of Medical 
and Dental Sciences, Japan.
Background and aims: Leptin plays an impotant role in body weight regula-
tion. Administration of leptin reduces food intake and body weight. How-
ever, we have shown that food intake did not decrease in rAAV-leptin treated 
(overexpression of leptin in the hypothalamus) wild type (wt) mice on a daily 
basis compared to control mice, though there was a decrease in body weight. 
To elucidate this discrepancy, we evaluated feeding behavior in short-term 
fasted rAAV-leptin treated wt mice.
Methods: rAAV-leptin and rAAV-GFP as a control was injected icv in wild 
type mice and daily (24 hours) food intake was measured. They were fasted 
for 3 hours and re-fed for 3 hours. Food intake was measured during the re-
feeding period. Blood samples were collected before and after 3 hours fasting 
and blood glucose, plasma insulin, ghrelin and leptin levels were measured. 
Another set of mice (rAAV-leptin and rAAV-GFP treated) was fasted for 3 
hours and glucose (1g/kg) was injected ip. The same blood samples were col-
lected before glucose injection and 1 hour after glucose injection. Blood pa-
rameters same as above were measured in the same way.
Results: There was no change in total daily food intake in rAAV-leptin 
treated and control mice (control: 3.69Â±0.21, rAAV-leptin: 3.56Â±0.07 
g). Food intake in rAAV-leptin treated mice during the re-feeding period 
was significantly increased compared to control mice (control: 0.19Â±0.04, 
rAAV-leptin: 0.38Â±0.05 g, p< 0.05). After fasting, blood glucose levels de-
creased (3.36Â±0.52 to 2.40Â±0.29 mmol/l, p< 0.01) in rAAV-leptin treated 
mice but not in control mice. Plasma ghrelin levels increased (1.32Â±0.32 
to 3.92Â±0.75 ng/ml, p< 0.01) in rAAV-leptin treated mice but not in con-
trol mice. Plasma leptin levels decreased in control mice (5.45Â±0.79 to 
3.81Â±0.45 ng/ml, p< 0.05) but stayed very low with no change in rAAV-
leptin treated mice (0.36Â±0.07 to 0.29Â±0.04 ng/ml). Glucose injection 
decreased circulating ghrelin levels (11.10Â±1.21 to 2.42Â±0.28 ng/ml, p< 
0.001) and increased leptin levels (0.42Â±0.12 to 0.77Â±0.15 ng/ml, p<0.05) 
in rAAV-leptin treated mice. No change was seen in the control group.
Conclusion: These results suggest that there was increased food intake when 
rAAV-leptin treated mice were fasted. Decrease in blood glucose or increase 
in circulating ghrelin in even short-term fasting periods may contribute to 
increased food intake in rAAV-leptin treated wt mice. This may explain, at 
least in part, the lack of difference in feeding behavior in rAAV-leptin treated 
wt mice and control mice. After glucose injection, reduction in circulating 
ghrelin and elevation in leptin levels may inhibit their increased food intake 
result in the normal daily food intake as if there is a feedback system.
789
Reduced insulin gene dosage prevents diet-induced obesity
A.E. Mehran, X. Hu, J.D. Johnson; 
Cellular and physiological sciences, University of British Columbia, 
Vancouver, Canada.
Background and aims: Obesity has become a worldwide epidemic and can 
often lead to insulin resistance, hyperinsulinemia and type 2 diabetes, but the 
relationship amongst these phenomena remains enigmatic. Although insu-
lin is a potent adipogenic hormone, it is thus far unclear whether hyperin-
sulinemia itself can be a causal factor in the pathogenesis of obesity and/or 
type 2 diabetes. Unlike humans, mice possess two non-allelic insulin genes. 
It has been previously established that mice lacking one of their two insulin 
genes are phenotypically normal. Furthermore, it is reported that only Insulin 
1 (Ins1) is exclusively expressed in the pancreatic beta cells whereas Insulin 
2 (Ins2) is also expressed in extra-pancreatic tissues where it can have non-
endocrine functions. We therefore hypothesized that mice with only one ac-
tive Ins1 allele would be protected from diet-induced obesity and associated 
pathologies.
Materials and methods: To test hyperinsulinemia as an endocrine pathol-
ogy, we used Ins2 knockout mice. We compared mice with only a single copy 
of Ins1 (Ins1+/-:Ins2-/-) with those with two copies of Ins1 (Ins1+/+:Ins2-
/-) with respect to the adverse effects of high-fat feeding. We studied body 
weight, glucose- and insulin- tolerance, insulin mRNA levels, islet insulin 
content, total body lipid content by NMR, epididymal fat pad weight, lipid 
accumulation in multiple tissues, and pancreatic beta cell mass by immun-
ofluorescence microscopy.
Result: Ins1+/-:Ins2-/- mice were protected from adult-onset diet-induced 
weight gain compared with Ins1+/+:Ins2-/- controls (P < 0.01). High-fat fed 
mice with one or two active Ins1 gene allele showed early elevated levels of cir-
culating insulin when compared to chow fed mice of either of the genotypes. 
This was positively correlated with a slight increased overall body growth as 
per measured by tibial length at one year of age. However, one year old high-
fat fed Ins1+/-:Ins2-/- mice had significantly reduced basal circulating insulin 
levels (P < 0.01), reduced insulin response to glucose stimulation, lower beta 
cell mass, lower whole-body fat ratio (P < 0.05), smaller epididymal fat pads 
(P < 0.01), smaller adipocytes, and no hepatic steatosis when compared with 
Ins1+/+:Ins2-/- mice on the same diet. Mice of either genotypes on the chow 
diet showed comparable phenotypes and were similar to that of observed in 
the high-fat fed Ins1+/-:Ins2-/- mice. Mice across all groups showed normal 
and comparable glucose tolerance and insulin sensitivity.
Conclusion: We have shown that prevention of diet-induced hyperinsuline-
mia through partial ablation of insulin gene can protect mice from obesity 
and its associated complications. Hyperinsulinemia may not just simply be an 
adaptive response to obesity-induced insulin resistance and may play a causal 
role in the pathogenesis of obesity and/or diabetes. Therapeutic interventions 
that reduce circulating insulin may be worth exploring in the context of obes-
ity and pre-diabetes.
Supported by: JDRF, CDA, CIHR
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Micro-ribonucleic acid expression profiling and expression quantitative 
trait loci analysis in human gluteal and abdominal adipose tissue
M. Rantalainen1, B.M. Herrera2, G. Nicholson1, Q.F. Wills1, R. Bowden1, 
M.J. Neville3, J.C. Randall2, A. Barrett3, M. Allen3, M.I. McCarthy3,  
K.T. Zondervan2, F. Karpe3, C.C. Holmes1, C.M. Lindgren2; 
1Department of Statistics, University of Oxford, 2Wellcome Trust Centre 
for Human Genetics, University of Oxford, 3Oxford Centre for Diabetes, 
Endocrinology and Metabolism, University of Oxford, United Kingdom.
Background and aims: Obesity is a large and growing public health prob-
lem associated with increased risks of type 2 diabetes, cardiovascular disease, 
hypertension and increased mortality. Adipose tissue distribution relates to 
morbidity with increased levels of abdominal adipose tissue relative gluteal 
adipose tissue associated with metabolic deregulation and related disease. 
Hence, characterization of the molecular phenotypes in these two adipose tis-
sues is an essential starting point when attempting to understand molecular 
mechanisms associated with obesity and related disease. Here we character-
ise micro-RNA (miRNA) expression and how it contributes to the molecular 
phenotype in gluteal and abdominal adipose deposits, which are known to 
affect risk of obesity-related disorders.
Materials and methods: The expression of 1131 miRNAs was profiled in 
these two fat depots in 70 human subjects using the Illumina DASL miR-
NA beadarray. The study includes male and female subjects diagnosed with 
metabolic-syndrome as well as healthy controls. Here we focus on investi-
gating tissue-specific miRNA expression. All subjects were genotyped using 
the Illumina HumanHap317 Beadchip, enabling assessment of whether there 
are individual genetic variants driving miRNA expression levels, by miRNA 
expression quantitative trait loci (eQTL) analysis. Tissue-differential expres-
sion was analysed using a linear mixed effects model with miRNA expression 
as response; tissue type, batch, gender, metabolic-syndrome status and age 
included as fixed effects; and a subject identifier included as random effect. 
Significance of the tissue effect was assessed by a permutation test of the like-
lihood-ratio statistic. A similar model and test was used for eQTL analysis, 
with the genotype included as an additive fixed effect. eQTL models were 
fitted separately for each tissue type.
Results: We found that 154 miRNAs were differentially expressed between 
gluteal and abdominal fat tissue (FDR corrected (Benjamini and Hoch-
berg’s method) p-value < 0.05). These miRNAs include hsa-miR-211 (p-
value=0.006), hsa-miR-27b (p-value=0.006), hsa-miR-27a (p-value=0.011), 
hsa-miR-34a (p-value=0.020) and hsa-miR-143 (p-value=0.020), which have 
previously been reported to be associated with adipose tissue development, 
obesity and metabolic disorders. We detected 10 miRNA-eQTL candidates in 
gluteal adipose tissue and 23 miRNA-eQTL candidates in abdominal adipose 
tissue (nominal p-values < 0.002). Currently we are undertaking a confir-
mation study in 40 additional subjects, with the objective of replicating the 
current findings.
Conclusion: The results indicate a substantial difference in miRNA expres-
sion patterns between gluteal and abdominal adipose tissues, which may 
indicate an important role of miRNAs in contributing to the molecular phe-
notype of these two tissue types. Presence of miRNA-eQTLs indicate a direct 
genetic influence on the expression of specific miRNAs, and consequently 
also indirectly on the general molecular phenotype of gluteal and abdominal 
adipose tissue.
Supported by: MolPAGE(EU/FP6), MRC, Wellcome Trust
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Human adipose tissue - a novel source of eotaxin-3
K. Vleugels1, S. Glund2, U. Buro1, S.R. Bornstein1, M. Ehrhart-Bornstein1; 
1Molecular Endocrinology, University Hospital Carl Gustav Carus, Dresden, 
2Department of CardioMetabolic Diseases Research, Boehringer Ingelheim 
Pharma GmbH & Co. KG, Biberach, Germany.
Background and aims: Obesity and overweight are major risk factors for 
chronic diseases, including type 2 diabetes, cardiovascular disease, hyperten-
sion and stroke, as well as certain forms of cancer. Obesity is characterized by 
a chronic, systemic low-grade state of inflammation. Adipose tissue secretes 
a multitude of factors, e.g. adipokines and cytokines that are involved in the 
body’s homeostasis and metabolism. A causal relationship of obesity associ-
ated inflammation with metabolic disorders is indicated. We aimed at iden-
tifying cytokines released from human adipocytes and identified eotaxin-3 
(CCL26). Eotaxin-3 is a member of the CC chemokine family, known to be 
expressed in several tissues, e.g. heart and lung, and is an important effector 
chemokine in allergic conditions. Eotaxin-3 acts mainly via the CCR3 recep-
tor and is a potent chemoattractant for eosinophils. Additionally, evidence 
exists that eotaxin-3 acts as an antagonist on chemokine receptors CCR1, 
CCR2 and CCR5, suggesting a modulatory function of eotaxin-3 in inflam-
mation. No data, however, exists so far on the expression in and/or secretion 
of eotaxin-3 from adipose tissue.
Materials and methods: Mature adipocytes and preadipocytes were isolated 
from white human adipose tissue obtained from healthy women undergo-
ing surgical mammary reduction or liposuction. Preadipocytes and in vitro 
differentiated adipocytes were stimulated with IL-4, TNFα, and/or IFNγ. 
Visceral and subcutaneous fat tissue was obtained from patients undergoing 
abdominal surgery. Eotaxin-3 gene expression was determined with quanti-
tative PCR. Eotaxin-3 secretion was measured with a specific RIA.
Results: In the present study, eotaxin-3 was expressed in most samples of 
human adipocytes and secreted constitutively. Intra-individual comparism of 
eotaxin-3 gene expression from subcutaneous and visceral fat depots showed 
higher eotaxin-3 levels in subcutaneous fat tissue. The eotaxin-3 expression 
in subcutaneous fat tissue is correlated to donor BMI. Furthermore, its ex-
pression was higher in adipose tissue than in isolated adipocytes. Preadipo-
cytes and in vitro differentiated adipocytes expressed and secreted eotaxin-3 
at low levels; its expression and secretion, however, was strongly induced by 
stimulation with IL-4, via STAT6 pathway, but not TNFα or IFNγ. Co-stimu-
lation of preadipocytes with IL-4 and IFNγ decreased IL-4 induced eotaxin-3 
expression; prestimulation with IFNγ decreased IL-4 induced eotaxin-3 ex-
pression in a dose-dependent manner.
Conclusion: We could identify human adipocytes as a novel source of eo-
taxin-3. Eotaxin-3 expression in subcutaneous fat tissue was positively corre-
lated with BMI. Its expression is inducible by IL-4, an anti-inflammatory cy-
tokine produced e.g. by adipose tissue. IFNγ inhibits IL-4 induced eotaxin-3 
expression. A possible role of eotaxin-3 in obesity-associated disorders needs 
to be elucidated.
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Human adipocytes express P2X7 receptors able to modulate some 
inflammatory responses in subjects with metabolic syndrome
A. Solini1, S. Madec1, C. Rossi1, M. Chiarugi2, E. Santini1, A. Salvati1,  
E. Ferrannini1; 
1Department of Internal Medicine, University of Pisa, 2Department of 
Surgery, University of Pisa, Italy.
Backgound and aims: No information is available on the presence of P2X7 
receptor in human adipocytes and their potential involvement in the chronic 
inflammation associated with metabolic syndrome (MS). Adipocytes were 
isolated from samples of visceral (VAT) and subcutaneous (SAT) adipose tis-
sue of 40 patients with MS (defined as by ATP-III criteria) and 20 controls 
(CLT), recruited among patients undergoing laparoscopic cholecistectomy.
Materials and methods: We measured adipocyte gene expression of 
TNFα,IL-6 and PAI-1 (by realtime-PCR) and their plasma concentrations 
(ELISA), as well as gene and protein expression of P2X7 (using realtime-PCR, 
Western blot and immunocytochemistry). In a subgroup of 15 MS and 10 
CLT we also evaluated P2X7 functional activity by measuring the effect of 
benzoyl-benzoyl-ATP (BzATP, a P2X7 specific agonist) and KN62 (a selective 
P2X7 blocker) on intracellular calcium fluxes (([Ca2+]I, by fluorimetry) and 
adipocytoke release (by ELISA).
Results: In VAT, TNFα, IL-6 and PAI-1 were more espressed in MS than in 
CLT (T/R ratio: 3.29±1.47 vs 1.79±1.19; 8.99±4.24 vs 5.65±4.03; 6.06±2.32 vs 
2.91±0.34, p =0.005-0.0001). These differences were confirmed in SAT for 
IL-6 (3.56±1.56 vs 1.98±1.49, p=0.0004) and PAI-1 (3.87±1.87 vs 2.25±1.16, 
p=0.008), but not for TNFα (1.49±0.83 vs 1.24±0.68, p=ns). Plasma IL-6 and 
PAI-1 levels were higher in MS (IL-6: 2.81±1.55 vs 4.32±2.67 pg/ml, p=0.002; 
PAI-1: 32.08±11.21 vs 42.26±11.6 ng/ml, p=0.002). TNFα levels were higher 
in MS (3.22±1.26 vs 2.51±0.88 pg/ml, p<0.05). P2X7 mRNA, found both in 
VAT and SAT, was more abundant in MS than in CLT (T/R ratio: 2.13±0.68 
vs 1.56±0.49 in VAT, p=0.0013 and 1.76±0.54 vs 1.46±0.41 in SAT, p=0.03). 
Protein expression confirmed this observation, with the typical “ring-like” ar-
rangement of P2X7 receptor at the plasma membrane. BzATP 0.5 mM raised 
[Ca2+]i in VAT and SAT, without differences between MS and CLT (VAT: 
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+128 vs +98%, p=ns; SAT: +107 vs +110%, p=ns). In both MS and CLT cells 
BzATP induced IL-6 and TNFα release, partially inhibited by KN62 (VAT: 
IL-6 from 141±33 to 308±28 and 233±33 with KN62 in CLT; from163±27 
to 318±64 and 254±59 pg/ml/mg tissue with KN62 in MS, p<0.0001; TNFα 
from 2.3±0.7 to 3.7±0.8 and 3.1±0.9 with KN62 in CLT; from 2.3±0.6 to 
4.0±0.8 and 3.2±0.9 pg/ml/mg tissue with KN62 in MS, p<0.0001). BzATP 
did not induce any change in PAI-1 release, either in MS or CLT.
Conclusion: Human adipocytes express functionally active P2X7 recep-
tors, which modulate the release of some inflammatory cytokines. Adipo-
cytes from MS patients show an enhanced P2X7 receptor expression, which 
might contribute to the subclinical inflammatory status characterising these 
patients.
793
OCT-1 expression in adipocytes could contribute to increased metformin 
action in obese subjects
J.M. Moreno-Navarrete, F.J. Ortega, J.-I. Rodríguez-Hermosa, M. Sabater,  
G. Pardo, W. Ricart, J. Fernández-Real; 
Department of Diabetes, Endocrinology and Nutrition. Institut 
d’Investigació Biomédica de Girona. CIBER Fisiopatología de la Obesidad y 
Nutrición CB06/03/010, Spain.
Background and aims: Metformin is an insulin-sensitizer widely used to 
treat type 2 diabetes mellitus. The metabolic effects of metformin on human 
adipocytes have not been well studied. Organic cationic transporters (OCT-1 
and OCT-2) have been described to mediate metformin effects. We investi-
gated the expression of OCT-1 and OCT-2 in human adipose tissue and dur-
ing adipogenesis and evaluated their possible role in metformin action on 
human adipocytes.
Materials and methods: OCT-1 and OCT-2 gene expressions were analyzed 
in 118 visceral and subcutaneous adipose tissue, in stromo-vascular cells 
(SVCs) and mature adipocytes obtained from adipose tissue and during hu-
man pre-adipocytes differentiation. To test the functionality of OCT in re-
sponse to metformin, co-treatments with cimetidine (OCT blocker, 0.5 and 
5 mM) and metformin (5 mM) were made on human pre-adipocytes. The 
pre-adipocyte differentiation was monitored measuring adipogenic (FASN, 
ACC1, PPARg and Adipoq) and inflammatory (IL-6 and MCP-1) gene expres-
sions, the formation of lipid droplets and AMPK activity.
Results: OCT-1 (but not OCT-2) gene expression was detected in subcutane-
ous and visceral adipose tissue. In both fat depots, OCT-1 gene expression 
and protein was associated significantly with the obesity phenotype. OCT-
1 gene expression was significantly higher in SVCs than mature adipocytes 
(1.8-fold increased, p=0.01) and increased during differentiation the process 
in parallel to adipogenic genes. Metformin (5mM) decreased significantly the 
differentiation of human pre-adipocytes, decreasing the expression of lipo-
genic genes, lipid droplets accumulation, increasing AMPK activation. Co-
treatments with cimetidine restored adipogenesis. Furthermore, metformin 
decreased IL-6 and MCP-1 gene expression in comparison with differentiated 
adipocytes.
Conclusion: OCT-1 might mediate the action of metformin on human adi-
pose tissue. 
Supported by: Ministerio de Educación y Ciencia (SAF2008-02073) and CI-
BERobn
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The role of proliferin (PLF) in adipose tissue
T. Ishizuka, K. Kajita, T. Hanamoto, K. Fujioka, H. Okada, M. Yamauchi,  
Y. Uno, H. Morita; 
Department of General Internal Medicine, Gifu University Graduate School 
of Medicine, Japan.
Background and aims: Last year, we reported that mature adipocytes have 
the ability to proliferate, which is enhanced with pioglitazone (Pio) treatment. 
We demonstrated that 5-Bromo-2’-Deoxyuridine (BrdU), a thymidine ana-
log, incorporation into mature adipocytes was observed in BrdU-pretreated 
rats. Quantified results showed that amount of BrdU incorporation was equal 
in adipocytes and total stromal vascular fraction cells, and that BrdU incor-
poration was less active in subcutaneous adipocytes than visceral ones. Treat-
ment with 0.005% Pio containing food for 2w increased BrdU incorporation 
predominantly in subcutaneous, but not visceral adipocytes. Moreover, we 
found that an increase in cell number and the cell cycle analyzed with flow cy-
tometry were recognized in fully differentiated 3T3-L1 adipocytes. Treatment 
with PPARγ ligands, 10 μM Pio and 10 μM 15-deoxy-Δ12,14-prostaglandin 
J2 increased adipocytes proliferation. In this study, we screened genes regu-
lated by Pio, and we took note of PLF as a growth factor in adipocytes. PLF, 
also termed mitogen-regulated proteins, is a member of the prolactin/GH 
family is involved in angiogenesis of placenta. PLF, secreted as a paracrine 
agent, binds to the insulin-like growth factor II (IGF-II)/cation-independent 
mannose 6-phosphate (M6P) receptor which can couple with Gi protein. We 
clarify the role of PLF in adipocytes replication.
Materials and methods: Effects of PLF knockdown with siRNA and treat-
ment with anti-PLF antibody (PLF-Ab) on 3T3-L1 adipocytes were exam-
ined. Expression of PLF in adipocytes isolated from rats during treatment 
with or without Pio was measured. In addition, effect of PLF-Ab administra-
tion on adipocytes growth was evaluated.
Results: Treatment with Pio increased PLF mRNA levels and protein lev-
els in cell lysate and medium in 3T3-L1 adipocytes. Both PLF knockdown 
and an addition of PLF-Ab reduced adipocytes proliferation evaluated by cell 
number and BrdU incorporation. Treatment with IGF-II enhanced cell pro-
liferation, whereas pertussis toxin suppressed its proliferation. These results 
indicated that PPARγ-induced PLF positively regulates cell replication in 
3T3-L1 adipocytes. and that involvement of IGF-II/cation-independent M6P 
receptor was also suggested. PLF was more abundantly expressed in visceral 
adipocytes than subcutaneous ones, while treatment with Pio increased sub-
cutaneous adipocytes, but not visceral ones, which closely correlated to the 
extent of BrdU incorporation in each adipose tissue. PLF-Ab injection re-
sulted in decreased BrdU incorporation in adipocytes. These results strongly 
supported the notion that PLF is actually involved in mature adipocyte rep-
lication in vivo.
Conclusion: PLF was suggested to be involved in cell replication as a PPARγ-
induced growth factor in mature adipocytes.
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Mammalian Ste20 kinase stimulates adipogenesis by activation of PPARγ
T. Oh1, B. Park2, S. Park2, Y. Lee2; 
1Internal Medicine, Chungbuk National University, Cheongju, 
2Biochemistry, Chungbuk National University, Cheongju, Republic of Korea.
Background and aims: Recent studies have shown that mammalian ste20 
kinase (MST) signaling pathway plays an important role in the regulation 
of apoptosis and cell cycle control and is thus emerging as a novel tumor 
suppressor pathway. MST pathway, originally identified as hippo pathway 
in Drosophila, involves several participating proteins including a scaffold-
ing protein Salvador (SAV1). The idea of MST signaling pathway function-
ing in cell differentiation seems plausible but needs investigation. Based on 
our finding that MST2 interacts with PPARγ, a key regulator of adipogenesis, 
through SAV1, we sought to understand the novel role of the MST signaling 
pathway in adipocyte differentiation.
Materials and methods: Proteins of interest were overexpressed or knocked 
down by siRNA in cell cultures of HEK293 cells and 3T3-L1 adipocytes. We 
employed various protein analysis methods and Oil red staining to analyze 
the MST signaling pathway.
Results: We found that MST2 bound to PPARγ through SAV1 and stabi-
lized PPARγ protein. Interaction was dependent on the N-terminal portion 
of SAV1 including WW domains and the N-terminal portion of PPARγ in-
cluding PPXY motif. We could not find the evidence that PPARγ is a direct 
substrate of MST2. Coexpression of MST2 and SAV1 resulted in a profound 
induction of PPARγ activity even in the absence of stimulation by an agonist 
rosiglitazone. During the differentiation period of 3T3-L1 cells, the protein 
expression of MST2 and SAV1 showed increases preceding that of PPARγ 
and the protein complex of endogenous SAV1 and PPARγ could be detected. 
Finally, adipocyte differentiation of 3T3-L1 cells was increased by overex-
pression of MST2 and SAV1 while it was decreased by knockdown of SAV1 
using siRNA.
Conclusion: From the results, we propose that the activation of PPARγ by the 
MST signaling pathway may be a novel and important regulatory mechanism 
of adipocyte differentiation.
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Association of human obesity with altered adipose PTX3 gene expression 
and protein plasma levels 
A.M. Gómez-Foix1, O. Osorio1, M. Guitart1, M.R. Chacon2, E. Maymó-
Masip2, J.M. Moreno3, M. Montori1, J.M. Fernández-Real3, J. Vendrell2; 
1Dep. Bioquimica i Biologia Molecular, CIBERDEM, Universitat de 
Barcelona, 2Joan XXIII University Hospital, CIBERDEM, Rovira i Virgili 
University IISPV, Tarragona, 3Unit of Diabetes, Endocrinology and 
Nutrition, Hospital de Girona, Spain.
Background and aims: PTX3 is a secreted acute-phase long pentraxin that is 
believed to mediate innate immunity and inflammation. PTX3 gene is mainly 
expressed in adipose tissue, and smooth and cardiac muscle in humans. Plas-
ma PTX3 protein concentration has been negatively correlated with human 
obesity, and positively with atherosclerotic inflammation, and is a risk marker 
for myocardial infarction. The PTX3 gene expression is stimulated by TNFα 
and IL-1β in cultured human fibroblasts and endothelial cells. We examine 
the relationship between plasma PTX3 protein and adipocyte PTX3 gene ex-
pression levels with human obesity. We also aim to provide insight into the 
mechanisms of PTX3 alterations.
Materials and methods: Subjects: Two different cohorts were included in the 
study. For adipose tissue gene expression, 43 obese and 19 lean age- and gen-
der-matched subjects were selected. A second cohort of 75 apparently healthy 
men (mean age 50.7 ± 11.2 years) was selected for the study of insulin sen-
sitivity and insulin secretion using the minimal model approach. Methods: 
Paired subcutaneous (sc) and visceral (v) adipose tissue (AT) biopsies and 
isolated adipocytes. PTX3 gene expression was assessed by quantitative real 
time PCR. PTX3 protein plasma levels were measured by ELISA. Human pre-
adipocyte SGBS cell line was differentiated in vitro to mature adipocytes and 
subjected to various stimuli.
Results: A negative correlation between plasma PTX3 protein levels, body 
weight (r=-0.32, p=0.016) and waist-hip ratio (r=-0.37, p=0.006) was shown. 
We also found a negative correlation between plasma PTX3 protein and total 
triglyceride levels (r=-0.33, p=0.004), and insulin secretion after intravenous 
glucose administration (acute insulin response to glucose) (r=-0.34, p=0.006) 
and oral glucose administration (measured as serum insulin at 30 minutes of 
the oral glucose tolerance test) (r=-0.25, p=0.04). Total PTX3 gene expres-
sion was similar in vAT and scAT, regardless of obesity. Expression in vAT 
was significantly lower in non-obese (BMI ≤ 25 Kg/m2) than in obese (BMI > 
25 Kg/m2) subjects (p=0.039). The PTX3 gene expression was higher in adi-
pocytes isolated from vAT than from scAT (p=0,034). Likewise, in vAT, the 
PTX3 gene was more strongly expressed in the isolated adipocytes than in the 
stromovascular fraction (p=0,028). In cultured SGBS adipocytes, PTX3 gene 
expression was enhanced by TNFα and IL-1β, whereas IL-6, insulin, hypoxia, 
antimycin A and H2O2 had no significant effect.
Conclusion: Plasma PTX3 protein levels correlate negatively with obesity 
markers and insulin secretion in human subjects. In contrast, the PTX3 gene 
expression is upregulated in vAT depots of obese subjects and it is enhanced in 
cultured human adipocytes by proinflammatory cytokines. These data indicate 
that PTX3 may have a role in the inflammatory process that drives obesity.
Supported by: SAF2009-07559 MCI, PI08/0733 and CP06/00119 ISCIII, 
Spain
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Ask1 is regulated in intra-abdominal adipocytes and human fat 
through combinatorial phosphorylation input and by stress-specific 
transcriptional regulation
Y. Beck-Haim1, N. Palgi1, M. Blüher2, N. Klöting2, T. Tarnovscki1,  
B. Kirshtein3, I. Harman-Boehm4, N. Bashan1, A. Rudich1; 
1Department of Clinical Biochemistry, Ben Gurion University of the 
Negev, Beer-Sheva, Israel, 2Department of Medicine, University of Leipzig, 
Germany, 3Department of Surgery, Soroka University Medical Center, Beer-
Sheva, Israel, 4Department of Internal Medicine C, Ben Gurion University of 
the Negev, Beer-Sheva, Israel.
Background and aims: We have recently demonstrated that omental fat in 
human obesity is associated with a MAP kinase stress signaling pathway 
involving the MAP3K5 Ask1 in adipocytes. Moreover, Ask1 exhibited both 
increased levels of the activating phosphorylation site Thr845, and increased 
protein and mRNA expression, the latter demonstrated as an independent 
predictor of whole-body insulin sensitivity. Here we aimed at unraveling the 
molecular basis for the regulation of Ask1 in intra-abdominal adipocytes.
Materials and methods: We utilized novel differentiated depot-specific 
pre-adipocyte cell lines, which we have demonstrated to retain various de-
pot-specific characteristics to study phosphorylation- and expression medi-
ated regulation of Ask1 by Western blot and qRT-PCR analyses, respectively. 
Findings were also determined in human omental and subcutaneous (SC) 
adipose tissue.
Results: Intra-abdominal (IA) adipocytes exhibited larger increase in Thr845 
phosphorylation than subcutaneous (SC) adipocytes in response to TNFα. 
In contrast, TNF-induced phosphorylation on the inhibitory Ser83 site was 
lower in IA adipocytes and peaked later than the activatory site. Like p-Ser83, 
Thr966 phosphorylation also peaked later than Thr845 in both cell lines. Ask1 
mRNA levels increased approximately 2-fold in response to TNFα (at 4 and 
24h), FasL and oxidative stress (at 24h), but no activation was observed with 
the ER stress inducer tunicamycin. Intriguingly, in human omental compared 
to SC fat despite elevated p-Thr845, different levels of the inhibitory phos-
phorylation sites could be observed, suggesting that activity is influenced by 
a combinatorial phosphorylation input. With regards to gene expression, we 
assessed members of the E2F family of transcription factors, since they have 
been implicated in the regulation of Ask1 expression in-vitro. Human omen-
tal fat displayed increased mRNA and protein expression of members of the 
transcription factors members E2F1 and E2F4 in omental versus SC fat, and 
in obesity compared to lean persons.
Conclusion: Ask1 in intra-abdominal adipocytes may be regulated in a com-
plex manner: i. by a combinatorial input of Ask1 kinases acting on activatory 
and inhibitory phosphorylation sites. ii. by changes in gene regulation, poten-
tially mediated by changes in E2F family of transcription factors in response 
to inflammatory and oxidative stress.
Supported by: German-Israeli Foundation for Scientific Research and Develop-
ment (41-2008)
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TNF-like inducer of apoptosis prevents TNF-alpha-induced insulin 
resistance in human visceral adipocytes
A. Vazquez-Carballo1, M.R. Chacon2, R. Vila-Bedmar1, M. Lorenzo1,  
J. Vendrell2, S. Fernandez-Veledo1; 
1Biochemistry and Molecular Biology II, Complutense University, Madrid, 
2Research Department, Pere Virgili Institute. University Hospital of 
Tarragona Joan XXIII, Spain.
Background and aims: Insulin resistance is an important contributor to 
the pathogenesis of type 2 diabetes (T2D) and obesity is a risk factor for its 
development. In the obese state an altered secretion pattern, with increase 
in pro-inflammatory and decrease in anti-inflammatory factors is found. In 
fact, obesity is considered a low-grade inflammatory state. Several mediators 
released from adipocytes and macrophages, including TNF family members, 
have been suggested to impair insulin action in peripheral tissues. Tumor 
necrosis factor-like weak inducer of apoptosis (TWEAK) is a relatively re-
cently identified pro-inflammatory cytokine that regulates multiple cellular 
responses. Tweak could be involved in the pathogenesis of chronic inflamma-
tory diseases but its physiological role in adipose tissue is still not known. The 
objective of the present study was to dissect the differential effects of Tweak 
vs. TNF-α on human visceral adipocytes.
Materials and methods: We analyzed the impact of TNF-α and Tweak on 
glucose uptake and insulin action in a human visceral adipocytic cell line 
with high capacity to differentiate.
Results: TNF-α and Tweak activates different intracellular signaling path-
ways in human visceral adipocytes. In this regard, TNF-α induces insulin 
resistance by JNK1/2-dependent mechanism, impairing insulin-stimulated 
glucose uptake and insulin signaling at the insulin receptor substrate (IRS)-
1/Akt level. By contrast, Tweak does not induce JNK1/2 activation and in 
consequence insulin sensitivity on glucose uptake is not affected. Moreover, 
pre-treatment with Tweak prevented TNF-α-dependent JNK1/2 activation, 
restoring insulin signaling and insulin-induced glucose uptake.
Conclusion: Tweak shows a protective role against TNF-α-induced insulin 
resistance in human visceral adipocytes. Our results suggest the balance of 
TNF family members on adipose tissue as a key factor in the pathogenesis of 
obesity-associated metabolic disorders.
Supported by:  MCINN and FIS
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Adipose reduction in the activity of the repressor ICER is responsible for 
insulin resistance elicited by the transcriptional factors CREB in obesity
D. Favre1, E. Legouil1, C. Verdumo2, D. Fahmi1, R. Regazzi3, P. 
Vollenweider1, V. Giusti2, G. Waeber1, A. Abderrahmani1; 
1Service of Internal Medicine, University Hospital of Lausanne (CHUV), 
2Service of Endocrinology and Diabetotologia, University Hospital of 
Lausanne (CHUV), 3Department of Cell Biology and Morphology, 
University of Lausanne, Switzerland.
Background and aims: Sustained adipose activation of the transcriptional 
activators cAMP response binding proteins (CREB) in obesity leads to im-
paired expression of the glucose transporter GLUT4 and adiponectin (adi-
poq) in mice model of obesity. Diminution of GLUT4 and adipoq caused by 
CREB is indirect and relies on the increased repressive activity of the CREB 
target gene activating transcription factor 3 (ATF3). Specific inactivation of 
CREB in adipocytes decreases ATF3 production and improves whole-body 
insulin sensitivity of mice in the context of diet-induced obesity. Thus, el-
evation of CREB activity is a key mechanism responsible for adipocyte dys-
function and systemic insulin resistance. The inducible cAMP early repressor 
(ICER) is a negative regulator of the CREB activity. In fact, ICER antagonizes 
the CREB factor by competing for the regulation of similar target genes. The 
goal of the study was to investigate whether loss of ICER expression in adi-
pocytes could be responsible for increased CREB activity in obesity.
Materials and methods: Mice C57bl6 were fed with a high fat diet (HFD) for 
12 weeks to increase body weight and generate insulin resistance. Biopsies of 
visceral adipose tissues (VAT) were prepared from human lean (BMI=24±0.5 
Kg/m2) or obese subjects (BMI>35 Kg/m2). Total RNA and protein were pre-
pared from white adipose tissues (WAT) of chow- or HFD-fed mice and VAT 
of lean and obese subjects. Activities of CREBs and ICER were monitored 
by electromobility shift assays (EMSA). The role of ICER on CREB activity 
was confirmed in 3T3-L1 adipocytes cells. Briefly after differentiation, the 
cells were electroporated with the plasmid coding for ICER cDNA. Gene ex-
pression was quantified by quantitative real-time PCR and western Blotting 
experiments.
Results: The expression of ICER is reduced in WAT of HFD-induced obese 
mice when compared to chow mice as measured by real-time PCR and 
EMSA. Similar result was found in human tissues. Reduction in ICER expres-
sion was associated with increased ATF3 expression and decreased adipoq 
and GLUT4 contents. Diminution in ICER levels was observed in adipocytes 
fraction whereas its expression was unchanged in stroma vascular fraction of 
WAT. Overexpression of ICER in 3T3-L1 adipocytes silenced the expression 
of ATF3, confirming the regulation of the factor by ICER. The expression 
of ICER is regulated by histone deacetylases activity (HDAC). Inhibition of 
HDACs in 3T3-L1 adipocytes cells using trichostatin inhibited the produc-
tion of ICER. The whole activity of HDAC was reduced in WAT and VAT of 
obese mice and human obese subjects.
Conclusion: Impaired adipose expression of ICER is responsible of increased 
CREB activity in adipocytes in obesity. This mechanism relies on reduction 
of the HDAC activity.
PS 71 Adipose tissue inflammation
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IL-1β is a putative mediator in disturbed adipocyte-hepatocyte crosstalk 
that is induced by adipose inflammation
O. Nov1, S. Wueest2, D. Konrad2, E.C. Lewis1, I. Dvir1, S. Fishman3,  
N. Bashan1, A. Rudich1; 
1Department of Clincal Biochemistry, Ben Gurion University, Beer Sheva, 
Israel, 2Division of Pediatric Endocrinology and Diabetology, University 
Children’s Hospital, Zurich, Switzerland, 3Department of Gastroenterology 
and Hepatology, Tel Aviv Sourasky Medical Center, affiliated to Sackler 
School of Medicine, Israel.
Background and aims: Although the role of IL-1β in (auto)inflammatory 
cascades is well established, its involvement as an endocrine mediator of 
adipose tissue-liver crosstalk in obesity is still debated. Here we hypothesized 
that secreted IL-1β by adipose tissue plays a role in mediating hepatic insulin 
resistance in response to adipose inflammation.
Materials and methods: We utilized primary rat hepatocytes or human and 
rat hepatoma cell lines, and tested direct modulation of proximal and distal 
insulin signalling by IL-1β. In addition, we used conditioned medium from 
human omental fat explants. Furthermore, we measured systemic and portal 
IL-1β levels and mRNA expression in different fat depots in mice.
Results: The release of IL-1β from human omental fat explants ranged be-
tween 0.15 and 1.5 ng/gr tissue per 24h, and correlated with BMI (R2=0.639, 
p<0.01). Human hepatoma cells (HepG2) incubated with omental fat condi-
tioned medium exhibited impaired insulin-stimulated phosphorylation of IR, 
IRS, PKB and GSK3. This effect has been strongly attenuated (p<0.05) by co-
incubation with human recombinant IL-1 receptor antagonist (IL-1Ra). Mice 
fed high fat diet for 8 weeks (i.e., before marked infiltration by macrophages 
occur) exhibited no detectable increase in IL-1β mRNA in the systemically-
drained peripeipdidymal fat pad, but a 1.8-fold increase in IL-1β expression 
in portal-drained mesenteric fat. Consistently, whereas no increase in sys-
temic circulating IL-1β levels was observed in these mice, portal blood lev-
els of the cytokine were 2.4-fold elevated (p<0.05). The potential of IL-1β to 
induce insulin resistance was further demonstrated utilizing rat primary he-
patocytes, and in the Fao hepatoma cells could be shown to engage impaired 
insulin-stimulated tyrosine phosphorylation of both IRS1 and IRS2.
Conclusion: While clear pathophysiological role for IL-1β as a mediator of 
hepatic insulin resistance in response to adipose inflammation still awaits ap-
propriate in-vivo models, this study provides compelling in-vitro support for 
this notion. Reported beneficial effects of IL-1Ra or neutralizing anti-IL-1β 
Ab may therefore prove to be at least partly contributed by interference with 
a dysfunctional visceral fat-liver communication.
Supported by: ISF and Israeli Ministry of Health.
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The role of IL-1RI mediated T cell accumulation in adipose tissue - 
insights to the development of obesity-induced insulin resistance
K.A. Harford1, C.M. Reynolds1, F.C. McGillicuddy1, M. Claessens1,  
E. Oliver1, O. Finucane1, K.H.G. Mills2, H.M. Roche1; 
1Nutrigenomics, UCD Conway Institute, Dublin, 2School of Biochemistry 
and Immunology, Trinity College Dublin, Ireland.
Background and aims: Immune cell infiltration into adipose tissue during 
high-fat feeding has recently been characterised with T cell recruitment evi-
dent prior to macrophage recruitment. Immune cell-derived cytokines are 
hypothesized to augment adipose tissue inflammation and insulin resistance. 
Cytotoxic T cells are effector T cells that have been implicated in adipose tis-
sue macrophage differentiation, activation and migration. Helper T cells are a 
sub-group of T cells involved in the activation and direction of other immune 
cells. γδ T cell receptor (TCR) expressing cells represent a small subset of T 
cells that possess a distinct γδ TCR on their surface and play a key role in 
amplifying the immune response bridging the innate with the adaptive im-
mune system. IL-1 plays a key role in activation of γδ TCR expressing cells 
and thus in this study we hypothesized that lack of IL-1 signalling may alter 
T cell subset recruitment into obese adipose tissue, in particular affecting γδ 
TCR expressing cell recruitment.
Materials and methods: C57BL/6 WT and IL-1RI-/- mice were fed a high-fat 
diet (HFD) (45 % palm oil) for 16 weeks. At weeks 0, 6, 12 and 16, glucose 
tolerance tests (GTT) were performed (1.5g/kg glucose, ip) and epididymal 
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adipose tissue (EAT) was harvested. Adipocytes and stromal vascular cells 
(SVC) were separated by collagenase treatment. SVC were labelled with an-
tibodies for T cell markers CD3, CD4, CD8 and the γδ T cell receptor (TCR) 
and analysed by flow cytometry. CD3+CD4-CD8+ cells are cytotoxic T cells 
while CD3+CD4+CD8- cells represent helper T cells. Cells expressing the γδ 
TCR were also determined. Results presented as percentage total SVC.
Results: IL-1RI-/- mice exhibited a more glucose tolerant phenotype at base-
line and after 12 and 16 weeks on HFD. Development of obesity was associ-
ated with a steady rise in the number of cytotoxic T cells (CD3+CD4-CD8+) 
in adipose tissue of WT mice after 6 (from 0.06±0.02% to 2.45±0.3%) and 12 
(6.57±1.2%) weeks of high-fat feeding (p<0.001), with no difference between 
WT and IL-1RI-/- genotypes. The population of helper T cells (CD3+CD4+CD8-
) remained low throughout with significantly higher levels observed in WT 
mice at week 16 compared to IL-1RI-/- (5.8±0.7% vs 2.8±0.9%) (p<0.001). 
Interestingly the number of γδ TCR expressing cells recruited into adipose 
tissue during HFD was much higher (19.3±1.5% at week 12) than other T cell 
subsets. Further, there was significantly less in the IL-1RI-/- mice compared 
to WT after 12 (19.3±1.5% vs 15.3±1.0%) and 16 (13.4±0.7% vs 9.5±1.4%) 
weeks of high-fat feeding (p<0.05) consistent with an important role for IL-1 
in activation of γδ TCR expressing cells.
Conclusion: In the present study we demonstrate that during obesity both 
cytotoxic T cells and γδ TCR expressing cells infiltrate adipose tissue and thus 
may play a crucial role in initiating the inflammatory response and recruit-
ing adipose tissue macrophages. Further, IL-1 plays a key role in mediating 
infiltration of γδ TCR expressing cells into adipose tissue but does not affect 
recruitment of other T-cell subsets. Reduced recruitment of γδ TCR express-
ing cells into adipose tissue of IL-1RI-/- mice may in turn partially account for 
protection from HFD-induced insulin resistance.
Supported by: SFI Principal Investigator programme
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Human adipose tissue macrophage activation and impairment of 
adipocyte functions by osteopontin
M. Zeyda1, K. Gollinger1, J. Todoric1, O. Aszmann2, G. Prager2,  
T.M. Stulnig1; 
1Dept. of Medicine III, 2Dept. of Surgery, Medical University of Vienna, 
Austria.
Background and aims: Osteopontin (OPN) is highly upregulated in adipose 
tissue in human and murine obesity and has been recently shown to be func-
tionally involved in the pathogenesis of obesity-induced adipose tissue in-
flammation and associated insulin resistance in mice. OPN is a protein with 
multiple functions and acts as a chemokine and an inflammatory cytokine 
through a variety of different receptors (CD44, integrins). It is expressed in 
many cell types including adipose tissue macrophages (ATM). However, the 
target cells of OPN action in obese adipose tissue are still elusive. Here, we 
investigated expression of OPN receptors and the impact of OPN on ATM, 
adipocytes and other cells of human adipose tissue.
Materials and methods: Receptor expression was assessed by immunostain-
ing of human omental adipose tissue sections and mRNA expression in frac-
tionated subcutaneous adipose tissue. Human in vitro differentiated macro-
phages and primary adipose tissue macrophages isolated by flow-cytometry 
were stimulated with OPN. Human adipocytes differentiated from primary 
preadipocytes were pretreated or not with OPN prior to insulin stimulation.
Results: We found broad expression of OPN receptors in different adipose 
tissue cell types including adipocytes. OPN stimulated phosphorylation of 
Akt and MAP kinases, degradation of IκB-α, as well as secretion of Mcp-1, 
TNFα, and IL-10 in model macrophages and isolated human ATM. More-
over, OPN impaired differentiation and function of primary adipocytes as 
determined by PPARγ and adiponectin gene expression and insulin-stimu-
lated glucose uptake.
Conclusion: OPN activates adipose tissue macrophages and interferes with 
adipocyte function thereby underlining the potential use of OPN as a thera-
peutic target for obesity-induced complications.
Supported by: Austrian FWF 
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High-fat diet induced insulin resistance triggers infiltration of dendritic 
cells into adipose tissue and primes the inflammatory response of bone 
marrow dendritic cells
C.M. Reynolds1, F.C. McGillicuddy1, K.A. Harford1, K.H.G. Mills2,  
H.M. Roche1; 
1Conway Institute, University College Dublin, 2Immune Regulation 
Research Group, Trinity College Dublin, Ireland.
Background and aims: Dendritic cells (DC) provide the first line of defence 
against invading pathogens and play a key role in facilitating cross-talk be-
tween the innate and adaptive immune systems. High-fat diet (HFD) induced 
obesity and insulin resistance (IR) is associated with a heightened inflamma-
tory state and infiltration of macrophages and T-cells into adipose tissue. In 
this study we hypothesized that a HFD would result in recruitment of DC 
into adipose tissue, activate the DC immune response, with functional effects 
on adipocyte insulin sensitivity.
Materials and methods: C57BL/6J mice were fed a HFD (45% palm oil) for 
16 weeks, glucose tolerance was monitored pre- and post-HFD. Stromal vas-
cular fraction (SVF) cells were isolated from adipose and analyzed by flow 
cytometry for CD11c+CD11b+F480- DC. Bone-marrow DC (BMDC) were 
isolated and stimulated ± LPS (100ng/ml) for 24h and cytokine release mea-
sured by ELISA. To characterize the effects of DC on adipocyte biology 3T3-
L1 adipocytes were co-cultured with DC (± LPS stimulation), then insulin-
stimulated 3H-glucose uptake and insulin signaling was monitored.
Results: Mice developed overt insulin resistance after 16 wks HFD with 
marked delay in clearance of plasma glucose during GTT compared with 
chow-fed and week 0 control mice. DC infiltration into adipose tissue was 
evident after high fat feeding. BMDC derived from HFD-fed mice exhibited 
a much more pronounced inflammatory response, with greater IL-12p70, IL-
10, and IL-1β secretion, in response to LPS compared to age-matched chow-
fed control cells. BMDC TLR4 mRNA and protein expression was enhanced 
in these cells pre-LPS stimulation. Co-culture of BMDC with 3T3L1 adipo-
cytes induced marked insulin resistance in adipocytes with marked reduction 
in insulin-stimulated 3H-glucose uptake.
Conclusion: HFD induces IR which is associated with infiltration of DC into 
adipose. BMDC from these HFD fed animals are primed to be more respon-
sive to inflammatory stimuli and can block insulin mediated glucose uptake 
in adipocytes.
Supported by: SFI (Principal Investigator Programme)
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Inflammatory adipocyte activation by heat shock protein 60 involves 
MAP-kinase- and NFkB-dependent signalling pathways
V. Burkart, J. Kriebel, T. Märker, C. Habich; 
Institute for Clinical Diabetology, German Diabetes Center, Düsseldorf, 
Germany.
Background and aims: Adipocytes and their mediators have been recog-
nized to play central roles in the development of the metabolic syndrome 
and in the pathogenesis of diabetes. Recent studies in the New Zealand obese 
(NZO) mouse, an animal model of the metabolic syndrome, identified heat 
shock protein 60 (Hsp60) as an endogenous stress signal with pronounced 
adipocyte stimulating capacity. Hsp60 was found to induce the release of 
proinflammatory cytokines and chemokines from adipocytes in a receptor-
mediated process. With regard to the development of intervention strategies 
aiming at the modulation of adipocyte-driven proinflammatory processes, 
our present study was designed to identify key components of signalling 
pathways involved in the Hsp60-induced release of inflammatory adipocyte 
mediators.
Materials and methods: Hsp60-mediated activation (phosphorylation) 
of MAP-kinase family members (p38, ERK1/2, JNK) and of the transcrip-
tion factor NFκB was analysed by immunoblotting lysates of primary NZO 
mouse-derived preadipocytes and mature adipocytes. The potential contri-
bution of these signalling molecules to the Hsp60-induced release of the in-
flammatory mediators IL-6, KC and MCP-1 was assessed by applying specific 
inhibitors and the use of multiplex beads analyses.
Results: We could demonstrate for the first time that the stress protein 
Hsp60 activates members of the MAP-kinase family and the transcription 
factor NFkB in primary adipocytes of the NZO mouse. Hsp60 exposure 
(10 µg/ml) slightly activated ERK1/2 phosphorylation in mature adipocytes 
(1.4±0.4-fold), but not in preadipocytes. JNK was weakly activated in mature 
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adipocytes as well as in preadipocytes up to 2.2±1.2-fold. No Hsp60-induced 
activation of p38 was observed in the cells. NFkB activation was significantly 
increased (up to 2.6±0.9-fold) in Hsp60 exposed adipocytes independent of 
their maturation state (p<0.05). The ERK1/2-inhibitor PD98059 suppressed 
the release of the inflammatory mediator MCP-1 depending on the matura-
tion state of the adipocytes. In preadipocytes the MCP-1 release was slightly 
decreased in a dose-dependent manner from 5.3±2.0 ng/ml to 3.6±1.4 ng/
ml (inhibition by 22.1%), whereas in mature adipocytes the MCP-1 release 
was strongly reduced from 8.3±5.1 ng/ml to 1.9±2.3 ng/ml (inhibition up to 
80.8%, p<0.001). The release of IL-6 and KC was not affected by the inhibi-
tory drug. Selective inhibition of JNK by SP600125 caused a weak inhibition 
of KC-release from mature adipocytes and of MCP-1 release from preadipo-
cytes and mature adipocytes. Inhibition of NFkB activation by SN50 resulted 
in a strong, dose-dependent reduction of the release of IL-6 (up to 99.9% 
inhibition, p<0.001), KC (up to 91.8% inhibition, p<0.001) and MCP-1 (up 
to 94.1% inhibition, p<0.01) from adipocytes independent of their matura-
tion state.
Conclusion: The results of our study point to the involvement of different sig-
nalling pathways in the proinflammatory activation of NZO mouse-derived 
adipocytes by Hsp60. Whereas ERK1/2 and JNK are differentially activated 
depending on the adipocyte maturation state, NFκB activation is largely in-
dependent of the maturation state of the cells. Our findings will contribute 
to identify components of the intracellular signalling cascades as potential 
targets for the modulation of diabetes-associated inflammatory adipocyte ac-
tivities induced by endogenous stress signals.
Supported by: DFG, DDG
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Short chain fatty acid regulation of inflammatory response in human 
primary macrophages 
O. Pivovarova1,2, S. Weimer1, A.F.H. Pfeiffer1,2; 
1Department of Clinical Nutrition, German Institute of Human Nutrition 
Potsdam-Rehbruecke, Nuthetal, 2Department of Endocrinology, Diabetes 
and Nutrition, CBF, Charité University Medicine, Berlin, Germany.
Background and aims: Insulin resistance in adiposity and type 2 diabetes is 
associated with low grade system inflammation characterized by macrophage 
infiltration of adipose tissue. Short chain fatty acids (SCFA) produced by in-
testinal microbiota modulate inflammatory responses. This effect have been 
demonstrated in various immune cells (neutrophiles, monocytes, PBMC 
fraction), tumor cell lines, tissue culture and animal studies, but not in mature 
human macrophages. The aim of this study was to investigate SCFA effects on 
the cytokine expression in human primary macrophages of proinflammatory 
M1- and antiinflammatory M2-subtypes.
Materials and methods: For the culture of human primary macrophages, 
monocytes were isolated from the whole blood and differentiated in RPMI 
medium supplemented with 50 ng/ml GM-CSF (M1-macrophages) or M-
CSF (M2-macrophages) and 10% foetal bovine serum for 7 days. For the 
experiment, mature cells were incubated in the medium with acetate or pro-
pionate (2, 20 mM) for two hours with following LPS treatment (100 ng/ml) 
for 22 hours. The expression of cytokines (MCP1, IL-1β, IL-6, IL-8, IL-10, 
TNF-α) and SCFA receptors was assessed by quantitative real-time PCR.
Results: The low level of mRNA expression of SCFA receptors GPR41 and 
GPR43 activated by acetate and propionate was detected in both studied sub-
types of human primary macrophages. Interestingly, LPS treatment signifi-
cantly increased the expression of both receptors with this effect being more 
apparent in M2-macrophages (219-fold for GPR41 and 46-fold for GPR43). 
Acetate (20 mM) and propionate (2, 20 mM) treatment considerably attenu-
ated LPS-induced receptor expression. SCFA effects on the basal and LPS-
induced cytokine expression were studied. Propionate at high concentration 
(20 mM) corresponding to the concentration in human colon demonstrates 
antiinflammatory effect due to significantly decrease of the LPS-induced cy-
tokine expression. Interestingly, the same propionate treatment increased cy-
tokine expression in macrophages incubated without LPS stumulation. These 
effects were detected both in M1- and in M2-cell subtypes. For acetate, no 
influence on the cytokine expression was found.
Conclusion: Propionate demonstrates modulatory effects on the inflam-
matory response in the culture of human primary macrophages which are 
possibly mediated by metabolic, rather than receptor-coupled mechanism. 
Thus, propionate produced by intestinal microbiota may contribute to the 
regulation of inflammatory responses of tissue macrophages in adiposity and 
type 2 diabetes.
Supported by: DFG 
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Acute and chronic saturated fatty acid treatment as a key instigator of the 
TLR mediated inflammatory response in human adipose tissue in vitro
A.L. Harte1, E.M. Youssef-Elabd2, K.C. McGee1, G. Tripathi1, M.S. Abdalla3, 
H.M. Sharada3, E. Ashour2, A.I. Amin4, J.P. O’Hare1, S. Kumar1,  
P.G. McTernan1; 
1Unit for Diabetes and Metabolism, University of Warwick, United 
Kingdom, 2Biochemistry Dept, National Research Centre, Dokki, Giza, 
Egypt, 3Chemistry Dept, Helwan University, Egypt, 4Clinical Pathology 
Dept, National Institute of Diabetes & Endocrinology, Cairo, Egypt.
Background and aims: Chronic elevation of saturated fatty acids (SFAs) and 
glucose (Glc) appears to activate an inflammatory response; compounded 
by habitual feeding. Restoration of physiological SFAs and Glc levels post-
prandially may not attenuate the original insult; a concept termed ‘metabolic 
memory’. Therefore we investigated (1) the effect of chronic and oscillating 
SFAs and Glc on the inflammatory pathway in human abdominal subcutane-
ous (AbdSc) adipose tissue (AT) and adipocytes (Ads) (2) whether there is a 
sustained inflammatory response in absence of treatment.
Materials and methods: AbdSc AT (age 45±3.3 yrs; BMI: 21.9±2.4 kg/m2; 
n=6) was obtained with ethics approval. Explants and Ads were treated with 
chronic low glucose (L-Glc): 5.6mM and high glucose (H-Glc): 7.5mM, with 
low (0.2 mM) and high (2 mM) doses of a palmitate:stearic tri-mix (SFA) for 
48 hrs. Further, AbdSc AT explants and Ads were also exposed to the afore-
mentioned treatment regimen for 12hr periods, with alternating rest periods 
of 12hr in L-Glc. Western blot and ELISAs were utilised to examine compo-
nents of the NFκB pathway.
Results: Chronic treatment with H-Glc and high SFAs up-regulated key 
proteins of the NFκB pathway in AbdSc AT explants and Ads (TLR4, NFκB, 
p<0.05) whilst down-regulating MyD88 protein levels. Oscillating treatment 
with Glc and SFAs increased TLR4, NFκB, IKKβ and MYD88 in explants and 
Ads (p<0.05). Downstream TNFα and IL-6 (p<0.05) secretion were mark-
edly increased in chronically treated explants and Ads whilst, with oscillating 
treatments, a sustained inflammatory effect was noted in absence of treat-
ment.
Conclusion: In summary, this study implicates elevated SFAs as a key instiga-
tor of the inflammatory response in both AT and Ads, via NFκB, and suggests 
that short-term exposure of cells to uncontrolled levels of SFAs and Glc leads 
to a longer-term inflammatory insult within the Ads. As such, these findings 
highlight a potential molecular mechanism linking high SFA dietary intake 
and an adverse inflammatory response in patients with obesity and T2DM.
Supported by: BHF
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Distinct gene expression and cytokine release profiles identify 
three different adipose tissue progenitor cells in human abdominal 
subcutaneous and visceral adipose tissue
S. Perrini, R. Ficarella, A. Cignarelli, A. Peschechera, M. Barbaro, P. Nigro, 
A. Conserva, M.C. Carreira, A. Natalicchio, L. Laviola, F. Giorgino; 
Endocrinology & Metabolic Diseases, D.E.T.O., University of Bari, Italy.
Background and aims: Adipose-derived stem cells (ASCs) can be isolated 
from the stromal-vascular fraction (SVF) of adipose tissue (AT) (ASC-SVF). 
ASCs can be also isolated both from a pre-adipocyte fraction present in the 
fat cake at the top of the supernatant not previously collected together with 
the ASC-SVF (ASC-B), and from mature adipocytes through in vitro de-dif-
ferentiation (ASC-C). The aim of this study was to investigate the biological 
features of these three different ASCs.
Materials and methods: All ASCs were isolated from paired abdominal 
subcutaneous (SC) and visceral (V) AT biopsies obtained from 16 subjects 
(8F/8M, age 65±1 yrs, BMI 24.9±1.4). A genome-wide differential gene ex-
pression analysis followed by quantitative RT-PCR was performed on each 
SC and V ASC population. Cytokine secretion was analyzed by Bioplex pro-
tein array of the ASC conditioned medium.
Results: The six distinct ASCs were positive for the adipogenic lineage mark-
ers CD105, CD44, and CD49d, and were able to differentiate into adipocytes, 
chondrocytes, and osteocytes, respectively. To investigate whether ASC-SVF, 
ASC-B and ASC-C from SC and V fat depots were homogenous or genetical-
ly heterogeneous, a genome-wide analysis was performed using a GeneChip 
Gene 1.0 ST array with 764,885 probe sets, representing 28,869 annotated 
genes. Of these, we identified 367 and 984 genes that differed among ASC-
SVF, ASC-B and ASC-C in SC and V, respectively. These genes were identi-
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fied by first testing for significant differences among all ASCs in the 764,885 
probe sets with sequence-specific hybridization in at least one sample (Bayes-
ian ANOVA with a P value <0.05). A secondary filter was applied to those 
genes that resulted significantly different, to identify the genes that varied by 
at least 1.4-fold among V and SC ASCs. In SC ASCs, of the 367 genes, 169 
were found to have a conjoint differential expression in ASC-SVF, ASC-B and 
ASC-C, while 16, 76 and 106 were the genes that resulted to be differentially 
expressed in each subset of ASC, respectively. In addition, no gene was found 
to have a conjoint differential expression in SC ASC-SVF, ASC-B and ASC-C. 
In V ASCs, 984 genes were found to be differently expressed among ASC-
SVF, ASC-B and ASC-C. Of these, 230 genes were found to have a conjoint 
differential expression in each V ASC population, while 235, 426 and 89 were 
the genes that resulted to be differentially expressed in each subset of ASC, re-
spectively. In addition, 4 genes resulted to have a conjoint differential expres-
sion in all V ASCs. Both in SC and V ASCs, hierarchical clusters identified the 
presence of large contiguous color patches representing groups of genes that 
shared a similar expression pattern over multiple conditions both in ASC-
SVF and ASC-C, while highly dissimilar was the gene expression pattern in 
ASC-B compared to ASC-SVF and ASC-C. Of the 26 cytokines measured, 
IL-6 was secreted at higher levels in SC ASC-C compared to SC ASC-SVF 
and ASC-B (p<0.01), while it was significantly lower in SC ASC-SVF and 
ASC-B than in V ASCs (p<0.01). Secretion of IL-8, VEGF and MCP-1 was 
also significantly different among the 6 SC and V ASCs.
Conclusion: These results demonstrate the existence of genetically hetero-
geneous fat-derived populations of progenitor cells, which may add to the 
complexity and specificity of SC and V AT in humans.
Supported by: Italian Ministry of University and Research (MUR)
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Plasma glucose levels are associated with gene expression levels in 
subcutaneous and visceral adipose tissue of morbidly obese individuals
M.G.M. Wolfs1, E.J. Bruin1, S.S. Rensen2, J.W. Greve2, W.A. Buurman2,  
T.W. Van Haeften1,3, C. Wijmenga4, L. Franke4,5, M.H. Hofker1; 
1Department of Pathology and Medical Biology, Medical Biology Section, 
Molecular Genetics, University Medical Center Groningen, Netherlands, 
2Nutrition and Toxicology Research Institute Maastricht (NUTRIM), 
Department of General Surgery, Maastricht University Medical Center, 
Netherlands, 3Department of Internal Medicine, University Medical Center 
Utrecht, Netherlands, 4Department of Genetics, University Medical Center 
Groningen, Netherlands, 5Institute of Cell and Molecular Science, Barts and 
The London School of Medicine and Dentistry, United Kingdom.
Background and aims: Morbid obesity (BMI>35) dramatically increases the 
risk to develop type 2 diabetes. The biological mechanisms that drive this 
increased risk are largely unclear. In this study we aimed to identify genes 
that are differentially expressed in subcutaneous and visceral adipose tissue 
of diabetic and non-diabetic obese individuals in order to get insight in the 
pathologic changes related to diabetes.
Materials and methods: We determined whole-transcriptome gene expres-
sion levels in subcutaneous adipose tissue and visceral adipose tissue of 70 
morbidly obese individuals by using microarrays (Illumina HumanHT12 
BeadChips). From these data we extracted modules of highly coexpressed 
genes and we tested for each tissue whether these modules correlate with 
traits that are relevant to diabetes (plasma levels of glucose, insulin, and 
HbA1c). These modules are driven by the phenotypic differences in our study 
group, which range from metabolically normal to diabetic.
Results: In both tissues we detected several modules of highly coexpressed 
genes. Gene Set Enrichment Analysis of the genes within all separate mod-
ules showed that the genes within most modules are functionally related. This 
indicates that our approach yields a biologically meaningful gene classifica-
tion. Assessment of the correlation between each module and metabolic traits 
related to diabetes, revealed that in subcutaneous adipose tissue one module 
is significantly negatively correlated to plasma glucose levels (p = 7.0 x 10-6). 
This module consists of 28 genes of which most are involved in metabolism. 
In visceral adipose tissue one module - consisting of 103 genes - is signifi-
cantly correlated to plasma glucose levels (p = 2.1 x 10-5). Some genes that 
constitute this module were recently reported to be specifically expressed in 
macrophages, and are highly enriched in genes related to innate immunity 
(GO-terms).
Conclusion: In both subcutaneous and visceral adipose tissue we identified 
several genes that have expression levels which are correlated with plasma 
glucose levels. In subcutaneous adipose tissue expression levels of a set of 
metabolic genes were inversely correlated with plasma glucose levels. In vis-
ceral adipose tissue a set of genes related to innate immunity were positively 
correlated to plasma glucose levels. In particular, these genes play a role in 
the complement system (C1QA, C1QB, C1QC, C3AR1), Toll-like receptor 
signaling (TLR7, CD14), inflammasome (PYCARD), autophagy (ATG7), 
and lysosomal function (CTSB, CTSC, CTSZ, FUCA1, GUSB, LGMN). In 
conclusion, our data indicate that both metabolic and innate immunity re-
lated processes in subcutaneous and visceral adipose tissue, bridge the gap 
between diabetes and obesity.
Supported by: DFN
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Effect of hyperinsulinaemia on selected plasma and subcutaneous 
adipokines during angiotensin II type 1 receptor inhibition in patients 
with impaired fasting glucose
P. Wohl, E. Švehlíková, S. Kratochvílová, M. Klementová, J. Kopecký Jr.,  
T. Pelikánová; 
Diabetes center, IKEM, Prague, Czech Republic.
Background and aims: Only a few studies have investigated the in vivo ef-
fect of insulin on adipokines during angiotensin II type 1 receptor inhibi-
tion. The aim of our study was to test the effect of insulin on selected plasma 
and subcutaneous adipokines and their insulin-stimulated changes during 
telmisartan administration.
Materials and methods: 12 patients with impaired fasting glucose were en-
rolled in randomized, placebo-controlled, cross-over study of 3 weeks treat-
ment with telmisartan (T) (160 mg/d) or placebo (P). Acute hyperinsuline-
mia has been induced by one-step hyperinsulinemic euglycemic clamp (120 
minutes; 1 mU.kg -1.min -1, 5 mmol/l) conducted at the end of each treatment 
period. Before and during the clamp (0, 30, 120 minutes) plasma levels of 
adiponectin, resistin, tumor necrosis factor-alfa (TNF) and leptin were meas-
ured and needle biopsy of abdominal subcutaneous adipose tissue (SAT; 0, 30 
minutes) was performed to evaluate their expressions by the real-time PCR. 
Results: Hyperinsulinemia did not affect plasma TNF, but decreased TNF ex-
pression (p<0.001). Plasma adiponectin concentrations and SAT expression 
of adiponectin did not changed during insulin-stimulated conditions. Hyper-
insulinemia did not change plasma leptin concentrations, but the decrease 
in leptin expression in SAT was found (p<0.001). Plasma resistin rise during 
hyperinsulinemia (p<0.001), while the drop in resistin expression was ob-
served (p<0.01). Telmisartan decreased plasma TNF (p<0.05) and increased 
plasma leptin (p<0.01) and resistin (p<0.001) as compared to P. Moreover, 
telmisartan increased the plasma adiponectin (p<0.05), leptin (p<0.05) and 
resistin (p<0.01) concentrations during hyperinsulinemia.
Conclusion: Acute hyperinsulinemia increases plasma resistin concentra-
tions and decreases resistin, leptin and TNF expressions in SAT. Telmisartan 
decreases plasma TNF and increases plasma leptin and resistin concentra-
tions and changes the effects of insulin on plasma adiponectin, leptin and 
resistin concentrations. Our results support the hypothesis that telmisartan 
might play the beneficial metabolic role in patients with impaired fasting 
glucose.
Supported by: MZO 
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Absence of the NLRP-3 inflammasome protects against the development 
of obesity and insulin resistance
R. Stienstra1,2, J.A. van Diepen3, C.J. Tack1, P.C.N. Rensen3, L.A.B. Joosten1, 
M.G. Netea1, T. Devi Kanneganti2; 
1General Internal Medicine, Nijmegen, Netherlands, 2Department of 
Immunology, St Jude Children’s Research Hospital, Memphis, USA, 
3Department of Internal Medicine, Endocrinology and Metabolic Diseases, 
Leiden University Medical Center, Netherlands.
Background and aims: The innate immune system is part of the host defence 
and responds to invading pathogens by inducing an inflammatory reaction. 
Recognition of pathogens depends on PRRs that are present both on the outer 
membrane and intracellular components. The nucleotide-binding and oligo-
merization domain (NOD)-like receptor (NLR) protein NLRP3 responds to 
microbial ligands and endogenous danger signals present in the cytosol and 
triggers the formation of a protein complex including the eminent adaptor 
molecule ASC. The protein complex is named the NLRP-3 inflammasome 
and, upon formation, it enables the activation of Caspase-1, a cysteine prote-
ase that controls release of the pro-inflammatory cytokines IL-1β and IL-18. 
Obesity is characterized by elevated secretion of numerous cytokines includ-
ing IL-1β and IL-18 that contribute to the development of insulin resistance 
and type 2 diabetes. Previously we have shown that Caspase-1 is activated 
in adipose tissue of obese and insulin resistant animals, which suggests that 
the innate immune system is involved in the development of metabolic ab-
normalities associated with obesity. In the present study we tested whether 
(NLRP-3) inflammasome-dependent Caspase-1 activation mediates high fat 
diet-induced obesity and insulin resistance.
Materials and methods: To induce obesity and insulin resistance, Wildtype 
(Wt), NLRP3-/-, ASC-/- and Caspase-1-/- animals were fed a high fat diet 
(HFD) or low fat diet (LFD) for 16 weeks.
Results: Despite a similar daily food intake, HFD-fed NLRP3-/-, ASC-/- and 
Caspase-1-/- animals were protected against the development of high fat 
diet induced obesity. Whereas HFD-feeding of wildtype mice led to signifi-
cantly elevated plasma insulin, leptin and resistin levels, animals lacking the 
NLRP3-inflammasome were protected against the harmful effects of chronic 
overfeeding. Importantly, ASC-/- and Caspase-1-/- animals were resistant to 
the development of high-fat diet induced insulin resistance. In addition to 
a decrease in total adipose tissue mass, adipocyte cell size was reduced in 
HFD-fed ASC-/- and Caspase-1-/- animals compared to Wt mice. Detailed 
analysis of HFD-fed Caspase-1-/- mice using immunohistochemical local-
ization of adipose tissue-resident macrophages revealed a robust reduction 
of macrophage influx into the adipose tissue. Using microarray analyses of 
white adipose tissue from HFD-fed Wt vs. Caspase-1-/- animals, we estab-
lished that over 500 genes involved in immune response, signal transduction 
and chemotaxis were differentially expressed. Finally, metabolic cage studies 
of HFD-fed Wt and Caspase-1-/- animals revealed an enhancement in total 
energy expenditure in the absence of Caspase-1.
Conclusion: Our results show that NLRP-3 inflammasome-mediated cas-
pase-1 activity is involved in the development of obesity, insulin sensitivity, 
adipogenic gene expression and energy expenditure during chronic overfeed-
ing and suggest that inhibition of inflammasome-dependent caspase-1 acti-
vation may be a useful therapeutic strategy for treatment of obesity-induced 
insulin resistance.
Supported by: The Dutch Diabetes Research Foundation
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Deletion of macrophage migration inhibitory factor promotes obesity-
associated insulin resistance while attenuating inflammation in mice fed 
a high-fat diet
I. Stojanović1, T. Cvjetićanin1, S. Sandler2, S. Stošić-Grujičić1; 
1Immunology, Institute for Biological Research “Siniša Stanković”, Belgrade, 
Serbia, 2Medical Cell Biology, Biomedical Centre, Uppsala University, 
Sweden.
Background and aims: Macrophage migration inhibitory factor (MIF) is a 
multifunctional molecule generally described as pro-inflammatory and glu-
cocorticoid-induced regulator involved in both innate and adaptive immu-
nity. MIF is produced by various immune and non-immune cells including 
pancreatic β cells. Elevated MIF concentration and MIF mRNA expression 
was found in the mononuclear cells of obese individuals and serum MIF 
concentrations are highly increased in individuals with impaired glucose 
tolerance and type 2 diabetes. Furthermore, an increased expression of 
MIF mRNA and its protein in pancreatic islets isolated from high-fat diet 
(HFD)-fed C57BL/6 mice (B6) compared to control diet (CD)-fed mice has 
been seen (unpublished). Also, increased MIF levels were found in serum of 
starved animals on HFD. Since obesity is characterized as a state of low grade 
inflammation, the aim of this study was to investigate the effect of mif gene 
deletion on development of obesity, insulin resistance and inflammatory state 
in HFD-fed mice.
Materials and methods: Knock-out mice for mif gene (MIF-KO) and their 
wild type counterparts B6 mice were fed a HFD containing 60% fat and con-
trol groups were fed a control diet (CD - 10% fat). The weight of mice was 
measured weekly, triglyceride levels in non-fasting mice were determined 
spectrophotometrically, while serum markers of inflammation and insulin 
were measured by ELISA. Glucose and insulin tolerance tests were performed 
on fasting animals by intraperitoneal injection of D-glucose (2 mg/g b.w) or 
insulin (0.75 mU/g), respectively. Glucose concentration was determined 
from blood drawn from tail vein by Glucometer.
Results: Even on standard chow MIF-KO mice gained more weight than B6 
mice on the same diet. Furthermore, body mass increment of MIF-KO on 
HFD was higher compared to HFD-fed B6 mice. As for triglyceride levels, 
they were similar between MIF-KO and B6 when mice were on CD. Interest-
ingly, although MIF-KO on HFD diet weighed more then B6 on the same 
diet, their triglycerides were lower, at least at some time points tested. On 
the other hand, leptin levels corresponded to the weight increase of HFD-fed 
MIF-KO. Similar values of hyperglycemia were found in both HFD-fed B6 
and MIF-KO mice. Although MIF-KO mice on CD were euglycemic, they 
showed slightly impaired glucose and insulin tolerance. Moreover, marked 
insulin resistance (judged by both glucose and insulin tolerance test) was evi-
dent in HFD-fed MIF-KO mice and was significantly altered compared to B6 
mice on HFD. Serum insulin in MIF-KO on HFD was higher compared to 
CD-fed mice and similar to B6 mice on HFD. Finally, at the end of observa-
tion period (11 weeks), inflammatory markers such as CRP and IL-6 were 
down-regulated in HFD-fed MIF-KO compared to B6, while anti-inflamma-
tory cytokine TGF-β was moderately increased.
Conclusion: These results implicate that in vivo MIF deletion exacerbates 
obesity-induced insulin resistance, but reduces an underlying inflammation 
during high nutrient intake.
Supported by: EFSD/AstraZeneca Young Investigator Award
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Expression of human chemerin induces insulin resistance in the skeletal 
muscle but does not affect weight, lipid levels and atherosclerosis in LDL 
receptor knockout mice on high fat diet
U.C. Brödl1, M. Becker1, K. Rabe1, C. Lebherz2, J. Zugwurst1, B. Göke1,  
K.G. Parhofer1, M. Lehrke1; 
1Department of Internal Medicine II, 2Department of Internal Medicine I, 
University of Munich, Germany.
Background and aims: Chemerin is a recently discovered hepatoadipokine 
that regulates adipocyte differentiation as well as chemotaxis and activation 
of dendritic cells and macrophages. Chemerin was reported to modulate in-
sulin sensitivity in adipocytes and skeletal muscle cells in vitro. In humans, 
chemerin was shown to be associated with multiple components of the meta-
bolic syndrome including body mass index, triglycerides, HDL-cholesterol 
and hypertension. So far, however, the effect of chemerin on these various 
metabolic parameters has not been studied in vivo.
Materials and methods: To investigate the effect of chemerin on weight, glu-
cose and lipid metabolism as well as atherosclerosis in vivo, we used recom-
binant adeno-associated virus to express human chemerin in LDL receptor 
knockout mice on high fat diet.
Results: Expression of chemerin did not significantly alter weight, lipid lev-
els, and extent of atherosclerosis. Chemerin, however, significantly increased 
glucose levels during both intraperitoneal glucose tolerance test and insulin 
tolerance test. Chemerin reduced insulinstimulated Akt1 phosphorylation 
and activation of 5´AMP activated protein kinase (AMPK) in the skeletal 
muscle, but had no effect on insulin signaling and AMPK activation in the 
liver and gonadal adipose tissue.
Conclusion: Chemerin induces insulin resistance in the skeletal muscle in 
vivo. Chemerin is involved in the cross talk between liver, adipose tissue and 
skeletal muscle.
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Adipose tissue-specific activation of polyamine catabolism improves 
energy homeostasis in mice
T.E. Koponen1, E. Pirinen1, A. Uimari1, S. Vuohelainen1, S. Pirnes-Karhu1, 
E. Hohtola2, M. Laakso3, L. Alhonen1; 
1A.I. Virtanen Institute for Molecular Sciences, University of Eastern 
Finland, Kuopio, 2Department of Biology, University of Oulu, 3Department 
of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.
Background and aims: Polyamines are cationic and water-soluble com-
pounds found in all eukaryotic cells. A well-known function of polyamines is 
their ability to promote cell growth but all their functions are not known. Our 
previous study in transgenic mice having whole-body overexpression of the 
key enzyme in polyamine catabolism, spermidine/spermine-N1-acetyltrans-
ferase (SSAT), showed that enhanced polyamine catabolism regulates glucose 
and energy metabolism. The aim of this study was to investigate the effect 
of adipose tissue-specific activation of polyamine catabolism on glucose and 
energy metabolism in mice.
Materials and methods: We generated a transgenic mouse line (aP2-SSAT 
mice) overexpressing SSAT under an adipose tissue specific aP2 promoter. 
The SSAT activity was analyzed in a reaction where [14C]-acetyl-CoA was 
incorporated into polyamines. Basal metabolic rate was determined by in-
direct calorimetry. Both aP2-SSAT and wild type mice were challenged with 
high-fat diet providing 42 % calories from fat for three months. AMPK (AMP 
kinase) and PGC-1 α (peroxisome proliferator-activated receptor γ co-acti-
vator 1 α) levels in WAT were determined by western blotting. Glucose me-
tabolism in wild type (wt) and transgenic (tg) mice was studied using intra-
peritoneal glucose and insulin tolerance tests (GTT and ITT). Plasma glucose 
levels were determined microfluorometrically and plasma insulin levels with 
a commercial insulin kit. 
Results: SSAT enzyme activity was significantly higher in white (wt: 0.19 ± 
0.03 vs. tg: 17.69 ± 2.42 pmol/µg DNA/10 min, p<0.0001) and brown (wt: 
0.08 ± 0.05 vs. tg: 1.84 ± 0.46 pmol/µg DNA/10 min, p<0.005) adipose tissues 
in aP2-SSAT mice than in wt mice. aP2-SSAT mice had significantly reduced 
perigonadal WAT mass (wt: 2.28 ± 0.16 vs. tg: 1.65 ± 0.15 % of body weight, 
p<0.005), and white adipocytes had an increased amount of mitochondria. 
In addition, aP2-SSAT mice had significantly greater oxygen consumption in 
comparison with wt mice (wt: 1.81 ± 0.05 vs. tg: 2.02 ± 0.06 VO2 ml/min/100g, 
p<0.05) implicating that energy expenditure is enhanced in aP2-SSAT mice. 
When challenged with high-fat diet (HFD), aP2-SSAT mice were resistant to 
HFD-induced body weight gain (wt control vs. wt HFD body weight p<0.005; 
tg control vs. tg HFD body weight p>0.05). These findings were explained by 
increased protein levels of the key regulators of energy metabolism, PGC-
1α (wt: 0.68 ± 0.27 vs. tg: 1.86 ± 0.22, p<0.05) and AMPK (wt: 0.94 ± 0.17 
vs. tg 1.94 ± 0.25) in WAT of aP2-SSAT mice. Based on glucose and insulin 
tolerance tests, no changes in glucose metabolism were observed (GTT; wt: 
1123.00 ± 114.00 vs. tg: 1237.00 ± 69.48 area under the curve for plasma 
glucose, p>0.05; GTT; wt vs. tg plasma insulin levels p>0.05 and ITT; wt vs. 
tg relative glucose levels p>0.05).
Conclusion: Our results suggest that adipose tissue-specific activation of 
polyamine catabolism does not improve glucose homeostasis but causes ben-
eficial changes in energy metabolism.
Supported by: Academy of Finland
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Anti-diabetic effect of sodium tungstate in IRS2-deficient mice model
J. Oliveira1,2, S. Rebuffat1,2, A. Garcia1,2, R. Gomis1,2; 
1IDIBAPS, 2CIBERDEM, Barcelona, Spain.
Background and aims: The insulin receptor substrate-2 (IRS2) branch of 
the insulin/IGF signalling mediates peripheral insulin action and plays an 
essential role in pancreatic β-cell function and survival. In fact, IRS-2 is a key 
molecule in the control of beta cell mass and is directly phosphorylated by 
the insulin receptor after insulin binds the latter, leading to the recruitment 
and activation of additional signalling proteins. Ablation of the IRS-2 gene 
in mice results in a phenotype with characteristics of human type-2 diabetes 
- they progress toward diabetes as beta cell mass decreases and insulin secre-
tion fails. Sodium Tungstate could be involved in the reversion of the diabetic 
phenotype observed by acting independently of the insulin signalling path-
way. In the present work, we used IRS2 knockout mice and examined the 
effects of tunsgtate administration in order to check for its potential targets as 
well as its therapeutic potential.
Materials and methods: 10 weeks wild type and knockout IRS2 C57Bl/6 
mice were divided into two groups, untreated and treated with a solution 
of 2mg/ml of sodium tungstate in distilled water. After 21 days metabolic 
studies such as glucose tolerance tests and morphometric analysis of pancre-
atic sections by immunofluorescence techniques were performed in order to 
identify the effects of a tungstate treatment.
Results: Our results illustrated that tungstate administered orally normalised 
blood glucose concentration in IRS2 knockout, despite the initial high gly-
caemic values (fasting initial values: 221±26 mg/dl compared to 139±23 mg/
dl at day 21). This was accompanied by an improvement of glucose toler-
ance of IRS-2 -/- treated versus untreated group, assessed by an intraperitoneal 
glucose tolerance test performed both before and after treatment (figure). 
Morphometric analysis of pancreatic sections of these animals revealed as 
expected a reduced total islet and beta cell area in the untreated IRS-2 -/- 
mice (45295um2±29239 and 38402um2±25014 respectively) when compared 
to wild-type animals (145722um2±78299 and 137357um2±77630); however, 
treated knockout mice showed comparable values (140211um2± 84245 and 
121277um2± 74254).
Conclusion: Our results indicate that sodium tungstate may have an anti-
diabetic effect in IRS-2 knockout mice and could help us understand the mo-
lecular mechanisms underlying the regulation of glucose homeostasis and 
endocrine plasticity.
815
The effects of mildronate and metformin on energy metabolism pathways 
in experimental model of obesity
E. Liepins1, E. Skapare1,2, I. Konrade2, M. Dambrova1; 
1Latvian Institute of Organic Synthesis, 2Riga Stradins University, Riga, 
Latvia.
Background and aims: Mildronate is a cardioprotective drug, which mecha-
nism of action is based on the regulation of carnitine concentration. In ad-
dition to its cardioprotective effects mildronate lowers blood glucose con-
centration and protects against diabetes complications in Goto-Kakizaki rats. 
The present study was carried out to investigate the metabolic effects of mil-
dronate, metformin and a combination of the two in the experimental Zucker 
rat model of obesity and impaired glucose tolerance.
Materials and methods: Zucker rats were perorally (p.o.) treated daily with 
mildronate (200 mg/kg), metformin (300 mg/kg), and a combination of both 
drugs for 4 weeks. Weight gain and plasma metabolites reflecting glucose and 
lipid metabolism were measured by commercially available kits. The amounts 
of PPAR-alpha and PPAR-gamma as well as their target gene expression in 
heart and liver tissues were detected by Western blot and qRT-PCR analysis, 
respectively.
Results: Both tested drugs and the combination similarly decreased fed 
and fasted state blood glucose by 1-2 mmol/l. In addition, mildronate, met-
formin and the combination significantly decreased fed state plasma insulin 
concentration for 31%, 29% and 47%, respectively. Mildronate significantly 
stimulated the expression of PPAR-alpha in the heart and PPAR-gamma in 
the heart and liver. Also the increased expression of PPAR-alpha target genes 
in the heart, but not in liver tissues was observed. In contrast to monotherapy, 
treatment with the combination of mildronate and metformin significantly 
decreased the weight gain for 19%, while it did not affect food intake.
Conclusion: In conclusion, our results demonstrate that mildronate, an in-
hibitor of L-carnitine biosynthesis, enhances the anti-diabetic activity of met-
formin, mediates PPAR-alpha and PPAR-gamma activation and improves 
the adaptive responses against hyperglycemia- and hyperlipidemia-induced 
metabolic disturbances.
Supported by: EEA Financial Mechanism, European Social Fund
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Analysis of spontaneous obese and diabetic mice induced by selective 
breeding with high fat diet
M. Nagao, F. Okajima, Y. Sato, S. Takemitsu, M. Sudo, T. Harada,  
Y. Nakajima, K. Tanimura, A. Asai, S. Oikawa; 
Division of Endocrinology and Metabolism, Department of Medicine, 
Nippon Medical School, Tokyo, Japan.
Background and aims: Diabetes and obesity become more common due to 
modern lifestyle as environmental factor, and familial clustering as genetic 
factor is indicated in such a dysmetabolism. To elucidate the influence of 
present lifestyle to the next generation, we performed selective breeding of 
mice that had glucose dysmetabolism induced by high fat diet (HFD).
Materials and methods: Hybrid mice with male C57BL/6J, female C3H/HeJ 
and female AKR were used in this study. At first, male C57BL/6J mice were 
crossed with female C3H/HeJ mice, and mice were fed with 25% HFD for 10 
weeks (5-15 weeks of age). Then casual blood glucose was checked and mice 
with higher blood glucose level were selected for breeding. At the 3rd genera-
tion, birth rate was reduced, so we crossed these male mice with female AKR 
mice, and fed these mice with 13.5% HFD for 10 weeks. From the 4th genera-
tion to date, oral glucose tolerance test (OGTT) was performed around 11 
weeks old, and mice with higher blood glucose levels at 2 hours (2hr BG) 
were selected and bred as high glucose colony, H-strain. In the present proto-
col, mice were fed with 13.5% HFD from 5 to 10 weeks old to keep the normal 
birth rate. Despite HFD feeding, some of mice showed normal GTT pattern. 
These mice were also selected and bred as control (normal glucose colony; C-
strain). Messenger RNA expression of several genes in liver, skeletal muscle, 
and fat tissues, which influence glucose metabolism and body weight, was 
evaluated by real time quantitative PCR at 5 weeks old before HFD feeding.
Results: Now we have maintained the 12th generation of H-strain and the11th of 
C-strain. At 10 weeks old (after HFD feeding), the frequency of IGT and DM 
(2hr BG level is 140-199 mg/dl and over 200 mg/dl, respectively) was significantly 
higher in H10 (96.4% in male and 45.0% in female) than C9 (9.1% and 0%, re-
spectively) by chi-square test. Body weight gain after HFD feeding was accelerated 
in H-strain compared to C-strain, and increased to 32.3±3.1 vs 29.2±2.4 g (male, 
P=0.0003) and 24.0±1.9 vs 20.7±1.4 g (female, P<0.0001), respectively. There was 
no difference in food intake between the two groups. At 5 weeks old (before HFD 
feeding), 2hr BG level of OGTT was 161±42.6 vs 105±25.3 mg/dl (H vs C-strain of 
male, P=0.042) and 112±34.1 vs 67±12.2 mg/dl(H vs C strain of female, P=0.046), 
therefore H-strain already had abnormal glucose metabolism before fat load. Real 
time PCR analysis of 5 weeks old male mice showed that UCP-2 expression of liver 
and muscle was significantly elevated, and UCP-1 / -3 expressions of BAT were 
significantly decreased in H-strain compared to C-strain.
Conclusion: Abnormal glucose metabolism and obesity induced by HFD 
were accelerated by selective breeding, thus the susceptibility to HFD was 
transmitted to next generation. It is concluded that the new strain of obese 
and diabetic mice was established. Additionally, further analysis of these mice 
could reveal the genetic factors that regulate sensitivity to HFD.
817
In vivo efficient gene transfer to murine white adipose tissue using 
adeno-associated viral vectors
V. Jimenez1,2, S. Muñoz1,2, E. Ayuso1,2, X. Leon1,2, M. Molas1,2, M. Moya1,2,  
I. Elias1,2, T. Ferre1,2, S. Franckhauser1,2, F. Bosch1,2; 
1CBATEG and Department of Biochemistry and Molecular Biology, School 
of Veterinary Medicine, Universitat Autonoma de Barcelona, Bellaterra, 
2CIBER of Diabetes and Associated Metabolic Disorders, Barcelona, Spain.
Background and aims: Obesity is a worldwide growing health problem and 
this alteration of the metabolic and endocrine functions of adipose tissue is 
frequently associated with insulin resistance and type 2 diabetes. In order to 
increase our knowledge about the molecular mechanisms that underlie obes-
ity, the overexpression or knockdown/silencing of specific genes in adipose 
tissue may offer great potential. However efficient gene transfer postnatally 
into adipocytes in vivo has not been achieved. Therefore, this study was de-
signed to test the ability of adeno-associated viral vectors (AAV) serotypes 1, 
2, 4, 5, 6, 7, 8 and 9 to achieve broad, efficient and persistent gene transfer to 
murine white adipose tissue in vivo.
Materials and methods: AAV vectors coding GFP as a marker gene or the 
enzyme Hexokinase II (HKII) were generated by triple transfection in 293 
cells and were purified by double cesium chloride gradient. AAV vectors were 
injected into the epididymal white adipose tissue of mice.
Results: To asses the in vivo transduction efficiency of the adipose tissue with 
adeno-associated viral vectors, AAV serotypes 1, 2, 4, 5, 6, 7, 8 and 9 encod-
ing the marker protein GFP were injected into the epididymal white adipose 
tissue (eWAT) of mice. Two weeks after the injection, fat pads treated with 
AAV8 and AAV9 presented the highest GFP content that paralleled the high-
est numbers of transduced adipocytes indicating that these two serotypes 
were the most efficient transducing adipocytes in vivo. In addition, to ex-
amine whether in vivo AAV-transduced adipocytes may be a viable model 
to study adipose function, differentiation and metabolism, gene transfer of 
key metabolic genes such as HKII into eWAT was also evaluated. Two weeks 
after injection, isolated adipocytes from mice injected with AAV9 vectors 
coding HKII presented a 3-fold overexpression of HKII mRNA compared 
with adipocytes from AAV9 null-injected mice. In AAV9-HkII-transduced 
adipocytes, insulin produced a marked increased in the 2-[1-3H]deoxy-D-
glucose uptake compared to AAV9 null-transduced adipocytes at low and 
maximal insulin concentrations in a dose dependent manner.
Conclusion: All together, these results show that AAV vectors may be very 
useful for genetic modification of adipose cells in vivo to analyze adipocyte 
function or to assay new gene therapy approaches targeting the adipose tis-
sue.
Supported by: SAF2008-00962 and the EC 
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Sitagliptin and metformin increase active GLP-1 by complementary 
mechanisms in treatment-naïve patients with type 2 diabetes 
E.M. Migoya1, J. Miller1, W.-L. Luo1, E. O’Neill1, L. Morrow1, M.J. Gutierrez2, 
A. Stoch1, J.A. Wagner1; 
1Merck Sharp & Dohme Corp, Rahway, 2Comprehensive Phase I, Miramar, 
USA.
Background and aims: Sitagliptin (SITA) and metformin (MET) are oral 
antihyperglycemic agents with different, complimentary mechanisms-of-ac-
tion. Because treatment of type 2 diabetes mellitus (T2DM) usually requires 
combination therapy we assessed the potential combination effects of SITA 
and MET on GLP-1 in patients with T2DM.
Materials and methods: This was a randomized, placebo (PBO)-controlled, 
double-blind, 4-period crossover study in 18 treatment-naïve patients with 
T2DM. In each 2-day period, subjects received either SITA 100 mg in AM on 
Days 1 and 2, MET 500 mg in AM and PM on Day 1 and 1000 mg in AM on 
Day 2, co-administration of SITA+MET on Days 1 and 2 or PBO on Days 1 
and 2. On Day 2, at 2 hrs post-AM dose, patients ate a standard meal. Blood 
samples were collected pre- and at specified times post-meal.
Results: Compared with PBO, SITA, MET, and SITA+MET reduced 2-hr 
post-meal glucose by 31, 40, and 74 mg/dL, respectively. Compared with 
PBO, MET alone increased cumulative 4-hr post-meal weighted mean (WM) 
total GLP-1 levels by 1.5-times while SITA slightly decreased levels by ~10%, 
consistent with feedback inhibition of GLP-1 release by increased active GLP-
1. SITA or MET alone each increased cumulative 4-hr post-meal active GLP-
1 levels by 2.2- and 1.7-times, respectively, and in combination by 3.4-times. 
MET increased active GLP-1 in proportion to the increase in total GLP-1, 
suggesting that the increase in active was primarily due to the increase in to-
tal GLP-1. In contrast, SITA increased active, but not total GLP-1, consistent 
with stabilization of the active peptide. These data are similar to previously 
reported results in healthy non-diabetic subjects.
Conclusion: Co-administration of SITA and MET enhances reductions in 
glucose and increases in active GLP-1, and may provide a unique benefit to 
patients with T2DM as a result of these complementary mechanisms-of-ac-
tion.
Treatment Geometric LS Mean  (95% CI)†
Ratio of Geometric LS Means
(Active/Placebo)(95% CI)
4-hr WM Total GLP-1 (pM)
SITA 4.98 (4.24, 5.84) 0.87 (0.78, 0.97)
MET 8.73 (7.44, 10.2) 1.52 (1.37, 1.70)
SITA+MET 6.95 (5.93, 8.15) 1.21 (1.09, 1.35)
PBO 5.74 (4.89, 6.73) ---
4-hr WM Active GLP-1 (pM)
SITA 9.06 (7.82, 10.5) 2.16 (1.87, 2.49)
MET 6.98 (6.02, 8.08) 1.66 (1.44, 1.92)
SITA+MET 14.3 (12.3, 16.6) 3.41 (2.95, 3.93)
PBO 4.20 (3.62, 4.86) ---
†Back-transformed from log scale
Supported by: Merck Sharp & Dohme Corp
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Sitagliptin compared with glimepiride provides similar efficacy with 
weight loss and less hypoglycaemia when added to metformin therapy in 
patients with type 2 diabetes mellitus 
B.J. Goldstein, T. Seck, Y. Chen, L. Duran, A.O. Johnson-Levonas,  
K.D. Kaufman, D.E. Williams-Herman; 
Merck Sharp & Dohme Corp, Rahway, USA.
Background and aims: Current guidelines recommend the addition of a 
second antihyperglycemic agent when glycemic control is not achieved with 
metformin monotherapy. Sulfonylureas are the most common antihyperg-
lycemic agents used in combination with metformin among patients who 
do not achieve or maintain glycemic control on metformin alone. In pre-
vious studies, the DPP-4 inhibitor sitagliptin (SITA) significantly improved 
glycemic control and was well tolerated when added to ongoing metformin 
monotherapy. The current study compared the efficacy and safety of SITA 
with the commonly-used sulfonylurea glimepiride (GLIM).
Materials and methods: A randomized, double-blind study was conducted 
in patients with T2DM who had inadequate glycemic control (A1C of 6.5%-
9.0%) while on a stable dose of metformin (>1500 mg/day for >12 weeks). 
After a 2-week placebo run-in period, 1035 patients were randomized to the 
addition of SITA 100 mg/day (N=516) or GLIM 1 mg/day (uptitrated to a 
potential maximum 6 mg/day; N=519) to ongoing metformin monotherapy 
for 30 weeks. The primary analysis evaluated whether SITA was non-inferior 
to GLIM in reducing A1C from baseline at Week 30 using a predefined non-
inferiority margin of 0.4%.
Results: From a mean baseline A1C of 7.49% across treatment groups, LS 
mean changes at Week 30 were -0.47% for the SITA group and -0.54% for 
the GLIM group (between-group difference = 0.07% [95% CI: -0.03, 0.16]). 
The upper limit of the 95% CI for the between-group difference in change 
from baseline in A1C (0.16%) was less than the non-inferiority margin of 
0.4%, supporting a conclusion of non-inferiority for SITA versus GLIM. The 
percentages of patients with A1C <7.0% at Week 30 were 52.4% (SITA) and 
59.6% (GLIM). LS mean changes from baseline in fasting plasma glucose 
were -14.6 mg/dL and -17.5 mg/dL for SITA and GLIM, respectively. The per-
centage of patients for whom at least one adverse event of hypoglycemia was 
reported was significantly (p<0.001) lower with SITA (7%) than with GLIM 
(22%), with 73 and 460 events, respectively, reported. Treatment with SITA 
led to mean weight loss (-0.8 kg; 95% CI: -1.1, -0.5) while treatment with 
GLIM led to mean weight gain (1.2 kg; 95% CI: 0.9, 1.5), with a significant 
(p<0.001) between-group difference of -2.0 kg (95% CI: -2.3, -1.6).
Conclusion: In this study, the addition of SITA compared with the addition 
of GLIM to ongoing metformin monotherapy in patients with T2DM provid-
ed similar A1C-lowering efficacy after 30 weeks. Sitagliptin was generally well 
tolerated, with a lower risk of hypoglycemia and with weight loss compared 
with weight gain with glimepiride. 
Supported by: Merck Sharp & Dohme Corp
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Efficacy and safety of sitagliptin and the fixed-dose combination of 
sitagliptin and metformin versus pioglitazone in drug-naïve patients 
with type 2 diabetes 
A. Pérez-Monteverde1, T. Seck2, L. Xu2, G. Liu2, M.A. Lee2, C. McCrary 
Sisk2, D.E. Williams-Herman2, K.D. Kaufman2, B.J. Goldstein2; 
1Centro Médico Docente la Trinidad, Caracas, Bolivarian Republic of 
Venezuela, 2Merck Sharp & Dohme Corp, Rahway, USA.
Background and aims: Combination therapy has been recommended for 
patients with type 2 diabetes mellitus (T2DM) who have greater degrees of 
hyperglycemia. The DPP-4 inhibitor sitagliptin (SITA) and the fixed-dose 
combination of sitagliptin + metformin (SITA/MET) are recent additions to 
the treatment options for patients with T2DM. This study assessed the effi-
cacy and safety of therapy with SITA monotherapy and compared the efficacy 
and safety of SITA/MET with pioglitazone (PIO) monotherapy in patients 
with T2DM and moderate to severe hyperglycemia.
Materials and methods: After a 2-wk single-blind placebo run-in period 492 
eligible patients (18-78 yr of age, HbA1c 7.5-12%, not on an antihyperglyc-
emic agent) were randomized 1:1 to SITA 100 mg once daily (qd) or PIO 15 
mg qd (up-titrated to 30 mg after 6 wk). After the initial 12-wk double-blind 
active treatment period (Phase A) with SITA or PIO monotherapy, patients 
entered a 28-wk double-blind active treatment period (Phase B). At the be-
ginning of Phase B, patients receiving SITA during Phase A were switched 
to SITA/MET (up-titrated to 50/1000 mg twice daily over 4 wk) and patients 
receiving PIO 30 mg qd at the end of Phase A were up-titrated to PIO 45 mg 
qd at the beginning of Phase B. No inferential testing for between-group dif-
ferences (SITA vs. PIO) in HbA1c change from baseline was done at the end 
of Phase A, since maximum glycemic efficacy of PIO was likely not achieved 
at this time point.
Results: Mean baseline HbA1c was 9.0%. At the end of Phase A, SITA and PIO 
resulted in significant LS mean changes from baseline in HbA1c (-1.0% SITA, 
-0.9% PIO), fasting plasma glucose (FPG; -1.5 mmol/L SITA, -1.6 mmol/L 
PIO) and 2-h post-meal glucose (-2.9 mmol/L SITA, -2.8 mmol/L PIO). At 
the end of Phase B, the LS mean changes from baseline in HbA1c were -1.8% 
and -1.4% for SITA/MET and PIO, respectively (between-group difference -
0.4%; p=0.002). A significantly greater proportion of patients had HbA1c <7% 
in the SITA/MET group vs. the PIO group (55.0% vs. 40.5%, respectively; 
p=0.004). Significantly larger LS mean reductions at the end of Phase B were 
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observed with SITA/MET vs. PIO for FPG (-2.6 mmol/L vs. -2.1 mmol/L; 
p=0.03) and 2-h post-meal glucose (-5.0 mmol/L vs. -3.8 mmol/L; p=0.001). 
Both SITA/MET and PIO were generally well tolerated. A slightly higher in-
cidence of adverse events (AEs) of abdominal pain (3.2% vs. 0.9%; p=0.083), 
nausea (2.7% vs. 0.9%; p=0.140), and vomiting (0.9% vs. 0.0%; p=0.150), and 
a lower incidence of edema (0.9% vs. 6.1%; p=0.003) were observed with 
SITA/MET vs. PIO. The incidence of hypoglycemia was low and similar in 
both groups (2.3% and 2.2% with SITA/MET and PIO, respectively). At the 
end of Phase B, SITA/MET resulted in a LS mean decrease in body weight (-
1.1 kg) compared with a LS mean increase (3.4 kg) with PIO (between-group 
difference -4.5 kg; p<0.001).
Conclusion: In drug-naïve patients, SITA and PIO led to clinically meaning-
ful improvements in glycemic control. Combination therapy with SITA/MET 
produced a significantly greater improvement in glycemic control compared 
with PIO. SITA/MET resulted in a decrease in body weight compared with an 
increase in body weight with PIO. SITA/MET was associated with a signifi-
cantly lower incidence of edema and a slightly higher incidence of gastroin-
testinal AEs compared with PIO.
Supported by: Merck Sharp & Dohme Corp
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Safety and efficacy of linagliptin as add-on therapy to a sulphonylurea in 
inadequately controlled type 2 diabetes
A.J. Lewin1, L. Arvay2, D. Liu2, S. Patel3, H.-J. Woerle4; 
1National Research Institute, Los Angeles, USA, 2Boehringer Ingelheim, 
Ridgefield, USA, 3Boehringer Ingelheim, Bracknell, United Kingdom, 
4Boehringer Ingelheim, Biberach, Germany.
Background and aims: Linagliptin is an oral dipeptidyl peptidase (DPP-4) 
inhibitor under development for the treatment of type 2 diabetes (T2D). This 
18-week (wk) multi-centre, randomised, double-blind, placebo-controlled 
parallel group study investigated the efficacy, safety and tolerability of lina-
gliptin administered with sulphonylurea (SU) background therapy in partici-
pants with T2D and insufficient glycaemic control.
Materials and methods: Before being randomised to linagliptin (5 mg qd) 
(n=161), or placebo (n=84), all participants had a 2-wk placebo run-in. Any 
oral anti-diabetic (OAD) agent other than SU was withdrawn at the begin-
ning of a 4-wk washout period prior to run-in. The SU drug was adminis-
tered in an unchanged dosage throughout the entire trial duration (including 
washout and placebo run-in periods). The primary endpoint for the trial was 
the change in HbA1c from baseline (BL) after 18 wks of treatment evaluat-
ed with an analysis of covariance (ANCOVA) adjusted for treatment, prior 
OAD(s) and BL HbA1c.
Results: Mean BL characteristics (HbA1c 8.6% [SD, 0.8]; fasting plasma glu-
cose (FPG) 179.6 [50.9] mg/dL; age 56.9 [9.9] yrs; BMI 28.3 [5.0] kg/m2) 
were similar between the groups. At Wk 18, the adjusted mean change in 
HbA1c from BL was -0.47%, showing superiority of linagliptin over placebo 
(p<0.0001). Statistically significant differences between linagliptin and pla-
cebo for HbA1c were sustained at all post-BL visits (wks 6, 12 and 18, all 
p<0.0001). Participants with a BL HbA1c of ≥7.0% were 6 times more likely to 
achieve a response of HbA1c to ≤7.0% at 18 wks when treated with linagliptin 
(15.2%) than those receiving placebo (3.7%) (odds ratio (OR) 6.47, p=0.006). 
The odds of achieving a HbA1c reduction of ≥0.5% at 18 wks was greater for 
participants treated with linagliptin than in participants treated with placebo 
(OR 5.12, p<0.0001). At 18 wks, the improvements in glycaemic control were 
reflected in the difference in adjusted mean change in FPG from BL of -6.4 
mg/dL (p=0.24) in favour of linagliptin. The proportion of participants re-
quiring rescue therapy was twice as great for placebo (15.9%) compared to 
linagliptin (7.6%). Overall, the frequency of reported adverse events (AEs) 
was similar for the groups (42.2% in the linagliptin group and 42.9% in the 
placebo group). Of these AEs, 13/161 (8.1%) and 8/84 (9.5%) in the lina-
gliptin and placebo groups, respectively, were considered drug-related by the 
investigator. AEs of severe intensity were reported for 4 participants (2.5%) 
in the linagliptin group and none in the placebo group; all other AEs were of 
mild or moderate intensity. None of the severe AEs was considered as drug-
related. Investigator-defined cases of hypoglycaemia occurred in 5.6% and 
4.8% of participants in the linagliptin and placebo groups, respectively. No 
changes in body weight or waist circumference were recorded.
Conclusion: Linagliptin treatment in combination with SU was well toler-
ated and produced statistically significant and clinically relevant reductions 
in HbA1c. The safety results were comparable between linagliptin and placebo 
and, importantly, the addition of linagliptin did not result in a significant 
increase in hypoglycaemia. Linagliptin may provide an alternative option to 
uptitrating SU in participants failing on therapy with SU alone or in combi-
nation.
Supported by: Boehringer Ingelheim Pharma GmbH & Co. KG
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Linagliptin, a novel DPP-4 inhibitor: No need for dose adjustment in 
patients with renal impairment
U. Graefe-Mody1, C. Friedrich1, A. Port1, A. Ring1, T. Heise2, A. Halabi3,  
H.-J. Woerle1; 
1Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, 2Profil Institut 
fuer Stoffwechselforschung GmbH, Neuss, 3CRS Clinical Research Services 
Kiel GmbH, Germany.
Background and aims: Linagliptin is a potent and highly selective DPP-4 
inhibitor in late stage development for the treatment of type 2 diabetes (T2D). 
Elimination of linagliptin occurs primarily non-renally; this is unique among 
the currently available DPP-4 inhibitors, which either require dose adjust-
ment or are not recommended in patients with a creatinine clearance (CrCl) 
of ≤50 mL/min. The purpose of this study was to evaluate the influence of 
various degrees of renal impairment (RI) on the pharmacokinetics (PK) of 
linagliptin.
Materials and methods: Linagliptin PK was investigated in subjects with dif-
ferent degrees of RI: mild (CrCl 51-80 mL/min; n=6), moderate (CrCl 31-
50 mL/min; n=6), severe (CrCl ≤30 mL/min; n=6), end-stage renal disease 
(ESRD, n=6) and in healthy volunteers (HV, CrCl >80 mL/min, n=6). In ad-
dition, linagliptin PK was compared in 10 patients with T2D with severe RI 
and in 11 patients with normal renal function (RF). Subjects received 5 mg 
linagliptin qd as single dose (severe RI and ESRD groups) or for 7 days (HV, 
mild or moderate RI) or for 10 days (patients with T2D). Plasma and urine 
concentrations of linagliptin, inhibition of plasma DPP-4, and plasma pro-
tein binding were determined. The primary analysis was the comparison of 
linagliptin exposure in steady state (subjects with mild or moderate RI vs HV 
and T2D patients with severe RI vs normal RF) or after single-dose (subjects 
with severe RI/ESRD vs HV).
Results: Steady-state total linagliptin exposure (AUCτ,ss) and maximum con-
centrations (Cmax,ss) were comparable between subjects with mild RI and the 
control group, and showed a modest increase of 71 and 42 % in patients with 
moderate or severe RI, respectively (see table). Under single dose conditions, 
all patients with RI showed a 30-60% increase in total exposure (AUC0-24) rel-
ative to the control groups, regardless of their degree of RI. There was no con-
sistent increase in terminal half-life with deterioration of RF. Accumulation 
half-lives ranged from 14-15 h in the control groups to 18 h in severe RI. Only 
a weak correlation was seen between CrCl and steady state exposure or accu-
mulation factor which is further evidence that RI plays a subordinate role in 
the elimination of linagliptin. Steady state renal excretion of unchanged drug 
was <7% of the dose in all groups. RI did not alter the plasma protein binding 
or the correlation between PK and DPP-4 inhibition.
Conclusion: Decreases in renal function had only a minor effect on the 
elimination of linagliptin. Based on the large safety window of linagliptin, 
the observed changes in exposure (~40% in severe RI) do not require dose 
adjustment in patients with T2D and renal impairment when treated with 
linagliptin.
Steady-state Single-dose
RI Groups Cmax,ss [nM] AUCτ,ss [nM·h] Cmax [nM] AUC0-24 [nM·h]
Mild RI* 0.98 (0.70-1.39) 1.08 (0.91-1.28) 1.26 (0.80-1.96) 1.29 (1.01-1.66)
Moderate RI* 1.46 (0.98-2.19) 1.71 (1.34-2.18) 1.57 (0.77-3.19) 1.56 (1.06-2.32)
T2DM with 
severe RI# 1.36 (0.97-1.90) 1.42 (1.10-1.82) 1.23 (0.82-1.84) 1.22 (0.92-1.62)
Severe RI* - - 1.47 (0.83-2.61) 1.41 (1.04-1.91)
ESRD* - - 1.50 (0.94-2.41) 1.54 (1.18-2.00)
*compared with healthy volunteers
#compared with T2D patients with normal RF
Data are geometric mean ratios (90% CI)
Supported by: Boehringer Ingelheim Pharma GmbH & Co. KG
Diabetologia (2010) 53:[Suppl1]S1–S556 S 327
1 C
823
Linagliptin monotherapy improves glycaemic control in type 2 diabetes 
patients for whom metformin therapy is inappropriate
A.H. Barnett1, R. Harper2, R. Toorawa2, S. Patel2, H.-J. Woerle3; 
1University of Birmingham and Heart of England NHS Foundation Trust, 
United Kingdom, 2Boehringer Ingelheim, Bracknell, United Kingdom, 
3Boehringer Ingelheim, Biberach, Germany.
Background and aims: Dose-related adverse events, such as diarrhoea, nau-
sea and abdominal bloating, and a potential risk for lactic acidosis in subjects 
with renal impairment, may limit metformin use in patients (pts) with type 
2 diabetes (T2D). This multi-centre, 18-wk, randomised, double-blind, pla-
cebo (PBO)-controlled, parallel group study (followed by an ongoing 34-wk 
double-blind extension period in which PBO pts were switched to glimepir-
ide) assessed the efficacy, safety and tolerability of the oral DPP-4 inhibitor 
linagliptin (LI) (5 mg qd) in pts with inadequately controlled T2D for whom 
metformin therapy is inappropriate due to intolerability or contraindication.
Materials and methods: Hyperglycaemic T2D pts who were treatment-naive 
(HbA1c ≥7.0 to ≤10.0%, or HbA1c ≥7.0 to ≤9.0% in Canada) or pre-treated 
with 1 oral anti-diabetes agent (OAD) (HbA1c ≥6.5 to ≤9.0% after a 6-wk 
washout period) were randomised to LI (n=151) or PBO (n=76) followed a 
2-wk PBO run-in (previously treated pts went without medication for 4 wks 
prior to this). The primary endpoint for the trial was the change in HbA1c 
from baseline (BL) after 18 wks of treatment evaluated with an analysis of 
covariance (ANCOVA) adjusted for prior OAD(s), BL HbA1c and reason for 
metformin ineligibility. This interim analysis was conducted after all pts had 
completed 18 wks of treatment.
Results: There were no differences between the LI and PBO groups for mean 
BL characteristics (overall HbA1c 8.09% [SD, 0.93]; fasting plasma glucose 
(FPG), 10.12 [2.54] mmol/L; age, 56.5 [10.3] yrs; BMI, 29.5 [5.4] kg/m2). Most 
of the pts (61.2%) were female. The majority of pts had either normal renal 
function (55.9%) or mild renal impairment (34.4%). Metformin was inappro-
priate due to intolerance from gastrointestinal adverse events (AEs) in 93% 
of the randomised pts, with the remainder of cases due to raised creatinine.
After 18 wks of treatment, the adjusted mean difference between LI and PBO 
was -0.57% with 95% confidence interval (-0.86, -0.29) (p<0.0001) in favour 
of LI for change in HbA1c (%). Statistically significant differences between LI 
and PBO for HbA1c were seen by Wk 6 and were sustained through Wk 18. 
Among pts with BL HbA1c ≥7.0%, 11.8% of pts in the PBO group and 23.5% 
of the pts in the LI group achieved HbA1c <7.0% at Wk 18. At Wk 18, lina-
gliptin was superior to placebo in reducing the mean FPG from BL (adjusted 
mean difference -1.14 mmol/L with 95% confidence interval (-31.1, -9.9); 
p=0.0002). The percentage of pts requiring rescue therapy was higher in the 
PBO group (17.8%) compared with the LI group (11.6%). The proportion of 
pts experiencing ≥1 AE classed as drug-related within the LI and PBO groups 
was 6.6% and 1.3%, respectively. Hypoglycaemia was rare, occurring in 2 pts 
(1.3%) in the LI group and none in the PBO group and there were no severe 
cases in either group. No difference in weight was seen between groups.
Conclusion: LI showed superiority, with clinically relevant reduction in 
HbA1c from BL to Wk 18 compared to PBO. LI was well tolerated, with com-
parable safety results between LI and PBO. The incidence of hypoglycaemic 
events during treatment with LI was very low, with no episodes of severe 
hypoglycaemia, and there was no weight difference between groups. This 
study shows that LI would be a valuable treatment option for pts with T2D 
for whom metformin therapy was inappropriate.
Supported by: Boehringer Ingelheim Pharma GmbH & Co. KG
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Diabetes duration and its impact on the effect of dutogliptin, a novel 
DPP4 inhibitor, on HbA1c and fasting plasma glucose in type 2 diabetes 
mellitus
N. Rosenberg1, L. Xie1, H. Schneier1, A. Genovese1, H.-P. Guler2; 
1Forest Research Institute, Inc., Jersey City, 2Phenomix Corporation, San 
Diego, USA.
Background and aims: Type 2 diabetes mellitus (T2DM) is characterized by 
a progressive decline in glycemic control, and disease duration may impact 
patient therapeutic response to medication. Dutogliptin is a novel and potent 
dipeptidyl peptidase 4 (DPP4) inhibitor currently in Phase III development 
for the treatment of T2DM. This post-hoc analysis of a 12-week, multicenter, 
randomized, double-blind, placebo-controlled trial evaluated the effect of di-
abetes duration on glycemic response to dutogliptin treatment vs. placebo in 
patients whose T2DM was not optimally controlled with metformin and/or 
thiazolidinediones (TZD).
Materials and methods: Patients with HbA1c >7.3% currently receiving met-
formin (≥1500 mg/day or maximally tolerated dose for at least 4 weeks prior 
to study entry) and/or TZD (at any labeled dose) were stratified by diabetes 
duration at study entry (< and ≥5 years). Patients were randomized to receive 
oral doses of dutogliptin 200 mg, 400 mg or placebo once daily. Changes from 
baseline in HbA1c and fasting plasma glucose (FPG) were assessed after 12 
weeks of treatment.
Results: Overall, absolute LS mean reductions from baseline in HbA1c were 
significantly greater in both the dutogliptin 200 mg (-0.64%) and 400 mg (-
0.82%) arms compared to placebo (-0.30%, p<0.01) at week 12. Similarly, the 
LS mean change from baseline in fasting plasma glucose (FPG, mmol/L) was 
significantly reduced compared to placebo in the dutogliptin 200 mg (-0.88; 
p=0.003) and 400 mg (-1.00; p<0.001) groups. However, in patients with <5 
years of diabetes duration, reductions in HbA1c and FPG were greater than 
in patients with ≥5 years of diabetes duration compared to placebo. Patients 
with diabetes duration <5 years experienced the greatest absolute decrease 
from baseline in HbA1c in both the dutogliptin 200 mg (-0.778%) and 400 
mg (-0.991%) groups compared to placebo (p<0.05). Patients in the dutoglip-
tin 400 mg group with diabetes duration ≥5 years also had statistically sig-
nificant improvements in both HbA1c (-0.641%) and FPG (-0.976 mmol/L) 
compared to placebo (p<0.05).
Conclusion: These results demonstrate the positive effects of dutogliptin in 
early diabetes and support earlier treatment of T2DM with dutogliptin. 
Placebo
Dutogliptin  
200 mg
Dutogliptin  
400 mg
Diabetes Duration <5 years ≥5 years <5 years ≥5 years <5 years ≥5 years
HbA1c
n 30 53 56 112 69 87
Baseline Mean  
HbA1c, %
8.439 8.321 8.240 8.559 8.477 8.348
LS Mean Change from 
Baseline, % (SE)
-0.323
(0.168)
-0.236
(0.127)
-0.778*
(0.124)
-0.522
(0.874)
-0.991*
(0.111)
-0.641*
(0.099)
Fasting Plasma Glucose
n 31 52 58 109 71 86
Baseline Mean FPG, 
mmol/L
8.633 9.568 9.273 9.867 9.416 10.128
LS Mean Change from 
Baseline, mmol/L (SE)
0.254
(0.392)
-0.122
(0.301)
-1.214*
(0.285)
-0.697
(0.285)
-1.017*
(0.258)
-0.976*
(0.235)
*p<0.05 compared to placebo
Supported by: Phenomix Corporation
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Efficacy of saxagliptin in relation to baseline HbA1c in a pooled analysis 
of 3 add-on pivotal randomised phase 3 clinical trials
P. Maheux1, M. Donovan2, E. Allen2, N. Berglind2, H. Bouzamondo3; 
1AstraZeneca, Brussels, Belgium, 2Bristol-Myers Squibb, Princeton, USA, 
3Bristol-Myers Squibb, Paris, France.
Background and aims: Saxagliptin (SAXA) is a potent, selective dipeptidyl 
peptidase-4 (DPP-4) inhibitor, approved in Europe for treatment of type 2 
diabetes (T2D) in combination with metformin, a sulphonylurea, or a thia-
zolidinedione (TZD). In the phase 3 programme, SAXA improved control of 
the glucose triad (HbA1c, PPG and FPG) via a physiological pathway, with 
weight neutrality and a low incidence of hypoglycaemia. This analysis ex-
amines 2 key relationships within the pooled efficacy database with SAXA 5 
mg dose, between (1) HbA1c reduction and baseline HbA1c levels, and (2) the 
proportion of patients reaching HbA1c target (<7.0%) without hypoglycaemia 
and baseline HbA1c levels, particularly the subgroup of T2D patients slightly 
above HbA1c target.
Materials and methods: T2D patients (>18y) recruited into the stud-
ies, with HbA1c ≥7% and on stable doses of metformin (study CV181-014; 
NCT00121667), submaximal glibenclamide (CV181-040; NCT00313313), or 
TZD (CV181-013; NCT00295633). Following a placebo (PBO) run-in period, 
patients were randomised to SAXA (2.5 or 5 mg od - CV181-040 and CV181-
013) or SAXA (2.5, 5 or 10 mg once daily - CV181-014) or (PBO) in addition 
to ongoing antihyperglycaemic agent. In CV181-040, blinded up-titration of 
glibenclamide was allowed for patients on PBO. The primary endpoint in all 
studies was change from baseline HbA1c at week 24. The analysis was carried 
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out on all patients with a baseline HbA1c value randomised to SAXA 5 mg 
(n=628) or PBO (n=630) in the 3 studies. Subgroups were defined by baseline 
HbA1c: <7.5% (SAXA n=126, PBO n=134); ≥7.5−<8% (SAXA n=116, PBO 
n=135); ≥8−<8.5% (SAXA n=129, PBO n=113); ≥8.5−<9% (SAXA n=102, 
PBO n=100); ≥9% (SAXA n=155, PBO n=148). Hypoglycaemia was con-
sidered to be all symptomatic episodes including confirmed hypoglycaemia 
(fingerstick glucose <2.8 mmol/L + symptoms). Patients missing data at week 
24 were counted as not achieving target HbA1c.
Results: Treatment groups were well balanced for baseline characteristics. 
SAXA 5 mg od resulted in reduction from baseline to week 24 in mean PBO-
corrected HbA1c in all subgroups; greater reductions were seen with increas-
ing HbA1c at baseline (Fig). Percentage of patients reaching target HbA1c 
(<7.0%) without hypoglycaemia with SAXA 5 mg od and PBO in each sub-
group are also shown.
Conclusion: Add-on therapy with SAXA 5 mg od for 24 wks provided clini-
cally relevant reductions in HbA1c vs PBO in patients with inadequately con-
trolled T2D. Pooled subgroup analysis showed that HbA1c reductions were 
greatest in those with higher baseline HbA1c values. The proportion of pa-
tients who achieved target HbA1c without associated hypoglycaemic episodes 
was highest in those with lower baseline HbA1c. Among patients who were 
close to target HbA1c at baseline (eg <7.5%), >50% achieved target HbA1c 
without associated hypoglycaemic episodes over 24 wks, reinforcing the po-
tential role of SAXA as an early add-on therapeutic option.
Supported by: BMS & AZ
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Efficacy of saxagliptin according to patient baseline characteristics: a 
pooled analysis of three add-on pivotal randomised phase 3 clinical trials
E. Allen1, M. Donovan1, N. Berglind1, P. Maheux2; 
1Bristol-Myers Squibb, Princeton, USA, 2AstraZeneca, Brussels, Belgium.
Background and aims: Saxagliptin (SAXA) is a potent, selective dipeptidyl 
peptidase-4 (DPP-4) inhibitor, approved in Europe for the treatment of type 
2 diabetes (T2D) in combination with metformin, a sulphonylurea or a thia-
zolidinedione (TZD). In phase 3 trials, SAXA demonstrated comprehensive 
glycaemic control with improvements in all components of the glucose triad 
(HbA1c, postprandial plasma glucose, fasting plasma glucose) and was as-
sociated with weight neutrality and a low incidence of hypoglycaemia. The 
present analysis, using pooled data from the pivotal phase 3 studies, was con-
ducted to evaluate any potentially important relationships between patient 
characteristics at baseline and the efficacy of SAXA.
Materials and methods: Patients with T2D recruited into the studies were 
aged >18 years, HbA1c ≥7%, and were on stable doses of metformin (study 
CV181-014; NCT00121667), submaximal glibenclamide (CV181-040; 
NCT00313313), or TZD (CV181-013; NCT00295633). Following a pla-
cebo run-in period, patients were randomised to SAXA (2.5 or 5 mg once 
daily - CV181-040 and CV181-013) or SAXA (2.5, 5 or 10 mg once daily 
- CV181-014) or placebo in addition to their ongoing antihyperglycaemic 
agent. In CV181-040, blinded up-titration of the glibenclamide dose was al-
lowed for patients randomised to placebo. The primary endpoint in all stud-
ies was change from baseline HbA1c at week 24. This analysis was conducted 
using placebo-corrected pooled data from all patients randomised to SAXA 
5 mg/day in the 3 studies. The following subgroups were defined according to 
baseline characteristics: gender (male, female); body mass index (BMI; <30, 
≥30); age (<65, ≥65 y); T2D duration (≤1.5, ≤3, >3-<5, ≥5, ≥10 y); creatinine 
clearance (≤80, >80 mL/min,), homeostasis model assessment 2 β-cell func-
tion (HOMA-2B; ≤ and >58.6; baseline study median). The efficacy of SAXA 
(mean change from baseline in HbA1c vs placebo at week 24) was determined 
for each subgroup category.
Results: Overall, 630 patients were treated with SAXA 5 mg/day in the 3 
studies. Baseline characteristics were well balanced across treatment groups 
within each study (data not shown). Adjusted mean decreases in HbA1c with 
SAXA 5 mg/day, relative to placebo, were observed for each of the subgroups 
(figure). Numerically, these mean decreases ranged from -0.52 to -0.93 with 
relatively larger mean decreases in patients with longer duration of T2D, low-
er baseline creatinine clearance, and lower baseline HOMA-2B.
Conclusion: This analysis demonstrates that HbA1c lowering from baseline 
was greater than placebo across diverse demographic and diabetes subgroups 
over a 24-week period. It supports the use of SAXA 5 mg once daily, as an 
add-on therapy, in a broad range of patient types.
Supported by: BMS & AZ
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Addition of alogliptin vs uptitration of pioglitazone dose in type 2 
diabetes mellitus patients on metformin plus pioglitazone therapy
E. Bosi1, G. Ellis2, P. Moneuse3, C. Wilson4, P. Fleck4; 
1Istituto Scientifico San Raffaele, Milano, Italy, 2Helderberg Diabetes and 
Medical Centre, Cape Town, South Africa, 3Takeda Global Research & 
Development Centre (Europe), London, United Kingdom, 4Takeda Global 
Research & Development Center, Inc., Lake Forest, USA.
Background and aims: Maintaining target HbA1c levels in type 2 diabe-
tes mellitus (T2DM) usually necessitates escalation of drug doses and use 
of combination therapies. In this study, the efficacy of adding alogliptin, an 
investigational dipeptidyl peptidase 4 inhibitor, was compared with that of 
increasing the pioglitazone dose in patients experiencing inadequate glyce-
mic control on a regimen of metformin plus pioglitazone.
Materials and methods: The addition of alogliptin 25mg (A25) vs the titra-
tion of pioglitazone 30 (P30) to 45mg (P45) was evaluated in 803 randomized 
patients with inadequately controlled T2DM currently treated with metfor-
min (MET; ≥1500mg or maximum tolerated dose) plus P30. The primary 
endpoint was glycosylated hemoglobin A1c (HbA1c) changes from Baseline 
(CFB) at Weeks 26 and 52, and the primary analysis involved sequential test-
ing for non-inferiority at Weeks 26 and 52 and superiority at Week 52 only.
Results: The addition of alogliptin (A25+MET+P30) demonstrated supe-
rior glycemic control vs the titration of pioglitazone to 45mg (MET+P45), 
as measured by HbA1c least squares (LS) mean CFB at Week 26 (-0.89% vs 
-0.42%) and Week 52 (-0.70% vs -0.29%). A25+MET+P30 resulted in signifi-
cantly (P<0.001) greater HbA1c reductions at all time points (Fig A), regard-
less of baseline HbA1c (<8%, ≥8%, <9%, ≥9%), and significantly (P<0.001) 
higher proportions of patients taking A25+MET+P30 vs MET+P45 achieved 
target HbA1c ≤7.0% (33.2% vs 21.3%) and ≤6.5% (8.7% vs 4.3%) at Week 52. 
A25+MET+P30 also was significantly more effective than MET+P45 in de-
creasing FPG (LS mean CFB at Week 52 were -14.6 vs -3.7 mg/dL; P<0.001).
Conclusion: The addition of A25 to an existing T2DM regimen of MET+P30 
provided superior glycemic control and potentially improved β-cell function 
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when compared with MET+P45, with no clinically important differences in 
safety.
Figure
*P<0.001 vs MET+P45.
†Non-inferior to MET+P45.
††Non-inferior and superior to MET+P45.
Measures of β-cell function significantly (P<0.001) improved with 
A25+MET+P30 vs MET+P45, as shown by LS mean CFB to Week 52 in pro-
insulin/insulin ratio (-0.048 vs -0.007) and HOMA β-cell function (15.02 vs 
2.06), while effects on insulin sensitivity were similar (HOMA insulin resis-
tance was 0.35 vs 0.54). Overall, 3.0% of patients reported hypoglycemia.
Supported by: TGRD
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Efficacy and safety of alogliptin, a potent and highly selective DPP-4 
inhibitor, in Japanese patients with type 2 diabetes mellitus
Y. Seino1, K. Kaku2; 
1Kansai Electric Power Hospital, 2Kawasaki Medical School, Okayama, 
Japan.
Background and aims: Alogliptin (ALO) is a potent and highly selective 
DPP-4 inhibitor used for treatment of type 2 diabetes mellitus (T2DM). We 
investigated the efficacy and safety of ALO used alone and in combination 
with an α-glucosidase inhibitor (Voglibose : VOG), a thiazolidinedione (Pio-
glitazone : PIO), a sulfonylurea (Glimepiride : GLIM), or a biguanide (Met-
formin : MET) in Japanese patients with T2DM.
Materials and methods: Efficacy (decrease in HbA1C, fasting plasma glucose, 
2-hr postprandial glucose) and safety (adverse events) of ALO were evalu-
ated after 12-week treatment in five randomized, placebo-controlled, double-
blind studies in Japanese patients with T2DM. In addition, long-term efficacy 
and safety were evaluated in 40-week, open-label extension studies in sub-
jects who had completed the corresponding 12-week study (total treatment 
duration: 52 weeks). HbA1C was measured by HPLC method according to the 
Japanese Diabetes Society standard.
Results: A total of 1649 patients were randomized into one of five studies: 
a monotherapy study (N=480; mean baseline HbA1C 7.53%), a combination 
study with VOG (N=230; mean baseline HbA1C 7.62%), a combination study 
with PIO (N=339; mean baseline HbA1C 7.50%), a combination study with 
GLIM (N=312; mean baseline HbA1C 8.17%), or a combination study with 
MET (N=288; mean baseline HbA1C 7.57%). At week 12, patients treated with 
ALO in monotherapy or in combination with VOG, PIO, GLIM, or MET 
showed statistically significant decreases in HbA1C (Figure), fasting plasma 
glucose and 2-hr postprandial glucose from baseline compared to placebo. 
In all 12-week studies, incidences of adverse events, serious adverse events, 
drug-related adverse events, and hypoglyceamia were similar between ALO 
and placebo. In the open-label extension studies, ALO as monotherapy or 
in combination therapies provided substantial improvement in glyceamic 
control over 52 weeks without weight gain or increased incidence of hypo-
glyceamia.
Conclusion: Treatment with ALO, whether as monotherapy and in combina-
tion with VOG, PIO, GLIM, or MET, significantly improved glyceamic con-
trol and was well tolerated in Japanese patients with T2DM.
Supported by: Takeda Pharmaceutical Company Limited
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benefits
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Efficacy and safety of liraglutide compared with glimepiride, both 
combined with metformin, in an Asian population
Y. Wenying1, L. Chen2, Q. Ji3, A. Bhattacharyya4, K.-W. Kim5, K.-H. Yoon6, 
H. Xu7, A. Shinde8, N. Tandon9; 
1China-Japan Friendship Hospital, Beijing, China, 2Endocrinology, Wuhan 
Union Hospital, Hubei, China, 3Xijing Hospital, Shaanxi, China, 4Manipal 
Hospital, Bangalore, India, 5Samung Medical Centre, Seoul, Republic of 
Korea, 6Endocrinology and Metabolism, Seoul St Mary’s Hospital, Seoul, 
Korea, Republic of, 7Novo Nordisk Pharmaceuticals Ltd, Beijing, China, 
8Novo Nordisk Private Ltd, Bangalore, India, 9All India Institute of Medical 
Sciences, New Delhi, India.
Background and aims: Liraglutide has been investigated for the treatment of 
type 2 diabetes in Caucasian, African-American and Hispanic populations as 
part of the LEAD programme. This study aimed to compare liraglutide with 
glimepiride, both added to metformin, in an Asian population from China, 
South Korea and India.
Materials and methods: In this 16-week, randomised, double-blind, active 
controlled trial, 929 patients were randomised to receive either liraglutide 
(0.6, 1.2 or 1.8 mg once daily; OD) or glimepiride (4 mg OD), both in combi-
nation with metformin (1 g twice daily; BD).
Results: Substantial reductions in HbA1c were observed in all treatment 
groups (Table). Improvements in HbA1c observed with liraglutide 1.2 and 1.8 
mg were non-inferior to those reported for glimepiride. Both treatments let 
to greater improvements in HbA1c in patients previously treated with oral 
antidiabetic drug (OAD) monotherapy. The proportion of patients reaching 
HbA1c <7.0% was 36%, 45% and 47% for liraglutide 0.6, 1.2 and 1.8 mg, re-
spectively, compared to 44% for glimepiride. Reductions in fasting plasma 
glucose were comparable across treatment groups. Liraglutide treatment led 
to weight loss of 1.8-2.4 kg, while glimepiride treatment resulted in 0.08kg 
weight gain. Greater reductions in systolic blood pressure (SBP) were ob-
served for liraglutide than glimepiride. Liraglutide was associated with a 
~10-fold lower incidence of minor hypoglycaemia than glimepiride. No 
major hypoglycaemia was reported for liraglutide. The composite endpoint 
‘HbA1c <7.0%, no weight gain, no hypoglycaemia’ was achieved by 29%, 39% 
and 41% of patients treated with liraglutide 0.6, 1.2 and 1.8 mg, respectively, 
compared with 17% of patients treated with glimepiride. The most common 
adverse effects associated with liraglutide were gastrointestinal disorders; 
however, these were transient in nature and led to very few withdrawals.
Conclusion: These results suggest that treatment with once-daily liraglutide 
leads to similar improvements in glycaemic control to glimepiride with ad-
ditional benefits on body weight and SBP and a lower risk of hypoglycaemia. 
Patients treated with liraglutide are more likely to achieve HbA1c target <7.0% 
without weight gain and hypoglycaemia. Both liraglutide and glimepiride ap-
pear to be efficacious when used early on in patients inadequately controlled 
with OAD monotherapy. These results from an Asian population are similar 
to those reported for Caucasian, African-American and Hispanic popula-
tions.
Liraglutide
0.6 mg
(n=231)
Liraglutide
1.2 mg
(n=233)
Liraglutide
1.8 mg
(n=233)
Glimepiride
4 mg
(n=231)
Baseline HbA1c, % 8.5 (0.07) 8.6 (0.07) 8.6 (0.07) 8.5 (0.07)
Change in HbA1c, % -1.14 (0.07)* -1.36 (0.07) -1.45 (0.07) -1.39 (0.07)
% HbA1c <7.0% 35.8* 45.0 46.6 43.9
Baseline FPG, mmol/L 9.8 (0.16) 9.5 (0.14) 9.9 (0.17) 9.6 (0.16)
Change in FPG, mmol/L -1.7 (0.13)* -2.1 (0.13) -2.1 (0.13) -2.2 (0.13)
Change in weight, kg -1.80 (0.16)* -2.35 (0.16)* -2.44 (0.16)* 0.08 (0.16)
Change in SBP, mmHg -3.14 (0.82) -4.25 (0.82)* -3.54 (0.82)* -0.91 (0.81)
Minor hypoglycaemia, 
events/subject year
0.091*** 0 0.084*** 1.16
Data are mean (SE). ***p<0.0001, *p<0.05 vs glimepiride
Supported by: Novo Nordisk
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Monotherapy with GLP-1 receptor agonist, Lixisenatide, significantly 
improves glycaemic control in type 2 diabetic patients
J.E. Gerich1, V.A. Fonseca2, R. Alvarado-Ruiz3, D. Raccah4, I. Zieleniuk5,  
G. Boka5, P. Miossec5; 
1University of Rochester School of Medicine, Rochester, USA, 2Tulane 
University Health Sciences Center, New Orleans, USA, 3Clínica 
Cardioprevent, Durango, Mexico, 4University Hospital Sainte Marguerite, 
Marseille, France, 5sanofi-aventis, Antony, France.
Background and aims: This 12-week, randomised, double-blind, placebo-
controlled, parallel-group, multicentre, Phase III study assessed the efficacy 
and safety of lixisenatide (AVE0010; a GLP-1 receptor agonist) as monother-
apy in type 2 diabetic patients.
Materials and methods: A total of 361 patients with type 2 diabetes (mean 
age 53.7 yrs, mean diabetes duration 2.5 yrs) not currently receiving glucose-
lowering therapy (HbA1c 7-10%) were randomised to one of four once-daily 
treatment regimens: lixisenatide 2-step titration (10 μg for 1 week, 15 μg for 
1 week then 20 μg; n=120), lixisenatide 1-step titration (10 μg for 2 weeks 
then 20 μg; n=119), placebo 2-step titration (n=61) or placebo 1-step titration 
(n=61). A 1-week, single-blind placebo run-in was followed by a 12-week, 
double-blind, placebo-controlled treatment period. The study was double-
blind for active and placebo treatments, and not blinded for drug volume and 
titration regimens. The primary endpoint was change in HbA1c from baseline 
to Week 12, analysed using ANCOVA with treatment group, screening strata 
for HbA1c (<8.0, ≥8.0%) and BMI (<30, ≥30 kg/m²), and country as fixed 
effects, and baseline HbA1c as covariate. A step-down testing procedure was 
applied. The two placebo groups were combined in all analyses.
Results: There were significant improvements in HbA1c in both lixisenatide 
titration groups vs placebo (p<0.0001) (Table). Significantly more patients in 
the lixisenatide groups achieved HbA1c ≤6.5% (31.9% 2-step, 25.4% 1-step) 
and <7.0% (52.2% 2-step, 46.5% 1-step) vs placebo (12.5% and 26.8%, re-
spectively; p<0.01). There were also significant improvements in 2-h post-
prandial and fasting plasma glucose in the lixisenatide groups vs placebo 
(Table). Mean decreases in body weight were observed in all groups. There 
was only one (0.4%) serious treatment-emergent adverse event (TEAE) in a 
lixisenatide-treated patient (2-step group) compared with five (4.1%) in the 
placebo group. Nine patients discontinued due to a TEAE: five (4.2%) in the 
lixisenatide 2-step group, three (2.5%) in the lixisenatide 1-step group and 
one (0.8%) in the placebo group. The most common TEAEs were gastrointes-
tinal: nausea was the most frequent (24.2% for lixisenatide 2-step, 20.2% for 
lixisenatide 1-step, 4.1% for placebo). Symptomatic hypoglycaemia occurred 
in three patients (2.5%) in the lixisenatide 2-step group, one (0.8%) in the 
lixisenatide 1-step group and two (1.6%) in the placebo group, with no cases 
of severe hypoglycaemia.
Conclusion: Lixisenatide monotherapy administered once daily significantly 
improved glycaemic control with a pronounced postprandial effect. Lixisena-
tide monotherapy was safe and well tolerated in patients with type 2 diabe-
tes.
Supported by: sanofi-aventis
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Exenatide significantly improved 24-hour average glucose compared to 
sitagliptin in patients with type 2 diabetes
S.K. Shenouda1, J.H. Holcombe2, C.R. Heilmann3; 
1Global Medical Communications, Eli Lilly and Company, Indianapolis, 
2Lilly USA, LLC, Indianapolis, 3Eli Lilly and Company, Indianapolis, USA.
Background and aims: This study compared exenatide, a GLP-1 receptor 
agonist, and sitagliptin, a DPP-4 inhibitor, with respect to average 24-hour 
glucose (primary objective) and 2-hour postprandial glucose (PPG), insulin, 
glucagon, and active GLP-1 (aGLP-1) concentrations and caloric intake in 
patients with type 2 diabetes.
Materials and methods: This double-blind, double-dummy, randomized 
crossover study was conducted in 86 metformin or TZD-treated patients: 
58% female; BMI 35±5 kg/m2; A1C 8.3±1.0%. Patients received either ex-
enatide [5μg twice a day (BID) for 1 week, then 10μg BID for 3 weeks] or 
sitagliptin (100mg one every morning) for 4 weeks. After 4 weeks, each group 
crossed to the other therapy for 4 weeks. At baseline and the end of each pe-
riod, patients underwent 24-hour inpatient assessment with hourly or more 
frequent blood sampling for glucose, insulin, glucagon and aGLP-1. Based 
on gender and weight, each patient received the same individualized meals 
across the three 24-hour inpatient periods. 64 patients completed the study.
Results: The figure represents the 24-hour blood glucose profiles for exenatide 
and sitagliptin at baseline (BL) and endpoint (EP). Both treatments decreased 
average 24-hour glucose [exenatide 175±40 (BL) to 133±28 (EP) mg/dL; sita-
gliptin 175±39 (BL) to 146±33 (EP) mg/dL] and 2-hour PPG [exenatide 233±57 
(BL) to 122±34 (EP) mg/dL; sitagliptin 233±57 (BL) to 186±51 (EP) mg/dL] 
from baseline (p<0.001), with the differences favoring exenatide (p<0.001). Both 
drugs decreased postprandial glucagon and improved the insulinogenic index 
from BL (p<0.05), but the improvements with exenatide were greater (p<0.001). 
Sitagliptin increased fasting and postprandial aGLP-1 from BL (p<0.001), while 
exenatide decreased postprandial aGLP-1 (p<0.05). There was no severe hypo-
glycaemia during the study and no dropouts due to an adverse event. Adverse 
events were mild to moderate in intensity and gastrointestinal in nature.
Conclusion: In conclusion, while exenatide and sitagliptin are both incretin-
based therapies, exenatide demonstrated significantly better clinical effects 
compared to sitagliptin on average 24-hour glucose, PPG, insulinogenic in-
dex, and glucagon suppression.
Supported by: Eli Lilly and Company and Amylin Pharmaceuticals
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Treatment satisfaction in patients with type 2 diabetes is significantly 
improved with liraglutide, the once-daily GLP-1 analogue versus 
sitagliptin, both combined with metformin
E. Montanya Mias1, R. Cuddihy2, R. Pratley3, M. Hammer4, A. Thomsen4, 
M.J. Davies5; 
1IDIBELL-Hospital Universitari de Bellvitge, Barcelona, Spain, 
2International Diabetes Center, Minneapolis, USA, 3University of Vermont, 
Burlington, United States, 4Novo Nordisk, Søborg, Denmark, 5Leicester 
University, United Kingdom.
Background and aims: Patient-reported outcomes (PRO) from clinical trials 
provide information on the impact of a disease on patients’ health status, and may 
identify the extent to which treatments meet patients’ needs and expectations. In a 
26-week randomised, open-label study (n=665), the injectable once-daily human 
GLP-1 analogue liraglutide (1.2 or 1.8 mg), led to superior HbA1c reduction vs oral-
ly-administered sitagliptin (100 mg OD), both added to metformin (MET; ≥1500 
mg daily). Mean HbA1c reduction (%) was 1.5, 1.2 and 0.9 for liraglutide 1.8 mg, 1.2 
mg and sitagliptin, respectively (p<0.0001 for both liraglutide doses vs. sitagliptin). 
Liraglutide patients also lost significantly more weight (~3 kg vs. ~1 kg; p<0.0001). 
Here we report PRO results from a pre-defined subpopulation of this clinical trial.
Materials and methods: Treatment satisfaction (TS) was assessed using 
the Diabetes Treatment Satisfaction Questionnaire (DTSQ) at baseline and 
26 weeks. Overall TS was calculated by adding satisfaction scores for ‘cur-
rent treatment’, ‘convenience’, ‘flexibility’, ‘understanding’, ‘recommend’, and 
‘continue’. Higher scores indicate improved TS. For evaluation of perceived 
frequency of hyper- and hypoglycaemia, higher negative scores indicate im-
provement. TS scores were analysed by ANCOVA with treatment and coun-
try as fixed effects and baseline value as covariate.
Results: 505 subjects were included in the PRO analysis (liraglutide 1.2 mg, 
n=164; liraglutide 1.8 mg, n=171; sitagliptin, n=170). Baseline characteristics 
of the PRO subpopulation treatment groups were well balanced. Overall TS 
was similar between groups at baseline and improved in all groups after 26 
weeks. Improvement in overall TS was significantly greater with liraglutide 1.8 
mg (4.35) than sitagliptin (2.96) (difference=1.39; 95%CI 0.13; 2.64; p=0.03) 
(Figure). Patients also reported significantly greater improvement in TS with 
liraglutide 1.8 mg than sitagliptin on three sub-items: ‘current treatment’ (dif-
ference=0.35; p=0.01), ‘recommend’ (difference=0.41; p=0.003) and ‘continue’ 
(difference=0.44; p=0.01). Patients perceived themselves to be hyperglycaemic 
significantly less frequently with liraglutide 1.8 mg than sitagliptin (differ-
ence=-0.88; p<0.0001, and the same was found with the 1.2 mg dose (differ-
ence=-0.49; p=0.01). ‘Convenience’, ‘flexibility’, ‘understanding’ and ‘perceived 
hypoglycaemia’ were not statistically different between groups.
Conclusion: Injectable liraglutide leads to greater TS than oral sitagliptin, 
potentially by facilitating greater improvements in glycaemic control, weight 
loss and/or perception of superior treatment efficacy.
Supported by: Novo Nordisk
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Exenatide added to a thiazolidinedione with or without metformin 
resulted in superior glycaemic control versus placebo after 26 weeks of 
treatment
J. Liutkus1, J. Rosas Guzman2, P. Norwood3, L. Pop4, J. Northrup5, D. Cao5, 
M. Trautmann5; 
1Medicine Professional Corporation, Cambridge, Canada, 2Centro de 
Especialidades Médicas de Celaya, Celaya, Mexico, 3Valley Research, Fresno, 
USA, 4Diabetes Center-Emergency County Hospital, Baia Mare, Romania, 
5Eli Lilly and Company, Indianapolis, USA.
Background and aims: Exenatide, thiazolidinediones (TZDs), and metform-
in regulate blood glucose through unique and potentially complementary 
mechanisms. The objective of this 26-week study was to investigate the ef-
ficacy and safety of exenatide added to a TZD with or without metformin.
Materials and methods: A 26-week, multicountry, randomised, double-blind 
placebo-controlled study compared exenatide twice-daily vs. placebo, in 165 
subjects with type 2 diabetes suboptimally controlled (HbA1c >7.0%) with 
a TZD or metformin + TZD (mean HbA1c 8.2% [SD 0.9], fasting glucose 
9.1 [2.6] mmol/L, weight 93.9 [17.8] kg, diabetes duration 6.4 [4.3] years). 
After a 2-week, single-blind, placebo lead-in period, subjects were randomly 
assigned (2:1) to add exenatide or placebo to their current regimens. The pri-
mary endpoint was the change in HbA1c from baseline to endpoint (Week 26 
or last-observation-carried-forward), using an analysis of covariance model 
with change in HbA1c from baseline to endpoint as the response variable 
and treatment, TZD stratum, country, and baseline HbA1c as explanatory 
variables.
Results: Approximately 95% (157/165) of the subjects were being treated 
with a TZD and metformin. At endpoint, exenatide reduced HbA1c sig-
nificantly more than placebo (-0.84% [SE 0.20] vs. -0.10% [0.23], p<0.001; 
mean treatment difference, -0.74 [95% CI: -1.06% to -0.41%]). Reduction 
in mean fasting glucose was also significantly greater with exenatide (-0.65 
mmol/L [SE 0.46] vs. +0.37 mmol/L [0.52], p=0.009). More subjects achieved 
HbA1c targets with exenatide (HbA1c ≤7.0%: 49% vs. 37%, p=NS; HbA1c 
≤6.5%: 34% vs. 13%, p=0.004). Mean reductions in body weight were -1.4 
[SE 0.6] kg with exenatide and -0.8 [0.7] kg with placebo; the between-treat-
ment difference was not significant. Exenatide-treated subjects demonstrated 
a higher homeostasis model assessment of beta-cell function (HOMA-B in-
dex, geometric mean ratio of endpoint to baseline, 1.08 [0.12] vs. 0.84 [0.11]; 
p=0.009). Change in insulin sensitivity (HOMA-S index) was similar between 
treatment groups. The most commonly reported adverse events (exenatide 
vs. placebo) were nausea (12% vs. 2%) and vomiting (8% vs. 0%). Confirmed 
(blood glucose <3.0 mmol/L) minor hypoglycaemia was experienced by 4% 
and 2% of subjects treated with exenatide and placebo, respectively.
Conclusion: Adverse events were similar to those previously reported with 
exenatide with more gastrointestinal symptoms compared to placebo and a 
low risk of hypoglycaemia. Exenatide added to a TZD, with or without met-
formin, significantly improved HOMA-B and glycaemic control compared 
with placebo.
Supported by: Eli Lilly and Company and Amylin Pharmaceuticals, Inc.
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Liraglutide treatment provides greater weight loss with improved 
glycaemic control than sitagliptin, both combined with metformin
A. Garber1, A. Thomsen2, A. Falahati2, R. Pratley3; 
1Baylor College of Medicine, Houston, USA, 2Novo Nordisk, Søborg, 
Denmark, 3University of Vermont College of Medicine, Burlington, USA.
Background and aims: Many standard diabetes treatments are associated 
with weight gain. Recently, incretin-based therapies have become available 
for the treatment of type 2 diabetes. In contrast to commonly used diabetes 
treatments, these incretin-based treatments promote weight loss (GLP-1 ago-
nists) or are weight-neutral (DPP-4 inhibitors). How weight loss relates to 
improvements in HbA1c remains unclear.
Materials and methods: In a 26-week randomised, open-label study liraglu-
tide (1.2 or 1.8 mg), a once-daily human GLP-1 analogue, was compared 
with sitagliptin (100 mg), a once-daily DPP-4 inhibitor, both as add-on to 
metformin, in patients with type 2 diabetes (n=665; baseline HbA1c: 8.5%). 
This study showed significantly greater reduction in HbA1c (1.2% and 1.5% vs 
0.9%, p<0.0001) and weight (2.9 kg and 3.4 kg vs 1.0 kg, p<0.0001) for liraglu-
tide 1.2 mg and 1.8 mg, respectively, than sitagliptin. An ANCOVA analysis 
using the last observation carried forward (LOCF) intention to treat (ITT) 
population including effects of treatment, weight and their interaction with 
baseline HbA1c as a covariate was carried out to investigate the impact of >3% 
weight reduction on the decrease in HbA1c with liraglutide 1.2 mg (n=215), 
liraglutide 1.8 mg (n=214) and sitagliptin (n=215).
Results: This analysis demonstrated that treatment with liraglutide 1.2 mg 
and 1.8 mg led to significantly more patients losing >3% body weight (BW) 
than sitagliptin (51% [1.8 mg; p<0.0001] vs 21%). Also, weight reductions 
in the >3% BW change group were significantly greater for liraglutide 1.2 
and 1.8 mg than sitagliptin (-5.75 kg and -6.30 kg [p=0.0342], respectively, 
vs -5.3 kg), while weight changes in the ≤3% BW change group were -0.02 
kg, -0.17 kg and +0.38 kg, respectively for liraglutide 1.2 mg, liraglutide 1.8 
mg, and sitagliptin. Patients treated with liraglutide who lost >3% weight had 
significantly greater reductions in HbA1c compared to those who lost ≤3% 
weight (Figure). In contrast, similar reductions in HbA1c were observed for 
patients treated with sitagliptin in both weight loss categories. Also, within 
each weight category, liraglutide treatment led to significantly greater im-
provements in HbA1c compared with sitagliptin.
Conclusion: Liraglutide treatment resulted in significantly greater reductions 
in HbA1c in those patients who experienced weight loss of >3%. Importantly, 
HbA1c reductions were greater following liraglutide treatment in both weight 
loss categories compared with sitagliptin.
Supported by: Novo Nordisk
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A meta-analysis of weight loss incurred by liraglutide in patients with 
type 2 diabetes with and without gastro-intestinal side-effects
D. Russell-Jones1, G. Sesti2, A. Garber3, B. Zinman4, K. Jensen5, A. Falahati5, 
S. Colagiuri6; 
1Diabetes and Endocrinology, Royal Surrey County Hospital, Guildford, 
United Kingdom, 2University Magna Graecia of Catanzaro, Italy, 3Baylor 
College of Medicine, Houston, USA, 4Mt Sinai Hospital, University of 
Toronto, Canada, 5Novo Nordisk, Søborg, Denmark, 6University of Sydney, 
Australia.
Background and aims: The once-daily human GLP-1 analogue liraglutide is 
licensed for use as a blood-glucose lowering agent in type 2 diabetes mellitus 
(T2DM), but also improves cardiovascular risk factors associated with the con-
dition, including systolic blood pressure, and weight. Gastro-intestinal (GI) 
symptoms such as nausea, vomiting or diarrhoea (NVD) are commonly report-
ed class effects associated with GLP-1 agonists. Clinical studies of liraglutide 
suggest NVD side-effects are generally experienced early in therapy, and are 
usually transient and lead to very few withdrawals. Theoretically, NVD could 
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impact on eating habits and therefore caloric intake; our data explore whether 
these symptoms alone explain weight loss in patients taking liraglutide.
Materials and methods: This meta-analysis pools data from 6 phase 3 trials 
conducted in patients (n=2783) with T2DM treated with once-daily liraglu-
tide or placebo for 26 weeks. Our aim was to explore the relationship between 
weight reduction and the occurrence of NVD. Changes in weight (kg) from 
baseline were analysed in patients with or without NVD in the different treat-
ment arms using ANCOVA. The analysis included randomised treatment ef-
fect, previous anti-diabetes treatment effect, interaction between treatment 
and NVD, and correction for baseline body weight as covariates.
Results: Weight decrease from baseline to 26 weeks was significant for all 
groups, except those patients without NVD who were randomised to placebo, 
and numerical, but non-significant differences in weight loss were seen for the 
individual liraglutide doses (1.2 vs 1.8 mg) (Figure). The majority of patients 
taking liraglutide lost weight without NVD (75%). NVD symptoms were re-
ported by 29%, 28% and 10% of patients treated with 1.8 mg liraglutide, 1.2 
mg liraglutide and placebo, respectively. Symptoms were generally transient, 
whereas the weight-loss effect was sustained throughout the studies. No over-
all interaction was found between the effect of treatment and presence of NVD 
(p=0.26); however, patients with NVD lost more weight than those without: 
(p<0.0001 and p=0.0365) for liraglutide 1.8 mg and 1.2 mg, respectively.
Conclusion: Over 2/3 of patients included in the meta-analysis lost signifi-
cant amounts of weight with liraglutide without experiencing nausea, vomit-
ing or diarrhoea. Weight loss occurs regardless of NVD but is greater in those 
patients with NVD then in those without NVD.
Supported by: Novo Nordisk
836
Meta-analysis of the efficacy of GLP-1R agonists and DPP-4 inhibitors 
for treatment of type 2 diabetes mellitus
V.R. Aroda1, R.R. Henry2, J. Han3, W. Huang3, Y. Peters3, T. Darsow3,  
B.J. Hoogwerf4; 
1Med Star Clinical Research Center, Hyattsville, 2University of California 
at San Diego, 3Amylin Pharmaceuticals, Inc., San Diego, 4Lilly USA, LLC, 
Indianapolis, USA.
Background and aims: The number of incretin-based therapies (glucagon-
like peptide 1 receptor [GLP-1R] agonists and dipeptidyl peptidase 4 [DPP-4] 
inhibitors) and the amount of clinical data on their efficacy for treatment of 
type 2 diabetes mellitus (T2DM) are rapidly increasing. The aim of this meta-
analysis was to summarize changes in HbA1c, fasting glucose (FG), and weight 
for approved or late-stage GLP-1R agonists or DPP-4 inhibitors in studies pub-
lished or presented at major scientific meetings before Dec 31, 2009.
Materials and methods: Medline, Embase, Biosis, and 2009 ADA and EASD ab-
stract databases were searched for multiple terms including GLP-1, DPP-4, and 
individual drug names (exenatide [weekly-Ex QW; twice daily-Ex BID], liraglu-
tide, alogliptin, saxagliptin, sitagliptin, vildagliptin). A database of search results 
was assessed by independent reviewers. Random effects meta-analysis models of 
the final studies for each therapy examined HbA1c, FG, and weight data.
Results: Reviewers identified 219 unique clinical studies in patients with T2DM. 
Of these, 63 were randomized controlled clinical trials of 12 to 52 weeks dura-
tion with the primary endpoint of change from baseline in HbA1c. The high-
est maintenance doses of GLP-1R agonists reduced HbA1c to a greater extent 
than the highest maintenance doses of DPP-4 inhibitors. Ex QW and liraglutide 
treatment resulted in the greatest mean reductions in FG, whereas lesser mean 
reductions in FG were observed for Ex BID and DPP-4 inhibitors. Mean weight 
loss (>2.0 kg) was observed with GLP-1R agonists but not DPP-4 inhibitors. 
Limitations of the analysis include high inter-trial variation due to differences in 
amount of data, computation, blinding, comparators, and background therapy.
GLP-1R Agonists DPP-4 Inhibitors
Exenatide
2 mg QW
Exenatide 
10 mcg 
BID
Liraglutide 
1.8 mg QD
Alogliptin
25 mg QD
Saxagliptin
5 mg QD
Sitagliptin 
100 mg 
QD
Vildagliptin 
100 mg/d
Studies 
included
3 12 6 5 4 13 17
Subjects, N 323 2216 1345 902 581 2689 5210
Baseline 
HbA1c, %
8.5 8.4 8.4 8.1 8.2 8.2 8.3
Δ HbA1c, %  
[95% CI]
-1.7
[-2.0, -1.4]
-1.0
[-1.2, -0.9]
-1.2
[-1.3, -1.1]
-0.7
[-0.9, -0.5]
-0.7
[-0.8, -0.5]
-0.7
[-0.7, -0.6]
-0.9
[-1.0, -0.8]
Δ FG, mmol/
L[95% CI]
-2.0
[-2.4, -1.6]
-1.1
[-1.3, -0.9]
-1.7
[-2.0, -1.4]
-1.0
[-1.3, -0.7]
-0.9
[-1.3, -0.5]
-0.9
[-1.0, -0.7]
-1.1
[-1.2, -1.0]
Δ Weight, kg 
[95% CI]
-3.2
[-3.9, -2.4]
-2.1
[-2.6, -1.7]
-2.1
[-2.9, -1.2]
-0.3
[-0.9, 0.3]
-0.4
[-1.0, 0.1]
-0.1
[-0.5, 0.3]
0.0
[-0.3, 0.3]
Number of studies and subjects are for the primary HbA1c analysis. All Δs are from baseline.
Conclusion: All incretin therapies significantly reduced HbA1c and FG from 
baseline. Treatment with GLP-1R agonists appeared to be associated with 
greater reductions in HbA1c, FG, and body weight than were achieved with 
DPP-4 inhibitors. Further investigation of differences in efficacy between the 
GLP-1R agonists is warranted.
Supported by: Amylin Pharmaceuticals, Inc. and Eli Lilly & Co.
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Risk of cardiovascular events in patients with type 2 diabetes treated with 
exenatide or other glucose-lowering therapies: a retrospective analysis of 
the LifeLinkTM database
J.H. Best1, B.J. Hoogwerf2, E.M. Pelletier3, D.B. Smith3, M. Wenten1,  
M.A. Hussein4; 
1Medical Research, Amylin Pharmaceuticals, San Diego, 2Eli Lily and Co., 
Indianapolis, 3IMS Health, Watertown, 4IMS Health, Falls Church, USA.
Background and aims: Studies of agents that reduce hyperglycemia in pa-
tients with type 2 diabetes have shown differing effects on cardiovascular 
(CV) outcomes. Glucose-lowering therapies have been associated with in-
creased risk, decreased risk, or neutral risk for CV events and/or mortality. 
The primary study objective was to assess the relative incidence rate of first 
CV events among patients with type 2 diabetes prescribed exenatide BID, a 
GLP-1 receptor agonist, compared to patients treated with glucose-lowering 
agent(s) other than exenatide (non-Ex).
Materials and methods: Analyses utilized the LifeLinkTM database and in-
cluded patients initiating a new prescription (Rx) for a glucose-lowering agent 
between June 1, 2005, and March 31, 2009, without Rx for the same agent in 
the prior 9 months. Patients were initially assigned to the exenatide or non-
Ex group based on first new Rx and reassigned if exenatide was prescribed or 
discontinued. Patients were followed until one of the following occurred: CV 
event (acute myocardial infarction, stroke, or coronary revascularization pro-
cedure), insurance disenrollment, or study end. Patient outcomes adjusted for 
differences in clinical and demographic characteristics were compared using 
propensity-score-weighted discrete time survival analysis with time-varying 
exposure. An ITT analysis of hospitalization was also conducted.
Results: During the study, 39,275 and 381,218 patients were exposed to ex-
enatide and non-Ex therapies, respectively. Age was similar_exenatide: 53 
(±9) years; non-Ex: 53 (±11) years; 43.8% of exenatide patients were male and 
51.5% of non-Ex patients were male. Exenatide patients were more likely than 
non-Ex patients to have hyperlipidemia (66.3% vs. 51.7%) and hypertension 
(65.4% vs. 56.3%). Exenatide-treated patients were 20% less likely to have a 
CV event than non-Ex patients (HR = 0.80; CI, 0.67-0.95). The exenatide 
group also had significantly lower rates of CV-related hospitalization (HR = 
0.85; CI, 0.76-0.95; P = 0.005) and all-cause hospitalization (HR = 0.95; CI, 
0.92-0.99; P = 0.004) than the non-Ex group.
Conclusion: In this analysis, exenatide treatment was associated with a lower 
risk of CV-related events than treatment with other classes of glucose-lower-
ing therapies.
S 334 Diabetologia (2010) 53:[Suppl1]S1–S556
1 C
PS 75 Long acting GLP-1 agonists
838
Taspoglutide, a once-weekly human GLP-1 analogue, is superior to 
Sitagliptin in improving glycaemic control and achieving weight loss in 
patients with type 2 diabetes: the T-emerge 4 Trial
J.-L. Chiasson1, L.A. Leiter2, A. Forti3, R.M. Bergenstal4, M. Woloschak5,  
M. Boldrin5, R. Balena6; 
1University of Montreal, Research Centre - CHUM, Montreal, Canada, 
2Keenan Research Centre in the Li Ka Shing Knowledge Institute of St. 
Michael’s Hospital, Toronto, Canada, 3Universidade Federal do Ceará, 
Fortaleza, Brazil, 4International Diabetes Center, Minneapolis, USA, 5Roche 
Pharmaceuticals, Nutley, USA, 6F. Hoffman-La Roche, Basel, Switzerland.
Background and aims: This trial compared taspoglutide, a once-weekly hu-
man GLP-1 analog undergoing Phase 3 clinical trials, with sitagliptin and 
placebo in adult patients (pts) with type 2 diabetes (T2DM) inadequately 
controlled on metformin.
Materials and methods: In this double-blinded, 24-wk study, 666 adult pts 
with an A1c between 7%-10% were randomized (2:2:2:1) to subcutaneous 
taspoglutide 10 mg weekly (Taspo10), taspoglutide 20 mg weekly (Taspo20; 
titrated after 4 wks of 10 mg), sitagliptin 100 mg QD orally (SIT), or placebo 
(PL). The primary endpoint was change from baseline in A1c at week 24 us-
ing the intent-to-treat population. Superiority of Taspo10 and Taspo20 with 
PL and non-inferiority (NI) with SIT were tested. If NI with sitagliptin was 
shown (using 2 sided 95% CI difference and NI margin of ≤0.3), then superi-
ority was tested under closed test procedure.
Results: Baseline characteristics were similar across the groups; average age 
was 56 yrs, A1c 8.0%, body mass index 32 kg/m2, and duration of T2DM 
6 yrs. Taspo10 and Taspo20, relative to SIT and PL, significantly reduced 
LS mean (SE) A1c (-1.23% [0.06], -1.30% [0.06], -0.89% [0.06], and -0.10% 
[0.08], respectively), body weight (Fig), and LS mean (SE) FPG (-2.16 [0.14], -
2.33 [0.14], -1.35 [0.14], and -0.07 [0.20] mmol/l, respectively). Both Taspo10 
and Taspo20 were superior to SIT for all 3 parameters. Target A1c of ≤7% was 
achieved by 68%, 72%, 55%, and 18% of pts receiving Taspo10, Taspo20, SIT, 
and PL, respectively. Gastrointestinal (GI) complaints were the most frequent 
adverse events and were reported in more pts receiving Taspo than SIT. GI 
events with Taspo were mostly mild and moderate in severity and transient in 
most pts; the withdrawal rate was 15%, 10%, 0.5%, and 1% of pts on Taspo10, 
Taspo20, SIT, and PL, respectively.
Conclusion: Once-weekly Taspo provided superior glycemic control and 
weight loss compared with SIT, while SIT had a lower incidence of GI adverse 
events. (NCT00754988)
Supported by: Roche
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Taspoglutide, a once-weekly human GLP-1 analog, as monotherapy 
significantly lowers HbA1c and body weight in patients with type 2 
diabetes: results from the T-emerge 1 phase 3 trial
I. Raz1, V.A. Fonseca2, M.S. Kipnes3, L. Durrwell4, J. Hoekstra5, M. Boldrin6,  
R. Balena4; 
1Hadassah Ein Kerem Hospital, Jerusalem, Israel, 2Tulane University, New 
Orleans, USA, 3DGD Research/Cetero Research, San Antonio, USA, 4F. 
Hoffmann-La Roche, Basel, Switzerland, 5National Clinical Research, 
Richmond, USA, 6Roche Pharmaceuticals, Nutley, USA.
Background and aims: Taspoglutide is a once-weekly human GLP-1 analog 
in Phase 3 clinical trials for T2D. This was a randomized, double-blind, pla-
cebo-controlled trial of taspoglutide monotherapy in drug-naïve patients.
Materials and methods: Adults (n=373) uncontrolled on diet and exercise 
with HbA1c between ≥6.5% and ≤10% were randomized 1:1:1 to subcutaneous 
taspoglutide 10 mg weekly (Taspo10), taspoglutide 20 mg weekly (Taspo20; af-
ter 4 weeks of Taspo10), or placebo (PL) for 24 weeks. The primary endpoint 
was the absolute change from baseline in HbA1c (%) after 24 weeks.
Results: Patient demographics were similar among the 3 groups; ~63% were 
women, mean age 54 yrs, body mass index 32 kg/m2, mean HbA1c was 7.6% and 
duration of T2D ~2 yrs. Primary efficacy results at week 24 in the intent-to-treat 
population (ITT), using last observation carried forward (LOCF) are shown in 
the Table. Reductions from baseline in HbA1c and FPG were significantly greater 
with Taspo10 and Taspo20 than with PL. Target HbA1c of ≤6.5% was achieved by 
59.8% (95% confidence interval [CI], 50.1-69.0), 66.1% (95 % CI, 57.2-74.3), and 
17.4% (95% CI, 11.0-25.6) in the Taspo10, Taspo20, and PL groups, respectively. 
Reduction in body weight in the Taspo20 group was significantly greater than in 
PL (Table). The most frequently reported adverse events were nausea and vomit-
ing, occurring at a greater incidence in the Taspo10 and Taspo20 groups than PL. 
Withdrawals due to gastrointestinal adverse events occurred in 5.2%, 7.8% and 
0.8% of patients in the Taspo10, Taspo20, and PL groups, respectively.
Conclusion: Once-weekly taspoglutide as monotherapy in drug-naive pa-
tients with low baseline HbA1c, significantly improved glycemic control, re-
duced body weight, and was well tolerated. (NCT00744926)
LSMean ± SE Taspo10 (n=112)
Taspo20 
(n=127)
PL
(n=115)
Baseline HbA1c (%) 7.52±0.10 7.66±0.09 7.62±0.09
Change from baseline HbA1c 
(95% Confidence Interval [CI])
-1.01±0.07 
(-1.14, -0.88)
-1.18±0.06 
(-1.31, -1.06)
-0.09±0.07 
(-0.22, 0.04)
Diff from PL -0.92±0.09** -1.09±0.09** _
Baseline FPG (mmol/l) 8.75±0.24 8.97±0.22 8.64±0.23
Change from baseline FPG  
(95% CI)
-1.55±0.17 
(-1.89, -1.21)
-1.90±0.17 
(-2.23, -1.58)
-0.08±0.17 
(-0.42, 0.25)
Difference from PL -1.47±0.24** -1.82±0.23** _
Baseline body weight (kg) 88.40±1.70 84.97±1.60 87.40±1.68
Change from baseline body 
weight (95% CI)
-1.45±0.32 
(-2.07, -0.84)
-2.25±0.30 
(-2.84, -1.65)
-1.23±0.31 
(-1.84, -0.62)
Difference from PL -0.22±0.43 -1.01±0.42* _
*P<0.05; **P<0.0001 vs PL
Supported by: Roche
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Taspoglutide, once-weekly human GLP-1 analogue, compared to BID 
Exenatide improves glucose tolerance and insulin secretion in patients 
with type 2 diabetes: T-emerge 2 meal tolerance test
R. Ratner1, J. Rosenstock2, B. Balas3, B. Charbonnel4, G.B. Bolli5,  
M. Boldrin6, R. Balena3; 
1Medstar Research Institute, Hyattsville, USA, 2Dallas Diabetes and 
Endocrine Center at Medical City, Dallas, USA, 3F. Hoffmann-La Roche, 
Basel, Switzerland, 4Universite de Nantes, France, 5University of Perugia, 
Italy, 6Roche Pharmaceuticals, Nutley, USA.
Background and aims: T-emerge 2 was a randomized, open-label, 24-week 
trial comparing subcutaneous taspoglutide 10 mg weekly (Taspo10), taspo-
glutide 20 mg weekly (Taspo20; titrated after 4 wks of Taspo10), with exena-
tide 10 mcg BID (Exe; after 4 weeks of Exe 5 mcg) in patients inadequately 
controlled on metformin, a thiazolidinedione, or both. T-emerge 2 demon-
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strated that once-weekly Taspo provided better glycemic control than Exe. 
This report focuses on a subset of T-emerge 2 participants undergoing a stan-
dardized meal comparing Taspo to Exe which has been previously shown to 
lower postprandial glucose.
Materials and methods: Meal tolerance tests (MTT) were performed at base-
line and at week 24 in a subset of Taspo 10, Taspo 20 and Exe patients (n=42, 
39, and 67, respectively). Blood samples for glucose, insulin, glucagon, and 
C-peptide were obtained before and after (30, 60, 90, 120, and 180 min) in-
gestion of a standardized liquid meal.
Results: The 2-h postprandial, mean0-3h and AUC0-3h glucose during the MTT was 
reduced to a similar extent in all groups and the time profile of the postprandial 
glucose showed a similar pattern. Taspo10 and Taspo20 significantly increased 
insulin from baseline (both mean and AUC0-3h) while the increase in insulin from 
baseline was not significant for Exe (Table). Although changes from baseline in 
C-peptide were not significant within any treatment group, the mean change 
from baseline (both mean0-3h and AUC0-3h) was significantly increased in Taspo10 
vs. Exe. Mean glucagon showed significant decreases in all groups (Table).
Conclusion: Taspoglutide and Exe improved glucose tolerance and re-
duced glucagon responses to a similar extent while taspoglutide alone sig-
nificantly improved insulin secretion from baseline in patients with T2DM. 
(NCT00717457)
LSMean ± SE Taspo10 Taspo20 Exe
BL glucose AUC(0-3hr) 
(mmol*h/L)
35.91±1.17 39.05±1.21 37.47±0.92
Percent change from BL 
glucose
AUC(0-3h) (95% CI)
-24.97±3.60
(-32.09, -17.85)
-27.05±4.16
(-35.27, -18.83)
-24.50±3.62
(-31.65, -17.35)
BL insulin AUC(0-3hr) 
(uU*h/mL)
77.99±8.40 110.40±8.40 77.87±6.93
Percent change from BL 
insulin
AUC(0-3h) (95% CI)
53.80±15.44 
(23.09, 84.52)
47.23±20.07 
(7.32, 87.14)
26.36±18.33
(-10.09, 62.81)
BL glucagon(0-3hr)  
(pmol/L)
26.58±1.20 26.35±1.25 25.23±0.93
Percent change from BL 
glucagon (95% CI)
-2.33±1.08
(-4.46, -0.20)
-2.64±1.22
(-5.05, -0.22)
-2.17±1.06
(-4.26, -0.07)
BL C-peptide AUC(0-3hr) 
pmol*h/L
5025 5229 4936
Percent change from BL 
C-peptide (95% CI)
9.49±6.05*
(-2.49, 21.46)
-2.24±7.02
(-16.14, 11.66)
-4.54±6.05
(-16.52, 7.45)
BL, baseline; CI, confidence interval*P<0.05 vs Exe
Supported by: Roche
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Disease progression modelling to quantify the effects of exenatide twice 
daily and once weekly formulations on HbA1c in patients with type 2 diabetes
J.T. Mondick1, P. Kothare2, M.R. Gastonguay1, B. Cirincione3; 
1Metrum Research Group, Tariffville, 2Eli Lilly and Company, Indianapolis, 
3Amylin Pharmaceuticals, Inc., San Diego, USA.
Exenatide, a GLP-1 receptor agonist, is given twice daily (Ex BID) and indicat-
ed for patients with type 2 diabetes; and a once weekly (Ex QW) formulation 
is under development. The purpose of this analysis was to implement a popu-
lation disease progression pharmacodynamic modeling approach to quantify 
the effects of demographic, clinical, and formulation characteristics on HbA1c 
and to examine the effects of exenatide exposure on HbA1c when transition-
ing patients (PT) from the Ex BID formulation to Ex QW. Clinical data was 
pooled from: (a) 3 Ex BID Phase 3 trials in PT treated with metformin (MET) 
and/or a sulphonylurea (SU); (b) 1 Ex QW Phase 2 trial in PT treated with 
MET and/or Diet and Exercise (DE); and (c) 1 comparative Phase 3 trial where 
PT, treated with MET, SU, thiazolidinedione (TZD), and/or DE, were initially 
randomised to Ex BID or Ex QW. Patients on Ex BID transitioned to Ex QW. 
The data set included HbA1c measurements from 1272 exenatide and 496 pla-
cebo PT for up to 52 wk. A disease progression model was constructed using 
nonlinear mixed effects modeling for repeated measures data to describe the 
natural HbA1c time course, placebo effects, exenatide effects, and the effects 
of patient and formulation characteristics on HbA1c. The placebo and drug 
effects on HbA1c were calculated from the estimated model parameters. The 
estimated baseline HbA1c was 8.4% for the typical patient (100 kg, male, 55 y, 
no concomitant MET, TZD, or SU therapy). No significant differences in base-
line HbA1c were detected for gender or for concomitant administration with 
MET or SU. The baseline HbA1c value was reduced by 0.44% (0.12, 0.69) for PT 
administered TZD. The placebo effect translated to a mean absolute reduction 
of 0.3% at 8 wk, and returned to baseline by approximately 30 wk. Mean (95% 
CI) steady-state HbA1c levels were reduced by 0.8% ( 0.7, 0.9) and 1.2% (1.0, 
1.5) for 5 μg and 10 μg Ex BID, respectively, and reduced by 1.4% (0.7, 2.8) for 
a 2 mg Ex QW dose. Patients who transitioned from 10 μg Ex BID to 2 mg 
Ex QW demonstrated an additional 0.2% response to Ex QW administration, 
demonstrating a clinical advantage of prolonged exenatide exposure.
Supported by: Amylin Pharmaceuticals, Inc. and Eli Lilly & Co.
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DURATION-2: effect of switching to once-weekly exenatide from 
maximum daily doses of sitagliptin or pioglitazone
C.H. Wysham1, R.M. Bergenstal2, J. Malloy3, B. Walsh3, P. Yan3, J. Malone4,  
K. Taylor3; 
1Rockwood Clinic, Spokane, 2International Diabetes Center, Minneapolis, 
3Amylin Pharmaceuticals, Inc., San Diego, 4Eli Lilly and Company, 
Indianapolis, USA.
Background and aims: In the 26-week, double-blind, double-dummy assess-
ment period of the DURATION-2 trial in patients with type 2 diabetes on 
metformin, treatment with the once-weekly GLP-1 receptor agonist exenatide 
(Ex QW) resulted in greater improvements in glycaemic control and weight 
compared to maximum approved doses of sitagliptin and pioglitazone. In the 
subsequent 26-week, open-label, uncontrolled assessment period, randomised 
oral medications were discontinued and all patients received Ex QW. The 
safety and efficacy of Ex QW treatment for 52 weeks, as well as the effects of 
switching from sitagliptin or pioglitazone to Ex QW, were evaluated.
Materials and methods: Of the 364 patients who continued into the open-
label period and received at least 1 Ex QW dose (study entry baseline: HbA1c 
8.5±1.1%, fasting plasma glucose [FPG] 9.0±2.5 mmol/L, weight 88±20 kg), 
319 patients (88%) completed 52 weeks. Results are reported for the 52-week 
evaluable population.
Results: Patients who received Ex QW throughout the trial demonstrated sig-
nificant improvements from baseline in HbA1c, FPG, and weight. At the end 
of the 52-week assessment period, 39% of patients treated with Ex QW for 52 
weeks achieved HbA1c ≤6.5% and 62% achieved the FPG target ≤7.0 mmol/L. 
Patients who switched from sitagliptin to Ex QW demonstrated significant 
incremental improvements in HbA1c, FPG, and weight, and significantly more 
patients achieved HbA1c ≤6.5% (week 26: 18% → week 52: 36%; P<0.001) 
and FPG ≤7 mmol/L (week 26: 38% → week 52: 58%; P<0.001). Patients who 
switched from pioglitazone maintained the improvements in HbA1c and FPG 
observed during the initial 26 weeks, and a similar proportion of patients 
achieved HbA1c ≤6.5% (40%) and FPG ≤7 mmol/L (59%) compared to pa-
tients treated with Ex QW for 52 weeks. However, switching from pioglitazone 
to Ex QW resulted in a significant weight reduction that reversed the weight 
gain associated with 26 weeks of pioglitazone treatment. Improvements in 
systolic blood pressure (SBP) with Ex QW and pioglitazone at week 26 were 
maintained at week 52 (-2.9±1.3 mmHg and -2.2±1.3 mmHg, respectively), 
while SBP was reduced by -2.7±1.1 mmHg (P<0.05) in patients who switched 
from sitagliptin to Ex QW (week 52: -2.9±1.2 mmHg). Ex QW was generally 
well tolerated and adverse events were predominantly mild or moderate in 
severity. Treatment-emergent nausea was the most frequent adverse event in 
this assessment period (ITT: Ex QW-only: 5%; sitagliptin → Ex QW: 11%; pi-
oglitazone → Ex QW: 10%). No major hypoglycaemia was observed.
Conclusion: Switching to once-weekly exenatide from daily sitagliptin or pi-
oglitazone resulted in improved or sustained glycaemic control with weight 
loss.
HbA1c (%) FPG 
(mmol/L)
Body Weight 
(kg)
EQW-only (week 0-52)
Δ from baseline at week 52 -1.6±0.1 -1.8±0.3 -1.8±0.5
Sitagliptin (week 0-26) → EQW (week 26-52)
Δ from week 26 to week 52 -0.3±0.1* -0.7±0.2* -1.1±0.3*
Δ from baseline at week 52 -1.4±0.1 -1.7±0.3 -2.0±0.5
Pioglitazone (week 0-26) → EQW (week 26-52) 
Δ from week 26 to week 52 -0.1±0.1 0.0±0.2 -3.0±0.3*
Δ from baseline at week 52 -1.6±0.1 -1.7±0.3 +0.4±0.5
LS mean ± SE; *P<0.05 vs. week 26
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DURATION-5: Exenatide once weekly resulted in significantly greater 
improvement in glycaemic control than exenatide twice daily in patients 
with type 2 diabetes
J. Pullman1, T.C. Blevins2, J. Malloy3, P. Yan3, K. Taylor3, C. Schulteis3,  
M. Trautmann4, L. Porter3; 
1Mercury St. Medical, Butte, 2Texas Diabetes and Endocrinology Center, 
Austin, 3Amylin Pharmaceuticals, Inc., San Diego, 4Eli Lilly and Company, 
Indianapolis, USA.
Background and aims: Treatment with the GLP-1 receptor agonist exenatide 
results in improved glycaemic control and weight loss in patients with type 
2 diabetes. This 24-week, randomised, open-label, comparator-controlled 
study compared treatment with exenatide once weekly (Ex QW; 2 mg) to ex-
enatide twice daily (Ex BID; 10 mcg).
Materials and methods: The study was conducted in 252 intent-to-treat 
patients with type 2 diabetes (baseline [mean±SD]: HbA1c 8.4±1.2%, fast-
ing plasma glucose [FPG] 9.5±2.6 mmol/L, weight 96±20 kg). Patients were 
drug-naïve (18.7%) or treated with one (46.8%) or a combination (34.5%) of 
oral antidiabetic medications.
Results: Over 24 weeks of therapy, Ex QW resulted in significantly greater 
decreases from baseline (LS mean±SE) versus Ex BID in HbA1c (-1.6±0.1% 
[Ex QW] versus -0.9±0.1% [Ex BID]; P<0.0001) and FPG (-1.9±0.3 mmol/L 
[Ex QW] versus -0.7±0.3 mmol/L [Ex BID]; adjusted P=0.0008). Improve-
ments in HbA1c were consistently observed across different background 
antidiabetic therapies. A significantly greater percentage of Ex QW patients 
(58.1%) achieved the HbA1c target of <7% compared to Ex BID patients 
(30.1%; adjusted P<0.0001). A total of 41.1% of Ex QW patients achieved 
the HbA1c target of ≤6.5% compared to 16.3% Ex BID patients (P<0.0001). 
Progressive reductions in mean body weight were observed in both treat-
ment groups (change from baseline to Week 24 (LS mean±SE): -2.3±0.4 kg 
[Ex QW]; -1.4±0.4 kg [Ex BID]; not significant). A total of 71% of Ex QW 
patients and 51% of Ex BID patients had improvements in both body weight 
and HbA1c after 24 weeks of therapy. Reductions in sitting systolic blood pres-
sure from baseline to Week 24 were observed with Ex QW (LS mean [95% 
CI]: -2.9 [-5.2,-0.7] mm Hg) and Ex BID (-1.2 [-3.5, 1.2] mm Hg). Ex QW 
and Ex BID were well tolerated. Nausea, the most frequent adverse event, 
occurred less frequently with Ex QW (14%) than with Ex BID (35%) and 
was predominantly transient and mild or moderate in intensity. Injection-site 
reactions were infrequent and generally mild in intensity, but occurred more 
often with Ex QW compared to Ex BID. No major hypoglycaemia occurred. 
Minor hypoglycaemia was infrequent and occurred only in patients using 
a concomitant sulphonylurea. No change in mean calcitonin concentrations 
was observed during the study. Pancreatic-amylase and lipase concentrations 
were variable, both pre- and postbaseline, and changes in these enzymes were 
not predictive of gastrointestinal adverse events.
Conclusion: Continuous exenatide exposure via Ex QW therapy resulted in 
superior glycaemic control with fewer gastrointestinal adverse events com-
pared to Ex BID in patients with type 2 diabetes. Both groups lost weight.
844
VRS-859, a monthly dosed glucagon-like peptide-1 (GLP-1) analogue, 
provides long-term glucose control in mouse models and lacks toxicity in 
mice and monkeys
J. Cleland1, N. Geething2, W. To2, B. Spink2, L. Lee2, Y. Yao2, J. Silverman2; 
1Versartis, Inc., Mountain View, 2Amunix, Inc., Mountain View, USA.
Background and aims: VRS-859 is a novel, monthly dosed glucagon-like 
peptide-1 (GLP-1) analogue, being developed for treatment of type 2 dia-
betes (T2DM). VRS-859 is a fusion protein containing the GLP-1 analogue, 
exenatide, and a long hydrophilic tail of natural amino acids, XTEN, which 
increases the half-life. Mouse studies were performed to determine the rela-
tionship between the pharmacokinetics (PK) and pharmacodynamics (PD) 
of VRS-859. Toxicology studies were performed in mice and monkeys to 
ensure adequate safety for the proposed human dose. Single subcuntaneous 
doses of VRS-859 are being evaluated in a placebo controlled blinded study 
of patients with T2DM.
Materials and methods: Normal mice were treated with VRS-859 (1.2 to 120 
nmol/kg) or exenatide and assessed for glycemic control and insulin secre-
tion after intraperitoneal glucose tolerance test (IP GTT; AUCGlu measured 
over 120 min and compared to placebo treatment) performed at intervals 
up to 72 hrs post-dose. VRS-859 (120 nmol/kg Q2D or 240 nmol/kg Q4D) 
or exenatide (infusion pump) was administered to diet induced obese (DIO) 
mice for 28 days. PK and toxicology of VRS-859 were assessed in mice dosed 
every other day with up to 50 mg/kg VRS-859 and cynomolgus monkeys 
dosed weekly with up to 35 mg/kg VRS-859 for 28 days. Clinical pathology, 
cardiovascular safety, and complete histology were performed in the toxicol-
ogy studies. T2DM patients are being enrolled in a Phase 1 placebo controlled 
single ascending dose study of VRS-859. Patient evaluations include safety, 
tolerability, fasting plasma glucose, glycated albumin, HbA1c, oral glucose 
tolerance tests, insulin, and antibodies to VRS-859.
Results: Up to 48 hrs after IP VRS-859 dosing (120 nmol/kg), mice main-
tained a significant improvement in glucose tolerance (AUCGlu = -53%), while 
exenatide only demonstrated significant improvement up to 1 hr post-dose. 
Insulin secretion after IP GTT was also increased up to 48 hrs after IP VRS-
859 (120 nmol/kg) administration. There was a dose dependent glucose toler-
ance noted at 1 hr after dosing 1.2, 12 or 120 nmol/kg VRS-859 (AUCGlu : -1, 
-54, and -66%, respectively). Correlating plasma levels of VRS-859 with the 
PD effects suggested that a human plasma level of 200 ng/mL VRS-859 may 
be sufficient to ensure glycemic control. After 28 days, DIO mice treated with 
VRS-859 had a significantly decreased body weight (p < 0.01) and fasting 
blood glucose (p < 0.05) compared to placebo, but exenatide infusion did not 
cause significant reduction in fasting blood glucose. The no observed adverse 
effect level of VRS-859 was 50 mg/kg in mice and 35 mg/kg in monkeys. Al-
lometric scaling of the VRS-859 pharmacokinetics indicated a projected hu-
man terminal half-life of 139 hrs. Therefore, a 100 mg dose of VRS-859 may 
provide plasma levels sufficient to ensure glycemic control for one month 
in humans. Preliminary Phase 1 results including the pharmacokinetics and 
pharmacodynamics as well as safety and tolerability will also be presented.
Conclusion: VRS-859 provides sustained glycemic control and weight loss. 
A single subcutaneous dose of VRS-859 may enable glycemic control in a 
T2DM patient for one month.
845
Treatment with LY2189265 (GLP-1 analogue) causes larger decreases in 
postprandial glucose excursion in Hispanics compared to Non-Hispanic 
Caucasians with uncontrolled type 2 diabetes: an EGO Study exploratory 
analysis
E.J. Bastyr1,2, J. Noriega1,2, F.T. Botros1, J. Shu3, L.C. Glass1; 
1Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, 2Indiana 
University School of Medicine, Indianapolis, 3i3 Statprobe, Ann Arbor, USA.
Background and aims: The Hispanic population is severely affected by the 
increasing incidence of type 2 diabetes mellitus, but studies of the differential 
responses to drug therapy in this group have received little attention. The ob-
jective of this exploratory analysis of the EGO study is to examine differences 
in glycemic control between Hispanic (H) and Non-Hispanic (NH) Cauca-
sian populations in response to treatment with the long-acting glucagon-like 
peptide-1 (GLP-1) analog LY2189265 (LY).
Materials and methods: Subjects were randomized to once-weekly subcu-
taneous injections of either placebo or 1 of 3 LY dose regimens: 1) 1.0 mg 
for 16 weeks; 2) 0.5 mg for 4 weeks then titrated to 1.0 mg for 12 weeks; 
or 3) 1.0 mg for 4 weeks then titrated to 2.0 mg for 12 weeks. The primary 
metabolic measure for comparison between the 2 ethnic groups was glycemic 
control, as measured by HbA1c change from baseline at 16 weeks. Secondary 
measures were change in 1) fasting blood glucose (FBG); 2) β-cell function 
(HOMA2%B); and 3) glucose excursion (AUC) response to a solid mixed 
meal test. Differences between groups were tested using a two-sample T-test 
and nominal significance level of 0.05 for comparisons.
Results: In all randomized subjects, the H group had a statistically signifi-
cantly higher baseline HbA1c compared to the NH group (8.4±1.0%, n=88 
vs. 8.1±0.9%, n=150, p=0.006). The 177 patients randomized to LY treatment 
(62 H and 115 NH) had similar baseline characteristics; however, baseline 
HbA1c was 8.5±1.0% in H (n=62) compared to 8.2±0.9% in NH (n=114), 
p=0.078, and baseline postprandial AUC glucose excursion was significant-
ly higher in H compared to NH (12.2±3.9 [mmol/L]•hr, n=60 vs. 10.3±5.3 
[mmol/L]•hr, n=112, p=0.007). In response to LY treatment, both groups 
achieved statistically significant reductions in FBG and HbA1c. The H popu-
lation experienced a greater reduction in HbA1c compared to NH at end-
point (-1.5±1.0%, n=61 vs. -1.1±0.8%, n=111, p=0.020), but changes in FBG 
were not significantly different between groups (-2.3±2.8 mmol/L, n=55 H vs. 
-1.8±2.5 mmol/L, n=92 NH, p=0.253). Changes in HOMA2%B were not sig-
nificantly different between groups, but there was a 5.6-fold greater decrease 
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in postprandial AUC glucose excursion in the H group compared to the NH 
group (-2.8±3.8, n=56 vs. -0.5±5.7, n=89, [mmol/L]•hr, p=0.003). The per-
centage of subjects with ≥1 treatment-emergent adverse event in response to 
treatment with LY was similar between groups (58.1%, n=36 in H vs. 60%, 
n=69 in NH, p=0.803).
Conclusion: In conclusion, in response to treatment with LY, reductions in 
HbA1c were significantly greater in H compared to NH. This greater decrease 
in HbA1c in the H population appears to be due to the greater reduction in 
postprandial glucose excursion in H. Further studies are warranted to pro-
spectively evaluate differential effects of LY treatment in the Hispanic popula-
tion with type 2 diabetes mellitus.
PS 76 Incretin based therapies: 
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Normalising action of GLP-1 and Exendin-4 on bone metabolism in 
obese state
B. Nuche-Berenguer1, I. Gutiérrez-Rojas1, D. Lozano2, P. Esbrit2,  
M.L. Villanueva-Peñacarrillo1; 
1Metabolism, Nutrition & Hormones, 2Bone & Mineral Metabolism, IIS-
Fundación Jiménez Díaz, Madrid, Spain.
Background and aims: The bone anabolic action of GLP-1 and exendin-4 
(Ex-4) in normal, insulin resistant and type 2 diabetic rats has been dem-
onstrated, the effect of GLP-1 being suggested to take part, at least partially, 
through specific receptors, distinct in structure and/or function from the 
pancreatic GLP-1 receptor. Hypercholesterolemia seems to be related with 
low levels of bone mineral density. Here we have explored the possible in vivo 
effect of GLP-1 and Ex-4 on bone turnover and other markers, in a diet-in-
duced obesity rat model (OB), compared to normal (N).
Materials and methods: OB was obtained in adult Wistar rats by chronic 
feeding during five weeks with a cafeteria diet, consisting in standard chow 
supplemented with cookies, liver paste, bacon, and whole milk containing 
sucrose (333 g/l) and 10 g/l of a mineral and vitamin complex (65% energy 
from lipids). The N group was fed with standard chow and water ad libitum 
(8% energy as fat). Although weight was not different between N and OB 
rats, the OB model showed higher plasma glucose (78±2 mg/dl, n=12), tri-
glycerides (153±13 mg/dl, n=11) and cholesterol (92±4 mg/dl, n=12) than 
those in N (overall mean: 37±5% Δ N-rats, p<0.02); no significant differences 
with N were detected in plasma insulin or GLP-1 -by RIA-. OB rats were 3-
days continuously treated -osmotic pump- with saline (control), GLP-1 (0.86 
nmol/kg/h) or Ex-4 (0.1 nmol/kg/h). In fed conditions, blood samples were 
taken before (basal) and by the end of the treatment for plasma measure-
ments; then, rats were sacrificed and the femorae, tibiae and L1-L4 vertebrae 
were collected. In the tibia, after total RNA extraction, osteocalcin (OC), 
osteoprogeterin (OPG) and RANK ligand (RANKL) gene expression -by 
RT-PCR- was determined; femoral and lumbar spine bone mineral densities 
(BMD) were also measured (Lunar Piximus).
Results: In the OB group, GLP-1 lowered the higher than normal triglycer-
ides value (-33±6% Δ OB-basal, p<0.05, n=6 rats), without modifying that of 
cholesterol; however, Ex-4 induced a reduction in both triglycerides (-44±5% 
Δ OB-basal, p<0.01, n=6) and cholesterol (-19±3% Δ OB-basal, p<0.01, n=5). 
While plasma glucose, creatinin and insulin were not apparently different 
in any group or condition, calcium in OB was slightly higher (p<0.01) than 
that in N, without differences in the phosphates values; GLP-1 induced a de-
crease in the two latter parameters (overall mean: -8±2% Δ OB-basal, p<0.01, 
n=6) while Ex-4 reduced only the phosphate levels (-17.1±3.2% Δ OB-basal, 
p<0.01, n=6). In OB rats (n=12), BMD in femur (0.144±0.03 g/cm3) and lum-
bar spine (0.128±0.03 g/cm3) was lower (overall mean: -19±3% Δ N, p<0.001) 
than those in N-control rats (n=6-12), and either GLP-1 or Ex-4 exerted a 
normalizing effect (overall mean: 94±1% N, p<0.001). In the tibia of OB rats, 
OC mRNA level was equal to that in N, and both GLP-1 and Ex-4 induced 
an increase (overall mean: 2.23±0.21 times OB-control, p<0.05). In OB rats, 
bone OPG/RANKL mRNA ratio was 0.39, a value below that in N (consid-
ered as unity), indicating a high resorptive activity in this model; treatment 
with either GLP-1 or Ex-4 increased this ratio to values close to normal (0.76 
and 0.80, respectively).
Conclusion: These data suggest that both GLP-1 and Ex-4 not only could 
correct the high lipid levels present in obese state, but also to normalize its 
possible deleterious bone metabolism through their common anabolic ac-
tion.
Supported by: FIS, CIBERDEM
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The GLP-1 analogue liraglutide activates brainstem and hypothalamic 
neurons involved in appetite regulation
K. Raun1, N. Vrang2, J. Jelsing2, M. Tang-Christiansen1, K. Dahl1, L. Bjerre 
Knudsen1; 
1Novo Nordisk, Måløv, 2Gubra, Frederiskberg, Denmark.
Background and aims: The glucagon-like peptide-1 (GLP-1) analogue li-
raglutide is emerging as an important drug for the treatment of diabetes. 
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However, in both rodents and humans liraglutide also reduces appetite and 
lowers body weight.
Materials and methods: To identify the possible brain sites mediating li-
raglutide induced anorexia, we examined the expression of the immediate 
early gene c-Fos in male Sprague-Dawley rats. Based on the onset of liraglu-
tide-induced anorexia, rats were terminated by perfusion fixation 4 and 8 h 
following s.c. or i.p. administration of liraglutide (0.1 mg/kg). Brain sections 
were immunoreacted for c-Fos and immunoreactive (ir) nuclei were assessed 
qualitatively throughout the brain. Six areas were selected for quantitative 
assessment.
Results: In the forebrain liraglutide increased c-Fos-ir nuclei in the central 
nucleus of amygdala (32±11; liraglutide s.c. 115±12; liraglutide i.p. 140±10, 
p<0.05 vehicle vs liraglutide s.c., i.p.) and in the hypothalamic paraventricu-
lar nucleus (PVN; vehicle 42±5; liraglutide s.c. 43±8; liraglutide i.p. 144±23, 
p<0.05 vehicle vs liraglutide i.p.). Conversely, liraglutide reduced c-Fos-ir 
nuclei in the arcuate nucleus (vehicle 45±10; liraglutide s.c. 16±4; liraglutide 
i.p. 21±6, p<0.05 vehicle vs liraglutide s.c., i.p.). In the hindbrain, liraglu-
tide increased c-Fos in the area postrema (AP; vehicle 49±8; liraglutide s.c. 
188±20; liraglutide i.p. 276±27, p<0.05 vehicle vs liraglutide s.c., i.p.), nucleus 
of the solitary tract (NTS; vehicle 27±5; liraglutide s.c. 150±17; liraglutide i.p. 
161±21, p<0.05 vehicle vs liraglutide i.p.) and lateral parabrachial nucleus 
(lPBN; vehicle 13±4; liraglutide s.c. 87±15; liraglutide i.p. 117±13, p<0.05 ve-
hicle vs liraglutide i.p., s.c.). Immunofluorescence was used to characterise 
liraglutide activated neurons. In the AP, liraglutide induced c-Fos in tyro-
sine-hydroxylase (TH)-ir neurons (vehicle 0±0; liraglutide s.c. 12.4±1.7; li-
raglutide i.p. 27.5±4%, p<0.05 vehicle vs liraglutide s.c., i.p.), whereas neither 
GLP-1-ir nor TH-ir neurons were activated in the NTS. In the PVN, liraglu-
tide induced c-Fos in corticotrophin-releasing hormone-ir (CRH) neurons 
(vehicle 2±1; liraglutide s.c. 16±5; liraglutide i.p. 79±7%, p<0.05 vehicle vs 
liraglutide s.c., i.p.).
Conclusion: The data demonstrate that liraglutide activates the functional 
continuum involved in appetite regulation extending from the AP/NTS com-
plex via the lPBN and amygdala to the PVN.
Supported by: Novo Nordisk
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Extended, 3-year, exenatide therapy shows sustainable effects on beta cell 
disposition index in metformin treated patients with type 2 diabetes
M.C. Bunck1, A. Corner2, B. Eliasson3, R.J. Heine1,4, R.M. Shaginian5,  
M.-R. Taskinen2, U. Smith3, H. Yki-Järvinen2, M. Diamant1; 
1Department of Endocrinology / Diabetes Center, VU university medical 
center, Amsterdam, Netherlands, 2Department of Medicine, Helsinki 
University Medical Center, Finland, 3Lundberg Laboratory for Diabetes 
Research, Sahlgrenska University Hospital, Goteborg, Sweden, 4Eli Lilly and 
Company, Indianapolis, USA, 5Eli Lilly and Company, Houten, Netherlands.
Background and aims: We have previously showed that exenatide improved 
beta-cell function after 1-year treatment, relative to insulin glargine, with a 
similar glucose lowering effect. However, this effect was not sustained after 
a 4-week off-drug period. Here we report the effects on beta-cell function, 
presented relative to whole body insulin sensitivity as the disposition index, 
after the 2-year extension study.
Materials and methods: Sixty-nine metformin-treated patients with type 2 
diabetes (mean±SD: age 59±8 y; HbA1c 7.5±0.8%; BMI 31±4 kg/m2; body 
weight 91.5±13.1 kg) were randomised to exenatide (n=36; 5µg BID for 4 
weeks, 10µg BID with treat to HbA1c target ≤7%, maximum dose 20µg TID 
thereafter) or insulin glargine (n=33; treat to fasting plasma glucose (FPG) 
target <5.6 mmol/L). Forty-seven patients entered the 2-year open-label ex-
tension study of which 36 completed (exenatide n=16; insulin glargine n=20). 
Insulin sensitivity (M) and beta-cell function was measured by a combined 
euglycaemic-hyperinsulinaemic and arginine-stimulated hyperglycaemic 
clamp at baseline, and after a 4-week off-drug period, following the total 3-
year treatment period. 1st-phase glucose stimulated C-peptide secretion was 
adjusted for the insulin-stimulated whole body glucose uptake (M) and pre-
sented as the disposition index (DI; AIRgluc*M).
Results: Both therapies reduced HbA1C similarly: by -0.7±0.3%, and -
0.5±0.2% to 6.6±0.2% and 6.9±0.2% for exenatide and insulin glargine, re-
spectively, after 3-years of treatment (P=0.186). Exenatide significantly re-
duced body weight compared to insulin glargine (between group difference: -
7.9±1.8 kg; P<0.001), whereas treat to fasting plasma glucose insulin glargine 
more effectively lowered FPG (between group difference: -1.8±0.4 mmol/L; 
P<0.001). After the 4-week off-drug period, exenatide increased M by 39% 
(p=0.006) while insulin glargine had no effect on M (p=0.647). Following the 
4-week off-drug period the DI was, compared to pre-treatment, higher with 
exenatide, and reduced with insulin glargine (+1.43±0.78 and -0.99±0.65, 
respectively; P=0.028). These findings are in contrast to the results follow-
ing the 1-year treatment period, after which the DI did not show a sustained 
effect after the 4-week washout with either exenatide or insulin glargine. 2nd-
phase glucose-stimulated, and combined glucose and arginine-stimulated C-
peptide secretion did not show any significant between-group differences.
Conclusion: Exenatide and insulin glargine sustained HbA1C over 3-year 
treatment, while exenatide significantly reduced, and insulin glargine in-
creased body weight. 1st-phase insulin secretion was sustained following a 
4-week off-drug period, after 3-year treatment with Ex. This improvement 
cannot only be explained by glucose lowering.
Supported by: Amylin Pharmaceuticals, Inc. & Eli Lilly and Company
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Molecular mechanism of DPP-IV inhibitor vildagliptin effect on 
pancreatic beta cell preservation in diabetic mice: evidence for anti-
oxidative and ER stress mechanism
S. Hamamoto, Y. Kanda, M. Shimoda, K. Tawaramoto, M. Hashiramoto,  
K. Kaku; 
Diabetes and Endocrine Division, Kawasaki Medical School, Kurashiki, 
Japan.
Background and aims: DPP-IV inhibitors are known to produce several bio-
logical actions including glucose-dependent insulin secretion, increase pan-
creatic beta cell mass by stimulating cell proliferation and inhibit apoptosis. 
The aim of this study is to assess the molecular mechanism for preventive 
effect of vildagliptin on beta cell damage in diabetic animal model.
Materials and methods: Eight week-old male KK-Ay/TaJcl mice received 
vildagliptin (VILDA) (50mg/kg once daily orally) or vehicle (control) for 4 
weeks (n=5). Body weight (BW), food intake, fasted blood glucose (FBG), 
fasted insulin (FIRI), TG and NEFA were measured at 8, 10 and 12 weeks of 
age. Intraperitoneal insulin tolerance test (ipITT:1 IU/kg BW), oral glucose 
tolerance test (OGTT:1 g/kg BW) and glucose stimulated insulin secretion 
(GSIS) from isolated pancreatic islet was performed at 12 weeks. The beta cell 
mass and cell proliferation were assessed by histological analysis including 
PCNA immunostaining of the islet tissue. Gene expressions specific for the 
core area of pancreatic islet were analyzed by Laser Capture Microdissection 
method and real time RT-PCR. Primer pairs encoding genes associated with 
pancreatic hormones, cell proliferation, apoptosis, cell cycle, and oxidative/ 
endoplasmic reticulum (ER) stress were prepared, and real-time RT-PCR 
with Sybr Green was applied.
Results: BW, food intake, FBG, FIRI, HOMA-IR, TG, NEFA, and ipITT were 
not different between the control and VILDA-treated groups. On the other 
hand, VILDA ameliorated glucose tolerance analyzed by OGTT, and a sig-
nificantly higher plasma insulin response to glucose challenge was observed 
in VILDA group compared with the control group. Furthermore, GSIS with 
16.7mM glucose was more significantly facilitated in VILDA group than in 
the control (2.24±0.72 vs. 1.57±0.42 ng/ml/islet, p < 0.05). The pancreatic 
beta cell mass was greater in VILDA-treated mice than in the control mice 
(5.0±0.9 vs. 2.9±0.9mg, p < 0.01, n=5 for each). The mRNA levels of Nkx2.2, 
Pax6, ERK1 and CyclinD associated with cell differentiation/proliferation 
were significantly higher in VILDA-treated mice than in the control mice. 
CAD and caspase3 mRNA levels were significantly decreased by VILDA 
treatment. VILDA significantly down-regulated XBP-1 gene expression re-
lated with ER stress, and up-regulated GSHPx gene expression related with 
anti-oxidative stress. The PCNA-positive cell ratio in the islet was increased 
significantly by VILDA treatment. On the other hand, VILDA decreased the 
4-HNE-positive cell ratio. Morphometric results for PCNA and 4HNE ob-
served corresponded with the data obtained in gene expression analysis.
Conclusion: Vildagliptin preserves the pancreatic beta cell function and cell 
mass in diabetic KK-Ay mice. The present results suggest that the effect of 
vildagliptin is resulted not only from the direct action on the cell kinetics 
regulation but also from the suppression of oxidative and/or ER stress mecha-
nism.
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Restoration of insulin release with lixisenatide in patients with type 2 
diabetes
R.H.A. Becker1, P. Ruus1, Y.-H. Liu1, C. Kapitza2; 
1Sanofi-Aventis Deutschland GmbH, Frankfurt/Main, 2Profil Institut für 
Stoffwechselforschung GmbH, Neuss, Germany.
Background and aims: Glucagon-like peptide (GLP-1) receptor agonists 
improve post-meal blood glucose levels in subjects with type 2 diabetes by 
restoring insulin release. We assessed the pharmacokinetics and pharmaco-
dynamics of lixisenatide, a new GLP-1 receptor agonist.
Materials and methods: A two-period, two-sequence, single-centre, single-
dose, cross-over study was performed. Twenty subjects with type 2 diabe-
tes (treated with metformin or diet and exercise alone) with mean HbA1c of 
6.8% (range = 6.2-8.0%) and mean BMI of 30 kg/m² (range = 26-35 kg/m²) 
received single s.c. doses of 20 μg lixisenatide once-daily (intended therapeu-
tic dose) or placebo injection 2 h prior to an intravenous glucose challenge 
(IVG; 0.3 g/kg body weight over 30 s). Baseline blood glucose was lowered 
to 5.5 mmol/L by fasting or insulin infusion (4 subjects) 30 min before the 
IVG. First (AUC0-10min) and second (AUC10-120min) phase insulin secretion, plus 
C-peptide and glucagon release and glucose disposition rate (Kglu) were as-
sessed and lixisenatide exposure was measured over 12 h.
Results: The maximum lixisenatide plasma concentration (Cmax) was 84 pg/
mL (coefficient of variation [CV], 25%), with a mean time to maximum con-
centration of 2 h (range 1-4 h). Lixisenatide 20 μg s.c. enhanced first-phase 
insulin secretion to IVG by 2.8-fold relative to placebo (90% CI 2.5-3.1), and 
second-phase secretion by 1.6-fold (90% CI 1.4-1.7) (Figure); correspond-
ing changes were seen in insulin (1st-phase: 6.6-fold; 90% CI 5.0-8.7 and 2nd-
phase: 3.0-fold; 90% CI 2.7-3.3) and C-peptide concentrations and glucose 
disposition (accelerated by 1.8-fold; 90% CI 1.6-1.9). Lixisenatide had little 
effect on basal insulin and glucose levels and did not affect glucagon suppres-
sion. Mild-to-moderate gastrointestinal symptoms (e.g. nausea and vomit-
ing) were reported by two subjects following lixisenatide administration and 
one following placebo.
Conclusion: Lixisenatide 20 μg s.c. restored insulin release and accelerated 
glucose disposition following an IVG in subjects with type 2 diabetes, con-
firming this action as the basis of its control of postprandial blood glucose 
levels.
Supported by: sanofi-aventis
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Liraglutide improves two indicators of beta cell function - HOMA-B and 
proinsulin:insulin ratio - in a meta-analysis of 6 clinical trials
D.R. Matthews1, T. Vilsbøll2, J.-P. Courrèges3, M. Zychma4, A. Falahati5,  
B.W.  Bode6; 
1Oxford Centre for Diabetes, Endocrinology & Metabolism, The Churchill 
Hospital, Oxford, United Kingdom, 2Diabetes Research Division, Copenhagen, 
Denmark, 3Diabetology and Vascular Disease Unit, General Hospital, 
Narbonne, France, 4Novo Nordisk Pharma Sp.z.o.o., Warszawa, Poland, 5Novo 
Nordisk, Søborg, Denmark, 6Atlanta Diabetes Associates, Atlanta, USA.
Background and aims: The once-daily human GLP-1 analogue liraglutide re-
duced HbA1c by 1.0-1.5% during the phase 3 development programme. A meta-
analysis of 6 large phase 3 trials was conducted to investigate if HbA1c reductions 
were associated with improvement in HOMA-B, a surrogate marker of beta-cell 
function based on fasting insulin and glucose levels, and proinsulin-to-insulin 
ratio. Failing beta-cells secrete an abnormally high amount of proinsulin relative 
to insulin, reflecting incomplete or defective proinsulin processing.
Materials and methods: The effect of 26 weeks of treatment with liraglutide 
(1.2 mg/1.8 mg OD), rosiglitazone (4 mg OD), glimepiride (4 mg/8 mg OD), 
exenatide (10 µg BID) or placebo on HOMA-B and proinsulin:insulin ratio 
was examined using an ANCOVA model adjusted for treatment, trial, prior 
treatment and baseline HOMA-B and proinsulin:insulin ratio.
Results: A significant increase from baseline in HOMA-B was observed with 
liraglutide and with glimepiride (both p<0.0001). The increase in HOMA-B 
was significantly greater with liraglutide 1.8 mg vs. exenatide, rosiglitazone 
and placebo (Table). Significant decreases from baseline in proinsulin:insulin 
ratio were observed with liraglutide (p<0.0001) and exenatide (p<0.001). De-
creases in proinsulin:insulin ratio were significantly greater with liraglutide 
vs. rosiglitazone, glimepiride and placebo (Table). Liraglutide and glimepir-
ide increased HOMA-B to a similar extent. However, these two agents can 
be differentiated on the basis of their effects on proinsulin:insulin ratio. Li-
raglutide stimulates insulin secretion in a glucose dependent manner while 
glimepiride produces a continuous, glucose-independent signal, potentially 
resulting in constant stress on beta-cells.
Conclusion: Liraglutide improves HOMA-B and proinsulin:insulin ratio, two 
indicators of beta-cell function. Since beta-cell function is a primary deter-
minant of type 2 diabetes progression, it is possible that liraglutide may alter 
the decline in beta-cell function seen in patients with this disease. However, 
long-term studies will be necessary to confirm this effect.
Mean change in HOMA-B and P/IR from baseline to week 26
Treatment Δ HOMA-B (%) Δ P/IR
Liraglutide 1.8 mg OD (n=1363) 35.1 -0.08
Liraglutide 1.2 mg OD (n=896) 31.7 -0.08
Rosiglitazone 4 mg OD (n=231) 9.5** -0.01*,††
Glimepiride 2-4 mg OD (n=490) 31.8 -0.02*,††
Exenatide 10 μg BID (n=231) 5.7* -0.10
Placebo (n=524) 7.4*,† 0.03*,†
*p<0.0001 and **p<0.05 vs. liraglutide 1.8 mg; †p<0.0001 and ††p<0.001 vs. 
liraglutide 1.2 mg
Supported by: Novo Nordisk
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Comparison between exenatide and glimepiride on metabolic control 
and on insulin resistance in type 2 diabetic patients with metformin 
therapy
S.A.T. Salvadeo1, P. Maffioli1, I. Ferrari1, F. Querci2, L. Ciccarelli3,  
M. Piccinni4, A. D’Angelo1, A.F.G. Cicero5, G. Derosa1; 
1Internal Medicine and Therapeutics, University of Pavia, IRCCS Policlinico 
S.Matteo, 2Ospedale Pesenti Fenaroli, Bergamo, 3Department of Internal 
Medicine, RSA Don Leone Porta, Milano, 4Department of Clinical 
Medicine, Ospedale della Carità, Cremona, 5Clinical Medicine and Applied 
Biotechnology Department, University of Bologna, Italy.
Background and aims: Our study aimed to compare the effect of Exenatide 
(Ex) vs Glimepiride (Gl) on glycemic control and on insulin resistance re-
lated-parameters in type 2 diabetic patients taking metformin.
Materials and methods: One hundred and thirty type 2 diabetic patients 
with uncontrolled type 2 diabetes [glycated hemoglobin (HbA1c > 8 %)] were 
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randomised to Ex 5 μg b.i.d. or Gl 1.0 mg t.i.d. and titrated after 1 month 
to Ex 10 μg b.i.d. or Gl 2 mg t.i.d. They were resulted intolerant to metfor-
min at maximum dosage (3000 mg/day) and were taking various different 
doses (1000-2000 mg/day). The treatment period had a 12 months duration. 
We evaluated body mass index (BMI), HbA1c, fasting plasma glucose (FPG), 
post-prandial glucose (PPG), fasting plasma insulin (FPI), Homa index and 
collected plasma samples of adiponectin (ADN), and tumor necrosis factor-α 
(TNF-α) at baseline, and after 12 months.
Results: One hundred and eleven patients completed the study (57 in Ex and 
54 in Gl group). BMI was significantly reduced by Ex, but not by Gl (from 
28.4±1.3 to 26.6±0.9 Kg/m2, p< 0.05, and from 28.5±1.4 to 28.2±1.3 Kg/m2, 
ns vs baseline, p< 0.05 vs Ex, respectively). HbA1c was decreased by 1.2±0.06 
% (p< 0.01), and by 1.4±0.05 % (p< 0.01); FPG was reduced by 27±6 mg/dl 
(p< 0.01), and by 28±7 mg/dl (p< 0.01); PPG was decreased by 45±8 mg/dl 
(p< 0.01), and by 46±9 mg/dl (p< 0.01), in Ex and Gl group, respectively. FPI 
was decreased by 5.0±0.6 μU/ml (p< 0.05) in Ex group, and was increased 
by 1.2±0.09 μU/ml in Gl group (ns vs baseline, p< 0.05 vs Ex). Homa index 
was reduced by 2.7±0.8 (p< 0.05), and by 0.7±0.1 (ns vs baseline, p< 0.05 vs 
Ex), in Ex and Gl group, respectively. ADN was increased by 1.5±0.4 μg/ml 
(p< 0.05), and by 0.8±0.03 μg/ml (ns vs baseline, p< 0.05 vs Ex), in Ex and Gl 
group, respectively; TNF-α was reduced by 0.7±0.04 ng/ml (p< 0.05), and by 
0.2±0.01 ng/ml (ns vs baseline, p< 0.05 vs Ex), in Ex and Gl group, respec-
tively. There was a significant correlation between BMI value decrease and 
ADN increase (r= -0.57, p< 0.01), and TNF-α decrease (r= 0.61, p< 0.01).
Conclusion: Both Ex and Gl improved diabetes control when added to met-
formin, but only Ex improved insulin resistance related-parameters. The 
ADN increase, and TNF-α reduction seems to be related to weight loss.
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Treatment of type 1 diabetic patients with residual beta cell function 
with the once-daily glucagon-like peptide-1 analogue liraglutide 
U. Kielgast1, J.J. Holst2, S. Madsbad1; 
1Department of Endocrinology, Hvidovre University Hospital, Copenhagen, 
2Department of Biomedical Sciences, University of Copenhagen, the Panum 
Institute, Copenhagen, Denmark.
Background and aims: Information about the effects of treatment with GLP-
1 receptor analogues in people with type 1 diabetes is sparse. Therefore, we 
investigated the effect of the once-daily GLP-1 analogue liraglutide on daily 
insulin dose, 24-hour glucose profile, glycaemic control, weight change and 
side effects in type 1 diabetic patients with residual beta cell function.
Materials and methods: Eight type 1 diabetic patients with HbA1c 6.6 ± 0.3 %, 
male/female ratio 7/1, age 27 ± 1.6 yr, BMI 24.3 ± 1.0 kg x m-2, diabetes dura-
tion 3.7 ± 0.8 yr, and with plasma C-peptide concentration after 1 mg glucagon 
of 472 ± 107 pmol/l (range: 79-940) performed at a blood glucose of 15 mM, 
were treated for four weeks with liraglutide (0.6 mg for one week hereafter 1.2 
mg daily if tolerated). All patients were treated with basal/bolus insulin therapy. 
Before initiation of liraglutide treatment, glycaemic control was optimized, and 
throughout the study patients were encouraged to maintain the best possible 
glycaemic control taking the risk of hypoglycaemia into consideration. Gly-
caemic control was evaluated during three days before start of liraglutide and 
the last three days of treatment through HbA1c, fructosamin and with patient 
blinded Guardian monitoring with logbook of meals and physical activity.
Results: Daily dose of insulin was significantly reduced from 0.53 ± 0.1 to 0.33 
± 0.1 U/kg/day, p< 0.001 during treatment with liraglutide despite no change 
in mean blood glucose, which was 6.1 ± 0.3 and 6.3 ± 0.4 mmol/l before and 
during the last three days of treatment, p=NS. Two patients completely discon-
tinued their insulin treatment without loss of glycaemic control. The percent-
age of plasma glucose measurements below 3.9 mmol/l significantly decreased 
from 12.0 ± 4 to 5.1 ± 2, p=0.03. HbA1c decreased during treatment from 6.6 
± 0.3 to 6.2 ± 0.2, p=0.05 whereas no change was observed for fructosamin. All 
patients lost weight with a mean of -2.6 kg (range -1.5 to -3.6). Six patients had 
minor nausea, which was mostly transient, two patients experienced vomiting 
and four patients complained of abdominal pain and distension. Two patients 
tolerated only 0.9 mg liraglutide daily because of side effects.
Conclusion: Treatment with liraglutide in people with type 1 diabetes with 
residual beta cell function, may reduce the daily dose of insulin with im-
proved or unaltered glycaemic control evaluated from fructosamin, HbA1c 
and mean glucose level evaluated during 3 days of Guardian monitoring. In 
type 1 diabetic patients with considerable residual insulin secretion, insulin 
treatment may be discontinued without impairment of glycaemic control. All 
patients lost weight during liraglutide treatment. Gastrointestinal side effects 
occurred frequently, but were mostly transient.
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Increased collagen production of human hepatic stellate cells (Ito Cells) 
induced by Exendin-4 (Exenatide) treatment
G. Firneisz1, K. Baghy2, K. Kiss1, T. Varga1, G. Nagy1, I. Kovalszky2,  
A. Somogyi1; 
12nd Department of Medicine, 21st Institute of Pathology and Experimental 
Cancer Research, Semmelweis University, Budapest, Hungary.
Background and aims: There are precautions about the potential for acute 
pancreatitis in patients taking Exenatide and these concerns were confirmed 
in experimental animal studies. Provided that a proportion of active gluca-
gon-like peptide-1 (GLP-1) hormone also reaches the hepatic portal tract 
via the superior mesenteric vein after release form the small intestine we 
hypothesized that a hepatic effect should also exist even under physiologic 
conditions. We studied the potential effect of Exenatide on extracellular ma-
trix (ECM) production of hepatic stellate cells (HSCs) that are thought to 
primarily produce the ECM proteins in the liver. These cells with fibrogenic 
potential were treated and co-treated with Exenatide and TGF- β1.
Materials and methods: Immortalized human HSC LX-2 cells were cultured 
at 37 °C atmosphere containing 5% CO2 with DMEM containing 10% FBS. 
Passages were made after 3-4 days using trypsin-EDTA. Cells were then cul-
tured for 48 hours in FBS-free media that in the treated groups either con-
tained Exenatide (cc=200 pg/mL) or TGF-β1 (cc=2ng/mL) or both (co- treat-
ment). After mRNA isolation and RT-PCR Taq-Man real-time PCR assays 
were run in ABI 7000 System and human 18S rRNA was used for normaliza-
tion. To evaluate the ECM production of HSCs ELISA assay was performed 
from the culture media using rabbit polyclonal primary antibodies against 
collagen-I and collagen-III. ECM protein synthesis was also assessed using 
Western Blots. Immun-cytochemistry (αSmooth Muscle Actin) was used to 
prove the activation of HSCs. All treatments were repeated 3 times and all 
runs were run in duplicates. Two-tailed T-test was used for statistical analy-
sis.
Results: ECM protein production results measured by ELISA in the cul-
ture media are indicated in the following table (*= significantly increased 
compared to untreated controls, * * = significantly increased compared to 
TGF- β1 treatment). The collagen-III production of HSCs after Exendin-4 
treatment was also assessed by Western blots that confirmed the ELISA re-
sults (collagen-I production was more preponderant after TGF-β1 treatment 
on Western Blot compared to ELISA) . The alterations of mRNA expression 
levels were reflecting the changes observed at protein level (upregulation) 
although to a less remarkable extent than the degree of change in collagen 
production.
Conclusion: These data confirm the existence of an incretin mediated en-
tero-hepatic axis. Specifically we intended to uncover the distinct nature of 
the GLP-1 mimetic Exendin-4 and its effect on Hepatic Stellate Cells with 
fibrogenic potential. The surprising induction of human HSC collagen-III 
production by Exendin-4 treatment established a novel path of regulating 
the ECM production in the liver and urges further clinical trials not only to 
clarify the pancreatic effects but also with hepatic fibrosis and chronic liver 
disease endpoints.
Supported by: Hungarian Diabetes Association
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Liraglutide protects against traumatic brain injury in a mouse model
B. Della Valle1,2, J. Kurtzhals2, M. Penkowa1; 
1Panum Institute, Copenhagen, 2Centre for Medical Parasitology, Dept of 
Clinical Microbiology, Copenhagen University Hospital, Denmark.
Background and aims: Glucagon-like peptide-1 (GLP-1) analogues are emerg-
ing as an important drug class for the treatment of diabetes because they not only 
lower blood glucose but also body weight. Recently, several articles have pointed to 
a protective effect of GLP-1 or analogues on the brain and potential efficacy in ani-
mal models of stroke, Alzheimer’s, Huntington’s and Parkinson’s disease. However, 
in some cases the compounds were dosed by the intracerebroventricular route. We 
here report the effect of liraglutide treatment during traumatic brain injury (TBI) 
in a mouse model. Liraglutide is a once-daily human GLP-1 analogue, the first to 
give 24 hours’ coverage in patients. Since the effects in the brain are mediated at 
least in part by a protective mechanism, 24-hour coverage could be important.
Materials and methods: Liraglutide was injected s.c. (0.4 mg/kg) twice daily 
before and after mice received a cryo-induced cortical lesion until 7 days post-
lesion. Control mice received a match volume of s.c. saline. Mice were proc-
essed for immunohistochemistry.
Results: When compared to the saline-treated controls, liraglutide-treated mice 
had less inflammation as reflected by a decrease in lectin + microglial activation. 
In liraglutide-treated mice 8-oxoguanine DNA adduct formation was reduced 
and largely specific to endothelial cells, whereas in saline-treated mice adducts 
were widespread through the lesion and present primarily in neurons, microglia 
and endothelial cells. Liraglutide improved tissue-healing response in TBI mice 
through concerted, lesion-directed astrogliosis, increased migration into the le-
sion and meninges formation, and improved blood-brain barrier reconstitution 
through reduced albumin leakage and increased perivascular astroglia.
Conclusion: Our data demonstrate that the GLP-1 analogue liraglutide promotes 
an anti-inflammatory, antioxidant state in a murine traumatic brain injury model 
and improves tissue healing and blood-brain barrier reconstitution. These find-
ings warrant further investigation into the mechanisms of action and future stud-
ies will explore the potential of liraglutide in protecting against neuropathology.
Supported by: Novo Nordisk
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The GLP-1 analogue liraglutide does not induce pancreatitis in mice, rats 
or monkeys
A.-M. Mølck, L. Madsen, N.C. Berg Nyborg, L. Bjerre Knudsen; 
Novo Nordisk, Måløv, Denmark.
Background and aims: GLP-1 receptor agonists may be associated with an in-
creased risk of pancreatitis in patients with type 2 diabetes. However the low 
overall incidence of pancreatitis and a 3-fold increase in pancreatitis rates in dia-
betes patients makes it difficult to assess if the association is true. Phase 3 studies 
with liraglutide in 4400 type 2 diabetes patients did not demonstrate a clear asso-
ciation between diabetes treatment and pancreatitis. A mechanism linking GLP-
1 receptor activation to pancreatic inflammation has not been forthcoming.
Materials and methods: We report pancreas safety data in mice, rats and 
monkeys during the non-clinical development programme for liraglutide. 
Pancreases from mice, rats and cynomolgus monkeys were examined mac-
ro- and microscopically using state-of-the-art diagnostic criteria. Mice and 
rats were dosed for 2 years, monkeys 87 weeks (n=66-79/sex/group for mice, 
n=50 for rats, n=5 for monkeys; doses up to 3, 0.75, and 5 mg/kg/day, respec-
tively in mice, rats and monkeys). Proliferation was measured using PCNA 
staining in rats after 26 weeks. The evaluation in monkeys included detection 
of signs of pancreatic intraepithelial neoplasia in the ductal epithelium.
Results: There were no macroscopic observations of pancreatitis in mice, rats or 
monkeys. After 2 years treatment, 8 out of 359 male (3 in the control group and 2, 
1, 1, 1 in the different liraglutide groups) and 12 out of 354 female mice (0 in the 
control group and 3, 3, 3, 3 in the liraglutide groups) were diagnosed microscopi-
cally with pancreatitis based on histological criteria of inflammatory infiltrates with 
or without fibrosis and/or loss of exocrine tissue. Pancreatitis was not the cause of 
death in any of these animals and pancreatitis is seen spontaneously in mice. There 
were no cases of pancreatitis in 400 male and female rats, after 2 years dosing. Cell 
proliferation in the exocrine pancreas was not increased in rats dosed with liraglu-
tide for 26 weeks. Neither pancreatitis nor pre-neoplastic proliferative lesions were 
found in monkeys dosed for 87 weeks, resulting in plasma liraglutide exposure 60-
fold higher than that observed in humans at the maximal clinical dose.
Conclusion: In conclusion, liraglutide does not induce pancreatitis in rats or 
mice dosed for 2 years or in non-human primates dosed for 87 weeks.
Supported by: Novo Nordisk
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The incidence of antibody formation and the levels of antibodies are 
lower with liraglutide than exenatide in a head-to-head comparison
J.B. Buse1, E. Montanya2, G. Sesti3, M. Düring4, H. Solberg4, J. Rosenstock5,  
M. Nauck6, J.J. Holst7; 
1University of North Carolina School of Medicine, Chapel Hill, USA, 
2IDIBELL-Hospital Universitari Bellvitge, Barcelona, Spain, 3University 
Magna Graecia, Catanzaro, Italy, 4Novo Nordisk, Bagsvaerd, Denmark, 
5Dallas Diabetes and Endocrine Center, Dallas, USA, 6Diabeteszentrum, Bad 
Lauterberg im Harz, Germany, 7Panum Instituttet, Copenhagen, Denmark.
Background and aims: Antibody formation to therapeutic proteins can po-
tentially affect pharmacokinetics, trigger adverse events, and/or diminish 
clinical response. Liraglutide (LIRA), a human GLP-1 analog, and exenatide 
(EXE), synthetic exendin-4 (a peptide originally identified in Gila monster 
saliva), are GLP-1 receptor agonists indicated for treatment of T2D with 97% 
and 53% homology to human GLP-1, respectively. Our objective was to de-
tect and characterize antibodies to LIRA and EXE.
Materials and methods: LIRA and EXE antibodies were measured at wks 
0, 12, 26, 40, 41, 78 and 79 in the LEAD-6 trial, which had a 26-wk head-to-
head comparison of LIRA (1.8mg, once daily) and EXE (10µg, twice daily 
before meals), both + met and/or SU, followed by a 52-wk extension when 
EXE-treated patients switched to LIRA. Fasting samples collected prior to 
administration of trial products were screened for LIRA or EXE antibodies 
using a validated radioimmunoprecipitation assay. Plasma LIRA (30nM) re-
duced the sensitivity of the assay to detect low LIRA antibody levels from 
25-50ng/mL to ~1500ng/mL. Thus, to avoid assay interference with plasma 
LIRA, LIRA antibody values presented were from end of trial after a ≥5-d 
(~7-9*t1/2) wash-out. Because of its ~100-fold lower plasma concentration 
and short half-life (2.4h), plasma EXE levels were below the level of interfer-
ence with the assay at the time samples were collected; therefore, EXE anti-
bodies could be accurately measured during treatment.
Results: Of 467 patients, 389 (83%) entered the extension and 299 (64%) 
completed 78 wks. After 78 wks on LIRA, 4/154 (2.6%) patients off drug ≥5 
d had low-titer LIRA antibodies (Fig, range: 1.9-5.3% Bound/Total [B/T]). 
HbA1c changes in these 4 patients were 0.4, 0.8, -1.4 and -1.9% at 78 wks. 
After 26 wks on EXE, 113/185 (61%) extension patients had EXE antibodies 
(Fig, range: 2.4-60.2%B/T). EXE patients with high antibody titers (>20%B/
T) had smaller HbA1c reductions (-0.5%, N=47) than those with low titers (-
1.0%, N=132). Patients with the highest EXE antibody titers (>50%B/T, N=6) 
had a -0.1% HbA1c reduction. After switching from EXE to LIRA at wk 26, 
90/181 (50%) and 25/143 (18%) patients had EXE antibodies at wks 40 and 
78, respectively. Persistent EXE antibodies did not appear to affect glycemic 
efficacy with LIRA. Only 4/134 (3.0%) patients who switched from EXE to 
LIRA for 1 yr had LIRA antibodies.
Conclusion: LIRA resulted in a much lower frequency and magnitude of 
antibody formation than EXE. High-titer EXE antibodies affected glycemic 
response to EXE, but after switching to LIRA, persistent EXE antibodies did 
not compromise glycemic response to LIRA.
Supported by: Novo Nordisk
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Antibodies to exenatide did not cross-react with human GLP-1 or 
glucagon or alter the efficacy or safety of exenatide
M. Fineman1, K. Mace2, M. Diamant3, T. Darsow1, B. Cirincione1, T. Booker 
Porter1, M. Trautmann4; 
1Amylin Pharmaceuticals, Inc., San Diego, USA, 2Eli Lilly and Company, 
Indianapolis USA, 3Diabetes Center, VU University Medical Center, 
Amsterdam, Netherlands, 4Eli Lilly and Company, Hamburg, Germany.
Background and aims: Consistent with the immunogenic properties of 
protein and peptide pharmaceuticals, patients may develop antibodies to ex-
enatide with exenatide treatment. This analysis characterised the time course 
and cross-reactivity of antibodies produced against exenatide and effects on 
efficacy and safety.
Materials and methods: Antibody titers, and glycaemic and safety param-
eters were frequently sampled in 12 long-term controlled (2225 ITT patients, 
12-52 wk duration) and 5 long-term uncontrolled (1538 ITT patients, up to 
3 y) exenatide BID (Ex BID) trials and 4 long-term controlled (653 ITT pa-
tients, 26-30 wk) exenatide once weekly (Ex QW) trials.
Results: For Ex BID, mean antibody titers peaked between wks 6 and 16, 
and were reduced by 39.4% and 65.2% at wks 30 and 52, respectively. At wk 
30, 37% of patients were positive for antibodies to exenatide. Of those, 32% 
exhibited low antibody titers (≤125) and a minority (5%) had higher antibody 
titers (≥625). At wk 52, 25% of patients were antibody positive (3% higher 
titer), and at 3 y, 17% were positive (1% higher titer). Lower titer antibodies 
had no effect on efficacy as evidence by comparable reductions in HbA1c at 
endpoint in controlled trials (-1.0% for both antibody-negative and low-titer 
subjects). In the small number of patients with higher titers (5%), the impact 
on efficacy was variable, with the majority experiencing a glycaemic response 
consistent with antibody-negative patients. Similar trends were observed at 
1 and 3 y. Other than injection-site reactions, no increased incidence of ad-
verse events was observed with antibodies to exenatide. Cross-reactivity was 
examined in vitro for a subset of patients (106 antibody-positive patients), 
and treatment-emergent antibodies to exenatide did not cross-react with hu-
man GLP-1 or glucagon. Consistent with Ex BID, patients treated with Ex 
QW experienced titers that peaked between wks 6 and 16 and subsequently 
declined, with 56.8% of patients antibody positive (11.8% higher titer) at wk 
26-30 and similar consequences on efficacy and safety.
Conclusion: Although patients may develop antibodies to exenatide, the tit-
ers peak early in treatment and decline thereafter, and are not predictive of 
safety and efficacy. Importantly, as antibodies to exenatide do not cross-react 
with the glucoregulatory hormones GLP-1 or glucagon and diminish over 
time, long-term clinical consequences are unlikely.
Supported by: Amylin Pharmaceuticals, Inc. and Eli Lilly & Co.
859
Relevance of sample collection method and specificity for the 
quantification of GLP-1-1 in two new ELISA assays for active and total 
GLP-1
A. Carlsson, M. Simonsson, R. Boman, M. Eberlein, P. Lindstedt; 
Research and Development, Mercodia AB, Uppsala, Sweden.
Background and aims: The processing of proglucagon in the pancreas and 
small intestine give rise to a number of different peptides, including GLP-1. 
Intestinal derived GLP-1 (7-37) and (7-36)amide (often called active GLP-1) 
are rapidly degraded by the enzyme dipeptidyl peptidase-4 (DPP-IV) to GLP-
1 (9-37) and (9-36)amide, resulting in very low amount of active GLP-1 in the 
circulation. The immunological determination of GLP-1 in a plasma sample 
is complicated by the potential cross reaction of the various proglucagon-
derived peptides with antibodies raised against GLP-1 and the low amounts 
and rapid degradation of active GLP-1. In this study we investigated different 
sample collection methods including different inhibitors of the DPP-4 en-
zyme in two novel ELISA assays for GLP-1. The specificity for different GLP-1 
isoforms were also determined.
Materials and methods: The crossreaction of GLP-1 (7-36)amide, (1-
36)amide, (1-37), (7-37) and (9-36)amide were analyzed in two newly devel-
oped GLP-1 ELISAs for active and total GLP-1. Blood samples were collected 
from 9 healthy donors in 4 different EDTA tubes at the same occasion. Tube 
types 1 and 2 were precoated with lyophilized inhibitors (1 = DPP-IV inhibi-
tors and 2 = A cocktail of protease, esterase and DPP-IV inhibitors). Tube 3 
contained no DPP-IV inhibitor. A liquid DPP-IV inhibitor was added imme-
diately after blood collection to tube 4. Plasma was prepared and the 4 sample 
types were then analyzed in the active and total GLP-1 ELISA assays.
Results: The GLP-1 active ELISA is specific for GLP-1 (7-36)amide (100% 
crossreaction) and do not detect GLP-1 (7-37), (1-37) or (9-36) (<0.4% cross-
reaction). The crossreaction for GLP-1 (1-36)amide was 3.5%. The GLP-1 
total ELISA is specific for GLP-1 (1-36)amide, (7-36)amide and (9-36)amide 
but do not detect non-amidated forms of GLP-1. When the 4 different sample 
types were analyzed in the GLP-1 active ELISA, tube 3 (EDTA only) showed 
a significantly lower content of GLP-1. There were no differences in GLP-1 
content between the different inhibitors used in tubes 1, 2 and 4. (mean±SEM 
2.1±0.3 pM for tube 3 vs. 4.5±0.7 pmol for tube 1, 4.6±0.7 pM for tube 2 and 
4.5±0.8 pM for tube 4, p < 0.002, ANOVA). When samples were analyzed 
for total GLP-1, tube 2 contained somewhat higher amounts of total GLP-1 
compared to tubes 1, 3 and 4 (mean±SEM 13.7±1.7 pM for tube 2 vs. 12.6±1.6 
pmol for tube 1, 12.8±1.6 pM for tube 3 and 12.2±1.5 pM for tube 4, p < 
0.001, ANOVA).
Conclusion: The ELISA for active GLP-1 is specific for GLP-1 (7-36)amide. 
The total GLP-1 ELISA was shown to be specific for all amidated isoforms 
of GLP-1. For detection of active GLP-1, it is important to include a DPP-
IV inhibitor to prevent degradation. Both lyophilized and liquid DPP-IV 
inhibitors gave comparable results in preserving active GLP-1 in a plasma 
sample. DPP-IV inhibition does not seem to be essential for preservation of 
total amidated forms of GLP-1, but addition of protease and esterase inhibi-
tors seem to induce some protection from degradation of total GLP-1 in a 
plasma sample.
Supported by: Mercodia AB
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Liraglutide: short-lived effect on gastric emptying - long-lasting effects 
on body-weight
L. Bjerre Knudsen1, M. Tang-Christiansen1, J. Jelsing2, N. Vrang2, K. Raun1; 
1Novo Nordisk, Maaloev, 2Gubra, Frederiksberg, Denmark.
Background and aims: Previous studies with the novel once-daily GLP-1 
analogue liraglutide and the GLP-1 mimetic exenatide have revealed pro-
found insulinotrophic and anti-diabetic effects, but also long-term and last-
ing reductions in body-weight. Considering the marked inhibitory effects of 
GLP-1 on gastric emptying (GE), it is tempting to speculate that inhibition of 
GE could play a major role in the body-weight-lowering effects of liraglutide 
and exenatide. However, data for liraglutide indicate that the marked inhibi-
tion of GE diminishes over time, and thus cannot be the sole mechanism for 
body weight lowering.
Materials and methods: The present study was designed to test the effect 
of acute and chronic exposure of liraglutide and exenatide on GE, food in-
take and body weight. Based on a series of dose-finding studies we identi-
fied doses of exenatide (0.01 mg/kg) and liraglutide (0.2 mg/kg) with similar 
anorectic effects. GE was assessed using a standard acetaminophen release 
assay. Acetaminophen (40 mg/kg) was administered by gavage 30 min after 
an intravenous dose of exenatide and liraglutide. Rats were subsequently sub-
cutaneously dosed bi-daily for 14 days after which GE was assessed again 30 
min following the final sc injection of compounds.
Results: While both compounds exerted robust acute reductions on GE (area 
under the curve (µg/ml x min); vehicle 8520±290, liraglutide 1088±214, ex-
enatide 1488±315; p<0.0001 vehicle vs liraglutide, exenatide) the effects on 
GE almost disappeared following 14 days dosing with liraglutide (vehicle 
9362±469, liraglutide 8135±380; p=0.022). In contrast, exenatide treated rats 
still displayed a profound reduction in GE at the 14-day time-point (exenatide 
591±137 µg/ml x min; p<0.001). Both compounds exerted similar chronic ef-
fects on body-weight (vehicle 350±4 g, liraglutide 318±5 g, exenatide 303±8; 
p<0.0001 vehicle vs liraglutide, exenatide).
Conclusion: The data suggest that the ‘gastric inhibitory’ GLP-1 receptors 
in rats are subject to desensitisation only during full 24 h exposure as ob-
tained by liraglutide, whereas the GLP-1 receptors mediating the effects on 
body-weight are not. These data indicate that regulation of appetite signals 
in the brain, and not gastric emptying, is the main mechanism for liraglutide 
induced weight loss.
Supported by: Novo Nordisk
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Safety and efficacy of using exenatide in combination with insulin in 
the Association of British Clinical Diabetologists (ABCD) nationwide 
exenatide audit
B. Jose1, R.E.J. Ryder1, K.Y. Thong1, S. Thozhukat2, W. Shafiq2,  
ABCD Nationwide Exenatide Audit Contributors; 
1Diabetes, City Hospital, Birmingham, 2Diabetes, Hull Royal Infirmary, 
Hull, United Kingdom.
Background and aims: To learn from experience of exenatide in real clinical 
use in the UK, ABCD began a nationwide audit in December 2008. Though 
exenatide is not licensed for use with insulin, many contributors used the 
combination. We aimed to assess the extent, safety and efficacy of this off 
license usage.
Materials and methods: ABCD website hosted, password protected, on-line 
questionnaire for collection of anonymised patient data. Paired T tests com-
pared baseline and latest weight and HbA1c. Hypoglycaemia reports were 
quantified.
Results: 315 contributors from 126 centres submitted data on 6717 patients 
- mean baseline age 54.9, HbA1c 9.47%, weight 113.83 kg, BMI 38.9 kg/m2, 
55.5% male. Of these 4691 had dated baseline and latest HbA1c; 4506 dated 
baseline and latest weight. Latest HbA1c and weight were at a median (range) 
of 26.3 (6.6-164.1) and 26.1 (6.6-159.0) weeks respectively after exenatide start. 
Insulin treatment status was assessable in 6158/6717 (91.7%) patients. These 
were divided into 5 groups (see table). 2061/6158 (33.5%) were on insulin at 
exenatide start (groups 2-4). 1584/6158 (25.7%) continued on insulin (group 
4). For those with dated baseline and latest data, the response of HbA1c and 
weight in the different insulin treatment groups are shown in the table. It can 
be seen that the addition of exenatide to insulin (group 4) was associated with 
significant falls of HbA1c and weight by 0.43% and 5.8 kg respectively. Insulin 
was stopped at the time of exenatide start in 477/2061 (23.1%) of those on 
insulin. Of these 325/477 (68.1%) substitution of exenatide for insulin proved 
highly effective with HbA1c falling by 0.69% and weight by 9 kg. However in 
152/477 (31.9%) discontinuing insulin at the time of exenatide start resulted 
in significant deterioration in glycaemic control and restart of insulin. In total 
2257/6165 (36.7%) experienced exenatide with insulin at some stage (groups 
3-5). Of these 133/2257 (5.9%) experienced hypoglycaemia prior to insulin 
exenatide combination and 193/2257 (8.6%) after (p=0.001). However severe 
hypoglycaemia was reported in only 1/2257 (0.04%). 201/1584 (12.7%) of the 
patients who continued insulin at exenatide start (group 4) came off insulin 
during exenatide treatment. In this group both HbA1c and weight fell by con-
siderable amounts: mean HbA1c by 0.81% from 9.4 to 8.59% (p<0.001) and 
weight by 10 kg from 116 to 106 kg (p<0.001).
Conclusion:
1. The combination of insulin with exenatide was used in 36.7% (2257/6158) 
patients in the ABCD nationwide exenatide audit.
2. Exenatide with insulin in real clinical use in the UK has been both safe and 
effective with significant reductions in both weight and HbA1c and only one 
reported case of severe hypoglycaemia.
3. Exenatide allowed some patients to be weaned off insulin and this group 
may experience a considerable improvement in glycaemic control and a large 
reduction in weight.
Supported by: Eli Lilly Ltd
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Exenatide vs. insulin aspart in patients with type 2 diabetes: results of a 
randomised, open-label study
B. Gallwitz1, M. Böhmer2, T. Segiet3, A. Mölle4, K. Milek5, B. Becker6,  
K. Helsberg7, H. Petto8, N. Peters7, O. Bachmann7; 
1Department of Medicine IV, University Hospital Tübingen, Germany, 
2Diabetologist, Warburg, Germany, 3Diabetologist, Speyer, Germany, 
4Center of Angiology and Diabetology, Dresden, Germany, 5Diabetologist, 
Hohenmölsen, Germany, 6Diabetologist, Essen, Germany, 7Medical 
Department, Lilly Deutschland GmbH, Bad Homburg, Germany, 8Eli Lilly 
GmbH, Vienna, Austria.
Background and aims: Cardiovascular trials suggest that hypoglycemia 
(hypo) may be underestimated as risk factor for type 2 diabetes (T2DM). This 
26wk, randomized, open label study was designed to test if exenatide (EX) is 
noninferior to insulin aspart (IA) for glycemic control, and associated with a 
lower hypo risk in patients (pts) pretreated with metformin (MET; primary 
objective, hierarchical test). Pts pretreated with MET+sulfonylurea (SU) were 
enrolled into an additional exploratory arm.
Materials and methods: Adults with T2DM (HbA1c 6.5-10.0%, BMI 25-40 
kg/m2) pretreated with MET only (confirmatory) or MET+SU (exploratory) 
were enrolled at 3:1 ratio. Within each arm, pts were randomized 1:1 to EX 
(4wks 5µg, then 10µg BID) or premixed IA 70/30 twice daily (ADA targets). 
For noninferiority of EX, the upper 95% CI limit of the group difference in 
HbA1c change (EX minus IA; MMRM, MET only) needed to be <0.4%. If 
noninferiority was met, hypo rates (pts with ≥1 documented [BG ≤3.9 mmol/
l] or severe hypo up to wk26) were compared by Kaplan-Meier analysis (over-
lap of 95% CIs; all pts treated). Corresponding exploratory analyses were per-
formed for the MET+SU arm.
Results: Of 494 pts randomized (363 MET only; 131 MET+SU), 480 started 
study drug (MET only: EX 181/IA 173; MET+SU: EX 66/IA 60). 341 pts 
completed the study (MET-only: EX 135/IA 137; MET+SU: EX 31/IA 38). 
Compared to pts pretreated with MET only, MET+SU pts were older (mean 
age [95% CI]: 60 [58.2; 61.8] vs 57 [56.0; 58.1] y, and had a longer diabetes 
duration (8 [7.3; 9.4] vs 5 [4.6; 5.5] y). Baseline BMI (32.0 [31.3; 32.8] vs 33.2 
[32.7; 33.6] kg/m2) and HbA1c (7.98 [7.85; 8.12] vs 7.88 [7.79; 7.97] %) were 
similar. MET+SU pts required higher insulin doses (mean final dose [95% 
CI]: 0.43 [0.36; 0.50] vs 0.29 [0.27; 0.32] IU/kg/d). Within each pretreatment 
arm, characteristics of EX and IA groups were similar. For patients pretreated 
with MET only, glycemic control with EX was non-inferior to IA (LS mean 
difference at Wk 26: 0.14; 95% CI [-0.003; +0.291]); EX was associated with 
lower hypo rates (Table; p<0.05). For patients pretreated with MET+SU, gly-
cemic control with EX was inferior (+0.80 [+0.41; +1.19]). The difference in 
hypo rates (Table) was not significant. Body weight decreased with EX and 
increased with IA irrespective of pretreatment (p<0.001).
Conclusion: In pts pretreated with MET only, EX was non-inferior to IA for 
glycemic control and superior for control of hypoglycemia and body weight 
(confirmatory arm). In the small exploratory arm pretreated with MET+SU, 
EX was inferior for glycemic control, this might be due to more advanced 
disease and therefore smaller beta cell reserve. 
Table: Summary of results
Pretreated MET only
(confirmatory)
Pretreated MET+SU
(exploratory)
EX
(N=181)
IA
(N=173)
EX
(N=66)
IA
(N=60)
HbA1c (%)
LSmean change, wk26 -1.0 -1.1 -0.2 -0.9
95% CI
-1.10;
-0.89
-1.24;
-1.04
-0.42;
+0.13
-1.21;
-0.67
Hypo rate(%)
Rate to wk26 8.0 20.5 12.4 27.0
95% CI 4.7;13.4 15.0;27.7 6.4;23.3 16.8;41.8
Body weight (kg)
LSmean change, wk26 -4.1 +1.0 -4.9 +0.5
95% CI -4.5;-3.7 +0.6;+1.4 -5.6;-4.2 -0.2;+1.2
Supported by: Eli Lilly and Company and Amylin Pharmaceuticals, Inc
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Impact of exenatide once weekly and insulin glargine on glucose control 
and cardiovascular risk factors in subjects with type 2 diabetes
M. Diamant1, L.F. Van Gaal2, S.N. Stranks3, J. Northrup4, D. Cao4,  
K. Taylor5, M. Trautmann4; 
1Diabetes Centre, VU University Medical Centre, Amsterdam, Netherlands, 
2Department of Diabetology, Metabolism, and Clinical Nutrition, Antwerp 
University Hospital, Belgium, 3Southern Adelaide Diabetes and Endocrine 
Services, Australia, 4Eli Lilly and Company, Indianapolis, USA, 5Amylin 
Pharmaceuticals, Inc., San Diego, USA.
Background and aims: Many patients failing to achieve blood glucose con-
trol on oral agents have elevated cardiovascular (CV) risk factors including 
hypertension and hyperlipidaemia. We examined glycaemic control (prima-
ry endpoint, change in HbA1c) and select CV risk factors (secondary end-
points) in subjects who were randomised to receive a glucagon-like peptide-1 
receptor agonist (exenatide once weekly [EQW]) or a common starter insulin 
(insulin glargine [IG]) for 26 weeks.
Materials and methods: A 26-week, open-label, multicountry, randomised, 
superiority study compared EQW to IG titrated to target in 456 subjects 
with type 2 diabetes (mean HbA1c 8.3 [SD 1.1] %, fasting glucose 9.8 [2.6] 
mmol/L, weight 90.9 [17.5] kg, diabetes duration 7.9 [6.0] years, endpoint 
insulin dose 31 IU/day). Randomisation was stratified by country and oral 
blood glucose-lowering therapy (70% metformin alone; 30% metformin plus 
sulphonylurea). Changes in concomitant lipid-lowering and antihypertensive 
medications were allowed if deemed necessary by the investigator. Post hoc 
assessments were performed: 1) Change in CV risk factors in subjects with 
abnormal baseline (defined in Table 1) and; 2) Correlations between CV risk 
factors and body weight.
Results: EQW and IG both reduced HbA1c significantly from baseline (-1.5 
[SE 0.05] % vs. -1.3 [0.06] % respectively, treatment difference -0.16 [0.07] %, 
p=0.017). The majority of subjects had elevated lipids and/or blood pressure 
at baseline (Table 1). EQW subjects experienced small but statistically signifi-
cant improvements in total cholesterol and high-sensitivity C-reactive pro-
tein (hsCRP), whereas IG subjects experienced improvements in triglycerides 
and alanine aminotransaminase (ALT). In both treatment groups, greater im-
provements in blood pressure, fasting serum lipids, ALT, and hsCRP were 
observed in subjects with abnormal baseline values. Subjects treated with 
EQW lost body weight while IG subjects gained weight (-2.6 [SE 0.2] kg vs. 
1.4 [0.2] kg, treatment difference -4.0 [0.3] kg, p<0.001). Body weight change 
was weakly correlated with change in ALT (EQW: adjusted r=0.03, p=0.008) 
and SBP (IG: adjusted r=0.02, p=0.03).
Conclusion: In this 26-week study, superior improvements in HbA1c and 
body weight were observed with EQW treatment relative to IG. Treatment 
with either EQW or IG for 26 weeks resulted in small but significant changes 
in different surrogate markers of cardiovascular risk. Subjects with abnor-
mal baseline CV risk factors exhibited the greatest improvements in those 
parameters.
Table 1. 
SBP
mmHg
DBP
mmHg
LDL-C
mmol/L
HDL-C  
mmol/L
TG
mmol/L
TC
mmol/L
ALT
IU/L hsCRP mg/L
Abnormal threshold ≥130 ≥80 >2.6 <1.3/1.0† >1.7 >5.2 >19/30† >3
EQW: Mean BL (overall) 135 (1) 81 (1) 2.7 (0.1) 1.2 (0.0) 2.1 (0.1) 4.8 (0.1) 32 (1) 5 (1)
EQW: Week 26 Δ (overall) -3 (1)* -1 (1) -0.1 (0.1) 0.0 (0.0) -0.1 (0.1) -0.1 (0.1)* -2 (1) -2 (1)*
EQW: Week 26 Δ (BL abnormal) -6 (1)* -5 (1)* -0.2 (0.1)* 0.06 (0.01)* -0.5 (0.1)* -0.4 (0.1)* -7 (2)* -3 (1)*
EQW: BL/EP
(% abnormal) 66/58 58/56 51/44 47/50 54/51 33/32 59/41 46/34
IG: Mean BL (overall) 133 (1) 80 (1) 2.7 (0.1) 1.2 (0.0) 2.1 (0.1) 4.8 (0.1) 31 (1) 5 (1)
IG: Week 26 Δ (overall) -1 (1) -1 (1) 0.0 (0.1) 0.0 (0.0) -0.2 (0.1)* 0.0 (0.1) -2 (1)* -1 (1)
IG: Week 26 Δ (BL abnormal) -5 (1)* -3 (1)* -0.2 (0.1)* 0.04 (0.02)* -0.4 (0.2)* -0.3 (0.1)* -7 (2)* -1 (2)
IG: BL/EP
(% abnormal) 61/61 61/60 51/56 45/45 53/47 34/31 54/49 45/43
* p≤0.05 vs. baseline; BL = baseline; EP = endpoint; † Female/Male; TG = triglycerides; TC = total cholesterol; SBP = 
systolic blood pressure; DBP = diastolic blood pressure; Data are mean (SE).
Supported by: Amylin Pharmaceuticals, Inc. and Eli Lilly and Company
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Taspoglutide added to metformin provides comparable glycaemic 
control as insulin glargine with superior weight loss and less 
hypoglycaemia in type 2 diabetes: The T-emerge 5 Trial
F.J. Ampudia-Blasco1, M. Nauck2, M. Andjelkovic3, E. Horton4,  
M. Boldrin5, R. Balena3; 
1Clinic University Hospital, Valencia, Spain, 2Diabeteszentrum Bad 
Lauterberg, Bad Lauterberg im Harz, Germany, 3F.Hoffmann-La Roche, 
Basel, Switzerland, 4Joslin Diabetes Center, Boston, USA, 5Roche 
Pharmaceuticals, Nutley, USA.
Background and aims: Taspoglutide is a once-weekly (QW) human GLP-1 
analog in Phase 3 development for the management of type 2 diabetes (T2D). 
This trial evaluated a forward strategy replacing sulfonylureas (SU) by taspo-
glutide or insulin glargine in combination with previous metformin (MET) 
therapy.
Materials and methods: T-emerge 5 compared QW taspoglutide to once-
daily (QD) insulin glargine (INS) in adult insulin-naïve patients with T2D 
inadequately controlled with MET+SU. After discontinuation of SU for 5±1 
days, 1049 patients were randomized 1:1:1 to QW taspoglutide 10 mg (Ta-
spo10), QW taspoglutide 20 mg (Taspo20; up-titrated after 4 weeks of 10 mg), 
or QD INS for 24 weeks. INS was adjusted using a forced titration algorithm 
to achieve optimal target fasting plasma glucose of 6.1 mmol/L (110 mg/dL). 
The primary endpoint was the change from baseline in HbA1c at week 24. The 
analysis was conducted using the intent-to-treat population to test the non-
inferiority of Taspo10 and Taspo20 with INS (using 2-sided 95% CI for HbA1c 
difference and non-inferiority margin of 0.4%).
Results: Baseline characteristics were comparable across groups (mean val-
ues: age 58 yrs, BMI 32 kg/m2, BW 91 kg, and HbA1c 8.3%). LS mean (SE) 
change from baseline in HbA1c was -0.8% (0.05), -1.0% (0.05) and -0.8% 
(0.05) for Taspo10, Taspo20 and INS groups, respectively, with both Taspo10 
and Taspo20 being non-inferior to INS. Proportion of patients achieving 
HbA1c ≤7.0% was greater for both Taspo arms compared with INS (Taspo10, 
39%; Taspo20, 47%; INS, 32%). Taspo10 and Taspo20 produced significantly 
greater weight loss vs. INS (Figure). In addition, the proportion of patients 
who experienced hypoglycaemia (confirmed/unconfirmed) was significantly 
lower with Taspo10 (5%) and Taspo20 (6%) vs. INS (17%) (P<0.0001 for 
both). Serious AE incidence was similar among the groups. Withdrawals due 
to adverse events (AEs) were higher with Taspo vs. INS, primarily due to 
gastrointestinal (GI) AEs (Taspo10, 6%; Taspo20, 10%; INS, 0%).
Conclusion: Compared to daily INS, addition of once-weekly Taspo to previ-
ous MET in patients failing on MET+SU improved similarly glycaemic con-
trol with additional weight loss and less hypoglycaemia, but more GI AEs. 
(NCT00755287)
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Effects of long term administration of miglitol and voglibose on plasma 
glucagon-like peptide-1 and gastric inhibitory polypeptide after a mixed 
meal ingestion
T. Narita1, H. Yokoyama2, R. Yamashita2, M. Hosoba1, T. Sato1, T. Morii1,  
H. Fujita1, K. Tsukiyama1, Y. Yamada1; 
1Department of Endocrinology, Diabetes and Geriatric Medicine, Akita 
University Graduate School of Medical Science, Akita, 2Jiyugaoka Medical 
Clinic, Internal Medicine, Obihiro, Japan.
Background and aims: Recently, we have reported that a two-week admin-
istration of miglitol (M), an alpha-gucosidase inhibitor (AGI), induces pro-
longed and enhanced glucagon-like peptide-1 (GLP-1) and reduced gastric 
inhibitory polypeptide (GIP) responses after a mixed meal ingestion in Japa-
nese type 2 diabetics (T2Ds). However, such effects of AGI on plasma incre-
tins during long term or whether those effects of AGIs would be different 
according to types of AGIs (M, absorbed type; voglibose [V], non-absorbed 
type) have not been reported.
Materials and methods: In this multicenter, open 12-week trial, 26 and 24 Jap-
anese T2Ds (age and HbA1c [mean]: 58.5, 59.5; 7.11 %, 7.08 %, respectively) 
with diet therapy and/or oral hypoglycemic agents other than AGIs were ran-
domly assigned to receive 50 mg of M or 0.3 mg of V three times per day, re-
spectively. We measured plasma glucose (PG), insulin (IRI), active GLP-1 and 
total GIP 0, 30, 60, 120 min after ingestion of a mixed meal (meal tolerance test 
[MTT]) at baseline and 12 weeks after administration of M or V. Active GLP-1 
and total GIP levels were measured using commercially available ELISA kits 
(Linco Research, St Charles, MO, USA). Data are expressed as mean (SE).
Results: Baseline values of PG, IRI, GLP-1 and GIP during MTT were similar 
in both groups. PGs (mg/dL) at 30 and 60 min during MTT were signifi-
cantly decreased both after M and V (at 30 min, 204.6 (6.4) vs. 160.0 (4.8) [M, 
p<0.001] and 208.6 (10.1) vs. 178.8 (7.4) [V, p<0.001]; at 60 min, 247.0 (8.6) 
vs. 184.2 (5.4) [M, p<0.001] and 246.0 (10.4) vs. 197.2 (7.9) [V, p<0.001]). 
PG at 30 min during MTT after M was significantly lower than that after V 
(p<0.05). IRIs at 30 and 60 min during MTT were also significantly decreased 
both after M and V. GLP-1 values at 60 and 120 min during MTT were sig-
nificantly increased after M whereas only at 60 min value was significantly 
increased after V (figure). AUC (area under the curve during MTT) of GLP-1 
was significantly increased after M (p<0.01) despite of marginal increase after 
V (p=0.059). GIPs at 30, 60 and 120 min during MTT were significantly de-
creased both after M and V (figure). GIPs at 30 and 60 min during MTT after 
M were significantly lower than those after V (figure). AUC of GIP after M 
was significantly lower than that after V (p<0.05). During the 12-week treat-
ment, BMI reduction was significant after M (from 25.1 [1.0] to 24.7 [1.0], 
p<0.01) but not after V (from 25.6 [1.0] to 25.5 [1.0]).
Conclusions: Long term AGI administration induces increased GLP-1 and 
decreased GIP responses after a mixed meal ingestion in Japanese T2Ds. Ab-
sorbed type of M may have relatively strong effects modifying postprandial 
incretin responses compared with non-absorbed type of V. Slight but signifi-
cant BMI reduction after M not but V might be attributable to these different 
effects on incretins.
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Improved glycaemic control with once-daily insulin detemir in 
combination with sitagliptin/metformin vs. sitagliptin/metformin ± 
sulphonylurea drugs
P.A. Hollander1, K. Rašlová2, T.V. Skjøth3, J. Råstam3, J. Liutkus4; 
1Baylor University Medical Center, Dallas, USA, 2Metabolicke Centrum, 
Bratislava, Slovakia, 3Novo Nordisk A/S, Copenhagen, Denmark, 4Vascular 
Risk Modification Clinic, Cambridge, Canada.
Background and aims: Once-daily insulin detemir (IDet) provides stable, 
24 hour glucose control and is often prescribed for patients with T2D as add-
on to OADs. DPP-4 inhibitors, a new class of OADs, reduce degradation of 
GLP-1 mobilized in response to glucose intake, thereby improving endog-
enous glucose-dependent insulin secretion at mealtime. This study was a ran-
domized, open-label, parallel group, 26-week trial designed to compare the 
efficacy and safety of two treatment regimens comprised of IDet in combina-
tion with the DPP-4 inhibitor sitagliptin (SITA) or SITA in combination with 
a subjects’ prior sulphonylurea (SU) regimen, if any, and both groups con-
tinuing on metformin (Met), in insulin-naïve T2D patients who were poorly 
controlled by their previous regimens with Met ± other OADs.
Materials and methods: Treatment was for 26 weeks with once-daily IDet + 
SITA (100 mg QD) + Met (at pre-trial dose >1000 mg) (IDet/SITA; n=107) 
but with any prior SU discontinued, or with SITA + Met ± SU (continuing 
each subject’s pretrial SU dosing, if any) (SITA ± SU; n=110). Both arms 
contained a similar percentage of subjects (75 and 77%, IDet/SITA vs. SITA, 
respectively) with pre-trial SU treatment experience.
Results: Observed baseline A1C in both arms was 8.5%. Estimated mean 
A1C reductions of 1.44 and 0.89% were achieved (IDet/SITA vs. SITA ± SU; 
est. mean diff. = 0.55%, 95% CI [-0.77, -0.33], p<0.001); estimated final mean 
A1c values were 7.08 and 7.64%, respectively; 45 vs. 24% of patients reached 
A1C ≤7% (Adjusted Odds Ratio (OR) = 3.20, 95% CI [1.65, 6.19], p=0.001) 
and 19 vs. 10% reached A1C ≤6.5% (OR 2.23, 95% CI [0.96, 5.20], p=0.063). 
Observed FPG baselines were 9.7 mmol/L (174.8 mg/dL) and 9.8 mmol/L 
(176.5 mg/dL), with final mean estimated FPG values 6.1 mmol/L (109.5 mg/
dL) and 8.5 mmol/L (153.5 mg/dL), respectively (IDet/SITA vs. SITA ± SU; 
est. mean diff. = -2.45, 95% CI [-3.01, -1.88], p<0.001). After 26 weeks 9-point 
PG profiles were significantly lower for IDet/SITA at all time points except 
before dinner. No major hypoglycemia occurred in either arm. Rates for mi-
nor hypoglycemia (PG <3.1 mmol/L [56 mg/dL]) were low in both treatment 
arms, with no statistically significant differences between arms (0.47 vs. 0.48 
episodes/patient-year, IDet/SITA vs. SITA ± SU; Adjusted Rate Ratio = 0.97, 
95% CI: [0.35, 2.74]; p=NS). 36% of the subjects taking IDet/SITA achieved 
the HbA1c <7% target without hypoglycemia in the last 3 months of treatment 
vs. 20% in the SITA ± SU arm (OR = 2.47, 95% CI [1.26; 4.81], p=0.008). 
Mean IDet dose rose from 0.11 to 0.59 U/kg during the 26 weeks’ treatment. 
Body weight and BMI decreased in both arms (-0.81 vs. -1.66 kg and -0.30 vs. 
-0.58 kg/m2 in IDet/SITA vs. SITA ± SU, respectively; p=NS). Data analysis 
of the subgroup who received SU pre-trial mirrored the data presented here 
for the full analysis set.
Conclusion: Glucose control was significantly more improved in patients on 
once-daily IDet/SITA vs. patients on SITA ± SU (Met in both arms) with 
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larger reductions in A1c and FPG occurring in the IDet/SITA arm. This was 
achieved with modest weight reductions and low hypoglycemia in both arms. 
These data support the use of once-daily IDet in combination with a DPP-4 
inhibitor, SITA, and Met, with SU discontinued, as a safe and effective treat-
ment option for insulin-naïve patients with T2D.
Supported by: Novo Nordisk
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Short-term effects of bed-time insulin versus GLP-1 analogue on resting 
energy expenditure in patients with type 2 diabetes
C. Gonzalez, S. Salandini, A. Pierreisnard, M.-C. Beauvieux, H. Gin,  
V. Rigalleau; 
USN, Hopital Haut-Lévêque, Pessac, France.
Background and aims: GLP-1 analogues can be used instead of bed-time 
insulin therapy for poorly controlled type 2 diabetic (T2D) patients, with op-
posite influences on body weight. Beside the effect of GLP-1 on energy intake, 
it is not known whether changes of the Resting Energy Expenditure (REE) 
contribute to these distinct weight courses. We compared the early (first days) 
effects of both treatments on REE in T2D patients.
Materials and methods: Twenty-five T2D patients (8 women, 17men) poorly 
controlled despite maximal oral therapy, were included: 8 patients received 
GLP-1 analogue (exenatide® 5 µg twice-a-day); 17 received bed-time insulin 
analogue (Glargine® or Detemir®, initial dose 0.2UI/kg). REE was measured 
by indirect calorimetry before the first injection (Day0) and during two days 
(Day1 and 2) after initiating the treatments. Respiratory exchanges were 
monitored using a Sensor Medics Vmax 29N apparatus: VCO2 and VO2 were 
determined on 30 minutes intervals from 8 a.m. to 8h30 a.m., before break-
fast, and REE was calculated according to Weir’s equation. Body weight was 
assessed three months later.
Results: The two groups did not differ for age (GLP-1 group: 57±10 years; In-
sulin group: 56±10 years), gender, body weight (GLP-1: 90.7±10.0 kg; Insulin: 
91.2±15.2 kg); HbA1c (GLP-1: 10.1±0.8%; Insulin: 9.4±1.3%), fasting plasma 
glucose level (GLP-1: 210 ± 85 mg/dl; Insulin: 210±46 mg/dl) and initial REE 
(Day0: GLP-1: 1821±240 kcal/24h; Insulin: 1883±363 kcal/24h). On insulin 
treatment, REE decreased by -3.5 % after the first injection (Day1:1816±386 
kcal/24h, p=0.07 vs Day0) and by -5.8 % after the second injection (Day2: 
1774±333 kcal/24h, p=0.03 vs Day0). REE was unchanged on GLP-1 analogue 
treatment (Day1:1842±255 kcal/24h, Day2:1798±240 kcal/24h, both NS vs 
Day0). Body weight increased after three months of insulin analogue therapy 
(M3: 92.2±15.2 kg vs Day0: 91.2 kg±15.6; p=0.08) whereas it decreased on 
GLP-1 analogue (M3:86.7±9.2kg vs 90.7±10.0; p=0.06), with significantly dif-
ferent body weight changes at three months (p=0.002).
Conclusion: REE decreases early after the introduction of insulin therapy, 
whereas it is not affected by the GLP-1 analogue. These different effects on 
REE probably contribute to the opposite weight changes with these treat-
ments.
PS 79 SGLT-2 inhibitors
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Efficacy of dapagliflozin as monotherapy administered in the morning or 
evening to treat type 2 diabetes mellitus
A. Salsali1, W. Tang1, J.F. List1, E. Ferrannini2; 
1Bristol Myers Squibb, Princeton, USA, 2University of Pisa School of 
Medicine, Italy.
Background and aims: Dapagliflozin is a highly selective and reversible in-
hibitor of the renal sodium glucose co-transporter-2, being developed as an 
oral antidiabetic agent.
Materials and methods: We report here data from a 24-week randomized, 
double-blind, phase 3 trial of dapagliflozin administered in the morning or 
the evening to treatment-naïve type 2 diabetes mellitus patients (study ID: 
MB102013). Patients (n=485) with HbA1c 7.0-10% were randomized equally 
to receive placebo, or dapagliflozin 2.5, 5 or 10 mg, once-daily in the morn-
ing (main cohort) or evening (exploratory cohort). All patients received 
diet/exercise counselling. Efficacy measures included change from baseline 
in HbA1c, fasting plasma glucose (FPG) and body weight at week 24. Adverse 
events were assessed throughout the study. Patients were actively monitored 
for signs/symptoms suggestive of urinary tract infections (UTIs) and genital 
infections and MedDRA (Medical Dictionary for Regulatory Activities, ver-
sion 11.1) preferred terms relating to these were prospectively defined.
Results: Reductions in mean HbA1c and FPG were seen in all treatment 
groups and were statistically significant in 5 and 10 mg dapagliflozin arms of 
the main cohort (Table). Mean body weight decreases were greater with all 
dapagliflozin doses than in placebo, although not reaching statistical signifi-
cance. Efficacy with morning and evening dose of dapagliflozin was similar 
when compared to placebo. There were no clinically meaningful changes in 
serum electrolytes, creatinine, or cystatin-C in any treatment arm. Signs/
symptoms/other reports suggestive of UTI and genital infection were more 
frequent with dapagliflozin than placebo (4.6-12.5% in dapagliflozin arms 
vs 4.0% with placebo for UTI; and 2.6-12.9% in dapagliflozin arms vs 1.3% 
with placebo for genital infection). The reported signs and symptoms of UTI 
and genital infection were resolved with standard care and rarely led to study 
discontinuation. There was no increase in hypoglycemia with dapagliflozin 
and hypoglycemic events were well balanced in all treatment arms including 
placebo. Overall rate of adverse events was similar between the morning and 
evening dosing groups. There were no reports of nocturia in the main morn-
ing cohort and 1, 2, and 3 patients with nocturia in dapagliflozin 2.5, 5 or 10 
mg evening dose arms, respectively.
Conclusion: Dapagliflozin is equally efficacious with morning or evening 
dosing with no notable difference in the number or type of adverse events 
between the two cohorts. Treatment with dapagliflozin resulted in clinically 
meaningful decreases in HbA1c and FPG in type 2 diabetes mellitus patients 
along with a favorable effect on weight.
Table. Change from baseline at week 24 in HbA1c, FPG, and body weight*
Dapagliflozin morning 
dose (main cohort)
Dapagliflozin evening dose 
(exploratory cohort)**
Placebo
N=75
2.5mg
N=65
5mg
N=64
10mg
N=70
2.5mg
N=67
5mg
N=68
10mg
N=76
HbA1c (%)
-0.23
(0.10)
-0.58
(0.11)
-0.77a
(0.11)
-0.89b
(0.11)
-0.83
(0.11)
-0.79
(0.11)
-0.79
(0.10)
FPG (mg/dL) -4.1(3.9)
-15.2
(4.2)
-24.1a
(4.3)
-28.8b
(4.0)
-25.6
(4.1)
-27.3
(4.2)
-29.6
(4.0)
Weight (kg) -2.2(0.4)
-3.3
(0.5)
-2.8
(0.5)
-3.2
(0.5)
-3.8
(0.5)
-3.6
(0.5)
-3.1
(0.4)
Data are mean (SE). *Mean value after adjusting for baseline value with last 
observation carried forward. **Per study design, the exploratory cohort was 
not statistically tested. aP<0.001; bP<0.0001
Supported by: Bristol-Myers Squibb and AstraZeneca
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Dapagliflozin: an effective treatment option in patients with type 2 
diabetes across stages of disease 
S. Parikh1, J. Sugg1, L. Ying2, J.F. List2; 
1AstraZeneca, Wilmington, 2Bristol-Myers Squibb, Princeton, USA.
Background and aims: Dapagliflozin, a selective inhibitor of the renal so-
dium glucose co-transporter 2 (SGLT2), helps lower excess glucose levels in 
an insulin-independent manner by increasing urinary glucose excretion. We 
analysed data from 3 double-blind, randomised, placebo-controlled trials of 
dapagliflozin in patients with inadequate glycaemic control at different stages 
of type 2 diabetes (T2DM), as reflected by their treatment regimens.
Materials and methods: Patients with T2DM were treated with dapagliflozin 
2.5, 5 or 10 mg or placebo as monotherapy (study MB102013; N = 485 [main 
cohort N = 274]), as an add-on to metformin (MB102014; N = 546) and as 
an add-on to insulin with or without up to 2 oral anti-diabetic drugs (AZ006; 
N = 807). The primary end point for all trials was change in HbA1c at Week 
24.
Results: Significant improvements in the glycaemic measures of HbA1c and 
fasting plasma glucose (FPG) were observed with dapagliflozin (Table) re-
gardless of T2DM stage and background medication and with no increase in 
major hypoglycaemia. The need for rescue therapy with anti-diabetic agents 
(monotherapy and metformin studies) or insulin for failing to achieve pre-
specified glycaemic targets was reduced with dapagliflozin. Weight loss was 
seen in all studies, which reached statistical significance for patients in the 
metformin and insulin studies in dapagliflozin treatment groups compared 
to placebo. Adverse events (AE), serious AEs and study discontinuations 
were similar across all groups, although active solicitation revealed increased 
reports of signs, symptoms and events suggestive of genital infection in da-
pagliflozin groups. There were increased reports suggestive of urinary tract 
infection with dapagliflozin in the monotherapy and insulin trials but not in 
the metformin trial.
Conclusion: Dapagliflozin produced significant improvement in glycaemic 
control in patients at various stages in the progression of T2DM, from treat-
ment-naïve to those on insulin with or without oral anti-diabetic agents. Da-
pagliflozin, due to its insulin-independent mechanism, is a potential therapy 
to improve glycaemic control and body weight in patients with T2DM across 
stages of disease.
MON MET INS
PLA DAPA 10 mg PLA + MET DAPA 10 mg + 
MET
PLA + INS DAPA 10 mg 
+ INS
n 75 70 137 135 193 194
HbA1ca (%) ± SE -0.23± 0.10 -0.89b± 0.11 -0.30± 0.07 -0.84b± 0.07 -0.30± 0.05 -0.90b± 0.05
FPGa (mg/dL) ± SE -4.1± 4.0 -28.8c± 4.3 -6.0± 2.7 -23.5c± 2.7 3.3± 3.4 -21.7c± 3.3
Body Weighta (kg) ± SE -2.2± 0.4 -3.2± 0.5 -0.9± 0.2 -2.9c± 0.2 0.02± 0.2 -1.7c± 0.2
Patients (%) reaching HbA1c 
Goal <7.0%, Week 24 32 51 26 41
c 9 22d
Patients rescued or discontin-
ued due to hyperglycemia (%), 
Week 24e
12 0 15 4 29 10
10 mg data shown for presentation
aAdjusted mean change from baseline to Week 24 (LOCF)
bPrimary endpoint, P≤.0001 vs PLA
cStatistically significant based on sequential testing for secondary end points at α = 0.05
dNominal P = 0.0003 vs PLA + INS
eAdjusted percent of patients rescued with anti-diabetic agents (monotherapy and metformin studies) or insulin up-
titration (insulin study), or discontinued, based on pre-specified glycaemic targets.
Supported by: Bristol-Myers Squibb and AstraZeneca
870
Efficacy and safety of dapagliflozin in patients with type 2 diabetes 
mellitus and inadequate glycaemic control on glimepiride monotherapy
K. Strojek1, V. Hruba2, M. Elze3, A. Langkilde4, S. Parikh5; 
1Silesian Medical University, Zabrze, Poland, 2AstraZeneca, Prague, Czech 
Republic, 3ClinResearch, Koeln, Germany, 4AstraZeneca, Mölndal, Sweden, 
5AstraZeneca, Wilmington, USA.
Background and aims: In management of patients with type 2 diabetes mel-
litus (T2DM), progressive deterioration of glycaemic control is commonly 
observed, requiring treatment intensification with additional drug therapy. 
Dapagliflozin (DAPA), a selective inhibitor of sodium-glucose co-transporter 
2 that inhibits renal glucose reabsorption, has been shown to reduce hyper-
glycaemia and body weight in patients with T2DM without a significantly 
increased risk of hypoglycaemia. We assessed efficacy, safety and tolerability 
of DAPA as add-on to glimepiride in patients with uncontrolled T2DM.
Materials and methods: This 24-week (wk) randomized, double-blind, pla-
cebo-controlled, parallel-group multicentre trial (D1690C00005) in Europe/
Asia-Pacific enrolled patients with T2DM uncontrolled on at least half the 
maximum recommended dose of sulfonylurea alone (HbA1c 7.0-10.0%). A 
total of 597 adult subjects were randomized to DAPA (2.5, 5, or 10 mg/d) or 
placebo (PLA) added to open-label glimepiride 4 mg/d for 24 wk. Primary 
endpoint was change from baseline in HbA1c at 24 wk. Secondary endpoints 
included changes in other glycaemic parameters and body weight. Interim 
safety data are also described.
Results: At 24 wk, DAPA showed dose-dependent significant reductions in 
HbA1c from baseline vs PLA (Table). DAPA showed weight loss relative to 
PLA at wk 24 (-0.46, -0.84, -1.54 kg for DAPA 2.5, 5,10 mg, respectively) 
which was statistically significant for DAPA 5 and 10 mg treatment groups. 
DAPA 5 and 10 mg caused significant improvements in oral glucose toler-
ance test (OGTT) response and in fasting plasma glucose (FPG) at wk 24. 
Compared with PLA, significantly more DAPA 5 and 10 mg-treated patients 
achieved HbA1c <7.0% at wk 24. Adverse events (AEs) were reported in 
47%, 52%, 48%, and 50% of patients receiving PLA and DAPA 2.5, 5, 10 mg, 
respectively; frequency of drug-related AEs was similar across all treatment 
groups. Actively solicited events suggestive of urinary tract infections were 
6.2%, 3.9%, 6.9% and 5.3% in PLA and DAPA 2.5, 5, 10 mg, respectively. No 
AE of kidney infection was reported. Actively solicited events suggestive of 
genital infections were 0.7%, 3.9%, 6.2% and 6.6% in PLA and DAPA 2.5, 5, 
10 mg, respectively. No cases of genital tract infection led to treatment dis-
continuation. Hypoglycaemic events were 4.8%, 7.1%, 6.9% and 7.9% in PLA 
and DAPA 2.5, 5, 10 mg groups, respectively. No clinically meaningful mean 
changes from baseline in serum creatinine or electrolytes were observed. Ad-
justed mean changes from baseline at wk 24 in seated systolic/diastolic blood 
pressure were -1.2/-1.4, -4.7/-1.1, -4.0/-1.7 and -5.0/-2.8 mmHg for PLA, and 
DAPA 2.5, 5,10 mg, respectively.
Conclusions: DAPA added to glimepiride in T2DM patients uncontrolled 
with sulphonylurea monotherapy significantly improves HbA1c, reduces 
weight and is well tolerated. 
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PLA + glim
[n=145]
DAPA 2.5 mg + 
glim [n=154]
DAPA 5 mg + 
glim [n=142]
DAPA 10 mg + 
glim [n=151]
HbA1c, baseline (%), mean (SD) 8.15 (0.74) 8.11 (0.75) 8.12 (0.78) 8.07 (0.79)
Week 24 (LOCF) absolute change from baseline 
in HbA1c (%), adjusted mean (SE)
-0.13 (0.063) -0.58 (0.060)# -0.63 (0.063)# -0.82 (0.061)#
Body weight, baseline (kg), mean (SD) 80.9 (15.8) 81.9 (19.0) 81.0 (18.6) 80.6 (17.9)
Week 24 (LOCF) absolute change from baseline 
in body weight (kg), adjusted mean (SE) -0.72 (0.23) -1.18 (0.22) -1.56 (0.23)
† -2.26 (0.22)#
OGTT, baseline (mg/dL)*, mean (SD) 158.6 (58.75) 140.4 (68.18) 151.2 (64.21) 157.3 (69.03)
Week 24 (LOCF) change from baseline in 
OGTT (mg/dL)*, adjusted mean (SE)
-6.0 (5.02) -37.5 (4.68) -32.0 (4.84)† -34.9 (4.56)#
Week 24 (LOCF) adjusted proportion (%) of 
patients with HbA1c <7%, (95% CI)
13.0 (7.6, 18.4) 26.8 (20.2, 33.3) 30.3 (23.4, 37.1)† 31.7 (24.7, 38.7)#
*measured 2 h after ingestion of 75 g glucose
#p<0.0001, †p<0.01 vs PLA
Primary endpoint tested at alpha=0.019 applying Dunnett adjustment; secondary endpoints tested following a se-
quential procedure at alpha=0.05
Supported by: AZ and BMS
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Effect of dapagliflozin, a novel insulin-independent treatment, over 48 
weeks in patients with type 2 diabetes poorly controlled with insulin
J.P.H. Wilding1, V. Woo2, A. Pahor3, J. Sugg4, A. Langkilde4, S. Parikh5; 
1Department of Medicine, University of Liverpool, United Kingdom, 
2University of Manitoba, Winnipeg,  Canada, 3AstraZeneca, Wedel, 
Germany, 4AstraZeneca, Mölndal, Sweden, 5AstraZeneca, Wilmington, 
USA.
Background and aims: Escalating insulin doses to achieve glycaemic tar-
gets in type 2 diabetes mellitus (T2DM) increases risk of weight gain, fluid 
retention and hypoglycaemia, often presenting a therapeutic dilemma. Da-
pagliflozin, a selective inhibitor of sodium glucose co-transporter 2 (SGLT2), 
reduces glucose levels in T2DM patients in an insulin-independent manner 
by inducing urinary glucose excretion. Resulting caloric loss may also help 
prevent weight gain in insulin-treated patients.
Materials and methods: To determine efficacy and safety of dapagliflozin in 
T2DM poorly controlled with insulin, patients were randomised to placebo, 
2.5, 5, or 10 mg dapagliflozin added to unchanged background insulin thera-
py with or without concomitant oral antidiabetic drugs (Trial D1690C00006). 
Primary outcome measure was change from baseline in HbA1c at week (wk) 
24 (LOCF). Patients completing the 24-wk primary efficacy phase continued 
in a 24-wk site- and subject-blinded extension phase.
Results: A total of 808 patients were randomised. Mean baseline values were: 
HbA1c, 8.5%; fasting plasma glucose (FPG), 178 mg/dL; body weight (BW), 
94 kg; insulin dose, 77 IU/day. Of 711 patients who completed the primary 
efficacy phase, 676 completed 48 wks of double-blind treatment. Significant 
reductions in HbA1c, FPG, BW and insulin dose were observed with dapagli-
flozin relative to placebo in primary efficacy phase with no clinically relevant 
increase in hypoglycaemia. Reductions in glycemic parameters and BW were 
sustained over 48 wks. Insulin requirements over the 48 wks continued to 
increase with placebo but not in dapagliflozin groups. Overall, adverse events 
(AEs), serious AEs, and study discontinuations were comparable across 
groups. Active solicitation revealed increased reports of signs and symptoms 
suggestive of urinary (7.9-10.8% vs 5.1% for placebo) and genital (6.4-10.7% 
vs 2.5% for placebo) tract infection with dapagliflozin, most of which oc-
curred during first 24 wks, were generally mild and responded to routine 
management. Two cases of pyelonephritis (1 each in 2.5 and 5 mg groups) 
responded to antibiotic therapy and did not lead to discontinuation. There 
were no discontinuations due to hypoglycaemia. There was a trend of small 
mean decreases in systolic blood pressure, without increased frequency of 
orthostatic hypotension, in dapagliflozin groups.
Conclusion: Once-daily oral dapagliflozin improved glycaemic control with-
out an increase in daily insulin requirements and led to weight loss in patients 
with T2DM poorly controlled with insulin over a 48-wk treatment period. 
Attenuating the cycle of escalating insulin dose and weight gain represents an 
improvement for this patient population.
Dapagliflozin dose + INS
Adjusted mean change from 
baseline (SE) at Week 24
PBO + INS
(n = 193)d
2.5 mg
(n = 202)d
5 mg
(n = 211)d
10 mg
(n = 194)d
HbA1c (%)e -0.30 (0.05) -0.75 (0.05)a -0.82 (0.05)a -0.90 (0.05)a
Body weight (kg)e 0.02 (0.18) -0.98 (0.18)a -0.98 (0.17)a -1.67 (0.18)a
insulin dose (IU/d)f 5.08 (0.94) -1.80 (0.92)a -0.61 (0.90)a -1.16 (0.94)a
FPG (mg/dL)e 3.3 (3.4) -12.5 (3.2)b -18.8 (3.1) -21.7 (3.3)a
Mean change from baseline (SE) at Week 48c
HbA1c (%)e -0.43 (0.07) -0.74 (0.06) -0.94 (0.06) -0.93 (0.06)
Body weight (kg)e -0.18 (0.30) -1.11 (0.26) -1.21 (0.25) -1.79 (0.26)
Total daily insulin dose (IU/d)f 10.54 (1.49) -0.92 (1.43) 0.30 (1.41) -0.70 (1.44)
FPG (mg/dL)e -4.4 (4.1) -17.0 (3.4) -20.8 (3.3) -21.5 (3.4)
Dapagliflozin dose + INS
PBO + INS
(n =197)g
2.5 mg
(n =202)g
5 mg
(n =212)g
10 mg
(n =196)g
Seated systolic blood pressure 
(mmHg) mean change from 
baseline (SE) at Week 48
-0.2 (1.3) -5.4 (1.2) -3.8 (1.1) -5.2 (1.1)
Seated diastolic blood pressure 
(mmHg) mean change from 
baseline (SE) at Week 48
-1.3 (0.7) -2.3 (0.7) -3.1 (0.6) -2.9 (0.7)
Major hypoglycemia (n [%]) 
over 48 weeks 2 (1.0) 3 (1.5) 2 (0.9) 3 (1.5)
Total hypoglycemia (n [%]) 
over 48 weeks 102 (51.8) 122 (60.4) 118 (55.7) 105 (53.6)
P value (vs PBO + INS): a≤0.0001; b0.0008 cp-values were not calculated for the exten-
sion phase
d Randomized patients who took at least one dose of study medication and who have 
baseline and at least one post-baseline efficacy assessment
e Excluding data after insulin up-titration
f Including data after insulin up-titration
g Randomized patients who took at least one dose of study medication
Supported by: AstraZeneca and Bristol-Myers Squibb
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Dapagliflozin lowered rate of insulin uptitration/study discontinuation 
from lack of glycaemic control in 48-week study of type 2 diabetes 
patients poorly controlled on insulin therapy
N.G. Soler1, J.P.H. Wilding2, V. Woo3, A. Pahor4, J. Sugg5, A. Langkilde6,  
S. Parikh5; 
1Springfield Diabetes & Endocrine Center, Springfield, USA, 2University 
of Liverpool, United Kingdom, 3University of Manitoba, Winnipeg, 
Canada, 4AstraZeneca, Wedel, Germany, 5AstraZeneca, Wilmington, USA, 
6AstraZeneca, Möndal, Sweden.
Background and aims: In patients with poorly controlled type 2 diabetes 
(T2DM) receiving insulin (INS), the clinical utility of escalating INS doses 
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to achieve glycaemic control is often limited by associated weight gain, fluid 
retention, hypoglycaemia and patient acceptance. Dapagliflozin (DAPA), a se-
lective inhibitor of sodium-glucose cotransporter 2 in development for T2DM 
treatment, increases renal excretion of glucose and lowers blood glucose via an 
INS-independent mechanism. The coadministration of DAPA with INS can 
potentially attenuate escalating INS doses and associated side effects.
Materials and methods: Patients with poorly controlled T2DM (n=808; mean 
baseline HbA1c 8.53%) were randomized to placebo (PLA), 2.5, 5, or 10 mg/d 
DAPA in addition to background INS (mean baseline dose 77 IU/d) ± other oral 
antidiabetic drugs. Primary glycaemic and safety endpoints have been reported 
separately; here we report time to study discontinuation or INS up-titration due 
to lack of glycaemic control (DISC-UP) for up to 48 weeks (wk) of continued 
centre- and patient-blinded treatment. INS was up-titrated if HbA1c was >8% or 
fasting plasma glucose was >9.9mmol/L from 24-48 wk. Weight gain, peripheral 
oedema and DISC due to hypoglycaemia and other causes were also assessed.
Results: Time to reach DISC-UP was substantially prolonged in all DAPA + INS 
groups vs PLA + INS (figure). At 48 wk, the proportion of patients with DISC-UP 
was 42.8% in the PLA + INS group vs 21.7%, 15.6% and 15.3% in the DAPA + INS 
groups, with the greatest difference seen between the DAPA 10 mg + INS vs PLA 
+ INS groups (−27.5%; 95% CI −35.9 to −19.1%). Patients receiving DAPA main-
tained glycaemic control and sustained reductions in body weight from 24-48 wk 
compared with placebo. At 24 wk, the proportion of patients with weight loss >3% 
was 10.4% in the PLA + INS group vs 17.7-23.3% in the DAPA + INS groups. Cor-
responding values at 48 wk were 10.4% and 21.6-24.5%, respectively. The frequency 
of peripheral oedema was 7.6% in the PLA + INS group vs 4%, 2.4% and 4.6% in 
the DAPA + INS groups. The frequency of DISC due to adverse events (AEs) in the 
PLA + INS group was 4.6% vs 3.5%, 7.1%, and 5.1% in the DAPA + INS groups, re-
spectively. Corresponding values for DISC due to serious AEs were 1.5%, 1%, 2.4% 
and 2.6%, respectively. There were no DISCs due to hypoglycaemia.
Conclusion: Over 48 wk, DAPA treated patients were less likely to require 
DISC-UP due to poor glycaemic control. This insulin sparing effect of DAPA 
was further demonstrated by an increased frequency of weight loss and a re-
duced frequency of peripheral oedema over time.
Supported by: AstraZeneca and Bristol-Myers Squibb
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Canagliflozin, an inhibitor of sodium glucose co-transporter 2, improves 
glycaemic control, lowers body weight, and improves beta cell function 
in subjects with type 2 diabetes on background metformin
J. Rosenstock1, D. Polidori2, Y. Zhao3, S. Sha3, D. Arbit3, K. Usiskin3,  
G. Capuano3, W. Canovatchel3; 
1Dallas Diabetes and Endocrine Center, Dallas, 2Johnson & Johnson, La 
Jolla, 3Johnson & Johnson, Raritan, USA.
Background and aims: Inhibition of sodium glucose co-transporter 2 
(SGLT2) is being studied as a novel modality of treatment for type 2 diabetes 
mellitus (T2DM). We therefore sought to evaluate the safety, tolerability, and 
efficacy of canagliflozin (CANA, JNJ-28431754/TA-7284), a potent inhibitor 
of SGLT2, in subjects with T2DM with inadequate glycemic control on back-
ground metformin therapy. Since loss of beta cell function (BCF) underlies 
the progressive deterioration of glycemic control in T2DM, we also assessed 
the effect of CANA on a measure of BCF.
Material and methods: In a double-blind, placebo (PBO)-controlled, dose-
ranging study, subjects (N=451) were randomized to PBO; CANA 50, 100, 
200, 300 mg once daily (OD); 300 mg BID; or sitagliptin (SITA) 100 mg OD 
for 12 weeks. BCF was assessed using HOMA2-B% calculated from plasma 
glucose (PG) and C-peptide concentrations at week 12.
Results: Mean baseline characteristics (age 53 years, HbA1c 7.7%, fasting 
plasma glucose [FPG] 9.0 mmol/l, BMI 31.5 kg/m2) were similar across treat-
ment groups. A significant increase in urinary glucose (UG)/creatinine in all 
CANA doses was observed. At week 12, the reductions from baseline in FPG 
and HbA1C were statistically significant for all CANA arms and for SITA com-
pared with PBO, with maximal/similar decreases at CANA 300 mg OD and 
BID doses (Table). Significant, dose-related weight reductions vs PBO were 
seen across all CANA arms but not with SITA (Table). Significant improve-
ments in HOMA-2B% were seen in subjects treated with 100 mg of CANA 
and greater (Table). In general, adverse events (AEs) were transient, mild 
to moderate in intensity, and balanced across arms except for an increase 
in symptomatic genital infections that were non dose-dependent: 3-8% in 
CANA arms, 2% in PBO, and 2% in SITA. Similar incidences of discontinu-
ations due to AEs and serious AEs across arms were observed. Urinary tract 
infections were reported in 3-9% of CANA arms, without dose-dependency, 
6% of PBO, and 2% of SITA. Hypoglycemia was reported in 0-6% of CANA 
arms, without dose-dependency, 2% of PBO, and 5% of SITA. In CANA arms, 
after 12 weeks of treatment, no safety signals in laboratory studies, ECG, or 
vital signs were observed.
Conclusion: In subjects with T2DM with mild to moderate hyperglycemia 
on metformin background therapy, adding CANA was generally well toler-
ated, provided clinically meaningful HbA1c reductions, reduced body weight, 
and led to suggestive improvements in BCF.
874
Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, 
increases 24-hour urinary glucose excretion and reduces body weight in 
obese subjects over 2 weeks of treatment
T. Sarich1, D. Devineni1, A. Ghosh1, D. Wexler1, K. Shalayda1, J. Blake1,  
M. Saraiva1, M.J. Gutierrez2, D. Polidori1, K. Demarest1, P.L. Rothenberg1; 
1Pharmaceutical Research & Development, Johnson & Johnson, Raritan, 
2Comprehensive Phase One, Miramar, USA.
Background and aims: Sodium glucose co-transporter 2 (SGLT2) inhibition 
is considered a promising new approach for the treatment of patients with 
type 2 diabetes. This phase 1 study aimed to assess the pharmacodynamics 
and safety of canagliflozin (CANA; JNJ-28431754/TA-7284), an inhibitor 
of SGLT2, in obese subjects, including some with impaired fasting glucose 
(IFG) or impaired glucose tolerance (IGT).
Materials and methods: In a double-blind, ascending, multiple-dose inpa-
tient study, 80 obese subjects (40 women) were randomized to CANA (30, 
100, 300, or 600 mg daily [OD] or 300 mg BID) or placebo (PBO) for 14 days. 
Subjects followed a fixed weight-maintaining diet 15 days prior to dosing un-
til the end of the study. IFG (5.5 mmol/l ≤ fasting plasma glucose [FPG] < 
6.93 mmol/l) and/or IGT (plasma glucose [PG] 2 h after a morning meal of 
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7.7-10.95 mmol/l) was present in 31 subjects. Renal threshold for glucose ex-
cretion (RTG) was calculated from urinary glucose excretion (UGE), glomer-
ular filtration rate, and PG.
Results: At baseline, subjects had a median age of 43 years (range, 21-59), 
a BMI of 33 kg/m2 (range, 30-39), and an FPG of 5.12 mmol/l (range, 3.14-
7.26). CANA significantly increased 24-h UGE (UGE24h) on days 1-14 (Ta-
ble), but there were no significant changes in FPG, mean 24-h PG, or insulin 
levels. Body weight decreased over the 14 days. Self-reported appetite and 
satiety measures did not change significantly. 
PBO CANA
Mean (SD) n=20 30 mg OD
n=12
100 mg OD
n=12
300 mg OD
n=12
600 mg OD 
n=12
300 mg BID
n=12
UGE24h
day -1, g
<0.1 (0.05) 0.2
(0.3)
0.2
(0.6)
<0.1 (0.02) <0.1
(0.02)
0.1
(0.1)
UGE 24h day 
14, g
<0.1 (0.04) 9
(4.2)
33a
(9.7)
47a
(23)
50a
(13)
61a
(16)
Body weight
day -1, kg
89.9
(12.8)
83.2
(12.9)
90.1
(10.0)
85.1
(9.6)
90.5
(16.3)
98.0
(13.3)
ΔBody 
weight
day 14 vs day 
-1, kg
-1.4 (1.1) -2.9b
(1.5)
-2.7b
(0.9)
-2.1
(1.6)
-3.4a
(1.3)
-3.5a
(1.4)
ap<0.0001; bp<0.01.
CANA decreased RTG in a dose-dependent manner, with maximal effect on 
lowering of the RTG to 3.5±0.9 mmol/l. In subjects with IFG and /or IGT 
on day -1, (n=31), treatment with CANA (n=22, all doses pooled) produced 
a significant reduction in 24-h mean PG (MPG) from 6.1±0.52 mmol/l on 
day -1 to 5.6 ±0.48 mmol/l on day 14 (p<0.05) compared with a correspond-
ing change from 6.1±0.66 mmol/l to 5.9±0.77 mmol/l (p>0.05) after PBO. 
CANA was generally well tolerated, with no hypoglycemia. Adverse events 
were transient and mild to moderate in severity. The most frequently report-
ed treatment-emergent adverse events were mild gastrointestinal disorders 
(20% in PBO and 0-50% across CANA dose groups). There were no clini-
cally meaningful changes in urine volume or frequency, vital signs, ECGs, or 
laboratory tests.
Conclusion: CANA was well tolerated and increased 24-h UGE, decreased 
RTG, and reduced body weight in obese healthy subjects. In addition, the data 
suggest that CANA is effective in reducing MPG in patients with IFG and/or 
IGT.
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Canagliflozin lowers the renal threshold for glucose excretion in lean, 
obese and type 2 diabetic subjects
D. Polidori1, S. Sha2, T. Sarich2, D. Devineni2, P.L. Rothenberg2; 
1Johnson & Johnson, La Jolla, 2Johnson & Johnson, Raritan, USA.
Background and aims: Urinary glucose excretion (UGE) can be approxi-
mated by a threshold relationship in which almost no glucose is excreted 
when plasma glucose (PG) concentrations are below the renal threshold for 
glucose excretion (RTG), and the rate of UGE increases with PG when PG 
exceeds RTG. The value of RTG is dependent on the capacity of renal glucose 
transporters; pharmacological inhibitors of the transporters reduce RTG. We 
aimed to determine the effects of canagliflozin (CANA; JNJ-28431754/TA-
7284), an inhibitor of sodium glucose co-transporter 2 (SGLT2), on RTG in 
healthy lean and obese subjects and subjects with type 2 diabetes (T2DM).
Materials and methods: Data from 3 clinical studies assessing the safety, tol-
erability, and pharmacodynamics of CANA were used. In study 1, lean males 
(BMI=20-30 kg/m2) were treated with 1 dose of 10-800 mg or 400 mg BID 
CANA (n=6/group). In study 2, obese otherwise healthy subjects (BMI=30-39 
kg/m2) were treated with 30-600 mg once daily (OD) or 300 mg BID CANA 
(n=12/group) for 2 weeks. In study 3, subjects with T2DM were treated with 
30-400 mg OD or 300 mg BID CANA (n=14-16/group) for 2 weeks. 24-h 
PG profiles, creatinine clearance (to estimate GFR), and UGE over 6 time 
intervals were measured. RTG was determined from these measurements by 
assuming a threshold relationship between UGE and PG and determining 
the value of RTG so that UGE calculated from the threshold approximation 
equals the measured UGE. This approach extends methods used for renal 
thresholds of other analytes by accounting for the dynamic changes in PG. 
24-h mean RTG (MRTG) was calculated from RTG values in each interval.
Results: CANA was well tolerated in the 3 studies with no observed hy-
poglycemia. Adverse events were transient and mild to moderate in sever-
ity. Urine volume, electrolyte excretion, renal function, and lab safety values 
did not change meaningfully. The method for determining RTG provided 
highly reproducible results in placebo-treated T2DM subjects (within-sub-
ject CV <3%). CANA dose-dependently reduced RTG; maximally effective 
doses (>200 mg OD in lean, >300 mg OD obese) reduced MRTG to 3.5±0.4 
mmol/l (mean±SD) in lean and 3.5±0.6 mmol/l in obese subjects (Figure). In 
subjects with T2DM, MRTG was elevated before CANA (13.8±1.6 mmol/l vs 
commonly reported values of 10-11 mmol/l in healthy subjects), consistent 
with reports of increased renal glucose reabsorption in T2DM, and CANA 
dose-dependently reduced MRTG to a minimum of 5.2±0.9 mmol/l at doses 
200 mg. Maximally effective doses maintained maximal suppression of RTG 
for the full 24-h period; with lower doses, RTG rose from the nadir in later 
intervals.
Conclusion: RTG in T2DM subjects before treatment was higher than often 
quoted values of 10-11 mmol/l. CANA dose-dependently decreased RTG in 
all 3 studies and values in subjects with T2DM were modestly higher than 
nondiabetic subjects given the same doses. CANA reduces RTG in T2DM 
subjects to ~5 mmol/l, a level not predicted to increase the risk of hypogly-
cemia.
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Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, 
improved glucose control in subjects with type 2 diabetes: Results of a 
phase 1b study
P.L. Rothenberg1, D. Devineni1, A. Ghosh1, D. Polidori2, M. Hompesch3, S. 
Arnolds4, L. Morrow3, H. Spitzer4, J. Blake1, D. Wexler2, Y. Tan2,  
K. Smulders5, K. Demarest5, S. Sha5; 
1Pharmaceutical Research and Development, Johnson & Johnson 
Pharmaceuticals, Raritan, USA, 2Pharmaceutical Research and 
Development, Johnson & Johnson Pharmaceuticals, La Jolla, USA, 3Profil 
Institute for Clinical Research Inc., Chula Vista, USA, 4Profil Institut für 
Stoffwechselforschung GmbH, Neuss, Germany, 5Johnson & Johnson 
Pharmaceuticals, Raritan, USA.
Background and aims: Inhibition of renal sodium glucose co-transporter 
2 (SGLT2) is a promising new approach for treating type 2 diabetes mellitus 
(T2DM). This study evaluated the safety, tolerability, and pharmacodynamic 
effects of canagliflozin (CANA, JNJ-28431754/TA-7284), a novel SGLT2 in-
hibitor, in subjects with T2DM. The effects of CANA on urinary glucose ex-
cretion (UGE), renal threshold for glucose excretion (RTG), plasma glucose 
(PG), body weight (BW), and beta cell function (BCF) were assessed.
Materials and methods: In this double-blind, multiple-dose study, subjects 
with T2DM discontinued their anti-hyperglycemic medications for 2 weeks 
and were then randomized to 2 weeks of treatment with CANA 30, 100, 200, 
400 mg daily (OD) or 300 mg BID, or placebo (PBO) while domiciled at study 
centers and maintaining an isocaloric diet. Subjects were domiciled from day 
-2 before treatment until 4 days after final treatment. At pretreatment base-
line (day -1) and at day 16, UGE, PG, fasting plasma glucose (FPG), C-pep-
tide, and RTG (calculated from UGE, PG, and GFR) were measured. BCF 
was assessed using the calculated insulin secretion rate (ISR) at 10 mM PG, 
determined from a model-based method using the frequently measured PG 
and C-peptide concentrations.
Results: 97 subjects (70 M/27 F; mean age 53 years, weight 91.8 kg, BMI 
30.88 kg/m2, HbA1C 8%) were randomized to CANA (5 doses) or PBO. 
CANA treatment increased UGE and decreased RTG in a dose-dependent 
manner (Table). CANA reduced 24-h PG, FPG, and BW (by approximately 1-
1.5 kg >PBO). BCF also improved in subjects treated with ≥100 mg of CANA 
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(Table). Adverse events were transient, mild to moderate in intensity, and 
balanced across treatment groups; 1 episode of vaginal candidiasis occurred 
in a CANA-treated subject. CANA treatment did not cause hypoglycemia, 
consistent with the RTG with CANA remaining above a hypoglycemic thresh-
old. There were no clinically meaningful changes in urine volume, electrolyte 
excretion, renal function, or routine lab safety test values.
Conclusion: In subjects with T2DM, CANA lowered RTG, lowered PG con-
centrations without causing hypoglycemia, reduced BW, and also improved 
BCF. In this study, CANA was well tolerated. If this profile is demonstrated in 
further studies, CANA could be a useful choice for treating T2DM.
Mean Parameter PBO n=19
30 mg 
n=16
100 mg 
n=16
200 mg 
n=16
400 mg 
n=16
300 mg 
BID n=14
24-h UGE day -1, g (SD) 24.5 (31.9)
10.9 
(11.9)
11.5 
(11.5)
22.2 
(32.9)
43.7 
(67.9)
12.5 
(16.4)
Δ24-h UGE day -1 to 16, 
g (SD)
-9.71 
(19.1)
69.1a 
(31.2)
76.4a 
(28.1)
88.0a 
(35.4)
113a 
(29.0)
88.3a 
(36.5)
24-h RTG day -1, mmol/l 
(SD)
13.4
(1.4)
14.4
(1.5)
13.5
(1.4)
13.7
(1.9)
14.5
(1.9)
13.3
(1.6)
24-h RTG day 16, mmol/l 
(SD)
12.9
(1.4)
8.4a
(1.3)
6.5 a
(1.0)
5.6 a
(1.2)
5.0 a
(0.8)
5.0 a
(0.7)
24-h PG on day -1, 
mmol/l (SD)
12.4
(2.8)
12.4
(1.9)
11.8
(2.3)
12.3
(2.9)
13.4
(3.9)
11.4
(2.9)
Δ24-h PG day -1 to 16, 
mmol/l (SD)
-1
(1.4)
-1.2
(1.0)
-2.6a
(1.4)
-3.2a
(2.4)
-3.6a
(2.1)
-3.0a
(1.7)
FPG day -1, mmol/l
(SD)
11.7
(2.4)
11.1
(1.7)
11.4
(2.0)
11.6
(2.8)
11.6
(3.0)
11.1
(2.5)
ΔFPG day-1 to 16,  
mmol/l (SD)
-1.4
(2.0)
-1.2
(1.2)
-3.0a
(1.3)
-3.6a
(2.9)
-3.3a
(2.7)
-3.7a
(2.0)
ISR at 10 mmol/l glucose, 
day -1, pmol/min/m2 
(SD)
135
(76)
139
(59)
160
(89)
155
(104)
145
(71)
181
(84)
ΔISR at 10 mmol/l glu-
cose, day -1 to 16, pmol/
min/m2 (SD)
24
(40)
20
(36)
94b 
(32)
86b 
(66)
94b 
(74)
120b 
(86)
ap<0.01; bp≤0.05; vs placebo.
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The potent and highly selective sodium-glucose co-cransporter (SGLT-2) 
inhibitor BI 10773 is safe and efficacious as monotherapy in patients with 
type 2 diabetes mellitus
E. Ferrannini1, L.J. Seman2, E. Seewaldt-Becker3, S. Hantel3, S. Pinnetti3, 
H.-J. Woerle4; 
1Medicine, University of Pisa, Italy, 2Clinical Research, Boehringer-
Ingelheim Pharmaceuticals, Inc, Ridgefield, USA, 3Clinical Operations 
and BDM, Boehringer Ingelheim GmbH & Co. KG, Ingelheim, Germany, 
4Medicine, Clinical Development and Medical Affairs, Boehringer 
Ingelheim GmbH & Co. KG, Ingelheim, Germany.
Background and aims: The aim of this randomized double-blind, placebo 
(PBO)-controlled, parallel-group comparison study was to investigate the ef-
ficacy and safety of BI 10773 for 12 weeks in patients with T2DM and insuf-
ficient glycemic control.
Materials and methods: A total of 408 patients (baseline means [standard 
deviation]: HbA1c 7.9 [0.8]%, age 57.5 [9.8] years, body mass index 29.0 [4.6] 
kg/m2) who were treatment naive or had undergone a 4-week washout peri-
od, were randomized to 12 weeks of double-blind treatment with BI 10773 5, 
10, 25 mg qd, PBO, or to open-label metformin (MET) 1000 mg bid or max. 
tolerated dose The primary endpoint was the change in HbA1c from baseline 
after 12 weeks of treatment.
Results: After 12 weeks, BI 10773 showed a dose-dependent and statistically 
significant reduction in FPG and HbA1c, compared with PBO (Table). Patients 
on BI 10773 25 mg qd showed a comparable reduction in FPG and HbA1c to 
those on MET. There was a significant reduction in body weight (BW) by ~2 
kg on BI 10773, 0.75 kg on PBO, and 1.32 on MET. Compared with PBO, 
mean BW reductions were statistically significant for all BI 10773groups 
(p<0.001), but not for MET. The number of adverse events (AEs) was compa-
rable among treatment groups (32.9% in PBO group, 38.8% in MET group, 
29.1% in BI 10773 groups). Most frequently reported AEs (>2%) in the BI 
10773 groups (average of AEs incidence of all BI doses) included pollakiuria 
(3.3% vs 0% in PBO), thirst (3.3% vs 0% in PBO) and nasopharyngitis (2.0% 
vs 1.2% in PBO). Frequency of urinary tract infection was low with BI 10773 
(1.2%) and comparable to PBO (1.2 %) and MET (1.3%). Incidence of genital 
infections was low; mycosis was reported in 0.8% and pruritus in 1.2% on BI 
10773 but none on PBO or MET. Six patients experienced at least 1 serious 
AE, of which none was drug related. (1.2 %vs 0% vs. 3.8 % Bi10773, PBO and 
MET, respectively).
Conclusion: In patients with T2DM, once daily administration of BI 10773, 
demonstrated a dose-dependent clinically meaningful reduction in glycemic 
control, comparable to those of metformin. Furthermore BI 10773 was as-
sociated with a clinically meaningful reduction in body weight. and showed 
a favourable safety profile.
PBO BI 5mg qd BI 10mg qd BI 25mg qd PBO MET
HbA1c(%) 0.09 -0.43* -0.48* -0.63* 0.07 -0.75*
HbA1c vs PBO (%) ----- -0.52* -0.57* -0.72* ----- -0.82*
FPG (mg/dL) 0.8 -23.3* -28.9* -31.1* 1.0 -29.7*
BW (kg) -.75 -1.81* -2.33* -2.03* -.75 -1.32
*p<0.001 vs PBO
Supported by: Boehringer Ingelheim GmbH & Co. KG
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Increased secretion of GLP-1 mediated by a newly discovered ligand for 
GPR119
K.B. Hansen1,2, F.K. Knop3, N.W. Andersen4, T.A. Diep4, M.M. Rosenkilde5, 
J.J. Holst2, H.S. Hansen4; 
1Department of Clinical Physiology, Glostrup Hospital, University of 
Copenhagen, Glostrup, 2Department of Biomedical Sciences, Faculty of 
Health Sciences, University of Copenhagen,  3Department of Internal 
Medicine F, Gentofte Hospital, University of Copenhagen, Hellerup, 
4Department of Pharmacology and Pharmacotherapy, Faculty of 
Pharmaceutical Sciences, University of Copenhagen, Copenhagen, 
5Department of Neuroscience and Pharmacology, Faculty of Health 
Sciences, University of Copenhagen, Denmark.
Background and aims: GPR119 is a G protein-coupled receptor expressed in 
pancreatic beta cells and the L-cells in the gastrointestinal tract in humans. 
In the intestine, activation of GPR119 results in the release of glucagon-like 
peptide-1 (GLP-1), which has been shown to improve glucose homeostasis 
through several mechanisms: e.g. stimulation of glucose-induced insulin 
secretion, inhibition of glucagon secretion and reduction of food intake. In 
search for activators of the GPR119 receptor our group recently identified a 
naturally occurring ligand with high affinity for the receptor (EC50 <1 μM), 
designated XX (patent protection; name of compound will be official at the 
Annual Scientific Meeting of EASD 2010). We aimed to investigate the im-
pact of XX on endogenous GLP-1 secretion in healthy subjects.
Materials and methods: Six healthy Caucasian male subjects (age: 23±2 years 
(mean±SEM); BMI: 23±1 kg/m2, fasting plasma glucose: 5.2±0.1 mM, HbA1c: 
5.2±0.04%) were investigated in a randomised single-blinded cross-over 
study. The subjects were given four different solutions on four different days 
using glycerol as vehicle: A) XX+glycerol (50 ml), B) glycerol, C) XX+glycerol 
and glucose (10 g), and D) glycerol and 10 g glucose. To prevent degradation 
in the stomach the solutions were delivered to the proximal jejunum through 
a tube placed distally to the ligament of Treitz. Plasma GLP-1, insulin and 
glucose were measured for four hours following delivery.
Results: The solution of XX (day A) elicited a significant greater initial GLP-1 
response compared to glycerol (day B) (AUC0-30 min: 98±33 vs. -39±21 pM×30 
min, p=0.036). We observed a significant greater initial plasma insulin re-
sponse following delivery of XX (day A) compared to glycerol (day B) (AUC0-
30 min: 809±168 vs. 321±104 pM×30 min, p=0.037). When the two solutions 
were administered along with glucose (day C and D) trends toward increased 
initial GLP-1 and insulin responses were observed.
Conclusion: These data show that XX induces secretion of GLP-1. This li-
gand might be a promising new way of stimulating endogenous GLP-1 secre-
tion using an oral regime. Further studies defining doses, formulation and 
long-term effects are needed.
879
Insulin sensitizer, BGP-15 prevents saturated fatty acid induced 
mitochondrial dysfunction
A. Kolonics1, C. Magyar2, E. Kiss3, Z. Literati-Nagy1, L. László4,  
P. Literati-Nagy1, K. Tory1; 
1Molecular Pharmacology, N-Gene Research Laboratories, 2Institute of 
Enzymology, Biological Research Center, 3Immunology, Eötvös Loránd 
University, 4General Zoology, Eötvös Loránd University, Budapest, Hungary.
Background and aims: Mitochondrial rotenone-sensitive NADH:ubiqui-
none oxidoreductase (complex I) activity and substrate switching were found 
to be diminished in obese and type 2 diabetic patients. Saturated long chain 
fatty acids, like palmitate inhibit complex I activity and result in increased 
mitochondrial ROS production. BGP-15 (R,S-O-(3-piperidino-2-hydroxy-1-
propyl)-nicotinic-acid-amidoxime) is a new type insulin sensitizer drug can-
didate in human phase 2 developmental stage. It has been demonstrated that 
BGP-15 facilitates the expression of inducible heat shock protein resulting in 
decreased activation of JNK, which is a common mediator of obesity associ-
ated insulin resistance. Affinity binding assay revealed binding of BGP-15 to 
NDUFS1, a 75 kDa iron-sulfure protein subunit of mitochondrial complex 
I. Now we report the effect of BGP-15 treatment on the activity of complex I 
and II and ROS production in palmitate and hyperglycemia exposed cells. We 
also aimed to characterize the possible docking site of BGP-15 at NDUFS1.
Materials and methods: The effects of BGP-15 on the activity of complex I 
and II was evaluated in human HaCaT keratinocytes and L6 murine myocytes 
using a specific electron acceptor, DCIP and NADH or succinate electron do-
nor. ROS production was measured by MitoSox or Amplex Red fluorescent 
probes. Vina and Surflex programs were used for molecular docking.
Results: BGP-15 treatment resulted in a rapid increase in the activity of com-
plex I while the activity of complex II was inhibited in hyperglycemia exposed 
cells. The elevated activity of complex I was maintained in the presence of the 
drug for days in hyperglycemic culture conditions. Palmitate treatment de-
creased the activity of complex I and increased the activity of complex II, and 
elevated mitochondrial ROS production in L6 myocytes. BGP-15 treatment 
restored the activity of complex I and reduced the activity of complex II. In 
addition super-oxide production was lowered back to the level of untreated 
control. Molecular docking analysis on the bacterial (Thermus Thermophy-
lus) homologue of human NDUFS1 identified a specific binding site (DG = 
- 7.2 kcal/mol) for BGP-15.
Conclusion: Data indicate that BGP-15 ameliorates the effects of palmitate 
on complex I resulting in balanced substrate oxidation and reduced ROS 
production. Molecular docking results support the concept that BGP-15 may 
target complex I, the main substrate entry and ROS producing site of mito-
chondria. Prevention of saturated fatty acid induced mitochondrial dysfunc-
tion can significantly contribute to insulin sensitizing effect of BGP-15.
Supported by: GOP 1.1.1
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GFT505, a new PPARα/δ agonist improves lipid and glucose homeostasis 
in prediabetic patients with atherogenic dyslipidaemia and/or impaired 
fasting glucose
R. Hanf1, E. Bruckert2, B. Cariou3, R. Darteil1, D. Hum1, B. Staels4; 
1GENFIT, Loos, 2Hopital de la Salpetrière, Paris, 3CHU Nantes, 4UMR 1011, 
Institut Pasteur de Lille,  France.
GFT505 is a drug candidate for the treatment of metabolic disorders associ-
ated with metabolic syndrome and Type 2 diabetes. GFT505 and GFT1007, 
its main active circulating metabolite, activate the PPARα and PPARδ sub-
types. GFT505 potently reduces plasma triglycerides and total cholesterol 
and increases HDL cholesterol in animal models of dyslipidemia. GFT505 
prevents the development of atherosclerotic plaques and has insulin-sen-
sitizing properties in mice. In Phase I trials in healthy volunteers, GFT505 
was well tolerated with no clinically relevant emergent adverse event. The 
maximum tolerated dose in humans has not been reached while a reduction 
in plasma triglycerides and increase in HDL-C was observed at doses from 
40 to 100 mg/d. The safety of GFT505 was confirmed in the ensuing phase 
IIa trials. In a double blind, placebo controlled phase IIa trial conducted in 
98 patients with atherogenic dyslipidemia (high triglycerides, low HDL-C), 
treatment with GFT505 at 80 mg/day for 28 days led to a 21 % (p=0.0027 vs 
placebo) reduction in triglycerides and a 9 % (p=0.003 vs placebo) increase 
in HDL-C. GFT505 significantly reduced ApoCIII (-17 %, p=0.04) and 
ApoB (-7 %, p=0.02), increased ApoA1 (+6%, p=0.002) and ApoA2 (+15 %, 
p<0.0001) and reduced fibrinogen and haptoglobin. These effects are compa-
rable to those reported with fibrates, such as fenofibrate, in this population. 
In contrast, GFT505 did not induce clinically significant effects on homocys-
teine and creatinine. Finally, GFT505 reduced two distinct indicators of liver 
dysfunction: alanine aministransferase (ALAT, -15 % vs placebo, p=0.02) and 
Gamma Glutamyl Transpeptidase (-20 % vs placebo) while it did not affect 
plasma levels of aspartate aminotransferase. In a phase II clinical trial con-
ducted in 47 patients with impaired fasting plasma glucose, impaired glucose 
tolerance and abdominal obesity, treatment with GFT505 (80mg/day) for 28-
days led to a significant reduction in fasting plasma glucose levels (-5% vs 
placebo, p=0,03). In parallel, significant reductions in fasting plasma insulin 
(-25% vs placebo, p=0,009) and C-peptide (-11% vs placebo, p=0,03) were 
also obtained. Thus, the HOMA insulin-resistance index (HOMA-IR) was 
significantly reduced by -31% vs placebo (p=0,0027). Moreover, a beneficial 
effect of the compound on plasma lipids was observed with a significant re-
duction of LDL-C (-11% vs placebo, p=0,0049) and triglycerides (-25% vs 
placebo, p=0,0003) and an increase in HDL-C (+9% vs placebo, p=0,003). Fi-
nally, treatment with GFT505 led to a significant reduction in markers of in-
flammation (fibrinogen, -10%, p=0,0128; haptoglobin, -16%, p=0,007) while 
homocysteine levels remained unchanged. These first clinical trials position 
GFT505 as a new efficient and safe drug candidate for the treatment of predi-
abetic patients with impaired fasting glucose and atherogenic dyslipidemia.
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P1738, a novel insulin sensitizer improves metabolic control with a 
favourable weight profile in mice
R.A. Marita, G.S. Raza, R. Rathish, S. Bhumra, J. Anthony, V. Bhor,  
G. Chimote, N. Deka, S. Sharma; 
Piramal Life Sciences Limited, Mumbai, India.
Background and aims: Type 2 Diabetes is characterized by peripheral insu-
lin resistance and insulin deficiency. While most of the current treatments 
have focused on improving glycemic control, measures that can prevent 
co-morbidities such as dyslipidemia, hypertension and obesity are useful in 
reducing cardiovascular disease. Thiazolidinedione (TZD) drugs, including 
rosiglitazone exhibit potent antidiabetic and insulin sensitizing effects. How-
ever, TZD therapy has been associated with adverse cardiovascular outcomes 
and weight gain. Therefore, insulin sensitizers with improved safety profile 
are urgently needed. In this regard, we have used a phenotypic screening par-
adigm, capable of selecting modulators of insulin sensitivity, and identified 
P1738 as the lead compound. The present study describes the in vitro and in 
vivo pharmacology of P1738.
Materials and methods: We screened our chemical library in the phenotypic 
assay of adipogenesis using 3T3-L1 cells. The positives were evaluated for glu-
cose uptake in the insulin resistant adipocytes and were identified as hits. The 
antidiabetic efficacy of these hits was investigated in ob/ob and db/db mice. 
Further, cardiac and developmental toxicity was determined using the zebra 
fish model.
Results: P1738 (20 µg/ml) enhanced insulin-induced adipogenesis of 3T3 
fibroblasts. P1738 stimulated glucose uptake (EC50 - 0.5 µM) in the insu-
lin resistant adipocytes. P1738 did not cause activation of PPARα/γ receptors 
in transactivation assays. Chronic oral treatment of ob/ob mice with P1738 
induced a dose-related reduction in plasma glucose (23% at 200 mg/kg) and 
triglyceride levels (18% at 100 mg/kg and above). An oral glucose tolerance 
test carried out on day18 revealed that P1738 improved (p<0.01) glucose tol-
erance similar to rosiglitazone. Interestingly, P1738 treatment did not induce 
weight gain in mice, at all the tested doses (50 to 200 mg/kg) compared to 
rosiglitazone treatment (5 mg/kg) which induced 12% gain (p<0.001). Fur-
ther, P1738 treatment did not significantly affect hematocrit and plasma pro-
tein levels, in contrast to rosiglitazone which induced significant reduction 
(p<0.001). P1738 exhibited an excellent liver safety profile with no changes 
in weight or triglyceride levels, even at 200 mg/kg while rosiglitazone (5 
mg/kg) caused hepatomegaly and 30% (p<0.01) increase in liver triglyceride 
levels. P1738 was also efficacious in db/db mice wherein administration of 
100 mg/kg resulted in 26% reduction in glucose levels while rosiglitazone 
(5 mg/kg) induced 35% reduction. Importantly, while rosiglitazone caused 
significant (p<0.05) weight gain, animals exposed to P1738 did not register 
significant change in body weight. When administered to diet-induced obese 
mice, P1738 did not cause weight gain while rosiglitazone induced significant 
increase during the same period. In a zebrafish model, P1738 (100 µg/ml) did 
not induce any adverse effects whereas pericardial edema was observed with 
rosiglitazone (25 µg/ml).
Conclusion: This study shows that P1738 is a novel insulin sensitizer with no 
PPARα/γ transactivation potential. Improvement in glycemic and extraglyce-
mic parameters caused by P1738, in mouse models of obesity, is associated 
with a favorable weight profile. Thus P1738, with its unique pharmacology 
and improved safety profile, may represent an alternative treatment for Type 
2 Diabetes.
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A selective GPR40 agonist, TAK-875, stimulates glucose-dependent 
insulin secretion without beta cell toxicity and decreases blood 
glycosylated haemoglobin levels in diabetic rats
K. Takeuchi, Y. Tsujihata, R. Ito, M. Suzuki, A. Harada, M. Hazama; 
Pharmaceutical Research Division, Takeda Pharmaceutical Company 
Limited, Osaka, Japan.
Background and aims: GPR40 is highly and dominantly expressed in pan-
creatic beta cells and is activated by medium- to long-chain free fatty acids 
(FFAs) to potentiate glucose stimulated insulin secretion. While GPR40 is 
an attractive target for Type 2 diabetes, it is unclear whether agonists or an-
tagonists represent the best therapeutic approach. TAK-875 is a novel, oral, 
and selective small molecule agonist of GPR40 under development as a once-
daily treatment for type 2 diabetes. In this study, pharmacological effects of 
TAK-875 were examined.
Materials and methods: EC50 for inositol monophosphate (IP) produc-
tion was assessed in Chinese hamster ovary cells expressing human GPR40 
(hGPR40-CHO). Acute effects (2h) of TAK-875 and glibenclamide were mea-
sured in rat insulinoma INS-1 833/15 cells. Chronic effects (72h) of TAK-875 
and FFAs were measured in rat insulinoma INS-1 832/13 cells. Oral glucose 
tolerance test (OGTT) was performed in male N-STZ-1.5 diabetic rats (18w). 
Measurement of metabolic parameters after chronic treatment with TAK-875 
for 6 weeks were performed in female Wistar fatty (WF) rats (14w).
Results: TAK-875 (EC50=0.072 μM) showed over 400-fold stronger agonist 
activity compared to oleic acid (EC50=29.9 μM) in IP production assay in 
hGPR40-CHO cells. In rat insulinoma INS-1 833/15 cells, TAK-875 increased 
intracellular IP and calcium concentration, indicating that the compound 
activates Gαq signaling pathway. Unlike the sulfonylurea glibenclamide (10 
μM), the insulinotropic action by TAK-875 (10 μM) in INS-1 833/15 was 
glucose-dependent. Chronic exposure to TAK-875 (100 μM) for 72h in INS-
1 832/13 cells did not affect insulin secretion, insulin content, or caspase 
3/7 activity, while similar exposure to palmitic acid (1 mM) decreased both 
insulin secretion and insulin content, and increased caspase 3/7 activity. In 
an oral glucose tolerance test in N-STZ-1.5 diabetic rats, TAK-875 showed 
dose dependent improvement of glucose tolerance and potently augmented 
insulin secretion. Chronic treatment with TAK-875 in WF rats dose depend-
ently decreased glycosylaed hemoglobin with no effects on body weight or 
pancreatic insulin content.
Conclusion: Our results support the concept that TAK-875 therapy may be 
an effective treatment of Type 2 diabetes without causing beta-cell toxicity.
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Chemokine receptor 2 antagonist CCX140-B in Phase 2 for type 2 
diabetes
T. Sullivan, S. Miao, R. Berahovich, N. Zhao, S. Ungashe, D. Johnson,  
P. Bekker, J. Jaen, T.J. Schall; 
ChemoCentryx, Inc, Mountain View, USA.
Background and aims: CCX140-B is a highly specific oral chemokine recep-
tor 2 (CCR2) antagonist in Phase 2 development for treatment of type 2 dia-
betes mellitus. Increased adiposity leads to elevated recruitment of inflamma-
tory monocytes/macrophages into adipose tissue. Concurrent with increased 
adipose macrophage numbers, local and systemic elevations in inflamma-
tory markers, such as TNFα, IL-6, and monocyte chemoattractant protein-1 
(MCP-1)/chemokine ligand 2 (CCL2) are also seen and these inflammatory 
mediators have been shown to impair insulin sensitivity in multiple tissues. 
Studies in rodent models of insulin resistance and type 2 diabetes have indi-
cated that the CCR2:MCP-1 axis is a primary control point for the entry of 
inflammatory macrophages in the adipose tissue of obese subjects.
Materials and methods: Male C57Bl/6 mice were placed on high-fat diet at 6 
weeks of age for 18 to 24 weeks. Metabolic profiling (blood glucose, insulin, 
adiponectin) was determined in fasted mice. CCR2 antagonist or placebo was 
delivered once daily via subcutaneous injection for 7 to 28 days. Adipose tis-
sue macrophage numbers were determined by fractionation of epididymal fat 
pads followed by flow cytometry to identify macrophages. Preclinical stud-
ies were followed by single and multiple ascending dose placebo-controlled 
Phase 1 clinical trials of the CCR2 antagonist CCX140-B at doses ranging 
from 0.05 mg to 10 mg in 88 healthy volunteers.
Results: Daily treatment with CCR2 antagonist significantly improved fasting 
glucose and HOMA-IR levels in obese, diabetic mice over 28 days of treat-
ment (see table). Circulating adiponectin levels were significantly reduced in 
obese, diabetic mice and this was reversed by CCR2 antagonist treatment. 
The metabolic improvements correlated with a significant reduction in adi-
pose tissue macrophage numbers. CCL2 levels were unchanged in mice treat-
ed with CCR2 antagonist. Additionally, circulating populations of monocytes 
were unchanged in the mice. CCX140-B was well tolerated in Phase 1 clini-
cal trials. No serious adverse events (AEs) or withdrawals due to AEs were 
observed. No clinically significant laboratory abnormalities, vital signs, or 
ECG changes were observed. CCX140 pharmacokinetics were relatively lin-
ear across the dose range, with Tmax of 1.4 to 3.2 hr and plasma half life of 40 
to 58 hrs. Plasma MCP-1 levels, as well as circulating monocyte populations 
were unchanged after CCX140-B dosing, in contrast to results observed with 
other CCR2 antagonists. Based on the encouraging results from preclinical 
and Phase 1 clinical trials, a Phase 2 study in subjects with type 2 diabetes 
mellitus was initiated.
Conclusion: Oral CCR2 antagonist treatment improved metabolic function 
in mice without a corresponding increase in MCP-1. CCX140-B was well tol-
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erated in Phase 1 with an attractive PK profile suitable for 5 to 10 mg once 
daily oral treatment.
CCR2 Antagonist Effect on Metabolic Profile in C57Bl/6 Mice (mean ± SD)
Variable Normal Lean 
Mice
Vehicle-Treated 
Obese Mice
CCR2 Antagonist 
Treated Obese 
Mice
Fasting Blood Glucose 
(mg/dL)
105 ± 5 205 ± 9 140 ± 9*
Serum Adiponectin 
(ng/mL)
18.0 ±1.1 8.0 ± 0.5 14.3 ± 0.5*
HOMA-IR 1.7 ± 0.5 39.5 ± 9.0 9.4 ± 1.7*
Adipose Macrophages 
(cells/g)
34000 ± 9300 65000 ± 8500 27000 ± 6500*
* p < 0.005 vs vehicle
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Imeglimin, a novel glimin oral antidiabetic, exhibits good glycaemic 
control in type 2 diabetes mellitus patients
V. Pirags1, H. Lebovitz2, P. Fouqueray3; 
1Faculty of Medicine, Pauls Stradins Clinical University Hospital, Riga, 
Latvia, 2Department of Medicine, State University of New York, Staten 
Island, USA, 3Poxel Pharma, Lyon, France.
Background and aims: Imeglimin is the first in the new glimin class of oral 
antidiabetic agents that targets insulin resistant organs and addresses beta cell 
failure. In decreasing mitochondrial oxidation, imeglimin inhibits excessive 
hepatic glucose production and restores peripheral glucose uptake as well as 
glucose-dependent insulin secretion. We investigated imeglimin’s effects on 
glycaemic control compared with metformin in T2D patients.
Material and methods: Two phase II studies were conducted. In one, a 4-
week repeat dose of imeglimin (2000 mg once daily [od], N=20; 1000 mg 
twice daily [bid] N=19) was compared with metformin (850 mg bid, N=19) 
over 4 weeks on glucose AUC during an OGTT. In the other, two daily doses 
of imeglimin (500 mg bid, N=31; 1500 mg bid, N=31) were compared with 
placebo (N=33) and metformin (850 mg bid, N=33) over 8 weeks and AUC 
glucose during a prolonged meal test, fasting plasma glucose (FPG) and 
HbA1c were recorded.
Results: Baseline-adjusted changes in the OGTT AUC were -33% for imegli-
min bid (p<0.0001), -30% for metformin (p<0.0004) and -10% for imeglimin 
od (p=0.0305). In the second study, the least square mean changes in AUC0-6h 
were significantly different from placebo for imeglimin 1500 mg and met-
formin with no statistical difference between the two treatment groups. De-
creases in FPG and HbA1c were observed for imeglimin 1500 mg and metfor-
min. Only limited efficacy of the imeglimin 500 mg dose was noted. A greater 
response in all glycaemic parameters was generally observed for treatment 
naïve subjects compared with those previously treated and those with more 
severe hyperglycemia (HbA1c ≥8%) compared with less severe hyperglycemia 
(HbA1c <8%). 
Mean Change from Baseline (Standard Error of the Mean)
Parameter
Imeglimin 
500 mg bid
Imeglimin 
1500 mg bid
Metformin 
850 mg bid
Placebo
AUC0-6h glucose (mmol/L)
Overall 103.4 (158.5) -365.7 (179.5) -629.4 (144.7) 463.1 (165.1)
p-value 0.086 0.003 <0.0001 --
Treatment naïve -58.1 (153.8) -515.9 (349.5) -672.3 (191.1) 855.7 (159.1)
FPG (mmol/L)
Overall 0.24 (0.35) -0.88 (0.29) -1.39 (0.21) 0.75 (0.35)
Treatment naïve -0.15 (0.07) -1.13 (0.29) -1.63 (0.19) 1.21 (0.22)
HbA1c (%)
Overall 0.37 (0.18) -0.13 (0.11) -0.26 (0.09) 0.29 (0.12)
Treatment naïve -0.40 (0.08) -0.54 (0.07) -0.44 (0.14) 0.11 (0.1)
No serious or severe adverse events associated with imeglimin were reported. 
No imeglimin-related adverse events were noted at its highest dose. In addi-
tion, no clinically significant changes in laboratory parameters, vital signs or 
ECGs were observed.
Conclusions: It was demonstrated that imeglimin was as effective as met-
formin at reducing AUC0-6h, FPG and HbA1c, with no safety issues. Imeglimin 
is suitable for use as monotherapy at diagnosis of T2D and may be effective at 
any stage in the T2D continuum, from diagnosis through to disease compli-
cations. Because of its unique mechanism of action it may be well suited for 
combination therapy with most other classes of antidiabetic agents.
885
A multicenter, randomised, placebo-controlled, paralled group, double-
blind, Phase II trial to evaluate the efficacy and safety and to determine 
the optimal dose of LC15-0444 in Korean subjects with type 2 diabetes
S.W. Kim1, W.Y. Lee1, K.-H. Yoon2, S.J. Yoo3, I.-K. Lee4, S.H. Baek5, Y.K. Kim6, 
M.K. Lee7, K.S. Park8, J.Y. Park9, B.S. Cha10, H.W. Lee11, K.W. Min12,  
H.-Y. Bae13, E.J. Rhee1; 
1Department of Internal Medicine, Kangbuk Samsung Hospital, Seoul,  
2Seoul St. Mary’s Hospital, 3Holy Family Hospital, Bucheon, 4Kyungpook 
National University Hospital, Daegu, 5Korea University Guro Hospital, 
Seoul, 6Pusan National University Hospital, 7Samsung Medical Center, 
Seoul, 8Seoul National University Hospital, 9Asan Medical Center, Seoul, 
10Severance Hospital, Seoul, Korea, Republic of, 11Yeungnam University 
Medical Center, Daegu,  12Eulji Medical Center Medical Corporation, Seoul, 
13Chosun University Hospital, Gwangjoo, Republic of Korea.
Background and aims: The objective of this study was to evaluate the efficacy 
and the safety of a novel dipeptidyl peptidase-4 (DPP-4) inhibitor, LC15-0444 
and determine the optimal dose in Korean subjects with exercise/diet-con-
trolled type 2 diabetes mellitus.
Materials and methods: In a double-blind, randomized, multicenter, paral-
lel group, dose-range finding study, 145 patients (91 men and 54 women) 
with median age 53 years and with median BMI 25.1 kg/m2 participated the 
study. Median fasting plasma glucose at baseline was 145 mg/dL and median 
HbA1c was 7.9%. Median duration since diagnosis of diabetes was 3 years. 
After 2 weeks of exercise/diet program and 2 weeks of placebo period after 
that, subjects were randomized to one of 4 groups, placebo, 50, 100 and 200 
mg, for 12-week active treatment period.
Results: All three doses of LC15-0444 reduced HbA1C level from baseline 
to week 12 significantly compared to placebo (-0.06 vs. -0.98, -0.74, -0.78% 
in placebo, 50,100 and 200 mg respectively), with no significant differences 
among different dosings. Subjects with higher HbA1c level(≥8.5 %) at base-
line experienced greater HbA1c reductions compared with the subjects with 
lower HbA1c level(<8.5%). Insulin secretory function assessed by HOMA-β, 
and C-peptide, and insulinogenic index was significantly improved by LC15-
0444 treatment, and insulin sensitivity, assessed by HOMA-IR, was also sig-
nificantly improved after 12 weeks of treatment. For lipid parameters, 50 and 
200 mg groups showed significantly reduced total cholesterol and LDL-C 
level at week 12 from baseline compared with placebo. All 3 dosing groups 
did not have any effects on body weight nor on waist circumference, and the 
incidence of adverse events was similar in all four groups.
Conclusion: Once-daily LC15-0444 monotherapy for 12 weeks improved 
glycemic control in HbA1c, FPG, post oral glucose tolerance test (OGTT) 
glucose, improved measures of β-cell function and insulin sensitivity, and was 
well tolerated in Korean subjects with type 2 diabetes.
Supported by: LGLS
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The new dual glucagon-GLP-1 agonist ZP2929 improves glycaemic 
control and reduces body weight in murine models of obesity and insulin 
resistance
J.R. Daugaard1, D. Riber1, K.S. Larsen1, E. Maier1, C.Æ. Bæk1, G. Kampen2; 
1Zealand Pharma A/S, Glostrup, 2Novo Nordisk A/S, Bagsværd, Denmark.
Background and aims: Oxyntomodulin is released from L cells of the small 
intestine in response to meal ingestion, and is believed to exert its biological 
effects by activating both the GLP-1 receptor and the glucagon receptor, 
i.e. by acting as a dual glucagon-GLP-1 agonist. ZP2929 is a potent dual 
glucagon-GLP-1 receptor agonist with a pharmacokinetic profile compatible 
with once daily dosing. The effect of ZP2929 was studied in eight months 
high fat fed C57Bl/6J mice, as an animal model of insulin resistance and in 
four weeks high fat fed C57Bl/6J mice, as a model of obesity. ZP2929 was 
compared to vehicle and exendin-4.
Materials and methods: To assess the effect of ZP2929 on insulin resistance, 
eight months high fat fed C57Bl/6J male mice were randomized into groups 
with similar average fasting glucose, and treated twice daily s.c. with ZP2929 
(10 nmol/kg), exendin-4 (10 nmol/kg), or vehicle. After 3 weeks of treatment, 
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following an initial blood sample for the determination of fasting blood glu-
cose level, oral glucose tolerance tests were performed. To investigate the ef-
fect of ZP2929 on body weight gain, four weeks high fat fed C57Bl/6J male 
mice were randomized into groups with similar average body weight and 
treated twice daily s.c. with ZP2929 (0.6, 1.6, 3.2, 6.4 and 12.7 nmol/kg), ex-
endin-4 (0.2, 0.5, 2, 5, 10 and 20 nmol/kg) or vehicle. Before treatment and 
after four and six weeks of treatment, blood samples were taken and blood 
lipids (low and high density lipoproteins (LDL and HDL), total cholesterol 
(TC) and triglycerides) measured.
Results: In eight months high fat fed C57Bl/6J mice, treatment with ZP2929 
and exendin-4 for three weeks significantly (p<0.05) prevented the increase 
in fasting blood glucose seen in vehicle-treated animals. ZP2929 and exend-
in-4 improved glucose tolerance (measured as decrease in the area under the 
glucose curve) by 15.7 % and 30.3 %, respectively. In four weeks high fat fed 
C57Bl/6J mice, treatment with ZP2929 and exendin-4 significantly (p<0.05) 
and dose-dependently reduced body weight gain over time, compared to 
vehicle-treated animals. ZP2929 (12.7 nmol/kg) was significantly (p<0.05) 
more efficient than a similar dose of exendin-4 (10 nmol/kg) in preventing 
body weight gain. Plasma lipid parameters demonstrated a tendency to in-
crease over time in vehicle-treated animals. At the two highest doses, ZP2929 
and exendin-4 reduced the increase in plasma LDL, HDL and TC.
Conclusion: In conclusion, the new glucagon-GLP-1 agonist ZP2929 im-
proves glucose control, markedly decreases body weight gain and improves 
blood lipid profile in murine models of insulin resistance and obesity.
887
Long-term effect of amylin on the glucose metabolism of extrapancreatic 
tissues in insulin-resistant and type 2 diabetic states
A. Acitores1, P. Moreno1, I. Gutiérrez-Rojas1, B. Nuche-Berenguer1,  
M. El Assar2, L. Rodrigrez-Mañas2, I. Valverde1, A. Novials3,  
M.L. Villanueva-Peñacarrillo1; 
1IIS-Fundación Jiménez Díaz, Madrid, 2Hospital de Getafe, Madrid, 
3Hospital Clinic, Barcelona, Spain.
Background and aims: Amylin is glucose dependently co-secreted with insu-
lin from the pancreatic β-cell, one another perhaps in an independent man-
ner; it inhibits gastric emptying and glucagon release, reduces postprandial 
hepatic glucose productions, and shows anorexic effects. In type 2 diabetes, 
amylin secretion could is impaired. We studied the effect of amylin treatment 
on parameters related to the glucose metabolism of extrapancreatic tissues, 
in insulin-resistant (IR) and type 2 diabetic (T2D) rat models, compared to 
normal (N) animals.
Materials and methods: Male Wistar rats were used. IR was induced by 
chronic feeding -8 weeks- with standard chow combined with D-fructose 
(20% in the drinking water). T2D was developed by streptozotocin injection 
(100 μg/g bw) at birth. IR, T2D and N were treated (3 days) with saline (con-
trol) or 100 pM amylin (n=5-10 rats/group), through an osmotic pump; in 
fed conditions, blood samples were taken before and by the end of treatment 
for plasma glucose and insulin (RIA) measurements; GLUT-2 and GLUT-4 
expression -Western blot and RT-PCR- was respectively studied in liver, mus-
cle and fat; liver glycogen content, soleus muscle glycogen synthase a (GSa) 
-UDP-[14C]glucose incorporation into glycogen- and isolated adipocytes 
glucose transport (GT) -2-deoxi-D-[1,2-3H]glucose uptake-, were measured.
Results: The liver of IR (n=7 rats) and T2D (n=5), both showed GLUT-2-
mRNA lower than (0.23±0.03 and 0.16±0.1 times N-control; p<0.001) and 
protein (overall mean: 62±6% N-control, p<0.001); amylin further reduced 
(p<0.01) mRNA in IR, without altering that in T2D; while failing to mod-
ify GLUT-2-protein in either group, amylin increased it in N (182±15% N-
control, p<0.001). Respect N, liver glycogen content in IR (193±20 µg/mg 
protein) and T2D (230±18 µg/mg protein) was close to half lower (p<0.01); 
amylin increased the value in IR and T2D (573±66 µg/mg protein and 
398±4, p<0.01 vs respective control). Muscle Glut-4-mRNA (n=10 rats) in 
IR and T2D were higher and lower, respectively, than in N (both p<0.01); 
amylin failed to modify the level in N or T2D, but apparently increased it in 
IR (1.49±0.39 times IR-control); Glut-4-protein was higher in IR (243±39% 
N-control p<0.05) and slightly lower in T2D (p<0.05); amylin, further re-
duced it in T2D (72±4% T2D-control, p<0.001) while increased it in IR 
(157±15% IR-control, p<0.05). GSa in IR and T2D was lower (38±14% N and 
40±13%, respectively; p<0.05), and amylin normalized it in IR (53±3% N). In 
adipose tissue (n=11 rats), GLUT-4-mRNA in IR and T2D was lower (both 
p<0.02 vs N), while the protein was higher in T2D (p<0.001 vs N); amylin 
reduced GLUT-4-protein in N, but increased it in IR and T2D (p<0.01). GT 
in IR (8.1±0.5 fmol/105 cells, n=6) was lower (p<0.01 vs N) and that in T2D 
(45.1±2.7, n=23) higher (p<0.001); amylin normalized it in both groups, by 
respectively increasing (p<0.02) and reducing (p<0.001) the value. No major 
changes in plasma parameters were detected in any group after treatment.
Conclusion: In insulin-resistant and type 2 diabetic states, amylin could exert 
a restoring action on the deleterious glucose metabolism of extrapancreatic 
tissues participating in the glucose homeostasis, by perhaps increasing insu-
lin sensitivity through its normalizing effect upon their altered glucotrans-
porters expression.
Supported by: FIS, CIBERDEM, ENDODIAB
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Vitamin D and calcium supplementation in adults at risk for type 2 
diabetes. The CADDM randomised controlled trial
A. Pittas1, J. Goetz1, B. Dawson-Hughes2; 
1Tufts Medical Center, Boston, 2Tufts University, Boston, USA.
Background and aims: Vitamin D and calcium have been shown to modify 
risk of type 2 diabetes in observational studies, but evidence from trials is 
lacking. The aim of the study was to determine whether vitamin D or calcium 
supplementation either alone or in combination improve glucose homeosta-
sis in adults with glucose intolerance.
Materials and methods: Ninety-two adults with fasting plasma glucose 
(FPG) ≥100 mg/dl or 2-hour glucose (2hPG) ≥140 mg/dl after 75 grams of 
dextrose and Hemoglobin A1c 5.8 - 7% were randomized in a 2x2 factorial 
design to 1 of 4 arms as follows: vitamin D3 (2,000 IU once daily) and calcium 
carbonate (400 mg twice daily), vitamin D3 and placebo-calcium, calcium 
and placebo-vitamin D or placebo-vitamin D and placebo-calcium between 
October 2007 and November 2009. Outcome was change in glycemia (hemo-
globin A1c, FPG and 2hPG) from baseline to 16 weeks. [ClinicalTrials.gov 
Identifier: NCT00436475]
Results: Enrolled participants had a mean age of 57 years, BMI of 32 kg/
m2, 25-hydroxyvitamin D of 32 ng/ml and A1c of 5.9%. The difference in 
25-hydroxyvitamin D between vitamin D3 and placebo-vitamin D was 13.3 
ng/ml (p<0.001). Participants assigned to vitamin D3 had a smaller rise in 
hemoglobin A1c compared to those on placebo-vitamin D (0.05 vs. 0.15% 
respectively; p=0.034). Fasting plasma glucose (-0.08 vs. 2.2 mg/dl; p=0.12) 
and 2hrPG (-10.1 vs. 0.54 mg/dl; p=0.14) also improved, but the difference 
between groups was not statistically significant. Combined vitamin D3 and 
calcium carbonate improved glycemia more than vitamin D3 alone or cal-
cium alone compared to the group assigned to placebos (0.04 vs. 0.08 vs. 0.11 
vs. 0.20% respectively).
Conclusion: In adults at risk for type 2 diabetes, supplementation with vita-
min D3 attenuates the increase in glycemia that occurs over time. The addi-
tion of calcium carbonate appears to further improve glycemia. Our findings 
need to be confirmed in long-term randomized trials.
Supported by: National Institutes of Health
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The effect of vitamin D supplementation on beta cell function and 
insulin sensitivity during a mixed meal tolerance test in healthy humans
G. Bock1, B. Prietl1, J.K. Mader1, J. Fruhmann1, S. Pilz1, N. Hueter1,  
B.M. Obermayer-Pietsch1, T.R. Pieber1,2; 
1Endocrinology and Nuclear Medicine, University Hospital Graz, 2Joaneum 
Research, Graz, Austria.
Background and aims: Increasing evidence from animal and human stud-
ies suggests that vitamin D may play a role in modifying risks of diabetes 
and other autoimmune diseases. Potential mechanisms of action of vitamin 
D on glucose metabolism include direct effects on the beta cell function and 
insulin sensitivity. The aim of our study was to evaluate the effect of a short 
time, high dose 25-OH vitamin D [25(OH)D] supplementation on glucose 
metabolism in healthy humans.
Materials and methods: 35 healthy subjects (16 females / 19 males, 35±11.4 
years, 24.1±3.8 kg/m² BMI) were randomised to vitamin D supplementation 
(140.000IU monthly) or placebo (almond oil). A standard liquid mixed meal 
tolerance test (MMTT) (6ml Isosource /KG bodyweight) was performed at 
baseline and after 3 months of treatment. Areas under the curve (AUC) for 
glucose, insulin and C-peptide from pre-meal to 120min after consumption 
were calculated as were the Matsuda index of insulin sensitivity.
Results: 25(OH) D serum levels increased from 27.2±11.0 (mean ±SD) to 
60.2±21.1ng/ml in the treatment group (n= 17) whereas 25(OH) D levels de-
creased from 25.6±7.1 to 18.8±7.2 ng/ml in the placebo group (n=18) during 
the 12 week study period. In the group receiving 25(OH) D supplementation 
the AUC for glucose (12258.2±1760.6 vs. 11577.8±2024.1 mg/dl; p=0.020) 
and insulin (5656±3207 vs. 4935.5±3363 µU/ml; p=0.087) decreased, with 
the main improvement of the AUC delta glucose (43.5±23.0 vs. 25.6±15.8mg/
dl; p=0.014) and AUC delta insulin (83.4±56.5 vs. 59.9±50.8µU/ml; p=0.003) 
from 0 to 30min of the MMTT. Changes in AUC for C-peptide did not 
reach significant levels. The Matsuda insulin sensitivity index values in-
creased slightly from 11.1±5.3 to 12.6±9.5 (p n.s.) in the treatment group 
but decreased significantly in the placebo group from 15.1±13.3 to 10.4±5.9 
(p=0.023). In both groups no clinically relevant adverse events occurred.
Conclusion: Our data show that vitamin D supplementation in apparently 
healthy humans with insufficient 25(OH)D levels improves beta cell function 
and insulin sensitivity over a short period of time and support the beneficial 
effects of vitamin D on glucose metabolism.
Supported by: an EASD/MSD grant
890
Anti-diabetic effect of add-on gynostemma pentaphyllum tea therapy 
with sulfonylureas in randomly assigned type 2 diabetic patients
H.T.T. Vu1,2, P.V. Dao3, T. Pham4, H.K. Nguyen5, C.-G. Ostenson1; 
1Department of Molecular Medicine & Surgery, Endocrine & Diabetes Unit, 
Karolinska Institute, Stockholm, Sweden, 2Department of Internal Medicine, 
Hanoi Medical University, Viet Nam, 3Department of Pharmacology, Hanoi 
Medical University, Viet Nam, 4National Institute of Gerontology, Hanoi, 
Viet Nam, 5Dept of Internal Medicine, University of Manitoba, Winnipeg, 
Canada.
Background and aims: In Vietnam, herbs have been used traditionally to 
treat diabetic patients. Our previous works on Gynostemma pentaphyllum 
(GP) have revealed the anti-diabetic effect of GP extract in normal rats, asso-
ciated with a novel insulin releasing gypenoside - phanoside. In addition GP 
tea has been proven in our recent clinical study to possess anti-diabetic effect 
with good safety data in newly diagnosed T2D patients, and to have effect on 
insulin sensitivity. The aim of the study was to investigate the anti-diabetic 
effect of the traditional Vietnamese herb GP as add-on therapy with sulfony-
lurea (SU) in 25 drug-naïve type 2 diabetic (T2D) patients.
Materials and methods: After 4-week treatment with gliclazide modified-
release preparation, 30 mg daily, all patients were randomly assigned into 2 
groups to add-on GP tea or placebo tea, 6g daily, during eight weeks. Fasting 
plasma glucose (FPG), C-peptide and insulin levels, HbA1C and oral glucose 
tolerance tests (OGTT) were measured before, during and after the treat-
ment.
Results: After 4-week treatment with SU, FPG and HbA1C significantly de-
creased (p<0.001), C-peptide and insulin levels increased, and lipid profile 
improved significantly. There were no statistically significant differences be-
tween the groups allotted to GP and placebo tea. The decrease in FPG after 
eight weeks was 2.9 ± 1.7 mmol/l in the GP group and 0.9 ± 0.6 mmol/l in the 
control group (p < 0.001). Therapy with GP tea also significantly decreased 
30 and 120 minute OGTT post-load values. HbA1C levels decreased ap-
proximately 2%-units in the GP group compared to 0.7%-unit in the controls 
(p=0.001). The glycometabolic improvements were achieved without any ma-
jor change of circulating insulin and C-peptide levels. There were no changes 
in Homeostasis Model Assessment-Insulin Resistance, lipids, body measure-
ments, blood pressure and no reported hypoglycemias, or acute adverse ef-
fects regarding kidney and liver parameters.
Conclusion: The results of this study show that GP tea in addition to SU 
could offer an advantage over the addition of other oral medication to treat 
type 2 diabetic patients.
Supported by: SIDA/SAREC,
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Silibinin reverses insulin resistance in an animal model of high-fructose 
diet by an inhibition of glucose-6-phosphatase activity
C. Sánchez-Martín1, M.N. Sanz1, D. Detaille2, O. Bourron3, F. Foufelle3,  
J.M. Recio-Córdova4, F. Gómez-Peralta5, G. R.-Villanueva1, M.Y. El-Mir1; 
1Physiology and Pharmacology, University of Salamanca, Spain, 2University 
of Grenoble-I, Grenoble, France, 3Centre de Recherches des Cordeliers, 
Paris, France, 4Endocrinology Unit, University Hospital of Salamanca, 
Spain, 5Endocrinology and Nutritional Unit, Nuestra Señora de Sonsoles 
Hospital, Ávila, Spain.
Background and aims: High fructose diet causes insulin resistance (IR) and 
alterations in glucose metabolism in Wistar rats. The flavonoid silibinin (SB) 
has recently showed important properties to be used in the treatment of type 
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2 diabetes. Previous studies in vitro of our group have shown that SB inhibits 
hepatic gluconeogenesis in perifused rat hepatocytes by an inhibition of glu-
cose-6-phosphatase enzyme. The aim of this study was to explore the capacity 
in vivo of silibinin to reverse the particular alterations to IR induced in high 
fructose-fed rats, as well as the underlying mechanisms.
Materials and methods: Male Wistar rats were divided into two batches. 
One batch received a standard diet, and the other received a fructose-en-
riched diet. After 4 weeks, each group of rats was divided into two groups. 
One group received SB (50 mg/kg/day, i.p.) for additional two weeks, while 
the other received SB vehicle. Hepatocytes were isolated from starved rats, 
perifused at 37ºC and titrated with increasing substrate concentrations of 
dihydroxyacetone (DHA). We measured glucose concentrations in cellular 
perifusate and dihydroxyacetone phosphate (DHAP), glucose-6-phosphate 
(G6P) and fructose-6-phosphate (F6P) in the cellular fraction. The effect in 
vivo of SB on glucose-6-phosphatase activity was also investigated.
Results: In perifused hepatocytes, fructose diet increased gluconeogenesis 
(JGlucose) as compared with control by 25% (DHA 2.4 mM, p<0.001). Adminis-
tration of SB normalized this metabolic alteration in fructose-fed rats (DHA 
2.4 mM, p<0.001). Also, fructose-enriched diet increased DHAP, G6P and 
F6P concentrations at each steady state, giving a double relationship between 
JGlucose and DHAP, F6P and G6P. SB normalized this effect. On the other hand, 
high fructose diet increased glucose-6-phosphatase activity as compared with 
control by 10% (G6P 20 mM, p<0.05). SB fully reversed this effect. Regarding 
the kinetic parameters of glucose-6-phosphatase enzyme, fructose diet in-
creased the maximal velocity (Vmax; p<0.05) and decreased Michaelis-Menten 
constant (Km; p<0.01). Administration of SB only reversed Vmax (p<0.05) 
compared to fructose fed rats.
Conclusion: SB reverses metabolic alterations proper to insulin resistance in 
Wistar rats by an inhibition of glucose-6-phosphatase enzyme. These results 
suggest that SB could be beneficial as complementary therapy for the treat-
ment of type 2 diabetes.
892
The natural flavonoid Resveratrol reduces hepatic gluconeogenesis and 
respiration by a direct and a non-gene modification manner 
M.N. Sanz1, C. Sànchez-Martin1, D. Detaille2, C. Pueyo1, C. Ortega-la1,  
O. Bourron3, F. Foufelle3, X. Leverve2, M.Y. El-Mir1; 
1Physiology and Pharmacology, University of Salamanca, Spain, 2Laboratoire 
de Bioénergétique Fondamentale et Appliquée, University of Grenoble I, 
INSERM U884, France, 3Centre de Recherches des Cordeliers, INSERM, 
UMR-S 872, Paris, France.
Background and aims: Resveratrol is a polyphenolic flavonoid with potent 
antioxidant activity. It is present in a variety of plants, notably berry fruit, 
and has emerged as a promising chemotherapeutic molecule due to its health 
benefits, especially in cancer, type 2 diabetes, cardiovascular and neurologi-
cal diseases. The diverse biological effects of resveratrol refer to its ability to 
target many intracellular molecules, mainly through the activation of sirtu-
ins, a class of NAD+-dependent deacetylases that affect multiple transcription 
factors and other protein targets.To investigate other possible mechanisms of 
action of Resveratrol without involvement of gene activation in the liver, the 
most important organ of insulin resistance in type 2 diabetes.
Material and methods: Hepatocytes were isolated from 24h starved rats ac-
cording to the method of Berry and Friend. They were perifused at 37ºC with 
Krebs-bicarbonate-calcium satured with O2/CO2 at a flow rate of 5 ml/min. 
Saturating concentrations of dihydroxyacetone (DHA) (0; 0.15; 0.30; 0.60; 
1.20; 2.40; 4.80 mM) were used as exogenous substrate, in the presence or 
absence of 10 µM Resveratrol, to get seven consecutive steady states. Glucose, 
pyruvate and lactate concentrations were measured in cell perifusate for each 
steady state. We also studied the direct effect of Resveratrol on oxygen con-
sumption rate (JO2) using mitochondria isolated by differential centrifuga-
tion from livers of fed Wistar rats. JO2 was measured polarographically at 37° 
using a Clark-type oxygen electrode, with either glutamate/malate (GM) or 
succinate/ malate (SM) as energy substrates of complex I or II, respectively.
Results: In perifused hepatocytes, Resveratrol (10 µM) inhibited hepatic 
glucose output (Jglucose; p<0.01) by 28% and glycolysis (JL+P), determined by 
the addition of lactate+pyruvate, by 22% (DHA 2.4 mM; p<0.005). Accord-
ing to these results, we obtained an inhibition of total DHA metabolic flux 
(J2glucose+L+P) by 25% (p<0.005) and a decrease of cytosolic NADH/NAD
+ redox 
state, estimated as the lactate/pyruvate ratio, of nearly 25 % as well (p<0.005). 
Resveratrol did not significatively affect the state 4 of respiration whatever 
the respiratory substrates used. On the contrary, the flavonoid inhibited the 
phosphorylating state 3 (in presence of ADP) by 15% with either substrate.
Conclusion: Resveratrol, a potent antioxidant flavonoid, is recently investi-
gated for its therapeutic and preventive potential in age-related diseases like 
type 2 diabetes. For the first time we demonstrate that this compound exerts 
direct effects upon hepatic metabolism, i.e. inhibitions of hepatic gluconeo-
genesis and cell respiration. This acute response could be beneficial for the 
treatment of such metabolic disorders.
Supported by: Junta de Castilla y León, Spain
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A prescribed Chinese medicine improves glucose profile and ameliorates 
oxidative stress in GK rats fed with high fat diet
L. Wu1, X. Gao2; 
1Geriatrics, 2Endocrinology & Metabolism, Fudan University, Shanghai, 
China.
Background: The intrinsic anti-oxidative defence system of pancreatic β cells 
is fragile and oxidative stress is an underlying mechanism of β cell dysfunction. 
High-fat diet increases oxidative stress and exacerbates hyperglycemia in GK 
rat. We previously observed the prescribed traditional Chinese medicine prep-
aration “Qing Huo Yi Hao” (QHYH) decreased urinary micro-albumin excre-
tion in type 2 diabetic patients and also demonstrated its anti- oxidative activ-
ity by electron paramagnetic resonance. Recently we confirmed that QHYH 
protect endothelial cells from high glucose induced ROS production. So we 
hypothetized that QHYH might also protect β cell and improve glucose profile. 
We use GK rats fed with high-fat diet treated by QHYH to determine whether 
QHYH will improve glucose metabolism and ameliorate oxidative stress.
Materials and methods: 4-week-old male GK rats were given high fat diet 
(4.8kcal/g, 52% of the energy from fat) and divided randomly into 2 groups: 
QH group(n=10), rats were administered QHYH solution twice a day (3ml/
Kg/d); and control (HFD) (n=10). Meanwhile, rats (ND) (n=10) fed normal 
chow (3.2kcal/g, 12% of the energy from fat)as normal control. Blood glu-
cose and glycated serum protein(GSP) concentrations were measured every 4 
week. IPGTT were done in 5 rats of each group at 4th and 16th week. Serum 
MDA concentration and activities of antioxidant enzymes were measured at 
the 4th and 16th week. Rats were sacrificed at the end of 16th week. Pan-
creas were taken out for morphological studies by immunohistochemistry to 
quantitatively determine β cell mass and relative volume. Nitrotyrosine and 
8OHdG staining was also done.
Results: Of the QH group, fasting glucose level was significantly lower at 
4th and 8th week(Fig 1A) , non-fasting blood glucose at the 4th week (1B) 
and GSP at the 12th week(1C) than HFD group. QHYH improved glucose 
tolerance by decreasing blood glucose level markedly at 15’ and 30’ after 
glucose load at the 4th week (1D). QHYH markedly decreased serum MDA 
concentrations(1F), increased serum CAT (1H) and SOD (1I) activities com-
pared to HFD group only at the 4th week, however, GSH-Px activity(1G)was 
also markedly decreased. At the 16th week, neither glucose profile, nor glucose 
tolerance, nor serum MDA level or antioxidant enzyme activities was mark-
edly different. Furthermore, in morphometry study, QHYH intervention did 
not restore the significant decrease of both beta cell mass and relative volume 
induced by high fat diet (ND vs HFD vs QH: 3.31±1.07mg vs 1.48±1.24mg vs 
2.33±2.48mg, 27.6%±4.27% vs 19.4%±1.14% vs 18.1%±3.08%), nor with NT 
and 8OHdG staining.
Conclusions: QHYH improved glucose profile (4&8 weeks) and ameliorate 
oxidative stress (4 weeks) in GK rats fed with a high fat diet, which might be 
compromised by chronic glucotoxicity to pancreatic β cells
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Initial treatment with metformin + colesevelam provides greater 
glycaemic control than metformin alone in Hispanic patients with type 2 
diabetes mellitus
E. Hernandez-Triana1, W.T. Garvey2, R.B. Goldberg3, Y. Handelsman4, V.A. 
Fonseca5, M.R. Jones6, S.L. Abby6, M. Markiewicz6, X. Jin7, S. Misir6,  
S. Nagendran6, J. Rosenstock8; 
1Endocare Research Institute, Universidad del Rosario, Bogota, Colombia, 
2UAB Diabetes Research and Training Center, University of Alabama at 
Birmingham, USA, 3University of Miami Miller School of Medicine, USA, 
4Metabolic Institute of America, Tarzana, USA, 5Tulane University Health 
Sciences Center, New Orleans, USA, 6Daiichi Sankyo, Inc., Parsippany, USA, 
7Daiichi Sankyo Pharma Development, Edison, USA, 8Dallas Diabetes and 
Endocrine Center at Medical City, Dallas, USA.
Background and aims: Colesevelam is indicated for glycemic control and 
LDL-C lowering in patients with type 2 diabetes mellitus (T2DM) and hy-
percholesterolemia, respectively. A 16-week (wk), randomized, double-blind, 
placebo-controlled, multinational study evaluated the effect of initial therapy 
with metformin + colesevelam in drug-naïve patients with T2DM.
Materials and methods: This post-hoc analysis evaluated the efficacy of 
metformin + colesevelam in a subpopulation of Hispanic patients (those 
self identified enrolled in Colombia, Mexico, and the US) included in the 
16-wk study. Drug-naïve adults with T2DM (HbA1c 6.5%-10.0%), LDL-C 
≥2.6 mmol/L, and triglycerides (TG) <5.7 mmol/L were randomized 1:1 to 
metformin + colesevelam 3.75 g/d or metformin + placebo. Metformin was 
initiated at 850 mg/d and was uptitrated at Wk 2 to 1700 mg/d. Efficacy pa-
rameters included change in HbA1c (primary) and LDL-C (secondary) from 
baseline to Wk 16. All efficacy analyses were performed with last observation 
carried forward at Wk 16.
Results: In total, 173 Hispanic patients were treated with metformin + cole-
sevelam (n=85) or metformin + placebo (n=88). Mean baseline HbA1c was 
7.7% (metformin + colesevelam) and 7.6% (metformin + placebo). At Wk 
16, the mean change from baseline in HbA1c was significantly greater with 
metformin + colesevelam vs metformin + placebo (-1.2% vs -0.8%; treatment 
difference [TD]: -0.4%; P=0.001), resulting in significantly more patients 
achieving HbA1c <7.0% (75% vs 56%; P=0.02). Metformin + colesevelam 
resulted in significantly greater mean reductions in LDL-C vs metformin + 
placebo (-22.8% vs -3.4%; TD: -19.4%; P<0.0001), resulting in significantly 
more patients achieving LDL-C <2.6 mmol/L (49% vs 14%; P<0.0001). There 
were significant LS mean changes from baseline with metformin + coleseve-
lam vs metformin + placebo in non-HDL-C (-13.6% vs -3.3%; TD: -10.3%; 
P<0.0001), total cholesterol (-9.1% vs -1.2%; TD: -7.9%; P<0.0001), TG (me-
dian: 9.5% vs -11.1%; TD: 21.2%; P<0.0001), apoA-I (9.7% vs 5.4%; TD: 4.2%; 
P=0.01), and apoB (-11.4% vs -1.7%; TD: -9.8%; P<0.0001). Overall, met-
formin + colesevelam was well tolerated (Table).
Conclusion: Metformin + colesevelam may be an appropriate initial treat-
ment option to improve glycemic and lipid control in Hispanic patients with 
T2DM.
Summary of Adverse Events
AEs occurring in ≥5%  
of patients, n (%)
Metformin + Colesevelam
(n=89)
Metformin + Placebo
(n=90)
Abdominal pain 5 (6) 7 (8)
Abdominal pain upper 5 (6) 2 (2)
Back pain 0 5 (6)
Constipation 6 (7) 2 (2)
Diarrhea 13 (15) 21 (23)
Dizziness 8 (9) 4 (4)
Dyspepsia 3 (3) 5 (6)
Headache 9 (10) 13 (14)
Hypertension 1 (1) 8 (9)
Influenza 11 (12) 9 (10)
Nausea 9 (10) 8 (9)
Supported by: Daiichi Sankyo, Inc.
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Plasma 25-hydroxyvitamin D concentration and metabolic syndrome in 
Chinese individuals - Shanghai Changfeng Study
H. Lin1, H. Ma1, X. Li1, J. Gao1, B. Song2, B. Pan2, J. Sheng3, X. Chen3,  
X. Gao1; 
1Department of Endocrinology and Metabolism, Zhongshan Hospital, 
Fudan University, Shanghai, China, 2Department of Laboratory Medicine, 
Zhongshan Hospital, Fudan University, 3Shanghai Changfeng Community 
Health Care Center, Shanghai, China.
Background and aims: Several evidence suggests that 25-hydroxyvitamin D 
concentration is associated with metabolic syndrome (MetS), but the others 
consider that parathyroid hormone, but not vitamin D is related. We aimed to 
explore whether vitamin D or parathyroid hormone is associated with meta-
bolic syndrome among a cross-sectional population of over 45 years old in 
Shanghai Changfeng community of China.
Materials and methods: The study population consisted of 538 inhabitants 
(40.5% men, median age 63.4 years) recruited from Changfeng community in 
Shanghai. A standard interview (included life style, diseases history through 
questionnaires). Anthropometrics (height, weight, waist and hip circumfer-
ence, blood pressure), Laboratory parameters (including serum lipid, fasting 
plasma glucose [FPG], 2h postload plasma glucose [2hPG] after oral glucose 
tolerance test [OGTT], 25-hydroxyvitamin D and parathyroid hormone 
[Electrochemiluminescence assay, Roche E170], calcium and phosphorus) 
were conducted for each participant. Metabolic syndrome was defined using 
International Diabetes Federation criteria for Chinese.
Results: 495 inhabitants (40.4% men, median age 63.2 years) had completed 
data were included into analysis. The mean of plasma 25-hydroxyvitamin D 
concentration was 45.00±15.58nmol/l in this population. The frequency of 
metabolic syndrome is 33.7% (27.0% in men and 38.3% in women). Sub-
jects with MetS had lower 25-hydroxyvitamin D concentration than those 
individuals without MetS (42.67nmol/l vs 46.18nmol/l, P=0.017). Compared 
with the highest tertile of 25-hydroxyviatamin D concentration(≥49.46nmol/
l), the Odds ratio for metabolic syndrome in the middle (37.38-49.46nmol/l) 
and lowest tertile of 25-hydroxyviatamin D (≤37.38nmol/l) was 1.29 and 1.47 
(95% CI 0.81-2.05 and 0.93-2.33) respectively. We observed that metabolic 
syndrome was negative associated with 25-hydroxyvatamin D (OR=0.963, 
95%CI 0.945-0.981) in the logistic regression analysis. Significant inverse 
associations also existed between 25-hydroxyviatamin D concentration and 
metabolic syndrome (OR=0.941, 95%CI 0.901-0.983) when plus parathyroid 
hormone, blood calcium and phosphorus into model.
Conclusion: The occurrence of metabolic syndrome had increasing trend 
with the decline in the level of 25-hydroxyvitamin D. Lower 25-hydroxyvi-
tamin D level is significantly associated with an increased risk of metabolic 
syndrome independent of parathyroid hormone in this Chinese population.
Supported by: 2008BAI52B03, 08GWZX0203
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Effects of RSG/MET FDC on glycaemic control and BMD after 80 weeks 
of treatment in drug-naïve type 2 diabetes mellitus subjects
A.J. Nino1, J. Bilezikian2, J. Borges3, P.L. Adams1, A.R. Jones1, A. Acusta1,  
P. Ambery4, A. Cobitz1, L.A. Fitzpatrick5; 
1MDC CVM, GlaxoSmithKline, King of Prussia, USA, 2College 
of Physicians & Surgeons, Columbia University, New York, USA, 
3Clínica de Endocrinologia e Metabologia, Brasílla, Brazil, 4MDC 
CVM, GlaxoSmithKline, Harlow, United Kingdom, 5Biopharm R&D, 
GlaxoSmithKline, King of Prussia, USA.
Background and aims: Avandamet is a fixed-dose combination tablet com-
prised of rosiglitazone (RSG) and metformin (MET), which have comple-
mentary modes of action. Clinical studies have suggested that earlier use of 
combination therapy may improve long-term glycemic control. The purpose 
of this study (CT.gov NCT00386100) was to assess if RSG/MET significantly 
lowers A1c compared to MET alone, and if glycemic effects attained with 
AVM are durable over 80 weeks. A bone sub-study was added to this trial to 
further investigate the effects of RSG/MET on bone in light of an increased 
fracture rate in female subjects who received RSG in the ADOPT study. 
Presently, understanding of the clinical significance of these findings is in-
complete, and the mechanism(s) for the observed increase in fractures are 
uncertain.
Materials and methods: In this double-blind, randomized study, RSG/MET 
was compared to MET in drug-naïve T2DM subjects with A1c ≥7.5% to 
≤10.5%. Subjects (n=688) were randomized to either RSG/MET 4/500mg 
(max daily dose, 8/2000mg) or MET 500mg (max dose, 2000mg) and were 
assessed for 80 weeks. Doses were titrated at 4-week intervals up to Week 20 
(unless mean daily glucose was <100mg/dL) and at 12-week intervals from 
Weeks 32 to 80 (unless A1c ≤6.5%). BMD by DXA at lumbar spine, total hip, 
femoral neck, trochanter, distal radius, and total body were assessed at Weeks 
0, 20, 56 & 80.
Results: RSG/MET (-1.9%) was superior to MET (-1.4%) with respect to 
mean change from baseline A1c at Week 80 (-0.50%, p<0.0001). RSG/MET 
showed significant improvements in insulin sensitivity (HOMA-%S) at 80 
weeks compared to MET alone (% treatment difference: 31.1%, p<0.0001). 
There were significantly greater reductions in fasting insulin, c-peptide, and 
free fatty acids for RSG/MET vs MET. No statistically significant between-
group BMD reductions occurred in femoral neck, distal radius, or total body. 
Significant between-group BMD changes at Week 80 occurred at: lumbar 
spine in the overall, total female, and post-menopausal female groups; tro-
chanter in the overall and total female groups; and total hip in all subgroups 
except post-menopausal females. MET alone was not associated with sig-
nificant bone loss for the duration of the trial. Both agents were generally 
well-tolerated: withdrawals due to an AE occurred in 7% (25/344) and 5% 
(15/334) of RSG/MET and MET subjects. There were a total of nine on-thera-
py fractures (5 for RSG/MET, 4 for MET) reported as AE/SAEs. In the overall 
study, there were no unexpected adverse events.
Conclusion: RSG/MET significantly reduced A1c vs MET and maintained 
glycemic control over 80 weeks. These data confirm that RSG/MET is su-
perior to MET in improving insulin sensitivity in drug-naïve subjects with 
T2DM. The observed BMD changes may be relevant to fracture risk in this 
population.
Supported by: GlaxoSmithKline
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Efficacy and safety of repaglinide and metformin combination therapy 
compared to repaglinide monotherapy in Chinese oral anti-diabetic drug 
(OAD) naïve type 2 diabetic patients
W. Wang1, G. Ning1, Q. Su2, J. Liu3, R. Bu4, AGEE3705 Study Group; 
1Shanghai Jiaotong University Affiliated Ruijin Hospital, Shanghai, 
2Shanghai Jiaotong University Affiliated Xinhua Hospital, Shanghai, 3The 
First Affiliated Hospital of Nanchang University, Nanchang, 4Wuxi People’s 
Hospital, Wuxi, China.
Background and aims: The ADA and EASD recommend early initiation of 
combination therapy when HbA1c > 8.5 %. Combination therapy with repa-
glinide and metformin is a good treatment option for type 2 diabetes. This 
trial was designed to investigate the efficacy and safety of this combination 
treatment compared to repaglinide monotherapy in Chinese OAD naïve type 
2 diabetic patients with HbA1c > 8.5 %.
Materials and methods: This was a 16-week, open-label, multicentre, ran-
domised, active-controlled, parallel study involving 17 sites in China. Sub-
jects were randomised 1:1 to receive either repaglinide in combination with 
metformin (1 mg/500 mg QD) or repaglinide alone (1mg TID), and then 
underwent a 6-week dose titration period followed by a 10-week mainte-
nance period. During the dose titration period, subjects whose fasting plasma 
glucose (FPG) ≥ 6.1 mmol/L without clinically unacceptable hypoglycaemic 
episodes continued to titrate the daily dose until the FPG target of 4.4-6.1 
mmol/L or the maximum recommended daily dose (repaglinide/metformin 
4mg/500mg, TID; repaglinide 4 mg, TID) was reached.
Results: A total of 432 subjects (female 313, mean ± SD: age 49.9 ± 10 years, 
BMI 24.5 ± 3.0 kg/m2, HbA1c 10.8 ± 1.5 %) were exposed to trial drugs. After 
16-weeks treatment, the glucose control was improved in both groups. Mean 
HbA1c decreased from 10.9 ± 1.5 % at baseline to 6.4 ± 1.1 % at 16 weeks in 
the combination therapy group, and from 10.7 ± 1.5 % to 6.7 ± 1.0 % in the 
monotherapy group. The mean reduction was 4.5 ± 1.6 % point and 4.1 ± 
1.6% point, respectively (P = 0.002). HbA1c < 7 % was achieved in 78.9 % 
of the subjects with combination therapy, and in 69.6 % of those with repa-
glinide alone (P = 0.010). Compared to monotherapy, the combination treat-
ment also achieved a superior outcome in FPG, 2-hour postprandial plasma 
glucose, mean 7-point plasma glucose, and mean prandial plasma glucose in-
crement (Table). No major hypoglycaemia was reported during the trial, and 
the overall hypoglycaemia rate was 2.04 events per subject year in the combi-
nation treatment group and 1.35 events per subject year in the monotherapy 
group (P = 0.058). Adverse events reported during the trial were comparable 
between groups. At the end of the trial, mean weight gain was small in both 
groups; 0.2 ± 0.2 (mean ± SD) kg in the combination therapy group and 0.5 ± 
0.2 kg in the monotherapy group, respectively (P = 0.322).
Conclusion: Combination therapy with repaglinide and metformin and re-
paglinide monotherapy improved glucose control significantly in OAD naïve 
Chinese type 2 diabetic patients with baseline HbA1c > 8.5 %. However, com-
bination treatment provided superior glycaemic control compared to repa-
glinide monotherapy. The safety profile was comparable between groups.
Comparision of glucose control parameters between groups
Glucose control parameters 
(mean ± SD), mmol/L
Baseline After 16-week 
treatment
Change from 
baseline
Fasting plasma glucose Repaglinide + Metformin
11.30 ± 3.20 6.34 ± 1.50** -4.98 ± 3.23**
 
Repaglinide 11.23 ± 3.56 6.71 ± 1.72** -4.44 ± 3.50** 
2-hour postprandial plasma 
glucose after breakfast
Repaglinide + 
Metformin
17.08 ± 5.34 9.18 ± 3.46 -7.86 ± 5.93
Repaglinide 16.96 ± 5.24 9.61 ± 3.23 -7.30 ± 5.57
Mean 7-point plasma 
glucose
Repaglinide + 
Metformin
14.27 ± 3.93 7.39 ± 1.76** -6.84 ± 3.95**
 
Repaglinide 14.03 ± 3.86 8.16 ± 2.13** -5.86 ± 3.82** 
Mean prandial plasma 
glucose increment
Repaglinide + 
Metformin
4.13 ± 2.42 2.05 ± 1.85* -1.99 ± 2.85*
Repaglinide 3.87 ± 2.71 2.51 ± 1.88* -1.35 ± 2.92*
*: P< 0.05; **: P< 0.01 between groups.
Supported by: Novo Nordisk (China) Pharmaceuticals Co., Ltd.
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Metformin therapy and outcomes of viral C cirrhosis in type 2 diabetic 
patients. A retrospective study
G. Nkontchou1, P. Valensi2, M. Aout3, N. Ganne-Carrie1, V. Grando-
Lemaire1, E. Vicaut3, J.-C. Trinchet1, M. Beaugrand1, E. Cosson2; 
1Hepato-Gastro-Enterology, Jean Verdier Hospital, BONDY, 
2Endocrinology-Diabetology-Nutrition, Jean Verdier Hospital, BONDY, 
3Direction de la Recherche Clinique, Fernand Widal Hospital, Paris, France.
Background and aims: Insulin resistance seems to play a crucial role in the 
poor prognosis associated with overweight and obesity for viral C cirrho-
sis. The aim of the study was to retrospectively examine whether metformin 
therapy (which activates AMP kinase and decreases insulin resistance) may 
be associated with a better prognosis in patients with type 2 diabetes.
Materials and methods: Between 1988 and 2007, 100 consecutive diabetic 
patients, 53 men, 61±11 years old, body mass index 27±5 kg/m2, with ongo-
ing viral C infection and cirrhosis were included in a screening program for 
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hepato-cellular carcinoma (HCC) detection including serum alpha foeto pro-
tein (AFP) measurement and ultrasound examination every 3 to 6 months. 
The patients were followed up for HCC and liver related death or hepatic 
transplantation.
Results: Diabetic patients were treated either by metformin (n=22) or not 
(insulin (n=28), insulin secretory drugs (n=20) or diet alone (n=30)). No 
statistically significant difference was observed at inclusion between the two 
groups. During a mean follow-up of 5.9±4.4 years, 38 patient developed an 
HCC and 38 had a liver related death. The 5-year HCC incidence was 10.9% 
and 29.8% in patients who received metformin or did not receive metformin 
respectively (log rank 7.47, p=0.006). In multivariate analysis, metformin 
treatment was associated with a reduced incidence of HCC (Odds ratio 0.23 
[95% CI 0.06-0.96], p=0.04) whereas age (OR 2.33 [1.14-4.77], p=0.02) and 
serum AFP level (OR 1.02 [1.01-1.03], p=0.005) were predictive of HCC oc-
currence. Metformin therapy was also associated with a lower incidence of 
liver related deaths or transplantation (log rank 6.3, p<0.05).
Conclusion: In diabetic patients with cirrhosis and persistent HCV infection, 
metformin use is associated with a reduced risk of HCC occurrence and liver 
related death or transplantation.
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Treatment with pioglitazone plus insulin is well tolerated and shows 
metabolic benefits compared to a combination of insulin and metformin. 
Interim results from the PIOcomb study 
A. Pfützner1, M. Hanefeld2, C. Hohberg1, C. Köhler2, J. Müller3, T. Forst1; 
1IKFE Institute for Clinical Research and Development, Mainz, 2GWT, 
Dresden, 3Acromion, Frechen, Germany.
Background and aims: Addition of basal insulin to oral therapy in type 2 
diabetes (basal insulin supported oral therapy, BOT) is a very common thera-
peutic strategy in Germany. Our investigation aimed at comparing a pioglita-
zone plus insulin (PI) regime with a metformin plus insulin (MI) treatment, 
and with triple therapy (PMI). Observation parameters included glycemic 
control, insulin sensitivity, insulin consumption, beta-cell preservation, and 
the intensity of chronic systemic inflammation.
Materials and methods: In an interim analysis of the double-blinded, mul-
ticentre PIOcomb study, we included 78 type 2 diabetic patients with previ-
ous insulin therapy (52 men, 26 women, age [mean±SD]: 63±8 years, BMI: 
32.7±5.6 kg/m2, diabetes duration: 9±5 years, HbA1c: 7.3±0.5%). Patients 
received an optimised and individualised regimen with insulin glargine (ti-
tration) and were randomised to an additional treatment with pioglitazone 
(2 x 15 mg/day) or metformin (2 x 850 mg/day), or a combination of both 
oral antidiabetic drugs. Efficacy parameters (HbA1c, insulin dosage, HOMA 
score, intact proinsulin, adiponectin, and hs-CRP) were assessed at baseline 
and after a six-month observation period.
Results: HbA1c remained stable in the dual therapy groups, and decreased 
in the PMI treatment arm (PI/MI/PMI: -0.1±0.6 %/-0.1±0.7 %/-0.5±0.6 %, 
p<0.05 vs. baseline). Improved insulin sensitivity was only demonstrated in 
the two groups receiving pioglitazone. The baseline and endpoint values of the 
observation parameters are provided in the Table. There were no differences in 
the reported number of hypoglycemic events between the groups (8/8/10).
Conclusion: Addition of metformin and/or pioglitazone to a basal insulin 
therapy with insulin glargine provided stable metabolic control in all cases, 
without increasing the risk for hypoglycemia. A significant improvement 
in insulin resistance and cardiometabolic syndrome, as indicated by related 
biomarkers and a reduction in daily insulin dose, was only observed with 
pioglitazone administration.
Observation parameters at baseline and endpoint (*: p<0.05 vs. baseline)
Parameter MI (n=25) PI (n=28) PMI (n=25)
baseline endpoint baseline endpoint baseline endpoint
HbA1c [%] 7.3±0.6 7.2±0.5 7.4±0.6 7.3±0.8 7.3±0.5 6.8±0.7*
Daily Insulin dose 
[IU]
37±17 41±21* 37±17 29±16* 36±21 28±22*
HOMA-IR 4.5±4.2 4.8±4.2 4.4±4.1 2.4±1.8* 3.3±2.9 1.8±1.4*
Adiponectin 
[mg/L] 4.2±2.4 4.1±2.2 4.0±2.5 12.6±8.6
* 4.7±3.2 12.2±7.5*
Intact Proinsulin 
[pmol/L]
12±21 6±5* 7±5 5±3* 5±4 3±1*
hsCRP [mg/L] 3.6±2.7 3.3±2.7 3.3±2.7 2.5±1.9* 2.6±1.9 1.4±1.0*
Supported by: Takeda Pharma
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Comparison of the effects of pioglitazone vs. placebo when given in 
addition to standard insulin treatment in patients with type 2 diabetes 
mellitus requiring haemodialysis: interim results from the PIOren study
J. Galle1, V.H.R. Schmid2, C. Forkel2, T. Forst2, A. Pfützner2; 
1Klinikum Lüdenscheid, 2IKFE - Institute for Clinical Research and 
Development, Mainz, Germany.
Background and aims: Patients with type 2 diabetes mellitus and clinical-
ly significant kidney disease are usually treated with insulin. However, the 
modified pharmacokinetic insulin profile and vascular insulin resistance in 
patients with delayed renal insulin elimination frequently impairs a success-
ful therapy and, additionally, results in increased oxidative stress and cardio-
vascular risk. Therefore, the aim of this study was to investigate the effect of 
the insulin sensitizer pioglitazone (PIO) vs. placebo treatment on total daily 
insulin requirements and the overall metabolic status in type 2 diabetes pa-
tients with renal failure requiring hemodialysis.
Materials and methods: The effect of pioglitazone (30 mg) vs. placebo was 
explored by an interim analysis of this multi-centre, randomized, double-
blind study in 23 patients with Type 2 diabetes and kidney failure and dialysis 
therapy (16 male, 7 female, age (mean±STD): 68.2±8.8 yrs., HbA1c: 7.5±0.8 
%, disease duration: 11.8±8.5 yrs.). Efficacy parameters collected before di-
alysis and after an overnight fast at baseline and after 6 months were: total 
daily insulin dose, HbA1c, fasting blood glucose, adiponectin, HDL, LDL, 
triglycerides, NT-proBNP and ultra filtrate volume.
Results: Application of PIO resulted in a significant decrease in insulin re-
sistance as indicated by a reduction in daily insulin dose by 32 % (p<0.05 vs. 
baseline; placebo: -5 %., n.s.), and clinically relevant improvements in HbA1c 
(-0.62±0.75 %, p<0.01; placebo: +0.57±1.08 %, n.s.), fasting glucose (-56±73 
mg/dl, p<0.05 vs. +20±35 mg/dl, n.s.), adiponectin (+6.9±8.4 mg/l, p<0.01 vs. 
+1.0±6.5 mg/l, n.s.), and triglycerides (-111±178 mg/dl, p<0.05 vs. +65±70 
mg/dl, p<0.05). Slight improvements or no changes were seen with HDL, 
LDL, NTproBNP and the ultra filtrate volume. The absolute values at baseline 
and endpoint are provided in the Table.
Conclusion: Addition of pioglitazone to insulin in hemodialysis patients was 
well tolerated. Without changing the ultra filtrate volume, treatment with 
pioglitazone in addition to insulin in patients with late stage kidney failure 
requiring hemodialysis was associated with a lower insulin dose and with an 
improved glycaemic control and lower triglyceride levels, indicating a poten-
tial impact of pioglitazone on the long-term disease prognosis in late stage 
diabetes.
Observation parameters at baseline and endpoint (*: p<0.05 vs. baseline)
Parameter Pioglitazone (n = 14) Placebo (n = 9)
Baseline 6 months Baseline 6 months
Daily insulin dose [IU] 68.3±54.5 46.2±35.3* 53.3±18.5 50.5±17.5
HbA1c [%] 7.6±1.0 7.0±0.9* 7.4±0.6 7.9±0.6
Glucose [mg/dL] 178±61 122±32* 151±56 170±57
Adiponectin [mg/L] 10.0±4.9 16.9±7.3* 8.9±8.3 9.8±5.9
HDL [mg/dL] 32±10 36±10 35±10 32±9
LDL [mg/dL] 99±49 117±40 102±33 111±47
Triglycerides [mg/dL] 333±237 222±87* 244±113 309±140*
NT-proBNP [pg/mL] 6028±10144 4470±6294 7752±9427 14272±19287
Ultra filtrate volume [ml] 2402±920 2576±1021 2792±993 2923±1125
Supported by: Takeda Pharma
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PIOcomb study interim analysis: Pioglitazone added to insulin treatment 
reduces chronic systemic inflammation in patients with type 2 diabetes
B. Stratmann1, T. Forst2, A. Pfützner2, J. Müller3, D. Tschöpe1, M. Hanefeld4; 
1Heart and Diabetes Center, Bad Oeynhausen, 2IKFE - Institute for Clinical 
Research and Development, Mainz, 3Acromion, Frechen, 4GWT, Dresden, 
Germany.
Background and aims: Combination therapy with insulin glargine and met-
formin is a common therapy in type 2 diabetes. The purpose of the PIOcomb 
study was to investigate, whether use of pioglitazone instead of metformin 
has additional impact on the underlying disease pathophysiology, and in par-
ticular on chronic systemic inflammation (CSI). CSI leads to macrovascular 
complications, the major cause of mortality in patients with type 2 diabetes.
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Materials and methods: Here we report on an interim analysis of the double-
blinded, multicentre PIOcomb trial (78 patients with previous insulin ther-
apy, 52 men, 26 women, age [mean±SD]: 63±8 years, BMI: 32.7±5.6 kg/m2, 
diabetes duration: 9±5 years, HbA1c: 7.3±0.5%). Patients were switched for 6 
months to an individualised once daily insulin glargine injection (with forced 
titration to normal fasting glucose values) and were additionally randomised 
to receive either pioglitazone (PI; 2 x 15 mg/day), or metformin (MI; 2 x 850 
mg/day), or a combination of both oral antidiabetic drugs (PMI). Efficacy 
parameters for this analysis (determined at baseline and after 24 weeks) were 
HbA1c, MMP9, hsCRP, E-selectin, fibrinogen, PAI-I, nitrotyrosine, and the 
NFkB mRNA expression of peripheral circulating monocyte/macrophages.
Results: Daily insulin dose increased with MI and decreased with PI and 
PMI, which was associated with stable or improved glycemic control (HbA1c, 
PI/MI/PMI: -0.1±0.6 %/-0.1±0.7 %/-0.5±0.6 %, PMI: p<0.05 vs. baseline). 
With PI and PMI, there were significant reductions in hsCRP and E-selectin 
and improvements were also seen for macrophage activation (NFkB) with PI 
and PAI-I with PMI. All other parameters showed tendencies for improve-
ment with PI and PMI that did not reach the level of statistical significance. 
The baseline and endpoint values are provided in the Table. None of these 
beneficial changes were seen with MI treatment.
Conclusion: While reaching comparable glycemic control (compared to 
metformin) with lower insulin requirements, addition of pioglitazone to in-
sulin glargine improved several biomarkers of chronic systemic inflamma-
tion and vascular function in patients with Type 2 diabetes. This may trans-
late into a lower macrovascular mortality as has been previously indicated in 
the PROactive study.
Observation parameters at baseline and endpoint (*: p<0.05 vs. baseline)
Parameter MI (n = 25) PI (n = 28) PMI (n = 25)
Baseline Endpoint Baseline Endpoint Baseline Endpoint
HbA1c [%] 7.3±0.6 7.2±0.5 7.4±0.6 7.3±0.8 7.3±0.5 6.8±0.7*
hsCRP [mg/L] 3.6±2.7 3.3±2.7 3.3±2.8 2.5±1.9* 2.6±1.9 1.4±1.0*
MMP-9 [ng/mL] 615±365 673±415 522±171 516±222 577±266 534±179
E-selectin [ng/mL] 46±21 46±22 49±19 45±18* 46±16 41±15*
Fibrinogen [g/L] 3.7±0.8 3.6±1.0 3.4±0.9 3.3±1.2 3.6±1.2 3.4±1.0
PAI-I [ng/mL] 66±25 60±29 68±27 60±31 61±28 44±30*
Nitrotyrosine 
[nmol/L]
398±136 428±152 377±125 364±104 387±110 383±147
NFkB [RLU] 0.74±0.12 0.74±0.07 0.69±0.09 0.67±0.08* 0.69±0.09 0.67±0.09
Daily Insulin dose 
[IU]
37±17 41±21* 37±17 29±16* 36±21 28±22*
Supported by: Takeda Pharma
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Effect of acarbose on inflammatory parameters at baseline and after an 
oral fat load: a double-blind, placebo controlled trial 
P. Maffioli, S.A.T. Salvadeo, I. Ferrari, A. Gravina, R. Mereu, A. D’Angelo,  
I. Palumbo, S. Randazzo, G. Derosa; 
Internal Medicine and Therapeutics, University of Pavia, IRCCS Policlinico 
S.Matteo, Italy.
Background and aims: To evaluate the effects of acarbose compared to pla-
cebo on inflammatory biomarkers in diabetic patients at baseline and after a 
standardized oral fat load (OFL).
Materials and methods: A multicenter, randomised, double-blind, controlled 
study was conducted; 188 type 2 diabetic patients were randomised to titrate 
acarbose til 100 mg three times a day or placebo. We evaluated at the baseline, 
and after 1, 2 and 7 months: body mass index (BMI), glycemic profile, fasting 
plasma insulin (FPI), post-prandial plasma insulin (PPI), homeostasis model 
assessment index (HOMA index), lipid profile, soluble intercellular adhesion 
molecule-1 (sICAM-1), interleukin-6 (IL-6), high-sensitivity C reactive pro-
tein (Hs-CRP), soluble vascular cell adhesion molecule-1 (sVCAM-1), solu-
ble E-selectin (sE-selectin). Furthermore, at the baseline and at the end of the 
study, all patients underwent OFL. Repeated measures analysis of variance 
(ANOVA), analysis of covariance (ANCOVA), and paired tests were used: a 
one-sample t test and two-sample t tests.
Results: We observed a significant decrease of body weight, and BMI in both 
groups (p<0.05, for both). An improvement of glycemic profile was observed 
in both groups, but acarbose gave a faster and better decrease of these param-
eters compared to placebo (p<0.01 for glycated hemoglobin, and p<0.05 for 
fasting and post-prandial glucose). No variation of FPI, or PPI were observed 
in control group, while there was a reduction of these parameters after 7 
months with acarbose (p<0.05), even if no differences between the two treat-
ments were recorded. Acarbose reduced HOMA index after 3, and 7 months 
(p<0.05, and p<0.01, respectively), while no modifications were registered in 
controls; moreover HOMA index obtained with acarbose was significantly 
lower than the value in control group (p<0.05). Neither of treatments influ-
enced HDL-cholesterol; instead acarbose significantly reduced total choles-
terol (p<0.05), and LDL-cholesterol (p<0.05) after 7 months compared to 
baseline, and with control group (p<0.05). No variation of tryglicerides (Tg) 
was reached in controls, while acarbose decreased Tg value after 3, and 7 
months compared to baseline (p<0.05, and p<0.01, respectively), and with 
controls (p<0.05). We did not observe any variation of s-ICAM-1, sVCAM-1, 
IL-6, and Hs-CRP in controls, while there was a reduction of these parameters 
with acarbose (p<0.05 for all), even if no differences were obtained between 
the two groups. No variation of E-selectin was recorded in neither of groups. 
Regarding OFL, there was a decrease of blood glucose levels in both groups 
comparing OFL administered at baseline, and at the end of the study. There 
was an improvement of all lipid parameters in acarbose group, while there 
was only a reduction of Tg in control group. A reduction of sICAM, sVCAM, 
IL-6, Hs-CRP, and sE-Selectin was registered in both groups, even if acarbose 
had a longer effect in reducing inflammatory parameters during OFL.
Conclusion: Acarbose gave a faster and better improvement of glycemic, 
lipid profile and inflammatory parameters compared to placebo. Regarding 
OFL, acarbose had a longer effect in reducing inflammatory parameters com-
pared to controls.
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Acarbose compared to placebo on insulin resistance biomarkers in a 
double-blind, placebo-controlled trial
G. Derosa, S.A.T. Salvadeo, I. Ferrari, A. Gravina, R. Mereu, A. D’Angelo,  
I. Palumbo, S. Randazzo, P. Maffioli; 
Internal Medicine and Therapeutics, University of Pavia, IRCCS Policlinico 
S.Matteo, Italy.
Background and aims: To evaluate the effects of acarbose compared to pla-
cebo on insulin resistance biomarkers in a randomised, double-blind, pla-
cebo controlled trial.
Materials and methods: We randomised 188 type 2 diabetic patients to ti-
trate acarbose til 100 mg three times a day or placebo. We evaluated: body 
mass index (BMI), glycated hemoglobin (HbA1c), fasting plasma glucose 
(FPG), post-prandial plasma glucose (PPG), fasting plasma insulin (FPI), 
post-prandial plasma insulin (PPI), homeostasis model assessment index 
(HOMA index), lipid profile, tumor necrosis factor-α (TNF-α), resistin (r), 
retinol binding protein-4, adiponectin (ADN), high-sensitivity C reactive 
protein (Hs-CRP) at the baseline, and after 1, 2 and 7 months. Furthermore, 
at the baseline and at the end of the study, all patients underwent euglycemic 
hyperinsulinemic clamp to evaluate M value and total glucose requirement 
(TGR); an oral fat load (OFL) was also performed at baseline, and after 7 
months of therapy. Repeated measures analysis of variance (ANOVA), analy-
sis of covariance (ANCOVA), and paired tests were used: a one-sample t test 
and two-sample t tests.
Results: We observed a significant decrease of body weight and BMI in both 
groups (p<0.05 for both). An improvement of HbA1c, FPG, and PPG was 
reached in both groups, even if acarbose gave a faster and better improve-
ment of these parameters compared to placebo (p<0.01 for HbA1c, and p<0.05 
for both FPG, and PPG). Placebo did not reduce FPI, or PPI, while acarbose 
decreased these parameters after 7 months of therapy (p<0.05), even if no 
differences between the two treatments were recorded. Acarbose significantly 
reduced HOMA index compared to baseline after 3, and 7 months (p<0.05, 
and p<0.01 respectively), and with controls after 7 months (p<0.05). Acar-
bose significantly decreased total cholesterol (p<0.05), tryglicerides (Tg) 
(p<0.01), and LDL-cholesterol (p<0.05) after 7 months compared to baseline, 
and with controls (p<0.05). We did not observe any variation of TNF-α in 
neither of groups. We obtained a reduction of r, and Hs-CRP after 7 months 
with acarbose (p<0.05, for both) but not with placebo, even if no differences 
were recorded in group to group comparison. Moreover, acarbose, but not 
placebo, gave a decrease of RBP-4, and an increase of ADN compared to base-
line (p<0.05 for both), and the values obtained at 7 months were significantly 
better than the values obtained in control group (p<0.05). Regarding OFL, 
there was a decrease of blood glucose levels in both groups during OFL ad-
ministered at the end of the study compared to OFL at baseline. There was an 
improvement of all lipid parameters in acarbose group, while there was only 
a decrease of Tg in control group. A reduction of RBP-4, TNF-α, and Hs-CRP, 
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and an increase of ADN were observed in both groups, even if acarbose had a 
longer effect in reducing inflammatory parameters during OFL. We reached 
an increase of M value, and TGR after 7 months (p<0.05 for both) with acar-
bose, but not with placebo.
Conclusion: We reached a faster and better improvement of glycemic and 
lipid profile with acarbose compared to placebo. Acarbose also improved in-
sulin resistance biomarkers, while placebo did not decrease these parameters. 
Regarding OFL, acarbose had a longer effect in improving insulin resistance 
compared to control group.
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Efficacy of miglitol on postprandial glucose control assessed by 
continuous glucose monitoring
S. Nagasaka1, T. Tsuchita1, N. Takahashi1, D. Sekizawa1, N. Saito1,  
K. Okada1, I. Kusaka1, H. Yagyu1, H. Ogata2, S. Ishibashi1; 
1Endocrinology and Metabolism, Jichi Medical University, Shimotsuke, 
2Graduate School of Education, The University of Tokyo, Bunkyo-ku, Japan.
Background and aims: α-glucosidase inhibitors improve postprandial glu-
cose control, but their precise efficacy has not been evaluated by continuous 
glucose monitoring (CGM). The present study was undertaken to reveal ef-
ficacy of miglitol on postprandial glucose control.
Materials and methods: Nineteen diabetic subjects (4 with type 1 and 15 with 
type 2; with ages of 58±11yrs, BMI 22.8±3.2kg/m2, HbA1c 9.1±2.5%, glycated 
albumin 24.5±6.3%, and 1, 5-anhydroglucitol 6.5±3.9μg/ml, mean±SD, respec-
tively) were studied with CGM on 2 consecutive days. By a cross-over manner, 
their usual therapies (10 with multiple insulin injections, 4 with oral hypogly-
cemic agents, and the remaining 5 with diet therapy alone) were rendered on 
one day, and miglitol 150mg/day was additionally administered on another day. 
These measurements were performed while the patients were admitted and giv-
en controlled diet comprising 50% of energy intake as carbohydrate.
Results: Averaged glucose levels on their usual therapies were 137±49 (pre-
prandial), a peak of 177±49 observed at 60 min postprandial, and then the 
levels were gradually decreased to 151±57 mg/dl (at 180 min). The glucose 
levels on miglitol administration were 134±43 mg/dl (pre-prandial), and 
thereafter no apparent peak was observed until 180 min (P=0.0015 by two-
way repeated-measures ANOVA, Figure). There were also significant differ-
ences in glucose levels from 20 to 120 min postprandial between these two 
situations. On their usual therapies, pre-prandial glucose levels at breakfast, 
lunch, and supper were 136±52, 136±48, and 137±52 mg/dl, and maximal 
postprandial levels were 181±49 (at 65), 160±51 (at 65), and 192±42 mg/dl 
(at 55), respectively. By miglitol administration, postprandial glucose levels 
displayed essentially similar pattern as shown in Figure, so that the efficacy 
of miglitol was most evident after dinner. Some of the measures of glycemic 
variability assessed by CONGA (Diabetes Technol Ther 7: 253, 2005) were 
improved by miglitol administration.
Conclusion: Postprandial glucose levels were significantly reduced from as 
early as 20 min and until 120 min by miglitol administration. The efficacy was 
most evident after dinner.
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Gliclazide blocks cytotoxic effect of hydrogen peroxide
A. Sliwinska1, A. Rogalska2, Z. Jozwiak2, J. Kasznicki1, J. Drzewoski1; 
1Department of Internal Disease, Diabetology and Clinical Pharmacology, 
Medical University of Lodz, Zgierz, 2Department of Thermobiology, 
University of Lodz, Poland.
Background and aims: Apoptosis, a programmed cell death, is needed to 
maintain homeostasis of the cell under physiological condition. However, 
this process can be induced under pathological conditions such as an increase 
in reactive oxygen species (ROS) production in the mitochondria. It is be-
lieved that ROS-induced apoptosis is responsible for loss of beta cell mass in 
diabetes. It was found that gliclazide - a member of sulfonylureas group- may 
protect pancreatic beta cells against apoptosis induced by oxidative stress. 
The aim of our study was to explore the antiapoptotic action of gliclazide in 
vitro.
Materials and methods: Evaluation of the impact of gliclazide on apopto-
sis induced by hydrogen peroxide of pancreatic and mammary gland tumor 
cells (PANC-1 and Hs578T) was assessed by the 1-(4,5-Dimethylthiazol-2-
yl)-3,5-diphenylformazan (MTT) colorimetric assay and the neutral red up-
take (NRU) cytotoxicity assay. The effect of gliclazide on the level of ROS was 
measured by the 2’,7’-dichlorodihydrofluorescein diacetate (DCFH2-DA) as-
say. N-acetylcysteine (NAC), that possesses antioxidant properties similarly 
to gliclazide, was used as a control.
Results: We observed that hydrogen peroxide induced a concentration- and 
time-dependent loss of viability of PANC-1 and Hs578T cells. Gliclazide 
significantly diminished cytotoxic effect of hydrogen peroxide on both cell 
lines. It was also found that either gliclazide and NAC inhibited generation of 
ROS in both cell lines. Interestingly, there were not significant differences in 
inhibition of ROS generation between gliclazide and NAC after 24 h incuba-
tion. However, NAC was more sufficient after 72 h incubation than gliclazide 
(Figure).
Conclusion: Our findings indicate that gliclazide may prevent cells from 
cytotoxic effect of hydrogen peroxide by decreasing the generation of ROS. 
These results support previous observations suggesting protective effect of 
this antidiabetic drug on beta-cells loss. However, further studies are needed 
to evaluate the mechanism(s) of protective effects of gliclazide against oxida-
tive stress induced apoptosis. 
Figure. Induction of ROS by H2O2 in Hs578T and PANC cells in the pres-
ence and absence of antioxidant-NAC or gliclazide. The cells (104), seeded 
into 96-well microplates 24 h before the experiment, were treated with dif-
ferent H2O2 concentrations for 24 h or 72. Oxidation of 5 µM DCFH2-DA 
fluorescence probe was used for monitoring the produced ROS after drug 
treatment. In experiments with antioxidant or gliclazide, cells treated with 
200 µM of H2O2 were preincubated with 3 mM NAC or 5-25 μM gliclazide 
for 1 h, then H2O2 was added and incubation was continued for another 24 
h or 72 h. The results represent mean ± SD of four independent experiments. 
*P<0.05 in comparison to respective control cells taken as 100%, #P<0.05 in-
dicates significant differences between H2O2-treated cells and samples pre-
incubated with NAC or gliclazide.
Supported by: Medical University of Lodz 503 -0077-9
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Uncontrolled type 2 diabetes treated with oral hypoglycaemic agents 
(OHA): therapeutic behaviour in primary care in France
B. Detournay1, B.J. Balkau2, S. Halimi3, J.-F. Blickle4, I. Chartier5, E. Tocque6, 
E. Amelineau7; 
1CEMKA-EVAL, Bourg La Reine, 2Inserm U780-IFR69, Villejuif, 3CHU 
Michalon, Grenoble, 4Hôpital Civil de Strasbourg, 5AIXIAL Pharma, 
Levallois-Perret, 6AstraZeneca, Rueil Malmaison, 7Bristol-Myers Squibb, 
Rueil Malmaison, France.
Background and aims: Current diabetes guidelines recommend that treat-
ment should be intensified according to the HbA1c level. In France, HbA1c 
thresholds vary according to treatment patterns: mono-, bi- or tritherapy 
with OHA or with insulin. Recent epidemiologic data have confirmed that 
intensified therapies are still underused. The study objectives were: to identify 
the proportion of type 2 diabetic (T2D) patients with intensified treatment 
among those who needed such intensification according to HbA1c levels, to 
measure the time to intensification, to identify the factors related with this 
delay.
Materials and methods: A retrospective analysis was performed on a cohort 
of T2D patients from a large computerised longitudinal database in primary 
care. Patients analyzed were adult T2D patients, treated with OHA without 
insulin therapy or GLP-1 mimetic. Time to treatment intensification was 
measured from the last of two successive HbA1c levels above the recom-
mended thresholds in France (6.5% for patients treated with a monotherapy, 
7.0% for bitherapy and 8.0% for tri and quadritherapy). Treatment intensi-
fication was defined as an increase in the number of drug classes or an in-
creased dose of the class being used or the introduction of insulin therapy or 
GLP-1 mimetic. Switches to a different class were not considered. Predictive 
factors were identified by Cox regression multivariate models.
Results: In the overall sample of 17,493 patients treated with OHA without 
insulin therapy or GLP-1 mimetic, 3,118 (18%) were identified as requiring a 
treatment intensification. Such intensification was performed respectively for 
39% and 60% of those patients within a 6-month period and within a one-
year period following the date of the second HbA1c value: 38% and 56% for 
patients treated with a monotherapy, 42% and 65% for patients treated with 
a bitherapy and 44% and 70% treated with a tritherapy. The rate of treatment 
intensification over time is positively correlated with HbA1c levels and with 
OHA treatment (bi- and tritherapy as compared to monotherapy) and nega-
tively correlated with the age of the patient. No other explanatory variables 
related to the patients or to the physicians were identified.
Conclusion: With regard to current guidelines in T2D France, treatment in-
tensification is still underused in primary care in France. Adherence to the 
guidelines appears to be mainly restrained by the age of the patient, with 
older patients being prescribed less frequently intensive treatment. Future 
guidelines should consider those points.
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Patterns of use of glucose lowering treatments at baseline and during 
follow-up in ADVANCE
S. Czernichow1, S. Zoungas2, J. Chalmers2, A. Patel2, M. Marre3,  
S. Colagiuri4, P. Hamet5, Q. Li2, L. Billot2; 
1INSERM 557, University Paris 13, Hôpital Avicenne, Bobigny, France, 
2The George Institute for International Health, The University of Sydney, 
Australia, 3Hôpital Bichat-Claude Bernard and Université, Paris, France, 
4Boden Institute of Obesity, Nutrition and Exercise, The University of 
Sydney, Australia, 5Centre Hospitalier de I’Universite de Montreal and 
Universite de Montreal, Canada.
Background and aims: The ADVANCE and UKPDS trials are the only two 
large scale glucose lowering trials that have separately reported major benefits 
on cardiovascular and renal outcomes. Both used glucose lowering regimens 
that were based on sulphonylureas with addition of other drugs as required. 
In the present analyses we examine the patterns of use of various glucose 
lowering treatments at entry to ADVANCE and during follow-up.
Materials and methods: The treatment patterns applied to all 11,140 pa-
tients randomized to receive either gliclazide modified release (MR)-based 
intensive glucose control, targeting a mean glycated hemoglobin (HbA1c) 
of <=6.5% (n=5,571), or standard guideline based glucose control (n=5569) 
were analyzed both at baseline and during follow-up.
Results: At baseline, 9% of patients were managed with diet and lifestyle 
alone, 43% were receiving a single oral glucose lowering agent, 42% were re-
ceiving two oral agents and 6% were receiving three or more oral agents. 72% 
were on a sulphonylurea, 61% on metformin, and only 4%, 9% and 2% on thi-
azolidinediones, acarbose and glinides respectively. Of the patients on mono-
therapy at baseline, 59% and 38% were on sulphonylureas and metformin 
respectively. The median duration of follow up was 5.0 years. In the group 
assigned intensive glucose control, the HbA1c fell gradually to the target of 
<=6.5% after 36 months and was maintained till the end of the study. By the 
end of follow-up, 91% of patients in the intensive control group were still on 
gliclazide MR (average daily dose of 103mg/day) and 59% of patients in the 
standard control group were on other sulphonylureas. At that time, 74% and 
67% of patients were taking metforminin the intensive and standard glucose 
control groups respectively. Less than half of the subjects in the intensive con-
trol group required insulin by the end of follow-up (40%). The average time to 
the introduction of insulin in the intensive group was 44 months, consider-
ably later than the 36 months taken to achieve the HbAlc target of 6.5%.
Conclusion: The gliclazide MR-based intensive glucose control regimen 
achieved its target HbA1c of 6.5% within 3 years and maintained it to the 
end of 5 years of follow-up. At baseline, sulphonylureas were taken by 72% 
of all patients and at the end of follow-up by 91% of patients in the intensive 
glucose control group and by 59% of patients in the standard control group. 
Sulphonylureas continue to play a critically important role in glucose control 
and in vascular and renal protection for patients with type 2 diabetes, as dem-
onstrated with gliclazide MR in ADVANCE.
Supported by: Servier
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Reasons why UK general practitioners do not initiate antihyperglycaemic 
therapy in older and younger patients following diagnosis of type 2 
diabetes
Q. Zhang1, K. Jameson2, S. Meiler3, M.J. Davies1, L. Radican1, A. Sinclair4; 
1Global Outcomes Research, Merck, Whitehouse Station, USA, 2Outcomes 
Research, MSD, Hoddesdon, United Kingdom, 3KantarHealth GmbH, 
München, Germany, 4University of Bedfordshire, Luton, United Kingdom.
Background and aims: Research has reported benefits for early treatment of 
type 2 diabetes (T2DM). However, delayed treatment has been found more 
commonly in older patients. This study compared characteristics of younger 
and older patients with diagnosed T2DM who were untreated with antihy-
perglycaemic agents (AHAs) for at least 6 months following diagnosis and 
assessed physicians’ reasons for non-treatment.
Materials and methods: A survey was conducted in Nov 2009-Jan 2010 
among 358 UK general practitioners. Physicians provided data from chart re-
view on patients aged ≥18 years were untreated with any AHA for ≥6 months 
after diagnosis. Each physician also chose reasons for not initiating AHA 
therapy for their selected patients. Thirty six potential reasons were classified 
into 4 major categories: mild hyperglycaemia, factors related to AHA therapy, 
issues with co-morbidities and/or polypharmacy, and patient-related reasons. 
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All analyses were stratified by patient’s age at the time of T2DM diagnosis 
(younger [<65 years] vs. older [≥65 years]). Group differences were assessed 
with a t-test for mean, rank test for median and χ2 test for proportions.
Results: Of the 2,028 patients provided by the physicians, 1,023 were younger 
(mean age=51 years; mean most recent HbA1c=6.8%; 61% males) and 1,005 
were older (mean age=74 years; mean most recent HbA1c=6.8%; 54% males). 
Compared to younger patients, older patients had a longer duration of T2DM 
(median 25 vs. 18 months), lower BMI (29 vs. 31 kg/m2), and a higher prev-
alence of cardiovascular conditions (18% vs. 5%) and microvascular com-
plications (15% vs. 4%) (all p<0.001). The proportion of patients with most 
recent HbA1c ≥6.5% (UK treatment target <6.5%) did not differ significantly 
between older and younger patients (58% vs. 59%, respectively). The most 
commonly reported reason for not initiating an AHA by physicians was re-
lated to mild hyperglycaemia and was not different between groups (86% for 
older and 88% for younger patients). Compared to younger patients, factors 
related to AHAs (46% vs. 38%) and issues with co-morbidities/polypharmacy 
(33% vs. 19%), both including safety-related issues, were more commonly re-
ported reasons for not initiating AHA therapy in older patients (all p<0.001). 
The reported patient-related reasons were not different between older (41%) 
and younger (43%) patients.
Conclusion: Among patients who were untreated with an AHA for ≥ 6 
months following diagnosis of T2DM, nearly 60% had a most recent HbA1c 
above the recommended goal <6.5%. Mild hyperglycaemia was the most re-
ported reason by physicians for non-treatment in all patients, regardless of 
age. AHA-related factors, e.g., “may cause hypoglycaemia”, were more fre-
quently reported by physicians as reasons for non-treatment among older 
patients. Given older patients have higher prevalence of vascular complica-
tions, delay in diabetes treatment for this population may have greater health 
implications than for younger patients.
Supported by: Merck
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The likelihood of initiating insulin is increased in UK patients with 
newly diagnosed type 2 diabetes who received initial monotherapy with 
sulphonylurea compared with metformin
P. Mavros1, C. Zhao1, Q. Zhang1, S.S. Engel2; 
1Global Outcomes Research, Merck Sharp & Dohme, Corp., Whitehouse 
Station, USA, 2Merck Research Laboratories, Merck Sharp & Dohme, Corp., 
Rahway, USA.
Background and aims: Despite initial treatment with a single antihyperg-
lycaemic agent (AHA), the addition of other AHAs including insulin is ulti-
mately required in many patients. This study examined the association of ini-
tial oral AHA monotherapy choice with the likelihood of subsequent addition 
of insulin among patients with newly diagnosed type 2 diabetes (T2DM).
Materials and methods: This retrospective cohort study used a sample from 
the MediPlus database of general practitioners in the UK. Patients with newly 
diagnosed T2DM during 1992 to 2008 who were ≥30 years old at the first 
T2DM diagnosis and who received either metformin (MET) or sulphonylu-
rea (SU) as initial monotherapy in 1992 or beyond were included. The follow-
up period lasted to the end of 2008 or the patients’ latest data available. The 
time from initial oral AHA monotherapy (MET or SU) to insulin initiation 
was estimated based on prescription records. An adjusted Cox proportional 
hazards regression was conducted to evaluate the likelihood of insulin ad-
dition.
Results: Of the 15,926 patients with newly diagnosed T2DM who initiated 
either MET or SU monotherapy, 65% initiated with MET and 35% with SU. 
Patients initiated with SU were older at initial monotherapy (mean age 67 vs. 
61 years), had lower BMI (mean 28 vs. 33 kg/m2), and had higher incidence of 
insulin addition (21% vs. 9%) and shorter time to insulin initiation (median 
5,504 vs. 5,613 days) compared to those initiated with MET (all p<0.001). 
Adjusted for gender, age at and the year of initial monotherapy, BMI, selected 
co-morbidities, and other medication use, patients started with SU mono-
therapy were more likely to initiate insulin (adjusted hazard ratio: 1.77 [95% 
CI: 1.53, 2.06]; p<0.001) than those started with MET.
Conclusion: After adjustment for potential differences in patient profiles 
which may be associated with beta-cell dysfunction (i.e., lower weight and 
older age), patients with newly diagnosed T2DM in the UK who started with 
SU monotherapy tended to receive insulin significantly faster and more often 
compared with those who started with MET monotherapy.
Supported by: Merck
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Time to add-on medication use for patients with type 2 diabetes who 
failed metformin monotherapy
Y. Qiu1, A.Z. Fu2, L. Radican1; 
1Merck Sharp & Dohme, Corp., Whitehouse Station, USA, 2Quantitative 
Health Sciences, Cleveland Clinic, USA.
Background and aims: Add-on medication regimens are recommended 
if target glycaemic goals for patients with type 2 diabetes (T2DM) are not 
achieved or sustained after initial metformin monotherapy. However, it is not 
clear how long it takes for additional treatment to be used after metformin 
monotherapy failure in clinical practice. This study was undertaken to ad-
dress this question.
Materials and methods: The study cohort was selected from a large US elec-
tronic medical record database from 1/1/1997 to 12/31/2008. Included sub-
jects had to be aged ≥18 years with a diagnosis of T2DM who had HbA1c 
≥7.0% or at least two fasting blood glucose levels of ≥126mg/dL (7 mmol/L). 
Treatment failure was defined as HbA1c ≥7% (index date) after metformin 
monotherapy for at least 6 months. Baseline data were extracted during 1 year 
prior to the index date. Time to add-on medication use was the time between 
the index date to the first add-on medication use during follow-up period 
and was evaluated for the overall cohort and for three index HbA1c subgroups: 
7-8%, 8-9%, and >9%. A Cox proportional hazard model was employed to 
determine baseline clinical and demographic characteristics associated with 
shorter time to add-on medication use.
Results: There were 12,566 patients meeting the inclusion criteria; 8656, 2175 
and 1735 had index HbA1c 7-8%, 8-9%, and >9%, respectively. The overall 
mean (SD) age was 63 (12) years and 51% were female. The median time 
to add-on medication use was 15.7 months overall and 17.0, 13.9 and 11.3 
months for patients with index HbA1c 7-8%, 8-9%, and >9%, respectively. 
Higher index HbA1c, greater body mass index, higher Charlson comorbidity 
index, younger age, males, lower LDL-cholesterol were significantly associ-
ated with shorter time to add-on medication use (all p<0.05).
Conclusion: In clinical practice in the US, it takes nearly 16 months for 
T2DM patients with sub-optimal glycemic level after initial metformin mon-
otherapy to receive additional antihyperglycaemic therapies. There is room 
for improvement through disease management so that patients who fail met-
formin monotherapy and are eligible and appropriate for treatment intensifi-
cation, receive add-on therapy sooner rather than later.
Supported by: Merck
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Is three months sufficient to assess HbA1c reduction in high-baseline 
patients? An analysis of HbA1c time course after initiation of metformin 
alone or in combination with sitagliptin
S.S. Engel, H. Katzeff, H. Wang, Q. Dong, R.B. Langdon, D.E. Williams-
Herman, K.D. Kaufman, B. Goldstein; 
Merck Research Laboratories, Rahway, USA.
Background and aims: The ADA/EASD consensus algorithm for treatment 
of type 2 diabetes recommends that antihyperglycemic (AHA) medications 
be added if target A1C levels are not achieved within 2-3 months. We exam-
ined whether this timeframe is adequate to assess the full response to a new 
course of therapy.
Materials and methods: The time course of change in A1C was analyzed in 
data pooled from 2 randomized, double-blind, multicenter studies of drug-
naïve patients treated for 30-31 weeks with metformin (MET) 2000 mg/day 
(uptitrated during Weeks 0-4) as monotherapy (N=803) or in combination 
with sitagliptin 100 mg/day (SITA/MET) (N=807). The analysis determined 
each patient’s maximum A1C reduction (ΔA1CMAX) and the cumulative pro-
portions of patients first achieving 95% of ΔA1CMAX at Weeks 6, 12, 18, and 
30. It included all patients who completed treatment without rescue (n=514 
and 538 in the MET and SITA/MET groups, respectively) and 3 subgroups 
composed of patients with baseline A1C ≤8.0% (n=253), >8.0-≤9.5% (n=376), 
and >9.5 % (n=423).
Results: Mean ΔA1CMAX was −2.2% and −2.6% in the overall MET and SITA/
MET treatment groups. Both groups had significant reductions in A1C at the 
earliest time point measured. At Week 12, however, only 32.7% and 29.9% of 
patients on MET and SITA/MET, respectively, had reached 95% of ΔA1CMAX; 
at Week 18, the proportions were 71.4% and 73.0%, respectively. Evaluation 
after 12 weeks appeared to be especially premature in high-baseline A1C 
patients who received SITA/MET and had the greatest reductions in A1C 
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during treatment. Among SITA/MET-treated patients in the subgroup with 
baseline A1C>9.5% (n=223; mean ΔA1CMAX = −3.7%), only 22.9% reached 
95% of ΔA1CMAX by Week 12, compared with 40.7% in the baseline A1C≤8% 
subgroup (n=123; mean ΔA1CMAX = −1.2%).
Conclusion: This analysis found that full A1C-lowering efficacy of AHA 
medications was not demonstrated in most patients after only 3 months of 
treatment. Further, these findings suggest that patients with higher baseline 
A1C levels may require longer periods of time to reach a steady-state A1C 
level.
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Discontinuing SU and initiating insulin detemir + sitagliptin: improved 
efficacy and similar safety vs. adding sitagliptin to a prior SU regimen. A 
TRANSITIONTM trial subanalysis
K. Rašlová1, J. Liutkis2, T.V. Skjøth3, J. Råstam3, P.A. Hollander4; 
1Metabolicke Centrum, Bratislava, Slovakia, 2Vascular Risk Modification 
Clinic, Cambridge, Canada, 3Novo Nordisk A/S, Copenhagen, Denmark, 
4Baylor University Medical Center, Dallas, USA.
Background: Once-daily insulin detemir (IDet) is often prescribed for pa-
tients with T2D as add-on to OAD. IDet has not previously been evaluated 
in combination with a newer class of OAD, dipeptidyl peptidase-4 (DPP-4) 
inhibitors, which reduce enzymatic degradation of the incretin glucagon-like 
peptide-1 (GLP-1) and thereby enhance glucose-dependent insulin secretion. 
In this randomized, open-label, parallel group, 26-week trial of insulin-naïve 
T2D patients who were poorly controlled by a previous regimen with met-
formin (Met) ± sulphonylurea (SU) or other OADs, IDet was administered in 
combination with the DPP-4 inhibitor sitagliptin (SITA) and Met with prior 
SU, if any, discontinued. This was compared for efficacy and safety against 
SITA + Met in combination with the subjects’ prior SU regimens, if any, con-
tinued. This is a sub-group analysis which reports outcomes only for patients 
with pre-trial SU treatment regimens.
Materials and methods: This subgroup analysis is comprised of the 75% of 
subjects (n=80) in the IDet + SITA group and the 77% of subjects (n=85) in 
the SITA ± SU group who had a pre-trial SU regimen (SITA + SU). Treatment 
groups compared IDet + SITA as add-on to Met, coupled with discontinua-
tion of prior SU therapy, vs. SITA as add-on to Met + pre-trial SU. Results 
described herein are after 26 weeks’ treatment with once-daily IDet + SITA 
(100 mg QD) + Met (>1000 mg) (IDet/SITA) with discontinuation of pre-
trial SU, vs. SITA + Met + SU (SU/SITA) (at each subject’s pretrial SU dose). A 
normal linear regression model was used to analyze HbA1c, FPG, body weight 
and BMI.
Results: Observed baseline A1c was 8.46 and 8.58%, with final mean esti-
mated A1c of 7.23 and 7.63% for the IDet/SITA and SU/SITA groups, re-
spectively. Estimated reductions in A1c, after baseline adjustment for covari-
ates, were 1.29 and 0.88% (est. mean diff. = -0.40%; 95% CI = [-0.66; -0.15], 
p=0.002), for IDet/SITA and SU/SITA, respectively. FPG fell to 6.20 and 8.53 
mmol/L from observed baselines of 9.61 vs. 9.79 mmol/L for the IDet/SITA 
and SU/SITA groups, respectively, with estimated reductions of 3.51 vs. 1.18 
mmol/L (est. mean diff. = -2.34 mmol/L, 95% CI = [-3.00;-1.68], p<0.001). 
Body weight and BMI decreased in both subgroup treatment arms with no 
significant differences between groups (-1.10 vs. -1.42 kg, and -0.40 vs. -0.52 
kg/m2, p=NS, IDet/SITA vs. SU/SITA, respectively). No major hypoglycemia 
was reported. Minor hypoglycemia (PG <3.1 mmol/L) was low in both arms 
(0.58 and 0.70 estimated events/patient-year, Adjusted Rate Ratio = 0.84 
[95% CI: 0.27, 2.65]; p=NS, IDet/SITA vs. SU/SITA, respectively). Final insu-
lin dose was 0.59 U/kg at trial end.
Conclusion: The results of this subgroup analysis - improved A1c, FPG, low 
hypoglycemia and modest decreases in body weight and BMI in both arms 
- supports substitution of IDet/SITA for SU, or addition of SITA to SU + Met. 
Better glycemic control (i.e. lower A1c and FPG) was achieved for IDet/SITA 
compared to the SU/SITA arm among these pre-trial SU users with low in-
cidence of hypoglycemia. Therefore, discontinuation of SU and substitution 
of once-daily IDet in combination with a DPP-4 inhibitor, SITA and Met is 
a safe and more effective treatment option for insulin-naïve T2D patients, 
compared to adding SITA to an existing SU and Met regimen.
Supported by: Novo Nordisk
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Long-term patterns of statin therapy in patients with type 2 diabetes 
mellitus compared to long-term oral anti-diabetic medication patterns
E.J.F. Lamberts1, M.L. Bouvy1, P.C. Souverein1, G. Nijpels2, L.M.C. Welschen2, 
J.G. Hugtenburg2, J.M. Dekker2; 
1Division of Pharmacoepidemiology and Pharmacotherapy, Utrecht 
Institute for Pharmaceutical Sciences Faculty of Science, 2EMGO, VU 
University Medical Center, Amsterdam, Netherlands.
Background and aims: Statins are effective in the prevention of cardiovascular 
disease in type 2 diabetes mellitus. However studies on long-term use of statins 
among type 2 diabetes mellitus patients are scarce. The aim of this study was to 
describe long-term patterns of statin use among patients with type 2 diabetes 
mellitus and compare discontinuation of statins and oral antidiabetics.
Methods: A cohort study among 2072 patients with type 2 diabetes mellitus 
who initiated treatment with statins between 1999 and 2007. Drug dispensing 
data were extracted from 17 community pharmacies in a geographically well-
defined region in The Netherlands. Patients were classified as using statins be-
fore (prevalent users) or after (incident users) the initiation of oral antidiabetics. 
Patients were considered to have discontinued statin therapy when an interval of 
180 days or more occurred between the theoretical end date of a statin prescrip-
tion and a subsequent statin prescription. This was done in the same way for oral 
antidiabetics in order to compare discontinuation between the drug groups.
Results: The proportion of patients with type 2 diabetes mellitus using 
statins increased between 1999 and 2007. Discontinuation rates for statins 
were higher compared to discontinuation of oral antidiabetic drugs (52.1 
vs.15.0%). Moreover, incident statin users were more likely to discontinue 
statin therapy compared to prevalent statin users (62.8 vs. 48.2%).
Conclusions: Although statins are increasingly prescribed to patients with 
type 2 diabetes mellitus, discontinuation of statins is high compared to dis-
continuation of antidiabetics. This could result in suboptimal therapeutic 
outcomes for patients with type 2 diabetes mellitus.
Supported by: St. MAG
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Remission of the metabolic syndrome three years after screening for 
increased waist circumference
C. den Engelsen, M.C. Busser, M. van den Donk, K.J. Gorter, P.L. Salomé, 
G.E.H. Rutten; 
Julius Center for Health Sciences and Primary Care, University Medical 
Center Utrecht, Netherlands.
Background and aims: Screening for cardiovascular risk factors and diabetes 
among overweight and obese individuals might be an attractive option with 
potential health benefits. In 2006, such a screening in primary care was per-
formed to detect individuals with the metabolic syndrome (MetS) by letting 
them measure their waist circumference at home as a first step. Among indi-
viduals aged 20-70 years, previously not known with hypertension, diabetes 
or dyslipidemia and selected by means of a self-measured increased waist 
circumference, 473 new MetS cases were detected. They were advised to con-
tact their general practitioner. However, screening of individuals with a high 
cardiovascular risk is only meaningful if adequate subsequent and effective 
action is undertaken. The aim of this study was to assess the remission of the 
MetS three years after screening followed by usual care in general practice.
Materials and methods: 432 individuals with screen-detected MetS (those of 
the original group of 473 patients that still visited the same general practice) 
were invited for follow-up measurements, which included a physical exami-
nation and laboratory tests. The MetS was defined according to the NCEP 
ATP III criteria. We also invited a random selection of 280 individuals who 
had an increased self-measured waist circumference during screening, but 
did not meet the MetS criteria at that time.
Results: The overall response rate was 84%. 63% of the responders indicated 
to be interested in follow-up measurements (the ‘participants’). 197 individu-
als with MetS at screening and 179 individuals without MetS at screening un-
derwent all follow-up measurements. A significant improvement in all MetS 
components, except for glucose, was seen in the group with screen-detected 
MetS (table). The remission rate was 53%. The only significant changes in 
the group without MetS in 2006 were a decrease in diastolic blood pressure, 
an increase in triglyceride level and a decrease in HDL-cholesterol level in 
women. 15% of the participants in this group developed the MetS at fol-
low-up. Non-participants and participants were comparable in age, gender 
and mean level of MetS components in 2006. The 16% non-responders with 
screen-detected MetS were significantly younger than the responders (both 
participants and non-participants) with screen detected MetS.
Conclusion: Screening for MetS among overweight and obese individuals, 
followed by care as usual, leads to significant improvements in all MetS com-
ponents and a remission rate of 53% among the individuals with screen-de-
tected MetS. This might be an attractive option with potential health ben-
efits.
Mean levels (SD) of MetS components, BMI and weight in 2006 (screening) 
and 2009 (follow-up)
2006 2009 P-value
BMI (kg/m2) 30.2 (3.6) 29.3 (4.1) <0.001
Weight (kg) 93.2 (15.2) 90.8 (16.1) <0.001
Waist circumference men (cm) 109.9 (7.4) 106.1 (10.0) <0.001
Waist circumference women (cm) 99.6 (8.8) 96.1 (10.7) <0.001
Systolic blood pressure (mmHg) 143.7 (15.0) 135.5 (13.5) <0.001
Diastolic blood pressure (mmHg) 88.0 (7.5) 82.4 (7.7) <0.001
Triglycerides (mmol/L) 2.2 (1.1) 1.9 (0.9) 0.001
HDL-cholesterol men(mmol/L) 1.1 (0.3) 1.2 (0.3) <0.001
HDL-cholesterol women (mmol/L) 1.3 (0.3) 1.4 (0.3) <0.001
Fasting blood glucose (mmol/L) 5.3 (1.2) 5.4 (0.8) 0.02
Supported by:  Investigator Initiated Studies Program of MSD
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Improving cardiometabolic risk by lifestyle modification in viscerally 
obese men: is weight loss the best therapeutic target?
A.-L. Borel1, N. Alméras1, J. Bergeron2, A. Tremblay1,3, P. Poirier1,4,  
J.-P. Després1,3; 
1Centre de recherche de l’Institut universitaire de cardiologie et de 
pneumologie de Québec, 2Centre de recherche du Centre hospitalier de 
l’Université Laval, 3Faculté de médecine, Département de médecine sociale 
et préventive, Division de kinésiologie, 4Faculté de pharmacie, Quebec, 
Canada.
Background and aims: Visceral obesity is associated with a diabetogenic/
atherogenic cardiometabolic risk (CMR) profile. Most intervention studies 
aiming to reduce CMR have used magnitude of weight loss as their main 
outcome measure. The present work compared the CMR profile response 
to a one-year healthy eating/physical activity lifestyle modification program 
of high risk viscerally obese men (waist girth ≥ 90 cm, triglycerides ≥ 1.69 
mmol/L and/or HDL cholesterol < 1.03 mmol/L) classified into two groups 
according to both weight loss and loss of visceral adipose tissue (VAT).
Materials and methods: From the 144 viscerally obese men who participated 
in the study (age 47.5 ± 9.0 years, waist girth 107.8 ± 8.5 cm, triglycerides 
2.52 ± 0.89 mmol/L, HDL-cholesterol 0.95 ± 0.16 mmol/L), 109 completed 
the first year of intervention. In the present analysis, we examined the rela-
tionship between weight loss and loss of VAT in the subgroup of 100 men 
who lost both weight and VAT. Body weight, body composition and fat distri-
bution were assessed by anthropometry and DEXA/computed tomography. 
Cardiorespiratory fitness and fasting lipoprotein/lipid profile were assessed, 
and an oral glucose tolerance test (75 g) was performed. The regression line 
between weight loss and loss of VAT was used to define two groups of men, 
below and above the regression line (figure). Group 1 and group 2 were de-
fined as men having lost more (group 1: 10 ± 4 %) or less (group 2: 6 ± 4 %) 
body weight than predicted by the regression line.
Results: At baseline, group 1 presented higher body weight and subcutane-
ous adipose tissue (SAT) volume than group 2 (97 ± 13 vs. 92 ± 9 kg and 1886 
± 558 vs. 1585 ± 476 cm3, for group 1 and 2 respectively, p < 0.05), but lower 
VAT volume (1843 ± 493 vs. 2043 ± 431 cm3, respectively, p = 0.03). After the 
one-year intervention, group 1 had lost more weight and SAT than group 2 
(-9.2 ± 4.1 vs. -5.2 ± 3.9 kg and -446 ± 284 vs. -245 ± 195 cm3, respectively, p 
< 0.0001). However, loss of VAT was similar between the two groups. Finally, 
despite greater absolute and relative losses of body weight and body fat in 
group 1 than 2, both groups showed essentially similar improvements in their 
CMR profile.
Conclusion: Provided that loss of visceral AT is similar, magnitude of weight 
loss does not appear to have any additional effects on the response of the 
CMR profile to a one-year lifestyle modification program. Therefore, our re-
sults suggest that magnitude of VAT loss may be a better therapeutic target 
than weight loss.
Supported by: the CIHR.
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Optimal serum alanine aminotransferase cutoffs for the metabolic 
syndrome in Chinese
M. Xia1, H. Yan1, H. Bian1, B. Pan2, X. Gao1; 
1Endocrinology, 2Laboratory Medicine, Zhongshan Hospital, Shanghai, 
China.
Background and aims: Non-alcoholic fatty liver disease (NAFLD) is the 
most frequent liver disease in China and western countries. It has been dem-
onstrated that NAFLD was significantly correlated with all components of 
the metabolic syndrome (MetS), and could independently predict the risks 
of type 2 diabetes and coronary vascular disease (CVD). Serum alanine 
aminotransferase(ALT) concentration is the most commonly measured vari-
able for assessment of liver disease. However, the current ALT upper limit 
(40 IU/L) often fails to identify patients with MetS and potential hepatic fat 
infiltration, thus underestimating the risks of type 2 diabetes and CVD. It 
has been recently recommended that the normal upper limit for ALT should 
be revised to 30 IU/L for men and 19 IU/L for women to identify NAFLD 
or chronic HCV infection in western countries. However, the optimal ALT 
cutoffs for metabolic syndrome in Chinese communities were poorly studied. 
The aim of the present study was to determine the optimal cutoffs for ALT 
linking to the risk of the MetS in Chinese subjects.
Materials and methods: The study population consisted of 440 subjects (242 
male and 198 female) aged from 18 to 80 years recruited from the local com-
munity and outpatient department of endocrinology, Shanghai Zhongshan 
Hospital. Participants with hepatitis B or C, excessive alcohol intake and 
other hepatic disease were excluded. A standard interview, anthropometrics 
(height, weight, waist, hip circumference and blood pressure), Laboratory 
parameters (ALT, serum lipid, fasting plasma glucose, 2 h postload plasma 
glucose) were conducted for each participant. Metabolic syndrome was de-
fined according to the International Diabetes Federation criteria. Statistical 
analyses were performed with SPSS for windows 15.0. All reported p values 
were two-tailed and p-values less than 0.05 were considered statistically sig-
nificant. Univariate analysis of variance was used to detect the association 
between ALT level and all MetS components. Receive operating characteristic 
(ROC) curve analyses were utilized to determine the appropriate cutoffs of 
ALT for identifying individuals with MetS.
Results: In 242 men there were 97(40.1%) with MetS, and in 198 women 
there were 89(55.1%) with MetS. The frequency of MetS was elevated with 
increased ALT level in both male and female participants. Stratified accord-
ing to sex, Univariate analysis showed ALT level was associated with waist 
circumference, serum cholesterol and LDL-c in female, but only associated 
with waist circumference in male. The optimal cutoffs were 36IU/L in male 
and 19IU/L in female for ALT to identify MetS patients. Compared with the 
current ALT upper limit, the revised ALT cutoffs were more sensitive and ef-
ficacious in identifying MetS, especially in women (Table 1).
Conclusion: The optimal cutoffs of ALT for MetS are 36IU/L for men and 
19IU/L for women in Chinese. The current used ALT upper limit (40 IU/L) 
could underestimate MetS accompanied by NAFLD, especially in women.
Supported by: 2008BAI52B03, 08GWZX0203
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Two major patterns of dynamics in adipokine serum concentrations over 
2 years of dietary weight-loss intervention
M. Blüher1, A. Rudich2, N. Klöting1, R. Golan3, E. Rubin3, D. Schwarzfuchs4, 
M. Fiedler1, Y. Gepner3, O. Tangi3, M. Stampfer5, J. Thiery1, M. Stumvoll1, I. 
Shai3; 
1Department of Medicine, University of Leipzig, Germany, 2The Department 
of Clinical Biochemistry, Ben-Gurion University, Beer-Sheva, Israel, 3S. 
Daniel Abraham Center for Health and Nutrition, Ben-Gurion University, 
Beer-Sheva, Israel, 4Nuclear Research Center Negev, Nuclear Research 
Center Negev, Dimona, Israel, 5Brigham and Women’s Hospital, Harvard 
School of Public Health, Boston USA.
Background and aims: During dietary interventions, adipokines’ serum 
concentrations may be affected by changes in adipose tissue mass and/or by 
direct effects of healthier dieting. However, which are the adipokines that fol-
low hormones and lipid parameters that mainly reflect weight changes, versus 
those that are primarily affected by the dietary change that could persist be-
yond weight change is largely unknown.
Materials and methods: In the 2-year Dietary Intervention Randomized Control-
led Trial (DIRECT) among patients with type 2 diabetes (T2D, n=45) and non-
diabetics (n=277), which have been randomly assigned to one of three diets: low-
fat, Mediterranean, or low-carbohydrate, we analyzed the dynamics in circulating 
levels of adipokines, as well as serum concentrations of traditional biomarkers, and 
their association with 2-year changes in homeostasis model assessment-insulin 
resistance (HOMA-IR) and carotid artery intima-media thickness (IMT).
Results: Both qualitative analysis of the changes in biomarker levels at base-
line, 6 and 24 months of intervention, and utilizing a non-biased mathemati-
cal modeling approach, revealed 2 major patterns of dynamics. Pattern A 
included biomarkers whose dynamics closely reflect changes in body weight, 
which exhibited a rapid decline (0-6 months) followed by weight stabilization 
or regain (7-24 months). This pattern included fasting circulating levels of 
insulin, triglycerides (TG), leptin, chemerin, monocyte chemoattractant pro-
tein-1 (MCP-1), and retinol binding protein-4 (RBP4). Pattern B consisted 
of biomarkers that displayed a continuing, cumulative increase or decrease 
throughout the 24 months of dietary intervention, despite the partial regain 
in mean body weight. This group included high molecular weight (HMW) 
adiponectin, HDL-cholesterol, CRP, fetuin-A, progranulin, and vaspin. Pat-
terns A and B were similar among patients with T2D and non-diabetics. In 
models adjusted for age, sex and assigned diet group, a greater decline in ei-
ther chemerin (beta=0.136, p=0.034) or leptin (beta=0.250, p<0.001) within 
the first 6 months of intervention were associated with lower levels of HOMA-
IR at 24 months. In multivariate models adjusted for age, sex, assigned diet 
group, and 24 months changes in weight, chemerin, progranulin and MCP-1, 
greater decrease in fetuin-A predicted a larger decline in IMT of the carotid 
artery by the end of the 2 years intervention (beta = 0.201, p=0.040).
Conclusion: During a 2-year dietary intervention, leptin, chemerin, MCP-1 and 
RBP4 corresponded mainly to body weight, similar to serum insulin and TG lev-
els. In contrast, HMW adiponectin, fetuin-A, progranulin, and vaspin exhibited 
cumulative improvement despite partial weight regain, similar to the changes in 
HDL-cholesterol and CRP. The two patterns underscore weight -associated versus 
healthy diet -induced beneficial effects beyond weight loss, and suggest a potential 
predictive value for clinically-relevant metabolic and cardiovascular endpoints.
Supported by: Israeli Ministry of Health, DFG, AF
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Effect of dietary fat modification on insulin secretion in subjects with the 
metabolic syndrome
H.L. Gulseth1,2, I.M.F. Gjelstad1,2, J.A. Lovegrove3, C. Defoort4, E.E. Blaak5, J. 
Lopez-Miranda6, A. Dembinska-Kiec7, U. Risérus8, H.M. Roche9, 
C.A. Drevon2, K.I. Birkeland1; 
1Department of Endocrinology, Oslo University Hospital, Norway, 2Department 
of Nutrition, University of Oslo, Norway, 3University of Reading, Reading, United 
Kingdom, 4INSERM, Marseille, France, 5Maastricht University, Netherlands, 
6University of Cordoba, Spain, 7Jagiellonian Medical College, Krakow, Poland, 
8Uppsala University, Sweden, 9University College Dublin, Ireland.
Background and aims: Both β-cell dysfunction and insulin resistance con-
tribute to the development of type 2 diabetes. Dietary fat may have beneficial 
effects on insulin sensitivity, but the effect on insulin secretion is less clear. 
We investigated the effect of dietary fat modification on insulin secretion in 
European subjects with the metabolic syndrome.
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Material and methods: In a 12 weeks parallel, randomized controlled di-
etary intervention trial (LIPGENE) 486 subjects were randomly assigned to 
isoenergetic diets: High fat (38 energy%) diets rich in saturated fat (HSFA) or 
monounsaturated fat (HMUFA) or low-fat (28 energy%), high complex car-
bohydrate diets with (LFHCC n-3) and without (LFHCC-control) 1.2 g/day 
of n-3 PUFA. The β-cell function was measured as acute insulin response 
(AIRg) and disposition index (DI), modeled from intravenous glucose toler-
ance test (IVGTT). The mean age was 54.4 ± 9.0 years, BMI was 32.3 ± 4.1 
kg/m2 and 45% were males.
Results: There was no overall effect on AIRg and DI of the dietary interven-
tion, but there were significant diet*fasting category of glucose interactions 
for AIRg (p=0.021) and DI (p=0.001). In subjects with normal fasting glucose 
and preserved first phase insulin secretion the effects of dietary intervention 
were significantly different between the HMUFA and the HSFA diets for both 
AIRg (p=0.015) and DI (p=0.010). There were no differences between the 
LFHCC diets.
Conclusion: The effects of dietary fat modification on β-cell function were 
minor in the total cohort, but in normoglycemic subjects the HMUFA diet 
improved AIRg and DI as compared to the HSFA diet.
Supported by: EU 6FP 
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Defining waist circumference cut points for South Asians in the United 
Kingdom using measures of dysglycaemia
L.J. Gray1, T. Yates2, E.M. Brady3, M.J. Davies2, D.R. Webb2, N. Sattar4,  
K. Khunti1; 
1Department of Health Sciences, University of Leicester, , 2Department of 
Cardiovascular Sciences, University of Leicester, , 3Department of Diabetes 
and Endocrinology, University Hospitals of Leicester, 4BHF Glasgow 
Cardiovascular Research Centre, University of Glasgow, United Kingdom.
Background and aims: To determine waist circumference cut-points in 
South Asians giving equivalent levels of dysglycaemia as in white Europeans 
with waist levels equivalent to obese BMI cut-points.
Materials and methods: 4688 white Europeans and 1353 South Asians aged 
40- 75 years were screened for Type 2 diabetes. Regression models for fast-
ing glucose, two-hour post-challenge glucose, HbA1c and a glucose factor 
(derived using principal components from the three glucose parameters), 
adjusted for centred age and stratified by sex, were used to identify waist cir-
cumference cut points in South Asians that correspond to glycaemic values at 
the recommended ‘obese’ waist circumferences of 102cm for males and 88cm 
for females in white Europeans.
Results: For South Asians the derived waist circumference cut points were sub-
stantially lower than for white European males and females across all glucose 
parameters. An overall glucose factor score at a cut point of 102cm in white Eu-
ropeans was met by South Asian males at a waist circumference of 84cm. Simi-
larly, a cut point of 88cm for white European females was equivalent to cut point 
69cm for South Asian females. Here 7.5% of South Asian males have a waist 
circumference ≤84cm and 4.2% of females have a waist circumference ≤69cm.
Conclusion: Remarkably low cut points for defining very high waist circumfer-
ences for males and females are needed in South Asians for detecting equivalent 
levels of dysglycaemia as in obese white Europeans. Although the IDF already 
accepts a lower cut point for South Asian males (90cm), the even lower cut 
points suggested herein suggest that South Asian people should be considered 
at high risk of diabetes irrespective of waist circumference measurements.
Supported by: LNR CLARHC
920
Assessing cardiometabolic risk among shift workers
G. Jermendy1, T. Hidvégi2, J. Osztovits1, J. Nadas1, I. Hegyi3, I. Vasas3; 
13rd Medical Department, Bajcsy-Zsilinszky Hospital, Budapest, 2Petz 
Hospital, Győr, 3Kardirex Health Center, Győr, Hungary.
Background and aims: The term of cardiometabolic risk includes a cluster 
of cardiovascular risks beyond the metabolic syndrome. Shift workers, pos-
sibly due to impairment in circadian biological rhythm, may be at higher 
cardiometabolic risk. In order to assess cardiometabolic risk in shift work-
ers, a cross-sectional study was performed among active workers (aged 25-66 
years, with a minimal shift working experience of 5 years).
Materials and methods: We investigated 481 workers (121 male, 360 female) 
in our study, most of them were employees in light industry (58.2%) or in 
public service (23.9%). At enrolment, past medical history was recorded and 
anthropometric measurements and physical examination were performed in 
each subject. Validated questionnaires were used to characterize daily activ-
ity, eating and smoking habits. Fasting venous blood sample was taken for 
measuring laboratory parameters. Data from shift workers (n=234, 54 men 
and 180 women, age 43.9±8.1 years) were compared to those of day workers 
(n=247, 67 men and 180 women, age: 42.8±8.5 years).
Results: Weight (76.6±16.1 vs 73.9±17.6 kg; p<0.05), BMI index (27.5±5.3 vs 
26.0±4.9 kg/m2; p<0.01), systolic blood pressure (123±19 vs 119±16 mmHg, 
p<0.01), the prevalence rate of diabetes (4.3 vs 1.2 %; p<0.05) and cardiovas-
cular diseases (3.8 vs 0.8 %; p<0.05) in the past medical history were higher 
in shift workers as compared to day workers. In addition, proportion of sub-
jects with regular physical activity in leisure time were lower (20.6 vs 38.7 %; 
p<0.001) and that of current smokers were higher (35.0 % vs 19.5 %; p<0.001) 
in shift workers than in day workers. As for laboratory findings, HDL-cho-
lesterol level was lower in female shift workers than in female day workers 
(1.56±0.32 vs 1.68±0,36 mmol/l; p<0.01).
Conclusion: These data indicate that middle-aged, active shift workers, as 
compared to day workers, are at higher cardiometabolic risk. Thus, our study 
highlights the importance of measures for preventing cardiovascular diseases 
in shift workers.
Supported by: Hungarian Diabetes Association
921
Immunological and cardiometabolic risk scores in the prediction of 
incident type 2 diabetes and coronary events: MONICA/KORA Augsburg 
case-cohort study
C. Herder1, J. Baumert2, A. Zierer2, M. Roden1,3, C. Meisinger2, W. Koenig4, 
B. Thorand2; 
1Institute for Clinical Diabetology, German Diabetes Center, Düsseldorf, 
2Helmholtz Zentrum München, Neuherberg, 3University Hospital 
Düsseldorf, 4University of Ulm Medical Center, Germany.
Background and aims: Systemic concentrations of acute-phase proteins, cy-
tokines, chemokines and soluble adhesion molecules are associated with the 
risk of type 2 diabetes and coronary events. The association of each of these 
biomarkers alone with incident disease is too weak for the prediction of out-
comes, but the predictive value of combinations of multiple inflammation-
related biomarkers is still unclear. This study aims to address the following 
questions: (i) what is the predictive value of inflammation-related biomarkers 
for incident type 2 diabetes and coronary events, (ii) are these predictive val-
ues comparable with the those of established biomarkers of cardiometabolic 
risk, and (iii) can the predictive value be improved by combining both sets 
of risk factors?
Materials and methods: The study investigates inflammation-related bi-
omarkers (measured in non-fasting serum samples) and additional cardi-
ometabolic risk factors in a prospective case-cohort study within the popula-
tion-based MONICA/KORA Augsburg cohort. Analyses with the endpoint 
type 2 diabetes are based on 436 individuals with and 1413 individuals with-
out incident type 2 diabetes. Analyses for coronary events are based on 314 
individuals with and 1662 individuals without incident coronary events. The 
follow-up was 10±5 years. Receiver operator characteristic (ROC) analyses 
were used to calculate areas under the ROC curve (AROC) for different sets 
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of risk factors for both incident type 2 diabetes and incident coronary events: 
(a) basic model: adjusted for age, sex, and survey; (b): immunological model: 
factors from (a) plus CRP, IL-6, IL-18, MIF, TGF-beta1, MCP-1, IL-8, IP-
10, RANTES, adiponectin, leptin, sE-selectin, sICAM-1; (c) cardiometabolic 
model: factors from (a) plus BMI, systolic blood pressure, total cholesterol/
HDL cholesterol ratio, parental history of diabetes or myocardial infarction 
(according to the respective endpoint), smoking, alcohol, physical activity; 
(d) full model: combination of risk factors in (b) and (c).
Results: For the prediction of type 2 diabetes, the AROC for the basic model 
was 0.733. Addition of either inflammation-related biomarkers (as continu-
ous variables) or cardiometabolic risk factors resulted in an increase to 0.803 
in both models. A combination of all risk factors predicted type 2 diabetes 
with an AROC of 0.845. For the prediction of coronary events, the basic 
model had a higher predictive value (AROC 0.802), whereas the addition of 
inflammation-related or cardiometabolic risk factors led to less pronounced 
increases (AROC 0.825 and 0.836). The combination of all risk factors re-
sulted in a similar predictive value as for type 2 diabetes (AROC 0.849).
Conclusion: The addition of multiple inflammation-related biomarkers to a 
basic prediction model and to a model including cardiometabolic risk fac-
tors increased the AROC in the prediction of type 2 diabetes and coronary 
events, although the increase was less pronounced for the latter endpoint. As 
limitation, it is important to note that the results were based on non-fasting 
blood samples and cannot be extrapolated to different study settings with 
more complete assessment of diabetes risk factors including glucose, insulin 
and HbA1c measurements.
Supported by: DFG 
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Significant type 2 diabetes incidence reduction in high risk participants, 
after three years of an intensive lifestyle intervention in primary care 
(DE-PLAN-CAT)
X. Cos1, B. Costa1, F. Barrio1, J.J. Cabré1, S. Sarret1, M. Cot1, X. Mundet1,  
F. Pujol1, J. Caula1, T. Mur1, J.L. Piñol1, J. Basora1, B. Bolíbar1, C. Castell2,  
y el Grupo de Investigación DE-PLAN-CAT.; 
1IDIAP Jordi Gol, 2Public Health Department, Barcelona, Spain.
Background and aims: Many Lifestyle interventions have demonstrated 
their efficacy preventing Type 2 Diabetes although none of them have shown 
their benefits into real clinical practice. Public health strategy on type2 diabe-
tes prevention in primary health care. The European coordinated project DE-
PLAN (Diabetes in Europe-Prevention using Lifestyle, Physical Activity and 
Nutritional intervention) evaluates its effectiveness in Primary Health Care.
Materials and methods: Public health strategy on type2 diabetes prevention 
in primary health care. Two-step multicentre cohort study: cross-over period 
(1y-screening) plus a follow-up period (3y-preventive intervention). In Cata-
lonia (DE-PLAN-CAT) has 18 participating centres, more than 150 profes-
sionals (GP+nurses) and a representative randomized population based sam-
ple between 45-75 yo. Randomized non-invasive diabetes screening program 
by means of the FINDRISC score comparing with the oral glucose tolerance 
test (OGTT). All those high risk participants, without Diabetes, received a 
lifestyle intervention (self-acting informative intervention or intensive). Both 
groups were followed by “usual care” (self administered group) or by periodi-
cally motivation reinforcement. We performed an OGTT after 3 year of the 
intervention (An OGTT was yearly performed).
Results: A total of 2547 non-diabetic subjects > 45 y were contacted with a 
80.6% positive response rate (n=2054). Of them 552 (26.9%) had high dia-
betes risk and 251 (45.5%) type 2 prediabetes. 210 (38%) were allotted to 
self-acting informative intervention and 342 (62%) to intensive lifestyle in-
tervention. No differences in risk factor profile or in glycaemic status were 
detected. Mean annual drop-out rate was 11.4%, statistically higher in the 
informative group (14,4% / 9,6%; p<0,001). First year (n=476), 37 partici-
pants (7.8%) developed Diabetes, finishing the study. Second year (n=383) 
were diagnosed 32 new cases (8.4 %) and 21 (7.2%) in the third year (n=293). 
Cumulated diabetes incidence was 24.9%, 32,8% self-acting group vs 21% in 
the intensive intervention (p<0,01) [RRR 36%]. Progression rates (normal-
ity to prediabetes or diabetes and prediabetes to diabetes) were 40.3% and 
31.7% (RR=21,3%). Regression rates (prediabetes to normality) were 5.9% 
and 13.6%, respectively (relative increase =130,5%).
Conclusion: Lifestyle intensive intervention has reduced significantly Type 2 
Diabetes incidence, compared with a self-acting informative, in the Spanish 
Primary Health Care usual practice.
Supported by: DGSanco, FIS and Generalitat de Catalunya (Public Health)
923
Prenatal environmental exposures that may influence beta cell function 
or insulin sensitivity in middle age
H.S. Kahn1, A.D. Stein2, L.H. Lumey3; 
1Division of Diabetes Translation, Natl Ctr for Chronic Dis Prevn & 
Health Promotion, Atlanta, 2Hubert Department of Global Health, Emory 
University, Atlanta, , 3Epidemiology, Columbia University, New York, USA.
Background and aims: Patterns of fetal and childhood growth are associated 
with subsequent diabetes, but the underlying mechanisms remain unclear. 
Few studies have associated the early gestational environment with postna-
tal physiologic impairments to normal glucose metabolism. Fingerprints are 
permanently fixed in the first half of pregnancy, and increased values of a 
marker that contrasts fingerprint ridge counts between the thumbs and fifth 
fingers (Md15) have been linked to type 2 diabetes. Fingerprint Md15 has 
been associated also with seasonal features of the early prenatal environment. 
We studied adults metabolically to explore mechanisms explaining prenatal 
influences on insulin physiology in later life.
Materials and methods: Among 763 adults without known diabetes from the 
Dutch Hunger Winter Families Study we tested the associations of Md15 with 
homeostatic-assessment indices of pancreatic beta-cell function (HOMA-b) 
and insulin sensitivity (QUICKI). For either outcome index, linear regression 
analyses included terms for Md15 tertiles and for maternal history of diabetes 
as reported by each participant. All models were corrected for sibling pairs and 
adjusted for age, sex, and gestational and periconceptional famine exposures.
Results: Fingerprint Md15 was inversely associated with HOMA-b (p<0.05 for 
linear trend) but not with QUICKI. In contrast, a maternal history of diabetes 
was associated with decreased QUICKI (p<0.001) but not with HOMA-b. Pater-
nal history of diabetes was not associated significantly with either index. Birth 
weight (available for 520 participants) was positively associated with increased 
QUICKI (p<0.05 for linear trend across tertiles) but not with HOMA-b.
Conclusion: Since Md15 describes variation in the anterior-posterior growth 
gradient of the early fetal hand, it is noteworthy that this permanent finger-
print characteristic is associated also with beta-cell function in later life. This 
finding appears consistent with rodent data on the role played by hedgehog 
signaling proteins in development of the fetal pancreas as well as the fetal 
forelimb. Research into the environmental circumstances associated with 
morphological features in the hand may suggest prenatal strategies for opti-
mizing beta-cell function in adult life.
Supported by: NIH
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PS 85 Diabetes in childhood
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Seasonal variation of type 1 diabetes incidence in childhood in Germany
J. Rosenbauer1, C. Bächle2, A. Stahl2, R. Holl3, M. Grabert3, G. Giani2, in 
cooperation with the German Pediatric Surveillance Unit and the DPV-
Science Initiative; 
1Institute of Biometrics and Epidemiology, German Diabetes Centre, 
Leibniz Institute at Duesseldorf University, 2Institute of Biometrics 
and Epidemiology, German Diabetes Centre, Düsseldorf, 3Institute of 
Epidemiology, University of Ulm, Germany.
Background and aims: Seasonal variation of T1DM onset has been inves-
tigated in various studies and the results are conflicting. A sufficiently large 
cohort of cases is an important precondition for valid estimation of seasonal 
variation. Aim of the study was to investigate the seasonal variation of T1DM 
in children 0-14 years of age in the large risk population of the German fed-
eral state North Rhine-Westphalia (NRW) during the 12-year period 1996-
2007.
Materials and methods: Data were taken from the NRW diabetes incidence 
register ascertaining newly diagnosed cases of T1DM by means of three data 
sources. During the study period a total of 7,128 newly diagnosed diabetic 
children aged 0-14 years (3,678 boys, 3,371 girls) were registered, the average 
risk population was 2.84 million children. The completeness of ascertainment 
was estimated to be 98%. Overall, sex- and age-specific (0-4, 5-9, 10-14 years) 
seasonal variation of the monthly T1DM incidence were analysed assuming 
a Poisson distribution of cases. The monthly expected mean of the incidence 
was modelled using a log-linear regression including a linear term for tem-
poral trend and sinus and cosine terms for seasonal variation. The analyses 
were additionally adjusted for overdispersion of incidence data and, where 
appropriate, for sex and age at onset. Month of diagnosis was used as inde-
pendent time variable. Seasonal variation was assumed to be constant over 
the study period.
Results: Overall, the average monthly incidence rates ranged between 16.6 
per 100.000 person-years in July and 24.9 in January. Lower average inci-
dences were found from April to August and higher incidences between 
September and March. According to the fitted sinusoidal regression model 
the seasonal variation of T1DM incidence was significant (p<0.001) with the 
trough at the end of June-July and the peak in December-January. The ratio 
of model-based maximum and minimum incidences was 1.34. Similar sig-
nificant seasonal patterns (p<0.001) were observed among male and female 
patients, however, the amplitude was larger for males than for females (max/
min-ratio: 1.46 vs. 1.24). Further, among males the trough was slightly earlier 
than among females. Significant seasonal variation was also detected for all 
age groups (0-4yrs: p=0.005; 5-9 and 10-14 yrs p<0.001). The magnitude of 
seasonal variation was similar in both older groups (max/min-ratio: 5-9 yrs: 
1.43; 10-14 yrs: 1.38) but was considerably minor among the youngest chil-
dren (max/min-ratio: 1.25). The model-based troughs in the age groups 0-4, 
5-9 and 10-14 yrs were in May, June, and July, respectively.
Conclusion: This study based on a large cohort of T1DM cases showed sig-
nificant seasonal variation in both sexes and all age groups. Seasonal patterns 
differed slightly between sexes and more distinctly between age groups. Sea-
sonality of T1DM onset points to the importance of environmental factors in 
disease aetiology. Seasonal factors stressing beta cells (e.g. viral infections) 
may account for the variation. Delayed diagnosis in older children may ac-
count for the shift of the trough with age. Further research is needed to iden-
tify causes of the differing seasonal patterns between age groups.
Supported by: BMG, MIWFT of NRW, Kompetenznetz Diabetes mellitus 
funded by BMBF
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Seasonal variability of HbA1c in children and adolescents with type 1 
diabetes
B. Mianowska, W. Fendler, A. Szadkowska, I. Pietrzak, E. Czerniawska,  
A. Zmysłowska, A.I. Baranowska, A. Ciepiela, W. Mlynarski; 
Department of Pediatrics, Oncology, Hematology and Diabetology, Medical 
University, Lodz, Poland.
Background and aims: Hemoglobin A1c (HbA1c) is an useful measure of 
average glycemic control and a widely accepted marker of the risk of long-
term microvascular complications in people with type 1 diabetes (T1DM). 
The aim of the study was to determine whether there is a seasonal variability 
in glycated hemoglobin levels.
Materials and methods: Inclusion criteria to the study were: T1DM with 
duration of at least 1 year and patient’s age below 18 years at inclusion. Data 
from the laboratory database were cross-referenced with the clinical database 
application and verified manually by two independent researchers. During 
the analyzed period Feb-2006 to Oct-2009 a total of 6001 HbA1c results were 
recorded within the laboratory. HbA1c was measured by means of ion-ex-
change high-performance liquid chromatography using the Bio-Rad VARI-
ANT Hemoglobin A1c Program (Bio-Rad Laboratories, USA). Trend and 
autocorrelation of residuals were analyzed.
Results: Out of 6001 available measurements, 5656 valid results were ana-
lyzed. Median HbA1c was 7.40% (25-75% range: 6.80-8.30%). The highest 
concentrations of HbA1c were observed in February, November and Decem-
ber, while August and September showed the lowest HbA1c levels. The maxi-
mum difference between medians of HbA1c in any two months of the study 
period equalled 0.85% (Aug-2008 vs Feb-2006). Linear, decreasing trend of 
HbA1c values over the study period was statistically significant (Beta=-0.39; 
p=0.008). Detrended residuals of HbA1c levels showed a sine-wave pattern 
of autocorrelations with a period of 12-14 months, suggestive of positive cor-
relation between months one year apart and of negative correlations for in-
tervals of 6-7 months (Figure).
Conclusion: 1) HbA1c levels in young T1DM patients are seasonally vari-
able and the lowest levels may be found in late summer. 2) Seasonal change 
in HbA1c levels should be considered in clinical practice and in short-time 
(lasting several months) clinical trials or research schedules.
Supported by: The Foundation for Polish Science, TEAM Programme 1.2 PO 
IG
926
Epidemiology of type 1 diabetes mellitus in children in Uzbekistan
G.N. Rakhimova, N. Alimova; 
Centre for the Scientific and Clinical Study of Endocrinology, Tashkent, 
Uzbekistan.
Background and aims: Assessment and monitoring of basic epidemiologi-
cal parameters of type 1 DM among children in the course of the 2000-2007 
National Register.
Materials and methods: Epidemiological data was studied on the basis of 
annual reports from 13 regional endocrinological dispensaries and Tashkent 
endocrinological dispensary as well as on the basis of register cards filled up 
by local endocrinologists-pediatricians.
Results: In Uzbekistan within the period from 2000 to 2007 type 1 DM prev-
alence increased from 7.5 to 11.0 per 100,000 of pediatric population. The 
highest prevalence was observed in Tashkent (17.7), in Bukhara region (16.6) 
and in Tashkent region (14.5), the lowest one in Kashkadarya region (7.1) and 
in Surkhandarya region (7.7). Pediatric incidence in 2007 as compared with 
2000 reduced from 2.7 to 2.1 per 100,000 of pediatric population. Analysis of 
pediatric incidence in 2007 revealed the highest one in Tashkent (4.6) and in 
Syrdarya region (2.7), the lowest being found in Navoi region (0.9). As to age 
distribution children aged from 10 to 14 comprised the largest group (66.6%), 
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the smallest including children from 0 to 4 years (5.0%), 28.3% accounting 
for patients aged from 5 to 9. As to the disease duration children with type 
1 DM duration less than 5 years comprised the largest group (70.9%), in 
the smallest one (2.1%) including patients with 10-year DM duration. As a 
whole, in Uzbekistan within the period of the Register fulfilment mortality 
level reduced from 0.1 to 0.03 per 100, 000 of pediatric population. In 2007 
mortality cases were registered in Kashkadarya region (0.1), Navoi region 
(0.4) and Samarkand region (0.09 per 100, 000 of pediatric population. As a 
whole in Uzbekistan mortality reduction in children with type 1 DM within 
the period from 1998 to 2007 was 99%.
Conclusion: Within the period of the National Register reduction in mortal-
ity paralleling alterations in structure of death cause and increase of survival 
can be noted to suggest perfect choice of strategy and tactics of the Register 
fulfillment.
927
The impact of intrauterine hyperglycaemia on glucose metabolism in the 
offspring five years after delivery
L. Bozkurt1, C.S. Göbl1, B. Rami2, A. Handisurya1, Y. Winhofer1,  
E. Schober2, A. Kautzky-Willer1; 
1Department of Internal Medicine III, Division of Endocrinolgy and 
Metabolism, 2Department of Pediatrics, Medical University of Vienna, 
Austria.
Background and aims: Diabetes in pregnancy is associated with a higher risk 
of obesity and abnormal glucose homeostasis for the offspring in later life. 
The aim of the study is to assess features of glucose metabolism and insulin 
secretion as well as the prevalence of obesity in young children of diabetic 
mothers.
Materials and methods: In a prospective cross-sectional analysis data on an-
thropometric and metabolic parameters of 58 children (f:29; m:29) aged 4-9 
years were collected. 13 mothers of these children had at the time of pregnan-
cy a normal glucose tolerance (NGT) and served as a control group whereas 
31 mothers were affected by gestational diabetes (GDM) and 14 women by 
Type 1 diabetes (T1D). Differences in BMI-SDS (Standard Deviation Score) 
were suggested as the primary outcome of this study. Further, a 2h-OGTT 
was performed in all children and circulating levels of adiponectin and leptin 
were measured.
Results: Children of mothers with T1D (-0.83±0.94) showed significantly 
higher BMI-SDS as compared to GDM (-0.11±0.94; p=0.003) and NGT (-
0.20±0.88; p=0.021) exposed children. There were no differences between 
the NGT and GDM subgroups (p=0.77). However, the glucose profile during 
the 2h-oGTT was comparable (G0:p=0.51; G60:p=0.26; G120:p=0.47) and 
also indices of insulin resistance were not different (HOMA:p=0.64; Quicki:
p=0.64). Regarding adipokine levels, we found no differences for Leptin 
(p=0.33) but when comparing adiponectin levels of GDM and T1D groups 
we found higher levels for T1D children (p= 0.047).
Conclusion: Children of women with T1D in pregnancy were more obese 
than children of mothers with NGT and GDM despite comparable plasma 
leptin concentrations and similar degree of insulin sensitivity at the age of five 
years. Further longitudinal studies are needed to detect as early as possible 
those children at highest risk in follow-up.
928
Plasma vitamin D and preservation of C-peptide in youth with recently 
diagnosed autoimmune positive type 1 diabetes: SEARCH Nutrition 
Ancillary Study
E.J. Mayer-Davis1, K.Y. Wojcik1, D. Dabelea2, R.B. D’Agostino3, J.M. Norris4,  
I. King5, C. Pihoker6; 
1Nutrition, University of North Carolina, Chapel Hill, 2Epidemiology, 
University of Colorado Denver, Aurora, 3Biostatistical Sciences, Wake Forest 
University, Winston-Salem, 4Epidemiology, University of Colorado, Denver, 
5Internal Medicine, University of New Mexico, Albuquerque, 6Seattle 
Children’s Hospital, United States.
Background and aims: Preservation of insulin secretion following a diagno-
sis of diabetes predicts improved prognosis, yet little is known of the potential 
nutritional determinants of sustained beta cell function. We explored associa-
tions of plasma 25-hydroxyvitamin D concentration with baseline and short-
term (~ 24 months) change in fasting c-peptide (FCP) within the SEARCH 
for Diabetes in Youth cohort diagnosed between 2002 and 2005.
Materials and methods: Included were 1224 youth (mean age at diagnosis, 
9.8 yr) with at least one diabetes autoantibody positive (GAD65 or IA-2) and 
a clinical diagnosis of type 1 diabetes. About 77% were non-Hispanic white 
and gender was about equally distributed (52% male). Mean diabetes dura-
tion at baseline was 10 months. Mixed models regression analyses account-
ing for repeated measures were fit adjusting for onset age, sex, race/ethnicity, 
clinical center, baseline waist circumference, A1c, insulin regimen, HLA risk 
group and change in an index of insulin resistance. Vitamin D was analyzed 
as a continuous measure with values at the 25th, 50th, and 75th percentiles 
used for illustration.
Results: From the fully adjusted model, higher baseline vitamin D was asso-
ciated with higher FCP at baseline (p=0.04) but unexpectedly was associated 
with more rapid decline in FCP (see figure; fully adjusted p-value=0.009).
Conclusion: Higher plasma vitamin D may provide some protection of the 
beta cell near the time of T1D diagnosis, although this protective effect ap-
pears to be of limited durability. The mechanisms for a potential protective 
effect of vitamin D on beta cell function near the diagnosis of diabetes, and 
whether such an effect would hold clinical significance, remains to be deter-
mined.
Supported by: NIH/NIDDK
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The benefits of continuous subcutaneous insulin infusion in children 
with type 1 diabetes mellitus started at diabetes recognition. A 7 year 
follow-up
A. Szypowska, K. Dżygało, A. Ramotowska, M. Lipka, M. Procner-
Czaplińska, H. Trippenbach-Dulska; 
Medical University of Warsaw, Poland.
Background and aims: Intensive management, achieved by multiple daily 
insulin injections (MDI) or continuous subcutaneous insulin infusion (CSII), 
improves long-term outcomes in patients with Type 1 diabetes (T1DM). CSII 
and MDI are both effective in achieving near-euglycaemia, but CSII offers the 
opportunity to change the basal infusion rate according to the needs of pa-
tients and allows precise insulin dosing to cover a different kind of meals. In 
pediatric patients, CSII has been demonstrated to achieve glucose target and 
reduce frequency of severe hypoglycemia, without sacrifices in safety, quality 
of life, or excessive weight gain. In long-term follow up patients treated at 
T1DM onset with CSII therapy may achieve better metabolic control than pa-
tients switched from injections to CSII. The aim of this study was to compare 
efficacy of CSII at diabetes recognition with CSII after MDI in children with 
T1DM. The primary end-point was glycated haemoglobin.
Materials and methods: 169 children with T1DM treated with CSII for at 
least 5 years were divided into two groups depending on time of starting CSII 
therapy. I group: 97 children (girls) with mean age 6.7±2.3 years switched 
from MDI to CSII, the mean time with MDI therapy was 2.2±1.6 years; II 
group: 72 children (girls) with mean age 6.2±2.1 years started with CSII 
within 3 month after diabetes onset. Data was collected every three months: 
HbA1c, BMI, diabetic ketoacidosis (DKA) and severe hypoglycaemia (SH), 
total daily insulin dose was downloaded from pump memory.
Results: During the 7-year follow-up better metabolic control was achieved 
in the group II, the differences between group I and group II from the 2nd to 
the 4th year were not quite significant (2nd yr:7.33 vs. 7.08; 3rd yr: 7.33 vs. 
7.09; 4th yr: 7.54 vs. 7.26%) , and statistically significant: in the 1st year (7.58 
vs. 7.13%) and from the 5th to the 7th year (5th yr: 7.89 vs. 7.27; 6th yr: 8.11 
vs. 7.48; 7th yr: 8.18 vs. 7.45%) p<0.05 . In the group II HbA1c was <7.5% 
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and in the group I increased to 8.2% at the time of follow-up. TDD increased 
from 0.4U/kg/d to 0.7U/kg/d p<0.0001. The insulin daily dose increased in 
the I group from 0,7 to 0.87 U/kg/die and in the II group from 0.48 to 0.87 
U/kg/die, the significant differences between both groups were observed in 
the 1st and 2nd year. BMI increased in the I group from 16.3 after the 1st year 
to 19.8 kg/m2 after the 7th year and in the group II from 15.9 after the 1st year 
to 18.4 kg/m2 after the 7th year. BMI was significantly higher in the group I 
in the 6th and 7th year of the follow-up. There was no significant difference 
between both groups in the number of episodes of DKA and SH.
Conclusion: In longitudinal observation children started with CSII at dia-
betes recognition achieved better metabolic control than children initiated 
with CSII after MDI. The long- term benefits of CSII therapy started at T1DM 
onset should be taken under consideration before making a decision on CSII 
initiation. 
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Long-term efficacy of insulin pump therapy in young children with 
diabetes
R. Bonfanti, F. Meschi, M. Viscardi, A. Rigamonti, V. Biffi, G. Frontino,  
R. Battaglino, V. Favalli, C. Bonura, G. Chiumello; 
Department of Pediatrics, San Raffaele Scientific Institute, Milano, Italy.
Background and aims: To compare effectiveness of continuous subcutane-
ous insulin infusion (CSII) to multiple daily injections with rapid-acting in-
sulin analogues and NPH insulin (MDIs) in preschoolers after more than 1 
year of treatment.
Materials and methods: We evaluated 25 preschool patients (11 males, 14 fe-
males) with a history of type 1 diabetes of at least one year duration (14 CSII, 
11 MDIs). Outcomes included measures of: glycated haemoglobin (HbA1c), 
mean blood glucose (BG) and standard deviation (SD), percent of BG values 
above and below target regarding the last 3 months of follow up, and the 
average daily risk range (ADRR) regarding the last month of follow up. Un-
paired nonparametric two-tailed Mann-Whitney tests were used to analyze 
data from the two groups.
Results: The 25 subjects’ ages ranged from 2 to 6 years (mean age CSII 4,6 
yrs; mean age MDII 4.6 yrs), duration of diabetes ranged from 1 to 4.9 years 
(mean disease duration CSII: 2.9; mean disease duration MDIs: 2.3), duration 
of CSII ranged from 1 to 3.9 years (mean CSII duration 2.45 yrs). Compari-
son of overall metabolic control showed no statistically significant differences 
between the two groups when considering HbA1c (CSII 7.09%; MDIs 7.38%), 
mean BG (CSII 161.8 mg/dL; MDIs 168 mg/dL) and SD (CSII 82.1 mg/dL; 
MDIs 85.2 mg/dL), and percent of BG values below target (CSII 12,7%; MDIs 
15.2%). However a statistically significant difference was found when com-
paring percent of BG values above target (CSII 35.1%; MDIs 47.2%; p<0.05). 
Furthermore, the MDIs group showed ADRR values consistent with moder-
ate risk of BG excursions, while the CSII group showed an ADRR value con-
sistent with high risk. However, no statistically significant differences were 
found regarding ADRR values of the two groups (CSII 44.9; MDIs 35.6).
Conclusion: Although CSII can be a safe and effective method to deliver 
insulin in young children, long-term pump therapy in our young patients 
was not associated with significant differences in glycemic control as com-
pared with intensive injection therapy, confirming short-term results from 
past studies. Our study also showed that both CSII and MDII may allow the 
achievement of target glycemic control (HbA1c < 7.5 for all age-groups ac-
cording to ISPAD 2009 guidelines), underlining that optimal control may be 
obtained independently of the means of insulin administration. Furthermore, 
evaluation of ADRR showed a greater risk for glycemic excursions in the CSII 
group, although comparison of ADRR values between the two groups showed 
no statistically significant difference. Consequently, rationale for initiating 
CSII in this age group should be primarily based on patient/parent selection 
and lifestyle preference. Nonetheless, further studies involving sensor aug-
mented CSII in this age group are warranted in order to evaluate potential 
benefits on diabetic complications, thus going beyond lifestyle improvements 
which currently appear to be the only achievement in preschoolers.
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Intervention with metformin in childhood diabetes may slow decline of 
C peptide - the accelerator hypothesis
L.M. Saranac, B. Bjelakovic, S. Zivanovic, M. Novak; 
Pediatric Clinic Clinical Centre Nis, Serbia.
Background and aims: Diabetes results from beta cell insufficiency. The ac-
celerator hypothesis proposes that type 1 and type 2 diabetes are not differ-
ent disorders, but poles of a single spectrum. Variable interaction between 
insulin resistance and the immune response to it determines the tempo of 
beta cell loss, and with it age at onset and incidence. The hypothesis is suf-
ficiently well developed to consider use of metformin in children with new 
onset of type 1 diabetes. The aim of the study was to investigate the impact of 
metformin on the progression of childhood diabetes.
Materials and methods: Twenty-one children, mean age 10,9± 2,8y with re-
cently diagnosed and insulin-treated type 1 diabetes were studied. Metformin 
was added after two weeks as insulin sensitizer and apoptosis reducing agent. 
Inclusion criteria were basal C peptide over 0.2 nmol/l and preserved pul-
satility of insulin secretion. Twenty-six children and adolescents on insulin 
monotherapy acted as controls.
Results: Insulin was gradually reduced according to daily glycemic profiles 
and the metformin-treated children entered remission faster. Six of them 
achieved complete remission for longer than 12 months. Mean C-peptide 
level after 18 months was 0.57 nmol/l in metformin group versus 0.20 in the 
group on insulin alone ( p<0.05). HbA1C tended to be lower in the met-
formin group; (7.7 % compared with 9.0 % , NS) .
Conclusion: Our first experiences with combined treatment (insulin and 
metformin) are favourable, suggesting that metformin use in childhood dia-
betes may reverse C peptide decline. Further studies are necessary.
932
Relationship between depressive symptoms and quality of life and 
metabolic control in children and adolescents with diabetes type 1
B.M. Zdunczyk1, J. Sendela2, K. Dz¯ygat¯o3, H. Trippenbach-Dulska3,  
M. Lipka2, M. Procner-Czaplińska2, A. Szypowska3; 
1Clinical Pediatric Hospital, 2The Department of Pediatrics, Clinical 
Pediatric Hospital, 3The Department of Pediatrics, Medical University of 
Warsaw, Poland.
Background and aims: As many studies show depression is a factor involved 
in pathogenesis of diabetes and a major complication affecting metabolic con-
trol in patients with diabetes. There is a higher incidence of diabetes among 
patients with depression and patients with diabetes and depressive symptoms 
achieve worse metabolic control. These studies are usually conducted on 
adults with diabetes type 2. It is still little known about children and adoles-
cents with diabetes type 1. The aim of this study was to assess the prevalence 
of depression and examine its effect on metabolic control and quality of life 
in children and adolescents with diabetes type 1.
Materials and methods: 214 children so far took part in this study: 107 girls 
and 107 boys. Mean age: 13.1 <7-17, SD 2.7>. Mean diabetes duration: 5.2 
(SD 2.7). During the routine visit in the outpatient clinic all children and ado-
lescents with diabetes type 1 age 7 and above were asked to fill in Children’s 
Depression Inventory (Polish version), a self-report questionnaire consisting 
of 27 items. Patients from age 11 and above were asked to answer questions 
in Quality of Life Questionnaire, a 58 item questionnaire based on the DCCT 
Diabetes Quality of Life Measure. At the same time other data was collected: 
sex, age, diabetes duration, HbA1c, BMI, daily insulin dose.
Results: 35 participants (16.35%) scored ≥ 13, indicating elevated depressive 
symptoms. In the group with scores below 13 (179) there were 76 partici-
pants (42.45%) who scored above average in one of subscales. There was an 
extremely significant correlation between scores on the CDI and quality of 
life (r=0.6510, p<0.0001). A very significant correlation was found between 
scores on the CDI and HbA1c (r=0.2088, p=0.005) and age of participants 
(r=0.2000, p=0.005). There was also a significant correlation between scores 
on the CDI and diabetes duration (r=0.1576, p=0.023), BMI (r=0.1356, 
p=0.049) and insulin daily dose (r=0.1785, p=0.011). There was no difference 
between girls and boys on the CDI scores.
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Conclusion: 16.35% participants show elevated depressive symptoms as as-
sessed with Children’s Depression Inventory. 42.45% participants without 
depressive symptoms score above the average on one of the CDI subscales. 
Children and adolescents with higher scores on the CDI have worse quality 
of life and achieve worse metabolic control. The longer diabetes duration and 
the older participant the more likely he presents depressive symptoms. It is 
necessary to pay attention to emotional wellbeing of children and adolescents 
with diabetes type 1, especially the older ones who are longer ill. It is neces-
sary to develop an intervention program aimed at prevention of emotional 
problems in youths with diabetes.
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Longitudinal associations between depressive symptoms and glycaemic 
control among adolescents and young adults with type 1 or type 2 
diabetes
J.M. Lawrence1, K. Hood2, A. Anderson3, J.P. Yi-Frazier4, L.D. Case3,  
D. Dabelea5, R. Bell3, D.E. Williams6, R. McKeown7; 
1Kaiser Permanente Southern California, Pasadena, 2Cincinnati Children’s 
Hospital, Cincinnati, 3Wake Forest Univ., Winston-Salem, 4Univ. of 
Washington, Seattle, 5Univ. of Colorado Denver, 6Centers for Disease 
Control and Prevention, 7Univ. of South Carolina, Columbia, USA.
Background and aims: Depression is associated with poor glycemic control 
in youth with diabetes (DM). We assessed the association between depression 
scores and change in depression score over time with change in A1c among 
youth in the SEARCH for Diabetes in Youth study.
Materials and methods: 861 youth (age 15.3 ± 2.5 years; 78% type 1 DM; 
50% female; 81% non-Hispanic White) had a baseline visit (time1) within ≈ 
1 year of DM diagnosis and completed a follow-up visit (time2). At each visit, 
symptoms of depression were evaluated with the Center for Epidemiologic 
Studies-Depression (CES-D) scale, blood was drawn for A1c analysis, and 
DM duration was assessed. CES-D score was categorized to indicate minimal 
(0-15), moderate (16-23) and frequent (24-60) symptoms of depression, and 
also used as a continuous measure in regression analyses. A linear regression 
model was fit to examine the effects of CES-D score at time1 and the change 
in CES-D score from time1 to time2 (predictors) on the change in A1c from 
time1 to time2 (outcome) adjusting for age, gender, race/ethnicity, DM type, 
DM duration, BMI-Z score, and presence of co-morbidities, all measured at 
time1, as well as time between visits.
Results: Youth had DM for 26.8±9.1 months at their time2 visit which was, on 
average, 17.2±6.0 months after their time1 visit. At time1, 80%, 13%, and 8% 
had minimal, moderate, and frequent symptoms of depression, respectively, 
while a similar distribution observed at time2. CES-D category at time1 and 
time2 were significantly associated (p<0.001); continuous scores on the CES-
D were also correlated (r=0.56, p<0.0001). Of youth with minimal symptoms 
at time1, 87% remained minimal at time2 while 8% were moderate and 5% 
had frequent symptoms of depression. Of youth with moderate symptoms 
at time1, 56% improved while 17% moved to the frequent category at time2. 
Of those with frequent symptoms at time1, 34% stayed the same, while 29% 
were in the moderate and 37% in the minimal symptom categories. In the 
multiple linear regression analyses, there was a positive association between 
both the CES-D score at time1 and change in CES-D from time1 to time2 and 
change in A1c. Larger changes in CES-D and higher CES-D scores at time1 
were both associated with greater increases in A1c. Race/ethnicity, gender, 
DM duration and BMI-Z were also significant in the final model while DM 
type was not.
Conclusion: Most youth with minimal symptoms at time1 remained in that 
category at time2 while about 2/3 of youth with frequent symptoms experi-
enced some improvement. Youth who had more frequent symptoms of de-
pression as well as a greater increase in symptoms tended to have worsening 
glycemic control at follow-up while improvement in depressive symptoms 
was associated with improved glycemic control. Screening for and treatment 
of depressive symptoms in adolescents and young adults with DM may help 
improve glycemic control in this population.
Supported by: U.S. CDC & NIH
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Dose-dependent effects of protein ‘preloads’ on gastrointestinal 
hormones, glycaemia, and energy intake in type 2 diabetes
J. Ma1,2, J.M. Wishart1,2, K.L. Jones1,2, M. Horowitz1,2, C.K. Rayner1,2; 
1Discipline of Medicine, University of Adelaide, Royal Adelaide Hospital, 
2Centre of Clinical Research Excellence in Nutritional Physiology, 
University of Adelaide, Australia.
Background and aims: Whey protein ‘preloads’ can stimulate glucagon-like 
peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), in-
sulin and cholecystokinin (CCK) release, slow gastric emptying of a subse-
quent meal, and improve postprandial glycaemia. We aimed to determine the 
effects of different doses of whey, when ingested before a buffet-style meal, on 
gastrointestinal hormones, glycaemia, and energy intake in type 2 diabetes.
Materials and methods: Nine patients with diet-controlled type 2 diabetes 
(glycated haemoglobin 6.7 ± 0.3 %) were studied on 3 separate days in rand-
omized order. Subjects consumed a chocolate-flavoured liquid ‘preload’ (100 
ml water mixed with either a flavoured ‘placebo’ (8 kcal), or with 25 g (89 
kcal) or 55 g (195 kcal) flavoured whey protein), 30 minutes before an ad 
libitum meal (T = 0 to 30 min). Blood was sampled frequently for hormone 
measurements.
Results: Data are shown as mean ± standard error. Both whey preloads stimu-
lated GLP-1, GIP, insulin and CCK before the meal (P < 0.05); the stimulation 
of insulin and CCK were greater (P < 0.05) with 55 g whey. The incremental 
area under the curve (iAUC) for GLP-1 was greater after 55 g whey than the 
other days, while iAUC for insulin was greater after 25 g and 55 g whey than 
placebo. The peak postprandial blood glucose was slightly lower with 25 g 
and 55 g whey than placebo (P < 0.05). Both whey preloads increased post-
prandial fullness slightly (P < 0.05), but neither affected energy intake.
Conclusion: Acute administration of a whey protein ‘preload’ in patients 
with diet-controlled type 2 diabetes dose-dependently stimulated GIP, GLP-
1, insulin and CCK, and reduced postprandial glycaemia, as well as increas-
ing fullness, but had no significant effect on energy intake.
- 
Supported by: NHMRC
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Sustained effects of a protein ‘preload’ on gastric emptying and glycaemia 
in type 2 diabetes over 4 weeks
M. Horowitz1,2, J. Ma1,2, D.R. Jesudason2,3, A. Russo1,2, J.E. Stevens1,2,  
J.B. Keogh2, K.L. Jones1,2, P.M. Clifton2, C.K. Rayner1,2; 
1Discipline of Medicine, University of Adelaide, Royal Adelaide Hospital, 
2Centre of Clinical Research Excellence in Nutritional Physiology, 
University of Adelaide, 3Endocrine & Metabolic Unit, Royal Adelaide 
Hospital, Australia.
Background and aims: Whey protein ‘preloads’ acutely reduce glycaemia 
after a subsequent meal in type 2 diabetes, associated with slowing of gastric 
emptying and stimulation of incretin and insulin release. The aim of the cur-
rent study was to evaluate whether the effects of protein preloads on gastric 
emptying and glycaemia are sustained with ‘chronic’ (4 weeks) administra-
tion.
Materials and methods: Seven patients with uncomplicated type 2 diabetes 
treated by diet alone (glycated haemoglobin 5.9 ± 0.2 %) participated in the 
study. Each consumed a chocolate-flavoured ‘preload’ (containing either 25 g 
whey or placebo), 30 min before each of the three main meals for 4 weeks, fol-
lowed by a ‘washout’ period of 2 weeks, and then the alternative preload for 4 
weeks, in a randomized crossover design. Gastric emptying of (scintigraphy), 
and the glycaemic response to, a standard potato meal consumed 30 min after 
the preload, were measured at the beginning and end of each 4 week period, 
as was serum fructosamine.
Results: Data are shown as mean ± standard error. Whey slowed gastric emp-
tying and reduced postprandial blood glucose compared to placebo, both at 
baseline and after 4 weeks exposure to whey (repeated measures ANOVA, P 
< 0.05 for all comparisons), without any difference between baseline and 4 
week values. Fructosamine was non-significantly lower after 4 weeks whey 
than placebo (253 ± 15 vs 279 ± 10 μmol/L, P = 0.15).
Conclusion: Administration of a whey preload for 4 weeks results in sus-
tained slowing of gastric emptying and reduction in postprandial glycaemia 
in type 2 diabetes. A larger trial of longer duration is indicated to determine 
whether this strategy can improve glycaemic control.
Supported by: NHMRC
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Thorough chewing stimulates postprandial increases of plasma GLP-1 
and peptide YY in normal subjects
M. Eto, M. Saito, Y. Hattori, R. Terasawa; 
Clinical Medicine, Ohu University, Koriyama, Japan.
Background and aims: Glucagon like peptide (GLP)-1 and peptide YY (PYY) 
are secreted from intestinal L cells, and plasma levels of both hormones rise 
after a meal. GLP-1 stimulates glucose-dependent insulin secretion. PYY de-
creases appetite and reduces food intake by acting on receptors in the hypo-
thalamus. GLP-1 also reduces food intake. Therefore, GLP-1 and PYY seem 
important to control plasma glucose and triglyceride (TG) levels and body 
weight. On the other hand, it has been conventionally thought that “chewing 
well” i.e. “thorough chewing” is good for health. Much remains unknown on 
the relationship between thorough chewing and GLP-1 and PYY which are 
secreted from intestine after a meal. The aim of this study is to investigate ef-
fects of thorough chewing on postprandial levels of plasma GLP-1 and PYY 
in normal subjects.
Materials and Methods: Twenty two normal subjects were recruited. They 
were not obese and not diabetic. Plasma mean fasting glucose was 96 mg/dl. 
Mean age was 37 years and mean BMI was 23.1. The subjects were given the 
test meal early in the morning after 12h fasting. They ate it for 20 minutes 
and chewed each mouthful 5 times (5 times chewing). On the other day the 
subjects ate it for 20 minutes and chewed each mouthful 30 times (30 times 
chewing, i.e. thorough chewing). Plasma GLP-1 and PYY were measured be-
fore and 1 h after ingestion of the test meal. Plasma glucose and insulin were 
measured before and 1 h after ingestion of the test meal. Plasma TG was mea-
sured before and 2 h after ingestion of the test meal. The test meal consisted of 
bread, margarine, a boiled egg, steamed vegetables, a banana, and milk. Total 
calories were 630 kcal, with 16% protein, 32% fat, and 52% carbohydrate. 
Plasma PYY was measured as PYY(3-36) using an enzyme immunoassay kit. 
Plasma GLP-1 was measured as GLP-1(7-36) using ELISA kit.
Results: Plasma mean PYY levels with 5 times chewing tended to increase 
from 41.0 pg/ml (before a meal) to 46.1 pg/ml (after a meal). Plasma PYY 
levels with 30 times chewing significantly increased from 41.7 pg/ml (before 
a meal) to 65.4 pg/ml (after a meal). Postprandial PYY level with 30 times 
chewing was significantly higher than with 5 times chewing. Plasma mean 
GLP-1 levels with 5 times chewing significantly increased from 4.8 pmol/l 
(before a meal) to 18.9 pmol/l (after a meal). Plasma GLP-1 levels with 30 
times chewing significantly increased from 5.0 pmol/l (before a meal) to 25.1 
pmol/l (after a meal). Postprandial GLP-1 level with 30 times chewing was 
significantly higher than with 5 times chewing. Plasma mean TG level with 5 
times chewing significantly increased from 107 mg/dl (before a meal) to 170 
mg/dl (after a meal). Plasma TG level with 30 times chewing significantly 
increased from 114 mg/dl (before a meal) to 147 mg/dl (after a meal). Post-
prandial TG level with 30 times chewing was significantly lower than with 
5 times chewing. There was no significant difference in increases of plasma 
glucose and insulin after a meal between 5 times and 30 times chewing in 
normal subjects.
Conclusions: This is the first report that thorough chewing stimulates post-
prandial increases of plasma GLP-1 and PYY in normal subjects. In addi-
tion, thorough chewing suppresses postprandial increase of plasma TG level. 
Thorough chewing may be clinically effective in normal subjects. 
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Carbohydrate substitution for protein, fat, and their subtypes and risk of 
type 2 diabetes in men
M.E. Similä1, J.P. Kontto1, L.M. Valsta1, D. Albanes2, J. Virtamo1; 
1National Institute for Health and Welfare, Helsinki, Finland, 2National 
Cancer Institute, Bethesda, USA.
Background and aims: Interest in optimal macronutrient proportions to 
avoid type 2 diabetes has grown recently. We examined the associations of 
intakes of carbohydrates, protein, fat, and their subtypes (low, medium, and 
high GI carbohydrates; protein from meat, milk products, and plant sources; 
and fatty acids) with diabetes risk.
Materials and methods: The cohort comprised 25 943 Finnish male smokers 
aged 50-69 years. Diet was assessed at baseline with a validated diet history 
questionnaire. During a 12-year follow-up, 1 098 incident diabetes cases were 
identified from a national register. Cox proportional hazard modeling was 
used to estimate the risk for diabetes and multivariate nutrient density mod-
els to examine the effects of substitutions of different macronutrients.
Results: The substitution of carbohydrates for protein was inversely associ-
ated with diabetes risk: change in the multivariate relative risk when carbohy-
drates replaced two percent of energy of protein was 0.85 (95% CI: 0.80, 0.90). 
The substitutions of carbohydrates for protein subtypes, protein from meat, 
milk products and plant origin, were each inversely associated with diabetes 
risk, but plant protein intake itself showed no association with diabetes risk. 
The substitution of carbohydrates for total fat was also inversely associated 
with diabetes risk, but not significantly for all the fatty acids.
Conclusion: Greater carbohydrate intake at the expense of protein, especially 
from meat or milk products, was associated with decreased diabetes risk. 
Carbohydrate intake at the expense of total fat intake was associated with 
decreased diabetes risk, but the beneficial association may depend on which 
fatty acids are substituted.
Supported by: Academy of Finland, DPPH, Foundations: JuhoVainio, Lehikoin-
en, FinnishCultural
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Effect of changes in the intake of specific food groups on weight loss; a 
two year dietary intervention trial
Y. Gepner1, A. Canfi1,2, D. Schwarzfuchs2, R. Golan1, D. Shahar1, D. Fraser1, 
S. Witkow1, I. Greenberg1, H. Vardi1, B. Sarusi2, M. Friger1, M.J. Stampfer3, 
I. Shai1; 
1Epidemiology and Health Systems Evaluation, Ben Gurion University of 
the Negev, Beer-Sheva, Israel, 2Nuclear Research Center Negev, Dimona, 
Israel, 3Harvard School of Public Health, Channing laboratory, Department 
of Medicine, Brigham and Women’s Hospital and Harvard Medical School, 
and Departments of Epidemiology and Nutrition, Boston, USA. 
Background and aims: Adherence to distinct dietary strategies is associated 
with changes in specific food-groups consumption. We aimed to address the 
effect of changes in the intake of specific weight of food-groups on weight-loss 
in a 2-year low-fat, Mediterranean and low-carbohydrate dietary interven-
tion trial.
Materials and methods: Electronic-food-frequency questionnaires were 
used to assess changes in the intake of 11-food-groups (beverages, vegetables, 
fruits, dairy products, meat, breads/cereals/pasta/potatoes, sweets/cakes, le-
gumes, fish, fats/oils, and eggs) among patients with type 2 diabetes (n=45) 
and non-diabetics (n=277) moderately obese participants (BMI=31kg/m2; 
age=52years; 86%men).
Results: Mean weight-losses at 6-months were -4.6kg, -4.7kg and -6.4kg 
for the low-fat, Mediterranean and low-carbohydrate groups, respectively 
(p<0.026 between groups). Reduction in total weight of food consumption, 
however, was similar across diet-groups (Figure 1): from 3,593 g/day, the par-
ticipants reduced (p<0.005) their food intake by -284g/day at 6-months and 
by -963g/day at 24-months. In multivariate regression models, adjusted for 
age, sex, baseline body-weight and simultaneous changes of 11-food-groups 
weight intake (g/day), independent dietary predictors of 6-month weight-
loss (rapid weight-loss-phase) were: decreased consumption of sweets and 
cakes (β=0.493;p=0.008) in the low-fat, increased intake of crude legumes 
(β=-0.196;p=0.061) in the Mediterranean, and increased vegetables intake 
(β=-0.249;p=0.018) in the low-carbohydrate diet-group. In the entire study 
population, in models further adjusted for diet-type, the leading predictors 
for weight loss after 6-months were increased vegetables (β=-0.116;p=0.045) 
and decreased sweets and cakes intake (β=0.162;p=0.010). Predictors for 
2-year successful weight loss in the entire group were: increased vegeta-
bles (β=-0.192;p=0.007) and meat (β=-0.146;p=0.026) and decreased eggs 
(β=0.187;p=0.003), processed legumes (β=0.195;p=0.002), and beverages 
intake (β=0.135;p=0.032). Analyses were similar when stratifying by diabetes 
status.
Conclusion: Weight loss may be achieved by a variety of changes in specific 
food-groups consumption within different diet strategies, while in overall, 
the leading universal predictors for weight loss are increased vegetables and 
decreased sweets and cakes intake.
939
Special dietary regimen and nutrient intake of patients with type 1 
diabetes
A.J. Ahola1,2, V. Mikkilä2, S. Mäkimattila1, C. Forsblom1,3, R. Freese2,  
P.-H. Groop1,3, on behalf of the FinnDiane Study Group; 
1Folkhälsan Research Center, Helsinki, 2University of Helsinki, 3Helsinki 
University Central Hospital, Finland.
Background and aims: Patients with type 1 diabetes are instructed to eat 
a healthy, balanced diet with the aim to optimize metabolic control. Type 1 
diabetes is, however, associated with a number of conditions that may require 
dietary modifications. We aimed to evaluate the frequency of adhering to 
special dietary regimen and to study whether such adherence would rise any 
concern in the sufficiency of dietary intake.
Materials and methods: Cross-sectional data were collected from 810 par-
ticipants [40% men, mean age 47 (range 18-84) years, diabetes duration 32 
(1-68) years] in the Finnish Diabetic Nephropathy Study. Data on energy and 
nutrient intake were collected with a three-day food record (two weekdays 
and a weekend day) that was completed twice with a 2-3 month interval. Self-
report questionnaire was applied to assess adherence to a lactose free, protein 
restriction, gluten free, or vegetarian diet. Whether diet was introduced based 
on a recommendation from a health care professional or was self-initiated, 
was also enquired.
Results: A total of 225 (28%) patients reported adhering to a special diet. Ad-
herence to a lactose free diet was the most frequent (15%), followed by protein 
restriction (7%), vegetarian (6%) and gluten free diet (4%). Vegetarian (93%) 
and lactose free (63%) diets were most frequently self-initiated, while gluten 
free and protein restriction diets were primarily initiated based on a diagnosis 
(88% and 85%, respectively). Frequencies of reaching the recommendations 
for carbohydrate intake (45-60 E%) ranged from 50% (gluten free) to 63% 
(vegetarian). Those not reaching the recommendations mainly consumed 
less carbohydrates than recommended. A total of 24% (protein restriction) 
to 37% (vegetarian) of the patients exceeded the recommendations for su-
crose intake (<10 E%). Recommendations for protein intake (10-20 E%) were 
frequently met in all four groups (86 to 92%). At least 50% of patients in all 
groups met the recommendations for total fat (25-35 E%), monounsaturated 
fatty acids (10-20 E%), and polyunsaturated fatty acids (5-10 E%). However, a 
substantial proportion of patients exceeded the recommended levels for total 
fat (28 to 46%) and saturated fatty acid (<10 E%) intakes (61 to 84%). Moreo-
ver, the proportion of patients achieving the recommendations for fibre (0 
to 3%) and salt intake (30 to 50%) were low in all four groups. Mean intakes 
of vitamin A and D per 1000 kcal were below recommendations in all spe-
cial diet groups. The mean intake of folic acid was below recommendations 
among all but those adhering to a vegetarian diet. Moreover, those on a gluten 
free diet did not, in average, meet the recommended level for iron intake.
Conclusion: Special diets were found to be common among patients with 
type 1 diabetes. Dietary intake of those following a special dietary regimen 
did not, for many parts, meet the recommendations. Particular attention 
should be paid to fibre, saturated fatty acid, salt, vitamin A and vitamin D 
intakes. Moreover, those adhering to gluten free diets are encouraged to ad-
dress their iron intake.
Supported by: Gyllenberg Foundation, Folkhälsan Research Foundation, Stock-
mann Foundation
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Glycaemic responses of RP-13 (Bangladeshi Origin) and Jasmine 
(Thailand) rice in type 2 diabetic subjects
F. Rahman1, N. Sumi1, K. Kobura1, C.B. Mikkelsen2, K. Fatema1, L. Ali3; 
1Dept of Epidemiology and Biostatistics, Bangladesh Institute of Health 
Sciences (BIHS), Dhaka, Bangladesh, 2ISIS Food Products, Skanderborgvej, 
Denmark, 3Dept of Biochemistry & Cell Biology, Bangladesh Institute of 
Health Sciences (BIHS), Dhaka, Bangladesh.
Background and aims: In the context of the importance of Glycemic Index 
(GI) and Glycemic Load (GL, an applied tool calculated from GI and serving 
size) in determining the health of carbohydrate rich foods. The present study 
was carried out to determine these parameters for Jesmine Rice (Thailand 
origin) and RP-13 rice (produced in Bangladesh by ISIS Food Products, Den-
mark), Insulinemic response and NEFA response, as important covariables, 
were also determined.
Materials and methods: Eighteen diabetic subjects (male 12, female 6), 
under a cross-over design, consumed equi-carbohydrate amount of the test 
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foods and two times glucose (as reference food), with a run in period of 7 
days between the consecutive items. The (mean±SD) age (years) of the pa-
tients was 41± 6, waist hip ratio 0.93 ± 0.04, body mass index (BMI) 25 ± 
3 and they had basal serum HbA1c value of 6.56 ± 0.83 %. The test meals 
contained 50 g of total carbohydrate and were given to the participants for 
ingestion within 10 minutes with 200 ml water. Serum levels of glucose were 
estimated at 0, 30, 60, 90, 120, 150 and 180 minutes respectively. NEFA, TG 
and Insulin levels were measured at 0 and 180 minutes only. Serum glucose 
and TG were measured by glucose-oxidase method, serum Insulin by chemi-
luminescent ELISA, NEFA by colorimetric method and HbA1c was measured 
by HPLC method.
Results: RP-13 showed significantly lower serum glucose value than that of 
Glucose and Jasmine rice (Incremental area under the curve 289.4±111.3 
in RP-13 vs. 591.4±198.8 in Glucose and 499.1±180.3 in Jasmine Rice; 
(p<0.001)). RP-13 had significantly lower GI value than that of Jasmine rice 
[(Mean±SD): 51.5 ± 8.3 in RP-13 vs. 86.4 ± 21 in Jasmine rice (p<0.001) ]. The 
GL of RP-13 and Jasmine rice are 22 and 41 respectively. There were no sig-
nificant difference between RP-13 and Jasmine Rice regarding serum Insulin, 
serum TG and serum NEFA responses.
Conclusion: As judged against the mean values of the international table (GI: 
High ≥ 70, Medium 56-69 and low ≤ 55; GL: High ≥ 20, Medium 11-19 and 
low ≤ 10) RP-13 is a low GI and Jasmine is a high GI rice. However, from the 
dietary practices in Bangladesh both the items may be used as high GL rice. 
The data emphasizes the necessity of constructing GI and GL tables based on 
studies from individual societies. 
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Both higher serum vitamin D and dairy calcium intake are related to a 
greater 2-year diet induced weight loss, especially in diabetes
R. Golan1, D.R. Shachar1, D. Schwarzfuchs2, D. Fraser1, Y. Gepner1,  
O. Tangi-Rosental1, H. Vardi1, J. Thiery3, G. Fiedler3, M. Blüher3,  
M. Stumvoll3, M. Stampfer4, I. Shai1; 
1Epidemiology, Ben Gurion University, Beer Sheva, Israel, 2Epidemiology, 
Nuclear Research Center Negev, Dimona, Israel, 3Medicine, Department 
of Medicine and Institute of Laboratory Medicine, University of Leipzig, 
Germany, 4Public Health, Channing laboratory, Department of Medicine, 
Brigham and Women’s Hospital and Harvard Medical School, and 
Departments of Epidemiology and Nutrition, Harvard School of Public 
Health, Boston, Boston, USA.
Background: The role of serum 25-OH vitamin D levels and dairy calcium 
intake on weight loss is controversial. 
Objective: To address the association of dairy calcium intake and serum 25-
OH vitamin D levels with long-term weight loss in persons with type 2 diabe-
tes (T2D) and with persons with normal glucose tolerance (NGT).
Design: We analyzed the 2-year Dietary Intervention Randomized Con-
trolled Trial (DIRECT)[NGT: n=277, T2D: n=45, mean body-mass-index 
(BMI)=31kg/m2;mean age=52years]. A representative sample (n=126) was 
followed for 6-months for serum vitamin D changes. Dietary intake, includ-
ing dairy products, was evaluated by a validated food frequency question-
naire (FFQ).
Results: Serum baseline 25-OH Vitamin D levels were significantly low-
er within the higher tertile of baseline BMI in both groups (entire group: 
25.6ng/m, 24.1ng/ml and 22.9ng/ml; p for tend=0.02). Baseline levels of vita-
min D and dairy calcium intake were not associated with subsequent weight 
loss. In repeated measures models, adjusted for age, sex, baseline BMI, total 
fat intake and diet group assignment, the six months tertiles of dairy cal-
cium intake (mean for tertiles: T2D: 160.8mg/day, 364.1mg/day, 743.5mg/
day, NGT: 153.3mg/day, 353.9mg/day, 638.2mg/day) and the six months 
tertiles of serum 25-OH vitamin D (T2D: 14.0ng/ml, 21.1ng/ml, 30.4ng/ml, 
NGT:13.8ng/ml, 20.8ng/ml, 31.0ng/ml) were associated with weight loss 
across the two-years of intervention. However, these associations were much 
stronger in persons with T2D. (-1.3kg; -4.1kg and -7.7kg; across tertiles of 
dairy calcium; p=0.018, and -0.8kg, -5.3kg and -8.7kg; across tertiles of serum 
25-OH vitamin D; p=0.042).
Conclusion: Higher dairy calcium intake and increased serum vitamin D are 
related to greater dietary-intervention two-year weight loss, especially among 
persons with type 2 diabetes.
Supported by: The Israeli Ministry of Health and the Dairy Council
942
Nutritional assessment in type 2 diabetic elderly patients admitted to an 
internal medicine ward 
M.C.M. Carvalho1, R. Carvalho2, H. Figueiredo3; 
1Nutrition, 2Endocrinology, 3Internal Medicine, ULS Guarda EPE, Seia, 
Portugal.
Background: Type 2 Diabetes is more prevalent in elderly people (≥ 65 years) 
contributing to a major malnutrition risk in this age group. There are few data 
about nutritional state in elderly diabetic patients in Portugal.
Aim: The authors pretended to evaluate nutritional state in type 2 diabetic 
patients over 65 years admitted to the internal medicine ward of Hospital of 
Nossa Senhora da Assunção of ULS Guarda EPE.
Materials and methods: The authors evaluated consecutively 103 elderly 
diabetic patients from February to December 2009 and compared them to a 
group of 115 non-diabetic elderly patients. The clinical tool was the Mini Nu-
tritional Assessment (MNA) who stratifies nutritional state from 0 to 30 in: 
malnutrition (<17), malnutrition risk (17,5-23,5) and normal (>24). Statisti-
cal analysis was performed by SPSS 13.0 for Windows, when appropriate.
Results: The 103 elderly diabetic patients (59,2% female and 40,8% male) had 
a mean age of 81,55 ± 7,08 years. There was no statistical significant difference 
from the 115 non-diabetic control group (59,1% female, 40,9% male with a 
mean age of 83,27 ± 7,02 anos, p > 0,05). Mean MNA score in Diabetic elderly 
patients was 13,64 ±4,11 which was significantly lower than in the control 
group (16,50±4,46, p < 0,001). In Diabetic patients, 13,6% had a normal score 
evaluation at screening and did not need to follow MNA evaluation, 66 % 
were classified with malnutrition , 19,4 % with malnutrition risk and 1 % 
were normal (values of 40,9%, 27,8%, 23,5% e 7,8% respectively for control 
group, p<0,001).
Conclusion: This study suggests that malnutrition is more prevalent in 
elderly people with type 2 diabetes admitted to a medical ward for various 
reasons, which implies that they must be identified for specific nutritional 
intervention. There will be necessarily more studies to evaluate the causes 
and the complex relationship between type 2 diabetes and malnutrition in 
elderly patients.
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N-3 fatty acids as phospholipids are superior over triacylglycerols in 
ameliorating hepatic steatosis in mice fed a high-fat diet
T. Jelenik1, Z. Macek Jilkova1, M. Rossmeisl1, D. Medrikova1, P. Janovska1,  
P. Flachs1, B. Kristinsson2, G.G. Haraldsson2, H. Svensen3, I. Stoknes3,  
M. Bryhn4, J. Kopecky1; 
1Department of Adipose Tissue Biology, Institute of Physiology, AS CR, 
v.v.i., Prague, Czech Republic, 2University of Iceland, Science Institute, 
Reykjavik, Iceland, 3EPAX AS, Aalesund, Norway, 4Silentia AS, Svelvik, 
Norway.
Background and aims: n-3 polyunsaturated fatty acids (PUFA), such as 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), could pre-
vent development of obesity and insulin resistance. In this study, metabolic 
consequences of dietary n-3 PUFA supplemented to a high-fat diet either as 
phospholipids (PL) or triacylglycerols (TG) concentrates were studied in the 
obesity-prone C57BL/6J strain of mice.
Materials and methods: In the Prevention study, 3-mo-old male mice were 
fed ad libitum for 9 weeks either a corn oil-based high-fat diet (cHF; lipids 
~35% wt/wt) or cHF-based experimental diets, matched for the total EPA 
and DHA content (3.15% wt/wt), in which part of dietary lipids (corn oil) was 
replaced by the EPA and DHA concentrates (EPAX a.s., Aalesund, Norway) 
in the form of either TG-concentrate (EPAX 1050 TG; 60% EPA+DHA wt/
wt) or novel PL-concentrate (27% EPA+DHA wt/wt). In the Reversal study, 
obesity was induced by cHF feeding for 4 mo prior to dietary treatments by 
either TG- or PL-concentrates. Obese mice were then subjected to one of 
the following treatments: 1) cHF diet; 2) cHF and metformin (2 g/kg diet; 
cHF+M diet); 3) cHF+M and TG-concentrate (cHF+M+TG diet); 4) cHF+M 
and PL-concentrate (cHF+M+PL diet). Markers of glucose and lipid homeos-
tasis, glucose tolerance (AUC), hepatic steatosis, adipocyte hypertrophy and 
adipose tissue inflammation were analyzed.
Results: In the Prevention study, the concentrates did not affect weight gain or 
adiposity, while reducing plasma NEFA (cHF, 0.44 ± 0.04 vs. TG-concentrate, 
0.30 ± 0.02 vs. PL-concentrate, 0.27 ± 0.04 mmol/l; p≤0.01 cHF vs. either con-
centrate). PL-concentrate more effectively (p<0.05 vs. cHF) reduced plasma 
TG (cHF, 1.12 ± 0.13 vs. TG-concentrate, 0.91 ± 0.13 vs. PL-concentrate, 0.71 
± 0.13 mmol/l) and increased high-molecular weight adiponectin (cHF, 0.60 
± 0.11 vs. TG-concentrate, 0.88 ± 0.10 vs. PL-concentrate, 0.93 ± 0.09 A.U.). 
Only PL-concentrate (p<0.01) improved glucose tolerance during a 3-hr toler-
ance test (AUC: cHF, 2221 ± 78 vs. TG-concentrate, 2299 ± 84 vs. PL-concen-
trate, 1831 ± 84 mmol), and prevented hepatic lipid accumulation (cHF, 41 ± 
7 vs. TG-concentrate, 36 ± 4 vs. PL-concentrate, 27 ± 4 mg/g tissue). In the 
Reversal study, both concentrates reduced abdominal fat depot, plasma TG, 
NEFA and cholesterol, and induced adiponectin. However, hepatic steatosis 
was more effectively reduced by PL-concentrate (cHF, 212 ± 28 vs. cHF+M, 
160 ± 17 vs. cHF+M+TG, 83 ± 15 vs. cHF+M+PL, 41 ± 4 mg/g tissue; p<0.001 
cHF+M vs. either treatment), and only PL-concentrate (p<0.05 vs. cHF+M) 
reduced adipocyte hypertrophy (cHF, 5532 ± 553 vs. cHF+M, 5961 ± 381 vs. 
cHF+M+TG, 5195 ± 349 vs. cHF+M+PL, 4433 ± 127 µm2).
Conclusion: As compared to TG, dietary n-3 PUFA administered as PL exert 
a number of superior effects on obesity-associated metabolic disorders. The 
PL-concentrate was especially effective in reducing hepatic lipid accumula-
tion and adipocyte hypertrophy associated with high-fat feeding. Thus, the 
use of n-3 PUFA as PL might be a preferred way of dietary supplementation 
to help prevent or even reverse hepatic steatosis associated with obesity and 
insulin resistance.
Supported by: IGA of the Ministry of Health of the Czech Republic 
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The effects of omega-3 polyunsaturated fatty acids on cardiometabolic 
parameters and oxidative stress after 1-year administration in metabolic 
syndrome patients
A.D. Dragomir1, G. Radulian2, E.D. Rusu1, S. Dragan3, D. Cheta2; 
1Healthy Food Foundation, Bucharest, 2University of Medicine “Carol 
Davila”, Bucharest, 3University of Medicine, Timisoara, Romania.
Background and aims: To observe if one year administration of a diet con-
taining omega-3 PUFA supplements vs. baseline diet recommended to pa-
tients with metabolic syndrome has a significant impact on oxidative stress, 
atherosclerosis progression and metabolic parameters.
Materials and methods: A total of 270 patients with metabolic syndrome 
(MS) according to IDF criteria, aged 61±6.8 years, without clinical evidence 
of atherosclerosis were allocated to 2 groups, matched by sex, age and weight: 
group A (140 patients) - diet according to ESC/EASD recommendations and 
individual needs; group B (130 patients) - the same diet + capsules of fish oil 
(1,0 g eicosapentanoic acid, 1,0 g docosahexanoic acid and 0,1 g α-tocopherol 
acetate). Body fat mass (BFM) and body fat percent (%BF) were measured 
by bioimpedance analysis (BIA) using InBody 3.0 Analyzer. Fasting plasma 
glucose, HbA1c, total cholesterol, LDL cholesterol, HDL cholesterol, triglyc-
erides, plasma insulin, adiponectin and leptin were measured according to 
standard procedures. Insulin resistance was measured using HOMA-IR in-
dex. Oxidative stress was assessed using FormOx systems monitor on a blood 
drop. The progression of atherosclerosis was determined by measuring in-
tima-media thickness (IMT) at commune carotid artery (ACC). The patients 
were evaluated at baseline, after 6 months and after 1 year.
Results: Baseline characteristics were similar between groups. After 6 months, 
omega-3 supplements determined a significant improvement of metabolic 
parameters, decrease of oxidative stress and a statistically significant increase 
in adiponectin levels (from 9.46 ± 2.76 to 10.86 ± 2.68). Mean BMI, mean 
%BF, mean BFM and mean waist-to-hip ratio (WHR) were significantly low-
er in group B vs. group A (BMI- 29.1 vs 31.12 kg/m2; %BF - 27.48 vs 30.48; 
BFM - 26.78 vs 29.42 kg; WHR - 1.02 vs 1.07). BMI was statistically correlated 
with BFM (p<0.0001) and %BF (p<0.0001). Intima-media thickness (IMT) 
was significantly decreased in group B (IMT in left ACC - 0.610 ± 0.06 vs. 
0.621 ± 0.071 mm p=0.002; IMT in right ACC - 0.593 ± 0.074 vs. 0. 612 ± 
0.068). Considering the results at 6 months comparing with those at 1 year, 
all the parameters considered in the study were significantly improved (Table 
1). IMT was correlated with %BF (p<0.0001), WHR (p=0.002), leptin values 
(p<0.001), adiponectin values (p<0.001), leptin/adiponectin ratio (p<0.001) 
and oxidative stress (p<0001). The decrease of oxidative stress was correlated 
with increased HDL-cholesterol levels (p<0.05), %BF (p<0.0001) and WHR 
(p<0.001).
Conclusion: Omega-3 PUFA enriched diets bring metabolic parameters 
closer to target values, thus lowering cardiovascular risk of MS patients. Also, 
oxidative stress is decreased, underlying the role of omega-3 in the delay of 
endothelial cells damage.
Table 1
Parameters Group B - at  
6 months
Group B - at  
1 year
P value
Total cholesterol (mg/dl) 198 ± 18.9 186 ± 16.5 P<0.001
HDL-cholesterol (mg/dl) 55 ± 12 58 ± 9 P<0.0001
Triglycerides (mg/dl) 132 ± 58 120 ± 43 P=0.012
Fasting Plasma Glucose (mg/dl) 110 ± 14 107 ± 9 P<0.05
FormOx (Fort Units) 268 ± 76 258 ± 81 P<0.001
IMT - right ACC 0.610 ± 0.06 0.598 ± 0.082 P<0.001
IMT - left ACC 0.593 ± 0.074 0.589 ±0. 063 P<0.05
%BF 27.48 ± 2.8 25.92 ± 1.6 P=0.016
Supported by: PNCDI2 program - DIADIPOHEP; CEEX 
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Metabolic inflexibility to carbohydrates in dietary obese mice: 
improvement by combination treatment with n-3 polyunsaturated fatty 
acids and calorie restriction
K. Bardova, P. Janovska, P. Flachs, D. Medrikova, V. Kus, Z. Macek Jilkova, 
T. Jelenik, M. Rossmeisl, J. Kopecky; 
Department of Adipose Tissue Biology, Institute of Physiology, AVCR, v.v.i., 
Prague, Czech Republic.
Background and aims: Metabolic flexibility is the capacity for the organism 
to adapt fuel oxidation to fuel availability and it is usually impaired in obese, 
insulin-resistant subjects. In this study, we attempted to validate the use of 
intragastric glucose gavage and indirect calorimetry (INCA) for the meas-
urement of metabolic flexibility to carbohydrates in lean and dietary obese 
C57BL/6J mice. In addition, we used this approach to assess the effects of a 
combination treatment by n-3 polyunsaturated fatty acids (PUFA) and 10% 
calorie restriction (CR) on metabolic flexibility in mice fed a high-fat diet.
Materials and methods: Female C57BL/6J mice were fed either a standard 
chow (STD) or corn oil-based high-fat diet (cHF; lipids ~35% wt/wt) from 
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the weaning (4 wk of age) until 7 mo of age (n = 6-9). Metabolic flexibility 
was assessed as a maximal change in respiratory quotient (ΔRQ) measured 
by INCA during a 4-hr period following a glucose load (0.45 ml of 50% D-
glucose) administered by intragastic gavage to overnight (~12 hr) fasted ani-
mals. In the second experiment, 3-mo-old male C57BL/6J mice were habitu-
ated for 2 wk to the cHF diet, followed by differential dietary treatments (n 
= 8-9) for 5 wk: (1) cHF, ad libitum; (2) cHF with n-3 PUFA concentrate 
(EPAX 1050TG; EPAX, a.s., Lysaker, Norway) replacing 15% of dietary lip-
ids, ad libitum (cHF+F); (3) cHF, 10% CR (cHF+CR); or (4) cHF+F, 10% CR 
(cHF+F+CR). Changes in plasma NEFA in response to fasted to fed transi-
tions were also analyzed.
Results: In the first experiment, cHF feeding for 6 mo induced a weight gain 
of 31.7 ± 2.5 as compared to a gain of 10.8 ± 0.5 g in the STD mice (body 
weight: cHF, 45.8 ± 2.4 vs. STD, 25.0 ± 0.6 g; p<0.001). Although there were 
no differences between cHF and STD mice in RQ following overnight fasting 
(cHF, 0.746 ± 0.010 vs. STD, 0.773 ± 0.008; p=0.057), cHF-fed mice showed 
a ~2-fold lower increase in RQ in response to the glucose load as compared 
to STD controls (ΔRQ; cHF, 0.062 ± 0.006 vs. STD, 0.120 ± 0.010; p<0.001), 
suggesting impaired metabolic flexibility. In the second experiment, com-
pared with cHF mice, all the treatments tended to prevent body weight gain 
(cHF > cHF+F > cHF+CR > cHF+F+CR), while a significant reduction was 
found only in mice subjected to the combination treatment (cHF, 28.7 ± 0.7 
vs. cHF+F+CR, 25.8 ± 0.4 g; p<0.001). This treatment was also the most ef-
fective in elevating RQ in response to glucose (ΔRQ; cHF, 0.086 ± 0.002 vs. 
cHF+F, 0.095 ± 0.006 vs. cHF+CR, 0.096 ± 0.005 vs. cHF+F+CR, 0.107 ± 
0.006; p<0.05 cHF vs. cHF+F+CR). At the same time, cHF+F+CR induced a 
most prominent decrease in plasma NEFA following fasted (cHF, 0.89 ± 0.05 
vs. cHF+F+CR, 1.13 ± 0.04 mmol/l) to fed (cHF; 0.59 ± 0.09 vs. cHF+F+CR, 
0.43 ± 0.04; p<0.001 cHF vs. cHF+F+CR mmol/l) transition, while the other 
treatments were less effective.
Conclusion: Metabolic inflexibility to carbohydrates could be demonstrated 
using intragastric glucose gavage and INCA in dietary obese mice. Combina-
tion treatment using n-3 PUFA and 10% CR preserved metabolic flexibility 
better than any of these treatments applied separately. 
Supported by: IGA of the Ministry of Health of the Czech 
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Cross-linked dairy protein attenuates postprandial glucose and insulin 
levels and increases fullness in healthy young men
K.-H. Herzig1, K.R. Juvonen2, L.J. Karhunen2, E. Vuori1, M. Lille3, T. Karhu1, 
A. Jurado Acosta1, D. Laaksonen4, H. Mykkanen2, L.K. Niskanen4,  
K. Poutanen3; 
1Dept of Physiology, Medical School, Institute of Biomedicine, University of 
Oulu, 2Department of Clinical Nutrition, Food and Health Research Centre, 
University of Eastern Finland, 3VTT, Technical Research Centre of Finland, 
4Department of Medicine, Kuopio University Hospital, Finland.
Background and aims: Food induces many signals in the gastrointestinal 
tract, important for digestion, satiety and further systemic responses. The 
properties of foods are determined by their chemical composition and physi-
cal properties. Protein has the highest satiety value of among the different 
macronutrients. Furthermore, the textural properties of a single protein can 
be tailored by cross-linking enzymes e.g. transglutaminase (Tg). However, 
little is known about the effects of modified protein structures on these re-
sponses. Our aim was to examine the effects of intact and transglutaminase 
(TG) cross-linked dairy protein on postprandial hormonal, metabolic and 
appetitive responses.
Materials and methods: The study had a randomized repeated-measures 
crossover design. All participants tested each test product with a minimum 
of 2 d separating the individual test days. Eight healthy males (24.0±0.82 y, 
23.3±0.5 BMI kg/m2) consumed with 400 ml water isocaloric (850 kJ) and 
isovolumic (400 ml) test product containing either 50 g whey (Wh), casein 
(Cas) or casein protein cross-linked with transglutaminase (Cas-TG) in a 
randomized order. Blood samples were drawn for plasma glucose, insulin, 
CCK, GLP-1 and PYY analysis for 240 min. Appetite ratings were assessed at 
concomitant time points using visual analogue scales.
Results: Glucose levels significantly decreased in the first hour and returned 
close to baseline at the end of sampling at 240 min. Cas and Wh were more 
potent in lowering glucose levels than Cas-Tg. Release of insulin, GLP-1, PYY 
and CCK differed significantly in response to the three protein meals, with 
the highest insulin release 30 min after Wh. The insulin response to Cas-Tg 
was attenuated and peaked at 60 min. GLP-1 peaked at 15 - 30 min after Wh 
and 60 min after Cas, whereas the response to Cas-Tg was attenuated. PYY 
peaked after 30 - 60min, with the highest levels after Cas and the lowest after 
Cas-Tg. CCK increased similarly in the first 15 min after the Wh or Cas meal, 
while the release after Cas-Tg was lower, but more sustained. The feeling of 
fullness was the strongest after the Cas-TG compared to Cas and Wh.
Conclusion: Cross-linked milk protein attenuates the release of the GI hor-
mones affecting plasma glucose and insulin levels and enhances fullness. 
The modification of protein texture could thus offer a tool for optimizing 
the postprandial glucose and insulin metabolism and postprandial appetite 
and thereby promote weight management and glycaemic control in obese 
and DM 2 patients.
Supported by: TEPESS /ELVIRA Academy of Finland
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Effects of different types of meal on the expression on oxidative 
mitochondrial genes in skeletal muscle of healthy subjects
A.A. Turco1, M. Guescini2, V. Valtucci1, C. Colosimo1, V. Stocchi2,  
G. Riccardi1, B. Capaldo1; 
1Department of Clinical and Experimental Medicine, Federico II, University, 
Naples, 2Institute of Biological Chemistry, University of Urbino “Carlo Bo”, 
Urbino, Italy.
Background and aims: Recent studies have shown an impaired mitochondri-
al oxidative capacity in skeletal muscle of individuals with insulin resistance, 
suggesting that mitochondrial dysfunction may be a primary, genetically de-
termined defect. There is also evidence that mitochondrial dysfunction may 
be a consequence of adverse environmental factors, such as sedentary lifestyle 
and over nutrition. To evaluate the impact of acute administration of differ-
ent dietary fat on the expression of muscle mitochondrial genes regulating 
replication and function in healthy subjects.
Material and methods: Six healthy subjects (3F/3M; age 29±3 years; BMI 
25.0±3 Kg/m2) received in a random order a test meal with the same energy 
content (970 Kcal) but different composition in macronutrients and quality of 
fat: Mediterranean meal (M) (Lipid 30% of which 6% saturated), SAFA meal 
(Lipid 67% of which 36% saturated) and MUFA meal (Lipid 63% of which 
37% monounsaturated). At fast and after 180 min, a fine needle aspiration 
(FNA) was performed from the vastus lateralis muscle for determination of 
mithocondrial gene expression by quantitative PCR.
Results: M meal was associated with a significant increase (p<0.05) of tran-
scription factor PPARs expression levels, whereas expression of regulator 
genes PGG1α and PGG1β remained substantially unchanged. No change was 
detected in the expression of COX5b, COX2 and GLUT 4 genes. After MUFA 
meal, no modification was observed in the expression of PPARs, but a signifi-
cant increase of PGC1α (p=0.07) and PGC1β (p<0.001) gene expression was 
observed. COX5b e COX2 gene expression remained unchanged whereas 
GLUT4 gene expression increased significantly (p<0.05). After SAFA meal, 
PGG1α, PGG1β, and PPARs gene expression were unchanged whereas COX2 
expression decreased by 38 % (p<0.02), COX5b decreased by 31% (p=0.07), 
and GLUT4 decreased by 11% (p<0.05).
Conclusion: The present data indicate that mitochondrial gene expression 
in skeletal muscle of healthy subjects can be modulated by acute changes of 
nutrient intake. Dietary fat have a differential impact on the gene transcrip-
tional profile since saturated fat, but not monounsaturated, downregulate the 
expression of genes involved in glucose transport and substrate oxidation.
948
Dose-dependent anti-obesity and anti-diabetic effects of synbiotics in 
high-fat fed C57BL/6J mice
K. Berger, U. Andersson, C. Holm; 
Experimental Medical Science, Lund University, Lund, Sweden.
Background and aims: We have recently shown that plants rich in polyphe-
nols (with antioxidants and prebiotic effects) administered alone or together 
with the probiotic dietary bacteria Lactobacillus plantarum (Lp) exerts anti-
obesity and anti-diabetic effects in HFD-fed C57BL/6J mice, a model of hu-
man obesity and insulin resistance. For instance, we observed an almost com-
plete prevention of body weight gain, as an effect of decreased adiposity, in 
groups receiving the supplemented diets. In addition, we observed an inhib-
ited inflammatory activity in mice receiving the combination of supplement. 
Based on these results where the dramatic effects were attained with relatively 
high polyphenol concentration, we here aim to evaluate the dose-response 
relationship for the studied plant-associated polyphenol, both in absence and 
presence of probiotic bacteria.
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Materials and methods: C57BL/6J mice were fed high fat diet supplemented 
with different concentrations of plant-associated polyphenols (pph 0, 0.4, 2 
and 4%) without or with Lactobacillus plantarum (Lp 3 x 109 cfu/ml drinking 
water) for 12 weeks. Body weight, body fat and metabolic blood parameters 
were registered throughout the study. Oral glucose tolerance (OGTT) was 
performed in the end of the study. At the time of sacrifice, plasma and tissues 
were collected.
Results: Supplement of the plant-associated polyphenol, without or with 
probiotics, decreased body weight gain (pph: 0%:10.2±0.4, 0.4%:9.7±0.7, 
2%:7.8±0.5, 4%:5.8±0.4g, pph+Lp: 0%:10.5±1.5, 0.4%:10.0±0.8, 2%:9.4±1.2, 
4%:5.7±0.5g) and adiposity (pph: 29.2±1.3, 28.7±1.5, 25.7±1.6, 20.4±0.8%, 
pph+Lp: 31.2±3.3, 31.3±2.2, 26.1±2.6, 17.7±0.7%) in a dose-dependent 
manner. Dose-dependent decrease was also observed in the liver weights 
(pph: 1.2±0.0.4, 1.2±0.05, 1.1±0.0.5, 0.9±0.03g, pph+Lp: 1.2±0.13, 1.0±0.06, 
1.2±0.07, 0.8±0.04g), and more pronounced in mice receiving the combina-
tion of polyphenols and probiotics than in mice receiving polyphenols alone, 
indicating a synbiotic beneficial effect. Also, mice fed the combination of 
supplements showed decreased fasting plasma glucose (pph+Lp: 6.9±0.7, 
5.9±0.4, 6.2±0.0.6, 4.6±0.2 mM) with increasing concentration of polyphe-
nols, although only the highest concentration (4%) of polyphenols was sig-
nificantly decreased compared to ctrl.
Conclusion: High-fat diet supplemented with different concentrations of a 
polyphenol-rich plant powder, without or with addition of probiotics, gives 
dose-dependent beneficial effects on body weight, adiposity and glucose con-
trol. The observed advantageous effects are more pronounced in the presence 
of Lactobacillus plantarum, indicating a synbiotic effect.
Supported by: Antidiabetic Food Center (AFC), Lund university
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Effects of supplementation with red wine polyphenols on inflammation, 
mitochondrial function and oxidative stress muscle
K. Lambert, M. Coisy-Quivy, P. Sirvent, A. Sultan, C. Bisbal, J. Mercier,  
A. Avignon; 
INSERM ERI 25, Montpellier, France.
Background and aims: The mechanisms responsible for skeletal muscle in-
sulin resistance (IR) remain incompletely understood. However, chronic low-
grade inflammation, oxidative stress and mitochondrial alterations have been 
suggested to take part in the development of IR. Recent studies have found 
that polyphenolic compounds found in red grape have interesting properties 
against IR. Thus, the aim of this study was to investigate the impact of a sup-
plementation with phenolic compounds from red grape marc in a genetically 
modified mouse (CD4dnTGFbRII; TGF) presenting a chronic inflammation 
compared to C57BL/66 (CTL).
Materials and methods: 14 TGF mice and 16 CTL mice were randomized be-
tween a control group (placebo, PL) and a group supplemented with polyphe-
nols (PP) administered in drinking water (50mg/kg/jour) for a period of 4 
weeks. The mice were sacrificed and their muscles taken for the study of mus-
cle inflammation (RT-PCR), oxidative stress (mitochondrial carbonylated 
proteins) and fiber size (atrophy marker). The mitochondrial respiration was 
measured on mitochondria isolated from skeletal muscle.
Results: In TGF mice, the PP decreased muscle atrophy by 20% (p<0,0001) 
without reducing the expression of mRNA of inflammation markers (TNFal-
pha, OAS1, OAS2). In CTL mice, the PP increased the amount of TNFalpha 
mRNA by 700% (p=0,001) and decreased fiber size by 12% (p<0,0001). In 
CTL and TGF mice, the PP supplementation decreased mitochondrial res-
piration (TGF mice: 387 ± 35 vs 276 ± 33 nmol O / min / mg prot; CTL 
mice 277 ± 38 vs 178 ± 41 nmol O/min / mg prot, comparison PL vs PP by 
Anova p=0,009) without changing the amount of ATP synthesized. We also 
observed a decrease in the level of carbonylated mitochondrial proteins with 
PP supplementation in both strains of mice (comparison PL vs PP by Anova 
p=0,03).
Conclusion: The PP supplementation decreased mitochondrial oxidative 
stress and improved mitochondrial function in muscle of inflammatory and 
control mice. They also reduced muscle atrophy in inflammatory mice. Para-
doxally, the PP increased the markers of inflammation and decreased fiber 
size in CTL mice. Further research should be persued to evaluate the effects 
of PP on muscle mass preservation in inflammatory states.
Supported by: ALFEDIAM
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Reduction of glycaemic index enhances levels of midregional-pro-atrial-
natriuretic peptide: evidences for gut-heart-axis?
A.F.H. Pfeiffer1,2, A. Ernst3, M.O. Weickert1,4, O. Pivovarova1,2,  
A.M. Arafat2,1, N.G. Morgenthaler3, A. Bergmann3, N.N. Rudovich1,2; 
1Clinical Nutrition, German Institute of Human Nutrition Potsdam-
Rehbrücke, Nuthetal, Germany, 2Endocrinology, Diabetes and Nutrition, 
Charité University Medicine Berlin, Germany, 3B.R.A.H.M.S AG, 
Biotechnology Centre Berlin-Hennigsdorf, Germany, 4Warwickshire 
Institute for the Study of Diabetes, Endocrinology and Metabolism, 
Coventry, United Kingdom.
Background and aims: Reduction of glycemic index is an effective strategy 
for prevention of hypertension and CVD events in the subjects with metabol-
ic syndrome and T2DM. Atrial natriuretic peptide (ANP) is a potent natriu-
retic and vasorelaxant hormone that is secreted mainly by cardiomyocytes 
and plays contributory roles in cardiovascular homeostasis. In the subjects 
with Metabolic Syndrome (MS) circulating level of N-terminal natriuretic 
peptides are decreased for unknown reason. The midregional-pro-atrial-
natriuretic peptide (MR-proANP) is a stabile fragment of the ANP precursor 
proANP, which is co-secreted with mature ANP from cardiomyocytes. We 
hypothesized that reduction of glycemic index by alpha-glucosidase inhibitor 
acarbose may modulate MR-proANP levels.
Materials and methods: Subjects with MS (n=28) were studied in the double 
blind, placebo controlled, crossover intervention study. Interventions with 
acarbose (3x100 mg/d) or placebo for 12 weeks (with a respective 12-week 
washout period) were performed. Changes in MR-proANP, postprandial glu-
cose/insulin responses during liquid meal challenge test, body weight, and 
insulin sensitivity in the euglycemic clamp were assessed. Furthermore, in 
a cohort of normotensive non-diabetic subjects (n=46), the effect of insulin 
application on MR-proANP was analyzed during a hyperinsulinemic-eugly-
cemic clamp.
Results: Fasting MR-proANP increased after 12 weeks of acarbose treat-
ment (p=0.001). Acarbose decreased postprandial insulin and glucose con-
centrations (p=0.0001 and p = 0.024, respectively). Changes in MR-proANP 
levels correlated negatively with changes in postprandial insulin (r= -0.53, 
p<0.0001). No effects on body weight and insulin sensitivity were observed. 
Exogenous insulin suppresses plasma levels of MR-proANP (p<0.001).
Conclusion: Reduction of glycemic index by acrabose increases MR-proANP 
levels in subjects with MS. Moreover modulation of insulin levels has a strong 
effect on circulating MR-proANP. These observations provide a novel link 
between postprandial metabolism and hormonal heart action.
Supported by: Firma Bayer Vital, Leverkusen, Germany
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Rose hip exerts anti-diabetic effects via a mechanism involving 
downregulation of the hepatic lipogenic program
U. Andersson1, E. Henriksson1, K. Ström1, J. Alenfall2, O. Göransson1,  
C. Holm1; 
1Experimental Medical Science, 2Probi AB, Lund, Sweden.
Background and aims: In the recent decades there has been a dramatic 
increase in the prevalence of obesity and type 2 diabetes worldwide. Both 
type 2 diabetes and obesity are strongly associated with non-alcoholic fatty 
liver disease, the most common liver disease worldwide. Rose hips are a rich 
source of antioxidants such as ascorbic acid, phenolic compounds and carot-
enoids. Recently it was shown that administration of an acetone extract from 
fruit and seeds from Rosa canina prevented body weight gain in mice fed a 
normal chow diet. The aim of this study was to explore the beneficial meta-
bolic effects of rose hip in greater detail and to elucidate some of the mecha-
nisms underlying the observed anti-diabetic effects. We used the high-fat fed 
C57BL/6J mouse which is a model for obesity, impaired glucose tolerance 
and early type 2 diabetes.
Materials and methods: Long-term metabolic effects were investigated in 
this mouse model following administration of powdered rose hip together 
with high-fat diet to lean mice. Parameters related to obesity and glucose tol-
erance were monitored, and livers were examined for lipids and expression of 
genes and proteins related to lipid metabolism and gluconeogenesis.
Results: A supplement of rose hip was capable of preventing the increase 
in body weight imposed by a high-fat diet in the C57BL/6J mouse (7.1±0.4 
vs. 17.1±1.1g, p<0.001). The decreased body weight gain mirrored a lower 
body fat content, measured by dexa-scan technique. Lower basal levels of in-
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sulin (91±15 vs. 351±99 pM, p<0.001) and glucose (5.5±0.3 vs. 9.4±0.5 mM, 
p<0.001) together with a reduced insulin response (AUC; 132531±19516 vs. 
40427±7143, p<0.001) following an OGTT showed improved glucose toler-
ance in mice fed a supplement of rose hip compared to control mice. Hepatic 
triacylglycerol accumulation was reduced in mice fed rose hip compared to 
control (26±3 vs. 66±5 mg/g liver, p<0.001) and the expression of several 
lipogenic proteins was downregulated, whereas AMPK and other proteins 
involved in fatty acid oxidation were unaltered. Further, rose hip intake low-
ered plasma cholesterol (4.9±0.1 vs. 6.6±0.3, p<0.001) via a mechanism not 
involving altered gene expression of sterol regulatory element binding pro-
tein 2 and HMG-CoA reductase.
Conclusion: Taken together, these data show that a dietary supplement with 
rose hip prevents the development of a diabetic state in the C57BL/6J mouse. 
Downregulation of the hepatic lipogenic program appears to be at least one 
mechanism underlying the anti-diabetic effect of rose hip.
Supported by: Swedish Research Council, Swedish Diabetes Association, Novo 
Nordisk
952
Vegetarian diet improves plasma concentrations of adipokines and 
oxidative stress markers more than conventional diabetic diet in subjects 
with type 2 diabetes 
H. Kahleova1, M. Matoulek2, H. Malinska1, O. Oliyarnik1, L. Kazdovā1,  
T. Pelikánová1; 
1Diabetes Centre, Institute for Clinical and Experimental Medicine, 23rd 
Internal Clinic of Endocrinology and Metabolism, General University 
Hospital, Prague, Czech Republic.
Background and aims: Trials using vegetarian diet in subjects with type 2 
diabetes (T2D) have shown greater improvement in HbA1c compared to 
conventional diabetic. We sought to investigate the effect of vegetarian diet 
on plasma concentrations of adipokines and oxidative stress markers.
Materials and methods: Subjects with T2D (n=74) were randomly assigned 
to experimental group (EG, n=37) following vegetarian diet or control group 
(CG, n=37) following conventional diabetic diet with the same caloric re-
striction. Participants were examined at baseline, 12 weeks of diet interven-
tion and 24 weeks (second 12 weeks of diet were combined with aerobic 
exercise). Plasma concentrations of chosen adipokines and oxidative stress 
markers were measured using commercial kits.
Results: 43% of EG and 5% of CG participants reduced diabetes medica-
tion. Body weight decreased by 6.2 kg in EG and by 3.2 kg in CG (interac-
tion between group and time p=0.001). Plasma concentrations of vitamin C 
increased in EG by 22% (p=0.002; group x time p=0.002). Superoxide dis-
mutase increased in EG by 49% (p<0.001), whereas in CG it decreased by 30% 
(p<0.001; group x time p<0.001). Catalase increased in both groups (p<0.001 
for EG and p=0.01 for CG). TBARS decreased in both groups (p<0.001 for 
both groups). Reduced glutathione increased in EG by 27% (p=0.02), where-
as in CG it decreased by 11% (p=0.05; group x time p<0.001). Glutathione 
reductase decreased in EG by 42% (p<0.001) while glutathione peroxidase 
increased in CG by 20% (p<0.001) and glutathione transferase increased in 
both groups, more in CG (by 59% vs. 14% in EG; group x time p=0.003). 
Plasma concentrations of total adiponectin increased in EG by 19% (p=0.05; 
group x time p=0.02). HMW adiponectin increased in EG by 15% (p=0.02; 
group x time p=0.05). Resistin increased by 24% in CG (p=0.01; group x time 
p=0.005). Leptin decreased by 35% in EG (p=0.02; group x time p=0.05).
Conclusion: Vegetarian diet led to greater weight loss and reduction of dia-
betes medication and to greater improvement in plasma levels of adipokines 
and oxidative stress markers. Vegetarian diet could be a more convenient al-
ternative in treatment of T2D.
Supported by: Grant IGA MZCR NS/10534-3
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Negative attitudes towards insulin treatment in type 2 diabetes seems 
to be a rather temporal and benign phenomenon: Results of an 
observational longitudinal study
N. Hermanns1, B. Kulzer1, M. Mahr1, S. Skovlund2, T. Haak1; 
1Research Institute of Diabetes Academy Mergentheim (FIDAM), Bad 
Mergentheim, Germany, 2Novo Nordisk AS, Bagsværd, Denmark.
Background and aims: Cross sectional findings indicate that negative atti-
tudes towards insulin therapy are rather frequent in type 2 diabetes. These 
attitudes may be based on beliefs that the need for insulin therapy indicates 
a higher severity of diabetes and proves a failure of successful diabetes self-
management. Worries about painful injections and the risk of hypoglycaemia 
or weight gain are also common. These negative attitudes may be one reason 
for the delay of insulin treatment initiation. In this observational longitudinal 
study with a three month follow-up the course of negative attitudes towards 
insulin treatment was analysed in three different groups of type 2 diabetic 
patients facing an intensification of diabetes treatment.
Materials and methods: The first subgroup was on insulin therapy at base-
line (n = 57; age 56.0 ±8.9, disease duration 12.7 ±7.2 yrs, HbA1c 8.5 ±1.6%) 
and remained on insulin at follow-up. Of an initial 73 insulin-naïve patients, 
44 were switched to insulin therapy (group 2: age 58.1 ±6.8, disease duration 
7.7 ±5.0 yrs, HbA1c 9.1 ±1.7%) and 29 patients remained on an oral regimen 
(group 3: age 52.7 ±10.7 yrs, disease duration 5.3 ±4.6 yrs, HbA1c 8.3 ±1.4%). 
Barriers towards insulin therapy were measured using the Insulin Treatment 
Appraisal Scale (ITAS). As generic instruments of health related quality of 
life patients completed also the Problem Areas of Diabetes Questionnaire 
(PAID), the WHO-5 Well-Being Scale (WHO-5), the Centre for Epidemio-
logic Studies Depression Scale (CES-D) and the Trait Version of the State 
Trait Anxiety Inventory (STAI) at baseline and at a three month follow-up.
Results: In the three month follow-up HbA1c improved in all three groups 
(7.7 ±1.2% vs. 7.1 ±1.1% vs. 6.7 ±1.7%). The course of negative appraisal of 
insulin therapy was significantly different in the 3 groups (p=-003): It increased 
in patients remaining on an oral regimen (51.2 ±12.2 to 53.6 ±12.3), whereas 
the ITAS score decreased in patients who switched to insulin (:49.2 ±9.8 to 46.2 
±9.9) and patients who remained on insulin (45.8 ±8.3 to 44.5 ±8.0). More ge-
neric psychological variables like diabetes related distress, trait-anxiety or well-
being showed an improvement in all three groups, but no significant differences 
between the groups. In patients who switched to insulin therapy the depression 
score improved significantly (16.1±10.2 to 11.9±9.8) compared to the groups 
who remained on oral medication (11.7 ±8.2 to 10.8 ±7.9) respectively who 
remained on insulin therapy (CES-D: 17.8 ±10.9 to 16.4 ±9.8 p=,045).
Conclusion: In type 2 diabetic patients who switched to insulin therapy 
negative appraisal of insulin therapy was reduced to the level of type 2 dia-
betic patients already treated with insulin. Patients remaining on an oral regi-
men increased negative appraisal towards insulin therapy. In summary this 
study shows that negative appraisal of insulin treatment is modifiable by the 
initiation of insulin therapy, indicating that features of “psychological insulin 
resistance” are a benign, temporary phenomenon. More meth-odological ro-
bust randomized studies are needed to corroborate this result further.
Supported by: Novo Nordisk
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Beginning insulin in people with type 2 diabetes mellitus in real life 
practice − 1-year results of the 4-year CREDIT Study
P. Home1, B.J. Balkau2, N. Danchin3, E. Genestin4, M. Marre5, G. Vespasiani6, 
R. Kawamori7, N. Freemantle8; 
1Institute of Cellular Medicine – Diabetes, Newcastle University, United 
Kingdom, 2INSERM CESP U1018, Villejuif, France, 3Division of Coronary 
Artery Disease and Intensive Cardiac Care, Paris, France, 4sanofi-aventis, 
Paris, France, 5Université Paris, INSERM U695, France, 6Diabetology 
and Metabolic Disorders Centre, San Benedetto Del Tronto (AP), Italy, 
7Department of Medicine, Juntendo University, Tokyo, Japan, 8Department 
of Primary Care and General Practice, University of Birmingham, 
Edgbaston, United Kingdom.
Background and aims: CREDIT, a 314-centre, non-interventional study, in-
vestigates the effects of long-term glycaemic control with insulin treatment 
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on the risk reduction of cardiovascular events associated with type 2 diabetes 
mellitus (T2DM). Here, we present the 1-year findings of the CREDIT study 
in patients who initiated insulin at baseline.
Materials and methods: People with T2DM (n=3031) who had recently 
started insulin (basal, short-acting or premix insulin at the physician’s dis-
cretion) were eligible for evaluation. Changes in therapy, metabolic control 
parameters and lipid profiles of 2734 people at baseline and at 1 year (9−18 
months) after insulin initiation are described.
Results: Most people (75%) had the same insulin regimen at baseline and at 
1 year (Table). Those starting with short-acting insulin regimen alone were 
more likely to have changed insulin regimen. Overall, the insulin dose in-
creased from 19.7 ± 14.5 U/day at baseline to 34.4 ± 25.3 U/day at 1 year. 
Substantial reductions in HbA1c (−1.8 %), fasting plasma glucose (FPG; −3.6 
mmol/L) and postprandial PG (PPPG; −4.7 mmol/L) were observed; 32% of 
patients had HbA1c <7.0 %. Symptomatic hypoglycaemia occurred in 20% 
of patients (2% experiencing at least one severe episode). Mean weight in-
creased marginally by 1.7 ± 4.8 kg (from 80 ± 19 at baseline to 81 ± 18 at 1 
year). LDL cholesterol levels were reduced slightly by −0.2 mmol/L (from 2.9 
± 0.9 to 2.7 ± 0.9 mmol/L) and triglycerides by −0.3 mmol/L (from 2.2 ± 2.4 
to 1.8 ± 1.4 mmol/L). Mean HDL cholesterol levels were unchanged.
Conclusion: Although the results of the 1-year analysis of the CREDIT study 
are encouraging, the majority of patients remain above the HbA1c target level 
of ≤7.0 % commonly advocated. The high FPG and PPPG levels indicate that 
there may be suboptimal insulin dose titration over the first year. In contrast 
to the substantial decrease in HbA1c, the small decrease in LDL levels indi-
cates that physicians focus on glucose control rather than on other aspects of 
secondary prevention.
Table 
Baseline
(n=3031)
1-year follow-up
(n=2734)
Change from baseline 
(n=2734)
Insulin regimen (%)*
Basal 52 41
Basal + short-acting 15 21
Short-acting 7 3
Premix 23 27
Other 3 6
HbA1c (%) 9.5 ± 2.0 7.7 ± 1.4 −1.8 ± 2.1
FPG (mmol/L) 11.6 ± 3.7 7.9 ± 2.5 −3.6 ± 3.9
PPPG (mmol/L) 14.2 ± 4.6 9.6 ± 3.2 −4.7 ± 4.9
Data are % or mean ± SD; *No insulin at 1 year: 2.3%
Supported by: sanofi-aventis
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Fasting plasma glucose 6 to 12 weeks after starting insulin glargine 
predicts success in reaching HbA1c ≤7.0% at weeks 24 to 28
D.M. Karl; 
The Endocrine Clinic, PC, Portland, USA.
Background and aims: Adding insulin glargine, using a treat-to-target meth-
od, restores glycated hemoglobin A1C (A1C) to ≤7.0% for many patients with 
type 2 diabetes (T2DM) with inadequate glycemic control on oral agents, but 
some need further therapy to reach this goal. The purpose of this analysis was 
to assess whether early fasting plasma glucose (FPG) values predict glycemic 
control at week 24, and to help identify patients who may need prandial insu-
lin after initiation of basal insulin.
Materials and methods: We analyzed patient-level data from 7 prospective, 
randomized controlled trials of insulin glargine with/without oral antidiabetic 
drugs in adults with T2DM with 24- or 28-week measurements and lab-meas-
ured FPG at week 6 or 8 and at week 12. These studies utilized strict, predefined 
insulin titration algorithms to achieve FPG concentrations ≤5.55 mmol/L.
Results: A total of 1036 patients (56% men; 81% white) had (mean±SD) age 
56±10 y, duration of diabetes 8.4±5.9 y, baseline A1C 8.8%±1.0%. Mean A1C 
at endpoint was 7.03%±0.86%; mean FPG at endpoint was 6.67±1.9 mmol/
L; 56% of patients reached A1C ≤7.0%. Mean FPG was 11.2±3.0 mmol/L at 
baseline, 7.33±2.2 mmol/L at week 6/8, and 6.77±1.9 mmol/L at week 12. 
Lower FPG at baseline was associated with lower A1C at week 24 (r=0.169, 
P<0.0001), but this correlation was stronger at week 6/8 (r=0.319, P<0.0001) 
and week 12 (r=0.317, P<0.0001). The figure shows percentage of patients 
reaching A1C ≤7.0% after having FPG in various ranges at baseline, week 
6/8, and week 12. Patients with FPG ≥8.88 mmol/L at baseline had a likeli-
hood of reaching A1C ≤7.0% similar to that of the whole population (55% vs 
56%), but just 37% of those in this range at week 6/8 and 35% at week 12 did 
so. However, patients with FPG <8.88 mmol/L vs ≥8.88 mmol/L at week 12 
had greater rates of symptomatic hypoglycemia (64.9% vs 51.8%). Laboratory 
FPG measurements correlated strongly with values self-measured at home 
(r=0.778, P<0.0001).
Conclusion: 1) Even a single FPG measurement (by laboratory or at home) 
can help identify persons starting insulin glargine who may need prandial 
therapy as well; 2) a value ≥8.88 mmol/L between weeks 6 and 12 indicates 
reaching target A1C ≤7.0% is unlikely and calls for individualized attention.
Supported by: sanofi-aventis, US
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Basal supported oral therapy (BOT) and risk of transition to intensified 
regimens: a retrospective cohort study
R. Quinzler1, F.-W. Dippel2, M. Ude3, A. Franzmann1, K. Schuessel1,  
S. Feldt1, K. Leuner3, W.E. Mueller3, M. Schulz1,3; 
1GIDE - German Institute for Drug Use Evaluation (DAPI), Eschborn, 
2Sanofi-Aventis Deutschland GmbH, Berlin, 3Department of Pharmacology, 
Goethe-University, Frankfurt at Main, Germany.
Background and aims: After failure of oral antidiabetic drugs (OAD), treat-
ment with long acting insulin plus oral antihyperglycaemic agents (basal 
supported oral therapy, BOT) is preferably recommended in type 2 diabetic 
(T2D) patients according to the consensus statement of the American Dia-
betes Association (ADA) and the European Association for the Study of Dia-
betes (EASD). We aimed to assess the persistence of T2D patients starting a 
BOT with either insulin glargine (GLA) or NPH insulin (NPH) until modi-
fication of insulin therapy.
Materials and methods: A retrospective cohort study was performed using 
claims data for ambulatory prescriptions within the German statutory health-
insurance scheme, based on a representative sample of more than 80 % of 
community pharmacies. Patients on BOT with either GLA or NPH between 
01/2003 and 12/2006 were included and followed up until 12/2007. Persist-
ence was defined as the duration of time from initiation of BOT with GLA 
or NPH until modification of insulin therapy, with either premixed insulin 
(CT), bolus insulin alone (SIT) or bolus insulin added to basal insulin (ICT). 
Univariate and multivariate proportional hazards models were used to com-
pare both cohorts.
Results: In total, 97,976 patients (61,053 GLA and 36,923 NPH) were includ-
ed. Altogether, 44.1 % of GLA patients and 48.7 % of NPH patients modified 
initial BOT. On average, these patients stayed 373 days on BOT with GLA 
and 305 days on BOT with NPH (incidence rate per 100 person-years: 25.8 
vs. 33.4). During the observation period 23.7 % of the patients switched to 
ICT, 17.6 % to CT, and 4.5 % to SIT. The risk of switching from BOT to one 
of these intensified insulin regimens was significantly higher for NPH com-
pared to GLA patients (HR 1.25, 99 % CI 1.22-1.28). After adjustment for 
predefined covariables i.e., type of physician, region, insurance status, health 
insurance company, comedication, number of OADs, dose of basal insulin, 
the risk for NPH patients remained significantly higher (HR 1.17, 99 % CI 
1.14-1.20).
Conclusion: T2D patients under BOT with GLA remain significantly longer 
compared to NPH before they have to be switched to more intensified regi-
mens. This might also be of economic importance, since BOT causes less 
resource consumption than CT, SIT or ICT regimens as has been shown by 
other investigators.
Supported by: MU: Lesmüller Stiftung, Munich; GIDE: sanofi-aventis Deutsch-
land GmbH
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The STEPwise™ randomised, controlled, 48-week trial: intensifying 
treatment with stepwise addition of prandial insulin aspart, based on 
largest prandial glucose increment or largest meal, to once-daily basal 
insulin detemir in subjects with type 2 diabetes
K. Hermansen1, S. Kumar2, H. Mersebach3, A.L. Svendsen3, L. Meneghini4; 
1Aarhus University Hospital, Denmark, 2Warwick University, United 
Kingdom, 3Novo Nordisk A/S, Copenhagen, Denmark, 4University of Miami 
Miller School of Medicine, United States.
Background and aims: Adding bolus insulin doses step by step is one ap-
proach for intensifying treatment in patients on basal insulin when glycaemic 
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control is no longer maintained. The aim of this randomised, controlled, par-
allel-group, open-label, 48-week trial (STEPwise™) was to compare the effect 
on glycaemic control and safety endpoints of sequential addition of prandial 
insulin aspart (IAsp) to: (a) largest perceived meal (SimpleSTEP); or (b) meal 
with the largest post-prandial glucose increment (ExtraSTEP).
Materials and methods: 296 subjects with type 2 diabetes inadequately con-
trolled on basal insulin+OADs (mean age 58.3 yrs; mean HbA1c 8.8%; mean 
diabetes duration 12.3 yrs) underwent a 12-week run-in and were transferred 
to once-daily bedtime insulin detemir with continuation of their previous 
stable pre-trial OAD regimen and optimisation of basal insulin doses. Sub-
jects with HbA1c ≥7% after run-in were randomised to one of the two groups, 
and sulphonylureas were discontinued. Bolus insulin titration was based on 
pre-meal glucose values for SimpleSTEP and post-meal glucose values for 
ExtraSTEP. After 12 weeks’ treatment with the 1-IAsp regimen (Period 1), 
subjects not at HbA1c<7% received a second IAsp titrated bolus at the next 
largest meal or uncovered meal with largest post-prandial glucose increment 
for an additional 12 weeks (Period 2); subjects with HbA1c <7% continued 
with one IAsp injection. At 24 weeks, subjects with HbA1c ≥7% received IAsp 
at a second/third meal and subjects with HbA1c <7% continued on the 1- or 
2-IAsp regimens for 12 more weeks (Period 3).
Results: At study end, both groups showed significant improvements in 
HbA1c (~1.2%) with no difference between regimens. HbA1c decreased by 
~0.5% in Period 1, by a further ~0.5% in Period 2, and by ~0.2% in Period 3 
in both groups. The overall rate of hypoglycaemia was low.
Conclusion: Improvement in glycaemic control with a low risk of hypogly-
caemia can be achieved by the stepwise addition of insulin aspart to insulin 
detemir based on perceived meal size or measured post-prandial glucose in-
crements.
Supported by: Novo Nordisk
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Stepwise intensification of prandial insulin versus basal−bolus insulin 
therapy in patients with type 2 diabetes mellitus
D. Raccah1, T. Haak2, D. Huet3, L. Monnier4, J.S. Ramon5, D. Robertson6,  
P. Labard7, A. Penfornis8, OSIRIS Study Group; 
1Hôpital Sainte Marguerite, Marseille, France, 2Diabetes Zentrum, Bad 
Mergentheim, Germany, 3Centre Hospitalier Saint Joseph, Paris, France, 
4Hôpital Lapeyronie, Montpellier, France, 5Ciutat Sanitaria i Universitaria 
de Bellvitge, Barcelona, Spain, 6Sandwell Medical Research, West Bromwich, 
United Kingdom, 7sanofi-aventis, Paris, France, 8CHU Hôpital Jean Minjoz, 
Besançon, France.
Background and aims: Insulin therapy intensification is important for pa-
tients with poorly controlled type 2 diabetes mellitus (T2DM). This interna-
tional, randomized, parallel-group, non-inferiority study compared stepwise 
addition of prandial insulin with a basal−bolus regimen.
Materials and methods: A total of 811 patients (mean ± standard deviation 
[SD] age: 58.6 ± 8.9 years) with T2DM poorly controlled on basal insulin 
(HbA1c 9.1 ± 1.4%; fasting plasma glucose [FPG] 9.7 ± 3.3 mmol/L [174 ± 
59 mg/dL]) were switched to insulin glargine (GLAR) for 6 months, and 
continued oral therapy. At 6 months, mean GLAR dose was 36 U/day and 
mean HbA1c was 8.3%. Patients with HbA1c >7% and FPG <6.7 mmol/L (<120 
mg/dL) (n=476) were then randomized to: Group 1) GLAR + metformin 
(MET) + 3× insulin glulisine (GLU); Group 2) GLAR + MET + 1−3× GLU; or 
Group 3) GLAR + MET + sulfonylurea + 1−3× GLU for 12 months. Patients 
in Group 1 received GLU at each meal; patients in Groups 2 and 3 injected 
GLU at the meal with the highest postprandial plasma glucose (PPPG), with 
two further doses added at Months 4 and 8 if HbA1c was >7% (target PPPG 
6.1−8.9 mmol/L [110−160 mg/dL]). Initial GLU dose was half the meal PPPG 
and titrated according to an algorithm based on the PPPG. Non-inferiority of 
Group 2 to Group 1 was concluded if the 95% confidence interval (CI) upper 
limit for the HbA1c difference was ≤0.4%.
Results: The adjusted difference of Group 2 versus Group 1 for the per-pro-
tocol population (PP; primary analysis) crossed the non-inferiority margin 
(0.228 [95% CI: −0.018, 0.473]) but did not for the intent-to-treat population 
(ITT; secondary analysis; 0.122 [95% CI: −0.114, 0.358]). In both the PP and 
ITT, Group 1 was not superior to Groups 2 or 3 (Table). At endpoint, the 
GLAR dose was similar in all three groups with mean doses of 37, 40 and 40 
U/day for Groups 1, 2 and 3, respectively. The mean GLU dose at endpoint 
was 29, 20 and 17 U/day, respectively; 33 and 40% of patients remained on 
one GLU injection in Groups 2 and 3, respectively. The incidence of symp-
tomatic hypoglycaemia was highest in Group 3 and lowest in Group 2, al-
though between-group differences were not significant (Table). Mean change 
in body weight was slightly increased in all three groups but the increase was 
significantly lower in Group 2 compared with Group 1 (Table).
Conclusion: Stepwise intensification of GLU added to GLAR showed efficacy 
similar to a basal−bolus approach with less symptomatic hypoglycaemia and 
significantly less weight gain, although non-inferiority was not achieved.
Table 
Group 1 
(n=144)
Group 2 
(n=197)
Group 3 
(n=123)
HbA1c (%; per protocol)
Randomization
Endpoint
Change
8.5 ± 1.1
7.7 ± 1.2
−0.72 ± 1.25
8.4 ± 1.1
7.9 ± 1.2
−0.47 ± 1.05
8.3 ± 1.1
7.9 ± 1.3
−0.40 ± 1.11
Symptomatic hypoglycaemia
(mean events/pt year) 4.36 4.23 5.46
Body weight (kg)
Randomization
Endpoint
Change
82.7 ± 15.6
84.7 ± 15.1
+2.03 ± 3.21
81.6 ± 15.8
82.9 ± 16.0
+1.30 ± 3.17*
83.6 ± 17.0
85.5 ± 17.5
+1.90 ± 3.38
*p<0.05 versus Group 1
Supported by: sanofi-aventis
959
Premeal injection of rapid-acting insulin reduces postprandial glycaemic 
excursions, a randomised controlled trial
Y.M. Luijf, A.C. van Bon, J.B.L. Hoekstra, J.H. DeVries; 
Internal Medicine, Academic Medical Centre, Amsterdam, Netherlands.
Background and aims: To assess the effect of three premeal timings of rap-
id-acting insulin on postprandial glucose excursions in patients with CSII 
treated type 1 diabetes.
Materials and methods: 10 subjects (3 females and 7 males) with T1DM 
participated. Mean (± SD) age was 45.5 ± 12.09 years, HbA1c 8.55 ± 1.50%, 
duration of diabetes 23.8 ± 7.81 years and duration of CSII therapy 8.5 ± 6.10 
years. Patients were served an identical breakfast on three study days. Insulin 
aspart was randomly administered at 30, 15 or 0 minutes before the meal. All 
patients started the study with admission blood glucose between 3.5 and 7.8 
mmol/L. Blood was sampled for glucose determination from one hour before 
the meal until four hours after.
Results: The area under the curve was significantly lower in the -15 group 
(0.41 ± 0.51 mmol/L/min) compared to the -30 group (1.89 ± 0.72 mmol/
L/min, P = 0.029) and 0 group (2.11 ± 0.655 mmol/L/min, P = 0.030). The 
maximum blood glucose excursion was also lower in the -15 group (4.77 ± 
0.52 mmol/L) compared to the -30 (6.48 ± 0.76 mmol/L, P = 0.025) and 0 
group (6.93 ± 0.76 mmol/L, P = 0.022). The peak blood glucose level was 
significantly lower in the -15 group (9.26 ± 0.72 mmol/L) compared to the 
-30 group (11.74 ± 0.80 mmol/L, P = 0.007) and the 0 group (12.29 ± 0.93, 
P=0.009). Time spent in the 3.5 to 10 mmol/L range was highest in the -15 
group (224.5 ± 25.0 min) and this difference was significant in comparison 
with the 0 group (90.5 ± 23.2 min, P=0.001) but not when compared to the 
-30 group (182.5 ± 28.2 min, P=0.212). There was no significant difference 
between the occurrences of glucose levels <3.5mmol/L between groups 
(P=0.901).
Conclusion: Administration of rapid acting insulin analogues at 15 minutes 
before mealtime results in lower postprandial glucose excursions and more 
time spent in the 3.5-10.0 mmol/L glucose range, without increased risk of 
hypoglycaemia.
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Clinical outcomes after basal insulin initiation correlate with baseline 
oral antidiabetic drug therapy: a pooled analysis of clinical trial data
J. Leahy1, J. Gill2, R. Zhou3, V.A. Fonseca4; 
1University of Vermont College of Medicine, Burlington, 2sanofi-aventis US, 
Bridgewater, 3Medpace, Cincinnati, 4Tulane University Medical Center, New 
Orleans, USA.
Background and aims: This analysis evaluated the association between base-
line oral antidiabetic drug (OAD) therapy and clinical outcomes after insulin 
initiation.
Materials and methods: The analysis included data from 11 prospective ran-
domized controlled trials of insulin glargine (without prandial insulin) with/
without OADs in adults with type 2 diabetes; 2171 patients received insulin 
glargine. These studies used strict, predefined insulin titration algorithms to 
achieve fasting glucose concentrations ≤5.55 mmol/L. Study duration var-
ied from 24 to 48 weeks; outcomes for the pooled analysis were assessed at 
week 24. Statistical analysis compared patients taking 0 or 1 OAD at baseline 
(low use; 1.8% and 45.2% of patients, respectively) with those taking 2 OADs 
(52.2%), and patients on metformin (MET) only (8.5%) with those on sulfo-
nylurea (SU) only (36.5%) or MET + SU (49.9%).
Results: Mean age was 58.6 years, 55.6% were male, and 88.3% were white. 
At week 24, patients with low baseline OAD use and those taking only MET 
had significantly greater A1C reductions (Table). Weight gain from base-
line to week 24 was not significantly different based on the number or type 
of baseline OADs. However, patients with low baseline OAD use had sig-
nificantly lower rates of symptomatic hypoglycemia vs those taking 2 OADs 
(P=0.0009), and those taking only MET had lower rates than those taking SU 
or MET + SU (P<0.0001) despite higher insulin doses (53 vs 37.5 vs 38.8 U).
Conclusion: Patients adding insulin to 0 or 1 baseline OAD, who may be in 
earlier stages of diabetes, showed a greater reduction in A1C with lower risk 
of hypoglycemia than those taking 2 OADs. The more favorable results of 
adding insulin to baseline MET vs SU or combined therapy support the Tier 
1 recommendations of the current algorithm of the American Diabetes As-
sociation/European Association for the Study of Diabetes.
Table: A1C and Baseline (BL) OAD Use
BL OAD BL A1C, %a Week 24 A1C, %a
Δ in A1C From 
BL to Week 
24, %b
Week 24 A1C 
≤7.0%, n (%)
0/1 OAD 8.87 (1.07) 7.05 (0.97) -1.83 (0.05) 558 (54.7)
2 OADs 8.68 (1.02) 7.04 (0.89) -1.68 (0.03) 643 (56.7)
P valuec 0.0198 0.0541
MET only 9.08 (1.28) 6.87 (0.93) -1.98 (0.07) 126 (68.1)
SU only 8.84 (1.02) 7.11 (0.99) -1.69 (0.06) 399 (50.4)
MET + SU 8.67 (1.03) 7.04 (0.89) -1.69 (0.03) 646 (56.8)
P valuec 0.0009 <0.0001
aMean (SD); bLeast squares mean (SE); cFrom analysis of covariance model.
Supported by: sanofi-aventis, US
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The DURABLE Trial: comparing durability of lispro mix 25 vs glargine
B.H.R. Wolffenbuttel1, J.B. Buse2, W.H. Herman3, S.E. Hippler4,  
S.A. Martin5, H.H. Jiang5, J.L. Scism-Bacon5, J.L. Fahrbach5; 
1Endocrinology, University Medical Center Groningen, Netherlands, 2UNC 
School of Medicine, Chapel Hill, 3Internal Medicine and Epidemiology, U of 
Michigan, Ann Arbor, 4OSFMG Clinical Research Center, OSFMG Center 
for Health Internal Medicine, Peoria, 5Eli Lilly and Company, Indianapolis, 
USA.
Background and aims: To evaluate if adding twice-daily (bid) insulin lispro 
mix 25 (LM25: 25% lispro/75% insulin lispro protamine suspension) to oral 
antihyperglycaemic medications (OAMs) results in longer durability of gly-
caemic control than adding once daily (qd) insulin glargine (G). Durability 
was defined as duration of time patients (pts) maintained hemoglobin A1c 
(HbA1c) goal (HbA1c ≤7.0% or HbA1c >7.0% but an increase of <0.4% from 
the last HbA1c ≤7.0%).
Materials and methods: A total of 2091 pts with type 2 diabetes (T2D) aged 
30-80 yrs, HbA1c >7.0% on at least 2 OAMs were randomised to either LM25 
bid or G qd. OAMs were continued. Insulin was titrated to fasting plasma 
glucose (FPG) and pre-evening meal plasma glucose <6.1 mmol/L for LM25, 
and FPG ≤5.5 mmol/L for G. All pts had up to 6 months (initiation phase) to 
achieve HbA1c ≤7.0%, after which, pts with HbA1c ≤7.0% advanced into the 
maintenance phase for up to an additional 2 years (total = 30 month study). 
Pts were discontinued from maintenance phase if HbA1c was >7.5%. The pri-
mary objective was duration of time at HbA1c goal, from when pts first at-
tained HbA1c goal.
Results: Of the 900 pts on LM25 and 918 pts on G who completed the initia-
tion phase, 473 and 419, respectively, had an HbA1c ≤7.0% at 6 months and 
continued into the maintenance phase. Baseline characteristics were similar 
across therapies except for age (LM25: 59±9 yrs; G: 57±9 yrs). The median 
time at HbA1c goal was 16.8 months (95% CI, 14.0-19.7) for LM25 and 14.4 
months (95% CI, 13.4-16.8) for G (p=0.040, log-rank test). At endpoint, 
HbA1c goal was maintained for 202 (43%) pts on LM25 and 147 (35%) pts on 
G (p=0.006). Compared to pts unable to maintain HbA1c goal, pts on LM25 
who maintained HbA1c goal throughout the study had lower baseline HbA1c 
(p=0.043). Pts on G who maintained goal had: shorter duration of diabetes; 
lower baseline HbA1c, mean post-meal plasma glucose (PG), and mean PG; 
and higher 1,5-anhydroglucitol (p<0.05 for all). There was no difference in 
the rate (episodes/patient/year) of overall (LM25 19; G 18), nocturnal (LM25 
6; G 9), or severe (LM25 0.02; G 0.02) hypoglycaemia. Incidence of serious 
adverse events was not different.
Conclusion: LM25 therapy resulted in statistically longer durability than 
treatment with G, though the clinical relevance of this difference is unclear. 
Patients with a lower baseline HbA1c were more likely to maintain HbA1c goal, 
which supports the concept of early introduction of insulin therapy in T2D. 
In both groups, the median time to starter insulin failure illustrates the pro-
gressive nature of T2D, necessitating continued diligence and advancement 
of therapy.
Supported by: Eli Lilly and Company
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Switching from premixed insulin to basal−bolus insulin glargine plus 
rapid-acting insulin: results of the ATLANTIC study
G. Storms1, I. Colin2, T. Veneman3, C. Mathieu4; 
1St. Antonius Hospital, Utrecht, Netherlands, 2CHR Clinique Saint-Joseph, 
Mons, Belgium, 3Twenteborg Hospital, Almelo, Netherlands, 4Katholieke 
Universiteit, Leuven, Belgium.
Background and aims: This study evaluated the efficacy and safety of switch-
ing from twice-daily premixed insulin to basal−bolus glargine (GLAR) plus 
rapid-acting insulin in a ‘real-world’ clinical practice setting in Belgium and 
The Netherlands.
Materials and methods: This was a prospective, 6-month, multicentre, non-
interventional, observational study. Adults with Type 2 diabetes mellitus 
(T2DM) could be enrolled if they were being switched from twice-daily pre-
mixed insulin to basal−bolus GLAR plus insulin glulisine (GLU; The Neth-
erlands) or any rapid-acting insulin (Belgium) due to poor glycaemic con-
trol. The primary objective was the proportion of patients with HbA1c <7% 
at Month 6. Secondary objectives included changes in mean HbA1c, fasting 
plasma glucose (FPG), self-monitored blood glucose (SMBG), weight, insu-
lin dose, fasting blood lipid profile (FBLP), safety (including the incidence of 
symptomatic nocturnal and severe hypoglycaemia) and treatment satisfac-
tion (DTSQs and DTSQc).
Results: A total of 214 patients were included: mean ± standard deviation 
age 64.4 ± 9.8 years, diabetes duration 12.1 ± 7.8 years, weight 89.5 ± 17.2 
kg. GLAR was initiated with GLU, regular human insulin or insulin aspart 
in 81.7, 8.9 and 8.5% of patients, respectively. At baseline, 3.3% had HbA1c 
<7%, which increased significantly at Months 3 and 6 to 20.1 and 24.9%, 
respectively (Table). Significant reductions over 6 months were observed in 
mean HbA1c, FPG and SMBG. The mean total premixed insulin dose prior to 
switching was 65.2 U/day and the starting doses of GLAR and rapid-acting 
insulin were 28.1 and 35.7 U/day, respectively. Mean GLAR and rapid-acting 
insulin doses were significantly higher at Month 6. Mean weight increased by 
0.67 ± 4.8 kg at Month 6 (not significant). No statistically significant changes 
in FBLP were observed at Month 6, although there was a trend toward a re-
duction in triglycerides (−14 mg/dL; p=0.063). At Month 6, 33.9 and 27.8% 
of patients reported a reduction in the incidence of nocturnal and severe 
hypoglycaemia, respectively, compared to the initial visit (both p<0.0001). 
Increases in these events were reported by 1.8 and 2.5%, with the remaining 
patients reporting no change. Overall, 22 adverse events were reported by 
19 patients, including nine episodes of hypoglycaemia, which were consid-
ered non-serious. Treatment satisfaction improved significantly at Month 6 
(DTSQs +5.9 and DTSQc +10.4; both p<0.0001).
Conclusion: In a Belgian and Dutch clinical practice setting, patients with 
T2DM poorly controlled on premixed insulin experienced significant im-
provements in glycaemic control and treatment satisfaction, without a con-
comitant increase in hypoglycaemic events or weight, when switched to 
basal−bolus GLAR plus rapid-acting insulin.
Table 
Baseline Month 3 Month 6 p value*
% of patients with HbA1c 
<7% (95% CI)
3.3 (1.6−6.7) 20.1 
(14.9−26.5)
24.9 
(19.0−31.8)
p<0.0001
HbA1c (%) 9.2 ± 4.5 7.7 ± 1.0 7.5 ± 0.9 p<0.0001
FPG, mmol/L (mg/dL) 10.4 ± 4.1  (187 ± 73)
8.4 ± 5.3  
(152 ± 96)
7.8 ± 2.7 
(140 ± 48)
p<0.0001
7-point SMBG,  
mmol/L (mg/dL)
10.8 ± 2.7  
(195 ± 48)
8.5 ± 2.0  
(153 ± 36)
8.5 ± 2.0 
(153 ± 36)
p<0.0001
Weight (kg) 89.5 ± 17.2 89.8 ± 17.1 90.4 ± 17.6 NS
Insulin glargine dose 
(U/day)
28.1± 17.4 32.8 ± 16.8 34.7 ± 22.1 p<0.0001
Rapid-acting insulin 
dose (U/day)
35.7 ± 17.5 43.0 ± 20.0 43.8 ± 20.9 p<0.0001
Hypoglycaemia, reduc-
tion/no change/increase 
(%)*
Nocturnal
Severe
−
−
29.4 / 66.1 /  
4.4
25.7 / 70.9 /  
3.4
33.9 / 64.2 
/ 1.8
27.8 / 69.8 
/ 2.5
p<0.0001
p<0.0001
Data are mean ± standard deviation unless otherwise stated. *Change from 
baseline to Month 3 and 6; CI=confidence interval; NS=not significant
Supported by: sanofi-aventis
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Pharmacokinetics of novel formulations of insulin analogues that 
provide a more rapid onset of action in diabetic miniature swine
R. Pohl, Y. Zhang-Benoit, N. Kashyap, S.S. Steiner; 
Biodel Inc., Danbury, USA.
Background and aims: Commercial prandial insulin analog formulations 
have a more rapid onset of action than traditional regular human insulin 
preparations. A faster absorption profile is desirable to improve the timing of 
insulin release and reduce hypoglycemic events between meals. In this pre-
clinical study, Insulin lispro (ILV), insulin aspart (IAV) and insulin glulisine 
(IGV) were re-formulated with safe excipients to improve their rate of sub-
cutaneous absorption. The aim of this study was to evaluate the pharmacoki-
netic (PK) timing of these new rapid acting insulin analog formulations.
Materials and methods: ILV, IAV and IGV were formulated in a similar 
manner to VIAject (containing EDTA and citrate) and were compared to 
their commercial preparations (insulin lispro (IL), insulin aspart (IA), and 
insulin glulisine (IG)) in diabetic miniature swine (DMS). DMS were given a 
dose of 0.25 U/kg in lieu of their daily porcine insulin injection. Immediately 
following dosing, the swine were fed 500 g of their normal swine diet. Blood 
glucose and plasma insulin were sampled at -30, -20, -10, 0, 5, 10, 15, 20, 30, 
45, 60, 75, 90, 120, 150, 240, 300, 360, 420, and 480 min. post dose. Insulin 
analog plasma levels were measured by ELISA technique.
Results: Results of timing related PK parameters Tmax and 1/2Tmax are 
shown in table below. In all cases, the new formulations ILV, IAV and IGV 
had significantly faster insulin absorption than their commercial counter-
parts, IL, IA and IG. Pharmacodynamics were consistent with the PK.
Conclusion: Viaject, a formulation of RHI combined with these exipients has 
completed phase III trials as an improved prandial insulin and is currently 
being reviewed by the FDA. The phase III clinical trials showed that not only 
was insulin absorption more rapid than RHI and analog insulins, but there 
was also a significant beneficial decrease in weight gain and reduction in hy-
poglycemia compared to RHI. This information, coupled with results of the 
present study, suggest existing rapid acting analogs could be reformulated 
with these safe excipients and result in a safe and efficacious improvement of 
these prandial insulins.
Pharmacokinetic data
ILV(n=8) IL(n=10) IAV(n=4) IA(n=4) IGV(n=5) IG(n=11)
Tmax(min.) 23.0+/-5.5 30.0+/-6.1 17.5+/-2.5** 63.8+/-9.4 26.0+/-6.2 37.3+/-6.4
1/2Tmax(min.) 4.1+/-0.8** 15.1+/-3.4 6.9+/-1.8* 29.6+/-7.4 5.8+/-0.8* 9.4+/-1.1
*p<0.05, **p<0.01, +/-SEM
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Comparative pharmacokinetics and pharmacodynamics of high-dose 
human regular U-500 insulin versus human regular U-100 insulin in 
healthy obese subjects
H. Linnebjerg1, A. de la Pena2, L. Morrow3, H.H. Jiang2, K. Win3,  
L.L. Wolka2, M. Hompesch3, M. Riddle4, J.A. Jackson5; 
1Lilly Research Laboratories, Eli Lilly and Company, UK, Surrey, United 
Kingdom, 2Eli Lilly and Company, Indianapolis, USA, 3Profil Institute for 
Clinical Research, Inc., Chula Vista, USA, 4Oregon Health and Science 
University, Portland, USA, 5Lilly USA, LLC, Indianapolis, USA.
Background and aims: Human regular U-500 (U-500R) insulin is used in 
the US and UK in high-dose insulin-treated diabetes patients with the ad-
vantages of smaller injection volumes and fewer injections as compared to 
U-100 insulins/analogues. However, only a few pharmacokinetic (PK) and 
pharmacodynamic (PD) studies of U-500R have been conducted since its in-
troduction in 1997. The primary aim of this study was to evaluate the relative 
exposure after 2 clinically relevant doses of U-500R vs U-100 human regular 
insulin (U-100R) in healthy obese subjects. Other comparative PK/PD re-
sponses were evaluated.
Materials and methods: Twenty-four healthy obese subjects (male/female 
14/10; age [mean±SD] 39.6±12.1 years; body weight 98.1±12.9 kg; BMI 
34.4±2.6 kg/m2) participated in a single-centre, 4-period, 4-sequence, cross-
over, randomised, double-blinded, euglycaemic clamp study. Following ad-
ministration of 50-IU and 100-IU doses of each formulation, subjects un-
derwent euglycaemic clamps up to 24 hours. Serum immunoreactive insulin 
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was measured for PK evaluation. Glucose infusion rates were recorded for 
PD analysis.
Results: Results for the 100-IU dose are shown in the table. While overall 
exposure (AUC from time zero to return to baseline, AUC0-t’) was similar 
between formulations at both 50-IU and 100-IU doses, the U-500R peak con-
centration (Cmax) was significantly lower than that for U-100R at both doses . 
The time-to-peak concentration (tmax) was significantly longer for U-500R at 
the 100-IU dose only. Overall effect (Gtot) for U-500R was similar to U-100R 
at both doses. Peak effect (Rmax) was lower for U-500R vs U-100R at both 
doses. Time-to-peak effect (tRmax) was shown to be prolonged for U-500R 
vs U-100R at the 100-IU dose only. Time variables reflective of duration of 
action (early and late tRmax50, tRlast) were prolonged for U-500R vs U-100R at 
both doses.
Conclusion: While AUC0-t’ was similar at both 50-IU and 100-IU, the peak 
concentration was significantly lower for U-500 at both doses. The PD results 
are generally consistent with the PK. Both U-500R and U-100R exhibited 
long time-to-peak effect and duration of effect, with U-500R being signifi-
cantly longer for these parameters vs U-100R. For T2D patients requiring 
high-dose U-100R therapy, this may have important clinical implications for 
bolus/basal insulin calculations. The longer duration of effect of U500R com-
pared to U100R suggests that multiple daily injections of U500R without use 
of a basal insulin may be a plausible treatment option for obese patients with 
type 2 diabetes; further study is required to determine the safety and efficacy 
of such an approach.
100-IU Dose Human Regular 
U-500 Insulin
Human Regular 
U-100 Insulin
Ratio (†) or 
Difference (‡) 
of LS Means
90% CI
PK
AUC0-t’ (pmol·min/L) 12300 (19) 12400 (22) 0.98† (0.92, 1.05)
Cmax (pmol/L) 1020 (31) 1400 (28) 0.72† (0.66, 0.78)
*
tmax (hr) 8.00 (0.50 - 8.00) 3.00 (1.00 - 8.00) 2.50
¥ (0.00, 4.00)*
PD
Gtot (g) 621 (33) 586 (23) 1.09† (1.01, 1.17)
Rmax (mg/min) 826 (37) 966 (22) 0.87† (0.80, 0.95)
*
tRonset (hr) 0.221 (77) 0.184 (78) 0.04‡ (-0.06, 0.14)
tRmax (hr) 6.37 (25) 5.32 (22) 1.04‡ (0.38, 1.70)
*
Early tRmax50 (hr) 2.02 (59) 1.51 (41) 0.60‡ (0.34, 0.87)
*
Late tRmax50 (hr) 15.1 (16) 11.7 (16) 3.39‡ (2.54, 4.25)
*
tRlast (hr) 21.5 (11) 18.3 (15) 3.24‡ (2.29, 4.19)
*
Parameters are expressed as geometric mean (CV%), except for tmax, expressed as median 
(range).
*p<0.05
¥ Median difference
Supported by: Lilly USA, LLC
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More rapid onset and shorter duration of insulin exposure and action for 
3 rapid insulin analogues coinjected with human hyaluronidase
D. Muchmore1, L. Morrow2, M. Hompesch2, E. Ludington1, D. Vaughn1; 
1Halozyme Therapeutics, Inc., San Diego, 2Profil Institute for Clincal 
Research, Chula Vista, USA.
Background and aims: This study compared the pharmacokinetic (PK) and 
glucodynamic (GD) responses to 3 rapid-acting insulin analogs (glulisine, 
lispro and aspart) ± coinjected recombinant human hyaluronidase (PH20)
Materials and methods: A 6-way crossover glucose clamp study was con-
ducted in 14 healthy volunteers [8 male, 6 female; mean age 34 (23-53); mean 
BMI 24.7 kg/m2 (21.1-27.0)]. Euglycemic clamps (8h at 90% FBG w/o basal 
insulin infusion) were performed following 0.15 U/kg doses of each study 
drug SC in a random order. Specificity and sensitivity of the insulin immu-
noassay used for PK analysis was slightly different for the three analogs; data 
are graphed as cumulative values to allow direct comparison of timing differ-
ences for exposure and action across the 3 analogs.
Results: The three analogs w/o PH20 had generally comparable insulin time-
exposure and time-action profiles [time to 50% of total insulin exposure 
(AUC) were 124, 123 & 131 min; time to 50% insulin action (Gtot) were 183, 
186 & 187 min, for glulisine, lispro and aspart; all P>0.2] although glulisine 
had modestly more rapid onset (time to 10%) of exposure (40 v. 47 & 48 
min; P=.005 & .0004) and action (67 v. 76 & 76 min; P=.025 & .021). PH20 
accelerated the absorption of all three rapid-acting analogs, resulting in more 
physiologic fast-in, fast-out profiles: insulin exposure in the 1st hr increased 
to 191%, 229%, and 246% control and after 2 hrs decreased by 43%, 54%, and 
57%; glucose infused in the 1st 2 hrs increased to 157%, 161%, and 182% con-
trol, and after 4 hours decreased by 48%, 44%, and 50% for glulisine, lispro 
and aspart, respectively (all P<.0001). With PH20, all 3 analogs had compara-
ble profiles (times to 50% of total insulin exposure were 79, 71 & 73 min and 
time to 50% insulin action were 135, 140 & 127 min, for glulisine, lispro and 
aspart respectively; all P≥.1 between analogs w/ PH20) and each was notably 
faster than any marketed products alone (all P<.0001). All injections were 
well tolerated; all adverse events (mild or moderate) were procedure related. 
Also shown in the figure are cumulative insulin exposure and action for regu-
lar human insulin (RHI) from data collected in a separate but similar study.
Conclusion: Coinjection with PH20 was well tolerated and accelerated the 
absorption of all 3 insulin analogs to a comparable degree, resulting in more 
rapid onset and shorter duration of both insulin exposure and action.
966
Dissolving microneedles for percutaneous delivery of insulin
K. Takada, Y. Itoh; 
Pharmacokinetics, Kyoto Pharmaceutical University, Japan.
Insulin (Ins) chip having 300 2-layered dissolving microneedle (DM) arrays 
on 254mm2 were prepared by microfabrication technology where water-
soluble thread-forming polymer, chondroitin sulfate (Chon) was used as the 
base. The obtained Ins DM chips were evaluated as a new TDDS. The mean 
lengths of the DM were 473.3±3.7(SE)μm, though the mean length of Ins 
loaded space was 328.1±3.5μm from the top of DMs. The diameters of the 
basement were 301.6±1.6μm. One chip contained 5.7±0.04 and 7.1±0.7 IU 
Ins by HPLC analysis. After administration of Ins chip to the abdominal skin 
of dogs, plasma glucose levels were measured. Maximum hypoglycemic ef-
fect appeared at 1.0±0.0 h. The minimum glucose levels were 46.5±3.9 and 
36.1±5.8% as compared to the pre-dose level. By comparing the AAC (area 
above the plasma glucose level vs. time curve) obtained after sc injection of Ins 
solution, 4.0 IU, relative pharmacological availabilities (RPA) were 54.9±5.9 
and 56.3±5.1%. Plasma Ins levels were also measured by ELISA. Cmaxs were 
148.2±57.2 and 163.8±44.2 mIU/mL and Tmaxs were 0.75±0.0 and 0.75±0.0h. 
Relative bioavailabilities (RBA) against sc Ins injection were 72.0±34.4 and 
79.7±26.5 %. Fluorescence microscopy experiment using a DM chip contain-
ing FITC-insulin (F-ins) showed that DM was dissolved in the inserted epi-
dermal site of the skin within 5 min and thereafter F-ins diffused both hori-
zontal and vertical directions of the skin within 30 min. Histological study on 
the administered skin showed that there was no damage on the skin. As chip 
is made of Ins and Chon, safety is established. Ins DM chip is a useful TDDS 
and we want to proceed to clinical phase I study.
Keywords: Insulin microneedle chip
Supported by: Ministry of Education, Culture, Sports, Science and Technology, 
MEXT
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No generation of insulin antibodies in subjects with impaired glucose 
tolerance treated with buccal spray insulin 
A. Palermo, N. Napoli, D. Tuccinardi, S. Manfrini, M. Altomare, S. Leotta, 
P. Pozzilli; 
Campus Bio-Medico di Roma, Italy.
Background and aims: In patients with impaired glucose tolerance (IGT), 
upon implementation of life style changes and metformin, a third returns 
to normal glucose tolerance, a third continues with IGT and the rest goes 
on to develop clinical type 2 diabetes. An increased risk for cardiovascular 
disease occurs in the latter two groups even though there is no progression 
to diabetes. The implementation of treatment strategies to lower postprandial 
hyperglycaemia has been recommended by the IDF guidelines. A previous 
proof of concept study demonstrated that treatment with buccal spray insu-
lin (Oral-lyn™) can be a valuable tool for managing subjects with IGT. Thus, 
treatment with 12 puffs was followed by a significant 29.6% decrease in mean 
plasma glucose at two-hours and a 26.8% decrease at three-hours Consider-
ing all time points OGTT, there was a mean reduction of 15.8% in mean 
plasma glucose following buccal spray insulin. No hypoglycaemia episodes 
were recorded. The aim of this study was to evaluate the effect of Oral-lyn™ 
on metabolic and immunological parameters in subjects affected by IGT who 
were exposed to long term treatment with this insulin formulation.
Material and Methods: We have designed a randomized controlled trial in 
36 subjects with IGT comparing buccal spray insulin (12 puffs per meal) plus 
physical exercise and diet vs. physical exercise and diet only (control group). 
Primary endpoint is the reduction of HbA1c of 0.3 % at 6 month treatment 
between the experimental vs control group. Secondary endpoints include the 
evaluation of production of antibodies against insulin (IA), glucose variabil-
ity (measured with continuous glucose monitoring), changes in body weight, 
number of hypoglycemic events after buccal spray insulin treatment. Insuiln 
antibodies were measured using a DASP recognized assay.
Results: Subjects enrolled in the treatment group did not suffer of hypogly-
caemia episodes. IA were negative at entry into the study in IGT subjects and 
treatment with buccal spray insulin did not induce generation of IA .
Conclusion: Our preliminary data show that subjects treated with buccal 
spray insulin do not develop autoimmunity vs insulin as usually occurs with 
subcutaneous or other forms of insulin delivery (pulmonary). This may rep-
resent an additional benefit of buccal insulin, considering also the more ac-
ceptable route of administration.
Supported by: Generex
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Clinical performance of the insulin infusion set InsuPatch that applies 
local heat to the infusion site
G. Freckmann1, A. Westhoff1, S. Pleus1, N. Jendrike1, E. Zschornack1,  
C. Haug1, L. Krinelke2; 
1Institute for Diabetes-Technology GmbH at the University of Ulm, 
Germany, 2Roche Diabetes Care AG, Burgdorf, Switzerland.
Background and aims: The importance of good glycemic control in thera-
py of people with type 1 diabetes is well known. Using rapid acting insulin 
analogues, early postprandial hyperglycemias and late postprandial hypogly-
cemias are still common. In this study, the effect of the local skin heating 
device InsuPatch on postprandial blood glucose levels after differently com-
posed meals was investigated.
Materials and methods: Twenty-four type 1 diabetic subjects on CSII (10 
male, 14 female, age: 43.5±11.3 years, diabetes duration 18.3±10.5 years, 
HbA1c 7.4±0.8%, daily insulin need 0.58±0.15 U/kg/d, BMI 25.0±3.0 kg/
m2 [mean ± SD]) were included in this study. With data from an intensive 
monitoring phase of five days, the therapy parameters were optimized. Dur-
ing a clinical visit, subjects had standardized meals on four days, with the 
InsuPatch device heating on two days. Two pairs of breakfast meals (65% 
carbohydrates, 15% protein, 20% fat) and two pairs of dinner meals (40% car-
bohydrates, 20% protein, 40% fat) were obtained for evaluation. The impact 
of local skin heating on insulin absorption was measured using the normal-
ized AUC 0-120 min above baseline blood glucose (BG).
Results: A total of 42 breakfast meal pairs and 38 dinner meal pairs were us-
able for the analysis. A significant difference between heated and not heated 
InsuPatch was found for the normalized AUC 0-120 min. The difference 
for dinner meals (p<0.005; AUC 0-120 for BG above baseline not heated 
30.8±31.0 mg/dl, heated 18.4±23.9 mg/dl), representing slowly resorbed 
meals, was stronger than for breakfast meals, representing fast resorbed meals 
(p<0.05, AUC 0-120 for BG above baseline not heated 66.4±32.8 mg/dl, heat-
ed 56.8±34.0 mg/dl). The BG level above baseline 90 minutes after the meal 
was significantly lower with heated InsuPatch device especially after dinner 
meals (p<0.001, BG90 above baseline not heated 41.1±47.9 mg/dl, heated 
25.1±37.2 mg/dl). The AUC 0-60 minutes for the venous insulin concentra-
tion after breakfast was significantly larger with heated InsuPatch (p<0.001, 
AUC 0-60 for insulin concentration above baseline not heated 42.8±23.4 
mU/l, heated 53.1±28.8 mU/l). The number of hypoglycemic events showed 
no statistically significant difference.
Conclusion: This study shows that local heating of the skin around the infu-
sion site was significantly increasing early insulin levels post delivery as well 
as significantly reducing post-prandial blood glucose increase without caus-
ing more hypoglycemia. The device provides faster insulin action, however 
it has to be further evaluated to which extent the device is effective in daily 
life use.
Supported by: Roche Diagnostics GmbH
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Biocompatibility of the ultra-rapid insulin VIAject® with continuous 
insulin infusion sets 
F. Flacke1, P.B. Musholt2, A. Weise2, C. Schipper2, A. Krasner1, T. Forst2,  
S.S. Steiner1, A. Pfützner2; 
1Biodel, Inc., Danbury, USA, 2IKFE-Institute for Clinical Research & 
Development, Mainz, Germany.
Background and aims: Use of prandial insulins with a more rapid absorp-
tion profile would be expected to provide improved postprandial glucose 
control with lower risk of hypoglycemia during treatment with continuous 
subcutaneous insulin infusion. Viaject is a formulation of recombinant hu-
man insulin that has been shown to be more rapidly absorbed than insu-
lin lispro or regular insulin. The goal of this investigation was to explore the 
biocompatibility of VIAject with CSII infusion systems from several insulin 
pump manufacturers.
Materials and methods: Infusion sets used for the following insulin pumps 
were included into this investigation: (ACCUCHEK® Combo (Roche Diag-
nostics), Paradigm® 722 (Minimed-Medtronic), Animas® IR2020 (Animas, 
Johnson&Johnson), and Omnipod® (Insulet®). Three catheters (steel needle 
and/or Teflon catheter) of each product were tested. The pumps were filled 
with VIAject and emptied over 96 h at 37°C though the infusion systems. 
Samples of the delivered insulin product composition were collected after 
0, 1, 3 and 4 days. Determinations of insulin, its degradation products and 
high molecular weight proteins were performed by a USP-conform HPLC-
method.
Results: All mean insulin concentrations and by-product concentrations 
were in the acceptable ranges by USP specifications (insulin: 95-105 %, A21 
desamido insulin < 2 %, total contamination excl. A21 desamido insulin < 2 
%, high molecular weight products < 1.7 %). The results were similar to those 
of a reference sample of insulin VIAject stored in a glass vial under the same 
environmental conditions.
Conclusion: This investigation confirmed that VIAject is pharmacologically 
stable when delivered though clinically used infusion systems under the con-
ditions of CSII therapy. The pharmacological properties of VIAject appear 
suitable for pump use which can now be investigated in clinical trials.
Supported by: Biodel, Inc.
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A pocket instrument for calculating insulin need in the management of 
type 1 diabetes
A. Maurizi, A. Palermo, G. Beretta Anguissola, D. Benevento, A. Lauria,  
E. Cipponeri, D. Tuccinardi, S. Manfrini, P. Pozzilli; 
Campus Bio-Medico di Roma, Italy.
Background: Intensive insulin therapy is today the gold standard form of 
therapy in patients with type 1 diabetes. For achieving optimal metabolic 
control, adjustments of the insulin dose at meal times must be made before 
each injection by taking into account several parameters including blood glu-
cose levels, the insulin/carbohydrate ratio, the carbohydrate intake at each 
meal and the intensity of physical exercise post injection. A new tool recently 
developed for the establishment of the insulin dose to be administer (Cal-
sulin) takes into account all above parameters in a matter of seconds and 
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displays the insulin units to be injected. Aim of this randomised trial was to 
evaluate the efficacy of Calsulin on metabolic control as assessed by HbA1c in 
patients with type 1 diabetes undergoing intensive insulin therapy.
Material and methods: A total of 40 consecutive patients affected by type 
1 diabetes aged 18-65 years with disease duration > 1 year, were included in 
the study. HbA1c was evaluated at entry into the trial and at 3 and 6 months 
follow-up. Patients were randomised to Calsulin or standard education for 
insulin treatment (control group). Paired t test (two tailed) and analysis of 
variance were used to evaluate differences in HbA1c at different time points.
Results: HbA1c at entry was 7.9% ± 1.0 (SD) in Calsulin treated group and 
7,8% ± 1.6 (SD) in control patients (p:NS). Already after 3 months follow-up 
there was a tendency for an improvement in HbA1c levels in the Calsulin 
treated group vs. control group (7.3% ± 0.5 vs. 7.7% ± 1.0, respectively, p:NS). 
Taking into account the 6 months period of observation, a statistically signifi-
cant reduction in HbA1c levels was observed in the Calsulin treated group vs. 
control group (-0.85% vs. -0.07% difference, respectively, p<0.05).
Conclusions: The results of this study showed that this simple pocket in-
strument of the size of a small calculator is an acceptable and practical tool 
to make the process of calculating the number of insulin units very simple 
and, most importantly, helps to improve metabolic control as shown by a sig-
nificant reduction of HbA1c levels compared to standard methods used for 
calculating the required insulin doses.
PS 90 Long-acting insulin analogues
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Insulin degludec: less pharmacodynamic variability than insulin glargine 
under steady state conditions
T. Heise1, L. Hermanski1, L. Nosek1, A. Feldmann1, S. Rasmussen2,  
T.K. Stryhn2, H. Haahr2; 
1Profil Institut für Stoffwechselforschung, Neuss, Germany, 2Novo Nordisk 
A/S, Søborg, Denmark.
Background and aims: Insulin degludec (IDeg) is a new generation basal 
insulin analogue with an ultra-long (>24-hour half-life) duration of action. 
We compared the pharmacodynamic (PD) variability of IDeg and insulin 
glargine (IGlar) under steady-state conditions.
Materials and methods: In this randomised, double-blind, parallel-group 
study, 54 subjects with type 1 diabetes (48 male, 6 female, age 38±10 years 
(mean±SD), HbA1c 7.7±0.9%, BMI 24.6±2.2 kg/m²) received 0.4 U/kg of ei-
ther IDeg or IGlar once daily for 12 days. On treatment days 6, 9 and 12 PD-
profiles were investigated over 24h with the euglycaemic glucose clamp tech-
nique (Biostator, pre-dose blood glucose (BG) stabilisation at the clamp level 
of 5.5 mmol/l with iv insulin that was stopped post-dose when BG decreased 
by 0.3 mmol/l and when glucose infusion was initiated). Within-subject vari-
ability (expressed as coefficient of variation - CV) was estimated using a lin-
ear mixed model on log-transformed PD endpoints. All PD endpoints were 
derived from the glucose infusion rate (GIR) profiles during the clamps.
Results: IDeg produced significantly less overall PD variability than IGlar 
between days 6, 9 and 12 on all protocol-specified PD variability parameters 
including total metabolic effect (AUC-GIR0-24h, CV 20 vs. 82%, p<0.0001), the 
effect in the last 22 hours (AUC-GIR2-24h (not influenced by iv insulin dur-
ing the clamp), CV 22 vs. 92%, p<0.0001) and the maximum effect (GIRmax, 
CV 18 vs. 60%, p<0.0001). Total metabolic effect (AUC-GIR0-24h) tended to 
be higher with IDeg than with IGlar (geometric mean 2618 vs 1953 mg/kg, 
ratio 134%). The individual within-subject variability was consistently lower 
for IDeg compared with IGlar when the individual CVs were compared in a 
ranked order (figure). IDeg’s metabolic effect was exactly evenly distributed 
between the first and the second twelve hours (ratio of AUC-GIR0-12h/AUC-
GIR0-24h geometric mean: 0.50 vs. 0.57 with IGlar) and this distribution was 
also less variable than with IGlar (CV 10 vs 17%, p<0.001). Both insulin for-
mulations were well tolerated. No serious adverse events occurred. In total, 
166 (20 nocturnal) hypoglycaemic episodes, defined as BG < 2.8 mmol/l with 
or without hypoglycaemic symptoms, were observed with IDeg compared 
with 182 (37 nocturnal) episodes with IGlar. There were no severe hypogly-
caemic episodes in this study. No injection site reactions occurred with either 
insulin.
Conclusion: Under steady-state conditions after once daily administration, 
the effect of the novel basal insulin analogue insulin degludec is evenly dis-
tributed over each 24 h period and significantly less variable than that of insu-
lin glargine. The results suggest a less variable and more stable glucose-lower-
ing insulin effect for IDeg compared with IGlar.
Figure: Individual within-subject variability in AUC-GIR0-24h for IDeg and 
GLA
Supported by: Novo Nordisk A/S
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Insulin degludec: multi-hexamer formation is the underlying basis for 
this new generation ultra-long acting basal insulin
I. Jonassen1, S. Havelund1, U. Ribel1, T. Hoeg-Jensen1, D.B. Steensgaard1,  
T. Johansen2, H. Haahr2, E. Nishimura1, P. Kurtzhals1; 
1Diabetes Research Unit, Novo Nordisk A/S, Maaleov, 2Global Development, 
Novo Nordisk A/S, Soeborg, Denmark.
Background and aims: Insulin degludec is a new generation ultra-long act-
ing basal insulin analogue in clinical development. The insulin degludec mol-
ecule retains the human insulin amino acid sequence except for the deletion 
of ThrB30 and the addition of a 16-carbon fatty diacid attached to LysB29 
via a glutamic acid spacer. It is well established that absorption rate from 
subcutaneous tissue is determined by molecular size. Therefore the aim of 
this study was to demonstrate that under in vitro conditions mimicking the 
physiological injection site, insulin degludec self-associates to form large 
multi-hexamer assemblies and that this ultimately results in an ultra-long 
and peak-less pharmacokinetic profile when administered to people with 
type 1 diabetes.
Materials and methods: Size exclusion chromatography (SEC) experiments 
were performed to characterise the molecular size of self-assembled units of 
insulin degludec, in particular, hexamers, di-hexamers and multi-hexam-
ers. Various pharmaceutical formulations containing zinc ions, phenol and 
m-cresol were examined by SEC analysis to simulate conditions before and 
after sub-cutaneous injection. To examine the pharmacokinetic (PK) profile 
of insulin degludec, a clinical pharmacology study was conducted in subjects 
(n=12) with type 1 diabetes. The steady state PK profile (24 hour) was deter-
mined after 6 consecutive days of once daily dosing with insulin degludec 
(5.0 nmol/kg).
Results: SEC analysis demonstrated that insulin degludec forms di-hexamers 
in the presence of phenol and m-cresol. To mimic a subcutaneous injection, 
further SEC analysis was conducted in the absence of phenol and m-cresol 
and it was revealed that there occurs a reorganisation from di-hexamers to 
multi-hexamer assemblies which remain in solution at physiological pH. In 
the clinical pharmacology study where insulin degludec was administered 
to subjects with type 1 diabetes, the steady-state PK profile demonstrated a 
smooth and stable exposure over 24 hours (see figure). Insulin degludec was 
found to have a t½ longer than 24 hours and was detectable in circulation for 
at least 96 hours after the final injection.
Conclusion: In summary, insulin degludec is a new generation soluble basal 
insulin with an ultra-long, peak-less pharmacokinetic profile attributed to 
multi-hexamer formation and slow release of insulin degludec monomers. 
Insulin degludec has the potential to address major challenges in diabetes 
care such as hypoglycaemia as well as compliance by providing more flexible 
dosing schedules.
Supported by: Novo Nordisk A/S
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Insulin deglucec, a new generation ultra-long acting insulin, in a 
mealtime + basal regimen in people with type 1 diabetes: comparison to 
insulin glargine
L. Meneghini1, P. Home2, J.H. DeVries3, J. Jendle4, L. Endahl5, K. Lyby5,  
T. Johansen5, A. Roberts6, R. Ratner7, U. Wendisch8, K.I. Birkeland9; 
1University of Miami School of Medicine, USA, 2Newcastle University, 
United Kingdom, 3University of Amsterdam, Netherlands, 4Örebro 
University Hospital, Sweden, 5Novo Nordisk A/S, Soeborg, Denmark, 6Royal 
Adelaide Hospital, Australia, 7MedStar Research Institute, Washington, 
USA, 8Gemeinschaftspraxis für Innere Medizin und Diabetologie, Hamburg, 
Germany, 9Oslo University Hospital, Norway.
Background and aims: Insulin degludec (IDeg) is a novel insulin analogue 
that forms soluble multi-hexamer assemblies after subcutaneous injection 
(s.c.), resulting in ultra-long duration of action. This phase 2, 16-week, open-
label, randomised, three-arm, parallel-group trial investigated the efficacy 
and safety of candidate formulations of IDeg in people with type 1 diabetes.
Materials and methods: Participants (mean age 45.8 years, HbA1c 8.4 %, fast-
ing plasma glucose (FPG) 9.9 mmol/l, BMI 26.9 kg/m2) injected (s.c.) IDeg 
(n=59), an alternative formulation of IDeg (development discontinued, data 
not shown; n=60) or insulin glargine (IGlar; n=59) once daily in the evening, 
combined with meal-time insulin aspart. Basal insulin was titrated to achieve 
FPG 4.0-6.0 mmol/l.
Results: At 16 weeks, mean HbA1c was comparable (IDeg 7.8%, IGlar 7.6%; 
estimated treatment difference = 0.1% (SE 0.1%)), as was FPG (IDeg 8.3 
mmol/l, IGlar 8.9 mmol/l; estimated treatment difference = -0.6 mmol/l (SE 
0.7 mmol/l)). At end-of-trial, mean total daily insulin dose was comparable 
to baseline (IDeg 60 U/day; IGlar 51 U/day), with minimal increases in mean 
basal insulin dose for both IDeg (from 29 to 30 U/day) and IGlar (from 23 
to 26 U/day). The rate of confirmed hypoglycaemia (plasma glucose < 3.1 
mmol/l or requiring assistance) was 28% lower for IDeg compared to IGlar 
(47.9 vs. 66.2 events/patient year; relative rate = 0.72 (95% CI: 0.52; 1.00)). 
The overall rate of confirmed nocturnal hypoglycaemia was 58% lower for 
IDeg compared with IGlar (5.1 vs. 12.3 events/patient year; relative rate = 
0.42 (0.25; 0.69)). Very few severe hypoglycaemic events were reported for 
IDeg and IGlar (7 vs. 6 events). The overall rate of adverse events was similar 
between basal insulins, with no specific pattern or clustering. No injection 
site reactions were observed.
Conclusion: In this proof-of-concept trial, IDeg was safe and well-tolerated 
and provided comparable glycaemic control to IGlar at similar doses, with a 
reduced rate of confirmed hypoglycaemia.
Supported by: Novo Nordisk A/S
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Insulin degludec: a new ultra-long, basal insulin designed to maintain 
full metabolic effect while minimizing mitogenic potential
E. Nishimura, A.R. Sørensen, B.F. Hansen, C.E. Stidsen, G.S. Olsen,  
L. Schäffer, C. Bonnesen, A.C. Hegelund, A. Lundby, I. Jonassen; 
Diabetes Research Unit, Novo Nordisk A/S, Maaleov, Denmark.
Background and aims: Insulin degludec (IDeg) is a new generation basal 
insulin analogue in clinical development, designed to allow the formation of 
soluble multi-hexamer assemblies upon subcutaneous injection to give an ul-
tra-long peak-less pharmacokinetic profile. The aim of the present study was 
to investigate the metabolic responses and molecular safety (IGF-1 receptor 
affinity and in vitro mitogenicity) of IDeg.
Materials and methods: Insulin and IGF-1 receptor binding studies were 
conducted using recombinant human insulin receptors (both isoforms, hIR-
A and hIR-B) and human IGF-1 receptors. Scintillation proximity assays us-
ing solubilised receptors from transfected BHK cells were conducted in the 
absence of albumin. Receptor kinetic studies were conducted using intact 
BHK cells expressing the hIR-A. The mitogenic effect of insulin degludec was 
determined by measuring 3H-thymidine incorporation into L6 myoblasts ex-
pressing HIRs (L6-HIR), primary human mammary epithelial cells (HMEC) 
as well as COLO-205 and MCF-7cell lines (from human colon and mam-
mary adenocarcinomas, respectively). The metabolic effects of IDeg were 
determined by: (1) lipogenesis in rat adipocytes (3H-glucose into lipid), (2) 
glycogen accumulation in rat hepatocytes and (3) glycogen synthesis in rat 
skeletal muscle cells, L6-HIR and MCF-7 cells (14C-glucose into glycogen).
Results: The affinity of IDeg for both human insulin receptor isoforms (HIR-
A and - B) was found to be similar (13% and 15% relative to human insulin, 
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HI) while the affinity for the human IGF-1 receptor was lower (2% relative 
to HI). The kinetics of IDeg binding to the hIRA was not significantly differ-
ent from that of HI. The mitogenic response measured in L6-HIR, HMEC, 
COLO-205 and MCF-7 cells, in the absence of alubmin, ranged from 4-14% 
relative to HI. IDeg elicited the same metabolic responses and same maximal 
effect as HI: lipogenesis in rat adipoctes, glycogen accumulation in rat hepa-
tocytes and glycogen synthesis in rat muscle cells. Furthermore, in cellular 
assays where no albumin was added (hepatocytes and MCF-7 cells), the in 
vitro metabolic potency was determined to be in the range of 8-20% resulting 
in a mitogenic/metabolic potency ratio of ≤1.
Conclusion: In summary, insulin degludec is a full agonist at the insulin receptor 
and maintains the metabolic responses of HI. This is in agreement with phase 2 
trial results, where IDeg gave comparable glycaemic control as insulin glargine at 
similar molar and unit doses in subjects with type 1 or 2 diabetes. The low IGF-1 
receptor binding affinity and the low mitogenic/metabolic potency ratio indicate 
that the modifications made to IDeg do not compromise molecular safety.
Supported by: Novo Nordisk A/S
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Once-daily use of a new generation ultra-long acting basal insulin with 
a bolus boost in insulin-naïve people with type 2 diabetes: comparison 
with insulin glargine
R. Cuddihy1, C.J. Tack2, T. Heise3, J. Davidson4, D. Gouet5, A. Liebl6,  
E. Romero7, H. Mersebach8, P. Dykiel8, R. Jorde9; 
1International Diabetes Center, Minneapolis, USA, 2Radboud 
University Nijmegen Medical Centre, Netherlands, 3Profil Institut für 
Stoffwechselforschung, Neuss, Germany, 4Southwestern Medical School, 
Dallas, USA, 5Hôpital Saint Louis, La Rochelle, France, 6Center for Diabetes 
and Metabolism, Bad Heilbrunn, Germany, 7Instituto de Endocrinologia, 
UVA, Valladolid, Spain, 8Novo Nordisk A/S, Soeborg, Denmark, 9University 
of Tromsø, Norway.
Background and aims: Insulin degludec (IDeg) is a novel insulin analogue 
that forms soluble multi-hexamer assemblies after subcutaneous injection, re-
sulting in ultra-long duration of action. IDegAsp is a soluble insulin product 
comprising IDeg (70%) and insulin aspart (IAsp, 30%). The aim of this phase 
2, 16-week, open-label, randomised, parallel-group, treat-to-target trial was 
to investigate the safety and efficacy of IDegAsp in insulin-naïve people with 
type 2 diabetes inadequately controlled on oral antidiabetic drugs.
Materials and methods: Subjects (mean: 59.1 yrs, HbA1c 8.5%, fasting plasma 
glucose (FPG) 11.6 mmol/l, BMI 30.3 kg/m2) received once-daily IDegAsp 
(n=59), an alternative formulation of IDegAsp (AF: 55% IDeg and 45% IAsp; 
n=59) or insulin glargine (IGlar; n=60), all in combination with metformin, 
for 16 weeks. Insulin was dosed (s.c.) before dinner and titrated to a FPG 
target of 4.0-6.0 mmol/l. At the end of the 16-week treatment period, patients 
underwent a 72-h continuous glucose measurement (CGM).
Results: After 16 weeks, mean HbA1c decreased from baseline in all treatment 
groups (IDegAsp: -1.31%; AF: -1.46%; IGlar: -1.29%) to comparable end-of-trial 
values (IDegAsp: 7.0%; AF: 7.2%; IGlar: 7.1%; p=NS for all pairwise compari-
sons). A similar proportion of subjects achieved HbA1c<7.0% without confirmed 
hypoglycaemia in the last 4 weeks of treatment (IDegAsp: 51%; AF: 47%; IGlar: 
50%). Mean self-measured 2-h post-dinner PG increment was lower for IDegAsp 
(0.13 mmol/l) and AF (0.24 mmol/l) than IGlar (1.63 mmol/l). These findings 
were mirrored by mean 2-h post-dinner interstitial glucose (IG) increments de-
termined by CGM. The mean total time spent in hyperglycaemia (IG>12 mmol/
l) per day tended to be lower for IDegAsp (2.2 h) and AF (2.2 h) compared to 
IGlar (2.7 h). Mean FPG was similar across treatments (IDegAsp: 6.8 mmol/l; 
AF: 7.4 mmol/l; IGlar: 7.0 mmol/l). At end-of-trial, mean daily insulin doses were 
lower for IDegAsp (0.38 U/kg) and AF (0.36 U/kg) than IGlar (0.45 U/kg).
No severe hypoglycaemic events were reported. Rates of confirmed hypogly-
caemia (PG<3.1 mmol/l) were lower for IDegAsp and IGlar than AF (1.2, 
0.7 and 2.4 events/patient year). The proportion of subjects having at least 
one episode of near-hypoglycaemia (IG<3.5 mmol/l) over the course of a 72-
h CGM was similar amongst groups (IDegAsp: 46%; AF: 44%; IGlar: 54%). 
Very few confirmed nocturnal hypoglycaemic events were reported for IDe-
gAsp (1 subject; 1 event) and IGlar (3 subjects; 3 events) compared to AF (10 
subjects; 27 events). Adverse events with a possible or probable relation to 
insulin were only reported for AF (5 subjects; 5 events). 
Conclusion: This proof-of-concept trial showed once-daily IDegAsp to be 
safe, well tolerated and effective. IDegAsp provided comparable overall gly-
cemic control to IGlar at similar rates of hypoglycaemia, with the additional 
benefit of post-dinner PG control.
Supported by: Novo Nordisk A/S
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Efficacy and goal attainment with insulin glargine vs comparators
M.A. Banerji1, M. Baron2, L. Blonde3; 
1SUNY Downstate Medical Center, Brooklyn, 2sanofi-aventis US, 
Bridgewater, 3Ochsner Medical Center, New Orleans, USA.
Background and aims: Clinicians have many type 2 diabetes (T2DM) treat-
ment options. We evaluated patient level data from similar prospective, rand-
omized, controlled studies to assess the likelihood of achieving glycemic con-
trol after 24 weeks of insulin glargine (GLAR) vs comparators (C) by baseline 
glycated hemoglobin A1C (A1C) category (<8.0%, 8.0% to <9.0%, 9.0% to 
<10.0%, and ≥10.0%).
Materials and methods: Data were pooled from 9 similar studies (N=2938) 
meeting the following criteria: included insulin-naive patients with T2DM, 
uncontrolled on oral antidiabetic drugs (OADs), randomized to addition of 
GLAR (n=1462) or C (OADs, NPH, lispro, or premix; n=1476) and utilized 
similar insulin titration algorithms.
Results: Groups were comparable at baseline (56% male, 83.5% white, mean 
age 57 y, diabetes duration 8.6 y, A1C 8.7%, body mass index 31.6 kg/m2). 
A1C reductions at week 24 were greater with GLAR vs all C (-1.68 and -
1.51%, P<0.001); and when evaluated vs specific comparators, reductions 
were greater with GLAR vs OADs and vs. premixed insulin, but similar to 
NPH and lispro. Proportions of patients achieving ≥1.0% reduction in A1C 
and achieving A1C ≤7.0% were greater with GLAR vs all C, and vs OADs 
(Table). The comparisons vs specific insulins failed to reach significance. 
When stratified by baseline A1C category, A1C improvements were simi-
lar between GLAR and OADs if A1C <8.0% but greater with GLAR if A1C 
≥8.0%; similar between GLAR and other insulin C for all categories except 
a greater reduction if <8.0% vs premixed insulin. Hypoglycemia event rates 
were significantly lower for GLAR vs NPH, lispro, and premixed insulin, and 
higher for GLAR vs OADs (Table). Severe hypoglycemia was lower for GLAR 
than premixed insulin (0.02 vs 0.08 events\patient\year, P< 0.05), and not 
different between GLAR and OADs, NPH, or lispro. Changes in weight were 
similar between GLAR and any C. Incidence of edema was higher with OADs 
than GLAR, largely as the result of 2 trials in which the OAD comparator was 
a thiazolidinedione.
Conclusion: Initiating GLAR in patients uncontrolled on OADs was associ-
ated with better efficacy and goal attainment overall, vs C across the A1C 
continuum, and compared with OADs when baseline A1C was ≥8.0%. Ef-
ficacy across A1C categories was similar for insulin comparators; however, 
hypoglycemia rates were lower with GLAR.
Supported by: sanofi-aventis, US
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Improved glycaemic controls for patients on twice daily dosing regime of 
insulin glargine compared to those on a once daily dosing regime
K. Dhatariya1, J. Yeong2; 
1Elsie Bertram Diabetes Centre, Norfolk and Norwich University Hospital 
NHS Trust, 2School of Medicine, Health Policy and Practice, Norwich, 
United Kingdom.
Background and aims: Insulin glargine is a long acting once-daily insulin 
formulation, which is used to achieve glycemic control in patients with type 
1 or type 2 diabetes mellitus. It is unclear whether better glycaemic control, 
in terms of HbA1C, is achieved with twice daily dosing of insulin glargine 
compared to once daily adminstration.
Materials and methods: We conducted a retrospective case note analysis to 
evaluate whether there is any change in HbA1C values among type 1 or type 
2 diabetic patients after switching from a once-daily to twice daily insulin 
glargine regime. Data was collected as a part of a local service evaulation on 
diabetes care using patient notes and database laboratory results.
Results: A total of 206 patients were included with 38% on once daily insulin 
glargine (n=78) and 62% on twice daily insulin glargine (n=128). Of the 128 
patients using a twice daily insulin glargine dosing regime, we found that 
switching from previous insulin therapy to once daily insulin glargine was 
associated with a average decrease in HbA1C of 0.27% (3 mmol.mol) and there 
was a further decrease of 0.49% (5.4 mmol/mol) when the insulin glargine 
was changed to a twice daily dosing regime. This decrease was further evident 
when starting HbA1C was greater than 9%.
Conclusion: Our data suggests that patients on a one daily dosing regime of 
insulin glargine may benefit from reduction in HbA1C levels by switching to a 
twice-daily insulin glargine regime.
978
MAGE revisited: Evaluation of glucose variability with once daily 
glargine vs NPH insulin in type 2 diabetes
G. Silvani, S. Acquati, R. Manini, C. Ragazzini, S. Taroni, F. Donadio,  
L. Buci, L. Gagliardi, A. Tartaglia, M. Nizzoli; 
Endocrinology, G.B. Morgagni - L. Pierantoni Hospital, Forlì, Italy.
Background and aims: Insulin combination regimens, i.e. a single bedtime 
injection of long-acting insulin added to oral anti-hyperglycaemic agents, are 
widely used in the secondary failure treatment of type 2 diabetes (t2DM); 
however most basal insulin formulations do not provide a constant and reli-
able 24-h insulin supply and are associated with an high risk of nocturnal or 
early morning hypoglycaemia. Aim of this perspective study was to evalu-
ate the efficacy and safety of once daily glargine vs NPH insulin on glucose 
control and variability, expressed by Service’s MAGE (Mean Amplitude of 
Glycaemic Excursions), in combination therapy of t2DM.
Materials and methods: In 40 t2DM patients, aged 62.5±8.3, overweight 
(BMI 29.1±6.0 kg/sq.m)and in a poor glycaemic control (HbA1c 9.1±1.2%)on 
a combination treatment with once daily bedtime NPH insulin 0.21±0.07 
IU/kg/day and oral agents, sulphonylureas and metformin, after a 2-weeks 
run-in-period NPH was replaced by the same dose of glargine at the same 
time while oral agents were unchanged. Body weight, HbA1c and fasting C-
peptide were evaluated at baseline and after 6 weeks during which, as well as 
in 2-weeks run-in-period, the patients provided a weekly self-monitored 6-
points blood glucose profile (before and 2 h after breakfast, lunch and dinner) 
and recorded daily any hypoglycarmic episode. The mean glucose values of 
self-monitored profiles in run-in-period were compared point by point with 
the glargine treatment last 2 weeks profiles and MAGE was calculated.
Results: After glargine 6-weeks treatment body weight (as BMI) and C-pep-
tide levels were unchanged; a slight but not significant decrease was observed 
in HbA1c (8.8±1.4 p=0.052); only fasting blood glucose (p=0.042)and 2-h 
post-breakfast glucose (p=0.028)significantly decreased while MAGE reached 
a more significant difference (71.4±15.6 vs 92.3±16.5 mg/dl p<0.001); more-
over on glargine treatment the percentage of symptomatic hypoglycaemias 
was significantly lower (- 39.5% p=0.012).
Conclusion: Glargine insulin instead of NPH did not improve the short-term 
glycaemic control in combination therapy of t2DM patients:only two mean 
glucose levels significantly decreased in the six-points self-monitored profile 
while decrease of HbA1c was not significant. On the contrary glargine treat-
ment was effective to reduce glucose variability, according to highly signifi-
cant decrease of MAGE, and to lower the frequency and seriousness of hypo-
glycaemic episodes. In a blind post-study interview with DTSQ 29 patients 
(72.5%) declared an improvement of well-being, likely due to the lesser extent 
of glycaemic excursions.
979
Efficacy and safety of insulin lispro protamine suspension versus insulin 
glargine added to oral antihyperglycaemic medications and exenatide in 
patients with type 2 diabetes
R.F. Arakaki1, T.C. Blevins2, D.R. Liljenquist3, J.K. Wise4, H.H. Jiang5,  
K.K. Schneider5, J.G. Jacobson5, S.A. Martin5, J.A. Jackson5; 
1University of Hawaii, Honolulu, 2Texas Diabetes and Endocrinology, 
Austin, 3Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls, 
4Diabetes and Metabolism Assoc, Metairie, 5Eli Lilly and Co, Indianapolis, 
USA.
Background and aims: Patients (pts) with type 2 diabetes (T2D) on oral anti-
hyperglycaemic medications (OAMs) and exenatide (Ex) may encounter pro-
gressive metabolic deterioration requiring additional treatment. Intensifica-
tion of therapy with insulin added to OAM(s) plus Ex has not been previously 
reported. The primary aim of this study was to determine if insulin lispro prot-
amine suspension (ILPS) is noninferior to glargine (G) in change in HbA1c 
when added to OAMs plus Ex in adults with suboptimally controlled T2D.
Materials and Methods: This open-label, multicenter, randomised, 24-week 
clinical trial enrolled pts with T2D (BMI ≤45 kg/m2, HbA1c ≥7.0% and ≤10%) 
who had been treated ≥3 months with 1 or 2 OAMs (metformin ± sulphonyl-
urea or pioglitazone) and Ex (10 μg twice-daily). Pts were randomly assigned 
to receive either ILPS (n=171) or G (n=168) at bedtime added to pre-study 
OAM(s) and Ex. Insulin was titrated from 6 units daily, using dosing algo-
rithms to achieve fasting plasma glucose (FPG) targets 4.4-5.5 mmol/l for 
ILPS and 4.1-5.5 mmol/l for G. Statistical analysis was performed based on 
intent-to-treat population using last observation carried forward method. 
Prespecified noninferiority margin was 0.4%.
Results: Baseline demographics (age 56 years; T2D duration 9.9 years; 
weight 102 kg; BMI 34.9 kg/m2) and disease characteristics (table) were 
similar across treatment groups. At 24-week endpoint (table), least squares 
mean difference in HbA1c change between treatment groups (ILPS minus G) 
was 0.22% (95% CI: 0.06 to 0.38), demonstrating noninferiority of ILPS to 
G. However, mean reduction in HbA1c was statistically less for ILPS-treated 
patients than G-treated pts. Percentage of pts who achieved HbA1c <7.0% was 
not significantly different between treatment groups. Endpoint FPG was sim-
ilar between treatment groups. Insulin dose was lower for ILPS vs G. Overall 
and severe hypoglycemic rates were similar in both groups but nocturnal hy-
poglycaemia rate was higher in ILPS- vs G-treated pts. Weight gain, <1 kg, 
was similar between treatments. Serious adverse events were infrequent and 
similar between groups.
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Conclusion: ILPS is noninferior to G for change in HbA1c. Compared to G, 
ILPS-treated pts had higher nocturnal hypoglycaemia rates, but similarly low 
overall and severe hypoglycaemia and minimal weight gain over the 24-week 
study duration. This is the first study demonstrating that addition of ILPS or 
G as treat-to-target basal insulin is an effective option for improving glycae-
mic control in pts with suboptimally controlled T2D treated with OAM(s) 
and Ex. 
ILPS
(n=171)
Glargine 
(n=168) p-value
Baseline HbA1c (%) 8.20 ± 0.77 8.23 ± 0.80 0.888
Endpoint HbA1c (%) 7.04 ± 0.81 6.83 ± 0.78 0.008
HbA1c change (%) -1.16 ± 0.84 -1.40 ± 0.97 0.008
Pts achieving HbA1c<7.0% (n [%]) 87 (53.7%) 100 (61.7%) 0.177
Baseline FPG (mmol/l) 9.74 ± 2.19 10.04 ± 2.16 0.231
Endpoint FPG (mmol/l) 7.20 ± 1.75 7.05 ± 1.61 0.179
Insulin dose (IU) 31.1 ± 18.9 37.9 ± 18.5 <0.001
Insulin dose (IU/kg) 0.30 ± 0.17 0.37 ± 0.17 <0.001
Overall hypoglycaemia rate  
(episodes/pt/yr)
16.27 ± 23.19 18.05 ± 24.59 0.570
Nocturnal hypoglycaemia rate 
(episodes/pt/yr)
4.88 ± 8.43 3.01 ± 7.21 0.004
Severe hypoglycaemia incidence  
(n [%])
3 (1.8%) 0 0.249
Baseline Weight (kg) 101.6 ± 18.7 102.3 ± 19.7 0.718
Weight gain (kg) 0.27 ± 3.38 0.66 ± 3.93 0.343
Patients with ≥1 serious adverse 
event (n[%])
9 (5.3%) 5 (3.0%) 0.414
Values are presented at mean ± standard deviation unless otherwise 
noted
Supported by: Eli Lilly and Company
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Basal insulin NPH, glargine and detemir in type 2 diabetes: 
hepatospecificity, effects on glucose and lipid metabolism, and pancreatic 
islet alpha and beta cell rest: a PK-PD study
P. Lucidi, P. Rossetti, F. Porcellati, P. Candeloro, P. Cioli, S. Marzotti,  
A. Marinelli Andreoli, R. Fede, G.B. Bolli, C.G. Fanelli; 
Internal Medicine, University of Perugia, Italy.
Background and aims: To compare pharmacokinetics (PK) and pharmaco-
dynamics (PD) of insulins NPH, glargine (Gla) and detemir (Det).
Materials and methods: 18 persons with type 2 diabetes (age 60±7 yrs, known 
diabetes duration 12.8±7.5 yrs, BMI 29.1±3.2 kg/m2, A1C 7.5±0.6%, treat-
ment insulin+OHA) (mean±SD) were studied after 1-week treatment with 
either NPH, Gla or Det 1/day (at 10 pm). Plasma glucose (PG) was clamped 
at 100 mg/dl for 32 h after s.c. injection of 0.4 U/kg at 10 pm (randomized, 
single-blind, crossover study). The primary endpoint was the glucose infu-
sion rate (GIR) over 0-32 h (AUC0-32h).
Results: All 18 persons completed the Gla study, but 2 persons on NPH and 3 
on Det, interrupted the study because PG >150 mg/dl. The target PG was best 
achieved by Gla, followed by NPH and Det (102±2, 108±15, 108±14 mg/dl, 
p<0.05). However, PG increased overnight with NPH to a peak (119±18 mg/
dl) at 07.00 h (NPH vs Gla and Det, p<0.05). The GIR AUC0-32h was greater 
for Gla vs Det and NPH (1538±688, 1081±785, 1170±703 mg/Kg, p<0.05). 
Plasma insulin peaked with NPH at 05.00h and then decreased (peak 95±46, 
32h 44±24 pmol/l), whereas it decreased less with with Gla (peak at 07.00h 
108±42, 32h 61±30 pmol/l). Det (bound+free) had a plateau of ~1.800 pmol/l 
between 6-10 am followed by relatively faster decrease vs Gla. Gla suppressed 
endogenous glucose production more than NPH and Det (p<0.05), with no 
effect on glucose utilization. Glucagon was lower with Gla vs Det by 10% 
(p<0.05) likewise C-peptide with Gla vs Det and NPH (-17% and -12%) 
(p<0.05). FFA were higher with Det vs Gla by 22% and NPH by 15% (p<0.05) 
likewise ketones vs Gla (41%) and NPH (20%) (p<0.05).
Conclusion: All 3 basal insulins have similar hepato-specific effects, but there 
is no unit-to-unit equivalence on glucose-lipid metabolism. NPH is limited by 
nocturnal peak and decreased PK/PD at dawn. Det and Gla are superior to NPH 
for overnight-morning PG control, but Det is less potent than Gla and NPH in 
the afternoon. Each basal insulin should be used according to its PK/PD.
981
Mechanism for the differential effect of the long-acting insulin analog 
detemir on weight in patients with type 1 diabetes
S. Zachariah1, B. Sheldon1, F. Shojaee-Moradie2, N. Jackson2, K. Backhouse2, 
S. Johnsen3, M. Umpleby2, D. Russell-Jones1; 
1Diabetes and Endocrinology, Royal Surrey County Hospital, 2Diabetes and 
Endocrinology, Postgraduate Medical school, Guildford, 3Surrey Clinical 
Research Centre, Guildford, United Kingdom.
Background: The acylated long-acting insulin analog detemir appears to lack 
the usual propensity for insulin to cause weight gain. Possible mechanisms 
include insulin detemir’s predominant action on liver giving it a more physi-
ological profile as well as a direct and indirect effect on appetite. Elucidation 
of the mechanism(s) of weight sparing with insulin detemir could provide 
valuable insights into the cause of insulin induced weight gain.
Research, design and methods: A single-centre, 32 week, open-label ran-
domized crossover design trial was undertaken in 23 subjects (14 men, age 
36.8 ±10.6 years, BMI 28.0 ±3.6 kg/m2) (mean±SD) with type 1 diabetes. 
Patients on a basal-bolus regime (with insulin aspart as bolus insulin) were 
randomized to receive either insulin detemir or NPH insulin as basal insulin 
for 16 weeks, followed by a switch to the other basal insulin for 16 weeks. At 
the end of each 16 week period the following were measured: total energy 
expenditure (by double labelled water), resting energy expenditure and diet 
induced thermogenesis (by indirect calorimetry), activity energy expendi-
ture, (with an Actiheart monitor) and energy intake (by a 7 day food diary). 
Weight change, glycemic control, hypoglycemic episodes and hormones that 
affect satiety/fuel partitioning were also measured. Following a standard meal 
(600 kcals), serial measurements of GLP-1, ghrelin, pancreatic polypeptide 
and peptide YY were undertaken for 180 minutes. Statistical analysis was 
done using a general linear mixed model, and it was modified to include 
additionally a repeated measure effect for the times of measurement of the 
metabolic hormones.
Results: After 16 weeks of treatment, the weight change was -0.69 ± 1.85 
kg with insulin detemir and +1.7 ± 2.46 kg with NPH (p=0.0006).Total en-
ergy expenditure was not different with insulin detemir compared to NPH 
insulin (p=0.334) but total energy intake was significantly less with insu-
lin detemir (2016± 501 kcal/day) than NPH insulin (2181± 559 kcal/day) 
(p=0.026). There was no significant difference in HbA1c or the number of 
hypoglycemic episodes. Statistical modeling showed there was no relation-
ship between HbA1c or hypoglycemia and weight change. Leptin was sig-
nificantly lower with insulin detemir (9.45±7.29 ng/ml) compared to NPH 
insulin (10.83±9.15 ng/ml, p=0.039). Resistin was significantly higher with 
detemir compared to NPH insulin treatment (12.10±9.43 ng/ml vs. 9.28±4.13 
ng/ml, p=0.047). There was no difference in adiponectin and IGF-1. Follow-
ing the meal, ghrelin (610.9 pg/ml vs. 528.39 pg/ml, p=0.002) and pancre-
atic polypeptide (813.4 vs. 777.13 pg/ml, p=0.001) were significantly higher 
with insulin detemir compared to NPH treatment. There was no difference 
in GLP-1 and PYY levels.
Conclusion: Insulin detemir caused less weight gain in type 1 diabetes pa-
tients compared to NPH insulin. This study suggests this is due to reduced 
energy intake rather than an increase in energy expenditure. This may be 
mediated by a direct or indirect effect of insulin detemir on hormones that 
control satiety.
Supported by: Novo Nordisk
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PS 91 Body and soul: the 
psychological aspects of diabetes
982
Psychological distress predicts the development of the metabolic 
syndrome: a prospective, population-based study
P.J. Puustinen1, H. Koponen1, H. Kautiainen2,3, P. Mäntyselkä1,  
M. Vanhala1,2; 
1Institute of Public Health and Clinical Nutrition, University of Eastern 
Finland, Kuopio, 2Unit of Family Practice, Central Hospital of Middle 
Finland, Jyväskylä, 3ORTON, Rehabilitation Unit, Helsinki, Finland.
Background and aims: To prospectively examine the association of psycho-
logical distress with the development of metabolic syndrome (MetS) and the 
role of potential mediators (demographic characteristics, health behaviors 
and inflammation) in this association.
Materials and methods: A total of 466 (185 male and 281 female) subjects, 
aged 36 to 56 years and free of MetS at baseline, participated in a population-
based study from 1997-1998 and again from 2004-2005. Mean observation 
time was 6.4 years. Various clinical, biochemical and behavioral factors were 
measured at baseline, including assessment of psychological distress using 
the 12-item General Health Questionnaire (GHQ-12). The development of 
MetS was measured at follow-up based on National Cholesterol Education 
Program (NCEP) criteria.
Results: Subjects with high psychological distress at baseline (GHQ score 
4-12) were more than twice as likely to develop MetS than those with low 
psychological distress (OR 2.18, 95% CI 1.30 to 3.64). Adjustments for age 
and gender, health behaviors (smoking, alcohol use and leisure time physical 
activity) and C-reactive protein (CRP) in the analysis diminished the odds of 
developing MetS in the distressed group (OR 1.87, 1.82 and 1.80, respectively); 
however, the association remained statistically significant (p=0.022 - 0.037).
Conclusions: Psychological distress at baseline increases the risk of develop-
ing MetS during follow-up. This association remained robust after adjusting 
for age, gender, baseline health behaviors and CRP. These prospective find-
ings are evidence of a significant association between psychological distress 
and the development of MetS. Thus, effective treatment of psychological dis-
tress may reduce the incidence of MetS.
TABLE 1. Logistic Regression Models for the Metabolic Syndrome across 
Follow-up (Odds Ratios, 95% Confidence Intervals, p-values). Models In-
clude Psychological Distress, Age, Gender, Health Behaviors and C - reactive 
Protein. 
Model 1 = Psychological distress.
Model 2 = Psychological distress, age, gender.
Model 3 = Psychological distress, age, gender, smoking, use of alcohol, leisure 
time physical activity.
Model 4 = Psychological distress, age, gender, smoking, use of alcohol, leisure 
time physical activity, hsCRP.
GHQ-12 = 12-item General Health Questionnaire; hsCRP = high-sensitivity 
C-reactive protein
Leisure time physical activity (min. 30 minutes) = Low: < 1 time/week, Me-
dium: 1-3 times/week, High: >3 times/week
† Denominator (reference group) of following odds ratios
‡ p-value for linearity across the leisure time physical activity groups
983
A matched case-control study of depressive symptoms in type 2 diabetes
W.A. Davis1, M. Hunter2, K. Peters1, T.M.E. Davis1; 
1School of Medicine and Pharmacology, University of Western Australia, 
Fremantle, 2Busselton Health Study, University of Western Australia, 
Busselton, Australia.
Background and aims: Diabetes and depression are important co-morbid 
conditions. Patients with diabetes are 1.5-2 times more likely to have depres-
sion compared with people without diabetes, although this risk is attenuated 
after adjustment for age, sex and cardiovascular disease (CVD). Risk factors 
for depression include both clinical and personal factors, and there is some 
evidence that psychiatric conditions including depression are more common 
in rural vs. urban environments. We conducted an age- and sex-matched 
case-control study to elucidate the relationship between type 2 diabetes and 
depression in a rural setting.
Materials and methods: In 2009, residents of Busselton Shire in the south-
west of Western Australia who had been diagnosed with diabetes and ran-
domly selected age- and sex-matched normoglycaemic residents were invited 
for a comprehensive assessment. In addition to medical history, examination 
and biochemical testing, participants completed the Personal Health Ques-
tionnaire Depression Scale (PHQ-9). Paired tests were used to compare po-
tential associates of depression between cases and controls. Multiple logistic 
regression was used to determine independent associates of prevalent depres-
sion.
Results: We assessed 172 adults with type 2 diabetes and 172 controls. Half 
(51.2%) were male. Cases and controls did not differ significantly in age 
(70.7±10.4 vs. 71.0±10.0, P=0.80), but cases had significantly higher mean 
body mass index (BMI) than controls (30.4±5.3 vs. 27.0±4.0, P<0.001) and 
higher prevalence of self-reported CVD, exertional chest pain, and current 
smoking habit. Those with diabetes had median duration of 8.9 [5.0-14.3] 
years; 35.7% were diet-treated, 46.8% were on oral treatment and 17.5% were 
using insulin. Those with type 2 diabetes were significantly more likely to 
have a current major or any depressive syndrome compared with those with 
normoglycaemia (5.9% vs. 0.6%, P=0.012, and 11.8% vs. 4.1%, P=0.019, re-
spectively), but were no more likely to have been prescribed antidepressant 
therapy (11.6% vs. 12.6%, P=0.86). The majority (22/25 or 88.0%) of normo-
glycaemic subjects with any depressive syndrome and/or taking antidepres-
sants were being treated for depression compared with less than two-thirds 
(20/35 or 57.1%) of those with type 2 diabetes. BMI, current smoking habit 
and exertional chest pain but not diabetes status were independently associ-
ated with the presence of a) any depressive syndrome, and b) any depressive 
syndrome and/or antidepressant medication use. Age, sex, income, marital 
status, born overseas, education, alcohol intake, and self-reported CVD were 
also not associated with depression.
Conclusion: Depressive syndromes, especially major depression, were sig-
nificantly more prevalent in rural-dwelling Australian adults with type 2 
diabetes compared with age- and sex-matched normoglycaemic controls, but 
those with diabetes were less likely to be treated for depression. The higher 
prevalence of depressive syndrome in adults with type 2 diabetes compared 
with normoglycaemic adults may be explained largely by their significantly 
higher BMI.
Supported by: Perpetual Trustees
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Depression, glycaemic control, and physical activity in a multi-ethnic 
population screened for type 2 diabetes
L.V. Murray1, E.G. Wilmot1, M.J. Davies1, T. Yates1, K. Khunti2; 
1Cardiovascular Sciences, 2Health Sciences, University of Leicester, United 
Kingdom.
Background and aims: Individuals with type 2 diabetes mellitus (T2DM) 
suffer from higher levels of diagnosed depression and depressive symptoms 
compared to healthy controls. Evidence also exists for this relationship in in-
dividuals with impaired glucose regulation (IGR), defined as impaired fasting 
glucose (IFG) and/or impaired glucose tolerance (IGT). It is unclear whether 
this association is related to lifestyle factors such as physical activity (PA) 
or pathophysiological changes related to insulin resistance. Previous studies 
have shown an association between depression and PA levels, and individu-
als with T2DM and IGR are less physically active than healthy controls. We 
hypothesised that glucose regulation is associated with depression, independ-
ent of PA levels.
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Materials and methods: Participants were identified from general practices 
in Leicestershire (UK), using the Leicester Diabetes Risk Score. Individu-
als attended a baseline screening visit that involved questionnaires, blood 
samples and clinical assessment. Glucose status was assessed using the Oral 
Glucose Tolerance Test. Depression status was assessed using the Hospital 
Anxiety and Depression Scale (HADS). Participants wore a pedometer for a 
7 day period to objectively measure PA levels. SPSS v.16 was used to calculate 
means (± s.d.) and correlation coefficients. ANOVA and chi squared tests as-
sessed differences between groups.
Results: 926 individuals (38.4%female) were screened; 88.6% White Euro-
pean and 11.4% Black and Minority Ethnic. Mean age was 63 years (±8.3); 
25.7% had screen-detected IGR and 4.4% had screen-detected T2DM. Mild-
severe depression was detected in 9.6% of screened individuals and 17.8% 
reported a history of depressive illness. Mean steps per day was 6801 (±3202). 
Mild to severe depressive symptoms were more prevalent in individuals with 
screen-detected T2DM (19% vs. 12% with IGR vs. 9% with normal glucose 
tolerance (NGT), p < 0.05 for trend). Across the whole sample fasting glucose 
was weakly correlated with depression score when controlling for age, sex 
and ethnic origin (r = 0.087, p < 0.05), which was maintained after further 
controlling for PA levels (r = 0.083, p < 0.05). In addition, fasting glucose 
was higher in those with moderate-severe depressive symptoms, compared 
to those without depressive symptoms (mean difference = 0.48mmol/l, p = < 
0.05). No significant associations were found between depression score and 
2-hour glucose or HbA1c. In participants with screen-detected IGR, fasting 
glucose was more strongly correlated with depression score when controlled 
for age, sex and ethnic origin (r = 0.247, p = < 0.01), which was maintained 
after further controlling for PA levels (r = 0.269, p < 0.01). Those with IGR 
performed significantly less steps/day than individuals with NGT (mean dif-
ference = -850 steps, p < 0.01).
Conclusion: This study reveals a positive association between depression 
score and fasting glucose, independent of PA levels, in individuals that are 
unaware of their glycaemic status. This suggests that the higher levels of de-
pression seen in those with T2DM are not simply due to the impact of living 
with a chronic illness or to the low levels of PA seen in this group. We did 
not observe an association between depression score and 2-hour glucose or 
HbA1c, suggesting that the mechanisms underlying IFG may be more related 
to depression than those relating to IGT.
Supported by: NIHR and CLARHC
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Interaction between depressive symptoms and illness representations in 
predicting self-care behaviours in type 2 diabetic patients
M. Pibernik-Okanovic, D. Ajdukovic, Z. Metelko; 
Outpatient Clinic, Vuk Vrhovac Institute, Zagreb, Croatia.
Background and aims: Predictive value of illness representations including 
seriousness, treatment effectiveness and control, on multiple diabetes out-
comes has been well established. This study aimed to determine how depres-
sive symptoms interacted with personal model’s domains in predicting eating 
behaviour, physical activity, blood glucose self-monitoring and foot care in 
type 2 diabetic patients.
Materials and methods: A randomly selected sample of 172 type 2 outpatients 
(55% female, aged 63±8, educated for 10.5±4 yrs., with diabetes duration of 
10±8 yrs., 29% insulin-treated, with 6.5%±0.9 HbA1C and 30±4 kg/m2 BMI) 
was interviewed for psychological anamnesis and examined for depressive 
symptoms and personal model of diabetes. Respondents’ mood and illness 
representations were assessed by The Patient Health Questionnaire-Depres-
sion (PhQ-9) and the 8-item Personal Model of Diabetes Questionnaire (PM), 
and their self-care behaviours were approximated by the Summary of Diabe-
tes Self-Care Activities (SDSCA). Participants were divided into three groups: 
without depressive symptoms (PhQ<5), with minimal symptoms (PhQ=5-9) 
and with moderate to severe depressive symptoms (PhQ≥10), which were 
compared as to personal model, self-reported self-care and disease-related 
characteristics. Kruskal-Wallis ANOVA was used to compare psychological 
and disease-related variables in the groups with different depressive symp-
tom levels, and ordinal multinomial regression model to determine to what 
degree depressive symptoms and personal model of diabetes predicted par-
ticular self-care behaviours.
Results: Minimal depressive symptoms were reported by 20% of the patients, 
and moderate to severe symptoms by another 9%. No differences in age, dia-
betes duration, type of therapy, HbA1C and BMI were found between the 
non-depressed group and patients with depressive symptoms (all p>0.05). 
Self-reported eating behaviour, exercise and foot care were comparable across 
the groups (all p>0.05). Blood glucose self-monitoring was most frequent in 
patients with minimal depressive symptoms, followed by the non-depressed 
and moderately to severely depressed ones (H=5.80 p=0.05). Diabetes im-
pact on daily life as measured by PM was reported greater by both depressed 
groups as compared to the non-depressed one (H=6.18 p=0.04), while other 
domains - seriousness, diabetes control and prevention of complications - 
did not differ across the groups. Non-linear regression model indicated that 
the control beliefs independently predicted patients’ eating behaviour and 
physical activity as measured by SDSCA (Wald Stat=9.3 p=0.002 and Wald 
Stat=7.4 p=0.006, respectively). Foot care was predicted by seriousness beliefs 
(Wald Stat=4.6 p=0.03), while depressive symptoms were the only independ-
ent predictor of blood glucose self-monitoring (Wald Stat=7.9 p=0.01).
Conclusion: Even mild depressive symptoms were found to be associated 
with illness representations in type 2 diabetic patients, implying a more 
highly perceived impact of diabetes on daily activities. Beliefs that self care 
controlled diabetes were the best predictors of eating behaviour and exercise, 
while feelings about diabetes seriousness and worry predicted foot care. De-
pressive symptoms rather than personal model domains predicted blood glu-
cose self-monitoring, showing a positive effect in mild depressive symptoms 
and adverse in moderate to severe ones.
Supported by: Ministry of Science, Education and Sports of the Republic of 
Croatia
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Pain self-efficacy and pain catastrophising predict depression in people 
with painful diabetic neuropathy
B.E. McGuire1, M. Treacy1, K. Sarma1, S. Dinneen2, T. O’Brien2, F. Dunne2; 
1Psychology, 2Medicine, National University of Ireland, Galway, Ireland.
Background and aims: Neuropathy is one of the most common and trouble-
some complications of diabetes and neuropathic pain can result in significant 
morbidity and reduced quality of life. The objective of the study was to in-
vestigate whether pain self-efficacy (belief in one’s ability to function, despite 
pain) and pain catastrophizing (fearful and anxious thoughts about pain) in-
fluenced depression levels in those with painful diabetic neuropathy.
Materials and methods: We identified a sample of 138 patients with painful 
diabetic neuropathy on the basis of database recordings and issued a postal 
survey pack including a measure on pain (Brief Pain Inventory - BPI), pain 
self-efficacy (Pain Self-Efficacy Scale - PSE), pain catastrophizing (Pain Cata-
strophizing Scale - PCS), and depression (Hospital Anxiety and Depression 
Scale - HADS).
Results: We received responses from 62 patients (45% response) of mean age 
54 years; 79% had Type 2 diabetes. Depression “caseness” on the HADS was 
reported by 55% of respondents. There was a statistically significant negative 
correlation between Pain Self-Efficacy and Depression (r=-.54, p≤.005) and 
a significant positive correlation between Pain Catastrophizing and Depres-
sion (r=.511, p≤.005). When applied as a predictive model of depression, 
together Self Efficacy and Catastrophizing were moderately associated with 
Depression (Multiple R=.56) and predicted 33% of this variable’s variance. 
The standardised regression coefficients suggest that Self Efficacy (β=-.357) 
is a stronger predictor of Depression than total Pain Catastrophizing score 
(β=.259).
Conclusion: The results indicate that severity of depression in those with dia-
betic neuropathic pain is predicted by a lower sense of control over the pain 
(as indicated by Self Efficacy measure) and is also predicted by a tendency to 
think about the pain in an unhelpful way (as indicated by the Pain Catastro-
phizing Scale). The results highlight a role for cognitive-behavioural inter-
ventions to assist patients with diabetes in coping with neuropathic pain.
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Association of self-reported hypoglycaemia and quality of life and 
depression among adults with type 2 diabetes mellitus
S. Grandy1, H.W. Rodbard2, K.M. Fox3, J.R. Gavin III4, E. Hardy1, SHIELD 
Study Group; 
1AstraZeneca Pharmaceuticals LP, Wilmington, 2Endocrine and Metabolic 
Consultants, Rockville, 3Strategic Healthcare Solutions, LLC, Monkton, 
4Emory University, Atlanta, USA.
Background and aims: This study examined the association of hypoglycemia 
with quality of life and depression among adults with type 2 diabetes mellitus 
(T2DM) with and without hypoglycemia.
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Materials and methods: Respondents to the 2008 U.S. Study to Help Im-
prove Early evaluation and management of risk factors Leading to Diabe-
tes (SHIELD) survey were asked the number of times they experienced 
hypoglycemia in the past 4 weeks and past 12 months. Respondents also 
completed the Short Form-12 (SF-12) quality-of-life questionnaire and the 
Patient Health Questionnaire (PHQ-9) depression questionnaire. T2DM re-
spondents reporting at least 1 hypoglycemia (low blood sugar) episode were 
compared with T2DM respondents who did not report hypoglycemia in the 
previous 12 months.
Results: There were 3,000 respondents with T2DM, and 2,718 (91%) com-
pleted the SF-12 and PHQ-9; 23% reported experiencing hypoglycemia in the 
past 12 months. Respondents reporting at least 1 hypoglycemic episode (n = 
627) had significantly lower (p<0.001) SF-12 scores for both physical health 
(PCS) (mean + SD: 37.4 ± 12.7 vs. 40.9 ± 12.7) and mental health (MCS) 
(50.1 ± 11.7 vs. 52.4 ± 10.1) compared with those without hypoglycemia (n = 
2,091). Mean PCS scores decreased as the number of hypoglycemia episodes 
increased: PCS 39.0+ 14.4 for 1 episode, 38.3 + 12.0 for 2-3 episodes, 38.1 + 
13.3 for 4-5 episodes, and 35.1 + 12.6 for >6 episodes (p = 0.03). Mean MCS 
scores did not differ by across these same groupings (p = 0.09). Mean PHQ-
9 scores were significantly higher (p <0.001) among respondents reporting 
hypoglycemia (5.2 ± 5.8), compared with respondents who did not report 
hypoglycemia (3.9 ± 5.0), indicating greater depression burden. Significantly 
more respondents experiencing hypoglycemia (10.1% ± 3.8%) reported 
moderately severe to severe depression (PHQ-9 scores >15), compared with 
respondents without hypoglycemia (5.1% ± 2.1%). Mean PHQ-9 scores in-
creased as the number of hypoglycemia episodes increased: score 4.1 + 4.9 
for 1 episode, 4.9 + 5.7 for 2-3 episodes, 5.7 + 6.3 for 4-5 episodes, and 6.0 + 
6.0 for > 6 episodes (p = 0.01).
Conclusion: T2DM respondents experiencing hypoglycemia report a lower 
quality of life, in the domains of both physical and mental health, and greater 
burden of depression than respondents without hypoglycemia. These findings 
suggest that hypoglycemia and depression need to be considered together in 
routine clinical practice settings.
Supported by: AstraZeneca Pharmaceuticals LP
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Can affects and self image affect diabetes mellitus?
E.O.M. Melin1, M. Landin-Olsson1, H.O. Thulesius2; 
1Department of Clinical Sciences. Lund University, Lund, 2Division of 
Family Medicine, Department of Clinical Sciences. Lund University, Malmö, 
Sweden.
Background and aims: Depression is common in patients with DM and as-
sociated with impaired metabolic control and increased risk of all diabetic 
complications. Other types of psychological and psychosomatic factors in-
volved in DM morbidity are not so well investigated. Our aims in this study 
were to explore depression, anxiety, alexithymia and self image and their 
correlations with HbA1c among young and middle aged patients with DM. 
Alexithymia was here defined by three factors: Difficulties Identifying Feel-
ings (DIF), Difficulties Describing Feelings (DDF) and Externally Oriented 
Thinking (EOT). Self image was in this study composed of three positive 
factors: “self-affirm”, “active self-love”, “self-protect”; three negative factors: 
“self-blame”, “self-attack”, “self-neglect”; and two neutral factors reflecting au-
tonomy: “self-emancipate” and “self-control”.
Materials and methods: At a Swedish specialist outpatient clinic, 353 DM 
patients 18-59 years old (median age 42 years; 56% men, 44% women) par-
ticipated in this study. Depression and anxiety were assessed by the Hospital 
Anxiety and Depression Scale (HAD), Alexithymia by the Toronto Alex-
ithymia Scale-20 (TAS-20), and Structural Analysis of Social Behaviour 
(SASB) was used for assessing the eight factors of self image described above. 
We also measured waist circumference and determined Body Mass Index 
(BMI) for the 353 DM patients. We did bivariate correlation, linear regres-
sion, and combined variable correlations analyses with HbA1c as dependant 
variable.
Results: Mean HbA1C was 7.13 % (SD=1.37, N=353) and mean waist cir-
cumference 0.87 m (SD 0.13, N=339). An elevated anxiety score was found 
in 35% (111/320), a negative self image in 22% (69/309), alexithymia in 16% 
(51/318), and an elevated depression score in 12% (37/320) of the 353 DM 
patients. We found that 45% (N=144) of DM patients did not have any signs 
of depression, anxiety or alexithymia and had a normal self image score. 
Their mean HbA1c was 6.96 % (SD=1.18). Alexithymia had the greatest im-
pact (p=0.037) and the combination with negative self image (p=0.035) was 
particularly severe. For 17 patients with a high alexithymia score, a negative 
self image, but with a normal depression score HbA1c was 7.82 % (SD=1.57). 
For 12 patients with a combination of a high alexithymia score, a negative 
self image and a high depression score HbA1c was 8.57 % (SD=1.78). For 46 
women with a waist circumference of > 0.88 m the HbA1c was 7.92 %, and for 
21 men with >1.02 it was 7.35%. Bivariate correlation between HbA1c and 17 
variables showed a significant r below the 5% p-level for the following 8 vari-
ables: anxiety, depression, DIF, “self-control”, ”self-attack”, “self-neglect”, BMI, 
and waist circumference. Age, DDF, EOT, “self-emancipate“, “self-affirm”, “ac-
tive self-love”, “self- protect”, “self-blame” and duration of DM showed no cor-
relation with HbA1c. In linear regression analyses, including the 8 variables 
above, DIF (p<0.0001) and waist circumference (p<0.001) remained signifi-
cantly associated with HbA1c.
Conclusion: In this study we show that alexithymia and negative self image 
had a greater impact on HbA1c levels than depression in patients with DM. 
Particularly, the alexithymia sub factor DIF (difficulties identifying feelings) 
correlated with HbA1c, and the waist circumference in a linear regression 
model.
Supported by: Research and Development Commité. County of Kronoberg
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Longitudinal motivational predictors of dietary self-care, life satisfaction 
and diabetes control in adults with newly diagnosed type 2 diabetes 
mellitus
A. Nouwen1, T. Ford2, A. Balan1, J.W.R. Twisk3, D.G. White2; 
1School of Psychology, University of Birmingham, United Kingdom, 2School 
of Psychology, Staffordshire University, Stoke-on-Trent, United Kingdom, 
3Faculty of Earth and Life Sciences, Vrije Universiteit, Amsterdam, 
Netherlands.
Background and aims: Changing dietary habits is considered the most dif-
ficult part of diabetes self-management after being diagnosed with type 2 
diabetes (T2DM). The tendency to overeat at diagnosis has been associated 
with weight gain and intake of energy four years after diagnosis. Therefore, 
better understanding of the motivational factors involved in adopting and 
maintaining dietary self-care activities during the critical period following 
the diagnosis of T2DM is needed. This study aimed to examine whether mo-
tivational factors from Social-Cognitive Theory (self-efficacy, positive and 
negative outcome expectancies and self-evaluation) and Self-Determination 
Theory (autonomous self-regulation and autonomy support) are associated 
with the course of dietary self-care, life satisfaction and diabetes control in a 
sample of people newly diagnosed with type 2 diabetes.
Materials and methods: Participants, 237 people (65% male) newly diag-
nosed with type 2 diabetes, completed questionnaires assessing perceptions 
of support from health care professionals fostering autonomy, autonomous 
motivation, dietary self-efficacy, positive and negative outcome expectancies, 
self-evaluation, dietary self-care, life-satisfaction and diabetes knowledge at 
five occasions, each three months apart. BMI and HbA1c were also assessed 
on each occasion.
Results: Multivariate analyses, using Generalised Estimating Equations 
(GEE), showed that autonomous motivation (β = 0.06, p < 0.05), dietary self-
efficacy (β = 0.006, p < 0.001), and self evaluation (β = 0.23, p < 0.001) were 
significantly associated with the course of dietary self-care, even when adjust-
ed for demographic and illness-related variables. The course of life satisfac-
tion over the 18-month period was significantly associated with self-efficacy 
(β = 0.008, p < 0.01), and positive (β = 0.005, p < 0.01) and negative outcome 
expectancies (β = -0.002, p < 0.01), while changes in HbA1c were significantly 
associated with self-efficacy (β = -0.007, p < 0.05), and negative outcome ex-
pectancies (β = -0.005, p < 0.01). However, for the latter two analyses, self-ef-
ficacy was no longer a significant predictor after controlling for a number of 
demographic and illness-related variables.
Conclusion: Together with self-efficacy and autonomous motivation, self-
evaluation is an important motivational construct associated with dietary 
self-care over the first 18 months after diagnosis of T2DM. Whether people 
newly diagnosed with T2DM remain satisfied with their lives over that pe-
riod depends on their positive and negative perceptions they have about their 
diabetes. Because HbA1c reflects diabetes control over the past 2-3 months, 
the significant longitudinal association with negative outcome expectancies 
is likely to indicate poorer control of diabetes leading to more negative per-
ceptions of diabetes. In teaching how to cope with newly diagnosed T2DM, 
health care professionals may want to include specific interventions targeting 
these motivational constructs.
Supported by: Diabetes-UK
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The association of screening anxiety with fasting and 2-hour plasma 
glucose, and HbA1c
N. Aujla1, M.J. Davies2, T.C. Skinner3, D.R. Webb1, B. Srinivasan1, K. Khunti1;
1Health Sciences, University of Leicester, United Kingdom, 2Cardiovascular 
Sciences, University of Leicester, United Kingdom, 3Combined Universities 
Centre for Rural Health, Geraldton, Australia.
Background and aims: Previous work has identified that feelings of stress 
can result in hyperglycaemia, which may become problematic during diabe-
tes screening involving Oral Glucose Tolerance Tests (OGTTs). OGTTs are 
currently the ‘gold standard’ approach for screening for diabetes, and involve 
collection of both fasting and 2-hour plasma samples. Some research has 
identified that for diabetes screening, anxiety may be intensified in people 
with negative perceptions about the condition being life-threatening and re-
sulting in complications. Importantly, research has not yet explored the ex-
tent to which raised anxiety levels can affect glucose results obtained from 
OGTTs. HbA1C has recently been suggested for use as a diagnostic test for 
diabetes. The aim of this study was to investigate associations between anxi-
ety and fasting and 2-hour plasma glucose levels collected from OGTTs, and 
HbA1C.
Materials and methods: In a community screening study, 4688 White-Euro-
pean (WE, 40-75 years) and 1353 South-Asian participants (SA, 25-75 years) 
without a previous diagnosis of Type 2 Diabetes Mellitus (T2DM) under-
went an OGTT, HbA1C, full lipid profile, detailed history, anthropometric 
measurements and completed the short-form Spielberger State Trait Anxi-
ety Inventory. Data was analysed with means and standard deviations (for 
continuous variables) and percentages (for categorical variables). Pearson’s 
correlation coefficient was computed to identify relationships. Linear model-
ling was conducted to further explore associations, with adjustment for con-
founding factors.
Results: Overall prevalence of T2DM and Impaired Glucose Regulation 
(IGR) was 3% and 16%, respectively. Anxiety levels were significantly higher 
in SA (mean 34.1; SD 0.37) compared to WE participants (mean 29.8; SD 
0.13). Fasting glucose levels (mean 5.3mmol/l; SD 0.9, p=0.001) and HbA1C 
(mean 5.9%; SD 0.62, p<0.001) were also significantly higher among SA 
participants. Significant correlations were not identified between fasting 
(r -0.005, p=0.75) or 2-hour glucose levels (r -0.10, p=0.24) and HbA1C (r 
0.01, p=0.40). Statistically non-significant associations of anxiety with fast-
ing glucose and HbA1C remained following adjustment for age, gender or 
ethnicity.
Conclusion: This study found that anxiety levels at screening were height-
ened among people of SA ethnicity. In addition, the study found that fasting 
and 2-hour plasma glucose levels and HbA1C are not affected by anxiety dur-
ing screening tests for diabetes. Therefore, current and proposed screening 
methods are not affected by anxiety at screening.
Supported by: DoH
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Patient-centered outcomes and glycaemic variability in type 1 and type 
2 diabetes: a cross-over trial of insulin glargine + glulisine vs premix 
analogue insulin
M.A. Testa1, L. Blonde2, J. Gill3, R.R. Turner4, D.C. Simonson5; 
1Biostatistics, Harvard School of Public Health, Boston, 2Endocrinology, 
Ochsner Medical Center, New Orleans, 3sanofi-aventis, Bridgewater, 4Phase 
V Technologies, Wellesley, 5Endocrinology, Diabetes and Hypertension, 
Brigham and Women’s Hospital, Boston, USA.
Background and aims: Intensive insulin therapy with multiple daily injec-
tions (MDI) offers superior glycemic control; however, regimen burden and 
hypoglycemia remain barriers to acceptance. The primary objective of this 
study was to test for superiority in improvements from baseline in patient-
centered outcomes of patient satisfaction (PS) and quality of life (QoL) in 
subjects with type 1 or type 2 diabetes when treated with insulin glargine plus 
premeal rapid acting insulin glulisine versus treatment with premix analogue 
insulin. The secondary objectives were to compare glycemic control and vari-
ability between the two insulin regimens.
Materials and methods: We studied 388 insulin-treated patients (82 T1DM, 
306 T2DM, 47% male, age 54±11 yrs, HbA1c 7.8±0.7%) who were rand-
omized to either open-label daily insulin glargine plus premeal glulisine (GG; 
n=192) or BID premix 75/25 or 70/30 (PM; n=196) for 12 wks (P1), and 
then crossed over to the alternate treatment arm for an additional 12 wks of 
treatment (P2). Patients followed an insulin titration algorithm with a target 
HbA1c < 7.0% with the aid of an electronic diary transmitting data daily to 
a web-based remote monitoring system. Clinic personnel reviewed daily 4-
point glucose readings, insulin dosages, hypoglycemia, other symptoms, and 
adverse events, and called the patient weekly to provide insulin dosing rec-
ommendations. Patients completed clinic-based PS and QoL questionnaires 
at Wks 0, 8, 12, 20 and 24, and underwent continuous glucose monitoring 
(CGM) for three-day periods at Wks 0, 12 and 24.
Results: Mean±SE HbA1c change for GG vs PM was -0.53±0.10% vs -
0.20±0.10% for P1, and -0.25±0.10% vs +0.10±0.10% for P2 (both p<0.0001). 
At P1 Wk 12, 55% of GG reached HbA1c <7.0% vs 31% for PM (p<0.0001), 
with no differences in serious adverse events (5.4 vs 4.9%, p=0.7) or daytime 
or nocturnal hypoglycemia. Combined linear, mixed model P1 and P2 base-
line-adjusted Wk 12 mean±SE estimates are reported for PS, QoL and CGM. 
The PS Net Benefit scale (0-100) improved from 51.1 to 60.5±1.2 for GG, 
but worsened to 45.4±1.2 for PM (p<0.0001). Overall QoL favored GG by 
0.13±0.04 Z-score units (p<0.001). All 4 Net Benefit subscales favored GG 
(p<0.0001). The PS Regimen Acceptance scale was comparable (67.3±0.5 for 
GG vs 66.5.±0.5 for PM, p=0.33) with 3 lifestyle and side effects subscales 
favoring GG (p<0.001) and 3 convenience subscales favoring PM (p<0.02). 
QoL scales favoring GG vs PM were perceived health, symptom distress (both 
p<0.0001), general health perceptions (p<0.01) and psychosocial (p<0.02). 
Emotional and cognitive scales were comparable. CGMS daily mean, daily 
SD and % time > 7.8 mmol/l were lower for GG than PM by 0.7±0.1 mmol/l, 
0.3±0.07 mmol/l and 7.3±1.6% respectively (all p< 0.0001), with no differ-
ence in CGM % time < 3.9 mmol/l (p=0.10).
Conclusion: Patient perception of net benefit and treatment satisfaction was 
more heavily weighted by the beneficial changes in health status and quality 
of life associated with improvements in glycemic control and reduced vari-
ability with insulin glargine plus premeal insulin glulisine than by the burden 
of additional daily insulin injections.
Supported by: sanofi-aventis
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Clinical heterogeneity of type 1 diabetes mellitus at onset
Z. Huang1, Y. Chen2, F. Li3, Y. Li1; 
1Department of Endocrinology and Diabetes Center, The First Affiliated 
Hospital of Sun yat-sen University, Guangzhou, 2Department of 
Endocrinology, Guangzhou No.458 Hospital,  3Department of Internal 
Medicine, Traditional Chinese Medical Hospital of Gaoming County, 
Foshan, China.
Background and aims: Retrospective analysis was performed in 489 consec-
utive patients with discharge diagnosis of type 1 diabetes (T1DM) between 
1999 and 2009 in our hospital to examine the clinical heterogeneity of the 
disease.
Materials and methods: A total of 205 out of 489 patients were newly on-
set T1DM. In these patients, clinical characteristics and laboratory data at 
onset were compared among fulminant type 1 diabetes (FT1DM, diagnostic 
criteria according to Imagawa et al.) and those with duration of symptoms 
before diagnosis shorter (acute-onset) or longer (slow-onset) than 3 months. 
One-way ANOVA and multivariate chi square were employed to compare the 
differences among groups.
Results: The proportions of FT1DM (n=18), acute-onset (n=137) and slow-
onset (n=50) T1DM were 8.8%, 66.8%, 24.4% respectively. The onset of FT-
1DM was so abrupt that the concentration of plasma glucose was prominently 
elevated, whereas HbA1C was disproportionately near normal, and the dura-
tion of symptoms before diagnosis was extremely shorter than the other two 
groups. More female patients tended to develop FT1DM, and flu-like symp-
toms (44.4% vs 22.6%, 18%) were more frequently observed in this group, 
but the differences failed to reach significance. Two patients who developed 
T1DM during or after pregnancy belonged to the FT1DM group. Ketoaci-
dosis was almost inevitable phenomenon at diagnosis and the accompanied 
metabolic derangement (hyponatremia, acidosis, dysfunction of kidney and 
liver etc) was more severe in FT1DM group. The acute-onset T1DM consti-
tuted the maximum ratio of the disease, and patients were with the youngest 
age at onset and with the leanest somalotype before diagnosis. Patients with 
slow-onset type were relatively older and had greater body mass index but 
lost more weight at diagnosis. The fasting as well as post-load C-peptides in 
this group were relatively higher, and ketoacidosis at onset was less likely.
Conclusion: Clinical heterogeneity in the three groups was apparent, which 
might indicate different trigger mechanisms, especially the impacts of virus 
infection, feminine hormones or state of pregnancy on the extent of β cell 
damage as well as the development of T1DM, more so the fulminant type.
Table 1 Comparisons of clinical features of FT1DM, acute-onset and slow-
onset T1DM. 
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Ketosis prone diabetes in south London - are we discontinuing insulin 
appropriately?
M.S.B. Huda, R. Maitland, S.R. Henderson, O. Poole-Wilson, J. Miell,  
S.R. Kottegoda; 
Department of Diabetes & Endocrinology, University Hospital Lewisham, 
London, United Kingdom.
Background and aims: Ketosis prone diabetes is a common, but frequently 
unrecognised presentation of diabetes in an African/Caribbean population. 
An ideal approach to insulin discontinuation in these patients is unclear. We 
examined rates of insulin discontinuation, initial management and subse-
quent follow up in a large cohort of patients from a south London popula-
tion.
Materials and methods: Patients that presented with diabetic ketoacidosis 
(DKA) or unprovoked ketosis (defined as ≥2+ ketones on urine dipstick) be-
tween 2003 and 2009 to University Hospital Lewisham, London were identi-
fied from hospital notes and a clinic database. Those with known or a clear 
clinical new diagnosis of type 1 diabetes were excluded.
Results: 53 patients were identified; 28 with DKA and 27 with unpro-
voked ketosis. 36 (68%) were male. The median age was 41 (range 17-71). 
Mean±SEM body mass index was 30.1±1.3. The majority were African-Car-
ibbean in origin (76%), with 8(15%) Caucasian patients and 5(9%) from the 
Indian subcontinent. Thirty-seven (70%) patients presented as a new diag-
nosis of diabetes. Forty-six (86%) patients were discharged on subcutaneous 
insulin. Twenty-eight (53%) had islet cell and GAD antibodies measured; 
only 2 patients had positive antibodies. Sixteen (30%) patients had fasting 
c-peptides measured; only 1 patient had a value <330pmol/l (value used to 
define adequate insulin secretory capacity in a previous large cohort). The 
mean follow up was 31±8.4 months (range 3- 120) and 39 (74%) were still on 
insulin. Five patients taking insulin experienced hypoglycaemia in the first 
three months, leading to insulin discontinuation in 2 cases. The mean time to 
insulin discontinuation was 13.1±3.0 months. Only one patient had a relapse 
of DKA seven years after discontinuing insulin. Mean HbA1c on admission 
was 12.3±0.6, decreasing significantly to 8.1±0.4 at follow-up (p<0.01). Body 
weight did not significantly increase over follow up (90.1±3.1 admission to 
91.8±3.2 follow up p=0.66).
Conclusion: This is the first large cohort of ketosis prone diabetic patients 
described in a UK population. Our data show that the majority of patients are 
discharged on insulin and continue with insulin at follow up, which may ex-
plain the extremely low incidence of relapse in DKA .Patients have a signifi-
cant decrease in HbA1c with minimal weight gain, suggesting a conservative 
approach to insulin withdrawal may be appropriate in this population.
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Post-transplant diabetes mellitus and its impact on survival of liver 
transplant patients
X.Y. Chen1, M.X. Yu1, J. Zhou2, J. Gao3, X. Gao1; 
1Department of Endocrinology, 2Department of Liver Surgery, 3Department 
of Nutrition, Zhongshan Hospital, Fudan University, Shanghai, China.
Background and aims: Post-transplant diabetes mellitus (PTDM) has great 
effects on complications in relation to cardiovascular system, infections, neu-
ropsychiatric system et al, resulting in greater morbidity and affecting graft 
survival and patients’ long-term outcome. The aim of our study was to discuss 
the impact of PTDM on patient survival and long-term complications.
Materials and methods: Retrospective analysis 438 patients who performed 
orthotopic liver transplantation (OLT) in our center between April, 2001 and 
December 2008, patients with previous history of using steroids, or data not 
completed or died within 3 months after OLT were excluded. All patients 
were divided to PTDM (n=140) and non-PTDM (n=298) group according 
to fasting plasma glucose (FPG) after operation. We compared two groups 
on survival rate and complications after OLT, including sepsis, chronic re-
nal insufficiency, fungal infection, biliary complication, CMV infection, fatty 
liver. Cox regression analysis was used to analyze those factors affecting pa-
tient survival. We used Chi-square test to compare qualitative variables and 
Kaplan-Meier method and log-rank test to analyze survival rate. P value less 
than 0.05 was considered statistically significant. Statistic analysis was done 
by SPSS 16.0.
Results: Cox regression analysis indicated that FPG before or after operation, 
tumor relapse or metastasis and renal insufficiency after OLT were independ-
ent risk factors for patients’ death, while the hazard ratio of each factor was 
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1.57 (P=0.02), 1.84 (P<0.0001), 2.08 (P=0.0001) in PTDM group towards 
non-PTDM group. The mean survival time in PTDM group was 4.216±0.260 
years, while non-PTDM group was 6.133±0.198 years, which showed statistic 
meaning between each group (P<0.01). Compared with non-PTDM group, 
PTDM group had higher rate in sepsis (151/298:87/140) (P=0.025) and 
chronic renal insufficiency (65/298:51/140) (P=0.001), and showed statistic 
meaning, while no difference were found in fungal infection, biliary compli-
cation, CMV infection and fatty liver (All P>0.05).
Conclusion: PTDM has great effect on patient’s survival and complication 
after OLT, reduces patient’s survival and raises the odds of sepsis and chronic 
renal insufficiency. 
Supported by: Zhongshan Hospital, Fudan University
995
Patients with long-standing type 2 diabetes can develop absolute insulin 
deficiency
S.V. Hope1,2, M. Shepherd2, B.M. Shields2, T. McDonald2,3, B.A. Knight2,  
A.T. Hattersley2; 
1Geriatrics, Royal Devon & Exeter NHS Foundation Trust, 2Peninsula NIHR 
Clinical Research Facility, 3Clinical Biochemistry, Royal Devon & Exeter 
NHS Foundation Trust, Exeter, United Kingdom.
Background and aims: Insulin treatment is increasing in Type 2 diabetes, re-
flecting the aim for tight glycaemic control, progressive beta-cell failure, and 
prolonged life expectancy. It is unclear whether the progressive beta-cell fail-
ure found in T2D can result in absolute insulin deficiency, with the resulting 
risk of increased fluctuations in glucose, including severe hypoglycaemia and 
diabetic ketoacidosis. This may need different treatment from the majority 
of patients with T2D who have endogenous insulin production. Recent work 
has developed Urinary C-Peptide Creatinine Ratio (UCPCR) as a non-inva-
sive, stable measure of endogenous insulin production utilising a single urine 
sample. This has been shown to correlate well with the gold-standard Mixed 
Meal Tolerance Test in insulin-treated patients. We aimed to assess if absolute 
insulin deficiency, measured by UCPCR, occurs in T2D.
Materials and methods: We studied 171 insulin-treated subjects who clini-
cally met criteria for type 2 diabetes (diagnosed > 45 years (median age 73, 
IQR 67-78), and who started insulin >12 months post-diagnosis). They pro-
vided a spot 2hr post-prandial urine sample, on which UCPCR was meas-
ured. Absolute insulin deficiency is defined by UCPCR <0.2nmol/mmol.
Results: 23/171 (13.5%) had absolute insulin deficiency (UCPCR<0.2). Du-
ration of diabetes was significantly longer in those with insulin deficiency 
(18vs12yrs, p=0.02), and insulin dose in units/kg/24hrs was higher (0.77vs0.5, 
p=0.01). There was no difference between those with insulin deficiency versus 
those with endogenous insulin production (UCPCR>0.2) for age of diagnosis 
(median 58vs58yrs, p= 0.27), BMI (29vs29, p=0.87), HbA1c (8vs7.8, p=0.76), 
time to insulin from diagnosis (6vs5.5yrs, p=0.31), or number taking oral hy-
poglycaemic agents (OHA) (12/23 vs 92/148, p=0.36). Of those with absolute 
insulin deficiency, only 4/23 (17%) were on a basal bolus treatment regime, 
and 8/23 (34.8%) were on long-acting insulin alone. 
Conclusion: UCPCR suggested 13.5% of elderly diabetic patients who met 
clinical criteria for type 2 diabetes had absolute insulin deficiency. Those who 
were insulin deficient had had a diagnosis of diabetes for significantly longer 
than those who retained endogenous insulin secretion, and were on higher 
doses of insulin. The insulin treatment regimes in the majority of these pa-
tients suggested insulin deficiency had not been recognised. Identifying in-
sulin deficiency in long-standing patients with diabetes is important as their 
management will differ, and UCPCR may have a valuable role in detecting 
these patients.
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How should HbA1c be incorporated into the diagnostic pathway for 
diabetes mellitus? 
S.E. Manley1, P.G. Nightingale2, K.A. Sikaris3, I.M. Stratton4, R. Cramb1, 
S.C.L. Gough5; 
1Clinical Biochemistry, University Hospital Birmingham NHS Foundation 
Trust, United Kingdom, 2Wellcome Trust Clinical Research Facility, 
University Hospital Birmingham NHS Foundation Trust,  United Kingdom, 
3Melbourne Pathology, Australia, 4English National Screening Programme 
for Diabetic Retinopathy, Gloucestershire Hospitals NHS Foundation Trust, 
Cheltenham, United Kingdom, 5Oxford Centre for Diabetes, Endocrinology 
and Metabolism, United Kingdom.
Background and aims: Alternative strategies have been suggested for using 
HbA1c to diagnose diabetes mellitus. An HbA1c cut-point of ≥6.5% has been 
included by the American Diabetes Association (ADA) in their guidelines for 
2010. Other approaches involve limits for HbA1c to ‘rule diabetes out/in’ and 
a combination of HbA1c and glucose to reduce oral glucose tolerance testing 
(OGTT). These strategies are examined in patients referred for OGTT in the 
UK with impaired fasting glucose (IFG) and patients at risk of diabetes in 
Australia, 26% with IFG at OGTT.
Materials and methods: OGTT were performed in 500 UK patients by 
capillary sampling with HbA1c measured by Tosoh G7 & G8 IE HPLC (ion 
exchange high performance liquid chromatography) analysers and in 1175 
Australian patients using venous samples with HbA1c from Bio-Rad Variant 
II Turbo analysers.
Results: The prevalence of diabetes by WHO criteria was 49% in UK pa-
tients, age, median IQ range, 62(53-72) years/52% male, and 35% for Austral-
ian patients, age 59(49-68) years/54% male. Those identified with diabetes 
by WHO in UK cohort were aged 62(53-73) years/52% male and by ADA 
64(54-73) years/50% male, p = 0.12 for age & p = 0.54 for gender, and for 
Australian patients, 61(51-71) years/55% and 59(50-70) years/57%, p = 0.004 
& p = 0.056. When limits of <5.5% HbA1c (NHbA1c not diabetic) and ≥7.5% 
(DHbA1c diabetic) are applied to ‘rule out/in diabetes’, 12% (6%/6% respec-
tively) of UK and 27% (17%/10%) of Australian patients would be identified. 
Those with NHbA1c in the UK cohort were aged 56(46-65) years/63% male, 
IHbA1c (intermediate 5.5% to 7.4%) 62(53-72) years/51% male and DH-
bA1c 68(53-74) years/52% male, p=0.26 for age and p=0.42 for gender. For 
Australian patients, values were 50(39-60) years/53%, 60(52-69) years/54% 
and 55(47-69) years/57%, p <0.001 & p=0.48. An algorithm combining FPG 
<7.0mmol/l and HbA1c <6.0% could provide additional benefit by reducing 
OGTT further as 20% of UK and 28% of Australian patients had HbA1c be-
tween 5.5% and 5.9%.
Conclusion: Further studies are required to establish the sensitivity and spe-
cificity of HbA1c limits in other populations. The means of referral, age and 
ethnicity of populations and analyser used for HbA1c may influence limits 
chosen. In addition, use of a surrogate marker for diagnosis of diabetes will 
require careful assessment in individual patients of conditions, either clinical 
or iatrogenic, which could affect haemoglobin or its turnover.
997
Diagnosis of diabetes applying the new and old ADA guidelines - 
characterisation of patients who do not hit both criteria
L. Bäz, E. Beluchin, N. Müller, T. Heller, C. Kloos, W. Hunger-Battefeld,  
G. Wolf, U.A. Müller; 
Endocrinology, University Hospital Jena, Germany.
Background and aims: For the diagnosis of diabetes the new ADA guidelines 
for the diagnosis of diabetes recommended the use of the HbA1c test to di-
agnose diabetes, with a threshold of >=6.5%. Moreover the common criteria 
for the diagnosis of diabetes, FPG >=7.0mmol/l and 2-h PG >=11,1mmol/l, 
stay valid. Not in every case the new and the old criterion lead to a diagnosis 
at the same time. There are patients whose glycaemic status is categorized 
differently either by the HbA1c or the 2 hour post challenge plasma glucose. 
These patients have to get characterized, to identify, which criteria is better 
to use in this situation.
Patients and methods: Data of 729 Patients who had 864 oral glucose toler-
ance tests and an HbA1c test in proximity of time were analyzed. Patients 
characteristics: age 40.3 y; HbA1c according to oGTT 5.5%; BMI 29.2 kg/m². 
HbA1c was DCCT adjusted. The conformity of diabetes-diagnosis of diabetes 
following the different criteria and potential reasons for non conformance 
were checked in the digital patient record EMIL.
Results: 28 (3.8%) of 729 patients hit both criteria for the diagnosis of dia-
betes (HbA1c >=6.5% and 2-h PG >=11.1 mmol/l). 641 patients (87.9%) met 
none of both criteria and 22 patients (3.0%) met the HbA1c (>=6.5%)- but 
not the glucose criterion (2-h PG >11.1mmol/l). Lots of these patients, hit-
ting only the HbA1c criteria, had an IFG (n=16), or an IGT (n=16) or both 
(n=14). Four of these 22 patients had whether IFG nor IGT. In 12 patients 
(1.6% of all patients) with a follow up the diagnosis could be confirmed by 
abnormal 2h-PG at a later time. In 4 patients HbA1c dropped below 6.5%, 
stayed or increased and 6 patients had no or only short follow up. 5.2% 
(n=38) of all patients had abnormal 2-h PG (>=11.1 mmol/l) at diagnosis 
but HbA1c below the limit (<6.5%). In 15 patients (2.1% of all patients) with 
follow up HbA1c rose above 6.5% and they met both criteria for diagnosis of 
diabetes. Nine patients with follow up (1.9%) stayed below an HbA1c 6.5%. 
Fourteen 14 patients (1.9%) had no or only short follow up to show changes 
in HbA1c. Confounder which could interfere with Hba1c were rare (severe 
illness 3, anaemia 2, hypoglycaemic agents 0, corticoids 0).
Conclusion: Applying the new ADA criteria for diabetes diagnose to an cau-
casian population we found concordance between HbA1c criterion and 2h 
post challenge criterion in in 91.7% of the all patients and an additional 3.7% 
within 12 month after the first test. Thus, HbA1c is a suitable parameter for 
diagnosis of diabetes mellitus.
Conformity of HbA1c and 2h post challange plasma glucose for diagnosis 
of diabetes
2-h PG <11,1mmol/l 2-h PG >=11,1mmol/l
Hba1c < 6.5% 641 patients
(87.9%)
38 patients
(5.2%)
Hba1c >= 6.5% 22 patients
3.0%)
28 patients
(3.8%)
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Detecting undiagnosed diabetes using HbA1c, an automated screening 
test in hospitalised patients
N.A. Valentine1, T.M. Alhawassi2, G.W. Roberts3, P.P. Vora4, S.N. Stranks4, 
M.P. Doogue1; 
1Discipline of Pharmacology, Flinders University, Bedford Park, Australia, 
2College of Pharmacy, King Saud University, Saudi Arabia, 3Pharmacy 
Department, Repatriation General Hospital, Daw Park, Australia, 4Southern 
Adelaide Diabetes and Endocrine Services, Bedford Park, Australia.
Background and aims: Diabetes is associated with morbidity, mortality and 
use of health care resources. The prevalence of diabetes in hospitalised pa-
tients is approximately three times community prevalence. HbA1c has been 
recently recommended as a diagnostic tool for diabetes. The aims of this 
study were to assess the utility of A1C as an automated screening test for 
undiagnosed diabetes in hospitalised patients and to estimate the prevalence 
of undiagnosed diabetes in hospitalised patients.
Materials and methods: A 3 month prospective observational study of all 
adult patients admitted to a tertiary hospital. An A1C test was automatically 
undertaken on admission for all patients with random plasma glucose (RPG) 
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≥5.5mmol/L. Demographic, admission and biochemical data were obtained 
from hospital databases. A subset of patients were recruited for an oral glu-
cose tolerance test (OGTT) post discharge. Undiagnosed diabetes was de-
fined as A1C ≥6.5% in accordance with International Expert Committee and 
American Diabetes Association recommendations.
Results: The prevalence of undiagnosed diabetes was 11% (95%CI 9.8-12.4) 
(262/2360) during the 3 month study (figure 1). A further 312 patients with 
known diabetes were admitted. The prevalence of undiagnosed diabetes was 
highest in the 65-74 age group. In this study, the A1C test cost was US$152 
per new diagnosis of diabetes. Conservatively assuming an annual incidence 
of undiagnosed diabetes of 0.8% the ongoing cost of testing hospitalised pa-
tients using A1C would be US$1,900 per new diagnosis of diabetes. RPG was 
not sensitive or specific in diagnosing diabetes. Patients were poorly compli-
ant with OGTT, with a 27% completion rate.
Conclusion: Undiagnosed diabetes is common in hospitalised patients. A1C 
is a simple, inexpensive screening test that can be automated using existing 
clinical blood samples. Hospital screening for diabetes needs to be coupled 
with resources for follow up and management in the community.
Figure 1: Prevalence (%) of diabetes in hospitalised patients according to age. 
The number in each group is shown within the columns. White bars indicate 
patients with previously known diabetes, black bars indicate patients with 
undiagnosed diabetes. Diamonds indicate the Australian community popu-
lation prevalence.
Supported by: General Practice Education and Training
999
Challenging the “Monnier Concept”: High basal (not postprandial) 
glucose dominates hyperglycaemic exposure over a wide range of HbA1c 
on oral therapy and contributes significantly even after addition of basal 
insulin
M. Riddle1, G.E. Umpierrez2, A. DiGenio3, R. Zhou4, J. Rosenstock5; 
1Oregon Health & Science University, Portland, 2Emory University, Atlanta, 
3sanofi-aventis, Bridgewater, 4Medpace, Cincinnati,  5Dallas Diabetes & 
Endocrine Center, USA.
Background and aims: Monnier et al reported that there was more contribu-
tion to overall hyperglycemia by postprandial hyperglycemia (PPHG) and 
less from basal hyperglycemia (BHG) at lower vs higher glycated hemoglobin 
A1C (A1C) levels. That analysis of 4-point profiles, from 290 patients treated 
with diet ± oral agents without insulin, is often interpreted as supporting the 
treatment of PPHG rather than BHG, unless the A1C is quite high. The cur-
rent analysis was designed to study these effects of basal insulin in a larger 
population with more detailed glucose profiles.
Materials and methods: We evaluated data from a large population of pa-
tients with type 2 diabetes and 7-point self-measured plasma-referenced 
glucose profiles pooled from 6 studies in which basal insulin alone (insulin 
glargine or NPH insulin) was added to diet ± oral agents and was systemati-
cally titrated. 
Results: 1699 participants (aged 59 ± 9 y, type 2 diabetes duration 9 ± 6 y) 
had baseline laboratory-measured fasting plasma glucose (FPG) of 10.7 ± 2.7 
mmol/L and A1C of 8.7% ± 0.9%. After 24 to 28 weeks of insulin treatment, 
FPG was 6.94 ± 2.1 mmol/L, A1C was 7.0% ± 0.9%, and symptomatic hy-
poglycemia occurred in 60.9% of patients. We computed the contributions of 
BHG and PPHG to total hyperglycemic exposure above 5.55 mmol/L. Results 
for ranges of A1C at baseline and after treatment are shown below. 
Baseline On Basal Insulin
<8.0 8.0-8.4 8.5-8.9 9.0-9.4 ≥9.5 <6.5 6.5-6.9 7.0-7.4 7.5-7.9 ≥8.0
N 422 348 298 245 386 437 449 351 237 225
A1C, % 7.6 8.2 8.7 9.2 10.0 6.0 6.7 7.2 7.7 8.7
BHG, % 76 78 79 79 80 42 41 42 43 48
PPHG, % 24 22 21 21 20 58 59 58 57 52
A1C correlated weakly with hyperglycemic exposure from BHG vs PPHG at 
baseline (P=0.074) and more significantly after improvements on basal in-
sulin (P=0.0155). Insulin therapy reduced the basal contribution from 76%-
80% to 41%-48%.
Conclusion: 1) When oral therapy is unsuccessful, BHG dominates hyperg-
lycemic exposure over a wide range of A1C. 2) Adding basal insulin reduces 
basal hyperglycemic exposure and A1C, increasing the relative contribution 
of PPG, independent of A1C ranges. 3) BHG contributes >40% to hyperg-
lycemic exposure, and A1C may be lowered further with basal insulin even 
when A1C approaches 7.0%.
Supported by: sanofi-aventis
1000
1, 5-Anhydroglucitol as a marker of short term glucose variability in 
well-controlled type 2 diabetes mellitus
Y.J. Lee1, K.S. Suh2, M.C. Choi1, Y.C. Hwang1, S. Chon3, I.-K. Jeong3, S. Oh3, 
K.J. Ahn3, H.Y. Chung3, J.-T. Woo3, S.-W. Kim3, J.-W. Kim3, Y.K. Choi4,  
Y.S. Kim3;
1Department of Endocrinology and Metabolism, Kyung Hee University 
Hospital, Seoul, 2Department of Endocrinology and Metabolism, Hyundae 
Hospital, Namyangju Si, Gyeonggi-Do, 3Department of Endocrinology and 
Metabolism, Pochon CHA University, Seoul, Republic of Korea.
Background and aims: 1, 5-Anhydroglucitol (AG) is a glucose analogue 
present in the blood and its levels decrease when there is glycosuric hypergly-
cemia. The usefulness of 1, 5-AG in reflecting glycemic excursions have been 
demonstrated in moderately controlled patients to some extent, although 
some studies reveal controversial results. However, even patients with well-
controlled diabetes, demonstrated by HbA1C<7%, may be subject to glyc-
emic excursions and postprandial hyperglycemia. The aim of this study was 
to evaluate the role of 1,5-AG in patients with well-controlled type 2 diabetes 
in monitoring short term glycemic control and glucose variability, as assessed 
by the continuous glucose monitoring system (CGMS), when compared to 
fructosamine (FA).
Materials and methods: 33 patients with type 2 diabetes with HbA1C <7% 
with stable glycemic control were recruited. CGMS was applied to the pa-
tients for two consecutive 72-h periods. A standardized and objective ap-
proach to measure glycemic variability by CGMS_the absolute group of signs 
(GOS) method, which has a high correlation with the mean amplitude of glu-
cose excursion (MAGE), was calculated. This, along with the mean postmeal 
maximum glucose (MPMG) and area under the curve for glucose above 180 
mg/dL (AUC180), which all reflect the daily glycemic status, were compared 
with 1,5-AG and FA at baseline, day 4, and day 7.
Results: Baseline characteristics of the enrolled subjects were as follows: 
age, 56 ± 9.6 yrs; BMI, 25.5 ± 3.6 kg/m²; DM duration, 4.9±5.0 yrs; HbA1C, 
6.3±0.3%; basal 1,5-AG, 15.8±7.6 ug/mL; basal fructosamine, 276.1±23.5 
umol/L. Mean 1,5-AG levels were negatively correlated with MPMG (r = 
-0.287, p < 0.05), AUC180 (r = -0.264, p < 0.05) and absolute GOS (r = -
0.253, p < 0.05), whereas FA levels were correlated positively with fasting 
plasma glucose (r = 0.519, p < 0.01), MPMG (r = 0.498, p< 0.01), AUC180 
(r = 0.52, p < 0.01), and absolute GOS (r = 0.285, p < 0.05). When 1,5-AG 
levels were divided into two groups using 14ug/mL as the cut-off value 
for well controlled DM, there was a statistically significant difference: 1,5-
AG<14ug/mL group, compared to the 1,5-AG>14ug/mL group, had higher 
fasting plasma glucose (120.84±15.46mg/dL vs 109.24±11.13mg/dL, p=.002), 
MPMG (201.84±34.75mg/dL vs 173.13±24.41mg/dL, p=.001), AUC180 
(5.10±5.49 mg/dL/day vs 1.56±2.27mg/dL/day, p=.003), and absolute GOS 
values (67.05±25.62 mg/dL vs 54.54 ±20.52mg/dL , p=.035), meaning greater 
glycemic variability.
Conclusion: 1, 5-AG reflects glycemic variability and postprandial hypergly-
cemia even in well-controlled DM patients, which suggests the usefulness of 
this as a complementary marker along with fructosamine.
Supported by: Korea Health 21 R&D Project, Ministry of Health & Welfare, 
Rep. of Korea
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Defining the phenotype of the fast and slow deglycators by analysis of the 
glycation gap
B.M. Singh, A.U. Nayak; 
Wolverhampton Diabetes Centre, United Kingdom.
Background and aims: Despite the reliability of the Haemoglobin A1c (HbA1c) 
assays discordance between HbA1c and other measures of glycaemia is often 
encountered. It is now recognised that there are enzyme dependent processes 
in the red blood cells that cause deglycation and thus influence the HbA1c in-
dependent of the prevailing glycaemia. Thus the HbA1c is the net of the glyca-
tion and deglycation. The rates of intracellular deglycation may vary between 
individuals. Fructosamine is the glycation of albumin which is extracellular 
and so is not affected by the intracellular deglycating enzymes. Co-analysis 
of HbA1c and Fructosamine pairs, utilising the Fructosamine to determine 
a predicted HbA1c, can define the ‘glycation gap’ (G-gap). Our objective is to 
determine if the glycation gap in any individual is consistent over time.
Materials and methods: We analysed all HbA1c estimations (n=111205) 
done over a 4 year period at New Cross Hospital. 4724 people had simultane-
ous HbA1c-Fructosamine estimations. 2263 people had at least two paired 
HbA1c-Fructosamine estimations separated by 10±8 months. The G-gap was 
calculated as the HbA1c minus the standardised Fructosamine derived HbA1c 
equivalent (FHbA1c). A negative G-gap may denote a fast deglycation state 
with the HbA1c appearing to read lower than predicted, and a positive G-gap 
denotes a slow deglycation state. To ascertain the consistency of the G-gap, 
the G-gap for the 2nd HbA1c-Fructosamine pair was calculated expecting 
a consistency of distribution of negative through positive values. If so, the 
multiple of G-gap1 and G-gap2 (whether negative or positive) will always be 
positive if consistent but negative with any discordance.
Results: Of the 2263 people with at least two paired HbA1c-Fructosamine, 
their characteristics were age 60±14 years, males 55%, HbA1c 8.3±1.7 (4.0-
17.7) % (mean±SD (range)) and Fructosamine 308±77 (143-978) µmol/l. The 
FHbA1c was 8.3±1.7 (4.6 - 23.4) % and the HbA1c minus FHbA1c was 0.0±1.2 
(-8.2 to +5.9). Setting G-gap cut offs at <= -1, >-1 to <+1, and >= +1 as Fast, 
Neutral and Slow deglycators the cohort’s distribution was 421 (19%), 1448 
(64%) and 394 (17%) respectively. The G-gap multiple (multiple of G-gap1 
and G-gap2) was 1.2±2.6 (-6.1 to +40.9). The G-gap consistency was 97% in 
421 Fast deglycators (G-gap <= -1) and 99% in 394 Slow deglycators (G-gap 
>= +1).
Conclusion: The G-gap is consistent over time, thus by inference an indi-
vidual’s rates of deglycation appear to be consistent and thus this may be a 
method of defining the phenotypic expression of underlying metabolic and 
genetic processes.
1002
Association between grip strength and glycaemic control or diabetic 
complications in Korean patients with type 2 diabetes
S.-K. Kim1, J.-H. Noh2, Y.-J. Cho3, J.-H. Kim4, H.-U. Nam3, J. Lee5, I.-J. Kim6, 
H.-W. Baik7, H.C. Jang8, H.-Y. Bae9, Y.-H. Ahn10, Y.-W. Cho1, H.-J. Yoo11; 
1Department of Internal Medicine, CHA Bundang Medical Center, CHA 
University, Seongnam, 2Department of Internal Medicine, Inje University 
College of Medicine, Koyang, 3Department of Internal Medicine, National 
Medical Center, Seoul4Department of Internal Medicine, Sung-Ae General 
Hospital, Seoul5Department of Internal Medicine, School of Medicine, 
Catholic University of Daegu, 6Department of Internal Medicine, Pusan 
National University School of Medicine, Busan, 7Department of Internal 
Medicine, Bundang Jesaeng Hospital, Daejin Medical Center, Seongnam, 
8Department of Internal Medicine, Seoul National University Bundang 
Hospital, Seongnam, 9Department of Internal Medicine, Chosun University 
Hospital, Gwangju, 10Department of Internal Medicine, Hanyang University 
College of Medicine, 11Department of Internal Medicine, Hallym University 
College of Medicine, Seoul, Republic of Korea.
Background and aims: Age-related decline of muscle strength is closely re-
lated with a loss of muscle mass and an increase in fat, which are the impor-
tant features in insulin-resistant states. However, very little data are available 
on the association of muscle strength with diabetic complications in patients 
with type 2 diabetes. The aim of this study was to investigate whether grip 
strength is associated with glycemic control and status of diabetic complica-
tion in patients with type 2 diabetes.
Materials and methods: This was an observational study performed in 193 
type 2 diabetic patients with duration of diabetes within 3 years and age- and 
sex-matched 40 healthy individuals. Grip strength was measured by isomet-
ric dynamometry. Thigh circumference was measured for each subject. Dia-
betic complications were ascertained via review of medical records. Chronic 
kidney disease was defined as estimated glomerular filtration rate < 60 mL/
min/1.73 m2.
Results: Grip strength was correlated with age (r=-0.491, P<0.001), body 
mass index (r=0.133, P<0.05), and diabetes duration (r=-0.184, P<0.001). 
Diabetic patients had lower grip strength than healthy individuals. Espe-
cially, grip strength of poorly glycemic controlled patients (HbA1c > 7.5%) 
had lower than that of well controlled patients (HbA1c ≤ 7.5%). And grip 
strength was lower in diabetic patients with retinopathy, neuropathy, chronic 
kidney disease, or cardiovascular disease, compared to those without these 
complications. With the exception of retinopathy, these trends remained sig-
nificant after adjusting for age, body mass index, waist, diabetes duration, 
and medications.
Conclusion: Our findings suggest that grip strength is associated with glyc-
emic control and diabetic complications. The potential for grip strength to be 
used in the clinical practice of diabetic patients needs to be explored.
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HbA1c and sensor use in adults during a 1-year randomised controlled 
trial comparing sensor-augmented pump therapy and multiple daily 
injection therapy
A. Ahmann1, J.B. Buse2, R.M. Berganstal3, R. Tanenberg4; 
1Oregon Health & Science University, Portland, 2University of North 
Carolina School of Medicine, Chapel Hill, 3International Diabetes Center at 
Park Nicollet, Minneapolis, 4Diabetes and Obesity Center, Greenville, USA.
Background and aims: Recent studies have shown that continuous glucose 
monitoring (CGM) can improve glycemic control. The purpose of the STAR 
3 study was to evaluate whether CGM combined with insulin pump therapy 
(sensor augmented pump, SAP) might improve A1C without increasing hy-
poglycemia.
Materials and methods: STAR 3 was a 1-year multicenter randomized con-
trolled trial comparing SAP therapy to glargine- and aspart-based multiple 
daily injection (MDI) therapy in 329 adult (age 19-70 years) and 156 pediat-
ric (age 7-18 years) subjects with type 1 diabetes. Preliminary results for the 
adult cohort of the following outcomes are given for overall A1C, A1C by age 
group, sensor use, and severe hypoglycemia.
Results: The primary endpoint of change in A1C from baseline to 1 year 
showed the decline in mean A1C levels was greater with SAP therapy com-
pared to MDI therapy (SAP: from 8.3±0.5% to 7.3±0.7%; MDI: from 8.3±0.5% 
to 7.9±0.9%; treatment difference -0.6%; 95% CI, -0.77, -0.45; p<0.001). Se-
vere hypoglycemia did not differ between treatment cohorts (p=0.53). There 
was a decrease in A1C from baseline to 1 year for all SAP adults of -0.9; for 
those 19-35 years (n=59), the decrease was -0.7; for those 36-50 years (n=58), 
the decrease was -1.1; and for those 51-70 years (n=49), it was -1.1. Treat-
ment differences between groups in change in A1C significantly favored SAP 
therapy for all adults (-0.6, p<0.001) and in 2 age cohorts (-0.6 among sub-
jects 19-35 years, p=0.01; -0.8 among subjects 36-50 years, p<0.001; with a 
favorable downward trend of -0.3 among subjects 51-70 years, p=0.16). Most 
SAP subjects used the glucose sensor ≥60% of the time (57.6% among sub-
jects 19-35 years of age, 82.8% among subjects 36-50 years of age, and 91.8% 
among subjects 51-70 years of age). The Figure shows the r value of -.28 be-
tween sensor use and change in A1C from baseline to 1 year.
Conclusion: SAP therapy reduces A1C in adults of all ages with type 1 dia-
betes. Reduction in A1C appears to be related to sensor use, which showed a 
tendency to increase with age, but was relatively high across all ages.
Supported by: Medtronic, Inc
1004
Improved glucose control with sensor-augmented pump therapy in youth 
with type 1 diabetes and elevated HbA1c levels on multiple daily injection 
therapy in the STAR 3 Study
W.V. Tamborlane1, R. Slover2, A. Criego3, M. Daniels4, C.M. Foster5, R.C. 
McEvoy6, C. Orlowski7, S. Weinzimer1, N. White8, S.M. Willi9, STAR 3 Study 
Group; 
1Pediatrics, Yale School of Medicine, New Haven, 2Pediatrics, Barbara 
Davis Center for Childhood Diabetes, Aurora, 3International Diabetes 
Center, Minneapolis, 4CHOC, Orange, 5University of Utah, Salt Lake City, 
6Children’s Hospitals and Clinics of Minnesota, Minneapolis, 7University 
of Rochester, Rochester, 8Washington University, St. Louis, 9CHOP, 
Philadelphia, USA.
Background and aims: The effectiveness of continuous glucose monitoring 
(CGM) in children with type 1 diabetes (T1D) maintained on pre-existing 
insulin pump or multiple daily injection (MDI) treatment remains unproven. 
No previous study has examined the effect of initiating both CGM and insu-
lin pump therapy simultaneously in a large pediatric cohort with T1D.
Materials and methods: This 1-year multicenter, randomized controlled 
trial compared an integrated sensor-augmented pump (SAP) system to MDI 
therapy in 156 youths with T1D with sub optimal control (A1C =7.4 - 9 .5%). 
A1C values were measured every 3 months and the primary outcome was the 
change in A1C from baseline to 12 months in the total cohort. Results were 
also stratified according to age (82 children, age 7-12 and 74 adolescents, age 
13-18) and by the amount of time glucose sensors were worn in the SAP 
group.
Results: Baseline A1C levels did not differ between the SAP group 
(8.26±0.55%) and the MDI group (8.30±0.53%). At the end of 12 months, 
the change in A1C from baseline in the SAP group was -0.39±93% versus 
+0.16±0.95% in the MDI group, a between-groups difference of -0.49% (95% 
CI, -0.75 to -0.18; P=.002). The proportion of subjects reaching ISPAD-rec-
ommended A1C values (i.e., <7.5%) was 29.5% in the SAP group versus 10.3% 
in the MDI group (P=0.0075). As shown in the Figure, the change in A1C at 
12 months in 7-12 yr old subjects favored the SAP group by -0.44% (95% CI, 
-0.80 to -0.07; P=0.02 vs MDI subjects) and by -0.62% (95% CI, -1.09 to -0.15, 
P= 0.01) in 13-18 year olds. In the entire SAP cohort, greater decrements in 
A1C were associated with increasing sensor wear (r=-0.30, P=0.008). Rates of 
severe hypoglycemia (<10 events/100 pt yrs) and DKA were low and did not 
differ between the two treatment groups.
Conclusion: SAP is an effective means of improving metabolic control and in 
achieving target A1C levels without increasing the frequency of acute com-
plications in youth with T1D who have elevated A1C levels on MDI therapy. 
Increasing sensor use tends to improve the effectiveness of the SAP system.
Supported by: Medtronic, Inc.
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Long term outcomes of intensive treatment with subcutaneous insulin 
infusion (CSII) in patients with type 1 diabetes mellitus
I. Gonzalez-Molero1, M.E. Domínguez-López1, E. Rubio1, M. Carreira2,  
S. Gonzalez-Romero1, M.S. Ruiz de Adana-Navas1, F. Soriguer-Escofet1; 
1Endocrinology, 2Psichology, Carlos Haya Hospital, Malaga, Spain.
Introduction: Several studies have shown that treatment with insulin pump 
is an effective therapy for selected type1diabetes. Nevertheless, most of them 
analyse results in short period of time. The objective of this study is to evaluate 
long term effects on quality of life (DQOL) and metabolic control of CSII.
Material and methods: We did a longitudinal study of type 1 diabetic pa-
tients previously treated with multiple daily insulin (MDI) therapy who ini-
tiated insulin pump and maintained it for longer than three years. Initially 
we recruited 105 patients and after we excluded pregnant and patients using 
S 402 Diabetologia (2010) 53:[Suppl1]S1–S556
1 C
combined sensor-pump systems. Finally we analysed in 69 patients: diabetes 
duration, complications, cause of initiating CSII, total daily insulin require-
ments, hypoglycaemias, Hba1c, DQOL, physical evaluation, number of con-
trols and number of medical visits.
Results: The criteria for csii initiation were: 21,9% hypoglycaemic events, 
37,5% poor metabolic control and 40,6% glycemic lability. After three years, 
79,64% continue using insulin pump, 12,2% dropped out and 8,16% with-
drawn following medical reasons.
*P<0,05 Basal 6 month 12 month 24 month 36 month
HbA1c 8.11±2,2 7.6±1,3* 7,8±0.9* 7,2±2,6* 8,2 ±0.97
Severe Hypoglycemic 
events/year
0,43 0,06 0 0 0,03
Hypoglycemic events/
week
4,5±3 3,3±2,8 2,1±1,7* 2,8±2,2* 2,7±1,6
Ketoacidosis with hospi-
talary admission
0 0 0 0 0
Sensibility factor 37,6 ±17.8 45,3±19.04 40.7±18.9 38,8±18,4 41,3±10,3
CHRatio 1.05±0,5 0,88±0,44 0.95±0.46 0.97±0,44 1,03±0,29
Autoanalysis/day 3,6±2.5 3,1±1,99 3,8±1,9 3,7±2,2 3,2±1,4
Visits / month - 0,62±0,22 0,28±0,14 0,30±0,11 0,30±0,11
DQOL 92± 16,15 80,82± 19,2* 82,12±19,1* 82,5±14,0* 82,5±14,0*
[Long term evaluation of CSII]
Conclusions: CSII achieve a good metabolic control during the first two 
years and an improvement in DQOL that is maintained during all the evalu-
ated period of time.
1006
Insulin requirements, basal-bolus distribution and basal patterns used 
by type 1 diabetic patients (T1DM) starting insulin pump therapy (CSII) 
and after glucose control optimisation
I. Saigi1, D. Tundidor1, L. Jordana1, M.A. María1, R. Corcoy2, A. Chico2; 
1Endocrinology, 2Endocrinology, Eduab-HSP, Hospital Sant Pau, Barcelona, 
Spain.
Introduction: Insulin requirements of insulin at the beginning of CSII thera-
py is usually calculated from total daily doses (TDD) used with multiple daily 
injections (MDI). Basal-bolus distribution of 50%-50% with only one basal 
rate per day is the usual pattern at that time. However, there are only few 
evidences about the best form to start CSII in MDI treated patients.
Aim: The aim of the study was to assess insulin requirements, basal-bolus 
distribution and basal rate pattern used by a group of T1DM subjects using 
CSII after glucose optimization.
Patients and methods: 50 T1DM patients who started CSII therapy at 2008 were 
included (10 males, 40 women; 39.6±11 years; diabetes duration 19.9±11 years; 
HbA1c 7.9±0.9%). Indications: suboptimal glucose control (n=31) and pre-ges-
tational optimization (n=19). TDD was calculated reducing around 20% the pre-
vious TDD in MDI regimen. TDD was divided into 50% basal (proportionally 
distributed along the 24 hours) and 50% pre-meal boluses (distributed according 
to carbohydrates at each meal). Doses and pattern distribution were modified ac-
cording to glucose profile during the follow-up (1, 2 and 3-5 months after CSII 
initiation). After glucose profile optimization (4-6 months), TDD, basal-bolus dis-
tribution and number of basal rates were recorded and HbA1c was measured.
Results: In comparison to TDD in MDI, TDD at the beginning of CSII was 
reduced by 18.3%. At the end of the study the reduction of TDD was only 
15.8% (non-significant). Basal rate was initially reduced by 17% and at the 
end by 8.6% (p<0.05). Basal rate represented 52.3 ± 11% of TDD at the be-
ginning, however at the end of the study represented 58.5 ± 18% (p<0.05). 
Women needed more proportion of basal rate than males (60.6 ± 18 vs. 49.1 ± 
13%; p<0.05), and those patients with diabetes duration >15 years, compared 
to those with <15 years of duration (61.8 ± 20 vs. 51.9 ± 12; p<0.05). Final 
number of basal rates/day were 5 ± 3 and this number was higher in patients 
with HbA1c<6.5% compared to those with HbA1c >6.5% at the end of the 
study (7.8 ± 4 vs. 4.1 ± 2; p<0.05). Basal rate infusion range was 0.81-1.01 
units/hour (maximum 5-8 h AM, minimum 9-12 h AM). No differences were 
found between reduction in boluses at the beginning or at the end of the study 
for each meal. The distribution of the doses dedicated to boluses was 37% for 
lunch, 33% for dinner and 30% for breakfast). HbA1c levels decreased signifi-
cantly 4-6 months after CSII initiation (HbA1c 7.1±0.9%; p <0.05).
Conclusion: In our T1DM patients starting CSII, the reduction of TDD from 
TDD used in MDI should be around 15%. Basal rate should be >50% of TDD 
especially in women and patients with longer diabetes duration (around 
60%). Basal profile should be divided in > 3 patterns/day, because higher 
number of basal rates/day was related with better glucose control. HbA1c 
decreased by 0.8% 4-6 months after CSII initiation.
Supported by: FIS PI080669
1007
Good metabolic control with a continuous subcutaneous insulin infusion 
(CSII) in type 2 diabetic patients uncontrolled by insulin optimisation
J.-P. Donnet1, J.-P. Courrèges2, S. Clavel3, T. Gabreau4, D. Gouet5, E. Verlet6, 
E. Cosson7, P. Jan8, B. Cirette9, E. Leutenegger10; 
1University Hospital Centre, Pointe à Pitre-Guadeloupe, 2Hospital Centre, 
Narbonne, 3Hospital Centre, Le Creusot, 4Hospital Centre, Auxerre, 
5Hospital Centre, La Rochelle, 6Hospital Centre, Dunkerque, 7Hospital 
Centre, Bondy, 8Hospital Centre, Bar le Duc, 9Dinno Santé, Marne la Vallée, 
10ABR Pharma, Paris, France.
Background and aims: Metabolic control in type 2 diabetic patients (T2D) 
treated with a continuous subcutaneous insulin infusion (CSII) is a real chal-
lenge. Moreover, it is a real great difficulty to reach in T2D the classic targets 
of GMC defined by normalization of Hba1c associated with no weight in-
creasing and no severe hypoglycemia, so what is the efficacy of ambulatory 
insulin pump in this T2D population?
Materials and methods: A longitudinal observational study is performed 
since 2009, involving 28 French hospital centres in order to described cir-
cumstances of insulin pump initiation and patient management over 3 years. 
We have selected a population of T2D patients with a poor metabolic control 
despite optimization of insulin treatment (3 or 4 injections/day).
Results: To date, 161 patients have been included in the study. Follow-up 
data are available for 60 patients. 5 patients have stopped CSII (patient’s wish 
- n=3, psychological reasons - n=2), and 55 patients were followed since one 
year: mean age 58±10 years old, 49% male and mean BMI 34±6 kg/m². 27 
patients (54%) have lost at least 10% of HbA1c since their inclusion and 19 
patients didn’t gain over 2 kg per point of HbA1c losing between inclusion 
and 1 year follow-up. A Good Metabolic Control (GMC) group has been de-
fined a posteriori with the following criteria: patient with no hypoglycaemia 
reported since inclusion who didn’t gain over 2 kg per point of HbA1c losing 
between inclusion and 1 year follow-up and who have lost at least 10% of 
HbA1c since their inclusion. According to those criteria, 16 patients (30%) in 
our cohort are in GMC. Despite the low number of patients, comparisons on 
principal criteria are presented in the table below: significant differences have 
been logically observed on weight and HbA1c criteria. A significant higher 
level of HbA1c at inclusion seems to be a predictive factor for targeting GMC 
criteria at 1 year follow-up (p=0.07).
Comparisons on principal criteria : GMC group versus Others group
*responding  
patients
GMC group Others 
group
Test 
value
Age (years) T0 62±6 57±11 ns
Sex (% women/ % men) T0 56/44 49/51 ns
Weight (kg) T0
T12
Δ* T0/T12
92±16
93±17
+0.37±3.08
96±20
99±21
+4.36±5.9
ns
ns
0.005
IMC (kg/m²) T0
T12
Δ* T0/T12
33.15±3.77
33.72±3.83
+0.23±1.27
34.41±6.50
35.51±6.49
+1.47±3.84
ns
ns
ns
HbA1c (%) T0
T12
Δ* T0/T12
9,99±2,34
7.75±1.52
-2.24±1.65
8,78±1,51
8.04±1.37
-0.62±1.58
0.07
ns
0.0004
Severe hypoglycaemia 
(%)
Before T0
Since T0
6
0
5
0
ns
ns
CSII associated with 
metformin (%)
T0 63 41 ns
Insulin dose (unit/kg/
day)
T0
Δ* Before T0/T0
Δ* Before T0/T12
0.76±0.3
-0.35±0.55
-0.34±0.49
0.83±0.32
-0.23±0.37
-0.10±0.43
ns
ns
ns
Conclusion: After 1 year of CSII, half of our patients obtain a good glucose 
control, and a third reach the targets of good metabolic control. These pre-
liminary data emphasize the benefit of this treatment for T2D patients with 
poor metabolic control despite basal bolus optimization. At this stage, it is 
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difficult to show predictive factors of targeting GMC criteria, but further data 
on the global cohort could be conclusive.
Supported by: DinnoSanté
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Insulin pump therapy safely improved glycaemic control and patient 
reported outcomes in patients with type 2 diabetes suboptimally 
controlled with multiple daily injections
J.P. Frias1, S.V. Edelman2, B.W. Bode3, T.S. Bailey4, M.S. Kipnes5,  
R.L. Brunelle6, X. Chen1; 
1Clinical Affairs, LifeScan, Inc., Milpitas, 2Department of Endocrinology 
and Metabolism, VA San Diego Healthcare Center, 3Atlanta Diabetes 
Association, 4AMCR Institute, Inc., Escondido, 5Cetero Research, San 
Antonio, 6Bowsher Brunelle Smith LLC, Carmel, USA.
Background and aims: Insulin pump therapy is an important treatment option 
for patients with type 2 diabetes (T2DM) who are suboptimally controlled with 
multiple daily injections (MDI). Limited data exist about pump therapy in this 
patient population. The objective of the present sub-analysis of a larger study was 
to assess the efficacy, safety and patient reported outcomes (PRO) of 16 wks of 
pump therapy in patients with T2DM suboptimally controlled with MDI therapy.
Materials and methods: In this 16-wk, open-label, multicenter study, 21 in-
sulin pump naïve patients treated with MDI ± oral antidiabetic agents (9 male, 
12 female, anti-GAD antibody negative, age 57±13, DM duration 15±6y, A1C 
8.4±1.0%, FPG 9.2±3.2mmol/l, body weight 98±20kg, BMI 34±5kg/m2, total 
daily insulin dose 99±65U [1.0U/kg], mean±SD) discontinued all diabetes 
medications except metformin and initiated insulin pump therapy (Animas® 
2020 insulin pump with insulin glulisine) with one daily basal rate and bolus 
doses at each meal. Insulin doses were titrated to safely achieve the best pos-
sible glycemic control. The primary outcome was assessment of insulin dose 
and insulin dosing patterns at Wk 16. Secondary outcomes included change 
in A1C, fasting and postprandial glucose, body weight, PRO (Insulin Deliv-
ery System Rating Questionnaire), and hypoglycemia.
Results: Glycemic control improved significantly after 16 wks of pump 
therapy: A1C 7.3±1.0% (-1.1±1.2%, p<0.001) and FPG 7.2±2.1mmol/l (-
2.0±4.1mmol/l, p<0.001). In patients with baseline A1C >8.5% (n=11, mean 
baseline A1C 9.1±0.5%), A1C was reduced by 1.9±1.3% (p<0.005). Mild hy-
poglycemia was experienced by 81% of patients at least once during the 16-
wk study with no episodes of severe hypoglycemia. At Wk 16, the mean daily 
basal, bolus, and total insulin doses were 66±36U, 56±40U, and 122±72U 
(1.2U/kg), respectively. 90% of patients were treated with ≤2 basal rates per 
day (1 basal rate 80%; 2 basal rates 10%). Body weight increased by 2.7±2.6kg 
(p<0.001). PRO measures improved significantly from baseline (Treatment 
satisfaction: 65±15 vs 81±15, p<0.001; Overall treatment preference: 58±14 
vs 93±16, p<0.001; Scale of 0-100, Mean±SD).
Conclusion: Insulin pump therapy using a simple dosing regimen signifi-
cantly improved glycemic control in patients with T2DM who were subop-
timally controlled with MDI therapy. Patients experienced moderate weight 
gain, no severe hypoglycemia and preferred pump therapy to baseline treat-
ment with insulin injections. Efforts to develop simple, cost-effective insulin 
pumps for patients with T2DM must continue. Future controlled trials are 
needed to further assess the benefits of insulin pump therapy in T2DM. 
Supported by: Animas Corporation
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A head-to-head-to-head comparison of three bolus calculators in 
subjects with type 1 diabetes
H.C. Zisser1, R. Wagner2, S. Pleus3, C. Haug3, N. Jendrike3, C. Parkin4,  
G. Freckmann3; 
1Clinical Research, Sansum Diabetes Research Institute, Santa Barbara, USA, 
2Global Medical Affairs, Roche Diagnostics Operations, Indianapolis, USA, 
3Institute for Diabetes Technology, Ulm, Germany, 4Health Management 
Resources, Inc., Carmel, USA.
Background: Insulin pump systems now provide automated bolus calculators 
(ABCs) that electronically calculate insulin boluses to address carbohydrate 
(CHO) intake and out-of-range blood glucose (bG) levels. We compared the 
efficacy of three ABCs (ACCU-CHEK® Combo [Roche IDS] / Animas® 2020 
[Animas] / MiniMed Paradigm Bolus Wizard® [MiniMed]) to safely reduce 
postprandial hyperglycemia (PPH) in type 1 diabetes mellitus (T1DM).
Methods: T1DM subjects (n=24) were recruited at a single center for a pro-
spective, triple cross-over study. ABCs with programmed target range (80-
140 mg/dl) were used in random order. PPH was induced by reducing the 
calculated bolus by 25%. At two hours after test meals, the ABCs were allowed 
to determine whether a correction bolus was needed. Differences between bG 
values at six hours after test meals that achieved 2-hour PPH and the mean of 
the target range (110 mg/dl) were determined.
Results: The mean difference between 6-h bG levels following test meals and 
the 110 mg/dl bG target with the MiniMed device (47.4 ±31.8 mg/dl) was 
significantly (P<0.05) higher than the Animas (17.3 ±30.9 mg/dl) and Roche 
(18.8 ±33.8 mg/dl) devices. The number of meals with 2-hour PPH and the 
bG levels at 2 hours was similar. Roche and Animas devices recommended 
correction boluses significantly more frequently than the MiniMed device 
(P<0.05). Significant hypoglycemia was not associated with ABC use.
Conclusion: In this study, the Roche and Animas devices were more effica-
cious in controlling PPH than the MiniMed device. Use of ABCs can assist in 
controlling postprandial glycemia without significant hypoglycemia.
Supported by: Roche
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Effects of evening meals with complex nutrient content on the nocturnal 
blood glucose levels of type 1 diabetes patients
S. Carstensen1, J.W. Huber1, M. Schönauer2, A. Thomas3; 
1Life Sciences, Roehampton University, London, United Kingdom, 
2Akademische Lehrpraxis der Universität Leipzig, Germany, 3Medtronic 
GmbH, Meerbusch, Germany.
Background and aims: Currently no therapy recommendations are available 
as to how postprandial blood glucose levels can be improved after meals rich 
in protein and fat. Recent epidemiological studies reported reduced insulin 
sensitivity resulting from fat and protein intake. This implies a need for ad-
ditional insulin in response to fat and protein intake; otherwise glycaemic 
control will be compromised. The aim of this study was to examine the ef-
fectiveness of calculating the insulin dosage required for an evening meal, 
taking into account the carbohydrate and the fat and protein content, in con-
trast to the usual concept of pure carbohydrate cover in adults with type 1 
(T1) diabetes using insulin pumps. The study focused on pump-treated T1 
diabetes patients.
Methods: Postprandial glucose values were examined over 12 hrs by con-
tinuous glucose monitoring (CGMS Medtronic), using a cross-over design. 
Fourteen insulin pump users took part in the study (10 females; age 39 ± 
9 years (mean ± SD), diabetes duration 16.4 ± 6.7 years, insulin pump use 
7.6 ± 3.3 years, HbA1c 7.3 ± 0.5%, BMI 26.4 ± 1.9 kg/m²). Patients with co-
morbidities or diabetes related complications were excluded. Participants 
received the same test meal (meat, potatoes, salad and vanilla ice-cream) on 
three successive evenings. The insulin doses were calculated using 5.5 carbo-
hydrate unit (1 carbohydrate unit = 10g carbohydrate) and 5.5 fat protein unit 
(1 fat protein unit (FPU) = 100kcal fat and protein). The insulin cover for the 
carbohydrate was a standard bolus (100% fast-acting) and a dual bolus (50% 
fast, 50% delayed over 8 hrs). As additional cover for fat protein unit the same 
insulin amount was used as for a carbohydrate unit. The insulin for the carbo-
hydrate was administered immediately before the meal (quick acting) and for 
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the fat protein unit delayed over 8 hrs (FPU bolus). Compared were the area 
under the curve (AUC) as a numerical integral from 145 (1 preprandial, 144 
postprandial) sensor glucose values, as well as the number of values under 
(<80 mg/dl), within (80-140 mg/dl) and above (>140 mg/dl) the target area 
from the sensor glucose values.
Results: The FPU bolus in comparison with the standard bolus led to a signifi-
cant improvement in the AUC (22.399 ± 5.909 versus 25.419 ± 6.139, p=.02) and 
highly significant both within (67 ± 51 versus 34 ± 36, p<.01) and above (74 ± 
52 vs. 108 ± 40, p=.01) the target area. For carbohydrate only based insulin dos-
age, no significant difference could be shown between the standard and the dual 
bolus; this applies to the total area under the curve and all 3 target areas from the 
sensor glucose values (25.419 ± 6.139 versus 25.292 ± 5.399, under 3 ± 7 versus 
1 ± 2; within 34 ± 36 versus 31 ± 26, above target 108 ± 40 versus 108 ± 40; all 
p-values >.5). Regarding the comparison between FPU bolus and dual bolus, 
significantly more values lay within (67 ± 51 versus 31 ± 26, p=.04) and signifi-
cantly fewer values above (74 ± 52 versus 108 ± 40, p=.03). The FPU bolus did 
not result in a difference for the lower target area (3 ± 6 versus 1 ± 2, p=.62).
Conclusion: The study therefore suggests that the therapy of T1 diabetes pa-
tients should consider insulin cover for the fat and protein portion of a meal 
as well as the carbohydrates, with the aim of optimising postprandial glucose 
values and glycaemic control. The study should be repeated in a larger group 
of insulin pump users with T1 diabetes.
Supported by: Abbott Diabetes Care
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Should the amount of fat and protein be taken into consideration to 
calculate preprandial insulin bolus?
M. Gonzalez-Rodriguez, A. Prieto-Tenreiro, M. Pazos-Couselo, P. Andujar-
Plata, R. Villar-Taibo, D. Peteiro-Gonzalez, C. Guillin-Amarelle, F.F. 
Casanueva-Freijo, J. Garcia-Lopez; 
Hospital Universitario de Santiago de Compostela, Spain.
Background and aims: Continuous subcutaneous insulin infusion (CSII) 
provides the most physiological way of insulin administration as we can 
program different basal rates and deliver different types of insulin boluses. 
Traditionally theses boluses are calculated according to the amount of car-
bohydrate (CH) eaten. However, there are very few data published related to 
changes in glycemic response according to meal composition(only carbohy-
drates (CH) or CH with protein and fat). Our aim is to determine whether the 
presence of protein and fat could involve a different postprandial glycemic 
response than that obtained with only CH.
Materials and methods: Observational prospective study. 19 type 1 diabetic 
patients (for at least 2 years) on CSII (for at least 3 months) wore a blind con-
tinuous glucose monitoring system sensor ( Minilink real time, Medtronic) 
for three days. They ingested on different days two meals with the same CH 
content but different fat and protein content. Mean A1c was 7.7% (range 6.5-
8.4%) and mean age was 34 years old (range 30-52 ).Exclusion criteria: celiac 
disease or any gastrointestinal disease, any diabetes complication and any 
medication that could modify gastric emptying. Our protocol was next:
- First day: The sensor was inserted and calibrated
- Second day: Patients ate meal 1: 60g of pasta + 50ml of tomato sauce (meal 
composition: 50g CH, 3.3g of protein and 8.9g of fat)
- Third day: Patients ate meal 2: 60g of pasta + 50ml of tomato sauce + 150g of 
veal chop + 10ml of olive oil (meal composition: 50g of CH, 28.9g of proteins 
and 37.4g of fat)
- Fourth day: Sensor was removed
During the monitoring, alcohol intake and exercise were not allowed. They 
performed one self-monitoring capillary blood glucose per hour and re-
mained in rest for a least 3 hours after each meal. They used the standard 
single-wave insulin bolus based on each subjects´s CH- to- insulin ratio and 
CH counting. Once downloaded the CGMS we analysed:
- Mean glucose 60 min pre-meal (Gm)
- Glucose Standard desviation (SD)
- Area under the curve described from the beginning of the meal until the 
glucose returned to levels pre-meal (AUC)
- Time (minutes) until glucose returned to values pre-meal (Tn)
- Maximum glucose peak (P)
- Time (minutes) to reach the maximum glucose peak (Tp)<br
A p value <0.05 was considered statistically significant.
Results: Patients started both meals with similar glucose levels. There were 
no statistical differences between both meals in Tn, AUC, P and Tp (Table 1). 
The greatest glucose peak was reached at 60 min and 79 min with meal 1 and 
2 respectively.
Conclusion: The presence of protein and fat did not determine a different 
glycemic response. Although a delayed postprandial glucose peak was found 
in meal 2, this did not reach statistical significance. According to our results, 
there is no need in using a different insulin bolus when we ate an equilibrated 
amount of CH, fat and protein in a meal.
Table 1. Gm, AUC, Tn, P and Tp with meal 1 and 2
Meal 1 Meal 2 p value
Mean Gm (mg/dl) 125.5 124 0.8
Mean AUC (mg/dl.min) 28.1 32.3 0.7
Mean Tn (minutes) 104.6 114 0.9
Mean P (mg/dl) 50 58.6 0.7
Mean Tp (minutes) 59.6 79 0.6
Supported by: sanofi-aventis
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The PANORAMA pan-European survey: glycaemic control and 
treatment patterns in patients with type 2 diabetes
P. de Pablos-Velasco1, C. Bradley2, E. Eschwège3, L.A. Gönder-Frederick4,  
K.G. Parhofer5, H. Vandenberghe6, D. Simon7; 
1Dr Negrin Hospital, Las Palmas University, Spain, 2Royal Holloway, 
University of London, United Kingdom, 3INSERM U-1018, Paris, France, 
4University of Virginia, Health System, USA, 5Klinikum der Universität, 
München, Germany, 6AstraZeneca, Zaventem, Belgium, 7Hôpital de la Pitié 
/ INSERM U-1018, Paris, France.
Background and aims: The prevalence of type 2 diabetes (T2D) continues 
to rise across Europe. Despite effective treatments initiated after diet/lifestyle 
modifications, many patients still do not achieve an HbA1c target of <7%. 
PANORAMA is a large pan-European cross-sectional survey (NCT00916513) 
of patients with T2D treated with glucose-lowering therapies, aimed at as-
sessing treatment satisfaction, quality of life and the proportion of patients 
achieving an HbA1c <7%. This abstract reports recent data from 8 countries 
on glycaemic control in patients with T2D in relation to treatment patterns.
Materials and methods: Patients with T2D were randomly or consecutively 
selected from physician practices (mainly in primary care) in 8 countries 
(Belgium, Germany, Greece, Italy, Netherlands, Spain, Turkey and UK). Eli-
gible patients: aged ≥40 y, with a diagnosis of T2D for >1 y prior to study en-
try and an available medical record at the clinic of >1 y. All patients received 
dietary and exercise advice. Most patients were also being treated with either 
oral hypoglycaemic agents (OHAs) or injectables (insulin and GLP-1 recep-
tor analogues) with or without OHAs. Treatment type was unchanged in the 
previous 3 months. HbA1c levels were measured using an identical portable 
diabetes monitoring system (Bayer’s A1Cnow®) in each centre.
Results: 5,156 patients were included in the study from June to November 
2009: 47.8% women; mean age 65.9 y (SD 10.3). Mean time since diagnosis: 
9.0 y (SD 7.4). Patients were treated with advice only (10.9%), advice plus 
either 1 OHA only (33.3%), 2 OHAs only (26.6%), ≥3 OHAs only (7.6%), or 
injectables with or without OHAs (21.6%). Treatment patterns varied consid-
erably between countries. Mean HbA1c of the entire group was 6.9% (SD 1.1). 
However, 36.7% of patients did not achieve an HbA1c <7%. The figure shows 
the percentage of patients in each treatment category who did not achieve the 
target HbA1c <7%.
Conclusion: When comparing the PANORAMA survey results with previous 
data, it appears that the level of glycaemic control in Europe may be improv-
ing. However, there is still a gap between current management and optimal 
treatment of patients with T2D. Furthermore, the percentage of patients not 
achieving target HbA1c increased as treatment was intensified. Possible ex-
planations are that concern over hypoglycaemia may have delayed treatment 
intensification, reduced treatment adherence or patients on more intensive 
treatment may have had more difficult to control T2D perhaps due to a longer 
duration of T2D. These results suggest that earlier and/or more effective in-
tensification of treatment may be needed to enable patients to achieve target 
HbA1c as the disorder progresses.
Supported by: AZ & BMS
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The Mapping Glycaemic Control Across Australia (MGCAA) study: a 
population based national diabetes surveillance study
C. Michaelides1, M. Daja2; 
1Mater Hill Family Medical Centre, Brisbane, Australia, 2Novo Nordisk, 
Sydney, Australia.
Background and aims: There are approximately 1.4 million Australians over 
the age of 25 with diabetes. More than half experience suboptimal glycaemic 
control, placing themselves at significant risk of complications and hospi-
talisation. Benchmarking glycaemic control is the first step in establishing a 
Diabetes Surveillance System, which allows for the development of targeted 
interventions to regions with the greatest need, as well as the subsequent 
monitoring of any intervention success. In Australia, previous studies have 
provided good quality data benchmarking glycaemic control at a national 
level. However, none have been able to benchmark, quantitate or qualify gly-
caemic control geographically at a national, state, Division of Primary Care 
and postcode level. Furthermore, none have been inclusive of demographic, 
clinical and biochemical markers. Considering the population diversity in a 
country as large and geographically diverse as Australia, such information is 
critical to the optimisation of diabetes resource management. The MGCAA 
study has achieved this.
Materials and methods: De-identified data including HbA1c, lipids, age and 
gender were collected from private pathology laboratories. The data were 
cleaned (duplicates and screening HbA1c values removed) and stratified 
geographically, providing a community population sample of approximately 
250,000 diabetes patients. Demographic data including socioeconomic, life-
style and cultural data were obtained and incorporated into the sample. The 
data were reported at a national, state and division of primary care regional 
level and made available via electronic mapping tools. Data from this first 
year of collection were regarded as benchmark data. Data were collected the 
following year and the cohort identified in year 1, were tracked and analysed, 
establishing a diabetes surveillance system. This is the first of a 5 year follow 
up period.
Results: Of the original 250,000 patient data collected in 2007, 56% had 
repeat data available in 2008 for follow-up (~140,000 patient samples), rep-
resenting 10% of the estimated diabetes population of Australia. Although 
change in national glycaemic control was marginal (7.7% in 2007 vs 7.6% in 
2008), there were clear regional differences in both mean HbA1c as well the 
proportion of patients achieving HbA1c targets (Fig 1). Regional differences 
were apparent with the proportion of these patients achieving HbA1c glycae-
mic targets of <7% increasing in 4 states, remaining the same in 2 states and 
decreasing in 2 states.
Conclusion: The diabetes surveillance system can be interrogated to iden-
tify trends in glycaemic control, regional differences and those Divisions of 
Primary Care and the associated postcodes with the greatest glycaemic im-
provement (Fig 1) as well as those with the greatest need. Strategic interven-
tions incorporating processes identified from areas with the greatest success 
can then be implemented and effectiveness monitored through prospective 
surveillance.
Supported by: Novo Nordisk
1014
Development in quality of treatment and changes in treatment regimens 
in complicated type 2 diabetes
L. Lundby-Christensen, A. Anker-Nielsen, T.P. Almdal; 
Steno Diabetes Center, Gentofte, Denmark.
Background and aims: Optimal treatment of Type 2 Diabetes (T2D) relies 
on a multifactorial approach. Approximately 1800 patients with T2D are con-
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trolled at the outpatient clinic at Steno Diabetes Center (SDC), which is a 
specialized diabetes hospital in Denmark. A high proportion of these suffers 
from one or more complications, i.e. app. 60% have micro or macro-albu-
minuria, app. 9% have undergone retinal laser treatment and app. 30% suffers 
from severe neuropathy. The purpose of this study was to assess to which 
degree the treatment goals as defined by ADA and documented in the Steno 
2 study published 2003 is achieved, before and after the publication of these 
results.
Materials and methods: Patients treated at SDC have since 2001 all been reg-
istered in an electronic patient record system. All patients with T2D who have 
attended the outpatient clinic for ≥6 month in the years 2002, 2006 and 2009 
were identified. The proportion of patients reaching ADA treatment goals 
with regard to HbA1c, blood pressure (BP) and lipids was identified as shown 
in the table. Furthermore, the proportion of patients receiving different anti-
diabetic treatment regimens (oral antidiabetics (OAD) only, insulin only or a 
combination of OAD and insulin) was identified.
Results: The survey shows that it was possible to achieve the treatment goals in 
the majority of the patients with regard to lipid levels and diastolic BP, whereas 
this was not the case with regard to systolic BP and HbA1c. However, it was 
possible to approximately double the proportion of patients achieving the treat-
ment goal of HbA1c in the years 2002 to 2006. In the same period the propor-
tion of patients receiving a combination of OAD and insulin increased by 13%, 
whereas the proportion of patients receiving insulin monotherapy decreased by 
10%. The proportion of patients treated with either diet (3-4%) or OAD only 
(19-20%) was unchanged throughout the period. With regard to BP lowering 
agents the proportion of patients receiving two or more agents increased from 
55 to 67% in the period whereas the proportion of patients receiving lipid low-
ering medication increased from < 40% to >80% (data not shown).
Conclusion: The results suggest that in patients with complicated T2D it is 
possible to achieve near optimal results with regard to lipid levels and di-
astolic BP and acceptable control with regard to systolic BP. With regard to 
glucose control, it is possible to markedly increase the proportion of patients 
achieving treatment goal, however, even more focus is needed.
Changes in treatment regimens and achievement of clinical goals provided in percentages of patients
Year Treatment 
with OAD 
only
Treatment 
with insulin 
only
Treatment 
with OAD 
+insulin
HbA1c 
≤ 7.0%
Diastolic BP  
≤ 80 mmHg
Systolic BP ≤ 
130 mmHg
Total cholesterol 
≤4.5 mmol/l
LDL cholesterol 
≤2.5mmol/l
2002 20 48 28 15 60 27 35 44
2006 19 38 41 28 68 27 70 80
2009 20 39 39 25 66 38 71 79
1015
Socio-economic status, incidence of type 2 diabetes and relative 
mortality in Scotland 2001-2007
S.H. Wild, Scottish Diabetes Research Network Epidemiology Group; 
Centre for Population Health Sciences, University of Edinburgh, United 
Kingdom.
Background and aims: Relative risks of mortality associated with type 2 dia-
betes (T2DM) have declined in recent years but are higher in women than 
men in many populations. The role of socio-economic status (SES) in risk of 
mortality among people with diabetes is not clear.
Materials and methods: We used data from a population-based national dia-
betes register to investigate the associations between T2DM, socio-economic 
status (SES) and mortality. SES was categorised with Q5 and Q1 representing 
the most deprived and most affluent quintiles from an area-based measure. 
Age-standardised incidence for 2004 and relative risks (RR) for all-cause 
mortality among people with incident T2DM of 35 to 84 years of age between 
2001 and 2007 were estimated using general population data, the European 
standard population and Poisson regression models.
Results: Complete data were available for 111,441 people who developed type 
2 diabetes between 2001 and 2007 and there were 8,775 deaths before the end 
of 2007. SES had a more marked effect on age-standardised incidence among 
of T2DM women (717.5 vs 357.2 per 100,000, age-adjusted RR for Q5 vs Q1 
(95% confidence interval [CI]) 1.91 (1.62-2.25)) than men (comparable esti-
mates 918.6 vs 568.9 per 100,000, 1.59 (1.38-1.84)). Age and SES adjusted RR 
(95% CI) for mortality were 0.97 (0.93 to 1.01) for men and 1.11 (1.07 to 1.16) 
for women. Age and sex adjusted RR for mortality associated with type 2 dia-
betes was lower for Q5 (0.93 (0.89-0.97)) than for Q1 (1.19 (1.12 to 1.27)).
Conclusion: Relative risks for mortality associated with incident T2DM were 
lower in this population than reported in previous studies. Incident diabetes 
was not associated with increased mortality among men but was associated 
with higher mortality in women compared to women without diabetes. SES 
modifies the effect of T2DM on mortality but does not explain sex differences 
in RR. Further work is required to establish whether these findings can be 
explained by risk factor patterns.
Supported by: Scottish Government, Scottish Health Informatics Programme
1016
The national inpatient diabetes audit reveals poor levels of inpatient foot care
G. Rayman1, C.G. Taylor Jr.1, R. Malik2, R. Hilson3; 
1The Diabetes Centre, Ipswich Hospital, 2Kings College Hospital, London, 
3The Department of Health, London, United Kingdom.
Background and aims: The standards of expected inpatient foot care have been 
recently outlined in the document “Putting feet first” however there has been no 
previous national assessments of the burden or quality of inpatient foot care.
Materials and methods: A national audit of clinical care was undertaken in 
acute hospitals in the UK on a single day between the 21st and 25th of Sep-
tember to determine diabetes prevalence, quality of care and patient experi-
ence. The audit form included key questions related to areas of foot care. The 
National Diabetes Inpatient Audit Day database was analysed to assess the 
standard of foot care.
Results: 14,259 patients in 219 hospitals were audited. 11.6% had a past his-
tory of foot disease. When diabetes was the primary reason for admission a 
foot problem was the most frequent diagnosis (24.9%), yet only 79% were 
referred to the foot team. 26% of hospitals did not have a multidisciplinary 
foot team. Mean length of stay was 22 days for those admitted with a foot 
complication compared with 15 days for other diabetes related admissions. 
Only 34% of patients recalled a visual foot inspection and only 30% a physical 
foot examination. In-hospital foot complications developed in 3%.
Conclusion: The figures are concerning. The audit confirms the significant 
inpatient burden of foot disease but also a disturbingly poor level of foot 
care. The results support the urgent need to implement foot awareness pro-
grammes such as “Putting Feet First”.
Supported by: NHS Diabetes, Leicester, UK
1017
Clinical inertia in patients with type 2 diabetes and poor glycaemic 
control in a multicentric sample of patients cared for in primary in 
Catalonia (Spain)
B. Benito-Badorrey1, M. Mata-Cases1, P. Roura-Olmeda1, G. Coll de Tuero2, 
J. Pepió-Vilaubí2, J. Franch-Nadal1, Gedaps (Primary Care Group for the 
Study of Diabetes). Catalonian Society Family & Community Medicine; 
1Gedaps, 2Camfic, Barcelona, Spain.
Background and aims: To assess clinical inertia (the providers’ failure to 
increase therapy when treatment goals are unmet) in patients with type 2 
diabetes (DM2) cared for in primary care.
Materials and methods: A multicentric cross-sectional study. Clinical in-
ertia, defined as absence of modification of the treatment in patients with 
HbA1c> 7 %, was assessed in a random sample of patients with DM2 cared 
for in 52 primary care centres of Catalonia (Spain) in 2007.
Results: A total of 3130 patients were evaluated of whom 2783 had some 
HbA1c value. Of these, 997 had an HbA1c>7 %; 51.1 % males; mean age 67.1 
years, standard deviation (SD) 12.1; 8.2 years of diabetes evolution-SD 6.3. 
Some changes were made in 66.8% patients: insulin dose increase in 40.5%, 
the addition of an oral agent in 45.8% or the start of insulinization in 3.7%. 
The mean value of HbA1c in patients for whom treatment was changed was 
8.4%. Clinical inertia was observed in 33.2% of patients (CI95% 30.31-36.1); 
decreasing with the complexity of treatment: diet 38,8% (CI95% 20.2-57.4%), 
a single oral drug 40.3% (CI95% 35.2-45.4), two or more oral agents 34,5% 
(CI95% 23,3-45,7), insulin in monotherapy 26.1% (CI95% 18,2-34.0) and 
insulin plus oral agents 21.4% (CI95% 20,9-33,3). Clinical inertia decreased 
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as HbA1c increased: 37.3% (CI95% 33.2-41.4) between 7.1 and 8%; 29.4% 
(CI95% 23.5-34.9) between 8.1 and 9% and 27.1% (CI95% 20.9-33.3) if ≥9%. 
There were no differences in the characteristics of the patients in which the 
treatment was modified or not. The greatest opportunity for improvement 
lies in patients treated with diet or oral monotherapy (40.5%)
Conclusion: Clinical inertia affects a third of diabetic patients with poor gly-
cemic control and is more related to a close to objective HbA1c value than to 
the complexity of the treatment or the patient characteristics. The changes are 
introduced with a mean HbA1c well above the therapeutic goal.
1018
Poor glycaemic control in secondary care insulin treated patients 
correlates with bad process indicators
N. Debacker1, P. Van Crombrugge2, C. Mathieu3, F. Nobels2, V. Van 
Casteren1, A.J.L. Scheen4; 
1Public Health & Surveillance, Scientific Institute of Public Health, Brussel, 
2Endocrinology, OLV Ziekenhuis, Aalst, 3Experimental Medicine and 
Endocrinology, KU Leuven, 4Division of Diabetes, Nutrition, and Metabolic 
Disorders, CHU Sart Tilman, Liège, Belgium.
Background and aims: Evidence based medicine and quality control systems 
drive diabetes care, but room for improvement, not only in glycemic control, 
but also in follow up of other outcome and process indicators, exists. In the 
present study we examine how glycemic control is related to other outcome 
and process indicators.
Materials and methods: We used the 2009 data from a Belgian quality assur-
ance study that has been carried out since 2001 in all hospital-based diabetes 
centres (n=113) and provides data (demographics, blood glucose control, 
cardiovascular risk status, diabetes complications, self-monitoring, and drug 
treatment) on a cross-sectional random 10% sample of the adult type 1 and 
type 2 diabetes patients on ≥ 2 daily insulin injections. Logistic regression 
analysis was used to examine the relationship of HbA1c with 5 process and 5 
outcome indicators, while adjusting for age, diabetes duration and gender.
Results: In the type 1 diabetes population (n=3407; 57% males) the median 
age, diabetes duration and HbA1c were 47 years, 17 years and 7.8%, respec-
tively. In the type 2 diabetes population (n=7879; 49% males) the median age, 
diabetes duration and HbA1c were 69 years, 14 years and 7.5%, respectively. 
Table 1 shows the performance in terms of process and intermediate out-
come by HbA1c and diabetes type (Table legend: (1) p<0.05; (2) p<0.01; (3) 
p<0.001: Results from logistic regression analysis, after adjustment for age, 
gender and diabetes duration. HbA1c < 7% is used as reference.). Especially 
in type 2 and to a minor extent in type 1 diabetes, patients with the worst 
glycemic control (HbA1c ≥ 9%) were significantly less likely to be screened 
for complications (except for microalbuminuria screening) than the patients 
with optimal glycemic control (HbA1c < 7%). In both diabetes types, pa-
tients with suboptimal glycemic control (HbA1c ≥ 7%) were significantly less 
likely to reach blood pressure and blood lipid targets compared to patients 
with optimal glycemic control. Moreover in type 1 diabetes the proportion 
of smokers increased significantly with increasing HbA1c. These results were 
independent of age, diabetes duration and gender.
Conclusion: Quality of care in this population of diabetes patients with ad-
vanced disease stage was relatively good in terms of process and intermedi-
ate outcome. However suboptimal glycemic control was found to go hand in 
hand with poorer results for both other outcome and process indicators. The 
identification of patients characterised by this cluster of poor performance 
and of the causal factors merits further investigation.
Type 1 diabetes Type 2 diabetes
HbA1c <7%(n=692)
7-7.9%
(n=1119)
8-8.9%
(n=891)
≥9%
(n=677)
<7%
(n=2473)
7-7.9%
(n=2689)
8-8.9%
(n=1589)
≥9%
(n=1031)
% Screening microalbuminuria 89 88 88 87 86 86 84 82
% Eye examination 85 87 87 80(2) 83 82 84 76(3)
% Foot sensation examination 88 87 85 84 81 81 81 77(3)
% Foot pulses examination 88 89 91 88 87 88 88 85(1)
% ≥ 3 HbA1c determinations/year 68 75(1) 70 60(2) 57 60 57 48(3)
% Blood pressure < 130/80 mmHg 40 32(2) 33(1) 32(1) 24 21(2) 19(3) 20(2)
% LDL < 100 mg/dl 63 59 52(2) 49(2) 65 66 62(1) 53(3)
% Cholesterol < 175 mg/dl 53 45(1) 42(2) 36(3) 60 58(1) 55(3) 46(3)
% BMI < 25 kg/m² 52 45 45 46 15 13 13 12
% non-smoking 84 82(1) 77(3) 67(3) 88 87 87 83
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Fifteen years of improvement in process and outcome indicators in 
the management of type 2 diabetes mellitus in primary care centres in 
Catalonia, Spain
M. Mata-Cases1, B. Benito-Badorrey1, P. Roura-Olmeda1, G. Coll de Tuero2, 
J. Pepió-Vilaubí2, J. Franch-Nadal1, Gedaps (Primary Care Group for the 
Study of Diabetes). Catalonian Family &Community Medicine Society; 
1GEDAPS, 2Catalonian Family & Community Medicine Society, Barcelona, 
Spain.
Background and aims: To assess the evolution of the quality indicators of 
type 2 diabetes care in Primary Health Care centres in Catalonia over 15 years 
(1993-2007).
Materials and methods: A multicentric cross sectional study with the same 
sampling methodology in 7 evaluations. Continuous quality improvement 
program of GEDAPS (Primary care Group for the study of Diabetes) from 
the Catalonian Society of Family and Community Medicine. Assessment of 
the process and outcomes indicators in a randomized sample from each cen-
tre. Number of participating centres: 57 in 1993, 75 in 1995, 75 in 1998, 78 
in 2000, 96 in 2002 and 52 in 2007. Sample sizes: 2239 in 1993, 3532 in 1995, 
4217 in 1998, 45667 in 2000, 5819 in 2002 and 3130 in 2007.
Results: We observed a significant improvement in the following process in-
dicators: foot examination from 49% (CI95% 46.9-51.1) to 64% (CI95% 62.3-
65.7); laboratory measurements: HbA1c from 69% (CI95% 67.1-70.9) to 89% 
(CI95% 87.9-90.1), cholesterol from 76% (CI95% 74.2-77.8) to 91% (CI95% 
90.0-92.0) and albuminuria from 34% (CI95% 32.0-35.9) to 59% (CI95% 
57.3-60.7). A significant improvement in intermediate outcome indicators 
was seen in glycemic control (HbA1c <7%) from 39% (CI95% 37.0-41.0) to 
65% (CI95% 63.3-66.7) and cholesterol (total cholesterol <200 mg / dl) from 
26% (CI95% 24.2-27.8) to 61% (CI95% 59.3-62.7). There was no change in 
the strict control of blood pressure (BP <130/80 mmHg) 22% vs 21%, but 
an improvement was seen with a less stringent criteria (BP <140/90 mmHg) 
45% (CI95% 42.3-47.1) vs 57% (CI95% 55.3-58.7). We observed a significant 
reduction in the prevalence of the following final outcome indicators: foot ul-
cer 7.9% (CI95% 6.8-9.0) vs 2.6% (CI95% 2.0-3.2), amputation 2.1% (CI95% 
1.5-2.7) vs 0.6% (CI95% 0.3-0.9) and retinopathy 37% (CI95% 35.0-39.0) vs 
15% (CI95% 13.7-16.2).
Conclusion: There were significant improvements in some of the process 
indicators, the glycemic, blood pressure and lipid control and a decrease in 
complications like retinopathy and diabetic foot.
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PS 96 Monitoring and delivering: 
practicalities for every day practice
1020
Use of an alcohol-based hand sanitiser did not affect readings of a blood 
glucose monitoring system
D. Price, J. Mahoney, J. Ellison, C. Chu, S. Nandagopalan, J.P. Frias; 
LifeScan, Inc., Milpitas, USA.
Background and aims: People with diabetes mellitus (DM) are instructed to 
wash their skin with soap and water prior to self-monitoring of blood glucose 
(BG) to remove any dirt or food residue that might alter the reading. Alco-
hol-based hand sanitizers have become popular when soap and water are not 
available. The aim of this study was to determine whether the use of a com-
mon hand sanitizer has any effect on BG results from a meter system.
Materials and methods: We enrolled 34 non-fasting subjects (14 male/20 
female, mean age 45(SD: 9.4)y, 2 with DM). Laboratory personnel prepared 
four separate fingers on one hand of each subject by: 1) washing with soap 
and water and towel drying (control finger); 2) cleaning with hand sanitizer 
(Purell® Instant Hand Sanitizer with Aloe, active ingredient 65% ethyl alco-
hol, Johnson & Johnson Consumer Products, Skillman, NJ) per instructions 
(Purell finger); 3) coating with cola (Coca-cola, Coca-Cola Company, Atlanta, 
GA) and air drying (cola finger); and 4) coating with cola and cleaning with 
Purell after cola dried (Purell after cola finger). Fingersticks were performed 
on each prepared finger and BG was measured with the OneTouch® Ultra® 
Blood Glucose Monitoring System (LifeScan Inc., Milpitas CA). YSI plasma 
glucose was also measured using the control finger. BG tests, shown in the 
table, were completed within 10 minutes.
Results: Mean BG values from the Purell finger and Purell after cola finger 
did not differ significantly from the Control finger (p=0.07 and 0.08, respec-
tively). Cleaning with Purell resulted in 100% and 99% accurate readings 
versus YSI based on ISO 15197 and consensus error grid (zone A) analysis, 
respectively. Cola finger BG was substantially higher than the other skin con-
ditions. In 16 cases, cola residue caused blood samples to smear and produce 
error messages and in 3 cases, cola residue caused BG values > 600 mg/dL 
(excluded).
Conclusion: In our study, cleaning with Purell hand sanitizer did not affect 
fingerstick BG tests performed with the OneTouch® Ultra® System.
Table: Glucose Mean (SD), N, and Finger Condition after Preparation (as 
described).
Finger Skin Condition N Glucose, Mean (SD), mg/dL
Control finger 34 100.6 (16.5)
Purell finger 34 103.6 (17.1)
Cola finger 15 182.9 (102.8)
Purell after Cola finger 34 103.8 (17.4)
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Improving the reliability of capillary blood glucose monitoring: using 
the first or second drop of blood
J. Hortensius1, R.J. Slingerland2, M.J. Fokkert2, N. Kleefstra1,  
K.H. Groenier3, S.T. Houweling4, R.O.B. Gans5, H.J.G. Bilo1; 
1Diabetes Centre, Isala Clinics, Zwolle, 2Clinical Chemistry, Isala Clinics, 
Zwolle, 3General practice, University of Groningen, 4General practice, 
Sleeuwijk, 5Internal Medicine, University Medical Center, Groningen, 
Netherlands.
Background and aims: Self monitoring of blood glucose (SMBG) is an im-
portant tool to achieve good glycemic control. Several aspects concerning 
SMBG need attention. Eg, there is no general agreement regarding the use 
of the first or second drop of blood for glucose monitoring. Various inter-
national studies and recommendations, advise to use the first drop of blood, 
after washing hands with water and soap. Still, in daily practice patients can 
not or do not always wash their hands. Our aim was to investigate the influ-
ence of having clean or soiled hands on glucose concentration in the first and 
second drop of blood.
Materials and methods: Eligibility criteria were patients with diabetes mel-
litus type 1 (T1DM) or type 2 (T2DM), using insulin, age above 18 years. A 
cross-sectional, ‘within subjects’ design was used. Wilcoxon Signed Rank Test 
was used to test for differences in glucose concentrations. Capillary glucose 
concentrations were measured in two consecutive drops of blood in the fol-
lowing three circumstances. Firstly, without washing hands, secondly, after 
washing hands with water and soap, and thirdly, after soiling the fingers with 
apple or banana. Results were compared to a control measurement in each 
finger used in the study. Results were also assessed, looking at the frequency 
of differences ≥ 10 % higher glucose concentrations vs control.
Results: Recruitment took place between September 2009 and January 2010. 
Our study population consisted of 123 patients, 63 (51%) men, 66 (54%) 
T1DM patients, and 57 (46%) T2DM patients, mean age was 54,4 years (SD 
14,2) mean HbA1c was 58 mmol/mol (or 7,5% SD 1,3) and mean BMI was 29 
kg/m2 (SD 6,2). The table shows glucose concentrations for the three different 
circumstances. Not washing hands led to more than 10% higher glucose con-
centrations in the first and in the second drops of blood in 10% of the patients 
(p<0.001). Fingers soiled with fruit led to more than 10% higher glucose con-
centrations in the first and in the second drop of blood in 91% and 13% of the 
patients, respectively (p<0.001 and p=0.002 respectively). After washing the 
soiled fingers, glucose concentrations were more than 10% higher in 2% and 
4% of the patients, respectively. In 2 - 3% of the patients the glucose concen-
trations in the first drop of blood of clean hands were 10% higher than in the 
second drop of blood (not significant).
Conclusion: The first drop of blood of unclean hands should not be used 
to allow a reliable glucose measurement. Although wiping the first drop of 
blood of unclean hands improves readings considerably, in 10 - 13% of the 
patients the glucose concentrations are still 10% higher than the control 
measurement. The first drop of blood can probably only be used when the 
fingers are clean.
glucose concentrations (mmol/L ) and median (interquartile ranges) in dif-
ferent circumstances
first drop of blood second drop control
not washing hands 8.9 (6.4 - 12.6) 8.9 (6.5 - 12.3) 8.7 (5.9 - 12.2)
washing hands 8.5 (6.3 - 12.2) (is control) 8.7 (5.9 - 12.2)
soiled finger 15.0 (10.5 - 21.7) 8.8 (6.5 - 12.4) 8.9 (6.4 - 12.3)
washing hands after  
soiling the finger
8.3 (6.3 - 11.9) 8.2 (6.3 - 12.0) 8.6 (6.2 - 12.0)
Supported by: sanofi aventis, Roche Diagnostics Nederland BV
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The effect of haematocrit on the results of measurements using glucose 
meters based on different techniques
B. Solnica1, B. Kusnierz-Cabala1, K. Slowinska-Solnica1, J. Skupien2,  
P. Witek3, A. Cempa3, M.T. Malecki3; 
1Dept. of Diagnostics, Jagiellonian University Medical College, Krakow, 
Poland, 2Joslin Diabetes Center, Harvard Medical School, Boston, USA, 
3Dept. of Metabolic Diseases, Jagiellonian University Medical College, 
Krakow, Poland.
Background and aims: Hematocrit (HT) affects the measurement accuracy 
of glucose meters. Glucose concentrations measured in samples with high 
HT values are decreased whereas in samples with low HT are increased as 
compared to the laboratory method. This effect caused mainly by plasma dis-
placement may vary between different devices. The aim of the study was to 
evaluate the effect of HT on glucose meter assays based on different measure-
ment techniques.
Materials and methods: We studied glucose meters utilizing the glucose 
dehydrogenase reaction and four measurement techniques. The HemoCue 
(HemoCue AB) uses colorimetry, the Accu-Chek Active (Roche Diagnostics) 
- reflectometry, The Optium Xido (Abbott Diabetes Care) - amperometry 
and the Optium Omega - coulometry. EDTA venous blood samples with glu-
cose concentrations ranging from 40 to 412 mg/dL were used. We modified 
the samples HT by adding or removing defined aliquots of plasma. Glucose 
concentrations measurements were performed using each evaluated meter 
in 27 batches, each containing 5 blood samples with HT amounting to 20%, 
30%, 40%. 50%, and 60%. Altogether, 540 glucose assays (108 batches) were 
performed.
Results: A significant relationship between HT and glucose reading in all 
meters was found - the relative decrease in glucose concentration per 1% in-
crease in the HT value amounted from 0.51% for Optium Omega to 1.28% 
for Optium Xido (p<0.0001). Moreover, for all meters, except Optium Xido, 
there was a significant modification of this relationship by glucose level. The 
mixed effects model after logarithmic transformation of glucose concentra-
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tions, stratified by glucose level (200 mg/dL) showed a significant (p<0.0001) 
relative decrease in glucose level per 1% increase in HT for all meters in all 
strata ranging from 0.30% for Optium Omega in stratum <100 mg/dl to 
1.32% for HemoCue in the same stratum. According to the ADA recom-
mendations, the glucose meter error should not exceed 5%. In <100 mg/dL 
stratum this threshold would be reached after about 3.6% to 4.1% HT change 
in all meters except of Optium Omega, for which a change of 16.6% would 
be needed (p<0.0001). In 100-200 mg/dL stratum Optium Xido reached the 
error threshold after 4.2% change in HT, compared to values in the range 
of 7.9% to 11.1% for other devices (p200 mg/dL stratum, similarly, Optium 
Xido reached this threshold after 3.9% change in HT (p<0.0001), while for 
the other meters it varied from 7.2% to 12.5%.
Conclusion: There is a significant continuous effect of HT on measurement 
accuracy of glucose meters across the wide range of HT values and glucose 
concentrations. Amperometric measurements seem to be more sensitive, 
while the coulometric technique appears to be less sensitive to the HT inter-
ference than photometric techniques.
1023
Use of GDH-PQQ glucose meter systems in patients receiving maltose-
containing therapies
N.S. Virdi1, D. Price1, J. Ellison1, S. Yadalam2, S. Nigam2; 
1LifeScan, Inc, Milpitas, 2Johnson &Johnson, New Brunswick, USA.
Background and aims: Blood glucose measurement (BGM) systems utiliz-
ing the enzyme, glucose dehydrogenase pyrroloquinoline quinone (GDH-
PQQ), have lead to falsely elevated “glucose” readings in patients on medica-
tions containing maltose or a maltose precursor. Examples include icodex-
trin (a peritoneal dialysate metabolized to maltose), and OCTAGAM® and 
abatacept, which contain maltose as excipients. Over the past 10 years FDA’s 
MAUDE Database and the literature have included multiple reports of severe 
hypoglycemia and death related to overtreatment with insulin or delayed de-
tection of hypoglycemia, because of falsely high readings on GDH-PQQ me-
ters. We reviewed a payor database to assess how frequently patients receiving 
OCTAGAM or abatacept also use a GDH PQQ meter system . Data were 
not available for peritoneal dialysis and limited for other maltose-containing 
therapies.
Materials and methods: The analysis used the Thomson Reuters Marketscan 
Database (years 2007 through Q1 2009), a large U.S. administrative claims 
database representing about 35.7 million employed, commercially-insured 
persons. We queried for persons with diabetes using glucose meters. This 
population was divided into three groups: Group 1 - Patients using only 
GDH-PQQ meters, Group 2 - Patients using only non-GDH-PQQ meters, 
and Group 3 - Patients using both GDH-PQQ and non-GDH-PQQ meters. 
The query identified patients who had received abatacept or OCTAGAM and 
ordered BGM test strips during the same quarter. As each quarter in the data-
base is updated over time, the most recent quarters may be incomplete.
Results: The search identified 798,110 patients ordering BGM test strips dur-
ing the two and one-quarter year period: 40.7% in Group 1, 54.7% in Group 
2, and 4.6% in Group 3. Of these patients, 366 had also received abatacept 
or OCTAGAM infusions: 43.2% in Group 1, 45.6% in Group 2, and 11.2% 
in Group 3. Including those not using BGM, 5503 patients had received 
abatacept or OCTAGAM. The chart below compares the number of infusion 
events per group over the period Q1/2007 - Q1/2009. The majority (60%) of 
infusions were associated with Group 1 vs. 40% for Group 2. During the time 
period of observation, no decrease in the proportion of infusions associated 
with GDH-PQQ meters has occurred.
Conclusion: This study demonstrated that patients with diabetes on thera-
py with either abatacept or OCTAGAM frequently use GDH-PQQ meters, 
which are susceptible to maltose interference. Despite labeling (on both 
BGMs and medications) and FDA safety alerts, there is evidence that health 
care professionals and patients continue to prescribe and use, respectively, 
BGM systems susceptible to maltose interference despite patient exposure 
to therapies containing maltose. While use of abatacept and OCTAGAM is 
limited, the common usage of GDH-PQQ meters by patients taking these 
medications puts them at risk for obtaining falsely elevated blood glucose 
results that may contribute to or delay detection of hypoglycemia.
1024
Comparison of insulin diluent leakage post injection using two different 
needle lengths and injection volumes in obese patients with type 1 or 
type 2 diabetes mellitus
K.R. Kelly1, S. Sarwat1, M.A. Carey2, D.A. Ignaut1; 
1Eli Lilly and Company, Indianapolis, 2i3 Statprobe/UHG, Minneapolis, 
USA.
Background and aims: Although the current market offers several different 
needle lengths for the injection of insulin, obese patients with diabetes are 
often advised to use longer needles (≥8-mm). Smaller, shorter needles have 
been shown to be safe and effective for insulin delivery while reducing patient 
discomfort. This study compared injections with 5-mm needles to injections 
with 8-mm needles regarding leakage, blinded pain, bleeding, and bruising at 
abdominal injection sites in obese patients with diabetes.
Materials and methods: Patients (n=56; 54% male; mean age=56; mean 
BMI=36 kg/m2; insulin pen-naïve) with type 1 (n=13) or type 2 (n=43) dia-
betes participated in a randomised feasibility trial with patients blinded to 
needle length. Patients were injected by the investigator 3-5 times (to obtain 
3 injections without bleeding to accurately measure leakage) in the abdomen 
with either 20 U equivalent (200 μL) volumes or 60 U equivalent (600 μL) 
volumes of sterile insulin diluent with both a 5-mm and 8-mm needle us-
ing a conventional insulin pen injector, HumaPen® MemoirTM. The primary 
objective was to evaluate leakage at the injection site (by blotting with filter 
paper and weighing the filter paper using a tared, calibrated analytical bal-
ance) following injections (20 U and 60 U equivalent volumes) with 5-mm 
and 8-mm needles using a 4-step gatekeeping strategy. The success criterion 
for each gatekeeping step was defined such that the upper limit of the 90% 
CI for median leakage was <5% of the injected volume. Non-inferiority of 
5-mm needle leakage compared to 8-mm leakage was evaluated with similar 
methodology. Secondary objectives were to compare injections (20 U and 
60 U equivalent volumes) with 5-mm and 8-mm needles for blinded pain, 
bleeding, and bruising at injection sites.
Results: Leakage with the 5-mm needle for both the 20 U and 60 U equiva-
lent volumes was <5% of the total volumes and was non-inferior to the 8-mm 
needle (see table). Pain scores were numerically similar for both needles (see 
table). Proportions of injections with bleeding (5-mm/20 U, 10.5%; 5-mm/60 
U, 4.9%; 8-mm/20 U, 5.8%; 8-mm/60 U, 6.6%) and proportions of patients 
with bruising (5-mm/20 U, 8.1%; 8-mm/20 U, 10.8%, p=0.6; 5-mm/60 U, 
21.1%; 8-mm/60 U, 26.3%, p=0.7) at injection sites were similar.
Conclusion: The results of this study support the suitability of the 5-mm nee-
dle for the injection of insulin in obese patients with diabetes with regard to 
leakage, pain, bleeding, and bruising at abdominal injection sites. 
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Needle Length (mm) 5 5 minus 8* 5 5 minus 8*
Injection Volume (U) 20 20 60 60
Leakage (U)‡
Gatekeeping†
Step 1 2 3 4
N 37 37 18 18
Mean 0.0734 0.0094 0.1389 0.0820
Median 0.0372 0.0075 0.0351 0.0185
SD 0.0830 0.1064 0.1968 0.1605
90% CI^ (0.024, 0.0569)
(-0.004, 
0.017)
(0.0116, 
0.126)
(-0.0113, 
0.097)
Needle Length (mm) 5 8 5 8
Injection Volume (U) 20 20 60 60
Pain#
N 37 37 19 19
Mean 1.27 1.14 1.68 0.95
SD 2.76 1.70 2.45 1.58
* Difference in leakage between 5-mm and 8-mm needles
† The “gatekeeping” approach requires all previous tests to demonstrate a statis-
tically significant result at the 0.05 level before analyzing the next test in the list
‡ 1 U = 10 μL = 10,000 μg
^ The CI was calculated for both the median and median difference (5 mi-
nus 8) using exact order statistics
# 0-20 point Visual Analog Scale (VAS)
Supported by: Eli Lilly and Company
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Safety evaluation of a new reusable insulin pen (ClikSTAR®) in 2526 
Canadian patients (pts) with type 1 and type 2 diabetes mellitus (DM) 
receiving insulin glargine
I. Gottesman1, P. Perron2, L. Berard3, J. Stewart4, K. Mettimano5; 
1University of Toronto, Mississauga, 2Sherbrooke University, Sherbrooke, 
3Diabetes Research Group, Health Sciences Centre, Winnipeg, 4Sanofi-
aventis, Laval, 5Signature Medicine Centre Pharmacy, Calgary, Canada.
Background and aims: Insulin pens have increased the convenience, accu-
racy and flexibility of insulin therapy in comparison with traditional vial and 
syringe administration. ClikSTAR® is a novel reusable insulin pen developed 
for use with insulin glargine and insulin glulisine. The aim of the study was to 
assess the safety profile of ClikSTAR® after 6-12 weeks of use in type 1 & type 
2 DM pts receiving insulin glargine.
Materials and methods: In this open-label, multicenter, non-randomized, un-
controlled, observational, prospective study pts with type 1 & type 2 diabetes re-
ceiving insulin glargine were eligible to participate. At baseline all pts received the 
ClikSTAR® pen, instruction leaflet and a free-toll number for Technical Support 
and had been trained on the pen use with insulin glargine cartridges. Baseline 
information was collected at the first visit. A follow-up visit assessment was per-
formed by investigators at 6-12 weeks to collect any Product Technical Complaint 
(PTC). PTCs could be reported throughout the study and investigators used a de-
cision tree guide to handle PTCs. All pens associated with a PTC were tested for 
Product Technical Failure (PTF) at the pen laboratory in Frankfurt. The risk ac-
ceptance criterion was that no validated PTF leading to a Serious Adverse Event 
(SAE) would occur within 2500 pts during a period of 6 to12 weeks.
Results: 2526 pts were enrolled (56% male and 44% female) in 104 sites across 
Canada, average age was 56 (SD = 14) years, 31% were type 1 DM and 69 % 
type 2 DM. 93% of pts were pen users prior to study enrolment. 9% and 8% had 
visual and dexterity impairment respectively. A total of 84 PTCs, 24 SAEs and 
85 non serious adverse events (AEs) were reported. 3 pts with SAEs and 9 with 
AEs were reported as having a causal relation with a PTC. Investigation results 
of PTCs associated with an SAEs showed that they were not due to a pen failure. 
A total of 75 (3%) pts withdrew from the study; 15 for a PTC and 19 for an AE. 
The most common PTCs were related to the plunger, the dose selector and in-
sulin delivery. No PTF related to an AE or SAE identified throughout the study 
and most PTCs were due to handling error of the pen and not requesting ad-
ditional information or assistance from their site personnel or the Call Center.
Conclusion: This first real life observational safety study had been designed 
to collect complaints and adverse events reported by pts with diabetes us-
ing ClikSTAR® pen and insulin glargine. PTCs were infrequent and No PTF 
related to an AE or SAE reported. Results show that this new reusable pen is 
safe to be used with insulin glargine.
Supported by: sanofi-aventis
PS 97 Education: in the right hands 
- an effective therapy for diabetes
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Rapid reductions in insulin requirements in patients with type 1 diabetes 
participating in the DAFNE (Dose Adjustment for Normal Eating) 
structured education programme
L. Leelarathna1, C. Ward2, F. Finucane3, K. Davenport2, A. Housden2,  
M.L. Evans1; 
1Institute of Metabolic Science, University of Cambridge & Cambridge 
University Hospitals NHS Foundation Trust, 2Wolfson Diabetes 
Clinic, Cambridge University Hospitals NHS Foundation Trust, 3MRC 
Epidemiology Unit, Institute of Metabolic Science, Cambridge, United 
Kingdom.
Background and aims: The Dose Adjustment for Normal Eating (DAFNE) 
programme consists of 4.5 days of structured education for patients with 
type 1 diabetes (T1D), to enable them to adjust their own insulin doses as 
required. This programme has previously been shown to lower HbA1c, re-
duce the incidence of hypoglycaemia and improve quality of life. There is 
anecdotal evidence that these improvements are associated with significant 
reductions in insulin doses, suggesting that some are over-insulinised prior 
to the programme. However, to date no formal analysis of changes in insulin 
doses associated with participation in DAFNE training has been conducted. 
We sought to determine whether DAFNE training is associated with changes 
in insulin requirements.
Materials and methods: We conducted a retrospective cohort analysis of 
adults with T1D who attended DAFNE training in our centre between Octo-
ber 06 and December 09. The type and dose of insulin used at the pre-course 
assessment and on the fourth day of the DAFNE course were recorded. 
HbA1c at the pre-course assessment and the first measured HbA1c between 
3 and 12 months after completion of the course were also recorded, as was the 
presence of clinically apparent lipohypertrophy(LH). Data are presented as 
means ± SD. A two-tailed t-test was used to compare pre- and post- DAFNE 
training variables.
Results: Over the three year study period, 335 patients underwent DAFNE 
training at our centre. Complete pre-course and follow-up data were avail-
able for 259 patients (77%) and these were included in the current analyses. 
124(48%) were female, 97% were Caucasian, mean age was 41 ± 14 years 
(range 18- 74) and mean duration of diabetes was 19 ± 14 years. 43.1 % of 
patients had documented LH. There were significant reductions in daily total 
insulin (52 ± 22 to 44 ±16 units), quick acting insulin (28 ±14 to 24 ±9) and 
basal insulin (24 ±12 to 20 ± 10) on day 4 of DAFNE training compared to 
the pre-course doses ( all p<0.001). The dose reduction was greater in patients 
with LH than in those with no LH (10.1 and 6.5 units, respectively). However, 
the insulin dose reductions were statistically significant even in those with no 
LH (p < 0.001). Most patients were using insulin analogues (Insulin Aspart 
66%, Insulin Lispro 25%, Insulin Glargine 65%, Insulin Detemir 22%). We es-
timate that the 16% reduction in total daily insulin dose would lead to an an-
nual reduction in insulin cost of approximately 90GBP (100 euro), based on 
current drug costs. Importantly, insulin dose reduction did not worsen gly-
caemic control, with a small trend for HBA1c to improve when first checked 
after DAFNE (8.4 ± 1.3 vs 8.30 ± 1.2 pre vs post-course, p =0.11).
Conclusion: We observed significant reductions in the short term in insulin 
requirements in T1D patients undergoing DAFNE training. Although it is 
possible that changes in physical activity during the course may have contrib-
uted, the changes seen likely reflect more appropriate insulinisation of these 
patients, which would account for reductions in hypoglycaemia. Our data 
suggest that patients with T1D who do not have access to structured educa-
tion may be systematically over treated with insulin.
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Lifestyle intervention by group-based rehabilitation versus individual 
counselling in type 2 diabetes: 1-year follow-up
E.S. Vadstrup1, A. Frølich2, H. Perrild1, E. Borg3, M. Røder4; 
1Dept of Endocrinology and Gastroenterology, Bispebjerg Hospital, 
Copenhagen NV, Denmark, 2Department of Integrated Healthcare, 
Bispebjerg Hospital, Copenhagen, 3Health Care Centre Oesterbro, 
Copenhagen, 4Department of Cardiology and Endocrinology, Hillerød 
University Hospital, Denmark.
Background and aims: To compare the longer term effectiveness of deliv-
ering lifestyle intervention to type 2 diabetes patients as either group-based 
rehabilitation in primary care or individual counselling in an outpatient set-
ting.
Materials and methods: We randomised 143 patients with type 2 diabetes 
to a 6-months group-based rehabilitation programme, including patient 
education, supervised exercise, and diet intervention, or to a 6-months indi-
vidual counselling programme. Follow-up time was 12 months after baseline. 
Outcome measures were glycated haemoglobin (HbA1c), cardiovascular risk 
factors, quality-of-life (SF-36, Medical Outcomes Study Short Form 36-item 
Health Survey) and self-rated health (DSC-R, Diabetes Symptom Checklist 
- Revised).
Results: In the rehabilitation group there was a decrease in HbA1c (-0.2%-
point, 95%CI [-0.4 to 0.03]), systolic blood pressure (-6 mmHg [-9.3 to -2.5]), 
diastolic blood pressure (-4 mmHg [-6.3 to -2.4], weight (-2.2 kg [-3.2 to -
1.3]), and waist circumference (-2.0 cm [-2.9 to -1.1]). In the individual group 
there was a decrease in HbA1c (-0.4%-point [-0.6 to -0.1]), systolic blood pres-
sure (-3 mmHg [-6.3 to 0.7]), diastolic blood pressure (-3 mmHg [-4.7 to 
-0.7]), weight (-1.6 kg [-2.6 to -0.7]), and waist circumference (-1.6 cm [-2.5 
to -0.6]). Self-rated vitality, fatigue distress, physical functioning and cardio-
vascular distress improved over time (P<0.05) in the two groups combined. 
Repeated measurement analysis did not result in significant differences be-
tween the groups of any outcome.
Conclusion: There were no significant differences between the two groups 
over time, but improvements in HbA1c, blood pressure, weight, waist circum-
ference, self-rated vitality and fatigue distress in the two groups combined 
were significant. However, the resource use of the rehabilitation programme 
was twice as much as the individual programme.
Supported by: Jascha Foundation, National Board of Health, Danish Ministry 
of Health
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Randomised controlled trial of the DESMOND structured education 
programme for people newly diagnosed with type 2 diabetes: biomedical 
outcomes, psychosocial measures and illness beliefs at three years
K. Khunti1, S. Heller2, T.C. Skinner3, L.J. Gray1, H.M. Dallosso4, K. Realf4, 
M.E. Carey4, M.J. Davies5; 
1Health Sciences, University of Leicester, United Kingdom, 2University of 
Sheffield, United Kingdom, 3Combined Universities Centre for Rural Health, 
Geraldton, Australia, 4Diabetes Research, University Hospitals of Leicester, 
United Kingdom, 5Cardiovascular Sciences, University of Leicester, United 
Kingdom.
Background and aims: DESMOND is a structured group self-management 
education programme (6 hours contact time) for patients newly diagnosed 
with type 2 diabetes. A multi-site cluster randomised controlled trial showed 
that DESMOND is associated with benefits in illness beliefs, weight loss, 
physical activity, smoking and depression. A three year follow-up of the par-
ticipants has been carried out to see if these benefits are sustained beyond 12 
months and the results are reported.
Materials and methods: Participants in the original trial who were eligi-
ble for follow-up at 3 years were sent a postal questionnaire (illness beliefs, 
symptoms of depression, quality of life, physical activity and smoking) and 
asked to visit their practice for biomedical measures (HbA1c, blood pressure, 
weight, blood lipids, waist circumference).
Results: Of the 743 people eligible for follow-up, biomedical data were col-
lected on 604 (81.3%) and questionnaire data on 513 (69.0%). No statistically 
significant differences in biomedical measures were seen at 3 years, although 
a trend to greater improvement across all biomedical factors, smoking and 
physical activity was seen in those who received the intervention, for example 
mean change in HbA1c -1.32 (-1.57,-1.06) versus -0.81 (-1.02,-0.59). The sig-
nificant benefits in the intervention group across 4 out of 5 health beliefs seen 
at 12 months were sustained at 3 years. For example, those in the intervention 
group report higher illness coherence compared to the control group (0.93, 
95% confidence interval (CI) 0.20 to 1.65, p=0.01). At 3 years there is a trend 
to lower depression scores in the intervention group (-0.29, 95% CI -0.74 to 
0.15, p=0.19). There are no differences between the groups for the problems 
areas in diabetes scale or the measures of quality of life at 3 years.
Conclusion: A one-off structured group self-management education pro-
gramme for patients with newly diagnosed type 2 diabetes showed significant 
improvements in weight and smoking status at 12 months with sustained 
positive changes in a range of illness beliefs at 3 years.
Supported by: Diabetes UK
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Fear of hypoglycaemia: low incidence in educated patients with diabetes 
mellitus
V. Hartung, K. Reise, C. Kloos, N. Müller, G. Wolf, U.A. Müller; 
University Hospital Jena, Department of Internal Medicine III, Germany.
Background and aims: Hypoglycaemia is the most frequent adverse effect of 
drug treatment of diabetes and can in worst cases cause death, either by itself 
or, for instance, when driving or operating heavy machinery. Hence fear of 
hypoglycaemia is a reasonable reaction but in which dimensions concerning 
ratio and intensity and what are the definite reasons? Novel contraction of 
diabetes and inability to handle could be the most likely assumption. Suffer-
ing from hypoglycaemia frequently in the past could be another reason. To 
find out exactly we studied the prevalence and intensity of fear in patients 
with diabetes mellitus type 1 and 2 in a German cohort.
Materials and methods: We assessed fear of hypoglycaemia (FOH) in 719 
patients taking any diabetes medication (age 62.2years; time since diagnosis 
16.3years; BMI 31.2kg/m²; HbA1c 7.31%) and treated at a university outpa-
tient department using a standardised questionnaire. All patients had at least 
one structured education in the preceding 20 years. We used a scale from 1-6 
to rate FOH (1: no fear at all; 6: extensive fear). The patients were grouped to 
no fear (score 1, 2) and fear (score 4-6). Score 3 was discounted to exclude 
indecisive or uncertain decisions. Clinical and laboratory data are drawn 
from the electronic patient record EMIL (http://www.itc-ms.de). HbA1c was 
DCCT adjusted.
Results: 118 patients (8.1%) stated to have FOH. 492 patients (68.4%) are 
unafraid of hypoglycaemia. Patients with FOH were more female (49.2 vs 
35.8%; p=0.007), younger (58.6 vs 63.7y; p<0.001), had a higher HbA1c (7.47 
vs 7.24%; p=0.026), higher overall lifetime incidence of severe hypoglycaemia 
(0.69 vs 0.26; p=0.005), more non-severe hypoglycaemia (0.92 vs 0.46 per 
week; p<0.001), a higher plasma glucose threshold for symptoms of hypogly-
caemia (3.8 vs 3.5mmol/l; p=0.01), did more blood glucose self monitoring 
(26 vs 21 per week; p<0.001), had more insulin injections (3 vs 2 per day; 
p=0.006) and had predominantly diabetes type 1 (33.1 vs 19.9%; p=0.002). 
Furthermore patients with FOH had a lower WHO (Five) Well-Being Index 
(12 vs 16; p<0.001; max. score 25), an increased impairment by hypoglycae-
mia (4 vs 3; p<0.001; max. score 6) and more difficulties at work caused by 
hypoglycaemia (3 vs 1; p<0.001; max. score 6) compared to the ones with 
no FOH. No significant differences were observed regarding time since di-
agnosis (17.2 vs 16.3years), the kind of therapy differentiated into therapy 
with insulin and oral hypoglycaemic agents (84.4 vs 76.4%), the daily insulin 
dose (52.7 vs 47.1U/d), last BMI (30.9 vs 31.5kg/m²), incidence of severe hy-
poglycaemia during the last 12 months (0.08 vs 0.04), the social status (10 vs 
11; max. score 21), when nobody was around while hypoglycaemia (46.2 vs 
40.2%) or when it arose at night (46.7 vs 39.7%).
Conclusion: There are proportionally fewer patients with diabetes who suf-
fer from noteworthy fear of hypoglycaemia. General reasons for this fear are 
more likely its consequences such as impairment or difficulties at work, than 
the conditions per se. It may also be related to a certain type of personality, 
based on or interrelated with a poor Well-being Index. Because the patients 
in this survey were a selection from a university outpatient department, it is 
unclear to what extent these results can be transferred to the general popula-
tion in which fear could either be less frequent or even more, when, for exam-
ple, less participation in educational programmes is considered.
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Coaching by a dietician: a cost-effective alternative to diabetes 
management?
P. Perron, M. Labonté, F. Jean Denis, J. Ménard, G. Houde, J.-L. Ardilouze; 
Endocrinology, Centre hospitalier universitaire de Sherbrooke, Canada.
Background and aims: World prevalence of diabetes and associated burden 
of care and complications are rising. Cost-effective management alternatives 
are badly needed. Cardiovascular risk (CVR) management by dieticians is 
one alternative worth assessing over a long term. This 3-year randomized trial 
aimed to show that dietician-led therapy management with an endocrinolo-
gist, for purposes of annual follow-up and advice as needed, enables recom-
mended diabetes outcomes and is less costly than regular care.
Materials and methods: Diabetic subjects (n=101, HbA1c>7%) were rand-
omized to a Dietician-Coached Group (DCG) or a Conventional Group (CG) 
with follow-up as usual by endocrinologists ± general practitioners. DCG 
met with coach every 3 months (physical and biochemical measures, exercise, 
diet, smoking cessation, hypoglycaemia recording, capillary glucose moni-
toring and motivation), had monthly follow-up phone calls with coach and 
a yearly endocrinologist follow-up. Variables were measured every 3 months 
for DCG vs. yearly for CG.
Results: At baseline, groups (DCG n=51/CG n=50) were similar in age 
(60±10/60±11 yrs), duration of diabetes (16±9/16±10 yrs), systolic and di-
astolic BP (sBP: 131±15/131±24; dBP: 74±9/77±10 mmHg), fasting plasma 
glucose (FPG: 8.8±3.2/8.4±3.3 mM), HbA1c (8.1±0.9/8.1±1.1%), triglycerides 
(1.88±1.28/1.78±1.23 mM), LDL (1.94±0.70/2.03±0.64 mM) and total cho-
lesterol/HDL (3.39±1.16/3.50±1.27 mM). DCG subjects were heavier (BMI: 
34±8/31±5 kg/m2; p=0.03, waist circumference (WC): 113±18/106±12 cm; 
p=0.03). At 2 years (DCG n=39/CG n=42), ANOVA with repeated measures 
showed evolution between groups differed for HbA1c (DCG: baseline: 8.1±0.9; 
1 yr.: 7.3±0.8; 2 yrs.: 7.4±0.9% vs. CG: 8.1±1.1; 8.2±1.5; 7.8±1.1%; p≤0.001), 
dBP (74±9; 69±10; 69±10 vs. 77±10; 79±10; 76±9 mmHg; p=0.004), and WC 
(111±18; 110±18; 110±20 vs. 106±13; 108±13; 108±14 cm; p=0.015). At 2 
years, DCG had an HbA1c value of 0.4% lower than CG, which is clinically 
significant. Moreover, in DCG, the greater improvement in HbA1c was ob-
served at 1yr. vs. baseline (p≤0.001) compared to 2yrs. vs. 1yr. (p=0.08). There 
was no difference for BMI, FPG, microalbuminuria and lipid profile which 
was already on target at baseline.
Conclusion: After 2 years, diabetic patients coached by a dietician clinically 
improve HbA1c and dBP. This simpler model of dietician coaching seems to 
be superior to regular care at improving diabetes outcomes and CVR factors. 
Should our 3-year analysis confirm our preliminary results? Cost analyses 
are ongoing.
Supported by: Pfizer
1031
Including community health workers in an effective model of diabetes 
self-management education
D. Fillman1, D. Tomky2, L. Vukovljak1, K. Fitzner1; 
1American Association of Diabetes Educators, Chicago, 2ABQ Health 
Partners, Albuquerque, USA.
Background and aims: 24 million people in the USA have diabetes, a costly 
chronic disease. Self-management education or training (DSME) is a key step 
in improving health outcomes and quality of life for these people. A team 
approach to providing DSME is described by the Guidelines for the Practice 
of Diabetes Education and is being adopted in practice. The aims of our study 
were to: a) define a model for DSME provided by a multi-level diabetes edu-
cation team; and b) answer the question, “what are the unique roles and re-
sponsibilities of those who deliver diabetes education and care?”
Materials and methods: From 10/09-2/10, we conducted desk audits of 100 
applications to the Diabetes Education Accreditation Program and examined 
10 additional programs identified as having “best practices” to define the role 
of community health workers (CHW) in actual DSME practice and identify the 
education delivery models in which they worked. To be inclusive, the definition 
of CHWs included community health advocates, lay health advisors, lay health 
educators, community health representatives, tribal diabetes educators, peer 
health promoters, community health outreach workers, and promotores de 
salud. Findings from our review were compared to the National Standards for 
Diabetes Education and requirements put forth by the U.S. Centers for Medi-
care and Medicaid Services. These criteria were used to examine the strengths 
and weaknesses of the different approaches, roles and models identified.
Results: The review found that CHWs are frontline public health workers 
who are trusted members of and/or have a uniquely close understanding of 
the community served. CHWs can effectively serve as bridges between ethnic, 
cultural and geographic communities and the health care providers. There are 
four scenarios in which CHWs and experienced and/or credentialed diabetes 
educators can effectively work together. These four distinct DSME models are: 
1) Shared Teaching; 2) Top Down; 3) Multi-Class at One Time; and 4) Sup-
portive Role. In these models, the professional educator provides the clinical 
instruction and serves as supervisor. CHWs, who are non-professional health 
care providers with little expertise in DSME and/or management, support the 
DSME services provided to people with diabetes.
Conclusion: A DSME team approach is effective in helping people with dia-
betes gain the skill and knowledge necessary to change their behaviors and 
effectively manage their illness. Diabetes education is provided by health care 
professionals from many disciplines, involving practitioners with varying 
levels of experience/expertise in diabetes management, diabetes education, 
and clinical care. Moreover, DSME is most effective and sustainable when it 
is delivered by individuals who are prepared, competent, and function within 
the practice level articulated in the Guidelines for the Practice of Diabetes Edu-
cation. Within the context of four models of DSME, and when supervised by 
a professional and/or credentialed diabetes educator, CHWs can effectively 
assist, provide important linkages to the local community, and successfully 
serve as part of the DSME team.
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An interactive 1 hour educational programme for junior doctors 
delivered at their induction improves the quality of inpatient diabetes 
care
C.G. Taylor Jr.1, A. Scott1, R. Herring2, A. Crown3, D. Russell-Jones2,  
S.R. Kottegoda4, J. Quin3, N. Vaughan3, C. Morris5, G. Rayman1; 
1The Diabetes Centre, Ipswich Hospital, 2Royal Surrey County Hospital, 
3Royal Sussex County Hospital, Brighton, 4University Hospital Lewisham, 
London, 5University of Bedfordshire, United Kingdom.
Background and aims: The prevalence of diabetes amongst the inpatient 
population is increasing and more rapidly than that in the general population 
as this represents a more aged population. This has increased the manage-
ment decisions having to be made by junior doctors. Unfortunately postgrad-
uate education does not routinely address the skills needed to appropriately 
manage this patient group and in hospitals in the UK relatively little time is 
given to teaching junior doctors about diabetes care.
Materials and methods: We designed interactive teaching programmes for 
medical and surgical junior doctors which can be delivered in 1 hour at their 
induction or within scheduled teaching. These were centered on adults learn-
ing theories. Key aspects of care were covered in a case based format. Reac-
tion to the teaching sessions was evaluated using questionnaires. Learning 
was evaluated by assessing the change in the rating by trainees of their con-
fident in managing 5 key areas of care assessed before and immediately after 
sessions. Whether this influenced practice was assessed by auditing aspects of 
inpatient care in the hospitals before and 3-5 months after completing educa-
tion.
Results: 174 (85%) of 206 trainees provided feedback using Likert scales of 
1-5. Clarity and ease of understanding scored highly (4.5) as did the response 
to the question of whether the designs of the programmes increase participa-
tion (4.5). The programmes were highly recommended (4.5). The most liked 
aspects were interactivity (21%), the case based format (22%) and teaching 
design (47%). Confidence in juniors’ management in five key areas of care 
increased significantly [from 17.4 (SD 3.9) to 24.7 (SD 2.6), p < 0.001]. Fol-
lowing the teaching sessions the most common key take home points and 
planned changes in their clinical practice were related to improved glycaemic 
management (24 and 25% respectively), improved insulin infusion use (22 
and 26%), avoiding prescription errors (20 and 22%) and foot assessment (19 
and 13%). There were statistically significant improvements in the frequency 
of foot assessments, appropriate insulin infusion management and prescrip-
tion errors (p < 0.05).
Conclusion: We have demonstrated that a well designed teaching pro-
gramme on inpatient diabetes care can be effectively delivered within 1 hour 
and hence easily introduced to most hospitals. The interactive design, based 
on learning theories and using a case based format were likely to be central to 
the significant changes seen in trainees confidence; more importantly in the 
quality of inpatient care.
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Improving diabetes care through multidisciplinary training: The 
Christian Medical College-Vellore/WDF diabetes education project
A. Joseph1, V. Aruldas2, R. Daniel3, A.E.I. Pittard4, A. Kapur5, N. Thomas3; 
1Schieffelin Institute of Health Research & Leprosy Centre, Karigiri, Tamil 
Nadu, India, 2Christian Medical Association of India, New Dehli, India, 
3Christian Medical College, Vellore, Tamil Nadu, India, 4Albert Einstein 
College of Medicine, Bronx, USA, 5World Diabetes Foundation, Kongens 
Lyngby, Denmark.
Background and aims: Diabetes is a major health care issue in India, yet 
doctors and nurses often have outdated information on standards of care, and 
foot care is underemphasized despite low rates of footwear use. We sought 
to improve diabetes care in rural and semi-urban areas by training doctors, 
nurses, foot care technicians (FCTs), and cobblers through an existing net-
work of mission hospitals.
Materials and methods: A multidisciplinary training program was devel-
oped by the Departments of Endocrinology and Biochemistry at Christian 
Medical College-Vellore (CMC), the Schieffelin Institute of Health Research 
& Leprosy Centre (SIHRLC) and the Christian Medical Association of India 
(CMAI). Eligible hospitals were identified by the Dept of Endocrinology and 
CMAI. Each hospital was invited to send at least 1 doctor, 2 nurses, 1 FCT, 
and 1 cobbler to receive comprehensive training in diabetes care. Doctors 
were trained in a 10-day course and nurses in a 14-day course taught by pro-
fessors and diabetes nurse educators from CMC’s Department of Endocrinol-
ogy, with support from other departments including Biochemistry, Rehabili-
tation and Ophthalmology. At SIHLRC, FCTs received 2 weeks of training in 
foot care and treatment of neuropathic foot problems, and cobblers received 
1 month of training in orthopedic shoemaking. Key components of the pro-
gram included emphasis on a team approach to diabetes care and the role 
of diabetes educators. Baseline data was collected from application forms. 
Evaluations were gathered for all teaching sessions. Follow-up questionnaires 
were sent by e-mail to all hospitals 6 months after completion of training. On-
site monitoring visits were conducted for 20% of the trained hospitals.
Results: During 2004-2009, multidisciplinary training in diabetes care was 
provided for 100 mission hospitals in 22 states across India. At least 1 doctor 
was trained at 100% of hospitals, at least 1 nurse at 100%, at least 1 FCT at 58%, 
and at least 1 cobbler at 47%. Follow-up questionnaires were received from 
36% of hospitals. Among those returning questionnaires, 89% had started dia-
betes clinics. There was an average of 53 new diabetes outpatients per hospital, 
an increase of 34% in patient capacity, by 6 months after training. Most hospi-
tals (74%) joined CMC’s laboratory quality control program. Other activities 
by trained hospitals included outreach clinics (25%), diabetes camps (39%), 
and health education (53%). These successes occurred despite significant at-
trition at some hospitals: trained doctors left at 17%; trained nurses at 35%; 
trained FCTs at 47%; and trained cobblers at 36%. Trained sites reported lack 
of staff as the most significant challenge they faced in providing quality diabe-
tes care (74%), followed by the cost of care (53%) and lack of facilities (31%); 
difficulty procuring drugs was a relatively unimportant factor (6%).
Conclusion: Comprehensive, multidisciplinary training of doctors and 
nurses promotes the establishment of diabetes clinics in underserved areas 
and markedly increases the number of diabetic patients receiving treatment. 
Trainings should take attrition rates into account, and should emphasize low-
cost treatment options.
Supported by: WDF
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Physician-patient ethnic concordance improves diabetes care for ethnic 
minority patients
B.R. Shah1,2, S. Anand3, D.G. Manuel2,4, J.E. Hux1,2; 
1Department of Medicine, University of Toronto, 2Institute for Clinical 
Evaluative Sciences, Toronto, , 3McMaster University, Hamilton, 4Ottawa 
Hospital Research Institute, Canada.
Background and aims: Non-White patients who receive care from physi-
cians from the same ethnic group have greater satisfaction with care and im-
proved health care utilisation. However, no studies have examined whether 
physician-patient ethnic concordance influences the quality of diabetes care, 
where greater cultural understanding may lead to improved dietary, physical 
activity and medication adherence. This study evaluated whether the quality 
of diabetes care for minority patients is influenced by the ethnicity of their 
family physicians.
Methods: Family physicians were randomly recruited from mutually exclu-
sive neighbourhoods in the Toronto area with high concentrations of people 
with Chinese origins or people with South Asian origins. Recruitment was 
stratified by physician ethnicity. From each physician’s practice, up to 10 dia-
betic patients with Chinese or South Asian origins were randomly selected. 
Diabetes quality indicators were collected by chart abstraction. The primary 
outcome was the last A1c achieved. Other outcomes were the last blood pres-
sure and LDL-cholesterol achieved, and documentation in the chart of a foot 
examination. Within each ethnic group, outcomes were compared based on 
whether the physician was ethnically concordant or discordant with the pa-
tient. Generalised linear models were used to determine statistical signifi-
cance, accounting for the clustered nature of the data within physician prac-
tices and adjusting for patient age, sex and diabetes duration.
Results: 45 family physicians were recruited and 416 patients were included. 
Most Chinese diabetic patients had Chinese family physicians. Chinese pa-
tients with Chinese family physicians achieved better glycaemic control than 
those with ethnically discordant family physicians. No difference in glycae-
mic control was seen among South Asian patients with ethnically concordant 
versus discordant family physicians, and no differences were seen in either 
group for other outcomes. There was a strong trend towards differences in 
foot examination rates, but because this outcome was highly clustered within 
physician practices, it was not statistically significant in either ethnic group.
Table: Quality of care for ethnic minority patients, stratified by physician ethnicity.
Chinese diabetic patients South Asian diabetic patients
Chinese 
physicians
Non-Chinese 
physicians
Adjusted 
p-value
South Asian 
physicians
Non-South 
Asian 
physicians
Adjusted 
p-value
n 148 22 129 117
A1c 0.070±0.010 0.077±0.013 0.009 0.075±0.012 0.074±0.0130.4
Systolic BP 129±12 128±14 0.6 130±16 127±16 0.3
Diastolic BP 76±8 78±8 0.2 76±10 79±8 0.2
LDL-cholesterol 
(mmol/L)
2.2±0.8 2.6±0.9 0.4 2.4±0.9 2.2±0.8 0.3
Foot examination 84% 59% 0.2 46% 57% 0.3
Conclusion: Among diabetes patients with Chinese origins, those whose 
family physician also had Chinese origins achieved better glycaemic control. 
These differences persisted even after adjusting for patient age, sex and dia-
betes duration. The absence of an effect in the South Asian population may 
be due in part to their greater linguistic and cultural heterogeneity compared 
to the Chinese population, or because there is greater English-language use 
among Canadians with South Asian origins than those with Chinese origins. 
The findings suggest that health care providers with better cultural under-
standing can influence diabetes care for patients from certain ethnic groups.
Supported by: Heart and Stroke Foundation of Ontario
1035
Effects of a systematic smoking cessation intervention in diabetic 
patients
R. Candido1, E. Tommasi1, G. Jagodnik1, R. Alberti1, B. Baskar1, M. Stuper1, 
N. Daris1, E. Presti1, E. Caroli1, E. Manca1, A. Petrucco1, A. Vegliach2,  
R. Purich2, B. Fabris3, R. Tominz4; 
1Diabetes Center, A.S.S. 1 Triestina, 2Smokers Clinic, A.S.S. 1 Triestina, 
3Department of Clinical Medicine and Neurology, University of Trieste, 
4Department of Prevention, A.S.S. 1 Triestina, Trieste, Italy.
Background and aims: Cigarette smoking is the leading preventable cause of 
illness and premature death in developed countries. Several clinical studies 
have reported significant links between smoking and development of diabe-
tes, micro- and macrovascular complications, and impairment of metabolic 
control. Although several studies have demonstrated the efficacy and cost-
effectiveness of smoking cessation counseling in changing smoking behav-
ior among the general population, the role of system-based approaches that 
make smoking a routine part of office contacts and provide multiple prompts, 
advice, assistance, and follow-up support in diabetic subjects remains to be 
clarified. Therefore, the aim of this study was to evaluate the effectiveness of 
a systematic smoking cessation intervention in diabetic patients as a routine 
component of diabetes care.
Materials and methods: All the afferent type 1 or type 2 diabetic patients 
at the Diabetes Center were systematically reviewed to confirm their smok-
ing status. The diabetic subjects who were current smokers were considered 
S 414 Diabetologia (2010) 53:[Suppl1]S1–S556
1 C
to be candidates for intervention. The intervention protocol consisted of: 1) 
assessment of dependence and motivation to stop smoking; 2) measurement 
of carbon monoxide concentration of expired air by smokerlyzer; 3) face-
to-face interview with a nurse who was a member of the team; 4) optional 
nicotine replacement therapy or other smoking cessation medication; 5) fol-
low-up support program which included a telephone call 2 and 4 weeks after 
the cessation date, a follow-up visit after 3-4 months and a final visit after 12 
months.
Results: A total of 95 diabetic smokers were invited to participate to the in-
tervention program and 82 (78%) agreed to take part in the study. After 6 
months, 22 patients (27%) reported that they had stopped smoking and this 
was confirmed by measuring the carbon monoxide concentration of expired 
air. Among participants who continued smoking, a significant reduction was 
evident in the average cigarette consumption. Of the 82 patients participat-
ing to the intervention program 23% were treated with nicotine replacement 
therapy or varenicline and 28% were referred to smokers clinic for a more 
comprehensive evaluation.
Conclusion: The present study shows that a structured intervention that 
makes smoking a routine part of office contacts seems to be effective in in-
ducing smoking cessation in diabetic patients, thus suggesting that a system-
atic intervention including smoking cessation counseling and other forms of 
treatment should be a routine component of diabetes care.
PS 98 Tools for improving diabetes 
control
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Design and development of a computer assisted clinical decision support 
system to help physicians manage patients with type 2 diabetes mellitus
D. Rodbard1, R.A. Vigersky2; 
1Clinical Research and Medical Informatics, Biomedical Informatics 
Consultants LLC, Potomac, 2Diabetes Institute, Walter Reed Army Medical 
Center, Washington, USA.
Background and aims: The increasing number of options for therapy and the 
failure of most patients to achieve A1C goals in a timely manner suggest the 
need for clinical decision support at the point of care. We sought to develop a 
customizable software system that could provide advice to primary care phy-
sicians at the point of care, providing recommendations and explanations.
Materials and methods: We have developed a computer-assisted decision 
support (CADS) system with customizable modules for patient, provider, and 
administrator. CADS is based on extensive statistical analysis and graphical 
displays of uploaded glucose data (SMBG); medication history; individualized 
glycemic goals; analysis of laboratory data (A1C, renal and hepatic function); 
and co-morbidities (cardiac, renal, hepatic, gastrointestinal). The software 
provides a concise report to the clinician regarding overall quality of glycemic 
control and identifies problems such as hypo- and hyperglycemia, excessive 
variability, insufficient glucose monitoring, and presence of various patterns. 
A rule-based expert system then makes recommendations to adjust dosage 
of current medications, discontinue medications, add new medications, or 
change the treatment regimen. We have constructed algorithms with recom-
mended sequences for 61 regimens, including therapeutic lifestyle changes, 
8 forms of monotherapy, 22 forms of dual therapy, and 30 forms of triple 
therapy utilizing 8 classes of medications: metformin, DPP-4 inhibitors, GLP-
1 analogs, thiazolidenediones, sulfonylureas and glinides, alpha-glucosidase 
inhibitors, and basal insulins. Treatment pathways can be customized by the 
individual physician or clinic. The algorithm considers pharmacodynamics as 
well as relative and absolute contraindications, and offers alternatives and op-
tions. The user can override the program’s recommendations and can readily 
access brief or detailed prescribing information, clinical practice guidelines, 
or the medical literature. The logic of the program can be modified using a 
series of tables, without the need for reprogramming.
Results: A prototype system has been constructed, tested with real and synthet-
ic data, and found to perform well. The program analyzes SMBG data, identi-
fies problems (hypoglycemia, hyperglycemia, variability, or insufficient glucose 
data) and recommends adjustment of dosages, addition or discontinuation of 
medications. The program provides caveats appropriate to each case. Extensive 
safety testing has been performed. The recommendations of the program are 
consistent with the judgment of highly experienced endocrinologists in a large 
series of test cases. The software has been integrated with a Comprehensive Di-
abetes Management Program that provides reminders and alerts and interfaces 
with an electronic medical record. The program can also operate in a stand 
alone mode with manual entry of laboratory data and medication history.
Conclusion: This study demonstrates that computer assisted clinical decision 
support is feasible. The logic of the program can be custom tailored to the 
preferences of individual clinics and physicians.
Supported by: TATRC
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Acceptance and outcome of knowledge-based decision support in routine 
diabetes care is strongly related to HbA1c at baseline
P. Augstein1, L. Vogt2, K.-D. Kohnert1, P. Heinke1, E. Salzsieder1; 
1Research, Institue of Diabetes, 2Research, Diabetes Service Center 
Karlsburg, Karlsburg, Germany.
Background and aims: The Diabetiva© program launched 2006 by the Ger-
man health insurance fund BBK Gesundheit offers continuous glucose moni-
toring (CGM) and decision support generated by the Karlsburg diabetes 
management system KADIS® to their insured diabetics. Diabetiva© is open 
for diabetics with cardiovascular risk and focuses on improvement of routine 
out-patient diabetes care according to the guidelines of the German Diabetes 
Association. We addressed the question, whether acceptance of decision sup-
port and metabolic outcome differs between general practitioners (GP) and 
diabetes specialists (DSP) involved in the Diabetiva© program.
Diabetologia (2010) 53:[Suppl1]S1–S556 S 415
1 C
Materials and methods: The Diabetiva© timeline includes an annual CGM 
followed by decision support for therapy optimization and quarterly medi-
cal check-up including HbA1c detection. Patients with two CGM readings 
(n=352) were analyzed retrospectively for acceptance of the KADIS®-based 
decision support by the GP or DSP using a questionnaire and the outcome of 
the Diabetiva© program, with HbA1c as primary outcome parameter.
Results: After running Diabetiva® for 36 months 799 insured diabetics (95.9% 
Type 2 diabetes) were enrolled and had received 1,354 CGMs. Patients were 
cared for by 299 GPs and 44 DSPs. 352 Patients performed already two or 
more CGM trails and could therefore be considered for the final outcome 
evaluation. For these patients approximately 74% of physicians accepted 
KADIS® as patient-focused support to optimize diabetes therapies; 39% used 
the therapeutic regimes without changes and 35 % used slight modifications. 
26% of physicians did not accept KADIS®-based decision support. Logistic 
regression revealed that KADIS® acceptance was significantly depended on 
HbA1c at baseline (p<0.05). GP or DSP and type of therapy had no influ-
ence whether on acceptance nor on outcome parameters. Multiple regression 
analysis revealed that HbA1c and secondary outcome parameters 24 months 
after enrolment into Diabetiva© depend only from acceptance of KADIS® and 
from HbA1c at baseline (p<0.001). Again, GP or DSP type of therapy, age, on-
set of diabetes, BMI, and gender had no significant influence on the outcome 
parameters. If KADIS® was accepted HbA1c could be decreased overall by 
-0.38 ± 0.69% (p<0.01), whereas HbA1c at baseline <6.5% HbA1c increased 
by +0.05 ± 0.39% (p<0.01) abd decreased at 6.5 - 7.0% by -0.22% ± 0.49% 
(p< 0.01); at 7.0 to 7.5% by -0.42 ± 0.52% (p< 0.01); at 7.5 to 8.0% by -0.52 ± 
0.0.44% (p<0.01); and at >8.0% by -1.31 ± 0.79%. But if KADIS®-based deci-
sion support was declined the impact of Diabetiva© was completely dimin-
ished: overall increase of HbA1c by +0.40 ± 0.77% (p<0.01).
Conclusion: Decision support is highly accepted by GPs as well as DSPs es-
pecially for diabetics with elevated HbA1c at baseline. The high acceptance 
rate of 74% and the significant decrease in HbA1c reveal that KADIS® in com-
bination with CGM is an useful tool to support effectively outpatient man-
agement in routine diabetes care.
1038
Self-management support - a comparison of current practices for 
diabetes care in the Danish Healthcare System and Kaiser Permanente
M.L. Schiøtz1, M. Strandberg-Larsen2, A. Frølich3, A. Krasnik2, J. Bellows4, 
J.K. Kristensen5, P. Vedsted5, P. Eskildsen6, H. Beck-Nielsen7, J. Hsu8; 
1Steno Health Promotion Centre, Steno Diabetes Centre, Gentofte, 
Denmark, 2Section of Health Services Research, Institute of Public Health, 
Copenhagen, Denmark, 3Copenhagen Hospital Corporation, Bispebjerg 
Hospital, Copenhagen, Denmark, 4Care Management Institute, Oakland, 
USA, 5Research Unit for General Practice, Aarhus, Denmark, 6Køge 
Hospital, Denmark, 7Odense University Hospital, Denmark, 8Massachusetts 
General Hospital Department of Health Care Policy, Clinical Economics 
and Policy Analysis Program, Boston, USA.
Background and aims: Self-management support is considered an essential 
part of care for people with diabetes. Despite the availability of international-
ly-accepted treatment guidelines describing optimal management of patients 
with diabetes many patients do not receive such level of care and support. 
The aim of this study was to investigate receipt of self-management support 
(SMS), and self-management behaviours of patients with diabetes in two 
healthcare settings: Kaiser Permanente, Northern California (KPNC) and the 
Danish Healthcare System (DHS).
Materials and methods: Using self-administered questionnaires admin-
istered in 2006 and 2007, 1871 diabetic patients (DHS=1548 subjects, 75% 
response rate; KPNC=323, 61% response rate) reported on the amount of 
SMS received during the past year. Using logistic regression approaches, we 
compared the percentages of patients reporting any receipt of each type of 
SMS and SM behaviours.
Results: Receipt of SMS varied substantially between the two systems. Dia-
betic patients in KPNC more frequently reported receiving all types of SMS 
for their disease than did patients in DHS: among KPNC and DHS patients 
respectively, 85% vs. 72% (p<0.0001) discussed methods to prevent disease 
deterioration with their doctor; 77% vs. 58% (P<0.0001) received support to 
set individual disease control goals; 73% vs. 47% (P<0.0001) engaged in mak-
ing plans for their treatment; 59% vs. 26% (P<0.0001) had adverse effects of 
the medication prescribed to them explained; and 72% vs. 62% (p<0.005) 
experienced shared decision making. Substantially fewer patients in both 
systems used tools and approaches to support SM, though more patients in 
KPNC reported any use compared to DHS patients: 34% vs. 11% (P<0.0001) 
used existing patient education programs or support groups; 38% vs. 28% 
(P<0.0005) used websites with information about health and illness; and 
56% vs. 34% (P<0.0001) used written materials about managing their health 
condition. Less than half of the respondents in both systems reported that 
they took their diabetes medication as prescribed and followed the national 
guidelines for exercise.
Conclusion: While patient self-management is associated with better pa-
tient outcomes, not all patients receive support from their physicians in these 
efforts. We found substantial differences in the frequency of SMS received 
across the two health care systems. For all aspects of SMS KP performed 
better that the DHS. Patient self-management represents an important but 
under-supported area of care for those with chronic conditions. Efforts to 
improve SMS could help address quality concerns in both Denmark and the 
United States.
Supported by: The Rockwool Foundation and the Agency for Healthcare Re-
search and Quality
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Type 2 diabetes treatment information for patients in the Internet. Is it 
useful for shared decision making?
G. Gimenez-Perez, O. Simó, A. Recasens, I. Castells; 
Diabetes, Endocrinology and Nutrition Unit, Hospital General de 
Granollers, Spain.
Internet is widely used by patients to retrieve updated health information. 
Consumer oriented treatment information should facilitate shared decision 
making between patients and health providers. The DISCERN tool has been 
developed and validated to evaluate quality of information about treatment 
choices. It scores 15 different items plus a global score from 1 (poor) to 5 
(excellent). To facilitate shared decision making, uncertainty topics should be 
covered, and readability should be adequate.
Objective: To evaluate the quality of the information about treatment choices 
for type-2 diabetes available in consumer oriented websites using the DIS-
CERN tool. To evaluate readability of consumer oriented web pages about 
diabetes treatments.
Materials and methods: The first thirty websites obtained from Google, Ya-
hoo and MSN search engines using the terms “type 2 diabetes” and “treat-
ment” were retrieved. Websites were selected by one investigator according 
to pre-specified inclusion and exclusion criteria. Non-selected websites were 
additionally reviewed by a second investigator to confirm the appropriateness 
of its non-selection. Selected websites were evaluated by a third investigator 
using the DISCERN instrument adapted to type-2 diabetes treatments. Two 
random samples of websites were evaluated by two additional investigators 
to evaluate the agreement of the evaluation between investigators using the 
weighted kappa statistic. Readability was evaluated using the Flesch Reading 
Ease and the Flesch-Kinkaid Grade Level scores obtained using a Microsoft 
Word processor. Additionally we evaluated the presence of any reference to 
the DCCT, UKPDS, ACCORD, ADVANCE and VADT studies.
Results: After the selection process 37 websites were finally evaluated. The 
main reason for exclusion was being retrieved in various search engines. 
Sixty-five percent of websites scored 3 or more in the global item indicat-
ing a moderate to excellent global information quality. More than 50% of 
websites scored less than 3 in the items “addressing uncertainty areas” (59%), 
“sources of information” (54%) and “benefits of treatments” (51%). We could 
not find any reference to the DCCT or UKPDS studies in 46% of websites and 
to the ACCORD, ADVANCE or VADT studies in 81% of them. Flesch Read-
ing Ease was 44±13.2 (mean±SD) and Flesch-Kinkaid Grade Level 10.6±1.8 
(mean±SD).
Conclusion: Although the global quality of diabetes information in the Inter-
net seems adequate, flaws still exist in items of special interest for shared deci-
sion making about type-2 diabetes treatment choices such as uncertainty and 
benefits of diabetes treatments. The information available shows a tendency 
to more frequently cite studies with positive results instead of their counter-
parts. Readability scores of the evaluated websites are below the readability 
recommended for information addressed to the general population.
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Telemedicine support using the DIABEO software on a smartphone 
improves HbA1c in poorly controlled type 1 diabetic patients: the 
randomised, 6-month, multicenter TeleDiab-1 trial
P.-Y. Benhamou1, J.-L. Bosson2, A. Penfornis3, D. Dardari4, S. Franc4,  
P. Schaepelynck5, B. Catargi6, H. Hanaire7, L. Chaillous8, E.M. Renard9,  
J.-L. Quesada2, S. Halimi1, G. Charpentier4, TeleDiab Study Group; 
1Endocrinologie Diabétologie Nutrition, CHU de Grenoble, 2Centre 
d’Investigation Clinique - INSERM, CHU de Grenoble, 3Service de 
diabétologie Endocrinologie, CHU Jean Minjoz, Besancon, 4Service 
diabétologie, Hôpital Sud Francilien, Corbeil Essonnes, 5Service de 
Nutrition - Endocrinologie - Maladies Metaboliques, CHU Marseille 
Hopitaux Sud,  6Endocrinologie Diabétologie Nutrition, Hopital Haut 
Leveque, Pessac, 7Service de Diabétologie, CHU Toulouse (Rangueil),  
8Service d’endocrinologie, CHU Nantes, 9Service des maladies 
endocriniennes, CHU Montpellier, France.
Background and aims: Diabeo software uploaded to a smartphone can de-
termine the appropriate prandial insulin dose and basal adjustments for the 
patient, using personally tailored algorithms. Data transmission then facili-
tates follow-up through teleconsultations. We assessed the efficacy on HbA1c 
of the home use of Diabeo by chronically poorly controlled type 1 diabetic 
(T1D) patients.
Materials and methods: Adult patients (n=180) with T1D (> 1 year), using 
a basal-bolus insulin regimen (> 6 months), with HbA1c ≥ 8%, were rand-
omized to a continuation of usual quarterly follow-up (G1), the home use of 
Diabeo on a smartphone suggesting insulin doses with quarterly visits (G2) 
or the similar use of Diabeo associated with phone calls every 2 weeks but no 
visit (G3) for 6 months.
Results: Six month HbA1c in G3 (8.41% ± 1.04%) was lower than in G1 
(9.10% ± 1.16%; p = 0.0019). G2 displayed intermediate results (8.63 % ± 
1.07%). HbA1c decreased from baseline by 0.49% ± 0.89% (p<0.001) in G2 
and 0.73% ± 0.84 (p<0.001) in G3; no improvement was seen for G1 (+0.18% 
± 0.93%). HbA1c improvement in G3 compared to G1 was 0.91% [0.60; 1.21] 
(improvement in G2: 0.67% [0.35; 0.99])). There was no difference in the fre-
quency of hypoglycemia or in medical time spent for hospital or telephone 
consultations. However, patients in G1 and G2 spent nearly five hours more 
than G3 patients attending hospital visits.
Conclusion: The Diabeo system allows a substantial improvement in HbA1c 
in poorly controlled T1D patients without requiring more medical time than 
usual care.
Supported by: sanofi-aventis
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Patient evaluation of education using US Diabetes Conversation Maps™ 
in the IDEA Study
J.M. Sperl-Hillen1, S.J. Beaton2, E. Parker1, O.D. Fernandes1, A. Von 
Worley2, A.M. Hanson1, D. Baumer2, J. Lavin-Tompkins1, P. Glasrud2,  
C. Spain3; 
1HealthPartners Research Foundation, Minneapolis, 2LCF Research, 
Albuquerque, 3Merck and Co., Inc., North Wales, USA.
Background and aims: In an effort to improve self-efficacy and clinical 
outcomes, a new international approach to diabetes education using Con-
versation Maps™ (CM) has emerged. We are conducting a randomized trial 
to evaluate the effectiveness of this interactive, group-based learning experi-
ence using CM, which we call IDEA (Interactive Dialogue to Educate and 
Activate). In addition to clinical and behavioural outcomes, it is important 
to evaluate patient satisfaction with the experience of this novel, group-based 
learning method in comparison to conventional one-on-one diabetes educa-
tion. The objective of this analysis is to report the data collected on the expe-
rience of patients who participated in the group and individual educational 
arms of the IDEA study.
Methods: 623 consented subjects with pre-existing type 2 diabetes and an 
A1c>=7% were randomized to group or individual education or to usual care 
(no education). Subjects receiving education were asked to complete a stand-
ardized evaluation regarding the subject content and the educator after each 
educational session. Evaluation forms contained no personally identifiable 
information, and included a sealable return envelope pre-addressed to the 
study coordinator. They were made up of likert scale questions with responses 
from 1-5, with 5 being the most affirmative. Overall evaluation scores were 
the sum of responses scaled to 100 for the content, educator, and group-spe-
cific evaluation questions. Means and standard deviations were computed for 
overall scores. Patient experience in each treatment arm was compared by t-
tests. Relationships of demographic, psychosocial and behavioural measures 
with patient experience were estimated by correlations with overall evalua-
tion scores stratified by treatment arm.
Results: Of the 489 patients attending the educational sessions, with a mean 
A1c of 8.2 and age 62, evaluations were collected from 87% of GE and 93% 
of IE participants. Both GE and IE were rated high, but overall educator rat-
ings were slightly higher for IE, mean(SD) for GE 90.3(8.7) and IE 94.6(7.3), 
(p<0.0001). No significant difference was found between GE and IE for over-
all content ratings. No associations were found between evaluation scores and 
completion of the intervention in either education arm. No significant cor-
relations were found between evaluation scores and baseline depression, self-
care profiles or quality of life. Extroverted personality was weakly correlated 
with a more positive group experience. Diabetes empowerment was weakly 
correlated with favorable content and educator ratings in IE and favorable 
content and group experience ratings in the GE arm.
Conclusion: Overall, both education arms were perceived quite positively by 
patients, though IE was rated slightly higher than GE. However, higher evalu-
ations scores were not associated with intervention completion rates. More 
empowered patients tended to rate both methods of education higher. Not 
surprisingly, extroversion was positively correlated with more positive group 
experiences. These findings support the opinions we heard from educators 
that more outgoing patients particularly liked the group experience. Forth-
coming clinical, emotional, and behavioural outcomes of IDEA educational 
interventions will be very interesting and important.
Supported by: Merck and Co., Inc.
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Carelink, Skype and Facebook improve diabetes control in adolescents 
on pump therapy
G. Petrovski, C. Dimirovski, M. Bogoev, I. Ahmeti; 
University Clinic of endocrinology, Skopje, The Former Yugoslav Republic 
of Macedonia.
Background and aims: To report results from Carelink, Skype and Facebook 
as tools to improve diabetes control in diabetic adolescents on Medtronic 
PRT (insulin pump with glucose sensor).
Materials and methods: A total of 38 adolescents with type 1 diabetes, ages 
13-22, were randomized in to groups: Regular visits (Group 1)-as standard 
medical protocol with regular visits at clinic, where data was downloaded 
at the clinic and intervention (pump settings-basal bolus insulin, education) 
were given to the patient and Internet visits (Group 2)- as protocol using 
Carelink personal program (Medtronic Diabetes), where the data was down-
loaded by the patient at home and interventions (same as group 1) were given 
via Skype (sound and video) and Facebook (written reports and chats). A1C 
was obtained before, three and six months after the study.
Results: Regular visits were 11.2±1.2 patients in group 1 and Internet visits 
were 12.8±2.4 per patient in group 2 retrospectively. There was significantly 
improvement in both groups (group 1 and 2 retrospectively, 7.4 ±0.9% and 
7.5±1.1% on beginning with 6.2±0.8 % and 6.3±1.0%, p<0.05). Internet visits 
were more preferable by the patients.
Conclusion: This brief trial suggests that adolescents with type 1 diabetes 
prefer to make contact with their health care providers via internet, where 
new technologies using specific software like Carelink, Skype and Facebook 
can improve diabetes control same as regular clinic visits.
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Structured blood glucose monitoring intervention leads to significant 
glycaemic improvement in poorly controlled, non-insulin treated type 2 
diabetes: results from the STeP study
W. Polonsky1, L. Fisher2, C. Schikman3, D. Hinnen4, C. Parkin5,  
Z. Jelsovsky6, B. Petersen7, M. Schweitzer7, R. Wagner7; 
1University of California, San Diego, 2University of California, San 
Francisco, 3NorthShore University Health System, Skokie, 4Mid America 
Diabetes Associates, Wichita, 5Health Management Resources, Inc., 
Carmel, 6BioStat International, Tampa, 7Roche Diagnostics Corporation, 
Indianapolis, USA.
Background and aims: While blood glucose monitoring (SMBG) is known 
to be beneficial among insulin users, its value and utility in insulin-naïve 
type 2 diabetes (T2DM) remains uncertain. The Structured Testing Protocol 
(STeP) study assessed the effectiveness of structured SMBG use in poorly-
controlled, insulin-naïve T2DM subjects.
Materials and methods: This 1-year, prospective, cluster-randomized, multi-
center, clinical trial recruited 522 poorly-controlled (HbA1c ≥7.5%), insulin-
naïve T2DM subjects from 35 US primary care practices. Subjects were rand-
omized to a structured testing protocol (STG) or active control (ACG). STG 
subjects used the Accu-Chek® 360° View Blood Glucose Analysis System, an 
easy-to-use paper tool that facilitates collection and interpretation of 7-point 
glucose profiles over 3 consecutive days. STG subjects completed the tool on 
a quarterly basis and brought it to medical visits. All STG subjects received 
standardized instruction in SMBG, pattern recognition and interpretation. 
STG physicians received an algorithm for suggested medication strategies in 
response to observed SMBG patterns. All STG and ACG subjects received 
free blood glucose meters and test strips.
Results: Intent-to-treat (ITT) analysis revealed that STG subjects evidenced 
significantly greater mean improvement in HbA1c than ACG subjects over 
the 12 months (-1.2% vs. -0.9%; Δ=-0.3%; p=0.04). Unlike previous studies, 
there was a high degree of protocol adherence: 70% of STG subjects who 
completed the study recorded >80% of all SMBG measurements at >4 of the 
5 quarterly protocol visits. Per protocol analysis revealed an even greater 
HbA1c reduction in STG vs. ACG subjects than was seen in the ITT analysis 
(-1.3% vs. -0.8%; Δ=-0.5%; p<0.003). Examination of STG subjects’ 7-point 
profiles revealed significant reductions from baseline in glucose levels at all 
pre- and postprandial time points (p<0.01) and in MAGE (p=0.005). Sub-
group analysis of HbA1c changes over the 12 months indicated that STG sub-
jects who reported no SMBG at baseline profited more from the intervention 
than those who had been previously using SMBG (-1.6% vs. -0.9%; Δ=-0.7%; 
p<0.0001). Similar benefits were seen among STG subjects who were taking 
<1 oral hypoglycemic agent (OHA) compared with those taking >1 OHA (-
1.5% vs. -0.9%; Δ=-0.6%; p<0.0001).
Conclusion: Structured SMBG promotes significantly better glycemic con-
trol over time in non-insulin-treated T2DM when both patients and physi-
cians collaborate in the collection, interpretation and appropriate utilization 
of SMBG. Approximately two-thirds of patients adhered well to the treatment 
protocol, suggesting that structured quarterly testing is practical as well as 
beneficial. Structured SMBG may be of even greater benefit in those patients 
with little previous history of SMBG use and among those on relatively few 
OHAs at baseline.
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Influence of glucose self-monitoring on glycaemic control in patients 
with type 2 diabetes mellitus 
L.G. Strongin1, A.V. Petrov1, A.A. Kalinnikova1, S.P. Glebov2; 
1Endocrinology and internal medicine of FOA, Nizhny Novgorod State 
Medical Academy, 2Regional Clinical Hospital, Nizhny Novgorod, Russian 
Federation.
Background and aims: The aim of study is to assess if glucose monitoring 
patients with diabetes mellitus type 2 (DM2) is associated with better glucose 
control in different groups of patients being observed in primary health care 
settings.
Materials and methods: Data have been collected as part of mobile diabetic 
center program in patients with DM2 observed in primary health care. Glu-
cose self-monitoring was assessed by questioning the patient about use of 
glucometer, usual frequency of glucose self-measurement and glucose levels 
in the week before visit. Patients measuring glucose at least once a week were 
referred to as performing glucose self-measurement. Glycemic control was 
determined by HbA1c level. Data are presented in M(SD) format, compari-
son of groups is done with Mann-Whitney U-criteria.
Results: 235 patients with DM2 have been examined with average age of 
59(9.0) years and duration of diabetes of 9(6.7) years. 79% of patients were fe-
male. Level of HbA1c was 7.8(1.9)%. Peripheral neuropathy has been detected 
in 88% of patients, retinopathy in 44% and nephropathy in 53%. Treatment 
of diabetes included sulfonurea drugs in 52%, metformin in 63% and insulin 
in 31% of cases (combined use of several drugs possible). 32% of patients 
performed glucose self-measurement. No statistically significant difference 
was observed in level of HbA1c between patients with and without glucose 
self-monitoring (7.6(1.58) vs. 7.9(2.01)% p=0.48) as well as between those 
who did and did not perform measurement of postprandial glucose levels 
(7.6(1.63)% vs. 7.5(1.52)% p = 0.47). Among patients who were treated with 
insulin and with duration of insulin treatment more than 1 year HbA1c was 
significantly lower if they performed glucose self-measurement (8.3(1.32) 
vs. 9.3(2.0)% p = 0.035). Also lower HbA1c level (9.1(0.82) vs. 9.8(1.42)% 
p = 0.007) was present in glucose self-measurement group in patients with 
HbA1c>8%. Levels of glucose reported by patients correlated with HbA1c 
level (Spearman R = 0.59 for average glucose level, p < 0.0001).
Conclusion: Glucose self-monitoring improves effectiveness of insulin 
treatment in patients with DM2 if patients have some experience in using 
insulin. This confirms necessity of more frequent glucose monitoring in this 
group and can be explained by maximal flexibility of insulin therapy. Among 
decompensated patients with DM2 there is better glucose control in peo-
ple using glucose self-measurement due to lower number of persons with 
severe decompensation (there were no patients with HbA1c >12% among 
self-measurement group while such levels were observed in several patients 
without self-monitoring). Here results of glucose measurement may become 
warning signs and motivate patients and doctors for change in treatment 
therefore reducing time and severity of decompensation. At the same time 
among patients with moderate decompensation glucose measurements may 
be not so convincing evidence of poor treatment and therefore do not influ-
ence level of compensation. Also there can be significant group of patients 
with DM2 in whom good compensation can be achieved without need for 
complex changes in treatment and lifestyle and in whom glucose self-meas-
urement will not affect results of treatment. These factors explain absence of 
difference of HbA1c depending on glucose monitoring in patients with DM2 
without marked decompensation.
1045
ACT: Actions with the CONTOUR blood glucose meter and behaviours 
in frequent testers
B.W. Bode1, R.M. Bergenstal2, R. Tamler3, D.L. Trence4, J. Fullam5, P. 
Stenger5,  
H.C. Schachner5, S. Pardo5, T. Brown3, R. Jackson1, D. Khakpour4,  
A.M. Monk2, W.A. Fisher6; 
1Atlanta Diabetes Associates, Atlanta, USA, 2International Diabetes 
Center, Minneapolis, USA, 3Mount Sinai School of Medicine, New York, 
USA 4University of Washington School of Medicine, Seattle, USA, 5Bayer 
HealthCare Diabetes Care, Tarrytown, USA, 6University of Western Ontario, 
London, Canada.
Background and aims: Self monitoring of blood glucose (SMBG) is a self-
management tool for patients with diabetes. Features on blood glucose (BG) 
meters, such as meal markers for pre- and post-prandial BG levels and re-
minders for post-prandial testing, may prompt more focused self manage-
ment, especially around mealtimes. This 6-month randomized, multicenter 
study evaluated if use of a BG meter (Bayer’s CONTOUR) with meal marker 
+ audible reminder and diabetes education maintains or increases the fre-
quency of post-prandial testing in frequent testers compared to diabetes 
education and standard meter features alone. The impact of the 2 trial condi-
tions on patients’ SMBG information, motivation, and behavioral skill, and 
via changes in these parameters, on SMBG practice and decision-making was 
evaluated.
Materials and methods: Subjects (n = 211) had type 1 (n = 120) or type 2 
(n = 90) diabetes, used meal-time insulin at least 1 meal per day and tested 
their BG levels at least 3 times per day. Subjects received diabetes education 
and were randomized to Basic (no meal marker or reminder) or Advanced 
(meal marker + reminder) and were instructed to record BG levels in their 
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logbook. Subjects were seen at baseline, 6 weeks, 3 months, and 6 months 
with no mandated actions between visits. Baseline testing frequency was self-
reported, and meters were downloaded at visit 2-4.
Results: For the primary endpoint of frequency of post-prandial testing, the 
Advanced testing group had significantly more frequent post-prandial tests 
per week (Table 1) and significantly more paired pre- and post-prandial tests 
than the Basic group at each follow-up.
Table 1. Post-prandial Weekly Tests
Visit 2
6 wks
Visit 3
12 wks
Visit 4
24 wks
V3-V2 V4-V3
Basic 9.2 7.9 7.1 P <0.01 P = 0.07
Advanced 13 12 10.2 P = 0.01 P = 0.001
P values (Basic vs Advanced) <0.001 <0.001 <0.001
Both groups had significant declines in A1c values (Basic 8.3 to 7.9 and Ad-
vanced 8.0 to 7.8). Correlation of changes in SMBG information, motivation, 
and behavioral skills as they relate to changes in SMBG frequency and under-
standing of results, as well as markers of glycemic control, including A1c, are 
seen in both type 1 and type 2 diabetes.
Conclusion: Current findings demonstrate that a meter with a meal marker + 
audible reminder increases post-prandial and paired testing.
Supported by: Bayer HealthCare Diabetes Care
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Can glucose meters meet tighter accuracy requirements?
R. Ng1, J. Lock2; 
1Abbott Diabetes Care, Alameda, 2Internal Medicine and Endocrinology, 
Worcester, USA.
Background and aims: The ISO Standard (ISO 15197:2003) and various 
CLSI guidelines are undergoing revisions that are likely to result in tightening 
the accuracy requirements on blood glucose monitoring systems (BGMS). 
We evaluated four of the latest generation of BGMS to assess the potential 
impact of tighter criteria on system accuracy.
Materials and methods: The following 4 BGMS, each with 3 lots of strips, 
were evaluated for finger blood testing at a clinic: Bayer Contour®, LifeScan 
OneTouch® Ultra®2 (with the new OneTouch Ultra Blue test strip), Roche 
Accu-Chek® Aviva and Abbott FreeStyle Freedom Lite® system (with the new 
GDH-FAD test strip). A total of 150 diabetic subjects were included in the 
study. A trained operator tested the subject’s fingertip blood in duplicate with 
the 4 systems and 2 YSI glucose analyzers, which served as the reference. 
The order of testing the 4 systems was rotated after each subject. To ensure 
sufficient number of finger blood samples with glucose concentrations below 
2.8 mmol/L (50 mg/dL) and above 22.2 mmol/L (400 mg/dL) were tested, 8 
samples were modified to lower the glucose concentration below 2.8 mmol/L 
(50 mg/dL) and another eight samples were modified to elevate above 22.2 
mmol/L (400 mg/dL). The accuracy of the YSI analyzers was validated by 
testing the National Institute of Standards and Technology (NIST) Standard 
Reference Material SRM 965b. All systems and supplies were stored, handled 
and operated according to the manufacturer’s instructions.
Results: The blood glucose concentrations of the 150 subjects and the 16 
modified samples ranged from 1.3 - 25.5 mmol/L (23 to 460 mg/dL), with 
a mean value of 9.7 mmol/L (175 mg/dL) and a median of 8.6 mmol/L (155 
mg/dL). The hematocrits of the 150 subjects ranged from 32% to 54% (mean 
and median, 42%), and were within the product specifications. A total of 331 
to 332 tests were performed on each BGMS with 166 blood samples from 150 
patients. All 4 BGMS met the minimum acceptable accuracy required by ISO 
15197:2003, with ≥95% of the individual glucose results falling within ±20% 
of the reference, and within ±0.83 mmol/L (15 mg/dL) at glucose concentra-
tions <4.2 mmol/L (<75 mg/dL)**. When the accuracy criterion was tight-
ened to ±15% of the reference, and within ±0.83 mmol/L (15 mg/dL) at glu-
cose concentrations <5.6 mmol/L (<100 mg/dL)*, less than 95% of the Bayer 
Contour results met criterion. When the accuracy criterion was tightened to 
±10% of the reference, and within ±0.56 mmol/L (10 mg/dL) at glucose con-
centrations <5.6 mmol/L (<100 mg/dL)*, less than 95% of the Bayer Contour, 
LifeScan OneTouch Ultra2 and Roche Accu-Chek Aviva results met criterion; 
only the Abbott FreeStyle Freedom Lite system met this criterion.
Conclusion: Not all BGMS can meet tighter accuracy criteria. Manufactur-
ers will need to be vigilant in improving the accuracy performance of their 
BGMS to be ready for the anticipated changes in accuracy standards and 
guidelines.
System Within 
±5% or
±0.28 mmol/L 
(±5 mg/dL)*
Within 
±10% or
±0.56
mmol/L 
(±10 mg/
dL)*
Within 
±15% or 
±0.83
mmol/L
(±15 mg/
dL)*
Within 
±20% or 
±0.83 
mmol/L
(±15 mg/
dL)**
FreeStyle Freedom Lite 72.3% 95.5% 99.7% 100%
Accu-Chek Aviva 60.5% 91.9% 99.1% 100%
OneTouch Ultra2 49.2% 80.4% 95.2% 97.0%
Contour 27.2% 59.5% 85.8% 97.3%
1047
Glucose self-measurement results and life quality in patients with type 2 
diabetes mellitus
A.V. Petrov1, L.G. Strongin1, A.A. Kalinnikova1, S.P. Glebov2; 
1Endocrinology and internal medicine of FOA, Nizhny Novgorod State 
Medical Academy, 2Regional clinical hospital, Nizhny Novgorod, Russian 
Federation.
Background and aims: Health-related quality of life (HRQL) can be differ-
ently influenced by self-measurement of glucose in patients with diabetes 
mellitus type 2 (DM2). Improved HRQL can be expected if it improves glu-
cose control and is associated with reduction in diabetes complication. At the 
same time results of glucose measurement can become additional stress-fac-
tors if patient is decompensated and is not able to improve disease control 
due to lack of knowledge, training or support. Aim of current study was to 
assess whether patients performing glucose self-measurement are different 
in life quality compared to these who are not and to evaluate association be-
tween results of glucose measurement and indicators of HRQL.
Materials and methods: HRQL was assessed with use of SF-12 v.2 ques-
tionnaire in patients with DM2 referred for examination in mobile diabetic 
center in local areas of region by internists and endocrinologists in primary 
healthcare. Patients have been asked about use of glucometers and if present 
- about usual frequency of glucose measurement and levels of glucose during 
a week before visit. These who checked glucose levels at least once a week 
were referred to as performing glucose self-measurement. Maximal, mini-
mal and average glucose levels have been used for further assessment. HbA1c 
level was measured at the visit for evaluation of glycemic control. Data are 
presented in M(SD) format unless specified otherwise. Mann-Whitney U-
criteria has been used for comparison of groups and Spearman R-criteria to 
find out correlations.
Results: Data were received about 104 patients whose average age was 56(9.2) 
years and diabetes duration 8(6.2) years. 84% of patients were female. 39% of 
patients received insulin with average insulin treatment duration of 5(3.0) 
years. Patients who did and did not perform glucose self-measurement had 
statistically significant differences only on role-physical scale of questionnaire 
(45(24) vs. 55(26) p = 0.025) with patients performing glucose monitoring 
having poorer life quality. Patients with HbA1c below 7% had better HRQL in 
physical functioning (51(32) vs. 38(33) p = 0.045), role physical scale (54(25) 
vs. 44(26) p = 0.044), social functioning (67(25) vs. 56(27) p = 0.048) and 
role emotional scale of SF-12 questionnaire (61(23) vs. 50(24) p = 0.013). In 
correlation analysis there was significant although weak negative correlation 
between glucose levels in self-measurement and physical functioning, role 
physical and bodily pain scales ( R = -0.27 -0.31 and -0.25 with p = 0.02 0.012 
and 0.035 correspondingly).
Conclusion: HRQL was significantly lower in patients with decompensated 
diabetes. This can be a result of hyperglycemia symptoms or development of 
diabetes complications in this group. Life quality was not convincingly con-
nected with presence of glucose self-measurement. In patients who performed 
glucose self-measurement it worsened together with increase in glucose levels 
for aspects of physical health and pain. Symptoms of hyperglycemia and dia-
betes complications may also play a role here but psychological perception of 
high glucose levels is not to be forgotten. Many diabetic patients do complain 
that poor results of glucose by self-measurement worsen their psychological 
status and this may affect results of HRQL evaluation.
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Association between HbA1c and self-monitoring blood glucose values in 
patients with type 2 diabetes
K. Kyriakopoulos1, S. Liatis2, K. Makrilakis2, A. Papazafeiropoulou3, C. 
Fytili2, I. Tombrou2, I. Vasileiou2, A. Sotiropoulos3, S. Pappas3,  
N. Katsilambros2; 
1Diabetes outpatient Clinic, Ika Vyronas, Athens, 2First Department of 
Propaedeutic Medicine, Athens University Medical School, 3Diabetes 
Center, Nikaia General Hospital, Piraeus, Greece.
Background and aims: The role of self-monitoring of blood glucose (SMBG) 
in Type 2 diabetes (T2D) management is not adequately established. Aim of 
the present study was to assess the relationship between HbA1c and SMBG 
values in T2D patients, as well as determine SMBG values that define a satis-
factory glycaemic control.
Materials and methods: A total of 1,000 consecutive T2D patients were ex-
amined in 3 outpatient Diabetes centers. SMBG values of the previous week 
were recorded as well as the HbA1c value at the index visit.
Results: A total of 926 patients reported they were performing SMBG at 
home, of which 872 had pre-prandial values and 774 also post-prandial val-
ues in their records. A very strong correlation was found between HbA1c and 
both pre-prandial and post-prandial SMBG values (r=0.649, p<0.001 and 
r=0.641, p<0.001, respectively). The correlation between HbA1c and the to-
tal SMBG values (both pre-prandial and post-prandial) was even stronger 
(r=0.706, p<0.001). In a multivariate analysis, pre- and post-prandial SMBG 
values had an independent association with HbA1c. According to these asso-
ciations, the target value of HbA1c=7.0% corresponded to a mean pre-pran-
dial SMBG value of 120 mg/dl and to a mean 2-hour post-prandial SMBG 
value of 151 mg/dl.
Conclusion: In patients with T2D, SMBG values for 1 week satisfactorily de-
fine glycaemic control. Post-prandial values offer additional data for assessing 
diabetic control. Pre-prandial values <120 mg/dl and 2-hour post-prandial 
values <151 mg/dl correspond to HbA1c values <7.0%.
1049
Structured blood glucose monitoring reduces distress and depression, 
and enhances well-being in poorly controlled, non-insulin treated type 2 
diabetes: results from the STeP Study
L. Fisher1, W. Polonsky2, C. Parkin3, Z. Jelsovsky4, M. Schweitzer5,  
R. Wagner5; 
1University of California, San Francisco, 2University of California, San 
Diego, 3Health Management Resources, Inc., Carmel, 4BioStat International, 
Tampa, 5Roche Diagnostics Corporation, Indianapolis, USA.
Background and aims: Recent reports have suggested that the promotion 
of SMBG among non-insulin treated patients with T2DM is associated with 
more depressive symptoms. In the Structured Testing Protocol (STeP) study, 
we investigated the impact of a structured SMBG intervention on diabetes 
distress, clinical depression and well-being over 12 months.
Materials and methods: In this prospective, cluster-randomized, multi-cen-
tered clinical trial with 522 randomly assigned, poorly-controlled (HbA1c 
≥7.5%), insulin-naïve T2DM patients, we showed that patients in a struc-
tured testing SMBG group (STG) displayed larger reductions in HbA1c over 
12 months than patients in an active control group (ACG). STG subjects used 
the Accu-Chek® 360° View Blood Glucose Analysis System, an easy-to-use 
paper tool that facilitates collection and interpretation of 7-point glucose pro-
files over 3 consecutive days. STG subjects completed the tool on a quarterly 
basis and brought it to medical visits. All STG subjects received standardized 
instruction in SMBG, pattern recognition and interpretation. STG physi-
cians received an algorithm for suggested medication strategies in response 
to observed SMBG patterns. All STG and ACG subjects received free blood 
glucose meters and test strips. At baseline, 3, 6, 9 and 12 months, all subjects 
completed self-report measures to assess diabetes-specific distress (the Dia-
betes Distress Scale, DDS), clinical depression (the Patient Health Question-
naire 8, PHQ8), and positive well-being (the WHO5).
Results: Intent-to-treat (ITT) analyses indicated significant reductions from 
baseline in DDS (p<0.001) and PHQ8 (p<0.001) scores and significant in-
creases in positive well-being (PWB) scores (p<0.001) for subjects in both 
STG and ACG at 3, 6, 9 and 12 months. STG patients who reached criteria for 
significant diabetes distress (mean item DDS score ≥3) and STG subjects who 
reached criteria for clinical depression (total PHQ8 ≥10) at baseline showed a 
significantly greater reduction in distress and depression over time than ACG 
subjects at 9 and 12 months (p<0.03 in both cases) No between-group differ-
ences were found for PWB over time.
Conclusion: Contrary to previous reports and using well-validated meas-
ures, we found that both treatment groups experienced significant reductions 
in diabetes distress and depression and increased PWB over time. Further-
more, among patients with elevated diabetes distress or clinical depression at 
baseline, the structured SMBG intervention was associated with significantly 
greater improvement in these conditions over time than for control subjects. 
In sum, these findings suggest that when both patients and physicians col-
laborate to gather, interpret and appropriately utilize structured SMBG data, 
emotional distress is alleviated, not worsened.
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An information-motivation-behavioural skills analysis in frequent 
testers
T. Kohut1, P. Stenger2, H.C. Schachner3, J. Fullam3, S. Pardo3, R.M. Bergenstal4, 
B.W. Bode5, R. Tamler6, D.L. Trence7, W.A. Fisher1; 
1Department of Psychology, University of Western Ontario, London, 
ON, Canada, 2Medical Communications, Bayer HealthCare, Diabetes 
Care, Tarrytown, USA, 3Medical Affairs, Bayer HealthCare, Diabetes 
Care, Tarrytown, USA, 4International Diabetes Center, Minneapolis, 
USA, 5Atlanta Diabetes Associates USA, 6Department of Endocrinology, 
Diabetes and Metabolism, Mount Sinai Medical Center, New York, USA, 
7Department of Endocrinology and Diabetes, University of Washington 
Medical Center, Seattle, USA.
Background and aims: Self monitoring of blood glucose (SMBG) is a behav-
ioral tool for patients with diabetes. Features on blood glucose (BG) meters, 
such as meal markers for pre- and post-prandial BG levels and reminders 
for post-prandial testing, may better inform self-management decisions, 
especially around mealtimes. This 6 month randomized, multicenter study 
evaluated if use of a BG meter with meal marker + audible reminder and dia-
betes education maintains or increases frequency of postprandial testing in 
frequent testers compared to diabetes education and standard meter features 
alone. The impact of the two trial conditions on patients’ SMBG informa-
tion, motivation and behavioral skills on SMBG practice and decision-mak-
ing, were evaluated from baseline to completion via an IMB survey. Clinical 
parameters reported previously. IMB correlation to clinical parameters are 
presented here.
Materials and methods: Subjects (n=211) had type 1 (n=120) or type 2 
(n=90) diabetes, used meal time insulin at least 1 meal/day and tested their 
BG levels at least 3x/day. All subjects received diabetes education and were 
randomized to Basic (no meal marker or reminder) or Advanced (meal mark-
er + reminder) and instructed to record BG levels in their logbook. Subjects 
were seen at baseline, 6 weeks, 3 months, and 6 months with no mandated 
actions between visits.
Results: Baseline A1c correlated with motivation at baseline and across the 
study, most strongly in the type 1 population (r= -0.24, p<0.01 Visit 1; r= -
0.22, p<0.05 Visit 4). In patients with type 2, increased information correlated 
with increased Glycomark, a reported measure of improved post-prandial 
glucose control (r=0.32, p<0.007 Visit 1: r=0.38, p< 0.003 Visit 4). At comple-
tion, the Advanced group had stronger understanding and belief that food 
and/or exercise have an effect on BG levels and were less anxious about blood 
sugar testing compared to subjects who did not use this feature. In subjects 
with type 1 and type 2 diabetes, using the meal marker resulted in significant 
increase in post-prandial testing (15% Visit 1 to 50% Visit 4) as well as sig-
nificant improvement in understanding pre- and post-meal results over time 
(33% at time 1 to 72% at time 4).
Conclusion: SMBG can be an effective self-management tool that may be in-
strumental in achieving glycemic control among adults with type 1 and type 
2 diabetes. Understanding and utilization of particular meter features may 
improve the value of SMBG. Correlation of changes in SMBG information, 
motivation, behavioral skills as they relate to changes in SMBG frequency 
and understanding of results, as well as markers of glycemic control, includ-
ing A1c, are seen in both type 1 and type 2 diabetes.
Supported by: BHC, BDC
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Prospective data evaluation of the application of a multisensor device for 
non invasive continuous glucose monitoring
M.S. Talary1, M. Mueller1, O. De Feo1, P. Zakharov1, A. Megej1, M. Donath2, 
J. Klisic1, W.A. Stahel3, A. Caduff1; 
1R&D, Solianis Monitoring, 2Division of Endocrinology and Diabetes, 
University Hospital Zurich, 3Seminar for Statistics, ETH Zurich, 
Switzerland.
Background and aims: We have previously reported about the findings in 
clinical-experimental studies with a novel Multisensor system for non in-
vasive continuous glucose monitoring. The Multisensor measures skin im-
pedance and optical skin characteristics in several frequency bands of the 
electromagnetic spectrum as well as temperature, acceleration and humidity. 
In this study a Multisensor version with fully integrated sensors and battery 
in a miniaturised housing (54 x 65 x 13 mm) was experimentally tested to 
compare the outcome to previous findings using earlier versions.
Materials and methods: Six T1DM patients (age 44±16 y; BMI 24.1±1.3 kg/
m2, duration of diabetes 27±12 y; HbA1c 7.3±1.0%) wore the same Multi-
sensor at the upper arm. In total these patients performed 45 in-clinic study 
days; each patient performed on average seven study days (min. 5 and max. 
10 days). A study day lasted approximately 10 hrs (min. 8 and max. 11 hrs) 
and glucose changes were induced by the administration of an oral or i.v. glu-
cose solution. Blood glucose was measured for reference using a HemoCue 
analyser. Several prospective data evaluation routines were applied. The first 
22 study day’s data spanning all subjects were used to train a linear regression 
model. The global model derived was then prospectively applied to the data 
of the remaining 23 study days allowing for external validation. One initial 
baseline adjustment at the very beginning of each study day was used to ad-
just the level of the glucose estimate.
Results: Figure 1 shows the time series of all 23 externally validated study 
days. These profiles were obtained with fully prospective data evaluation us-
ing a global model with one initial calibration point. When comparing the 
estimated glucose to the blood glucose reference values, the model yielded a 
Mean Absolute Relative Difference (MARD) of 40.8%, a Mean Absolute Dif-
ference (MAD) of 51.9 mg/dL, and an R2 of 0.70 on average per study day. 
The Clarke error grid analyses showed 89.0% of paired glucose values in A+B, 
4.5% in C, 4.6% in D and 1.9% in the E region.
Conclusion: This work demonstrates that glucose variations under control-
led conditions can be monitored non invasively by a prospectively applied 
multiple regression statistical model. The findings from this study indicate 
that further development steps in the Multisensor system should not affect 
the estimation performance. In this respect, the expected model performance 
can be more reliably judged at the stage of clinical validation.
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Simultaneous non invasive continuous glucose monitoring on the left 
and right arm using two multisensor devices
A. Caduff1, M. Mueller1, O. De Feo1, P. Zakharov1, A. Megej1, M. Donath2,  
J. Klisic1, W.A. Stahel3, M.S. Talary1; 
1R&D, Solianis Monitoring, Zurich, 2Division of Endocrinology and 
Diabetes, University Hospital Zurich, 3Seminar for Statistics, ETH Zurich, 
Switzerland.
Background and aims: We have previously reported about the findings in 
clinical-experimental studies with a novel Multisensor system for non inva-
sive continuous glucose monitoring. The Multisensor measures skin imped-
ance and optical skin characteristics in several frequency bands of the electro-
magnetic spectrum. In this study a Multisensor version with fully integrated 
sensors and battery in a miniaturised housing (54 x 65 x 13 mm) was experi-
mentally tested, investigating location related measurement characteristics.
Materials and methods: Four T1DM patients (age 43±9 y; BMI 24.5±3.7 kg/
m2, duration of diabetes 22±11 y; HbA1c 7.7±0.5%) performed 4 in-clinic 
study days with a Multisensor attached to the left and right upper arm. As a 
result, 32 datasets from 16 study days were obtained. The Multisensors were 
exchanged between the patients and the left and right arm according to a 
Graeco-Latin Square. Glycaemia was varied using 4 different glucose profiles. 
For each study day, one of the four different glucose profiles was induced 
via oral Carbohydrate loads. Blood glucose was measured for reference using 
a HemoCue analyser. Different data evaluation routines were applied to the 
Multisensor data in order to obtain global (identical coefficients) and per-
sonal (personal coefficients) models that were used for cross validation.
Results: Figure 1 shows all 32 glucose profiles obtained during the 16 study 
days, using the global model with a prospective initial baseline calibration 
(CEG A 44.9, B 48.0, C 3.6, D 3.0, E 0.5%). The following performance met-
rics was obtained from the different models. In each model an initial baseline 
calibration was used at the beginning of each study day (IB) as well as a full 
day baseline calibration (FB), with Average R2 = coefficient of determination 
on average over the study days, MAD= Mean Absolute Difference [mg/dL], 
MARD= Mean Absolute Relative Difference [%]. Global IB: 0.76, 47, 32.3; 
Global FB: 0.75, 29.9, 21.3; Personal IB: 0.85, 43.3, 30.7; Personal FB: 0.84, 
24.1, 17.6.
Conclusion: The glucose time courses estimated by the Multisensors from 
the two arms are repeatably comparable, even with a global model with one 
initial baseline calibration only. This indicates that the sensor signal char-
acteristics are robust enough to allow changing from one arm to the other 
using the same device settings and calibration. That represents thus a further 
indication that the Multisensor approach for non invasive glucose monitor-
ing under such conditions is possible. It is also an indication that a personal 
model may be able to track glucose more accurately than a global model.
Figure 1: Overview of all 32 predicted glucose profiles with a fully prospec-
tive data evaluation of the two Multisensor devices on the left (red) and right 
(green) arm using a global model with one initial calibration point (Global 
IB).
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Measuring within-patient glycaemic variability: a best practice
L. Kerr, C.R. Heilmann, C. Jones, J.A. Jackson, S. Jacober; 
Eli Lilly and Company, Indianapolis, USA.
Background and aims: The role of glycaemic variability (GV) in the develop-
ment of diabetes complications and hypoglycaemia in patients (pts) with dia-
betes remains controversial. Our aim was to compare current GV measures 
through simulated self-monitored blood glucose (SMBG) and continuous 
glucose monitoring (CGM) data points to determine which measure carries 
the highest statistical power and effect size.
Materials and methods: We simulated datasets for 1,000 trials with pts with 
type 1 (20%) and type 2 (80%) diabetes. Three days of 7-point SMBG profiles 
(n=240 pts/trial) and 288-point CGM profiles (n=20/trial) were generated 
using a gamma distribution which created two patient groups, Groups 1 and 
2. To assess the effect of different GV measures independent of mean BG, 
both groups had a mean BG of 7.94 mmol/L. GV (defined as velocity of BG 
change over time [mmol/L per minute]) for Group 2 (“BG Change”) was 50% 
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greater than for Group 1 (“Reference”). Patients were randomised to diabetes 
type, then mealtime pattern (3 meals a day ± snack ± dawn phenomenon) and 
meal start time, which varied by patient-day, were also randomised. Groups 
were compared using a t-test for each measure. Power was calculated as the 
proportion of trials with a p-value <0.05. Effect size (estimate of the meas-
ure’s strength to detect the difference in GV between Groups 1 and 2) was 
calculated by averaging the difference between groups (Group 2 - Group 1) 
divided by the standard deviation for the pooled groups. A Pearson’s matrix 
was obtained for total [SD], within-day and day-to-day measures to further 
characterise them.
Results: See table.
Results for total GV for all measures (only SD results shown) were similar to 
within-day GV results. For SMBG within-day GV, SD had the highest power 
and effect size and for SMBG day-to-day GV, ADRR had the highest power 
and effect size. For CGM within-day GV, ACM had the highest power and 
effect size and for CGM day-to-day GV, ADRR had the highest power and 
effect size. For total GV, SD resulted in 100% power for both SBGM and CGM 
and a 2.19 and 3.14 mmol/L effect size for SMBG and CGM, respectively. For 
SMBG within-day, all measures correlated with each other (rho > 0.59). For 
SMBG day-to-day measures, CONGA and MODD highly correlated (rho = 
0.73). For CGM within-day, all measures (except ARC and SD[ARC]) high-
ly correlated with each other (rho > 0.81). For CGM day-to-day measures, 
ADRR, CONGA, and MODD highly correlated (rho > 0.75).
Conclusions: Effect size helped differentiate measures, and the lower power 
for CGM suggests more pts per trial are needed. For analysing SMBG and 
CGM within-patient GV data, SD is recommended for within-day and ADRR 
for day-to-day GV. Although ACM had a slightly higher effect size and Range 
and IQR had a similar effect size for CGM within-day GV, SD is preferred 
because it is consistent with the SMBG results. Because within-day (SMBG) 
and day-to-day (SMBG, CGM) measures are highly correlated, using only SD 
(within-day) and ADRR (day-to-day) to measure GV is currently justified.
Supported by: Eli Lilly and Company
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Assessment of the variance of the ambulatory glucose profile over 3 to 20 
days of continuous glucose monitoring
T.C. Dunn, N. Crouther; 
Abbott Diabetes Care, Alameda, USA.
Background and aims: The Ambulatory Glucose Profile (AGP) has been 
proposed as an effective way to identify trends in glucose abnormalities in 
people with diabetes using continuous glucose monitoring (CGM). The aim 
of this study was to evaluate the minimum number of days of CGM needed 
to arrive at stable glucose patterns revealed by AGP analysis.
Materials and methods: AGP analysis was performed utilizing 67 adult sub-
jects (T1DM = 47, T2DM = 20) who participated in a study that began with 
20 days of masked CGM, using the FreeStyle Navigator® System. Subjects were 
not able to see their CGM glucose values or trends and did not have glucose 
threshold or projected alarms available. Only masked data were evaluated in 
order to minimize effects of therapy adjustments on the evaluation. Statistics 
for each of 3 to 19 days of CGM data were compared to the 20-day values 
and evaluated on a per-subject basis. For overall summary statistics (mean, 
standard deviation, 10th, 25th, 50th, 75th, 90th percentiles, inter-quartile range, 
mean change in the hourly median curve), equivalence criteria of 90-110% of 
the 20-day value were evaluated. For overall rates of glucose above, below or 
within the target of 3.89-7.78 mmol/L (70-140 mg/dL), the absolute difference 
compared to the 20-day value was evaluated at equivalence criteria (based on 
scaling the standard error of the overall mean) of 6.40%, 1.45%, and 5.46%, 
respectively. For hourly AGP percentile lines (10th, 25th, 50th, 75th, 90th) the 
mean absolute relative difference compared to the corresponding 20-day line 
was calculated and evaluated against the equivalence criteria <10%.
Results: A summary of the 20-day statistics and the relationship between the 
number of days needed for an AGP statistic to meet the equivalence criteria 
for 70%, 80% and 90% of subjects is shown in Table 1. After 10 days, the glu-
cose mean, standard deviation, 50th, 75th, and 90th percentiles are within 10% 
of the 20-day value for more than 80% of subjects. After 14 days, the rates of 
above, below and within target, the 10th and 25th percentiles, and the hourly 
AGP percentile lines met the equivalence criteria for over 80% of patients. 
The interquartile range and mean change in the hourly median curve needed 
more days of CGM to approximate the 20-day value for 80% of subjects: 15 
and 18 days, respectively.
Conclusion: AGP analysis promises to be an effective tool for identifying 
glucose abnormalities and may allow the use of evidence-based and proto-
col-driven medical practices to select appropriate therapies to address those 
abnormalities. Clinical evidence is lacking to support the assumption used in 
this study that AGP analysis of 20 days of CGM can identify clinically impor-
tant glucose trends and patterns. Within that context, however, this analysis 
suggests that a minimum of 14 days of CGM provides identification of in-
dividual glucose patterns. Prospective studies are needed to provide clinical 
evidence establishing the benefits of identifying patterns with AGP analsyis 
that affect treatment and improve outcomes.
Supported by: Abbott Diabetes Care
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Assessment of postprandial glucose control; a consideration from 
continuous glucose monitoring
T. Tsuchita, S. Nagasaka, N. Takahashi, D. Sekizawa, I. Kusaka, N. Saito,  
H. Yagyu, S. Ishibashi; 
Endocrinology and Metabolism, Jichi Medical University, Shimotsuke-city, 
Japan.
Background and aims: Importance of postprandial glucose control has been 
appreciated, although the consensus on its assessment is not established. This 
study was undertaken to reveal characteristics of postprandial glucose con-
trol and make a consideration on its assessment.
Materials and methods: Glucose levels until 3-hrs postprandial were meas-
ured with Continuous Glucose Monitor (CGM) in a total of 491 meals. These 
were obtained from a total of 103 diabetic patients (41 with type 1, 56 with 
type 2, and 6 with other types; with ages of 52.6±13.7years, BMI 23.0±3.9kg/
m2, and HbA1c 9.1±2.2%, mean±SD). Eighty-one patients were treated with 
insulin (mostly with multiple injections or CSII), 11 with oral hypoglycemic 
agents, and 11 with diet therapy alone. Most of the patients were admitted 
and given controlled diet comprising 50% of energy intake as carbohydrate.
Results: Median glucose levels of the 491 meals were 126 (pre-prandial), 155 
(at 30 min postprandial), 175 (at 60), 172 (at 90), 166 (at 120), 156 (at 150), 
and 149 mg/dl (at 180), respectively. Maximal median value was 176 mg/dl at 
65 min. Pre-prandial and maximal postprandial glucose levels after breakfast, 
lunch, and supper were 130 and 191 (at 60), 127 and 163 (at 75), 135 and 186 
(at 80), respectively. Postprandial glucose levels 45~130 min after lunch were 
significantly lower than those after breakfast and supper, suggesting presence 
of second meal effect. Between patients with or without insulin therapy, glu-
cose excursions after meal were essentially analogous and both glucose peaks 
were at around 60 min. When the subjects were divided into 4 groups accord-
ing to pre-prandial glucose levels (-109, 110-129, 130-159, and 160- mg/dl), 
corresponding maximal postprandial glucose levels were 150 (at 95), 165 (at 
75), 183 (at 80), and 232 mg/dl (at 60), respectively. There was a trend that 
a glucose peak appears earlier as pre-prandial glucose levels increase. When 
the subjects were divided into 4 groups according to glucose levels at 2-hours 
postprandial (-140, 140-179, 180-219, and 220- mg/dl), corresponding maxi-
mal postprandial glucose levels were 133 (at 45), 173 (at 65), 205 (at 65), and 
262 mg/dl (at 105), respectively. There was a trend that a glucose peak ap-
pears later as 2-hours postprandial glucose levels increase. Then we divided 
the subjects into 4 groups according to glucose levels at 1-hour postprandial 
by using the same criteria at 2-hours. Corresponding maximal postprandial 
glucose levels were 117 (at 55), 163 (at 70), 205 (at 70), and 256 mg/dl (at 65), 
respectively. The glucose peaks were observed at around 60 min, irrespective 
of glucose control (Figure).
Conclusion: When postprandial glucose levels are assessed at 2-hours, “real” 
glucose peaks are observed at 45~105 min depending on glucose control. 
Given the glucose spike plays an important role on vascular complications, 
assessment at 1-hour would be appreciated since the glucose peaks are cap-
tured at this point irrespective of glucose control.
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Predictors of continuous glucose monitoring (CGM) variability and 
associations with patient satisfaction and health perceptions in insulin-
treated diabetes
D.C. Simonson1, M.A. Testa2, J. Gill3, R.R. Turner4, L. Blonde5; 
1Endocrinology, Diabetes and Hypertension, Brigham and Women’s 
Hospital, Boston, 2Biostatistics, Harvard School of Public Health, 
Boston, 3sanofi-aventis, Bridgewater, 4Phase V Technologies, Wellesley, 
5Endocrinology, Ochsner Medical Center, New Orleans, USA.
Background and aims: Glycemic variability is typically estimated using 7-point 
glucose profiles, which might not be sensitive to clinical predictors and patient-
centered health outcomes. We modeled continuous glucose monitor (CGM) 
variability to determine if insulin regimen, type of diabetes, age, sex, BMI and 
HbA1c predict CGM within-day standard deviations (SD), and if SD changes 
are associated with patient satisfaction (PS) and perceived health (PH).
Materials and methods: We analyzed CGM data from 306 insulin-treated 
T2DM and 82 T1DM (47% male, age 54±11 yrs, HbA1c 7.8±0.7%) who were 
randomized to open-label daily insulin glargine + premeal glulisine (GG; 
n=192) or BID analogue premix 75/25 or 70/30 (PM; n=196) for 12 wks (P1), 
and then crossed over to the alternate treatment for 12 wks (P2). Patients 
were contacted weekly to ensure compliance with a titration algorithm with 
a target HbA1c < 7.0%. Three-day CGM and HbA1c were obtained at Wks 0, 
12 and 24. Patients completed clinic-based PS and PH questionnaires at Wks 
0, 8, 12, 20 and 24. CGM estimates were obtained for each patient from the 
3-day session (288 glucoses/day), and regression used to model independ-
ent variables. PS was represented by the net benefit composite scale, which 
included 4 subscales of advocacy, general satisfaction, glycemic effectiveness 
and preference. The PH scale included 3 subscales of health status, vitality 
and sleep quality.
Results: During P1, reductions from baseline for glycemic measures were 
larger for GG vs PM (*p<0.001; see Table), except for % time < 3.9 mmol/l. P2 
cross-over results (not shown) were similar to the between-group differences 
in P1. Baseline-adjusted PS (60.5±1.2 vs 45.4±1.2) and PH (427±3 vs 418±3) 
were higher for GG compared to PM during P1 and P2 (both p<0.01). CGM 
SD decreased with GG (-0.1±0.06 mmol/l, p=0.037), increased with T1DM 
(0.6±0.09 mmol/l), decreased by 0.02±0.004 and 0.01±0.003 mmol/l per unit 
increase in BMI and age, and increased by 0.4±0.04 mmol/l per unit increase 
in HbA1c (all p<0.001). Sex was not a significant predictor of CGM SD. The 
% time < 3.9 mmol/l was higher by 6.8±1.0% for T1DM vs T2DM, p<0.001. 
Improvement in PS was independently associated with decreases in HbA1c, 
CGM BG and SD (all p<0.015). PH improved with decreased CGM BG, SD 
and % time > 7.8 mmol/l (all p<0.05). 
Table 1. Glycemic Control and Variability During Period 1 Treatment
Period 1 GGBaseline
GG
Wk 12
PM
Baseline 
PM
Wk 12
HbA1c (%) 7.8±0.05 7.1±0.05* 7.8±0.05 7.4±0.06
BG (mmol/l) 9.7±0.10 8.2±0.09* 9.7±0.09 9.1±0.09
SD (mmol/l) 2.7±0.04 2.4±0.05* 2.7±0.04 2.7±0.04
% time > 7.8 mmol/l 63.0±1.0 46.5 ±1.1* 63.9±1.0 55.6±1.0
% time < 3.9 mmol/l 5.3±0.4 7.4±0.4 (ns) 5.4±0.4 5.8±0.4
Conclusion: Lower CGM variability was associated with insulin glargine 
plus glulisine vs premix, and was predictive of improved PS and PH. Glucose 
variability was higher with increased HbA1c and lower among T2DM, older, 
and higher weight patients. CGM variability, PS, and PH are useful patient-
oriented measures to evaluate the comparative effectiveness of diabetes treat-
ments.
Supported by: sanofi-aventis
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Continuous glucose monitoring: effect on glucose control and treatment 
satisfaction in diabetes mellitus type 1
L.L. Langeland1, Ø. Salvesen1, H. Selle2, S.M. Carlsen1,2, K.J. Fougner1,2; 
1Norwegian University of Science and Technology, 2St. Olavs Hospital, 
Trondheim, Norway.
Background: The effect of a continuous glucose monitoring system (CGMS) 
on glucose control in patients with diabetes type 1 has been explored in sever-
al studies. These have reached different conclusions, and the value of a CGMS 
used for short periods of time has yet to be determined.
Material and methods: In a randomized controlled cross-over trial we as-
sessed whether one month’s use of a CGMS (Medtronic Guardian RT) lowers 
HbA1c levels and frequency of hypoglycemic episodes, compared to intensi-
fied conventional finger-prick measurements (ICFM) in patients with diabe-
tes type 1. Treatment satisfaction (DTSQ) and health status (SF-36) was also 
assessed. Thirty patients (mean age 34 ± 9 yrs) with moderately good glu-
cose control (HbA1c 7.0 - 10.0%) were included in the study. They were ran-
domized to perform either ICFM or CGMS of blood glucose for one month 
followed by a two months wash-out (observation) period before they were 
crossed over to the opposite intervention. HbA1c was measured both at the 
end of the intervention period and the wash-out period.
Results: At inclusion mean HbA1c was 7.84 ± 0.94%. The mean change in 
HbA1c was -0.23 ± 0.10% for the CGMS period and -0.24 ± 0.09% for the 
ICFM period (p = 0.91). The mean change in HbA1c during treatment and 
washout periods was -0.14 ± 0.09% for the CGMS period and -0.16 ± 0.08% 
for the ICFM period (p = 0.86). The frequency of hypoglycemic events was 
8.2 ± 1.6 during CGMS period and 7.3 ± 1.4 during the ICFM period (p = 
0.67). Treatment satisfaction and health status were also equal between treat-
ments.
Discussion: This study does not support previous findings that CGMS is 
superior to ICFM in order to lower HbA1c or reduce the burden of hypogly-
cemic episodes in adults. It could be argued that our results are based on 
a limited number of patients, evaluated over a short period of time, and in 
a patient population with moderate problems with glucose control and hy-
poglycemic episodes. However, we used a crossover design making the pa-
tients their own controls which strengthens the validity of our findings. The 
mean HbA1c level was fairly low at inclusion. This may have contributed to 
the small decline in HbA1c levels during intervention and the absence of a 
superior effect of GCMS in achieving good blood glucose control with less 
hypoglycemic events. CGMS compared to ICFM did not improve treatment 
satisfaction. Remarks from the participants indicate that the burden of car-
rying an electronic device outweighted the benefit of real-time information 
on glucose levels.
Conclusion: In conclusion the present study shows that the average blood 
glucose, evaluated by HbA1c, decreased equally in both patients performing 
frequent self-monitoring of blood glucose, and in patients carrying a contin-
uous glucose monitoring system for one month. The frequency of hypoglyc-
emic episodes and treatment satisfaction were also equal in the two interven-
tion periods. Future studies should aim at identifying subgroups of patients 
that show a clear benefit of using a continuous glucose monitoring system for 
a short time period.
Supported by: Norwegian Association of Diabetes
PS 101 Optimising resource 
utilisation
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Insulin initiation in accordance to NICE guidance: audit and review of 
Trust practice
S. Dampetla, J.M. Ng, A.J. Dawson, D.D. Mellor, J. Patmore, C. Walton; 
Diabetes and endocrinology, Hull Royal Infirmary, United Kingdom.
Background and aims: National Institute of Clinical Excellence (NICE) in 
the UK most recent guidance on the management of patients with type 2 
diabetes mellitus (T2DM) were published in 2008 A key recommendation of 
this guidance was to recommend the use of NPH insulin over basal analogue 
insulins. These changes were performed in the light of evidence by the com-
mittee showing no definitive advantage on the use of basal analogue insulin 
therapy in all patients with T2DM. From mid 2008, the diabetes specialist 
team in our Trust changed its insulin prescribing trends in parallel with NICE 
guidelines. This was following the service undergoing a review using pro-
gramme budgeting marginal analysis (PBMA), a methodology that uses cost 
savings made from one aspect of the service and reinvest in another aspect.
Materials and methods: All patients with T2DM initiated on insulin therapy 
by the specialist team from February 2009 to January 2010 inclusive were in-
cluded in the analysis. Data of prescribing trends and patient information was 
obtained from electronic diabetes record system, clinical handwritten notes 
and dictated letters. The decision for insulin initiation was undertaken by 
the specialist diabetes team for all patients. Patients were started on insulin 
both in community and hospital care settings. Initiation of basal therapy was 
in concordance with NICE insulin prescribing recommendations. Cost for 
insulin and savings were based on an average patient use of 40 units of insulin 
a day and the current market price for insulin.
Results: There were a total of 82 patients (39M, 43F, median age 65 years 
(IQR 55-77)) patients with T2DM who were commenced on basal insulin 
therapy over the study period.. There were a total of 75.6% (n=62) patients 
initiated on NPH therapy and 24.4% (n=20) patients commenced on insulin 
analogues. This was a change from the prescribing pattern of 79.1% analogue 
insulin and 20.9% insulin NPH during the previous year. Mean HbA1c of in-
sulin on patients on NPH improved from (mean±SE) 10.4±0.2% to 9.1±0.3% 
and for analogue insulin 10.9±0.6% to 9.8±0.7%. There was no difference 
between Hba1c levels pre and post insulin therapy between the two groups. 
(Mann Whitney U test). For the NPH group, there were 20 (32.2%) patients 
who self reported hypoglycaemia compared to 4 (20%) patient on analogue 
(p=0.23, chi squared test). There were no episodes of severe hypoglycaemia 
where third party intervention was required over the study period. The total 
cost savings calculated over the period based on the change in insulin pre-
scribing from the previous year was over £ 14,300.
Conclusion: From 2002 to 2008 in England, the number of diabetes items 
prescribed increased by 73.3% and the total cost has risen by 93.2%. Simi-
larly, prescribing costs for intermediate insulin and long acting insulin has 
increased by 13.4% from the year 2007 to 2008. There is currently no conclu-
sive evidence in the literature to support the use of basal analogue insulin in 
improving mortality, morbidity or quality of life in all treated patients over 
the NPH insulin. The selection of patients continuing to be initiated on insu-
lin analogues introduced a bias into the review, in that they were more likely 
to be residing in institutional care, therefore our data does not suggest a dif-
ference in hypoglycaemia rates. The findings of our study illustrate the cost 
savings that can be achieved which could be reinvested in diabetes services, it 
is likely over time the cost savings are likely to increase by at least this amount 
on a yearly basis.
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Structured blood glucose monitoring reduces HbA1c levels and annual 
test strip consumption in poorly controlled, non-insulin treated type 2 
diabetes: results from the STeP Study
O. Mast1, W. Polonsky2, L. Fisher3, C. Parkin4, Z. Jelsovsky5, M. Schweitzer1, 
R. Wagner1; 
1Roche Diagnostics Corporation, Indianapolis, 2University of California, 
San Diego, 3University of California, San Francisco, 4Health Management 
Resources, Inc., Carmel, 5BioStat International, Tampa, USA.
Background and aims: Conclusions from recent systematic reviews have 
been inconsistent regarding the cost-effectiveness of self monitoring of blood 
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glucose (SMBG) in insulin-naïve type 2 diabetes (T2DM). The Structured 
Testing Protocol (STeP) study examined the utility of structured SMBG in 
comparison to enhanced usual care (which included SMBG based on USA 
standard of care recommendations) in this population. We hypothesized that 
structured SMBG would be associated with improved HbA1c outcomes with-
out increasing test strip consumption, compared with standard SMBG use.
Materials and methods: The STeP study is a prospective, cluster-randomized, 
multi-center, clinical trial with 522 poorly-controlled (HbA1c ≥7.5%), insu-
lin-naïve T2DM subjects who were assigned to a structured testing protocol 
(STG) or an active control (ACG). STG subjects used the Accu-Chek® 360° 
View Blood Glucose Analysis System, an easy-to-use paper tool that facilitates 
collection and interpretation of 7-point glucose profiles over 3 consecutive 
days. STG subjects completed the tool on a quarterly basis and brought it to 
medical visits. All STG subjects received standardized instruction in SMBG, 
pattern recognition and interpretation. STG physicians received an algorithm 
for suggested medication strategies in response to observed SMBG patterns. 
All STG and ACG subjects received free blood glucose meters and test strips. 
Test strip consumption was measured using electronic data uploaded from 
blood glucose meters in both study groups.
Results: Although both groups demonstrated significant reductions in 
HbA1c over 12 months, intent-to-treat analysis showed a significantly greater 
HbA1c reduction in the STG than in the ACG (-1.2% vs. -0.9%; Δ=-0.3%; 
p=0.04). SMBG frequency was negatively associated with HbA1c in both 
groups (p<0.05) over time. However, STG subjects performed significantly 
fewer tests/day than ACG subjects (mean = 0.9 vs. 1.2, p=0.0003) over the 
12 months. Extrapolating over time, this equates to a 25% difference in an-
nual test strip consumption between the STG (329 tests/year) and ACG (438 
tests/year).
Conclusion: Structured SMBG use was associated with greater reductions 
in HbA1c compared with standard SMBG use, and structured SMBG use re-
quired 25% less test strip consumption on average over the 12-month period 
than the standard approach. Therefore, structured SMBG use may be a more 
cost-effective approach to improving glycemic control in poorly controlled, 
non-insulin treated T2DM.
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Healthcare costs of fast-acting insulin analogues vs. short-acting human 
insulin in combination with long-acting insulin analogues for Danish 
patients with type 2 diabetes
J. Gundgaard1, T. Christensen2, T. Thomsen2; 
1Health & Economics, COWI A/S, Kongens Lyngby, 2Novo Nordisk A/S, 
Virum, Denmark.
Background and aims: The aim of this study was to compare the direct 
healthcare costs incurred by patients with type 2 diabetes (T2D) on a basal-
bolus regimen using either fast-acting insulin analogues (Insulin Aspart, In-
sulin Lispro or Insulin Glulusine) or short-acting human insulin. Due to local 
registry regulations it was not possible to analyse brand specific data.
Materials and methods: Data were extracted from registers covering the 
total Danish population, and included prescription data, in- and outpatient 
hospital data, primary care data, and demographic variables. Patients were 
identified in a 1-year inclusion period (2005). Inclusion criteria were at least 2 
prescriptions in the index period of a long-acting insulin analogues in combi-
nation with either fast-acting insulin analogues or short-acting human insu-
lin with no switch to the other product during follow-up. Patients with at least 
one oral antidiabetic drug prescription were included as T2D, and patients 
with >1 prescription of fast-acting insulin analogues or short-acting human 
insulin were classified as basal-bolus. Individual patients from the fast-act-
ing insulin analogues group (n=445) were matched individually with patients 
from the short-acting human insulin group (n=85) with respect to observable 
variables using propensity scores. Annual healthcare costs were extracted and 
analysed for a follow-up period of maximum 2 years after the inclusion date.
Results: Overall annual direct healthcare costs, including prescription medi-
cine, amounted to €4,163 in the fast-acting insulin analogue group and €5,130 
in the short-acting human insulin group. Bolus insulin treatment costs were 
significantly higher for patients using fast-acting insulin analogues compared 
to patients using short-acting human insulin (€521 vs. €445). However, these 
costs were offset elsewhere in the health care system. Hospital cost estimates 
were considerably lower for the analogue group (€1,738 vs. €2,647). Given 
the small sample size, bootstrapped confidence intervals showed that the cost 
reductions were not statistically significant.
Conclusion: Using a matched cohort technique, patients with T2D on a ba-
sal-bolus regimen and fast-acting analogues are not more costly to the Dan-
ish healthcare system than patients using short-acting human insulin despite 
higher insulin costs. The register-based study is ongoing and is expected to be 
updated with a longer time-horizon and more complete hospital data.
Figure. Follow-up annual healthcare costs 2005/6. Exchange rate: Average 
of 2006.
Supported by: Novo Nordisk A/S
1062
Comparison of adherence and cost outcomes in patients with type 2 
diabetes initiating rapid-acting insulin analogue with a prefilled pen 
versus vial/syringe
L.J. Lee1, Q. Li2, M.W. Reynolds2, K. Sarsour1, S.M. Corrigan3; 
1Global Health Outcomes, Eli Lilly and Company, Indianapolis, 2United 
BioSource Corporation, Lexington, 3US Medical Division, Lilly USA, LLC, 
Indianapolis USA.
Background and aims: Outcomes data on insulin pens compared to vial/sy-
ringe for rapid-acting insulin analog (RAIA) are limited in the literature. The 
aim of this research was to compare the adherence and cost outcomes of a 
newly available prefilled pen with insulin lispro vs. vial/syringe with insulin 
lispro or aspart in patients with type 2 diabetes (T2D). RAIA in premixed 
formulations were not included due to small sample size.
Materials and methods: A retrospective analysis was conducted using a US 
claims database. The study included patients who were ≥18 years old, new in-
itiators of RAIA, with T2D, and ≥12-month continuous eligibility of medical 
and pharmacy benefits. After using a propensity score matching technique to 
match the 2 study cohorts, a difference-in-difference analysis was conducted 
by comparing the mean change in outcomes from 6 months prior (pre-index) 
to 6 months after (post-index) initiating the prefilled pen vs. vial/syringe. The 
Wilcoxon rank sum test was used to test for significance of the differences 
in outcomes across the 2 cohorts. Adherence was measured by dividing the 
number of days with RAIA by the 6-month post-index period (range: 0-100% 
with a higher percent indicating higher adherence). Cost outcomes (2009 US 
Dollars) included total costs, diabetes-related costs, and the subgroups of 
pharmacy, outpatient, emergency room (ER), and inpatient costs.
Results: Post-matched baseline patient characteristics including cost meas-
ures were similar between the prefilled pen (n=239) and vial/syringe (n=590) 
cohorts. Mean age and percentage of females were 59 vs. 60 years (p=0.22) 
and 47% vs. 48% (p=0.67), respectively. Adherence to the newly initiated 
RAIA in the post-index period was higher in the prefilled pen cohort than the 
vial/syringe cohort (55% vs. 45%; p<0.001). The increase in diabetes-related 
pharmacy costs after RAIA initiation was significantly greater in the prefilled 
pen cohort than the vial/syringe cohort (Table 1). A significant reduction in 
total diabetes-related costs was observed in the prefilled pen cohort when 
compared to the vial/syringe cohort (Table 1). There were no significant dif-
ferences in changes to total costs, diabetes-related outpatient, ER, or inpatient 
costs between the 2 cohorts.
Conclusion: Our findings suggest that even with a greater increase in dia-
betes-related pharmacy costs, initiating RAIA with a prefilled pen was as-
sociated with greater adherence and lower total diabetes-related costs than 
vial/syringe. Further research is needed to elucidate the key drivers of this 
greater reduction in the total diabetes-related costs. 
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Table 1: Results of Diabetes-Related Pharmacy and Total Costs
Diabetes-related 
costs (mean, US 
Dollars)
Prefilled Pen Vial/Syringe
Pre-
Index
Post-
Index
Difference 
from pre- to 
post-index
Pre-
Index
Post-
Index
Difference 
from pre- to 
post-index
p-value of 
difference-
in-difference
Pharmacy costs 963 1,864 +901 880 1,486 +606 <0.001
Total costs 3,049 2,814 -235 2,914 2,975 +61 0.01
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German real-life data indicate lower costs for basal supported oral 
therapy (BOT) with insulin glargine compared to combination therapy 
with exenatide and oral antidiabetic drugs
S.M. Fuchs1, F.-W. Dippel2, K. Kostev3, W. Kotowa1; 
1Health Economics & Outcomes Research, IMS Health GmbH & Co. OHG, 
Nuernberg, 2Evidenzbasierte Medizin und Gesundheitsökonomie, Sanofi-
Aventis Deutschland GmbH, Berlin, 3IMS Health GmbH & Co. OHG, 
Frankfurt/Main, Germany.
Background and aims: Clinical efficacy of the new antihyperglycaemic in-
jectable exenatide (EXE) in combination with oral antidiabetic drugs (OAD) 
is reported to be comparable to basal supported oral therapy (BOT) with 
insulin glargine (GLA). This study investigated the costs of a combination 
therapy of exenatide (EXE) and OAD vs. a BOT with GLA in type-2-diabetics 
(T2D) in Germany based on real-life data.
Materials and methods: A historical cohort study was performed using a 
representative patient database (IMS® Disease Analyzer). T2D who initiated 
a BOT with GLA or a combination therapy with EXE and OAD between 
1/2007 and 12/2008 and whose data were continuously documented at least 
12 months before and 12 months after therapy initiation were included. The 
following variables were collected: age, gender, insurance status, region and 
specification of the practice, diabetes duration, HbA1c level and BMI. Re-
source utilization (RU) and costs (based on public prices) were determined 
for a time period of 12 months after initiation of therapy with GLA (BOT) 
and EXE (OAD), respectively. The diabetes-related direct treatment costs 
(DR-costs) were identified for both treatment regimens, containing GLA, 
EXE, OADs, glucose [i.v.]/glucagon, blood glucose test strips (BGT strips) 
and consumables such as lancets and needles. Additionally, direct costs for 
co-medication (antihypertensive, lipid lowering, antithrombotic and cardio-
vascular drugs) were assessed for GLA (BOT) and EXE (OAD). RU included 
the evaluation of the number of physician visits, referrals to specialists and 
hospital admissions. Applying regression analysis, adjusted RU and costs for 
GLA (BOT) vs. EXE (OAD) were calculated. The variables age, gender, speci-
fication of the practice, region, diabetes duration, HbA1c level and BMI were 
included into the model.
Results: 1,934 T2D were included, of which 1,484 received GLA (BOT) and 
450 patients were treated with EXE (OAD). GLA-patients were older (70.2 
years vs. 58.1 years; p<0.0001), had a longer diabetes duration (5.4 years vs. 
3.9 years; p<0.0001), a higher HbA1c level (7.6% vs. 7.3%; p<0.0001) and 
a lower BMI (30.7kg/m2 vs. 35.6 kg/m2; p<0.0001) than EXE-patients at 
baseline. The unadjusted annual DR-costs were 1,068 € for GLA (BOT) and 
1,740 € for EXE (OAD) (Δ = 672 €). The total adjusted annual DR-costs were 
lower in T2D on GLA (BOT) than on EXE (OAD); cost savings amounted to 
640 € (p<0.0001) per year. This is mainly driven by the lower costs of GLA 
compared to EXE (Δ = 809 €; p<0.0001). Additionally, a cost advantage of 
GLA (BOT) vs. EXE (OAD) was found for the use of consumables (Δ = 37 € 
p<0.0001). In contrast, the adjusted cost of BGT strips were lower in EXE-pa-
tients than in GLA-patients (Δ = 203 €; p<0.0001). No significant differences 
were found for the expenses of OAD and co-medication, as well as for RU in 
both groups.
Conclusion: A randomized controlled trial showed similar efficacy of EXE 
and GLA, both in combination with OADs. This cost comparison yielded 
substantial cost savings in favour of the GLA treatment regimen. After adjust-
ment the cost advantage of GLA remained stable. Therefore, the BOT treat-
ment based on GLA compared to a combination therapy of EXE and OAD in 
T2D could lead to relevant cost savings in Germany.
Supported by: sanofi-aventis Deutschland GmbH
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Resource utilization and diabetes-related treatment costs of type-1-
diabetics treated with ICT based on insulin glargine, insulin detemir or 
NPH insulin in Germany
R.A. Bierwirth1, F.-W. Dippel2, K. Kostev3, S.S. Fuchs4, W. Kotowa4; 
1Ambulantes Diabteszentrum am Elisabeth-Krankenhaus, Essen, 2Sanofi-
Aventis Deutschland GmbH, Berlin, 3IMS Health GmbH & Co. OHG, 
Frankfurt/Main, 4Health Economics & Outcomes Research, IMS Health 
GmbH & Co. OHG, Nuernberg, Germany.
Background and aims: The chronic course of the disease and the specific 
long-term complications of type 1 diabetes mellitus lead to substantial costs 
for the German health care system. Hence, the cost-effectiveness of different 
insulin formulations is gaining increasing importance. The aim of this study 
was to compare resource utilization and associated direct treatment costs of 
an intensified conventional therapy (ICT) with three different basal insulins 
in type-1-diabetics: human basal insulin (NPH), insulin glargine (GLA) and 
insulindetemir (DET).
Materials and methods: Type-1-diabetics who had started an ICT with 
NPH, GLA or DET between 7/2000 and 2/2008 were identifyed by using a 
representative German database (IMS® Disease Analyzer). Patients whose 
data were continuously documented at least 12 months before and 18 months 
after initiation of an ICT were included. Patients who had a prescription of 
premixed insulin or were switched to another basal insulin within the obser-
vational period were excluded. The following variables were collected: age, 
gender, diabetes duration, HbA1c-level, Body Mass Index (BMI), insurance 
status (private versus statutory), geographical region and specification of the 
practice. Resource utilization was determined for a time period of 12 months 
and included the evaluation of basal and bolus insulin, blood glucose test 
strips, number of physician visits (general practitioner and specialist) and 
hospital admissions. Diabetes-related direct treatment costs (insulin, test 
strips, lancets, pens, needles, glucose i.v., glucagon) were calculated based on 
public prices for patients receiving NPH, GLA and DET, respectively. Finally, 
the evaluated resources and costs were adjusted for the variables age, gender, 
diabetes duration, HbA1c-level, BMI, specification of the practice and region, 
applying a multivariate regression model.
Results: 2,740 type-1-diabetics were included, of which 1,218 received an ICT 
with NPH, 1,079 with GLA and 443 with DET, respectively. The unadjusted 
annual diabetes-related direct treatment costs were 1,308 € for NPH, 1,512 € 
for GLA and 1,729 € for DET. After adjusting for potential confounders ICT 
with GLA showed economic advantages compared to ICT with NPH (-234 
€/year; p<0.0001) or DET (-425 €/year; p=0.2800). The consumption of basal 
insulin and test strips was lower in patients treated with GLA compared to 
NPH (-6.00 U/day; p=0.3514 und -0.31 units/day; p=0.8291) or DET (-3.23 
U/day; p<0.0001 und -0.59 units/day; p=0.0235). The number of referrals 
to specialists was lower for patients with GLA than in DET treated patients 
(-0.51/year; p=0.0009) but higher than in NPH treated patients (0.16/year; 
p=0.9184).
Conclusion: After adjustment for potential confounders this analysis of Ger-
man real-life data showed that the ICT with GLA is related to lower annual 
treatment costs than the ICT with NPH or DET. In view of the equal clinical 
efficacy as reported in several randomized clinical trials and the economic 
advantages in comparison to NPH or DET, GLA should be regarded as the 
favored therapeutic option for type-1-diabetics in Germany.
Supported by: sanofi-aventis Deutschland GmbH
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Acute day hospital for medical care of hyperglycaemic crises in the last 
years of life
J.F. Cano1, C. Claret1, D. Benaiges1, J. Puig1, M. Carrera1, F. Cots2,  
E. Corominas1, J. Flores1, J. Chillaron1, A. Goday1; 
1Endocrinology and Nutrition, 2Sevei d’Estudis, Hospital Universitari del 
Mar, Barcelona, Spain.
Background and aims: Hyperglycemic crises in oldest elder people have usu-
ally been treated in a hospitalization ward. The inhospital management is an 
expensive way of care and it may involve nosocomial complications. There 
are no studies comparing effectiveness and feasibility of Day Hospital treat-
ment versus conventional hospitalization for patients older than 74 years. 
Aims: 1.To assess the effectiveness of treating acute complications of diabetes 
(ACD) in a day hospital (DH) versus conventional hospitalization (CH) in 
older elder patients. 2. To evaluate glycaemic control at 3-6 months in both 
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groups. 3. To compare short term re-admissions (3 months) due to diabetes 
and nosocomial morbidity between study groups. 
Materials and methods: A prospective, non randomized, cohorts study with 
6 months follow-up. We included all diabetic patients aged >74 years con-
secutively admitted in our hospital, with ketosis and/or acute hyperglycemia 
>300 mg/dl. We excluded patients presenting with HC03 < 14 mEq, pH < 
7.20, blood glucose >600 mg/dl, hemodynamic instability, severe intercurrent 
illness (infectious, CV disease .... ), or Activities of Daily Living > D (Katz 
Index). Patients were assigned to DH or CH according to time of admission 
to the emergency-room. If patients were admitted out of DH opening hours 
they were assigned to CH. AII patients included in the CH cohort could have 
been treated in DH if they had arrived during the DH-opening hours. Inves-
tigators did not participate in group assignment The cost calculation included 
structural cost and all visits (emergency ward, day hospital and outpatients 
consultations).
Results: During the four years study period, 101 patients met the inclusion 
criteria. 64 were attended in DH and 37 in CH. The average age was 80.5 ± 
4.7 years (range 75-95), and there were 62.7% females, without differences 
between the groups. Cause of admission was acute hyperglycemia in 63.4% 
and Ketosis in 36.6%. Infection (37.5%) was the most common cause of ACD, 
followed by new onset diabetes (11.5%) and corticosteroid therapy (12.5%). 
During the first 15 days after dischange we observed 4 severe hypoglycemic 
events without differences between groups. The average cost per patient and 
year was 584,9 euros for the DH cohort and 1.796,0 euros for the CH group.
Conclusion: Our results prove the effectiveness and safety of ACD manage-
ment in Day Hospital with a net economic saving of 1.211,1 euros/case with 
no differences in short term glycaemic control and hypoglycemic events, and 
with less frequent readmissions and pressure ulcers.
DAY HOSPITAL Hospitalization significance
Charlson index 3.22 ± 2.0 3.22 ± 1.7 p>0.05
Katz index (A or B%) 73 72.2 p>0.05
Blood Glucose (mg/dl) 420 ±74.8 449 ± 97.8 p>0.05
PH 7.39 ± 0.05 7.39 ± 0.06 p>0.05
HbA1C (baseline) 10.9 ± 1.92 10.7 ± 2.1 p>0.05
HbA1C (3 months) 7.6 ± 1.1 7.9 ± 1.0 p>0.05
HbA1C (6 months) 7.3 ± 0.7 7.6 ± 0.6 p>0.05
hypoglycemic episodes 
(3 months)
1.1 ± 1.8 0.4 ± 0.51 p>0.05
pressure Ulcer (% patients) 0 16 p>0.05
Readmissions (3 months)  
(% patients)
6.3 20 p>0.05
Follow up visits 4.9 ± 2.2 2.6 ± 1.9 p>0.05
Supported by: Spanish Health Ministry Fundació Agrupaciómutua: ambit de
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Cost-effectiveness analysis of medical intervention in patients with early 
detection of diabetic retinopathy in a tertiary care hospital in Bangladesh
S.H. Habib, S. Saha, L. Ali; 
Health Economics Unit, BADAS, Dhaka, Bangladesh.
Background and aims: The economic burden resulting from diabetic retin-
opathy (DR) consumes a major portion of resources allocated for health-care 
services. Cost-effectiveness of various interventions on DR and its complica-
tions has relatively been well explored in developed countries, but these are 
almost absent in developing countries. The present study was undertaken to 
assess the cost-effectiveness of medical intervention in patients with DR.
Materials and methods: Two hundred patients with DR, with at least 1 year 
of follow-up, were purposively selected from the Out-Patient Department of 
BIRDEM (tertiary diabetes care hospital), Bangladesh. Of them 100 were late 
in detection of DR (LDR) & 100 were detected early (EDR). The degree & ex-
tent of complications like cardiopathy, peripheral neuropathy, nephropathy & 
vasculopathy, treatment outcome, clinical effectiveness of interventions and 
direct, indirect & incremental cost of complications were calculated. Com-
parison was made between the groups. Cost included drugs, hospitalizations, 
diagnostics & visits.
Results: A total of 200 patients were considered for an average of 365 days, 
amounting to 656 person-years of observation in total. In LDR group, 42.4% 
had mild nonproliferative DR (NPDR), 31.4% had moderate, 15.1% had se-
vere NPDR & 11.1% had proliferative DR (PDR). In EDR group, 58.4% had 
mild and 41.6% had moderate NPDR. The mean±SD fasting serum glucose 
of the groups (LDR & EDR respectively) was 9.36±0.40 & 4.78±0.38 mmol/
l, total cholesterol was 206.50±42.60 & 104.20±35.50 mg/dl, HbA1c was 
9.80±0.50% & 5.70±0.38%, TG was 163.76±99.46 & 155.67±94.84 mg/dl, SBP 
was 172.5 ± 20.9 & 109.5±11.9 mmHg and DBP was 97.7±10.0 & 70.7±9.3 
mmHg. About 17% patients in LDR & 34% in EDR were free of diabetic com-
plications other than DR. In LDR & EDR, 18% & 46% had one complica-
tion, 27% & 8% had two and 30% & 4% had more than two complications 
respectively. The most frequent complication was cardiopathy, which affected 
31% patients in LDR & 25% in EDR, followed by peripheral neuropathy 19% 
& 16%, nephropathy 15% & 11%, and vasculopathy 8 % & 4% respectively. 
The average annual cost of care was US$ 27954 (direct US$ 16983 & indirect 
US$ 10971), with an average US$ 140 per patient. Among the average annual 
cost LDR consumed US$ 19737 (US$ 197 per patient) & EDR US$ 8217 (US$ 
82 per patient). US$ 13473 (48%) of costs was attributable to drugs for both 
groups of which US$ 10817 (80%) was for LDR & US$ 2656 (20%) for EDR, 
US$ 8739 (31%) to hospitalizations of which US$ 5211 (60%) for LDR & 3528 
(40%) for EDR. In case of diagnostics & visits the corresponding values were 
US$ 2136 (60%) & 1419 (40%) and US$ 1673 (76%) & 514 (24%) for LDR 
& EDR respectively. The annual medical costs increased with the increased 
number of complications from US$ 1322 to 2298 & to 3991 in LDR with one, 
two & more than two complications (other than DR) which is increasing at a 
rapid rate and US$ 917 to 1556 & to 2372 in EDR respectively, increasing at a 
diminishing marginal rate. The regression equation showed that medical cost 
is significantly related to complications tested in both univariate (P<0.0001) 
& multiple linear regression analyses (R2=0.53; F=82.3, P<0.0001).
Conclusion: Proper management with regular screening substantially re-
duces the expenditure related to care of patients with diabetic retinopathy & 
related complications even in a developing country. Strategies aimed at pre-
venting DR & early detection of the onset of retinopathy will reduce medical 
costs in a substantial way.
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Assessment of medication adherence among patients with type 2 diabetes
M. Linnemann Jensen, B. Carstensen, A. Nielsen, T.P. Almdal, D.R.  Witte,  
P. Rossing; 
Steno Diabetes Center A/S, Gentofte, Denmark.
Background and aims: Poor adherence to prescribed medication may mark-
edly limit physicians’ ability to achieve and maintain adequate glycaemic and 
cardiovascular risk control in patients with diabetes. However, much remains 
unknown about patterns of adherence to treatment in patients with complex 
treatment strategies. We sought to assess and summarize patterns of medica-
tion adherence to oral anti-diabetic medication in patients with type 2 diabe-
tes (T2DM), attending a specialised diabetes hospital in Copenhagen.
Materials and methods: Registrations of drug prescriptions issued by physi-
cians at the outpatient clinic for type 2 diabetic patients followed for at least 
two years between 2002 and 2007 were linked to registrations of filled pre-
scriptions at Danish pharmacies at an individual level. Medication episodes 
were defined based on prescriptions issued at the hospital. Within each epi-
sode the number of days with and without adherence was calculated based on 
pharmacy data. A binomial regression model was used to assess the associa-
tion between the degree of adherence and sex, age and duration of diabetes.
Results: 1,634 patients with T2DM (60.5% men, mean age at entry: 59.4 years 
(men), 60.3 years (women), mean duration of diabetes at entry: 9.7 years 
(men), 10.5 years (women), with an average clinic attendance duration of 4.3 
years contributed with over 7,000 person-years of time. The median degree 
of adherence was 0.85. An adherence ratio of 0.73 and above was achieved by 
75% of the patients. More than 15% of the patients were adherent to treat-
ment less than half the time. We found a higher degree of adherence by in-
creasing age. Women at age 60 with a duration of diabetes of 10 years had a 
2.6 %-points higher degree of adherence than women at age 50. There was no 
statistically significant difference between men and women or according to 
duration of diabetes.
Conclusion: The degree of adherence to oral anti-diabetic medication ranged 
from not picking up any prescription to full adherence. Only age was posi-
tively associated with the degree of adherence. Further explanatory factors 
such as socio-economic variables and analysis of adherence patterns to stat-
ins, antithrombotic and anti-hypertensive medication deserve consideration. 
Our findings indicate that a considerable improvement in glycaemic control 
can be achieved by improving adherence to medication.
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Foetal exposure to maternal diabetes is associated with insulin secretory 
defect in females at adult age 
L.-S. Fetita1,2, P. Boudou1, S. Choukem4, J.-P. Riveline5, S. Hadjadj6,  
C. Abi Khalill7, E. Larger8, L. Morbois9, T. Meas10, A. Penfornis11,  
R. Porcher1, P. Vexiau1, M. Marre7, F. Calvo1, J.-F. Gautier1,2; 
1Saint-Louis Hospital, Paris, France, 2Centre de Recherche des Cordeliers, 
INSERM, U 872, Paris, France, 4Medecine and Diabetes, Douala General 
Hospital, Douala, Cameroon, 5Diabetes and Endocrinology, Centre 
Hospitalier Sud Francilien, Corbeil-Essonne, France, 6Diabetes and 
Endocrinology, CHU Poitiers, France, 7Diabetes and Endocrinology, Bichat 
Hospital, Paris, France, 8Diabetes and Endocrinology, Hotel Dieu Hospital, 
Paris, France, 9Diabetes and Endocrinology, Institut Mutualiste Montsouris, 
Paris, France, 10Diabetes and Endocrinology, Lariboisiere Hospital, Paris, 
France, 11Diabetes and Endocrinology, CHU Besançon, Paris, France.
Background and aims: In humans, excess maternal transmission of type 2 
diabetes supports the hypothesis that the intrauterine environment contrib-
utes to increased risk of type 2 diabetes in offspring. We have shown that fetal 
exposure to maternal diabetes is associated with an insulin secretion defect in 
response to glucose at adult age. The aim of the present study was to investigate 
whether fetal exposure to maternal diabetes is associated with a global (endo-
crine and exocrine) pancreatic dysfunction in non diabetic adult offspring.
Materials and methods: We investigated offspring of type 1 diabetic patient 
to circumvent the confounding effect of genetic factors related to type 2 dia-
betes. 29 adult offspring exposed to maternal type 1 diabetes during preg-
nancy (exposed group) were compared with 29 offspring of type 1 diabetic 
fathers (control group). Early insulin secretion in response to oral glucose 
defined as the ratio of Δ insulin 0-30 to Δ glucose 0-30 was measured during 
OGTT. Insulin and glucagon secretion were assessed during graded glucose 
infusion from 4 to 16 mg/kg/min followed by a 5-g arginine bolus. Insulin 
action was measured using a euglycemic hyperinsulinaemic clamp and per-
cent body fat mass by DEXA. Exocrine pancreatic function was evaluated by 
quantitative stools analyses.
Results: Mean age, sex ratio, mean percent body fat and mean insulin sensi-
tivity were similar in the exposed and control groups: 25.9 ± 6.2 (SD) vs 26.2 
± 6.1 years, 55 (F/M) vs 52 %, 26.3 ± 8.7 vs 24.5 ± 7.9% fat mass and 11.5 
± 2.9 vs 11.7 ± 2.5 mg/kg of body fat free mass/min respectively. Impaired 
glucose tolerance was diagnosed in two offspring in each group. Early insulin 
secretion was lower in the exposed group than in the control group: 7.8 (me-
dian) (5.5-10.6 Q1-Q3) vs 11.3 (6.4-17.1) µUI/mmol (p = 0.06). In response 
to IV glucose and arginine there was no difference between the 2 groups with 
respect to insulin secretion and glucagon concentrations. However, women 
exposed in utero to maternal diabetes had a significantly decrease in insulin 
secretion rate compared to those of the control group: 12.5 ± 4.5 vs 15.2 ± 5.2 
pmol/kg/min (p=0.03). Fecal fat output was similar in the 2 groups but fecal 
chymotrypsin activity was significantly lower in the exposed group: 14.5 ± 7.2 
vs 22.8 ± 13 U/g (p = 0.016).
Conclusion: Fetal exposure to maternal type 1 diabetes seems to be associ-
ated with a global pancreatic dysfunction at adult age. Insulin secretory defect 
in response to IV glucose is only observed in women suggesting sex-depend-
ent epigenetic mechanisms.
Supported by: PHRC, SFD
1069
Glycaemic control, pre-eclampsia and gestational hypertension in 
pregnant women with type 1 diabetes 
V.A. Holmes1, I.S. Young2, C.C. Patterson2, D.W.M. Pearson3, J.D. Walker4, 
M.J.A. Maresh5, D.R. McCance6, Diabetes and Preeclampsia (DAPIT) Study 
Group; 
1School of Nursing and Midwifery, Queen’s University Belfast, 2Centre for 
Public Health, School of Medicine, Dentistry and Biomedical Sciences, 
Queen’s University Belfast, 3Department of Diabetes, Aberdeen Royal 
Infirmary, 4Department of Diabetes, St. John’s Hospital at Howden, West 
Lothian, , 5Department of Obstetrics and Gynaecology, St Mary’s Hospital 
for Women and Children, Manchester, 6Regional Centre for Endocrinology 
and Diabetes, Royal Victoria Hospital, Belfast, United Kingdom.
Background and aims: An association between glycaemic control and 
preeclampsia has been reported but the results are conflicting and the rela-
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tive importance of early and late control for hypertensive complications of 
pregnancy remains unclear. The aim of this study was to assess the relation-
ship between glycaemic control, preeclampsia and gestational hypertension 
in women with type 1 diabetes.
Materials and methods: HbA1c measurements were available from women 
taking part in the Diabetes and Preeclampsia Intervention Trial (a multicen-
tre randomized controlled trial investigating the effect of antioxidants on 
the incidence of preeclampsia) at up to 6 months pre-pregnancy, at the first 
antenatal visit (booking), and at 26 and 34 weeks gestation. Results were cat-
egorized as poor (>8%), moderate (7-8%) and good (<7%) glycaemic control. 
Preeclampsia and gestational hypertension were defined using the Interna-
tional Society for the Study of Hypertension in Pregnancy guidelines. Logis-
tic regression was used to estimate the odds on preeclampsia and gestational 
hypertension in women with poor and moderate control relative to women 
with good control both before and after adjustment for potentially confound-
ing variables.
Results: Preeclampsia and gestational hypertension developed in 17% and 
11% of pregnancies, respectively. Poor/moderate glycaemic control both be-
fore and during pregnancy were associated with significantly increased risk 
of preeclampsia compared with good glycaemic control. After adjustment for 
confounding variables the association between HbA1c and preeclampsia re-
mained significant throughout pregnancy with highest odds ratios observed 
in the last trimester (see table). Glycaemic control during pregnancy was not 
significantly associated with gestational hypertension either before or after 
adjustment for confounders.
Glycaemic control before and during pregnancy and risk of preeclampsia and 
gestational hypertension
Time-point n Glycaemiccontrol (HbA1c) Preeclampsia*
Gestational
hypertension*
Pre-pregnancy 542
<7%
7-8% vs <7%
>8% vs <7%
1.00
1.70 [0.79-3.64]
2.53 [1.19-5.36]
1.00
0.62 [0.30-1.29]
0.72 [0.36-1.43]
First
antenatal visit 721
<7%
7-8% vs <7%
>8% vs <7%
1.00
2.29 [1.22-4.31]
3.46 [1.83-6.55]
1.00
1.00 [0.54-1.86]
0.91 [0.49-1.72]
26 weeks
gestation 592
<7%
7-8% vs <7%
>8% vs <7%
1.00
2.01 [1.17-3.47]
2.15 [0.84-5.50]
1.00
0.80 [0.41-1.54]
0.79 [0.26-2.46]
34 weeks
gestation 519
<7%
7-8% vs <7%
>8% vs <7%
1.00
2.32 [1.14-4.72]
5.87 [1.64-21.1]
1.00
1.09 [0.53-2.24]
0.79 [0.16-3.80]
*Adjusted Odds Ratio [95% Confidence Interval]. Adjusted for: treatment 
group, centre group, BMI, diabetes duration, parity, smoking, age, plasma 
ascorbate and serum α-tocopherol at randomisation, microalbuminuria be-
fore pregnancy.
Conclusion: Poor glycaemic control is associated with an increased risk of 
preeclampsia but not gestational hypertension. While glycaemic control is 
important before and throughout pregnancy, HbA1c during the last trimester 
of pregnancy is the strongest predictor of preeclampsia.
Supported by: The Wellcome Trust
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In women with type 1 diabetes mellitus, maternal insulin requirements 
are potent predictors of excess fetal growth 
D. Ovejero1, I. Miñambres1, A. Chico1, A. García-Patterson1,  
J.M. Adelantado2, A. de Leiva1, R. Corcoy1; 
1Endocrinology and Nutrition, 2Gynaecology and Obstetrics, Hospital de la 
Santa Creu i Sant Pau, Barcelona, Spain.
Background and aims: Excessive fetal growth remains as an important issue 
in diabetic pregnancies, glycemic control being one among other predictor 
variables.
Materials and methods: To perform a comprehensive analysis of potential 
predictors of excessive fetal growth Singleton pregnancies of women with 
T1DM delivering in the center between January 1981 and December 2006 
and receiving the same treatment schedule (multiple injections/insulin 
pump; regular/lispro insulin) since before pregnancy until delivery. Out-
come variables: macrosomia (birthweight >=4000g), large for gestational 
age newborn (LGA, >P90 of national growth charts). Potential predictors: 
maternal anthropometric variables, smoking habit, obstetric history (prior 
pregnancies, macrosomia, poor obstetric history), maternal hypertension, fe-
tal sex, delivery-related variables (gestational age, calendar year and number 
of pregnancies in that year) and diabetes-related variables (duration, treat-
ment, microangiopathic complications, prepregnancy care and mean blood 
glucose, insulin requirements (IR, IU/kg/d) and glycated haemoglobin in 1st, 
2nd and 3rd trimesters of pregnancy). Statistics: Logistic regression analyses 
were performed (backward method) with macrosomia and LGA as outcome 
variables and all aforementioned variables as potential predictors.
Results: 315 consecutive pregnancies fulfilling entry criteria were included. 
The rate of macrosomia was 13.3% and that of LGA 38.6%. In the predic-
tion model of LGA, 9 predictors were identified including 3 diabetes-related 
variables (1st trimester IR (OR 72.4, CI 2.4, 2208), 3rd trimester IR (0.04, CI 
0.001, 1.043) and 3nd trimester HbA1c (2.871, CI 1.438, 5.732)). The predic-
tion model of macrosomia was consistent with that of LGA.
Conclusion: In women with T1DM, maternal IR are potent predictors of ex-
cess fetal growth. The association with 3rd trimester IR can be a consequence 
of fetal siphoning in overgrown babies whereas the association with 1st tri-
mester IR suggests a causal role of maternal insulin.
Supported by: CIBER-BBN
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Pregnancy outcomes in women with type 1 and type 2 diabetes in a 
polish population
K. Cyganek1, A. Hebda-Szydło1, B. Katra1, I. Janas1, A. Borodako1, I. Kaim2, 
J. Skupien3, A. Reron2, J. Sieradzki1, M.T. Malecki1; 
1Department of Metabolic Disease, Jagielonian University, Medical College, 
Krakow, Poland, 2Department of Obstetrics and Perinatology, Jagielonian 
University, Medical College, Krakow, Poland, 3Section on Genetics and 
Epidemiology, Joslin Diabetes Center, Boston, USA.
Introduction and aim: The number of pregnant women with type 2 (T2DM) 
is increasing worldwide. However, the majority of scientific reports on preges-
tational diabetes is associated with type 1 diabetes (T1DM). The knowledge 
on pregnancies of T2DM women is still incomplete. The purpose of this ob-
servational study was to assess glycemic control and pregnancy outcomes in 
women with pregestational T2DM and to compare them with T1DM.
Methods: Medical records of 415 consecutive singleton pregnancies in 
women with pregestational diabetes from 1999 to 2009 were analysed at the 
Department of Metabolic Diseases, Krakow, Poland. All women were Cauca-
sians. Among them, there were 70 women with T2DM and 345 with T1DM. 
We compared HbA1c levels as well as selected maternal and foetal outcomes 
in both groups.
Results: Compared to T1DM, women with T2DM were significantly older 
(mean 33.1 years±5.2 vs. 27.8±5.0, respectively), heavier before pregnancy 
(mean weight 80.7 kg±17.8 vs. 64.5±10.1) and had shorter duration of dia-
betes (mean 3.3 years±3.2 vs. 11.5±7.3); (p=0.00001 for all comparisons). 
T2DM women less weight gain during pregnancy than T1DM (mean 10.4 
years±7.6 vs. 13.8±6.5; p=0.0001), but final body weight before delivery were 
higher in T2DM group (mean 90.6 years±16.9 vs. 78.2±11.3; p=0.0000). 
The gestational age of the first visit was higher in T2DM women (mean 11.4 
weeks±7.1 vs. 8.6±4.5, respectively; p=0.00001). Nevertheless, they had better 
glycemic control in the 1st trimester as measured by HbA1c (6.1% ±1.1 vs. 
6.9±1.6; p=0.0008). We observed a decrease of HbA1c level in both groups in 
the 2nd (5.7 % ±0.9 vs. 5.9±0.8) and 3rd trimester (5.6 % ±0.6 vs. 5.8±0.9), the 
differences in HbA1c were no longer significant. The rate of perinatal mortal-
ity (2.9% vs. 3.5%) and major congenital malformations (7.1% vs. 6.1%) as 
well as the proportion of pregnancies ended by caesarean sections (56.3% vs. 
63.9%) were similar in both groups. The birth weight was slightly smaller in 
T2DM than in T1DM (mean weight 3194.6 g±880 vs. 3419.2±681.3; p=0.04). 
The rate of babies born before 37 week of pregnancy was comparable in both 
groups, respectively 12.9% vs.17.1%. We also observed a similar rate of still-
births in both groups (8.6% vs. 7.0%; p=0.4).
Conclusion: In this large observational study we found similar pregnancy 
outcomes in women with T1DM and T2DM in a Polish population, despite 
better glycemic control at the beginning of pregnancy in T2DM.
Supported by: Polish Ministry of Science 
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Pre-pregnancy body mass index and the risk of adverse pregnancy out-
come in two thousand type 2 diabetes mellitus Bangladeshi women
S. Jahan1, M.A. Chowdhury2, S.H. Habib3, S. Saha3; 
1Department of Gynaecology & Obstetrics, BIRDEM, , 2Department of Car-
diology, BSMMU, 3Health Economics Unit, BADAS, Dhaka, Bangladesh.
Background and aims: Obesity before pregnancy is associated with an in-
creased risk of late fetal death, early neonatal death, preeclampsia & hyper-
tensive disorders, preterm delivery, shoulder dystocia & macrosomia. The 
mother’s being leaner than average on the other hand, is associated with an 
increased risk of delivering an infant of small for gestational age (SGA). The 
study was undertaken to assess the effect of the pre-pregnancy body mass 
index (BMI) on maternal & fetal outcome of 2000 type 2 diabetes singleton 
pregnant women who attended the obstetrics-diabetology Out-Patient clinic 
of a tertiary care hospital in Bangladesh.
Materials and methods: The women were categorized according to their 
BMI (kg/m2): lean < 20.0, normal from 20.0 to 24.9 and obese > 30.0 kg/m2. 
Information regarding maternal age, parity, complications during pregnancy 
or delivery and perinatal outcomes were obtained from hospital records. Late 
fetal death was defined as still birth occurring at 28 or more completed weeks 
of gestation and early neonatal death as death occurring during the first week 
after birth, preterm delivery was less than 37 completed weeks of gestation. 
SGA infants were defined as the birth weight more than 2SD below the mean 
birth weight for gestational age. Gestational age was estimated as based on ul-
trasound examination performed routinely at less than 12 weeks of gestation. 
The estimates were adjusted for maternal age, parity, smoking, education, and 
weight gain during pregnancy. The effect of pre-pregnancy BMI was analyzed 
by comparing the frequencies of various outcomes in three BMI groups by 
both univariate and multivariate logistic regression analysis. The results were 
expressed as odds ratio (ORs) and the corresponding 95% confidence inter-
vals (CIs) & p values.
Results: The mean±SD age of the study subjects were 34±5 years, the median 
(range) duration of diabetes was 4 (3-5) years. The risk of late fetal death was 
consistently increasing with BMI (ORs were 1.2 (0.9-1.7), 1.6 (1.1-2.3) & 2.6 
(1.7-3.8) for lean, normal & obese respectively). The risk of early neonatal 
death was also higher among women with higher BMI (ORs was 1.6 (1.1-2.3) 
for obese) (p<0.001). The rate of preeclampsia increased with increasing BMI 
(the values were 1.8%, 2.5% & 7.0% for lean, normal & obese respectively). 
Hypertensive disorders was also more common among obese (4.6%) com-
pared with lean (1.3%) and normal (2.6%) (ORs 3.8 (2.5-5.6), 1.6 (1.1-2.2) & 
2.5(1.7-3.5) respectively). The risk of preterm delivery was significantly in-
creased for obese group (4.2%), as compare to lean (2.2%) & normal weight 
(2.4%) (ORs 1.6 (1.3-2.1), 1 (0.8-1.6) & 1.2 (0.9-1.6) respectively) (p<0.001). 
The risk of SGA was significantly more in lean (2.7%) compared to normal 
weight (1.5%) & obese group (1.9%) (ORs 2.2 (1.7-2.8), 1.2 (0.9-1.5) & 1.0 
(0.6-1.3) respectively). The risk of shoulder dystocia & macrosomic baby was 
higher in obese group.
Conclusion: Pre-pregnancy obesity increases the risk of late fetal death and 
perinatal mortality. As obesity prevents small for gestation age infant in Type 
2 Diabetes subjects, the Type 2 DM lean women were advised to take ad-
equate diet to meet the basic requirements of pregnancy. On the contrary 
obese women should reduce the body weight before pregnancy.
1073
What is determined by impaired cardiac function in pregnancy with 
gestational, types 1 and 2 diabetes mellitus: maternal or neonatal 
prognosis7
V.A. Petrukhin, S.R. Mravyan, F.F. Burumkulova, T.S. Kovalenko,  
A.N. Aksenov, A.F. Bashakin; 
First obstetric clinic, Moscow regional institute of obstetrics and gynecology, 
Moscow, Russian Federation.
Background and aims: Cardiac autonomic neuropathy is a common dys-
function in manifest diabetes mellitus (DM) and is proportional to the du-
ration of diabetes and/or a poor glycaemic control. Heart rate variability 
(HRV) reflects autonomic heart function. The aim of the present study was to 
investigate whether in pregnant women with prior gestational DM (GDM), 
insulin-dependent DM (IDDM) and insulin-independent DM (IIDM) altera-
tions of cardiac autonomic function can be observed at the 37-39 weeks of 
gestation in relation to maternal or neonatal prognosis.
Methods: Fifty four women (10 with GDM - group 1, 17 with IIDM - group 
2, 13 with IDDM until 5 years duration - group 3, 7 with IDDM from six to 
fifteen years duration - group 4 and 7 with IDDM more, than sixteen years 
duration - group 5) underwent 24-h Holter monitoring at the 37-39 weeks of 
gestation and 3-6 days postpartum. Heart rate variability (HRV) measures 
derived from 24-hour electrocardiography monitoring, calculated in the time 
(standard deviation of all normal RR intervals (SDNN), standard deviation 
of 5-minute RR intervals (SDANN), root-mean-square of difference of suc-
cessive RR intervals (rMSSD), and percentage of adjacent RR intervals >50 
ms different (pNN50) and frequency domain (total power - TP, power within 
low-frequency band - LF, and power within high-frequency band - HF).
Results: In group 3 HRV was higher: SDNN was 122,4±24,4ms vs 
86,0±34,3ms in GDM; 110,7±60,5ms in group 2; 104,5±40,6ms in group 4 
and 50,2±6,7ms (p<0,05) in group 5 respectively. HRV patients of groups 2 
and 4 were characterized by wide dispersion of HRV, which reflected from 
other diseases (hypertension, preeclampsia etc). In type 1 diabetes mellitus 
HRV progressively declines with duration of illness. Extremely low activity of 
sympatic nervous system (SDANN less than 68ms) in the 5 group was con-
nected with lower Apgar score, but in common with higher parasympathic 
activity (rMSSD more than 45 ms) - with poor neonatal and maternal prog-
nosis. After delivery there were no observed restoration HRV to normal in 
women with diabetes type 1.
Conclusion: The loss of the variability of the cardiac rhythm confirms that in 
women with IDDM has a chaos in cardiac pacing, which reflects autonomic 
neuropathy and other complications. In type IDDM neonatal prognosis cor-
relates with maternal activity of sympatric nervous system.
Supported by: RFBR №07-01-00376
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Hypertension and end stage renal disease in women with a past history of 
gestational hypertension
K. Jahan1, F. Jebunnesa2, S. Sultana2, H. Chowdhury2, N. Sultana2, L. Ali2; 
1Obstetrics and Gynecology, DMC, 2Biochemistry and Cell Biology, 
BIRDEM, Dhaka, Bangladesh.
Background and aims: Insulin resistance is thought to be a converging point 
in the pathophysiology of GH and it is postulated that women with this dis-
order have a much higher chance of developing hypertension and end stage 
renal disease (ESRD) at a later period after delivery. Prospective studies on 
this issue, however, are still limited. The aim of the present study was to in-
vestigate the long-term effect of GH on the postpartum development of hy-
pertension and ESRD.
Materials and methods: The study design had both a cross- sectional and 
retrospective component. A total of 140 women [age in years 32.4±8.1(yrs) 
and BMI 25.1±4.1(kg/m2, m±SD)] with a previous history of GH in any preg-
nancy were included. Clinical and anthropometric parameters were meas-
ured by standard techniques, lipids were measured by enzymetic colorimetric 
method, urinary total protein by pyrogallol red method, urinary protein by 
strip method and serum urinary creatinine were measured by alkaline picrate 
method. Systolic blood pressure 130 mmHg or diastolic blood pressure 
90mmHg were taken as cut-off values for hypertension and urinary protein 
>35mg/dl was the marker for ESRD.
Results: Out of the 140 subjects 49 (35%) developed hypertension and 46 
(32.9%) developed ESRD over duration of 5 to 12 yrs. 45(32%) of the subjects 
had both the complications. The hypertensive subjects had higher age (years, 
m±SD, 35.8±9.7 vs 30.5±6.4, p=0.001), BMI (kg/m2 , 26.09±4.3 vs 24.6±3.9; 
p=0.045), uric acid (mg/dl, 7.38±1.1 vs 4.6±1.6; p=<0.001) and total protein 
(mg/dl, 47.7±13.5 vs 15.5±5.4; p=<0.001). On logistic regression analysis, 
hypertension showed a strong positive association with uric acid and total 
protein when the effects of age and BMI were adjusted. On the other hand 
ESRD showed strong positive association with uric acid when the effects of 
age, BMI, fasting blood sugar and Triglyceride were adjusted.
Conclusion: Women with history of GH has a high probability of developing 
hypertension and ESRD in postpartum life, and both the conditions seem to 
have association with uric acid as a risk factor.
Supported by: BADAS
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ATLANTIC DIP: persistent postpartum glucose intolerance in women 
with previous gestational diabetes along the Irish Atlantic seaboard
M.W. O’Reilly, G. Avalos, M.C. Dennedy, E.P. O’Sullivan, F. Dunne; 
Endocrinology/Diabetes Mellitus, University College Hospital, Galway, 
Ireland.
Background and aims: Gestational diabetes / Impaired Glucose Tolerance 
(GDM/IGT) is associated with adverse fetal and maternal outcomes. It also 
identifies women at risk of developing IGT and Type 2 diabetes (T2DM) later 
in life and in the postpartum period. Up to date prospective figures are not 
available for persistent glucose intolerance postpartum in the Irish popula-
tion.
Materials and methods: We compared 357 women with abnormal (GDM/
IGT) and 137 women with normal (NGT) glucose tolerance in pregnancy 
identified by 75g oral glucose tolerance test (OGTT) at 24-28 weeks gestation. 
This was repeated post partum to reassess glucose tolerance. Logistic regres-
sion analysis was used to identify maternal factors that increased the risk of 
persistent glucose intolerance.
Results: 494 women were tested. OGTT results were classified as NGT 
(FPG<5.6mmol/l; 2h<7.8mmol/l) or abnormal (IFG; 5.6-6.9, IGT; 2h 7.8-
11.0, IFG+IGT; T2DM FPG≥7 ± 2h≥11.1). 2 of 137 (1.4%) women with NGT 
in pregnancy had abnormal glucose tolerance postpartum. 54 of 357 (15.1%) 
women with abnormal glucose tolerance (GDM/IGT) in pregnancy remained 
glucose intolerant post partum. Risk factors for persistent glucose intolerance 
were family history of T2DM (OR 2.92, 95% CI 1.15-7.41, P=0.02), insulin 
use in pregnancy (OR 3.65, 95% CI 1.41-9.45,P=0.007). Fasting plasma glu-
cose in pregnancy of 5.6-6.9mmol/l (OR 3.73, 95% CI 1.25-11.09, P=0.01) 
and ≥7(OR 16.89, 95% CI 3.31-86.02, P<0.001) were strong predictors of 
postpartum dysglycaemia. Age, BMI, ethnicity did not predict persistent dys-
glycaemia.
Conclusion: Along the Irish Atlantic seaboard the prevalence of persistent 
glucose intolerance in women with GDM/IGT in pregnancy is 15.1% com-
pared to 1.4% in control women. This high prevalence suggests a robust fol-
low up programme is necessary for early identification and intervention.
Pregnancy and postpartum glucose status
Pregnancy glucose 
status
Postpartum 
glucose status
Normal IFG IGT IFG+IGT T2DM
Normal (n=137) 135 (98.5%) 1 (0.7%) 0 1 (0.7%) 0
IGT (n=263) 237 (90.1%) 14 (5.3%) 5 (1.9%) 4 (1.5%) 3 (1.1%)
GDM (n=94) 66 (70.2%) 7 (7.45%) 5 (5.3%) 10 (10.6%) 6 (6.4%)
Total (n=494) 438 22 10 15 9
Supported by: HRB
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Perinatal outcome in women with gestational diabetes mellitus in 
relation with fetal sex
D. Tundidor1, A. García-Patterson1, M. María1, J. Úbeda1, G. Ginovart2,  
J.M. Adelantado3, A. de Leiva1, R. Corcoy1; 
1Endocrinology and Nutrition, 2Pediatrics, 3Obstetrics and Gynaecology, 
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Background and aims: Male sex is a well-known risk factor for unfavorable 
perinatal outcome that has only occasionally been assessed in diabetic preg-
nancy. The aim of this study was to evaluate perinatal outcome in women 
with gestational diabetes mellitus (GDM) according to fetal sex.
Materials and methods: Database review including all singleton pregnancies 
of women with GDM progressing to >= 22 weeks, delivering in the center be-
tween 01/01/1981 and 31/12/2006. Evaluated maternal characteristics: anthro-
pometrics, obstetric history, diagnosis characteristics (gestational age, blood 
glucose values), HbA1c (after diagnosis and in the third trimester). Outcome 
variables: preterm birth, abnormal Apgar, large and small for gestational age 
newborns, obstetric trauma, major and minor malformations, polycythemia, 
neonatal hypoglycemia, hypocalcemia, jaundice, respiratory distress and fetal 
loss (intrauterine, neonatal, perinatal). Statistics: Chi-square, Student T and 
Mann-Whitney U tests. Significance was set at a two-sided p <0.05.
Results: A total of 2216 pregnancies were included. Maternal characteristics did 
not differ between groups except for a higher maternal weight in male newborns 
(59 vs. 58) and a higher rate of prior pregnancy in female newborns (65.5 vs. 
61.1%). Higher figures were observed in 13 out of 15 perinatal outcome variables 
in male newborns but statistical significance was not reached in any of them.
Conclusion: In this group of women with GDM, perinatal outcome is not 
significantly worse in male newborns.
Supported by: CIBER BBN
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Prevalence and outcome of gestational diabetes in Turkmenistan
K.G. Parhofer1, A. Ulugberdiyeva2, M. Abdullayeva2,  
A. Annamuhammedov3, M. Gaipov4, B. Melebayeva2, U. Hasbargen5,  
A.W. Flemmer6; 
1Medizinische Klinik II - Grosshadern, Klinikum der Universitaet 
Muenchen, Germany, 2Department of Gynecology and Obstetrics, Ene 
Maehri Merkezi, Ashgabat, Turkmenistan, 3Department of Pediatrics, Ene 
Maehri Merkezi, Ashgabat, Turkmenistan, 4Department of Anesthesiology, 
Ene Maehri Merkezi, Ashgabat, Turkmenistan, 5Department of Gynecology 
and Obstetrics, Perinatal Center, Klinikum der Universitaet Muenchen, 
Germany, 6Division of Neonatology, Childrens Hospital, Perinatal Center, 
Klinikum der Universitaet Muenchen, Germany.
Background and aims: Very few data are available about the health care system 
in Turkmenistan a central Asian country with huge gas resources and rapidly 
increasing wealth and rates of obesity. As for other central Asian countries the 
prevalence of gestational diabetes (GDM) is unknown. The aim of this investi-
gation was to prospectively determine the prevalence of GDM in Turkmenistan 
and the frequency of complications in newborns from GDM mothers.
Materials and methods: From March 2008 until September 2009 all pregnant 
women presenting to the perinatal center at the Ene Maehri Merkezi Hospi-
tal (University of Ashgabat) obtained a glucose screening (after 26 weeks of 
pregnancy; 50 g glucose orally). If the 60-min glucose concentration was ≥ 
7.8 mmol/l an oral glucose tolerance test (75 gr) was performed. GDM was 
diagnosed if one or more glucose values were abnormal (≥5.0, ≥10.0, ≥8.0 
mmol/l at 0-, 60-, 120-min, respectively). Birth weight, APGAR and 30 min 
glucose concentration was determined in all newborns.
Results: 25.4% of 1271 screened patients had a pathological screening test. Of 
those, 28.5% had GDM (overall prevalence 7.3%). Screening glucose (60-min) 
correlated with age (r=0.13; p>0.001), BMI (r=0.12, p<0.001), gravidity (r=0.12, 
p<0.001) and blood pressure (r=0.06, p=0.03). GDM patients were older 
(30.2±5.3 years vs. 27.1±4.9 years; p<0.001) and more obese (BMI 27.7±4.9 vs. 
26.5±4.5 kg/m²; p=0.03) than controls. GDM patients obtained more frequently 
scheduled caesarean sections (12.0% vs. 8.9%, ns) and less frequently emergency 
caesarean sections (8.8% vs. 13.3%, ns). In newborns delivered after ≥37 weeks 
gestational age (controls vs. GDM) birth weight (3500±462 vs. 3605±409 g, 
p=0.06) and APGAR (8.4±1.5 vs. 8.3±1.3, ns) did not differ between both groups 
but GDM children had more often hypoglycaemia (13.9% vs. 27.3%, p<0.05).
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Conclusion: In Turkmenistan GDM is characterized by the same risk fac-
tors as in European countries. Because of the rapidly increasing wealth and 
increasing prevalence of obesity the prevalence of GDM will probably further 
increase. Newborns from GDM patients tended to be heavier and had high 
rates of hypoglycemia. This study shows that medical prevention programs 
can also be successfully implemented in Turkmenistan.
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Analysis of pregnancy outcomes in immigrate women with gestational 
diabetes
M. Dalfrà1, E. Ragazzi2, M. Masin1, B. Bonsembiante1, C. Cosma1,  
A. Barison1, R. Toniato1, D. Fedele1, A. Lapolla1; 
1Medical and Surgical Sciences, 2Pharmacology and anaesthesiology, 
University of Padova, Italy.
Background and aims: Immigration is growing in all European countries, 
the populations diversity poses specific problems related to health care serv-
ice and socio-demographic factors. Recent studies show adverse outcomes 
of pregnancy among immigrant women from countries with high diabetes 
rates. So we found of interest to analyse the outcomes in immigrate pregnant 
women affected by GDM compared to Italian ones.
Materials and methods: We compared maternal and fetal outcomes in 94 
immigrant (ImPW) and1246 Italian women (IPW) with GDM followed up 
at our center. Maternal characteristics considered were age, pre-pregnancy 
BMI, HbA1c, frequency of insulin treatment, timing and mode of delivery, 
and hypertensive disorders; and, for fetal outcome, infants large(LGA) or 
small(SGA) for gestational age and fetal complications.
Results: Pre-pregnancy BMI (26.9 ± 4.6 Kg/m2 vs 24.8 ± 5.3 Kg/m2, 
p<0.0001) and HbA1c (at diagnosis and at 3rd trimester 5.6 ± 0.6% vs 5.2 
± 0.6%, p<0.0001) were higher in ImPW than in IPW, and more of them 
were on insulin (26.6% vs 17%, p=0.024).Gestational age at screening was 
not different: 23.6±5.8g.w. in ImPW vs 24.6±5.4 g.w. in IPW No differences 
in time and mode of delivery(cesarean section 46.1% in immigrate women 
vs 42.9% in Italian ones) and hypertensive disorders (6.8% vs 8.8%) emerged 
between the 2 groups. A higher rate of LGA babies (30.3% vs 19.8%, p=0.03) 
were born to immigrant women than to Italians, but fetal morbidity was not 
different (4.2% vs 6.5%).In a regression logistic analysis LGA newborns were 
related to maternal age (p=0.002) and HbA1c at 3rd trimester.
Conclusion: Our ImPW show higher glucose levels during pregnancy, but 
their outcome could be considered satisfied and comparable with IWP, prob-
ably because these women were subjected to GDM screening, diagnosis and 
treatment at the recommended gestational age . So immigrant GDM women 
have favorable outcomes if given access to health care, language and cultural 
barriers are removed.
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HbA1c above normal range in late pregnancy is associated with risk of 
infants’ large-for-gestational age in women with gestational diabetes 
mellitus
S.B. Nielsen, M.R. Mikkelsen, E. Stage, E.R. Mathiesen, P. Damm; 
Departments of Endocrinology and Obstetrics, Rigshospitalet, Copenhagen, 
Denmark.
Background and aims: HbA1c is widely used as a measure of metabolic control 
during pregnancy and documented to be associated with diabetes related preg-
nancy complications in type 1 diabetes. In addition HbA1c can be measured in-
dependent of the patients’ compliance to glucose monitoring and is therefore of 
special value in women where the compliance to treatment is sub optimal. The 
value of using HbA1c as a treatment goal and risk marker of complications in the 
newborns of women with GDM is to our knowledge not previously described in 
the literature. The aims of the present study were 1) to determine the prevalence of 
pregnant women with gestational diabetes mellitus (GDM) not obtaining HbA1c 
within normal range before delivery and 2) examine whether elevated HbA1c val-
ues are associated with increased risk of large-for-gestational age (LGA) infants.
Materials and methods: The study population was 148 GDM women deliv-
ering during 2007 at Rigshospitalet. Inclusion criteria; GDM diagnosed <34 
weeks, singleton pregnancies and at least two HbA1c test with more than 3 
weeks interval. Data was extracted from medical records. The study popula-
tion was divided in those obtaining HbA1c less than or equal to 5.6% or not. 
The primary outcome was LGA infants. Secondary outcomes were preec-
lampsia, preterm delivery, birth complications, neonatal hypoglycaemia, res-
piratory distress syndrome and jaundice.
Results: Fifty-one (35%) women did not obtain HbA1c less than or equal to 
5.6% before delivery. The median HbA1c before delivery was 5.9% (range 5.7-
6.6) vs. 5.3% (4.5-5.6) in the two groups. At baseline, BMI and HbA1c were 
higher in the women not obtaining the goal compared to the remaining women 
(30.9 (SD6) vs. 27.8 (SD7); 5.9% (5.7-7.8) vs. 5.1% (4.3-6.3)). Women with el-
evated HbA1c before delivery were characterised by a higher risk of LGA infants 
and neonatal hypoglycaemia (adjusted OR 3.1 (95% CI 1.3-7.6), and 6.2 (95% 
CI 1.3-29.0)). Other secondary outcomes were similar in the two groups.
Conclusion: Women with GDM not obtaining HbA1c within normal range 
before delivery had a three-fold increased risk of LGA infants and six-fold 
increased risk of neonatal hypoglycaemia.
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The prevalence of large for gestational age offspring and pregnancy 
complications before and after implementation of a new insulin 
treatment guideline in women with gestational diabetes
M.R. Mikkelsen, S.B. Nielsen, E. Stage, N. Begum, P. Damm,  
E.R. Mathiesen; 
Departments of Endocrinology and Obstetrics, Rigshospitalet, Copenhagen, 
Denmark.
Background and aims: The best strategy for insulin treatment of women with 
gestational diabetes (GDM) under routine conditions is not well described. 
In 2008 we decided to change from biphasic human insulin (Mixtard) to bi-
phasic insulin aspart (Novomix), which has a better impact on postprandial 
glucose levels, and furthermore to implement a written algorithm for initiat-
ing and adjusting insulin dose. Thus the aim of our study was to evaluate 
the effect of this change in the routine insulin treatment guideline on birth 
weight and the prevalence of pregnancy related complications.
Materials and methods: The study population included all insulin treated wom-
en with GDM delivering in 2007 and 2009 at our hospital fulfilling the following 
inclusion criteria; GDM diagnosed and insulin treatment initiated < 34 weeks 
with the first HbA1c below 6.5%, singleton pregnancies and at least two HbA1c 
tests with ≥3 weeks’ interval. Data was extracted from medical records. The in-
sulin treatment was initiated and adjusted by a nurse the first 14 days and there-
after by an endocrinologist. The 2007-cohort received biphasic human insulin 
twice daily with individual start dose and adjustments while biphasic insulin 
aspart was initiated in the 2009-cohort with 0.3 IU /kg twice daily and thereafter 
adjusted according to a written titration guideline. The primary study outcome 
was the prevalence of large for gestational age (LGA) infants. Secondary out-
come was a combined endpoint of pregnancy related complications including at 
least one of the following: preeclampsia, preterm delivery, birth complications, 
neonatal hypoglycaemia, respiratory distress syndrome and jaundice.
Results: The two cohorts were comparable with regard to baseline HbA1c and 
HbA1c prior to delivery (table). The total insulin dose was comparable, but 
the second cohort was diagnosed and initiated insulin treatment on average 
10 days earlier and tended to be less overweight (NS). In the 2009-cohort off-
spring birth weight was significantly lower, evaluated by the Z-score as well as 
the prevalence of LGA. Moreover less pregnancy related complications were 
seen in the 2009-cohort (table).
Conclusion: The prevalence of large for gestational age infants and pregnan-
cy related complications were lower after implementation of the new insulin 
treatment guideline as part of routine treatment. Whether this is due to the 
change in insulin treatment or other factors, as earlier initiation of treatment, 
remains speculative.
Clinical parameters before and after change in insulin treatment
2007-cohort
n=54
2009-cohort
n=47
Pre-pregnancy BMI (kg/m2) 31.5(7) 29.6(7)
Gestational age at GDM diagnosis(days) 190(43) 180(51)
HbA1c at diagnosis of GDM (%) 5.7(0.4) 5.8(0.3)
Gestational age at delivery (days) 267(9) 269(8)
HbA1c; last before delivery (%) 5.8(0.4) 5.8(0.4)
Insulin dose; last before delivery (IU) 52(40) 49(36)
Birth weight (g) 3516(441) 3297(491)*
Birth weight z-score (standard deviations) 0.8(1.4) 0.1(1.3)**
Large for gestational age 20(39%) 8(16%)*
Pregnancy related complication 20(37%) 9(19%)*
*Denotes p<0.05 and ** p<0.01 between groups. Mean(SD) or Number(%)
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Major congenital malformations in women with gestational diabetes 
mellitus: a systematic review and meta-analysis
M. Balsells1, A. García-Patterson2, I. Gich3, R. Corcoy2; 
1Servei d’Endocrinologia i Nutrició, Hospital Mútua de Terrassa, 2Servei 
d’Endocrinologia i Nutrició, Hospital de la Santa Creu i Sant Pau, Barcelona, 
3Servei d’Epidemiologia Clinica, Hospital de la Santa Creu i Sant Pau, 
Barcelona, Spain.
Background: Gestational diabetes mellitus (GDM) has been associated with 
a higher rate of congenital malformations, but the association is not univer-
sally accepted.
Aim: To perform a systematic review and meta-analysis on major congenital 
malformations (MCM) in GDM.
Methods: A MEDLINE search using the terms ((malformation OR outcome) 
AND (gestational diabetes) AND pregnancy)) was performed, limiting the 
search to the period January 2000 to December 2009. Selection criteria: 1) 
GDM and control populations are not openly biased; 2) Paper contains infor-
mation on MCM in women with GDM and in the reference population; data 
on MCM in pregestational DM was not an inclusion criteria, but if included 
in the paper, information was recorded. Statistical analysis: Revman 5.0, with 
a fixed effect analysis method for meta-analysis.
Results: 1924 abstracts were retrieved, 108 full-text articles were revised 
and finally 9 cohort observational studies and 2 case control studies were in-
cluded. In women with GDM, cohort studies displayed a high heterogeneity, 
precluding meta-analysis; in case-control studies, they had a higher rate of 
MCM (OR 1.40, CI95 1.22-1.62) in relation with the reference group. Women 
with pregestational DM had a higher rate of MCM vs reference group in both 
cohort (RR 2.34, CI95 2.02, 2.70) and case-control studies (OR 4.57, CI95 
3.01, 6.95).
Conclusion: Infants of GDM mothers have a slightly higher increased risk of 
MCM, lower than that of women with pregestational DM.
Supported by: CIBER BBN
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Peripartum and gestational factors influencing neonatal hypoglycaemia 
in gestational diabetes: a prospective study
J.A. Flores-Le Roux1, D. Benaiges1, E. Sagarra1, E. Hernandez-Rivas1,  
M.A. Lopez-Vilchez2, A. Mur2, J. Puig De Dou1, C. Claret1, A. Goday1,  
J.F. Cano1; 
1Endocrinology, 2Pediatrics, Hospital del Mar, Barcelona, Spain.
Background: Most studies on neonatal hypoglycemia in GDM women only 
take into consideration gestational and neonatal parameters whereas the 
possible influence of peripartum factors hasn’t been fully explored.
Objective: To evaluate peripartum, gestational and maternal factors influ-
encing the development of neonatal hypoglycemia in infants of women with 
gestational diabetes.
Study design: Prospective observational study including all infants of GDM 
mothers born at our institution between October 2006 and February 2010. 
Data collected include maternal characteristics, gestational parameters 
(GDM treatment, weight gain, HbA1c), peripartum glycemic control (ma-
ternal capillary blood glucose (CBG) ketonemia, use of insulin) and CBG 
measurements in the newborn during the first 24 hours of life.
Results: A total of 183 infants were included with a mean weight of 3353 ± 
505 grams and a gestational age of 39.2 ± 1.4 weeks. 30 newborns (16.4%) 
presented at least one CBG of less than 40mg/dl during the first 24 hours of 
life. The main maternal, gestational and peripartum characteristics in new-
borns with or without neonatal hypoglycemia are presented in Table 1. There 
were no significant differences between hypoglycemic and euglycemic infants 
in terms of neonatal weight, apgar scores at 5 and 10 minutes, umbilical cord 
artery and vein pH nor in the rate of small for gestational age. Macrosomia 
was more frequent in hypoglycemic newborns (21.2% vs 8%, p=0.024). Re-
garding maternal characteristics, Latin-American mothers were more likely 
to have infants with hypoglycemia than caucasian mothers (37% vs 17%, 
p=0.03). No significant differences were observed between other ethnicities 
(Pakistani, Moroccan, Asian).
Conclusions: Neonatal hypoglycemia does not seem to be influenced by gly-
cemic control during labour. Other factors, such as ethnicity (latin-ameri-
cans), insulin use during pregnancy and macrosomia, associate an increased 
risk for neonatal hypoglycemia.
Gestational and peripartum characteristics according to neonatal hypogly-
cemia
Newborn 
CBG>40mg/dl
(n=153)
Newborn 
CBG<40mg/dl
(n=30)
p value
Age (years), mean (SD) 32.7 (5.6) 33.3 (5.9) 0.572
Previous BMI (kg/m2)
mean (SD)
27.1 (5.5) 26.2 (4.1) 0.417
Pregnancy weight gain (kg). mean 
(SD)
9.1 (4.2) 8.8 (2.7) 0.673
GDM treatment: diet/insulin (n/n) 84/44 11/14 0.041
Gestational age (week) mean (SD) 39.2 (1.4) 38.9 (1.4) 0.119
Preterm delivery, n (%) 6 (3.9) 3 (10) 0.167
Intrapartum mean maternal CBG, 
mean (SD)
99.7 (22.4) 94.9 (15.1) 0.269
Intrapartum maternal CBG> 
130mg/dl n (%)
21 (13.7) 7 (23.3) 0.177
Intrapartum Ketosis, n (%) 20 (16.1) 2 (8) 0.372
Intrapartum insulin use, n (SD) 14 (9.2) 4 (13.3) 0.503
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In gestational diabetes mellitus, pregestational body mass index is an 
independent predictor of neonatal hypoglycaemia
A. García-Patterson1, A. Aulinas1, M.A. María1, J. Úbeda1, I. Orellana1,  
J.M. Adelantado2, G. Ginovart3, A. de Leiva1, R. Corcoy1; 
1Servei d’Endocrinologia i Nutrició, 2Servei d’Obstetricia, 3Servei de 
Pediatria, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Background: Recently published data from the HAPO study reveal pregesta-
tional body mass index (BMI) as a predictor of cord blood C peptide; signifi-
cance was not reached for the prediction of neonatal hypoglycemia (NH).
Aim: To assess pregestational BMI as a predictor of NH in women with ges-
tational diabetes mellitus (GDM).
Methods: Database review of all GDM pregnancies (singleton and twins) 
attended in the Diabetes and Pregnancy Clinic of the center from 1st Janu-
ary 1981 to 31st December 2006. Outcome variable: NH defined as capil-
lary blood glucose fulfilling Cornblath cut-off criteria in >=2 occasions in 
the first 48h of life. Screening for GDM was universal and used O’Sullivan 
test; diagnosis used NDDG criteria. We considered the following as poten-
tial predictors of NH: age, weight, height, BMI, weight increase during preg-
nancy, prior poor obstetric outcome, smoking habit, family history of DM, 
prior GDM/abnormal glucose tolerance, gestational age and glucose values at 
diagnosis, delay between diagnosis and treatment initiation, capillary blood 
glucose & HbA1c during pregnancy, insulin treatment, twin pregnancy and 
newborn sex; as potentially intermediate variables we considered maternal 
hypertension (chronic/pregnancy-induced), preterm birth, cesarean section, 
small and large-for gestational age newborns, abnormal Apgar and respira-
tory distress. Statistical analysis: bivariate analyses comparing characteristics 
of pregnancies with and without NH; logistic regression analysis (backward 
method) with NH as the dependent variable and aforementioned variables as 
potential predictors.
Results: During the study period, 2492 newborns of mothers with GDM 
were delivered (2228 singleton) and NH was observed in 3% of them. Moth-
ers of NH newborns differed in a number of characteristics, one of them be-
ing prepregnancy BMI (24.45 vs 23.19 kg/m2, p <0.02). Logistic regression 
analysis identified pregestational BMI as a predictor of NH both when poten-
tially intermediate variables were included (OR 1.293, CI 1.007, 1.660) or not 
(OR 1.359, CI 1.073, 1.721).
Conclusion: Pregestational BMI is an independent predictor of NH in this 
cohort of women with GDM.
Supported by: CIBER BBN
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Intensive glycaemic control in type 1 diabetic pregnancy: a comparison 
of continuous subcutaneous insulin infusion and multiple daily injection 
therapy
K. Neff1, A. McCarthy1, R. Forde1, M. Foley2, S. Coulter-Smith3, S. Daly4,  
R. Firth1, M.M. Byrne1, B.T. Kinsley1; 
1Mater Misericordiae University Hospital, 2National Maternity Hospital, 
3Rotunda Maternity Hospital, 4Coombe Womens and Infants Hospital, 
Dublin, Ireland.
Background and aims: Continuous subcutaneous insulin infusion (CSII) 
has been used in pregnancy and to date is thought to be non-inferior to a 
multiple daily injection (MDI) regimen. We reviewed a cohort of pregnant 
patients with type 1 diabetes mellitus (T1DM), and compared a cohort on 
CSII with a cohort treated with MDI, with the aim of assessing any difference 
in glycaemic control and pregnancy outcomes.
Materials and methods: We reviewed 507 women with TIDM who presented 
for antenatal care with our service over a 5-year period. There were 46 women 
treated with CSII and 461 treated with MDI. All subjects were asked to main-
tain daily 7-point profiles and these were reviewed weekly. Blood glucose 
measurement (BGM) targets were 5mmol/l or less pre-meals and 7mmol/l 
at one hour post-prandial. Maternal parameters including age, parity and 
weight were recorded. Glycaemic control represented by HbA1c in each tri-
mester, attendance at a pre-pregnancy counseling clinic, and pregnancy out-
come including Cesarean section rate, were recorded and differences were 
compared with Students’ t-test and an odds ratio where appropriate.
Results: Women on CSII were older (35 ± 4 years Vs 31 ± 5 years, p<0.001), 
and booked earlier (6 weeks ± 2 Vs 8 weeks ± 5, p<0.05) to ante-natal diabetes 
care. Women treated with CSII had lower HbA1c levels at booking (6.5% ± 
0.8 Vs 7.8% ± 1.4, p<0.001) and delivery (5.9% ± 0.3 Vs 6.3% ± 0.6, p<0.05). 
Cesarean section was recorded at a higher rate in those on CSII (67% Vs 46%, 
p<0.05). Birth weight did not differ between groups (3.6kg ± 0.6 Vs 3.5kg 
± 0.8). There was no significant difference in peri-natal mortality between 
groups. Those treated with CSII were more likely to attend the pre-pregnancy 
service (40% of all pregnancies Vs 10%, OR 5.8, p<0.001). Women attending 
the pre-pregnancy service had lower HbA1c values at booking than those 
who did not attend (6.7% ± 1.4 Vs 7.8% ± 1.5, p<0.001). Patients treated with 
CSII attending the pre-pregnancy clinic had lower HbA1c values at booking 
than those treated with MDI (6.5% ± 0.7 Vs 7.0% ± 0.9, p<0.05), but there 
was no significant difference in HbA1c values at delivery between these two 
groups (6.3% ± 0.6 Vs 6.2% ± 0.7).
Conclusion: Women treated with CSII were more likely to book earlier to 
ante-natal services, to have attended pre-pregnancy services, and had better 
glycemic control than women treated with MDI. Cesarean section rates were 
higher in women treated with CSII despite similar birth weights at delivery 
in both groups. Peri-natal outcomes did not differ between groups. In our 
cohort CSII and MDI are both effective in improving maternal glycaemic 
control both pre-pregnancy and in pregnancy. CSII achieved lower HBA1c 
values by delivery. Both CSII and MDI are effective therapies for the manage-
ment of T1DM in pregnancy.
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Conversion of pregnant patients with type 1 diabetes from multiple 
injection therapy to continuous subcutaneous insulin infusion in early 
pregnancy is safe and efficacious
M. Shanmugasundaram1, H. Rogers1, P. Marks1, A. Jain2, M.S. Marsh2,  
C. Gayle1, S.A. Amiel1, P. Choudhary1; 
1Diabetes Research Group, 2Obstetrics, Kings College Hospital, London, 
United Kingdom.
Background and aims: Adverse risks to mother and fetus in pregnant type 
1 diabetic (T1DM) patients are attributed to poor maternal glycaemic con-
trol. Continuous subcutaneous insulin infusion (CSII) has not been proven 
to improve pregnancy outcome. Initiating CSII in early gestation due to poor 
glycaemic control or to replace long acting analogues may be associated with 
risk, as patients learn to use it. This study aimed to compare maternal glycae-
mic control, obstetric and fetal outcomes in diabetic pregnancies managed 
with CSII and multiple daily injections (MDI).
Materials and methods: In a retrospective case notes audit of 90 T1DM preg-
nancies (52 treated with CSII) between 2002 and 2009, we recorded HbA1c 
pre-conception and in each trimester; fetal ultrasound measurements; mode 
of delivery; age-corrected birth weight; APGAR scores and admission to neo-
natal intensive care unit (NICU). Primary comparison was between MDI and 
CSII. Secondary comparisons were between groups: CSII pre- (n=20) and 
post- (n=32) conception, MDI HbA1c <7.5% in trimester 1 (n=20) and MDI 
HbA1c >7.5% in trimester 1 (n=18). We compared MDI >7.5% with those 
converted to CSII due to poor control (n=8).
Results: CSII and MDI patients were comparable for age (31.9± 5.58 vs 29.9± 
6.13 yrs p=0.1) and BMI (26.4± 4.04 vs 27.9± 5.92 yrs, p=0.2). CSII users 
were 84.6% Caucasian (vs 57.9% MDI, p=0.005), with longer diabetes du-
ration (17.0± 7.05 vs 10.7± 7.98 yrs, p<0.001). CSII group achieved lower 
HbA1c in trimester 1 (7.0± 1.0 vs 7.6± 1.7%; p=0.03) and 2 (6.3± 0.7 vs. 6.8± 
1.5%; p=0.04), with no significant difference in trimester 3 (6.2± 0.58 vs. 6.4± 
1.0 p=0.3). Severe hypoglycaemia rates were not different. Fetal growth veloc-
ity was not different. There were more emergency Caesarean sections (42 vs 
24% p=0.07) in MDI patients, with no differences in macrosomia, age-cor-
rected birth weight centiles, or NICU admission. There were no differences in 
outcome between CSII pre-conception and MDI < 7.5%, nor between these 
groups combined and CSII post- conception. MDI >7.5% had significantly 
greater HbA1c in all trimesters, lower 5 minute APGAR score and greater 
NICU admission. Those converted to CSII post- conception due to poor con-
trol had lower HbA1c in trimester 1 (8.3± 0.67 vs 9.5± 2.0 p=0.06), 2 (6.9± 
0.96 vs 7.8± 1.46 p= 0.15), and 3 (6.7± 0.83 vs 6.9± 1.06 p=0.6), than MDI 
>7.5%. This CSII converted group had higher 5 minute APGAR score (9.17± 
0.76 vs 8.71± 2.08 p=0.09) and less NICU admission (38 vs 56% p=0.6).
Conclusion: Appropriately used, MDI can provide similar pregnancy out-
comes to those using CSII for clinical indications. In those with raised HbA1c 
at booking, or requiring different basal insulin replacement regimens, initia-
tion of CSII in early pregnancy is safe and efficacious leading to improved 
glycaemic control, and less neonatal intervention requirement. 
Comparison between MDI and CSII in type 1 diabetic pregnancies
MDI CSII P-value ANOVA
HbA1c < 
7.5% in 
trimester 1 
(n=20)
HbA1c > 
7.5% in 
trimester 1 
(n=18)
Using CSII 
pre-concep-
tion (n=20)
Initiated 
CSII post- 
conception 
(n=32)
1st trimester HbA1c  
mean (SD)
6.4 (0.61) 9.1 (1.50) 6.9 (0.80) 7.5 (1.08) p<0.001
2nd trimester HbA1c 
mean (SD)
6.0 (0.92) 7.8 (1.45) 6.3 (0.67) 6.2 (0.72) P<0.001
3rd trimester HbA1c 
mean (SD)
5.9 (0.61) 7.0 (1.06) 6.3 (0.51) 6.1 (0.63) P<0.001
Corrected birth weight 
centiles mean (SD)
63.0 (30.10) 68.8 (36.68) 63.0 (33.75) 77.7 (28.86) P=0.3
% Macrosomia 25 44 35 50 P=0.3
% emergency Caesarian 
section
40 44 20 23 P=0.4
APGAR 5 minute mean 
(SD)
9.5 (0.61) 8.7 (2.08) 9.7 (0.49) 9.5 (0.79) P=0.05
% admitted to NICU 11 56 30 24 P=0.02
Congential malforma-
tions
1 1 0 1 P=0.4
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Glycaemic control and pregnancy outcomes in women with type 1 
diabetes: a systematic review and meta-analysis comparison between 
lispro and regular insulin
C. González-Blanco1, A. Chico2, I. Gich3, R. Corcoy2; 
1Endocrinology, Eduab-HSP, 2Endocrinology, Eduab-HSP, 3Clinical 
Epidemiology, Hospital Sant Pau, Barcelona, Spain.
Background: There is limited evidence of the influence of insulin lispro (LP) 
vs regular (RI) on glycemic control and pregnancy outcomes in pregnancies 
of women with Type 1 diabetes mellitus (T1DM).
Aim: To perform a systematic review and meta-analysis on glycemic control 
and pregnancy outcomes in women with T1DM treated with insulin LP vs. 
RI since before pregnancy.
Methods: A Medline and EMBASE search were performed using the terms 
((lispro OR Humalog OR (insulin analog) AND pregnancy) without any 
limit. Abstracts (and full papers when appropriate) were reviewed by two 
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independent researchers and differences set with a third one if needed. In-
clusion criteria: T1DM, data on women treated with RI and LP since before 
pregnancy until delivery in the same paper, minimum number of 5 pregnan-
cies in each group, information on at least one pregnancy outcome. Baseline 
characteristics, metabolic control during pregnancy and outcome data were 
extracted using predefined templates. Baseline characteristics were compared 
without performing a formal statistical analysis and outcome data were sum-
marised with Revman 5.0.
Results: 267 abstracts were identified and 5 papers fulfilled inclusion criteria, 
all of them corresponding to observational studies. Women treated with LP 
or RI were similar in terms of age, BMI, diabetes duration, chronic hyperten-
sion and pre-pregnancy clinic attendance. Outcome data: HbA1c were lower 
in patients treated with LP, at the beginning of pregnancy (mean difference 
(MD) -0.12; CI -0.49,-0.24) and in first (MD -0,33; CI -0.59,-0.08), second 
(MD -0.51; CI -0.83,-0.2) and third trimesters (MD -0.17;CI -0.38, 0.03). 
Gestational age at birth (MD 0.41; CI -0.04, 0.87), birthweight (MD 133.68; 
CI 19.35, 248) and the rate of large for gestational age newborns (LGA) (RR 
1.35; CI 1.12-1.61) were higher in the LP group. No differences were observed 
in the rate of pregnancy induced hypertension, preeclampsia, diabetic ke-
toacidosis episodes, spontaneous miscarriages, interruptions, total abortions, 
caesarean section, preterm birth, macrosomia, small for gestational age new-
borns, stillbirth, neonatal and perinatal mortality, neonatal hypoglycemia 
and major malformations.
Conclusions: In relation with women with T1DM treated with RI, those 
treated with LP display similar baseline characteristics, achieve better glyc-
emic control, deliver at a higher gestational age but birthweight and rate of 
LGA are higher.
1087
Exposure to teratogenic drugs and concomitant contraception in women 
of child-bearing age with type 2 diabetes: a population based cohort 
study
D.A. Webster1, K. Khunti2, E.G. Wilmot3, B. Thakrar4, M.J. Davies2,  
A. Anwar1; 
1University Hospital Coventry and Warwickshire, Coventry, United 
Kingdom, 2University Hospitals of Leicester, United Kingdom, 3University 
of Leicester, United Kingdom, 4PDB Epidemiology, Roche AG, Coventry, 
Switzerland.
Background and aims: Twenty years after the St. Vincent declaration, preg-
nancy outcomes remain poor in women with diabetes. Perinatal mortality 
and congenital anomaly rates are four and two times that of the background 
population respectively. Preconception care, optimal glycaemic control and 
folate supplementation are known to reduce pregnancy risk in women with 
type 2 diabetes (T2DM). Despite this, many women remain poorly prepared 
for pregnancy and it is often unplanned. Since the introduction of the Pay 
for Performance in the UK in 2004, there has been more aggressive manage-
ment of cardiovascular risk in people with diabetes. Some of the medications 
advocated for primary and secondary prevention of cardiovascular disease 
are potentially teratogenic. The aim of this longitudinal study was to identify 
changes in the prescription of cardiovascular medications and contraception 
for women of childbearing age with T2DM between 2000 and 2007 in the 
UK.
Materials and methods: Data were extracted from the General Practice Re-
search Database (GPRD) for all women of child bearing age (14-49 years) 
with T2DM. Data were collected from seven consecutive annual time points 
between 2000 and 2007 and included details on age, body mass index (BMI), 
blood pressure, diabetes complications and prescription of statins, ACE-
inhibitors, angiotensin-II receptor blockers (ARBs) and oral contraception 
(OC). Data were analysed in SAS 9.1.
Results: In 2001 the GPRD contained records of 1,195,600 female patients, 
of whom 1968 (0.16%) were aged 14-49 with T2DM. The study cohort size 
increased yearly to 5263 in 2007 (0.34% of GPRD female records). The pro-
portion of women in each age group was consistent across the seven year pe-
riod: 40% of women were aged 45-49 years, 28.5% 40-44 years, 16.5% 35-39 
years, 8% 30-34 years, 3.5% 25-29 years, 2% 20-24 years and 1% 14-19 years. 
Of the 2007 cohort, 40% had an HbA1c >8%, 70% were obese and 27% had 
hypertension. Retinopathy was recorded in 11%, acute coronary syndrome in 
1% and stroke or transient ischaemic attack in 1%. The use of statin therapy 
increased significantly in these women from 14% in 2001 to 55% in 2007 
(p<0.0001 for trend) whilst OC use remained around 11% (p= 0.8 for trend) 
(see figure). In 2007, only 9.1% of women on a statin were also prescribed 
oral contraception.
Conclusion: Women of child bearing age with T2DM represent a high risk 
group. Despite increasing use of statins, ACE inhibitors and ARBs for pri-
mary and secondary prevention, OC prescription remains unchanged. This 
would suggest many women are at risk of pregnancy despite the prescription 
of potentially teratogenic drugs, further increasing the risk of poor pregnancy 
outcome. There is an urgent need to address preconception care in this rap-
idly expanding cohort of high risk women with T2DM.
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Low glycaemic index and hypocaloric diet therapy versus conventional 
approach in gestational diabetes/one abnormal value in pregnancy, after 
medical nutritional therapy failure
A. Napoli, C. Festa, G. Merola, M. Bongiovanni, L. Mattei, A. Colatrella; 
Clinical and Molecular Medicine, 2nd Faculty of Medicine, Sapienza 
University, Rome, Italy.
Background and aims: We compared the efficacy of a low glycemic index 
and hypocaloric diet vs a conventional approach by insulin treatment in 
terms of maternal and fetal outcome, in GDM and OAV after medical nutri-
tional therapy failure.
Materials and methods: Prospective Randomized open-label study (based 
on math criteria) exploring the two approaches. In 2007-2009, 97 pregnant 
women (63 GDM; 34 OAV; age 34,86±4,86; BMI 25,23 ±4,93 Kg/m²), were 
enrolled, at our diabetic and pregnancy unit. At the first visit (27,74± 7,25th 
gestational week) proper nutritional therapy was prescribed. In 18 women 
the total daily expenditure was measured by Metabolic Holter Body Me-
dia. Women with fasting glycemia ≤105mg/dl and postprandial glycemia 
≤160mg/dl were assigned to “conventional medical nutrition therapy” (“A“ 
Diet: about 30 cal/kg: 50-55%CHO; 20% protein; 25-30% lipids); for ethical 
reasons the women exceeding these cutoff BG levels, were directly treated 
with insulin injections (group EI). The elegible patients, were randomly 
shifted to a low glycemic index hypocaloric diet (“B” Diet: about 27 cal/kg: 
45% CHO; 20% protein; 35% lipids) or to a classical approach with insulin 
(group I), when one week later, fasting BG was ≥90mg/dl and/or postprandial 
BG≥130mg/dl in ≥30% of each time point /week. Then, all the patients were 
strictly monitored, including daily self-control of ketonuria. Those belong-
ing to group B were further shifted to insulin if the metabolic goals were not 
reached with low glycemic index and hypocaloric diet. STATISTICS: paired 
and Un-paired t-test and χ2.
Results: 22 subjects (23,17% of the population) kept being under diet A up 
the end of pregnancy (age: 34,95± 4,73; BMI 24,86±4 Kg/m²),17 (17,89%) 
were directly shifted to insulin for ethical reasons (34,4± 5 BMI 26,4 ±3,41 
Kg/m²), whilst 30 women were randomized to B and 28 to I. The two groups 
were matched for the main anthropometric and metabolic indexes. 21 sub-
jects of B (70% of B) achieved the metabolic goals until the delivery (age 35,9 
±4,3; BMI 24,48± 3,63 Kg/m²), whilst 9 needed to add insulin (30% of B) 
at 26,11±7,66th gestational week (age 33±2,87; BMI 32,42±6,63 Kg/m²). Sig-
nificant differences were observed between B and BI for BMI (p=0,003). All 
groups are similar for type (CS=49; Spontaneous=37) and week of delivery 
(38,54± 1,69th gestational week). No differences were found for birth weight 
among B and I groups, but significant differences were observed between A 
and I as well between EI and I, with a total of 5 macrosomic births (EI=2; I=1; 
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A=2). In addiction levels for significance were observed for Ponderal Index 
((kg/length m³) comparing A to I. No differences were observed for length 
(49,77± 2,24cm), APGAR 1’ (8,7±0,62), APGAR 5’(9,7± 0,46), n° of hypogly-
caemia (tot=5; 2 in EI and 3 in I), n° of hypocalcemia (2 in I).
Table 1. Maternal and fetal outcome
Weight gain in pregnancy 
(kg)
Birth Weight (g) Birth Ponderal Index 
(kg/m³)
A 12.14±3.87 3434.95±427.86 27,4±3,8
B 8.57±3.68 3209.44±380.75 25,4±2,1
BI 5.87±5.55 3326.66±412.00 27.06±3.03
I 9.63±3.93 3057.27±446.07 25.44±2.10
EI 13.61±6.11 3438.75±543.20 26.17±2.81
Weight gain in pregnancy (kg): A vs I p=0.03; A vs BI p=0.002; B vs EI 
p=0.003; BI vs EI p=0.006; BI vs I p=0.03; EI vs I p=0.01
Birth Weight (g): A vs I p=0.008; EI vs I p=0.02
Birth Ponderal Index (kg/m³): A vs I p=0.04
Conclusion: A low glycemic index and hypocaloric diet can be safely pre-
scribed since the 1st visit in GDM and OAV.
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Effects of moderate physical activity on metabolic control in women with 
gestational diabetes
A. Ghio1, A. Bertolotto1, V. Resi1, C. Lencioni1, L. Battini2, S. Politi1,  
M. Corfini1, S. Del Prato1, L. Volpe1, G. Di Cianni1; 
1Department of Endocrinology and Metabolism, Section of Diabetes and 
Metabolic Diseases, 2Department Maternal-Childish, University Hospital, 
Pisa, Italy.
Background and aims: Diet and exercise have been shown to be effective 
tools for prevention and treatment of all metabolic abnormalities. In spite of 
that, little information is available on the effect of lifestyle on glucose con-
trol in women with gestational diabetes (GDM). Therefore, we performed 
this study to evaluate whether moderate physical activity (PA) may improve 
metabolic control in women with GDM.
Materials and methods: After stabilization standardized diet based on pre-
pregnant BMI, 32 GDM women (age 34.5±4.7 yrs, 31% primiparous, pre-
pregnancy BMI 26.7±6.8 kg/m2) were invited to walk 30-min a day four 
times a week during pregnancy. At the beginning of 27±1 week of gestation, 
upon collection of anthropometric and metabolic parameters, a sensewear 
armband (SWA) was applied to all women for a 7-days monitoring of PA’s 
intensity and duration, active energetic output and number of steps. During 
the same period, diet compliance was evaluated by a food frequency ques-
tionnaire and data elaborated using a computerized program (Metadieta®). 
All women were requested to measure capillary blood glucose 4 times a day 
during test week (fasting, 1hr after breakfast, after dinner and after lunch). 
Insulin treatment was allowed at the investigator’s discretion.
Results: Study population was arbitrarily divided in active (n=16) and seden-
tary (n=16) women, based on median level of PA activity. There was no differ-
ence in age, parity, pre-pregnant BMI, and weight gain between the two groups. 
Active women had higher intensity (1.5±0.2 vs. 1.2±0.1 mets/day) and duration 
(102.5±57.2 vs. 47±20.4 minutes/day) of PA, greater active energetic output 
(466±235 vs. 244±99 Kcal/day) and higher number of steps (11,764±2,839 vs. 
7,080±1,840) as compared to sedentary women (all p<0.05). There was no ap-
parent difference in caloric intake (active: 1,895±477 vs. sedentary: 2,089±434 
Kcal) and diet composition in the two groups (carbohydrates: 47.4±5.5% vs. 
46.4±6.6%, fat: 35.5±2.5% vs. 36.1±2.7, proteins: 18.4±2.3% vs. 16.1±23%). No 
difference was found in blood glucose readings with the exception of lower 1-
hr post-breakfast values in active women (5.9±0.8 vs. 6.6±0.1 mg/dl; p<0.04). 
Insulin therapy was deemed necessary in 12.5% of active women as compared 
to 50% of sedentary women (p<0.05), and when needed insulin requirement 
was lower in the former (0.1±0.5 vs. 0.3±0.2 IU/Kg/day; p<0.05). End-preg-
nancy HbA1c levels were lower in active than in sedentary women (4.8±0.3 vs. 
5.5±0.2%; p<0.04). The former also higher serum HDL-cholesterol (77±11 vs. 
63±14 mg/dl, p=0.006), while no differences were observed in total- and LDL 
cholesterol as well as triglycerides. The difference in PA had no effect on deliv-
ery time, percent of caesarean sections, and newborn health status.
Conclusion: Mild physical activity contribute to improve metabolic control 
in women with GDM reducing the number of women requiring insulin treat-
ment and reducing insulin dose in those requiring it.
Supported by: Laboratori Guidotti S.p.A
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Comparing pregnancy outcomes for intensive versus routine antenatal 
treatment of gestational diabetes based on a 75gram oral glucose 
tolerance test 2-hour blood glucose 7.8 - 8.9mmol/l
C. Gayle1, S. Germain2, M.S. Marsh3, D. Rajasingham2, A. Brackenridge2,  
P. Carroll2, S.A. Amiel3, S. Thomas2; 
1Diabetes and Obstetrics, Kings College Hospital NHS Foundation Trust, 
London, 2Diabetes & Obstetrics, Guys and St Thomas’ Hospital NHS Foundation 
Trust, 3School of Medicine, Kings College London, United Kingdom.
Background and aims: The recent consensus guideline for gestational diabe-
tes, from the HAPO group suggests a diagnostic 75 gram oral glucose toler-
ance test (OGTT) 2-hour blood glucose (2hr-BG) of 8.5mmol/l. Although 
HAPO and other trials show adverse outcomes for dysglycaemia in pregnan-
cy, debate continues as to the efficacy of treating gestational diabetes (GDM) 
when the 2-hour blood glucose (2hr-BG) in the diagnostic 75 gm OGTT lies 
between 7.8 and 8.9 mmol/l. Our aim was to look at the effect of interven-
tional treatment based on an OGTT 2-hr blood glucose 7.8 - 8.9mmol/l.
Materials and methods: A retrospective study covering 3.5 years between 2005 
and 2008 between two clinics in teaching hospitals serving the same local popula-
tion. Clinic A used, WHO (2-hr BG 7.8 mmol/l) and clinic B used, EASD (2-hr 
BG 9.0 mmol/l ) diagnostic criteria for GDM. We compared the maternal and 
fetal outcomes for women whose 2-hr BG was between 7.8 and 8.9mmol/l. Clinic 
A patients were treated as GDM and managed intensively in the diabetes antena-
tal service and Clinic B were given dietary advice and managed conventionally.
Results: Demographics; women in clinic A N= 79 and Clinic B N=130 were 
well matched for age (33.2± 5.8 vs 33.1± 4.8 years) and BMI (28.6± 5.5 vs 
27.2± 6.4). Values mean± sd. Centres were well matched for ethnic distri-
bution and represented a multi-ethnic population: 39 vs 35% Black African 
and Caribbean: 14 vs 12% Asian: 47 vs 25% Caucasian and 0 vs 28% not 
documented. Screening values (mean±sd) showed no statistically significant 
difference: OGTT 2hr- BG (8.3± 0.32 vs 8.3± 0.34mmol/l) and HbA1c (5.39± 
0.53% vs 5.44± 0.48%). Maternal Outcomes: women in clinic A had higher 
rates of induction (43% vs 21%), similar rates of caeasarian section (CS) 
(39%); with lower emergency CS rates (35% vs 74%). Fetal outcomes: wom-
en in clinic A had earlier gestational age for delivery (38.6± 1.3 vs 39.7± 1.9 
weeks P<0.001); lower birthweight (3332± 504 vs 3556± 625grams P<0.05) 
and lower macrosomia rate (>4Kg 9% vs 25%). 
Conclusion: Diagnosis of GDM with a OGTT 2hr-BG 7.8 - 8.9 mmol/l and 
treatment in a combined diabetes antenatal clinic is worthwhile with a de-
creased macrosomia rate and fewer emergency CS. There was an increased 
rate of induction, but no associated increase in CS.
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Metformin vs insulin in the treatment of gestational diabetes: impact of 
maternal pregestational BMI on birth weight and need for additional 
insulin during metformin
T. Rönnemaa1, K. Tertti2, U. Ekblad2; 
1Department of Medicine, University of Turku, 2Department of Obstetrics 
and Gynecology, University of Turku, Finland.
Background and aims: In the previous MiG trial metformin and insu-
lin treated mothers with gestational diabetes had infants with similar birth 
weights and rates of macrosomia. It can be hypothesized that with respect to 
neonatal weight, obese mothers could benefit more than non-obese mothers 
from metformin treatment vs insulin as metformin is known to induce less 
maternal weight gain, which in turn associates with fetal growth.
Materials and methods: We analyzed birth weight data from first 150 preg-
nancies in an ongoing randomized trial comparing metformin and insulin 
treatment of GDM. (Women with fasting P-glucose > 7.0 mmol/L or post-
prandial glucose > 11.0 mmol/L were not included in this trial.) In the present 
study we stratified the mothers by pregestational BMI 30 kg/m2 into obese 
and non-obese. Seventy-five mothers were included in both treatment groups. 
Mean maternal age (metformin vs insulin 31.8 vs 32.2 yrs), pregestational BMI 
(29.6 vs 28.5), glucose values in pretreatment OGTT or gestational weeks at 
delivery (39.3 vs 39.5 wks) did not differ between the two treatment groups.
Results: Birth weights tended to be higher (3658 g vs 3556 g, p = 0.19) in chil-
dren of pregestationally obese compared with non-obese mothers (treatment 
groups combined). Birth weights were similar in metformin and insulin groups 
irrespective of maternal pregestational BMI. Need for additional insulin, de-
fined as fasting P-glucose with metformin > 5.5 mmol/L and/or postprandial 
glucose > 7.8 mmol/L, was equally common in obese and non-obese metform-
in treated mothers. Rates of macrosomia were low in all study groups.
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Conclusion: Compared with insulin, metformin is equally effective in the 
treatment of gestational diabetes in both obese (BMI > 30) and non-obese 
(BMI < 30) mothers. Additional insulin is needed in ca 20% of metformin 
treated mothers irrespective of obesity.
Birth weight and macrosomia stratified by treatment group and pregesta-
tional BMI
Group n additional 
insulin
birth 
weight,  
g
p for birth 
weight, 
metfo vs 
insulin
macrosomia, 
n (p metfo vs 
insulin)
Metformin, all 75 19 % 3629 0.41 4 (p=0.37)
Insulin, all 75 3567 1
BMI < 30, metformin 41 20 % 3601 0.35 1
BMI < 30, insulin 48 3519 1
BMI > 30, metformin 34 18 % 3663 0.94 3
BMI > 30, insulin 27 3652 0
Supported by: Local EVO grant
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Two year’s outcomes following the institution of combined ADIPS 
Guidelines for the management of diabetes in pregnancy
G. Fulcher1, C. Johnson2, S. Buchanan2, W.B. Giles2; 
1Endocrinology, 2Obstetrics and Gynaecology, Royal North Shore Hospital, 
St Leonards, Australia.
Background and aims: In mid 2007, we reviewed our approach to the man-
agement of pregnant women with diabetes following a review of published 
guidelines. We noted that the recommendations for maternal and fetal moni-
toring and timing of delivery were not unified. For example North American 
authors suggest twice weekly non-stress CTG from 28-32 weeks. By contrast 
the Australian Diabetes in Pregnancy Society (ADIPS) Consensus Document 
states. Formal testing of fetal wellbeing (eg, cardiotocography, umbilical Dop-
pler blood flow studies or biophysical profile) is not necessary in an otherwise 
uncomplicated pregnancy before 36 weeks gestation.
Materials and methods: In 2008 we adopted a more conservative approach to 
obstetric monitoring of diabetic women in pregnancy. This consisted of rou-
tine fetal heart rate (FHR) monitoring at 36 weeks and growth ultrasounds at 
28, 32 and 36 weeks gestation. Insulin requiring women with unstable control 
were delivered at 39 weeks and those with optimal control were delivered at 
40 weeks. Women with diet controlled gestational diabetes mellitus (GDM) 
were delivered by 41 weeks. The latter were followed throughout pregnancy 
in a routine antenatal clinic with review by obstetricians, diabetes educators, 
and dieticians. The aim of this review was to examine the outcomes of women 
managed with this approach during 2008 and 2009.
Results: The data are listed in the table 1. The one perinatal mortality was a fe-
tus terminated at 20+6 weeks for Trisomy 13. There were fewer caesarean deliv-
eries in those women with diet controlled GDM than in women taking insulin 
(34% vs. 48% P=0.005), fewer instrumental deliveries (9 vs. 22 P=0.028) and 
fewer admissions to SCN (1 vs. 16 P<0.001). There were no differences in birth 
weight, shoulder dystocia, admissions to NICU or 5 minute Apgar scores ≤7.
Conclusions: A more conservative approach in the management of diabetes 
in pregnancy is associated with good outcomes for a cohort of almost 400 
women managed in our unit over a 2-year period. The majority of women in 
both groups delivered before the need for induction of labour.
Table 1. Pregnancy outcomes of the 390 women with diabetes in pregnancy..
Median±SE (range)
Diet GDM 
(N=187)
Insulin 
Requiring 
(N=203)
Delivery 
(weeks)
39.3 ± 0.21 
(20.6-41.5)
39.1 ± 0.15 
(24.5-40.6) P=0.0005
Birth Weight 
(g)
3240 ± 47 
(395-4560)
3325 ± 43 
(661-4850) NS
Spont Lab 
(N=112).
Induction 
(N=50)
Spont Lab. 
(N=87)
Induction 
(N=68)
Delivery (wks)
39.2 ±0.26 
(25.5-41.3)
40 ±0.44 
(20.6-41.5) P=0.0027
38.5 ± 0.27 
(24.5-40.1)
39.6 ± 0.13 
(34.1-40.4) P<0.001
Birth Weight 
(g)
3200 ± 67 
(685-4560)
3347 ± 92 
(395-4238) P=0.03
3105 ± 69 
(661-4390
3422 ± 62 
(2020-4730) P=0.0007
PS 105 Biomarkers in pregnancy
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Circulating vaspin levels are increased during pregnancy but shown 
no association with parameters of insulin sensitivity in women with 
gestational diabetes
L. Kosi1, A. Handisurya2, Y. Winhofer1, J. Todoric3, A. Tura4, K. Klein5,  
D. Bancher-Todesca5, G. Pacini4, H. Esterbauer3, A. Kautzky-Willer1; 
1Department of Internal Medicine III, Division of Endocrinology and 
Metabolism, Medical University of Vienna, Austria, 2Department of Internal 
Medicine III, Division of Nephrology and Dialysis, Medical University of 
Vienna, Austria, 3Clinical Institute for Medical and Chemical Laboratory 
Diagnostics, Medical University of Vienna, Austria, 4Metabolic Unit, 
National Research Council, Institute of Biomedical Engineering, Padova, 
Italy, 5Department of Obstetrics and Gynecology, Division of Feto-Maternal 
Medicine, Medical University of Vienna, Austria.
Background and aims: Visceral adipose tissue-derived serpin (Vaspin) is a 
novel adipokine that might be play a role in glucose metabolism. In humans, 
circulating vaspin levels were found to be increased in subjects with T2DM 
and to positively correlate with BMI and parameters of insulin sensitivity. In 
women with GDM, no differences in serum vaspin levels have been observed. 
However, acute glucose-induced changes under standardized conditions as 
well as effects of pregnancy itself on circulating vaspin levels remain to be 
elucidated.
Materials and methods: Plasma vaspin concentrations were measured in 20 
pregnant women (10 GDM and 10 NGT) at 0, 30, 60 and 120 min of a 2h-
75g-oral glucose tolerance test (OGTT) during gestational week 21-28 and 
three months after delivery by a commercially available ELISA kit (human 
Vaspin ELISA kit, Adipogen, Seoul, South Korea). Fasting insulin sensitiv-
ity was estimated by the homeostasis model assessment of insulin resistance 
(HOMA-IR).
Results: At all timepoints of the OGTT, circulating vaspin concentrations 
were similar in women with GDM and NGT during pregnancy (1.54±0.86 
vs. 1.33±0.76, p>0.05) as well as three months after delivery (0.26±0.42 vs. 
0.32±0.69, p>0.05). Post-partum, plasma vaspin levels decreased significantly 
in both groups (p<0.01, respectively), however, to similar extent (p>0.05). 
Only in women with GDM, circulating vaspin was significantly decreased 
60 and 120 min after glucose ingestion during pregnancy (p<0.01). Plasma 
vaspin concentrations correlated signficantly with glutamic-oxaloacetic 
transaminase during pregnancy (r=-0.49, p=0.03) as well as serum estrogen 
levels (r=-0.51, p=0.03), sexual hormone-binding globuline (r=-0.46, p=0.05) 
and serum creatinine (r=0.53, p=0.02) three months after delivery. No asso-
ciation between circulating vaspin levels and parameters of insulin sensitivity 
including HOMA-IR, fasting glucose, insulin or C-peptide levels have been 
observed.
Conclusion: In contrast to previous studies, we found no association be-
tween parameters of insulin sensitivity and circulating vaspin concentrations 
in women with GDM. Interestingly, following glucose loading plasma vaspin 
concentrations decreased only in women with GDM. Additionally, pregnan-
cy seems to result in an elevation of circulating vaspin.
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Plasma chemerin concentrations in relation to parameters of insulin 
sensitivity in women with gestational diabetes
A. Handisurya1, Y. Winhofer2, J. Todoric3, A. Tura4, K. Klein5,  
D. Bancher-Todesca5, G. Pacini4, H. Esterbauer3, A. Kautzky-Willer2; 
1Department of Internal Medicine III, Division of Nephrology and Dialysis, 
Medical University of Vienna, Austria, 2Department of Internal Medicine 
III, Division of Endocrinology and Metabolism, Medical University of 
Vienna, Austria, 3Clinical Institute for Medical and Chemical Laboratory 
Diagnostic, Medical University of Vienna, Austria, 4Metabolic Unit, 
National Research Council, Institute of Biomedical Engineering, Padova, 
Italy, 5Department of Obstetrics and Gynecology, Division of Feto-Maternal 
Medicine, Medical University of Vienna, Austria.
Background and aims: Chemerin, a novel adipokine, is a chemoattractant 
protein with several functions in innate and adaptive immunity and impli-
cated in the regulation of glucose homeostasis. Previously, chemerin was 
found to enhance insulin-stimulated glucose uptake in 3T3-L1 adipocytes, 
to induce insulin resistance in skeletal muscle and to exacerbate glucose in-
tolerance in mice, when administered exogenously. In humans, circulating 
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chemerin levels are increased in insulin-resistant states, including obesity, 
polycystic ovaries syndrome or non-alcoholic fatty liver disease, and to de-
crease following bariatric surgery. Further, insulin and metformin were sug-
gested to regulate circulating chemerin concentrations. The objective of the 
present study was to evaluate whether GDM is associated with changes in 
plasma chemerin concentrations.
Materials and methods: Plasma chemerin concentrations were measured 
in 20 pregnant women (10 GDM and 10 NGT) at 0, 30, 60 and 120 min of 
a 2h-75g-oral glucose tolerance test (OGTT) during gestational week 21-28 
and three months after delivery by a commercially available ELISA kit (R&D 
Systems, Minneapolis, MO). Fasting insulin sensitivity was estimated by the 
homeostasis model assessment of insulin resistance (HOMA-IR).
Results: No differences in circulating chemerin levels at any timepoint of the 
OGTT were observed between GDM and NGT during pregnancy or after 
delivery (p>0.05). However, the decrease in plasma chemerin concentration 
between 0 min and 30, 60 or 120 min of the OGTT was more pronounced 
in women with GDM during pregnancy (p<0.05, respectively) but not post-
partum. Fasting plasma chemerin levels correlated with HOMA-IR (r=0.54, 
p=0.01), fasting insulin (r=.0.53, p=0.02) and fasting C-peptide levels (r=0.69, 
p<0.001), HDL-cholesterol (r=-0.47, p=0.04), CRP (r=0.58, p=0.008) and 
usCRP (r=0.65, p=0.004) during pregnancy and with HOMA-IR (r=0.54, 
p=0.02), fasting insulin (r=0.56, p=0.02) three months after delivery. The de-
crease in plasma chemerin following delivery (p<0.05, respectively) tended to 
be higher in women with GDM (p=0.08).
Conclusion: Our study shows that plasma chemerin levels correlated with 
parameters of insulin sensitivity and inflammation also in women with GDM. 
However, no significant differences have been found in women with GDM as 
compared to pregnant, normal-glucose tolerant women. Thus, the potential 
role of chemerin in the pathogenesis of GDM remains to be determined.
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Circulating endothelial progenitor cells are reduced in pregnant women 
with abnormalities of glucose tolerance
L. Pucci1, D. Lucchesi1, C. Lencioni1, E. Storti1, M.C. Iorio2, R. Vanacore2,  
V. Resi1, R. Miccoli1, G. Penno1, G. Di Cianni1, S. Del Prato1; 
1Endocrinology and Metabolism, 2Blood Bank, University of Pisa and 
Azienda Universitaria Ospedaliera Pisana, Pisa, Italy.
Background and aims: Bone marrow-derived endothelial progenitor cells 
(EPCs) contribute to support vascular integrity. A role for EPCs has been 
claimed also in development and maintenance of the vasculature during 
pregnancy whose cardiovascular adaptation sustains the developing foetus. 
Gestational diabetes is associated with systemic endothelial dysfunction, but 
only a very few data about EPCs in pregnancies complicated by diabetes are 
available.
Materials and methods: We quantified circulating EPCs in pregnant wom-
en with abnormalities of glucose tolerance undergoing a three-hour, 100-g 
oral glucose tolerance test (OGTT). Insulin sensitivity and β-cell function 
indexes were derived from fasting steady-state and from the OGTT. EPCs 
(CD34+KDR+CD133+ cells) were quantified by three colours flow cytom-
etry in 23 women with normal glucose tolerance (NGT), 18 women with ges-
tational impaired glucose tolerance (GIGT) - defined as a single abnormal 
value on OGTT - and 24 subjects with gestational diabetes mellitus (GDM). 
Tests were performed at 27±3.2 weeks of gestation.
Results: Women with GDM, GIGT and NGT were comparable for age, fam-
ily history of diabetes, pre-pregnancy body weight, BMI, incremental ges-
tational body weight and blood pressure. GDM showed mean glycemic re-
sponse higher than women with GIGT and NGT. AUCGluc (p<0.0001) and 
AUCIns (p=0.06) increased from NGT to GIGT to GDM. Insulin sensitivity 
indexes, ISIcomp and OGIS, reduced progressively in women with NGT to 
those with GIGT and GDM (ISIcomp: 4.92±2.05, 4.43±2.68, and 3.35±1.87, 
respectively, p<0.05; OGIS 387±53, 357±70, and 316±79 mg/min/m2, respec-
tively, p<0.005). Finally, the ISSI index that estimates insulin secretion with 
respect to prevalent insulin sensitivity, was higher (p<0.0001) in women with 
NGT. The number of circulating CD34+ cells resulted similar in the three 
groups (NGT: 353.7±165.9; GIGT: 417.2±242.5; GDM: 423.3±220.0 cells/106 
events), while circulating EPCs differed among women with GDM, GIGT and 
NGT (p=0.0172). Namely, EPCs were significantly higher in NGT (55.6±57.8) 
when compared to both GIGT (26.5±19.6; p=0.018), and GDM (26.5±20.4 
cells/106 events; p=0.011), with no differences between GIGT and GDM. 
EPCs were inversely correlated with age (r=-0.26, p=0.04), as well as with 
1-h (r=-0.30, p<0.02) and 2-h post-load plasma glucose (r=-0.36, p<0.005), 
and AUCgluc (r=-0.37, p<0.005), but not with insulin levels or AUCins. A 
weak positive correlation was also observed between EPCs and ISSI (r=0.25, 
p<0.05). Finally, no associations have been shown between EPCs and fasting 
(HOMA%S: r=-0.13, p=0.32) or dynamic indexes of insulin sensitivity (ISI-
comp: r=0.01, p=0.95; OGIS: r=0.15, p=0.24). In a multiple linear regression 
model, only age (p=0.021) and AUCgluc (p=0.027) remained significantly 
associated with EPCs count.
Conclusion: Alterations of glucose tolerance during pregnancy, other than 
affecting insulin sensitivity and secretion, seems to act as the triggering factor 
for the EPC depletion.
1096
A high level of prorenin in early pregnancy is associated with 
development of preeclampsia in women with type 1 diabetes
L. Ringholm1,2, U. Pedersen-Bjergaard3, B. Thorsteinsson3,4, F. Boomsma5,  
P. Damm4,2, E.R. Mathiesen1,2; 
1Endocrinology, University Hospital of Copenhagen Rigshospitalet, 
Copenhagen, Denmark, 2Center for Pregnant Women with Diabetes, 
Copenhagen, Denmark, 3Endocrinology Section, Department of Cardiology 
and Endocrinology, Hillerød Hospital, Denmark, 4Faculty of Health 
Sciences, University of Copenhagen, Denmark, 5Internal Medicine, Erasmus 
Medical Center, Rotterdam, Netherlands.
Background and aims: Preeclampsia is characterised by abnormal placenta-
tion in early pregnancy, maternal systemic endothelial dysfunction and per-
turbation of the renin-angiotensin-system. Levels of semicarbazide-sensitive 
amine oxidase (SSAO) have been shown to be positively associated with an-
giotensin converting enzyme (ACE) activity and are elevated in patients with 
diabetes. SSAO is implicated in the pathophysiology of diabetic late compli-
cations and may be a marker of endothelial dysfunction and preeclampsia. 
We investigated whether SSAO and components of the renin-angiotensin 
system in early pregnancy are associated with development of preeclampsia 
in women with type 1 diabetes.
Materials and methods: Observational study of 107 consecutive pregnant 
women with type 1 diabetes for median 16 years (range 1-36) and HbA1c 
6.6% (4.9-10.5) in early pregnancy. At 8, 14, 21, 27 and 33 weeks blood sam-
ples were drawn for measurements of prorenin, renin, angiotensinogen, ACE 
and SSAO; HbA1c, blood pressure and urinary albumin excretion (UAE) were 
recorded. Preeclampsia was defined as blood pressure >140/90 mmHg (two 
measurements) accompanied by UAE ≥300 mg/24h later than 20 weeks.
Results: Preeclampsia was recorded in nine women (8%) characterised by 
a longer duration of diabetes (median 20 years (range 10-32) vs. 16 (1-36), 
p=0.04) and higher levels of SSAO at 8 weeks (592 (372-914) mU/L vs. 522 
(264-872), p=0.04, normal range 352±102 mU/l) compared with women 
without preeclampsia. At 8 weeks prorenin levels tended to be elevated in 
women with subsequent preeclampsia (136 (50-296) mU/L vs. 101 (21-316), 
p=0.06, normal range 88 to 390 mU/L), whereas levels of renin, angiotensino-
gen and ACE were comparable (p=0.90, 0.73 and 0.91, respectively). From 
8 to 33 weeks prorenin levels decreased slightly and similarly in women 
with and without preeclampsia, but throughout pregnancy, prorenin levels 
remained 28% higher (p=0.0096) and SSAO levels 16% higher (p=0.04) in 
women developing preeclampsia whereas levels of renin, angiotensiongen 
and ACE were comparable between the two groups (p=0.49, 0.75 and 0.53, 
respectively). In univariate logistic regression analyses of continuous vari-
ables, development of preeclampsia was associated with prorenin levels at 8 
weeks (odds ratio 4.4 [95% confidence interval 1.5-13.0], p=0.007), UAE (≥30 
vs. <30 mg/24h ) at 8 weeks (3.1 [1.3-7.7], p=0.01), SSAO levels at 8 weeks 
(1.8 [1.1-3.1], p=0.01) and duration of diabetes (1.1 [1.003-1.2], p=0.04). In 
multivariate logistic regression analysis, the only independent predictor of 
preeclampsia was prorenin levels at 8 weeks (4.4 [1.5-13.0], p=0.007), i.e. an 
increase of prorenin of 100 mU/L results in a 4.4 times higher risk of develop-
ing preeclampsia.
Conclusion: In women with type 1 diabetes, a high level of prorenin in early 
pregnancy was associated with development of preeclampsia. Whether these 
changes in the renin-angiotensin system mainly reflect maternal susceptibil-
ity present before pregnancy or represent changes secondary to abnormal 
placentation remain speculative.
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Relationship between perinatal outcomes and thyroid-peroxidase 
antibodies (TPO) in a cohort of pregnant women with gestational 
diabetes (GD)
S. Azriel1, A. Garcia Burguillo2, I. Camaño2, D. Montañez2; 
1Endocrinology, Hospital Infanta Sofia, Madrid, 2Hospital Doce de Octubre, 
Obstetrics, Spain.
Background and aims: The prevalence of TPO antibodies in pregnant wom-
en ranges between 6-10%, in line with what is found in the average popula-
tion. Various non-organ specific auto-antibodies have been found associated 
with GD. The presence of TPO antibodies has been independently related to 
increasing rates of spontaneous abortion, preterm delivery, and it has recently 
been demonstrated that in the first trimester there is a risk factor of perinatal 
death. The aim of this study was to evaluate the effect of maternal autoim-
munity on perinatal outcomes and on maternal morbidities.
Materials and methods: GD was diagnosed in a cohort of 1501 pregnant 
women without pregestational thyroid dysfunction, gestational age in the first 
visit >12 week, singleton pregnancy and availability of TPO antibodies titer
Results: 341 patients (22.72%) were TPO antibodies positive (>11.9 U/ml). 
There were no differences between the groups of pregnancies according to 
TPO antibodies status in mean maternal age [32.6 (SD: 4,2) vs 32.7 (7.5) 
years], BMI [24.9 (4.7) vs 24.9 (6.6) kg/m2], frequency of nulliparities [163 
(47,8) vs 553 (47,6)], percentage of insulinizations [61 (17,8) vs 72 (14,8) %] 
and average of A1c hemoglobin [4,24 (0,47) vs 4,26 (0,53) %]. There were no 
significant differences as regards the prevalence of the hypertension (preges-
tational + gestational) [18 (5,2) vs 56 (4,8) %], preeclampsia [4 (1,1) vs 16 
(1,3) %] among the women with positive TPO antibodies and the group with 
negative TPO antibodies. We demonstrated a higher frequency of recurrent 
miscarriages (≥ 3 abortions) among pregnant GDM with TPO+ vs pregnant 
GDM with TPO- [12 (1.35) vs 14 (1.2), RR: 2,61: CI 95: 1.22-5.60)].There 
were no differences between the percentage of preterm deliveries (<34 weeks 
of pregnancy [7 (2,05) vs 12 (1,03) %] nor in <32 weeks [3 (0,87) vs 6 (0,51)]).
Perinatal mortality was equiparable between both groups of women [1 (0,29) 
vs 2 (0,17)]. There were no differences between the mean weight of neonates, 
no differences in the prevalence of big for gestational age [14 (4,1) vs 53 (4,5) 
%] nor in the neonates with weight <2500 g [13 (3,8) vs 36 (3,1) %].
Conclusion: Considering the high prevalence of positive TPOantibodies in 
women with GD and the increasing risk of developing postpartum dysfunc-
tion in this group, a screening of thyroid function during pregnancy and a 
postpartum follow-up are recommended for these women. This study con-
firms the correlation between positive TPO during the pregnancy and higher 
frequency of recurrent miscarriage. In our cohort, thyroid autoimmunity is 
not related with an adverse effect on perinatal outcome in the babies born to 
patients with GD.
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The influence of pregnancy and gestational diabetes on serum levels of 
osteocalcin, osteoprotegerin and RANKL
B. Telejko1, K. Kalejta1, M. Kuzmicki2, A. Nikolajuk1, J. Szamatowicz2,  
A. Kretowski1, M. Górska1; 
1Department of Endocrinology, Diabetology and Internal Medicine, 
2Department of Gynecology, Medical University of Balystok, Bialystok, 
Poland.
Background and aims: Osteoprotegerin (OPG), a soluble tumor necrosis 
factor-like protein secreted by osteoblasts, exerts an inhibitory effect on os-
teoclastic bone resorption by binding and neutralizing the receptor activa-
tor of nuclear factor-κB ligand (RANKL). Besides, OPG has other biological 
functions, including anti-inflammatory and anti-apoptotic effects. Recent 
studies suggest also that osteocalcin, another osteoblast - derived protein act-
ing locally on bone formation, increases beta-cell proliferation and insulin 
secretion and improves insulin sensitivity. Conflicting results concerning se-
rum osteocalcin and osteoprotegerin concentrations have been obtained in 
patients with obesity, type 2 diabetes,as well as gestational diabetes (GDM). 
The aim of the present study was to evaluate possible changes in serum os-
teocalcin, OPG and RANKL levels in pregnant women with normal glucose 
tolerance (NGT) and GDM.
Materials and methods: Serum osteocalcin, OPG and RANKL levels were 
measured, using enzyme-linked immunosorbent assays, in 47 patients with 
GDM and 35 healthy pregnant women in the 3rd trimester of pregnancy and 
12 weeks postpartum.
Results: There were no significant differences in the concentrations of os-
teocalcin, OPG and RANKL between the women with GDM and NGT both 
before (7.8 [5.6-10.5] ng/ml vs 9.5 [5.1-12.7] ng/ml, 6.3 [4.9-7.2] pmol/l vs 
5.4 [3.8-7.2] pmol/l and 0.22 [0.14-0.59] pmol/l vs 0.31 [0.12-0.46] pmol/l, 
respectively) and after delivery (22.1 [16.5-29.6] ng/ml vs 23.1 [17.4-29.7] ng/
ml, 4.2 [3.7-5.2] pmol/l vs 3.9 [3.4-4.5] pmol/l and 0.26 [0.13-0.48] pmol/l vs 
0.31 [0.10-0.62 pmol/l, respectively). Twelve weeks postpartum serum osteo-
calcin concentrations increased (p<0.0001), whereas OPG levels decreased 
significantly (p<0.0001) in both groups of patients in comparison with the 
pregnant state. In the whole group studied there was a significant correlation 
between osteocalcin levels and gestational age (R=0.30, p=0.02). In healthy 
pregnant women osteocalcin levels correlated with gestational age (R=0.45, 
p=0.04) and BMI values (R=0.83, p=0.04), while OPG concentrations were 
related to glucose levels 60 and 120 min after glucose load (R=0.57, p=0.005 
and R=0.50, p=0.01, respectively). In the same group there was also a negative 
correlation between RANKL concentrations and gestational age (R=-0.42, 
p=0.04). No associations of the parameters studied with insulin and HOMA-
IR were noted.
Conclusion: It could be hypothesized that lower osteocalcin levels may be 
related to decreased insulin sensitivity and increased fat mass in pregnant 
women. On the other hand, increased OPG concentrations, possibly due to 
elevated estrogen levels during pregnancy, may play protective roles includ-
ing an inhibition of excessive bone resorption and anti-inflammatory actions. 
No effect of GDM on serum osteocalcin and OPG/RANKL system was found 
in the present study.
Supported by: State Committee for Scientific Research
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Vitamin D deficiency and isolated fasting hyperglycaemia in pregnancy
E. Anastasiou, A. Athanasiadou, V. Vasileiou, A. Giakoumi,  
G. Papageorgiou, E. Zapanti, M. Alevizaki; 
Alexandra Hospital, Athens, Greece.
Background and aims: The relation between vitamin D deficiency and Ges-
tational Diabetes Mellitus (GDM) has been rarely addressed in the literature 
with conflicting results. The aim is to determine the association between 
maternal serum 25(OH)D and glucose metabolism in Caucasian pregnant 
women.
Materials and methods: In a prospective study 157 pregnant women aged 
31.2±5.8 years underwent a 100g OGTT in the third trimester of preg-
nancy, during which serum 25(OH)D, PTH, Ca, and P concentrations were 
also measured. For GDM diagnosis the ADA 2000 criteria were used. For 
25(OH)D deficiency a cut-off point of 20ng/ml was chosen. Age, height, pre-
pregnancy weight, BMI and blood pressure (BP) were recorded. Indices of 
insulin secretion and sensitivity were calculated. 25(OH)D was converted to 
its natural logarithm(Ln).
Results: 25(OH)D deficiency was found in 88 out of 157 pregnant wom-
en(56%). There was no difference in mean serum 25(OH)D between Normal 
(n=95, 20.2±7.0ng/ml), Isolated Hyperglycaemia (n=30, 22.1±7.7) and GDM 
(n=32, 19.4±8.3) women. Ln-25(OH)D was negatively correlated with fast-
ing plasma glucose (r=-0.174, 95% CI 0.020-0.326, p=0.029). The relation-
ship remained significant after adjustment for BMI, age, gestational age and 
seasonal variation. The percentage of isolated fasting hyperglycaemia (Glu0 
≥ 95mg/dl) was significantly increased in the subgroup of pregnant women 
with vitamin D deficiency (<20ng/ml) compared to the counterparts with 
25(OH)D>20ng/ml (27.3% vs7.2% respectively, p<0.01). The odds ratio of 
isolated fasting hyperglycaemia in women with 25(OH)D<20ng/ml was 
4.8 (95% CI 1.7-13.3). Also, a weak but significant correlation was found 
between Ln-25(OH)D and indices of insulin resistance (QUICKI: r=0.191, 
p<0.05, HOMA-IR: r= -0.192, p<0.05). There was no correlation between Ln-
25(OH)D and indices of insulin secretion. Further, we confirmed the expect-
ed negative correlation of Ln-25(OH)D with PTH (r=-0.446, p<0.001), and 
also with systolic (r=-0.203, p=0.011) and diastolic BP(r=-0.238, p=0.003).
Conclusion: We found an independent negative correlation of 25(OH)D 
with fasting glucose in pregnant women. Furthermore 25(OH)D deficiency 
was significantly associated with increased risk for isolated fasting hypergly-
caemia. Finally 25(OH)D deficiency is common in Greek pregnant women.
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Markers oxidative stress and antioxidant status in women with late-onset 
gestational diabetes mellitus
C. López-Tinoco1, A. García-Valero1, J. Bartha2, M. Aguilar-Diosdado1; 
1Endocrinology, 2Obstetric, Hospital Puerta del Mar, Cádiz, Spain.
Background and aims: The relationship between late-onset gestational diabe-
tes mellitus [GDM] and oxidative stress is not well known and the importance 
of the oxidant/antioxidant equilibrium in the clinical evolution and complica-
tions of late-onset GDM require elucidation. The aim of the present study was to 
evaluate the relationships between maternal serum levels of markers of oxidative 
stress in women with late-onset GDM which potentially may have considerable 
clinical implications in the pathogenesis and/or the evolution of GDM.
Material and methods: We performed a nested case-control study within 
a sample of a total of 126 pregnant women (63 with GDM, 63 controls), 
between the 24th and 29th week of gestation. Both groups were analyzed for 
demographic data, perinatal and obstetrics results and the levels of the mark-
ers oxidative stress and antioxidants status, that were measured in serum or 
plasma using a commercial kit (Cayman Chemical, Ann Arbor, MI, USA).
Results: In the univariate analysis, control versus patient results were: ma-
ternal age 30.52±4.05 vs. 31.43±4.4 years (p=0,1); pre-gestational body 
mass index [BMI] 23.31±4.2 vs. 27.13±4.6 kg/m2 (p=0.001); weeks at de-
livery 39.2±3.05 vs. 38.9±1.8 (p=0.09); Caesarean delivery 12.5 vs. 43% 
(p=0.004); macrosomia 4 vs. 9.4% (p=0.6); lipoperoxides [LPO] 2.06±1.00 
vs. 3.14±1.55 μmol/mg (p=0.001); catalase 3.23±1.41 vs. 2.52±1.3 nmol/min/
ml (p=0.03); superoxide dismutase [SOD] 0.11±0.04 vs. 0.08±0.01 U/ml 
(p=0.0003); glutathione peroxidase [GPX] 0.03±0.006 vs. 0.025±0.006 nmol/
min/ml (p=0.01); glutathione reductase [GSH] 0.004±0.002 vs. 0.004±0.004 
nmol/min/ml (p=0.9); glutathione transferase [GST] 0.0025±0.0012 vs. 
0.0027±0.00017 nmol/min/ml (p=0.7). Multivariate analysis that was per-
formed using non-conditional logistic regression showed catalase having a 
protective effect against (OR=0.39, p=0.006) and LPO carried a significant 
risk for GDM (OR=2.44, p=0.034).
Conclusion: These data suggest an increase in oxidative stress and a decrease 
in antioxidative defence in women with late-onset GDM and, as such, may 
have considerable clinical implications in the pathogenesis and/or the course 
of the pregnancy in these patients.
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Oxidative stress may stay elevated after gestational diabetic and even 
healthy pregnancies
E.M. Horvath1, R. Benko1, R. Magenheim2, G. Tamas2, Z. Lacza1, T. Pek1,  
C. Szabo3; 
1Institute of Human Physiology and Clinical Experimental Research, 
Semmelweis University, Budapest, Hungary, 21st Department of Internal 
Medicine, Semmelweis University, Budapest, Hungary, 3Department of 
Anesthesiology, The University of Texas Medical Branch, Galveston, USA.
Background and aims: The number of pathological and moreover healthy 
pregnancies increases the risk of cardiovascular morbidity. Parous women 
with no complicated births have a 1.95-fold higher cardiovascular disease 
prevalence compared to nulliparas. Among women with one or more preg-
nancy complications, cardiovascular disease prevalence is 2.67 times higher. 
It was shown that increased oxidative stress can be observed during the course 
of normal pregnancy. Gestational diabetes mellitus (GDM) is associated with 
a pronounced degree of oxidative stress in placental and umbilical cord tis-
sues and also in the plasma of the mother and the newborn. It is also known 
that elevated levels of oxygen and nitrogen derived reactive species are major 
contributors in the development of cardiovascular morbidities. Our aim was 
to examine the level of possibly persisting oxidative stress and its correlation 
to other known cardiovascular risk factors after pregnancy.
Materials and methods: Serum total peroxide level was measured in healthy 
volunteers three years following healthy (n=20), moderate GDM (carbo-
hydrate-restricted diet, n=30) and severe GDM (insulin treatment, n=12) 
pregnancies. Controls were age and BMI matched males (n=10) and nullipa-
rous women (n=14). In order to characterize their carbohydrate metabolism 
fasting glucose, HbA1c levels were measured and oral glucose tolerance test 
(oGTT, 75g) was performed. Serum glucose and insulin levels were deter-
mined in every 30 minutes, area under the curve was calculated. The follow-
ing clinical parameters were also gauged: inflammatory markers, lipid profile, 
liver and kidney function, thyroid and sex hormones. Serum total peroxide 
level was measured in fasting conditions and 2hours following oGTT.
Results: The oGTT did not change the peroxide level in any study group. 
In fasting conditions the peroxide level of nulliparous women and men was 
similar. Previous healthy pregnancy significantly elevated (586.2±66.8 vs. 
332.3±34.5umol/l, p<0.05) the peroxide level and previous moderate GDM 
did not increased it further on (657.2±46 umol/l). However severe GDM re-
sulted in additional significant increase (951±147.7 umol/l p<0.05, vs. nul-
liparous, moderate GDM). Factors that may influence peroxide level were 
analyzed in multivariate regression model, in order to select significant vari-
ables stepwise method was used. According to the model peroxide level is 
significantly influenced by CRP (33.9umol/l, p<0.05) SHBG (2.7umol/l, 
p<0.05), total serum protein (22.8μmol/l, p<0.05) and the number of preg-
nancies (b=78.6 umol/l, p<0.05) (r2=0.46). The number of pregnancies sig-
nificantly correlates with CRP (Pearson correlation: 0.32, p<0.05), which 
shows that the effect of previous pregnancy on peroxide level is partially due 
to the increase in CRP level.
Conclusion: According to our results the elevated oxidative stress that can be 
measured during pregnancy can be still observed three years after delivery. 
The level of oxidative stress is only altered by previous severe GDM, but not 
moderate GDM. Immunological processes may play important role in this 
phenomenon. The elevated level of oxidative stress may contribute to the in-
creased cardiovascular morbidity of child-bearing women.
Supported by: OTKA 
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Metabolic variables (fructosamine, HbA1c) as predictors and 
pathophysiologic markers of gestational diabetes mellitus and diabetic 
fetopathy
B. Biesenbach; 
Department of Internal Medicine II, Landes- Frauen- und Kinderklinik 
Linz, Austria.
Background and aims: The current therapeutic strategies to reduce macro-
somia rates in GDM have focused on normalization of maternal glucose levels 
throughout pregnancy. This study compares HbA1c, fructosamine, a fructos-
amine/total protein ratio and an index consisting of fructosamine/ total pro-
tein x 1-h-postprandial glucose/100 in regard to their possibility as predictors 
and pathophyiological markers of GDM and infant´s macrosomia.
Materials and methods: A total of 715 pregnant women underwent an oral 
glucose tolerance test and were grouped in four categories according to their 
glucose tolerance and infant´s birthweight. 85.9% (307) women with NGT 
had normal weight children, while 13.9% (50) presented with macrosomia. 
For women with GDM, 89.1% (319) gave birth to a child with normal weight, 
while 39 (10.9%) delivered macrosomic infants. In all pregnant women 89 
women (~12%) presented with fetal macrosomia. Subsequent HbA1c, fruc-
tosamine, ratio and index were compared in regard to their accurancy for the 
diagnosis of GDM and macrosomia by ROC curves.
Results: We found a poor correlation of fructosamine with oGTT data, al-
though the ratio was developed as a more sensitive form than single serum 
fructosamine concentration. According to correlations between HbA1c and 
oGTT values, we can conclude that HbA1c measurements have low sensitiv-
ity as predictive markers for diagnosis of GDM as well as for macrosomia, 
both in NGT and GDM subjects.Due to strict glycemic control (blood glu-
cose fasting < 91 mg/dL, 1 hour postprandial < 131 mg/dL) there was no 
difference in the rate of macrosomia. In all women birthweight was associ-
ated with BMI, fasting plasma glucose, calculated ratio, HbA1C, weight and 
gestational age (all data preconceptional). For women with NGT only obesity 
seems to have an impact on infants´ birthweight, while for women with GDM 
additional metabolic parameters apart from obesity affect fetal growth. Ratio 
was the only variable able to differentiate within the GDM subgroups and 
was the best predictor for birthweight of infants. On the other hand the index 
achieved a satisfying sensitivity in regard of diagnosis of GDM. For women 
with macrosomic infants again the index was superior in detecting GDM.
Conclusion: In conclusion, women with GDM feature higher levels of HbA1c 
and fructosamine as well as higher index values. Due to overlap of NGT and 
GDM groups none of these parameters can offer an alternative to standard 
oGTT screening procedures but could be used as additional parameters for 
confirmation of impaired glucose tolerance and prediction of worse outcome. 
It remains the central target to modify the traditional GDM screening process 
in order to provide a test that should be more reliably detecting those women 
at risk of developing GDM during pregnancy and/or delivering a macrosom-
ic infant despite negative testing for GDM.
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The effect of weight gain on gestational diabetes mellitus
Y. Bacı1, I. Üstüner2, L. Keskin2, R. Ersoy3, A. Sivaslıoğlu2, A.F. Avşar2; 
1Department of Family Medicine, 2Department of Obstetrics and 
Gynecology, 3Department of Endocrinology and Metabolism, Ankara 
Atatürk Education and Research Hospital, Turkey.
Background and aims: To evaluate the association between gestational dia-
betes mellitus (GDM) and weight gain during pregnancy.
Materials and methods: A prospective cohort study of 614 consecutive grav-
id patients, screened for GDM using 50-gram glucose challenge test (GCT) 
between June - December 2009. The pregnant women were divided into 4 
groups according to their pre-pregnancy body mass index (BMI). Group I, 
II, III and IV constituted when the BMI <18.5 kg/m2 (n=16), 18.5-24.9 kg/m2 
(n=455), 25-29.9 kg/m2 (n=122) and >30 kg/m2 (n=21), respectively. All the 
pregnant women were also evaluated in terms of their weight gain during 
pregnancy and these cases were recruited in 3 groups as low, ideal and high 
weight gained groups.
Results: Overall, a positive GCT result was identified in 109/614 (17.8%) 
women. GDM was further diagnosed in 12/614 (1.95%) of subjects. While 
the prevalence of GDM in patients with a normal pre-pregnancy weight was 
1.31%, in over-weight and obese patients it was 3.28% and 9.52% respectively. 
The frequency of the GDM significantly increases in obese patients at the 
pre-pregnancy period compared to the ones with normal BMI. The cases of 
group II and group III showed statistically significant positive results of 50 g 
GCT when they had excess weight gain compared to the ones whose weight 
gain stand in a normal range.
Conclusion: If the women with normal BMI gain more than the recom-
mended weight range during their pregnancy, they should be regarded as 
having risk for GDM.
1104
The effect of lactation on glucose and lipid metabolism in women with 
prior gestational diabetes
A. Colatrella, C. Festa, G. Merola, M. Bongiovanni, L. Mattei, A. Napoli; 
Clinical and molecular medicine, 2nd faculty of, Rome, Italy.
Background and aims: Lactation confers health benefits to women with a 
history of gestational diabetes (GDM). Breastfeeding improves glucose toler-
ance in the early postpartum period, but it is unclear whether future risk of 
metabolic alterations, like type 2 diabetes, is reduced. The aim of this study 
was to investigate the effect of lactation, three years after pregnancy, on glu-
cose and lipid metabolism in women with prior gestational diabetes.
Materials and methods: A population of women with prior gestational 
diabetes, according to Carpenter and Coustan Criteria, was evaluated with 
comparison of results for lactating versus nonlactating women. A total of 81 
women participated ( 62 breastfeeding [ BF] and 19 nonbreastfeeding [<4 
weeks , nonBF]). Each woman completed a 75-g oral glucose tolerance test 
(OGTT) to analyze glucose tolerance, insulin sensitivity / resistance and b-
cell function. Fasting serum was used to investigate lipid profile (total cho-
lesterol, high-density lipoprotein [HDL] cholesterol, low-density lipoprotein 
[LDL] cholesterol, and triglycerides), apolipoprotein B, apolipoprotein A1, 
homocysteine, fibrinogen, hs- CRP, uric acid, microalbuminuria. STATIS-
TICS: paired and Un-paired t-test, Mann-Whitney and χ2 tests were used, 
as appropriate.
Results: The mean (+/- standard deviation) maternal age (37.1 +/- 4.6 versus 
37.4 +/- 4.9 years), body mass index (26.3+/- 5.6 versus 26.4 +/- 5.3 kg/m2), 
and parity (1.9+/- 0.8 versus 1.7 + 0.8) , were not different between the lac-
tating and nonlactating women. No effect was visible on glucose tolerance, 
HOMA-IR and other b-cell function indexes as well as hs- CRP (not signifi-
cantly lower in non BF), uric acid, total cholesterol, HDL and LDL choles-
terol. Levels for significance were only found for: HOMA-IS (BF1.0 +/- 0.7 vs 
non BF 0.6 +/- 0.4, p = 0.04), Triglycerides (BF 83.8 +/- 46.7 vs non BF 123.2 
+/- 94.0 mg/dl, p = 0.02).
Conclusion: Breastfeeding had no effects on glucose tolerance status three 
years after the delivery of women with prior GDM.
1105
Association of fatty liver index (FLI) with parameters of insulin 
sensitivity in women with prior gestational diabetes
C.S. Göbl1, L. Bozkurt1, A. Tura2, A. Luger1, G. Pacini2, A. Gastaldelli3,  
A. Kautzky-Willer1; 
1Department of Internal Medicine III, Division of Endocrinology and 
Metabolism, Medical University of Vienna, Austria, 2Metabolic Unit, 
Institute of Biomedical Engineering, Padova, Italy, 3Department of 
Biochemistry clinical Physiology, Consiglio Nazionale delle Richerche 
(CNR), Pisa, Italy.
Background and aims: Most of the important risk determinants of the meta-
bolic syndrome, including obesity, insulin resistance, glucose intolerance, 
dyslipidemia and hypertension are present in women with prior gestational 
diabetes (pGDM) and indicate their high risk for developing type 2 diabetes 
and cardiovascular disease (CVD) in later life. Fatty liver (FL) is associated 
with insulin resistance, in particular in the liver, and with CVD. The aim of 
the study was to evaluate the relationship between pGDM, presence of FL and 
insulin resistance.
Materials and methods: A cross-sectional analysis was performed in 62 
pGDM women and 28 women with normal glucose tolerance during preg-
nancy (NGT) until 3 months after delivery. According to ivGTT insulin sen-
sitivity index (SI), pGDM were divided into insulin resistant (IR; SI<2.8 10-4 
min-1/(µU/ml)) or insulin sensitive (IS). The fatty liver index (FLI>60 =like-
lihood >78% presence of FL; FLI<20=likelihood >91% absence of FL) was 
calculated for each group and was correlated with metabolic parameters.
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Results: Women with pGDM presented significantly higher FLI levels than 
women with NGT (30.0±3.6[SEM] vs. 20.6±5.6[SEM], p=0,008). In particular 
IR women showed higher FLI-values compared to IS (45.9±6.5 vs. 19.2±3.3, 
p=0.002). 16.1% of pGDM vs. 10.7% of NGT had FLI-values >60. In the 
whole sample FLI was negatively correlated with OGIS (rS=-0.58, p<0.001) 
and HDL-cholesterol (rS =-0.45, p<0.001). In addition, FLI was positively 
correlated with systolic and diastolic blood pressure, CRP, usCRP and liver 
enzymes. Further, we found a negative association with Adiponectin as well 
as a positive association with Leptin.
Conclusion: Results suggest that women with pGDM are at higher risk for 
fatty liver disease. In particular insulin resistance is associated with signifi-
cantly high FLI-values indicating that fatty liver could be another early mark-
er for progression of the disease.
Parameters included in FLI
PGDM NGT p-value
BMI (kg/m2) 27.4±0.7 25.4±1.2 0.113
Triglycerides (mg/dl) 111.7±7.9 90.1±8.6 0.102
γGT (U/l) 8.6±0.6 11.5±2.0 0.083
Waist (cm) 92.4±1.8 80.8±3.1 0.001
Supported by: Grant of the Austrian National Bank to AKW
1106
Changes in humoral autoimmunity in pregnant women with abnormal 
glucose tolerance
K.N. Todorova - Ananieva1, K.V. Petkova2, E.I. Konova3, M.G. Stamenova2; 
1High-risk Pregnancy Department, Specialized Hospital of Obstetrics and 
Gynaecology, Sofia, 2Institute of Biology and Immunology of Reproduction, 
Sofia, 3Clinical Institute of Immunology of Reproduction, Pleven, Bulgaria.
Background and aims: Autoantibodies (AAs) against pancreatic β-cell an-
tigens cause autoimmune destruction, followed by β-cell dysfunction. The 
presence of autoimmune markers in pregnant women is the potential for in-
creased risk for the future development of type 1 diabetes mellitus (T1DM). 
The aim of the study is to evaluate the changes in hummoral autoimmunity 
in high risk for T1DM pregnant women with normal and abnormal glucose 
tolerance.
Materials and methods: A one year prospective study among 96 pregnant 
women was performed in the period March 2008 - March 2009. A 75 grams 
Oral Glucose Tolerance Test (OGTT) was performed between 24 - 26 gesta-
tional weeks. The levels of blood glucose (BG) and immunoreactive insulin 
(IRI) has been measured at 0 min., 60 min. and 120 min. According to the 
results of OGTT the patients were divided into two groups: pregnant with 
normal carbohydrate tolerance (g1= 53) and pregnant with impaired carbo-
hydrate tolerance (g2 = 43). The presence of antibodies against insulin (AIA), 
glutamic acid decarboxylase (GAD65) and one of the heat stress shock pro-
tein (AHspA) was examined in sera using indirect ELISA (AIA and AHspA) 
and EIA (GAD65) methods. All statistical analyses were performed with sta-
tistic panel - SPSS for Windows version 11.0.1. The difference between groups 
was compared by two tailed Student,s t-test.
Results: Seven sera from the g1 (13.2%) and five sera from the g2 (11.6%) were 
positive for AIA (P>0.05). GAD65 autoantibodies were found in one serum 
from the g1 (1.8%) and seven sera from the g2 (16.2%); (P<0.001). Sequent 
analysis for AHspA has found two positive sera in g1 (3.8%) and four posi-
tive sera in g2 (9.3%); (P>0.05). There were statistically significant difference 
in total percentage of presence of autoantibodies between g1 and g2 groups 
(18.8% vs. 37.2%; P<0.03). We have fond positive correlation between BG lev-
els during OGTT and presence of AHspA in g2 (P<0.04). There was positive 
correlation between basal IRI levels at 0 min. and presence of AIA (P<0.02) 
in group2. Four pregnant women positive for IAI of g1 (51.7%) and three preg-
nant positive for IAI of g2 (60.0%) have first and second degree relatives with 
T2DM. Five pregnant of GAD65 positive of g2 (71.4%) have first and second 
degree relatives with T1DM.
Conclusion: These data support that autoimmune markers for pancreatic β-
cell destruction are elevated in pregnant women with abnormal OGTT. In 
the absence of effective methods for prevention of T1DM measurement of 
immunologic markers in pregnant with high hereditary risk should be im-
portant tool for studying the progress of β-cell dysfunction.
1107
Pancreatic islets in human gestational diabetes
M. Tancredi1, L. Marselli1, L. Volpe1, M. Masini1, C. Lencioni1, M. Bugliani1, 
F. Dotta2, P. Masiello1, G. Di Cianni1, P. Marchetti1; 
1University of Pisa, Pisa, Italy, 2University of Siena, Italy.
Background and aims: Autoptic studies have shown an increased amount 
of islets and beta-cells in human pregnancy. However, no information is cur-
rently available on the properties of islet cells in human gestational diabetes. 
Here we describe several morphological, ultrastructural and functional prop-
erties of islets from a 33 yrs old woman with gestational diabetes (GD), who 
died for cerebral hemorrhage (rupture of a congenital aneurysm) at the 27th 
week of gestation. GD had been diagnosed at the 22th week, and therapy at 
time of death was with 32 IU insulin per day. At last control, fasting plasma 
glucose was 104 mg/dl and HbA1c was 6.1%.
Materials and methods: Immunohistochemical stainings and electron mi-
croscopy (EM) analyses were performed on pancreatic samples before islet 
isolation. Islet preparation was accomplished by collagenase digestion and 
gradient purification. Insulin secretion from the isolated islets was studied in 
response to glucose (3.3 and 16.7 mM), arginine (20 mM) and glibenclamide 
(100 µM).
Results: Islets area (diameter > 50 μm) was reduced in GD (0.55%) compared 
to non-diabetic controls (Ctrl) (1.32 and 1.47%), whilst islet insulin-positive 
area was higher in GD (66.0%) compared to Ctrl (51.9 and 47.2%). Apop-
tosis (cleaved caspase 3 immunohistochemistry and EM) was not different 
between the three cases, and Ki67 immunohistochemistry did not show repli-
cating cells in the islets studied. The percentage of ducts with insulin-positive 
cells in the wall or within five nuclei far from it was not different between GD 
(27%) and Ctrl (45 and 23%); however, clusters (<10 cells) of insulin-posi-
tive cells scattered in the acinar tissue were more frequent in GD (1.35 per 
mm2) compared to Ctrl (0.18 and 0.26 per mm2). Ex-vivo insulin secretion 
was similar in GD and control islets.
Conclusion: In this case of human GD, a reduced amount of islets was ob-
served; since apoptotic phenomena were similar in GD and control beta-cells, 
it is possible that not sufficient regeneration played a major role.
Supported by: European Community
1108
Hepatic and nonhepatic glucose uptake in a diet-induced model of 
gestational diabetes
M.C. Moore1, K.C. Coate1, M.S. Smith1, M. Shiota1, P.E. Williams2; 
1Molecular Physiology & Biophysics, 2Surgery, Vanderbilt University, 
Nashville, USA.
Background and aims: Glucose delivery via the hepatic portal vein (or the 
“portal signal”) enhances net hepatic glucose uptake (NHGU) but recipro-
cally inhibits nonhepatic and skeletal muscle glucose uptake. Thus the portal 
signal directs the partitioning of a glucose load among the tissues but does not 
increase whole body glucose uptake. Activation of glucokinase (GK) might 
explain the liver’s response. We have shown that feeding a high-fat and -sugar 
diet (HFD; energy: 60% fat, 12% fructose or sucrose) to pregnant (P) dogs 
during gestational wks 5-8 (total gest=9 wk) alters the response to an OGTT, 
resulting in a canine model of gestational diabetes (GDM). It also worsens P-
induced whole body and muscle insulin resistance and impairs suppression 
of hepatic glucose output during a hyperinsulinemic euglycemic clamp. We 
hypothesized that glucose disposal under hyperinsulinemic, hyperglycemic 
conditions in the presence of the portal signal would be impaired in HFD-fed 
P dogs.
Materials and methods: P dogs with chronic vascular catheterization to al-
low assessment of hepatic and hindlimb balance received a meat/chow diet 
(C; 26% fat, 42% CHO [2% sugar]) or the HFD during gest wks 5-8; n=7/
group. In overnight-fasted conscious dogs during the 8th gest wk, somato-
statin was infused to disable the endocrine pancreas, and glucagon (basal), 
insulin (4×basal), and glucose (4 mg·kg-1·min-1) were infused via the portal 
vein for 4h. Glucose was infused i.v. as needed to clamp the hepatic glucose 
load at 2×basal.
Results: Clamp period arterial (157±1 and 158±1 mg/dl) and portal (172±2 
mg/dl in both) blood glucose, and arterial plasma insulin (25±2 and 28±3 
µU/ml) and glucagon (48±5 and 37±2 ng/l) were not different in C and HFD, 
respectively. Subsequent data are for the last h of the clamp unless otherwise 
stated, and data are for C and HFD groups, respectively. The total glucose 
infusion rate was not different between groups (9.6±0.6 and 9.4±1.0 mg·kg 
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body wt-1·min-1). NHGU was reduced in HFD (15.0±1.5 vs 5.8±3.0 mg·100g 
liver-1·min-1,P<0.05), and net hepatic lactate uptake was enhanced (13.3±10.0 
vs 42.3±7.6 µmol·100g liver-1·min-1, P<0.05). Net hepatic carbon retention 
(17.9±1.4 and 9.7±2.6 mg glucose equivalents·100g liver-1·min-1, P<0.05) was 
reduced and terminal hepatic glycogen concentrations tended to be reduced 
(3.7±0.8 vs 2.4±0.4 g/100g liver; P=0.17) in HFD. Hepatic GK activity did 
not differ between C and HFD. Hindlimb (an index of skeletal muscle) glu-
cose uptake was higher in HFD (9.8±1.1 and 19.8±1.9 mg/min, P<0.05), and 
nonhepatic glucose uptake tended to be higher in HFD (5.9±0.7 and 8.0±1.2 
mg·kg body wt-1·min-1, P=0.06).
Conclusion: NHGU in the presence of hyperinsulinemia, hyperglycemia and 
the portal signal was reduced in HFD-fed dogs, but not in association with 
impaired catalytic activity of GK. Despite the presence of insulin resistance 
in the HFD dogs, the reciprocal nature of liver and skeletal muscle glucose 
disposal was maintained such that there was no reduction in whole body glu-
cose disposal. In P women with impaired glucose tolerance or GDM, blunted 
NHGU could contribute to postprandial hyperglycemia, increasing the pe-
ripheral glucose load.
Supported by: ADA and NIH
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Maternal diabetes increases apoptosis in mice oocytes but not in 2-cell 
embryos
S. Lin, K. Lin, W. Li; 
The First Affiliated Hospital of Shantou University Medical College, China.
Background and aims: It has been reported that diabetes-induced inap-
propriate apoptosis in the developing embryos and oocytes may be one of 
the mechanisms leading to congenital malformation or miscarriage. The 
objective of this study was to investigate the occurrence of apoptosis at an 
early stage of development, the oocytes and 2-cell embryos in streptozotocin 
(STZ)-induced diabetic mouse.
Materials and methods: Bax and Caspase-3 protein and mRNA were de-
tected respectively by Immunofluorescent and quantitative reverse transcrip-
tion-polymerase chain reaction in oocytes and 2-cell embryos from diabetic 
vs nondiabetic mice. Apoptosis was detected by Annexin-V staining. Fur-
thermore, HE-stained ovarian sections were made to see the effect of hyper-
glycemia on the oocytes maturation and development, electron microscopy 
was used to see the effect of hyperglycemia on the ultrastructure of 2-cell 
embryos.
Results: The increased number of Annexin-V-positive cells occurred in 
diabetic oocytes compared to nondiabetic oocytes (P<0.05). In quantitative 
RT-PCR and immunofluorescent, Bax and caspase-3 expression were signifi-
cantly increased in diabetic oocytes than in nondiabetic oocytes (P<0.05). 
HE-stained ovarian sections demonstrated that hyperglycemia resulted in 
delayed follicular growth as detailed by reduced number of growing follicles 
(P<0.05) and a reduction in follicle size (P<0.01). In contrast, no any An-
nexin-V-positive cells in 2-cell embryos were found in diabetic and nondia-
betic mice. Although Bax expression was elevated in diabetic 2-cell embryos 
(P<0.05), caspase-3 expression in 2-cell embryos was no significant differ-
ence between diabetic and nondiabetic mice (P>0.05). Electron-Microscopy 
study revealed that more swollen mitochondrias were found in diabetic 2-cell 
embryos.
Conclusion: Maternal diabetes might increase oocyte apoptosis by a Bax-
caspase-3 pathway to play a role in embryonic malformations by delayed 
oocyte development. Development of 2-cell embryos might be adversely af-
fected by maternal diabetes, but not through Bax-regulated caspase-3 apop-
totic pathway.
Typical images were from diabetic (left) and nondiabetic (right) mice. Im-
munofluorescent showed Bax expression was higher in diabetic oocytes (A1) 
than nondiabetic oocytes (A2). HE-stained ovarian sections demonstrated 
mature follicles were less in diabetic ovary (B1) than nondiabetic ovary (B2). 
Electron microscopy revealed the proportion of swollen mitochondria was 
significantly higher in diabetic (C1) than nondiabetic 2-cell embryos (C2).
1110
Placental antioxidant capacity in gestational diabetes
P.G. Halvatsiotis1, M. Vythoulka1, K. Patsouras2, M. Tsilika1,  
G. Salamalekis2, E. Salamalekis2, T. Economopoulos1; 
12nd Department of Internal Medicine - Propaedeutic, 23rd Department of 
Obstretics and Gynecology, Athens University Medical School, Greece.
Increasing evidence in experimental and clinical studies suggests that there is 
a close link between hyperglycemia, oxidative stress and diabetic complica-
tions. Gestational diabetes mellitus (GD) is a pathological state of carbohy-
drate intolerance first recognized during pregnancy. The incidence of major 
congenital malformations is much higher in pregnancies complicated by 
diabetes and it has been suggested that oxygen free radicals are involved in 
the fetal dysmorphogenesis associated with diabetic pregnancies. Decreas-
ing activities of antioxidant enzyme capacity could be part of the pathogen-
esis and thus the purpose of our study was to examine whether the level of 
the antioxidant biomarker superoxide dismutase (SOD) activity in placental 
tissue is altered in GDM. We studied 6 women with GD (GDM) (29,2±2,2 
y.o.) and 7 age matched (31,6±1,7y.o.) (p=0,392) women with normal glu-
cose tolerance (NGT) who served as controls. We measured a biomarker 
activity of antioxidant defense, namely superoxide dismutase (SOD) (colori-
metric based assay) in placental tissue samples, taken while the surgery for 
caesarean section. Statistical analysis performed with unpaired T-test. All 
pregnancies were fully termed, uncomplicated with normal newborns with 
no difference in birth weight (GDM: 3209,17±181,3 vs NGT: 2956,43±65,5 
g) (p=0,236). GDM group demonstrated significantly higher plasma insulin 
levels vs NGT (12,87±1,5 vs 6,70±0,8 μIU/ml) (p=0,008), while at euglycemic 
levels 82,83±7,5 vs 67,75±5,2 mg/dl (p=0,18) indicating lower insulin sensi-
tivity in GDM. GHbA1c levels in GDM were within normal limits (5,10±0,6). 
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There was no difference in BMI between groups, before pregnancy (GDM: 
24,76±1,3 vs NGT: 25,71±1,6) (p=0,66) as well as for the weight gained during 
pregnancy (GDM:13,58±1,6 vs NGT: 12,34±1,8 kg) (p=0,615). The placen-
tal superoxide dismutase levels were significantly lower in GDM than NGT 
(519,98±29,5 vs 671,17±49,1 μΜ) (p=0,028). In conclusion, the difference in 
the antioxidant biomarker level indicate that regardless the euglycemic con-
dition in GD, there is an increased oxidative load and thus an exhaustion of 
the cell antioxidant capacity. These data may point toward a cellular pathway 
that may contribute in the higher prevalence of adverse outcomes in GD.
PS 107 Neuropathy - diagnostic 
tools
1111
Validity of DN4 as a screening tool for neuropathic pain of painful 
diabetic polyneuropathy
V. Spallone1, R. Morganti1, C. D’Amato1, C. Greco1, L. Cacciotti1, S. Rotella1, 
G. Marfia2; 
1Internal Medicine, Endocrinology, 2Neurological Sciences, Neurology, Tor 
Vergata University, Rome, Italy.
Background and aims: Among the screening tools developed for distinguish-
ing neuropathic from nociceptive pain, the DN4 (Douleur Neuropathique en 
4 Questions) use both interview questions (DN4-interview) and limited bed-
side physical tests. DN4 has not been specifically validated in diabetes. This 
study was aimed at assessing the validity and diagnostic accuracy of DN4 
as a screening tool in identifying neuropathic pain associated with painful 
diabetic polyneuropathy (PDPN).
Materials and methods: In 135 diabetic patients (age 53±16 years, diabetes 
duration 16±12 years, BMI 30±7 Kg/m2, 68 male, 38 with type 1 diabetes), 
clinical parameters, symptoms and signs of diabetic polyneuropathy (DPN), 
the vibration perception threshold (VPT), the cold (CTT) and warm sen-
sation thresholds (WTT), and neuropathic pain were evaluated using the 
Michigan Neuropathy Screening Instrument Questionnaire (MNSI-Q), 
the Michigan Diabetic Neuropathy Score (MDNS), the Biothesiometer, the 
Neuro Sensory Analyzer TSA-II, a pain history, an 11-point numerical rating 
scale (NRS), the Short-Form McGill Pain Questionnaire (SF-MPQ), the Brief 
Pain Inventory (BPI), and DN4 (the latter administered by “a blinded” inves-
tigator). PDPN was defined as the presence of DPN (at least 2 abnormalities 
among symptoms, signs, VPT, thermal thresholds, and 10 g monofilament) 
plus clinician-diagnosed chronic neuropathic pain with the same distribu-
tion as the neurological deficits and attributable to DPN.
Results: Forty-five patients fulfilled the criteria for PDPN (PDPN+), 33 for 
DPN (DPN+) and 57 were DPN free (DPN-). The DN4 score was related to 
both neurological (Vs. MNSI-Q: rho=0.82, P<0.0001; Vs. MDNS: rho=0.62, 
P<0.0001; Vs. VPT hallux: rho=0.48, P<0.0001; Vs. number of 10 g monofila-
ment correct answers: rho=-0.42, P<0.0001; Vs. CTT: rho=-0.28, P=0.0026; Vs. 
WTT: rho=0.31, P=0.0009) and neuropathic pain indices (Vs. 24h average pain 
NRS: rho=0.30, P=0.049; Vs. SF-MPQ sensory dimension: rho=0.56, P=0.0003; 
Vs. BPI pain now: rho=0.43, P=0.005; Vs. BPI general activity interference: 
rho=0.33, P=0.029; Vs. BPI mood interference: rho=0.32, P=0.033). Using 
ROC analysis, the DN4 score showed a high diagnostic accuracy in discrimi-
nating between PDPN+ and both DPN+ and DPN- (AUC: 0.95±0.02, 95% C.I. 
0.91-0.98), as well as between PDPN+ and DPN+ or DPN- (AUC: 0.93±0.03 and 
0.96±0.02, respectively). The DN4-interview score showed a similar diagnostic 
accuracy (AUC: 0.94±0.02, 95% C.I. 0.89-0.97). At the cut-off score of 4, DN4 
displayed a sensitivity of 79%, a specificity of 92%, a positive predictive value 
of 84%, a negative predictive value of 89%, and a likelihood ratio for a positive 
result of 9.89. At the cut-off score of 3, DN4-interview displayed a sensitivity of 
79%, a specificity of 85%, a positive predictive value of 74%, a negative predic-
tive value of 88%, and a likelihood ratio for a positive result of 5.33.
Conclusion: This study demonstrates for the first time the diagnostic ac-
curacy of DN4 in identifying neuropathic pain in PDPN and supports its 
usefulness as a screening tool for diabetic peripheral neuropathic pain. The 
DN4-interview has quite similar diagnostic accuracy as the full version of 
DN4 with the additional advantage of a possible use as a self-questionnaire.
1112
Neuropad and corneal confocal microscopy: new indicators for human 
diabetic neuropathy
M. Tavakoli, C. Quattrini, P. Begum, H. Fadavi, A.J.M. Boulton, R.A. Malik; 
University of Manchester, United Kingdom.
Objectives: Evaluation of early nerve damage is important to define diabetic 
patients at risk of developing pain and foot ulceration. The earliest nerve 
damage occurs to the small fibres detected by skin biopsy. Corneal confocal 
microscopy (CCM) and the Neuropad test provide non-invasive structural 
(c-fibres) and functional (sympathetic cholinergic fibres) measures of small 
fibre damage and may act as screening tools for diabetic neuropathy.
Methodology: 100 diabetic patients (Type I/II: 61/39) and 14 healthy volun-
teers underwent assessment of neuropathic severity using the Neuropathy 
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disability score (NDS), vibration perception threshold (VPT), Neuropad as-
sessment, and CCM.
Findings: All control subjects had a normal response to Neuropad (100% 
Pink). Patient response was classified into three groups: Normal response 
(100% Pink), Intermediate response (patchy pink), and abnormal response 
(100% Blue).
Demographic characteristics of the controls and patients according to the 
three categories of Neuropad responses.
Controls Diabetic Patients
Normal 
response
Normal 
response
Patchy re-
sponse
Abnormal 
response
Number 14 31 43 26
Age (yrs) 48 ± 2.50 46 ± 3 53.5± 2 52± 2.50
Type diabetes ( I/II) - 19/12 22/21 20/6
Duration of diabetes (yrs) - 15± 2.00 22.00± 2.00 21± 2.00
HbA1c (%) <6.5 7.5 ± 0.3 7.9± 0.3 8.0 ± 0.5
NDS (0-10) 0 1.3±0.3 4.5±0.5 6.3±0.7
VPT(Hz) 6.5±0.4 10.5±1.1 19.4±1.8 28.5±3.1#
NFD (no/mm2) 48.3±3.3 32.9±1.8# 25.0±2.1* 16.5±2.5*
NBD (no/mm2) 30.1±1.4 17.0±2.1* 11.4±1.4* 7.8±1.7*
NFL ( mm/mm2) 9.7±0.7 6.0±0.6 4.3±0.4 3.0±0.6*
Post Hoc: v control *P<0.001, #P<0.05,
Diabetic patients with a normal NDS and VPT i.e. no neuropathy have a nor-
mal Neuropad response which becomes patchy in those with mild neuropa-
thy and abnormal in those with more severe neuropathy. However, CCM ab-
normalities are present even in patients with no neuropathy and progressively 
worsen with increasing neuropathic severity. The Neuropad response corre-
lated with NDS (rs=0.456, p= 0.000), VPT (rs= 0.330, p=0.000), NFD (rs=-
0.365, p=0.000), NBD (rs=-0.377, p=0.000), and NFL (rs=-0.395, p=0.000).
Conclusion: Neuropad therefore detects mild neuropathy whilst CCM de-
tects nerve damage at the very earliest stage. As both tests are non-invasive 
they offer considerable potential as screening tools.
1113
A simple method for detecting ‘at risk feet’ in hospitalised individuals 
with diabetes
P.R.J. Vas1, N. Baker1, C. Taylor1, A.I. Adler2, G. Rayman1; 
1The Diabetes Centre, Ipswich Hospital NHS Trust, 2The Wolfson Diabetes 
and Endocrine Clinic, Cambridge University Hospitals NHS Foundation 
Trust, United Kingdom.
Background and aims: Approximately 3% of hospitalised individuals with 
diabetes develop a foot lesion during admission. Yet, care providers infre-
quently screen patients on admission for at-risk feet citing the unavailability 
of screening instruments. We wanted to assess a novel, simple, readily-avail-
able method - the touch test [TT] - to detect sensory neuropathy.
Materials and methods: The TT involves lightly touching with the operator’s 
finger the dorsum of 1st and tips of 1st, 3rd, 5th toes bilaterally. We assessed the 
performance of monofilament [MF] and TT in 122 diabetic subjects against 
a vibration perception threshold of >25V from neurothesiometry in either 
foot. Assessments were performed by 8 individuals.
Results: MF and TT have similar and good sensitivity, specificity and operat-
ing characteristics. Applying the criterion of ≥2/8 insensate areas to signify 
neuropathy, the sensitivities and specificities for TT were 70% and 88% (MF 
78% and 91%), The area under the curve for TT is 0.80 (MF, 0.85). Inter-rater 
agreement for TT indicated substantial agreement, Cohen’s kappa (k) = 0.68.
Conclusion: This equipment-free test which is ‘an arms length away’ per-
forms well against a recognised standard known to predict risk of ulceration. 
Health care providers should use this simple, handy test to assess all patients 
admitted with diabetes.
1114
Comparing skin biopsy with corneal confocal microscopy: diagnostic 
yield of nerve fiber density
C. Quattrini1, M. Tavakoli1, P. Kallinikos1, A. Marshall2, N. Efron3, A.J.M. 
Boulton1, R.A. Malik1; 
1University of Manchester, United Kingdom, 2Department of 
Neurophysiology, Manchester, United Kingdom, 3Institute of Health and 
Biomedical Innovation, Brisbane, Australia.
Background and aims: The assessment of intra-epidermal nerve fiber den-
sity (IENFD) in skin biopsies and corneal nerve fiber density (CNFD) using 
corneal confocal microscopy (CCM) provides promising techniques to detect 
small nerve fiber damage in patients with peripheral neuropathy. To help de-
fine the clinical utility of each of these techniques in patients with diabetic 
neuropathy we have assessed sensitivity and specificity of IENFD and CNFD 
in predicting the following: 1) diabetic polyneuropathy (DPN); 2) risk of foot 
ulceration (RFU); 3) initial small fiber neuropathy (iSFN); 4) severe small 
fiber neuropathy (sSFN).
Materials and methods: 55 diabetic patients underwent assessment of neu-
ropathic deficits using neuropathy disability score (NDS), nerve conduction 
studies, vibration perception threshold (VPT) using the Neurothesiometer, 
cooling detection threshold (CDT), minimal heat-as-pain threshold (0.5 
HP-VAS) and autonomic function testing (DB-HRV) using the CASE IV. 
Definition of DPN was: 1) NDS ≥ 3/10, 2) peroneal motor nerve conduction 
velocity (PMNCV) ≤ 42 m/sec, 3) at least one positive small fiber assessment 
among DB-HRV≤5th pc, CDT≥95th pc, HP-VAS≥95th pc (CASE IV normality 
range); 4) VPT ≥ 15 V. Definition of RFU was: 1) NDS ≥6/10, 2) VPT ≥25, 
and one among the following: PMNCV ≤35 m/sec, CDT ≥98th pc, HP-VAS 
≥98th pc, DB-HRV ≤3rd pc. Definition of iSFN was: any value outside the 5th - 
95th pc range (whichever end of the distribution applied) for CDT, 0.5 HPVAS 
and DB-HRV Definition of sSFN was: all values outside the same range for 
all available CDT, 0.5 HPVAS and DB-HRV. All patients then underwent skin 
biopsy to quantify IENFD and CCM to quantify CNFD.
Results: The sensitivity of IENFD in diagnosing DPN was 78%, RFU-88%, 
iSFN-69% and sSFN-86% with respective specificities of 56%, 54%, 63% and 
46%. The sensitivity of CNFD in diagnosing DPN was 56%, RFU-63%, iSFN- 
50% and sSFN-86% with respective specificities of 75%, 72%, 84% and 69%.
Conclusion: Although the sensitivity for detecting different severities of 
DPN is greater for IENFD compared to CNFD, the specificities for the latter 
are greater. Specifically for detecting SFN, CNFD has a comparable and high 
sensitivity but higher specificity than IENFD. However, the major advantage 
of CCM is that it is a non-invasive technique.
1115
Extensor digitorum brevis muscle atrophy in diabetic patients
M. Baba, C. Suzuki, M. Tomiyama, A. Arai, Y. Miki, H. Nishijima, T. Ueno, 
R. Haga; 
Department of Neurology, Aomori Prefecture Medical Centre, Aomori-City, 
Japan.
Background and aims: Diabetic polyneuropathy is clinically sensory domi-
nant. However, electrophysiological assessment i.e. F-wave latency study 
indicates early motor fibre involvement even in an asymptomatic patient. 
We assessed atrophy of extensor digitorum brevis (EDB) muscle in diabetic 
patients, whether this small foot muscle atrophy has diagnostic value for dia-
betic polyneuropathy or not.
Materials and methods: We examined EDB muscle atrophy and other neu-
ropathic signs in 42 diabetic patients, and score of the michigan neuropa-
thy diagnostic instruments (MNDI) was assessed. Motor and sensory nerve 
conduction studies were carried out in the tibial, peroneal and sural nerves 
bilaterally. The EDB muscle atrophy was graded as follows: Grade 0; no at-
rophy, Grade I: just wasted and visible, Grade II; palpable or visible by toes 
dorsiflexon, Grade III; neither palpable nor visible.
Results: EDB muscle atrophy was clearly and easily detectable by inspection 
and palpation. Number of patients of each group was as follows: G-0; 7, G-I; 
15, G-II; 13, G-III; 7. Average scores of MNDI are: G-0; 2.4, G-I; 3.5, G-II; 
3.7, G-III; 3.9. CMAP amplitudes of EDB after giving supramaximal electric 
shock to the deep peroneal nerve at the ankle are: G-I; 2.9mV, G-II; 1.4mV, 
G-II; 0.9mV, G-III; 0.3mV. Distal latency time and MCV were most abnormal 
in G-III. CMAP of the abductor hallucis muscle evoked by the tibial nerve 
stimulation and CSAP of the sural nerve were as follows, respectively: G-0; 
10.5mV, 6.2uV, G-I; 8.0mV, 5.8uV, G-II; 7.9mV, 6.0uV, G-III; 2.9mV, 2.3uV. 
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Distal latency, MCV and Minimal F-wave latency of the tibial nerve, and SCV 
of the sural nerve were markedly delayed in G-III patients.
Conclusion: EDB muscle atrophy well reflects clinical and electrophysiologi-
cal severity of diabetic polyneuropathy, and appears to be a simple and useful 
sign indicating progressive motor fibre loss in diabetic polyneuropathy.
1116
Spinal cord atrophy and thalamic neuronal dysfunction in distal 
symmetrical diabetic polyneuropathy
I.D. Wilkinson1, D. Selvarajah2, R. Gandhi2, C. Emery2, S. Tesfaye2; 
1Academic Unit of Magnetic Resonance Imaging, University of Sheffield, 
2Diabetes Research Department, Royal Hallamshire Hospital, Sheffield, 
United Kingdom.
Central nervous system involvement in diabetic sensorimotor neuropathy 
(DN) is being increasingly recognised. We have previously demonstrated the 
presence of spinal cord atrophy not only in subjects with established-DN but 
also in early, subclinical DSP. In a further proton magnetic resonance spec-
troscopy (H+MRS) study, subjects with established-DN were found to exhibit 
thalamic neuronal dysfunction. In this study we looked at the relationship 
between spinal cord atrophy and thalamic neuronal function in DSP.
Methods: Twenty subjects [6 healthy volunteers; 14 diabetic subjects (8 
No-DN and 6 Established-DN)] underwent detailed assessment of pe-
ripheral nerve function including: neuropathic symptom evaluation, clini-
cal examination to determine the Neuropathy Impairment Score of Lower 
Limbs (NIS[LL]), 5 attributes of nerve electrophysiology, vibration detection 
threshold and heart rate with deep breathing test. MR imaging of the cervical 
spine and thalamic H-MRS were conducted within one year. Cervical cord 
cross-sectional area at disc level C2/C3 was calculated. Established markers 
of neuronal function [N-acetyl aspartate:choline (NA:Cho)] were obtained 
from the thalamus using long echo time H+MRS.
Results: There was no significant difference in subgroup demographics 
[age: HV 42.5(15.4), No-DN 42.8(8.7), and Established-DN 48.4 (11.3)]. 
NIS[LL]+7 test score was significantly higher in subjects with Established-
DN [21.8(15.2)] compared with No-DN [1.14(1.07); p<0.05]. Subjects with 
Established-DN had significant reduction in both cervical cord area [ANO-
VA p=0.002; Established-DN mean(SD) 52.1(4.1) vs No-DSP 68.8(8.20), 
p=0.001 and Established-DN vs HV 68.7(10.4), p=0.002] and thalamic NA:
Cho [ANOVA p=0.013; Established-DN 1.58(0.16) vs No-DN 1.80(0.15) and 
Established-DN vs HV 1.74(1.0)] compared to the other groups. Among sub-
jects with diabetes, cervicalcord area was significantly related to thalamic NA:
Cho (r=0.42, p=0.04).
Conclusion: Diabetic subjects with Established-DN had the greatest level of 
spinal cord atrophy and thalamic neuronal dysfunction compared those with 
No-DN and HV. Significant positive correlations between spinal cord area 
and thalamic NA:Cho suggest progressive, concomitant involvement of the 
central nervous system in DN. The pathophysiological insult on the nervous 
system caused by DN appears more generalised, involving both the periph-
eral and central nervous systems.
Supported by: Diabetes UK
1117
Symptomatic neuropathy in type 1 diabetes is preceded by subclinical 
electrophysiological abnormalities - a prospective study
N. Alstrand1, J. Ludvigsson2, L. Hyllienmark3, J. Wahlberg1; 
1Department of Medical and Health Sciences, Division of Internal Medicine, 
Faculty of Health Sciences, Linköping, 2Department of Clinical and 
Experimental Medicine, Division of Pediatrics, Faculty of Health Sciences, 
Linköping, 3Department of Clinical Neuroscience, sections of Neurology 
and Clinical Neurophysiology, Karolinska Institutet, Stockholm, Sweden.
Background and aims: It is assumed that overt neuropathy with symptoms 
is preceded by a subclinical form which can be detected by studies of nerve 
conduction velocity. However, long-term studies in patients with type 1 dia-
betes with multiple insulin-injection therapy are lacking. The aim of the study 
was to elucidate if subclinical electrophysiological abnormalities can predict 
symptomatic neuropathy in patients with type 1 diabetes.
Materials and methods: Fifty-nine patients with type 1 diabetes were ex-
amined twice, 43 already in year 1994, and 16 in year 2000. From onset of 
diabetes all patients were treated with multiple insulin-injection therapy. 
Duration of diabetes at the second examination was 20.1 +/- 5.4 (range 10-
31) years. The first examination included motor nerve conduction velocity 
(MCV), compound muscle action potential (CMAP) in peroneal and me-
dian nerves and sensory nerve conduction velocity (SCV) and nerve action 
potential (SNAP) in sural and median nerves. The second examination in-
cluded also assessment of quantitative sensory thresholds (QST), neuropathy 
impairment assessment (NIA) and neuropathy symptom assessment (NSA). 
Symptomatic neuropathy was defined as NSA of ≥ 1.
Results: At the second examination symptomatic neuropathy was found in 
12/ 59 (20%) of the patients. Those with symptoms on follow-up had lower 
peroneal and median MCV at baseline compared to those without symptoms 
(p < 0.05 for both parameters). In a logistic regression model, baseline long-
term HbA1c and baseline median MCV predicted symptoms of neuropathy 
at follow-up. A decrease in peroneal MCV by more than two standard devia-
tions at baseline significantly increased the risk of symptomatic neuropathy 
(OR=17; p < 0.03) A combination of both long term HbA1c ≥ 7.0 and a base-
line decrease in peroneal MCV (≥ 2 SD) increase the risk of future symptoms 
(OR=21; p<0.000). In addition, the decrease in peroneal MCV at baseline 
showed a positive correlation with all parameters of nerve conduction at fol-
low up (p < 0.003).
Conclusion: Despite multiple insulin-injection therapy symptomatic neu-
ropathy is seen in 20 percent of patients after 20 years of type 1 diabetes. 
Overt diabetic neuropathy with symptoms is preceded by a subclinical form 
detectable by studies of nerve conduction.
Supported by: County Council of Östergötland
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Significant impact of mood disturbances on pain perception in painful 
DPN: time to re-evaluate current practice?
A. Sankar1, D. Selvarajah2, R. Gandhi2, M. Oleolo2, C. Emery2, S. Tesfaye2; 
1Diabetes Research Department, University of Sheffield, 2Diabetes Research 
Department, Royal Hallamshire Hospital, Sheffield, United Kingdom.
Painful diabetic peripheral neuropathy (DN) is common and has a nega-
tive impact on mood, functionality and quality of life. Unfortunately, cur-
rent clinical practice focuses on pharmacological interventions directed at 
pain relief without adequate assessment of mood. An understanding of the 
impact of mood disorders on pain reporting and perception may result in 
better characterisation of the pain experience and patient tailored manage-
ment strategies.
Method: 60 patients with painful DPN [mean age: 56.5(10.2), male:61%, type 
2 DM: 79.7%] underwent: 1) clinical examination and nerve conduction stud-
ies to quantify DPN; 2) assessment of pain intensity with Neuropathic Pain 
Scale (NPS) and 3) assessment of mood with Hospital Anxiety and Depres-
sion Scale, Pain Acceptance Questionnaire (CPAQ) and Pain Catastrophising 
Scale (PCS). Based on these assessments on subjects that had been referred to 
our tertiary, specialist painful DN clinic were found to have severe symptoms 
[diabetes duration: 13.9(8.3), pain intensity VAS: 7.2(2.1)].
Results: All subjects had moderate to severe painful DPN with group average 
NIS(LL) + 7 test score of 26.9(14.1). There was a high prevalence of mood 
disturbance with 70% suffering with either anxiety and/or depression. The 
presence of anxiety appears to result in reporting a greater variety of pain 
[anxiety vs no anxiety, NPS: 5.3(1.8) vs 4.3(1.1); p=0.03] and significantly 
higher pain scores [NPS: 6.2(1.9) vs 4.6(2.2); p=0.002]. However, subjects 
who were depressed were less likely to accept pain [CPAQ depression vs no 
depression, pain willingness: 20.6(11.8) vs 40.0(14.9); p=0.009] and engage 
in social and/or physical activity [CPAQ, activities engagement: 29.0(11.8) vs 
46.1(18.3); p=0.04]. Anxiety [PCS: 5.2(3.0) vs 2.0(1.5); p=0.03] and depres-
sion [PCS: 5.4(2.8) vs 1.9(1.7); p=0.01] both result in a significant magnifica-
tion of symptoms.
Conclusion: This study found a very high prevalence of mood disorders in 
patients with severe painful DN. It also highlights the differing but significant 
impacts of anxiety and depression on an individual’s pain experience. As we 
have quick and simple screening tools and effective treatments for mood dis-
orders, an appreciation/assessment of the psychological impact of mood on 
pain may lead to better clinical outcomes for sufferers.
1119
Prevalence of painful diabetic neuropathy and quality of life in patients 
with type 1 or type 2 diabetes mellitus in specialist care
K. Algür, H.W. de Valk; 
Department of Internal Medicine, University Medical Centre Utrecht, 
Netherlands.
Background and aims: Chronic painful distal neuropathy (CPDN) is a major 
complication in diabetes mellitus. However, little is known about prevalence, 
severity, determinants and impact of CPDN on quality of life. This informa-
tion is necessary to improve care of patients as well as to design preventive 
strategies and evaluate current and future therapies. In this observational 
study we assessed prevalence and effect on quality of life in patients with 
CPDN in one large hospital in the Netherlands.
Materials and methods: A total of 720 patients with either type 1 (DM1, 
n=334)) or type 2 (DM2, n=386)) attending the out-patient clinic for Dia-
betology of the University Medical Centre Utrecht received a set of ques-
tionnaires by mail. Response rate in DM1 was 50.6% and in DM2 51.0%. 
Questionnaires sent were pain visual analogue scale (0-10 point VAS), a 0-
100 rating scale of quality of life on the day of the questionnaire (S100) and 3 
quality of life (QoL) questionnaires (Euro-QoL EQ-5D, QoL-Enjoyment and 
satisfaction, and Medical outcomes study sleep scale). Other study data were 
collected from medical records. A diagnosis of CPDN was established when 
vibration sense at the level of the hallux was diminished or absent in combi-
nation with a VAS-score ≥4. No obvious other causes of painful neuropathy 
(severe alcoholism, inflammatory nerve damage, untreated B12 deficiency) 
were present.
Results: Mean age DM1 44.1±12.9, DM2 61.9±12.6 years (p<0.001); dura-
tion of disease DM1: 25.9±14.7, DM2: 15.0±8.3 years (p<0.001); males: DM1: 
43.5; DM2: 60.2% (p<0.01); 93.4% patients with DM2 on insulin. Prevalence 
of CPDN in DM1 was 13.4% and 26.6% in DM2 (p<0.001). Both in DM1 and 
DM2, CPDN had a major, statistically highly significant (p<0.001) negative 
effect on daily activities, mood and well-being, professional activities, domes-
tic and family activities, social relations, sexual activities as well as on sleep 
quality. S100 was 57.6±19.3 with pain and 77.0±16.5 without pain in DM1 
(p<0.001); percentages in DM2 50.9±18.8 and 70.2±18.8 (p<0.001). S100 was 
significantly higher in DM1 than in DM2 in subjects without CPDN whereas 
S100 was comparable between DM1 and DM2 with CPDN.
Conclusion: In conclusion, chronic painful distal neuropathy is a common 
feature in both type 1 and type 2 diabetes, significantly more so in DM2 com-
pared to DM1 and has a major negative influence on all aspects of quality of 
life. Quality of life constitutes a major effect parameter.
Supported by: Pfizer
1120
BMI and nerve dysfunction in diabetic patients
C.N. Manes, T. Exiara, M. Psallas, G. Tsiantas, D. Skoutas; 
Diabetes Center, Teaching Hospital “PAPAGEORGIOU”, Thessaloniki, 
Greece.
Background and aims: Recent epidemiological studies have found a strong 
correlation between diabetic neuropathy and body weight. Furthermore small 
fiber neuropathy tends to develop within a few years of diabetes as relatively 
early complication. Early recognition of potentially modifiable risk factors for 
diabetic neuropathy - a known risk factor for foot ulcers - is crucial if we are 
to succeed in prevention of diabetic foot lesions. The aim of the present study 
was to investigate the relationship between BMI (modifiable risk factor) and 
small and overall nerve fiber dysfunction in diabetic patients.
Materials and methods: 278 consecutive diabetic patients (type 2) were in-
vestigated. Males=147, Mean age (yrs) was 63,31±11,25, Mean duration of 
diabetes (yrs) 12,85±8,56. The Neuropathy Disability Score (sensory signs) 
was used to identify those patients with overall nerve dysfunction (NDS≥3: 
abnormal). The sum of deficits of pain and cold sensation was used to identify 
any impairment of small fiber dysfunction (NDS1≥2: abnormal). BMI was 
calculated as usual (kg/m2). Statistical analysis was performed in a univariate 
and multivariate model (level of significance 0,05).
Results: 1) BMI<25 (NDS1: 0,4±0,3), 25<BMI<29 (NDS1: 0,53±1,05), BMI≥30 
(NDS1: 1,04±1,01). p<0,05 for every comparison between two groups. Cor-
relation between BMI and NDS1 was significant (p: 0,05 r
2:0,026). 2) BMI<25 
(NDS: 0,7±0,8), 25<BMI<29 (NDS: 1,1±0,9), BMI≥30 (NDS: 2,01±2,0). 
p<0,05 for every comparison between two groups. Correlation between BMI 
and NDS was also significant (p: 0,05 r2:0,026). 3) In the multivariate analysis 
BMI and duration of Diabetes were significant factors for overall nerve dys-
function (p<0,05).
Conclusion: The present study shows that nerve fiber dysfunction is also as-
sociated with the body weight e.g. elevated BMI. This finding supports the 
role of other factors (modifiable) apart from the already known in the patho-
genesis and progression of diabetic neuropathy and prevention of foot ulcers. 
Larger studies are needed to confirm this finding.
1121
Association between peripheral nerve function and bone mineral density 
in patients with type 2 diabetes mellitus
W. Wang, Y. Xie, D. Yu; 
Diabetic neuropathy department, Metabolic Disease Hospital of Tianjin 
Medical University, China.
Background and aims: To investigate the association between peripheral 
nerve function and bone mineral density (BMD) in patients with type 2 dia-
betes mellitus(T2DM).
Materials and methods: A total of 169 patients with type 2 diabetes were 
enrolled. All the patients were tested with fasting blood glucose (FBG), post-
prandial 2h blood glucose (P2BG), hemoglobin A1c (HbA1c), triglycerides, 
cholesterol, urinary albumin excretion,serum , serum calcium, serum phos-
phorus, serum magnesium, serum bone alkaline phosphatase isoenzyme . 
Lumbar and hip BMD were measured by dual-energy X-ray absorptiometry 
and according to the T-score ,all the patients were categorized into the os-
teoporosis group (T-score≤-2.5), the osteopenia group(-2.5<T-score≤-1)and 
the control group(-1< T-score≤1). The factor affecting T-score was analyzed 
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too. Nerve function was assessed by 10-g monofilament detection, vibra-
tion threshold, and bilateral sural nerve amplitude(CMAP) and conduction 
velocit(NCV) y, peroneal amplitude and NCV on the dominant side, and me-
dian motor and sensory amplitudes and NCVs on the nondominant side.
Results: Among the female patients, a higher proportion of postmenopausal 
women in osteoporosis group compared with controls(P<0.05). Patients with 
osteoporosis had older age(P<0.05) and longer T2DM duration (P<0.05) than 
control group both in male and female patients .No difference of the param-
eters of laboratory was seen among the groups, while, except the parameter of 
bone metabolism, B-ALP was elevated in osteoporosis group compared with 
controls . monofilament detection, and peroneal NCV) and CMAP were sig-
nificantly lower in Patients with osteoporosis as well as the vibration thresh-
old was significantly higher in them compared with control group. Relative 
analysis showed that the lumbar spine and hip BMD of T2DM group had 
negative correlation with age, duration menopause, severity of diabetic neu-
ropathy and positive correlation of B-ALP . After adjusting for age, diabetic 
course, B-ALP, menopause, poor nerve function (lower nerve conduction 
amplitude and velocity) was associated with lower T-score of both lumbar 
spine and hip BMD significantly.
Conclusion: Lower BMD was associated with poor peripheral nerve function 
(both sensory nerve and motor nerve) in the type 2 diabetes mellitus, diabetic 
neuropathy was an independent risk factors of osteoporosis inT2DM. The 
pathophysiological mechanisms of bone metabolism and diabetic neuropa-
thy should be the concern of further research.
1122
High prevalence of vitamin D deficiency in type 2 diabetic patients with 
neuropathy
S. Skalli1,2, M. Muller1, S. Pradines1, S. Halimi1, N. Wion-Barbot1; 
1Diabetology Department, 2Pharmacy Department, CHU Grenoble, France.
Background and aims: The pro-inflammatory profile (IL-6, TNF-α, IL-
1, IL-8) in monocytes from type 2 diabetic patients is down-regulated by 
1,25(OH)2D3, and levels of acute-phase proteins are significantly associated 
with neuropathic deficits in diabetic patients. Several studies have demon-
strated alterations in vitamin D metabolism in those patients and adverse 
outcomes associated with vitamin D insufficiency have been described in the 
human musculoskeletal, innate immune, and cardiovascular systems. We re-
port a pilot study assessing the relationship between peripheral neuropathy 
in type 2 diabetic patients and vitamin D depletion.
Materials and methods: We conducted a prospective and observational 
study of 111 consecutive type 2 diabetic patients ambulatory treated in Dia-
betology Department between January and April 2009. Subjects were tested 
for deep tendon reflexes at patella, and Achilles, sensory loss using vibra-
tion perception with 128-Hz tuning fork by the on-off method, and pressure 
perception with 10 g Semmes-Weinstein monofilament. Exclusion criteria 
were neuropathy from other etiologies (e.g., familial, alcoholic, nutritional 
and uremic) and vitamin D supplementation. Following data were recorded: 
Age, body mass index (BMI), glycated haemoglobin (HbA1c), duration of 
diabetes, peripheral neuropathy status (PN), intact serum parathyroid hor-
mone (PTH), serum 25-OH vitamin D (25OHD) concentration, total serum 
calcium concentration and serum creatinine.
Results: Overall, 111 patients were evaluated and the majority (55.85%) of 
them had peripheral neuropathy. Patients with PN were significantly older, 
70.58±10.85 vs 57.57±12.27 years respectively (p<0.0001) and had signifi-
cantly longer diabetes duration, 17.61± 9.52 vs 10.21±6.97 years respectively 
(p<0.0001). No significant differences were observed in BMI and HbA1c. Sig-
nificantly decreased 25OHD levels were found in the PN group, 24.6±11.98 
vs 34.74±17,26 nmol/l (p<0.0001). Frank vitamin D deficiency rate (25OHD 
< 50 nmol/l or 20 ng/ml) was significantly higher in PN group, 95% vs 79,5% 
(p<0,05). Vitamin D insufficiency rate (25OHD between 50-75 nmol/l or 20-
30 ng/ml) did not differ significantly between the two groups 5% in the PN 
group vs 16.5%. PTH levels and creatininemia were significantly increased in 
the PN group (p<0.05).
Conclusion: In type 2 diabetic patients, peripheral neuropathy is associated 
with significantly lower levels of 25OHD. Although these data do not prove 
the existence of a causal link between vitamin D deficiency/insufficiency and 
PN, they have major clinical and therapeutic implications for the manage-
ment of PN. Vitamin D-deficient status potentially increases risk of non 
vertebral and hip fracture in this older population with muscle weakness at 
higher risk for falls. Vitamin D deficiency/insufficiency also decreases anti-
bacterial responses in this PN population at higher risk for foot ulcers. On the 
other hand, the importance of the Nerve Growth Factor, which is up-regu-
lated by Vitamin D, has been established in the development of diabetic PN 
using diabetic animal model. Further studies are needed to understand the 
causes and to investigate the clinical significance of vitamin D replacement 
therapy in PN diabetic patients. Determining what is the adequate vitamin D 
level for PN diabetic patients and how much supplementation is necessary is 
now a matter of crucial concern in the management of diabetic PN.
1123
Association between symptoms of neuropathy, nerve conduction and 
levels of heat shock protein 27 in type 2 diabetes
K. Pourhamidi1, L.B. Dahlin2, O. Rolandsson1; 
1Family Medicine, Department of Public Health and Clinical Medicine, 
Umeå University, 2Department of Clinical Sciences Malmö – Hand Surgery, 
Skåne University Hospital, Lund University, Malmö, Sweden.
Background and aims: Increased levels of serum HSP27 (sHSP27) are as-
sociated with distal symmetric polyneuropathy (DSPN) in type 1 diabetic 
patients. However, the association between nerve function and sHSP27 has 
not been studied in subjects with type 2 diabetes (T2D) and impaired glucose 
tolerance (IGT). Thus, our objectives were to investigate the association be-
tween nerve conduction in the legs, symptoms of distal polyneuropathy and 
sHSP27 levels.
Methods: Subjects were consecutively recruited from the population-based 
Västerbotten Intervention Program; controls (n=39, m/f=19/20, mean 
age=61± 0.6 years), IGT (n=29, m/f=15/14, mean age=61± 0.8 years), T2D 
(n=51, m/f=30/21, mean age=61± 1.3 years). Nerve conduction studies were 
performed. Z-scores for motor conduction velocity (CV) of the peroneal 
nerve, and the sensory CV and amplitude of the sural nerve were measured 
and compiled into a composite Z-score of the right leg (Z-score leg). Neuro-
logical Disability Score (NDS), including examination of sensory perception, 
reflexes and muscle strength, were used to evaluate symptoms of neuropathy 
in the leg. NDS and Z-score leg were categorized into tertiles, respectively. 
sHSP27 levels were measured and divided into low and high levels.
Results: Subjects in the highest NDS tertile had lower sHSP27 levels (328 ± 
287 pg/mL) compared to subjects in the lowest NDS tertile (558 ± 404 pg/
mL, p=0.04). Subjects in the lowest tertile of Z-score leg were in the lowest 
sHSP27 group (63%) compared to the subjects in the highest group (38%, 
p=0.034). The highest tertile of Z-score leg was associated with high levels of 
sHSP27 (OR 3.8, 95% CI 1.2; 11.5, p=0.02); adjusted for age and sex. How-
ever, this association was attenuated when adjusted for T2D status (OR 3.1, 
95% CI 0.9; 9.9, p=0.06).
Conclusion: In summary, increased sHSP27 levels were associated with an 
increasing Z-score of the leg; thus, a better nerve conduction, and fewer 
symptoms using the whole study population. The attenuation of the associa-
tion when including diabetic status indicates an altered HSP27 production in 
T2D patients compared to controls and subjects with IGT.
1124
The relationship between brachial-ankle pulse wave velocity and 
peripheral neuropathy in type 2 diabetes
J.Y. Park1, C.W. Lee1, B.H. Kim2, J.Y. Mok2; 
1Internal medicine, Busan St. Mary’s Medical Center, 2Internal medicine, 
Pusan national university school of medicine, Busan, Republic of Korea.
Background and aims: Brachial-ankle pulse wave velocity ( baPWV) has 
been shown to be a good surrogate marker of clinical atherosclerosis. The 
aim of the study was to determine the relationship between baPWV and pe-
ripheral neuropathy in patients with type 2 diabetes.
Materials and methods: We assessed 692 patients with type 2 diabetes (314 
men, 376 women, mean age 56.9 ± 10.9 years, mean diabetes duration 7.9 ± 
6.3 years). The intensity of neuropathic symptoms (pain, burning sensation, 
paresthesia, and numbness) was scored according to numeric visual analog 
scales. The total symptom score was calculated from the sum of each neu-
ropathic symptom scores. The neurological assessment (ankle reflexes and 
10-g monofilament test) was performed. The baPWV was measured using 
an automated device.
Results: In bivariate correlation analysis, the presence of peripheral neuropa-
thy (increased total symptom scores or abnormal neurological assessment) 
was significantly correlated with maximal baPWV ( r =0.127, p < 0.01), age 
( r =0.119, p < 0.01) and sex ( r =0.128, p < 0.01). After analysis using inde-
pendent t- test, the patients with peripheral neuropathy had higher maximal 
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baPWV, systolic blood pressure and subject number of female sex and older 
age compared with control (Table).
Conclusion: Peripheral neuropathy was significantly correlated with baPWV 
in patients with type 2 diabetes.
Comparison of anthropometric characteristics of diabetes with and without 
peripheral neuropathy
Variables DPN(n = 253)
Control
(n = 439) P-value
Age (years) 59 ± 11 56 ± 11 < 0.01
Male (%) 63 ± 5 50 ± 5 < 0.01
Diabetes duration (years) 8.5 ± 7.1 7.6 ± 5.8 NS
Height (m) 1.6 ± 0.1 1.6 ± 0.1 NS
Weight (kg) 64 ± 10 64 ± 10 NS
Systolic BP (mmHg) 139 ± 21 135 ± 17 < 0.01
Diastolc BP (mmHg) 82 ± 12 81 ± 9 NS
PS 109 Neuropathy - experimental
1125
Dyslipidaemia and peripheral prediabetic neuropathy
U.A. Julius1, Y. Maksimchyk2, P. Watcho2, S. Lupachyk2, I.G. Obrosova2; 
1Medizinische Klinik III, Universitätsklinikum Dresden, Germany, 
2Pennington Biomedical Research Center, Louisiana State University 
System, Baton Rouge, USA.
Background and aims: Evidence for the presence of diabetes-like neuropathy 
at prediabetic stage, prior to development of overt hyperglycemia, is emerg-
ing from both experimental and clinical studies. Until now, it has not been 
sorted out whether prediabetic neuropathy results from glucose intolerance, 
or other factors such as impaired insulin signaling, hypertriglyceridemia, 
hypercholesterolemia, and/or increased fatty acid concentrations come into 
play. This study was aimed at evaluating relative roles of the afore-mentioned 
factors in peripheral nerve function in prediabetic condition.
Materials and methods: Experiments were performed in Zucker lean and 
Zucker fa/fa rats, a model of prediabetes and obesity. Zucker fa/fa rats of 16 
wks of age displayed obesity, glucose intolerance, hyperinsulinemia, hyperc-
holesterolemia, and increased serum NEFA concentrations. They developed 
sensory nerve conduction velocity (SNCV) deficit and small sensory nerve 
fiber dysfunction manifest by thermal and mechanical hypoalgesia and tac-
tile allodynia.
Results: In the Zucker fa/fa rats, a 4-wk treatment with the niacin derivative 
acipimox significantly reduced serum insulin (p < 0.01), NEFA (p < 0.05), and 
triglyceride concentrations (p < 0.01) without affecting impaired glucose tol-
erance and total and VLDL-LDL cholesterol concentrations. It also reversed 
SNCV deficit (p < 0.01) and alleviated small sensory fiber neuropathy.
Conclusion: Our findings suggest that impaired insulin signaling, hyper-
triglyceridemia, and/or increased fatty acids, but not impaired glucose toler-
ance or hypercholesterolemia are responsible for development of prediabetic 
neuropathy. The latter provides rationale for new early stage interventions, to 
stop progression of this devastating diabetic complication.
1126
Effects of long-term administration of moderate amounts of insulin on 
small and large peripheral nerve fiber function and structure in non-
diabetic Wistar rats
K. Sugimoto1, K. Kojima1, M. Baba2, M. Yasujima1; 
1Laboratory Medicine, Hirosaki University, 2Neurology, Aomori Prefectural 
Central Hospital, Japan.
Background and aims: Insulin exerts neurotrophic and neuroprotective ef-
fects on peripheral nerves. In animal models of insulin deficient type 1 di-
abetes, trace amounts of insulin can ameliorate small and large peripheral 
nerve fiber dysfunction without influencing the level of glycemia. On the 
other hand, we have reported that chronic hyperinsulinemic hypoglycemia 
caused by insulinoma leads to peripheral nerve microangiopathy and large 
fiber degeneration in non-diabetic rats. Here we aim to investigate the effect 
of chronic treatment with moderate amounts of insulin on small and large 
peripheral nerve fiber function and structure in non-diabetic rats in the ab-
sence of severe hypoglycemia.
Mterials and methods: Sustained-release insulin pellets were subcutane-
ously implanted in 10-wk-old non-diabetic male Wistar rats (Ins-rats; n = 
17) and delivered 2 to 4 IU/day of insulin continuously to these animals for 
14 wks (14Ins-rats; n = 9) or for 30 wks (30Ins-rats; n = 8). Small and large pe-
ripheral nerve fiber function and structure of these animals were investigated 
using behaviorial, histologic and electrophysiological analysis. Age- and sex-
matched untreated Wistar rats served as controls (14C-rats; n = 8 for 14 wks, 
30C-rats; n=8 for 30 wks).
Results: Both 14Ins-rats and 30Ins-rats showed occasional mild to moder-
ate reduction in blood glucose level of no less than 2.4 mmol/l during the 
observation period. Final HbA1c level was decreased by 13% (p < 0.0005) 
in 14Ins-rats and by 7% (p < 0.005) in 30Ins-rats compared with controls. 
Final body weight and serum insulin levels did not differ between 14Ins-rats 
and 14C-rats, whereas final body weight increased by 14% (p < 0.005) and 
serum insulin level increased by 104% (p < 0.05) in 30Ins-rats compared with 
30C-rats. Behavioral analysis revealed unmyelinated nociceptive fiber dys-
function, as indicated by an 11 to 26% increase in tail flick latency to noxious 
heat stimulus (p < 0.05), until 14 wks after insulin treatment in 14Ins-rats 
compared with 14C-rats. We also found a 9 to 21% increase in tail flick la-
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tency (p < 0.05) between 12 and 16 wks after insulin treatment in 30Ins-rats 
compared with 30C-rats. Final intraepidermal nerve fiber (unmyelinated) 
density was marginally decreased (p = 0.057) in 14Ins-rats compared with 
14C-rats (mean ± SE; 47.7 ± 4.5/mm vs 60.0 ± 3.8/mm) and was unchanged 
in 30Ins-rats compared with 30C-rats (40.4 ± 6.7/mm vs 40.1 ± 4.7/mm). In 
contrast, final electrophysiological analysis of the sciatic-tibial nerve showed 
unchanged sensory (SNCV) and motor nerve conduction velocities (MNCV) 
in 14Ins-rats compared with 14C-rats, while SNCV increased by 10% (p < 
0.05) and MNCV by 11% (p < 0.01) in 30Ins-rats compared with 30C-rats. 
The increased nerve conduction was associated with a 12% increase (p < 0.05) 
in myelinated fiber density in the tibial nerve in 30Ins-rats compared with 
30C-rats.
Conclusion: Treatment of non-diabetic rats with moderate amounts of insu-
lin, without causing severe hypoglycemia, appeared to induce transient un-
myelinated (small) fiber dysfunction and loss for periods up to 16 wks, and 
led to increased myelinated (large) fiber function and density for the more 
extended period of 30 wks. These functional and structural changes in small 
and large peripheral nerve fibers merit further investigation to elucidate the 
mechanism whereby insulin exerts its effects on peripheral nerves.
1127
The comparison of peripheral nerve damage according to the glucose 
control period in the experimental diabetes
J. Heung Yong, K.A. Lee, J.H. Park, T. Park, H. Baek; 
Chonbuk National University, JeonJu, Republic of Korea.
Background and aims: Besides just tight glucose control, early intensive 
therapy has been reported to be more important for the prevention of dia-
betic micro-and macro-complication. However, it was not known exactly 
about the quantitative difference according to the timing delay in the glucose 
control and whether early period control is really better than late control in 
the diabetic peripheral neuropathy. Therefore, in this study we investigated 
the effect of timing difference in glucose control on the peripheral nerves in 
the course of diabetes.
Materials and methods: The five groups (6-8 number in each group) com-
prised : Normal glucose rats (Normal), rats with hyperglycemia (designated: 
DM), rats with glucose control for entire 28-week period (designated: INS 
(W0-28)), rats with glucose control for early 14-week period followed by 
hyperglycemia for late 14 weeks (designated: INS (W0-14)), and rats with 
hyperglycemia for early 14 weeks followed by glucose control for late 14-week 
period (designated: INS (W15-28)).
Results: In the results, the current perception threshold (CPT) was more re-
duced in INS (W0-28) and INS (W15-28) group compared with INS (W0-14) 
or DM group (P<0.05). Mean myelinated axon area was larger significantly in 
INS (W0-28) and INS (W15-28) group (63.5±2.32 and 60.1±2.14 um) than 
INS (W0-14) or DM group (55.5± 2.81 or 51.5± 2.64 um) (P<0.05) and in-
traepidermal nerve fibers (IENF) density was less reduced significantly INS 
(W0-28) and INS (W15-28) group (6.9±0.46 and 6.8±0.11) than INS (W0-
14) or DM group (5.9.5± 0.32 or 5.3± 0.39) (P<0.05). More increased trend 
of nerve fiber quantity was also observed in INS (W0-28) group than INS 
(W15-28) group although there was no significant difference.
Conclusion: Our results indicate that continuous glucose control is neces-
sarily important to alleviate the peripheral nerve damage and moreover poor 
glycemic control during the later period prone to aggravate the neuropathy 
is more harmful than inappropriate early period management. Therefore, 
besides earlier management, the importance of continuous glucose control 
including later period of diabetes should also be emphasized in the diabetic 
peripheral neuropathy.
1128
Amelioration of diabetic enteropathy in chronic experimental diabetic 
rats transplanted with autologous adipose-tissue-derived mesenchymal 
stem cells
H. Mizukami1, K. Takahashi1, K. Sugimoto2, M. Baba3, S. Yagihashi1; 
1Department of Pathology and Molecular Medicine, Hirosaki University 
Graduate School of Medicine, 2Department of Laboratory Medicine, 
Hirosaki University Graduate School of Medicine, 3Department of 
Neurology, Aomori Prefectural Central Hospital, Japan.
Background and aims: Gastroenteropathy is a serious complication of diabe-
tes and impairs quality of life, leading to bleak prognosis in diabetic patients. 
There is no effective treatment for this serious disorder. Cell therapy using 
adipose-tissue derived mesenchymal stem cells (ADSC) is now a promising 
approach for the reparative therapy and we applied ADSC to enteropathy in 
chronic diabetic rats.
Materials and methods: Streptozotocin-induced diabetic rats with 16 wk-
duration were transplanted with autologous ADSC (x106), retrieved from 
subcutaneous region prior to diabetes onset, into the serosa of terminal ile-
um. After 6 wk observation period, thickness of mucosal villi, mRNA expres-
sions of various growth factors and neuronal nitric oxide synthase (nNOS) as 
well as choline acetyltransferase (CHAT), and neuropathology of intestinal 
walls were examined in transplanted diabetic rats and compared with those 
in untreated diabetic rats and non-diabetic control animals.
Results: Mucosal villi in the intestine were thickened in diabetic rats and 
ADSC transplantation (Tx) nearly normalized the thickness of the mocosal 
wall. Neuronal distribution as demonstrated by PGP9.5 staining disclosed 
significant reduction of myenteric neuronal area and intramural axonal fibers 
in diabetic rats and these changes were improved by ADSC-Tx. Consistent 
with PGP9.5 staining, tissue contents of PGP9.5 were reduced in diabetic rats 
and corrected by Tx. Similarly, expressions of both PKB/Akt and pAkt were 
suppressed in the intestinal tissues of diabetic rats and corrected by Tx. There 
were also reduced mRNA expressions of fibroblast growth factor (FGF), vas-
cular endothelial growth factor (VEGF), insulin-like growth factor (IGF)-I, 
nNOS and CHAT in the intestine of diabetic rats, and Tx all upregulated the 
expressions. There was no significant influence of Tx on the mRNA expres-
sions of these factors in normal control rats. The microscopy of transplanted 
sites revealed increased microvessels and sparse infiltration of inflammatory 
cells in diabetic and normal control animals.
Conclusion: The results demonstrated that topical application of autologous 
ADSC into the gut wall improved diabetic enteropathy in rats, warranting the 
future clinical application of ADSC transplantation for hitherto untreatable 
condition of diabetic enteropathy.
1129
Oxidative stress damage at pain control serotoninergic and 
noradrenergic brainstem centres during diabetic neuropathy
C.S.C. Morgado1,2, P. Pereira-Terra1,2, M. Martins-Oliveira1,2, F. Neto1,2,  
I. Tavares1,2; 
1Institute of Histology and Embryology, Faculty of Medicine of Oporto, 
2IBMC, Porto, Portugal.
Background and aim: Painful diabetic neuropathy was recently shown to 
be due to central mechanisms, both in humans and animals. Loss of serot-
oninergic and noradrenergic neurons at brainstem pain control centres was 
shown to occur in streptozotocin-diabetic rats (STZ-rats). This impairment 
in descending modulation may account for spinal hyperactivity and exacer-
bated pain behavioural responses. Oxidative stress is common in diabetes, 
affecting peripheral sensory system and central areas involved in cognition 
and memory. Here, we evaluated the occurrence of oxidative stress damage 
at serotoninergic and noradrenergic brainstem areas directly involved in de-
scending pain modulation.
Materials and methods: Male Wistar rats were injected with streptozotocin 
(60 mg/kg) or saline and were sacrificed at 10 weeks post-injection. Brainstem 
sections were immunoreacted for thryptophan hydroxylase (TpH) and tyrosine 
hydroxylase (TH) to detect serotoninergic and noradrenergic neurons, respec-
tively; and for 8-hydroxy-2’-deoxuguanosine (8-OH-dG), the marker of oxida-
tive DNA damage. Rostroventrolateral medulla (RVM) was analysed for TpH 
immunoreactivity. The A5, A6 and A7 noradrenergic cell groups were studied 
for TH expression. Another set of sections was analysed for 8-OH-dG expres-
sion in the above mentioned serotoninergic and noradrenergic areas. Data were 
compared by independent sample t test and presented as mean±SEM.
Results: STZ-rats presented marked hyperglycaemia and behavioural signs 
of painful diabetic neuropathy (mechanical hyperalgesia and tactile allodynia 
evaluated by the Randall-Selitto and von Frey tests, respectively). Significant-
ly lower numbers of TpH labelled neurons were detected at RVM of STZ-rats 
(STZ: 4.9±1.71; Saline: 15.8±4.17). Regarding the noradrenergic cell groups, 
significant low numbers of TH immunoreactive neurons were detected at the 
A5 (STZ: 9.8±0.73; Saline: 13.9±1.34) with a tendency for reduction in A7 
cell group (STZ: 15.6±3.49; Saline: 21.6±2.17). No difference was detected at 
the A6 noradrenergic cell group. Oxidative stress damage was significantly 
higher in RVM (STZ: 11.2±2.60; Saline: 1.6±0.80), A5 (STZ: 18.0±5.22; Sa-
line: 4.9±1.49) and A7 (STZ: 10.1±2.49; Saline: 2.3±0.59) noradrenergic cell 
groups in STZ-rats. In the A6 noradrenergic cell group, oxidative damage was 
similar in both groups.
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Conclusion: The association between decreases in the numbers of serot-
oninergic and noradrenergic neurons and oxidative stress damage suggests 
that this may be a leading mechanism in the impairment of inhibitory de-
scending pain modulation in STZ rats. It is likely that a reversal of oxidative 
stress damage at the brainstem should prevent the observed neuronal losses. 
This study shows the importance of increasing the intake of antioxidants in 
diabetic patients in order to control neuronal dysfunction and pain during 
diabetic neuropathy.
Supported by: FCT project – PTDC/SAU/64643/2006
1130
Role for endoplasmic reticulum stress in prediabetic and diabetic 
neuropathy
I.G. Obrosova, P. Watcho, Y. Maksimchyk, H. Shevalye, R. Stavniichuk,  
S. Lupachyk; 
Mechanisms of Diabetes Complications, Pennington Biomedical Research 
Center, Baton Rouge, USA.
Background and aims: Endoplasmic reticulum (ER) stress caused by ac-
cumulation of unfolded proteins in the ER lumen, contributes to beta-cell 
loss, insulin resistance, and plays an important role in the pathogenesis of 
both Type 1 and Type 2 diabetes. Taking into consideration that ER stress is 
associated with impaired cell signaling and oxidative damage, we evaluated 
the role of this phenomenon in the pathogenesis of prediabetic and diabetic 
peripheral neuropathies.
Materials and methods: The experiments have been performed in 1) Zucker 
lean and Zucker fa/fa rats, a model of obesity and Type 2 prediabetes, and 
2) control and streptozotocin (STZ)-diabetic rats, a model of Type 1 diabe-
tes. Peripheral neuropathy endpoints included sciatic motor nerve conduc-
tion velocity (MNCV), hind-limb digital sensory nerve conduction velocity 
(SNCV), thermal algesia (paw withdrawal latency), tactile allodynia (tactile 
response thresholds), and intraepidermal nerve fiber density (fluorescent im-
munohistochemistry). ER was evaluated by expression of BiP/GRP78 and 
GRP94 in the sciatic nerve (Western blot analysis).
Results: Both 16-wk-old Zucker fa/fa rats and STZ-diabetic rats with 12-wk 
duration of diabetes displayed ER stress response manifest by overexpres-
sion of BiP/GRP78 and GRP94 in the peripheral nerve. They also had nerve 
conduction velocity slowing and small sensory nerve fiber dysfunction. STZ-
diabetic rats displayed reduced intraepidermal nerve fiber density. Treatment 
with the chemical chaperone trimethylamine N-oxide (TMAO), 1 mmol kg-
1d-1 in the drinking water, for 4 wks, reversed SNCV deficit and alleviated 
thermal hypoalgesia and tactile allodynia in Zucker fa/fa rats. The same treat-
ment also prevented SNCV deficit and partially prevented MNCV deficit and 
small sensory nerve fiber dysfunction and degeneration in STZ-diabetic rats. 
In both studies, TMAO did not affect blood glucose concentrations.
Conclusion: ER stress is implicated in the pathogenesis of prediabetic and 
diabetic peripheral neuropathies. Studies of biochemical mechanisms of ER 
stress-induced peripheral nerve damage are in progress.
PS 110 Autonomic neuropathy - 
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The reproducibility of cardiovascular reflex tests is not influenced by 
actual glucose values in young type 1 diabetic patients
T.T. Várkonyi1, V. Szidor1, A. Szász1, R. Laurentzi1, É. Börcsök1, C. Lengyel1, 
T. Nyári2, P. Kempler3, T. Wittmann1; 
11st Department of Medicine, University of Szeged, 2Department of 
Medical Informatics, University of Szeged, 31st Department of Medicine, 
Semmelweis University, Budapest, Hungary.
Background and aims: The reproducibility of cardiovascular reflex tests 
(CRT) is well-documented, but the possible role of the current glucose levels 
on the heart rate and blood pressure responses in diabetic patients is un-
known. The aim of our study was to analyse the CRT-s as well as continuously 
measured glucose values during the tests on three consecutive days in young 
patients with short-standing type 1 diabetes (DM).
Materials and methods: 10 young type 1 DM patients were included into 
the study (duration of DM: 8.2±6.7 yrs, age: 23.3±0.7 yrs, HbA1c: 8.8±0.6%; 
mean±SE). The five conventional Ewing CRT-s were performed on three 
consecutive days. During the tests the current glucose values were detected 
by continuous subcutaneous glucose measuring system (CGMS; Medtronic 
Ltd). One-way ANOVA test was applied for the statistical evaluation.
Results: The CRT results did not differ significantly between the days (mean 
values of the days: Valsalva ratio: 1.57-1.54-1.67; heart rate response to deep 
breathing: 26.4-22-25.7 beats/min; 30/15 ratio: 0.96-0.99-0.96; diastolic blood 
pressure response to handgrip: 24.8-19.8-23.9 mm Hg; orthostatic systolic 
blood pressure response: 7.7-8.9-6.3 mm Hg; AN scores: 2.7-2.4-2.5, p>0.05 
for all tests). The subcutaneous current glucose levels did not show any statis-
tical association with the daily results of the CRT-s. The fluctuation of glucose 
was not significant during the three days (mean glucose levels of the days: 
7.2-9.6-5.7 mmol/l; p>0.05).
Conclusion: Our results confirm the high reproducibility of the cardiovas-
cular reflexes in young type 1 diabetic patients. Data suggest that the short-
term variability of cardiovascular responses is not influenced by the actual 
glucose levels. Our observations might indirectly support the importance of 
long-term glycemic exposure on the cardiovascular autonomic function in 
type 1 diabetes.
1132
Gastric neurostimulation significantly relieves symptoms of severe 
diabetic gastroparesis and reduces frequency of hospital contacts
P. Rask1, P.F. Jensen1, N. Ejskjaer2; 
1Department of Surgery, 2Department of Endocrinology MEA, Aarhus 
University Hospital, Aarhus, Denmark.
Background: In its most unremitting form diabetic gastroparesis may 
present with continous nausea and vomiting leading to hospitalisation for 
fluid substitution and blood glucose control. Fortunately the condition is of-
ten more limited, although frequently resistant to standard pharmacological 
and symptomatic treatment.It is, however, commonly accepted that diabetic 
gastroparesis, symptomatic or asymptomatic, may severely impact blood glu-
cose control and hamper the eficiency of pharmacotherapy.
Method: Selected Type 1 diabetes patients suffering severe symptoms of dia-
betic gastroparesis underwent extensive clinical examination to exclude other 
causes of dyspepsia. All were before and after implantation of a high-frequen-
cy low-intensity gastric neurostimulator subjected to detailed clinical studies 
including scintigraphic gastric emptying studies, cardiac autonomic function 
tests, gastroscopies, visceral-biomechanical studies, 24h-antroduodenal mo-
tility testing and qualitative symptomatic testing using a validated question-
naire. Patients: Fifteen patients, 7 male and 8 female, all Type 1 diabetes, all 
long duration of diabetes, all presenting with an array of late diabetic com-
plications and attending the out-patient clinic at Department of Endocrinol-
ogy MEA, Aarhus University Hospital. All had suffered symptoms of diabetic 
gastroparesis for several years resistant to standard treatment measures and 
all attempts of pharmacotherapy. All were frequently admitted to hospital for 
this condition. A proportion of the patients had been considered to be candi-
dates for irreversible gastrointestinal surgery.
Results: Fifteen patients have been relieved to varying degrees of their symp-
toms of diabetic gastroparesis. Two male patients and three female patients 
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are completely relieved of nausea and vomiting. Several patients demonstrate 
halving of admission frequency and are predominantly admitted for treat-
ment of competing diabetic late complications. Some have not been admitted 
to hospital after implantation of the gastric neurostimulator, whereas they 
were frequently so before. Some have returned to full-time work. We were 
not able to demonstrate improvements in glycaemic control in this small co-
horte.
Conclusion: We conclude that the patients selected and included in our study 
were significantly relieved of severe symptoms of diabetic gastroparesis and 
the frequency of hospital contacts overall were reduced.
1133
The association between diabetic autonomic neuropathy and 
microalbuminuria
E.S. Kim, S. Beom, S.A. Kim, W. Shim, E.H. Lee, J. Yoo, J. Nam, M. Cho,  
J.S. Park, C. Ahn, B. Cha, E.J. Lee, S. Lim, K.R. Kim, H.C. Lee; 
Division of Endocrinology, Department for Internal Medicine, Yonsei 
University College of Medicine, Seoul, Republic of Korea.
Background and aims: Diabetic autonomic neuropathy (DAN) has a nega-
tive impact on quality of life and survival in patients with type 2 diabetes 
(T2DM). However, as most of affected patients remain asymptomatic for 
a long period, it is frequently overlooked. As microvascular diseases share 
pathogenesis mainly originated from chronic hyperglycemia, microalbumiu-
ria which is annually measured in patients with T2DM might be associated 
with DAN. We performed this study to investigate whether urinary albumin 
excretion (UAE) could predict diabetic autonomic neuropathy (DAN).
Materials and methods: We retrospectively reviewed records of patients with 
type 2 diabetes (n=953) who had received annual diabetes-related compli-
cation screening between January 2007 and June 2009. Tests for autonomic 
functions (AFT) measured heart rate variability during breathing, Valsalva 
maneuver, 30:15 ratio, blood pressure (BP) response to standing and hand-
grip. The results of each test were scored as 0 for normal and 1 for abnormal 
and assessed total score considering positive DAN larger than 2. Urinary al-
bumin excretion (UAE) was calculated in spot urine estimating ratio of uri-
nary albumin (mg) dividing urinary creatinine (g).
Results: The prevalence of DAN was 42.1% (n=401). Subjects with DAN had 
less prevalent of male and significantly higher age, longer diabetes duration 
and increased CAVI and IMT. On the contrary there was no difference in 
glycemic control status (FBS, HbA1C), hypertension, lipid profiles. Urinary 
albumin excretion was linearly increased according to AFT score [0 (n=176), 
1 (n=221), 2 (n=194), 3 (n=79), 4 (n=31), 5 (n=3); UAE 36.1 ± 66.5, 49.7 ± 
113.8, 68.3 ± 138.8, 89.9 ± 149.7, 89.8 ± 149.6, 146.1 ±224.2, 403.1 ± 386.0 
mg/g, P for trend <0.001]. In the multivariate logistic analysis, UAE was 
significantly associated with DAN [odds ratio (OR) 1.002; 95% confidence 
interval (CI) 1.001-1003, besides age, female sex, duration, smoking status, 
previous CAD.
Conclusion: Elevated urinary albumin excretion was significantly associated 
with AFT score and a predictor for DAN in patient with T2DM. This result 
suggests that annual exam of UAE could additionally give information to dis-
criminate high risk patients in DAN in addition of diabetic nephropathy.
1134
Effect of adjuvant influenza vaccine on systemic inflammation and 
cardiac autonomic function in patients with type 2 diabetes
G.A. Lanza1, D. Pitocco2, F. Zaccardi2, L. Barone1, F. Crea1, G. Ghirlanda2; 
1Cardiology, 2Internal Medicine, Catholic University, Rome, Italy.
Background and aims: Both inflammation and impaired cardiac autonomic 
function are known to increase the risk of coronary events. Recent data points 
out a pathogenetic link between nervous autonomic system (ANS) and in-
flammation, but the exact terms of this relation in the clinical are still poorly 
defined. In this study we assessed the effect on cardiac autonomic function of 
the administration of an inflammatory stimulus, represented by influenza A 
vaccine. The effect on platelet reactivity was also assessed to better define the 
cardiovascular risk profile consequent to the inflammatory stimulus.
Materials and methods: A 24-hour electrocardiogram Holter recording was 
performed both at baseline and after 24 hours from adjuvant influenza A vac-
cine in 30 patients with type II diabetes mellitus (age 62±8 years, 19 men). 
C-reactive protein (CRP) and interleukin-6 serum levels were measured, and 
monocytes platelets aggregates (MPA) were assessed before and 48 hours af-
ter vaccination.
Results: Following vaccination, inflammatory cytokines, MPAs and mono-
cyte-platelet receptor expression increased (e.g., CRP: 2.6±2.8 vs. 7.1±5.7 
mg/L; p<0.0001), whereas HRV decreased (e.g., very low frequency [VLF] 
amplitude: 34.6±11.8 vs. 31.0±10.2 ms; p=0.002). The changes in CRP cor-
related with those of most HRV variables, but greater CRP increases were 
associated with lower HRV reductions; the most significant correlation was 
between changes in CRP and in SDNN(r=0.43; p=0.02) and VLF amplitude 
(r=0.39; p=0.03). MPA changes did not correlate with changes in CRP levels 
or in HRV variables.
Conclusion: In this study we show that exposition to an attenuated infec-
tious stimulus induces, together with the expected inflammatory reaction, a 
relative increase of adrenergic tone in the sympatho-vagal balance of cardiac 
autonomic function. However, enhanced inflammatory reaction seemed to 
cause a vagal activation which limited the impairment of HRV and was likely 
finalized to antagonize the inflammatory related tissue damage. Influenza 
vaccination in our type 2 diabetic patients also induced increased monocyte 
and platelet activation that might transiently increase the risk of acute cardio-
vascular events after the treatment.
1135
Erectile dysfunction, androgen deficiency and chronic complications in 
male diabetic patients
O. Georgescu, M. Ursache, C. Barbu, S. Fica; 
Endocrinology, Diabetes and Nutrition, Elias Emergency Hospital, 
Bucharest, Romania.
Background and aims: Erectile disfunction (ED) can be present in male dia-
betic patients not only induced by androgen deficiency, but also as a conse-
quence of chronic complications.
The aim of our study was to evaluate the corelation between ED, sex-hor-
monal status and chronic complications in patients with diabetes mellitus 
(DM).
Materials and methods: 292 patients (44 T1DM/ 248 T2DM) aged between 
20-75 years (mean 52.06±3.7 years) were evaluated by sex-hormonal status ( 
DHEA , free testosterone) and by presence of chronic micro- and macrovas-
cular angiopathy. ED was diagnosed by a score under 22 of the 5-item IIEF 
questionnaire. All patients with free-testosterone under 70 pg/ml were con-
sidered hypogonadic.
Results: The prevalence of ED was 84.24% in whole study group ( higher in 
T2DM 87.5%, than in T1DM 65.9%). In patients with ED the prevalence of 
hypogonadism was 31.57% in T1DM and 26.73% in T2DM. From hypog-
onadic T2DM subjects 93.9% have ED, while in hypogonadic T1DM only 
66.6% have ED (p=0.04). In older man with T2DM (over 60 years) IIEF-score 
was significant corelated with DHEA value r=0.57, p=0.008. We did not found 
any corelation between ED and macrovascular diseases. There was a signifi-
cant corelation between ED and retinopathy( r=0.37, p=0.003) in T1DM and 
also with neuropathy ( r=0.42, p=0.04) in T2DM.
Conclusion: ED is frequent in diabetic patients more associated with micro-
vascular complications. Hypogonadic status can explain 30% of ED. In older 
diabetic men the severity of ED is related to low DHEA-value.
1136
Erectile dysfunction in diabetics and non-diabetics due to macrovascular 
lesions
A.Z. Akbarov, G.N. Rakhimova; 
Diabetology, Centre for the Scientific and Clinical Study of Endocrinology, 
Tashkent, Uzbekistan.
Background and aims: To study incidence of erectile dysfunction (ED) in 
the diabetics and non-diabetics by macrovascular lesions.
Materials and methods: We examined 601 male patients with type 1 and 
type 2 diabetes mellitus and 413 non-diabetic persons aged from 20 to 70 
in both groups. The examinees were differentiated by presence of ischaemic 
heart disease (IHD), myocardial infarction, cerebral circulation disturbance 
and stroke as per medical history, clinical-laboratory investigations and in-
strumental data. They were inquired with the International Erectile Function 
Index questionnaire.
Results: ED incidence in the diabetics with IHD (85.4+2.65%) was 18.7% 
higher (P<0.001) than in the diabetics without macrovascular lesions 
(66.7+2.5%). Similar tendency in ED incidence was observed in the non-dia-
betics, thus in persons with IHD but without DM the incidence (79.2+8.29%) 
was 45.3% higher (P<0.001) than in the non-diabetics and macrovascular 
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lesions (33.9+2.44%). Comparison of ED incidence in groups of the non-
diabetics without macrovascular lesions with ED incidence in the group of 
the diabetics without macrovascular lesions (66.7+2.5%) showed that it was 
32.8% higher (P<0.001) than in the non-diabetics without macrovascular le-
sions (33.9+2.44%). ED incidence in the diabetics with myocardial infarction 
(85.0+5.6%) was 18.3% higher (P<0.001) than in the diabetics without mac-
rovascular lesions (66.7+2.5%). Similar tendency was observed in the non-
diabetics with and without myocardial infarction. Thus, in 3 of 3 non-diabet-
ics with IHD (100+0%) ED of moderate severity was found in one person, the 
most severe one being registered in two, while in the non-diabetics without 
IHD the parameter was 33.9+2.44% (P<0.001). ED incidence in the diabetics 
with cerebral circulation disturbances was 83.3+7.6%. It is 16.6% lower than 
the parameter in the non-diabetics. The highest ED incidence could be seen 
in the diabetics after the stroke (100%). In the group of the non-diabetics 
without macrovascular lesions the stroke was registered in one patient with 
ED of intermediate severity.As a whole in both diabetics and non-diabetics 
with macrovascular lesions higher ED incidence can be observed than in pa-
tients without the lesions. Thus, in the diabetics and non-diabetics without 
the lesions ED incidence was 66.7+2.5% and 33.9+2.44% respectively. At the 
same time in the diabetics and non-diabetics with the macrovascular lesions 
ED incidence was found 85.9+2.1% and 84.2+5.9%, respectively.
Conclusion: Thus, in patients with macrovascular lesions (IHD, myocardial 
infarction, cerebral circulation disturbance and stroke) regardless of DM 
presence ED incidence is higher than in persons without the lesions in ques-
tion.
1137
Sexual dysfunction in pre-menopausal normal and diabetic women; 
clinical, psychologic, cardiovascular, and neurophysiological correlates
A.E. Pontiroli1,2, D. Cortelazzi1, C. Mauri1, A. Marconi1, M. Guazzi1,  
M. Cristina2, B. Zecchini2, C. Cattalini2, A. Innocenti1, G. Bosco1; 
1Dipartimento di Medicina, Chirurgia e Odontoiatria, Università degli studi 
di Milano, 2Ospedale San Paolo, Milano, Italy.
Background and aims: Female Sexual Dysfunction (FSD) is frequent in 
women with diabetes mellitus or metabolic syndrome. Aim of this study was 
to analyze clinical, cardiovascular, and neurophysiological correlates of FSD.
Materials and methods: We evaluated 66 pre-menopausal women, 42 healthy 
and 24 with diabetes (8 T1DM, 16 T2DM, duration 9.6±1.91 y, with no clini-
cal micro-, macro-angiopathic, or neurologic complications), through ad-
ministration of Female Sexual Function Index questionnaire (FSFI). In all 
women we studied: physical activity, smoking habits, parity, weight, BMI, 
waist circumference (WC), Beck Depression Inventory (BDI), Diabetic So-
matic Neuropathy Score (DSN), endothelial-mediated blood flow, ECG (for 
heart rate and Qtc, indexes of sympathetic activity), intima-media thickness 
(IMT), insulin, fasting glucose, HOMA-IR index, fibrinogen, cholesterol (to-
tal, HDL-, LDL-), triglycerides, HbA1c, HS-PCR, electromyography (ampli-
tude and conduction of peroneal, posterior tibial, and sural nerves).
Results: Diabetic women differed from healthy women for BDI, fasting 
glucose, triglycerides, HbA1c, nerve conduction (p<0.05 to p<0.001), and 
at FSFI for orgasm (p<0.05). In healthy and diabetic women considered to-
gether, FSFI score was directly correlated with physical activity (r = .266), and 
with peroneal nerve amplitude (r = .289), and inversely with parity (r = .298), 
BDI (r = .483), SDN (r = .439), IMT (r = .329), (p<0.05 to p<0.01).
Conclusion: These data indicate that: 1) FSFI is reduced in reasonably healthy 
diabetic women even in the absence of complications; 2) FSFI correlates with 
psychologic, neurophysiologic, and cardiovascular parameters. Longer ob-
servation periods are required to evaluate FSFI as a possible risk factor for 
cardiovascular events.
PS 111 Autonomic neuropathy - 
blood pressure and heart
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Heart rate variability during the night is related to hyperglycaemia in 
patients with type 2 diabetes
K. Makrilakis1, S. Liatis1, P. Thomakos1, S. Kalopita1, I. Vlahodimitris2,  
N. Katsilambros1; 
1First Department of Propaedeutic Medicine, Athens University Medical 
School, 2Department of Cardiology, Laiko General Hospital, Athens, Greece.
Background and aims: Heart rate variability (HRV) represents a non-inva-
sive technique that allows a detailed study of the cardiac autonomic nerv-
ous system, by assessing the spontaneous fluctuations of heart rate. HRV is 
reduced in patients with diabetes and is considered a risk factor for cardio-
vascular mortality. Aim of the present study was to assess the relationship 
between glycaemia (measured by continuous glucose monitoring subcutane-
ously [CGMS]) and HRV (measured by continuous ECG monitoring) simul-
taneously in patients with Type 2 diabetes (T2D).
Materials and methods: A total of 31 (20 males) T2D patients (mean age 
[±SD] 56.2±9.9 years, diabetes duration 5.5±4.2 years), treated with oral 
antidiabetic agents, underwent ECG recording and CGMS, simultaneously 
and continuously, for 48 hours. HRV was calculated by frequency and time 
domain analysis. A separate analysis was performed regarding HRV during 
the day and night period (11.00 pm to 08.00 am). CGMS was performed by a 
needle electrode placed subcutaneously in the abdomen, acquiring data every 
5 min (288 measurements/day), with a microdialysis system.
Results: There was no correlation between HRV and HbA1c or 48-h mean 
plasma glucose. Weak negative correlations were found between HRV in-
dices and hyperglycemia, expressed as the area under the curve (AUC) of 
glucose values above 180 mg/dl (AUCG180). Strong negative correlations were 
observed, however, between HRV indices during the night period and 48-h 
AUCG180. No such correlations were observed during the day time (Table). 
HRV, in both frequency and time domain analysis, was significantly high-
er during the night period than during the day (P values for all indices < 
0.001).
Conclusion: HRV during the night period is negatively correlated with 48-
h hyperglycemia, while no such association is observed during the day. It 
may be hypothesized that this finding reflects a relation between HRV and 
hyperglycemia, being unmasked during sleep, when HRV is not affected by 
day-time activities.
Linear regression of indices of HRV during night and AUCG180 (adjusted 
for duration of diabetes)
Indices of HRV β-coefficient β-coefficient P P
A. Time domain analysis Day Night Day Night
Percent of differences between normal-to-
normal RR intervals >30 ms (PNN-30) -0.19 -0.40 0.30 0.03
Percent of differences between normal-to-
normal RR intervals >50 ms (PNN-50) 0.03 -0.48 0.97 <0.01
Root mean square of successive normal-
to-normal RR interval difference in ms 
(RMSSD)
-0.05 -0.36 0.80 0.052
B. Frequency domain analysis
Total power of HRV (TP) -0.1 -0.38 0.87 0.03
High-frequency domain of HRV (HF) -0.25 -0.38 0.18 0.051
Low-frequency domain of HRV (LF) 0.10 -0.20 0.61 0.29
1139
Heavy smoking blunts the circadian rhythm of heart rate variability in 
patients with type 2 diabetes
S. Liatis1, K. Makrilakis1, P. Thomakos1, S. Kalopita1, I. Vlahodimitris2, N. 
Katsilambros1; 
1First Department of Propaedeutic Medicine, Athens University Medical 
School, 2Department of Cardiology, Laiko General Hospital, Athens, Greece.
.
Background and aims: Autonomic nervous system control of the cardiovas-
cular system has a distinct circadian rhythm and this may be an important 
mechanism underlying the diurnal distribution of cardiac events. Heart rate 
variability (HRV) represents a non-invasive technique that allows a detailed 
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study of the cardiac autonomic nervous system, by assessing the spontane-
ous fluctuations of heart rate. HRV is reduced in patients with T2D, while 
it is known that smoking also decreases HRV. Aim of the present study was 
to assess the effect of smoking on circadian rhythm of HRV in patients with 
Type 2 diabetes (T2D).
Materials and methods: Sixty three consecutive non-smokers and 35 con-
secutive smokers, attending the diabetes outpatient clinic of a University 
Hospital, treated with oral antidiabetic agents, underwent continuous ECG 
monitoring for 24 hours. HRV was calculated by frequency and time domain 
analysis. A separate analysis was performed regarding HRV during the day 
and night period. Smokers were further divided into heavy smokers (n=29), 
defined as being exposed to ≥10 pack-years (py), and light smokers, being 
exposed to <10 py.
Results: Smokers were younger (mean age: 54.4±9.6, vs. 61.5±8.8 years, 
P<0.01) and had a shorter duration of diabetes (median duration: 4 vs. 7 
years: P=0.054). Smokers had higher HRV indices than non-smokers, al-
though statistical significance was attained only for high and low-frequency 
domain analysis during the day. Both smokers and non-smokers had higher 
HRV during the night (all P values <0.05). Heavy smokers, however, showed 
a statistically significant increase in HRV during the night period only for 
some domains of HRV analysis (high-frequency domain (HF), low frequency 
domain (LF) and percentage of differences between normal-to-normal RR 
intervals >30 ms [PNN-30]). In one-way repeated-measures ANOVA, heavy 
smoking was associated with a blunted increase of HRV during the night 
(Figure). This finding was consistent for all indices of HRV, both in frequency 
and time domain analysis.
Conclusion: Smoking >10 pack-years blunts the circadian rhythm of HRV in 
patients with T2D. This effect may be implicated in the increased cardiovas-
cular risk of this population. 
1140
Autonomic neuropathy as the cause of the QTc dispersion in diabetes 
type 2
J. Tatoń1, M. Bernas1, Z. Szczeklik-Kumala1, M. Chmielewski2; 
1Department of Internal Diseases and Diabetology, 2Department of 
Cardiology, Medical University of Warsaw, Poland.
Background and aims: The increase of the QTc dispersion reflects the electri-
cal instability of the diabetic heart. It is an important risk factor of sudden 
death caused by ventricular fibrillation. It occurs in persons with diabetes 
mellitus more frequently than in the general population. A closer determina-
tion of the pathogenetic factors involved in QTc dispersion should improve 
the preventive measures.
Materials and methods: For the study, a) a general cohort of 185 males 
with diabetes mellitus type 2 without symptoms of ischemic heart disease, 
aged 57.6±7.1 years, and b) 52 persons without diabetes mellitus and with-
out symptoms of ischemic heart disease - males, aged 58.8±7.2 years - were 
qualified. The following investigations were conducted on those under study: 
standard clinical examination, indices of metabolic compensation of diabe-
tes mellitus (daily glycaemia profiles, HbA1c, lipid profile), serum potassium, 
natrium calcium and magnesium levels, resting ECG, exercise test according 
to Bruce protocol and the battery of tests for the autonomic innervation of the 
heart according to Clarke protocol. The subgroup of diabetes mellitus type 
2 with a diagnosis of autonomic neuropathy was composed of 84 subjects, 
males aged 56.8±6.5 years. The QT length was derived from the average of 
readings from a 12-leads ECG and calculated with the Bazett’s formula: QTcd 
= QTc max - QTc min.
Results: In diabetes mellitus type 2 under study, without clinical symptoms 
of ischemic heart disease, the statistically significant (p<0.001) increase of 
QTc - to 41±21 ms - in comparison with the QTc in the control group, 22±11 
ms - was revealed. In the subgroup of diabetes mellitus type 2 with the silent 
ischemia of the heart, the QTc values were similar to those in the subgroup 
of diabetes mellitus type 2 without such ischemia. This was in contrast to the 
finding of a correlation between the presence of autonomic neuropathy and 
the increase of the QTc dispersion.
Conclusion: In persons with diabetes mellitus type 2 without clinical symp-
toms of heart ischemia the disturbances of the ventricular repolarization as 
manifested by an increase of the dispersion of QTc, are correlated with the 
markers of autonomic neuropathy. Such correlation was not found in the 
subgroup without symptoms of heart ischemia or with the asymptomatic 
ischemia of the heart without autonomic neuropathy. Therefore, in cardiolog-
ical care for diabetic persons, early testing for autonomic neuropathy should 
be included as a matter of routine.
Diabetes mellitus type 2
no clinical heart ischemia
no silent heart ischemia
Diabetes mellitus type 2
silent heart ischemia present
24±11 ms 23±14 ms (p>0.05)
Diabetes mellitus type 2
no clinical symptoms
of heart ischemia
autonomic neuropathy present
Diabetes mellitus type 2
no clinical symptoms
of heart ischemia
autonomic neuropathy absent
53±18 ms 38±2 ms (p<0.05)
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The prognostic value of sudomotor function for the development of 
cardiovascular disease and retinopathy: a 3-year follow up of diabetic 
patients 
D.S. Tesic1, V. Popovic2, M. Mitrovic1, J. Novakovic-Paro1, B. Vukovic1; 
1Clinic of Endocrinology, Diabetes and Metabolic Diseases, Institut for 
Internal Diseases, 2Clinic of Vascular Surgery, Institut for Surgical Diseases, 
Novi Sad, Serbia.
Background and aims: The aim of the present study was to evaluate the risk 
for vascular morbidity or death and retinopathy in relation to an abnormal 
response to a commercially available test of distal autonomic function (Neu-
ropad®).
Materials and methods: To that end, we performed a 3-year follow- study of 
type 2 diabetic patients attending the outpatient clinic. A total of 348 adult 
patients were evaluated for the degree of retinopathy and levels of HbA1c, 
blood pressure, serume creatinine and proteinuria. Somatic sensory neuropa-
thy was documented using the Neuropathy Disability Score, and autonomic 
neuropathy (sudomotor neuropathy) was determined on the sole of the foot 
using the Neuropad® response including time to colour change. Patients were 
divided into two groups: those without and with new vascular morbidity and 
causes of death which were registered by one and the most severe event only.
Results: Initially there were 348 patients with type 2 (159 male, mean age 
62.0±8.8y; mean disease duration 14.8±8.6y). NDS was >5 (abnormal) in 83 
(23.9%) and no change in Neuropad colour by 10 minutes was observed in 
103 (29.6%). Significant direct correlations were observed between an abnor-
mal Neuropad test and age (rs=0.31, p<0.001), waist circumference (rs=0.17, 
p=0.003), BMI (rs=0.25, p<0.001); significant negative correlations were ob-
served with height (rs=-0.17, p<0.001) and serum HDL cholesterol (rs=-0.13, 
p=0.003).The data represent values taken 3±1years (mean±SD) after initial 
evaluation. Twenty-two patients developed atherosclerotic vascular disease, 
i.e. myocardial infarction (n=9), cerebrovascular disease (n=9), or amputation 
(n=4), and 19 died. The observed annual mortality rate was 18.4/1000 com-
pared to an expected rate of 12.6/1000 for the general population with corre-
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sponding age and sex. Male gender (62.8% vs. 45.6%, p=0.04), age (68.8±6.1y 
vs. 61±8.1y, p<0.001), high BMI (30.3±4.9 vs. 27.1±2.3, p<0.01), high triglyc-
erides (3.1±0.9 vs. 2.0±0.7mmol/l, p<0.01), low HDL cholesterol (1.06±0.3 
vs. 1.16±0.17mmol/l, p<0.01) and time to complete Neuropad colour change 
(22.6±5.8mins vs. 9.1±6.7mins, p<0.01) were associated with vascular disease 
or death. Time until total colour change was found to be a prognostic marker 
for the development of vascular disease and death in patients treated with 
insulin at baseline (23.3±5.9mins vs. 8.7±4.7mins, p<0.01), whereas this was 
not the case in patients treated with oral agents at baseline (11.3±4.5mins 
vs. 7.4±5.6mins, NS). However, insulin treatment per se was not associated 
with an icreased mortality or morbidity. Time until total colour change was 
correlated with incidence of prolipherative retinopathy regardless of diabetes 
treatment (17.3±6.9mins vs. 9.1± 5.4mins, p<0.01).
Conclusion: This study showed that abnormal test of sudomotor function 
was a prognostic factor for vascular morbidity and death in type 2 diabetic 
patients treated with insulin but not in patients treated with oral agents.
1142
99mTc - Myoview gated - SPET and heart rate variability measurement in 
detection of early cardiovascular changes in diabetic patients
M. Mokan1, M. Migra1, M. Kutlák1, A. Lacko2, P. Galajda1; 
11. Internal Clinic, Faculty Hospital in Martin, Slovakia, 2Internal Clinic, 
Central Military Hospital, Ružomberok, Slovakia.
Background and aims: Chronic metabolic alteration in diabetic disease im-
plicates the changes in myocardial perfusion and autonomic nervous system. 
Risk of myocardial infarction is 3 times higher compared to whole popula-
tion. We decided to examine diabetic patients without history of cardiovascu-
lar disease for presence of cardiac autonomic cardiomyopathy and compare 
the results from standard examinating methods (treadmill test and echocar-
diography) to 99mTc - Myoview gated - SPET findings.
Materials and methods: We examined 47 patients, 20 individuals with 
T1DM (13 men, 7 women), average age 37 ± 12,7 years and 27 individuals 
with T2DM (14 women, 13 men), average age 60 ± 9,2 years. Written consent 
was obtained from all patients prior the study. In all patients we provided 
echocardiography and battery of Ewing´s testing combined with heart rate 
variability (HRV) examination. Thereafter patients underwent treadmill test 
and stress 99mTc - Myoview gated-SPET. Vascular and metabolic determi-
nants were recorded. Colected data were analysed using nonparametric sta-
tistic methods.
Results: Treadmill test was negative in all patients. Echocardiography re-
vealed diastolic dysfunction in 10 % of T1DM and 11 % of T2DM, no pa-
tient had systolic dysfunction. Scintigraphy confirmed hypoperfusion in 35 
% T1DM (p = 0,01) and in 60 % T2DM (p = 0,001). Diagnose of cardiac 
autonomic neuropathy based on Ewing´s testing and examination of HRV 
was estimated in 60 % of T1DM patients (p = 0,001) and 77 % of T2DM 
patients (p = 0,001). In T1DM group we found association between cardiac 
autonomic neuropathy (CAN) and frequency of hypoglycaemia (p = 0,04) 
and trend with duration of diabetes mellitus (p = 0,069). We did not find any 
correlation among all examined parameters in paciwnts with T2DM.
Conclusion: We revealed high incidence of cardiovascular changes charac-
terised with myocardial hypoperfusion and cardiac autonomic neuropathy 
among diabetic patients while treadmill test and echocardiography showed 
negative finding. Therefore we suggest that heart disease develops in dia-
betic patient many years undetected and advanced preventive arrangement 
is needed.
1143
The effect of cardiovascular autonomic neuropathy on progressing 
chronic heart failure in patients with type 2 diabetes mellitus
S.N. Botova, L.G. Strongin, I.G. Pochinka; 
Nizhny Novgorod State Medical Academy, Russian Federation.
Background and aims: Chronic heart failure (CHF) in patients with diabetes 
mellitus (DM) is a frequent and with poor prognosis. Cardiovascular auto-
nomic neuropathy (CAN) is a common complication of DM, associated with 
increased mortality and myocardial ischemia. Aim: to study the influence of 
CAN on progressing CHF in patients with Type 2 DM.
Materials and methods: Fifty - nine patients with CHF and Type 2 DM with 
CAN (Group A) and 29 patients with CHF and Type 2 DM without CAN 
(Group B) were enrolled in the study. Both groups were comparable in age, 
gender, BMI, stage of CHF, there were no patients with acute myocardial in-
farction (MI) or advanced diabetic nephropathy. The 6 minutes walking test, 
echocardiography, and evaluation of the heart rate variability (HRV) by 5 
minutes ECG monitoring were performed. The study lasted for a year.
Results: Within a year the MI has developed in 10 patients of group A and 
1 patient of group B (p = 0,049). The patients of group A, who have suffered 
MI during supervision, were characterized by especially low parameters of 
standard deviation of all NN-intervals (SDNN). In particular, of patients of 
group A with the level SDNN <20 ms 8 patients (32 % from all patients with 
level SDNN <20 ms) have suffered MI, on the contrary, in patients with pa-
rameter of SDNN within the limits of 20 - 33 ms MI has developed only in 
2 (p = 0,016). In both groups severity of CHF has increased, but in group A 
progressing CHF was more expressed. It has been demonstrated by worsen-
ing of clinical features, decrease of the left ventricle function. The decrease of 
the ejection fraction of the left ventricle, in 1 year was significantly higher in 
group A compared to group B (Median [25th; 75th percentiles] 4 [3; 7] v 2 [2; 
5]), p = 0,019). In a year a decrease according to 6 minutes walking test was 
significantly higher in group A than in group B (Median [25th; 75th percen-
tiles] 50 [20; 80] v 15 [4; 45], p = 0,023).
Conclusion: The risk of myocardial infarction of the patients with combina-
tion of Type 2 diabetes mellitus and chronic heart failure was higher in the 
presence of cardiovascular autonomic neuropathy. The level of SDNN lower 
than 20 ms is the precursor of a negative cardiovascular prognosis. Cardio-
vascular autonomic neuropathy causes the progressing chronic heart failure 
in the patients with Type 2 diabetes mellitus.
1144
Autonomic function and circadian blood pressure changes in patient 
with impaired glucose tolerance
N. Nemeth1, Z. Putz1,2, Á.G. Tabák1, I. Istenes1, T. Martos1, A. Körei1,  
Z. Hermányi1,2, K. Keresztes1, G. Jermendy2, P. Kempler1; 
1Ist Dept of Internal Medicine, Semmelweis University, 23rd Dept of Internal 
Medicine, Bajcsy Zsilinszky Hospital, Budapest, Hungary.
Background and aims: Diminished circadian blood pressure changes may 
be present in patients with diabetes mellitus, in partly related to autonomic 
neuropathy.
Materials and methods: The aim of our study was to evaluate whether or not 
a similar connection may exist in patients with impaired glucose tolerance 
(IGT). We examined 46 patients with IGT (age: 53.04±11.10 years, fasting 
blood glucose 5.40±0.57 mmol/l; 120 min blood glucose: 8.61±1.01 mmol/l; 
HbA1c: 5.97±0.38 %; x±SD) while 45 healthy subjects (age: 55.84±11.41 years) 
served as controls. Cardiovascular autonomic neuropathy was detected by 
the five standard tests of cardiovascular function. Systolic and diastolic blood 
pressure (BP) means just as systolic and diastolic diurnal indices were as-
sessed by 24-hour ambulatory blood pressure monitoring.
Results: Significant differences were found between IGT and control subjects re-
garding the following parameters: beat-to-beat variation (11.90±5.70 vs. 19.50±4.10 
beats/min; p=0.0001), Valsalva ratio (1.23±0.25 vs. 1.46±0.22; p=0.0001) and 
increase of diastolic blood pressure during sustained handgrip (19.90±7.90 vs. 
23.70±6.10 mmHg; p=0.012) were lower, while postural systolic blood pressure 
changes (4.37±5.70 vs. -0.60±2.00 mmHg; p=0.0001) were higher in patients with 
IGT versus control group. Both systolic (9.58±7.59 vs. 13.70±5.90; p=0.003) just as 
diastolic (15.50±10.71 vs. 18.93±7.13; p=0.095) diurnal indices were lower in IGT 
subjects compared to controls. The 24-hour systolic (121.80±5.49 vs. 116.75±9.85; 
p=0.048) and diastolic (74.95±3.86 vs. 71.61±6.10; p=0.008) blood pressure means 
were significant higher in IGT versus control group.
Conclusion: Our data suggest that the presence of cardiovascular autonomic 
neuropathy is associated with diminished circadian blood pressure changes 
in patients with impaired glucose tolerance.
1145
Influence of vagosympathetic changes on arterial stiffness in diabetic and 
obese patients
Q. Chen1,2, H. Dabire1,3, S. Chiheb1, I. Banu1, E. Cosson1; 
1Endocrinology-Diabetology-Nutrition, Jean Verdier Hospital, BONDY, 
France, 2Shanghai Clinical Center for Endocrine and Metabolic diseases, 
Shanghai Institute of Endocrine and Metabolic Diseases, China, 3INSERM 
U841, Maisons alfort, France.
Background and aims: Arterial stiffness is often increased in patients with 
diabetes or obesity. Several data suggest the role of vagosympathetic changes 
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in arterial hypertension. The aims of the present study were to examine the 
role of cardiovascular vagosympathetic changes on peripheral and central 
arterial stiffness in patients with type 2 diabetes or obesity.
Materials and methods: We included 207 patients (142 hypertensive) with 
type 2 diabetes (T2D) and 68 non diabetic obese (22 hypertensive) patients. 
Arterial stiffness was evaluated by measuring carotid to femoral pulse wave 
velocity (PWV) (Complior®) and by brachial and finger pulse pressure (PP), 
vagosympathetic activity by spectral analysis of heart rate (HR) and blood 
pressure (BP) variations (Finapres ; HF : high frequency and LF : low fre-
quency peak).
Results: In T2D patients as compared with obese patients, PWV (p <0.01), 
brachial (p < 0.001) and finger (p <0.05) pulse pressure (PP) were signifi-
cantly higher and HF-HR (p < 0.05) lower, and this was confirmed after age 
and blood pressure adjustment. In T2D patients, PWV correlated signifi-
cantly with age, systolic BP, LF-systolic BP, microalbuminuria and duration 
of diabetes and negatively with creatinine clearance and HF-HR and was 
significantly higher in the patients with peripheral neuropathy or peripheral 
vascular disease (p<0.05 to <0.001) ; brachial and finger PP also correlated 
significantly with all these parameters. In obese patients PWV and similarly 
brachial and finger PP correlated with age, systolic BP, microalbuminuria and 
negatively with creatinine clearance and HF-HR (p = <0.01 to < 0.001). In 
multivariate analyses including these parameters as independent variables, 
PWV was significantly associated with age both in T2D and obese patients, 
and with systolic BP and BMI in T2D patients; brachial PP correlated with 
age in both groups; finger PP correlated with HF-HR, LF-systolic BP and age 
in T2D patients (p<0.001, 0.01 and 0.05) and with HF-HR and systolic BP in 
obese patients (p <=0.01for both).
Conclusion: These data strongly suggest that in T2D and non diabetic obese 
patients, vagosympathetic changes play a major role in stiffness of small but 
not large peripheral arteries.
PS 112 Diabetic foot - clinical 
observations
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Diabetes related amputation incidence in an inner city multiethnic 
population in the UK before and after the introduction of 
multidisciplinary diabetes foot care, 2000-2008
M. Rossi1, P. Tzoulis1, D. Brudney1, J. Buchanan1, J. Preece1, A. Wilson2; 
1Department of Diabetes, 2Department of Surgery, The Whittington 
Hospital NHS Trust, London, United Kingdom.
Background and aims: Previous studies have suggested that appropriate 
multidisciplinary diabetes care can reduce the incidence of lower extremity 
amputations. According to the U.K. National Centre for Health Development 
Data for 2003-04, our inner city area in London was reported to have a higher 
number of diabetic amputations than the national average and amongst the 
highest within London. The Combined Foot Clinic was established in 2005 to 
offer multidisciplinary diabetes care for patients with diabetes related foot ul-
cers. We introduced care pathways and protocols for managing diabetic foot 
ulcers and raised awareness of the diabetic foot among primary care health-
care professionals through an educational programme. The aim of this study 
was to assess changes in diabetes-related lower extremity amputations in a 
multiethnic population over an 8-year period following the introduction of 
a multidisciplinary foot team. We reviewed the diabetes care of patients with 
diabetic amputations prior to, during and after admission.
Materials and methods: Our hospital covers a multiethnic population in an 
inner city area of London. All diabetes related lower extremity amputations 
in our insitution between 2000 and 2008 were identified via coding. Data 
were collected retrospectively and were analysed for the period before (2000 
- 2005) and after (2006 - 2008) the introduction of the multidisciplinary foot 
team.
Results: From 2000 to 2005, 104 amputations in 64 patients (mean age 68.6 
years, 70% males and 30% females, mean duration of diabetes 15 years) were 
identified with an incidence of 17.3 amputations/year. There were 38 major 
amputations (6.3/year) and 66 minor (11/year). Perioperative mortality was 
6.6 %. From 2006 to 2008, 44 amputations in 33 patients (mean age 70.1 years, 
72% males and 28% females, mean duration of diabetes 15 years) were iden-
tified with an incidence of 14.7 amputations/year. There were 9 major am-
putations (3/year) and 35 minor (11.7/year). Perioperative mortality was 4.6 
%. During admission, between 2006 and 2008, 75 % of patients had HbA1c 
(median HbA1c 7.3%) compared with 41% between 2000 and 2005 (medi-
an HbA1c 7.9%). During admission, 81% of the patients were reviewed by 
Podiatry/Tissue Viability team compared with 40% for the previous period. 
After discharge, the proportion of patients who had follow-up by the Dia-
betes team increased from 62% to 73% and by Podiatrist from 43% to 80%. 
Overall, considerable improvement in the involvement of diabetes team and 
podiatry services was reported. Improvement in foot care services after 2005 
led to a 53 % reduction in the incidence of major diabetes related amputa-
tions from 6.3/year to 3/year and a 15 % reduction in total diabetic amputa-
tions in our population from 17.3/year to 14.7/year. Overall, the incidence of 
major diabetes related amputations in our area has decreased to 1.2/100,000 
general population/year and of total amputations to 5.8/100,000 population/
year and is much lower than the national incidence of 3.4/100,000/year and 
8.7/100,000/year respectively. Our perioperative (1-month) mortality rate is 
4.6 % compared to 6.6 % nationally.
Conclusion: We demonstrated considerable improvements in outcomes of 
diabetes related amputations following improvements in foot care through 
multidisciplinary team work.
1147
Changes in the incidence of lower extremity amputations in people with 
and without diabetes in England between 2004 and 2008
E.P. Vamos, A. Bottle, A. Majeed, C. Millett; 
Department of Primary Care & Public Health, Imperial College London, 
United Kingdom.
Background and aims: During the last decade, there was a consistent upward 
trend in the number of non-traumatic lower extremity amputations in people 
with diabetes in England. However, there is a lack of national data on the in-
cidence of diabetes-related amputations. The aim of this study was to describe 
recent trends in non-traumatic amputations in people with and without dia-
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betes and estimate the relative risk of amputations in diabetes between 2004 
and 2008 in England.
Materials and methods: We identified all patients who underwent any non-
traumatic amputation in England between 2004 and 2008 using national hos-
pital-activity data from all NHS hospitals. Age- and sex-specific incidence 
rates were calculated using the total diabetes population in England every 
year. 
Results: Overall amputation rates (minor and major combined) decreased by 
9.1%, from 27.5 per 10,000 persons with diabetes in 2004 to 25.0 per 10,000 
persons with diabetes in 2008. The rate of minor LEAs fell from 15.7 to 14.9 
per 10,000 persons with diabetes and major LEA rates decreased from 11.8 
to 10.2 per 10,000 persons with diabetes. The absolute reductions in minor 
and major LEA rates were slightly greater in men with a decline from 19.9 to 
18.3 per 10,000 persons with diabetes compared to a fall from 7.6 to 6.7 per 
10,000 persons with diabetes in women. Poisson regression analysis showed 
no statistically significant change in amputation rates over time in people 
with diabetes after adjustment for age, sex, level of amputation and year (0.97 
decrease per year 95% CI 0.92-1.02, p=0.374). Amputation rates (minor and 
major combined) decreased from 13.6 per 100,000 persons without diabetes 
in 2004 to 11.9 per 100,000 persons without diabetes in 2008. Minor and 
major LEA rates showed a decline from 5.9 to 5.0 100,000 persons without 
diabetes and from 7.7 to 6.9 100,000 persons without diabetes, respectively. 
Poisson regression analysis showed that the decline in non-diabetes-related 
LEAs did not reach statistical significance (0.96 decrease per year, 95% CI 
0.93-1.00, p= 0.07). The relative risk of a person with diabetes undergoing a 
LEA increased slightly from 20.3 to 21.2 when compared with persons with-
out diabetes between 2004 and 2008.
Conclusion: This national study suggests that incidence rates of lower ex-
tremity amputation in people with diabetes England remained unchanged 
between 2004 and 2008. The increased relative risk of amputation among 
persons with diabetes compared to those without appears to have margin-
ally increased during the study period although this might be explained by 
decreased risk among people without diabetes.
Supported by: European Community 
1148
High prevalence of limb amputation in people with diabetic foot 
syndrome
S. Lauterbach; 
Red Cross Hospital Kassel, Germany.
Background and aims: The diabetic foot syndrome is a preventable long-
term complication of diabetes mellitus. One of the St. Vincent targets from 
1989 was a 50% reduction in amputation. This target is generally not reached. 
But to show the prevalence and incidence of limb-amputation is difficult be-
cause complete epidemiological data do not exist. The aim of the study was 
to show the prevalence of limb-amputation in people with diabetic foot syn-
drome and the mean survival time after the first diagnosis in Germany.
Materials and methods: Anonymous data were obtained from the prospec-
tively compiled IMS Disease Analyzer database. All patients with a first diag-
nosis of diabetic foot syndrome between January 1, 2001 and December 31, 
2005 were included. Patients were required to have continuous data for at least 
5 years after the first diagnosis of diabetic foot syndrome (ID). The maximum 
observation period was 10 years. The primary outcome measure of the study 
was disease-free survival following a diagnosis of diabetic foot syndrome. The 
documentation of an amputation [ICD10-Codes: Z894-899] indicated the end 
of disease-free survival. Kaplan-. Meier plots were generated to analyse the 
probability of amputation and the amputation-free survival time.
Results: A total of 4,068 patients with diabetic foot syndrome were included 
in the analysis. The overall mean age at diagnosis was 64.9 (SD: 11.9) years, 
39.2% were female, the middle HbA1c was 8.05% (SD: 2.24) and 13.1% of 
the patient with DFS has a polyneurpathy and 12.1% has peripheral angiopa-
thy. 3,407 patients were in 697 general practitioner practices and 661 patients 
were in 57 diabetology practices. Within observation time 737 (18.1%) pa-
tients had a limb-amputation: 45.2% an amputation of foot and ankle or toes, 
32.7% of leg at or below knee 18.1% of leg above knee and 4.0% amputation of 
both lower limbs. Limb-amputations were registered among 16.6% in general 
practitioner practices and 26.0% in diabetology practices, 20.2% in male and 
15.5% in female patients. The mean amputation-free survival time was 7.8 
years (SD: 17.2 days).
Conclusion: Results from this analysis of a large representative German da-
tabase show, that the prevalence of limb-amputation in people with diabetic 
foot syndrome is high. Screening methods to find out high risk foot problems 
and appropriate education in protective foot care for people with diabetes 
mellitus are established but obviously not effective enough. More long lasting 
avoiding methods are necessary.
1149
Cost of an episode of diabetic foot ulcer in Spain
J. Marinello1, J.R. March2, J.I. Blanes3, E. Martínez-Aguilar4, J.R. Escudero5, 
A. Masegosa6; 
1Hospital de Mataró, 2Hospital de Getafe, Madrid, 3Hospital Dr Peset, 
Valencia, 4Hospital de Navarra, Pamplona, 5Hospital Sant Creu I Sant Pau, 
Barcelona, 6Complejo Hospitalario Universitario, Albacete, Spain.
Background and aims: The economic burden of diabetic foot is substantial, 
due to long term treatments, high recurrence rate and high risk of lower ex-
tremity amputation associated. In addition, diabetic foot ulcers cause high 
disability and decrease the health related quality of life. The objective of this 
study was to obtain data concerning resource consumption in patients with 
diabetic foot syndrome and to estimate the direct sanitary costs per patient 
associated to an episode of non-complicated superficial full-thickness neuro-
pathic ulcer of diabetic foot in Spain.
Materials and methods: This is an observational, retrospective and multi-
center design. Diabetics with non-complicated superficial neuropathic ulcer 
of at least 10 cm2 without lower extremity ischemia, and with the study ulcer 
completely resolved due to wound healed or amputation. Ischemic or neuro-
ischemic ulcers or with foot infection at the time of inclusion were excluded. 
The study period for each patient was the duration of the complete selected 
ulcer episode. Collection of study data was performed in an unique visit. The 
estimation of costs was performed by identification and subsequent quantifi-
cation of health resources used in the treatment of the diabetic foot episode, 
assigning a specific unitary cost to each of these resources. Analysis was car-
ried out according to the perspective of the National Health System, taking 
into account direct sanitary costs, exclusively. Results are shown as total cost 
per ulcer episode and expressed in Euros (€) from year 2009. The study was 
performed from a hospital perspective.
Results: The average cost per patient with an episode of diabetic foot ulcer in 
Spain is estimated at 12525.12€. Only direct sanitary costs have been consid-
ered and not the indirect costs related to the loss of productivity of patients 
and caregivers. The hospital admissions, topical ulcer care and surgery rep-
resent the highest percentages of the direct costs, 50.4%, 19.2% and 22.8% 
respectively. In our study the average cost of amputations as unitary resource 
cost, and considering the Diagnosis-related groups values, was estimated as 
7.730,14€. Taking into account the percentage of patients in the sample that 
suffered an amputation, this cost represent 1649.49€ per amputation (surgery 
procedure only) and ulcer episode. In consequence, our study could be un-
derestimating the cost of amputations, one of the costs with highest impact in 
the average cost per patient.
Conclusion: Diabetic foot is one of the complications of diabetes mellitus 
that produces a high economic impact in the health systems. In consequence, 
after estimation in this study and others published in different countries, of 
the costs that its management involves, it would be necessary to carry out 
primary and secondary prophylaxis programs in order to decrease the occur-
rence of diabetic foot ulcers in patients with diabetes. Additionally, it would 
be necessary to establish an adequate management of the lesion including 
treatments for accelerating the healing process and cures at home in order 
to shorten hospital stays. By doing this, the decrease in health related qual-
ity of life of these patients would be avoided, as well as the risk of losing the 
extremity and also the use of the high number of sanitary resources its treat-
ment involves.
1150
Comparison of outcome of diabetic foot ulcer treatment in 3 different 
centres of North West England
M.S.A. Soliman1, G. Jones2, E.B. Jude3, S. Rajbhandari1; 
1Medicine, Lancashire Teaching Hospitals foundation trust, NHS, Chorley, 
2Medicine, East Lancashire Hospitals foundation trust, NHS, Blackburn, 
3Medicine, Tameside General Hospital, NHS, Ashton Under-Lyne, United 
Kingdom.
Background and aims: Diabetic foot ulcers are managed at different centres 
as per local protocol, which may vary from place to place depending on avail-
ability of local expertise. This may affect the outcome of ulcers. To assess this 
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we retrospectively studied the outcome of 50 diabetic foot ulcers that pre-
sented to 3 different centres in the North West England. The aim of this study 
was to assess outcome of diabetic foot ulcers in these centres.
Materials and methods: We retrospectively analysed the clinic notes of first 
50 patients that attended 3 diabetic foot clinics of North West England from 
1st January 2008. The list of patients that presented to diabetic foot clinic was 
obtained from the hospital system and their notes retrieved. Data was collect-
ed in pre-designed form. If needed other hospital IT systems were checked.
Results: Case notes of 148 patients (Mean age 66.3 +/- 12.9 years & 33.8% Fe-
males) were studied. Centre A had 46 patients (Mean age 68.7 +/- 13.2 years & 
32.6% Females), Centre B had 51 (Mean age 66.0 +/- 11.4 years & 23.5% Females) 
and Centre C had 51 (Mean age 64.6 +/- 14.0 years & 45.1% Females) patients. 
There was no difference (p >0.05) in age and sex of patients between these centres. 
Similarly there was no difference in HbA1c, total cholesterol serum creatinine and 
blood pressure in patients attending these centres. Table 1 shows the results com-
paring these 3 centres, which clearly shows improved outcome in Centre B.
Discussion: Our study shows that there was significantly more proportion of 
ulcers healed by 12 weeks in Centre B, which is due to extensive use of cast 
and higher proportion of neuropathic ulcers. This trend of improved healing 
continued for 52 weeks of the study. There was no difference in the presence 
of infection, proportion of osteomyelitis confirmed on X-ray and amputation 
rate between these centres. There was a trend for reduced mortality in centre 
C that could be due to more proportion females in that centre.
Conclusion: This study confirms that there is variable outcome of diabetic 
foot ulcers even within a small geographical area. This is mainly due to varia-
ble use of cast. Similar comparative studies are necessary in order to compare 
quality of care provided to patients with diabetic foot ulcers.
Table (1): comparison of centre A, B, and C for different aspects of the 
outcome
Parameter Centre A Centre B Centre C P value
Healing by 12 weeks 34.8% 47.1% 19.6% 0.01
Healing by 24 weeks 41.3% 68.6% 47.1% 0.06
Healing by 36 weks 60.9% 76.5% 56.9% 0.09
Healing by 52 weeks 69.6% 86.3% 70.2% 0.09
Total Death by 52 weeks 4% 17.6% 17.3% 0.06
Use of Cast 23.9% 72.5% 9.8% <0.001
Presence of Infection 56.5% 47.1% 62.7% > 0.05
Osteomyelitis in X ray 34.8% 19.6% 19.6% > 0.05
Neuropathic ulcers 45.7% 74.5% 52.9% <0.01
Amputation 17.9% 15.7% 7.8% > 0.05
1151
Diabetic foot screening: an observational study in a population of 
diabetics in Forli’ (Northern Italy)
S. Acquati, L. Gagliardi, S. Taroni, A. Tartaglia, L. Buci, R. Manini,  
F. Donadio, C. Ragazzini, G. Silvani, M. Nizzoli; 
Endocrinology and metabolic disease department, Forlì, Italy.
Background and aims: Diabetic foot problems are among the most serious 
and costly complications of diabetes. Epidemiologic reports indicate that over 
one million amputations are performed on people with diabetes each year. A 
majority of these amputations are preceded by ulcers. Despite being the most 
serious complications of diabetes, foot complications can be effectively pre-
vented. Several studies show how the identification of patients at high risk of 
ulcer and the subsequent education of these patients represent an important 
step to prevent this complication.
Subjects and methods: In April 2006 in our department we start a diabetic 
foot screening for all diabetics followed in our clinic, in a managed care or-
ganization, in order to intensify primary prevention. Until October 2008 we 
evaluated 920 patients affected by diabetes (mean age 67.4±12.2 yrs, mean 
duration of diabetes 10.5±10.8 yrs, mean HbA1c 7.58±1.5 %). Every patient 
underwent accurate anamnesis, foot examination, ABI and VPT measure-
ment, Semmes-Weinstein monofilament perception, HbA1c measurement. 
Patients were then stratified into 4 classes of risk according to diabetic foot 
international guidelines (class 0: absence of neuropathy; class I: presence of 
neuropathy; class II presence of neuropathy and vasculopathy and/or de-
formity; class III: previous ulcer or amputation).
Results: Deformities were present in 250 diabetics (27.1%), onychomycosis 
in 240 (26%), hyperkeratosis in 310 (33.6%), ocycochriptosis in 28 (3%). In 
68 subjects we found an incidental lesion or prelesion (7.4%). 435 diabetics 
(47.2%) showed VPT ≥25. Monofilament was not detectable in 184 patients 
(19.9%). In 75 patients (8.1%) we found ABI<0,9 while in 41 (4.4%) ABI was 
>1,3. ABI was undetectable in 90 subjects (9.7%). Of all patients screened 
only 156 (17%) used proper shoes. In the table we summerised data of the 
different classes of risk.
Class of Risk 0 I II III
N° (%) 388 (42) 202 (22) 241 (26) 89 (9)
Age (yrs) 61.3±12.1 70.9±9.9 70.4±11.1 70.7±11.4
Diabetes Duration (yrs) 8.1±9.9 11.9±9.5 11.4±9.9 14.7±13.7
HbA1c (%) 7.4±1.5 7.7±1.5 7.7±1.5 7.9±1.4
microangiopathy n° (%) 80 (20) 71 (35) 74 (31) 46 (52)
macroangiopathy n° (%) 89 (23) 59 (29) 79 (33) 48 (54)
Conclusion: This study showed a high prevalence of diabetics at risk of ulcer 
and underlined the importance of an accurate screening in all diabetics at 
least once. The subsequent classification of the patients in different classes of 
risk is an important step in order to strengthen both educational and thera-
peutical strategy in those patients at higher risk of developing ulcers. Our 
data showed that many patients are not at glycaemic target and underlined 
the necessity to intensify treatment both in low risk classes, in order to really 
prevent the development of complications, and in high risk classes, in order 
to reduce the progression of the complications already present.
1152
Characteristics of diabetic charcot foot in Western Pacific region - 
ASIPAC foot study 2
S. Kono1, R. Nakagawachi1, E. Yunir2, G.Z. Zhao3, H. Kajio4, M. Noda4,  
Y. Seino5, M. Hattori6, H. Kuzuya1, B.V. Ta7, E.A. de Jesus8, S. Krittiyawong9, 
A.J. Boulton10; 
1WHO-collaborating Centre for Diabetes, Kyoto, Japan, 2Internal Medicine, 
University of Indonesia, Jakarta, Indonesia, 3Henan Provincial People’s 
Hospital, Zhengzhou, China, 4National Center for Global Health and 
Medicine, Tokyo, Japan, 5Kansai Electric Power Hospital, Osaka, Japan, 
6Division of Diabetes, Kyoto Medical Center, Japan, 7Hanoi Medical 
University, Viet Nam, 8Orthopedics and traumatology, Jose R., Reyes 
Memorial Center, Kyoto, Philippines, 9Theptarin Hospital, Bangkok, 
Thailand, 10Universities of Manchester and Miami, United Kingdom.
Aims: The aim of this study (ASIPAC FOOT STUDY-2) was to investigate 
the characteristics of diabetic patients with Charcot foot in 6 tertiary care 
hospitals in 6 countries (Thailand, Indonesia, China, Philippines, Vietnam 
and Japan), and to increase awareness of diabetic Charcot foot problems in 
Western Pacific Region (WPR).
Methods: The study population includes 54 patients presenting with Char-
cot foot. Data on patient characteristics, as well as foot characteristics were 
obtained.
Results: General patient characteristics were different in some points between 
countries. The patients at the onset were in their fifties in most countries ex-
cept China ( average age (years): 50.0 in Philippines (P), 50.7 in Japan (J), 52.9 
in Thailand (T), 53.3 in Indonesia (I), 56 in Vietnam, and 65.2 in China (C)). 
Body mass index (BMI) was lower than 26.0 kg/mm2 in most countries (mean 
BMI: 22.4 in V, 25.0 in J, 25.9 in P, 25.9 in C 25.8 in I and 28.4 in T). Most 
patients have past history of foot ulcer and amputation before the onset (ulcer 
(%) / amputation (%): 100/42.9 in C, 100/28.6 in I, 61.5/23.1 in T, 50/5 in J, 
40/0 in P, 0/0 in V). Many patients in hot countries such as Philippines, Thai-
land, Indonesia and Vietnam walked with sandals before the onset. It took a 
long time until the diagnosis of Charcot foot after the onset ( average months: 
10.9 in T, 5.7 in J, 4.7 in C, 3.1 in I, 2.2 in P and 0.5 in V ). About 50% were 
diagnosed after presenting with mid-foot deformity together with ulcer (at di-
agnosis, stage 0 (prodromal period): 1.9%, stage 1 (development): 41.5%, stage 
2 (coalescence): 5.7%, stage 3 (reconstruction): 50.9% / location (%) : forefoot: 
15.8, mid-foot: 59.7, hindfoot: 24.6 / prevalence of ulcer (%) : 71.4 in C, I, and 
T, 30 in J, and 20 in P). Even after the initiation of the treatment of Charcot 
foot, many patients showed the progression of foot deformity, chronic foot 
ulcer and were undertaken amputation (progression of deformity (%): 42.9 in 
I, and C, 25 in T, and 5 in J / chronic ulcer (%): 90 in T, 66.7 in C, 71.4 in I and 
15 in J / amputation (%): 100 in P, 30.8 in T and 14.3 in C). Most patients were 
not provided with custom-made footwear despite severe foot deformity.
Conclusion: Characteristics of Charcot patients in the WPR differed from 
those in Western countries in that the BMI was lower, the diagnosis was made 
later and the overall prognosis was poorer. It is very likely that there are many 
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more cases of Charcot foot that are misdiagnosed or undetected in the WPR. 
In order to improve prognosis and reduce amputations in the WPR, it is es-
sential to have a high index of suspicion for Charcot foot, increase awareness 
of it and to encourage early presentation of the patient.
Supported by: Japanese Government
1153
Brachial-ankle pulse wave velocity predicts healing of diabetic foot ulcers 
among patients with type 2 diabetes
D. Cho, J. Chung, D. Chung, M. Chung; 
Department of Internal Medicine, Chonnam National University Hospital, 
Gwangju, Republic of Korea.
Background and aims: Some 7-10% of diabetic patients develop chronic foot 
ulcers, a severe and expensive complication that leads to minor or major am-
putation in 10-15% of the patients. Peripheral arterial occlusive disease con-
tributes to the impaired healing process. Measurement of pulse wave velocity 
(PWV) is a useful non-invasive index of arterial distensibility, and predicts 
cardiovascular morbidity and mortality. Several studies demonstrated that 
pulse wave velocity a sensitive predicator for peripheral artery disease and 
cerebrovascular disease among diabetic patients. The objective of this study 
was to determine whether brachial-ankle pulse wave velocity (baPWV) can 
predict healing of diabetic foot ulcers.
Materials and methods: We recruited a total of 86 type 2 diabetic patients 
(52 men and 34 women) with chronic foot ulcers. The age was 62.7±12.3 
years, and the diabetes duration was 15.6±11.2 years. Anthropometric, clini-
cal, and laboratory data were measured. All patients were seen weekly for 
debridement, offloading, and other treatments during the initial 8 weeks. The 
PWV was measured between the brachial and ankle regions (baPWV), and 
the baPWV was measured in all patients using a waveform analyser.
Results: At 8 weeks, 31 of the 86 ulcers had completely healed. The 86 patients 
were divided into two groups according to the clinical outcome of ulcer heal-
ing at 8 weeks. There were no differences in age, duration of diabetes, HbA1c, 
or initial size of the ulcer between the healed and unhealed groups. The heal-
ing time of foot ulcers in healed group was 5.2±2.3 weeks (range 1.2-7.7). The 
baPWV was significantly (P<0.05) higher in the unhealed group (1768±290 
cm/s) as compared with the healed group (1553±312 cm/s). Age (r = 0.504; 
p< 0.01), duration of diabetes (r = 0.279; p< 0.05), ankle-brachial index (ABI) 
(r = -0.328; p< 0.05) and toe-brachial index (TBI) (r = -0.281; p< 0.05) were 
significantly correlated with baPWV. But BMI, lipid profiles, HbA1c, and 
systolic and diastolic BP were not correlated with baPWV. Univariate analysis 
revealed that baPWV was significantly correlated with healing rate of diabetic 
ulcers (r = 0.283, p < 0.05) and age (r = 0.452, p < 0.01).
Conclusion: We report that increased baPWV is closely associated with the 
healing time of diabetic ulcers. Our results suggest that the degree of systemic 
arterial stiffness is predictor of the healing of diabetic ulcers in patients with 
type 2 diabetes.
1154
Does the type of off-loading have any impact on the quality of life in 
patients treated for the diabetic foot?
V. Fejfarova1, A. Jirkovská1, E. Dragomirecka2, R. Bem1, M. Dubský1,  
V. Woskova1, V. Lanska1; 
1Diabetes Center, Institute for Clinical and Experimental Medicine, 
2Psychiatric Center, Prague, Czech Republic.
Background: We often meet in patients with the diabetic foot ulcers (DFU) 
with invalidisation, higher morbidity and mortality that could lead to dete-
rioration of quality of life (QoL) and enhancement of depression scale. How-
ever, there exist extensive inter-individual psychological differences even in 
patients with DFU that could be influenced by variety of external factors in-
cluding the method of DFU off-loading which affects patient’s mobility, social 
relations, employment possibilities, etc.
Aims: In our study we assessed the differences in QoL and depression scale in 
relation to the type of DFU off-loading and DFU duration between patients 
with DFU treated by half shoes, orthoses and wheelchairs.
Methods: In total, 48 patients with chronic DFU (mean age 60.6±9.4 years, 
77% of males, 80% of patients with Type 2 diabetes, mean diabetes duration 
20.5±9.6 years, mean DFU duration 16.5±18.7 months) treated in our out-
patient foot clinic from 1/2010 to 3/2010 were consecutively included into 
our study. Patients were divided into 3 study groups according to the type of 
using off-loading device - patients treated by half shoes (HS group - 26), by 
different types of orthoses including TCC (O group - 10) and by wheelchairs 
(WCh group - 12). QoL was evaluated by standardize questionnaire WHO-
QoL-Bref assessing 4 domains (physical capacity, psychological well being, 
social relationships and environment). Depression scale was assessed by Gen-
der Depression Scale (GDS).
Results: The WCh group did not differ significantly in the depression scale 
when compared to the HS and O groups (mild form of depression was pre-
sented in 85.7% vs. 82.6% vs. 100% of patients; NS; no severe form of de-
pression was found in all study subjects). Moreover, in particular domains 
of the WHOQoL-Bref, the results of WCh group were similar to the HS and 
O group (physical capacity-12.5±3.5 vs. 12.3±2.7 vs. 12.7±3.2; psychological 
well being-14.3±3.1 vs. 14.7±2.7 vs. 15.1±1.6; social relationships-15.3±4.7 
vs. 14.7±2.7 vs. 13.5±1.8; environment-14±2.6 vs. 14±2.1 vs. 14.6±1.5; all 
NS). Study groups differed significantly only in DFU duration (7.3±7.8 in 
WCh group vs. 14.5±15.9 in HS group vs. 33±25.9 months in O group; p< 
0.01); other evaluated parameters did not differ significantly between the 
study groups. Suicidal tendencies and pain symptoms were described in 9.1% 
(4/44) and 56.1% (23/41) of all questioned patients.
Conclusion: The type of off-loading device including wheelchairs did not 
influence significantly QoL nor depression scale in patients treated for DFU. 
We suggest the DFU duration rather than the type of DFU off-loading has a 
greater impact on QoL and depression in diabetic foot patients.
Supported by: VZ MZO 00023001.
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The study on mechanisms of epidermal keratinocyte migration impaired 
by glycated matrix 
Z. Song1, Y. Demin1, W. Runxiu2, T. Ming3, X. Ting3, H. Fei2, Y. Guozhi2,  
L. Shuliang3; 
1Key Lab of Hormones and Development, Ministry of Health, China, 
Tianjin, 2First Affiliated Hospital of Guangxi Medical University, Nanning, 
Guangxi Zhuang Autonomous Region, 3Ruijin Hospital, Shanghai Second 
Medical University, China.
Background and aims: Diabetes mellitus is one of the most common disease 
in human life. Many kinds of complications caused by diabetes metabolism 
disorder and its metabolite, including nonhealing wound, now is becoming 
a difficulty in clinical treatment and academic research. Keratinocyte is the 
mainly repair cell participating wound healing, whose migration function is 
the base of wound re-epithelization. Keratinocyte continuously migrates on 
the wound edge, while wound size reduces to complete healing. If keratinoc-
yte migration is blocked, then it means that the wound can’t heal. So the study 
of keratinocyte migration behavior is of profound significance for exploring 
the rule of wound healing. This study is to discuss that keratinoctye migration 
is impaired by glycated matrix and its mechanism.
Materials and methods: Keratinocytes from six male Sprague-Dawley rats’ 
back, cultured for two to three generations, were used for experiments. Gly-
cated laminin model were made by laminin cultured in glycolaldehyde and 
AGEs concentrations were assessed by detecting total fluorescence in gly-
cated laminin model and immunohistochemistry assay. Keratinocytes were 
cultured on glycated laminin and normal laminin as study group and control 
group respectively. Keratinocyte migration was measured by scratch wound 
healing assay. Adhesion rate was expressed by Optical Density(OD), deter-
mined with MTT assay. Keratinocyte morphous was observed by scanning 
electron microscopy and inverted microscope. F-actin was observed by im-
munofluorescence. Integrinα3 was determined by flow cytometry.
Results: The amount of migrating keratinocyte in study group is significantly 
less than control (13±4/HP vs 61±11/HP, P<0.05), which confirmed that ke-
ratinocyte migration was obviously inhibited by glycated matrix. There was no 
difference of adhesion rate between study group and control group(12h OD: 
0.102±0.014 vs 0.134±0.062; 24h OD: 0.181±0.050 vs 0.187±0.061,P>0.05), 
however the morphous of keratinocyte on glycated laminin indicates that the 
cell body was small and hardly spread compared with that on normal lam-
inin. Microfilament of the keratinocyte on the glycated laminin was sparsely 
distributed in the cytoplasm and around cell nuclear, but the expression of 
microfilament in the control group was intensively and distributed on the 
cell membrane, especially on the free edge. The expression of keratinocyte 
integrinα3 on normal laminin is significantly higher than that on glycated 
laminin(11.23±5.27% vs 36.58±11.24%, P<0.05).
Conclusion: Keratinocyte migration is inhibited by the glycated laminin. 
The reason behind the phenomenon is possibly that integrin signaling disor-
der leads to decrease of integrin and actin expression, followed by the drop 
of lamellipodia and filopodia development, and the ultimate consequence 
would be the contribution to the restrained migration.
Supported by: Major State Basic Research Development Program of China
1156
IGF-1 is a mediator of inflammation in Charcot Neuroarthropathy and 
could play an important role in its pathogenesis
T. Musella1, D. Pitocco1, F. Zaccardi1, G. Pozzoli2, M. Galli3, C. Torriani2,  
G. Tringali2, C. Dello Russo2, G. Scavone1, S. Caputo1, G. Ghirlanda1; 
1Internal Medicine, 2Pharmacology, 3Orthopedic Surgery, Catholic 
University, Rome, Italy.
Background and aims: Charcot neuroarthropathy (CN) is a multifactorial 
disease in which genetics of the axis RANK-RANK-L- osteoprotegerin and 
a dysregulation of inflammation seem to be involved. A simultaneous im-
provement of bone mass density of the foot and a reduction of IGF-1 levels 
was showed after a treatment with alendronate. Aim of this study was to in-
vestigate the possible role of IGF-1 in the modulation of inflammation in CN 
and further support the functional involvement of the axis RANK-RANK-L-
osteoprotegerin (OPG) in its pathogenesis.
Materials and methods: Monocytes were obtained from peripheral blood of 
10 healthy Donors (C), 10 subjects with CN not in acute phase and 10 sub-
jects with diabetic neuropathy (DN) but without CN. They were incubated 
with LPS, that is an inflammatory stimulus and in vitro inhibits RANK rna 
expression, or IGF-1 and then was measured the production of RANK (ex-
pressed as percentage variation compared to C) and prostaglandin E2(PGE-
2) levels (RIA method, pg/ml) as marker of inflammatory activation.
Results: At baseline there were no differences about Rank expression and 
PGE-2 levels among CN, ND and C. After incubation with LPS, CN showed 
a significant smaller reduction of RANK compared to ND and C, while there 
were not significant differences about PGE-2 levels, although they were 
slightly higher in CN (402.2 ± 35.64 vs 353.2 ± 40.88 in C and 381.6 ± 54.87 
in ND). After incubation with IGF-1 there were not significant differences 
about RANK expression among three groups while CN showed a significant 
increase of PGE-2 levels (144.9 ± 30.93) if compared to DN (46.33 ± 12.24) 
and C (28.89 ± 6.24) p<0.01.
Conclusion: This study seems to support for the first time the possible in-
volvement of IGF-1 as mediator of inflammation, demonstrated by the in-
creased production of PGE-2 after its stimulus, in the pathogenesis of CN, and 
further confirm the pivotal role played by the axis RANK-RANK-l-OPG.
1157
Wound healing is selectively modulated by estrogen receptors in diabetes
V.G. Sunkari1, J. Grünler1, S. Lindberg1, I.R. Botusan1, O. Savu1,  
K.R. Steffensen2, K. Brismar1, S.-B. Catrina1; 
1Department of Molecular Medicine and Surgery, 2Department of 
Biosciences, Karolinska Institutet, Stockholm, Sweden.
Background and aims: Impaired wound healing in diabetes is a major medi-
cal and economical problem. It is therefore a need to find new therapeuti-
cal approaches. The effects of estrogen on cutaneous wound healing are well 
established and it might explain the defective wound healing in elderly. Es-
trogen receptors beta (ERβ) have been linked to venous ulcers. However, the 
effect on diabetic wounds is still unexplored. The present study analyzed the 
contribution of the Estrogen receptors (ERα and ERβ) to wound healing in 
diabetic mice.
Materials and methods: We studied the effect of streptozotocin induced dia-
betes on wound healing rate in estrogen receptor knock out (ERα-ERKO & 
ERβ-BERKO) and in wild type mice (C57BL/6). The wound model consists 
of full-thickness wounds made on the dorsum of the animals. The wound 
area were determined every second day using a digital camera. Wound gran-
ulation, dermal and epidermal regeneration were evaluated by hematoxylin 
and eosin staining and angiogenesis by GS-1 isolectin staining. Markers for 
inflammation, endothelial precursor´s cell recruitment and cell migration 
were analyzed by qRT-PCR. Invitro cell migration assay was carried out in 
Human dermal fibroblasts (HDFs) in order to determine rate of migration in 
presence of agonists for estrogen receptors alpha and beta.
Results: Diabetic BERKO mice but not diabetic ERKO mice have a faster 
wound healing rate compared to diabetic wild type mice (50% wound closure 
at 3.4 +/- 0.3 days (p<0.05), 4.5 +/- 0.5 days respectively 4.7 +/- 0.5 days). 
HDFs treated with either specific alpha or beta estrogen receptor agonists 
showed a significant increase in migration rate.
Conclusion: After induction of diabetes β-receptor knock-out (BERKO) 
mice display an accelerated wound healing rate when compared to α-receptor 
knock-out (ERKO) or wild type mice (C57BL/6). These data suggest the use 
of specific ER agonists for therapeutic trials. The different effect of the ERs on 
wound healing rate is not due to a specific effect on fibroblast migration rate.
Supported by: Erling Persson Foundation
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Emotional distress may impede diabetic foot ulcer healing through 
elevated levels of interleukin-6: preliminary findings
L. Vileikyte1, B.-J. Shen2, M.J. Hardman3, R.S. Kirsner4, A.J.M. Boulton1,  
N. Schneiderman5; 
1Medicine, University of Manchester, United Kingdom, 2Psychology, 
University of Southern California, Los Angeles, USA, 3Life Sciences, 
University of Manchester, United Kingdom, 4Dermatology, University of 
Miami, USA, 5Psychology, University of Miami, USA.
Background and aims: Emotional distress induced up-regulation of Inter-
leukin-6 (IL-6) has been found to be detrimental to health. As diabetic foot 
ulcers are characterized by chronic inflammation, it is plausible that emo-
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tional distress could delay the healing of such ulcers by up-regulating and 
sustaining high levels of pro-inflammatory cytokines such as IL-6.
Materials and methods: Forty five type 2 DM patients (76% male; mean age 
55yrs) with plantar neuropathic diabetic foot ulcers (University of Texas Clas-
sification: 82% grade 1A; 12% 1B; 3% 2A; and 3% 2B) completed at baseline the 
self-report measures both of generalized emotional distress (Perceived Stress 
Scale, PSS: 1.3±0.8 and Hospital Anxiety and Depression Scales: HADS-Anxi-
ety: 13.5±4.4; HADS-Depression: 11.7±5.0) and foot ulcer-specific emotional 
responses (Neuropathy and Foot Ulcer-Specific Quality of Life, NeuroQoL-
Interpersonal Burden scale: 3.7±1.2 and Patient Interpretation of Neuropa-
thy, PIN, scales: PIN-Amputation Worry: 4.1±0.8; PIN-Anger at Practition-
ers: 2.3±1.0). Ulcer-specific IL-6 levels were determined via quantification of 
immunohistochemical wound biopsy tissue localization; systemic IL-6 was 
measured from patient serum via enzyme-linked immunosorbent assay.
Results: In the bivariate analyses, more severe generalized and foot-ulcer-
specific emotional distress was associated with higher baseline levels of ulcer 
biopsy log-transformed IL-6 (raw mean: 608.3±545.5 cells/mm2): HADS-
Anxiety (r=0.44; p=0.031), PSS (r=0.44; p=0.034), PIN-Amputation Worry 
(r=0.54; p=0.007) and NeuroQoL-Interpersonal Burden (r=0.60; p=0.004). 
Similarly, more severe PSS (r=0.35; p=0.05), PIN-Anger at Practitioners 
(r=0.33; p=0.03) and NeuroQoL-Interpersonal Burden (r=0.39; p=0.03) were 
associated with higher baseline serum IL-6 levels (mean: 8.9±4.2pg/ml). Fur-
thermore, patients with higher baseline levels of serum IL-6 were less likely to 
achieve 80% or greater wound area reduction at 6 weeks (r=-0.35; p=0.03).
Conclusion: These preliminary findings suggest that emotional distress-re-
lated IL-6 up-regulation may be one of the mechanisms linking psychological 
stress to chronicity of diabetic foot ulcers.
Supported by: NIH/NIDDKRO1DK71066-01A4
1159
Characterisation of circulating stem and progenitor cells in type 2 
diabetic patients with foot ulceration
T. Koblik1, E.K. Zuba-Surma2, P. Witek1, W. Nowak2, A. Jozkowicz2,  
M.T. Malecki1, J. Dulak2; 
1Department of Metabolic Diseases, 2Department of Medical Biotechnology, 
Jagellonian University of Krakow, Poland.
Background and aims: Type 2 diabetes (T2DM) is a major health problem in 
Europe due to severe complications, for example the diabetic foot syndrome 
(DFS). Ulcerations that are often difficult to heal. Their pathogenesis may be 
associated not only with metabolic abnormalities but also with alterations in 
stem and progenitor cell mobilization. It has been shown that both the func-
tionality and the number of endothelial progenitor cells (EPC) circulating in 
peripheral blood (PB) are altered in diabetic patients. However, other stem 
cell (SC) populations potentially involved in wound healing and regenera-
tion such as i) mesenchymal SC (MSC) and ii) adult pluripotent SC (PSC), 
including very small embryonic-like (VSEL) SC, have never been examined 
in T2DM. Aim of the study was to examine the phenotype and level of SC 
circulating in PB in T2DM subjects with and without DFS as compared to 
healthy controls.
Materials and methods: Three groups of subjects were included: a) T2DM 
patients without DFS (n=9); b) T2DM with DFS with ulceration(s) (n=3), 
c) controls without diabetes (n=4). We employed flow cytometry to evaluate 
the presence of the following SC populations based on the surface markers: i) 
EPC (CD31+CD133+CD45-, CD31+KDR+CD34+CD45-); ii) MSC (STRO-
1+CD105+CD45-, CD90+CD29+CD45-) and PSC (Lin-CD45-CD133+, 
Lin-CD45-Tra1.81+).
Results: We found that when compared to healthy subjects, the number of 
EPC was decreased in both T2DM groups (w/o and with DFS) (9.6±2.1, 
5.3±0.7* and 3.4±2.3 of CD31+CD133+CD45- cells/1ml PB, respectively). 
Similarly, the number of MSC were smaller in both T2DM groups (6.4±1.1, 
3.9±0.5* and 2.2±0.4 of STRO-1+CD105+CD45- cells/ 1ml PB, respectively). 
Interestingly, the numbers of PSC was slightly decreased in healthy controls 
as compared to T2DM patients (0,27±0.7, 0.30±0.08 and 0.38±0.07of Lin-
CD45-CD133+ cells/ 1ml PB, respectively). * P<0.05 vs. control.
Conclusion: For the first time we characterized several subsets of SC circulat-
ing in the blood of T2DM patients. Our initial results indicate that as com-
pared to healthy controls, their mobilization may be different, particularly 
in the subgroup with DFS and ulceration; a potential pathogenic role of this 
phenomenon should be considered.
Supported by: European Union structural funds, Innovative Economy Opera-
tional Programme
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The diabetic foot: relevance of endothelial progenitor cells as a 
prognostic marker of mortality and disease progression
O. Fortunato1, G. Spinetti1, D. Cordella1, P. Portararo1, E. Faglia1,  
P. Madeddu2; 
1IRCCS MultiMedica, Milan, Italy, 2University of Bristol, United Kingdom.
Background and aims: Ischemic diabetic foot ulcers represent an unmet 
clinical need. To date, the prediction of clinical outcome relies on clinical 
data rather than on endogenous repair mechanisms. Circulating endothelial 
progenitor cells (EPC) are implicated in healing processes but reduced in pa-
tients with diabetes and inversely correlated with severity of vascular compli-
cations. Here, we report the preliminary results of a longitudinal study aimed 
to verify whether the abundance and functional activity of EPCs predict ma-
jor endpoints such as amputation and post-angioplasty restenosis. 
Materials and methods: The project was designed to enrol 109 diabetic (type 
1 and 2) patients and 30 age- and sex-matched non-diabetic subjects referring 
to our Institution for chronic critical ischemia as defined by the guidelines of 
the Inter-Society Consensus (TASC) for the management of peripheral artery 
disease. Baseline testing includes measurement of glycemia, HbA1c, echo-
doppler, transcutaneous oximetry (TO) and angiography. A blood sample 
(30mL) is obtained for isolation of mononuclear cells (MNCs). The migrato-
ry activity of isolated MNCs is measured in a transwell migration assay using 
SDF-1α (100ng/ml) as a stimulus. The antigenic profile of freshly isolated and 
migrated/non migrated MNCs is evaluated by flow cytometry. All patients 
are subjected to percutaneous angioplasty and follow up visits are scheduled 
at 1, 3, 6, 12 and 18 months.
Results: Thirty-four diabetic patients and seven non-diabetic subjects 
were enrolled to date with an average follow up of 7 months. No fatal 
event was recorded; 1 major amputation and 5 restenosis occurred in the 
diabetic group. The number of MNCs did not differ between the 2 groups. 
EPCs (CD34+KDR+CXCR4+CD45low) tended to be reduced in diabetic 
(0.009±0.002% vs. 0.012±0.003% in non-diabetic p=0.4). In non-diabetics, 
SDF-1α stimulation resulted in a 2-fold enrichment of EPCs in the migrated 
fraction, whereas the response of diabetic EPCs to SDF-1α was totally abro-
gated. With regard to clinical endpoints, complications were associated with 
a higher migratory activity of lineage-positive subpopulations of the MNC 
pool, whereas no difference was found in the number and migratory activity 
of EPCs. Ad interim analysis of independent variables (number and migra-
tory activity) indicates that the designed study is adequately powered to reach 
definite conclusions on the predictive value on major endpoints.
Conclusion: This is the first longitudinal study assessing the predictive value 
of circulating progenitor cells in patients with foot ulcers and critical limb 
ischemia. Results indicate that diabetes impairs the migratory deficit of circu-
lating progenitors and that unbalanced migratory activity of different MNC 
subfractions may be associated to a higher risk for complications in the dia-
betic cohort. Our preliminary data also indicate that the study has enough 
power to determine whether circulating progenitor cells may represent a 
valuable biomarker of vascular events in patients with foot ulcers undergoing 
revascularization.
Supported by: RF-MUL-2007-633361
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Explanations for lower peak plantar foot pressures in Indian Asians 
versus Europeans with type 2 diabetes
C.A. Abbott1, S. Naqvi1, N. Chaturvedi2, R.A. Malik1, A.J.M. Boulton1; 
1Cardiovascular Research Group, University of Manchester, 2National Heart 
& Lung Institute, Imperial College, London, United Kingdom.
Background and aims: Risk of diabetes-related foot ulceration and amputa-
tion is substantially lower in Indian Asians versus White Europeans in the 
UK. We have also recently demonstrated that neuropathy (large and small 
fibre) is less prevalent in Asians, probably accounting for much of the reduced 
Asian ulcer risk. We now aimed to: (i) compare peak plantar foot pressures, 
an established risk factor for ulceration, in Indian Asian and European dia-
betic subjects; (ii) explain any ethnic pressure differences found.
Materials and methods: From our cross-sectional study of a population-
based sample of age- and sex-matched adults with type 2 diabetes of Euro-
pean and Asian descent in the UK, a random sub-cohort of 104 Europeans 
(50 female: 54 male) and 105 Indian Asians (36 female: 69 male) underwent 
plantar foot pressure measurements using the semi-quantitative PressureStat® 
system. Ethnic differences in peak pressures were determined at the meta-
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tarsal heads, great toe, second toe and heel. Comparisons with a group of 34 
age-matched, non-diabetic control subjects (European (12 female: 5 male) 
and Asian (7 female: 10 male)) were also sought.
Results: Peak pressures (>6kg/cm2) at metatarsal heads 1, 2, 3, and 5 were con-
sistently more prevalent in the European vs. Asian diabetic group (p<0.01). 
Furthermore, 32% Europeans had ≥4 peak pressure sites compared with just 
6% Asians (p<0.0001). Logistical regression analysis revealed that fewer peak 
pressures in Asians vs. Europeans could be partly explained by Asians’ lower 
weight, less plantar callus and more vigilant footcare (attenuating the Odds 
Ratio from 0.13 (0.05-0.32, 95% CI; p<0.0001) to 0.28 (0.10-0.78; p=0.014)), 
however most of this ethnic difference remained unaccounted for. Asian and 
European control groups showed a consistent trend for fewer peak pressures 
at plantar sites than their diabetic counterparts, yet peak pressures at the great 
toe were, conversely, greater. PressureStat® demonstrated a high degree of in-
tra-user agreement with 97.4-99.0% of scores within one range of each other 
on re-scoring.
Conclusion: Type 2 diabetic Indian Asians have significantly lower peak 
plantar pressures than their European counterparts, which can, in part, be 
attributed to lower weight and less plantar callus in Asians. These data may 
further help explain the substantially reduced Asian foot ulcer risk.
Supported by: Diabetes UK
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Methicillin resistant staphylococcus aureus in diabetic foot ulcers of a 
Chinese care hospital: risk factors for infection and prevalence
S. Wang1, Y. Guo2, Y. Yuan1, Z.-L. Sun1; 
1The Department of Endocrinology, 2Department of Neurology and 
Institution of Cerebral Vascular Disease, affiliated ZhongDa Hospital of 
Southeast University, NanJing, China.
Background and aims: Retrospective case-control study of 118 (M: F, 68:50) 
Chinese type 2 diabetic patients with foot ulcers (Wagner’s grade 3-5) were 
studied to determine the prevalence and risk factors for methicillin-resistant 
Staphylococcus aureus (MRSA) infection, in relation to community or hos-
pital original parameters.
Materials and methods: Ulcer specimens were processed for smear for 
Gram’s staining, aerobic culture, and susceptibility identifications. Staphylo-
coccus species were tested for methicillin resistance by using oxacillin.
Results: S.aureus was the most frequent pathogen (25.6%) in this popula-
tion, a high proportion of S.aureus isolates were MRSA (63.4%). 65.4% met 
the definition of hospital associated MRSA (HA-MRSA) infections. Size of 
ulcer (adjusted OR 1.61; 95% CI 1.22-2.12) and osteomyelitis (adjusted OR 
18.51, 95% CI 2.50-137.21) were independent predictors of MRSA infection. 
The HA-MRSA group had significantly different distributions from the com-
munity associated MRSA (CA-MRSA) group with respect to age, long his-
tory of diabetes, and length of hospital stay (all P<.001). Neuropathy, vascular 
disease (all P= .049), and osteomyelitis (P= .026) were the most common 
underlying conditions observed in the HA-MRSA group.
Conclusion: This study makes contribution to precaution against the emer-
gence of MRSA including different acquired MRSA among the Chinese popu-
lation with diabetic foot ulcers based on their original or clinical parameter.
Supported by: National Nature Science Foundation of China
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The influence of contrast medium on renal function in diabetic patient 
with critical limb ischaemia after contrast angiography/peripherial 
transluminal angioplasty
O. Bondarenko, K. Pryakhina, I. Sitkin, G. Galstyan, I.I. Dedov; 
Department of the Therapeutic and Surgical treatment methods of Diabetic 
foot, Research Center of Endocrinology, Moscow, Russian Federation.
Background and aims: The aim of the study was to assess the renal function 
of diabetic patient with critical limb ischemia (CLI), who underwent contrast 
angiography (CA)/peripherial transluminal angioplasty (PTA) before and af-
ter administration contrast medium (CM).
Materials and methods: 82 patients with PAD recruited in the study (mean 
age 65±17 years; male/female 47/53%; Type 2 DM 92%; mean diabetes mel-
litus (DM) duration 17±10 years). Peripherial artery disease was assessed by 
palpation of pedal pulse, ankle brachial index (ABI) measurement, doppler, 
transcutaneous oximetry (TcPO2) and duplex scanning (DS). Patients were 
divided according frequency and volume of CM and accuracy of DS results 
into 3 groups. The groups were matched by type of DM, age, duration of DM, 
sex. Group A (n=28) were underwent CA with the mean volume of CM 200 
ml and consecutively PTA with the mean volume CM 130 ml. In group B 
(n=36) endovascular revascularizations were performed with the mean vol-
ume CM 130 ml without CA, because of highly valuable of DS results. In 
group C (n=18) multiple CA and PTA were done with the mean volume CM 
480 ml summary. Glomerular filtration rate (GFR calculated by MDRD equa-
tion) assessed before and after administration CM on 3-5 days and in a 14 
months in all groups.
Results: Initial albumin excretion rate (AER) and GFR were not different in 
comparing groups. The decrease of mean GFR was 20,2±2,1 ml/min/1.73m2 
in group A; 14,3±1,7 ml/min/1.73m2 in group B; 19,1±1,9 ml/min/1.73m2 
in group C on 3-5 days after administration of CM. pA-B <0.01, pA-C<0.2, pB-
C<0.01. The decrease of mean GFR was 22,2±1,6 ml/min/1.73m
2 in group A; 
15±1,6 ml/min/1.73m2 in group B; 24±1,7 ml/min/1.73m2 in group C in a 
14 months. pA-B <0.01, pA-C<0.2, pB-C<0.01. 1 case of contrast-induced acute 
renal failure was registered in group A. Microalbuminuria progression ac-
cording AER was observed in 3 cases in group A and in 2 cases in group C. 
Neither AER progression nor renal failure were documented in group B. The 
accuracy and sensitivity of duplex scanning was comparable in the selection 
of aorto-iliac lesions (86% and 88%) and femoro-popliteal lesions (91% and 
93%) in A and B groups, but in infrapopliteal axis these characteristics were 
significantly higher in group B versus group A, 90% and 78%, respectively.
Conclusion: The results of this study showed that the risk of progression dia-
betic nephropathy in patients with CLI after CA/PTA increased and depend 
on frequency and volume of CM. The high accuracy DS in diabetic patients 
with CLI permits to reduce the frequency of preliminary angiography and 
prevent the development of deteriorating of renal function.
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Podiatric insoles cause foot ulcers in diabetic patients
M. van Putten1, P. Leffers2, N.C. Schaper3; 
1School of Podiatry Eindhoven, 2Epidemiology, University Maastricht, 
3Internal Medicine, Maastricht University Medical Center, Netherlands.
Background and aims: Inadequate footwear is an important contributor of 
foot ulceration in diabetic patients with polyneuropathy and prescription of 
protective footwear is seen as a cornerstone in preventing ulcers. In several 
countries preventive diabetic foot care is provided by podiatrists, who can also 
prescribe insoles. However, recent publications have casted doubt about the 
effectiveness of these insoles to reduce plantar pressure. Therefore we studied 
the effect of podiatric insoles on the incidence of diabetic foot ulcers.
Materials and methods: This study was part of the Podopoof trial; in this 
RCT we compared podiatric (n=284) with usual care by diabetologists 
(n=285), in diabetic patients with neuropathy and moderate risk (category 
2 IWDGF) for ulceration. Podiatric care consisted of ≥ 2 consultations/year 
and included preventive foot care as well as prescription of podiatric insoles 
to reduce plantar pressure, if deemed necessary. New cases of diabetic foot 
ulcers were ascertained during a follow-up period of up to 3 years.
Results: As reported earlier no difference were observed in ulcer incidence 
between the podiatry and usual care groups, 28 vs 30; data of the intervention 
and control group were therefore combined. The mean age was 63 years, the 
modified neuropathy disability score was 3,1, 52% were male. Insoles were 
prescribed in 184 patients, 177 (62%) in the podiatry and 7 (2%) in the usual 
care group. Of the patients with an ulcer 65% had insoles. Of the patients with 
insoles 22 (12%) developed an ulcer, while this occurred in 6 (1%) without 
insoles (p<0.01). Multivariable Cox regression analysis showed that the time 
to ulceration in the insole-group is shorter than in the non-insole group. Sub-
group analysis showed that men develop more ulcers than women and that 
the detrimental effect of insoles was also larger in men.
Conclusion: Prescribing preventive insoles for diabetic patients with mod-
erate risk for ulceration with the goal to prevent ulceration can have oppo-
site effects: in the insole-group more ulcers occurred than in the non-insole 
group. It is our belief that podiatrists should not prescribe insoles in these 
patients to prevent ulceration.
Supported by: CVZ, Netherlands
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Rate of relapses diabetic osteoarthropathy and its dependence on the 
terms and a carrying mode of weight-bearing bandage TotalContactCast 
at patients with acute Charcot foot
M. Vanyan, I. Ulyanova, G. Galstyan, M. Yaroslavtseva; 
Therapeutical and Surgical treatment methods of Diabetic Foot, Scientific 
research Center of Endocrinology, Moscow, Russian Federation.
Background and aims: The aim was to estimate the results of the treatment 
Charcot foot (Ch.f) in type 1 and 2 diabetic patients with weight- bearing by 
TotalContactCast at acute stage of Ch.f.
Materials and methods: In total 47 patients with diabetes mellitus (DM) 1 
type (n = 21) and 2 types (n=26), mean age of patients - 49,7 ±13,8 years. All 
patients divided in 2 groups by temperature criteria: group 1 at 22 patients 
(Δtº- 5,7º±2,7), and Group 2 - at 25 (Δtº-4,2±2,1). Mean of HbAlc at patients 
in Group 1 was 9,3 ± 2,34 %, in Group 2 - 8,7 ± 1,6. Difference between occur-
rence of clinical symptoms diabetic osteoarthropathy and start of treatment 
was 10,5 ±9 month at patients in group 1, 19,7±15,9 years at patients in group 
2. To all patients duration with treatment by TotalContactCast of group 1 
was 4,9 ± 1,8 month, in group 2 -7,7 ± 3,6 month. To all patients’ correction 
of therapy diabetes mellitus (DM) metabolic control has done. Differences 
between groups were examined by using Fisher criteria, significance level is 
p<0,05. Duration of follow-up period was 24 ± 2.4 months.
Results: In 24 months the decrease of Δ HbAlc achieved at patients in group 
1 - 7,2 ± 1,53%, and 6,9 ± 1,9% in group 2. From 47 patients, 68 %( n=32) had 
good compliance of caring TotalContactCast and at 28% (n=9) relapse oste-
oarthropathy was observed. 31% of patients (n=15) didn’t follow the term of 
recommended treatment and the relapse of osteoarthropathy was significantly 
high and observed in 67 % cases (n = 10); remission in 23%, ( p = 0,023). In 
group 1- 22 patients only 63 % (n =14) followed recommendations about carry-
ing period of TotalContacCast and unloading, thus relapse in group 1 observed 
at 43 % (n=6). Significantly associated in 36 % (n=8) patients, who stopped 
therapy before term, relapse was revealed at 62 % of patients (n=5), (p = 0,008). 
In group 2 of 25 patients - of 72 % (n=18) followed the term of carrying Total-
ContactCast and lower extremity unloading (relapse - at 17 % of patients, n=3). 
From 28 % (n=7) the patients without observing a mode of unloading, in 71 % 
of cases (n=5) relapse osteoarthropathy (p = 0,037) is revealed.
Conclusion: Weight-bearing bandage is a highly effective method of treat-
ment of the first choice for therapy Charcot foot: remission of the complica-
tion is reached in 72 % of cases, in both groups. At non-observance of condi-
tions fixating therapies remission in 2 year evaluating period makes only 23 % 
of investigated patients. Thus, the mode of weight-bearing and its duration is 
crucial to lower the relapse rate of diabetic patients with acute osteoarthropa-
thy, within glycemic control.
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Diabetic foot osteomyelitis can be successfully treated with antibiotics
S. Acharya; 
Endocrinology and Diabetes, Lancashire Teaching Hospitals NHS Trust, 
Chorley, United Kingdom.
Background: Osteomyelitis (OM), a common complication of diabetic foot 
ulcer, is associated with higher risk of amputation. In our centre we treat OM 
primarily with antibiotics and we wanted to study the outcome of patient who 
had diagnosis of OM.
Aims of study: The aim of this study was to analyse clinical outcome of sub-
jects who had diagnosis of OM in the past 5 years.
Subjects and methods: In this retrospective study, cases were selected from 
the electronic record with the diagnosis of OM. Results were crosschecked 
with radiology database. Pathology and microbiology database were also 
used to collect data.
Results: 147 cases had clinical diagnosis of OM out of which 130 (mean age 
66.2±14.4 years and mean duration of diabetes 13.2±10.9 years) had diag-
nosis reconfirmed on at least one of the established criteria (Probe to bone 
102, X-Ray changes 69, Bone scan 27, leukoscan 4 and bone biopsy 5). Of 
these reconfirmed cases, majority (66.9%) were male and had type 2 diabetes 
(80%) with mean HbA1c of 8.1± 2.1% and cholesterol of 4.2±1.5 mmol/L. Pe-
ripheral vascular disease, defined by absence of palpable pulses, was present 
in 61 (46.9%) subjects. Blood count performed on 112 cases showed raised 
neutrophil count (>7.5) only in 26 (23.2%). 64 had staphylococcus isolated 
from wound swab of which 20 (31.3%) had MRSA. Flucloxacillin and fusi-
date combination was used in 81 cases whereas ciprofloxacin and clindamy-
cin combination was used only in 17 cases. 87 (66.9%) healed with single 
(n=46) or multiple (n=41) courses of antibiotics. 18 (13.8%) had amputation 
of which 16 (12.3%) were minor (Toes or Ray amputation) and 2 (1.5%) were 
major (above or below knee). 12 (9.2%) had vascular intervention (8 angi-
oplasty & 4 bypass) and 8 (6.2%) died within 12 months of diagnosis due to 
other causes. There were no differences in outcome between subjects with or 
without x-ray changes. When compared between those which healed (n=87) 
and those patients who died or needed amputation (n=26), there was no dif-
ference in age sex, duration of diabetes, site of ulcer, presence of x-ray changes 
or peripheral vascular disease. OM due to MRSA was the only factor that 
predicted adverse outcome (21.1% vs 53.3%; p=0.04). Higher rate (p=0.01) 
of adverse outcome was noted in patients using combination of ciprofloxacin 
and clindamycin, which may be due to its use as a last resort in our clinic.
Discussion: Our data confirms that OM can be successfully treated with an-
tibiotics. Flucloxacillin and fusidate can be used as first line treatment in ma-
jority of cases. Surgery should be reserved only for cases that fail to respond 
to medical treatment.
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Efficacy of moxifloxacin in the treatment of diabetic foot infections: 
results of the RELIEF study
N. Schaper1, M. Dryden2, P. Kujath3, D. Nathwani4, P. Arvis5, P. Reimnitz6,  
J. Alder7, B. Hampel8, I. Gyssens9; 
1University Medical Centre, Maastricht, Netherlands, 2Royal Hampshire 
Hospital, Winchester, United Kingdom, 3University Clinic of Luebeck, 
Germany, 4Ninewells Hospital and Medical School, Dundee, United Kingdom, 
5Bayer Schering Pharma, Loos, France, 6Bayer Schering Pharma AG, Wuppertal, 
Germany, 7Bayer HealthCare, Montville, USA, 8Bayer Schering Pharma AG, 
Berlin, Germany, 9Radboud University Nijmegen Medical Centre, Netherlands.
Objectives: Diabetic foot infections (DFIs) cause substantial morbidity. As 
DFIs are usually polymicrobial, broad-spectrum antibiotics play an important 
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role in therapy. Due to their wide antimicrobial coverage and pharmacody-
namic properties, fluoroquinolones, such as moxifloxacin (MXF), may have 
several advantages over other antimicrobial classes. The RELIEF study was 
conducted to provide further data on the efficacy of MXF in specific compli-
cated skin and skin structure infections. Data on DFIs are presented here.
Methods: In this double-dummy, double-blind, randomised, controlled trial, 
patients with a DFI requiring antimicrobial therapy were stratified according 
to infection severity and the requirement for surgery. Patients received either 
IV/PO MXF 400 mg qd or IV piperacillin/tazobactam 4.0/0.5 g tds followed 
by PO amoxicillin/clavulanate 875/125 mg bd (PIP/TAZ-AMC), for 7-21 
days. The DFI diagnosis was based on predetermined criteria, documented 
by repeated photographs and confirmed by an independent data review com-
mittee (DRC). The primary efficacy variable was resolution of infection 14-28 
days after completion of study medication (test-of-cure, TOC) as determined 
by the DRC.
Results: A total of 206 patients (mean age 59.2 years) were valid for the effi-
cacy analysis (MXF=110, PIP/TAZ-AMC=96). Of these, 65.5% of MXF- and 
70.8% of PIP/TAZ-AMC-treated patients had clinical signs of peripheral ar-
terial disease (ankle brachial index <0.9, foot pulses barely or non-palpable). 
Most patients had DFIs with a PEDIS score of 3, i.e. moderate in severity 
(MXF 81.3%; PIP/TAZ-AMC 86.2%). In the microbiologically-valid (MBV) 
population, polymicrobial infections were common (MXF: 60.9%; PIP/TAZ-
AMC: 62.4%); the most frequently isolated pathogen was S. aureus (MXF 
69.6%; PIP/TAZ-AMC 81.2%). Meticillin-resistant S. aureus was relatively 
uncommon in the MBV population (MXF 12.0%; PIP/TAZ-AMC 14.1%). A 
total of 150 (72.8%) patients had initial surgery (MXF 70.9%; PIP/TAZ-AMC 
75.0%), including amputation in 46.4% (MXF) and 34.4% (PIP/TAZ-AMC) 
of PP patients. MXF and PIP/TAZ-AMC had similar efficacy with respect to 
clinical cure at TOC (Table). A total 20.9% MXF and 25.0% PIP/TAZ-AMC 
patients had additional surgeries >48 hours after the start of therapy and were 
assessed as clinical failures. Bacteriological success rates were comparable be-
tween treatment arms (Table).
Conclusion: IV/PO MXF had similar efficacy to IV PIP/TAZ-AMC in pa-
tients with DFI. MXF can be considered a valuable option for the treatment 
of moderate-to-severe DFI. 
Table: Clinical and bacteriological success rates at TOC overall and by most 
commonly isolated pathogen
MXF PIP/TAZ-AMC P‡ (95% CI)
n/N (%)
Clinical cure§ 84/110 (76.4) 75/96 (78.1) 0.650 (-14.5, 9.0)
Bacteriological success (MBV population)
Overall 66/92 (71.7) 61/85 (71.8) 0.658 (-16.9, 10.7)
Staphylococcus aureus
Meticillin-susceptible
Meticillin-resistant
43/53 (81.1)
8/11 (72.7)
39/57 (68.4)
10/12 (83.3)
-
-
Escherichia coli 6/8 (75.0) 6/9 (66.7) -
Enterococcus faecalis 19/30 (63.3) 20/29 (69.0) -
‡Cochran-Mantel-Haenszel test
§n/N=number of patients experiencing clinical cure/ total number of pa-
tients
n/N = number of patients experiencing eradication or presumed eradica-
tion/number of patients with pathogen isolated and an evaluable bacterio-
logical response
CI: confidence interval; MBV: microbiologically valid population (all effi-
cacy valid patients with a pathogen isolated at baseline)
Supported by: Bayer Schering Pharma AG
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The effect of topical phenytoin on healing in diabetic foot ulcers: a 
randomised controlled trial
J. Shaw1, C.M. Hughes2, K.M. Lagan2, M.R. Stevenson3, C.R. Irwin4, P.M. 
Bell5; 
1Podiatry, Regional Centre for Endocrinology and Diabetes, 2University of 
Ulster, 3Department of Medical Statistics, Epidemiology and Public Health, 
Queen’s University, 4School of Dentistry, Queen’s University, 5Regional 
Centre for Endocrinology and Diabetes, Belfast, United Kingdom.
Background and aims: Phenytoin (PHT) may have a positive effect on 
wound healing by increasing collagen production and reducing bacterial 
load and wound exudate. A randomised, controlled, double-blind, clinical 
trial was conducted to evaluate the effect of topical PHT on healing in dia-
betic foot ulcers (DFU).
Materials and methods: A PHT dressing and a control dressing were manu-
factured. Participants of ≥ 18 years of age with peripheral neuropathy, stable 
vascular status, and a DFU ≥ 4 weeks duration were included. Participants 
with renal disease, acute ischaemia, necrosis, worsening infection or osteo-
myelitis were excluded. Subjects were independently randomised to either 
PHT or Control groups, received standard wound care, and dressing ap-
plication. Primary end-point analysis (DFU closed or not at 16 weeks) was 
calculated by Survival Analysis. Analysis of secondary outcome (percentage 
change in DFU area over time) used an Ordinal Regression Model.
Results: Participants (n=65, 52 with Type 2 Diabetes) were randomised to the 
PHT (31) or Control group (34). Following a maximum of 16 weeks treat-
ment, 60% of the DFUs closed overall (18 PHT: 20 Controls) with no statisti-
cally significant differences in complete healing or in DFU area over time 
between the two groups. Pain levels were reduced in the PHT-treated group. 
At 24 weeks, 1 DFU had recurred.
Conclusion: There were no differences in DFU closure rates or in DFU area 
over time between the two groups. This study does not support the use of 
PHT in the treatment of DFUs.
Supported by: HSCR&DNI
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Improved survival in patients with diabetes and chronic foot ulcers after 
hyperbaric oxygen therapy. Outcome of a randomised double-blind 
placebo controlled study
M. Löndahl1, P. Katzman1, A. Nilsson2, M. Landin-Olsson1; 
1Endocrinology, Clinical Sciences, Lund, 2Internal Medicine, Ängelholm, 
Sweden.
Background and aims: Presence of diabetic chronic foot ulcers (DFU) is 
associated with an increased mortality risk. Hyperbaric Oxygen Therapy 
(HBOT) has been suggested as a treatment modality of DFU. HBOT in-
creases oxygenation and stimulates angiogenesis. The aim of this study was 
to evaluate if HBOT improves survival in patients with diabetes and chronic 
foot ulcers.
Materials and methods: Hyperbaric Oxygen therapy in patients with Dia-
betes and chronic Foot Ulcers (HODFU) study is a prospective randomized 
double-blind placebo-controlled study evaluating the effect of 40 HBOT ses-
sions as compared to 40 treatments with hyperbaric air (placebo). Patients 
receiving more than 35 treatment sessions were included in the predefined 
per-protocol analysis. Three-year mortality rates were evaluated in this study. 
Categorical variables were analyzed using Fischer´s exact test, continuous 
variables using Mann-Whitney U-test and Kaplan-Meier curves using Cox-
Mantel test. A two-sided p-value <0.05 was taken as statistical significant.
Results: 75 patients (38 HBOT and 37 placebo) with a similar median age (67 
and 71 years (n.s.) (HBOT and placebo)) and a diabetes duration of 22 and 
21 years (n.s.) were included in this analysis. No differences were seen in co-
morbidity between groups. Mortality rates were 10.5 % and 29.7 % (p=0.04) 
respectively after three years follow-up. Median ages of deceased patients 
were 79 and 75 years (n.s.).
Conclusion: This study indicates that HBOT may improve survival in pa-
tients with diabetes and chronic foot ulcers.
Supported by: Mrs Thelma Zoegas Foundation
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Pathogenetic criteria of differentiation tactics at surgical treatment of 
purulent necrotic wounds in patients with diabetic foot
M.V. Svyrydov1, N. Bondarenko1,2, S. Bolgarska2; 
1Surgery, National Medical University, Donetsk, 2Diabetology, State 
Institution “V.P. Komisarenko Institute of endocrinology and metabolism of 
the Academy of Medical Sciences”, Kiev, Ukraine.
Background: A search for informative criteria for a wound process course in 
the treatment of destructive forms of Diabetic Foot Syndrome (DFS) presents 
a serious clinical problem, which requires new scientific approaches in its 
solution.
Aims: Development of prognostic criteria for a wound process course al-
lowing choosing pathogenetically justified methods of surgical treatment of 
wounds in patients with DFS.
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Material and methods: The results of a surgical treatment of 186 patients 
with destructive forms of DFS have been analyzed in accordance with PEDIS 
classification with P1-2E1-2D2-3I2-3 present. The condition of the intracellular 
tyrosinase system, the content of cytokines (IL-1β, IL-4, TNGα, IFNγ) and 
eicosanoids (PGE2, LTB4, PGI2) in blood at different stages of the treatment 
have been studied. A wound coating, autoplasty, a tamponade by dermo-fat 
flap (DFF) and a culture of cultivated autofibroblasts have been used as means 
of covering postoperative wound defects, stabilization of a destructive proc-
ess and acceleration of tissue reparation.
Results: The individual peculiarities of a wound process course were directly 
dependent on the area and depth of tissue destruction, power of the tyrosi-
nase system, which finds its expression in the results of the tyrosinase index. 
After a surgical treatment of the wound, changes in the intercytokine coeffi-
cient allowed prognosing the course of a proliferation phase - 50% and higher 
increase of the coefficient was a favorable sign and an indication for the use 
of a wound coating or autoplasty. 10% decrease of the coefficient and lower 
appeared to be an unfavorable sign and required the use of a tamponade of a 
great wound defect by DFF and/or a culture of cultivated autofibroblasts with 
a further plastic covering of the wound. 14.3% decrease of the eicosanoid 
coefficient during 3-5 days after a necrosectomy was accompanied by a high 
efficiency of a wound coating and autoplasty application, quick wound heal-
ing. 33.5% and higher increase of the eicosanoid coefficient against the back-
ground of LTB4 and PGI2 deficiency testified to the humoral control disorder 
of inflammatory reparative processes which were accompanied by spread of 
a destructive process, a more prolonged period of wound healing and/or re-
sulted in performing big amputations.
Conclusion: The reparation humoral regulators revealed reflect individual 
peculiarities of a wound process course and give an opportunity to make a 
prognosis concerning the outcome of wound healing in patients with DFS 
operated on.
1171
Outcome of surgical treatment in diabetic forefoot osteomyelitis
R. Da Ros, R. Assaloni, B. Brunato, S. Carlucci, C. Tortul; 
Diabetologic Service, Monfalcone Hospital, Italy.
Background and aims: Osteomyelitis is one of the most frequent infections 
of the diabetic foot. The treatment of osteomyelitis of the foot in diabetic 
patients continues to be debated, most experts considered that the standard 
should be the surgical removal of infected bone. Aim of this study is to deter-
mine efficacy and relapse rate of surgical treatment of osteomyelitis.
Materials and methods: We performed a surgical removal of infected bone 
in 206 consecutives diabetic patients. Forefoot osteomyelitis were confirmed 
by probe to bone test and radiological signs of osteomyelitis.
Results: Osteomyelitis were localized in 140 patients at phalangeal level 
(68%), in remaining 66 patients at metatarsal head level: 19 first head (9%), 9 
second head (4%), 5 third head (3%), 4 forth head (2%), 29 fifth head (14%). 
Bone culture was performed in 122 patients, in 118 patients was positive 
and Staphylococcus aureus was the organism isolated in majority of cultures 
(42%). Kind of surgical treatment: 152 conservative surgical procedures were 
performed (74%), in the remaining cases: 23 distal finger amputations , 20 
finger amputations, 11 ray amputations. 154 patients (75%) healed, mean 
healing time was 62±42 days. Causes of healing failure were: 19 patients for 
ischemic relapse, 21 patients for residual osteomyelitis, 12 patients for other 
causes. 37 patients (18%) healed with a second surgical procedure. Once 
healed wound relapse was observed in only 5 patients (3%) in a mean follow 
up of 12±4 months.
Conclusion: Surgical removal of infected bone in forefoot osteomyelitis seem 
a safe procedure with an elevated healing rate and large possibility of con-
servative management. Relapse rate is low when healing is reached.
1172
Health Technology Assessment (HTA) on the importance of growth 
factors for the treatment of Diabetic Foot Ulcers (DFU)
B. Buchberger1, M. Follmann2, H. Huppertz1, J. Wasem1; 
1University of Duisburg-Essen, Essen, 2German Cancer Society, Berlin, 
Germany.
Background: Ulcers as a result of Diabetes mellitus are a serious problem 
with an enormous impact on the overall global disease burden due to the in-
creasing prevalence of diabetes. Because of long hospital stays, rehabilitation, 
often required home care and the use of social services diabetic foot compli-
cations are costly. Therapy with growth factors could be an effective and in-
novative add-on to standard wound care. The aim of the HTA on behalf of the 
German Institute of Medical Documentation and Information DIMDI is to 
assess the safety and efficacy of growth factors alone or in combination with 
other technologies in the treatment of DFU including medical, economical, 
social, ethical and juridical aspects.
Methods: We systematically searched relevant data bases limited to English 
and German language and publications since 1990. Cost values were adjusted 
for the price level in 2008 and converted into Euro. Review and assessment of 
the quality of publications followed methods conforming to widely accepted 
standards for evidence-based medicine and health economics.
Results: We identified 25 studies (14 randomized controlled trials (RCT), 
nine cost-effectiveness analyses, two meta-analyses). The RCTs compared an 
add-on therapy to standard wound care with standard wound care/placebo 
alone or extracellular wound matrix: 6 studies used becaplermin, two rhEGF, 
one bFGF, and five studies the metabolically active skin grafts Dermagraft 
and Apligraf. Study duration ranged from 12 to 20 weeks and the study popu-
lation comprised between 17 and 382 patients, average 130 patients. Treat-
ment with becaplermin, rhEGF and growth factors secreting skin implants 
Dermagraft and Apligraf showed in eight out of 13 studies an advantage con-
cerning complete wound  closure and the time to complete wound healing 
with statistically significant differences. Evidence for a benefit of treatment 
with bFGF could not be found. In four out of the 14 studies the proportion 
of adverse events was 30 % per study group with no difference between the 
treatment groups. The methodological quality of the studies was affected by 
significant deficiencies. Economic evaluations showed becaplermin being 
cost-effective whereas no obvious statement can be made regarding Derma-
graft and Apligraf because of diverging cost bases and incremental cost-ef-
fectiveness ratios.
Discussion: Differences in standard wound care are complicating the com-
parison of study results. Taking into consideration the small to very small 
sample sizes and other methodological flaws with high potential of bias the 
validity of the results with regard to effectiveness and cost-effectiveness has to 
be considered limited. The duration of treatment and follow-up examinations 
is not long enough to assess sustainability of intervention and surveillance of 
ulcer recurrences or potential treatment related adverse events like develop-
ment of malignancy.
Conclusion: There are indications of an advantage for the add-on therapy 
with growth factors in DFU concerning complete wound closure and the 
time to complete wound healing. Further more studies of high methodologi-
cal quality with adequate sample sizes and sufficient follow-up periods are 
necessary, also investigating patient-relevant parameters like health-related 
quality of life, acceptance and tolerance of intervention in addition to clinical 
outcomes.
Supported by: DIMDI
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Prevalence of diabetic retinopathy at first screening event in a national 
screening programme in Wales UK: 2005 - 2009
S. Roy Chowdhury1, R.L. Thomas1, S.D. Luzio1, S.L. Hale2, R.V. North3, D.R. 
Owens1; 
1Diabetes Research Unit, Cardiff University, 2Department of Ophthalmology, 
Cardiff and Vale University Health Board, 3School of Optometry, Cardiff Uni-
versity, United Kingdom.
Background and aims: To report the prevalence of diabetic retinopathy (DR) 
in subjects with diabetes who attended for their first screening event with the 
Diabetic Retinopathy Screening Service for Wales (DRSSW) between 2005 
and 2009.
Materials and methods: 135,152 subjects with diabetes (55.3% male, 42.6% 
female, 2.1% not documented) attended for their first screening event. Digital 
photography (2x 45° field of each eye) was performed following mydriasis 
with tropicamide 0.5%; retinal grading was based on the UK National Con-
sensus Grading Protocol with the highest (worst) grade for either eye taken 
as the final grade. Referral to hospital eye services were made for those cases 
where the level of DR seen was pre-proliferative (PPDR) or proliferative 
(PDR) with or without the presence of maculopathy or maculopathy only i.e. 
referable diabetic retinopathy (RDR). The level of DR was considered to be 
of a sight-threatening level (STDR) if either or both PDR and maculopathy 
were present.
Results: 88,131 subjects (65.2%) had no DR and 47,021 (34.8 %) (57.5% male, 
40.1% female, 1.5% not documented) had evidence of DR. In those subjects 
with DR at first screen the mean (±SD) age was 63.3 (14.8) years, duration of 
diabetes was 9.6 (9.0) years; 11.6% were T1DM, 64.9% T2DM and for 23.5% 
type not recorded. 13.9% of subjects were diet controlled, 42.2% received ad-
ditional oral hypoglycaemic agents and 23.8% insulin. In 20.1% the treatment 
modality was not documented. During the five year screening period (Table 
1) the prevalence of BDR at first screening remained essentially unchanged 
at approximately 80% of those patients with any evidence of DR. PDR in-
creased from 0.9 to 2.6% over the 5 year period but maculopathy remained 
essentially unchanged between 4.4-5.1%. The number of people requiring re-
ferral to ophthalmologists increased slightly following the first year but then 
remained unchanged.
Conclusion: In a national screening programme at first screen 65.2 % of pa-
tients had no DR. Of those with DR (34.8 %) the majority had BDR (~80%) 
which did not require referral to the hospital eye service. In summary only 
5.6% of the total population at first screen required further assessment at the 
hospital eye service.
Table 1 Presence of DR at first screen (2005 - 2009)
All Years 2005 2006 2007 2008 2009
N % % % % % %
BDR 36,724 78.1 80.8 76.5 77.6 76.5 76.7
PPDR 2,490 5.3 4.9 5.6 5.6 5.1 5.3
PDR 736 1.6 0.9 1.4 1.7 2.5 2.6
Maculopathy 2,222 4.7 4.4 5.1 4.8 4.6 4.6
STDR1 5,115 3.8 3.1 4.2 4.0 3.7 3.9
STDR2 5,115 10.9 8.5 11.8 11.5 12.5 12.6
RDR1 7,605 5.6 4.9 6.3 6.0 5.3 5.5
RDR2 7,605 16.2 13.4 17.4 17.1 17.6 17.9
BDR-Background DR; PPDR-Preproliferative DR; PDR-Proliferative DR; 
Maculopathy-Exudates within 1 disc diameter of fovea ±retinal thickening; 
STDR1-Sight threatening DR of the total population; STDR2-Sight threaten-
ing DR of those with DR; RDR1-Referable DR of the total population; RDR2 
- Referable DR of those with DR.
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Prevalence and associated risk indicators of retinopathy in rural 
Bangladeshi population with and without diabetes
A. Akhter1, K. Fatema1, A. Afroz1, S.M.A. Hannan Miah2, A.S.M. Nurullah 
Awal3, A. Raihan3, L. Ali4, A. Hussain5; 
1Dept of Epidemiology & Biostatistics, Bangladesh Institute of Health 
Sciences (BIHS), Dhaka, Bangladesh, 2Dept of Ophthalmology, Thakurgaon 
Swasthoseba Hospital, Thakurgaon, Bangladesh, 3ORBIS International, 
Dhaka, Bangladesh, 4Dept of Biochemistry & Cell Biology, Bangladesh 
Institute of Health Sciences (BIHS), Dhaka, Bangladesh, 5Dept of 
International Health, University of Oslo, Norway.
Background and aims: Retinopathy, a potential sight threatening condi-
tion, is a significant public health problem. The absence of reliable popula-
tion based epidemiological data on retinopathy in Bangladesh is a serious 
impediment to the effective national planning of eye care programmes. In the 
above context, we planned to carry out an epidemiological study to create a 
baseline data focused on retinopathy. We aimed to observe the prevalence of 
retinopathy among people with normal and abnormal glucose metabolism in 
a remote rural community of Northern Bangladesh and to identify the associ-
ated risk indicators for developing retinopathy in this population.
Materials and methods: This population based cross-sectional study was 
conducted through screening in camp settings, which included a total of 836 
participants (468 male, 368 female), aged at or above 25 years. Retinopathy 
was determined by ophthalmoscope and fundus photography. Anthropo-
metric measurements (BMI and WHR), OGTT, glycosylated haemoglobin 
(HbA1c), blood pressure, lipid profile, serum creatinine and urine albumin-
creatinine ratio (UACR) were also observed. Serum glucose (fasting and 2 
hr after 75 gm glucose) was measured by glucose oxidase method, HbA1c by 
high performance liquid chromatography (HPLC), total cholesterol, triglyc-
eride and HDL were analyzed by enzymatic-colorimetric method, LDL was 
estimated by Friedewald’s formula, serum creatinine and urine creatinine 
were measured by alkaline picrate method and urine albumin by pyrogallol 
red method. Logistic regression analysis was used with adjustment for poten-
tial confounders.
Results: The overall prevalence rate of retinopathy was 5.4% (95% CI 3.9-
6.9). Moreover, the prevalence of retinopathy among the diabetic, prediabetic 
and nondiabetic subjects were 21.6% (95% CI 11.2-32.0), 13% (95% CI 3.4-
22.6) and 3.5% (95% CI 2.2-4.8), respectively. Females (6.0%) had higher 
prevalence of retinopathy compared to males (4.9%). The peak prevalance 
of retinopathy (10.7%) was found in the older age group (above 55 years). 
Age, BMI, WHR, blood pressure, serum glucose (fasting and 2 hr after 75 
gm glucose), HbA1c, triglyceride, total cholesterol, LDL-cholesterol, serum 
creatinine and UACR were significantly (p<0.05) higher among the subjects 
with retinopathy compared to those without retinopathy. The retinopathy 
subjects with abnormal glucose metabolism had significantly (p<0.05) higher 
BMI, blood pressure, triglyceride, total cholesterol, LDL-cholesterol, serum 
creatinine and UACR compared to retinopathy subjects with normal glucose 
metabolism. On logistic regression analysis age, BMI, abnormal glucose me-
tabolism, hypertension and UACR were found as significant independent risk 
indicators for the occurrence of retinopathy in this population.
Conclusion: The data suggest that, in addition to serum glucose control in 
diabetic patients, screening for hypertension, general obesity, and proteinuria 
as well as adequate treatment of these risk indicators may prevent retinopathy 
in rural Bangladeshi population.
Supported by: Bangladesh Diabetic Somiti & ORBIS International Bangladesh
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Early-onset type 2 diabetes: high risk for premature significant diabetic 
retinopathy
S.H. Song, C.A. Hardisty; 
Diabetes Centre, Northern General Hospital, Sheffield, United Kingdom.
Background and aims: The incidence of early onset (age of diagnosis <40) 
type 2 diabetes (T2D) is increasing. Given the potential long duration of ex-
posure to the deleterious diabetic milieu, this cohort is at risk of developing 
premature diabetes complications. Diabetic retinopathy is a significant cause 
of morbidity in T2D and at present, the impact of early age of diabetes onset 
on the burden, severity and prematurity of retinopathy complication remains 
unclear.
Materials and methods: A cross-sectional study using hospital diabetes reg-
ister and eye screening database to identify T2D subjects and quantify se-
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verity of diabetic retinopathy. Early and later onset is defined as age of T2D 
diagnosis below and above 40 years respectively. Severity of retinopathy is 
classified into background, pre-proliferative, proliferative and maculopathy. 
Significant retinopathy (SigR) refers to pre-proliferative, proliferative or 
maculopathy. Prevalence and severity of retinopathy was analysed at diabetes 
durations of <10, 10-20 and >20 yrs.
Results: 2516 T2D subjects were identified of whom 455 were diagnosed be-
low age 40 yrs. Mean age of diagnosis for early and later onset cohort was 32.2 
and 54.6 yrs respectively. Despite the short diabetes duration (early vs later; 
6.2 vs 6.4 yrs, p=NS), early-onset T2D subjects with mean age of 38.4 yrs had 
substantial burden of retinopathy of all severity (26.9%), similar to later-onset 
cohort (29.5%) with mean age of 62.4 yrs. Prevalence of retinopathy of all 
severity increased with diabetes duration (p<0.05) in both cohort. Diabetes 
duration was a significant predictor of retinopathy complications (p<0.05). 
The prevalence of SigR increased substantially after 10 yrs of diabetes with 
both early and later onset cohort experienced similar complication burden 
(duration <10 yrs: early vs later; 5.7 vs 8.2%, p=NS; duration 10-20 yrs: early 
vs later; 26.6 vs 24.3%, p=NS; duration >20 yrs: early vs later, 45.5 vs 38.5%, 
p=NS) which occurred approximately 15-25 years earlier among early-onset 
cohort (mean age - duration <10 yrs: early vs later; 38.4 vs 62.4 yrs, p<0.05; 
duration 10-20 yrs: early vs later; 46.5 vs 68.6 yrs, p<0.05 and duration >20 
yrs: early vs later; 58.4 vs 73.8 yrs, p<0.05). Early-onset cohort were more 
likely to have suboptimal glycaemic control (HbA1c >7.5%) than later-onset 
cohort irrespective of diabetes duration (duration <10 yrs: early vs later; 67.5 
vs 58.6%, p<0.05; duration 10-20 yrs: early vs later; 82.6 vs 67.5%, p<0.005; 
duration >20: early vs later; 81.0 vs 71.1%, p<0.05).
Conclusion: Early onset T2D subjects have substantial risk of developing 
sight-threatening eye disease in later years but at an earlier age than later 
onset cohort. Important contributing factors include suboptimal diabetes 
control and prolonged exposure to diabetic milieu.
1176
Glycated haemoglobin as a surrogate marker for the appearance and 
progression of retinopathy in type 2 diabetes mellitus: systematic review 
and meta-analysis
P. Rys1, A. Wieczorek1, A. Marcisz1, I. Skrzekowska-Baran2, M.T. Malecki3; 
1HTA Consulting, Krakow, 2NovoNordisk, Warsaw, 3Department of 
Metabolic Diseases, Jagiellonian University, Krakow, Poland.
Background and aims: Glycated hemoglobin (HbA1c) is commonly em-
ployed in clinical trials as a surrogate marker of diabetes control and the risk 
for diabetic complications in type 2 diabetes mellitus (T2DM). To date, sev-
eral trials have examined the relationship between HbA1c and microvascular 
complications, but no systematic review (SR) has been published. We per-
formed a SR and meta-analysis to examine the association between HbA1c 
and the appearance and progression of diabetic retinopathy (DR) in T2DM.
Materials and methods: We conducted a systematic literature search in 
electronic medical databases (MEDLINE, CENTRAL) with highly sensi-
tive search strategy, including over 100 terms grouped into three categories: 
population (e.g. “diabetes mellitus”, “non insulin dependent diabetes melli-
tus”); surrogate (e.g. “glycosylated hemoglobin”) and clinically outcomes (e.g. 
“retinopathy”). Observational studies (OS) and randomized, controlled trials 
(RCT) of retinopathy in T2DM patients that reported HbA1c level were in-
cluded. Estimates were made of the adjusted relative risk (RR) of complica-
tions for an increase in HbA1c of 1%. Weighted mean differences (WMD) 
in HbA1c level between the case (with DR) and the control group (without 
DR) were also calculated. Meta-regression was used to explain heterogeneity 
between the studies with respect to the risk of DR. The following covariates 
were considered: follow-up, HbA1c level, age, disease duration, BMI, choles-
terol level and blood pressure.
Results: We identified 17 trials that fulfilled the inclusion criteria, involving a 
total of 10 236 patients. Based on two RCT (n = 240), pooled RR for incidence 
of DR was calculated as 1.57 (confidence interval [CI]: 1.21-2.03; p < 0.001) 
for an increase in HbA1c of 1%. Meta-analysis of OS confirmed the results 
from RCT (RR = 1,61; CI95% [1.29-2.01]; p < 0.001). Pooled data from 5 RCT 
(n = 514) showed that RR of the incidence or progression of DR was 1.48 
(CI95% [1.04-2.10]; p < 0.029) for an HbA1c increase of 1%. The cumulative 
results of five OS were similar (RR = 1,50, CI95% [1.28-1.77]; p < 0.0001. 
Based on data from RCTs and OS there were no significant correlation be-
tween incidence of proliferative DR and increase of HbA1c of 1%. Data from 
one RCT demonstrated that increase in HbA1c level of 1% increased the risk 
of blindness (RR = 6.20, CI95% [0.95-40.61]; p = 0.057), but this but was of 
borderline statistical significance. A meta-analysis of two OS (n = 238) dem-
onstrated a lower mean HbA1c level in patients without DR compared with 
patients with DR (WMD = 0.43, 95%CI [0.15-0.72]; p = 0.003). Pooled results 
of 5 OS (n = 1874) revealed that HbA1c was significantly lower in the group 
without progression of DR than in the group with DR progression (WMD = 
0.74, 95%CI [0.39-1.08]; p < 0.001). In meta-regression HbA1c explained the 
heterogeneity in 65.4%. The directional coefficient was statistically significant 
and equals 0.58, which means that increase HbA1c level by 1% results in in-
crease the risk of DR by 1.79 times (CI95% [1.28-2.51]; p = 0.003). The impact 
of other covariates on heterogeneity between trials was small and statistically 
insignificant.
Conclusion: The results of our SR indicate a significant correlation between 
HbA1c level, and appearance and progression of DR in T2DM. Thus, HbA1c 
may be considered an appropriate surrogate endpoint for DR in T2DM.
Supported by: Novo Nordisk Poland
1177
High glucose alters mitochondrial morphology and membrane potential 
heterogeneity in retinal pericytes
K. Trudeau, A. Molina, S. Roy; 
Medicine and Ophthalmology, Boston University School of Medicine, 
Boston, USA.
Background and aims: Mitochondrial dysfunction is known to play a role in 
retinal vascular cell loss, which is a prominent lesion of diabetic retinopathy. 
We have previously reported that high glucose (HG) induces mitochondrial 
fragmentation and membrane potential heterogeneity in retinal endothe-
lial cells, which contributes to cytochrome c release and apoptosis. Thus, we 
sought to determine the effects of HG on mitochondrial morphology and 
membrane potential heterogeneity in retinal pericytes.
Materials and methods: Bovine retinal pericytes (BRPs) were grown in 
normal (5mM) or HG (30mM) medium for 6 days. Both sets of cells were 
double-stained with MitoTracker Green FM (MTG, 125nM) and tetrameth-
ylrhodamine-ethyl-ester-perchlorate (TMRE, 8nM) and imaged using confo-
cal microscopy. Images were analyzed for average mitochondria shape within 
a cell using Form Factor (FF) and Aspect Ratio (AR) values of the mitochon-
dria. FF value of 1 corresponds to a circular, un-branched mitochondrion, 
and higher FF values indicate a longer, more-branched mitochondrion. AR 
of 1 corresponds to a circular mitochondrion, and higher AR values indicate 
more elliptical mitochondrion. The images were also analyzed for heteroge-
neity of mitochondrial membrane potential within a cell, using deviation of 
fluorescence intensity (FI) values for the ratio of red (TMRE) to green (MTG) 
dye for several mitochondria within each cell.
Results: BRPs grown in HG media exhibited significant fragmentation of 
mitochondria compared to BRPs grown in normal media (FF for HG: 1.85 
compared to 2.51 in normal, p=0.004, AR for HG: 2.32 compared to 2.80 in 
normal, p=0.009). Simultaneously, the BRPs grown in HG showed greater 
heterogeneity of mitochondrial membrane potential compared to normal 
BRPs (FI deviation for HG: 224 ± 78% of normal, p<0.001).
Conclusion: Under HG condition, mitochondria of retinal pericytes dis-
play significant fragmentation and membrane potential heterogeneity. The 
observed mitochondrial fragmentation and increased membrane potential 
heterogeneity in HG could play a role in the accelerated apoptosis associated 
with the retinal pericytes in diabetic retinopathy.
Supported by: NEI, NIH EY018218
1178
Enhanced thrombin formation, platelet activation in patients with 
diabetic retinopathy
P. Yu, D. Yu; 
Department of Nephropathy & dialysis, University of Tianjin Medicine, 
Metabolic Disease Hospital, China.
Background and aims: Diabetic retinopathy (DR) is the commonest mi-
crovascular complication of diabetes, and remains one of the leading causes 
of blindness worldwide. Postulated mechanisms of this observation include 
prothrombotic effects. The aim of the study was to evaluate potential pro-
thrombotic alterations in diabetic retinopathy patients in relation to hyper-
glycemia, including thrombin formation, platelet activation, and fibrin net-
work structure/function.
Materials and methods: The participants were 120 healthy subjects and 150 
diabetic patients. We excluded patients with nephropathy, cardiovascular dis-
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ease, and clotting disorder. On the basis of the fundus photography, the partic-
ipants were divided into four groups, including normal individuals (n=120), 
diabetes mellitus (DM) (n=45), DM with non-proliferative DR(NPDR) 
(n=60), and DM with proliferative DR(PDR)(n=45). The lipid profile, C-re-
active protein (CRP), glucose, insulin, platelet count, prothrombin time (PT), 
activated partial thromboplastin time (aPTT), D-dimmer and Fibrinogen 
were determined using routine laboratory methods. We determined genera-
tion of thrombin-antithrombin complexes (TATs) and soluble CD40 ligand 
(sCD40L), a platelet activation marker, at the site of microvascular injury, 
together with ex vivo plasma fibrin clot permeability and lysis time.
Results: The DR patients had increased maximum rates of formation and 
total production of TATs (by 52.9%, P <0.01, and by 22.5%, P <0.01, respec-
tively) as well as sCD40L release (by 19.2%, P<0.01, and by 18.3%, P<0.01, 
respectively) compared with those with hyperglycemia, whereas PDR pa-
tients had the highest values of TATs and sCD40L variables (P < 0.01 for all 
comparisons). Patients with DR had longer clot lysis time (by 21%, P<0.01) 
similar to that in diabetic subjects, but not lower clot permeability compared 
with that in normoglycemic subjects. PT and aPTT were similar for all the 
four groups; however, their corresponding fibrinogen levels were significantly 
different between PDR group and controls (4.55 ±2.12g/L vs. 3.06±1.25g/L, 
P<0.05). There was no difference in fibrinogen levels between NPDR group, 
DM group and control group.
Conclusion: Diabetic patients, with retinopathy especially with proliferative 
retinopathy, are associated with enhanced local thrombin generation and 
platelet activation, as well as unfavorably altered clot features. Our results 
suggested that prothrombotic alterations in diabetic patients might be impli-
cated in the pathogenesis of diabetic retinopathy.
Supported by: National Nature Science Grant by Chinese Government
1179
Retinopathy modulates taurine transporter expression in peripheral 
mononuclear blood cells of type 2 diabetic patients 
G. Seghieri1, R. Anichini1, A. De Bellis1, A. Berti1, L. Bianchi2, Z. Napoli2,  
L. Della Corte3, F. Franconi4; 
1Dpt. of Internal Medicine, Spedali Riuniti, Pistoia, 2Dpt. of Clinical 
Chemistry, Spedali Riuniti, Pistoia, 3Dpt. of Pharmacology, University of 
Florence, 4Dpt. of Pharmacology, University of Sassari, Italy.
Background and aims: Taurine, a semi-essential aminoacid which acts as 
an antioxidant, cell osmolyte, and modulator of trans-membrane calcium 
and glucose metabolism, is more concentrated (about 103-fold) in the intra-
cellular compartment than in the extra-cellular milieu due to the action of 
a specific Na-dependent amino acid-transporter namely the taurine trans-
porter (TauT), whose expression has so far been either morphologically and 
functionally well characterized. TauT is well represented in retinal epithelial 
cells where is acutely down regulated by high glucose concentrations ‘in vitro’. 
At the same time taurine appears to be very important in the retinal function 
besides its known role as modulator of glucose metabolism. However since 
no study has ever investigated the relationship between TauT expression and 
diabetes, we conceived this preliminary study to test ‘in vivo’ whether TauT 
expression is modified in blood mononuclear peripheral cells (MPC) of pa-
tients with type 2 diabetes with or without micro/macrovascular complica-
tions.
Materials and methods: We measured plasma taurine by HPLC and TauT 
gene expression by real-time PCR analysis in MPC of 74 type 2 diabetic pa-
tients with or without micro/macro-vascular complications and in 44 age-
and-sex matched controls. In diabetic patients, presence of retinopathy, ne-
phropathy, neuropathy and cardiovascular disease was ascertained by appro-
priate clinical and instrumental investigations.
Results: Median value [interquartile range] of TauT expression, represented 
as arbitrary units (AU), was significantly higher in diabetic patients than in 
age-and-sex matched controls (2.08 [2.42]AU vs. 1.07 [2.68]AU; p=0.009) and 
was weakly related to HbA1c (r=0.29; p=0.001). As compared with uncom-
plicated individuals a trend toward decreased TauT expression was observed 
in patients with macroangioapthy (n=16; 1.16 [1.55]AU vs 2.24 [2.23]AU), 
peripheral neuropathy (n=17; 1.71[0.96]AU vs 2.16 [2.10]AU) or persistent 
micro/macroalbuminuria (n=21; 2.06 [2.35]AU vs 2.30 [4.20]AU; p>0.05 in 
all cases). Patients with retinopathy (n=23) had a significantly lower TauT 
expression than those who were unaffected, exhibiting a median value simi-
lar to the value of controls (1.159 [1.554]AU vs. 2.240 [2.226]AU; p=0.006). 
There was no difference in median plasma taurine levels between controls 
and diabetics, either with or without retinopathy (29.6 [15]μmol/l vs. 28.9 
[17.2]μmol/l).
Conclusion: TauT gene expression in MPC is modified by type 2 diabetes, 
being significantly increased in patients without retinopathy, hypothesising 
its possible selective protective role against the development of this microv-
ascular complication.
Supported by: Fondazione Cassa di Risparmio di Pistoia e Pescia, Italy
1180
Immunoexpression of the vascular endothelial growth factor and its 
receptors in diabetic lens
D.V. Lipatov, A.G. Kuzmin, A.U. Abrosimov, O.M. Smirnova,  
M.V. Shestakova; 
Endocrinology Research Centre, Moscow, Russian Federation.
Background and aims: The diabetic cataract is one of the causes of blindness 
among diabetic patients. There are many different factors leading to the cata-
ract formation. It is known that cataract appears earlier in diabetic patients 
than in general population and has several morphological features. Excessive 
glucose oxidation, polyol pathway, hyperosmolarity, deposition of advanced 
glycation end products in the lens and damage of its matrix are shown to lead 
to lens opacity in diabetic patients. The aim of the study was to indentify the 
vascular endothelial growth factor (VEGF) and its receptors 1 and 2 types 
(VEGF-R1 and VEGF-R2 respectively) in lens tissue after cataract surgery car-
ried put in diabetic patients.
Materials and methods: 10 extracted diabetic lenses were studied. The mean 
age of included patients was 69,9±7,69 years, all patients had type 1 and type 
2 diabetes mellitus, almost all patients were treated with insulin. For the im-
munohistochemical staining the paraffin-embedded tissue sections (4 µm) 
of the formalin-fixed lenses were prepared. Before staining the slides were 
deparaffinized and rehydrated. The 20 min heat-induced epitope retrieval 
was done (for VEGF determining - with DakoCytomation Target Retrieval 
Solution, Ph9; for VEGF-R1 and VEGF-R2 - with Citrate buffer, Ph6). The sec-
tions were incubating in 10% hydrogen peroxide for 20 min to blocking the 
endogenous peroxidase activity. The primary anti-VEGF (monoclonal mouse 
anti-human VEGF, clone VG1, “DAKO”) was using at a dilution range of 
1:50 and applied on sections using 30 min incubation at room temperature. 
The primary anti-VEGF-R1 and anti-VEGF-R2 (rabbit polyclonal anti-VEGF 
Receptor 1 and rabbit polyclonal anti-VEGF receptor-2 respectively, “Novus 
biologicals”) were using at a dilution range of 1:50 and applied on sections 
using 60 min incubation at 36,6°C. The colored end product were developed 
by using the universal secondary antibodies, detection system “EnVision”, 
“DAKO”, and following incubation with 3,3’-diaminobenzidine for 5 min in 
dark place.
Results: We observed immunoexpression of VEGF only in 2 of 10 diabetic 
cataracts on the cytoplasmic membrane of the lens fibers. There wasn’t found 
the immunoexpression of VEGF-R1 in lens sections. But in all lenses the 
VEGF-R2 was found both on the cortical subcapsular lens fibers and lens epi-
thelium cells. The immunoexpression was strong and higher in the superficial 
subcapsular lens fibers.
Conclusion: VEGF is known as the necessary factor for normal growth and 
development of the eye. For example, it supplies metabolic effect to the reti-
nal pigment epithelium and also is detected in normal lens during ontogen-
esis. In diabetic patients the lens opacification develops earlier than among 
nondiabetic population. Our investigation may explain the intensive cataract 
formation and cortical localization of lens opacity due to the metabolic and 
proliferative effects of VEGF to lens epithelium via its receptor VEGF-R2. Ac-
tivation of VEGF-R2 in lens epithelium and subcapsular lens fibers may cause 
excessive permeability and proliferation of lens epithelium and lead to the 
lens opacity.
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Characterising the development of diabetic retinopathy in the Diabetes 
Care System West-Friesland, the Netherlands
H. Zavrelova1, T. Hoekstra2,3, M. Alssema2, L.M.C. Welschen4, G. Nijpels4, 
A.C. Moll1, B.C.P. Polak1, J.M. Dekker2; 
1Ophthalmology, , 2The EMGO Institute for Health and Care Research, 
3Health Sciences, 4General Practice, VU University Medical Center, 
Amsterdam, Netherlands.
Background and aims: The development and progression of diabetic retin-
opathy is known to be influenced by risk factors such as HbA1c, blood pres-
sure and lifestyle variables. It is also known that the pace at which diabetic 
retinopathy develops, progresses or regresses is heterogeneous. Firstly, we 
therefore identified distinct developmental patterns of diabetic retinopathy; 
secondly, we assessed the patient characteristics of these patterns.
Materials and methods: A cohort of type 2 diabetes patients participating in 
the Diabetes Care System in West-Friesland, The Netherlands was followed 
for 2 to 8 years, between 1998 and 2005. The first visit was considered base-
line. Annually, risk factors were measured and 2-field fundus photographs 
were taken with a non-mydriatic camera and graded according to EURO-
DIAB. Latent Class Growth Analyses were used to identify distinct devel-
opmental patterns of diabetic retinopathy. Baseline characteristics of these 
patterns were assess with ANOVA with post hoc Bonferroni corrections and 
Chi-square tests or with a Kurskal Wallis test in case of skewed distribution.
Results: A total of 3392 patients were included in the study. Five clusters of 
patients with distinct developmental patterns of diabetic retinopathy were 
identified: A) patients without any signs of diabetic retinopathy, B) patients 
with fluctuating background diabetic retinopathy, C) patients with mild 
background diabetic retinopathy progressing to preproliferative diabetic 
retinopathy, D) patients with severe non-proliferative diabetic retinopathy 
progressing to (pre)proliferative diabetic retinopathy, and E) patients with 
persistent proliferative diabetic retinopathy. Risk factors characterizing the 
various patterns are shown in Table 1. Results show cluster A as the largest 
cluster characterized by low fasting plasma glucose levels and HbA1c and a 
short diabetes duration.
Conclusion: Identification of different developmental patterns of diabetic 
retinopathy is possible and might help understand the influence of certain 
risk factors on the course of diabetic retinopathy in individual diabetes pa-
tients.
Table 1. Selected baseline characteristics of five distinct developmen-
tal patterns of diabetic retinopathy (mean ± sd or median (interquartile 
range)). 
Cluster A
(n=2955)
Cluster B
(n=297)
Cluster C
(n=71)
Cluster D
(n=41)
Cluster E
(n=28)
P < 0.05 
between 
clusters:
Albumin-creatinine 
Ratio
3.2 ± 14.0 5.5 ± 17.9 6.4 ± 19.5 9.7 ± 25.1 11.2 ± 22.3 A vs. E
HDL cholesterol 
(mmol/l)
1.19 ± 0.32 1.20 ± 0.32 1.35 ± 0.81 1.13 ± 0.31 1.26 ± 0.35 C vs. A/B/D
Fasting plasma glu-
cose (mmol/l)
8.8 ± 3.4 9.8 ± 3.1 9.9 ± 2.8 10.9 ± 3.6 10.7 ± 4.2 A vs. B/D/E
BMI (kg/m2) 30.1 ± 5.3 28.8 ± 4.8 29.3 ± 4.6 30.7 ± 5.7 31.6 ± 5.6 A vs. B
Systolic blood pres-
sure (mmHg)
142 ± 21 145 ± 22 149 ± 24 143 ± 26 149 ± 22 A vs. C
HbA1c (%) 7.6 ± 1.8 8.1 ± 1.9 8.1 ± 1.6 9.5 ± 2.1 9.0 ± 1.8 A vs. B/D/E
D vs. B/C
Diabetes duration 
(years)
2 (1 - 5) 5 (1 - 9) 6 (3 - 12.5) 10 (4.5 -14) 13 (7.5 - 24.5) P < 0.001
1182
Information technology to control screening for diabetic retinopathy
A. Gudmundsdottir1, E. Stefansson1, E. Olafsdottir1, T. Aspelund2,  
O. Palsson3, O. Thorisdottir4, T. Bek4; 
1Landspitali, Reykjavik, Iceland, 2University of Iceland, Reykjavik, Iceland, 
3Risk Medical Solutions, Reykjavik, Iceland, 4Aarhus University, Denmark.
Background and aims: Annual screening for diabetic eye disease is effec-
tive, but may be too frequent and costly for low risk patients. The aim of the 
study is to use computer based individual risk assessment to make diabetic 
eye screening programs less expensive and safer.
Materials and methods: We used epidemiological data to create a mathemat-
ical algorithm, which calculates individual risk of sight threatening retinopa-
thy. The individual´s risk level is then used to determine his/her screening 
interval. The algorithm was tested against the diabetes database in Århus, 
Denmark (5210 patients, 20 years).
Results: In the diabetes database the algorithm (set at risk margin 4%) sug-
gested an average screening interval of 27 months, with a range of 6 to 60 
months. 95 patients progressed to sight threatening retinopathy within the 
recommended screening interval. At risk margin 2% the respective numbers 
are 17 months and 32 patients. In comparison, with the standard 12 month 
screening program 149 patients progressed to sight threatening retinopathy 
within the recommended screening interval. Our algorithm, at risk margin 
4%, increases safety by 36% while reducing cost of diabetic screening pro-
grams by 55% as compared to yearly screening exams. At 2% risk margin 
increased safety was 79% and cost reduction 30%.
Conclusion: The use of information technology based on epidemiological 
data allows individual risk assessment, standardization of risk and an indi-
vidualized determination of screening intervals. The reduction in screening 
visits decreases cost of diabetic screening programs by more than 50% com-
pared to programs with yearly screening exams.
Supported by: Technology Development Fund
1183
Genomic and proteomic characterisation of non-proliferative 
retinopathy in a mouse model
A. Ribera1,2, P. Villacampa1,2, V. Haurigot1,2, C.J. Mann1,2, F. Bosch1,2; 
1CBATEG and Department of Biochemistry and Molecular Biology, School 
of Veterinary Medicine, Universitat Autonoma de Barcelona, 2CIBER of 
Diabetes and Associated Metabolic Disorders, Barcelona, Spain.
Background and aims: Diabetic retinopathy is the leading cause of loss 
of visual acuity and blindness in adulthood. Transgenic mice overexpress-
ing Insulin-like Growth Factor (IGF-I) in the retina have retinal alterations 
characteristic of non-proliferative retinopathy and, with age, mice develop 
alterations that mimic the proliferative stage of diabetic retinopathy such as 
neovascularization in the vitreous cavity and retinal neovascularisation. The 
aim of this study was to perform genomic and proteomic analyses in IGF-I 
transgenic retinas to identify key molecular markers in early developmental 
stages of the pathology.
Materials and methods: Retinas from 4 month-old transgenic and wild-type 
animals were collected, homogenised and total RNA and protein extracts 
were obtained. We compared gene expression profiles in transgenic and wild-
type retinas with microarrays and confirmed the expression of selected genes 
by RT-PCR. Retinal protein extracts were separated by bidimensional elec-
trophoresis and protein spots were identified using mass-spectrometry.
Results: Gene profile analysis detected 37 genes differentially expressed, 25 of 
which were up-regulated and 12 genes were down-regulated more than 1.5-
fold in transgenic retinas compared with wild-type. Most of the up-regulated 
genes were classified in three categories: gliosis, retinal stress and angiogen-
esis, whereas down-regulated genes were related with CNS development and 
angiogenesis. By RT-PCR we found that transgenic retinas already overex-
pressed gliosis-related genes (Gfap, S100b, Gja) at an early age (1.5 months 
old), when transgenic mice neither presented morphological nor biochemical 
alterations.This overexpression was maintained or even increased in trans-
genic animals with time. The same pattern was observed with retinal-stress-
related genes such as Nupr1, Lcn2 and Edn2. Proteomic studies showed 37 
proteins differentially produced in transgenic retinas relative to wild-type, 18 
of which were increased, with 19 were decreased. The majority of the identi-
fied proteins contribute to metabolic processes.
Conclusion: Most of the alterations found in gene profile analysis in trans-
genic retinas have also been reported in retinas from diabetic rats and in 
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human diabetic retinas, suggesting that the activation of glial and stress-re-
sponse genes play a key role in initiating the pathology. Overall, these results 
also validate the IGF-I transgenic mouse model as an excellent tool to find 
therapeutic targets for early stages of retinopathy and to assay new therapies.
1184
Metabolic fingerprints of proliferative diabetic retinopathy. An 1H NMR-
based metabonomic approach using vitreous humor
R. Simó1, I. Barba2, C. Hernández1, M.A. Alonso3, L. Masmiquel4,  
D. García-Dorado2, M. Garcia-Ramírez1; 
1Diabetes Research Unit and CIBERDEM, Institut de Recerca Hospital 
Universitari Vall d’Hebron, Barcelona, 2Laboratory of Experimental 
Cardiology and RECAVA, Institut de Recerca Hospital Universitari Vall 
d’Hebron, Barcelona, 3Ophthalmology Department, Hospital Son Llàtzer, 
Palma, 4Endocrinology Department, Hospital Son Llàtzer, Palma, Spain.
Background and aims: To explore the metabolic profile of vitreous fluid 
from patients with proliferative diabetic retinopathy (PDR) using 1H NMR 
based metabonomic analysis.
Material and methods: Vitreous samples from 22 type 1 diabetic patients 
with PDR and 22 vitreous samples from non-diabetic patients with macu-
lar hole (MH) (control group), closely matched in terms of age (46·1±9·2 vs. 
45·3±11·5 years) were selected from our vitreous bank. The exclusion crite-
ria were as follows: 1) previous vitreoretinal surgery; 2) photocoagulation in 
the preceding 6 months; 3) recent vitreous hemorrhage (less than 3 months 
before vitrectomy), macroscopic hemovitreous or intravitreous hemoglobin 
>5 mg/ml; 4) history of glaucoma; 5) renal failure (plasma creatinine ≥ 120 
μmol/l); and 6) other chronic diseases apart from diabetes. 1H NMR spectra 
were acquired on a 400 MHz (9·4 T) magnet interfaced to a Bruker Avance 
400 spectrometer (Bruker, Rheinstetten, Germany). Data analysis included a 
principal component analysis (PCA) and partial least squares discriminant 
analysis (PLS-DA). In addition, 1H-1H and 1H-13C HMQC (Heteronuclear 
Multiple Quantum Coherence) correlation spectra were acquired for the 
identification of metabolites. Furthermore, the main metabolites account-
ing for the differences in metabolic profile were also assessed by current bio-
chemical methods.
Results: Lactate was the most abundant metabolite and it was higher in sam-
ples from PDR patients than non-diabetic patients (p=0.02). Glucose was 
significantly higher in samples from PDR patients than non-diabetic patients 
(p=0.03). After removing the lactate peak at 1.35 ppm, and using PLS-DA, a 
model was obtained which was able to correctly classify 19 out of 22 patients 
with PDR and 18 out of 22 controls, resulting in a sensitivity of 86% and a 
specificity of 81%. The main metabolites involved in this specific pattern rec-
ognition were galactitiol and ascorbic acid (AA), and they were significantly 
lower in PDR patients.
Conclusion: 1H NMR based metabonomic analysis of vitreous fluid permits 
to obtain a metabolic signature of PDR. Apart from the higher abundance 
of lactate and glucose, significant deficits of galactitiol and AA are the main 
metabolic fingerprints of vitreous fluid from PDR patients.
Supported by: SAF2009-07408 (MCINN), CIBERDEM 
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Identification of new pathogenic candidates for diabetic macular oedema 
using fluorescence-based difference gel electrophoresis (DIGE) analysis
M. Villarroel1, M. Garcia-Ramírez1, C. Hernández1, N. Colomé2,  
L. Corraliza1, L. García-Pascual3, J. Casado4, F. Canals2, R. Simó1; 
1Diabetes Research Unit and CIBERDEM, Institut de Recerca Hospital 
Universitari Vall d’Hebron, 2Proteomics Laboratory, Vall d’Hebron Institute 
of Oncology, 3Endocrinology Department, Hospital Mútua de Terrassa, 
4Ophthalmology Department, Hospital Mútua de Terrassa, Barcelona, 
Spain.
Background and aims: Diabetic macular edema (DME) is the main cause of 
visual impairment in diabetic patients. The aim of the present study was to 
explore the differential proteomic pattern of the vitreous fluid from DME pa-
tients by means of fluorescence-based difference gel electrophoresis (DIGE).
Material and methods: Samples of vitreous from 8 type 2 diabetic patients 
(4 with DME without proliferative diabetic retinopathy [PDR] and 4 with 
PDR without DME), and 8 from non-diabetic subjects with idiopathic macu-
lar hole (control group) were selected from our vitreous bank for proteomic 
analysis. To further confirm the potential candidates identified by DIGE 
eighteen additional samples (6 PDR, 6 DME and 6 MH, matched by age) 
were analyzed by ELISA. Exclusion criteria included photocoagulation dur-
ing the preceding 6 months and recent vitreous hemorrhage or intravitreous 
hemoglobin higher than 5 mg/ml.
Results: Selecting an abundance ratio of 1.5-fold, p<0.05, as the threshold 
for the study, 4 proteins were specifically associated with DME. Hemopexin 
was significantly higher in the vitreous fluid of patients with DME in com-
parison with both control subjects and PDR patients. By contrast, clusterin, 
transthyretin and crystalline S were significantly decreased in the vitreous 
of patients with DME. The differential production of hemopexin, clusterin 
and transthyretin was further confirmed by ELISA. In view of the current 
information, hemopexin and clusterin seems to be more directly related to 
the development of DME. Hemopexin is the best-characterized permeabil-
ity factor in steroid-sensitive nephrotic sindrome (SSNS). T-cell-associated 
cytokines like tumor necrosis factor-alpha (TNF-alpha) are able to enhance 
hemopexin production in mesangial cells in vitro and this effect is prevented 
by corticosteroids. It should be noted that proinflammatory cytokines have 
been involved in the development of DME and, therefore, hemopexin might 
be a mediator of the disruption of the blood-retinal barrier. Clusterin is asso-
ciated with protection from apoptotic retinal cell death. Recently, it has been 
demonstrated that clusterin effectively inhibited vascular endothelial growth 
factor-induced hyperpermeability in human retinal microvascular endothe-
lial cells (HRMECs) and in retinal vessels from streptozotocin-induced dia-
betic mice. Since clusterin plays an essential role in restoring tight junctions 
and limiting the inflammatory response after injury (two capital features in 
the pathogenesis of DME), it seems reasonable to propose clusterin deficit as 
a contributor to DME development.
Conclusion: Proteomic analysis by DIGE was useful in identifying new po-
tential candidates involved in the pathogenesis of DME. These results could 
open up new strategies in the treatment of DME.
Supported by: SAF2009-07408 (MCINN) and CIBERDEM
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Retinal blood flow in patients with type 1 diabetes mellitus with and 
without diabetic retinopathy
H.-T. Nguyen1, E. van Duinkerken2,3, M. Diamant2, P.J. Ringens1,  
B.C.P. Polak1, F.D. Verbraak4, A.C. Moll1; 
1Department of Ophthalmology, 2Diabetes Centre / Department of 
Internal Medicine, 3Department of Medical Psychology, 4Department of 
Ophthalmology, Academic Medical Centre, Amsterdam, Netherlands.
Background and aims: Proliferative diabetic retinopathy (pDRP) is a com-
mon microvascular complication in patients with long-standing type 1 diabe-
tes (T1DM) and is oftenly associated with poor glycemic control. However, it 
is currently uncertain whether T1DM, and more in particular, pDRP causes 
hemodynamic changes in the retina. Therefore, we measured retinal hemo-
dynamic function in T1DM patients with and without pDRP and controls.
Materials and methods: Thirty-three T1DM patients with DRP treated with 
panretinal photocoagulation (pDRP), 8 T1DM patients with background retin-
opathy (bDRP) and 32 T1DM patients without retinopathy or other microvas-
cular complications (nDRP) were compared to 44 controls. Retinal blood flow 
was measured temporal and nasal of the optic disc, using Heidelberg scanning 
laser doppler flowmetry. Blood flow values of the right eye were used. To con-
trol for possible effects of extreme blood glucose values, the T1DM patients had 
to range between 4 - 15 mmol/l. Blood was drawn to determine lipid levels and 
HbA1c; 24-hour urine samples were collected to determine albumine:creati-
nine ratio. MANCOVA corrected for age and hypertension was used to deter-
mine group differences and regression analysis for determinants of changes.
Results: Overall, the T1DM group showed increased retinal blood flow as 
compared to controls for both the nasal and temporal locations (both P < 
0.05). Regression analysis showed proliferative DRP, and albumin:creatinine 
ratio to be positively associated with retinal flow (both P < 0.05). In a separate 
analysis, the pDRP group showed significantly higher levels of flow as com-
pared to nDRP patients and controls. Furthermore, a linear trend for retinal 
blood flow across groups was found (all P < 0.05).
Conclusion: In T1DM as compared to controls, retinal blood flow was in-
creased, most pronounced in patients with pDRP. The significant linear trend 
might be an indication of increasing retinal blood flow with increasing retin-
opathy severity. The increased blood flow might be a compensatory mecha-
nism for hypoxia, caused by the closure of retinal capillaries. Interestingly, the 
pDRP group shows higher blood flow even though this group is treated with 
panretinal photocoagulation. This is most likely caused by the remaining vas-
culopathy and reduced number of retinal vessels after photocoagulation.
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Positive effects of insulin in early pericyte loss
E. Berrone, E. Beltramo, S. Tarallo, M. Porta; 
Internal Medicine, University of Turin, Italy.
Background and aims: Hyperglycaemia is a major risk factor for the typi-
cal alterations of diabetic retinopathy, such as loss of retinal pericytes and 
thickening of the basement membrane. Although many believe “pericyte 
drop-out” to be the result of glucose damage, the exact mechanism(s) un-
derlining their degeneration has not been conclusively elucidated. Recently, 
a protective role of insulin from microvascular cell apoptosis was suggested. 
The objective of this study was to verify the effects of insulin on survival, 
intracellular glucose and expression of glucose transporters (GLUT 1, 2, 3, 4) 
in HRP cultured in intermittent high glucose (HGint).
Materials and methods: Pericytes were kept alternatively in high (28 mmol/l, 
HG) or normal (5.6 mmol/l, NG) glucose at 48h intervals for 8 days, with or 
without insulin (Ins) 100nM or 1µM. Control cells were cultured in stable 
NG or HG. GLUT transporter mRNA expression was determined by RT-
PCR, intracellular glucose and apoptosis by ELISA, and cell proliferation by 
cell counts.
Results: HRP express GLUT 1, 3 e 4, but not GLUT2. GLUT1 expression 
was increased in intermittent HG (HGint) (+19.7% p<0.05 vs NG) but re-
duced when insulin was added to HGint (Ins100nM: -30.4%, Ins1µM: -31%, 
vs HGint). In contrast, GLUT4 was reduced in HGint (-48.7% p<0.05 vs NG) 
and increased in the presence of insulin 100nM (+34.6% p<0.004 vs HGint). 
GLUT3 mRNA was unchanged in all the above experimental conditions. In 
HGint, intracellular glucose levels were increased (+72.4% p<0.05 vs NG), 
and reduced by 1µM insulin (-68.3% p<0.05 vs HGint). Cell counts were re-
duced in HGint (-19,2% p<0.05 vs NG) and increased by insulin (Ins100nM: 
+49.5%, Ins1µM: +83.6%, p<0.05 vs HGint). Apoptosis increased with HGint 
(p<0.001 vs NG) and was completely normalized by insulin at both concen-
trations (p<0.001 vs HGint).
Conclusion: Insulin may influence the expression of glucose transporters in 
HRP and protect them from proliferation impairment and increased apopto-
sis induced by intermittent HG.
Supported by: Compagnia di SanPaolo, Torino, Italy and Regione Piemonte, 
Italy
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Fenofibric acid activates survival signalling and prevents activation of 
stress kinases in human retinal pigment epithelial cells
A.M. Valverde1,2, S. Miranda1,2, A. Gonzalez-Rodriguez1,2,  
M. Garcia-Ramírez3,4, C. Hernández3,4, R. Simó3,4; 
1Consejo Superior Investigaciones Cientificas, Madrid, 2CIBERDEM, 
Madrid, 3Institut de Recerca Hospital Universitari Vall d’Hebron, Barcelona, 
4CIBERDEM, Barcelona, Spain.
Background and aims: Diabetic retinopathy (DR) remains the leading cause 
of blindness among working-age individuals in developed countries. In the 
FIELD study on DR, fenofibrate reduced the frequency of first laser treatment 
for macular edema by 31% and for proliferative retinopathy by 30%. Howev-
er, little is known regarding the molecular mechanisms by which fenofibrate 
exerts its beneficial effects. The aim of the present study was to explore for the 
first time the effects of fenofibric acid (the active metabolite of fenofibrate) on 
stress and survival signalling pathways in human retinal pigment epithelium 
(RPE) cell line under culture conditions mimicking the diabetic milieu.
Materials and methods: Human RPE cells (ARPE-19) were cultured in 5 
mM or 25 mM glucose for 21 days. Then, some dishes were treated with 
fenofibric acid (100 μM) for a further 3 days. At day 3, cells were placed into 
the hypoxic chamber (1 % oxygen) for 6 or 24 h. As a control, some dishes 
were maintained under normoxic conditions. At the end of this experimental 
protocol, cells were harvested and collected for RNA or protein extraction. 
Immunoprecipitations, Western blot analysis and quantitative real-time PCR 
were performed.
Results: ARPE-19 cells cultured under hyperglycaemic conditions induced 
the expression of the hypoxia-inducible factor HIF-1α and the phosphoryla-
tion of stress-activated kinases (JNK and p38 MAPK). Under hypoxic con-
ditions, the phosphorylation of JNK as well as its substrate c-Jun and p38 
MAPK was increased in parallel with the induction of HIF-1α. This effect 
was increased by the combination of hyperglycaemic and hypoxic conditions. 
Cells pre-treated with fenofibric acid were protected against the activation 
of stress-inducible kinases by hyperglycaemia, hypoxia or both conditions. 
Moreover, fenofibric acid increased the survival signalling, measured by the 
expression and phosphorylation of insulin-like growth factor (IGF-I) recep-
tor, IRS-1, IRS-2, Akt/PKB and p44/p42 MAPK, at 6 h of hypoxia plus hy-
perglycaemia.
Conclusion: The diabetic milieu triggers the activation of stress-inducible ki-
nases in cultured ARPE-19 cells. Under this condition, fenofibric acid elicited 
a dual protective effect through the down-regulation of stress signalling and 
the induction of survival pathways. These mechanisms could be involved in 
the reported beneficial effects of fenofibrate on DR.
Supported by: Grants SAF2009-08114, SAF2009-07408 (MCINN) and CIBER-
DEM (ISCIII), Spain
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Fenofibrate reduces fibronectin overexpression in human retinal pigment 
epithelial cells cultured under conditions mimicking the diabetic milieu
S. Roy1, K. Trudeau1, C. Hernández2, M. Villarroel2, R. Simó2, S. Roy1; 
1Medicine and Ophthalmology, Boston University School of Medicine, 
Boston, USA, 2Diabetes and Metabolism Research Unit, Institut de Recerca 
Hospital Universitari Vall d’Hebron and CIBERDEM, Barcelona, Spain.
Background and aims: Diabetic retinopathy is the leading cause of blindness 
and vision loss in the working age population. The fenofibrate Intervention 
and Event Lowering in Diabetes (FIELD) study showed significant benefit 
of reducing the risk of microvascular complications in diabetic patients in-
cluding the need for laser treatment for diabetic macular edema (DME) and 
proliferative diabetic retinopathy (PDR) by 30%. However, it is unclear how 
fenofibrate prevents the progression of DME. Having shown that inhibition 
of fibronectin overexpression restores blood retinal barrier in diabetes, in 
this study, we examined the effect of fenofibrate on fibronectin expression in 
a human retinal pigment epithelial (RPE) cell line under culture conditions 
mimicking the diabetic milieu.
Materials and methods: ARPE-19, a spontaneously immortalized human 
RPE cell line, was cultured for 18 days in medium supplemented with 10% 
fetal bovine serum in high glucose condition (25 mM D-glucose). To study 
the effect of fenofibrate on fibronectin expression, 100 μM fenofibric acid was 
added in the last 3 days of the experiment (days 19, 20, 21) to cells grown 
in high glucose medium or high glucose medium plus IL1β (10 ng/ml for 2 
days: days 20, 21) until the end of the experiment. The combination of high 
glucose + IL1β was used to provoke the disruption of the monolayer, thus 
mimicking the effects of the diabetic milieu. The cells were subjected to se-
rum starvation (1% FBS) during the treatments. Fibronectin expression was 
evaluated by real time RT-PCR and Western blot analysis. Barrier function of 
RPE (permeability) was assessed by measuring apical-basolateral movements 
of FICT-dextran (40 kDa).
Results: Compared to cells grown in normal (5.5 mM glucose) medium, cells 
grown in high glucose medium or in high glucose medium plus IL1b showed 
significant upregulation of fibronectin mRNA expression, the latter group 
showing a more robust (3 fold) fibronectin upregulation. Similarly, fibronec-
tin protein expression was also upregulated in both experimental groups 
compared to the control. Treatment of cells with fenofibric acid significantly 
reduced overexpression of fibronectin both at the mRNA and protein level in 
cells grown in high glucose medium or cells grown in high glucose medium 
plus IL1β. Tubulin and beta-actin protein levels used as controls were not 
altered by fenofibric acid. Treatment with fenofibric acid decreased excess 
permeability induced by high glucose and IL1β.
Conclusion: These results indicate that downregulation of fibronectin over-
expression by fenofibric acid may have a protective effect on the leakage of the 
outer blood-retinal barrier. This could be one of the mechanisms involved in 
the beneficial effects of fenofibrate against the development of excess perme-
ability associated with diabetic retinopathy.
Supported by: NEI, NIH; UROP, BU
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Puerarin inhibits advanced glycation end products-induced retinal 
pericyte apoptosis in vitro and in vivo by blocking Rac1-dependent 
signalling and the nuclear factor-kappaB pathway 
J. Kim, K.M. Kim, C.-S. Kim, J.M. Kim, D.S. Jang, J.S. Kim; 
Diabetic Complications Research Center, Korea Institue of Oriental 
Medicine, Daejeon, Republic of Korea.
Background and aims: Retinal pericyte loss is one of the histopathological 
hallmarks of early diabetic retinopathy. Puerarin (4’-7-dihydroxy-8-beta-d-
glucosylisoflavone), an isoflavone-C-glucoside isolated from Puerarin lobata, 
has various pharmacological effects, including anti-hyperglycemic and anti-
inflammatory activities.
Materials and methods: In the present study, we determined the efficacy 
and the possible mechanism of puerarin on advanced glycation end products 
(AGEs)-induced apoptosis of cultured bovine retinal pericytes and retinal mi-
crovascular cells in intravitreally AGEs-modifed rat serum albumin-injected 
eyes of rats. We also examined the potential preventive effect of puerarin on 
diabetic retinopathy in streptozotocin (STZ)-induced diabetic rat. Puerarin 
(10 and 50 mg/kg body weight) was treated once a day orally for 16 weeks.
Results: Puerarin significantly inhibited pericyte apoptosis as well as reactive 
oxygen species (ROS) generation, NADPH oxidase activity and phosphor-
ylation of Rac1 and p47phox induced by AGEs treatment. Further studies 
revealed that puerarin treatment remarkably suppressed the activation of 
nuclear factor-kappaB (NF-κB). In vivo retinal pericyte apoptosis of rats 
evoked by intravitreally injection of AGEs was evidently attenuated by the 
treatment of puerarin. In addition, the long-term administration of puerarin 
also prevented several histological changes, such as pericyte ghost and acel-
lular formation of capillaries in STZ-induced diabetic rats. In fluorescein an-
giography, the changes of retinal vasculature (non-perfusion of fluorescein, 
fluorescein leakage and vessel narrowing) were significantly reduced in STZ-
induced diabetic rats treated with puerarin.
Conclusion: These results demonstrate that puerarin may exert inhibitory 
effects on AGEs-induced pericyte apoptosis via interfering with Rac1-de-
pendent ROS pathways and blocking NF-κB activation, thus resulting in the 
amelioration of diabetic retinopathy in STZ-induced diabetic rats.
Figure 1. Effects of puerarin on diabetic retinopathy. The trypsin-digested 
retinal vessels from a normal rat (NOR), STZ-induced diabetic rat (DM) and 
diabetic rat treated with peurarin (10 and 50mg/kg, Puerarin-10 and -50) 
were stained with Periodic acid-Schiff and TUNEL. Acelluar capillary (black 
arrow) and TUNEL-positive retinal pericytes (white arrow) were observed 
in STZ-induced diabetic rats. In fluorescein angiography, white thick arrow 
and white arrowhead indicate the vessel narrowing and fluorescein leakage, 
respectively. All data were expressed as mean±SE. *p<0.01 vs. normal rat, 
#p<0.01 vs. diabetic rat.
Supported by: Korea Institute of Oriental Medicine
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Somatostatin 28 (SST-28) prevents the breakdown of human retinal 
pigment epithelial cells induced by the diabetic milieu
L. Corraliza, M. Garcia-Ramírez, M. Villarroel, A. Ciudin, C. Hernández, 
R. Simó; 
CIBERDEM (Centro de Investigación Biomédica en Red de Diabetes y 
Enfermedades Metabólicas) (Instituto de Salud Carlos III) and Diabetes 
Research Unit, Institut de Recerca Hospital Universitari Vall d’Hebron, 
Universitat Autònoma de Barcelona, Spain.
Background and aims: Diabetic macular edema (DME) results from fluid 
accumulation due to the breakdown of the inner and outer blood retinal bar-
riers (BRBs). The outer BRB is formed by the tight junctions (TJs) between 
retinal pigment epithelial (RPE). Somatostatin (SST) has been involved in the 
transport of water and ions in several tissues. Various ion/water transport 
systems are located on the apical side of the RPE, adjacent to the subretinal 
space, and, indeed, a high expression of SSTR2 has been shown in this api-
cal membrane of the RPE. In addition, we have previously demonstrated a 
significantly lower intravitreous concentration of SST in patients with DME 
in comparison with non-diabetic control subjects, being SST-28 the main 
molecular variant accounting for this deficit. These findings suggest that SST 
could have a relevant physiological role in preventing fluid accumulation 
within the retina, and the deficit of retinal SST observed in diabetic patients 
could favour the development of DME. On this basis, the aim of the study was 
to explore the SST effects on the outer BRB permeability in a human retinal 
pigment epithelial (RPE) cell line under culture conditions mimicking the 
diabetic milieu.
Material and methods: ARPE-19 cells (an spontaneous immortalized RPE 
cell line) were cultured in hyperglycemic conditions (25 mM D-glucose) for 
18 days at 37ºC under 5% CO2 in medium (DMEM/F12) supplemented with 
10% fetal bovine serum. SST-14 and SST-28 (1x10-7 M) were added to the api-
cal side of the monolayer the last 4 days of the experiment (days 14, 15, 16 and 
17) (1 application/day). Cells were also treated with IL1β (10 ng/ml) for 48 
hours until the end of the experiment in order to mimic the diabetic milieu 
(days 16, 17). The permeability of RPE cells was determined at 18 days by 
measuring the apical-to-basolateral movements of fluorescein isothiocyanate 
(FICT) dextran (70 kDa). Lactate dehydrogenase production and cell count 
was used to determine putative changes in the citotoxicity or proliferation 
related to the different treatments.
Results: Treatment of ARPE-19 cells with SST-28 (1X10-7) was able to pre-
vent the increase of permeability induced by IL-1β. By contrast, treatment 
with SST-14 did not produce significant changes on monolayer permeability. 
No differences in cell number or citotoxicity were observed among the dif-
ferent treatments.
Conclusion: SST-28 but not SST14 has a significant protective effect on RPE 
disruption caused by conditions mimicking the diabetic milieu. Further in-
vestigation addressed to determining the mechanisms by which SST-28 ex-
erts its effects in reducing permeability and their potential efficacy in DME 
treatment are needed.
Supported by: BCN Peptides S.A. and CIBERDEM (ISCIII)
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Efficacy and safety of ranibizumab monotherapy or adjunctive with laser 
versus laser therapy in patients with diabetic macular oedema: 12-month 
results of the RESTORE study
P. Massin, on behalf of the RESTORE study group; 
Ophthalmology, Hôpital Lariboisière, Paris, France.
Background and aims: Diabetic macular edema (DME) is the leading cause 
of blindness in diabetic patients (pts). The pathogenesis of DME is character-
ized by elevated levels of vascular endothelial growth factor (VEGF) in the 
vitreous of patients. The RESTORE study was designed to demonstrate supe-
riority of ranibizumab 0.5mg monotherapy or as adjunctive therapy to laser 
photocoagulation compared to laser alone, based on mean best-corrected 
visual acuity (BCVA) change from baseline over 12 months in patients with 
DME. We present the 12-month efficacy and safety results of the RESTORE 
study.
Materials and methods: Randomized, double-masked, multicenter, laser 
controlled Phase III study of 12 months duration with ranibizumab 0.5mg 
in DME pts. A total of 345 pts were randomized in a 1:1:1 ratio to one of the 
three treatment arms: intravitreal ranibizumab 0.5mg and sham laser (ranibi-
zumab) or ranibizumab adjunctive to laser (ranibizumab + laser) or sham in-
jections plus laser (laser) for 12 months. The primary endpoint was the mean 
change of BCVA from baseline (bsl) to the average BCVA from Month 1 to 
12. Treatment arm difference relative to laser were analyzed as least square 
means [dLSM]) using a two-sided stratified Cochran-Mantel-Haenszel test. 
Key secondary endpoints were mean BCVA change, safety assessed by 12-
month incidence of adverse events (AEs).
Results: A total of 88% pts completed the study. The superiority of ranibi-
zumab compared to laser was demonstrated when administered both as 
monotherapy and as an adjunct therapy to laser treatment with mean average 
BCVA changes (SD) of 6.1 (6.43), 5.9 (7.92), 0.8 (8.56), respectively (dLSM: 
5.4 [ranibizumab] and 4.9 [ranibizumab + laser], both [p<0.0001]). The inci-
dence of ocular serious AEs was low (2 pts in each of the ranibizumab + laser 
and laser arms). Non-ocular serious AEs were reported in 19.8% (ranibizu-
mab), 14.4% (ranibizumab + laser) and 13.5% (laser) pts. Two deaths were 
reported in each treatment arm, none of which were suspected to be related 
to study drug or injection procedure. Ocular AEs were reported in 42.2% 
(ranibizumab), 43.2% (ranibizumab + laser), 38.7% (laser); eye pain being 
the most frequently reported ocular AE (9-10%). Non-ocular AEs were re-
ported in 57.8% (ranibizumab), 46.6% (ranibizumab + laser) and 61.3% (la-
ser) pts; nasopharyngitis being the most frequently reported non-ocular AE 
(10-14%).
Conclusion: Ranibizumab monotherapy or as adjunctive therapy with laser 
photocoagulation provided significantly superior benefits in BCVA as com-
pared to laser therapy. No new safety findings were identified for ranibizu-
mab in either arm within this study.
Supported by: Novartis
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Green tea (Camellia sinensis) ameliorates the oxidative stress and nitric 
oxide synthase isoforms in the retina of diabetic hypertensive rats
K.C. Silva, M.A.B. Rosales, J.B. Lopes de Faria, J.M. Lopes de Faria; 
Faculty of Medical Sciences, State University of Campinas, Brazil.
Background and aims: Green tea (GT, Camellia sinensis), a popular beverage 
consumed in some parts of the world, is a rich source of polyphenols and acts 
as an antioxidant, antiproliferative, antitumor, and anti-angiogenic, so also 
may be useful to prevent diabetes in humans. A polyphenolic constituent, 
(-)-epigallocatechin-3-gallate (EGCG), is the major and most effective che-
mopreventive agent in GT. Because several lines of evidence suggest that oxi-
dative stress and nitric oxide (NO) system contributes to the pathogenesis of 
diabetic retinopathy (DR), we tested the hypothesis that GT prevents retinal 
oxidative/nitrosative stress and thus ameliorating the early markers of DR.
Materials and methods: Diabetes was induced in spontaneously hyperten-
sive rats (SHR) with 12 week-old. Control rats received only vehicle (citrate 
buffer). The diabetic SHR (DM-SHR) groups were assigned to receive or not 
receive, daily freshly prepared GT (13.3 g/L). After 12 weeks, the animals 
were euthanized and the retinas collected. The results were compared by 
Analysis of Variance (ANOVA) followed by Fisher’s protected least signifi-
cant difference test.
Results: As expected, body weight was lower and glycaemia was greater in 
diabetic SHR’s than in non-diabetic rats (p < 0.0001); the systolic blood pres-
sures were equal in all studied groups. The early molecular markers of DR 
were evaluated through glial reaction by expression of glial fibrillary acidic 
protein (GFAP) and blood retinal barrier breakdown by the estimation of the 
tight junction protein expression occludin. It was observed that there was a 
significant increase in GFAP expression (p=0.0003) and a decrease in occlu-
din levels in retina (p=0.01) of non-treated DM-SHR group compared with 
control rats. Retinal oxidative damage evaluated by immunohistochemistry 
for 8-hydroxy-2’-deoxyguanosine (8-OHdG) and nitrotyrosine (NT) levels, 
were greater in diabetic than in nondiabetic rats (p<0.0001 for 8-OHdG 
and p=0.04 for NT). Similarly, the retinal inflammation estimated by im-
munolocalization of ED1/microglial positive cells was significantly higher 
in diabetic than in control SHR’s (p=0.003). The phospho-serine isoforms of 
neuronal (Ser 847-nNOS) and endothelial nitric oxide synthases (NOS) (Ser 
113-eNOS) were also increased in retina of diabetic SHR rats compared with 
control (p=0.0002 for Ser 847-nNOS and p=0.02 for Ser 113-eNOS). The Cu/
Zn superoxide dismutase enzyme (Cu/Zn-SOD), an important antioxidant 
defense, was marked elevated only in animals which received oral treatment 
with GT compared with no treated groups (p=0.0006). The treatment with 
GT reestablished all of the above-mentioned parameters.
Conclusion: GT prevented the oxidative damage and reduced the activation 
of the constitutive NOS isoforms in retina from diabetic hypertensive rats. 
As a consequence, it was observed an ameliorating in DR indicators. These 
findings suggest that GT displays protective effects against retinal diabetic 
disease.
Supported by: State of São Paulo Research Foundation (FAPESP)
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Diabetic retinopathy before and after cataract surgery
S. Khutsurauli1, A. Memarne2, R. Kurashvili3, L. Tsutskiridze3; 
1High Medical School “Aieti”, 2High Medical School, 3Georgian Diabetes 
Center, Tbilisi, Georgia.
Background and aims: Increased retinopathy progression has been reported 
after cataract surgery in patients with diabetes mellitus. To assess the influ-
ence of cataract surgery on visual acuity and retinopathy progression, all dia-
betic patients who were subjected to cataract surgery during 2007-2009 have 
been followed up at the Ophthalmology Clinic.
Materials and methods: One eye of each of 70 patients was included in the 
study, 35 monocularly and 35 binocularly operated on. Sixteen of the 70 pa-
tients had proliferative diabetic retinopathy (PDR) at baseline. The degree of 
glycaemic control was assessed by measurements of HbA1c.
Results: Most patients obtained improved visual acuity; a postoperative visual 
acuity of 0.5 or better was achieved in 89% of diabetic surgical eyes. Progres-
sion of the retinopathy occurred in 30 out of the 70 eyes, and was associated 
with mean level of HbA1c (p=0.04), duration of diabetes (p=0.02), insulin 
treatment (p=0.001), and presence of retinopathy at baseline (p=0.01). Pa-
tients who progressed had a significantly higher incidence of macular oede-
ma (p=0.006) than those who did not progress. No significant differences 
were found when operated and non-operated eyes were compared in the 35 
patients with monocular surgery. Two patients in this group, however, ended 
up with macular oedema and worse vision in the operated eye than in the 
eye which was not operated on. Both patients had background retinopathy 
before surgery.
Conclusion: Patients in this study, also those with PDR, obtained good visual 
acuity, better than in most previous studies. Poor glycaemic control was a 
factor of importance for the progression of diabetic retinopathy after cataract 
surgery.
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Prescription of medications: Cumulative costs in outpatients with type 1 
diabetes (The FinnDiane Study)
R.H. Lithovius1,2, V. Harjutsalo1,2, P.-H. Groop1,2, C. Forsblom1,2, FinnDiane 
Study Group; 
1Institute of genetics, Folkhälsan Research Center, 2Department of Medicine, 
Helsinki University Central Hospital, Helsinki, Finland.
Background and aims: Diabetes’ high prevalence, chronic nature, and its as-
sociation with complications increase the use and the costs of medications. 
The identification of subgroups of patients may give a more precise view of 
the real costs. The aim of this study was to estimate the cumulative costs of 
medications according to the complication status and duration of diabetes.
Materials and methods: The Finnish Diabetic Nephropathy Study (FinnDi-
ane) data (N=3 721) were linked to the Drug Prescription Register (mean age 
39.1±11.8 yrs, 51% men, mean duration of diabetes 30.9±11.4 yrs). 11-year 
cumulative costs of medication for each patient were calculated between 1998 
and 2008. Costs were inflated to year 2008 Euros using the Consumer Price 
Index. Patients were divided in 10-year groups according to the duration of 
diabetes in 1998. Data on macrovascular diseases (MVD) and progression to 
end stage renal disease (ESRD) were retrieved from follow-up visits, medical 
files, or death certificates for all patients until 2008. One quarter of patients 
(n=883) had MVD (stroke, AMI, CHD, coronary revascularization, amputa-
tion) and/or ESRD (dialysis, kidney transplantation). Based on the complica-
tion status the patients were divided into 4 groups: no MVD or ESRD, MVD 
only, ESRD only, and both MVD and ESRD. Generalized linear mixed mod-
els were used to evaluate the 11-year cumulative costs. Costs were adjusted 
for age, sex, duration of diabetes, total insulin dose/day and body mass index, 
complication status and contributing years.
Results: The observed cumulative medication costs were 11 000 (no MVD or 
ESRD), 15 200 (MVD only), 80 900 (ESRD only), and 67 200 € (both MVD 
and ESRD) in the respective complication status groups. The average costs 
per year were 1 000, 1 600, 8 000, and 7 500 €, respectively. On average men’s 
costs were 16% higher than women’s. After adjustment, the cumulative costs 
of medications were 65% higher when MVD was present (increased from 
11 600 to 19 000 € per patient). Notably, costs increased substantially when 
ESRD was present, being 7.5 times higher and, when antidiabetic medica-
tions (ATC A10) were excluded, even 22 times higher. The costs were approx-
imately 10% lower when both MVD and ESRD were present probably due 
to the high mortality rate in this group (54% of the patient died during 1998 
- 2008) and hospitalisation (inpatient medications costs were not included). 
The costs of antidiabetic medication remained rather stable, irrespective of 
complication status or duration of diabetes. However, when complications 
were present these costs were markedly lower in all 10-year duration groups. 
Without complications the costs of medications related to comorbidity (other 
than ATC A10) were rather low in all duration groups (3 000 - 5 700 €). In 
contrast, with complications these costs increased remarkably.
Conclusion: The cumulative costs of medications increased substantially 
when ESRD was present. Since no considerable differences were observed in 
the costs of antidiabetic medications, the observed increase was entirely due 
to the increase in the costs of medications related to comorbidity.
1196
Cardiovascular risk factors differ between type 2 diabetic patients with 
and without renal impairment
M.K. Svensson1, J. Cederholm2, B. Eliasson1, B. Zethelius3, H. Afghahi4,  
H. Hadimeri4, S. Gudbjörnsdottir1; 
1Department of Medicine, Sahlgrenska Academy at the University of 
Gothenburg, 2Department of Public Health and Caring Sciences, Family 
Medicine and Clinical Epidemiology, Uppsala University, 3Department 
of Public Health and Caring Sciences/Geriatrics, University of Uppsala, 
4Department of Nephrology, Kärnsjukhuset, Skövde, Sweden.
Background and aims: Diabetes, albuminuria and renal impairment are all ma-
jor determinants of cardiovascular disease. The aim of this cross-sectional study 
was to assess potential differences in cardiovascular risk factors in type 2 diabetic 
patients with and without renal impairment. This was done in National Diabetes 
Register (NDR), a large nation-wide population-based diabetes register.
Materials and methods: 62 661 patients with T2D aged 18-80 years with 
complete datasets on albumin excretion, renal function (serum creatinine) 
and clinical characteristics reported to the Swedish National Diabetes Reg-
ister in 2008 were included. Albuminuria was defined as urinary albumin 
excretion rate > 20 µg/min and renal impairment as estimated glomerular 
filtration rate; eGFR< 60 ml/min/1.73 m2 according to MDRD. Values are 
given as crude means and standard deviations (SDs). In addition, data was 
analysed with least square (LS) means and frequencies, standard errors (SE) 
for clinical characteristics, comparing patients with renal impairment and 
those with no renal impairment at GLM regression adjusting for all other 
variables. P-values for each variable are given after these adjustments.
Results: 15% of all patients had renal impairment (n=9 308) and 58% of these 
patients were non-albuminuric. Several differences in cardiovascular risk factors 
were found between patients with and without renal impairment. Patients with 
renal impairment were older (71.2±6.7 vs. 64.0 ±9.3), had a longer diabetes dura-
tion (11.1±7.7 vs. 7.8±6.4 years), were more often women (50 vs. 40%), had sig-
nificantly lower total- and HDL-cholesterol (4.6±1.0 vs. 4.7±1.0 and 1.23±0.4 vs. 
1.28±0.4 mmol/L, respectively), higher triglycerides (2.0±1.2 vs. 1.8±1.1 mmol/
L), higher HbA1c (7.1±1.1 vs. 7.0± 1.1 % (DCCT)), higher BMI (30.2±5.3 vs. 
29.7±5.2 kg/m2) and higher systolic blood pressure (138±18 vs. 137±16 mmHg). 
In addition, fewer patients with renal impairment performed physical activity >3 
times a week (44 vs. 52%) and a smaller proportion were smoking (10 vs. 15%) 
(All p-values <0.001) compared to patients without renal impairment. When 
patients with renal impairment were compared with those without renal impair-
ment at GLM regression adjusting for all other variables similar relationships 
were found for all variables except for HbA1c and systolic blood pressure where 
adjusted values were lower in patients with renal impairment (7.0±0.01 vs. 7.1± 
0.01 % (DCCT) and 135±0.2 vs. 137±0.1 mmHg) (adjusted LS means±SE).
Conclusion: The majority of patients with type 2 diabetes and renal impair-
ment were non-albuminuric. Several differences in cardiovascular risk fac-
tor pattern were found between type 2 diabetic patients with and without 
renal impairment. Interestingly, patients with renal impairment had better 
glycemic control and blood pressure when adjusting for all other variables. 
This finding should be further investigated. The cause-effect relationship and 
potential treatment effects could not be assessed in this cross-sectional study 
and thus prospective studies are warranted.
1197
Relation between echocardiography and coronary artery disease in 
asymptomatic type 2 diabetic patients with elevated urinary albumin 
excretion rate
H. Reinhard1, P.R. Hansen2, N. Wiinberg3, C.L. Petersen3, H.-H. Parving4,5, 
P. Rossing1, P.K. Jacobsen1,6; 
1Steno Diabetes Center, Gentofte, 2Department of Cardiology, Gentofte 
University Hospital, 3Department of Clinical Physiology and Nuclear 
Medicine, Frederiksberg University Hospital, 4Department of Medical 
Endocrinology, University Hospital of Copenhagen, 5Faculty of Health 
Science, Aarhus University, 6The Heart Centre, University Hospital 
Rigshospitalet, Copenhagen, Denmark.
Background and aims: Coronary artery disease (CAD) is the major cause of 
morbidity and mortality in type 2 diabetic patients, especially in patients with 
elevated urinary albumin excretion rate. Left ventricular (LV) hypertrophy 
and systolic/diastolic abnormalities has been suggested as part of the diabetic 
cardiomyopathy, but relation to CAD is unclear. This study examined echocar-
diographic parameters, including LV mass index, LV systolic and diastolic 
function, and their relation to screen detected previously undiagnosed CAD 
in type 2 diabetic with urinary albumin excretion rate (UAER) >30mg/24h.
Materials and methods: The study included 200 type 2 diabetic patients without 
prior clinical CAD. Patients with plasma NT-proBNP >45.2 ng/L and/or coro-
nary calcium score >400 were arbitrarily stratified as high risk patients for CAD 
(n=133), and all other patients as low risk patients (n=67). High risk patients were 
examined by myocardial perfusion imaging (MPI; n=109), and/or CT-angiogra-
phy (CTA; n=20), and/or coronary angiography (CAG; n=86). LV systolic and/or 
diastolic dysfunctions were evaluated in all patients by conventional echocardi-
ography and tissue Doppler imaging. Moderate-severe LV hypertrophy was de-
fined by LV mass index >131 g/m2 in men and >108 g/m2 in women.
Results: Patients received multifactorial treatment, yielding mean (SD) HbA1c 
7.9 (1.3)%, plasma total cholesterol 3.9 (0.9) mmol/L and arterial blood pres-
sure 130 (17)/75 (11) mmHg. The LV mass index was 87 (21) g/m2 and 8 (4%) 
patients had moderate-severe LV hypertrophy. LV systolic function was well 
preserved (LV ejection fraction 59 (5)%) and impaired (<50%) in only 5% of 
patients. LV diastolic dysfunction (LVDD) was found in 109 patients (54.5%), 
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of whom 7 (3.5%) had impaired relaxation and 102 (51%) had a pseudonor-
mal pattern of LV filling. In 70 high risk patients, significant CAD was dem-
onstrated by MPI, and/or CAG. In a multiple regression model, the adjusted 
odd ratio (OR, 95% CI) for having significant CAD was 2.91 (1.41-6.00) in 
patients with LV mass index above the median. Patients with right atrial vol-
ume above the median (>49.1 ml) had higher risk of CAD (unadjusted OR 
2.20 (1.06-4.56) than other patients. LVDD was not associated with LV mass 
index or significant CAD but was associated with poor metabolic control (ad-
justed OR 1.46 (1.14-1.87) per 1% increase of HbA1c (p=0.003)).
Conclusion: In our study of asymptomatic type 2 diabetic patients with el-
evated UAER but receiving multifactorial treatment, the prevalence of ab-
normal LV mass and function was low. However, even within normal range 
LV mass index was an independent predictor of significant CAD. LVDD was 
common but not associated with CAD.
Supported by: an EFSD Clinical Research Grant
1198
Changes in skin microcirculation and large arterial vessels in patients 
with diabetic nephropathy
M. Walus-Miarka1, P. Miarka2, M. Dubiel3, M. Stompór3, E. Chowaniec2,  
M. Krzanowski2, T. Grodzicki3, B. Idzior-Walus1, W. Sulowicz2; 
1Department of Metabolic Diseases, 2Department of Nephrology, 
3Department of Internal Medicine, Medical College, Jagiellonian University, 
Krakow, Poland.
Introduction: Diabetic vascular complications are divided into microangio-
pathies (pertaining to microvasculature) and macroangiopathies (pertaining 
to large vessels) that lead to the development of atherosclerosis that clinically 
manifests as ischemic heart disease or cerebral stroke. Increasing vessels stiff-
ness and intima-media thickness (IMT) are indicators of macroangiopathy 
progression. Abnormalities of microcirculation are the basis of microvascu-
lar complications in diabetes and present in many organs. The doppler laser 
method allows for direct evaluation of skin microcirculation.
Aim: Study aim was to assess changes in the macro - and microcirculation in 
patients with diabetic nephropathy, as well as the influence of nephroprotec-
tive therapy on the evaluated parameters.
Materials and methods: 70 patients diagnosed with diabetes mellitus type II 
were studied: group 1- 48 patients with nephropathy, group 2 - 22 patients 
with diabetes mellitus without vascular complications (comprising the control 
group), and group 3- 25 patients with nephropathy, examined 36 months post 
intensive nephroprotective therapy. Visual diagnostic procedures evaluating 
macro- and microvessels were performed in all patient groups using usg (IMT) 
and laser doppler [skin mean basal flow (MFb), post occlusion flow (PF)].
Results: In the group with diabetic nephropathy, significantly higher values 
of PWV, as well as IMT were noted in cervical arteries when compared to 
the control group (p<0.01). In this group, significantly slower flow in micro-
circulation (MFb) at rest was noted (p< 0.01); as well as post occlusion (PF) 
(p=0.05) when compared to the group without complications. After 36 months 
of nephroprotective therapy in the studied group - stabilization of renal func-
tion was found and no substantial differences were noted in aortic pulse wave 
velocity (AoPWV) and also in IMT when compared to initial values at the 
beginning of the study. However, improvement was noted in skin microcir-
culation parameters when compared to initial values (p= 0.05); as well as a 
trend for improvement of maximal flow post occlusion (p= 0.09) and at the 
temperature of 44oc (MF44) (p= 0.05). Results are presented in the table.
Conclusion: Study results point to an existence of advanced atherosclerotic 
changes and decreased microcirculation skin flow in the group of patients 
with nephropathy than in the patient group without diagnosed nephropathy. 
After 36 months of observation and intensive nephroprotective therapy - sta-
bilization of macrocirculation changes and regression of skin microcircula-
tory abnormalities were observed.
*p<0,01
Parameter Study group Control group Study groupafter 36 month
AoPWV m/s 14.1±2.9* 11.8±2.1* 13.5±2.1
IMT-L mm 0.87±0.22 0.81±0.22 0.9±0.2
IMT-P mm 0.86±0.2* 0.77±0.21* 0.9±0.2
MFb PU 7.7±5.1* 12.1±7.1* 10.5±8.1*
PF PU 27.4±22.2* 30.8±10.7* 33.7±24.9*
MF44 PU 88.5±46.8* 94.6±47.3 103.9±67.1*
1199
Serum uric acid is related to cardiovascular events and correlates to NT-
proBNP and albuminuria in patients with diabetes mellitus
M. Clodi1, M. Resl1, H. Kormoser1, S. Neuhold2, M. Hülsmann2, A. Luger1, 
R. Pacher2; 
1Department of Endocrinology and Metabolism, 2Department of 
Cardiology, Medical University of Vienna, Austria.
Background and aims: Hyperuricemia is a risk factor for cardiovascular 
events and renal insufficiency. It correlates to intima media thickness and 
microalbuminuria. The aim of this study was to evaluate the relationship be-
tween NT-proBNP as an established marker for subclinical cardiovascular 
disease and uric acid in patients with diabetes mellitus.
Materials and methods: In a prospective observational study we recruited 
494 patients with diabetes mellitus. Serum uric acid, NT-proBNP, urinary 
albumin to creatinine ratio and HbA1c as well as other cardiovascular risk 
factors were evaluated at baseline. Patients were then followed for 12 months 
and hospitalisations due to cardiac events (ischemic heart disease, rhythm 
disturbances, heart failure) were recorded.
Results: The mean duration of diabetes was 13 ± 11 years. Patients were 60 ± 
13 years old and mean HbA1c was 7.7 ± 3.2%. At baseline mean uric acid was 
5.3 ± 1.6 mg/dl, NT-proBNP was 248 ± 412 pg/ml and mean urinary albu-
mine to creatinine ratio was 96 ± 361 mg/g; Uric acid significantly correlated 
to NT-proBNP (r= 0.258 p < 0.001) and urinary albumin to creatinine ratio 
(r = 0.198 p< 0.001). In a logistic regression model including the variables 
uric acid, NT-proBNP, systolic blood pressure and urinary albumin to creati-
nine ratio, NT-proBNP was the best predictor of cardiac events (Hazard Ratio 
1.002, Wald 37.2 p < 0.001). In a second step uric acid provided additional 
prognostic information (Hazard Ratio 1.353 Wald 7.0 p < 0.05).
Conclusion: Serum uric acid is a predictor of cardiac events and correlates 
to NT-proBNP underscoring the importance of uric acid as a cardiovascular 
risk marker in patients with diabetes mellitus.
1200
Serum osteoprotegerin is related coronary artery calcification, urinary 
albumin excretion, and diabetic retinopathy in Japanese patients with 
type 2 diabetes
N. Takebe, M. Masaya, K. Nagasawa, T. Takahashi, H. Honma,  
M. Yamashina, M. Ishii, F. Fujiwara, T. Kajiwara, H. Taneichi, K. Takahashi, 
J. Satoh; 
Division of Diabetes and Metabolism, Department of Internal Medicine, 
Iwate Medical University, Morioka, Japan.
Background and aims: Osteoprotegerin (OPG), a secreted glycoprotein 
identified as an inhibitor of bone resorption, has recently been indicated to 
act as an important regulatory molecule in the vasculature. Recent studies 
also suggest that serum OPG levels are associated with endothelial dysfunc-
tion, coronary artery calcification (CAC), and micro- and macroangiopathy 
in Type 2 diabetes, and, in addition, diabetic microangiopathy is correlated 
with macroangiopathy. However, a mechanism(s) underlining a relationship 
between diabetic macro- and microangiopathy is unclear. Therefore, we have 
measured serum OPG levels and cross-sectionally investigated relationships 
among OPG levels, macroangiopathy, and diabetic microangiopathy (retin-
opathy and nephropathy) in 82 Japanese patients with type 2 diabetes mel-
litus.
Materials and methods: Blood samples were obtained in fasting state. Vari-
ables analyzed were age, sex, blood pressure, BMI, waist/hip ratio, daily blood 
glucose profile, M value and MAGE as markers of blood glucose fluctuation, 
HbA1c, glycated albumin (GA), serum levels of OPG, IRI, TC, TG, HDL-C, 
LDL-C, Lp(a), uric acid (UA), homocysteine, adiponectin, leptin, and PAI-1, 
and urine C-peptide (CPR), surrogate markers of macroangiopathy [carotid 
IMT and plaque, pulse wave velocity (PWV), ankle-brachial index (ABI), and 
CAC score (CACS)], and presence of microangiopathy [DR > simple retin-
opathy, and urine albumin excretion (UAE) as a marker of nephropathy].
Results: Serum OPG levels were positively correlated with age, DM duration, 
systolic BP, PWV, log(CACS+1), BUN, logUAE, and presence of DR, whereas 
inversely with U-CPR, and postprandial glucose excursion. Multiple regres-
sion analysis showed that significantly independent predictors for the OPG 
levels were systolic BP and DR. Log(CACS+1) tended to be significant. On 
the next step, we analyzed focusing on an association of macroangiopathy 
[log(CACS+1)], and micropangiopathy (DR and logUAE) with the serum 
levels of OPG. Log(CACS+1) was positively correlated with OPG levels, age, 
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waist, systolic BP, PWV, IMT, BUN, UA, postprandial glucose excursion, and 
MAGE, whereas inversely with ABI. Multiple regression analysis showed that 
independent predictors for log(CACS+1) were OPG, DR, age, and waist. In 
comparison with patients without DR, those with DR had significantly higher 
levels of serum OPG, DM duration, PWV, UA, and log(CACS+1), whereas 
significantly lower levels of HDL, U-CPR, and diastolic BP. Logistic analysis 
revealed that independent predictors for DR were OPG levels, diastolic BP, 
GA, and log(CACS+1). Finally, logUAE was positively correlated with OPG, 
SBP, PWV, UA, LDH, and postprandial glucose excursion. Multiple regres-
sion analysis showed that independent predictors for logUAE were OPG, 
ABI, PWV, and MAGE.
Conclusion: Thus, these results indicate serum OPG level was an independ-
ent predictor for CAC, DR, and UAE, and vice versa in Japanese patients with 
type 2 diabetes. The results imply that there may be a bilateral interaction be-
tween coronary artery atherosclerosis, diabetic retinopathy and nephropathy 
in Type 2 diabetic patients.
1201
Chronic cigarette smoking could contribute to diabetic nodular 
glomerulosclerosis
R. Halmai, I.A. Szijártó, P. Degrell, Á. Mérei, P. Brasnyó, I. Wittmann; 
2nd Department of Internal Medicine, University of Pécs, Medical Faculty, 
Hungary.
Background and aims: Nodular glomeruloclerosis, glomerulomegaly, 
thickening of glomerular basement membrane and arteriolar hyalinosis are 
present both in diabetic nephropathy with nodular glomerulosclerosis and 
in idiopathic nodular glomerulosclerosis, which suggests a common mecha-
nism. Chronic smoking is known as a risk factor in the former and a potential 
causative factor in the latter disease. We hypothesized that there are more 
smokers among patients with diabetic nephropathy with glomerulosclero-
sis (DNP + NGS), than among patients with diabetic nephropathy without 
nodular glomerulosclerosis (DNP without NGS).
Materials and methods: A retrospective analysis of all native renal biopsy 
specimens (n=890) available in the Renal Pathology Laboratory at our clinic 
from 2002 to 2009 was performed. The characteristics of patients were col-
lected from medical documents and the smoking habits were confirmed by 
a questionnaire.
Results: The data revealed significantly more smokers (10 out of 11) among 
patients with diabetic nephropathy and nodular glomerulosclerosis com-
pared to the random selected patients (4 out of 10) with diabetic nephropathy 
without histological signs of nodular glomerulosclerosis (p=0.024). Between 
the two group of patients (DNP + NGS and DNP without NGS) no signifi-
cant difference was found in the age (56±14.7 vs. 53.7±7.7years, p=0.875), 
body mass index (30.5±5.6 vs. 31.9±4.1 kg/m2, p=0.578), duration of diabe-
tes mellitus (12.11±5.67 vs. 8.89±6.51 years, p=0.279), prevalence (89% both) 
and duration (10.43±8.92 vs. 12.25±13.55 years, p= 0.573) of hypertension, 
serum total cholesterol (7.5±5.3 vs. 6.9±2.2mmol/l, p=0.781), serum triglyc-
eride (4.5±4.4 vs. 2.8±1 mmol/l, p=0.344), serum creatinine (225.6±136.2 
vs. 180.6±88.1, p=0.479), estimated (MDRD) renal function (39.51±24.58 
vs. 45.24±26.92ml/min, p= 0.685) and the renin-angiotensin system blocker 
treatment (100% vs. 75%, p=0.155) at the time of the kidney biopsy.
Conclusion: Our results show, that chronic cigarette smoking could be a 
potential cause of nodular glomerulosclerosis seen in diabetic nephropathy 
patients.
1202
Erythropoetin therapy affects HbA1c levels in patients with diabetes 
mellitus and chronic kidney disease not on haemodialysis
J.M. Ng1, M. Cooke2, S. Bhandari2, S.L. Atkin1, E.S. Kilpatrick2; 
1Hull York Medical School, 2Hull Royal Infirmary, United Kingdom.
Background and aims: Glycated haemoglobin (HbA1c) is the most widely 
accepted and used method of assessing chronic glycaemia in patients with di-
abetes mellitus (DM). Treatment of anaemia in patients with chronic kidney 
disease (CKD) using erythropoietin stimulating agents (ESAs) has resulted in 
significant improvements to quality of life and levels of anaemia without the 
need for blood transfusions . Although some studave shown a fall in HbA1c 
in patients treated with ESA therapy it is not known whether there is a change 
in mean blood glucose. This study has therefore sought to establish the effect 
of ESA therapy on both HbA1c and mean blood glucose amongst a group of 
patients with diabetes and known CKD.
Materials and methods: This was a prospective study of patients with DM 
and CKD stage III or IV selected for treatment with erythropoietin stimulat-
ing agents (ESA) from Jan 2009 to December 2009 inclusive. All patients were 
requested to perform 7 point glucose monitoring (7PGM) 3 times weekly for 
a month before commencement of ESA until the end of the study. Continu-
ous glucose monitoring (CGMS) was performed measurements of interstitial 
glucose levels were made. Mean blood glucose (MBG) of each patient was 
calculated by averaging daily capillary glucose readings on days where pa-
tients had more than 3 readings a day or more and discerning the results of 
the CGMS.
Results: There were 15 patients (11M 4F, median age 70 (IQR 62,75)) with 
Type 2 DM. The mean follow up time of was (mean±SD) 17.3±3.3 weeks. 
There was a statistically significant rise in haemoglobin and haemotocrit lev-
els following ESA therapy and no significant change in the eGFR. The HbA1c 
levels fell without discernible alteration in glycaemic control. The mean 
HbA1c fell from 7.3 to 6.6% (p=0.001, paired t test). This change occurred 
in the presence of a MBG which remained unchanged (8.7 mmol/L vs 8.7 
mmol/L, p= 0.89).
Conclusion: Anaemia is a common phenomenon in patients with CKD. This 
study confirms the fall in HbA1c as a result of ESA treatment and proves 
that this is independent of a change in glycaemia. In these patients, therefore, 
alternative markers of glycaemia are needed to accurately assess their glucose 
control.
Patients on ESA therapy
Before ESA
mean (95% CI)
After ESA
mean (95% CI) p (paired t test)
HbA1c(%) 7.31 (6.42,8.54) 6.63 (6.03,7.36) 0.01
Hb (g/dl) 9.52 (9.18,9.86) 11.51 (11.15,11.85) <0.01
Haematocrit 0.324 (0.296,0.350) 0.378 (0.341,0.398) <0.01
Mean blood glucose 
(mmol/L) 8.72 (7.31,10.12) 8.78 (7.47,9.99) 0.89
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Irbesartan treatment does not influence plasma levels of the advanced 
glycation end products CML and CEL in patients with type 2 diabetes 
and microalbuminuria. An IRMA2 substudy
L. Engelen1,2, F. Persson3, I. Ferreira1,4, P. Rossing3, P. Hovind3,5, T. Teerlink6, 
C.D.A. Stehouwer1,2, H.-H. Parving7,8, C.G. Schalkwijk1,2; 
1Internal Medicine, Maastricht University Medical Centre, Netherlands, 
2Cardiovascular Research Institute Maastricht (CARIM), Netherlands, 
3Steno Diabetes Center, Gentofte, Denmark, 4Clinical Epidemiology and 
Medical Technology Assessment (KEMTA), Maastricht University Medical 
Centre, Netherlands, 5Clinical Physiology and Nuclear Medicine, Glostrup 
Hospital, Denmark, 6Clinical Chemistry, VU University Medical Center, 
Amsterdam, Netherlands, 7Medical Endocrinology, University Hospital of 
Copenhagen, Denmark, 8Faculty of Health Science, University of Aarhus, 
Denmark.
Background and aims: Guidelines state that patients with type 2 diabetes 
who develop microalbuminuria should be treated with angiotensin receptor 
blockers (ARBs). In vitro studies and animal experiments have shown inhib-
iting effects of ARBs on advanced glycation end products (AGEs), which are 
known to be involved in the development of cardiovascular complications in 
diabetes. However, human data to confirm such beneficial effects of ARBs 
are lacking.
Materials and methods: We analysed data from a multicentre, double-blind, 
randomised controlled trial in patients with type 2 diabetes and microalbu-
minuria, the primary goal of which was to examine the renoprotective effects of 
irbesartan (150 or 300 mg once daily). Secondary endpoints included, among 
others, measures of the plasma levels of the AGEs Nε(carboxymethyl)lysine 
(CML) and Nε(carboxyethyl)lysine (CEL) in the treatment arm receiving 300 
mg irbesartan (n =139) and in the placebo group (n =125). Effects of treat-
ment at 1- and 2-year follow-up were analysed by means of generalized esti-
mating equations.
Results: Levels of CML and CEL (as well as all other patients’ characteris-
tics) did not differ between groups at baseline. No significant changes were 
observed in CML and CEL over time in either group and there was no effect 
of treatment at any time-point. Mean differences between groups over time 
were -0.96 nM/mM lysine (95%CI: -3.43; 1.51) for CML and -0.10 nM/mM 
lysine (95%CI: -0.76; 0.56) for CEL (Figure 1).
Conclusion: Long-term irbesartan treatment does not influence plasma lev-
els of the AGEs CML and CEL in patients with type 2 diabetes and micro-
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albuminuria. These findings do not support the concept that ARBs inhibit the 
process of advanced glycation in humans.
Supported by: the Netherlands Heart Foundation for I. Ferreira
PS 119 Nephropathy - role of renal 
function
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Direct correlation between initial glomerular filtration rate and long-
term urinary albumin excretion in patients with type 1 diabetes
S.L. Hyer1, C. Soper2, A. Tran1, A. Rodin1; 
1Diabetes, St Helier University Hospital, Carhsalton, United Kingdom, 
2Diabetes, Mayday University Hospital, Croydon, United Kingdom.
Background: Increased glomerular filtration pressure and glomerular filtra-
tion rate (GFR) occur early in type 1 diabetes although their significance in 
the pathogenesis of diabetic nephropathy remains controversial.
Aims: To examine the relationship between initial GFR and urinary albumin 
excretion after at least 10 years follow-up.
Methods: 77 male patients (aged 18-42) with type 1 diabetes of short dura-
tion (4-8 years) and normal urinary albumin excretion (albumin: creatinine 
ratio (ACR)< 2.5 mg/mmol on 3 occasions) were studied at baseline using 
inulin clearance (ICL) to assess GFR. At baseline, 13 patients had evidence of 
glomerular hyperfiltration (ICL>145 ml/min/1.73m2). Mean HbA1c: 8.3%. 
All patients were invited to attend a follow-up study after a median of 163 
(151-168) months where they provided 3 consecutive early morning urine 
samples for ACR.
Results: Complete data collection was available for 12 patients; the others 
were either untraceable or declined to participate in the follow-up study. At 
follow-up, all were normotensive (mean BP: 127/75), with normal renal func-
tion; mean HbA1c 7.6%; eight patients were taking statins and 3 were on 
ACE-inhibitor drugs. One patient had developed overt microalbuminuria. A 
significant correlation was shown between baseline ICL and follow-up mean 
(log) ACR (r2 =0.4; p=0.028). Baseline and follow-up HbA1c were closely cor-
related (r2 =0.52; p=0.008). When HbA1c was entered as a covariate, the cor-
relation between ICL and ACR just failed to achieve significance (p=0.055).
Conclusion: The results of this study support a link between GFR measured 
by inulin clearance and the development of nephropathy reflected by urinary 
albumin excretion. The relationship is, however, strongly influenced by the 
prevailing glycaemic control.
Supported by: UK CRN
1205
High-normal albuminuria and cardiovascular risk factors in patients 
with type 2 diabetes and no evidence of kidney impairment
O. Lamacchia1, M. Cignarelli1, L. Gesualdo2, S. Fariello1, A. Pacilli3, S.A. 
Santini4, S. De Cosmo3; 
1Department of Medical Sciences, Unit of Endocrinology, 2Department of 
Molecular Medicine, Unit of Nephrology, 3Unit of Endocrinology, Scientific 
Institute “Casa Sollievo della Sofferenza”, SGR, 4Unit of Clinical Chemistry, 
Scientific Institute “Casa Sollievo della Sofferenza”, SGR, Foggia, Italy.
Background and aims: Albuminuria in the ‘high-normal’ range, is a predic-
tor of cardiovascular morbidity and mortality. Which factors account for this 
increased risk and whether such a prediction is maintained also in the absence 
of a concomitant reduction of glomerular filtration rate (GFR) is unclear yet. 
The aim of the present study was to explore, in a large cohort of patients with 
type 2 diabetes (T2DM) with normoalbuminuria and no evidence of kidney 
impairment, the association between traditional cardiovascular risk factors 
and urinary albumin excretion.
Materials and methods: This was a cross-sectional study investigating 1148 
(556M/592F) patients with T2DM, age 60.4 ± 10.1 yrs, duration of diabetes 
10.5 ± 9.1 yrs, with normoalbuminuria [ACR 0.80 (0.01 - 3.49) mg/mmol] 
and estimated-GFR > 60 ml/min/1.73m2 (89.5 ± 20.8 ml/min/1.73m2). Nor-
moalbuminuria was defined if the albumin/creatinine ratio (ACR) was <2.5 
in men and < 3.5 mg/mmol in women. Estimated-GFR was derived by serum 
creatinine.
Results: ACR significantly and independently correlated with gender 
(p=0.016), age (b=0.112, p=0.001), HbA1c (b=0.137, p <0.0001), BMI 
(b=0.106, p=0.036) and SBP (b=0.076, p=0.013). A gradual increase by ter-
tiles of ACR in the proportion of patients with HbA1c > 7% [ 269 (70.4%) 
vs 305 (79.6%) vs 313 (81.7%), p<0.0001], hypertension [282 (73.8%) vs 286 
(74.6%) vs 322 (84.0%), p =0.020], Metabolic Syndrome [291 (76.1%) vs 298 
(77.8%) vs 324 (84.5%), p=0.021] and retinopathy [83 (21.7%) vs 120 (31.3%) 
vs 128 (33.4%), p=0.001] was also observed.
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Conclusion: Our data indicate that patients with T2DM and albuminuria in 
the high-normal range, even in the absence of GFR reduction, are character-
ized by the presence of several cardiovascular risk factors and suggest they 
may deserve a careful clinical follow-up. Prospective studies are needed to 
investigate whether a new threshold to define microalbuminuria and to be 
used as cut-off in the stratification of global cardiovascular risk is needed.
1206
Association of renal function with anaemia in diabetic kidney disease
S.A. Martynov, M.V. Shestakova, Y.I. Suntsov, O.V. Maslova, I.I. Dedov; 
Endocrinology Scientific Center, Moscow, Russian Federation.
Background and aims: Anemia is a common complication of chronic kid-
ney disease (CKD) particularly in patients (pts) with diabetic kidney disease 
(DKD). In DKD anemia occurs early and is more severe than in non diabetic 
CKD. The aim of the study was to estimate the prevalence of anemia in diabe-
tes mellitus (DM) pts with and without renal damage.
Materials and methods: A total 2015 DM type 1 (DM 1) (n=807; 40%) and 
type 2 (DM 2) (n=1208; 60%) pts were screened for presence of anemia. Their 
mean clinical data: age - 50,0±16,1 years, DM duration - 12,2±8,6 years, 
HbA1c - 8,7±2,0 %, hemoglobin (Hb) - 134,8±17,8 g/l. Mean glomerular fil-
tration rate (GFR) was calculated using the MDRD formula - 107,6±39,8 ml/
min/1,73 m2, The 66.3% pts had arterial hypertension. Anemia was defined as 
Hb < 13.0 g/dl for men and Hb < 12.0 g/dl for women by the gender specific 
definition of WHO for pts without DKD and Hb < 13.5 g/dl for men and Hb 
<12.0 g/dl for women by the definition of anemia in CKD by National Kid-
ney Foundation/Kidney Disease Outcome Quality Initiative (NKF/KDOQI) 
for pts with DKD. Evaluation of the distribution of anemia was based on 5 
stages of CKD categories according NKF/KDOQI. Patients with GFR<15 
ml/min/1,73 m2 (5 stage of CKD) and treated by erythropoesis-stimulating 
agents were not included.
Results: The prevalence of anemia in DKD pts (n=971; 48.2%) was 32.4% 
compared to 13.8% in pts without renal damage (n=1044; 51.8%) (p<0.001). 
In DM 1 with DKD, the anemia prevalence was significantly higher than in 
DM 2 (41.9% and 23.7%, respectively (p<0.001)). Comparison of anemia 
prevalence based on pts gender did not find significant discrepancy in total 
group of DKD pts and pts DM 1 with DKD, except in pts DM 2 (male - 30.5% 
vs female - 21.9%, respictevely (p<0.05). The prevalence of anemia signifi-
cantly increased in pts with evident renal injury and achieved to 47.1% in 
proteinuric pts (n=323), that greatly higher compared to pts with microalbu-
minuria - 25.7% (n=607) (p<0.001) and normoalbuminuria - 14.3% (n=1085) 
(p<0.001). Anemia prevalence significantly increased when the renal failure 
progresses (Table 1; *P<0.05; **P<0.01 between CKD 1 stage and other CKD 
stages). In DKD the Hb had strong association with GFR (R=0,41; p<0,001), 
DM duration (R=-0.27; p<0.001). Independent factors for Hb level by multi-
ple logistic regression analysis were DM type - 1 (beta = -0.21), gender - male 
(beta = -0.30), albuminuria (beta = -0.10), hypertension (beta = -0.08) and 
GFR (beta = 0.33) (p<0.001).
Conclusion: Anemia is a prevalent finding in pts with DKD, especially in 
DM 1. In half of DM 1 pts and in one-of third type DM 2 pts anemia develops 
when the mild decrease of GFR (60-89 ml/min/1,73 m2). The prevalence of 
anemia in DKD is clearly related to the degree of albuminuria and decreasing 
of renal function.
Anemia prevalence in diabetic kidney disease patients according to CKD stages (%)
CKD 1 stage
(GFR ≥ 90 ml/
mi/1,73 m2),  
n=523
CKD 2 stage 
(GFR 60-89 ml/ 
min/1,73 m2), 
n=231
CKD 3 stage 
(GFR 30-59 ml/ 
min/1,73 m2), 
n=169
CKD 4 stage  
(GFR 15-30 ml/
min/1,73 m2),  
n=48
All patients 
(n=971)
21.1 35.9** 46.7** 87.5**
Type 1  
(n=403)
25.5 46.5** 66.1** 85.3**
Type 2  
(n=568)
18.2 27* 36.4** 92.8**
1207
Renal perfusion is reduced in apparently uncomplicated type 1 diabetic 
patients
S.M. Marshall1, R. Taylor2, P.E. Thelwall2; 
1ICM, Newcastle University, 2Newcastle Magnetic Resonance Centre, 
Newcastle University, United Kingdom.
Background and aims: Magnetic resonance imaging (MRI) offers novel, 
non-invasive techniques for investigation of diabetic nephropathy. We as-
sessed renal perfusion in control subjects and Type 1 diabetic patients with 
and without microalbuminuria.
Materials and methods: 8 Type 1 diabetic patients (T1C) (age 40.1±6.7 years, 
duration diabetes 28.4±6.2 years, eGFR 76.1±8.24 ml/min/1.73 m2, albumin:
creatinine ratio (ACR) persistently <2.5 mg/mmol, BP <130/80 mmHg on 
no treatment, no or minimal background retinopathy), 8 Type 1 diabetic 
patients with microalbuminuria (T1M) (ACR persistently >5.0 mg/mmol), 
eGFR 78.1±9.9 ml/min/1.73 m2 , age 41.2±7.3 years, duration diabetes 27.3±5.6 
years, all with significnat retinopathy, and seven healthy control subjects (C), 
age 39.0±7.9 years, on no medication, participated. Six T1M participants were 
studied on (T1Mon) and after 4 weeks off (T1Moff) RAAS inhibition. Blood 
pressure (BP) control off RAAS inhibition was maintained by non-RAAS 
agents. Studies were performed fasting. Blood glucose was maintained at 4.0-
6.0 mmol/l in the diabetic subjects by IV insulin infusion. Phase-contrast an-
giography was performed to measure renal artery flux over the cardiac cycle 
before and after water loading (20 ml/kg body weight), when urine flow >8 
ml/min.
Results: Renal artery flow rate (RAF), corrected for body surface area and 
pulse rate, was higher in the control subjects (791±253 ml/min/1.73 m2 body 
surface area) compared to T1C (622±128) and T1Moff (580±188; ANOVA 
p=0.05), with no significant difference between T1C and T1Moff. There was 
no change with water loading. RAF (587±118 vs 580±188 ml/min/1.73m2) 
and eGFR (71.1±10.4 vs 78.1±9.9 ml/min/1.73m2) were similar in T1Mon 
and T1Moff. RAF correlated with eGFR in all diabetic patients (r=0.59, 
p=0.031), and in T1C (r=0.84, p=0.01) but not in T1Mon (r=0.39, p=0.52) or 
T1Moff (r=0.008, p=0.99).
Conclusion: In longstanding apparently otherwise healthy Type 1 diabetic 
patients with clinically normal renal function, renal perfusion is decreased 
to a level similar to that in Type 1 microalbuminuric patients. Perfusion is 
unaltered by water diuresis or RAAS blockade. The different relationships 
between eGFR and RAF in the normo- and micro-albuminuric patients sug-
gest different haemodynamic changes. The reasons for reduced perfusion are 
unclear.
Supported by: DRWF
1208
Determinants of decline in glomerular filtration rate in association with 
progression of albuminuria in type 2 diabetes
H. Yokoyama1, S. Kannno1, S. Takahashi1, D. Yamada1, J. Honjo1,2, H. 
Sone1,3, M. Haneda2; 
1Internal Medicine, Jiyugaoka Clinic, Obihiro, 2Department of Medicine, 
Asahikawa Medical College, 3Department of Internal Medicine, University 
of Tsukuba Institute of Clinical Medicine, Japan.
Background and aims: Some normoalbuminuric type 2 diabetic subjects 
have a reduced glomerular filtration rate (GFR), but common and independ-
ent risks for GFR decline and albuminuria progression remain unclear.
Materials and methods: An observational 4-year cohort study was per-
formed on 1,002 subjects with preserved GFR (699 normoalbuminuric), and 
the predictive value of baseline variables on the GFR slope was investigated. 
GFR decliner and albuminuria progressor were defined as a GFR slope <-4.0 
%/year and changes in the geometric mean in urinary albumin from baseline 
to follow-up >150%, respectively.
Results: Multiple linear regression analysis indicated that GFR slope was 
predicted by baseline variables of urinary albumin, GFR, HbA1C, systolic 
blood pressure, plasma total protein, and retinopathy. The effects of these 
risks appeared variable according to whether individuals had high or low 
urinary albumin and GFR levels. Subjects cross-classified according to GFR 
decliner/albuminuria progressor consisted of 51%(-/-), 13%(-/+), 28%(+/-), 
and 8%(+/+). Common risks for GFR decline and albuminuria progression 
were retinopathy, neuropathy, HbA1C, and urinary albumin. Independent 
significant risks for GFR decline were baseline GFR, systolic blood pressure, 
total protein, and hypertension. Proportion of progression to albuminuria 
was similar between GFR decliners and non-decliners.
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Conclusion: In type 2 diabetes, the GFR slope was predicted and affected 
at various stages by multiple factors. Isolated GFR decline and albuminuria 
progression are not rare, and common and independent risk factors predic-
tive for GFR decline and albuminuria progression exist.
1209
The chronic kidney disease collaboration equation: not of additional 
value compared to the modification of diet in renal disease equation in 
diabetic patients
I. Drion1, H. Joosten1,2, L.J. Ubink-Veltmaat3, L.G. Lieverse4, K.J.J. Van 
Hateren1, K.H. Groenier5, N. Kleefstra1,6, H.J.G. Bilo7,1; 
1Diabetes Center, Zwolle, 2Internal Medicine, University Medical Center 
Groningen, 3General practice ‘t Veen, Hattem, 4Internal medicine, Maxima 
Medical Center, Eindhoven,5General practice, University Medical Center 
Groningen, 6Langerhans Medical Research Group, Zwolle, 7University 
Medical Center Groningen, Netherlands.
Background and aims: Equations to estimate the glomerular filtration rate 
(GFR) are routinely used to assess kidney function. Due to the systematic 
underestimation and limited precision of the current prediction equations, 
especially when GFR is ≥60ml/min/1.73m2, a new prediction equation was 
developed with the aim to reduce these problems: the chronic kidney disease 
collaboration equation (CKD-EPI). We aimed to compare the outcomes of 
the CKD-EPI and MDRD-4 equation with the creatinine clearance (CrCl) in 
a cohort of diabetic adults.
Materials and methods: In this retrospective cohort study of 844 diabetic 
outpatients, the MDRD-4 and the CKD-EPI were calculated and compared 
by means of correlation to the 24 hour CrCl, ‘the golden standard of daily 
practice’. MDRD-4 was correlated to CKD-EPI to assess in which clearance 
ranges differences between the two prediction equations were present. Bias 
and precision were evaluated to determine the degree of reliability and con-
sistency of both equations. Furthermore, the percentage of subjects having an 
under- or overestimated kidney function was calculated.
Results: Both the MDRD-4 and the CKD-EPI equation were similarly, though 
only moderately correlated with CrCl (r=0.69 and r=0.73, respectively). The 
MDRD-4 showed a high correlation with the CKD-EPI (r=0.98) for patients 
with an eGFR ≤90ml/min. The correlation decreased to r=0.46 for patients 
with an eGFR >90ml/min (figure 1). Mean overall bias (SD) of the MDRD-4 
and CKD-EPI compared to CrCl were -32.8 (±32.3) ml/min/(1.73m2) and -
33.3 (±32.6) ml/min/(1.73m2), respectively (p=0.2). Mean bias (SD) between 
CrCl and MDRD-4 / CKD-EPI in the clearance category >60ml/min were 
-37.1 (±31.5) ml/min (1.73m2) / -37.8 (±31.5) ml/min (1.73m2) respectively 
(p=0.14). In the different KDOQI stages, the differences between MDRD-4 
and CKD-EPI were small and non-significant. When using either CKD-EPI 
or MDRD-4 for identifying patients with CKD, only approximately 50% of 
the patients were correctly classified, even when a dispersion of 30% com-
pared to CrCl was accepted.
Conclusion: The CKD-EPI appeared to have no additional value compared 
to the MDRD-4 when used in a cohort of diabetic patients with a relative 
preserved renal function. Our data do not support adjustment of current 
guidelines towards the use of this new prediction equation.
1210
Estimation of glomerular filtration rate in patients with diabetes mellitus 
type 2: comparison of CKD EPI equation and cystatin C-based formula
T. Didangelos1, A. Ntemka1, F. Iliadis1, A. Makedou2, C. Margaritidis1, E. 
Papanastasiou3, K. Makedou2, A. Gotzamani-Psarakou3, D. Grekas1; 
1Diabetes Division,1st Propeudetic Department of Internal Medicine, 2Labo-
ratory of Lipids, 2nd Paediadtric Department, 3Laboratory of Nuclear Medi-
cine, ‘’AHEPA’’ Hospital of Thessaloniki, Aristotle University of Thessaloniki, 
Greece.
Background and aims: The estimation of Glomerular Filtration Rate (GFR) 
by the Modification of Diet in Renal Disease (MDRD) equation, which is 
based on serum creatinine (Scr), has recognised limitations. A new equation 
was proposed by the Chronic Kidney Disease Epidemiology Collaboration 
(CKD EPI) to improve estimation of GFR. The CKD-EPI equation showed 
improved performance compared to the MDRD equation. Moreover, serum 
cystatin C (ScysC) has been proposed as a potential replacement of Scr in 
GFR estimation. We compared the CKD-EPI equation to a Scyst based for-
mula for GFR estimation in patients with type 2 diabetes.
Materials and methods: We studied 368 Caucasians participants with type 2 
diabetes, 168 (45.7%) men, with [mean (SD)]: age 65 (10) years, BMI 30.7(5.1) 
Kg/m2, HbA1c 7.0 (1.5)%. GFR was measured using plasma clearance of 51Cr-
EDTA (mGFR). In parallel, GFR was estimated twice, using the CKD-EPI 
equation [If female and Scr ≤ 0.7 mg/dl, CKD-EPIGFR = 144 × (Scr/0.7)-0.329 × 
(0.993)Age - if female and Scr >0.7 mg/dl, CKD-EPIGFR = 144 × (Scr/0.7)-1.209 
× (0.993)Age - if male and Scr ≤0.9 mg/dl, CKD-EPIGFR = 141 × (Scr/0.9)-0.411 
× (0.993)Age - if male and Scr >0.9 mg/dl, CKD-EPIGFR= 141 × (Scr/0.9)-1.209 
× (0.993)Age] and the Stevens equation which is based on ScystC [cystCGFR: 
127.7 / (ScystC 1.17) × (age -0.13) × (0.91 if female)]. Estimated GFR results were 
compared with isotopic GFR by means of two-tailed, paired t tests and by Lev-
ene’s test for equality of variance. Bland-Altman plots were obtained.
Results: MGFR was 72.0 (22.3) ml/min per 1.73 m2 , CKD-EPIGFR was 83.0 
(20.3) ml/min per 1.73 m2 (p<0.05 for difference from mGFR) and cystCG-
FR was 72.5 (27.9) ml/min per 1.73 m2 (NS difference between mGFR and 
cystCGFR). Bland-Altman plots showed that 95.1% and 93.9% of estimations 
for CKD-EPIGFR and cystCGFR respectively, lie within the ± 1.96SD of the 
mean difference. Bias (mean difference between estimated GFR and mGFR) 
was 10.5 and 0.45 ml/min per 1.73 m2 for CKD-EPIGFR and cystCGFR re-
spectively (p<0.05 for difference in bias between CKD-EPIGFR and cystCG-
FR). Precision (SD of the bias) was 13.8 and 21.96 ml/min per 1.73 m2 for 
CKD-EPIGFR and cystCGFR respectively (p<0.05 for difference in precision 
between CKD-EPIGFR and cystCGFR). Accuracy 10% (proportion of esti-
mated GFR results within 10% of mGFR) was 34.8% and 33.2% for CKD-
EPIGFR and cystCGFR respectively (NS difference in accuracy 10% between 
CKD-EPIGFR and cystCGFR). Accuracy 30% (proportion of estimated GFR 
results within 30% of mGFR) was 72.4% and 72.6% for CKD-EPIGFR and 
cystCGFR respectively (NS difference in accuracy 30% between CKD-EP-
IGFR and cystCGFR).
Conclusion: Stevens cystatin C based formula was less biased than and CKD-
EPI equation. On the other hand CKD-EPI equation was more precise and 
presented higher agreement with measured GFR. These results support the 
superiority of CKD-EPI equation over Stevens cystatin C based formula for 
estimation of GFR in patients with type 2 diabetes.
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Orosomucoid excretion in urine predicts mortality in type 1 and type 2 
diabetes
M.S. Christiansen1, J. Mølvig1, E. Magid2; 
1Department of Internal medicine, Amager Hospital, Copenhagen, 
2Department of Clinical Biochemistry, Amager Hospital, Copenhagen, 
Denmark.
Background and aims: Increased mortality compared to the background 
population is still a problem of serious concern in diabetes mellitus. Previ-
ously we have shown that increased urinary excretion of the inflammatory 
protein orosomucoid (UOER) independently predicts cardiovascular mortal-
ity in patients with type 2 diabetes (T2DM). The evaluation was in a dichoto-
mous comparison. The aim of the present study was to evaluate the predictive 
value of UOER in a continuous scale on mortality in patients with type 1 
(T1DM) and T2DM.
Materials and methods: Patients with diabetes were consecutively included 
from the outpatient clinic at Amager Hospital provided they had negative 
urine sticks. Urine samples were analysed for orosomucoid and albumin by 
immunoturbidimetry. Cut-off value for increased UOER was 2.04 µg/min. 
Survival analyses were done using Kaplan-Meier survival curves and com-
pared by log-rank test. Cox proportional hazards regression analysis with 
backward stepwise regression was used for multivariate analysis.
Results: 195 patients with T1DM and 706 patients with T2DM were followed 
for mean (SD) period of 4.6 (1.3) years. For T1DM mean age was 42 (14) years, 
HbA1c was 8.6 (1.9) %, median (range) duration of diabetes was 10 (0-44) years 
and median UOER was 1.00 (0.02-350) µg/min. For T2DM mean age was 59 (11) 
years, HbA1c was 8.2 (1.8) %, median duration of diabetes was 6 (0-44) years and 
median UOER was 2.05 (0.03-225) µg/min. Eight patients with T1DM and 120 
patients with T2DM died in the follow-up period. In T1DM there was a signifi-
cant difference in survival between patients with normal (NO) versus increased 
(MO) UOER (p<0.006). There was also a highly significant difference in survival 
in T2DM (p<0.0003) (figure). Using multivariate regression analysis we found 
that increased UOER (µg/min) (OR: 1.12 (95% CI: 1.04-1.20); p< 0.003), age 
(years) (1.37 (1.27-1.46); p< 0.00001) and male sex vs. female (1.12 (1.04-1.20); 
p< 0.002) independently predicted mortality in T2DM. The analyses were ad-
justed for BMI, HbA1c and systolic blood pressure. When albumin was included 
in the analysis UOER was not a significant predictor of mortality in T2DM. In a 
dichotomous comparison UOER was still an independent predictor of mortal-
ity in T2DM: NO vs. MO: (1.12 (1.04-1.20); p< 0.004), age (1.35 (1.26-1.45); p< 
0.00001) and sex (1.10 (1.02-1.18); p< 0.02) independently predicted mortality. 
For T1DM: NO vs. MO (1.24 (1.06-1.44; p< 0.008)), age (1.18 (1.01-1.37); p< 
0.04) and BMI (0.83 (0.72-0.97); p< 0.02) independently predicted mortality. 
The latter 2 analyses were adjusted for BMI, HbA1c, systolic blood pressure and 
microalbuminuria. In a dichotomous comparison microalbuminuria was not an 
independent predictor of mortality in T1DM or T2DM.
Conclusion: For the first time we have shown that UOER independently pre-
dicts mortality in patients with T1DM and confirmed the results in T2DM in 
a dichotomous comparison. In a continuous scale albuminuria was superior 
to UOER in T2DM.
1212
Microalbuminuria but not reduced GFR is a marker of subclinical 
atherosclerosis and arterial stiffness in type 2 diabetes
P. Sjöblom1, J. Engvall2, T. Länne1, F. Nyström1, C. Östgren1; 
1Department of Medical and Health Sciences, Linköping University, 
2Department of Clinical Physiology, Linköping University Hospital, Sweden.
Background and aims: Microlbuminuria is a strong predictor for cardiovas-
cular disease in patients with type 2 diabetes. However, the role of reduced re-
nal function, expressed as an estimated Glomerular Filtration Rate (GFR) as 
a risk assessment tool for macrovascular complications is unclear. The aim of 
this study was to explore the associations between GFR vs. microulbuminuria 
and subclinical organ damage in patients with type 2 diabetes.
Materials and methods: Baseline data were analysed from 706 patients who 
participated in the Cardiovascular Risk factors in Patients with Diabetes -
a Prospective study in Primary care (CARDIPP). The Patients, aged 55-65 
years, were consecutively recruited 2005-2008 from 22 primary health care 
centres in Sweden. Urine and blood samples for laboratory analyses were tak-
en in the morning following 10 hours fasting. Presence of microalbuminuria 
(alb) was defined as u-albumin/creatinine ratio (ACR) >3.0 mg/mmol. GFR 
was calculated by use of the MDRD formula and reduced renal function de-
fined as < 60 ml/min/1,73m2. Office blood pressure (BP) was measured by 
dedicated nurses and 24h-ambulatory BP was also performed. The carotid 
intima-media thickness (IMT) was determined by ultrasonography. Arterial 
stiffness was evaluated by pulse wave velocity (PWV) measured as transit 
time between the carotid and femoral arterial pulse waves. Left ventricular 
mass was measured echocardiographically, corrected for body surface area 
expressed as left ventricular mass index (LVMI)
Results: Patients with alb had increased IMT (0.78 vs 0.73 mm), PWV (11.5 
vs 10.1 m/s) and LVMI (134.4 vs 118.3 g/m2) compared to subjects with no 
alb. The table shows the results further divided and analysed for significance. 
There were no statistically significant differences in IMT, PWV or LVMI be-
tween patients with reduced renal function according to GFR compared to 
subjects with GFR > 60 ml/min/1.73m2.
Conclusion: We conclude that microalbuminuria defined as ACR, but not 
impaired renal function according to GFR, is a marker for subclinical organ 
damage in terms of atherosclerosis, arterial stiffness and increased left ven-
tricular mass in patients with type 2 diabetes.
Supported by: FORSS
1213
Albuminuria is associated with angiographically determined coronary 
atherosclerosis both in patients with type 2 diabetes and in non-diabetic 
individuals
C. Boehnel1,2, P. Rein1,2, C.H. Saely1,2, A. Vonbank1,2, S. Beer1,2, V. Jankovic1,2, 
J. Breuss1,2, L. Risch1, H. Drexel1,2; 
1Vorarlberg Institute for Vascular Investigation and Treatment, Feldkirch, 
Austria, 2Private University of the Prinicpality of Liechtenstein, Triesen, 
Liechtenstein.
Background and aims: Albuminuria is associated with atherothrombotic 
events and all-cause mortality in patients with diabetes as well as in non-
diabetic individuals. In the present study we aimed at investigating whether 
albuminuria is associated with directly visualised atherosclerosis in the same 
manner.
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Materials and methods: We enrolled 909 consecutive Caucasian patients, 
including 226 patients with type 2 diabetes (T2DM) and 683 non-diabetic 
subjects who were referred to coronary angiography for the evaluation of 
stable coronary artery disease (CAD). Elevated urinary albumin excretion 
(UAE) was defined as an urinary albumin to creatinine ratio (ACR) ≥30 μg/
mg; significant CAD was diagnosed in the presence of coronary artery lumen 
narrowing ≥50%.
Results: The prevalence of significant CAD was significantly higher in pa-
tients with an elevated UAE than in those with normal UAE (65.9 vs. 51.4%; 
p <0.001). Logistic regression analysis adjusting for age, gender, smoking, 
hypertension, LDL cholesterol, HDL cholesterol, CRP, BMI, use of ace/angi-
otensin II antagonists, aspirin and statins, as well as for the gomerular filtra-
tion rate (eGFR) and for T2DM confirmed elevated UAE as a significant pre-
dictor of angiographically determined CAD (OR=1.68 [1.15-2.44]; p=0.007). 
Similarly, the ACR was significantly associated with significant CAD when 
treated as a continuous variable (standardized adjusted OR=1.45 [1.13-1.86]; 
p=0.004). The prevalence of elevated UAE was significantly higher in patients 
with T2DM than in non-diabetic patients (38.9 vs. 18.0%; p <0.001). Like in 
the total study cohort, the prevalence of significant CAD was higher in pa-
tients with elevated UAE than in those with normal UAE out both in patients 
with diabetes (75.0 vs. 60.9%; p = 0.028) and in those without diabetes (59.3 
vs. 49.1; p = 0.040). Concordantly, the ACR proved significantly predictive of 
significant CAD both in patients with T2DM (1.66 [1.01 - 2.74]; p = 0.045) 
and in patients without diabetes (1.42 [1.05 - 1.92]; p = 0.023) in a fully ad-
justed model.
Conclusion: In conclusion, an elevated UAE is strongly associated with an-
giographically determined coronary atherosclerosis both in patients with 
T2DM and in non-diabetic patients, independent of conventional cardiovas-
cular risk factors and of the eGFR.
1214
Seasonal variations of urinary albumin/creatinine ratio in subjects with 
type 2 diabetes and nephropathy
Y. Wada1, Y. Hamamoto1, Y. Iwasaki1, J. Fujikawa2, S. Honjo1, Y. Kawasaki1, 
K. Mori1, H. Ikeda3, K. Nomura4, H. Koshiyama1; 
1Center for Diabetes and Endocrinology, The Tazuke Kofukai Foundation 
Medical Research Institute Kitano Hospital, Osaka, 2Department of 
Laboratory Medicine, The Tazuke Kofukai Foundation Medical Research 
Institute Kitano Hospital, Osaka, 3Ikeda Hospital, Amagasaki, 4Division of 
Diabetes, Metabolism and Endocrinology, Kobe University Graduate School 
of Medicine, Japan.
Background and aims: It has been recognized that blood pressure shows 
a seasonal variation. There have been some reports about seasonal change 
of glycemic control and onset of diabetes. But it remains unknown whether 
diabetic nephropathy may show a seasonal variation in relation to blood pres-
sure. In the present study, we investigated whether there may be a seasonal 
change in albumin/creatinine ratio (ACR).
Materials and methods: A total of 430 subjects (male : n=275, female : n=155) 
with type 2 diabetes and early nephropathy were included, whose mean age 
was 64.8±0.8 SE years. Those who had advanced stage of nephropathy with 
increased creatinine were excluded. Data were obtained from 2006 to 2009 at 
each time of the visit and one-way ANOVA (SPSS-II for windows) was used 
to determine the presence of seasonal variation.
Results: There were significant seasonal variations in ACR, systolic blood 
pressure and A1C. The mean ACR was higher in winter (December - Febru-
ary ; 72.8±4.4mg/gCr) than that in summer (June - August ; 54.6±3.4mg/
gCr) (p=0.001). The mean systolic blood pressure was higher in winter 
(136±0.68mmHg) than that in summer (133±0.68mmHg) (p<0.001). The 
ACR variation showed similar curve to that of the seasonal variation of systo-
lic blood pressure. In contrast, A1C did not show similar curve to that of 
ACR or systolic blood pressure. The mean A1C was higher in spring (March 
- May ; 7.39±0.03 %) than that in fall (September - November ; 7.16±0.03 
%) (p<0.001). No significant seasonal variation was observed in estimated 
glomerular filtration rate and diastolic blood pressure.
Conclusion: Our results suggest that there is a hitherto unknown season-
al variation in ACR, and that it may be necessary to consider the seasonal 
change of ACR especially when we perform intervention study of the neph-
ropathy.
1215
Factors associating with renal interstitial fibrosis in type 2 diabetics 
with renal artery stenosis and in type 1 and 2 diabetics with diabetic 
nepropathy
K.O. Kurumova, M. Shamkhalova, I. Klefortova, M.V. Shestakova, I. Sitkin, 
A. Ilin, M. Arbuzova, N. Goncharov, G. Katsaya, S. Saveleva; 
Diabetic Nephropathy, Endocrinology Research Cenre, Moscow, Russian 
Federation.
Aims: to estimate renal interstitial fibrosis and endothelial dysfunctions fac-
tors in type 2 diabetics patients (T2DP) with renal artery stenosis or diabetic 
nephropathy (DN) and in type 1 diabetics with DN.
Methods: We studied 33 T2DP without renal pathology (I group), 33 T2DP 
with renal artery stenosis (II group), 24 T2DP with DN (III group) and 30 
diabetic type 1 patients with DN (IV group). Patients with T2DP were in-
vited to undergo multispiral computer tomography or selective angiography 
of renal arteries to define the presence of renal artery stenosis (renal artery 
stenosis more than 60%). We have measured following parameters in blood: 
transforming growth factor (TGF - β 1), monocyte chemotactic peptide-1 
(MCP-1), regulated on activation normal T-cell expressed and secreted 
(RANTES), matrix metalloproteinase 9 (MMP - 9),vascular endothelial 
growth factor (VEGF), vascular cell adhesion molecule (VCAM-1), inhibitor 
activator of plasminogen (IAP-1), asymmetric dimethylarginine (ADMA), 
factor von Willebrand (FW), homocystein (HCYST) were measured. The 
control group included normotensive persons of more than 45 years with-
out diabetes (n=20). Glomerular filtration rate (GFR) was calculated by the 
MDRD equation.
Results: Studied parameters were higher in groups with renal pathology than 
in group I (Table 1).
Studied parameters in groups Table 1
Parameter I group
n=33
II group
n=33
III group
n=24
IV group
n=30
TGF - β 1 ng/ml 40,6 [8,6; 81] 121 [11,9; 78]*** 80,6 [31,7; 128]** 65 [18,3; 104]***
MMP-9 ng/ml 123 [88,5;149] 141 [102; 176]*** 258 [156; 319]*** 269[160;362]***
MCP-1 pg/ml 127 [60;175] 198 [59; 262]* 282 [220; 346] 268 [169;345]***
RANTES pg/ml 21972[8747; 
32747]
22896[10494; 
27193]
28316 [14604; 
35758]*
39509 [17882; 
72576]**
HCYST  
mkmol/L
9,8 [7,8; 11,7] 13,5 [8,9; 14,3]* 73,8 [8,3; 75,2] 13,5[8,9;14,3]
FW UE/ml 0,74 [0,191;1,9] 0,9 [0,79; 1,14]*** 10,1 [0,2; 1,3]* 0,76[0,13;0,85]***
IAP-1 ng/ml 40,8 [13,9; 55] 61,9 [31,7; 81]* 48,2 [17;
69]
58,9 [25; 87]**
ADMA mkmol/l 1,42 [0,02; 1,46] 14,1 [0,02; 1,4]** 1,7 [0,4; 1,6] -
VEGF pg/ml 182 [49; 263] 284 [140; 386]** 203 [61,9; 223] 184 [81; 259]
Results are Me[25%;75%]
* - p <0,05 ** - p<0,01 *** - p<0,0001 vs group I
In groups with renal pathology TGF - β 1, MCP-1, RANTES, MMP - 9, 
HCYST, were negative correlated with GFR and were positive correlated with 
albuminuria.
Conclusion: DN in type 1 and 2 patients and renal artery stenosis in T2DP 
were associated with significant increase of mediators of fibrosis and en-
dothelial dysfunctions factors which is known to have a predictive role in 
the development of the tubulointerstitial expansion and reduction of renal 
function.
1216
Urinary proteomics for early diagnosis in diabetic nephropathy
P. Rossing1, P. Zürbig2, S. Panagiotopoulos3, S.E. Nielsen1, P. Hovind1, R.J. 
Maclsaac3, H. Mischak2, G. Jerums3, H.-H. Parving4,5; 
1Steno Diabetes Center, Gentofte, Denmark, 2Mosaiques-diagnostics 
GMBH, Hannover, Germany, 3Austin Healths, Melbourne, Australia, 
4Endocrinology, Rigshospitalet, University of Copenhagen, Denmark, 
5Faculty of Health Sciences, University of Aarhus, Denmark.
Background and aims: Diabetic nephropathy may be detectable even at early 
stages in the urinary proteome. In this study we present recent data indicat-
ing that urinary proteome analysis is a valuable tool for early and sensitive 
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detection of diabetes-associated patho-physiological changes, assessment of 
disease progression and monitoring of therapy success.
Materials and methods: High-resolution capillary-electrophoresis coupled 
to time-of-flight mass-spectrometry (CE-MS) was used to profile the low-
molecular-weight proteome in urine of diabetic patients collected in longi-
tudinal trials for up to 15 years at two different clinical centers in Denmark 
and Australia.
Results: When applying previously defined biomarker patterns for chronic 
kidney disease onto the data obtained from urine samples of normoalbu-
minuric subjects, we could demonstrate that these biomarkers enabled pre-
diction of development of macroalbuminuria with an AUC=0.92 for a period 
of 3-4 years. One of the hallmarks of diabetes and associated complications 
appears to be the increase in extracellular matrix (ECM) and the release of its 
components, most notably collagen. This process appears to be in part due 
to reduced proteolysis and is reflected at a very early stage by the decrease 
in urinary collagen fragments. Assessment of these results in a much higher 
accuracy of predicting DN than clinical parameters like urinary albumin or 
serum creatinine. 
Conclusion: Urinary proteome analysis enables the non-invasive assessment 
of diabetic kidney disease at an early stage via determination of specific colla-
gen fragments, opening an avenue towards targeted therapeutic intervention. 
Further, prognosis of progression towards DN will help targeting therapeutic 
intervention, ideally before irreversible damage has occurred.
1217
Adiponectin is differently associated with nephropathy in type 1 and type 
2 diabetes
S. Ljubic1, B. Novak1, A. Jazbec2, A. Piljac1, T. Kerum1, M. Vucic Lovrencic1; 
1Vuk Vrhovac University Clinic, 2University of Zagreb, Croatia.
Background and aims: The aim of this study was to compare the relation 
between adiponectin and nephropathy in type 1 and type 2 diabetes.
Materials and methods: ApN, C-reactive protein (CRP), fibrinogen (FIB), 
homocysteine (HCY), lipoprotein(a) [Lp(a)], creatinine clearance (CrCl), 
creatinine, fasting (fPG) and postprandial plasma glucose (ppPG), glycated 
haemoglobin (A1c), blood pressure (BP), liver function, lipids, ferritin, uric 
acid (UA), creatine phosphokinase and leucocyte count (WBC) were deter-
mined in 164 patients with type 1 (DM1) and type 2 diabetes (DM2). The pa-
tients were assigned to subgroups based on their 24-h albumin excretion rate 
(AER) [<30 (NA), 30-300 (MI), >300 (MA)] and CrCl (normal >0.83 mL/sec 
for women and >1.17 mL/sec for men (CrCl1)). Differences between types of 
DM were tested using Student t test or Mann Whitney test if assumption of 
homogeneity of variance was not met. Differences between ApN according to 
AER and CrCl were tested using factorial analysis of variance.
Results: Statistically significant differences were found among ApN val-
ues according to AER (F=8,45, df=2, p<0.001) in DM1 (NA=12.37±6.62, 
MI=21.38±7.98 and MA=31.85±18.05) and DM2 (NA=9.05±5.63, 
MI=7.46±4.58 and MA=5.26±3.3). A statistically significant difference in 
ApN between the types of DM (F=73.402, df=1; p<0.001), and an interaction 
between DM type and AER (F=18.12, df=2; p<0.001) were also observed. 
DM1 had significantly higher ApN than DM2. Significant within-group dif-
ferences for ApN were found in DM1 between the NA and MI, and the NA and 
MA subgroups using Tukey post hoc test, while between-group differences in 
ApN were found in the MI and MA subgroups of DM1 and DM2. In a model 
for ApN as a dependent variable and the type of DM, CrCl and interaction 
DM type and CrCl as factors, a statistically significant difference was found 
for all analysed factors. ApN was found to be higher in CrCl2 than in CrCl1 
(F=12.7, df=1, p<0.001) in both types of diabetes (DM1: CrCl1=13.9±7.93 vs. 
CrCL2=23±12.8 and DM2: CrCl1=7.63±4.76 vs. CrCl2=9.86±6.25). Post hoc 
test showed that ApN was significantly increased in both CrCl subgroups of 
DM1 as compared to DM2. In a model for Lp(a) as a dependent variable and 
the type of DM (F=0.82; df=1; p=0.37), AER (F=0.21, df=2, p=0.81) and in-
teraction between DM type and AER (F=0.06; df=2; p=0.93) as factors, there 
were no statistically significant differences. After stepwise regression in DM1 
for ApN, the best model (R2=0.9002) included CrCl, BMI, LDL, WBC, CRP 
and age, whereas in DM2 the best model (R2=0.2882) included ppPG, LDL, 
and UA. In DM1 ApN correlated significantly (p<0.05) with HCY (r=0.57), 
CrCL (r=-0.61), AER (r=0.61) and creatinine (r=0.40), and in DM2 with 
HCY (r=0.25), CrCl (r=-0.22), creatinine (r=0.20) and diastolic BP (r=-0.19). 
ApN and HDL were significantly increased (p<0.001) in DM1, whereas CRP 
(p=0.04), FIB (p<0.001), HCY (p<0.001) and gamma-glutamyl-transpepti-
dase (p<0.05) were significantly increased in DM2.
Conclusion: ApN was increased in both DM1 and DM2 in the subgroups 
with decreased CrCl, but with a different albuminuria-related behaviour, 
showing an increase with a progression of albuminuria in DM1, and a de-
crease with a progression of albuminuria in DM2. Other inflammatory mark-
ers were decreased in DM1. The interaction between renal insufficiency and 
albumin loss appears to significantly affect ApN level, which is consistent 
with different courses of nephropathy in DM1 and DM2.
Supported by: Ministry of Science of the Republic of Croatia
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The expression of pigment epithelium-derived factors, matrix 
metalloproteinase-2 and transforming growth factor-β1 and the effects of 
rosiglitazone in diabetic rat kidney
L.-X. Tan, Z.-J. Wang; 
Endocrinology, Hebei Medical University, Shijiazhuang, China.
Background and aims: To investigate the expressions of pigment epithe-
lium- derived factor, matrix metalloproteinase-2 and transforming growth 
factor-β1 in the kidney of diabetic rats and the effects of rosiglitazone on such 
changes.
Materials and methods: 45 male SD rats were randomly divided into normal 
group(NC), diebetic control group(DC) and rosiglitazone treated group(DR), 
with 15 respectively. After 12 weeks, kidney mass/body mass, 24-hour uri-
nary albumin excretion (UAE), serum creatinine(Scr), blood ureanitrogen 
(BUN) of every group were measured and the expression of PEDF, MMP-2 
and TGF-β1 in the kidney were determined by immunohisto- chemistry and 
RT-PCR methods.
Results: (1)KI, BUN, Scr, UAE, TG in DC group were higher than NC group, 
but decreased in DR group compared with DC group, the differences were 
statistically significant. (2) Immunohistochemistry showed that renal PEDF, 
MMP-2 expression in DC and DR group of were lower than NC group (P 
<0.01), while increased in DR group compared with DC group (P <0.01); the 
expression of TGF-β1 in DC and DR group were higher than NC group (P 
<0.01), while TGF-β1 expression in DR group decreased compared with DC 
group (P <0.01). (3)RT-PCR analysis showed that rosiglitazone can enhance 
the expression of PEDF mRNA in the kidney, the differences were statistically 
significant. (4)Correlation analysis showed that there was a negative correla-
tion between the protain expression levels of PEDF or MMP-2 and TGF-β1 
in the kindey of diabetic rats (r=-0.964,P<0.01;r=-0.916,P<0.05). The protein 
expression levels of PEDF and MMP-2 showed a positive correlation in the 
kindey of these rats(r = 0.827,P <0.01).
Conclusion: Renoprotection of rosiglitazone on diabetic rats may be medi-
ated through increasing the expression of PEDF and MMP-2 and decreasing 
the expression of TGF-β1.
1219
Abnormalities of the OPG/RANKL axis in progressive kidney failure: the 
variable influence of diabetes
D.K. Singh1, P. Winocour2, B. Summerhayes2, A. Viljoen3, G. Sivakumar3, K. 
Farrington4; 
1Diabetes and Renal, Lister Hospital, Stevenage, 2Diabetes and 
Endocrinology, QEII Hospital, Welwyn Garden City, 3Biochemistry, 
Lister Hospital, Stevenage, 4Renal Unit, Lister Hospital, Stevenage, United 
Kingdom.
Background and aims: The high prevalence of cardiovascular disease and 
vascular calcification in chronic kidney disease (CKD) is associated with 
both traditional and uremic-specific risk factors. These include hyperphos-
phatemia, high calcium x phosphate product, chronic inflammation, dyslipi-
demia and other dialysis-related factors. Recently the role of osteoprotegerin 
(OPG) and receptor activator of nuclear factor kappa-β-ligand (RANKL) in 
bone and vascular adaptations has become apparent. This study was designed 
to investigate the influence of kidney failure on this axis in diabetic and non 
diabetic subjects.
Materials and methods: Seventy patients were studied - 20 with Stage 3 CKD 
(CKDMod), 20 with Stage 4 and 5 CKD (CKDAdv) and 30 on Haemodialysis 
(CKDHD). Each groups had equal number of diabetics and non-diabetics. Se-
rum OPG and RANKL were measured along with parameters reflecting renal 
function and mineral metabolism.
Results: Mean OPG levels in the CKDHD group were higher than in the CK-
DAdv group (p< 0.001) and the CKDMod group (p<0.001) (9.8 vs. 5.8 vs 5.4 
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respectively). There were no differences in RANKL levels across the groups. 
The OPG/RANKL ratio was significantly different across the groups (p = 
0.038). Median OPG/RANKL ratio was higher in the CKDHD group than in 
the CKDAdv group (p = 0.016) and the CKDMod group (p = 0.066) (109 vs. 45: 
vs. 61 respectively). In the CKDMod group OPG levels were higher in diabetic 
patients than in non-diabetics (6.1 vs. 4.5 pmol/l: p = 0.032). The same was 
true in the CKDAdv group (6.7 vs. 4.6 pmol/l: p = 0.032). However, in the CK-
DHD group, diabetics had lower OPG levels (8.6 vs. 10.9 pmol/l), though this 
difference did not reach statistical significant (p = 0.079).
Conclusion: OPG is secreted by endothelial cells and tends to protect against 
VC. Rising OPG levels in progressive kidney failure imply mobilisation of 
protective adaptations to the increased calcific stimulus generated by falling 
kidney function. The higher OPG levels in diabetics in moderate to advanced 
CKD can be similarly interpreted. The reversed ratio in HD patients suggests 
relative failure of protective mechanisms in diabetics in this setting, resulting 
in an increased calcification potential.
Supported by: Shire Pharmaceuticals
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Blockade of advanced glycation end products receptor signalling 
prevents the glycated albumin induced overexpression of collagen IV
A.I. Serban1, M.C. Munteanu2, M. Costache2, A. Dinischiotu2; 
1Biochemistry and Molecular Biology, University of Agricultural Science 
and Veterinary Medicine, 2Biochemistry and Molecular Biology, University 
of Bucharest, Faculty of Biology, Romania.
Background and aims: The expansion of mesangial cells, accumulation of 
extracellular matrix protein, thickening of glomerular and tubular basement 
membranes, tubulointerstitial fibrosis and glomerulosclerosis occur in the di-
abetic kidney and AGEs play an important role in these pathological changes. 
AGEs may promote pro-fibrotic cellular responses by interacting with their 
receptor-RAGE or by other pathways in which TGF-β has a pivotal role. Our 
aim was to investigate the relationship between AGE, RAGE and TGF-β in 
collagen IV expression in cultured human embryonic kidney cells (HEK293) 
exposed to glycated BSA (AGE-BSA).
Materials and methods: Cultured cells were treated for 24 hours with AGE-
BSA or BSA (control) at concentrations between 50-200 μg/ml in the pres-
ence or absence of 20 ng/ml anti-RAGE antibodies. The level of RAGE, TGF-
β1 and procollagen α1 (IV) mRNAs was analyzed by quantitative real-time 
PCR whereas their protein expression was assessed by Western immunoblot 
(RAGE and collagen IV) and ELISA (TGF-β1).
Results: The mRNA relative expression ratio (R) increased for all target genes 
proportionately with AGE-BSA concentration. At 100 μg/ml AGE-BSA, R 
increased to 1.41+/- 0.12, 1.23+/- 0.05, 2.68+/- 0.17 for RAGE, TGF-β1 
and procollagen α1 (IV), whereas at 200 μg/ml AGE-BSA was the highest 
increase of R to 1.83+/- 0.2, 3.4+/- 0.09 respectively 4+/-0.12. The protein 
levels of RAGE, TGF-β1 and collagen IV were in good correlation with the 
mRNA expression. The co-treatment with anti-RAGE antibody and 100μg/
ml AGE-BSA versus anti-RAGE antibody and 100μg/ml BSA decreased R to 
0.65+/-0.09 for procollagen α1 (IV), whereas the mRNA expression of TGF-
β1 remained unchanged. In addition, R increased to 2.1 +/-0.2 for RAGE. The 
relative proteins levels decreased to 0.42 for collagen IV and to 0.62+/-0.12 
for protein TGF-β1 but the RAGE one was 1.6 suggesting that the presence of 
ligand stimulated RAGE expression.
Conclusion: This study demonstrated that the collagen IV synthesis is modu-
lated by the axis AGE-RAGE-TGF-β1, and was increased in an AGE-BSA 
concentration dependent manner. It appeared that the presence of AGE-BSA 
induced the increase of RAGE expression when the number of receptors was 
diminished by anti-RAGE antibodies treatment. These events were probably 
involved in the development of fibrosis processes related to diabetic neph-
ropathy.
Supported by: The National Research Council of Higher Education Romania
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Aldosterone blockade ameliorates nephropathy by increasing glucose-
6-phosphate dehydrogenase activity and reducing oxidative stress in 
diabetic hypertensive rats
M.V. Shanmuganathan, B.S. Pessoa, E.B. Peixoto, J.M. Lopes de Faria, J.B. 
Lopes de Faria; 
Renal Pathophysiology Laboratory, University of Campinas (UNICAMP), 
Sao Paulo, Brazil.
Background and aims: Oxidative stress is at the center of pathogenesis of 
diabetic nephropathy. Hyperglycemia decreases glucose-6-phosphate dehy-
drogenase (G6PD) activity that makes cells very sensitive to oxidant damage 
via reducing NADPH formation. Spironolactone, a mineralocorticoid recep-
tor blocker, diminishes hyperglycemia induced reduction in G6PD activity. 
In the present study we investigated whether spironolactone improves neph-
ropathy by increasing G6PD activity and reducing oxidative stress in hyper-
tensive diabetic rats.
Methods: Spontaneously hypertensive rats were rendered diabetic by in-
travenous injection of streptozotocin (50 mg/kg), control rats received cit-
rate buffer. The diabetic animals were randomized to receive or not receive 
spironolactone (50mg/kg/day) for 8 weeks. Albumin excretion rate was de-
termined in 24 h urine by ELISA. Renal expression of fibronectin and p47phx 
were assessed by Western blot. G6PD activity was determined in renal cortex 
by estimation of the rate of production of NADPH. The antioxidant system, 
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glutathione, was estimated as the ratio of reduced form of glutathione (GSH) 
/ oxidized form of glutathione (GSSG) by an enzymatic method. Compari-
sons between groups were done with one-way analysis of variance (ANOVA) 
followed by Bonferroni test. Nonparametric data were analyzed by Kruskal-
Wallis test (for multiple groups) and Mann-Whitney U test (for 2 groups). A 
value of p<0.05 was considered significant.
Results: Plasma glucose levels were higher (p<0.0001) in diabetic rats and 
it was not modified by spironolactone. Likewise, systolic blood pressure was 
unaltered by diabetes or by treatment. Albuminuria and renal expression 
of fibronectin were higher (p=0.01 and p=0.03, respectively) in the diabetic 
group compared to control, and these parameters were reduced with the 
mineralocorticoid receptor blockade. G6PD activity and the GSH / GSSG 
ratio were reduced (p=0.008 and p=0.02, respectively) in diabetic rats and 
the treatment restored to control levels. Urinary levels of 8-hydroxi-deoxi-
guanosine (8-OHdG), a marker of oxidative stress-induced DNA damage 
was determined by ELISA and found to be higher (p=0.02) in diabetic rats 
when compared to controls, and the treatment reduced to control levels. 
The production of superoxide induced by NADPH oxidase (lucigenin) and 
p47phox, an isoform of NADPH oxidase, was higher (p=0.009 and p=0.004, 
respectively) in diabetic rats when compared to controls and was significantly 
reduced in treated rats.
Conclusion: These results suggest that spironolactone ameliorates nephropa-
thy in the diabetic hypertensive rats by restoring G6PD activity and dimin-
ishes oxidative stress without affecting blood pressure.
Supported by: CAPES and FAPESP
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Uncoupled endothelial nitric oxide synthase is ameliorated by green tea 
(camellia sinensis) in diabetic SHR rats
A.M. Faria, M.V. Shanmuganathan, J.M. Lopes de Faria, J.B. Lopes de Faria; 
Faculty of Medical Sciences, State University of Campinas, Brazil.
Background and aims: It has been shown that in hypertensive diabetic rats 
green tea (GT, Camellia sinensis) ameliorates nephropathy by reducing oxi-
dative stress. In experimental diabetic nephropathy, NADPH oxidase and 
eNOS uncoupling are major sources of local superoxide production. Uncou-
pled eNOS is a consequence of a reduction in tetrahydrobiopterin (BH4), an 
essential cofactor required for the synthesis of nitric oxide (NO). Therefore, 
uncoupled eNOS leads to a reduction of NO bioavailability which is associ-
ated with progression of diabetic nephropathy. The aim of the present study 
was to investigate if green tea can ameliorates uncoupled eNOS in hyperten-
sive diabetic rats.
Materials and methods: Twelve-week-old spontaneously hypertensive rats 
(SHR) were rendered diabetic by intravenous injection of streptozotocin 
(50 mg/Kg), control rats received citrate buffer. Diabetic SHR rats were ran-
domized to receive no treatment or treatment with daily, freshly prepared, 
GT (13.3 g/L). After 12 weeks of treatment, endothelial and oxidative stress 
markers were assessed in renal cortex. The levels of BH4 were measured in 
urine and renal cortex samples using UPLC (Ultra Performance Liquid Chro-
matography). The results were compared by analysis of variance (ANOVA) 
followed by Fisher’s protected least-significant difference test.
Results: The systolic blood pressure did not differ between groups of the 
study. However, body weight was less (p < 0.0001) and glycemia was greater 
in diabetic SHR rats (treated or not with GT) than in nondiabetic rats (p 
< 0.0001). Oxidative stress, assessed by NADPH oxidase induced superox-
ide production, was higher in diabetic rats than in controls (p=0.01). The 
formation of peroxynitrite, a result of the binding of NO to superoxide also 
increased in diabetic rats (p = 0.01). GT attenuated renal ROS production 
by decreasing the production of superoxide (p=0.01) and nitrotyrosine (NT) 
(p=0.04). In diabetic animals, the caveolin-1 (CAV-1), a negative regulator of 
eNOS expression, was significantly increased (p=0.02) and reinstated by GT 
treatment (p=0.01). Immuno-precipitation studies revealed a significant de-
crease in the CAV1-eNOS binding in diabetic rats (p=0.03). Total biopterin, 
BH4 and oxidation rate of BH4 were measured in urine and renal cortex to 
assess the bioavailability of NO and the eNOS uncoupling. In diabetic rats, we 
observed a significant decrease (p<0.0001) in the levels of total biopterin and 
BH4 and moderate change (p=0.004) in oxidation rate of BH4 in both urine 
and renal tissue. GT reversed oxidation of BH4 (p=0.05), but not modified 
BH4 production.
Conclusion: In summary, green tea GT ameliorated superoxide production 
and improved the eNOS uncoupling by reversing CAV-1 expression and oxi-
dation of BH4.
Supported by: CNPq and FAPESP
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Cilnidipine additively inhibits the progression of renal impairment in 
diabetic rats when used in combination with an angiotensin II receptor 
blocker (ARB)
K. Matsuura1, Y. Mori1, S. Aritomi2, K. Niinuma2, T. Konda2, Y. Itoh1, J. 
Yokoyama1, N. Tajima1; 
1Division of Diabetes, Metabolism and Endocrinology, Department of 
Internal Medicine, Jikei University School of Medicine, Tokyo, 2R & D 
Division, Exploratory Research Laboratories, Ajinomoto Pharmaceuticals 
Co., Ltd, Kawasaki, Japan.
Background and aims: Cilnidipine represents the only calcium channel 
blocker (CCB) currently available that antagonizes not only the L-type but 
the N-type calcium channels and is known to provide renal protection by 
decreasing the activity of the sympathetic nervous system and the renin-an-
giotensin system (RAS). However, very few studies evaluated cilnidipine for 
renal protection in diabetic nephropathy. In this study, therefore, we investi-
gated the effect of the L/N-type CCB cilnidipine, as compared to the L-type 
CCB amlodipine, on diabetic nephropathy in spontaneously type 2 diabetic 
rats (OLETF rats), when used in combination with an angiotensin II receptor 
blocker (ARB).
Materials and methods: Seventeen-week-old OLETF rats were randomly as-
signed to receive cilnidipine (Cil), amlodipine (Aml), valsartan (Val), Cil + 
Val, Aml + Val, or vehicle (5% HMC; control) for 22 weeks via a gastric tube, 
with a total of 16 rats assigned to each group.
Results: Antihypertensive potency was found to be nearly equal between 
the monotherapy groups and between the combination therapy groups com-
pared. Blood pressure lowering with either treatment did not significantly 
affect the glycemic variables evaluated. However, the increases in urinary al-
bumin excretion (UAE) seen with progression of diabetic renal impairment 
were significantly suppressed in the rats given Cil or Val, with their additive 
suppression seen in those given Cil + Val. Furthermore, the norepinephrine 
(NE) level in the renal tissue as an indicator of sympathetic nervous system 
activity was shown to be significantly decreased in those given Cil + Val. With 
regard to the plasma RAS-related variables, Val tended to increase plasma 
renin activity (PRA) and angiotensin II (Ang II) activity through a feedback 
mechanism resulting from inhibition of the Ang II type 1 receptor (AT1-
R). Additionally, while significant increases in PRA and Ang II were seen in 
those given Aml + Val, as may be the case with antihypertensive therapy, no 
increases in PRA and Ang II were seen in those given Cil + Val, a comparably 
potent antihypertensive regimen.
Conclusion: Study results revealed that cilnidipine produces additive anti-
hypertensive and UAE-lowering effects when combined with an ARB even 
in type 2 diabetic rats. Furthermore, combination therapy with cilnidipine 
and valsartan has been shown to significantly reduce NE secretion, suggest-
ing that cilnidipine suppresses the increases in PRA and Ang II associated 
with antihypertensive therapy by inhibiting the activity of the sympathetic 
nervous system through its N-type calcium channel antagonism. Thus it is 
suggested that cilnidipine may inhibit the progression of nephropathy in type 
2 diabetes by inhibiting the activity of the sympathetic nervous system as an 
N-type CCB.
1224
Telmisartan, an angiotensin II type 1 receptor blocker, prevents renal 
injury via inhibition of the Notch pathway in Ins2 Akita diabetic mice
M. Koshizaka, M. Takemoto, K. Yokote; 
Clinical Cell Biology and Medicine, Chiba University, Japan.
Background and aims: There are an increasing number of patients with end-
stage renal disease caused by diabetic nephropathy (DN). It has been recently 
reported that the Notch pathway is involved in the pathogenesis of DN and 
the activated Notch pathway induces apoptosis to the podocytes. We inves-
tigated the activation of the Notch pathway in Ins2 Akita (Akita mouse), a 
murine model of DN, and the effects of telmisartan, an angiotensin II type1 
receptor blocker, on the Notch pathway and whether telmisartan could pre-
vent podocytes apoptosis.
Materials and methods: Akita mice and control mice received telmisartan (5 
mg/kg/day) or no treatment, respectively, for 15 weeks. Body weight, blood 
pressure, and urinary albumin excretion were measured. The effects of tel-
misartan on the Notch pathway were studied by RT-PCR and immunohis-
tochemisty both in vivo and in vitro using cultured murine podocytes. And 
podocytes were treated with angiotensin II (AII) in the presence or absence 
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of telmisartan. After that, apoptosis was defined as the presence of nuclear 
condensation on Hoechst staining. Alternatively, the Annexin V/propidium 
iodide assay was carried out and analyzed by flow cytometry.
Results: Compared to the control mice, the levels of urinary albumin excre-
tion, serum BUN, and creatinine were higher in the Akita mice (10.9 mg/day, 
22.2 ± 3.8 mg/dl, and 0.07 ± 0.01 mg/dl vs. 50 mg/day, 64.7 ± 12.3 mg/dl, 
and 0.19 mg/dl, respectively; P < 0.05). Telmisartan treatment significantly 
decreased those in Akita mice (33 mg/day, 30.2 ± 6.7 mg/dl, and 0.09 ± 0.01 
mg/dl, respectively; P < 0.05). The intracellular domain of Notch1 (ICN1) is 
proteolytically cleaved from the cell membrane in the course of the Notch 
activation. The expression of ICN1 and its ligand, Jagged1, were increased 
in the glomeruli of Akita mice, especially in the podocytes. Administration 
of telmisartan significantly ameliorated the expression of ICN1 and Jagged1. 
Telmisartan inhibited the AII-induced increased expression of transforming 
growth factor β (TGF-β) and vascular endothelial growth factor A (VEGF-
A) which could directly activate the Notch pathway in cultured murine po-
docytes. TGF-β and VEGF-A increased the expression of the Notch target 
gene, Hairy /Enhancer of split-related 1 (Hes1), and telmisartan suppressed 
those expression. Flow cytometer studies showed that apoptotic cells were in-
creased in the podocytes treated with AII (12.56 ± 1.9% vs. 7.09 ± 1.4% in the 
control group, P < 0.01) and telmisartan treatment significantly decreased the 
AII-induced apoptotic cells (8.51 ± 2.0% vs. 12.56 ± 1.9% in the AII group, P 
< 0.01). We also examined the apoptosis by the use of Hoechst 33342 stain-
ing. Nuclear condensations were observed in the podocytes in the presence of 
AII and those changes were significantly decreased when the podocytes were 
treated with telmisartan.
Conclusion: The Notch signaling pathway was activated in podocytes in 
Akita mice. Telmisartan suppressed the Notch pathway both in vivo and in 
vitro. And telmisartan suppressed the podocyte apoptosis induced by AII. 
The AII induced podocytes apoptosis via the activating Notch pathway and 
telmisartan inhibited that through the inhibition of the Notch pathway. Our 
results indicate that telmisartan prevents DN through the inhibition of the 
Notch pathway.
1225
Tubular damage in type 2 diabetic nephropathy: the effect of ultrahigh 
doses of irbesartan
S.E. Nielsen1, K. Rossing1, B.R. Jensen1, H.-H. Parving2,3, P. Rossing1; 
1Steno Diabetes Center, Gentofte, 2Department of Medical Endocrinology, 
Rigshospitalet, Copenhagen, 3Aarhus University, Denmark.
Background and aims: Blockade of the renin-angiotensin-aldosteron system 
(RAAS) is renoprotective in diabetic kidney disease, and has been shown to 
affect both the glomerulus and tubules. We aimed to investigate the effect 
of the angiotensin II receptor blocker irbesartan on the tubular markers: 
urinary(u) neutrophil gelatinase associated protein(NGAL), kidney injury 
molecule 1(KIM1) and liver-fatty acid-binding protein(LFABP).
Materials and methods: Substudy of a double-masked, randomized, cross-over 
study including 52 hypertensive type 2 diabetic patients with microalbuminu-
ria. After 2 months washout of all antihypertensive medication except bend-
roflumethiazid, patients were treated with irbesartan 300, 600 and 900 mg o.d. 
for 2 months. Endpoints: 3x24hour(h) urine albumin excretion(UAER), 24h 
blood pressure, glomerular filtration rate (GFR, 51CrEDTA) and tubular mark-
ers measured at baseline and after each treatment period with ELISA (Roche).
Results: Fifty-two patients completed the study(41 male). Age (mean(SD)): 
58(10) years and diabetes duration 13(8) years. At baseline, ambulatory 
blood pressure was 140(11)/ 77(7) mmHg, GFR 101 (24)ml/min/1.73m2 
and UAER [geometric mean (95%CI)] 133 (103-172)mg/24h. As previously 
reported UAER was significantly more reduced on 900 mg Irbesartan com-
pared to lower doses. Levels of the tubular markers at baseline were: [geomet-
ric mean (95%CI)]: u-KIM1 3.6 (2.9-4.5)(pg/ml)/creatinine, u-NGAL 139 
(104-187)(pg/ml)/creatinine, and u-LFABP 42 (29-59)(pg/ml)/creatinine. 
U-NGAL at baseline were tightly related to GFR (R=0.46, p<0.01), whereas 
u-LFABP and u-KIM 1 were not (p>0.5). U-albumin at baseline was not as-
sociated with any of the tubulus markers: NGAL (R=0.08, p=0.6), u-LFABP 
(R=0.07, p=0.7) or u-KIM1(R=0.03, p=0.8). With increasing doses of irbe-
sartan (300, 600, 900 mg) u-KIM1 was reduced to (geometric mean) 3.1, 
3.3 and 3.1 (p=0.07 between 900 mg vs. baseline and no difference between 
doses). U-NGAL did not change significantly (135, 135 and 138) (p>0.7 
compared to baseline, N.S. between doses). U-LFABP did not change during 
treatment (57.9, 61.8 and 45.1).
Conclusion: Ultrahigh doses of irbesartan treatment reduced levels of the tu-
bular markers u-KIM1 and u-NGAL in type 2 diabetic patients, although not 
significant. This is in contrast to previous studies in diabetic nephropathy where 
an ACE inhibitor has reduced markers of tubular damage. More studies with 
longer follow up are needed to determine the role of tubular markers in moni-
toring treatment effect and prediction of prognosis in diabetic nephropathy.
1226
Influence of rosiglitazone on proteinuria and renal haemodynamic in 
type 2 diabetic patients with overt diabetic nephropathy
F. Pistrosch1,2, K. Herbrig1, J. Passauer1, B. Kindel3, P. Gross1, S.R. Bornstein3; 
1Nephrology, Dept of Medicine, University Hospital, 2Centre for Clinical 
Studies, Technical University, 3Endocrinology, Dept of Medicine, University 
Hospital, Dresden, Germany.
Background and aims: Proteinuria reflects overt glomerular damage and 
its degree determines the progression of diabetic nephropathy (DN). Recent 
studies demonstrated an improvement of renal endothelial function and a 
reduction of microalbuminuria by activation of the PPAR gamma receptor 
in early stages of DN. The aim of the present study was to investigate the in-
fluence of the thiazolidindione rosiglitazone (RSG) on proteinuria and renal 
endothelial function in overt DN.
Materials and methods: We conducted a double blind placebo (PLC) con-
trolled study in 28 patients (24 men, 4 women, mean age 66.1 ± 9.1 yr) with 
type 2 diabetes, proteinuria > 300 mg/24 hr (despite the use of ACE-inhibitor 
or angiotensin receptor blocker) and an estimated glomerular filtration rate 
(GFR) < 60ml/min. Patients were randomly assigned to RSG (4mg b.i.d.) or 
matching PLC in addition to their previous antidiabetic medication. GFR and 
renal plasma flow were measured by inulin- and p-aminohippurate-clearance 
before and after the blockade of nitric oxide (NO) by intravenous administra-
tion of N-monomethyl-L-arginine-acetate (L-NMMA).
Results: During 12 months of follow up there was a significant reduction of 
proteinuria in the RSG group (2.46 ± 2.3; 1.25 ± 1.2 and 1.6 ± 1.4 g/24 hr at 
baseline; 6 and 12 months respectively; P<0.05) but not in the PLC group 
(1.56 ± 1.4; 1.63 ± 1.9 and 1.66 ± 1.9 mg/24 hr at baseline; 6 and 12 months re-
spectively). HbA1c within each treatment group did not change significantly 
(7.3 ± 0.8 vs. 7.3 ± 1.1 % for PLC and 6.9 ± 0.8 vs. 6.5 ± 0.7 % for RSG; base-
line vs. 12 months follow up; respectively). Decline of GFR during the study 
was equal between RSG and PLC (4 ml/min). RSG increased intrarenal NO 
bioavailability as indirectly shown by the infusion of L-NMMA. RSG treat-
ment was associated with more adverse events: most common were increase 
of body weight and development of peripheral edema, however congestive 
heart failure did not occur.
Conclusion: RSG reduced proteinuria in overt DN and improved intrarenal 
NO bioavailability. RSG treatment did not deteriorate GFR but was associ-
ated with fluid retention.
1227
Comparison of nifedipine retard and ACE inhibitor with respect to the 
influence on renal function in hypertensive patients with type 2 diabetes 
- J-MIND study / reanalysis using eGFR
G. Yoshino1, T. Kazumi2, R. Kikkawa3; 
1Division of Diabetes, Metabolism and Endocrinology, Department of 
Internal Medicine, Toho University School of Medicine, Tokyo, 2Department 
of Food Science and Nutrition, School of Human Environment, Mukogawa 
Women’s University, Nishinomiya, 3Health and Welfare Policy Division, 
Shiga Prefecture, Ohtsu, Japan.
Background and aims: It has been described in JSH2009 that strict blood 
pressure control as well as glycemic control is important for hypertensive 
patients with diabetes, and the target blood pressure is aimed at lower than 
130/80 mmHg. However, although the first-line drug for this disease is ARB 
or ACE inhibitor, administration of Ca antagonist with strong antihyperten-
sive effect is needed for attaining the target blood pressure. We have con-
ducted the J-MIND (The Japan Multicenter Investigation of Antihypertensive 
treatment for Nephropathy in Diabetes) study, a 2-year randomized com-
parative study of nifedipine retard (N group) and enalapril (E group) with 
respect to the effect on the onset/progression of nephropathy in hypertensive 
patients with type 2 diabetes, and reported that the renal protection effect 
indexed by urinary albumin excretion rate was similar in both groups. Since a 
formula for estimated glomerular filtration rate (e-GFR) suitable for Japanese 
was newly established currently, the influence on renal function was com-
paratively studied using eGFR between the 2 groups.
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Patients and methods: The subjects of this study were 424 hypertensive pa-
tients with type 2 diabetes at the age of lower than 75 years with 140 mmHg or 
higher baseline systolic blood pressure (SBP), or 90 mmHg or higher diastolic 
blood pressure (DBP), in whom eGFR could be calculated. Patients were clas-
sified based on CKD Stage (eGFR<60, 60-89, >90) (stage 1: 121 cases, stage 2: 
199 cases, stage 3: 104 cases), and the 2-year transition of renal function was 
compared between the 2 groups. The transitions of blood pressure and eGFR 
were evaluated using Student’s t-test.
Results: The mean dose in the N group and the E group was 28.2 ± 11.5 
mg/day and 6.4 ± 2.5 mg/day, respectively, and no significant difference was 
observed in the status of glycemic control between the 2 groups. In both 
groups, SBP and DBP showed significant decrease during the period after 
6 to 24 months (p<0.001), whereas SBP showed significant decrease after 6 
and 12 months in the N group compared with the E group (p<0.001, <0.05) 
and DBP showed significant decrease after 6 and 24 months in the N group 
compared with the E group (p<0.001, <0.05). No significant fluctuation 
was observed in eGFR throughout the period of 2 years in all cases in both 
groups, showing the maintenance of renal function. When the 2 groups were 
compared with respect to changes of eGFR by CKD stage, continuous in-
crease in eGFR was observed in the stage 3 patients (eGFR<60) during the 
period after 6-24 months in the N group (p<0.05). Whereas in the stage 1 
and 2 patients (60<eGFR<90), no significant increase in eGFR was observed 
in both groups.
Conclusion: The results of this study suggested that long-term administra-
tion of nifedipine retard has renal protection effect similar to or higher than 
ACE inhibitor in terms of eGFR, and the effect is notable in patients with 
lower eGFR.
1228
Prevention of microalbuminuria: predictors for a good response to 
olmesartan treatment (ROADMAP Trial)
G. Viberti1, E. Ritz2, L. Ruilope3, H. Haller4, for the ROADMAP Steering 
Committee; 
1King’s College London School of Medicine, London, United Kingdom, 
2University of Heidelberg, Germany, 3Leiden university Medical Centre, 
Netherlands, 4Medical School Hannover, Germany.
Background and aims: Microalbuminuria (MAU) is an early sign of diabetic 
nephropathy and increased cardiovascular risk. We investigated whether ear-
ly treatment with an angiotensin receptor blocker (ARB) in diabetic subjects 
with normal albumin excretion delays the occurrence of MAU and analysed 
subgroups that would benefit most from treatment.
Materials and methods: We studied 4,447 subjects with type 2 diabetes and 
at least one additional cardiovascular risk factor in a randomized, double-
blind, multicentre, controlled, and event-driven (MAU) trial. They received 
either 40 mg olmesartan medoxomil (OM) or placebo (Pb) od. For a median 
duration of 3.2 years. In both groups, additional antihypertensive treatment 
(except ACE inhibitors or ARBs) was used to reach the target BP of <130/80 
mmHg.
Results: During the double blind period, 178 (8.2%) subjects in the OM group 
and 210 (9.8 %) subjects in the Pb group developed MAU (HR: 0.770; 95.1% 
CI: 0.630 to 0.941, p: 0.01). To identify factors influencing the response to 
OM treatment, explorative post-hoc subgroup analysis using the correspond-
ing median at baseline as a cut-off were performed. This analysis revealed 
that the treatment effect on time to onset of MAU was better in subjects with 
a SBP >135 mmHg than with SBP values ≤135 mmHg. A baseline HbA1c 
≤7.3% and an eGFR ≤83.79 were predictors for a better response to OM treat-
ment. Furthermore, less than 5% of patients with a baseline UACR ≤4 mg/g 
developed MAU during the study and the rate was similar between the OM 
and Pb treated patients. In contrast, 13.9% in the OM group and 18.1% in the 
placebo group with a baseline UACR >4 mg/g developed MAU (time-to-on-
set: HR: 0.75, 95% CI: 0.60 to 0.96, p-value= 0.02).
Conclusion: In subjects with type 2 diabetes olmesartan showed a significant 
23% risk reduction regarding time to onset of microalbuminuria. Patients 
with a baseline SBP>135 mmHg, an eGFR ≤83.79, or an UACR >4mg/g benefit 
most from olmesartan treatment. ClinicalTrials.gov ID no.: NCT00185159.
Supported by: Daiichi Sankyo Europe GmbH
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Benchmarking cardiovascular event rates in type 2 diabetes controlled 
clinical studies by modification of the UKPDS risk engine
M. Stewart1, J. Ye2, F. Yang1; 
1GlaxoSmithKline, King of Prussia, 2GlaxoSmithKline, Research Triangle 
Park, USA.
Background and aims: With the release of the new FDA recommendations 
for evaluating CV risk in new antidiabetic therapies, models predicting popu-
lation CV event rates have become critical to the design of clinical trials. In 
order to successfully demonstrate no increased CV risk, these trials must be 
adequately powered, with consideration of the appropriate patient demo-
graphics and CV history. Although recent outcomes studies have provided 
evidence of CV safety for specific agents or agent combinations, baseline 
patient characteristics and underlying CV risk in these populations are not 
uniform across studies. While the UKPDS risk engine provides a well-ac-
cepted basis for estimating CV risk in patients with newly diagnosed disease, 
the aim of this analysis was to develop a CV risk prediction benchmark for 
the general diabetes population.
Materials and methods: Summary CV risk data from ADOPT, ADVANCE, 
VADT, ACCORD, RECORD, PROactive and BARI-2D studies was directly 
applied to the UKPDS model, and an evaluation/comparison on the predic-
tion of annualized Major Acute Coronary Events (MACE) event rates (myo-
cardial infarction, stroke and CV death) was performed.
Results: The direct prediction of the annualized CV event rate based on 
the original UKPDS model was inconsistently over-estimated for all stud-
ies except for PROactive [predicted event rate vs. observed event rate with 
mean (SD) = 1.5 (0.26)]. However, when previous CV history is added to 
the UKPDS model and evaluated across these studies, a more consistent (yet 
higher) prediction across all studies was generated [Table, observed vs. pre-
dicted rate mean (SD) = 2.1 (0.12)].
Conclusion: The modified UKPDS risk model provides a consistent bench-
mark for CV event rates in clinical study populations more closely resembling 
a general population of patients with type 2 diabetes. 
ACCORD ADVANCE VADT RECORD PROactive ADOPT BARI-2D
Original UKPDS Model
Observed 
annualized 
MACE 
event rate
(overall)
2.2 2.1 4.2 1.5 3.6 0.8 4.7
Predicted 
annualized 
MACE 
event rate
3.7 3.8 5.4 2.2 3.3 1.6 5.4
Predicted 
event rate 
/observed 
event rate
1.7 1.8 1.3 1.5 0.9 2.0 1.2
Modified UKPDS Model
Predicted 
annualized 
MACE 
event rate
5.0 5.0 8.8 2.5 6.6 1.6 10.8
Predicted 
event rate 
/observed 
event rate
2.3 2.4 2.1 1.8 1.8 2.0 2.3
Supported by: GSK
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The role of coronary risk assessment in planning and assessing treatment 
of type 2 diabetes
T.M. Phillips1, P.J. Phillips2, J. Wang2; 
1Southern Adelaide Health Service, 2North West Adelaide Health Service, 
Australia.
Background and aims: Coronary heart disease (CHD) is the major compli-
cation in type 2 diabetes. An individual’s risk for coronary events is important 
for planning future treatment. Furthermore information on the changes in 
coronary risk over time is useful in assessing the effectiveness of interven-
tions. Finally coronary risk assessment can assist explaining potential treat-
ment benefits for patients and thereby increasing treatment adherence. This 
study assessed initial and at follow-up (two years later) coronary risk in a 
cohort of type 2 diabetes patients managed in Australian general practice and 
reviewed in a tertiary teaching hospital. We also reported the risk factors as-
sociated with significant reductions in coronary risk.
Materials and methods: Over 1402 type 2 diabetes patients who had both the 
initial and the follow-up assessment were included in the study. The data on 
the following variables have been analysed: age, BMI, HBA1c, blood pressure, 
cholesterol level, self-reported smoking and exercise data. The CHD risk is 
calculated using the UKPDS risk engine.
Results: At the follow-up assessment after an average of two years, apart from 
age, the other contributing variables to CHD risk - HbA1c, blood pressure, 
cholesterol and % of the smoking patients have all improved. The 5 year CHD 
risk has significantly increased due to the effects of increasing age (Table 1). 
After removing age effect (i.e. assuming same age as on the initial assessment) 
the mean 5 year CHD risk at the follow-up assessment is 13.1%, significantly 
lower than that at the initial assessment. The improvement of the lipids over 
the period is the single biggest beneficial factor for the CHD risk. The im-
provement of these risk factors is mostly due to increased use of medication 
for cholesterol and blood pressure control, oral anti-hyperglycaemic medica-
tion and insulin for controlling blood glucose level. Patients with lower initial 
HbA1c had maintained their CHD risk after adjusting for age while those 
who had HbA1c >8% had their CHD risk significantly reduced after age ad-
justed although the risk remained higher than those with lower HbA1c.
Conclusion: The results showed that all major targeted risk factors for dia-
betes management, including HbA1c, blood pressure, cholesterol levels and 
smoking, have improved in this cohort of type 2 diabetes patients. The in-
creased CHD risk is solely a function of age increase and the age adjusted 5 
year CHD risk is actually reduced. This reflected an overall adequate manage-
ment of this cohort of diabetes patients while the biggest beneficial effect is 
from the improvement of lipid profile.
1231
Residual cardiovascular risk due to persistent dyslipidaemia in 
statin-treated patients with diabetes mellitus in Ireland: results of the 
Dyslipidaemia International Study
J.O. Ryan1, J. Crowley2, J. Feely3, B. McAdam4, E. Shanahan5, C. Vaughan6; 
1Department of Endocrinology & Metabolism, Cork University Hospital, 
2Cardiology Department, University College Hospital Galway, 3Department 
of Pharmacology & Therapeutics, St. James’ Hospital, Dublin, 4Department 
of Cardiology, Beaumont Hospital, Dublin, 5General Practice, Farranfore, 
6Department of Cardiology, Mercy University Hospital, Cork, Ireland.
Background and aims: Dyslipidaemia is an established independent risk factor 
for cardiovascular disease (CVD) in patients with diabetes mellitus (DM). This 
study examined the number of patients with DM on treatment with a statin that 
had normal and abnormal lipid levels according to ESC/EASD guidelines.
Materials and methods: The Dyslipidaemia International Study (DYSIS) 
was a multi-national cross-sectional study. In Ireland, patients were recruited 
consecutively by 58 general practitioners and 4 cardiologists. Entry require-
ments included age >45 years, statin-treatment for >3 months, consent to 
physical examination, and at least one lipid profile in the past 6-12 months.
Results: In Ireland 980 eligible patients were studied. 181 patients (20.1%) 
had DM. Despite patients with DM having significantly lower LDL-c levels 
than patients without DM, triglyceride and HDL-c levels were less likely to be 
normal in patients with DM (Table 1). The Odds Ratio (O.R.) for a parental 
history of DM was 3.32 in the DM group versus the non-DM group. Signifi-
cant differences in systolic blood pressure levels and anti-hypertensive agents 
used existed between the groups.
Conclusions: The results of DYSIS in Ireland show that triglyceride and 
HDL-c levels remain abnormal in statin-treated patients with DM. This is in 
keeping with the international findings in this study. These patients remain at 
increased CVD risk and supplementary treatment may be indicated.
Table 1. Biochemical and historical results for DYSIS in Ireland
Patients with DM
N=181 (20.1%)
Patients without DM
N=719 (79.9%)
LDL-c (mmol/L)
[Median and Quartiles]
1.9 (1.4 - 2.3) 2.3 (1.8 - 3.0)*
LDL-c <2.59mmol/L 82.4% (145/176) 62.1% (428/689)*
Triglycerides <1.7mmol/L 53.3% (96/180) 68.3% (477/698)**
HDL-c >1.03 Male/ 1.29  
Female (mmol/L)
44.9% 67.1%*
Systolic B.P. (mmHg)
[Mean and S.D.]
136.9 (+/- 17.9) 133.9 (+/- 17.4) ***
ACE Inhibitor treatment 59.7% 31.3%* O.R.=3.25
HbA1c (available in 150/181 - 82.9%) 6.9 (6.2 - 8.0) -
Anti-diabetic therapy 77.3% (140/181) -
Parental history DM 23.2% (42/181) 8.3%* (60/719) O.R.=3.32
*p<0.0001; **p<0.001; ***p <0.05
EASD/ESC Guidelines 2007: LDL-c target = 1.8 - 2.0mmol/L if DM and CVD;
Increased risk of CVD if triglycerides >1.7mmol/L, HDL<1 Male/<1.2 Female
Supported by: M.S.D.
1232
Factors predicting cardiovascular events in statin-treated diabetic and 
non-diabetic coronary patients: a prospective cohort study
H. Drexel1,2, S. Greber1, T. Gansch1, P. Rein1,2, A. Vonbank1,2, C.H. Saely1,2; 
1Vorarlberg Institute for Vascular Investigation and Treatment, Feldkirch, 
Austria, 2Private University of the Prinicpality of Liechtenstein, Triesen, 
Liechtenstein.
Background and aims: Statins are a cornerstone in the management of high 
risk patients. However, residual risk in patients with established coronary ar-
tery disease (CAD) remains high. We aimed at identifying which lipid factors 
drive vascular risk in statin treated patients with CAD.
Materials and methods: We recorded vascular events over a mean period 
of 7.2 years in 491 consecutive statin-treated patients with angiographically 
proven stable CAD, covering 3518 patient-years.
Results: In the total population, low HDL cholesterol (standardized adjust-
ed HR 0.80 [0.67-0.94]; p=0.009), low apolipoprotein A1 (0.84 [0.72-0.98]; 
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p=0.022), a small LDL particle diameter (0.84 [0.72-0.98]; p=0.023), and high 
triglycerides (1.18 [1.04-1.35]; p=0.013) predicted vascular events, but not 
total cholesterol, LDL cholesterol, or apolipoprotein B. Factor analysis in the 
lipid profiles of our patients revealed an HDL-related factor and an LDL-re-
lated factor. Concordant with the results for individual lipid parameters, the 
HDL-related factor (0.76 [0.65-0.90]; p = 0.001) but not the LDL-related fac-
tor (p=0.644) predicted vascular events. Patients with type 2 diabetes (T2DM; 
n=116) were at a higher vascular risk than non-diabetic subjects (52.6% vs. 
36.8%; p = 0.002), and like in the total population the HDL-related factor 
(0.63 [0.49-0.81]; p<0.001) but not the LDL-related factor (p=0.976) predict-
ed vascular risk in diabetic patients.
Conclusion: The pattern of low HDL cholesterol, low apolipoprotein A1, 
small LDL particles, and high triglycerides drives vascular risk in statin-
treated coronary patients, particularly in those with T2DM.
1233
Cardiovascular disease risk communication for patients with type 2 
diabetes: The @RISK Study
L.M.C. Welschen1, S.D.M. Bot1, T. van der Weijden2, D.R.M. Timmermans1, 
J.M. Dekker1, G. Nijpels1; 
1EMGO Institute for Health and Care Research, Amsterdam, 2CAPHRI 
School for Public Health and Primary Care, Maastricht, Netherlands.
Patients with type 2 diabetes (T2DM) underestimate their risk to develop severe 
complications, and they do not understand the risk communication of caregiv-
ers. According to Leventhal’s Self-regulation Theory, patients are not willing 
to change their lifestyle if they are not informed why this is important. People 
have correct or incorrect perceptions concerning their disease which deter-
mine how they manage their risks to develop severe complications. Providing 
understandable information on the disease by means of risk communication 
may change illness perceptions. The aim is to investigate the effects of an inter-
vention focussed on the communication of the absolute 10-year risk to develop 
CVD on risk perception and illness perceptions in patients with T2DM.
Materials and methods: A randomised controlled trial was performed with 
newly referred T2DM patients to the Diabetes Care System West-Friesland, a 
managed care system in the Netherlands. The intervention group (n=131) re-
ceived CVD risk communication, consisting of an explanation on the causes 
and consequences of CVD, and possibilities for prevention on top of standard 
managed care of the DCS. The 10 year risk of developing CVD was explained 
in natural frequencies and visualised by a population diagram. Controls 
(n=130) received standard managed care. Outcome measures were appro-
priateness of risk perception and illness perceptions assessed at baseline, at 
2 weeks (immediately after the intervention or control visit), and 12 weeks. 
Risk perception was measured by asking ‘How would you rate your risk of 
developing CVD in the next 10 years?’ The absolute difference between risk 
perception and the actual CVD risk on the UKPDS risk engine was calcu-
lated. The Brief Illness Perception Questionnaire was used to assess illness 
perceptions. An overall score was calculated by summarizing scores on the 8 
items, measured on a 10-point Likert scale. A higher score indicates a more 
threatening view of the illness. Differences in changes between time points 
were analysed by t-tests in the intervention and control group.
Results: Mean age was 58.4 ± 10.3 years, the median of diabetes duration was 
0.36 (IQR 0.1 - 1.4) years, HbA1c was 6.7 ± 1.3% and 57% were men. In the 
intervention group, the difference between the actual CVD risk and the risk 
perception improved significantly between baseline and 2 weeks (see Table 
1). This effect remained at 12 weeks. In the control group, no changes were 
found. No effects were found on illness perceptions.
Conclusion: This innovative risk communication method improved patients’ 
risk perception and this effect remained at the long term. The hypothesis that 
patients might be better able to manage their disease was not supported, as 
their illness perceptions showed no changes. Table. Differences in risk per-
ception and illness perceptions in the intervention and control groups.
Baseline 2 weeks 12 weeks p (baseline -  
2 weeks) 
p (baseline -  
12 weeks)
Risk perception (difference between risk perception and CVD risk)
Intervention 9.7 (4.7 - 18.5) 4.6 (1.9 - 11.5) 5.8 (1.8 - 12.1) 0.00 * 0.00 *
Control 8.9 (4.9 - 13.5) 8.9 (5.0 - 14.7) 8.0 (3.6 - 16.3) 0.79 0.22
Illness perceptions
Intervention 31.7 (12.0) 31.0 (11.4) 30.5 (11.5) 0.54 0.85
Control 31.9 (11.2) 32.0 (12.5) 32.3 (12.4) 0.75 0.55
Data are means (± SD) or median (interquartile range). * P < 0.05
Supported by: Dutch Diabetes Research Foundation
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Characteristics, complications and management of a large multiethnic 
cohort of younger adults with type 2 diabetes
K. Benhalima1, S.H. Song2, E.G. Wilmot3, K. Khunti4, L.J. Gray4, I. 
Lawrence1, M.J.  Davies3; 
1Diabetes Research, University Hospital of Leicester, 2Diabetes Centre, 
Northern General Hospital, Sheffield, 3Cardiovascular Sciences, University 
of Leicester, 4Health Sciences, University of Leicester, United Kingdom.
Background and aims: An increasing number of young people are diagnosed 
with type 2 diabetes (T2DM), leading to a high lifetime risk for developing 
diabetes-related complications. Whether this cohort receives appropriate risk 
factor management in relation to older T2DM subjects remains uncertain. 
Our aim is to describe the characteristics and management of a multiethnic 
cohort of people with T2DM <40 years (<40 cohort) and to compare with 
T2DM subjects aged ≥ 40 years (≥ 40 cohort).
Petients and methods: Retrospective analysis of data extracted from the last 
clinic visit of 648 adults (< 40 cohort) attending 2 specialist diabetes centres 
(A and B) in the UK and a ≥ 40 cohort of 3582 T2DM subjects coming from 
the specialist centre A. In the < 40 cohort, differences between the first (≤22) 
vs. fifth quintile (≥33) of age of diagnosis were analysed.
Results: Characteristics of the <40 cohort: 57.9% female, 54.5% Caucasian, 
45.5% Black or Minority Ethnic origin (BME, 91.9% from South Asian ori-
gin). Median age at diagnosis was 28 years (24-31). Data were extracted after 
a median diabetes duration of 4.0 years (1.9-7.0). The median BMI was 33.0 
kg/m² (28.3-38.7), higher in Caucasians (35.0 vs. 30.9 in BME, p<0.0001) 
and women (34.0 vs. 31.9 in men, p=0.003). Median HbA1c was 8.2% (6.8-
9.9) with an HbA1c > 7% in 70%. Cardiovascular risk factors were frequent: 
71.8% total cholesterol > 4mmol/l, 54.9% triglycerides > 1.7mmol/l, 45% 
hypertension. Microvascular complications were also prevalent: 19.8% retin-
opathy, 14.6% abnormal foot exam, 24.0% microalbuminuria (only available 
for centre A). Oral antidiabetic drugs were used in 71.6%, insulin alone in 
18.6% and both in 24.7%. Insulin was more often used in Caucasians (49.4% 
vs. 36.2% in BME, p=0.001). 27.7% received antihypertensives, 31.5% a sta-
tin and 13.9% aspirin. Women were less likely to be treated for hypertension 
(22.7% vs. 34.8%, p<0.0001) and dyslipidaemia (22.1% vs. 45.1%, p<0.0001) 
than men. The first quintile of age of diagnosis had more often retinopathy 
(22.1% vs. 16.9%, p=0.021) and was treated less aggressively compared with 
the fifth quintile. Fewer were on insulin (45.6% vs. 46.4%, p=0.039), many 
were managed with diet only (9.6% vs. 6.2%, p=0.005) and they were less 
likely to be treated for hypertension (23.2% vs. 32.3%, p=0.583) and dysli-
pidaemia (30.4% vs. 39.2%, p=0.495). Data were generally comparable be-
tween the 2 centres, except for a higher proportion of BME (50.6% vs. 36.1%, 
p<0.0001) and women (61.3% vs. 51.5%, p=0.009) and lower median HbA1c 
(8.1% vs. 8.7%, p=0.012) in centre A compared to centre B. Compared to 
the ≥ 40 cohort, patients in the < 40 cohort were more often female (57.9 vs. 
46.1, p<0.0001) and of BME origin (45.5 vs. 30.2 , p<0.0001), had a higher 
median BMI (33.0 vs. 30.4, P<0.0001) and a higher median HbA1c (8.2 vs. 
7.5, p<0.0001).
Conclusion: The <40 cohort represents a more extreme phenotype compared 
to the ≥ 40 cohort with a high prevalence of inadequately treated risk fac-
tors. In particular, patients from the first quintile of age of diagnosis were 
less aggressively treated. There is a need for tailored strategies to manage this 
high-risk group.
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LDL-cholesterol is not the best blood lipid predictor of CHD risk in type 
2 diabetes
B. Eliasson1, S. Gudbjörnsdottir1, K. Eeg-Olofsson1, A.-M. Svensson2,  
B. Zethelius3, J. Cederholm3; 
1University of Gothenburg, 2Center of Registers Vastra Gotaland, 
Gothenburg, 3Uppsala University, Sweden.
Background and aims: Although frequently used in clinical practice, the 
validity of LDL-cholesterol (LDL) as a risk factor for coronary heart disease 
(CHD) is uncertain. We assessed the roles of different measures of blood li-
pids in an observational study of type 2 diabetes from the Swedish National 
Diabetes Register (NDR).
Material and methods: 23,001 patients aged 30-75 years, 16% with previ-
ous CVD, 43% with lipid-lowering drugs, were followed from 2003 to 2007, 
with 1709 fatal/nonfatal CHD events. LDL was calculated with Friedewald’s 
equation.
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Results: Adjusted hazard ratios (HR) at Cox regression for fatal/nonfatal 
CHD per 1 SD of each lipid measure were 1.21 (1.15-1.26) with non-HDL/
HDL, 1.19 (1.13-1.24) with LDL/HDL, 1.18 (1.13-12.4) with non-HDL, and 
1.14 (1.09-1.19) with LDL; all p<0.001 when adjusted for age, sex, diabetes 
duration, HbA1c, type of hypoglycaemic treatment, systolic blood pressure, 
antihypertensive drug use, smoking, BMI, and microalbuminuria (>20 µg/
min). Goodness-of-fit with global likelihood ratio X2 values were 771, 762, 
757, 739, respectively. Figure 1 shows splines for adjusted 5-year CHD rates as 
a cubic function of lipids in a Cox model. CHD rates increased progressively 
with higher non-HDL/HDL ratio as well as non-HDL. When 7889 patients 
with a combination of non-HDL/HDL >2.9, non-HDL >3.6, and LDL >2.8 
mmol/l was used as reference (median values chosen as limits), fully adjusted 
HR for CHD risk was 0.61 (0.53-0.70) with non-HDL/HDL <2.3 mmol/l (re-
cently often used target; n=6116), HR was 0.67 (0.60-0.76) with non-HDL 
<3.3 mmol/l (recent target, suggested useful if higher triglycerides; n=7623), 
while HR was higher 0.74 (0.66-0.83) with LDL <2.5 mmol/l (recent target 
in guidelines; n=7166). HR with LDL <1.9 mmol/l was 0.65 (0.54-0.80) (sug-
gested target in high-risk patients; n=1889). All HR were p<0.001.
Conclusion: Non-HDL/HDL and non-HDL, which both are reliably meas-
ured in the non-fasting state, were more strongly associated with risk of CHD 
than LDL. Risk reductions for CHD were larger with targets presented here 
for the non-HDL/HDL ratio and non-HDL, than for LDL. Splines of CHD 
rate by non-HDL/HDL and non-HDL values underline the “the lower the 
better” concept for these lipids and CHD risk in type 2 diabetes.
Supported by: The Swedish Association of Local Authorities and Regions
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Silent myocardial ischaemia and prediabetes in combination are 
associated with adverse prognosis in healthy subjects
T. Intzilakis1,2, A. Sajadieh1,2, S.B. Haugaard3,2; 
1Dept. of Cardiology, University Hospital of Copenhagen, Bispebjerg, 2Dept. 
of Internal Medicine, University Hospital of Copenhagen, Amager, 3Clinical 
Research Centre, University Hospital of Copenhagen, Hvidovre, Denmark.
Background and aims: Silent myocardial ischemia (SMI) is prognostic for 
deaths and myocardial infarction. Prediabetes increases risk of diabetes and 
cardiovascular disease. It was hypothesized, therefore, that prediabetes dete-
riorates prognosis in persons with SMI.
Materials and methods: Five-hundred-and-ninety-six non-diabetic subjects 
from the community of age 55 to 75 years and free of any known cardiovas-
cular disease and cancer were examined by ambulant 48h continuous electro-
cardiogram monitoring. SMI was defined as at least 1 mm depression of the 
ST interval on the electrocardiogram of at least 1 min duration. Prediabetes 
was defined as fasting plasma glucose ≥ 5.6 but < 7.0 mmol/L. During a medi-
an follow-up of 6.3 years, 77 subjects met the predefined combined endpoint 
of acute myocardial infarction and/or death.
Results: Two-hundred-and-twenty-nine subjects had prediabetes (38%), 
which was not associated with SMI (P=0.69). Subjects with prediabetes and 
SMI (5% of subjects) more often met the combined endpoint (36%) than 
subjects with prediabetes and non-SMI (15%), subjects with normal fasting 
glucose (NFG) and SMI (12%), and subjects with NFG and non-SMI (10%), 
respectively, (P<0.001). Both in a univariate analysis and in a Cox multivari-
ate analysis, the latter of which included the four study groups of interest, and 
in addition, gender, age, smoking habits, blood pressure and total cholesterol, 
respectively, only subjects with combined prediabetes and SMI exhibited an 
increased risk for meeting the predefined endpoint (hazard ratio, HR: 4.0 
(2.0-8.1), P<0,001 and HR: 2.5, CI95% 1.2-5.2, P=0.016, respectively; sub-
jects with combined NFG and non-SMI as reference). Including also high 
sensitive C-reactive protein and NT pro-brain natriuretic peptide in the Cox 
multivariate model, subjects with prediabetes and SMI exhibited more than a 
3-fold increased risk of meeting endpoint compared with reference subjects 
(HR: 3.2, CI95% 1.5-6.7, P<0.005).
Conclusion: Combined silent myocardial ischemia and prediabetes sug-
gest increased risk of myocardial infarction and/or death among apparently 
healthy subjects living in the community, thus, this clinical entity calls for 
screening and treatment.
Supported by: The Danish Heart Foundation
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Incident myocardial infarction is five-fold higher in subjects at high risk 
for type 2 diabetes
M.P. McKenna1, M.W. Rowe1, J.A. Kolberg1, O. Pedersen2, K. Borch-Johnsen3, 
T. Jørgensen4; 
1Research, Tethys Bioscience, Emeryville, USA, 2Faculty of Health Science, 
University of Copenhagen, Denmark, 3Steno Diabetes Center, Copenhagen, 
Denmark, 4Research Centre for Prevention and Health, Glostrup University 
Hospital, Denmark.
Background and aims: A simple and accurate test comprised of circulating 
biomarkers (Diabetes Risk Score, DRS) provides a quantitative estimate of the 
5-year risk of developing type 2 diabetes mellitus (T2DM). It is established 
that T2DM is a major risk factor for cardiovascular disease, and that a sig-
nificant portion of that risk occurs in the prediabetic state. A model using the 
circulating biomarkers composing the DRS was applied to the Inter99 study 
to assess the 5-year risk of cardiovascular events (CVE) in groups of subjects 
at low, moderate and high risk for T2DM.
Materials and methods: Serum samples collected at baseline from 5452 sub-
jects free of diabetes were tested. 2924 (53.6%), 1975 (36.2%) and 553 (10.1%) 
subjects were classified as low, moderate and high risk for T2DM, with 5 yr 
T2DM conversion rates of 0.5%, 3.1% and 15.2%, respectively. Relative risk 
(RR) estimates for overall CVEs and for each of the 4 classes of CVEs (myo-
cardial infarction (MI), re-vascularization (RV), angina (ANG), and stroke 
(STR)) were calculated as ratios of moderate:low and high:low. P values and 
confidence intervals were calculated by bootstrap estimation.
Results: The results are summarized in the table below. Relative risks for 
overall CVEs and all classes of CVEs were significant with the exception of 
STR.
Conclusion: Several studies have demonstrated that risk of MI is 3-fold high-
er in diabetics compared to non-diabetics. The data shown here demonstrate 
similar levels of cardiovascular risk stratification among non-diabetics using 
the DRS, suggesting that cardiovascular risk factors for patients with a high 
DRS should be managed carefully.
Relative Risks for Overall Cardiovascular Events by Diabetes Risk Score
CVE
(n=108)
MI
(n=42)
RV
(n=42)
ANG
(n=27)
STR
(n=41)
Low DRS 1 1 1 1 1
Moderate DRS 2.7
(p<0.001)
2.6
(p=0.013)
4.1
(p<0.001)
6.5
(p<0.001)
1.8
(p<0.11)
High DRS 3.6
(p<0.001)
4.8
(p=0.003)
6.0
(p=0.004)
6.7
(p=0.03)
2.6
(p=0.09)
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Assessing the influence of modelling subsequent cardiovascular events 
into a type 2 diabetes cost-effectiveness model
P.H. McEwan1, M. Evans2, K. Bergenheim3; 
1Cardiff Research Consortium Ltd, United Kingdom, 2University Hospital 
Wales, Cardiff, United Kingdom, 3AstraZeneca, Mölndal, Sweden.
Background and aims: Type 2 diabetes mellitus (T2DM) is associated with 
increased risk of cardiovascular morbidity and mortality. Assessing the cost-
effectiveness of risk factor modification is commonly based on the analysis 
of avoiding primary events. The aim of this study was to calibrate published 
equations to allow the prediction of primary and subsequent events and to 
assess the economic implications of this within a cost-effectiveness model.
Materials and methods: Routine hospital data from across the UK were 
analysed between 2000 and 2005 to identify patients with T2DM with first, 
second and third myocardial infarction (MI) or stroke admissions. The ratio 
of events (primary + subsequent) to primary event was used to calibrate the 
cardiovascular risk equations using a published diabetes prevalence-based 
model. The impact of the calibrated equations was then assessed using a 
published cost-effectiveness model assessing two treatment strategies: 1st 
line metformin (a) and (b); 2nd line sulphonylurea add-on (a) versus DPP-
4 inhibitor add-on (b); 3rd line thiazolidinedione add-on (a) versus DPP-4 
inhibitor add-on (b). The model was run using a UKPDS demographic and 
risk factor profile with a payer perspective for 40 years with costs and benefits 
discounted at 3.5%.
Results: Between 2000 and 2005, 1,124,846 T2DM patients were identified, of 
whom 55,868 and 65,436 experienced a primary MI and stroke, respectively. 
There were 2,159 (3.86%) and 185 (0.003%) second and third MI admissions, 
respectively, and 5,808 (8.88%) and 755 (0.012%) second and third stroke 
admissions, respectively. Incorporating subsequent events into the model 
had little impact on the cost per quality-adjusted-life-years (QALYs), which 
ranged from £3,105 to £3,129 with and without subsequent events allowed, 
respectively. The impact on cost per life-year gained (LYG) was more notice-
able; £257,902 with primary events only, and £90,055 with primary and sub-
sequent events.
Conclusion: The inclusion of subsequent cardiovascular events into diabetes 
models provides greater face validity; however, this has little impact on cost-
effectiveness. This study supports the conclusion that the economic assess-
ment of therapies that modify cardiovascular risk factors but do not incor-
porate subsequent MI and stroke events are not significantly biased - due to 
the relatively small number of subsequent events. Importantly, this does not 
imply that treatment in clinical practice should be stopped after first event. 
Where concerns are raised regarding the suitability and generalisability of 
risk equations in general, and the UKPDS equations in particular, research 
should focus on deriving and/or validating primary event risk equations to 
ensure that the assumption of generalisability is indeed robust. For a general 
cohort of T2DM patients this would appear to be more pressing than the ac-
curate prediction of subsequent events.
PS 123 Biomarkers and 
cardiovascular disease
1239
Effects of six years intensified multifactorial treatment versus usual care 
on levels of hs-CRP and adiponectin in patients with screen-detected 
type 2 diabetes. The ADDITION Netherlands study
J. Berends, M. van den Donk, K.J. Gorter, G.E.H. Rutten; 
Julius Center for Health Sciences and Primary Care, University Medical 
Center Utrecht, Netherlands.
Background and aims: Biomarkers as high-sensitivity C-reactive protein 
(hs-CRP) and adiponectin are associated with cardiovascular disease. Hs-
CRP may be a mediator of atherosclerosis. Elevated levels of hs-CRP and 
decreased levels of adiponectin are independent markers of cardiovascular 
disease. It is unknown to what extent these biomarkers are influenced by the 
intensity of a multifactorial therapy aimed at reduction of cardiovascular 
disease in type 2 diabetes. We compared the effects of six years intensified 
multifactorial therapy or usual care on levels of hs-CRP and adiponectin in 
498 screen-detected type 2 diabetes patients and the association with cardio-
vascular morbidity and mortality.
Materials and methods: This study is embedded in the Dutch part of the An-
glo-Danish-Dutch ADDITION study, a cluster-randomised clinical trial that 
studies the effectiveness of intensified multifactorial treatment compared to 
usual care on cardiovascular morbidity and mortality in screen-detected type 
2 diabetes patients. Baseline serum levels of hs-CRP and adiponectin were 
measured at time of diagnosis of type 2 diabetes by screening (2002-2004). 
Serum hs-CRP was determined by chemiluminescent enzyme immunoassay. 
Adiponectin was assessed by immunoassay technique. Final measurements 
were performed in the second half of 2009. In the stored serum hs-CRP and 
adiponectin will be determined. We will analyse the difference in change in 
serum hs-CRP and adiponectin levels between both treatment groups with 
multilevel modelling, to be able to adjust for clustering at the level of the 
general practice.
Results: Baseline characteristics in both treatment groups (usual care vs. in-
tensive treatment) are comparable, except for the levels of adiponectin (Ta-
ble). Hs-CRP was 6.9 mg/dl (SD 8.6) in the usual care group vs. 7.3 (SD 9.9) 
in the intensified treatment group; adiponectin 6759 ng/ml x100 (SD 3845) 
in the usual care group vs. 5868 (SD 3172) in the intensified treatment group 
(p=0.006). A total of 330 (66%) patients from 79 general practices partici-
pated in the final measurement. Their data are currently analysed and will be 
presented at the EASD meeting.
Conclusion: This more than 5 years follow-up of multifactorial treatment in 
screen-detected type 2 diabetes patients will demonstrate whether intensi-
fied therapy leads to a significant change in hs-CRP and adiponectin levels 
and whether such a change is associated with cardiovascular mortality and 
morbidity.
Baseline characteristics of the ADDITION Netherlands study
Variables Usual care  
group (n=243)
Intensive treatment  
group (n=255)
Age (years) 59.9 ± 5.1 60.1 ± 5.4
Gender (% male) 56.0 51.8
BMI (kg/m2) 30.4 ± 4.6 31.2 ± 5.1
Systolic blood pressure (mmHg) 163 ± 23 166 ± 23
Diastolic blood pressure (mmHg) 89 ± 10 90 ± 11
Fasting blood glucose (mmol/l) 8.1 ± 2.8 7.8 ± 2.3
HbA1c (%) 7.4 ± 1.7 7.3 ± 1.6
Cholesterol (mmol/l) 5.6 ± 1.1 5.6 ± 1.1
Hs-CRP (mg/l) 6.9 ± 8.6 7.3 ± 9.9
Adiponectin (ng/ml x100) 6759 ± 3845 5868 ± 3172
Data are percentages or means ± SD
Supported by: Novo Nordisk
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The ENPP1 K121Q polymorphism predicts accelerated cardiovascular 
events in obese patients with type 2 diabetes
S. Bacci1, C. Powers2, A. Pacilli1, A. Facciorusso3, T.H. Hauser4, S.A. De 
Cosmo1, Y.-Y. Zhang5, E.V. Gervino6, G. Di Stolfo3, D. Mangiacotti7, R. Xu5, 
M. Copetti8, S. Prudente9, A. Doria5, V. Trischitta10,11; 
1Endocrinology Unit, IRCCS, Casa Sollievo della Sofferenza, San Giovanni 
Rotondo, Italy, 2Joslin Diabetes Center, Harvard Medical School, Boston, 
USA, 3Cardiology Unit, IRCCS, Casa Sollievo della Sofferenza, San Giovanni 
Rotondo, Italy, 4Cardiovascular Division, Beth Israel Deaconess Medical 
Center, Boston, USA, 5Joslin Diabetes Center, Harvard Medical School, 
Boston, USA, 6Cardiovascular Division, Beth Israel Deaconess, Boston, 
USA, 7Laboratory of Diabetology, IRCCS, San Giovanni Rotondo, Italy, 
8Biostatistics Unit, IRCCS, Casa Sollievo della Sofferenza, San Giovanni 
Rotondo, Italy, 9Genetics laboratory, IRCCS, Casa Sollievo della Sofferenza-
Mendel, Rome, Italy, 10Diabetes Laboratory, IRCCS, Casa Sollievo della 
Sofferenza, San Giovanni Rotondo, Italy, 11Sapienza Univesity, Rome, Italy.
Type 2 diabetes is characterized by insulin resistance and accelerated athero-
sclerosis. The ENPP1 K121Q polymorphism has been associated with both 
of these traits, especially among obese individuals. We investigated the role 
of the ENPP1 K121Q polymorphism - separately in non-obese and obese 
individuals (body mass index < or > 30 kg/m2) - as a predictor of major 
cardiovascular events in a prospective study of 330 type 2 diabetic patients 
with coronary artery disease at baseline. Study subjects were followed for 
37.1±19.4 months, during which 43 major cardiovascular events occurred 
(32 cardiovascular deaths, 3 non-fatal myocardial infarctions, and 8 non-fa-
tal strokes). Carriers of the Q121 variant (either KQ or QQ individuals) had 
an increased risk of incident events among obese subjects (n=159, HR=3.56, 
95% CI=1.21-10.46, p=0.02), but not among non-obese individuals (n=171, 
HR=0.90, 95% CI=0.39-2.06, p=0.81). A similar pattern of association was 
observed in a cross-sectional study of 339 type 2 diabetic patients (169 sub-
jects from Italy and 170 from the US) who had survived a myocardial infarc-
tion. In this analysis, patients who had had the myocardial infarction at a 
younger age (< 50 years, n=112) were compared to those who had had the 
myocardial infarction at an older age (n=237). Since no genotype-by-sam-
ple interaction was observed, data from Italy and the US were pooled and 
analyzed together. As seen in the prospective study, the Q121 variant was 
associated with a significantly increase in the risk of early myocardial infarc-
tion among obese subjects (n=188; OR=2.51, 95% CI=1.29-4.88, p=0.007), 
but not among non-obese individuals (n=151; OR, 95% CI=1.11, 0.51-2.42 
p=0.878). In conclusion, among obese individuals with type 2 diabetes, the 
ENPP1 Q121 variant contributes in accelerating cardiovascular events.
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Leptin and glucose intolerance predict independently a first-ever 
myocardial infarction with a sex difference - data from a large 
prospective population-based study in northern Sweden
M. Eriksson1, G. Hallmans1, J.-H. Jansson1, T. Olsson1, P. Vennberg1, L. 
Weinehall2, S. Söderberg1; 
1Dept of Public Health and Clinical Medicine, Medicine, 2Dept of Public 
Health and Clinical Medicine, Epidemiology, Umeå, Sweden.
Background and aims: The adipocyte-derived hormone leptin mediates sev-
eral processes associated with glucose hemostasis and atherosclerosis, and 
data suggests that high leptin may predict diabetes and cardiovascular disease 
(CVD). As circulating levels and signalling differ between males and females 
we explored whether leptin also predict first-ever myocardial infarction or 
sudden death with a sex difference, independent of glucose intolerance.
Materials and methods: This is a prospective nested case-referent study. Sub-
jects (n=564, 40% females) with a first-ever acute myocardial infarction (MI) 
(fatal and non-fatal, and classified according to WHO) that had participated 
in population-based studies (the Väserbotten project, the MONICA survey, 
and the mammary screening cohort) prior to the event (3.9 years) were iden-
tified in the Northern Sweden MI registry. Matched (age, sex, survey date and 
location) referents (n=1082, 40% women) free of CVD were recruited from 
the same database. Glucose intolerance was categorised into impaired fasting 
glucose (IFG), impaired glucose tolerance (IGT) and diabetes mellitus (DM) 
based on an OGTT and data on treatment at baseline. The impact of leptin 
and glucose intolerance on future MI was explored in conditional logistic 
regression analyses and odds ratios (OR) with 95 % confidence intervals were 
calculated.
Results: At baseline, both males and females with MI had higher leptin levels 
(5.0 ng/mL vs. 4.1 ng/mL, p<0.001 and 15.4 ng/mL vs. 14.0 ng/mL, p=0.03) 
compared to referents. High leptin levels predicted MI in males but not in 
females, independently of glucose intolerance, 1.9 (1.1-3.0) and 1.0 (0.5-2.0), 
respectively. After further stratification, leptin predicted ST elevation MI but 
not non-ST elevation MI in males, 2.9 (1.4-6.4) and 1.4 (0.6-3.6), respectively. 
After adjustments including leptin, DM and IGT associated with MI, ORs 
2.3 (1.3-4.1) and 2.4 (1.3-4.0), respectively. After stratification for sex, DM 
associated with MI in men and IGT with MI in women, ORs 2.5 (1.4-4.5) and 
4.1 (1.4-12.1), respectively.
Conclusion: High leptin and glucose intolerance predict first-ever fatal and 
non-fatal MI, notably with a clear gender difference.
Supported by: Västerbotten and Norrbotten County Councils and Faculty of 
Medicine, Umeå
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Assessment of matrix metalloproteinase-9 as a non-traditional 
cardiovascular risk marker in prediabetes and newly diagnosed type 2 
diabetes
N. Chakarova1, T. Tankova1, G. Kirilov1, L. Dakovska1, A. Tsakova2; 
1Clinical Center of Endocrinology, 2Department of Clinical Laboratory and 
Immunology, Medical University, Sofia, Bulgaria.
Background and aims: Matrix metalloproteinase-9 (MMP-9) is a proteo-
lytic enzyme which main substrate is basement membrane collagen and it 
has been lately recognized as a non-traditional marker of cardiovascular risk. 
There is growing evidence that MMP-9 plays a key role in extracellular ma-
trix degradation and remodeling and is involved in all stages of the athero-
sclerotic process. The aim of the present study was to assess MMP-9 levels 
in prediabetic states - impaired fasting glucose (IFG) and impaired glucose 
tolerance (IGT), and in newly diagnosed type 2 diabetes (NDD) as well as 
to evaluate the relationship between MMP-9 and glycaemic control (blood 
glucose, HbA1c), anthropometric parameters (body mass index, visceral fat 
area) and common cardiovascular risk factors (hsCRP, serum lipids).
Materials and methods: 249 subjects, distributed into four age-, sex- and 
BMI-matched groups, were enrolled in the study - 63 subjects with normal 
glucose tolerance (NGT) (32 males and 31 females, mean age 49.6±14.2 years, 
mean BMI 30.0±5.0 kg/m2), 62 subjects with IFG (32 males and 30 females, 
mean age 49.4±11.1 years, mean BMI 30.6±5.8 kg/m2), 62 subjects with IGT 
(31 males and 31 females, mean age 49.0±13.8 years, mean BMI 30.6±6.7 
kg/m2) and 62 subjects with newly diagnosed type 2 diabetes (32 males and 
30 females, mean age 48.7±10.6 years, mean BMI 30.4±5.3 kg/m2). Glucose 
tolerance was studied during oral glucose tolerance test with evaluation of 
venous plasma glucose at 0 min and 120 min by a hexokinase method (Roche 
Diagnostics). hsCRP, lipid profile, MMP-9 and HbA1c were estimated at fast-
ing state. hsCRP was measured turbidimetrically (Roche Diagnostics). Lipid 
profile (total cholesterol, HDL-cholesterol, triglycerides) was assessed by an 
enzymatic colorimetric method (Roche Diagnostics). LDL-cholesterol was 
calculated using Friedewald’s formula. MMP-9 was assessed immunoenzy-
matically (ELISA, CalBiochem) and HbA1c - immunoturbidimetrically (Ro-
che Diagnostics). BMI and visceral fat area were measured with body com-
position analyzer using eight-point multi-frequency bioelectric impedance 
analysis (InBody 720, BIOSPACE). Statistical analysis was performed with 
SPSS 16. 
Results: No significant difference in MMP-9 level was found between the 
groups with NGT and NDD as well as between NGT group and either of 
the prediabetic groups. No correlation was established between MMP-9 level 
and glycaemic control parameters. Significant negative correlation was es-
tablished between MMP-9 and HDL-cholesterol level (r=-0.24, p<0.05). We 
have found significant correlation between MMP-9 and hsCRP (r=0.482, 
p=0.04) as well as between MMP-9 and BMI (r=0.391, p<0.01) and visceral 
fat area (r=0.346, p<0.02).
Conclusion: In early stages of impaired glucose homeostasis - prediabetes 
and newly diagnosed type 2 diabetes, serum MMP-9 levels do not differ sig-
nificantly from those in subjects with normal glucose tolerance. In prediabe-
tes and NDD serum MMP-9 correlates mainly with anthropometric (BMI, 
visceral fat area) and inflammatory (hsCRP) markers and shows weak cor-
relation with parameters of metabolic control (HDL-cholesterol). Probably 
MMP-9 activity in these states is related to inflammatory changes rather than 
to metabolic ones.
Supported by: Medical University, Sofia
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High osteoprotegerin serum levels in newly diagnosed type 2 diabetic 
males with or without known coronary artery disease
M. Boyadzhieva1, K. Hristozov1, S. Georgiev2, R. Yordanov2, T. 
Chervenkov3, N. Usheva4; 
1Endocrinology, University Hospital, 2Clinic of Interventional Cardiology, 
University Hospital, 3Laboratory of Clinical Immunology, University 
Hospital, 4Social Medicine and Health Care, Medical University, Varna, 
Bulgaria.
Background and aims: Osteoprotegerin (OPG) is an inhibitor of osteoclas-
togenesis, but is produced from vasculature too. Recently increased circulat-
ing OPG levels were found in diabetics and in patients with coronary artery 
disease (CAD). Elevated serum OPG appears to be a powerful predictor for 
cardiovascular mortality. Up to date there are insufficient data for OPG con-
centrations in newly diagnosed type 2 diabetic patients. The aim of our study 
was to determine serum OPG in males with newly diagnosed T2DM associ-
ated or not with known concomitant CAD and to investigate the relationship 
between OPG and metabolic components.
Materials and methods: Serum OPG levels were measured in 45 newly diag-
nosed type 2 diabetic males and 20 age- and BMI-matched normoglycemic 
male subjects. The newly diagnosed diabetics consisted of 28 diabetics with-
out history of CAD and 17 diabetic patients who underwent percutaneous 
coronary interventions (PCI) for CAD. Mean intima-media thickness (IMT) 
of common carotid arteries in diabetics without known CAD was measured 
by B-mode ultrasonography. All newly diagnosed glucose abnormalities were 
detected during 2 screening programs among risk groups. Glucose tolerance 
was defined by performing a standard OGTT. OPG was measured by ELISA 
(BioMedica).
Results: OPG was significantly higher in newly diagnosed type 2 diabetics 
compared to controls (4.4 ± 0.2 vs 3.3 ± 0.4 pmol/l; p=0.02) but there was no 
significant difference between diabetic males with performed PCI or those 
without known CAD - 4.2± 0.3 vs 4.6 ± 0.3 pmol/l, p=0.41 respectively. In 
total group of subjects, there was positive correlation of OPG levels with fast-
ing plasma glucose (r=0.37, p=0.008), 120 min post-OGTT glucose (r=0.42, 
p=0.004) and HbA1c (r=0.50, p=0.0002). Interestingly, in newly diabetic 
males OPG correlated only with HbA1c (Pr 0.40, p=0.009). Moreover in dia-
betics without known CAD, OPG correlated significantly with carotid IMT 
(Pr 0.48, p=0.03) and age (p=0.04). There was no association with fasting 
insulin, homeostasis model assessment of insulin resistance (HOMA-IR), 
systolic and diastolic blood pressure, BMI or waist circumference. From li-
pid parameters OPG showed positive correlation only with HDL-cholesterol 
(r=0.34, p=0.02).
Conclusion: We found higher serum OPG levels in newly diagnosed type 2 
diabetic males independently of presence of known CAD. OPG showed as-
sociation with glucose parameters, early markers of atherosclerosis and prob-
ably they may be involved in the regulation of OPG. We suggest that OPG 
rises early in the evolution of diabetic disorders but further investigations 
are needed.
Supported by: Medical University-Varna
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Serum YKL-40 levels predict the development of vascular complications 
in patients with type 2 diabetes
Y. Suzuki1, Y. Sakuma2, R. Iwai2, T. Yamane1, S. Yoshida1, N. Hashimoto3; 
1Diabetes and Metabolic disease, Asahi General Hospital, Asahi-City, 
Chiba, 2Clinical Laboratory, Asahi General Hospital, Asahi-City, Chiba, 
3Diabetes,Endocrine and Metabolic disease, Tokyo Women’s Medical 
University, Yachiyo-City, Chiba, Japan.
Background and aims: Macrophages in atherosclerotic plaques and vascular 
smooth muscle cells secrete YKL-40, associated with inflammation, endothe-
lial dysfunction and increased tissue remodeling. Progression of nephropa-
thy with increasing levels of albuminuria has been reported to be intimately 
linked to an increased risk of cardiovascular (CV) disease. The aim of the 
present study was to examine the changes in serum YKL-40 levels in patients 
with type 2 diabetes with increasing levels of albuminuria and macroangio-
pathy.
Materials and methods: A total of 396 patients with type 2 diabetes were 
enrolled in this study: 212 males/184 females, age 60±13 years, estimated 
duration of the disease 12±8 years, body mass index (BMI) 26.0±4.6 kg/
m²,HbA1c 7.4±1.4%. Two hundred fifteen patients had normoalbuminu-
ria, and 122 had persistent microalbuminuria, and 59 had overt proteinuria 
(macroalbuminuria). Ninety patients showed the past history of CV events 
(macroangiopathy). The control group consisted of 100 healthy individuals 
with normal glucose tolerance matched for gender and age. Examination in-
cluded blood and urine samples for CV risk factors, and markers including 
lipids, high sensitive C-reactive protein (hsCRP), interleukin (IL)-6 and adi-
ponectin in addition to YKL-40.
Results: Serum YKL-40 levels were positively correlated with age (r=0.333, 
p<0.0001), systolic blood pressure (r=0.144, p<0.005), serum creatinine 
(r=0.218, p<0.0001), urinary albumin-to-creatinine ratio (r=0.279, p<0.0001) 
and IL-6 (r=0.243, p<0.0001). However no significant correlation was found 
between YKL-40 and parameters such as BMI, HbA1c and hsCRP. Serum lev-
els of adiponectin were not related to levels of YKL-40 in patients with nor-
moalbuminuria (r=0.005.p=0.9405) but both parameters interestingly showed 
significant correlation in patients with microalbuminuria (r=0.266, p<0.005). 
YKL-40 levels had no gender differences, and were significantly elevated in 
patients with type 2 diabetes compared with control subjects (135.8±94.7 vs. 
80.7±58.3 ng/ml; p<0.0001). YKL-40 levels were evidently increasing with 
advancing stages of nephropathy (normoalbuminuria 105.2±74.0, micro-
albuminuria 156.5±98.0 and macroalbuminuria 205.3±107.8 ng/ml; p<0.005 
for all comparisons). Patients with the past CV events showed significantly 
higher YKL-40 levels than other patients (165.4±99.4 vs. 126.3±91.5 ng/ml; 
p<0.001).
Conclusion: YKL-40 levels are significantly elevated in patients with type 
2 diabetes with advancing stages of nephropathy, and also in patients with 
macroangiopathy. These findings suggest that YKL-40 has the usefulness as 
a novel marker predicting the progressing vascular complications in patients 
with type 2 diabetes.
1245
Insulin resistance: a risk marker in coronary population without known 
diabetes
E. Hernandez1, J.M. De la Hera1, I. Lozano1, J.M. Vegas2, J.M. Garcia-
Ruiz1, P. Avanzas1, C. Fernandez-Cimadevilla1, A. Carro1, T. Menendez3, E. 
Delgado3; 
1Cardiology, Hospital Universitario Central de Asturias, Oviedo, 
2Cardiology, Hospital Clínico Universitario, Valladolid, 3Endocrinology, 
Hospital Universitario Central de Asturias, Oviedo, Spain.
Background and aims: The impact of clinically established diabetes in the 
prognosis of the patients with coronary disease is well known. However, con-
tradictory data exist about the prognosis if these patients present unknown 
diabetes, newly detected diabetes or prediabetes. As the phisiopathologic 
substrate is the insulin resistance the purpose is to validate its role as progno-
sis factor in our series.
Materials and methods: We studied a cohort of 472 patients with coronary 
disease [(who underwent percutaneous coronary intervention (PCI)]. In 
those 338 patients without known diabetes an analysis including fasting plas-
ma glucose, oral glucose tolerance test, glycated hemoglobin, insulinemia, 
and renal and lipid profiles was performed 15 days after discharge. The real 
glycometabolic profile of the population was addressed following the OMS 
criteria of 1999. The HOMA was calculated with Matthews´formula. Insulin 
resistance was defined as HOMA>3 (Sekiguchi et al). A composite end-point 
of major cardiac events (MACE) that included death, non-fatal AMI, new PCI 
and stroke was registered after a 12-month follow-up. Kaplan-Meier and mul-
tivariable analysis were performed to determine the predictors of MACE.
Results: Age: 66.5 (56-74), males 80.1%, active smokers 28.4%, hypertension 
49.7%, obesity 35.5%, peripheral or cerebrovascular disease 15.4%. The real 
distribution of the cohort after the glycometabolic study was: known diabetes 
28.8%, newly detected diabetes 16.2%, prediabetes 25.5% and normoglyc-
emic 29.5%. Forty patients were classified as resistance to insulin and 298, 
non insulin resistance. In the multivariable analysis the predictors of MACE 
were the presence of known diabetes (30.6%) and insulin resistance (27.5%). 
The MACE in non insulin resistance, normoglycemics, prediabetes and new-
ly detected diabetes were 11%, 10.7%, 10.7% and 12.9%, respectively. (See 
Kaplan-Meier curve, DM is known diabetes).
Conclusion: In our cohort of patients with coronary disease who underwent 
PCI the presence of known diabetes and the insulin resistance were predic-
tors of MACE at 12 months. Prediabetes and newly detected diabetes did not 
increase the risk of MACE in comparison with the normoglycemics.
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Abdominal obesity, hypertension and cardiovascular risk in diabetic 
patients: Poland compared to North-West Europe Region - insights from 
IDEA sub-study
M. Wróbel1, M. Chrostowska2, A. Szymborska-Kajanek1, P. Paczwa3, J.-P. 
Després4, K. Narkiewicz2, K. Strojek1; 
1Department of Internal Diseases Diabetology & Nephrology, SIilesian 
Medical University, Zabrze, Poland, 2Hypertension Unit, Dept. of 
Hypertension & Diabetology, Medical University Gdańsk, Poland, 3Sanofi 
Aventis, Warszawa, Poland, 4Quebec Heart and Lung Institute, Université 
Laval, Canada.
Background and aims: The cluster of anthropometric and metabolic disor-
ders define the risk of cardiovascular disease (CVD). The IDEA (Internation-
al Day for Evaluation of Abdominal Obesity) study was an international cross 
sectional study including 168159 primary care patients in 62 countries. The 
aims of the present report were: (i) to compare the prevalence of abdominal 
obesity (AO), hypertension (HT) and cardiovascular disease (CVD) in Po-
land-PL and North-West Europe Region -NW (Austria, Belgium, Denmark, 
Finland, France, Germany, Ireland, Netherlands, Norway, Sweden, Switzer-
land) in diabetic (DM) sub-population of IDEA study; (ii) to assess the im-
pact of DM and AO, HT on CVD in Polish population.
Materials and methods: In Poland, 200 randomly selected general practi-
tioners included 5371 consecutive patients, aged 18 to 80 years, 2024 men and 
3347 women. Waist circumference (WC), BMI, the presence of DM, HT and 
CVD (defined as coronary heart disease, stroke, or revascularization) were 
recorded. AO was diagnosed according to the NCEP criteria (WC >102 cm 
for male (M) and >88 cm for female (F).
Results: The prevalence of DM in PL vs. NW was 12.7% vs. 12.9% in M and 
10.8% vs. 8.8% in F (p<0.001), respectively. The prevalence (%) of abnor-
malities in risk factors in diabetic sub-population is shown in the table. . In 
multiple logistic model, age (OR=1.075, 95% C.I. 1.07-1.08, P<0.001), AO 
(OR=1.41, 95% C.I. 1.15-1.73, P<0.001), male gender (OR= 1.60, 95% C.I. 
1.37 - 1.85, P<0.001), DM (OR= 1.70, 95% C.I. 1.4 - 2.06, P<0.001) and HT 
(OR= 3.15, 95% C.I. 2.7 - 3.68, P<0.001) were independent predictors for 
CVD in Poland. The impact of AO, HT and DM on CVD were independent 
of gender (P>0.1 for interaction). DM added to combination of AO and HT 
increased the aged-adjusted probability of CVD (95% C.I) from 41% to 54% 
in M (p<0.001) and from 30% to 42% in F (p<0.001), respectively.
Conclusion: The population profile of cardiovascular risk factors in diabetic 
patients is worse in Poland when compared with North and Western Europe. 
This difference was more striking for women. These results contribute to in-
creased burden of CVD, and require novel intensive preventive strategies in 
Poland.
Table
Male Female
PL n=257) NW (n=1646) PL (n=364) NW (n=1473)
BMI>30 kg/m2 56** 43 59** 51
AO 65 59 85* 80
HT 76 72 77 73
CVD 62** 41 55** 35
*p<0.05; ** p<0.001 vs. NW
Supported by: sanofi-aventis
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Gender differences in the progression of atherosclerosis of carotid and 
coronary arteries using MDCT and carotid ultrasonography 
N. Hashimoto1, T. Haruki1, H. Matsuura1, C. Karasawa1, J. Ogino1, Y. 
Suzuki2; 
1Diabetes, Endocrine, and Metabolic Diseases, Yachiyo Medical Center, 
2Diabetes, and Metabolic Diseases, Asahi General Hospital, Japan.
Background and aims: Cardiovascular disease (CVD) is a leading causes in 
death with type 2 diabetes and it is important to prevent onset of CVD. One 
of the clinical intervention and screening of CVD is multiple detector-row 
computed tomography (MDCT) to detect the progression of atherosclerosis. 
Ultrasonic evaluation of early carotid is also a useful tool for the prediction of 
occurrence of ischemic cerebrovascular events. We are routinely using these 
examinations for early detection of atherosclerotic evaluation and interven-
tion with medical treatment. Here, we tried to clarify the significance of ca-
rotid ultrasonography and MDCT in gender in order to screen the athero-
sclerotic changes.
Materials and methods: A total of 115 patients (men: 74, women: 41) with 
type 2 diabetes attending Yachiyo Medical Center,Tokyo Women’s University 
were studied. Mean patients ages were 64.4 years old for men and 66.8 for 
women. Mean body mass index (BMI) was 24.2±3.4 kg/m2. Ultrasound ex-
amination for carotid intima-media thickness (IMT), max IMT, plaque char-
acter, number (plaques score) and echolucency were used. The plague score 
was calculated by summing the maximum of intima-media complex (plaque 
thickness) measured in millimeters on the near and far walls at each of four 
divisions of both sides of the carotid arteries. Quantification of coronary ar-
tery calcium was examined according to Agaston scores. 
Results: Plaque score in men was 8.03±0.70 and 6.37±0.60 in women and 
there was no significant difference. Calcium score in coronary arteries in men 
was 630.4±156.5, and 157.8±34.6 in women and there was a significant dif-
ference between them (P<0.05). There was a tendency to increase in a ratio of 
calcium score and plaque scores in men compared with in women, but there 
was not significant difference (P=0.06). Not calcium score but plaque score 
was positively significantly correlated with the duration of diabetes (p<0.05). 
Calcium scores were positively correlated with numbers of echorich plaques 
in both men and women (P<0.01) but not with echolucent plaques. Interest-
ingly, significant correlation between calcium score and plaque score was not 
observed in total subjects (r=0.12, P=0.21) and there was no correlation in 
men (r=0.07, P=0.52), but there was strong correlation in women (r=0.389, 
P<0.01).
Conclusion: Carotid ultrasonography is a useful non-invasive screening for 
atherosclerotic evaluation and prediction for coronary and cerebrovascular 
events, but there is a significant correlation between plaque score and calcium 
score in MDCT in women, but not in men. Carotid ultrasonography is pre-
dictive for coronary atherosclerosis in women suggesting that the investiga-
tion of active coronary atherosclerosis examination is necessary regardless of 
severity of carotid ultrasonograhy results in men.
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Screening strategy for asymptomatic coronary heart disease in Japanese 
patients with diabetes mellitus
Y. Kawasaki, S. Honjo, Y. Hamamoto, H. Ikeda, Y. Wada, H. Koshiyama; 
Center for Diabetes and Endocrinology, Kitano Hospital, Osaka, Japan.
Background and aims: Although type 2 diabetes has been indicated to be 
equivalent risk to myocardial infarction in Finnish study, Japanese subjects 
with type 2 diabetes has been indicated to be less frequently associated with 
coronary heart disease (CHD) than Caucasians. In the present study we in-
vestigated screening methods of asymptomatic CHD with type 2 diabetes.
Materials and methods: All patients with type 2 diabetes of our outpatient 
department (OPD) (n=558) were checked with electrocardiography (ECG) 
at rest, and all of inpatients with type 2 diabetes (IN) (n= 573) were checked 
with both ECG at rest and Treadmill tolerance test (TTT). Those with previ-
ous history of CHD or contraindication for TTT were excluded. The OPD 
patients with abnormal ECG findings were investigated with TTT and/or 
thalium 201 cardiac scanning (TCS). Thereafter the subjects (both IN and 
OUT) with abnormal TTT and/or TCS findings were examined with coro-
nary angiography (CAG) in order to make a final diagnosis of CHD.
Results: Among 558 OPD patients, 134 subjects had abnormal ECG at rest, 
and 52 of them received TTT and/or TCS. A total of 4 subjects received CAG 
and all of them were finally indicated to have CHD. Among 573 IN patients, 
a total of 70 had positive TTT, and 61 patients received TCS. Among 61 pa-
tients, a total of 22 (36.1%, ie 3.8 % of total) had positive TCS. There were 
no significant differences of basal clinical parameters between the TCS-posi-
tive group and TCS-negative group, except for female dominance in nega-
tive group.Thirty-seven (52.9%) of TTT-positive patients and 10 (45.5%) of 
TCS-positive patients had one or more of the following; abnormal ECG at 
rest, history of other macroangiopathy, or more than two cardiovascular risk 
factors. Among TCS-positive patients, a total of 14 subjects received CAG, 
and eight of them (ie 57.1%) were finally indicated to have CHD; five cases 
received percutanous coronary intervention (PCI), two cases received coro-
nary bypass surgery (CABG), and the remaining one case was followed with 
medication.
Conclusion: These results suggest that a risk factor-guided screening ap-
proach for asymptomatic CHD may not be sufficiently adequate, at least, in 
Japanese patients with type 2 diabetes.
1249
Diabetic retinopathy is a risk factor for cardiovascular disease in 
Japanese patients with type 2 diabetes. The Otowa Hospital Diabetes 
Observational Study 2 (OHDOS 2)
K. Inoue1, T. Shimada2, H. Koyama1, M. Shigemoto1, K. Doi1; 
1Department of Endocrinology and Metabolism, 2Department of General 
Internal Medicine, Rakuwakai Otowa Hospital, Kyoto, Japan.
Background and aims: Type 2 diabetes is a potent risk factor for cardiovas-
cular disease (CVD). Recently microvascular complications of diabetes are 
increasingly recognized as independent risk factors for CVD. For example, 
there is increasing evidence that nephropathy has strongly and independently 
been associated with the development of CVD. Diabetic retinopathy is also 
increasingly recognized as an independent CVD risk factor, but there is less 
evidence than nephropathy. Therefore, the aims of our study were to further 
explore the relationship of retinopathy with CVD in Japanese patients with 
type 2 diabetes.
Materials and methods: Overall 568 consecutive outpatients with type 2 dia-
betes who came to Rakuwakai Otowa Hospital in Kyoto, which is a teaching 
hospital with 588 beds, in 2003 were studied retrospectively for 6 years or 
until they experienced a cardiovascular event or died. CVD during follow-up 
was defined as myocardial infarction, angina, silent myocardial ischemia and 
stroke. Retinal findings were classified into three categories according to the 
status of the more impaired eye: no retinopathy, nonproliferative retinopathy, 
and proliferative retinopathy. Statistical analysis was performed by Cox pro-
portional hazard model to estimate hazard ratios of retinopathy.
Results: The mean age of 568 patients was 63±12 years. Approximately 38% 
of patients were women (350 men and 218 women). Median duration of 
diabetes were 10.0±9.7 years, and 21% of patients were taking aspirin. The 
mean glycated hemoglobin (HbA1c) was 7.8%. One hundred four patients 
had nonproliferative retinopathy (18.3%) and 69 patients had proliferative 
retinopathy (12.1%). After 6 years follow-up, 102 patients had incident CVD 
(18.0%). Figure 1 shows Kaplan-Meier curves for the cumulative incidences 
of CVD by the grade of retinopathy. After 6 years follow-up, both nonprolif-
erative retinopathy (Cox model hazard ratio [HR], 2.58; 95% confidence in-
terval [CI] 1.58 to 4.20; p<0.001) and proliferative retinopathy (HR 3.59; 95% 
CI 2.00 to 6.44; p<0.001) had increased CVD risks. These associations were 
independent of sex, age, duration of diabetes, history of smoking, LDL cho-
lesterol, HDL cholesterol, chronic kidney disease (CKD), hypertension, and 
history of CVD. In the group of patients with history of CVD, HRs of incident 
CVD were 2.29 (95% CI 1.07 to 4.89; p=0.032) and 3.26 (95% CI 1.39 to 7.64; 
p=0.007) in patients with nonproliferative and proliferative retinopathy. In 
the group of patients without history of CVD, both nonproliferative retin-
opathy (HR 2.98; 95% CI 1.54 to 5.75; p=0.001) and proliferative retinopathy 
(HR 4.00; 95% CI 1.67 to 9.61; p=0.002) had strongly increased CVD risks.
Conclusion: This study shows that Japanese type 2 diabetes patients with 
nonproliferative or proliferative retinopathy had an increased risk for inci-
dent CVD.
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Targeting intensive glycaemic control versus conventional glycaemic 
control in type 2 diabetes mellitus - a meta-analysis of 29,000 patients 
B. Hemmingsen1, S.S. Lund2, C. Gluud1, A.A. Vaag2, T.P. Almdal2, C. 
Hemmingsen1, J. Wetterslev1; 
1Copenhagen Trial Unit, Centre of Clinical Intervention Research, 
Rigshospitalet, 2Steno Diabetes Center, Gentofte, Denmark.
Background and aims: Patients with type 2 diabetes mellitus (T2D) have 
increased mortality primarily due to increased risk of cardiovascular disease 
(CVD). Epidemiological studies suggested an association between elevated 
blood glucose and the development of both micro- and macrovascular com-
plications. However, recent randomised clinical trials (RCTs) have questioned 
the benefit of intensive glucose control. The aim of this systematic review was 
to assess the effects of targeting intensive versus conventional glycaemic con-
trol in patients with T2D.
Materials and methods: RCTs that prespecified different targets of blood 
glucose control in the intervention arms were identified through searches 
of The Cochrane Library, MEDLINE, EMBASE, Science Citation Index Ex-
panded, LILACS and CINAHL. We contacted relevant companies, experts 
and conference proceedings from major diabetes congresses. RCTs in adults 
with T2D irrespective of language and publication status were included. Two 
authors independently extracted data. If needed additional information was 
obtained from authors.
Results: Nineteen RCTs were included, randomising 29,977 patients with 
T2D (16,085 to intensive control, 13,860 to conventional control). The mean 
duration of the intervention varied from 3 days to 12.5 years. The relative risk 
(RR) for the primary outcomes of all-cause mortality (fixed RR 1.00, 95% 
CI 0.93 to 1.08) or CVD mortality (fixed RR 1.05, 95% CI 0.95 to 1.17) was 
not significant. Meta-regression for all-cause mortality showed no significant 
influence of disease duration, HbA1c or fasting blood glucose at baseline. 
However, the risk of all-cause mortality was negatively correlated to duration 
of the intervention (P= 0.08). The risk of CVD mortality was not influenced 
by the variables explored by meta-regression. Intensive glycaemic control 
significantly reduced the risk of non-fatal myocardial infarction (fixed RR 
0.86, 95% CI 0.78 to 0.96; P=0.006) and amputation of lower extremity (fixed 
RR 0.64, 95% CI 0.44 to 0.95; P=0.03). The RRs of non-fatal stroke, cardial 
revascularization and peripheral revascularization were not significant. In-
tensive glycaemic control reduced the risk of all microvascular complications 
(fixed RR 0.85, 95% CI 0.78 to 0.93; P=0.0003), including nephropathy (fixed 
RR 0.80, 95% CI 0.70 to 0.91; P=0.0007) and retinal photocoagulation (fixed 
RR 0.79, 95% CI 0.69 to 0.91; P=0.002). Non-hypoglycaemic serious adverse 
events were more common when targeting intensive glycaemic control (fixed 
RR 1.06, 95% CI 1.02 to 1.11; P=0.003). The risk of severe hypoglycaemia was 
increased when targeting intensive glycaemic control (fixed RR 2.71, 95% CI 
2.42 to 3.02; P<0.00001). The cost-effectiveness of intensive glycaemic control 
was neutral. It was not possible to meta-analyse quality of life.
Conclusion: There is insufficient evidence to determine whether targeting in-
tensive glycaemic control versus conventional glycaemic control reduces all-
cause mortality and CVD mortality. Meta-regression showed negative corre-
lation between duration of the intervention and all-cause mortality. Intensive 
glycaemic control reduces key clinical, including all microvascular outcomes. 
However, conventional glycaemic control reduces the risk of severe hypogly-
caemia and other serious adverse events.
Supported by: CIMT Group
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Differences in the short-term medium-term and long-term outcomes 
between newly diagnosed diabetes patients known diabetic and 
prediabetic patients after an acute coronary syndrome
A. Koutsovasilis1, A. Melidonis1, I. Protopsaltis1, A. Kamaratos1, V. 
Dragoumanos1, A. Charamis1, A. Sereti1, S. Foussas2; 
1Diabetes Center, 2Cardiology Department, Tzaneio General Hospital, 
Piraeus, Greece.
Background and aims: Diabetes is a major contributor to cardiovascular dis-
eases, as well as an independent predictor for adverse outcomes in patients 
after an Acute Coronary Syndrome (ACS). The impact of different categories 
of glucose metabolism on patient outcome after discharge varies according to 
elapsed time after ACS. The aim of this study is to determine the correlation 
of these categories with the incidence of short-term and long-term complica-
tions after an ACS.
Materials and methods: 520 patients mean aged 66.14±11.94 years that 
were admitted to the coronary care unit and discharged were included in 
this longitudinal, prospective, observational, study. The study’s end- points 
were: death (of cardiovascular cause), myocardial infarction, cardiac failure 
(clinical and echocardiographic determination) and unstable angina after 
hospitalization. Short-term was defined at 30 days after discharge, medium-
term at 6 months, and long-term at 12 months. Non-diabetic patients went 
through an Oral Glucose Tolerance Test one month after discharge and IGTs 
were categorized. Adjusted and unadjusted logistic regression analyses were 
carried out in order to find the correlation between the glycemic status of the 
patients and the incidence of complications during the first 30 days and one 
year after their discharge.
Results: Out of the study’s 520 patients, diabetes was previously diagnosed 
(Group A) in 152 (29.2%) patients, newly diagnosed (Group B) in 57 (10.9%) 
patients, and IGT (Group C) was observed in 110 (21.1%) patients while 201 
(38.8%) were patients with normal glucose regulation (Group D). Regard-
ing the patient outcome after the first 30 days following ACS, group B had 
the worst outcome (HR:2.15, 95%CI: 1.109-4.156, p=0.001), followed by 
groups Α (HR:1.87, 95%CI: 1.228-5.231, p=0.003) and C (HR:1.22, 95%CI: 
0.976-2.985, p=0.112) using group D as a reference group after adjustment 
for age, gender, smoking, waist circumference, HDL, triglycerides, total cho-
lesterol, metabolic syndrome (NCEP-ATP III criteria) and hypertension. 
According to patients’ outcome six months after ACS, group A shows the 
worst outcome (HR: 2.05, 95%CI:1.211-5.781, p=0.001) followed by group B 
(HR:1.92, 95%CI:1.149-4.483, p=0.001) and group C(HR:1.23, 95%CI:0.985-
3.244, p=0.109) using group D as reference category. There was no differ-
ence between group A and B (p=0.244). Concerning patient outcome during 
the first 12 months after ACS, group A showed the worst outcome (HR:2.66, 
95%CI:1.234-5.135,p=0.001) followed by groups Β(HR:1.84, 95%CI:1.129-
4.328,p=0.022) and C(HR:1.25, 95%CI: 1.115-3.289,p=0.046) using group D 
as reference group after adjustment to the before mentioned factors.
Conclusion: Newly diagnosed diabetic patients with ACS show a worse 
short-term outcome compared to known diabetic patients due to the fact that 
those patients have diabetes that was neither appropriately recognized nor 
treated before hospitalization. Patients with known diabetes mellitus have a 
worse long-term outcome after ACS compared with newly diagnosed and 
IGT patients, while there are no differences between known and newly diag-
nosed diabetes patients in medium-term outcome.
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Ethnic differences in the prevalence of cardiovascular disease and its risk 
factors in subjects with and without diabetes in Oslo, Norway
A.T. Tran1, A.K. Jenum2, H.E. Meyer3, K.I. Birkeland2, J. Straand1; 
1Section for General Practice and Community Health, Institute of Health 
and Community, University of Oslo, 2The Diabetes Research Center, Aker 
University Hospital, 3Institute of Health and Community, University of Oslo, 
Norway.
Background and aims: The population in Oslo is multiethnic due in large 
part to immigration from Asia and Africa in the last decades. In these ethnic 
minority groups, we have previously reported a high prevalence of diabe-
tes, diabetes was diagnosed at a younger age and the glycaemic control was 
poorer compared to Norwegians. The aim of the present study was to assess 
the prevalence of self-reported diabetes and cardiovascular disease (CVD) 
and its risk factors related to diabetes status in five minority groups compared 
with the Norwegians.
Materials and methods: Data from three population-based health surveys 
conducted in Oslo between 2000 and 2002 were merged. Of 54473 invited 
individuals 24749 (45.4%) participated. Our study was restricted to partici-
pants born in Norway, Turkey, Iran, Sri-Lanka, Pakistan and Vietnam be-
tween 1940 and 1971 (N=18417). Data about self-reported diabetes, CVD 
(coronary heart disease and/or stroke), physical inactivity, body mass index 
(BMI), blood pressure (BP), glucose and lipids for subjects with and without 
diabetes were analyzed. We used country of birth as proxy for ethnicity as 
the minorities in this study are mainly 1. Generation immigrants. Chi-square 
testes, multiple regression and logistic regression were used.
Results: Of the 17854 study subjects with known diabetes status, 562 report-
ed diabetes. Table 1 gives the age, ethnic composition, disease prevalence and 
risk factors of the study population. The prevalence of self-reported diabetes 
varied from 1.9 % (Norwegians) to 13.3% (Pakistanis), p<0.001, and the eth-
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nic minority groups reported more CVD (4.1 to 7.6%) compared to Norwe-
gians (2.9%, p<0.001), despite being younger. Ethnic differences were found 
for most risk factors irrespective of diabetes status. For subjects not report-
ing diabetes, the OR for CVD adjusted for age and gender was higher in all 
the ethnic minority groups (2.6 to 4.1, p<0.001) compared with Norwegians, 
whereas for subjects with diabetes OR for CVD was only significantly higher 
compared to Norwegians for the Vietnamese 4.0 (p=0.01).
Conclusion: All ethnic minority groups reported higher prevalence of dia-
betes and CVD than Norwegians. The excess risk of CVD in ethnic minori-
ties was more profound in subjects not reporting diabetes than in those with 
diabetes, indicating the need to improve primary prevention of CVD in these 
groups.
Table 1. Crude prevalence of self-reported diabetes, CVD and risk factor levels by ethnicity
Norway
(n=13967)
Turkey
(n=548)
Iran
(n=695)
Sri-Lanka
(n=1127)
Pakistan
(n=859)
Vietnam
(n=658)
P
ANOVA
Age,years
Mean
(95% CI)
45.2
(45.0-45.4)
41.5
(40.9-
42.2)
41.6
(41.1-
42.1)
39.6
(39.2-
39.9)
43.3
(42.7-
43.9)
43.2
(42.6-
43.8)
<0.001
Men (%) 44.5 55.3 59.9 60.0 54.2 45.7 <0.001
Self-reported  
diabetes (%)
1.9 6.0 2.4 8.8 13.3 5.8 <0.001
Self-reported  
CVD (%)
2.9 6.4 6.1 4.1 7.6 7.2 <0.001
Systolic blood 
pressure
Mean (mmHg)
Diabetes, yes
Diabetes, no
136.8
128.3
129.7
122.1
125.9
120.3
126.5
121.7
132.2
123.6
123.3
120.3
<0.001
<0.001
Cholesterol/
hdl-cholesterolratio
Mean
Diabetes, yes
Diabetes, no
4.5
4.0
4.9
4.7
4.7
4.5
4.9
4.9
5.1
4.8
4.4
4.1
0.005
<0.001
BMI > 25kg/m2
(%)
Diabetes, yes
Diabetes, no
77.1
49.7
93.9
78.1
82.4
62.2
62.9
57.1
92.0
76.4
55.3
26.9
<0.001
<0.001
Physical inactivity
(%)
Diabetes, yes
Diabetes, no
26.8
21.1
71.4
56.3
71.4
46.3
48.1
53.6
59.1
56.5
43.8
58.1
<0.001
<0.001
Current smoker
(%)
Diabetes, yes
Diabetes, no
25.3
28.9
53.1
39.6
23.5
35.1
11.8
11.9
12.1
21.1
16.2
18.4
<0.001
<0.001
Supported by: The Norwegian Medical Association
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The effect of different glucose values during hospitalisation on one-year 
outcome after an acute coronary syndrome
A. Melidonis1, A. Koutsovasilis1, G. Tsourous1, A. Nikolaou1, I. 
Chrysomallis1, V. Dragoumanos1, S. Iraklianou1, S. Foussas2; 
1Diabetes Center, 2Cardiology Department, Tzaneio General Hospital, 
Piraeus, Greece.
Background and aims: Elevated glucose at the time of hospital admission is 
associated with increased mortality rates among patients hospitalized with 
Acute Coronary Syndrome (ACS). Admission glucose represents only a single 
measurement in time while in-hospital hyperglycemia during the first days 
after admission or during the entire ACS hospitalization period is obtained 
by the use of multiple glucose values. The aim of this study is to evaluate the 
impact of different glucose values (admission, fasting, postprandial, mean 
hospitalization glucose and HbA1c) for these patients’ first-year outcome.
Materials and methods: 520 patients were admitted to the coronary care unit 
and discharged February 2006 - October 2007 were included in this longi-
tudinal, prospective, observational, study. First-year end points were: death 
(of cardiovascular cause), myocardial infarction, cardiac failure (clinical and 
echocardiographic determination) and unstable angina after hospitalization. 
Non-diabetic patients went through an OGTT one month after discharge and 
IGTs were categorized. To evaluate the impact of different glucose measure-
ments on first-year complications after the ACS incidence, separate logistic 
regression models were performed for each measurement. The accuracy of 
these logistic regression models in predicting complications for the predeter-
mined time period was assessed using the Receiver- Operating Characteristic 
(ROC) curves, and their respective areas under the curve (AUC).
Results: Diabetes was previously diagnosed (Group A) in 152 (29.2%) pa-
tients, newly diagnosed (Group B) in 57 (10.9%) patients, an IGT (Group C) 
was observed in 110 (21.1%) patients while 201 (38.8%) were patients with 
normal glucose regulation (Group D). The incidence of one-year complica-
tions was 24.3%, 21.1%, 13.6% and 11.9% in groups A, B, C and D respectively 
(p=0.014). AUC of ROC curves for the probabilities of the logistic regression 
models (adjusted for age, gender, smoking, waist circumference, HDL, trig-
lycerides, total cholesterol, metabolic syndrome (NCEP-ATP III) and hyper-
tension) for the admission glucose was 0.697 (p=0.001) 0.627 (p=0.010) 0.601 
(p=0.022) and 0.578 (p=0.049) for A, B, C and D Group respectively. AUC 
for the fasting glucose was 0.632 (p=0.021), 0.581 (p=0.033) for groups A, B 
respectively. Statistically significant AUC for the postpandial glucose was just 
for Group A [0.611, (p=0.033)] while significant AUC for the mean value of 
the glucose during hospitalization was 0.601 (p=0.026) 0.578 (p=0.036) and 
0.557 (p=0.048) for Groups A, B and C respectively. AUC for the HbA1c was 
0.592 (p=0.033) and 0.522 (p=0.043) for groups A and B respectively, show-
ing no statistical significance as to the outcome of the other two groups.
Conclusion: Admission glucose in ACS incidents shows the most significant 
correlation with first-year end-points even in normoglycemic patients among 
different glucose values during hospitalization. The postprandial glucose is 
related with end-points only in known diabetics while the fasting glucose 
shows a significant correlation only in diabetic patients. Prolonged hypergly-
cemia expressed by mean glucose values during hospitalization affects newly 
diagnosed, known diabetic patients and IGT patients.
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Evidence of diastolic dysfunction in NAFLD: A study using tissue 
Doppler echocardiography
C.K. Wong1, M.I. Burgess1, A. Irwin1, C.J. Pugh2, K. George2, P. Richardson3, 
D.J. Cuthbertson1; 
1Clinical Sciences Centre, University of Liverpool, 2Liverpool John Moores 
University, 3Royal Liverpool and Broadgreen University Hospital Trust, 
United Kingdom.
Background and aims: Non alcoholic fatty liver disease (NAFLD) is consid-
ered the hepatic manifestation of metabolic syndrome and such patients have 
increased risk of cardiovascular events (myocardial infarction, stroke, coro-
nary revascularisation and cardiovascular death). Recent data suggests that 
patients with NAFLD had a hazard ratio of 2 for developing a cardiovascular 
endpoint in 6.5 years. Abnormalities in diastolic function often presage car-
diac disease. Diastolic dysfunction may progress to symptomatic heart failure 
without systolic impairment. The aim of this study is to compare diastolic 
dysfunction in patients with NAFLD compared with age matched controls 
using tissue Doppler echocardiography, a method which can measure dif-
ferential velocities within a region of interest.
Materials and methods: 15 patients with NAFLD and 15 normal controls 
were recruited. The diagnosis of NAFLD was as per local guidelines. Subjects 
underwent transthoracic echocardiography using a GE Vivid Q machine 
(2.5MHz phased array transducer). Colour tissue Doppler loops (3 cardiac 
cycles) in each of the apical 4-chamber, 2-chamber and long axis imaging 
planes were acquired triggered to the ECG and saved digitally for subsequent 
off line analysis by a single experienced operator data who produced the 
strain and strain rate curves using Echopac V9.01 (GE, Horten, Norway).
Results: The control and NAFLD groups were matched for age, BMI and 
systolic blood pressure: 50.8±8.6 vs 48.4±13.2 years, 28.1±5.0 vs 28.1±4.9kg/
m2, 126.4±12.8 vs 128.6±8.8mmHg. Nor was there a significant difference 
in ejection fraction 57.1±12.3 vs 62.4±8.9% or left ventricular mass index 
74.1±14.2 vs 79.8±15.1.E/Ea ratio is significantly elevated in patients with 
NAFLD (table 1). E/Ea ratio is a marker of LA pressure which acts as a sur-
rogate for diastolic dysfunction. Patients with NAFLD showed significant re-
ductions in both diastolic velocities and peak early diastolic strain rate com-
pared with normal controls, supporting the presence of diastolic dysfunction. 
There is also a non significant trend suggesting patients with NAFLD have 
reduced systolic velocity and strain.
Conclusion: These results suggest diastolic dysfunction in patients with 
NAFLD compared with controls. Diastolic dysfunction, left untreated, may 
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progress to heart failure which may explain the excess cardiovascular events 
in this group.
Table 1: Tissue doppler results for the left ventricle
Controls
(n=15)
NAFLD
(n=15)
p
mean sd mean sd
Mean early left ventricular inflow velocity/mean 
early diastolic myocardial velocity at the septum 
(E/Ea)
10.5 2.5 13.0 3.1 0.02
Peak systolic myocardial velocity (cm/s) 6.5 .9 5.8 1.2 0.08
Peak early diastolic myocardial velocity (cm/s) 7.9 2.1 6.3 1.8 0.04
Peak late diastolic myocardial velocity (cm/s) 10.1 1.3 7.2 2.9 0.002
Peak systolic strain (%) 22.9 4.4 20.7 3.3 0.14
Peak systolic strain rate (1/s) 1.4 0.4 1.4 0.3 ns
Peak early diastolic strain rate (1/s) 2.4 0.5 1.8 0.4 0.002
Peak late diastolic strain rate (1/s) 2.0 0.5 1.6 0.4 0.06
Supported by: an EFSD Clinical Research Grant
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Alterations in diastolic function and lipid metabolism occur with the 
onset of overt hyperglycaemia in women with prior gestational diabetes
Y. Winhofer1, M. Krssak2, D. Jankovic1, L. Bozkurt1, G. Reiter3, C. 
Anderwald1, G. Pacini4, S. Trattnig2, A. Luger1, M. Krebs1, A. Kautzky-
Willer1; 
1Department of Internal Medicine III, Medical University of Vienna, 
Austria, 2Department of Radiodiagnostics, Medical University of Vienna, 
Austria, 3Siemens Austria, Vienna, Austria, 4ISIB CNR, Padua, Italy.
Background and aims: Heart failure is still the main cause of death in pa-
tients with type 2 diabetes and especially women with diabetes have an in-
creased cardiovascular risk compared to their male counterparts. Since car-
diac complications are often present at the time of diagnosis of diabetes mel-
litus type 2 the question appeared if alterations in cardiac function are already 
present in prediabetic stages or if the diagnosis of diabetes is often delayed. 
Since women with prior gestational diabetes (pGDM) display a young, female 
population at increased risk for developing type 2 diabetes, the aim of this 
study was to investigate cardiac function via magnetic resonance (MR) imag-
ing in women with pGDM with normal glucose tolerance, impaired glucose 
tolerance and overt type 2 diabetes as well as in women with no history of 
gestational diabetes and normal glucose tolerance (CON).
Materials and methods: 1H magnetic resonance imaging of the myocar-
dium, an oral glucose tolerance test for the assessment of glucose tolerance 
and blood sampling for the measurement of HbA1C and lipid profile were 
performed in 8 pGDM with normal glucose tolerance (NGT), 6 pGDM with 
impaired glucose tolerance (IGT), 12 pGDM with type 2 diabetes (DM) and 
10 women with no history of gestational diabetes and normal glucose toler-
ance during pregnancy (CON), who served as controls. The median follow-
up period since pregnancy was 10 years.
Results: DM showed a significant reduction of the E/A-ratio compared to 
IGT (1.09 vs 1.9; p=0.002) as well as a decreased stroke volume compared to 
all other groups (60.1±14.5 vs 79.47±14.6 ml;p=0.008) and significantly high-
er triglycerides (p=0.03) and lower HDL-values compared to NGT and CON 
(CON:64.8±9.2, NGT:66.4±17.6, IGT:53.5±12.8, DM:46.8±12.0; p=0.0047). 
E/A ratio and stroke volume were inversely correlated with systolic blood 
pressure (R=-0.6; p=0.002), triglycerides (R=-0.5; p=0.003) and HbA1C (R=-
0.5; p=0.001) and positively correlated with HDL (R=0.4; p=0.03). DM were 
older compared to NGT and IGT, but comparable to CON. There was no dif-
ference in BMI between the groups.
Conclusion: According to our results women with overt diabetes are char-
acterized by alterations of diastolic cardiac funtion and lipid metabolism. 
The latter seems to develop at the prediabetic stage. Hence, early detection of 
overt hyperglycemia and dyslipidemia in women at high risk should be the 
primary aim in the prevention of cardiac complications in diabetes mellitus 
type 2.
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Effects of hyperglycaemia and hyperinsulinaemia on cardiac function 
and lipid metabolism: A magnetic resonance spectroscopy and imaging 
study
M. Krebs1, M. Krssak2, D. Jankovic1, C. Anderwald1, G. Reiter3, S. Trattnig4, 
A. Luger1, Y. Winhofer1; 
1Dept.of Internal Medicine III, Medical University of Vienna, Austria, 
2Dept.of Radiodiagnostics, Medical University of Vienna, Austria, 3Siemens 
Austria, Vienna, Austria, 4Medical University of Vienna, Austria.
Background and aims: Diabetic cardiomyopathy is a disease specific entity 
which is present in patients with diabetes even in the absence of coronary 
artery disease and arterial hypertension. The pathophysiology of this disease 
is still unknown. However, recent evidence suggests that increased myocar-
dial lipid accumulation (lipotoxicity) likely contributes to its development. 
Although our recent investigations confirmed increased myocardial lipid 
content in patients with type 2 diabetes, we could not find any evidence for 
cardiac steatosis in prediabetic subjects. Therefore we hypothesized that myo-
cardial lipid accumulation might be linked to overt hyperglycemia .There-
fore the aim of this study was to investigate the impact of hyperglycemia and 
hyperinsulinemia during a 6-h clamp on cardiac function and intramyocel-
lular lipids in vivo by non-invasive magnetic resonance (MR) imaging and 
spectroscopy.
Materials and methods: Hyperglycemic (~ 200 mg/dl, 6h) clamps were per-
formed in 8 healthy subjects (5 males, 3 females; BMI: 22,8±2,9 kg/m²; age: 
29,7±7,2 a). 1H magnetic resonance imaging and breath movement navigated 
and ECG triggered localized 1H single voxel MR spectroscopy (TE= 30ms) 
were used to measure left ventricular dynamic parameters and myocardial 
lipid accumulation in cardiac septum at baseline and after 6 hours of hyper-
glycemia.
Results: During hypertglycemia myocardial lipid content increased by 27,7% 
(p=0.04) and this increase in myocardial lipids was inversely correlated with 
changes in stroke volume (R=-0.82; p=0.02). Furthermore, a small increase in 
ejection fraction (+6.2%; p=0.007) was observed.
Conclusion: Our preliminary results suggest that hyperglycemia induces 
cardiac lipid accumulation in healthy subjects and might lead to impaired 
diastolic myocardial function.
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Are revascularisation procedures in asymptomatic diabetic patients with 
myocardial ischaemia beneficial? A retrospective study
P. Valensi1, M. Nguyen1, K. Takbou1, S. Cattan2, B. Chanu1, I. Banu1, E. 
Cosson1; 
1Department of Endocrinology, Diabetology, Nutrition, Jean Verdier 
Hospital, Bondy, 2Department of Cardiology, Le Raincy Montfermeil 
Hospital, Montfermeil, France.
Background and aims: Screening diabetic patients for silent myocardial 
ischemia (SMI) is controversial but some studies have suggested that revas-
cularization may improve the prognosis of the patients with silent coronary 
artery disease (CAD). The aim was to determine in a retrospective study if 
coronary revascularization may improve the prognosis of patients with silent 
CAD.
Material and methods: Between 1992 and 2008, a total of 787 asymptomatic 
diabetic patients with a normal ECG at rest but with at least another risk fac-
tor were screened for SMI by performing a stress myocardial scintigraphy. In 
the present study we included the 263 patients with SMI (169 men, diabe-
tes duration 14±8 years, nephropathy 45%, hypertension 72%, dyslipidemia 
67%, smoking 29%, other artery disease 14%, family history of premature 
CAD 11%). Coronary angiography was performed in all of them and 93 had 
silent CAD (1-/2-/3-vessel disease: 49/19/17 patients; and 8 patients with an 
unknown number of vessel disease). The incidence of a first cardiac event 
was compared in the patients with SMI but no CAD (group SMI-no CAD, 
n=171) and in those with SMI and CAD with initial coronary revasculariza-
tion (group CAD-revascularization: 29 percutaneous coronary intervention 
(PCI) and 7 coronary artery by pass (CABG)) or without initial revasculari-
zation (group CAD-medical, n=56).
Results: The proportion of men was higher in the CAD-revascularization 
group than in the CAD-medical group (83 vs 54%, p<0.05) with no other 
clinical or biological significant difference at baseline across both groups. Af-
ter a mean follow-up of 5.5±4.2 years, 36 cardiac events occurred: 8 cardiac 
deaths, 23 acute coronary syndromes, 3 secondary coronary revasculariza-
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tions, 1 cardiac failure and 1 ventricular fibrillation. The incidence of events 
differed significantly between the three groups (Kaplan Meier analysis: log 
rank 23.0, p<0.0001). It was the lowest in the SMI-no CAD group, the highest 
in the CAD-medical group and intermediate in the CAD-revascularization 
group. In the patients with 3-vessel disease, the incidence of cardiac events 
was lower in those who were revascularized by CABG than in those who were 
medically treated (log rank 6.5, p<0.05).
Conclusion: The cardiac prognosis is poor in the diabetic patients with silent 
CAD. The data suggest that CABG may improve the prognosis of those with 
3-vessel disease.
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The role of soluble ST2 in diabetic patients with preserved left 
ventricular systolic function and the parameters that influence its value
E. Fousteris1, A. Koutsovasilis2, A. Theodosis Georgilas3, S. Matsagos4, G. 
Dimitriadis5, A. Melidonis2; 
1First Clinic of Internal Medicine, Tzanio General Hospital, Piraeus, 
2Diabetes Center, Tzanio General Hospital, Piraeus, 3Cardiology 
Department, Tzanio General Hospital, Piraeus, 4Blood Bank service, Tzanio 
General Hospital, Piraeus, 52nd Department of Internal Medicine, Research 
Institute and Diabetes Center, University of Athens, Medical School, Greece.
Background and aims: Soluble ST2 is a member of the IL-1R receptor fam-
ily and it has been used in several studies as a sensitive biomarker of cardiac 
failure. This biomarker has never been studied before in diabetic population, 
compared to healthy controls. The aim of this study was to find any possible 
differences of the value of sST2 among diabetic and non diabetic subjects 
with preserved LV systolic function. The second aim was the revelation of 
any other biological parameters of diabetic patients that impact on the value 
of sST2.
Materials and methods: We recruited 106 subjects, 36 healthy and 70 diabetic 
volunteers that underwent extensive ultrasonographic check of their cardiac 
function, using the latest revised guidelines of ACC/AHA. All subjects that 
had an ejection fraction < 50% were excluded. Exclusion criteria were also 
subjects with history of active malignancy and/or chemotherapy, chronic use 
of corticosteroids or thiazolinediones and history of autoimmune diseases. 
We measured all the classical biomarkers (where as blood count, biochemis-
try, lipidemic profile, hs CRP, Fibrinogen, BNP) and the sST2 with the ELISA 
technique by using the PresageTM ST2 assay kit by Critical Diagnostics.
Results: Mean age of the total 106 subjects were at 56,45 ± 9,19 years, without 
any differences between the 2 groups. No difference was observed also at the 
sex distribution in the groups. The mean value of sST2 in group A (non dia-
betic controls) was 9,76 ± 5,21, statistically significant lesser than the 13,48 ± 
5,75 of group B (diabetic patients) (p=0,017). There was no significant differ-
ence on the BNP levels among the 2 groups (group A: 26,08 ± 13,10, group B: 
31,36 ± 31,85, p=0,507). Similarly, no statistically significant difference was 
noticed on the values of hsCRP, Fibrinogen, estimated GFR. In the analysis of 
all the population, it seems that sST2 value is affected by fasting glucose level 
(r=0,360, p=0.034), HbA1C (r=0.389, p=0.023) and HDL (r=0.304, p=0.048). 
The multivariable analysis accrues that HbA1C is an independent correlation 
factor to the sST2 (β=0.186, p=0.045).
Conclusion: No study until now has focused on the role of sSt2 on diabetic 
people. In our study we showed that diabetic people with preserved LV systo-
lic function have higher levels of sST2 compared to non diabetic controls. 
This value seems to be affected by the level of glycemic control (HbA1c), fast-
ing glucose and H.D.L. Further research needs to be done to uncover the 
underlying pathophysiological mechanisms.
Supported by: H.N.D.C.
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The impact of smoking cessation on metabolic factors in newly 
diagnosed patients with type 2 diabetes: a one-year prospective study
C. Voulgari, C. Stathi, A. Kokkinos, K. Makrilakis, N. Katsilambros, N. 
Tentolouris; 
First Department of Propaedeutic and Internal Medicine, Laiko Hospital, 
Athens, Greece.
Background and aims: Smoking is an independent risk factor for cardiovas-
cular morbidity and mortality. Patients with type 2 diabetes-mellitus (T2DM) 
are at increased risk for cardiovascular events and smoking cessation is a pri-
ority for the prevention of macrovascular and microvascular complications. 
In the present prospective study we evaluated the impact of smoking cessa-
tion on glycaemic control and metabolic factors in subjects with newly-diag-
nosed T2DM.
Materials and methods: We recruited 193 smokers (96 male/97 female: 
age 57±7.8 years) with newly-diagnosed T2DM, without macrovascular 
complications, who were educated to smoking cessation, diet and exercise. 
A detailed history of smoking habits (years-frequency of smoking, types of 
tobacco used) was obtained. All subjects were contacted by phone every 2-
weeks in the first 2-months and monthly thereafter with emphasis on smok-
ing cessation. Ankle-brachial-pressure index (ABI) was measured by ultra-
sonography. Demographic, biochemical parameters, insulin-resistance and 
albumin-excretion-rate (AER) were measured at baseline and 1 year after 
smoking cessation.
Results: At baseline, smoking habit was associated significantly with younger 
age [OR, 95% C.I. 1.86 (1.79-1.94)], female gender [1.19 (1.04-1.96)], higher 
BMI [1.85 (1.73-2.00)], systolic-blood-pressure (SBP) [1.02 (1.00-1.05)], 
HbA1c [1.97 (1.05-1.99)] and insulin-resistance [1.62 (1.03-2.54)], dysli-
pidemia (low HDL-cholesterol and/or high triglyceride levels and /or high 
LDL-cholesterol) [1.96 (1.94-1.99)], higher AER [1.62 (1.00-1.90)] and lower 
ABI [0.005 (0.00-0.85)]. Marital status was associated with lower odds [0.09 
(0.01-0.68)] whereas a higher education level with higher odds of smoking 
[3.80 (1.02-4.15)]. At the end of the 12-month period, 62.2% (n=120) of the 
studied population reported successful cessation. Pharmacological interven-
tions for hyperglycaemia, dyslipidaemia and blood-pressure control were not 
different between the studied groups. Towards baseline, after adjustment for 
dietary-factors and exercise-level, smoking cessation had the highest contri-
bution in the reduction of HbA1c [0.116 (0.081-0.158], insulin-resistance 
[0.184 (0.03-0.35)], dyslipidaemia [0.94 (0.82-0.99)], SBP [0.34 (0.32-0.43], 
AER [0.50 (0.23-0.72)] and increased ABI [0.001 (0.00-0.15)]. No significant 
differences were found between patients who continued smoking and those 
who quitted regarding BMI and waist-circumference. Microalbuminuria was 
reduced by 38% in subjects quitting smoking and by 16% in those who con-
tinued smoking (P<0.001).
Conclusion: Smoking cessation strategies are effective in subjects with 
T2DM. Smoking cessation improves glycaemic control and lipid profile and 
reduces blood-pressure and microalbuminuria. Stricter counselling and in-
terventions for quitting smoking are warranted in patients with T2DM for the 
prevention of microvascular and macrovascular complications.
1260
Achievement of specified lipid and hs-CRP levels with ezetimibe/
simvastatin vs atorvastatin in metabolic syndrome patients with and 
without atherosclerotic vascular disease
J. Rosen1, J. Robinson2, H.-H. Parving3, C. Ballantyne4, S. Grundy5, W. 
Hsueh6, J. Lin7, A. Shah7, M.E. Hanson8, A.M. Teshakovec8; 
1Clinical Research of South Florida, Coral Gables, USA, 2Departments of 
Epidemiology & Medicine, University of Iowa, Iowa City, USA, 3University 
Hospital of Copenhagen, Denmark, 4Baylor College of Medicine and 
Methodist DeBakey Heart and Vascular Center, Houston, USA, 5University 
of Texas Southwestern Medical Center, Dallas, USA, 6Diabetes Research 
Center, The Methodist Hospital Research Institute, Houston, USA, 7Merck & 
Co, Inc, Rahway, USA, 8Merck & Co, Inc, North Wales, USA.
Background and aims: Atherosclerotic vascular disease (AVD) and meta-
bolic syndrome (MetS) are each associated with an increased risk of CHD. In-
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tensive treatment of modifiable factors associated with AVD and MetS, such 
as dyslipidemia, is recommended by treatment guidelines, including achieve-
ment of specific LDL-C, non-HDL-C and Apo B levels. The aim of this post 
hoc analysis was to assess the proportion of patients with and without AVD 
treated with ezetimibe/simvastatin combination therapy versus atorvastatin 
reaching specified lipid and hs-CRP levels.
Materials and methods: Adult patients (N=1143) with MetS and hypercho-
lesterolemia were randomized to ezetimibe/simvastatin combination tablet 
10/20 or 10/40 mg or atorvastatin 10, 20, or 40 mg for 6 weeks. Prespecified 
dose comparisons were ezetimibe/simvastatin 10/20 mg vs atorvastatin 10 
mg or 20 mg and ezetimibe/simvastatin 10/40 mg vs atorvastatin 40 mg.
Results: The rates and ratios of the predictive odds of achieving specified lev-
els and 95% confidence intervals are presented in the table. Significantly more 
patients without AVD achieved the single LDL-C, non-HDL-C and Apo B 
levels and the combination of these three levels with ezetimibe/simvastatin 
vs atorvastatin for the specified dose comparisons, except in the ezetimibe/
simvastatin 40 mg vs atorvastatin 40 mg dose comparison. Significantly more 
patients with AVD achieved the single LDL-C and non-HDL-C levels and the 
combined triple levels with ezetimibe simvastatin vs atorvastatin at all dose 
comparisons, and the single Apo B level only with the ezetimibe/simvastatin 
10/20 mg vs atorvastatin 10 mg comparison. In both subgroups achievement 
of hs-CRP<2.0 mg/L was similar with both treatments at all dose compari-
sons.
Conclusions: Compared with atorvastatin at prespecified dose comparisons, 
treatment with ezetimibe/simvastatin combination resulted in significantly 
more MetS patients with or without AVD achieving most of the specified 
lipid levels and the combined lipid endpoints. Clinical benefit from reduction 
in cardiovascular outcomes through treatment with ezetimibe/simvastatin or 
through hs-CRP lowering has not been proven.
Table 
Patients  
without AVD*
LDL-C<100 
mg/dL
non-HDL-C 
<130 mg/dL
Apo B<90 
mg/dL
Triple 
target†
hs-CRP<2.0 
mg/L
E/S 20 vs A 10
OR‡ (95% CI)
90% vs 70%
3.76  
(1.99, 7.12)
87% vs 63%
4.00  
(2.23, 7.18)
65% vs 41%
2.72  
(1.70, 4.35)
65% vs 41%
2.64  
(1.65, 4.22)
46% vs 40%
1.31  
(0.82, 2.07)
E/S 20 vs A 20
OR‡ (95% CI)
90% vs 76%
2.76 (1.44, 
5.28)
87% vs 73%
2.50 (1.38,  
4.55)
65% vs 49%
1.98 (1.25, 
3.15)
65% vs 49%
1.92 (1.21, 
3.06)
46% vs 39%
1.33 (0.84, 
2.11)
E/S 40 vs A 40
OR‡ (95% CI)
92% vs 86%
2.00 (0.95, 
4.20)
90% vs 84%
1.74 (0.87, 3.45)
75% vs 66%
1.49 (0.91, 
2.44)
75% vs 66%
1.53 (0.94, 
2.51)
42% vs 44%
0.92 (0.59, 
1.44)
Patients with 
AVD*
LDL-C<70 
mg/dL
non-HDL-C 
<100 mg/dL
Apo B<80 
mg/dL
Triple 
target§
hs-CRP<2.0 
mg/L
E/S 20 vs A 10
OR‡ (95% CI)
65% vs 39%
2.87 (1.43, 
5.78)
65% vs 39%
2.87 (1.43, 5.78)
53% vs 29%
2.74 (1.33, 
5.64)
50% vs 24%
3.13 (1.49, 
6.61)
49% vs 52%
0.89 (0.45, 
1.75)
E/S 20 vs A 20
OR‡ (95% CI)
65% vs 39%
2.88 (1.41, 
5.89)
65% vs 41%
2.68 (1.32, 5.47)
53% vs 41%
1.59 (0.79, 
3.21)
50% vs 28%
2.62 (1.25, 
5.51)
49% vs 39%
1.46 (0.72, 
2.98)
E/S 40 vs A 40
OR‡ (95% CI)
79% vs 46%
4.33 (1.97, 
9.52)
80% vs 49%
4.21 (1.89, 9.40)
63% vs 48%
1.90 (0.92, 
3.91)
63% vs 40%
2.63 (1.27, 
5.44)
45% vs 41%
1.16 (0.57, 
2.38)
A=atorvastatin; Apo=apolipoprotein; AVD=atherosclerotic vascular disease; CI=confidence 
interval; E/S=ezetimibe/simvastatin; hs-CRP=high sensitivity C-reactive protein; LDL-
C=low-density lipoprotein cholesterol; non-HDL-C=non-high-density lipoprotein choles-
terol; OR=odds ratio.
*Treatment comparisons are based on the logistic model with terms for treatment only
†LDL-C<100 and non-HDL-C<130 and Apo B<90 mg/dL
‡The ratio of the predictive odds of achieving the specified goal on E/S vs the comparison dose 
of A
§LDL-C<70 and non-HDL-C<100 and Apo B<80 mg/dL
Supported by: Merck & Co, Inc.
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Statin therapy and serum transaminases among patients with type 2 
diabetes and hepatitis C
E.D. Rusu1, G. Radulian2, F. Rusu1, V. Stoica2, M. Jinga2, A.D. Dragomir3,  
G. Enache3, D. Cheta4; 
1Healthy Nutrition Foundation, 2University of Medicine Carol Davila, 
3Nutrition, diabetes, Healthy Nutrition Foundation, 4Nutrition, diabetes, 
National Institute of Diabetes Nutrition and Metabolic Diseases, Bucharest, 
Romania.
Background and aims: Statins are the most efficacious drugs for decreas-
ing low-density lipoprotein cholesterol levels; they reduce both primary and 
secondary cardiovascular risk in the general population. The objective of this 
study was to determine the effect of statin therapy (atorvastatin) on serum 
aspartataminotransferase and alaninaminotransferese levels in patient with 
type 2 diabetes (T2DM) and hepatitis C. However, less is known about the 
safety of statin use in patients with liver disease.
Materials and methods: We selected 64 patients with type 2 diabetes mel-
litus and chronic hepatitis C who are treated with atorvastatin, 20 mg for 
6 month. We evaluated body weight, blood pressure, liver enzymes, lipids, 
adipocytokines (adiponectin, leptin, resistin, TNFalfa, IL-6), insulin resist-
ance (by Homeostasis model assessment - HOMA-IR) at baseline, 1 and 6 
months. The liver fibrosis was non-invasively assessed using the Forns index; 
a value < 4.2 excludes liver fibrosis and a value > 6.9 is a predictor for signifi-
cant fibrosis.
Results: Plasma triglycerides and cholesterol decreased (p<0.05), HDL-cho-
lesterol and HOMA-IR increased (p<0.05), after 6 months. Aspartatami-
notransferase and alaninaminotransferese increased but we did not find sig-
nificant statistically differences (median increased was 15.6 U/L for ALT and 
7.2 U/L for AST). Forns index decreased at 6 months (p=0.048). Atorvastatin 
treatment had no effect on plasma adiponectin (p=0.569) but we observed re-
ducing of leptin and resistin level (p=0.032 respectively p=0.0048). TNFalpha 
and IL-6 decreased but not significant statistically.
Conclusion: Among patients with hepatic C no significant elevation of liver 
enzymes during statin treatment was observed. Statin therapy should not be 
stopped or contraindicated in this patient population; however, more pro-
spective clinical trials are needed to confirm the safety and efficacy.
Supported by: Romanian National Authority for Scientific Research
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Effect of nicotinic acid on combined hyperlipidaemia: A kinetic study on 
reverse cholesterol transport in humans
M. Krempf, Y.  Zair, M. Chetiveau, L. Flet, T. Magot, K. Ouguerram; 
Clinique d’endocrinologie, Institut du Thorax, Nantes, France.
Nicotinic acid improves the combined dyslipidemia frequently observed in 
patients with type 2 diabetes or metabolic syndrome. The highest treatment 
increase of HDL-C is observed with this drug but the underlying mechanisms 
are unclear. The aim of this study was to give further insights on the effect 
of nicotinic acid in humans by using a new dual stable isotope technique to 
estimate the cholesterol transport and metabolism in HDL and other lipopro-
teins. We recruited 8 patients with combined hyperlipidemia submitted to 8 
week treatment with LAR nicotinic acid (2 g/d) associated with aspirin (300 
mg/d). The patients were submitted before and at the end of the treatment to 
a dual infusion of 2H3 leucine and 13C2 acetate. The tracer/trace ratio was 
analyzed by mass spectrometry in Apo B100, Apo AI and cholesterol (free and 
esterified) in VLDL, IDL, LDL and HDL. The compartmental model to ana-
lyze the data was developed on SAAM II. With LAR nicotinic acid triglycer-
ides declined (2.21±0.67 vs 1.19±0.62, p<0.05) as total cholesterol (2.15±0.47 
vs 1.80±0.38, p<0.05) and LDL-C (1.28±0.45 vs 1.03±0.29, p<0.05) while 
HDL-C increased (0.41± 0.13 vs 0.49±0.10, p<0.05). There was no change on 
hepatic ApoB100-VLDL production but conversion rate of ApoB100-VLDL 
to ApoB100-LDL increased (0.091±0.039 h-1 vs 0.123h-1 ±0.039, p<0.05). 
There was no significant change on ApoAI-HDL kinetics. An increase of 
free cholesterol esterification was observed within HDL ( 0.13±0.045h-1 vs 
0.23±0.13h-1, p<0,05)and an increase of esterified cholesterol catabolism in 
HDL ( 0.049± 0.014 vs 0.074± 0.036 mg.kg-1. h-1, p<0,09)associated with a 
decrease of esterified cholesterol transfer to VLDL and LDL( 0.45± 0.11 vs 
0.32± 0.14 h-1, p<0,05) through CETP. We concluded that LAR nicotinic acid 
decreased triglycerides by increasing vascular lipolysis and increased reverse 
cholesterol transport by increasing cholesterol esterification and catabolism 
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within HDL. The increase oh plasma HDL-C is mainly related to a decrease 
(30 %) of CETP cholesterol transfer.
Supported by: GSK
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Study of apparent aspirin resistance in 100 consecutive patients with type 
2 diabetes in primary cardiovascular prevention
A. Decaudain1, S. Legal1, C. Baralon1, N. Lamrache1, S. Charriere1, L. 
Groisne1, M. Hanss2, M. Moulsma3, P. Moulin4; 
1Endocrinology, cv hospital, Lyon Bron, 2hemostasis, GHE, Lyon Bron, 
3Biochemistry, HEH, Lyon, 4Endocrinology, HCL/univ Lyon1, Lyon Bron, 
France.
Background and aims: Occurrence of aspirin resistance in type 2 diabetes 
(D2) is controversial. It has been considered as a cardiovascular risk factor 
whatever the underlying mechanism. However it is difficult to distinguish 
authentic platelet resistance to the inhibitory effect of acetyl salicylic acid 
from non compliance. The aim of this study was to establish the prevalence of 
aspirin resistance in type 2 diabetic patients in primary cardiovascular pre-
vention, submitted to multiple therapies and consequently more likely to be 
inobservant.
Materials and methods: 100 consecutive aspirin treated D2 patients in pri-
mary cardiovascular prevention were included in an observational prospec-
tive mono centric study. Patients were 65±8 years old, had D2 for 16±8 years, 
HbA1c = 7.7±1.1%, and were treated by low dose of aspirin (75 - 325 mg /d, 
mean 120±6 mg/d). Platelet aggregation was assessed by arachidonic acid 
(0.5 mg/ml) on platelet rich plasma. Normal platelet function was established 
in 55 D2 patients not treated by aspirin (CTRL), (57±11 years old, D2 for 
11±7 years, HbA1c 7.6±1.2%). Blood was drawn in the fasting state, in the 
morning, before any treatment administration.
Results: Mean aggregation level in CTRL D2 was 81.3±13.7%. 83% of D2 
patients treated by low dose of aspirin had an aggregation level below 60%, 
cut off corresponding to the lowest aggregation level found in CTRL D2. All 
these aspirin sensitive D2 patients had an aggregation level lower than 25% 
(mean 6.3±7.9%). In univariate analysis, no criteria (age, sex, duration of 
diabetes, micro-angiopathic complications, smoking, number of pills taken 
daily¼ ) was associated with the occurrence of unaltered aggregation func-
tion under aspirin treatment. In the 17 D2 patients with apparent resistance, 
6 (35%) admitted to have omitted to take aspirin the day before assessment of 
platelet function. In the 11 remaining patients, 6 were tested again after giv-
ing special advice to take aspirin the day before. Platelet aggregation level was 
found below 25% in all these patients upon this second test.
Conclusion: In the present study, 17% of D2 patients in primary cardiovas-
cular prevention had an apparent aspirin resistance. However the second test 
showing the expected platelet aggregation inhibition suggests that non com-
pliance plays a major role in the occurrence of apparent resistance to aspirin.
Supported by: HCL
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Metformin use among patients with type 2 diabetes and renal 
impairment 
S.X. Sun1, M. Bron1, R. Spanheimer2, S. Hudgens1, R. Ramalakar1, A. Hariri2; 
1Takeda Pharmaceuticals International, Inc., Deerfield, 2Takeda 
Pharmaceuticals North America, Inc., Deerfield, LYON BRON.
Background and aims: The most prescribed oral antidiabetic medication for 
treating type 2 diabetes (T2D), metformin is contraindicated in T2D patients 
with renal impairment due to risk of lactic acidosis.
Materials and methods: Metformin use among T2D patients with renal im-
pairment was examined with a retrospective analysis of the I3 Innovus da-
tabase from May 1, 2000 to December 31, 2008. T2D patients (ICD-9 codes 
250.x0 or 250.x2) with renal impairment (serum creatinine concentration 
≥1.5 mg/mL in males and ≥1.4 mg/mL in females) were identified. Stage 
of chronic kidney disease (CKD) was based on estimated glomerular filtra-
tion rate (eGFR), calculated from serum creatinine, age and gender (using 
MDRD formula). The index date was the same or later diagnosis date of 
T2D or CKD. The baseline period was 6 months prior to index date, and 
the follow-up period was 12 months after index date. Patients were 18 years 
or older and had at least one serum creatinine value and at least one claim 
for antidiabetic medications during the study period. Patients with type 1 
diabetes were excluded.
Results: After applying all inclusion and exclusion criteria to 1.7 million T2D 
patients, a total of 1,985 patients were identified with CKD and T2D; the ma-
jority (76%) had stage 3 CKD (table). Mean age was 61 years, and two-thirds 
were male. In the follow-up period after diagnosis of T2D and renal impair-
ment, 666 (34%) were prescribed metformin. Metformin use was highest 
in CKD stage 2, followed by stages 3 and 5 (table). Patients <65 years more 
often received metformin than those ≥65 years (37% vs. 27%, p<0.0001). 
Metformin use between female (34%) and male patients (33%) was similar 
(p=0.8175).
Conclusion: Metformin was maintained in T2D patients with varying de-
grees of renal impairment including severe kidney disease and kidney failure 
despite contraindications for use. Further studies are needed to investigate 
risk of lactic acidosis and glycemic control in this at-risk population.
Table: 
Stages of CKD Group 1: Patients with CKD and T2D (n=1,985)
Group 2: Patients in Group 1 on 
metformin [34% (666/1,985)]
2 mild
(eGFR 60-89) 12% (235) 46% (108/235)
3 moderate
(eGFR 30-59) 76% (1,517) 35% (525/1,517)
4 severe
(eGFR 15-29) 9% (179) 9% (17/179)
5 renal failure
(eGFR < 15) 3% (54) 30% (16/54)
Supported by: TPNA, Inc.
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Pioglitazone in addition to metformin improves erythrocyte 
deformability in patients with type 2 diabetes mellitus. Results from the 
PIOfix study
S. Forst1, M. Löbig1, U. Lehmann2, C. Hohberg1, C. Friedrich1, W. Fuchs2, A. 
Pfützner1, T. Forst1; 
1Institute for Clinical Research and Development, Mainz, 2Medical 
Department, Takeda Pharma, Aachen, Germany.
Background and aims: Changes in hemorheology and blood viscosity were 
shown to contribute to the development of micro- and macrovascular com-
plications. In patients with diabetes mellitus, increased hematocrit levels and 
reduced erythrocyte deformability are considered to impair microvascular 
blood flow and to reduce tissue oxygenation. In recent studies, treatment with 
pioglitazone was shown to improve endothelial function and to improve the 
overall risk for vascular complications in patients with type 2 diabetes mel-
litus. The aim of this study was to compare the effect of adding pioglitazone or 
glimepiride to metformin treatment on erythrocyte deformability in patients 
with type 2 diabetes mellitus (T2DM).
Materials and methods: This two arm, parallel study, covered 23 metformin 
treated T2DM patients (16 male, age: 57.2±10.7 years; BMI 32.7±4.3 kg/m²) 
with an HbA1c above 6.5%. Patients were randomized to receive either 15 
mg Pioglitazone (PIO) bid. or 1 mg Glimepiride (GLIM) bid. in combination 
with 850 mg Metformin bid. for 6 months. Blood samples were taken for the 
measurement of fasting glucose, HbA1c, fasting insulin, intact proinsulin, 
adiponectin, and heamatocrit (Hct). In addition, the erythrocyte elongation 
index (EI) was measured using laserdiffractoscopy (Rheodyn SSD, Myrenne 
GmbH, Roetgen, Germany) at a shear stress range from 0.3 Pa to 60 Pa.
Results: Both treatments significantly improved HbA1c levels (PIO -
0.9±0.8%; GLIM -0.6±0.4%; p<0.05 respectively) and end up in comparable 
HbA1c levels after 6 months (PIO 6.5 ± 1.2; GLIM 6.2 ± 0.4) Treatment with 
PIO reduced fasting insulin (-8.2±15.1 mU/L; p=0.097), and intact proinsulin 
levels (-11.3±9.2 pmol/L; p<0.05), and increased adiponectin levels (8.1±4.6 
µg/mL; p<0.05). Hkt slightly decreased during PIO treatment (-1.3±2.3%; 
p=0.09). No significant changes in these parameters could be observed dur-
ing GLIM treatment. As shown table 1, PIO improved the EI, resulting in a 
significant improvement at all physiological shear stress ranges (0.6 to 6.0 
PA). At a physiological shear stress rate of 1.2 Pa, the improvement in EI 
correlated with the increase in adiponectin levels (r=0.74; p<0.0001), and in-
versely with intact proinsulin levels (r=-0.47; p<0.05).
Conclusion: This is the first study showing an improvement in erythrocyte 
flexibility during treatment with pioglitazone which was correlated to an 
increase in adiponectin and a decrease in intact proinsulin levels, but inde-
pendent from glycaemic control.
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Change in erythrcyte elongation index (EI; * p<0.05 vs baseline; $ p<0.05 PIO vs. GLIM)
Shear stress  
(PA)
0.30 0.60 1.20 3.00 6.00 12.00 30.00 60.00
GLIM (EI) -0.4± 1.7 -0.5±1.1* -1.1±2.5* -1.5±3.1 -2.1±3.8 -1.3±2.9* -1.3±3.5 -1.3±3.9
PIO (EI) 1.3±2.1 2.4±1.3*,$ 3.2±2.2*,$ 3.3±2.8*,$ 3.1±2.9*,$2.7±2.8$ 2.5±2.6 2.7±2.6
Supported by: Takeda Pharma
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Examination of the cardiovascular safety of pramlintide with a meta-
analysis of five controlled clinical trials in patients with type 2 diabetes 
mellitus
S. Chen, C. Burns, K. Shan, H. Dong, K. Herrmann, S. Miller, I. 
Yushmanova; 
Amylin Pharmaceuticals, Inc., San Diego, USA.
Background and aims: Pramlintide was approved by the US FDA in 2005 
as an adjunctive treatment for patients with diabetes who use mealtime in-
sulin with or without oral antihyperglycaemic drugs who have not achieved 
desired glucose control. The FDA recently issued guidance on the type of 
evidence required to demonstrate that a new type 2 diabetes therapy is not as-
sociated with unacceptable cardiovascular risk. In the absence of guidance for 
currently marketed antidiabetic therapies, the cardiovascular risk of pramlin-
tide was examined following the guidance for new therapies.
Materials and methods: Analysis of an integrated database of 5 randomised 
controlled type 2 diabetes trials (16 to 52 weeks) compared relative risk (RR) 
and hazard ratio (HR) of cardiovascular events with pramlintide vs a pooled 
comparator treated with either placebo or rapid-acting insulin. Background 
therapies included at least one type of insulin and in some cases oral antidi-
abetic agents. The primary endpoint was primary major adverse cardiovascu-
lar events (MACE) including cardiovascular mortality, myocardial infarction, 
stroke, acute coronary syndrome hospitalisation, and urgent revascularisa-
tion procedures. Subset MACE analysis used narrower criteria including 
only cardiovascular mortality, myocardial infarction, and stroke, while SMQ 
MACE included all Standardised MedDRA Query terms for these events. The 
broader secondary endpoint included the primary endpoint terms plus ar-
rhythmia, heart failure, and mechanical-related events.
Results: The population included 1434 pramlintide and 582 pooled compa-
rator subjects treated for a total of 960 and 359 patient-years, respectively. 
Demographics were comparable between groups (mean age 56-57 y, 52-54% 
M, BMI 32-33 kg/m2, HbA1c 9.0-9.1%). RRs and HRs between pramlintide 
and pooled comparator ranged from 0.86 to 1.11, depending on the endpoint 
and analysis method used. Corresponding 95% upper CI limits were below or 
close to the FDA-specified 1.8 threshold, suggesting no unacceptable increase 
in cardiovascular risk.
Primary MACE Subset MACE SMQ MACE Secondary CV
Ratio (95% CI) Ratio (95% CI) Ratio (95% CI) Ratio (95% CI)
RR (Mantel-
Haenszel)
0.86 (0.55, 1.34) 0.90 (0.46, 1.76) 1.10 (0.62, 1.96) 1.03 (0.74, 1.43)
HR (Cox) 0.88 (0.56, 1.38) 0.92 (0.47, 1.78) 1.11 (0.62, 1.99) 1.05 (0.74, 1.49)
HR (An-
dersen-Gill)
0.93 (0.62, 1.38) 0.95 (0.50, 1.81) 1.10 (0.64, 1.86) 0.92 (0.69, 1.21)
In addition, study of postmarketing reports has not revealed evidence of a 
signal for cardiovascular risk.
Conclusion: Based on these analyses, there appears to be no increased risk of 
cardiovascular adverse events associated with pramlintide treatment. How-
ever, interpretation of this type of analysis has the following caveats: these 
trials were not designed to assess cardiovascular outcomes, events were adju-
dicated retrospectively after unblinding, the number of cardiovascular events 
was small, and the duration of the trials was ≤52 weeks.
Supported by: Amylin Pharmaceuticals, Inc. and Eli Lilly & Co.
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Therapeutic effects of a selective estrogen receptor modulator (SERM) on 
bone and lipid metabolism in postmenopausal type 2 diabetic patients
H. Mori, Y. Okada, Y. Tanaka; 
The First Department of internal medicine, School of Medicine, University 
of Occupational and Environmental Health, Kitakyusyu, Japan.
Background and aims: Diabetic patients are at risk of bone fracture due to 
poor bone quality, despite the preservation of bone mineral density, therefore 
management should include control of osteoporosis and vascular events as 
well as blood glucose. Raloxifene, a selective estrogen receptor modulator, 
prevents bone mass reduction and vertebral bone fractures in postmenopau-
sal women, improves bone quality and prevents atherosclerosis and breast 
cancer. We investigated its effects on not only bone but also lipid, and glucose 
metabolism in postmenopausal patients with type 2 diabetes.
Materials and methods: Subjects were 144 female patients with type 2 di-
abetes who were younger than 80 years and have been menopausal for at 
least 2 year. The study was a randomized trial and subjects were assigned to 
one of 3 groups: No medication; 1 μg alfacalcidol daily; or 60 mg raloxifene 
daily. Outcomes were measured at baseline and at 6 and 12 months, including 
serum N-telopeptide (NTx), bone-specific alkaline phosphatase (BAP), ho-
mocysteine, TC, HDL-C, LDL-C, TG, HbA1c, fasting blood glucose, insulin, 
and HOMA-R. The primary outcome of the study was changes in LDL-C at 
6 months and secondary outcome was serum NTx, BAP, homocysteine, and 
HbA1c at 6 and 12 months.
Results: Glucose metabolism was unchanged in all 3 groups. Regarding bone 
metabolism, both NTx and BAP were reduced at 6 months and further re-
duced at 12 months in the treatment groups (alfacalcidol group, p=0.001; 
raloxifene group, p=0.000, compared with baseline). These effects were most 
remarkable in the raloxifene group. Concerning lipid metabolism, LDL-C at 
6 months, a major evaluation item, was significantly reduced in the raloxifene 
group only (p=0.029). Thus, this study meets the primary outcome by the 
treatment with raloxifen. HDL-C was elevated in the alfacalcidol group 
(p=0.007) whereas TG tended to decrease in the raloxifene group. Homo-
cysteine, a bone quality marker, was significantly reduced in the raloxifene 
group at both time-points (p=0.001). There was no correlation between the 
rate of improvement of LDL-C and changes in markers of bone metabolism 
or of bone quality. Multivariate analysis identified TC, HDL-C, and the per-
cent change of TG, but not markers of bone metabolism or quality, as signifi-
cant determinants of the raloxifene-induced change in LDL-C.
Conclusion: Raloxifene improved lipid metabolism, especially significantly 
reduced LDL-C at 6 months after the treatment, and reduced homocysteine 
in postmenopausal type 2 diabetic patients. It has been suggested that this 
agent could improve defective crosslinks related to bone quality. In type 2 
diabetic patients, poor bone quality is linked to increased risk of bone frac-
ture. Since raloxifene improves bone quality as well as lipid metabolism, it is 
considered useful for all-round health care of postmenopausal type 2 diabetic 
patients.
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Effects of early detection and intensive treatment on peripheral arterial 
disease - ADDITION Denmark 
M. Charles1, D.R. Witte2, N. Ejskjaer3, K. Borch-Johnsen2, T. Lauritzen1, A. 
Sandbaek1; 
1Dept of General Practice, School of Public Health, Aarhus, 2Steno Diabetes 
Center, Gentofte, 3Dept of Endocrinology, Aarhus University Hospital, 
Denmark.
Background: Peripheral arterial disease (PAD) is a marker of systemic 
atherosclerotic disease and an independent risk factor for foot ulcers and am-
putations. Measurement of ankle brachial index (ABI) is widely used in the 
diagnosis of PAD. People with diabetes have an increased risk of developing 
PAD. Prevalence among diabetic individuals aged over 50 years is estimated 
to be 29%. Evidence exists on treatment of these patients but there is no evi-
dence on treatment or prevention of PAD in people with screen detected dia-
betes. Our aim was to study the effect of intensive multifactorial treatment 
and routine care on PAD in persons with screen detected diabetes in a cluster 
randomized controlled study.
Methods: We recruited 466 individuals with screen-detected diabetes identi-
fied through a screening programme in 87 general practices in the Danish 
arm of the ADDITION Study. Practices were randomized to intensive treat-
ment (IT) or routine care (RC) before initiation of the screening programme. 
Individuals in the IT practices (45 practices) received a multi-factorial treat-
ment programme including lifestyle advice (concerning diet, physical activ-
ity, medication adherence, and smoking cessation), prescription of aspirin 
and stepwise increases in pharmacological treatment of blood pressure, glu-
cose and lipids according to strict targets. The RC group (42 practices) were 
offered treatment according to national guidelines. Anthropometric meas-
ures and blood samples were collected at baseline and at five year follow-up. 
At follow-up ABI was measured according to a standardized protocol. ABI 
was calculated using the highest blood pressure in each foot divided by the 
highest blood pressure in either arm. An ABI of <0.9 in either leg was consid-
ered “abnormal”. A Χ² test was used to assess the hypothesis of no difference 
in prevalence of PAD between the IT and RC group at follow-up. Logistic 
regression, accounting for the cluster design, was used to calculate the odds 
of ABI<0.9 in the IT compared to the RC group.
Results: Baseline characteristics are shown in Table 1. The IT group had a 
prevalence of abnormal ABI in either leg of 7% (4; 10) compared to 9% (4; 
13) in the RC group (p=0.43). The odds ratio of ABI<0.9 in IT compared to 
RC was 0.76 (0.38; 1.52), p=0.43.
Conclusion: The prevalence of PAD 5 years after a screen-detected diagnosis 
of diabetes was lower in the Danish arm of the ADDITION trial compared 
to cohorts of people with known diabetes. This could indicate that screening 
for diabetes identifies people at an earlier stage in the trajectory of PAD and/
or that general diabetes prevention and treatment has improved significantly 
over the past decade. We did not find that intensive multi-factorial treatment 
in general practice led to a significant reduction in the prevalence of PAD 
compared to routine care as recommended by national guidelines.
Table 1 - Baseline Characteristics
Routine Intensive
No. of Patients 171 295
Male 57.9% 56.7%
Age (yr) 59.0 (7.0) 59.3 (6.6)
HbA1c 6.4 (1.1) 6.4 (1.4)
Systolic BP (mmHg) 145.1 (17.6) 144.4 (18.5)
Body Mass Index 30.4 (5.43) 30.3 (5.12)
Waist (cm) 103.1 (13.9) 103.3 (13.0)
Total Cholesterol (mmol/l) 5.82 (1.19) 5.64 (1.10)
HDL (mmol/l) 1.37 (0.32) 1.38 (0.37)
Triglycerides 1.7 (1.3) 1.6 (1.0)
Smoking Current 33.7% 31.3%
Supported by: DCSR, DRFGP, DCEHTA, AURF, NNF, NBH, DMRC, DDA, 
APMoller, BMKT, CINE, DCN
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The association between long term glycaemia and arterial stiffness is 
detectable with HbA1c but not advanced glycation end-products in 
people with diabetes risk. The ADDITION-PRO study
N.B. Johansen1, S.S.S. Rasmussen2, N. Wiinberg3, D. Vistisen1, D.R. Witte1; 
1Steno Diabetes Center A/S, Gentofte, 2Department of Endocrinology, 
Hvidovre University Hospital, 3Department of Clinical Physiology, 
Frederiksberg Hospital, Denmark.
Background and aims: Increased arterial stiffness is one of the initial steps in 
the development of atherosclerosis. Long term exposure to hyperglycaemia 
is associated with arterial stiffness. Glycated proteins such as haemoglobin 
(HbA1c) and advanced glycation end-products (AGE) reflect glycaemia dur-
ing a longer period. HbA1c is the frequently used assessment of long term 
exposure to glycaemia and is known to be associated with arterial stiffness. 
However, it is unknown whether the non-invasive assessment of AGE can 
detect the same association. We aimed to study how strongly HbA1c and AGE 
are associated with arterial stiffness in a population at high diabetes risk.
Materials and methods: A Danish population at high diabetes risk originally 
identified through a stepwise screening programme was invited for a health 
examination in 2009 including assessments of HbA1c and AGE by non-inva-
sive skin autofluorescence. Plasma lipids, blood pressure, height, weight, and 
carotid-femoral pulse wave velocity (PWV) as an assessment of arterial stiff-
ness were measured. Information of antidiabetic treatment and smoking was 
self-reported. Individuals on antidiabetic medication were excluded in the 
analysis. The effect of HbA1c and AGE on PWV was assessed through linear 
regression models adjusted for age, sex, and pulse pressure, and furthermore 
adjusted for BMI, smoking, HDL cholesterol, and triglycerides. The standard-
ized regression coefficients were compared.
Results: 378 individuals (mean age 66.2 years (SD: 6.2), 57% men, mean BMI 
27.7 kg/m2 (SD: 4.4), mean HbA1c 5.9% (SD: 0.4), mean AGE 2.25 arbitrary 
units (SD:0.52)) are included in the analysis. HbA1c was associated with PWV 
in the model adjusted for age, sex and pulse pressure (Table 1). This associa-
tion remained significant after further adjustments. AGE was not associated 
with PWV at a statistically significant level.
Conclusion: Among individuals at high diabetes risk HbA1c but not AGE 
measured by a non-invasive method is associated with arterial stiffness. These 
differences in associations could be explained by the high risk population, 
and that HbA1c reflects a shorter period of glycaemia than AGE. The other 
explanation could be that HbA1c is a more precise measurement of long term 
glycaemia than AGE measured by skin autofluorescence.
Supported by: an EFSD/Pfizer grant, the Danish Strategic Research Fund and 
Steno Diabetes Center
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Increased chemerin levels are associated with peripheral arterial 
occlusive disease and increased urinary albumin excretion rate in type 2 
diabetic patients
F. Hoellerl1, J.M. Brix1, G.-H. Schernthaner2, G. Schernthaner1; 
1Department of Medicine I, Rudolfstiftung Hospital, Vienna, 2Department 
of Medicine II, Medical University Vienna, Austria.
Background and aims: Chemerin is a recently discovered adipokine that 
regulates adipocyte differentiation and modulates chemotaxis and activation 
of dendritic cells and macrophages. Chemerin was found to be associated 
with obesity, insulin resistance and the metabolic syndrome. In addition, re-
cent studies have demonstrated that chemerin has angiogenetic properties. 
Given the convergence of adipocyte and macrophage function, chemerin 
may provide an interesting link between obesity, inflammation and athero-
sclerosis in humans. Thus, the aim of our study was to determine whether 
S 502 Diabetologia (2010) 53:[Suppl1]S1–S556
1 C
serum chemerin levels are associated with vascular disease and urinary albu-
min excretion rate in type 2 diabetic patients.
Materials and methods: Serum Chemerin levels were determined in 128 pa-
tients with Type 2 diabetes mellitus (T2DM) and different levels of albuminu-
ria (54 with normoalbuminuria (NA), 45 with microalbuminuria and 29 with 
macroalbuminuria (MA)) as well as in 28 healthy control subjects (CO). 
Mean Age of the patients was 66±11 years and mean duration of diabetes was 
13±8 years. Chemerin was measured by an ELISA (BioVendor, Heidelberg, 
Germany). Within the T2DM patients 32 patients had a history of peripheral 
arterial occlusive disease (PAOD), 26 with coronary heart disease, 11 with 
stroke and 57 with any cardiovascular disease (CVD).
Results: Circulating Chemerin levels are significantly elevated in diabetic 
patients compared to CO (240.7±77.5 vs 175.6±46.5 ng/ml, p<0.001). In 
the diabetic patients, serum chemerin levels are significantly associated 
with urinary albumin excretion rate (UAE, mg/24h; p=0.001). The highest 
chemerin levels were observed in patients presenting with MA (290.9±84.5 
vs 223.1±53.9 ng/ml in NA, p<0.001). In univariate regression analysis of 
all quantitative variables chemerin was significantly associated with BMI 
(p=0.009), HbA1c (p=0.019), creatinine (p<0.001), estimated glomerular fil-
tration rate (p=0.002), age (p<0.001) and UAE (p=0.001). The multivariate 
model revealed UAE (β=0.341, p=0.001), age (β=0.229, p=0.029) and BMI 
(β=0.231, p=0.028) as predictors of chemerin.Chemerin levels were signifi-
cantly higher in patients with PAOD versus those without PAOD (264.6±74.9 
vs. 217.0±72.5 ng/ml, p=0.002) and in those with any CVD vs those without 
(255.3±71.6 vs. 208.0±70.5 ng/ml, p<0.001), but did not differ between pa-
tients with or without history of myocardial infarction and stroke.
Conclusion: These are the first findings demonstrating that chemerin levels 
are significantly increased in T2DM patients presenting with PAOD, the most 
advanced vascular disease in diabetic patients, but not in those with a history 
of myocardial infarction or stroke. The strong relationship between chemerin 
and urinary albumin excretion rate could be of clinical relevance in particular 
since proangiogenic properties were recently found for this adipokine.
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Severe peripheral arterial obstructive disease predicts cardiovascular 
events in type 2 diabetes mellitus: Is there a gender difference?
K. Bonomo, M. Chirio, M. Secchi, P. Poy, A. Pagliarino, M. Trovati, F.L. 
Cavalot; 
Dept of Clinical and Biological Sciences, Faculty of Medicine San Luigi 
Gonzaga, University of Turin, Orbassano (TO), Italy.
Background and aims: Peripheral Arterial Obstructive Disease (PAOD) 
predicts cardiovascular (CV) events both in the general and in the diabetic 
population: aim of the present study is to evaluate whether this predictive 
power is different in men and women affected by Type 2 diabetes mellitus 
(T2DM).
Materials and methods: We examined all Type 2 diabetic patients submitted 
to revascularization procedures (mainly percutaneous angioplasty) because 
of severe PAOD at our Unit from 1997 to 2009: 50 women and 87 men (iden-
tified as “Cases”). Each of them was associated with a control subject matched 
for gender, age, diabetes duration and lengths of follow-up at our Unit, but 
without PAOD (identified as “Controls”). In Cases and Controls, we evalu-
ated: a)CV risk factors at the entry in the study (i.e., in Cases at the time of 
revascularization procedure and in Controls at a corresponding time period); 
b)the first fatal or non fatal coronary or cerebral vascular event and total and 
CV mortality during the follow-up. By Cox analysis, we calculated the Haz-
ard Ratios (HR) for the first CV event, CV and total mortality.
Results: In Cases, women differed from men for age (73.8+7.5 vs 69.4+8.8 
years, p< 0.0001) and diabetes duration (21.7+11.8 vs 16.4+10.0 years, 
p<0.0001); similarly in Controls (age 73.7+8.3 vs 69.6+8.3 years, p<0.0001, 
diabetes duration 21.4+11.8 vs 16.1+10.3 years, p<0.0001). Smoking habit 
(actual or previous) was present in 41.4% of men Controls vs 88.5% of men 
Cases and in 4% of women Controls vs 44% of women Cases. CV events 
occurred in 16/50 (32%) women Cases vs 7/50 (14%) women Controls, and 
in 33/87 (37.9%) men Cases vs 18/87 (20.7%) men Controls. CV mortality 
occurred in 16/50 (32%) women Cases vs 6/50 (12%) women Controls and 
in 26/87 (29.9%) men Cases vs 10/87 (11.5%) men Controls. Total mortality 
occurred in 23/50 (46%) women Cases vs 10/50 (20%) women Controls, and 
in 34/87 (39.1%) men Cases vs 17/87 (19.5%) men Controls. HR (and C.I.) of 
Cases vs Controls corrected for smoking habit were: a)for CV events, 3.177 
(1.126-8.967, p=0.029) in women and 3.505 (1.666-7.373, p=0.001) in men; 
b)for CV mortality, 3.261 (1.169-9.094, p=0.024) in women and 3.303 (1.281-
8.521, p=0.013) in men; c)for total mortality, 3.122 (1.352-7.210, p=0.008) 
in women and 2.818 (1.301-6.105, p=0.009) in men. After correction for 
HbA1c, serum creatinine, LDL-cholesterol, HDL-cholesterol, triglycerides 
and smoking habit, HR for CV events were 7.71 (2.101-28.289, p=0.002) in 
women and 3.513 (1.423-8.676, p=0.006) in men. HR conferred by male vs 
female gender adjusted for age, diabetes duration and smoking habit were: a) 
for CV events, 3.565 (1.222-10.403, p=0.020) in Controls and 0.867 (0.439-
1.710) in Cases; b) for CV mortality, 3.752 (0.912-15.40, p=0.067) in Controls 
and 0.932 (0.448-1.939) in Cases; c) for total mortality, 3.080 (1.050-9.033, 
p=0.040) in Controls and 0.961 (0.501-1.843) in Cases.
Conclusion: In T2DM, PAOD requiring revascularization affects women at 
a more advanced age and after a longer diabetes duration: women are thus 
partly protected from this complication. However, when severe PAOD oc-
curs, it completely effaces the CV protection conferred by female gender also 
in T2DM and predicts CV events, CV and total mortality with a comparable 
strength in the two genders.
Supported by: Regione Piemonte Research Grant
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The association between serum osteoprotegerin levels with lower 
extremity arterial calcification in patients with type 2 diabetes mellitus
I. Eleftheriadou1, P. Grigoropoulou1, V. Argiana1, I. Balla1, A. Kokkinos1, D. 
Perrea2, N. Katsilambros1, N. Tentolouris1; 
1First Department of Propaedeutic and Internal Medicine, Laiko General 
Hospital, 2Laboratory of Experimental Surgery and Surgical Research, 
Athens University Medical School, Greece.
Background and aims: Increased OPG levels have been found in diabetic 
patients with micro- and macrovascular complications. Recent studies have 
shown that serum osteoprotegerin (OPG) concentrations correlate with coro-
nary artery calcification in patients with type 2 diabetes mellitus (T2DM). 
Lower extremity arterial calcification (LEAC) is common diabetes. However, 
no data exists on the association between serum OPG concentrations with 
LEAC in patients with T2DM. The aim of this study was to look for potential 
association between serum OPG levels and LEAC in patients with T2DM.
Materials and methods: A total of 74 patients (148 feet) with T2DM were 
recruited (mean age 67.8±9.0 years, duration of diabetes 15.3±10.9 years). In 
all patients radiographs were taken of both feet and ankles. LEAC was graded 
in a scale from 0-5 at 4 locations (posterior tibial and dorsalis pedis arteries 
bilaterally) as 0: absent; 1: barely visible; 2: slightly visible; 3: specific outline; 
4: very dense equal to or lower than 2 cm; 5: very dense greater than 2 cm. 
The total LEAC score (0-20) at all 4 locations was calculated. Serum OPG 
levels were measured using ELISA. Diagnosis of peripheral arterial disease 
(PAD) was based on the presence of either biphasic, monophasic or blunted 
waveforms at the posterior tibial artery, while diagnosis of PN on neuropathy 
symptom score (NSS), neuropathy disability score (NDS) and vibration per-
ception threshold (VPT).
Results: Patients with PAD (n=36) had significantly higher serum OPG 
levels in comparison with those without PAD (18.9±5.9 vs 14.2±3.9 pmol/
l, p<0.001). Patients with PN (n=34) had also higher OPG levels than pa-
tients without PN (17.8±6.2 vs 14.9±4.0 pmol/l, p=0.021). Patients without 
or with less LEAC (grade 0-2 based on the maximum LEAC grade at one 
out of 4 locations; n=44) had lower OPG levels compared with patients 
with more severe LEAC (grade 3-5; n=30) (14.99±4.4 vs 18.61±6.0 pmol/l, 
p<0.001). The total LEAC score was significantly associated with age (r=0.23, 
p=0.011), pulse pressure (r=0.41, p<0.001), glomerular filtration rate (r= -
0.20, p= 0.026), albumin-to-creatinine ratio (r=0.36, p<0.001), VPT (r=0.26, 
p=0.002), serum OPG levels (r= 0.25, p=0.004) and there was a trend for as-
sociation with diabetes duration (r=0.17, p=0.055). The association between 
the total LEAC score and OPG concentrations remained significant after ad-
justment for age (p=0.035), GFR (p=0.021), diabetes duration (p=0.009) and 
PN status (p=0.003).
Conclusion: Serum OPG levels are increased in diabetic patients with PAD 
and are associated with severity of LEAC.
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Urinary D-lactate levels are increased in type 2 diabetic patients and are 
inversely associated with ankle arm index: The CODAM study
N.M.J. Hanssen1, J. Scheijen1, M.S. Huijberts1, I. Ferreira2,  
M.M.J. van Greevenbroek1, C.J.H. van der Kallen1, E.E. Blaak3,  
E.J.M. Feskens4, C.D.A. Stehouwer1, C.G. Schalkwijk1; 
1Internal medicine, Cardiovascular Research Institute Maastricht (CARIM), 
Maastricht University Medical Centre (MUMC), 2Internal medicine/ 
Clinical Epidemiology and Medical Technology Assessment, Cardiovascular 
Research Institute Maastricht (CARIM), Maastricht University Medical 
Centre (MUMC), 3Human biology, Maastricht University, 4Division of 
human nutrition, Wageningen University, Netherlands.
Background and aims: Diabetes is associated with increased incidence of pe-
ripheral arterial disease (PAD) and its complications (ulcers, cardiovascular 
mortality). Intracellular glycosylation is increased in diabetes and is linked 
to vascular complications and may thus be involved in the increased risk for 
PAD in diabetes. Methylglyoxal is the key precursor for intracellular glyco-
sylations. The glyoxalase pathway catalyzes the conversion of methylglyoxal 
to D-lactate. The aim of the present study was to investigate, first, whether 
urinary D-lactate, possibly a reflection of methylglyoxal, is increased in type 
2 diabetes; second, whether D-lactate levels are associated with the presence 
of PAD; and third, whether this association is explained by intracellular hy-
perglycaemia.
Materials and methods: We investigated 510 (192 women, mean age: 
59.5±7.0) participants of the Cohort on Diabetes and Atherosclerosis (CO-
DAM) study with normal glucose metabolism (NGM; n=269), impaired glu-
cose metabolism (IGM; n=114) and type 2 diabetes (DM2; n=127). Urinary 
D-lactate levels were measured with UPLC-MSMS and corrected for urine 
creatinine levels. Severity of PAD was determined by the ankle arm index 
(AAIx). We used linear regression analyses to investigate the association be-
tween D-lactate and AAIx, first with adjustments for sex, age and smoking 
and then for other risk factors (i.e. HDL, triglycerides, eGFR, mean arterial 
pressure and body mass index). We next determined whether the association 
could be explained by intracellular hyperglycaemia by further adjustment for 
HbA1c.
Results: We developed a new method for the detection of D-lactate with 
UPLC-MSMS with intra- and interassay coefficients of variation of 2.6% 
(n=10) and 5.6% (n=10) respectively. Median and interquartile range of 
D-lactate levels were 0.65 (0.34-1.39), 0.78 (0.37-1.51) and 1.39 (0.55-3.89) 
μmol/mmol creatinine for NGM, IGM and DM respectively (p for trend 
<0.001). AAIx decreased by 0.016 (95%CI: -0.027 to -0.005, p=0.005) per each 
standard deviation increase in D-lactate in analyses adjusted for age, sex and 
smoking, and by 0.014 (-0.020 to -0.003), p=0.013 after adjustments for other 
risk factors. After additional adjustment for HbA1c, this association was at-
tenuated by 40%: to -0.010 (-0.022 to 0.001), p=0.077.
Conclusion: We found that higher urinary D-lactate, as a marker of intra-
cellular methylglyoxal levels, is associated with PAD (as reflected by lower 
AAIx) in the CODAM study. This association was independent of potential 
confounders and other risk factors but could at least partially (40%) be ex-
plained by HbA1c, a marker for intracellular hyperglycaemia. Our results 
suggest that intracellular glycation may play an important role in the devel-
opment of PAD.
Supported by: CTMM, NHS, DDRF, DKF, PREDICCT. Dr Ferreira is supported 
by NHS 
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Evaluation and comparison of stroke neurological scales regarding long-
term outcome of ischaemic stroke in diabetic patients
V. Dragoumanos1, D. Athanasopoulos1, A. Koutsovasilis1, G. Konstantinou1, 
S. Tsiaglis2, D. Vrana2, A. Melidonis1; 
1Diabetes Center, 21st Internal Medicine Clinic, Tzaneio General Hospital, 
Piraeus, Greece.
Background and aims: Neurological impairment scales are frequently used 
to determine the neurological status of patients suffered ischemic stroke 
(IS). Stroke scales owe to be able to describe in detail the severity of neuro-
logical deficits and predict functional outcomes. The most common neuro-
logical impairment scales are: the National Institutes of Health Stroke Scale 
(NIHSS), the Orpington Prognostic Scale (OPS) and the Scandinavian Stroke 
Scale (SSS). The purpose of the present study is to evaluate and compare of 
NIHSS, OSS and SSS to the end points of (IS) - explicitly new stroke or death 
- in diabetic patients.
Materials and methods: We studied 212 diabetic patients [80(37.7%) men 
and 132(62.3%) women], 74.9±6 (SD) years old suffered IS. Acute stroke was 
defined according to World Health Organization criteria. The diagnosis of 
ischemic stroke was established by neurological examination and confirmed 
by computed tomography. Baseline neurological examination developed ac-
cordingly to NIHSS, OPS and SSS at admission to the hospital. End point 
was considered new incidence of stroke or death during one year. Evalua-
tion of the linear relationship between NIHSS, OPS and SSS was calculated 
using Spearman’s rank correlation coefficient. Logistic regression analysis 
models were conducted to investigate how accurate the neurological scales 
predict end points. The goodness of fit of the models was tested by Hosmer 
and Lemeshow Test and by Omnibus Test. Statistically significant values were 
considered for p<0.05.
Results: After 12 months 48(22.6%) diabetic patients [8(3.8%) men and 
40(18.9%) women] have had new stroke or died. Analysis using Spearman’s 
rank correlation coefficient indicates a statistically significant linear relation-
ship between NIHSS and OPS (r=0.93, p<0.001). For these data mean±(SD) 
for NIHSS is 14.85±8.82 and for OPS 3.62±1.22. There was also significant 
correlation between NIHSS and SSS using Spearman’s rank correlation coef-
ficient (r=-0.88, p<0.001). For these data mean±(SD) for NIHSS is 14.85±8.82 
and for SSS 35.26±12.2. OPS and SSS were also strongly correlated (r=-
0.85, p<0.001). For these data mean±(SD) for OPS is 3.62±1.22 and for SSS 
35.26±12.2. At logistic regression model baseline NHISS (RR=0.69 95% CI: 
0.56-0.85, p=0.001) and SSS (RR=0.780 95% CI: 0.69-0.87, p<0.001) were sig-
nificant predictors of new stroke or death, but OPS (RR=4.08 95% CI: 0.92-
18.06, p=0.064) was not related to the end-points of IS in one year. For every 
one point increase in NIHSS, the relative risk of new stroke or death in dia-
betic patients increased by a factor of 0.69, while for every one point decrease 
in SSS, such risk increased by a factor of 0.78.
Conclusion: Neurological stroke scales can be used to predict likelihood of 
outcome in diabetic patients that suffered IS. NHISS, OPS and SSS are strong-
ly correlated and a lot of the standardized assessments of each scale are com-
parable to each other. Baseline NIHSS and SSS are significant predictors of 
new stroke or death in diabetic patients in one year. SSS has a slightly higher 
prognostic capacity compared with NIHSS in diabetic patients. Further stud-
ies in larger population may reveal more interesting conclusions.
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Impact of different glycaemic indices during hospitalisation on long-
term outcome of diabetic patients after an ischaemic stroke
D. Athanasopoulos1, V. Dragoumanos1, A. Koutsovasilis1, G. 
Giannikopoulos1, E. Loizos2, D. Vrana2, A. Melidonis1; 
1Diabetes Center, 21st Internal Medicine Clinic, Tzaneio General Hospital, 
Piraeus, Greece.
Background and aims: Diabetes is well recognized as a major risk factor for 
the development of stroke. It doubles the risk of ischemic stroke (IS) and 
worsens survival of patients with acute stroke. Hyperglycemia is prevalent in 
the early phase of acute ischemic stroke and is associated with worse neuro-
logical outcome and increased stroke mortality. The purpose of the present 
study is to assess the significance of a selection of admission and during 
hospitalization glycemic indices in the prediction of neurological outcome 
among diabetic patients that suffered IS.
Materials and methods: We studied 212 diabetic patients [80(37.7%) men 
132(62.3%) women], 74.9±6 (SD) years old suffered IS for one year period 
time. Acute stroke was defined according to World Health Organization cri-
teria. The diagnosis of ischemic stroke was established by neurological ex-
amination and confirmed by computed tomography. Neurological examina-
tion was developed according to the National Institute of Health Stroke Scale 
(NIHSS). Improvement of neurological outcome was considered a modifica-
tion of equal or less than 4 points in NIHSS. Adjusted and unadjusted logistic 
regression analyses was conducted to investigate how accurate improvement 
in neurological outcome can be predicted by admission plasma glucose con-
centration (APG), fasting plasma glucose concentration (FPG), postprandial 
plasma glucose concentration (PPG), glucose spikes (GS), glycosylated he-
moglobin (HbA1c) and diabetes duration in years for discharge, 3 months, 6 
months and 12 months period time.
Results: At discharge neurological improvement observed on 32(15,1%) 
men and 44(20.8%) women [total 76(35.8%)], at 3 months 48(22.6%) 
men and 56(26.4%) women [total 104(49.1%)], at 6 months 72(34%) men 
and 76(35.8%) women [total 148(69.8%)] and at 12 months 72(34%) men 
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and 80(37.7%) women [total 152(71.7%)]. At discharge diabetes duration 
(OR=0.93 95% CI: 0.89-0.98, p=0.005) was significant predictor of outcome 
but APG, FPG, PPG, GS and HbA1c were not significant to functional out-
come. At 3 months significant prediction of outcome was made by diabe-
tes duration (OR=0.91 95% CI: 0.86-0.96, p=0.001) and HbA1c (OR =2.72, 
95% CI: 1.27-5.83, p=0.01). At 6th month significant predictors of aggrava-
tion were diabetes duration (OR=1.08 95% CI: 1.01-1.15, p=0.012) and APG 
(OR=1.01 95%CI: 1.00-1.03, p=0.039). At 12th month APG (OR=1.01 95% 
CI: 1.00-1.03, p=0.018) and HbA1c (OR=1.76 95% CI: 1.06-2.91, p=0.027) 
predicted significantly the outcome.
Conclusion: Hyperglycemia worsens the neurological outcome of IS in dia-
betic patients. Each glycemic index corresponds to a significant predicting 
factor in different time period. Diabetes duration in addition to its recent 
prior regulation as expressed by HbA1c contribute critically to prognosis of 
IS in diabetic patients. Long diabetes duration predicts negative outcome of 
IS at discharge, 3rd and 6th month. HbA1c is a significant predictor of neuro-
logical outcome at 3 and 12 months. APG appears to have an important effect 
on the prognosis of IS at 6th and 12th month.
PS 127 Complications in type 1 
diabetes
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Macrovascular complications may be associated with tighter glycaemic 
control in patients with type 1 diabetes: An analysis of primary care data 
in the UK
E.J. Edson1, T.K. Le1, D.R. Nelson1, D. Haldane1, A.B. Mendelsohn2, S. 
Pillemer2, B.H. Curtis1; 
1Global Health Outcomes, Eli Lilly and Company, Indianapolis, 2Clinical 
Research, Macrogenics, Inc., Rockville, USA.
Background and aims: The Diabetes Control and Complications Trial 
(DCCT) and follow-on Epidemiology of Diabetes Interventions and Com-
plications Study (EDIC) conducted in the US and Canada demonstrated 
beneficial effects of tight glycemic control on the micro- and macrovascular 
complications of type 1 diabetes mellitus (T1DM) in a randomised control-
led clinical trial setting. However, the outcomes of intensive glycemic con-
trol in clinical practice are not known. We conducted the present study to 
1) identify and describe a cohort of patients with T1DM from the General 
Practice Research Database (GPRD) and 2) compare cumulative rates of mi-
cro- and macrovascular complications, based on the degree of HbA1c control 
achieved within 10 years of diagnosis.
Materials and methods: Data were derived from GPRD that collects data 
from medical practices within the UK. Logistic regression was used to create 
pairwise propensity scores between three groups of patients: tightly controlled 
(TC=HbA1c ≤6.5%); reasonably controlled (RC= HbA1c >6.5 and ≤7.5%); 
poorly controlled (PC=HbA1c >7.5%). Analyses of clinical endpoints utilized 
logistic regression with independent variables of propensity score quintiles, 
pairwise comparison of the HbA1c control group, and interaction of those 
two. Adjusted event rates were based on logistic regression models with all 
three groups included. Endpoints included microvascular complications (e.g. 
diabetic retinopathy, nephropathy) and macrovascular/cardiovascular (CV) 
events (e.g. myocardial infarction, ischemic heart disease, stroke). Endpoints 
were determined by diagnosis codes within the GPRD.
Results: The average age of study patients (N= 1086) at baseline was 25.8 
(SD: 16.0) years; 60% male. Microvascular complications did not differ sig-
nificantly between groups, although numerically the RC group demonstrated 
lower adjusted rates when compared to both the TC and PC groups (Table 1). 
There were no significant differences in macrovascular/CV events between 
either TC or PC patients when compared to RC, however a significant differ-
ence was noted after propensity score adjustment in the TC group compared 
to the PC group (OR=3.13; 95% CI, 1.39-7.14; p=0.006).
Conclusion: Using data from routine medical practice, we found, in contrast 
with the DCCT/EDIC results, no significant microvascular or CV benefit 
in T1DM patients treated intensively to control blood glucose versus those 
treated conventionally. Additionally, we observed increased macrovascu-
lar/CV events in TC versus PC patients. In light of results from recent high 
profile trials in type 2 diabetes mellitus which suggest increased mortality 
related to intensive glycemic control and its inherent risk of hypoglycemia, 
additional investigation of this association is warranted in T1DM patients.
Table 1: Microvascular Complications and Macrovascular/CV Events by Glycemic Control 
Groups
Microvascular Complications Macrovascular/CV Events
TC vs. RC PC vs. RC TC vs. PC TC vs. RC PC vs. RC TC vs. PC
Odds Ratio 
(95% CIs) 
p-value
2.0  
(0.75-5.26) 
p=0.17
1.72  
(0.97-3.07) 
p=0.07
1.05
(0.53-2.13) 
p=0.88
2.08
(0.79-5.56) 
p=0.14
0.58  
(0.29-0.13)  
p=0.11
3.13
(1.39-7.14) 
p=0.006
Adjusted 
Rates
16.9% /  
9.6%
16.4% /  
9.6%
16.9% /  
16.4%
6.1% /  
2.4%
2.7% /  
2.4%
6.1% / 2.7%
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Tei Index identifies the early phase of left ventricular dysfunction in 
young patients with long-lasting type 1 diabetes mellitus and preserved 
systolic function
K. Kurnicka, B. Lichodziejewska, D. Liszewska-Pfejfer, A. Lipinska, M. 
Ciurzynski, K. Grudzka, P. Pruszczyk; 
Internal Medicine and Cardiology, Medical University of Warsaw, Poland.
Background and aims: The Tei Index (TI) is an easily obtained and reproduc-
ible Doppler parameter which reflects combined left ventricular (LV) systolic 
and diastolic function. Increased values of TI were found in patients with 
dilated cardiomyopathy and myocardial infarction and were proved to be an 
independent prognostic factor for higher mortality. The clinical usefulness of 
TI for young patients with type 1 diabetes mellitus (DM1) has not yet been 
fully studied. The aim of our study was an echocardiographic assessment of 
LV global function in patients with long-lasting DM 1, below 45 years of age, 
treated with intensive insulin therapy.
Materials and methods: The study group (DM): 100 pts (51F, 49M), mean 
age 30,0 yrs, with mean diabetes duration 15,7yrs, without drugs except insu-
lin (mean 44 units/24h), with mean HbA1c 9,4%, without hypertension and 
overt heart disease, with good LV ejection fraction (>60%). The control group 
(C): 60 healthy persons (29F, 31M) in similar age. Mitral valve flow (MVF) 
and aortic valve flow spectra were registrated using pulse-wave Doppler. The 
TI, which is a ratio of the sum of isovolumetric contraction time and isovolu-
metric relaxation time (IVRT) to LV ejection time was calculated.
Results: There were no differences in mean values of heart rate, systolic and 
diastolic blood pressure, Body Mass Index, Body Surface Area, LV mass and 
LV mass index, lipids parameters and percentage of cigarette smokers be-
tween groups. In MVF assessment the mean E/A value (the ratio of early 
to atrial maximal velocity) was significantly lower in DM than in C group 
(1.33±0.3 vs 1.44±0.3, p=0.03), but it remained within the normal range 
for this age group. Mean TI value was especially significantly higher in DM 
than in C group (0.48±0.09 vs 0.38±0.05, p<0.001). In 51 pts of DM group 
TI exceeded the value of 0.49, the upper normal limit (mean value = 0.55 ± 
0.05). All persons in C group had normal TI, with maximal value 0.46. The 
TI elevation is probably dependent on LV prolonged relaxation, due to the 
mean IVRT value was significantly higher in DM than in C group (60.1±8.0 
vs 57.6±6.2 ms, p=0.03). There were no significant differences between the TI 
values related to duration and the level of metabolic control of DM1, number 
and type of complications, as well as between subgroups of women and men 
or younger and older patients. Correlation and multivariate analyses did not 
identify any important factor which might exert a significant effect on in-
creased TI values in young diabetics.
Conclusion: Significantly higher Tei Index values observed in young patients 
with long-lasting type 1 diabetes mellitus with preserved LV systolic function 
may identify subjects with preclinical impairment of LV diastolic function. 
The significance of this phenomenon requires further investigation.
1278
Family history of hypertension or diabetes predicts IMT in well-
controlled patients with type 1 diabetes
A. Hiukka1, E. Häppölä2,3, M.-R. Taskinen1, P.-H. Groop2,3, S. Mäkimattila3; 
1Department of Medicine, Helsinki University Central Hospital and 
Biomedicum, 2Department of Medicine, Helsinki University Central 
Hospital, 3Folkhälsan Institute of Genetics, Folkhälsan Research Center and 
Biomedicum, Helsinki, Finland.
Background and aims: In middle-aged subjects with type 1 diabetes, mor-
tality due to ischemic heart disease is increased four- to seven-fold. Carotid 
intima-media thickness (IMT) is used as a surrogate marker of preclinical 
atherosclerosis. We searched for predictors of IMT in adults with type 1 dia-
betes in a prospective setting.
Materials and methods: A total of 57 patients (F/M = 27/30) were followed 
after their diagnosis until they reached 41±4 years of age, when duration of 
diabetes averaged 31±3 years. Cardiovascular risk markers [lipids, blood 
pressure, smoking, urinary albumin excretion rate (AER), alcohol consump-
tion, family history] were evaluated at the 10 year, 20 year, and 30 year visits. 
During follow-up, IMT of the carotid arteries was determined.
Results: The patients were reasonably well-controlled with HbA1C 
of 7.7±0.9%, blood pressure of 133±16/78±9mmHg and LDL-Chol of 
2.8±0.9mmol/L. Altogether 30 patients had positive family history of hyper-
tension and/or diabetes (FHD+). These patients and those with FHD- did not 
differ concerning smoking, glycemia, lipids, AER, or BMI at any study visit. 
FHD+ patients had higher systolic blood pressure at the 20 year visit (129 
±16 vs. 117±11, p=0.042), despite having more antihypertensive medications. 
At any visit, other blood pressure values did not differ. At the 30 year visit, 
measures of IMT were significantly higher in FHD+ patients (eg. maximum 
IMT 1.03±0.12mm vs. 0.95±0.09mm, p=0.005) and their carotid plaque score 
was two-times higher compared to the FHD- group (p=0.005). Of the single 
measures from the 10 year visit, BMI showed the best correlation to the 30-
year IMT (r=0.437, p<0.001).
Conclusion: Patients with type 1 diabetes and a positive family history of 
diabetes or hypertension have higher carotid IMT than patients without such 
a history. Even if well-controlled regarding risk factors, these patients are ex-
posed to high cardiovascular risk.
Supported by: Foundations: Wilhelm and Else Stockmann, Folkhälsan Re-
search, HUCH
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Association of risk factors and glycaemic control with endothelium-
dependent vascular dysfunction in type 1 diabetes
A.S.M. da Costa1, E. Tibiriçá1,2, P.B. da Silva1, M.B. da Matta1, M.B. Gomes1; 
1Diabetes Unit, State University of Rio de Janeiro (UERJ), 2Laboratory of 
Neuro-Cardiovascular Pharmacology, Oswaldo Cruz Institute, Fiocruz, Rio 
de Janeiro, Brazil.
Background and aims: Endothelial dysfunction in patients with type 1 dia-
betes (T1DM) is an early event in the pathogenesis of vascular complications. 
However, little is known about the potential risk factors associated with im-
pairment of the vascular reactivity in this population. The purpose of this 
study was to assess endothelial function in the microcirculation, correlating 
with possible factors involved such as glycemic control and potential markers 
of cardiovascular risk (uric acid and C reative protein- CRP) , and compare 
the results with those of healthy controls.
Materials and methods: A cross-sectional study was conducted in 57 T1DM 
patients , aged 32.5 (13-61) years and with a 15 (1-48) years disease dura-
tion, and 53 age-, sex-, and weight- matched controls. The median Hba1c 
was 9,3 (5,4-12,1).Skin perfusion was measured at the forearm using laser 
Doppler flowmetry during low-current iontophoresis of acethylcoline (ACh) 
(endothelium dependent response)and sodium nitroprusside(SNP)(Endothe
lium-independent response) . Post occlusive reactive hyperemia (PORH) and 
maximum vasodilator function during thermal hyperemia were also assessed. 
Diabetic patients underwent clinical and laboratory evaluation (disease dura-
tion, daily insulin dose, blood pressure, body mass index, urinary albumin 
excretion, lipid profile, glycemic control , uric acid and CRP).
Results: Microvascular response to ACh was significantly reduced in patients 
(p=0,002). However, despite the reduction of area under curve (AUC) of 
NPS, the analysis with repeated measures disclosed no difference between 
the groups in relation to the doses(p=0,15). Maximal skin microvascular 
vasodilation induced by thermal hyperemia was found to be higher in the 
control group than among patients {93,6 PU(perfusion units) (24,5-379-,9) 
and 56,6 PU (31,5-204,5)}, respectively p=0,004). On the other hand, during 
PORH, maximal increase in flux and AUC of hyperemic response did not 
differ between patients and controls, although the time frame to reach maxi-
mum flux and the time to half recovery after hyperemia was longer in patients 
than in controls (P=0.02). Endothelium-dependent response was correlated 
to diabetes duration (r= -0,33 p=0,01), tryglicerides (r= -0,37 p=0,005), insu-
lin dose (r= -0,28 p=0,03), fasting glycemia (r= -0,3 p=0,02), hba1c (r= -0,34 
p=0,001) and uric acid (r= -0,3 p=0,005), as well as independent-endothe-
lium responses were correlated to capilar glycemia(r=0,30 p=0,02) and CRP 
(r=0,29 p=0,02). Uric acid levels were higher in non-diabetic than in diabetic 
subjects (4,40± 1,48 x 3,6 ± 1,0, respectively p=0,03), and were unrelated to 
endothelium-dependent response(r=0,08 p=0,55). In diabetics, on stepwise 
multivariate analysis, age, hba1c and uric acid were the most important fac-
tors associated with the AUC of ACh (p=0,02), and CRP with AUC of NPS 
(p=0,04).
Conclusion: We conclude that in T1DM patients the endothelium-depend-
ent vascular response and maximal vasodilator capacity are significantly re-
duced and normal serum urate, glycemic control, age and CRP were the most 
important contributing factors to the variation of microvascular reactivity. 
And the inverse association of uric acid levels and ACh response can be ex-
plained probably by the loss of the antioxidant properties of urate.
Supported by: FAPERJ
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Impaired 24-hour blood pressure variation in adolescents and adult 
normoalbuminuric type 1 diabetes patients
L.J. Machnica1, G. Deja1, P. Jarosz-Chobot1, L. Czupryniak2, M. Pawlowski2, 
E. Szymanska-Garbacz2, M. Saryusz-Wolska2, J. Loba2; 
1Pediatrics, Endocrinology and Diabetes, Medical University of Silesia, 
Katowice, 2Internal Medicine and Diabetology Department, Medical 
University of Lodz, Poland.
Background and aims: The absence of >=10% blood pressure (BP) drop at 
night (“non-dipping” phenomenon) is being recognized as a significant risk 
factor of vascular complications of diabetes. Little is known on the role of 
vascular factors like endothelium function and subclinical inflammation in 
the development of disturbed 24-hour blood pressure rhythm in type 1 dia-
betes (T1DM). The aim of the study was to assess blood pressure rhythm in 
adolescent and adult subjects with type 1 diabetes.
Materials and methods: The study comprised two groups of normoalbu-
minuric T1DM patients: Group A - 52 adolescents (mean age 14.1±3.0 yrs, 
diabetes duration 5.1±2.2 yrs, HbA1c 7.2±1.0%) with; Group B - 62 adults 
(mean age 34.1±7.2 yrs, diabetes duration 4.8±2.5 yrs, HbA1c 7.2±1.1%) and 
a group of healthy controls (Group C; mean age 23.1±4.4 yrs). All subjects 
had 24-hour blood pressure monitoring performed with the use of SpaceLabs 
90207. Fasting plasma adhesion molecules sVCAM and sICAM, sE-selectin, 
adiponectin, interleukin IL-6, and TNF-alfa concentration were measured.
Results: 25 (48%) subjects from Group A and 9 (15%) from Group B were 
“non-dippers”; no “non-dippers” were found in Group C. There were no 
statistically significant differences in vascular and inflammatory parameters 
between “dippers” and “non-dippers” from Group A and Group B or the 
controls (table). However, mean 24-hour systolic (SBP) and diastolic blood 
pressure (DBP) was significantly lower in Group A than in Group B and C: 
118±10 and 66±5; 126±11 and 73±6, and 128±12 and 73±6 mmHg (p<0.01). 
In particular, SBP at night was significantly lower in “non-dippers” than in 
“dippers” from Group A: 105±8 and 113±10 mmHg (p<0.01), while DBP was 
similar: 57±3 and 60±7 mmHg, respectively. There was a significant positive 
correlation between 24-hour SBP and body mass index (BMI) in Group A 
and B subjects (r=0.41 and r=0.32, respectively).
Conclusion: In adolescent or adult patients with T1DM non-dipping phe-
nomenon is not associated with endothelial dysfunction or increased sub-
clinical inflammation. In addition, unusually high prevalence of non-dipping 
in adolescent subjects with T1DM suggests that establishing this diagnosis 
with traditional criteria might not be at all appropriate in this population. 
Children and adolescents with T1DM display lower BP than the older per-
sons, therefore they physiologically might not be subject to >=10% decrease 
of BP at night. For the assessment of diurnal blood pressure variation in ado-
lescent T1DM patients different criteria of BP nighttime reduction might be 
necessary to apply.
Gr. A Gr. B Gr. C
dippers non-dippers dippers non-dippers
sVCAM
(ng/ml)
1035±412 1039±537 1212±849 1025±832 924±428
sICAM
(ng/ml)
370±129 410±170 427±153 399±293 354±164
sE-selectin
(ng/ml)
43.4±15.9 40.8±25.3 42.1±15.9 46.0±22.3 38.3±29.1
Adiponectin
(ng/ml)
13178±11439 11644±10441 12569±8638 11792±11222 13954±10319
TNF-alfa
(pg/ml)
19.8±11.1 15.0±7.7 14.9±10.2 16.2±12.7 13.2±6.9
IL-6 (pg/ml) 4.9±4.7 6.7±10.2 5.9±4.2 6.8±6.5 6.2±5.7
Supported by: KBN 
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Co-morbidity and survival of patients with type 1 diabetes on renal 
replacement therapy
J. Helve1, M. Haapio2, C. Grönhagen-Riska3, P. Finne4; 
1Department of Medicine, Lappi Central Hospital, Rovaniemi, Finland, 
2Division of Nephrology, Helsinki University Central Hospital, Helsinki, 
3Department of Medicine, Helsinki University Central Hospital, 4Finnish 
Registry for Kidney Diseases, Helsinki, Finland.
Background and aims: Mortality among patients with type 1 diabetes on re-
nal replacement therapy is high. The effect of co-morbidities on their survival 
has not been previously estimated. The aim of this study was to estimate effect 
of co-morbidities on survival of type 1 diabetes patients on renal replacement 
therapy.
Materials and methods: An incident cohort of all type 1 diabetes patients 
entering chronic renal replacement therapy (n=656) in Finland between 2000 
and 2008 was followed until death or the end of follow-up on 31 December 
2008. All data were obtained from the Finnish Registry for Kidney Diseases, 
which collects information on co-morbidities at the start of renal replace-
ment therapy. The main outcome was crude and adjusted relative risk of 
death according to co-morbidities.
Results: At start of renal replacement therapy 22% of the type 1 diabetic pa-
tients had coronary artery disease, 18% had peripheral vascular disease, 10% 
had cerebrovascular disease, 33% had left ventricular hypertrophy, and 7% 
had heart failure. All observed co-morbidities were significant predictors of 
death when analyzed univariably (RR 1.56-4.87). The 5-year survival prob-
ability of patients without (reported) co-morbidities was 74%, while it was 
56% and 37%, respectively, for those with one or more than one co-mor-
bidities. When the co-morbidities were studied in a multivariate model, also 
adjusting for age and gender, peripheral vascular disease (RR 1.88), left ven-
tricular hypertrophy (RR 1.68) and heart failure (RR 2.50) remained inde-
pendent risk factors of death.
Conclusion: Co-morbidities are common among type 1 diabetes patients 
entering renal replacement therapy, and they are strong predictors of death. 
Therefore, it is essential to diagnose and adequately treat co-morbidities.
Supported by: Diabetes Research Foundation
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Increased oxidative damage to de novo synthesized ApoA-1 in untreated 
type 1 diabetic patients - a novel method to identify the relative age of 
proteins 
A. Jaleel, G. Henderson, B. Madden, K. Klaus, D. Morse, S. Gopala, K. Nair; 
Endocrinology, Mayo Clinic & Foundation, Rochester, USA.
Background and aims: Oxidative damage and other post-translational mod-
ifications (PTM) in proteins, and accumulation of these proteins, may cause 
complications in diabetes. In order to address this issue, we developed a novel 
methodology to identify relative age of protein isoforms and to assess post-
translational modifications by studying Apolipoprotein A-1.
Materials and methods: This method involves in vivo stable isotope labeling 
of proteins, protein isoform purification by two dimensional gel electrophore-
sis (2DGE), and isotopic enrichment (IE) and PTM analysis by tandem mass 
spectrometry. To label newly synthesized proteins, [ring-13C6]phenylalanine 
was intravenously infused for 8 hours in type 1 diabetic (T1D) participants 
with (I+) and without (I-) insulin treatment and non-diabetic (ND) partici-
pants (plasma glucose mmol/L; T1D I- = 17.0 ± 0.6, T1D I+ = 5.2 ± 0.2, ND 
= 4.9 ± 0.1).
Results: Only protein isoforms synthesized during infusion would incorpo-
rate the isotope label. In 2DGE and we identified 5 isoforms of ApoA-1. Pro-
ApoA-1 (gel spot E) contained higher IE (ratio of [ring-13C6]phenylalanine to 
total phenylalanine), while older forms with higher degrees of damage (oxi-
dation, deamidation) displayed less IE. Insulin deprivation in T1D increased 
the amount of oxidation in ApoA-1 (P<0.05) with more rapid maturation and 
damage of de novo synthesized pro-ApoA-1 (P<0.05) (% 13C-labeling of ma-
ture ApoA-1 vs pro-ApoA-1: T1D I-= 13 ± 3, T1D I+ = 6 ± 1, ND = 5 ± 1).
Conclusion: The results show that ApoA-1, important for lipoprotein metab-
olism, is oxidatively damaged soon after synthesis during insulin deficiency 
that likely contributes to the cardiovascular complications during insulin de-
ficiency and poor glycemic control in T1D.
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The adverse effects of diabetic ketosis on the heart in young and middle-
aged patients
Z. Qiumei; 
Tianjin Medical University Metabolic Disease Hospital, China.
Background and aims: To observe the changes of myocardial enzymogram 
and electrocardiogram confirmed the myocardial damage during diabetic ke-
tosis (DK)or diabetic ketoacidosis(DKA) in middle-aged patients.
Materials and methods: 78 hospitalized patients (45 male and 33 female) 
with DKA were recruited. Standard of Admission: Under 45 years old ; Above 
urine acetone bodies 2+; Without evidence of overt ischaemic heart disease; 
Without obvious infection and chronic disease history.Myocardial enzymo-
gram which included creatine phosphokinase (CK), creatine phosphokinase 
isoenzyme(CK-MB) and aspart aminotransferases(AST) were measured on 
admission at ketosis stage and at 7 days after ketosis recovery. Electrocardio-
graphs were also performed and compared during two stages.
Results: 78 hospitalized patients with DK or DKA had significantly higher 
levels of myocardial enzymogramCK,CK-MB and AST at ketosis stage com-
pared to at stable stage. The changes of ECG were found in 46 cases (58.9% )of 
all the patients. The highest morbidity of ECG abnormality was ST-T change 
which was found in 32 cases(41.0%),ST segment depression in 8 cases, ST 
segment height in 1 case,T wave flat or inversion in 24 cases, sinus tachycar-
dia in 18 cases (23.1%). 32 cases out of abnormal ECG in 46 cases improved 
at 7 day after ketosis recovery; in 20 cases recovered to normal. The levels of 
CK,CK-MB and AST with abnormal ECG at acute stage were significantly 
higher than those with normal ECG.. 3 patients with severe ketoacidosis in 
78 cases, minute elevations of myocardial biomarkers 2 folds above reference 
value , ST segment depression 0.1mV in 2 cases and ST segment height in 
1 case compatible with myocardial infarction. The higher levels of CK,CK-
MBand AST restored to normal and change of ECG overtly improved at the 
stable stage, ST segment raised up 0.05 mV in 2 patient those ST segment 
depression,ST segment height in 1 case restored to normal also.
Conclusion: Diabetic ketoacidosis, particularly when severe, has a nonspecif-
ic myocardial injury, the level of myocardial enzymogram caused by diabetic 
ketosis could be abnormally higher. We should monitor the heart change and 
take an effective protective action during ketosis episode, the patients should 
be followed up and evaluated after recovery.
1284
Genetic variability of histone methyltransferases and the risk of diabetic 
complications in patients with type 1 diabetes
A. Tiitu1, A. El-Osta2, C. Forsblom1,3, L. Tarnow4, H.-H. Parving5, M.E. 
Cooper2, P.-H. Groop1,3; 
1Folkhälsan Institute of Genetics, Folkhälsan Research Center, Helsinki, 
Finland, 2Epigenetics in Human Health and Disease, Baker IDI Heart and 
Diabetes Institute, Melbourne, Australia, 3Div Nephrology, Department of 
Medicine, Helsinki University Central Hospital, Finland, 4Steno Diabetes 
Center, Gentofte, Denmark, 5Department of Medical Endocrinology, 
University Hospital, Copenhagen, Denmark.
Background and aims: There appears to be a complex interplay between 
genes and lifetime glucose exposure, which increases the risk of diabetic 
complications in patients with type 1 diabetes (T1D). However, the underly-
ing molecular mechanism responsible for this phenomenon remains unex-
plained. We have demonstrated that exposure to glucose may lead to altera-
tions of the methylation patterns of DNA and histones of essential genes, an 
epigenetic phenomenon that is increasingly considered to maintain the hy-
perglycaemic memory of critical cells. Since it has recently been shown that 
altered histone methylation is associated with an inflammatory phenotype in 
white blood cells and vascular cells when exposed to diabetic conditions, we 
hypothesized that genes coding for the enzymes that methylate histones, the 
histone methyltransferases SuV39 and SetD7, play a role in the development 
of diabetic complications.
Materials and methods: The first dataset included 2991 patients with T1D 
from the FinnDiane study. 811 patients had diabetic nephropathy (DN) de-
fined as macroalbuminuria or ESRD, and 1070 patients had normal AER de-
spite being exposed to diabetes for at least 15 years. 1168 patients were laser 
treated for retinopathy. The replication dataset included 888 patients from 
the Steno Diabetes Center, 452 were diagnosed with DN and 432 had normal 
AER. 416 patients had proliferative retinopathy. Genetic data on the CEPH 
population in the HapMap database (phase II) was used to select tagSNPs 
covering all SNPs in the genes SuV39h1, SuV39h2 and SetD7. A total of 37 
SNPs were selected for genotyping with the Sequenom MassARRAY iPLEX 
system or the TaqMan chemistry. P-values are presented both for raw data 
(p) and corrected for multiple testing (pcorr). Classical risk factors included in 
the logistic regression models are duration of T1D, systolic blood pressure, 
triglycerides, HbA1c, male sex, smoking and BMI.
Results: In the FinnDiane, the SNP most strongly associated with DN was 
rs11100112 (SetD7) with minor allele frequencies of 18.0% in cases and 
20.7% in controls (p=0.043/pcorr=NS). The minor allele of rs11100112 seemed 
protective after adjustment (OR=0.790[0.638-0.978], p=0.031). The SNP 
rs12572872 (near SuV39h2) showed a genotypic association with laser-treated 
retinopathy (p=0.0007/pcorr=0.030) with minor allele frequencies of 15.6% in 
cases and 18.7% in controls (p=0.003/pcorr=NS). When adjusted for classical 
risk factors, the minor allele containing genotype was protective (OR=0.814 
[0.662-1.000], p=0.05). Six SNPs were chosen for replication but there were 
no significant associations, although the effects showed the same direction 
for both SNPs rs11100112 and rs12572872. When both study populations 
were combined (Fisher’s method) no significant results were observed. When 
patients with HbA1c and duration above/below medians were analyzed sepa-
rately, no significant results were either recorded.
Conclusion: No clear association of polymorphisms in the specific histone 
methyltransferase genes examined and diabetic complications could be seen. 
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Initial combination therapy with aliskiren and hydrochlorothiazide 
is more effective than amlodipine in patients with stage 2 systolic 
hypertension and diabetes mellitus
R.R. Townsend1, A. Forker2, P. Rumpelt3, C. Cherif Papst4, A. Yadao3; 
1University of Pennsylvania Medical Center, Philadelphia, USA, 2Saint 
Luke’s Lipid and Diabetes Research Center, Kansas City, USA, 3Novartis 
Pharmaceuticals Corporation, East Hanover, USA, 4Novartis Pharma AG, 
Basel, Switzerland.
Background and aims: Agents that act on the renin-angiotensin-aldosterone 
system (RAAS) are considered drugs of choice for the treatment of hyperten-
sion in patients with diabetes mellitus. Direct renin inhibitors (DRIs) bind 
to and inhibit renin, which catalyzes the rate-limiting step of the RAAS. This 
8-week, double-blind study compared the blood pressure lowering (BP) ef-
ficacy and safety of aliskiren/hydrochlorothiazide (ALI/HCT) combination 
vs. amlodipine (AML) in 860 male and female adults with stage 2 systolic 
hypertension (mean sitting systolic BP [msSBP] ≥ 160 and < 200 mmHg) and 
type 2 diabetes mellitus.
Materials and methods: After a 1-4 week washout, eligible patients (mean 
age: 59.8 years; mean BMI: 34.6 kg/m2) were randomized to ALI/HCT 
150/12.5 mg (n = 428) or AML 5 mg (n = 432). After 1 week, doses were 
force-titrated to ALI/HCT 300/25 mg or AML 10 mg, and patients were treat-
ed for an additional 7 weeks. The primary efficacy variable was change from 
baseline in msSBP at the Week 8 endpoint. Analysis to assess non-inferiority 
was performed, followed by superiority testing if ALI/HCT was shown to be 
non-inferior to AML.
Results: Baseline BPs were similar between the two groups: ALI/HCT: 
168.0/91.4 mmHg and AML: 167.4/91.3 mmHg. At Week 8 endpoint, least 
squares (LS) mean reductions in msSBP were significantly greater with ALI/
HCT vs. AML (-28.8 mmHg vs. -26.2 mmHg, LS mean difference: -2.6 mmHg; 
p <0.0001 non-inferiority; p = 0.0102 superiority). At study endpoint, a sig-
nificantly greater percentage of patients receiving ALI/HCT achieved the BP 
goal of <130/80 mmHg compared with AML (23.2% vs. 13.8%; p <0.0001). 
Both treatments were generally well tolerated. Peripheral edema was more 
frequent with AML (16.2% vs. 2.1%) while dizziness was more frequent with 
ALI/HCT (3.0% vs. 0.9%).
Conclusion: Initial treatment with ALI/HCT 300/25 mg is significantly more 
effective than AML 10 mg at reducing msSBP and attaining BP control in 
patients with stage 2 systolic hypertension and type 2 diabetes mellitus.
Supported by: Novartis Pharmaceuticals Corporation
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Aliskiren reduces albuminuria independent of baseline blood pressure 
in combination with losartan in patients with type 2 diabetes and 
nephropathy
H.-H. Parving1,2, F. Persson3, J.B. Lewis4, E.J. Lewis5, N.K. Hollenberg6; 
1Medical Endocrinology, Rigshospitalet, Copenhagen, Denmark, 2Faculty 
of Health Sciences, Aarhus University, Denmark, 3Steno Diabetes Center, 
Gentofte, Denmark, 4School of Medicine, Vanderbilt University, Nashville, 
USA, 5Medical Center, Rush University, Chicago, USA, 6Brigham and 
Women’s Hospital, Harvard Medical School, Boston, USA.
Background and aims: Elevated blood pressure (BP) is a key contributor 
to development and progression of proteinuria and nephropathy in patients 
with type 2 diabetes. Direct renin inhibition with aliskiren (ALI) may offer 
renoprotective effects beyond BP reduction. This post hoc analysis assessed 
the influence of baseline BP on the antiproteinuric effect of ALI or placebo 
(PBO) added to losartan (LOS) in the Aliskiren in the EValuation of PrO-
teinuria In Diabetes (AVOID) study.
Materials and methods: In AVOID, 599 patients aged 18-85 years with hy-
pertension and diabetic nephropathy received 6 months’ ALI (150 mg force 
titrated to 300 mg after 3 months) or PBO added to LOS 100 mg daily and 
optimal antihypertensive therapy. Key exclusion criteria were non-diabetic 
kidney disease, eGFR <30 ml/min/1.73 m2 and serum potassium >5.1 mmol/
l. Changes in early morning urinary albumin:creatinine ratio (UACR) and 
eGFR at week 24 endpoint were assessed by subgroups of baseline BP: Group 
A, <130/80 mmHg (n = 159); Group B, <140/90 mmHg but >130/80 mmHg 
(n = 189) and Group C, >140/90 mmHg (n = 251).
Results: Mean baseline BP values (mmHg) for each subgroup were 120/71 
(Group A), 133/78 (Group B) and 145/81 (Group C).The demographic, clini-
cal and laboratory data were balanced between the three groups. The antipro-
teinuric effects of ALI were consistent across BP subgroups (19-22% reduc-
tion in UACR vs PBO, p = 0.977 for interaction). In Group C (BP >140/90 
mmHg at baseline), the decline in eGFR was significantly lower with ALI 
than with PBO (p = 0.0096). There were no significant differences in the 
change in BP from baseline in any subgroup.
Conclusion: This post hoc analysis of the AVOID trial suggests that aliskiren 
300 mg added to losartan 100 mg plus optimal antihypertensive therapy pro-
vides renoprotective effects independent of baseline BP in patients with type 
2 diabetes and nephropathy.
Supported by: Novartis
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Patients with type 1 or type 2 diabetes have similarly increased pulsatility 
stress at comparable age of 50 years
A.J.L. Scheen, J.-C. Philips, M. Marchand; 
Division of Diabetes, Nutrition and Metabolic Disorders, CHU Sart Tilman, 
Liège, Belgium.
Background and aims: Arterial pulse pressure (PP) is considered as an inde-
pendent cardiovascular risk factor in both patients with type 1 (T1DM) and 
type 2 (T2DM) diabetes mellitus. However, patients with each type of diabe-
tes are exposed to a quite different toxic vascular environment. We compared 
PP and PP x heart rate (HR) double product (PPxHR = “pulsatile stress”) dur-
ing an active orthostatic test in patients with T1DM and patients with T2DM 
matched for age (40-60 years).
Materials and methods: 40 patients with T1DM (mean age 50 years, diabetes 
duration 23 years, body mass index - BMI - 23.0 kg/m², HbA1c 8.4%) were 
compared to 40 patients with T2DM (respectively, 50 years, 8 years, 29.7 kg/
m², 7.6%). Patients taking antihypertensive agents or with renal insufficiency 
were excluded. All patients were evaluated with a continuous noninvasive ar-
terial blood pressure monitoring (Finapres®) in standing (1 min), squatting 
(1 min) and standing position again (1 min). Patients with T1DM or T2DM 
were compared with two groups of 40 age- and BMI-matched healthy sub-
jects (sex ratio 1/1 in all groups)( Figure).
Results: Despite similar mean arterial pressure (MAP), patients with T1DM 
and patients with T2DM showed significantly higher PP, HR and PPxHR 
double product levels than corresponding controls : in T1DM, 59 vs 52 mm 
Hg for PP (P= 0.016) and 5263 vs 4121 mmHg/min for PPxHR (P=0.0004); 
in T2DM, 58 vs 52 mm Hg for PP (P= 0.045) and 5359 vs 4321 mmHg/min 
for PPxHR (P=0.0023). However, there were no significant differences be-
tween patients with T1DM and T2DM regarding mean overall values of MAP 
(126 vs 128 mmHg), PP (59 vs 58 mmHg), HR (89 vs 88/min), and PPxHR 
product (5263 vs 5359 mmHg/min). During the transition from standing to 
squatting position, PP increase (+10 vs +8 mmHg) and HR reduction (-6 vs -
6 beats/min) were significant but similar in both groups, resulting in a similar 
modest and non significant rise in PPxHR (+557 vs +449 mmHg/min).
Conclusion: Patients with T1DM have similarly increased PP, an indirect 
marker of arterial stiffness, and PPxHR double product, an index of pulsa-
tile stress, as non-hypertensive patients with T2DM at similar mean age of 
50 years. We hypothesize that such comparable pulsatile stress despite quite 
different natural history of the diabetic disease may be explained by a much 
longer exposure to chronic hyperglycaemia in patients with T1DM, on the 
one hand, and by the presence of associated risk factors such as obesity and 
insulin resistance in patients with T2DM, on the other hand.
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Pulse pressure and systolic non-dipping, but not ambulatory arterial 
stiffness index, are independent predictors of macrovascular disease in 
patients with type 2 diabetes mellitus
E. Laugesen1, N.B. Rossen1, P.L. Poulsen1, K.W. Hansen2, E. Ebbehøj1, S.T. 
Knudsen2,1; 
1Department of Endocrinology and Internal Medicine, Aarhus University 
Hospital, 2Department of Internal Medicine, Regional Hospital Silkeborg, 
Denmark.
Background and aims: Patients with type 2 diabetes mellitus are at increased 
risk of cardiovascular disease (CVD). We examined the predictive ability of 
ambulatory blood pressure monitoring (ABPM) parameters for fatal and 
non-fatal CVD in patients with type 2 diabetes mellitus.
Material and methods: 108 patients with type 2 diabetes mellitus (mean 
duration 6.6 years) were followed for 9.5 (0.5-14.5) years. At baseline, all pa-
tients underwent ABPM.
Results: 45 patients experienced at least one CV event (35 non-fatal and 10 
fatal). In bivariate analysis, CVD during follow-up was predicted by 24-h 
ambulatory pulse pressure (PP), (p<0.01), ambulatory arterial stiffness index 
(AASI), 24-h systolic blood pressure (BP) and systolic and diastolic non-dip-
ping (defined as less than 10% nightly BP reduction) (p<0.05 for all). In Cox 
regression analysis with adjustment for established risk markers, 24-h PP and 
systolic night:day BP ratio both independently predicted CVD during fol-
low-up: the adjusted hazards ratio (HR) for subsequent CVD per 10 mmHg 
increase in 24-h PP was 1.37 (95%CI 1.01;1.89, p<0.05), and the HR per 10 % 
increase in systolic night:day BP ratio was 1.54 (95CI 1.03; 2.30, p<0.05). Only 
8 out of 31 (26%) patients with both 24-PP below the median (57 mmHg) and 
normal nocturnal systolic BP dipping pattern had incident CVD during follow 
up, whereas 19 out of 28 patients (68%) with both 24-h PP above or equal to 
the median and systolic non-dipping had incident CVD (p<0.01), figure 1.
Conclusion: 24-h PP and impaired nocturnal systolic BP decline, but not 
AASI, were independent predictors for CVD in type 2 diabetes patients.
Figure 1:
Supported by: Central Region Denmark Research Fund
1289
Mechanisms of effect of weight loss on blood pressure
L. Flores1, R. Morínigo1, J. Vidal1, J. Viaplana2, E. Esmatjes3; 
1Obesity Unit, Clinic Hospital, 2Obesity Unit, Institut d’Investigacions 
Boimèdiques August Pi i Sunyer, 3Diabetes Unit, Clinic Hospital, Barcelona, 
Spain.
Weight loss has a clear blood pressure-lowering effect, the pathophysiologi-
cal mechanisms are not completely understood. The aim of this study was to 
evaluate the effect of significant weight loss on blood pressure (BP) and its 
pathological mechanisms.
Patients and methods: Patients with documented hypertension who under-
went laparoscopic gastric bypass were studied. Antihypertensive treatment 
was withdrawn one week before the evaluation. Anthropometric, BP (24-h 
ambulatory BP measurement) assessment, and blood samples for renin-angi-
otensin-aldosterone system [RAAS, plasma renin activity (PRA), aldosterone, 
angiotensin II and angiotensin converting enzyme] and sympathetic nervous 
system (metanephrine, normetanephrine and noradrenaline) analysis were 
performed before surgery at 4 and at 12 months postoperatively.
Results: Eighteen patients were studied, 12 females, with 50.8 (38-63) years 
old, with hypertension duration of 6.4 (1-20) years and excess body weight of 
55.6 (36-73) kg. Twelve months after surgery: the BMI decreased from 45.6 
to 32.1 Kg/m2; excess body weight loss was -37.2 Kg; 13 (72%) patients had 
completed resolution of hypertension while 5 (28%) patients had improve-
ment; 24-h (systolic -18.8/diastolic -7-7 mmHg), daytime and night-time BP 
values decreased significantly. The PRA (0.30 to 0.21 ng/mL*h), aldosterone 
(5.3 to 3.1 ng/dl) and noradrenaline (121.5 to 77.5 pg/mL) also had a signifi-
cant decrease.
Conclusion: Weight loss is associated with reduction of the BP, RAAS and 
sympathetic system in obese hypertensive subjects.
1290
Assessment of pulsepen for detection of pseudohypertension in diabetic 
patients
C. Cugnet Anceau1, A. Serusclat2, X. André-Fouet3, G. Finet3, G. Rioufol3, F. 
Gueyffier3, P. Douek2, P. Moulin1; 
1U11 Fédération d’endocrinologie, 2Service d’imagerie Hôpital 
Cardiologique, 3Service de cardiologie, Bron, France.
Background and aims: In the diabetic population, hypertension is often se-
vere and resistant despite the combination of several antihypertensive drugs. 
Stiffness of brachial arteries may induce an overestimation of intra-arterial 
S 510 Diabetologia (2010) 53:[Suppl1]S1–S556
1 C
blood pressure (BP) called pseudohypertension. Evidence for pseudohyper-
tension is difficult to establish in clinical practice. A new non invasive method 
(Pulsepen) based on the estimation of central aortic pressure by applanation 
tonometry has been proposed for this purpose but was not previously as-
sessed in diabetic patients.
Materials and methods: To compare Pulsepen and Dinamap versus intra-ar-
terial pressure (method of reference) and to assess the capacity of Pulsepen to 
screen pseudohypertension in diabetic patients with resistant hypertension, 
BP was simultaneously recorded in diabetic patients by the three methods 
during an endovascular procedure (arteriography or coronarography).
Results: Our study population included 11 type 2 diabetic patients (7 men 
and 4 women), aged 66.5±6.9 years, with a duration of diabetes of 23.7±5.4 
years, a mean BMI of 31.5±5.5 kg/m2and a mean HbA1c level of 8.5±1.5%, 
with persistent hypertension despite two antihypertensive drugs at the time 
of inclusion. Seven patients were in secondary prevention of cardiovascular 
disease. Systolic BP (SBP) was significantly underestimated by: - 10.6± 8.24 
% with Pulsepen (p=0.009) and by -4.63± 6.89 % with Dinamap (p=0.04). 
Diastolic BP (DBP) was insignificantly overestimated of +11.7±19.5 % 
(p=0.09) and by +15.3±19.9 % (p=0.06), respectively. The regression coef-
ficients versus intra-arterial values were: SBP r2 0.82 (p=0.0001), DBP r2 0.64 
(p=0.002) for Pulsepen and SBP r2 0.87 (p<0.001), DBP r2 0.65 (p=0.002) for 
Dinamap. According to pseudohypertension determined from the dinamap 
measurements, one patient had systolic pseudohypertension and two patients 
diastolic pseudohypertension. The Pulsepen was unable to detect the 3 cases 
of pseudohypertension.
Conclusion: Our data suggest that Pulsepen is not a reliable method in or-
der to estimate intraarterial BP and to detect pseudohypertension in diabetic 
patients with resistant hypertension. This study underlies the difficulties to 
accurately measure BP in diabetic patients.
Systolic, Diastolic, Mean, Pulse blood pressure differences
Pulsepen BP- 
intraarterial BP
(mmHg)
p Dinamap BP- 
Intraarterial BP
(mmHg)
p
SBP - 18.8 ± 15.5 0.009 - 8.7 ± 12.3 0.04
DBP + 7.6 ± 15.1 0.09 + 10.1± 15.4 0.06
Mean BP - 3.2 ± 10.7 0.26 + 3.8 ± 9.9 0.09
Pulse BP - 28.6 ± 24.7 0.03 - 18.8 ± 22.3 0.004
1291
A proteomic approach to the long-term experimental hypertensive-
diabetic myocardium
Ó. Lorenzo1, B. Picatoste1, S. Ares1, A. Caro2, E. Ramírez1, E. Camafeita3, J.A. 
López3, J. Egido1, J. Tuñón1; 
1Vascular Pathology, Instituto de Investigaciones Sanitarias Fundación 
Jiménez Díaz, 2Veterinary Faculty, Universidad Complutense de 
Madrid, 3Unidad de Proteómica, Centro Nacional de Investigaciones 
Cadiovasculares, Madrid, Spain.
Background and aims: Diabetes is a worldwide pandemic that may dam-
age the heart. Myocardial protein alteration has been described in short-term 
injury. However there is not information about the chronic pathology and its 
association with hypertension.
Aim: To analyze the myocardial proteome and molecular pathways of long-
term diabetic/hypertensive rats.
Materials and methods: Normotensive and spontaneously hypertensive 
(SHR) rats received either streptozotocin or vehicle. After 22 weeks, type-I 
diabetic (DM1), SHR, DM1/SHR and control rats were sacrificed and the left 
ventricles studied by a proteomic approach based on DIGE and MALDI-MS. 
Differential proteins were validated by immuno-histochemistry, Western blot 
and Electrophoretic Mobility Shift assay (EMSA) and clustered into different 
biochemical pathways using bioinformatics tools.
Results: Long-term DM1 and hypertensive hearts are characterized by 
hypertrophy, fibrosis and apoptosis. By proteomics, we found 29, 55 and 58 
proteins altered in the myocardium of long-term DM1, SHR and DM1/SHR 
rats, respectively (ratio≥ 1.35-fold with p≤0.05). Among these, DM1 myocar-
dium presented over-expression of cytoskeleton and apoptosis proteins and 
down-regulation of anti-apoptotic and mitochondrial metabolic enzymes. In 
SHR and DM1/SHR rats these changes were exacerbated and, in addition, 
fatty acid ß-oxidation enzymes were decreased. Other enzymes for amino 
acid and alcohol metabolism were also altered. Bioinformatics suggested the 
implication of specific cytoskeleton factors, cytokines and fatty acid nuclear 
receptors in these pathologies. Peroxisome-activated receptors (PPARs) were 
stimulated whereas hepatocyte nuclear factor-4α receptor (HNF-4α) was 
not.
Conclusion: Long-term DM1 and markedly SHR and DM1/SHR hearts pre-
sented altered proteomes. Down-regulation of fatty acid and carbohydrate 
metabolisms and up-regulation of hypertrophic and apoptotic proteins may 
contribute to the hypertensive and diabetic-hypertensive cardiomyopathy. 
New unveiled factors as fatty acid nuclear receptors may be used as potential 
therapeutic targets for these diseases.
Supported by: SAF2009-08367
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In subjects with type 2 diabetes, liraglutide, a once-daily human GLP-1 
analogue, reduces systolic blood pressure with negligible impact from 
weight loss
V.A. Fonseca1, R.R. Henry2, R. Tabanera y Palacios3, J. Brett3, J. Plutzky4; 
1Tulane University Medical Center, Tulane University Health Sciences 
Center, New Orleans, 2University of California, San Diego, 3Novo Nordisk 
Inc, Princeton, 4Harvard Medical School, Brigham & Women’s Hospital, 
Boston, USA.
Background and aims: Hypertension is a major risk factor for myocardial in-
farction and stroke, and is more common in individuals with type 2 diabetes 
(T2D) than in the general population. Modest weight loss can result in sig-
nificant long-term reductions in blood pressure and thereby reduce the risk 
for hypertension. In phase 3 clinical trials, in addition to improving glycated 
haemoglobin (HbA1c) by 1.0-1.5%, liraglutide also improved systolic blood 
pressure (SBP) by 2-7 mmHg and produced sustained body weight (BW) re-
ductions of 2-3 kg. However, the specific nature of the relationship between 
the effect of liraglutide on SBP and BW is not well-characterised.
Materials and methods: A meta-analysis of six randomised phase 3 clinical 
trials (n=3967) was performed in the liraglutide (1.2 and 1.8 mg) and placebo 
arms to investigate the relationship between changes in SBP and BW from 
baseline at each post-randomisation visit up to 26 weeks using an analysis of 
covariance (ANCOVA) model with treatment, trial, previous OAD treatment 
as fixed effects, country as random effect, and change in BW from baseline as 
covariate. The percentage of the change in SBP predicted by the change in BW 
is given by the 100 × R2 (the square of the Pearson correlation coefficient), a 
goodness-of-fit index. The closer the R2 is to 1, the stronger the relationship 
between change in SBP and BW.
Results: The analyses show a consistent trend of a very weak correlation be-
tween change in SBP and change in BW over time. At Week 2, up to 2% of the 
change in SBP could be predicted by the change in BW for both liraglutide 
doses and placebo. At Week 26, both liraglutide arms and placebo had a per-
centage of R2 below 2%. The Pearson correlation between the change in SBP 
and the predicted change in SBP obtained from the ANCOVA model was also 
very weak with R2 below 4%.
Conclusion: A minimal amount of the observed effect of liraglutide on change 
in SBP is predicted by change in BW. As a result, the effect of liraglutide on 
SBP cannot be explained by weight loss alone. In order to better understand 
the effect of liraglutide on SBP, mechanistic studies are warranted.
Supported by: Novo Nordisk
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The prevalence and severity of hypertension in patients with type 2 
diabetes of Yemenite origin is lower than in non-Yemenite diabetics
M. Blaychfeld Magnazi1, N. Reshef1, T. Zornitzki1, S. Weitzman2, H. 
Knobler1; 
1Metabolic Unit, Kaplan Medical Center, Rehovot, 2Department of 
Epidemiology, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
Background and aims: Yemenite Jews who immigrated to Israel during 
the years 1948-1950 had a very low prevalence of diabetes (0.05%) which 
increased to 12% within 40 years in parallel with their lifestyle changes. How-
ever, previous limited data suggested that the prevalence of hypertension 
(HTN) in Yemenite Jews remained lower than the prevalence in the general 
Israeli population. The aims of the current study were to determine in a group 
of patients with type 2 diabetes of Yemenite (Y-DM) or non-Yemenite (NY-
DM) origin the prevalence of HTN and lifestyle patterns including their ad-
herence to the Dietary Approaches to Stop Hypertension (DASH) diet.
Materials and methods: A cross-sectional study of 63 Y-DM patients (2 par-
ents of Yemenite origin) and 120 NY-DM patients (neither parent of Yemenite 
origin) was conducted at a Diabetes Clinic. Medical and lifestyle information 
was collected including food frequency questionnaire (FFQ).
Results: The age and sex distribution were similar in the Y-DM and NY-DM 
groups (63 ± 7 years vs. 64 ± 7 years; 57% males vs. 56% males, respectively). 
The duration of diabetes in the Y-DM group was 16 ± 10 years vs. 13 ± 9 years 
in the NY-DM (P = 0.07) and the Y-DM group had lower weight and waist 
circumference (72 ± 13 kg vs. 85 ± 17 kg and 95 ± 11 cm vs. 105 ± 13 cm, P 
< 0.001). The prevalence of HTN was significantly lower in the Y-DM group 
compared with the NY-DM group (63% vs. 83%, P= 0.003). Despite having 
similar blood pressure control, patients in the Y-DM group necessitated less 
blood pressure medications than patients in the NY-DM (1.6 ± 1.8 vs. 2.5 
± 1.7, P= 0.002). In addition, in only 30% of the Y-DM group HTN was di-
agnosed before or concomitantly with the diagnosis of diabetes compared 
with 51% in the NY-DM (P= 0.035). In a logistic regression analysis, Non-
Yemenite origin was independently associated with a higher prevalence of 
HTN (odd ratio 3.0, 95% CI :1.5-6.3, P= 0.0025). There were no significant 
differences between the 2 groups in physical activity, total calories consumed 
and the DASH score (30 ± 3 vs. 31 ± 3).
Conclusion: Despite the marked increase in the prevalence of type 2 diabetes 
in Yemenite Jews who immigrated to Israel, the prevalence of HTN in dia-
betics of Yemenite origin remained significantly lower compared with Non-
Yemenite diabetics and blood pressure control necessitated less medications. 
These results are not due to differences in life style including adherence to the 
DASH diet and other mechanisms have to be explored.
PS 129 Dyslipidaemia and 
lipoproteins
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Colesevelam for Hispanic patients with hypercholesterolaemia and 
prediabetes
Y. Handelsman1, R.B. Goldberg2, J. Rosenstock3, W.T. Garvey4, V.A. 
Fonseca5, E. Hernandez-Triana6, M.R. Jones7, Y.-L. Lai7, X. Jin8, S. Misir7, S. 
Nagendran7, S.L. Abby7; 
1Metabolic Institute of America, Tarzana, USA, 2University of Miami 
Miller School of Medicine, Miami, USA, 3Dallas Diabetes and Endocrine 
Center at Medical City, Dallas, USA, 4UAB Diabetes Research and Training 
Center, University of Alabama at Birmingham, USA, 5Tulane University 
Health Sciences Center, New Orleans, USA, 6Endocare Research Institute, 
Universidad del Rosario, Bogota, Colombia, 7Daiichi Sankyo, Inc., 
Parsippany, USA, 8Daiichi Sankyo Pharma Development, Edison, USA.
Background and aims: Both hypercholesterolemia and prediabetes increase 
cardiovascular disease risk. Colesevelam has been shown to reduce LDL-C 
and fasting plasma glucose (FPG) in patients (pts) with hypercholesterolemia 
and prediabetes. A 16-week (wk), randomized, double-blind, placebo-con-
trolled, multinational study evaluated the lipid- and glucose-lowering effect 
of colesevelam in pts with hypercholesterolemia and prediabetes.
Materials and methods: This post-hoc analysis evaluated the effect of cole-
sevelam in a subpopulation of Hispanic pts (those self identified enrolled in 
Colombia, Mexico, and the US) included in the 16-wk study. Adults with un-
treated prediabetes (2-h post-OGTT glucose: 7.8-11.1 mmol/L and/or FPG: 
6.1-6.9 mmol/L), LDL-C ≥2.6 mmol/L, and triglycerides (TG) <5.7 mmol/L 
were randomized 1:1 to colesevelam 3.75 g/d or placebo. Primary endpoint 
was percent change in LDL-C from baseline to Wk 16. All efficacy analyses 
were performed using last observation carried forward at Wk 16.
Results: In total, 153 Hispanic pts received colesevelam (n=77) or placebo 
(n=76). There was a significant LS mean percent change with colesevelam vs 
placebo from baseline to Wk 16 in: LDL-C (-14.7% vs 4.8%; treatment dif-
ference [TD]: -19.4%; P<0.0001), non-HDL-C (-10.2% vs 1.8%; TD: -12.0%; 
P<0.0001), total cholesterol (-6.9% vs 2.8%; TD: -9.7%; P<0.0001), apoB (-
8.0% vs 2.2%; TD: -10.2%; P=0.0002), and TG (median: 5.9% vs -8.1%; TD: 
15.4%; P=0.003). ApoA-I increased with both colesevelam (5.0%) and place-
bo (4.4%) at Wk 16. A significantly greater proportion of pts achieved LDL-C 
<2.6 mmol/L with colesevelam vs placebo at Wk 16 (27% vs 11%; P=0.002). 
Colesevelam vs placebo also produced significantly greater reductions from 
baseline in FPG (median: -0.2 vs -0.1 mmol/L; TD: -0.1 mmol/L; P=0.024) 
and HbA1c (mean: -0.14% vs -0.02%; TD: -0.12%; P=0.009) at Wk 16. The 
proportion of pts achieving normalization of glucose (FPG <5.6 mmol/L) was 
significantly greater with colesevelam vs placebo (44% vs 23%; P=0.0497). 
Overall, colesevelam was well tolerated in Hispanic pts with hypercholestero-
lemia and prediabetes (Table).
Conclusion: In Hispanic pts with hypercholesterolemia and prediabetes, 
colesevelam may be a suitable option for lowering LDL-C and improving the 
metabolic profile. Further investigation regarding the effect of colesevelam on 
progression to type 2 diabetes is warranted.
Summary of Adverse Events
n (%) Colesevelam
(n=81)
Placebo
(n=78)
Patients reporting AEs 44 (54) 46 (59)
Patients reporting drug-related AEs 13 (16) 10 (13)
Patients reporting SAEs 1 (1) 2 (3)
AEs occurring in ≥5% of patients
Back pain 3 (4) 5 (6)
Constipation 9 (11) 3 (4)
Diarrhea 4 (5) 6 (8)
Headache 6 (7) 10 (13)
Hypertension 1 (1) 5 (6)
Influenza 9 (11) 7 (9)
Supported by: Daiichi Sankyo, Inc., who markets colesevelam in the US
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Meta-analysis evaluating the proportions of patients with and without 
diabetes achieving lipid/lipoprotein goals with ezetimibe/statin 
combination therapy versus statin alone
P. Brudi1, J.R. Guyton2, J. Betteridge3, M. Farnier4, L.A. Leiter5, J. Lin6,  
A. Shah6, A.O. Johnson-Levonas6; 
1Merck Sharp & Dohme Corp, Whitehouse Station, USA, 2Duke University 
Medical Center, Rahleigh, USA, 3Royal Free & University College London 
Medical School, USA, 4Point Medical, Dijon, France, 54Keenan Research 
Centre in the Li Ka Shing Knowledge Institute of St. Michael’s Hospital, 
Toronto, Canada, 6Merck Sharp & Dohme Corp, Rahway, USA.
Background and aims: Treatment guidelines identify low-density lipopro-
tein cholesterol (LDL-C) as a major target of treatment in hypercholestero-
lemic patients with non-high-density lipoprotein cholesterol (non-HDL-C), 
apolipoprotein (apo) B and high-sensitivity C-reactive protein (hs-CRP) as 
secondary targets or emerging risk factors. This meta-analysis compared pro-
portions of hypercholesterolemic patients with and without diabetes achiev-
ing various targets specified levels following treatment with ezetimibe 10 mg 
plus statin therapy (pooled across statin dose/type; EZE/statin) versus statin 
monotherapy (pooled across statin dose/type).
Materials and methods: This was a pooled analysis of 27 previously pub-
lished, randomized, double-blind, active or placebo-controlled clinical trials 
conducted in 21794 adult patients (age range: 18-81 yr) with elevated LDL-C 
(LDL-C range: 1.81-6.48 mmol/L) receiving EZE/statin or statin alone for 
4-24 wk. Patients were classified as having diabetes (either type 1 or 2). This 
analysis evaluated % of patients achieving various treatment goals at study 
endpoint in patients with (n=6541) and without diabetes (n=15253). Ad-
justed odds ratios (95% CIs) were calculated to evaluate the between-treat-
ment ability to achieve specified levels in the overall population and within 
subgroups.
Results: Calculated odds ratios for the single levels are presented in the Ta-
ble. Significantly more patients with and without diabetes achieved LDL-C 
(<2.59, <1.99, and <1.81 mmol/L), non-HDL-C (<3.37 and <2.59 mmol/L), 
apo B (<0.9 and <0.80 g/L) and hs-CRP (<2 and <1 mg/L) levels with EZE/
statin vs statin alone. Patients with diabetes were more likely to reach single 
LDL-C and apo B targets than were non-diabetes patients. Greater goal at-
tainment rates with EZE/statin vs statin alone also were seen for the dual 
(LDL <2.59 mmol/L and apo B <0.9 g/dL, LDL-C <1.81 mmol/L and apo B 
<0.8 g/L, LDL-C <1.99 mmol/L and apo B <0.8 g/L as well as hs-CRP <2 mg/L 
and LDL-C <2.59 mmol/L) and triple targets (LDL-C <2.59 mmol/L and apo 
B <0.9 g/L and non-HDL-C <3.37 mmol/L as well as LDL-C <1.81 mmol/L 
and apo B <0.8 g/L and non-HDL-C <2.59 mmol/L) both in the overall popu-
lation and by diabetes status.
Conclusion: In this meta-analysis, significantly more patients with and with-
out diabetes achieved specified LDL-C, non-HDL-C, apo B and hs-CRP levels 
with treatment with EZE/statin combination therapy vs statin monotherapy. 
The goal attainment for LDL-C, non-HDL-C and Apo B were significantly 
greater in patients with diabetes than those without diabetes.
Supported by: Merck
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Comparative efficacy of fenofibrate/pravastatin/ezetimibe and 
simvastatin/ezetimibe therapies in type 2 diabetic patients with 
combined hyperlipidaemia and cardiovascular disease
M. Farnier1, A. Steinmetz2, A. Csaszar3, K. Retterstol4, M. Dluzniewski5; 
1Point Médical, Dijon, France, 2St Nikolaus-Stiftshospital GmbH, 
Andernach, Germany, 3State Health Center, Budapest, Hungary, 4Oslo 
University Hospital - Rikshospitalet, Norway, 5Warsaw Hospital, Poland.
Background and aims: Very high risk patients with type 2 diabetes (T2D) 
and cardiovascular disease often require combination therapy to achieve rec-
ommended LDL-cholesterol (LDL-C) and non HDL-cholesterol (non-HDL-
C) goals. This study evaluated the efficacy and safety of Fenofibrate (F) 160 
mg/Pravastatin (P) 40 mg fixed dose combination and Ezetimibe (E) 10 mg 
compared to Simvastatin (S) 20 mg and E10 mg in T2D patients with cardio-
vascular disease and not at goals on S20 mg.
Materials and methods: This randomized, double-blind, parallel group 
study was conducted at 73 European centers. After a 6-week run-in peri-
od on S20 mg, 273 patients with non-HDL-C ≥ 100 mg/dL or LDL-C ≥ 70 
mg/dL and triglycerides (TG) 150-600 mg/dL were randomized (week 0) 
for a 12-week treatment period to the F160 mg/P40 mg and E10 mg triple 
therapy or the combination of S20 mg and E10 mg, followed by a 12-week 
open-label period where all patients received the triple therapy. The primary 
efficacy comparison was the mean percent (%) changes in non-HDL-C (F/
P+E vs S+E). Secondary end-points included LDL-C, HDL-C, TG, ApoB 
and fibrinogen.
Results: At week 12, no significant differences were observed between the 
F160/P40+E10 group and the S20+E10 group in reducing non-HDL-C 
(-21.2% vs -24.7%; p=0.09) and ApoB (-15.7% vs -18.1%; p=0.149), and 
in increasing HDL-C (+3.5% vs +0.5%; p=0.066). The changes in LDL-C 
were -19.8% in the F160/P40+E10 group and -25.1% in the S20+E10 group 
(p=0.05). The triple therapy was more effective than S20+E10 in reducing TG 
(-22.8% vs -8.2%; p=0.007) and fibrinogen (-11.8% vs +0.6%; p<0.0001). The 
triple therapy was generally well tolerated with a safety profile comparable to 
the S20+E10 combination therapy. Especially no cases of myopathy or rhab-
domyolysis were reported.
Conclusion: The Fenofibrate160 mg/Pravastatin 40 mg fixed-dose combina-
tion associated with Ezetimibe 10 mg was a new alternative to improve the 
global atherogenic lipid profile in T2D patients with combined hyperlipi-
demia in secondary prevention.
Supported by: SMB Laboratories Belgium
1297
Effect of one year treatment with insulin and oral glucose-lowering 
agents on lipid levels in non-obese patients with type 2 diabetes
S.S. Lund1, L. Tarnow1, B.B. Nielsen1, B.V. Hansen1, M. Frandsen1, O. 
Pedersen2, H.-H. Parving3, A.A. Vaag1; 
1Steno Diabetes Center, Gentofte, 2Hagedorn Research Institute, Gentofte, 
3Dep of Medical Endocrinology, Rigshospitalet, Copenhagen, Denmark.
Background and aims: In non-obese patients with type-2 diabetes (T2DM), 
metformin has been suggested to improve cholesterolaemia more so than an 
insulin secretagogue despite similar glycaemic control. Also, the cholesterol-
lowering effect of metformin has been suggested to be enhanced by concomi-
tant statin therapy. It is unknown if these effects persist when treatments are 
combined with insulin therapy. We aimed to study the effect of repaglinide 
(an insulin secretagogue) versus metformin both in combination with insulin 
therapy on lipid levels in non-obese T2DM patients. Furthermore, the effect 
of statin use was of interest.
Materials and methods: 101 non-obese T2DM patients (BMI ≤27 kg/m2) 
with HbA1c ≥6.5% on oral agents were randomised to one year treatment with 
insulin (biphasic insulin aspart 70/30) in combination with either repaglinide 
6 mg or metformin 2g (double-masked). Insulin doses were adjusted aiming 
for HbA1c<6.5%. Those patients who did not start or stop statin therapy dur-
ing follow-up were analysed (n=88).
Results: In statin users, insulin plus metformin (n=43) significantly lowered 
fasting total and Non-HDL cholesterol (Non-HDLC) compared with insu-
lin plus repaglinide (n=40) (mean [95% CI] baseline-adjusted difference be-
tween treatments for Non-HDLC: −0.26 mmol/l [−0.49; −0.02], p=0.039). In 
patients not using statins (n=5), no statistical significant differences of plas-
ma lipid levels was observed between patients using insulin plus metformin 
versus insulin plus repaglinide. Conclusions were similar after adjusting for 
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changes in statin doses. Insulin doses and HbA1c were similar between treat-
ments (previously reported).
Conclusion: In non-obese T2DM patients using statins one-year treatment 
with insulin plus metformin rather than insulin plus an insulin secretagogue 
might improve proatherogenic cholesterolaemia. This supports potential car-
dioprotective effects of metformin when combined with insulin even in statin 
users.
Supported by: Novo Nordisk A/S
1298
Loss of the association between plasma Pro-protein Convertase 
Subtilisin/Kexin type 9 (PCSK9) and LDL-apoB100 catabolism in type 2 
diabetes
B. Vergès1,2, P. Costet3, L. Duvillard2, M.-C. Brindisi2, M. Krempf3, B. Cariou3;
1Endocrinology-Diabetology, Hôpital du Bocage, Dijon, 2INSERM CRI866, 
Dijon, 3INSERM U915, Nantes, France.
Background and aims: Pro-protein convertase subtilisin/kexin type 9 
(PCSK9) is an important regulator of LDL metabolism because of its ability to 
facilitate degradation of LDL-receptors. It has recently been shown, in non-
diabetic men, that plasma PCSK9 level was inversely correlated with LDL 
apoB100 fractional catabolic rate (FCR) suggesting an influence of plasma 
PCSK9 on LDL catabolism. However, the association between plasma PCSK9 
and LDL catabolism remains unknown, in patients with type 2 diabetes.
Materials and methods: This prompted us to perform a kinetic study of 
LDL-apoB100, using C13 leucine, in 38 individuals (20 men, 18 women) in-
cluding 23 non diabetic normolipidemic subjects and 15 patients with type 
2 diabetes.
Results: Plasma PCSK9 levels were not significantly different between non 
diabetic subjects and patients with type 2 diabetes (271 ± 109 vs. 301 ± 96 
ng/ml). In the non diabetic group, plasma PCSK9 was positively corre-
lated with age (r=0.38, p=0.018), LDL-cholesterol (r= 0.43, p=0.006), apoB 
(r=0.44, p=0.005) and inversely correlated with LDL-apoB100 FCR (r=-0.52, 
p=0.001). In multivariate analysis, LDL-apoB100 FCR was independently as-
sociated with PCSK9 (p=0.0006) and gender (p=0.038), but not with age or 
BMI. Plasma PCSK9 concentration explained, in this non diabetic popula-
tion, 37% of the variance in LDL-apoB100 FCR. On the other hand, in the 
population with type 2 diabetes no correlation was found between plasma 
PCSK9, on the one hand, and LDL-cholesterol, apoB and and LDL-apoB100 
FCR, on the other hand. In both groups, no correlations were found between 
plasma PCSK9 and LDL-apoB Production Rate.
Conclusion: Our data indicate that plasma PCSK9 influences significantly 
the catabolism of LDL-apoB100 in individuals without diabetes but not in 
patients with type 2 diabetes. The reasons for this loss of association between 
plasma PCSK9 and LDL catabolism, in type 2 diabetes, remain to be deter-
mined.
1299
Effects of extended release niacin/laropiprant on lipoprotein 
subfractions in patients with type 2 diabetes mellitus
E. O’Neill1, A. MacLean1, H. Giezek2, D. Maccubbin1; 
1Merck Sharp & Dohme Corp, Rahway, USA, 2Merck Sharp & Dohme Corp, 
Brussels, Belgium.
Background and aims: Lipid management guidelines emphasize reducing 
LDL cholesterol as the primary goal of pharmacologic treatment. However 
other lipoprotein parameters, including increased plasma concentrations of 
small LDL, and IDL particles, and reduced plasma concentration of medium/
large HDL particles, may also place patients at increased risk for coronary 
heart disease. Patients with T2D are especially prone to this atherogenic li-
poprotein phenotype Extended release niacin/laropiprant (ERN/LRPT) is a 
fixed-dose combination tablet containing 1 g of ERN and 20 mg of LRPT, 
a prostaglandin D2 receptor antagonist that reduces ERN-induced flushing 
while preserving ERN’s LDL-C and triglyceride lowering, and HDL-C raising 
effects. In this assessment, the effects of 12 weeks of treatment with ERN/
LRPT in patients with T2D on plasma lipoprotein particles were evaluated.
Materials and methods: In a multicenter, double-blind, placebo-controlled, 
36-week study, T2D patients (n=796) were randomized 4:3 to ERN/LRPT (1 
tablet / day) or placebo (PBO). After 4 weeks 2 tablets / day of ERN/LRPT 
were given for the remainder of the study. HDL, LDL, VLDL, and chylomi-
cron particle size and concentration were evaluated at week 12 by NMR. Li-
poprotein subfraction data are reported as summary statistics without adjust-
ment for covariates.
Results: At week 12, ERN/LRPT produced significant (p≤0.001 for all) 
changes in LDL-C (-17.9%), HDL-C (23.2%), and triglycerides (-23.1%). 
Compared with PBO, ERN/LRPT treatment was associated with a relative 
shift in the plasma concentration of HDL particles from small to large diam-
eter, and a decrease in the plasma concentrations of all LDL and IDL particles 
(Table). ERN/LRPT also produced large reductions in the plasma concentra-
tions of all VLDL and chylomicron particles relative to PBO.
Conclusion: In patients with T2D, 12 weeks of treatment with ERN/LRPT 
shifted the overall lipoprotein profile toward a potentially less atherogenic 
pattern: reducing the plasma concentration of small LDL and IDL particles 
and increasing the plasma concentration of large HDL particles compared 
with PBO.
PLASMA LIPOPROTEIN CONCENTRATIONS MEDIAN baseline / MEDIAN 
CHANGE from Baseline at Week 12 *
TREAT-
MENT
HDL 
Small†
HDL 
Medium†
HDL 
Large†
LDL Very 
Small‡
LDL 
Small‡
LDL Medium / 
Small‡
LDL 
Large‡
IDL‡
ERN/
LRPT 
(N=382)
23.5 / 
-2.9
0.7 / 0.0 5.7 / 2.0 602.0 / 
-100.0
746.5 / 
-116.0
148.0 / -12.0 350.0 / 
-24.5
15.5 / 
-3.5
PBO 
(N=304)
23.9 / 
-1.0
0.8 / 0.0 6.0 / 0.0 634.0 /  
-9.0
793.0 / 
-7.0
163.0 / -3.0 325.0 / 
1.0
20.0 / 
-1.0
*evaluation by NMR: initial summary statistics, full analysis set; †µmol/L; ‡nmol/L
Supported by: Merck Sharp & Dohme Corp
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Role of HDL glycation and glycoxidation in counteracting the inhibitory 
effect of oxidized LDL on endothelium-dependent vasorelaxation
M.-C. Brindisi1,2, L. Perségol2, L. Duvillard2, D. Rageot3, B. Vergès1,2; 
1Diabetology, Teaching Hospital, 2Physiopathology of dyslipidemia, Inserm 
Research Center 866, 3Research Federative Institute 100, Teaching Hospital, 
Dijon, France.
Background and aims: In healthy normolipidaemic and normoglycaemic 
control subjects, HDL are able to reverse the inhibition of vasodilation in-
duced by oxidized LDL. We have previously shown that in type 1 diabetic 
patients, HDL do not protect against the inhibition of endothelium depend-
ant vasorelaxation induced by oxidized LDL. This defect was not explained 
by abnormalities in HDL composition, size or paraoxonase activity. The aim 
of this study was to analyse the role of glycation or glycoxidation of HDL on 
this vasodilation effect.
Materials and methods: Blood samples were collected from healthy patients. 
Extracted HDL particles, separated by ultracentrifugation, were glycated or 
glycoxidized in vitro. Vasoreactivity was evaluated by the relaxation response 
to acetylcholine of rabbit aorta rings pre-contracted with noradrenaline, 
before and after two hours incubation with or without different lipoprotein 
fractions (Krebs’buffer; ox-LDL; normal, glycated or glycoxidized HDL alone; 
normal, glycated or glycoxidized HDL + ox-LDL).
Results: The lipid composition of normal, glycated and glycoxidized HDL 
was similar. The mean of the Fructosamine/ApoA1 ratio was 17.58 µmole 
/g of protein for normal HDL and 48.67 and 53.63 µmole /g of protein for 
glycated and glycoxidized HDL, respectively. The oxysterol level of glycoxi-
dized HDL was significantly higher than that for normal and glycated HDL 
(p=0.009 and p=0.016 respectively). Oxidized LDL inhibited endothelium 
vasodilation (maximal relaxation (Emax) = 53.34 ± 27.06 vs 98.67 ± 10.16 % 
for incubation in Krebs’buffer, p<0.005). Normal HDL were able to counter-
act the oxidized LDL-induced inhibition of vasorelaxation (Emax = 78.75 ± 
19.72 vs 53.34 ± 27.06 %, p=0.003), whereas glycated and glycoxidized HDL 
had no effect (p=0.35 and 0.092 respectively). No difference was observed 
between glycated and glycoxidized HDL (p=0.28).
Conclusion: Our data indicate that glycation of HDL, is responsible for the 
inability of HDL particles to counteract the oxidized LDL-induced inhibition 
of endothelium-dependent vasorelaxation. The oxidation of glycated HDL 
brings no additional effects. Glycation of HDL is probably one important fac-
tor that explains the absence of the vasodilation effect of HDL particles in 
patients with diabetes.
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Insulin restores selective insulin resistance in type 2 diabetic mellitus 
patients with severe hypertriglyceridaemia
S.R. Henderson, R. Maitland, O.G. Mustafa, M. Crook, S.R. Kottegoda; 
Metabolic Medicine Unit, University Hospital Lewisham, London, United 
Kingdom.
Introduction: Severe hypertriglyceridaemia (SHTG) is a recognised com-
plication of type 2 Diabetes Mellitus (T2DM) and poses significant risk of 
premature atherosclerosis and pancreatitis. Altered regulation of triglyceride 
(TG) metabolism by hepatic and adipose tissue remains critical in T2DM 
patients. Hyperglycaemia is associated with resistance of hepatic transcrip-
tion factor FoxO1 and adipose tissue lipoprotein lipase (LPL) to the actions 
of insulin, resulting in uncontrolled gluconeogenesis and reduced hydrolysis 
of serum TG. Conversely, recent research has highlighted that hepatic TG 
production remains sensitive to circulating insulin, through the activation 
of transcription factor SREBP-1c, perpetuating the detrimental effects of hy-
perglycaemia and SHTG. We report the novel use of continuous intravenous 
(IV) insulin to restore this selective insulin resistance and reduce the risk of 
SHTG in T2DM.
Methods: Patients with hyperglycaemia and SHTG (serum TG >15mmol/L) 
treated with continuous insulin were retrospectively evaluated within our 
centre. Demographics, admission details, lipid profiles, glycaemic control 
and adverse events were recorded. Patients receiving treatment dose heparin 
were excluded to minimise effect on LPL.
Results: Fifteen patients were reviewed. Mean patient age 46 (27 - 70) years. 
Patients included 8 Caucasians, 5 Afro-caribbeans and 2 Indo-asians. New 
onset T2DM was diagnosed in 7 cases. Mean disease duration in the remain-
ing cohort was 60 (2 - 96) months. Median admission HbA1c measured 9.6% 
(6.1 - 16.1). Pre-admission Insulin was utilised in 75% (n=6) and Metformin 
in 25% (n=2) patients. Acute pancreatitis was diagnosed in 3 patients prior 
to insulin infusion. Median admission serum TG measured 26.23mmol/L 
(15.09 - 48.43) and serum cholesterol 11.24mmol/L (5.39 -19.62). Continu-
ous insulin was infused for an average 48 hours (24 - 72). Median serum TG 
reduced to 15.79mmol/L (0.79 - 36.59) following 24 hours insulin infusion 
(n=15) and 12.15mmol/L (5.74 - 32.49) at 48 hours duration (n=8). Insulin 
infusion continued for 72 hours in 7 patients with median serum TG meas-
uring 10.20mmol/L (5.74 - 24.03). Median discharge serum TG measured 
5.75mmol/L (0.79 - 11.66) and serum cholesterol 5.90mmol/L (3.65 - 10.74) 
correlating with significant reduction in serum TG following IV insulin 
(p=<0.05). Median length of hospitalisation was 4 days (3 - 15). Concomitant 
lipid lowering therapy included statins (n=9) and omega-3-acid ethyl esters 
(n=9). Continued administration of Fenofibrate occurred in 2 patients. Pro-
phylactic low molecular weight heparin was given to all patients (Enoxaparin 
20-40mg).
Conclusion: These results detail SHTG associated with hyperglycaemia in a 
heterogeneous group of T2DM patients ranging from new onset diabetes to 
established disease. Yet, in all patients, administration of continuous insulin 
appears to not only achieve normoglycaemia but also dramatically correct 
SHTG. Insulin stimulates the action of LPL in adipocytes and these findings 
support this theory owing to the rapid clearance of serum TG. In addition, we 
speculate that administration of insulin may also regulate gluconeogenesis 
and hepatic TG synthesis in hyperinsulinaemic patients; restoring selective 
insulin resistance. Ultimately, the administration of continuous insulin in 
T2DM patients with SHTG is a simple method of reducing the immediate 
risk associated with this metabolic complication.
1302
Underutilisation of statins in patients with type 2 diabetes treated with 
an antihyperglycaemic regimen
L. Radican1, A.Z. Fu2, Q. Zhang1, S.-R. Pentakota3, T. Seck4; 
1Global Outcomes Research, Merck Sharp & Dohme, Corp., Whitehouse 
Station, 2Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, 
3School of Public Health, University of Medicine & Dentistry of New Jersey, 
Whitehouse Station, 4Merck Research Laboratories, Rahway, USA.
Background and aims: Patients with type 2 diabetes (T2DM) are at a high 
risk for cardiovascular (CV) events. Diabetic dyslipidaemia is a key CV risk 
factor and statin therapy has been demonstrated to reduce CV risk. Therefore 
use of statins is widely recommended in current treatment guidelines for pa-
tients with T2DM. The purpose of this study was to estimate the proportions 
of patients with T2DM treated with an antihyperglycaemic agent (AHA) who 
needed a statin therapy based on ADA recommendations and of patients who 
received statin therapy in clinical practice.
Materials and methods: The study used the GE Healthcare’s electronic medi-
cal record database, and included patients who were ≥25 years with T2DM 
and received AHA (oral or insulin) prescription (Rx) between 7/2006 and 
6/2008 (index period). The index date was the date of the first AHA Rx within 
the index period. Patient eligibility for statin therapy according to the ADA 
Standards of Medical Care in Diabetes (2008) was assessed using patient 
medical records 1 year prior to (baseline) and 1 year after (follow-up) the in-
dex date. Concomitant statin use with AHA therapy was based on Rx records 
during the follow-up period. Logistic regression was performed to estimate 
the likelihood of statin use in relation to baseline characteristics, co-morbidi-
ties, clinical and laboratory measures, and medication use.
Results: Of the 113,906 patients with T2DM treated with AHAs, 48% were 
male and mean (SD) age was 63 (13) years. At baseline, LDL-C was ≥ 2.6 
mmol/L (100 mg/dL) in 49% of the patients not on a lipid-lowering agent 
(LLA) and in 34% of the patients on a LLA. While 98% of the patients met 
ADA eligibility standards for statin therapy, only 64% of patients actually re-
ceived a statin Rx during the follow-up period. The adjusted logistic regres-
sion showed that older age, male, smoking, baseline antihypertensive Rx, and 
baseline blood thinner Rx are factors associated with increased likelihood of 
statin use (all p<0.001).
Conclusion: Although nearly all patients with T2DM on AHA were eligible 
for statin therapy per ADA recommendations, only 64% were treated with 
statin in our study. This indicates that statins are underused in current clinical 
practice and a more integrated approach is needed to improve statin utiliza-
tion to reduce CV risk in patients with T2DM.
Supported by: Merck
Diabetologia (2010) 53:[Suppl1]S1–S556 S 515
1 C
PS 130 Endothelial function
1303
Arterial stiffness and endothelial dysfunction in type 1 diabetes mellitus
G. LLaurado1, M.P. Gil1, N. Freixenet1, A. Caixàs1, O. Giménez-Palop1, M. 
Rigla1, J. Vendrell2, J.M. González-Clemente1; 
1Diabetes, Endocrinology and Nutrition, Hospital de Sabadell, 
Corporació Sanitària i Institut Universitari Parc Taulí, Sabadell, 2Diabetes, 
Endocrinology and Nutrition, Hospital Universitari Joan XXIII. Institut 
Universitari Pere Virgili. CIBERDEM, Tarragona, Spain.
Background and aims: Subjects with type 1 diabetes mellitus (T1DM) have a 
very high cardiovascular (CV) risk, which is not fully understood by the clas-
sical CV risk factors. Arterial stiffness (AS) could provide some additional 
information regarding CV risk in these subjects. Endothelial dysfunction is 
involved in the atherosclerotic process. The studies regarding the relationship 
between AS and endothelial dysfunction in T1DM are few and contradictory. 
We aimed at evaluating the relationship between: (1) AS and CV risk factors 
and (2) AS and endothelial dysfunction.
Materials and methods: Sixty-eight subjects with T1DM were evaluated by 
(1) sex, age, BMI, WHR, systolic (SBP) and diastolic (DBP) blood pressure, 
smoking, HbA1c and lipid profile; (2) microvascular complications; (3) insu-
lin resistance (by way of the William’s mathematical estimation of the glucose 
disposal rate -eGDR-); (4) AS assessed as aortic pulse wave velocity (PWV) 
measured by applanation tonometry (SphygmoCor®) and (5) endothelial dys-
function assessed non-invasively by reactive hyperemia-peripheral arterial 
tonometry (RH-PAT; EndoPAT2000).
Results: We evaluated 34 men (aged 35.5±9 years, diabetes duration: 14.5±8.5 
years, BMI: 26.0±3.3 kg/m2, WHR: 0.91±0.08, SBP: 131.5±10.9 mmHg, DBP: 
76.7±7.1 mmHg, smokers: 36.4%, fasting plasma glucose (FPG) 156.2±68.7 
mg/dl, HbA1c: 7.4±1.1%, LDL: 100.5±26.1 mg/dl, microvascular complica-
tions: 27.3%) and 34 women (aged 35.2±11.2 years, diabetes duration: 12.9±8 
years, BMI: 25.3±3.9 kg/m2, WHR: 0.81±0.07, SBP: 118.3±9.6 mmHg, DBP: 
69.1±7.9 mmHg, smokers: 35.3%, FPG 172.7±64.0, HbA1c: 7.97±1.2%, LDL 
104.5±27.5mg/dl, microvascular complications: 23.5%). In the whole group, 
PWV correlated positively with age (r=0.53, p<0.001), diabetes duration 
(r=0.27, p=0.028), BMI (r=0.57, p<0.001), WHR (r=0.38, p=0.001), SBP 
(0.36, p=0.003) and DBP (r=0.26, p=0.031). In addition, we found a negative 
correlation between PWV and eGDR (r=-0.31, p=0.011). No association was 
found between PWV and smoking, lipid profile, FPG, HbA1c, microvascular 
complications and RH-PAT. In multivariate regression analysis, age (ß=0.46, 
p<0.001) and BMI (ß=0.40, p<0.001) were the only predictors of PWV (mod-
el R=0.686). Although PWV was similar in both genders (men: 7.13±1.34 vs 
women: 6.86±1.71, p=0.48), in multivariate regression analysis stratifying for 
sex, age (ß=0.43, p=0.007) and BMI (ß=0.34, p=0.029) were the only pre-
dictors of PWV in men (R=0.609) and age (ß=0.29, p=0.020), BMI (ß=0.48, 
p<0.001) and diabetes duration (ß=0.35, p=0.012) in women (R=0.786).
Conclusion: In subjects with T1DM, the main determinants of PWV were 
age and BMI. Additionally, diabetes duration was another determinant in 
women. We did not find any other independent relationship between PWV 
and the rest of the classical CV risk factors or glycemic control, suggesting 
that the measurement of PWV could be useful in the assessing of CV risk. 
Finally, we did not find any association between PWV and endothelial dys-
function measured by RH-PAT.
Supported by: ACD (2ª Beca G. Lloveras); F. Marató TV3 (081410)
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Endothelial dysfunction and arterial stiffness are linked in hypertensive 
patients with type 2 diabetes mellitus
E. Russo1, L. Pucci1, D. Lucchesi1, R.M. Bruno2, E. Storti1, C. Bianchi1, G.A. 
Daniele1, L. Ghiadoni2, S. Taddei2, R. Miccoli1, G. Penno1, S. Del Prato1; 
1Endocrinology and Metabolism, 2Internal Medicine, University of Pisa and 
Azienda Universitaria Ospedaliera Pisana, Pisa, Italy.
Background and aims: In diabetic as well as in hypertensive patients, in-
creased arterial stiffness and endothelial dysfunction both have been both 
associated with an increased risk of cardiovascular events. Arterial stiffness 
has been usually ascribed to vascular structural alterations, although a “func-
tional” component contributing to the compliance of large arteries has been 
demonstrated recently. An inverse correlation between endothelial dysfunc-
tion and arterial stiffness was reported in healthy subjects, while this inter-
relationship has been poorly explored in subjects at high risk of cardiovascu-
lar disease, such as patients with hypertension or diabetes. In this study this 
relationship has been evaluated in hypertensive patients with or without type 
2 diabetes mellitus.
Materials and methods: Hypertensive patients with (DM+, n. 69) and with-
out diabetes (DM-, n. 68), matched for age, gender, blood pressure, duration 
of hypertension and number and class of antihypertensive medications, were 
included. Brachial artery endothelium-dependent flow-mediated dilation 
(FMD) and endothelium-independent dilation by 25 µg sublingual glyceryl 
trinitrate (GTN) were assessed by high-resolution ultrasound and compu-
terized edge detection system. Applanation tonometry was used to measure 
aortic pulse wave velocity (aPWV), as index of arterial stiffness.
Results: DM+ patients showed higher BMI, waist circumference, blood glu-
cose and HbA1c values, as well lower total, LDL and HDL cholesterol levels 
compared with DM-. Urinary albumin to creatinine ratio (UACR) was with-
in the normal range in both groups and no difference in hsCRP was found. 
DM+ showed lower FMD (3.3±2.0 vs 5.0±3.2%, p<0.0001) than DM-, while 
GTN response was similar. Aortic PWV was higher in DM+ than in DM- 
patients (10.3±12.2 vs 8.8±1.4 m/s, p<0.0001). The difference remained sta-
tistically different (p=0.003) when mean BP, age and BMI were considered as 
covariates. An increased PWV, defined on the basis of the cut-off of 8.3 m/s, 
was found in 84% of DM+ and in 64% of DM- (p=0.006). Multiple regres-
sion analysis, driven by simple regression, was used to identify independent 
predictors of aPWV, including in the model age, systolic blood pressure, heart 
rate, blood glucose, HDL cholesterol, tryglicerides, BMI and waist circum-
ference. Age (r2=0.05, p=0.002), systolic blood pressure (r2=0.08, p=0.001), 
BMI (r2=0.07, p=0.003), and FMD (r2=0.04, p=0.03), were independently re-
lated to PWV (full model r2=0.45). In DM+, FMD (r2=0.11, p=0.003), systo-
lic BP (r2=0.14, p=0.006) and BMI (r2=0.08, p=0.02), remained independent 
predictors of aPWV (full model: r2=0.33). In DM-, age, but not FMD, was an 
independent predictor of PWV (r2=0.16).
Conclusion: We demonstrated that increased aortic stiffness is associated 
with endothelial dysfunction in hypertensive type 2 diabetic patients. The 
absence of this correlation in normoglycemic hypertensive patients, who 
have lower aortic stiffness and better endothelial function, suggests specific 
mechanisms related to the presence of diabetes.
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Circulating omentin-1 is associated with endothelial function 
independently of insulin sensitivity in subjects with altered glucose 
tolerance
J.M. Fernández-Real, J.M. Moreno-Navarrete, F.J. Ortega, A. Castro,  
M. Sabater, E. Esteve, W. Ricart; 
Department of Diabetes, Endocrinology and Nutrition. Institut 
d’Investigació Biomédica de Girona. CIBER Fisiopatología de la Obesidad y 
Nutrición CB06/03/010, Spain.
Background and aims: Omentin-1 is a novel soluble lectin expressed ex-
clusively in the endothelial cells of the blood vessels found in the visceral 
adipose tissue. Omentin has a vasodilating effect on isolated blood vessels, 
which is mediated through endothelium-derived NO. To gain insight in the 
relationship between obesity and cardiovascular risk factors, we aimed to 
explore the interaction among circulating omentin-1, metabolic parameters 
and endothelial function according to glucose tolerance status in a human 
cross-sectional study.
Materials and methods: Circulating omentin-1 (ELISA) was studied in 155 
healthy Caucasian men according to glucose tolerance status. Insulin sensi-
tivity was measured using the frequently sampled intravenous glucose toler-
ance test in 106 subjects. Vascular reactivity was measured by high-resolution 
ultrasound of the brachial artery in 58 of these subjects.
Results: Circulating omentin-1 concentration was significantly increased 
in non-obese compared with obese subjects with altered glucose tolerance 
(AGT, 47.6 ± 15.8 vs. 40.5 ± 13.2 ng/ml, p=0.04). In AGT subjects, serum 
omentin-1 was negatively associated with obesity parameters [body mass 
index (r=-0.24, p=0.04), waist to hip ratio (r= -0.25, p= 0.04) and fat mass 
(r=-0.29, 0.01)], blood pressure [systolic and diastolic blood pressure (r=-
0.27, p=0.02 and r=-0.26, p=0.025, respectively)] and circulating IL-6 (r=-
0.43, p=0.001) and positively linked to insulin sensitivity (r=0.36, p=0.03), 
endothelium-independent (r=0.50, p=0.007) and dependent (r= 0.33, p= 
0.04) vasodilation. Circulating omentin-1 (p=0.02) and systolic blood pres-
sure (p=0.01) contributed independently to endothelium-dependent but not 
to endothelium-independent vasodilation variance after controlling for con-
founding factors in AGT subjects.
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Conclusion: Omentin-1 might constitute a biomarker for endothelial func-
tion in AGT subjects.
Supported by: Ministerio de Educación y Ciencia and CIBERobn
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The extent of endothelial dysfunction in polycystic ovarian syndrome is 
moderated by obesity status
V.S. Sprung1, D.J. Cuthbertson2, C.J. Pugh1, G. Atkinson1, A. Irwin2, N. 
Aziz3, G.J. Kemp4, H. Jones1; 
1Research Institute for Sport and Exercise Sciences, Liverpool John Moores 
University, 2Department of Diabetes and Endocrinology, University Hospital 
Aintree, 3Department of Gynaecology, Liverpool Women’s Hospital, 
4Magnetic Resonance and Image Analysis Research Centre (MARIARC), 
University of Liverpool, United Kingdom.
Background and aims: Females with PCOS are at increased risk of cardio-
vascular disease (CVD). Recent reports suggest that endothelial dysfunction, 
an early marker of CVD, measured using the flow mediated dilatation (FMD) 
is evident in PCOS patients. Nevertheless, the supporting evidence remains 
equivocal, potentially due to differences in obesity and/or insulin resistance 
which are associated with increased CVD risk and also manifest in PCOS. 
The aim of this study was to examine the degree to which obesity moderates 
endothelial function in PCOS patients and controls using a formal meta-ana-
lytical approach.
Materials and methods: A systematic review of published studies comparing 
endothelial function in PCOS patients to control individuals was performed. 
Nine published and 1 recent unpublished study (PCOS n=621; control n=297 
participants) that measured endothelial-dependent FMD were included. At 
whole study level PCOS patient demographics included age range of 22.7-
35.2 yrs and BMI 23.8-33.8kg/m2 while control participants age ranged be-
tween 21.9-36.7yrs and the BMI from 22.8-37.3 kg/m2. All participants were 
normotensive and PCOS patients demonstrated at least two out of the three 
Rotterdam criteria. The FMD values for PCOS and controls were compared 
and meta-regressed against BMI. Data are described as mean±SD.
Results: The meta-analysed pooled reduction in FMD was found to be 3.7% 
(95% CI = 2.7 to 4.8%) in PCOS patients when compared with matched con-
trols (P<0.0005). Significant inter-study heterogeneity was detected (I-square 
= 68%, P=0.001). Therefore, meta-regression methods were used to explore 
the impact of BMI status on FMD reduction. The difference in FMD between 
PCOS and controls was less pronounced (group difference reduced by 0.2% 
per kg/m2) when participants were obese (P<0.0005). There was no evident 
publication bias (P=0.52).
Conclusion: There is overwhelming evidence that FMD is lower in PCOS 
patients compared with controls matched for BMI. Nevertheless, it is appar-
ent from this analysis that the endothelial dysfunction in PCOS is influenced 
by obesity; with larger differences in FMD between PCOS and control in-
dividuals when these individuals are normal weight, suggesting that obesity 
outweighs the PCOS effect on FMD.
1307
Integrated endothelial function assessment in morbidly obese subjects
M. Pawlowski1, P. Grzelak2, M. Saryusz-Wolska1, E. Szymanska-Garbacz1, A. 
Borkowska1, M. Gilewska1, J. Loba1, L. Stefanczyk2, L. Czupryniak1; 
1Diabetology, 2Radiology, Medical University of Lodz, Poland.
Background and aims: Endothelial function, particularly endothelium-de-
pendent vasodilation is impaired in overweight subjects and is thought to 
contribute to their increased risk of cardiovascular events. The mechanisms 
responsible for the adiposity-related reduction in endothelial vasodilatation 
function are not completely understood. We investigated endothelial func-
tion, inflammatory and glucose metabolism parameters in morbidly obese 
(BMI>40kg/m2) but otherwise healthy subjects.
Materials and methods: We studied 17 (5 men, 12 women, mean age 37,1+/-
8,4, BMI 44,14+/-3,9 kg/m2) normotensive obese subjects without prior 
diabetes diagnosis. 13 age-matched healthy non-overweight subjects served 
as controls. All subjects underwent oral 75 g glucose tolerance test (OGTT) 
with plasma insulin measurements. Fasting plasma subclinical inflammation 
markers (interleukin-6, IL-6; tumor necrosis factor-α, TNF- α), leptin, en-
dothelial dysfunction parameters (intercellular adhesion molecule, ICAM; 
vascular cell adhesion molecule, VCAM; E-selectin, thrombomodulin) were 
measured. In addition, endothelial function was assessed in vivo as flow-me-
diated dilation (FMD) and sublingual nitroglycerin response (nitrate-induced 
dilation, NID) in the brachial artery in all subjects. Intima-media thickness 
(IMT) of caroid artery was measured as well.
Results: During OGTT, as compared to the controls, obese subjects had 
higher glucose level at 60 min (141±38 vs 103±36 mg/dl; p<0.03) and 120 
min (121±33 vs 90±28 mg/dl; p<0.03) as well as fasting insulin level (28±25 
vs 10±8 µIU/mL; p<0.04) and insulin level at 60 min (115±63 vs 33±21 
µIU/mL; p<0.001). Moreover, in the obese subjects HOMA-IR (6.2±5.4 vs 
2.34±1.86, p<0.03), TNF-α (24.1±11.0 vs. 13.3±6.9 ng/ml), IL-6 (6.82±4.1 
vs 3.85±1.4 pg/ml; p<0.001), leptin (63.2±16.3 vs 26.2±18.1 mg/ml), VCAM 
(857±312 vs 613±210 ng/ml; p<0.02), sE-selectin (40.7±17.6 vs 25.8±19.6 pg/
ml, p<0.04), thrombomodulin (3.67±2.8 vs 1.1±0.53 pg/ml, p<0.004) were 
greater than in the controls, whilst NID (8.67±2.2 vs 14.5±3.2%, p<0.001) 
and FMD (4.73±1.9 vs 8.4±1.9%, p<0.001) parameters were lower than in 
the controls. IMT was higher in the study group (0.69±0.12 vs 0.59±0.1 mm, 
p<0.04). There was a significant and remarkable correlation between body 
weight and NID (r = -0.69, p<0.04) as well as FMD (r = -0.7; p<0.04) in the 
obese subjects, but a positive one with IMT (r=0.48; p<0.04). Glucose at 60 
and 120 min of OGTT inversely correlated with NID (r = -0.51 and r= -0,54; 
respectively, p<0,04) and FMD (r= -0,76 and r= -0.63; p<0.04), also plasma 
insulin at 60 and 120 min showed the same relationship with NID (r = -0.56 
and r= -0.45; respectively, p<0.04) and FMD (r= -0.76 and r= -0.51; respec-
tively, p<0.04). There were no differences between both groups in regard to 
plasma lipid profile, systolic and diastolic blood pressure.
Conclusion: Non-diabetes morbidly obese subjects already present with mild 
post-challenge hyperglycemia and hyperinsulinemia as well as endothelial 
dysfunction and sucblinical inflammation. The results of our study suggest 
that vascular injury associated with obesity precedes diabetes development. 
This finding might have important implications for adopting prevention 
measures of cardiovascular disease in morbidly obese individuals.
Supported by: 502-18-835
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Brown fat lipoatrophy with age is sufficient to induce obesity, vascular 
dysfunction and vascular insulin resistance
Y.F. Otero1,2, A. Gomez-Hernandez1,2, N. de las Heras3,4, O. Escribano1,2, V. 
Cachofeiro3,4, V. Lahera3,4, M. Benito1,2; 
1Biochemistry and Molecular Biology, School of Pharmacy, Madrid, 2CI-
BERDEM, Barcelona, 3Physiology, School of Medicine, Madrid, 4RECAVA, 
Madrid, Spain.
Background and aims: Recently, it has been described that functional brown 
adipose tissue (BAT) is prevalent in adult humans and has a protector role 
against obesity in older patients. Our aim was to study glucose metabolism 
and vascular alterations in BAT insulin receptor knockout mice (BATIRKO), 
a mouse model characterized by a conditional-dependent loss of interscapu-
lar brown fat and an insulin secretion defect.
Material and methods: In the present work, we have analyzed vascular func-
tion, vascular insulin signaling and the expression of genes involved in vas-
cular alterations in the aorta artery from 33- and 52-weeks old Control and 
BATIRKO mice.
Results: BATIRKO mice at 52 weeks had a significant decrease of BAT mass, 
as well as a significant increase of body weight, visceral WAT mass and TNF-α 
and leptin circulating levels. High circulating levels of these cytoadipokines are 
due to a significant increase of their expression by BAT and WAT. In addition, 
BATIRKO mice at 52 weeks showed more severe glucose intolerance and mild 
fasted hyperglycemia as compared with BATIRKO mice at 33 weeks. This fact 
is owing to an insulin secretion defect. We have also observed a significantly 
reduction of endothelium-dependent relaxation induced by acetylcholine 
in aortic rings from BATIRKO mice at 52 weeks-old as compared with at 33 
weeks-old BATIRKO mice. In contrast, endothelium-independent relaxations 
to sodium nitroprusside were comparable in all groups. In addition to endothe-
lial dysfunction, we observed a higher constrictor response to angiotensin II 
in aortic rings in 52 weeks BATIRKO mice as compared with all other groups 
studied. In addition, we observed a significant increase of genes markers of 
vascular dysfunction (ET-1 and ICAM-1) and inflammation (MCP-1, iNOS, 
TNF-α, TNFRs and PAI-1) in the aorta artery from 52 weeks BATIRKO mice 
as compared with all other groups studied. Finally, we analyzed vascular insulin 
resistance as vasorelaxing response to insulin in phenylephrine pre-contracted 
rings. A significant decrease trend of relaxing response to insulin in aortic rings 
was observed in 52 weeks BATIRKO mice versus all other groups studied. 
Concurrently, insulin signaling was dramatically impaired in aorta artery from 
BATIRKO mice at 52 weeks as revealed the lack of phosphorylation of AKT 
(Ser473) and eNOS (Ser1177) as compared with all other groups.
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Conclusion: Our results demonstrate that the lack of brown fat tissue mass 
during aging is sufficient to induce obesity, glucose intolerance, vascular 
dysfunction and vascular insulin resistance without an overall insulin resist-
ance.
Supported by: GRANTS SAF2005/00014, SAF2007/00058 AND SAF2008/ 
00031 FROM MICINN
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Microvascular reactivity and oxidative stress after standard breakfast in 
patients with recently diagnosed type 2 diabetes
E. Horova, M. Prazny, J. Škrha; 
3rd Department of Internal Medicine, 1st Faculty of Medicine, Charles 
University, Prague, Czech Republic.
Background and aims: The aim of the study was to compare skin microv-
ascular reactivity (MVR) with oxidative stress and metabolic parameters at 
fasting status and postprandially in patients with recently diagnosed Type 2 
diabetes.
Materials and methods: Twenty patients with Type 2 diabetes (mean age 
58±6 years, HbA1C 4.8±0.5%, diabetes duration 2.3±1.3 years, metformin 
treatment only) were included in the study. Blood samples were taken before 
and after 60, 120 and 180 minutes after standard breakfast. MVR was meas-
ured before and after 60 and 180 minutes. Standard breakfast consisted of 
one roll (40 g), jam (20 g), butter (10 g) and 200 ml of defined supplemental 
nutrition Resource (in total 2006 kJ, proteins 22.36 g, carbohydrates 62.94 g, 
fat 15.51 g). Skin MVR was measured by the laser Doppler flowmetry during 
post-occlusive (PORH) and thermal hyperemia (TH). Glycemia, insulinemia 
and β-hydroxybutyrate (BHB) concentration were evaluated and malonyldi-
aldehyde (MDA) and conjugated dienes (CD) were used for the estimation 
of oxidative stress.
Results: Blood glucose increased from baseline 6.9±0.6 mmol/l up to 8.0±1.6 
mmol/l after 60 minutes and 7.6±1.2 mmol/l (p<0.01) after 120 minutes in 
the postprandial phase. Glycemia consequently decreased after 120 minutes 
down to baseline level (6.2 ± 0.8 mmol/l). Insulinemia increased significantly 
(baseline, 60, 120, 180 minutes, respectively: 39±16 - 142±82 - 106±63 - 55±39 
mIU/l, p<0.01) while BHB decreased (0.24±0.16 - 0.16±0.06 - 0.15±0.07 - 
0.16±0.06 mmol/l, p<0.01). MDA concentration was significantly lower af-
ter 120 minutes than at baseline (3.02±0.48 vs. 2.80±0.40 μmol/l, p<0.05). 
Changes of several parameters of MVR were detected: maximal perfusion 
during PORH decreased after 180 minutes compared to baseline (235±66 vs. 
198±53 PU, p<0.01), although maximal perfusion (expressed in % of baseline 
perfusion) during PORH increased after 60 and 180 minutes (baseline, 60, 
120 minutes, respectively: 165±46 - 237±211 - 273±194 %, p<0.05). Signifi-
cant decrease was found in maximal perfusion during TH after 180 minutes 
compared to baseline (113±53 vs. 145±71 PU, p<0.05). Negative correlation 
was found between fasting glycemia and maximal perfusion during PORH 
(r=-0.51, p<0.05) and positive correlation was observed between the concen-
tration of CD and velocity of perfusion increase during TH (r=0.63, p<0.01). 
Positive correlation was found also between fasting concentration of CD and 
MDA (r=0.53, p<0.05) as well as between maximal perfusion during PORH 
and insulinemia after 60 minutes (r=0.65, p<0.01). Statistically significant 
positive relation was found between blood glucose and insulin after 180 
minutes (r=0.90, p<0.001) as well as between CD concentration and time to 
maximal perfusion during TH at the same time (r=0.59, p<0.01).
Conclusion: Significant metabolic changes were observed postprandially in 
patient with early stage of Type 2 diabetes in this study. In accordance with 
other studies, microvascular reactivity was probably mostly influenced by in-
creased insulinemia and vasodilatory effect of insulin. Moreover, MVR may 
also be modulated by the oxidative stress. The relationship between MVR and 
insulinemia may imply that the B-cell dysfunction can consequently lead to 
microvascular dysfunction through the effect of insulin. However, to confirm 
this hypothesis, further research in this field is necessary.
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Reduced number of early circulating vascular progenitor cells and 
increased central arterial stiffness in polycystic ovary syndrome
J. Karalliedde, M. Reza, G. Sivakumar, C. Dessapt, L. Gnudi; 
Cardiovascular Division, King’s College London, United Kingdom.
Background and aims: Subjects with Polycystic ovarian syndrome (PCOS) 
are at risk of type 2 diabetes and associated cardiovascular disease. The mech-
anism of this enhanced risk is unclear. The number and function of circu-
lating vascular progenitor cells (VPC) and arterial stiffness are independent 
predictors of cardio-metabolic risk. Aim: To study the number and function 
of VPC and arterial stiffness in non-obese PCOS subjects as compared to age 
and body mass index (BMI) matched healthy controls.
Materials and methods: Subjects with a confirmed diagnosis of PCOS with 
BMI<30 (n=17) attending a University hospital outpatient clinic and healthy 
controls (n=12) were studied. VPC number was measured by fluorescence ac-
tivated cell sorting. VPC function was assesed in vitro by tube formation and 
VPC migration assay. Augmentation index (AIx) a measure of central arterial 
stiffness and central aortic blood pressures were measured by applanation 
tonometry at the radial artery.
Results: There was no statistically significant differences between the PCOS 
vs. control group in, mean ± SEM, age (26.4±1.0vs. 23.2±1.5 yrs ), weight 
(61.0± 1.2 vs. 65.9±3.1 kg), BMI (24.2± 0.8 vs. 23.0± 0.7 kg/m2 p=0.26) and 
waist circumference (86.3± 2.5 vs. 82.1± 1.8 cm) p>0.05 for all. Brachial 
systolic blood pressure, mean arterial pressure and pulse pressures were 
similar between the two groups. Compared to controls subjects with PCOS 
had higher central SBP (103.7±2.4 vs. 94.9± 2.2 mmHg p=0.01), central DBP 
(75.6±1.8 vs. 69.7±2.4 mmHg p=0.06) and central pulse pressure (28.2±1.0 
vs. 25.1±1.1 p=0.04). AIx was significantly, more than 3 fold, higher in PCOS 
subjects compared to control (18.4±1.9 vs. 4.9± 2.0 p<0.0001). Subjects 
with PCOS had reduced a significantly reduced number of the early VPC 
CD34+133+ , mean ±SEM, 328.1± 47.9 vs. 591.0±120.5 p =0.02. Other puta-
tive VPC (CD34+KDR+, CD34+133+KDR+) were not statisically different 
between groups. VPC function was not impaired in PCOS as compared to 
healthy controls. CD34+133+ VPC number and AIx was not correlated.
Conclusion: Non obese PCOS is characterized by reduced numbers of early 
VPC but preserved function. PCOS subjects have increased central arterial 
stiffness. These two unrelated changes may explain the enhanced cardio-met-
abolic risk of this population.
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Hypertension and neuropathy are the main determinants of impaired 
total arterial compliance in type 2 diabetic patients
M. Nguyen1, E. Cosson1, I. Pham2, A. Nitenberg2, P. Valensi1; 
1Endocrinology-Diabetology-Nutrition, 2Department of Physiology, Jean 
Verdier Hospital, Bondy, France.
Background and aims: Total arterial compliance (TAC) of the systemic arte-
rial tree may be estimated by left ventricle stroke volume index/ pulse pres-
sure ratio (i.e. a substitute for volume changes of the arterial system/ an index 
of arterial stiffness). This ratio has been validated against invasive measure-
ments of arterial compliance. A low TAC level has been associated with an in-
creased risk of subsequent cardiovascular events in hypertensive patients and 
in elderly men. TAC has not yet been evaluated in the diabetic population, in 
particular as regards to cardiac ischemic disease. Objective was to examine 
the determinants of TAC in asymptomatic high-risk diabetic patients with 
known cardiac ischemic status.
Materials and methods: We included 287 asymptomatic patients, 166 men, 
59±8 years, with diabetes duration 13±7 years, with at least one additional 
risk factor (hypertension 73%, dyslipidemia 70%, smokers 22%, nephropa-
thy 38%) and without heart failure. All of them were prospectively screened 
for silent myocardial ischemia (SMI), defined as an abnormal stress myocar-
dial scintigraphy. TAC was calculated using echocardiographic left ventricle 
measurements and brachial blood pressure measurement. Cardiac autonomic 
neuropathy (CAN) was assessed using standard tests (deep-breathing, lying-
to-standing and Valsalva).
Results: Mean TAC was 0.68±0.23 ml/m²/mmHg. Lower TAC levels were 
associated with higher age (p=0.006), body mass index (p=0.03), diabetes du-
ration (p=0.04) and LDL cholesterol (p=0.004), and with peripheral neurop-
athy (p=0.001) and hypertension (p<0.001), respectively), but neither with 
SMI nor CAN. In multivariate analysis including all the significant correlates, 
hypertension (OR 2.5 [1.2-5.0], p<0.01) and peripheral neuropathy (OR 2.2 
[1.3-3.7], p=0.004) were independent predictors of TAC <0.56 (first tertile). 
In addition left ventricle stroke volume index was lower (p=0.02) and pulse 
pressure higher (p<0.01) in patients with than in patients free of peripheral 
neuropathy.
Conclusion: In high-risk but asymptomatic type 2 diabetic patients, hyper-
tension and peripheral neuropathy are the main determinants of a reduced 
TAC. Peripheral neuropathy might contribute to impair TAC by altering ves-
sel tone and vasomotion and increasing blood volume.
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Involvement of p66Shc in TNF-alpha-induced endothelial dysfunction
M.R. Orlando, L. Laviola, F. Tortosa, M. Incalza, A. Leonardini, M. 
Melchiorre, R. Labarbuta, S. Perrini, A. Natalicchio, F. Giorgino; 
Endocrinology & Metabolic Diseases, D.E.T.O., University of Bari, Italy.
Background and aims: The pro-inflammatory cytokine TNF-alpha impairs 
endothelial function by modulating gene expression and increasing intracel-
lular reactive oxygen species (ROS). The p66Shc isoform has been proposed 
as a sensor of cellular oxidative stress, through its phosphorylation on Ser36, 
and mediates stress signals in multiple cell types. The aim of our study was to 
investigate the role of p66Shc in TNF-alpha action in human umbilical vein 
endothelial cells (HUVEC).
Materials and methods: Expression and phosphorylation levels of specific 
signaling molecules were assessed by immunoblotting techniques. Intracel-
lular ROS generation, in the presence of the DHE probe, was evaluated by 
fluorimetric analysis. Gene expression was evaluated by quantitative RT-PCR 
(qRT-PCR). Wild-type p66Shc and mutant p66Shc, in which Ser36 had been 
replaced by Ala (p66Shc-Ala36), were selectively overexpressed following in-
fection with recombinant adenoviruses.
Results: Exposure of HUVEC to TNF-alpha (10-50 ng/ml) resulted in in-
creased E-Selectin and IL-8 mRNA levels (p<0.05), evaluated by qRT-PCR, 
and in increased intracellular ROS concentrations (p<0.05), assessed by 
fluorimetry. Treatment with TNF-alpha was also associated with increased 
phosphorylation of the stress kinase JNK-1/2 (p<0.05 at 30 min), of ERK 1/2 
(p<0.05 at 30 min), and of p66Shc on Ser36 (p<0.05 at 30 min). Pre-incuba-
tion of HUVEC with the JNK inhibitor SP600125 prevented JNK activation 
by TNF-alpha and the effect of this cytokine on E-Selectin mRNA (p<0.05 
vs TNF-alpha alone), but not that on IL-8 gene expression, and also reverted 
TNF-alpha-induced p66Shc phosphorylation on Ser36 and ROS generation. 
By contrast, treatment of HUVEC with the ERK inhibitor PD98059 blocked 
TNF-alpha-induced ROS production (p<0.05 vs TNF-alpha alone), but 
had no effects on E-Selectin gene expression and p66Shc phosphorylation 
on Ser36. We next obtained a selective 3-fold overexpression of p66Shc in 
HUVEC by adenoviral transfer (HUVEC/p66Shc). HUVEC/p66Shc showed 
increased p66Shc Ser36 phosphorylation both under basal conditions and 
following exposure to TNF-alpha (p<0.05 vs controls). This was associated 
with an increase in E-Selectin mRNA and ROS levels, both basally and after 
TNF-alpha exposure (p<0.05 vs controls). Pretreatment of HUVEC/p66Shc 
with the JNK inhibitor SP600125 significantly reduced the induction of E-
Selectin mRNA levels and ROS synthesis following TNF-alpha (p<0.05). In 
addition, pretreatment of HUVEC/p66Shc with the ERK inhibitor PD98059 
prevented TNF-alpha-induced ROS generation (p<0.05), but did not modify 
p66Shc phosphorylation on Ser36. Conversely, overexpression of a phospho-
rylation-defective p66Shc protein, in which Ser36 had been mutated to Ala, 
did not augment E-Selectin mRNA and ROS levels beyond those found in 
wild-type cells.
Conclusion: p66Shc acts as a novel signaling intermediate in the TNF-al-
pha-MAPK pathways mediating endothelial cell dysfunction, and its action 
requires p66Shc phosphorylation at Ser36.
Supported by: Italian Ministry of University and Research (MUR)
1313
Liraglutide down regulates endoplasmic reticulum stress in human 
endothelial cells exposed to hyperglycaemia
B. Schisano1, G. Tripathi1, A.L. Harte1, P.G. McTernan1, L. Knusden2,  
A. Ceriello3; 
1CSRI, University of Warwick, Coventry, United Kingdom, 2Novo Nordisk 
A/S, Copenhagen, Denmark, 3IDIBAPS, Barcelona, Spain.
Background: The endoplasmic reticulum (ER) is a key organelle where mem-
brane and secreted proteins fold into their tertiary and quaternary structure. 
The ER stress occurs when there is an accumulation of unfolded/misfolded 
proteins due to disruption of ER homeostasis. The accumulation of unfolded 
proteins results in the activation of the unfolded protein response (UPR) 
which is regulated by proteins such as IRE1α, PERK and ATF6. ER stress 
increases PERK activity, which phosphorylates eIF2α to reduce protein trans-
lation. ER contains molecular chaperone proteins including PDI, calnexin, 
Ero1-Lα and Grp78/BiP and others that promote oxidative protein folding. 
Data on pancreatic beta cells function indicate that augmented ER stress to-
gether with reduced insulin signalling both occur before the onset of frank 
diabetes. It has also been observed that ER stress may play a causative role in 
diabetic atherogenesis. Also recent data in mice suggests that hyperglycaemia 
increases intracellular ER stress, prior to the onset of atherosclerosis. Liraglu-
tide is a GLP-1 analogue that has been proven to enhance insulin signalling 
and reduce apoptosis in pancreatic beta cells. Investigating its effectiveness in 
reducing ER stress levels in endothelium might be of great use to determine 
its capacity in ameliorating not only the pancreatic function and insulin sen-
sitivity, but also prevent atherogenesis and thus cardiovascular complications 
in diabetics.
Materials and methods: Confluent human vascular endothelial cells (HU-
VECs) were exposed to a 15mM high glucose media with (HGL) or without 
(HG) 100nM of liraglutide. Controls were kept in a 5mM normal glucose 
media with (NGL) or without (NG) 100nM liraglutide with 10mM of man-
nitol for osmotic balance. After 12 hours of exposure to the hyperglycaemic 
media, proteins from all the conditions were extracted. Protein analysis was 
conducted by western blotting.
Results: HuVEC cells exposed to hg media lead to a significant (*p<0.01) up 
regulation of all the ER stress markers as detailed: PDI, calnexin, BiP, Ero1-
Lα, IRE1, phospho-eIF2α, compared to cells treated with ng. However in cells 
exposed to hg and liraglutide there was a significant reduction in ER stress 
protein expression levels compared to hg alone (PDI, BiP, Ero1-Lα, IRE1, 
phospho-eIF2α: p<0.01; calnexin, p<0.05) in HUVEC cells treated with and 
high glucose. Liraglutide had no additional effects on the basal expression of 
ER stress markers in normal glucose compared to control.
Conclusion: Our in vitro data demonstrates that liraglutide significantly 
down-regulates ER stress markers in endothelial cells exposed to high glu-
cose levels. This study indicates that liraglutide has additional beneficial ef-
fects to reduce ER stress and may support prevention of atherogenesis and 
thus cardiovascular complications in diabetic patients.
Supported by: Novo Nordisk
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Tissue kallikrein is essential for invasive capacity of circulating 
proangiogenic cells
G. Spinetti1, O. Fortunato1, D. Cordella1, P. Portararo1, N. Kraenkel2, G. 
Sala-Newby2, G. Tonolo3, S. Cherchi3, C. Emanueli2, P. Madeddu2; 
1IRCCS MultiMedica, Milan, Italy, 2University of Bristol, United Kingdom, 
3OC San Giovanni di Dio, Olbia, Italy.
Background and aims: The function of circulating proangiogenic cells 
(PACs) is altered in diabetes and inversely correlated with severity of vascular 
complications, but underpinning mechanisms remain unclear. We investigat-
ed the possibility that components of the kallikrein-kinin system, which are 
constitutively expressed in human PACs, may be downregulated in diabetes 
thus contributing to reduced PAC motility and invasiveness.
Materials and methods: Type 2 diabetic patients (T2D, n=22) and age- and 
gender-matched healthy subjects (n=16) were studied. Circulating mononu-
clear cells (MNCs) and culture-selected PACs were analyzed for expression 
of human tissue kallikrein (hK1) and kinin B2 receptor (B2R) by Q-RT-PCR, 
western blotting, immunofluorescence staining, and flow cytometry. Secre-
tion of hK1 by PACs was determined by measuring hK1 levels in conditioned 
media by ELISA and enzymatic activity assay. Moreover, the functional role 
of the hK1/B2R duo was assayed by analyzing in vitro cellular invasive po-
tential (modified Boyden chambers assay), proangiogenic action (matrigel 
assay) and activation of matrix metalloproteinase-2 (MMP2, in situ- and gel-
zymography) in the presence or absence of hK1 silencing by siRNA, B2R an-
tagonism by icatibant or MMP inhibition by GM6001. The activity of Akt was 
assayed as a measure of B2R coupling to its downstream signaling machinery. 
Adenovirus-mediated gene transfer of hK1 (Ad.hK1) and B2R (Ad.B2R) was 
used to rescue the impaired T2D PACs phenotype.
Results: The two groups did not differ in smoking habit and LDL levels. T2D 
patients had higher BMI (30.2 + 6.4 vs. 25.2+ 3.5% in healthy) and Hba1c 
levels ranging between 5 and 7.5 (average value 6.6+0.8), all patients were 
on diabetic diet, 18 out 22 were on metformin therapy. MNCs and culture-
selected PACs from healthy subjects express and release mature hK1 protein. 
HK1 gene silencing impaired migration/invasion and proangiogenic capaci-
ties and reduced MMP2 activity in healthy PACs. T2D PACs showed reduced 
invasion and proangiogenic potential (-1.8 and 2.0 fold vs. controls, p<0.05) 
and lower hK1 protein (-56.6 %, p<0.05), but normal hK1 mRNA abundance, 
pointing at a post-transcriptional defect. Furthermore, T2D-PACs expressed 
normal levels of B2R, but the receptor was not conductive as verified by re-
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duced Akt activity following kinin stimulation. Ad.hK1 increased the migra-
tory (1.6 fold) and invasive (1.8 fold) activity of healthy PACs, and stimulated 
their capacity to promote angiogenesis on matrigel (1.4 fold) (p<0.05 vs. 
Ad.Null, for all comparisons). Inhibitory experiments ascribed the effects of 
hK1 overexpression to B2R- and MMP-dependent mechanisms. Importantly, 
Ad.hK1 was unable to rescue the impaired invasion capacity of T2D-PACs 
and combined genetic engineering with hK1 and B2R was necessary to correct 
the diabetic phenotype.
Conclusion: Human PACs bear active hK1, which cooperates with B2R and 
MMP2 for invasion. T2D-induced deficit of hK1 results in PACs dysfunc-
tion. In diabetes, different components of the kallikrein-kinin system need 
to be overexpressed to restore proper invasiveness. This study unravels new 
molecular mechanisms underpinning PACs dysfunction in T2D.
Supported by: PG/06/035/20641, RBIN04N8YA
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Exendin-4, GLP-1(7-36) and GLP-1(9-36) stimulate proliferation of 
human coronary artery endothelial cells through PKA- and PI3K/Akt/
eNOS-dependent pathways
Ö. Erdogdu1, D. Nathanson2, Å. Sjöholm2, T. Nyström2, Q. Zhang1; 
1Department of Clinical Science and Education, 2Department of Internal 
Medicine, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden.
Background and aims: We recently showed that the glucagon-like peptide-
1 (GLP-1) receptor is expressed in human coronary artery endothelial cells 
(HCAECs) and that GLP-1 improves endothelial dysfunction in type 2 dia-
betic patients with coronary artery disease. Exendin-4 is a stable GLP-1 re-
ceptor agonist and has been approved for clinical use against type 2 diabetes. 
In contrast to their glycemic effects, the role of GLP-1 and its analogues on 
endothelial regeneration is not known. The aim of the present study was to 
investigate the effects of exendin-4, GLP-1(7-36) and GLP-1(9-36) on cell 
proliferation in HCAECs in vitro.
Materials and methods: HCAECs were treated with exendin-4 (1-10 nM), 
GLP-1 (7-36) (100 nM) or the major GLP-1 metabolite GLP-1 (9-36) (100 
nM), respectively, in serum-deficient medium in the presence of 5 mM glu-
cose for 48 h. Phosphorylation and expression of the endothelial nitric oxide 
synthase (eNOS), Akt and MAP kinase were examined by Western blotting 
using anti-phospho-eNOS (Ser1177), anti-eNOS, anti-phospho-Akt (Ser 
473), anti-Akt, and anti-phospho-MAPK ½ antibodies, respectively. 3H-thy-
midine incorporation was assayed in 96-well plates as a measure of DNA syn-
thesis after 48 h incubation.
Results: Incubation of HCAECs with exendin-4 for 48 h resulted in a dose-
dependent increase in DNA synthesis; subsequent neogenesis was confirmed 
by an increased cell number. Exendin-4 dose-dependently enhanced phos-
phorylation of eNOS after a 48 h-incubation. The exendin-4-induced activa-
tion of eNOS was associated with an increased NO production. In addition, 
incubation of HCAECs with exendin-4 resulted in an increased Akt phos-
phorylation, The exendin-4-stimulated activation of eNOS and Akt was pre-
vented after treatment of the cells with Rp-cAMP[S], LY294002, Akt inhibitor 
IV or L-NAME, the specific inhibitor for PKA, the phosphoinositide 3-kinase 
(PI3K), Akt and eNOS, respectively. Subsequently, the exendin-4-induced 
proliferation was abolished. Incubation of HCAECs with exendin-4 also 
caused activation of MAP kinase. However, suppressing MAP kinase activity 
did not affect exendin-4-induced cell proliferation. The effects of exendin-4 
on enzyme activation and cell proliferation were mimicked by GLP-1(7-36) 
and GLP-1(9-36), but blocked by the GLP-1 receptor antagonist exendin (9-
39). Co-incubation of exendin-4 with GLP-1(7-36) did not produce additive 
effects.
Conclusion: Our results indicate that exendin-4, GLP-1(7-36) and GLP-1(9-
36) stimulate proliferation of HCAECs by PKA and PI3K/Akt/ eNOS de-
pendent pathways. Proliferation of endothelial cells is involved in endothelial 
repair (arterial healing) and angiogenesis, a powerful mechanism to ensure 
blood supply to tissue at risk if a main artery is chronically occluded. These 
beneficial effects of exendin-4, GLP-1(7-36) and GLP-1(9-36) on human 
coronary artery endothelial cells may add yet another salutary non-glycemic 
property to incretin-based antidiabetic therapy, increasing its clinical utility 
in type 2 diabetic patients in whom endothelial dysfunction is a salient fea-
ture that adversely affect their survival.
Supported by: an EFSD/GSK grant
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The role of osteopontin in endothelial progenitor cell function
E.E. Vaughan1, A. Duffy2, T. O’Brien1; 
1REMEDI, NUI Galway, 2Medtronic Inc, Galway, Ireland.
Background and aims: We, and others, have shown that endothelial pro-
genitor cells (EPCs) obtained from patients with diabetes are dysfunctional. 
We previously identified the angiogenic protein osteopontin (OPN) as be-
ing down regulated in diabetic EPCs and furthermore we determined that 
OPN deficient mice do not recover as well as wild-type mice from hindlimb 
ischemia. Thus, we hypothesized that OPN may play a critical role in the an-
giogenic response mediated by EPCs. We aimed to establish the role OPN 
plays in EPC function and to determine if exposure to OPN could restore the 
function of OPN knockout EPCs in vivo.
Materials and methods: EPCs were obtained from OPN knockout mice 
as well as wild-type controls and cultured for 7 days followed by use in a 
matrigel tubule formation assay. Conditioned media from these cells was also 
used in the tubule formation assay as well as in a protein array. OPN knock-
out EPCs or knockout EPCs incubated with recombinant OPN were injected 
into the ischemic hindlimb of OPN knockout mice and laser Doppler blood 
flow analysis was performed immediately following surgery as well as at days 
7 and 14.
Results: To elucidate the role of OPN in EPCs, a matirgel tubule assay was 
used to assess in vitro angiogenic potential. KO EPCs induced significantly 
less tubule formation than WT EPC (p<.05, n=3). However, knockout EPCs 
that were pre-incubated with recombinant OPN induced tubule formation 
at levels similar to WT and significantly higher than KO cells that were not 
incubated with OPN (p<.05, n=3). Further, conditioned media (CM) from 
WT cells induced tubule formation to the same levels as the EPCs themselves 
suggesting that secreted proteins are responsible for angiogenic effect. Inter-
estingly, when KO EPC were pre-incubated with OPN, the CM media in-
duced tubule formation to WT levels(n=3), even though there was no OPN 
directly in the media. Hence, we further hypothesized that OPN is acting on 
EPC to induce the secretion of angiogenic cytokines. Thus a protein-array 
was performed on EPC from WT, KO and KO EPCs exposed to OPN. WT 
EPCs expressed FGFα at a much higher level than KO cells. Further, WT cells 
expressed Il-6 and TGF-α whereas KO cells did not express these proteins 
at detectable levels. Interestingly, when KO cells are exposed to OPN these 
proteins are expressed at WT levels. Additionaly, we demonstrated that EPCs 
from humans and diabetic rabbits incubated with OPN had increased ang-
iogenic potential in a tubule assay (p<.05 n=3) further suggesting that OPN 
plays a critical role n EPC funtion. When OPN KO EPCs were injected into 
the ischemic hindlimb of OPN KO mice blood flow to the limb was improved 
significantly at days 7 (p<.05 n=6) and 14 (p<.01).
Conclusion: Taken together, this data suggests that the decreased OPN ex-
pression in diabetic EPCs may contribute to their dysfunction. We propose 
that OPN increases the angiogenic potential of EPCs via an autocrine mech-
anism whereby OPN is secreted by the EPC and subsequently induces the 
expression of a variety of angiogenic proteins. Futher, we have demonstrated 
that incubation of OPN deficent EPCs with recombinant OPN is sufficent to 
restore function of the EPCs even when returned to an in vivo setting.
Supported by: SFI and Medtronic
1317
Impaired ischaemia-induced angiogenesis in diabetic mice depends on 
glycaemic variability
D. Pitocco, F. Zaccardi, F. Biscetti, G. Straface, P. Rizzo, T. Musella, A. Flex, 
S. Caputo, G. Ghirlanda; 
Internal Medicine, Catholic University, Rome, Italy.
Background and aims: Glycemic variability (GV) is an adjunctive risk factor 
for diabetic vascular complications. However, neither a cause-effect correla-
tion between glucose instability and vascular dysfunction, nor the molecular 
bases of such a dysfunction have been investigated previously. The aim of this 
study was to investigate the role of GV in diabetic vascular complications and 
to explore the molecular pathways modulated by glycemic “swings”.
Materials and methods: Diabetes was first induced by streptozocin in 60 
mice. Then 30 diabetic mice received basal insulin administration once daily 
plus two oral boluses of glucose solution (variable group, VG) and another 30 
mice received basal insulin once daily plus two oral boluses of saline solution 
(stable group,SC) for a period of 30 days. Glycemia was measured eight times 
daily to detect GV. Post-ischemic neovascularization, induced by hindlimb 
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ischemia 30 days after diabetes onset, was studied and compared in VG, SC 
and untreated groups.
Results: Indices of GV were significantly different between VG and SG 
groups, whereas there was no significant difference in the mean glycemic 
values. Laser Doppler perfusion imaging revealed that the mean blood flow 
of control mice reached 94% of the pre-ischemic flow 28 days after hindlimb 
surgery. Perfusion recovery was significantly attenuated in SC mice compared 
to control mice 7, 14, 21 and 28 days after surgery. Interestingly, recovery was 
significantly impaired in VG compared to the SG 7, 14, 21 and 28 days after 
ischemic injury. Histological analysis revealed a higher increase in the capil-
lary density of ischemic limbs in SG respect to the VG. Immunostaining and 
western blot analysis revealed that the impaired angiogenic response in VG 
occurred in association with reduced VEGF production and decreased eNOS 
and Akt phosphorylation.
Conclusion: This is the first murine model of GV. Our data indicate that GV 
causes a significant impairment of ischemia-induced angiogenesis in diabetes, 
regardless of average blood glucose levels, and that this impaired collateral 
vessel formation depends on an altered VEGF pathway. These findings provide 
new information to understand the biological and clinical effects of GV.
1318
Overexpression of glyoxalase-I improves vascular function in a rat model 
of diabetes 
O. Brouwers1, P.M.G. Niessen1, T. Miyata2, T. Teerlink3, B.J. Janssen4, J.G.R. 
De Mey4, C.D.A. Stehouwer1, C.G. Schalkwijk1; 
1Internal Medicine, Maastricht University, Netherlands, 2Centre of 
Translational and Advanced Research, Tohoku University, Sendai, 
Japan, 3Clinical Chemistry, VU University Medical Center, Amsterdam, 
Netherlands, 4Pharmacology & Toxicology, Maastricht University, 
Netherlands.
Background and aims: The reactive advanced glycation endproduct (AGE) 
precursor methylglyoxal (MGO) and MGO-derived AGEs are associated with 
diabetic vascular complications. In this study glyoxalase-I (GLO-I) transgen-
ic rats were used to explore whether overexpression of this MGO-detoxifying 
enzyme reduces levels of AGEs, and thereby improves cardiovascular func-
tion in a rat model of diabetes.
Materials and methods: Diabetes was induced in wild type (WT) and GLO-
I overexpressing animals by a single tail vein injection with streptozotocin 
(STZ). After 12 and 24 weeks of diabetes, before termination, cardiac function 
was monitored by ultrasound and mean arterial blood pressure was measured 
intra-arterially, under isoflurane anaesthesia. After termination, vascular 
function of isolated mesenteric resistance arteries (MrA) was assessed by wire 
myography. Blood was drawn and multiple tissues were collected for further 
analysis. Circulating levels of glyoxal (GO), MGO, 3-deoxyglucosone (3-DG), 
and the AGEs Nε-(1-carboxymethyl)lysine, Nε-(1-carboxyethyl)lysine and 
hydroimidazolone, were assessed by high performance liquid chromatogra-
phy with fluorescence or tandem mass spectrometry detection. Gene-expres-
sion levels of vascular cell adhesion molecule-1 (VCAM-1) and intercellular 
adhesion molecule 1 (ICAM-1) in MrA were measured by real time PCR.
Results: GLO-I activity was significantly elevated in multiple tissues of all 
transgenic rats. STZ treatment resulted in a fivefold increase of blood glucose 
concentrations irrespective of GLO-I overexpression. Levels of GO, MGO, 
3-DG and AGEs were elevated in the diabetic WT rats (p<0.01). In diabetic 
GLO-I rats, GO and MGO were significantly decreased by 80 % (p<0.05), and 
plasma AGEs by 50% (p<0.05). In WT rats, STZ treatment significantly de-
creased mean arterial pressure (91±2 vs. 59±3 mmHg; p<0.01) and cardiac 
output (108±12 vs. 81±7 mL/min; p<0.05). GLO-I overexpression in diabetic 
rats significantly blunted the fall in mean arterial blood pressure (76±7 3 
mmHg; p<0.05 compared with WT diabetic rats) without affecting the cardiac 
output response following administration of STZ (80±7 mL/min). In isolated 
MrA, STZ treatment significantly attenuated potassium-induced contractions 
and endothelium-dependent relaxations (p<0.05). These consequences of dia-
betes were significantly reduced by GLO-I overexpression (p<0.05). Further-
more, the increased mRNA levels of VCAM-1 and ICAM-1 in the MrA of the 
diabetic WT rats were normalised by GLO-I overexpression.
Conclusion: This study shows that overexpression of GLO-I detoxifies 
(methyl)glyoxal and thereby decreases (M)GO-derived AGEs in diabetic rats. 
The fact that GLO-I overexpression is associated with higher blood pressures 
and improved vascular function ex vivo, but not cardiac function, suggests 
that GLO-I protects arterial rather than cardiac function after STZ induced 
diabetes in rats.
Supported by: Dutch Diabetes Foundation
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The role of MRP8 and MRP14 in in stent restenosis in the diabetic rat
A. Stocca1, D. O’Toole2, A. Duffy3, T. O’Brien1; 
1Medicine, REMEDI, 2Anesthesia, Lung Biology Group, 3Medtronic, Galway, 
Ireland.
Background and aims: The prevalence of type 2 diabetes mellitus is reaching 
pandemic proportions. The most common cause of death in diabetes mellitus 
is cardiovascular disease. Patients frequently undergo vascular interventions 
such as stenting, as a therapy for this disorder. While the occurrence of in 
stent restenosis has been reduced by the use of drug eluting stents, this is less 
effective in diabetes mellitus than in non-diabetic subjects. In addition, drug 
eluting stents may impair endothelial recovery post-stenting which may lead 
to an increased risk of in stent thrombosis, a condition with mortality of ap-
proximately 40%. Novel approaches to the prevention of in stent restenosis 
which do not impair endothelial function are required.
Materials and methods: The Zucker fatty rat has been chosen as model of 
type 2 diabetes for its metabolic characteristics. Stent implant was performed 
in fatty rats and lean controls in the left internal carotid artery: the animals 
were sacrificed before stenting, 3 days and 14 days post surgery. Samples from 
day 14 were plastic embedded for histomorphometry; unstented carotid ar-
teries and 3 day post surgery arteries have been used for RNA isolation. Rat 
Aortic Endothelial Cells (RAOEC) were cultured in normal glucose (5.5mM) 
and high glucose (22mM) for 48hr before performing cell count, apoptosis, 
proliferation and migration assays.
Results: The Zucker fatty rat demonstrated exaggerated intimal hyperplasia 
14 days post surgery in comparison to lean rats (30% vs 15%). Microarray 
analysis showed MRP8 and MRP14 mRNAs were upregulated ∼8-fold in the 
carotid artery of the fatty rats versus lean controls. Quantitative PCR con-
firmed this result. RAOEC incubated in high glucose showed a reduction in 
the cell number (approx 30%) as a result of increased apoptosis and reduced 
proliferation. Migration of rat aortic endothelial cells (RAOECs) was impaired 
(60% reduction) when the cells are exposed to high glucose. Interestingly en-
dothelial cells (ECs) incubated in high glucose displayed a 75-fold upregula-
tion of MRP8 and a 5-fold upregulation of MRP14. MRP8 and MRP14 were 
cloned and shRNAs designed targetting them: RAOEC overexpressing MRP8 
or MRP14 showed similar migration impairment to RAOECs exposed to high 
glucose; the migratory capacity was partially restored when the high glucose 
cells were treated with the shRNA against MRP8, but not against MRP14.
Conclusion: We show that MRP8 and MRP14 have an active role in endothe-
lial cell dysfunction in diabetes. MRP8 and MRP14 are overexpressed in the 
arteries of diabetic rats and its expression is augmented in endothelial cells 
exposed to high glucose. MRP8 and MRP14 expression reduces the migra-
tion of endothelial cells. Endothelial cell proliferation and migration are 
fundamental to re-endothelialization of implanted stents, and thus limiting 
restenosis. Blocking MRP8 expression using shRNA we have been able to re-
store the migrational capacity of endothelial cells inhibited by high glucose 
incubation. MRP8 could be considered a good target to reduce in stent rest-
enosis in diabetes.
Supported by: SFI, IRSCET, Medtronic
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Ablation of vascular endothelial phosphoinositide-dependent protein 
kinase 1 deteriorates the volume of blood flow in skeletal muscle
K. Tawaramoto1, M. Hashiramoto1, K. Kotani1, W. Ogawa2, F. Tatsumi1, S. 
Hamamoto1, M. Shimoda1, Y. Kanda1, M. Kasuga3, K. Kaku1; 
1Department of Diabetes, Endocrinology and Metabolism, Kawasaki 
Medical School, Okayama, 2Department of Internal Medicine, Division of 
Diabetes, Metabolism and Endocrinology, Kobe University Graduate School 
of Medicine, Hyogo, 3Research Institute, International Medical Center of 
Japan, Tokyo, Japan.
Background and aims: Diabetes mellitus was well-known disorder com-
plicated with lowered angiogenesis and ischemic status especially in heart 
and skeletal muscle. Regulation of abundant endothelial growth factor with 
phosphoinositide 3-kinease (PI3K) and phosphoinositide-dependent protein 
kinase 1 (PDK1)-Akt signal in vascular endothelial cells (ECs) is believed 
the most important signal during the step of angiogenesis, which might be 
interfered by hyperglycemia. To evaluate the systemic pathway of angiogen-
esis under PI3K signal, we generated ECs specific PDK1 knock out mice us-
ing Cre-loxP system and investigated the degree of impaired angiogenesis of 
skeletal muscles under the normo- and hyperglycemia status.
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Materials and methods: Mice with PDK1 deficiency in ECs (VEPDK1KO) 
were obtained by crossing PDK1lox/lox mice with Tie2-Cre PDK1lox/+ mice. To 
obtain diabetic VEPDK1KO, streptozotocin (STZ; 150mg/kg BW, i.p.) was 
intraperitonealy injected into 2-month-old male mice. After 1 month of in-
jection, blood flow in lower leg-skeletal muscle was evaluated by the non-in-
vasive blood flowmeter (ADVANCE co.).
Results: PDK1 protein levels in ECs were reduced by 80-90 % in VEPDK1KO. 
The phospholylation of Akt at Thr308 stimulated with insulin or vascular en-
dothelial growth factor (VEGF) was reduced by 58% or 64%, respectively. 
In STZ-induced diabetic mice, body weight decreased and blood glucose 
was elevated, though which were similar between both genetics (BW: CON 
33.9±1.7, KO 32.2±1.3, STZ-CON 21.5±1.3, STZ-KO 23.6±1.7 g, blood glu-
cose: CON 83.3±7.9, KO 70.0±7.0, STZ-CON 152±15.1, STZ-KO143.4±34.7 
mg/dl). In normoglycemic mice, the basal blood flow in lower leg was similar 
in both groups of mice (CON 4.0±0.9, KO 4.3±2.1 ml/min/100g), but the 
blood flow stimulated with insulin (10μU/g BW, 10min) was significantly 
lower in VEPDK1KO mice compared with the control (CON 5.9±1.4, KO 
4.0±1.2 ml/min/100g). The phospholylation of eNOS, critical regulator of an-
giogenesis, at Ser-1177 of skeletal muscle was also decreased in VEPDK1KO 
by 40%. On the other hand, the basal blood flow readily decreased in diabetic 
mice (STZ-CON 2.4±0.8, STZ-KO 2.3±0.1 ml/min/100g), and insulin injec-
tion did not alter the blood flow in both control and VEPDK1KO mice (STZ-
CON 2.2±0.2, STZ-KO 2.2±0.4 ml/min/100g). VEGF expression in skeletal 
muscles was similar in normoglycemic CON and KO (102 % of CON), but 
lowerd in diabetic mice (STZ-CON 71%, STZ-KO 68% of CON).
Conclusion: The present results suggest that the PI3K signal of ECs is criti-
cal for insulin-induced angiogenic phenomena in normoglycemic status. In 
diabetic state, however, other pathways related with complicated metabolic 
disorders might be comprehensively meaningful for angiogenesis in skeletal 
muscle.
1321
Human C-peptide decreases hyperglycaemia-induced reactive oxygen 
species (ROS) and activation of apoptotic pathways in human aortic 
endothelial cell
V. Cifarelli, M. Trucco, P. Luppi; 
Pediatrics, University of Pittsburgh Medical School, Pittsburgh, USA.
Background and aim: High glucose is toxic to endothelial cells through 
stimulation of reactive oxygen species (ROS) and inflammation, which cause 
cellular stress leading to apoptosis. Our previous studies have shown that 
C-peptide antagonizes high glucose-induced endothelial dysfunction by dis-
playing a beneficial anti-inflammatory activity directly on endothelial cells. 
The aim of this study was to investigate whether C-peptide is able to retrieve 
high glucose-induced vascular damage by reducing the generation of ROS 
in Human Aortic Endothelial Cells (HAEC). We focused on the possible ef-
fect of C-peptide on the assembly of the NAD(P)H oxidase machinery under 
high glucose conditions. Activation of apoptotic pathways in HAEC was also 
investigated.
Materials and methods: HAEC were exposed to high glucose (25mmol/
L) and Tumor Necrosis Factor-α (TNF-α; 20ng/μl) for 12-48h in presence 
or absence of physiologic concentrations of either C-peptide (2-10 nM) or 
scrambled C-peptide as a control. ROS production was determined by using 
the fluorescent probes 5-(and-6)-carboxy-2’,7’-dichlorofluorescein diacetate 
(carboxy-DCFDA) by Flow Cytometry. Translocation of the NAD(P)H oxi-
dase subunits p47phox and Rac-1 from the cytosol to the plasma membrane 
was investigated as a prove of the activated enzymatic machinery for ROS 
generation. Apoptosis was assessed by determination of cytoplasmic his-
tone-associated-DNA-fragments and Caspase-3 activity using ELISA kits. 
Mitochondrial and cytoplasmic protein extracts were separated and analyzed 
by Western blotting using anti-Bcl-2, anti-Caspase-3, anti-p47phox and anti-
Rac-1 antibodies.
Results:
• High glucose-induced ROS generation is significantly reduced by C-peptide 
(p<0.01) in HAEC to levels detected in normal glucose (see figure below). C-
peptide affects translocation of NAD(P)H subunits p47phox and Rac-1 from 
cytoplasm to plasma membrane.
• C-peptide decreases high glucose-induced apoptosis of HAEC (38% lower 
vs. control) compared to high glucose alone as shown by reduced DNA frag-
mentation and Caspase-3 enzymatic activity.
• C-peptide increases Bcl-2 expression (survival gene) in HAEC exposed to 
high glucose and TNF-α.
Conclusion: Our results indicate that C-peptide at physiologic concentra-
tions reduces high glucose-induced oxidative stress and activates cell survival 
pathway in endothelial cells. These results strengthen the idea that supple-
mentation of C-peptide in Type 1 diabetic patients might prevent endothelial 
dysfunction and high glucose-associated vascular complications.
Supported by:  Children’s Hospital of Pittsburgh, PA, USA
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PS 132 Thrombosis and haemostasis
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Impaired glucose metabolism and type 2 diabetes are associated with 
hypercoagulability as determined by thrombin generation in plasma: the 
role of central obesity and low-grade inflammation. The Hoorn Study
I. Ferreira1,2, H.J.B. Beijers3, H.M. Spronk4, B. Bravenboer3, J.M. Dekker5, G. 
Nijpels5, H. ten Cate1,4, C.D.A. Stehouwer1; 
1Internal Medicine, Maastricht University Medical Centre, 2Clinical 
Epidemiology and Medical Technology Assessment, Maastricht University 
Medical Centre, 3Internal Medicine, Catharina Hospital, Eindhoven, 
Netherlands, 4Laboratory for Clinical Thrombosis and Haemostasis, 
Maastricht University Medical Centre, 5EMGO Institute for Health and Care 
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Background and aims: Individuals with type 2 diabetes (DM2) have a greater 
risk for cardiovascular disease (CVD). A substantial portion of the diabetes-
related CVD is due to atherothrombotic events, which could, at least in part, 
be explained by prothrombotic alterations in these individuals. Recently, a 
method was developed - the Calibrated Automated Thrombogram (CAT) - 
to quantitatively measure thrombin generation in vitro; in brief, it generates 
a thrombin generation curve that mimics the overall plasma coagulability 
potential when a thrombogenic stimulus appears. Prothrombotic alterations 
in individuals with impaired glucose metabolism (IGM) and DM2 have not 
been examined before according to this method. We have therefore inves-
tigated the extent to which individuals with IGM and/or DM2 had greater 
levels of thrombin generation than those with normal glucose metabolism 
(NGM). In addition, we examined whether any such differences were inde-
pendent of other cardiovascular risk factors, such as smoking, hypertension, 
dyslipidaemia, (micro)albuminuria, glycemic control and (central) obesity, 
and/or were mediated by low-grade inflammation (high-sensitivity C-reac-
tive protein - hsCRP).
Materials and methods: We studied 747 individuals (374 women, mean age 
68.5±7.1 years) from the Hoorn Study, a population-based cohort study in-
cluding individuals with NGM (n=276), IGM (n=177) and DM2 (n=294). 
Thrombin generation in platelet-poor plasma was measured using the CAT 
method and two parameters were derived: the endogenous thrombin poten-
tial (ETP, i.e. area under the thrombin generation curve, which represents the 
total amount of active thrombin formed after activation of the coagulation 
cascade) and the peak height of this curve. Data were analyzed with the use 
of multiple linear regression analyses.
Results: After adjustments for age, sex, prior CVD and smoking status, in-
dividuals with IGM or DM2, were characterized by a higher ETP [ß=41.39 
nM*min (95%CI: 6.19 to 76.59)] and peak height [ß=8.92 nM (0.12 to 17.71)] 
as compared with those with NGM (but did not differ from each other with 
regard to these parameters). These differences were attenuated to ß=2.99 nM 
(-7.09 to 13.06) and 23.52 nM*min (-16;66 to 63.70), respectively, and were 
thus no longer significant, when further adjusted for waist circumference and 
hsCRP. Adjustments for other risk factors did not materially change the dif-
ferences between groups, however.
Conclusion: Individuals with IGM or DM2 have higher levels of thrombin 
generation as compared with subjects with NGM and these differences may 
be explained, to a great extent, by their higher levels of central adiposity and 
low-grade inflammation.
Supported by: a Netherlands Heart Foundation grant to I. Ferreira
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Body composition as determinant of thrombin generation in plasma. The 
Hoorn Study
H.J.B. Beijers1, I. Ferreira2,3, H.M. Spronk4, B. Bravenboer1, J.M. Dekker5, G. 
Nijpels5, H. Ten Cate2,6, C.D.A. Stehouwer2; 
1Internal Medicine, Catharina Hospital Eindhoven, Eindhoven, 2Internal 
Medicine and Cardiovascular Research Institute Maastricht, Maastricht 
University Medical Centre, 3Clinical Epidemiology and Medical Technology 
Assessment and Care and PublicHealth Research Institute, Maastricht 
University Medical Centre, 4Cardiovascular Research Institute Maastricht 
and Laboratory for Clinical Thrombosis and Haemostasis, Maastricht 
University Medical Centre, 5EMGO Institute for Health and Care Research, 
VU University Medical Centre, Amsterdam, 6Laboratory for Clinical 
Thrombosis and Haemostasis, Maastricht University Medical Centre, 
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Background and aims: The association between obesity and cardiovascu-
lar disease might, at least partially, be explained by a hypercoagulable state. 
The extent to which body fat mass and its distribution contribute to a hyper-
coagulable state is unknown. We investigated the association between body 
composition and thrombin generation, and evaluated the potential mediat-
ing role of low-grade inflammation (i.e. high-sensitivity C-reactive protein 
- hsCRP) herein.
Materials and methods: We studied 588 individuals from the Hoorn Study, 
a population-based cohort of individuals with normal and impaired glucose 
metabolism and type 2 diabetes (mean age 69.7 ± 6.5 years, 300 women) in 
whom total and regional (i.e. trunk, arms and legs) body composition was as-
sessed by whole body dual-energy absorptiometry. Thrombin generation was 
measured using the Calibrated Automated Thrombogram, a method devel-
oped recently which generates a thrombin generation curve that mimics the 
overall plasma coagulability when a thrombogenic stimulus appears. The area 
under this curve is the endogenous thrombin potential (ETP) and represents 
the total amount of active thrombin formed after activation of the coagula-
tion cascade. Data were analyzed with multiple linear regression models in 
men and women separately. All analyses were adjusted for age, glucose me-
tabolism status and smoking.
Results: Men and women differed with respect to total body fat % (28±7 
vs. 42±7), trunk (12.7±5.5 vs. 14.7±5.5) and peripheral (i.e. arms + legs) fat 
(9.5±2.9 vs.14.9±4.6) and lean (24.9±3.4 vs.17.1±2.4) masses (in kg), but not 
with respect to ETP (1188±234 vs.1186±204 nM*min, respectively). Total 
body fat % was positively associated with ETP in women [standardized re-
gression coefficient (ß)=0.20 (95%CI: 0.09 to 0.32)], but not in men [ß=-0.02 
(-0.15 to 0.11)]. Detailed analyses of regional body composition in women 
showed that trunk [ß=0.23 (0.05 to 0.40)], but not peripheral fat mass [ß=-
0.02 (-0.18; 0.15)] was associated with greater ETP, and that there was a trend 
towards an inverse association with peripheral lean mass [ß=-0.12 (-0.25 to 
0.01)]. The strength of the positive associations between total and trunk fat 
and ETP in women did not materially change after further adjustments for 
blood pressure, dyslipidaemia or microalbuminura, but were attenuated by 
35% [to ß=0.13 (0.01 to 0.26)] and 45% [to ß=0.10 (-0.04; 0.23)], respectively, 
when further adjusted for hsCRP.
Conclusion: Body fat mass, in particular a central pattern of fat distribution, 
is associated with higher levels of thrombin generation in elderly women, but 
not in men. This association is partially explained by adiposity-related low-
grade inflammation.
Supported by: a Netherlands Heart Foundation grant to I. Ferreira
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Oxidative stress is involved in the inhibitory effects exerted by high 
glucose on platelet sensitivity to aspirin
G. Anfossi, I. Russo, M. Viretto, L. Mattiello, G. Doronzo, M. Trovati; 
Department of Clinical and Biological Sciences, University of Turin, 
Internal Medicine and Metabolic Disease Unit, San Luigi Gonzaga Hospital, 
Orbassano, Italy.
Background and aims: According to therapeutic guidelines, the largest ma-
jority of type 2 diabetic patients should be treated by aspirin: a high preva-
lence of aspirin-resistance, however, has been observed in these subjects, 
inducing to investigate the mechanisms involved. Aspirin reduces platelet 
function both by decreasing the synthesis of Thromboxane A2 (TXA2)and 
by increasing the synthesis on nitric oxide (NO), a powerful physiological 
anti-aggregating agent. In a recent study carried out in 45 healthy subjects, 
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we demonstrated that a short-time in vitro platelet exposure to high glucose 
reduces the aspirin anti-aggregating effect by decreasing the aspirin ability 
to increase NO synthesis, without influencing TXA2 formation. Aim of this 
study is to evaluate whether oxidative stress is involved in this intriguing phe-
nomenon.
Materials and methods: The study has been carried out in 8 healthy vol-
unteers (M/F:4/4; age: 24.1±0.9 years; BMI: 22.58±0.4 kg/m2), non smokers, 
with normal glucose tolerance and insulin sensitivity. In platelet-rich plasma 
(PRP) and washed platelets from venous blood samples, we evaluated the in-
fluence of a 30-min exposure to lysine acetylsalicylate (LAS: 5-300 micromol/
l) on platelet aggregation induced by sodium arachidonate (NaAA; 1 mmol/l) 
and ADP (20 micromol/l) (Born’s method), and on the NO synthesis (conver-
sion of 3H-arginine to 3H-citrulline) without and with a 60 min pre-incuba-
tion with 25 mmol/l D-glucose, both in the absence and in the presence of 
the thiol antioxidant compound amifostine (200 micromol/l) added 20 min 
before LAS.
Results: High glucose reduced LAS ability to inhibit platelet responses ag-
onists: actually, in PRP, Maximal Aggregation (MA) in response to NaAA 
was 70.4±2.9 without vs 84.7±2.3 with 25 mmol/l glucose (p<0.002) and MA 
in response to ADP was 64.5±1.4% without vs 90.1±4.0% with 25 mmol/l 
glucose (p<0.0001). Platelet exposure to amifostine did not modify platelet 
responses to agonists, but blunted the inhibitory effects exerted by high glu-
cose on the LAS anti-aggregating action: in the presence of amifostine, MA 
in response to NaAA was 64.6±1.5 without and 67.1±1.8% with 25 mmol/l 
glucose (ns), MA in response to ADP was 56.8±2.1 without and 61.8±2.4% 
with 25 mmol/l glucose (ns). Furthermore, in washed platelets, high glu-
cose inhibited the LAS-induced ability to enhance NO synthesis, which was 
(pmol/min/mg protein): 0.134±0.019 at baseline, 0.272±0.022 with LAS in 
the presence of 5 mmol glucose (p<0.001) and 0.127±0.026 with LAS in the 
presence of 25 mmol/l glucose (ns vs baseline). Washed platelet exposure to 
amifostine did not modify NO synthesis, but blunted the inhibitory effect 
exerted by high glucose on LAS-induced NO enhancements: in the presence 
of amifostine, NO synthesis (pmol/min/mg protein) was 0.142±0.005 at base-
line, 0.318±0.02 with LAS in the presence of 5 mmol glucose (p<0.0001 vs 
baseline) and 0.211±0.013 with LAS in the presence of 25 mmol/l glucose 
(p<0.0001 vs baseline).
Conclusion: Oxidative stress is involved in the ability of high glucose to re-
duce the anti-aggregating effect of aspirin by impairing the aspirin-induced 
increase of NO synthesis. This information explains a potential mechanism 
involved in the aspirin resistance observed in diabetes.
Supported by: an EFSD/Sanofi Aventis grant
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The platelet-inhibitory effect of low-dose acetylsalicylic acid is dependent 
on glycaemic control in type 2 diabetes
B.A. Lemkes1, L. Bahler1, P.W. Kamphuisen2, V.E.A. Gerdes2, A.K. 
Stroobants3, E.J. van den Dool3, R. Nieuwland3, J.B.L. Hoekstra1, F. 
Holleman1; 
1Internal Medicine, Academic Medical Centre, 2Vascular Medicine, 
Academic Medical Centre, 3Clinical Chemistry, Academic Medical Centre, 
Amsterdam, Netherlands.
Background and aims: The clinical benefit of low-dose acetylsalicylic acid 
(ASA) treatment in primary prevention of cardiovascular events in type 2 
diabetes (DM2) remains controversial. The platelet response to ASA has been 
suggested to be diminished in diabetes, but the role of hyperglycaemia has 
not yet been elucidated. In this study we determined whether (i) the base-
line platelet activity and response to ASA differs in patients with DM2 as 
compared to healthy controls, (ii) glycaemic control influences the platelet 
response to ASA in DM2 and (iii) higher doses of ASA improve the platelet 
response in DM2.
Materials and methods: This is a prospective, single-centre, open-label tri-
al. We aim to include 125 subjects and report here the preliminary data for 
102 subjects. DM2 patients are categorized by HbA1c value < 7.0% (DC1: 
n=34), 7.0- 8.5% (DC2: n=33) and > 8.5% (DC3: n=22) and compared to 
healthy controls (HC: n=13). All subjects underwent three treatment periods, 
sequentially using 30 mg, 100 mg and 300 mg of ASA for ten days. Labora-
tory measurements were performed at baseline and following each treatment 
period. To assess the pharmacological efficacy of ASA, urinary 11-dehydro-
thromboxane B2 (11dhTxB2) was measured by ELISA. Platelet function was 
measured by optical platelet aggregation and Verify Now.
Results: Median baseline urinary 11dhTxB2 excretion was 45 pg/mmol (IQR 
36-59) in HC, compared to 69 in DC1 (IQR 37-93), 84 in DC2 (IQR 47-
101) and 95 in DC3 (IQR 73-143) (p=0.007, ANOVA). Treatment with ASA 
30 mg significantly reduced 11dhTxB2 by 62%, 67%, 64% and 68% respec-
tively. Absolute excretion remained significantly different between groups, 
and followed the same pattern as baseline (p=0.001). Subsequent treatment 
with 100 mg ASA further reduced 11dhTxB2 in DC2 (p<0.001) and DC3 
(p=0.05) Increasing ASA to 300 mg resulted in a further 10% reduction in 
DC1 (p=0.026).Verify Now showed incomplete suppression of arachodonic 
acid(AA)-induced platelet aggregation at 30 mg ASA in all DM2 groups when 
compared to healthy controls (p=0.001). This difference became smaller with 
ASA 100 mg, with no further changes at 300mg. Interestingly, optical aggre-
gation induced by 1 mmol/L AA was completely suppressed by 30 mg ASA 
in all groups, but a concentration of 2 mmol/L resulted in an escape from the 
ASA suppression in DC3.
Conclusion: Our results show that urinary 11dhTxB2 excretion as a measure 
of platelet activity is increased in DM2 and is highly associated with glycae-
mic control. ASA 30 mg only partially suppresses platelet activity in DM2, 
but ASA 100 mg is sufficient for adequate suppression of urinary 11dhTxB2 
excretion.
Supported by: a NFCVE grant to BL
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In vitro platelet exposure to high glucose reduces the inhibitory effects 
exerted by chronic aspirin therapy on responses to agonists in non 
diabetic patients
I. Russo, C. Frascaroli, L. Mattiello, M. Viretto, G. Doronzo, K. Bonomo, M. 
Trovati, G. Anfossi; 
Department of Clinical and Biological Sciences, University of Turin, 
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Background and aims: We previously observed that “in vitro” incubation 
with high glucose of platelets from healthy subjects does not modify platelet 
responses to agonists but reduces the ability of aspirin added “in vitro” to 
inhibit platelet responses to agonists, suggesting that hyperglycaemia plays 
a role in the aspirin resistance described in diabetic patients. In the present 
study we investigated whether “in vitro” exposure of platelets to high glucose 
influences platelet responses to agonists in non diabetic patients on chronic 
aspirin treatment.
Materials and methods: We studied 56 non diabetic patients on chronic as-
pirin therapy (100 mg/day) owing to the presence of severe cardiovascular 
risk factors and/or previous cardiovascular events: M/F 33/23; age: 60.5±0.82 
years; body mass index: 27.7±0.5 kg/m2. Platelet sensitivity to aspirin was eval-
uated in platelet-rich plasma (PRP) by determining by Born’s method Maxi-
mal Aggregation (MA) in response to Sodium Arachidonate (NaAA): patients 
were defined as “aspirin resistant” when MA in response to NaAA was greater 
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than 20%. In PRP from both aspirin sensitive and aspirin resistant patients, we 
evaluated by Borns’ method platelet aggregation induced by 1 mmol/l NaAA, 
10 μmol/l ADP, 4 μmol/l epinephrine and 4 mg/l Collagen in the presence or 
in the absence of a 60-min preincubation with high glucose (25 mmol/l).
Results: In aspirin sensitive patients (49/56), PRP incubation with high 
glucose significantly increased agonist-induced aggregation, being MA in 
response to NaAA 6.4±0.5% without vs 10.8±0.5% with 25 mmol/l glucose 
(p<0.0001), MA in response to ADP 67.7±4.8% without vs 77.0±4.7% with 25 
mmol/l glucose (p<0.005), MA in response to epinephrine 24.7±3.0% with-
out vs 28.0±4.1% with 25 mmol/l glucose (p<0.05), MA in response to Colla-
gen 29.8±3.8% without vs 36.4±4.8% with 25 mmol/l glucose (p<0.006). The 
seven aspirin resistant patients presented higher baseline platelet responses 
to agonist vs the aspirin sensitive-ones: in particular, MA was: 30.4±3.0% 
vs 6.4±0.5% (p<0.0001) in response to NaAA ; 100.3±5.9% vs 67.7±4.8% 
(p<0.015) in response to ADP; 48.1±6.9% vs 24.7±3.0% (p<0.007) in response 
epinephrine; 49.6±2.5% vs 29.8±3.8% (p<0.05) in response to Collagen. In 
vitro exposure to high glucose of PRP of aspirin resistant patients did not 
modify responses to agonists, being MA without or with 25 mmol/l glucose 
30.4±3.0% and 28.1±4.1% with NaAA (ns); 100.3±5.9% and 98.6±7.9% with 
ADP (ns); 48.1±6.9% and 46.7±7.6% with epinephrine (ns); 49.6±2.5% and 
54.0±9.3% with collagen (ns).
Conclusion: In aspirin sensitive non diabetic patients on chronic aspirin 
treatment, high glucose added “in vitro” increases platelet responses to ago-
nists, demonstrating that it partially overcomes the inhibitory effect of aspirin 
on platelet responses with direct effects on platelets, adding another piece of 
information on the role of hyperglycaemia in the reduction of aspirin sensi-
tivity in diabetes mellitus. The lack of this glucose effect in aspirin resistant 
patients indicates that when platelets are already aspirin resistant the modu-
lating effect of glucose on platelet sensitivity to aspirin disappears.
Supported by: an EFSD/sanofi-aventis grant
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Fibrin clot structure characteristics in type 2 diabetes: relationship with 
cardiometabolic risk factors
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Background and aims: Atherothrombotic complications are the main cause 
of mortality and morbidity in individuals with diabetes. A compact fibrin 
network structure with increased resistance to fibrinolysis has been docu-
mented in individuals at high risk of cardiovascular disease. The aim of the 
present work was to study the relationship between fibrin clot structure and 
fibrinolysis and cardiometabolic risk factors and a history of ischemic heart 
disease (IHD) in a large cohort of type 2 diabetes (T2DM) subjects.
Materials and methods: Using a previously validated turbidimetric assay, 
clot structure and fibrinolysis were assessed in 875 individuals with T2DM 
(mean age 68 (CI 67.7-68.3) 450 males) enrolled on the Edinburgh T2DM 
study. The following parameters were analysed: maximum absorbance (MA), 
a measure of clot density, time from start to full clot formation (CT), an in-
dicator of clotting potential and lysis time (LT) from full clot formation to 
50% lysis, assessing the efficacy of the fibrinolytic pathway. We also measured 
cardiac inflammatory markers including C-reactive protein (CRP) and com-
plement C3 levels using ELISA techniques.
Results: Female patients had denser clots than males (MA=0.37±0.005 
and 0.34±0.004 au respectively, p<0.01) and CT was longer (567.1±6.6 and 
522±5.6 sec respectively, p<0.01). LT was prolonged in female subjects at 
803.1±19.8 sec compared with males (664.7±12.1 sec; p<0.01). Males with 
a previous history of IHD had a weak increase in MA (0.35±0.008 and 
0.33±0.006 au IHD and non-IHD, respectively, p<0.05), a relationship not 
seen in female subjects. We analysed the effects of aspirin therapy which was 
associated with an increase in LT (755±16.1 sec) compared to those not on as-
pirin (662±12.7 sec, p<0.05). The longer lysis time in aspirin-treated subjects 
was still evident after excluding individuals with a history of IHD.C-reactive 
protein (CRP) correlated with MA in both females and males (r=0.24 and 
0.27, respectively; p<0.01), whereas C3, which is incorporated into the fibrin 
network, correlated with LT in both females and males (r=0.25 and r=0.27, 
respectively; p<0.01). HbA1c showed a weak correlation with MA and LT in 
male subjects only (r=0.10 and 0.10, respectively, p<0.05), whereas estimated 
glomerular filtration rate negatively correlated with MA in both males and 
females (r=0.18 and 0.29 respectively; p<0.01).
Conclusion: i) female patients with diabetes have a more thrombotic clot 
structure which may contribute to loss of cardiovascular protection in this 
group. ii) aspirin treatment in diabetes is associated with a paradoxical in-
crease in clot lysis time, suggesting one mechanism for the reduced clinical 
efficacy of this agent in diabetes. iii) clot structure in T2DM subjects is related 
to inflammatory and metabolic parameters.
Supported by: King Fahad Medical City and NIHR(UK)
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Abnormal glucose tolerance in atrial fibrillation and impact on 
inflammation, endothelial/platelet function, fibrinolysis, extracellular 
matrix metabolism and NT-pro-BNP
O. Johansen1, I. Seljeflot2, S.F. Ulimoen1, S. Enger1, H. Arnesen2, A. Tveit1; 
1Medical department, Vestre Viken, Asker and Baerum Hospital, RUD, 
2Department of Cardiology, Oslo University Hospital, Ullevål, Norway.
Background and aims: Although an abnormal glucose tolerance (AGT), i.e. 
diabetes mellitus (DM) or pre-DM, increases the risk for atrial fibrillation 
(AF) few studies have assessed the extent to which AGT modulates CV risk 
factors/parameters in patients with AF.
Materials and methods: In a case control study amongst 75-year old sub-
jects with AF or in sinus rhythm (all previously undiagnosed with DM or 
pre-DM), we examined the prevalence of undiagnosed AGT (by a 75-g oral 
glucose tolerance test [OGTT] classified according to World Health Organi-
sation criteria) and explored its association to AF duration as well as to circu-
lating CV risk biomarkers of inflammation (C-reactive protein [CRP], Inter-
leukin [IL]-6), endothelial/platelet function (Monocyte chemotactic protein 
[MCP]-1, P-selectin, CD-40 ligand), fibrinolysis (tissue plasminogen acti-
vator antigen [tPAag], plasminogen activator inhibitor-1 [PAI-1] activity), 
extracellular matrix metabolism (matrix metalloproteinase [MMP]-9, tissue 
inhibitor metalloproteinase [TIMP]-1) and ventricular function (N-terminal 
fragment pro-brain natriuretic peptide [NT-pro-BNP]). Between group com-
parison was conducted non-parametric (Kruskal-Wallis).
Results: Prevalence of undiagnosed DM among the 108 subjects (male/fe-
male 73/35, BMI 25.4±3.2) in sinus rhythm and the 46 (male/female 34/12, 
BMI 25.3±3.7) with AF (median AF duration 5 years) where 3.7% and 13.0%, 
respectively (p=0.031). Patients with AF duration ≥ 5 years had a higher 
prevalence of DM and pre-DM (61.1%) as compared to AF duration < 5 years 
(25%, p=0.0014) or no AF (39.0%, p=0.17). Patients with AF duration ≥ 5 
years also had elevated levels of IL-6 (4.27±3.10, p=0.017), MCP-1 (329±82, 
p= 0.004), CD40 ligand (135±196, p=0.026), PAI-1 activity (16.0±9.5, 
p=0.004), TIMP-1 (165.6±26.3, p=0.008) and NT-ProBNP (1023±1212, p< 
0.001) as compared to those with AF < 5 years (IL-6: 2.89±1.42, MCP-1: 
295±85, CD40 ligand: 77±73, PAI-1 activity: 13.7±8.3 TIMP-1: 142.9±20.7, 
NT-Pro-BNP 741±630) or no AF (IL-6: 2.80±1.85, MCP-1: 290±202, CD40 
ligand: 91±95, PAI-1 activity: 10.1±6.7, TIMP-1: 156.1±27.4, NT-Pro-BNP: 
186±353). A dosage related, and in part synergistic, impact on the CV risk 
biomarker levels of AF in the presence of AGT was seen for most parameters 
assessed; with statistical significance reached for MCP-1, PAI-1 activity and 
NT-ProBNP (table 1).
Conclusion: Undiagnosed dysglycaemia is prevalent in long standing AF and 
CV risk biomarkers were adversely modulated by the presence of both AF 
and AGT. The aggravated CV biomarker profile seen in patients with both AF 
(especially if long standing) and AGT may play a causal role for the increased 
CV morbidity and premature mortality observed in this patient group and 
calls for further attention and research.
Table 1. Levels of circulating CV risk biomarkers according to AF and OGTT status.
Sinus rythm + 
normoglycaemia 
(n=61)
AF + normo- 
glycaemia 
(n=28)
Sinus rythm + 
AGT (n=47)
AF + AGT 
(n=18)
p-value 
(Kruskal- 
Wallis)
CRP (mg/L) 3.2±2.9 3.4±3.0 3.9±3.7 3.5±2.9 0.865
IL-6 (pg/mL) 2.64±1.63 2.94±1.19 3.01±2.11 4.19±3.30 .0126
MCP-1 (pg/mL) 311±261 288±70 262±65 339±98 0.003
P-selectin (ng/mL) 31.6±12.3 31.1±9.3 33.8±9.7 32.8±10.3 0.455
CD40 ligand (pg/mL) 88±50 81±72 96±133 128±198 0.263
tPAag (ng/mL) 15.7±4.2 15.5±6.4 15.0±4.4 17.5±5.6 0.412
PAI-1 activity (U/mL) 8.9±5.7 12.6±8.2 11.5±7.7 17.6±8.9 <0.001
MMP-9 (ng/mL) 204.9±98.9 203.0±106.0 199.5±95.9 168.7±74.0 0.493
TIMP-1 (ng/mL) 153.4±26.9 146.5±21.9 159.6±28.0 160.0±28.6 0.148
NT-ProBNP (pg/mL) 114±83 720±561 281±515 1117±1255 <0.001
HOMA-IR (%) 3.8±1.6 4.1±3.1 4.3±2.1 6.1±5.6 0.505
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Plasminogen activator inhibitor-1 and thrombin activable fibrinolysis 
inhibitor in patients with type 2 diabetes
A. Blaszkowski, M. Galar, J. Sokolowski, J. Kloczko; 
Hematology, Medical University, Bialystok, Poland.
Background and aims: Hypofibrinolysis is a common finding in patients 
with diabetes mellitus and risk factor for developement of cardiovascular 
disease. The present study was undertaken to assess the plasma levels of two 
main inhibitors of fibrinolysis - plasminogen activator inhibitor (PAI-1) and 
thrombin activable fibrinolysis inhibitor (TAFI) and their relation with clini-
cal and metabolic parameters in diabetic patients with and without vascular 
complications.
Materials and methods: The study was carried out on 53 patients with type 
2 diabetes mellitus (25 women, 28 men). In the examined group 21 patients 
had coronary heart disease (CHD), 22 hypertension and 17 diabetic rethin-
opathy. The control group comprised 24 healthy subjects matched for sex and 
age. The PAI-1 level was measured using Asserachrom PAI-1 set and TAFI by 
means of Imuclone TAFI ELISA.
Results: In comparison to the healthy controls diabetics revealed significantly 
higher PAI-1 (27,7±16,4 vs 55,3±29,9 ng/ml, p<0,0001) but lower TAFI levels 
(115,2±24,0 vs 87,3±20,3%, p<0,0001). The diabetics with CHD and hyper-
tension but not with rethinopathy had significantly increased level of PAI-
1 in comparison to the patients without these complications (67,8±33,7 vs 
47,1±24,3 ng/ml, p=0,02; 67,0±30,8 vs 47,0±26,7 ng/ml, p=0,01; 57,3±27,5 vs 
54,4±31,3 ng/ml, p>0,05, respectively). We found significant positive correla-
tions between the levels of PAI-1 and BMI as well as the levels of triglicerides 
and negative correlations between PAI-1 and plasmin-antiplasmin complexes 
(PAP). There were no significant correlations between PAI-1 levels and the 
levels of HbA1c and GFR. There were no significant differences in the mean 
levels of TAFI in diabetics with CHD, hypertension and rethinopathy and 
those without these complications. No significant correlations between TAFI 
levels and BMI, lipids, HbA1c, PAP and GFR were found.
Conclusion: The data prove the important role of PAI-1 - but not TAFI - in 
the impairment of fibrinolysis and the developement of cardiovascular com-
plications in patients with type 2 diabetes mellitus.
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PAI-1 is an independent maker of metabolic disorders in young adults 
born small for gestational age
T. Meas1, S. Deghmoun1, D. Chevenne2, B. Gaborit3, M.-C. Alessi3,  
C. Lévy-Marchal1; 
1Internal medicin, Université Paris 7, 2Sevice de biochimie hormonale, 
APHP, Paris, 3Faculté de médecine Timone, Marseille, France.
Background and aims: Insulin resistance, metabolic syndrome (MS) and 
cardiovascular diseases have been associated with being born small for ges-
tational age (SGA). However, the mechanisms underlying these associations 
are still unknown. Fibrinolysis is regulated by plaminogen activator inhibi-
tor type-1 (PAI-1), secreted by the adipose tissue. Increased PAI-1 levels 
predispose to the development of atherosclerotic plaques prone to rupture. 
In epidemiological studies PAI-1 levels have been associated with MS and 
identified as a predictive factor for myocardial infarction. Few studies have 
examined these associations in subjects born SGA.
Materials and methods: The study population is made of a community-
based cohort of young adults, mean age 29.4 years, selected on their birth 
characteristics. 557 adults born SGA (birth weight under the 10th percentile) 
were compared to 671 subjects born appropriate for gestational age (AGA) 
(birth weight between 25th and 75th percentiles). MS was defined using the 
WHO definition. PAI-1 activity was measured in citrated plasma with a bio 
immunoassay.
Results: BMI (24.1 ± 4.4 vs 24.2 ± 5.3 kg/m2) was similar between in AGA 
and SGA whereas body fat (22.0 ± 8.2 vs 23.2 ± 9.0 %) was significantly in-
creased in the SGA group, p=0.01. MS was more prevalent in the SGA group 
(8.7%) versus AGA group(5.5%), p=0.03. PAI-1 concentration was correlated 
with waist circumference, plasma triglycerides, HOMA-IR and associated 
with male gender and MS in both groups. After adjustment on these varia-
bles, PAI-1 concentrations remained significantly increased in the SGA group 
(12.2 ± 21.2 UI/ml vs 10.0 ± 13.5 UI/ml, p=0.01). PAI-1 concentration above 
4.9 UI/ml (median of PAI-1 concentration in the AGA group) was present 
in 94% of the subjects with MS. Moreover, OR for having elevated PAI-1 was 
1.48 [1.08; 1.95] in the SGA group (p=0.005).
Conclusion: PAI-1 plasma concentrations were significantly increased in 
SGA subjects independently of MS. These data suggest that elevation of PAI-
1 concentrations could be taken as an indication of an abnormal secretion at 
the level of the adipose tissue and could consequently be implicated in the 
development of the metabolic disorders reported in SGA subjects.
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Soluble receptor for advanced glycation endproducts and its 
inflammatory ligands EN-RAGE and HMGB1 in type 1 and type 2 
diabetes mellitus
J. Škrha Jr.1,2, A. Germanova2, J. Svarcova2, M. Kalousova2, T. Zima1, J. 
Škrha1; 
1Third Department of Medicine, 2Institute of Clinical Chemistry and 
Laboratory Diagnostics, First Faculty of Medicine and General University 
Hospital, Charles University, Prague, Czech Republic.
Background and aims: The aim of the study was to compare concentration of 
soluble receptor for advanced glycation endproducts (sRAGE) and its natural 
pro-inflammatory ligands, EN-RAGE (extracellular newly identified RAGE-
binding protein, S100A12) and HMGB1 (high mobility group box-1) with 
diabetes control, albuminuria, cell adhesion molecules and von Willebrand 
factor (vWF) in Type 1 (T1DM) and Type 2 (T2DM) diabetes mellitus.
Materials and methods: Total number of 45 T1DM (age 47±13 yrs, diabetes 
duration 21±12 yrs) and 68 T2DM (age 64±10 yrs, diabetes duration 12±9 
yrs) were examined. Control group consisted of 41 healthy persons of com-
parable age. Serum concentrations of sRAGE, EN-RAGE, HMGB1, ICAM-1, 
VCAM-1, P-selectin, E-selectin and vWF have been determined by ELISA 
kits. HbA1c was estimated by HPLC and albuminuria by radioimmunoassay. 
Both groups of T1DM and T2DM were divided according to microalbuminu-
ria (MA) to MA+ subgroup with MA > 3 g/mol creatinine and MA- subgroup 
with MA < 3 g/mol creatinine.
Results: Serum sRAGE concentration was significantly higher in both T1DM 
(1137±78 μg/l, p<0,001) and T2DM (995±63 μg/l, p<0,001) compared to 
healthy persons and it was higher in MA+ than in MA- subgroups. In T1DM 
the RAGE ligand (HMGB1 and EN-RAGE) concentrations were more el-
evated in MA- than in MA+ subgroup in which levels were similar to con-
trols. Significant positive relationship was found between sRAGE and HbA1c 
(r=0.36, p<0.01), diabetes duration (r=0.58, p<0.01), von Willebrand factor 
(r=0.36, p<0.005) and albuminuria (r=0.43, p<0.001) in T2DM. sRAGE levels 
were not related to the above parameters in T1DM, but they significantly cor-
related with ICAM (r=0.39, p<0.01) and VCAM (r=0.63, p<0.0001). Positive 
relationship was found between HMGB1 and MA (r=0.79, p<0.05), ICAM 
(r=0.84, p<0.05) and E-selectin (r=0.79, p<0.05) in MA+ T1DM. No relation-
ship was observed between sRAGE and its ligands.
Conclusion: Serum sRAGE concentration reflects protective ability against 
AGEs created more significantly in diabetes with increased albuminuria. It 
corresponds to higher sRAGE levels in these patients. Our results demon-
strate differences in RAGE ligands between T1DM and T2DM. Their higher 
levels found in younger T1 and T2 diabetic patients with other risk factors 
compared to older patients with already established micro- and macrovas-
cular disease are suspicious from the higher activity promoting RAGE ligand 
creation in former patients. Their role as markers in development of chronic 
vascular complications will be evaluated in the follow-up study.
Results:
T1DM T2DM Controls
MA- 
(n = 38)
MA+
(n = 7)
MA-
(n = 50)
MA+
(n = 18)
(n = 41)
HbA1c (%, IFCC) 7.40a±0.22 8.33a±0.25 6.43a±0.24 8.10a±0.69 3.60±0.20
MA (g/mol creat.) 1.15±0.14 12.04a±5.35 1.27±0.15 47.94a±11.51 0.80±0.10
HMGB1 (μg/l) 2.45by±0.27 1.02±0.27 2.58a±0.29 2.65a±0.42 0.95±0.14
sRAGE (μg/l) 1078±89 1461a±117 877±55 1322ay±162 824±48
EN-RAGE (μg/l) 277ax±33 125±33 266a±28 365a±53 110±10
vWF (μg/l) 110±7 135a±25 109±5 177ay±17 88±32
ICAM (μg/l) 249b±12 320b±42 285b±26 325b±35 206±10
VCAM (μg/l) 863a±72 1194a±147 796a±39 991a±107 365±11
Results are mean±SEM, significant difference to controls: ap<0.001, bp<0.01, and between 
MA+ and MA-: xp<0.05, yp<0.01.
Supported by: MSM0021620807
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Intermittent high glucose promotes expression of proinflammatory 
cytokines in monocytes
L. Yang, W. Qi; 
Endocrinology and metabolism, Taian City Central Hospital, China.
Background and aims: Diabetes confers an increased propensity to athero-
sclerosis. Postprandial hyperglycemia seems to impose more deleterious ef-
fects on vessels. The aim of this study was to examine expression of proin-
flammatory cytokines from monocytes under fluctuating glucose condition.
Materials and methods: Monocytic cells (THP-1) were divided into four 
groups and cultured in the presence of 5mmol/l or 15 mmol/l glucose and in 
a fluctuating condition(12h exposure to 15mmol/l glucose or mannitol me-
dium followed by 12h exposure to 5 mM glucose or mannitol medium) re-
spectively.Concentrations of IL-6 and TNF-α in the supernatants and CD11b 
MFI(mean fluorescence intensity) in monocytes surfaces were measured af-
ter 72h’ culture.
Results: Monocytes exposed to fluctuating glucose condition expressed 
highest levels of IL-6,TNF-α and CD11b, and in the second place were 
monocytes exposed to fluctuating mannitol condition. Monocytes cultured 
in 15mmol/l glucose medium expressed a lower level of cytokines than 
those cultured in such fluctuating conditions, but a higher level compared 
with those in 5mmol/l glucose medium (for IL-6: 204.99±25.08 pg/ml, 
179.97±37.14 pg/ml,151.61±21.82 pg/ml and 122.41±18.19 pg/ml respective-
ly; for TNF-α:148.73±15.71 pg/ml, 131.46±16.67 pg/ml, 96.91±15.14 pg/ml 
and 74.08±7.46 pg/ml respectively; for CD11b MFI: 77.73±7.51,68.75±4.01, 
61.58±3.05 and 53.82±6.68 respectively). Differences of these cytokines 
among the four groups were statistically significant.
Conclusion: The results indicate that exposure to fluctuating glucose concen-
trations enhances activation of monocytes compared with stable elevations 
in glucose concentration. The effects are partly attributable to the inherent 
osmotic changes.These findings indicated that reducing fluctuations in cir-
cadian glucose concentrations has important implications for the treatment 
strategies in diabetic patients with macrovascular complications.
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Association of urine adiponectin levels and marker of endothelial 
damage in type 2 diabetes without microalbuminuria
Y.J. Lee1, K.S. Suh2, M.C. Choi1, Y.C. Hwang1, S. Chon3, I.-K. Jeong3, S. Oh3, 
K.J. Ahn3, H.Y. Chung3, J.-T. Woo3, S.-W. Kim3, J.-W. Kim3, Y.K. Choi4, Y.S. Kim3;
1Department of Endocrinology and Metabolism, Kyung Hee University 
School of Medicine, 2Endocrine Research Institute, Kyung Hee 
University School of Medicine, 3Department of Endocrinology and 
Metabolism,Endocrine Research Institute, Kyung Hee University School of 
Medicine, 4Department of Endocrinology and Metabolism, Pochon CHA 
University, Seoul, Republic of Korea.
Background and aims: Urinary albumin excretion (UAE) and intima media 
thickness (IMT) of the carotid artery are considered subclinical markers of 
endothelial cell damage preceding atherosclerosis in type 2 diabetes. Recent 
studies reported that Urine (U-) adiponectin was significantly increased in 
type 2 diabetes. U-adiponectin reflects early vascular damage in a more ef-
ficient way compared to serum adiponectin, which is easily influenced by 
metabolic changes. Our observational study assessed whether there is an as-
sociation between U-adiponectin and UAE, change of IMT at baseline and 
after 1 year in type 2 diabetes without microalbuminuria.
Materials and methods: We enrolled 90 (37 men, 53 women) type 2 dia-
betic patients without microalbuminuria who presented with good glycemic 
control for 1 year. Total plasma (P-) and U-adiponectin were determined by 
enzyme-linked immunosorbent assay kit. U-adiponectin levels were adjusted 
for urinary creatinine excretion. The measurements were performed on both 
common carotid arteries avoiding areas of atherosclerotic plaque formation, 
and the mean IMT was used in this study. 
Results: Baseline characteristics of the patients were: age 58.7 ± 8 years, mean 
body mass index (BMI) 25.1 ± 3.1 kg/m2, HbA1c value 6.9 ± 1.2 %, and UAE 
8.2 ± 6.8 ug/mg creatinine. The mean duration of diabetes was 9.5 years. 
BMI, HbA1c and triglyceride levels were not significantly different between 
baseline and at 1 year (p=.160, p=590, p=.418, respectively). Mean IMT was 
0.70 ± 0.1 mm at baseline, and slightly increased to 0.75 ± 0.1 mm after 1 
year, with a statistically significant difference (p<0.001). Baseline P-adiponec-
tin and U-adiponectin were 13.0 ± 15.7 ug/mL, 4.7 ± 6.8 ug/mg creatinine, 
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respectively, and at 1 year, 11.0 ± 11.4 ug/mL, 4.8 ± 6.5 ug/mg creatinine, 
not demonstrating a significant difference (p=.226, p=.913, respectively). We 
analyzed the two groups, one with the increased IMT at 1 year (n=53) com-
pared to the baseline IMT and the other with the decreased IMT at 1 year 
(n=31). HbA1c was significantly higher in the increased IMT group com-
pared to the decreased IMT group (7.1 ± 0.1 % vs 6.6 ± 0.2 %, p=.039), while 
BMI, blood pressure and lipid levels were not significantly different between 
the two groups. U-adiponectin was higher in the increased IMT group than 
in the decreased IMT group, although there was no significant difference (5.1 
± 6.9 ug/mg creatinine vs 3.2 ± 4.6 ug/mg creatinine, p=.133). U-adiponectin 
revealed a significant positive correlation with UAE (r=.259, p=.014), while 
it was not significantly correlated with IMT (r=-.100, p=.350) in our study 
subjects. 
Conclusion: Our study implies that U-adiponectin levels may reflect early 
glomerula vascular damage in the pre-albuminuric level in type 2 diabetic 
patients. On the other hand, U-adiponectin may not be associated with mac-
rovascular damage. The exact mechanism and association between U-adi-
ponectin and vascular damage need further investigating.
Supported by: Korea Health 21 R&D Project, Ministry of Health & Welfare, 
Republic of Korea
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Formation of methionine-sulfoxide at position 1606 of Von Willebrand 
Factor inhibits cleavage by ADAMTS-13: a new prothrombotic 
mechanism promoted by oxidative stress in diabetes
F. Zaccardi1, D. Pitocco1, S. Lancellotti2, V. De Filippis3, B. Rocca4, R. De 
Cristofaro2, G. Ghirlanda1; 
1Internal Medicine, Catholic University, Rome, 2Hemostasis Research 
Center, Catholic University, Rome, 3University of Padua, 4Pharmacology, 
Catholic University, Rome, Italy.
Background and aims: An enhanced formation of reactive oxygen species 
and peroxynitrite occurs in diabetes. Peroxynitrite oxidizes methionine and 
tyrosine residues to methionine sulfoxide (MetSO) and 3-nitrotyrosine (NT), 
respectively. Notably, ADAMTS-13 cleaves von Willebrand factor (VWF), 
which bind and activate platelets in the microcirculation, exclusively at the 
Tyr1605-Met1606 peptide bond. We hypothesized that peroxynitrite could 
oxidize either or both of these amino acid residues, thus potentially affecting 
ADAMTS-13-mediated cleavage.
Materials and methods: Nonsmokers-healthy subjects (n=13, age 38-55), 
without risk factors for cardiovascular disease and 16 age- and sex-matched 
subjects with type 2 DM (T2DM) not on chronic medications including 
NSAIDs, vitamin E, or statins, were consecutively enrolled. The plasma 
level of VWF was measured as antigen and ristocetin cofactor. Moreover, 
we tested our hypothesis using synthetic peptide substrates based on: (1) 
VWF Asp1596-Ala1669 sequence (VWF74) and (2) VWF Asp1596-Ala1669 
sequence containing nitrotyrosine (VWF74-NT) or methionine sulfoxide 
(VWF74-MetSO). The peptides were treated with recombinant ADAMTS-13 
and the cleavage products analyzed by RP-HPLC. As adjunctive analysis, in 
15 type 1 diabetic subjects we explored the relationship between the 24hrs-
glycemic variability (obtained from Continuous Glucose Monitoring System 
and measured with CONGA index) and total carbonyls (a surrogate marker 
of oxidative stress) and ADAMTS-13 activity.
Results: T2DM subjects showed a significantly increased plasma level of 
VWF (p<0.001). The carbonyl content of VWF (a marker of oxidative modi-
fication of the protein) was significantly higher in T2DM than in controls 
(p<0.01). Moreover, compared to VWF purified from control subjects, VWF 
preparations from T2DM patients showed a relative resistance to ADAMTS-
13 hydrolysis. In particular, VWF74 oxidized by peroxynitrite underwent a 
severe impairment of its hydrolysis. Likewise, VWF74-MetSO was minimally 
hydrolyzed, whereas VWF74-NT was hydrolyzed slightly more efficiently 
than VWF74. Oxidation of purified VWF multimers did not alter their elec-
trophoretic pattern nor their ability to induce platelet aggregation by ristoce-
tin. Furthermore, we found a strong and positive linear correlation between 
CONGA1 and total carbonyls and ADAMTS-13 activity (P=0.013, R=0.904; 
P=0.003, R=0.952, respectively).
Conclusion: Overall, these findings indicate that oxidative stress and glycemic 
variability may contribute to prothrombotic effects, hindering the proteolytic 
processing by ADAMTS-13 of high-molecular-weight VWF multimers.
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Association of serum endothelin-1 with insulinaemic status in 
prediabetic and newly diagnosed type 2 diabetic subjects
I. Khan1, S. Mohajan2,3, R.M. Mazumder2,3, D. Sikdar3, M.O. Faruque2, Z. 
Hassan1, L. Ali2,4; 
1Dept of Physiology and Molecular Biology, BIRDEM, Dhaka, 2Dept of 
Biochemistry and Cell Biology, BIRDEM, Dhaka, 3Dept of Biochemistry 
and Molecular Biology, Chittagong University, Chittagong, 4Dept of 
Biochemistry, Bangladesh Institute of Health Sciences, Dhaka, Bangladesh.
Background and aims: Endothelin-1 (ET-1), an atherogenic marker, has 
been shown to be raised in T2DM subjects. However, the factors contribut-
ing to the elevation of ET-1 in T2DM is still unclear. Since IFG and IGT are 
intermediate stages in the development of diabetes, we have studied ET-1 in 
relation to glycaemic and insulinemic status in these prediabetic groups to get 
better insight on this issue.
Materials and methods: A total number of 160 subjects of Bangladeshi origin, 
consisting of 18 IFG, 47 IGT, 46 newly diagnosed T2DM patients and 49 healthy 
subjects were included in the study. Glucose was estimated by glucose-oxidase, 
lipids by enzymatic- colorimetric, and insulin and endothelin-1 were estimated 
by enzyme linked immunosorbent assay (ELISA). Results were expressed as 
mean±SD and appropriate tools were used in statistical comparison.
Results: Age and BMI were matched among all the groups. Absolute insu-
lin (μIU) level in IGT and T2DM were significantly higher compared to the 
controls (p<0.001 for both). HOMA%B (mean±SD) was significantly lower 
in IFG and T2DM groups (p=0.004 and <0.001) and higher in IGT (p=0.006) 
group compared to controls. HOMA%S was significantly lower in IGT and 
T2DM groups (p=0.002 and 0.003 respectively) compared to the Control, but 
it did not show any significant difference between IFG and Control groups. 
Lipid levels were almost similar in all three groups compared to the Control 
except significantly higher triglyceride and total cholesterol level in T2DM 
groups (p=0.001 and p=0.024 respectively). Mean value of serum endothe-
lin-1 was 6.85±4.4, 10.34±4.7, 10.14±6.8 and 10.48±5.7 in the Control, IFG, 
IGT and T2DM subjects respectively. This atherogenic marker was found to 
be significantly higher in prediabetic (IFG: p=0.009 and IGT: p=0.006) and 
T2DM (p=0.001) groups. On Spearman’s correlation analyses ET-1 showed 
association with fasting glucose in T2DM subjects, although it did not show 
any significant correlation with HOMA%S or HOMA%B in the prediabetic 
and T2DM groups. Multinomial logistic regression analyses showed that ET-
1 was associated with all the three hyperglycemic groups (IFG: p=0.005; IGT: 
p=0.007 and T2DM: p=0.003) when adjusted for age, WHR and gender.
Conclusions: Endothelin-1 is raised in hyperglycemic conditions regardless 
the stages of its natural history and this elevation is directly associated with 
hyperglycemia rather than insulin deficiency or insulin resistance.
Supported by: BADAS, Bangladesh and IPICS, Uppsala, Sweden
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Inducible Nitric Oxide Synthase (iNOS)regulation by Ca2+/Calmodulin-
dependent protein kinase II in vascular Smooth Muscle Cells (vSMCs) 
from diabetic rats
N. Di Pietro1,2, P. Di Tomo1,2, A. Giardinelli1,2, S. Di Silvestre1,2, C. Pipino1,2, 
C. Morabito3,2, G. Formoso4,2, M.A. Mariggiò3,2, A. Consoli4,2, A. Pandolfi1,2; 
1Department of Biomedical Sciences, University “G. d’Annunzio”, 2Aging 
Research Center , Ce.S.I., “Gabriele d’Annunzio” University Foundation, 
3Department of Basic and Applied Sciences, University “G. d’Annunzio”, 
4Department of Medicine and Aging Science, University “G. d’Annunzio”, 
Chieti, Italy.
Background and aims: In diabetes, increased cytokine plasma levels could 
induce iNOS expression contributing to vascular damage. In addition to 
transcriptional regulation, iNOS activity may be posttranslationally regulated 
by palmitoylation and intracellular trafficking. It has been recently demon-
strated that the multifunctional protein kinase CaMKII, a known contribu-
tor to vascular dysfunction in diabetes, may also play a significant role in 
iNOS-specific trafficking and activity following cytokine induction. Thus, the 
aim of the present study was to investigate the relationships between cytokine 
increased iNOS activity and Ca2+/CaMKII/CaMKIIdelta2 pathway involve-
ment in vSMCs from diabetic rats (DR).
Materials and methods: We measured iNOS expression (RT-PCR, Western 
Blot) and activity (conversion L-(3H)-arginine into L-(3H)-citrulline), intra-
cellular Ca2+ levels (fluorescence video imaging), CaMKII phosphorylation 
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(Western Blot), iNOS/CaMKIIdelta2 co-immunoprecipitation (Western Blot) 
and nitrotyrosine levels (immunofluorescence) in cultures of aortic vSMCs 
from 10 diabetic (90% pancreatectomy, DR) and 10 control (sham surgery, 
CR) rats, after 24 hrs incubation with 20 µg/ml Lipopolysaccharide (LPS).
Results: LPS increased iNOS expression to the same extent in CR and DR, 
while iNOS activity was about 7 folds greater in DR. As to the effect of LPS 
on increased Nitric Oxide (NO) production in DR, exposure to LPS led to an 
increase of intracellular calcium levels (1.9 folds increase) and Ca2+-depend-
ent CaMKII phosphorylation (3 folds increase) followed, as expected, by the 
absence of iNOS/CaMKIIdelta2 co-immunoprecipitation. These LPS effects 
were associated to the greater induced iNOS-specific activity in DR. In CR, 
instead, LPS failed to affect these parameters, which were not different from 
basal levels after LPS stimulation. In addition, the increased iNOS activity in 
DR was accompanied by a significant increase in intracellular nitrotyrosine 
levels (1.5 folds increase).
Conclusion: In conclusion, as compared to CR vSMCs, DR cells showed a 
greater LPS induced iNOS activity associated to an activation of Ca2+/CaM-
KII/CaMKIIdelta2 pathway. In addition, as we have previously shown, DR 
cells exhibit in this culture conditions a marked increase in O2- levels. Thus, 
the LPS increased NO release in diabetic pro-oxidant milieu gets converted 
into peroxinytrite and then enhanced nitrotyrosine generation. Together 
these results indicate for the first time that signal pathway involving CaMKII 
contributes to increase iNOS activity and nitrotyrosine generation in diabe-
tes and might provide new insight in the mechanisms linking diabetes and 
atherosclerosis.
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Multifactorial risk factor intervention in type 2 diabetic patients 
significantly improves global arginine bioavailability ratio
N.J. Tripolt1, A. Meinitzer2, M. Eder1, W.B. Graninger3, T.R. Pieber1,  
T.C. Wascher4, H. Sourij1; 
1Internal Medicine, Div. of Endocrinology and Nuclear Medicine, Vascular 
Biology Research Group, Medical University of Graz, 2Clinical Institute of 
medical and chemical laboratory diagnostics, Medical University of Graz, 
3Internal Medicine, Div. of Rheumatology, Medical University of Graz, 
4Department of Internal Medicine, Hanuschkrankenhaus, Vienna, Austria.
Background and aims: Endothelial dysfunction is defined by reduced bio-
availability of nitric oxide (NO) and has been shown to be associated with 
increased cardiovascular risk. The unique source for NO-synthesis is arginine 
and ornithine and citrulline are the products of arginine metabolism. Glo-
bal arginine bioavailability ratio (GABR) is defined as arginine/(ornithine + 
citrulline). Recently published data showed an inverse association between 
GABR and cardiovascular events. The aim of our study was to investigate the 
impact of a multifactorial risk factor intervention on GABR as a cardiovascu-
lar surrogate parameter in type 2 diabetic patients.
Materials and methods: We investigated type 2 diabetic patients, that did 
not reach treatment targets according to current local guidelines in two out of 
three oft the following parameters: HbA1c <6,5%, LDL-cholesterol <100 mg/
dl or blood pressure <130/80 mmHg. GABR was measured at baseline and 
after 3 months. During this time therapy was intensified according to current 
guidelines aiming to reach the treatment targets. Arginine, ornithine and cit-
rulline were chromatographically determined after precolumn-derivatisation 
followed by fluorescent detection. Intima media thickness was measured by 
B-mode ultrasound.
Results: We investigated 41 patients (25 males/16 females) with a mean age 
of 60±10 years. Baseline characteristics and treatment outcomes are shown 
in table 1. Intensified risk factor management significantly improved GABR 
(0,33±0,12 at baseline vs. 0,38±0,14 after 3 months; p=0,018). A significant 
improvement was only seen in patients with short diabetes duration (<5 years) 
whereas in patients with longer diabetes duration improvement did not reach 
statistical significance. A linear model including the duration of diabetes, 
the change of LDL-cholesterol, change of HbA1c, change in blood pressure 
turned out diabetes duration as the only significant predictor (p=0.049) of 
GABR improvement. Furthermore the change of GABR was inversely cor-
related with mean intima media thickness (r=-0,381, p=0.014).
Conclusion: In type 2 diabetic patients intensified risk factor intervention 
improves global arginine bioavailability ratio as a parameter of endothelial 
function. Duration of diabetes seems to be an important factor influencing 
the capacity of GABR improvement.
Treatment outcomes
Baseline 3 months p-value
sex (m/f) 25/16
age (years) 60±10
Duration of diabetes (years) 8±7
LDL cholesterol (mg/dl) 108±52 79±48 <0,001
HDL cholesterol (mg/dl) 46±13 50±16 <0,001
HbA1c (%) 8,5±1,2 7,9±1,4 <0,001
RR systolic (mmHg) 151±17 131± 23 <0,001
RR diastolic (mmHg) 89±9 77± 14 <0,001
Supported by: MSD, AESCA, AstraZeneca, Takeda, Novo Nordisk
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Formation of methylglyoxal-adducts in plasma is associated with LDL 
and triglyceride level: implications for diabetic atherosclerosis
Z. Turk1, J. Boras2; 
1Department for Laboratory Medicine, 2Department for Diabetic 
Complications, Vuk Vrhovac University Clinic for Diabetes, Zagreb, Croatia.
Background and aims: Protein glycation leading to AGE is enhanced in dia-
betes by increases in blood glucose per se, and collaterally, by endogenous 
production of reactive carbonyls. Low weight α-dicarbonyls are formed as 
glycolytic intermediates during metabolic conversion of glucose and/or dur-
ing lipid peroxidation. Among AGE precursors, methylglyoxal (MG) is con-
sidered as one of the key intermediates. We hypothesized it to be a common 
product of both carbonyl and oxidative stress, and investigated the MG bio-
genesis in relation to glycemic and lipid status in diabetic patients.
Material and methods: Serum and urine MG-adduct content was measured 
by DELFIA method in 83 diabetic patients and 20 controls. Fasting (FG) and 
postprandial (PPG) glucose level, HbA1c, LDL and HDL cholesterol, plasma 
triglyceride and homocysteine level were determined along with routine bio-
chemical parameters.
Results: Significant positive relationship was observed between serum level 
of MG-adducts and LDL (r=0.31 p=0.003) whereas fasting glucose correlated 
inversely (r= -0.33 p=0.001) as well as PPG (r= -0.23 p=0.041) and HbA1c (r= 
-0.22 p=0.036). Similarly, significant correlations were also found between 
urinary levels of MG-adducts and postprandial glucose (r= -0.28 p=0.023), 
serum triglycerides (r=0.31 p=0.003), homocystein (r=0.57 p=0.0007), HDL 
(r= -0.28 p=0.007) and urine albumine/creatinine ratio (r=0.53 p=0.002). 
Stepwise linear regression was performed using serum or urine MG-adducts 
as dependent variable and HbA1c, fasting and postprandial glucose, LDL, 
HDL, triglycerides, serum creatinine, homocystein and urine albumine/
creatinine ratio as independent variables. Of these, only LDL-cholesterol 
(regression coefficient=0.29) and FG (regression coefficient=-0.28) were in-
dependent predictors of MG-adducts in serum (p<0.00046), whereas urine 
albumine/creatinine ratio, PPG, and triglycerides were independently as-
sociated with their urine content (p<0.0062). LDL-cholesterol >3.0 mmol/L 
discriminate patients who had a higher serum level of MG-adducts (median 
(10th and 90th percentile) 465 (251-1254) vs 331(169-706) mgEq/L, p=0.0052), 
although there was no between-subgroup difference in glycemic control. Pa-
tients on statin treatment had lower MG-adducts although the difference did 
not reach statistical significance. The positive relationship between LDL-c 
and MG-adducts (r=0.38, p=0.042) was noted in the patients (n=54) free of 
statin treatment, whereas in the statin-treated subgroup, there was an inverse 
tendency (r=-0.28, p=0.83) but no significant yet. A significant correlation 
between homocysteine and urinary excretion of MG-adducts (r=0.8; p=0.02) 
was recorded in patients with a history of macrovascular disease.
Conclusion: A highly significant relationship between LDL and MG-adduct 
production, as well as tight correlation between triglycerides and urinary 
MG-adduct excretion suggest that lipoxidation and glyceraldehyde-3-phos-
phate route, along with the glycolytic pathway, might be an important source 
of MG generation. The glycotoxin methylglyoxal seems to be a common fac-
tor linking the two dominant metabolic changes in diabetes, hyperglycemia 
and intensive lipolysis, with vascular pathobiochemistry of diabetes.
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Vitamin B1 analogue benfotiamine improves survival and proliferation 
of diabetic or high glucose challenged resident cardiac stem cells 
R.G. Katare, A. Oikawa, A. Caporali, C. Emanueli, P. Madeddu; 
Bristol Heart Institute, University of Bristol, United Kingdom.
Background and aims: Diabetes mellitus (DM) is a potent and prevalent risk 
factor for coronary artery disease and heart failure. Furthermore, DM direct-
ly impinges on the heart’s function by accelerating the aging of cardiomyo-
cytes and resident cardiac progenitor cells (CPCs). Treatments able to prevent 
CPC senescence and thereby preserve heart reparative capacity are urgently 
needed. Our earlier studies demonstrated the ability of vitamin B1 analog 
benfotiamine (BFT) to prevent the development of diabetic cardiomyopathy. 
Here, we aimed to verify whether BFT may benefit the survival, proliferation 
and differentiation of resident CPCs.
Methods and results: Sca-1+ CPCs were extracted from left ventricle of 
STZ induced type-1 DM mice after 20 weeks of DM induction using com-
mercially available kit. Flowcytometric analysis revealed marked reduction 
in the number (23±4% vs 12±2%, P<0.01) and increased apoptosis (28±3% 
vs 10±4%, P<0.001) of CPCs from diabetic mice compared to age-matched 
healthy controls (n=7 mice per group). When cultured under normal glucose 
(5%) conditions, diabetic CPCs showed increased apoptosis and reduced 
protein expression of the cell survival Pim-1/Bcl-2 signalling pathway and 
significantly lost their ability to differentiate into cardiomyocytes when ex-
posed to differentiation medium. However, treating diabetic animals with 
BFT (70mg/kg/day, for 16 weeks), markedly inhibited the apoptosis of CPCs 
through activation of Bcl-2 and phosphorylation of Bad. Importantly, BFT 
treatment induced 2 fold increase in proliferation of CPCs that was markedly 
attenuated by DM (P<0.01). In addition BFT also increased the differentiat-
ing ability of CPCs into cardiomyocytes, as evidenced by measuring the per-
cent of cells positive for α-sarcomeric actin and connexin-43. Finally, CD45-
CD90+CD105+ CPCs isolated from atrial appendages of patients undergo-
ing on-pump by pass cardiac surgery were exposed to high glucose (30µM) 
with or without BFT (150µM). Importantly, high glucose induced apoptosis 
(55±5% vs 12±4%, P<0.001) and reduced the proliferation (45±8% vs 80±4%, 
P<0.001) and differentiation potential of human CPCs, with these effects be-
ing prevented by BFT (P<0.01 for all comparisons).
Conclusion: Both DM and high glucose cause quantitative and functional 
deficits in CPCs. BFT contrasted these detrimental effects in a murine dia-
betic model as well as in in vitro assays using human CPCs exposed to high 
glucose. These data highlight the direct protective action of BFT on CPCs 
and potential underpinning mechanisms centred on survival Pim-1/Bcl-2 
signalling pathway. Thus, BFT merit attention as a global therapeutic target 
to combat DM-associated cardiac damage.
Supported by: UK Diabetes
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Gene silencing of Toll-like receptor attenuates myocardiac apoptosis in 
diabetic mice 
Y. Zhang1,2, H. Zhu1, X. Zheng1, X. Zhang1, N. Jiang1, A. Shunnar1, N. Tong2, 
T. Peng1, W. Min1; 
1University of Western Ontario, London, Canada, 2West China Hospital, 
Chengdu, China.
Background and aims: Myocardiac apoptosis is an early event involved in 
the process of cardiomyopathy in diabetes mellitus. Toll-like receptors (TLR) 
signaling triggers cell apoptosis through multiple mechanisms. Up-regula-
tion of TLR4 expression has been shown in diabetic hearts. This study aims 
to delineate the role of TLR4 in cardiac apoptosis, and to block this process 
through gene silencing of TLR4 in diabetic hearts.
Materials and methods: The C57/BL6 mice were made diabetic by ip injec-
tion of streptozotocin (STZ, 150mg/kg body weight). Three days after STZ 
treatment, the diabetes was confirmed by blood glucose level. Diabetic mice 
were treated with 50 μg of TLR4 shRNA (treatment group) or scrambled 
shRNA (control group). Other control groups include non-treated diabetic 
mice (diabetes group) and naïve mice (normal group).
Results: After 7 days of hyperglycemia, the level of TLR4 in the heart tissue 
was significantly elevated in the diabetic mice, as comparing normal mice. 
Treatment of TLR4 shRNA knocked down the gene expression as comparing 
control mice, as well as diminished its elevation in diabetic mice. Pathologi-
cally, apoptosis was evident in the cardiac tissues of diabetic mice, as detected 
by TUNEL assay. In contrast, treatment with TLR4 shRNA minimized apop-
tosis in heart tissues. Mechanistically, caspase 3 activation was remarkably 
inhibited in the mice that were treated with TLR4 shRNA, but not in the mice 
treated with control shRNA or non-treated mice. Furthermore, gene silenc-
ing of TLR4 resulted in suppression of apoptosis cascades, such as caspase 3, 
caspase 8 and Fas gene expression.
Conclusion: In summary, we demonstrated here a piece of novel evidence 
that TLR4 plays a critical role in cardiac apoptosis. This is the first demonstra-
tion of preventing in cardiac apoptosis in diabetic mice through gene silenc-
ing of TLR4 gene.
Supported by: LHRI
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Prevalence of glucose intolerance in patients with chronic hepatitis C
G. Radulian1, F. Rusu2, A.D. Dragomir2, G. Enache2, M. Jinga3, V. Stoica3, D. 
Cheta3, E.D. Rusu1; 
1National Institute of Diabetes, Nutrition and Metabolic Diseases, 2Healthy 
Nutrition Foundation, 3University of Medicine Carol Davila, Bucharest, 
Romania.
Background and aims: The association of glucose intolerance with chronic 
hepatitis C (CHC) virus infection remains controversial. The aim of this 
study was to evaluate the prevalence of glucose intolerance by oral glucose 
tolerance test (OGTT) in patients with CHC in comparison with matched 
controls and to analyze if adipocytokines levels correlate with insulin secre-
tion (IS) and insulin resistance (IR).
Materials and methods: 176 consecutive outpatients with CHC (group A) 
and 123 subjects individually (group B) matched for age, sex and body mass 
index (BMI) were included. OGTT was performed in all cases with HbA1c 
over 5.5%. Glucose intolerance was defined as IFG (impaired fasting glu-
cose), IGT (impaired glucose tolerance) or diabetes. IR was determined using 
Homeostasis model assessment (HOMA-IR). The liver fibrosis was non-inva-
sively assessed using the Forns index; a value < 4.2 excludes liver fibrosis and 
a value > 6.9 is a predictor for significant fibrosis.
Results: The average age was 56.21±10.28 in group A and 54.27±10.22 years 
in group B. After age and BMI adjustment, patients with CHC had signifi-
cantly higher prevalence of glucose intolerance (23.86% vs 9.75%, P = 0.037). 
Median HOMA-IR (3.75 versus 1.23), adiponectin (6.72 versus 2.98 µg/ml), 
TNF alpha (2.79 versus 0.61 pg/ml), IL-6 (4.78 versus 1.81 pg/ml) were sig-
nificantly higher in CHC patients (all p < 0.05). In patients with CHC, by 
multiple linear regression, independent predictors of HOMA-IR included 
the body mass index, apparent liver disease duration, and the serum levels 
of leptin, TNF alpha, IL-6 (positive correlation) and adiponectin (negative 
correlation). In patients with HCH infection, plasma insulin and C-peptide 
levels were lower (al p <0.05).
Conclusion: In hepatitis C patients, higher prevalence of glucose intolerance 
are present. Adipocytokines and inflammatory cytokines play an important 
part in this relationship. Screening for diabetes (HbA1c or OGTT) is neces-
sary in patients with hepatitis C.
Supported by: Romanian National Authority for Scientific Research
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Prevalence and determinants of diabetes mellitus in Dutch patients with 
liver cirrhosis
N. Wlazlo1, H.J.B. Beijers1, E.J. Schoon2, H.P. Sauerwein3, C.D.A. 
Stehouwer4, B. Bravenboer1; 
1Department of Internal Medicine, Catharina Hospital, Eindhoven, 
2Department of Gastroenterology, Catharina Hospital, Eindhoven, 
3Department of Endocrinology and Metabolism, Academic Medical 
Centre, Amsterdam, 4Department of Internal Medicine and Cardiovascular 
Research Institute Maastricht, Maastricht University Medical Centre, 
Netherlands.
Background and aims: The reported prevalence of type 2 Diabetes mellitus 
(DM2) in patients with liver cirrhosis is 20-40%, about five times higher than 
in the general population. However, these data were never adjusted for clas-
sical risk factors for DM2, like age, body mass index (BMI) or family history 
of DM2 (first or second degree relatives). We therefore investigated the as-
sociation between cirrhosis and DM2 controlling for known risk factors for 
DM2.
Materials and methods: We reviewed medical files for presence of DM2 and 
potential confounders in 94 patients with cirrhosis visiting our hospital be-
tween 2001 and 2009 (cases) and compared these to a control group of 107 
patients with non-ulcer dyspepsia (NUD). Multiple logistic regression analy-
sis was used to adjust for potential confounders.
Results: The etiology of our cirrhosis population was alcohol (59%), viral 
hepatitis (10%), biliary cirrhosis (3%) or cryptogenic (28%). Prevalence of 
DM2 was significantly higher in patients with cirrhosis than in controls: 35/94 
(37%) vs. 7/107 (7%) (OR 8.5, 95%CI 3.5 - 20.2, p < 0.001). After adjustment 
for age, sex, family history of DM2, alcohol use and BMI, cirrhosis remained 
significantly associated with DM2 (OR 13.6, 95% CI 4.3 - 42.9, p < 0.001). 
Most DM2 was already diagnosed before diagnosis of cirrhosis (21/35, 60%) 
or was incidentally found together with cirrhosis (5/35, 14%). In multivariate 
analysis in patients with cirrhosis, male sex (OR 4.6, 95% CI 1.3 - 15.9, p = 
0.016), positive family history of DM2 (3.7, 95% CI 1.0 - 12.8, p = 0.042) and 
BMI (OR 1.2 per kg/m2, 95% CI 1.0 - 1.3, p = 0.015) were positively associated 
with DM2, whereas alcohol consumption protected (moderate vs. no alco-
hol consumption (OR 0.11, 95% CI 0.02 - 0.57, p = 0.009), excessive vs. no 
alcohol consumption (OR 0.14, 95% CI 0.03 - 0.63, p = 0.010)). Etiology and 
severity of the cirrhosis, expressed in Child-Pugh score, were not associated. 
The final model explained about 30% of diabetes prevalence in cirrhosis.
Conclusion: Liver cirrhosis was strongly associated with DM2, even after 
adjustment for age, BMI and family history of DM2. Although sex, family 
history, BMI and alcohol consumption were significantly associated with the 
presence of DM2, this only explained part of the high DM2 prevalence in 
cirrhosis. Therefore a liver-specific factor, such as low-grade inflammation, 
might cause DM2 in cirrhosis.
1343
Chromatin structure and Sirt1 and PGC-1alpha expressions in liver cells 
of NOD mice
F.G. Ghiraldini1, I.M. Toni2, M.L.S. Mello1; 
1Anatomy, Cell Biology, Physiology and Biophysics, 2Genetics, Evolution 
and Bioagents, State University of Campinas, Brazil.
Background and aims: Evidences point out that hyperglycemia caused by di-
abetes mellitus is the main factor that contributes to early-ageing in diseased 
patients. This metabolic alteration could lead to changes in chromatin struc-
ture and dynamics, as those previously observed in hepatocytes of a group of 
NOD mice presenting glycemia higher than 600 mg/dl. Alterations in chro-
matin structure caused by epigenetic factors may change the expression pro-
files of genes involved in cell ageing. Sirt1 is a NAD+ dependent deacetylase 
recently related to cellular metabolic changes and ageing. Together with the 
transcriptor factor PGC-1α, Sirt1 could act as a nutritional sensor. The aim of 
this study was to compare chromatin accessibility to microococcal nuclease 
(MNase) and expressed Sirt1 and PGC-1α protein in liver cells of moderate 
and severe diabetic adult and non-diabetic mice.
Materials and methods: Young adults (8 weeks old) with moderate diabetes 
(glycemia: 200-400 mg/dl), severe (glycemia > 500 mg/dl) diabetic adults and 
old non-diabetic (56 weeks old) mouse groups were used (n = 5). Normogly-
cemic Balb/c and NOD mice with the same ages as the diabetic animals were 
used as controls. Chromatin accessibility was evaluated by Mnase assay, fol-
lowed by DNA extraction and agarose gel electrophoresis. PGC-1α and Sirt1 
were determined by Western Blot for the same groups.
Results: The chromatin in mice with severe diabetes presented the highest 
unraveling degree (2.62 ± 0.44, P<0.05) in comparison with that of the control 
with the same age (Balb 0.66 ± 0.22; NOD 0.46 ± 0.11). Although chromatin 
accessibility index of the older mice was higher in comparison with that of 
young mice (1.41 ± 0.2 vs 0.67 ± 0.18, P<0.05), it was still lower than that in 
mice with severe diabetes (2.62 ± 0.44, P<0.05). The Sirt1 protein was abundant 
in mice with severe diabetes compared to their respective controls (moder-
ate diabetic mice 1.62 ± 0.17 vs control Balb/c 0.92 ± 0.07, P<0.05; severe dia-
betic mice 1.60 ± 0.18 vs control Balb/c 0.94 ± 0.09 and normoglycemic NOD 
0.75 ± 0,09 P<0.05) while old mice presented the lowest values (0.30 ± 0.03) in 
comparison to young mice (1.00) (P<0.05). The PGC-1α abundance was higher 
than that of controls only when considering mice with severe diabetes (2.15 
± 0.4) vs Balb/c mice (0.66 ± 0.06) and normoglycemic NOD (0.88 ± 0.42). 
Similar to the Sirt1 expression, PGC-1α abundance was lower (0.51 ± 0.15 
fold) in older mice in comparison with young ones.
Conclusion: Severe hyperglycemia induces enhancement of an open form of 
chromatin in hepatocytes, surpassing the phenotype exhibited in old speci-
mens. Sirt1, together with PGC-1α, could act as nutritional sensor, because 
it is highly expressed in severe diabetic mice but attains normal levels in nor-
moglycemic mice of same age. Therefore, the decondensed chromatin pheno-
type observed in hepatocytes of mice with severe diabetes is not assumed to 
be affected by Sirt1, as this protein, when acting as histone deacetilase, would 
lead to a more compact state of the chromatin structure. Considering that 
the expressions of Sirt1 and PGC-1α in old mice differed from diabetic adult 
mice, we suggest that the early ageing observed in diabetic individuals does 
not follow the same metabolic pathway as natural ageing.
Supported by: FAPESP and CNPq 
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Effects of early undernutrition on the insulin sensitivity and on both 
glucose and ketone body transporters in the liver from suckling rats
E. Lizárraga-Mollinedo1, E. Fernández-Millán1, J. De Toro-Martín2, C. 
Martinez-Honduvilla2, C. Álvarez1,2, F. Escrivá1,2; 
1Ciber de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM). 
ISCIII, 2Bioquímica y Biología Molecular II, Facultad de Farmacia. 
Universidad Complutense, Madrid, Spain.
Background and aims: The suckling imposes biochemical adaptations to 
nutrition, since milk is a high-fat low-carbohydrate diet. As well, this period 
is a critical window of growth for the brain, which accomplishes part of its 
development before weaning. Immature brain uses large amounts of glucose 
and ketone bodies to obtain energy and for biosynthesis, thus increased rates 
of hepatic gluconeogenesis and ketogenesis are compulsory. Consistently, 
plasma insulin and glucagon remain in low and high concentration respec-
tively, throughout the suckling, adapting liver metabolism to diet. What is 
more, hepatic low insulin responsiveness is the most suitable condition dur-
ing this period. The shortage of nutrients during development can have grave 
consequences later in life. Impaired glucose tolerance, diabetes and cognitive 
defects can arise from early undernutrition. As previously shown, insulin re-
sponses are enhanced in heart, skeletal muscle and adipose tissue of restricted 
rats, but the effects on liver sensitivity has not been explored yet. Changes 
in hepatic insulin sensitivity might alter the rate of the indicated metabolic 
pathways, modifying the production of endogenous substrates. Our aim is to 
search whether maternal undernutrition influences the insulin responses in 
the liver of suckling pups.
Materials and methods: Wistar rats were submitted to a 60% restriction of 
a commercial diet from 14th day of pregnancy and during lactation. 10-day 
old rats from restricted dams and their controls were studied. Rats were de-
capitated. Blood was got from the neck. Liver was rapidly frozen. Plasma in-
sulin and glucagon were determined by RIA. Glycogen was quantified with 
amyloglucosidase and ketone bodies spectrophotometrically. Liver gluco-
neogenesis was evaluated by a glycerol test. Components of insulin signalling 
were analyzed by Western. IRS-1/2 associated PI3-kinase was assayed with 
[32P]ATP.
Results: Glycaemia was depressed in the restricted rats. Blood and liver ke-
tone bodies remained above control values. Undernutrition decreased plas-
ma insulin and glucagon. Liver glycogen was enhanced. Glycerol gluconeo-
genesis did not change, nor liver expression of insulin receptor, but IRS-1/2 
increased with undernutrition. PI3-kinase was more activated by insulin in 
restricted rats, as was Akt and GSK3 phosphorylation.
Conclusion: Early undernutrition increases the risk for defects in glucose 
homeostasis and for neurological damages. Herein we show that undernour-
ished rats are hypoglycaemic, due to the liver insulin hypersensitivity (as in 
other tissues) together with a low plasma glucagon. These changes mean a 
dramatic modification of the most convenient hepatic metabolic setting dur-
ing suckling. The high ketogenic ability in restricted animals is rather surpris-
ing, considering the enhanced insulin responsiveness. The improved plasma 
levels of ketone body probably constitutes an adaptation to nutritional re-
striction. It might prevent or minimize the impact on immature organs, as the 
brain. However, glucose is required for normal brain functioning under most 
conditions, including perinatal time. So imbalance between plasma glucose 
and ketone body concentrations might have deleterious consequences for the 
developing brain.
Supported by: CIBERDEM and MEC Spain
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The morphometric characteristics of pulmonary tissue and arteries in 
type 2 diabetic patients
O.A. Pivovarova1, B.N. Mankovsky2; 
1Internal medicine №2, Lugansk State Medical University, Lugansk, 
2National Medical Academy of Postgraduate Education, Kiev, Ukraine.
Background and aims: Diabetes mellitus is associated with the damage of 
different organs. However, the changes of the lungs in patients with diabetes 
are not fully characterized. Therefore, the aim of our study was to investigate 
the morphometric characteristics of an alveolar tissue and pulmonary arter-
ies in type 2 diabetic patients.
Materials and methods: We studied the materials obtained from the autopsy 
of 25 deceased subjects with type 2 diabetes mellitus (mean age - 58,3±1,3 
years) and 11 deceased persons without diabetes (mean age - 50,2±1,6 years) 
as the control group. The causes of death in those subjects were not related 
to pulmonary disease. The tissue samples were sectioned and fixed in 10% 
neutral formol by standard histological methods and embedded in paraffin 
wax. The tissue slides were stained with hematoxylin-eosin. We analyzed the 
morphometric characteristics of pulmonary tissues and arteries using the 
light-optical microscope (Olympus, Japan, BX - 41).
Results: We found the trend toward an increase of the lumen of alveoli in 
those with diabetes compared to controls - 137,2±10,8 µm vs. 101,2±12,6 
µm, respectively, 0,05<p<0,1 (data are presented as mean±SEM). These 
changes were accompanied by the significant decrease of the external di-
ameter (100,8±1,6 µm vs. 172,3±27,4 µm, (p<0,001) and internal diameter 
(76,03±5,5 µm vs. 111,3±18,6 µm, (p<0,001) of pulmonary arteries in diabet-
ic subjects compared to controls. Moreover, we found the significant decrease 
of the thickness of the arteries wall in those with diabetes (12,3±0,53 µm 
vs. 35,6±4,9 µm, (p<0,001), the vascular index was 14,3±0,42 vs. 22,6±0,97, 
(p<0,001), in those with and without diabetes, respectively.
Conclusion: We may conclude that the revealed morphometric changes of 
alveolar tissue and arteries in type 2 diabetic patients may underlie the higher 
susceptibility to pulmonary diseases in these patients.
Supported by: OAP
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Serum levels of bone turnover markers in type 2 diabetes and their 
relationship with bone mineral density
P. Rozas-Moreno1, R. Reyes-García2, M. Muñoz-Torres2; 
1Endocrinology Division, Hospital General de Ciudad Real, 2Bone 
Metabolic Unit, Endocrinology Division, San Cecilio University Hospital, 
Granada, Spain.
Background and aims: Several studies indicate that hyperglycemia induces 
a low turnover state with osteoblast dysfunction. Studies of bone resorption 
in diabetes are limited, and the results are conflicting. Our aim was to analyse 
serum levels of bone turnover markers (BTM), PTH-i and 25 OH vitamin D 
in patients with type 2 diabetes mellitus (T2DM), and the relationship with 
bone mineral density (BMD). We also compared BTM between T2DM and 
controls.
Materials and methods: Case-Control study including 133 subjects, 78 pa-
tients with T2DM and 55 healthy controls. Lumbar spine and femoral BMD 
were measured by dual X-Ray absorptiometry (Hologic QDR 4500). We 
measured: bone alkaline phosphatase (b-ALP) by an ELISA (OCTEIATM 
IDS Ltd Boldon UK), osteocalcin (OC) by radioimmunoassay (DiaSorin, 
Stillwater, Minnesota USA; TRAP (Bone TRAP ® Assay. IDS Ltd); CTX by 
ELISA (Elecsys ß CrossLaps,Roche Diagnostics SL, Barcelona, Spain); PTH-i 
(Intact PTH, Roche Diagnostics SL); 25 OH vitamin D (25-Hydroxyvitamin 
D 125I RIA DiaSorin).
Results: Mean age was 56,7± 6,8 yr (57.8± 6.4 and 55,1± 7,1 in T2DM and con-
trol group respectively; p=0.024). Among the T2DM patients (n=78), 47.2% 
were females (n=35) and 52.8% males (n=43). In the control group 56.5% 
were females (n=30) and 43.5% males (n=25). Serum levels of bone resorp-
tion markers were lower in T2DM compared with controls (TRAP: T2DM 
1.39±0.99 UI/l vs controls 1.85±0.81 UI/l, p<0.05; CTX: T2DM 0.20±0.12 ng/
ml vs controls 0.33±0.15 ng/ml, p<0.05). There were no differences in bone 
formation markers (b-ALP: T2DM 14.83±6.5 ug/L vs controls 12.96±6.73 
ug/L, p 0.11; OC: T2DM 1.48±1.25 ng/ml vs controls 1.45±1.2 ng/ml, p 0.91). 
PTH-i serum levels were lower in T2DM (PTH-i: T2DM 38.35±18.20 pg/ml 
vs controls 50.22±18.99 pg/ml, p<0.05). T2DM have lower levels of 25 OH 
vitamin D with respect to controls, although differences were not significant 
(T2DM 17.81±11.14 ng/ml vs controls 21.30±11.05 ng/ml, p 0.07). In T2DM 
there was a negative correlation between CTX levels and BMD at different 
sites (LS BMD -0.460, P<0.001; TF BMD -0.530, p<0.001).
Conclusion: T2DM patients have lower levels of bone resorption markers 
and PTH-i compared with controls. CTX serum levels were negatively cor-
related with BMD at different sites.
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Predictors of impaired glucose regulation in patients with non-alcoholic 
fatty liver disease
E. Hatziagelaki1, D. Karageorgopoulos2, A. Chounta3, A. Tsiavou1, T. 
Economopoulos1, M. Falagas4; 
12nd Dept. of Internal Medicine, “Attikon” University Hospital, 2Alfa 
Institute of Biomedical Sciences (AIBS), 34th Dept. of Internal Medicine, 
“Attikon” University Hospital, 4Dept. of Medicine, Henry Dunant Hospital 
and Alfa Institute of Biomedical Sciences (AIBS), Athens, Greece.
Background and aims: Many patients with non-alcoholic fatty liver disease 
(NAFLD) have impaired glucose tolerance or type 2 diabetes mellitus (DM). 
We sought to identify characteristics of NAFLD patients associated with hy-
perglycemia.
Materials and methods: We prospectively studied a cohort of NAFLD pa-
tients. They underwent a 2-hour oral glucose tolerance test (using 75 g). Se-
rum glucose and insulin were measured at 30 min intervals. Common bio-
chemical laboratory tests were also done.
Results: We included 152 patients with NAFLD; 74 (48.7%) had hyperglyc-
emia (45 had impaired fasting glucose or impaired glucose tolerance, and 29 
had type 2 DM). Patients with hyperglycemia had higher body mass index 
(BMI; 30.5±4.5 vs. 28.5±4.8 kg/m2, p=0.01), lower high-density lipoprotein 
cholesterol (HDL-C; 46.5±13.6 vs. 53.7±18.8 mg/dL, p=0.02), lower serum 
albumin (4.1±0.5 vs. 4.4±0.4 g/dL, p<0.01) and were older (53.0±10.7 vs. 
47.3±11.4 years, p<0.01), in comparison with patients with normoglycemia. 
In multivariate analysis including the above 4 variables as covariates, age 
(odds ratio [OR]: 1.08, 95% confidence interval [CI]: 1.03-1.13), BMI (OR: 
1.12, 95% CI: 1.01-1.25), and HDL-C (OR: 0.95, 95% CI: 0.92-0.98) proved 
independent predictors of hyperglycemia in NAFLD patients. Additionally, 
30-min insulin after the oral glucose challenge was lower in patients with 
hyperglycemia (74.2±49.7 vs. 94.5±53.9 μIU/ml, p= 0.02), while 90-min 
insulin (170.1±84.6 vs. 122.9±97.7 μIU/ml, p=0.01) and 120-min insulin 
(164.0±101.2 vs. 85.3±61.9 μIU/ml, p<0.01) were higher and insulin at 60-
min did not differ between patients with or without hyperglycemia.
Conclusion: NAFLD patients with higher BMI, lower HDL-C, or older age 
were more likely to have impaired glucose metabolism. We suggest that oral 
glucose tolerance test should be considered for patients with non-alcoholic 
fatty liver disease, particularly in those with one or more with the above men-
tioned predictor characteristics of hyperglycemia, to readily diagnose and 
treat disorders of glucose metabolism.
1348
Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus
B. Resuli1, F. Agaçi2, B. Kraja1, K. Sema3, N. Dhigoi1, M. Kapia2, I. Burda2; 
1University Clinic of Gastrohepatology, University Hospital Center Mother 
Theresa, 2University Clinic of Endocrinology, University Hospital Center 
Mother Theresa, 3Clinic of Gastrohepatology, Ambulatory Service, Tirana, 
Albania.
Background and aim: Non-alcoholic fatty liver disease (NAFLD) is a grow-
ing medical problem worldwide. It has gained considerable attention for its 
appealing relations with insulin resistance and the slow-evolving course to-
wards the end-stage liver disease. We conducted a prospective study of in-
cidence and risk factors of NAFLD in patients with type 2 diabetes mellitus 
(DM).
Methods: 127 consecutive patients with type 2 DM [60 (47.2%) males and 
67 (52.8%) females, mean age 59.3±9.3 years old] hospitalized in University 
Service of Endocrinology in Tirana, Albania during 2009 and fulfilling diag-
nostic criteria adopted by WHO 1999 were included in the study. The diagno-
sis of NAFLD was based on 1) sonographic findings, 2) ethanol intake equal 
or lower than 20 g/day and 3) exclusion of all other liver diseases. The clinical 
and laboratory parameters, such as age, sex, mean duration of diabetes, body 
mass index (BMI), glycosylated hemoglobin (HbA1c), transaminases levels, 
serum cholesterol and triglyceride levels were analyzed as predictors of sono-
graphic findings by using multiple logistic regression model.
Results: 74% (N=94) of the patients had NAFLD [39/94 (41.5%) mild, 45/94 
(47.9%) moderate, 10/94 (10.6%) severe]. The value of BMI, WHR (waist-hip 
ratio), ALT (alanine aminotransferase), serum cholesterol and triglyceride 
in type 2 DM patients with NAFLD were significantly higher than in those 
without NAFLD [26.5 vs. 33.9 kg/m2, 0.91 vs. 1.12, 26.8 vs. 40.19 (UI/L), 
193.9 vs.230.1 (mg/dl) and 141.7 vs. 227.9 (mg/dl), respectively, P<0.001). 
All patients (N=13; 14%) with ALT greater than normal had NAFLD. In mul-
tivariable-adjusted models significant predictors were age (OR=1.04, 95% 
CI=0.03-0.85), BMI (OR=1.53, 95% CI=0.10-0.32) and HbA1c (OR=1.1, 95% 
CI=0.11-0.23).
Conclusion: In Albania, the incidence of NAFLD seems to be higher in pa-
tients with type 2 diabetes mellitus. Older age, obesity and HbA1c were the 
independent risk factors of NAFLD in diabetic patients.
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High prevalence of advanced NAFLD in type 2 diabetic patients with 
unremarkable liver enzymes and effect of liraglutide on NAFLD: meta-
analysis of the LEAD Program
M.J. Armstrong1, A. Falahati2, B. Elbrønd2, W.E. Schmidt3, S. Gough4, P.N. 
Newsome1; 
1Centre for Liver Research, University of Birmingham, United Kingdom, 
2Novo Nordisk A/S, Copenhagen, Denmark, 3St-Josef Hospital, Ruhr-
University Medical Faculty, Bochum, Germany, 4Oxford Centre for 
Diabetes, Endocrinology and Metabolism, United Kingdom.
Background and aims: Non-alcoholic fatty liver disease (NAFLD) is the 
most common cause of liver disease in type 2 diabetes. Predicting patients at 
risk of progressing to the advanced stages of NAFLD (liver inflammation and 
fibrosis) is a clinical challenge as the majority of patients are asymptomatic 
and have normal liver enzyme levels. The NAFLD Fibrosis Score (NFS) is a 
well-validated non-invasive scoring system (comprising age, BMI, AST:ALT 
ratio, platelets and albumin) used to predict the severity of advanced liver 
fibrosis. The aims of this study are: (i) to estimate the severity of NAFLD us-
ing the NFS and (ii) to evaluate the effect of 1.8mg liraglutide, a once-daily 
human GLP-1 analogue, on NAFLD in a cohort of poorly controlled diabetic 
subjects.
Materials and methods: Meta-analysis was performed on individual data 
from patients enrolled in the Liraglutide Effect and Action in Diabetes 
(LEAD) program. ANCOVA analysis was performed on the intent-to-treat 
population to estimate change from baseline after 26 weeks.
Results: Data from 3967 adults at baseline: 53% male; 79% Caucasian; Age 56 
years [10]; HbA1c 8.3% [1.0]; duration of diabetes 7.8 years [5.8]; systolic BP 
131 [15.3]; BMI 31.6 kg/m2 [5.40]; males ALT 32 and females ALT 24 IU/L 
(values expressed as mean [SD]). 70% of subjects had metabolic syndrome 
based on ATP III classification. 54% of subjects had abnormal ALT (upper 
limit of normal range 30 IU/L for males and 19 IU/L for females), with mean 
ALT 39 IU/L. The NFS predicted that 6.4% had advanced liver fibrosis (score 
> +0.676) and 61.0% had an indeterminate score (-1.455 to 0.676) requiring 
further liver specialist review. Duration of diabetes significantly correlated 
with ALT (rs = 0.17, p<0.0001) and severity of NFS (rs = 0.14, p<0.0001). 
Liraglutide significantly reduced ALT versus placebo (LS mean 3.48 vs 1.36; 
p<0.001), although the proportion of patients normalizing their ALT was 
similar (25.2% vs 22.7%). Liraglutide significantly improved NFS in compari-
son to placebo (LS mean -0.40 vs -0.13; p<0.0001), with significant chang-
es in BMI (LS mean -0.66; p<0.0001) and platelet count (LS mean +15.90; 
p<0.0001). There was no relationship between changes in NFS and HbA1c 
after 26 weeks liraglutide treatment (rs = 0.00, p 0.96).
Conclusion: Advanced NAFLD fibrosis is present in a significant proportion 
of diabetic patients in the LEAD program, despite the absence of clinically 
significant serum transaminases. Duration of diabetes, but not level of gly-
caemic control was correlated with elevation of ALT and worsening sever-
ity of NFS. 26 weeks treatment with Liraglutide reduces ALT and NFS. The 
increase in platelets after Liraglutide treatment may indicate an effect inde-
pendent of weight loss in NAFLD.
Supported by: MJA; Wellcome Trust Fellowship
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Insulinaemic status and nonalcoholic fatty liver disease in Bangladeshi 
type 2 diabetic subjects
Z. Zeba, A. Alam, R. Zinnat, L. Ali; 
Biochemistry and Cell Biology, BIRDEM, Dhaka, Bangladesh.
Background and aims: Nonalcoholic fatty liver disease (NAFLD) is becom-
ing a public health problem with increasing incidence and it has been shown 
to be associated with T2DM and other disorders of metabolic syndrome 
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(MS)). Insulin resistance (IR) is a central feature of both T2DM and MS, but 
the association of IR with NAFLD has yet not been fully clarified taking into 
account the racial heterogenecity and confounders like BMI. Moreover, the 
pathogenesis of T2DM Bangladeshi subjects has pancreatic β cell dysfunc-
tion as a predominant defect and its association with NAFLD needs to be 
investigated. The issue was addressed in this study through exploring the as-
sociation of NAFLD with insulin secretion and sensitivity as measured by 
homeostasis model assessment.
Materials and methods: Under a Case-control design this analytic obser-
vational study was conducted on 127 T2DM with NAFLD and 129 T2DM 
without NAFLD subjects. T2DM was diagnosed by WHO Study Group Cri-
teria and NAFLD was diagnosed by 4D ultrasound. Insulin was assayed by 
an ELISA technique, and insulin secretory capacity (HOMA% B) and insulin 
sensitivity (HOMA% S) were estimated by homeostasis model assessment 
using a HOMA-SIGMA software. Data were analyzed by appropriate uni-
variate as well as multivariate tests including logistic regression analysis with 
NAFLD as dependent variable and others as independent/confounding vari-
ables as appropriate.
Results: The NAFLD group was found to have higher BMI as compared to 
the Control (BMI, M± SD, 26.19± 3.69 vs 25.32± 3.47, p= 0.053); however, 
no significant difference was observed in case of WHR. The fasting blood 
glucose and lipid levels did not differ between the two groups. Serum fast-
ing insulin was significantly higher in case of NAFLD group [fasting serum 
insulin in IU/L, of NAFLDr vs Non-NAFLD, Median (Range), 19.8(3.0-81.6) 
vs 16.67(3-100.6), p=0.005]. HOMA%B was significantly higher in NAFLD 
group compared to T2DM subjects [HOMA%B, NAFLD vs Non-NAFLD, 
108.9 (6.30-462.70) vs 90.8 (11.1-451.3), p=0.014]. In case of insulin sensitiv-
ity a significant difference was present between NAFLD and Non- NAFLD 
groups [HOMA%S, NAFLD vs Non-NAFLD, 31.9(5.8-212.10) vs 34 (6.8-
190.8), p=0.005]. In logistic regression analysis, taking fatty liver as the de-
pendent variable, and WHR, BMI, FBG, HOMA%S and HOMA%B as inde-
pendent variables a significant negative association of fatty liver was found 
with HOMA% S (p= 0.033).
Conclusion: The data suggest that NAFLD is associated with insulin resist-
ance in Bangladeshi T2DM subjects, and the association of IR and NAFLD is 
independent to obesity and glycemic- insulinemic status.
Supported by: BADAS
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Alpha-lipoic acid attenuates steatohepatitis through inhibiting CYP2E1 
and endoplasmic reticulum stress
M. Kim1, G.-S. Jung1, N.-K. Kim1, H.-S. Kim1, K.-G. Park1, A.-K. Min2, I.-K. 
Lee2; 
1Department of Internal Medicine, Keimyung University School of 
Medicine, Daegu, 2Department of Internal Medicine, Kyungpook National 
University School of Medicine, Daegu, Republic of Korea.
Background and aims: Nonalcoholic fatty liver disease (NAFLD) is closely 
associated with obesity, and type 2 diabetes. In the insulin-resistant state, in-
creased hepatic fat accumulation and reactive oxygen species (ROS) stimu-
lates the activity of CYP2E1 and endoplasmic reticulum (ER) stress. Here, we 
examined whether alpha-lipoic acid (ALA) prevents steatohepatitis through 
the inhibition of molecular mediators involved in hepatic injury including 
CYP2E1 and ER stress.
Materials and methods: C57BL/6 mice were fed a methionine choline de-
ficient (MCD) diet with or without ALA for 4 weeks. The plasma levels of 
ALT and AST were measured to check hepatic inflammation. For histological 
analysis, we conducted hematoxylin and eosin staining and Oil red O stating. 
We investigated the effect of ALA on CYP2E1 and ER stress in the liver of 
MCD-diet mice using Northern blot analysis and Western blot analysis.
Results: Dietary supplementation with ALA reduced MCD diet-induced 
hepatic lipid accumulation, hepatic inflammation and plasma ALT and AST 
levels. Upon histological examination, the livers of MCD mice exhibited stea-
tohepatitis, including fat accumulation and infiltration by inflammatory cells. 
Mice fed an MCD diet supplemented with ALA exhibited significantly at-
tenuated hepatic fat accumulation and inflammation. CYP2E1 expression in 
the liver of MCD mice was significantly higher than that of control mice, and 
ALA inhibited the MCD diet-induced expression of CYP2E1 at the mRNA 
and protein levels. Moreover, ALA inhibited MCD diet-induced expression of 
the nuclear factor-E2-related factor 2 (Nrf2) and Nrf2 target gene NAD(P)H 
quinone oxidoreductase 1. MCD diet increased the activation of ER stress 
markers, such as phosphorylation of eIF2α and expression of GRP78, ATF6, 
and CHOP, and also induced an increase in levels of MAP kinase activity, 
including JNK and ERK phosphorylation. MCD diet fed mice with ALA at-
tenuated these expressions.
Conclusion: Taken together, the results of the present study indicate that ALA 
attenuates steatohepatitis through inhibition of CYP2E1 and ER stress. It pro-
vides the possibility that ALA can be used to prevent the development and 
progression of NAFLD in patients who have strong risk factors for NASH.
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Specifically-PNPLA3-mediated accumulation of liver fat in type 2 
diabetic patient
J.-M. Petit1, B. Guiu2, D. Masson3, L. Duvillard3, P. Buffier1, M.-C. Brindisi1, 
B. Bouillet1, P. Hillon1, I. Robin1, J. Cercueil2, B. Vergès1; 
1Diabetologie, 2Radiology, 3Inserm u866, CHU du Bocage, Dijon, France.
Background and aims: Non-alcoholic fatty liver disease (NAFLD) is com-
monly associated with obesity, metabolic syndrome and type 2 diabetes. 
Recently, it has been shown in the general population that an allele in the 
adiponutrin (PNPLA3) gene (rs738409[G]) was strongly associated with 
increased hepatic fat levels, independently of visceral adiposity and insulin 
resistance. In this study, we set out to determine whether liver fat content 
(LFC), evaluated using 1H-MR Spectroscopy, was associated with PNPLA3 
rs738409 polymorphism in people with type 2 diabetes. We also evaluated the 
influence of this polymorphism on the relationship between LFC and either 
visceral adiposity or intima media thickness (IMT).
Materials and methods: 218 type 2 diabetic patients were included in this 
study. LFC (1H-magnetic resonance spectroscopy), area of visceral fat 
(RMN), and IMT were measured.
Results: 139 (63.7 %) patients had steatosis. Patients with steatosis had a 
higher BMI (34.9 +/- 6.3 vs 32.9 +/- 6.6; p= 0.01), higher visceral fat area 
(284 +/- 94 vs 246 +/- 100 cm2, p= 0.005), higher plasma ALAT levels (42.8 
+/- 22.5 vs 31.6 +/- 36.7 UI/l, p< 0.001), and higher plasma triglyceride levels 
(2.42 +/- 1.77 vs 1.78 +/- 1.05 mmol/l, p= 0.004) than did patients without st-
eatosis. The rs738409 minor G allele was associated with LFC. The number of 
patients with steatosis is significantly higher among minor G allele carriers in 
comparison to C allele homozygote carriers (70.3% vs 57.2%; p=0.04) In the 
sub group of C allele homozygote carriers, LFC correlated with BMI (r=0.27, 
p=0.003), and visceral fat area (r=0.30, p=0.002) but not with IMT. In the 
sub group of minor G allele carriers, LFC correlated negatively with IMT 
(r=-0.23, p=0.03), but not with BMI, or with visceral fat area. Circulating trig-
lycerides, total cholesterol, HDL cholesterol, LDL cholesterol, AST and ALAT 
levels were similar for minor G and C allele homozygote carriers.
Conclusion: This study suggests that in people with type 2 diabetes, LFC is 
related to rs738409 polymorphism. Moreover, an interesting finding of this 
study was that the relationship between metabolic factors and LFC were very 
different in each subgroup of the rs738409 polymorphism. The lack of a rela-
tionship with visceral obesity and the negative correlation with IMT suggest 
that fatty liver associated with the minor G allele of the PNPLA3 rs738409 
polymorphism may not be linked to metabolic disorders. The reason why 
liver fat content is negatively associated with carotid atherosclerosis among 
PNPLA3-minor G allele carriers is not yet known. The possibility that in such 
patient, hepatic triglyceride synthesis could protect other tissues from the po-
tential lipotoxicity of free fatty acids needs to be evaluated.
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